-DOCSTART- -X- O O 25453593

A DT N
step-by-step JJ N
introduction NN N
to TO N
vegetables NNS N
at IN N
the DT N
beginning NN N
of IN N
complementary JJ N
feeding NN N
. . N

The DT N
effects NNS N
of IN N
early JJ N
and CC N
repeated JJ N
exposure NN N
. . N

Breastfeeding NNP 4_p
( ( 4_p
BF NNP 4_p
) ) 4_p
is VBZ N
associated VBN N
with IN N
willingness NN N
to TO N
accept VB N
vegetables NNS N
. . N

This DT N
may MD N
be VB N
due JJ N
to TO N
the DT N
variety NN N
of IN N
flavours NNS N
delivered VBN N
via IN N
breast NN N
milk NN N
. . N

Some DT N
mothers NNS N
add VBP N
vegetables NNS N
to TO N
milk VB N
during IN N
complementary JJ N
feeding NN N
( ( N
CF NNP N
) ) N
to TO N
enhance VB N
acceptance NN N
. . N

The DT N
present JJ N
study NN N
tested VBD N
a DT N
step-by-step JJ N
exposure NN N
to TO N
vegetables NNS N
in IN N
milk NN N
then RB N
rice NN N
during IN N
CF NNP N
, , N
on IN N
intake NN N
and CC N
liking NN N
of IN N
vegetables NNS N
. . N

Just NNP N
before IN N
CF NNP N
, , N
enrolled VBD N
mothers NNS N
were VBD N
randomised VBN N
to TO N
an DT N
intervention NN N
( ( N
IG NNP N
, , N
n JJ N
= VBP N
18 CD N
; : N
6 CD N
BF NNP N
) ) N
or CC N
control VB N
group NN N
( ( N
CG NNP N
, , N
n JJ N
= VBP N
18 CD N
; : N
6 CD N
BF NNP N
) ) N
. . N

IG JJ N
infants NNS N
received VBD N
12 CD N
daily JJ N
exposures NNS N
to TO N
vegetable JJ N
puree NN N
added VBD N
to TO N
milk VB N
( ( N
days NNS N
1-12 RB N
) ) N
, , N
then RB N
12 CD N
× NNS N
2 CD N
daily JJ N
exposures NNS N
to TO N
vegetable JJ N
puree NN N
added VBD N
to TO N
rice VB N
at IN N
home NN N
( ( N
days NNS N
13-24 RB N
) ) N
. . N

Plain NNP N
milk NN N
and CC N
rice NN N
were VBD N
given VBN N
to TO N
CG NNP N
. . N

Then RB N
both DT N
received VBD N
11 CD N
daily JJ N
exposures NNS N
to TO N
vegetable JJ N
puree NN N
. . N

Intake NNP N
was VBD N
weighed VBN N
and CC N
liking VBG N
rated VBN N
on IN N
days NNS N
25-26 JJ N
and CC N
33-35 JJ N
after IN N
the DT N
start NN N
of IN N
CF NNP N
in IN N
the DT N
laboratory NN N
, , N
supplemented VBN N
by IN N
the DT N
same JJ N
data NN N
recorded VBD N
at IN N
home NN N
. . N

Vegetables NNS N
were VBD N
rotated VBN N
daily RB N
( ( N
carrots NNS N
, , N
green JJ N
beans NNS N
, , N
spinach NN N
, , N
broccoli NN N
) ) N
. . N

Intake NNP N
, , N
liking VBG N
and CC N
pace NN N
of IN N
eating VBG N
were VBD N
greater JJR N
for IN N
IG NNP N
than IN N
CG NNP N
infants NNS N
. . N

Intake NNP N
and CC N
liking NN N
of IN N
carrots NNS N
were VBD N
greater JJR N
than IN N
green JJ N
beans NNS N
. . N

However RB N
, , N
at IN N
6m CD N
then RB N
18m CD N
follow VBP N
up RB N
, , N
vegetable JJ N
( ( N
carrot JJ N
> NN N
green JJ N
beans NNS N
) ) N
but CC N
not RB N
group NN N
differences NNS N
were VBD N
observed VBN N
. . N

Mothers NNS N
reported VBD N
appreciation NN N
of IN N
the DT N
structure NN N
and CC N
guidance NN N
of IN N
this DT N
systematic JJ N
approach NN N
. . N

Early JJ N
exposure NN N
to TO N
vegetables NNS N
in IN N
a DT N
step-by-step JJ N
method NN N
could MD N
be VB N
included VBN N
in IN N
CF NNP N
guidelines NNS N
and CC N
longer JJR N
term NN N
benefits NNS N
assessed VBN N
by IN N
extending VBG N
the DT N
exposure NN N
period NN N
. . N

-DOCSTART- -X- O O 7080985

[ RB N
Comparative NNP N
study NN N
of IN N
cinoxacin NN N
( ( N
Cinobac NNP N
) ) N
, , N
nitrofurantoin FW N
( ( N
Furadantine NNP N
MC NNP N
) ) N
and CC N
oxolinic JJ N
acid NN N
( ( N
Uritrate NNP N
) ) N
in IN N
urinary JJ N
tract NN N
infections NNS N
. . N

Results NNS N
of IN N
a DT N
random NN N
study NN N
of IN N
three CD N
groups NNS N
of IN N
30 CD N
patients NNS N
with IN N
uncomplicated JJ N
urinary JJ 4_p
infections NNS 4_p
] VBP N
. . N

-DOCSTART- -X- O O 384024

Butorphanol NNP N
and CC N
meperidine NN N
compared VBN N
in IN N
patients NNS N
with IN N
acute JJ 4_p
ureteral JJ 4_p
colic NN 4_p
. . N

Pain NNP N
relief NN N
was VBD N
evaluated VBN N
in IN N
81 CD N
patients NNS N
with IN N
acute JJ 4_p
ureteral JJ 4_p
colic NN 4_p
and CC N
the DT N
confirmed JJ N
presence NN N
of IN N
a DT N
calculus NN N
. . N

A DT N
randomized JJ N
double-blind JJ N
comparison NN N
of IN N
intramuscular JJ N
2 CD N
and CC N
4 CD N
mg. NN N
butorphanol NN N
and CC N
80 CD N
mg. NNS N
meperidine NN N
was VBD N
used VBN N
. . N

Pain NNP N
intensity NN N
and CC N
pain NN N
relief NN N
were VBD N
evaluated VBN N
at IN N
half JJ N
hour NN N
and CC N
hourly JJ N
intervals NNS N
for IN N
4 CD N
hours NNS N
. . N

A DT N
2 CD N
mg. NN N
dose NN N
of IN N
butorphanol NN N
was VBD N
found VBN N
to TO N
be VB N
analgesically RB N
equivalent JJ N
to TO N
80 CD N
mg. NNS N
meperidine NN N
, , N
while IN N
a DT N
4 CD N
mg. NN N
dose NN N
of IN N
butorphanol NN N
was VBD N
found VBN N
to TO N
be VB N
more RBR N
effective JJ N
than IN N
80 CD N
mg. JJ N
meperidine NN N
and CC N
2 CD N
mg. NN N
butorphanol NN N
. . N

Each DT N
patient NN N
received VBD N
up RB N
to TO N
2 CD N
doses NNS N
of IN N
analgesic JJ N
medication NN N
when WRB N
necessary JJ N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
incidence NN N
of IN N
side JJ N
effects NNS N
among IN N
treatments NNS N
. . N

One CD N
patient NN N
had VBD N
visual JJ N
hallucinations NNS N
after IN N
a DT N
2 CD N
mg. NN N
dose NN N
of IN N
butorphanol NN N
, , N
possibly RB N
owing VBG N
to TO N
its PRP$ N
antagonistic JJ N
activity NN N
to TO N
significant JJ N
narcotic JJ N
experience NN N
given VBN N
previously RB N
at IN N
another DT N
hospital NN N
. . N

There EX N
was VBD N
no DT N
other JJ N
evidence NN N
of IN N
toxicity NN N
with IN N
butorphanol NN N
. . N

It PRP N
was VBD N
found VBN N
to TO N
be VB N
a DT N
safe JJ N
, , N
effective JJ N
and CC N
wall RB N
tolerated JJ N
drug NN N
for IN N
the DT N
treatment NN N
of IN N
ureteral JJ N
colic NN N
and CC N
is VBZ N
recommended VBN N
in IN N
place NN N
of IN N
narcotics NNS N
. . N

-DOCSTART- -X- O O 16220761

Adhesion-prevention JJ N
effects NNS N
of IN N
fibrin NN N
sealants NNS N
after IN N
laparoscopic JJ N
myomectomy NN N
as IN N
determined VBN N
by IN N
second-look JJ N
laparoscopy NN N
: : N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
controlled VBN N
study NN N
. . N

OBJECTIVE NNP N
To TO N
examine VB N
the DT N
adhesion NN N
prevention NN N
effects NNS N
of IN N
2 CD N
types NNS N
of IN N
fibrin NN N
sealant NN N
after IN N
laparoscopic JJ N
myomectomy NN N
( ( N
LM NNP N
) ) N
. . N

STUDY NNP N
DESIGN NNP N
A NNP N
prospective JJ N
, , N
randomized VBN N
study NN N
( ( N
Canadian JJ N
Task NNP N
Force NNP N
I PRP N
) ) N
was VBD N
conducted VBN N
at IN N
a DT N
University-affiliated JJ N
hospital NN N
. . N

A DT N
total NN N
of IN N
91 CD N
patients NNS N
showing VBG N
a DT N
minimal JJ N
myoma NN N
> VBD N
5 CD N
cm NN N
, , N
excluding VBG N
pedunculated VBN N
myomas NN N
, , N
underwent JJ N
LM NNP N
alone RB N
: : N
32 CD N
patients NNS N
in IN N
the DT N
control NN N
group NN N
, , N
29 CD N
in IN N
the DT N
fibrin NN N
gel NN N
group NN N
and CC N
30 CD N
patients NNS N
in IN N
the DT N
fibrin JJ N
sheet NN N
group NN N
. . N

After IN N
LM NNP N
, , N
postoperative JJ N
adhesions NNS N
were VBD N
evaluated VBN N
by IN N
second-look JJ N
laparoscopy NN N
. . N

The DT N
frequency NN N
of IN N
postoperative JJ N
adhesions NNS N
was VBD N
the DT N
main JJ N
outcome NN N
. . N

RESULTS VB N
The DT N
frequency NN N
of IN N
postoperative JJ N
adhesions NNS N
of IN N
the DT N
uterus NN N
was VBD N
significantly RB N
lower JJR N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
in IN N
the DT N
fibrin NN N
gel NN N
group NN N
, , N
with IN N
20/32 CD N
( ( N
62.5 CD N
% NN N
) ) N
in IN N
the DT N
control NN N
group NN N
, , N
10/29 CD N
( ( N
34.5 CD N
% NN N
) ) N
in IN N
the DT N
fibrin NN N
gel NN N
group NN N
and CC N
20/30 CD N
( ( N
67.7 CD N
% NN N
) ) N
in IN N
the DT N
fibrin JJ N
sheet NN N
group NN N
. . N

Although IN N
no DT N
significant JJ N
differences NNS N
were VBD N
found VBN N
in IN N
the DT N
incidence NN N
of IN N
de FW N
novo FW N
adnexal JJ N
adhesions NNS N
, , N
the DT N
lowest JJS N
rate NN N
was VBD N
found VBN N
in IN N
the DT N
fibrin NN N
gel NN N
group NN N
, , N
with IN N
4/32 CD N
patients NNS N
( ( N
12.5 CD N
% NN N
) ) N
in IN N
the DT N
control NN N
group NN N
, , N
2/29 CD N
patients NNS N
( ( N
6.8 CD N
% NN N
) ) N
in IN N
the DT N
fibrin NN N
gel NN N
group NN N
and CC N
5/30 CD N
patients NNS N
( ( N
16.7 CD N
% NN N
) ) N
in IN N
the DT N
fibrin JJ N
sheet NN N
group NN N
. . N

No DT N
bilateral JJ N
adnexal NN N
adhesions NNS N
were VBD N
observed VBN N
in IN N
the DT N
3 CD N
groups NNS N
. . N

CONCLUSION NNP N
After IN N
LM NNP N
for IN N
myomas NN N
as RB N
large JJ N
as IN N
> NN N
or CC N
= $ N
5 CD N
cm NN N
, , N
postoperative JJ N
adhesions NNS N
were VBD N
observed VBN N
in IN N
> NN N
or CC N
= VB N
50 CD N
% NN N
of IN N
patients NNS N
. . N

The DT N
use NN N
of IN N
fibrin NN N
gel NN N
after IN N
LM NNP N
is VBZ N
recommended VBN N
. . N

-DOCSTART- -X- O O 19109542

Modified VBN N
constraint-induced JJ N
therapy NN N
combined VBN N
with IN N
mental JJ N
practice NN N
: : N
thinking NN N
through IN N
better JJR N
motor NN N
outcomes NNS N
. . N

BACKGROUND NNP N
AND CC N
PURPOSE NNP N
Modified NNP N
constraint-induced JJ N
therapy NN N
( ( N
mCIT NN N
) ) N
is VBZ N
an DT N
outpatient JJ N
therapy NN N
encouraging VBG N
repetitive JJ N
, , N
task-specific JJ N
practice NN N
with IN N
the DT N
affected JJ N
arm NN N
. . N

mCIT NN N
has VBZ N
shown VBN N
efficacy NN N
in IN N
all DT N
stages NNS N
poststroke VBP N
. . N

Given VBN N
its PRP$ N
efficacy NN N
when WRB N
combined VBN N
with IN N
other JJ N
therapy NN N
regimens NNS N
, , N
the DT N
current JJ N
study NN N
examined VBD N
the DT N
efficacy NN N
of IN N
mental JJ N
practice NN N
when WRB N
combined VBN N
with IN N
mCIT JJ N
versus NN N
mCIT NN N
only RB N
using VBG N
randomized VBN N
, , N
controlled VBN N
methods NNS N
. . N

METHOD NNP N
Ten CD N
patients NNS N
with IN N
chronic JJ N
stroke NN N
( ( N
7 CD N
males NNS N
; : N
mean JJ N
age NN N
, , N
61.4+/-3.02 JJ N
years NNS N
; : N
age NN N
range NN N
, , N
48 CD N
to TO N
79 CD N
years NNS N
; : N
mean JJ N
time NN N
since IN N
stroke NN N
, , N
28.5 CD N
months NNS N
; : N
range NN N
, , N
13 CD N
to TO N
42 CD N
months NNS N
) ) N
exhibiting VBG N
stable JJ N
, , N
affected JJ N
arm NN N
motor NN N
deficits NNS N
were VBD N
administered VBN N
mCIT NN N
, , N
consisting VBG N
of IN N
: : N
( ( N
1 CD N
) ) N
structured VBD N
therapy NN N
emphasizing VBG N
affected JJ N
arm NN N
use NN N
in IN N
functional JJ N
activities NNS N
3 CD N
days/week NN N
for IN N
10 CD N
weeks NNS N
; : N
and CC N
( ( N
2 CD N
) ) N
less RBR N
affected JJ N
arm NN N
restraint NN N
5 CD N
days/week NN N
for IN N
5 CD N
hours NNS N
. . N

Both DT N
of IN N
these DT N
components NNS N
were VBD N
administered VBN N
during IN N
a DT N
10-week JJ N
period NN N
. . N

Subjects NNS N
randomly RB N
assigned VBN N
to TO N
the DT N
mCIT+mental JJ N
practice NN N
experimental JJ N
condition NN N
also RB N
received VBD N
30-minute JJ N
mental JJ N
practice NN N
sessions NNS N
provided VBD N
directly RB N
after IN N
therapy NN N
sessions NNS N
. . N

These DT N
mental JJ N
practice NN N
sessions NNS N
required VBN N
daily RB N
cognitive JJ N
rehearsal NN N
of IN N
the DT N
activities NNS N
of IN N
daily JJ N
living NN N
practiced VBD N
during IN N
mCIT JJ N
clinical JJ N
sessions NNS N
. . N

RESULTS NNP N
No NNP N
pre-existing JJ N
differences NNS N
were VBD N
found VBN N
between IN N
groups NNS N
on IN N
any DT N
demographic JJ N
variable NN N
or CC N
movement NN N
scale NN N
. . N

All DT N
subjects NNS N
exhibited VBN N
marked JJ N
reductions NNS N
in IN N
affected JJ N
arm NN N
impairment NN N
and CC N
functional JJ N
limitation NN N
. . N

However RB N
, , N
subjects NNS N
in IN N
the DT N
mCIT+mental JJ N
practice NN N
group NN N
exhibited VBD N
significantly RB N
larger JJR N
changes NNS N
on IN N
both DT N
movement NN N
measures NNS N
after IN N
intervention NN N
: : N
Action NNP N
Research NNP N
Arm NNP N
Test NNP N
, , N
+15.4-point JJ N
change NN N
versus IN N
+8.4-point JJ N
change NN N
for IN N
mCIT NN N
only RB N
subjects VBZ N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
; : N
Fugl-Meyer NNP N
, , N
+7.8-point JJ N
change NN N
versus IN N
+4.1-point JJ N
change NN N
for IN N
the DT N
mCIT NN N
only RB N
subjects VBZ N
( ( N
P=0.01 NNP N
) ) N
. . N

These DT N
changes NNS N
were VBD N
sustained VBN N
3 CD N
months NNS N
after IN N
intervention NN N
. . N

CONCLUSIONS NNP N
mCIT NN N
remains VBZ N
a DT N
promising JJ N
motor NN N
intervention NN N
. . N

However RB N
, , N
its PRP$ N
efficacy NN N
appears VBZ N
to TO N
be VB N
enhanced VBN N
by IN N
use NN N
of IN N
mental JJ N
practice NN N
provided VBD N
directly RB N
after IN N
mCIT JJ N
clinical JJ N
sessions NNS N
. . N

-DOCSTART- -X- O O 11132252

Effect NN N
of IN N
secretin NN N
on IN N
children NNS 4_p
with IN 4_p
autism NN 4_p
: : N
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

To TO N
determine VB N
the DT N
effect NN N
of IN N
intravenous JJ N
porcine NN N
secretin NN N
on IN N
autistic JJ N
behaviours NNS N
in IN N
children NNS N
aged VBD N
2 CD N
to TO N
7 CD N
years NNS N
, , N
the DT N
effects NNS N
of IN N
secretin NN N
on IN N
( ( N
1 CD N
) ) N
performance NN N
on IN N
a DT N
standardized JJ N
language NN N
measure NN N
, , N
and CC N
( ( N
2 CD N
) ) N
autistic JJ N
behaviours NN N
, , N
as IN N
rated VBN N
by IN N
parents NNS N
and CC N
child NN N
development NN N
professionals NNS N
was VBD N
examined VBN N
. . N

Employing VBG N
a DT N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
design NN N
, , N
95 CD N
participants NNS N
were VBD N
assigned VBN N
to TO N
one CD N
of IN N
two CD N
groups NNS N
and CC N
administered VBD N
a DT N
single JJ N
dose NN N
of IN N
either DT N
secretin NN N
or CC N
placebo NN N
. . N

A DT N
follow-up JJ N
assessment NN N
was VBD N
conducted VBN N
3 CD N
weeks NNS N
after IN N
the DT N
injection NN N
. . N

No DT N
significant JJ N
differences NNS N
in IN N
language NN N
or CC N
autistic JJ N
behaviour NN N
measures NNS N
were VBD N
observed VBN N
at IN N
the DT N
3-week JJ N
follow-up NN N
between IN N
the DT N
groups NNS N
. . N

Also RB N
, , N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
proportion NN N
of IN N
individuals NNS N
who WP N
improved VBN N
by IN N
> NN N
or CC N
= $ N
6 CD N
points NNS N
on IN N
the DT N
language NN N
measure NN N
at IN N
follow-up NN N
. . N

This DT N
study NN N
showed VBD N
no DT N
significant JJ N
effects NNS N
of IN N
secretin NN N
on IN N
children NNS N
with IN N
autism NN 4_p
. . N

Our PRP$ N
results NNS N
are VBP N
consistent JJ N
with IN N
a DT N
systematic JJ N
review NN N
of IN N
randomized VBN N
controlled JJ N
trials NNS N
evaluating VBG N
the DT N
effect NN N
of IN N
secretin NN N
in IN N
children NNS N
with IN N
autism NN 4_p
. . N

-DOCSTART- -X- O O 3926042

Relief NN N
of IN N
pain NN N
by IN N
infusion NN N
of IN N
morphine NN N
after IN N
operation NN N
: : N
does VBZ N
tolerance VB N
develop VB N
? . N
To TO N
see VB N
whether IN N
continuous JJ N
intravenous JJ N
infusion NN N
of IN N
opiates NNS N
provides VBZ N
more RBR N
effective JJ N
postoperative JJ N
relief NN N
of IN N
pain NN N
than IN N
conventional JJ N
intramuscular JJ N
injection NN N
these DT N
regimens NNS N
were VBD N
compared VBN N
in IN N
a DT N
prospective JJ N
double NN N
blind IN N
trial NN N
. . N

Thirty NN N
patients NNS N
undergoing VBG N
elective JJ N
cholecystectomy NN 4_p
were VBD N
allocated VBN N
randomly RB N
to TO N
receive VB N
an DT N
infusion NN N
of IN N
morphine NN N
or CC N
an DT N
infusion NN N
of IN N
placebo NN N
( ( N
control VB N
group NN N
) ) N
for IN N
24 CD N
hours NNS N
. . N

Both DT N
groups NNS N
were VBD N
allowed VBN N
supplementary JJ N
morphine NN N
boluses NNS N
as IN N
requested JJ N
. . N

During IN N
the DT N
first JJ N
48 CD N
hours NNS N
after IN N
operation NN N
the DT N
degree NN N
of IN N
pain NN N
was VBD N
almost RB N
identical JJ N
between IN N
the DT N
groups NNS N
. . N

Surprisingly RB N
, , N
the DT N
group NN N
that WDT N
was VBD N
given VBN N
the DT N
infusion NN N
of IN N
morphine NN N
received VBN N
as IN N
much JJ N
supplementary JJ N
morphine NN N
as IN N
the DT N
control NN N
group NN N
during IN N
the DT N
first JJ N
24 CD N
hours NNS N
and CC N
appreciably RB N
more RBR N
during IN N
the DT N
24 CD N
hours NNS N
after IN N
the DT N
infusion NN N
had VBD N
been VBN N
withdrawn VBN N
. . N

Nausea NN N
and CC N
vomiting NN N
were VBD N
more RBR N
prevalent JJ N
among IN N
the DT N
patients NNS N
given VBN N
the DT N
infusion NN N
of IN N
morphine NN N
. . N

These DT N
results NNS N
suggest VBP N
that IN N
continuous JJ N
infusion NN N
of IN N
morphine NN N
may MD N
be VB N
an DT N
inferior JJ N
regimen NNS N
to TO N
intermittent VB N
bolus JJ N
administration NN N
in IN N
the DT N
relief NN N
of IN N
postoperative JJ N
pain NN N
. . N

This DT N
may MD N
be VB N
explained VBN N
by IN N
the DT N
development NN N
of IN N
tolerance NN N
in IN N
patients NNS N
who WP N
received VBD N
the DT N
infusion NN N
of IN N
morphine NN N
. . N

-DOCSTART- -X- O O 25238860

A DT N
neuropsychological JJ N
rehabilitation NN N
program NN N
for IN N
patients NNS 4_p
with IN 4_p
Multiple NNP 4_p
Sclerosis NNP 4_p
based VBN 4_p
on IN 4_p
the DT 4_p
model NN 4_p
of IN 4_p
the DT 4_p
ICF NNP 4_p
. . N

BACKGROUND NNP N
Forty NNP N
to TO N
sixty VB N
percent NN N
of IN N
MS NNP N
patients NNS N
suffer VBP N
from IN N
cognitive JJ N
impairments NNS N
. . N

Cognitive JJ N
deficits NNS N
are VBP N
a DT N
great JJ N
burden NN N
for IN N
patients NNS N
affected JJ N
. . N

In IN N
particular JJ N
they PRP N
may MD N
lead VB N
to TO N
a DT N
reduced JJ N
quality NN N
of IN N
life NN N
, , N
loss NN N
of IN N
work NN N
and CC N
problems NNS N
with IN N
the DT N
social JJ N
environment NN N
. . N

OBJECTIVE IN N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
a DT N
specific JJ N
neuropsychological JJ N
rehabilitation NN N
program NN N
for IN N
MS NNP 4_p
patients NNS N
according VBG N
to TO N
the DT N
ICF NNP N
to TO N
be VB N
able JJ N
to TO N
meet VB N
more JJR N
properly RB N
individual JJ N
requirements NNS N
on IN N
the DT N
therapy NN N
level NN N
of IN N
function NN N
as RB N
well RB N
as IN N
of IN N
activities NNS N
and CC N
participation NN N
. . N

METHODS NNP N
Forty NNP N
patients NNS N
with IN N
MS NNP N
were VBD N
randomised VBN N
in IN N
an DT N
intervention NN N
( ( N
IG NNP N
) ) N
- : N
and CC N
a DT N
control NN N
group NN N
( ( N
CG NNP N
) ) N
. . N

The DT N
outcome JJ N
measure NN N
of IN N
the DT N
IG NNP N
, , N
who WP N
started VBD N
an DT N
intensive JJ N
computer NN N
based VBN N
home NN N
training NN N
of IN N
attention NN N
and CC N
attended VBD N
psychological JJ N
counselling NN N
was VBD N
compared VBN N
to TO N
the DT N
untrained JJ N
CG NNP N
. . N

RESULTS NNP N
In IN N
specific JJ N
domains NNS N
of IN N
attention NN N
( ( N
simple JJ N
and CC N
cued JJ N
alertness NN N
and CC N
divided JJ N
attention NN N
) ) N
significant JJ N
group NN N
differences NNS N
between IN N
CG NNP N
and CC N
IG NNP N
could MD N
be VB N
found VBN N
. . N

The DT N
IG NNP N
reported VBD N
an DT N
improvement NN N
of IN N
mental JJ N
fatigue NN N
and CC N
retardation NN N
. . N

CONCLUSION NNP N
These DT N
findings NNS N
support VBP N
the DT N
idea NN N
that IN N
a DT N
neuropsychological JJ N
rehabilitation NN N
program NN N
, , N
which WDT N
based VBN N
on IN N
the DT N
model NN N
of IN N
ICF NNP N
, , N
could MD N
improve VB N
cognitive JJ N
impairment NN N
and CC N
could MD N
also RB N
have VB N
a DT N
positive JJ N
influence NN N
of IN N
activities NNS N
and CC N
participation NN N
. . N

-DOCSTART- -X- O O 14699228

The DT N
effect NN N
of IN N
use NN N
of IN N
pyridostigmine NN N
and CC N
requirement NN N
of IN N
vecuronium NN N
in IN N
patients NNS 4_p
with IN 4_p
myasthenia JJ 4_p
gravis NN 4_p
. . 4_p

CONTEXT NNP N
Patients NNPS N
with IN N
myasthenia NNP N
gravis FW N
receive JJ N
pyridostigmine NN N
, , N
an DT N
anticholinesterase NN N
agent NN N
, , N
as IN N
a DT N
part NN N
of IN N
therapy NN N
. . N

These DT N
patients NNS N
demonstrate VBP N
a DT N
heightened JJ N
sensitivity NN N
towards IN N
non-depolarising JJ N
muscle NN N
relaxants NNS N
. . N

Continuing VBG N
pyridostigmine NN N
till IN N
the DT N
day NN N
of IN N
the DT N
surgery NN N
or CC N
omitting VBG N
it PRP N
on IN N
the DT N
night NN N
before IN N
surgery NN N
could MD N
provide VB N
variable JJ N
results NNS N
with IN N
regards NNS N
to TO N
the DT N
effect NN N
of IN N
vecuronium NN N
. . N

AIMS NNP N
Myographic NNP N
evaluation NN N
of IN N
a DT N
dose NN N
of IN N
vecuronium NN N
in IN N
patients NNS N
with IN N
myasthenia JJ N
gravis NN N
on IN N
pyridostigmine NN N
therapy NN N
. . N

SETTING NN N
AND CC N
DESIGN NNP N
A NNP N
randomised JJ N
, , N
double-blind JJ N
, , N
clinical JJ N
study NN N
conducted VBN N
in IN N
a DT N
teaching JJ N
hospital NN N
. . N

SUBJECTS NNP N
AND NNP N
METHODS NNP N
Medically NNP N
( ( N
oral JJ N
pyridostigmine NN N
) ) N
well-controlled JJ N
adult NN N
patients NNS N
with IN N
myasthenia JJ N
gravis NNS N
who WP N
were VBD N
posted VBN N
for IN N
thymectomy NN N
, , N
were VBD N
randomly RB N
divided VBN N
into IN N
two CD N
groups NNS N
. . N

Patients NNS N
in IN N
Group NNP N
1 CD N
received VBD N
their PRP$ N
last JJ N
dose NN N
of IN N
pyridostigmine NN N
on IN N
the DT N
night NN N
before IN N
surgery NN N
while IN N
those DT N
in IN N
Group NNP N
2 CD N
received VBD N
even RB N
the DT N
morning NN N
dose NN N
of IN N
the DT N
drug NN N
on IN N
the DT N
day NN N
of IN N
surgery NN N
. . N

Neostigmine NNP N
( ( N
1-2 JJ N
mg NN N
) ) N
intravenously RB N
was VBD N
used VBN N
as IN N
rescue JJ N
medication NN N
. . N

Vecuronium NNP N
( ( N
0.01 CD N
mg/kg NN N
) ) N
was VBD N
used VBN N
for IN N
intubation NN N
and CC N
muscle NN N
relaxation NN N
during IN N
trans-sternal JJ N
thymectomy NN N
and CC N
its PRP$ N
effect NN N
was VBD N
reversed VBN N
using VBG N
neostigmine NN N
and CC N
atropine NN N
. . N

RESULTS NNP N
Fourteen JJ N
patients NNS N
( ( N
7 CD N
in IN N
each DT N
group NN N
) ) N
belonging NN N
to TO N
both DT N
sexes NNS N
were VBD N
enrolled VBN N
in IN N
the DT N
study NN N
. . N

The DT N
intubating VBG N
dose NN N
of IN N
vecuronium NN N
showed VBD N
quicker JJR N
onset JJ N
time NN N
( ( N
155 CD N
sec NN N
or CC N
2.7 CD N
min NN N
approx NN N
. . N

) ) N
and CC N
peak JJ N
effect NN N
( ( N
99 CD N
% NN N
T1 NNP N
suppression NN N
) ) N
in IN N
patients NNS N
belonging VBG N
to TO N
Group NNP N
1 CD N
, , N
and CC N
3/7 CD N
( ( N
43 CD N
% NN N
) ) N
complained VBD N
of IN N
respiratory JJ N
discomfort NN N
while IN N
waiting VBG N
for IN N
surgery NN N
. . N

By IN N
giving VBG N
the DT N
morning NN N
dose NN N
of IN N
pyridostigmine NN N
( ( N
Group NNP N
2 CD N
) ) N
, , N
an DT N
identical JJ N
intubating NN N
dose NN N
of IN N
vecuronium NN N
showed VBD N
relative JJ N
resistance NN N
( ( N
peak JJ N
effect-97 NN N
% NN N
T1 NNP N
suppression NN N
) ) N
and CC N
delayed VBN N
onset NN N
time NN N
( ( N
198 CD N
sec NN N
approx. NN N
) ) N
. . N

However RB N
, , N
the DT N
reversal NN N
was VBD N
complete JJ N
at IN N
the DT N
end NN N
of IN N
surgery NN N
in IN N
both CC N
the DT N
regimens NNS N
. . N

CONCLUSIONS NNP N
Omission NNP N
of IN N
the DT N
pyridostigmine NN N
dose NN N
on IN N
the DT N
day NN N
of IN N
surgery NN N
predisposed VBN N
patients NNS N
with IN N
myasthenia JJ N
gravis NN N
to TO N
the DT N
possibility NN N
of IN N
respiratory JJ N
discomfort NN N
and CC N
sensitivity NN N
to TO N
vecuronium NN N
. . N

Continued VBN N
administration NN N
significantly RB N
prolonged VBD N
the DT N
onset JJ N
time NN N
of IN N
vecuronium NN N
and CC N
the DT N
patients NNS N
required VBD N
a DT N
higher JJR N
dose NN N
of IN N
vecuronium NN N
. . N

-DOCSTART- -X- O O 21851906

Impact NN N
of IN N
pentoxifylline NN N
on IN N
platelet NN N
function NN N
profiles NNS N
in IN N
patients NNS 4_p
with IN 4_p
type JJ 4_p
2 CD 4_p
diabetes NNS 4_p
mellitus NN 4_p
and CC 4_p
coronary JJ 4_p
artery NN 4_p
disease NN 4_p
on IN 4_p
dual JJ 4_p
antiplatelet NN 4_p
therapy NN 4_p
with IN 4_p
aspirin NN 4_p
and CC 4_p
clopidogrel NN 4_p
. . 4_p

OBJECTIVES CC N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
impact NN N
of IN N
the DT N
phosphodiesterase NN N
( ( N
PDE NNP N
) ) N
inhibitor NN N
pentoxifylline NN N
on IN N
platelet NN N
function NN N
profiles NNS N
in IN N
patients NNS N
receiving VBG N
dual JJ N
antiplatelet NN N
therapy NN N
( ( N
DAPT NNP N
) ) N
. . N

BACKGROUND NNP N
Previous NNP N
studies NNS N
have VBP N
shown VBN N
that IN N
, , N
in IN N
patients NNS N
receiving VBG N
DAPT NNP N
, , N
the DT N
adjunctive JJ N
use NN N
of IN N
a DT N
PDE NNP N
inhibitor NN N
enhances NNS N
platelet NN N
inhibition NN N
, , N
particularly RB N
in IN N
those DT N
presenting VBG N
with IN N
diabetes NNS N
mellitus NNS N
( ( N
DM NNP N
) ) N
. . N

However RB N
, , N
the DT N
pharmacodynamic NN N
( ( N
PD NNP N
) ) N
effects NNS N
of IN N
the DT N
PDE NNP N
inhibitor NN N
pentoxifylline NN N
on IN N
platelet NN N
function NN N
profiles NNS N
in IN N
DM NNP N
patients NNS N
receiving VBG N
DAPT NNP N
are VBP N
unknown JJ N
. . N

METHODS NNP N
This DT N
was VBD N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
parallel JJ N
design NN N
study NN N
conducted VBN N
in IN N
DM NNP 4_p
patients NNS 4_p
with IN 4_p
stable JJ 4_p
coronary JJ 4_p
artery NN 4_p
disease NN 4_p
receiving VBG 4_p
DAPT NNP 4_p
. . 4_p

Patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
either DT N
pentoxifylline NN N
400 CD N
mg NN N
or CC N
placebo NN N
3 CD N
times NNS N
daily RB N
for IN N
14 CD N
days NNS N
. . N

The DT N
PD NNP N
effects NNS N
were VBD N
assessed VBN N
by IN N
vasodilator-stimulated JJ N
phosphoprotein NN N
phosphorylation NN N
assay NN N
, , N
light JJ N
transmittance NN N
aggregometry NN N
, , N
VerifyNow NNP N
P2Y12 NNP N
assay NN N
( ( N
Accumetric NNP N
, , N
Inc. NNP N
, , N
San NNP N
Diego NNP N
, , N
California NNP N
) ) N
, , N
and CC N
multiple JJ N
electrode NN N
aggregometry NN N
at IN N
baseline NN N
and CC N
14 CD N
days NNS N
. . N

The DT N
PD NNP N
effects NNS N
were VBD N
also RB N
assessed VBN N
according VBG N
the DT N
presence NN N
or CC N
absence NN N
of IN N
high JJ N
on-treatment JJ N
platelet NN N
reactivity NN N
status NN N
. . N

RESULTS VB N
A DT N
total NN N
of IN N
40 CD 4_p
patients NNS 4_p
were VBD N
available JJ N
for IN N
analysis NN N
. . N

At IN N
14 CD N
days NNS N
, , N
there EX N
were VBD N
no DT N
differences NNS N
in IN N
the DT N
P2Y NNP N
( ( N
12 CD N
) ) N
reactivity NN N
index NN N
as IN N
assessed VBN N
by IN N
vasodilator-stimulated JJ N
phosphoprotein NN N
phosphorylation NN N
between IN N
treatment NN N
groups NNS N
( ( N
primary JJ N
endpoint NN N
; : N
p CC N
= VB N
0.93 CD N
) ) N
. . N

Intra-group JJ N
comparisons NNS N
also RB N
failed VBD N
to TO N
show VB N
any DT N
differences NNS N
between IN N
baseline NN N
and CC N
14-day JJ N
P2Y NNP N
( ( N
12 CD N
) ) N
reactivity NN N
index NN N
assessment NN N
in IN N
the DT N
placebo NN N
and CC N
pentoxifylline NN N
arms NNS N
( ( N
p JJ N
= NNP N
0.61 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
significant JJ N
inter- JJ N
and CC N
intra-group JJ N
differences NNS N
in IN N
all DT N
other JJ N
PD NNP N
measures NNS N
. . N

The DT N
PD NNP N
effects NNS N
did VBD N
not RB N
vary JJ N
according VBG N
the DT N
presence NN N
or CC N
absence NN N
of IN N
high JJ N
on-treatment JJ N
platelet NN N
reactivity NN N
. . N

CONCLUSIONS NNP N
Adjunctive NNP N
treatment NN N
with IN N
pentoxifylline NN N
is VBZ N
not RB N
associated VBN N
with IN N
increased JJ N
platelet NN N
inhibitory NN N
effects NNS N
in IN N
DM NNP 4_p
patients NNS 4_p
with IN 4_p
coronary JJ 4_p
artery NN 4_p
disease NN 4_p
receiving VBG 4_p
DAPT NNP 4_p
. . 4_p

-DOCSTART- -X- O O 2105256

Effect NN N
of IN N
total JJ N
enteral JJ N
nutrition NN N
on IN N
the DT N
short-term JJ N
outcome NN N
of IN N
severely RB N
malnourished VBN 4_p
cirrhotics NNS 4_p
. . N

A DT N
randomized JJ N
controlled JJ N
trial NN N
. . N

Thirty-five JJ N
severely RB N
malnourished VBN 4_p
cirrhotic JJ 4_p
patients NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
enteral-tube JJ N
feeding NN N
as IN N
the DT N
sole JJ N
nutritional JJ N
support NN N
( ( N
n JJ N
= NNP N
16 CD N
) ) N
or CC N
an DT N
isocaloric JJ N
, , N
isonitrogenous JJ N
, , N
low-sodium JJ N
standard JJ N
oral JJ N
diet NN N
( ( N
n JJ N
= NNP N
19 CD N
) ) N
. . N

Both DT N
groups NNS N
were VBD N
homogeneous JJ N
regarding VBG N
age NN N
, , N
sex NN N
distribution NN N
, , N
etiology NN N
of IN N
liver JJ N
cirrhosis NN N
, , N
history NN N
of IN N
previous JJ N
complications NNS N
, , N
clinical JJ N
status NN N
, , N
liver RB N
and CC N
renal JJ N
function NN N
, , N
modified VBD N
Child NNP N
's POS N
score NN N
, , N
and CC N
nutritional JJ N
status NN N
at IN N
admission NN N
. . N

The DT N
enteral JJ N
formula NN N
diet NN N
was VBD N
energy NN N
dense NN N
, , N
containing VBG N
40 CD N
mmol NN N
Na/day NNP N
, , N
whole JJ N
protein NN N
plus CC N
branched-chain JJ N
amino NN N
acids NNS N
, , N
medium- JJ N
and CC N
long-chain JJ N
triglycerides NNS N
, , N
and CC N
maltodextrin NN N
. . N

It PRP N
supplied VBD N
2115 CD N
kcal/day NN N
. . N

The DT N
amount NN N
of IN N
vitamins NNS N
and CC N
trace NN N
elements NNS N
was VBD N
at IN N
the DT N
upper JJ N
limit NN N
of IN N
the DT N
recommended JJ N
dietary JJ N
allowances NNS N
. . N

The DT N
orally RB N
fed JJ N
patients NNS N
were VBD N
encouraged VBN N
to TO N
eat VB N
all DT N
meals NNS N
served VBD N
. . N

Total JJ N
enteral JJ N
nutrition NN N
was VBD N
well RB N
tolerated VBN N
without IN N
major JJ N
complications NNS N
. . N

Serum NNP N
albumin NN N
and CC N
Child NNP N
's POS N
score NN N
improved VBD N
in IN N
the DT N
enterally RB N
fed JJ N
patients NNS N
but CC N
not RB N
in IN N
controls NNS N
. . N

Mortality NNP N
rate NN N
while IN N
in IN N
the DT N
hospital NN N
was VBD N
lower JJR N
in IN N
patients NNS N
on IN N
enteral JJ N
feeding NN N
than IN N
in IN N
controls NNS N
( ( N
12 CD N
% NN N
vs JJ N
47 CD N
% NN N
) ) N
. . N

These DT N
results NNS N
show VBP N
that IN N
total JJ N
enteral JJ N
nutrition NN N
is VBZ N
safe JJ N
and CC N
effective JJ N
in IN N
improving VBG N
the DT N
short-term JJ N
clinical JJ N
outcome NN N
in IN N
severely RB N
malnourished JJ 4_p
cirrhotics NNS 4_p
. . N

-DOCSTART- -X- O O 16394797

Similar JJ N
compliance NN N
and CC N
effect NN N
of IN N
treatment NN N
in IN N
chronic JJ N
hepatitis NN N
C NNP N
resulting VBG N
from IN N
intravenous JJ N
drug NN N
use NN N
in IN N
comparison NN N
with IN N
other JJ N
infection NN N
causes NNS N
. . N

OBJECTIVES NNP N
There EX N
is VBZ N
some DT N
reluctance NN N
to TO N
treat VB N
intravenous JJ N
drug NN N
users NNS N
( ( N
IVDUs NNP N
) ) N
with IN N
chronic JJ N
hepatitis NN N
C NNP N
( ( N
CHC NNP N
) ) N
because IN N
of IN N
presumed JJ N
lower JJR N
compliance NN N
and CC N
response NN N
to TO N
antiviral JJ N
therapy NN N
. . N

We PRP N
intended VBD N
to TO N
evaluate VB N
the DT N
compliance NN N
and CC N
response NN N
to TO N
antiviral JJ N
treatment NN N
for IN N
CHC NNP N
in IN N
IVDUs NNP N
compared VBN N
with IN N
non-IVDUs JJ N
. . N

METHODS VB N
A DT N
retrospective JJ N
cohort NN N
study NN N
-- : N
secondary JJ N
analysis NN N
of IN N
the DT N
results NNS N
of IN N
a DT N
treatment NN N
trial NN N
-- : N
was VBD N
performed VBN N
in IN N
Belgium NNP N
and CC N
The DT N
Netherlands NNP N
. . N

A NNP N
total NN N
of IN N
406 CD N
previously RB N
untreated JJ N
CHC NNP N
patients NNS N
, , N
including VBG N
98 CD N
( ( N
24 CD N
% NN N
) ) N
IVDUs NNP N
, , N
were VBD N
studied VBN N
for IN N
compliance NN N
( ( N
presentation NN N
at IN N
the DT N
end NN N
of IN N
treatment NN N
) ) N
, , N
complete JJ N
response NN N
( ( N
alanine JJ N
aminotransferase NN N
within IN N
normal JJ N
limits NNS N
and CC N
serum NN N
hepatitis NN N
C NNP N
virus NN N
polymerase NN N
chain NN N
reaction NN N
negative JJ N
) ) N
at IN N
the DT N
end NN N
of IN N
therapy NN N
and CC N
sustained VBD N
virological JJ N
response NN N
( ( N
SVR NNP N
) ) N
. . N

RESULTS JJ N
Non-compliance NNP N
( ( N
8.2 CD N
% NN N
) ) N
in IN N
IVDUs NNP N
was VBD N
not RB N
different JJ N
from IN N
non-IVDUs JJ N
( ( N
6.8 CD N
% NN N
) ) N
( ( N
relative JJ N
risk=1.20 NN N
; : N
95 CD N
% NN N
confidence NN N
interval=0.55-2.62 NN N
) ) N
. . N

Complete JJ N
response NN N
after IN N
controlling VBG N
for IN N
hepatitis NN N
C NNP N
virus NN N
was VBD N
similar JJ N
( ( N
relative JJ N
risk=1.19 NN N
; : N
95 CD N
% NN N
confidence NN N
interval=0.89-1.60 NN N
) ) N
. . N

Controlling VBG N
for IN N
treatment NN N
arm NN N
, , N
age NN N
, , N
sex NN N
, , N
presence NN N
of IN N
cirrhosis NN N
or CC N
hepatitis NN N
C NNP N
virus NN N
viral JJ N
load NN N
before IN N
treatment NN N
did VBD N
not RB N
change VB N
these DT N
results NNS N
. . N

There EX N
was VBD N
a DT N
marginally RB N
significant JJ N
difference NN N
in IN N
the DT N
sustained JJ N
virological JJ N
response NN N
between IN N
IVDUs NNP N
( ( N
46.6 CD N
% NN N
) ) N
and CC N
non-IVDUs JJ N
( ( N
34.6 CD N
% NN N
) ) N
( ( N
relative JJ N
risk=1.35 NN N
; : N
95 CD N
% NN N
confidence NN N
interval=1.00-1.81 NN N
) ) N
, , N
also RB N
disappearing VBG N
after IN N
adjusting VBG N
for IN N
genotype NN N
. . N

No DT N
difference NN N
in IN N
compliance NN N
or CC N
sustained VBN N
virological JJ N
response NN N
was VBD N
found VBN N
between IN N
active JJ N
and CC N
non-active JJ N
IVDUs NNP N
or CC N
between IN N
IVDU NNP N
patients NNS N
in IN N
or CC N
without IN N
a DT N
methadone NN N
maintenance NN N
program NN N
. . N

CONCLUSIONS NNP N
In IN N
this DT N
group NN N
of IN N
Benelux NNP N
patients NNS N
, , N
IVDUs NNP N
showed VBD N
similar JJ N
compliance NN N
and CC N
response NN N
to TO N
treatment NN N
with IN N
interferon NN N
and CC N
ribavirin NN N
compared VBN N
with IN N
other JJ N
patients NNS N
with IN N
CHC NNP N
infection NN N
. . N

Therefore RB N
, , N
it PRP N
is VBZ N
no RB N
longer RBR N
justifiable JJ N
to TO N
withhold VB N
treatment NN N
to TO N
chronic VB N
hepatitis NN N
C NNP N
patients NNS N
who WP N
use VBP N
intravenous JJ N
drugs NNS N
. . N

-DOCSTART- -X- O O 25577772

The DT N
development NN N
and CC N
feasibility NN N
of IN N
a DT N
composite JJ N
score NN N
of IN N
echocardiographic JJ N
indices NNS N
that WDT N
may MD N
stratify VB N
outcome NN N
in IN N
patients NNS 4_p
with IN 4_p
diabetes NNS 4_p
mellitus NNS 4_p
. . N

BACKGROUND NNP N
Early JJ N
detection NN N
of IN N
changes NNS N
in IN N
cardiac JJ N
structure NN N
and CC N
function NN N
associated VBN N
with IN N
type NN 4_p
2 CD 4_p
diabetes NNS 4_p
( ( 4_p
T2DM NNP 4_p
) ) 4_p
is VBZ N
important JJ N
. . N

However RB N
when WRB N
multiple JJ N
abnormalities NNS N
are VBP N
present JJ N
, , N
combining VBG N
individual JJ N
measurements NNS N
can MD N
be VB N
subjective JJ N
. . N

This DT N
study NN N
sought VBD N
to TO N
create VB N
a DT N
simple JJ N
echo NN N
score NN N
that WDT N
summarises VBZ N
measurements NNS N
that WDT N
may MD N
detect VB N
early JJ N
and CC N
prognostically RB N
important JJ N
changes NNS N
in IN N
cardiac JJ N
function NN N
. . N

METHODS NNP N
Standard NNP N
echocardiography NN N
was VBD N
performed VBN N
on IN N
849 CD N
people NNS N
with IN N
T2DM NNP N
( ( N
median JJ N
age NN N
65years CD N
, , N
40 CD N
% NN N
female NN N
, , N
median JJ N
duration NN N
of IN N
diabetes NNS 4_p
5.5years CD N
) ) N
. . N

Principal JJ N
components NNS N
analysis NN N
was VBD N
performed VBN N
on IN N
measurements NNS N
of IN N
LV NNP N
mass NN N
, , N
LA NNP N
volume NN N
, , N
E NN N
: : N
e NN N
' '' N
, , N
and CC N
s NN N
' '' N
, , N
to TO N
create VB N
an DT N
objective JJ N
summary NN N
score NN N
. . N

The DT N
score NN N
was VBD N
included VBN N
in IN N
two CD N
Cox NNP N
proportional JJ N
hazard NN N
models NNS N
adjusted VBN N
for IN N
CV NNP N
risk NN N
factors NNS N
: : N
one CD N
estimated VBD N
the DT N
development NN N
of IN N
heart NN N
failure NN N
( ( N
HF NNP N
) ) N
and CC N
the DT N
second JJ N
estimated VBN N
any DT N
CV NNP N
event NN N
. . N

RESULTS VB N
The DT N
first JJ N
two CD N
principal JJ N
components NNS N
represented VBD N
75 CD N
% NN N
of IN N
the DT N
variation NN N
between IN N
the DT N
four CD N
echo NN N
measurements NNS N
. . N

A DT N
continuous JJ N
score NN N
that WDT N
represents VBZ N
the DT N
residual JJ N
difference NN N
between IN N
these DT N
two CD N
components NNS N
was VBD N
derived VBN N
that IN N
only RB N
requires VBZ N
measurement NN N
of IN N
medial JJ N
E NN N
: : N
e NN N
' '' N
and CC N
s VB N
' '' N
. . N

The DT N
score NN N
was VBD N
significantly RB N
associated VBN N
with IN N
the DT N
development NN N
of IN N
HF NNP N
within IN N
four CD N
years NNS N
( ( N
hazard RB N
ratio VBZ N
1.34 CD N
; : N
95 CD N
% NN N
CI NNP N
1.15 CD N
, , N
1.56 CD N
) ) N
. . N

CONCLUSIONS NNP N
We PRP N
have VBP N
developed VBN N
a DT N
simple NN N
, , N
objective JJ N
score NN N
that WDT N
enhances VBZ N
the DT N
use NN N
of IN N
echocardiography NN N
in IN N
the DT N
detection NN N
of IN N
sub-clinical JJ N
cardiac JJ N
disease NN N
in IN N
people NNS N
with IN N
T2DM NNP 4_p
. . N

Initial JJ N
findings NNS N
suggest VBP N
that IN N
it PRP N
may MD N
help VB N
identify VB N
those DT N
at IN N
increased VBN N
risk NN N
of IN N
developing VBG N
HF NNP N
within IN N
four CD N
years NNS N
. . N

-DOCSTART- -X- O O 15960148

Lanthanum NNP N
carbonate NN N
( ( N
Fosrenol NNP N
) ) N
efficacy NN N
and CC N
tolerability NN N
in IN N
the DT N
treatment NN N
of IN N
hyperphosphatemic JJ N
patients NNS N
with IN N
end-stage JJ N
renal JJ N
disease NN N
. . N

AIMS NNP N
High NNP N
serum NN N
phosphorus NN N
levels NNS N
are VBP N
a DT N
common JJ N
problem NN N
in IN N
patients NNS N
receiving VBG N
long-term JJ N
dialysis NN N
treatment NN N
. . N

Lanthanum NNP N
carbonate NN N
( ( N
Fosrenol NNP N
) ) N
is VBZ N
a DT N
new JJ N
non-aluminum JJ N
, , N
non-calcium JJ N
phosphate NN N
binder NN N
developed VBD N
for IN N
the DT N
treatment NN N
of IN N
hyperphosphatemia NN N
in IN N
patients NNS N
with IN N
end-stage JJ N
renal JJ N
disease NN N
( ( N
ESRD NNP N
) ) N
. . N

We PRP N
report VBP N
data NNS N
from IN N
a DT N
recent JJ N
trial NN N
, , N
which WDT N
, , N
for IN N
the DT N
first JJ N
time NN N
, , N
assessed VBD N
the DT N
efficacy NN N
and CC N
tolerability NN N
of IN N
lanthanum JJ N
carbonate NN N
treatment NN N
, , N
compared VBN N
with IN N
placebo NN N
, , N
in IN N
Chinese JJ N
patients NNS N
with IN N
ESRD NNP N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
Following VBG N
a DT N
one- JJ N
to TO N
three-week JJ N
washout NN N
phase NN N
and CC N
a DT N
four-week JJ N
, , N
open-label JJ N
lanthanum NN N
carbonate NN N
dose-titration NN N
phase NN N
, , N
male NN N
and CC N
female JJ N
hemodialysis NN N
patients NNS N
were VBD N
randomized VBN N
( ( N
1:1 CD N
) ) N
to TO N
receive VB N
either DT N
lanthanum NN N
carbonate NN N
or CC N
placebo NN N
for IN N
four CD N
weeks NNS N
. . N

The DT N
primary JJ N
efficacy NN N
parameter NN N
of IN N
the DT N
study NN N
was VBD N
the DT N
control NN N
of IN N
serum JJ N
phosphorus NN N
levels NNS N
( ( N
< CD N
or CC N
=1.8 VB N
mmol/l JJ N
[ NNP N
< NN N
or CC N
= $ N
5.6 CD N
mg/dl NN N
] NN N
) ) N
. . N

Secondary JJ N
endpoints NNS N
included VBD N
the DT N
profile NN N
of IN N
serum JJ N
phosphorus NN N
during IN N
titration NN N
and CC N
parathyroid NN N
hormone NN N
, , N
calcium NN N
, , N
and CC N
calcium NN N
x NN N
phosphorus NN N
( ( N
Ca NNP N
x NNP N
P NNP N
) ) N
product NN N
levels NNS N
. . N

The DT N
safety NN N
and CC N
tolerability NN N
of IN N
lanthanum NN N
carbonate NN N
were VBD N
assessed VBN N
by IN N
monitoring VBG N
adverse JJ N
events NNS N
throughout IN N
the DT N
study NN N
. . N

RESULTS NNP N
Mean NNP N
serum VBZ N
phosphorus JJ N
level NN N
at IN N
the DT N
end NN N
of IN N
washout NN N
was VBD N
2.5 CD N
+/- JJ N
0.5 CD N
mmol/l NN N
( ( N
7.7 CD N
+/- JJ N
1.5 CD N
mg/dl NN N
; : N
n=73 CC N
) ) N
, , N
and CC N
there EX N
was VBD N
no DT N
evidence NN N
of IN N
a DT N
difference NN N
in IN N
levels NNS N
between IN N
the DT N
treatment NN N
groups NNS N
pre-randomization NN N
. . N

At IN N
the DT N
end NN N
of IN N
the DT N
study NN N
, , N
lanthanum JJ N
carbonate-treated JJ N
patients NNS N
had VBD N
significantly RB N
lower JJR N
phosphorus NN N
levels NNS N
( ( N
1.6 CD N
+/- JJ N
0.5 CD N
mmol/l NN N
[ VBD N
5.1 CD N
+/- JJ N
1.5 CD N
mg/dl NN N
] NN N
; : N
n=30 CC N
) ) N
than IN N
those DT N
receiving VBG N
placebo NN N
( ( N
2.3 CD N
+/- JJ N
0.4 CD N
mmol/l NN N
[ VBD N
7.2 CD N
+/- JJ N
1.3 CD N
mg/dl NN N
] NN N
; : N
n=31 CC N
; : N
p CC N
< VB N
0.001 CD N
) ) N
. . N

In IN N
addition NN N
, , N
a DT N
significantly RB N
higher JJR N
proportion NN N
of IN N
patients NNS N
receiving VBG N
lanthanum JJ N
carbonate NN N
had VBD N
controlled VBN N
serum JJ N
phosphorus NN N
levels NNS N
( ( N
60 CD N
% NN N
) ) N
compared VBN N
with IN N
the DT N
placebo NN N
group NN N
( ( N
10 CD N
% NN N
; : N
p CC N
< VB N
0.001 CD N
) ) N
. . N

Ca NNP N
x JJ N
P NNP N
product NN N
levels NNS N
were VBD N
also RB N
significantly RB N
lower JJR N
in IN N
the DT N
lanthanum NN N
carbonate NN N
group NN N
at IN N
the DT N
end NN N
of IN N
randomized JJ N
treatment NN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

Lanthanum NNP N
carbonate NN N
was VBD N
well RB N
tolerated VBN N
; : N
only RB N
one CD N
serious JJ N
adverse JJ N
event NN N
was VBD N
reported VBN N
, , N
which WDT N
was VBD N
unrelated JJ N
to TO N
treatment NN N
. . N

CONCLUSIONS NNP N
Lanthanum NNP N
carbonate NN N
was VBD N
shown VBN N
to TO N
be VB N
an DT N
effective JJ N
and CC N
well-tolerated JJ N
phosphate NN N
binder NN N
for IN N
the DT N
treatment NN N
of IN N
hyperphosphatemia NN N
in IN N
Chinese JJ N
patients NNS N
with IN N
ESRD NNP N
. . N

This DT N
finding NN N
supports VBZ N
the DT N
results NNS N
of IN N
previous JJ N
US NNP N
and CC N
European JJ N
studies NNS N
, , N
which WDT N
have VBP N
also RB N
shown VBN N
that IN N
lanthanum NN N
carbonate NN N
treatment NN N
effectively RB N
controls VBZ N
serum JJ N
phosphorus NN N
levels NNS N
. . N

-DOCSTART- -X- O O 15915547

Enhancement NN N
of IN N
blood NN N
glucose NN N
lowering VBG N
effect NN N
of IN N
a DT N
sulfonylurea NN N
when WRB N
coadministered VBN N
with IN N
an DT N
ACE NNP N
inhibitor NN N
: : N
results NNS N
of IN N
a DT N
glucose-clamp JJ N
study NN N
. . N

BACKGROUND NNP N
To TO N
investigate VB N
if IN N
coadministration NN N
of IN N
enalapril NN N
alters NNS N
the DT N
metabolic JJ N
effect NN N
of IN N
glibenclamide NN N
by IN N
employing VBG N
an DT N
euglycemic JJ N
glucose-clamp NN N
technique NN N
in IN N
healthy JJ N
volunteers NNS N
. . N

METHODS VB N
A DT N
double-blind JJ N
crossover NN N
study NN N
with IN N
nine CD N
healthy JJ N
normotensive JJ N
volunteers NNS N
( ( N
age NN N
27 CD N
+/- JJ N
3 CD N
y NN N
, , N
BMI NNP N
23.3 CD N
+/- JJ N
2.0 CD N
kg NN N
m NN N
( ( N
-2 NNP N
) ) N
; : N
mean JJ N
+/- JJ N
SD NNP N
) ) N
-randomly RB N
assigned VBN N
to TO N
a DT N
3-day JJ N
treatment NN N
of IN N
either CC N
5 CD N
mg NN N
enalapril NN N
or CC N
placebo NN N
. . N

In IN N
the DT N
morning NN N
of IN N
the DT N
fourth JJ N
day NN N
, , N
volunteers NNS N
orally RB N
received VBD N
3.5 CD N
mg NNS N
glibenclamide RB N
together RB N
with IN N
either DT N
10 CD N
mg NN N
enalapril NN N
or CC N
placebo NN N
. . N

Blood NNP N
glucose JJ N
levels NNS N
of IN N
volunteers NNS N
were VBD N
allowed VBN N
to TO N
fall VB N
by IN N
10 CD N
% NN N
from IN N
fasting NN N
levels NNS N
and CC N
were VBD N
kept VBN N
constant JJ N
thereafter NN N
by IN N
employing VBG N
a DT N
Biostator-based JJ N
euglycemic JJ N
glucose NN N
clamp NN N
. . N

RESULTS NNP N
Coadministration NNP N
of IN N
enalapril-compared JJ N
with IN N
placebo-resulted JJ N
in IN N
a DT N
temporarily RB N
higher JJR N
metabolic JJ N
effect NN N
of IN N
glibenclamide NN N
( ( N
AUC NNP N
GIR NNP N
( ( N
0-120 NNP N
) ) N
229 CD N
+/- JJ N
173 CD N
vs JJ N
137 CD N
+/- JJ N
44 CD N
mg NN N
kg NN N
( ( N
-1 NNP N
) ) N
, , N
p JJ N
< VBP N
0.01 CD N
; : N
mean JJ N
+/- JJ N
SD NNP N
) ) N
, , N
which WDT N
lasted VBD N
from IN N
120 CD N
min NNS N
to TO N
240 CD N
min NNS N
after IN N
enalapril DT N
administration NN N
. . N

In IN N
parallel NN N
, , N
the DT N
maximal JJ N
metabolic JJ N
effect NN N
of IN N
glibenclamide NN N
tended VBD N
to TO N
be VB N
higher JJR N
with IN N
enalapril NN N
( ( N
GIR NNP N
( ( N
max NN N
) ) N
5.2 CD N
+/- JJ N
1.9 CD N
vs JJ N
4.1 CD N
+/- JJ N
1.3 CD N
mg NN N
kg NN N
( ( N
-1 NNP N
) ) N
min NN N
( ( N
-1 NNP N
) ) N
; : N
p CC N
= VB N
0.19 CD N
) ) N
. . N

However RB N
, , N
the DT N
total JJ N
metabolic JJ N
effect NN N
of IN N
glibenclamide NN N
was VBD N
almost RB N
identical JJ N
between IN N
volunteers NNS N
taking VBG N
enalapril NN N
or CC N
placebo NN N
( ( N
AUC NNP N
GIR NNP N
( ( N
0-600 CD N
) ) N
1267 CD N
+/- JJ N
334 CD N
vs JJ N
1286 CD N
+/- JJ N
249 CD N
mg NN N
kg NN N
( ( N
-1 NNP N
) ) N
, , N
ns RB N
) ) N
. . N

In IN N
contrast NN N
, , N
serum JJ N
insulin NN N
levels NNS N
, , N
C-peptide NNP N
levels NNS N
, , N
and CC N
serum JJ N
glibenclamide NN N
profiles NNS N
were VBD N
not RB N
significantly RB N
different JJ N
between IN N
enalapril NN N
and CC N
placebo NN N
. . N

CONCLUSIONS VB N
The DT N
results NNS N
of IN N
this DT N
study NN N
may MD N
explain VB N
the DT N
higher JJR N
incidence NN N
of IN N
hypoglycemic JJ N
episodes NNS N
observed VBN N
in IN N
patients NNS N
with IN N
type JJ N
2 CD N
diabetes NNS N
when WRB N
taking VBG N
ACE NNP N
inhibitors NNS N
together RB N
with IN N
sulfonylureas NNS N
or CC N
insulin NN N
. . N

ACE NNP N
inhibitors NNS N
may MD N
cause VB N
a DT N
temporary JJ N
increase NN N
of IN N
the DT N
insulin NN N
sensitivity NN N
, , N
which WDT N
leads VBZ N
to TO N
an DT N
increased VBN N
risk NN N
of IN N
hypoglycemia NN N
under IN N
these DT N
conditions NNS N
. . N

-DOCSTART- -X- O O 24637998

Omitting VBG N
radiotherapy NN N
in IN N
early JJ N
positron NN N
emission NN N
tomography-negative JJ N
stage NN N
I/II NNP N
Hodgkin NNP N
lymphoma NN N
is VBZ N
associated VBN N
with IN N
an DT N
increased VBN N
risk NN N
of IN N
early JJ N
relapse NN N
: : N
Clinical JJ N
results NNS N
of IN N
the DT N
preplanned JJ N
interim JJ N
analysis NN N
of IN N
the DT N
randomized JJ N
EORTC/LYSA/FIL NNP N
H10 NNP N
trial NN N
. . N

PURPOSE NNP N
Combined-modality NNP N
treatment NN N
is VBZ N
standard JJ N
treatment NN N
for IN N
patients NNS N
with IN N
clinical JJ N
stage NN N
I/II NNP N
Hodgkin NNP N
lymphoma NN N
( ( N
HL NNP N
) ) N
. . N

We PRP N
hypothesized VBD N
that IN N
an DT N
early JJ N
positron NN N
emission NN N
tomography NN N
( ( N
PET NNP N
) ) N
scan NN N
could MD N
be VB N
used VBN N
to TO N
adapt VB N
treatment NN N
. . N

Therefore RB N
, , N
we PRP N
started VBD N
the DT N
randomized VBN N
EORTC/LYSA/FIL NNP N
Intergroup NNP N
H10 NNP N
trial NN N
evaluating VBG N
whether IN N
involved-node JJ N
radiotherapy NN N
( ( N
IN-RT NNP N
) ) N
could MD N
be VB N
omitted VBN N
without IN N
compromising VBG N
progression-free JJ N
survival NN N
in IN N
patients NNS N
attaining VBG N
a DT N
negative JJ N
early JJ N
PET NNP N
scan NN N
after IN N
two CD N
cycles NNS N
of IN N
ABVD NNP N
( ( N
doxorubicin NN N
, , N
bleomycin NN N
, , N
vinblastine NN N
, , N
and CC N
dacarbazine NN N
) ) N
as IN N
compared VBN N
with IN N
standard JJ N
combined-modality NN N
treatment NN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
Patients NNP N
age NN N
15 CD N
to TO N
70 CD N
years NNS N
with IN N
untreated JJ N
clinical JJ N
stage NN N
I/II NNP N
HL NNP N
were VBD N
eligible JJ N
. . N

Here RB N
we PRP N
report VBP N
the DT N
clinical JJ N
outcome NN N
of IN N
the DT N
preplanned JJ N
interim JJ N
futility NN N
analysis NN N
scheduled VBN N
to TO N
occur VB N
after IN N
documentation NN N
of IN N
34 CD N
events NNS N
in IN N
the DT N
early JJ N
PET-negative JJ N
group NN N
. . N

Because IN N
testing VBG N
for IN N
futility NN N
in IN N
this DT N
noninferiority NN N
trial NN N
corresponds NNS N
to TO N
testing VBG N
the DT N
hypothesis NN N
of IN N
no DT N
difference NN N
, , N
a DT N
one-sided JJ N
superiority NN N
test NN N
was VBD N
conducted VBN N
. . N

RESULTS VB N
The DT N
analysis NN N
included VBD N
1,137 CD N
patients NNS N
. . N

In IN N
the DT N
favorable JJ N
subgroup NN N
, , N
85.8 CD N
% NN N
had VBD N
a DT N
negative JJ N
early JJ N
PET JJ N
scan JJ N
( ( N
standard JJ N
arm NN N
, , N
one CD N
event NN N
v NN N
experimental JJ N
arm NN N
, , N
nine CD N
events NNS N
) ) N
. . N

In IN N
the DT N
unfavorable JJ N
subgroup NN N
, , N
74.8 CD N
% NN N
had VBD N
a DT N
negative JJ N
early JJ N
PET JJ N
scan JJ N
( ( N
standard JJ N
arm NN N
, , N
seven CD N
events NNS N
v JJ N
experimental JJ N
arm NN N
, , N
16 CD N
events NNS N
) ) N
. . N

The DT N
independent JJ N
data NNS N
monitoring NN N
committee NN N
concluded VBD N
it PRP N
was VBD N
unlikely JJ N
that IN N
we PRP N
would MD N
show VB N
noninferiority NN N
in IN N
the DT N
final JJ N
results NNS N
for IN N
the DT N
experimental JJ N
arm NN N
and CC N
advised VBD N
stopping VBG N
random JJ N
assignment NN N
for IN N
early JJ N
PET-negative JJ N
patients NNS N
. . N

CONCLUSION NNP N
On IN N
the DT N
basis NN N
of IN N
this DT N
analysis NN N
, , N
combined-modality NN N
treatment NN N
resulted VBD N
in IN N
fewer JJR N
early JJ N
progressions NNS N
in IN N
clinical JJ N
stage NN N
I/II NNP N
HL NNP N
, , N
although IN N
early JJ N
outcome NN N
was VBD N
excellent JJ N
in IN N
both DT N
arms NNS N
. . N

The DT N
final JJ N
analysis NN N
will MD N
reveal VB N
whether IN N
this DT N
finding NN N
is VBZ N
maintained VBN N
over IN N
time NN N
. . N

-DOCSTART- -X- O O 7670096

Results NNS N
of IN N
a DT N
phase NN N
I/II NNP N
trial NN N
of IN N
recombinant JJ N
human JJ N
granulocyte-macrophage NN N
colony-stimulating NN N
factor NN N
in IN N
very RB N
low JJ N
birthweight NN N
neonates NNS N
: : N
significant JJ N
induction NN N
of IN N
circulatory NN N
neutrophils NNS N
, , N
monocytes NNS N
, , N
platelets NNS N
, , N
and CC N
bone NN N
marrow NN N
neutrophils NNS N
. . N

Neonates NNS N
, , N
especially RB N
those DT N
of IN N
very RB N
low JJ N
birthweight NN N
( ( N
VLBW NNP N
) ) N
, , N
have VBP N
an DT N
increased VBN N
risk NN N
of IN N
nosocomial JJ N
infections NNS N
secondary JJ N
to TO N
deficiencies NNS N
in IN N
development NN N
. . N

We PRP N
previously RB N
demonstrated VBD N
that IN N
granulocyte-macrophage JJ N
colony-stimulating JJ N
factor NN N
( ( N
GM-CSF NNP N
) ) N
production NN N
and CC N
mRNA JJ N
expression NN N
from IN N
stimulated VBN N
neonatal JJ N
mononuclear JJ N
cells NNS N
are VBP N
significantly RB N
less JJR N
than IN N
that DT N
from IN N
adult NN N
cells NNS N
. . N

Recombinant JJ N
murine JJ N
GM-CSF NNP N
administration NN N
to TO N
neonatal JJ N
rats NNS N
has VBZ N
resulted VBN N
in IN N
neutrophilia JJ N
, , N
increased JJ N
neutrophil NN N
production NN N
, , N
and CC N
increased VBD N
survival NN N
of IN N
pups NNS N
during IN N
experimental JJ N
Staphylococcus NNP N
aureus NN N
sepsis NN N
. . N

In IN N
the DT N
present JJ N
study NN N
, , N
we PRP N
sought VBD N
to TO N
determine VB N
the DT N
safety NN N
and CC N
biologic JJ N
response NN N
of IN N
recombinant JJ N
human JJ N
( ( N
rhu NN N
) ) N
GM-CSF NNP N
in IN N
VLBW NNP N
neonates NNS N
. . N

Twenty NNP N
VLBW NNP N
neonates NNS N
( ( N
500 CD N
to TO N
1,500 CD N
g NN N
) ) N
, , N
aged VBD N
< JJ N
72 CD N
hours NNS N
, , N
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
placebo NN N
( ( N
n JJ N
= NNP N
5 CD N
) ) N
or CC N
rhuGM-CSF NN N
at IN N
5.0 CD N
micrograms/kg NN N
once RB N
per IN N
day NN N
( ( N
n JJ N
= NNP N
5 CD N
) ) N
, , N
5.0 CD N
micrograms/kg NN N
twice RB N
per IN N
day NN N
( ( N
n JJ N
= NNP N
5 CD N
) ) N
, , N
or CC N
10 CD N
micrograms/kg NN N
once RB N
per IN N
day NN N
( ( N
n JJ N
= NNP N
5 CD N
) ) N
given VBN N
via IN N
2-hour JJ N
intravenous JJ N
infusion NN N
for IN N
7 CD N
days NNS N
. . N

Complete JJ N
blood NN N
counts NNS N
, , N
differential NN N
, , N
and CC N
platelet NN N
counts NNS N
were VBD N
obtained VBN N
, , N
and CC N
tibial JJ N
bone NN N
marrow NN N
aspirate NN N
was VBD N
performed VBN N
on IN N
day NN N
8 CD N
. . N

Neutrophil NNP N
C3bi NNP N
receptor NN N
expression NN N
was VBD N
measured VBN N
at IN N
0 CD N
and CC N
24 CD N
hours NNS N
. . N

GM-CSF JJ N
levels NNS N
were VBD N
measured VBN N
by IN N
a DT N
sandwich JJ N
enzyme-linked JJ N
immunosorbent NN N
assay NN N
at IN N
2 CD N
, , N
4 CD N
, , N
6 CD N
, , N
12 CD N
, , N
and CC N
24 CD N
hours NNS N
after IN N
the DT N
first JJ N
dose NN N
of IN N
rhuGM-CSF NN N
. . N

At IN N
all DT N
doses NNS N
, , N
rhuGM-CSF NN N
was VBD N
well RB N
tolerated VBN N
, , N
and CC N
there EX N
was VBD N
no DT N
evidence NN N
of IN N
grade NN N
III NNP N
or CC N
IV NNP N
toxicity NN N
. . N

Within IN N
48 CD N
hours NNS N
of IN N
administration NN N
, , N
there EX N
was VBD N
a DT N
significant JJ N
increase NN N
in IN N
the DT N
circulating VBG N
absolute JJ N
neutrophil NN N
count NN N
( ( N
ANC NNP N
) ) N
at IN N
5.0 CD N
micrograms/kg NN N
twice RB N
per IN N
day NN N
and CC N
10.0 CD N
micrograms/kg NN N
once RB N
per IN N
day NN N
, , N
which WDT N
continued VBD N
for IN N
at IN N
least JJS N
24 CD N
hours NNS N
after IN N
discontinuation NN N
of IN N
rhuGM-CSF NN N
. . N

When WRB N
the DT N
ANC NNP N
was VBD N
normalized VBN N
for IN N
each DT N
patient NN N
's POS N
first JJ N
ANC NNP N
, , N
there EX N
was VBD N
a DT N
significant JJ N
increase NN N
in IN N
the DT N
ANC NNP N
on IN N
days NNS N
6 CD N
and CC N
7 CD N
at IN N
each DT N
dose JJ N
level NN N
. . N

By IN N
day NN N
7 CD N
, , N
all DT N
tested JJ N
doses NNS N
of IN N
rhuGM-CSF NN N
resulted VBD N
in IN N
an DT N
increase NN N
in IN N
the DT N
absolute NN N
monocyte NN N
count NN N
( ( N
AMC NNP N
) ) N
compared VBN N
with IN N
placebo-treated JJ N
neonates NNS N
. . N

In IN N
those DT N
receiving VBG N
rhuGM-CSF JJ N
5.0 CD N
micrograms/kg NN N
twice RB N
per IN N
day NN N
, , N
there EX N
was VBD N
additionally RB N
a DT N
significant JJ N
increase NN N
in IN N
the DT N
day NN N
7 CD N
and CC N
8 CD N
platelet NN N
count NN N
. . N

Tibial NNP N
bone NN N
marrow NN N
aspirates VBZ N
demonstrated VBD N
a DT N
significant JJ N
increase NN N
in IN N
the DT N
bone NN N
marrow NN N
neutrophil JJ N
storage NN N
pool NN N
( ( N
BM NNP N
NSP NNP N
) ) N
at IN N
5.0 CD N
micrograms/kg NN N
twice RB N
per IN N
day NN N
and CC N
10.0 CD N
micrograms/kg NN N
once RB N
per IN N
day NN N
. . N

Neutrophil NNP N
C3bi NNP N
receptor NN N
expression NN N
was VBD N
significantly RB N
increased VBN N
24 CD N
hours NNS N
after IN N
the DT N
first JJ N
dose NN N
of IN N
rhuGM-CSF NN N
at IN N
5.0 CD N
micrograms/kg NN N
once RB N
per IN N
day NN N
. . N

The DT N
elimination NN N
half-life NN N
( ( N
T1/2 NNP N
) ) N
of IN N
rhuGM-CSF NN N
was VBD N
1.4 CD N
+/- JJ N
0.8 CD N
to TO N
3.9 CD N
+/- JJ N
2.8 CD N
hours NNS N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
400 CD N
WORDS NNP N
) ) N
-DOCSTART- -X- O O 1721246

Bradykinin-induced JJ N
cough NN N
reflex NN N
markedly RB N
increases VBZ N
in IN N
patients NNS N
with IN N
cough NN 4_p
associated VBN 4_p
with IN 4_p
captopril NN 4_p
and CC 4_p
enalapril NN 4_p
. . N

We PRP N
studied VBD N
the DT N
effects NNS N
of IN N
angiotensin NN N
converting VBG N
enzyme NN N
( ( N
ACE NNP N
) ) N
inhibitors NNS N
on IN N
cough NN N
responses NNS N
to TO N
bradykinin VB N
( ( N
BK NNP N
) ) N
, , N
substance NN N
P NNP N
( ( N
SP NNP N
) ) N
and CC N
citric JJ N
acid NN N
in IN N
a DT N
double JJ N
blind NN N
, , N
random NN N
study NN N
on IN N
10 CD N
hypertensive JJ 4_p
patients NNS N
receiving VBG N
ACE NNP N
inhibitors NNS N
. . N

Of IN N
these DT N
patients NNS N
, , N
five CD N
had VBD N
reported VBN N
cough NN 4_p
with IN N
ACE NNP N
inhibitors NNS N
. . N

Cough NNP N
responses VBZ N
to TO N
citric VB N
acid NN N
were VBD N
similar JJ N
between IN N
patients NNS N
with IN N
and CC N
without IN N
cough NN N
, , N
and CC N
SP NNP N
up RB N
to TO N
10 CD N
( ( N
-5 NN N
) ) N
M NNP N
did VBD N
not RB N
cause VB N
cough NN N
in IN N
any DT N
of IN N
the DT N
subjects NNS N
. . N

BK NNP N
caused VBD N
cough NN N
at IN N
13.4 CD N
+/- JJ N
1.2 CD N
( ( N
-log NNP N
M NNP N
) ) N
in IN N
5 CD N
patients NNS N
with IN N
cough NN N
associated VBN N
with IN N
ACE NNP N
inhibitors NNS N
, , N
but CC N
it PRP N
did VBD N
not RB N
cause VB N
cough NN N
at IN N
concentrations NNS N
up RB N
to TO N
10 CD N
( ( N
-5 NN N
) ) N
M NNP N
in IN N
other JJ N
5 CD N
patients NNS N
. . N

One CD N
month NN N
after IN N
the DT N
withdrawal NN N
of IN N
ACE NNP N
inhibitors NNS N
, , N
5 CD N
patients NNS N
were VBD N
free JJ N
from IN N
cough NN N
symptoms NNS N
, , N
and CC N
BK NNP N
did VBD N
not RB N
cause VB N
cough NN N
up RB N
to TO N
10 CD N
( ( N
-5 NN N
) ) N
M NNP N
in IN N
these DT N
patients NNS N
, , N
except IN N
for IN N
one CD N
who WP N
coughed VBD N
at IN N
10 CD N
( ( N
-9 NN N
) ) N
M NNP N
, , N
without IN N
changes NNS N
in IN N
responses NNS N
to TO N
citric VB N
acid NN N
. . N

BK NNP N
caused VBD N
cough NN N
at IN N
14.3 CD N
+/- JJ N
0.7 CD N
( ( N
-log NNP N
M NNP N
) ) N
although IN N
BK1-7 NNP N
, , N
a DT N
major JJ N
metabolite NN N
of IN N
BK NNP N
by IN N
ACE NNP N
, , N
caused VBD N
cough NN N
at IN N
5.7 CD N
+/- JJ N
0.7 CD N
( ( N
-log NNP N
M NNP N
) ) N
in IN N
another DT N
3 CD N
patients NNS N
with IN N
cough NN N
associated VBN N
with IN N
ACE NNP N
inhibitor NN N
. . N

These DT N
results NNS N
suggest VBP N
that IN N
impaired JJ N
metabolism NN N
of IN N
BK NNP N
induced VBN N
by IN N
ACE NNP N
inhibitors NNS N
may MD N
relate VB N
to TO N
the DT N
manifestation NN N
of IN N
cough NN N
in IN N
hypertensive JJ N
patients NNS N
receiving VBG N
ACE NNP N
inhibitors NNS N
. . N

-DOCSTART- -X- O O 12663340

Dose-response JJ N
characteristics NNS N
during IN N
long-term JJ N
inhalation NN N
of IN N
nitric JJ N
oxide NN N
in IN N
patients NNS N
with IN N
severe JJ 4_p
acute JJ 4_p
respiratory NN 4_p
distress JJ 4_p
syndrome NN 4_p
: : N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
controlled VBN N
study NN N
. . N

Inhaled VBN N
nitric JJ N
oxide NN N
( ( N
NO NNP N
) ) N
improves VBZ N
systemic JJ N
oxygenation NN N
( ( N
PaO2/FIO2 NNP N
) ) N
in IN N
adult NN N
patients NNS N
with IN N
acute JJ 4_p
respiratory NN 4_p
distress NN 4_p
syndrome NN 4_p
( ( 4_p
ARDS NNP 4_p
) ) 4_p
. . N

However RB N
, , N
individual JJ N
response NN N
varies NNS N
, , N
and CC N
previous JJ N
trials NNS N
demonstrated VBD N
no DT N
outcome NN N
benefit NN N
. . N

This DT N
prospective JJ N
, , N
randomized VBN N
study NN N
in IN N
40 CD N
ARDS NNP 4_p
patients NNS N
analyzed VBD N
dose-response JJ N
( ( N
DR NNP N
) ) N
characteristics NNS N
during IN N
long-term JJ N
inhaled JJ N
NO NNP N
. . N

Patients NNS N
were VBD N
randomized VBN N
for IN N
conventional JJ N
therapy NN N
( ( N
control NN N
) ) N
or CC N
continuous JJ N
treatment NN N
with IN N
10 CD N
parts NNS N
per IN N
million CD N
( ( N
ppm NN N
) ) N
inhaled VBD N
NO NNP N
until IN N
weaning VBG N
was VBD N
initiated VBN N
. . N

We PRP N
measured VBD N
DR NNP N
curves NNS N
of IN N
PaO2/FIO2 NNP N
versus IN N
the DT N
inhaled JJ N
NO NNP N
dose NN N
at IN N
regular JJ N
intervals NNS N
. . N

Before IN N
treatment NN N
( ( N
Day NNP N
0 CD N
) ) N
, , N
peak JJ N
improvement NN N
in IN N
PaO2/FIO2 NNP N
was VBD N
achieved VBN N
at IN N
10 CD N
ppm NN N
for IN N
both DT N
control NN N
and CC N
NO-treated JJ N
patients NNS N
. . N

After IN N
4 CD N
days NNS N
, , N
the DT N
DR NNP N
curve NN N
of IN N
the DT N
NO-treated JJ N
patients NNS N
was VBD N
left VBN N
shifted VBN N
with IN N
a DT N
peak JJ N
response NN N
at IN N
1 CD N
ppm NN N
. . N

At IN N
higher JJR N
doses NNS N
( ( N
10 CD N
and CC N
100 CD N
ppm NN N
) ) N
, , N
oxygenation NN N
deteriorated VBD N
, , N
and CC N
the DT N
response NN N
to TO N
inhaled VB N
NO RB N
disappeared VBN N
in IN N
several JJ N
patients NNS N
. . N

This DT N
effect NN N
was VBD N
not RB N
observed VBN N
in IN N
the DT N
control NN N
group NN N
. . N

There EX N
was VBD N
no DT N
effect NN N
of IN N
inhaled JJ N
NO NNP N
on IN N
duration NN N
of IN N
mechanical JJ N
ventilation NN N
or CC N
stay VB N
at IN N
the DT N
intensive JJ N
care NN N
unit NN N
. . N

In IN N
conclusion NN N
, , N
long-term JJ N
inhaled VBD N
NO NNP N
with IN N
constant JJ N
doses NNS N
of IN N
10 CD N
ppm NNS N
leads VBZ N
to TO N
enhanced VB N
sensitivity NN N
after IN N
several JJ N
days NNS N
and CC N
does VBZ N
do VB N
not RB N
allow VB N
reduction NN N
of IN N
ventilation NN N
parameters NNS N
. . N

Hence NNP N
, , N
previous JJ N
trials NNS N
on IN N
therapy NN N
with IN N
inhaled JJ N
NO NNP N
in IN N
ARDS NNP N
should MD N
be VB N
carefully RB N
interpreted VBN N
, , N
as IN N
they PRP N
used VBD N
constant JJ N
NO NNP N
concentrations NNS N
, , N
which WDT N
may MD N
have VB N
become VBN N
overdoses NNS N
leading VBG N
to TO N
deterioration NN N
of IN N
oxygenation NN N
after IN N
several JJ N
days NNS N
. . N

-DOCSTART- -X- O O 12928692

Evaluation NN N
of IN N
the DT N
effect NN N
of IN N
acetazolamide NN N
on IN N
cystoid NN 4_p
macular NN 4_p
oedema NN 4_p
in IN N
patients NNS N
with IN N
Behcet NNP 4_p
's POS 4_p
disease NN 4_p
. . N

AIM NNP N
To TO N
study VB N
the DT N
effect NN N
of IN N
acetazolamide NN N
on IN N
cystoid NN N
macular NN N
oedema NN N
( ( N
CMO NNP N
) ) N
in IN N
patients NNS N
with IN N
Behcet NNP 4_p
's POS 4_p
disease NN 4_p
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
A NNP N
total NN N
of IN N
67 CD N
eyes NNS N
of IN N
35 CD N
Behcet NNP N
's POS N
patients NNS N
with IN N
chronic JJ 4_p
, , 4_p
but CC 4_p
well-controlled JJ 4_p
uveitis NN 4_p
, , 4_p
and CC 4_p
CMO NNP 4_p
were VBD N
randomised VBN N
into IN N
a DT N
double-masked JJ N
, , N
crossover JJ N
trial NN N
comparing VBG N
the DT N
effect NN N
of IN N
acetazolamide NN N
vs NN N
placebo NN N
. . N

The DT N
patients NNS N
received VBD N
an DT N
initial JJ N
4-week JJ N
course NN N
of IN N
either CC N
250 CD N
mg NN N
acetazolamide JJ N
twice RB N
daily RB N
( ( N
b.i.d NN N
. . N

) ) N
or CC N
placebo NN N
, , N
followed VBN N
by IN N
a DT N
4-week JJ N
washout NN N
period NN N
. . N

They PRP N
then RB N
received VBD N
a DT N
4-week JJ N
course NN N
of IN N
the DT N
reverse NN N
study NN N
medication NN N
. . N

An DT N
improvement NN N
in IN N
visual JJ N
acuity NN N
and CC N
fundus NN N
fluorescein VBP N
angiographic JJ N
findings NNS N
was VBD N
assessed VBN N
. . N

RESULTS NNP N
In IN N
total JJ N
, , N
29 CD N
patients NNS N
( ( N
55 CD N
eyes NNS N
) ) N
completed VBD N
the DT N
trial NN N
and CC N
were VBD N
available JJ N
for IN N
analysis NN N
. . N

Of IN N
the DT N
29 CD N
, , N
16 CD N
men NNS N
and CC N
13 CD N
were VBD N
women NNS N
. . N

The DT N
age NN N
range NN N
was VBD N
13-50 JJ N
years NNS N
( ( N
mean JJ N
33.6 CD N
years NNS N
) ) N
. . N

Patients NNS N
on IN N
acetazolamide NN N
showed VBD N
a DT N
slightly RB N
better RBR N
improvement NN N
of IN N
angiographic JJ N
signs NNS N
( ( N
at IN N
least JJS N
by IN N
one CD N
grade NN N
improvement NN N
) ) N
over IN N
that DT N
of IN N
placebo NN N
( ( N
12 CD N
vs NN N
five CD N
eyes NNS N
) ) N
. . N

They PRP N
also RB N
had VBD N
less JJR N
deterioration NN N
of IN N
angiographic JJ N
signs NNS N
over IN N
that DT N
of IN N
placebo NN N
( ( N
three CD N
vs NN N
seven CD N
eyes NNS N
) ) N
. . N

However RB N
, , N
these DT N
findings NNS N
were VBD N
not RB N
statistically RB N
significant JJ N
( ( N
P=0.99 NNP N
) ) N
. . N

Acetazolamide NNP N
had VBD N
no DT N
statistically RB N
significant JJ N
effect NN N
( ( N
P=0.53 NNP N
) ) N
on IN N
the DT N
improvement NN N
of IN N
visual JJ N
acuity NN N
of IN N
patients NNS N
over IN N
that DT N
of IN N
placebo NN N
( ( N
13 CD N
vs NN N
eight CD N
eyes NNS N
) ) N
, , N
nor CC N
on IN N
the DT N
deterioration NN N
of IN N
visual JJ N
acuity NN N
( ( N
three CD N
vs NN N
11 CD N
eyes NNS N
) ) N
. . N

CONCLUSION NNP N
Despite IN N
seemingly RB N
favourable JJ N
results NNS N
, , N
the DT N
4-week JJ N
course NN N
of IN N
acetazolamide NN N
( ( N
250 CD N
mg NN N
b.i.d NN N
. . N

) ) N
has VBZ N
no DT N
statistically RB N
significant JJ N
effect NN N
on IN N
the DT N
improvement NN N
of IN N
the DT N
visual JJ N
acuity NN N
and CC N
the DT N
fluorescein NN N
angiographic JJ N
findings NNS N
in IN N
Behcet NNP 4_p
's POS 4_p
patients NNS N
with IN N
CMO NNP N
. . N

-DOCSTART- -X- O O 16950955

A DT N
controlled VBN N
, , N
randomized VBN N
, , N
double-blind JJ N
trial NN N
to TO N
evaluate VB N
the DT N
effect NN N
of IN N
a DT N
supplement NN N
of IN N
cocoa NN N
husk NN N
that WDT N
is VBZ N
rich JJ N
in IN N
dietary JJ N
fiber NN N
on IN N
colonic JJ N
transit NN N
in IN N
constipated JJ 4_p
pediatric JJ N
patients NNS 4_p
. . 4_p

OBJECTIVE NNP N
Although IN N
a DT N
diet JJ N
that WDT N
is VBZ N
rich JJ N
in IN N
fiber NN N
is VBZ N
widely RB N
recommended VBN N
for IN N
preventing VBG N
and CC N
treating VBG N
constipation NN N
, , N
the DT N
efficacy NN N
of IN N
fiber NN N
supplements NNS N
have VBP N
not RB N
been VBN N
tested VBN N
sufficiently RB N
in IN N
children NNS N
. . N

Our PRP$ N
aim NN N
with IN N
this DT N
pilot NN N
study NN N
was VBD N
to TO N
evaluate VB N
if IN N
fiber JJ N
supplementation NN N
is VBZ N
beneficial JJ N
for IN N
the DT N
treatment NN N
of IN N
children NNS N
with IN N
idiopathic JJ N
chronic JJ N
constipation NN N
. . N

METHODS NNP N
Using VBG N
a DT N
parallel NN N
, , N
randomized VBN N
, , N
double-blind NN N
, , N
controlled VBN N
trial NN N
, , N
we PRP N
conducted VBD N
an DT N
interventional JJ N
study NN N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
a DT N
supplement NN N
of IN N
cocoa NN N
husk NN N
rich JJ N
in IN N
dietary JJ N
fiber NN N
on IN N
intestinal JJ N
transit NN N
time NN N
and CC N
other JJ N
indices NNS N
of IN N
constipation NN N
in IN N
children NNS 4_p
with IN 4_p
constipation NN 4_p
. . 4_p

After IN N
screening VBG N
, , N
the DT N
patients NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
receive VB N
, , N
for IN N
a DT N
period NN N
of IN N
4 CD N
weeks NNS N
, , N
either CC N
a DT N
cocoa NN N
husk NN N
supplement NN N
or CC N
placebo NN N
plus CC N
standardized JJ N
toilet NN N
training NN N
procedures NNS N
. . N

Before IN N
and CC N
after IN N
4 CD N
weeks NNS N
of IN N
treatment NN N
, , N
we PRP N
( ( N
1 CD N
) ) N
performed VBD N
anthropometry NN N
, , N
a DT N
physical JJ N
examination NN N
, , N
and CC N
routine JJ N
laboratory NN N
measurements NNS N
, , N
( ( N
2 CD N
) ) N
determined VBN N
total JJ N
and CC N
segmental JJ N
colonic JJ N
transit NN N
time NN N
, , N
( ( N
3 CD N
) ) N
evaluated VBD N
bowel JJ N
movement NN N
habits NNS N
and CC N
stool NN N
consistency NN N
using VBG N
a DT N
diary JJ N
, , N
and CC N
( ( N
4 CD N
) ) N
received VBD N
a DT N
subjective JJ N
evaluation NN N
from IN N
the DT N
parents NNS N
regarding VBG N
the DT N
efficacy NN N
of IN N
the DT N
treatment NN N
. . N

The DT N
main JJ N
variable NN N
for IN N
verifying VBG N
the DT N
efficacy NN N
of IN N
the DT N
treatment NN N
was VBD N
the DT N
total JJ N
colonic JJ N
transit NN N
time NN N
. . N

RESULTS VB N
Fifty-six NNP N
chronically RB 4_p
constipated VBD 4_p
children NNS 4_p
were VBD 4_p
randomly RB 4_p
assigned VBN 4_p
into IN 4_p
the DT 4_p
study NN 4_p
, , 4_p
but CC 4_p
only RB 4_p
48 CD N
children NNS 4_p
completed VBD 4_p
it PRP 4_p
. . 4_p

These DT N
children NNS N
, , N
who WP N
were VBD N
aged VBN N
between IN N
3 CD N
and CC N
10 CD N
years NNS N
, , N
had VBD N
a DT N
diagnosis NN N
of IN N
chronic JJ 4_p
idiopathic JJ 4_p
constipation NN 4_p
. . N

With IN N
respect NN N
to TO N
total JJ N
, , N
partial JJ N
colon NN N
, , N
and CC N
rectum VB N
transit NN N
time NN N
, , N
there EX N
seemed VBN N
to TO N
be VB N
a DT N
trend NN N
, , N
although IN N
statistically RB N
nonsignificant JJ N
, , N
toward IN N
faster JJR N
transit NN N
times NNS N
in IN N
the DT N
cocoa NN N
husk NN N
group NN N
than IN N
in IN N
the DT N
placebo NN N
group NN N
. . N

When WRB N
we PRP N
analyzed VBD N
the DT N
evolution NN N
of IN N
the DT N
intestinal JJ N
transit NN N
time NN N
throughout IN N
the DT N
study NN N
of IN N
children NNS N
whose WP$ N
total JJ N
basal JJ N
intestinal JJ N
transit NN N
time NN N
was VBD N
> JJ N
50th JJ N
percentile NN N
, , N
significant JJ N
differences NNS N
were VBD N
observed VBN N
between IN N
the DT N
groups NNS N
. . N

The DT N
total JJ N
transit NN N
time NN N
decreased VBN N
by IN N
45.4 CD N
+/- JJ N
38.4 CD N
hours NNS N
in IN N
the DT N
cocoa NN N
husk NN N
group NN N
and CC N
by IN N
8.7 CD N
+/- JJ N
28.9 CD N
hours NNS N
in IN N
the DT N
placebo NN N
group NN N
( ( N
-38.1 NNP N
hours NNS N
) ) N
. . N

In IN N
the DT N
case NN N
of IN N
the DT N
right JJ N
colon NN N
, , N
changes NNS N
in IN N
transit NN N
time NN N
also RB N
were VBD N
significant JJ N
between IN N
groups NNS N
. . N

Mean NNP N
changes NNS N
tended VBD N
toward IN N
faster RBR N
transit NN N
times NNS N
in IN N
the DT N
left NN N
colon NN N
and CC N
the DT N
rectum NN N
, , N
although IN N
the DT N
differences NNS N
were VBD N
not RB N
statistically RB N
significant JJ N
. . N

The DT N
children NNS N
who WP N
received VBD N
cocoa NN N
husk NN N
supplements NNS N
tended VBD N
to TO N
increase VB N
the DT N
number NN N
of IN N
bowel NN N
movements NNS N
by IN N
more JJR N
than IN N
that DT N
of IN N
the DT N
children NNS N
of IN N
the DT N
placebo NN N
group NN N
. . N

We PRP N
also RB N
observed VBD N
a DT N
reduction NN N
in IN N
the DT N
percentage NN N
of IN N
patients NNS N
who WP N
reported VBD N
hard JJ N
stools NNS N
( ( N
hard JJ N
scybalous JJ N
or CC N
pebble-like JJ N
stools NNS N
) ) N
, , N
although IN N
this DT N
reduction NN N
was VBD N
significantly RB N
greater JJR N
in IN N
the DT N
cocoa NN N
husk NN N
group NN N
. . N

At IN N
the DT N
end NN N
of IN N
the DT N
intervention NN N
, , N
41.7 CD N
% NN N
and CC N
75.0 CD N
% NN N
of IN N
the DT N
patients NNS N
who WP N
received VBD N
cocoa NN N
husk NN N
supplementation NN N
or CC N
placebo NN N
, , N
respectively RB N
, , N
reported VBD N
having VBG N
hard JJ N
stools NNS N
. . N

Moreover RB N
, , N
a DT N
significantly RB N
higher JJR N
number NN N
of IN N
children NNS N
( ( N
or CC N
their PRP$ N
parents NNS N
) ) N
reported VBD N
a DT N
subjective JJ N
improvement NN N
in IN N
stool JJ N
consistency NN N
. . N

No DT N
significant JJ N
adverse JJ N
effects NNS N
were VBD N
reported VBN N
during IN N
the DT N
study NN N
. . N

CONCLUSIONS NNP N
This DT N
study NN N
confirms VBZ N
the DT N
beneficial JJ N
effect NN N
of IN N
a DT N
supplement NN N
of IN N
cocoa NN N
husk NN N
that WDT N
is VBZ N
rich JJ N
in IN N
dietary JJ N
fiber NN N
on IN N
chronic JJ N
idiopathic JJ N
constipation NN N
in IN N
children NNS N
. . N

These DT N
benefits NNS N
seem VBP N
to TO N
be VB N
more RBR N
evident JJ N
in IN N
pediatric JJ N
constipated JJ N
patients NNS N
with IN N
slow JJ N
colonic JJ N
transit NN N
time NN N
. . N

-DOCSTART- -X- O O 10470636

Effect NN N
of IN N
spinal JJ N
versus NN N
general JJ N
anesthesia NN N
on IN N
bladder NN N
compliance NN N
and CC N
intraabdominal JJ N
pressure NN N
during IN N
transurethral JJ N
procedures NNS N
. . N

STUDY NNP N
OBJECTIVE NNP N
To TO N
evaluate VB N
the DT N
influence NN N
of IN N
spinal JJ N
versus NN N
general JJ N
anesthesia NN N
on IN N
bladder NN N
compliance NN N
and CC N
intraabdominal JJ N
pressure NN N
in IN N
elderly JJ N
males NNS N
undergoing VBG 4_p
elective JJ 4_p
transurethral JJ 4_p
resection NN 4_p
of IN 4_p
the DT 4_p
prostate NN 4_p
. . N

DESIGN NNP N
Prospective NNP N
, , N
randomized VBD N
, , N
open-label JJ N
study NN N
. . N

SETTING NN N
Teaching NNP N
hospital NN N
. . N

PATIENTS CC N
21 CD N
ASA NNP 4_p
physical JJ 4_p
status NN 4_p
I PRP 4_p
, , 4_p
II NNP 4_p
, , 4_p
and CC 4_p
III NNP 4_p
patients NNS 4_p
at IN N
least JJS N
18 CD N
years NNS N
of IN N
age NN N
, , N
undergoing VBG N
transurethral JJ N
surgery NN N
. . N

INTERVENTIONS NNP N
According VBG N
to TO N
a DT N
computer-generated JJ N
randomization NN N
schedule NN N
, , N
patients NNS N
were VBD N
allocated VBN N
to TO N
one CD N
of IN N
two CD N
groups NNS N
. . N

In IN N
Group NNP N
Spinal NNP N
( ( N
S NNP N
) ) N
, , N
10 CD N
mg NN N
of IN N
hyperbaric JJ N
tetracaine NN N
was VBD N
administered VBN N
intrathecally RB N
. . N

In IN N
Group NNP N
General NNP N
Anesthesia NNP N
( ( N
GA NNP N
) ) N
, , N
patients NNS N
received VBD N
, , N
fentanyl RB N
intravenous JJ N
( ( N
i.v JJ N
. . N

1 CD N
to TO N
2 CD N
micrograms/kg NNS N
and CC N
propofol NN N
i.v NN N
. . N

1.0 CD N
to TO N
2.0 CD N
mg/kg NN N
for IN N
induction NN N
of IN N
anesthesia NN N
. . N

Thereafter NNP N
, , N
a DT N
laryngeal JJ N
mask NN N
airway NN N
was VBD N
inserted VBN N
and CC N
, , N
with IN N
spontaneous JJ N
ventilation NN N
, , N
anesthesia NN N
was VBD N
maintained VBN N
by IN N
administering VBG N
isoflurane NN N
( ( N
end-tidal JJ N
0.7 CD N
% NN N
to TO N
1.2 CD N
% NN N
) ) N
and CC N
70 CD N
% NN N
nitrous JJ N
oxide NN N
( ( N
N2O NNP N
) ) N
in IN N
oxygen NN N
. . N

Intraabdominal JJ N
pressure NN N
and CC N
bladder NN N
compliance NN N
were VBD N
recorded VBN N
prior RB N
to TO N
the DT N
induction NN N
of IN N
anesthesia NN N
and CC N
immediately RB N
before IN N
the DT N
onset NN N
of IN N
the DT N
surgical JJ N
procedure NN N
. . N

MEASUREMENTS NNP N
AND CC N
MAIN NNP N
RESULTS NNP N
The DT N
two CD N
groups NNS N
were VBD N
demographically RB N
comparable JJ N
. . N

In IN N
Group NNP N
S NNP N
, , N
mean JJ N
bladder NN N
compliance NN N
was VBD N
significantly RB N
( ( N
p JJ N
= NNP N
0.003 CD N
) ) N
higher JJR N
and CC N
mean JJ N
intraabdominal JJ N
pressure NN N
significantly RB N
lower JJR N
( ( N
p JJ N
= NNP N
0.007 CD N
) ) N
when WRB N
compared VBN N
to TO N
baseline VB N
preanesthetic JJ N
values NNS N
. . N

In IN N
Group NNP N
GA NNP N
, , N
mean JJ N
intraabdominal JJ N
pressure NN N
significantly RB N
( ( N
p JJ N
= NNP N
0.006 CD N
) ) N
decreased VBD N
when WRB N
compared VBN N
to TO N
baseline VB N
preanesthetic JJ N
recordings NNS N
. . N

Following VBG N
the DT N
induction NN N
of IN N
general JJ N
anesthesia NN N
, , N
a DT N
small JJ N
change NN N
in IN N
bladder NN N
compliance NN N
was VBD N
noted VBN N
. . N

However RB N
, , N
statistical JJ N
significance NN N
was VBD N
not RB N
reached VBN N
. . N

Data NNS N
were VBD N
analyzed VBN N
and CC N
compared VBN N
using VBG N
Student NNP N
's POS N
t-test NN N
( ( N
p JJ N
< NN N
0.05 CD N
was VBD N
considered VBN N
statistically RB N
significant JJ N
) ) N
. . N

CONCLUSION NNP N
Both NNP N
spinal JJ N
and CC N
general JJ N
anesthesia NN N
induced VBD N
a DT N
significant JJ N
decrease NN N
in IN N
intraabdominal JJ N
pressure NN N
. . N

While IN N
both DT N
techniques NNS N
were VBD N
associated VBN N
with IN N
an DT N
increase NN N
in IN N
bladder NN N
compliance NN N
, , N
statistical JJ N
significance NN N
was VBD N
demonstrated VBN N
only RB N
in IN N
the DT N
spinal JJ N
anesthesia NN N
treatment NN N
group NN N
. . N

-DOCSTART- -X- O O 20508979

Effects NNS N
of IN N
cognitive JJ N
behavioral JJ N
therapy NN N
on IN N
daily JJ N
living NN N
skills NNS N
in IN N
children NNS N
with IN N
high-functioning JJ N
autism NN N
and CC N
concurrent JJ N
anxiety NN N
disorders NNS N
. . N

CBT NNP N
is VBZ N
a DT N
promising JJ N
treatment NN N
for IN N
children NNS N
with IN N
autism NN N
spectrum NN N
disorders NNS N
( ( N
ASD NNP N
) ) N
and CC N
focuses VBZ N
, , N
in IN N
part NN N
, , N
on IN N
children NNS N
's POS N
independence NN N
and CC N
self-help JJ N
skills NNS N
. . N

In IN N
a DT N
trial NN N
of IN N
CBT NNP N
for IN N
anxiety NN N
in IN N
ASD NNP N
( ( N
Wood NNP N
et RB N
al RB N
. . N

in IN N
J NNP N
Child NNP N
Psychol NNP N
Psychiatry NNP N
50:224-234 CD N
, , N
2009 CD N
) ) N
, , N
children NNS N
's POS N
daily JJ N
living NN N
skills NNS N
and CC N
related JJ N
parental JJ N
intrusiveness NN N
were VBD N
assessed VBN N
. . N

Forty NNP N
children NNS N
with IN N
ASD NNP N
( ( N
7-11 CD N
years NNS N
) ) N
and CC N
their PRP$ N
primary JJ N
caregiver NN N
were VBD N
randomly RB N
assigned VBN N
to TO N
an DT N
immediate JJ N
treatment NN N
( ( N
IT NNP N
; : N
n JJ N
= NNP N
17 CD N
) ) N
or CC N
3-month JJ N
waitlist NN N
( ( N
WL NNP N
; : N
n CC N
= VB N
23 CD N
) ) N
condition NN N
. . N

In IN N
comparison NN N
to TO N
WL NNP N
, , N
IT NNP N
parents VBZ N
reported VBN N
increases NNS N
in IN N
children NNS N
's POS N
total NN N
and CC N
personal JJ N
daily JJ N
living NN N
skills NNS N
, , N
and CC N
reduced JJ N
involvement NN N
in IN N
their PRP$ N
children NNS N
's POS N
private JJ N
daily JJ N
routines NNS N
. . N

Reductions NNS N
correlated VBD N
with IN N
reduced JJ N
anxiety NN N
severity NN N
. . N

These DT N
results NNS N
provide VBP N
preliminary JJ N
evidence NN N
that IN N
CBT NNP N
may MD N
yield VB N
increased JJ N
independence NN N
and CC N
daily JJ N
living NN N
skills NNS N
among IN N
children NNS N
with IN N
ASD NNP N
. . N

-DOCSTART- -X- O O 9101947

[ JJ N
Laparoscopic NNP N
or CC N
conventional JJ N
inguinal JJ 4_p
hernia NN 4_p
repair NN 4_p
with IN N
or CC N
without IN N
implant JJ N
. . N

A DT N
prospective JJ N
randomized NN N
study NN N
] NNP N
. . N

-DOCSTART- -X- O O 8942899

Is VBZ N
there EX N
a DT N
difference NN N
? . N
A DT N
prospective JJ N
study NN N
comparing VBG N
lateral JJ N
and CC N
standard JJ N
SMAS NNP N
face NN N
lifts NNS N
with IN N
extended JJ N
SMAS NNP N
and CC N
composite JJ N
rhytidectomies NNS N
. . N

Presented VBN N
is VBZ N
a DT N
prospective JJ N
study NN N
comparing VBG N
limited JJ N
SMAS NNP N
( ( N
lateral JJ N
SMASectomy NNP N
) ) N
, , N
conventional JJ N
SMAS NNP N
, , N
extended VBD N
SMAS NNP N
, , N
and CC N
composite JJ N
rhytidectomies NNS N
. . N

Randomized VBN N
patients NNS N
received VBD N
either CC N
a DT N
limited JJ N
SMAS NNP N
or CC N
conventional JJ N
SMAS NNP N
face NN N
lift NN N
on IN N
one CD N
side NN N
and CC N
an DT N
extended JJ N
SMAS NN N
or CC N
composite JJ N
rhytidectomy NN N
on IN N
the DT N
other JJ N
. . N

All DT N
procedures NNS N
were VBD N
performed VBN N
at IN N
Manhattan NNP N
Eye NNP N
, , N
Ear NNP N
and CC N
Throat NNP N
Hospital NNP N
in IN N
accordance NN N
with IN N
their PRP$ N
well-defined JJ N
surgical JJ N
descriptions NNS N
. . N

Postoperative JJ N
courses NNS N
were VBD N
followed VBN N
clinically RB N
for IN N
at IN N
least JJS N
1 CD N
year NN N
. . N

Photographs NNP N
were VBD N
taken VBN N
preoperatively RB N
and CC N
at IN N
6 CD N
and CC N
12 CD N
months NNS N
postoperatively RB N
. . N

Photographs NNP N
were VBD N
reviewed VBN N
by IN N
three CD N
independent JJ N
experienced VBD N
face NN N
lift NN N
surgeons NNS N
. . N

The DT N
study NN N
comprises VBZ N
21 CD N
patients NNS N
, , N
20 CD N
women NNS N
and CC N
1 CD N
man NN N
, , N
with IN N
a DT N
mean JJ N
age NN N
of IN N
59 CD N
years NNS N
( ( N
range VB N
47 CD N
to TO N
70 CD N
years NNS N
) ) N
. . N

Nineteen JJ N
patients NNS N
underwent JJ N
primary JJ N
rhytidectomies NNS N
; : N
two CD N
underwent JJ N
secondary JJ N
face NN N
lifts NNS N
. . N

For IN N
the DT N
first JJ N
12 CD N
patients NNS N
, , N
each DT N
had VBD N
an DT N
extended JJ N
SMAS NNP N
procedure NN N
performed VBD N
on IN N
one CD N
side NN N
; : N
on IN N
the DT N
other JJ N
, , N
7 CD N
had VBD N
a DT N
conventional JJ N
SMAS NNP N
and CC N
5 CD N
had VBD N
a DT N
limited JJ N
SMAS NNP N
( ( N
lateral JJ N
SMASectomy NNP N
) ) N
face NN N
lift NN N
. . N

In IN N
the DT N
last JJ N
9 CD N
patients NNS N
, , N
a DT N
conventional JJ N
SMAS NNP N
was VBD N
carried VBN N
out RP N
on IN N
one CD N
side NN N
in IN N
8 CD N
, , N
a DT N
limited JJ N
SMAS NNP N
in IN N
1 CD N
, , N
and CC N
on IN N
the DT N
opposite JJ N
side NN N
, , N
a DT N
composite JJ N
rhytidectomy NN N
was VBD N
performed VBN N
. . N

Complications NNS N
were VBD N
few JJ N
. . N

Temporary NNP N
weakness NN N
of IN N
the DT N
buccal JJ N
branch NN N
of IN N
the DT N
facial JJ N
nerve NN N
occurred VBD N
in IN N
2 CD N
patients NNS N
on IN N
the DT N
side NN N
of IN N
the DT N
more RBR N
extensive JJ N
surgery NN N
. . N

On IN N
the DT N
operating NN N
table NN N
at IN N
completion NN N
of IN N
the DT N
surgery NN N
, , N
there EX N
was VBD N
more RBR N
improvement NN N
in IN N
reversal NN N
of IN N
midfacial JJ N
ptosis NN N
and CC N
flattening NN N
of IN N
the DT N
nasolabial JJ N
folds NNS N
with IN N
both DT N
extended JJ N
SMAS NNP N
and CC N
composite JJ N
rhytidectomies NNS N
. . N

The DT N
composite JJ N
flap NN N
had VBD N
the DT N
most RBS N
dramatic JJ N
effect NN N
on IN N
the DT N
nasolabial JJ N
folds NNS N
and CC N
oral JJ N
commissure NN N
. . N

After IN N
24 CD N
hours NNS N
, , N
once RB N
swelling VBG N
developed VBN N
and CC N
facial JJ N
motion NN N
became VBD N
reactivated VBN N
, , N
the DT N
noticeable JJ N
differences NNS N
in IN N
the DT N
midface NN N
and CC N
nasolabial JJ N
folds NNS N
were VBD N
lost VBN N
. . N

No DT N
discernible JJ N
differences NNS N
in IN N
facial JJ N
halves NNS N
were VBD N
noted VBN N
again RB N
. . N

Differences NNS N
between IN N
facial JJ N
sides NNS N
on IN N
the DT N
6- JJ N
and CC N
12-month JJ N
postoperative JJ N
photographs NNS N
were VBD N
not RB N
detectable JJ N
. . N

We PRP N
conclude VBP N
that IN N
for IN N
routine JJ N
facial JJ N
plasty NN N
, , N
comparable JJ N
clinical JJ N
outcomes NNS N
are VBP N
obtained VBN N
at IN N
6 CD N
months NNS N
and CC N
1 CD N
year NN N
with IN N
limited JJ N
( ( N
lateral JJ N
SMASectomy NNP N
) ) N
and CC N
conventional JJ N
SMAS NNP N
face NN N
lifts NNS N
compared VBN N
with IN N
extended JJ N
SMAS NNP N
and CC N
composite JJ N
rhytidectomies NNS N
. . N

All DT N
procedures NNS N
are VBP N
lacking VBG N
in IN N
their PRP$ N
improvement NN N
of IN N
midface NN N
ptosis NN N
and CC N
the DT N
nasolabial JJ N
folds NNS N
. . N

The DT N
increased JJ N
surgical JJ N
risks NNS N
, , N
morbidity NN N
, , N
and CC N
convalescence NN N
associated VBN N
with IN N
those DT N
more RBR N
extensive JJ N
procedures NNS N
do VBP N
not RB N
seem VB N
to TO N
be VB N
warranted VBN N
in IN N
the DT N
average JJ N
patient NN N
. . N

-DOCSTART- -X- O O 7761019

[ JJ N
Effects NNS N
of IN N
betamethasone NN N
on IN N
neuromuscular JJ N
blockade NN N
induced VBN N
by IN N
vecuronium NN N
in IN N
continuous JJ N
infusion NN N
] NN N
. . N

The DT N
aim NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
determine VB N
a DT N
possible JJ N
interaction NN N
between IN N
a DT N
corticosteroid NN N
( ( N
betamethasone NN N
) ) N
and CC N
vecuronium NN N
, , N
a DT N
nondepolarizing JJ N
muscle NN N
relaxant NN N
. . N

The DT N
authors NNS N
studied VBD N
20 CD 4_p
patients NNS N
, , N
ASA NNP N
I-II NNP N
, , N
aged VBD N
20-54 JJ N
, , N
both DT 4_p
sexes NNS 4_p
, , N
scheduled VBN N
for IN N
abdominal JJ 4_p
surgery NN 4_p
. . N

Mechanomyographic NNP N
and CC N
clinical JJ N
evaluation NN N
by IN N
single JJ N
twitch NN N
and CC N
TOF NNP N
stimulation NN N
of IN N
the DT N
ulnar JJ N
nerve NN N
at IN N
the DT N
wrist NN N
and CC N
measurement NN N
of IN N
the DT N
concomitant JJ N
abductor NN N
pollicis NN N
muscle NN N
was VBD N
applied VBN N
. . N

The DT N
onset JJ N
time NN N
of IN N
vecuronium NN N
after IN N
a DT N
single JJ N
bolus NN N
dose NN N
of IN N
0.08 CD N
mg/kg NN N
, , N
duration NN N
of IN N
action NN N
to TO N
10 CD N
% NN N
single JJ N
twitch NN N
recovery NN N
, , N
duration NN N
of IN N
continuous JJ N
infusion NN N
of IN N
0.4-0.5 JJ N
micrograms/kg/min NN N
of IN N
vecuronium NN N
started VBN N
at IN N
10 CD N
% NN N
single JJ N
twitch NN N
recovery NN N
, , N
and CC N
the DT N
effects NNS N
of IN N
0.1 CD N
mg/kg NNS N
betamethasone CD N
administration NN N
10 CD N
min NN N
after IN N
continuous JJ N
infusion NN N
were VBD N
evaluated VBN N
. . N

The DT N
recovery NN N
rate NN N
of IN N
vecuronium NN N
after IN N
stopping VBG N
infusion NN N
at IN N
10 CD N
% NN N
recovery NN N
was VBD N
also RB N
evaluated VBN N
. . N

Corticosteroids NNS N
may MD N
interact VB N
with IN N
non-depolarizing JJ N
muscle NN N
relaxants NNS N
both DT N
in IN N
prejunctional NN N
and CC N
postjunctional JJ N
acetylcholine NN N
receptors NNS N
by IN N
several JJ N
mechanisms NNS N
of IN N
action NN N
. . N

-DOCSTART- -X- O O 500415

New NNP N
methods NNS N
applied VBN N
to TO N
the DT N
analysis NN N
and CC N
treatment NN N
of IN N
ovarian JJ 4_p
cancer NN 4_p
. . 4_p

-DOCSTART- -X- O O 25056444

Prior JJ N
experience NN N
with IN N
a DT N
pain NN 4_p
stimulus NN 4_p
as IN N
a DT N
predictor NN N
of IN N
placebo NN N
analgesia NN N
. . N

Placebo NNP N
effects NNS N
are VBP N
important JJ N
in IN N
pain NN N
reduction NN N
, , N
but CC N
the DT N
effects NNS N
are VBP N
inconsistent JJ N
. . N

Prior JJ N
experience NN N
with IN N
a DT N
pain NN N
stimulus NN N
may MD N
moderate VB N
placebo NN N
analgesia NN N
. . N

The DT N
current JJ N
study NN N
tests VBZ N
the DT N
effect NN N
of IN N
prior JJ N
experience NN N
with IN N
a DT N
pain NN N
stimulus NN N
on IN N
placebo NN N
analgesia NN N
during IN N
a DT N
laboratory NN N
pain NN N
task NN N
. . N

Healthy NNP N
normotensive JJ N
undergraduates NNS N
( ( N
66 CD N
women NNS N
, , N
68 CD N
men NNS N
) ) N
who WP N
either DT N
did VBD N
or CC N
did VBD N
not RB N
report VB N
prior JJ N
experience NN N
with IN N
pain NN N
from IN N
submerging VBG N
a DT N
limb NN N
in IN N
cold JJ N
water NN N
were VBD N
enrolled VBN N
. . N

In IN N
the DT N
laboratory NN N
, , N
an DT N
experimenter NN N
applied VBD N
an DT N
inert NN N
, , N
medicinal-smelling JJ N
cream NN N
to TO N
participants NNS N
' POS N
non-dominant JJ N
hand NN N
. . N

Participants NNS N
randomized VBD N
to TO N
the DT N
no-expectation JJ N
group NN N
were VBD N
told VBN N
that IN N
the DT N
cream NN N
was VBD N
a DT N
hand NN N
cleanser NN N
. . N

Participants NNS N
randomized VBD N
to TO N
the DT N
placebo NN N
expectation NN N
group NN N
were VBD N
told VBN N
that IN N
the DT N
cream NN N
would MD N
reduce VB N
the DT N
pain NN N
associated VBN N
with IN N
the DT N
cold JJ N
pressor NN N
task NN N
. . N

Participants NNS N
then RB N
completed VBD N
the DT N
cold JJ N
pressor NN N
task NN N
and CC N
reported VBD N
their PRP$ N
pain NN N
on IN N
the DT N
short JJ N
form NN N
of IN N
the DT N
McGill NNP N
Pain NNP N
Questionnaire NNP N
. . N

Analysis NN N
of IN N
variance NN N
revealed VBD N
a DT N
main JJ N
effect NN N
of IN N
expectation NN N
( ( N
p JJ N
< NNP N
.05 NNP N
) ) N
, , N
such JJ N
that IN N
participants NNS N
in IN N
the DT N
placebo NN N
expectation NN N
group NN N
reported VBD N
less JJR N
pain NN N
. . N

An DT N
interaction NN N
was VBD N
also RB N
found VBN N
between IN N
expectation NN N
and CC N
prior JJ N
experience NN N
( ( N
p JJ N
< NNP N
.05 NNP N
) ) N
, , N
such JJ N
that IN N
participants NNS N
with IN N
prior JJ N
experience NN N
with IN N
pain NN N
from IN N
cold JJ N
water NN N
immersion NN N
showed VBD N
no DT N
difference NN N
in IN N
pain NN N
reports NNS N
between IN N
expectation NN N
groups NNS N
. . N

In IN N
a DT N
pain NN N
context NN N
, , N
prior JJ N
experience NN N
with IN N
the DT N
pain NN 4_p
stimulus NN 4_p
may MD N
prevent VB N
a DT N
placebo JJ N
expectation NN N
from IN N
reducing VBG N
the DT N
experience NN N
of IN N
pain NN N
. . N

-DOCSTART- -X- O O 21385351

Vascular JJ N
pedicle NN N
width NN N
in IN N
acute JJ N
lung JJ N
injury NN N
: : N
correlation NN N
with IN N
intravascular JJ N
pressures NNS N
and CC N
ability NN N
to TO N
discriminate VB N
fluid NN N
status NN N
. . N

INTRODUCTION NNP N
Conservative NNP N
fluid NN N
management NN N
in IN N
patients NNS N
with IN N
acute JJ N
lung NN N
injury NN N
( ( N
ALI NNP N
) ) N
increases VBZ N
time NN N
alive JJ N
and CC N
free JJ N
from IN N
mechanical JJ N
ventilation NN N
. . N

Vascular JJ N
pedicle NN N
width NN N
( ( N
VPW NNP N
) ) N
is VBZ N
a DT N
non-invasive JJ N
measurement NN N
of IN N
intravascular JJ N
volume NN N
status NN N
. . N

The DT N
VPW NNP N
was VBD N
studied VBN N
in IN N
ALI NNP N
patients NNS N
to TO N
determine VB N
the DT N
correlation NN N
between IN N
VPW NNP N
and CC N
intravascular JJ N
pressure NN N
measurements NNS N
and CC N
whether IN N
VPW NNP N
could MD N
predict VB N
fluid JJ N
status NN N
. . N

METHODS NNP N
This DT N
retrospective JJ N
cohort NN N
study NN N
involved VBD N
152 CD N
patients NNS N
with IN N
ALI NNP N
enrolled VBD N
in IN N
the DT N
Fluid NNP N
and CC N
Catheter NNP N
Treatment NNP N
Trial NNP N
( ( N
FACTT NNP N
) ) N
from IN N
five CD N
NHLBI NNP N
ARDS NNP N
( ( N
Acute NNP N
Respiratory NNP N
Distress NNP N
Syndrome NNP N
) ) N
Network NNP N
sites NNS N
. . N

VPW NNP N
and CC N
central JJ N
venous JJ N
pressure NN N
( ( N
CVP NNP N
) ) N
or CC N
pulmonary JJ N
artery NN N
occlusion NN N
pressure NN N
( ( N
PAOP NNP N
) ) N
from IN N
the DT N
first JJ N
four CD N
study NN N
days NNS N
were VBD N
correlated VBN N
. . N

The DT N
relationships NNS N
between IN N
VPW NNP N
, , N
positive JJ N
end-expiratory JJ N
pressure NN N
( ( N
PEEP NNP N
) ) N
, , N
cumulative JJ N
fluid NN N
balance NN N
, , N
and CC N
PAOP NNP N
were VBD N
also RB N
evaluated VBN N
. . N

Receiver NNP N
operator NN N
characteristic NN N
( ( N
ROC NNP N
) ) N
curves NNS N
were VBD N
used VBN N
to TO N
determine VB N
the DT N
ability NN N
of IN N
VPW NNP N
to TO N
detect VB N
PAOP NNP N
< NNP N
8 CD N
mmHg NN N
and CC N
PAOP NNP N
≥ NNP N
18 CD N
mm NN N
Hg NNP N
. . N

RESULTS VB N
A DT N
total NN N
of IN N
71 CD N
and CC N
152 CD N
patients NNS N
provided VBD N
118 CD N
and CC N
276 CD N
paired VBN N
VPW/PAOP NNP N
and CC N
VPW/CVP NNP N
measurements NNS N
, , N
respectively RB N
. . N

VPW NNP N
correlated VBD N
with IN N
PAOP NNP N
( ( N
r VB N
= RB N
0.41 CD N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
less RBR N
well RB N
with IN N
CVP NNP N
( ( N
r VB N
= RB N
0.21 CD N
; : N
P NNP N
= NNP N
0.001 CD N
) ) N
. . N

In IN N
linear JJ N
regression NN N
, , N
VPW NNP N
correlated VBD N
with IN N
PAOP NNP N
1.5-fold JJ N
better JJR N
than IN N
cumulative JJ N
fluid NN N
balance NN N
and CC N
2.5-fold JJ N
better JJR N
than IN N
PEEP NNP N
. . N

VPW NNP N
discriminated VBD N
achievement NN N
of IN N
PAOP NNP N
< NNP N
8 CD N
mm NN N
Hg NNP N
( ( N
AUC NNP N
= NNP N
0.73 CD N
; : N
P NNP N
= NNP N
0.04 CD N
) ) N
with IN N
VPW NNP N
≤67 NNP N
mm VBD N
demonstrating VBG N
71 CD N
% NN N
sensitivity NN N
( ( N
95 CD N
% NN N
CI NNP N
30 CD N
to TO N
95 CD N
% NN N
) ) N
and CC N
68 CD N
% NN N
specificity NN N
( ( N
95 CD N
% NN N
CI NNP N
59 CD N
to TO N
75 CD N
% NN N
) ) N
. . N

For IN N
discriminating VBG N
a DT N
hydrostatic JJ N
component NN N
of IN N
the DT N
edema NN N
( ( N
that WDT N
is VBZ N
, , N
PAOP NNP N
≥ VBZ N
18 CD N
mm NN N
Hg NNP N
) ) N
, , N
VPW NNP N
≥ VBZ N
72 CD N
mm NN N
demonstrated VBD N
61.4 CD N
% NN N
sensitivity NN N
( ( N
95 CD N
% NN N
CI NNP N
47 CD N
to TO N
74 CD N
% NN N
) ) N
and CC N
61 CD N
% NN N
specificity NN N
( ( N
49 CD N
to TO N
71 CD N
% NN N
) ) N
( ( N
area NN N
under IN N
the DT N
curve NN N
( ( N
AUC NNP N
) ) N
0.69 CD N
; : N
P NNP N
= NNP N
0.001 CD N
) ) N
. . N

CONCLUSIONS NNP N
VPW NNP N
correlates VBZ N
with IN N
PAOP NNP N
better JJR N
than IN N
CVP NNP N
in IN N
patients NNS N
with IN N
ALI NNP N
. . N

Due NNP N
to TO N
its PRP$ N
only JJ N
moderate JJ N
sensitivity NN N
and CC N
specificity NN N
, , N
the DT N
ability NN N
of IN N
VPW NNP N
to TO N
discriminate VB N
fluid NN N
status NN N
in IN N
patients NNS N
with IN N
acute JJ N
lung NN N
injury NN N
is VBZ N
limited JJ N
and CC N
should MD N
only RB N
be VB N
considered VBN N
when WRB N
intravascular JJ N
pressures NNS N
are VBP N
unavailable JJ N
. . N

-DOCSTART- -X- O O 10790473

Language NN N
, , N
speech NN N
sound NN N
production NN N
, , N
and CC N
cognition NN N
in IN N
three-year-old JJ 4_p
children NNS 4_p
in IN 4_p
relation NN 4_p
to TO 4_p
otitis VB 4_p
media NNS 4_p
in IN 4_p
their PRP$ 4_p
first JJ 4_p
three CD 4_p
years NNS 4_p
of IN 4_p
life NN 4_p
. . 4_p

OBJECTIVE CC N
As IN N
part NN N
of IN N
a DT N
prospective JJ N
study NN N
of IN N
possible JJ N
effects NNS N
of IN N
early-life JJ N
otitis NN N
media NNS N
on IN N
speech NN N
, , N
language NN N
, , N
cognitive JJ N
, , N
and CC N
psychosocial JJ N
development NN N
, , N
we PRP N
tested VBD N
relationships NNS N
between IN N
children NNS N
's POS N
cumulative JJ N
duration NN N
of IN N
middle JJ N
ear JJ N
effusion NN N
( ( N
MEE NNP N
) ) N
in IN N
their PRP$ N
first JJ N
3 CD N
years NNS N
of IN N
life NN N
and CC N
their PRP$ N
scores NNS N
on IN N
measures NNS N
of IN N
language NN N
, , N
speech NN N
sound NN N
production NN N
, , N
and CC N
cognition NN N
at IN N
3 CD N
years NNS N
of IN N
age NN N
. . N

METHODS NNP N
We PRP N
enrolled VBD N
6350 CD N
healthy JJ N
infants NNS N
by IN N
2 CD N
months NNS N
of IN N
age NN N
who WP N
presented VBD N
for IN N
primary JJ N
care NN N
at IN N
1 CD N
of IN N
2 CD N
urban JJ N
hospitals NNS N
or CC N
1 CD N
of IN N
2 CD N
small JJ N
town/rural JJ N
and CC N
4 CD N
suburban JJ N
private JJ N
pediatric JJ N
practices NNS N
. . N

We PRP N
intensively RB N
monitored VBD N
the DT N
children NNS N
's POS N
middle JJ N
ear NN N
status NN N
by IN N
pneumatic JJ N
otoscopy NN N
, , N
supplemented VBN N
by IN N
tympanometry NN N
, , N
throughout IN N
their PRP$ N
first JJ N
3 CD N
years NNS N
of IN N
life NN N
; : N
we PRP N
monitored VBD N
the DT N
validity NN N
of IN N
the DT N
otoscopic JJ N
observations NNS N
on IN N
an DT N
ongoing JJ N
basis NN N
; : N
and CC N
we PRP N
treated VBD N
children NNS N
for IN N
otitis NN N
media NNS N
according VBG N
to TO N
specified VBN N
guidelines NNS N
. . N

Children NNP N
who WP N
met VBD N
specified VBN N
minimum JJ N
criteria NNS N
regarding VBG N
the DT N
persistence NN N
of IN N
MEE NNP N
became VBD N
eligible JJ N
for IN N
a DT N
clinical JJ N
trial NN N
in IN N
which WDT N
they PRP N
were VBD N
assigned VBN N
randomly RB N
to TO N
undergo VB N
tympanostomy JJ N
tube NN N
placement NN N
either CC N
promptly RB N
or CC N
after IN N
a DT N
defined JJ N
extended JJ N
period NN N
if IN N
MEE NNP N
remained VBD N
present JJ N
. . N

From IN N
among IN N
those DT N
remaining VBG N
, , N
we PRP N
selected VBD N
randomly RB N
, , N
within IN N
sociodemographic JJ N
strata NNS N
, , N
a DT N
sample NN N
of IN N
241 CD N
children NNS N
who WP N
represented VBD N
a DT N
spectrum NN N
of IN N
MEE NNP N
experience NN N
from IN N
having VBG N
no DT N
MEE NNP N
to TO N
having VBG N
MEE NNP N
whose WP$ N
cumulative JJ N
duration NN N
fell VBD N
just RB N
short RB N
of IN N
meeting VBG N
randomization NN N
criteria NNS N
. . N

In IN N
subjects NNS N
so RB N
selected VBN N
, , N
the DT N
estimated JJ N
duration NN N
of IN N
MEE NNP N
ranged VBD N
from IN N
none NN N
to TO N
65.6 CD N
% NN N
of IN N
the DT N
first JJ N
year NN N
of IN N
life NN N
and CC N
44.8 CD N
% NN N
of IN N
the DT N
first JJ N
3 CD N
years NNS N
of IN N
life NN N
. . N

In IN N
these DT N
241 CD N
children NNS N
we PRP N
assessed VBD N
language NN N
development NN N
, , N
speech NN N
sound NN N
production NN N
, , N
and CC N
cognition NN N
at IN N
3 CD N
years NNS N
of IN N
age NN N
, , N
using VBG N
both DT N
formal JJ N
tests NNS N
and CC N
conversational JJ N
samples NNS N
. . N

RESULTS NNP N
We PRP N
found VBD N
weak JJ N
to TO N
moderate VB N
, , N
statistically RB N
significant JJ N
negative JJ N
correlations NNS N
between IN N
children NNS N
's POS N
cumulative JJ N
durations NNS N
of IN N
MEE NNP N
in IN N
their PRP$ N
first JJ N
year NN N
of IN N
life NN N
or CC N
in IN N
age NN N
periods NNS N
that WDT N
included VBD N
their PRP$ N
first JJ N
year NN N
of IN N
life NN N
, , N
and CC N
their PRP$ N
scores NNS N
on IN N
formal JJ N
tests NNS N
of IN N
receptive JJ N
vocabulary NN N
and CC N
verbal JJ N
aspects NNS N
of IN N
cognition NN N
at IN N
3 CD N
years NNS N
of IN N
age NN N
. . N

However RB N
, , N
the DT N
percent NN N
of IN N
variance NN N
in IN N
these DT N
scores NNS N
explained VBN N
by IN N
time NN N
with IN N
MEE NNP N
in IN N
the DT N
first JJ N
year NN N
of IN N
life NN N
beyond IN N
that DT N
explained VBN N
by IN N
sociodemographic JJ N
variables NNS N
ranged VBD N
only RB N
from IN N
1.2 CD N
% NN N
to TO N
2.9 CD N
% NN N
, , N
and CC N
the DT N
negative JJ N
correlations NNS N
were VBD N
concentrated VBN N
in IN N
the DT N
subgroup NN N
of IN N
children NNS N
whose WP$ N
families NNS N
had VBD N
private JJ N
health NN N
insurance NN N
( ( N
rather RB N
than IN N
Medicaid NNP N
) ) N
. . N

We PRP N
found VBD N
no DT N
significant JJ N
correlations NNS N
in IN N
the DT N
study NN N
population NN N
as IN N
a DT N
whole NN N
or CC N
in IN N
any DT N
subgroup NN N
between IN N
time NN N
with IN N
MEE NNP N
during IN N
antecedent JJ N
periods NNS N
and CC N
children NNS N
's POS N
scores NNS N
on IN N
measures NNS N
of IN N
spontaneous JJ N
expressive JJ N
language NN N
, , N
speech NN N
sound NN N
production NN N
, , N
or CC N
other JJ N
measured JJ N
aspects NNS N
of IN N
cognition NN N
. . N

In IN N
contrast NN N
, , N
by IN N
wide JJ N
margins NNS N
, , N
scores NNS N
on IN N
all DT N
measures NNS N
were VBD N
consistently RB N
highest JJS N
among IN N
the DT N
most RBS N
socioeconomically RB N
advantaged JJ N
children NNS N
and CC N
lowest JJS N
among IN N
the DT N
most RBS N
socioeconomically RB N
disadvantaged JJ N
children NNS N
. . N

CONCLUSIONS NNP N
Our PRP$ N
findings NNS N
suggest VBP N
either RB N
that DT N
persistent JJ N
early-life JJ N
MEE NNP N
actually RB N
causes VBZ N
later RB N
small JJ N
, , N
circumscribed JJ N
impairments NNS N
of IN N
receptive JJ N
language NN N
and CC N
verbal JJ N
aspects NNS N
of IN N
cognition NN N
in IN N
certain JJ N
groups NNS N
of IN N
children NNS N
or CC N
that DT N
unidentified JJ N
, , N
confounding VBG N
factors NNS N
predispose JJ N
children NNS N
both DT N
to TO N
early-life NN N
otitis NN N
media NNS N
and CC N
to TO N
certain JJ N
types NNS N
of IN N
developmental JJ N
impairment NN N
. . N

Findings NNS N
in IN N
the DT N
randomized JJ N
clinical JJ N
trial NN N
component NN N
of IN N
the DT N
larger JJR N
study NN N
should MD N
help VB N
distinguish VB N
between IN N
causality NN N
and CC N
confounding NN N
as IN N
explanations NNS N
for IN N
our PRP$ N
findings.language NN N
, , N
speech NN N
, , N
cognition NN N
, , N
development NN N
, , N
otitis NN N
media NNS N
, , N
middle JJ N
ear JJ N
effusion NN N
. . N

-DOCSTART- -X- O O 1412152

Desmopressin NNP N
has VBZ N
no DT N
beneficial JJ N
effect NN N
on IN N
excessive JJ N
postoperative JJ N
bleeding NN 4_p
or CC N
blood NN 4_p
product NN 4_p
requirements NNS 4_p
associated VBN N
with IN N
cardiopulmonary JJ 4_p
bypass NN 4_p
. . N

Cardiopulmonary JJ N
bypass NN N
during IN N
open-heart JJ N
surgery NN N
is VBZ N
sometimes RB N
associated VBN N
with IN N
excessive JJ N
perioperative JJ N
bleeding NN N
. . N

Following VBG N
a DT N
non-randomized JJ N
study NN N
suggesting VBG N
that IN N
desmopressin NN N
acetate NN N
( ( N
desmopressin NN N
) ) N
reduced VBD N
blood NN N
product NN N
requirements NNS N
in IN N
these DT N
patients NNS N
, , N
we PRP N
conducted VBD N
a DT N
double-blind JJ N
, , N
placebo-controlled JJ N
randomized JJ N
trial NN N
of IN N
desmopressin NN N
( ( N
0.3 CD N
micrograms/kg NN N
, , N
i. JJ N
v. NN N
) ) N
in IN N
92 CD N
patients NNS N
with IN N
overt JJ 4_p
bleeding NN 4_p
and CC N
a DT N
prolonged JJ 4_p
bleeding NN 4_p
time NN 4_p
. . N

Mean JJ N
blood NN N
loss NN N
during IN N
the DT N
first JJ N
24 CD N
h JJ N
post-treatment NN N
was VBD N
similar JJ N
in IN N
the DT N
desmopressin NN N
and CC N
placebo NN N
groups NNS N
( ( N
582 CD N
vs RB N
465 CD N
ml NN N
, , N
respectively RB N
; : N
p VB N
= $ N
0.15 CD N
) ) N
. . N

Red-cell NNP N
( ( N
p JJ N
= NNP N
0.76 CD N
) ) N
, , N
fresh JJ N
frozen JJ N
plasma NN N
( ( N
r JJ N
= NNP N
0.66 CD N
) ) N
and CC N
platelet JJ N
unit NN N
( ( N
p JJ N
= NNP N
0.74 CD N
) ) N
requirements NNS N
were VBD N
also RB N
similar JJ N
. . N

The DT N
haemostatic JJ N
effect NN N
of IN N
desmopressin NN N
has VBZ N
been VBN N
attributed VBN N
to TO N
the DT N
release NN N
of IN N
von JJ N
Willebrand NNP N
factor NN N
( ( N
vWF NN N
) ) N
and CC N
a DT N
reduced JJ N
bleeding NN N
time NN N
. . N

In IN N
our PRP$ N
study NN N
, , N
vWF NN N
and CC N
factor NN N
VIII NNP N
: : N
C NNP N
levels NNS N
increased VBN N
while IN N
the DT N
bleeding NN N
time NN N
decreased VBN N
significantly RB N
at IN N
90 CD N
min NN N
and CC N
24 CD N
h NN N
in IN N
both DT N
groups NNS N
and CC N
, , N
although IN N
vWF NN N
and CC N
factor NN N
VIII NNP N
: : N
C NN N
levels NNS N
were VBD N
slightly RB N
higher JJR N
in IN N
desmopressin-treated JJ N
patients NNS N
at IN N
90 CD N
min NN N
, , N
the DT N
difference NN N
was VBD N
not RB N
significant JJ N
. . N

Thrombin-antithrombin JJ N
III NNP N
complex NN N
, , N
fibrinogen NN N
degradation NN N
product NN N
and CC N
tissue NN N
plasminogen NN N
activator NN N
levels NNS N
, , N
reflecting VBG N
activation NN N
of IN N
the DT N
coagulation NN N
and CC N
fibrinolytic JJ N
systems NNS N
, , N
respectively RB N
, , N
decreased VBD N
uniformly RB N
in IN N
both DT N
groups NNS N
. . N

We PRP N
conclude VBP N
that DT N
desmopressin NN N
is VBZ N
not RB N
useful JJ N
in IN N
reducing VBG N
blood NN N
loss NN N
or CC N
blood NN N
product NN N
requirements NNS N
in IN N
patients NNS N
with IN N
excessive JJ N
immediate JJ N
postoperative JJ N
bleeding NN N
. . N

-DOCSTART- -X- O O 18983318

Two-year JJ N
prospective JJ N
clinical JJ N
comparison NN N
of IN N
immediate JJ N
replacement NN N
vs. FW N
immediate JJ N
restoration NN N
of IN N
single JJ 4_p
tooth NN 4_p
in IN N
the DT N
esthetic JJ 4_p
zone NN 4_p
. . N

AIM NNP N
To TO N
compare VB N
the DT N
immediate JJ N
restoration NN N
of IN N
single JJ N
implants NNS N
in IN N
the DT N
esthetic JJ N
zones NNS N
performed VBN N
on IN N
implants NNS N
placed VBN N
immediately RB N
after IN N
tooth JJ N
extraction NN N
or CC N
8 CD N
weeks NNS N
later RB N
( ( N
immediate JJ N
replacement NN N
vs. FW N
immediate JJ N
restoration NN N
) ) N
. . N

METHODS NNP N
Sixteen JJ N
patients NNS N
( ( N
10 CD N
women NNS N
and CC N
6 CD N
men NNS N
) ) N
with IN N
a DT N
mean JJ N
age NN N
of IN N
35 CD N
years NNS N
( ( N
ranging VBG N
from IN N
21 CD N
to TO N
49 CD N
years NNS N
old JJ N
) ) N
were VBD N
treated VBN N
from IN N
2004 CD N
to TO N
2005 CD N
for IN N
single-tooth JJ 4_p
replacement NN 4_p
in IN 4_p
the DT 4_p
upper JJ 4_p
arch NN 4_p
. . N

The DT N
patients NNS N
were VBD N
randomly RB N
divided VBN N
into IN N
two CD N
groups NNS N
: : N
in IN N
the DT N
test NN N
group NN N
patients NNS N
received VBD N
implants NNS N
placed VBN N
and CC N
restored VBN N
( ( N
non-occlusal JJ N
loading NN N
) ) N
at IN N
the DT N
time NN N
of IN N
tooth JJ N
extraction NN N
; : N
in IN N
the DT N
control NN N
group NN N
implants NNS N
were VBD N
placed VBN N
8 CD N
weeks NNS N
after IN N
tooth DT N
extraction NN N
and CC N
immediately RB N
restored VBN N
. . N

All PDT N
the DT N
patients NNS N
received VBD N
tapered JJ 4_p
effect NN 4_p
( ( 4_p
TE NNP 4_p
) ) 4_p
implants NNS 4_p
from IN N
the DT N
Straumann NNP 4_p
Dental NNP 4_p
Implant NNP 4_p
System NNP 4_p
. . N

The DT N
following JJ N
parameters NNS N
were VBD N
evaluated VBN N
at IN N
the DT N
moment NN N
of IN N
provisional JJ N
restoration NN N
( ( N
within IN N
48 CD N
h NN N
after IN N
implant JJ N
placement NN N
) ) N
and CC N
at IN N
the DT N
2 CD N
years NNS N
follow-up JJ N
visit NN N
: : N
marginal JJ N
bone NN N
resorption NN N
, , N
papilla NN N
index NN N
, , N
position NN N
of IN N
the DT N
mucosal NN N
margin NN N
. . N

The DT N
implant JJ N
stability NN N
quotient NN N
was VBD N
measured VBN N
at IN N
the DT N
moment NN N
of IN N
implant JJ N
placement NN N
and CC N
at IN N
the DT N
moment NN N
of IN N
the DT N
delivery NN N
of IN N
the DT N
definitive JJ N
restoration NN N
. . N

RESULTS NNP N
No NNP N
statistically RB N
significant JJ N
differences NNS N
were VBD N
found VBN N
in IN N
any DT N
of IN N
the DT N
studied JJ N
parameters NNS N
between IN N
the DT N
test NN N
and CC N
the DT N
control NN N
groups NNS N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

The DT N
implant JJ N
stability NN N
quotient NN N
values NNS N
between IN N
the DT N
test NN N
and CC N
control NN N
groups NNS N
were VBD N
significant JJ N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
at IN N
the DT N
moment NN N
of IN N
implant JJ N
placement NN N
but CC N
were VBD N
no DT N
more RBR N
significant JJ N
at IN N
the DT N
loading NN N
of IN N
the DT N
definitive JJ N
restoration NN N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

CONCLUSION VB N
The DT N
results NNS N
of IN N
the DT N
present JJ N
study NN N
suggest VBP N
that IN N
immediate JJ N
replacement NN N
without IN N
functional JJ N
loading NN N
may MD N
be VB N
considered VBN N
a DT N
valuable JJ N
therapeutic JJ N
option NN N
for IN N
selected VBN N
cases NNS N
of IN N
single-tooth JJ N
replacement NN N
in IN N
the DT N
esthetic JJ N
area NN N
when WRB N
TE NNP N
implants NNS N
are VBP N
used VBN N
. . N

Implant JJ N
stability NN N
at IN N
the DT N
moment NN N
of IN N
implant JJ N
placement NN N
is VBZ N
slightly RB N
inferior JJ N
in IN N
the DT N
immediate JJ N
replacement NN N
group NN N
, , N
but CC N
it PRP N
does VBZ N
not RB N
affect VB N
the DT N
treatment NN N
result NN N
. . N

-DOCSTART- -X- O O 17958625

Oral NNP N
amoxicillin NN N
vs. FW N
oral JJ N
erythromycin NN N
in IN N
the DT N
treatment NN 4_p
of IN 4_p
pyoderma NN 4_p
in IN 4_p
Bamako NNP 4_p
, , 4_p
Mali NNP 4_p
: : 4_p
an DT N
open JJ N
randomized VBN N
trial NN N
. . N

BACKGROUND NNP N
Pyoderma NNP 4_p
( ( 4_p
bacterial JJ 4_p
superficial NN 4_p
skin NN 4_p
infection NN 4_p
) ) 4_p
is VBZ N
an DT N
extremely RB N
common JJ N
disorder NN N
in IN N
tropical JJ 4_p
developing VBG 4_p
countries NNS 4_p
. . 4_p

In IN N
these DT N
settings NNS N
, , N
Streptococcus NNP N
pyogenes NNS N
is VBZ N
considered VBN N
to TO N
be VB N
the DT N
main JJ N
etiological JJ N
agent NN N
. . N

Apart RB N
from IN N
epidemics NNS N
of IN N
poststreptococcal JJ N
glomerulonephritis NN N
where WRB N
mass NN N
treatment NN N
with IN N
intramuscular JJ N
benzathine-penicillin NN N
is VBZ N
recommended VBN N
, , N
no DT N
recommendation NN N
exists VBZ N
for IN N
the DT N
treatment NN N
of IN N
pyoderma NN N
in IN N
this DT N
setting NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
oral JJ N
amoxicillin NN N
in IN N
the DT N
treatment NN N
of IN N
pyoderma NN N
in IN N
Mali NNP N
, , N
by IN N
comparison NN N
with IN N
oral JJ N
erythromycin NN N
. . N

METHODS NNP N
In IN N
Bamako NNP N
, , N
132 CD N
patients NNS N
with IN N
pyoderma NN N
, , N
diagnosed VBN N
and CC N
graded VBN N
as IN N
" NN N
severe JJ N
" NN N
on IN N
clinical JJ N
grounds NNS N
, , N
were VBD N
randomly RB N
assigned VBN N
to TO N
an DT N
oral JJ N
treatment NN N
by IN N
either DT N
amoxicillin NN N
( ( N
50 CD N
mg/kg NNS N
per IN N
day NN N
) ) N
or CC N
erythromycin $ N
; : N
infections NNS N
of IN N
the DT N
follicular JJ N
appendage NN N
were VBD N
excluded VBN N
. . N

Both DT N
drugs NNS N
were VBD N
associated VBN N
with IN N
the DT N
topical JJ N
application NN N
of IN N
povidone NN N
iodine NN N
. . N

The DT N
patients NNS N
were VBD N
evaluated VBN N
openly RB N
at IN N
the DT N
seventh JJ N
day NN N
of IN N
treatment NN N
for IN N
cure NN N
or CC N
marked JJ N
improvement NN N
of IN N
the DT N
clinical JJ N
features NNS N
, , N
indicating VBG N
successful JJ N
treatment NN N
. . N

RESULTS NNP N
Three CD N
patients NNS N
were VBD N
lost VBN N
to TO N
follow-up JJ N
. . N

Treatment NN N
was VBD N
successful JJ N
in IN N
57 CD N
of IN N
64 CD N
patients NNS N
treated VBN N
with IN N
amoxicillin NN N
vs. FW N
58 CD N
of IN N
65 CD N
patients NNS N
treated VBN N
with IN N
erythromycin NN N
( ( N
P NNP N
= NNP N
0.00 CD N
) ) N
. . N

CONCLUSIONS NNP N
Amoxicillin NNP N
was VBD N
as RB N
efficacious JJ N
as IN N
erythromycin NN N
in IN N
the DT N
treatment NN N
of IN N
severe JJ 4_p
pyoderma NN 4_p
in IN 4_p
Mali NNP 4_p
. . 4_p

Owing VBG N
to TO N
its PRP$ N
efficacy NN N
, , N
added VBD N
to TO N
high JJ N
availability NN N
and CC N
low JJ N
cost NN N
, , N
this DT N
compound NN N
should MD N
be VB N
considered VBN N
a DT N
first-line JJ N
treatment NN N
of IN N
this DT N
disorder NN N
in IN N
this DT N
country NN N
, , N
and CC N
perhaps RB N
in IN N
other JJ N
countries NNS N
where WRB N
this DT N
condition NN N
presents VBZ N
in IN N
a DT N
similar JJ N
way NN N
. . N

-DOCSTART- -X- O O 21996146

Residual JJ N
platelet NN N
reactivity NN N
, , N
bleedings NNS N
, , N
and CC N
adherence NN N
to TO N
treatment NN N
in IN N
patients NNS N
having VBG N
coronary JJ N
stent JJ N
implantation NN N
treated VBN N
with IN N
prasugrel NN N
. . N

Recent JJ N
guidelines NNS N
have VBP N
recommended VBN N
the DT N
use NN N
of IN N
aspirin NN N
and CC N
prasugrel NN N
in IN N
patients NNS N
with IN N
acute JJ N
coronary JJ N
syndromes NNS N
undergoing VBG N
percutaneous JJ N
coronary JJ N
intervention NN N
. . N

However RB N
, , N
prasugrel NN N
use NN N
has VBZ N
been VBN N
evaluated VBN N
only RB N
in IN N
randomized JJ N
trials NNS N
. . N

This DT N
study NN N
sought VBD N
to TO N
evaluate VB N
bleeding NN N
rates NNS N
and CC N
adherence NN N
to TO N
treatment NN N
in IN N
" JJ N
real-world JJ N
" NN N
patients NNS N
treated VBN N
with IN N
prasugrel NN N
. . N

In IN N
total JJ N
298 CD N
consecutive JJ N
patients NNS N
68 CD N
± JJ N
10 CD N
years NNS N
old JJ N
( ( N
31 CD N
% NN N
> JJ N
75 CD N
years NNS N
old JJ N
) ) N
underwent JJ N
stent JJ N
implantation NN N
and CC N
received VBD N
prasugrel JJ N
therapy NN N
. . N

Indications NNS N
to TO N
prasugrel VB N
therapy NN N
were VBD N
( ( N
1 CD N
) ) N
ST-elevation NNP N
acute JJ N
myocardial JJ N
infarction NN N
( ( N
41 CD N
% NN N
) ) N
, , N
( ( N
2 CD N
) ) N
drug-eluting NN N
stent JJ N
implantation NN N
in IN N
diabetics NNS N
( ( N
24 CD N
% NN N
) ) N
, , N
( ( N
3 CD N
) ) N
stent NN N
thrombosis NN N
( ( N
3 CD N
% NN N
) ) N
, , N
( ( N
4 CD N
) ) N
left VBD N
main JJ N
coronary JJ N
artery NN N
drug-eluting JJ N
stent NN N
implantation NN N
( ( N
6 CD N
% NN N
) ) N
, , N
and CC N
( ( N
5 CD N
) ) N
percutaneous JJ N
coronary JJ N
intervention NN N
in IN N
patients NNS N
with IN N
high JJ N
residual JJ N
platelet NN N
reactivity NN N
on IN N
clopidogrel NN N
therapy NN N
( ( N
26 CD N
% NN N
) ) N
. . N

All DT N
patients NNS N
received VBD N
a DT N
loading NN N
of IN N
prasugrel NN N
60 CD N
mg NN N
. . N

Patients NNS N
≥75 CD N
years NNS N
old JJ N
and CC N
with IN N
body NN N
weight JJ N
≤60 NNP N
kg NN N
received VBD N
a DT N
maintenance NN N
dose NN N
of IN N
5 CD N
mg/day NN N
( ( N
10 CD N
mg/day NN N
for IN N
all PDT N
the DT N
other JJ N
patients NNS N
) ) N
. . N

Follow-up NNP N
data NNS N
including VBG N
adherence NN N
to TO N
prasugrel VB N
therapy NN N
were VBD N
collected VBN N
by IN N
telephone NN N
interviews NNS N
or CC N
outpatient JJ N
visits NNS N
. . N

Minimal JJ N
follow-up JJ N
length NN N
was VBD N
6 CD N
months NNS N
( ( N
mean JJ N
9 CD N
± RB N
3 CD N
) ) N
. . N

Major NNP N
, , N
minor NN N
, , N
and CC N
minimal JJ N
bleedings NNS N
( ( N
Thrombolysis NNP N
In IN N
Myocardial NNP N
Infarction NNP N
criteria NNS N
) ) N
occurred VBD N
in IN N
2.7 CD N
% NN N
, , N
4.7 CD N
% NN N
, , N
and CC N
15.1 CD N
% NN N
of IN N
enrolled JJ N
patients NNS N
. . N

Low JJ N
residual JJ N
platelet NN N
reactivity NN N
( ( N
p JJ N
= NNP N
0.001 CD N
) ) N
and CC N
female JJ N
gender NN N
( ( N
p JJ N
= NNP N
0.29 CD N
) ) N
were VBD N
independent JJ N
predictors NNS N
of IN N
bleeding VBG N
events NNS N
. . N

The DT N
most RBS N
frequent JJ N
minimal JJ N
bleeding VBG N
event NN N
was VBD N
epistaxis RB N
. . N

Only RB N
8 CD N
patients NNS N
( ( N
2.7 CD N
% NN N
) ) N
permanently RB N
discontinued VBN N
prasugrel NN N
therapy NN N
because IN N
of IN N
bleeding VBG N
events NNS N
( ( N
n JJ N
= NNP N
4 CD N
) ) N
, , N
possible JJ N
side NN N
effects NNS N
( ( N
n JJ N
= NNP N
2 CD N
) ) N
, , N
or CC N
medical JJ N
decisions NNS N
not RB N
associated VBN N
with IN N
bleeding NN N
or CC N
side NN N
effects NNS N
( ( N
n JJ N
= NNP N
2 CD N
) ) N
. . N

Fourteen JJ N
patients NNS N
( ( N
4.7 CD N
% NN N
) ) N
temporarily RB N
discontinued VBN N
prasugrel NN N
( ( N
average JJ N
6.5 CD N
days NNS N
) ) N
mainly RB N
because IN N
of IN N
surgical JJ N
procedures NNS N
. . N

No DT N
definite NN N
or CC N
probable JJ N
stent JJ N
thrombosis NN N
occurred VBD N
, , N
although IN N
3 CD N
patients NNS N
develop VB N
de FW N
novo FW N
myocardial JJ N
infarction NN N
and CC N
1 CD N
an DT N
ischemic JJ N
stroke NN N
. . N

There EX N
were VBD N
11 CD N
deaths NNS N
because IN N
of IN N
heart NN N
failure NN N
or CC N
refractory NN N
cardiogenic JJ N
shock NN N
in IN N
9 CD N
, , N
pulmonary JJ N
embolism NN N
in IN N
1 CD N
, , N
and CC N
cancer NN N
in IN N
1 CD N
. . N

In IN N
conclusion NN N
, , N
in IN N
clinical JJ N
practice NN N
, , N
major JJ N
and CC N
minor JJ N
bleeding NN N
event NN N
rates NNS N
associated VBN N
with IN N
prasugrel NN N
therapy NN N
are VBP N
comparable JJ N
to TO N
those DT N
reported VBN N
in IN N
controlled JJ N
randomized JJ N
trials NNS N
. . N

The DT N
minimal JJ N
bleeding JJ N
event NN N
rate NN N
is VBZ N
higher JJR N
than IN N
reported VBN N
but CC N
does VBZ N
not RB N
seem VB N
to TO N
affect VB N
adherence NN N
to TO N
treatment NN N
. . N

-DOCSTART- -X- O O 9303285

Dose-response JJ N
and CC N
concentration-response JJ N
relation NN N
of IN N
rocuronium NN N
infusion NN N
during IN N
propofol-nitrous JJ N
oxide NN N
and CC N
isoflurane-nitrous JJ N
oxide NN N
anaesthesia NN N
. . N

The DT N
dose-response JJ N
and CC N
concentration-response JJ N
relation NN N
of IN N
rocuronium NN N
infusion NN N
was VBD N
studied VBN N
in IN N
20 CD N
adult NN N
surgical JJ N
patients NNS N
during IN N
propofol-nitrous JJ N
oxide NN N
and CC N
isoflurane NN N
( ( N
1 CD N
MAC NNP N
) ) N
-nitrous JJ N
oxide JJ N
anaesthesia NN N
. . N

Neuromuscular JJ N
block NN N
was VBD N
kept VBN N
constant JJ N
, , N
initially RB N
at IN N
90 CD N
% NN N
and CC N
then RB N
at IN N
50 CD N
% NN N
with IN N
a DT N
closed-loop JJ N
feedback NN N
controller NN N
. . N

At IN N
90 CD N
% NN N
block NN N
the DT N
steady-state JJ N
infusion NN N
of IN N
rocuronium NN N
was VBD N
0.55 CD N
+/- JJ N
0.16 CD N
mg JJ N
kg-1 JJ N
h-1 NN N
and CC N
the DT N
corresponding JJ N
concentration NN N
1714 CD N
+/- JJ N
281 CD N
ng JJ N
mL-1 NN N
in IN N
patients NNS N
receiving VBG N
propofol NN N
. . N

At IN N
50 CD N
% NN N
block NN N
the DT N
corresponding JJ N
infusion NN N
rate NN N
was VBD N
0.27 CD N
+/- JJ N
0.11 CD N
mg JJ N
kg-1 JJ N
h-1 NN N
and CC N
the DT N
concentration NN N
1077 CD N
+/- JJ N
244 CD N
ng JJ N
mL-1 NN N
, , N
respectively RB N
. . N

At IN N
50 CD N
% NN N
block NN N
isoflurane NN N
reduced VBD N
the DT N
rate NN N
of IN N
infusion NN N
by IN N
52 CD N
% NN N
( ( N
P NNP N
< NNP N
0.005 CD N
) ) N
and CC N
the DT N
concentration NN N
by IN N
59 CD N
% NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
; : N
at IN N
90 CD N
% NN N
block NN N
both CC N
the DT N
mean JJ N
infusion NN N
rate NN N
and CC N
the DT N
concentration NN N
of IN N
rocuronium NN N
were VBD N
reduced VBN N
by IN N
35 CD N
% NN N
( ( N
P NNP N
< NNP N
0.005 CD N
) ) N
. . N

The DT N
mean JJ N
rocuronium NN N
clearance NN N
at IN N
50 CD N
% NN N
block NN N
was VBD N
unaffected VBN N
by IN N
the DT N
type NN N
of IN N
anaesthesia NN N
; : N
it PRP N
was VBD N
4.1 CD N
+/- JJ N
1.6 CD N
and CC N
4.9 CD N
+/- JJ N
2.7 CD N
mL JJ N
kg-1 JJ N
min-1 NN N
in IN N
the DT N
groups NNS N
receiving VBG N
propofol NN N
and CC N
isoflurane NN N
anaesthesia NN N
, , N
respectively RB N
. . N

We PRP N
conclude VBP N
that IN N
isoflurane NN N
reduces VBZ N
the DT N
infusion NN N
requirements NNS N
of IN N
rocuronium NN N
by IN N
changing VBG N
the DT N
pharmacodynamic JJ N
behaviour NN N
. . N

-DOCSTART- -X- O O 20630604

Effect NN N
of IN N
explicit JJ N
instruction NN N
on IN N
Japanese JJ N
Verbal NNP N
Learning NNP N
Test NNP N
in IN N
schizophrenia NN 4_p
patients NNS N
. . N

After IN N
random JJ N
assignment NN N
of IN N
20 CD N
schizophrenia NN 4_p
patients NNS N
to TO N
either DT N
an DT N
explicit NN N
or CC N
normal JJ N
instruction NN N
group NN N
, , N
the DT N
Japanese JJ N
Verbal NNP N
Learning NNP N
Test NNP N
was VBD N
administered VBN N
to TO N
them PRP N
. . N

Results VB N
reveal NN N
that IN N
explicit JJ N
instruction NN N
group NN N
patients NNS N
demonstrated VBD N
more RBR N
improved JJ N
memory NN N
performance NN N
using VBG N
semantic JJ N
clustering NN N
, , N
suggesting VBG N
that IN N
explicit NN N
and CC N
direct JJ N
teaching NN N
facilitates VBZ N
patients NNS N
' POS N
learning NN N
of IN N
information NN N
. . N

-DOCSTART- -X- O O 24277510

Comparative JJ N
evaluation NN N
of IN N
percutaneous JJ N
laser NN N
and CC N
radiofrequency NN N
ablation NN N
in IN N
patients NNS N
with IN N
HCC NNP 4_p
smaller JJR N
than IN N
4 CD N
cm NN N
. . N

OBJECTIVE CC N
This DT N
study NN N
was VBD N
done VBN N
to TO N
compare VB N
percutaneous JJ N
laser NN N
ablation NN N
( ( N
PLA NNP N
) ) N
and CC N
radiofrequency NN N
thermoablation NN N
( ( N
RFA NNP N
) ) N
for IN N
the DT N
treatment NN N
of IN N
hepatocellular JJ 4_p
carcinoma NN 4_p
( ( N
HCC NNP N
) ) N
≤ VBD N
4 CD N
cm NN N
, , N
in IN N
patients NNS N
with IN N
liver JJ 4_p
cirrhosis NN 4_p
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
Thirty NNP N
patients NNS N
with IN N
single JJ N
HCC NNP N
≤ NNP N
4 CD N
cm NN N
in IN N
diameter NN N
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
two CD N
treatments NNS N
: : N
15 CD N
patients NNS N
were VBD N
treated VBN N
with IN N
PLA NNP N
, , N
using VBG N
a DT N
multifibre NN N
system NN N
connected VBN N
to TO N
a DT N
neodymium JJ N
yttrium-aluminium-garnet NN N
laser NN N
source NN N
; : N
15 CD N
patients NNS N
were VBD N
treated VBN N
with IN N
RFA NNP N
, , N
using VBG N
an DT N
expandable JJ N
needle JJ N
electrode NN N
. . N

Patients NNS N
were VBD N
followed VBN N
up RP N
for IN N
up RB N
to TO N
12 CD N
months NNS N
. . N

RESULTS VB N
A NNP N
complete JJ N
response NN N
was VBD N
obtained VBN N
in IN N
87 CD N
% NN N
lesions NNS N
treated VBN N
with IN N
PLA NNP N
and CC N
in IN N
93 CD N
% NN N
lesions NNS N
treated VBN N
with IN N
RFA NNP N
( ( N
p JJ N
= NNP N
ns NN N
) ) N
. . N

The DT N
overall JJ N
local JJ N
recurrence-free JJ N
survival NN N
rates NNS N
at IN N
3 CD N
, , N
6 CD N
and CC N
12 CD N
months NNS N
were VBD N
comparable JJ N
. . N

However RB N
, , N
a DT N
higher JJR N
rate NN N
of IN N
recurrence NN N
was VBD N
observed VBN N
in IN N
the DT N
PLA NNP N
group NN N
for IN N
lesions NNS N
≥ VBP N
21 CD N
mm NN N
( ( N
p JJ N
= NNP N
0.0081 CD N
) ) N
. . N

A DT N
postablation NN N
syndrome NN N
was VBD N
documented VBN N
in IN N
13 CD N
patients NNS N
( ( N
1 CD N
PLA NNP N
; : N
12 CD N
RFA NNP N
) ) N
. . N

Tumour JJ N
necrosis NN N
factor-α NN N
was VBD N
significantly RB N
higher JJR N
in IN N
the DT N
RFA NNP N
group NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSIONS NNP N
RFA NNP N
is VBZ N
more RBR N
effective JJ N
in IN N
the DT N
treatment NN N
of IN N
HCC NNP N
compared VBN N
to TO N
PLA NNP N
for IN N
lesions NNS N
≥ VBP N
21 CD N
mm NN N
. . N

However RB N
, , N
PLA NNP N
should MD N
be VB N
considered VBN N
a DT N
viable JJ N
treatment NN N
option NN N
for IN N
HCC NNP N
≤ NNP N
20 CD N
mm NN N
, , N
in IN N
view NN N
of IN N
the DT N
lower JJR N
incidence NN N
of IN N
complications NNS N
. . N

-DOCSTART- -X- O O 26181707

Brief JJ N
Report NNP N
: : N
Cobicistat NNP N
Compared NNP N
With IN N
Ritonavir NNP N
as IN N
a DT N
Pharmacoenhancer NNP N
for IN N
Atazanavir NNP N
in IN N
Combination NNP N
With IN N
Emtricitabine/Tenofovir NNP N
Disoproxil NNP N
Fumarate NNP N
: : N
Week JJ N
144 CD N
Results NNPS N
. . N

BACKGROUND NNP N
Cobicistat NNP N
( ( N
COBI NNP N
) ) N
is VBZ N
a DT N
pharmacoenhancer NN N
with IN N
no DT N
antiretroviral JJ N
activity NN N
. . N

METHODS NNP N
International NNP N
, , N
randomized VBD N
double-blind JJ N
active-controlled JJ N
trial NN N
to TO N
evaluate VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
COBI NNP N
vs FW N
ritonavir NN N
( ( N
RTV NNP N
) ) N
as IN N
a DT N
pharmacoenhancer NN N
of IN N
atazanavir NN N
in IN N
combination NN N
with IN N
emtricitabine/tenofovir JJ N
disoproxil NN N
fumarate NN N
in IN N
HIV NNP 4_p
treatment-naive JJ 4_p
patients NNS 4_p
followed VBD N
through IN N
week NN N
144 CD N
. . N

RESULTS NN N
At IN N
Week NNP N
144 CD N
, , N
virologic JJ N
suppression NN N
was VBD N
achieved VBN N
in IN N
72 CD N
% NN N
( ( N
COBI NNP N
) ) N
and CC N
74 CD N
% NN N
( ( N
RTV NNP N
) ) N
of IN N
patients NNS N
. . N

Adverse JJ N
events NNS N
leading VBG N
to TO N
study VB N
drug NN N
discontinuation NN N
occurred VBD N
in IN N
11 CD N
% NN N
of IN N
patients NNS N
in IN N
each DT N
group NN N
. . N

Median JJ N
changes NNS N
in IN N
serum NN N
creatinine NN N
( ( N
mg/dL NN N
) ) N
were VBD N
+0.13 NNP N
( ( N
COBI NNP N
) ) N
and CC N
+0.07 NNP N
( ( N
RTV NNP N
) ) N
and CC N
were VBD N
unchanged JJ N
from IN N
week NN N
48 CD N
. . N

CONCLUSIONS VB N
Once-daily JJ N
COBI NNP N
is VBZ N
a DT N
safe JJ N
and CC N
effective JJ N
pharmacoenhancer NN N
of IN N
the DT N
protease NN N
inhibitor NN N
atazanavir NN N
. . N

-DOCSTART- -X- O O 23482575

Effects NNS N
of IN N
low JJ N
and CC N
high JJ N
protein NN N
: : N
carbohydrate JJ N
ratios NNS N
in IN N
the DT N
diet NN N
of IN N
pregnant JJ N
gilts NNS N
on IN N
maternal JJ N
cortisol NN N
concentrations NNS N
and CC N
the DT N
adrenocortical JJ N
and CC N
sympathoadrenal JJ N
reactivity NN N
in IN N
their PRP$ N
offspring NN N
. . N

Inadequate NNP N
maternal JJ N
nutrition NN N
during IN N
gestation NN N
may MD N
cause VB N
an DT N
adverse JJ N
environment NN N
for IN N
the DT N
fetus NN N
leading VBG N
to TO N
alterations NNS N
of IN N
the DT N
hypothalamic-pituitary-adrenal JJ N
( ( N
HPA NNP N
) ) N
and CC N
sympatho-adrenomedullary JJ N
( ( N
SAM NNP N
) ) N
systems NNS N
later RBR N
in IN N
life NN N
. . N

In IN N
the DT N
present JJ N
study NN N
, , N
we PRP N
investigated VBD N
the DT N
effects NNS N
of IN N
diets NNS N
with IN N
low JJ N
and CC N
high JJ N
protein NN N
: : N
carbohydrate JJ N
ratios NNS N
on IN N
cortisol JJ N
concentrations NNS N
of IN N
pregnant JJ N
gilts NNS N
as RB N
well RB N
as IN N
the DT N
long-term JJ N
effects NNS N
on IN N
the DT N
function NN N
of IN N
the DT N
HPA NNP N
and CC N
SAM NNP N
axes NNS N
in IN N
their PRP$ N
offspring NN N
. . N

Throughout IN N
gestation NN N
, , N
33 CD 4_p
German JJ 4_p
Landrace NNP 4_p
gilts NNS 4_p
were VBD N
fed VBN N
high JJ N
( ( N
HP NNP N
, , N
30 CD N
% NN N
) ) N
, , N
low JJ N
( ( N
LP NNP N
, , N
6.5 CD N
% NN N
) ) N
, , N
or CC N
adequate NN N
( ( N
AP NNP N
, , N
12.1 CD N
% NN N
) ) N
protein NN N
diets NNS N
, , N
which WDT N
were VBD N
made VBN N
isocaloric JJ N
by IN N
adjusting VBG N
the DT N
carbohydrate NN N
content NN N
. . N

The DT N
salivary JJ N
cortisol NN N
concentrations NNS N
of IN N
the DT N
sows NNS N
were VBD N
measured VBN N
in IN N
the DT N
course NN N
of IN N
the DT N
gestation NN N
period NN N
. . N

The DT N
offspring VBG N
were VBD N
cross-fostered JJ N
, , N
and CC N
the DT N
plasma NN N
cortisol NN N
and CC N
catecholamine JJ N
concentrations NNS N
of IN N
the DT N
offspring NN N
were VBD N
determined VBN N
on IN N
postnatal JJ N
d NN N
( ( N
PND NNP N
) ) N
1 CD N
and CC N
27 CD N
and CC N
under IN N
specific JJ N
challenging JJ N
conditions NNS N
: : N
after IN N
weaning VBG N
( ( N
PND NNP N
29 CD N
) ) N
and CC N
after IN N
ACTH NNP N
and CC N
insulin NN N
challenges NNS N
( ( N
PND NNP N
68 CD N
and CC N
70 CD N
, , N
respectively RB N
) ) N
. . N

Glucocorticoid NNP N
receptor NN N
( ( N
GR NNP N
) ) N
binding NN N
and CC N
neurotransmitter JJ N
concentrations NNS N
were VBD N
measured VBN N
in IN N
stress-related JJ N
brain NN N
regions NNS N
, , N
and CC N
histological JJ N
analyses NNS N
of IN N
the DT N
adrenal JJ N
were VBD N
performed VBN N
. . N

Maternal NNP N
salivary JJ N
cortisol NN N
concentrations NNS N
increased VBD N
throughout IN N
gestation NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
the DT N
LP NNP N
gilts NNS N
had VBD N
greater JJR N
salivary JJ N
cortisol NNS N
compared VBN N
with IN N
the DT N
AP NNP N
and CC N
HP NNP N
gilts NNS N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

No UH N
differences NNS N
between IN N
diets NNS N
were VBD N
found VBN N
for IN N
cortisol NN N
, , N
corticosteroid-binding JJ N
globulin NN N
, , N
and CC N
catecholamine JJ N
concentrations NNS N
in IN N
plasma NN N
and CC N
for IN N
GR NNP N
binding NN N
in IN N
hippocampus NN N
and CC N
hypothalamus NN N
in IN N
piglets NNS N
at IN N
PND NNP N
1 CD N
and CC N
27 CD N
. . N

However RB N
, , N
the DT N
cortisol NN N
response NN N
to TO N
weaning NN N
was VBD N
increased VBN N
in IN N
LP NNP N
piglets NNS N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
, , N
and CC N
in IN N
HP NNP N
offspring VBG N
the DT N
basal NN N
plasma VBZ N
noradrenaline JJ N
concentrations NNS N
were VBD N
increased VBN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
cortisol NN N
response NN N
to TO N
the DT N
ACTH NNP N
and CC N
the DT N
insulin NN N
challenge NN N
did VBD N
not RB N
differ VB N
between IN N
diets NNS N
. . N

On IN N
PND NNP N
81 CD N
, , N
an DT N
increased VBN N
adrenal JJ N
medulla NN N
area NN N
was VBD N
observed VBN N
in IN N
LP NNP N
offspring VBG N
compared VBN N
with IN N
the DT N
AP NNP N
offspring NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Our PRP$ N
results NNS N
show VBP N
that IN N
maternal JJ N
diets NNS N
with IN N
aberrant JJ N
protein NN N
: : N
carbohydrate JJ N
ratios NNS N
during IN N
gestation NN N
have VBP N
moderate VBN N
long-term JJ N
effects NNS N
on IN N
the DT N
function NN N
of IN N
the DT N
HPA NNP N
and CC N
SAM NNP N
system NN N
in IN N
the DT N
offspring NN N
, , N
which WDT N
indicates VBZ N
that IN N
pigs NNS N
show VBP N
a DT N
considerable JJ N
plasticity NN N
to TO N
cope VB N
with IN N
maternal JJ N
malnutrition NN N
. . N

-DOCSTART- -X- O O 8499152

Prognostic JJ N
value NN N
of IN N
clinical JJ N
, , N
laboratory NN N
, , N
and CC N
histological JJ N
characteristics NNS N
in IN N
multiple JJ N
myeloma NN N
: : N
improved JJ N
definition NN N
of IN N
risk NN N
groups NNS N
. . N

Follow-up NNP N
data NN N
of IN N
320 CD 4_p
multiple JJ 4_p
myeloma NN 4_p
( ( 4_p
MM NNP 4_p
) ) 4_p
patients NNS 4_p
entering VBG 4_p
the DT 4_p
German JJ 4_p
Myeloma NNP 4_p
Treatment NNP 4_p
Group NNP 4_p
( ( 4_p
GMTG NNP 4_p
) ) 4_p
trial NN 4_p
MM01 NNP 4_p
were VBD N
analysed VBN N
for IN N
factors NNS N
predicting VBG N
overall JJ N
( ( N
OAS NNP N
) ) N
and CC N
tumour $ N
related VBN N
survival NN N
( ( N
TRS NNP N
) ) N
. . N

Response NN N
to TO N
primary JJ N
induction NN N
chemotherapy NN N
was VBD N
relevant JJ N
for IN N
prognosis NN N
if IN N
a DT N
limit NN N
of IN N
25 CD N
% NN N
tumour NN N
cell NN N
mass NN N
( ( N
TCM NNP N
) ) N
reduction NN N
was VBD N
used VBN N
to TO N
separate JJ N
responders NNS N
from IN N
non-responders NNS N
. . N

Furthermore NNP N
, , N
TCM NNP N
, , N
histological JJ N
grading NN N
of IN N
myeloma NN N
cells NNS N
, , N
degree NN N
of IN N
bone NN N
marrow NN N
infiltration NN N
, , N
haemoglobin NN N
, , N
platelet NN N
counts NNS N
, , N
calcium NN N
, , N
creatinine NN N
, , N
albumin NN N
, , N
beta NN N
2M CD N
, , N
and CC N
Bence NNP N
Jones NNP N
proteinuria NNS N
correlated VBD N
to TO N
both DT N
OAS NNP N
and CC N
TRS NNP N
. . N

Age NNP N
was VBD N
relevant JJ N
for IN N
OAS NNP N
only RB N
. . N

The DT N
multivariate NN N
analysis NN N
revealed VBD N
histological JJ N
grading NN N
, , N
TCM NNP N
and CC N
platelets NNS N
as IN N
the DT N
most RBS N
reliable JJ N
prognostic JJ N
factors NNS N
. . N

Based VBN N
on IN N
these DT N
data NNS N
the DT N
Durie/Salmon NNP N
classification NN N
could MD N
be VB N
improved VBN N
by IN N
defining VBG N
poor JJ 4_p
prognosis NN 4_p
patients NNS 4_p
( ( 4_p
50 CD 4_p
% NN 4_p
TRS NNP 4_p
: : 4_p
16 CD 4_p
months NNS 4_p
) ) 4_p
characterised VBN 4_p
by IN 4_p
pretreatment JJ 4_p
platelets NNS 4_p
of IN 4_p
< NN 4_p
or CC 4_p
= $ 4_p
150,000 CD 4_p
and/or JJ N
poorly RB N
differentiated VBN N
myeloma NN N
cell NN N
morphology NN N
. . N

Patients NNS N
lacking VBG N
both DT N
risk NN N
factors NNS N
displayed VBD N
50 CD N
% NN N
survival JJ N
times NNS N
of IN N
46 CD N
months NNS N
in IN N
stage NN N
III NNP N
and CC N
88 CD N
months NNS N
in IN N
stage NN N
II NNP N
. . N

-DOCSTART- -X- O O 15943172

A DT N
short-term JJ N
cognitive JJ N
group NN N
treatment NN N
program NN N
gives VBZ N
substantial JJ N
weight NN N
reduction NN N
up RB N
to TO N
18 CD N
months NNS N
from IN N
the DT N
end NN N
of IN N
treatment NN N
. . N

A DT N
randomized JJ N
controlled JJ N
trial NN N
. . N

OBJECTIVE UH N
To TO N
describe VB N
and CC N
evaluate VB N
long-term JJ N
efficacy NN N
( ( N
18 CD N
months NNS N
from IN N
the DT N
end NN N
of IN N
treatment NN N
) ) N
of IN N
a DT N
new JJ N
cognitive JJ N
short-term JJ N
weight NN N
reducing VBG N
treatment NN N
program NN N
for IN N
obese JJ N
patients NNS N
. . N

SUBJECTS NNP N
One CD N
hundred CD N
and CC N
five CD N
obese JJ N
[ NN N
Body NNP N
Mass NNP N
Index NNP N
( ( N
BMI NNP N
) ) N
> VBD N
or CC N
= $ N
30 CD N
] JJ N
patients NNS N
participated VBN N
in IN N
the DT N
study NN N
. . N

Of IN N
these DT N
, , N
62 CD N
took VBD N
part NN N
in IN N
the DT N
treatment NN N
program NN N
and CC N
43 CD N
served VBD N
as IN N
controls NNS N
. . N

METHOD NNP N
From IN N
an DT N
obesity NN 4_p
unit NN 4_p
's POS 4_p
waiting VBG 4_p
list NN 4_p
, , N
the DT N
patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
either VB N
a DT N
treatment NN N
group NN N
or CC N
remained VBN N
in IN N
the DT N
waiting VBG N
list NN N
to TO N
serve VB N
as IN N
a DT N
control NN N
group NN N
. . N

The DT N
treatment NN N
group NN N
participated VBD N
in IN N
a DT N
10-week JJ N
( ( N
30 CD N
hours NNS N
) ) N
cognitive VBP N
group NN N
treatment NN N
program NN N
. . N

All DT N
participants NNS N
were VBD N
weighed VBN N
at IN N
the DT N
outset NN N
of IN N
the DT N
study NN N
, , N
directly RB N
after IN N
treatment NN N
and CC N
at IN N
a DT N
6- JJ N
, , N
12- JJ N
and CC N
18-month JJ N
post-treatment JJ N
follow-up NN N
without IN N
any DT N
booster NN N
treatment NN N
after IN N
the DT N
10-week JJ N
program NN N
. . N

RESULTS NNP N
Fifty-seven NNP N
( ( N
92 CD N
% NN N
) ) N
patients NNS N
completed VBN N
treatment NN N
. . N

For IN N
the DT N
34 CD N
( ( N
60 CD N
% NN N
) ) N
patients NNS N
who WP N
participated VBD N
in IN N
the DT N
study NN N
18 CD N
months NNS N
after IN N
treatment NN N
was VBD N
terminated VBN N
, , N
the DT N
mean JJ N
weight NN N
loss NN N
at IN N
treatment NN N
's POS N
end NN N
was VBD N
8.5 CD N
kg NN N
( ( N
SD=16.1 NNP N
) ) N
. . N

Eighteen JJ N
months NNS N
later RB N
their PRP$ N
mean JJ N
weight NN N
loss NN N
was VBD N
10.4 CD N
kg NN N
( ( N
SD=10.8 NNP N
) ) N
. . N

The DT N
control NN N
patients NNS N
( ( N
n=31.72 JJ N
% NN N
) ) N
that WDT N
participated VBD N
in IN N
the DT N
study NN N
during IN N
the DT N
same JJ N
period NN N
increased VBD N
in IN N
weight NN N
by IN N
2.3 CD N
kg NNS N
( ( N
SD=7.0 NNP N
) ) N
. . N

The DT N
weight NN N
difference NN N
between IN N
the DT N
treatment NN N
and CC N
control NN N
group NN N
at IN N
the DT N
18-month JJ N
follow-up NN N
was VBD N
highly RB N
significant JJ N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

CONCLUSION VB N
The DT N
cognitive JJ N
group NN N
treatment NN N
program NN N
was VBD N
highly RB N
acceptable JJ N
among IN N
the DT N
participants NNS N
and CC N
was VBD N
completed VBN N
by IN N
nearly RB N
all PDT N
the DT N
patients NNS N
. . N

The DT N
10-week JJ N
treatment NN N
program NN N
resulted VBD N
in IN N
satisfactory JJ N
weight JJ N
loss NN N
. . N

The DT N
weight NN N
difference NN N
between IN N
the DT N
treatment NN N
group NN N
and CC N
controls NNS N
was VBD N
nearly RB N
the DT N
same JJ N
at IN N
18 CD N
months NNS N
after IN N
end NN N
of IN N
treatment NN N
as IN N
at IN N
six CD N
months NNS N
. . N

The DT N
study NN N
, , N
therefore RB N
, , N
does VBZ N
not RB N
provide VB N
support NN N
for IN N
the DT N
contention NN N
that IN N
a DT N
lengthy JJ N
therapy NN N
for IN N
obesity NN N
is VBZ N
necessary JJ N
if IN N
treatment NN N
results NNS N
are VBP N
lasting VBG N
. . N

-DOCSTART- -X- O O 18716736

Behavior NNP N
in IN N
children NNS N
with IN N
Down NNP 4_p
syndrome NN 4_p
. . N

OBJECTIVE UH N
To TO N
highlight VB N
the DT N
differences NNS N
in IN N
behaviors NNS N
in IN N
children NNS N
with IN N
diagnosis NN N
of IN N
Down NNP N
syndrome NN N
. . N

METHOD NNP N
Eight NNP N
children NNS N
with IN N
Down NNP 4_p
syndrome NN 4_p
who WP N
displayed VBD N
autistic JJ 4_p
features NNS N
were VBD N
compared VBN N
with IN N
eight CD N
Down NNP 4_p
syndrome NN 4_p
children NNS 4_p
without IN N
autistic JJ N
features NNS N
. . N

These DT N
children NNS N
were VBD N
randomly RB N
selected VBN N
and CC N
were VBD N
matched VBN N
for IN N
age NN N
and CC N
level NN N
of IN N
retardation NN N
. . N

Standardized JJ N
Psychological JJ N
tests NNS N
were VBD N
administered VBN N
to TO N
tap VB N
the DT N
behavioral JJ N
differences NNS N
. . N

Mann-Whitney NNP N
U NNP N
test NN N
was VBD N
used VBN N
for IN N
significance NN N
of IN N
difference NN N
between IN N
both CC N
the DT N
groups NNS N
. . N

RESULTS NNP N
Down NNP N
syndrome JJ N
children NNS N
without IN N
Autism NNP N
Spectrum NNP N
Disorder NNP N
had VBD N
better JJR N
communication NN N
and CC N
socialization NN N
skills NNS N
than IN N
children NNS N
with IN N
Down NNP N
syndrome NN N
with IN N
Autism NNP N
Spectrum NNP N
Disorder NNP N
. . N

Down NNP N
syndrome JJ N
children NNS N
with IN N
Autism NNP N
Spectrum NNP N
Disorder NNP N
displayed VBD N
more RBR N
restricted JJ N
repetitive NN N
and CC N
stereotyped VBD N
patterns NNS N
of IN N
behaviors NNS N
, , N
interests NNS N
and CC N
activities NNS N
. . N

CONCLUSION NNP N
Our PRP$ N
findings NNS N
indicate VBP N
that IN N
Autism NNP N
Spectrum NNP N
Disorder NNP N
manifests VBZ N
as IN N
a DT N
distinct JJ N
behavioral JJ N
phenomenon NN N
in IN N
Down NNP N
syndrome NN N
. . N

Hence NN N
it PRP N
is VBZ N
important JJ N
for IN N
professionals NNS N
to TO N
consider VB N
the DT N
possibility NN N
of IN N
a DT N
dual JJ N
diagnosis NN N
which WDT N
will MD N
entitle VB N
the DT N
child NN N
to TO N
a DT N
more JJR N
specialized JJ N
and CC N
effective JJ N
educational JJ N
and CC N
intervention NN N
services NNS N
. . N

-DOCSTART- -X- O O 8104273

Citalopram NNP N
for IN N
post-stroke JJ N
pathological JJ N
crying NN N
. . N

Post-stroke NNP N
pathological JJ N
crying NN N
is VBZ N
a DT N
distressing VBG N
condition NN N
in IN N
which WDT N
episodes VBZ N
occur VBP N
in IN N
response NN N
to TO N
minor VB N
stimuli NNS N
without IN N
associated VBN N
mood NN N
changes NNS N
. . N

There EX N
is VBZ N
preliminary JJ N
evidence NN N
of IN N
disturbed JJ N
serotoninergic JJ N
neurotransmission NN N
in IN N
such JJ N
cases NNS N
. . N

We PRP N
investigated VBD N
the DT N
effect NN N
of IN N
the DT N
selective JJ N
serotonin NN N
reuptake NN N
inhibitor NN N
citalopram NN N
on IN N
uncontrolled JJ N
crying NN N
in IN N
stroke NN 4_p
patients NNS N
in IN N
a DT N
double-blind JJ N
placebo-controlled JJ N
crossover NN N
study NN N
. . N

16 CD N
consecutive JJ N
patients NNS N
( ( N
median JJ N
age NN N
58.5 CD N
years NNS N
, , N
range VB N
40-83 JJ N
) ) N
entered VBD N
the DT N
9-week JJ N
study NN N
a DT N
median NN N
of IN N
168 CD N
days NNS N
( ( N
range VB N
6-913 NNP N
) ) N
post NN N
stroke NN N
and CC N
were VBD N
treated VBN N
with IN N
citalopram JJ N
10-20 JJ N
mg NNS N
daily RB N
for IN N
3 CD N
weeks NNS N
. . N

Crying VBG 4_p
history NN 4_p
was VBD N
determined VBN N
from IN N
semistructured VBN N
interviews NNS N
and CC N
from IN N
diaries NNS N
kept VBN N
by IN N
the DT N
patients NNS N
. . N

Psychiatric NNP N
assessment NN N
was VBD N
made VBN N
with IN N
the DT N
Hamilton NNP N
depression NN N
scale NN N
( ( N
HDS NNP N
) ) N
, , N
and CC N
unwanted JJ N
effects NNS N
were VBD N
measured VBN N
with IN N
the DT N
UKU NNP N
side-effect JJ N
scale NN N
. . N

In IN N
13 CD N
patients NNS N
in IN N
whom WP N
frequency NN N
of IN N
crying NN 4_p
could MD N
be VB N
assessed VBN N
, , N
the DT N
number NN N
of IN N
daily JJ N
crying VBG N
episodes NNS N
decreased VBN N
by IN N
at IN N
least JJS N
50 CD N
% NN N
in IN N
all DT N
cases NNS N
during IN N
citalopram JJ N
treatment NN N
vs NN N
2 CD N
patients NNS N
during IN N
placebo JJ N
treatment NN N
( ( N
p JJ N
< NN N
0.005 CD N
, , N
McNemar NNP N
's POS N
test NN N
) ) N
, , N
the DT N
effect NN N
being VBG N
rapid JJ N
( ( N
1-3 JJ N
days NNS N
) ) N
and CC N
pronounced VBN N
in IN N
11 CD N
( ( N
73 CD N
% NN N
) ) N
. . N

There EX N
was VBD N
a DT N
concomitant JJ N
significant JJ N
decrease NN N
in IN N
depression NN N
rating NN N
from IN N
HDS NNP N
8.9 CD N
to TO N
5.3 CD N
( ( N
p NN N
< VBZ N
0.005 CD N
, , N
Wilcoxon NNP N
's POS N
test NN N
) ) N
. . N

Citalopram NNP N
was VBD N
well RB N
tolerated VBN N
, , N
the DT N
few JJ N
side-effects NNS N
being VBG N
mild JJ N
and CC N
transient JJ N
. . N

We PRP N
conclude VBP N
that IN N
serotoninergic JJ N
neurotransmission NN N
plays VBZ N
an DT N
important JJ N
part NN N
in IN N
post-stroke JJ N
pathological JJ N
crying NN N
and CC N
that DT N
citalopram NN N
is VBZ N
an DT N
effective JJ N
and CC N
well-tolerated JJ N
treatment NN N
. . N

-DOCSTART- -X- O O 393286

A DT N
comparative JJ N
study NN N
of IN N
methyldopa NN N
and CC N
labetalol NN N
in IN N
the DT N
treatment NN N
of IN N
hypertension NN 4_p
. . N

1 CD N
Twenty CD N
patients NNS N
with IN N
essential JJ N
hypertension NN N
completed VBD N
a DT N
double-blind JJ N
, , N
dose-tritrated JJ N
, , N
cross-over JJ N
comparison NN N
of IN N
methyldopa NN N
and CC N
labetalol NN N
. . N

2 CD N
Average JJ N
lying VBG N
BPs NNP N
( ( N
systolic/diastolic JJ N
) ) N
were VBD N
reduced VBN N
by IN N
28/15 CD N
mmHg NNS N
with IN N
methyldopa NN N
and CC N
by IN N
23/15 CD N
mmHg NNS N
with IN N
labetalol NN N
. . N

3 CD N
Average JJ N
standing VBG N
BPs NNP N
( ( N
systolic/diastolic JJ N
) ) N
were VBD N
reduced VBN N
by IN N
29/14 CD N
mmHg NNS N
with IN N
methyldopa NN N
and CC N
by IN N
29/15 CD N
mmHg NNS N
with IN N
labetalol NN N
. . N

4 CD N
Both DT N
lying NN N
and CC N
standing VBG N
heart NN N
rates NNS N
were VBD N
reduced VBN N
with IN N
labetalol NN N
. . N

5 CD N
It PRP N
is VBZ N
concluded VBN N
that IN N
the DT N
antihypertensive JJ N
properties NNS N
of IN N
labetalol NN N
and CC N
methyldopa NN N
are VBP N
similar JJ N
but CC N
that IN N
larger JJR N
patient NN N
populations NNS N
are VBP N
needed VBN N
to TO N
study VB N
the DT N
relative JJ N
incidence NN N
of IN N
subjective JJ N
adverse JJ N
effects NNS N
. . N

-DOCSTART- -X- O O 24323035

Randomized VBN N
, , N
placebo-controlled JJ N
, , N
phase JJ N
III NNP N
trial NN N
of IN N
sunitinib JJ N
plus CC N
prednisone JJ N
versus NN N
prednisone NN N
alone RB N
in IN N
progressive JJ 4_p
, , 4_p
metastatic JJ 4_p
, , 4_p
castration-resistant JJ 4_p
prostate NN 4_p
cancer NN 4_p
. . 4_p

PURPOSE NNP N
We PRP N
evaluated VBD N
angiogenesis-targeted JJ N
sunitinib NN N
therapy NN N
in IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
trial NN N
of IN N
metastatic JJ N
castration-resistant JJ N
prostate NN N
cancer NN N
( ( N
mCRPC NN N
) ) N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
Men NNP N
with IN N
progressive JJ N
mCRPC NN N
after IN N
docetaxel-based JJ N
chemotherapy NN N
were VBD N
randomly RB N
assigned VBN N
2:1 CD N
to TO N
receive VB N
sunitinib NN N
37.5 CD N
mg/d NN N
continuously RB N
or CC N
placebo VB N
. . N

Patients NNS N
also RB N
received VBD N
oral JJ N
prednisone NN N
5 CD N
mg NN N
twice RB N
daily RB N
. . N

The DT N
primary JJ N
end NN N
point NN N
was VBD N
overall JJ N
survival NN N
( ( N
OS NNP N
) ) N
; : N
secondary JJ N
end NN N
points NNS N
included VBD N
progression-free JJ N
survival NN N
( ( N
PFS NNP N
) ) N
. . N

Two CD N
interim JJ N
analyses NNS N
were VBD N
planned VBN N
. . N

RESULTS NNP N
Overall NNP N
, , N
873 CD N
patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
sunitinib NN N
( ( N
n JJ N
= NNP N
584 CD N
) ) N
or CC N
placebo NN N
( ( N
n JJ N
= NNP N
289 CD N
) ) N
. . N

The DT N
independent JJ N
data NNS N
monitoring VBG N
committee NN N
stopped VBD N
the DT N
study NN N
for IN N
futility NN N
after IN N
the DT N
second JJ N
interim JJ N
analysis NN N
. . N

After IN N
a DT N
median JJ N
overall JJ N
follow-up NN N
of IN N
8.7 CD N
months NNS N
, , N
median JJ N
OS NNP N
was VBD N
13.1 CD N
months NNS N
and CC N
11.8 CD N
months NNS N
for IN N
sunitinib NN N
and CC N
placebo NN N
, , N
respectively RB N
( ( N
hazard JJ N
ratio NN N
[ NNP N
HR NNP N
] NNP N
, , N
0.914 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.762 CD N
to TO N
1.097 CD N
; : N
stratified VBN N
log-rank JJ N
test NN N
, , N
P NNP N
= NNP N
.168 NNP N
) ) N
. . N

PFS NNP N
was VBD N
significantly RB N
improved VBN N
in IN N
the DT N
sunitinib NN N
arm NN N
( ( N
median JJ N
5.6 CD N
v JJ N
4.1 CD N
months NNS N
; : N
HR NNP N
, , N
0.725 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.591 CD N
to TO N
0.890 CD N
; : N
stratified VBN N
log-rank JJ N
test NN N
, , N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

Toxicity NN N
and CC N
rates NNS N
of IN N
discontinuations NNS N
because IN N
of IN N
adverse JJ N
events NNS N
( ( N
AEs NNP N
; : N
27 CD N
% NN N
v JJ N
7 CD N
% NN N
) ) N
were VBD N
greater JJR N
with IN N
sunitinib JJR N
than IN N
placebo NN N
. . N

The DT N
most RBS N
common JJ N
treatment-related JJ N
grade NN N
3/4 CD N
AEs NNP N
were VBD N
fatigue JJ N
( ( N
9 CD N
% NN N
v JJ N
1 CD N
% NN N
) ) N
, , N
asthenia RB N
( ( N
8 CD N
% NN N
v JJ N
2 CD N
% NN N
) ) N
, , N
and CC N
hand-foot JJ N
syndrome NN N
( ( N
7 CD N
% NN N
v JJ N
0 CD N
% NN N
) ) N
. . N

Frequent JJ N
treatment-emergent JJ N
grade NN N
3/4 CD N
hematologic JJ N
abnormalities NNS N
were VBD N
lymphopenia JJ N
( ( N
20 CD N
% NN N
v JJ N
11 CD N
% NN N
) ) N
, , N
anemia NN N
( ( N
9 CD N
% NN N
v JJ N
8 CD N
% NN N
) ) N
, , N
and CC N
neutropenia NN N
( ( N
6 CD N
% NN N
v NN N
< CD N
1 CD N
% NN N
) ) N
. . N

CONCLUSION VB N
The DT N
addition NN N
of IN N
sunitinib NN N
to TO N
prednisone VB N
did VBD N
not RB N
improve VB N
OS NNP N
compared VBN N
with IN N
placebo NN N
in IN N
docetaxel-refractory JJ N
mCRPC NN N
. . N

The DT N
role NN N
of IN N
antiangiogenic JJ N
therapy NN N
in IN N
mCRPC NN N
remains VBZ N
investigational JJ N
. . N

-DOCSTART- -X- O O 11832869

Changes NNS N
in IN N
selected VBN N
fitness NN N
parameters NNS N
following VBG N
six CD N
weeks NNS N
of IN N
snowshoe JJ N
training NN N
. . N

BACKGROUND NNP N
Recently RB N
, , N
there EX N
has VBZ N
been VBN N
an DT N
increase NN N
in IN N
popularity NN N
and CC N
participation NN N
in IN N
the DT N
sport NN N
of IN N
snowshoeing VBG N
. . N

While IN N
the DT N
sport NN N
has VBZ N
gained VBN N
considerable JJ N
recognition NN N
, , N
to TO N
date NN N
there EX N
is VBZ N
little JJ N
or CC N
no DT N
scientific JJ N
research NN N
regarding VBG N
training NN N
responses NNS N
to TO N
snowshoeing VBG N
as IN N
a DT N
form NN N
of IN N
exercise NN N
. . N

Therefore RB N
, , N
the DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
whether IN N
snowshoe JJ N
training NN N
could MD N
improve VB N
fitness NN N
measures NNS N
. . N

A DT N
further JJ N
purpose NN N
was VBD N
to TO N
compare VB N
responses NNS N
from IN N
a DT N
snowshoe JJ N
training NN N
program NN N
to TO N
a DT N
similarly RB N
designed VBN N
run RP N
training VBG N
program NN N
. . N

METHODS NNP N
This DT N
prospective JJ N
, , N
comparative JJ N
study NN N
was VBD N
conducted VBN N
with IN N
healthy JJ 4_p
males NNS N
and CC N
females NNS N
between IN N
the DT N
ages NNS N
of IN N
19 CD N
and CC N
24 CD N
. . N

These DT N
subjects NNS N
were VBD N
recruited VBN N
from IN N
the DT N
University NNP N
of IN N
Vermont NNP N
population NN N
and CC N
surrounding VBG N
community NN N
. . N

Following VBG N
baseline NN N
measurements NNS N
in IN N
VO2max NNP N
, , N
running VBG N
time NN N
to TO N
exhaustion NN N
( ( N
RTE NNP N
) ) N
, , N
and CC N
anthropometry NN N
, , N
17 CD N
subjects NNS N
( ( N
10 CD N
snowshoers NNS N
and CC N
7 CD N
runners NNS N
) ) N
participated VBD N
in IN N
a DT N
six CD N
week NN N
conditioning VBG N
program NN N
. . N

Both DT N
groups NNS N
exercised VBD N
for IN N
30 CD N
min NNS N
at IN N
75-85 CD N
% NN N
age NN N
predicted VBD N
maximum JJ N
heart NN N
rate NN N
, , N
3-4 JJ N
times NNS N
per IN N
week NN N
, , N
for IN N
a DT N
total NN N
of IN N
18 CD N
sessions NNS N
. . N

RESULTS NNP N
VO2max NNP N
improved VBD N
significantly RB N
in IN N
both DT N
running NN N
and CC N
snowshoeing VBG N
groups NNS N
, , N
6.3 CD N
and CC N
8.5 CD N
% NN N
, , N
respectively RB N
. . N

Run VB N
time NN N
to TO N
exhaustion NN N
also RB N
improved VBN N
significantly RB N
in IN N
both DT N
groups NNS N
, , N
23.3 CD N
and CC N
33.5 CD N
% NN N
, , N
respectively RB N
. . N

There EX N
were VBD N
no DT N
changes NNS N
in IN N
anthropometry NN N
for IN N
either DT N
group NN N
. . N

With IN N
the DT N
exception NN N
of IN N
RTE NNP N
, , N
there EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
between IN N
groups NNS N
in IN N
any DT N
other JJ N
measurements NNS N
at IN N
baseline NN N
. . N

CONCLUSIONS NNP N
These DT N
results NNS N
support VBD N
the DT N
acceptability NN N
of IN N
snowshoeing VBG N
as IN N
a DT N
valid JJ N
means NN N
to TO N
improve VB N
or CC N
maintain VB N
cardiovascular JJ N
endurance NN N
. . N

-DOCSTART- -X- O O 15830983

Disc NNP N
coablation NN N
and CC N
epidural JJ N
injection NN N
of IN N
steroids NNS N
: : N
a DT N
comparison NN N
of IN N
strategies NNS N
in IN N
the DT N
treatment NN N
of IN N
mechanical JJ 4_p
spinal JJ 4_p
discogenic NN 4_p
pain NN 4_p
. . 4_p

In IN N
this DT N
study NN N
two CD N
strategies NNS N
in IN N
the DT N
treatment NN N
of IN N
Mechanical NNP N
Spinal NNP N
Discogenic NNP N
Pain NNP N
have VBP N
been VBN N
compared VBN N
: : N
Disc NNP N
Coablation NNP N
and CC N
Epidural NNP N
Injection NNP N
of IN N
Steroids NNP N
. . N

In IN N
2003 CD N
50 CD N
patients NNS N
treated VBN N
with IN N
one CD N
or CC N
two CD N
epidural JJ N
injections NNS N
have VBP N
been VBN N
selected VBN N
" JJ N
ad NN N
random NN N
" NNP N
and CC N
50 CD N
patients NNS N
treated VBN N
with IN N
disc JJ N
coablation NN N
. . N

Comparison NNP N
of IN N
the DT N
data NNS N
indicated VBD N
an DT N
improvement NN N
of IN N
average JJ N
VAS NNP N
when WRB N
relaxed NN N
for IN N
both DT N
groups NNS N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
, , N
while IN N
after IN N
slight-moderate JJ N
strain NN N
, , N
this DT N
value NN N
was VBD N
significant JJ N
only RB N
after IN N
coablation NN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

Finally RB N
, , N
average JJ N
VAS NNP N
was VBD N
clearly RB N
lower JJR N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
after IN N
coablation NN N
as IN N
compared VBN N
to TO N
epidural JJ N
injections NNS N
. . N

-DOCSTART- -X- O O 20304413

Efficacy NN N
and CC N
safety NN N
of IN N
a DT N
high JJ N
protein NN N
, , N
low JJ N
carbohydrate NN N
diet NN N
for IN N
weight JJ N
loss NN N
in IN N
severely JJ N
obese JJ N
adolescents NNS N
. . N

OBJECTIVE NNP N
To TO N
evaluate VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
a DT N
carbohydrate NN N
restricted VBN N
versus IN N
a DT N
low JJ N
fat NN N
diet NN N
on IN N
weight JJ N
loss NN N
, , N
metabolic JJ N
markers NNS N
, , N
body NN N
composition NN N
, , N
and CC N
cardiac JJ N
function NN N
tests NNS N
in IN N
severely RB N
obese JJ N
adolescents NNS N
. . N

STUDY NNP N
DESIGN NNP N
Subjects NNP N
were VBD N
randomly RB N
assigned VBN N
to TO N
1 CD N
of IN N
2 CD N
diets NNS N
: : N
a DT N
high JJ N
protein NN N
, , N
low JJ N
carbohydrate NN N
( ( N
20 CD N
g/d NN N
) ) N
diet NN N
( ( N
high JJ N
protein NN N
, , N
low JJ N
carbohydrate NN N
, , N
HPLC NNP N
) ) N
or CC N
low JJ N
fat NN N
( ( N
30 CD N
% NN N
of IN N
calories NNS N
) ) N
regimen VBP N
for IN N
13 CD N
weeks NNS N
; : N
close JJ N
monitoring NN N
was VBD N
maintained VBN N
to TO N
evaluate VB N
safety NN N
. . N

After IN N
the DT N
intervention NN N
, , N
no DT N
clinical JJ N
contact NN N
was VBD N
made VBN N
until IN N
follow-up JJ N
measurements NNS N
were VBD N
obtained VBN N
at IN N
24 CD N
and CC N
36 CD N
weeks NNS N
from IN N
baseline NN N
. . N

The DT N
primary JJ N
outcome NN N
was VBD N
change NN N
in IN N
body NN N
mass NN N
index NN N
Z-score NNP N
for IN N
age NN N
and CC N
sex NN N
( ( N
BMI-Z NNP N
) ) N
at IN N
13 CD N
, , N
24 CD N
, , N
and CC N
36 CD N
weeks NNS N
. . N

RESULTS NNP N
Forty-six JJ N
subjects NNS N
( ( N
24 CD N
HPLC NNP N
, , N
22 CD N
in IN N
low JJ N
fat NN N
) ) N
initiated VBD N
and CC N
33 CD N
subjects NNS N
completed VBD N
the DT N
intervention NN N
; : N
follow-up JJ N
data NNS N
were VBD N
available JJ N
on IN N
approximately RB N
half NN N
of IN N
the DT N
subjects NNS N
. . N

Significant JJ N
reduction NN N
in IN N
( ( N
BMI-Z NNP N
) ) N
was VBD N
achieved VBN N
in IN N
both DT N
groups NNS N
during IN N
intervention NN N
and CC N
was VBD N
significantly RB N
greater JJR N
for IN N
the DT N
HPLC NNP N
group NN N
( ( N
P NNP N
= NNP N
.03 NNP N
) ) N
. . N

Both DT N
groups NNS N
maintained VBD N
significant JJ N
BMI-Z JJ N
reduction NN N
at IN N
follow-up NN N
; : N
changes NNS N
were VBD N
not RB N
significantly RB N
different JJ N
between IN N
groups NNS N
. . N

Loss NNP N
of IN N
lean JJ N
body NN N
mass NN N
was VBD N
not RB N
spared VBN N
in IN N
the DT N
HPLC NNP N
group NN N
. . N

No DT N
serious JJ N
adverse JJ N
effects NNS N
were VBD N
observed VBN N
related VBN N
to TO N
metabolic JJ N
profiles NNS N
, , N
cardiac JJ N
function NN N
, , N
or CC N
subjective JJ N
complaints NNS N
. . N

CONCLUSIONS VB N
The DT N
HPLC NNP N
diet NN N
is VBZ N
a DT N
safe JJ N
and CC N
effective JJ N
option NN N
for IN N
medically RB N
supervised VBN N
weight JJ N
loss NN N
in IN N
severely JJ N
obese JJ N
adolescents NNS N
. . N

-DOCSTART- -X- O O 21692873

Effects NNS N
of IN N
dietary JJ N
pyridoxine NN N
on IN N
haemato-immunological JJ N
responses NNS N
of IN N
Labeo NNP N
rohita JJ N
fingerlings NNS N
reared VBD N
at IN N
higher JJR N
water NN N
temperature NN N
. . N

A DT N
sixty-day JJ N
feeding NN N
trial NN N
was VBD N
carried VBN N
out IN N
to TO N
elucidate VB N
the DT N
effect NN N
of IN N
dietary JJ N
pyridoxine NN N
( ( N
PN NNP N
) ) N
on IN N
hemato-immunological JJ N
parameters NNS N
in IN N
Labeo NNP N
rohita VBP N
fingerlings NNS N
exposed VBN N
to TO N
an DT N
elevated JJ N
temperature NN N
( ( N
ET NNP N
) ) N
of IN N
33 CD N
°C NNS N
. . N

Two CD N
hundred VBD N
and CC N
seventy JJ N
fingerlings NNS N
( ( N
6.71 CD N
± RB N
0.32 CD N
g NN N
) ) N
were VBD N
randomly RB N
distributed VBN N
into IN N
six CD N
treatments NNS N
in IN N
triplicates NNS N
( ( N
15 CD N
fish/tank NN N
) ) N
. . N

Five CD N
iso-nitrogenous JJ N
( ( N
356.3 CD N
± RB N
2.7 CD N
g/kg JJ N
crude NN N
protein NN N
) ) N
purified VBD N
diets NNS N
were VBD N
prepared VBN N
with IN N
graded JJ N
levels NNS N
( ( N
0 CD N
, , N
10 CD N
, , N
50 CD N
, , N
100 CD N
and CC N
200 CD N
mg/kg NNS N
diet JJ N
) ) N
of IN N
PN NNP N
. . N

Six NNP N
treatment NN N
groups NNS N
were VBD N
P10T26 NNP N
( ( N
10 CD N
mg NN N
PN NNP N
+ NNP N
ambient JJ N
temperature NN N
( ( N
26 CD N
°C NN N
) ) N
, , N
P0T33 NNP N
( ( N
0 CD N
mg NN N
PN NNP N
+ NNP N
ET NNP N
) ) N
, , N
P10T33 NNP N
( ( N
10 CD N
mg NN N
PN NNP N
+ NNP N
ET NNP N
) ) N
, , N
P50T33 NNP N
( ( N
50 CD N
mg NN N
PN NNP N
+ NNP N
ET NNP N
) ) N
, , N
P100T33 NNP N
( ( N
100 CD N
mg NN N
PN NNP N
+ NNP N
ET NNP N
) ) N
and CC N
P200T33 NNP N
( ( N
200 CD N
mg NN N
PN NNP N
+ NNP N
ET NNP N
) ) N
. . N

The DT N
responses NNS N
of IN N
L. NNP N
rohita JJ N
fingerlings NNS N
to TO N
dietary JJ N
PN NNP N
were VBD N
assessed VBN N
in IN N
terms NNS N
of IN N
growth NN N
and CC N
by IN N
analysing VBG N
some DT N
hemato-immunological JJ N
parameters NNS N
. . N

When WRB N
PN NNP N
supplementation NN N
increased VBD N
from IN N
10 CD N
to TO N
200 CD N
mg/kg NNS N
diet JJ N
, , N
a DT N
significant JJ N
improvement NN N
in IN N
weight JJ N
gain NN N
percentage NN N
was VBD N
observed VBN N
. . N

Erythrocyte NNP N
( ( N
RBC NNP N
) ) N
count NN N
, , N
leucocyte NN N
( ( N
WBC NNP N
) ) N
count NN N
, , N
haemoglobin NN N
content NN N
and CC N
respiratory JJ N
burst NN N
activity NN N
were VBD N
significantly RB N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
higher JJR N
in IN N
100 CD N
mg JJ N
PN/kg NNP N
diet-fed NN N
group NN N
than IN N
their PRP$ N
non-PN-fed JJ N
counterpart NN N
. . N

Also RB N
, , N
serum JJ N
albumin NN N
, , N
globulin NN N
and CC N
lysozyme JJ N
activity NN N
were VBD N
found VBN N
significantly RB N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
higher JJR N
in IN N
PN-fed NNP N
groups NNS N
. . N

The DT N
overall JJ N
results NNS N
indicated VBD N
that IN N
dietary JJ N
PN NNP N
supplementation NN N
at IN N
100 CD N
mg/kg NNS N
diet JJ N
may MD N
reverse VB N
the DT N
negative JJ N
effects NNS N
caused VBN N
by IN N
ET NNP N
and CC N
may MD N
protect VB N
the DT N
haemato-immunological JJ N
status NN N
of IN N
L. NNP N
rohita JJ N
fingerlings NNS N
reared VBD N
at IN N
higher JJR N
water NN N
temperature NN N
. . N

-DOCSTART- -X- O O 25801501

The DT N
Effects NNPS N
of IN N
Naltrexone NNP N
on IN N
Subjective NNP N
Response NNP N
to TO N
Methamphetamine NNP N
in IN N
a DT N
Clinical JJ N
Sample NN N
: : N
a DT N
Double-Blind NNP N
, , N
Placebo-Controlled NNP N
Laboratory NNP N
Study NNP N
. . N

Methamphetamine NNP 4_p
( ( 4_p
MA NNP 4_p
) ) 4_p
use NN 4_p
disorder NN 4_p
is VBZ N
a DT N
serious JJ N
psychiatric JJ N
condition NN N
for IN N
which WDT N
there EX N
are VBP N
no DT N
FDA-approved JJ N
medications NNS N
. . N

Naltrexone NNP N
( ( N
NTX NNP N
) ) N
is VBZ N
an DT N
opioid JJ N
receptor NN N
antagonist NN N
with IN N
demonstrated JJ N
efficacy NN N
, , N
albeit IN N
moderate JJ N
, , N
for IN N
the DT N
treatment NN N
of IN N
alcoholism NN N
and CC N
opioid JJ N
dependence NN N
. . N

Preclinical NNP N
and CC N
clinical JJ N
studies NNS N
suggest VBP N
that IN N
NTX NNP N
may MD N
be VB N
useful JJ N
for IN N
the DT N
treatment NN N
of IN N
MA NNP N
use NN N
disorder NN N
. . N

To TO N
inform VB N
treatment NN N
development NN N
, , N
we PRP N
conducted VBD N
a DT N
double-blind NN N
, , N
randomized VBN N
, , N
crossover NN N
, , N
placebo-controlled JJ N
human JJ N
laboratory NN N
study NN N
of IN N
NTX NNP N
. . N

Non-treatment-seeking JJ N
individuals NNS N
meeting VBG N
DSM-IV NNP N
criteria NNS N
for IN N
MA NNP 4_p
abuse NN 4_p
or CC 4_p
dependence NN 4_p
( ( N
n=30 NN N
) ) N
completed VBD N
two CD N
separate JJ N
5-day JJ N
inpatient NN N
stays NNS N
. . N

During IN N
each DT N
admission NN N
, , N
participants NNS N
completed VBD N
testing VBG N
sessions NNS N
comprised VBN N
of IN N
MA NNP N
cue-reactivity NN N
and CC N
intravenous JJ N
MA NNP N
administration NN N
( ( N
30 CD N
mg NN N
) ) N
after IN N
receiving VBG N
oral JJ N
NTX NNP N
( ( N
50 CD N
mg NN N
) ) N
or CC N
placebo NN N
for IN N
4 CD N
days NNS N
. . N

This DT N
study NN N
tested VBD N
the DT N
hypotheses NNS N
that WDT N
NTX NNP N
would MD N
( ( N
a DT N
) ) N
attenuate NN N
cue-induced JJ N
MA NNP N
craving NN N
, , N
and CC N
( ( N
b NN N
) ) N
reduce VB N
subjective JJ N
responses NNS N
to TO N
MA NNP N
administration NN N
. . N

Results NNP N
largely RB N
supported VBD N
the DT N
study NN N
hypotheses NNS N
such JJ N
that IN N
( ( N
a DT N
) ) N
NTX NNP N
significantly RB N
blunted VBD N
cue-induced JJ N
craving NN N
for IN N
MA NNP N
and CC N
( ( N
b NN N
) ) N
attenuated VBD N
several JJ N
of IN N
the DT N
hedonic JJ N
subjective JJ N
effects NNS N
of IN N
MA NNP N
, , N
including VBG N
craving NN N
, , N
during IN N
controlled VBN N
MA NNP N
administration NN N
and CC N
as IN N
compared VBN N
with IN N
placebo NN N
. . N

NTX NNP N
decreased VBD N
overall JJ N
subjective JJ N
ratings NNS N
of IN N
'crave JJ N
drug NN N
, , N
' '' N
'stimulated VBN N
, , N
' '' N
and CC N
'would MD N
like VB N
drug NN N
access NN N
, , N
' '' N
decreased VBD N
the DT N
the DT N
post-MA JJ N
administration NN N
timecourse NN N
of IN N
'anxious JJ N
' POS N
and CC N
increased VBD N
ratings NNS N
of IN N
'bad JJ N
drug NN N
effects NNS N
, , N
' '' N
as IN N
compared VBN N
with IN N
placebo NN N
. . N

These DT N
findings NNS N
support VBP N
a DT N
potential JJ N
mechanism NN N
of IN N
action NN N
by IN N
showing VBG N
that IN N
NTX NNP N
reduced VBD N
cue-induced JJ N
craving NN N
and CC N
subjective JJ N
responses NNS N
to TO N
MA NNP N
. . N

This DT N
is VBZ N
consistent JJ N
with IN N
positive JJ N
treatment NN N
studies NNS N
of IN N
NTX NNP N
for IN N
amphetamine JJ N
dependence NN N
, , N
as RB N
well RB N
as IN N
ongoing VBG N
clinical JJ N
trials NNS N
for IN N
MA NNP N
. . N

-DOCSTART- -X- O O 17224353

Dynamic NNP N
surface NN N
electromyographic JJ N
responses NNS N
in IN N
chronic JJ 4_p
low JJ 4_p
back RB 4_p
pain NN 4_p
treated VBN N
by IN N
traditional JJ N
bone NN N
setting NN N
and CC N
conventional JJ N
physical JJ N
therapy NN N
. . N

OBJECTIVE CC N
This DT N
study NN N
compared VBN N
the DT N
dynamic JJ N
surface NN N
electromyographic JJ N
( ( N
EMG NNP N
) ) N
activities NNS N
of IN N
back JJ N
muscles NNS N
and CC N
pain NN N
before IN N
and CC N
after IN N
traditional JJ N
bone NN N
setting NN N
and CC N
physical JJ N
therapy NN N
. . N

METHODS NNP N
This DT N
study NN N
was VBD N
a DT N
prospective JJ N
clinical JJ N
trial NN N
that WDT N
compared VBN N
surface NN N
EMG NNP N
dynamic JJ N
activities NNS N
after IN N
traditional JJ N
bone NN N
setting NN N
and CC N
physical JJ N
therapy NN N
. . N

Sixty-one CD 4_p
patients NNS 4_p
( ( 4_p
mean JJ 4_p
age NN 4_p
, , 4_p
41 CD 4_p
years NNS 4_p
) ) 4_p
with IN 4_p
nonspecific JJ 4_p
low JJ 4_p
back RB 4_p
pain NN 4_p
were VBD 4_p
randomized VBN 4_p
into IN N
two CD N
subgroups NNS N
by IN N
treatment NN N
. . N

The DT N
patients NNS N
underwent VBD N
a DT N
dynamic JJ N
EMG NNP N
evaluation NN N
for IN N
which WDT N
they PRP N
were VBD N
asked VBN N
to TO N
stand VB N
and CC N
then RB N
bend VB N
forward RB N
as RB N
far RB N
as IN N
possible JJ N
, , N
stay VB N
fully RB N
flexed VBN N
, , N
and CC N
return NN N
to TO N
standing VBG N
. . N

A DT N
flexion-relaxation JJ N
ratio NN N
was VBD N
calculated VBN N
by IN N
comparing VBG N
maximal JJ N
EMG NNP N
activity NN N
while IN N
flexing VBG N
with IN N
the DT N
average JJ N
EMG NNP N
activity NN N
in IN N
full JJ N
flexion NN N
. . N

Concentric NNP N
( ( N
maximal JJ N
EMG NNP N
activity NN N
during IN N
extension NN N
) ) N
and CC N
eccentric JJ N
( ( N
maximal JJ N
EMG NNP N
activity NN N
during IN N
flexion NN N
) ) N
ratios NNS N
were VBD N
also RB N
used VBN N
in IN N
the DT N
analyses NNS N
. . N

RESULTS NNP N
Disability NNP N
, , N
depression NN N
, , N
and CC N
visual JJ N
analog NN N
scale NN N
scores NNS N
decreased VBN N
significantly RB N
after IN N
both DT N
treatments NNS N
. . N

The DT N
concentric JJ N
ratio NN N
increased VBD N
statistically RB N
in IN N
both DT N
groups NNS N
after IN N
the DT N
treatments NNS N
. . N

The DT N
study NN N
failed VBD N
to TO N
show VB N
a DT N
significant JJ N
association NN N
between IN N
experienced VBN N
back RB N
pain NN N
and CC N
EMG NNP N
parameters NNS N
. . N

CONCLUSIONS NNP N
Both NNP N
treatments NNS N
seem VBP N
to TO N
have VB N
a DT N
positive JJ N
influence NN N
on IN N
back JJ N
muscle NN N
function NN N
by IN N
improving VBG N
muscle NN N
symmetry NN N
; : N
however RB N
, , N
the DT N
treatments NNS N
had VBD N
no DT N
effect NN N
on IN N
the DT N
flexion-relaxation NN N
phenomenon NN N
after IN N
1 CD N
month NN N
. . N

Active NNP N
back RB N
exercise NN N
at IN N
home NN N
together RB N
with IN N
rehabilitation NN N
treatments NNS N
might MD N
be VB N
effective JJ N
and CC N
improve VB N
function NN N
for IN N
patients NNS N
with IN N
chronic JJ N
low JJ N
back RB N
pain NN N
. . N

-DOCSTART- -X- O O 10649829

The DT N
relationship NN N
between IN N
repetitive JJ N
behaviors NNS N
and CC N
growth NN N
hormone NN N
response NN N
to TO N
sumatriptan VB N
challenge NN N
in IN N
adult NN N
autistic JJ 4_p
disorder NN 4_p
. . N

Autism NNP N
is VBZ N
heterogeneous JJ N
with IN N
respect NN N
to TO N
clinical JJ N
symptoms NNS N
and CC N
etiology NN N
. . N

To TO N
sort VB N
out RP N
this DT N
heterogeneity NN N
in IN N
autism NN N
, , N
we PRP N
investigated VBD N
whether IN N
specific JJ N
neurobiological JJ N
markers NNS N
vary VBP N
in IN N
parallel NN N
to TO N
core VB N
symptomatology NN N
. . N

Specifically RB N
, , N
we PRP N
assessed VBD N
growth NN N
hormone NN N
response NN N
to TO N
the DT N
5-HT JJ N
1d CD N
agonist NN N
, , N
sumatriptan NN N
, , N
and CC N
linked VBD N
this DT N
measure NN N
of IN N
serotonergic JJ N
function NN N
to TO N
the DT N
severity NN N
of IN N
repetitive JJ N
behaviors NNS N
in IN N
adult NN N
autistic JJ 4_p
patients NNS N
. . N

Eleven NNP N
adult NN N
patients NNS N
with IN N
autism NN 4_p
or CC N
Asperger NNP 4_p
's POS 4_p
disorder NN 4_p
were VBD N
randomized VBN N
to TO N
single JJ N
dose JJ N
sumatriptan NN N
( ( N
6 CD N
mg RB N
SQ NNP N
) ) N
and CC N
placebo NN N
challenges NNS N
, , N
separated VBN N
by IN N
a DT N
one-week JJ N
interval NN N
. . N

In IN N
adult JJ N
autistic JJ N
disorders NNS N
, , N
severity NN N
of IN N
repetitive JJ N
behaviors NNS N
at IN N
baseline NN N
, , N
as IN N
measured VBN N
by IN N
YBOCS-compulsion NNP N
score NN N
, , N
significantly RB N
positively RB N
correlated VBN N
with IN N
both DT N
peak JJ N
delta NN N
growth NN N
hormone NN N
response NN N
and CC N
area NN N
under IN N
the DT N
curve NN N
growth NN N
hormone NN N
response NN N
to TO N
sumatriptan VB N
. . N

Thus RB N
, , N
the DT N
severity NN N
of IN N
a DT N
specific JJ N
behavioral JJ N
dimension NN N
in IN N
autism NN N
( ( N
repetitive JJ N
behaviors NNS N
) ) N
parallels VBP N
the DT N
sensitivity NN N
of IN N
the DT N
5-HT JJ N
1d CD N
receptor NN N
, , N
as IN N
manifest NN N
by IN N
sumatriptan NN N
elicited VBN N
GH NNP N
response NN N
. . N

-DOCSTART- -X- O O 16452103

Sham NNP N
device NN N
v NN N
inert NN N
pill NN N
: : N
randomised VBN N
controlled VBD N
trial NN N
of IN N
two CD N
placebo NN N
treatments NNS N
. . N

OBJECTIVE NNP N
To TO N
investigate VB N
whether IN N
a DT N
sham JJ N
device NN N
( ( N
a DT N
validated VBN N
sham NN N
acupuncture NN N
needle NN N
) ) N
has VBZ N
a DT N
greater JJR N
placebo NN N
effect NN N
than IN N
an DT N
inert NN N
pill NN N
in IN N
patients NNS 4_p
with IN 4_p
persistent JJ 4_p
arm NN 4_p
pain NN 4_p
. . 4_p

DESIGN VB N
A DT N
single JJ N
blind NN N
randomised VBD N
controlled VBN N
trial NN N
created VBD N
from IN N
the DT N
two CD N
week NN N
placebo IN N
run-in JJ N
periods NNS N
for IN N
two CD N
nested JJ N
trials NNS N
that WDT N
compared VBN N
acupuncture NN N
and CC N
amitriptyline NN N
with IN N
their PRP$ N
respective JJ N
placebo NN N
controls NNS N
. . N

Comparison NNP N
of IN N
participants NNS N
who WP N
remained VBD N
on IN N
placebo NN N
continued VBN N
beyond IN N
the DT N
run-in JJ N
period NN N
to TO N
the DT N
end NN N
of IN N
the DT N
study NN N
. . N

SETTING NNP N
Academic NNP N
medical JJ N
centre NN N
. . N

PARTICIPANTS CC N
270 CD N
adults NNS N
with IN N
arm NN N
pain NN N
due JJ N
to TO N
repetitive VB N
use NN N
that WDT N
had VBD N
lasted VBN N
at IN N
least JJS N
three CD N
months NNS N
despite IN N
treatment NN N
and CC N
who WP N
scored VBD N
> NNP N
or CC N
=3 VBN N
on IN N
a DT N
10 CD N
point NN N
pain NN N
scale NN N
. . N

INTERVENTIONS NNP N
Acupuncture NNP N
with IN N
sham JJ N
device NN N
twice RB N
a DT N
week NN N
for IN N
six CD N
weeks NNS N
or CC N
placebo NN N
pill NN N
once RB N
a DT N
day NN N
for IN N
eight CD N
weeks NNS N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Arm NNP N
pain NN N
measured VBD N
on IN N
a DT N
10 CD N
point NN N
pain NN N
scale NN N
. . N

Secondary JJ N
outcomes NNS N
were VBD N
symptoms NNS N
measured VBN N
by IN N
the DT N
Levine NNP N
symptom NN N
severity NN N
scale NN N
, , N
function NN N
measured VBN N
by IN N
Pransky NNP N
's POS N
upper JJ N
extremity NN N
function NN N
scale NN N
, , N
and CC N
grip JJ N
strength NN N
. . N

RESULTS NNP N
Pain NNP N
decreased VBD N
during IN N
the DT N
two CD N
week NN N
placebo JJ N
run-in JJ N
period NN N
in IN N
both CC N
the DT N
sham NN N
device NN N
and CC N
placebo NN N
pill NN N
groups NNS N
, , N
but CC N
changes NNS N
were VBD N
not RB N
different JJ N
between IN N
the DT N
groups NNS N
( ( N
-0.14 NNP N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
-0.52 NN N
to TO N
0.25 CD N
, , N
P NNP N
= NNP N
0.49 CD N
) ) N
. . N

Changes NNS N
in IN N
severity NN N
scores NNS N
for IN N
arm NN N
symptoms NNS N
and CC N
grip JJ N
strength NN N
were VBD N
similar JJ N
between IN N
groups NNS N
, , N
but CC N
arm JJ N
function NN N
improved VBD N
more RBR N
in IN N
the DT N
placebo NN N
pill NN N
group NN N
( ( N
2.0 CD N
, , N
0.06 CD N
to TO N
3.92 CD N
, , N
P NNP N
= NNP N
0.04 CD N
) ) N
. . N

Longitudinal JJ N
regression NN N
analyses VBZ N
that IN N
followed VBD N
participants NNS N
throughout IN N
the DT N
treatment NN N
period NN N
showed VBD N
significantly RB N
greater JJR N
downward JJ N
slopes NNS N
per IN N
week NN N
on IN N
the DT N
10 CD N
point NN N
arm NN N
pain NN N
scale NN N
in IN N
the DT N
sham JJ N
device NN N
group NN N
than IN N
in IN N
the DT N
placebo NN N
pill NN N
group NN N
( ( N
-0.33 NNP N
( ( N
-0.40 UH N
to TO N
-0.26 VB N
) ) N
v FW N
-0.15 FW N
( ( N
-0.21 UH N
to TO N
-0.09 VB N
) ) N
, , N
P NNP N
= NNP N
0.0001 CD N
) ) N
and CC N
on IN N
the DT N
symptom JJ N
severity NN N
scale NN N
( ( N
-0.07 NNP N
( ( N
-0.09 UH N
to TO N
-0.05 VB N
) ) N
v FW N
-0.05 FW N
( ( N
-0.06 UH N
to TO N
-0.03 VB N
) ) N
, , N
P NNP N
= NNP N
0.02 CD N
) ) N
. . N

Differences NNS N
were VBD N
not RB N
significant JJ N
, , N
however RB N
, , N
on IN N
the DT N
function NN N
scale NN N
or CC N
for IN N
grip JJ N
strength NN N
. . N

Reported VBN N
adverse JJ N
effects NNS N
were VBD N
different JJ N
in IN N
the DT N
two CD N
groups NNS N
. . N

CONCLUSIONS VB N
The DT N
sham NN N
device NN N
had VBD N
greater JJR N
effects NNS N
than IN N
the DT N
placebo NN N
pill NN N
on IN N
self NN N
reported VBN N
pain NN N
and CC N
severity NN N
of IN N
symptoms NNS N
over IN N
the DT N
entire JJ N
course NN N
of IN N
treatment NN N
but CC N
not RB N
during IN N
the DT N
two CD N
week NN N
placebo NNS N
run VBP N
in IN N
. . N

Placebo NNP N
effects NNS N
seem VBP N
to TO N
be VB N
malleable JJ N
and CC N
depend VB N
on IN N
the DT N
behaviours NN N
embedded VBD N
in IN N
medical JJ N
rituals NNS N
. . N

-DOCSTART- -X- O O 16099893

Effect NN N
of IN N
exercise NN N
, , N
training NN N
, , N
and CC N
glycogen NN N
availability NN N
on IN N
IL-6 NNP N
receptor NN N
expression NN N
in IN N
human JJ 4_p
skeletal JJ 4_p
muscle NN 4_p
. . 4_p

The DT N
cytokine JJ N
interleukin-6 JJ N
( ( N
IL-6 NNP N
) ) N
exerts VBZ N
it PRP N
actions NNS N
via IN N
the DT N
IL-6 NNP N
receptor NN N
( ( N
IL-6R NNP N
) ) N
in IN N
conjunction NN N
with IN N
the DT N
ubiquitously RB N
expressed VBN N
gp130 NN N
receptor NN N
. . N

IL-6 NNP N
is VBZ N
tightly RB N
regulated VBN N
in IN N
response NN N
to TO N
exercise NN N
, , N
being VBG N
affected VBN N
by IN N
factors NNS N
such JJ N
as IN N
exercise NN N
intensity NN N
and CC N
duration NN N
, , N
as RB N
well RB N
as IN N
energy NN N
availability NN N
. . N

Although IN N
the DT N
IL-6 NNP N
response NN N
to TO N
exercise NN N
has VBZ N
been VBN N
extensively RB N
studied VBN N
, , N
little JJ N
is VBZ N
known VBN N
about IN N
the DT N
regulation NN N
of IN N
the DT N
IL-6R NNP N
response NN N
. . N

In IN N
the DT N
present JJ N
study NN N
, , N
we PRP N
aimed VBD N
to TO N
investigate VB N
the DT N
effect NN N
of IN N
exercise NN N
, , N
training NN N
, , N
and CC N
glycogen NN N
availability NN N
, , N
factors NNS N
known VBN N
to TO N
affect VB N
IL-6 NNP N
, , N
on IN N
the DT N
regulation NN N
of IN N
gene NN N
expression NN N
of IN N
the DT N
IL-6R NNP N
in IN N
human JJ N
skeletal JJ N
muscle NN N
. . N

Human NNP N
subjects VBZ N
performed VBD N
either CC N
10 CD N
wk NN N
of IN N
training VBG N
with IN N
an DT N
acute JJ N
exercise NN N
bout NN N
before IN N
and CC N
after IN N
the DT N
training NN N
period NN N
, , N
or CC N
a DT N
low-glycogen JJ N
vs. NN N
normal-glycogen JJ N
acute NN N
exercise NN N
trial NN N
. . N

The DT N
IL-6R JJ N
mRNA NN N
response NN N
was VBD N
evaluated VBN N
in IN N
both DT N
trials NNS N
. . N

In IN N
response NN N
to TO N
acute VB N
exercise NN N
, , N
an DT N
increase NN N
in IN N
IL-6R NNP N
mRNA NN N
levels NNS N
was VBD N
observed VBN N
. . N

Neither CC N
training VBG N
nor CC N
intramuscular JJ N
glycogen NN N
levels NNS N
had VBD N
an DT N
effect NN N
on IN N
the DT N
IL-6R NNP N
mRNA NN N
response NN N
to TO N
exercise NN N
. . N

However RB N
, , N
after IN N
10 CD N
wk NN N
of IN N
training NN N
, , N
the DT N
skeletal JJ N
muscle NN N
expressed VBD N
a DT N
higher JJR N
mRNA JJ N
level NN N
of IN N
IL-6R NNP N
compared VBN N
with IN N
before RB N
training VBG N
. . N

The DT N
present JJ N
study NN N
demonstrated VBD N
that IN N
the DT N
IL-6R NNP N
gene NN N
expression NN N
levels NNS N
in IN N
skeletal JJ N
muscle NN N
are VBP N
increased VBN N
in IN N
response NN N
to TO N
acute VB N
exercise NN N
, , N
a DT N
response NN N
that WDT N
is VBZ N
very RB N
well RB N
conserved VBN N
, , N
being VBG N
affected VBN N
by IN N
neither DT N
training NN N
status NN N
nor CC N
intramuscular JJ N
glycogen NN N
levels NNS N
, , N
as IN N
opposed VBN N
to TO N
IL-6 NNP N
. . N

However RB N
, , N
after IN N
the DT N
training NN N
period NN N
, , N
IL-6R JJ N
mRNA NN N
production NN N
was VBD N
increased VBN N
in IN N
skeletal JJ N
muscle NN N
, , N
suggesting VBG N
a DT N
sensitization NN N
of IN N
skeletal JJ N
muscle NN N
to TO N
IL-6 NNP N
at IN N
rest NN N
. . N

-DOCSTART- -X- O O 9449870

Randomised VBN N
community-based JJ N
trial NN N
of IN N
annual JJ N
single-dose JJ N
diethylcarbamazine NN N
with IN N
or CC N
without IN N
ivermectin NN N
against IN N
Wuchereria NNP 4_p
bancrofti JJ 4_p
infection NN 4_p
in IN N
human JJ N
beings NNS N
and CC N
mosquitoes NNS N
. . N

BACKGROUND NNP N
WHO NNP N
has VBZ N
targeted VBN N
lymphatic JJ N
filariasis NN N
for IN N
elimination NN N
. . N

Studies NNS N
of IN N
vector-parasite JJ N
relations NNS N
of IN N
Wuchereria NNP N
bancrofti NN N
suggest VBP N
that IN N
a DT N
reduction NN N
in IN N
the DT N
microfilarial JJ N
reservoir NN N
by IN N
mass NN N
chemotherapy NN N
may MD N
interrupt VB N
transmission NN N
and CC N
thereby RB N
eliminate VB N
infection NN N
. . N

However RB N
, , N
no DT N
field NN N
data NNS N
exist VBP N
on IN N
the DT N
impact NN N
of IN N
chemotherapy NN N
alone RB N
on IN N
vector NN N
efficiency NN N
and CC N
transmission NN N
intensity NN N
of IN N
W NNP N
bancrofti NN N
. . N

We PRP N
compared VBN N
the DT N
impact NN N
of IN N
an DT N
annual JJ N
community-wide JJ N
single-dose JJ N
treatment NN N
with IN N
diethylcarbamazine JJ N
alone NN N
or CC N
with IN N
ivermectin JJ N
on IN N
rate NN N
and CC N
intensity NN N
of IN N
microfilaraemia NN N
, , N
and CC N
transmission NN N
intensity NN N
in IN N
an DT N
area NN N
of IN N
Papua NNP N
New NNP N
Guinea NNP N
endemic VBZ N
for IN N
intense JJ N
W NNP N
bancrofti NN N
transmission NN N
. . N

METHODS NNP N
We PRP N
carried VBD N
out RP N
clinical JJ N
and CC N
parasitological JJ N
surveys NNS N
in IN N
14 CD N
communities NNS N
in IN N
matched JJ N
pairs NNS N
. . N

People NNS N
aged VBD N
5 CD N
years NNS N
or CC N
older JJR N
in IN N
seven CD N
communities NNS N
received VBD N
randomly RB N
assigned VBN N
diethylcarbamazine NN N
6 CD N
mg/kg NN N
and CC N
people NNS N
in IN N
the DT N
other JJ N
seven CD N
communities NNS N
received VBD N
diethylcarbamazine JJ N
6 CD N
mg/kg NN N
plus CC N
ivermectin JJ N
400 CD N
micrograms/kg NN N
. . N

We PRP N
made VBD N
physical JJ N
examinations NNS N
for IN N
hydroceles NNS N
and CC N
leg NN N
oedema NN N
and CC N
investigated JJ N
microfilarial JJ N
densities NNS N
by IN N
membrane NN N
filtration NN N
before IN N
and CC N
after IN N
treatment NN N
. . N

We PRP N
selected VBD N
five CD N
communities NNS N
for IN N
monthly JJ N
entomological JJ N
surveys NNS N
between IN N
September NNP N
, , N
1993 CD N
, , N
and CC N
September NNP N
, , N
1995 CD N
. . N

Mosquitoes NNS N
were VBD N
collected VBN N
in IN N
these DT N
communities NNS N
by IN N
the DT N
all-night JJ N
landing NN N
catch NN N
method NN N
and CC N
were VBD N
individually RB N
dissected VBN N
to TO N
identify VB N
rates NNS N
of IN N
infection NN N
and CC N
infectiveness NN N
. . N

FINDINGS JJ N
2219 CD N
( ( N
87.6 CD N
% NN N
) ) N
of IN N
2534 CD N
eligible JJ N
people NNS N
received VBD N
treatment NN N
. . N

Microfilarial JJ N
rate NN N
and CC N
density NN N
had VBD N
decreased VBN N
1 CD N
year NN N
after IN N
treatment NN N
in IN N
all DT N
14 CD N
communities NNS N
; : N
this DT N
decrease NN N
was VBD N
significantly RB N
higher JJR N
in IN N
communities NNS N
given VBN N
combined VBD N
therapy NN N
than IN N
in IN N
those DT N
given VBN N
diethylcarbamazine VBP N
alone RB N
( ( N
mean JJ N
decreases VBZ N
57.5 CD N
% NN N
and CC N
30.6 CD N
% NN N
, , N
respectively RB N
; : N
p VB N
= $ N
0.0013 CD N
) ) N
. . N

Greater NNP N
decreases NNS N
were VBD N
also RB N
seen VBN N
in IN N
community-specific JJ N
microfilarial JJ N
intensity NN N
with IN N
combined JJ N
therapy NN N
( ( N
mean JJ N
reductions NNS N
91.1 CD N
% NN N
and CC N
69.8 CD N
% NN N
, , N
respectively RB N
; : N
p VB N
= $ N
0.0047 CD N
) ) N
. . N

The DT N
rate NN N
of IN N
leg NN N
oedema NN N
was VBD N
not RB N
altered VBN N
, , N
but CC N
the DT N
frequency NN N
of IN N
advanced JJ N
hydroceles NNS N
decreased VBN N
by IN N
47 CD N
% NN N
with IN N
combined JJ N
therapy NN N
and CC N
56 CD N
% NN N
with IN N
diethylcarbamazine JJ N
alone RB N
. . N

26,641 CD N
Anopheles NNPS N
punctulatus NN N
mosquitoes NNS N
were VBD N
caught VBN N
during IN N
499 CD N
person-nights NNS N
of IN N
landing VBG N
catches NNS N
. . N

Exposure NN N
to TO N
infective VB N
third-stage NN N
larvae NN N
decreased VBN N
in IN N
all DT N
monitored JJ N
five CD N
communities NNS N
. . N

Annual JJ N
transmission NN N
potential NN N
decreased VBN N
by IN N
between IN N
75.7 CD N
% NN N
and CC N
98.8 CD N
% NN N
in IN N
combined-therapy JJ N
communities NNS N
and CC N
between IN N
75.6 CD N
% NN N
and CC N
79.4 CD N
% NN N
in IN N
communities NNS N
given VBN N
diethylcarbamazine JJ N
alone RB N
. . N

Transmission NN N
was VBD N
almost RB N
interrupted VBN N
in IN N
two CD N
communities NNS N
treated VBN N
with IN N
combined JJ N
therapy NN N
. . N

INTERPRETATION NNP N
Annual JJ N
single-dose JJ N
community-wide JJ N
treatment NN N
with IN N
diethylcarbamazine JJ N
alone NN N
or CC N
with IN N
ivermectin NN N
is VBZ N
effective JJ N
for IN N
the DT N
control NN N
of IN N
lymphatic JJ N
filariasis NN N
in IN N
highly RB N
endemic JJ N
areas NNS N
, , N
but CC N
combination NN N
therapy NN N
brings VBZ N
about IN N
greater JJR N
decreases NNS N
in IN N
rates NNS N
and CC N
intensity NN N
of IN N
microfilaraemia NN N
. . N

-DOCSTART- -X- O O 24229362

Study NNP N
protocol NN N
: : N
Rehabilitation NN N
including VBG N
Social NNP N
and CC N
Physical NNP N
activity NN N
and CC N
Education NN N
in IN N
Children NNP N
and CC N
Teenagers NNP N
with IN N
Cancer NNP 4_p
( ( N
RESPECT NNP N
) ) N
. . N

BACKGROUND NNP N
During IN N
cancer NN N
treatment NN N
children NNS N
have VBP N
reduced VBN N
contact NN N
with IN N
their PRP$ N
social JJ N
network NN N
of IN N
friends NNS N
, , N
and CC N
have VBP N
limited VBN N
participation NN N
in IN N
education NN N
, , N
sports NNS N
, , N
and CC N
leisure NN N
activities NNS N
. . N

During IN N
and CC N
following VBG N
cancer NN N
treatment NN N
, , N
children NNS N
describe VBP N
school NN N
related VBN N
problems NNS N
, , N
reduced VBD N
physical JJ N
fitness NN N
, , N
and CC N
problems NNS N
related VBN N
to TO N
interaction NN N
with IN N
peers NNS N
. . N

METHODS/DESIGN NNP N
The DT N
RESPECT NNP N
study NN N
is VBZ N
a DT N
nationwide JJ N
population-based JJ N
prospective NN N
, , N
controlled VBN N
, , N
mixed-methods NNS N
intervention NN N
study NN N
looking VBG N
at IN N
children NNS N
aged VBN N
6-18 CD N
years NNS N
newly RB 4_p
diagnosed VBN 4_p
with IN 4_p
cancer NN 4_p
in IN N
eastern JJ N
Denmark NNP N
( ( N
n=120 NN N
) ) N
and CC N
a DT N
matched JJ N
control NN N
group NN N
in IN N
western JJ N
Denmark NNP N
( ( N
n=120 NN N
) ) N
. . N

RESPECT NNP N
includes VBZ N
Danish-speaking NNP N
children NNS N
diagnosed VBD N
with IN N
cancer NN 4_p
and CC N
treated VBN N
at IN N
pediatric JJ N
oncology NN N
units NNS N
in IN N
Denmark NNP N
. . N

Primary JJ N
endpoints NNS N
are VBP N
the DT N
level NN N
of IN N
educational JJ N
achievement NN N
one CD N
year NN N
after IN N
the DT N
cessation NN N
of IN N
first-line JJ N
cancer NN N
therapy NN N
, , N
and CC N
the DT N
value NN N
of IN N
VO2max NNP N
one CD N
year NN N
after IN N
the DT N
cessation NN N
of IN N
first-line JJ N
cancer NN N
therapy NN N
. . N

Secondary JJ N
endpoints NNS N
are VBP N
quality NN N
of IN N
life NN N
measured VBN N
by IN N
validated JJ N
questionnaires NNS N
and CC N
interviews NNS N
, , N
and CC N
physical JJ N
performance NN N
. . N

RESPECT NNP N
includes VBZ N
a DT N
multimodal JJ N
intervention NN N
program NN N
, , N
including VBG N
ambassador-facilitated JJ N
educational JJ N
, , N
physical JJ N
, , N
and CC N
social JJ N
interventions NNS N
. . N

The DT N
educational JJ N
intervention NN N
includes VBZ N
an DT N
educational JJ N
program NN N
aimed VBN N
at IN N
the DT N
child NN N
with IN N
cancer NN 4_p
, , N
the DT N
child NN N
's POS N
schoolteachers NNS N
and CC N
classmates NNS N
, , N
and CC N
the DT N
child NN N
's POS N
parents NNS N
. . N

Children NNP N
with IN N
cancer NN 4_p
will MD N
each DT N
have VB N
two CD N
ambassadors NNS N
assigned VBD N
from IN N
their PRP$ N
class NN N
. . N

The DT N
ambassadors NNS N
visit VBP N
the DT N
child NN N
with IN N
cancer NN 4_p
at IN N
the DT N
hospital NN N
at IN N
alternating VBG N
2-week JJ N
intervals NNS N
and CC N
participate VB N
in IN N
the DT N
intervention NN N
program NN N
. . N

The DT N
physical JJ N
and CC N
social JJ N
intervention NN N
examines VBZ N
the DT N
effect NN N
of IN N
early JJ N
, , N
structured VBN N
, , N
individualized VBN N
, , N
and CC N
continuous JJ N
physical JJ N
activity NN N
from IN N
diagnosis NN N
throughout IN N
the DT N
treatment NN N
period NN N
. . N

The DT N
patients NNS N
are VBP N
tested VBN N
at IN N
diagnosis NN N
, , N
at IN N
3 CD N
and CC N
6 CD N
months NNS N
after IN N
diagnosis NN N
, , N
and CC N
one CD N
year NN N
after IN N
the DT N
cessation NN N
of IN N
treatment NN N
. . N

The DT N
study NN N
is VBZ N
powered VBN N
to TO N
quantify VB N
the DT N
impact NN N
of IN N
the DT N
combined JJ N
educational JJ N
, , N
physical JJ N
, , N
and CC N
social JJ N
intervention NN N
programs NNS N
. . N

DISCUSSION NNP N
RESPECT NNP N
is VBZ N
the DT N
first JJ N
population-based JJ N
study NN N
to TO N
examine VB N
the DT N
effect NN N
of IN N
early JJ N
rehabilitation NN N
for IN N
children NNS N
with IN N
cancer NN N
, , N
and CC N
to TO N
use VB N
healthy JJ N
classmates NNS N
as IN N
ambassadors NNS N
to TO N
facilitate VB N
the DT N
normalization NN N
of IN N
social JJ N
life NN N
in IN N
the DT N
hospital NN N
. . N

For IN N
children NNS N
with IN N
cancer NN 4_p
, , N
RESPECT NNP N
contributes VBZ N
to TO N
expanding VBG N
knowledge NN N
on IN N
rehabilitation NN N
that WDT N
can MD N
also RB N
facilitate VB N
rehabilitation NN N
of IN N
other JJ N
children NNS N
undergoing VBG N
hospitalization NN N
for IN N
long-term JJ N
illness NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
Clinical NNP N
Trials.gov NNP N
: : N
file NN N
. . N

NCT01772849 NNP N
and CC N
NCT01772862 NNP N
. . N

-DOCSTART- -X- O O 9006472

Feasibility NN N
and CC N
effects NNS N
of IN N
nurse JJ 4_p
run NN 4_p
clinics NNS 4_p
for IN 4_p
patients NNS 4_p
with IN 4_p
epilepsy NN 4_p
in IN 4_p
general JJ 4_p
practice NN 4_p
: : 4_p
randomised VBN N
controlled JJ N
trial NN N
. . N

Epilepsy NNP N
Care NNP N
Evaluation NNP N
Group NNP N
. . N

OBJECTIVE NNP N
To TO N
test VB N
the DT N
feasibility NN N
and CC N
effect NN N
of IN N
nurse JJ 4_p
run NN 4_p
epilepsy NN 4_p
clinics NNS 4_p
in IN 4_p
primary JJ 4_p
care NN 4_p
. . 4_p

DESIGN VB N
A DT N
randomised JJ N
controlled JJ N
trial NN N
of IN N
nurse JJ N
run NN N
clinics NNS N
versus VBP N
" RB N
usual JJ N
care NN N
. . N

" CC N
SETTING NNP N
Six NNP N
general JJ N
practices NNS N
in IN N
the DT N
South NNP N
Thames NNPS N
region NN N
. . N

SUBJECTS NNP N
251 CD N
patients NNS N
aged VBN N
over IN N
15 CD N
years NNS N
who WP N
were VBD N
taking VBG N
anti-epileptic JJ N
drugs NNS N
or CC N
had VBD N
a DT N
diagnosis NN N
of IN N
epilepsy NN 4_p
and CC N
an DT N
attack NN N
in IN N
the DT N
past JJ N
two CD N
years NNS N
who WP N
met VBD N
specified VBN N
inclusion NN N
criteria NNS N
and CC N
had VBD N
responded VBN N
to TO N
a DT N
questionnaire NN N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Questionnaire NNP N
responses NNS N
and CC N
recording NN N
of IN N
key JJ N
variables NNS N
extracted VBN N
from IN N
the DT N
clinical JJ N
records NNS N
before IN N
and CC N
after IN N
the DT N
intervention NN N
. . N

RESULTS CC N
127 CD N
patients NNS N
were VBD N
randomised VBN N
to TO N
a DT N
nurse JJ N
run NN N
clinic NN N
, , N
of IN N
whom WP N
106 CD N
( ( N
83 CD N
% NN N
) ) N
attended VBD N
. . N

The DT N
nurse JJ N
wrote VBD N
28 CD N
letters NNS N
to TO N
the DT N
general JJ N
practitioners NNS N
suggesting VBG N
changes NNS N
in IN N
epilepsy NN N
management NN N
. . N

For IN N
this DT N
intervention NN N
group NN N
compared VBN N
with IN N
the DT N
usual JJ N
care NN N
group NN N
there EX N
was VBD N
a DT N
highly RB N
significant JJ N
improvement NN N
in IN N
the DT N
level NN N
of IN N
advice NN N
recorded VBN N
as IN N
having VBG N
been VBN N
given VBN N
on IN N
drug NN N
compliance NN N
, , N
adverse JJ N
drug NN N
effects NNS N
, , N
driving VBG N
, , N
alcohol NN N
intake NN N
, , N
and CC N
self PRP N
help VBP N
groups NNS N
. . N

CONCLUSIONS NNP N
Nurse NNP 4_p
run VBP 4_p
clinics NNS 4_p
for IN 4_p
patients NNS 4_p
with IN 4_p
epilepsy NN 4_p
were VBD N
feasible JJ N
and CC N
well RB N
attended VBD N
. . N

Such JJ N
clinics NNS N
can MD N
significantly RB N
improve VB N
the DT N
level NN N
of IN N
advice NN N
and CC N
drug NN N
management NN N
recorded VBN N
. . N

-DOCSTART- -X- O O 18779477

Treatment NN N
of IN N
posterior JJ 4_p
uveitis NN 4_p
with IN N
a DT N
fluocinolone NN N
acetonide NN N
implant NN N
: : N
three-year JJ N
clinical JJ N
trial NN N
results NNS N
. . N

OBJECTIVES NNP N
To TO N
evaluate VB N
the DT N
safety NN N
and CC N
efficacy NN N
of IN N
0.59-mg JJ N
and CC N
2.1-mg JJ N
fluocinolone NN N
acetonide NN N
( ( N
FA NNP N
) ) N
intravitreous JJ N
implants NNS N
in IN N
noninfectious JJ 4_p
posterior JJ 4_p
uveitis NN 4_p
. . N

DESIGN VB N
A DT N
3-year JJ N
, , N
multicenter NN N
, , N
randomized VBN N
, , N
historically RB N
controlled VBN N
trial NN N
of IN N
the DT N
0.59-mg JJ N
FA NNP N
intravitreous JJ N
implant NN N
in IN N
110 CD N
patients NNS N
and CC N
the DT N
2.1-mg JJ N
FA NNP N
intravitreous JJ N
implant NN N
in IN N
168 CD N
patients NNS N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Recurrence NNP N
rate NN N
, , N
vision NN N
, , N
and CC N
complications NNS N
. . N

RESULTS NNP N
Uveitis NNP N
recurrence NN N
was VBD N
reduced VBN N
in IN N
implanted JJ N
eyes NNS N
from IN N
62 CD N
% NN N
( ( N
during IN N
the DT N
1-year JJ N
preimplantation NN N
period NN N
) ) N
to TO N
4 CD N
% NN N
, , N
10 CD N
% NN N
, , N
and CC N
20 CD N
% NN N
during IN N
the DT N
1- JJ N
, , N
2- JJ N
, , N
and CC N
3-year JJ N
postimplantation NN N
periods NNS N
, , N
respectively RB N
, , N
for IN N
the DT N
0.59-mg JJ N
dose NN N
group NN N
( ( N
P NNP N
< NNP N
.01 NNP N
) ) N
and CC N
from IN N
58 CD N
% NN N
to TO N
7 CD N
% NN N
, , N
17 CD N
% NN N
, , N
and CC N
41 CD N
% NN N
, , N
respectively RB N
, , N
for IN N
the DT N
2.1-mg JJ N
dose NN N
group NN N
( ( N
P NNP N
< NNP N
.01 NNP N
) ) N
. . N

More RBR N
implanted JJ N
eyes NNS N
than IN N
nonimplanted JJ N
eyes NNS N
had VBD N
improved VBN N
visual JJ N
acuity NN N
( ( N
P NNP N
< NNP N
.01 NNP N
) ) N
. . N

Implanted VBN N
eyes NNS N
had VBD N
higher JJR N
incidences NNS N
of IN N
intraocular JJ N
pressure NN N
elevation NN N
( ( N
> CD N
or CC N
= VB N
10 CD N
mm NNS N
Hg NNP N
) ) N
than IN N
nonimplanted VBN N
eyes NNS N
( ( N
P NNP N
< NNP N
.01 NNP N
) ) N
, , N
and CC N
glaucoma NN N
surgery NN N
was VBD N
required VBN N
in IN N
40 CD N
% NN N
of IN N
implanted JJ N
eyes NNS N
vs VBP N
2 CD N
% NN N
of IN N
nonimplanted JJ N
eyes NNS N
( ( N
P NNP N
< NNP N
.01 NNP N
) ) N
. . N

Cataracts NNPS N
were VBD N
extracted VBN N
in IN N
93 CD N
% NN N
of IN N
phakic NN N
implanted VBN N
eyes NNS N
vs VBP N
20 CD N
% NN N
of IN N
phakic NN N
nonimplanted VBN N
eyes NNS N
( ( N
P NNP N
< NNP N
.01 NNP N
) ) N
. . N

CONCLUSIONS VB N
The DT N
FA NNP N
implant NN N
significantly RB N
reduced VBN N
uveitis JJ N
recurrence NN N
and CC N
improved VBD N
or CC N
stabilized VBN N
visual JJ N
acuity NN N
in IN N
subjects NNS N
with IN N
noninfectious JJ 4_p
posterior JJ 4_p
uveitis NN 4_p
. . N

Most JJS N
subjects NNS N
required VBN N
cataract JJ N
extraction NN N
, , N
and CC N
a DT N
significant JJ N
proportion NN N
required VBN N
intraocular JJ N
pressure-lowering JJ N
surgery NN N
. . N

APPLICATION NNP N
TO NNP N
CLINICAL NNP N
PRACTICE NNP N
The DT N
FA NNP N
implant NN N
provides VBZ N
an DT N
alternative JJ N
therapy NN N
for IN N
prolonged JJ N
control NN N
of IN N
inflammation NN N
in IN N
noninfectious JJ N
posterior JJ N
uveitis NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
clinicaltrials.gov NN N
Identifier NNP N
: : N
NCT00407082 NN N
. . N

-DOCSTART- -X- O O 10352330

Effect NN N
of IN N
granulocyte/colony-stimulating JJ N
factor NN N
on IN N
the DT N
onset NN N
of IN N
the DT N
adult NN N
respiratory NN 4_p
distress JJ 4_p
syndrome NN 4_p
. . N

To TO N
evaluate VB N
the DT N
effect NN N
of IN N
granulocyte/colony-stimulating JJ N
factor NN N
( ( N
G-CSF NNP N
) ) N
on IN N
the DT N
onset NN N
of IN N
the DT N
adult NN N
respiratory NN N
distress NN N
syndrome NN N
( ( N
ARDS NNP N
) ) N
, , N
we PRP N
investigated VBD N
whether IN N
the DT N
incidence NN N
of IN N
ARDS NNP N
due JJ N
to TO N
pulmonary JJ N
infection NN N
differed VBD N
between IN N
the DT N
G-CSF NNP 4_p
group NN 4_p
which WDT 4_p
received VBD 4_p
chemotherapy NN 4_p
with IN 4_p
G-CSF NNP 4_p
and CC N
historical JJ 4_p
controls NNS 4_p
without IN 4_p
G-CSF NNP 4_p
. . N

We PRP N
evaluated VBD N
132 CD N
patients NNS 4_p
with IN 4_p
hematological JJ 4_p
malignancy NN 4_p
in IN 4_p
complete JJ 4_p
remission NN 4_p
without IN 4_p
any DT 4_p
main JJ 4_p
organ JJ 4_p
dysfunction NN 4_p
who WP 4_p
had VBD 4_p
been VBN 4_p
treated VBN 4_p
between IN 4_p
April NNP 4_p
1983 CD 4_p
and CC 4_p
December NNP 4_p
1997 CD 4_p
. . 4_p

We PRP N
compared VBN N
the DT N
incidence NN N
of IN N
ARDS NNP N
due JJ N
to TO N
pulmonary JJ N
infection NN N
between IN N
those DT N
who WP N
received VBD N
G-CSF NNP N
and CC N
those DT N
who WP N
did VBD N
not RB N
. . N

There EX N
was VBD N
no DT 4_p
remarkable JJ 4_p
difference NN 4_p
in IN 4_p
the DT 4_p
number NN 4_p
of IN 4_p
patients NNS 4_p
, , 4_p
gender NN 4_p
, , 4_p
age NN 4_p
, , 4_p
or CC 4_p
distribution NN 4_p
of IN 4_p
primary JJ 4_p
diseases NNS 4_p
between IN 4_p
the DT 4_p
two CD 4_p
groups NNS 4_p
. . N

The DT N
intensity NN N
of IN N
chemotherapy NN N
was VBD N
not RB N
considered VBN N
to TO N
significantly RB N
differ VB N
between IN N
the DT N
two CD N
groups NNS N
, , N
though IN N
the DT N
chemotherapy NN N
regimens VBZ N
administered VBN N
differed VBD N
slightly RB N
. . N

In IN N
the DT N
G-CSF NNP N
group NN N
, , N
the DT N
duration NN N
of IN N
neutropenia NN N
was VBD N
significantly RB N
shorter JJR N
and CC N
the DT N
frequency NN N
of IN N
documented JJ N
infection NN N
was VBD N
significantly RB N
decreased VBN N
. . N

We PRP N
could MD N
not RB N
find VB N
any DT N
relationship NN N
between IN N
ARDS NNP N
due JJ N
to TO N
pulmonary JJ N
infection NN N
and CC N
any DT N
anticancer JJ N
agent NN N
or CC N
antibiotics NNS N
. . N

There EX N
was VBD N
no DT N
relationship NN N
between IN N
the DT N
kind NN N
of IN N
G-CSF NNP N
and CC N
the DT N
incidence NN N
of IN N
ARDS NNP N
due JJ N
to TO N
pulmonary JJ N
infection NN N
( ( N
per IN N
chemotherapy NN N
session NN N
; : N
p CC N
> $ N
0.10 CD N
, , N
per IN N
case NN N
; : N
p CC N
> $ N
0.30 CD N
, , N
chi2 JJ N
test NN N
) ) N
. . N

The DT N
incidence NN N
of IN N
ARDS NNP N
due JJ N
to TO N
pulmonary JJ N
infection NN N
per IN N
chemotherapy NN N
session NN N
was VBD N
4.21 CD N
% NN N
, , N
and CC N
showed VBD N
a DT N
higher JJR N
tendency NN N
in IN N
the DT N
G-CSF NNP N
group NN N
( ( N
p JJ N
< NN N
0.100 CD N
, , N
chi2 JJ N
test NN N
) ) N
. . N

The DT N
incidence NN N
of IN N
ARDS NNP N
due JJ N
to TO N
pulmonary JJ N
infection NN N
per IN N
case NN N
was VBD N
25.4 CD N
% NN N
and CC N
was VBD N
significantly RB N
higher JJR N
in IN N
the DT N
G-CSF NNP N
group NN N
( ( N
p JJ N
< NN N
0.025 CD N
, , N
chi2 JJ N
test NN N
) ) N
. . N

The DT N
incidence NN N
of IN N
ARDS NNP N
due JJ N
to TO N
pulmonary JJ N
infection NN N
was VBD N
higher RBR N
in IN N
the DT N
G-CSF NNP N
group NN N
than IN N
in IN N
the DT N
controls NNS N
, , N
suggesting VBG N
that IN N
G-CSF NNP N
promotes VBZ N
the DT N
development NN N
of IN N
ARDS NNP N
due JJ N
to TO N
pulmonary JJ N
infection NN N
. . N

-DOCSTART- -X- O O 21060033

Denosumab NNP N
compared VBN N
with IN N
zoledronic JJ N
acid NN N
for IN N
the DT N
treatment NN N
of IN N
bone NN N
metastases NNS N
in IN N
patients NNS N
with IN N
advanced JJ 4_p
breast NN 4_p
cancer NN 4_p
: : N
a DT N
randomized JJ N
, , N
double-blind JJ N
study NN N
. . N

PURPOSE VB N
This DT N
randomized VBN N
study NN N
compared VBN N
denosumab NN N
, , N
a DT N
fully RB N
human JJ N
monoclonal JJ N
antibody NN N
against IN N
receptor NN N
activator NN N
of IN N
nuclear JJ N
factor NN N
κ NN N
B NNP N
( ( N
RANK NNP N
) ) N
ligand NN N
, , N
with IN N
zoledronic JJ N
acid NN N
in IN N
delaying VBG N
or CC N
preventing VBG N
skeletal-related JJ N
events NNS N
( ( N
SREs NNP N
) ) N
in IN N
patients NNS N
with IN N
breast JJ 4_p
cancer NN 4_p
with IN 4_p
bone NN 4_p
metastases NNS 4_p
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
Patients NNPS N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
either RB N
subcutaneous JJ N
denosumab NN N
120 CD N
mg NN N
and CC N
intravenous JJ N
placebo NN N
( ( N
n JJ N
= NNP N
1,026 CD N
) ) N
or CC N
intravenous JJ N
zoledronic JJ N
acid NN N
4 CD N
mg NN N
adjusted VBN N
for IN N
creatinine JJ N
clearance NN N
and CC N
subcutaneous JJ N
placebo NN N
( ( N
n JJ N
= NNP N
1,020 CD N
) ) N
every DT N
4 CD N
weeks NNS N
. . N

All DT N
patients NNS N
were VBD N
strongly RB N
recommended VBN N
to TO N
take VB N
daily JJ N
calcium NN N
and CC N
vitamin NN N
D NNP N
supplements NNS N
. . N

The DT N
primary JJ N
end NN N
point NN N
was VBD N
time NN N
to TO N
first VB N
on-study JJ N
SRE NNP N
( ( N
defined VBN N
as IN N
pathologic JJ N
fracture NN N
, , N
radiation NN N
or CC N
surgery NN N
to TO N
bone VB N
, , N
or CC N
spinal JJ N
cord NN N
compression NN N
) ) N
. . N

RESULTS NNP N
Denosumab NNP N
was VBD N
superior JJ N
to TO N
zoledronic JJ N
acid NN N
in IN N
delaying VBG N
time NN N
to TO N
first VB N
on-study JJ N
SRE NNP N
( ( N
hazard NN N
ratio NN N
, , N
0.82 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.71 CD N
to TO N
0.95 CD N
; : N
P NNP N
= NNP N
.01 NNP N
superiority NN N
) ) N
and CC N
time NN N
to TO N
first RB N
and CC N
subsequent JJ N
( ( N
multiple JJ N
) ) N
on-study NN N
SREs NNP N
( ( N
rate NN N
ratio NN N
, , N
0.77 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.66 CD N
to TO N
0.89 CD N
; : N
P NNP N
= NNP N
.001 NNP N
) ) N
. . N

Reduction NN N
in IN N
bone NN N
turnover NN N
markers NNS N
was VBD N
greater JJR N
with IN N
denosumab NN N
. . N

Overall JJ N
survival NN N
, , N
disease NN N
progression NN N
, , N
and CC N
rates NNS N
of IN N
adverse JJ N
events NNS N
( ( N
AEs NNP N
) ) N
and CC N
serious JJ N
AEs NNP N
were VBD N
similar JJ N
between IN N
groups NNS N
. . N

An DT N
excess NN N
of IN N
renal JJ N
AEs NNP N
and CC N
acute-phase JJ N
reactions NNS N
occurred VBD N
with IN N
zoledronic JJ N
acid NN N
; : N
hypocalcemia NN N
occurred VBD N
more RBR N
frequently RB N
with IN N
denosumab NN N
. . N

Osteonecrosis NN N
of IN N
the DT N
jaw NN N
occurred VBD N
infrequently RB N
( ( N
2.0 CD N
% NN N
, , N
denosumab NN N
; : N
1.4 CD N
% NN N
, , N
zoledronic JJ N
acid NN N
; : N
P NNP N
= NNP N
.39 NNP N
) ) N
. . N

CONCLUSION NNP N
Denosumab NNP N
was VBD N
superior JJ N
to TO N
zoledronic JJ N
acid NN N
in IN N
delaying VBG N
or CC N
preventing VBG N
SREs NNP N
in IN N
patients NNS N
with IN N
breast JJ N
cancer NN N
metastatic NN N
to TO N
bone NN N
and CC N
was VBD N
generally RB N
well RB N
tolerated VBN N
. . N

With IN N
the DT N
convenience NN N
of IN N
a DT N
subcutaneous JJ N
injection NN N
and CC N
no DT N
requirement NN N
for IN N
renal JJ N
monitoring NN N
, , N
denosumab JJ N
represents VBZ N
a DT N
potential JJ N
treatment NN N
option NN N
for IN N
patients NNS N
with IN N
bone NN N
metastases NNS N
. . N

-DOCSTART- -X- O O 22510874

Osteopontin NNP N
is VBZ N
a DT N
prognostic JJ N
factor NN N
for IN N
survival NN N
of IN N
acute JJ 4_p
myeloid JJ 4_p
leukemia NN 4_p
patients NNS 4_p
. . 4_p

Osteopontin NNP N
( ( N
OPN NNP N
) ) N
is VBZ N
a DT N
glycoprotein NN N
that WDT N
is VBZ N
secreted VBN N
by IN N
osteoblasts NNS N
and CC N
hematopoietic JJ N
cells NNS N
. . N

OPN NNP N
suppresses VBZ N
the DT N
proliferation NN N
of IN N
hematopoietic JJ N
stem NN N
cells NNS N
in IN N
vitro NN N
and CC N
may MD N
regulate VB N
the DT N
hematopoietic JJ N
stem NN N
cell NN N
pool NN N
. . N

Increased VBN N
serum NN N
OPN NNP N
concentrations NNS N
occur VBP N
in IN N
chronic JJ N
myeloid NN N
leukemia NN N
, , N
multiple JJ N
myeloma NN N
, , N
and CC N
acute JJ N
myeloid NN N
leukemia NN N
( ( N
AML NNP N
) ) N
. . N

In IN N
the DT N
present JJ N
study NN N
, , N
we PRP N
analyzed VBD N
the DT N
prognostic JJ N
impact NN N
of IN N
OPN NNP N
in IN N
AML NNP N
by IN N
investigating VBG N
the DT N
expression NN N
and CC N
relevance NN N
of IN N
OPN NNP N
in IN N
newly RB N
diagnosed VBN N
AML NNP N
patients NNS N
from IN N
2 CD N
large JJ N
study NN N
groups NNS N
( ( N
the DT N
German JJ N
AML NNP N
Cooperative NNP N
Group NNP N
and CC N
the DT N
Dutch-Belgian JJ N
Hematology NNP N
Oncology NNP N
Cooperative NNP N
group NN N
) ) N
. . N

IHC NNP N
( ( N
n JJ N
= NNP N
84 CD N
) ) N
, , N
ELISAs NNP N
of IN N
blood/BM NN N
sera NN N
( ( N
n JJ N
= NNP N
41 CD N
) ) N
, , N
and CC N
microarray NN N
data NNS N
for IN N
mRNA NN N
levels NNS N
( ( N
n JJ N
= NNP N
261 CD N
) ) N
were VBD N
performed VBN N
. . N

Expression NN N
of IN N
OPN NNP N
protein NN N
was VBD N
increased VBN N
in IN N
AML NNP N
patients NNS N
both DT N
in IN N
BM NNP N
blasts NNS N
( ( N
IHC NNP N
) ) N
and CC N
in IN N
BM NNP N
serum NN N
( ( N
ELISA NNP N
) ) N
compared VBN N
with IN N
healthy JJ N
controls NNS N
. . N

Patients NNS N
expressing VBG N
high JJ N
levels NNS N
of IN N
OPN NNP N
within IN N
the DT N
BM NNP N
( ( N
IHC NNP N
) ) N
experienced VBD N
shortened VBN N
overall JJ N
survival NN N
( ( N
OS NNP N
; : N
P NNP N
= NNP N
.025 NNP N
) ) N
. . N

Multivariate NNP N
analysis NN N
identified VBD N
karyotype NN N
, , N
blast JJ N
clearance NN N
( ( N
day NN N
16 CD N
) ) N
, , N
and CC N
the DT N
level NN N
of IN N
OPN NNP N
expression NN N
as IN N
independent JJ N
prognostic JJ N
factors NNS N
for IN N
OS NNP N
. . N

This DT N
prompted VBD N
us PRP N
to TO N
analyze VB N
microarray NN N
data NNS N
from IN N
261 CD N
patients NNS N
from IN N
a DT N
third JJ N
cohort NN N
. . N

The DT N
analysis NN N
confirmed VBD N
OPN NNP N
as IN N
a DT N
prognostic JJ N
marker NN N
. . N

In IN N
summary JJ N
, , N
high JJ N
OPN NNP N
mRNA NN N
expression NN N
indicated VBD N
decreased JJ N
event-free JJ N
survival NN N
( ( N
P NNP N
= NNP N
.0002 NNP N
) ) N
and CC N
OS NNP N
( ( N
P NNP N
= NNP N
.001 NNP N
) ) N
. . N

The DT N
prognostic JJ N
role NN N
of IN N
OPN NNP N
was VBD N
most RBS N
prominent JJ N
in IN N
intermediate-risk JJ N
AML NNP N
. . N

These DT N
data NNS N
provide VBP N
evidence NN N
that IN N
OPN NNP N
expression NN N
is VBZ N
an DT N
independent JJ N
prognostic JJ N
factor NN N
in IN N
AML NNP N
. . N

-DOCSTART- -X- O O 24101715

Group NNP N
therapy NN N
for IN N
anxiety NN N
in IN N
children NNS N
with IN N
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
. . N

AIM NNP N
To TO N
investigate VB N
the DT N
acceptability NN N
and CC N
feasibility NN N
of IN N
adapted VBN N
group NN N
therapy NN N
for IN N
anxiety NN N
in IN N
children NNS 4_p
with IN 4_p
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
in IN N
a DT N
pilot NN N
randomised VBN N
controlled VBN N
trial NN N
. . N

METHOD VB N
A DT N
total NN N
of IN N
32 CD N
children NNS N
aged VBN N
9-13 CD N
years NNS N
were VBD N
randomised VBN N
to TO N
immediate VB N
or CC N
delayed VBN N
therapy NN N
using VBG N
the DT N
'Exploring VBG N
Feelings NNP N
' POS N
manual JJ N
( ( N
Attwood NNP N
, , N
2004 CD N
) ) N
. . N

Child NN N
and CC N
parent NN N
groups NNS N
were VBD N
run VBN N
in IN N
parallel NN N
, , N
for IN N
seven CD N
weekly JJ N
sessions NNS N
, , N
under IN N
the DT N
supervision NN N
of IN N
experienced JJ N
psychologists NNS N
. . N

The DT N
primary JJ N
blinded VBD N
outcome JJ N
measures NNS N
addressed VBD N
change NN N
in IN N
overall JJ N
functioning NN N
and CC N
in IN N
severity NN N
of IN N
the DT N
primary JJ N
anxiety NN N
diagnosis NN N
after IN N
3 CD N
months NNS N
. . N

RESULTS NNP N
Children NNP 4_p
met VBD 4_p
diagnostic JJ 4_p
criteria NNS 4_p
for IN 4_p
1-6 JJ 4_p
anxiety NN 4_p
disorders NNS 4_p
( ( 4_p
median JJ 4_p
3 CD 4_p
) ) 4_p
. . 4_p

At IN N
end NN N
point NN N
, , N
both DT N
parents NNS N
and CC N
children NNS N
in IN N
the DT N
immediate JJ N
therapy NN N
group NN N
were VBD N
more RBR N
likely JJ N
to TO N
report VB N
a DT N
reduction NN N
in IN N
anxiety NN N
symptoms NNS N
. . N

Fidelity NNP N
of IN N
delivery NN N
of IN N
the DT N
group NN N
therapy NN N
was VBD N
high JJ N
, , N
and CC N
attendance NN N
was VBD N
91 CD N
% NN N
. . N

CONCLUSIONS NNP N
This DT N
pilot NN N
trial NN N
established VBD N
that IN N
children NNS N
and CC N
families NNS N
were VBD N
willing JJ N
to TO N
be VB N
recruited VBN N
and CC N
randomised VBN N
, , N
the DT N
outcome NN N
measures NNS N
were VBD N
acceptable JJ N
, , N
the DT N
format NN N
and CC N
content NN N
of IN N
the DT N
groups NNS N
were VBD N
feasible JJ N
within IN N
UK NNP N
child NN N
and CC N
adolescent JJ N
mental NN N
health NN N
services NNS N
, , N
the DT N
intervention NN N
was VBD N
appreciated VBN N
by IN N
families NNS N
and CC N
attrition NN N
was VBD N
very RB N
small JJ N
. . N

-DOCSTART- -X- O O 17631392

A DT N
randomized JJ N
placebo-controlled JJ N
trial NN N
comparing VBG N
the DT N
efficacy NN N
of IN N
etoricoxib $ N
30 CD N
mg NN N
and CC N
ibuprofen NN N
2400 CD N
mg NN N
for IN N
the DT N
treatment NN N
of IN N
patients NNS N
with IN N
osteoarthritis NN 4_p
. . N

OBJECTIVE IN N
We PRP N
compared VBN N
the DT N
efficacy NN N
of IN N
etoricoxib $ N
30 CD N
mg NN N
to TO N
placebo VB N
and CC N
ibuprofen VB N
2400 CD N
mg NN N
for IN N
the DT N
treatment NN N
of IN N
osteoarthritis NN 4_p
( ( 4_p
OA NNP 4_p
) ) 4_p
of IN 4_p
the DT 4_p
hip NN 4_p
and CC 4_p
knee NN 4_p
. . N

DESIGN NN N
In IN N
this DT N
12-week JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo- JJ N
and CC N
active-comparator-controlled JJ N
trial NN N
, , N
548 CD N
patients NNS N
( ( N
median JJ N
age NN N
63 CD N
years NNS N
) ) N
with IN N
OA NNP 4_p
of IN 4_p
the DT 4_p
hip NN 4_p
or CC 4_p
knee NN 4_p
were VBD N
randomized VBN N
to TO N
receive VB N
placebo NN N
, , N
etoricoxib VBZ N
30 CD N
mg NN N
q.d. NN N
, , N
or CC N
ibuprofen VB N
800 CD N
mg NN N
t.i.d NN N
. . N

Demonstration NN N
of IN N
etoricoxib NN N
's POS N
efficacy NN N
vs NN N
placebo NN N
and CC N
comparison NN N
of IN N
its PRP$ N
efficacy NN N
to TO N
ibuprofen VB N
were VBD N
assessed VBN N
using VBG N
three CD N
co-primary JJ N
endpoints NNS N
: : N
Western JJ N
Ontario NNP N
and CC N
McMaster NNP N
's POS N
University NNP N
Osteoarthritis NNP N
Index NNP N
( ( N
WOMAC NNP N
) ) N
Pain NNP N
Subscale NNP N
( ( N
WOMAC-PS NNP N
) ) N
; : N
WOMAC NNP N
Physical NNP N
Function NNP N
Subscale NNP N
( ( N
WOMAC-PFS NNP N
) ) N
; : N
and CC N
Patient NNP N
Global NNP N
Assessment NNP N
of IN N
Disease NNP N
Status NNP N
( ( N
PGADS NNP N
) ) N
. . N

Each DT N
primary JJ N
endpoint NN N
utilizes VBZ N
a DT N
0-100 JJ N
mm NN N
visual JJ N
analog NN N
scale NN N
. . N

To TO N
demonstrate VB N
comparable JJ N
efficacy NN N
of IN N
etoricoxib JJ N
vs NN N
ibuprofen NN N
, , N
the DT N
95 CD N
% NN N
confidence NN N
intervals NNS N
( ( N
CIs NNP N
) ) N
for IN N
the DT N
difference NN N
in IN N
the DT N
least JJS N
squares NNS N
( ( N
LS NNP N
) ) N
mean VBP N
change NN N
over IN N
12 CD N
weeks NNS N
for IN N
all DT N
three CD N
co-primary JJ N
endpoints NNS N
had VBD N
to TO N
fall VB N
within IN N
+/-10 JJ N
mm NN N
. . N

Safety NNP N
and CC N
tolerability NN N
data NNS N
were VBD N
collected VBN N
throughout IN N
the DT N
study NN N
. . N

RESULTS NNP N
Mean NNP N
baseline NN N
values NNS N
for IN N
the DT N
three CD N
co-primary JJ N
endpoints NNS N
ranged VBD N
from IN N
62.52 CD N
to TO N
70.14 CD N
mm NN N
. . N

Both DT N
etoricoxib JJ N
and CC N
ibuprofen JJ N
demonstrated VBN N
superior JJ N
( ( N
P NNP N
< NNP N
or CC N
=0.002 NNP N
) ) N
efficacy NN N
for IN N
all DT N
primary JJ N
endpoints NNS N
. . N

The DT N
LS NNP N
mean NN N
( ( N
mm NN N
) ) N
changes NNS N
( ( N
95 CD N
% NN N
CI NNP N
) ) N
over IN N
12 CD N
weeks NNS N
for IN N
etoricoxib NN N
and CC N
ibuprofen NN N
, , N
respectively RB N
, , N
compared VBN N
to TO N
placebo VB N
were VBD N
given VBN N
as IN N
follows VBZ N
: : N
WOMAC-PS JJ N
: : N
-11.66 NN N
( ( N
-16.31 UH N
, , N
-7.01 NNP N
) ) N
and CC N
-7.62 NNP N
( ( N
-12.30 NNP N
, , N
-2.94 NNP N
) ) N
; : N
WOMAC-PFS JJ N
: : N
-10.15 NN N
( ( N
-14.74 UH N
, , N
-5.57 NNP N
) ) N
and CC N
-7.23 NNP N
( ( N
-11.85 NNP N
, , N
-2.61 NNP N
) ) N
; : N
PGADS NNP N
: : N
-11.65 NN N
( ( N
-16.81 UH N
, , N
-6.50 NNP N
) ) N
and CC N
-8.11 NNP N
( ( N
-13.30 NNP N
, , N
-2.92 NNP N
) ) N
. . N

The DT N
efficacy NN N
of IN N
etoricoxib $ N
30 CD N
mg NN N
was VBD N
comparable JJ N
to TO N
ibuprofen VB N
2400 CD N
mg. NN N
All DT N
treatments NNS N
were VBD N
similarly RB N
well RB N
tolerated VBN N
. . N

CONCLUSION NNP N
Treatment NNP N
with IN N
etoricoxib JJ N
30 CD N
mg NN N
q.d NN N
. . N

provides VBZ N
superior JJ N
efficacy NN N
vs NN N
placebo NN N
and CC N
comparable JJ N
clinical JJ N
efficacy NN N
vs NN N
ibuprofen NN N
2400 CD N
mg NN N
( ( N
800 CD N
mg NN N
t.i.d NN N
. . N

) ) N
for IN N
the DT N
treatment NN N
of IN N
OA NNP 4_p
of IN 4_p
the DT 4_p
hip NN 4_p
and CC 4_p
knee NN 4_p
. . N

-DOCSTART- -X- O O 9885327

Comparative JJ N
efficacy NN N
and CC N
safety NN N
of IN N
calcium NN N
carbasalate NN N
plus CC N
metoclopramide JJ N
versus NN N
ergotamine NN N
tartrate NN N
plus CC N
caffeine NN N
in IN N
the DT N
treatment NN N
of IN N
acute JJ 4_p
migraine NN 4_p
attacks NNS N
. . N

This DT N
randomized JJ N
, , N
double-blind JJ N
, , N
double-dummy JJ N
, , N
multicenter NN N
, , N
parallel-group JJ N
study NN N
aimed VBN N
at IN N
comparing VBG N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
calcium NN N
carbasalate NN N
( ( N
equivalent JJ N
to TO N
900 CD N
mg NNS N
aspirin RB N
) ) N
plus CC N
metoclopramide $ N
10 CD N
mg NN N
( ( N
CM NNP N
) ) N
with IN N
ergotamine JJ N
tartrate NN N
1 CD N
mg NN N
plus CC N
caffeine JJ N
100 CD N
mg NN N
( ( N
EC NNP N
) ) N
administered VBN N
in IN N
the DT N
treatment NN N
of IN N
2 CD N
acute JJ N
migraine NN N
attacks NNS N
. . N

A DT N
total NN N
of IN N
296 CD N
patients NNS N
fulfilling VBG N
the DT N
International NNP N
Headache NNP N
Society NNP N
diagnostic JJ N
criteria NNS N
for IN N
migraine NN 4_p
were VBD N
enrolled VBN N
. . N

In IN N
total JJ N
, , N
one CD N
or CC N
two CD N
migraine NN N
attacks NNS N
were VBD N
treated VBN N
in IN N
268 CD N
and CC N
235 CD N
patients NNS N
, , N
respectively RB N
. . N

The DT N
primary JJ N
endpoint NN N
for IN N
the DT N
first JJ N
treated VBD N
attack NN N
was VBD N
headache NN N
relief NN N
, , N
with IN N
intensity NN N
decreasing VBG N
from IN N
moderate JJ N
or CC N
severe JJ N
to TO N
mild VB N
or CC N
absent VB N
2 CD N
h NN N
after IN N
drug NN N
intake NN N
. . N

Usual JJ N
secondary JJ N
efficacy NN N
endpoints NNS N
were VBD N
assessed VBN N
. . N

A DT N
superiority NN N
of IN N
CM NNP N
over IN N
EC NNP N
was VBD N
observed VBN N
for IN N
both DT N
treated JJ N
attacks NNS N
for IN N
the DT N
main JJ N
endpoint NN N
: : N
success NN N
in IN N
54 CD N
versus NN N
36 CD N
% NN N
, , N
p NN N
= VBD N
0.003 CD N
for IN N
the DT N
first JJ N
attack NN N
and CC N
60 CD N
versus NN N
44 CD N
% NN N
, , N
p NN N
= VBD N
0.02 CD N
for IN N
the DT N
second JJ N
attack NN N
. . N

CM NNP N
was VBD N
also RB N
significantly RB N
superior JJ N
to TO N
EC NNP N
during IN N
the DT N
first JJ N
attack NN N
for IN N
complete JJ N
headache NN N
relief NN N
( ( N
20 CD N
vs. FW N
8 CD N
% NN N
, , N
p NN N
= NNP N
0.006 CD N
) ) N
, , N
nausea NN N
( ( N
42 CD N
vs. FW N
63 CD N
% NN N
, , N
p NN N
= VBD N
0 CD N
. . N

007 CD N
) ) N
and CC N
willingness NN N
to TO N
take VB N
the DT N
drug NN N
again RB N
( ( N
90 CD N
vs. FW N
80 CD N
% NN N
, , N
p NN N
= NNP N
0.043 CD N
) ) N
. . N

The DT N
global JJ N
efficacy NN N
evaluation NN N
, , N
rated VBN N
by IN N
the DT N
investigators NNS N
, , N
was VBD N
significantly RB N
more RBR N
favorable JJ N
to TO N
CM NNP N
for IN N
both DT N
attacks NNS N
( ( N
p VB N
= $ N
0.001 CD N
for IN N
the DT N
first JJ N
attack NN N
and CC N
p NN N
= VBP N
0.02 CD N
for IN N
the DT N
second JJ N
) ) N
. . N

The DT N
patients NNS N
' POS N
evaluation NN N
was VBD N
significant JJ N
for IN N
the DT N
first JJ N
attack NN N
( ( N
p JJ N
= NNP N
0.002 CD N
) ) N
. . N

The DT N
global JJ N
incidence NN N
of IN N
adverse JJ N
events NNS N
was VBD N
45 CD N
% NN N
higher JJR N
with IN N
EC NNP N
, , N
though IN N
not RB N
significant JJ N
( ( N
32 CD N
vs. FW N
22 CD N
% NN N
, , N
p NN N
= NNP N
0.075 CD N
) ) N
. . N

They PRP N
were VBD N
most RBS N
often RB N
unspecific JJ N
and CC N
mild JJ N
to TO N
moderate VB N
in IN N
intensity NN N
. . N

Gastrointestinal JJ N
side NN N
effects NNS N
were VBD N
significantly RB N
less RBR N
frequent JJ N
with IN N
CM NNP N
than IN N
EC NNP N
( ( N
7 CD N
vs. FW N
21 CD N
% NN N
, , N
p NN N
= NNP N
0.001 CD N
) ) N
. . N

Thus RB N
, , N
CM NNP N
is VBZ N
more RBR N
effective JJ N
and CC N
has VBZ N
a DT N
better JJR N
gastrointestinal JJ N
safety NN N
than IN N
EC NNP N
in IN N
the DT N
acute JJ N
treatment NN N
of IN N
migraine NN N
attacks NNS N
. . N

-DOCSTART- -X- O O 1742482

Recombinant JJ N
human JJ N
granulocyte-macrophage NN N
colony-stimulating NN N
factor NN N
ameliorates VBZ N
zidovudine-induced JJ N
neutropenia NN N
in IN N
patients NNS N
with IN N
acquired JJ 4_p
immunodeficiency NN 4_p
syndrome NN 4_p
( ( 4_p
AIDS NNP 4_p
) ) 4_p
/AIDS-related VBD 4_p
complex JJ 4_p
. . N

To TO N
evaluate VB N
the DT N
effect NN N
of IN N
recombinant JJ N
granulocyte-macrophage JJ N
colony-stimulating JJ N
factor NN N
( ( N
GM-CSF NNP N
) ) N
on IN N
patients NNS N
with IN N
acquired JJ 4_p
immunodeficiency NN 4_p
syndrome NN 4_p
( ( 4_p
AIDS NNP 4_p
) ) 4_p
or CC N
AIDS-related JJ 4_p
complex NN 4_p
( ( 4_p
ARC NNP 4_p
) ) 4_p
who WP N
were VBD N
intolerant JJ N
to TO N
zidovudine VB N
because IN N
of IN N
neutropenia NN 4_p
, , N
we PRP N
performed VBD N
a DT N
randomized VBN N
, , N
open-label JJ N
study NN N
in IN N
which WDT N
patients NNS N
were VBD N
assigned VBN N
to TO N
one CD N
of IN N
two CD N
groups NNS N
. . N

Zidovudine NNP N
was VBD N
discontinued VBN N
in IN N
group NN N
A NNP N
patients NNS N
before IN N
instituting VBG N
GM-CSF NNP N
treatment NN N
and CC N
was VBD N
restarted VBN N
in IN N
a DT N
graduated JJ N
fashion NN N
over IN N
4 CD N
weeks NNS N
. . N

Group NNP N
B NNP N
patients NNS N
continued VBD N
on IN N
full-dose JJ N
( ( N
1,200 CD N
mg/d NN N
) ) N
zidovudine NN N
therapy NN N
while IN N
beginning VBG N
GM-CSF NNP N
therapy NN N
. . N

A DT N
total NN N
of IN N
17 CD N
patients NNS N
were VBD N
entered VBN N
, , N
eight CD N
in IN N
group NN N
A NNP N
and CC N
nine CD N
in IN N
group NN N
B NNP N
. . N

Five CD N
of IN N
eight CD N
patients NNS N
in IN N
group NN N
A NNP N
and CC N
seven CD N
of IN N
nine CD N
in IN N
group NN N
B NNP N
had VBD N
a DT N
history NN N
of IN N
Pneumocystis NNP 4_p
carinii NN 4_p
pneumonia NN 4_p
( ( 4_p
PCP NNP 4_p
) ) 4_p
. . N

All DT N
were VBD N
homosexual JJ N
males NNS N
, , N
except IN N
one CD N
female NN N
in IN N
group NN N
A NNP N
who WP N
was VBD N
the DT N
sex NN N
partner NN N
of IN N
a DT N
bisexual JJ N
male NN 4_p
with IN N
AIDS NNP 4_p
. . N

All DT N
patients NNS N
had VBD N
neutropenia VBN 4_p
( ( N
absolute JJ N
neutrophil NN N
count NN N
[ NNP N
ANC NNP N
] VBZ N
less JJR N
than IN N
1,000/microL CD N
) ) N
while IN N
taking VBG N
full-dose JJ N
zidovudine NN N
. . N

The DT N
mean JJ N
CD4 NNP N
( ( N
+/- JJ N
SD NNP N
) ) N
lymphocyte VBD N
level NN N
was VBD N
37 CD N
( ( N
+/- JJ N
29 CD N
) ) N
/microL NN N
and CC N
39 CD N
( ( N
+/- JJ N
44 CD N
) ) N
/microL NN N
in IN N
groups NNS N
A NNP N
and CC N
B NNP N
, , N
respectively RB N
. . N

After IN N
randomization NN N
, , N
patients NNS N
were VBD N
begun VBN N
on IN N
subcutaneous JJ N
GM-CSF NNP N
at IN N
a DT N
dose NN N
of IN N
1.0 CD N
microgram/kg/d NNS N
. . N

Patients NNS N
in IN N
group NN N
A NNP N
received VBD N
2 CD N
weeks NNS N
of IN N
daily JJ N
GM-CSF NNP N
, , N
at IN N
which WDT N
time NN N
zidovudine NN N
was VBD N
restarted VBN N
if IN N
the DT N
ANC NNP N
was VBD N
greater JJR N
than IN N
1,000/microL CD N
; : N
if IN N
the DT N
ANC NNP N
was VBD N
less JJR N
than IN N
1,000/microL CD N
, , N
the DT N
dose NN N
of IN N
GM-CSF NNP N
was VBD N
increased VBN N
to TO N
3.0 CD N
micrograms/kg NN N
, , N
and CC N
at IN N
2-week JJ N
intervals NNS N
either CC N
zidovudine NN N
was VBD N
restarted VBN N
or CC N
the DT N
dose NN N
of IN N
GM-CSF NNP N
was VBD N
increased VBN N
to TO N
5 CD N
micrograms/kg NNS N
and CC N
then RB N
10 CD N
micrograms/kg NNS N
, , N
to TO N
maintain VB N
the DT N
ANC NNP N
greater JJR N
than IN N
1,000/microL CD N
. . N

Group NNP N
B NNP N
patients NNS N
received VBD N
full-dose JJ N
zidovudine NN N
concurrently RB N
with IN N
GM-CSF NNP N
administration NN N
. . N

The DT N
dose NN N
of IN N
GM-CSF NNP N
was VBD N
increased VBN N
every DT N
2 CD N
weeks NNS N
if IN N
necessary JJ N
to TO N
keep VB N
the DT N
ANC NNP N
greater JJR N
than IN N
1,000/microL CD N
while IN N
maintaining VBG N
full-dose JJ N
zidovudine NN N
therapy NN N
. . N

Patients NNS N
in IN N
each DT N
group NN N
showed VBD N
an DT N
increase NN N
in IN N
total JJ N
white JJ N
blood NN N
cell NN N
( ( N
WBC NNP N
) ) N
count NN N
. . N

Neutrophils NNP N
and CC N
eosinophils NNS N
were VBD N
responsible JJ N
for IN N
the DT N
majority NN N
of IN N
this DT N
increase NN N
. . N

Patients NNS N
in IN N
group NN N
A NNP N
had VBD N
a DT N
more RBR N
rapid JJ N
increase NN N
in IN N
WBC NNP N
than IN N
those DT N
in IN N
group NN N
B NNP N
; : N
however RB N
, , N
by IN N
week NN N
8 CD N
, , N
the DT N
WBC NNP N
in IN N
each DT N
group NN N
was VBD N
essentially RB N
equal JJ N
. . N

Viral JJ N
replication NN N
as IN N
measured VBN N
by IN N
human JJ N
immunodeficiency NN N
virus NN N
( ( N
HIV NNP N
) ) N
p24 NN N
antigen NN N
( ( N
Ag NNP N
) ) N
was VBD N
decreased VBN N
in IN N
four CD N
patients NNS N
in IN N
each DT N
group NN N
, , N
increased VBN N
in IN N
one CD N
patient NN N
in IN N
each DT N
group NN N
, , N
and CC N
remained VBD N
unchanged JJ N
in IN N
the DT N
remainder NN N
. . N

The DT N
ability NN N
to TO N
culture NN N
virus NN N
from IN N
peripheral JJ N
blood NN N
mononuclear NN N
cells NNS N
was VBD N
not RB N
changed VBN N
by IN N
the DT N
regimen NNS N
. . N

The DT N
major JJ N
toxicities NNS N
of IN N
the DT N
regimen NNS N
were VBD N
fever RB N
and CC N
malaise VB N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
400 CD N
WORDS NNP N
) ) N
-DOCSTART- -X- O O 1420057

Prevention NN N
of IN N
acute JJ N
postoperative JJ N
pressure NN N
rises VBZ N
in IN N
glaucoma NN 4_p
patients NNS N
undergoing JJ N
cataract JJ N
extraction NN N
with IN N
posterior JJ 4_p
chamber NN 4_p
lens NNS 4_p
implant VBP 4_p
. . N

Acute JJ N
elevations NNS N
in IN N
intraocular JJ N
pressure NN N
( ( N
IOP NNP N
) ) N
commonly RB N
follow VBP N
extracapsular JJ N
cataract NN N
extraction NN N
and CC N
lens VBZ N
implant NN N
in IN N
glaucoma NN N
patients NNS N
. . N

Thirty NNP N
six CD N
patients NNS N
with IN N
glaucoma JJ N
undergoing JJ N
cataract NN N
extraction NN N
and CC N
posterior JJ N
chamber NN N
lens VBZ N
implantation NN N
received VBD N
one CD N
of IN N
three CD N
treatments NNS N
. . N

Group NNP N
1 CD N
: : N
500 CD N
mg NN N
of IN N
Diamox NNP N
Sustets NNP N
( ( N
acetazolamide RB N
) ) N
1 CD N
hour NN N
preoperatively RB N
( ( N
10 CD N
patients NNS N
) ) N
; : N
Group NNP N
2 CD N
: : N
peroperative JJ N
intracameral JJ N
Miochol NNP N
( ( N
acetylcholine NN N
) ) N
( ( N
11 CD N
patients NNS N
) ) N
; : N
Group NNP N
3 CD N
: : N
the DT N
above IN N
treatments NNS N
combined VBN N
( ( N
15 CD N
patients NNS N
) ) N
. . N

IOPs NNP N
were VBD N
measured VBN N
at IN N
3 CD N
, , N
6 CD N
, , N
9 CD N
, , N
and CC N
24 CD N
hours NNS N
postoperatively RB N
. . N

The DT N
average NN N
of IN N
the DT N
maximum JJ N
pressure NN N
rises VBZ N
above IN N
the DT N
preoperative JJ N
level NN N
over IN N
the DT N
24 CD N
hour NN N
period NN N
was VBD N
greatest JJS N
for IN N
the DT N
group NN N
receiving VBG N
acetazolamide IN N
only RB N
at IN N
8.9 CD N
mm NN N
Hg NNP N
; : N
for IN N
the DT N
acetylcholine NN N
group NN N
the DT N
average NN N
maximum JJ N
rise NN N
was VBD N
6.3 CD N
mm JJ N
Hg NNP N
; : N
while IN N
the DT N
combined JJ N
treatment NN N
group NN N
showed VBD N
a DT N
decrease NN N
of IN N
0.7 CD N
mm NN N
Hg NNP N
. . N

IOP NNP N
rises VBZ N
of IN N
> $ N
6 CD N
mm NN N
Hg NNP N
were VBD N
seen VBN N
in IN N
7 CD N
% NN N
of IN N
patients NNS N
( ( N
one CD N
of IN N
15 CD N
) ) N
in IN N
the DT N
combined JJ N
treatment NN N
group NN N
, , N
45 CD N
% NN N
( ( N
five CD N
of IN N
11 CD N
) ) N
of IN N
the DT N
acetylcholine NN N
group NN N
, , N
and CC N
70 CD N
% NN N
( ( N
seven CD N
of IN N
10 CD N
) ) N
of IN N
the DT N
acetazolamide NN N
group NN N
. . N

IOP NNP N
rises VBZ N
of IN N
> $ N
10 CD N
mm NN N
Hg NNP N
were VBD N
seen VBN N
in IN N
7 CD N
% NN N
of IN N
the DT N
combined JJ N
treatment NN N
group NN N
, , N
in IN N
18 CD N
% NN N
of IN N
the DT N
acetylcholine NN N
only RB N
group NN N
, , N
and CC N
in IN N
50 CD N
% NN N
of IN N
the DT N
acetazolamide NN N
only RB N
group NN N
. . N

A DT N
pressure NN N
rise NN N
> VBZ N
20 CD N
mm NN N
Hg NNP N
was VBD N
seen VBN N
in IN N
one CD N
patient NN N
receiving VBG N
acetazolamide IN N
only RB N
and CC N
one CD N
patient NN N
receiving VBG N
acetylcholine NN N
only RB N
. . N

The DT N
difference NN N
between IN N
the DT N
acetylcholine NN N
group NN N
and CC N
the DT N
combined VBN N
group NN N
for IN N
rises NNS N
> VBP N
6 CD N
mm NN N
Hg NNP N
was VBD N
significant JJ N
using VBG N
the DT N
chi NN N
2 CD N
test NN N
while IN N
the DT N
acetazolamide NN N
group NN N
showed VBD N
a DT N
significant JJ N
difference NN N
for IN N
rises NNS N
> VBP N
6 CD N
and CC N
10 CD N
mm NN N
Hg NNP N
compared VBN N
with IN N
the DT N
combined VBN N
group NN N
. . N

All DT N
acute JJ N
pressure NN N
rises NNS N
were VBD N
recorded VBN N
before RB N
or CC N
at IN N
9 CD N
hours NNS N
following VBG N
operation NN N
except IN N
in IN N
the DT N
combined JJ N
treatment NN N
patient NN N
where WRB N
the DT N
rise NN N
occurred VBD N
at IN N
24 CD N
hours NNS N
. . N

To TO N
prevent VB N
the DT N
acute JJ N
IOP NNP N
rises VBZ N
seen VBN N
following VBG N
cataract NN N
surgery NN N
with IN N
lens NNS N
implant VBP N
in IN N
glaucoma NN N
patients NNS N
we PRP N
recommend VBP N
combined VBN N
ocular JJ N
hypotensive JJ N
therapy NN N
. . N

-DOCSTART- -X- O O 11348533

Clinical JJ N
description NN N
of IN N
encephalopathic JJ N
syndromes NNS N
and CC N
risk NN N
factors NNS N
for IN N
their PRP$ N
occurrence NN N
and CC N
outcome NN N
during IN N
melarsoprol NN N
treatment NN N
of IN N
human JJ 4_p
African JJ 4_p
trypanosomiasis NN 4_p
. . 4_p

Encephalopathies NNS N
are VBP N
the DT N
most RBS N
feared JJ N
complications NNS N
of IN N
sleeping VBG N
sickness JJ N
treatment NN N
with IN N
melarsoprol NN N
. . N

To TO N
investigate VB N
the DT N
existence NN N
of IN N
risk NN N
factors NNS N
, , N
the DT N
incidence NN N
of IN N
encephalopathic JJ N
syndromes NNS N
and CC N
the DT N
relationship NN N
between IN N
the DT N
development NN N
of IN N
different JJ N
types NNS N
of IN N
encephalopathies NNS N
and CC N
the DT N
clinical JJ N
outcome NN N
was VBD N
studied VBN N
in IN N
a DT N
clinical JJ N
trial NN N
with IN N
588 CD N
patients NNS N
under IN N
treatment NN N
with IN N
melarsoprol NN N
. . N

The DT N
38 CD N
encephalopathy JJ N
cases NNS N
were VBD N
classified VBN N
into IN N
three CD N
types NNS N
according VBG N
to TO N
the DT N
leading VBG N
clinical JJ N
picture NN N
: : N
coma NN N
type NN N
, , N
convulsion NN N
type NN N
and CC N
psychotic JJ N
reactions NNS N
. . N

Nine JJ N
patients NNS N
were VBD N
attributed VBN N
to TO N
the DT N
convulsion NN N
type NN N
, , N
defined VBD N
as IN N
a DT N
transient JJ N
event NN N
of IN N
short JJ N
duration NN N
with IN N
convulsions NNS N
followed VBN N
by IN N
a DT N
post-ictal JJ N
phase NN N
, , N
without IN N
signs NNS N
of IN N
a DT N
generalized JJ N
disease NN N
. . N

None NN N
of IN N
these DT N
patients NNS N
died VBD N
from IN N
the DT N
reaction NN N
. . N

Febrile JJ N
reactions NNS N
in IN N
the DT N
48 CD N
h NN N
preceding VBG N
the DT N
reaction NN N
were VBD N
generally RB N
not RB N
observed VBN N
in IN N
this DT N
group NN N
. . N

Twenty-five JJ N
patients NNS N
were VBD N
attributed VBN N
to TO N
the DT N
coma NN N
type NN N
, , N
which WDT N
is VBZ N
a DT N
progredient JJ N
coma NN N
lasting VBG N
several JJ N
days NNS N
. . N

Those DT N
patients NNS N
often RB N
had VBD N
signs NNS N
of IN N
a DT N
generalized JJ N
disease NN N
such JJ N
as IN N
fever NN N
( ( N
84 CD N
% NN N
) ) N
, , N
headache NN N
( ( N
72 CD N
% NN N
) ) N
or CC N
bullous JJ N
skin NN N
( ( N
8 CD N
% NN N
) ) N
reactions NNS N
. . N

The DT N
risk NN N
of IN N
mortality NN N
was VBD N
high JJ N
in IN N
this DT N
group NN N
( ( N
52 CD N
% NN N
) ) N
. . N

About IN N
14/16 CD N
patients NNS N
with IN N
encephalopathic JJ N
syndrome NN N
of IN N
the DT N
coma NN N
type NN N
were VBD N
infected VBN N
with IN N
malaria NNS N
. . N

Patients NNS N
with IN N
psychotic JJ N
reactions NNS N
or CC N
abnormal JJ N
psychiatric JJ N
behaviour NN N
( ( N
3/38 CD N
) ) N
and CC N
one CD N
patient NN N
who WP N
died VBD N
after IN N
alcohol NN N
intake NN N
were VBD N
excluded VBN N
from IN N
the DT N
analysis NN N
. . N

The DT N
overall JJ N
rate NN N
of IN N
encephalopathic JJ N
syndromes NNS N
in IN N
the DT N
cases NNS N
analysed VBD N
( ( N
n=34 NN N
) ) N
was VBD N
5.8 CD N
% NN N
, , N
of IN N
which WDT N
38.2 CD N
% NN N
died VBD N
. . N

We PRP N
did VBD N
not RB N
find VB N
any DT N
parameters NNS N
of IN N
predictive JJ N
value NN N
for IN N
the DT N
risk NN N
of IN N
developing VBG N
an DT N
encephalopathic JJ N
syndrome NN N
based VBN N
on IN N
the DT N
symptoms NNS N
and CC N
signs NNS N
before IN N
treatment NN N
initiation NN N
. . N

The DT N
appearance NN N
during IN N
treatment NN N
of IN N
febrile JJ N
reactions NNS N
( ( N
RR NNP N
11.5 CD N
) ) N
, , N
headache NN N
( ( N
RR NNP N
2.5 CD N
) ) N
, , N
bullous JJ N
eruptions NNS N
( ( N
RR NNP N
4.5 CD N
) ) N
and CC N
systolic JJ N
hypotension NN N
( ( N
RR NNP N
2.6 CD N
) ) N
were VBD N
associated VBN N
with IN N
an DT N
increased VBN N
risk NN N
for IN N
the DT N
occurrence NN N
of IN N
encephalopathic JJ N
syndromes NNS N
especially RB N
of IN N
the DT N
coma NN N
type NN N
. . N

-DOCSTART- -X- O O 10337083

Getting VBG N
a DT N
high JJ N
response NN N
rate NN N
of IN N
sexual JJ N
behavior JJ N
survey NN N
among IN N
the DT N
general JJ N
population NN N
in IN N
Japan NNP N
: : N
three CD N
different JJ N
methods NNS N
of IN N
survey NN N
on IN N
sexual JJ N
behavior NN N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
specify VB N
the DT N
most RBS N
accurate JJ N
, , N
reliable JJ N
and CC N
valid JJ N
technique NN N
for IN N
a DT N
general JJ N
sexual JJ N
behavioral JJ N
survey NN N
in IN N
Japan NNP N
. . N

This DT N
pilot NN N
study NN N
was VBD N
conducted VBN N
to TO N
assure VB N
a DT N
high JJ N
response NN N
rate NN N
and CC N
to TO N
keep VB N
respondents NNS N
' POS N
privacy NN N
confidential NN N
by IN N
using VBG N
an DT N
anonymous JJ N
questionnaire NN N
survey NN N
technique NN N
. . N

The DT N
sample NN N
( ( N
360 CD N
potential JJ N
respondents NNS N
) ) N
was VBD N
selected VBN N
randomly RB N
from IN N
basic JJ N
resident NN N
registers NNS N
in IN N
two CD N
geographically RB N
different JJ N
areas NNS N
. . N

From IN N
the DT N
registries NNS N
, , N
90 CD N
residents NNS N
, , N
aged VBD N
20 CD N
to TO N
49 CD N
years NNS N
old JJ N
, , N
were VBD N
randomly RB N
selected VBN N
to TO N
represent VB N
each DT N
sex NN N
from IN N
each DT N
area NN N
. . N

The DT N
subjects NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
three CD N
groups NNS N
each DT N
having VBG N
a DT N
different JJ N
procedure NN N
of IN N
requesting VBG N
the DT N
completion NN N
of IN N
the DT N
survey NN N
and CC N
providing VBG N
the DT N
questionnaires NNS N
: : N
( ( N
1 CD N
) ) N
Postal NNP N
Group NNP N
, , N
( ( N
2 CD N
) ) N
Telephone CD N
Group NNP N
, , N
and CC N
( ( N
3 CD N
) ) N
Face-to-face NN N
Group NNP N
. . N

The DT N
survey NN N
was VBD N
carried VBN N
out RP N
from IN N
October NNP N
1995 CD N
to TO N
February NNP N
1996 CD N
. . N

Effective JJ N
response NN N
rates NNS N
for IN N
the DT N
above NN N
mentioned VBD N
three CD N
groups NNS N
were VBD N
69.2 CD N
% NN N
, , N
69.2 CD N
% NN N
and CC N
55.8 CD N
% NN N
, , N
respectively RB N
. . N

It PRP N
is VBZ N
difficult JJ N
to TO N
determine VB N
the DT N
best JJS N
method NN N
when WRB N
only RB N
considering VBG N
the DT N
effective JJ N
response NN N
rates NNS N
. . N

However RB N
, , N
judging VBG N
from IN N
our PRP$ N
effort NN N
and CC N
expense NN N
, , N
the DT N
mail NN N
survey NN N
is VBZ N
the DT N
best JJS N
possible JJ N
procedure NN N
and CC N
would MD N
be VB N
a DT N
reasonable JJ N
method NN N
for IN N
a DT N
national JJ N
sexual JJ N
behavior NN N
survey NN N
. . N

-DOCSTART- -X- O O 12233987

Multimodal NNP N
evaluation NN N
of IN N
risperidone NN N
for IN N
destructive JJ N
behavior NN N
: : N
functional JJ N
analysis NN N
, , N
direct JJ N
observations NNS N
, , N
rating NN N
scales NNS N
, , N
and CC N
psychiatric JJ N
impressions NNS N
. . N

Risperidone NNP N
, , N
an DT N
atypical JJ N
neuroleptic NN N
, , N
has VBZ N
become VBN N
a DT N
popular JJ N
option NN N
for IN N
treating VBG N
destructive JJ N
behaviors NNS N
of IN N
persons NNS N
with IN N
developmental JJ 4_p
disabilities NNS 4_p
. . N

A DT N
few JJ N
studies NNS N
have VBP N
been VBN N
conducted VBN N
that IN N
evaluate VBP N
the DT N
effects NNS N
of IN N
risperidone NN N
on IN N
destructive JJ N
behavior NN N
; : N
however RB N
, , N
none NN N
of IN N
these DT N
studies NNS N
have VBP N
combined VBN N
objective JJ N
measures NNS N
with IN N
rating NN N
scales NNS N
to TO N
evaluate VB N
the DT N
effects NNS N
of IN N
risperidone NN N
on IN N
destructive JJ N
behavior NN N
across IN N
home NN N
and CC N
clinical JJ N
settings NNS N
. . N

This DT N
study NN N
evaluated VBD N
the DT N
wide JJ N
range NN N
of IN N
effects NNS N
of IN N
risperidone NN N
on IN N
destructive JJ N
behavior NN N
of IN N
2 CD N
persons NNS N
with IN N
developmental JJ 4_p
disabilities NNS 4_p
using VBG N
weekly JJ N
functional JJ N
analysis NN N
sessions NNS N
, , N
daily JJ N
observations NNS N
, , N
hourly RB N
home NN N
data NNS N
, , N
weekly JJ N
rating NN N
scales NNS N
, , N
and CC N
monthly JJ N
psychiatric JJ N
impressions NNS N
. . N

Results NNS N
indicate VBP N
that IN N
risperidone NN N
does VBZ N
decrease VB N
destructive JJ N
behavior NN N
and CC N
that IN N
, , N
for IN N
the DT N
most JJS N
part NN N
, , N
all DT N
of IN N
the DT N
various JJ N
measures NNS N
yielded VBD N
similar JJ N
results NNS N
. . N

-DOCSTART- -X- O O 2865615

Use NNP N
of IN N
transdermal JJ N
glyceryl NN N
trinitrate NN N
to TO N
reduce VB N
failure NN N
of IN N
intravenous JJ N
infusion NN N
due JJ N
to TO N
phlebitis VB 4_p
and CC 4_p
extravasation NN 4_p
. . N

Self-adhesive JJ N
patches NNS N
which WDT N
release VBP N
glyceryl JJ N
trinitrate NN N
at IN N
a DT N
slow JJ N
continuous JJ N
rate NN N
or CC N
placebo NN N
patches NNS N
were VBD N
applied VBN N
to TO N
the DT N
skin NN N
of IN N
patients NNS N
distal JJ N
to TO N
intravenous JJ N
infusion NN N
sites NNS N
in IN N
a DT N
double-blind JJ N
manner NN N
. . N

The DT N
frequency NN N
of IN N
infusion NN N
failure NN N
was VBD N
three CD N
times NNS N
lower RBR N
with IN N
the DT N
glyceryl NN N
trinitrate NN N
than IN N
with IN N
placebo JJ N
patches NNS N
. . N

The DT N
decrease NN N
was VBD N
of IN N
similar JJ N
magnitude NN N
whether IN N
failure NN N
was VBD N
due JJ N
to TO N
extravasation NN N
or CC N
phlebitis NN N
. . N

Headaches NNS N
were VBD N
more JJR N
common JJ N
in IN N
patients NNS N
with IN N
active JJ N
patches NNS N
but CC N
were VBD N
relieved VBN N
by IN N
simple JJ N
analgesics NNS N
. . N

-DOCSTART- -X- O O 1578953

DNA NN N
as IN N
a DT N
carrier NN N
for IN N
anthracyclines NNS N
in IN N
the DT N
treatment NN N
of IN N
acute JJ 4_p
myelocytic JJ 4_p
leukemia NN 4_p
( ( 4_p
AML NNP 4_p
) ) 4_p
. . N

-DOCSTART- -X- O O 14713377

Intervention NN N
in IN N
children NNS N
with IN N
Developmental NNP 4_p
Coordination NNP 4_p
Disorder NNP 4_p
: : N
the DT N
role NN N
of IN N
parents NNS N
and CC N
teachers NNS N
. . N

BACKGROUND NNP N
Children NNP N
with IN N
Developmental NNP 4_p
Coordination NNP 4_p
Disorder NNP 4_p
( ( 4_p
DCD NNP 4_p
) ) 4_p
are VBP N
a DT N
heterogeneous JJ N
group NN N
who WP N
have VBP N
a DT N
marked JJ N
impairment NN N
in IN N
the DT N
performance NN N
of IN N
functional JJ N
skills NNS N
. . N

Provision NN N
for IN N
these DT N
children NNS N
is VBZ N
usually RB N
made VBN N
via IN N
a DT N
paediatrician JJ N
through IN N
occupational JJ N
or CC N
physiotherapy JJ N
though IN N
, , N
with IN N
a DT N
prevalence NN N
rate NN N
of IN N
5 CD N
% NN N
, , N
regular JJ N
provision NN N
is VBZ N
not RB N
possible JJ N
due JJ N
to TO N
limited JJ N
professional JJ N
resources NNS N
. . N

AIMS VB N
The DT N
study NN N
aimed VBD N
to TO N
determine VB N
the DT N
extent NN N
to TO N
which WDT N
parents NNS N
and CC N
teachers NNS N
, , N
with IN N
guidance NN N
, , N
can MD N
assist VB N
in IN N
the DT N
management NN N
of IN N
children NNS N
with IN N
DCD NNP N
; : N
whether IN N
children NNS N
with IN N
DCD NNP N
are VBP N
helped VBN N
in IN N
this DT N
way NN N
and CC N
how WRB N
this DT N
may MD N
contribute VB N
to TO N
our PRP$ N
understanding NN N
of IN N
the DT N
condition NN N
. . N

SAMPLE NNP N
Thirty-one CD N
children NNS N
with IN N
DCD NNP N
aged VBD N
7 CD N
to TO N
9 CD N
years NNS N
participated VBN N
in IN N
the DT N
study NN N
. . N

METHODS NNP N
Following VBG N
assessment NN N
, , N
individual JJ N
profiles NNS N
were VBD N
developed VBN N
and CC N
each DT N
week NN N
teachers NNS N
and CC N
parents NNS N
were VBD N
given VBN N
guidelines NNS N
for IN N
working VBG N
with IN N
the DT N
children NNS N
and CC N
each DT N
child NN N
had VBD N
three CD N
to TO N
four CD N
sessions NNS N
a DT N
week NN N
lasting VBG N
approximately RB N
for IN N
20 CD N
minutes NNS N
. . N

In IN N
Phase NNP N
1 CD N
, , N
one CD N
group NN N
of IN N
children NNS N
worked VBN N
with IN N
teachers NNS N
and CC N
the DT N
other JJ N
group NN N
worked VBD N
with IN N
parents NNS N
. . N

In IN N
Phase NNP N
2 CD N
, , N
the DT N
two CD N
groups NNS N
of IN N
children NNS N
swapped VBN N
over IN N
. . N

The DT N
children NNS N
were VBD N
assessed VBN N
regularly RB N
throughout IN N
the DT N
project NN N
using VBG N
the DT N
Movement NNP N
ABC NNP N
, , N
together RB N
with IN N
diaries NNS N
and CC N
comments NNS N
from IN N
teachers NNS N
and CC N
parents NNS N
. . N

RESULTS NN N
At IN N
the DT N
end NN N
of IN N
the DT N
40-week JJ N
study NN N
, , N
27 CD N
children NNS N
showed VBD N
significant JJ N
improvement NN N
in IN N
their PRP$ N
motor NN N
skills NNS N
. . N

CONCLUSIONS NNP N
Both NNP N
teachers NNS N
and CC N
parents NNS N
were VBD N
able JJ N
to TO N
provide VB N
effective JJ N
intervention NN N
for IN N
the DT N
majority NN N
of IN N
the DT N
children NNS N
. . N

It PRP N
is VBZ N
possible JJ N
that IN N
the DT N
children NNS N
who WP N
did VBD N
not RB N
improve VB N
have VB N
difficulties NNS N
that WDT N
are VBP N
of IN N
a DT N
more RBR N
complex JJ N
type NN N
which WDT N
require VBP N
more JJR N
specialist JJ N
therapy NN N
to TO N
meet VB N
their PRP$ N
need NN N
. . N

-DOCSTART- -X- O O 20603436

Comorbidity NN N
, , N
age NN N
and CC N
overall JJ N
survival NN N
in IN N
cetuximab-treated JJ N
patients NNS N
with IN N
advanced JJ 4_p
colorectal JJ 4_p
cancer NN 4_p
( ( 4_p
ACRC NNP 4_p
) ) 4_p
-- : N
results NNS N
from IN N
NCIC NNP N
CTG NNP N
CO.17 NNP N
: : N
a DT N
phase NN N
III NNP N
trial NN N
of IN N
cetuximab NN N
versus NN N
best RBS N
supportive JJ N
care NN N
. . N

BACKGROUND IN N
the DT N
interplay NN N
between IN N
comorbidity NN N
, , N
age NN N
and CC N
performance NN N
status NN N
( ( N
PS NNP N
) ) N
as IN N
predictors NNS N
of IN N
outcome NN N
in IN N
advanced JJ N
colorectal JJ N
cancer NN N
( ( N
ACRC NNP N
) ) N
is VBZ N
poorly JJ N
understood NN N
. . N

We PRP N
examined VBD N
these DT N
factors NNS N
as IN N
predictors NNS N
of IN N
treatment NN N
toxicity NN N
and CC N
outcome NN N
in IN N
cetuximab-treated JJ 4_p
patients NNS 4_p
with IN N
ACRC NNP 4_p
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
comorbidity NN N
was VBD N
independently RB N
evaluated VBN N
using VBG N
the DT N
Charlson NNP N
Comorbidity NNP N
Index NNP N
( ( N
CCI NNP N
) ) N
, , N
a DT N
validated JJ N
measure NN N
of IN N
comorbidity NN N
based VBN N
on IN N
the DT N
presence NN N
of IN N
medical JJ N
conditions NNS N
weighted VBD N
according VBG N
to TO N
their PRP$ N
effect NN N
on IN N
mortality NN N
. . N

CCI NNP N
score NN N
was VBD N
correlated VBN N
with IN N
clinical JJ N
and CC N
outcome JJ N
data NNS N
. . N

RESULTS NNP N
five CD N
hundred VBD N
and CC N
seventy-two JJ N
patients NNS N
were VBD N
included VBN N
; : N
41 CD N
% NN N
were VBD N
≥ JJ N
65 CD N
years NNS N
and CC N
25 CD N
% NN N
had VBD N
comorbidities NNS N
at IN N
randomization NN N
. . N

In IN N
multivariate JJ N
analysis NN N
( ( N
MVA NNP N
) ) N
of IN N
all DT N
covariates NNS N
, , N
only RB N
older JJR N
age NN N
was VBD N
associated VBN N
with IN N
greater JJR N
comorbidity NN N
( ( N
P NNP N
= NNP N
0.008 CD N
) ) N
. . N

Overall JJ N
survival NN N
( ( N
OS NNP N
) ) N
was VBD N
significantly RB N
better JJR N
for IN N
patients NNS N
with IN N
greater JJR N
comorbidity NN N
in IN N
univariate JJ N
analysis NN N
( ( N
P NNP N
= NNP N
0.047 CD N
) ) N
. . N

Conversely RB N
, , N
better JJR N
PS NNP N
was VBD N
associated VBN N
with IN N
better JJR N
OS NNP N
in IN N
MVA NNP N
( ( N
hazard JJ N
ratio NN N
1.92 CD N
for IN N
PS NNP N
= NNP N
2 CD N
versus NN N
PS NNP N
= NNP N
0 CD N
, , N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

Age NNP N
was VBD N
not RB N
associated VBN N
with IN N
OS NNP N
( ( N
P NNP N
= NNP N
0.13 CD N
) ) N
. . N

Elderly JJ N
patients NNS N
had VBD N
significantly RB N
less JJR N
grade JJ N
≥ NN N
3 CD N
vomiting NN N
( ( N
P NNP N
= NNP N
0.034 CD N
) ) N
but CC N
more JJR N
dyspnea NN N
( ( N
P NNP N
= NNP N
0.005 CD N
) ) N
. . N

Patients NNS N
with IN N
greater JJR N
comorbidity NN N
had VBD N
significantly RB N
less JJR N
grade JJ N
≥ NN N
3 CD N
vomiting NN N
( ( N
P NNP N
= NNP N
0.002 CD N
) ) N
but CC N
more JJR N
non-neutropenic JJ N
fever NN N
( ( N
P NNP N
= NNP N
0.005 CD N
) ) N
. . N

CONCLUSION NNP N
better JJR N
PS NNP N
was VBD N
associated VBN N
with IN N
improved JJ N
OS NNP N
. . N

For IN N
patients NNS N
with IN N
good JJ N
PS NNP N
, , N
restricting VBG N
cetuximab NN N
use NN N
in IN N
the DT N
setting NN N
of IN N
significant JJ N
comorbidity NN N
does VBZ N
not RB N
appear VB N
justified VBN N
. . N

-DOCSTART- -X- O O 9190129

Low JJ N
intensity NN N
physical JJ N
training NN N
in IN N
older JJR 4_p
subjects NNS 4_p
. . 4_p

BACKGROUND NNP N
This DT N
study NN N
was VBD N
designed VBN N
to TO N
evaluate VB N
the DT N
effects NNS N
of IN N
a DT N
low JJ N
intensity NN N
general JJ N
training NN N
program NN N
( ( N
< JJ N
50 CD N
% NN N
of IN N
heart NN N
rate NN N
reserve NN N
) ) N
on IN N
physical JJ N
fitness NN N
of IN N
healthy JJ N
older JJR N
subjects NNS N
, , N
by IN N
comparing VBG N
maximal JJ N
and CC N
submaximal JJ N
indices NNS N
of IN N
training NN N
response NN N
. . N

METHODS NNP N
Twenty-two JJ N
volunteers NNS N
over IN N
60 CD N
years NNS N
of IN N
age NN N
participated VBN N
in IN N
the DT N
present JJ N
study NN N
. . N

The DT N
sample NN N
was VBD N
randomly RB N
divided VBN N
in IN N
an DT N
experimental JJ N
group NN N
of IN N
13 CD N
older JJR N
subjects NNS N
( ( N
3 CD N
men NNS N
and CC N
10 CD N
women NNS N
, , N
mean JJ N
age NN N
63.5 CD N
+/- JJ N
3 CD N
years NNS N
) ) N
while IN N
the DT N
remaining VBG N
9 CD N
subjects NNS N
( ( N
3 CD N
men NNS N
and CC N
6 CD N
women NNS N
, , N
mean JJ N
age NN N
64.2 CD N
+/- JJ N
4 CD N
years NNS N
) ) N
served VBD N
as IN N
inactive JJ N
control NN N
group NN N
. . N

After IN N
medical JJ N
screening VBG N
all DT N
participants NNS N
were VBD N
evaluated VBN N
before IN N
and CC N
after IN N
12 CD N
weeks NNS N
in IN N
which WDT N
the DT N
experimental JJ N
subjects NNS N
underwent VBD N
a DT N
low JJ N
intensity NN N
training NN N
. . N

Each DT N
subjects-either JJ N
inactive JJ N
or CC N
active-performed JJ N
two CD N
treadmill NN N
tests NNS N
at IN N
two-days JJ N
interval NN N
, , N
to TO N
measure VB N
maximal JJ N
and CC N
submaximal JJ N
responses NNS N
to TO N
exercise VB N
, , N
respectively RB N
. . N

Heart NNP N
rate NN N
( ( N
HR NNP N
) ) N
, , N
oxygen JJ N
uptake NN N
( ( N
VO2 NNP N
) ) N
and CC N
pulmonary JJ N
ventilation NN N
( ( N
VE NNP N
) ) N
were VBD N
measured VBN N
using VBG N
a DT N
telemetric JJ N
apparatus NN N
. . N

RESULTS VB N
The DT N
major JJ N
finding NN N
of IN N
the DT N
study NN N
was VBD N
the DT N
significant JJ N
improvement NN N
in IN N
submaximal JJ N
response NN N
to TO N
exercise NN N
of IN N
experimental JJ N
subjects NNS N
, , N
expressed VBN N
by IN N
the DT N
reduction NN N
in IN N
HR NNP N
, , N
VO2 NNP N
VE NNP N
while IN N
VO2 NNP N
max NN N
did VBD N
not RB N
change NN N
. . N

CONCLUSIONS NNP N
Thus NNP N
, , N
it PRP N
appears VBZ N
that IN N
a DT N
low JJ N
intensity NN N
general JJ N
training NN N
similar JJ N
to TO N
that DT N
followed VBN N
in IN N
the DT N
present JJ N
study NN N
may MD N
represent VB N
a DT N
good JJ N
means NN N
to TO N
improve VB N
physical JJ N
fitness NN N
in IN N
healthy JJ N
elderly JJ N
people NNS N
. . N

Similarly RB N
, , N
this DT N
study NN N
supports VBZ N
the DT N
effectiveness NN N
of IN N
evaluation NN N
tests NNS N
based VBN N
on IN N
submaximal JJ N
responses NNS N
to TO N
exercise VB N
in IN N
this DT N
population NN N
. . N

-DOCSTART- -X- O O 25022743

Weighted VBN N
blankets NNS N
and CC N
sleep NN N
in IN N
autistic JJ 4_p
children NNS 4_p
-- : 4_p
a DT 4_p
randomized JJ N
controlled JJ N
trial NN N
. . N

OBJECTIVE UH N
To TO N
assess VB N
the DT N
effectiveness NN N
of IN N
a DT N
weighted-blanket JJ N
intervention NN N
in IN N
treating VBG N
severe JJ 4_p
sleep NN 4_p
problems NNS 4_p
in IN 4_p
children NNS 4_p
with IN 4_p
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
( ( 4_p
ASD NNP 4_p
) ) 4_p
. . 4_p

METHODS NNP N
This DT N
phase NN N
III NNP N
trial NN N
was VBD N
a DT N
randomized JJ N
, , N
placebo-controlled JJ N
crossover NN N
design NN N
. . N

Participants NNS 4_p
were VBD 4_p
aged VBN 4_p
between IN 4_p
5 CD 4_p
years NNS 4_p
and CC 4_p
16 CD 4_p
years NNS 4_p
10 CD 4_p
months NNS 4_p
, , 4_p
with IN 4_p
a DT 4_p
confirmed JJ 4_p
ASD NNP 4_p
diagnosis NN 4_p
and CC 4_p
severe JJ 4_p
sleep NN 4_p
problems NNS 4_p
, , 4_p
refractory NN 4_p
to TO 4_p
community-based JJ 4_p
interventions NNS 4_p
. . 4_p

The DT N
interventions NNS N
were VBD N
either RB N
a DT N
commercially RB N
available JJ N
weighted JJ N
blanket NN N
or CC N
otherwise RB N
identical JJ N
usual JJ N
weight NN N
blanket NN N
( ( N
control NN N
) ) N
, , N
introduced VBN N
at IN N
bedtime NN N
; : N
each DT N
was VBD N
used VBN N
for IN N
a DT N
2-week JJ N
period NN N
before IN N
crossover NN N
to TO N
the DT N
other JJ N
blanket NN N
. . N

Primary JJ N
outcome NN N
was VBD N
total JJ N
sleep JJ N
time NN N
( ( N
TST NNP N
) ) N
recorded VBN N
by IN N
actigraphy NN N
over IN N
each DT N
2-week JJ N
period NN N
. . N

Secondary JJ N
outcomes NNS N
included VBD N
actigraphically RB N
recorded VBN N
sleep-onset JJ N
latency NN N
, , N
sleep JJ N
efficiency NN N
, , N
assessments NNS N
of IN N
child NN N
behavior NN N
, , N
family NN N
functioning NN N
, , N
and CC N
adverse JJ N
events NNS N
. . N

Sleep NNP N
was VBD N
also RB N
measured VBN N
by IN N
using VBG N
parent-report JJ N
diaries NNS N
. . N

RESULTS NNP N
Seventy-three JJ N
children NNS N
were VBD N
randomized VBN N
and CC N
analysis NN N
conducted VBN N
on IN N
67 CD N
children NNS N
who WP N
completed VBD N
the DT N
study NN N
. . N

Using VBG N
objective JJ N
measures NNS N
, , N
the DT N
weighted JJ N
blanket NN N
, , N
compared VBN N
with IN N
the DT N
control NN N
blanket NN N
, , N
did VBD N
not RB N
increase VB N
TST NNP N
as IN N
measured VBN N
by IN N
actigraphy NN N
and CC N
adjusted VBN N
for IN N
baseline NN N
TST NNP N
. . N

There EX N
were VBD N
no DT N
group NN N
differences NNS N
in IN N
any DT N
other JJ N
objective NN N
or CC N
subjective JJ N
measure NN N
of IN N
sleep NN N
, , N
including VBG N
behavioral JJ N
outcomes NNS N
. . N

On IN N
subjective JJ N
preference NN N
measures NNS N
, , N
parents NNS N
and CC N
children NNS N
favored VBD N
the DT N
weighted JJ N
blanket NN N
. . N

CONCLUSIONS VB N
The DT N
use NN N
of IN N
a DT N
weighted JJ N
blanket NN N
did VBD N
not RB N
help VB N
children NNS N
with IN N
ASD NNP N
sleep NN N
for IN N
a DT N
longer JJR N
period NN N
of IN N
time NN N
, , N
fall VB N
asleep RB N
significantly RB N
faster RBR N
, , N
or CC N
wake VB N
less JJR N
often RB N
. . N

However RB N
, , N
the DT N
weighted JJ N
blanket NN N
was VBD N
favored VBN N
by IN N
children NNS N
and CC N
parents NNS N
, , N
and CC N
blankets NNS N
were VBD N
well RB N
tolerated VBN N
over IN N
this DT N
period NN N
. . N

-DOCSTART- -X- O O 2590611

Differential JJ N
effect NN N
of IN N
aspirin NN N
on IN N
thromboxane NN 4_p
and CC 4_p
prostaglandin JJ 4_p
biosynthesis NN 4_p
in IN N
man NN N
. . N

1 CD N
. . N

Effects NNS N
of IN N
a DT N
single JJ N
intravenous JJ N
dose NN N
of IN N
aspirin NN N
( ( N
600 CD N
mg NN N
) ) N
on IN N
bradykinin-stimulated JJ N
prostaglandin NN N
( ( N
PG NNP N
) ) N
and CC N
on IN N
thromboxane NN N
( ( N
TX NNP N
) ) N
biosynthesis NN N
were VBD N
determined VBN N
in IN N
nine CD N
healthy JJ 4_p
male NN N
volunteers NNS N
. . N

Plasma NNP N
concentrations NNS N
of IN N
6-oxo-PGF1 JJ N
alpha NN N
and CC N
13,14-dihydro-15-oxo-PGF2 JJ N
alpha NN N
were VBD N
measured VBN N
in IN N
samples NNS N
obtained VBN N
during IN N
repeated JJ N
10 CD N
min NN N
intravenous JJ N
infusions NNS N
of IN N
bradykinin NN N
before IN N
and CC N
up RB N
to TO N
6 CD N
h NN N
after IN N
the DT N
dose NN N
of IN N
aspirin NN N
. . N

TXB2 NNP N
was VBD N
measured VBN N
in IN N
serum NN N
from IN N
blood NN N
allowed VBN N
to TO N
clot VB N
at IN N
37 CD N
degrees NNS N
C. NNP N
2 CD N
. . N

Aspirin NNP N
inhibited VBD N
bradykinin NN N
stimulated VBN N
PG NNP N
and CC N
platelet VB N
TX NNP N
biosynthesis NN N
0.5 CD N
h NN N
after IN N
the DT N
dose NN N
. . N

Serum NNP N
TXB2 NNP N
remained VBD N
low JJ N
, , N
whereas JJ N
PG NNP N
synthesis NN N
recovered VBD N
within IN N
6 CD N
h. JJ N
3 CD N
. . N

Effects NNS N
of IN N
intravenous JJ N
sodium NN N
salicylate NN N
( ( N
600 CD N
mg NN N
) ) N
were VBD N
studied VBN N
identically RB N
in IN N
eight CD N
subjects NNS N
. . N

Prostanoid NNP N
biosynthesis NN N
was VBD N
not RB N
inhibited VBN N
. . N

4 CD N
. . N

Biosynthesis NN N
of IN N
prostacyclin NN N
and CC N
TXA2 NNP N
under IN N
basal NN N
conditions NNS N
was VBD N
studied VBN N
in IN N
eight CD N
subjects NNS N
by IN N
measuring VBG N
2,3-dinor-6-oxo-PGF1 JJ N
alpha NN N
and CC N
2,3-dinor-TXB2 JJ N
in IN N
hourly JJ N
urine JJ N
samples NNS N
obtained VBN N
during IN N
and CC N
after IN N
intravenous JJ N
infusion NN N
of IN N
aspirin NN N
and CC N
, , N
on IN N
a DT N
separate JJ N
occasion NN N
, , N
of IN N
vehicle NN N
. . N

5 CD N
. . N

Aspirin NNP N
infusion NN N
reduced VBD N
urinary JJ N
excretion NN N
of IN N
both DT N
metabolites NNS N
greater JJR N
than IN N
90 CD N
% NN N
, , N
but CC N
excretion NN N
of IN N
2,3-dinor-6-oxo-PGF1 JJ N
alpha NN N
recovered VBD N
more RBR N
rapidly RB N
than IN N
did VBD N
that IN N
of IN N
2,3-dinor-TXB2 JJ N
. . N

6 CD N
. . N

We PRP N
conclude VBP N
that DT N
cyclo-oxygenase NN N
is VBZ N
rapidly RB N
synthesised VBN N
in IN N
bradykinin-responsive JJ N
tissues NNS N
in IN N
vivo NN N
and CC N
that IN N
this DT N
reflects VBZ N
similarly RB N
rapid JJ N
enzyme JJ N
biosynthesis NN N
in IN N
tissues NNS N
that WDT N
produce VBP N
PGI2 NNP N
under IN N
basal NN N
conditions NNS N
. . N

-DOCSTART- -X- O O 21859314

Effect NN N
of IN N
ozone NN N
application NN N
on IN N
the DT N
resin-dentin JJ N
microtensile NN N
bond NN N
strength NN N
. . N

When WRB N
ozone NN N
is VBZ N
used VBN N
during IN N
caries NNS N
treatment NN N
, , N
bond NN N
strength NN N
can MD N
be VB N
compromised VBN N
by IN N
the DT N
release NN N
of IN N
oxygen NN N
. . N

The DT N
use NN N
of IN N
antioxidant JJ N
agents NNS N
neutralizes VBZ N
the DT N
free JJ N
oxygen NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
effects NNS N
of IN N
ozone NN N
and CC N
sodium NN N
ascorbate NN N
on IN N
resin-dentin JJ N
microtensile NN N
bond NN N
strength NN N
( ( N
μTBS NN N
) ) N
. . N

Forty NNP N
human JJ N
third JJ N
molars NNS N
were VBD N
divided VBN N
into IN N
four CD N
groups NNS N
: : N
Group NNP N
1 CD N
, , N
not RB N
treated VBN N
with IN N
ozone NN N
; : N
Group NNP N
2 CD N
, , N
ozone NN N
application NN N
followed VBN N
by IN N
acid NN N
etching NN N
; : N
Group NNP N
3 CD N
, , N
acid NN N
etching VBG N
followed VBN N
by IN N
ozone NN N
application NN N
; : N
and CC N
Group NNP N
4 CD N
, , N
ozone NN N
and CC N
application NN N
of IN N
sodium NN N
ascorbate NN N
. . N

Bonded VBN N
beams NN N
( ( N
1.0 CD N
mm NN N
( ( N
2 CD N
) ) N
) ) N
were VBD N
tested VBN N
under IN N
tension NN N
( ( N
0.5 CD N
mm NN N
min NN N
( ( N
-1 NNP N
) ) N
) ) N
. . N

The DT N
μTBS JJ N
values NNS N
were VBD N
analyzed VBN N
using VBG N
one-way JJ N
analysis NN N
of IN N
variance NN N
( ( N
ANOVA NNP N
) ) N
and CC N
the DT N
Tukey NNP N
test NN N
( ( N
p=0.05 NN N
) ) N
. . N

All DT N
beams NNS N
that WDT N
fractured VBD N
were VBD N
analyzed VBN N
under IN N
stereomicroscopy NN N
( ( N
40× CD N
) ) N
. . N

Group NNP N
1 CD N
had VBD N
significantly RB N
higher JJR N
μTBS NN N
values NNS N
than IN N
Group NNP N
2 CD N
or CC N
3 CD N
. . N

The DT N
μTBS JJ N
values NNS N
of IN N
Groups NNP N
1 CD N
and CC N
4 CD N
were VBD N
similar JJ N
and CC N
higher JJR N
than IN N
those DT N
of IN N
Group NNP N
2 CD N
. . N

The DT N
use NN N
of IN N
ozone NN N
in IN N
Group NNP N
2 CD N
resulted VBD N
in IN N
lower JJR N
values NNS N
of IN N
μTBS NN N
in IN N
all DT N
conditions NNS N
evaluated VBN N
. . N

The DT N
predominant JJ N
failure NN N
mode NN N
was VBD N
adhesive JJ N
. . N

The DT N
application NN N
of IN N
ozone NN N
decreased VBD N
the DT N
μTBS NN N
of IN N
the DT N
dentin-composite JJ N
resin NN N
interface NN N
. . N

These DT N
values NNS N
were VBD N
reversed VBN N
when WRB N
compared VBN N
with IN N
Groups NNP N
1 CD N
and CC N
2 CD N
when WRB N
sodium NN N
ascorbate NN N
was VBD N
used VBN N
. . N

-DOCSTART- -X- O O 24113340

Effects NNS N
of IN N
repetitive JJ N
transcranial JJ N
magnetic JJ N
stimulation NN N
in IN N
performing VBG N
eye-hand JJ N
integration NN N
tasks NNS N
: : N
four CD N
preliminary JJ N
studies NNS N
with IN N
children NNS N
showing VBG N
low-functioning JJ N
autism NN 4_p
. . N

This DT N
report NN N
, , N
based VBN N
on IN N
four CD N
studies NNS N
with IN N
children NNS 4_p
with IN 4_p
low-functioning JJ 4_p
autism NN 4_p
, , N
aimed VBN N
at IN N
evaluating VBG N
the DT N
effects NNS N
of IN N
repetitive JJ N
transcranial JJ N
magnetic JJ N
stimulation NN N
delivered VBN N
on IN N
the DT N
left NN N
and CC N
right JJ N
premotor NN N
cortices NNS N
on IN N
eye-hand JJ N
integration NN N
tasks NNS N
; : N
defining VBG N
the DT N
long-lasting JJ N
effects NNS N
of IN N
high-frequency NN N
repetitive JJ N
transcranial JJ N
magnetic JJ N
stimulation NN N
; : N
and CC N
investigating VBG N
the DT N
real JJ N
efficacy NN N
of IN N
high-frequency NN N
repetitive JJ N
transcranial JJ N
magnetic JJ N
stimulation NN N
by IN N
comparing VBG N
three CD N
kinds NNS N
of IN N
treatments NNS N
( ( N
high-frequency JJ N
repetitive JJ N
transcranial JJ N
magnetic JJ N
stimulation NN N
, , N
a DT N
traditional JJ N
eye-hand JJ N
integration NN N
training NN N
, , N
and CC N
both DT N
treatments NNS N
combined VBN N
) ) N
. . N

Results $ N
showed VBD N
a DT N
significant JJ N
increase NN N
in IN N
eye-hand JJ N
performances NNS N
only RB N
when WRB N
high-frequency NN N
repetitive JJ N
transcranial JJ N
magnetic JJ N
stimulation NN N
was VBD N
delivered VBN N
on IN N
the DT N
left JJ N
premotor NN N
cortex NN N
; : N
a DT N
persistent NN N
improvement NN N
up IN N
to TO N
1 CD N
h NN N
after IN N
the DT N
end NN N
of IN N
the DT N
stimulation NN N
; : N
better JJR N
outcomes NNS N
in IN N
the DT N
treatment NN N
combining VBG N
high-frequency NN N
repetitive JJ N
transcranial JJ N
magnetic JJ N
stimulation NN N
and CC N
eye-hand JJ N
integration NN N
training NN N
. . N

Based VBN N
on IN N
these DT N
preliminary JJ N
findings NNS N
, , N
further JJ N
evaluations NNS N
on IN N
the DT N
usefulness NN N
of IN N
high-frequency NN N
repetitive JJ N
transcranial JJ N
magnetic JJ N
stimulation NN N
in IN N
rehabilitation NN N
of IN N
children NNS N
with IN N
autism NN 4_p
are VBP N
strongly RB N
recommended VBN N
. . N

-DOCSTART- -X- O O 25045936

Egg NNP N
intake NN N
during IN N
carbohydrate JJ N
restriction NN N
alters NNS N
peripheral JJ N
blood NN N
mononuclear NN N
cell NN N
inflammation NN N
and CC N
cholesterol NN N
homeostasis NN N
in IN N
metabolic JJ N
syndrome NN N
. . N

Egg NNP N
yolk NN N
contains NNS N
bioactive JJ N
components NNS N
that WDT N
improve VBP N
plasma NN N
inflammatory NN N
markers NNS N
and CC N
HDL NNP N
profiles NNS N
in IN N
metabolic JJ N
syndrome NN N
( ( N
MetS NNP N
) ) N
under IN N
carbohydrate NN N
restriction NN N
. . N

We PRP N
further RB N
sought VBD N
to TO N
determine VB N
whether IN N
egg NN N
yolk NNS N
intake VBP N
affects NNS N
peripheral JJ N
blood NN N
mononuclear NN N
cell NN N
( ( N
PBMC NNP N
) ) N
inflammation NN N
and CC N
cholesterol NN N
homeostasis NN N
in IN N
MetS NNP N
, , N
as IN N
HDL NNP N
and CC N
its PRP$ N
associated JJ N
lipid JJ N
transporter NN N
ATP-binding NNP N
cassette NN N
transporter NN N
A1 NNP N
( ( N
ABCA1 NNP N
) ) N
reduce VB N
the DT N
inflammatory JJ N
potential NN N
of IN N
leukocytes NNS N
through IN N
modulation NN N
of IN N
cellular JJ N
cholesterol NN N
content NN N
and CC N
distribution NN N
. . N

Thirty-seven JJ N
men NNS N
and CC N
women NNS N
classified VBN N
with IN N
MetS NNP 4_p
consumed VBD N
a DT N
moderate JJ N
carbohydrate-restricted JJ N
diet NN N
( ( N
25 CD N
% NN N
-30 CD N
% NN N
of IN N
energy NN N
) ) N
for IN N
12 CD N
weeks NNS N
, , N
in IN N
addition NN N
to TO N
consuming VBG N
either DT N
three CD N
whole JJ N
eggs NNS N
per IN N
day NN N
( ( N
EGG NNP N
) ) N
or CC N
the DT N
equivalent JJ N
amount NN N
of IN N
yolk-free JJ N
egg NN N
substitute NN N
( ( N
SUB NNP N
) ) N
. . N

Interestingly RB N
, , N
lipopolysaccharide-induced JJ N
PBMC NNP N
IL-1β NNP N
and CC N
TNFα NNP N
secretion NN N
increased VBD N
from IN N
baseline NN N
to TO N
week NN N
12 CD N
in IN N
the DT N
SUB NNP N
group NN N
only RB N
, , N
despite IN N
increases NNS N
in IN N
PBMC NNP N
toll-like JJ N
receptor NN N
4 CD N
( ( N
TLR4 NNP N
) ) N
mRNA NN N
expression NN N
in IN N
the DT N
EGG NNP N
group NN N
. . N

Compared VBN N
to TO N
baseline VB N
, , N
ABCA1 NNP N
and CC N
3-hydroxy-3-methyl-glutaryl NNP N
( ( N
HMG NNP N
) ) N
-CoA VBP N
reductase NN N
mRNA JJ N
expression NN N
increased VBN N
by IN N
week NN N
12 CD N
in IN N
the DT N
EGG NNP N
group NN N
only RB N
, , N
whereas NNS N
changes NNS N
in IN N
PBMC NNP N
total JJ N
cholesterol NN N
positively RB N
correlated VBN N
with IN N
changes NNS N
in IN N
lipid JJ N
raft NN N
content NN N
. . N

Together RB N
, , N
these DT N
findings NNS N
suggest VBP N
that IN N
intake NN N
of IN N
whole JJ N
eggs NNS N
during IN N
carbohydrate JJ N
restriction NN N
alters NNS N
PBMC NNP N
inflammation NN N
and CC N
cholesterol NN N
homeostasis NN N
in IN N
MetS NNP N
. . N

-DOCSTART- -X- O O 23688859

Effects NNS N
of IN N
exposure NN N
to TO N
thin-ideal JJ N
media NNS N
images NNS N
on IN N
body NN N
dissatisfaction NN N
: : N
testing VBG N
the DT N
inclusion NN N
of IN N
a DT N
disclaimer NN N
versus NN N
warning VBG N
label NN N
. . N

The DT N
current JJ N
study NN N
was VBD N
designed VBN N
to TO N
determine VB N
whether IN N
the DT N
inclusion NN N
of IN N
a DT N
disclaimer NN N
( ( N
i.e. FW N
, , N
" FW N
Retouched NNP N
photograph NN N
aimed VBN N
at IN N
changing VBG N
a DT N
person NN N
's POS N
physical JJ N
appearance NN N
. . N

" NN N
) ) N
or CC N
warning VBG N
( ( N
i.e. FW N
, , N
" FW N
Warning VBG N
: : N
Trying NN N
to TO N
look VB N
as RB N
thin JJ N
as IN N
this DT N
model NN N
may MD N
be VB N
dangerous JJ N
to TO N
your PRP$ N
health NN N
. . N

" NN N
) ) N
added VBD N
to TO N
images NNS N
of IN N
thin/attractive JJ N
models NNS N
would MD N
affect VB N
body NN N
dissatisfaction NN N
and CC N
intent NN N
to TO N
diet VB N
in IN N
female JJ N
undergraduate JJ N
students NNS N
( ( N
n=342 NN N
) ) N
. . N

Participants NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
four CD N
groups NNS N
: : N
( ( N
a DT N
) ) N
disclaimer NN N
, , N
( ( N
b NN N
) ) N
warning NN N
, , N
( ( N
c NN N
) ) N
model NN N
control NN N
, , N
or CC N
( ( N
d NN N
) ) N
car NN N
control NN N
. . N

Results NNP N
revealed VBD N
a DT N
significant JJ N
interaction NN N
between IN N
group NN N
and CC N
time NN N
, , N
whereby WRB N
only RB N
the DT N
car NN N
control NN N
group NN N
reported VBD N
a DT N
significant JJ N
change NN N
( ( N
i.e. FW N
, , N
decrease NN N
) ) N
in IN N
body NN N
dissatisfaction NN N
over IN N
time NN N
. . N

Groups NNP N
did VBD N
not RB N
differ VB N
on IN N
intent NN N
to TO N
diet VB N
measured VBN N
at IN N
post-exposure NN N
. . N

The DT N
results NNS N
largely RB N
replicate VBP N
other JJ N
findings NNS N
in IN N
this DT N
area NN N
and CC N
call VB N
into IN N
question NN N
advocacy NN N
efforts NNS N
to TO N
label VB N
media NNS N
images NNS N
as IN N
a DT N
strategy NN N
to TO N
decrease VB N
women NNS N
's POS N
identification NN N
with IN N
the DT N
stimuli NNS N
. . N

-DOCSTART- -X- O O 19608530

A DT N
double-blind JJ N
placebo-controlled JJ N
study NN N
to TO N
evaluate VB N
valacyclovir NN N
alone RB N
and CC N
with IN N
aspirin NN N
for IN N
asymptomatic JJ N
HSV-1 NNP N
DNA NNP N
shedding VBG N
in IN N
human JJ N
tears NNS N
and CC N
saliva NN N
. . N

PURPOSE NNP N
To TO N
test VB N
the DT N
effect NN N
of IN N
valacyclovir NN N
alone RB N
and CC N
with IN N
aspirin NN N
on IN N
the DT N
asymptomatic JJ N
shedding NN N
of IN N
HSV-1 NNP N
DNA NNP N
in IN N
tears NNS N
and CC N
saliva NN N
of IN N
healthy JJ 4_p
individuals NNS N
. . N

METHOD NNP N
. . N

The DT N
subjects NNS N
( ( N
n JJ N
= NNP N
45 CD N
) ) N
were VBD N
randomized VBN N
into IN N
three CD N
groups NNS N
without IN N
regard NN N
to TO N
age NN N
, , N
sex NN N
, , N
or CC N
race NN N
. . N

Group NNP N
1 CD N
( ( N
n JJ N
= NNP N
14 CD N
) ) N
received VBD N
the DT N
placebo NN N
, , N
group NN N
2 CD N
( ( N
n JJ N
= NNP N
15 CD N
) ) N
received VBD N
a DT N
dose NN N
of IN N
500 CD N
mg NNS N
valacyclovir JJ N
once RB N
daily JJ N
, , N
and CC N
group NN N
3 CD N
( ( N
n JJ N
= NNP N
16 CD N
) ) N
received VBD N
a DT N
dose NN N
of IN N
500 CD N
mg NNS N
valacyclovir JJ N
once RB N
daily JJ N
and CC N
350 CD N
mg NN N
aspirin JJ N
twice RB N
daily RB N
for IN N
30 CD N
days NNS N
. . N

Ocular JJ N
and CC N
oral JJ N
swabs NNS N
were VBD N
collected VBN N
twice RB N
daily RB N
for IN N
30 CD N
days NNS N
. . N

DNA NN N
was VBD N
extracted VBN N
from IN N
all DT N
swabs NNS N
and CC N
HSV-1 NNP N
DNA NNP N
copy NN N
numbers NNS N
were VBD N
determined VBN N
. . N

Statistical JJ N
analysis NN N
was VBD N
performed VBN N
to TO N
compare VB N
the DT N
DNA NNP N
copy NN N
numbers NNS N
of IN N
the DT N
three CD N
groups NNS N
. . N

RESULTS NNP N
There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
HSV-1 NNP N
DNA NNP N
copy NN N
numbers NNS N
in IN N
the DT N
tears NNS N
or CC N
saliva NN N
among IN N
any DT N
of IN N
the DT N
three CD N
treatment NN N
groups NNS N
. . N

The DT N
mean JJ N
copy NN N
numbers NNS N
+/- JJ N
SE NNP N
of IN N
mean NN N
( ( N
SEM NNP N
) ) N
of IN N
HSV-1 NNP N
DNA NNP N
in IN N
tears NNS N
were VBD N
340 CD N
+/- JJ N
35 CD N
, , N
1074 CD N
+/- JJ N
320 CD N
, , N
and CC N
630 CD N
+/- JJ N
51 CD N
for IN N
groups NNS N
1 CD N
, , N
2 CD N
, , N
and CC N
3 CD N
, , N
and CC N
in IN N
saliva NN N
were VBD N
238 CD N
+/- JJ N
35 CD N
, , N
963 CD N
+/- JJ N
462 CD N
, , N
and CC N
493 CD N
+/- JJ N
25 CD N
, , N
respectively RB N
, , N
for IN N
groups NNS N
1 CD N
, , N
2 CD N
, , N
and CC N
3 CD N
. . N

CONCLUSIONS NNP N
No NNP N
correlation NN N
was VBD N
found VBN N
between IN N
HSV-1 NNP N
shedding VBG N
and CC N
valacyclovir NNS N
and CC N
valacyclovir NN N
with IN N
aspirin JJ N
treatment NN N
. . N

The DT N
HSV-1 NNP N
DNA NNP N
copy NN N
number NN N
was VBD N
not RB N
reduced VBN N
by IN N
treatment NN N
with IN N
500 CD N
mg NNS N
of IN N
valacyclovir JJ N
daily JJ N
or CC N
with IN N
a DT N
combination NN N
of IN N
daily JJ N
valacyclovir NN N
( ( N
500 CD N
mg NN N
) ) N
plus CC N
twice-daily JJ N
doses NNS N
of IN N
aspirin NN N
( ( N
350 CD N
mg NN N
) ) N
over IN N
30 CD N
days NNS N
. . N

-DOCSTART- -X- O O 25066648

Complex NNP N
decongestive JJ N
therapy NN N
and CC N
taping VBG N
for IN N
patients NNS 4_p
with IN 4_p
postmastectomy JJ 4_p
lymphedema NN 4_p
: : 4_p
a DT N
randomized NN N
controlled VBN N
study NN N
. . N

PURPOSE VB N
The DT N
purpose NN N
of IN N
our PRP$ N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
effects NNS N
of IN N
Kinesio NNP N
Taping NNP N
( ( N
® NNP N
) ) N
Application NN N
with IN N
Complex NNP N
Decongestive NNP N
Therapy NNP N
( ( N
CDT NNP N
) ) N
in IN 4_p
patients NNS 4_p
with IN 4_p
lymphedema NN 4_p
. . N

MATERIALS NNP N
AND NNP N
METHODS NNP N
45 CD N
patients NNS N
were VBD N
randomly RB N
divided VBN N
into IN N
3 CD N
groups NNS N
( ( N
CDT NNP N
including VBG N
Bandage NNP N
, , N
CDT NNP N
including VBG N
Bandage NNP N
+ NNP N
Kinesio NNP N
Tape NNP N
( ( N
® NNP N
) ) N
, , N
CDT NNP N
including VBG N
Kinesio NNP N
Tape NNP N
( ( N
® NNP N
) ) N
without IN N
bandage NN N
) ) N
. . N

Assessments NNS N
included VBD N
the DT N
severity NN N
of IN N
the DT N
symptoms NNS N
such JJ N
as IN N
pain NN N
, , N
discomfort NN N
, , N
heaviness NN N
, , N
tension NN N
, , N
stiffness NN N
and CC N
weakness NN N
. . N

Bilateral JJ N
circumference NN N
measurements NNS N
were VBD N
done VBN N
for IN N
evaluation NN N
of IN N
the DT N
edema NN N
. . N

RESULTS NNP N
Symptoms NNP N
were VBD N
decreased VBN N
in IN N
all DT N
three CD N
groups NNS N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

CDT NNP N
was VBD N
found VBN N
effective JJ N
only RB N
during IN N
treatment NN N
in IN N
arm NN N
volume NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

Kinesio NNP N
Taping NNP N
( ( N
® NNP N
) ) N
applied VBD N
with IN N
CDT NNP N
had VBD N
effect NN N
of IN N
decreasing VBG N
edema NN N
after IN N
10 CD N
days NNS N
of IN N
treatment NN N
period NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
and CC N
for IN N
control NN N
period NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

Only RB N
the DT N
application NN N
of IN N
Kinesio NNP N
Taping NNP N
( ( N
® NNP N
) ) N
group NN N
also RB N
had VBD N
significant JJ N
decrease NN N
at IN N
edema NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSION NNP N
Kinesio NNP N
Taping NNP N
( ( N
® NNP N
) ) N
Application NNP N
along IN N
with IN N
CDT NNP N
may MD N
have VB N
a DT N
better JJR N
effect NN N
on IN N
decreasing VBG 4_p
lymphedema NN 4_p
which WDT N
can MD N
stimulate VB N
the DT N
reduction NN N
of IN N
edema NN N
for IN N
long JJ N
term NN N
effects NNS N
. . N

-DOCSTART- -X- O O 11932900

Detection NN N
of IN N
recurrent NN 4_p
or CC 4_p
persistent JJ 4_p
nasopharyngeal NN 4_p
carcinomas NN 4_p
after IN 4_p
radiotherapy NN 4_p
with IN N
technetium-99m JJ N
methoxyisobutylisonitrile NN N
single JJ N
photon NN N
emission NN N
computed VBD N
tomography NN N
and CC N
computed VBD N
tomography NN N
: : N
comparison NN N
with IN N
18-fluoro-2-deoxyglucose JJ N
positron NN N
emission NN N
tomography NN N
. . N

BACKGROUND IN N
The DT N
diagnostic JJ N
accuracy NN N
of IN N
technetium-99m JJ N
methoxyisobutylisonitrile NN N
( ( N
Tc-MIBI NNP N
) ) N
single JJ N
photon NN N
emission NN N
computed VBN N
tomography NN N
( ( N
SPECT NNP N
) ) N
and CC N
computed VBN N
tomography NN N
( ( N
CT NNP N
) ) N
of IN N
the DT N
head NN N
and CC N
neck NN N
for IN N
differentiating VBG N
recurrent NN N
or CC N
residual JJ N
nasopharyngeal NN N
carcinomas NN N
( ( N
NPC NNP 4_p
) ) N
from IN N
benign JJ N
lesions NNS N
after IN N
radiotherapy NN N
was VBD N
compared VBN N
with IN N
positron NN N
emission NN N
tomography NN N
( ( N
PET NNP N
) ) N
with IN N
18-fluoro-2-deoxyglucose JJ N
( ( N
FDG NNP N
) ) N
. . N

METHODS NNP N
Thirty NNP N
six CD N
NPC NNP N
patients NNS N
underwent JJ N
head NN N
and CC N
neck NN N
CT NNP N
, , N
Tc-MIBI NNP N
SPECT NNP N
, , N
and CC N
FDG-PET NNP N
four CD N
months NNS N
after IN N
radiotherapy NN N
to TO N
differentiate VB N
recurrent NN N
or CC N
residual JJ N
NPC NNP N
from IN N
benign JJ N
lesions NNS N
. . N

Histopathologic NNP N
examinations NNS N
of IN N
nasopharyngeal JJ N
biopsies NNS N
were VBD N
performed VBN N
for IN N
all DT N
36 CD N
patients NNS N
. . N

No DT N
patients NNS N
had VBD N
multiple JJ N
foci NN N
of IN N
NPC NNP N
. . N

RESULTS NNP N
Based VBD N
on IN N
biopsy NN N
results NNS N
, , N
the DT N
sensitivity NN N
, , N
specificity NN N
, , N
and CC N
accuracy NN N
of IN N
CT NNP N
for IN N
differentiating VBG N
recurrent NN N
or CC N
residual JJ N
NPC NNP N
from IN N
benign JJ N
lesions NNS N
were VBD N
73 CD N
% NN N
, , N
88 CD N
% NN N
, , N
and CC N
83 CD N
% NN N
, , N
respectively RB N
. . N

The DT N
sensitivity NN N
, , N
specificity NN N
, , N
and CC N
accuracy NN N
of IN N
Tc-MIBI NNP N
SPECT NNP N
were VBD N
73 CD N
% NN N
, , N
96 CD N
% NN N
, , N
and CC N
89 CD N
% NN N
, , N
respectively RB N
. . N

The DT N
sensitivity NN N
, , N
specificity NN N
, , N
and CC N
accuracy NN N
of IN N
FDG-PET NNP N
were VBD N
100 CD N
% NN N
, , N
96 CD N
% NN N
, , N
and CC N
97 CD N
% NN N
, , N
respectively RB N
. . N

Combination NNP N
CT NNP N
and CC N
Tc-MIBI NNP N
SPECT NNP N
for IN N
28 CD N
NPC NNP N
patients NNS N
with IN N
congruent JJ N
results NNS N
showed VBD N
the DT N
same JJ N
sensitivity NN N
, , N
specificity NN N
, , N
and CC N
accuracy NN N
of IN N
100 CD N
% NN N
, , N
96 CD N
% NN N
, , N
and CC N
96 CD N
% NN N
, , N
respectively RB N
, , N
as IN N
FDG-PET NNP N
for IN N
differentiating VBG N
recurrent NN N
or CC N
residual JJ N
NPC NNP N
from IN N
benign JJ N
lesions NNS N
. . N

In IN N
eight CD N
patients NNS N
with IN N
incongruent JJ N
results NNS N
between IN N
CT NNP N
and CC N
Tc-MIBI NNP N
SPECT NNP N
, , N
FDG-PET NNP N
correctly RB N
differentiated VBD N
two CD N
benign JJ N
lesions NNS N
and CC N
six CD N
recurrent NN N
or CC N
residual JJ N
NPCs NNP N
. . N

CONCLUSIONS NNP N
In IN N
detecting VBG N
recurrent NN N
or CC N
residual JJ N
NPC NNP N
, , N
FDG-PET NNP N
is VBZ N
the DT N
best JJS N
tool NN N
. . N

However RB N
, , N
combined VBN N
use NN N
of IN N
CT NNP N
and CC N
Tc-MIBI NNP N
SPECT NNP N
can MD N
result VB N
in IN N
the DT N
same JJ N
accuracy NN N
as IN N
FDG-PET NNP N
. . N

-DOCSTART- -X- O O 21193295

Effect NN N
of IN N
weight JJ N
loss NN N
on IN N
inflammation NN N
in IN N
patients NNS 4_p
with IN 4_p
mild JJ 4_p
obstructive JJ 4_p
sleep NN 4_p
apnea NN 4_p
. . 4_p

BACKGROUND NNP N
AND CC N
AIMS NNP N
Inflammation NNP N
may MD N
be VB N
one CD N
mediating VBG N
mechanism NN N
for IN N
cardiovascular JJ 4_p
diseases NNS 4_p
in IN N
obstructive JJ 4_p
sleep NN 4_p
apnea NN 4_p
( ( 4_p
OSA NNP 4_p
) ) 4_p
. . N

However RB N
, , N
little JJ N
is VBZ N
known VBN N
about IN N
subclinical JJ N
inflammation NN N
or CC N
the DT N
effect NN N
of IN N
lifestyle JJ N
intervention NN N
on IN N
inflammation NN N
in IN N
early JJ N
stages NNS N
of IN N
OSA NNP N
. . N

The DT N
aim NN N
of IN N
this DT N
substudy NN N
of IN N
an DT N
existing VBG N
randomized NN N
controlled VBD N
trial NN N
, , N
with IN N
post NN N
hoc NN N
analyses NNS N
, , N
was VBD N
to TO N
determine VB N
the DT N
impact NN N
of IN N
lifestyle JJ N
changes NNS N
aimed VBN N
at IN N
weight JJ N
reduction NN N
on IN N
inflammatory NN N
biomarkers NNS N
in IN N
overweight JJ 4_p
patients NNS N
with IN N
mild JJ 4_p
OSA NNP 4_p
. . 4_p

METHODS NNP N
AND CC N
RESULTS NNP N
Patients NNPS N
were VBD N
randomized VBN N
to TO N
supervised VBN N
intensive JJ N
lifestyle JJ N
intervention NN N
group NN N
( ( N
N=28 NNP N
) ) N
or CC N
to TO N
control VB N
group NN N
( ( N
N=31 NNP N
) ) N
, , N
which WDT N
received VBD N
routine JJ N
lifestyle JJ N
advices NNS N
. . N

Circulating VBG N
concentrations NNS N
of IN N
pro- JJ N
and CC N
anti-inflammatory JJ N
mediators NNS N
were VBD N
measured VBN N
before IN N
and CC N
after IN N
the DT N
1-year JJ N
intervention NN N
. . N

The DT N
concentrations NNS N
of IN N
two CD N
pro-inflammatory JJ N
mediators NNS N
, , N
high-sensitivity JJ N
C-reactive JJ N
protein NN N
( ( N
hsCRP NN N
) ) N
and CC N
interleukin JJ N
( ( N
IL NNP N
) ) N
-6 NN N
, , N
decreased VBN N
significantly RB N
in IN N
both DT N
groups NNS N
. . N

Although IN N
the DT N
changes NNS N
in IN N
inflammatory JJ N
biomarkers NNS N
favored VBD N
the DT N
supervised JJ N
lifestyle NN N
intervention NN N
, , N
the DT N
only JJ N
significant JJ N
reduction NN N
observed VBD N
between IN N
the DT N
groups NNS N
was VBD N
for IN N
the DT N
anti-inflammatory JJ N
IL-1 NNP N
receptor NN N
antagonist NN N
( ( N
IL-1RA NNP N
) ) N
. . N

The DT N
change NN N
in IN N
hsCRP NN N
was VBD N
associated VBN N
with IN N
apnea-hypopnea JJ N
index NN N
, , N
and CC N
improving VBG N
night-time JJ N
oxygen NN N
saturation NN N
was VBD N
related VBN N
to TO N
tumor VB N
necrosis JJ N
factor NN N
alpha NN N
. . N

IL-1RA JJ N
and CC N
IL-6 NNP N
were VBD N
associated VBN N
with IN N
insulin NN N
metabolism NN N
. . N

CONCLUSION NNP N
Weight NNP N
loss NN N
resulted VBD N
in IN N
reductions NNS N
in IN N
concentrations NNS N
of IN N
some DT N
pro- JJ N
and CC N
anti-inflammatory JJ N
mediators NNS N
in IN N
overweight JJ 4_p
patients NNS N
with IN N
mild JJ 4_p
OSA NNP 4_p
, , N
overall JJ N
favoring VBG N
the DT N
supervised JJ N
lifestyle JJ N
intervention NN N
. . N

These DT N
findings NNS N
suggest VBP N
that IN N
more RBR N
intensive JJ N
treatment NN N
of IN N
obesity NN N
in IN N
OSA NNP 4_p
patients NNS N
might MD N
be VB N
well-justified JJ N
. . N

-DOCSTART- -X- O O 9989713

Effectiveness NN N
of IN N
active JJ N
physical JJ N
training NN N
as IN N
treatment NN N
for IN N
long-standing JJ N
adductor-related JJ 4_p
groin NN 4_p
pain NN 4_p
in IN N
athletes NNS 4_p
: : N
randomised VBN N
trial NN N
. . N

BACKGROUND NNP N
Groin NNP N
pain NN N
is VBZ N
common JJ N
among IN N
athletes NNS N
. . N

A DT N
major JJ N
cause NN N
of IN N
long-standing JJ N
problems NNS N
is VBZ N
adductor-related JJ 4_p
groin NN 4_p
pain NN 4_p
. . N

The DT N
purpose NN N
of IN N
this DT N
randomised JJ N
clinical JJ N
trial NN N
was VBD N
to TO N
compare VB N
an DT N
active JJ N
training NN N
programme NN N
( ( N
AT NNP N
) ) N
with IN N
a DT N
physiotherapy NN N
treatment NN N
without IN N
active JJ N
training NN N
( ( N
PT NNP N
) ) N
in IN N
the DT N
treatment NN N
of IN N
adductor-related JJ 4_p
groin NN 4_p
pain NN 4_p
in IN N
athletes NNS 4_p
. . N

METHODS NNP N
68 CD N
athletes NNS N
with IN N
long-standing JJ N
( ( N
median JJ N
40 CD N
weeks NNS N
) ) N
adductor-related JJ 4_p
groin NN 4_p
pain NN 4_p
-- : N
after IN N
examination NN N
according VBG N
to TO N
a DT N
standardised VBN N
protocol NN N
-- : N
were VBD N
randomly RB N
assigned VBN N
to TO N
AT NNP N
or CC N
PT NNP N
. . N

The DT N
treatment NN N
period NN N
was VBD N
8-12 JJ N
weeks NNS N
. . N

4 CD N
months NNS N
after IN N
the DT N
end NN N
of IN N
treatment NN N
a DT N
standardised JJ N
examination NN N
was VBD N
done VBN N
. . N

The DT N
examining VBG N
physician NN N
was VBD N
unaware JJ N
of IN N
the DT N
treatment NN N
allocation NN N
. . N

The DT N
ultimate JJ N
outcome NN N
measure NN N
was VBD N
full JJ N
return NN N
to TO N
sports NNS N
at IN N
the DT N
same JJ N
level NN N
without IN N
groin NN N
pain NN N
. . N

Analyses NNS N
were VBD N
by IN N
intention NN N
to TO N
treat VB N
. . N

FINDINGS NNP N
23 CD N
patients NNS N
in IN N
the DT N
AT NNP N
group NN N
and CC N
four CD N
in IN N
the DT N
PT NNP N
group NN N
returned VBD N
to TO N
sports NNS N
without IN N
groin NN N
pain NN N
( ( N
odds NNS N
ratio NN N
, , N
multiple-logistic-regression NN N
analysis NN N
, , N
12.7 CD N
[ JJ N
95 CD N
% NN N
CI NNP N
3.4-47.2 CD N
] NNP N
) ) N
. . N

The DT N
subjective JJ N
global JJ N
assessments NNS N
of IN N
the DT N
effect NN N
of IN N
the DT N
treatments NNS N
showed VBD N
a DT N
significant JJ N
( ( N
p=0.006 NN N
) ) N
linear VBP N
trend NN N
towards NNS N
a DT N
better JJR N
effect NN N
in IN N
the DT N
AT NNP N
group NN N
. . N

A DT N
per-protocol JJ N
analysis NN N
did VBD N
not RB N
show VB N
appreciably RB N
different JJ N
results NNS N
. . N

INTERPRETATION NNP N
AT NNP N
with IN N
a DT N
programme NN N
aimed VBN N
at IN N
improving VBG N
strength NN N
and CC N
coordination NN N
of IN N
the DT N
muscles NNS N
acting VBG N
on IN N
the DT N
pelvis NN N
, , N
in IN N
particular JJ N
the DT N
adductor NN N
muscles NNS N
, , N
is VBZ N
very RB N
effective JJ N
in IN N
the DT N
treatment NN N
of IN N
athletes NNS N
with IN N
long-standing JJ N
adductor-related JJ N
groin NN N
pain NN N
. . N

The DT N
potential JJ N
preventive JJ N
value NN N
of IN N
a DT N
short JJ N
programme NN N
based VBN N
upon IN N
the DT N
principles NNS N
of IN N
AT NNP N
should MD N
be VB N
assessed VBN N
in IN N
future JJ N
, , N
randomised VBN N
, , N
clinical JJ N
trials NNS N
. . N

-DOCSTART- -X- O O 1326734

Randomized VBN N
phase NN N
II NNP N
trial NN N
of IN N
high-dose JJ N
4'-epi-doxorubicin JJ N
+ NNP N
cyclophosphamide NN N
versus IN N
high-dose JJ N
4'-epi-doxorubicin JJ N
+ NN N
cisplatin NN N
in IN N
previously RB N
untreated JJ N
patients NNS N
with IN N
extensive JJ 4_p
small JJ 4_p
cell NN 4_p
lung NN 4_p
cancer NN 4_p
. . N

One CD N
hundred CD N
and CC N
eleven RB N
previously RB N
untreated JJ N
patients NNS N
with IN N
extensive JJ 4_p
small JJ 4_p
cell NN 4_p
lung NN 4_p
cancer NN 4_p
were VBD N
included VBN N
in IN N
a DT N
prospective JJ N
randomized VBN N
study NN N
with IN N
the DT N
aim NN N
to TO N
assess VB N
the DT N
efficacy NN N
and CC N
tolerance NN N
of IN N
high-dose JJ N
epirubicin NN N
( ( N
120 CD N
mg/m2 NN N
) ) N
in IN N
combination NN N
with IN N
either DT N
cyclophosphamide NN N
( ( N
800 CD N
mg/m2 NN N
; : N
arm CC N
1 CD N
) ) N
or CC N
cisplatin NN N
( ( N
60 CD N
mg/m2 NN N
; : N
arm CC N
2 CD N
) ) N
. . N

Ninety-six JJ N
patients NNS N
were VBD N
evaluable JJ N
for IN N
response NN N
and CC N
toxicity NN N
and CC N
additional JJ N
12 CD N
patients NNS N
for IN N
toxicity NN N
only RB N
. . N

The DT N
overall JJ N
response NN N
rate NN N
( ( N
CR+PR NNP N
) ) N
in IN N
arm NN N
1 CD N
and CC N
2 CD N
were VBD N
61.4 CD N
( ( N
27/44 CD N
) ) N
and CC N
67.3 CD N
% NN N
( ( N
35/52 CD N
) ) N
, , N
respectively RB N
. . N

The DT N
mean JJ N
duration NN N
of IN N
remission NN N
was VBD N
4.4 CD N
months NNS N
( ( N
arm JJ N
1 CD N
) ) N
and CC N
4.9 CD N
months NNS N
( ( N
arm JJ N
2 CD N
) ) N
. . N

The DT N
mean JJ N
survival NN N
time NN N
was VBD N
6.6 CD N
months NNS N
in IN N
arm NN N
1 CD N
and CC N
7.7 CD N
months NNS N
in IN N
arm NN N
2. CD N
WHO NNP N
grade VBD N
4 CD N
toxicity NN N
was VBD N
encountered VBN N
in IN N
25.5 CD N
and CC N
15.8 CD N
% NN N
of IN N
patients NNS N
in IN N
arm JJ N
1 CD N
and CC N
2 CD N
, , N
respectively RB N
. . N

One CD N
case NN N
of IN N
cardiotoxicity NN N
resulting VBG N
in IN N
the DT N
patient NN N
's POS N
death NN N
was VBD N
observed VBN N
in IN N
arm NN N
1 CD N
. . N

Both DT N
combinations NNS N
showed VBD N
considerable JJ N
antitumor NN N
activity NN N
. . N

Toxicity NN N
was VBD N
acceptable JJ N
. . N

-DOCSTART- -X- O O 16104966

Open JJ 4_p
flap NN 4_p
debridement NN 4_p
with IN N
or CC N
without IN N
intentional JJ N
cementum NN N
removal NN N
: : N
a DT N
4-month JJ N
follow-up NN N
. . N

OBJECTIVES IN N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
influence NN N
of IN N
cementum NN N
removal NN N
on IN N
periodontal JJ 4_p
repair NN 4_p
. . N

MATERIAL NNP N
AND NNP N
METHODS NNP N
Forty NNP N
subjects NNS N
with IN N
chronic JJ 4_p
periodontitis NN 4_p
and CC N
presenting NN 4_p
, , 4_p
at IN 4_p
least JJS 4_p
, , 4_p
two CD 4_p
proximal JJ 4_p
sites NNS 4_p
in IN 4_p
anterior JJ 4_p
teeth NNS 4_p
( ( 4_p
upper JJ 4_p
or CC 4_p
lower JJR 4_p
) ) 4_p
with IN 4_p
probing VBG 4_p
depth JJ 4_p
> NN 4_p
or CC 4_p
=5 JJ 4_p
mm NNS 4_p
were VBD N
selected VBN N
. . N

After IN N
oral JJ N
hygiene NN N
instructions NNS N
and CC N
ultrasonic JJ N
supragingival NN N
instrumentation NN N
, , N
the DT N
subjects NNS N
were VBD N
randomly RB N
assigned VBN N
for IN N
one CD N
of IN N
the DT N
following JJ N
groups NNS N
: : N
CIC NNP N
, , N
scaled VBD N
with IN N
Gracey NNP N
curettes NNS N
; : N
CIUS NNP N
, , N
scaled VBD N
with IN N
ultrasonic JJ N
device NN N
; : N
CDC NNP N
, , N
calculus JJ N
deattachment NN N
with IN N
Gracey NNP N
curettes NNS N
and CC N
brushing VBG N
with IN N
saline JJ N
solution NN N
; : N
and CC N
CDUS NNP N
, , N
calculus JJ N
deattachment NN N
with IN N
ultrasonic JJ N
device NN N
and CC N
brushing VBG N
with IN N
saline JJ N
solution NN N
. . N

Full-thickness JJ N
flaps NNS N
were VBD N
reflected VBN N
and CC N
the DT N
instrumentation NN N
was VBD N
performed VBN N
with IN N
a DT N
clinical JJ N
microscope NN N
. . N

Probing VBG N
depth NN N
( ( N
PD NNP N
) ) N
, , N
relative JJ N
gingival NN N
margin NN N
level NN N
( ( N
RGML NNP N
) ) N
and CC N
relative JJ N
attachment NN N
level NN N
( ( N
RAL NNP N
) ) N
were VBD N
registered VBN N
at IN N
five CD N
experimental JJ N
periods NNS N
: : N
baseline NN N
and CC N
30 CD N
, , N
60 CD N
, , N
90 CD N
and CC N
120 CD N
days NNS N
postoperative JJ N
. . N

RESULTS VB N
All PDT N
the DT N
approaches NNS N
were VBD N
able JJ N
to TO N
markedly RB N
reduce VB N
the DT N
PD NNP N
values NNS N
from IN N
the DT N
baseline NN N
to TO N
the DT N
other JJ N
evaluation NN N
periods NNS N
( ( N
p JJ N
< NNP N
0.0001 CD N
) ) N
. . N

The DT N
increase NN N
in IN N
RGML NNP N
values NNS N
was VBD N
statistically RB N
significant JJ N
only RB N
for IN N
the DT N
CDUS NNP N
group NN N
. . N

There EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
between IN N
the DT N
baseline NN N
and CC N
postoperative JJ N
values NNS N
in IN N
all DT N
groups NNS N
for IN N
the DT N
RAL NNP N
changes NNS N
. . N

The DT N
changes NNS N
in IN N
RAL NNP N
were VBD N
statistically RB N
significant JJ N
only RB N
among IN N
the DT N
groups NNS N
CDC NNP N
and CC N
CDUS NNP N
( ( N
p JJ N
< NNP N
0.0001 CD N
) ) N
. . N

CONCLUSION VB N
The DT N
conventional JJ N
scaling NN N
and CC N
root NN N
planing NN N
and CC N
the DT N
calculus JJ N
deattachment NN N
were VBD N
effective JJ N
in IN N
reducing VBG N
the DT N
probing VBG N
depth NN N
values NNS N
, , N
regardless RB N
of IN N
the DT N
instrumentation NN N
method NN N
. . N

-DOCSTART- -X- O O 3543069

Untoward NNP N
effects NNS N
of IN N
fenfluramine NN N
in IN N
autistic JJ N
children NNS N
. . N

Several JJ N
recent JJ N
studies NNS N
have VBP N
described VBN N
the DT N
benefits NNS N
of IN N
fenfluramine NN N
for IN N
the DT N
symptomatic JJ N
treatment NN N
of IN N
infantile JJ N
autism NN 4_p
. . 4_p

No DT N
large JJ N
surveys NNS N
of IN N
side JJ N
effects NNS N
of IN N
this DT N
drug NN N
have VBP N
been VBN N
reported VBN N
in IN N
autistic JJ N
children NNS N
. . N

To TO N
evaluate VB N
the DT N
untoward JJ N
effects NNS N
of IN N
fenfluramine NN N
in IN N
children NNS N
with IN N
autism NN N
, , N
12 CD N
subjects NNS N
were VBD N
systematically RB N
studied VBN N
. . N

Medication NNP N
was VBD N
administered VBN N
in IN N
a DT N
double-blind JJ N
, , N
placebo-controlled JJ N
cross-over NN N
study NN N
. . N

Parents NNS N
were VBD N
trained VBN N
in IN N
monitoring VBG N
untoward JJ N
effects NNS N
. . N

These DT N
observations NNS N
were VBD N
compiled VBN N
in IN N
detailed JJ N
daily JJ N
notes NNS N
. . N

In IN N
addition NN N
, , N
four CD N
cases NNS N
describing VBG N
unusual JJ N
effects NNS N
found VBN N
in IN N
a DT N
sample NN N
of IN N
170 CD N
patients NNS N
treated VBN N
with IN N
fenfluramine NN N
are VBP N
also RB N
reported VBN N
. . N

In IN N
the DT N
initial JJ N
2 CD N
weeks NNS N
of IN N
active JJ N
drug NN N
listlessness NN N
, , N
food NN N
refusal NN N
, , N
and CC N
stomach NN N
upset NN N
were VBD N
frequently RB N
seen VBN N
. . N

A DT N
different JJ N
pattern NN N
of IN N
untoward JJ N
effects NNS N
was VBD N
seen VBN N
in IN N
the DT N
final JJ N
14 CD N
weeks NNS N
of IN N
treatment NN N
. . N

Irritability NNP N
, , N
agitation NN N
, , N
and CC N
crying VBG N
along RB N
with IN N
continued VBN N
food NN N
refusal NN N
were VBD N
noted VBN N
. . N

The DT N
subjects NNS N
lost VBD N
2.1 CD N
% NN N
of IN N
body NN N
weight NN N
during IN N
active JJ N
drug NN N
phase NN N
, , N
but CC N
there RB N
was VBD N
a DT N
rebound NN N
weight NN N
gain NN N
during IN N
the DT N
subsequent JJ N
placebo NN N
phase NN N
. . N

A DT N
thorough JJ N
understanding NN N
of IN N
fenfluramine NN N
's POS N
side NN N
effects NNS N
and CC N
adverse JJ N
reactions NNS N
is VBZ N
necessary JJ N
so RB N
as IN N
to TO N
differentiate VB N
them PRP N
from IN N
the DT N
multiple NN N
symptoms NNS N
inherent NN N
in IN N
the DT N
syndrome NN N
of IN N
autism NN N
. . N

-DOCSTART- -X- O O 24112670

Use NNP N
of IN N
ketorolac NN N
is VBZ N
associated VBN N
with IN N
decreased VBN N
pneumonia NN N
following VBG N
rib NN 4_p
fractures NNS 4_p
. . N

BACKGROUND IN N
The DT N
effectiveness NN N
of IN N
the DT N
nonsteroidal JJ N
anti-inflammatory JJ N
drug NN N
ketorolac NN N
in IN N
reducing VBG N
pulmonary JJ 4_p
morbidity NN 4_p
after IN N
rib NN 4_p
fractures NNS 4_p
remains VBZ N
largely RB N
unknown JJ N
. . N

METHODS VB N
A DT N
retrospective JJ N
cohort NN N
study NN N
was VBD N
conducted VBN N
spanning VBG N
January NNP N
2003 CD N
to TO N
June NNP N
2011 CD N
assessing VBG N
pneumonia NN N
within IN N
30 CD N
days NNS N
and CC N
potential JJ N
adverse JJ N
effects NNS N
of IN N
ketorolac NN N
among IN N
all DT N
patients NNS N
with IN N
rib JJ 4_p
fractures NNS 4_p
who WP N
received VBD N
ketorolac NN N
< $ N
4 CD N
days NNS N
after IN N
injury NN N
compared VBN N
with IN N
a DT N
random JJ N
sample NN N
of IN N
those DT N
who WP N
did VBD N
not RB N
. . N

RESULTS NNP N
Among IN N
202 CD N
patients NNS N
who WP N
received VBD N
ketorolac NN N
and CC N
417 CD N
who WP N
did VBD N
not RB N
, , N
ketorolac NN N
use NN N
was VBD N
associated VBN N
with IN N
decreased VBN N
pneumonia NN N
( ( N
odds NNS N
ratio NN N
, , N
.14 NNP N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
.04 '' N
to TO N
.46 VB N
) ) N
and CC N
increased VBD N
ventilator-free JJ N
days NNS N
( ( N
difference NN N
, , N
1.8 CD N
days NNS N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
1.1 CD N
to TO N
2.5 CD N
) ) N
and CC N
intensive JJ N
care NN N
unit-free JJ N
days NNS N
( ( N
difference NN N
, , N
2.1 CD N
days NNS N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
1.3 CD N
to TO N
3.0 CD N
) ) N
within IN N
30 CD N
days NNS N
. . N

The DT N
rates NNS N
of IN N
acute JJ N
kidney NN N
injury NN N
, , N
gastrointestinal JJ N
hemorrhage NN N
, , N
and CC N
fracture NN N
nonunion NN N
were VBD N
not RB N
different JJ N
. . N

CONCLUSIONS NNP N
Early JJ N
administration NN N
of IN N
ketorolac NNS N
to TO N
patients NNS N
with IN N
rib JJ 4_p
fractures NNS 4_p
is VBZ N
associated VBN N
with IN N
a DT N
decreased JJ N
likelihood NN N
of IN N
pneumonia NN N
, , N
without IN N
apparent JJ N
risks NNS N
. . N

-DOCSTART- -X- O O 24919961

Video-feedback JJ N
Intervention NNP N
to TO N
promote VB N
Positive NNP N
Parenting NNP N
adapted VBD N
to TO N
Autism NNP N
( ( N
VIPP-AUTI NNP N
) ) N
: : N
A DT N
randomized NN N
controlled VBN N
trial NN N
. . N

In IN N
a DT N
randomized NN N
controlled VBN N
trial NN N
, , N
we PRP N
evaluated VBD N
the DT N
early JJ N
intervention NN N
program NN N
Video-feedback NNP N
Intervention NNP N
to TO N
promote VB N
Positive NNP N
Parenting NNP N
adapted VBD N
to TO N
Autism NNP 4_p
( ( N
VIPP-AUTI NNP N
) ) N
with IN N
78 CD N
primary JJ N
caregivers NNS N
and CC N
their PRP$ N
child NN N
( ( N
16-61 JJ N
months NNS N
) ) N
with IN N
Autism NNP 4_p
Spectrum NNP 4_p
Disorder NNP 4_p
. . N

VIPP-AUTI NNP N
is VBZ N
a DT N
brief JJ N
attachment-based JJ N
intervention NN N
program NN N
, , N
focusing VBG N
on IN N
improving VBG N
parent-child JJ N
interaction NN N
and CC N
reducing VBG N
the DT N
child NN N
's POS N
individual JJ N
Autism NNP N
Spectrum NNP N
Disorder-related NNP N
symptomatology NN N
in IN N
five CD N
home NN N
visits NNS N
. . N

VIPP-AUTI NNP N
, , N
as IN N
compared VBN N
with IN N
usual JJ N
care NN N
, , N
demonstrated VBD N
efficacy NN N
in IN N
reducing VBG N
parental JJ N
intrusiveness NN N
. . N

Moreover RB N
, , N
parents NNS N
who WP N
received VBD N
VIPP-AUTI NNP N
showed VBD N
increased JJ N
feelings NNS N
of IN N
self-efficacy NN N
in IN N
child NN N
rearing NN N
. . N

No DT N
significant JJ N
group NN N
differences NNS N
were VBD N
found VBN N
on IN N
other JJ N
aspects NNS N
of IN N
parent-child JJ N
interaction NN N
or CC N
on IN N
child JJ N
play NN N
behavior NN N
. . N

At IN N
3-months JJ N
follow-up NN N
, , N
intervention NN N
effects NNS N
were VBD N
found VBN N
on IN N
child-initiated JJ N
joint JJ N
attention NN N
skills NNS N
, , N
not RB N
mediated VBN N
by IN N
intervention NN N
effects NNS N
on IN N
parenting VBG N
. . N

Implementation NN N
of IN N
VIPP-AUTI NNP N
in IN N
clinical JJ N
practice NN N
is VBZ N
facilitated VBN N
by IN N
the DT N
use NN N
of IN N
a DT N
detailed JJ N
manual NN N
and CC N
a DT N
relatively RB N
brief JJ N
training NN N
of IN N
interveners NNS N
. . N

-DOCSTART- -X- O O 21660428

Effects NNS N
of IN N
cognitive-behavioral JJ N
therapy NN N
on IN N
anxiety NN N
in IN N
children NNS N
with IN N
autism NN N
spectrum NN N
disorders NNS N
: : N
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

We PRP N
compared VBN N
the DT N
effects NNS N
of IN N
a DT N
16-week JJ N
Cognitive-Behavioral JJ N
Therapy NNP N
( ( N
CBT NNP N
) ) N
program NN N
and CC N
a DT N
Social NNP N
Recreational NNP N
( ( N
SR NNP N
) ) N
program NN N
on IN N
anxiety NN N
in IN N
children NNS N
with IN N
Autism NNP N
Spectrum NNP N
Disorders NNP N
( ( N
ASD NNP N
) ) N
. . N

Seventy JJ N
children NNS N
( ( N
9-16 CD N
years NNS N
old JJ N
) ) N
were VBD N
randomly RB N
assigned VBN N
to TO N
either DT N
of IN N
the DT N
programs NNS N
( ( N
n FW N
( ( N
CBT NNP N
) ) N
= VBZ N
36 CD N
; : N
n NNS N
( ( N
SR NNP N
) ) N
= VBP N
34 CD N
) ) N
. . N

Measures NNS N
on IN N
child NN N
's POS N
anxiety NN N
using VBG N
the DT N
Spence NNP N
Child NNP N
Anxiety NNP N
Scale NNP N
-- : N
Child NNP N
( ( N
SCAS-C NNP N
) ) N
and CC N
the DT N
Clinical JJ N
Global NNP N
Impression-Severity NNP N
scale NN N
( ( N
CGI NNP N
-- : N
S NNP N
) ) N
were VBD N
administered VBN N
at IN N
pre- JJ N
, , N
post-treatment JJ N
, , N
and CC N
follow-ups NNS N
( ( N
3- CD N
and CC N
6-month JJ N
) ) N
. . N

Children NNP N
in IN N
both DT N
programs NNS N
showed VBD N
significantly RB N
lower JJR N
levels NNS N
of IN N
generalized VBN N
anxiety NN N
and CC N
total JJ N
anxiety NN N
symptoms NNS N
at IN N
6-month JJ N
follow-up NN N
on IN N
SCAS-C. NNP N
Clinician NNP N
ratings NNS N
on IN N
the DT N
CGI-S NNP N
demonstrated VBD N
an DT N
increase NN N
in IN N
the DT N
percentage NN N
of IN N
participants NNS N
rated VBN N
as IN N
" NNP N
Normal NNP N
" NNP N
and CC N
" NNP N
Borderline NNP N
" NN N
for IN N
both DT N
programs NNS N
. . N

Findings NNS N
from IN N
the DT N
present JJ N
study NN N
suggest JJS N
factors NNS N
such JJ N
as IN N
regular JJ N
sessions NNS N
in IN N
a DT N
structured JJ N
setting NN N
, , N
consistent JJ N
therapists NNS N
, , N
social JJ N
exposure NN N
and CC N
the DT N
use NN N
of IN N
autism-friendly JJ N
strategies NNS N
are VBP N
important JJ N
components NNS N
of IN N
an DT N
effective JJ N
framework NN N
in IN N
the DT N
management NN N
of IN N
anxiety NN N
in IN N
children NNS N
and CC N
adolescents NNS N
with IN N
ASD NNP N
. . N

-DOCSTART- -X- O O 22382875

Infrared NNP N
LED NNP N
irradiation NN N
applied VBD N
during IN N
high-intensity NN N
treadmill NN N
training VBG N
improves NNS N
maximal JJ N
exercise NN N
tolerance NN N
in IN N
postmenopausal JJ N
women NNS N
: : N
a DT N
6-month JJ N
longitudinal JJ N
study NN N
. . N

Reduced NNP N
aerobic JJ N
fitness NN N
is VBZ N
associated VBN N
with IN N
an DT N
increased VBN N
risk NN N
of IN N
cardiovascular JJ N
diseases NNS N
among IN N
the DT N
older JJR N
population NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
effects NNS N
of IN N
LED NNP N
irradiation NN N
( ( N
850 CD N
nm RB N
) ) N
applied VBD N
during IN N
treadmill JJ N
training VBG N
on IN N
the DT N
maximal JJ N
exercise NN N
tolerance NN N
in IN N
postmenopausal JJ N
women NNS N
. . N

At IN N
the DT N
beginning NN N
of IN N
the DT N
study NN N
, , N
45 CD N
postmenopausal JJ N
women NNS N
were VBD N
assigned VBN N
randomly RB N
to TO N
three CD N
groups NNS N
, , N
and CC N
30 CD N
women NNS N
completed VBD N
the DT N
entire JJ N
6 CD N
months NNS N
of IN N
the DT N
study NN N
. . N

The DT N
groups NNS N
were VBD N
: : N
( ( N
1 CD N
) ) N
the DT N
LED NNP N
group NN N
( ( N
treadmill IN N
training VBG N
associated VBN N
with IN N
phototherapy NN N
, , N
n JJ N
= NNP N
10 CD N
) ) N
, , N
( ( N
2 CD N
) ) N
the DT N
exercise NN N
group NN N
( ( N
treadmill IN N
training NN N
, , N
n JJ N
= NNP N
10 CD N
) ) N
, , N
and CC N
( ( N
3 CD N
) ) N
the DT N
sedentary JJ N
group NN N
( ( N
neither DT N
physical JJ N
training NN N
nor CC N
phototherapy NN N
, , N
n JJ N
= NNP N
10 CD N
) ) N
. . N

The DT N
training NN N
was VBD N
performed VBN N
for IN N
45 CD N
min NN N
twice RB N
a DT N
week NN N
for IN N
6 CD N
months NNS N
at IN N
intensities NNS N
between IN N
85 CD N
% NN N
and CC N
90 CD N
% NN N
maximal JJ N
heart NN N
rate NN N
( ( N
HRmax NNP N
) ) N
. . N

The DT N
irradiation NN N
parameters NNS N
were VBD N
39 CD N
mW/cm NN N
( ( N
2 CD N
) ) N
, , N
45 CD N
min NN N
and CC N
108 CD N
J/cm NNP N
( ( N
2 CD N
) ) N
. . N

The DT N
cardiovascular JJ N
parameters NNS N
were VBD N
measured VBN N
at IN N
baseline NN N
and CC N
after IN N
6 CD N
months NNS N
. . N

As IN N
expected VBN N
, , N
no DT N
significant JJ N
differences NNS N
were VBD N
found VBN N
in IN N
the DT N
sedentary JJ N
group NN N
( ( N
p JJ N
≥ NNP N
0.05 CD N
) ) N
. . N

The DT N
maximal JJ N
time NN N
of IN N
tolerance NN N
( ( N
Tlim NNP N
) ) N
, , N
metabolic JJ N
equivalents NNS N
( ( N
METs NNP N
) ) N
and CC N
Bruce NNP N
stage NN N
reached VBD N
significantly RB N
higher JJR N
values NNS N
in IN N
the DT N
LED NNP N
group NN N
and CC N
the DT N
exercise NN N
group NN N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
. . N

Furthermore UH N
, , N
the DT N
HR NNP N
, , N
double JJ N
product NN N
and CC N
Borg NNP N
score NN N
at IN N
isotime NN N
were VBD N
significantly RB N
lower JJR N
in IN N
the DT N
LED NNP N
group NN N
and CC N
in IN N
the DT N
exercise NN N
group NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

However RB N
, , N
the DT N
time NN N
of IN N
recovery NN N
showed VBD N
a DT N
significant JJ N
decrease NN N
only RB N
in IN N
the DT N
LED NNP N
group NN N
( ( N
p JJ N
= NNP N
0.003 CD N
) ) N
. . N

Moreover RB N
, , N
the DT N
differences NNS N
between IN N
before IN N
and CC N
after IN N
training NN N
( ( N
delta JJ N
values NNS N
) ) N
for IN N
the DT N
Tlim NNP N
, , N
METs NNP N
and CC N
HR NNP N
at IN N
isotime NN N
were VBD N
greater JJR N
in IN N
the DT N
LED NNP N
group NN N
than IN N
in IN N
the DT N
exercise NN N
group NN N
with IN N
a DT N
significant JJ N
intergroup NN N
difference NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

Therefore RB N
, , N
the DT N
infrared JJ N
LED NNP N
irradiation NN N
during IN N
treadmill JJ N
training NN N
can MD N
improve VB N
maximal JJ N
performance NN N
and CC N
post-exercise JJ N
recovery NN N
in IN N
postmenopausal JJ N
women NNS N
. . N

-DOCSTART- -X- O O 17950167

Covariation NN N
of IN N
adolescent JJ N
physical JJ N
activity NN N
and CC N
dietary JJ N
behaviors NNS N
over IN N
12 CD N
months NNS N
. . N

PURPOSE VB N
This DT N
study NN N
examined VBD N
covariation NN N
among IN N
changes NNS N
in IN N
dietary JJ N
, , N
physical JJ N
activity NN N
, , N
and CC N
sedentary JJ N
behaviors NNS N
over IN N
12 CD N
months NNS N
among IN N
adolescents NNS N
participating VBG N
in IN N
a DT N
health NN 4_p
behavior NN 4_p
intervention NN 4_p
. . N

Evidence NN N
of IN N
covariation NN N
among IN N
behaviors NNS N
would MD N
suggest VB N
multi-behavior JJ N
interventions NNS N
could MD N
have VB N
synergistic JJ N
effects NNS N
. . N

METHODS NNP N
Prospective JJ N
analyses NNS N
were VBD N
conducted VBN N
with IN N
baseline NN N
and CC N
12-month JJ N
assessments NNS N
from IN N
a DT N
randomized VBN N
controlled VBN N
trial NN N
to TO N
promote VB N
improved JJ N
diet JJ N
, , N
physical JJ N
activity NN N
, , N
and CC N
sedentary JJ N
behaviors NNS N
( ( N
experimental JJ N
condition NN N
) ) N
or CC N
SUN NNP N
protection NN N
behaviors NNS N
( ( N
comparison JJ N
condition NN N
) ) N
. . N

Participants NNS N
were VBD N
adolescent JJ N
girls NNS N
and CC N
boys NNS N
( ( N
N NNP N
= NNP N
878 CD N
) ) N
aged VBN N
11-15 CD N
years NNS N
on IN N
entry NN N
. . N

The DT N
main JJ N
outcomes NNS N
were VBD N
: : N
diet NN N
, , N
based VBN N
on IN N
multiple JJ N
24-hour JJ N
recalls NNS N
( ( N
total JJ N
fat NN N
, , N
grams NNS N
of IN N
fiber NN N
, , N
servings NNS N
of IN N
fruit NN N
and CC N
vegetables NNS N
, , N
total JJ N
calories NNS N
) ) N
; : N
average JJ N
daily JJ N
energy NN N
expenditure NN N
( ( N
kcals/kg NN N
) ) N
based VBN N
on IN N
7-day JJ N
physical JJ N
activity NN N
recall VBP N
interviews NNS N
; : N
daily JJ N
minutes NNS N
of IN N
moderate-vigorous JJ N
physical JJ N
activity NN N
minutes NNS N
from IN N
accelerometery NN N
; : N
and CC N
self-reported JJ N
daily JJ N
hours NNS N
of IN N
sedentary JJ N
behavior NN N
. . N

RESULTS NNP N
Covariation NNP N
was VBD N
found VBN N
between IN N
fat NN N
and CC N
calories NNS N
( ( N
r NN N
= NNP N
.16 NNP N
) ) N
, , N
fiber NN N
and CC N
calories NNS N
( ( N
r NN N
= NNP N
.53 NNP N
) ) N
, , N
fiber NN N
and CC N
fruit/vegetables NNS N
( ( N
r NN N
= NNP N
.53 NNP N
) ) N
, , N
calories NNS N
and CC N
fruit/vegetables NNS N
( ( N
r NN N
= NNP N
.34 NNP N
) ) N
, , N
and CC N
fruit NN N
and CC N
vegetables NNS N
and CC N
sedentary JJ N
behavior NN N
( ( N
r JJ N
= NNP N
-.12 NNP N
) ) N
for IN N
the DT N
total JJ N
sample NN N
( ( N
all DT N
p NN N
values NNS N
< NNP N
.01 NNP N
) ) N
. . N

The DT N
pattern NN N
of IN N
findings NNS N
was VBD N
similar JJ N
for IN N
most JJS N
subgroups NNS N
defined VBN N
by IN N
gender NN N
and CC N
study NN N
condition NN N
. . N

CONCLUSIONS VB N
The DT N
strongest JJS N
covariation NN N
was VBD N
observed VBN N
for IN N
diet JJ N
variables NNS N
that WDT N
are VBP N
inherently RB N
related VBN N
( ( N
calories NNS N
and CC N
fat NN N
, , N
fiber NN N
, , N
and CC N
fruit/vegetables NNS N
) ) N
. . N

Little JJ N
covariation NN N
was VBD N
detected VBN N
within IN N
or CC N
between IN N
other JJ N
diet JJ N
, , N
physical JJ N
activity NN N
and CC N
sedentary JJ N
behavior NN N
domains NNS N
suggesting VBG N
that IN N
interventions NNS N
to TO N
improve VB N
these DT N
behaviors NNS N
in IN N
adolescents NNS N
need VBP N
to TO N
include VB N
specific JJ N
program NN N
components NNS N
for IN N
each DT N
target NN N
behavior NN N
of IN N
interest NN N
. . N

-DOCSTART- -X- O O 8571077

No DT N
effect NN N
of IN N
beta-carotene JJ N
supplementation NN N
on IN N
the DT N
susceptibility NN N
of IN N
low JJ N
density NN N
lipoprotein NN N
to TO N
in IN N
vitro JJ N
oxidation NN N
among IN N
hypercholesterolaemic JJ 4_p
, , N
postmenopausal JJ 4_p
women NNS N
. . N

The DT N
effect NN N
of IN N
beta-carotene NN N
on IN N
the DT N
susceptibility NN N
of IN N
low JJ N
density NN N
lipoprotein NN N
( ( N
LDL NNP N
) ) N
to TO N
oxidative JJ N
modification NN N
was VBD N
investigated VBN N
in IN N
a DT N
double-blind NN N
, , N
randomized VBN N
placebo-controlled JJ N
study NN N
. . N

Hypercholesterolaemic NNP 4_p
, , N
postmenopausal JJ 4_p
women NNS 4_p
were VBD N
given VBN N
30 CD N
mg JJ N
beta-carotene JJ N
per IN N
day NN N
( ( N
n JJ N
= $ N
15 CD N
subjects NNS N
) ) N
or CC N
placebo JJ N
capsules NNS N
( ( N
n JJ N
= $ N
15 CD N
subjects NNS N
) ) N
for IN N
10 CD N
weeks NNS N
. . N

They PRP N
were VBD N
instructed VBN N
to TO N
follow VB N
the DT N
American NNP N
Heart NNP N
Association NNP N
Step NNP N
One NNP N
diet NN N
. . N

LDL NNP N
, , N
isolated VBD N
before IN N
and CC N
after IN N
treatment NN N
was VBD N
subjected VBN N
to TO N
copper-catalysed JJ N
lipid JJ N
peroxidation NN N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
LDL NNP N
from IN N
the DT N
beta-carotene NN N
and CC N
placebo NN N
groups NNS N
, , N
as IN N
assessed VBN N
by IN N
measuring VBG N
the DT N
lag NN N
time NN N
for IN N
formation NN N
of IN N
conjugated JJ N
dienes NNS N
; : N
the DT N
rate NN N
of IN N
formation NN N
and CC N
the DT N
amount NN N
of IN N
conjugated VBN N
dienes NNS N
formed VBN N
; : N
the DT N
amount NN N
of IN N
lipid JJ N
peroxides NNS N
generated VBD N
; : N
and CC N
the DT N
relative JJ N
electrophoretic JJ N
mobility NN N
, , N
at IN N
baseline NN N
and CC N
after IN N
treatment NN N
. . N

Dietary JJ N
records NNS N
showed VBD N
that IN N
the DT N
subjects NNS N
were VBD N
consuming VBG N
similar JJ N
amounts NNS N
and CC N
types NNS N
of IN N
fat NN N
. . N

No DT N
significant JJ N
differences NNS N
were VBD N
found VBN N
in IN N
the DT N
lipid JJ N
composition NN N
and CC N
fatty JJ N
acid JJ N
pattern NN N
of IN N
LDL NNP N
from IN N
the DT N
two CD N
groups NNS N
. . N

In IN N
conclusion NN N
, , N
the DT N
results NNS N
indicated VBD N
that IN N
supplementation NN N
with IN N
beta-carotene JJ N
in IN N
non-smoking JJ 4_p
, , N
hypercholesterolaemic JJ 4_p
, , N
postmenopausal JJ 4_p
women NNS 4_p
had VBD N
no DT N
protective JJ N
effect NN N
on IN N
the DT N
susceptibility NN N
of IN N
LDL NNP N
to TO N
copper-catalysed JJ N
modification NN N
in IN N
vitro NN N
. . N

-DOCSTART- -X- O O 6420374

The DT N
effect NN N
of IN N
surgical JJ N
trauma NN N
and CC N
insulin NN N
on IN N
whole-body NN N
protein NN N
turnover NN N
in IN N
parenterally-fed JJ 4_p
undernourished JJ 4_p
patients NNS 4_p
. . 4_p

Ten CD N
undernourished JJ 4_p
patients NNS N
receiving VBG N
total JJ N
parenteral JJ N
nutrition NN N
and CC N
undergoing JJ N
major JJ N
intestinal JJ N
surgery NN N
were VBD N
restarted VBN N
on IN N
intravenous JJ N
feeds NNS N
identical JJ N
to TO N
their PRP$ N
pre-operative JJ N
regimens NNS N
within IN N
24 CD N
h NNS N
of IN N
their PRP$ N
operation NN N
. . N

Five CD N
, , N
chosen VBN N
at IN N
random NN N
, , N
received VBD N
post-operatively RB N
1-2 JJ N
units NNS N
insulin/kg VBP N
body NN N
weight/24 JJ N
h NN N
with IN N
their PRP$ N
feed NN N
, , N
while IN N
the DT N
other JJ N
five CD N
received VBD N
the DT N
feed NN N
only RB N
. . N

Pre-operatively RB N
, , N
and CC N
2 CD N
h NN N
after IN N
commencing VBG N
their PRP$ N
post-operative JJ N
feeds NNS N
, , N
rates NNS N
of IN N
whole-body NN N
protein NN N
synthesis NN N
and CC N
breakdown NN N
were VBD N
measured VBN N
over IN N
a DT N
9-h JJ N
period NN N
following VBG N
intravenous JJ N
injection NN N
of IN N
a DT N
single JJ N
tracer NN N
dose NN N
of IN N
15N-glycine JJ N
by IN N
the DT N
ammonia NN N
and CC N
urea JJ N
end-product NN N
methods NNS N
. . N

During IN N
these DT N
9-h CD N
study NN N
periods NNS N
measurements NNS N
were VBD N
also RB N
made VBN N
of IN N
blood NN N
glucose NN N
, , N
plasma JJ N
insulin NN N
and CC N
glucagon NN N
, , N
urinary JJ N
ammonia NN N
, , N
nitrogen NN N
, , N
creatinine NN N
and CC N
3-methylhistidine JJ N
. . N

Blood NNP N
glucose NN N
and CC N
plasma JJ N
insulin NN N
and CC N
glucagon NN N
concentrations NNS N
rose VBD N
post-operatively RB N
whether IN N
or CC N
not RB N
insulin NN N
was VBD N
given VBN N
, , N
but CC N
the DT N
increment NN N
in IN N
insulin NN N
concentration NN N
was VBD N
significantly RB N
greater JJR N
when WRB N
insulin NN N
was VBD N
given VBN N
. . N

Apparent JJ N
nitrogen NN N
balance NN N
was VBD N
positive JJ N
pre-operatively RB N
and CC N
became VBD N
less RBR N
so RB N
post-operatively RB N
whether IN N
insulin NN N
was VBD N
given VBN N
or CC N
not RB N
. . N

Similarly RB N
, , N
post-operative JJ N
increments NNS N
in IN N
urinary JJ N
excretion NN N
of IN N
ammonia NN N
, , N
creatinine NN N
and CC N
3-methylhistidine JJ N
were VBD N
not RB N
altered VBN N
by IN N
addition NN N
of IN N
insulin NN N
. . N

Protein NNP N
turnover NN N
, , N
as IN N
estimated VBN N
by IN N
the DT N
ammonia JJ N
end-product NN N
method NN N
, , N
tended VBD N
to TO N
rise VB N
post-operatively RB N
, , N
but CC N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
increases NNS N
observed VBD N
with IN N
or CC N
without IN N
insulin NN N
. . N

The DT N
urea JJ N
end-product NN N
method NN N
suggested VBD N
that IN N
there EX N
was VBD N
no DT N
change NN N
in IN N
whole-body NN N
protein NN N
turnover NN N
after IN N
surgery NN N
, , N
whether IN N
or CC N
not RB N
insulin NN N
was VBD N
given VBN N
. . N

This DT N
study NN N
does VBZ N
not RB N
support VB N
the DT N
clinical JJ N
use NN N
of IN N
insulin NN N
as IN N
a DT N
means NN N
of IN N
modifying VBG N
protein JJ N
metabolic JJ N
losses NNS N
after IN N
major JJ N
surgery NN N
. . N

-DOCSTART- -X- O O 21987240

Oral JJ N
bioavailability NN N
of IN N
moxifloxacin NN N
after IN N
Roux-en-Y NNP N
gastric JJ N
bypass NN N
surgery NN N
. . N

OBJECTIVES CC N
Roux-en-Y JJ N
gastric JJ N
bypass NN N
surgery NN N
is VBZ N
the DT N
most RBS N
commonly RB N
performed JJ N
procedure NN N
for IN N
the DT N
treatment NN N
of IN N
morbid NN N
obesity NN N
. . N

This DT N
anatomical JJ N
alteration NN N
may MD N
affect VB N
the DT N
absorption NN N
and CC N
consequently RB N
the DT N
bioavailability NN N
of IN N
oral JJ N
drugs NNS N
. . N

This DT N
study NN N
aims VBZ N
to TO N
investigate VB N
the DT N
oral JJ N
bioavailability NN N
of IN N
moxifloxacin NN N
in IN N
12 CD 4_p
healthy JJ 4_p
volunteers NNS 4_p
who WP 4_p
underwent VBP 4_p
gastric JJ 4_p
bypass NN 4_p
surgery NN 4_p
. . 4_p

PATIENTS NNP N
AND CC N
METHODS NNP N
In IN N
this DT N
randomized VBN N
crossover NN N
study NN N
, , N
each DT N
subject NN N
received VBD N
two CD N
single JJ N
standard NN N
doses NNS N
of IN N
400 CD N
mg NN N
of IN N
moxifloxacin NN N
orally RB N
or CC N
intravenously RB N
administered VBN N
on IN N
two CD N
occasions NNS N
separated VBN N
by IN N
a DT N
washout JJ N
period NN N
of IN N
1 CD N
week NN N
. . N

Serial JJ N
venous JJ N
blood NN N
samples NNS N
were VBD N
drawn VBN N
up RB N
to TO N
72 CD N
h NN N
after IN N
dosing VBG N
and CC N
moxifloxacin JJ N
plasma NN N
levels NNS N
were VBD N
measured VBN N
by IN N
a DT N
validated JJ N
HPLC NNP N
method NN N
with IN N
fluorescence NN N
detection NN N
. . N

[ CC N
clinicaltrials.gov JJ N
database NN N
( ( N
identifier NN N
: : N
NCT01130922 NNP N
) ) N
. . N

] JJ N
RESULTS NNP N
After IN N
oral JJ N
dosing NN N
, , N
moxifloxacin FW N
plasma NN N
concentrations NNS N
reached VBD N
a DT N
maximum JJ N
( ( N
C NNP N
( ( N
max NN N
) ) N
) ) N
of IN N
3.38 CD N
± JJ N
1.41 CD N
mg/L NN N
after IN N
1.75 CD N
h NN N
( ( N
0.75-4.00 JJ N
) ) N
. . N

After IN N
intravenous JJ N
dosing NN N
, , N
C NNP N
( ( N
max NN N
) ) N
and CC N
T NNP N
( ( N
max NN N
) ) N
were VBD N
4.53 CD N
± JJ N
1.43 CD N
mg/L NN N
and CC N
1.03 CD N
h NN N
( ( N
0.75-2.50 JJ N
) ) N
, , N
respectively RB N
. . N

The DT N
mean JJ N
areas NNS N
under IN N
the DT N
plasma JJ N
concentration NN N
time NN N
curve NN N
extrapolated VBD N
to TO N
infinity NN N
( ( N
AUC NNP N
( ( N
∞ NNP N
) ) N
) ) N
were VBD N
46.2 CD N
± JJ N
1.4 CD N
mg NN N
· NNP N
h/L NN N
after IN N
oral JJ N
dosing NN N
and CC N
52.3 CD N
± NNS N
1.3 CD N
mg NNS N
· JJ N
h/L NN N
after IN N
intravenous JJ N
dosing NN N
, , N
resulting VBG N
in IN N
a DT N
mean JJ N
oral JJ N
bioavailability NN N
of IN N
88.32 CD N
% NN N
[ JJ N
90 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
85.64 CD N
% NN N
-91.08 CD N
% NN N
] NN N
. . N

CONCLUSIONS VB N
This DT N
study NN N
confirms VBZ N
that IN N
exposure NN N
to TO N
moxifloxacin VB N
is VBZ N
equivalent JJ N
for IN N
oral JJ N
and CC N
intravenous JJ N
administration NN N
of IN N
400 CD N
mg NN N
dosages NNS N
in IN N
healthy JJ N
volunteers NNS N
who WP N
underwent VBP N
gastric JJ N
bypass NN N
surgery NN N
. . N

But CC N
these DT N
exposures NNS N
were VBD N
more JJR N
than IN N
50 CD N
% NN N
higher JJR N
than IN N
those DT N
described VBN N
for IN N
subjects NNS N
without IN N
gastric JJ N
bypass NN N
. . N

This DT N
may MD N
suggest VB N
a DT N
higher JJR N
enterohepatic JJ N
recirculation NN N
of IN N
moxifloxacin NN N
after IN N
gastric JJ N
bypass NN N
. . N

-DOCSTART- -X- O O 11550726

Is VBZ N
psychotherapy VBN N
more RBR N
effective JJ N
when WRB N
therapists NNS 4_p
disclose VB N
information NN N
about IN N
themselves PRP N
? . N
Theorists NNS N
have VBP N
long RB N
debated VBN N
the DT N
wisdom NN N
of IN N
therapists NNS N
disclosing VBG N
personal JJ N
information NN N
during IN N
psychotherapy NN N
. . N

Some DT N
observers NNS N
have VBP N
argued VBN N
that IN N
such JJ N
therapist JJ N
self-disclosure NN N
impedes NNS N
treatment NN N
, , N
whereas IN N
others NNS N
have VBP N
suggested VBN N
that IN N
it PRP N
enhances VBZ N
the DT N
effectiveness NN N
of IN N
therapy NN N
. . N

To TO N
test VB N
these DT N
competing VBG N
positions NNS N
, , N
therapists NNS N
at IN N
a DT N
university NN N
counseling NN N
center NN N
were VBD N
instructed VBN N
to TO N
increase VB N
the DT N
number NN N
of IN N
self-disclosures NNS N
they PRP N
made VBD N
during IN N
treatment NN N
of IN N
one CD N
client NN N
and CC N
refrain NN N
from IN N
making VBG N
self-disclosures NNS N
during IN N
treatment NN N
of IN N
another DT N
client NN N
. . N

Analyses NNS N
revealed VBD N
that IN N
clients NNS N
receiving VBG N
psychotherapy NN N
under IN N
conditions NNS N
of IN N
heightened VBN N
therapist NN N
disclosure NN N
not RB N
only RB N
reported VBD N
lower JJR N
levels NNS N
of IN N
symptom NN N
distress NN N
but CC N
also RB N
liked VBD N
their PRP$ N
therapist NN N
more RBR N
. . N

Such JJ N
findings NNS N
suggest VBP N
that IN N
self-disclosure NN N
by IN N
the DT N
therapist NN N
may MD N
improve VB N
both PDT N
the DT N
quality NN N
of IN N
the DT N
therapeutic JJ N
relationship NN N
and CC N
the DT N
outcome NN N
of IN N
treatment NN N
. . N

-DOCSTART- -X- O O 18783414

Cemented VBN N
CeraOne NNP N
and CC N
porcelain NN N
fused VBD N
to TO N
TiAdapt NNP N
abutment JJ N
single-implant JJ N
crown JJ N
restorations NNS N
: : N
a DT N
10-year JJ N
comparative JJ N
follow-up NN N
study NN N
. . N

BACKGROUND NNP N
Long-term NNP N
data NNS N
comparing NN N
cemented VBN N
and CC N
noncemented VBN N
single-implant JJ N
restorations NNS N
has VBZ N
not RB N
been VBN N
reported VBN N
. . N

AIM NNP N
To TO N
compare VB N
clinical JJ N
and CC N
radiographic JJ N
performance NN N
of IN N
single-implant JJ N
crown NN N
restorations NNS N
made VBN N
by IN N
either DT N
directly RB N
baked VBN N
porcelain NN N
to TO N
custom-made JJ N
TiAdapt NNP N
titanium NN N
abutments NNS N
( ( N
Nobel NNP N
Biocare NNP N
AB NNP N
, , N
Göteborg NNP N
, , N
Sweden NNP N
) ) N
( ( N
test NN N
) ) N
or CC N
cement JJ N
crowns NNS N
onto IN N
CeraOne NNP N
( ( N
Nobel NNP N
Biocare NNP N
AB NNP N
) ) N
abutments NNS N
( ( N
control NN N
) ) N
after IN N
10 CD N
years NNS N
in IN N
function NN N
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
Altogether NNP N
, , N
35 CD N
consecutive JJ N
patients NNS N
were VBD N
provided VBN N
with IN N
41 CD N
turned VBD N
single JJ N
Brånemark NNP N
System NNP N
implants NNS N
( ( N
Nobel NNP N
Biocare NNP N
AB NNP N
) ) N
in IN N
the DT N
partially RB N
edentulous JJ N
upper JJ N
jaw NN N
. . N

By IN N
random NN N
, , N
15 CD N
and CC N
20 CD N
patients NNS N
were VBD N
provided VBN N
with IN N
18 CD N
test NN N
and CC N
23 CD N
control NN N
implant JJ N
crowns NNS N
, , N
respectively RB N
. . N

Thereafter NNP N
, , N
clinical JJ N
and CC N
radiographic JJ N
data NNS N
were VBD N
collected VBN N
and CC N
compared VBN N
between IN N
the DT N
two CD N
groups NNS N
. . N

RESULTS NNP N
None NN N
of IN N
the DT N
implants NNS N
were VBD N
found VBN N
loose RB N
during IN N
the DT N
follow-up JJ N
period NN N
( ( N
100 CD N
% NN N
) ) N
. . N

Few JJ N
clinical JJ N
problems NNS N
were VBD N
observed VBN N
, , N
and CC N
the DT N
overall JJ N
average JJ N
marginal JJ N
bone NN N
loss NN N
was VBD N
0.26 CD N
mm NN N
( ( N
SD NNP N
0.64 CD N
) ) N
during IN N
10 CD N
years NNS N
in IN N
function NN N
. . N

After IN N
the DT N
final JJ N
tightening NN N
of IN N
the DT N
crowns NNS N
, , N
no DT N
significant JJ N
differences NNS N
were VBD N
observed VBN N
between IN N
the DT N
test NN N
and CC N
control NN N
groups NNS N
( ( N
p JJ N
> NNP N
.05 NNP N
) ) N
. . N

The DT N
head NN N
of IN N
the DT N
implants NNS N
was VBD N
placed VBN N
on IN N
an DT N
average JJ N
6.3 CD N
mm NN N
( ( N
SD NNP N
2.24 CD N
) ) N
below IN N
the DT N
cement/enamel JJ N
junction NN N
of IN N
the DT N
adjacent JJ N
teeth NN N
( ( N
range JJ N
2.5-10.0 JJ N
mm NN N
) ) N
. . N

Implants NNS N
with IN N
reported JJ N
mechanical JJ N
and/or NN N
mucosal NN N
problems NNS N
or CC N
placed VBD N
more JJR N
apically RB N
in IN N
relation NN N
to TO N
the DT N
adjacent JJ N
teeth NN N
did VBD N
not RB N
present VB N
more JJR N
bone JJ N
loss NN N
as IN N
compared VBN N
with IN N
implants NNS N
with IN N
no DT N
problems NNS N
or CC N
placed VBD N
more RBR N
coronally RB N
, , N
respectively RB N
( ( N
p JJ N
> NNP N
.05 NNP N
) ) N
. . N

CONCLUSIONS NNP N
There EX N
seems VBZ N
to TO N
be VB N
no DT N
obvious JJ N
clinical JJ N
or CC N
radiographic JJ N
differences NNS N
between IN N
the DT N
test NN N
and CC N
control VB N
single-implant JJ N
restorations NNS N
during IN N
10 CD N
years NNS N
of IN N
follow-up JJ N
. . N

Occasionally NNP N
, , N
some DT N
restorations NNS N
presented VBD N
loose JJ N
abutment JJ N
screws NNS N
and/or VBP N
fistulas NNS N
during IN N
follow-up JJ N
. . N

This DT N
implies VBZ N
a DT N
certain JJ N
need NN N
for IN N
maintenance NN N
where WRB N
a DT N
one-piece JJ N
single-implant JJ N
protocol NN N
( ( N
test NN N
) ) N
allows VBZ N
both DT N
for IN N
a DT N
simple JJ N
clinical JJ N
procedure NN N
at IN N
placement NN N
without IN N
cementation NN N
problems NNS N
, , N
as RB N
well RB N
as IN N
for IN N
an DT N
easy JJ N
and CC N
simple JJ N
maintenance NN N
of IN N
installed JJ N
single JJ N
implant NN N
crowns NNS N
in IN N
long-term JJ N
function NN N
. . N

-DOCSTART- -X- O O 8276557

Enoxaparin NNP N
in IN N
the DT N
prevention NN N
of IN N
deep JJ N
venous JJ N
thrombosis NN N
after IN N
major JJ 4_p
surgery NN 4_p
: : N
multicentric NN N
study NN N
. . N

The DT N
Italian JJ N
Study NNP N
Group NNP N
. . N

DVT NNP N
is VBZ N
a DT N
very RB N
frequent JJ N
complication NN N
of IN N
general JJ N
surgery NN N
. . N

Heparin NNP N
and CC N
, , N
more RBR N
recently RB N
, , N
LMWHs NNP N
can MD N
successfully RB N
prevent VB N
post NN N
surgical JJ N
thromboembolism NN N
. . N

One CD N
thousand CD N
one CD N
hundred CD N
and CC N
twenty-two JJ N
patients NNS N
( ( N
533 CD N
males NNS N
and CC N
589 CD N
females NNS N
; : N
mean JJ N
age NN N
62.2 CD N
+/- JJ N
11.4 CD N
yrs NN N
) ) N
were VBD N
enrolled VBN N
in IN N
a DT N
multicentre NN N
controlled VBN N
study NN N
, , N
to TO N
evaluate VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
enoxaparin NN N
in IN N
comparison NN N
to TO N
calcium VB N
heparin NN N
in IN N
the DT N
prevention NN N
of IN N
deep JJ N
venous JJ N
thrombosis NN N
( ( N
DVT NNP N
) ) N
following VBG N
general JJ N
surgery NN N
. . N

Patients NNS N
assigned VBD N
to TO N
the DT N
enoxaparin NN N
and CC N
the DT N
calcium NN N
heparin NN N
groups NNS N
received VBD N
1 CD N
daily JJ N
dose NN N
of IN N
20 CD N
mg NN N
( ( N
2000 CD N
I.U NNP N
. . N

) ) N
and CC N
2 CD N
daily JJ N
doses NNS N
of IN N
0.2 CD N
ml NN N
( ( N
5000 CD N
I.U NNP N
. . N

) ) N
, , N
respectively RB N
starting VBG N
2 CD N
hours NNS N
before IN N
the DT N
operation NN N
. . N

Both DT N
drugs NNS N
were VBD N
given VBN N
by IN N
subcutaneous JJ N
route NN N
. . N

A DT N
Doppler NNP N
or CC N
Duplex NNP N
Scan NNP N
diagnosis NN N
of IN N
DVT NNP N
was VBD N
made VBN N
in IN N
3 CD N
( ( N
0.5 CD N
% NN N
) ) N
patients NNS N
in IN N
the DT N
enoxaparin NN N
group NN N
( ( N
2 CD N
cases NNS N
during IN N
treatment NN N
and CC N
1 CD N
patient NN N
at IN N
the DT N
end NN N
of IN N
treatment NN N
) ) N
and CC N
in IN N
6 CD N
( ( N
1.1 CD N
% NN N
) ) N
patients NNS N
in IN N
the DT N
calcium NN N
heparin NN N
group NN N
( ( N
5 CD N
cases NNS N
during IN N
treatment NN N
and CC N
1 CD N
, , N
bilateral NN N
, , N
after IN N
the DT N
end NN N
of IN N
treatment NN N
) ) N
. . N

Pulmonary JJ N
embolism NN N
( ( N
PE NNP N
) ) N
was VBD N
ascertained VBN N
by IN N
angiography NN N
in IN N
1 CD N
patient NN N
( ( N
0.18 CD N
% NN N
) ) N
in IN N
the DT N
enoxaparin NN N
group NN N
and CC N
in IN N
2 CD N
patients NNS N
( ( N
0.36 CD N
% NN N
) ) N
in IN N
the DT N
calcium NN N
heparin NN N
one CD N
. . N

Hemorrhagic NNP N
complications NNS N
occurred VBD N
in IN N
29 CD N
patients NNS N
( ( N
5.2 CD N
% NN N
) ) N
in IN N
the DT N
enoxaparin NN N
group NN N
and CC N
in IN N
34 CD N
( ( N
6.1 CD N
% NN N
) ) N
in IN N
the DT N
calcium NN N
heparin NN N
group NN N
. . N

Haematomas NNP N
located VBN N
in IN N
the DT N
injection NN N
site NN N
were VBD N
reported VBN N
in IN N
16.1 CD N
% NN N
and CC N
25.3 CD N
% NN N
in IN N
the DT N
enoxaparin NN N
and CC N
calcium NN N
heparin NN N
groups NNS N
respectively RB N
( ( N
p JJ N
= NNP N
0.0001 CD N
) ) N
. . N

Local JJ N
pain NN N
in IN N
the DT N
injection NN N
site NN N
at IN N
the DT N
5th JJ N
day NN N
of IN N
treatment NN N
was VBD N
reported VBN N
in IN N
8.4 CD N
% NN N
and CC N
16.6 CD N
% NN N
in IN N
the DT N
enoxaparin NN N
and CC N
calcium NN N
heparin NN N
groups NNS N
respectively RB N
( ( N
p JJ N
= NNP N
0.0001 CD N
) ) N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -X- O O 22800470

A DT N
six-month JJ N
crossover NN N
chemoprevention NN N
clinical JJ N
trial NN N
of IN N
tea NN N
in IN N
smokers NNS 4_p
and CC N
non-smokers NNS 4_p
: : N
methodological JJ N
issues NNS N
in IN N
a DT N
feasibility NN N
study NN N
. . N

BACKGROUND NNP N
Chemoprevention NNP N
crossover NN N
trials NNS N
of IN N
tea NN N
can MD N
be VB N
more RBR N
efficient JJ N
than IN N
parallel JJ N
designs NNS N
but CC N
the DT N
attrition NN N
and CC N
compliance NN N
rates NNS N
with IN N
such JJ N
trials NNS N
are VBP N
unknown JJ N
. . N

METHODS NNP N
Attrition NNP N
( ( N
dropouts NNS N
) ) N
and CC N
compliance NN N
with IN N
treatment NN N
were VBD N
assessed VBN N
in IN N
a DT N
25-week JJ N
randomized NN N
, , N
placebo NN N
controlled VBD N
, , N
crossover NN N
, , N
feasibility NN N
clinical JJ N
trial NN N
of IN N
four CD N
tea NN N
treatments NNS N
to TO N
investigate VB N
the DT N
effect NN N
of IN N
tea NN N
on IN N
oral JJ N
cancer NN N
biomarkers NNS N
. . N

Each DT N
treatment NN N
lasted VBD N
4 CD N
weeks NNS N
with IN N
2 CD N
weeks NNS N
of IN N
washout NN N
in IN N
between IN N
. . N

Participants NNS N
were VBD N
32 CD N
smokers NNS N
and CC N
33 CD N
non-smokers NNS N
without IN N
any DT N
evidence NN N
of IN N
premalignant JJ 4_p
oral JJ 4_p
lesions NNS 4_p
. . N

The DT N
interventions NNS N
consisted VBD N
of IN N
packets NNS N
of IN N
green JJ N
tea NN N
, , N
black JJ N
tea NN N
, , N
caffeinated JJ N
water NN N
, , N
or CC N
placebo NN N
. . N

Participants NNS N
were VBD N
assigned VBN N
to TO N
each DT N
treatment NN N
for IN N
four CD N
weeks NNS N
, , N
and CC N
were VBD N
instructed VBN N
to TO N
drink VB N
five CD N
packets NNS N
per IN N
day NN N
while IN N
on IN N
the DT N
treatment NN N
. . N

Dropout IN N
from IN N
the DT N
trial NN N
and CC N
compliance NN N
( ( N
consumption NN N
of IN N
≥85 NNP N
% NN N
of IN N
the DT N
prescribed JJ N
treatment NN N
packets NNS N
) ) N
are VBP N
the DT N
main JJ N
outcome NN N
measures NNS N
reported VBN N
. . N

RESULTS NNP N
There EX N
was VBD N
a DT N
high JJ N
rate NN N
of IN N
dropout NN N
( ( N
51 CD N
% NN N
) ) N
from IN N
the DT N
study NN N
, , N
and CC N
the DT N
rates NNS N
were VBD N
significantly RB N
higher JJR N
among IN N
smokers NNS N
( ( N
64 CD N
% NN N
) ) N
than IN N
non-smokers NNS N
( ( N
36 CD N
% NN N
) ) N
. . N

Among IN N
participants NNS N
who WP N
completed VBD N
the DT N
study NN N
the DT N
rate NN N
of IN N
compliance NN N
was VBD N
72 CD N
% NN N
. . N

The DT N
highest JJS N
rates NNS N
of IN N
dropouts NNS N
occurred VBD N
between IN N
the DT N
first JJ N
and CC N
second JJ N
treatment NN N
visits NNS N
in IN N
both DT N
smokers NNS N
( ( N
38 CD N
% NN N
dropout NN N
) ) N
and CC N
non-smokers NNS N
( ( N
18 CD N
% NN N
dropout NN N
) ) N
. . N

Throughout IN N
the DT N
study NN N
smokers NNS N
were VBD N
more RBR N
likely JJ N
to TO N
dropout VB N
than IN N
non-smokers NNS N
. . N

Black NNP N
tea NN N
treatment NN N
was VBD N
associated VBN N
with IN N
the DT N
highest JJS N
rates NNS N
of IN N
dropout NN N
among IN N
smokers NNS N
( ( N
37 CD N
% NN N
) ) N
, , N
but CC N
was VBD N
associated VBN N
with IN N
the DT N
lowest JJS N
rate NN N
of IN N
dropout NN N
among IN N
non-smokers NNS N
( ( N
4 CD N
% NN N
) ) N
. . N

CONCLUSIONS NNP N
In IN N
a DT N
study NN N
conducted VBN N
to TO N
test VB N
the DT N
feasibility NN N
of IN N
a DT N
four-treatment JJ N
crossover NN N
tea NN N
trial NN N
, , N
a DT N
high JJ N
rate NN N
of IN N
dropout NN N
among IN N
smokers NNS N
and CC N
non-smokers NNS N
was VBD N
observed VBN N
. . N

Multi-arm JJ N
crossover NN N
tea NN N
trials NNS N
might MD N
pose VB N
a DT N
higher JJR N
burden NN N
on IN N
participants NNS N
and CC N
research NN N
is VBZ N
needed VBN N
to TO N
improve VB N
adherence NN N
and CC N
treatment NN N
compliance NN N
in IN N
such JJ N
trials NNS N
. . N

TRIAL NNP N
REGISTRATION NNP N
NUMBER NNP N
ISRCTN70410203 NNP N
. . N

-DOCSTART- -X- O O 1492408

Effects NNS N
of IN N
a DT N
combination NN N
of IN N
evening VBG N
primrose JJ N
oil NN N
( ( N
gamma NN N
linolenic RB N
acid NN N
) ) N
and CC N
fish JJ N
oil NN N
( ( N
eicosapentaenoic JJ N
+ NNP N
docahexaenoic NN N
acid NN N
) ) N
versus NN N
magnesium NN N
, , N
and CC N
versus NN N
placebo NN N
in IN N
preventing VBG N
pre-eclampsia NN 4_p
. . 4_p

In IN N
a DT N
placebo NN N
controlled VBN N
, , N
partially RB N
double-blinded JJ N
, , N
clinical JJ N
trial NN N
, , N
a DT N
combination NN N
of IN N
evening VBG N
primrose JJ N
oil NN N
and CC N
fish JJ N
oil NN N
was VBD N
compared VBN N
to TO N
Magnesium NNP N
Oxide NNP N
, , N
and CC N
to TO N
a DT N
Placebo NNP N
in IN N
preventing VBG N
Pre-Eclampsia NNP N
of IN N
Pregnancy NNP N
. . N

All DT N
were VBD N
given VBN N
as IN N
nutritional JJ N
supplements NNS N
for IN N
six CD N
months NNS N
to TO N
a DT N
group NN N
of IN N
primiparous JJ N
and CC N
multiparous JJ N
pregnant JJ N
women NNS N
. . N

Some DT 4_p
of IN 4_p
these DT 4_p
women NNS 4_p
had VBD 4_p
personal JJ 4_p
or CC 4_p
family NN 4_p
histories NNS 4_p
of IN 4_p
hypertension NN 4_p
( ( 4_p
21 CD 4_p
% NN 4_p
) ) 4_p
. . 4_p

Only RB N
those DT N
patients NNS N
who WP N
received VBD N
prenatal JJ N
care NN N
at IN N
the DT N
Central NNP N
Maternity NNP N
Hospital NNP N
for IN N
Luanda NNP N
were VBD N
included VBN N
in IN N
the DT N
study NN N
. . N

Compared VBN N
to TO N
the DT N
Placebo NNP N
group NN N
( ( N
29 CD N
% NN N
) ) N
, , N
the DT N
group NN N
receiving VBG N
the DT N
mixture NN N
of IN N
evening VBG N
primrose JJ N
oil NN N
and CC N
fish JJ N
oil NN N
containing VBG N
Gamma-linolenic JJ N
acid NN N
( ( N
GLA NNP N
) ) N
, , N
Eicosapentaenoic NNP N
acid NN N
( ( N
EPA NNP N
) ) N
, , N
and CC N
Docosahexaenoic NNP N
acid NN N
( ( N
DHA NNP N
) ) N
had VBD N
a DT N
significantly RB N
lower JJR N
incidence NN N
of IN N
edema NN N
( ( N
13 CD N
% NN N
, , N
p NN N
= NNP N
0.004 CD N
) ) N
. . N

The DT N
group NN N
receiving VBG N
Magnesium NNP N
Oxide NNP N
had VBD N
statistically RB N
significant JJ N
fewer JJR N
subjects NNS N
who WP N
developed VBD N
hypertension NN N
of IN N
pregnancy NN N
. . N

There EX N
were VBD N
3 CD N
cases NNS N
of IN N
eclampsia NN N
, , N
all DT N
in IN N
the DT N
Placebo NNP N
group NN N
. . N

-DOCSTART- -X- O O 17391914

Information NNP N
source NN N
affects VBZ N
peers NNS N
' POS N
initial JJ N
attitudes NNS N
toward IN N
autism NN N
. . N

Authors NNS N
examined VBD N
the DT N
effects NNS N
of IN N
information NN N
source NN N
on IN N
peers NNS N
' POS N
cognitive NN N
and CC N
behavioral JJ N
attitudes NNS N
toward IN N
an DT N
unfamiliar JJ N
child NN N
with IN N
autism NN N
. . N

Children NNP N
( ( N
N=296 NNP N
; : N
M NNP N
age=10.21 IN N
years NNS N
) ) N
received VBD N
information NN N
about IN N
an DT N
unfamiliar JJ N
child NN N
with IN N
autism NN N
from IN N
one CD N
of IN N
the DT N
following JJ N
sources NNS N
: : N
( ( N
a DT N
) ) N
videotape NN N
, , N
( ( N
b NN N
) ) N
teacher NN 4_p
, , N
( ( N
c NN N
) ) N
hypothetical JJ N
mother NN N
, , N
( ( N
d NN N
) ) N
hypothetical JJ N
father NN N
, , N
or CC N
( ( N
e NN N
) ) N
hypothetical JJ N
" NNP N
doctor NN N
. . N

" JJ N
Interactive JJ N
effects NNS N
between IN N
source NN N
, , N
and CC N
sex NN N
and CC N
grade NN N
were VBD N
found VBN N
for IN N
cognitive JJ N
and CC N
behavioral JJ N
attitudes NNS N
. . N

Fifth-graders NNS N
reported VBD N
more RBR N
favorable JJ N
cognitive JJ N
and CC N
behavioral JJ N
attitudes NNS N
when WRB N
information NN N
was VBD N
provided VBN N
by IN N
extra-familial JJ N
sources NNS N
( ( N
i.e. NN N
, , N
" NNP N
doctor NN N
" NN N
) ) N
versus NN N
parent NN N
sources NNS N
. . N

Mother NNP N
yielded VBD N
more RBR N
persuasive JJ N
effects NNS N
on IN N
behavioral JJ N
attitudes NNS N
for IN N
third-graders NNS N
versus JJ N
fifth-graders NNS N
. . N

Attitudes NNS N
toward IN N
autism NN N
differ VBP N
depending VBG N
on IN N
who WP N
provides VBZ N
information NN N
about IN N
the DT N
disability NN N
. . N

Persuasion NNP N
theory NN N
appears VBZ N
useful JJ N
to TO N
guide VB N
evaluation NN N
of IN N
educational JJ N
interventions NNS N
to TO N
improve VB N
attitudes NNS N
towards IN N
autism NN N
. . N

Implications NNS N
of IN N
the DT N
findings NNS N
, , N
study NN N
limitations NNS N
, , N
and CC N
recommendations NNS N
for IN N
future JJ N
research NN N
are VBP N
discussed VBN N
. . N

-DOCSTART- -X- O O 18235151

Reduced VBN N
albuminuria NNS N
with IN N
sarpogrelate NN N
is VBZ N
accompanied VBN N
by IN N
a DT N
decrease NN N
in IN N
monocyte JJ N
chemoattractant JJ N
protein-1 NN N
levels NNS N
in IN N
type NN 4_p
2 CD 4_p
diabetes NNS 4_p
. . N

BACKGROUND NNP N
AND NNP N
OBJECTIVES NNP N
Sarpogrelate NNP N
has VBZ N
been VBN N
shown VBN N
to TO N
reduce VB N
albuminuria NNS N
in IN N
diabetic JJ N
nephropathy NN N
. . N

For IN N
examination NN N
of IN N
whether IN N
this DT N
is VBZ N
based VBN N
on IN N
the DT N
same JJ N
mechanisms NN N
as IN N
angiotensin NN N
II NNP N
receptor NN N
blockers NNS N
or CC N
thiazolidinedione NN N
, , N
effects NNS N
of IN N
sarpogrelate NN N
on IN N
atherosclerotic JJ N
inflammatory NN N
molecules NNS N
and CC N
their PRP$ N
relations NNS N
to TO N
albuminuria NNS N
in IN N
patients NNS N
who WP N
had VBD N
diabetes NNS 4_p
and CC N
had VBD N
already RB N
been VBN N
treated VBN N
with IN N
angiotensin NN N
II NNP N
receptor NN N
blockers NNS N
and CC N
with IN N
or CC N
without IN N
thiazolidinedione NN N
were VBD N
examined VBN N
. . N

DESIGN NNP N
, , N
SETTING NNP N
, , N
PARTICIPANTS NNP N
, , N
& CC N
MEASUREMENTS NNP N
Forty NNP N
patients NNS N
who WP N
had VBD N
diabetes NNS 4_p
with IN N
nephropathy JJ 4_p
and CC 4_p
arteriosclerosis NN 4_p
obliterans NNS 4_p
and CC N
had VBD N
already RB N
been VBN N
treated VBN N
with IN N
angiotensin NN N
II NNP N
receptor NN N
blocker NN N
( ( N
n JJ N
= NNP N
40 CD N
) ) N
were VBD N
randomly RB N
assigned VBN N
to TO N
sarpogrelate VB N
( ( N
300 CD N
mg/d NN N
; : N
n CC N
= VB N
20 CD N
) ) N
or CC N
aspirin JJ N
group NN N
( ( N
100 CD N
mg/d NN N
; : N
n CC N
= VB N
20 CD N
) ) N
. . N

Plasma NNP N
monocyte JJ N
chemoattractant JJ N
protein-1 NN N
and CC N
urinary JJ N
albumin-to-creatinine JJ N
ratio NN N
and CC N
monocyte NN N
chemoattractant JJ N
protein-1 NN N
were VBD N
measured VBN N
at IN N
baseline NN N
and CC N
16 CD N
wk NN N
after IN N
administration NN N
. . N

RESULTS NNP N
Only RB N
the DT N
sarpogrelate NN N
group NN N
showed VBD N
increases NNS N
in IN N
plasma NN N
adiponectin NN N
and CC N
decreases NNS N
in IN N
both DT N
plasma NN N
and CC N
urinary JJ N
monocyte NN N
chemoattractant JJ N
protein-1 JJ N
and CC N
albumin-to-creatinine JJ N
ratio NN N
levels NNS N
. . N

Moreover RB N
, , N
percentage NN N
change NN N
of IN N
monocyte NN N
chemoattractant JJ N
protein-1 JJ N
level NN N
correlated VBD N
positively RB N
to TO N
that DT N
of IN N
albumin-to-creatinine JJ N
ratio NN N
. . N

Even RB N
when WRB N
the DT N
sarpogrelate NN N
group NN N
was VBD N
further RB N
divided VBN N
into IN N
two CD N
groups NNS N
with IN N
( ( N
n JJ N
= NNP N
9 CD N
) ) N
or CC N
without IN N
thiazolidinedione NN N
( ( N
n JJ N
= NNP N
11 CD N
) ) N
, , N
changes NNS N
in IN N
monocyte NN N
chemoattractant JJ N
protein-1 JJ N
or CC N
albumin-to-creatinine JJ N
ratio NN N
did VBD N
not RB N
differ VB N
. . N

CONCLUSIONS NNP N
Sarpogrelate NNP N
can MD N
reduce VB N
albuminuria NNS N
and CC N
plasma NN N
and CC N
urinary JJ N
monocyte NN N
chemoattractant JJ N
protein-1 JJ N
levels NNS N
while IN N
increasing VBG N
plasma NN N
adiponectin NN N
in IN N
diabetic JJ N
nephropathy NN N
. . N

These DT N
effects NNS N
seem VBP N
to TO N
be VB N
mediated VBN N
via IN N
mechanisms NNS N
that WDT N
are VBP N
different JJ N
from IN N
those DT N
of IN N
angiotensin JJ N
II NNP N
receptor NN N
blocker NN N
or CC N
thiazolidinedione NN N
. . N

-DOCSTART- -X- O O 9672054

A DT N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
of IN N
risperidone NN N
in IN N
adults NNS N
with IN N
autistic JJ 4_p
disorder NN 4_p
and CC N
other JJ N
pervasive JJ N
developmental NN N
disorders NNS N
. . N

BACKGROUND NNP N
Neurobiological NNP N
research NN N
has VBZ N
implicated VBN N
the DT N
dopamine NN N
and CC N
serotonin JJ N
systems NNS N
in IN N
the DT N
pathogenesis NN N
of IN N
autism NN 4_p
. . 4_p

Open-label JJ N
reports NNS N
suggest VBP N
that IN N
the DT N
serotonin2A-dopamine JJ N
D2 NNP N
antagonist NN N
risperidone NN N
may MD N
be VB N
safe JJ N
and CC N
effective JJ N
in IN N
reducing VBG N
the DT N
interfering NN N
symptoms NNS N
of IN N
patients NNS N
with IN N
autism NN 4_p
. . N

METHODS NNP N
Thirty-one CD N
adults NNS N
( ( N
age NN N
[ VBZ N
mean+/-SD JJ N
] NNP N
, , N
28.1+/-7.3 JJ N
years NNS N
) ) N
with IN N
autistic JJ 4_p
disorder NN 4_p
( ( N
n=17 JJ N
) ) N
or CC N
pervasive JJ N
developmental JJ N
disorder NN N
not RB N
otherwise RB N
specified VBN N
( ( N
n=14 JJ N
) ) N
participated VBD N
in IN N
a DT N
12-week JJ N
double-blind NN N
, , N
placebo-controlled JJ N
trial NN N
of IN N
risperidone NN N
. . N

Patients NNS N
treated VBD N
with IN N
placebo NN N
subsequently RB N
received VBD N
a DT N
12-week JJ N
open-label JJ N
trial NN N
of IN N
risperidone NN N
. . N

RESULTS NNP N
For IN N
persons NNS N
completing VBG N
the DT N
study NN N
, , N
8 CD N
( ( N
57 CD N
% NN N
) ) N
of IN N
14 CD N
patients NNS N
treated VBN N
with IN N
risperidone NN N
were VBD N
categorized VBN N
as IN N
responders NNS N
( ( N
daily JJ N
dose VB N
[ JJ N
mean+/-SD JJ N
] NN N
, , N
2.9+/-1.4 JJ N
mg NN N
) ) N
compared VBN N
with IN N
none NN N
of IN N
16 CD N
in IN N
the DT N
placebo NN N
group NN N
( ( N
P NNP N
< NNP N
.002 NNP N
) ) N
. . N

Risperidone NN N
was VBD N
superior JJ N
to TO N
placebo VB N
in IN N
reducing VBG N
repetitive JJ N
behavior NN N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
, , N
aggression NN N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
, , N
anxiety NN N
or CC N
nervousness NN N
( ( N
P NNP N
< NNP N
.02 NNP N
) ) N
, , N
depression NN N
( ( N
P NNP N
< NNP N
.03 NNP N
) ) N
, , N
irritability NN N
( ( N
P NNP N
< NNP N
.01 NNP N
) ) N
, , N
and CC N
the DT N
overall JJ N
behavioral JJ N
symptoms NNS N
of IN N
autism NN N
( ( N
P NNP N
< NNP N
.02 NNP N
) ) N
. . N

Objective NNP N
, , N
measurable JJ N
change NN N
in IN N
social JJ N
behavior NN N
and CC N
language NN N
did VBD N
not RB N
occur VB N
. . N

Nine NNP N
( ( N
60 CD N
% NN N
) ) N
of IN N
15 CD N
patients NNS N
who WP N
received VBD N
treatment NN N
with IN N
open-label JJ N
risperidone NN N
following VBG N
the DT N
double-blind JJ N
placebo NN N
phase NN N
responded VBD N
. . N

Other JJ N
than IN N
mild JJ N
, , N
transient JJ N
sedation NN N
, , N
risperidone NN N
was VBD N
well RB N
tolerated VBN N
, , N
with IN N
no DT N
evidence NN N
of IN N
extrapyramidal JJ N
effects NNS N
, , N
cardiac JJ N
events NNS N
, , N
or CC N
seizures NNS N
. . N

CONCLUSION NNP N
Risperidone NNP N
is VBZ N
more RBR N
effective JJ N
than IN N
placebo NN N
in IN N
the DT N
short-term JJ N
treatment NN N
of IN N
symptoms NNS N
of IN N
autism NN 4_p
in IN N
adults NNS N
. . N

-DOCSTART- -X- O O 24447434

Phosphorylated VBN N
p-70S6K JJ N
predicts NNS N
tamoxifen JJ N
resistance NN N
in IN N
postmenopausal NN 4_p
breast NN 4_p
cancer NN 4_p
patients NNS 4_p
randomized VBD N
between IN N
adjuvant JJ N
tamoxifen NN N
versus IN N
no DT N
systemic JJ N
treatment NN N
. . N

INTRODUCTION NNP N
Activation NNP N
of IN N
the DT N
phosphatidylinositol-3-kinase NN N
( ( N
PI3K NNP N
) ) N
and/or VBD N
mitogen-activated JJ N
protein NN N
kinase NN N
( ( N
MAPK NNP N
) ) N
pathways VBZ N
results NNS N
in IN N
anti-estrogen JJ N
resistance NN N
in IN N
vitro NN N
, , N
but CC N
a DT N
biomarker NN N
with IN N
clinical JJ N
validity NN N
to TO N
predict VB N
intrinsic JJ N
resistance NN N
has VBZ N
not RB N
been VBN N
identified VBN N
. . N

In IN N
metastatic JJ 4_p
breast NN 4_p
cancer NN 4_p
patients NNS 4_p
with IN 4_p
previous JJ 4_p
exposure NN 4_p
to TO 4_p
endocrine VB 4_p
therapy NN 4_p
, , N
the DT N
addition NN N
of IN N
a DT N
mammalian JJ N
target NN N
of IN N
rapamycine NN N
( ( N
mTOR NN N
) ) N
inhibitor NN N
has VBZ N
been VBN N
shown VBN N
to TO N
be VB N
beneficial JJ N
. . N

Whether CC N
or CC N
not RB N
patients NNS N
on IN N
adjuvant JJ N
endocrine NN N
treatment NN N
might MD N
benefit VB N
from IN N
these DT N
drugs NNS N
is VBZ N
currently RB N
unclear JJ N
. . N

A DT N
biomarker NN N
that WDT N
predicts VBZ N
intrinsic JJ N
resistance NN N
could MD N
potentially RB N
be VB N
used VBN N
as IN N
companion NN N
diagnostic NN N
in IN N
this DT N
setting NN N
. . N

We PRP N
tested VBD N
the DT N
clinical JJ N
validity NN N
of IN N
different JJ N
downstream-activated JJ N
proteins NNS N
in IN N
the DT N
PI3K NNP N
and/or NN N
MAPK NNP N
pathways VBZ N
to TO N
predict VB N
intrinsic JJ N
tamoxifen NN N
resistance NN N
in IN N
postmenopausal NN N
primary JJ N
breast NN N
cancer NN N
patients NNS N
. . N

METHODS NNP N
We PRP N
recollected VBD N
primary JJ 4_p
tumor NN 4_p
tissue NN 4_p
from IN N
patients NNS N
who WP N
participated VBD N
in IN N
a DT N
randomized JJ N
trial NN N
of IN N
adjuvant JJ N
tamoxifen NN N
( ( N
1-3 CD N
years NNS N
) ) N
versus NN N
observation NN N
. . N

After IN N
constructing VBG N
a DT N
tissue NN N
micro-array NN N
, , N
cores NNS N
from IN N
563 CD N
estrogen NN N
receptor NN N
α NNP N
positive JJ N
were VBD N
immunostained VBN N
for IN N
p-AKT NN N
( ( N
Thr308 NNP N
) ) N
, , N
p-AKT JJ N
( ( N
Ser473 NNP N
) ) N
, , N
p-mTOR JJ N
, , N
p-p706SK JJ N
and CC N
p-ERK1/2 JJ N
. . N

Cox NNP N
proportional JJ N
hazard NN N
models NNS N
for IN N
recurrence NN N
free JJ N
interval NN N
were VBD N
used VBN N
to TO N
assess VB N
hazard JJ N
ratios NNS N
and CC N
interactions NNS N
between IN N
these DT N
markers NNS N
and CC N
tamoxifen JJ N
treatment NN N
efficacy NN N
. . N

RESULTS JJ N
Interactions NNPS N
were VBD N
identified VBN N
between IN N
tamoxifen NNS N
and CC N
p-AKT NN N
( ( N
Thr308 NNP N
) ) N
, , N
p-mTOR JJ N
, , N
p-p70S6K JJ N
and CC N
p-ERK1/2 JJ N
. . N

Applying VBG N
a DT N
conservative JJ N
level NN N
of IN N
significance NN N
, , N
p-p70S6K NN N
remained VBD N
significantly RB N
associated VBN N
with IN N
tamoxifen JJ N
resistance NN N
. . N

Patients NNS N
with IN N
p-p70S6K JJ N
negative JJ N
tumors NNS N
derived VBD N
significant JJ N
benefit NN N
from IN N
tamoxifen NN N
( ( N
HR NNP N
0.24 CD N
, , N
P NNP N
< NNP N
0.0001 CD N
) ) N
, , N
while IN N
patients NNS N
whose WP$ N
tumor NN N
did VBD N
express JJ N
p-p70S6K NN N
did VBD N
not RB N
( ( N
HR NNP N
= NNP N
1.02 CD N
, , N
P NNP N
=0.95 NNP N
) ) N
, , N
P NNP N
for IN N
interaction NN N
0.004 CD N
. . N

In IN N
systemically RB N
untreated JJ N
breast NN N
cancer NN N
patients NNS N
, , N
p-p70S6K NN N
was VBD N
associated VBN N
with IN N
a DT N
decreased JJ N
risk NN N
for IN N
recurrence NN N
. . N

CONCLUSIONS JJ N
Patients NNPS N
whose WP$ N
tumor NN 4_p
expresses VBZ N
p-p70S6K JJ N
, , N
as IN N
a DT N
marker NN N
of IN N
downstream NN N
PI3K NNP N
and/or NN N
MAPK NNP N
pathway NN N
activation NN N
, , N
have VBP N
a DT N
favorable JJ N
prognosis NN N
, , N
but CC N
do VBP N
not RB N
benefit VB N
from IN N
adjuvant JJ N
tamoxifen NN N
. . N

A DT N
potential JJ N
benefit NN N
from IN N
inhibitors NNS N
of IN N
the DT N
PI3K/Akt/mTOR NNP N
pathway NN N
in IN N
these DT N
patients NNS N
needs NNS N
to TO N
be VB N
further RB N
explored VBN N
. . N

-DOCSTART- -X- O O 2182521

The DT N
clinician NN N
's POS N
decision NN N
of IN N
whether IN N
CHOP NNP N
chemotherapy NN N
should MD N
be VB N
standard JJ N
therapy NN N
for IN N
treatment NN N
of IN N
patients NNS N
with IN N
diffuse NN 4_p
histiocytic JJ 4_p
lymphoma NN 4_p
. . N

-DOCSTART- -X- O O 22550938

B-type JJ N
natriuretic JJ N
peptide NN N
in IN N
the DT N
evaluation NN N
and CC N
management NN N
of IN N
dyspnoea NN 4_p
in IN N
primary JJ N
care NN N
. . N

OBJECTIVES IN N
The DT N
rapid JJ N
and CC N
accurate JJ N
diagnosis NN N
of IN N
heart NN N
failure NN N
in IN N
primary JJ N
care NN N
is VBZ N
a DT N
major JJ N
unmet JJ N
clinical JJ N
need NN N
. . N

We PRP N
evaluated VBD N
the DT N
additional JJ N
use NN N
of IN N
B-type NNP 4_p
natriuretic JJ 4_p
peptide NN 4_p
( ( 4_p
BNP NNP 4_p
) ) 4_p
levels NNS 4_p
. . N

DESIGN VB N
A DT N
randomized NN N
controlled VBN N
trial NN N
. . N

SETTING CC N
Twenty-nine JJ N
primary JJ N
care NN N
physicians NNS N
in IN N
Switzerland NNP N
and CC N
Germany NNP N
coordinated VBN N
by IN N
the DT N
University NNP N
Hospital NNP N
Basel NNP N
, , N
Switzerland NNP N
. . N

SUBJECTS NNP N
A NNP N
total NN N
of IN N
323 CD N
consecutive JJ N
patients NNS N
presenting VBG N
with IN N
dyspnoea NN 4_p
. . N

INTERVENTIONS NNP N
Assignment NNP N
in IN N
a DT N
1 CD N
: : N
1 CD N
ratio NN N
to TO N
a DT N
diagnostic JJ N
strategy NN N
including VBG N
point-of-care JJ N
measurement NN N
of IN N
BNP NNP N
( ( N
n JJ N
= NNP N
163 CD N
) ) N
or CC N
standard JJ N
assessment NN N
without IN N
BNP NNP N
( ( N
n JJ N
= NNP N
160 CD N
) ) N
. . N

The DT N
total JJ N
medical JJ N
cost NN N
at IN N
3 CD N
months NNS N
was VBD N
the DT N
primary JJ N
end-point NN N
. . N

Secondary JJ N
end-points NNS N
were VBD N
diagnostic JJ N
certainty NN N
, , N
time NN N
to TO N
appropriate VB N
therapy NN N
, , N
functional JJ N
capacity NN N
, , N
hospitalization NN N
and CC N
mortality NN N
. . N

The DT N
final JJ N
diagnosis NN N
was VBD N
adjudicated VBN N
by IN N
a DT N
physician NN N
blinded VBN N
to TO N
the DT N
BNP NNP N
levels NNS N
. . N

RESULTS NNP N
Heart NNP N
failure NN N
was VBD N
the DT N
final JJ N
diagnosis NN N
in IN N
34 CD N
% NN N
of IN N
patients NNS N
. . N

The DT N
number NN N
of IN N
hospitalizations NNS N
, , N
functional JJ N
status NN N
and CC N
total JJ N
medical JJ N
cost NN N
at IN N
3 CD N
months NNS N
[ JJ N
median JJ N
$ $ N
1655 CD N
, , N
interquartile JJ N
range NN N
( ( N
IQR NNP N
) ) N
, , N
850-3331 JJ N
vs. IN N
$ $ N
1541 CD N
, , N
IQR NNP N
859-2827 CD N
; : N
P NNP N
= VBD N
0.68 CD N
] NNS N
were VBD N
similar JJ N
in IN N
both DT N
groups NNS N
. . N

BNP NNP N
increased VBD N
diagnostic JJ N
certainty NN N
as IN N
defined VBN N
by IN N
the DT N
need NN N
for IN N
further JJ N
diagnostic JJ N
work-up NN N
( ( N
33 CD N
% NN N
vs. FW N
45 CD N
% NN N
; : N
P NNP N
= NNP N
0.02 CD N
) ) N
and CC N
accelerated VBD N
the DT N
initiation NN N
of IN N
the DT N
appropriate JJ N
treatment NN N
( ( N
13 CD N
days NNS N
vs. FW N
25 CD N
days NNS N
; : N
P NNP N
= NNP N
0.01 CD N
) ) N
. . N

The DT N
area NN N
under IN N
the DT N
receiver-operating JJ N
characteristics NNS N
curve NN N
for IN N
BNP NNP N
to TO N
identify VB N
heart NN N
failure NN N
was VBD N
0.87 CD N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
0.81-0.93 JJ N
) ) N
. . N

CONCLUSIONS VB N
The DT N
use NN N
of IN N
BNP NNP N
levels NNS N
in IN N
primary JJ N
care NN N
did VBD N
not RB N
reduce VB N
total JJ N
medical JJ N
cost NN N
, , N
but CC N
improved VBD N
some DT N
of IN N
the DT N
secondary JJ N
end-points NNS N
including VBG N
diagnostic JJ N
certainty NN N
and CC N
time NN N
to TO N
initiation NN N
of IN N
appropriate JJ N
treatment NN N
. . N

-DOCSTART- -X- O O 23185761

[ JJ N
Therapeutic NNP N
efficacy NN N
of IN N
youdujing VBG N
preparation NN N
in IN N
treating VBG N
cervical JJ N
high-risk JJ N
human JJ N
papilloma NN N
virus NN N
infection NN N
patients NNS N
] VBP N
. . N

OBJECTIVE NNP N
To TO N
study VB N
the DT N
clinical JJ N
efficacy NN N
and CC N
mechanisms NN N
of IN N
Youdujing NNP N
( ( N
YDJ NNP N
) ) N
preparation NN N
in IN N
treating VBG N
the DT N
cervical JJ N
high-risk JJ N
human JJ N
papilloma NN N
virus NN N
( ( N
HR-HPV NNP N
) ) N
infection NN N
. . N

METHODS NNP N
Totally RB N
HR-HPV NNP N
infection NN N
70 CD N
patients NNS N
were VBD N
assigned VBN N
to TO N
the DT N
treatment NN N
group NN N
and CC N
the DT N
control NN N
group NN N
using VBG N
random JJ N
single JJ N
blind NN N
method NN N
, , N
35 CD N
cases NNS N
in IN N
each DT N
group NN N
. . N

YDJ NNP N
external JJ N
lotion NN N
and CC N
YDJ NNP N
cream NN N
were VBD N
applied VBN N
to TO N
patients NNS N
in IN N
the DT N
treatment NN N
group NN N
, , N
while IN N
normal JJ N
saline NN N
was VBD N
applied VBN N
for IN N
those DT N
in IN N
the DT N
control NN N
group NN N
. . N

HR-HPV NNP N
DNA NNP N
detection NN N
was VBD N
performed VBN N
by IN N
the DT N
end NN N
of IN N
the DT N
1st CD N
menstruation NN N
after IN N
3 CD N
menstrual JJ N
cycles NNS N
. . N

The DT N
cervical JJ N
biopsy NN N
and CC N
cervical JJ N
smear NN N
were VBD N
performed VBN N
using VBG N
vaginoscope NN N
before IN N
and CC N
after IN N
treatment NN N
. . N

The DT N
mRNA JJ N
expression NN N
of IN N
human JJ N
telomerase NN N
reverse NN N
transcriptase NN N
( ( N
hTERT NN N
) ) N
was VBD N
detected VBN N
from IN N
fresh JJ N
tissues NNS N
of IN N
the DT N
cervical JJ N
lesion NN N
. . N

RESULTS VB N
The DT N
total JJ N
effective JJ N
rate NN N
was VBD N
96.6 CD N
% NN N
in IN N
the DT N
treatment NN N
group NN N
, , N
higher JJR N
than IN N
that DT N
of IN N
the DT N
control NN N
group NN N
( ( N
70.00 CD N
% NN N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

Before IN N
treatment NN N
there EX N
was VBD N
no DT N
statistical JJ N
difference NN N
in IN N
the DT N
pathological JJ N
results NNS N
of IN N
the DT N
cervix NN N
and CC N
the DT N
mRNA JJ N
expression NN N
of IN N
hTERT NN N
between IN N
the DT N
two CD N
groups NNS N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

The DT N
mRNA JJ N
expression NN N
of IN N
hTERT NN N
decreased VBN N
in IN N
the DT N
two CD N
groups NNS N
after IN N
treatment NN N
, , N
showing VBG N
statistical JJ N
difference NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

Better JJR N
effects NNS N
on IN N
the DT N
pathological JJ N
results NNS N
of IN N
the DT N
cervix NN N
and CC N
the DT N
mRNA JJ N
expression NN N
of IN N
hTERT NN N
were VBD N
obtained VBN N
in IN N
the DT N
treatment NN N
group NN N
after IN N
treatment NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSION NNP N
YDJ NNP N
played VBD N
a DT N
role NN N
in IN N
clearing VBG N
HR-HPV NNP N
infection NN N
and CC N
reversing VBG N
the DT N
cervical JJ N
precancerous JJ N
changes NNS N
possibly RB N
through IN N
down-regulating NN N
the DT N
mRNA JJ N
expression NN N
of IN N
hTERT NN N
and CC N
lowering VBG N
the DT N
telomerase NN N
activation NN N
. . N

-DOCSTART- -X- O O 3319640

Comparison NNP N
of IN N
nicardipine NN N
and CC N
propranolol NN N
in IN N
the DT N
treatment NN N
of IN N
mild NN N
and CC N
moderate JJ N
hypertension NN 4_p
. . N

In IN N
a DT N
double-blind NN N
controlled VBN N
trial NN N
22 CD N
patients NNS N
with IN N
mild JJ 4_p
or CC 4_p
moderate JJ 4_p
essential JJ 4_p
hypertension NN 4_p
were VBD N
treated VBN N
with IN N
nicardipine JJ N
30 CD N
mg NN N
t.d.s NN N
. . N

and CC N
19 CD N
patients NNS N
with IN N
propranolol JJ N
80 CD N
mg NN N
t.d.s NN N
. . N

as IN N
monotherapy NN N
for IN N
24 CD N
weeks NNS N
. . N

Blood NNP N
pressure NN N
in IN N
both DT N
groups NNS N
at IN N
the DT N
end NN N
of IN N
trial NN N
was VBD N
equally RB N
and CC N
significantly RB N
reduced VBN N
; : N
systolic JJ N
pressure NN N
22.2 CD N
mmHg NN N
and CC N
diastolic JJ N
pressure NN N
15.5 CD N
mmHg NN N
in IN N
the DT N
supine JJ N
position NN N
, , N
and CC N
24.4 CD N
mmHg NN N
and CC N
18.4 CD N
mmHg NN N
, , N
respectively RB N
, , N
in IN N
the DT N
standing VBG N
position NN N
in IN N
those DT N
on IN N
nicardipine NN N
, , N
and CC N
by IN N
23.7 CD N
and CC N
16.2 CD N
mmHg NN N
and CC N
28.0 CD N
and CC N
19.2 CD N
mmHg NN N
, , N
respectively RB N
, , N
in IN N
the DT N
propranolol NN N
group NN N
. . N

There EX N
was VBD N
an DT N
initial JJ N
increase NN N
in IN N
heart NN N
rate NN N
in IN N
the DT N
nicardipine NN N
group NN N
, , N
but CC N
the DT N
rise NN N
was VBD N
only RB N
moderate JJ N
( ( N
3 CD N
beats/min NN N
supine NN N
p NN N
= VBD N
0.3219 CD N
, , N
and CC N
7 CD N
beats/min NN N
standing NN N
, , N
p VBP N
= RB N
0.0203 CD N
) ) N
at IN N
the DT N
end NN N
of IN N
the DT N
24 CD N
weeks NNS N
. . N

In IN N
the DT N
propranolol NN N
group NN N
heart NN N
rate NN N
was VBD N
reduced VBN N
markedly RB N
. . N

Adverse JJ N
effects NNS N
occurred VBD N
in IN N
77 CD N
% NN N
of IN N
patients NNS N
on IN N
nicardipine NN N
and CC N
in IN N
63 CD N
% NN N
of IN N
those DT N
on IN N
propranolol NN N
, , N
and CC N
there EX N
were VBD N
no DT N
unexpected JJ N
findings NNS N
. . N

The DT N
effects NNS N
were VBD N
mild VBN N
in IN N
both DT N
groups NNS N
and CC N
did VBD N
not RB N
lead VB N
any DT N
patient NN N
to TO N
stop VB N
medication NN N
. . N

One CD N
patient NN N
on IN N
propranolol NN N
was VBD N
withdrawn VBN N
from IN N
the DT N
trial NN N
because IN N
of IN N
poor JJ N
blood NN N
pressure NN N
control NN N
and CC N
suspected VBD N
angina NNS N
pectoris VBP N
after IN N
5 CD N
weeks NNS N
on IN N
active JJ N
medication NN N
. . N

There EX N
were VBD N
no DT N
significant JJ N
changes NNS N
in IN N
blood NN N
chemistry NN N
, , N
including VBG N
lipoprotein NN N
classes NNS N
. . N

Overall JJ N
, , N
in IN N
comparison NN N
with IN N
propranolol NN N
, , N
nicardipine NN N
was VBD N
effective JJ N
, , N
well-tolerated JJ N
and CC N
safe JJ N
to TO N
use VB N
in IN N
the DT N
monotherapy NN N
of IN N
mild NN N
or CC N
moderate JJ N
essential JJ N
hypertension NN N
. . N

-DOCSTART- -X- O O 8077143

Milk NN N
production NN N
in IN N
cows NNS N
with IN N
endotoxin-induced JJ 4_p
mastitis NN 4_p
treated VBN N
with IN N
isotonic JJ N
or CC N
hypertonic JJ N
sodium NN N
chloride NN N
solution NN N
. . N

Milk NNP N
production NN N
was VBD N
monitored VBN N
in IN N
16 CD N
cows NNS N
for IN N
6 CD N
milkings NNS N
after IN N
intramammary JJ N
infusion NN N
of IN N
1 CD N
mg NN N
of IN N
endotoxin NN N
in IN N
a DT N
single JJ N
forequarter NN N
. . N

The DT N
cows NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
1 CD N
of IN N
2 CD N
treatment NN N
groups NNS N
; : N
8 CD N
cows NNS N
were VBD N
treated VBN N
with IN N
isotonic JJ N
saline NN N
solution NN N
and CC N
8 CD N
cows NNS N
were VBD N
treated VBN N
with IN N
hypertonic JJ N
saline JJ N
solution NN N
. . N

Saline JJ N
solutions NNS N
were VBD N
administered VBN N
IV NNP N
( ( N
5 CD N
ml/kg NN N
of IN N
body NN N
weight NN N
) ) N
4 CD N
hours NNS N
after IN N
infusion NN N
of IN N
endotoxin NN N
. . N

Mean NNP N
cumulative JJ N
change NN N
in IN N
milk NN N
yield NN N
and CC N
interval JJ N
change NN N
in IN N
milk NN N
yield NN N
were VBD N
greater JJR N
in IN N
cows NNS N
treated VBN N
with IN N
isotonic JJ N
saline NN N
solution NN N
than IN N
in IN N
cows NNS N
treated VBN N
with IN N
hypertonic JJ N
saline JJ N
solution NN N
. . N

Significant JJ N
differences NNS N
between IN N
treatment NN N
groups NNS N
were VBD N
not RB N
detected VBN N
. . N

-DOCSTART- -X- O O 19672771

Randomized VBN N
trial NN N
of IN N
daily JJ N
versus FW N
weekly JJ N
administration NN N
of IN N
2-chlorodeoxyadenosine JJ N
in IN N
patients NNS N
with IN N
hairy JJ N
cell NN N
leukemia NN N
: : N
a DT N
multicenter NN N
phase NN N
III NNP N
trial NN N
( ( N
SAKK NNP N
32/98 CD N
) ) N
. . N

Daily JJ N
administration NN N
of IN N
2-chlorodeoxyadenosine JJ N
( ( N
Cladribine NNP N
, , N
CDA NNP N
) ) N
is VBZ N
a DT N
standard JJ N
treatment NN N
for IN N
hairy NN N
cell NN N
leukemia NN N
, , N
but CC N
may MD N
cause VB N
severe JJ N
neutropenia NN N
and CC N
neutropenic JJ N
fever NN N
. . N

This DT N
trial NN N
compared VBN N
toxicity NN N
and CC N
efficacy NN N
of IN N
weekly JJ N
versus NN N
daily RB N
CDA NNP N
administration NN N
. . N

One CD N
hundred VBD N
patients NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
standard NN N
( ( N
CDA NNP N
0.14 CD N
mg/kg/day JJ N
day NN N
1-5 JJ N
[ NNP N
Arm NNP N
A NNP N
] NN N
) ) N
or CC N
experimental JJ N
treatment NN N
( ( N
CDA NNP N
0.14 CD N
mg/kg/day NN N
once RB N
weekly JJ N
for IN N
5 CD N
weeks NNS N
[ JJ N
Arm NNP N
B NNP N
] NN N
) ) N
. . N

The DT N
primary JJ N
endpoint NN N
was VBD N
average JJ N
leukocyte JJ N
count NN N
within IN N
6 CD N
weeks NNS N
from IN N
randomization NN N
. . N

Secondary JJ N
endpoints NNS N
included VBD N
response NN N
rates NNS N
, , N
other JJ N
acute JJ N
hematotoxicity NN N
, , N
acute JJ N
infection NN N
rate NN N
, , N
hospital NN N
admission NN N
, , N
remission NN N
duration NN N
, , N
event-free JJ N
, , N
and CC N
overall JJ N
survival NN N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
average JJ N
leukocyte JJ N
count NN N
. . N

Response JJ N
rate NN N
( ( N
complete JJ N
+ NNP N
partial JJ N
remission NN N
) ) N
at IN N
week NN N
10 CD N
was VBD N
78 CD N
% NN N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
64-88 CD N
% NN N
) ) N
in IN N
Arm NNP N
A NNP N
and CC N
68 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
54-80 CD N
% NN N
) ) N
in IN N
Arm NNP N
B NNP N
( ( N
p JJ N
= NNP N
0.13 CD N
) ) N
. . N

Best JJS N
response NN N
rates NNS N
during IN N
follow-up JJ N
were VBD N
identical JJ N
( ( N
86 CD N
% NN N
) ) N
in IN N
both DT N
arms NNS N
. . N

No DT N
significant JJ N
difference NN N
was VBD N
found VBN N
in IN N
the DT N
rate NN N
of IN N
grade NN N
3+4 CD N
leukocytopenia NN N
( ( N
94 CD N
% NN N
vs NN N
. . N

84 CD N
% NN N
) ) N
, , N
grade VBD N
3+4 CD N
neutropenia NN N
( ( N
90 CD N
% NN N
vs NN N
. . N

80 CD N
% NN N
) ) N
, , N
acute JJ N
infection NN N
( ( N
44 CD N
% NN N
vs NN N
. . N

40 CD N
% NN N
) ) N
, , N
hospitalization NN N
( ( N
38 CD N
% NN N
vs NN N
. . N

34 CD N
% NN N
) ) N
, , N
and CC N
erythrocyte JJ N
support NN N
( ( N
22 CD N
% NN N
vs NN N
. . N

30 CD N
% NN N
) ) N
within IN N
10 CD N
weeks NNS N
. . N

Overall JJ N
, , N
these DT N
findings NNS N
indicate VBP N
that IN N
there EX N
are VBP N
no DT N
apparent JJ N
advantages NNS N
in IN N
toxicity NN N
and CC N
efficacy NN N
by IN N
giving VBG N
CDA NNP N
weekly RB N
rather RB N
than IN N
daily RB N
. . N

-DOCSTART- -X- O O 16437191

Does VBZ N
an DT N
educational JJ N
leaflet NN N
improve VB N
self-reported JJ N
adherence NN N
to TO N
therapy VB N
in IN N
osteoporosis NN 4_p
? . N
The DT N
OPTIMA NNP N
study NN N
. . N

INTRODUCTION NNP N
Adherence NNP N
to TO N
treatment NN N
in IN N
osteoporosis NN N
remains VBZ N
poor JJ N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
effects NNS N
of IN N
an DT N
educational JJ N
leaflet NN N
on IN N
adherence NN N
to TO N
medication NN N
and CC N
to TO N
assess VB N
the DT N
association NN N
between IN N
adherence NN N
and CC N
health-related JJ N
quality NN N
of IN N
life NN N
( ( N
HRQOL NNP N
) ) N
. . N

METHODS CC N
A NNP N
naturalistic JJ N
, , N
observational JJ N
, , N
multi-center JJ N
, , N
prospective JJ N
study NN N
of IN N
12 CD N
months NNS N
' POS N
follow-up NN N
was VBD N
performed VBN N
. . N

Consecutive JJ N
post-menopausal JJ N
women NNS N
aged VBN N
50 CD N
years NNS N
to TO N
86 CD N
years NNS N
starting VBG N
treatment NN N
with IN N
raloxifene NN N
according VBG N
to TO N
daily JJ N
practice NN N
were VBD N
enrolled VBN N
from IN N
126 CD N
primary JJ N
care NN N
offices NNS N
in IN N
Spain NNP N
. . N

The DT N
women NNS N
were VBD N
assigned VBN N
to TO N
two CD N
study NN N
groups NNS N
. . N

Group NNP N
A NNP N
received VBD N
an DT N
educational JJ N
leaflet NN N
with IN N
general JJ N
information NN N
about IN N
osteoporosis NN N
; : N
group NN N
B NNP N
followed VBD N
current JJ N
practice NN N
. . N

To TO N
assess VB N
adherence NN N
to TO N
medication NN N
and CC N
HRQOL NNP N
, , N
the DT N
Morisky NNP N
test NN N
and CC N
the DT N
EuroQoL NNP N
questionnaire NN N
were VBD N
administered VBN N
. . N

A DT N
total NN N
of IN N
745 CD N
post-menopausal JJ N
women NNS N
( ( N
group NN N
A NNP N
, , N
n=366 RB N
; : N
group NN N
B NNP N
n=379 NN N
) ) N
, , N
with IN N
a DT N
mean JJ N
age NN N
of IN N
62 CD N
years NNS N
, , N
were VBD N
included VBN N
. . N

RESULTS NNP N
Most JJS N
patients NNS N
in IN N
both DT N
study NN N
groups NNS N
showed VBD N
high JJ N
adherence NN N
to TO N
raloxifene VB N
at IN N
the DT N
3-month JJ N
visit NN N
: : N
56.3 CD N
% NN N
vs JJ N
62.7 CD N
% NN N
for IN N
groups NNS N
A NNP N
and CC N
B NNP N
, , N
respectively RB N
; : N
this DT N
proportion NN N
at IN N
the DT N
12-month JJ N
visit NN N
was VBD N
47.4 CD N
% NN N
( ( N
P=0.15 NNP N
) ) N
and CC N
52.5 CD N
% NN N
( ( N
P=0.02 NNP N
) ) N
, , N
respectively RB N
. . N

At IN N
baseline NN N
, , N
" NNP N
pain/discomfort NN N
" NN N
was VBD N
the DT N
dimension NN N
showing VBG N
the DT N
highest JJS N
percentage NN N
of IN N
women NNS N
reporting VBG N
problems NNS N
: : N
86.4 CD N
% NN N
vs JJ N
83.2 CD N
% NN N
in IN N
groups NNS N
A NNP N
and CC N
B NNP N
, , N
respectively RB N
( ( N
P=0.22 NNP N
) ) N
. . N

HRQOL NNP N
improved VBN N
in IN N
both DT N
groups NNS N
throughout IN N
the DT N
study NN N
, , N
with IN N
an DT N
overall JJ N
mean JJ N
increment NN N
in IN N
the DT N
EuroQoL NNP N
visual JJ N
analog NN N
scale NN N
( ( N
EQ NNP N
VAS NNP N
) ) N
of IN N
9.2 CD N
at IN N
12 CD N
months NNS N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

Correlations NNS N
between IN N
adherence NN N
and CC N
HRQOL NNP N
were VBD N
weak JJ N
. . N

After IN N
receiving VBG N
an DT N
educational JJ N
leaflet NN N
, , N
young JJ N
post-menopausal JJ 4_p
women NNS N
suffering VBG N
osteoporosis NN N
did VBD N
not RB N
show VB N
improvement NN N
in IN N
adherence NN N
to TO N
therapy VB N
. . N

HRQOL NNP N
improved VBD N
at IN N
12-month JJ N
follow-up JJ N
under IN N
treatment NN N
. . N

CONCLUSION NNP N
No NNP N
consistent JJ N
correlation NN N
between IN N
adherence NN N
and CC N
HRQOL NNP N
was VBD N
found VBN N
. . N

-DOCSTART- -X- O O 21379582

Delayed VBN 4_p
perceptual JJ 4_p
awareness NN 4_p
in IN N
rapid JJ 4_p
perceptual JJ 4_p
decisions NNS 4_p
. . 4_p

The DT N
flourishing NN N
of IN N
studies NNS N
on IN N
the DT N
neural JJ N
correlates NNS N
of IN N
decision-making JJ N
calls NNS N
for IN N
an DT N
appraisal NN N
of IN N
the DT N
relation NN N
between IN N
perceptual JJ N
decisions NNS N
and CC N
conscious JJ N
perception NN N
. . N

By IN N
exploiting VBG N
the DT N
long JJ N
integration NN N
time NN N
of IN N
noisy JJ N
motion NN N
stimuli NN N
, , N
and CC N
by IN N
forcing VBG N
human JJ N
observers NNS N
to TO N
make VB N
difficult JJ N
speeded VBN N
decisions NNS N
-- : N
sometimes RB N
a DT N
blind JJ N
guess NN N
-- : N
about IN N
stimulus JJ N
direction NN N
, , N
we PRP N
traced VBD N
the DT N
temporal JJ N
buildup NN N
of IN N
motion NN N
discrimination NN N
capability NN N
and CC N
perceptual JJ N
awareness NN N
, , N
as IN N
assessed VBN N
trial NN N
by IN N
trial NN N
through IN N
direct JJ N
rating NN N
. . N

We PRP N
found VBD N
that IN N
both DT N
increased VBN N
gradually RB N
with IN N
motion NN N
coherence NN N
and CC N
viewing NN N
time NN N
, , N
but CC N
discrimination NN N
was VBD N
systematically RB N
leading JJ N
awareness NN N
, , N
reaching VBG N
a DT N
plateau NN N
much RB N
earlier RBR N
. . N

Sensitivity NNP N
and CC N
criterion NN N
changes NNS N
contributed VBD N
jointly RB N
to TO N
the DT N
slow JJ N
buildup NN N
of IN N
perceptual JJ N
awareness NN N
. . N

It PRP N
made VBD N
no DT N
difference NN N
whether IN N
motion NN N
discrimination NN N
was VBD N
accomplished VBN N
by IN N
saccades NNS N
or CC N
verbal JJ N
responses NNS N
. . N

These DT N
findings NNS N
suggest VBP N
that IN N
perceptual JJ N
awareness NN N
emerges VBZ N
on IN N
the DT N
top NN N
of IN N
a DT N
developing NN N
or CC N
even RB N
mature VBP N
perceptual JJ N
decision NN N
. . N

We PRP N
argue VBP N
that IN N
the DT N
middle JJ N
temporal JJ N
( ( N
MT NNP N
) ) N
cortical JJ N
region NN N
does VBZ N
not RB N
confer VB N
us PRP N
the DT N
full JJ N
phenomenic JJ N
depth NN N
of IN N
motion NN N
perception NN N
, , N
although IN N
it PRP N
may MD N
represent VB N
a DT N
precursor NN N
stage NN N
in IN N
building VBG N
our PRP$ N
subjective JJ N
sense NN N
of IN N
visual JJ N
motion NN N
. . N

-DOCSTART- -X- O O 10682031

[ JJ N
Administration NNP N
of IN N
tobramycin JJ N
aerosols NNS N
in IN N
patients NNS 4_p
with IN 4_p
nosocomial JJ 4_p
pneumonia NN 4_p
: : N
a DT N
preliminary JJ N
study NN N
] NNP N
. . N

OBJECTIVE CC N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
assess VB N
renal JJ N
and CC N
respiratory JJ N
tolerance NN N
of IN N
aerosolized JJ N
tobramycin NN N
in IN N
intubated JJ 4_p
and CC 4_p
mechanically RB 4_p
ventilated JJ 4_p
patients NNS 4_p
with IN N
nosocomial JJ 4_p
pneumonia NN 4_p
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
This DT N
was VBD N
a DT N
multicenter NN N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo NN N
controlled VBD N
study NN N
. . N

Thirty-eight NNP N
mechanically RB 4_p
ventilated VBD 4_p
patients NNS 4_p
with IN 4_p
documented JJ 4_p
nosocomial JJ 4_p
pneumonia NN 4_p
were VBD N
included VBN N
. . N

Patients NNS N
treated VBD N
with IN N
intravenous JJ N
betalactam NNS N
and CC N
tobramycin NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
receive VB N
aerosolized VBN N
tobramycin NN N
( ( N
6 CD N
mg/kg/day NN N
, , N
n JJ N
= NNP N
21 CD N
) ) N
or CC N
placebo NN N
( ( N
n JJ N
= NNP N
17 CD N
) ) N
. . N

The DT N
aerosol NN N
was VBD N
administered VBN N
via IN N
a DT N
pneumatic JJ N
nebulizer NN N
once RB N
a DT N
day NN N
for IN N
5 CD N
days NNS N
. . N

RESULTS NNP N
Respiratory NNP N
tolerance NN N
was VBD N
good JJ N
in IN N
all DT N
but CC N
two CD N
patients NNS N
. . N

No DT N
acute JJ N
renal JJ N
failure NN N
occurred VBD N
. . N

By IN N
day NN N
10 CD N
, , N
7 CD N
patients NNS N
in IN N
the DT N
tobramycin NN N
group NN N
( ( N
35 CD N
% NN N
) ) N
had VBD N
been VBN N
extubated VBN N
versus NN N
3 CD N
in IN N
the DT N
placebo NN N
group NN N
( ( N
18.5 CD N
% NN N
, , N
p NN N
= NNP N
0.18 CD N
) ) N
. . N

By IN N
day NN N
28 CD N
, , N
6 CD N
patients NNS N
had VBD N
died VBN N
( ( N
2 CD N
in IN N
the DT N
tobramycin NN N
group NN N
and CC N
4 CD N
in IN N
the DT N
placebo NN N
group NN N
, , N
p VBP N
= RB N
0.23 CD N
) ) N
. . N

CONCLUSION NNP N
Aerosolized NNP N
tobramycin NN N
was VBD N
well RB N
tolerated VBN N
in IN N
ventilated JJ 4_p
patients NNS 4_p
with IN 4_p
documented JJ 4_p
nosocomial JJ 4_p
pneumonia NN 4_p
. . N

-DOCSTART- -X- O O 16181530

[ JJ N
Effect NNP N
of IN N
Yufeining VBG N
on IN N
induced JJ N
sputum JJ N
interleukin-8 NN N
in IN N
patients NNS N
with IN N
chronic JJ 4_p
obstructive JJ 4_p
pulmonary JJ 4_p
disease NN 4_p
at IN N
the DT N
stable JJ 4_p
phase NN 4_p
] NNP N
. . N

OBJECTIVE NNP N
To TO N
evaluate VB N
the DT N
effect NN N
of IN N
Yufeining NNP N
, , N
a DT N
traditional JJ N
Chinese JJ N
medicine NN N
, , N
on IN N
induced JJ N
sputum NN N
interleukin-8 JJ N
( ( N
IL-8 NNP N
) ) N
in IN N
patients NNS N
with IN N
chronic JJ 4_p
obstructive JJ 4_p
pulmonary JJ 4_p
disease NN 4_p
( ( 4_p
COPD NNP 4_p
) ) 4_p
at IN N
the DT N
stable JJ 4_p
phase NN 4_p
. . N

METHODS NNP N
Thirty-six JJ N
patients NNS N
with IN N
COPD NNP 4_p
were VBD N
divided VBN N
into IN N
trial NN N
group NN N
( ( N
18 CD N
cases NNS N
) ) N
and CC N
control NN N
group NN N
( ( N
18 CD N
cases NNS N
) ) N
randomly RB N
. . N

The DT N
trial NN N
group NN N
was VBD N
treated VBN N
with IN N
Yufeining VBG N
pills NNS N
taken VBN N
orally RB N
for IN N
half PDT N
a DT N
year NN N
; : N
the DT N
control NN N
group NN N
was VBD N
not RB N
given VBN N
any DT N
medicine NN N
. . N

Routine NNP N
lung NN N
function NN N
was VBD N
recorded VBN N
before IN N
and CC N
after IN N
treatment NN N
. . N

Total JJ N
cell NN N
count NN N
( ( N
TCC NNP N
) ) N
, , N
differential JJ N
cell NN N
counts NNS N
( ( N
DCCs NNP N
) ) N
and CC N
IL-8 NNP N
in IN N
induced JJ N
sputum NN N
were VBD N
determined VBN N
at IN N
the DT N
baseline NN N
and CC N
6 CD N
months NNS N
later RB N
. . N

RESULTS VB N
The DT N
indices NNS N
of IN N
lung NN N
function NN N
improved VBD N
significantly RB N
after IN N
6 CD N
months NNS N
' POS N
treatment NN N
in IN N
trial NN N
group NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
; : N
TCC NNP N
and CC N
absolute JJ N
neutrophil NN N
count NN N
decreased VBD N
significantly RB N
compared VBN N
with IN N
baseline NN N
in IN N
the DT N
trial NN N
group NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
; : N
Sputum NNP N
IL-8 NNP N
concentration NN N
dropped VBD N
significantly RB N
after IN N
6 CD N
months NNS N
' POS N
treatment NN N
, , N
from IN N
a DT N
mean NN N
of IN N
5.216 CD N
+/- JJ N
2.914 CD N
microg/L NN N
to TO N
4.222 CD N
+/- JJ N
2.140 CD N
microg/L NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

There EX N
were VBD N
insignificant JJ N
changes NNS N
in IN N
the DT N
parameters NNS N
in IN N
the DT N
control NN N
group NN N
between IN N
baseline NN N
and CC N
6 CD N
months NNS N
later RB N
. . N

CONCLUSION NNP N
Yufeining NNP N
could MD N
improve VB N
lung NN N
function NN N
, , N
decrease NN N
sputum NN N
TCC NNP N
, , N
absolute JJ N
neutrophil NN N
count NN N
and CC N
IL-8 NNP N
concentration NN N
, , N
and CC N
relieve VB N
airway NN N
inflammation NN N
in IN N
patients NNS N
with IN N
COPD NNP 4_p
in IN N
the DT N
stable JJ N
phase NN N
. . N

-DOCSTART- -X- O O 11710599

Absence NN N
of IN N
cervical JJ N
radiation NN N
myelitis NN N
after IN N
hyperfractionated VBN N
radiation NN N
therapy NN N
with IN N
and CC N
without IN N
concurrent JJ N
chemotherapy NN N
for IN N
locally RB 4_p
advanced JJ 4_p
, , 4_p
unresectable JJ 4_p
, , 4_p
nonmetastatic JJ 4_p
squamous JJ 4_p
cell NN 4_p
carcinoma NN 4_p
of IN 4_p
the DT 4_p
head NN 4_p
and CC 4_p
neck NN 4_p
. . N

PURPOSE NNP N
To TO N
evaluate VB N
the DT N
risk NN N
of IN N
developing VBG N
radiation NN N
myelitis NN N
after IN N
a DT N
cervical JJ N
spinal NN N
cord NN N
dose NN N
of IN N
50.6 CD N
Gy NNP N
given VBN N
via IN N
1.1 CD N
Gy NNP N
b.i.d NN N
. . N

fractionation NN N
during IN N
a DT N
prospective JJ N
, , N
randomised JJ N
trial NN N
of IN N
hyperfractionated JJ N
radiation NN N
therapy NN N
( ( N
HFX NNP N
RT NNP N
) ) N
to TO N
a DT N
total JJ N
dose NN N
of IN N
77 CD N
Gy NNP N
given VBN N
in IN N
70 CD N
fractions NNS N
of IN N
1.1 CD N
Gy NNP N
b.i.d. NN N
, , N
with IN N
and CC N
without IN N
concurrent JJ N
low-dose JJ N
, , N
daily JJ N
cisplatin NN N
( ( N
CDDP NNP N
) ) N
for IN N
head NN 4_p
and CC 4_p
neck NN 4_p
cancer NN 4_p
. . N

METHODS NNP N
Of IN N
130 CD N
patients NNS N
with IN N
locally RB N
advanced VBN N
, , N
unresectable JJ N
, , N
nonmetastatic JJ N
squamous JJ N
cell NN N
carcinoma NN N
of IN N
the DT N
head NN N
and CC N
neck NN N
( ( N
SCC NNP N
H NNP N
& CC N
N NNP N
) ) N
who WP N
entered VBD N
a DT N
prospective JJ N
, , N
randomised JJ N
trial NN N
, , N
101 CD N
patients NNS N
received VBD N
50.6 CD N
Gy NNP N
to TO N
a DT N
portion NN N
of IN N
their PRP$ N
spinal JJ N
cord NN N
and CC N
survived VBD N
> NNS N
1 CD N
year NN N
following VBG N
the DT N
beginning NN N
of IN N
therapy NN N
. . N

Forty-five JJ N
patients NNS N
were VBD N
treated VBN N
with IN N
HFX NNP N
RT NNP N
alone RB N
and CC N
fifty-six JJ N
patients NNS N
also RB N
received VBD N
CDDP NNP N
. . N

RESULTS NNP N
None NN N
of IN N
these DT N
101 CD N
patients NNS N
developed VBD N
cervical JJ N
radiation NN N
myelitis NN N
. . N

Therefore RB N
, , N
it PRP N
was VBD N
not RB N
possible JJ N
to TO N
investigate VB N
the DT N
influence NN N
of IN N
potentially RB N
contributing VBG N
factors NNS N
on IN N
the DT N
occurrence NN N
of IN N
radiation NN N
myelitis NN N
, , N
such JJ N
as IN N
interfraction NN N
interval NN N
, , N
cord NN N
length NN N
, , N
and CC N
administration NN N
of IN N
concurrent JJ N
CDDP NNP N
. . N

CONCLUSIONS NNP N
Given NNP N
the DT N
increasing VBG N
number NN N
of IN N
studies NNS N
with IN N
both DT N
altered VBN N
fractionated VBN N
regimens NNS N
and CC N
concurrent JJ N
radio-chemotherapy NN N
in IN N
SCC NNP N
H NNP N
& CC N
N NNP N
, , N
new JJ N
studies NNS N
with IN N
more JJR N
patients NNS N
are VBP N
needed VBN N
to TO N
gain VB N
better JJR N
insight NN N
into IN N
the DT N
risks NNS N
of IN N
developing VBG N
cervical JJ N
radiation NN N
myelitis NN N
. . N

-DOCSTART- -X- O O 26746121

Efficacy NN N
of IN N
Low-Dose NNP N
Buspirone NNP N
for IN N
Restricted NNP N
and CC N
Repetitive NNP N
Behavior NNP N
in IN N
Young NNP N
Children NNP N
with IN N
Autism NNP 4_p
Spectrum NNP 4_p
Disorder NNP 4_p
: : N
A DT N
Randomized NNP N
Trial NNP N
. . N

OBJECTIVES NNP N
To TO N
determine VB N
safety NN N
and CC N
efficacy NN N
of IN N
the DT N
5HT1A CD N
serotonin NN N
partial JJ N
agonist NN N
buspirone NN N
on IN N
core NN N
autism NN N
and CC N
associated JJ N
features NNS N
in IN N
children NNS N
with IN N
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
( ( 4_p
ASD NNP 4_p
) ) 4_p
. . N

STUDY NNP N
DESIGN NNP N
Children NNP N
2-6 CD N
years NNS N
of IN N
age NN N
with IN N
ASD NNP 4_p
( ( N
N NNP N
= NNP N
166 CD N
) ) N
were VBD N
randomized VBN N
to TO N
receive VB N
placebo NN N
or CC N
2.5 CD N
or CC N
5.0 CD N
mg NN N
of IN N
buspirone NN N
twice JJ N
daily RB N
. . N

The DT N
primary JJ N
objective NN N
was VBD N
to TO N
evaluate VB N
the DT N
effects NNS N
of IN N
24 CD N
weeks NNS N
of IN N
buspirone NN N
on IN N
the DT N
Autism NNP N
Diagnostic NNP N
Observation NNP N
Schedule NNP N
( ( N
ADOS NNP N
) ) N
Composite NNP N
Total NNP N
Score NNP N
. . N

Secondary JJ N
objectives NNS N
included VBD N
evaluating VBG N
the DT N
effects NNS N
of IN N
buspirone NN N
on IN N
social JJ N
competence NN N
, , N
repetitive JJ N
behaviors NNS N
, , N
language NN N
, , N
sensory JJ N
dysfunction NN N
, , N
and CC N
anxiety NN N
and CC N
to TO N
assess VB N
side JJ N
effects NNS N
. . N

Positron NNP N
emission NN N
tomography NN N
measures NNS N
of IN N
tryptophan NN N
metabolism NN N
and CC N
blood NN N
serotonin NN N
concentrations NNS N
were VBD N
assessed VBN N
as IN N
predictors NNS N
of IN N
buspirone NN N
efficacy NN N
. . N

RESULTS NNP N
There EX N
was VBD N
no DT N
difference NN N
in IN N
the DT N
ADOS NNP N
Composite NNP N
Total NNP N
Score NNP N
between IN N
baseline NN N
and CC N
24 CD N
weeks NNS N
among IN N
the DT N
3 CD N
treatment NN N
groups NNS N
( ( N
P NNP N
= NNP N
.400 NNP N
) ) N
; : N
however RB N
, , N
the DT N
ADOS NNP N
Restricted NNP N
and CC N
Repetitive NNP N
Behavior NNP N
score NN N
showed VBD N
a DT N
time-by-treatment JJ N
effect NN N
( ( N
P NNP N
= NNP N
.006 NNP N
) ) N
; : N
the DT N
2.5-mg JJ N
buspirone NN N
group NN N
showed VBD N
significant JJ N
improvement NN N
( ( N
P NNP N
= NNP N
.003 NNP N
) ) N
, , N
whereas JJ N
placebo NN N
and CC N
5.0-mg JJ N
buspirone NN N
groups NNS N
showed VBD N
no DT N
change NN N
. . N

Children NNP N
in IN N
the DT N
2.5-mg JJ N
buspirone NN N
group NN N
were VBD N
more RBR N
likely JJ N
to TO N
improve VB N
if IN N
they PRP N
had VBD N
fewer JJR N
foci NN N
of IN N
increased JJ N
brain NN N
tryptophan NN N
metabolism NN N
on IN N
positron NN N
emission NN N
tomography NN N
( ( N
P NNP N
= NNP N
.018 NNP N
) ) N
or CC N
if IN N
they PRP N
showed VBD N
normal JJ N
levels NNS N
of IN N
blood NN N
serotonin NN N
( ( N
P NNP N
= NNP N
.044 NNP N
) ) N
. . N

Adverse JJ N
events NNS N
did VBD N
not RB N
differ VB N
significantly RB N
among IN N
treatment NN N
groups NNS N
. . N

CONCLUSIONS NNP N
Treatment NNP N
with IN N
2.5 CD N
mg NNS N
of IN N
buspirone NN N
in IN N
young JJ N
children NNS N
with IN N
ASD NNP 4_p
might MD N
be VB N
a DT N
useful JJ N
adjunct JJ N
therapy NN N
to TO N
target VB N
restrictive JJ N
and CC N
repetitive JJ N
behaviors NNS N
in IN N
conjunction NN N
with IN N
behavioral JJ N
interventions NNS N
. . N

TRIAL NNP N
REGISTRATION NNP N
ClinicalTrials.gov NNP N
: : N
NCT00873509 NN N
. . N

-DOCSTART- -X- O O 1562431

Slotted VBN N
versus IN N
non-slotted JJ N
locked JJ N
intramedullary JJ N
nailing NN N
for IN N
femoral JJ N
shaft NN N
fractures NNS N
. . N

Experimentally RB N
, , N
two CD N
slotted VBD N
nails NNS N
, , N
the DT N
Grosse-Kempf NNP N
nail NN N
and CC N
the DT N
AO/ASIF NNP N
universal JJ N
femoral JJ N
nail NN N
, , N
were VBD N
compared VBN N
to TO N
the DT N
non-slotted JJ N
Grosse-Kempf NNP N
nail NN N
and CC N
control NN N
bone NN N
using VBG N
a DT N
cadaver JJ 4_p
femoral JJ 4_p
osteotomy NN 4_p
. . N

The DT N
stiffnesses NNS N
and CC N
strengths NNS N
of IN N
the DT N
osteotomies NNS N
fixed VBN N
with IN N
slotted JJ N
nails NNS N
in IN N
10-30 JJ N
degrees NNS N
torsion NN N
were VBD N
6-8 CD N
% NN N
and CC N
the DT N
values NNS N
of IN N
non-slotted JJ N
nails NNS N
40 CD N
% NN N
of IN N
control NN N
bone NN N
. . N

The DT N
maximal JJ N
moments NNS N
were VBD N
14-18 CD N
% NN N
and CC N
48 CD N
% NN N
, , N
respectively RB N
. . N

In IN N
the DT N
" NNP N
clinical JJ N
range NN N
" NN N
of IN N
torsion NN N
, , N
the DT N
implant-bone JJ N
construct NN N
never RB N
failed VBD N
or CC N
was VBD N
deformed VBN N
. . N

Clinically NNP N
, , N
46 CD N
femoral JJ 4_p
shaft NN 4_p
fractures NNS 4_p
were VBD N
randomized VBN N
to TO N
treatment NN N
with IN N
Gross-Kempf NNP N
nails NNS N
, , N
24 CD N
with IN N
slotted VBN 4_p
nails NNS 4_p
and CC N
22 CD N
with IN N
non-slotted JJ 4_p
nails NNS 4_p
. . N

Four CD N
complications NNS N
in IN N
the DT N
slotted JJ N
nail NN N
group NN N
and CC N
three CD N
in IN N
the DT N
non-slotted JJ N
nail NN N
group NN N
were VBD N
considered VBN N
to TO N
be VB N
independent JJ N
of IN N
the DT N
choice NN N
of IN N
nail NN N
and CC N
did VBD N
not RB N
affect VB N
the DT N
end NN N
result NN N
. . N

Three CD N
splinterings NNS N
of IN N
the DT N
distal JJ N
fragment NN N
, , N
one CD N
resulting NN N
in IN N
a DT N
change NN N
of IN N
the DT N
osteosynthesis NN N
implant NN N
to TO N
a DT N
condylar JJ N
plate NN N
, , N
were VBD N
considered VBN N
to TO N
result VB N
from IN N
the DT N
high JJ N
stiffness NN N
of IN N
the DT N
non-slotted JJ N
nail NN N
. . N

Osteosynthesis NN N
of IN N
femoral JJ N
shaft NN N
fractures NNS N
using VBG N
slotted VBN N
nails NNS N
has VBZ N
not RB N
resulted VBN N
in IN N
healing VBG N
disturbances NNS N
, , N
which WDT N
could MD N
be VB N
accounted VBN N
for IN N
by IN N
the DT N
high JJ N
torsional JJ N
elasticity NN N
of IN N
the DT N
nail NN N
; : N
there RB N
seems VBZ N
to TO N
be VB N
no DT N
indication NN N
for IN N
high-stiffness NN N
nails NNS N
in IN N
femoral JJ 4_p
fractures NNS 4_p
. . N

-DOCSTART- -X- O O 18678578

Local JJ N
delivery NN N
of IN N
a DT N
recombinant NN N
adenoassociated VBN N
vector NN N
containing VBG N
a DT N
tumour JJ N
necrosis NN N
factor NN N
alpha IN N
antagonist JJ N
gene NN N
in IN N
inflammatory JJ N
arthritis NN N
: : N
a DT N
phase NN N
1 CD N
dose-escalation NN N
safety NN N
and CC N
tolerability NN N
study NN N
. . N

OBJECTIVE NNP N
To TO N
examine VB N
the DT N
safety NN N
and CC N
tolerability NN N
of IN N
a DT N
single JJ N
intra-articular JJ N
injection NN N
of IN N
rAAV2-TNFR NN N
: : N
Fc NNP N
, , N
an DT N
adenoassociated JJ N
virus NN N
serotype NN N
2 CD N
vector NN N
containing VBG N
the DT N
cDNA NN N
for IN N
the DT N
human JJ N
tumour JJ N
necrosis NN N
factor-immunoglobulin JJ N
Fc NNP N
fusion NN N
gene NN N
( ( N
tgAAC94 NN N
) ) N
, , N
in IN N
subjects NNS N
with IN N
inflammatory JJ N
arthritis NN N
. . N

METHODS NNP N
In IN N
a DT N
double-blind JJ N
, , N
placebo-controlled JJ N
, , N
phase JJ N
1 CD N
, , N
dose-escalation NN N
study NN N
, , N
15 CD N
subjects NNS N
with IN N
inflammatory JJ N
arthritis NN N
( ( N
14 CD N
with IN N
rheumatoid JJ N
arthritis NN N
and CC N
1 CD N
with IN N
ankylosing VBG N
spondylitis NN N
) ) N
not RB N
receiving VBG N
tumour JJ N
necrosis NN N
factor NN N
alpha NN N
( ( N
TNFalpha NNP N
) ) N
inhibitors NNS N
with IN N
persistent JJ N
moderate NN N
( ( N
grade JJ N
2 CD N
) ) N
or CC N
severe JJ N
( ( N
grade JJ N
3 CD N
) ) N
swelling NN N
in IN N
a DT N
target NN N
joint NN N
due JJ N
to TO N
inflammatory JJ N
arthritis NN N
received VBD N
a DT N
single JJ N
intra-articular JJ N
injection NN N
of IN N
rAAV2-TNFR NN N
: : N
Fc NN N
at IN N
1 CD N
x JJ N
10 CD N
( ( N
10 CD N
) ) N
( ( N
n JJ N
= NNP N
5 CD N
) ) N
or CC N
1 CD N
x JJ N
10 CD N
( ( N
11 CD N
) ) N
( ( N
n JJ N
= NNP N
6 CD N
) ) N
DNase NNP N
resistant JJ N
particles NNS N
per IN N
ml NN N
joint NN N
volume NN N
or CC N
placebo NN N
( ( N
n JJ N
= NNP N
4 CD N
) ) N
into IN N
a DT N
knee NN N
( ( N
n JJ N
= NNP N
14 CD N
) ) N
or CC N
ankle NN N
( ( N
n JJ N
= NNP N
1 CD N
) ) N
. . N

Safety NN N
was VBD N
assessed VBN N
through IN N
adverse JJ N
event NN N
monitoring NN N
. . N

As IN N
a DT N
secondary JJ N
objective NN N
, , N
changes NNS N
in IN N
injected JJ N
joint NN N
tenderness NN N
and CC N
swelling VBG N
scores NNS N
, , N
each DT N
measured VBN N
on IN N
a DT N
four-point JJ N
scale NN N
, , N
were VBD N
evaluated VBN N
. . N

RESULTS NNP N
Intra-articular JJ N
injections NNS N
of IN N
rAAV2-TNFR NN N
: : N
Fc NN N
were VBD N
well RB N
tolerated VBN N
with IN N
no DT N
major JJ N
safety NN N
issues NNS N
. . N

One CD N
event NN N
, , N
mild JJ N
knee NN N
pruritus NN N
, , N
was VBD N
considered VBN N
probably RB N
related VBN N
. . N

Synovial JJ N
fluid NN N
TNFR NNP N
: : N
Fc NNP N
protein NN N
was VBD N
not RB N
detected VBN N
( ( N
nor CC N
expected VBN N
) ) N
at IN N
the DT N
doses NNS N
used VBN N
. . N

At IN N
12 CD N
weeks NNS N
after IN N
injection NN N
, , N
a DT N
two-point JJ N
decrease NN N
in IN N
swelling VBG N
was VBD N
noted VBN N
in IN N
2/11 CD N
and CC N
2/4 CD N
subjects NNS N
injected VBN N
with IN N
rAAV2-TNFR NN N
: : N
Fc NNP N
and CC N
placebo NN N
, , N
respectively RB N
. . N

CONCLUSION VB N
A DT N
single JJ N
dose NN N
of IN N
intra-articular JJ N
rAAV2-TNFR NN N
: : N
Fc CD N
appears VBZ N
to TO N
be VB N
safe JJ N
and CC N
well RB N
tolerated VBN N
in IN N
subjects NNS N
without IN N
concurrent JJ N
systemic JJ N
TNFalpha NNP N
antagonist NN N
use NN N
. . N

It PRP N
is VBZ N
thus RB N
feasible JJ N
to TO N
proceed VB N
with IN N
larger JJR N
trials NNS N
to TO N
further JJ N
test NN N
the DT N
safety NN N
and CC N
efficacy NN N
of IN N
local JJ N
TNFR NNP N
: : N
Fc NNP N
gene NN N
transfer NN N
as IN N
a DT N
therapeutic JJ N
modality NN N
for IN N
patients NNS N
with IN N
inflammatory JJ N
arthritis NN N
. . N

-DOCSTART- -X- O O 9278836

Active JJ N
warming NN N
, , N
not RB N
passive JJ N
heat NN N
retention NN N
, , N
maintains VBZ N
normothermia JJ N
during IN N
combined JJ N
epidural-general JJ N
anesthesia NN N
for IN N
hip NN N
and CC N
knee NN N
arthroplasty NN 4_p
. . N

STUDY NNP N
OBJECTIVE NNP N
to TO N
compare VB N
passive JJ N
heat NN N
retention NN N
by IN N
low-flow JJ N
anesthesia NN N
, , N
alone RB N
and CC N
with IN N
additional JJ N
thermal JJ N
insulation NN N
by IN N
reflective JJ N
blankets NNS N
, , N
with IN N
forced-air JJ N
warming VBG N
preventing VBG N
intraoperative JJ N
hypothermia NN N
during IN N
combined JJ N
epidural-general JJ N
anesthesia NN N
. . N

DESIGN NNP N
Randomized NNP N
, , N
controlled VBD N
study NN N
. . N

SETTING NNP N
Inpatient NNP N
anesthesia NN N
at IN N
a DT N
university NN N
department NN N
of IN N
orthopedic JJ N
surgery NN N
. . N

PATIENTS CC N
30 CD N
ASA NNP N
physical JJ N
status NN N
I PRP N
and CC N
II NNP N
patients NNS N
, , N
who WP N
were VBD N
scheduled VBN N
for IN N
elective JJ N
hip NN N
or CC N
knee VB N
arthroplasty JJ N
and CC N
were VBD N
free JJ N
from IN N
systemic JJ 4_p
disease NN 4_p
. . 4_p

INTERVENTIONS JJ N
Patients NNPS N
received VBD N
epidural JJ N
block NN N
up RB N
to TO N
T10 NNP N
by IN N
alkalinized JJ N
lidocaine JJ N
2 CD N
% NN N
, , N
and CC N
then RB N
were VBD N
administered VBN N
standard JJ N
general JJ N
anesthesia NN N
by IN N
means NNS N
of IN N
low-flow JJ N
rebreathing NN N
system NN N
( ( N
fresh JJ N
gas NN N
flow NN N
= VBD N
1 CD N
L/min NNP N
) ) N
. . N

All DT N
procedures NNS N
started VBD N
between IN N
8 CD N
and CC N
10 CD N
AM NNP N
, , N
and CC N
operating NN N
room NN N
( ( N
OR NNP N
) ) N
temperature NN N
was VBD N
maintained VBN N
between IN N
21 CD N
degrees NNS N
and CC N
23 CD N
degrees NNS N
C NNP N
, , N
with IN N
relative JJ N
humidity NN N
ranging VBG N
between IN N
40 CD N
% NN N
and CC N
45 CD N
% NN N
. . N

For IN N
heat NN N
retention NN N
or CC N
warming VBG N
therapy NN N
, , N
patients NNS N
received VBD N
either RB N
low-flow JJ N
anesthesia NN N
only RB N
( ( N
control NN N
, , N
n JJ N
= NNP N
10 CD N
) ) N
, , N
low-flow JJ N
anesthesia NN N
with IN N
additional JJ N
reflective JJ N
blankets NNS N
( ( N
blanket NN N
, , N
n JJ N
= NNP N
10 CD N
) ) N
, , N
or CC N
low-flow JJ N
anesthesia NN N
with IN N
active JJ N
forced-air JJ N
warming NN N
( ( N
forced-air JJ N
, , N
n JJ N
= NNP N
10 CD N
) ) N
. . N

Tympanic JJ N
temperature NN N
was VBD N
measured VBN N
at IN N
OR NNP N
arrival NN N
( ( N
baseline NN N
) ) N
; : N
immediately RB N
following VBG N
general JJ N
anesthesia JJ N
induction NN N
; : N
30 CD N
, , N
60 CD N
, , N
90 CD N
, , N
and CC N
120 CD N
minutes NNS N
from IN N
general JJ N
anesthesia NN N
induction NN N
; : N
and CC N
at IN N
the DT N
end NN N
of IN N
surgery NN N
. . N

MEASUREMENTS NNP N
AND CC N
MAIN NNP N
RESULTS NNP N
Duration NNP N
of IN N
anesthesia NN N
, , N
invasiveness NN N
of IN N
surgery NN N
, , N
and CC N
baseline NN N
core NN N
temperature NN N
were VBD N
similar JJ N
in IN N
the DT N
three CD N
groups NNS N
. . N

Core NNP N
temperature NN N
decreased VBN N
in IN N
all PDT N
the DT N
three CD N
groups NNS N
30 CD N
minutes NNS N
after IN N
general JJ N
anesthesia NN N
induction NN N
compared VBN N
with IN N
baseline NN N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
; : N
afterwards NNS N
, , N
it PRP N
progressively RB N
decreased VBD N
in IN N
the DT N
control NN N
and CC N
blankets NNS N
groups NNS N
( ( N
p JJ N
= NNP N
0.004 CD N
) ) N
, , N
with IN N
a DT N
reduction NN N
from IN N
baseline NN N
values NNS N
measured VBN N
at IN N
the DT N
end NN N
of IN N
surgery NN N
of IN N
2.0 CD N
degrees NNS N
C NNP N
and CC N
1.6 CD N
degrees NNS N
C NNP N
, , N
respectively RB N
. . N

In IN N
the DT N
forced-air JJ N
group NN N
, , N
after IN N
the DT N
initial JJ N
significant JJ N
decrease NN N
( ( N
p JJ N
= $ N
0.01 CD N
vs. FW N
baseline NN N
) ) N
, , N
core JJ N
temperature NN N
progressively RB N
increased VBD N
to TO N
35.8 CD N
+/- JJ N
0.6 CD N
degrees NNS N
C NNP N
, , N
which WDT N
was VBD N
similar JJ N
to TO N
preoperative VB N
values NNS N
and CC N
significantly RB N
higher JJR N
than IN N
either CC N
the DT N
control NN N
or CC N
blankets NNS N
groups NNS N
( ( N
p JJ N
= NNP N
0.004 CD N
) ) N
. . N

CONCLUSIONS NNP N
During IN N
combined VBN N
epidural-general JJ N
anesthesia NN N
for IN N
elective JJ N
hip NN N
and CC N
knee NN N
arthroplasty NN N
, , N
passive JJ N
heat NN N
retention NN N
by IN N
means NNS N
of IN N
low-flow JJ N
anesthesia NN N
alone RB N
and CC N
in IN N
combination NN N
with IN N
reflective JJ N
blankets NNS N
is VBZ N
ineffective JJ N
in IN N
maintaining VBG N
intraoperative JJ N
normothermia NN N
and CC N
definitely RB N
inferior JJ N
to TO N
active JJ N
forced-air JJ N
warning NN N
. . N

-DOCSTART- -X- O O 9718870

Combined VBN N
modality NN N
therapy NN N
in IN N
advanced JJ N
Hodgkin NNP N
's POS N
disease NN N
: : N
a DT N
report NN N
on IN N
218 CD N
patients NNS N
with IN N
a DT N
median JJ N
follow-up NN N
of IN N
eight CD N
years NNS N
. . N

BACKGROUND NNP N
AND CC N
OBJECTIVE NNP N
This DT N
study NN N
was VBD N
designed VBN N
to TO N
evaluate VB N
the DT N
efficacy NN N
and CC N
toxicity NN N
of IN N
monthly JJ N
alternating VBG N
ABVD/MOPP NNP N
compared VBN N
to TO N
ABVD/OPP NNP N
regimens NNS N
in IN N
patients NNS N
with IN N
advanced JJ 4_p
stage NN 4_p
Hodgkin NNP 4_p
's POS 4_p
disease NN 4_p
( ( 4_p
HD NNP 4_p
) ) 4_p
, , N
as RB N
well RB N
as IN N
in IN N
early JJ 4_p
stage NN 4_p
patients NNS 4_p
with IN 4_p
systemic JJ 4_p
symptoms NNS 4_p
and/or VBP 4_p
bulky JJ 4_p
disease NN 4_p
. . N

DESIGN NNP N
AND NNP N
METHODS NNP N
218 CD N
patients NNS N
with IN N
previously RB N
untreated VBN N
HD NNP 4_p
entered VBD N
this DT N
study NN N
: : N
106 CD N
patients NNS N
in IN N
arm NN 4_p
A NNP 4_p
( ( 4_p
ABVD/MOPP NNP 4_p
) ) N
and CC N
112 CD N
in IN N
arm NN 4_p
B NNP 4_p
( ( 4_p
ABVD/OPP NNP 4_p
) ) 4_p
. . 4_p

Patients NNPS N
received VBD N
eight CD N
courses NNS N
of IN N
one CD N
of IN N
the DT N
two CD N
regimens NNS N
after IN N
stratification NN N
according VBG N
to TO N
the DT N
stage NN N
. . N

Patients NNS N
in IN N
complete JJ N
remission NN N
( ( N
CR NNP N
) ) N
received VBD N
20 CD N
Gy NNP N
to TO N
the DT N
involved JJ N
field NN N
and CC N
40 CD N
Gy NNP N
to TO N
the DT N
spleen NN N
. . N

The DT N
actuarial JJ N
survival NN N
curves NNS N
were VBD N
performed VBN N
according VBG N
to TO N
Kaplan NNP N
and CC N
Meier NNP N
. . N

RESULTS NNP N
No NNP N
statistically RB N
significant JJ N
differences NNS N
were VBD N
observed VBN N
between IN N
the DT N
two CD N
arms NNS N
in IN N
terms NNS N
of IN N
CR NNP N
rate NN N
and CC N
toxicity NN N
. . N

However RB N
, , N
analysis NN N
of IN N
total JJ N
relapses NNS N
revealed VBD N
that IN N
patients NNS N
treated VBN N
with IN N
ABVD/OPP NNP N
had VBD N
a DT N
significantly RB N
higher JJR N
likelihood NN N
of IN N
achieving VBG N
a DT N
second JJ N
CR NNP N
compared VBN N
to TO N
patients NNS N
who WP N
entered VBD N
the DT N
ABVD/MOPP NNP 4_p
arm NN 4_p
. . N

INTERPRETATION NNP N
AND CC N
CONCLUSIONS NNP N
Both NNP N
schemes NNS N
of IN N
chemotherapy NN N
followed VBN N
by IN N
radiotherapy NN N
produce VBP N
high JJ N
percentages NNS N
of IN N
CR NNP N
, , N
low JJ N
risk NN N
of IN N
relapse NN N
and CC N
an DT N
acceptable JJ N
toxicity NN N
. . N

-DOCSTART- -X- O O 24132766

Comparison NNP N
of IN N
three CD N
software NN N
systems NNS N
for IN N
semi-automatic JJ N
volumetry NN N
of IN N
pulmonary JJ N
nodules NNS N
on IN N
baseline NN N
and CC N
follow-up JJ N
CT NNP N
examinations NNS N
. . N

BACKGROUND NNP N
Early JJ N
diagnosis NN N
of IN N
lung NN N
cancer NN N
in IN N
a DT N
treatable JJ N
stage NN N
is VBZ N
the DT N
main JJ N
purpose NN N
of IN N
lung NN 4_p
cancer NN 4_p
screening NN N
by IN N
computed VBN N
tomography NN N
( ( N
CT NNP N
) ) N
. . N

Accurate NNP N
three-dimensional JJ N
size NN N
and CC N
growth NN N
measurements NNS N
are VBP N
essential JJ N
to TO N
assess VB N
the DT N
risk NN N
of IN N
malignancy NN N
. . N

Nodule NNP N
volumes NNS N
can MD N
be VB N
calculated VBN N
by IN N
using VBG N
semi-automated JJ N
volumetric JJ N
software NN N
. . N

Systematic JJ N
differences NNS N
in IN N
volume NN N
measurements NNS N
between IN N
packages NNS N
could MD N
influence VB N
nodule JJ N
categorization NN N
and CC N
management NN N
decisions NNS N
. . N

PURPOSE NNP N
To TO N
compare VB N
volumetric JJ N
measurements NNS N
of IN N
solid JJ N
pulmonary JJ N
nodules NNS N
on IN N
baseline NN N
and CC N
follow-up JJ N
CT NNP N
scans NNS N
as RB N
well RB N
as IN N
the DT N
volume NN N
doubling VBG N
time NN N
( ( N
VDT NNP N
) ) N
for IN N
three CD N
software NN N
packages NNS N
. . N

MATERIAL NNP N
AND CC N
METHODS NNP N
From IN N
a DT N
Lung NNP 4_p
Cancer NNP 4_p
Screening NNP N
study NN N
( ( N
NELSON NNP N
) ) N
, , N
50 CD N
participants NNS N
were VBD N
randomly RB N
selected VBN N
from IN N
the DT N
baseline NN N
round NN N
. . N

The DT N
study NN N
population NN N
comprised VBD N
participants NNS N
with IN N
at IN N
least JJS N
one CD N
pulmonary JJ N
nodule NN N
at IN N
the DT N
baseline NN N
and CC N
consecutive JJ N
CT NNP N
examination NN N
. . N

The DT N
volume NN N
of IN N
each DT N
nodule NN N
was VBD N
determined VBN N
for IN N
both DT N
time NN N
points NNS N
using VBG N
three CD N
semi-automated JJ N
software NN N
packages NNS N
( ( N
P1 NNP N
, , N
P2 NNP N
, , N
and CC N
P3 NNP N
) ) N
. . N

Manual JJ N
modification NN N
was VBD N
performed VBN N
when WRB N
automated JJ N
assessment NN N
was VBD N
visually RB N
inaccurate JJ N
. . N

VDT NNP N
was VBD N
calculated VBN N
to TO N
evaluate VB N
nodule JJ N
growth NN N
. . N

Volume NN N
, , N
VDT NNP N
, , N
and CC N
nodule JJ N
management NN N
were VBD N
compared VBN N
for IN N
the DT N
three CD N
software NN N
packages NNS N
, , N
using VBG N
P1 NNP N
as IN N
the DT N
reference NN N
standard NN N
. . N

RESULTS NNP N
In IN N
25 CD N
participants NNS N
, , N
147 CD N
nodules NNS N
were VBD N
present JJ N
on IN N
both DT N
examinations NNS N
( ( N
volume NN N
: : N
12.0-436.6 JJ N
mm NN N
( ( N
3 CD N
) ) N
) ) N
. . N

Initial JJ N
segmentation NN N
at IN N
baseline NN N
was VBD N
evaluated VBN N
to TO N
be VB N
satisfactory JJ N
in IN N
93.9 CD N
% NN N
of IN N
nodules NNS N
for IN N
P1 NNP N
, , N
84.4 CD N
% NN N
for IN N
P2 NNP N
, , N
and CC N
88.4 CD N
% NN N
for IN N
P3 NNP N
. . N

Significant NNP N
difference NN N
was VBD N
found VBN N
in IN N
measured JJ N
volume NN N
between IN N
P1 NNP N
and CC N
the DT N
other JJ N
two CD N
packages NNS N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

P2 NNP N
overestimated VBD N
the DT N
volume NN N
by IN N
38 CD N
± JJ N
24 CD N
% NN N
, , N
and CC N
P3 NNP N
by IN N
50 CD N
± JJ N
22 CD N
% NN N
. . N

At IN N
baseline NN N
, , N
there EX N
was VBD N
consensus NN N
on IN N
nodule JJ N
size NN N
categorization NN N
in IN N
80 CD N
% NN N
for IN N
P1 NNP N
& CC N
P2 NNP N
and CC N
74 CD N
% NN N
for IN N
P1 NNP N
& CC N
P3 NNP N
. . N

At IN N
follow-up JJ N
, , N
consensus NN N
on IN N
VDT NNP N
categorization NN N
was VBD N
present JJ N
in IN N
47 CD N
% NN N
for IN N
P1 NNP N
& CC N
P2 NNP N
and CC N
44 CD N
% NN N
for IN N
P1 NNP N
& CC N
P3 NNP N
. . N

CONCLUSION NNP N
Software NNP N
packages VBZ N
for IN N
lung NN N
nodule NN N
evaluation NN N
yield NN N
significant JJ N
differences NNS N
in IN N
volumetric JJ N
measurements NNS N
and CC N
VDT NNP N
. . N

This DT N
variation NN N
affects VBZ N
the DT N
classification NN N
of IN N
lung NN N
nodules NNS N
, , N
especially RB N
in IN N
follow-up JJ N
examinations NNS N
. . N

-DOCSTART- -X- O O 12037693

The DT N
impact NN N
of IN N
angiotensin NN N
II NNP N
receptor NN N
blockade NN N
and CC N
the DT N
DASH NNP N
diet NN N
on IN N
markers NNS N
of IN N
endogenous JJ N
fibrinolysis NN N
. . N

Hypertension NNP N
is VBZ N
associated VBN N
with IN N
impaired JJ N
fibrinolysis NN N
. . N

Both DT N
angiotensin JJ N
receptor NN N
blockers NNS N
( ( N
ARB NNP N
) ) N
and CC N
the DT N
DASH NNP N
( ( N
Dietary NNP N
Approaches NNP N
to TO N
Stop NNP N
Hypertension NNP N
) ) N
diet VBP N
effectively RB N
lower JJR N
blood NN N
pressure NN N
in IN N
hypertensive JJ 4_p
patients NNS 4_p
. . 4_p

Some DT N
evidence NN N
suggests VBZ N
that IN N
treatment NN N
with IN N
ARBs NNP N
could MD N
increase VB N
fibrinolysis NN N
, , N
however RB N
, , N
data NNS N
is VBZ N
conflicting VBG N
. . N

The DT N
impact NN N
of IN N
the DT N
DASH NNP N
diet NN N
on IN N
fibrinolytic JJ N
parameters NNS N
is VBZ N
not RB N
known VBN N
. . N

Fifty-five JJ N
hypertensive JJ N
participants NNS N
( ( N
35 CD N
African-American JJ N
, , N
20 CD N
white JJ N
) ) N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
8 CD N
weeks NNS N
of IN N
either CC N
a DT N
control NN N
diet NN N
or CC N
the DT N
DASH NNP N
diet NN N
. . N

The DT N
diets NNS N
did VBD N
not RB N
differ VB N
in IN N
sodium NN N
content NN N
( ( N
approximately RB N
3 CD N
g/day NN N
) ) N
. . N

Within IN N
each DT N
diet NN N
, , N
individuals NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
losartan NN N
or CC N
placebo NN N
for IN N
4 CD N
weeks NNS N
in IN N
double-blind NN N
, , N
cross-over JJ N
fashion NN N
. . N

Tissue NNP N
plasminogen NN N
activator NN N
( ( N
t-PA JJ N
) ) N
antigen NN N
, , N
t-PA JJ N
activity NN N
, , N
plasminogen NN N
activator NN N
inhibitor-1 JJ N
( ( N
PAI-1 NNP N
) ) N
activity NN N
and CC N
plasma NN N
renin NN N
activity NN N
( ( N
PRA NNP N
) ) N
were VBD N
measured VBN N
at IN N
the DT N
end NN N
of IN N
a DT N
2-week JJ N
run-in JJ N
period NN N
on IN N
the DT N
control NN N
diet NN N
and CC N
after IN N
each DT N
treatment NN N
period NN N
. . N

The DT N
DASH NNP N
diet NN N
did VBD N
not RB N
affect JJ N
markers NNS N
of IN N
fibrinolysis NN N
. . N

Losartan NNP N
significantly RB N
lowered VBD N
t-PA JJ N
antigen NN N
levels NNS N
( ( N
-1.8 NNP N
ng/mL RB N
, , N
P NNP N
= NNP N
0.045 CD N
) ) N
, , N
but CC N
had VBD N
no DT N
effect NN N
on IN N
t-PA NN N
or CC N
PAI-1 JJ N
activities NNS N
. . N

This DT N
effect NN N
was VBD N
more RBR N
pronounced JJ N
in IN N
whites NNS N
( ( N
-4.1 JJ N
ng/mL NN N
( ( N
P NNP N
= NNP N
0.003 CD N
) ) N
) ) N
compared VBN N
with IN N
African-Americans NNP N
( ( N
-0.3 JJ N
ng/mL NN N
( ( N
P NNP N
= NNP N
0.7 CD N
) ) N
, , N
P-interaction NNP N
= NNP N
0.03 CD N
) ) N
. . N

Results NNS N
were VBD N
not RB N
materially RB N
affected VBN N
by IN N
adjustment NN N
for IN N
basline NN N
values NNS N
or CC N
changes NNS N
in IN N
blood NN N
pressure NN N
. . N

This DT N
study NN N
demonstrates VBZ N
that IN N
losartan JJ N
reduces NNS N
t-PA JJ N
antigen NN N
levels NNS N
in IN N
white JJ 4_p
, , 4_p
but CC 4_p
not RB 4_p
African-American JJ 4_p
hypertensive JJ 4_p
individuals NNS 4_p
. . 4_p

In IN N
contrast NN N
, , N
the DT N
DASH NNP N
diet NN N
had VBD N
no DT N
significant JJ N
effect NN N
on IN N
markers NNS N
of IN N
fibrinolysis NN N
in IN N
whites NNS N
or CC N
African-Americans NNS N
. . N

-DOCSTART- -X- O O 11422660

Nicotine NNP N
infusion NN N
acutely RB N
impairs JJ N
insulin NN N
sensitivity NN N
in IN N
type NN 4_p
2 CD 4_p
diabetic JJ 4_p
patients NNS 4_p
but CC N
not RB N
in IN N
healthy JJ N
subjects NNS N
. . N

OBJECTIVES IN N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
examine VB N
if IN N
an DT N
acute JJ N
nicotine NN N
infusion NN N
alters NNS N
insulin VBP N
sensitivity NN N
to TO N
a DT N
similar JJ N
degree NN N
in IN N
type NN N
2 CD N
diabetic JJ N
patients NNS N
as IN N
in IN N
healthy JJ N
control NN N
subjects NNS N
. . N

DESIGN NNP N
. . N

Double-blind NNP N
, , N
cross-over NN N
, , N
placebo-controlled JJ N
, , N
randomized JJ N
experimental NN N
study NN N
. . N

Nicotine NNP N
0.3 CD N
microg NN N
kg-1 JJ N
min NN N
( ( N
-1 JJ N
) ) N
or CC N
NaCl NNP N
was VBD N
infused VBN N
( ( N
2 CD N
h NN N
) ) N
during IN N
a DT N
euglycaemic JJ N
hyperinsulinaemic NN N
clamp NN N
( ( N
4 CD N
h NN N
) ) N
to TO N
assess VB N
insulin JJ N
sensitivity NN N
. . N

SETTING NNP N
University NNP N
research NN N
laboratory NN N
. . N

SUBJECTS NNP N
Six NNP N
male NN N
and CC N
female JJ N
type NN N
2 CD N
diabetic JJ N
patients NNS N
[ JJ N
DM2 NNP N
; : N
age NN N
54 CD N
+/- JJ N
10 CD N
( ( N
mean JJ N
+/- NNP N
SD NNP N
) ) N
years NNS N
; : N
body NN N
mass NN N
index NN N
( ( N
BMI NNP N
) ) N
25.6 CD N
+/- JJ N
2.9 CD N
kg NN N
m NN N
( ( N
-2 NNP N
) ) N
] NN N
treated VBN N
with IN N
diet JJ N
or CC N
one CD N
oral JJ N
hypoglycaemic JJ N
agent NN N
and CC N
six CD N
age- JJ N
and CC N
BMI-matched JJ N
control NN N
subjects NNS N
( ( N
Ctr NNP N
) ) N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURE NNP N
Insulin NNP N
sensitivity NN N
( ( N
rate NN N
of IN N
glucose JJ N
infusion NN N
per IN N
kg NN N
fat JJ N
free JJ N
body NN N
mass NN N
and CC N
minute NN N
) ) N
, , N
nicotine JJ N
and CC N
free JJ N
fatty NN N
acid NN N
( ( N
FFA NNP N
) ) N
levels NNS N
, , N
pulse NN N
rate NN N
and CC N
blood NN N
pressure NN N
. . N

RESULTS VB N
The DT N
infusions NNS N
produced VBD N
similar JJ N
nicotine NN N
levels NNS N
in IN N
both DT N
groups NNS N
. . N

In IN N
the DT N
absence NN N
of IN N
nicotine NN N
, , N
DM2 NNP N
were VBD N
more JJR N
insulin NN N
resistant NN N
than IN N
Ctr NNP N
( ( N
6.7 CD N
+/- JJ N
0.4 CD N
vs. FW N
10.9 CD N
+/- JJ N
0.3 CD N
mg JJ N
kg-1 JJ N
LBM NNP N
min NN N
( ( N
-1 NNP N
) ) N
, , N
respectively RB N
; : N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

This DT N
insulin NN N
resistance NN N
was VBD N
further RBR N
aggravated VBN N
by IN N
the DT N
nicotine JJ N
infusion NN N
in IN N
DM2 NNP N
but CC N
not RB N
in IN N
Ctr NNP N
( ( N
4.6 CD N
+/- JJ N
0.3 CD N
vs. FW N
10.9 CD N
+/- JJ N
0.3 CD N
mg NN N
kg NN N
( ( N
-1 NNP N
) ) N
LBM NNP N
min NN N
( ( N
-1 NNP N
) ) N
; : N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

Only RB N
minor JJ N
differences NNS N
were VBD N
seen VBN N
in IN N
FFA NNP N
levels NNS N
, , N
pulse NN N
rates NNS N
and CC N
blood NN N
pressure NN N
. . N

CONCLUSIONS NN N
At IN N
this DT N
low JJ N
infusion NN N
rate NN N
, , N
nicotine NN N
aggravated VBD N
the DT N
insulin NN N
resistance NN N
in IN N
DM2 NNP N
but CC N
not RB N
in IN N
Ctr NNP N
. . N

This DT N
finding NN N
may MD N
be VB N
because IN N
of IN N
the DT N
( ( N
dysmetabolic JJ N
) ) N
diabetic JJ N
state NN N
per IN N
se NN N
or CC N
to TO N
an DT N
increased VBN N
sensitivity NN N
to TO N
environmental JJ N
factors NNS N
associated VBN N
with IN N
a DT N
genetic JJ N
predisposition NN N
for IN N
type NN N
2 CD N
diabetes NNS N
. . N

These DT N
results NNS N
show VBP N
that IN N
diabetic JJ N
subjects NNS N
are VBP N
particularly RB N
susceptible JJ N
to TO N
the DT N
detrimental JJ N
effects NNS N
of IN N
nicotine NN N
. . N

-DOCSTART- -X- O O 18333888

The DT N
dipeptidyl JJ N
peptidase-4 JJ N
inhibitor NN N
PHX1149 NNP N
improves VBZ N
blood NN N
glucose NN N
control NN N
in IN N
patients NNS N
with IN N
type JJ 4_p
2 CD 4_p
diabetes NNS 4_p
mellitus RB 4_p
. . N

AIM NNP N
To TO N
determine VB N
the DT N
efficacy NN N
and CC N
tolerability NN N
of IN N
PHX1149 NNP N
, , N
a DT N
novel JJ N
dipeptidyl NN N
peptidase-4 NN N
( ( N
DPP4 NNP N
) ) N
inhibitor NN N
, , N
in IN N
patients NNS N
with IN N
type JJ 4_p
2 CD 4_p
diabetes NNS 4_p
. . N

METHODS NNP N
This DT N
is VBZ N
a DT N
multicentre NN N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
, , N
4-week JJ N
study NN N
in IN N
patients NNS N
with IN N
type JJ 4_p
2 CD 4_p
diabetes NNS 4_p
with IN 4_p
suboptimal JJ 4_p
metabolic JJ 4_p
control NN 4_p
. . N

Patients NNS N
with IN N
a DT N
baseline NN 4_p
haemoglobin NN 4_p
A NNP 4_p
( ( 4_p
1c CD 4_p
) ) 4_p
( ( 4_p
HbA NNP 4_p
( ( 4_p
1c CD 4_p
) ) 4_p
) ) 4_p
of IN 4_p
7.3 CD 4_p
to TO 4_p
11.0 CD 4_p
% NN 4_p
were VBD N
randomized VBN N
1 CD N
: : N
1 CD N
: : N
1 CD N
: : N
1 CD N
to TO N
receive VB N
once-daily JJ N
oral JJ N
therapy NN N
with IN N
either DT N
PHX1149 NNP N
( ( N
100 CD N
, , N
200 CD N
or CC N
400 CD N
mg NN N
) ) N
or CC N
placebo NN N
; : N
patients NNS N
were VBD N
on IN N
a DT N
constant JJ N
background NN N
therapy NN N
of IN N
either DT N
metformin NN N
alone RB N
or CC N
metformin JJ N
plus CC N
a DT N
glitazone NN N
. . N

RESULTS NNP N
Treatment NNP N
with IN N
100 CD N
, , N
200 CD N
or CC N
400 CD N
mg NN N
of IN N
PHX1149 NNP N
significantly RB N
decreased VBD N
postprandial JJ N
glucose JJ N
area NN N
under IN N
the DT N
curve NN N
AUC NNP N
( ( N
0-2 JJ N
h NN N
) ) N
by IN N
approximately RB N
20 CD N
% NN N
( ( N
+0.11 JJ N
+/- JJ N
0.50 CD N
, , N
-2.08 VBD N
+/- JJ N
0.51 CD N
, , N
-1.73 VBD N
+/- JJ N
0.49 CD N
and CC N
-1.88 VB N
+/- JJ N
0.48 CD N
mmol/l NN N
x NN N
h NN N
, , N
respectively RB N
, , N
for IN N
placebo NN N
and CC N
100 CD N
, , N
200 CD N
and CC N
400 CD N
mg NN N
( ( N
p JJ N
= NN N
0.002 CD N
, , N
0.008 CD N
and CC N
0.004 CD N
vs. FW N
placebo NN N
) ) N
. . N

Postprandial JJ N
AUC NNP N
( ( N
0-2 JJ N
h NN N
) ) N
of IN N
intact JJ N
glucagon-like JJ N
peptide-1 NN N
, , N
the DT N
principal JJ N
mediator NN N
of IN N
the DT N
biological JJ N
effects NNS N
of IN N
DPP4 NNP N
inhibitors NNS N
, , N
was VBD N
increased VBN N
by IN N
3.90 CD N
+/- JJ N
2.83 CD N
, , N
11.63 CD N
+/- JJ N
2.86 CD N
, , N
16.42 CD N
+/- JJ N
2.72 CD N
and CC N
15.75 CD N
+/- JJ N
2.71 CD N
pmol/l NN N
x NN N
h NN N
, , N
respectively RB N
, , N
for IN N
placebo NN N
and CC N
100 CD N
, , N
200 CD N
and CC N
400 CD N
mg NN N
( ( N
p JJ N
= NN N
0.053 CD N
, , N
0.001 CD N
and CC N
0.002 CD N
vs. FW N
placebo NN N
) ) N
. . N

Mean JJ N
HbA NNP N
( ( N
1c CD N
) ) N
was VBD N
lower JJR N
in IN N
all DT N
dose JJ N
groups NNS N
; : N
the DT N
placebo-corrected JJ N
change NN N
in IN N
the DT N
groups NNS N
receiving VBG N
400 CD N
mg JJ N
PHX1149 NNP N
was VBD N
-0.28 VBN N
% NN N
( ( N
p JJ N
= NNP N
0.02 CD N
) ) N
. . N

DPP4 NNP N
inhibition NN N
on IN N
day NN N
28 CD N
was VBD N
53 CD N
, , N
73 CD N
and CC N
78 CD N
% NN N
at IN N
24 CD N
h NN N
postdose NN N
in IN N
the DT N
groups NNS N
receiving VBG N
100 CD N
, , N
200 CD N
and CC N
400 CD N
mg NN N
PHX1149 NNP N
, , N
respectively RB N
. . N

There EX N
were VBD N
no DT N
differences NNS N
in IN N
adverse JJ N
events NNS N
between IN N
PHX1149-treated NNP N
and CC N
placebo JJ N
subjects NNS N
. . N

CONCLUSIONS NNP N
Addition NNP N
of IN N
the DT N
DPP4 NNP N
inhibitor NN N
PHX1149 NNP N
to TO N
a DT N
stable JJ N
regimen NN N
of IN N
metformin NN N
or CC N
metformin NN N
plus CC N
a DT N
glitazone NN N
in IN N
patients NNS N
with IN N
type JJ 4_p
2 CD 4_p
diabetes NNS 4_p
was VBD N
well RB N
tolerated VBN N
and CC N
improved VBN N
blood NN N
glucose NN N
control NN N
. . N

-DOCSTART- -X- O O 15673801

Etanercept NNP N
plus CC N
standard JJ N
therapy NN N
for IN N
Wegener NNP N
's POS N
granulomatosis NN N
. . N

BACKGROUND IN N
The DT N
majority NN N
of IN N
patients NNS N
with IN N
Wegener NNP N
's POS N
granulomatosis NN N
have VBP N
disease NN N
flares NNS N
after IN N
conventional JJ N
medications NNS N
are VBP N
tapered VBN N
. . N

There EX N
is VBZ N
no DT N
consistently RB N
safe JJ N
, , N
effective JJ N
treatment NN N
for IN N
the DT N
maintenance NN N
of IN N
remission NN N
. . N

METHODS NNP N
We PRP N
conducted VBD N
a DT N
randomized VBN N
, , N
placebo-controlled JJ N
trial NN N
at IN N
eight CD N
centers NNS N
to TO N
evaluate VB N
etanercept NN N
for IN N
the DT N
maintenance NN N
of IN N
remission NN N
in IN N
180 CD N
patients NNS N
with IN N
Wegener NNP N
's POS N
granulomatosis NN N
. . N

The DT N
primary JJ N
outcome NN N
was VBD N
sustained VBN N
remission NN N
, , N
defined VBD N
as IN N
a DT N
Birmingham NNP N
Vasculitis NNP N
Activity NNP N
Score NNP N
for IN N
Wegener NNP N
's POS N
Granulomatosis NNP N
of IN N
0 CD N
for IN N
at IN N
least JJS N
six CD N
months NNS N
( ( N
scores NNS N
can MD N
range VB N
from IN N
0 CD N
to TO N
67 CD N
, , N
with IN N
higher JJR N
scores NNS N
indicating VBG N
more RBR N
active JJ N
disease NN N
) ) N
. . N

In IN N
addition NN N
to TO N
etanercept VB N
or CC N
placebo VB N
, , N
patients NNS N
received VBD N
standard JJ N
therapy NN N
( ( N
glucocorticoids JJ N
plus CC N
cyclophosphamide JJ N
or CC N
methotrexate NN N
) ) N
. . N

After IN N
remission NN N
, , N
standard JJ N
medications NNS N
were VBD N
tapered VBN N
according VBG N
to TO N
the DT N
protocol NN N
. . N

RESULTS VB N
The DT N
mean JJ N
follow-up NN N
for IN N
the DT N
overall JJ N
cohort NN N
was VBD N
27 CD N
months NNS N
. . N

Of IN N
the DT N
174 CD N
patients NNS N
who WP N
could MD N
be VB N
evaluated VBN N
, , N
126 CD N
( ( N
72.4 CD N
percent NN N
) ) N
had VBD N
a DT N
sustained VBN N
remission NN N
, , N
but CC N
only RB N
86 CD N
( ( N
49.4 CD N
percent NN N
) ) N
remained VBD N
in IN N
remission NN N
for IN N
the DT N
remainder NN N
of IN N
the DT N
trial NN N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
etanercept NN N
and CC N
control NN N
groups NNS N
in IN N
the DT N
rates NNS N
of IN N
sustained JJ N
remission NN N
( ( N
69.7 CD N
percent NN N
vs. FW N
75.3 CD N
percent NN N
, , N
P=0.39 NNP N
) ) N
, , N
sustained VBD N
periods NNS N
of IN N
low-level JJ N
disease NN N
activity NN N
( ( N
86.5 CD N
percent NN N
vs. FW N
90.6 CD N
percent NN N
, , N
P=0.32 NNP N
) ) N
, , N
or CC N
the DT N
time NN N
required VBN N
to TO N
achieve VB N
those DT N
measures NNS N
. . N

Disease NNP N
flares NNS N
were VBD N
common JJ N
in IN N
both DT N
groups NNS N
, , N
with IN N
118 CD N
flares NNS N
in IN N
the DT N
etanercept NN N
group NN N
( ( N
23 CD N
severe RB N
and CC N
95 CD N
limited VBN N
) ) N
and CC N
134 CD N
in IN N
the DT N
control NN N
group NN N
( ( N
25 CD N
severe RB N
and CC N
109 CD N
limited JJ N
) ) N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
etanercept NN N
and CC N
control NN N
groups NNS N
in IN N
the DT N
relative JJ N
risk NN N
of IN N
disease NN N
flares NNS N
per IN N
100 CD N
person-years NNS N
of IN N
follow-up NN N
( ( N
0.89 CD N
, , N
P=0.54 NNP N
) ) N
. . N

During IN N
the DT N
study NN N
, , N
56.2 CD N
percent NN N
of IN N
patients NNS N
in IN N
the DT N
etanercept NN N
group NN N
and CC N
57.1 CD N
percent NN N
of IN N
those DT N
in IN N
the DT N
control NN N
group NN N
had VBD N
at IN N
least JJS N
one CD N
severe JJ N
or CC N
life-threatening JJ N
adverse JJ N
event NN N
or CC N
died VBN N
( ( N
P=0.90 NNP N
) ) N
. . N

Solid JJ N
cancers NNS N
developed VBD N
in IN N
six CD N
patients NNS N
in IN N
the DT N
etanercept NN N
group NN N
, , N
as IN N
compared VBN N
with IN N
none NN N
in IN N
the DT N
control NN N
group NN N
( ( N
P=0.01 NNP N
) ) N
. . N

CONCLUSIONS NNP N
Etanercept NNP N
is VBZ N
not RB N
effective JJ N
for IN N
the DT N
maintenance NN N
of IN N
remission NN N
in IN N
patients NNS N
with IN N
Wegener NNP N
's POS N
granulomatosis NN N
. . N

Durable JJ N
remissions NNS N
were VBD N
achieved VBN N
in IN N
only RB N
a DT N
minority NN N
of IN N
the DT N
patients NNS N
, , N
and CC N
there RB N
was VBD N
a DT N
high JJ N
rate NN N
of IN N
treatment-related JJ N
complications NNS N
. . N

-DOCSTART- -X- O O 16293958

Efficacy NN N
of IN N
nebulized JJ N
flunisolide NN N
combined VBN N
with IN N
salbutamol NN N
and CC N
ipratropium NN N
bromide NN N
in IN N
stable JJ N
patients NNS N
with IN N
moderate-to-severe JJ 4_p
chronic JJ 4_p
obstructive JJ 4_p
pulmonary JJ 4_p
disease NN 4_p
. . N

BACKGROUND IN N
The DT N
efficacy NN N
of IN N
nebulized JJ N
corticosteroids NNS N
in IN N
the DT N
prevention NN N
of IN N
exacerbation NN N
of IN N
chronic JJ N
obstructive JJ N
pulmonary JJ N
disease NN N
( ( N
COPD NNP 4_p
) ) 4_p
has VBZ N
been VBN N
poorly RB N
studied VBN N
. . N

OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
efficacy NN N
and CC N
tolerability NN N
of IN N
nebulized JJ N
flunisolide NN N
( ( N
1 CD N
mg NN N
) ) N
+ VBZ N
salbutamol/ipratropium JJ N
bromide NN N
( ( N
1,875/375 CD N
microg NN N
) ) N
b.i.d NN N
. . N

in IN N
comparison NN N
with IN N
placebo NN N
+ NNP N
salbutamol/ipratropium NN N
bromide NN N
. . N

METHODS NNP N
This DT N
was VBD N
a DT N
randomized JJ N
, , N
parallel-group JJ N
, , N
double-blind JJ N
study NN N
on IN N
114 CD N
patients NNS N
with IN N
COPD NNP 4_p
of IN 4_p
moderate-to-severe JJ 4_p
degree NN 4_p
. . N

The DT N
main JJ N
outcome NN N
was VBD N
the DT N
frequency NN N
of IN N
severe JJ N
exacerbations NNS N
over IN N
a DT N
6-month JJ N
period NN N
. . N

Before IN N
and CC N
after IN N
treatment NN N
, , N
respiratory NN N
symptoms NNS N
, , N
forced VBD N
expiratory JJ N
volume NN N
in IN N
1 CD N
s NN N
( ( N
FEV NNP N
( ( N
1 CD N
) ) N
) ) N
, , N
shuttle JJ N
walking VBG N
test NN N
distance NN N
and CC N
St. NNP N
George NNP N
's POS N
Respiratory NNP N
Questionnaire NNP N
scores NNS N
were VBD N
evaluated VBN N
. . N

RESULTS VB N
The DT N
total JJ N
number NN N
of IN N
exacerbations NNS N
was VBD N
slightly RB N
lower JJR N
in IN N
the DT N
flunisolide NN N
group NN N
compared VBN N
to TO N
the DT N
placebo NN N
group NN N
( ( N
19 CD N
vs. FW N
34 CD N
, , N
p NN N
= NNP N
0.054 CD N
) ) N
; : N
the DT N
number NN N
of IN N
patients NNS N
experiencing VBG N
at IN N
least JJS N
one CD N
exacerbation NN N
during IN N
the DT N
study NN N
was VBD N
also RB N
decreased VBN N
( ( N
16 CD N
vs. FW N
26 CD N
, , N
p NN N
= NNP N
0.059 CD N
) ) N
. . N

In IN N
particular JJ N
, , N
type JJ N
3 CD N
Anthonisens NNP N
's POS N
exacerbations NNS N
were VBD N
significantly RB N
reduced VBN N
by IN N
flunisolide NN N
( ( N
p JJ N
= NNP N
0.044 CD N
) ) N
. . N

In IN N
the DT N
placebo NN N
group NN N
, , N
scores NNS N
were VBD N
higher JJR N
than IN N
in IN N
the DT N
flunisolide JJ N
group NN N
but CC N
nonsignificant NN N
for IN N
dyspnea NN N
, , N
cough NN N
, , N
sputum NN N
amount NN N
and CC N
purulence NN N
. . N

FEV NNP N
( ( N
1 CD N
) ) N
was VBD N
significantly RB N
increased VBN N
compared VBN N
to TO N
baseline VB N
in IN N
both DT N
groups NNS N
, , N
and CC N
the DT N
area NN N
under IN N
the DT N
FEV NNP N
( ( N
1 CD N
) ) N
-time NN N
curve NN N
during IN N
the DT N
6-month JJ N
period NN N
was VBD N
significantly RB N
greater JJR N
in IN N
the DT N
flunisolide NN N
group NN N
( ( N
5.2 CD N
+/- JJ N
10.6 CD N
vs. FW N
2.1 CD N
+/- JJ N
5.0 CD N
, , N
flunisolide RB N
vs. FW N
placebo NN N
, , N
respectively RB N
; : N
p VB N
= $ N
0.047 CD N
) ) N
. . N

For IN N
shuttle JJ N
walking VBG N
test NN N
distance NN N
and CC N
scores NNS N
of IN N
the DT N
St. NNP N
George NNP N
's POS N
Respiratory NNP N
Questionnaire NNP N
, , N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
baseline NN N
evaluation NN N
and CC N
the DT N
end NN N
of IN N
the DT N
study NN N
was VBD N
observed VBN N
in IN N
both DT N
groups NNS N
. . N

CONCLUSIONS NNP N
Nebulized NNP N
flunisolide NN N
is VBZ N
a DT N
good JJ N
alternative NN N
to TO N
other JJ N
inhaled JJ N
corticosteroids NNS N
when WRB N
added VBN N
to TO N
nebulized JJ N
salbutamol/ipratropium NN N
bromide NN N
in IN N
the DT N
long-term JJ N
treatment NN N
of IN N
moderate-to-severe JJ 4_p
COPD NNP 4_p
patients NNS N
. . N

-DOCSTART- -X- O O 20934759

The DT N
maximal JJ N
double JJ N
step NN N
length RB N
test NN N
can MD N
evaluate VB N
more RBR N
adequately RB N
the DT N
decrease NN N
of IN N
physical JJ N
function NN N
with IN N
age NN N
, , N
than IN N
the DT N
maximal JJ N
single JJ N
step NN N
length JJ N
test NN N
. . N

The DT N
maximal JJ N
double JJ N
step NN N
length NN N
( ( N
MDSL NNP N
) ) N
test NN N
is VBZ N
a DT N
modified JJ N
version NN N
of IN N
the DT N
maximal JJ N
step NN N
length NN N
( ( N
MSL NNP N
) ) N
test NN N
used VBN N
to TO N
evaluate VB N
the DT N
dynamic JJ N
balance NN N
related VBN N
to TO N
falls NNS N
in IN N
the DT N
elderly JJ N
. . N

Although IN N
this DT N
test NN N
can MD N
evaluate VB N
their PRP$ N
physical JJ N
function NN N
using VBG N
movements NNS N
similar JJ N
to TO N
daily JJ N
activities NNS N
as IN N
compared VBN N
to TO N
MSL NNP N
, , N
it PRP N
has VBZ N
not RB N
been VBN N
clarified VBN N
whether IN N
it PRP N
can MD N
adequately RB N
evaluate VB N
the DT N
activities NNS N
of IN N
daily JJ N
living NN N
( ( N
ADL NNP N
) ) N
abilities NNS N
of IN N
the DT N
elderly JJ N
, , N
as IN N
they PRP N
decrease VBP N
with IN N
age NN N
. . N

This DT N
study NN N
aimed VBD N
to TO N
examine VB N
the DT N
relationship NN N
between IN N
both DT N
MSL NNP N
and CC N
MDSL NNP N
on IN N
age NN N
and CC N
ADL NNP N
in IN N
elderly JJ N
subjects NNS N
. . N

Fifty-seven CD N
elderly JJ N
females NNS N
who WP N
live VBP N
independently RB N
( ( N
age NN N
74.8±5.6 CD N
years NNS N
) ) N
were VBD N
recruited VBN N
. . N

MSL NNP N
and CC N
MDSL NNP N
were VBD N
conducted VBN N
twice RB N
after IN N
completing VBG N
an DT N
ADL NNP N
questionnaire NN N
. . N

Intra-class JJ N
correlation NN N
coefficients NNS N
( ( N
ICCs NNP N
) ) N
of IN N
both DT N
tests NNS N
were VBD N
high JJ N
( ( N
for IN N
MSL NNP N
: : N
ICC=0.95 NNP N
, , N
for IN N
MDSL NNP N
: : N
ICC=0.81-0.82 NN N
) ) N
. . N

Age NNP N
and CC N
ADL NNP N
significantly RB N
correlated VBD N
to TO N
MDSL NNP N
( ( N
age NN N
: : N
r=-0.32-0.41 NN N
, , N
ADL NNP N
: : N
r=0.28-0.48 NN N
) ) N
, , N
but CC N
not RB N
to TO N
MSL NNP N
( ( N
age NN N
: : N
r=-0.19 NN N
, , N
ADL NNP N
: : N
r=0.15 NN N
) ) N
. . N

MDSL NNP N
has VBZ N
high JJ N
reliability NN N
as IN N
it PRP N
relates VBZ N
to TO N
age NN N
and CC N
ADL NNP N
. . N

It PRP N
may MD N
be VB N
more JJR N
useful JJ N
to TO N
evaluate VB N
ADL NNP N
required VBN N
for IN N
independent JJ N
living NN N
and CC N
prevent NN N
falls NNS N
in IN N
the DT N
elderly JJ N
better JJR N
than IN N
MSL NNP N
. . N

-DOCSTART- -X- O O 21869698

Symptomatic JJ N
and CC N
functional JJ N
improvement NN N
in IN N
employed NNS N
depressed JJ 4_p
patients NNS N
: : N
a DT N
double-blind JJ N
clinical JJ N
trial NN N
of IN N
desvenlafaxine NN N
versus NN N
placebo NN N
. . N

OBJECTIVE VB N
This DT N
is VBZ N
the DT N
first JJ N
study NN N
to TO N
assess VB N
the DT N
efficacy NN N
of IN N
desvenlafaxine NN N
( ( N
administered VBN N
as IN N
desvenlafaxine JJ N
succinate NN N
) ) N
for IN N
improving VBG N
depressive JJ N
symptoms NNS N
and CC N
functioning VBG N
exclusively RB N
in IN N
employed JJ N
patients NNS N
with IN N
major JJ 4_p
depressive JJ 4_p
disorder NN 4_p
( ( 4_p
MDD NNP 4_p
) ) 4_p
. . N

METHODS NNP N
Gainfully NNP N
employed VBD N
( ( N
≥20 NNP N
h/wk NN N
) ) N
male NN N
and CC N
female JJ N
outpatients NNS N
with IN N
MDD NNP N
were VBD N
randomly RB N
assigned VBN N
( ( N
2:1 CD N
ratio NN N
) ) N
to TO N
12 CD N
weeks NNS N
of IN N
double-blind JJ N
treatment NN N
with IN N
desvenlafaxine JJ N
50 CD N
mg/d NN N
or CC N
placebo NN N
. . N

Analysis NN N
of IN N
covariance NN N
was VBD N
used VBN N
to TO N
compare VB N
differences NNS N
in IN N
week NN N
12 CD N
adjusted VBN N
mean JJ N
changes NNS N
from IN N
baseline NN N
on IN N
the DT N
17-item JJ N
Hamilton NNP N
Depression NNP N
Rating NNP N
Scale NNP N
( ( N
HAM-D₁₇ NNP N
) ) N
( ( N
primary JJ N
outcome NN N
) ) N
and CC N
Sheehan NNP N
Disability NNP N
Scale NNP N
( ( N
SDS NNP N
) ) N
( ( N
key JJ N
secondary JJ N
outcome NN N
) ) N
in IN N
the DT N
intent-to-treat NN N
( ( N
ITT NNP N
) ) N
population NN N
. . N

A DT N
predefined JJ N
, , N
modified VBD N
ITT NNP N
population NN N
( ( N
ie JJ N
, , N
those DT N
in IN N
the DT N
ITT NNP N
population NN N
with IN N
baseline JJ N
HAM-D₁₇ NNP N
≥20 NN N
) ) N
was VBD N
also RB N
analyzed VBN N
. . N

Tolerability NNP N
was VBD N
assessed VBN N
by IN N
recording VBG N
adverse JJ N
events NNS N
and CC N
change NN N
on IN N
the DT N
Arizona NNP N
Sexual NNP N
Experience NNP N
Scale NNP N
. . N

RESULTS NNP N
Baseline NNP N
HAM-D₁₇ NNP N
scores NNS N
for IN N
desvenlafaxine NN N
( ( N
n JJ N
= NNP N
285 CD N
) ) N
and CC N
placebo NN N
( ( N
n JJ N
= NNP N
142 CD N
) ) N
were VBD N
22.0 CD N
and CC N
21.8 CD N
, , N
whereas NNS N
baseline VBP N
SDS NNP N
scores NNS N
were VBD N
19.8 CD N
and CC N
20.4 CD N
. . N

Adjusted VBN N
mean JJ N
differences NNS N
between IN N
desvenlafaxine NN N
and CC N
placebo NN N
were VBD N
2.1 CD N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
, , N
0.78-3.46 NNP N
; : N
P NNP N
= NNP N
0.002 CD N
) ) N
on IN N
the DT N
HAM-D₁₇ NNP N
and CC N
1.3 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
-0.09 NNP N
to TO N
2.76 CD N
; : N
P NNP N
= NNP N
0.067 CD N
) ) N
on IN N
the DT N
SDS NNP N
. . N

For IN N
the DT N
modified JJ N
ITT NNP N
sample NN N
, , N
desvenlafaxine NN N
( ( N
n JJ N
= NNP N
208 CD N
) ) N
and CC N
placebo NN N
( ( N
n JJ N
= NNP N
102 CD N
) ) N
, , N
baseline JJ N
HAM-D₁₇ JJ N
scores NNS N
were VBD N
23.8 CD N
and CC N
23.9 CD N
; : N
the DT N
SDS NNP N
baseline NN N
scores NNS N
were VBD N
20.1 CD N
and CC N
20.8 CD N
. . N

Mean JJ N
differences NNS N
were VBD N
2.6 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
0.93-4.22 NNP N
; : N
P NNP N
= NNP N
0.002 CD N
) ) N
on IN N
the DT N
HAM-D₁₇ NNP N
and CC N
2.1 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
0.36-3.76 NNP N
; : N
P NNP N
= NNP N
0.017 CD N
) ) N
on IN N
the DT N
SDS NNP N
. . N

Adverse JJ N
events NNS N
and CC N
Arizona NNP N
Sexual NNP N
Experience NNP N
Scale NNP N
scores NNS N
were VBD N
comparable JJ N
between IN N
groups NNS N
. . N

CONCLUSIONS NNP N
Desvenlafaxine NNP N
50 CD N
mg/d NN N
was VBD N
efficacious JJ N
for IN N
treating VBG N
MDD NNP N
in IN N
gainfully RB N
employed VBN N
adults NNS N
. . N

Between-group NNP N
differences NNS N
on IN N
the DT N
SDS NNP N
narrowly RB N
missed VBD N
statistical JJ N
significance NN N
in IN N
the DT N
ITT NNP N
population NN N
alone RB N
, , N
but CC N
the DT N
totality NN N
of IN N
data NNS N
suggests NNS N
functional JJ N
improvements NNS N
with IN N
active JJ N
treatment NN N
. . N

-DOCSTART- -X- O O 3884411

The DT N
treatment NN N
of IN N
senile JJ N
dementia NN N
associated VBN N
with IN N
cerebrovascular JJ N
insufficiency NN N
: : N
a DT N
comparative JJ N
study NN N
of IN N
buflomedil NN N
and CC N
dihydrogenated VBD N
ergot JJ N
alkaloids NNS N
. . N

Seventy-six JJ N
patients NNS N
took VBD N
part NN N
in IN N
a DT N
randomized JJ N
, , N
comparative JJ N
study NN N
of IN N
the DT N
efficacy NN N
of IN N
buflomedil NN N
hydrochloride NN N
and CC N
dihydrogenated VBD 4_p
ergot JJ N
alkaloids NNS N
in IN N
the DT N
treatment NN N
of IN N
senile JJ N
dementia NN N
associated VBN N
with IN N
cerebrovascular JJ N
insufficiency NN N
. . N

Efficacy NN N
was VBD N
assessed VBN N
by IN N
the DT N
patients NNS N
' POS N
performance NN N
in IN N
four CD N
psychometric JJ N
tests NNS N
. . N

The DT N
results NNS N
showed VBD N
that IN N
a DT N
trend NN N
in IN N
favour NN N
of IN N
the DT N
buflomedil NN N
group NN N
in IN N
three CD N
of IN N
the DT N
tests NNS N
became VBD N
statistically RB N
significant JJ N
in IN N
the DT N
fourth JJ N
. . N

Both DT N
drugs NNS N
appeared VBD N
to TO N
be VB N
safe JJ N
, , N
causing VBG N
no DT N
marked JJ N
adverse JJ N
reactions NNS N
. . N

In IN N
conclusion NN N
, , N
buflomedil NN N
is VBZ N
as IN N
effective JJ N
or CC N
more RBR N
effective JJ N
than IN N
dihydrogenated VBN N
ergot JJ N
alkaloids NNS N
in IN N
the DT N
treatment NN N
of IN N
senile JJ N
dementia NN N
associated VBN N
with IN N
cerebrovascular JJ N
insufficiency NN N
and CC N
could MD N
prove VB N
a DT N
valuable JJ N
addition NN N
to TO N
long-term JJ N
therapy NN N
if IN N
further JJ N
studies NNS N
support VBP N
the DT N
trend NN N
shown VBN N
in IN N
this DT N
study NN N
. . N

-DOCSTART- -X- O O 10735900

Use NNP N
of IN N
recombinant JJ N
human JJ N
granulocyte NN N
colony-stimulating NN N
factor NN N
to TO N
increase VB N
chemotherapy JJ N
dose-intensity NN N
: : N
a DT N
randomized JJ N
trial NN N
in IN N
very RB N
high-risk JJ N
childhood NN 4_p
acute NN 4_p
lymphoblastic JJ 4_p
leukemia NN 4_p
. . N

PURPOSE NNP N
To TO N
determine VB N
whether IN N
the DT N
use NN N
of IN N
a DT N
recombinant JJ N
human JJ N
granulocyte NN N
colony-stimulating NN N
factor NN N
( ( N
[ JJ N
G-CSF NNP N
] NNP N
lenogastrim NN N
) ) N
can MD N
increase VB N
the DT N
chemotherapy JJ N
dose-intensity NN N
( ( N
CDI NNP N
) ) N
delivered VBD N
during IN N
consolidation NN N
chemotherapy NN N
of IN N
childhood NN N
acute NN 4_p
lymphoblastic JJ 4_p
leukemia NN 4_p
( ( N
ALL DT 4_p
) ) N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
Sixty-seven NNP N
children NNS N
with IN N
very RB N
high-risk JJ N
ALL NNP N
were VBD N
randomized VBN N
( ( N
slow JJ N
early JJ N
response NN N
to TO N
therapy VB N
, , N
55 CD N
patients NNS N
; : N
translocation NN N
t NN N
( ( N
9 CD N
; : N
22 CD N
) ) N
or CC N
t NN N
( ( N
4 CD N
; : N
11 CD N
) ) N
, , N
12 CD N
patients NNS N
) ) N
. . N

Consolidation NNP N
consisted VBD N
of IN N
six CD N
courses NNS N
of IN N
chemotherapy NN N
; : N
the DT N
first JJ N
, , N
third JJ N
, , N
and CC N
fifth JJ N
courses NNS N
were VBD N
a DT N
combination NN N
of IN N
high-dose JJ N
cytarabine NN N
, , N
etoposide RB N
, , N
and CC N
dexamethasone NN N
( ( N
R3 NNP N
) ) N
, , N
whereas VBD N
the DT N
second JJ N
, , N
fourth JJ N
, , N
and CC N
sixth JJ N
courses NNS N
included VBD N
vincristine NN N
, , N
prednisone NN N
, , N
cyclophosphamide NN N
, , N
doxorubicin NN N
, , N
and CC N
methotrexate NN N
( ( N
COPADM NNP N
) ) N
. . N

G-CSF NNP N
was VBD N
given VBN N
after IN N
each DT N
course NN N
, , N
and CC N
the DT N
next JJ N
scheduled JJ N
course NN N
was VBD N
started VBN N
as RB N
soon RB N
as IN N
neutrophil JJ N
count NN N
was VBD N
> JJ N
1 CD N
x JJ N
10 CD N
( ( N
9 CD N
) ) N
/L NN N
and CC N
platelet NN N
count NN N
was VBD N
> JJ N
100 CD N
x JJ N
10 CD N
( ( N
9 CD N
) ) N
/L NN N
. . N

CDI NNP N
was VBD N
calculated VBN N
using VBG N
the DT N
interval NN N
from IN N
day NN N
1 CD N
of IN N
the DT N
first JJ N
course NN N
to TO N
hematologic VB N
recovery NN N
after IN N
the DT N
fifth JJ N
course NN N
( ( N
100 CD N
% NN N
CDI NNP N
= NNP N
105-day JJ N
interval NN N
) ) N
. . N

RESULTS NNP N
CDI NNP N
was VBD N
significantly RB N
increased VBN N
in IN N
the DT N
G-CSF NNP N
group NN N
compared VBN N
with IN N
the DT N
non-G-CSF JJ N
group NN N
( ( N
mean JJ N
+/- JJ N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
105 CD N
+/- JJ N
5 CD N
% NN N
v JJ N
91 CD N
+/- JJ N
4 CD N
% NN N
; : N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

This DT N
higher JJR N
intensity NN N
was VBD N
a DT N
result NN N
of IN N
shorter JJR N
post-R3 NN N
intervals NNS N
in IN N
the DT N
G-CSF NNP N
group NN N
, , N
whereas IN N
the DT N
post-COPADM JJ N
intervals NNS N
were VBD N
not RB N
statistically RB N
reduced VBN N
. . N

After IN N
the DT N
R3 NNP N
courses NNS N
, , N
the DT N
number NN N
of IN N
days NNS N
with IN N
fever NN N
and CC N
intravenous JJ N
antibiotics NNS N
and CC N
duration NN N
of IN N
hospitalization NN N
were VBD N
significantly RB N
decreased VBN N
by IN N
G-CSF NNP N
, , N
whereas JJ N
reductions NNS N
observed VBD N
after IN N
COPADM NNP N
were VBD N
not RB N
statistically RB N
significant JJ N
. . N

Duration NN N
of IN N
granulocytopenia NN N
was VBD N
reduced VBN N
in IN N
the DT N
G-CSF NNP N
group NN N
, , N
but CC N
thrombocytopenia NN N
was VBD N
prolonged VBN N
, , N
and CC N
the DT N
number NN N
of IN N
platelet NN N
transfusions NNS N
was VBD N
increased VBN N
. . N

Finally RB N
, , N
the DT N
3-year JJ N
probability NN N
of IN N
event-free JJ N
survival NN N
was VBD N
not RB N
different JJ N
between IN N
the DT N
two CD N
groups NNS N
. . N

CONCLUSION NNP N
G-CSF NNP N
can MD N
increase VB N
CDI NNP N
in IN N
high-risk JJ 4_p
childhood NN 4_p
ALL NNP 4_p
. . N

Its PRP$ N
effects NNS N
depend VBP N
on IN N
the DT N
chemotherapy NN N
regimen NNS N
given VBN N
before IN N
G-CSF NNP N
administration NN N
. . N

In IN N
our PRP$ N
study NN N
, , N
a DT N
higher JJR N
CDI NNP N
did VBD N
not RB N
improve VB N
disease NN N
control NN N
. . N

-DOCSTART- -X- O O 11069570

Probiotics NNS N
in IN N
the DT N
management NN N
of IN N
atopic NN 4_p
eczema NN 4_p
. . 4_p

BACKGROUND NNP N
Over IN N
the DT N
last JJ N
two CD N
decades IN N
the DT N
incidence NN N
of IN N
allergic JJ N
diseases NNS N
has VBZ N
increased VBN N
in IN N
industrialized JJ N
countries NNS N
, , N
and CC N
consequently RB N
new JJ N
approaches NNS N
have VBP N
to TO N
be VB N
explored VBN N
. . N

OBJECTIVE CC N
The DT N
potential NN N
of IN N
probiotics NNS N
to TO N
control VB N
allergic JJ 4_p
inflammation NN 4_p
at IN 4_p
an DT 4_p
early JJ 4_p
age NN 4_p
was VBD N
assessed VBN N
in IN N
a DT N
randomized JJ N
double-blind JJ N
placebo-controlled JJ N
study NN N
. . N

METHODS NNP N
A NNP N
total NN N
of IN N
27 CD N
infants NNS N
, , N
mean JJ N
age NN N
4.6 CD N
months NNS N
, , N
who WP N
manifested VBD N
atopic JJ N
eczema NN N
during IN N
exclusive JJ N
breast-feeding NN N
and CC N
who WP N
have VBP N
had VBN N
no DT N
exposure NN N
to TO N
any DT N
infant NN N
or CC N
substitute NN N
formula NN N
were VBD N
weaned VBN N
to TO N
probiotic-supplemented JJ N
, , N
Bifidobacterium NNP N
lactis VBZ N
Bb-12 NNP N
or CC N
Lactobacillus NNP N
strain VBP N
GG NNP N
( ( N
ATCC NNP N
53103 CD N
) ) N
, , N
extensively RB N
hydrolysed VBD N
whey JJ N
formulas NNS N
or CC N
to TO N
the DT N
same JJ N
formula NN N
without IN N
probiotics NNS N
. . N

The DT N
extent NN N
and CC N
severity NN N
of IN N
atopic NN N
eczema NN N
, , N
the DT N
growth NN N
and CC N
nutrition NN N
of IN N
infants NNS N
, , N
and CC N
concentrations NNS N
of IN N
circulating VBG N
cytokines/chemokines NNS N
and CC N
soluble JJ N
cell NN N
surface NN N
adhesion NN N
molecules NNS N
in IN N
serum NN N
and CC N
methyl-histamine NN N
and CC N
eosinophilic JJ N
protein NN N
X NN N
in IN N
urine JJ N
were VBD N
determined VBN N
. . N

RESULTS VB N
The DT N
SCORAD NNP N
score NN N
reflecting VBG N
the DT N
extent NN N
and CC N
severity NN N
of IN N
atopic NN N
eczema NN N
was VBD N
16 CD N
( ( N
7-25 JJ N
) ) N
during IN N
breast-feeding NN N
, , N
median JJ N
( ( N
interquartile JJ N
range NN N
) ) N
. . N

After IN N
2 CD N
months NNS N
, , N
a DT N
significant JJ N
improvement NN N
in IN N
skin JJ N
condition NN N
occurred VBD N
in IN N
patients NNS N
given VBN N
probiotic-supplemented JJ N
formulas NNS N
, , N
as IN N
compared VBN N
to TO N
the DT N
unsupplemented JJ N
group NN N
; : N
chi NNS N
( ( N
2 CD N
) ) N
= NN N
12.27 CD N
, , N
P NNP N
= VBZ N
0.002 CD N
. . N

SCORAD NNP N
decreased VBD N
in IN N
the DT N
Bifidobacterium NNP N
lactis VBZ N
Bb-12 NNP N
group NN N
to TO N
0 CD N
( ( N
0-3.8 NN N
) ) N
, , N
and CC N
in IN N
the DT N
Lactobacillus NNP N
GG NNP N
group NN N
to TO N
1 CD N
( ( N
0.1-8.7 NN N
) ) N
, , N
vs RB N
unsupplemented JJ N
13.4 CD N
( ( N
4.5-18.2 JJ N
) ) N
, , N
median JJ N
( ( N
interquartile JJ N
range NN N
) ) N
, , N
in IN N
parallel NN N
with IN N
a DT N
reduction NN N
in IN N
the DT N
concentration NN N
of IN N
soluble JJ N
CD4 NNP N
in IN N
serum NN N
and CC N
eosinophilic JJ N
protein NN N
X NN N
in IN N
urine JJ N
. . N

CONCLUSION VB N
The DT N
results NNS N
provide VBP N
the DT N
first JJ N
clinical JJ N
demonstration NN N
of IN N
specific JJ N
probiotic JJ N
strains NNS N
modifying VBG N
the DT N
changes NNS N
related VBN N
to TO N
allergic JJ N
inflammation NN N
. . N

The DT N
data NN N
further RB N
indicate VBP N
that IN N
probiotics NNS N
may MD N
counteract VB N
inflammatory JJ N
responses NNS N
beyond IN N
the DT N
intestinal JJ N
milieu NN N
. . N

The DT N
combined JJ N
effects NNS N
of IN N
these DT N
probiotic JJ N
strains NNS N
will MD N
guide VB N
infants NNS N
through IN N
the DT N
weaning JJ N
period NN N
, , N
when WRB N
sensitization NN N
to TO N
newly RB N
encountered VBN N
antigens NNS N
is VBZ N
initiated VBN N
. . N

The DT N
probiotic JJ N
approach NN N
may MD N
thus RB N
offer VB N
a DT N
new JJ N
direction NN N
in IN N
the DT N
search NN N
for IN N
future JJ N
foods NNS N
for IN N
allergy JJ N
treatment NN N
and CC N
prevention NN N
strategies NNS N
. . N

-DOCSTART- -X- O O 19051459

Pre-operative JJ N
radiochemotherapy NN N
for IN N
rectal JJ N
cancer NN N
. . N

A DT N
prospective JJ N
randomized VBN N
trial NN N
comparing VBG N
pre-operative JJ N
vs. FW N
postoperative JJ N
radiochemotherapy NN N
in IN N
rectal JJ N
cancer NN N
patients NNS N
. . N

PURPOSE VB N
The DT N
aim NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
find VB N
out RP N
whether IN N
pre-operative JJ N
radiochemotherapy NN N
had VBD N
any DT N
survival JJ N
advantage NN N
over IN N
postoperative JJ N
radiochemotherapy NN N
for IN N
rectal JJ N
carcinoma NN N
patients NNS N
without IN N
distant JJ N
metastasis NN N
or CC N
peritoneal JJ N
carcinomatosis NN N
. . N

MATERIAL NNP N
AND CC N
METHODS NNP N
Between NNP N
January NNP N
1998 CD N
and CC N
December NNP N
2003 CD N
, , N
51 CD N
rectal JJ N
carcinoma NN N
patients NNS N
without IN N
distant JJ N
metastasis NN N
or CC N
peritoneal JJ N
carcinomatosis NN N
were VBD N
randomly RB N
divided VBN N
into IN N
pre-operative JJ N
( ( N
PRE NNP N
) ) N
and CC N
postoperative JJ N
( ( N
POST NNP N
) ) N
radiochemotherapy NN N
groups NNS N
. . N

Twenty-six CD N
were VBD N
assigned VBN N
to TO N
the DT N
PRE NNP N
group NN N
and CC N
were VBD N
operated VBN N
on IN N
5 CD N
to TO N
8 CD N
weeks NNS N
after IN N
the DT N
completion NN N
of IN N
radiotherapy NN N
. . N

The DT N
other JJ N
25 CD N
patients NNS N
were VBD N
operated VBN N
on IN N
immediately RB N
and CC N
received VBD N
radiotherapy NN N
postoperatively RB N
2 CD N
to TO N
4 CD N
weeks NNS N
after IN N
surgery NN N
. . N

The DT N
patients NNS N
were VBD N
followed VBN N
up RP N
for IN N
between IN N
4 CD N
to TO N
51 CD N
months NNS N
. . N

RESULTS NNP N
In IN N
the DT N
PRE NNP N
group NN N
the DT N
rates NNS N
of IN N
disease-free JJ N
survival NN N
were VBD N
92 CD N
% NN N
, , N
70 CD N
% NN N
, , N
56 CD N
% NN N
and CC N
56 CD N
% NN N
at IN N
the DT N
end NN N
of IN N
the DT N
1st CD N
, , N
2nd CD N
, , N
3rd CD N
and CC N
4th CD N
years NNS N
, , N
respectively RB N
. . N

In IN N
the DT N
POST NNP N
group NN N
those DT N
percentages NNS N
were VBD N
83 CD N
% NN N
, , N
68 CD N
% NN N
, , N
51 CD N
% NN N
and CC N
51 CD N
% NN N
at IN N
the DT N
1st CD N
, , N
2nd CD N
, , N
3rd CD N
and CC N
4th CD N
years NNS N
, , N
respectively RB N
( ( N
p JJ N
= NNP N
0.707 CD N
) ) N
. . N

One-year JJ N
and CC N
4-year JJ N
overall JJ N
survival NN N
rates NNS N
in IN N
the DT N
PRE NNP N
group NN N
were VBD N
100 CD N
% NN N
and CC N
86 CD N
% NN N
respectively RB N
and CC N
100 CD N
% NN N
and CC N
60 CD N
% NN N
in IN N
the DT N
POST NNP N
group NN N
( ( N
p JJ N
= NNP N
0.520 CD N
) ) N
. . N

CONCLUSION NNP N
No NNP N
statistical JJ N
difference NN N
was VBD N
found VBN N
between IN N
the DT N
survival JJ N
rates NNS N
of IN N
the DT N
rectal JJ N
carcinoma NN N
patients NNS N
receiving VBG N
radiotherapy NN N
either CC N
pre-operatively RB N
or CC N
postoperatively RB N
. . N

However RB N
, , N
the DT N
disease-free JJ N
survival NN N
rates NNS N
of IN N
the DT N
PRE NNP N
group NN N
were VBD N
higher JJR N
than IN N
the DT N
POST NNP N
group NN N
's POS N
during IN N
each DT N
year NN N
and CC N
overall JJ N
survival NN N
rates NNS N
were VBD N
higher JJR N
after IN N
the DT N
third JJ N
and CC N
fourth JJ N
years NNS N
. . N

We PRP N
conclude VBP N
that IN N
pre-operative JJ N
radiotherapy NN N
is VBZ N
at IN N
least JJS N
as RB N
effective JJ N
as IN N
postoperative JJ N
radiotherapy NN N
. . N

-DOCSTART- -X- O O 3963358

[ JJ N
Aortofemoral NNP N
bifurcation NN N
bypass NN N
. . N

Effect NN N
of IN N
the DT N
anesthesia JJ N
procedure NN N
( ( N
NLA NNP N
, , N
thoracic RB N
continuous JJ N
catheter NN N
peridural JJ N
anesthesia NN N
) ) N
on IN N
circulation NN N
, , N
respiration NN N
and CC N
metabolism NN N
. . N

Homeostasis NNP N
and CC N
oxygen NN N
transport NN N
] NNP N
. . N

50 CD N
patients NNS N
were VBD N
investigated VBN N
during IN N
induction NN N
of IN N
anaesthesia NN 4_p
and CC N
infrarenal JJ 4_p
aortic JJ 4_p
bypass NN 4_p
surgery NN 4_p
. . N

26 CD N
were VBD N
operated VBN N
on IN N
under IN N
neuroleptanaesthesia NN 4_p
( ( N
NA NNP N
group NN N
) ) N
and CC N
24 CD N
under IN N
continuous JJ N
epidural JJ N
combined VBN N
with IN N
a DT N
light JJ 4_p
general JJ 4_p
anaesthesia NN 4_p
( ( N
epidural JJ N
group NN N
) ) N
. . N

Blood NN N
losses NNS N
were VBD N
replaced VBN N
with IN N
5 CD N
per IN N
cent NN N
human JJ N
albumin NN N
, , N
red JJ N
cell NN N
concentrates NNS N
, , N
and CC N
fresh JJ N
frozen JJ N
plasma NN N
. . N

Ringer NNP N
lactate JJ N
solution NN N
was VBD N
used VBN N
to TO N
replace VB N
the DT N
functional JJ N
extracellular JJ N
fluid NN N
volume NN N
. . N

During IN N
induction NN N
and CC N
maintenance NN N
of IN N
anaesthesia NN N
body NN N
temperature NN N
fell VBD N
( ( N
NA NNP N
group NN N
from IN N
36.7 CD N
to TO N
35.3 CD N
degrees NNS N
C NNP N
; : N
epidural JJ N
group NN N
from IN N
36.7 CD N
to TO N
34.9 CD N
degrees NNS N
C NNP N
) ) N
but CC N
no DT N
statistically RB N
significant JJ N
difference NN N
could MD N
be VB N
found VBN N
between IN N
the DT N
groups NNS N
, , N
in IN N
spite NN N
of IN N
better JJR N
surface NN N
perfusion NN N
of IN N
the DT N
lower JJR N
part NN N
of IN N
the DT N
body NN N
in IN N
the DT N
epidural JJ N
group NN N
. . N

The DT N
increase NN N
of IN N
plasma JJ N
glucose JJ N
concentration NN N
was VBD N
lower JJR N
in IN N
the DT N
epidural JJ N
group NN N
as IN N
compared VBN N
to TO N
the DT N
NA NNP N
group NN N
. . N

Stress NNP N
mediated VBD N
hypokalaemia NN N
was VBD N
of IN N
the DT N
same JJ N
degree NN N
in IN N
both DT N
groups NNS N
, , N
the DT N
median JJ N
values NNS N
of IN N
the DT N
plasma NN N
potassium NN N
concentrations NNS N
being VBG N
in IN N
the DT N
lower JJR N
reference NN N
range NN N
( ( N
3.5-3.7 JJ N
mmol NN N
X $ N
1 CD N
( ( N
-1 JJ N
] NN N
, , N
although IN N
large JJ N
amounts NNS N
of IN N
red JJ N
cell NN N
concentrates NNS N
were VBD N
given VBN N
. . N

During IN N
clamping NN N
of IN N
the DT N
aorta NN N
a DT N
moderate JJ N
compensated VBN N
acidosis NN N
developed VBN N
in IN N
both DT N
groups NNS N
. . N

Declamping VBG N
caused VBD N
a DT N
more RBR N
marked JJ N
increase NN N
of IN N
paCO2 NN N
and CC N
a DT N
greater JJR N
fall NN N
of IN N
pH NN N
in IN N
the DT N
NA NNP N
group NN N
as IN N
compared VBN N
to TO N
the DT N
epidural JJ N
group NN N
. . N

Induction NN N
of IN N
anaesthesia NN N
was VBD N
followed VBN N
by IN N
a DT N
fall NN N
in IN N
oxygen NN N
uptake NN N
( ( N
NA NNP N
group NN N
from IN N
221 CD N
to TO N
163 CD N
ml NNS N
X JJ N
min-1 JJ N
; : N
epidural JJ N
group NN N
from IN N
230 CD N
to TO N
189 CD N
ml NNS N
X NNP N
min-1 NN N
) ) N
which WDT N
appears VBZ N
to TO N
be VB N
delayed VBN N
in IN N
the DT N
epidural JJ N
group NN N
, , N
with IN N
a DT N
short JJ N
lasting NN N
statistically RB N
significant JJ N
difference NN N
between IN N
the DT N
groups NNS N
after IN N
eventration NN N
of IN N
the DT N
gut NN N
( ( N
NA NNP N
group NN N
: : N
162 CD N
ml NN N
X NNP N
min-1 NN N
less JJR N
than IN N
epidural JJ N
group NN N
184 CD N
ml NN N
X NNP N
min-1 NN N
) ) N
. . N

Later RBR N
on IN N
, , N
oxygen FW N
uptake NN N
was VBD N
equal JJ N
in IN N
both DT N
groups NNS N
, , N
with IN N
no DT N
further JJ N
changes NNS N
due JJ N
to TO N
clamping VBG N
or CC N
declamping NN N
of IN N
the DT N
aorta NN N
. . N

At IN N
the DT N
end NN N
of IN N
the DT N
operation NN N
, , N
when WRB N
nitrous JJ N
oxide NN N
had VBD N
been VBN N
turned VBN N
of IN N
, , N
the DT N
oxygen NN N
uptake NN N
increased VBD N
considerably RB N
in IN N
several JJ N
patients NNS N
, , N
despite IN N
continuing VBG N
artificial JJ N
ventilation NN N
and CC N
intravenous JJ N
hypnotics NNS N
and CC N
analgesics NNS N
having VBG N
been VBN N
given VBN N
. . N

Eventration NN N
and CC N
exterioration NN N
of IN N
the DT N
gut NN N
caused VBD N
the DT N
most RBS N
marked JJ N
changes NNS N
in IN N
haemodynamics NNS N
and CC N
oxygen NN N
transport NN N
with IN N
significant JJ N
differences NNS N
between IN N
the DT N
groups NNS N
. . N

Immediately RB N
after IN N
eventration NN N
there EX N
was VBD N
a DT N
sudden JJ N
fall NN N
in IN N
paO2 NN N
in IN N
both DT N
groups NNS N
( ( N
NA NNP N
group NN N
from IN N
99 CD N
to TO N
83 CD N
mm NNS N
Hg NNP N
; : N
epidural JJ N
group NN N
from IN N
96 CD N
to TO N
84 CD N
mm NNS N
Hg NNP N
) ) N
and CC N
an DT N
increase NN N
of IN N
the DT N
calculated JJ N
intrapulmonary JJ N
right-to-left-shunt NN N
( ( N
NA NNP N
group NN N
from IN N
7 CD N
to TO N
21 CD N
% NN N
; : N
epidural JJ N
group NN N
from IN N
10 CD N
to TO N
19 CD N
% NN N
) ) N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
400 CD N
WORDS NNP N
) ) N
-DOCSTART- -X- O O 17901383

Transcutaneous JJ N
electrical JJ N
nerve NN N
stimulation NN N
combined VBN N
with IN N
task-related JJ N
training NN N
improves NNS N
lower JJR N
limb NN N
functions NNS N
in IN N
subjects NNS N
with IN N
chronic JJ N
stroke NN N
. . N

BACKGROUND NNP N
AND NNP N
PURPOSE NNP N
Previous NNP N
studies NNS N
have VBP N
shown VBN N
that IN N
repeated VBD N
sensory JJ N
inputs NNS N
could MD N
enhance VB N
brain NN N
plasticity NN N
and CC N
cortical JJ N
motor NN N
output NN N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
whether IN N
combining VBG N
electrically RB N
induced JJ N
sensory NN N
inputs NNS N
through IN N
transcutaneous JJ N
electrical JJ N
nerve NN N
stimulation NN N
( ( N
TENS NNP N
) ) N
with IN N
task-related JJ N
training NN N
( ( N
TRT NNP N
) ) N
in IN N
a DT N
home-based JJ N
program NN N
would MD N
augment VB N
voluntary JJ N
motor NN N
output NN N
in IN N
chronic JJ N
stroke NN N
survivors NNS N
better RBR N
than IN N
either DT N
treatment NN N
alone RB N
or CC N
no DT N
treatment NN N
. . N

METHODS NNP N
Eighty-eight JJ N
patients NNS N
with IN N
stroke NN N
were VBD N
assigned VBN N
randomly RB N
to TO N
receive VB N
a DT N
home-based JJ N
program NN N
of IN N
( ( N
1 CD N
) ) N
TENS NN N
, , N
( ( N
2 CD N
) ) N
TENS+TRT NN N
, , N
( ( N
3 CD N
) ) N
placebo NN N
TENS+TRT NNP N
, , N
or CC N
( ( N
4 CD N
) ) N
no DT N
treatment NN N
( ( N
control NN N
) ) N
5 CD N
days NNS N
a DT N
week NN N
for IN N
4 CD N
weeks NNS N
. . N

Outcome NN N
measurements NNS N
included VBD N
Composite NNP N
Spasticity NNP N
Scale NNP N
, , N
peak NN N
torques NNS N
generated VBD N
during IN N
maximum JJ N
isometric JJ N
voluntary JJ N
contraction NN N
of IN N
ankle JJ N
dorsiflexors NNS N
and CC N
plantarflexors NNS N
, , N
and CC N
gait VBP N
velocity NN N
recorded VBN N
at IN N
baseline NN N
, , N
after IN N
2 CD N
and CC N
4 CD N
weeks NNS N
of IN N
treatment NN N
, , N
and CC N
4 CD N
weeks NNS N
after IN N
treatment NN N
ended VBN N
. . N

RESULTS VB N
When WRB N
compared VBN N
with IN N
TENS NNP N
, , N
the DT N
combined JJ N
TENS+TRT NNP N
group NN N
showed VBD N
significantly RB N
greater JJR N
improvement NN N
in IN N
ankle JJ N
dorsiflexion NN N
torque NN N
at IN N
follow-up JJ N
and CC N
in IN N
ankle JJ N
plantarflexion NN N
torque NN N
at IN N
week NN N
2 CD N
and CC N
follow-up JJ N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

When WRB N
compared VBN N
with IN N
placebo+TRT NN N
, , N
the DT N
TENS+TRT NNP N
group NN N
produced VBD N
earlier JJR N
and CC N
greater JJR N
reduction NN N
of IN N
plantarflexor NN N
spasticity NN N
and CC N
improvement NN N
in IN N
ankle JJ N
dorsiflexion NN N
torque NN N
at IN N
week NN N
2 CD N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

When WRB N
compared VBN N
with IN N
all DT N
3 CD N
groups NNS N
, , N
the DT N
TENS+TRT NNP N
group NN N
showed VBD N
significantly RB N
greater JJR N
improvement NN N
in IN N
gait NN N
velocity NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

CONCLUSIONS NNP N
In IN N
patients NNS N
with IN N
chronic JJ N
stroke NN N
, , N
20 CD N
sessions NNS N
of IN N
a DT N
combined JJ N
TENS+TRT NNP N
home-based JJ N
program NN N
decreased VBN N
plantarflexor JJ N
spasticity NN N
, , N
improved VBN N
dorsiflexor NN N
and CC N
plantarflexor NN N
strength NN N
, , N
and CC N
increased VBD N
gait NN N
velocity NN N
significantly RB N
more RBR N
than IN N
TENS NNP N
alone RB N
, , N
placebo+TRT NN N
, , N
or CC N
no DT N
treatment NN N
. . N

Such JJ N
improvements NNS N
can MD N
even RB N
be VB N
maintained VBN N
4 CD N
weeks NNS N
after IN N
treatment NN N
ended VBD N
. . N

-DOCSTART- -X- O O 1286738

A DT N
comparative JJ N
study NN N
of IN N
a DT N
new JJ N
food NN N
supplement NN N
, , N
ViviScal NNP N
, , N
with IN N
fish JJ N
extract NN N
for IN N
the DT N
treatment NN N
of IN N
hereditary JJ 4_p
androgenic JJ 4_p
alopecia NN 4_p
in IN N
young JJ N
males NNS N
. . N

A DT N
controlled JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
parallel-group JJ N
study NN N
compared VBN N
the DT N
effects NNS N
of IN N
ViviScal NNP N
( ( N
a DT N
new JJ N
food NN N
supplement NN N
incorporating VBG N
special JJ N
marine JJ N
extracts NNS N
and CC N
a DT N
silica JJ N
compound NN N
) ) N
with IN N
those DT N
of IN N
a DT N
fish JJ N
extract NN N
in IN N
the DT N
treatment NN N
of IN N
young JJ N
males NNS N
with IN N
hereditary JJ N
androgenic JJ 4_p
alopecia NN 4_p
. . N

The DT N
pretreatment JJ N
histological JJ N
diagnosis NN N
was VBD N
alopecia VBN 4_p
with IN N
a DT N
mild NN N
to TO N
moderate VB N
perifollicular JJ N
inflammation NN N
zone NN N
. . N

The DT N
study NN N
consisted VBD N
of IN N
20 CD N
subjects NNS N
who WP N
received VBD N
two CD N
tablets NNS N
of IN N
ViviScal NNP N
once RB N
daily RB N
and CC N
20 CD N
who WP N
received VBD N
two CD N
tablets NNS N
of IN N
fish JJ N
extract NN N
once RB N
daily JJ N
for IN N
6 CD N
months NNS N
. . N

The DT N
mean JJ N
patient NN N
age NN N
and CC N
mean JJ N
duration NN N
and CC N
severity NN N
of IN N
baldness NN N
compared VBN N
well RB N
between IN N
the DT N
two CD N
groups NNS N
. . N

Most JJS N
patients NNS N
had VBD N
been VBN N
treated VBN N
with IN N
long-term JJ N
topical JJ N
2 CD N
% NN N
minoxidil NN N
for IN N
1 CD N
year NN N
or CC N
more JJR N
prior JJ N
to TO N
the DT N
study NN N
. . N

At IN N
baseline NN N
and CC N
after IN N
6 CD N
months NNS N
' POS N
treatment NN N
, , N
a DT N
biopsy NN N
was VBD N
taken VBN N
for IN N
histological JJ N
examination NN N
. . N

A DT N
non-vellus JJ N
hair NN N
count NN N
was VBD N
performed VBN N
at IN N
baseline NN N
and CC N
after IN N
2 CD N
, , N
4 CD N
and CC N
6 CD N
months NNS N
. . N

In IN N
the DT N
fish JJ N
extract NN N
treatment NN N
group NN N
three CD N
patients NNS N
withdrew VBD N
from IN N
the DT N
study NN N
before IN N
the DT N
fourth JJ N
month NN N
due JJ N
to TO N
lack VB N
of IN N
therapeutic JJ N
effect NN N
. . N

After IN N
6 CD N
months NNS N
' POS N
treatment NN N
, , N
patients NNS N
receiving VBG N
ViviScal NNP N
showed VBD N
a DT N
mean JJ N
increase NN N
in IN N
non-vellus JJ N
hair NN N
of IN N
38 CD N
% NN N
compared VBN N
with IN N
a DT N
2 CD N
% NN N
increase NN N
in IN N
the DT N
fish JJ N
extract NN N
treatment NN N
group NN N
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

In IN N
the DT N
ViviScal NNP N
group NN N
, , N
19 CD N
( ( N
95 CD N
% NN N
) ) N
subjects VBZ N
showed VBN N
both DT N
clinical JJ N
and CC N
histological JJ N
cure NN N
, , N
whereas IN N
none NN N
treated VBN N
with IN N
fish JJ N
extract NN N
showed VBD N
any DT N
clinical JJ N
or CC N
histological JJ N
difference NN N
after IN N
6 CD N
months NNS N
' POS N
treatment NN N
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

In IN N
both DT N
groups NNS N
, , N
a DT N
minimal JJ N
decrease NN N
in IN N
the DT N
erythemal JJ N
index NN N
was VBD N
observed VBN N
. . N

In IN N
conclusion NN N
, , N
ViviScal JJ N
appears VBZ N
to TO N
be VB N
the DT N
first JJ N
highly RB N
active JJ N
treatment NN N
for IN N
androgenic JJ N
alopecia NN N
in IN N
young JJ N
males NNS N
. . N

-DOCSTART- -X- O O 11978262

Oat NNP N
ingestion NN N
reduces VBZ N
systolic JJ N
and CC N
diastolic JJ N
blood NN N
pressure NN N
in IN N
patients NNS 4_p
with IN 4_p
mild JJ 4_p
or CC 4_p
borderline JJ 4_p
hypertension NN 4_p
: : 4_p
a DT N
pilot NN N
trial NN N
. . N

OBJECTIVES IN N
We PRP N
assessed VBD N
the DT N
short-term JJ N
antihypertensive JJ N
effects NNS N
of IN N
soluble JJ N
fiber-rich JJ N
whole JJ N
oat NN N
cereals NNS N
when WRB N
added VBN N
to TO N
a DT N
standard JJ N
American JJ N
diet NN N
. . N

In IN N
addition NN N
, , N
multiple JJ N
assessments NNS N
of IN N
insulin NN N
sensitivity NN N
were VBD N
conducted VBN N
. . N

STUDY NNP N
DESIGN NNP N
This DT N
was VBD N
a DT N
randomized JJ N
, , N
controlled VBN N
, , N
parallel-group JJ N
pilot NN N
study NN N
designed VBN N
to TO N
compare VB N
an DT N
oat NN N
cereal NN N
group NN N
( ( N
standardized VBN N
to TO N
5.52 CD N
g/day JJ N
beta-glucan JJ N
) ) N
to TO N
a DT N
low-fiber JJ N
cereal NN N
control NN N
group NN N
( ( N
less JJR N
than IN N
1.0 CD N
g/day JJ N
total JJ N
fiber NN N
) ) N
over IN N
6 CD N
weeks NNS N
. . N

POPULATION VB N
A DT N
total NN N
of IN N
18 CD N
hypertensive JJ N
and CC N
hyperinsulinemic JJ N
( ( N
= JJ N
10 CD N
U/mL NNP N
or CC N
more JJR N
) ) N
men NNS N
and CC N
women NNS N
completed VBD N
the DT N
trial NN N
. . N

OUTCOMES NNP N
MEASURED NNP N
Primary NNP N
study NN N
outcomes NNS N
were VBD N
changes NNS N
in IN N
systolic JJ N
blood NN N
pressure NN N
( ( N
SBP NNP N
) ) N
and CC N
diastolic JJ N
blood NN N
pressure NN N
( ( N
DBP NNP N
) ) N
. . N

Secondary JJ N
outcomes NNS N
included VBD N
blood NN N
lipid NN N
, , N
fasting VBG N
glucose NN N
, , N
and CC N
insulin NN N
levels NNS N
and CC N
side NN N
effects NNS N
related VBN N
to TO N
elevated VBN N
blood NN N
pressure NN N
and CC N
increased VBD N
dietary JJ N
fiber NN N
intake NN N
. . N

RESULTS VB N
The DT N
oat NN N
cereal NN N
group NN N
experienced VBD N
a DT N
7.5 CD N
mm NN N
Hg NNP N
reduction NN N
in IN N
SBP NNP N
( ( N
P NNP N
& CC N
lt.01 NN N
) ) N
and CC N
a DT N
5.5 CD N
mm NN N
Hg NNP N
reduction NN N
in IN N
DBP NNP N
( ( N
P NNP N
& CC N
lt.02 NN N
) ) N
, , N
while IN N
there EX N
was VBD N
virtually RB N
no DT N
change NN N
in IN N
either DT N
SBP NNP N
or CC N
DBP NNP N
in IN N
the DT N
control NN N
group NN N
. . N

In IN N
the DT N
oat NN N
cereal NN N
group NN N
, , N
a DT N
trend NN N
was VBD N
observed VBN N
for IN N
a DT N
lower JJR N
total JJ N
insulin NN N
response NN N
to TO N
a DT N
glucose JJ N
load NN N
, , N
suggesting VBG N
improved VBN N
insulin JJ N
sensitivity NN N
. . N

However RB N
, , N
this DT N
could MD N
not RB N
be VB N
confirmed VBN N
using VBG N
estimates NNS N
from IN N
the DT N
Bergman NNP N
Minimal NNP N
Model NNP N
, , N
perhaps RB N
because IN N
of IN N
our PRP$ N
small JJ N
sample NN N
size NN N
. . N

The DT N
oats NNS N
group NN N
experienced VBD N
a DT N
significant JJ N
reduction NN N
in IN N
both DT N
total JJ N
cholesterol NN N
( ( N
9 CD N
% NN N
) ) N
and CC N
low-density JJ N
lipoprotein NN N
cholesterol NN N
( ( N
14 CD N
% NN N
) ) N
. . N

CONCLUSIONS VB N
The DT N
addition NN N
of IN N
oat NN N
cereals NNS N
to TO N
the DT N
normal JJ N
diet NN N
of IN N
patients NNS N
with IN N
hypertension NN N
significantly RB N
reduces VBZ N
both DT N
SBP NNP N
and CC N
DBP NNP N
. . N

Soluble JJ N
fiber-rich JJ N
whole JJ N
oats NNS N
may MD N
be VB N
an DT N
effective JJ N
dietary JJ N
therapy NN N
in IN N
the DT N
prevention NN N
and CC N
adjunct JJ N
treatment NN N
of IN N
hypertension NN N
. . N

-DOCSTART- -X- O O 25344395

Safety NN N
and CC N
possible JJ N
effects NNS N
of IN N
low-intensity NN N
resistance NN N
training NN N
associated VBN N
with IN N
partial JJ N
blood NN N
flow NN N
restriction NN N
in IN N
polymyositis NN 4_p
and CC 4_p
dermatomyositis NN 4_p
. . 4_p

INTRODUCTION NNP N
Our PRP$ N
aim NN N
was VBD N
to TO N
evaluate VB N
the DT N
safety NN N
and CC N
efficacy NN N
of IN N
a DT N
low-intensity JJ N
resistance NN N
training NN N
program NN N
combined VBN N
with IN N
partial JJ N
blow NN N
flow NN N
restriction NN N
( ( N
BFR NNP N
training NN N
) ) N
in IN N
a DT N
cohort NN N
of IN N
patients NNS 4_p
with IN 4_p
polymyositis NN 4_p
( ( 4_p
PM NNP 4_p
) ) 4_p
and CC 4_p
dermatomyositis NN 4_p
( ( 4_p
DM NNP 4_p
) ) 4_p
. . N

METHODS NNP N
In IN N
total JJ N
, , N
13 CD N
patients NNS N
with IN 4_p
PM NNP 4_p
and CC 4_p
DM NNP 4_p
completed VBD 4_p
a DT N
12-week JJ N
twice NN N
a DT N
week NN N
low-intensity NN N
( ( N
that WDT N
is VBZ N
, , N
30 CD N
% NN N
one-repetition-maximum JJ N
( ( N
1RM CD N
) ) N
) ) N
resistance NN N
exercise NN N
training NN N
program NN N
combined VBN N
with IN N
partial JJ N
blood NN N
flow NN N
restriction NN N
( ( N
BFR NNP N
) ) N
. . N

Assessments NNS N
of IN N
muscle NN N
strength NN N
, , N
physical JJ N
function NN N
, , N
quadriceps NNS N
cross VBP N
sectional JJ N
( ( N
CSA NNP N
) ) N
area NN N
, , N
health-related JJ N
quality NN N
of IN N
life NN N
, , N
and CC N
clinical JJ N
and CC N
laboratory JJ N
parameters NNS N
were VBD N
assessed VBN N
at IN N
baseline NN N
and CC N
after IN N
the DT N
intervention NN N
. . N

RESULTS VB N
The DT N
BFR NNP N
training NN N
program NN N
was VBD N
effective JJ N
in IN N
increasing VBG N
the DT N
maximal JJ N
dynamic JJ N
strength NN N
in IN N
both DT N
the DT N
leg-press NN N
( ( N
19.6 CD N
% NN N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
knee-extension NN N
exercises NNS N
( ( N
25.2 CD N
% NN N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
as RB N
well RB N
as IN N
in IN N
the DT N
timed-stands NNS N
( ( N
15.1 CD N
% NN N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
timed-up-and-go JJ N
test NN N
( ( N
-4.5 CD N
% NN N
, , N
P NNP N
=0.002 NNP N
) ) N
. . N

Quadriceps NNP N
CSA NNP N
was VBD N
also RB N
significantly RB N
increased VBN N
after IN N
the DT N
intervention NN N
( ( N
4.57 CD N
% NN N
, , N
P NNP N
=0.01 NNP N
) ) N
. . N

Similarly RB N
, , N
all DT N
of IN N
the DT N
components NNS N
of IN N
the DT N
Short NNP N
Form-36 NNP N
Health NNP N
Survey NNP N
, , N
the DT N
Health NNP N
Assessment NNP N
Questionnaire NNP N
scores NNS N
, , N
and CC N
the DT N
patient- JJ N
and CC N
physician JJ N
reported VBD N
Visual NNP N
Analogue NNP N
Scale NNP N
were VBD N
significantly RB N
improved VBN N
after IN N
training NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Importantly RB N
, , N
no DT N
clinical JJ N
evidence NN N
or CC N
any DT N
other JJ N
self-reported JJ N
adverse JJ N
event NN N
were VBD N
found VBN N
. . N

Laboratory JJ N
parameters NNS N
( ( N
creatine JJ N
kinase NN N
and CC N
aldolase NN N
) ) N
were VBD N
also RB N
unchanged JJ N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
after IN N
the DT N
intervention NN N
. . N

CONCLUSIONS NNP N
We PRP N
demonstrated VBD N
that IN N
a DT N
12-week JJ N
supervised JJ N
low-intensity NN N
resistance NN N
training NN N
program NN N
associated VBN N
with IN N
partial JJ N
blood NN N
flow NN N
restriction NN N
may MD N
be VB N
safe JJ N
and CC N
effective JJ N
in IN N
improving VBG N
muscle NN N
strength NN N
and CC N
function NN N
as RB N
well RB N
as IN N
muscle NN N
mass NN N
and CC N
health-related JJ N
quality NN N
of IN N
life NN N
in IN N
patients NNS N
with IN N
PM NNP N
and CC N
DM NNP N
. . N

TRIAL NNP N
REGISTRATION NNP N
Clinicaltrials.gov NNP N
NCT01501019 NNP N
. . N

Registered NNP N
November NNP N
29 CD N
, , N
2011 CD N
. . N

-DOCSTART- -X- O O 9066329

Comparison NNP N
of IN N
cuffed NN N
and CC N
uncuffed JJ N
endotracheal NN N
tubes NNS N
in IN N
young JJ N
children NNS N
during IN N
general JJ N
anesthesia NN 4_p
. . 4_p

BACKGROUND NNP N
Uncuffed NNP N
endotracheal NN N
tubes NNS N
are VBP N
routinely RB N
used VBN N
in IN N
young JJ N
children NNS N
. . N

This DT N
study NN N
tests VBZ N
a DT N
formula NN N
for IN N
selecting VBG N
appropriately RB N
sized VBN N
cuffed NN N
endotracheal NN N
tubes NNS N
and CC N
compares VBZ N
the DT N
use NN N
of IN N
cuffed NN N
versus NN N
uncuffed JJ N
endotracheal NN N
tubes NNS N
for IN N
patients NNS N
whose WP$ N
lungs NNS N
are VBP N
mechanically RB N
ventilated VBN N
during IN N
anesthesia NN N
. . N

METHODS NNP N
Full-term NNP N
newborns NNS N
and CC N
children NNS N
( ( N
n JJ N
= NNP N
488 CD N
) ) 4_p
through IN N
8 CD N
yr NN N
of IN N
age NN N
who WP N
required VBD N
general JJ 4_p
anesthesia NN 4_p
and CC 4_p
tracheal JJ 4_p
intubation NN 4_p
were VBD N
assigned VBN N
randomly RB N
to TO N
receive VB N
either CC N
a DT N
cuffed NN N
tube NN N
sized VBN N
by IN N
a DT N
new JJ N
formula NN N
[ NN N
size NN N
( ( N
mm JJ N
internal JJ N
diameter NN N
) ) N
= NN N
( ( N
age/4 NN N
) ) N
+ VBZ N
3 CD N
] NN N
, , N
or CC N
an DT N
uncuffed JJ N
tube NN N
sized VBN N
by IN N
the DT N
modified JJ N
Cole NNP N
's POS N
formula NN N
[ NN N
size NN N
( ( N
mm JJ N
internal JJ N
diameter NN N
) ) N
= NN N
( ( N
age/4 NN N
) ) N
+ VBZ N
4 CD N
] NN N
. . N

The DT N
number NN N
of IN N
intubations NNS N
required VBN N
to TO N
achieve VB N
an DT N
appropriately RB N
sized JJ N
tube NN N
, , N
the DT N
need NN N
to TO N
use VB N
more JJR N
than IN N
21.min-1 JJ N
fresh JJ N
gas NN N
flow NN N
, , N
the DT N
concentration NN N
of IN N
nitrous JJ N
oxide NN N
in IN N
the DT N
operating NN N
room NN N
, , N
and CC N
the DT N
incidence NN N
of IN N
croup NN N
were VBD N
compared VBN N
. . N

RESULTS NNP N
Cuffed NNP N
tubes RB N
selected VBN N
by IN N
our PRP$ N
formula NN N
were VBD N
appropriate JJ N
for IN N
99 CD N
% NN N
of IN N
patients NNS N
. . N

Uncuffed NNP N
tubes RB N
selected VBN N
by IN N
Cole NNP N
's POS N
formula NN N
were VBD N
appropriate JJ N
for IN N
77 CD N
% NN N
of IN N
patients NNS N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

The DT N
lungs NNS N
of IN N
patients NNS N
with IN N
cuffed JJ N
tubes NNS N
were VBD N
adequately RB N
ventilated VBN N
with IN N
2 CD N
1.min-1 JJ N
fresh JJ N
gas NN N
flow NN N
, , N
whereas RB N
11 CD N
% NN N
of IN N
those DT N
with IN N
uncuffed JJ N
tubes NNS N
needed VBN N
greater JJR N
fresh JJ N
gas NN N
flow NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Ambient NNP N
nitrous JJ N
oxide IN N
concentration NN N
exceeded VBD N
25 CD N
parts NNS N
per IN N
million CD N
in IN N
37 CD N
% NN N
of IN N
cases NNS N
with IN N
uncuffed JJ N
tubes NNS N
and CC N
in IN N
0 CD N
% NN N
of IN N
cases NNS N
with IN N
cuffed JJ N
tubes NNS N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Three CD N
patients NNS N
in IN N
each DT N
group NN N
were VBD N
treated VBN N
for IN N
croup NN N
symptoms NNS N
( ( N
1.2 CD N
% NN N
cuffed NN N
; : N
1.3 CD N
% NN N
uncuffed NN N
) ) N
. . N

CONCLUSIONS VB N
Our PRP$ N
formula NN N
for IN N
cuffed NN N
tube NN N
selection NN N
is VBZ N
appropriate JJ N
for IN N
young JJ N
children NNS N
. . N

Advantages NNS N
of IN N
cuffed JJ N
endotracheal JJ N
tubes NNS N
include VBP N
avoidance NN N
of IN N
repeated VBN N
laryngoscopy NN N
, , N
use NN N
of IN N
low JJ N
fresh JJ N
gas NN N
flow NN N
, , N
and CC N
reduction NN N
of IN N
the DT N
concentration NN N
of IN N
anesthetics NNS N
detectable JJ N
in IN N
the DT N
operating NN N
room NN N
. . N

We PRP N
conclude VBP N
that IN N
cuffed NN N
endotracheal VBP N
tubes NNS N
may MD N
be VB N
used VBN N
routinely RB N
during IN N
controlled VBN N
ventilation NN N
in IN N
full-term JJ N
newborns NNS N
and CC N
children NNS N
during IN N
anesthesia NN 4_p
. . N

-DOCSTART- -X- O O 18592368

The DT N
effects NNS N
of IN N
improvisational JJ N
music NN N
therapy NN N
on IN N
joint JJ N
attention NN N
behaviors NNS N
in IN N
autistic JJ 4_p
children NNS N
: : N
a DT N
randomized NN N
controlled VBN N
study NN N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
effects NNS N
of IN N
improvisational JJ N
music NN N
therapy NN N
on IN N
joint JJ N
attention NN N
behaviors NNS N
in IN N
pre-school JJ N
children NNS N
with IN N
autism NN 4_p
. . N

It PRP N
was VBD N
a DT N
randomized VBN N
controlled VBN N
study NN N
employing VBG N
a DT N
single JJ N
subject NN N
comparison NN N
design NN N
in IN N
two CD N
different JJ N
conditions NNS N
, , N
improvisational JJ N
music NN N
therapy NN N
and CC N
play NN N
sessions NNS N
with IN N
toys NNS N
, , N
and CC N
using VBG N
standardized JJ N
tools NNS N
and CC N
DVD NNP N
analysis NN N
of IN N
sessions NNS N
to TO N
evaluate VB N
behavioral JJ N
changes NNS N
in IN N
children NNS N
with IN N
autism NN 4_p
. . N

The DT N
overall JJ N
results NNS N
indicated VBD N
that IN N
improvisational JJ N
music NN N
therapy NN N
was VBD N
more RBR N
effective JJ N
at IN N
facilitating VBG N
joint JJ N
attention NN N
behaviors NNS N
and CC N
non-verbal JJ N
social JJ N
communication NN N
skills NNS N
in IN N
children NNS N
than IN N
play NN N
. . N

Session NN N
analysis NN N
showed VBD N
significantly RB N
more RBR N
and CC N
lengthier JJR N
events NNS N
of IN N
eye NN N
contact NN N
and CC N
turn-taking NN N
in IN N
improvisational JJ N
music NN N
therapy NN N
than IN N
play NN N
sessions NNS N
. . N

The DT N
implications NNS N
of IN N
these DT N
findings NNS N
are VBP N
discussed VBN N
further RBR N
. . N

-DOCSTART- -X- O O 17009630

Studies NNS N
on IN N
leptin NN N
and CC N
leptin NN N
receptor NN N
gene NN N
expression NN N
in IN N
myometrium NN N
and CC N
uterine JJ N
myomas NN N
of IN N
gnRH JJ N
analogue-treated JJ N
women NNS N
. . N

AIM NNP N
To TO N
test VB N
if IN N
treatment NN N
with IN N
GnRH NNP N
analogue NN N
, , N
which WDT N
leads VBZ N
to TO N
a DT N
significant JJ N
reduction NN N
in IN N
myoma NN N
volume NN N
, , N
changes NNS N
expression NN N
of IN N
leptin NN N
genes NNS N
and CC N
gene NN N
coding VBG N
leptin JJ N
receptor NN N
isoforms NNS N
in IN N
uterine JJ N
myomas NN N
and CC N
in IN N
the DT N
surrounding NN N
unaltered JJ N
myometrium NN N
. . N

METHODS NNP N
Using VBG N
RT-PCR NNP N
, , N
expression NN N
of IN N
leptin NN N
genes NNS N
and CC N
leptin NN N
receptor NN N
genes NNS N
was VBD N
studied VBN N
in IN N
myomas NN N
and CC N
in IN N
the DT N
surrounding VBG N
myometrium NN N
in IN N
women NNS N
with IN N
uterine JJ 4_p
myomas NN 4_p
, , N
untreated VBD 4_p
or CC 4_p
treated VBN 4_p
with IN 4_p
GnRH NNP 4_p
analogue NN 4_p
. . N

In IN N
the DT N
randomly RB N
selected VBN N
cases NNS N
presence NN N
of IN N
leptin NN N
protein NN N
and CC N
of IN N
leptin JJ N
receptor NN N
proteins NNS N
was VBD N
examined VBN N
also RB N
by IN N
Western JJ N
blotting NN N
. . N

RESULTS NNP N
Expression NNP N
of IN N
leptin NN N
genes NNS N
was VBD N
demonstrated VBN N
both DT N
in IN N
myomas NN N
and CC N
in IN N
the DT N
surrounding VBG N
myometrium NN N
, , N
and CC N
a DT N
similar JJ N
pattern NN N
of IN N
expression NN N
was VBD N
found VBN N
for IN N
leptin JJ N
receptor NN N
isoforms NNS N
. . N

The DT N
results NNS N
of IN N
RT-PCR NNP N
were VBD N
confirmed VBN N
by IN N
Western JJ N
blotting NN N
, , N
which WDT N
documented VBD N
the DT N
identical JJ N
distribution NN N
of IN N
leptin NN N
proteins NNS N
and CC N
leptin JJ N
receptor NN N
proteins NNS N
in IN N
studied JJ N
tissues NNS N
. . N

Treatment NN N
with IN N
GnRH NNP N
analogue NN N
had VBD N
no DT N
effect NN N
on IN N
the DT N
expression NN N
pattern NN N
of IN N
studied VBN N
genes NNS N
. . N

CONCLUSION NNP N
The DT N
results NNS N
of IN N
the DT N
present JJ N
study NN N
on IN N
the DT N
administration NN N
of IN N
GnRH NNP N
analogue NN N
to TO N
females NNS N
with IN N
myomas NN N
suggest VBP N
that IN N
no DT N
direct JJ N
or CC N
immediate JJ N
inter-relationship JJ N
exists NNS N
between IN N
expression NN N
of IN N
leptin NN N
genes NNS N
in IN N
uterine JJ N
myomas NN N
on IN N
one CD N
hand NN N
and CC N
estrogen NN N
, , N
progesterone NN N
and CC N
leptin NN N
levels NNS N
in IN N
the DT N
blood NN N
on IN N
the DT N
other JJ N
. . N

Expression NN N
seems VBZ N
to TO N
be VB N
of IN N
a DT N
more RBR N
durable JJ N
nature NN N
but CC N
factors NNS N
that WDT N
induce VBP N
such JJ N
expression NN N
remain VBP N
unknown JJ N
. . N

-DOCSTART- -X- O O 1440804

The DT N
relationship NN N
between IN N
the DT N
response NN N
of IN N
Plasmodium NNP N
falciparum NN N
malaria NN N
to TO N
mefloquine VB N
in IN N
African JJ N
children NNS N
and CC N
its PRP$ N
sensitivity NN N
in IN N
vitro NN N
. . N

The DT N
clinical JJ N
efficacy NN N
of IN N
two CD N
doses NNS N
of IN N
mefloquine NN N
( ( N
15 CD N
and CC N
25 CD N
mg/kg NN N
body NN N
weight VBD N
) ) N
was VBD N
evaluated VBN N
in IN N
85 CD N
children NNS N
suffering VBG N
from IN N
acute JJ 4_p
symptomatic JJ 4_p
falciparum NN 4_p
malaria NN 4_p
. . 4_p

The DT N
cure NN N
rate NN N
on IN N
day NN N
28 CD N
was VBD N
100 CD N
% NN N
in IN N
both DT N
groups NNS N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
in IN N
the DT N
mean JJ N
parasite NN N
and CC N
fever NN N
clearance NN N
times NNS N
in IN N
both DT N
groups NNS N
( ( N
48.5 CD N
+/- JJ N
14.6 CD N
and CC N
32.0 CD N
+/- JJ N
12.7 CD N
h NN N
respectively RB N
for IN N
the DT N
25 CD N
mg/kg NN N
group NN N
and CC N
49.0 CD N
+/- JJ N
15.1 CD N
and CC N
30.0 CD N
+/- JJ N
13.3 CD N
h NN N
respectively RB N
for IN N
the DT N
15 CD N
mg/kg NNS N
group NN N
) ) N
. . N

There EX N
was VBD N
also RB N
no DT N
significant JJ N
difference NN N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
in IN N
these DT N
values NNS N
between IN N
children NNS N
with IN N
hyperparasitaemia NN N
( ( N
53.6 CD N
+/- JJ N
11.1 CD N
and CC N
36.0 CD N
+/- JJ N
17.0 CD N
h NN N
respectively RB N
) ) N
and CC N
those DT N
without IN N
hyperparasitaemia NN N
( ( N
49.1 CD N
+/- JJ N
13.6 CD N
and CC N
31.8 CD N
+/- JJ N
14.6 CD N
h NN N
respectively RB N
) ) N
. . N

Recurrence NN N
of IN N
parasitaemia NN N
was VBD N
observed VBN N
after IN N
day NN N
30 CD N
in IN N
2 CD N
patients NNS N
in IN N
the DT N
15 CD N
mg/kg NN N
group NN N
and CC N
in IN N
1 CD N
patient NN N
in IN N
the DT N
25 CD N
mg/kg NN N
group NN N
. . N

In IN N
vitro NN N
, , N
3 CD N
of IN N
21 CD N
isolates NNS N
showed VBD N
reduced JJ N
susceptibility NN N
to TO N
mefloquine VB N
, , N
with IN N
minimum JJ N
inhibitory JJ N
concentrations NNS N
( ( N
MIC NNP N
) ) N
> VBD N
67 CD N
nM/litre NN N
. . N

The DT N
MIC NNP N
and CC N
50 CD N
% NN N
, , N
90 CD N
% NN N
and CC N
99 CD N
% NN N
inhibitory JJ N
concentrations NNS N
were VBD N
200.8 CD N
, , N
6.27 CD N
, , N
31.7 CD N
and CC N
119.6 CD N
nM/litre NNS N
respectively RB N
. . N

Four CD N
of IN N
22 CD N
isolates NNS N
were VBD N
resistant JJ N
to TO N
chloroquine VB N
( ( N
MIC NNP N
> NNP N
108 CD N
nM/litre NN N
) ) N
. . N

Isolates VBZ N
that IN N
showed VBD N
low JJ N
sensitivity NN N
to TO N
mefloquine VB N
in IN N
vitro NN N
were VBD N
sensitive JJ N
to TO N
chloroquine VB N
in IN N
vitro NN N
, , N
and CC N
the DT N
4 CD N
that WDT N
were VBD N
resistant JJ N
to TO N
chloroquine VB N
were VBD N
sensitive JJ N
to TO N
mefloquine VB N
. . N

Irrespective NNP N
of IN N
MIC NNP N
and CC N
dose NN N
of IN N
mefloquine NN N
, , N
parasitaemia NN N
cleared VBN N
in IN N
all DT N
subjects NNS N
in IN N
96 CD N
h NN N
or CC N
less JJR N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -X- O O 19692186

Aspirin-associated JJ 4_p
iron NN 4_p
loss NN 4_p
as IN N
an DT N
anticancer NN 4_p
mechanism NN N
. . N

A DT N
consensus NN N
view NN N
has VBZ N
emerged VBN N
favoring VBG N
an DT N
anticancer JJ N
effect NN N
of IN N
long-term JJ N
aspirin NN N
use NN N
. . N

Aspirin-induced JJ N
loss NN N
of IN N
stored VBN N
iron NN N
from IN N
chronic JJ N
gastrointestinal JJ N
bleeding NN N
is VBZ N
proposed VBN N
as IN N
a DT N
mechanism NN N
underlying VBG N
this DT N
beneficial JJ N
effect NN N
. . N

In IN N
iron NN N
depletion NN N
, , N
less JJR N
iron NN N
may MD N
be VB N
available JJ N
for IN N
carcinogenesis NN N
through IN N
free-radical JJ N
mediated VBN N
mechanisms NNS N
and CC N
for IN N
promotion NN N
of IN N
tumor NN N
growth NN N
. . N

Low-dose JJ N
aspirin NN N
increases NNS N
gastrointestinal JJ N
losses NNS N
of IN N
transfused VBN N
radiolabeled VBN N
autologous JJ N
red JJ N
cells NNS N
. . N

Observational JJ N
studies NNS N
report VBP N
lower JJR N
serum NN N
ferritin NN N
values NNS N
with IN N
regular JJ N
aspirin NN N
use NN N
. . N

A DT N
protective JJ N
effect NN N
of IN N
induced JJ N
iron NN N
reduction NN N
against IN N
cancer NN N
mortality NN N
has VBZ N
been VBN N
confirmed VBN N
in IN N
a DT N
recent JJ N
trial NN N
( ( N
FeAST NNP N
) ) N
with IN N
subjects NNS N
randomized VBN N
to TO N
iron VB N
reduction NN N
or CC N
observation NN N
. . N

Serum NNP N
ferritin JJ N
reductions NNS N
in IN N
the DT N
FeAST NNP N
trial NN N
were VBD N
within IN N
conventionally RB N
normal JJ N
reference NN N
ranges NNS N
and CC N
were VBD N
quantitatively RB N
similar JJ N
to TO N
ferritin VB N
reductions NNS N
in IN N
observational JJ N
studies NNS N
in IN N
regular JJ 4_p
aspirin NN 4_p
users NNS 4_p
. . N

Delayed NNP N
anticancer NN N
effects NNS N
of IN N
aspirin NN N
are VBP N
compatible JJ N
with IN N
the DT N
proposed VBN N
mechanism NN N
, , N
as IN N
continual JJ N
microbleeding NN N
has VBZ N
a DT N
gradual JJ N
cumulative JJ N
effect NN N
on IN N
stored VBN N
iron NN N
. . N

-DOCSTART- -X- O O 8034784

Effectiveness NN N
of IN N
a DT N
calculus NN N
scaling VBG N
gel NN N
. . N

This DT N
study NN N
evaluated VBD N
the DT N
effect NN N
of IN N
a DT N
calculus NN N
scaling VBG N
gel NN N
( ( N
SofScale NNP N
) ) N
on IN N
time NN N
and CC N
ease NN N
of IN N
the DT N
scaling NN N
procedure NN N
in IN N
a DT N
double-blind JJ N
, , N
split-mouth JJ N
clinical JJ N
study NN N
of IN N
32 CD 4_p
subjects NNS 4_p
. . 4_p

The DT N
Volpe-Manhold JJ N
calculus NN N
index NN N
was VBD N
used VBN N
to TO N
quantify VB N
the DT N
distribution NN N
and CC N
amount NN N
of IN N
calculus JJ N
deposition NN N
on IN N
the DT N
lingual JJ N
aspect NN N
of IN N
the DT N
mandibular JJ N
6 CD N
anterior JJ N
teeth NNS N
at IN N
baseline NN N
. . N

The DT N
gel NN N
was VBD N
applied VBN N
directly RB N
to TO N
the DT N
calculus NN N
and CC N
subgingivally RB N
to TO N
the DT N
area NN N
to TO N
be VB N
scaled VBN N
. . N

Pre- JJ N
and CC N
post-treatment JJ N
gingival NN N
and CC N
stain NN N
indices NNS N
were VBD N
taken VBN N
. . N

Operator NNP N
and CC N
subject JJ N
questionnaires NNS N
were VBD N
completed VBN N
immediately RB N
after IN N
treatment NN N
to TO N
determine VB N
ease NN N
of IN N
the DT N
scaling JJ N
procedure NN N
. . N

Results NNS N
were VBD N
analyzed VBN N
with IN N
paired JJ N
t-tests NNS N
. . N

The DT N
time NN N
difference NN N
in IN N
scaling VBG N
between IN N
the DT N
product NN N
and CC N
placebo JJ N
side NN N
was VBD N
not RB N
significant JJ N
. . N

This DT N
study NN N
found VBD N
that IN N
SofScale NNP N
is VBZ N
safe JJ N
to TO N
gingival VB N
tissues NNS N
and CC N
does VBZ N
not RB N
promote VB N
tooth JJ N
sensitivity NN N
. . N

However RB N
, , N
this DT N
study NN N
did VBD N
not RB N
find VB N
significant JJ N
differences NNS N
in IN N
scaling VBG N
time NN N
between IN N
product NN N
and CC N
placebo NN N
when WRB N
using VBG N
a DT N
2-minute JJ N
gel NN N
contact NN N
time NN N
. . N

-DOCSTART- -X- O O 15167457

Gender NNP N
difference NN N
in IN N
the DT N
response NN N
to TO N
an DT N
angiotensin-converting JJ N
enzyme NN N
inhibitor NN N
and CC N
a DT N
diuretic JJ N
in IN N
hypertensive JJ 4_p
patients NNS 4_p
of IN 4_p
African JJ 4_p
descent NN 4_p
. . N

BACKGROUND IN N
The DT N
efficacy NN N
of IN N
angiotensin-converting JJ N
enzyme NN N
( ( N
ACE NNP N
) ) N
inhibitors NNS N
in IN N
decreasing VBG N
blood NN N
pressure NN N
in IN N
African JJ N
patients NNS N
is VBZ N
controversial JJ N
. . N

OBJECTIVE IN N
We PRP N
examined VBD N
the DT N
ambulatory JJ N
blood NN N
pressure NN N
( ( N
ABP NNP N
) ) N
response NN N
to TO N
a DT N
diuretic JJ N
and CC N
an DT N
ACE NNP N
inhibitor NN N
in IN N
hypertensive JJ N
patients NNS N
of IN N
East JJ N
African JJ N
descent NN N
and CC N
evaluated VBD N
the DT N
individual JJ N
characteristics NNS N
that WDT N
determined VBD N
treatment NN N
efficacy NN N
. . N

DESIGN VB N
A DT N
single-blind JJ N
randomized JJ N
AB/BA NNP N
crossover NN N
design NN N
. . N

SETTING NN N
Hypertensive JJ N
families NNS N
of IN N
East JJ N
African JJ N
descent NN N
from IN N
the DT N
general JJ N
population NN N
in IN N
the DT N
Seychelles NNP N
. . N

PARTICIPANTS NNP N
Fifty-two NNP N
( ( N
29 CD N
men NNS N
and CC N
23 CD N
women NNS N
) ) N
out IN N
of IN N
62 CD N
eligible JJ N
hypertensive JJ N
patients NNS N
were VBD N
included.Main JJ N
outcome JJ N
measures NNS N
ABP NNP N
response NN N
to TO N
20 CD N
mg NNS N
lisinopril NN N
( ( N
LIS NNP N
) ) N
daily RB N
and CC N
25 CD N
mg NNS N
hydrochlorothiazide RB N
( ( N
HCT NNP N
) ) N
daily RB N
given VBN N
for IN N
a DT N
4-week JJ N
period NN N
. . N

Results VB N
The DT N
daytime JJ N
systolic/diastolic JJ N
ABP NNP N
response NN N
to TO N
HCT NNP N
was VBD N
4.9 CD N
[ JJ N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
1.2-8.6 CD N
] JJ N
/3.6 NNP N
( ( N
1.0-6.2 JJ N
) ) N
mmHg NN N
for IN N
men NNS N
and CC N
12.9 CD N
( ( N
9.2-16.6 CD N
) ) N
/6.3 NN N
( ( N
3.7-8.8 JJ N
) ) N
mmHg NN N
for IN N
women NNS N
. . N

With IN N
LIS NNP N
the DT N
response NN N
was VBD N
18.8 CD N
( ( N
15.0-22.5 CD N
) ) N
/14.6 NN N
( ( N
12.0-17.1 JJ N
) ) N
mmHg NN N
for IN N
men NNS N
and CC N
12.4 CD N
( ( N
8.7-16.2 CD N
) ) N
/7.7 NN N
( ( N
5.1-10.2 JJ N
) ) N
mmHg NN N
for IN N
women NNS N
. . N

The DT N
night-time JJ N
systolic/diastolic JJ N
response NN N
to TO N
HCT NNP N
was VBD N
5.0 CD N
( ( N
0.6-9.4 CD N
) ) N
/2.7 NN N
[ NNP N
( ( N
-0.4 NNP N
) ) N
-5.7 VBP N
] JJ N
mmHg NN N
for IN N
men NNS N
and CC N
11.5 CD N
( ( N
7.1-16.0 CD N
) ) N
/5.7 NN N
( ( N
2.6-8.8 JJ N
) ) N
mmHg NN N
for IN N
women NNS N
, , N
and CC N
to TO N
LIS NNP N
was VBD N
18.7 CD N
( ( N
14.2-22.1 JJ N
) ) N
/15.4 NN N
( ( N
12.4-18.5 JJ N
) ) N
mmHg NN N
for IN N
men NNS N
and CC N
3.5 CD N
[ NN N
( ( N
-1.0 NNP N
) ) N
-7.9 VBP N
] JJ N
/2.3 NNP N
[ NNP N
( ( N
-0.8 NNP N
) ) N
-5.4 VBP N
] JJ N
mmHg NN N
for IN N
women NNS N
. . N

Linear JJ N
regression NN N
analyses NNS N
showed VBD N
that IN N
gender NN N
is VBZ N
an DT N
independent JJ N
predictor NN N
of IN N
the DT N
ABP NNP N
responses NNS N
to TO N
HCT NNP N
and CC N
to TO N
LIS NNP N
. . N

CONCLUSIONS NNP N
Hypertensive NNP N
patients NNS N
of IN N
African JJ N
descent NN N
responded VBD N
better JJR N
to TO N
LIS NNP N
than IN N
to TO N
HCT NNP N
. . N

Men NNP N
responded VBD N
better RBR N
to TO N
LIS NNP N
than IN N
to TO N
HCT NNP N
and CC N
women NNS N
responded VBD N
similarly RB N
to TO N
both DT N
drugs NNS N
. . N

-DOCSTART- -X- O O 20484620

Clonidine JJ N
clearance NN N
matures NNS N
rapidly RB N
during IN N
the DT N
early JJ N
postnatal JJ N
period NN N
: : N
a DT N
population NN N
pharmacokinetic JJ N
analysis NN N
in IN N
newborns NNS N
with IN N
neonatal JJ 4_p
abstinence NN 4_p
syndrome NN 4_p
. . N

The DT N
population NN N
pharmacokinetic NN N
( ( N
PK NNP N
) ) N
profile NN N
of IN N
oral JJ N
clonidine NN N
was VBD N
characterized VBN N
in IN N
newborns NNS N
with IN N
neonatal JJ 4_p
abstinence NN 4_p
syndrome NN 4_p
, , N
and CC N
significant JJ N
covariates NNS N
affecting VBG N
its PRP$ N
PK NNP N
parameters NNS N
were VBD N
identified VBN N
. . N

Plasma NNP N
clonidine JJ N
concentration NN N
data NNS N
were VBD N
obtained VBN N
from IN N
a DT N
clinical JJ N
trial NN N
in IN N
which WDT N
36 CD N
newborns NNS N
, , N
aged VBD N
1 CD N
to TO N
25 CD N
days NNS N
( ( N
postnatal JJ N
age NN N
, , N
PNA NNP N
) ) N
and CC N
weighing VBG N
2.1 CD N
to TO N
3.9 CD N
kg NNS N
, , N
were VBD N
enrolled VBN N
to TO N
take VB N
multiple JJ N
oral JJ N
doses NNS N
of IN N
clonidine NN N
. . N

The DT N
population NN N
PK NNP N
model NN N
of IN N
clonidine NN N
was VBD N
developed VBN N
by IN N
NONMEM NNP N
, , N
and CC N
significant JJ N
covariates NNS N
were VBD N
identified VBN N
, , N
followed VBN N
by IN N
nonparametric JJ N
bootstraps NNS N
( ( N
2000 CD N
replicates NNS N
) ) N
and CC N
simulation NN N
experiments NNS N
. . N

A DT N
1-compartment JJ N
open JJ N
linear NN N
PK NNP N
model NN N
was VBD N
chosen VBN N
to TO N
describe VB N
plasma JJ N
concentrations NNS N
of IN N
clonidine NN N
, , N
and CC N
body NN N
weight NN N
and CC N
PNA NNP N
were VBD N
significant JJ N
covariates NNS N
for IN N
apparent JJ N
clearance NN N
( ( N
CL/F NNP N
) ) N
as IN N
follows VBZ N
: : N
CL/F NNP N
( ( N
L/h NNP N
) ) N
= VBD N
15.2 CD N
× NNP N
[ NNP N
body NN N
weight NN N
( ( N
kg NN N
) ) N
/70 NN N
] NNP N
( ( N
0.75 CD N
) ) N
× NN N
[ JJ N
PNA NNP N
( ( N
day NN N
) ) N
( ( N
0.441 CD N
) ) N
/ NN N
( ( N
4.06 CD N
( ( N
0.441 CD N
) ) N
+ NN N
PNA NNP N
( ( N
day NN N
) ) N
( ( N
0.441 CD N
) ) N
) ) N
] NN N
. . N

Furthermore NNP N
, , N
CL/F NNP N
of IN N
clonidine NN N
increased VBN N
rapidly RB N
with IN N
PNA NNP N
during IN N
the DT N
first JJ N
month NN N
of IN N
life NN N
after IN N
body NN N
weight NN N
was VBD N
adjusted VBN N
. . N

Any DT N
optimal JJ N
dosage NN N
regimen NNS N
for IN N
clonidine NN N
in IN N
term NN N
neonates NNS N
should MD N
be VB N
based VBN N
on IN N
infant NN N
's POS N
age NN N
and CC N
body NN N
weight NN N
, , N
and CC N
1.5 CD N
µg/kg NN N
every DT N
4 CD N
hours NNS N
is VBZ N
proposed VBN N
starting VBG N
the DT N
second JJ N
week NN N
of IN N
life NN N
based VBN N
on IN N
the DT N
simulation NN N
results NNS N
. . N

-DOCSTART- -X- O O 24974254

Visual JJ N
feedback NN N
and CC N
target NN N
size NN N
effects NNS N
on IN N
reach-to-grasp JJ N
tasks NNS N
in IN N
children NNS N
with IN N
autism NN 4_p
. . N

This DT N
study NN N
explores VBZ N
the DT N
effects NNS N
of IN N
visual JJ N
condition NN N
and CC N
target NN N
size NN N
during IN N
four CD N
reach-to-grasp JJ N
tasks NNS N
between IN N
autistic JJ 4_p
children NNS N
and CC N
healthy JJ 4_p
controls NNS 4_p
. . N

Twenty NNP N
children NNS N
with IN N
autism NN 4_p
and CC N
20 CD N
healthy JJ N
controls NNS N
participated VBN N
in IN N
the DT N
study NN N
. . N

Qualisys NNP N
motion NN N
capture NN N
system NN N
and CC N
kinematic JJ N
measures NNS N
were VBD N
used VBN N
to TO N
record VB N
movement NN N
. . N

Autistic NNP 4_p
group NN N
showed VBD N
significantly RB N
longer RBR N
movement NN N
time NN N
, , N
larger JJR N
normalized VBN N
jerk NN N
score NN N
, , N
more RBR N
movement NN N
unit NN N
than IN N
controls NNS N
, , N
especially RB N
in IN N
non-visual JJ N
feedback NN N
and CC N
small JJ N
target NN N
blocks NNS N
. . N

Autistic NNP 4_p
group NN N
also RB N
showed VBD N
significantly RB N
larger JJR N
maximal JJ N
grip NN N
aperture NN N
and CC N
normalized JJ N
maximal JJ N
grip NN N
aperture NN N
in IN N
visual JJ N
feedback NN N
condition NN N
than IN N
controls NNS N
. . N

Autistic JJ 4_p
children NNS N
demonstrate VBP N
motor NN N
coordination NN N
problems NNS N
and CC N
also RB N
depend VBP N
on IN N
more JJR N
visual JJ N
cuing NN N
in IN N
high JJ N
accuracy NN N
tasks NNS N
. . N

Autistic JJ 4_p
children NNS N
develop VB N
other JJ N
compensatory NN N
skills NNS N
while IN N
performing VBG N
tasks NNS N
. . N

-DOCSTART- -X- O O 22344198

Efficacy NN N
and CC N
safety NN N
of IN N
leuprolide JJ N
acetate JJ N
3-month JJ N
depot NN N
11.25 CD N
milligrams NNS N
or CC N
30 CD N
milligrams NNS N
for IN N
the DT N
treatment NN N
of IN N
central JJ N
precocious JJ N
puberty NN N
. . N

CONTEXT NNP N
GnRH NNP N
agonist NN N
( ( N
GnRHa NNP N
) ) N
monthly JJ N
injections NNS N
are VBP N
frequently RB N
used VBN N
in IN N
the DT N
treatment NN N
of IN N
central JJ N
precocious JJ N
puberty NN N
( ( N
CPP NNP N
) ) N
. . N

The DT N
3-month JJ N
leuprolide NN N
depot NN N
11.25- JJ N
and CC N
30-mg JJ N
formulations NNS N
are VBP N
newly RB N
approved VBN N
treatment NN N
options NNS N
. . N

OBJECTIVE IN N
The DT N
aim NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
safety NN N
and CC N
efficacy NN N
of IN N
leuprolide JJ N
acetate JJ N
3-month JJ N
depot NN N
formulations NNS N
for IN N
the DT N
treatment NN N
of IN N
CPP NNP N
in IN N
children NNS N
. . N

DESIGN NN N
This DT N
was VBD N
a DT N
phase NN N
III NNP N
, , N
randomized VBD N
, , N
open-label JJ N
, , N
dose-ranging JJ N
6-month JJ N
study NN N
. . N

SETTING NNP N
Twenty-two JJ N
U.S. NNP N
medical JJ N
centers NNS N
( ( N
including VBG N
Puerto NNP N
Rico NNP N
) ) N
participated VBD N
. . N

PATIENTS NNP N
Children NNP N
diagnosed VBD N
with IN N
CPP NNP N
( ( N
n JJ N
= NNP N
84 CD N
) ) N
, , N
who WP N
were VBD N
either CC N
treatment NN N
naive JJ N
or CC N
previously RB N
treated VBN N
with IN N
GnRHa NNP N
, , N
were VBD N
recruited VBN N
. . N

Chronological JJ N
age NN N
at IN N
onset NN N
of IN N
pubertal JJ N
signs NNS N
was VBD N
less JJR N
than IN N
8 CD N
yr NN N
in IN N
girls NNS N
and CC N
less JJR N
than IN N
9 CD N
yr NN N
in IN N
boys NNS N
, , N
and CC N
bone NN N
age NN N
was VBD N
advanced VBN N
over IN N
chronological JJ N
age NN N
at IN N
least JJS N
1 CD N
yr NN N
. . N

INTERVENTION NNP N
Leuprolide NNP N
acetate NN N
depot NN N
( ( N
11.25 CD N
or CC N
30 CD N
mg NN N
) ) N
was VBD N
administered VBN N
im JJ N
every DT N
3 CD N
months NNS N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Biochemical NNP N
[ NNP N
peak-stimulated JJ N
LH NNP N
, , N
estradiol NN N
( ( N
girls NNS N
) ) N
, , N
and CC N
testosterone NN N
( ( N
boys NNS N
) ) N
] NN N
and CC N
anthropometric JJ N
( ( N
growth NN N
rate NN N
, , N
bone NN N
age NN N
acceleration NN N
, , N
pubertal JJ N
progression NN N
) ) N
parameters NNS N
and CC N
safety NN N
were VBD N
assessed VBN N
. . N

RESULTS NNP N
Peak-stimulated JJ N
LH NNP N
was VBD N
suppressed VBN N
in IN N
the DT N
11.25- JJ N
and CC N
30-mg JJ N
dose NN N
groups NNS N
in IN N
78.4 CD N
and CC N
95.2 CD N
% NN N
, , N
respectively RB N
, , N
of IN N
children NNS N
from IN N
months NNS N
2 CD N
through IN N
6 CD N
. . N

There EX N
were VBD N
nine CD N
treatment NN N
failures NNS N
( ( N
peak-stimulated JJ N
LH NNP N
> NNP N
4 CD N
IU/liter NNP N
) ) N
in IN N
the DT N
11.25-mg JJ N
group NN N
and CC N
two CD N
in IN N
the DT N
30-mg JJ N
group NN N
. . N

Basal NNP N
sex NN N
steroid NN N
suppression NN N
, , N
growth NN N
rates NNS N
, , N
pubertal JJ N
progression NN N
, , N
bone NN N
age NN N
advancement NN N
, , N
and CC N
adverse JJ N
events NNS N
were VBD N
similar JJ N
with IN N
either DT N
dose NN N
. . N

CONCLUSIONS NNP N
Treatment NNP N
with IN N
leuprolide JJ N
acetate JJ N
3-month JJ N
depot NN N
formulations NNS N
( ( N
11.25 CD N
and CC N
30 CD N
mg NN N
) ) N
effectively RB N
suppressed VBD N
the DT N
GnRH NNP N
axis NN N
, , N
was VBD N
well RB N
tolerated VBN N
, , N
and CC N
may MD N
positively RB N
impact VB N
patient JJ N
convenience NN N
and CC N
compliance NN N
. . N

-DOCSTART- -X- O O 21439528

Efficacy NN N
and CC N
safety NN N
of IN N
transient JJ N
ulnar JJ N
artery NN N
compression NN N
to TO N
recanalize VB N
acute JJ N
radial JJ N
artery NN N
occlusion NN N
after IN N
transradial JJ N
catheterization NN N
. . N

Radial JJ N
artery NN N
occlusion NN N
( ( N
RAO NNP N
) ) N
can MD N
result VB N
from IN N
transradial JJ N
catheterization NN N
. . N

We PRP N
compared VBN N
the DT N
incidence NN N
of IN N
RAO NNP N
with IN N
2 CD N
heparin JJ N
dosage NN N
regimens NNS N
after IN N
transradial JJ N
coronary JJ N
angiography NN N
, , N
and CC N
we PRP N
evaluated VBD N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
transient JJ N
homolateral JJ N
ulnar JJ N
artery NN N
compression NN N
to TO N
achieve VB N
acute JJ N
radial JJ N
artery NN N
recanalization NN N
. . N

Patients NNS 4_p
referred VBD 4_p
for IN 4_p
coronary JJ 4_p
angiography NN 4_p
were VBD N
randomized VBN N
to TO N
very-low-dose JJ N
heparin NN N
( ( N
2,000 CD N
IU NNP N
) ) N
or CC N
low-dose JJ N
heparin NN N
( ( N
5,000 CD N
IU NNP N
) ) N
. . N

On IN N
sheath NN N
removal NN N
, , N
hemostasis NN N
was VBD N
obtained VBN N
using VBG N
the DT N
TR NNP N
band NN N
with IN N
a DT N
plethysmography-guided JJ N
patent NN N
hemostasis NN N
technique NN N
. . N

In IN N
the DT N
case NN N
of IN N
RAO NNP N
as IN N
assessed VBN N
by IN N
duplex JJ N
ultrasonography NN N
3 CD N
to TO N
4 CD N
hours NNS N
after IN N
hemostasis NN N
, , N
immediate JJ N
1-hour JJ N
ulnar JJ N
artery NN N
compression NN N
was VBD N
applied VBN N
. . N

Hematomas NNP N
> VBD N
15 CD N
cm NN N
( ( N
2 CD N
) ) N
were VBD N
also RB N
assessed VBN N
. . N

We PRP N
randomized VBD N
465 CD N
patients NNS N
, , N
222 CD N
in IN N
the DT N
2,000-IU JJ N
group NN N
and CC N
243 CD N
in IN N
the DT N
5,000-IU JJ N
group NN N
. . N

The DT N
baseline NN N
and CC N
procedural JJ N
characteristics NNS N
were VBD N
comparable JJ N
in IN N
both DT N
groups NNS N
. . N

The DT N
incidence NN N
of IN N
initial JJ N
RAO NNP N
was VBD N
5.9 CD N
% NN N
in IN N
the DT N
2,000-IU JJ N
group NN N
and CC N
2.9 CD N
% NN N
in IN N
the DT N
5,000-IU JJ N
group NN N
( ( N
p JJ N
= NNP N
0.17 CD N
) ) N
, , N
with IN N
a DT N
compression NN N
time NN N
of IN N
2.10 CD N
± JJ N
0.78 CD N
hours NNS N
and CC N
2.25 CD N
± NN N
0.82 CD N
hours NNS N
, , N
respectively RB N
( ( N
p JJ N
= NNP N
0.051 CD N
) ) N
. . N

After IN N
ulnar JJ N
artery NN N
compression NN N
, , N
the DT N
final JJ N
incidence NN N
of IN N
RAO NNP N
was VBD N
4.1 CD N
% NN N
in IN N
the DT N
2,000-IU JJ N
group NN N
and CC N
0.8 CD N
% NN N
in IN N
the DT N
5,000-IU JJ N
group NN N
( ( N
p JJ N
= NNP N
0.03 CD N
) ) N
. . N

The DT N
incidence NN N
of IN N
local JJ N
hematoma NN N
was VBD N
2.3 CD N
% NN N
and CC N
3.7 CD N
% NN N
in IN N
the DT N
2,000- JJ N
and CC N
5,000-IU JJ N
groups NNS N
, , N
respectively RB N
( ( N
p JJ N
= NNP N
0.42 CD N
) ) N
. . N

In IN N
conclusion NN N
, , N
acute JJ N
RAO NNP N
after IN N
transradial JJ N
catheterization NN N
can MD N
be VB N
recanalized VBN N
by IN N
early JJ N
1-hour JJ N
homolateral JJ N
ulnar JJ N
artery NN N
compression NN N
. . N

This DT N
simple JJ N
nonpharmacologic JJ N
method NN N
was VBD N
effective JJ N
and CC N
safe JJ N
in IN N
patients NNS N
with IN N
very-low- JJ N
and CC N
low-dose JJ N
heparin NN N
. . N

Nevertheless NNP N
, , N
the DT N
incidence NN N
of IN N
final JJ N
RAO NNP N
remained VBD N
significantly RB N
lower JJR N
after IN N
a DT N
higher JJR N
anticoagulation NN N
level NN N
. . N

-DOCSTART- -X- O O 20054544

Paracetamol NNP N
reduces NNS N
postoperative VBP N
pain NN N
and CC N
rescue NN N
analgesic JJ N
demand NN N
after IN N
robot-assisted JJ N
endoscopic NN N
thyroidectomy NN N
by IN N
the DT N
transaxillary JJ N
approach NN N
. . N

BACKGROUND NNP N
Postoperative NNP 4_p
pain NN 4_p
following VBG 4_p
endoscopic NN 4_p
thyroidectomy NN 4_p
, , N
although IN N
less JJR N
severe JJ N
than IN N
after IN N
open JJ N
methods NNS N
, , N
is VBZ N
still RB N
a DT N
source NN N
of IN N
marked JJ N
discomfort NN N
and CC N
surgical JJ N
stress NN N
. . N

This DT N
clinical JJ N
trial NN N
was VBD N
conducted VBN N
to TO N
determine VB N
if IN N
repeated VBN N
intravenous JJ N
paracetamol NN N
could MD N
decrease VB N
postoperative JJ N
pain NN N
and CC N
rescue NN N
analgesic NN N
requirements NNS N
after IN N
robot-assisted JJ N
endoscopic JJ N
thyroidectomy NN N
via IN N
the DT N
transaxillary JJ N
approach NN N
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
This DT N
prospective JJ N
, , N
randomized VBN N
, , N
double-blinded JJ N
, , N
and CC N
placebo-controlled JJ N
study NN N
enrolled VBD N
124 CD N
women NNS N
21-60 CD N
years NNS N
of IN N
age NN N
who WP N
were VBD N
scheduled VBN N
for IN N
elective JJ N
gasless NN N
robot-assisted JJ N
endoscopic NN N
thyroidectomy NN N
via IN N
the DT N
transaxillary JJ N
approach NN N
. . N

The DT N
patients NNS N
were VBD N
given VBN N
placebo NNS N
or CC N
1 CD N
g NN N
of IN N
paracetamol NN N
as IN N
a DT N
100 CD N
ml JJ N
solution NN N
infused VBD N
over IN N
15 CD N
min NNS N
1 CD N
h NN N
before IN N
the DT N
induction NN N
of IN N
anesthesia NN N
, , N
and CC N
then RB N
at IN N
6-h JJ N
intervals NNS N
for IN N
the DT N
following JJ N
24 CD N
h. JJ N
RESULTS NNP N
Postoperative NNP N
pain NN N
scores NNS N
were VBD N
significantly RB N
lower JJR N
at IN N
1 CD N
, , N
3 CD N
, , N
6 CD N
, , N
and CC N
24 CD N
h NN N
after IN N
surgery NN N
in IN N
the DT N
paracetamol NN N
group NN N
than IN N
in IN N
the DT N
placebo NN N
group NN N
. . N

Significantly RB N
fewer JJR N
patients NNS N
in IN N
the DT N
paracetamol NN N
group NN N
received VBD N
rescue NN N
analgesics NNS N
compared VBN N
to TO N
the DT N
placebo NN N
group NN N
( ( N
9.5 CD N
% NN N
vs. FW N
65.6 CD N
% NN N
, , N
respectively RB N
) ) N
. . N

First NNP N
analgesic JJ N
time NN N
was VBD N
similar JJ N
in IN N
the DT N
two CD N
groups NNS N
. . N

Postoperative JJ N
nausea NN N
( ( N
44.3 CD N
% NN N
vs. FW N
22.2 CD N
% NN N
) ) N
and CC N
vomiting VBG N
( ( N
21.3 CD N
% NN N
vs. FW N
6.3 CD N
% NN N
) ) N
were VBD N
more RBR N
frequent JJ N
in IN N
the DT N
placebo NN N
group NN N
than IN N
in IN N
the DT N
paracetamol NN N
group NN N
. . N

Other JJ N
postoperative JJ N
side NN N
effects NNS N
, , N
including VBG N
sedation NN N
, , N
confusion NN N
, , N
and CC N
pruritus NN N
, , N
were VBD N
similar JJ N
in IN N
the DT N
two CD N
groups NNS N
. . N

CONCLUSIONS NNP N
We PRP N
concluded VBD N
that IN N
repeated JJ N
administration NN N
of IN N
1 CD N
g NN N
of IN N
intravenous JJ N
paracetamol NN N
over IN N
24 CD N
h NN N
is VBZ N
easy JJ N
, , N
effective JJ N
, , N
safe JJ N
, , N
and CC N
well RB N
tolerated VBN N
for IN N
pain NN N
management NN N
in IN N
patients NNS N
with IN N
moderate JJ 4_p
to TO 4_p
severe VB 4_p
postoperative JJ 4_p
pain NN 4_p
after IN N
gasless JJ N
robot-assisted JJ N
endoscopic NN N
thyroidectomy NN N
performed VBD N
via IN N
the DT N
transaxillary JJ N
approach NN N
. . N

-DOCSTART- -X- O O 16505756

Longitudinal JJ N
quality NN N
of IN N
life NN N
study NN N
in IN N
patients NNS N
with IN N
metastatic JJ N
gastric JJ N
cancer NN N
. . N

Analysis NNP N
modalities NNS N
and CC N
clinical JJ N
applicability NN N
of IN N
QoL NNP N
in IN N
randomized JJ N
phase NN N
II NNP N
trial NN N
in IN N
a DT N
digestive JJ N
oncology NN N
. . N

OBJECTIVES CC N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
longitudinal JJ N
quality NN N
of IN N
life NN N
( ( N
QoL NNP N
) ) N
between IN N
LV5FU2-irinotecan JJ N
and CC N
LV5FU2 NNP N
alone RB N
or CC N
LV5FU2-cisplatin NNP N
in IN N
a DT N
randomized JJ N
Phase NNP N
II NNP N
trial NN N
in IN N
patients NNS N
with IN N
metastatic JJ N
gastric JJ N
adenocarcinoma NN N
. . N

METHODS NNP N
Among IN N
134 CD N
eligible JJ N
patients NNS N
, , N
QLQ-C30 JJ N
scores NNS N
were VBD N
collected VBN N
and CC N
described VBN N
at IN N
each DT N
2 CD N
monthly JJ N
follow-up JJ N
visit NN N
during IN N
6 CD N
months NNS N
. . N

The DT N
frequencies NNS N
of IN N
QLQ-C30 NNP N
score NN N
improvement NN N
were VBD N
calculated VBN N
and CC N
mixed JJ N
models NNS N
for IN N
repeated JJ N
measurements NNS N
were VBD N
applied VBN N
with IN N
or CC N
without IN N
extreme JJ N
poorest JJS N
imputation NN N
for IN N
missing VBG N
scores NNS N
. . N

The DT N
" JJ N
survival NN N
" NN N
until IN N
definitive JJ N
global JJ N
health NN N
score NN N
( ( N
GHS NNP N
) ) N
deterioration NN N
was VBD N
estimated VBN N
. . N

RESULTS NNP N
At IN N
the DT N
3rd CD N
follow-up NN N
, , N
patients NNS N
with IN N
a DT N
stable JJ N
or CC N
improved VBN N
global JJ N
health NN N
ranged VBD N
from IN N
11 CD N
% NN N
in IN N
the DT N
LV5FU2-cisplatin JJ N
arm NN N
to TO N
18 CD N
% NN N
in IN N
the DT N
LV5FU2-irinotecan JJ N
arm NN N
. . N

The DT N
irinotecan-based-therapy JJ N
presented VBD N
14 CD N
to TO N
15 CD N
scores NNS N
with IN N
a DT N
better JJR N
QoL NNP N
. . N

The DT N
time NN N
until IN N
definitive JJ N
GHS NNP N
deterioration NN N
was VBD N
globally RB N
similar JJ N
between IN N
treatment NN N
arms NNS N
. . N

CONCLUSION NN N
This DT N
study NN N
highlights VBZ N
a DT N
better JJR N
impact NN N
of IN N
LV5FU2-irinotecan JJ N
and CC N
the DT N
interest NN N
of IN N
QoL NNP N
assessment NN N
in IN N
phase NN N
II NNP N
trials NNS N
to TO N
complement VB N
the DT N
risk-benefit JJ N
judgement NN N
. . N

-DOCSTART- -X- O O 20068494

Monitoring VBG N
acute JJ N
effects NNS N
on IN N
athletic JJ N
performance NN N
with IN N
mixed JJ N
linear JJ N
modeling NN N
. . N

UNLABELLED IN N
There EX N
is VBZ N
a DT N
need NN N
for IN N
a DT N
sophisticated JJ N
approach NN N
to TO N
track VB N
athletic JJ N
performance NN N
and CC N
to TO N
quantify VB N
factors NNS N
affecting VBG N
it PRP N
in IN N
practical JJ N
settings NNS N
. . N

PURPOSE NNP N
To TO N
demonstrate VB N
the DT N
application NN N
of IN N
mixed JJ N
linear JJ N
modeling VBG N
for IN N
monitoring VBG N
athletic JJ N
performance NN N
. . N

METHODS NNP N
Elite NNP N
sprint NN N
and CC N
middle-distance NN N
swimmers NNS N
( ( N
three CD N
females NNS N
and CC N
six CD N
males NNS N
; : N
aged VBN N
21-26 JJ N
yr NN N
) ) N
performed VBD N
6-13 JJ N
time NN N
trials NNS N
in IN N
training NN N
and CC N
competition NN N
in IN N
the DT N
9 CD N
wk NN N
before IN N
and CC N
including VBG N
Olympic-qualifying JJ N
trials NNS N
, , N
all DT N
in IN N
their PRP$ N
specialty NN N
event NN N
. . N

We PRP N
included VBD N
a DT N
double-blind NN N
, , N
randomized VBN N
, , N
diet-controlled JJ N
crossover NN N
intervention NN N
, , N
in IN N
which WDT N
the DT N
swimmers NNS N
consumed VBN N
caffeine NN N
( ( N
5 CD N
mg NN N
x NN N
kg NN N
( ( N
-1 NNP N
) ) N
body NN N
mass NN N
) ) N
or CC N
placebo NN N
. . N

The DT N
swimmers NNS N
also RB N
knowingly RB N
consumed VBD N
varying VBG N
doses NNS N
of IN N
caffeine NN N
in IN N
some DT N
time NN N
trials NNS N
. . N

We PRP N
used VBD N
mixed JJ N
linear JJ N
modeling NN N
of IN N
log-transformed JJ N
swim JJ N
time NN N
to TO N
quantify VB N
effects NNS N
on IN N
performance NN N
in IN N
training VBG N
versus NN N
competition NN N
, , N
in IN N
morning NN N
versus NN N
evening NN N
swims NNS N
, , N
and CC N
with IN N
use NN N
of IN N
caffeine NN N
. . N

Predictor NN N
variables NNS N
were VBD N
coded VBN N
as IN N
0 CD N
or CC N
1 CD N
to TO N
represent VB N
absence NN N
or CC N
presence NN N
, , N
respectively RB N
, , N
of IN N
each DT N
condition NN N
and CC N
were VBD N
included VBN N
as IN N
fixed JJ N
effects NNS N
. . N

The DT N
date NN N
of IN N
each DT N
performance NN N
test NN N
was VBD N
included VBN N
as IN N
a DT N
continuous JJ N
linear JJ N
fixed VBN N
effect NN N
and CC N
interacted VBN N
with IN N
the DT N
random NN N
effect NN N
for IN N
the DT N
athlete NN N
to TO N
represent VB N
individual JJ N
differences NNS N
in IN N
linear JJ N
trends NNS N
in IN N
performance NN N
. . N

RESULTS NNP N
Most JJS N
effects NNS N
were VBD N
clear JJ N
, , N
owing VBG N
to TO N
the DT N
high JJ N
reliability NN N
of IN N
performance NN N
times NNS N
in IN N
training NN N
and CC N
competition NN N
( ( N
typical JJ N
errors NNS N
of IN N
0.9 CD N
% NN N
and CC N
0.8 CD N
% NN N
, , N
respectively RB N
) ) N
. . N

Performance NN N
time NN N
improved VBN N
linearly RB N
by IN N
0.8 CD N
% NN N
per IN N
4 CD N
wk NN N
. . N

The DT N
swimmers NNS N
performed VBD N
substantially RB N
better RBR N
in IN N
evenings NNS N
versus JJ N
mornings NNS N
and CC N
in IN N
competition NN N
versus IN N
training NN N
. . N

A DT N
100-mg JJ N
dose NN N
of IN N
caffeine NN N
enhanced VBN N
performance NN N
in IN N
training NN N
and CC N
competition NN N
by IN N
approximately RB N
1.3 CD N
% NN N
. . N

There EX N
were VBD N
substantial JJ N
but CC N
unclear JJ N
individual JJ N
responses NNS N
to TO N
training NN N
and CC N
caffeine NN N
( ( N
SD NNP N
of IN N
0.3 CD N
% NN N
and CC N
0.8 CD N
% NN N
, , N
respectively RB N
) ) N
. . N

CONCLUSIONS NNP N
Mixed NNP N
linear IN N
modeling VBG N
can MD N
be VB N
applied VBN N
successfully RB N
to TO N
monitor VB N
factors NNS N
affecting VBG N
performance NN N
in IN N
a DT N
squad NN N
of IN N
elite JJ N
athletes NNS N
. . N

-DOCSTART- -X- O O 12358871

Multifaceted VBN N
support NN N
to TO N
improve VB N
clinical JJ N
decision NN N
making NN N
in IN N
diabetes NNS N
care NN N
: : N
a DT N
randomized NN N
controlled VBN N
trial NN N
in IN N
general JJ N
practice NN N
. . N

AIMS NNP N
To TO N
evaluate VB N
the DT N
effectiveness NN N
of IN N
a DT N
multifaceted VBN N
intervention NN N
to TO N
improve VB N
the DT N
clinical JJ N
decision NN N
making NN N
of IN N
general JJ 4_p
practitioners NNS 4_p
( ( 4_p
GPs NNP 4_p
) ) 4_p
for IN 4_p
patients NNS 4_p
with IN 4_p
diabetes NNS 4_p
. . N

To TO N
identify VB N
practice NN N
characteristics NNS N
which WDT N
predict VBP N
success NN N
. . N

METHODS NNP N
Cluster NNP N
randomized VBD N
controlled VBN N
trial NN N
with IN N
124 CD N
practices NNS N
and CC N
185 CD N
GPs NNP N
in IN N
The DT N
Netherlands NNP N
. . N

The DT N
intervention NN N
group NN N
received VBD N
feedback JJ N
reports NNS N
and CC N
support NN N
from IN N
a DT N
facilitator NN N
; : N
the DT N
control NN N
group NN N
received VBD N
no DT N
special JJ N
attention NN N
. . N

Outcome JJ N
measures NNS N
were VBD N
the DT N
compliance NN N
rates NNS N
with IN N
evidence-based JJ N
recommendations NNS N
pertaining VBG N
to TO N
discussion NN N
of IN N
body NN N
weight NN N
control NN N
, , N
discussion NN N
of IN N
problems NNS N
with IN N
medication NN N
, , N
blood NN N
pressure NN N
measurement NN N
, , N
foot NN N
examination NN N
, , N
eye NN N
examination NN N
, , N
initiating VBG N
anti-diabetic JJ N
medication NN N
or CC N
increasing VBG N
the DT N
dosage NN N
in IN N
cases NNS N
of IN N
uncontrolled JJ N
blood NN N
glucose NN N
, , N
and CC N
scheduling VBG N
a DT N
follow-up JJ N
appointment NN N
. . N

RESULTS VB N
The DT N
GPs NNP N
reported VBD N
on IN N
their PRP$ N
clinical JJ N
decision NN N
making NN N
in IN N
1410 CD N
consultations NNS N
with IN N
Type NNP 4_p
2 CD 4_p
diabetic JJ 4_p
patients NNS 4_p
at IN N
baseline NN N
and CC N
1449 CD N
consultations NNS N
after IN N
the DT N
intervention NN N
period NN N
. . N

The DT N
intervention NN N
resulted VBD N
in IN N
statistically RB N
significant JJ N
improvement NN N
for IN N
two CD N
of IN N
the DT N
seven CD N
outcome JJ N
measures NNS N
: : N
foot NN N
examination NN N
( ( N
odds NNS N
ratio VBP N
1.68 CD N
; : N
95 CD N
% NN N
confidence NN N
interval JJ N
1.19-2.39 JJ N
) ) N
and CC N
eye NN N
examination NN N
( ( N
1.52 CD N
; : N
1.07-2.16 JJ N
) ) N
. . N

Discussion NN N
of IN N
problems NNS N
with IN N
medication NN N
showed VBD N
a DT N
near JJ N
significant JJ N
trend NN N
towards NNS N
increased VBD N
benefit NN N
for IN N
the DT N
intervention NN N
group NN N
( ( N
1.52 CD N
; : N
0.99-2.32 JJ N
) ) N
. . N

Practice NNP N
characteristics NNS N
were VBD N
not RB N
found VBN N
to TO N
be VB N
related VBN N
to TO N
the DT N
success NN N
of IN N
the DT N
intervention NN N
. . N

CONCLUSIONS NNP N
Feedback NNP N
reports NNS N
with IN N
support NN N
from IN N
facilitators NNS N
appear VBP N
to TO N
increase VB N
rates NNS N
of IN N
foot NN N
examination NN N
and CC N
eye NN N
examination NN N
in IN N
general JJ N
practice NN N
. . N

Alternative JJ N
interventions NNS N
should MD N
be VB N
explored VBN N
to TO N
improve VB N
the DT N
pursuit NN N
of IN N
metabolic JJ N
control NN N
by IN N
GPs NNP N
. . N

-DOCSTART- -X- O O 2382949

Comparison NNP N
of IN N
enflurane NN N
and CC N
halothane NN N
in IN N
hypotensive JJ 4_p
eye NN 4_p
surgery NN 4_p
. . 4_p

Thirty NN N
patients NNS N
undergoing VBG N
elective JJ 4_p
eye NN 4_p
surgery NN 4_p
had VBD N
anaesthesia NNS N
induced VBN N
with IN N
sodium NN N
thiopentone NN N
, , N
suxamethonium NN N
and CC N
d-tubocurarine JJ N
chloride NN N
. . N

Patients NNS N
were VBD N
ventilated VBN N
with IN N
nitrous JJ N
oxide NN N
, , N
oxygen NN N
and CC N
either DT N
halothane NN N
or CC N
enflurane NN N
. . N

The DT N
volatile JJ N
agents NNS N
were VBD N
used VBN N
to TO N
decrease VB N
the DT N
systolic JJ N
blood NN N
pressure NN N
to TO N
80 CD N
mmHg NN N
. . N

The DT N
volatile JJ N
agent NN N
concentration NN N
in IN N
the DT N
blood NN N
was VBD N
measured VBN N
at IN N
30 CD N
min NN N
intervals NNS N
. . N

Both DT N
agents NNS N
were VBD N
effective JJ N
in IN N
producing VBG N
hypotension NN N
, , N
but CC N
enflurane NN N
was VBD N
the DT N
more RBR N
potent JJ N
hypotensive JJ N
agent NN N
in IN N
terms NNS N
of IN N
MAC NNP N
equivalents NNS N
. . N

There EX N
was VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
agents NNS N
with IN N
respect NN N
to TO N
speed NN N
of IN N
recovery NN N
. . N

-DOCSTART- -X- O O 15176685

Clarithromycin NNP N
reduces VBZ N
the DT N
severity NN N
of IN N
bronchial JJ N
hyperresponsiveness NN N
in IN N
patients NNS N
with IN N
asthma NN 4_p
. . N

A DT N
randomised JJ N
double-blind JJ N
placebo-controlled JJ N
study NN N
was VBD N
designed VBN N
to TO N
evaluate VB N
the DT N
effects NNS N
of IN N
a DT N
semisynthetic JJ N
macrolide NN N
antibiotic JJ N
, , N
clarithromycin NN N
, , N
on IN N
bronchial JJ N
hyperresponsiveness NN N
to TO N
methacholine VB N
in IN N
patients NNS N
with IN N
a DT N
diagnosis NN N
of IN N
asthma NN 4_p
. . N

Adult NNP N
asthma JJ 4_p
patients NNS N
undergoing VBG N
treatment NN N
with IN N
budesonide JJ N
400 CD N
microg NN N
b.i.d NN N
. . N

and CC N
salbutamol JJ N
200 CD N
microg NN N
p.r.n NN N
. . N

less JJR N
than IN N
twice RB N
weekly JJ N
were VBD N
studied VBN N
. . N

Arm VB N
A NNP N
( ( N
16 CD N
males/six NN N
females NNS N
, , N
aged VBD N
48 CD N
+/- JJ N
16 CD N
yrs NN N
) ) N
received VBD N
clarithromycin JJ N
250 CD N
mg NN N
b.i.d NN N
. . N

for IN N
8 CD N
weeks NNS N
, , N
arm NN N
B NNP N
( ( N
eight CD N
males/12 NN N
females NNS N
, , N
aged VBD N
42 CD N
+/- JJ N
12 CD N
yrs NN N
) ) N
clarithromycin VBZ N
250 CD N
mg NN N
t.id NN N
. . N

and CC N
arm JJ N
C NNP N
( ( N
six CD N
males/15 NN N
females NNS N
, , N
aged VBD N
41 CD N
+/- JJ N
16 CD N
yrs NN N
) ) N
placebo NN N
dextrose JJ N
tablets NNS N
. . N

Bronchial NNP N
hyperresponsiveness NN N
was VBD N
quantified VBN N
by IN N
measurement NN N
of IN N
the DT N
provocative JJ N
dose NN N
of IN N
methacholine NN N
causing VBG N
a DT N
20 CD N
% NN N
fall NN N
in IN N
forced JJ N
expiratory NN N
volume NN N
in IN N
one CD N
second NN N
( ( N
PD20 NNP N
) ) N
. . N

Median JJ N
( ( N
interquartile JJ N
range NN N
) ) N
PD20 NNP N
in IN N
the DT N
three CD N
groups NNS N
before IN N
and CC N
after IN N
treatment NN N
with IN N
clarithromycin NNS N
were VBD N
: : N
arm NN N
A NN N
: : N
0.3 CD N
( ( N
0.1-1 NN N
) ) N
and CC N
1.3 CD N
( ( N
0.6-2 NN N
) ) N
mg NN N
; : N
arm NN N
B NN N
: : N
0.4 CD N
( ( N
0.1-0.9 NN N
) ) N
and CC N
2 CD N
( ( N
2-2 JJ N
) ) N
mg NN N
; : N
and CC N
arm JJ N
C NNP N
: : N
0.4 CD N
( ( N
0.1-0.9 NN N
) ) N
and CC N
0.3 CD N
( ( N
0.1-0.6 NN N
) ) N
mg NN N
, , N
respectively RB N
. . N

Serum NNP N
free JJ N
cortisol NN N
levels NNS N
were VBD N
determined VBN N
and CC N
remained VBN N
unchanged JJ N
from IN N
baseline NN N
in IN N
the DT N
clarithromycin-treated JJ 4_p
patients NNS N
. . N

It PRP N
is VBZ N
concluded VBN N
that IN N
clarithromycin NN N
reduces VBZ N
the DT N
degree NN N
of IN N
bronchial JJ N
hyperresponsiveness NN N
in IN N
patients NNS N
with IN N
asthma NN 4_p
. . N

-DOCSTART- -X- O O 10555930

The DT N
effect NN N
of IN N
Cys NNP N
LT1 NNP N
receptor NN N
blockade NN N
on IN N
airway NN N
responses NNS N
to TO N
allergen VB N
. . N

STUDY NNP N
OBJECTIVE NNP N
To TO N
evaluate VB N
the DT N
effect NN N
of IN N
a DT N
potent JJ N
experimental JJ N
leukotriene NN N
receptor NN N
antagonist NN N
, , N
MK-571 NNP N
, , N
on IN N
airway NN N
responses NNS N
to TO N
inhaled VB N
allergen NN N
. . N

DESIGN NNP N
Randomized NNP N
, , N
double-blind NN N
, , N
placebo-controlled JJ N
, , N
crossover JJ N
trial NN N
. . N

SETTING NNP N
Clinical NNP N
research NN N
center NN N
. . N

SUBJECTS NNP N
Eight NNP N
male NN N
volunteers NNS N
with IN N
allergic JJ 4_p
asthma NN 4_p
. . N

INTERVENTIONS NNP N
An DT N
intravenous JJ N
loading NN N
dose NN N
was VBD N
followed VBN N
by IN N
an DT N
8-hour JJ N
infusion NN N
of IN N
MK-571 NNP N
or CC N
placebo NN N
, , N
with IN N
a DT N
7- JJ N
to TO N
14-day JJ N
washout NN N
between IN N
treatments NNS N
. . N

Allergen NNP N
challenge NN N
was VBD N
performed VBN N
after IN N
the DT N
loading NN N
dose NN N
and CC N
a DT N
histamine NN N
challenge NN N
was VBD N
performed VBN N
before IN N
and CC N
24 CD N
hours NNS N
after IN N
allergen NN N
. . N

MEASUREMENTS NNP N
AND CC N
MAIN NNP N
RESULTS NNP N
Forced NNP N
expiratory JJ N
volume NN N
in IN N
1 CD N
second NN N
was VBD N
measured VBN N
serially RB N
. . N

MK-571 NNP N
provided VBD N
about IN N
50 CD N
% NN N
protection NN N
during IN N
maximum JJ N
early JJ N
and CC N
late JJ N
responses NNS N
compared VBN N
with IN N
placebo NN N
( ( N
p=0.005 NN N
) ) N
, , N
but CC N
airway RB N
obstruction NN N
persisted VBD N
8-24 CD N
hours NNS N
after IN N
allergen NN N
on IN N
both DT N
treatment NN N
days NNS N
. . N

Airway NNP N
responsiveness NN N
to TO N
histamine VB N
was VBD N
not RB N
significantly RB N
attenuated VBN N
at IN N
24 CD N
hours NNS N
. . N

CONCLUSION NNP N
Blocking NNP N
Cys NNP N
LT1 NNP N
receptors NNS N
for IN N
8 CD N
hours NNS N
attenuated VBD N
the DT N
early JJ N
and CC N
late JJ N
responses NNS N
but CC N
did VBD N
not RB N
interrupt VB N
the DT N
cascade NN N
of IN N
events NNS N
leading VBG N
to TO N
subsequent JJ N
allergen-induced JJ N
airway NN N
obstruction NN N
and CC N
hyperreactivity NN N
. . N

-DOCSTART- -X- O O 26573368

A DT N
randomised JJ N
double-blind JJ N
placebo-controlled JJ N
trial NN N
investigating VBG N
the DT N
behavioural JJ N
effects NNS N
of IN N
vitamin NN N
, , N
mineral JJ N
and CC N
n-3 JJ N
fatty JJ N
acid JJ N
supplementation NN N
in IN N
typically RB N
developing VBG N
adolescent JJ N
schoolchildren NN N
. . N

Nutrient JJ N
deficiencies NNS N
have VBP N
been VBN N
implicated VBN N
in IN N
anti-social JJ N
behaviour NN N
in IN N
schoolchildren NN N
; : N
hence NN N
, , N
correcting VBG N
them PRP N
may MD N
improve VB N
sociability NN N
. . N

We PRP N
therefore RB N
tested VBD N
the DT N
effects NNS N
of IN N
vitamin NN N
, , N
mineral JJ N
and CC N
n-3 JJ N
supplementation NN N
on IN N
behaviour NN N
in IN N
a DT N
12-week JJ N
double-blind NN N
randomised VBD N
placebo-controlled JJ N
trial NN N
in IN N
typically RB N
developing VBG N
UK NNP N
adolescents NNS N
aged VBN N
13-16 CD N
years NNS N
( ( N
n RB N
196 CD N
) ) N
. . N

Changes NNS N
in IN N
erythrocyte JJ N
n-3 JJ N
and CC N
6 CD N
fatty JJ N
acids NNS N
and CC N
some DT N
mineral NN N
and CC N
vitamin NN N
levels NNS N
were VBD N
measured VBN N
and CC N
compared VBN N
with IN N
behavioural JJ N
changes NNS N
, , N
using VBG N
Conners NNP N
' POS N
teacher NN N
ratings NNS N
and CC N
school NN N
disciplinary JJ N
records NNS N
. . N

At IN N
baseline NN N
, , N
the DT N
children NNS N
's POS N
PUFA NNP N
( ( N
n-3 JJ N
and CC N
n-6 JJ N
) ) N
, , N
vitamin FW N
and CC N
mineral JJ N
levels NNS N
were VBD N
low JJ N
, , N
but CC N
they PRP N
improved VBD N
significantly RB N
in IN N
the DT N
group NN N
treated VBD N
with IN N
n-3 JJ N
, , N
vitamins NNS N
and CC N
minerals NNS N
( ( N
P=0·0005 NNP N
) ) N
. . N

On IN N
the DT N
Conners NNP N
disruptive JJ N
behaviour NN N
scale NN N
, , N
the DT N
group NN N
given VBN N
the DT N
active JJ N
supplements NNS N
improved VBN N
, , N
whereas IN N
the DT N
placebo NN N
group NN N
worsened VBD N
( ( N
F=5·555 NNP N
, , N
d=0·35 NN N
; : N
P=0·02 NNP N
) ) N
. . N

The DT N
general JJ N
level NN N
of IN N
disciplinary JJ N
infringements NNS N
was VBD N
low JJ N
, , N
thus RB N
making VBG N
it PRP N
difficult JJ N
to TO N
obtain VB N
improvements NNS N
. . N

However RB N
, , N
throughout IN N
the DT N
school NN N
term NN N
school NN N
disciplinary JJ N
infringements NNS N
increased VBN N
significantly RB N
( ( N
by IN N
25 CD N
% NN N
; : N
Bayes NNP N
factor=115 NN N
) ) N
in IN N
both CC N
the DT N
treated VBN N
and CC N
untreated JJ N
groups NNS N
. . N

However RB N
, , N
when WRB N
the DT N
subjects NNS N
were VBD N
split VBN N
into IN N
high JJ N
and CC N
low JJ N
baseline NN N
infringements NNS N
, , N
the DT N
low JJ N
subset NN N
increased VBD N
their PRP$ N
offences NNS N
, , N
whereas IN N
the DT N
high-misbehaviour JJ N
subset NN N
appeared VBD N
to TO N
improve VB N
after IN N
treatment NN N
. . N

But CC N
it PRP N
was VBD N
not RB N
possible JJ N
to TO N
determine VB N
whether IN N
this DT N
was VBD N
merely RB N
a DT N
statistical JJ N
artifact NN N
. . N

Thus RB N
, , N
when WRB N
assessed VBN N
using VBG N
the DT N
validated JJ N
and CC N
standardised JJ N
Conners NNP N
teacher NN N
tests NNS N
( ( N
but CC N
less JJR N
clearly RB N
when WRB N
using VBG N
school NN N
discipline NN N
records NNS N
in IN N
a DT N
school NN N
where WRB N
misbehaviour NN N
was VBD N
infrequent NN N
) ) N
, , N
supplementary JJ N
nutrition NN N
might MD N
have VB N
a DT N
protective JJ N
effect NN N
against IN N
worsening VBG N
behaviour NN N
. . N

-DOCSTART- -X- O O 20966820

Five-year JJ N
outcome NN N
of IN N
surgical JJ N
treatment NN N
of IN N
migraine NN N
headaches NNS N
. . N

BACKGROUND NNP N
This DT N
study NN N
was VBD N
designed VBN N
to TO N
assess VB N
the DT N
long-term JJ N
efficacy NN N
of IN N
surgical JJ N
deactivation NN N
of IN N
migraine NN N
headache NN N
trigger NN N
sites NNS N
. . N

METHODS NNP N
One CD N
hundred VBD N
twenty-five JJ N
volunteers NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
the DT N
treatment NN N
( ( N
n JJ N
= NNP N
100 CD N
) ) N
or CC N
control VB N
group NN N
( ( N
n JJ N
= NNP N
25 CD N
) ) N
after IN N
examination NN N
by IN N
the DT N
team NN N
neurologist NN N
to TO N
ensure VB N
a DT N
diagnosis NN N
of IN N
migraine NN 4_p
headache NN 4_p
. . N

Patients NNS N
were VBD N
asked VBN N
to TO N
complete VB N
the DT N
Medical NNP N
Outcomes NNP N
Study NNP N
36-Item JJ N
Short NNP N
Form NNP N
Health NNP N
Survey NNP N
, , N
Migraine-Specific NNP N
Quality NNP N
of IN N
Life NNP N
, , N
and CC N
Migraine NNP N
Disability NNP N
Assessment NNP N
questionnaires VBZ N
before IN N
treatment NN N
and CC N
at IN N
12- JJ N
and CC N
60-month JJ N
postoperative JJ N
follow-up NN N
. . N

The DT N
treatment NN N
group NN N
received VBD N
botulinum RB N
toxin NN N
to TO N
confirm VB N
the DT N
trigger NN N
sites VBZ N
; : N
controls NNS N
received VBD N
saline JJ N
injections NNS N
. . N

Treated VBN N
patients NNS N
underwent JJ N
surgical JJ N
deactivation NN N
of IN N
trigger NN N
site NN N
( ( N
s JJ N
) ) N
. . N

Results NNS N
were VBD N
analyzed VBN N
at IN N
1 CD N
year NN N
( ( N
previously RB N
published VBN N
) ) N
and CC N
5 CD N
years NNS N
postoperatively RB N
( ( N
the DT N
subject NN N
of IN N
this DT N
report NN N
) ) N
. . N

RESULTS JJ N
Eighty-nine NNP N
of IN N
100 CD N
patients NNS N
in IN N
the DT N
treatment NN N
group NN N
underwent JJ N
surgery NN N
, , N
and CC N
79 CD N
were VBD N
followed VBN N
for IN N
5 CD N
years NNS N
. . N

Ten CD N
patients NNS N
underwent JJ N
deactivation NN N
of IN N
additional JJ N
( ( N
different JJ N
) ) N
trigger NN N
sites NNS N
during IN N
the DT N
follow-up JJ N
period NN N
and CC N
were VBD N
not RB N
included VBN N
in IN N
the DT N
data NN N
analysis NN N
. . N

The DT N
final JJ N
outcome NN N
with IN N
or CC N
without IN N
inclusion NN N
of IN N
these DT N
10 CD N
patients NNS N
was VBD N
not RB N
statistically RB N
different JJ N
. . N

Sixty-one NN N
( ( N
88 CD N
percent NN N
) ) N
of IN N
69 CD N
patients NNS N
have VBP N
experienced VBN N
a DT N
positive JJ N
response NN N
to TO N
the DT N
surgery NN N
after IN N
5 CD N
years NNS N
. . N

Twenty NNP N
( ( N
29 CD N
percent NN N
) ) N
reported VBD N
complete JJ N
elimination NN N
of IN N
migraine NN N
headache NN N
, , N
41 CD N
( ( N
59 CD N
percent NN N
) ) N
noticed VBD N
a DT N
significant JJ N
decrease NN N
, , N
and CC N
eight CD N
( ( N
12 CD N
percent NN N
) ) N
experienced VBD N
no DT N
significant JJ N
change NN N
. . N

When WRB N
compared VBN N
with IN N
the DT N
baseline NN N
values NNS N
, , N
all DT N
measured VBD N
variables NNS N
at IN N
60 CD N
months NNS N
improved VBN N
significantly RB N
( ( N
p JJ N
< NNP N
0.0001 CD N
) ) N
. . N

CONCLUSION NNP N
Based VBD N
on IN N
the DT N
5-year JJ N
follow-up JJ N
data NNS N
, , N
there EX N
is VBZ N
strong JJ N
evidence NN N
that IN N
surgical JJ N
manipulation NN N
of IN N
one CD N
or CC N
more JJR N
migraine JJ N
trigger NN N
sites NNS N
can MD N
successfully RB N
eliminate VB N
or CC N
reduce VB N
the DT N
frequency NN N
, , N
duration NN N
, , N
and CC N
intensity NN N
of IN N
migraine NN N
headache NN N
in IN N
a DT N
lasting JJ N
manner NN N
. . N

-DOCSTART- -X- O O 7485923

[ NN N
Erythropoietin NNP N
therapy NN N
during IN N
frequent JJ N
autologous JJ 4_p
blood NN 4_p
donations NNS 4_p
. . N

Dose-finding NN N
study NN N
] NNP N
. . N

Avoidance NN N
of IN N
homologous JJ N
blood NN N
products NNS N
and CC N
patients NNS N
' POS N
demand NN N
for IN N
preoperative JJ N
autologous JJ N
blood NN N
donation NN N
programs NNS N
are VBP N
increasing VBG N
. . N

As IN N
many JJ N
of IN N
these DT N
patients NNS N
are VBP N
older JJR N
, , N
with IN N
a DT N
compromised VBN 4_p
cardiovascular NN 4_p
system NN 4_p
and CC N
a DT N
slow JJ N
response NN N
of IN N
the DT N
erythropoietic JJ N
system NN N
when WRB N
anemia NN N
occurs VBZ N
, , N
the DT N
feasibility NN N
and CC N
benefit NN N
of IN N
autologous JJ N
blood NN N
donation NN N
is VBZ N
often RB N
limited JJ N
. . N

Augmentation NN N
of IN N
preoperative JJ N
blood NN N
donation NN N
by IN N
therapy NN N
with IN N
recombinant JJ N
human JJ N
erythropoietin NN N
( ( N
rHuEPO NN N
) ) N
has VBZ N
been VBN N
described VBN N
in IN N
animal JJ N
models NNS N
and CC N
in IN N
patients NNS N
. . N

METHODS NNP N
. . N

In IN N
a DT N
multicenter NN N
, , N
controlled VBN N
, , N
randomized VBN N
trial NN N
, , N
49 CD N
patients NNS N
scheduled VBN N
for IN N
orthopaedic JJ 4_p
or CC 4_p
vascular JJ 4_p
surgery NN 4_p
received VBD N
0 CD N
( ( N
control NN N
group NN N
, , N
n RB N
= VBZ N
9 CD N
) ) N
, , N
200 CD N
( ( N
n JJ N
= NNP N
10 CD N
) ) N
, , N
300 CD N
( ( N
n JJ N
= NNP N
11 CD N
) ) N
, , N
400 CD N
( ( N
n JJ N
= NNP N
10 CD N
) ) N
or CC N
500 CD N
( ( N
n JJ N
= NNP N
9 CD N
) ) N
U/kg NNP N
rHuEPO NN N
( ( N
Erypo NNP N
, , N
Cilag NNP N
, , N
Sulzbach NNP N
, , N
distributor NN N
Fresenius NNP N
, , N
Oberursel NNP N
, , N
Germany NNP N
) ) N
subcutaneously RB N
twice RB N
a DT N
week NN N
for IN N
3 CD N
weeks NNS N
while IN N
every DT N
week NN N
450 CD N
ml NN N
blood NN N
was VBD N
collected VBN N
. . N

Iron NNP N
sulphate NN N
100 CD N
mg NN N
was VBD N
prescribed VBN N
orally RB N
twice RB N
a DT N
day NN N
. . N

Patients NNS N
were VBD N
ineligible JJ N
if IN N
they PRP N
had VBD N
uncontrolled VBN N
hypertension NN N
, , N
recent JJ N
myocardial JJ N
infarction NN N
, , N
haematological JJ N
disorders NNS N
or CC N
a DT N
history NN N
of IN N
seizures NNS N
. . N

Blood NNP N
donation NN N
had VBD N
to TO N
be VB N
cancelled VBN N
if IN N
the DT N
haematocrit NN N
was VBD N
below IN N
30 CD N
% NN N
. . N

RESULTS NNP N
. . N

There EX N
was VBD N
a DT N
significant JJ N
( ( N
ANOVA NNP N
) ) N
drop NN N
of IN N
the DT N
haematocrit NN N
value NN N
only RB N
in IN N
the DT N
control NN N
group NN N
, , N
and CC N
end-point NN N
values NNS N
for IN N
haematocrit NN N
and CC N
haemoglobin NN N
were VBD N
significantly RB N
elevated VBN N
in IN N
the DT N
400 CD N
and CC N
500 CD N
U/kg NNP N
groups NNS N
compared VBN N
with IN N
the DT N
control NN N
group NN N
( ( N
Table NNP N
9 CD N
) ) N
. . N

DISCUSSION NNP N
. . N

The DT N
erythropoietic JJ N
stimulus NN N
of IN N
phlebotomy NN N
for IN N
autologous JJ N
blood NN N
donations NNS N
is VBZ N
often RB N
not RB N
efficient JJ N
enough RB N
to TO N
guarantee VB N
a DT N
constant JJ N
haematocrit NN N
. . N

Lowering VBG N
of IN N
the DT N
preoperative JJ N
haematocrit NN N
jeopardizes VBZ N
the DT N
aim NN N
of IN N
avoidance NN N
of IN N
homologous JJ N
blood NN N
transfusions NNS N
. . N

rHuEPO NN N
increased VBD N
the DT N
efficiency NN N
of IN N
autologous JJ N
blood NN N
collections NNS N
, , N
as IN N
predonation NN N
haematocrit NN N
values NNS N
could MD N
be VB N
preserved VBN N
in IN N
the DT N
high-dosage NN N
groups NNS N
. . N

As IN N
a DT N
consequence NN N
, , N
homologous JJ N
transfusions NNS N
could MD N
be VB N
avoided VBN N
. . N

However RB N
, , N
there EX N
were VBD N
broad JJ N
interindividual JJ N
differences NNS N
in IN N
the DT N
erythropoietic JJ N
response NN N
, , N
possibly RB N
due JJ N
to TO N
limitations NNS N
in IN N
iron NN N
availability NN N
. . N

Adverse JJ N
effects NNS N
of IN N
rHuEPO NN N
therapy NN N
, , N
such JJ N
as IN N
hypertension NN N
, , N
thrombosis NN N
or CC N
neurologic JJ N
disorders NNS N
, , N
are VBP N
mostly RB N
reported VBN N
in IN N
patients NNS N
with IN N
terminal JJ 4_p
kidney NN 4_p
failure NN 4_p
. . N

No DT N
such JJ N
disturbances NNS N
were VBD N
observed VBN N
in IN N
the DT N
present JJ N
study NN N
. . N

CONCLUSION NNP N
. . N

rHuEPO NN N
ameliorates VBZ N
the DT N
preoperative JJ N
decrease NN N
of IN N
haemoglobin NN N
and CC N
haematocrit NN N
values NNS N
due JJ N
to TO N
autologous JJ N
blood NN N
donations NNS N
in IN N
a DT N
dose-related JJ N
fashion NN N
. . N

The DT N
individually RB N
adjusted VBN N
dosage NN N
of IN N
rHuEPO NN N
and CC N
iron NN N
supplementation NN N
merits NNS N
further JJ N
investigation NN N
. . N

-DOCSTART- -X- O O 10492627

Chemotherapy NNP N
for IN N
operable JJ 4_p
gastric JJ 4_p
cancer NN 4_p
: : 4_p
results NNS N
of IN N
the DT N
Dutch NNP N
randomised VBD N
FAMTX NNP N
trial NN N
. . N

The DT N
Dutch JJ 4_p
Gastric NNP N
Cancer NNP N
Group NNP N
( ( N
DGCG NNP N
) ) N
. . N

The DT N
aim NN N
of IN N
this DT N
trial NN N
was VBD N
to TO N
investigate VB N
whether IN N
pre-operative JJ N
chemotherapy NN N
leads VBZ N
to TO N
a DT N
15 CD N
% NN N
higher JJR N
curative JJ N
resectability NN N
rate NN N
in IN N
patients NNS N
with IN N
operable JJ N
gastric JJ N
cancer NN N
. . N

In IN N
this DT N
randomised JJ N
trial NN N
, , N
patients NNS N
were VBD N
allocated VBN N
to TO N
receive VB N
either RB N
four CD N
courses NNS N
of IN N
chemotherapy NN N
using VBG N
5-fluorouracil JJ N
, , N
doxorubicin JJ N
and CC N
methotrexate NN N
( ( N
FAMTX NNP N
) ) N
prior RB N
to TO N
surgery NN N
or CC N
to TO N
undergo VB N
surgery NN N
only RB N
. . N

Patients NNS N
younger JJR N
than IN N
75 CD N
years NNS N
of IN N
age NN N
with IN N
a DT N
good JJ N
physical NN N
and CC N
mental JJ N
condition NN N
and CC N
a DT N
histologically RB N
proven JJ N
adenocarcinoma NN N
of IN N
the DT N
stomach NN N
without IN N
clinical JJ N
or CC N
radiographic JJ N
( ( N
computed JJ N
tomography NN N
scan NN N
) ) N
evidence NN N
of IN N
distant JJ N
metastases NNS N
were VBD N
eligible JJ N
for IN N
this DT N
trial NN N
. . N

Early JJ N
gastric JJ N
cancer NN N
or CC N
cardia VB N
carcinoma NN N
were VBD N
excluded VBN N
. . N

The DT N
response NN N
to TO N
chemotherapy NN N
was VBD N
evaluated VBN N
after IN N
two CD N
and CC N
four CD N
courses NNS N
. . N

In IN N
case NN N
of IN N
progressive JJ N
disease NN N
( ( N
PD NNP N
) ) N
after IN N
two CD N
courses NNS N
, , N
patients NNS N
were VBD N
operated VBN N
upon IN N
as RB N
soon RB N
as IN N
possible JJ N
. . N

Otherwise NNP N
complete JJ N
response NN N
( ( N
CR NNP N
) ) N
partial JJ N
response NN N
( ( N
PR NNP N
) ) N
or CC N
stable JJ N
disease NN N
( ( N
SD NNP N
) ) N
, , N
two CD N
more JJR N
courses NNS N
were VBD N
scheduled VBN N
. . N

The DT N
standard JJ N
surgical JJ N
procedure NN N
was VBD N
a DT N
limited JJ N
lymphadenectomy NN N
( ( N
D1 NNP N
) ) N
with IN N
staging VBG N
biopsy NN N
of IN N
the DT N
para-aortic JJ N
lymph NN N
nodes NNS N
. . N

Between NNP N
September NNP N
1993 CD N
and CC N
February NNP N
1996 CD N
, , N
56 CD N
eligible JJ N
and CC N
evaluable JJ N
patients NNS N
were VBD N
entered VBN N
: : N
27 CD N
were VBD N
randomised VBN N
to TO N
receive VB N
FAMTX NNP N
before IN N
surgery NN N
and CC N
29 CD N
to TO N
undergo VB N
surgery NN N
only RB N
. . N

In IN N
the DT N
FAMTX NNP N
+ NNP N
surgery NN N
treatment NN N
group NN N
, , N
15/27 CD N
( ( N
56 CD N
% NN N
) ) N
had VBD N
curative JJ N
resections NNS N
versus VBP N
18/29 CD N
( ( N
62 CD N
% NN N
) ) N
in IN N
the DT N
surgery NN N
only RB N
arm NN N
. . N

There EX N
was VBD N
no DT N
difference NN N
in IN N
the DT N
frequency NN N
of IN N
TNM NNP N
stages NNS N
I PRP N
+ VBP N
II NNP N
in IN N
both DT N
treatment NN N
arms NNS N
: : N
15/27 CD N
versus NN N
15/29 CD N
. . N

Due JJ N
to TO N
PD NNP N
and/or NN N
toxicity NN N
, , N
12 CD N
patients NNS N
( ( N
44 CD N
% NN N
) ) N
could MD N
not RB N
complete VB N
the DT N
planned VBN N
four CD N
courses NNS N
of IN N
FAMTX NNP N
. . N

Response NNP N
evaluation NN N
after IN N
chemotherapy NN N
was VBD N
possible JJ N
in IN N
25 CD N
patients NNS N
: : N
2 CD N
CR NNP N
, , N
6 CD N
PR NNP N
, , N
8 CD N
SD NNP N
and CC N
9 CD N
PD NNP N
. . N

The DT N
difference NN N
in IN N
curative JJ N
resectability NN N
rate NN N
was VBD N
6.5 CD N
% NN N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
-32 NN N
to TO N
+19 VB N
% NN N
) ) N
in IN N
favour NN N
of IN N
surgery NN N
only RB N
. . N

Downstaging VBG N
for IN N
stages NNS N
I PRP N
+ VBP N
II NNP N
did VBD N
not RB N
occur VB N
. . N

PD NNP N
was VBD N
more RBR N
often RB N
the DT N
reason NN N
for IN N
not RB N
completing VBG N
the DT N
planned VBN N
four CD N
courses NNS N
than IN N
toxicity NN N
. . N

More RBR N
active JJ N
regimens NNS N
than IN N
FAMTX NNP N
are VBP N
required VBN N
for IN N
future JJ N
randomised VBN N
trials NNS N
. . N

-DOCSTART- -X- O O 14763475

Prospective JJ N
, , N
randomized JJ N
trial NN N
of IN N
diclofenac NN N
and CC N
ketorolac NN N
after IN N
refractive JJ 4_p
surgery NN 4_p
. . N

PURPOSE NNP N
To TO N
compare VB N
the DT N
effectiveness NN N
of IN N
diclofenac NN N
and CC N
ketorolac NN N
in IN N
relieving VBG N
corneal NN 4_p
pain NN 4_p
after IN N
refractive JJ N
surgery NN N
, , N
and CC N
determine VB N
if IN N
there EX N
is VBZ N
a DT N
difference NN N
in IN N
stinging VBG N
on IN N
instillation NN N
. . N

METHODS NNP N
Thirty NNP N
patients NNS N
were VBD N
randomized VBN N
prospectively RB N
to TO N
postoperative VB N
diclofenac NN N
in IN N
one CD N
eye NN N
and CC N
ketorolac NN N
in IN N
the DT N
other JJ N
. . N

Patients NNS N
and CC N
surgeon NN N
did VBD N
not RB N
know VB N
which WDT N
medications NNS N
were VBD N
used VBN N
. . N

Ocular JJ N
postoperative JJ N
pain NN N
and CC N
discomfort NN N
on IN N
instillation NN N
of IN N
medication NN N
were VBD N
measured VBN N
after IN N
radial JJ N
keratotomy NN N
with IN N
a DT N
visual JJ N
analog NN N
scale NN N
and CC N
a DT N
questionnaire NN N
. . N

RESULTS NNP N
Both NNP N
medications NNS N
were VBD N
highly RB N
effective JJ N
in IN N
relieving VBG N
pain NN N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
pain NN N
relief NN N
, , N
or CC N
stinging VBG N
on IN N
instillation NN N
( ( N
P NNP N
= NNP N
.29 NNP N
) ) N
. . N

CONCLUSION NNP N
There EX N
was VBD N
no DT N
statistical JJ N
difference NN N
in IN N
the DT N
effectiveness NN N
of IN N
the DT N
medications NNS N
on IN N
pain NN N
relief NN N
, , N
or CC N
in IN N
stinging VBG N
on IN N
instillation NN N
. . N

-DOCSTART- -X- O O 15279417

[ JJ N
Structural NNP N
and CC N
immunohistochemical JJ N
changes NNS N
of IN N
conjunctiva NN N
induced VBN N
by IN N
topical JJ N
glaucoma NN N
medication NN N
] NNP N
. . N

PURPOSE VB N
The DT N
topical JJ N
medication NN N
represents VBZ N
the DT N
first JJ N
line NN N
therapy NN N
for IN N
the DT N
primary JJ N
open JJ N
angle NN N
glaucoma NN N
. . N

The DT N
study NN N
is VBZ N
aimed VBN N
at IN N
assessing VBG N
the DT N
structural JJ N
and CC N
immunohistochemical JJ N
changes NNS N
of IN N
conjunctiva NN N
induced VBN N
by IN N
topical JJ N
glaucoma NN N
medication NN N
. . N

METHODS NNP N
For IN N
this DT N
purpose NN N
, , N
we PRP N
carried VBD N
out RP N
a DT N
40 CD N
weeks NNS N
, , N
prospective JJ N
, , N
experimental JJ N
, , N
epidemiological-operational JJ N
and CC N
randomized JJ N
study NN N
enrolling VBG N
18 CD N
patients NNS N
( ( N
36 CD N
eyes NNS N
) ) N
with IN N
recently RB N
primary JJ 4_p
open JJ 4_p
angle NN 4_p
glaucoma NN 4_p
. . N

The DT N
eyes NNS N
were VBD N
divided VBN N
into IN N
treatment NN N
( ( N
non-selective JJ N
beta NN N
blockers NNS N
or CC N
selective JJ N
, , N
prostaglandin JJ N
analogues NNS N
, , N
topical JJ N
carbonic JJ N
anhydrase NN N
inhibitors NNS N
) ) N
in IN N
four CD N
groups NNS N
. . N

The DT N
assessment NN N
was VBD N
performed VBN N
by IN N
comparison NN N
with IN N
control NN N
group NN N
( ( N
4 CD N
patients NNS N
) ) N
who WP N
was VBD N
instilled VBN N
with IN N
natural JJ 4_p
tears NNS 4_p
( ( N
with IN N
different JJ N
preservative NN N
) ) N
. . N

Both CC N
the DT N
cytology NN N
and CC N
the DT N
conjunctival NN N
biopsy NN N
specimens NNS N
were VBD N
investigated VBN N
by IN N
histological JJ N
exams NNS N
and CC N
immunohistochemistry NN N
using VBG N
different JJ N
monoclonal JJ N
antibodies NNS N
. . N

The DT N
study NN N
was VBD N
performed VBN N
by IN N
collaboration NN N
with IN N
The DT N
National NNP N
Institute NNP N
of IN N
Research NNP N
and CC N
Development NNP N
in IN N
Pathology NNP N
and CC N
Biomedical NNP N
Sciences- NNP N
" NNP N
V. NNP N
Babes NNP N
" NNP N
-Bucharest NNP N
. . N

RESULTS VB N
The DT N
morphometric JJ N
analysis NN N
of IN N
histological JJ N
sections NNS N
of IN N
conjunctiva NN N
showed VBD N
the DT N
following JJ N
changes NNS N
: : N
squamous JJ N
metaplasia NN N
( ( N
significant JJ N
increases NNS N
in IN N
the DT N
thickness NN N
and CC N
number NN N
of IN N
epithelial JJ N
cell NN N
layers NNS N
) ) N
, , N
inflammation NN N
( ( N
increase VB N
the DT N
number NN N
of IN N
lymphocytes NNS N
, , N
macrophages NNS N
and CC N
fibroblasts NNS N
) ) N
and CC N
subconjunctival JJ N
fibrosis NN N
. . N

According VBG N
to TO N
the DT N
type NN N
of IN N
medication NN N
, , N
we PRP N
observed VBD N
the DT N
significant JJ N
increase NN N
of IN N
subepithelial JJ N
collagen NN N
density NN N
and CC N
degenerative JJ N
changes NNS N
of IN N
fibrocytes NNS N
, , N
the DT N
reduction NN N
of IN N
extracellular JJ N
matrix NN N
and CC N
also RB N
the DT N
up-regulation NN N
of IN N
antibodies NNS N
against IN N
matrix JJ N
metalloproteinase NN N
and CC N
allergic JJ N
changes NNS N
. . N

According VBG N
to TO N
structural JJ N
changes NNS N
, , N
the DT N
immunohistochemistry NN N
confirmed VBD N
the DT N
tendency NN N
of IN N
chronic JJ N
inflammation NN N
. . N

CONCLUSIONS VB N
This DT N
study NN N
revealed VBD N
important JJ N
structural JJ N
and CC N
immunohistochemical JJ N
changes NNS N
of IN N
conjunctiva NN N
after IN N
topical JJ N
glaucoma NN N
medication NN N
. . N

The DT N
category NN N
and CC N
the DT N
intensity NN N
of IN N
these DT N
changes NNS N
are VBP N
dependent JJ N
on IN N
the DT N
sort NN N
of IN N
therapy NN N
and CC N
the DT N
topical JJ N
treatment NN N
period NN N
. . N

The DT N
findings NNS N
showed VBD N
that IN N
benzalkonium NN N
chloride NN N
( ( N
the DT N
most RBS N
common JJ N
preservative NN N
of IN N
antiglaucoma NN N
drugs NNS N
) ) N
is VBZ N
a DT N
major JJ N
factor NN N
for IN N
conjunctival NN N
metaplasia NN N
. . N

-DOCSTART- -X- O O 12057986

Impact NN N
of IN N
different JJ N
platelet NN N
glycoprotein NN N
IIb/IIIa NNP N
receptor NN N
inhibitors NNS N
among IN N
diabetic JJ 4_p
patients NNS N
undergoing VBG N
percutaneous JJ 4_p
coronary JJ 4_p
intervention NN 4_p
: : N
: : N
Do VB N
Tirofiban NNP N
and CC N
ReoPro NNP N
Give NNP N
Similar NNP N
Efficacy NNP N
Outcomes NNP N
Trial NNP N
( ( N
TARGET NNP N
) ) N
1-year JJ N
follow-up NN N
. . N

BACKGROUND IN N
The DT N
platelet NN N
glycoprotein NN N
IIb/IIIa NNP N
receptor NN N
inhibitor NN N
abciximab NN N
, , N
a DT N
monoclonal JJ N
antibody NN N
, , N
has VBZ N
been VBN N
shown VBN N
to TO N
improve VB N
early JJ N
and CC N
late JJ N
outcomes NNS N
among IN N
diabetic JJ N
patients NNS N
undergoing VBG N
percutaneous JJ N
coronary JJ N
intervention NN N
( ( N
PCI NNP N
) ) N
. . N

It PRP N
is VBZ N
unknown JJ N
whether IN N
small-molecule JJ N
agents NNS N
confer VBP N
similar JJ N
benefits NNS N
. . N

METHODS NNP N
AND CC N
RESULTS NNP N
In IN N
18 CD N
countries NNS N
, , N
4809 CD N
patients NNS N
undergoing VBG N
PCI NNP N
with IN N
stent JJ 4_p
implantation NN 4_p
were VBD N
randomized VBN N
to TO N
tirofiban VB N
or CC N
abciximab VB N
. . N

At IN N
the DT N
time NN N
of IN N
enrollment NN N
, , N
patients NNS N
were VBD N
stratified VBN N
according VBG N
to TO N
diabetes NNS N
status NN N
. . N

As IN N
compared VBN N
with IN N
non-diabetic JJ N
patients NNS N
, , N
patients NNS N
with IN N
diabetes NNS N
( ( N
n=1117 NN N
) ) N
showed VBD N
similar JJ N
30-day JJ N
ischemic JJ N
outcomes NNS N
, , N
an DT N
increased JJ N
incidence NN N
of IN N
any DT N
target NN N
vessel NN N
revascularization NN N
( ( N
TVR NNP N
) ) N
at IN N
6 CD N
months NNS N
( ( N
10.3 CD N
% NN N
versus IN N
7.8 CD N
% NN N
; : N
P= NNP N
0.008 CD N
) ) N
, , N
and CC N
a DT N
trend NN N
toward IN N
higher JJR N
1-year JJ N
mortality NN N
( ( N
2.5 CD N
% NN N
versus IN N
1.6 CD N
% NN N
; : N
P=0.056 NNP N
) ) N
. . N

Among IN N
diabetic JJ N
patients NNS N
randomized VBN N
to TO N
tirofiban VB N
( ( N
n=560 NN N
) ) N
, , N
the DT N
incidence NN N
of IN N
death NN N
, , N
myocardial JJ N
infarction NN N
( ( N
MI NNP N
) ) N
, , N
or CC N
urgent JJ N
TVR NNP N
at IN N
30 CD N
days NNS N
was VBD N
6.2 CD N
% NN N
, , N
and CC N
among IN N
those DT N
randomized VBN N
to TO N
abciximab VB N
( ( N
n=557 NN N
) ) N
it PRP N
was VBD N
5.4 CD N
% NN N
( ( N
hazard JJ N
ratio NN N
[ NNP N
HR NNP N
] NNP N
1.16 CD N
; : N
P=0.540 NNP N
) ) N
. . N

At IN N
6 CD N
months NNS N
, , N
the DT N
composite NN N
of IN N
death NN N
, , N
MI NNP N
, , N
or CC N
any DT N
TVR NNP N
occurred VBD N
in IN N
15.7 CD N
% NN N
and CC N
in IN N
16.9 CD N
% NN N
of IN N
tirofiban NN N
and CC N
abciximab NN N
patients NNS N
, , N
respectively RB N
( ( N
HR NNP N
0.93 CD N
; : N
P=0.610 NNP N
) ) N
. . N

Any DT N
TVR NNP N
occurred VBD N
in IN N
9.5 CD N
% NN N
and CC N
11.1 CD N
% NN N
, , N
respectively RB N
( ( N
HR NNP N
0.84 CD N
; : N
P= NNP N
0.366 CD N
) ) N
. . N

The DT N
1-year JJ N
mortality NN N
was VBD N
2.1 CD N
% NN N
in IN N
the DT N
tirofiban NN N
group NN N
and CC N
2.9 CD N
% NN N
in IN N
the DT N
abciximab NN N
group NN N
( ( N
HR NNP N
0.74 CD N
; : N
P= NNP N
0.436 CD N
) ) N
. . N

CONCLUSIONS NNP N
Among IN N
diabetic JJ 4_p
patients NNS 4_p
undergoing VBG 4_p
PCI NNP 4_p
, , N
tirofiban NN N
and CC N
abciximab NN N
were VBD N
associated VBN N
with IN N
comparable JJ N
event NN N
rates NNS N
, , N
including VBG N
similar JJ N
rates NNS N
of IN N
6-month JJ N
TVR NNP N
and CC N
1-year JJ N
mortality NN N
. . N

These DT N
findings NNS N
suggest VBP N
that IN N
the DT N
non-glycoprotein JJ N
IIb/IIIa NNP N
properties NNS N
of IN N
abciximab NNS N
do VBP N
not RB N
translate VB N
into IN N
a DT N
discernible JJ N
long-term JJ N
clinical JJ N
benefit NN N
among IN N
diabetic JJ N
patients NNS N
. . N

-DOCSTART- -X- O O 22692114

The DT N
acute JJ N
effects NNS N
of IN N
fluid JJ N
intake NN N
on IN N
urine JJ N
specific JJ N
gravity NN N
and CC N
fluid JJ N
retention NN N
in IN N
a DT N
mildly RB 4_p
dehydrated JJ 4_p
state NN 4_p
. . N

Many JJ N
athletes NNS N
arrive VBP N
at IN N
training NN N
sessions NNS N
and CC N
competitions NNS N
in IN N
a DT N
mildly RB N
hypohydrated VBN N
( ( N
HYPO NNP 4_p
) ) N
state NN N
and CC N
are VBP N
instructed VBN N
to TO N
drink VB N
fluids NNS N
before IN N
exercise NN N
to TO N
reach VB N
a DT N
euhydrated JJ N
( ( N
HYD NNP N
) ) N
state NN N
. . N

Ten CD N
recreational JJ N
athletes NNS N
( ( N
6 CD N
women NNS N
, , N
4 CD N
men NNS N
; : N
71.9 CD N
± $ N
4.6 CD N
kg NN N
, , N
25.2 CD N
± JJ N
0.9 CD N
years NNS N
) ) N
participated VBD N
in IN N
the DT N
studies NNS N
to TO N
examine VB N
( ( N
a DT N
) ) N
the DT N
day-to-day JJ N
variability NN N
of IN N
morning NN N
urine NN N
specific JJ N
gravity NN N
( ( N
USG NNP N
) ) N
, , N
( ( N
b NN N
) ) N
the DT N
effects NNS N
of IN N
consuming VBG N
600 CD N
ml NN N
of IN N
water NN N
on IN N
the DT N
hydration NN N
status NN N
of IN N
HYD NNP N
and CC N
HYPO NNP N
( ( N
USG NNP N
> NNP N
1.020 CD N
) ) N
subjects NNS N
, , N
and CC N
( ( N
c NN N
) ) N
the DT N
effects NNS N
of IN N
consuming VBG N
water NN N
( ( N
W NNP N
) ) N
, , N
salt-water JJ N
( ( N
SW NNP N
, , N
40 CD N
mM NN N
Na NNP N
) ) N
, , N
a DT N
carbohydrate-electrolyte JJ N
solution NN N
with IN N
3 CD N
% NN N
or CC N
light JJ N
carbohydrate NN N
( ( N
CES-L NNP N
, , N
20 CD N
mM NN N
Na NNP N
) ) N
or CC N
a DT N
CES NN N
with IN N
6 CD N
% NN N
carbohydrate NN N
( ( N
CES NNP N
, , N
20 CD N
mM NN N
Na NNP N
) ) N
on IN N
the DT N
hydration NN N
status NN N
of IN N
HYPO NNP N
subjects NNS N
. . N

The DT N
hydration NN N
status NN N
was VBD N
assessed VBN N
with IN N
USG NNP N
and CC N
body NN N
mass NN N
measures NNS N
and CC N
urine JJ N
volume NN N
collections NNS N
. . N

The DT N
day-to-day JJ N
variability NN N
in IN N
morning NN N
USG NNP N
( ( N
coefficient NN N
of IN N
variation NN N
= FW N
0.2 CD N
± $ N
0.1 CD N
% NN N
) ) N
was VBD N
low JJ N
and CC N
the DT N
responses NNS N
to TO N
600 CD N
ml NN N
of IN N
W NNP N
ingestion NN N
were VBD N
repeatable JJ N
. . N

Pretrial JJ N
USG NNP N
was VBD N
1.022 CD N
± JJ N
0.001 CD N
in IN N
the DT N
HYPO NNP N
trial NN N
and CC N
decreased VBD N
< NNS N
1.020 CD N
by IN N
45 CD N
minutes NNS N
( ( N
1.013 CD N
± RB N
0.003 CD N
) ) N
. . N

In IN N
the DT N
CES NNP N
study NN N
, , N
HYPO NNP N
subjects VBZ N
reached VBN N
HYD NNP N
status NN N
at IN N
45 CD N
minutes NNS N
in IN N
all DT N
conditions NNS N
( ( N
W NNP N
1.013 CD N
± NNP N
0.003 CD N
, , N
SW NNP N
1.013 CD N
± NNP N
0.003 CD N
, , N
CES-L NNP N
1.011 CD N
± NNP N
0.003 CD N
, , N
CES NNP N
1.017 CD N
± NNP N
0.004 CD N
) ) N
because IN N
salt NN N
or CC N
CES NNP N
ingestion NN N
did VBD N
not RB N
affect VB N
fluid NN N
retention NN N
( ( N
W NNP N
68 CD N
% NN N
, , N
SW NNP N
72 CD N
% NN N
, , N
CES-L JJ N
68 CD N
% NN N
, , N
CES NNP N
76 CD N
% NN N
) ) N
. . N

This DT N
study NN N
demonstrated VBD N
that IN N
mildly RB N
HYPO NNP N
subjects NNS N
could MD N
reach VB N
euhydration NN N
within IN N
45 CD N
minutes NNS N
of IN N
the DT N
ingestion NN N
of IN N
600 CD N
ml NN N
of IN N
W NNP N
or CC N
a DT N
combination NN N
of IN N
salt NN N
and CC N
CES NNP N
solutions NNS N
. . N

Following VBG N
this DT N
practice NN N
will MD N
minimize VB N
the DT N
incidence NN N
of IN N
starting VBG N
a DT N
practice NN N
or CC N
competition NN N
hypohydrated VBN N
. . N

-DOCSTART- -X- O O 12356338

Acute NNP N
cardiac JJ N
effects NNS N
of IN N
nicotine NN N
in IN N
healthy JJ N
young JJ N
adults NNS N
. . N

BACKGROUND NNP N
Nicotine NNP N
is VBZ N
known VBN N
to TO N
have VB N
many JJ N
physiologic JJ N
effects NNS N
. . N

The DT N
influence NN N
of IN N
nicotine NN N
delivered VBN N
in IN N
chewing VBG N
gum NN N
upon IN N
cardiac JJ N
hemodynamics NNS N
and CC N
conduction NN N
has VBZ N
not RB N
been VBN N
well-characterized JJ N
. . N

METHODS NNP N
We PRP N
studied VBD N
the DT N
effects NNS N
of IN N
nicotine NN N
in IN N
nonsmoking VBG N
adults NNS N
( ( N
6 CD N
male NN N
, , N
5 CD N
female NN N
; : N
ages VBZ N
23-36 CD N
years NNS N
) ) N
using VBG N
a DT N
double-blind NN N
, , N
randomized VBN N
, , N
cross-over JJ N
study NN N
. . N

Subjects NNS N
chewed VBD N
nicotine JJ N
gum NN N
( ( N
4 CD N
mg NN N
) ) N
or CC N
placebo NN N
. . N

After IN N
20 CD N
minutes NNS N
( ( N
approximate JJ N
time NN N
to TO N
peak VB N
nicotine JJ N
levels NNS N
) ) N
, , N
echocardiograms JJ N
and CC N
signal-averaged JJ N
electrocardiograms NNS N
( ( N
SAECG NNP N
) ) N
were VBD N
obtained VBN N
. . N

After IN N
40 CD N
minutes NNS N
, , N
subjects NNS N
were VBD N
again RB N
given VBN N
nicotine JJ N
gum NN N
or CC N
placebo NN N
in IN N
cross-over JJ N
fashion NN N
. . N

Standard NNP N
echocardiographic JJ N
measurements NNS N
were VBD N
made VBN N
from IN N
two-dimensional JJ N
images NNS N
. . N

We PRP N
then RB N
calculated VBD N
end-systolic JJ N
wall NN N
stress NN N
( ( N
ESWS NNP N
) ) N
, , N
shortening VBG N
fraction NN N
( ( N
SF NNP N
) ) N
, , N
systemic JJ N
vascular NN N
resistance NN N
( ( N
SVR NNP N
) ) N
, , N
velocity NN N
for IN N
circumferential JJ N
fiber NN N
shortening NN N
corrected VBN N
for IN N
heart NN N
rate NN N
( ( N
Vcfc NNP N
) ) N
, , N
stroke VBD N
volume NN N
, , N
and CC N
cardiac JJ N
output NN N
. . N

P NNP N
wave NN N
and CC N
QRS NNP N
duration NN N
were VBD N
measured VBN N
from IN N
SAECG NNP N
. . N

RESULTS NNP N
Significant JJ N
differences NNS N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
from IN N
control NN N
or CC N
placebo NN N
were VBD N
found VBN N
for IN N
ESWS NNP N
, , N
mean JJ N
blood NN N
pressure NN N
, , N
cardiac JJ N
output NN N
, , N
SVR NNP N
, , N
heart NN N
rate NN N
, , N
and CC N
P NNP N
wave VBP N
duration NN N
. . N

No DT N
significant JJ N
changes NNS N
were VBD N
seen VBN N
in IN N
left JJ N
ventricular JJ N
ejection NN N
time NN N
( ( N
LVET NNP N
) ) N
, , N
LV NNP N
dimensions NNS N
, , N
SF NNP N
, , N
contractility NN N
( ( N
Vcfc NNP N
) ) N
, , N
or CC N
QRS NNP N
duration NN N
. . N

CONCLUSIONS NNP N
These DT N
results NNS N
suggest VBP N
that IN N
nicotine JJ N
chewing VBG N
gum NN N
increases NNS N
afterload NN N
and CC N
cardiac JJ N
output NN N
. . N

Cardiac JJ N
contractility NN N
does VBZ N
not RB N
change VB N
acutely RB N
in IN N
response NN N
to TO N
nicotine VB N
gum NN N
. . N

Heart NNP N
rate NN N
and CC N
P NNP N
wave VBP N
duration NN N
are VBP N
increased VBN N
by IN N
chewing VBG N
nicotine JJ N
gum NN N
. . N

-DOCSTART- -X- O O 8296409

[ JJ N
Hemostatic NNP N
balance NN N
during IN N
treatment NN N
with IN N
the DT N
newest JJS N
contraceptives NNS N
] RB N
. . N

Thirty-four CD N
healthy JJ 4_p
young JJ N
women NNS N
were VBD N
allocated VBN N
to TO N
12 CD N
consecutive JJ N
cycles NNS N
of IN N
treatment NN N
with IN N
monophasic JJ N
combinations NNS N
of IN N
: : N
20 CD N
micrograms NNS N
ethinyl VBP N
estradiol NN N
and CC N
150 CD N
micrograms NNS N
desogestrel NN N
( ( N
n JJ N
= NNP N
15 CD N
) ) N
or CC N
30 CD N
micrograms NNS N
ethinyl VBP N
estradiol NN N
and CC N
75 CD N
micrograms NNS N
gestodene NN N
( ( N
n JJ N
= NNP N
19 CD N
) ) N
. . N

In IN N
both DT N
groups NNS N
plasma VBP N
levels NNS N
of IN N
fibrinogen NN N
and CC N
factor NN N
VII NNP N
increased VBD N
while IN N
the DT N
capacity NN N
of IN N
coagulation NN N
inhibition NN N
was VBD N
affected VBN N
by IN N
increased JJ N
protein NN N
C NNP N
and CC N
decreased VBN N
protein NN N
S NNP N
levels NNS N
. . N

Increased VBN N
fibrinolytic JJ N
capacity NN N
was VBD N
indicated VBN N
by IN N
elevated JJ N
activity NN N
and CC N
reduced JJ N
antigen NN N
levels NNS N
of IN N
tissue NN N
plasminogen NN N
activator NN N
and CC N
reduced JJ N
activity NN N
and CC N
concentration NN N
of IN N
tissue NN N
plasminogen NN N
activator NN N
inhibitor NN N
. . N

The DT N
ratio NN N
between IN N
thrombin-antithrombin-III-complexes NNS N
and CC N
fibrin JJ N
degradation NN N
products NNS N
were VBD N
unchanged JJ N
signifying VBG N
no DT N
effect NN N
of IN N
hormonal JJ N
intake NN N
on IN N
the DT N
balance NN N
between IN N
thrombin JJ N
formation NN N
and CC N
fibrin JJ N
resolution NN N
. . N

In IN N
conclusion NN N
, , N
the DT N
dynamic JJ N
balance NN N
between IN N
generation NN N
and CC N
resolution NN N
of IN N
fibrin NN N
was VBD N
undisturbed JJ N
during IN N
treatment NN N
with IN N
both DT N
hormonal JJ N
compounds NNS N
and CC N
our PRP$ N
findings NNS N
do VBP N
not RB N
provide VB N
evidence NN N
for IN N
increased VBN N
risk NN N
of IN N
thrombosis NN N
in IN N
normal JJ 4_p
women NNS N
. . N

-DOCSTART- -X- O O 12973849

Outcome NN N
of IN N
children NNS N
with IN N
centrally RB N
reviewed VBN N
low-grade JJ 4_p
gliomas NN 4_p
treated VBN N
with IN N
chemotherapy NN 4_p
with IN 4_p
or CC 4_p
without IN 4_p
radiotherapy NN 4_p
on IN N
Children NNP N
's POS N
Cancer NNP N
Group NNP N
high-grade VBD N
glioma NN N
study NN N
CCG-945 NNP N
. . N

BACKGROUND NNP N
The DT N
objectives NNS N
of IN N
the DT N
current JJ N
study NN N
were VBD N
to TO N
determine VB N
the DT N
outcome NN N
of IN N
children NNS N
who WP N
were VBD N
treated VBN N
with IN N
chemotherapy NN 4_p
and CC N
radiotherapy NN 4_p
on IN N
the DT N
Children NNP N
's POS N
Cancer NNP N
Group NNP N
( ( N
CCG NNP N
) ) N
high-grade NN 4_p
glioma NN 4_p
protocol NN N
( ( N
CCG-945 NNP N
) ) N
who WP N
were VBD N
diagnosed VBN N
with IN N
low-grade JJ 4_p
gliomas NN 4_p
on IN N
post NN N
hoc JJ N
central JJ 4_p
pathologic NN 4_p
review NN 4_p
and CC N
to TO N
identify VB N
clinical JJ N
and CC N
biologic JJ N
features NNS N
associated VBN N
with IN N
prognosis NN N
. . N

METHODS NNP N
Between NNP N
1985 CD N
and CC N
1991 CD N
, , N
250 CD N
children NNS N
with IN N
institutionally RB N
classified VBN N
high-grade JJ 4_p
gliomas NNS 4_p
were VBD N
enrolled VBN N
on IN N
CCG-945 NNP N
. . N

Patients NNS N
older JJR N
than IN N
24 CD N
months NNS N
with IN N
intracranial JJ 4_p
lesions NNS 4_p
were VBD N
assigned VBN N
randomly RB N
to TO N
receive VB N
either DT N
lomustine NN N
, , N
vincristine NN N
, , N
and CC N
prednisone NN N
( ( N
control VB N
regimen NNS N
) ) N
or CC N
the DT N
8-drugs-in-1-day JJ N
regimen NNS N
( ( N
experimental JJ N
regimen NNS N
) ) N
; : N
younger JJR N
patients NNS N
and CC N
those DT N
with IN N
primary JJ 4_p
spinal JJ 4_p
cord NN 4_p
tumors NNS 4_p
were VBD N
assigned VBN N
nonrandomly RB N
to TO N
the DT N
experimental JJ N
regimen NNS N
. . N

Central NNP N
independent JJ N
review NN N
by IN N
5 CD N
neuropathologists NNS N
led VBD N
to TO N
a DT N
reclassification NN N
of IN N
low-grade JJ 4_p
glioma NN 4_p
in IN N
70 CD N
patients NNS N
, , N
who WP N
were VBD N
the DT N
focus NN N
of IN N
the DT N
current JJ N
study NN N
. . N

RESULTS VB N
The DT N
study NN N
involved VBD N
42 CD N
males NNS N
and CC N
28 CD N
females NNS N
( ( N
median JJ N
age NN N
, , N
7.7 CD N
years NNS N
) ) N
with IN N
a DT N
median JJ N
follow-up NN N
of IN N
10.4 CD N
years NNS N
. . N

At IN N
5 CD N
years NNS N
, , N
the DT N
progression-free JJ N
survival NN N
( ( N
PFS NNP N
) ) N
rate NN N
was VBD N
63 CD N
% NN N
+/- JJ N
6 CD N
% NN N
, , N
and CC N
the DT N
overall JJ N
survival NN N
( ( N
OS NNP N
) ) N
rate NN N
was VBD N
79 CD N
% NN N
+/- JJ N
5 CD N
% NN N
, , N
compared VBN N
with IN N
a DT N
PFS NNP N
rate NN N
of IN N
19 CD N
% NN N
+/- JJ N
3 CD N
% NN N
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
and CC N
an DT N
OS NNP N
rate NN N
of IN N
22 CD N
% NN N
+/- JJ N
3 CD N
% NN N
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
in IN N
the DT N
remainder NN N
of IN N
the DT N
cohort NN N
. . N

Significantly RB N
poorer JJR N
5-year JJ N
PFS NNP N
was VBD N
seen VBN N
in IN N
children NNS N
younger JJR N
than IN N
24 CD N
months NNS N
, , N
those DT N
with IN N
fibrillary JJ N
astrocytoma NN N
, , N
and CC N
those DT N
with IN N
posterior JJ N
fossa NN N
tumors NNS N
. . N

Patients NNS N
demonstrated VBD N
a DT N
modest JJ N
improvement NN N
in IN N
PFS NNP N
but CC N
no DT N
improvement NN N
in IN N
OS NNP N
compared VBN N
with IN N
children NNS N
with IN N
low-grade JJ N
gliomas NNS N
who WP N
were VBD N
treated VBN N
with IN N
contemporary JJ N
chemotherapy-alone NN N
approaches NNS N
. . N

CONCLUSIONS VB N
The DT N
current JJ N
report NN N
calls VBZ N
attention NN N
to TO N
the DT N
importance NN N
of IN N
central JJ N
pathologic JJ N
review NN N
in IN N
large JJ N
multiinstitutional JJ N
trials NNS N
of IN N
children NNS N
with IN N
gliomas NN N
and CC N
suggests VBZ N
that IN N
aggressive JJ N
front-line NN N
combined VBN N
chemoradiotherapy NN N
does VBZ N
not RB N
confer VB N
a DT N
survival JJ N
advantage NN N
in IN N
this DT N
highly RB N
selected VBN N
population NN N
of IN N
patients NNS N
. . N

-DOCSTART- -X- O O 11228756

Effect NN N
of IN N
acarbose NN N
on IN N
additional JJ N
insulin NN N
therapy NN N
in IN N
type NN 4_p
2 CD 4_p
diabetic JJ 4_p
patients NNS N
with IN N
late JJ 4_p
failure NN 4_p
of IN N
sulphonylurea JJ 4_p
therapy NN 4_p
. . N

AIM VB N
The DT N
present JJ N
study NN N
investigated VBD N
the DT N
effect NN N
of IN N
acarbose NN N
on IN N
insulin NN N
requirements NNS N
and CC N
glycaemic JJ N
control NN N
in IN N
patients NNS N
with IN N
type JJ 4_p
2 CD 4_p
diabetes NNS 4_p
receiving VBG N
exogenous JJ 4_p
insulin NN 4_p
due JJ N
to TO N
secondary JJ N
failure NN 4_p
of IN N
maximum NN N
dose JJ N
sulphonylurea JJ 4_p
therapy NN 4_p
. . N

METHODS VB N
A DT N
single-centre JJ N
, , N
double-blind JJ N
, , N
randomized VBN N
, , N
placebo-controlled JJ N
study NN N
was VBD N
performed VBN N
in IN N
48 CD N
type NN 4_p
2 CD 4_p
diabetic JJ 4_p
patients NNS N
with IN N
late-term JJ 4_p
failure NN 4_p
following VBG N
at IN N
least JJS N
3 CD N
years NNS N
of IN N
sulphonylurea JJ 4_p
therapy NN 4_p
requiring VBG N
additional JJ N
insulin NN 4_p
therapy NN 4_p
to TO N
determine VB N
the DT N
impact NN N
of IN N
acarbose NN N
on IN N
glycaemic JJ N
control NN N
and CC N
insulin NN N
requirements NNS N
. . N

The DT N
primary JJ N
end NN N
points NNS N
were VBD N
glycaemic JJ N
response NN N
rate NN N
( ( N
responders NNS N
being VBG N
predefined VBN N
as IN N
patients NNS N
who WP N
achieve VBP N
a DT N
decrease NN N
in IN N
HbA1c NNP N
to TO N
less JJR N
than IN N
8 CD N
% NN N
or CC N
a DT N
reduction NN N
by IN N
at IN N
least JJS N
15 CD N
% NN N
as IN N
compared VBN N
to TO N
the DT N
baseline NN N
values NNS N
) ) N
and CC N
the DT N
daily JJ N
insulin NN N
dose NN N
at IN N
6 CD N
months NNS N
. . N

Secondary JJ N
parameters NNS N
assessed VBD N
included VBN N
postprandial JJ N
changes NNS N
in IN N
blood NN N
glucose NN N
, , N
serum JJ N
insulin NN N
and CC N
C-peptide NNP N
during IN N
the DT N
treatment NN N
period NN N
. . N

RESULTS CC N
There EX N
were VBD N
significantly RB N
more JJR N
responders NNS N
in IN N
the DT N
acarbose-treated JJ N
group NN N
compared VBN N
with IN N
the DT N
placebo NN N
group NN N
( ( N
20/24 CD N
patients NNS N
vs. FW N
10/19 CD N
patients NNS N
; : N
p VB N
< $ N
0.05 CD N
) ) N
. . N

The DT N
mean JJ N
daily JJ N
insulin NN N
dose NN N
after IN N
24 CD N
weeks NNS N
of IN N
treatment NN N
was VBD N
16.4 CD N
+/- JJ N
10.1 CD N
IU NNP N
in IN N
the DT N
acarbose JJ N
group NN N
and CC N
22.4 CD N
+/- JJ N
12.2 CD N
IU NNP N
in IN N
the DT N
placebo NN N
group NN N
( ( N
mean JJ N
+/- JJ N
s.d NN N
. . N

; : N
p JJ N
< NNP N
0.07 CD N
) ) N
. . N

Postprandial JJ N
increases NNS N
in IN N
blood NN N
glucose NN N
, , N
insulin NN N
and CC N
C-peptide NNP N
were VBD N
consistently RB N
lower JJR N
in IN N
the DT N
acarbose-treated JJ N
group NN N
than IN N
in IN N
the DT N
placebo NN N
group NN N
. . N

For IN N
example NN N
, , N
the DT N
mean JJ N
increase NN N
in IN N
2-h JJ N
postprandial JJ N
serum NN N
insulin NN N
remained VBD N
almost RB N
unchanged JJ N
in IN N
the DT N
acarbose JJ N
group NN N
at IN N
the DT N
end NN N
of IN N
24 CD N
weeks NNS N
of IN N
treatment NN N
compared VBN N
to TO N
an DT N
increase NN N
to TO N
43 CD N
+/- JJ N
29 CD N
microU/ml NN N
( ( N
mean JJ N
+/- JJ N
s.d NN N
. . N

) ) N
at IN N
the DT N
end NN N
of IN N
the DT N
study NN N
period NN N
for IN N
the DT N
placebo NN N
group NN N
. . N

CONCLUSIONS VB N
The DT N
findings NNS N
of IN N
this DT N
study NN N
suggest VBP N
that IN N
the DT N
addition NN N
of IN N
acarbose NN N
to TO N
sulphonylurea/insulin VB N
combination NN N
therapy NN N
can MD N
improve VB N
glycaemic JJ N
control NN N
in IN N
type NN 4_p
2 CD 4_p
diabetic JJ 4_p
patients NNS N
. . N

Acarbose NNP N
may MD N
also RB N
reduce VB N
insulin NN N
resistance NN N
and CC N
hyperinsulinaemia NN N
. . N

-DOCSTART- -X- O O 17341994

Comparison NNP N
of IN N
increasing VBG N
doses NNS N
of IN N
olmesartan JJ N
medoxomil NN N
, , N
losartan JJ N
potassium NN N
, , N
and CC N
valsartan NN N
in IN N
patients NNS 4_p
with IN 4_p
essential JJ 4_p
hypertension NN 4_p
. . N

This DT N
12-week JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
forced-titration NN N
study NN N
compared VBN N
the DT N
efficacy NN N
of IN N
3 CD N
angiotensin NNS N
receptor NN N
blockers NNS N
. . N

Patients NNS N
received VBD N
olmesartan JJ N
medoxomil NN N
20 CD N
mg NN N
, , N
losartan JJ N
potassium NN N
50 CD N
mg NN N
, , N
valsartan JJ N
80 CD N
mg NN N
, , N
or CC N
placebo NN N
once RB N
daily JJ N
. . N

At IN N
week NN N
4 CD N
, , N
doses NNS N
were VBD N
titrated VBN N
to TO N
40 CD N
, , N
100 CD N
, , N
and CC N
160 CD N
mg NN N
once RB N
daily JJ N
for IN N
olmesartan NN N
, , N
losartan NN N
, , N
and CC N
valsartan NN N
, , N
respectively RB N
. . N

At IN N
week NN N
8 CD N
, , N
losartan NN N
was VBD N
increased VBN N
to TO N
50 CD N
mg NNS N
twice RB N
daily RB N
and CC N
valsartan NNS N
increased VBD N
to TO N
320 CD N
mg NNS N
once RB N
daily JJ N
( ( N
olmesartan JJ N
remained VBN N
at IN N
40 CD N
mg NNS N
once RB N
daily RB N
) ) N
. . N

The DT N
primary JJ N
end NN N
point NN N
was VBD N
mean JJ N
change NN N
from IN N
baseline NN N
in IN N
seated VBN N
diastolic JJ N
blood NN N
pressure NN N
( ( N
SeDBP NNP N
) ) N
at IN N
week NN N
8 CD N
. . N

All DT N
3 CD N
medications NNS N
significantly RB N
reduced VBN N
mean JJ N
SeDBP NNP N
from IN N
baseline NN N
compared VBN N
with IN N
placebo NN N
at IN N
weeks NNS N
4 CD N
, , N
8 CD N
, , N
and CC N
12 CD N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

At IN N
week NN N
8 CD N
, , N
olmesartan RB N
reduced VBN N
mean JJ N
SeDBP NNP N
more JJR N
than IN N
losartan NN N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
; : N
more JJR N
patients NNS N
in IN N
the DT N
olmesartan JJ N
medoxomil NN N
group NN N
achieved VBD N
a DT N
blood NN N
pressure NN N
goal NN N
of IN N
< $ N
140/90 CD N
mm NN N
Hg NNP N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

Olmesartan NNP N
did VBD N
not RB N
reduce VB N
mean NN N
SeDBP NNP N
significantly RB N
compared VBN N
with IN N
valsartan NN N
, , N
although IN N
more JJR N
patients NNS N
attained VBD N
blood JJ N
pressure NN N
goal NN N
with IN N
olmesartan NN N
( ( N
P=.031 NNP N
) ) N
. . N

At IN N
week NN N
12 CD N
, , N
all DT N
agents NNS N
lowered VBD N
blood NN N
pressure NN N
equivalently RB N
. . N

-DOCSTART- -X- O O 11362629

" JJ N
Confirmatory NNP N
" NN N
trials NNS 4_p
: : 4_p
symptom NN 4_p
reduction NN 4_p
as IN 4_p
efficacy NN 4_p
measure NN 4_p
. . N

-DOCSTART- -X- O O 3548346

Hepatorenal JJ N
syndrome NN N
. . N

Studies NNS N
of IN N
the DT N
effect NN N
of IN N
vascular JJ N
volume NN N
and CC N
intraperitoneal JJ N
pressure NN N
on IN N
renal JJ N
and CC N
hepatic JJ N
function NN N
. . N

Eleven JJ N
patients NNS N
with IN N
well-documented JJ N
hepatorenal JJ N
syndrome NN N
were VBD N
studied VBN N
by IN N
measurement NN N
of IN N
blood NN N
volume NN N
, , N
glomerular JJ N
filtration NN N
rate NN N
, , N
renal JJ N
plasma NN N
flow NN N
, , N
plasma VBP N
aldosterone JJ N
concentration NN N
, , N
renin JJ N
substrate NN N
concentration NN N
, , N
and CC N
plasma JJ N
renin NN N
activity NN N
. . N

They PRP N
were VBD N
then RB N
given VBN N
750 CD N
ml NN N
of IN N
stored JJ N
plasma NN N
, , N
750 CD N
ml NN N
of IN N
fresh JJ N
frozen JJ N
plasma NN N
, , N
and CC N
then RB N
an DT N
infusion NN N
of IN N
angiotensin NN N
II NNP N
, , N
in IN N
random JJ N
order NN N
on IN N
successive JJ N
days NNS N
. . N

Infusion NN N
of IN N
fresh JJ N
frozen JJ N
plasma NN N
improved VBD N
function NN N
more RBR N
than IN N
did VBD N
stored VBN N
plasma NN N
and CC N
in IN N
addition NN N
returned VBD N
a DT N
very RB N
low JJ N
filtration NN N
fraction NN N
toward IN N
normal JJ N
. . N

Angiotensin NNP N
II NNP N
infusion NN N
increased VBD N
filtration NN N
fraction NN N
, , N
but CC N
decreased VBD N
glomerular JJ N
filtration NN N
rate NN N
, , N
renal JJ N
plasma NN N
flow NN N
, , N
and CC N
urine JJ N
flow NN N
sharply RB N
. . N

Patients NNS N
were VBD N
then RB N
given VBN N
a DT N
daily JJ N
infusion NN N
of IN N
1,000 CD N
ml NNS N
of IN N
fresh JJ N
frozen JJ N
plasma NN N
for IN N
seven CD N
to TO N
18 CD N
days NNS N
to TO N
expand VB N
the DT N
blood NN N
volume NN N
to TO N
supranormal JJ N
levels NNS N
as IN N
assayed VBN N
by IN N
serial JJ N
measurement NN N
of IN N
blood NN N
volume NN N
. . N

Plasma NNP N
aldosterone NN N
levels NNS N
decreased VBN N
to TO N
a DT N
normal JJ N
range NN N
, , N
glomerular JJ N
filtration NN N
rate NN N
and CC N
renal JJ N
plasma NN N
flow NN N
both DT N
increased VBN N
, , N
and CC N
urinary JJ N
excretion NN N
of IN N
sodium NN N
and CC N
potassium NN N
both DT N
returned VBN N
toward IN N
normal JJ N
. . N

The DT N
effect NN N
of IN N
intraperitoneal JJ N
pressure NN N
was VBD N
then RB N
studied VBN N
by IN N
measuring VBG N
glomerular JJ N
filtration NN N
rate NN N
, , N
renal JJ N
plasma NN N
flow NN N
, , N
pressure NN N
in IN N
the DT N
vena NN N
cava NN N
, , N
hepatic JJ N
vein NN N
free JJ N
flow NN N
, , N
and CC N
hepatic JJ N
vein NNS N
wedged VBD N
pressure NN N
before IN N
, , N
during IN N
, , N
and CC N
after IN N
paracentesis NN N
to TO N
reduce VB N
the DT N
intraperitoneal JJ N
pressure NN N
from IN N
30 CD N
to TO N
40 CD N
cm NNS N
H2O NNP N
to TO N
12 CD N
to TO N
17 CD N
cm NN N
H2O NNP N
. . N

Venous JJ N
pressures NNS N
moved VBD N
parallel RB N
to TO N
ascitic JJ N
fluid NN N
pressures NNS N
, , N
and CC N
glomerular JJ N
filtration NN N
rate NN N
, , N
renal JJ N
plasma NN N
flow NN N
, , N
and CC N
urine JJ N
flow NN N
all DT N
improved VBD N
sharply RB N
; : N
then RB N
, , N
as IN N
ascitic JJ N
fluid NN N
continued VBD N
to TO N
form VB N
, , N
reducing VBG N
vascular JJ N
volume NN N
, , N
urine JJ N
flow NN N
, , N
glomerular JJ N
filtration NN N
rate NN N
, , N
and CC N
renal JJ N
plasma NN N
flow NN N
all DT N
decreased VBD N
slowly RB N
. . N

Six CD N
patients NNS N
then RB N
underwent JJ N
placement NN N
of IN N
a DT N
LeVeen NNP N
shunt NN N
. . N

Improvement NN N
in IN N
glomerular JJ N
filtration NN N
rate NN N
and CC N
renal JJ N
plasma NN N
flow NN N
and CC N
clinical JJ N
condition NN N
was VBD N
dramatic JJ N
. . N

During IN N
postoperative JJ N
observation NN N
of IN N
up IN N
to TO N
two CD N
years NNS N
, , N
progressive JJ N
improvement NN N
in IN N
hepatic JJ N
function NN N
has VBZ N
occurred VBN N
. . N

-DOCSTART- -X- O O 25178668

Angiographic NNP N
and CC N
electrocardiographic JJ N
parameters NNS N
of IN N
myocardial JJ N
reperfusion NN N
in IN N
angioplasty NN N
of IN N
patients NNS 4_p
with IN 4_p
ST NNP 4_p
elevation NN 4_p
acute NN 4_p
myocardial JJ 4_p
infarction NN 4_p
loaded VBN N
with IN N
ticagrelor NN N
or CC N
clopidogrel NN N
( ( N
MICAMI-TICLO NNP N
trial NN N
) ) N
. . N

INTRODUCTION NNP N
Ticagrelor NNP N
has VBZ N
been VBN N
shown VBN N
to TO N
improve VB N
outcomes NNS N
in IN N
patients NNS N
with IN N
ACS NNP 4_p
. . N

However RB N
, , N
the DT N
effects NNS N
of IN N
this DT N
drug NN N
on IN N
parameters NNS N
of IN N
microvascular JJ N
flow NN N
in IN N
patients NNS N
presenting VBG N
with IN N
ST-segment JJ N
elevation NN N
myocardial JJ 4_p
infarction NN 4_p
( ( 4_p
STEMI NNP 4_p
) ) 4_p
have VBP N
not RB N
been VBN N
completely RB N
evaluated VBN N
. . N

METHODS NNP N
Ninety-two JJ N
patients NNS N
presenting VBG N
with IN N
STEMI NNP N
where WRB N
randomized VBN N
to TO N
a DT N
loading VBG N
dose NN N
of IN N
clopidogrel NN N
( ( N
600 CD N
mg NN N
) ) N
or CC N
ticagrelor NN N
( ( N
180 CD N
mg NN N
) ) N
before IN N
undergoing VBG N
primary JJ N
angioplasty NN N
. . N

We PRP N
assessed VBD N
angiographic JJ N
and CC N
electrocardiographic JJ N
parameters NNS N
of IN N
myocardial JJ N
reperfusion NN N
. . N

Blinded VBN N
operators NNS N
calculated VBD N
angiographic JJ N
corrected VBN N
TIMI NNP N
Frame NNP N
count NN N
( ( N
cTFC NN N
) ) N
and CC N
myocardial JJ N
blush NN N
grade NN N
( ( N
MBG NNP N
) ) N
before IN N
and CC N
after IN N
stent JJ N
implantation NN N
. . N

ST NNP N
segment NN N
resolution NN N
was VBD N
also RB N
measured VBN N
in IN N
all DT N
patients NNS N
. . N

Primary JJ N
endpoint NN N
was VBD N
cTFC VBN N
after IN N
PCI NNP N
. . N

Secondary JJ N
endpoints NNS N
were VBD N
cTFC JJ N
prior RB N
to TO N
PCI NNP N
, , N
TIMI NNP N
flow NN N
grade NN N
, , N
MBG NNP N
and CC N
the DT N
percentage NN N
of IN N
ST NNP N
resolution NN N
. . N

RESULTS NNP N
Of IN N
the DT N
92 CD N
randomized JJ N
patients NNS N
, , N
70 CD N
patients NNS N
were VBD N
analyzed VBN N
. . N

Mean JJ N
age NN N
of IN N
patients NNS N
was VBD N
58.8±10 CD N
years NNS N
. . N

Patients NNS N
presented VBN N
with IN N
a DT N
mean JJ N
ischemic JJ N
time NN N
of IN N
4.4±2.6 CD N
hours NNS N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
the DT N
time NN N
between IN N
loading VBG N
dose NN N
and CC N
stent JJ N
deployment NN N
( ( N
35.2±36.4 CD N
in IN N
ticagrelor NN N
and CC N
42.7±29.5 CD N
min NN N
in IN N
clopidogrel NN N
, , N
p=0.36 NN N
) ) N
. . N

cTFC NN N
before IN N
angioplasty NN N
was VBD N
significantly RB N
lower JJR N
in IN N
ticagrelor NN N
than IN N
in IN N
clopidogrel NN N
( ( N
81.1±29.4 CD N
vs. FW N
95.1±17.5 CD N
frames NNS N
respectively RB N
, , N
p=0.01 NN N
) ) N
. . N

After IN N
angioplasty IN N
there EX N
were VBD N
no DT N
differences NNS N
between IN N
ticagrelor NN N
and CC N
clopidogrel NN N
in IN N
cTFC NN N
( ( N
24.6±9.3 CD N
vs. FW N
27.0±13.4 CD N
frames NNS N
respectively RB N
, , N
p=0.62 NN N
) ) N
; : N
MBG NNP N
grade VBD N
3 CD N
was VBD N
present JJ N
in IN N
76.4 CD N
vs. FW N
69.4 CD N
% NN N
of IN N
patients NNS N
, , N
respectively RB N
( ( N
p=0.41 NN N
) ) N
. . N

The DT N
percentage NN N
of IN N
ST NNP N
resolution NN N
did VBD N
not RB N
show VB N
any DT N
differences NNS N
between IN N
groups NNS N
( ( N
84.8±23.4 CD N
in IN N
ticagrelor NN N
vs. FW N
70.8±33.7 CD N
in IN N
clopidogrel NN N
, , N
p=0.36 NN N
) ) N
. . N

CONCLUSION NNP N
Compared NNP N
with IN N
clopidogrel NN N
, , N
ticagrelor NN N
loading NN N
in IN N
patients NNS N
presenting VBG N
with IN N
STEMI NNP N
is VBZ N
not RB N
associated VBN N
with IN N
an DT N
improvement NN N
of IN N
angiographic JJ N
and CC N
electrocardiographic JJ N
parameters NNS N
of IN N
myocardial JJ N
reperfusion NN N
after IN N
angioplasty NN N
. . N

-DOCSTART- -X- O O 17466465

Development NNP N
, , N
description NN N
, , N
and CC N
acceptability NN N
of IN N
a DT N
small-group NN N
, , N
behavioral JJ N
intervention NN N
to TO N
prevent VB N
HIV NNP N
and CC N
hepatitis NN N
C NNP N
virus NN N
infections NNS N
among IN N
young JJ N
adult NN N
injection JJ N
drug NN 4_p
users NNS 4_p
. . N

Young NNP N
injection NN 4_p
drug NN 4_p
users NNS 4_p
( ( 4_p
IDUs NNP 4_p
) ) 4_p
who WP N
are VBP N
not RB N
infected VBN N
with IN N
HIV NNP 4_p
or CC N
hepatitis NN 4_p
C NNP 4_p
virus NN 4_p
are VBP N
at IN N
great JJ N
risk NN N
of IN N
acquiring VBG N
one CD N
or CC N
both DT N
of IN N
these DT N
infections NNS N
through IN N
their PRP$ N
sexual JJ N
or CC N
injection NN N
behaviors NNS N
. . N

We PRP N
describe VBP N
the DT N
development NN N
of IN N
a DT N
behavioral JJ N
intervention NN N
designed VBN N
to TO N
decrease VB N
sexual JJ N
and CC N
injection NN N
risk NN N
behaviors NNS N
among IN N
young JJ N
IDUs NNP 4_p
. . N

The DT N
intervention NN N
was VBD N
developed VBN N
through IN N
a DT N
dynamic JJ N
and CC N
iterative JJ N
process NN N
that WDT N
involved VBD N
extensive JJ N
development NN N
activities NNS N
, , N
focus NN N
groups NNS N
with IN N
the DT N
target NN N
population NN N
to TO N
pilot VB N
individual JJ N
activities NNS N
and CC N
intervention NN N
sessions NNS N
, , N
and CC N
later RB N
, , N
pilot NN N
testing NN N
of IN N
the DT N
entire JJ N
intervention NN N
. . N

The DT N
six-session NN N
intervention NN N
that WDT N
emerged VBD N
from IN N
the DT N
development NN N
process NN N
relied VBN N
on IN N
both DT N
social-cognitive JJ N
theories NNS N
and CC N
peer VB N
influence NN N
models NNS N
. . N

We PRP N
also RB N
designed VBD N
a DT N
control NN N
intervention NN N
, , N
trained VBD N
facilitators NNS N
to TO N
deliver VB N
the DT N
interventions NNS N
, , N
and CC N
conducted VBD N
quality NN N
assurance NN N
of IN N
intervention NN N
delivery NN N
. . N

To TO N
better JJR N
understand VB N
intervention NN N
trial NN N
findings NNS N
, , N
we PRP N
asked VBD N
participants NNS N
about IN N
their PRP$ N
intervention NN N
experiences NNS N
and CC N
examined VBD N
potential JJ N
contamination NN N
across IN N
arms NNS N
. . N

Both DT N
interventions NNS N
were VBD N
delivered VBN N
with IN N
high JJ N
fidelity NN N
and CC N
participants NNS N
in IN N
both DT N
groups NNS N
reported VBD N
positive JJ N
experiences NNS N
. . N

More JJR N
perceived JJ N
impact NN N
was VBD N
reported VBN N
for IN N
injection NN N
risk NN N
behaviors NNS N
than IN N
for IN N
sexual JJ N
risk NN N
behaviors NNS N
among IN N
participants NNS N
in IN N
the DT N
intervention NN N
arm NN N
. . N

Minimal JJ N
evidence NN N
of IN N
contamination NN N
was VBD N
found VBN N
. . N

Lessons NNS N
learned VBD N
can MD N
help VB N
future VB N
researchers NNS N
to TO N
develop VB N
stronger JJR N
interventions NNS N
for IN N
this DT N
high-need JJ N
population NN N
. . N

-DOCSTART- -X- O O 18271235

[ JJ N
Effects NNS N
of IN N
early JJ N
acupuncture NN N
on IN N
motor NN N
function NN N
of IN N
the DT N
limb NN N
in IN N
the DT N
severe JJ N
head NN 4_p
injury NN 4_p
patients NNS N
] VBP N
. . N

UNLABELLED NNP N
OBJECTIVE NNP N
; : N
To TO N
observe VB N
the DT N
effects NNS N
of IN N
early JJ N
acupuncture NN N
on IN N
motor NN N
function NN N
of IN N
the DT N
limb NN N
in IN N
the DT N
severe JJ N
head NN N
injury NN N
patients NNS N
. . N

METHODS NNP N
Ninety-six JJ 4_p
patients NNS N
were VBD N
randomly RB N
divided VBN N
into IN N
an DT N
observation NN N
group NN N
and CC N
a DT N
control NN N
group NN N
, , N
48 CD 4_p
cases NNS N
in IN N
each DT N
group NN N
. . N

The DT N
patient NN N
in IN N
the DT N
control NN N
group NN N
were VBD N
treated VBN N
by IN N
routine JJ N
treatment NN N
of IN N
neurosurgical JJ N
operation NN N
and CC N
drug NN N
treatment NN N
( ( N
Mannitol NNP N
, , N
Citioline NNP N
Sodium NNP N
, , N
Cefeazidime NNP N
, , N
etc. NN N
) ) N
. . N

While IN N
the DT N
patient NN N
in IN N
the DT N
observation NN N
group NN N
were VBD N
treated VBN N
by IN N
the DT N
routine JJ N
treatment NN N
and CC N
acupuncture NN N
treatment NN N
48 CD N
h NN N
( ( N
-1 NNP N
) ) N
week NN N
after IN N
operation NN N
in IN N
different JJ N
stages NNS N
with IN N
different JJ N
acupoints NNS N
selected VBN N
when WRB N
the DT N
situation NN N
was VBD N
stable JJ N
. . N

The DT N
selected VBN N
main JJ N
points NNS N
were VBD N
Neiguan NNP N
( ( N
PC NNP N
6 CD N
) ) N
, , N
Qu-chi NNP N
( ( N
LI NNP N
11 CD N
) ) N
, , N
Waiguan NNP N
( ( N
TE NNP N
5 CD N
) ) N
, , N
Hegu NNP N
( ( N
LI NNP N
4 CD N
) ) N
, , N
Binao NNP N
( ( N
LI NNP N
14 CD N
) ) N
, , N
Jianyu NNP N
( ( N
LI NNP N
15 CD N
) ) N
, , N
Fengshi NNP N
( ( N
GB NNP N
31 CD N
) ) N
, , N
Xuehai NNP N
( ( N
SP NNP N
10 CD N
) ) N
, , N
Yinlingquan NNP N
( ( N
SP NNP N
9 CD N
) ) N
, , N
Sanyinjiao NNP N
( ( N
SP NNP N
6 CD N
) ) N
, , N
Taichong NNP N
( ( N
LR NNP N
3 CD N
) ) N
, , N
etc.. VBZ N
The DT N
limb NN N
motor NN N
function NN N
was VBD N
evaluated VBN N
with IN N
Fugl-Meyer NNP N
Assessment NNP N
( ( N
FMA NNP N
) ) N
scale NN N
before IN N
treatment NN N
and CC N
after IN N
10-week JJ N
treatment NN N
. . N

RESULTS NNP N
There EX N
was VBD N
a DT N
significant JJ N
improvement NN N
in IN N
the DT N
FMA NNP N
score NN N
in IN N
the DT N
two CD N
groups NNS N
after IN N
the DT N
treatment NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

The DT N
comparison NN N
between IN N
the DT N
two CD N
groups NNS N
after IN N
the DT N
treatment NN N
showed VBD N
that IN N
the DT N
improvement NN N
of IN N
FMA NNP N
score NN N
in IN N
the DT N
observation NN N
group NN N
was VBD N
significantly RB N
better JJR N
than IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
< VBZ N
0.05 CD N
or CC N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

CONCLUSION NNP N
Early JJ N
acupuncture NN N
can MD N
improve VB N
the DT N
limb NN N
motor NN N
function NN N
in IN N
the DT N
severe JJ N
head NN N
injury NN N
patients NNS N
. . N

-DOCSTART- -X- O O 23890774

Effects NNS N
of IN N
Positive NNP N
Action NNP N
on IN N
the DT N
emotional JJ N
health NN N
of IN N
urban JJ 4_p
youth NN 4_p
: : 4_p
a DT N
cluster-randomized JJ N
trial NN N
. . N

PURPOSE NNP N
We PRP N
examined VBD N
the DT N
effects NNS N
of IN N
Positive JJ N
Action NNP N
( ( N
PA NNP N
) ) N
, , N
a DT N
school-based JJ N
social-emotional JJ N
learning NN N
and CC N
health NN N
promotion NN N
program NN N
, , N
on IN N
the DT N
emotional JJ N
health NN N
of IN N
predominately RB 4_p
low-income JJ 4_p
and CC 4_p
ethnic JJ 4_p
minority NN 4_p
urban JJ 4_p
youth NN 4_p
. . 4_p

METHODS NNP N
The DT N
study NN N
was VBD N
a DT N
matched-pair JJ N
, , N
cluster-randomized JJ N
controlled VBN N
trial NN N
involving VBG N
14 CD N
Chicago NNP N
public JJ N
schools NNS N
. . N

Outcomes NNS N
were VBD N
assessed VBN N
over IN N
a DT N
6-year JJ 4_p
period NN 4_p
of IN 4_p
program NN 4_p
implementation NN 4_p
for IN 4_p
a DT 4_p
cohort NN 4_p
of IN 4_p
youth NN 4_p
in IN 4_p
each DT 4_p
school NN 4_p
, , 4_p
followed VBD 4_p
from IN 4_p
grades NNS 4_p
3 CD 4_p
to TO 4_p
8 CD 4_p
. . 4_p

Youth NN N
reported VBD N
on IN N
their PRP$ N
emotional JJ N
health NN N
( ( N
positive JJ N
affect NN N
, , N
life NN N
satisfaction NN N
, , N
depression NN N
, , N
anxiety NN N
) ) N
and CC N
social-emotional JJ N
and CC N
character NN N
development NN N
. . N

Growth-curve NNP N
and CC N
structural-equation NN N
modeling NN N
analyses NNS N
assessed VBD N
overall JJ N
program NN N
effects NNS N
on IN N
the DT N
emotional JJ N
health NN N
outcomes NNS N
as RB N
well RB N
as IN N
mediation NN N
of IN N
these DT N
effects NNS N
via IN N
the DT N
program NN N
's POS N
impact NN N
on IN N
youths NNS N
' POS N
social-emotional JJ N
and CC N
character NN N
development NN N
. . N

RESULTS JJ N
Students NNS N
in IN N
PA NNP N
schools NNS N
, , N
compared VBN N
with IN N
those DT N
in IN N
control NN N
schools NNS N
, , N
had VBD N
more RBR N
favorable JJ N
change NN N
over IN N
the DT N
course NN N
of IN N
the DT N
study NN N
in IN N
positive JJ N
affect NN N
( ( N
standardized JJ N
mean NN N
difference NN N
effect NN N
size NN N
[ NNP N
ES NNP N
] NNP N
= NNP N
.17 NNP N
) ) N
and CC N
life NN N
satisfaction NN N
( ( N
ES NNP N
= NNP N
.13 NNP N
) ) N
as RB N
well RB N
as IN N
significantly RB N
lower JJR N
depression NN N
( ( N
ES NNP N
= NNP N
-.14 NNP N
) ) N
and CC N
anxiety NN N
( ( N
ES NNP N
= NNP N
-.26 NNP N
) ) N
at IN N
study JJ N
end NN N
point NN N
. . N

Program NNP N
effects NNS N
for IN N
positive JJ N
affect NN N
, , N
depression NN N
, , N
and CC N
anxiety NN N
were VBD N
mediated VBN N
by IN N
more RBR N
favorable JJ N
change NN N
over IN N
time NN N
in IN N
social-emotional JJ N
and CC N
character NN N
development NN N
for IN N
students NNS N
in IN N
PA NNP N
schools NNS N
. . N

CONCLUSIONS NNP N
Results NNP N
suggest VBP N
that IN N
universal JJ N
, , N
school-based JJ N
programs NNS N
can MD N
benefit VB N
the DT N
emotional JJ N
health NN N
of IN N
youth NN N
in IN N
low-income JJ N
, , N
urban JJ N
settings NNS N
. . N

The DT N
modest JJ N
magnitude NN N
of IN N
effects NNS N
over IN N
an DT N
extended JJ N
period NN N
of IN N
program NN N
implementation NN N
, , N
however RB N
, , N
reflects VBZ N
the DT N
challenges NNS N
of IN N
both DT N
mounting VBG N
interventions NNS N
and CC N
offsetting VBG N
formidable JJ N
risks NNS N
for IN N
mental JJ N
health NN N
problems NNS N
in IN N
such JJ N
environments NNS N
. . N

-DOCSTART- -X- O O 17316832

Ciprofloxacin/dexamethasone NNP N
drops VBZ N
decrease VB N
the DT N
incidence NN N
of IN N
physician JJ N
and CC N
patient JJ N
outcomes NNS N
of IN N
otorrhea NN N
after IN N
tube JJ N
placement NN N
. . N

OBJECTIVE UH N
To TO N
evaluate VB N
ciprofloxacin JJ N
0.3 CD N
% NN N
/dexamethasone CD N
0.1 CD N
% NN N
( ( N
CIPRODEX NNP N
, , N
Alcon NNP N
, , N
Ft. NNP N
Worth NNP N
, , N
TX NNP N
) ) N
for IN N
the DT N
prevention NN N
of IN N
early JJ N
post-operative JJ N
otorrhea NN N
following VBG N
TT NNP N
placement NN N
. . N

METHODS NNP N
This DT N
was VBD N
a DT N
single-center JJ N
, , N
randomized VBN N
, , N
evaluator-blinded JJ N
, , N
parallel-group JJ N
study NN N
. . N

Two CD N
hundred VBD N
children NNS N
undergoing VBG N
bilateral JJ N
TT NNP N
placement NN N
were VBD N
categorized VBN N
as IN N
having VBG N
unilateral JJ N
( ( N
" JJ N
wet/dry NN N
" NN N
) ) N
, , N
bilateral JJ N
( ( N
" JJ N
wet/wet NN N
" NN N
) ) N
, , N
or CC N
no DT N
( ( N
" VB N
dry/dry RB N
" NNP N
) ) N
effusion NN N
at IN N
the DT N
time NN N
of IN N
surgery NN N
. . N

All DT N
patients NNS N
received VBD N
Ciprodex NNP N
or CC N
no DT N
treatment NN N
for IN N
5 CD N
days NNS N
post-operatively RB N
and CC N
returned VBN N
at IN N
2 CD N
weeks NNS N
. . N

RESULTS NNP N
Physician-observed JJ N
otorrhea NN N
was VBD N
reported VBN N
in IN N
5 CD N
( ( N
4.95 CD N
% NN N
) ) N
patients NNS N
receiving VBG N
Ciprodex NNP N
and CC N
39 CD N
( ( N
39.39 CD N
% NN N
) ) N
patients NNS N
receiving VBG N
no DT N
treatment NN N
( ( N
p JJ N
< NNP N
0.0001 CD N
) ) N
. . N

Treatment NN N
decreased VBD N
otorrhea NNS N
in IN N
all DT N
groups NNS N
, , N
while IN N
the DT N
greatest JJS N
benefit NN N
was VBD N
observed VBN N
in IN N
patients NNS N
with IN N
bilateral JJ N
effusion NN N
( ( N
93 CD N
% NN N
reduction NN N
) ) N
. . N

Ciprodex NNP N
treatment NN N
also RB N
decreased VBD N
the DT N
rate NN N
of IN N
clinically RB N
diagnosed VBN N
otitis NN N
media NNS N
( ( N
OM NNP N
) ) N
and CC N
effusion NN N
following VBG N
TT NNP N
placement NN N
( ( N
p JJ N
< NN N
or CC N
=0.0006 NN N
) ) N
. . N

CONCLUSION NNP N
Ciprodex NNP N
reduced VBD N
early JJ N
post-operative JJ N
otorrhea NN N
, , N
clinically RB N
diagnosed VBN N
OM NNP N
and CC N
effusion NN N
following VBG N
TT NNP N
insertion NN N
. . N

The DT N
greatest JJS N
reduction NN N
in IN N
otorrhea NN N
was VBD N
observed VBN N
in IN N
patients NNS N
with IN N
bilateral JJ N
effusion NN N
at IN N
the DT N
time NN N
of IN N
surgery NN N
. . N

-DOCSTART- -X- O O 17548021

Lowering VBG N
of IN N
glucose NN N
in IN N
critical JJ N
care NN N
: : N
a DT N
randomized JJ N
pilot NN N
trial NN N
. . N

BACKGROUND NNP N
Similar NNP N
to TO N
cardiac VB N
surgery NN N
patients NNS N
, , N
medical-surgical JJ 4_p
critically RB 4_p
ill JJ 4_p
patients NNS 4_p
may MD N
benefit VB N
from IN N
intensive JJ N
insulin NN N
therapy NN N
. . N

The DT N
objectives NNS N
of IN N
this DT N
pilot NN N
trial NN N
were VBD N
to TO N
evaluate VB N
the DT N
feasibility NN N
of IN N
a DT N
randomized JJ N
trial NN N
of IN N
intensive JJ N
insulin NN N
therapy NN N
with IN N
respect NN N
to TO N
( ( N
a DT N
) ) N
achieving VBG N
target NN N
glucose JJ N
values NNS N
in IN N
the DT N
2 CD N
ranges NNS N
of IN N
5 CD N
to TO N
7 CD N
and CC N
8 CD N
to TO N
10 CD N
mmol/L NNS N
and CC N
( ( N
b NN N
) ) N
uncovering VBG N
problems NNS N
with IN N
the DT N
protocol NN N
in IN N
anticipation NN N
of IN N
a DT N
larger JJR N
trial NN N
. . N

SETTING VB N
The DT N
trial NN N
was VBD N
conducted VBN N
in IN N
a DT N
15-bed JJ N
medical-surgical JJ N
university-affiliated JJ N
intensive JJ N
care NN N
unit NN N
( ( N
ICU NNP N
) ) N
. . N

METHODS NNP N
We PRP N
included VBD N
patients NNS N
older JJR N
than IN N
18 CD N
years NNS N
, , N
expected VBN 4_p
to TO 4_p
be VB 4_p
in IN 4_p
ICU NNP 4_p
for IN 4_p
more JJR 4_p
than IN 4_p
72 CD 4_p
hours NNS 4_p
, , N
with IN N
a DT N
glucose JJ N
value NN N
of IN N
more JJR N
than IN N
10 CD N
mmol/L NNS N
within IN N
48 CD N
hours NNS N
of IN N
ICU NNP N
admission NN N
. . N

Exclusion NN N
criteria NNS N
were VBD N
diabetic JJ N
ketoacidosis NN N
, , N
severe JJ N
hepatic JJ 4_p
failure NN 4_p
or CC 4_p
hepatic JJ 4_p
resection NN 4_p
, , 4_p
pancreatitis NN 4_p
, , 4_p
glucose NN 4_p
of IN N
less JJR N
than IN N
2.2 CD N
mmol/L NN N
on IN N
admission NN N
to TO N
hospital NN N
, , N
insulin JJ N
infusion NN N
on IN N
admission NN N
to TO N
ICU NNP N
, , N
planned VBD N
withdrawal NN N
of IN N
life NN N
support NN N
, , N
and CC N
inability NN N
to TO N
obtain VB N
informed JJ N
consent NN N
. . N

Patients NNS N
underwent JJ N
concealed JJ N
random NN N
allocation NN N
to TO N
a DT N
target NN N
glucose JJ N
range NN N
of IN N
5 CD N
to TO N
7 CD N
or CC N
8 CD N
to TO N
10 CD N
mmol/L NNS N
using VBG N
pretested JJ N
algorithms NN N
of IN N
insulin NN N
infusions NNS N
. . N

Dedicated VBN N
glucometer JJ N
measurement NN N
of IN N
arterial JJ N
glucose NN N
values NNS N
was VBD N
calibrated VBN N
daily RB N
to TO N
values NNS N
measured VBN N
in IN N
the DT N
laboratory NN N
. . N

RESULTS NNP N
We PRP N
enrolled VBD N
20 CD N
patients NNS N
with IN N
a DT N
mean NN N
( ( N
SD NNP N
) ) N
Acute NNP N
Physiology NNP N
and CC N
Chronic NNP N
Health NNP N
Evaluation NNP N
( ( N
APACHE NNP N
) ) N
II NNP N
score NN N
of IN N
32 CD N
( ( N
10.2 CD N
) ) N
; : N
14 CD N
were VBD N
insulin-dependent JJ N
pre-ICU JJ N
, , N
and CC N
all DT N
were VBD N
medical JJ N
admissions NNS N
. . N

Mean NNP N
glucose JJ N
values NNS N
were VBD N
different JJ N
in IN N
the DT N
2 CD N
groups NNS N
( ( N
7.1 CD N
+/- JJ N
2.6 CD N
vs JJ N
9.4 CD N
+/- JJ N
2.1 CD N
mmol/L NN N
, , N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

Although IN N
the DT N
intensive JJ N
insulin NN N
therapy NN N
group NN N
had VBD N
more RBR N
glucose JJ N
measurements NNS N
performed VBN N
than IN N
the DT N
control NN N
group NN N
, , N
a DT N
similar JJ N
proportion NN N
of IN N
values NNS N
were VBD N
within IN N
the DT N
target NN N
range NN N
( ( N
682 CD N
[ RB N
42.4 CD N
% NN N
] NN N
of IN N
1607 CD N
values NNS N
in IN N
the DT N
5- JJ N
to TO N
7-mmol/L JJ N
range NN N
; : N
250 CD N
[ $ N
38.7 CD N
% NN N
] NN N
of IN N
660 CD N
values NNS N
in IN N
the DT N
8- JJ N
to TO N
10-mmol/L JJ N
range NN N
, , N
P NNP N
= NNP N
.35 NNP N
) ) N
. . N

Glucose NNP N
values NNS N
of IN N
less JJR N
than IN N
2.5 CD N
mmol/L NN N
developed VBD N
7 CD N
times NNS N
in IN N
5 CD N
patients NNS N
, , N
4 CD N
of IN N
whom WP N
were VBD N
in IN N
the DT N
intensive JJ N
insulin NN N
therapy NN N
group NN N
; : N
however RB N
, , N
no DT N
adverse JJ N
consequences NNS N
were VBD N
documented VBN N
. . N

As IN N
expected VBN N
, , N
there EX N
were VBD N
no DT N
differences NNS N
in IN N
clinically RB N
important JJ N
outcomes NNS N
. . N

CONCLUSIONS NNP N
In IN N
this DT N
pilot JJ N
trial NN N
of IN N
ICU NNP N
patients NNS N
with IN N
high JJ 4_p
illness NN 4_p
severity NN 4_p
, , N
glucose JJ N
values NNS N
were VBD N
in IN N
the DT N
2 CD N
target NN N
ranges VBZ N
only RB N
40 CD N
% NN N
of IN N
the DT N
time NN N
, , N
using VBG N
well-accepted JJ N
initiation NN N
and CC N
maintenance NN N
insulin NN N
infusion NN N
algorithms NN N
. . N

A DT N
large JJ N
randomized JJ N
trial NN N
of IN N
glycemic JJ N
control NN N
is VBZ N
feasible JJ N
in IN N
this DT N
population NN N
to TO N
examine VB N
clinically RB N
important JJ N
outcomes NNS N
, , N
but CC N
will MD N
require VB N
refined JJ N
insulin NN N
algorithms NN N
and CC N
more RBR N
comprehensive JJ N
behavior NN N
change NN N
strategies NNS N
to TO N
achieve VB N
target NN N
values NNS N
. . N

-DOCSTART- -X- O O 12666946

Comparative JJ N
clinical JJ N
and CC N
microbiological JJ N
effects NNS N
of IN N
subgingival JJ N
metronidazole JJ N
application NN N
in IN N
adult NN N
periodontitis NN N
; : N
12-months JJ N
results NNS N
. . N

The DT N
aim NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
clinical JJ N
and CC N
microbiological JJ N
effects NNS N
of IN N
subgingival JJ N
application NN N
of IN N
25 CD N
% NN N
metronidazole JJ N
dental JJ N
gel NN N
as IN N
an DT N
adjunct NN N
to TO N
scaling NN N
and CC N
root NN N
planing NN N
( ( N
SRP NNP N
) ) N
in IN N
the DT N
treatment NN N
of IN N
adult NN N
periodontitis NN N
. . N

Eighty NNP 4_p
teeth VBZ 4_p
in IN 4_p
18 CD 4_p
patients NNS 4_p
were VBD N
evaluated VBN N
using VBG N
a DT N
split NN N
mouth NN N
design NN N
. . N

The DT N
test NN N
teeth NN N
received VBD N
SRP NNP N
and CC N
a DT N
25 CD N
% NN N
metronidazole JJ N
gel NN N
applied VBN N
subgingivally RB N
on IN N
days NNS N
0 CD N
and CC N
7 CD N
. . N

The DT N
control NN N
teeth VBZ N
received VBN N
SRP NNP N
only RB N
. . N

Clinical JJ N
and CC N
microbiological JJ N
examinations NNS N
were VBD N
carried VBN N
out RP N
before IN N
treatment NN N
and CC N
on IN N
weeks NNS N
1 CD N
, , N
3 CD N
, , N
7 CD N
, , N
13 CD N
, , N
26 CD N
, , N
38 CD N
and CC N
52 CD N
of IN N
the DT N
experimental JJ N
period NN N
. . N

Colony NNP N
forming VBG N
units NNS N
of IN N
Porphyromonas NNP N
gingivalis NN N
and CC N
Prevotella NNP N
intermedia VBP N
/ NNP N
Prevotella NNP N
nigrescens NNS N
were VBD N
determined VBN N
. . N

Both DT N
treatments NNS N
provided VBD N
significant JJ N
improvements NNS N
in IN N
all PDT N
the DT N
clinical JJ N
and CC N
microbiological JJ N
parameters NNS N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

However RB N
, , N
none NN N
of IN N
the DT N
differences NNS N
between IN N
the DT N
study NN N
groups NNS N
were VBD N
statistically RB N
significant JJ N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

As IN N
a DT N
conclusion NN N
, , N
the DT N
present JJ N
study NN N
does VBZ N
not RB N
provide VB N
evidence NN N
in IN N
favour NN N
of IN N
the DT N
routine JJ N
use NN N
of IN N
adjunctive JJ N
metronidazole JJ N
dental NN N
gel NN N
in IN N
the DT N
treatment NN N
of IN N
adult NN 4_p
periodontitis NN 4_p
. . 4_p

-DOCSTART- -X- O O 16540862

A DT N
randomized JJ N
trial NN N
of IN N
chiropractic JJ N
and CC N
medical JJ N
care NN N
for IN N
patients NNS N
with IN N
low JJ 4_p
back RB 4_p
pain NN 4_p
: : N
eighteen-month JJ N
follow-up JJ N
outcomes NNS N
from IN N
the DT N
UCLA NNP N
low JJ N
back RB N
pain NN N
study NN N
. . N

STUDY NNP N
DESIGN NNP N
Randomized NNP N
clinical JJ N
trial NN N
. . N

OBJECTIVES UH N
To TO N
compare VB N
the DT N
long-term JJ N
effectiveness NN N
of IN N
medical JJ N
and CC N
chiropractic JJ N
care NN N
for IN N
low JJ 4_p
back RB 4_p
pain NN 4_p
in IN N
managed VBN N
care NN N
and CC N
to TO N
assess VB N
the DT N
effectiveness NN N
of IN N
physical JJ N
therapy NN N
and CC N
modalities NNS N
among IN N
patients NNS N
receiving VBG N
medical JJ N
or CC N
chiropractic JJ N
care NN N
. . N

SUMMARY NNP N
OF IN N
BACKGROUND NNP N
DATA NNP N
Evidence NNP N
comparing VBG N
the DT N
long-term JJ N
relative JJ N
effectiveness NN N
of IN N
common JJ N
treatment NN N
strategies NNS N
offered VBD N
to TO N
low VB 4_p
back RB 4_p
pain NN 4_p
patients NNS N
in IN N
managed VBN N
care NN N
is VBZ N
lacking VBG N
. . N

METHODS NNP N
A NNP N
total NN N
of IN N
681 CD N
low JJ 4_p
back RB 4_p
pain NN 4_p
patients NNS N
presenting VBG N
to TO N
a DT N
managed-care JJ N
facility NN N
were VBD N
randomized VBN N
to TO N
chiropractic VB N
with IN N
or CC N
without IN N
physical JJ N
modalities NNS N
, , N
or CC N
medical JJ N
care NN N
with IN N
or CC N
without IN N
physical JJ N
therapy NN N
, , N
and CC N
followed VBD N
for IN N
18 CD N
months NNS N
. . N

The DT N
primary JJ N
outcome NN N
variables NNS N
are VBP N
low JJ N
back RB N
pain NN N
intensity NN N
, , N
disability NN N
, , N
and CC N
complete JJ N
remission NN N
. . N

The DT N
secondary JJ N
outcome NN N
is VBZ N
participants NNS N
' POS N
perception NN N
of IN N
improvement NN N
in IN N
low JJ N
back RB N
symptoms NNS N
. . N

RESULTS NNP N
Of IN N
the DT N
681 CD N
patients NNS N
, , N
610 CD N
( ( N
89.6 CD N
% NN N
) ) N
were VBD N
followed VBN N
through IN N
18 CD N
months NNS N
. . N

Among IN N
participants NNS N
not RB N
assigned VBN N
to TO N
receive VB N
physical JJ N
therapy NN N
or CC N
modalities NNS N
, , N
the DT N
estimated JJ N
improvements NNS N
in IN N
pain NN N
and CC N
disability NN N
and CC N
18-month JJ N
risk NN N
of IN N
complete JJ N
remission NN N
were VBD N
a DT N
little JJ N
greater JJR N
in IN N
the DT N
chiropractic JJ N
group NN N
than IN N
in IN N
the DT N
medical JJ N
group NN N
( ( N
adjusted VBN N
RR NNP N
of IN N
remission NN N
= NNP N
1.29 CD N
; : N
95 CD N
% NN N
CI NNP N
= NNP N
0.80-2.07 NN N
) ) N
. . N

Among IN N
participants NNS N
assigned VBN N
to TO N
medical JJ N
care NN N
, , N
mean JJ N
changes NNS N
in IN N
pain NN N
and CC N
disability NN N
and CC N
risk NN N
of IN N
remission NN N
were VBD N
larger JJR N
in IN N
patients NNS N
assigned VBN N
to TO N
receive VB N
physical JJ N
therapy NN N
( ( N
adjusted VBN N
RR NNP N
= NNP N
1.69 CD N
; : N
95 CD N
% NN N
CI NNP N
= NNP N
1.08-2.66 JJ N
) ) N
. . N

Among IN N
those DT N
assigned VBN N
to TO N
chiropractic JJ N
care NN N
, , N
however RB N
, , N
assignment NN N
to TO N
methods NNS N
was VBD N
not RB N
associated VBN N
with IN N
improvement NN N
or CC N
remission NN N
( ( N
adjusted VBN N
RR NNP N
= NNP N
0.98 CD N
; : N
95 CD N
% NN N
CI NNP N
= NNP N
0.62-1.55 NN N
) ) N
. . N

Compared VBN N
with IN N
medical JJ N
care NN N
only RB N
patients NNS N
, , N
chiropractic JJ N
and CC N
physical JJ N
therapy NN N
patients NNS N
were VBD N
much RB N
more RBR N
likely JJ N
to TO N
perceive VB N
improvement NN N
in IN N
their PRP$ N
low JJ N
back RB N
symptoms NNS N
. . N

However RB N
, , N
less JJR N
than IN N
20 CD N
% NN N
of IN N
all DT N
patients NNS N
were VBD N
pain-free JJ N
at IN N
18 CD N
months NNS N
. . N

CONCLUSIONS NNP N
Differences NNPS N
in IN N
outcomes NNS N
between IN N
medical JJ N
and CC N
chiropractic JJ N
care NN N
without IN N
physical JJ N
therapy NN N
or CC N
modalities NNS N
are VBP N
not RB N
clinically RB N
meaningful JJ N
, , N
although IN N
chiropractic JJ N
may MD N
result VB N
in IN N
a DT N
greater JJR N
likelihood NN N
of IN N
perceived JJ N
improvement NN N
, , N
perhaps RB N
reflecting VBG N
satisfaction NN N
or CC N
lack NN N
of IN N
blinding NN N
. . N

Physical JJ N
therapy NN N
may MD N
be VB N
more RBR N
effective JJ N
than IN N
medical JJ N
care NN N
alone RB N
for IN N
some DT N
patients NNS N
, , N
while IN N
physical JJ N
modalities NNS N
appear VBP N
to TO N
have VB N
no DT N
benefit NN N
in IN N
chiropractic JJ N
care NN N
. . N

-DOCSTART- -X- O O 19143691

Ondansetron NNP N
has VBZ N
similar JJ N
clinical JJ N
efficacy NN N
against IN N
both DT N
nausea NN N
and CC N
vomiting NN N
. . N

Ondansetron NNP N
is VBZ N
widely RB N
believed VBN N
to TO N
prevent VB N
postoperative JJ N
vomiting VBG N
more RBR N
effectively RB N
than IN N
nausea NN N
. . N

We PRP N
analysed VBD N
data NNS N
from IN N
5161 CD N
patients NNS N
undergoing VBG N
general JJ N
anaesthesia NN N
who WP N
were VBD N
randomly RB N
stratified VBN N
to TO N
receive VB N
a DT N
combination NN N
of IN N
six CD N
interventions NNS N
, , N
one CD N
of IN N
which WDT N
was VBD N
4 CD N
mg NN N
ondansetron NN N
vs NN N
placebo NN N
. . N

For IN N
the DT N
purpose NN N
of IN N
this DT N
study NN N
a DT N
20 CD N
% NN N
difference NN N
in IN N
the DT N
relative JJ N
risks NNS N
for IN N
the DT N
two CD N
outcomes NNS N
was VBD N
considered VBN N
clinically RB N
relevant JJ N
. . N

Nausea NN N
was VBD N
reduced VBN N
from IN N
38 CD N
% NN N
( ( N
969/2585 CD N
) ) N
in IN N
the DT N
control NN N
to TO N
28 CD N
% NN N
( ( N
715/2576 CD N
) ) N
in IN N
the DT N
ondansetron NN N
group NN N
, , N
corresponding VBG N
to TO N
a DT N
relative JJ N
risk NN N
of IN N
0.74 CD N
, , N
or CC N
a DT N
relative JJ N
risk NN N
reduction NN N
of IN N
26 CD N
% NN N
. . N

Vomiting NNP N
was VBD N
reduced VBN N
from IN N
17 CD N
% NN N
( ( N
441/2585 CD N
) ) N
to TO N
11 CD N
% NN N
( ( N
293/2576 CD N
) ) N
, , N
corresponding VBG N
to TO N
a DT N
relative JJ N
risk NN N
of IN N
0.67 CD N
, , N
or CC N
a DT N
relative JJ N
risk NN N
reduction NN N
of IN N
33 CD N
% NN N
. . N

The DT N
relative JJ N
risks NNS N
of IN N
0.67 CD N
and CC N
0.74 CD N
were VBD N
clinically RB N
similar JJ N
and CC N
the DT N
difference NN N
between IN N
them PRP N
did VBD N
not RB N
reach VB N
statistical JJ N
significance NN N
. . N

We PRP N
thus RB N
conclude VBP N
that IN N
ondansetron NN N
prevents NNS N
postoperative JJ N
nausea NN N
and CC N
postoperative JJ N
vomiting NN N
equally RB N
well RB N
. . N

-DOCSTART- -X- O O 2188871

Oral JJ N
S-adenosylmethionine NNP N
in IN N
the DT N
symptomatic JJ N
treatment NN N
of IN N
intrahepatic JJ 4_p
cholestasis NN 4_p
. . 4_p

A DT N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
. . N

Parenteral JJ N
S-adenosylmethionine JJ N
proved VBN N
to TO N
be VB N
effective JJ N
in IN N
reversing VBG N
intrahepatic JJ N
cholestasis NN N
in IN N
pregnant JJ N
women NNS N
. . N

Based VBN N
on IN N
these DT N
findings NNS N
, , N
a DT N
prospective JJ N
multicenter NN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
trial NN N
was VBD N
planned VBN N
to TO N
assess VB N
whether IN N
oral JJ N
S-adenosylmethionine NNP N
is VBZ N
effective JJ N
in IN N
cholestatic JJ N
patients NNS N
with IN N
chronic JJ N
liver NN N
disease NN N
. . N

Accordingly RB N
, , N
220 CD N
inpatients NNS N
( ( N
26 CD N
% NN N
chronic JJ N
active JJ N
hepatitis NN N
, , N
68 CD N
% NN N
cirrhosis NN N
, , N
6 CD N
% NN N
primary JJ N
biliary JJ N
cirrhosis NN N
) ) N
with IN N
stable JJ N
( ( N
1 CD N
month NN N
or CC N
more JJR N
) ) N
at IN N
least JJS N
twofold JJ N
increases NNS N
in IN N
serum JJ N
total NN N
and CC N
conjugated VBD N
bilirubin NN N
and CC N
alkaline JJ N
phosphatase NN N
volunteered VBD N
for IN N
the DT N
trial NN N
. . N

Serum NNP N
markers NNS N
of IN N
cholestasis NN N
significantly RB N
( ( N
P NNP N
less JJR N
than IN N
0.01 CD N
) ) N
decreased VBN N
after IN N
oral JJ N
S-adenosylmethionine JJ N
administration NN N
( ( N
1600 CD N
mg/day NN N
) ) N
, , N
and CC N
their PRP$ N
values NNS N
were VBD N
significantly RB N
( ( N
P NNP N
less JJR N
than IN N
0.01 CD N
) ) N
lower JJR N
than IN N
the DT N
corresponding JJ N
values NNS N
in IN N
the DT N
placebo NN N
group NN N
. . N

S-adenosylmethionine NNP N
significantly RB N
( ( N
P NNP N
less JJR N
than IN N
0.01 CD N
) ) N
improved VBN N
subjective JJ N
symptoms NNS N
such JJ N
as IN N
pruritus NN N
, , N
fatigue NN N
, , N
and CC N
feeling NN N
of IN N
being VBG N
unwell JJ N
, , N
whereas JJ N
placebo NN N
was VBD N
ineffective JJ N
. . N

Two CD N
patients NNS N
in IN N
the DT N
S-adenosylmethionine NNP N
group NN N
and CC N
9 CD N
controls NNS N
( ( N
P NNP N
less JJR N
than IN N
0.05 CD N
) ) N
withdrew NN N
from IN N
the DT N
trial NN N
for IN N
reduced VBN N
compliance NN N
because IN N
of IN N
inefficacy NN N
of IN N
treatment NN N
. . N

Oral JJ N
S-adenosylmethionine NNP N
was VBD N
tolerated VBN N
to TO N
the DT N
same JJ N
extent NN N
as IN N
placebo NN N
. . N

In IN N
conclusion NN N
, , N
short-term JJ N
administration NN N
of IN N
oral JJ N
S-adenosylmethionine NNP N
is VBZ N
more RBR N
effective JJ N
than IN N
placebo NN N
in IN N
improving VBG N
clinical JJ N
and CC N
laboratory JJ N
measures NNS N
of IN N
intrahepatic JJ N
cholestasis NN N
and CC N
offers VBZ N
a DT N
new JJ N
therapeutic JJ N
modality NN N
for IN N
the DT N
symptomatic JJ N
management NN N
of IN N
this DT N
syndrome NN N
. . N

-DOCSTART- -X- O O 9332112

Intravenous JJ N
magnesium NN N
sulfate NN N
in IN N
acute NN 4_p
severe JJ 4_p
asthma NN 4_p
not RB 4_p
responding VBG 4_p
to TO 4_p
conventional JJ 4_p
therapy NN 4_p
. . 4_p

OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
effectiveness NN N
of IN N
early JJ N
administration NN N
of IN N
intravenous JJ N
Magnesium NNP N
sulfate NN N
( ( N
i.v JJ N
. . N

MgSO4 NNP N
) ) N
in IN N
children NNS N
with IN N
acute NN 4_p
severe JJ 4_p
asthma NN 4_p
not RB 4_p
responding VBG 4_p
to TO 4_p
conventional JJ 4_p
therapy NN 4_p
. . N

DESIGN NNP N
Randomized NNP N
double-blind NN N
, , N
placebo-controlled JJ N
trial NN N
. . N

SETTING NN N
Pediatric NNP N
emergency NN N
service NN N
of IN N
a DT N
large JJ N
teaching NN N
hospital NN N
. . N

SUBJECTS CC N
47 CD N
children NNS N
aged VBN N
between IN N
1-12 CD N
years NNS N
with IN N
acute NN N
severe JJ N
asthma NN N
showing VBG N
inadequate JJ N
or CC N
poor JJ N
response NN N
to TO N
3 CD N
doses NNS N
of IN N
nebulized JJ N
salbutamol NN N
given VBN N
at IN N
an DT N
interval NN N
of IN N
20 CD N
min NNS N
each DT N
. . N

INTERVENTION VBZ N
The DT N
MgSO4 NNP N
group NN N
received VBD N
0.2 CD N
ml/kg NN N
of IN N
50 CD N
% NN N
MgSO4 NNP N
as IN N
intravenous JJ N
( ( N
i.v JJ N
. . N

) ) N
infusion NN N
over IN N
35 CD N
minutes NNS N
and CC N
the DT N
placebo NN N
group NN N
received VBD N
normal JJ N
saline JJ N
infusion NN N
in IN N
the DT N
same JJ N
dose NN N
and CC N
at IN N
the DT N
same JJ N
rate NN N
. . N

MgSO4 NNP N
solution NN N
and CC N
normal JJ N
saline NN N
were VBD N
coded VBN N
and CC N
dispensed VBN N
in IN N
identical JJ N
containers NNS N
. . N

Decoding VBG N
was VBD N
done VBN N
at IN N
the DT N
completion NN N
of IN N
the DT N
study NN N
. . N

All PDT N
the DT N
patients NNS N
received VBD N
oxygen NN N
, , N
nebulized JJ N
salbutamol NN N
, , N
i.v NN N
. . N

aminophylline NN N
and CC N
corticosteroids NNS N
. . N

RESULTS NNP N
MgSO4 NNP N
group NN N
showed VBD N
early JJ N
and CC N
significant JJ N
improvement NN N
as IN N
compared VBN N
to TO N
placebo VB N
group NN N
in IN N
PEFR NNP N
and CC N
SaO2 NNP N
at IN N
30 CD N
min NN N
and CC N
1 CD N
, , N
2 CD N
, , N
3 CD N
and CC N
7 CD N
hours NNS N
after IN N
stopping VBG N
the DT N
infusion NN N
( ( N
p JJ N
ranging VBG N
from IN N
< $ N
0.05 CD N
to TO N
< VB N
0.01 CD N
) ) N
. . N

The DT N
clinical JJ N
asthma NN N
score NN N
also RB N
showed VBD N
significant JJ N
improvement NN N
in IN N
the DT N
MgSO4 NNP N
group NN N
1 CD N
, , N
2 CD N
, , N
3 CD N
and CC N
11 CD N
hours NNS N
after IN N
stopping VBG N
the DT N
infusion NN N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
. . N

CONCLUSION NNP N
Addition NNP N
of IN N
MgSO4 NNP N
to TO N
conventional JJ N
therapy NN N
helps VBZ N
in IN N
achieving VBG N
earlier RBR N
improvement NN N
in IN N
clinical JJ N
signs NNS N
and CC N
symptoms NNS N
of IN N
asthma NN N
and CC N
PEFR NNP N
in IN N
patients NNS N
not RB N
responding VBG N
to TO N
conventional JJ N
therapy NN N
alone RB N
. . N

-DOCSTART- -X- O O 14605954

Micronized JJ N
flavonoids NNS N
in IN N
pain NN N
control NN N
after IN 4_p
hemorrhoidectomy NN 4_p
: : 4_p
a DT N
prospective JJ N
randomized NN N
controlled VBD N
study NN N
. . N

PURPOSE NNP N
We PRP N
conducted VBD N
a DT N
prospective JJ N
randomized NN N
controlled VBD N
study NN N
to TO N
evaluate VB N
the DT N
effect NN N
of IN N
micronized VBN N
flavonoid JJ N
fractions NNS N
( ( N
MFF NNP N
) ) N
on IN N
pain NN N
after IN N
hemorrhoidectomy NN N
. . N

METHODS NNP N
The DT N
subjects NNS N
were VBD N
112 CD N
consecutive JJ N
patients NNS N
randomly RB N
assigned VBD N
either CC N
to TO N
receive VB N
MFF NNP N
( ( N
group NN N
1 CD N
) ) N
for IN N
1 CD N
week NN N
or CC N
not RB N
to TO N
receive VB N
MFF NNP N
, , N
as IN N
a DT N
control NN N
( ( N
group NN N
2 CD N
) ) N
, , N
after IN N
hemorrhoidectomy NN N
, , N
The DT N
severity NN N
of IN N
pain NN N
and CC N
the DT N
number NN N
of IN N
intramuscular JJ N
analgesic JJ N
injections NNS N
required VBN N
were VBD N
recorded VBN N
for IN N
the DT N
first JJ N
3 CD N
days NNS N
, , N
then RB N
1 CD N
week NN N
after IN N
hemorrhoidectomy NN N
. . N

The DT N
number NN N
of IN N
days NNS N
that WDT N
intramuscular VBP N
analgesic JJ N
injections NNS N
were VBD N
required VBN N
, , N
hospital JJ N
stay NN N
, , N
and CC N
patient JJ N
satisfaction NN N
were VBD N
also RB N
assessed VBN N
. . N

RESULTS VB N
On IN N
postoperative JJ N
day NN N
( ( N
POD NNP N
) ) N
1 CD N
, , N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
parameters NNS N
of IN N
the DT N
two CD N
groups NNS N
, , N
but CC N
on IN N
PODs NNP N
2 CD N
and CC N
3 CD N
, , N
both PDT N
the DT N
pain NN N
score NN N
( ( N
P NNP N
= NNP N
0.033 CD N
and CC N
P NNP N
= NNP N
0.011 CD N
, , N
respectively RB N
) ) N
and CC N
the DT N
number NN N
of IN N
patients NNS N
who WP N
required VBD N
intramuscular JJ N
analgesic JJ N
injections NNS N
were VBD N
significantly RB N
less RBR N
in IN N
group NN N
1 CD N
( ( N
P NNP N
= NNP N
0.022 CD N
and CC N
P NNP N
= NNP N
0.007 CD N
, , N
respectively RB N
) ) N
. . N

Moreover RB N
, , N
the DT N
hospital NN N
stay NN N
was VBD N
shorter JJR N
and CC N
patient JJ N
satisfaction NN N
was VBD N
superior JJ N
in IN N
group NN N
1 CD N
( ( N
P NNP N
= NNP N
0.001 CD N
and CC N
P NNP N
= NNP N
0.001 CD N
, , N
respectively RB N
) ) N
. . N

After IN N
1 CD N
week NN N
, , N
the DT N
pain NN N
score NN N
and CC N
number NN N
of IN N
intramuscular JJ N
analgesic JJ N
injections NNS N
given VBN N
were VBD N
significantly RB N
less RBR N
in IN N
group NN N
1 CD N
( ( N
P NNP N
= NNP N
0.001 CD N
and CC N
P NNP N
= NNP N
0.021 CD N
) ) N
. . N

CONCLUSION NNP N
Using NNP N
MFF NNP N
after IN N
hemorrhoidectomy NN N
reduced VBD N
the DT N
severity NN N
of IN N
pain NN N
and CC N
intramuscular JJ N
analgesic JJ N
requirement NN N
. . N

-DOCSTART- -X- O O 18946011

Direct JJ N
and CC N
indirect JJ N
effects NNS N
of IN N
interdental JJ N
hygiene NN N
in IN N
a DT N
clinical JJ N
trial NN N
. . N

Many JJ N
randomized VBD N
controlled JJ N
trials NNS N
( ( N
RCTs NNP N
) ) N
in IN N
dental JJ N
research NN N
test NN N
the DT N
efficacy NN N
of IN N
interventions NNS N
on IN N
more JJR N
than IN N
one CD N
outcome NN N
variable NN N
. . N

Univariate NNP N
methods NNS N
, , N
such JJ N
as IN N
the DT N
t JJ N
test NN N
or CC N
analysis NN N
of IN N
covariance NN N
, , N
can MD N
not RB N
evaluate VB N
the DT N
efficacy NN N
of IN N
interventions NNS N
on IN N
multiple JJ N
outcomes NNS N
simultaneously RB N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
use VB N
structural JJ N
equation NN N
modeling NN N
( ( N
SEM NNP N
) ) N
to TO N
re-analyze VB N
a DT N
RCT NNP N
, , N
comparing VBG N
the DT N
effects NNS N
of IN N
pre-curved JJ N
interdental JJ N
brushes NNS N
and CC N
flossing VBG N
on IN N
probing VBG N
pocket NN N
depth NN N
( ( N
PPD NNP N
) ) N
, , N
plaque JJ N
indices NNS N
, , N
and CC N
bleeding VBG N
on IN N
probing VBG N
( ( N
BOP NNP N
) ) N
measured VBD N
at IN N
baseline NN N
, , N
intermediate NN N
, , N
and CC N
final JJ N
examinations NNS N
. . N

Results NNS N
of IN N
SEM NNP N
showed VBD N
that IN N
the DT N
observed JJ N
greater JJR N
reduction NN N
in IN N
PPD NNP N
and CC N
BOP NNP N
in IN N
persons NNS 4_p
using VBG 4_p
interdental JJ 4_p
brushing NN 4_p
than IN 4_p
in IN 4_p
those DT 4_p
flossing NN 4_p
is VBZ N
due JJ N
mainly RB N
to TO N
the DT N
greater JJR N
efficiency NN N
in IN N
plaque NN N
removal NN N
with IN N
the DT N
interdental JJ N
brushes NNS N
( ( N
indirect JJ N
effect NN N
) ) N
rather RB N
than IN N
to TO N
the DT N
compression NN N
of IN N
the DT N
interdental JJ N
papillae NN N
( ( N
direct JJ N
effect NN N
) ) N
. . N

In IN N
contrast NN N
, , N
smokers NNS 4_p
showed VBD N
less JJR N
BOP NNP N
at IN N
baseline NN N
but CC N
also RB N
less RBR N
improvement NN N
in IN N
BOP NNP N
through IN N
direct JJ N
effects NNS N
. . N

-DOCSTART- -X- O O 15625713

Group-based JJ N
HIV NNP N
risk NN N
reduction NN N
intervention NN N
for IN N
adolescent JJ 4_p
girls NNS 4_p
: : 4_p
evidence NN N
of IN N
feasibility NN N
and CC N
efficacy NN N
. . N

The DT N
purposes NNS N
of IN N
this DT N
pilot NN N
study NN N
were VBD N
( ( N
a DT N
) ) N
to TO N
assess VB N
the DT N
feasibility NN N
of IN N
a DT N
community-based JJ N
, , N
small JJ N
group NN N
HIV NNP N
risk NN N
reduction NN N
intervention NN N
with IN N
adolescent JJ 4_p
girls NNS 4_p
, , N
and CC N
( ( N
b NN N
) ) N
to TO N
obtain VB N
preliminary JJ N
evidence NN N
of IN N
the DT N
efficacy NN N
of IN N
this DT N
theoretically-guided JJ N
intervention NN N
using VBG N
a DT N
controlled JJ N
design NN N
. . N

The DT N
feasibility NN N
of IN N
the DT N
intervention NN N
was VBD N
demonstrated VBN N
by IN N
successfully RB N
implementing VBG N
it PRP N
with IN N
33 CD N
sexually-active JJ N
, , N
single JJ N
girls NNS N
. . N

Preliminary JJ N
evidence NN N
of IN N
the DT N
efficacy NN N
of IN N
the DT N
intervention NN N
was VBD N
obtained VBN N
using VBG N
a DT N
randomized JJ N
trial NN N
with IN N
62 CD N
sexually-active JJ N
, , N
single JJ N
girls NNS N
. . N

Data NNS N
obtained VBD N
at IN N
a DT N
3-month JJ N
follow-up JJ N
assessment NN N
showed VBD N
that IN N
girls NNS N
who WP N
received VBD N
the DT N
HIV-related JJ N
intervention NN N
improved VBD N
their PRP$ N
HIV-related JJ N
knowledge NN N
and CC N
enhanced VBD N
their PRP$ N
motivation NN N
for IN N
risk NN N
reduction NN N
compared VBN N
to TO N
girls NNS N
who WP N
received VBD N
a DT N
control NN N
( ( N
health NN N
promotion NN N
) ) N
intervention NN N
. . N

Effect JJ N
sizes VBZ N
suggest VBP N
that IN N
the DT N
HIV NNP N
intervention NN N
also RB N
reduced VBD N
several JJ N
risk NN N
behaviors NNS N
( ( N
e.g. NN N
, , N
vaginal JJ N
sex NN N
without IN N
a DT N
condom NN N
, , N
giving VBG N
oral JJ N
sex NN N
, , N
and CC N
alcohol NN N
and CC N
drug NN N
use NN N
before IN N
sex NN N
) ) N
. . N

Challenges VBZ N
to TO N
implementation NN N
and CC N
suggestions NNS N
for IN N
intervention NN N
enhancement NN N
are VBP N
discussed VBN N
. . N

-DOCSTART- -X- O O 12569977

Liposome-entrapped JJ N
D. NNP N
pteronyssinus NN N
vaccination NN N
in IN N
mild JJ 4_p
asthma JJ 4_p
patients NNS 4_p
: : 4_p
effect NN N
of IN N
1-year JJ N
double-blind NN N
, , N
placebo-controlled JJ N
trial NN N
on IN N
inflammation NN N
, , N
bronchial JJ N
hyperresponsiveness NN N
and CC N
immediate JJ N
and CC N
late JJ N
bronchial NN N
responses NNS N
to TO N
the DT N
allergen NN N
. . N

BACKGROUND NNP N
Allergen NNP N
vaccination NN N
is VBZ N
effective JJ N
in IN N
mite-allergic JJ N
asthma NN N
. . N

Liposomes NNS N
are VBP N
immunological JJ N
adjuvants NNS N
that WDT N
can MD N
act VB N
as IN N
allergen NN N
carriers NNS N
. . N

OBJECTIVE NNP N
To TO N
evaluate VB N
the DT N
immunological JJ N
and CC N
functional JJ N
effects NNS N
of IN N
a DT N
liposome-entrapped JJ N
D. NNP N
pteronyssinus NN N
vaccine NN N
on IN N
mite JJ 4_p
monosensitive NN 4_p
, , 4_p
mild JJ 4_p
asthma NN 4_p
patients NNS 4_p
. . 4_p

METHODS VB N
A DT N
double-blind JJ N
, , N
placebo-controlled JJ N
trial NN N
was VBD N
conducted VBN N
on IN N
26 CD N
asthma JJ N
patients NNS N
who WP N
randomly VBP N
received VBN N
vaccination NN N
or CC N
placebo NN N
for IN N
1 CD N
year NN N
. . N

The DT N
levels NNS N
of IN N
exposure NN N
to TO N
Der NNP N
p NN N
1 CD N
allergen NN N
were VBD N
constant JJ N
during IN N
the DT N
study NN N
. . N

Allergen NNP N
bronchial JJ N
challenge NN N
was VBD N
made VBN N
at IN N
the DT N
beginning NN N
( ( N
T0 NNP N
) ) N
and CC N
after IN N
1 CD N
year NN N
of IN N
treatment NN N
( ( N
T12 NNP N
) ) N
. . N

The DT N
day NN N
before IN N
and CC N
24 CD N
h NN N
after IN N
the DT N
allergen NN N
provocation NN N
, , N
patients NNS N
were VBD N
challenged VBN N
with IN N
methacholine NN N
( ( N
Mth NNP N
) ) N
( ( N
until IN N
FEV1 NNP N
fell VBD N
by IN N
40 CD N
% NN N
) ) N
and CC N
blood NN N
and CC N
sputum NN N
samples NNS N
were VBD N
obtained VBN N
. . N

Dose-response JJ N
curves NNS N
to TO N
Mth NNP N
were VBD N
evaluated VBN N
in IN N
terms NNS N
of IN N
Mth-PD20 NNP N
( ( N
dose NN N
of IN N
Mth NNP N
that WDT N
induced VBD N
20 CD N
% NN N
drop NN N
in IN N
FEV1 NNP N
) ) N
, , N
slope NN N
( ( N
Mth-DRS NNP N
) ) N
and CC N
level NN N
of IN N
plateau NN N
. . N

Blood NNP N
and CC N
sputum NN N
eosinophils NNS N
and CC N
serum NN N
levels NNS N
of IN N
eosinophil NN N
cationic JJ N
protein NN N
( ( N
ECP NNP N
) ) N
and CC N
intercellular JJ N
adhesion NN N
molecule-1 NN N
( ( N
ICAM-1 NNP N
) ) N
were VBD N
measured VBN N
. . N

RESULTS NNP N
Groups NNP N
were VBD N
comparable JJ N
at IN N
the DT N
start NN N
of IN N
the DT N
trial NN N
. . N

At IN N
TI2 NNP N
, , N
previous JJ N
to TO N
the DT N
allergen NN N
challenge NN N
, , N
the DT N
active JJ N
group NN N
showed VBD N
higher JJR N
values NNS N
of IN N
both DT N
FEV1 NNP N
and CC N
Mth-PD20 NNP N
and CC N
lower JJR N
values NNS N
of IN N
Mth-DRS NNP N
. . N

The DT N
number NN N
of IN N
patients NNS N
presenting VBG N
a DT N
level NN N
of IN N
plateau NN N
increased VBN N
in IN N
the DT N
active JJ N
group NN N
( ( N
from IN N
two CD N
to TO N
four CD N
) ) N
and CC N
decreased VBN N
in IN N
the DT N
placebo NN N
group NN N
( ( N
from IN N
two CD N
to TO N
one CD N
) ) N
. . N

At IN N
T12 NNP N
, , N
before IN N
the DT N
allergen NN N
challenge NN N
, , N
serum NN N
ECP NNP N
levels NNS N
increased VBN N
in IN N
the DT N
placebo NN N
group NN N
and CC N
blood NN N
eosinophils NNS N
showed VBD N
a DT N
trend NN N
towards NNS N
lower JJR N
numbers NNS N
in IN N
the DT N
active JJ N
one NN N
. . N

The DT N
immediate JJ N
response NN N
and CC N
the DT N
changes NNS N
in IN N
Mth-DRS NNP N
values NNS N
, , N
sputum NN N
eosinophils NNS N
and CC N
serum VB N
ECP NNP N
levels NNS N
following VBG N
the DT N
allergen NN N
challenge NN N
were VBD N
attenuated VBN N
in IN N
the DT N
active JJ N
group NN N
. . N

CONCLUSION NNP N
Liposome-entrapped NNP N
D. NNP N
Pteronyssinus NNP N
vaccination NN N
: : N
( ( N
i NN N
) ) N
protects VBZ N
mild JJ 4_p
asthma JJ 4_p
patients NNS 4_p
from IN N
the DT N
worsening NN N
of IN N
asthma NNS N
due JJ N
to TO N
sustained VBN N
mite JJ N
exposure NN N
; : N
and CC N
( ( N
ii NN N
) ) N
reduces VBZ N
the DT N
functional JJ N
and CC N
inflammatory JJ N
changes NNS N
induced VBN N
by IN N
allergen NN N
bronchial JJ N
provocation NN N
. . N

-DOCSTART- -X- O O 15623221

Rapeseed NNP N
and CC N
soybean NN N
products NNS N
as IN N
protein NN N
sources NNS N
for IN N
growing VBG N
turkeys NNS N
of IN N
different JJ N
ages NNS N
. . N

( ( N
1 CD N
) ) N
Apparent NNP N
ileal NN N
and CC N
total JJ N
tract NN N
protein NN N
digestibilities NNS N
of IN N
rapeseed NN N
meal NN N
and CC N
cake NN N
and CC N
soybean NN N
meal NN N
and CC N
cake NN N
were VBD N
assayed VBN N
in IN N
growing VBG N
turkeys NNS N
at IN N
4 CD N
, , N
8 CD N
and CC N
12 CD N
weeks NNS N
of IN N
age NN N
. . N

( ( N
2 CD N
) ) N
In IN N
addition NN N
, , N
the DT N
effect NN N
of IN N
killing VBG N
technique NN N
on IN N
apparent JJ N
ileal NN N
protein NN N
digestibility NN N
values NNS N
obtained VBN N
by IN N
a DT N
slaughter NN N
method NN N
and CC N
effect NN N
of IN N
rapeseed NN N
feeding VBG N
on IN N
size NN N
of IN N
specific JJ N
organs NNS N
were VBD N
studied VBN N
. . N

( ( N
3 CD N
) ) N
Protein NNP N
digestibility NN N
coefficients NNS N
of IN N
rapeseed NN N
products NNS N
were VBD N
mostly RB N
0.10 CD N
to TO N
0.15 CD N
units NNS N
lower JJR N
than IN N
those DT N
of IN N
soybean JJ N
products NNS N
. . N

Ileal NNP N
digestibility NN N
of IN N
protein NN N
increased VBD N
slightly RB N
or CC N
remained VBD N
unchanged JJ N
from IN N
4 CD N
to TO N
8 CD N
weeks NNS N
and CC N
decreased JJ N
thereafter NN N
. . N

No DT N
effect NN N
of IN N
feed NN N
processing NN N
method NN N
( ( N
meal JJ N
vs NNS N
cake VBP N
) ) N
on IN N
ileal NN N
digestibility NN N
was VBD N
observed VBN N
. . N

( ( N
4 CD N
) ) N
Killing VBG N
the DT N
birds NNS N
by IN N
carbon NN N
dioxide NN N
inhalation NN N
and CC N
bleeding NN N
led VBD N
to TO N
slightly RB N
lower JJR N
ileal JJ N
digestibility NN N
values NNS N
than IN N
mechanical JJ N
stunning NN N
and CC N
neck NN N
dislocation NN N
. . N

( ( N
5 CD N
) ) N
Total NNP N
tract JJ N
digestibility NN N
of IN N
protein NN N
decreased VBN N
from IN N
4 CD N
to TO N
8 CD N
weeks NNS N
of IN N
age NN N
for IN N
soybean JJ N
meal NN N
and CC N
rapeseed VB N
meal NN N
but CC N
increased VBD N
for IN N
soybean JJ N
cake NN N
and CC N
rapeseed VB N
cake NN N
. . N

From IN N
8 CD N
to TO N
12 CD N
weeks NNS N
of IN N
age NN N
total JJ N
tract JJ N
digestibility NN N
of IN N
protein NN N
decreased VBN N
for IN N
all PDT N
the DT N
products NNS N
tested VBN N
. . N

( ( N
6 CD N
) ) N
Feed NN N
containing VBG N
rapeseed NN N
led VBD N
to TO N
enlargement VB N
of IN N
thyroid JJ N
glands NNS N
and CC N
hearts NNS N
, , N
but CC N
did VBD N
not RB N
affect VB N
liver NN N
size NN N
or CC N
mortality NN N
. . N

-DOCSTART- -X- O O 26628383

Body NNP N
Mass NNP N
Index NNP N
and CC N
Adverse NNP N
Outcomes NNP N
in IN N
Elderly JJ N
Patients NNS N
With IN N
Atrial JJ 4_p
Fibrillation NN 4_p
: : N
The DT N
AMADEUS NNP N
Trial NNP N
. . N

BACKGROUND NNP N
AND CC N
PURPOSE NNP N
Obesity NNP N
has VBZ N
been VBN N
associated VBN N
with IN N
increased JJ N
cardiovascular NN N
risk NN N
in IN N
atrial JJ N
fibrillation NN N
, , N
but CC N
little JJ N
is VBZ N
known VBN N
in IN N
elderly JJ N
patients NNS N
with IN N
atrial JJ 4_p
fibrillation NN 4_p
. . N

METHODS NNP N
Post NNP N
hoc NN N
analysis NN N
of IN N
data NNS N
from IN N
the DT N
AMADEUS NNP N
( ( N
Evaluating VBG N
the DT N
Use NNP N
of IN N
SR34006 NNP N
Compared NNP N
to TO N
Warfarin NNP N
or CC N
Acenocoumarol NNP N
in IN N
Patients NNP N
With IN N
Atrial NNP 4_p
Fibrillation NNP 4_p
) ) N
trial NN N
. . N

RESULTS NNP N
We PRP N
studied VBD N
1588 CD N
elderly JJ N
patients NNS N
, , N
who WP N
were VBD N
categorized VBN N
as IN N
normal JJ N
body NN N
mass NN N
index NN N
( ( N
BMI NNP N
, , N
18.5-25 JJ N
kg/m NN N
( ( N
2 CD N
) ) N
; : N
n=515 CC N
[ VB N
32.4 CD N
% NN N
] NN N
) ) N
, , N
overweight JJ N
( ( N
BMI NNP N
, , N
25-30 JJ N
kg/m NN N
( ( N
2 CD N
) ) N
; : N
n=711 CC N
[ VB N
44.8 CD N
% NN N
] NN N
) ) N
, , N
and CC N
obese JJ N
( ( N
BMI≥30 NNP N
kg/m NNP N
( ( N
2 CD N
) ) N
; : N
n=362 CC N
[ VB N
22.8 CD N
% NN N
] NN N
) ) N
. . N

There EX N
was VBD N
a DT N
significant JJ N
reduction NN N
in IN N
the DT N
composite JJ N
outcome NN N
of IN N
cardiovascular JJ N
death NN N
and CC N
stroke/systemic JJ N
embolism NN N
with IN N
increasing VBG N
BMI NNP N
category NN N
, , N
being VBG N
5.0 CD N
% NN N
, , N
3.2 CD N
% NN N
, , N
and CC N
1.5 CD N
% NN N
per IN N
100 CD N
patient-years NNS N
, , N
respectively RB N
( ( N
P NNP N
for IN N
trend=0.01 NN N
) ) N
. . N

Cox NNP N
proportional JJ N
hazards NNS N
analysis NN N
found VBD N
obesity NN N
to TO N
be VB N
associated VBN N
with IN N
a DT N
lower JJR N
risk NN N
of IN N
the DT N
primary JJ N
composite JJ N
outcome NN N
( ( N
hazard JJ N
ratio NN N
, , N
0.29 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
0.11-0.77 JJ N
; : N
P=0.01 NNP N
) ) N
. . N

In IN N
the DT N
warfarin NN N
arm NN N
( ( N
n=814 NN N
) ) N
, , N
multivariate JJ N
logistic JJ N
regression NN N
analysis NN N
demonstrated VBD N
that IN N
obesity NN N
was VBD N
independently RB N
related VBN N
to TO N
higher JJR N
odds NNS N
of IN N
time NN N
in IN N
therapeutic JJ N
range NN N
≥60 CD N
% NN N
( ( N
odds JJ N
ratio NN N
, , N
1.84 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
1.21-2.80 JJ N
; : N
P=0.004 NNP N
) ) N
. . N

CONCLUSION NNP N
Obesity NNP N
was VBD N
associated VBN N
with IN N
a DT N
lower JJR N
stroke NN N
and CC N
mortality NN N
rate NN N
in IN N
elderly JJ N
anticoagulated VBN 4_p
atrial JJ 4_p
fibrillation NN 4_p
patients NNS N
. . N

Obesity NNP N
was VBD N
related VBN N
to TO N
good JJ N
quality NN N
anticoagulation NN N
control NN N
. . N

-DOCSTART- -X- O O 2885607

Methotrexate/nitrous-oxide NNP N
toxic JJ N
interaction NN N
in IN N
perioperative JJ 4_p
chemotherapy NN 4_p
for IN 4_p
early JJ 4_p
breast NN 4_p
cancer NN 4_p
. . N

-DOCSTART- -X- O O 11004058

The DT N
effect NN N
of IN N
systemic JJ N
lidocaine NN N
on IN N
pain NN 4_p
and CC 4_p
secondary JJ 4_p
hyperalgesia NN 4_p
associated VBN N
with IN N
the DT N
heat/capsaicin NN N
sensitization NN N
model NN N
in IN 4_p
healthy JJ 4_p
volunteers NNS 4_p
. . 4_p

UNLABELLED CC N
Although IN N
effective JJ N
in IN N
neuropathic JJ N
pain NN N
, , N
the DT N
efficacy NN N
of IN N
systemic JJ N
lidocaine NN N
in IN N
non-neuropathic JJ 4_p
pain NN 4_p
remains VBZ N
uncertain JJ N
. . N

We PRP N
investigated VBD N
the DT N
analgesic JJ N
effect NN N
of IN N
systemic JJ N
lidocaine NN N
on IN N
the DT N
heat/capsaicin NN N
sensitization NN N
model NN N
of IN N
experimental JJ 4_p
pain NN 4_p
in IN 4_p
24 CD 4_p
volunteers NNS 4_p
. . 4_p

Sensitization NN N
was VBD N
produced VBN N
by IN N
heating VBG N
the DT N
skin NN N
to TO N
45 CD N
degrees NNS N
C NNP N
for IN N
5 CD N
min NN N
, , N
followed VBN N
by IN N
a DT N
30-min JJ N
application NN N
of IN N
0.075 CD N
% NN N
capsaicin NN N
cream NN N
, , N
and CC N
maintained VBN N
by IN N
periodically RB N
reheating VBG N
the DT N
sensitized JJ N
skin NN N
. . N

Subjects VBZ N
received VBN N
IV NNP N
lidocaine NN N
( ( N
bolus JJ N
2 CD N
mg/kg NN N
, , N
then RB N
infusion NN N
3 CD N
mg. NN N
kg NN N
. . N

h NN N
) ) N
, , N
or CC N
saline NN N
for IN N
85 CD N
min NN N
. . N

Areas NNP N
of IN N
secondary JJ N
hyperalgesia NN N
, , N
heat NN N
pain NN N
detection NN N
thresholds NNS N
, , N
and CC N
painfulness NN N
of IN N
stimulation NN N
with IN N
45 CD N
degrees NNS N
C NNP N
for IN N
1 CD N
min NNS N
( ( N
long JJ N
thermal JJ N
stimulation NN N
) ) N
were VBD N
quantified VBN N
. . N

Systemic NNP N
lidocaine NN N
reduced VBD N
the DT N
area NN N
of IN N
secondary JJ N
hyperalgesia NN N
to TO N
brush VB N
, , N
but CC N
not RB N
to TO N
von VB N
Frey NNP N
hair JJ N
stimulation NN N
. . N

Lidocaine NNP N
did VBD N
not RB N
alter VB N
heat NN N
pain NN N
detection NN N
thresholds NNS N
or CC N
painfulness NN N
of IN N
long JJ N
thermal JJ N
stimulation NN N
in IN N
normal JJ N
skin NN N
. . N

We PRP N
conclude VBP N
that IN N
, , N
at IN N
infusion NN N
rates NNS N
in IN N
the DT N
low- JJ N
to TO N
mid-antiarrhythmic JJ N
range NN N
, , N
lidocaine NN N
has VBZ N
no DT N
effect NN N
on IN N
acute NN N
nociceptive JJ N
pain NN N
but CC N
does VBZ N
have VB N
a DT N
limited JJ N
and CC N
selective JJ N
effect NN N
on IN N
secondary JJ N
hyperalgesia NN N
. . N

IMPLICATIONS VBZ N
The DT N
efficacy NN N
of IN N
systemic JJ N
lidocaine NN N
in IN N
nonneuropathic JJ N
pain NN N
remains VBZ N
uncertain JJ N
. . N

This DT N
study NN N
investigates VBZ N
the DT N
effect NN N
of IN N
systemic JJ N
lidocaine NN N
on IN N
experimental-induced JJ N
hyperalgesia NN N
in IN N
25 CD N
volunteers NNS N
. . N

Hyperalgesia NNP N
was VBD N
induced VBN N
by IN N
using VBG N
an DT N
experimental JJ N
pain NN N
model NN N
that WDT N
uses VBZ N
heat NN N
and CC N
capsaicin NN N
in IN N
combination NN N
. . N

Systemic NNP N
lidocaine NN N
showed VBD N
a DT N
selective JJ N
effect NN N
on IN N
secondary JJ N
hyperalgesia NN N
. . N

-DOCSTART- -X- O O 5378631

A DT N
comparison NN N
of IN N
the DT N
effects NNS N
of IN N
( ( N
- : N
) ) N
-hyoscine NN N
and CC N
amylobarbitone NN N
sodium NN N
on IN N
measurements NNS N
of IN N
post-rotational JJ 4_p
turning VBG 4_p
sensation NN 4_p
and CC 4_p
nystagmus NN 4_p
. . 4_p

-DOCSTART- -X- O O 1697914

Use NNP N
of IN N
an DT N
alpha JJ N
1-blocker NN N
, , N
YM617 NNP N
, , N
in IN N
the DT N
treatment NN N
of IN N
benign JJ 4_p
prostatic JJ 4_p
hypertrophy NN 4_p
. . N

YM617 NNP N
Clinical NNP N
Study NNP N
Group NNP N
. . N

A DT N
recently RB N
synthesized VBN N
alpha JJ N
1-blocker CD N
, , N
( ( N
R NNP N
) ) N
( ( N
- : N
) ) N
-5- VBP N
[ JJ N
2- JJ N
[ NN N
[ CD N
2- JJ N
( ( N
o-ethoxyphenoxy JJ N
) ) N
ethyl FW N
] NNP N
amino NN N
] NNP N
propyl NN N
] NNP N
-2- NNP N
methoxybenzenesulfonamide NN N
hydrochloride NN N
( ( N
YM617 NNP N
) ) N
, , N
was VBD N
evaluated VBN N
in IN N
270 CD N
patients NNS N
with IN N
benign JJ N
prostatic JJ N
hypertrophy NN N
in IN N
a DT N
double-blind NN N
study NN N
. . N

After IN N
2 CD N
weeks NNS N
on IN N
placebo IN N
the DT N
patients NNS N
were VBD N
assigned VBN N
at IN N
random NN N
to TO N
4 CD N
groups NNS N
: : N
group NN N
P NNP N
-- : N
placebo NN N
, , N
group NN N
L NNP N
-- : N
0.1 CD N
mg. NN N
, , N
group NN N
M NNP N
-- : N
0.2 CD N
mg. NN N
and CC N
group NN N
H NNP N
-- : N
0.4 CD N
mg. NN N
of IN N
YM617 NNP N
. . N

Comparing VBG N
the DT N
placebo NN N
to TO N
the DT N
treatment NN N
period NN N
, , N
subjective JJ N
symptoms NNS N
, , N
such JJ N
as IN N
nocturia NNS N
and CC N
urgency NN N
, , N
were VBD N
significantly RB N
decreased VBN N
in IN N
group NN N
H NNP N
( ( N
p NN N
less JJR N
than IN N
0.01 CD N
) ) N
. . N

The DT N
sensation NN N
of IN N
incomplete JJ N
voiding NN N
was VBD N
significantly RB N
improved VBN N
in IN N
groups NNS N
M NNP N
and CC N
H NNP N
( ( N
p NN N
less JJR N
than IN N
0.01 CD N
) ) N
. . N

However RB N
, , N
the DT N
differences NNS N
among IN N
the DT N
groups NNS N
were VBD N
statistically RB N
insignificant JJ N
. . N

Residual JJ N
urine JJ N
volume NN N
was VBD N
significantly RB N
decreased VBN N
in IN N
groups NNS N
L NNP N
, , N
M NNP N
and CC N
H NNP N
after IN N
instillation NN N
of IN N
saline NN N
into IN N
the DT N
bladder NN N
( ( N
p NN N
less JJR N
than IN N
0.01 CD N
) ) N
but CC N
not RB N
in IN N
group NN N
P. NNP N
The DT N
maximum NN N
and CC N
average JJ N
flow JJ N
rates NNS N
were VBD N
significantly RB N
increased VBN N
in IN N
groups NNS N
L NNP N
, , N
M NNP N
and CC N
H NNP N
( ( N
p NN N
less JJR N
than IN N
0.01 CD N
) ) N
but CC N
not RB N
in IN N
group NN N
P. NNP N
Average NNP N
flow JJ N
rate NN N
showed VBD N
significant JJ N
differences NNS N
between IN N
groups NNS N
M NNP N
or CC N
H NNP N
versus NN N
group NN N
P. NNP N
Neither NNP N
orthostatic JJ N
hypotension NN N
nor CC N
a DT N
decrease NN N
in IN N
blood NN N
pressure NN N
was VBD N
noted VBN N
. . N

Adverse JJ N
side NN N
effects NNS N
and CC N
changes NNS N
in IN N
laboratory NN N
data NNS N
were VBD N
all DT N
slight JJ N
and CC N
disappeared VBD N
when WRB N
the DT N
second JJ N
tests NNS N
were VBD N
performed VBN N
. . N

In IN N
summary JJ N
, , N
the DT N
irritative JJ N
and CC N
obstructive JJ N
symptoms NNS N
caused VBN N
by IN N
benign JJ N
prostatic JJ N
hypertrophy NN N
were VBD N
decreased VBN N
and CC N
urodynamic JJ N
studies NNS N
were VBD N
markedly RB N
improved VBN N
by IN N
the DT N
alpha JJ N
1-blocker NN N
, , N
YM617 NNP N
. . N

The DT N
drug NN N
seems VBZ N
to TO N
be VB N
useful JJ N
in IN N
the DT N
treatment NN N
of IN N
patients NNS N
with IN N
benign JJ N
prostatic JJ N
hypertrophy NN N
. . N

-DOCSTART- -X- O O 1797999

Home NNP N
blood NN N
pressure NN N
monitoring NN N
: : N
advantages NNS N
and CC N
limitations NNS N
. . N

Home NNP N
blood NN N
pressure NN N
monitoring NN N
is VBZ N
a DT N
useful JJ N
tool NN N
for IN N
clinical JJ N
management NN N
of IN N
patients NNS N
with IN N
hypertension NN 4_p
. . N

Its PRP$ N
major JJ N
advantages NNS N
are VBP N
the DT N
ease NN N
with IN N
which WDT N
the DT N
techniques NNS N
can MD N
be VB N
learned VBN N
, , N
reproducibility NN N
of IN N
values NNS N
, , N
sensitivity NN N
of IN N
measurement NN N
and CC N
availability NN N
of IN N
normotensive JJ N
data NNS N
. . N

In IN N
spite NN N
of IN N
the DT N
ability NN N
to TO N
tell VB N
whether IN N
a DT N
subject NN N
has VBZ N
normal JJ N
or CC N
abnormal JJ N
values NNS N
, , N
because IN N
of IN N
the DT N
lack NN N
of IN N
prospective JJ N
mortality/morbidity NN N
data NNS N
, , N
home NN N
blood NN N
pressure NN N
monitoring NN N
can MD N
not RB N
be VB N
used VBN N
to TO N
decide VB N
whether IN N
treatment NN N
is VBZ N
indicated VBN N
. . N

The DT N
treatment NN N
decision NN N
must MD N
be VB N
based VBN N
on IN N
repeated VBN N
clinic JJ N
blood NN N
pressure NN N
readings NNS N
. . N

After IN N
that IN N
the DT N
home NN N
blood NN N
pressure NN N
monitoring NN N
can MD N
be VB N
used VBN N
to TO N
exclude VB N
individuals NNS N
who WP N
are VBP N
at IN N
risk NN N
for IN N
side NN N
effects NNS N
due JJ N
to TO N
low JJ N
out-of-office JJ N
blood NN N
pressure NN N
readings NNS N
and CC N
to TO N
precisely RB N
monitor VB N
the DT N
blood NN N
pressure NN N
response NN N
to TO N
therapy NN N
. . N

Home NNP N
blood NN N
pressure NN N
monitoring NN N
is VBZ N
frequently RB N
used VBN N
to TO N
find VB N
subjects NNS N
with IN N
'white-coat NNP N
' POS N
hypertension NN N
. . N

In IN N
our PRP$ N
study NN N
of IN N
borderline JJ 4_p
hypertension NN 4_p
in IN N
Tecumseh NNP N
, , N
white-coat JJ N
hypertension NN N
is VBZ N
present JJ N
in IN N
7.1 CD N
% NN N
of IN N
the DT N
whole JJ N
population NN N
and CC N
in IN N
58 CD N
% NN N
of IN N
all DT N
subjects NNS N
with IN N
elevated JJ N
blood NN N
pressures NNS N
in IN N
the DT N
clinic NN N
. . N

Subjects NNS N
with IN N
white-coat JJ N
hypertension NN N
in IN N
Tecumseh NNP N
appear VBP N
to TO N
be VB N
at IN N
an DT N
increased VBN N
risk NN N
for IN N
coronary JJ N
heart NN N
disease NN N
: : N
they PRP N
show VBP N
repeated VBN N
elevated JJ N
clinic NN N
readings NNS N
throughout IN N
their PRP$ N
life NN N
time NN N
, , N
their PRP$ N
parents NNS N
have VBP N
higher JJR N
blood NN N
pressure NN N
, , N
their PRP$ N
high-density NN N
lipoprotein NN N
is VBZ N
decreased VBN N
and CC N
insulin NN N
, , N
cholesterol NN N
and CC N
triglycerides NNS N
are VBP N
elevated VBN N
. . N

Whereas JJ N
subjects NNS N
with IN N
white-coat JJ N
hypertension NN N
should MD N
not RB N
be VB N
treated VBN N
with IN N
antihypertensive JJ N
agents NNS N
, , N
they PRP N
must MD N
be VB N
followed VBN N
and CC N
managed VBN N
through IN N
non-pharmacologic JJ N
means NNS N
. . N

-DOCSTART- -X- O O 12680863

A DT N
single JJ N
nasal NN N
allergen NN N
challenge NN N
increases NNS N
induced VBD N
sputum JJ N
inflammatory JJ N
markers NNS N
in IN N
non-asthmatic JJ 4_p
subjects NNS 4_p
with IN 4_p
seasonal JJ 4_p
allergic JJ 4_p
rhinitis NN 4_p
: : 4_p
correlation NN N
with IN N
plasma JJ N
interleukin-5 JJ N
. . N

BACKGROUND NNP N
Seasonal NNP N
allergic JJ N
rhinitis NN N
( ( N
SAR NNP N
) ) N
is VBZ N
a DT N
risk NN 4_p
factor NN 4_p
for IN 4_p
asthma NN 4_p
in IN 4_p
affected JJ 4_p
individuals NNS 4_p
. . 4_p

Nasal NNP N
allergic JJ N
inflammation NN N
enhances VBZ N
bone-marrow JJ N
eosinophil NN N
production NN N
, , N
mainly RB N
via IN N
IL-5 NNP N
, , N
and CC N
rhinitis NN N
patients NNS N
have VBP N
increased VBN N
airway JJ N
inflammation NN N
during IN N
the DT N
pollen NN N
season NN N
. . N

OBJECTIVE UH N
To TO N
assess VB N
the DT N
impact NN N
of IN N
nasal NN N
allergy NN N
on IN N
sputum NN N
inflammatory NN N
markers NNS N
. . N

METHODS NNP N
In IN N
an DT N
open-labelled JJ N
, , N
randomized VBN N
, , N
placebo-controlled JJ N
cross-over NN N
study NN N
with IN N
16 CD N
non-asthmatic JJ N
SAR NNP N
patients NNS N
( ( N
median JJ N
age NN N
25 CD N
years NNS N
, , N
56 CD N
% NN N
males NNS N
) ) N
, , N
the DT N
effect NN N
of IN N
a DT N
single JJ N
nasal NN N
allergen NN N
challenge NN N
performed VBD N
out IN N
of IN N
season NN N
on IN N
induced JJ N
sputum NN N
inflammatory NN N
parameters NNS N
was VBD N
evaluated VBN N
. . N

SAR JJ N
patients NNS N
were VBD N
identified VBN N
by IN N
history NN N
, , N
skin-prick JJ N
test NN N
and CC N
specific JJ N
IgE NNP N
. . N

All DT N
patients NNS N
had VBD N
normal JJ N
lung JJ N
function/bronchial JJ N
hyper-responsiveness NN N
out IN N
of IN N
season NN N
and CC N
a DT N
negative JJ N
asthma/wheezing NN N
history NN N
. . N

Sputum NNP N
cells NNS N
and CC N
supernatant JJ N
levels NNS N
of IN N
ECP NNP N
, , N
sICAM NN N
, , N
IL-5 NNP N
and CC N
IL-10 NNP N
, , N
and CC N
plasma NN N
levels NNS N
of IN N
IL-5 NNP N
and CC N
ECP NNP N
, , N
were VBD N
measured VBN N
before IN N
and CC N
24 CD N
h NN N
after IN N
nasal JJ N
allergen NN N
challenge NN N
. . N

After IN N
a DT N
washout JJ N
period NN N
of IN N
at IN N
least JJS N
4 CD N
weeks NNS N
, , N
the DT N
procedure NN N
was VBD N
repeated VBN N
with IN N
placebo NN N
challenge NN N
( ( N
diluent NN N
) ) N
. . N

RESULTS NNP N
Nasal NNP N
allergen VBZ N
challenge NN N
led VBD N
to TO N
an DT N
increase NN N
in IN N
sputum JJ N
ECP NNP N
( ( N
pre JJ N
= $ N
60 CD N
+/- JJ N
12 CD N
, , N
post NN N
= VBD N
212 CD N
+/- JJ N
63 CD N
micro NN N
g/L NN N
, , N
P NNP N
= VBZ N
0.02 CD N
vs. FW N
placebo NN N
) ) N
, , N
and CC N
sICAM NN N
( ( N
4.8 CD N
+/- JJ N
2.7 CD N
to TO N
6.5 CD N
+/- JJ N
2.9 CD N
ng/mL NN N
, , N
P NNP N
= VBZ N
0.02 CD N
vs. FW N
placebo NN N
) ) N
, , N
whereas JJ N
IL-10 NNP N
decreased VBD N
after IN N
provocation NN N
( ( N
44 CD N
+/- JJ N
11 CD N
to TO N
29 CD N
+/- JJ N
6 CD N
pg/mL NN N
, , N
P NNP N
= VBZ N
0.06 CD N
vs. FW N
placebo NN N
) ) N
. . N

Sputum NNP N
IL-5 NNP N
was VBD N
undetectable JJ N
in IN N
all DT N
patients NNS N
. . N

The DT N
absolute JJ N
number NN N
of IN N
blood NN N
and CC N
sputum NN N
eosinophils NNS N
did VBD N
not RB N
change VB N
significantly RB N
after IN N
allergen NN N
or CC N
placebo NN N
challenge NN N
( ( N
P NNP N
> NNP N
0.07 CD N
, , N
both DT N
comparisons NNS N
) ) N
. . N

Plasma NNP N
levels NNS N
of IN N
IL-5 NNP N
increased VBD N
after IN N
allergen NN N
challenge NN N
( ( N
8.7 CD N
+/- JJ N
2.9 CD N
to TO N
14.5 CD N
+/- JJ N
3.9 CD N
pg/mL NN N
, , N
P NNP N
= NNP N
0.001 CD N
) ) N
, , N
and CC N
the DT N
increase NN N
in IN N
plasma JJ N
IL-5 NNP N
was VBD N
positively RB N
correlated VBN N
with IN N
the DT N
rise NN N
in IN N
sputum NN N
ECP NNP N
in IN N
a DT N
subgroup NN N
of IN N
'responders NNS N
' POS N
( ( N
n JJ N
= NN N
12 CD N
, , N
r NN N
= VBD N
0.71 CD N
, , N
P NNP N
= NNP N
0.01 CD N
) ) N
. . N

CONCLUSIONS VB N
A DT N
single JJ N
nasal NN N
allergen NN N
challenge NN N
in IN N
SAR NNP N
patients NNS N
increased VBD N
markers NNS N
of IN N
allergic JJ N
inflammation NN N
in IN N
the DT N
lower JJR N
respiratory NN N
tract NN N
, , N
possibly RB N
via IN N
pronounced JJ N
activation NN N
of IN N
inflammatory NN N
cells NNS N
through IN N
circulating VBG N
immediate-type JJ N
reaction NN N
cytokines NNS N
like IN N
IL-5 NNP N
. . N

These DT N
findings NNS N
may MD N
provide VB N
additional JJ N
explanatory NN N
data NNS N
for IN N
the DT N
high JJ N
susceptibility NN N
of IN N
SAR NNP N
patients NNS N
to TO N
incident VB N
asthma NN N
. . N

-DOCSTART- -X- O O 16585808

Survey NNP N
response NN N
inducements NNS N
for IN N
registered JJ 4_p
nurses NNS 4_p
. . 4_p

The DT N
past JJ N
20 CD N
years NNS N
have VBP N
seen VBN N
an DT N
overall JJ N
decline NN N
in IN N
survey NN N
response NN N
rates NNS N
and CC N
an DT N
even RB N
more RBR N
pronounced JJ N
decline NN N
in IN N
samples NNS N
of IN N
health NN N
care NN N
professionals NNS N
. . N

The DT N
authors NNS N
tested VBD N
the DT N
use NN N
of IN N
a DT N
" NNP N
thank NN N
you PRP N
" VBP N
or CC N
" JJ N
reminder NN N
" NNP N
postcard NN N
as IN N
a DT N
method NN N
by IN N
which WDT N
to TO N
stem VB N
the DT N
tide NN N
of IN N
declining VBG N
response NN N
rates NNS N
. . N

The DT N
authors NNS N
conducted VBD N
a DT N
mail NN N
and CC N
telephone NN N
survey NN N
of IN N
49,605 CD N
registered JJ N
nurses NNS N
for IN N
the DT N
2000 CD N
National NNP N
Sample NNP N
Survey NNP N
of IN N
Registered NNP N
Nurses NNP N
and CC N
sent VBD N
an DT N
extra JJ N
mailing NN N
to TO N
a DT N
random JJ N
subsample NN N
( ( N
n JJ N
= NNP N
4,968 CD N
) ) N
. . N

They PRP N
then RB N
compared VBN N
response NN N
rates NNS N
for IN N
both DT N
groups NNS N
. . N

Contrary NNP N
to TO N
prior VB N
research NN N
, , N
this DT N
study NN N
found VBD N
that IN N
reminder NN N
postcards NNS N
did VBD N
not RB N
improve VB N
response NN N
rates NNS N
or CC N
rates NNS N
of IN N
return NN N
. . N

There EX N
may MD N
be VB N
several JJ N
reasons NNS N
for IN N
this DT N
finding NN N
, , N
including VBG N
the DT N
general JJ N
familiarity NN N
with IN N
, , N
and CC N
high JJ N
saliency NN N
of IN N
, , N
this DT N
research NN N
project NN N
for IN N
the DT N
nursing NN N
community NN N
. . N

These DT N
results NNS N
suggest VBP N
that IN N
even RB N
widely RB N
accepted VBN N
best JJS N
practices NNS N
for IN N
survey NN N
methods NNS N
deserve VBP N
scrutiny NN N
when WRB N
applied VBN N
to TO N
special JJ N
subpopulations NNS N
. . N

-DOCSTART- -X- O O 2406863

Bismuth NNP N
subsalicylate NN N
in IN N
the DT N
treatment NN N
of IN N
gastritis NN 4_p
due JJ 4_p
to TO 4_p
Campylobacter NNP 4_p
pylori NN 4_p
. . 4_p

Fifty JJ 4_p
patients NNS 4_p
completed VBD N
an DT N
investigator-blind JJ N
trial NN N
comparing VBG N
bismuth NN N
subsalicylate NN N
, , N
erythromycin JJ N
ethylsuccinate NN N
, , N
and CC N
placebo RB N
matched VBN N
to TO N
the DT N
bismuth NN N
salt NN N
in IN N
the DT N
treatment NN N
of IN N
gastritis NN N
associated VBN N
with IN N
Campylobacter NNP N
pylori NN N
. . N

C. NNP N
pylori NN N
was VBD N
cleared VBN N
from IN N
14 CD N
( ( N
77.8 CD N
% NN N
) ) N
of IN N
18 CD N
patients NNS N
given VBN N
locally RB N
active JJ N
bismuth NN N
, , N
from IN N
one CD N
( ( N
6.7 CD N
% NN N
) ) N
of IN N
15 CD N
patients NNS N
given VBN N
erythromycin NNS N
, , N
and CC N
from IN N
none NN N
of IN N
17 CD N
patients NNS N
given VBN N
placebo NNS N
. . N

Gastritis NNP N
resolved VBD N
in IN N
13 CD N
( ( N
81 CD N
% NN N
) ) N
of IN N
16 CD N
patients NNS N
treated VBN N
with IN N
bismuth NN N
but CC N
in IN N
only RB N
three CD N
of IN N
13 CD N
receiving VBG N
erythromycin NN N
and CC N
in IN N
none NN N
of IN N
16 CD N
patients NNS N
given VBN N
placebo NNS N
. . N

Results NNS N
of IN N
endoscopic JJ N
examination NN N
showed VBD N
greater JJR N
improvement NN N
in IN N
patients NNS N
cleared VBN N
of IN N
C. NNP N
pylori NN N
than IN N
in IN N
those DT N
with IN N
persistent JJ N
infection NN N
. . N

Heartburn NNP N
improved VBD N
in IN N
50 CD N
% NN N
of IN N
patients NNS N
who WP N
received VBD N
bismuth RB N
compared VBN N
with IN N
17 CD N
% NN N
of IN N
those DT N
given VBN N
placebo NN N
. . N

The DT N
success NN N
of IN N
bismuth NN N
is VBZ N
probably RB N
due JJ N
to TO N
its PRP$ N
local JJ N
antimicrobial JJ N
activity NN N
. . N

Erythromycin NN N
may MD N
have VB N
been VBN N
inactivated VBN N
by IN N
the DT N
low JJ N
pH NN N
in IN N
the DT N
areas NNS N
colonized VBN N
with IN N
C. NNP N
pylori NN N
. . N

Relapse NNP N
is VBZ N
less RBR N
frequent JJ N
when WRB N
a DT N
combination NN N
of IN N
bismuth NN N
and CC N
an DT N
antimicrobial JJ N
agent NN N
is VBZ N
used VBN N
; : N
such JJ N
a DT N
combination NN N
is VBZ N
characterized VBN N
by IN N
local JJ N
and CC N
systemic JJ N
activity NN N
, , N
stability NN N
at IN N
low JJ N
pH NN N
, , N
and CC N
good JJ N
penetration NN N
into IN N
gastric JJ N
mucus NN N
. . N

-DOCSTART- -X- O O 21740578

The DT N
IDvIP NNP N
trial NN N
: : N
a DT N
two-centre JJ N
randomised JJ N
double-blind NN N
controlled VBD N
trial NN N
comparing VBG N
intramuscular JJ N
diamorphine NN N
and CC N
intramuscular JJ N
pethidine NN N
for IN N
labour JJ N
analgesia NN N
. . N

BACKGROUND NNP N
Intramuscular NNP N
pethidine NN N
is VBZ N
routinely RB N
used VBN N
throughout IN N
the DT N
UK NNP N
for IN N
labour JJ N
analgesia NN N
. . N

Studies NNS N
have VBP N
suggested VBN N
that IN N
pethidine NN N
provides VBZ N
little JJ N
pain NN N
relief NN N
in IN N
labour NN N
and CC N
has VBZ N
a DT N
number NN N
of IN N
side JJ N
effects NNS N
affecting VBG N
mother NN N
and CC N
neonate NN N
. . N

It PRP N
can MD N
cause VB N
nausea NN N
, , N
vomiting VBG N
and CC N
dysphoria NNS N
in IN N
mothers NNS N
and CC N
can MD N
cause VB N
reduced VBN N
fetal JJ N
heart NN N
rate NN N
variability NN N
and CC N
accelerations NNS N
. . N

Neonatal JJ N
effects NNS N
include VBP N
respiratory JJ N
depression NN N
and CC N
impaired JJ N
feeding NN N
. . N

There EX N
are VBP N
few JJ N
large JJ N
studies NNS N
comparing VBG N
the DT N
relative JJ N
side NN N
effects NNS N
and CC N
efficacy NN N
of IN N
different JJ N
opioids NNS N
in IN N
labour NN N
. . N

A DT N
small JJ N
trial NN N
comparing VBG N
intramuscular JJ N
pethidine NN N
with IN N
diamorphine NN N
, , N
showed VBD N
diamorphine NN N
to TO N
have VB N
some DT N
benefits NNS N
over IN N
pethidine NN N
when WRB N
used VBN N
for IN N
labour JJ N
analgesia NN N
but CC N
the DT N
study NN N
did VBD N
not RB N
investigate VB N
the DT N
adverse JJ N
effects NNS N
of IN N
either DT N
opioid NN N
. . N

METHODS NNP N
The DT N
Intramuscular NNP N
Diamorphine NNP N
versus IN N
Intramuscular NNP N
Pethidine NNP N
( ( N
IDvIP NNP N
) ) N
trial NN N
is VBZ N
a DT N
randomised JJ N
double-blind NN N
two CD N
centre NN N
controlled VBD N
trial NN N
comparing VBG N
intramuscular JJ N
diamorphine NN N
and CC N
pethidine NN N
regarding VBG N
their PRP$ N
analgesic JJ N
efficacy NN N
in IN N
labour NN N
and CC N
their PRP$ N
side NN N
effects NNS N
in IN N
mother NN N
, , N
fetus NN N
and CC N
neonate NN N
. . N

Information NN N
about IN N
the DT N
trial NN N
will MD N
be VB N
provided VBN N
to TO N
women NNS N
in IN N
the DT N
antenatal JJ N
period NN N
or CC N
in IN N
early JJ N
labour NN N
. . N

Consent NN N
and CC N
recruitment NN N
to TO N
the DT N
trial NN N
will MD N
be VB N
obtained VBN N
when WRB N
the DT N
mother NN N
requests VBZ N
opioid JJ N
analgesia NN N
. . N

The DT N
sample NN N
size NN N
requirement NN N
is VBZ N
406 CD 4_p
women NNS 4_p
with IN 4_p
data NNS 4_p
on IN 4_p
primary JJ 4_p
outcomes NNS 4_p
. . 4_p

The DT N
maternal JJ N
primary NN N
outcomes NNS N
are VBP N
pain JJ N
relief NN N
during IN N
the DT N
first JJ N
3 CD N
hours NNS N
after IN N
trial NN N
analgesia NN N
and CC N
specifically RB N
pain VBP N
relief NN N
after IN N
60 CD N
minutes NNS N
. . N

The DT N
neonatal JJ N
primary JJ N
outcomes NNS N
are VBP N
need VBN N
for IN N
resuscitation NN N
and CC N
Apgar NNP N
Score NNP N
< VBD N
7 CD N
at IN N
1 CD N
minute NN N
. . N

The DT N
secondary JJ N
outcomes NNS N
are VBP N
an DT N
additional JJ N
measure NN N
of IN N
pain NN N
relief NN N
, , N
maternal JJ N
sedation NN N
, , N
nausea NN N
and CC N
vomiting NN N
, , N
maternal JJ N
oxygen NN N
saturation NN N
, , N
satisfaction NN N
with IN N
analgesia NN N
, , N
whether IN N
method NN N
of IN N
analgesia NN N
would MD N
be VB N
used VBN N
again RB N
, , N
use NN N
of IN N
Entonox NNP N
, , N
umbilical JJ N
arterial NN N
and CC N
venous JJ N
pH NN N
, , N
fetal JJ N
heart NN N
rate NN N
, , N
meconium NN N
staining NN N
, , N
time NN N
from IN N
delivery NN N
to TO N
first JJ N
breath NN N
, , N
Apgar NNP N
scores VBZ N
at IN N
5 CD N
mins NNS N
, , N
naloxone JJ N
requirement NN N
, , N
transfer NN N
to TO N
neonatal JJ N
intensive JJ N
care NN N
unit NN N
, , N
neonatal JJ N
haemoglobin NN N
oxygen NN N
saturation NN N
at IN N
30 CD N
, , N
60 CD N
, , N
90 CD N
, , N
and CC N
120 CD N
mins NNS N
after IN N
delivery NN N
, , N
and CC N
neonatal JJ N
sedation NN N
and CC N
feeding VBG N
behaviour NN N
during IN N
first JJ N
2 CD N
hours NNS N
. . N

DISCUSSION NNP N
If IN N
the DT N
trial NN N
demonstrates VBZ N
that IN N
diamorphine NN N
provides VBZ N
better RBR N
analgesia NN N
with IN N
fewer JJR N
side NN N
effects NNS N
in IN N
mother NN N
and CC N
neonate NN N
this DT N
could MD N
lead VB N
to TO N
a DT N
change NN N
in IN N
national JJ N
practice NN N
and CC N
result NN N
in IN N
diamorphine NN N
becoming VBG N
the DT N
preferred JJ N
intramuscular JJ N
opioid NN N
for IN N
analgesia NN N
in IN N
labour NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
ISRCTN14898678Eudra NNP N
No NNP N
: : N
2006-003250-18 JJ N
, , N
REC NNP N
Reference NNP N
No NNP N
: : N
06/Q1702/95 CD N
, , N
MHRA NNP N
Authorisation NNP N
No NNP N
: : N
1443/0001/001-0001 JJ N
, , N
NIHR NNP N
UKCRN NNP N
reference NN N
6895 CD N
, , N
RfPB NNP N
grant NN N
PB-PG-0407-13170_IR5 NNP N
. . N

-DOCSTART- -X- O O 6148879

A DT N
comparison NN N
of IN N
propranolol NN N
and CC N
nadolol JJ N
pharmacokinetics NNS N
and CC N
clinical JJ N
effects NNS N
in IN N
thyrotoxicosis NN 4_p
. . 4_p

For IN N
a DT N
comparison NN N
of IN N
propranolol NN N
and CC N
nadolol JJ N
pharmacokinetics NNS N
and CC N
clinical JJ N
effects NNS N
, , N
20 CD 4_p
newly RB 4_p
diagnosed VBN 4_p
patients NNS 4_p
with IN 4_p
thyrotoxicosis NN 4_p
were VBD N
randomly RB N
selected VBN N
to TO N
receive VB N
as IN N
sole JJ N
therapy NN N
, , N
either DT N
propranolol NN N
, , N
40 CD N
mg NN N
every DT N
6 CD N
hours NNS N
for IN N
14 CD N
days NNS N
, , N
or CC N
nadolol RB N
, , N
80 CD N
mg NNS N
each DT N
morning NN N
for IN N
14 CD N
days NNS N
. . N

The DT N
study NN N
was VBD N
repeated VBN N
when WRB N
the DT N
patients NNS N
were VBD N
in IN N
the DT N
euthyroid JJ N
state NN N
. . N

There EX N
was VBD N
a DT N
similar JJ N
and CC N
highly RB N
significant JJ N
degree NN N
of IN N
beta NN N
blockade NN N
and CC N
amelioration NN N
of IN N
symptoms NNS N
of IN N
thyrotoxicosis NN N
at IN N
the DT N
end NN N
of IN N
the DT N
dosage NN N
interval NN N
( ( N
trough IN N
) ) N
, , N
i.e. FW N
, , N
24 CD N
hours NNS N
after IN N
nadolol NN N
or CC N
6 CD N
to TO N
8 CD N
hours NNS N
after IN N
propranolol NN N
. . N

Trough NNP N
and CC N
peak VB N
serum NN N
levels NNS N
of IN N
propranolol NN N
were VBD N
significantly RB N
lower JJR N
when WRB N
the DT N
patients NNS N
were VBD N
in IN N
a DT N
thyrotoxic NN N
state NN N
than IN N
when WRB N
they PRP N
were VBD N
in IN N
a DT N
euthyroid JJ N
state NN N
, , N
whereas IN N
the DT N
pharmacokinetics NNS N
of IN N
nadolol NNS N
were VBD N
not RB N
appreciably RB N
altered VBN N
by IN N
thyrotoxicosis NN N
. . N

In IN N
thyrotoxicosis NN N
, , N
trough IN N
levels NNS N
of IN N
propranolol NN N
and CC N
nadolol NN N
were VBD N
significantly RB N
inversely RB N
correlated VBN N
with IN N
derived JJ N
creatinine JJ N
clearance NN N
values NNS N
. . N

In IN N
the DT N
symptomatic JJ 4_p
treatment NN 4_p
of IN 4_p
thyrotoxicosis NN 4_p
, , N
nadolol RB N
, , N
a DT N
once-daily JJ N
nonmetabolized JJ N
beta NN N
blocker NN N
, , N
has VBZ N
certain JJ N
advantages NNS N
compared VBN N
with IN N
propranolol NN N
. . N

It PRP N
is VBZ N
preferred VBN N
by IN N
patients NNS N
, , N
is VBZ N
more RBR N
convenient JJ N
, , N
and CC N
probably RB N
aids NNS N
compliance NN N
. . N

-DOCSTART- -X- O O 15960694

Just-in-time JJ N
evidence-based JJ N
e-mail JJ N
" NN N
reminders NNS N
" VBP N
in IN N
home NN N
health NN N
care NN N
: : N
impact NN 4_p
on IN 4_p
nurse JJ 4_p
practices NNS 4_p
. . 4_p

OBJECTIVE NNP N
To TO N
test VB N
the DT N
effectiveness NN N
of IN N
two CD N
interventions NNS N
designed VBN N
to TO N
improve VB N
the DT N
adoption NN N
of IN N
evidence-based JJ N
practices NNS N
by IN N
home NN N
health NN N
nurses NNS N
caring VBG N
for IN N
heart NN N
failure NN N
( ( N
HF NNP N
) ) N
patients NNS N
. . N

DATA NNP N
SOURCES/STUDY NNP N
SETTING NNP N
Information NNP N
on IN N
nurse NN N
practices NNS N
was VBD N
abstracted VBN N
from IN N
the DT N
clinical JJ N
records NNS N
of IN N
patients NNS N
admitted VBN N
between IN N
June NNP N
2000 CD N
and CC N
November NNP N
2001 CD N
to TO N
the DT N
care NN N
of IN N
354 CD N
study NN N
nurses NNS N
at IN N
a DT N
large JJ N
, , N
urban JJ N
, , N
nonprofit JJ N
home NN N
care NN N
agency NN N
. . N

STUDY NNP N
DESIGN NNP N
The DT N
study NN N
employed VBD N
a DT N
randomized JJ N
design NN N
with IN N
nurses NNS N
assigned VBN N
to TO N
usual JJ N
care NN N
or CC N
one CD N
of IN N
two CD N
intervention NN N
groups NNS N
upon IN N
identification NN N
of IN N
an DT N
eligible JJ N
patient NN N
. . N

The DT N
basic JJ N
intervention NN N
was VBD N
a DT N
one-time JJ N
e-mail JJ N
reminder NN N
highlighting VBG N
six CD N
HF-specific JJ N
clinical JJ N
recommendations NNS N
. . N

The DT N
augmented JJ N
intervention NN N
consisted VBN N
of IN N
the DT N
initial JJ N
e-mail JJ N
reminder NN N
supplemented VBN N
by IN N
provider NN N
prompts NNS N
, , N
patient JJ N
education NN N
material NN N
, , N
and CC N
clinical JJ N
nurse NN N
specialist NN N
outreach NN N
. . N

DATA NNP N
COLLECTION NNP N
At IN N
each DT N
home NN N
health NN N
visit NN N
provided VBN N
by IN N
a DT N
study NN N
nurse NN N
to TO N
an DT N
eligible JJ N
HF NNP N
patient NN N
during IN N
the DT N
45-day JJ N
follow-up JJ N
period NN N
, , N
a DT N
structured JJ N
chart NN N
abstraction NN N
tool NN N
was VBD N
used VBN N
to TO N
collect VB N
information NN N
on IN N
whether IN N
the DT N
nurse NN N
provided VBD N
the DT N
care NN N
practices NNS N
highlighted VBN N
in IN N
the DT N
e-mail JJ N
reminder NN N
. . N

PRINCIPAL NNP N
FINDINGS NNP N
Both NNP N
the DT N
basic JJ N
and CC N
the DT N
augmented JJ N
interventions NNS N
greatly RB N
increased VBD N
the DT N
practice NN N
of IN N
evidence-based JJ N
care NN N
, , N
according VBG N
to TO N
patient NN N
records NNS N
, , N
in IN N
the DT N
areas NNS N
of IN N
patient JJ N
assessment NN N
and CC N
instructions NNS N
about IN N
HF NNP N
disease NN N
management NN N
. . N

While IN N
not RB N
all DT N
results NNS N
were VBD N
statistically RB N
significant JJ N
at IN N
conventional JJ N
levels NNS N
, , N
intervention NN N
effects NNS N
were VBD N
positive JJ N
in IN N
virtually RB N
all DT N
cases NNS N
and CC N
effect NN N
magnitudes NNS N
frequently RB N
were VBD N
large JJ N
. . N

CONCLUSIONS VB N
The DT N
results NNS N
of IN N
this DT N
randomized JJ N
trial NN N
strongly RB N
support VB N
the DT N
efficacy NN N
of IN N
just-in-time JJ N
evidence-based JJ N
reminders NNS N
as IN N
a DT N
means NN N
of IN N
changing VBG N
clinical JJ N
practice NN N
among IN N
home NN 4_p
health NN 4_p
nurses NNS 4_p
who WP N
are VBP N
geographically RB N
dispersed VBN N
and CC N
spend VBP N
much RB N
of IN N
their PRP$ N
time NN N
in IN N
the DT N
field NN N
. . N

-DOCSTART- -X- O O 21864416

Effects NNS N
of IN N
a DT N
Chinese JJ N
medical JJ N
herbs NN N
complex NN N
on IN N
cellular JJ N
immunity NN N
and CC N
toxicity-related JJ N
conditions NNS N
of IN N
breast NN 4_p
cancer NN 4_p
patients NNS 4_p
. . 4_p

Rose NNP N
geranium NN N
( ( N
Pelargonium NNP N
graveolens VBZ N
, , N
Geraniaceae NNP N
) ) N
has VBZ N
anti-cancer JJ N
and CC N
anti-inflammatory JJ N
properties NNS N
, , N
and CC N
promotes VBZ N
wound IN N
healing VBG N
. . N

Similarly RB N
, , N
Ganoderma NNP N
tsugae NN N
( ( N
Ganodermataceae NNP N
) ) N
, , N
Codonopsis NNP N
pilosula NN N
( ( N
Campanulaceae NNP N
) ) N
and CC N
Angelica NNP N
sinensis NN N
( ( N
Apiaceae NNP N
) ) N
are VBP N
traditional JJ N
Chinese JJ N
herbs NNS N
associated VBN N
with IN N
immunomodulatory JJ N
functions NNS N
. . N

In IN N
the DT N
present JJ N
study NN N
, , N
a DT N
randomised JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
was VBD N
conducted VBN N
to TO N
examine VB N
whether IN N
the DT N
Chinese NNP N
medicinal JJ N
herb NN N
complex NN N
, , N
RG-CMH NNP N
, , N
which WDT N
represents VBZ N
a DT N
mixture NN N
of IN N
rose VBD N
geranium NN N
and CC N
extracts NNS N
of IN N
G. NNP N
tsugae NN N
, , N
C. NNP N
pilosula NN N
and CC N
A. NNP N
sinensis NN N
, , N
can MD N
improve VB N
the DT N
immune NN N
cell NN N
count NN N
of IN N
cancer NN N
patients NNS N
receiving VBG N
chemotherapy NN N
and/or NN N
radiotherapy NN N
to TO N
prevent VB N
leucopenia NN N
and CC N
immune JJ N
impairment NN N
that WDT N
usually RB N
occurs VBZ N
during IN N
cancer NN N
therapy NN N
. . N

A DT N
total NN N
of IN N
fifty-eight JJ 4_p
breast NN 4_p
cancer NN 4_p
patients NNS 4_p
who WP 4_p
received VBD 4_p
chemotherapy NN 4_p
or CC 4_p
radiotherapy NN 4_p
were VBD 4_p
enrolled VBN 4_p
. . 4_p

Immune NNP N
cell NN N
levels NNS N
in IN N
patient NN N
serum NN N
were VBD N
determined VBN N
before IN N
, , N
and CC N
following VBG N
, , N
6 CD N
weeks NNS N
of IN N
cancer NN N
treatment NN N
for IN N
patients NNS N
receiving VBG N
either DT N
an DT N
RG-CMH JJ N
or CC N
a DT N
placebo NN N
. . N

Administration NN N
of IN N
RG-CMH NNP N
was VBD N
associated VBN N
with IN N
a DT N
significant JJ N
reduction NN N
in IN N
levels NNS N
of IN N
leucocytes NNS N
from IN N
31·5 CD N
% NN N
for IN N
the DT N
placebo NN N
group NN N
to TO N
13·4 CD N
% NN N
for IN N
the DT N
RG-CMH NNP N
group NN N
. . N

Similarly RB N
, , N
levels NNS N
of IN N
neutrophils NNS N
significantly RB N
decreased VBN N
from IN N
35·6 CD N
% NN N
for IN N
the DT N
placebo NN N
group NN N
to TO N
11·0 CD N
% NN N
for IN N
the DT N
RG-CMH NNP N
group NN N
. . N

RG-CMH JJ N
intervention NN N
was VBD N
also RB N
associated VBN N
with IN N
a DT N
decrease NN N
in IN N
levels NNS N
of IN N
T NNP N
cells NNS N
, , N
helper JJR N
T NNP N
cells NNS N
, , N
cytotoxic NN N
T NNP N
cells NNS N
and CC N
natural JJ N
killer NN N
cells NNS N
compared VBN N
with IN N
the DT N
placebo NN N
group NN N
. . N

However RB N
, , N
these DT N
differences NNS N
between IN N
the DT N
two CD N
groups NNS N
were VBD N
not RB N
statistically RB N
significant JJ N
. . N

In IN N
conclusion NN N
, , N
administration NN N
of IN N
RG-CMH NNP N
to TO N
patients NNS N
receiving VBG N
chemotherapy/radiotherapy NN N
may MD N
have VB N
the DT N
capacity NN N
to TO N
delay VB N
, , N
or CC N
ease NN N
, , N
the DT N
reduction NN N
in IN N
levels NNS N
of IN N
leucocytes NNS N
and CC N
neutrophils NNS N
that WDT N
are VBP N
experienced VBN N
by IN N
patients NNS N
during IN N
cancer NN N
treatment NN N
. . N

-DOCSTART- -X- O O 8570776

Placebo-controlled JJ N
acute JJ N
dosage NN N
naltrexone NN N
study NN N
in IN N
young JJ 4_p
autistic JJ 4_p
children NNS 4_p
. . 4_p

In IN N
a DT N
double-blind JJ N
, , N
placebo-controlled JJ N
crossover NN N
trial NN N
23 CD N
autistic JJ N
children NNS N
were VBD N
treated VBN N
with IN N
a DT N
single JJ N
40-mg JJ N
dose NN N
of IN N
the DT N
opiate JJ N
antagonist NN N
naltrexone NN N
. . N

Drug JJ N
effects NNS N
were VBD N
monitored VBN N
by IN N
detailed JJ N
playroom NN N
observations NNS N
, , N
actometers NNS N
, , N
and CC N
parents NNS N
' POS N
checklist NN N
ratings NNS N
( ( N
Aberrant NNP N
Behavior NNP N
Checklist NNP N
, , N
social JJ N
items NNS N
and CC N
target NN N
behaviors NNS N
) ) N
. . N

Naltrexone CD N
treatment NN N
failed VBD N
to TO N
produce VB N
significant JJ N
changes NNS N
in IN N
social JJ N
behavior NN N
, , N
but CC N
it PRP N
did VBD N
reduce VB N
irritability NN N
and CC N
target NN N
scores NNS N
on IN N
behavior JJ N
checklists NNS N
. . N

The DT N
playroom NN N
data NNS N
indicated VBD N
that IN N
naltrexone NN N
significantly RB N
affected VBD N
indices NNS N
of IN N
activity NN N
and CC N
attention NN N
. . N

-DOCSTART- -X- O O 19590075

Preparation NN N
and CC N
immune JJ N
activity NN N
analysis NN N
of IN N
H5N1 NNP 4_p
subtype NN 4_p
avian JJ 4_p
influenza NN 4_p
virus NN 4_p
recombinant JJ 4_p
protein-based JJ 4_p
vaccine NN 4_p
. . N

Avian JJ N
influenza NN N
is VBZ N
a DT N
severe JJ N
disease NN N
among IN N
farmed JJ N
poultry NN N
and CC N
free-living JJ N
birds NNS N
and CC N
a DT N
constant JJ N
threat NN N
to TO N
the DT N
commercial JJ N
chicken NN N
industry NN N
around IN N
the DT N
world NN N
. . N

Hemagglutinin NNP N
( ( N
HA NNP N
) ) N
is VBZ N
the DT N
major JJ N
immunogen NN N
on IN N
the DT N
envelope NN N
of IN N
influenza NN N
A NNP N
virus NN N
and CC N
is VBZ N
the DT N
predominant JJ N
inducer NN N
of IN N
neutralizing VBG N
antibody NN N
. . N

To TO N
obtain VB N
the DT N
bioactive JJ N
antigen NN N
proteins NNS N
in IN N
large JJ N
quantities NNS N
, , N
a DT N
new JJ N
protein NN N
expression NN N
vector NN N
pBCX NN N
was VBD N
constructed VBN N
, , N
which WDT N
is VBZ N
based VBN N
on IN N
the DT N
pET32a NN N
vector NN N
. . N

The DT N
HA NNP N
gene NN N
of IN N
the DT N
H5N1 NNP N
subtype NN N
of IN N
avian JJ N
influenza NN N
virus NN N
( ( N
AIV NNP N
) ) N
was VBD N
inserted VBN N
into IN N
the DT N
pBCX NN 4_p
vector NN 4_p
and CC N
expressed VBD N
efficiently RB N
in IN N
Escherichia NNP N
coli NN N
BL21 NNP N
( ( N
DE3 NNP N
) ) N
. . N

Fused VBN N
expression NN N
of IN N
the DT N
exogenous JJ N
gene NN N
and CC N
msyB NN N
produced VBD N
a DT N
97-kDa JJ N
msyB-HA JJ N
fusion NN N
protein NN N
. . N

Sodium NNP N
dodecyl VBZ N
sulfate-PAGE NN N
combined VBN N
with IN N
scanning VBG N
analysis NN N
demonstrated VBD N
that IN N
the DT N
msyB-HA JJ N
fusion NN N
protein NN N
accounted VBD N
for IN N
29.5 CD N
% NN N
of IN N
the DT N
total JJ N
bacterial JJ N
protein NN N
, , N
90.5 CD N
% NN N
being VBG N
soluble JJ N
. . N

The DT N
msyB-HA JJ N
fusion NN N
protein NN N
was VBD N
purified VBN N
with IN N
nondenaturing VBG N
50 CD N
% NN N
Ni-NTA JJ N
column NN N
chromatography NN N
, , N
and CC N
the DT N
result NN N
showed VBD N
that IN N
24 CD N
mg NN N
of IN N
purified JJ N
msyB-HA JJ N
fusion NN N
protein NN N
could MD N
be VB N
obtained VBN N
from IN N
1 CD N
L NNP N
of IN N
induced JJ N
expression NN N
bacterial JJ N
culture NN N
medium NN N
. . N

The DT N
comparative JJ N
results NNS N
in IN N
the DT N
present JJ N
study NN N
showed VBD N
that IN N
pBCX NN N
was VBD N
superior JJ N
to TO N
pET32a VB N
as IN N
a DT N
protein NN N
expression NN N
vector NN N
. . N

Western JJ N
blotting NN N
showed VBD N
the DT N
recombinant JJ N
msyB-HA NN N
( ( N
rHA NN N
) ) N
to TO N
have VB N
better JJR N
antigenic JJ N
activity NN N
, , N
which WDT N
may MD N
be VB N
the DT N
result NN N
from IN N
the DT N
better JJR N
posttranslation NN N
protein NN N
modification NN N
and CC N
folding NN N
in IN N
the DT N
pBCX NN N
expression NN N
system NN N
. . N

With IN N
the DT N
rHA NN N
fusion NN N
protein NN N
as IN N
antigen NN N
, , N
we PRP N
successfully RB N
prepared VBD N
and CC N
screened VBD N
specific JJ N
monoclonal JJ N
antibodys NN N
against IN N
the DT N
H5N1 NNP N
subtype NN N
AIV NNP N
, , N
which WDT N
indicated VBD N
that IN N
the DT N
rHA NN N
had VBD N
antigen VBN N
epitopes NNS N
and CC N
biofunctions NNS N
. . N

The DT N
immune JJ N
test NN N
confirmed VBD N
that IN N
the DT N
rHA NN N
protein NN N
vaccine NN N
could MD N
also RB N
induce VB N
high JJ N
neutralizing NN N
antibodies NNS N
, , N
and CC N
the DT N
AIV NNP N
challenge NN N
test NN N
proved VBD N
that IN N
the DT N
rHA JJ N
protein-based JJ N
vaccine NN N
could MD N
prevent VB N
the DT N
corresponding JJ N
infection NN N
. . N

This DT N
study NN N
demonstrates VBZ N
that IN N
the DT N
recombinant JJ N
HA NNP N
protein NN N
produced VBN N
by IN N
the DT N
pBCX NN N
expression NN N
system NN N
could MD N
be VB N
used VBN N
as IN N
a DT N
recombinant JJ N
protein-based JJ N
vaccine NN N
and CC N
has VBZ N
potential NN N
for IN N
further JJ N
development NN N
for IN N
diagnosis NN N
. . N

-DOCSTART- -X- O O 2544249

Treatment NN N
of IN N
Wilms NNP 4_p
' POS 4_p
tumor NN 4_p
. . 4_p

Results NNS N
of IN N
the DT N
Third NNP N
National NNP N
Wilms NNP 4_p
' POS 4_p
Tumor NNP 4_p
Study NNP N
. . N

The DT N
Third NNP N
National NNP N
Wilms NNP N
' POS N
Tumor NNP N
Study NNP N
sought VBD N
to TO N
reduce VB N
treatment NN N
for IN N
low-risk JJ N
patients NNS N
and CC N
find VB N
better JJR N
chemotherapy NN N
for IN N
those DT N
at IN N
high JJ N
risk NN N
for IN N
relapse NN N
. . N

Eligible JJ N
patients NNS N
( ( N
1439 CD N
) ) N
were VBD N
randomized VBN N
according VBG N
to TO N
stage NN N
( ( N
I-IV NNP N
) ) N
and CC N
histology NN N
( ( N
favorable JJ N
[ NN N
FH NNP N
] NNP N
or CC N
unfavorable JJ N
[ JJ N
UH NNP N
] NNP N
) ) N
, , N
and CC N
contributed VBD N
data NNS N
to TO N
survival VB N
and CC N
relapse-free JJ N
survival NN N
( ( N
RFS NNP N
) ) N
analyses VBZ N
. . N

Four-year JJ N
( ( N
postnephrectomy NN N
) ) N
survival NN N
percentages NNS N
and CC N
randomized VBN N
treatment NN N
regimens NNS N
for IN N
low-risk JJ N
patients NNS N
were VBD N
96.5 CD N
% NN N
for IN N
607 CD N
Stage NNP N
I/FH NNP N
patients NNS N
who WP N
received VBD N
dactinomycin NN N
( ( N
Actinomycin NNP N
D NNP N
[ NNP N
AMD NNP N
] NNP N
, , N
Merck NNP N
Sharp NNP N
& CC N
Dohme NNP N
, , N
West NNP N
Point NNP N
, , N
PA NNP N
) ) N
and CC N
vincristine NN N
( ( N
VCR NNP N
) ) N
for IN N
10 CD N
weeks NNS N
versus RB N
6 CD N
months NNS N
; : N
92.2 CD N
% NN N
for IN N
278 CD N
Stage NNP N
II/FH NNP N
patients NNS N
; : N
and CC N
86.9 CD N
% NN N
for IN N
275 CD N
Stage NNP N
III/FH NNP N
patients NNS N
who WP N
received VBD N
AMD NNP N
+ NNP N
VCR NNP N
+/- JJ N
Adriamycin NNP N
( ( N
ADR NNP N
, , N
Adria NNP N
Laboratories NNPS N
, , N
Columbus NNP N
, , N
OH NNP N
) ) N
for IN N
15 CD N
months NNS N
. . N

Stage NNP N
II/FH NNP N
patients NNS N
also RB N
had VBD N
either CC N
zero CD N
or CC N
2000 CD N
cGy NN N
irradiation NN N
( ( N
RT NNP N
) ) N
postoperatively RB N
and CC N
Stage NNP N
III/FH NNP N
patients NNS N
either RB N
1000 CD N
or CC N
2000 CD N
cGy NN N
. . N

Four-year JJ N
survival NN N
was VBD N
73.0 CD N
% NN N
for IN N
279 CD N
high-risk JJ N
patients NNS N
( ( N
any DT N
Stage NNP N
IV NNP N
, , N
all DT N
UH NNP N
) ) N
who WP N
received VBD N
postoperative JJ N
radiation NN N
therapy NN N
( ( N
RT NNP N
) ) N
and CC N
AMD NNP N
+ NNP N
VCR NNP N
+ NNP N
ADR NNP N
+/- JJ N
cyclophosphamide NN N
( ( N
CPM NNP N
) ) N
. . N

Statistical JJ N
analysis NN N
of IN N
survival NN N
and CC N
RFS NNP N
experience NN N
shows VBZ N
that IN N
the DT N
less RBR N
intensive JJ N
therapy NN N
does VBZ N
not RB N
worsen VB N
results NNS N
for IN N
low-risk JJ N
patients NNS N
and CC N
CPM NNP N
does VBZ N
not RB N
benefit VB N
those DT N
at IN N
high JJ N
risk NN N
. . N

-DOCSTART- -X- O O 7010662

[ JJ N
Biological NNP N
and CC N
clinical JJ N
effects NNS N
of IN N
oral JJ N
magnesium NN N
and CC N
associated VBN N
magnesium-vitamin JJ N
B6 NNP N
administration NN N
on IN N
certain JJ 4_p
disorders NNS 4_p
observed VBN 4_p
in IN 4_p
infantile JJ 4_p
autism NN 4_p
( ( N
author NN N
's POS N
transl NN N
) ) N
] NN N
. . N

-DOCSTART- -X- O O 12375315

Combination NNP N
therapy NN N
with IN N
methotrexate NN N
and CC N
hydroxychloroquine NN N
for IN N
rheumatoid JJ 4_p
arthritis NN 4_p
increases NNS N
exposure VBP N
to TO N
methotrexate VB N
. . N

OBJECTIVE NNP N
To TO N
examine VB N
the DT N
bioavailability NN N
of IN N
methotrexate NN N
( ( N
MTX NNP N
) ) N
in IN N
the DT N
presence NN N
of IN N
hydroxychloroquine NN N
( ( N
HCQ NNP N
) ) N
, , N
and CC N
vice NN N
versa NN N
, , N
to TO N
determine VB N
a DT N
possible JJ N
pharmacokinetic JJ N
explanation NN N
for IN N
the DT N
observation NN N
that IN N
combination NN N
treatment NN N
of IN N
rheumatoid JJ N
arthritis NN N
with IN N
MTX NNP N
and CC N
HCQ NNP N
has VBZ N
been VBN N
shown VBN N
, , N
clinically RB N
, , N
to TO N
be VB N
more RBR N
potent JJ N
than IN N
MTX NNP N
used VBD N
alone RB N
. . N

METHODS NNP N
In IN N
a DT N
randomized VBN N
crossover NN N
study NN N
, , N
10 CD N
healthy JJ 4_p
subjects NNS N
received VBN N
, , N
on IN N
each DT N
of IN N
5 CD N
dosing VBG N
occasions NNS N
, , N
MTX NNP N
alone RB N
as IN N
tablets NNS N
or CC N
intravenous JJ N
solution NN N
, , N
HCQ NNP N
alone RB N
as IN N
a DT N
tablet NN N
or CC N
oral JJ N
solution NN N
, , N
or CC N
a DT N
coadministered JJ N
dose NN N
of IN N
MTX NNP N
tablets NNS N
with IN N
an DT N
HCQ NNP N
tablet NN N
. . N

The DT N
area NN N
under IN N
the DT N
concentration-time JJ N
curve NN N
( ( N
AUC NNP N
) ) N
was VBD N
determined VBN N
for IN N
each DT N
subject NN N
, , N
on IN N
each DT N
dosing VBG N
occasion NN N
, , N
for IN N
each DT N
compound NN N
. . N

RESULTS VB N
The DT N
mean JJ N
AUC NNP N
for IN N
MTX NNP N
was VBD N
increased VBN N
( ( N
p JJ N
= NNP N
0.005 CD N
) ) N
and CC N
the DT N
maximum JJ N
MTX NNP N
concentration NN N
( ( N
Cmax NNP N
) ) N
decreased VBD N
( ( N
p JJ N
= NNP N
0.025 CD N
) ) N
when WRB N
MTX NNP N
was VBD N
coadministered VBN N
with IN N
HCQ NNP N
, , N
compared VBN N
to TO N
MTX NNP N
administered VBD N
alone RB N
. . N

The DT N
time NN N
to TO N
reach VB N
Cmax NNP N
for IN N
MTX NNP N
administration NN N
, , N
tmax NN N
, , N
was VBD N
also RB N
increased VBN N
during IN N
the DT N
coadministration NN N
with IN N
HCQ NNP N
( ( N
p JJ N
= NNP N
0.072 CD N
) ) N
. . N

The DT N
AUC NNP N
of IN N
HCQ NNP N
showed VBD N
no DT N
significant JJ N
difference NN N
( ( N
p JJ N
= NNP N
0.957 CD N
) ) N
between IN N
any DT N
of IN N
the DT N
dosing NN N
occasions NNS N
. . N

CONCLUSION NNP N
These DT N
results NNS N
may MD N
explain VB N
the DT N
increased JJ N
potency NN N
of IN N
the DT N
MTX-HCQ NNP N
combination NN N
over RB N
MTX NNP N
as IN N
a DT N
single JJ N
agent NN N
and CC N
also RB N
the DT N
sustained JJ N
effects NNS N
of IN N
MTX NNP N
when WRB N
administered VBN N
with IN N
HCQ NNP N
. . N

In IN N
addition NN N
, , N
the DT N
reduced JJ N
Cmax NNP N
of IN N
MTX NNP N
observed VBD N
during IN N
the DT N
coadministration NN N
may MD N
explain VB N
diminution NN N
of IN N
acute JJ N
liver JJ N
adverse JJ N
effects NNS N
. . N

Extra NNP N
vigilance NN N
for IN N
MTX NNP N
adverse JJ N
effects NNS N
during IN N
combination NN N
therapy NN N
with IN N
HCQ NNP N
is VBZ N
recommended VBN N
, , N
especially RB N
if IN N
renal JJ N
function NN N
is VBZ N
known VBN N
to TO N
be VB N
decreased VBN N
. . N

-DOCSTART- -X- O O 10037531

Xylitol NN N
for IN N
prevention NN N
of IN N
acute NN 4_p
otitis NN 4_p
media NNS 4_p
. . 4_p

-DOCSTART- -X- O O 8331682

Low-dose JJ N
aspirin NN N
and CC N
incidence NN N
of IN N
colorectal JJ N
tumors NNS N
in IN N
a DT N
randomized JJ N
trial NN N
. . N

BACKGROUND NNP N
Laboratory NNP N
, , N
clinical JJ N
, , N
and CC N
epidemiologic JJ N
studies NNS N
have VBP N
recently RB N
suggested VBN N
that IN N
regular JJ N
use NN N
of IN N
aspirin NN N
can MD N
reduce VB N
colorectal JJ N
cancer NN N
incidence NN N
or CC N
mortality NN N
. . N

However RB N
, , N
observational JJ N
epidemiologic NN N
analyses NNS N
have VBP N
had VBN N
limited VBN N
opportunity NN N
to TO N
control VB N
for IN N
confounding VBG N
bias NN N
or CC N
to TO N
specify VB N
aspirin JJ N
doses NNS N
used VBN N
. . N

PURPOSE VB N
Our PRP$ N
purpose NN N
was VBD N
to TO N
examine VB N
the DT N
relationship NN N
between IN N
regular JJ N
use NN N
of IN N
low-dose JJ N
aspirin NN N
and CC N
incidence NN N
of IN N
invasive JJ N
and CC N
noninvasive JJ N
colorectal NN N
tumors NNS N
by IN N
utilizing VBG N
data NNS N
from IN N
the DT N
Physicians NNPS N
' POS N
Health NNP N
Study NNP N
, , N
a DT N
randomized VBN N
, , N
double-blinded JJ N
, , N
placebo-controlled JJ N
trial NN N
of IN N
aspirin NN N
and CC N
beta NN N
carotene NN N
. . N

We PRP N
also RB N
attempted VBD N
to TO N
determine VB N
whether IN N
invasive JJ N
cancers NNS N
among IN N
aspirin JJ N
users NNS N
were VBD N
associated VBN N
with IN N
rectal JJ N
bleeding NN N
and CC N
early JJ N
stage NN N
at IN N
diagnosis NN N
. . N

METHODS NNP N
The DT N
Physicians NNPS N
' POS N
Health NNP N
Study NNP N
includes VBZ N
22071 CD N
U.S. NNP N
male JJ N
physicians NNS N
. . N

The DT N
aspirin JJ N
arm NN N
was VBD N
terminated VBN N
in IN N
1988 CD N
after IN N
a DT N
mean JJ N
follow-up NN N
of IN N
5 CD N
years NNS N
. . N

Stage NN N
at IN N
diagnosis NN N
and CC N
signs NNS N
and/or VBP N
symptoms NNS N
during IN N
presentation NN N
were VBD N
abstracted VBN N
from IN N
medical JJ N
records NNS N
. . N

Cox NNP N
proportional JJ N
hazards NNS N
models NNS N
were VBD N
used VBN N
to TO N
estimate VB N
relative JJ N
risk NN N
( ( N
RR NNP N
) ) N
, , N
95 CD N
% NN N
confidence NN N
intervals NNS N
( ( N
CIs NNP N
) ) N
, , N
and CC N
the DT N
association NN N
between IN N
aspirin NN N
and CC N
bleeding NN N
. . N

Differences NNS N
between IN N
aspirin NN N
and CC N
placebo NN N
groups NNS N
in IN N
tumor NN N
risk NN N
over IN N
time NN N
were VBD N
visualized VBN N
with IN N
Kaplan-Meier NNP N
curves NNS N
. . N

We PRP N
assessed VBD N
the DT N
association NN N
between IN N
aspirin NN N
and CC N
stage NN N
at IN N
diagnosis NN N
with IN N
a DT N
Mann-Whitney NNP N
rank NN N
sum NN N
statistic NN N
for IN N
non-parametric JJ N
comparison NN N
of IN N
two CD N
ordinal JJ N
distributions NNS N
. . N

RESULTS VB N
The DT N
RR NNP N
of IN N
developing VBG N
colorectal JJ N
cancer NN N
for IN N
aspirin NNS N
compared VBN N
with IN N
placebo NN N
was VBD N
1.15 CD N
( ( N
95 CD N
% NN N
CI NNP N
= NNP N
0.80-1.65 NN N
) ) N
. . N

For IN N
in IN N
situ NN N
cancers NNS N
and CC N
polyps NNS N
, , N
the DT N
RR NNP N
was VBD N
0.86 CD N
( ( N
95 CD N
% NN N
CI NNP N
= NNP N
0.68-1.10 NN N
) ) N
. . N

There EX N
was VBD N
no DT N
significant JJ N
trend NN N
for IN N
decreasing VBG N
RR NNP N
by IN N
year NN N
of IN N
follow-up NN N
for IN N
invasive JJ N
cancers NNS N
( ( N
P NNP N
= NNP N
.09 NNP N
) ) N
or CC N
noninvasive JJ N
tumors NNS N
( ( N
P NNP N
= NNP N
.96 NNP N
) ) N
. . N

Aspirin NNP N
and CC N
placebo NN N
groups NNS N
did VBD N
not RB N
differ VB N
in IN N
stage NN N
or CC N
prevalence NN N
of IN N
rectal JJ N
bleeding NN N
at IN N
diagnosis NN N
. . N

CONCLUSIONS NNP N
Regular NNP N
aspirin NN N
use NN N
, , N
at IN N
a DT N
dose JJ N
adequate NN N
for IN N
preventing VBG N
myocardial JJ N
infarction NN N
, , N
was VBD N
not RB N
associated VBN N
with IN N
a DT N
substantial JJ N
reduction NN N
in IN N
the DT N
incidence NN N
of IN N
colorectal JJ N
cancer NN N
during IN N
5 CD N
years NNS N
of IN N
randomized JJ N
treatment NN N
and CC N
follow-up NN N
. . N

A DT N
small JJ N
decrease NN N
in IN N
polyps NNS N
in IN N
the DT N
aspirin NN N
group NN N
could MD N
not RB N
be VB N
reliably RB N
distinguished VBN N
from IN N
a DT N
chance NN N
association NN N
. . N

Our PRP$ N
results NNS N
suggest VBP N
that IN N
among IN N
low-dose JJ N
aspirin NN N
users NNS N
, , N
( ( N
a DT N
) ) N
colorectal NN N
cancer NN N
mortality NN N
is VBZ N
not RB N
likely JJ N
to TO N
be VB N
reduced VBN N
by IN N
earlier JJR N
detection NN N
and CC N
( ( N
b NN N
) ) N
incidence NN N
is VBZ N
not RB N
likely JJ N
to TO N
be VB N
increased VBN N
due JJ N
to TO N
aspirin-induced JJ N
gastrointestinal JJ N
bleeding NN N
. . N

IMPLICATIONS VBZ N
The DT N
potential NN N
for IN N
a DT N
benefit NN N
from IN N
higher JJR N
doses NNS N
of IN N
aspirin NN N
or CC N
longer JJR N
duration NN N
of IN N
use NN N
should MD N
be VB N
addressed VBN N
by IN N
more JJR N
detailed JJ N
observational JJ N
epidemiologic NN N
studies NNS N
and CC N
prevention NN N
trials NNS N
with IN N
longer JJR N
follow-up NN N
of IN N
randomized JJ N
participants NNS N
. . N

-DOCSTART- -X- O O 23323659

Divergence NN N
in IN N
student NN 4_p
and CC 4_p
educator NN 4_p
conceptual JJ 4_p
structures NNS 4_p
during IN N
auscultation NN 4_p
training NN 4_p
. . N

CONTEXT NNP N
Simulation-based JJ N
medical JJ N
education NN N
allows VBZ N
trainees NNS N
to TO N
engage VB N
in IN N
self-regulated JJ N
learning NN N
( ( N
SRL NNP N
) ) N
, , N
yet RB N
research NN N
aimed VBN N
at IN N
elucidating VBG N
the DT N
mechanisms NN N
of IN N
SRL NNP N
in IN N
this DT N
context NN N
is VBZ N
relatively RB N
absent JJ N
. . N

We PRP N
compared VBN N
'unguided VBD N
' POS N
SRL NNP N
with IN N
'directed NNP N
' POS N
SRL NNP N
( ( N
DSRL NNP N
) ) N
, , N
wherein JJ N
learners NNS N
followed VBD N
an DT N
expert-designed JJ N
booklet NN N
. . N

METHODS NNP N
Year $ N
1 CD N
medical JJ N
students NNS N
( ( N
n JJ N
= NNP N
37 CD N
) ) N
were VBD N
randomly RB N
assigned VBN N
to TO N
practise VB N
identifying VBG N
seven CD N
cardiac JJ N
murmurs NNS N
using VBG N
a DT N
simulator NN N
and CC N
video NN N
only RB N
( ( N
SRL NNP N
group NN N
) ) N
or CC N
a DT N
simulator NN N
and CC N
video NN N
plus CC N
the DT N
booklet NN N
( ( N
DSRL NNP N
group NN N
) ) N
. . N

All DT N
participants NNS N
completed VBD N
a DT N
22-item JJ N
test NN N
3 CD N
weeks NNS N
later RB N
. . N

To TO N
compare VB N
interventions NNS N
, , N
we PRP N
analysed VBD N
students NNS N
' POS N
diagnostic JJ N
accuracy NN N
. . N

As IN N
a DT N
novel JJ N
source NN N
of IN N
evidence NN N
, , N
we PRP N
documented VBD N
how WRB N
participants NNS N
autonomously RB N
sequenced VBD N
the DT N
seven CD N
murmurs NNS N
during IN N
initial JJ N
and CC N
delayed JJ N
practice NN N
sessions NNS N
. . N

In IN N
addition NN N
, , N
we PRP N
surveyed VBD N
clinical JJ N
educators NNS N
( ( N
n JJ N
= NNP N
17 CD N
) ) N
to TO N
find VB N
out RP N
how WRB N
they PRP N
would MD N
sequence VB N
their PRP$ N
teaching NN N
of IN N
these DT N
murmurs NNS N
. . N

RESULTS VB N
The DT N
DSRL NNP N
group NN N
used VBD N
50 CD N
% NN N
more JJR N
training NN N
time NN N
than IN N
the DT N
SRL NNP N
group NN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

The DT N
groups NNS N
' POS N
diagnostic JJ N
accuracy NN N
, , N
however RB N
, , N
did VBD N
not RB N
differ VB N
significantly RB N
on IN N
the DT N
post-test NN N
, , N
retention NN N
test NN N
or CC N
transfer VB N
test NN N
items NNS N
( ( N
p VB N
> RB N
0.12 CD N
) ) N
. . N

Despite IN N
practising VBG N
with IN N
the DT N
expert-defined JJ N
'timing-based JJ N
' POS N
approach NN N
to TO N
murmur VB N
diagnosis NN N
( ( N
i.e JJ N
. . N

systolic JJ N
versus IN N
diastolic NN N
) ) N
, , N
84 CD N
% NN N
of IN N
DSRL NNP N
participants NNS N
implemented VBD N
a DT N
location-based JJ N
approach NN N
( ( N
i.e JJ N
. . N

practising VBG N
aortic JJ N
murmurs NNS N
separately RB N
from IN N
mitral JJ N
murmurs NNS N
) ) N
during IN N
a DT N
second JJ N
, , N
unguided JJ N
practice NN N
session NN N
. . N

Notably RB N
, , N
most JJS N
SRL JJ N
participants NNS N
used VBD N
that IN N
same JJ N
approach NN N
spontaneously RB N
. . N

By IN N
contrast NN N
, , N
clinical JJ N
educators NNS N
were VBD N
split VBN N
in IN N
their PRP$ N
use NN N
of IN N
the DT N
timing-based JJ N
( ( N
n JJ N
= NNP N
10 CD N
) ) N
and CC N
the DT N
location-based JJ N
( ( N
n JJ N
= NNP N
6 CD N
) ) N
approaches NNS N
. . N

Chi-squared JJ N
analyses NNS N
suggested VBD N
educators NNS N
' POS N
conceptions NNS N
for IN N
organising VBG N
murmurs NNS N
differed VBN N
significantly RB N
from IN N
students NNS N
' POS N
conceptions NNS N
. . N

CONCLUSIONS NNP N
Contrary NNP N
to TO N
our PRP$ N
predictions NNS N
, , N
directing VBG N
students NNS N
' POS N
SRL NNP N
produced VBD N
no DT N
additional JJ N
benefit NN N
and CC N
increased VBD N
their PRP$ N
practice NN N
time NN N
. . N

Our PRP$ N
findings NNS N
suggest VBP N
one CD N
potential JJ N
source NN N
of IN N
these DT N
results NNS N
was VBD N
a DT N
divergence NN N
between IN N
student NN N
and CC N
educator NN N
conceptions NNS N
for IN N
structuring VBG N
the DT N
practice NN N
of IN N
cardiac JJ N
auscultation NN N
skills NNS N
. . N

This DT N
phenomenon NN N
has VBZ N
not RB N
been VBN N
well RB N
articulated VBN N
in IN N
the DT N
medical JJ N
education NN N
literature NN N
, , N
and CC N
may MD N
have VB N
important JJ N
implications NNS N
in IN N
many JJ N
( ( N
especially RB N
technology-mediated VBN N
) ) N
educational JJ N
contexts NN N
. . N

-DOCSTART- -X- O O 12769155

Preservative-free JJ N
ocular JJ N
hydrating VBG N
agents NNS N
in IN N
symptomatic JJ 4_p
contact NN 4_p
lens VBZ 4_p
wearers NNS 4_p
: : N
saline NN N
versus IN N
PVP NNP N
solution NN N
. . N

PURPOSE NNP N
To TO N
compare VB N
two CD N
preservative-free JJ N
hydrating VBG N
agents NNS N
, , N
in IN N
multidose NN N
( ( N
ABAK NNP N
) ) N
bottles NNS N
, , N
in IN N
contact NN 4_p
lens NN 4_p
wearers NNS 4_p
experiencing VBG N
symptoms NNS N
of IN N
ocular JJ 4_p
dryness NN 4_p
. . N

METHODS NNP N
The DT N
endpoint NN N
of IN N
this DT N
4-week JJ N
multicenter NN N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
parallel-group JJ N
study NN N
comparing VBG N
a DT N
2 CD N
% NN N
polyvinylpyrrolidone NN N
( ( N
PVP NNP N
) ) N
solution NN N
with IN N
a DT N
0.9 CD N
% NN N
NaCl NNP N
solution NN N
was VBD N
to TO N
assess VB N
ocular JJ N
discomfort NN N
using VBG N
a DT N
visual JJ N
analog NN N
scale NN N
. . N

A DT N
biomicroscopic NN N
examination NN N
and CC N
a DT N
test NN N
of IN N
tolerability NN N
on IN N
instillation NN N
were VBD N
also RB N
performed VBN N
, , N
and CC N
adverse JJ N
events NNS N
were VBD N
recorded VBN N
. . N

RESULTS NNP N
Thirty-nine JJ N
subjects NNS N
were VBD N
enrolled VBN N
( ( N
23 CD N
PVP NNP N
; : N
16 CD N
NaCl NNP N
) ) N
. . N

The DT N
average JJ N
age NN N
was VBD N
30 CD N
; : N
subjects NNS N
were VBD N
predominantly RB N
female JJ N
, , N
and CC N
mostly RB N
wore VBD 4_p
frequent-replacement JJ 4_p
contact NN 4_p
lenses NNS 4_p
. . N

They PRP N
were VBD N
all DT N
exposed VBN N
to TO N
environmental JJ N
factors NNS N
such JJ N
as IN N
routine JJ N
use NN N
of IN N
video NN N
monitors NNS N
or CC N
air NN N
conditioning NN N
. . N

The DT N
two CD N
groups NNS N
were VBD N
similar JJ N
at IN N
baseline NN N
( ( N
D0 NNP N
) ) N
. . N

Both DT N
PVP NNP N
and CC N
NaCl NNP N
improved VBD N
the DT N
comfort NN N
of IN N
contact NN N
lens NNS N
wear VBP N
( ( N
P NNP N
= NNP N
0.0003 CD N
) ) N
, , N
with IN N
no DT N
difference NN N
between IN N
them PRP N
( ( N
P NNP N
= NNP N
0.25 CD N
) ) N
. . N

The DT N
mean JJ N
daily JJ N
duration NN N
of IN N
lens NNS N
wear JJ N
and CC N
the DT N
daily JJ N
number NN N
of IN N
instillations NNS N
to TO N
relieve VB N
discomfort NN N
( ( N
4.2 CD N
+/- JJ N
2.0 CD N
for IN N
PVP NNP N
ABAK NNP N
; : N
4.6 CD N
+/- JJ N
1.9 CD N
for IN N
NaCl NNP N
ABAK NNP N
) ) N
were VBD N
comparable JJ N
. . N

However RB N
, , N
PVP NNP N
use NN N
led VBD N
to TO N
more RBR N
favorable JJ N
evolution NN N
of IN N
fluorescein-staining JJ N
corneal NN N
punctuations NNS N
( ( N
P NNP N
= NNP N
0.028 CD N
) ) N
. . N

Safety NN N
was VBD N
good JJ N
, , N
with IN N
minimal JJ N
adverse JJ N
events NNS N
considered VBN N
unrelated JJ N
to TO N
the DT N
products NNS N
. . N

Lens NNP N
wettability NN N
was VBD N
excellent JJ N
, , N
and CC N
there EX N
were VBD N
no DT N
clinically RB N
relevant JJ N
deposits NNS N
. . N

Most JJS N
subjects NNS N
also RB N
found VBD N
the DT N
ABAK NNP N
bottles NNS N
convenient NN N
. . N

CONCLUSIONS NNP N
Ocular NNP N
hydration NN N
improves VBZ N
comfort NN N
in IN N
contact NN N
lens NN N
wearers NNS N
. . N

NaCl NNP N
is VBZ N
an DT N
appropriate JJ N
first-line JJ N
treatment NN N
, , N
but CC N
for IN N
subjects NNS N
with IN N
fluorescein-staining JJ N
punctuations NNS N
, , N
lubrication NN N
with IN N
PVP NNP N
is VBZ N
preferable JJ N
. . N

-DOCSTART- -X- O O 21704300

Preoperative JJ N
beta-blocker NN N
usage NN N
: : N
is VBZ N
it PRP N
really RB N
worthy JJ N
of IN N
being VBG N
a DT N
quality NN N
indicator NN N
? . N
BACKGROUND NNP N
Since IN N
2007 CD N
, , N
the DT N
use NN N
of IN N
preoperative JJ N
β-blockers NNS N
has VBZ N
been VBN N
used VBN N
as IN N
a DT N
quality NN N
standard NN N
for IN N
patients NNS N
undergoing VBG N
coronary JJ N
artery NN N
bypass NN N
graft NN N
surgery NN N
. . N

Recent JJ N
studies NNS N
have VBP N
called VBN N
into IN N
question NN N
of IN N
the DT N
benefit NN N
of IN N
empiric JJ N
preoperative JJ N
β-blocker NN N
use NN N
. . N

METHODS NNP N
Data NNP N
were VBD N
extracted VBN N
from IN N
our PRP$ N
Society NN N
of IN N
Thoracic NNP N
Surgeons NNP N
certified VBD N
database NN N
for IN N
patients NNS N
undergoing VBG 4_p
isolated JJ 4_p
coronary JJ 4_p
artery NN 4_p
bypass NN 4_p
graft NN 4_p
surgery NN 4_p
from IN N
2000 CD N
to TO N
2008 CD N
. . N

We PRP N
compared VBN N
the DT N
outcomes NNS N
for IN N
patients NNS N
who WP N
received VBD N
preoperative JJ N
β-blockers NNS N
with IN N
those DT N
of IN N
patients NNS N
who WP N
did VBD N
not RB N
. . N

RESULTS VB N
The DT N
study NN N
group NN N
had VBD N
12,855 CD N
patients NNS N
, , N
of IN N
whom WP N
7,967 CD N
( ( N
62.0 CD N
% NN N
) ) N
were VBD N
treated VBN N
preoperatively RB N
with IN N
β-blockers NNS N
. . N

Using VBG N
propensity NN N
matching NN N
, , N
we PRP N
selected VBD N
two CD N
matched JJ N
groups NNS N
of IN N
4,474 CD N
patients NNS N
with IN N
preoperative JJ N
β-blocker NN N
use NN N
and CC N
4,474 CD N
not RB N
using VBG N
preoperative JJ N
β-blockers NNS N
. . N

In IN N
the DT N
unmatched JJ N
cohort NN N
, , N
only RB N
deep JJ N
sternal JJ N
infection NN N
( ( N
0.3 CD N
% NN N
versus IN N
0.5 CD N
% NN N
without IN N
β-blockers NNS N
; : N
p=0.032 NN N
) ) N
, , N
pneumonia NN N
( ( N
1.9 CD N
% NN N
versus IN N
2.4 CD N
% NN N
without IN N
β-blockers NNS N
; : N
p=0.039 NN N
) ) N
, , N
and CC N
intraoperative JJ N
blood NN N
usage NN N
( ( N
37.2 CD N
% NN N
versus IN N
34.1 CD N
% NN N
without IN N
β-blockers NNS N
; : N
p VB N
< $ N
0.001 CD N
) ) N
reached VBD N
statistically RB N
significant JJ N
difference NN N
. . N

In IN N
the DT N
matched JJ N
groups NNS N
, , N
there EX N
was VBD N
no DT N
difference NN N
between IN N
adverse JJ N
event NN N
rates NNS N
in IN N
patients NNS N
treated VBN N
with IN N
β-blockers NNS N
and CC N
those DT N
who WP N
were VBD N
not RB N
. . N

The DT N
number NN N
of IN N
patients NNS N
requiring VBG N
intraoperative JJ N
blood NN N
product NN N
use NN N
was VBD N
significantly RB N
higher JJR N
among IN N
β-blocker-treated JJ N
patients NNS N
( ( N
p=0.004 NN N
) ) N
. . N

Calculating VBG N
the DT N
adjusted VBN N
odds NNS N
ratios NNS N
showed VBD N
that IN N
in IN N
the DT N
matched JJ N
groups NNS N
, , N
the DT N
preoperative JJ N
use NN N
of IN N
β-blockers NNS N
was VBD N
not RB N
an DT N
independent JJ N
predictor NN N
of IN N
mortality NN N
. . N

CONCLUSIONS VB N
A DT N
rational NN N
for IN N
preoperative JJ N
β-blockade JJ N
exists NNS N
. . N

However RB N
, , N
as IN N
with IN N
any DT N
medical JJ N
intervention NN N
, , N
its PRP$ N
application NN N
should MD N
be VB N
tailored VBN N
to TO N
specific JJ N
clinical JJ N
scenarios NNS N
. . N

With IN N
no DT N
differences NNS N
in IN N
mortality NN N
or CC N
morbidity NN N
, , N
our PRP$ N
findings NNS N
do VBP N
not RB N
support VB N
preoperative JJ N
β-blockade NN N
as IN N
a DT N
useful JJ N
quality NN N
indicator NN N
for IN N
coronary JJ N
artery NN N
bypass NN N
graft NN N
surgery NN N
. . N

-DOCSTART- -X- O O 8137583

Intraperitoneal NNP N
distribution NN N
imaging VBG N
prior RB N
to TO N
chromic VB N
phosphate NN N
( ( N
P-32 NNP N
) ) N
therapy NN N
in IN N
ovarian JJ 4_p
cancer NN 4_p
patients NNS N
. . N

This DT N
study NN N
addressed VBD N
the DT N
technique NN N
of IN N
intraperitoneal JJ N
distribution NN N
imaging NN N
( ( N
IDI NNP N
) ) N
. . N

A DT N
literature NN N
search NN N
( ( N
MEDLINE NNP N
database NN N
) ) N
revealed VBD N
wide JJ N
variations NNS N
in IN N
IDI NNP N
techniques NNS N
without IN N
a DT N
basis NN N
for IN N
comparison NN N
. . N

From IN N
April NNP N
1990 CD N
to TO N
September NNP N
1992 CD N
, , N
the DT N
authors NNS N
studied VBD N
8 CD N
patients NNS N
( ( N
age NN N
43-65 CD N
years NNS N
) ) N
with IN N
ovarian JJ N
cancer NN N
. . N

A DT N
total NN N
of IN N
1000 CD N
ml NN N
of IN N
normal JJ N
saline NN N
and CC N
1 CD N
mCi NN N
of IN N
Tc-99m NNP N
SC NNP N
was VBD N
infused VBN N
intraperitoneally RB N
for IN N
IDI NNP N
. . N

In IN N
one CD N
patient NN N
loculation NN N
was VBD N
observed VBN N
, , N
but CC N
only RB N
250 CD N
ml NNS N
of IN N
normal JJ N
saline NN N
was VBD N
infused VBN N
with IN N
Tc-99m NNP N
SC NNP N
. . N

A NNP N
repeat NN N
study NN N
using VBG N
our PRP$ N
standard NN N
technique NN N
rendered VBD N
free JJ N
intraperitoneal NN N
distribution NN N
in IN N
this DT N
patient NN N
, , N
as RB N
well RB N
as IN N
in IN N
the DT N
other JJ N
seven CD N
cases NNS N
. . N

Some DT N
investigators NNS N
recommend VBP N
low JJ N
volumes NNS N
, , N
but CC N
in IN N
our PRP$ N
experience NN N
this DT N
produced VBD N
the DT N
finding NN N
of IN N
pseudoloculation NN N
, , N
which WDT N
could MD N
change VB N
treatment NN N
inappropriately RB N
. . N

Although IN N
the DT N
number NN N
of IN N
patients NNS N
studied VBN N
at IN N
our PRP$ N
institution NN N
was VBD N
small JJ N
, , N
administration NN N
of IN N
1 CD N
liter NN N
intraperitoneally RB N
provided VBD N
consistent JJ N
IDI NNP N
results NNS N
. . N

-DOCSTART- -X- O O 10382082

Cycle NNP N
control NN N
with IN N
oral JJ N
contraceptives NNS N
containing VBG N
20 CD N
micrograms NNS N
of IN N
ethinyl JJ N
estradiol NN N
. . N

A DT N
multicenter NN N
, , N
randomized VBD N
comparison NN N
of IN N
levonorgestrel/ethinyl JJ N
estradiol NN N
( ( N
100 CD N
micrograms/20 NN N
micrograms NNS N
) ) N
and CC N
norethindrone/ethinyl JJ N
estradiol NN N
( ( N
1000 CD N
micrograms/20 NN N
micrograms NNS N
) ) N
. . N

A DT N
randomized JJ N
, , N
open-label JJ N
, , N
multicenter NN N
study NN N
was VBD N
undertaken VBN N
to TO N
compare VB N
the DT N
effects NNS N
of IN N
oral JJ N
contraceptives NNS N
( ( N
OC NNP N
) ) N
containing VBG N
100 CD N
micrograms NNS N
levonorgestrel NN N
( ( N
LNG NNP N
) ) N
/20 VBP N
micrograms NNS N
ethinyl VBP N
estradiol NN N
( ( N
EE NNP N
) ) N
( ( N
Aless/Loette NNP N
) ) N
and CC N
1000 CD N
micrograms NNS N
norethindrone JJ N
acetate NN N
( ( N
NETA NNP N
) ) N
/20 VBP N
micrograms NNS N
EE NNP N
( ( N
Loestrin NNP N
Fe NNP N
1/20 CD N
) ) N
on IN N
menstrual JJ N
cycle NN N
control NN N
over IN N
four CD N
cycles NNS N
of IN N
use NN N
. . N

A DT N
total NN N
of IN N
84 CD N
evaluable JJ N
women NNS N
provided VBD N
274 CD N
cycles NNS N
of IN N
exposure NN N
in IN N
the DT N
LNG/EE NNP N
group NN N
, , N
and CC N
89 CD N
women NNS N
provided VBD N
289 CD N
cycles NNS N
of IN N
exposure NN N
in IN N
the DT N
NETA/EE NNP N
group NN N
. . N

Overall UH N
, , N
the DT N
LNG/EE NNP N
group NN N
achieved VBD N
a DT N
consistently RB N
higher JJR N
percentage NN N
of IN N
normal JJ N
menstrual JJ N
cycles NNS N
as RB N
well RB N
as IN N
a DT N
lower JJR N
rate NN N
of IN N
intermenstrual JJ N
bleeding NN N
and CC N
amenorrhea NN N
than IN N
the DT N
NETA/EE NNP N
group NN N
. . N

In IN N
cycle NN N
4 CD N
, , N
63.8 CD N
% NN N
of IN N
cycles NNS N
were VBD N
normal JJ N
in IN N
the DT N
LNG/EE NNP N
group NN N
compared VBN N
with IN N
41.9 CD N
% NN N
in IN N
the DT N
NETA/EE NNP N
group NN N
( ( N
p JJ N
< NNP N
0.005 CD N
) ) N
. . N

Of IN N
the DT N
total JJ N
cycles NNS N
in IN N
the DT N
NETA/EE NNP N
group NN N
, , N
10 CD N
% NN N
were VBD N
amenorrheic RB N
, , N
compared VBN N
with IN N
1.1 CD N
% NN N
in IN N
the DT N
LNG/EE NNP N
group NN N
. . N

The DT N
occurrence NN N
of IN N
bleeding VBG N
and/or JJ N
spotting NN N
was VBD N
significantly RB N
lower JJR N
in IN N
cycles NNS N
2 CD N
and CC N
3 CD N
in IN N
the DT N
LNG/EE NNP N
group NN N
( ( N
41.7 CD N
% NN N
and CC N
34.8 CD N
% NN N
, , N
respectively RB N
) ) N
compared VBN N
with IN N
the DT N
NETA/EE NNP N
group NN N
( ( N
62.3 CD N
% NN N
and CC N
56.3 CD N
% NN N
; : N
p CC N
< VB N
0.05 CD N
) ) N
. . N

Other JJ N
cycle NN N
variables NNS N
were VBD N
generally RB N
similar JJ N
between IN N
groups NNS N
, , N
as IN N
was VBD N
the DT N
incidence NN N
of IN N
adverse JJ N
events NNS N
. . N

These DT N
results NNS N
demonstrate VBP N
that IN N
good JJ N
cycle NN N
control NN N
was VBD N
achieved VBN N
with IN N
an DT N
OC NNP N
containing VBG N
20 CD N
micrograms NNS N
EE NNP N
and CC N
that IN N
100 CD N
micrograms NNS N
LNG/20 NNP N
micrograms NNS N
EE NNP N
produces VBZ N
better JJR N
cycle NN N
control NN N
than IN N
1000 CD N
micrograms NNS N
NETA/20 NNP N
micrograms NNS N
EE NNP N
. . N

-DOCSTART- -X- O O 12742556

Efficacy NN N
of IN N
second JJ N
versus NN N
third JJ N
generation NN N
oral JJ N
contraceptives NNS N
in IN N
the DT N
treatment NN N
of IN N
hirsutism NN N
. . N

OBJECTIVE UH N
To TO N
compare VB N
second JJ N
versus JJ N
third JJ N
generation NN N
combination NN N
oral JJ N
contraceptives NNS N
( ( N
OCs NNP N
) ) N
in IN N
the DT N
treatment NN N
of IN N
hirsutism NN N
. . N

METHODS NNP N
Women NNP N
with IN N
hirsutism NN N
, , N
as IN N
defined VBN N
by IN N
a DT N
minimum JJ N
Ferriman-Gallwey JJ N
score NN N
of IN N
10 CD N
, , N
were VBD N
randomized VBN N
in IN N
a DT N
double-blind JJ N
fashion NN N
to TO N
receive VB N
an DT N
OC NNP N
containing NN N
either CC N
ethinyl JJ N
estradiol/desogestrel NN N
or CC N
ethinyl NN N
estradiol/levonorgestrel NN N
for IN N
9 CD N
months NNS N
of IN N
treatment NN N
. . N

Ferriman-Gallwey JJ N
scores NNS N
, , N
androgen NN N
levels NNS N
and CC N
sex NN N
hormone-binding JJ N
globulin NN N
were VBD N
measured VBN N
at IN N
baseline NN N
and CC N
every DT N
3 CD N
months NNS N
for IN N
the DT N
duration NN N
of IN N
the DT N
study NN N
. . N

Hormones NNS N
were VBD N
measured VBN N
in IN N
duplicate NN N
by IN N
radioimmunoassay NN N
. . N

RESULTS NNP N
Of IN N
the DT N
47 CD N
women NNS N
enrolled VBD N
, , N
24 CD N
were VBD N
randomized VBN N
to TO N
ethinyl VB N
estradiol/desogestrel NN N
and CC N
23 CD N
were VBD N
randomized VBN N
to TO N
ethinyl VB N
estradiol/levonorgestrel NN N
. . N

Mean JJ N
sex NN N
hormone-binding JJ N
globulin NN N
increased VBD N
significantly RB N
in IN N
subjects NNS N
using VBG N
the DT N
desogestrel-containing JJ N
contraceptive NN N
compared VBN N
with IN N
the DT N
levonorgestrel-containing JJ N
contraceptive NN N
. . N

Ten CD N
subjects NNS N
completed VBD N
the DT N
9 CD N
months NNS N
of IN N
treatment NN N
in IN N
the DT N
levonorgestrel NN N
group NN N
and CC N
11 CD N
completed VBD N
the DT N
study NN N
in IN N
the DT N
desogestrel NN N
group NN N
. . N

Mean NNP N
free JJ N
testosterone NN N
and CC N
3alpha-androstanediol JJ N
glucuronide NN N
decreased VBD N
significantly RB N
in IN N
the DT N
group NN N
receiving VBG N
ethinyl JJ N
estradiol/desogestrel NN N
but CC N
not RB N
in IN N
the DT N
ethinyl NN N
estradiol/levonorgestrel NN N
group NN N
. . N

Mean JJ N
Ferriman-Gallwey JJ N
scores NNS N
decreased VBN N
significantly RB N
in IN N
both DT N
treatment NN N
groups NNS N
. . N

Improvement NNP N
in IN N
mean JJ N
Ferriman-Gallwey NNP N
score NN N
was VBD N
35.7 CD N
+/- JJ N
38.1 CD N
% NN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
for IN N
the DT N
ethinyl NN N
estradiol/desogestrel NN N
arm NN N
and CC N
33.4 CD N
+/- JJ N
27.3 CD N
% NN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
for IN N
the DT N
ethinyl NN N
estradiol/levonorgestrel NN N
arm NN N
. . N

There EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
found VBN N
in IN N
the DT N
improvement NN N
of IN N
Ferriman-Gallwey NNP N
scores NNS N
between IN N
the DT N
two CD N
treatment NN N
arms NNS N
, , N
although IN N
the DT N
power NN N
to TO N
detect VB N
a DT N
difference NN N
was VBD N
limited VBN N
by IN N
the DT N
small JJ N
sample NN N
size NN N
. . N

CONCLUSIONS NNP N
Treatment NNP N
of IN N
hirsute JJ N
women NNS N
with IN N
third JJ N
generation NN N
OCs NNP N
containing VBG N
desogestrel NN N
results NNS N
in IN N
a DT N
significant JJ N
increase NN N
in IN N
sex NN N
hormone-binding JJ N
globulin NN N
and CC N
decrease NN N
in IN N
free JJ N
testosterone NN N
and CC N
3alpha-androstanediol JJ N
glucuronide NN N
. . N

Both DT N
second JJ N
and CC N
third JJ N
generation NN N
OCs NNP N
were VBD N
clinically RB N
effective JJ N
in IN N
treating VBG N
hirsutism NN N
. . N

-DOCSTART- -X- O O 18278302

Microtensile NNP N
bond NN N
strength NN N
of IN N
a DT N
repair NN N
composite JJ N
to TO N
leucite-reinforced JJ N
feldspathic JJ N
ceramic NN N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
microtensile NN N
bond NN N
strength NN N
of IN N
a DT N
repair NN N
composite JJ N
resin NN N
to TO N
a DT N
leucite-reinforced JJ N
feldspathic JJ N
ceramic NN N
( ( N
Omega NNP N
900 CD N
, , N
VITA NNP N
) ) N
submitted VBD N
to TO N
two CD N
surface NN N
conditionings NNS N
methods NNS N
: : N
1 CD N
) ) N
etching VBG N
with IN N
hydrofluoric JJ N
acid NN N
+ NNP N
silane NN N
application NN N
or CC N
2 CD N
) ) N
tribochemical NN N
silica NN N
coating NN N
. . N

The DT N
null JJ N
hypothesis NN N
is VBZ N
that IN N
both DT N
surface NN N
treatments NNS N
can MD N
generate VB N
similar JJ N
bond NN N
strengths NNS N
. . N

Ten CD N
ceramic JJ N
blocks NNS N
( ( N
6x6x6 CD N
mm NN N
) ) N
were VBD N
fabricated VBN N
and CC N
randomly RB N
assigned VBN N
to TO N
2 CD N
groups NNS N
( ( N
n=5 NN N
) ) N
, , N
according VBG N
to TO N
the DT N
conditioning NN N
method NN N
: : N
G1- JJ N
10 CD N
% NN N
hydrofluoric JJ N
acid NN N
application NN N
for IN N
2 CD N
min NN N
plus CC N
rinsing NN N
and CC N
drying NN N
, , N
followed VBN N
by IN N
silane NN N
application NN N
for IN N
30 CD N
s NNS N
; : N
G2- NNP N
airborne JJ N
particle NN N
abrasion NN N
with IN N
30 CD N
microm NNS N
silica JJ N
oxide IN N
particles NNS N
( ( N
CoJet-Sand NNP N
) ) N
for IN N
20 CD N
s NNS N
using VBG N
a DT N
chairside JJ N
air-abrasion NN N
device NN N
( ( N
CoJet NNP N
System NNP N
) ) N
, , N
followed VBN N
by IN N
silane NN N
application NN N
for IN N
5 CD N
min NN N
. . N

Single NNP N
Bond NNP N
adhesive JJ N
system NN N
was VBD N
applied VBN N
to TO N
the DT N
surfaces NNS N
and CC N
light NN N
cured VBN N
( ( N
40 CD N
s NN N
) ) N
. . N

Z-250 JJ N
composite JJ N
resin NN N
was VBD N
placed VBN N
incrementally RB N
on IN N
the DT N
treated JJ N
ceramic JJ N
surface NN N
to TO N
build VB N
a DT N
6x6x6 CD N
mm NN N
block NN N
. . N

Bar NNP N
specimens VBZ N
with IN N
an DT N
adhesive JJ N
area NN N
of IN N
approximately RB N
1 CD N
+/- JJ N
0.1 CD N
mm NN N
( ( N
2 CD N
) ) N
were VBD N
obtained VBN N
from IN N
the DT N
composite-ceramic JJ N
blocks NNS N
( ( N
6 CD N
per IN N
block NN N
and CC N
30 CD N
per IN N
group NN N
) ) N
for IN N
microtensile NN N
testing VBG N
. . N

No DT N
statistically RB N
significant JJ N
difference NN N
was VBD N
observed VBN N
between IN N
G1 NNP N
( ( N
10.19 CD N
+/- JJ N
3.1 CD N
MPa NNP N
) ) N
and CC N
G2 NNP N
( ( N
10.17 CD N
+/- JJ N
3.1 CD N
MPa NNP N
) ) N
( ( N
p=0.982 NN N
) ) N
( ( N
Student NNP N
's POS N
t JJ N
test NN N
; : N
á CC N
= VB N
0.05 CD N
) ) N
. . N

The DT N
null JJ N
hypothesis NN N
was VBD N
, , N
therefore RB N
, , N
accepted VBD N
. . N

In IN N
conclusion NN N
, , N
both DT N
surface VBP N
conditioning VBG N
methods NNS N
provided VBD N
similar JJ N
microtensile NN N
bond NN N
strengths NNS N
between IN N
the DT N
repair NN N
composite JJ N
resin NN N
and CC N
the DT N
ceramic NN N
. . N

Further JJ N
studies NNS N
using VBG N
long-term JJ N
aging NN N
procedures NNS N
should MD N
be VB N
conducted VBN N
. . N

-DOCSTART- -X- O O 18166533

Impact NN N
of IN N
a DT N
16-community JJ N
trial NN N
to TO N
promote VB N
judicious JJ N
antibiotic JJ N
use NN N
in IN N
Massachusetts NNP N
. . N

OBJECTIVES NNP N
Reducing VBG N
unnecessary JJ N
antibiotic JJ N
use NN N
, , N
particularly RB N
among IN N
children NNS N
, , N
continues VBZ N
to TO N
be VB N
a DT N
public JJ N
health NN N
priority NN N
. . N

Previous JJ N
intervention NN N
studies NNS N
have VBP N
been VBN N
limited VBN N
by IN N
size NN N
or CC N
design NN N
and CC N
have VBP N
shown VBN N
mixed JJ N
results NNS N
. . N

The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
the DT N
impact NN N
of IN N
a DT N
multifaceted VBN N
, , N
community-wide JJ N
intervention NN N
on IN N
overall JJ N
antibiotic JJ N
use NN N
for IN N
young JJ N
children NNS N
and CC N
on IN N
use NN N
of IN N
broad-spectrum JJ N
agents NNS N
. . N

In IN N
addition NN N
, , N
we PRP N
sought VBD N
to TO N
compare VB N
the DT N
intervention NN N
's POS N
impact NN N
on IN N
commercially RB N
and CC N
Medicaid-insured JJ N
children NNS N
. . N

METHODS NNP N
We PRP N
conducted VBD N
a DT N
controlled VBN N
, , N
community-level JJ N
, , N
cluster-randomized JJ N
trial NN N
in IN N
16 CD N
nonoverlapping VBG N
Massachusetts NNP N
communities NNS N
, , N
studied VBN N
from IN N
1998 CD N
to TO N
2003 CD N
. . N

During IN N
3 CD N
years NNS N
, , N
we PRP N
implemented VBD N
a DT N
physician JJ N
behavior-change NN N
strategy NN N
that WDT N
included VBD N
guideline JJ N
dissemination NN N
, , N
small-group JJ N
education NN N
, , N
frequent JJ N
updates NNS N
and CC N
educational JJ N
materials NNS N
, , N
and CC N
prescribing VBG N
feedback NN N
. . N

Parents NNS N
received VBD N
educational JJ N
materials NNS N
by IN N
mail NN N
and CC N
in IN N
primary JJ N
care NN N
practices NNS N
, , N
pharmacies NNS N
, , N
and CC N
child NN N
care NN N
settings NNS N
. . N

Using VBG N
health-plan JJ N
data NNS N
, , N
we PRP N
measured VBD N
changes NNS N
in IN N
antibiotics NNS N
dispensed VBN N
per IN N
person-year NN N
of IN N
observation NN N
among IN N
children NNS N
who WP N
were VBD N
aged VBN N
3 CD N
to TO N
< VB N
72 CD N
months NNS N
, , N
resided VBN N
in IN N
study NN N
communities NNS N
, , N
and CC N
were VBD N
insured VBN N
by IN N
a DT N
participating VBG N
commercial JJ N
health NN N
plan NN N
or CC N
Medicaid NNP N
. . N

RESULTS VB N
The DT N
data NNS N
include VBP N
223,135 CD N
person-years NNS N
of IN N
observation NN N
. . N

Antibiotic-use JJ N
rates NNS N
at IN N
baseline NN N
were VBD N
2.8 CD N
, , N
1.7 CD N
, , N
and CC N
1.4 CD N
antibiotics NNS N
per IN N
person-year NN N
among IN N
those DT N
aged VBN N
3 CD N
to TO N
< VB N
24 CD N
, , N
24 CD N
to TO N
< VB N
48 CD N
, , N
and CC N
48 CD N
to TO N
< VB N
72 CD N
months NNS N
, , N
respectively RB N
. . N

We PRP N
observed VBD N
a DT N
substantial JJ N
downward JJ N
trend NN N
in IN N
antibiotic JJ N
prescribing NN N
, , N
even RB N
in IN N
the DT N
absence NN N
of IN N
intervention NN N
. . N

The DT N
intervention NN N
had VBD N
no DT N
additional JJ N
effect NN N
among IN N
children NNS N
aged VBD N
3 CD N
to TO N
< VB N
24 CD N
months NNS N
but CC N
was VBD N
responsible JJ N
for IN N
a DT N
4.2 CD N
% NN N
decrease NN N
among IN N
those DT N
aged VBN N
24 CD N
to TO N
< VB N
48 CD N
months NNS N
and CC N
a DT N
6.7 CD N
% NN N
decrease NN N
among IN N
those DT N
aged VBN N
48 CD N
to TO N
< VB N
72 CD N
months NNS N
. . N

The DT N
intervention NN N
effect NN N
was VBD N
greater JJR N
among IN N
Medicaid-insured JJ N
children NNS N
and CC N
for IN N
broad-spectrum JJ N
agents NNS N
. . N

CONCLUSIONS VB N
A DT N
sustained JJ N
, , N
multifaceted VBN N
, , N
community-level JJ N
intervention NN N
was VBD N
only RB N
modestly RB N
successful JJ N
at IN N
decreasing VBG N
overall JJ N
antibiotic JJ N
use NN N
beyond IN N
substantial JJ N
secular JJ N
trends NNS N
. . N

The DT N
more RBR N
robust JJ N
impact NN N
among IN N
Medicaid-insured JJ N
children NNS N
and CC N
for IN N
specific JJ N
medication NN N
classes NNS N
provides VBZ N
an DT N
argument NN N
for IN N
specific JJ N
targeting NN N
of IN N
resources NNS N
for IN N
patient NN N
and CC N
physician JJ N
behavior NN N
change NN N
. . N

-DOCSTART- -X- O O 18328868

Randomized VBN N
, , N
controlled VBD N
trial NN N
of IN N
Behavioral NNP N
Family NNP N
Systems NNP N
Therapy NNP N
for IN N
Diabetes NNPS 4_p
: : 4_p
maintenance NN N
and CC N
generalization NN N
of IN N
effects NNS N
on IN N
parent-adolescent JJ N
communication NN N
. . N

We PRP N
report VBP N
a DT N
randomized JJ N
trial NN N
of IN N
a DT N
revised JJ N
Behavioral NNP N
Family NNP N
Systems NNP N
Therapy NNP N
for IN N
Diabetes NNP N
( ( N
BFST-D NNP N
) ) N
intervention NN N
. . N

Families NNS N
of IN N
104 CD N
adolescents NNS N
with IN N
diabetes NNS 4_p
were VBD N
randomized VBN N
to TO N
standard VB N
care NN N
( ( N
SC NNP N
) ) N
or CC N
to TO N
6 CD N
months NNS N
of IN N
an DT N
educational JJ N
support NN N
group NN N
( ( N
ES NNP N
) ) N
or CC N
BFST-D. JJ N
Family NNP N
communication NN N
and CC N
problem-solving JJ N
skills NNS N
were VBD N
assessed VBN N
at IN N
0 CD N
, , N
6 CD N
, , N
12 CD N
, , N
and CC N
18 CD N
months NNS N
by IN N
independent JJ N
rating NN N
of IN N
videotaped JJ N
family NN N
problem-solving JJ N
discussions NNS N
. . N

BFST-D NNP N
improved VBD N
individual JJ N
communication NN N
of IN N
adolescents NNS N
and CC N
mothers NNS N
, , N
but CC N
not RB N
fathers NNS N
. . N

BFST-D NNP N
significantly RB N
improved VBD N
quality NN N
of IN N
family NN N
interaction NN N
compared VBN N
to TO N
SC NNP N
( ( N
10 CD N
of IN N
12 CD N
comparisons NNS N
) ) N
and CC N
ES NNP N
( ( N
6 CD N
of IN N
12 CD N
comparisons NNS N
) ) N
. . N

Changes NNS N
in IN N
family NN N
communication NN N
were VBD N
differentially RB N
associated VBN N
with IN N
changes NNS N
in IN N
glycemic JJ N
control NN N
, , N
adherence NN N
, , N
and CC N
family NN N
conflict NN N
. . N

BFST-D NNP N
improved VBD N
family NN N
communication NN N
and CC N
problem NN N
solving VBG N
relative JJ N
to TO N
SC NNP N
and CC N
modestly RB N
relative JJ N
to TO N
ES NNP N
. . N

-DOCSTART- -X- O O 15769967

Effects NNS N
of IN N
long-term JJ N
vitamin NN N
E NNP N
supplementation NN N
on IN N
cardiovascular JJ 4_p
events NNS 4_p
and CC N
cancer NN 4_p
: : N
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

CONTEXT NNP N
Experimental NNP N
and CC N
epidemiological JJ N
data NNS N
suggest VBP N
that IN N
vitamin NN N
E NNP N
supplementation NN N
may MD N
prevent VB N
cancer NN 4_p
and CC N
cardiovascular JJ 4_p
events NNS 4_p
. . N

Clinical JJ N
trials NNS N
have VBP N
generally RB N
failed VBN N
to TO N
confirm VB N
benefits NNS N
, , N
possibly RB N
due JJ N
to TO N
their PRP$ N
relatively RB N
short JJ N
duration NN N
. . N

OBJECTIVE UH N
To TO N
evaluate VB N
whether IN N
long-term JJ N
supplementation NN N
with IN N
vitamin JJ N
E NN N
decreases VBZ N
the DT N
risk NN N
of IN N
cancer NN 4_p
, , N
cancer NN N
death NN N
, , N
and CC N
major JJ N
cardiovascular JJ 4_p
events NNS 4_p
. . N

DESIGN NNP N
, , N
SETTING NNP N
, , N
AND NNP N
PATIENTS NNP N
A NNP N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
international JJ N
trial NN N
( ( N
the DT N
initial JJ N
Heart NNP N
Outcomes NNP N
Prevention NNP N
Evaluation NNP N
[ NNP N
HOPE NNP N
] NNP N
trial NN N
conducted VBD N
between IN N
December NNP N
21 CD N
, , N
1993 CD N
, , N
and CC N
April NNP N
15 CD N
, , N
1999 CD N
) ) N
of IN N
patients NNS N
at IN N
least JJS N
55 CD N
years NNS N
old JJ N
with IN N
vascular JJ 4_p
disease NN 4_p
or CC 4_p
diabetes VBZ 4_p
mellitus NN 4_p
was VBD N
extended VBN N
( ( N
HOPE-The NNP N
Ongoing NNP N
Outcomes NNP N
[ NNP N
HOPE-TOO NNP N
] NNP N
) ) N
between IN N
April NNP N
16 CD N
, , N
1999 CD N
, , N
and CC N
May NNP N
26 CD N
, , N
2003 CD N
. . N

Of IN N
the DT N
initial JJ N
267 CD N
HOPE NNP N
centers NNS N
that WDT N
had VBD N
enrolled VBN N
9541 CD N
patients NNS N
, , N
174 CD N
centers NNS N
participated VBN N
in IN N
the DT N
HOPE-TOO NNP N
trial NN N
. . N

Of IN N
7030 CD N
patients NNS N
enrolled VBN N
at IN N
these DT N
centers NNS N
, , N
916 CD N
were VBD N
deceased VBN N
at IN N
the DT N
beginning NN N
of IN N
the DT N
extension NN N
, , N
1382 CD N
refused VBD N
participation NN N
, , N
3994 CD N
continued VBD N
to TO N
take VB N
the DT N
study NN N
intervention NN N
, , N
and CC N
738 CD N
agreed VBD N
to TO N
passive VB N
follow-up NN N
. . N

Median JJ N
duration NN N
of IN N
follow-up NN N
was VBD N
7.0 CD N
years NNS N
. . N

INTERVENTION NNP N
Daily NNP N
dose NN N
of IN N
natural JJ N
source NN N
vitamin NN N
E NNP N
( ( N
400 CD N
IU NNP N
) ) N
or CC N
matching VBG N
placebo NN N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Primary NNP N
outcomes NNS N
included VBD N
cancer NN N
incidence NN N
, , N
cancer NN N
deaths NNS N
, , N
and CC N
major JJ N
cardiovascular JJ N
events NNS N
( ( N
myocardial JJ N
infarction NN N
, , N
stroke NN N
, , N
and CC N
cardiovascular JJ N
death NN N
) ) N
. . N

Secondary JJ N
outcomes NNS N
included VBD N
heart NN N
failure NN N
, , N
unstable JJ N
angina NN N
, , N
and CC N
revascularizations NNS N
. . N

RESULTS NNP N
Among IN N
all DT N
HOPE NNP N
patients NNS N
, , N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
the DT N
primary JJ N
analysis NN N
: : N
for IN N
cancer NN N
incidence NN N
, , N
there EX N
were VBD N
552 CD N
patients NNS N
( ( N
11.6 CD N
% NN N
) ) N
in IN N
the DT N
vitamin NN N
E NNP N
group NN N
vs VBD N
586 CD N
( ( N
12.3 CD N
% NN N
) ) N
in IN N
the DT N
placebo NN N
group NN N
( ( N
relative JJ N
risk NN N
[ NNP N
RR NNP N
] NNP N
, , N
0.94 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
, , N
0.84-1.06 NNP N
; : N
P NNP N
= NNP N
.30 NNP N
) ) N
; : N
for IN N
cancer NN N
deaths NNS N
, , N
156 CD N
( ( N
3.3 CD N
% NN N
) ) N
vs NN N
178 CD N
( ( N
3.7 CD N
% NN N
) ) N
, , N
respectively RB N
( ( N
RR NNP N
, , N
0.88 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.71-1.09 NNP N
; : N
P NNP N
= NNP N
.24 NNP N
) ) N
; : N
and CC N
for IN N
major JJ N
cardiovascular JJ N
events NNS N
, , N
1022 CD N
( ( N
21.5 CD N
% NN N
) ) N
vs NN N
985 CD N
( ( N
20.6 CD N
% NN N
) ) N
, , N
respectively RB N
( ( N
RR NNP N
, , N
1.04 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.96-1.14 NNP N
; : N
P NNP N
= NNP N
.34 NNP N
) ) N
. . N

Patients NNS N
in IN N
the DT N
vitamin NN N
E NNP N
group NN N
had VBD N
a DT N
higher JJR N
risk NN N
of IN N
heart NN N
failure NN N
( ( N
RR NNP N
, , N
1.13 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
1.01-1.26 JJ N
; : N
P NNP N
= NNP N
.03 NNP N
) ) N
and CC N
hospitalization NN N
for IN N
heart NN N
failure NN N
( ( N
RR NNP N
, , N
1.21 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
1.00-1.47 JJ N
; : N
P NNP N
= NNP N
.045 NNP N
) ) N
. . N

Similarly RB N
, , N
among IN N
patients NNS N
enrolled VBN N
at IN N
the DT N
centers NNS N
participating VBG N
in IN N
the DT N
HOPE-TOO NNP N
trial NN N
, , N
there EX N
were VBD N
no DT N
differences NNS N
in IN N
cancer NN N
incidence NN N
, , N
cancer NN N
deaths NNS N
, , N
and CC N
major JJ N
cardiovascular JJ N
events NNS N
, , N
but CC N
higher JJR N
rates NNS N
of IN N
heart NN N
failure NN N
and CC N
hospitalizations NNS N
for IN N
heart NN N
failure NN N
. . N

CONCLUSION NNP N
In IN N
patients NNS N
with IN N
vascular JJ 4_p
disease NN 4_p
or CC 4_p
diabetes VBZ 4_p
mellitus NNS 4_p
, , N
long-term JJ N
vitamin NN N
E NNP N
supplementation NN N
does VBZ N
not RB N
prevent VB N
cancer NN N
or CC N
major JJ N
cardiovascular JJ N
events NNS N
and CC N
may MD N
increase VB N
the DT N
risk NN N
for IN N
heart NN N
failure NN N
. . N

-DOCSTART- -X- O O 15374792

Association NNP N
of IN N
race NN N
with IN N
complications NNS N
and CC N
prognosis NN N
following VBG N
acute JJ N
coronary JJ N
syndromes NNS N
. . N

The DT N
baseline NN N
characteristics NNS N
, , N
complications NNS N
, , N
and CC N
survival NN N
of IN N
489 CD N
black JJ N
and CC N
6,890 CD N
non-black JJ N
patients NNS N
with IN N
acute JJ N
coronary JJ 4_p
syndromes NNS 4_p
were VBD N
studied VBN N
. . N

Important NNP N
racial JJ N
differences NNS N
were VBD N
observed VBN N
in IN N
demographic JJ N
features NNS N
, , N
atherosclerosis NN N
risk NN N
factors NNS N
, , N
and CC N
treatment NN N
strategies NNS N
; : N
however RB N
, , N
despite IN N
these DT N
differences NNS N
, , N
no DT N
independent JJ N
difference NN N
was VBD N
observed VBN N
in IN N
clinical JJ N
outcomes NNS N
according VBG N
to TO N
race NN N
. . N

The DT N
1-year JJ N
mortality NN N
rate NN N
was VBD N
2.9 CD N
% NN N
for IN N
black JJ N
patients NNS N
and CC N
2.5 CD N
% NN N
for IN N
non-black JJ N
patients NNS N
( ( N
p JJ N
= NNP N
0.93 CD N
) ) N
. . N

-DOCSTART- -X- O O 11471578

A DT N
comparison NN N
of IN N
acupuncture NN N
with IN N
advice NN N
and CC N
exercises NNS N
on IN N
the DT N
symptomatic JJ N
treatment NN N
of IN N
osteoarthritis NN 4_p
of IN 4_p
the DT 4_p
hip NN 4_p
-- : N
a DT N
randomised JJ N
controlled VBN N
trial NN N
. . N

Acupuncture NN N
is VBZ N
becoming VBG N
a DT N
common JJ N
technique NN N
within IN N
the DT N
physiotherapy NN N
profession NN N
as IN N
a DT N
treatment NN N
modality NN N
for IN N
pain NN N
relief NN N
; : N
however RB N
, , N
few JJ N
randomised VBD N
controlled VBN N
trials NNS N
have VBP N
been VBN N
undertaken VBN N
to TO N
assess VB N
the DT N
effectiveness NN N
of IN N
acupuncture NN N
, , N
particularly RB N
in IN N
the DT N
treatment NN N
of IN N
osteoarthritis NN N
( ( N
OA NNP N
) ) N
of IN N
the DT N
hip NN N
. . N

Therefore RB N
, , N
a DT N
randomised JJ N
trial NN N
to TO N
compare VB N
the DT N
effectiveness NN N
of IN N
acupuncture NN N
with IN N
advice NN N
and CC N
exercises NNS N
on IN N
the DT N
symptomatic JJ N
treatment NN N
of IN N
OA NNP N
of IN N
the DT N
hip NN N
was VBD N
carried VBN N
out RP N
. . N

Thirty-two JJ N
patients NNS N
awaiting VBG 4_p
a DT 4_p
total JJ 4_p
hip NN 4_p
arthroplasty NN 4_p
were VBD N
randomly RB N
allocated VBN N
to TO N
either CC N
the DT N
experimental JJ N
group NN N
, , N
( ( N
A DT N
) ) N
, , N
to TO N
have VB N
six CD N
sessions NNS N
of IN N
acupuncture NN N
each DT N
lasting VBG N
up RP N
to TO N
25 CD N
minutes NNS N
, , N
or CC N
the DT N
control NN N
group NN N
, , N
( ( N
B NNP N
) ) N
, , N
to TO N
be VB N
given VBN N
advice NN N
and CC N
exercises NNS N
for IN N
their PRP$ N
hip NN N
over IN N
a DT N
six CD N
week NN N
period NN N
. . N

Group NNP N
A NNP N
consisted VBD N
of IN N
three CD N
men NNS N
and CC N
13 CD N
women NNS N
, , N
and CC N
group NN N
B NNP N
consisted VBD N
of IN N
four CD N
men NNS N
and CC N
eight CD N
women NNS N
. . N

The DT N
average JJ N
age NN N
in IN N
group NN N
A NNP N
was VBD N
66 CD N
years NNS N
and CC N
in IN N
group NN N
B NNP N
it PRP N
was VBD N
68 CD N
years NNS N
. . N

Patients NNS N
were VBD N
assessed VBN N
for IN N
pain NN N
and CC N
functional JJ N
ability NN N
, , N
using VBG N
a DT N
modified JJ N
version NN N
of IN N
the DT N
WOMAC NNP N
questionnaire NN N
, , N
pre-treatment JJ N
, , N
immediately RB N
post-treatment JJ N
and CC N
at IN N
eight CD N
weeks NNS N
post-treatment JJ N
. . N

The DT N
pre-treatment JJ N
WOMAC NNP N
scores NNS N
in IN N
the DT N
two CD N
groups NNS N
were VBD N
similar JJ N
( ( N
p=0.85 NN N
) ) N
. . N

There EX N
was VBD N
a DT N
significant JJ N
improvement NN N
in IN N
group NN N
A NNP N
( ( N
decrease NN N
in IN N
WOMAC NNP N
score NN N
) ) N
immediately RB N
post-treatment JJ N
( ( N
p=0.002 NN N
) ) N
and CC N
this DT N
was VBD N
maintained VBN N
at IN N
the DT N
eight-week JJ N
follow-up NN N
( ( N
p=0.03 NN N
) ) N
. . N

There EX N
were VBD N
no DT N
significant JJ N
changes NNS N
in IN N
group NN N
B NNP N
. . N

When WRB N
the DT N
changes NNS N
in IN N
WOMAC NNP N
scores NNS N
were VBD N
compared VBN N
between IN N
groups NNS N
, , N
a DT N
significantly RB N
greater JJR N
improvement NN N
was VBD N
found VBN N
between IN N
pre-treatment JJ N
and CC N
immediately RB N
post-treatment JJ N
in IN N
group NN N
A NNP N
, , N
compared VBN N
with IN N
group NN N
B NNP N
( ( N
p=0.02 NN N
) ) N
. . N

The DT N
changes NNS N
between IN N
pre-treatment NN N
and CC N
the DT N
eight-week JJ N
follow-up NN N
also RB N
showed VBD N
a DT N
significant JJ N
improvement NN N
in IN N
group NN N
A NNP N
compared VBN N
with IN N
group NN N
B NNP N
( ( N
p=0.03 NN N
) ) N
. . N

In IN N
conclusion NN N
, , N
this DT N
trial NN N
supports VBZ N
the DT N
hypothesis NN N
that IN N
acupuncture NN N
is VBZ N
more RBR N
effective JJ N
than IN N
advice NN N
and CC N
exercises NNS N
in IN N
the DT N
symptomatic JJ N
treatment NN N
of IN N
OA NNP N
of IN N
the DT N
hip NN N
. . N

-DOCSTART- -X- O O 8614420

The DT N
sequencing NN N
of IN N
chemotherapy NN N
and CC N
radiation NN N
therapy NN N
after IN N
conservative JJ N
surgery NN N
for IN N
early-stage JJ N
breast NN 4_p
cancer NN 4_p
. . N

BACKGROUND NNP N
Patients NNPS N
with IN N
early-stage JJ N
breast NN 4_p
cancer NN 4_p
who WP N
are VBP N
at IN N
substantial JJ N
risk NN N
for IN N
systemic JJ N
metastases NNS 4_p
are VBP N
increasingly RB N
treated VBN N
with IN N
breast-conserving JJ N
therapy NN N
and CC N
adjuvant JJ N
chemotherapy NN N
. . N

However RB N
, , N
the DT N
optimal JJ N
sequencing NN N
of IN N
chemotherapy NN N
and CC N
radiation NN N
therapy NN N
is VBZ N
not RB N
clear JJ N
. . N

METHODS NNP N
Two CD N
hundred VBD N
forty-four JJ N
patients NNS N
with IN N
stage NN N
I PRP N
or CC N
II NNP N
breast NN 4_p
cancer NN 4_p
who WP N
were VBD N
at IN N
substantial JJ N
risk NN N
for IN N
distant JJ N
metastases NNS 4_p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
a DT N
12-week JJ N
course NN N
of IN N
chemotherapy NN N
either CC N
before IN N
or CC N
after IN N
radiation NN N
therapy NN N
. . N

All DT N
had VBD N
had VBN N
breast-conserving JJ N
surgery NN N
. . N

The DT N
median JJ N
length NN N
of IN N
follow-up NN N
in IN N
surviving VBG N
patients NNS N
was VBD N
58 CD N
months NNS N
( ( N
range NN N
, , N
10 CD N
to TO N
124 CD N
) ) N
. . N

RESULTS VB N
The DT N
five-year JJ N
actuarial JJ N
rates NNS N
of IN N
cancer NN N
recurrence NN N
at IN N
any DT N
site NN N
and CC N
of IN N
distant JJ N
metastases NNS N
in IN N
the DT N
radiotherapy-first JJ N
group NN N
and CC N
the DT N
chemotherapy-first JJ N
group NN N
were VBD N
38 CD N
percent NN N
and CC N
31 CD N
percent NN N
( ( N
P NNP N
= NNP N
0.17 CD N
) ) N
and CC N
36 CD N
percent NN N
and CC N
25 CD N
percent NN N
( ( N
P NNP N
= NNP N
0.05 CD N
) ) N
, , N
respectively RB N
. . N

Overall JJ N
survival NN N
was VBD N
73 CD N
percent NN N
and CC N
81 CD N
percent NN N
( ( N
P NNP N
= NNP N
0.11 CD N
) ) N
, , N
respectively RB N
. . N

The DT N
five-year JJ N
crude NN N
rates NNS N
of IN N
first JJ N
recurrence NN N
according VBG N
to TO N
site NN N
in IN N
the DT N
radiotherapy-first JJ N
and CC N
chemotherapy-first JJ N
groups NNS N
, , N
respectively RB N
, , N
were VBD N
5 CD N
percent NN N
and CC N
14 CD N
percent NN N
for IN N
local JJ N
recurrence NN N
and CC N
32 CD N
percent NN N
and CC N
20 CD N
percent NN N
for IN N
distant NN N
or CC N
regional JJ N
recurrence NN N
or CC N
both DT N
. . N

This DT N
difference NN N
in IN N
the DT N
pattern NN N
of IN N
recurrence NN N
was VBD N
of IN N
borderline JJ N
statistical JJ N
significance NN N
( ( N
P NNP N
= NNP N
0.07 CD N
) ) N
. . N

CONCLUSIONS VB N
This DT N
study NN N
suggests VBZ N
that IN N
for IN N
patients NNS N
ar VBP N
substantial JJ N
risk NN N
for IN N
systemic JJ N
metastases NNS 4_p
, , N
it PRP N
is VBZ N
preferable JJ N
to TO N
give VB N
a DT N
12-week JJ N
course NN N
of IN N
chemotherapy NN N
followed VBN N
by IN N
radiation NN N
therapy NN N
, , N
rather RB N
than IN N
radiation NN N
therapy NN N
followed VBN N
by IN N
chemotherapy NN N
. . N

-DOCSTART- -X- O O 12709801

Comparison NNP N
of IN N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
faropenem JJ N
daloxate NN N
and CC N
cefuroxime NN N
axetil NN N
for IN N
the DT N
treatment NN N
of IN N
acute JJ 4_p
bacterial JJ 4_p
maxillary JJ 4_p
sinusitis NN 4_p
in IN N
adults NNS N
. . N

In IN N
this DT N
multicentre NN N
, , N
multinational JJ N
, , N
comparative JJ N
, , N
double-blind JJ N
clinical JJ N
trial NN N
, , N
outpatients NNS N
with IN N
both DT N
clinical JJ N
signs NNS N
and CC N
symptoms NNS N
and CC N
radiographic JJ N
evidence NN N
of IN N
acute JJ 4_p
sinusitis NN 4_p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
for IN N
7 CD N
days NNS N
either CC N
a DT N
twice-daily JJ N
oral JJ N
regimen NNS N
of IN N
faropenem JJ N
daloxate NN N
( ( N
300 CD N
mg NN N
) ) N
or CC N
a DT N
twice JJ N
daily JJ N
oral JJ N
regimen NNS N
of IN N
cefuroxime NN N
axetil NN N
( ( N
250 CD N
mg NN N
) ) N
. . N

Among IN N
452 CD N
patients NNS N
considered VBN N
valid JJ N
for IN N
clinical JJ N
efficacy NN N
, , N
faropenem JJ N
daloxate NN N
treatment NN N
was VBD N
found VBN N
to TO N
be VB N
statistically RB N
equivalent JJ N
to TO N
cefuroxime VB N
axetil NN N
( ( N
89.0 CD N
% NN N
vs. FW N
88.4 CD N
% NN N
-95 CD N
% NN N
CI=-5.2 NNP N
% NN N
; : N
+6.4 CD N
% NN N
) ) N
at IN N
the DT N
7-16 JJ N
days NNS N
post-therapy JJ N
assessment NN N
. . N

At IN N
28-35 JJ N
days NNS N
post-therapy NN N
, , N
the DT N
continued JJ N
clinical JJ N
cure NN N
rate NN N
in IN N
the DT N
faropenem JJ N
daloxate NN N
group NN N
was VBD N
92.6 CD N
% NN N
and CC N
that IN N
for IN N
the DT N
cefuroxime NN N
axetil NN N
group NN N
was VBD N
94.9 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
: : N
-6.8 CD N
% NN N
; : N
+1.2 CD N
% NN N
) ) N
. . N

A DT N
total NN N
of IN N
148 CD N
organisms NNS N
was VBD N
obtained VBN N
in IN N
136 CD N
microbiologically RB N
valid JJ N
patients NNS N
( ( N
30.1 CD N
% NN N
) ) N
. . N

The DT N
predominant JJ N
causative JJ N
organisms NNS N
were VBD N
Streptococcus NNP N
pneumoniae NN N
( ( N
47.1 CD N
% NN N
) ) N
, , N
Haemophilus NNP N
influenzae NN N
( ( N
30.1 CD N
% NN N
) ) N
, , N
Staphylococcus NNP N
aureus NN N
( ( N
14.7 CD N
% NN N
) ) N
and CC N
Moraxella NNP N
catarrhalis NN N
( ( N
8.8 CD N
% NN N
) ) N
. . N

The DT N
bacteriological JJ N
success NN N
rate NN N
at IN N
the DT N
7-16 JJ N
days NNS N
post-therapy JJ N
evaluation NN N
was VBD N
similar JJ N
in IN N
both DT N
treatment NN N
groups NNS N
: : N
91.5 CD N
% NN N
and CC N
90.8 CD N
% NN N
in IN N
the DT N
faropenem NN N
daloxate NN N
and CC N
cefuroxime NN N
axetil NN N
groups NNS N
, , N
respectively RB N
( ( N
95 CD N
% NN N
CI=-9.2 NNP N
% NN N
; : N
+9.5 CD N
% NN N
) ) N
. . N

Eradication NN N
or CC N
presumed VBN N
eradication NN N
was VBD N
detected VBN N
for IN N
97.3 CD N
% NN N
and CC N
96.3 CD N
% NN N
of IN N
S. NNP N
pneumoniae NN N
, , N
85.0 CD N
% NN N
and CC N
90.5 CD N
% NN N
of IN N
H. NNP N
influenzae NN N
, , N
88.9 CD N
% NN N
and CC N
90.9 CD N
% NN N
of IN N
S. NNP N
aureus NN N
and CC N
100.0 CD N
% NN N
and CC N
83.3 CD N
% NN N
of IN N
M. NNP N
catarrhalis NN N
in IN N
faropenem JJ N
daloxate NN N
and CC N
cefuroxime NN N
axetil NN N
recipients NNS N
, , N
respectively RB N
. . N

At IN N
least JJS N
one CD N
drug-related JJ N
event NN N
was VBD N
reported VBN N
by IN N
9.5 CD N
% NN N
of IN N
the DT N
faropenem JJ N
daloxate-treated JJ N
patients NNS N
and CC N
by IN N
10.3 CD N
% NN N
of IN N
those DT N
who WP N
received VBD N
cefuroxime RB N
axetil JJ N
. . N

The DT N
most RBS N
frequently RB N
reported VBD N
drug-related JJ N
events NNS N
were VBD N
diarrhoea NNS N
( ( N
2.2 CD N
% NN N
versus IN N
2.9 CD N
% NN N
) ) N
, , N
nausea/vomiting VBG N
( ( N
1.5 CD N
% NN N
vs. FW N
0.7 CD N
% NN N
) ) N
, , N
abdominal JJ N
pain NN N
( ( N
0.7 CD N
% NN N
vs JJ N
1.5 CD N
% NN N
) ) N
and CC N
skin JJ N
reactions NNS N
( ( N
1.5 CD N
% NN N
vs. FW N
1.1 CD N
% NN N
) ) N
. . N

Overall JJ N
, , N
faropenem JJ N
daloxate NN N
was VBD N
at IN N
least JJS N
as IN N
effective JJ N
clinically NN N
and CC N
bacteriologically RB N
as IN N
cefuroxime NN N
axetil NN N
and CC N
was VBD N
well RB N
tolerated VBN N
. . N

-DOCSTART- -X- O O 11485124

Sulfasalazine NNP N
decreases VBZ N
acute JJ N
gastrointestinal JJ N
complications NNS N
due JJ N
to TO N
pelvic JJ N
radiotherapy NN N
. . N

BACKGROUND NNP N
Radiation-induced NNP N
gastrointestinal JJ N
toxicity NN N
is VBZ N
a DT N
significant JJ N
concern NN N
for IN N
patients NNS N
who WP N
are VBP N
treated VBN N
with IN N
this DT N
modality NN N
for IN N
pelvic JJ 4_p
malignancies NNS 4_p
. . 4_p

Eicosanoids NNS N
and CC N
free JJ N
radicals NNS N
are VBP N
thought VBN N
to TO N
be VB N
among IN N
the DT N
reasons NNS N
for IN N
this DT N
effect NN N
. . N

Sulfasalazine NNP N
is VBZ N
an DT N
inhibitor NN N
of IN N
their PRP$ N
synthesis NN N
in IN N
the DT N
mucosa NN N
. . N

OBJECTlVE NN N
: : N
To TO N
determine VB N
whether IN N
sulfasalazine NN N
can MD N
reduce VB N
the DT N
radiation-induced JJ N
acute JJ N
gastrointestinal JJ N
complications NNS N
. . N

METHODS NNP N
In IN N
this DT N
prospective JJ N
, , N
double-blind JJ N
study NN N
, , N
31 CD N
patients NNS N
receiving VBG N
pelvic JJ 4_p
radiotherapy NN 4_p
were VBD N
randomized VBN N
to TO N
receive VB N
two CD N
sulfasalazine JJ N
500-mg JJ N
tablets NNS N
twice JJ N
daily RB N
or CC N
placebo VB N
, , N
administered VBN N
orally RB N
from IN N
the DT N
first JJ N
day NN N
of IN N
irradiation NN N
. . N

Patients NNS N
were VBD N
evaluated JJ N
weekly JJ N
, , N
and CC N
gastrointestinal JJ N
toxicities NNS N
were VBD N
graded VBN N
according VBG N
to TO N
the DT N
Late JJ N
Effect NNP N
of IN N
Normal NNP N
Tissue-Subjective NNP N
Objective NNP N
Management NNP N
Analytic NNP N
( ( N
LENT-SOMA NNP N
) ) N
toxicity NN N
table NN N
during IN N
pelvic JJ N
radiotherapy NN N
. . N

On IN N
the DT N
last JJ N
day NN N
of IN N
week NN N
5 CD N
, , N
the DT N
subjects NNS N
were VBD N
graded VBN N
endoscopically RB N
, , N
and CC N
biopsies NNS N
taken VBN N
from IN N
the DT N
rectum NN N
were VBD N
classified VBN N
histopathologically RB N
. . N

RESULTS NNP N
Groups NNP N
did VBD N
not RB N
differ VB N
in IN N
age NN N
, , N
gender NN N
, , N
tumor NN N
site NN N
, , N
or CC N
irradiation NN N
procedure NN N
. . N

During IN N
radiotherapy NN N
, , N
grade VBD N
2 CD N
or CC N
higher JJR N
gastrointestinal JJ N
toxicity NN N
occurred VBD N
in IN N
20 CD N
% NN N
( ( N
3/15 CD N
) ) N
and CC N
63 CD N
% NN N
( ( N
10/16 CD N
) ) N
of IN N
the DT N
sulfasalazine NN N
and CC N
placebo NN N
groups NNS N
, , N
respectively RB N
. . N

This DT N
difference NN N
was VBD N
significant JJ N
( ( N
p JJ N
= NNP N
0.017 CD N
) ) N
. . N

No DT N
statistically RB N
significant JJ N
differences NNS N
were VBD N
found VBN N
in IN N
endoscopic NN N
and CC N
histopathologic JJ N
evaluations NNS N
. . N

CONCLUSIONS NNP N
Sulfasalazine NNP N
is VBZ N
effective JJ N
in IN N
decreasing VBG N
clinically RB N
acute JJ N
gastrointestinal JJ N
toxicities NNS N
. . N

Long-term JJ N
follow-up JJ N
with IN N
the DT N
subjects NNS N
will MD N
help VB N
to TO N
determine VB N
the DT N
net JJ N
effect NN N
of IN N
sulfasalazine NN N
on IN N
the DT N
radiation-induced JJ 4_p
gastrointestinal JJ 4_p
injuries NNS 4_p
. . N

-DOCSTART- -X- O O 20237484

Effect NN N
of IN N
topical JJ N
anesthesia NN N
and CC N
age NN N
on IN N
pain NN N
scores NNS N
during IN N
retinopathy NN N
of IN N
prematurity NN N
screening NN N
. . N

OBJECTIVE CC N
The DT N
efficacy NN N
of IN N
topical JJ N
anesthesia NN N
during IN N
retinopathy NN 4_p
of IN 4_p
prematurity NN 4_p
( ( 4_p
ROP NNP 4_p
) ) 4_p
screening NN N
has VBZ N
been VBN N
a DT N
controversial JJ N
issue NN N
. . N

To TO N
determine VB N
the DT N
efficacy NN N
of IN N
proparacaine NN N
eye NN N
drops NNS N
( ( N
0.5 CD N
% NN N
) ) N
, , N
we PRP N
compared VBN N
the DT N
Premature NNP N
Infant NNP N
Pain NNP N
Profile NNP N
( ( N
PIPP NNP N
) ) N
scores VBZ N
in IN N
40 CD N
preterm JJ N
infants NNS N
undergoing VBG N
ROP NNP 4_p
screening NN N
. . N

STUDY NNP N
DESIGN NNP N
Prospective NNP N
randomized VBD N
double JJ N
masked JJ N
cross-over JJ N
clinical JJ N
trial NN N
. . N

The DT N
study NN N
was VBD N
conducted VBN N
in IN N
the DT N
neonatal JJ N
intensive JJ N
units NNS N
for IN N
infants NNS N
undergoing VBG N
routine JJ N
ROP NNP N
screening VBG N
exams NNS N
. . N

Baseline NNP N
PIPP NNP N
scores NNS N
and CC N
post-examination NN N
PIPP NNP N
scores VBZ N
at IN N
1 CD N
and CC N
5 CD N
min NNS N
were VBD N
compared VBN N
for IN N
: : N
( ( N
1 CD N
) ) N
those DT N
receiving VBG N
saline JJ N
vs NN N
proparacaine NN N
eye NN N
drops NNS N
( ( N
2 CD N
) ) N
first RB N
ROP NNP N
screening VBG N
vs JJ N
second JJ N
ROP NNP N
screening NN N
, , N
regardless RB N
of IN N
the DT N
type NN N
of IN N
eye NN N
drops NNS N
used VBN N
. . N

Wilcoxon NNP N
signed-ranks JJ N
test NN N
was VBD N
used VBN N
to TO N
pair VB N
pain NN N
scores NNS N
. . N

RESULT NNP N
Forty NNP N
preterm NN N
infants NNS N
were VBD N
included VBN N
in IN N
the DT N
study NN N
. . N

Mean NNP N
gestational JJ N
age NN N
( ( N
GA NNP N
) ) N
at IN N
first JJ N
and CC N
second JJ N
examinations NNS N
was VBD N
33.3 CD N
and CC N
35.3 CD N
weeks NNS N
, , N
respectively RB N
. . N

Proparacaine NNP N
use VBP N
significantly RB N
lowered VBN N
mean JJ N
PIPP NNP N
scores NNS N
( ( N
P=0.027 NNP N
) ) N
and CC N
delta JJ N
scores NNS N
( ( N
P=0.013 NNP N
) ) N
at IN N
1 CD N
min NN N
after IN N
examination NN N
, , N
but CC N
there EX N
was VBD N
no DT N
difference NN N
at IN N
5 CD N
min NN N
after IN N
examination NN N
. . N

Second JJ N
examinations NNS N
showed VBD N
significantly RB N
lower JJR N
mean JJ N
PIPP NNP N
scores NNS N
after IN N
examination NN N
( ( N
1 CD N
min NN N
( ( N
P=0.003 NNP N
) ) N
and CC N
5 CD N
min NN N
( ( N
P=0.025 NNP N
) ) N
) ) N
, , N
regardless RB N
of IN N
the DT N
type NN N
of IN N
drop NN N
used VBN N
. . N

CONCLUSION NNP N
Proparacaine NNP N
eye NN N
drops NNS N
offer VBP N
significant JJ N
relief NN N
of IN N
pain NN N
that WDT N
is VBZ N
apparently RB N
short JJ N
lived VBD N
. . N

Significantly NNP N
lower JJR N
PIPP NNP N
scores NNS N
at IN N
second JJ N
ROP NNP N
examinations NNS N
suggested VBD N
that IN N
infants NNS N
of IN N
older JJR N
GA NNP N
may MD N
have VB N
a DT N
greater JJR N
ability NN N
to TO N
tolerate VB N
ROP NNP N
screening VBG N
. . N

We PRP N
recommend VBP N
the DT N
use NN N
of IN N
proparacaine NN N
eye NN N
drops NNS N
for IN N
the DT N
short JJ N
term NN N
, , N
immediate JJ N
relief NN N
of IN N
pain NN N
during IN N
ROP NNP N
screening VBG N
in IN N
preterm JJ N
infants NNS N
of IN N
lesser JJR N
GA NNP N
. . N

-DOCSTART- -X- O O 23562009

Daclizumab NNP N
high-yield JJ N
process NN N
in IN N
relapsing-remitting JJ 4_p
multiple JJ 4_p
sclerosis NN 4_p
( ( 4_p
SELECT NNP 4_p
) ) 4_p
: : 4_p
a DT N
randomised JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
trial NN N
. . N

BACKGROUND NNP N
Daclizumab NNP N
, , N
a DT N
humanised JJ N
monoclonal NN N
antibody NN N
, , N
modulates VBZ N
interleukin-2 JJ N
signalling NN N
by IN N
blocking VBG N
the DT N
α NN N
subunit NN N
( ( N
CD25 NNP N
) ) N
of IN N
the DT N
interleukin-2 JJ N
receptor NN N
. . N

We PRP N
assessed VBD N
whether IN N
daclizumab JJ N
high-yield JJ N
process NN N
( ( N
HYP NNP N
) ) N
would MD N
be VB N
effective JJ N
when WRB N
given VBN N
as IN N
monotherapy NN N
for IN N
a DT N
1 CD N
year NN N
treatment NN N
period NN N
in IN N
patients NNS 4_p
with IN 4_p
relapsing-remitting JJ 4_p
multiple JJ 4_p
sclerosis NN 4_p
. . N

METHODS NNP N
We PRP N
did VBD N
a DT N
randomised VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
trial NN N
at IN N
76 CD N
centres NNS N
in IN N
the DT N
Czech NNP N
Republic NNP N
, , N
Germany NNP N
, , N
Hungary NNP N
, , N
India NNP N
, , N
Poland NNP N
, , N
Russia NNP N
, , N
Ukraine NNP N
, , N
Turkey NNP N
, , N
and CC N
the DT N
UK NNP N
between IN N
Feb NNP N
15 CD N
, , N
2008 CD N
, , N
and CC N
May NNP N
14 CD N
, , N
2010 CD N
. . N

Patients NNS N
aged VBN N
18-55 JJ N
years NNS N
with IN N
relapsing-remitting JJ 4_p
multiple JJ 4_p
sclerosis NN 4_p
were VBD N
randomly RB N
assigned VBN N
( ( N
1:1:1 CD N
) ) N
, , N
via IN N
a DT N
central JJ N
interactive JJ N
voice NN N
response NN N
system NN N
, , N
to TO N
subcutaneous JJ N
injections NNS N
of IN N
daclizumab NN N
HYP NNP N
150 CD N
mg NN N
or CC N
300 CD N
mg NN N
, , N
or CC N
placebo NN N
, , N
every DT N
4 CD N
weeks NNS N
for IN N
52 CD N
weeks NNS N
. . N

Patients NNS N
and CC N
study NN N
personnel NNS N
were VBD N
masked VBN N
to TO N
treatment NN N
assignment NN N
, , N
except IN N
for IN N
the DT N
site NN N
pharmacist NN N
who WP N
prepared VBD N
the DT N
study NN N
drug NN N
for IN N
injection NN N
, , N
but CC N
had VBD N
no DT N
interaction NN N
with IN N
the DT N
patient NN N
. . N

The DT N
primary JJ N
endpoint NN N
was VBD N
annualised VBN N
relapse NN N
rate NN N
. . N

Analysis NN N
was VBD N
by IN N
intention NN N
to TO N
treat VB N
. . N

The DT N
trial NN N
is VBZ N
registered VBN N
with IN N
ClinicalTrials.gov NNP N
, , N
number NN N
NCT00390221 NNP N
. . N

FINDINGS NNP N
204 CD N
patients NNS N
were VBD N
assigned VBN 4_p
to TO 4_p
receive VB 4_p
placebo NN 4_p
, , N
208 CD N
to TO N
daclizumab VB 4_p
HYP NNP 4_p
150 CD 4_p
mg NN 4_p
, , N
and CC N
209 CD N
to TO N
daclizumab VB 4_p
HYP NNP N
300 CD N
mg NN N
, , N
of IN N
whom WP N
188 CD N
( ( N
92 CD N
% NN N
) ) N
, , N
192 CD N
( ( N
92 CD N
% NN N
) ) N
, , N
and CC N
197 CD N
( ( N
94 CD N
% NN N
) ) N
, , N
respectively RB N
, , N
completed VBD N
follow-up NN N
to TO N
week NN N
52 CD N
. . N

The DT N
annualised JJ N
relapse NN N
rate NN N
was VBD N
lower JJR N
for IN N
patients NNS N
given VBN N
daclizumab JJ N
HYP NNP N
150 CD N
mg NN N
( ( N
0·21 CD N
, , N
95 CD N
% NN N
CI NNP N
0·16-0·29 NN N
; : N
54 CD N
% NN N
reduction NN N
, , N
95 CD N
% NN N
CI NNP N
33-68 CD N
% NN N
; : N
p CC N
< VB N
0·0001 CD N
) ) N
or CC N
300 CD N
mg NN N
( ( N
0·23 CD N
, , N
0·17-0·31 CD N
, , N
50 CD N
% NN N
reduction NN N
, , N
28-65 JJ N
% NN N
; : N
p=0·00015 NN N
) ) N
than IN N
for IN N
those DT N
given VBN N
placebo NNS N
( ( N
0·46 CD N
, , N
0·37-0·57 NN N
) ) N
. . N

More JJR N
patients NNS N
were VBD N
relapse JJ N
free JJ N
in IN N
the DT N
daclizumab NN N
HYP NNP N
150 CD N
mg NN N
( ( N
81 CD N
% NN N
) ) N
and CC N
300 CD N
mg NN N
( ( N
80 CD N
% NN N
) ) N
groups NNS N
than IN N
in IN N
the DT N
placebo NN N
group NN N
( ( N
64 CD N
% NN N
; : N
p CC N
< $ N
0·0001 CD N
in IN N
the DT N
150 CD N
mg NN N
group NN N
and CC N
p=0·0003 NN N
in IN N
the DT N
300 CD N
mg NNS N
group NN N
) ) N
. . N

12 CD N
( ( N
6 CD N
% NN N
) ) N
patients NNS N
in IN N
the DT N
placebo NN N
group NN N
, , N
15 CD N
( ( N
7 CD N
% NN N
) ) N
of IN N
those DT N
in IN N
the DT N
daclizumab NN N
150 CD N
mg NN N
group NN N
, , N
and CC N
19 CD N
( ( N
9 CD N
% NN N
) ) N
in IN N
the DT N
300 CD N
mg NN N
group NN N
had VBD N
serious JJ N
adverse JJ N
events NNS N
excluding VBG N
multiple JJ N
sclerosis NN N
relapse NN N
. . N

One CD N
patient NN N
given VBN N
daclizumab JJ N
HYP NNP N
150 CD N
mg NN N
who WP N
was VBD N
recovering VBG N
from IN N
a DT N
serious JJ N
rash NN N
died VBD N
because IN N
of IN N
local JJ N
complication NN N
of IN N
a DT N
psoas NN N
abscess NN N
. . N

INTERPRETATION NNP N
Subcutaneous NNP N
daclizumab NN N
HYP NNP N
administered VBD N
every DT N
4 CD N
weeks NNS N
led VBD N
to TO N
clinically RB N
important JJ N
effects NNS N
on IN N
multiple JJ N
sclerosis NN N
disease NN N
activity NN N
during IN N
1 CD N
year NN N
of IN N
treatment NN N
. . N

Our PRP$ N
findings NNS N
support VB N
the DT N
potential NN N
for IN N
daclizumab NN N
HYP NNP N
to TO N
offer VB N
an DT N
additional JJ N
treatment NN 4_p
option NN 4_p
for IN 4_p
relapsing-remitting JJ 4_p
disease NN N
. . N

FUNDING NN N
Biogen NNP N
Idec NNP N
and CC N
AbbVie NNP N
Biotherapeutics NNP N
Inc NNP N
. . N

-DOCSTART- -X- O O 24675775

The DT N
effect NN N
of IN N
modified VBN N
eggs NNS N
and CC N
an DT N
egg-yolk NN N
based VBN N
beverage NN N
on IN N
serum NN 4_p
lutein NN 4_p
and CC 4_p
zeaxanthin JJ 4_p
concentrations NNS 4_p
and CC N
macular JJ N
pigment NN N
optical JJ N
density NN N
: : N
results NNS N
from IN N
a DT N
randomized JJ N
trial NN N
. . N

UNLABELLED CC N
Increasing VBG N
evidence NN N
suggests VBZ N
a DT N
beneficial JJ N
effect NN N
of IN N
lutein NN N
and CC N
zeaxanthin NN N
on IN N
the DT N
progression NN N
of IN N
age-related JJ N
macular JJ N
degeneration NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
effect NN N
of IN N
lutein NN N
or CC N
zeaxanthin NN N
enriched VBN N
eggs NNS N
or CC N
a DT N
lutein JJ N
enriched VBN N
egg-yolk NN N
based VBN N
buttermilk NN N
beverage NN N
on IN N
serum NN N
lutein NN N
and CC N
zeaxanthin JJ N
concentrations NNS N
and CC N
macular JJ N
pigment NN N
levels NNS N
. . N

Naturally RB N
enriched VBN N
eggs NNS N
were VBD N
made VBN N
by IN N
increasing VBG N
the DT N
levels NNS N
of IN N
the DT N
xanthophylls NNP N
lutein NN N
and CC N
zeaxanthin NN N
in IN N
the DT N
feed NN N
given VBN N
to TO N
laying VBG N
hens NNS N
. . N

One CD N
hundred VBD N
healthy JJ 4_p
volunteers NNS N
were VBD N
recruited VBN N
and CC N
randomized VBN N
into IN N
5 CD N
groups NNS N
for IN N
90 CD N
days NNS N
. . N

Group NNP N
one CD N
added VBD N
one CD N
normal JJ N
egg NN N
to TO N
their PRP$ N
daily JJ N
diet NNS N
and CC N
group NN N
two CD N
received VBD N
a DT N
lutein NN N
enriched VBD N
egg-yolk NN N
based VBN N
beverage NN N
. . N

Group NNP N
three CD N
added VBD N
one CD N
lutein NN N
enriched VBD N
egg NN N
and CC N
group NN N
four CD N
one CD N
zeaxanthin NN N
enriched VBD N
egg NN N
to TO N
their PRP$ N
diet JJ N
. . N

Group NNP N
five CD N
was VBD N
the DT N
control NN N
group NN N
and CC N
individuals NNS N
in IN N
this DT N
group NN N
did VBD N
not RB N
modify VB N
their PRP$ N
daily JJ N
diet NN N
. . N

Serum NNP N
lutein NN N
and CC N
zeaxanthin JJ N
concentrations NNS N
and CC N
macular JJ N
pigment NN N
densities NNS N
were VBD N
obtained VBN N
at IN N
baseline NN N
, , N
day NN N
45 CD N
and CC N
day NN N
90 CD N
. . N

Macular JJ N
pigment NN N
density NN N
was VBD N
measured VBN N
by IN N
heterochromatic JJ N
flicker NN N
photometry NN N
. . N

Serum NNP N
lutein JJ N
concentration NN N
in IN N
the DT N
lutein NN N
enriched VBD N
egg NN N
and CC N
egg NN N
yolk-based JJ N
beverage NN N
groups NNS N
increased VBD N
significantly RB N
( ( N
p JJ N
< NN N
0.001 CD N
, , N
76 CD N
% NN N
and CC N
77 CD N
% NN N
) ) N
. . N

A DT N
strong JJ N
increase NN N
in IN N
the DT N
serum NN N
zeaxanthin NN N
concentration NN N
was VBD N
observed VBN N
in IN N
individuals NNS N
receiving VBG N
zeaxanthin NN N
enriched VBN N
eggs NNS N
( ( N
P NNP N
< NNP N
0.001 CD N
, , N
430 CD N
% NN N
) ) N
. . N

No UH N
changes NNS N
were VBD N
observed VBN N
in IN N
macular JJ N
pigment NN N
density NN N
in IN N
the DT N
various JJ N
groups NNS N
tested VBN N
. . N

The DT N
results NNS N
indicate VBP N
that IN N
daily JJ N
consumption NN N
of IN N
lutein NN N
or CC N
zeaxanthin NN N
enriched VBN N
egg NN N
yolks NNS N
as RB N
well RB N
as IN N
an DT N
egg NN N
yolk-based JJ N
beverage NN N
show NN N
increases VBZ N
in IN N
serum NN N
lutein NN N
and CC N
zeaxanthin NN N
levels NNS N
that WDT N
are VBP N
comparable JJ N
with IN N
a DT N
daily JJ N
use NN N
of IN N
5 CD N
mg NN N
supplements NNS N
. . N

TRIAL NNP N
REGISTRATION NNP N
ClinicalTrials.gov NNP N
NCT00527553 NNP N
. . N

-DOCSTART- -X- O O 8403942

[ VB N
The DT N
effect NN N
of IN N
indobufen NN N
on IN N
aortocoronary JJ 4_p
bypass NN 4_p
patency NN 4_p
after IN N
1 CD N
week NN N
and CC N
after IN N
1 CD N
year NN N
] NN N
. . N

A DT N
randomized JJ N
clinical JJ N
study NN N
was VBD N
conducted VBN N
to TO N
compare VB N
the DT N
effect NN N
of IN N
" NNP N
conventional JJ N
" NNP N
antiaggregation NN N
therapy NN N
( ( N
ASA NNP N
plus CC N
dipyridamole NN N
) ) N
versus NN N
indobufen NN N
in IN N
patients NNS 4_p
after IN 4_p
aortocoronary JJ 4_p
bypass NN 4_p
( ( 4_p
ACB NNP 4_p
) ) 4_p
surgery NN 4_p
. . 4_p

The DT N
patency NN N
of IN N
venous JJ N
ACB NNP N
using VBG N
coronary JJ N
DSA NNP N
one CD N
week NN N
and CC N
one CD N
year NN N
after IN N
surgery NN N
was VBD N
evaluated VBN N
in IN N
52 CD N
patients NNS N
divided VBN N
into IN N
two CD N
groups NNS N
. . N

The DT N
study NN N
included VBD N
only RB N
ACB NNP N
's POS N
with IN N
intraoperative JJ N
blood NN N
flow NN N
rates NNS N
< VBP N
or CC N
= VBP N
40 CD N
ml/min NN N
as IN N
it PRP N
is VBZ N
just RB N
these DT N
ACB NNP N
's POS N
which WDT N
are VBP N
at IN N
the DT N
highest JJS N
risk NN N
of IN N
early JJ N
and CC N
late JJ N
occlusions NNS N
. . N

While IN N
, , N
in IN N
the DT N
ASA NNP N
plus CC N
dipyridamole-treated JJ N
group NN N
, , N
occlusions NNS N
were VBD N
found VBN N
in IN N
11 CD N
of IN N
the DT N
39 CD N
reconstructions NNS N
( ( N
28.2 CD N
% NN N
) ) N
, , N
the DT N
proportion NN N
was VBD N
nine CD N
out IN N
of IN N
37 CD N
procedures NNS N
( ( N
24.3 CD N
% NN N
) ) N
in IN N
the DT N
indobufen NN N
group NN N
. . N

One CD N
year NN N
after IN N
surgery NN N
, , N
occlusion NN N
was VBD N
found VBN N
in IN N
14 CD N
out IN N
of IN N
32 CD N
ACB NNP N
's POS N
( ( N
43.7 CD N
% NN N
) ) N
in IN N
the DT N
ASA NNP N
plus CC N
dipyridamole JJ N
group NN N
compared VBN N
to TO N
14 CD N
occlusions NNS N
in IN N
31 CD N
ACB NNP N
's POS N
( ( N
45.2 CD N
% NN N
) ) N
in IN N
the DT N
indobufen NN N
group NN N
. . N

The DT N
difference NN N
in IN N
the DT N
number NN N
of IN N
occlusions NNS N
between IN N
the DT N
two CD N
groups NNS N
was VBD N
not RB N
statistically RB N
significant JJ N
. . N

Because IN N
of IN N
some DT N
benefits NNS N
of IN N
indobufen NN N
compared VBN N
to TO N
ASA NNP N
( ( N
shorter JJR N
time NN N
of IN N
effect NN N
, , N
superior JJ N
tolerance NN N
in IN N
patients NNS N
with IN N
ulceration NN N
) ) N
, , N
the DT N
former JJ N
drug NN N
can MD N
be VB N
recommended VBN N
for IN N
use NN N
in IN N
some DT N
indicated JJ N
cases NNS N
. . N

-DOCSTART- -X- O O 18431444

A DT N
simplified JJ N
4-site JJ N
economical JJ N
intradermal JJ N
post-exposure NN N
rabies NNS 4_p
vaccine VBP 4_p
regimen NNS 4_p
: : N
a DT N
randomised JJ N
controlled VBN N
comparison NN N
with IN N
standard JJ N
methods NNS N
. . N

BACKGROUND IN N
The DT N
need NN N
for IN N
economical JJ N
rabies NNS 4_p
post-exposure JJ N
prophylaxis NN N
( ( N
PEP NNP N
) ) N
is VBZ N
increasing VBG N
in IN N
developing VBG N
countries NNS N
. . N

Implementation NN N
of IN N
the DT N
two CD N
currently RB N
approved VBN N
economical JJ N
intradermal NN N
( ( N
ID NNP N
) ) N
vaccine NN N
regimens VBZ N
is VBZ N
restricted VBN N
due JJ N
to TO N
confusion NN N
over IN N
different JJ N
vaccines NNS N
, , N
regimens NNS N
and CC N
dosages NNS N
, , N
lack NN N
of IN N
confidence NN N
in IN N
intradermal JJ N
technique NN N
, , N
and CC N
pharmaceutical JJ N
regulations NNS N
. . N

We PRP N
therefore RB N
compared VBN N
a DT N
simplified JJ N
4-site JJ N
economical JJ N
PEP NNP N
regimen NNS N
with IN N
standard JJ N
methods NNS N
. . N

METHODS NNP N
Two CD N
hundred VBD N
and CC N
fifty-four JJ N
volunteers NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
a DT N
single JJ N
blind NN N
controlled VBD N
trial NN N
. . N

Each DT N
received VBD N
purified JJ N
vero NN N
cell NN N
rabies NNS N
vaccine VBP N
by IN N
one CD N
of IN N
four CD N
PEP NNP N
regimens NNS N
: : N
the DT N
currently RB N
accepted VBN N
2-site JJ N
ID NNP N
; : N
the DT N
8-site JJ N
regimen NNS N
using VBG N
0.05 CD N
ml JJ N
per IN N
ID NNP N
site NN N
; : N
a DT N
new JJ N
4-site JJ N
ID NNP N
regimen NNS N
( ( N
on IN N
day NN N
0 CD N
, , N
approximately RB N
0.1 CD N
ml NNS N
at IN N
4 CD N
ID NNP N
sites NNS N
, , N
using VBG N
the DT N
whole JJ N
0.5 CD N
ml JJ N
ampoule NN N
of IN N
vaccine NN N
; : N
on IN N
day NN N
7 CD N
, , N
0.1 CD N
ml NN N
ID NNP N
at IN N
2 CD N
sites NNS N
and CC N
at IN N
one CD N
site NN N
on IN N
days NNS N
28 CD N
and CC N
90 CD N
) ) N
; : N
or CC N
the DT N
standard JJ N
5-dose JJ N
intramuscular JJ N
regimen NNS N
. . N

All DT N
ID NNP N
regimens NNS N
required VBD N
the DT N
same JJ N
total JJ N
amount NN N
of IN N
vaccine NN N
, , N
60 CD N
% NN N
less JJR N
than IN N
the DT N
intramuscular JJ N
method NN N
. . N

Neutralising VBG N
antibody NN N
responses NNS N
were VBD N
measured VBN N
five CD N
times NNS N
over IN N
a DT N
year NN N
in IN N
229 CD N
people NNS N
, , N
for IN N
whom WP N
complete JJ N
data NNS N
were VBD N
available JJ N
. . N

FINDINGS NNP N
All NNP N
ID NNP N
regimens VBZ N
showed VBD N
similar JJ N
immunogenicity NN N
. . N

The DT N
intramuscular JJ N
regimen NNS N
gave VBD N
the DT N
lowest JJS N
geometric JJ N
mean NN N
antibody NN N
titres NNS N
. . N

Using VBG N
the DT N
rapid JJ N
fluorescent JJ N
focus NN N
inhibition NN N
test NN N
, , N
some DT N
sera NN N
had VBD N
unexpectedly RB N
high JJ N
antibody NN N
levels NNS N
that WDT N
were VBD N
not RB N
attributable JJ N
to TO N
previous JJ N
vaccination NN N
. . N

The DT N
results NNS N
were VBD N
confirmed VBN N
using VBG N
the DT N
fluorescent NN N
antibody NN N
virus JJ N
neutralisation NN N
method NN N
. . N

CONCLUSIONS VB N
This DT N
4-site JJ N
PEP NNP N
regimen NNS N
proved VBD N
as RB N
immunogenic JJ N
as IN N
current JJ N
regimens NNS N
, , N
and CC N
has VBZ N
the DT N
advantages NNS N
of IN N
requiring VBG N
fewer JJR N
clinic JJ N
visits NNS N
, , N
being VBG N
more RBR N
practicable JJ N
, , N
and CC N
having VBG N
a DT N
wider JJR N
margin NN N
of IN N
safety NN N
, , N
especially RB N
in IN N
inexperienced JJ N
hands NNS N
, , N
than IN N
the DT N
2-site JJ N
regimen NNS N
. . N

It PRP N
is VBZ N
more RBR N
convenient JJ N
than IN N
the DT N
8-site JJ N
method NN N
, , N
and CC N
can MD N
be VB N
used VBN N
economically RB N
with IN N
vaccines NNS N
formulated VBN N
in IN N
1.0 CD N
or CC N
0.5 CD N
ml NN N
ampoules NNS N
. . N

The DT N
4-site JJ N
regimen NNS N
now RB N
meets VBZ N
all DT N
requirements NNS N
of IN N
immunogenicity NN N
for IN N
PEP NNP N
and CC N
can MD N
be VB N
introduced VBN N
without IN N
further JJ N
studies NNS N
. . N

TRIAL NNP N
REGISTRATION NNP N
Controlled-Trials.com NNP N
ISRCTN NNP N
30087513 CD N
. . N

-DOCSTART- -X- O O 1878735

Human NNP N
recombinant JJ N
GM-CSF NNP N
in IN N
allogeneic JJ N
bone NN N
marrow NN N
transplantation NN N
for IN N
leukaemia NN N
: : N
double-blind JJ N
placebo NN N
controlled VBN N
trial NN N
. . N

A DT N
double-blind NN N
randomised VBN N
trial NN N
compared VBN N
20 CD N
patients NNS N
with IN N
leukaemia JJ 4_p
receiving VBG N
human JJ N
recombinant JJ N
granulocyte NN N
macrophage NN N
colony NN N
stimulating VBG N
factor NN N
( ( N
GM NNP N
CSF NNP N
) ) N
, , N
with IN N
20 CD N
patients NNS N
receiving VBG N
placebo NN N
for IN N
14 CD N
days NNS N
after IN N
allogeneic JJ N
matched VBD N
sibling VBG N
bone NN N
marrow NN N
transplantation NN N
. . N

The DT N
median JJ N
neutrophil NN N
count NN N
at IN N
14 CD N
days NNS N
was VBD N
significantly RB N
higher JJR N
in IN N
the DT N
GM NNP N
CSF NNP N
group NN N
( ( N
1.90 CD N
vs. FW N
0.46 CD N
x $ N
10 CD N
( ( N
9 CD N
) ) N
/l NN N
) ) N
. . N

The DT N
duration NN N
of IN N
hospital NN N
stay NN N
, , N
the DT N
number NN N
of IN N
antibiotic JJ N
days NNS N
, , N
and CC N
the DT N
number NN N
of IN N
fever JJ N
days NNS N
was VBD N
the DT N
same JJ N
for IN N
both DT N
patient JJ N
groups NNS N
. . N

The DT N
lymphocyte NN N
count NN N
was VBD N
significantly RB N
higher JJR N
in IN N
the DT N
GM-CSF NNP N
group NN N
than IN N
in IN N
the DT N
placebo NN N
group NN N
between IN N
days NNS N
10 CD N
and CC N
15 CD N
after IN N
transplantation NN N
. . N

The DT N
GM-CSF NNP N
group NN N
had VBD N
lower JJR N
haemoglobin NN N
concentrations NNS N
and CC N
platelets NNS N
counts NNS N
, , N
and CC N
higher JJR N
plasma NN N
urea JJ N
creatinine NN N
and CC N
bilirubin NN N
, , N
than IN N
the DT N
placebo NN N
group NN N
. . N

There EX N
was VBD N
no DT N
evidence NN N
that IN N
GM NNP N
CSF NNP N
was VBD N
associated VBN N
with IN N
a DT N
greater JJR N
incidence NN N
of IN N
leukaemic JJ N
relapse NN N
. . N

-DOCSTART- -X- O O 10203382

Predictors NNS N
of IN N
survival NN N
and CC N
eradication NN N
of IN N
Mycobacterium NNP N
avium NN N
complex NN N
bacteremia NN N
( ( N
MAC NNP N
) ) N
in IN N
AIDS NNP 4_p
patients NNS N
in IN N
the DT N
Canadian NNP N
randomized VBD N
MAC NNP N
treatment NN N
trial NN N
. . N

Canadian JJ N
HIV NNP N
Trials NNP N
Network NNP N
Protocol NNP N
010 CD N
Study NNP N
Group NNP N
. . N

OBJECTIVE NNP N
To TO N
assess VB N
the DT N
importance NN N
of IN N
baseline NN N
characteristics NNS N
including VBG N
medical JJ N
history NN N
, , N
indicators NNS N
of IN N
current JJ N
disease NN N
status NN N
, , N
therapeutic JJ N
drug NN N
use NN N
, , N
in IN N
vitro JJ N
drug NN N
susceptibility NN N
, , N
immune JJ N
status NN N
and CC N
mycobacterial JJ N
load NN N
on IN N
bacteriologic JJ N
response NN N
and CC N
survival NN N
in IN N
HIV-positive JJ 4_p
patients NNS N
with IN N
Mycobacterium NNP 4_p
avium NN 4_p
complex NN 4_p
( ( 4_p
MAC NNP 4_p
) ) 4_p
bacteremia NN 4_p
. . N

DESIGN NNP N
An DT N
observational JJ N
substudy NN N
of IN N
an DT N
open-label JJ N
randomized NN N
controlled VBD N
trial NN N
of IN N
two CD N
alternative JJ N
therapeutic JJ N
regimens NNS N
for IN N
MAC NNP N
. . N

SETTING NNP N
Twenty-four JJ N
hospital-based JJ N
HIV NNP N
clinics NNS N
in IN N
16 CD N
Canadian JJ N
cities NNS N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
The DT N
main JJ N
outcome NN N
measures NNS N
were VBD N
survival JJ N
and CC N
bacteriologic JJ N
response NN N
, , N
defined VBN N
by IN N
consecutive JJ N
negative JJ N
blood NN N
cultures NNS N
for IN N
MAC NNP N
at IN N
least JJS N
2 CD N
weeks NNS N
apart RB N
within IN N
16 CD N
weeks NNS N
of IN N
study NN N
entry NN N
. . N

RESULTS NNP N
Prior NNP N
AIDS NNP N
diagnosis NN N
, , N
low JJ N
Karnofsky NNP N
score NN N
, , N
active JJ N
unstable JJ N
AIDS-related JJ N
conditions NNS N
, , N
absence NN N
of IN N
antiretroviral JJ N
therapy NN N
and CC N
absence NN N
of IN N
Pneumocystis NNP N
carinii NN N
pneumonia NN N
prophylaxis NN N
were VBD N
associated VBN N
with IN N
shorter JJR N
survival NN N
by IN N
univariate JJ N
regression NN N
using VBG N
the DT N
proportional JJ N
hazards NNS N
model NN N
. . N

On IN N
multivariate NN N
analysis NN N
, , N
antiretroviral JJ N
therapy NN N
was VBD N
not RB N
an DT N
independent JJ N
predictor NN N
of IN N
mortality NN N
, , N
and CC N
previous JJ N
rifabutin NN N
prophylaxis NN N
was VBD N
independently RB N
associated VBN N
with IN N
poor JJ N
survival NN N
outcomes NNS N
, , N
a DT N
result NN N
consistent JJ N
across IN N
study NN N
treatment NN N
. . N

Using VBG N
a DT N
logistic JJ N
regression NN N
model NN N
, , N
baseline JJ N
quantitative JJ N
mycobacterial JJ N
load NN N
[ NNP N
relative JJ N
odds NNS N
of IN N
clearing NN N
, , N
1.97 CD N
for IN N
a DT N
decrease NN N
of IN N
1 CD N
log10 JJ N
colony NN N
forming VBG N
count NN N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
, , N
1.36-2.87 JJ N
; : N
P NNP N
< VBD N
0.001 CD N
] NN N
and CC N
Karnofsky NNP N
score NN N
were VBD N
the DT N
only JJ N
statistically RB N
significant JJ N
univariate JJ N
predictors NNS N
of IN N
clearance NN N
, , N
although IN N
previous JJ N
prophylaxis NN N
with IN N
rifabutin NN N
was VBD N
also RB N
a DT N
significant JJ N
predictor NN N
in IN N
a DT N
multivariate NN N
model NN N
( ( N
relative JJ N
odds NNS N
of IN N
clearing NN N
, , N
0.39 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.17-0.88 NNP N
; : N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSIONS VB N
This DT N
study NN N
indicates VBZ N
that IN N
although IN N
the DT N
level NN N
of IN N
MAC NNP N
bacteremia NN N
is VBZ N
an DT N
important JJ N
predictor NN N
of IN N
clearance NN N
, , N
it PRP N
is VBZ N
not RB N
associated VBN N
with IN N
survival NN N
. . N

-DOCSTART- -X- O O 9683400

The DT N
effect NN N
of IN N
quality NN N
and CC N
amount NN N
of IN N
dietary JJ N
fat NN N
on IN N
the DT N
susceptibility NN N
of IN N
low JJ N
density NN N
lipoprotein NN N
to TO N
oxidation NN N
in IN N
subjects NNS N
with IN N
impaired JJ 4_p
glucose JJ 4_p
tolerance NN 4_p
. . N

OBJECTIVES IN N
We PRP N
examined VBD N
the DT N
effects NNS N
of IN N
a DT N
high JJ N
fat NN N
diet JJ N
rich JJ N
in IN N
monounsaturated JJ N
fat NN N
( ( N
MUFA-diet NNP N
) ) N
and CC N
a DT N
moderate JJ N
fat NN N
diet JJ N
rich JJ N
in IN N
polyunsaturated JJ N
fat NN N
( ( N
PUFA-diet NNP N
) ) N
on IN N
the DT N
susceptibility NN N
of IN N
LDL NNP N
to TO N
oxidation NN N
. . N

SUBJECTS NNP N
29 CD N
subjects NNS N
with IN N
impaired JJ N
glucose JJ N
tolerance NN N
. . N

METHODS NNP N
After IN N
consuming VBG N
a DT N
run-in JJ N
diet JJ N
[ FW N
37 CD N
% NN N
of IN N
energy NN N
( ( N
E NNP N
% NN N
) ) N
fat NN N
, , N
18 CD N
E NNP N
% NN N
saturated VBD N
fat JJ N
] NN N
for IN N
three CD N
weeks NNS N
, , N
subjects NNS N
were VBD N
randomly RB N
assigned VBN N
either RB N
to TO N
a DT N
MUFA-diet JJ N
( ( N
40 CD N
E NNP N
% NN N
fat NN N
, , N
19 CD N
E NNP N
% NN N
monounsaturated VBD N
fatty JJ N
acids NNS N
) ) N
or CC N
a DT N
PUFA-diet JJ N
( ( N
34 CD N
E NNP N
% NN N
fat NN N
, , N
10 CD N
E NNP N
% NN N
polyunsaturated VBD N
fat NN N
) ) N
for IN N
eight CD N
weeks NNS N
. . N

The DT N
susceptibility NN N
of IN N
LDL NNP N
to TO N
oxidation NN N
was VBD N
measured VBN N
by IN N
challenging VBG N
LDL NNP N
with IN N
hemin NN N
and CC N
H2O2 NNP N
and CC N
measuring VBG N
the DT N
time NN N
for IN N
the DT N
reaction NN N
to TO N
reach VB N
maximum JJ N
velocity NN N
. . N

Results NNS N
are VBP N
expressed VBN N
as IN N
lag NN N
time NN N
to TO N
oxidation NN N
in IN N
minutes NNS N
. . N

RESULTS NNP N
In IN N
the DT N
PUFA-diet JJ N
group NN N
( ( N
n JJ N
= NNP N
15 CD N
) ) N
lag NN N
time NN N
tended VBD N
to TO N
decrease VB N
during IN N
the DT N
experimental JJ N
diet NN N
( ( N
97 CD N
+/- JJ N
28 CD N
vs JJ N
90 CD N
+/- JJ N
25 CD N
min NN N
, , N
mean JJ N
+/- JJ N
s.d. NN N
, , N
P NNP N
= NNP N
0.073 CD N
) ) N
, , N
whereas RB N
in IN N
the DT N
MUFA-diet JJ N
group NN N
( ( N
n JJ N
= NNP N
14 CD N
) ) N
there EX N
was VBD N
no DT N
significant JJ N
change NN N
( ( N
lag JJ N
time NN N
96 CD N
+/- JJ N
24 CD N
vs JJ N
100 CD N
+/- JJ N
16 CD N
min NN N
, , N
P NNP N
= NNP N
0.408 CD N
) ) N
. . N

The DT N
mean JJ N
change NN N
in IN N
lag NN N
time NN N
was VBD N
-7 JJ N
+/- JJ N
14 CD N
min NN N
( ( N
-7.2 CD N
% NN N
) ) N
in IN N
the DT N
PUFA-diet JJ N
group NN N
and CC N
+4 VBZ N
+/- JJ N
16 CD N
min NN N
( ( N
+4.0 CD N
% NN N
) ) N
in IN N
the DT N
MUFA-diet JJ N
group NN N
( ( N
P NNP N
= NNP N
0.029 CD N
, , N
PUFA-diet JJ N
group NN N
vs VBD N
MUFA-diet NNP N
group NN N
) ) N
. . N

The DT N
alpha-tocopherol JJ N
concentration NN N
in IN N
LDL NNP N
increased VBD N
significantly RB N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
in IN N
both DT N
diet JJ N
groups NNS N
relative VBP N
to TO N
the DT N
run-in JJ N
diet JJ N
period NN N
, , N
but CC N
LDL NNP N
particle VBD N
score RB N
did VBD N
not RB N
change VB N
in IN N
either DT N
of IN N
the DT N
diet JJ N
groups NNS N
during IN N
the DT N
dietary JJ N
intervention NN N
. . N

In IN N
subjects NNS N
with IN N
impaired JJ N
glucose JJ N
tolerance NN N
a DT N
PUFA-rich JJ N
diet NN N
with IN N
a DT N
moderate JJ N
amount NN N
of IN N
fat NN N
tended VBN N
to TO N
increase VB N
the DT N
susceptibility NN N
of IN N
LDL NNP N
to TO N
oxidation NN N
as IN N
compared VBN N
to TO N
a DT N
higher JJR N
fat JJ N
diet JJ N
rich NN N
in IN N
MUFA NNP N
. . N

Furthermore NNP N
, , N
the DT N
negative JJ N
mean NN N
change NN N
in IN N
lag NN N
time NN N
to TO N
oxidation NN N
found VBN N
in IN N
the DT N
PUFA-diet JJ N
group NN N
differed VBD N
significantly RB N
from IN N
the DT N
slightly RB N
positive JJ N
mean NN N
change NN N
found VBD N
in IN N
the DT N
MUFA-diet JJ N
group NN N
. . N

-DOCSTART- -X- O O 15481334

Effect NN N
of IN N
ibuprofen NN N
on IN N
cyclooxygenase NN N
and CC N
nitric JJ N
oxide JJ N
synthase NN N
of IN N
gastric JJ N
mucosa NN N
: : N
correlation NN N
with IN N
endoscopic JJ N
lesions NNS N
and CC N
adverse JJ N
reactions NNS N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
effect NN N
of IN N
ibuprofen NN N
on IN N
gastric JJ N
mucosa NN N
and CC N
enzymes NNS N
involved VBN N
in IN N
gastroprotection NN N
in IN N
healthy JJ 4_p
volunteers NNS N
. . N

Twenty-four JJ N
Helicobacter NNP 4_p
pylori-negative JJ 4_p
subjects NNS N
were VBD N
randomized VBN N
to TO N
treatment NN N
with IN N
ibuprofen NN N
or CC N
ibuprofen-arginate NN N
( ( N
each DT N
600 CD N
mg/6 NN N
hr NN N
during IN N
3 CD N
days NNS N
) ) N
. . N

Endoscopies NNS N
were VBD N
performed VBN N
1 CD N
week NN N
before IN N
and CC N
after IN N
treatment NN N
. . N

Biopsies NNS N
were VBD N
taken VBN N
from IN N
the DT N
gastric JJ N
antrum NN N
and CC N
corpus NN N
for IN N
determination NN N
of IN N
prostaglandin NN N
E2 NNP N
( ( N
PGE2 NNP N
) ) N
by IN N
ELISA NNP N
and CC N
cyclooxygenase NN N
( ( N
COX-1 JJ N
and CC N
COX-2 NNP N
) ) N
and CC N
nitric JJ N
oxide NN N
synthase NN N
( ( N
eNOS JJ N
and CC N
iNOS NN N
) ) N
by IN N
western JJ N
blot NN N
. . N

All DT N
subjects NNS N
had VBD N
at IN N
least JJS N
one CD N
gastric JJ N
lesion NN N
except IN N
for IN N
two CD N
individuals NNS N
taking VBG N
ibuprofen-arginate NN N
. . N

Ibuprofen-arginate NNP N
caused VBD N
a DT N
lower JJR N
rate NN N
of IN N
clinical JJ N
adverse JJ N
reactions NNS N
than IN N
ibuprofen NN N
. . N

Subjects NNS N
with IN N
gastric JJ N
lesions NNS N
or CC N
adverse JJ N
reactions NNS N
had VBD N
lower JJR N
PGE2 NNP N
levels NNS N
. . N

COX-1 NNP N
, , N
COX-2 NNP N
, , N
eNOS NN N
, , N
and CC N
iNOS NNS N
were VBD N
detectable JJ N
in IN N
all DT N
subjects NNS N
. . N

The DT N
constitutive JJ N
enzymes NNS N
( ( N
COX-1 NNP N
and CC N
eNOS NN N
) ) N
did VBD N
not RB N
change VB N
after IN N
treatment NN N
. . N

COX-2 NNP N
was VBD N
higher RBR N
in IN N
corpus NN N
than IN N
antrum NN N
and CC N
it PRP N
increased VBD N
after IN N
ibuprofen JJ N
treatment NN N
. . N

iNOS NN N
tended VBD N
to TO N
increase VB N
mildly RB N
in IN N
the DT N
corpus NN N
in IN N
subjects NNS N
with IN N
adverse JJ N
reactions NNS N
or CC N
endoscopic JJ N
lesions NNS N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
ibuprofen NN N
and CC N
ibuprofen-arginate NN N
in IN N
PGE2 NNP N
, , N
or CC N
enzymes NNS N
. . N

-DOCSTART- -X- O O 12541005

A DT N
pilot NN N
randomised VBN N
control NN N
trial NN N
of IN N
a DT N
parent NN N
training NN N
intervention NN N
for IN N
pre-school JJ 4_p
children NNS 4_p
with IN 4_p
autism NN 4_p
. . N

Preliminary JJ N
findings NNS N
and CC N
methodological JJ N
challenges NNS N
. . N

Few JJ N
attempts NNS N
have VBP N
been VBN N
made VBN N
to TO N
conduct VB N
randomised VBN N
control NN N
trials NNS N
( ( N
RCTs NNP N
) ) N
of IN N
interventions NNS N
for IN N
pre-school JJ 4_p
children NNS 4_p
with IN 4_p
autism NN 4_p
. . N

We PRP N
report VBP N
findings NNS N
of IN N
a DT N
pilot NN N
RCT NNP N
for IN N
a DT N
parent NN N
training NN N
intervention NN N
with IN N
a DT N
focus NN N
on IN N
the DT N
development NN N
of IN N
joint JJ N
attention NN N
skills NNS N
and CC N
joint JJ N
action NN N
routines NNS N
. . N

Twenty-four CD N
children NNS N
meeting VBG 4_p
ICD-10 NNP 4_p
criteria NNS 4_p
for IN 4_p
childhood NN 4_p
autism NN 4_p
( ( N
mean JJ N
age NN N
= VBD N
23 CD N
months NNS N
) ) N
were VBD N
identified VBN N
using VBG N
the DT N
CHAT NNP N
screen NN N
and CC N
randomised VBD N
to TO N
the DT N
parent NN N
training VBG N
group NN N
or CC N
to TO N
local JJ N
services NNS N
only RB N
. . N

A DT N
follow-up NN N
was VBD N
conducted VBN N
12 CD N
months NNS N
later RB N
( ( N
mean JJ N
age NN N
= VBD N
35 CD N
months NNS N
) ) N
. . N

There EX N
was VBD N
some DT N
evidence NN N
that IN N
the DT N
parent NN N
training NN N
group NN N
made VBD N
more JJR N
progress NN N
in IN N
language NN N
development NN N
than IN N
the DT N
local JJ N
services NNS N
group NN N
. . N

However RB N
, , N
the DT N
present JJ N
pilot NN N
study NN N
was VBD N
compromised VBN N
by IN N
several JJ N
factors NNS N
: : N
a DT N
reliance NN N
on IN N
parental JJ N
report NN N
to TO N
measure VB N
language NN N
, , N
non-matching NN N
of IN N
the DT N
groups NNS N
on IN N
initial JJ N
IQ NNP N
, , N
and CC N
a DT N
lack NN N
of IN N
systematic JJ N
checking NN N
regarding VBG N
the DT N
implementation NN N
of IN N
the DT N
parent NN N
training NN N
intervention NN N
. . N

Furthermore RB N
, , N
three CD N
parents NNS N
in IN N
the DT N
local JJ N
services NNS N
group NN N
commenced VBD N
intensive JJ N
, , N
home-based JJ N
behavioural JJ N
intervention NN N
during IN N
the DT N
course NN N
of IN N
the DT N
study NN N
. . N

The DT N
difficulties NNS N
encountered VBN N
in IN N
the DT N
conduct NN N
of IN N
RCTs NNP N
for IN N
pre-school JJ N
children NNS N
with IN N
autism NN N
are VBP N
discussed VBN N
. . N

Methodological JJ N
challenges NNS N
and CC N
strategies NNS N
for IN N
future JJ N
well-designed JJ N
RCTs NNP N
for IN N
autism NN N
interventions NNS N
are VBP N
highlighted VBN N
. . N

-DOCSTART- -X- O O 12839657

[ RB N
Long NNP N
term NN N
observation NN N
in IN N
effects NNS N
of IN N
potassium NN N
and CC N
calcium NN N
supplementation NN N
on IN N
arterial JJ N
blood NN N
pressure NN N
and CC N
sodium NN N
metabolism NN N
in IN N
adolescents NNS 4_p
with IN 4_p
higher JJR 4_p
blood NN 4_p
pressure NN 4_p
] NNP 4_p
. . N

OBJECTIVE NNP N
To TO N
investigate VB N
the DT N
effects NNS N
of IN N
potassium NN N
and CC N
calcium NN N
supplementation NN N
in IN N
table JJ N
salt NN N
on IN N
reduction NN N
of IN N
arterial JJ N
blood NN N
pressure NN N
and CC N
sodium NN N
metabolism NN N
in IN N
adolescents NNS N
with IN N
higher JJR N
blood NN N
pressure NN N
. . N

METHODS CC N
A DT N
single JJ N
blind NN N
placebo-controlled JJ N
trial NN N
was VBD N
carried VBN N
out RP N
for IN N
two CD N
years NNS N
in IN N
220 CD N
adolescents NNS N
with IN N
higher JJR N
blood NN N
pressure NN N
, , N
aged VBD N
18 CD N
- : N
22 CD N
years NNS N
, , N
who WP N
were VBD N
randomly RB N
divided VBN N
into IN N
supplementary JJ N
group NN N
( ( N
n JJ N
= NNP N
110 CD N
) ) N
and CC N
control NN N
group NN N
( ( N
n JJ N
= NNP N
110 CD N
) ) N
. . N

Each DT N
of IN N
the DT N
subjects NNS N
in IN N
the DT N
supplementary JJ N
group NN N
and CC N
their PRP$ N
family NN N
members NNS N
was VBD N
given VBN N
10 CD N
mmol NN N
of IN N
potassium NN N
and CC N
10 CD N
mmol NN N
of IN N
calcium NN N
mixed VBN N
in IN N
their PRP$ N
table JJ N
salt JJ N
daily RB N
for IN N
24 CD N
months NNS N
. . N

RESULTS NNP N
Night NNP N
urinary JJ N
sodium NN N
and CC N
potassium JJ N
excretion NN N
increased VBD N
( ( N
urinary JJ N
Na NNP N
( ( N
+ NNP N
) ) N
, , N
P NNP N
< NNP N
0.05 CD N
; : N
urinary JJ N
K NNP N
( ( N
+ NNP N
) ) N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
and CC N
blood NN N
pressure NN N
lowered VBN N
by IN N
5.3 CD N
mm NNS N
Hg/1.8 NNP N
mm NN N
Hg NNP N
in IN N
average NN N
from IN N
the DT N
baseline NN N
in IN N
the DT N
supplementary JJ N
group NN N
two CD N
years NNS N
after IN N
potassium NN N
and CC N
calcium NN N
supplementation NN N
, , N
as IN N
compared VBN N
with IN N
that DT N
in IN N
the DT N
control NN N
group NN N
increased VBN N
by IN N
( ( N
1.3/1.7 CD N
) ) N
mm NN N
Hg NNP N
. . N

CONCLUSIONS NNP N
Adequate NNP N
supplement NN N
of IN N
potassium NN N
and CC N
calcium NN N
in IN N
daily JJ N
table JJ N
salt NN N
intake NN N
was VBD N
an DT N
effective JJ N
way NN N
to TO N
prevent VB N
form NN N
hypertension NN N
and CC N
could MD N
promote VB N
their PRP$ N
urinary JJ N
sodium NN N
excretion NN N
and CC N
reduction NN N
of IN N
arterial JJ N
blood NN N
pressure NN N
in IN N
adolescents NNS N
with IN N
higher JJR N
blood NN N
pressure NN N
. . N

-DOCSTART- -X- O O 11331049

A DT N
randomized VBN N
controlled VBN N
trial NN N
assessing VBG N
the DT N
health NN N
economics NNS N
of IN N
realtime NN N
teledermatology NN N
compared VBN N
with IN N
conventional JJ N
care NN N
: : N
an DT N
urban JJ N
versus NN N
rural JJ N
perspective NN N
. . N

A DT N
randomized JJ N
controlled JJ N
trial NN N
was VBD N
carried VBN N
out IN N
to TO N
measure VB N
the DT N
cost-effectiveness NN N
of IN N
realtime NN N
teledermatology NN N
compared VBN N
with IN N
conventional JJ N
outpatient NN N
dermatology NN N
care NN N
for IN N
patients NNS N
from IN N
urban JJ N
and CC N
rural JJ N
areas NNS N
. . N

One CD N
urban NN N
and CC N
one CD N
rural JJ N
health NN N
centre NNS N
were VBD N
linked VBN N
to TO N
a DT N
regional JJ N
hospital NN N
in IN N
Northern NNP N
Ireland NNP N
by IN N
ISDN NNP N
at IN N
128 CD N
kbit/s NN N
. . N

Over IN N
two CD N
years NNS N
, , N
274 CD N
patients NNS N
required VBD N
a DT N
hospital JJ N
outpatient NN N
dermatology NN N
referral JJ N
-- : N
126 CD N
patients NNS N
( ( N
46 CD N
% NN N
) ) N
were VBD N
randomized VBN N
to TO N
a DT N
telemedicine JJ N
consultation NN N
and CC N
148 CD N
( ( N
54 CD N
% NN N
) ) N
to TO N
a DT N
conventional JJ N
hospital NN N
outpatient JJ N
consultation NN N
. . N

Of IN N
those DT N
seen VBN N
by IN N
telemedicine NN N
, , N
61 CD N
% NN N
were VBD N
registered VBN N
with IN N
an DT N
urban JJ N
practice NN N
, , N
compared VBN N
with IN N
71 CD N
% NN N
of IN N
those DT N
seen VBN N
conventionally RB N
. . N

The DT N
clinical JJ N
outcomes NNS N
of IN N
the DT N
two CD N
types NNS N
of IN N
consultation NN N
were VBD N
similar JJ N
-- : N
almost RB N
half PDT N
the DT N
patients NNS N
were VBD N
managed VBN N
after IN N
a DT N
single JJ N
consultation NN N
with IN N
the DT N
dermatologist NN N
. . N

The DT N
observed JJ N
marginal JJ N
cost NN N
per IN N
patient NN N
of IN N
the DT N
initial JJ N
realtime NN N
teledermatology NN N
consultation NN N
was VBD N
52.85 CD N
Pounds NNS N
for IN N
those DT N
in IN N
urban JJ N
areas NNS N
and CC N
59.93 CD N
Pounds NNS N
per IN N
patient NN N
for IN N
those DT N
from IN N
rural JJ N
areas NNS N
. . N

The DT N
observed JJ N
marginal JJ N
cost NN N
of IN N
the DT N
initial JJ N
conventional JJ N
consultation NN N
was VBD N
47.13 CD N
Pounds NNS N
for IN N
urban JJ N
patients NNS N
and CC N
48.77 CD N
Pounds NNS N
for IN N
rural JJ N
patients NNS N
. . N

The DT N
total JJ N
observed JJ N
costs NNS N
of IN N
teledermatology NN N
were VBD N
higher JJR N
than IN N
the DT N
costs NNS N
of IN N
conventional JJ N
care NN N
in IN N
both DT N
urban JJ N
and CC N
rural JJ N
areas NNS N
, , N
mainly RB N
because IN N
of IN N
the DT N
fixed JJ N
equipment NN N
costs NNS N
. . N

Sensitivity NNP N
analysis NN N
using VBG N
a DT N
real-world NN N
scenario NN N
showed VBD N
that IN N
in IN N
urban JJ N
areas NNS N
the DT N
average JJ N
costs NNS N
of IN N
the DT N
telemedicine NN N
and CC N
conventional JJ N
consultations NNS N
were VBD N
about RB N
equal JJ N
, , N
while IN N
in IN N
rural JJ N
areas NNS N
the DT N
average JJ N
cost NN N
of IN N
the DT N
telemedicine NN N
consultation NN N
was VBD N
less JJR N
than IN N
that DT N
of IN N
the DT N
conventional JJ N
consultation NN N
. . N

-DOCSTART- -X- O O 7218018

Are NNP N
oral JJ N
cathartics NNS N
of IN N
value NN N
in IN N
optimizing VBG N
the DT N
gallium NN N
scan JJ N
? . N
Concise NNP N
communication NN N
. . N

The DT N
normal JJ N
intestinal JJ N
secretion NN N
of IN N
9-15 CD N
% NN N
of IN N
an DT N
administered VBN N
dose NN N
of IN N
gallium-67 NN N
may MD N
prevent VB N
early JJ N
detection NN N
of IN N
intra-abdominal JJ N
disease NN N
. . N

We PRP N
randomized VBD 4_p
50 CD N
patients NNS N
to TO N
receive VB N
either DT N
no DT N
bowel NN N
preparation NN N
or CC N
30 CD N
cc NN N
of IN N
milk NN N
of IN N
magnesia JJ N
plus CC N
5 CD N
cc NN N
of IN N
cascara NN N
. . N

No DT N
significant JJ N
difference NN N
was VBD N
found VBN N
between IN N
the DT N
two CD N
groups NNS N
in IN N
frequency NN N
with IN N
which WDT N
gallium NN N
interfered VBD N
with IN N
readings NNS N
or CC N
time NN N
to TO N
complete VB N
the DT N
study NN N
. . N

-DOCSTART- -X- O O 17377092

A DT N
comparison NN N
of IN N
laser-assisted JJ 4_p
drug NN 4_p
delivery NN 4_p
at IN N
two CD N
output NN N
energies NNS N
for IN N
enhancing VBG N
the DT N
delivery NN N
of IN N
topically RB N
applied VBN N
LMX-4 NNP N
cream NN N
prior RB 4_p
to TO 4_p
venipuncture NN 4_p
. . N

BACKGROUND NNP N
Laser-assisted JJ N
drug NN N
delivery NN N
( ( N
LAD NNP N
) ) N
has VBZ N
the DT N
potential NN N
for IN N
facilitating VBG N
topical JJ N
anesthesia NN N
with IN N
reduced JJ N
onset JJ N
time NN N
. . N

METHODS NNP N
In IN N
this DT N
randomized JJ N
, , N
double-blind JJ N
, , N
crossover NN N
study NN N
we PRP N
compared VBN N
the DT N
efficacy NN N
and CC N
adverse JJ N
event NN N
profile NN N
of IN N
LAD NNP N
for IN N
topical JJ N
anesthesia NN N
before IN 4_p
venipuncture NN 4_p
using VBG N
two CD N
output NN N
energies NNS N
( ( N
2.0 CD N
and CC N
3.5 CD N
J/cm2 NNP N
) ) N
. . N

RESULTS JJ N
Mean NNP N
Visual NNP N
Analog NNP N
Scale NNP N
pain NN N
scores NNS N
were VBD N
not RB N
statistically RB N
different JJ N
( ( N
P NNP N
= NNP N
0.57 CD N
) ) N
between IN N
the DT N
low-energy JJ N
( ( N
mean JJ N
= NNP N
6.7 CD N
) ) N
and CC N
high-energy JJ N
( ( N
mean JJ N
= NNP N
8.1 CD N
) ) N
lasers NNS N
. . N

CONCLUSIONS NNP N
LAD NNP N
at IN N
an DT N
energy NN N
of IN N
2.0 CD N
J/cm2 NNP N
( ( N
570 CD N
mJ NN N
) ) N
is VBZ N
as IN N
effective JJ N
, , N
with IN N
similar JJ N
adverse JJ N
events NNS N
, , N
as IN N
an DT N
energy NN N
of IN N
3.5 CD N
J/cm2 NNP N
( ( N
1000 CD N
mJ NN N
) ) N
in IN N
facilitating VBG N
topical JJ N
anesthesia NN N
. . N

-DOCSTART- -X- O O 18390022

Enrollment NN N
of IN N
racial JJ 4_p
and CC 4_p
ethnic JJ 4_p
minorities NNS 4_p
in IN 4_p
the DT 4_p
Prostate NNP 4_p
, , 4_p
Lung NNP 4_p
, , 4_p
Colorectal NNP 4_p
and CC 4_p
Ovarian JJ 4_p
Cancer NNP 4_p
Screening NNP 4_p
Trial NNP 4_p
. . 4_p

BACKGROUND NNP N
Minority NNP N
populations NNS N
in IN N
the DT N
United NNP N
States NNPS N
, , N
especially RB N
blacks NNS N
and CC N
Hispanics NNPS N
, , N
are VBP N
generally RB N
underrepresented VBN N
among IN N
participants NNS N
in IN N
clinical JJ N
trials NNS N
. . N

Here RB N
, , N
we PRP N
report VBP N
the DT N
experience NN N
of IN N
enrolling VBG N
ethnic JJ N
minorities NNS N
in IN N
a DT N
large JJ N
cancer NN N
screening VBG N
trial NN N
. . N

METHODS NNP N
The DT N
Prostate NNP N
, , N
Colorectal NNP N
, , N
Lung NNP N
and CC N
Ovarian NNP N
( ( N
PLCO NNP N
) ) N
Cancer NNP N
Screening NNP N
Trial NNP N
is VBZ N
a DT N
multicenter NN N
randomized VBN N
trial NN N
designed VBN N
to TO N
evaluate VB N
the DT N
effectiveness NN 4_p
of IN 4_p
screening VBG 4_p
for IN 4_p
the DT 4_p
PLCO NNP 4_p
cancers NNS 4_p
. . N

Subjects NNS N
were VBD N
recruited VBN N
at IN N
10 CD N
U.S. NNP N
centers NNS N
between IN N
1993 CD N
and CC N
2001 CD N
. . N

One CD N
screening NN N
center NN N
had VBD N
a DT N
major JJ N
special JJ N
recruitment NN N
effort NN N
for IN N
blacks NNS N
and CC N
another DT N
center NN N
had VBD N
a DT N
major JJ N
special JJ N
recruitment NN N
effort NN N
for IN N
Hispanics NNPS 4_p
. . N

RESULTS NNP N
Among IN N
almost RB N
155,000 CD N
subjects NNS N
enrolled VBN N
in IN N
PLCO NNP N
, , N
minority NN N
enrollment NN N
was VBD N
as IN N
follows VBZ N
: : N
black JJ N
( ( N
5.0 CD N
% NN N
) ) N
, , N
Hispanic NNP N
( ( N
1.8 CD N
% NN N
) ) N
and CC N
Asian NNP N
( ( N
3.6 CD N
% NN N
) ) N
. . N

This DT N
compares VBZ N
to TO N
an DT N
age-eligible JJ N
population NN N
in IN N
the DT N
combined JJ N
catchment JJ N
areas NNS N
of IN N
the DT N
PLCO NNP N
centers NNS N
that WDT N
was VBD N
14.0 CD N
% NN N
black JJ N
, , N
2.9 CD N
% NN N
Hispanic NNP N
and CC N
5.4 CD N
% NN N
Asian JJ N
, , N
and CC N
an DT N
age-eligible JJ N
population NN N
across IN N
the DT N
U.S. NNP N
that WDT N
was VBD N
9.5 CD N
% NN N
black JJ N
, , N
6.5 CD N
% NN N
Hispanic NNP N
and CC N
3.0 CD N
% NN N
Asian JJ N
. . N

About IN N
half NN N
( ( N
45 CD N
% NN N
) ) N
of IN N
Hispanics NNPS N
were VBD N
recruited VBN N
at IN N
the DT N
center NN N
with IN N
the DT N
special JJ N
Hispanic JJ N
recruitment NN N
effort NN N
. . N

Seventy NNP N
percent NN N
of IN N
blacks NNS N
were VBD N
recruited VBN N
at IN N
two CD N
centers NNS N
; : N
the DT N
one NN N
with IN N
the DT N
major JJ N
special JJ N
recruitment NN N
effort NN N
and CC N
a DT N
center NN N
in IN N
Detroit NNP N
whose WP$ N
catchment JJ N
area NN N
was VBD N
20 CD N
% NN N
black JJ N
among IN N
age-eligibles NNS N
. . N

Blacks NNS N
, , N
Hispanics NNPS N
and CC N
( ( N
non-Hispanic JJ N
) ) N
whites NNS N
were VBD N
all DT N
more RBR N
highly RB N
educated VBN N
, , N
less RBR N
likely JJ N
to TO N
currently RB N
smoke VB N
and CC N
more RBR N
likely JJ N
to TO N
get VB N
regular JJ N
exercise NN N
than IN N
their PRP$ N
counterparts NNS N
in IN N
the DT N
general JJ N
population NN N
. . N

CONCLUSION NNP N
Significant NNP N
efforts NNS N
were VBD N
made VBN N
to TO N
recruit VB N
racial/ NN N
ethnic JJ N
minorities NNS N
into IN N
PLCO NNP N
, , N
and CC N
these DT N
efforts NNS N
resulted VBD N
in IN N
enrollment NN N
levels NNS N
that WDT N
were VBD N
comparable JJ N
to TO N
those DT N
seen VBN N
in IN N
many JJ N
recent JJ N
cancer NN N
screening NN N
or CC N
prevention NN N
trials NNS N
. . N

Blacks NNS N
and CC N
Hispanics NNPS N
were VBD N
nonetheless RB N
underrepresented VBN N
in IN N
PLCO NNP N
compared VBN N
to TO N
their PRP$ N
levels NNS N
among IN N
age-eligibles NNS N
in IN N
the DT N
overall JJ N
U.S. NNP N
population NN N
or CC N
in IN N
the DT N
aggregate JJ N
PLCO NNP N
catchment NN N
areas NNS N
. . N

-DOCSTART- -X- O O 25348544

A DT N
5-year JJ N
randomized JJ N
trial NN N
to TO N
compare VB N
1 CD N
or CC N
2 CD N
implants NNS N
for IN N
implant JJ 4_p
overdentures NNS 4_p
. . N

The DT N
hypothesis NN N
of IN N
this DT N
5-y JJ N
randomized JJ N
clinical JJ N
trial NN N
was VBD N
that IN N
there EX N
would MD N
be VB N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
satisfaction NN N
of IN N
edentulous JJ N
participants NNS N
with IN N
removable JJ N
complete JJ N
overdentures NNS N
attached VBN N
to TO N
1 CD N
or CC N
2 CD N
mandibular JJ N
implants NNS N
. . N

Secondary JJ N
aims NNS N
were VBD N
to TO N
test VB N
changes NNS N
in IN N
satisfaction NN N
between IN N
and CC N
within IN N
the DT N
groups NNS N
from IN N
baseline NN N
to TO N
5 CD N
y NNS N
and CC N
differences NNS N
between IN N
the DT N
groups NNS N
in IN N
implant JJ N
survival NN N
and CC N
prosthodontic JJ N
maintenance NN N
over IN N
5 CD N
y NNS N
. . N

Each DT N
of IN N
the DT N
86 CD N
participants NNS N
( ( N
mean JJ N
age NN N
, , N
67 CD N
y NN N
) ) N
was VBD N
randomly RB N
allocated VBN N
to TO N
receive VB N
either RB N
1 CD N
implant NN N
in IN N
the DT N
midline NN N
( ( N
group NN N
1 CD N
) ) N
or CC N
2 CD N
implants NNS N
in IN N
the DT N
canine NN N
areas NNS N
( ( N
group NN N
2 CD N
) ) N
attached VBN N
to TO N
a DT N
mandibular JJ N
overdenture NN N
opposing VBG N
a DT N
maxillary JJ N
complete JJ N
denture NN N
. . N

Satisfaction NN N
was VBD N
self-assessed VBN N
by IN N
participants NNS N
on IN N
a DT N
visual JJ N
analog NN N
scale NN N
at IN N
baseline NN N
prior RB N
to TO N
implants NNS N
, , N
as RB N
well RB N
as IN N
at IN N
2 CD N
mo NN N
and CC N
1 CD N
, , N
3 CD N
, , N
and CC N
5 CD N
y NN N
with IN N
implant JJ N
overdentures NNS N
, , N
whereas JJ N
implant NN N
survival NN N
and CC N
prosthodontic JJ N
maintenance NN N
were VBD N
assessed VBN N
by IN N
clinical JJ N
examination NN N
. . N

After IN N
5 CD N
y NN N
, , N
29 CD N
participants NNS N
in IN N
group NN N
1 CD N
and CC N
33 CD N
in IN N
group NN N
2 CD N
were VBD N
available JJ N
, , N
with IN N
most JJS N
dropouts NNS N
due JJ N
to TO N
death NN N
. . N

Satisfaction NN N
with IN N
the DT N
implant JJ N
denture NN N
after IN N
5 CD N
y NN N
was VBD N
significantly RB N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
higher JJR N
than IN N
at IN N
baseline NN N
in IN N
both DT N
groups NNS N
and CC N
remained VBD N
with IN N
no DT N
significant JJ N
difference NN N
( ( N
P NNP N
= NNP N
0.32 CD N
) ) N
between IN N
the DT N
groups NNS N
. . N

No DT N
implants NNS N
failed VBD N
in IN N
group NN N
1 CD N
but CC N
5 CD N
failed VBD N
before IN N
loading VBG N
in IN N
4 CD N
participants NNS N
in IN N
group NN N
2 CD N
. . N

Most JJS N
participants NNS N
required VBN N
maintenance NN N
or CC N
occasionally RB N
denture JJ N
replacement NN N
, , N
and CC N
although IN N
differences NNS N
between IN N
the DT N
groups NNS N
were VBD N
not RB N
statistically RB N
significant JJ N
, , N
group NN N
1 CD N
experienced VBD N
almost RB N
twice RB N
as IN N
many JJ N
fractured JJ N
dentures NNS N
usually RB N
adjacent VBP N
to TO N
the DT N
implant JJ N
attachment NN N
. . N

We PRP N
conclude VBP N
that IN N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
after IN N
5 CD N
y NN N
in IN N
satisfaction NN N
or CC N
survival NN N
of IN N
implants NNS N
with IN N
mandibular JJ N
overdentures NNS N
retained VBN N
by IN N
1 CD N
implant NN N
or CC N
2 CD N
implants NNS N
. . N

Additional NNP N
research NN N
is VBZ N
required VBN N
to TO N
confirm VB N
long-term JJ N
treatment NN N
effectiveness NN N
of IN N
single-implant JJ N
dentures NNS N
and CC N
the DT N
implications NNS N
of IN N
prosthetic JJ N
maintenance NN N
with IN N
implant JJ N
overdentures NNS N
( ( N
ClinicalTrials.gov NNP N
: : N
NCT02117856 NN N
) ) N
. . N

-DOCSTART- -X- O O 22092536

Paracetamol NNP N
and CC N
opioid JJ N
pathways NNS N
: : N
a DT N
pilot NN N
randomized VBN N
clinical JJ N
trial NN N
. . N

Previous JJ N
studies NNS N
suggest VBP N
that IN N
the DT N
antinociceptive JJ N
action NN N
of IN N
paracetamol NN N
( ( N
acetaminophen NN N
, , N
APAP NNP N
) ) N
might MD N
involve VB N
descending VBG N
inhibitory JJ N
pain NN N
pathways NNS N
and CC N
the DT N
opioidergic JJ N
system NN N
: : N
this DT N
study NN N
explores VBZ N
this DT N
issue NN N
in IN N
humans NNS N
with IN N
naloxone NN N
, , N
the DT N
opioid JJ N
antagonist NN N
. . N

After IN N
ethical JJ N
approval NN N
, , N
12 CD N
healthy JJ N
male NN N
volunteers NNS N
were VBD N
included VBN N
in IN N
this DT N
randomized VBN N
, , N
controlled VBN N
, , N
double-blind NN N
, , N
crossover NN N
, , N
four-arm JJ N
study NN N
. . N

They PRP N
were VBD N
administered VBN N
intravenous JJ N
paracetamol NN N
( ( N
APAP NNP N
1 CD N
g NN N
) ) N
or CC N
saline NN N
( ( N
placebo NN N
, , N
pl NN N
) ) N
followed VBD N
at IN N
100 CD N
min NN N
with IN N
IV NNP N
naloxone NN N
( ( N
Nal NNP N
8 CD N
mg NN N
) ) N
or CC N
saline NN N
, , N
every DT N
week NN N
for IN N
4 CD N
weeks NNS N
. . N

The DT N
amplitude NN N
of IN N
cerebral JJ N
potentials NNS N
evoked VBN N
by IN N
thermal/painful JJ N
stimuli NNS N
applied VBN N
on IN N
the DT N
arm NN N
was VBD N
recorded VBN N
nine CD N
times NNS N
over IN N
150 CD N
min NNS N
, , N
witnessing VBG N
of IN N
pain NN N
integration NN N
at IN N
central JJ N
level NN N
. . N

Amplitude NNP N
changes NNS N
as RB N
well RB N
as IN N
areas NNS N
under IN N
the DT N
curve NN N
( ( N
AUCs NNP N
) ) N
over IN N
150 CD N
min NNS N
were VBD N
compared VBN N
for IN N
the DT N
four CD N
treatments NNS N
by IN N
repeated JJ N
measures NNS N
ANOVA NNP N
( ( N
significance NN N
0.05 CD N
) ) N
. . N

Amplitude NNP N
changes NNS N
were VBD N
significant JJ N
for IN N
APAP/pl NNP N
vs. FW N
pl/pl NN N
at IN N
t150 NN N
: : N
-44 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
-58 NNP N
to TO N
-30 VB N
) ) N
vs. FW N
-27 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
-37 NNP N
to TO N
-17 VB N
; : N
P NNP N
< NNP N
0.05 CD N
) ) N
but CC N
not RB N
vs. IN N
APAP/Nal NNP N
. . N

AUC NNP N
( ( N
0-150 JJ N
) ) N
of IN N
APAP/pl NNP N
is VBZ N
significantly RB N
different JJ N
from IN N
pl/pl NN N
( ( N
-3452 CD N
% NN N
.min NNP N
( ( N
95 CD N
% NN N
CI NNP N
-4705 NNP N
to TO N
-2199 VB N
) ) N
vs. FW N
-933 CD N
% NN N
min NN N
( ( N
95 CD N
% NN N
CI NNP N
-2273 NNP N
to TO N
407 CD N
; : N
P NNP N
= NNP N
0.015 CD N
) ) N
but CC N
not RB N
from IN N
APAP/Nal NNP N
( ( N
-1731 CD N
% NN N
min NN N
( ( N
95 CD N
% NN N
CI NNP N
-3676 NNP N
to TO N
214 CD N
; : N
P NNP N
= NNP N
0.08 CD N
) ) N
and CC N
other JJ N
treatments NNS N
. . N

AUC NNP N
( ( N
90-150 CD N
) ) N
is VBZ N
not RB N
significantly RB N
different JJ N
. . N

This DT N
pilot NN N
study NN N
shows VBZ N
for IN N
the DT N
first JJ N
time NN N
in IN N
human JJ N
volunteers NNS N
that WDT N
naloxone RB N
does VBZ N
not RB N
inhibit VB N
paracetamol JJ N
antinociception NN N
, , N
suggesting VBG N
no DT N
significant JJ N
implication NN N
of IN N
the DT N
opioid NN N
system NN N
in IN N
paracetamol JJ N
mechanism NN N
of IN N
action NN N
: : N
this DT N
needs VBZ N
be VB N
confirmed VBN N
on IN N
a DT N
larger JJR N
number NN N
of IN N
subjects NNS N
. . N

-DOCSTART- -X- O O 12591004

Bioavailability NN N
of IN N
omega-3 JJ 4_p
essential JJ 4_p
fatty JJ 4_p
acids NNS 4_p
from IN 4_p
perilla NN 4_p
seed NN 4_p
oil NN 4_p
. . 4_p

Increased VBD N
dietary JJ N
intake NN N
of IN N
fish JJ N
oil NN N
omega-3 JJ N
fatty NN N
acids NNS N
, , N
eicosapentanoic JJ N
acid NN N
and CC N
docosohexanoic NN N
acid NN N
, , N
and CC N
their PRP$ N
precursor NN N
, , N
alpha-linolenic JJ N
acid NN N
( ( N
ALA NNP N
) ) N
, , N
is VBZ N
associated VBN N
with IN N
various JJ N
health NN N
benefits NNS N
. . N

Enteric-coating NNP N
( ( N
Entrox NNP N
) ) N
, , N
which WDT N
improves VBZ N
stability NN N
of IN N
omega-3 JJ N
capsules NNS N
, , N
has VBZ N
been VBN N
shown VBN N
to TO N
facilitate VB N
fish JJ N
oil NN N
absorption NN N
after IN N
chronic JJ N
treatment NN N
. . N

To TO N
assess VB N
the DT N
effect NN N
of IN N
Entrox NNP N
coating VBG N
on IN N
the DT N
short-term JJ N
bioavailability NN N
of IN N
ALA NNP N
administered VBD N
in IN N
the DT N
form NN N
of IN N
ALA-rich NNP N
Perilla NNP N
seed NN N
oil NN N
, , N
12 CD 4_p
healthy JJ 4_p
subjects NNS 4_p
( ( 4_p
6 CD 4_p
males NNS 4_p
and CC 4_p
6 CD 4_p
females NNS 4_p
) ) 4_p
received VBN N
in IN N
a DT N
random JJ N
order NN N
Entrox-coated JJ N
and CC N
non-coated JJ N
ALA NNP N
formulations NNS N
, , N
each DT N
as IN N
a DT N
single JJ N
6g CD N
dose NN N
separated VBN N
by IN N
a DT N
3-week JJ N
washout NN N
period NN N
. . N

Measurements NNS N
of IN N
plasma NN N
ALA NNP N
concentrations NNS N
from IN N
0 CD N
to TO N
24h CD N
showed VBD N
no DT N
difference NN N
in IN N
ALA NNP N
pharmacokinetics NNS N
between IN N
the DT N
two CD N
formulations NNS N
. . N

However RB N
, , N
significantly RB N
greater JJR N
increases NNS N
in IN N
plasma JJ N
ALA NNP N
levels NNS N
from IN N
baseline NN N
to TO N
24h CD N
were VBD N
observed VBN N
after IN N
ingestion NN N
of IN N
Entrox NNP N
vs. IN N
non-coated JJ N
product NN N
, , N
suggesting VBG N
a DT N
possible JJ N
benefit NN N
of IN N
Entrox NNP N
with IN N
long-term JJ N
treatment NN N
. . N

-DOCSTART- -X- O O 14758586

Comparison NNP N
study NN N
of IN N
venlafaxine NN N
and CC N
paroxetine NN N
for IN N
the DT N
treatment NN N
of IN N
depression NN 4_p
in IN 4_p
elderly JJ 4_p
Chinese JJ 4_p
inpatients NNS 4_p
. . 4_p

-DOCSTART- -X- O O 20796074

Effect NN N
of IN N
thermal JJ N
stress NN N
, , N
restricted VBD N
feeding NN N
and CC N
combined VBN N
stresses NNS N
( ( N
thermal JJ N
stress NN N
and CC N
restricted VBD N
feeding VBG N
) ) N
on IN N
growth NN N
and CC N
plasma VB N
reproductive JJ N
hormone NN N
levels NNS N
of IN N
Malpura NNP N
ewes FW N
under IN N
semi-arid JJ N
tropical JJ N
environment NN N
. . N

A DT N
study NN N
was VBD N
conducted VBN N
to TO N
assess VB N
the DT N
effect NN N
of IN N
thermal NN N
, , N
nutritional JJ N
and CC N
combined JJ N
stresses NNS N
( ( N
thermal JJ N
and CC N
nutritional JJ N
) ) N
on IN N
the DT N
growth NN N
, , N
oestradiol NN N
and CC N
progesterone NN N
levels NNS N
during IN N
oestrus NN N
cycles NNS N
in IN N
Malpura NNP N
ewes NN N
. . N

Twenty-eight JJ N
adult NN N
Malpura NNP N
ewes NN N
were VBD N
used VBN N
in IN N
the DT N
present JJ N
study NN N
. . N

The DT N
ewes NN N
were VBD N
randomly RB N
allocated VBN N
into IN N
four CD N
groups NNS N
, , N
viz. NN N
, , N
GI NNP N
( ( N
n=7 RB N
; : N
control NN N
) ) N
, , N
GII NNP N
( ( N
n=7 RB N
; : N
thermal JJ N
stress NN N
) ) N
, , N
GIII NNP N
( ( N
n=7 RB N
; : N
restricted VBN N
feeding NN N
) ) N
and CC N
GIV NNP N
( ( N
n=7 RB N
; : N
combined VBN N
stress NN N
) ) N
. . N

The DT N
animals NNS N
were VBD N
stall JJ N
fed VBN N
with IN N
a DT N
diet JJ N
consisting NN N
of IN N
60 CD N
% NN N
roughage NN N
and CC N
40 CD N
% NN N
concentrate NN N
. . N

GI NNP N
and CC N
GII NNP N
ewes NN N
were VBD N
provided VBN N
with IN N
ad NN N
libitum NN N
feeding VBG N
while IN N
GIII NNP N
and CC N
GIV NNP N
ewes NN N
were VBD N
provided VBN N
with IN N
restricted JJ N
feed NN N
( ( N
30 CD N
% NN N
intake NN N
of IN N
GI NNP N
and CC N
GII NNP N
ewes NN N
) ) N
to TO N
induce VB N
nutritional JJ N
insufficiency NN N
. . N

GII NNP N
and CC N
GIV NNP N
ewes NN N
were VBD N
kept VBN N
in IN N
climatic JJ N
chamber NN N
at IN N
40°C CD N
and CC N
55 CD N
% NN N
RH NNP N
for IN N
6 CD N
h NNS N
a DT N
day NN N
between IN N
10:00 CD N
and CC N
16:00 CD N
hours NNS N
to TO N
induce VB N
thermal JJ N
stress NN N
for IN N
a DT N
period NN N
of IN N
two CD N
oestrous JJ N
cycles NNS N
. . N

Parameters NNS N
studied VBD N
were VBD N
body JJ N
weight NN N
, , N
oestrus NN N
incidences NNS N
, , N
plasma JJ N
oestradiol IN N
17-β JJ N
, , N
plasma JJ N
progesterone NN N
, , N
conception NN N
rate NN N
, , N
gestation NN N
period NN N
, , N
lambing VBG N
rate NN N
, , N
and CC N
birth NN N
weight NN N
of IN N
lambs NN N
. . N

The DT N
results NNS N
indicate VBP N
that IN N
combined VBD N
stress NN N
significantly RB N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
reduced VBN N
body NN N
weight NN N
, , N
oestrus JJ N
duration NN N
, , N
birth NN N
weight NN N
of IN N
lambs NN N
, , N
and CC N
oestradiol JJ N
17-β JJ N
whereas NNS N
significantly RB N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
increased VBD N
oestrus JJ N
cycle NN N
length NN N
and CC N
progesterone NN N
. . N

Furthermore RB N
, , N
the DT N
results NNS N
reveal VBP N
that IN N
on IN N
comparative JJ N
basis NN N
, , N
ewes NN N
were VBD N
able JJ N
to TO N
better VB N
adapt NN N
in IN N
terms NNS N
of IN N
growth NN N
and CC N
reproduction NN N
to TO N
restricted VB N
feeding NN N
than IN N
thermal JJ N
stress NN N
. . N

However RB N
, , N
when WRB N
restricted VBD N
feeding NN N
was VBD N
coupled VBN N
with IN N
thermal JJ N
stress NN N
it PRP N
had VBD N
significant JJ N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
influence NN N
on IN N
body NN N
weight NN N
, , N
average JJ N
daily JJ N
gain NN N
, , N
oestradiol JJ N
17-β JJ N
and CC N
progesterone JJ N
concentrations NNS N
. . N

This DT N
showed VBD N
that IN N
combined JJ N
stress NN N
were VBD N
more JJR N
detrimental JJ N
for IN N
these DT N
reproductive JJ N
hormones NNS N
in IN N
Malpura NNP N
ewes NN N
under IN N
a DT N
hot JJ N
semi-arid JJ N
environment NN N
. . N

-DOCSTART- -X- O O 21909698

Randomised VBN N
multicentre JJ N
trial NN N
of IN N
circular JJ N
stapling NN N
devices NNS N
. . N

PURPOSE NNP N
In IN N
a DT N
register NN N
study NN N
, , N
the DT N
risk NN N
of IN N
anastomotic JJ N
leakage NN N
correlated VBD N
to TO N
the DT N
choice NN N
of IN N
circular JJ N
stapling VBG N
device NN N
with IN N
a DT N
4 CD N
% NN N
difference NN N
between IN N
the DT N
two CD N
brands NNS N
used VBN N
. . N

Based VBN N
on IN N
those DT N
data NNS N
, , N
a DT N
randomised JJ N
multicentre NN N
study NN N
was VBD N
started VBN N
to TO N
explore VB N
the DT N
risk NN N
of IN N
an DT N
anastomotic JJ N
leakage NN N
based VBN N
upon IN N
the DT N
surgical JJ N
device NN N
. . N

METHODS NNP N
Patients NNPS N
above IN N
18 CD N
years NNS N
with IN N
a DT N
rectal JJ 4_p
cancer NN 4_p
, , N
able JJ 4_p
to TO 4_p
give VB 4_p
informed JJ 4_p
consent NN 4_p
, , N
and CC N
scheduled VBD 4_p
for IN 4_p
an DT 4_p
anterior JJ 4_p
resection NN 4_p
were VBD N
eligible JJ N
for IN N
the DT N
study NN N
. . N

Perioperative JJ N
randomisation NN N
was VBD N
to TO N
Ethicon™ NNP N
PROXIMATE™ NNP N
ILS™ NNP N
or CC N
Autosuture™ NNP N
Premium NNP N
Plus NNP N
CEEA™ NNP N
. . N

Anastomotic JJ N
leakage NN N
was VBD N
defined VBN N
as IN N
a DT N
clinically RB N
manifest JJS N
leak NN 4_p
. . N

RESULTS NNP N
Five CD N
hundred VBD N
twenty-nine NN N
patients NNS N
were VBD N
randomised VBN N
( ( N
58 CD N
% NN N
male NN N
) ) N
. . N

A DT N
leak NN N
occurred VBD N
in IN N
8.3 CD N
% NN N
. . N

The DT N
anastomoses NNS N
created VBN N
by IN N
PROXIMATE™ NNP N
ILS™ NNP N
leaked VBD N
in IN N
25/265 CD N
( ( N
9.4 CD N
% NN N
) ) N
anastomoses VBZ N
, , N
and CC N
the DT N
Premium NNP N
Plus NNP N
CEEA™ NNP N
leaked VBD N
in IN N
19/260 CD N
( ( N
7.3 CD N
% NN N
) ) N
, , N
p JJ N
= NNP N
.419 NNP N
. . N

CONCLUSION NNP N
No DT N
difference NN N
in IN N
the DT N
leak NN N
rate NN N
could MD N
be VB N
revealed VBN N
. . N

Several JJ N
centres NNS N
replaced VBD N
one CD N
of IN N
the DT N
staplers NNS N
by IN N
a DT N
new JJ N
product NN N
, , N
and CC N
the DT N
study NN N
was VBD N
ended VBN N
before IN N
the DT N
stipulated JJ N
number NN N
of IN N
patients NNS N
was VBD N
reached VBN N
. . N

In IN N
the DT N
future NN N
, , N
surgical JJ N
devices NNS N
may MD N
have VB N
to TO N
prove VB N
superiority NN N
in IN N
randomised JJ N
trials NNS N
or CC N
be VB N
monitored VBN N
in IN N
quality NN N
registers NNS N
before IN N
they PRP N
can MD N
be VB N
introduced VBN N
into IN N
day NN N
to TO N
day NN N
surgical JJ N
practice NN N
. . N

The DT N
study NN N
was VBD N
registered VBN N
at IN N
ClinicalTrials.gov NNP N
: : N
NCT00399009 NN N
. . N

-DOCSTART- -X- O O 21636141

Short-term JJ N
effect NN N
of IN N
pitavastatin NN N
on IN N
the DT N
reactive JJ N
hyperemic JJ N
index NN N
in IN N
post-menopausal JJ 4_p
women NNS N
with IN N
high JJ 4_p
levels NNS 4_p
in IN 4_p
serum JJ 4_p
LDL-cholesterol NNP 4_p
. . N

-DOCSTART- -X- O O 14616279

Vaginal JJ N
electrical JJ N
stimulation NN N
of IN N
the DT N
pelvic JJ N
floor NN N
: : N
a DT N
randomized JJ N
feasibility NN N
study NN N
in IN N
urinary JJ N
incontinent NN N
elderly JJ N
women NNS N
. . N

BACKGROUND NNP N
To TO N
evaluate VB N
the DT N
effectiveness NN N
of IN N
intravaginal JJ N
electrical JJ N
stimulation NN N
( ( N
ES NNP N
) ) N
of IN N
the DT N
pelvic JJ N
floor NN N
for IN N
urinary JJ N
incontinence NN N
in IN N
elderly JJ N
women NNS N
, , N
and CC N
to TO N
determine VB N
whether IN N
ES NNP N
of IN N
the DT N
pelvic JJ N
floor NN N
is VBZ N
a DT N
preferable JJ N
treatment NN N
for IN N
urinary JJ N
incontinence NN N
in IN N
elderly JJ N
women NNS N
. . N

METHODS NNP N
Postmenopausal NNP N
women NNS N
( ( N
age NN N
65 CD N
years NNS N
or CC N
older JJR N
) ) N
were VBD N
enrolled VBN N
in IN N
a DT N
randomized JJ N
clinical JJ N
trial NN N
and CC N
underwent JJ N
every-other-day JJ N
ES NNP N
of IN N
the DT N
pelvic JJ N
floor NN N
, , N
or CC N
a DT N
daily JJ N
Kegel NNP N
exercise NN N
( ( N
KE NNP N
) ) N
program NN N
. . N

Objective NNP N
outcome NN N
variables NNS N
were VBD N
: : N
( ( N
1 CD N
) ) N
Urinary JJ N
leakage NN N
( ( N
during IN N
a DT N
standardized JJ N
PAD NNP N
test NN N
) ) N
, , N
( ( N
2 CD N
) ) N
pelvic NN N
muscle NN N
strength NN N
( ( N
measured VBN N
by IN N
a DT N
perineometer NN N
) ) N
, , N
and CC N
( ( N
3 CD N
) ) N
detrusor NN N
instability NN N
( ( N
on IN N
ambulant NN N
urodynamic JJ N
registration NN N
) ) N
. . N

Subjective JJ N
outcome NN N
variables NNS N
were VBD N
women NNS N
's POS N
subjective JJ N
assessment NN N
of IN N
change NN N
in IN N
urinary JJ N
symptoms NNS N
based VBN N
on IN N
the DT N
PRAFAB NNP N
score NN N
. . N

Twenty-four JJ N
women NNS N
treated VBN N
with IN N
ES NNP N
and CC N
11 CD N
women NNS N
treated VBN N
with IN N
Kegel NNP N
exercises NNS N
completed VBD N
the DT N
8-week JJ N
study NN N
program NN N
. . N

The DT N
Chi-square JJ N
test NN N
was VBD N
used VBN N
for IN N
statistical JJ N
analysis NN N
. . N

RESULTS NNP N
No NNP N
significant JJ N
improvement NN N
in IN N
objective JJ N
outcome NN N
variables NNS N
was VBD N
observed VBN N
in IN N
the DT N
population NN N
treated VBD N
with IN N
ES NNP N
compared VBN N
with IN N
the DT N
population NN N
treated VBD N
with IN N
KE NNP N
( ( N
with IN N
29.2 CD N
% NN N
vs. FW N
36.4 CD N
% NN N
of IN N
the DT N
women NNS N
showing VBG N
objective JJ N
improvement NN N
in IN N
measured JJ N
urinary JJ N
leakage NN N
) ) N
. . N

Neither CC N
was VBD N
subjective JJ N
improvement NN N
significant JJ N
, , N
with IN N
29.2 CD N
% NN N
vs. FW N
27.3 CD N
% NN N
of IN N
the DT N
women NNS N
reporting VBG N
improvement NN N
in IN N
the DT N
amount NN N
of IN N
urinary JJ N
leakage NN N
. . N

CONCLUSIONS NNP N
Although IN N
the DT N
number NN N
of IN N
enrolled JJ N
women NNS N
was VBD N
very RB N
small JJ N
this DT N
study NN N
shows VBZ N
that IN N
: : N
1 CD N
. . N

Treating VBG N
elderly JJ N
women NNS N
with IN N
vaginal JJ N
ES NNP N
of IN N
the DT N
pelvic JJ N
floor NN N
has VBZ N
a DT N
high JJ N
physical JJ N
and CC N
emotional JJ N
cost NN N
for IN N
the DT N
individual NN N
. . N

2 CD N
. . N

The DT N
effectiveness NN N
of IN N
ES NNP N
of IN N
the DT N
pelvic JJ N
floor NN N
in IN N
urinary JJ N
incontinent NN N
elderly JJ N
women NNS N
is VBZ N
low JJ N
. . N

3 CD N
. . N

There EX N
is VBZ N
no DT N
great JJ N
discrepancy NN N
between IN N
objective JJ N
amelioration NN N
( ( N
PAD NNP N
test NN N
) ) N
and CC N
subjective JJ N
amelioration NN N
( ( N
PRAFAB NNP N
score/quantity NN N
of IN N
urinary JJ N
leakage NN N
) ) N
, , N
if IN N
the DT N
objective JJ N
improvement NN N
is VBZ N
adequately RB N
defined VBN N
. . N

4 CD N
. . N

It PRP N
is VBZ N
not RB N
reasonable JJ N
to TO N
advise VB N
elderly JJ N
women NNS N
with IN N
urinary JJ N
incontinence NN N
to TO N
undertake VB N
this DT N
treatment NN N
procedure NN N
. . N

The DT N
effectiveness NN N
of IN N
treatment NN N
does VBZ N
not RB N
compensate VB N
for IN N
the DT N
long-lasting JJ N
and CC N
intense JJ N
treatment NN N
protocol NN N
. . N

5 CD N
. . N

We PRP N
terminated VBD N
this DT N
study NN N
because IN N
of IN N
the DT N
negative JJ N
outcome NN N
with IN N
ES NNP N
. . N

-DOCSTART- -X- O O 7562882

Lisinopril NNP N
administration NN N
improves VBZ N
insulin JJ N
action NN N
in IN N
aged JJ N
patients NNS 4_p
with IN 4_p
hypertension NN 4_p
. . 4_p

Thirty NNP N
elderly JJ N
, , N
mildly RB 4_p
hypertensive JJ 4_p
patients NNS N
were VBD N
enrolled VBN N
for IN N
a DT N
single-blind NN N
, , N
randomised VBD N
cross-over NN N
placebo NN N
controlled VBD N
trial NN N
in IN N
which WDT N
placebo NN N
and CC N
lisinopril NN N
( ( N
20 CD N
mg/day NN N
before IN N
breakfast NN N
) ) N
were VBD N
given VBN N
for IN N
4 CD N
and CC N
8 CD N
weeks NNS N
, , N
respectively RB N
. . N

A DT N
wash-out JJ N
period NN N
of IN N
3 CD N
weeks NNS N
between IN N
placebo NN N
and CC N
lisinopril NN N
was VBD N
observed VBN N
. . N

In IN N
each DT N
patient NN N
a DT N
euglycaemic JJ N
glucose NN N
clamp NN N
with IN N
simultaneous JJ N
indirect JJ N
calorimetry NN N
allowed VBD N
us PRP N
to TO N
determine VB N
whole JJ N
body NN N
glucose JJ N
disposal NN N
and CC N
substrate JJ N
oxidation NN N
. . N

Changes NNS N
in IN N
morning NN N
SBP NNP N
and CC N
DBP NNP N
were VBD N
also RB N
determined VBN N
. . N

Lisinopril NNP N
vs. IN N
placebo NN N
significantly RB N
improved VBN N
whole JJ N
body NN N
glucose JJ N
disposal NN N
( ( N
40.4 CD N
+/- JJ N
0.4 CD N
vs. FW N
30.3 CD N
+/- JJ N
0.4 CD N
mumol/kg NN N
LBM NNP N
x NNP N
min NN N
; : N
P NNP N
< NNP N
0.01 CD N
) ) N
, , N
non-oxidative JJ N
glucose JJ N
metabolism NN N
( ( N
18.1 CD N
+/- JJ N
0.7 CD N
vs. FW N
10.9 CD N
+/- JJ N
0.6 CD N
mumol/kg NN N
LBM NNP N
x NNP N
min NN N
; : N
P NNP N
< NNP N
0.01 CD N
) ) N
and CC N
fasting VBG N
plasma JJ N
potassium NN N
levels NNS N
( ( N
4.8 CD N
+/- JJ N
3 CD N
vs. FW N
4.4 CD N
+/- JJ N
0.4 CD N
mmol/l NN N
; : N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

SBP NNP N
( ( N
175 CD N
+/- JJ N
3.3 CD N
vs. FW N
160 CD N
+/- JJ N
3.0 CD N
mm NN N
Hg NNP N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
DBP NNP N
( ( N
106 CD N
+/- JJ N
2.3 CD N
vs. FW N
95 CD N
+/- JJ N
2.0 CD N
mm NN N
Hg NNP N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
were VBD N
significantly RB N
reduced VBN N
by IN N
lisinopril JJ N
administration NN N
. . N

After IN N
ACE NNP N
inhibition NN N
, , N
fasting VBG N
plasma JJ N
potassium NN N
levels NNS N
correlated VBN N
with IN N
the DT N
decline NN N
in IN N
mean JJ N
arterial JJ N
BP NNP N
( ( N
r NN N
= NNP N
-0.71 NNP N
; : N
P NNP N
< NNP N
0.006 CD N
) ) N
. . N

In IN N
conclusion NN N
, , N
lisinopril JJ N
administration NN N
reduces VBZ N
arterial JJ N
BP NNP N
and CC N
improves VBZ N
insulin JJ N
sensitivity NN N
in IN N
elderly JJ N
hypertensive JJ 4_p
patients NNS N
. . N

-DOCSTART- -X- O O 9076457

Long-term JJ N
follow-up NN N
of IN N
cytostatic JJ N
intravesical JJ N
instillation NN N
in IN N
patients NNS 4_p
with IN 4_p
superficial JJ 4_p
bladder NN 4_p
carcinoma NN 4_p
. . 4_p

Is VBZ N
short-term JJ N
, , N
intensive JJ N
instillation NN N
better RBR N
than IN N
maintenance NN N
therapy NN N
? . N
OBJECTIVES NNP N
Comparisons NNPS N
of IN N
two CD N
3-year JJ N
protocols NNS N
, , N
one CD N
20-week JJ N
protocol NN N
of IN N
mitomycin NN N
C NNP N
instillation NN N
and CC N
one CD N
3-year JJ N
protocol NN N
of IN N
doxorubicin JJ N
instillation NN N
for IN N
the DT N
prevention NN N
of IN N
recurrent NN N
tumors NNS N
and CC N
progression NN N
in IN N
patients NNS 4_p
whose WP$ 4_p
superficial JJ 4_p
bladder NN 4_p
tumors NNS 4_p
had VBD 4_p
been VBN 4_p
removed VBN 4_p
by IN 4_p
transurethral JJ 4_p
resection NN 4_p
. . N

METHODS NNP N
A NNP N
prospective JJ N
, , N
randomized JJ N
parallel NN N
group NN N
multicenter RBR N
trial NN N
was VBD N
conducted VBN N
. . N

419 CD N
patients NNS N
were VBD N
evaluated VBN N
after IN N
a DT N
median JJ N
follow-up NN N
of IN N
57 CD N
months NNS N
. . N

Cox NNP N
proportional JJ N
hazards NNS N
analysis NN N
was VBD N
performed VBN N
. . N

RESULTS NNP N
An DT N
overall JJ N
recurrence NN N
rate NN N
of IN N
22.7 CD N
% NN N
and CC N
an DT N
overall JJ N
progression NN N
rate NN N
of IN N
9.8 CD N
% NN N
was VBD N
found VBN N
. . N

For IN N
time NN N
to TO N
progression VB N
a DT N
significant JJ N
overall JJ N
treatment NN N
effect NN N
was VBD N
detected VBN N
dependent NN N
on IN N
the DT N
recurrence NN N
status NN N
before IN N
entry NN N
into IN N
the DT N
study NN N
( ( N
p JJ N
= NNP N
0.0059 CD N
) ) N
. . N

Pairwise VB N
comparisons NNS N
showed VBD N
the DT N
mitomycin NN N
protocol NN N
with IN N
short-term JJ N
intensive JJ N
( ( N
weekly JJ N
) ) N
combined VBN N
with IN N
long-term JJ N
maintenance NN N
instillation NN N
to TO N
have VB N
a DT N
highly RB N
beneficial JJ N
effect NN N
compared VBN N
to TO N
long-term JJ N
maintenance NN N
instillation NN N
only RB N
especially RB N
for IN N
patients NNS N
entering VBG N
the DT N
study NN N
with IN N
recurrent JJ N
tumors NNS N
( ( N
RR NNP N
= NNP N
0.06 CD N
, , N
95 CD N
% NN N
CI NNP N
: : N
[ NN N
0.008 CD N
, , N
0.506 CD N
] NN N
. . N

CONCLUSION NNP N
These DT N
results NNS N
show VBP N
that IN N
intensive JJ N
therapeutic JJ N
instillation NN N
may MD N
have VB N
an DT N
advantage NN N
over IN N
less JJR N
intensive JJ N
, , N
prophylactic JJ N
regimens NNS N
. . N

-DOCSTART- -X- O O 9926538

Network NNP N
support NN N
for IN N
drinking NN N
, , N
Alcoholics NNP N
Anonymous NNP N
and CC N
long-term JJ N
matching NN N
effects NNS N
. . N

AIMS NNP N
( ( N
1 CD N
) ) N
To TO N
examine VB N
the DT N
matching JJ N
hypothesis NN N
that WDT N
Twelve NNP N
Step NNP N
Facilitation NNP N
Therapy NNP N
( ( N
TSF NNP N
) ) N
is VBZ N
more RBR N
effective JJ N
than IN N
Motivational NNP N
Enhancement NNP N
Therapy NNP N
( ( N
MET NNP N
) ) N
for IN N
alcohol-dependent JJ 4_p
clients NNS N
with IN N
networks NNS N
highly RB N
supportive JJ N
of IN N
drinking VBG N
3 CD N
years NNS N
following VBG N
treatment NN N
; : N
( ( N
2 CD N
) ) N
to TO N
test VB N
a DT N
causal NN N
chain NN N
providing VBG N
the DT N
rationale NN N
for IN N
this DT N
effect NN N
. . N

DESIGN NN N
Outpatients NNPS 4_p
were VBD N
re-interviewed JJ N
3 CD N
years NNS N
following VBG N
treatment NN N
. . N

ANCOVAs NNP N
tested VBD N
the DT N
matching JJ N
hypothesis NN N
. . N

SETTING NN N
Outpatients NNS N
from IN N
five CD N
clinical JJ N
research NN N
units NNS N
distributed VBN N
across IN N
the DT N
United NNP N
States NNPS N
. . N

PARTICIPANTS NNP N
Eight NNP N
hundred VBD N
and CC N
six CD N
alcohol-dependent JJ 4_p
clients NNS N
. . N

INTERVENTION JJ N
Clients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
three CD N
12-week JJ N
, , N
manually-guided JJ N
, , N
individual JJ N
treatments NNS N
: : N
TSF NNP N
, , N
MET NNP N
or CC N
Cognitive NNP N
Behavioral NNP N
Coping NNP N
Skills NNP N
Therapy NNP N
( ( N
CBT NNP N
) ) N
. . N

MEASUREMENTS NNP N
Network NNP N
support NN N
for IN N
drinking VBG N
prior JJ N
to TO N
treatment NN N
, , N
Alcoholics NNP N
Anonymous NNP N
( ( N
AA NNP N
) ) N
involvement NN N
during IN N
and CC N
following VBG N
treatment NN N
, , N
percentage NN N
of IN N
days NNS N
abstinent JJ N
and CC N
drinks NNS N
per IN N
drinking NN N
day NN N
during IN N
months NNS N
37-39 JJ N
. . N

FINDINGS NNP N
( ( N
1 CD N
) ) N
The DT N
a DT N
priori JJ N
matching NN N
hypothesis NN N
that IN N
TSF NNP N
is VBZ N
more RBR N
effective JJ N
than IN N
MET NNP N
for IN N
clients NNS N
with IN N
networks NNS N
supportive NN N
of IN N
drinking NN N
was VBD N
supported VBN N
at IN N
the DT N
3 CD N
year NN N
follow-up NN N
; : N
( ( N
2 CD N
) ) N
AA NNP N
involvement NN N
was VBD N
a DT N
partial JJ N
mediator NN N
of IN N
this DT N
effect NN N
; : N
clients NNS N
with IN N
networks NNS N
supportive NN N
of IN N
drinking NN N
assigned VBN N
to TO N
TSF VB N
were VBD N
more RBR N
likely JJ N
to TO N
be VB N
involved VBN N
in IN N
AA NNP N
; : N
AA NNP N
involvement NN N
was VBD N
associated VBN N
with IN N
better JJR N
3-year JJ N
drinking NN N
outcomes NNS N
for IN N
such JJ N
clients NNS N
. . N

CONCLUSIONS NNP N
( ( N
1 CD N
) ) N
In IN N
the DT N
long-term JJ N
TSF NNP N
may MD N
be VB N
the DT N
treatment NN N
of IN N
choice NN N
for IN N
alcohol-dependent JJ N
clients NNS N
with IN N
networks NNS N
supportive NN N
of IN N
drinking NN N
; : N
( ( N
2 CD N
) ) N
involvement NN N
in IN N
AA NNP N
should MD N
be VB N
given VBN N
special JJ N
consideration NN N
for IN N
clients NNS N
with IN N
networks NNS N
supportive NN N
of IN N
drinking NN N
, , N
irrespective NN N
of IN N
the DT N
therapy NN N
they PRP N
will MD N
receive VB N
. . N

-DOCSTART- -X- O O 12045163

Prospective JJ N
study NN N
of IN N
C-reactive NNP N
protein NN N
, , N
homocysteine NN N
, , N
and CC N
plasma VB N
lipid JJ N
levels NNS N
as IN N
predictors NNS N
of IN N
sudden JJ N
cardiac JJ N
death NN N
. . N

BACKGROUND NNP N
Sudden NNP N
cardiac JJ N
death NN N
( ( N
SCD NNP N
) ) N
is VBZ N
an DT N
important JJ N
cause NN N
of IN N
mortality NN N
even RB N
among IN N
apparently RB N
healthy JJ N
populations NNS N
. . N

However RB N
, , N
our PRP$ N
ability NN N
to TO N
identify VB N
those DT N
at IN N
risk NN N
for IN N
SCD NNP N
in IN N
the DT N
general JJ N
population NN N
is VBZ N
poor JJ N
, , N
and CC N
more RBR N
specific JJ N
markers NNS N
are VBP N
needed VBN N
. . N

METHODS NNP N
AND CC N
RESULTS NNP N
To TO N
compare VB N
and CC N
contrast VB N
the DT N
relative JJ N
importance NN N
of IN N
C-reactive JJ N
protein NN N
( ( N
CRP NNP N
) ) N
, , N
homocysteine NN N
, , N
and CC N
lipids NNS N
as IN N
long-term JJ N
predictors NNS N
of IN N
SCD NNP N
, , N
we PRP N
performed VBD N
a DT N
prospective JJ N
, , N
nested JJ N
, , N
case-control JJ N
analysis NN N
involving VBG N
97 CD N
cases NNS N
of IN N
SCD NNP 4_p
among IN N
apparently RB 4_p
healthy JJ 4_p
men NNS N
enrolled VBN N
in IN N
the DT N
Physician NNP N
's POS N
Health NNP N
Study NNP N
. . N

Of IN N
these DT N
plasma JJ N
markers NNS N
measured VBD N
, , N
only RB N
baseline JJ N
CRP NNP N
levels NNS N
were VBD N
significantly RB N
associated VBN N
with IN N
the DT N
risk NN N
of IN N
SCD NNP N
over IN N
the DT N
ensuing VBG N
17 CD N
years NNS N
of IN N
follow-up NN N
( ( N
P NNP N
for IN N
trend=0.001 NN N
) ) N
. . N

The DT N
increase NN N
in IN N
risk NN N
associated VBN N
with IN N
CRP NNP N
levels NNS N
was VBD N
primarily RB N
seen VBN N
among IN N
men NNS N
in IN N
the DT N
highest JJS N
quartile NN N
, , N
who WP N
were VBD N
at IN N
a DT N
2.78-fold JJ N
increased JJ N
risk NN N
of IN N
SCD NNP N
( ( N
95 CD N
% NN N
CI NNP N
1.35 CD N
to TO N
5.72 CD N
) ) N
compared VBN N
with IN N
men NNS N
in IN N
the DT N
lowest JJS N
quartile NN N
. . N

These DT N
results NNS N
were VBD N
not RB N
significantly RB N
altered VBN N
in IN N
analyses NNS N
that WDT N
( ( N
in IN N
addition NN N
to TO N
the DT N
matching JJ N
variables NNS N
of IN N
age NN N
and CC N
smoking NN N
status NN N
) ) N
controlled VBD N
for IN N
lipid JJ N
parameters NNS N
, , N
homocysteine NN N
, , N
and CC N
multiple JJ N
cardiac JJ N
risk NN N
factors NNS N
( ( N
relative JJ N
risk NN N
for IN N
highest JJS N
versus NN N
lowest JJS N
quartile NN N
2.65 CD N
, , N
95 CD N
% NN N
CI NNP N
0.79 CD N
to TO N
8.83 CD N
; : N
P NNP N
for IN N
trend=0.03 NN N
) ) N
. . N

In IN N
contrast NN N
to TO N
the DT N
positive JJ N
relationship NN N
observed VBD N
for IN N
CRP NNP N
, , N
neither DT N
homocysteine NN N
nor CC N
lipid JJ N
levels NNS N
were VBD N
significantly RB N
associated VBN N
with IN N
risk NN N
of IN N
SCD NNP N
. . N

CONCLUSIONS NNP N
These DT N
prospective JJ N
data NNS N
suggest VBP N
that IN N
CRP NNP N
levels NNS N
may MD N
be VB N
useful JJ N
in IN N
identifying VBG N
apparently RB N
healthy JJ N
men NNS N
who WP N
are VBP N
at IN 4_p
an DT 4_p
increased VBN 4_p
long-term JJ 4_p
risk NN 4_p
of IN 4_p
SCD NNP 4_p
. . N

-DOCSTART- -X- O O 21366734

Which JJ N
women NNS N
default NN N
from IN N
follow-up JJ N
cervical JJ N
cytology NN N
tests NNS N
? . N
A DT N
cohort NN N
study NN N
within IN N
the DT N
TOMBOLA NNP N
trial NN N
. . N

OBJECTIVE UH N
To TO N
identify VB N
factors NNS N
associated VBN N
with IN N
default NN N
from IN N
follow-up JJ N
cervical JJ N
cytology NN N
tests NNS N
. . N

METHODS NNP N
A NNP N
cohort NN N
study NN N
was VBD N
conducted VBN N
involving VBG N
2166 CD N
women NNS N
, , N
aged VBD N
20-59 JJ N
, , N
with IN N
recent JJ N
low-grade JJ N
cervical JJ N
cytology NN N
taken VBN N
within IN N
the DT N
NHS NNP N
Cervical NNP N
Screening NNP N
Programmes NNP N
in IN N
Scotland NNP N
and CC N
England NNP N
, , N
and CC N
managed VBN N
by IN N
6-monthly JJ N
cytology NN N
in IN N
primary JJ N
care NN N
. . N

For IN N
the DT N
first JJ N
( ( N
6-month JJ N
) ) N
and CC N
second JJ N
( ( N
12-month JJ N
) ) N
surveillance NN N
cytology NN N
tests NNS N
separately RB N
, , N
women NNS N
were VBD N
categorized VBN N
as IN N
'on-time JJ N
attendees NNS N
' POS N
( ( N
attended JJ N
≤6 NNP N
months NNS N
of IN N
test NN N
being VBG N
due JJ N
) ) N
, , N
'late '' N
attendees NNS N
' POS N
( ( N
attended VBD N
greater JJR N
than IN N
6 CD N
months NNS N
after IN N
test NN N
was VBD N
due JJ N
) ) N
or CC N
'non-attendees NNS N
' POS N
( ( N
failed VBN N
to TO N
attend VB N
) ) N
. . N

Multivariate NNP N
odds JJ N
ratios NNS N
( ( N
ORs NNP N
) ) N
were VBD N
computed VBN N
for IN N
factors NNS N
associated VBN N
with IN N
late JJ N
and CC N
non-attendance JJ N
. . N

RESULTS NNP N
For IN N
the DT N
first JJ N
surveillance NN N
test NN N
, , N
risk NN N
of IN N
non-attendance NN N
was VBD N
significantly RB N
higher JJR N
in IN N
younger JJR N
women NNS N
, , N
those DT N
without IN N
post-secondary JJ N
education NN N
, , N
and CC N
non-users NNS N
of IN N
prescribed JJ N
contraception NN N
. . N

Factors NNS N
significantly RB N
associated VBN N
with IN N
late JJ N
attendance NN N
for IN N
the DT N
first JJ N
test NN N
were VBD N
the DT N
same JJ N
as IN N
for IN N
non-attendance NN N
, , N
plus CC N
current JJ N
smoking NN N
and CC N
having VBG N
children NNS N
. . N

The DT N
most RBS N
important JJ N
predictor NN N
of IN N
non-attendance NN N
for IN N
the DT N
second JJ N
surveillance NN N
test NN N
was VBD N
late JJ N
attendance NN N
for IN N
the DT N
first JJ N
test NN N
( ( N
OR NNP N
= VBZ N
9.65 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
6.60-16.62 JJ N
) ) N
. . N

Non-attendance NN N
for IN N
the DT N
second JJ N
test NN N
was VBD N
also RB N
significantly RB N
higher JJR N
among IN N
women NNS N
who WP N
were VBD N
younger JJR N
, , N
smokers NNS N
and CC N
had VBD N
negative JJ N
cytology NN N
on IN N
the DT N
first JJ N
surveillance NN N
test NN N
. . N

Late JJ N
attendance NN N
for IN N
the DT N
second JJ N
surveillance NN N
test NN N
was VBD N
higher RBR N
in IN N
women NNS N
who WP N
were VBD N
younger JJR N
, , N
smokers NNS N
, , N
had VBD N
children NNS N
and CC N
attended VBD N
late RB N
for IN N
the DT N
first JJ N
test NN N
. . N

CONCLUSIONS NNP N
Women NNP N
at IN N
highest JJS N
risk NN N
of IN N
default NN N
from IN N
follow-up JJ N
cytology NN N
tend NN N
to TO N
be VB N
young JJ N
, , N
smoke NN N
, , N
lack NN N
post-secondary JJ N
education NN N
, , N
and CC N
have VBP N
defaulted VBN N
from IN N
a DT N
previous JJ N
surveillance NN N
appointment NN N
. . N

Tackling VBG N
default NN N
will MD N
require VB N
development NN N
of IN N
targeted JJ N
strategies NNS N
to TO N
encourage VB N
attendance NN N
and CC N
research NN N
to TO N
better JJR N
understand VB N
the DT N
reasons NNS N
underpinning VBG N
default NN N
. . N

-DOCSTART- -X- O O 7616334

Primary JJ N
care-based JJ N
ambulatory NN N
opioid JJ N
detoxification NN N
: : N
the DT N
results NNS N
of IN N
a DT N
clinical JJ N
trial NN N
. . N

OBJECTIVE NN N
To TO N
determine VB N
the DT N
feasibility NN N
of IN N
primary JJ N
care-based JJ N
ambulatory NN N
opioid JJ N
detoxification NN N
( ( N
AOD NNP N
) ) N
using VBG N
two CD N
protocols NNS N
: : N
clonidine NN N
and CC N
clonidine NN N
plus CC N
naltrexone NN N
. . N

SETTING CC N
The DT N
Central NNP N
Medical NNP N
Unit NNP N
( ( N
CMU NNP N
) ) N
-- : N
a DT N
freestanding JJ N
primary NN N
care NN N
medical JJ N
clinic NN N
staffed VBN N
by IN N
physicians NNS N
and CC N
nurse JJ N
practitioners NNS N
. . N

PATIENTS NNP N
Injection NNP N
drug NN N
users NNS N
( ( N
IDUs NNP N
) ) N
seeking VBG N
substance NN 4_p
abuse NN 4_p
treatment NN N
between IN N
the DT N
ages NNS N
of IN N
18 CD N
and CC N
50 CD N
years NNS N
who WP N
were VBD N
addicted VBN N
to TO N
opioids NNS N
( ( N
e.g. NN N
, , N
heroin NN N
) ) N
and CC N
not RB N
currently RB N
in IN N
drug NN N
treatment NN N
. . N

INTERVENTIONS NNP N
In IN N
the DT N
clonidine NN N
protocol NN N
, , N
clonidine NN N
was VBD N
administered VBN N
every DT N
4 CD N
hours NNS N
" RB N
as IN N
needed VBN N
" NN N
for IN N
up IN N
to TO N
12 CD N
days NNS N
. . N

In IN N
the DT N
clonidine NN N
plus CC N
naltrexone NN N
protocol NN N
, , N
clonidine NN N
was VBD N
administered VBN N
and CC N
naltrexone NN N
was VBD N
administered VBN N
in IN N
increasing VBG N
doses NNS N
over IN N
five CD N
days NNS N
. . N

Both DT N
protocols NNS N
included VBD N
" JJ N
adjuvant JJ N
" NN N
medications NNS N
for IN N
muscle NN N
cramps NNS N
, , N
insomnia NN N
, , N
and CC N
vomiting VBG N
. . N

Successfully RB N
detoxified JJ N
patients NNS N
were VBD N
referred VBN N
to TO N
ongoing VBG N
drug NN N
treatment NN N
. . N

DESIGN VB N
A DT N
prospective JJ N
nonrandomized JJ N
clinical JJ N
trial NN N
. . N

MEASUREMENTS NNP N
AND CC N
MAIN NNP N
RESULTS NNP N
One CD N
hundred VBD N
forty JJ N
opioid-addicted JJ N
IDUs NNP N
were VBD N
referred VBN N
to TO N
the DT N
medical JJ N
clinic NN N
for IN N
AOD NNP N
. . N

Among IN N
the DT N
125 CD N
patients NNS N
who WP N
enrolled VBD N
in IN N
the DT N
study NN N
, , N
57 CD N
selected VBN N
clonidine NN N
and CC N
68 CD N
selected VBN N
clonidine/naltrexone NN N
. . N

The DT N
treatment NN N
groups NNS N
( ( N
clonidine JJ N
vs IN N
clonidine/naltrexone NN N
) ) N
were VBD N
similar JJ N
at IN N
baseline NN N
with IN N
respect NN N
to TO N
: : N
age NN N
at IN N
first JJ N
heroin NN N
use NN N
( ( N
21 CD N
years NNS N
vs RB N
23 CD N
years NNS N
) ) N
, , N
mean JJ N
admission NN N
opioid IN N
craving VBG N
score NN N
( ( N
45/100 CD N
vs RB N
49/100 CD N
) ) N
, , N
and CC N
withdrawal NN N
symptom NN N
score NN N
( ( N
19/72 CD N
vs RB N
18/72 CD N
) ) N
. . N

Overall JJ N
, , N
70 CD N
% NN N
( ( N
88/125 CD N
) ) N
of IN N
the DT N
AODs NNP N
were VBD N
successful JJ N
, , N
including VBG N
42 CD N
% NN N
( ( N
24/57 CD N
) ) N
for IN N
clonidine NN N
and CC N
94 CD N
% NN N
( ( N
64/68 CD N
) ) N
for IN N
clonidine/naltrexone NN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

CONCLUSIONS VB N
This DT N
study NN N
suggests VBZ N
that IN N
primary JJ N
care-based JJ N
AOD NNP N
can MD N
be VB N
safely RB N
and CC N
effectively RB N
carried VBN N
out RP N
by IN N
primary JJ N
care NN N
providers NNS N
and CC N
that IN N
clonidine/naltrexone NN N
may MD N
be VB N
more RBR N
effective JJ N
in IN N
this DT N
setting NN N
than IN N
is VBZ N
clonidine JJ N
alone RB N
. . N

Ambulatory NNP N
opioid JJ N
detoxification NN N
can MD N
give VB N
internists NNS N
a DT N
larger JJR N
role NN N
in IN N
initiating VBG N
drug NN N
treatment NN N
for IN N
IDUs NNP N
who WP N
are VBP N
addicted VBN 4_p
to TO 4_p
opioids NNS 4_p
. . N

-DOCSTART- -X- O O 6849726

Interactions NNS N
of IN N
morphine NN N
and CC N
methotrimeprazine NN N
in IN N
mouse NN N
and CC N
man NN N
with IN N
respect NN N
to TO N
analgesia VB N
, , N
respiration NN N
and CC N
sedation NN N
. . N

Interactions NNS N
between IN N
morphine NN N
and CC N
methotrimeprazine NN N
have VBP N
been VBN N
studied VBN N
in IN N
mice NN N
and CC N
man NN N
with IN N
respect NN N
to TO N
analgesia VB N
or CC N
antinociceptive JJ N
activity NN N
, , N
respiratory NN N
effects NNS N
and CC N
sedation NN N
. . N

The DT N
volunteer NN N
study NN N
was VBD N
a DT N
double-blind JJ N
cross-over JJ N
trial NN N
with IN N
10 CD N
volunteers NNS N
. . N

In IN N
mice NN N
, , N
methotrimeprazine VBZ N
only RB N
possessed JJ N
antinociceptive JJ N
activity NN N
in IN N
doses NNS N
which WDT N
caused VBD N
marked JJ N
sedation NN N
. . N

However RB N
, , N
small JJ N
non-sedative JJ N
doses NNS N
of IN N
methotrimeprazine NN N
potentiated VBN N
the DT N
analgesic JJ N
action NN N
of IN N
morphine NN N
. . N

The DT N
volunteer NN N
study NN N
did VBD N
not RB N
confirm VB N
this DT N
finding NN N
in IN N
man NN N
. . N

Methotrimeprazine NNP N
7.5 CD N
mg NN N
i.m NN N
. . N

caused VBN N
significant JJ N
sedation NN N
, , N
but CC N
did VBD N
not RB N
alter VB N
the DT N
effects NNS N
of IN N
morphine NN N
5 CD N
mg NN N
on IN N
pain NN N
threshold NN N
or CC N
ventilatory NN N
response NN N
to TO N
carbon VB N
dioxide NN N
. . N

-DOCSTART- -X- O O 2576261

Effect NN N
of IN N
two CD N
monophasic JJ N
oral JJ N
contraceptives NNS N
containing VBG N
gestodene NN N
or CC N
desogestrel NN N
on IN N
serum NN N
lipoprotein NN N
lipid JJ N
levels NNS N
. . N

Forty-nine NNP N
healthy JJ N
women NNS N
aged VBN N
20-35 JJ N
years NNS N
who WP N
had VBD N
not RB N
been VBN N
pregnant JJ N
or CC N
using VBG N
an DT N
oral JJ 4_p
contraceptive NN 4_p
( ( N
OC NNP N
) ) N
for IN N
the DT N
previous JJ N
3 CD N
months NNS N
were VBD N
randomized VBN N
into IN N
two CD N
groups NNS N
, , N
one CD N
group NN N
taking VBG N
an DT N
OC NNP N
containing VBG N
75 CD N
micrograms NNS N
gestodene NN N
( ( N
GTD NNP N
) ) N
and CC N
30 CD N
micrograms NNS N
ethinyl VBP N
estradiol NN N
( ( N
EE NNP N
) ) N
, , N
and CC N
the DT N
other JJ N
group NN N
using VBG N
an DT N
OC NNP N
with IN N
150 CD N
micrograms NNS N
desogestrel NN N
( ( N
DSG NNP N
) ) N
and CC N
30 CD N
micrograms NNS N
EE NNP N
. . N

Fasting VBG N
blood NN N
samples NNS N
were VBD N
taken VBN N
before RB N
treatment NN N
, , N
and CC N
after IN N
cycles NNS N
3 CD N
and CC N
6 CD N
, , N
between IN N
the DT N
18th CD N
and CC N
the DT N
22nd CD N
day NN N
of IN N
the DT N
cycle NN N
. . N

Blood NNP N
lipoprotein JJ N
lipid JJ N
levels NNS N
were VBD N
measured VBN N
. . N

Serum NNP N
total JJ N
cholesterol NN N
did VBD N
not RB N
change VB N
significantly RB N
in IN N
both DT N
groups NNS N
. . N

However RB N
, , N
in IN N
the DT N
first JJ N
three CD N
cycles NNS N
, , N
serum JJ N
triglyceride NN N
increased VBN N
by IN N
46 CD N
% NN N
and CC N
40 CD N
% NN N
and CC N
HDL-cholesterol NNP N
by IN N
14 CD N
% NN N
and CC N
8 CD N
% NN N
in IN N
the DT N
GTD NNP N
and CC N
DSG NNP N
groups NNS N
, , N
respectively RB N
. . N

The DT N
serum NN N
LDL NNP N
level NN N
decreased VBN N
by IN N
6.2 CD N
% NN N
and CC N
11.8 CD N
% NN N
, , N
respectively RB N
. . N

Between VB N
the DT N
third JJ N
and CC N
sixth JJ N
cycle NN N
, , N
no DT N
further JJ N
significant JJ N
changes NNS N
were VBD N
observed VBN N
, , N
nor CC N
did VBD N
these DT N
changes NNS N
differ VBP N
significantly RB N
between IN N
the DT N
two CD N
groups NNS N
. . N

In IN N
conclusion NN N
, , N
both DT N
OC NNP N
preparations NNS N
exerted VBD N
small JJ N
and CC N
probably RB N
favorable JJ N
effects NNS N
on IN N
serum NN N
lipoprotein NN N
lipid JJ N
levels NNS N
. . N

-DOCSTART- -X- O O 9003876

Topical JJ N
beta-blockade NN N
with IN N
intrinsic JJ N
sympathomimetic JJ N
activity NN N
offers VBZ N
no DT N
advantage NN N
for IN N
the DT N
respiratory NN N
and CC N
cardiovascular JJ N
function NN N
of IN N
elderly JJ 4_p
people NNS 4_p
. . 4_p

Topical JJ N
therapy NN N
with IN N
beta-antagonists NNS N
, , N
such JJ N
as IN N
timolol NNS N
, , N
may MD N
cause VB N
unrecognized JJ N
impairment NN N
of IN N
respiratory NN N
and CC N
cardiovascular JJ N
function NN N
in IN N
elderly JJ N
people NNS N
. . N

Beta-antagonists NNS N
with IN N
intrinsic JJ N
sympathomimetic JJ N
or CC N
cardioselective JJ N
properties NNS N
, , N
such JJ N
as IN N
carteolol NN N
or CC N
betaxolol NN N
, , N
may MD N
cause VB N
less JJR N
impairment NN N
. . N

In IN N
a DT N
randomized JJ N
, , N
double-masked JJ N
study NN N
of IN N
glaucoma NN N
patients NNS N
, , N
over IN N
60 CD N
years NNS N
of IN N
age NN N
, , N
without IN N
history NN N
of IN N
bronchospasm NN N
and CC N
who WP N
were VBD N
using VBG N
timolol NN N
( ( N
0.5 CD N
% NN N
) ) N
, , N
60 CD N
patients NNS N
were VBD N
allocated VBN N
to TO N
betaxolol VB N
( ( N
0.5 CD N
% NN N
) ) N
or CC N
carteolol NN N
( ( N
2 CD N
% NN N
) ) N
or CC N
continued VBN N
timolol NNS N
( ( N
0.5 CD N
% NN N
) ) N
treatment NN N
. . N

Spirometry NNP N
, , N
pulse NN N
and CC N
blood NN N
pressure NN N
were VBD N
measured VBN N
on IN N
enrollment NN N
and CC N
after IN N
4 CD N
weeks NNS N
. . N

In IN N
the DT N
timolol NN N
and CC N
carteolol NN N
groups NNS N
there EX N
were VBD N
no DT N
significant JJ N
changes NNS N
in IN N
mean JJ N
spirometric JJ N
values NNS N
. . N

Changing VBG N
to TO N
betaxolol VB N
improved JJ N
mean JJ N
peak NN N
flow NN N
( ( N
PF NNP N
) ) N
by IN N
9.1 CD N
% NN N
, , N
from IN N
310 CD N
to TO N
3411/min CD N
( ( N
p NN N
< RB N
0.05 CD N
) ) N
and CC N
forced JJ N
expiratory NN N
volume NN N
in IN N
1 CD N
second JJ N
( ( N
FEV1 NNP N
) ) N
by IN N
9.4 CD N
% NN N
, , N
from IN N
1.74 CD N
to TO N
1.861 CD N
( ( N
p NN N
< RB N
0.05 CD N
) ) N
. . N

Differences NNS N
in IN N
the DT N
changes NNS N
in IN N
PF NNP N
and CC N
FEV1 NNP N
between IN N
betaxolol NN N
and CC N
timolol NN N
as RB N
well RB N
as IN N
betaxolol NN N
and CC N
carteolol NN N
groups NNS N
were VBD N
statistically RB N
significant JJ N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

Twenty-one CD N
per IN N
cent NN N
of IN N
those DT N
allocated VBN N
to TO N
betaxolol VB N
showed VBN N
clinically RB N
significant JJ N
improvement NN N
in IN N
FEV1 NNP N
. . N

There EX N
was VBD N
no DT N
change NN N
in IN N
pulse NN N
or CC N
blood NN N
pressure NN N
when WRB N
carteolol NN N
was VBD N
substituted VBN N
for IN N
timolol NN N
but CC N
an DT N
increase NN N
of IN N
10 CD N
beats NNS N
per IN N
minute NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
in IN N
mean NN N
resting VBG N
pulse NN N
in IN N
the DT N
betaxolol NN N
group NN N
. . N

Therapy NN N
with IN N
cardioselective JJ N
beta-blockade NN N
may MD N
offer VB N
significant JJ N
advantages NNS N
in IN N
respiratory NN N
function NN N
for IN N
elderly JJ N
people NNS N
with IN N
glaucoma NN N
over IN N
non-selective JJ N
drugs NNS N
, , N
even RB N
if IN N
they PRP N
have VBP N
sympathomimetic JJ N
activity NN N
. . N

-DOCSTART- -X- O O 20633669

Efficacy NN N
of IN N
patient JJ N
education NN N
and CC N
supervised VBD N
exercise NN N
vs NN N
patient JJ N
education NN N
alone RB N
in IN N
patients NNS N
with IN N
hip JJ 4_p
osteoarthritis NN 4_p
: : N
a DT N
single JJ N
blind NN N
randomized VBD N
clinical JJ N
trial NN N
. . N

OBJECTIVE UH N
To TO N
compare VB N
the DT N
efficacy NN N
of IN N
patient JJ N
education NN N
and CC N
supervised VBD N
exercise NN N
with IN N
that DT N
of IN N
patient JJ N
education NN N
alone RB N
for IN N
the DT N
management NN N
of IN N
pain NN N
in IN N
patients NNS N
with IN N
hip NN 4_p
osteoarthritis NN 4_p
( ( 4_p
OA NNP 4_p
) ) 4_p
. . N

DESIGN NNP N
Single NNP N
blind IN N
randomized JJ N
clinical JJ N
trial NN N
. . N

SETTING NNP N
Recruitment NNP N
of IN N
patients NNS N
from IN 4_p
hospitals NNS 4_p
, , N
primary JJ N
health NN N
care NN N
and CC N
advertisement NN N
, , N
Oslo NNP N
, , N
Norway NNP N
. . N

PARTICIPANTS NNP N
109 CD N
patients NNS N
with IN N
radiographic JJ 4_p
and CC 4_p
symptomatic JJ 4_p
hip NN 4_p
OA NNP 4_p
with IN N
mild NN N
to TO N
moderate VB N
symptoms NNS N
. . N

INTERVENTIONS NNP N
Patient NNP N
education NN N
( ( N
PE NNP N
) ) N
. . N

Patient JJ N
education NN N
and CC N
supervised VBN N
exercise NN N
( ( N
PE+SE NNP N
) ) N
. . N

PRIMARY NNP N
OUTCOME NNP N
MEASURE NNP N
The DT N
pain NN N
subscale NN N
of IN N
the DT N
Western NNP N
Ontario NNP N
and CC N
McMaster NNP N
Universities NNP N
Osteoarthritis NNP N
Index NNP N
( ( N
WOMAC NNP N
pain NN N
) ) N
. . N

RESULTS NNP N
No NNP N
significant JJ N
between IN N
group NN N
differences NNS N
were VBD N
found VBN N
for IN N
WOMAC NNP N
pain NN N
over IN N
the DT N
16-month JJ N
follow-up NN N
. . N

Significant JJ N
improvements NNS N
were VBD N
found VBN N
for IN N
the DT N
secondary JJ N
outcome NN N
WOMAC NNP N
physical JJ N
function NN N
( ( N
P=0.011 NNP N
) ) N
in IN N
the DT N
group NN N
receiving VBG N
PE+SE NNP N
compared VBN N
to TO N
the DT N
group NN N
receiving VBG N
PE NNP N
only RB N
. . N

No DT N
significant JJ N
differences NNS N
were VBD N
found VBN N
for IN N
WOMAC NNP N
stiffness NN N
, , N
the DT N
SF-36 JJ N
subscales NNS N
or CC N
the DT N
activity NN N
scale NN N
. . N

The DT N
effect NN N
sizes VBZ N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
) ) N
for IN N
WOMAC NNP N
pain NN N
were VBD N
-0.26 NNP N
( ( N
0.11 CD N
, , N
-0.64 NN N
) ) N
, , N
-0.35 NNP N
( ( N
0.07 CD N
, , N
-0.77 NN N
) ) N
, , N
and CC N
-0.30 NNP N
( ( N
0.15 CD N
, , N
-0.75 NN N
) ) N
, , N
and CC N
for IN N
WOMAC NNP N
physical JJ N
function NN N
-0.29 NNP N
( ( N
0.09 CD N
, , N
-0.67 NN N
) ) N
, , N
-0.48 NNP N
( ( N
-0.06 NNP N
, , N
-0.91 NNP N
) ) N
, , N
and CC N
-0.47 NNP N
( ( N
-0.02 NNP N
, , N
-0.93 NNP N
) ) N
at IN N
4 CD N
, , N
10 CD N
and CC N
16 CD N
months NNS N
, , N
respectively RB N
, , N
in IN N
favor NN N
of IN N
the DT N
group NN N
receiving VBG N
both DT N
PE NNP N
and CC N
SE NNP N
. . N

All DT N
patients NNS N
attended VBD N
the DT N
three-session JJ N
PE NNP N
program NN N
, , N
and CC N
75 CD N
% NN N
performed VBN N
≥16 JJ N
sessions NNS N
of IN N
the DT N
12-week JJ N
SE NNP N
program NN N
. . N

CONCLUSION NNP N
The DT N
study NN N
could MD N
not RB N
demonstrate VB N
a DT N
significant JJ N
difference NN N
in IN N
pain NN N
reduction NN N
over IN N
time NN N
between IN N
PE+SE NNP N
vs NNP N
PE NNP N
alone RB N
. . N

Adding VBG N
SE NNP N
to TO N
PE NNP N
may MD N
improve VB N
physical JJ N
function NN N
, , N
but CC N
the DT N
magnitude NN N
of IN N
possible JJ N
benefit NN N
is VBZ N
unknown JJ N
as IN N
the DT N
95 CD N
% NN N
confidence NN N
intervals NNS N
around IN N
the DT N
mean JJ N
difference NN N
were VBD N
wide JJ N
. . N

TRIAL NNP N
REGISTRATION NNP N
Clinical NNP N
Trials NNP N
NCT00319423 NNP N
. . N

-DOCSTART- -X- O O 26606872

Effectiveness NN N
of IN N
Neuromuscular NNP N
Electrical NNP N
Stimulation NNP N
on IN N
Patients NNS N
With IN N
Dysphagia NNP 4_p
With IN 4_p
Medullary NNP 4_p
Infarction NNP 4_p
. . N

OBJECTIVE NNP N
To TO N
evaluate VB N
and CC N
compare VB N
the DT N
effects NNS N
of IN N
neuromuscular JJ N
electrical JJ N
stimulation NN N
( ( N
NMES NNP N
) ) N
acting VBG N
on IN N
the DT N
sensory JJ N
input NN N
or CC N
motor NN N
muscle NN N
in IN N
treating VBG N
patients NNS N
with IN N
dysphagia NN 4_p
with IN 4_p
medullary JJ 4_p
infarction NN 4_p
. . N

DESIGN NNP N
Prospective NNP N
randomized VBD N
controlled VBN N
study NN N
. . N

SETTING NNP N
Department NNP N
of IN N
physical JJ N
medicine NN N
and CC N
rehabilitation NN N
. . N

PARTICIPANTS CC N
Patients NNPS N
with IN N
dysphagia NN 4_p
with IN 4_p
medullary JJ 4_p
infarction NN 4_p
( ( N
N=82 NNP N
) ) N
. . N

INTERVENTIONS JJ N
Participants NNS N
were VBD N
randomized VBN N
over IN N
3 CD N
intervention NN N
groups NNS N
: : N
traditional JJ N
swallowing NN N
therapy NN N
, , N
sensory JJ N
approach NN N
combined VBN N
with IN N
traditional JJ N
swallowing VBG N
therapy NN N
, , N
and CC N
motor NN N
approach NN N
combined VBN N
with IN N
traditional JJ N
swallowing VBG N
therapy NN N
. . N

Electrical JJ N
stimulation NN N
sessions NNS N
were VBD N
for IN N
20 CD N
minutes NNS N
, , N
twice RB N
a DT N
day NN N
, , N
for IN N
5d/wk CD N
, , N
over IN N
a DT N
4-week JJ N
period NN N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Swallowing NNP N
function NN N
was VBD N
evaluated VBN N
by IN N
the DT N
water NN N
swallow JJ N
test NN N
and CC N
Standardized NNP N
Swallowing NNP N
Assessment NNP N
, , N
oral JJ N
intake NN N
was VBD N
evaluated VBN N
by IN N
the DT N
Functional NNP N
Oral NNP N
Intake NNP N
Scale NNP N
, , N
quality NN N
of IN N
life NN N
was VBD N
evaluated VBN N
by IN N
the DT N
Swallowing-Related JJ N
Quality NN N
of IN N
Life NNP N
( ( N
SWAL-QOL NNP N
) ) N
Scale NNP N
, , N
and CC N
cognition NN N
was VBD N
evaluated VBN N
by IN N
the DT N
Mini-Mental JJ N
State NNP N
Examination NNP N
( ( N
MMSE NNP N
) ) N
. . N

RESULTS CC N
There EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
between IN N
the DT N
groups NNS N
in IN N
age NN N
, , N
sex NN N
, , N
duration NN N
, , N
MMSE NNP N
score NN N
, , N
or CC N
severity NN N
of IN N
the DT N
swallowing VBG N
disorder NN N
( ( N
P NNP N
> NNP N
.05 NNP N
) ) N
. . N

All DT N
groups NNS N
showed VBD N
improved JJ N
swallowing NN N
function NN N
( ( N
P≤.01 NNP N
) ) N
; : N
the DT N
sensory JJ N
approach NN N
combined VBN N
with IN N
traditional JJ N
swallowing VBG N
therapy NN N
group NN N
showed VBD N
significantly RB N
greater JJR N
improvement NN N
than IN N
the DT N
other JJ N
2 CD N
groups NNS N
, , N
and CC N
the DT N
motor NN N
approach NN N
combined VBN N
with IN N
traditional JJ N
swallowing VBG N
therapy NN N
group NN N
showed VBD N
greater JJR N
improvement NN N
than IN N
the DT N
traditional JJ N
swallowing NN N
therapy NN N
group NN N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

SWAL-QOL JJ N
Scale JJ N
scores NNS N
increased VBD N
more RBR N
significantly RB N
in IN N
the DT N
sensory JJ N
approach NN N
combined VBN N
with IN N
traditional JJ N
swallowing VBG N
therapy NN N
and CC N
motor NN N
approach NN N
combined VBN N
with IN N
traditional JJ N
swallowing VBG N
therapy NN N
groups NNS N
than IN N
in IN N
the DT N
traditional JJ N
swallowing NN N
therapy NN N
group NN N
, , N
and CC N
the DT N
sensory JJ N
approach NN N
combined VBN N
with IN N
traditional JJ N
swallowing VBG N
therapy NN N
and CC N
motor NN N
approach NN N
combined VBN N
with IN N
traditional JJ N
swallowing VBG N
therapy NN N
groups NNS N
showed VBD N
statistically RB N
significant JJ N
differences NNS N
( ( N
P=.04 NNP N
) ) N
. . N

CONCLUSIONS NNP N
NMES NNP N
that WDT N
targets VBZ N
either CC N
sensory JJ N
input NN N
or CC N
motor NN N
muscle NN N
coupled VBN N
with IN N
traditional JJ N
therapy NN N
is VBZ N
conducive JJ N
to TO N
recovery NN N
from IN N
dysphagia NN N
and CC N
improves VBZ N
quality NN N
of IN N
life NN N
for IN 4_p
patients NNS 4_p
with IN 4_p
dysphagia NN 4_p
with IN 4_p
medullary JJ 4_p
infarction NN 4_p
. . N

A DT N
sensory JJ N
approach NN N
appears VBZ N
to TO N
be VB N
better JJR N
than IN N
a DT N
motor NN N
approach NN N
. . N

-DOCSTART- -X- O O 23768813

Targeting VBG N
alpha-7 JJ N
nicotinic JJ N
neurotransmission NN N
in IN N
schizophrenia NN 4_p
: : 4_p
a DT N
novel JJ N
agonist NN N
strategy NN N
. . N

Alpha7 NNP N
nicotinic JJ N
acetylcholine NN N
receptor NN N
( ( N
α7 NNP N
nAChR RB N
) ) N
agonists NNS N
may MD N
be VB N
valuable JJ N
treatments NNS N
for IN N
negative JJ N
symptoms NNS N
and CC N
cognitive JJ N
impairment NN N
in IN N
schizophrenia NN N
. . N

Unfortunately RB N
, , N
chronic JJ N
exposure NN N
to TO N
an DT N
agonist NN N
may MD N
reduce VB N
the DT N
receptor NN N
's POS N
sensitivity NN N
. . N

Therefore RB N
, , N
we PRP N
combined VBD N
CDP-choline NNP N
, , N
a DT N
dietary JJ N
source NN N
of IN N
the DT N
direct JJ N
agonist NN N
choline NN N
, , N
with IN N
galantamine NN N
, , N
a DT N
positive JJ N
allosteric JJ N
modulator NN N
( ( N
PAM NNP N
) ) N
of IN N
nicotinic JJ N
acetylcholine NN N
receptors NNS N
, , N
to TO N
improve VB N
the DT N
efficiency NN N
of IN N
transducing VBG N
the DT N
choline JJ N
signal NN N
and CC N
, , N
possibly RB N
, , N
preserve VB N
the DT N
receptor NN N
in IN N
a DT N
sensitive JJ N
state NN N
. . N

We PRP N
conducted VBD N
a DT N
single-site JJ N
, , N
double-blind JJ N
randomized JJ N
clinical JJ N
trial NN N
comparing VBG N
galantamine/CDP-choline NN N
to TO N
placebos VB N
in IN N
schizophrenia NN N
patients NNS N
with IN N
negative JJ N
symptoms NNS N
who WP N
were VBD N
receiving VBG N
second JJ N
generation NN N
antipsychotics NNS N
. . N

Forty-three JJ N
subjects NNS N
received VBN N
galantamine JJ N
and CC N
CDP-choline JJ N
or CC N
matching JJ N
placebos NNS N
for IN N
16weeks CD N
. . N

The DT N
primary JJ N
outcome NN N
measure NN N
was VBD N
the DT N
5-item JJ N
Marder NNP N
negative-symptoms JJ N
factor NN N
of IN N
the DT N
Positive NNP N
and CC N
Negative NNP N
Syndrome NNP N
Scale NNP N
( ( N
PANSS NNP N
) ) N
. . N

Cognition NN N
and CC N
functioning NN N
were VBD N
also RB N
assessed VBN N
. . N

Trial JJ N
completion NN N
was VBD N
high JJ N
; : N
79 CD N
% NN N
. . N

There EX N
was VBD N
no DT N
significant JJ N
treatment NN N
effect NN N
on IN N
negative JJ N
symptoms NNS N
, , N
other JJ N
PANSS NNP N
symptom NN N
factors NNS N
, , N
or CC N
the DT N
MATRICS NNP N
Cognitive NNP N
Consensus NNP N
Battery NNP N
. . N

There EX N
were VBD N
significant JJ N
treatment NN N
effects NNS N
in IN N
overall JJ N
functioning NN N
and CC N
a DT N
test NN N
of IN N
free JJ N
verbal JJ N
recall NN N
. . N

Three CD N
subjects NNS N
discontinued VBN N
treatment NN N
in IN N
the DT N
active JJ N
treatment NN N
group NN N
for IN N
gastro-intestinal JJ N
adverse JJ N
events NNS N
( ( N
AE NNP N
) ) N
. . N

The DT N
most RBS N
common JJ N
AE NNP N
for IN N
galantamine/CDP-choline NN N
was VBD N
abdominal JJ N
pain NN N
; : N
for IN N
placebo NN N
it PRP N
was VBD N
headache NN N
and CC N
sweating NN N
. . N

Although IN N
there EX N
was VBD N
no DT N
significant JJ N
treatment NN N
effect NN N
on IN N
negative JJ N
symptoms NNS N
, , N
the DT N
direction NN N
of IN N
effect NN N
mirrored VBD N
the DT N
effects NNS N
on IN N
a DT N
cognitive JJ N
measure NN N
and CC N
overall JJ N
functioning NN N
. . N

Further NNP N
study NN N
of IN N
α7 NNP N
nAChR JJ N
agonist/PAMs NN N
is VBZ N
warranted VBN N
in IN N
larger JJR N
studies NNS N
that WDT N
will MD N
have VB N
greater JJR N
power NN N
. . N

-DOCSTART- -X- O O 3954130

Response NN N
to TO N
tubular VB N
airway RP N
resistance NN N
in IN N
normal JJ 4_p
subjects NNS N
and CC N
postoperative JJ N
patients NNS N
. . N

Critically NNP 4_p
ill JJ 4_p
patients NNS N
must MD N
often RB N
breathe VB N
spontaneously RB N
through IN N
an DT N
endotracheal JJ N
tube NN N
that WDT N
acts VBZ N
as IN N
a DT N
fixed JJ N
inspiratory NN N
and CC N
expiratory JJ N
tubular JJ N
airway NN N
resistor NN N
. . N

Although IN N
this DT N
practice NN N
is VBZ N
common JJ N
, , N
its PRP$ N
effect NN N
on IN N
the DT N
pattern NN N
of IN N
breathing NN N
is VBZ N
not RB N
known VBN N
. . N

The DT N
mean JJ N
breathing NN N
patterns NNS N
of IN N
seven CD N
normal JJ 4_p
, , 4_p
healthy JJ 4_p
male NN N
subjects NNS N
and CC N
eight CD N
male NN N
patients NNS N
who WP N
had VBD N
undergone JJ N
upper JJ N
abdominal JJ N
surgery NN N
2-4 JJ N
days NNS N
previously RB N
were VBD N
studied VBN N
breathing VBG N
through IN N
a DT N
mouthpiece NN N
fitted VBN N
in IN N
random JJ N
order NN N
with IN N
a DT N
5 CD N
, , N
6 CD N
, , N
7 CD N
, , N
8 CD N
, , N
or CC N
15 CD N
mm NNS N
diameter NN N
( ( N
17 CD N
mm RB N
long RB N
) ) N
resistor NN N
. . N

These DT N
diameters NNS N
were VBD N
selected VBN N
because IN N
they PRP N
simulate VBP N
the DT N
pressure-flow JJ N
relationships NNS N
of IN N
adult NN N
endotracheal NN N
tubes NNS N
. . N

With IN N
the DT N
15 CD N
mm NN N
aperture NN N
, , N
the DT N
patients NNS N
had VBD N
a DT N
greater JJR N
breathing NN N
frequency NN N
( ( N
f NN N
) ) N
than IN N
did VBD N
the DT N
normal JJ N
subjects NNS N
( ( N
21 CD N
+/- JJ N
5 CD N
[ JJ N
SD NNP N
] NNP N
vs. IN N
14 CD N
+/- JJ N
4 CD N
breaths/min NN N
, , N
P NNP N
less JJR N
than IN N
0.01 CD N
) ) N
as RB N
well RB N
as IN N
a DT N
smaller JJR N
mean JJ N
tidal NN N
volume NN N
( ( N
VT NNP N
) ) N
. . N

In IN N
both DT N
groups NNS N
, , N
minute JJ N
ventilation NN N
( ( N
VE NNP N
) ) N
and CC N
f $ N
progressively RB N
decreased VBN N
as IN N
resistance NN N
was VBD N
increased VBN N
by IN N
decreasing VBG N
the DT N
aperture NN N
size NN N
from IN N
15 CD N
to TO N
16 CD N
mm NN N
. . N

In IN N
the DT N
normal JJ N
subjects NNS N
but CC N
not RB N
the DT N
patients NNS N
, , N
VT NNP N
also RB N
progressively RB N
decreased VBN N
. . N

When WRB N
the DT N
diameter NN N
was VBD N
decreased VBN N
from IN N
6 CD N
mm NNS N
to TO N
5 CD N
mm NN N
, , N
there EX N
were VBD N
increases NNS N
in IN N
VT NNP N
and CC N
decreases NNS N
in IN N
f NN N
that WDT N
were VBD N
more JJR N
marked VBN N
in IN N
the DT N
normal JJ N
subjects NNS N
. . N

In IN N
both DT N
groups NNS N
, , N
the DT N
changes NNS N
in IN N
VE NNP N
were VBD N
accompanied VBN N
by IN N
decreases NNS N
in IN N
mean NN N
and CC N
peak JJ N
inspiratory NN N
and CC N
expiratory NN N
flow NN N
rates NNS N
. . N

Throughout IN N
the DT N
study NN N
, , N
oxygen NN N
consumption NN N
( ( N
VO2 NNP N
) ) N
and CC N
carbon NN N
dioxide NN N
production NN N
( ( N
VCO2 NNP N
) ) N
did VBD N
not RB N
change VB N
. . N

This DT N
, , N
coupled VBN N
with IN N
the DT N
decreases NNS N
in IN N
VE NNP N
resulted VBD N
in IN N
decreases NNS N
in IN N
the DT N
ventilatory NN N
equivalents NNS N
to TO N
CO2 NNP N
and CC N
O2 NNP N
( ( N
VE/VCO2 NNP N
, , N
VE/VO2 NNP N
) ) N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -X- O O 18582177

Cognitive JJ N
effects NNS N
of IN N
risperidone NN N
in IN N
children NNS N
with IN N
autism NN N
and CC N
irritable JJ N
behavior NN N
. . N

OBJECTIVE CC N
The DT N
objective NN N
of IN N
this DT N
research NN N
was VBD N
to TO N
explore VB N
the DT N
effects NNS N
of IN N
risperidone NN N
on IN N
cognitive JJ N
processes NNS N
in IN N
children NNS 4_p
with IN 4_p
autism NN 4_p
and CC 4_p
irritable JJ 4_p
behavior NN 4_p
. . 4_p

METHOD NNP N
Thirty-eight JJ N
children NNS N
, , N
ages VBZ N
5-17 CD N
years NNS N
with IN N
autism NN N
and CC N
severe JJ N
behavioral JJ N
disturbance NN N
, , N
were VBD N
randomly RB N
assigned VBN N
to TO N
risperidone VB N
( ( N
0.5 CD N
to TO N
3.5 CD N
mg/day NN N
) ) N
or CC N
placebo NN N
for IN N
8 CD N
weeks NNS N
. . N

This DT N
sample NN N
of IN N
38 CD N
was VBD N
a DT N
subset NN N
of IN N
101 CD N
subjects NNS N
who WP N
participated VBD N
in IN N
the DT N
clinical JJ N
trial NN N
; : N
63 CD N
were VBD N
unable JJ N
to TO N
perform VB N
the DT N
cognitive JJ N
tasks NNS N
. . N

A DT N
double-blind JJ N
placebo-controlled JJ N
parallel NN N
groups NNS N
design NN N
was VBD N
used VBN N
. . N

Dependent JJ N
measures NNS N
included VBD N
tests NNS N
of IN N
sustained JJ N
attention NN N
, , N
verbal JJ N
learning NN N
, , N
hand-eye JJ N
coordination NN N
, , N
and CC N
spatial JJ N
memory NN N
assessed VBN N
before IN N
, , N
during IN N
, , N
and CC N
after IN N
the DT N
8-week JJ N
treatment NN N
. . N

Changes NNS N
in IN N
performance NN N
were VBD N
compared VBN N
by IN N
repeated JJ N
measures NNS N
ANOVA NNP N
. . N

RESULTS NNP N
Twenty-nine JJ N
boys NNS N
and CC N
9 CD N
girls NNS N
with IN N
autism NN N
and CC N
severe JJ N
behavioral JJ N
disturbance NN N
and CC N
a DT N
mental JJ N
age NN N
> NNP N
or=18 JJ N
months NNS N
completed VBN N
the DT N
cognitive JJ N
part NN N
of IN N
the DT N
study NN N
. . N

No DT N
decline NN N
in IN N
performance NN N
occurred VBD N
with IN N
risperidone NN N
. . N

Performance NN N
on IN N
a DT N
cancellation NN N
task NN N
( ( N
number NN N
of IN N
correct JJ N
detections NNS N
) ) N
and CC N
a DT N
verbal JJ N
learning NN N
task NN N
( ( N
word NN N
recognition NN N
) ) N
was VBD N
better RBR N
on IN N
risperidone NN N
than IN N
on IN N
placebo NN N
( ( N
without IN N
correction NN N
for IN N
multiplicity NN N
) ) N
. . N

Equivocal JJ N
improvement NN N
also RB N
occurred VBD N
on IN N
a DT N
spatial JJ N
memory NN N
task NN N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
treatment NN N
conditions NNS N
on IN N
the DT N
Purdue NNP N
Pegboard NNP N
( ( N
hand-eye JJ N
coordination NN N
) ) N
task NN N
or CC N
the DT N
Analog NNP N
Classroom NNP N
Task NNP N
( ( N
timed VBN N
math RB N
test NN N
) ) N
. . N

CONCLUSION NNP N
Risperidone NNP N
given VBN N
to TO N
children NNS N
with IN N
autism NN N
at IN N
doses VBZ N
up RB N
to TO N
3.5 CD N
mg NN N
for IN N
up IN N
to TO N
8 CD N
weeks NNS N
appears VBZ N
to TO N
have VB N
no DT N
detrimental JJ N
effect NN N
on IN N
cognitive JJ N
performance NN N
. . N

-DOCSTART- -X- O O 9129469

Effects NNS N
of IN N
age NN N
at IN N
introduction NN N
of IN N
complementary JJ N
foods NNS N
to TO N
breast-fed JJ N
infants NNS N
on IN N
duration NN N
of IN N
lactational JJ N
amenorrhea NN N
in IN N
Honduran NNP N
women NNS N
. . N

Lactational JJ N
amenorrhea NN N
( ( N
LA NNP N
) ) N
is VBZ N
associated VBN N
with IN N
postpartum NN N
infertility NN N
and CC N
is VBZ N
known VBN N
to TO N
be VB N
related VBN N
to TO N
breast-feeding JJ N
frequency NN N
and CC N
duration NN N
, , N
but CC N
the DT N
exact JJ N
role NN N
of IN N
complementary JJ N
feeding NN N
of IN N
the DT N
infant NN N
has VBZ N
not RB N
been VBN N
clearly RB N
defined VBN N
. . N

Data NNS N
on IN N
LA NNP N
were VBD N
collected VBN N
during IN N
and CC N
after IN N
a DT N
2-mo JJ N
intervention NN N
trial NN N
in IN N
which WDT N
low-income JJ N
Honduran NNP N
women NNS N
who WP N
had VBD N
breast-fed VBN N
fully RB N
for IN N
4 CD N
mo NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
three CD N
groups NNS N
: : N
continued VBN N
full JJ N
breast-feeding NN N
until IN N
6 CD N
mo NNS N
( ( N
FBF NNP N
, , N
n JJ N
= NNP N
50 CD N
) ) N
, , N
introduction NN N
of IN N
complementary JJ N
foods NNS N
at IN N
4 CD N
mo NN N
with IN N
ad NN N
libitum NN N
breast-feeding NN N
from IN N
4 CD N
to TO N
6 CD N
mo NN N
( ( N
SF NNP N
, , N
n JJ N
= NNP N
47 CD N
) ) N
, , N
or CC N
introduction NN N
of IN N
complementary JJ N
foods NNS N
at IN N
4 CD N
mo NN N
with IN N
maintenance NN N
of IN N
baseline JJ N
breast-feeding JJ N
frequency NN N
from IN N
4 CD N
to TO N
6 CD N
mo NNS N
( ( N
SF-M NNP N
, , N
n JJ N
= NNP N
44 CD N
) ) N
. . N

Women NNS N
were VBD N
followed VBN N
up RP N
until IN N
the DT N
infant NN N
was VBD N
12 CD N
mo NN N
of IN N
age NN N
, , N
or CC N
later RB N
if IN N
menses NNS N
had VBD N
not RB N
occurred VBN N
by IN N
then RB N
. . N

All DT N
but CC N
six CD N
of IN N
the DT N
women NNS N
continued VBD N
to TO N
breast-feed VB N
for IN N
> NN N
or CC N
= $ N
12 CD N
mo NN N
. . N

With IN N
the DT N
exclusion NN N
of IN N
those DT N
whose WP$ N
menses NNS N
returned VBD N
before IN N
18 CD N
wk NN N
postpartum NN N
( ( N
which WDT N
could MD N
not RB N
have VB N
been VBN N
due JJ N
to TO N
the DT N
intervention NN N
) ) N
, , N
the DT N
proportion NN N
of IN N
women NNS N
who WP N
were VBD N
amenorrheic VBN N
at IN N
6 CD N
mo NN N
was VBD N
64.5 CD N
% NN N
in IN N
the DT N
SF NNP N
group NN N
, , N
80.0 CD N
% NN N
in IN N
the DT N
FBF NNP N
group NN N
, , N
and CC N
85.7 CD N
% NN N
in IN N
the DT N
SF-M NNP N
group NN N
( ( N
chi-square JJ N
test NN N
= NN N
4.13 CD N
, , N
P NNP N
= NNP N
0.02 CD N
; : N
one-tailed JJ N
test NN N
with IN N
the DT N
latter JJ N
two CD N
groups NNS N
combined VBN N
) ) N
. . N

The DT N
total JJ N
duration NN N
of IN N
LA NNP N
did VBD N
not RB N
differ VB N
significantly RB N
among IN N
groups NNS N
. . N

The DT N
most RBS N
significant JJ N
determinant NN N
of IN N
LA NNP N
was VBD N
time NN N
spent VBN N
breast-feeding NN N
( ( N
min/d NN N
) ) N
, , N
which WDT N
was VBD N
in IN N
turn NN N
negatively RB N
associated VBN N
( ( N
P NNP N
= NNP N
0.06 CD N
) ) N
with IN N
the DT N
infant NN N
's POS N
energy NN N
intake NN N
from IN N
complementary JJ N
foods NNS N
in IN N
regression NN N
analyses NNS N
. . N

These DT N
results NNS N
indicate VBP N
that IN N
there EX N
is VBZ N
a DT N
significant JJ N
effect NN N
of IN N
introducing VBG N
foods NNS N
at IN N
4 CD N
mo NN N
on IN N
the DT N
likelihood NN N
of IN N
amenorrhea NN N
at IN N
6 CD N
mo NN N
postpartum NN N
, , N
but CC N
not RB N
thereafter RB N
, , N
and CC N
that IN N
this DT N
effect NN N
is VBZ N
not RB N
seen VBN N
in IN N
mothers NNS N
who WP N
maintain VBP N
breast-feeding JJ N
frequency NN N
. . N

-DOCSTART- -X- O O 19713225

Arterial NNP N
cardiovascular JJ N
risk NN N
factors NNS N
and CC N
venous JJ N
thrombosis NN N
: : N
results NNS N
from IN N
a DT N
population-based JJ N
, , N
prospective JJ N
study NN N
( ( N
the DT N
HUNT NNP N
2 CD N
) ) N
. . N

BACKGROUND NNP N
An DT N
explanation NN N
for IN N
the DT N
increased VBN N
risk NN N
of IN N
myocardial JJ N
infarction NN N
and CC N
stroke NN N
in IN N
patients NNS 4_p
with IN 4_p
venous JJ 4_p
thrombosis NN 4_p
is VBZ N
lacking VBG N
. . N

The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
whether IN N
risk NN N
factors NNS N
for IN N
arterial JJ N
cardiovascular JJ N
disease NN N
also RB N
increase VBZ N
the DT N
risk NN N
of IN N
venous JJ N
thrombosis NN N
. . N

DESIGN NNP N
AND CC N
METHODS NNP N
Cases NNP N
who WP N
had VBD N
a DT N
first JJ N
venous JJ N
thrombosis NN N
( ( N
n=515 JJ N
) ) N
and CC N
matched VBN N
controls NNS N
( ( N
n=1,505 NN N
) ) N
were VBD N
identified VBN N
from IN N
a DT N
population-based JJ N
, , N
nested JJ N
, , N
case-cohort JJ N
study NN N
( ( N
the DT N
HUNT NNP N
2 CD N
study NN N
) ) N
comprising VBG N
71 CD N
% NN N
( ( N
n=66,140 JJ N
) ) N
of IN N
the DT N
adult NN N
residents NNS N
of IN N
Nord-Trøndelag NNP N
County NNP N
in IN N
Norway NNP N
. . N

RESULTS VB N
The DT N
age- JJ N
and CC N
sex-adjusted JJ N
odds NNS N
ratio NN N
of IN N
venous JJ N
thrombosis NN N
for IN N
subjects NNS N
with IN N
concentrations NNS N
of IN N
C-reactive JJ N
protein NN N
in IN N
the DT N
highest JJS N
quintile NN N
was VBD N
1.6 CD N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
: : N
1.2-2.2 JJ N
) ) N
compared VBN N
to TO N
subjects NNS N
with IN N
C-reactive JJ N
protein NN N
in IN N
the DT N
lowest JJS N
quintile NN N
. . N

This DT N
association NN N
was VBD N
strongest VBN N
in IN N
subjects NNS N
who WP N
experienced VBD N
venous JJ N
thrombosis NN N
within IN N
a DT N
year NN N
after IN N
blood NN N
sampling VBG N
with IN N
a DT N
three-fold JJ N
increased JJ N
risk NN N
of IN N
participants NNS N
in IN N
the DT N
highest JJS N
versus NN N
the DT N
lowest JJS N
quintile NN N
. . N

Having VBG N
first JJ N
degree JJ N
relatives NNS N
who WP N
had VBD N
a DT N
myocardial JJ N
infarction NN N
before IN N
the DT N
age NN N
of IN N
60 CD N
years NNS N
was VBD N
positively RB N
associated VBN N
with IN N
venous JJ N
thrombosis NN N
compared VBN N
to TO N
not RB N
having VBG N
a DT N
positive JJ N
family NN N
history NN N
[ NNP N
odds VBZ N
ratio NN N
1.3 CD N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
: : N
1.1-1.6 JJ N
) ) N
] NN N
. . N

Subjects NNS N
with IN N
blood NN N
pressure NN N
in IN N
the DT N
highest JJS N
quintile NN N
had VBD N
half PDT N
the DT N
risk NN N
of IN N
developing VBG N
venous JJ N
thrombosis NN N
compared VBN N
to TO N
subjects NNS N
whose WP$ N
blood NN N
pressure NN N
was VBD N
in IN N
the DT N
lowest JJS N
quintile NN N
. . N

There EX N
were VBD N
no DT N
associations NNS N
between IN N
the DT N
risk NN N
of IN N
venous JJ N
thrombosis NN N
and CC N
total JJ N
cholesterol NN N
, , N
low JJ N
density NN N
lipoprotein-cholesterol NN N
, , N
high JJ N
density NN N
lipoprotein-cholesterol NN N
, , N
triglycerides NNS N
, , N
glucose NN N
or CC N
smoking NN N
. . N

We PRP N
confirmed VBD N
the DT N
positive JJ N
association NN N
between IN N
obesity NN N
and CC N
venous JJ N
thrombosis NN N
. . N

CONCLUSIONS NNP N
C-reactive JJ N
protein NN N
and CC N
a DT N
family NN N
history NN N
of IN N
myocardial JJ N
infarction NN N
were VBD N
positively RB N
associated VBN N
with IN N
subsequent JJ N
venous JJ N
thrombosis NN N
. . N

Blood NNP N
pressure NN N
was VBD N
inversely RB N
correlated VBN N
to TO N
venous JJ N
thrombosis NN N
. . N

These DT N
findings NNS N
should MD N
be VB N
confirmed VBN N
by IN N
further JJ N
investigations NNS N
. . N

-DOCSTART- -X- O O 20730486

Reversal NNP N
of IN N
skeletal JJ N
effects NNS N
of IN N
endocrine NN N
treatments NNS N
in IN N
the DT N
Intergroup NNP N
Exemestane NNP N
Study NNP N
. . N

The DT N
adjuvant JJ N
use NN N
of IN N
aromatase NN N
inhibitors NNS N
in IN N
breast NN N
cancer NN N
is VBZ N
associated VBN N
with IN N
adverse JJ N
effects NNS N
on IN N
bone NN N
health NN N
. . N

We PRP N
previously RB N
reported VBD N
a DT N
decline NN N
in IN N
bone JJ N
mineral JJ N
density NN N
( ( N
BMD NNP N
) ) N
following VBG N
the DT N
switch NN N
from IN N
tamoxifen NN N
to TO N
exemestane VB N
in IN N
the DT N
Intergroup NNP N
Exemestane NNP N
Study NNP N
( ( N
IES NNP N
) ) N
. . N

Here RB N
we PRP N
report VBP N
effects NNS N
of IN N
endocrine JJ N
treatment NN N
withdrawal NN N
on IN N
BMD NNP N
, , N
bone NN N
turnover NN N
markers NNS N
( ( N
BTM NNP N
) ) N
and CC N
fracture JJ N
rates NNS N
. . N

4,724 CD N
patients NNS N
took VBD N
part NN N
in IN N
IES NNP N
, , N
and CC N
206 CD N
patients NNS N
were VBD N
included VBN N
in IN N
a DT N
bone NN N
sub-study NN N
. . N

BMD NNP N
and CC N
BTM NNP N
were VBD N
assessed VBN N
pre-randomization NN N
, , N
during IN N
and CC N
after IN N
the DT N
end NN N
of IN N
treatment NN N
( ( N
EOT NNP N
) ) N
. . N

To TO N
evaluate VB N
treatment NN N
withdrawal NN N
effects NNS N
, , N
12- JJ N
and CC N
24-month JJ N
post NN N
EOT NNP N
BMD NNP N
results NNS N
are VBP N
available JJ N
for IN N
122 CD N
and CC N
126 CD N
patients NNS N
, , N
respectively RB N
. . N

Similar JJ N
patient NN N
numbers NNS N
had VBD N
BTM NNP N
measured VBD N
post NN N
EOT NNP N
. . N

Following VBG N
treatment NN N
withdrawal NN N
, , N
the DT N
differences NNS N
in IN N
BMD NNP N
observed VBD N
between IN N
the DT N
two CD N
endocrine NN N
strategies NNS N
were VBD N
partially RB N
reversed VBN N
. . N

At IN N
24 CD N
months NNS N
from IN N
EOT NNP N
, , N
spine JJ N
BMD NNP N
increased VBN N
by IN N
1.53 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
0.63-2.43 CD N
; : N
p CC N
= VB N
0.001 CD N
) ) N
after IN N
stopping VBG N
exemestane NN N
and CC N
fell VBD N
by IN N
1.93 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
-2.91 NNP N
to TO N
0.95 CD N
; : N
p NN N
= VBZ N
0.0002 CD N
) ) N
following VBG N
tamoxifen NN N
withdrawal NN N
. . N

A DT N
similar JJ N
pattern NN N
of IN N
changes NNS N
was VBD N
observed VBN N
at IN N
the DT N
hip NN N
. . N

At IN N
2 CD N
years NNS N
post RB N
EOT NNP N
, , N
BMD NNP N
changes NNS N
from IN N
baseline NN N
were VBD N
similar JJ N
with IN N
both DT N
treatment NN N
strategies NNS N
. . N

Corresponding VBG N
inverse JJ N
changes NNS N
in IN N
BTM NNP N
were VBD N
seen VBN N
, , N
with IN N
an DT N
increase NN N
following VBG N
tamoxifen JJ N
withdrawal NN N
and CC N
a DT N
reduction NN N
after IN N
exemestane NN N
. . N

A DT N
higher JJR N
number NN N
of IN N
fractures NNS N
occurred VBD N
during IN N
exemestane NN N
treatment NN N
, , N
but CC N
fracture NN N
rates NNS N
were VBD N
similar JJ N
after IN N
treatment NN N
withdrawal NN N
. . N

With IN N
the DT N
switch NN N
strategy NN N
used VBN N
in IN N
IES NNP N
, , N
the DT N
on IN N
treatment NN N
adverse JJ N
bone NN N
effects NNS N
of IN N
exemestane NN N
are VBP N
reversed VBN N
. . N

Ongoing VBG N
monitoring NN N
of IN N
BMD NNP N
is VBZ N
therefore RB N
not RB N
routinely RB N
required VBN N
. . N

-DOCSTART- -X- O O 2108990

The DT N
effect NN N
of IN N
HCG NNP N
supplementation NN N
after IN N
combined VBN N
GnRH NNP N
agonist/HMG JJ N
treatment NN 4_p
in IN 4_p
an DT 4_p
IVF NNP 4_p
programme NN 4_p
. . 4_p

The DT N
necessity NN N
of IN N
luteal-phase JJ N
supplementation NN N
in IN N
an DT N
IVF NNP N
programme NN N
is VBZ N
of IN N
continuing VBG N
interest NN N
. . N

After IN N
ovarian JJ N
stimulation NN N
with IN N
clomiphene NN N
and CC N
human JJ N
menopausal NN N
gonadotrophin NN N
( ( N
HMG NNP N
) ) N
, , N
the DT N
beneficial JJ N
effect NN N
of IN N
supporting VBG N
the DT N
luteal NN N
phase NN N
has VBZ N
never RB N
been VBN N
scientifically RB N
demonstrated VBN N
. . N

After IN N
ovarian JJ N
stimulation NN N
with IN N
GnRH NNP N
agonist/HMG NN N
, , N
the DT N
luteal JJ N
phase NN N
seems VBZ N
to TO N
be VB N
inadequate JJ N
, , N
but CC N
in IN N
a DT N
previous JJ N
study NN N
we PRP N
did VBD N
not RB N
find VB N
evidence NN N
to TO N
support VB N
the DT N
need NN N
for IN N
oral JJ N
progesterone NN N
supplementation NN N
. . N

To TO N
evaluate VB N
the DT N
beneficial JJ N
effect NN N
of IN N
human JJ N
chorionic NN N
gonadotrophin NN N
( ( N
HCG NNP N
) ) N
supplementation NN N
, , N
we PRP N
performed VBD N
a DT N
multicentre NN N
, , N
double-blind NN N
, , N
randomized VBN N
study NN N
with IN N
HCG NNP N
( ( N
193 CD N
transfers NNS N
) ) N
against IN N
placebo NN N
( ( N
194 CD N
transfers NNS N
) ) N
. . N

The DT N
ongoing JJ N
pregnancy NN N
rate NN N
per IN N
transfer NN N
cycle NN N
was VBD N
significantly RB N
better RBR N
with IN N
HCG NNP N
( ( N
18.7 CD N
versus IN N
9.3 CD N
) ) N
. . N

This DT N
is VBZ N
the DT N
first JJ N
truly RB N
objective JJ N
( ( N
randomized VBN N
) ) N
study NN N
demonstrating VBG N
the DT N
beneficial JJ N
effect NN N
of IN N
supporting VBG N
the DT N
luteal JJ N
phase NN N
in IN N
an DT N
IVF NNP 4_p
programme NN 4_p
. . 4_p

-DOCSTART- -X- O O 25102328

A DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
pilot NN N
study NN N
of IN N
naltrexone NN N
to TO N
counteract VB N
antipsychotic-associated JJ N
weight JJ N
gain NN N
: : N
proof NN N
of IN N
concept NN N
. . N

Patients NNS 4_p
with IN 4_p
schizophrenia JJ 4_p
experience NN N
higher JJR N
rates NNS N
of IN N
obesity NN N
as RB N
well RB N
as IN N
related JJ N
morbidity NN N
and CC N
mortality NN N
than IN N
the DT N
general JJ N
population NN N
does VBZ N
. . N

Women VB N
with IN N
schizophrenia NN 4_p
are VBP N
at IN N
particular JJ N
risk NN N
for IN N
antipsychotic-associated JJ N
weight NN N
gain NN N
, , N
obesity NN N
, , N
and CC N
related JJ N
medical JJ N
disorders NNS N
such JJ N
as IN N
diabetes NNS N
and CC N
cardiovascular JJ N
disease NN N
. . N

Given NNP N
preclinical JJ N
studies NNS N
revealing VBG N
the DT N
role NN N
of IN N
the DT N
endogenous JJ N
opioid JJ N
systems NNS N
in IN N
human JJ N
appetite NN N
and CC N
the DT N
potential NN N
of IN N
antipsychotic JJ N
medications NNS N
to TO N
interfere VB N
with IN N
this DT N
system NN N
, , N
we PRP N
hypothesized VBD N
that IN N
opioid JJ N
antagonists NNS N
may MD N
be VB N
beneficial JJ N
in IN N
arresting VBG N
antipsychotic-associated JJ N
weight NN N
gain NN N
and CC N
promoting VBG N
further JJ N
weight JJ N
loss NN N
in IN N
women NNS N
with IN N
schizophrenia NN N
. . N

In IN N
the DT N
present JJ N
study NN N
, , N
24 CD N
overweight JJ N
women NNS N
with IN N
a DT N
diagnosis NN N
of IN N
schizophrenia NN 4_p
or CC 4_p
schizoaffective JJ 4_p
disorder NN 4_p
were VBD N
randomized VBN N
to TO N
placebo VB N
or CC N
naltrexone VB N
( ( N
NTX NNP N
) ) N
25 CD N
mg/d NN N
for IN N
8 CD N
weeks NNS N
. . N

The DT N
primary JJ N
outcome NN N
measure NN N
was VBD N
a DT N
change NN N
in IN N
body NN N
weight NN N
from IN N
baseline NN N
. . N

The DT N
patients NNS N
in IN N
the DT N
NTX NNP N
group NN N
had VBD N
significant JJ N
weight JJ N
loss NN N
( ( N
-3.40 JJ N
kg NN N
) ) N
compared VBN N
with IN N
weight JJ N
gain NN N
( ( N
+1.37 NNP N
kg NN N
) ) N
in IN N
the DT N
patients NNS N
in IN N
the DT N
placebo NN N
group NN N
. . N

Mainly RB N
, , N
nondiabetic JJ N
subjects NNS N
lost VBN N
weight NN N
in IN N
the DT N
NTX NNP N
arm NN N
. . N

These DT N
data NNS N
support NN N
the DT N
need NN N
to TO N
further VB N
investigate VB N
the DT N
role NN N
of IN N
D2 NNP N
blockade NN N
in IN N
reducing VBG N
food NN N
reward-based JJ N
overeating NN N
. . N

A NNP N
larger JJR N
study NN N
addressing VBG N
the DT N
weaknesses NNS N
of IN N
this DT N
pilot NN N
study NN N
is VBZ N
currently RB N
underway JJ N
. . N

-DOCSTART- -X- O O 21276573

Initial JJ N
clinical JJ N
experience NN N
with IN N
implantation NN N
of IN N
left JJ N
ventricular JJ N
lead NN N
guided VBN N
by IN N
Overlay NNP N
Ref NNP N
for IN N
the DT N
treatment NN N
of IN N
congestive JJ N
heart NN N
failure NN N
. . N

BACKGROUND NNP N
Cardiac NNP N
resynchronization NN N
therapy NN N
( ( N
CRT NNP N
) ) N
improves VBZ N
clinical JJ N
outcome NN N
in IN N
selected VBN 4_p
patients NNS 4_p
with IN 4_p
advanced JJ 4_p
congestive JJ 4_p
heart NN 4_p
failure NN 4_p
. . 4_p

The DT N
Overlay NNP N
Ref NNP N
technique NN N
may MD N
facilitate VB N
the DT N
procedure NN N
for IN N
implanting VBG N
left JJ N
ventricular NN N
( ( N
LV NNP N
) ) N
pacing VBG N
leads NNS N
to TO N
deliver VB N
CRT NNP N
. . N

AIM NNP N
To TO N
assess VB N
the DT N
feasibility NN N
of IN N
deploying VBG N
a DT N
LV NNP N
pacing VBG N
lead NN N
into IN N
a DT N
coronary JJ N
sinus NN N
side NN N
branch NN N
guided VBN N
by IN N
Overlay NNP N
Ref NNP N
. . N

METHODS NNP N
Data NNP N
from IN N
88 CD N
consecutive JJ N
patients NNS N
who WP N
met VBD N
the DT N
CRT NNP N
implantation NN N
criteria NNS N
in IN N
our PRP$ N
hospital NN N
between IN N
28 CD N
November NNP N
2007 CD N
and CC N
30 CD N
December NNP N
2009 CD N
were VBD N
randomly RB N
assigned VBN N
to TO N
two CD N
groups NNS N
. . N

Forty-four CD N
patients NNS N
underwent JJ N
CRT NNP N
device NN N
implantation NN N
using VBG N
Overlay NNP N
Ref NNP N
to TO N
guide VB N
target NN N
vein JJ N
selection NN N
and CC N
advance VB N
a DT N
specifically RB N
designed VBN N
pacing VBG N
lead NN N
into IN N
the DT N
target NN N
vein NN N
( ( N
Overlay NNP N
Ref NNP N
group NN N
) ) N
; : N
44 CD N
patients NNS N
were VBD N
conventionally RB N
implanted VBN N
( ( N
control VB N
group NN N
) ) N
. . N

RESULTS NNP N
LV NNP N
lead JJ N
implantation NN N
was VBD N
successful JJ N
in IN N
all DT N
patients NNS N
. . N

Mean NNP N
CRT NNP N
total JJ N
procedure NN N
times NNS N
( ( N
skin-to-skin JJ N
) ) N
were VBD N
: : N
Overlay NNP N
Ref NNP N
group NN N
, , N
80.7 CD N
± NN N
18.0 CD N
min NN N
; : N
control NN N
group NN N
, , N
98.5 CD N
± NN N
32.2 CD N
min NN N
; : N
p CC N
= $ N
0.029 CD N
. . N

Mean JJ N
placement NN N
of IN N
LV NNP N
pacing VBG N
lead NN N
into IN N
target NN N
vein JJ N
times NNS N
were VBD N
: : N
Overlay NNP N
Ref NNP N
group NN N
, , N
16.2 CD N
± NN N
7.7 CD N
min NN N
; : N
control NN N
group NN N
, , N
36.4 CD N
± NN N
23.4 CD N
min NN N
; : N
p=0.004 NN N
. . N

Mean NNP N
total JJ N
fluoroscopy NN N
times NNS N
were VBD N
: : N
Overlay NNP N
Ref NNP N
group NN N
, , N
13.6 CD N
± NN N
4.3 CD N
min NN N
; : N
control NN N
group NN N
, , N
23.8 CD N
± NN N
15.7 CD N
min NN N
; : N
p=0.007 NN N
. . N

Mean NNP N
LV NNP N
lead NN N
fluoroscopy NN N
times NNS N
were VBD N
: : N
Overlay NNP N
Ref NNP N
group NN N
, , N
5.7 CD N
± NN N
2.9 CD N
min NN N
; : N
control NN N
group NN N
, , N
14.4 CD N
± NN N
4.6 CD N
min NN N
; : N
p=0.003 NN N
. . N

No DT N
major JJ N
complications NNS N
occurred VBD N
. . N

CONCLUSIONS NNP N
Overlay NNP N
Ref NNP N
facilitates VBZ N
location NN N
of IN N
and CC N
entry NN N
into IN N
the DT N
coronary JJ N
sinus NN N
, , N
and CC N
shortens VBZ N
the DT N
duration NN N
of IN N
LV NNP N
pacing VBG N
lead JJ N
implantation NN N
into IN N
the DT N
target NN N
vein NN N
. . N

-DOCSTART- -X- O O 24710131

Low-dose JJ N
prednisolone NN N
treatment NN N
of IN N
early JJ 4_p
rheumatoid NN 4_p
arthritis NN 4_p
and CC N
late JJ N
cardiovascular JJ N
outcome NN N
and CC N
survival NN N
: : N
10-year JJ N
follow-up NN N
of IN N
a DT N
2-year JJ N
randomised JJ N
trial NN N
. . N

OBJECTIVE UH N
To TO N
examine VB N
the DT N
long-term JJ N
effects NNS N
of IN N
early JJ N
low-dose JJ N
prednisolone NN N
use NN N
in IN N
patients NNS N
with IN N
rheumatoid JJ 4_p
arthritis NN 4_p
( ( 4_p
RA NNP 4_p
) ) 4_p
on IN 4_p
cardiovascular NN 4_p
( ( 4_p
CV NNP 4_p
) ) 4_p
morbidity NN 4_p
and CC 4_p
mortality NN 4_p
. . N

DESIGN NNP N
Retrieval NNP N
of IN N
data NNS N
from IN N
a DT N
2-year JJ N
open JJ N
randomised VBN N
trial NN N
comparing VBG N
prednisolone NN N
7.5 CD N
mg/day NN N
in IN N
addition NN N
to TO N
disease-modifying JJ N
antirheumatic JJ N
drugs NNS N
( ( N
DMARDs NNP N
) ) N
with IN N
DMARD NNP N
therapy NN N
alone RB N
. . N

Participants NNS N
were VBD N
followed VBN N
for IN N
10 CD N
years NNS N
since IN N
inclusion NN N
into IN N
the DT N
original JJ N
prednisolone NN N
trial NN N
or CC N
until IN N
occurrence NN N
of IN N
the DT N
studied JJ N
outcomes NNS N
. . N

SETTING NN N
Secondary JJ N
level NN N
of IN N
care NN N
; : N
six CD N
participating VBG N
centres NNS N
from IN N
southern JJ N
Sweden NNP N
; : N
both DT N
urban JJ N
and CC N
rural JJ N
populations NNS N
. . N

PARTICIPANTS NNP N
Overall NNP N
, , N
223 CD N
patients NNS N
with IN N
early JJ N
RA NNP N
were VBD N
included VBN N
. . N

The DT N
participants NNS N
had VBD 4_p
no DT 4_p
history NN 4_p
of IN 4_p
CV NNP 4_p
events NNS 4_p
at IN 4_p
baseline NN 4_p
and CC N
incident JJ N
cases NNS N
were VBD N
identified VBN N
via IN N
the DT N
Swedish JJ N
Hospital NNP N
Discharge NNP N
and CC N
Cause NNP N
of IN N
Death NNP N
Registries NNP N
. . N

OUTCOMES NNP N
Composite NNP N
CV NNP N
events NNS N
, , N
that DT N
is VBZ N
, , N
ischaemic JJ N
coronary NN N
and CC N
cerebrovascular JJ N
events NNS N
, , N
components NNS N
of IN N
the DT N
composite JJ N
CV NNP N
outcome NN N
, , N
and CC N
death NN N
. . N

Relative JJ N
HRs NNP N
from IN N
Cox NNP N
proportional-hazards NNS N
regression NN N
models NNS N
were VBD N
calculated VBN N
. . N

RESULTS NNP N
Within IN N
2041 CD N
person-years NNS N
, , N
17 CD N
incident NN N
composite JJ N
CV NNP N
events NNS N
occurred VBD N
in IN N
112 CD N
patients NNS N
( ( N
15 CD N
% NN N
) ) N
randomised VBD N
to TO N
prednisolone VB N
, , N
and CC N
15 CD N
events NNS N
of IN N
111 CD N
patients NNS N
( ( N
14 CD N
% NN N
) ) N
who WP N
were VBD N
assigned VBN N
not RB N
to TO N
receive VB N
prednisolone NN N
. . N

There EX N
were VBD N
nine CD N
deaths NNS N
( ( N
8 CD N
% NN N
) ) N
in IN N
each DT N
group NN N
. . N

The DT N
age-adjusted JJ N
relative JJ N
hazards NNS N
( ( N
HRs NNP N
; : N
95 CD N
% NN N
CI NNP N
) ) N
for IN N
the DT N
first JJ N
composite JJ N
CV NNP N
event NN N
, , N
first RB N
coronary JJ N
event NN N
and CC N
death NN N
in IN N
the DT N
prednisolone NN N
group NN N
versus IN N
the DT N
group NN N
not RB N
treated VBN N
with IN N
prednisolone NN N
were VBD N
1.8 CD N
( ( N
0.9 CD N
to TO N
3.6 CD N
) ) N
, , N
0.98 CD N
( ( N
0.4 CD N
to TO N
2.6 CD N
) ) N
and CC N
1.6 CD N
( ( N
0.6 CD N
to TO N
4.1 CD N
) ) N
, , N
respectively RB N
. . N

The DT N
risk NN N
for IN N
the DT N
first JJ N
cerebrovascular JJ N
event NN N
showed VBD N
a DT N
3.7-fold JJ N
increased JJ N
relative JJ N
hazard NN N
( ( N
95 CD N
% NN N
CI NNP N
1.2 CD N
to TO N
11.4 CD N
) ) N
among IN N
prednisolone NN N
treated VBD N
patients NNS N
. . N

CONCLUSIONS NNP N
In IN N
this DT N
inception NN N
cohort NN N
study NN N
of IN N
low-dose JJ N
prednisolone NN N
use NN N
during IN N
the DT N
first JJ N
2 CD N
years NNS N
of IN N
RA NNP N
disease NN N
, , N
the DT N
incidence NN N
of IN N
ischaemic JJ N
coronary JJ N
artery NN N
events NNS N
was VBD N
similar JJ N
in IN N
the DT N
two CD N
treatment NN N
groups NNS N
, , N
whereas IN N
the DT N
long-term JJ N
risk NN N
of IN N
ischaemic JJ N
cerebrovascular JJ N
events NNS N
was VBD N
higher RBR N
in IN N
the DT N
prednisolone NN N
group NN N
. . N

There EX N
was VBD N
a DT N
trend NN N
towards NN N
reduced VBD N
survival NN N
in IN N
the DT N
prednisolone NN N
group NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
NUMBER NNP N
ISRCTN20612367 NNP N
. . N

-DOCSTART- -X- O O 22001361

Predictors NNS N
of IN N
recruited JJ N
melanoma NN 4_p
families NNS N
into IN N
a DT N
behavioral JJ N
intervention NN N
project NN N
. . N

BACKGROUND NNP N
Examination NNP N
of IN N
families NNS N
represents VBZ N
an DT N
important JJ N
priority NN N
in IN N
health NN N
research NN N
. . N

In IN N
this DT N
paper NN N
we PRP N
report VBP N
on IN N
individual JJ N
and CC N
family-level JJ N
factors NNS N
associated VBN N
with IN N
enrollment NN N
in IN N
a DT N
cancer NN N
prevention NN N
research NN N
project NN N
. . N

We PRP N
approached VBD N
families NNS N
affected VBN N
by IN N
melanoma NN 4_p
for IN N
possible JJ N
participation NN N
in IN N
a DT N
randomized NN N
controlled VBN N
trial NN N
of IN N
a DT N
web-based JJ N
communication NN N
and CC N
support NN N
intervention NN N
. . N

METHODS NNP N
We PRP N
recruited VBD N
three CD N
family NN N
members NNS N
per IN N
family NN N
for IN N
assessment NN N
- : N
the DT N
melanoma NN N
case NN N
, , N
a DT N
first-degree JJ N
relative NN N
( ( N
FDR NNP N
) ) N
, , N
and CC N
a DT N
relative NN N
who WP N
is VBZ N
a DT N
parent NN N
of IN N
a DT N
child JJ N
age NN N
18 CD N
or CC N
younger JJR N
. . N

Recruitment NNP N
involved VBD N
three CD N
steps NNS N
: : N
requesting VBG N
the DT N
physician NN N
's POS N
consent NN N
to TO N
approach VB N
the DT N
melanoma NN N
case NN N
, , N
approaching VBG N
the DT N
case NN N
to TO N
request VB N
their PRP$ N
participation NN N
and CC N
family NN N
contact NN N
information NN N
, , N
and CC N
they PRP N
approaching VBG N
the DT N
FDRs NNP N
and CC N
parents NNS N
. . N

RESULTS NNP N
Of IN N
the DT N
1380 CD N
families NNS N
approached VBD N
, , N
313 CD N
were VBD N
enrolled VBN N
, , N
263 CD N
were VBD N
excluded VBN N
because IN N
we PRP N
could MD N
not RB N
find VB N
or CC N
contact VB N
a DT N
family NN N
member NN N
( ( N
FDR CD N
or CC N
parent NN N
) ) N
, , N
331 CD N
did VBD N
not RB N
have VB N
eligible JJ N
family NN N
members NNS N
, , N
and CC N
473 CD N
refused VBD N
. . N

The DT N
most RBS N
frequently RB N
noted VBD N
reason NN N
for IN N
refusal NN N
was VBD N
being VBG N
too RB N
busy JJ N
or CC N
having VBG N
no DT N
time NN N
. . N

The DT N
primary JJ N
predictors NNS N
of IN N
participation NN N
for IN N
cases NNS N
( ( N
OR=1.6 NNP N
; : N
CI=1.01-2.51 NNP N
) ) N
and CC N
FDRs NNP N
( ( N
OR=2.15 NNP N
; : N
CI=1.11-4.13 NNP N
) ) N
included VBD N
higher JJR N
educational JJ N
attainment NN N
. . N

FDRs NNP N
were VBD N
more RBR N
likely JJ N
to TO N
enroll VB N
if IN N
they PRP N
were VBD N
female JJ N
( ( N
OR=1.77 NNP N
; : N
CI=1.1-.85 NNP N
) ) N
and CC N
parents NNS N
were VBD N
more RBR N
likely JJ N
to TO N
enroll VB N
if IN N
the DT N
case NN N
had VBD N
been VBN N
diagnosed VBN N
more RBR N
recently RB N
( ( N
OR=3.3 NNP N
; : N
CI=1.9-5.93 NNP N
) ) N
, , N
if IN N
the DT N
parent NN N
was VBD N
partnered VBN N
( ( N
OR=4.37 NNP N
; : N
CI=1.86-10.26 NNP N
) ) N
, , N
and CC N
if IN N
the DT N
parent NN N
lived VBD N
in IN N
the DT N
same JJ N
city NN N
as IN N
the DT N
case NN N
( ( N
OR=2.88 NNP N
; : N
CI=1.08-7.68 NNP N
) ) N
. . N

CONCLUSIONS VB N
The DT N
results NNS N
can MD N
provide VB N
information NN N
on IN N
potential JJ N
directions NNS N
for IN N
future JJ N
family NN N
recruitment NN N
. . N

-DOCSTART- -X- O O 11706697

Does NNP N
temporary JJ N
clamping NN N
of IN N
drains NNS N
following VBG N
knee NN N
arthroplasty JJ N
reduce VB N
blood NN N
loss NN N
? . N
A DT N
randomised JJ N
controlled VBN N
trial NN N
. . N

In IN N
a DT N
randomised JJ N
, , N
blinded VBD N
study NN N
76 CD N
patients NNS N
undergoing JJ N
primary JJ 4_p
total JJ 4_p
knee NN 4_p
arthroplasty NN 4_p
were VBD N
assigned VBN N
to TO N
either DT N
immediate JJ N
drain NN N
opening NN N
( ( N
n JJ N
= NNP N
45 CD N
) ) N
or CC N
drains NNS N
opened VBN N
at IN N
2 CD N
h NN N
( ( N
n JJ N
= NNP N
31 CD N
) ) N
. . N

No DT N
significant JJ N
differences NNS N
were VBD N
found VBN N
between IN N
the DT N
groups NNS N
for IN N
the DT N
volume NN N
of IN N
drained JJ N
blood NN N
, , N
transfusion NN N
requirements NNS N
, , N
knee JJ N
motion NN N
or CC N
wound NN N
status NN N
. . N

The DT N
authors NNS N
conclude VBP N
that IN N
the DT N
practice NN N
of IN N
clamping VBG N
drains NNS N
has VBZ N
no DT N
benefit NN N
in IN N
routine JJ N
knee NN N
arthroplasty NN N
. . N

However RB N
, , N
when WRB N
faced VBN N
with IN N
immediate JJ N
brisk JJ N
blood NN N
loss NN N
, , N
the DT N
results NNS N
suggest VBP N
that IN N
drains NNS N
can MD N
be VB N
clamped VBN N
without IN N
any DT N
excess JJ N
morbidity NN N
. . N

-DOCSTART- -X- O O 9788422

Preoperative JJ N
irradiation NN N
versus IN N
the DT N
use NN N
of IN N
nonsteroidal JJ N
anti-inflammatory JJ N
drugs NNS N
for IN N
prevention NN N
of IN N
heterotopic JJ N
ossification NN N
following VBG N
total JJ 4_p
hip JJ 4_p
replacement NN 4_p
: : N
the DT N
results NNS N
of IN N
a DT N
randomized JJ N
trial NN N
. . N

PURPOSE NNP N
Previous JJ N
studies NNS N
showed VBD N
the DT N
effectiveness NN N
of IN N
early JJ N
preoperative NN N
( ( N
4 CD N
h NN N
before IN N
operation NN N
) ) N
irradiation NN N
for IN N
prevention NN N
of IN N
heterotopic NN N
ossification NN N
( ( N
HO NNP N
) ) N
after IN N
total JJ N
hip NN N
replacement NN N
. . N

This DT N
procedure NN N
can MD N
result VB N
in IN N
logistic JJ N
problems NNS N
, , N
if IN N
there EX N
is VBZ N
a DT N
great JJ N
distance NN N
between IN N
the DT N
department NN N
of IN N
radiotherapy NN N
and CC N
the DT N
orthopedic JJ N
clinic NN N
. . N

To TO N
avoid VB N
these DT N
organizational JJ N
problems NNS N
a DT N
prospective JJ N
study NN N
was VBD N
undertaken VBN N
to TO N
analyze VB N
the DT N
effectiveness NN N
of IN N
preoperative JJ N
irradiation NN N
on IN N
the DT N
day NN N
preceding VBG N
surgery NN N
( ( N
16-20 JJ N
h NN N
before IN N
operation NN N
) ) N
. . N

METHODS NNP N
AND CC N
MATERIALS NNP N
Between NNP N
1995 CD N
and CC N
1996 CD N
, , N
100 CD N
patients NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
a DT N
prophylactic JJ N
therapy NN N
for IN N
prevention NN N
of IN N
heterotopic NN 4_p
ossification NN 4_p
. . N

Forty-six JJ N
patients NNS N
were VBD N
irradiated VBN N
with IN N
7 CD N
Gy NNP N
single JJ N
dose NN N
within IN N
16-20 JJ N
h NN N
before IN N
operation NN N
. . N

Fifty-four CD N
patients NNS N
were VBD N
treated VBN N
with IN N
nonsteroidal JJ N
anti-inflammatory JJ N
drugs NNS N
( ( N
NSAID NNP N
) ) N
( ( N
Voltaren NNP N
resinat VBZ N
2 CD N
x NN N
75 CD N
mg/day NN N
for IN N
2 CD N
weeks NNS N
) ) N
. . N

Heterotopic NNP N
ossification NN N
was VBD N
scored VBN N
according VBG N
to TO N
the DT N
Brooker NNP N
Grading NNP N
system NN N
. . N

One CD N
hundred VBD N
patients NNS N
receiving VBG N
no DT N
prophylactic JJ N
therapy NN N
after IN N
total JJ N
hip NN N
arthroplasty NN N
between IN N
1988 CD N
and CC N
1992 CD N
were VBD N
analyzed VBN N
and CC N
defined VBN N
as IN N
the DT N
historical JJ N
control NN N
group NN N
. . N

RESULTS NNP N
Incidence NNP N
of IN N
heterotopic NN N
ossification NN N
was VBD N
47.8 CD N
% NN N
in IN N
the DT N
7 CD N
Gy NNP N
preoperative JJ N
group NN N
( ( N
Brooker NNP N
Score NNP N
I PRP N
: : N
36.9 CD N
% NN N
; : N
II NNP N
: : N
8.7 CD N
% NN N
; : N
III NNP N
: : N
2.2 CD N
% NN N
; : N
IV NNP N
: : N
0 CD N
% NN N
) ) N
and CC N
11.1 CD N
% NN N
in IN N
the DT N
NSAID NNP N
group NN N
( ( N
Brooker NNP N
Score NNP N
I PRP N
: : N
9.3 CD N
% NN N
; : N
II NNP N
: : N
1.8 CD N
% NN N
; : N
III NNP N
: : N
0 CD N
% NN N
; : N
IV NNP N
: : N
0 CD N
% NN N
) ) N
. . N

Regarding VBG N
overall JJ N
heterotopic NN N
ossification NN N
there EX N
was VBD N
a DT N
significant JJ N
difference NN N
between IN N
the DT N
NSAID NNP N
group NN N
and CC N
the DT N
7 CD N
Gy NNP N
group NN N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
. . N

Analyzing VBG N
the DT N
clinically RB N
significant JJ N
heterotopic NN N
ossification NN N
( ( N
Brooker NNP N
Score NNP N
III NNP N
and CC N
IV NNP N
) ) N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
two CD N
treatment NN N
arms NNS N
( ( N
p JJ N
> NNP N
0.05 CD N
) ) N
. . N

In IN N
the DT N
untreated JJ N
historical JJ N
control NN N
group NN N
the DT N
incidence NN N
of IN N
heterotopic NN N
ossification NN N
was VBD N
65 CD N
% NN N
( ( N
Brooker NNP N
Score NNP N
I PRP N
: : N
26 CD N
% NN N
; : N
II NNP N
: : N
15 CD N
% NN N
; : N
III NNP N
: : N
19 CD N
% NN N
; : N
IV NNP N
: : N
5 CD N
% NN N
) ) N
. . N

Referring VBG N
to TO N
overall JJ N
and CC N
to TO N
clinically RB N
relevant JJ N
heterotopic NN N
ossification NN N
the DT N
incidence NN N
of IN N
HO NNP N
was VBD N
greater JJR N
in IN N
the DT N
control NN N
group NN N
than IN N
in IN N
the DT N
prophylactically RB N
treated VBN N
groups NNS N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSION NNP N
Irradiation NNP N
within IN N
16-20 JJ N
h NN N
before IN N
operation NN N
and CC N
use NN N
of IN N
NSAID NNP N
( ( N
Voltaren NNP N
resinat NN N
) ) N
can MD N
reduce VB N
the DT N
incidence NN N
of IN N
clinically RB N
relevant JJ N
heterotopic NN N
ossification NN N
after IN N
total JJ N
hip NN N
replacement NN N
. . N

-DOCSTART- -X- O O 787788

Vitamin NNP N
C NNP N
and CC N
acute JJ N
illness NN N
in IN N
Navajo NNP 4_p
school NN 4_p
children NNS 4_p
. . 4_p

To TO N
evaluate VB N
earlier JJR N
observations NNS N
, , N
including VBG N
our PRP$ N
own JJ N
, , N
showing VBG N
usefulness NN N
of IN N
vitamin NN N
C NNP N
for IN N
managing VBG N
the DT N
common JJ N
cold NN N
, , N
we PRP N
performed VBD N
a DT N
double-blind JJ N
trial NN N
of IN N
vitamin NN N
C NNP N
versus NN N
placebo NN N
in IN N
868 CD N
children NNS N
. . N

There EX N
was VBD N
no DT N
difference NN N
in IN N
number NN N
becoming VBG N
ill JJ N
( ( N
133 CD N
versus IN N
129 CD N
) ) N
, , N
number NN N
of IN N
episodes NNS N
( ( N
166 CD N
versus IN N
159 CD N
) ) N
or CC N
mean JJ N
illness JJ N
duration NN N
( ( N
5.5 CD N
versus NN N
5.8 CD N
days NNS N
) ) N
between IN N
the DT N
groups NNS N
. . N

Children NNP N
receiving VBG N
vitamin NN N
C NNP N
had VBD N
fewer JJR N
throat NN N
cultures NNS N
yielding VBG N
beta-hemolytic JJ N
streptococcus NN N
( ( N
six CD N
versus NN N
13 CD N
, , N
P NNP N
less JJR N
than IN N
0.10 CD N
) ) N
, , N
but CC N
no DT N
difference NN N
in IN N
overall JJ N
complicated JJ N
illness NN N
rate NN N
( ( N
24 CD N
versus IN N
25 CD N
) ) N
. . N

Plasma NNP N
ascorbic JJ N
acid NN N
levels NNS N
were VBD N
higher JJR N
in IN N
the DT N
vitamin NN N
group NN N
24 CD N
to TO N
26 CD N
hours NNS N
after IN N
supplementation NN N
( ( N
1.28 CD N
versus NN N
1.04 CD N
mg NN N
per IN N
100 CD N
ml NN N
, , N
P NNP N
less JJR N
than IN N
0.01 CD N
) ) N
. . N

Children NNP N
with IN N
high JJ N
plasma NN N
ascorbic JJ N
acid JJ N
concentrations NNS N
had VBD N
longer RBR N
mean JJ N
illness NN N
( ( N
6.8 CD N
versus NN N
4.0 CD N
days NNS N
, , N
P NNP N
less JJR N
than IN N
0.05 CD N
) ) N
than IN N
those DT N
with IN N
low JJ N
levels NNS N
. . N

Vitamin NNP N
C NNP N
does VBZ N
not RB N
seem VB N
to TO N
be VB N
an DT N
effective JJ N
prophylactic NN N
or CC N
therapeutic JJ N
agent NN N
for IN N
upper JJ N
respiratory NN N
illness NN N
. . N

-DOCSTART- -X- O O 1391736

Treatment NN N
of IN N
peptic JJ 4_p
ulcer JJ 4_p
disease NN 4_p
with IN N
furazolidone NN N
. . N

Furazolidone NNP N
( ( N
FZ NNP N
) ) N
has VBZ N
been VBN N
used VBN N
in IN N
China NNP N
as IN N
a DT N
treatment NN N
of IN N
peptic JJ 4_p
ulcer JJ 4_p
disease NN 4_p
for IN N
about IN N
20 CD N
years NNS N
. . N

Clinical JJ N
and CC N
experimental JJ N
studies NNS N
suggest VBP N
that IN N
it PRP N
has VBZ N
good JJ N
short-term JJ N
and CC N
long-term JJ N
effects NNS N
on IN N
both DT N
human JJ N
and CC N
animal JJ 4_p
ulcers NNS 4_p
. . N

The DT N
ulcer JJ N
healing NN N
rate NN N
is VBZ N
related VBN N
to TO N
the DT N
dosage NN N
and CC N
course NN N
of IN N
treatment NN N
. . N

The DT N
healing VBG N
rate NN N
of IN N
a DT N
high JJ N
dose NN N
, , N
2 CD N
week NN N
course NN N
is VBZ N
about IN N
70-75 CD N
% NN N
and CC N
the DT N
relapse NN N
rate NN N
after IN N
3 CD N
years NNS N
is VBZ N
9.5 CD N
% NN N
. . N

The DT N
adverse JJ N
reactions NNS N
to TO N
FZ NNP N
are VBP N
not RB N
severe JJ N
, , N
and CC N
are VBP N
well RB N
tolerated VBN N
in IN N
most JJS N
patients NNS N
. . N

However RB N
the DT N
mutagenic JJ N
studies NNS N
of IN N
several JJ N
biological JJ N
systems NNS N
indicate VBP N
that IN N
it PRP N
has VBZ N
a DT N
mutagenic JJ N
effect NN N
, , N
but CC N
the DT N
mutagenic JJ N
and CC N
carcinogenic JJ N
effects NNS N
on IN N
humans NNS N
and CC N
animals NNS N
remain VBP N
questionable JJ N
, , N
because IN N
FZ NNP N
has VBZ N
been VBN N
biotransformed VBN N
into IN N
other JJ N
metabolites NNS N
. . N

The DT N
mechanisms NN N
of IN N
FZ NNP N
in IN N
the DT N
treatment NN N
of IN N
peptic JJ 4_p
ulcer JJ 4_p
disease NN 4_p
are VBP N
not RB N
fully RB N
understood JJ N
, , N
perhaps RB N
partly RB N
due JJ N
to TO N
the DT N
monoamine NN N
oxidase NN N
( ( N
MAO NNP N
) ) N
inhibitory NN N
reaction NN N
and CC N
partly RB N
to TO N
the DT N
antibacterial JJ N
activity NN N
to TO N
Helicobacter NNP N
pylori NN N
( ( N
HP NNP N
) ) N
. . N

The DT N
long-term JJ N
effects NNS N
of IN N
FZ NNP N
are VBP N
still RB N
not RB N
clear JJ N
. . N

-DOCSTART- -X- O O 10757250

Antisaccade NNP N
and CC N
smooth JJ N
pursuit NN N
eye NN N
movements NNS N
in IN N
healthy JJ N
subjects NNS N
receiving VBG N
sertraline NN N
and CC N
lorazepam NN N
. . N

Patients NNS N
suffering VBG N
from IN N
some DT N
psychiatric JJ N
and CC N
neurological JJ N
disorders NNS N
demonstrate VBP N
abnormally RB N
high JJ N
levels NNS N
of IN N
saccadic JJ N
distractibility NN N
when WRB N
carrying VBG N
out RP N
the DT N
antisaccade NN N
task NN N
. . N

This DT N
has VBZ N
been VBN N
particularly RB N
thoroughly RB N
demonstrated VBN N
in IN N
patients NNS N
with IN N
schizophrenia NN N
. . N

A DT N
large JJ N
body NN N
of IN N
evidence NN N
has VBZ N
been VBN N
accumulated VBN N
from IN N
studies NNS N
of IN N
patients NNS N
which WDT N
suggests VBZ N
that IN N
such JJ N
eye NN N
movement NN N
abnormalities NNS N
may MD N
arise VB N
from IN N
frontal JJ N
lobe NN N
dysfunction NN N
. . N

The DT N
psychopharmacology NN N
of IN N
saccadic JJ N
distractibility NN N
is VBZ N
less RBR N
well RB N
understood JJ N
, , N
but CC N
is VBZ N
relevant JJ N
both DT N
to TO N
interpreting VBG N
patient JJ N
studies NNS N
and CC N
to TO N
establishing VBG N
the DT N
neurological JJ N
basis NN N
of IN N
their PRP$ N
findings NNS N
. . N

Twenty NNP N
healthy JJ N
subjects NNS N
received VBD N
lorazepam JJ N
0.5 CD N
mg NN N
, , N
1 CD N
mg NN N
and CC N
2 CD N
mg NN N
, , N
sertraline VBP N
50 CD N
mg NN N
and CC N
placebo NN N
in IN N
a DT N
balanced JJ N
, , N
repeated VBD N
measures NNS N
study VB N
design NN N
. . N

Antisaccade NNP N
, , N
no-saccade JJ N
, , N
visually RB N
guided VBN N
saccade NN N
and CC N
smooth JJ N
pursuit NN N
tasks NNS N
were VBD N
carried VBN N
out IN N
and CC N
the DT N
effects NNS N
of IN N
practice NN N
and CC N
drugs NNS N
measured VBN N
. . N

Lorazepam NNP N
increased VBD N
direction NN N
errors NNS N
in IN N
the DT N
antisaccade NN N
and CC N
no-saccade JJ N
tasks NNS N
in IN N
a DT N
dose-dependent JJ N
manner NN N
. . N

Sertraline NNP N
had VBD N
no DT N
effect NN N
on IN N
these DT N
measures NNS N
. . N

Correlation NN N
showed VBD N
a DT N
statistically RB N
significant JJ N
, , N
but CC N
rather RB N
weak JJ N
, , N
association NN N
between IN N
direction NN N
errors NNS N
and CC N
smooth JJ N
pursuit NN N
measures NNS N
. . N

Practice NNP N
was VBD N
shown VBN N
to TO N
have VB N
a DT N
powerful JJ N
effect NN N
on IN N
antisaccade JJ N
direction NN N
errors NNS N
. . N

This DT N
study NN N
supports VBZ N
our PRP$ N
previous JJ N
work NN N
by IN N
confirming VBG N
that IN N
lorazepam NN N
reliably RB N
worsens VBZ N
saccadic JJ N
distractibility NN N
, , N
in IN N
contrast NN N
to TO N
other JJ N
psychotropic NN N
drugs NNS N
such JJ N
as IN N
sertraline NN N
and CC N
chlorpromazine NN N
. . N

Our PRP$ N
results NNS N
also RB N
suggest VBP N
that IN N
other JJ N
studies NNS N
in IN N
this DT N
field NN N
, , N
particularly RB N
those DT N
using VBG N
parallel JJ N
groups NNS N
design NN N
, , N
should MD N
take VB N
account NN N
of IN N
practice NN N
effects NNS N
. . N

-DOCSTART- -X- O O 18492829

Gene NNP N
expression NN N
is VBZ N
altered VBN N
in IN N
piglet NN N
small JJ N
intestine NN N
by IN N
weaning VBG N
and CC N
dietary JJ N
glutamine NN N
supplementation NN N
. . N

Dietary JJ N
supplementation NN N
of IN N
glutamine NN N
prevents NNS N
intestinal JJ N
dysfunction NN N
and CC N
atrophy NN N
in IN N
weanling VBG N
piglets NNS N
, , N
but CC N
the DT N
underlying JJ N
mechanism NN N
( ( N
s NN N
) ) N
are VBP N
largely RB N
unknown JJ N
. . N

This DT N
study NN N
was VBD N
conducted VBN N
to TO N
test VB N
the DT N
hypothesis NN N
that IN N
weaning VBG N
or CC N
glutamine NN N
may MD N
modulate VB N
expression NN N
of IN N
genes NNS N
that WDT N
are VBP N
crucial JJ N
for IN N
intestinal JJ N
metabolism NN N
and CC N
function NN N
. . N

In IN N
Expt NNP N
. . N

1 CD N
, , N
we PRP N
obtained VBD N
small JJ N
intestine NN N
from IN N
28-d-old JJ N
pigs NNS N
weaned VBD N
at IN N
21 CD N
d NN N
of IN N
age NN N
and CC N
from IN N
age-matched JJ N
suckling VBG N
piglets NNS N
. . N

In IN N
Expt NNP N
. . N

2 CD N
, , N
piglets NNS N
were VBD N
weaned VBN N
at IN N
21 CD N
d NN N
of IN N
age NN N
and CC N
then RB N
had VBD N
free JJ N
access NN N
to TO N
diets NNS N
supplemented VBN N
with IN N
1 CD N
% NN N
L-glutamine NNP N
( ( N
wt NN N
: : N
wt NN N
) ) N
or CC N
isonitrogenous JJ N
L-alanine JJ N
( ( N
control NN N
) ) N
. . N

At IN N
d JJ N
28 CD N
, , N
we PRP N
collected VBD N
small JJ N
intestine NN N
for IN N
biochemical JJ N
and CC N
morphological JJ N
measurements NNS N
and CC N
microarray JJ N
analysis NN N
of IN N
gene NN N
expression NN N
using VBG N
the DT N
Operon NNP N
Porcine NNP N
Genome NNP N
Oligo NNP N
set NN N
. . N

Early JJ N
weaning NN N
resulted VBD N
in IN N
increased VBN N
( ( N
52-346 CD N
% NN N
) ) N
expression NN N
of IN N
genes NNS N
related VBN N
to TO N
oxidative JJ N
stress NN N
and CC N
immune JJ N
activation NN N
but CC N
decreased JJ N
( ( N
35-77 CD N
% NN N
) ) N
expression NN N
of IN N
genes NNS N
related VBN N
to TO N
macronutrient VB N
metabolism NN N
and CC N
cell NN N
proliferation NN N
in IN N
the DT N
gut NN N
. . N

Dietary NNP N
glutamine JJ N
supplementation NN N
increased VBD N
intestinal JJ N
expression NN N
( ( N
120-124 CD N
% NN N
) ) N
of IN N
genes NNS N
that WDT N
are VBP N
necessary JJ N
for IN N
cell NN N
growth NN N
and CC N
removal NN N
of IN N
oxidants NNS N
, , N
while IN N
reducing VBG N
( ( N
34-75 CD N
% NN N
) ) N
expression NN N
of IN N
genes NNS N
that WDT N
promote VBP N
oxidative JJ N
stress NN N
and CC N
immune JJ N
activation NN N
. . N

Functionally RB N
, , N
the DT N
glutamine NN N
treatment NN N
enhanced VBD N
intestinal JJ N
oxidative-defense JJ N
capacity NN N
( ( N
indicated VBN N
by IN N
a DT N
29 CD N
% NN N
increase NN N
in IN N
glutathione JJ N
concentration NN N
) ) N
, , N
prevented VBD N
jejunal JJ N
atrophy NN N
, , N
and CC N
promoted VBD N
small JJ N
intestine JJ N
growth NN N
( ( N
+12 CD N
% NN N
) ) N
and CC N
body NN N
weight JJ N
gain NN N
( ( N
+19 CD N
% NN N
) ) N
in IN N
weaned JJ N
piglets NNS N
. . N

These DT N
findings NNS N
reveal VBP N
coordinate JJ N
alterations NNS N
of IN N
gene NN N
expression NN N
in IN N
response NN N
to TO N
weaning VBG N
and CC N
aid NN N
in IN N
providing VBG N
molecular JJ N
mechanisms NNS N
for IN N
the DT N
beneficial JJ N
effect NN N
of IN N
dietary JJ N
glutamine NN N
supplementation NN N
to TO N
improve VB N
nutrition NN N
status NN N
in IN N
young JJ N
mammals NNS N
. . N

-DOCSTART- -X- O O 24431427

Multisensory JJ N
temporal JJ N
integration NN N
in IN N
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
. . N

The DT N
new JJ N
DSM-5 NNP N
diagnostic JJ N
criteria NNS N
for IN N
autism NN N
spectrum NN N
disorders NNS N
( ( N
ASDs NNP N
) ) N
include VBP N
sensory JJ N
disturbances NNS N
in IN N
addition NN N
to TO N
the DT N
well-established JJ N
language NN N
, , N
communication NN N
, , N
and CC N
social JJ N
deficits NNS N
. . N

One CD N
sensory NN N
disturbance NN N
seen VBN N
in IN N
ASD NNP N
is VBZ N
an DT N
impaired JJ N
ability NN N
to TO N
integrate VB N
multisensory JJ N
information NN N
into IN N
a DT N
unified JJ N
percept NN N
. . N

This DT N
may MD N
arise VB N
from IN N
an DT N
underlying JJ N
impairment NN N
in IN N
which WDT N
individuals NNS N
with IN N
ASD NNP 4_p
have VBP N
difficulty NN N
perceiving VBG N
the DT N
temporal JJ N
relationship NN N
between IN N
cross-modal JJ N
inputs NNS N
, , N
an DT N
important JJ N
cue NN N
for IN N
multisensory JJ N
integration NN N
. . N

Such JJ N
impairments NNS N
in IN N
multisensory NN N
processing NN N
may MD N
cascade VB N
into IN N
higher-level JJ N
deficits NNS N
, , N
impairing VBG N
day-to-day JJ N
functioning NN N
on IN N
tasks NNS N
, , N
such JJ N
as IN N
speech JJ N
perception NN N
. . N

To TO N
investigate VB N
multisensory JJ N
temporal JJ N
processing VBG N
deficits NNS N
in IN N
ASD NNP N
and CC N
their PRP$ N
links NNS N
to TO N
speech VB N
processing NN N
, , N
the DT N
current JJ N
study NN N
mapped VBD N
performance NN N
on IN N
a DT N
number NN N
of IN N
multisensory JJ N
temporal JJ N
tasks NNS N
( ( N
with IN N
both DT N
simple JJ N
and CC N
complex JJ N
stimuli NN N
) ) N
onto IN N
the DT N
ability NN N
of IN N
individuals NNS N
with IN N
ASD NNP 4_p
to TO N
perceptually RB N
bind VB N
audiovisual JJ N
speech NN N
signals NNS N
. . N

High-functioning JJ 4_p
children NNS N
with IN N
ASD NNP 4_p
were VBD N
compared VBN N
with IN N
a DT N
group NN N
of IN N
typically RB N
developing VBG N
children NNS N
. . N

Performance NN N
on IN N
the DT N
multisensory JJ N
temporal JJ N
tasks NNS N
varied VBN N
with IN N
stimulus JJ N
complexity NN N
for IN N
both DT N
groups NNS N
; : N
less CC N
precise JJ N
temporal JJ N
processing NN N
was VBD N
observed VBN N
with IN N
increasing VBG N
stimulus JJ N
complexity NN N
. . N

Notably RB N
, , N
individuals NNS N
with IN N
ASD NNP N
showed VBD N
a DT N
speech-specific JJ N
deficit NN N
in IN N
multisensory JJ N
temporal JJ N
processing NN N
. . N

Most JJS N
importantly RB N
, , N
the DT N
strength NN N
of IN N
perceptual JJ N
binding NN N
of IN N
audiovisual JJ N
speech NN N
observed VBN N
in IN N
individuals NNS N
with IN N
ASD NNP 4_p
was VBD N
strongly RB N
related VBN N
to TO N
their PRP$ N
low-level JJ N
multisensory JJ N
temporal JJ N
processing NN N
abilities NNS N
. . N

Collectively RB N
, , N
the DT N
results NNS N
represent VBP N
the DT N
first JJ N
to TO N
illustrate VB N
links NNS N
between IN N
multisensory JJ N
temporal JJ N
function NN N
and CC N
speech NN N
processing NN N
in IN N
ASD NNP N
, , N
strongly RB N
suggesting VBG N
that IN N
deficits NNS N
in IN N
low-level JJ N
sensory JJ N
processing NN N
may MD N
cascade VB N
into IN N
higher-order NN N
domains NNS N
, , N
such JJ N
as IN N
language NN N
and CC N
communication NN N
. . N

-DOCSTART- -X- O O 11994052

Metformin NNP N
does VBZ N
not RB N
enhance VB N
ovulation NN N
induction NN N
in IN N
clomiphene NN 4_p
resistant JJ 4_p
polycystic JJ 4_p
ovary JJ 4_p
syndrome NN 4_p
in IN N
clinical JJ N
practice NN N
. . N

AIMS NNP N
To TO N
determine VB N
whether IN N
metformin NN N
pretreatment NN N
has VBZ N
beneficial JJ N
effects NNS N
in IN N
clomiphene NN 4_p
resistant JJ 4_p
infertile JJ 4_p
women NNS N
with IN N
polycystic JJ 4_p
ovary JJ 4_p
syndrome NN 4_p
( ( N
PCOS NNP 4_p
) ) N
in IN N
an DT N
infertility NN N
clinic NN N
. . N

METHODS NNP N
This DT N
was VBD N
a DT N
randomized JJ N
placebo NN N
controlled VBD N
double-blind NN N
crossover NN N
study NN N
of IN N
3 CD N
months NNS N
metformin RB N
( ( N
1500 CD N
mg IN N
day-1 NN N
) ) N
/placebo NN N
, , N
followed VBN N
by IN N
3 CD N
months NNS N
metformin/placebo VBN N
together RB N
with IN N
clomiphene NN N
( ( N
50-100 JJ N
mg NN N
for IN N
5 CD N
days NNS N
) ) N
for IN N
three CD N
cycles NNS N
in IN N
clomiphene NN 4_p
resistant JJ 4_p
women NNS N
with IN N
PCOS NNP 4_p
. . N

The DT N
primary JJ N
outcomes NNS N
were VBD N
restoration NN N
of IN N
spontaneous JJ N
menses NNS N
, , N
ovulation NN N
induction NN N
( ( N
spontaneous JJ N
or CC N
clomiphene NN N
induced VBN N
) ) N
and CC N
pregnancy NN N
. . N

Secondary JJ N
endpoints NNS N
were VBD N
changes NNS N
in IN N
biochemical JJ N
parameters NNS N
related VBN N
to TO N
androgens NNS N
and CC N
insulin NN N
. . N

RESULTS NNP N
Twelve NNP N
women NNS N
completed VBD N
the DT N
metformin NN N
arm NN N
and CC N
14 CD N
the DT N
placebo NN N
arm NN N
. . N

Spontaneous JJ N
menstruation NN N
resumed VBD N
in IN N
five CD N
metformin NNS N
treated VBD N
patients NNS N
and CC N
in IN N
six CD N
placebo NN N
treated VBN N
women NNS N
, , N
P=0.63 NNP N
. . N

No NNP N
women NNS N
given VBN N
metformin NNS N
spontaneously RB N
ovulated VBD N
, , N
although IN N
one CD N
patient NN N
given VBN N
placebo NN N
did VBD N
, , N
P=0.30 NNP N
. . N

There EX N
was VBD N
no DT N
difference NN N
in IN N
the DT N
efficacy NN N
of IN N
clomiphene NN N
between IN N
the DT N
two CD N
groups NNS N
with IN N
ovulation NN N
being VBG N
induced VBN N
in IN N
five CD N
( ( N
out IN N
of IN N
12 CD N
) ) N
metformin NN N
treated VBN N
women NNS N
and CC N
four CD N
( ( N
out IN N
of IN N
14 CD N
) ) N
placebo NN N
treated VBN N
women NNS N
, , N
P=0.63 NNP N
. . N

Pregnancy NN N
occurred VBD N
in IN N
three CD N
( ( N
out IN N
of IN N
12 CD N
) ) N
women NNS N
given VBN N
metformin NNS N
and CC N
two CD N
( ( N
out IN N
of IN N
14 CD N
) ) N
women NNS N
given VBN N
placebo NNS N
, , N
P=0.59 NNP N
. . N

CONCLUSIONS NNP N
Metformin NNP N
is VBZ N
not RB N
always RB N
beneficial JJ N
when WRB N
given VBN N
to TO N
clomiphene VB 4_p
resistant JJ 4_p
infertile JJ 4_p
women NNS N
with IN N
PCOS NNP 4_p
in IN N
clinical JJ N
practice NN N
. . N

-DOCSTART- -X- O O 3117477

Metabolic NNP N
and CC N
ventilatory JJ N
responses NNS N
during IN N
very RB N
low JJ N
level NN N
exercise NN N
. . N

1 CD N
. . N

Nine NNP 4_p
male NN 4_p
and CC 4_p
six CD 4_p
female JJ 4_p
healthy JJ 4_p
subjects NNS 4_p
were VBD 4_p
studied VBN 4_p
during IN 4_p
supine JJ 4_p
bicycle NN 4_p
exercise NN 4_p
at IN 4_p
workloads NNS 4_p
of IN 4_p
12 CD 4_p
and CC 4_p
37 CD 4_p
W NNP 4_p
; : 4_p
pedalling VBG 4_p
rates NNS 4_p
varied VBD 4_p
between IN 4_p
30 CD 4_p
and CC 4_p
50 CD 4_p
cycles/min NN 4_p
at IN 4_p
each DT 4_p
workload NN 4_p
. . 4_p

Measurements NNS N
were VBD N
made VBN N
of IN N
oxygen NN N
consumption NN N
( ( N
VO2 NNP N
) ) N
, , N
carbon NN N
dioxide NN N
production NN N
( ( N
VCO2 NNP N
) ) N
, , N
minute JJ N
ventilation NN N
( ( N
VE NNP N
) ) N
, , N
tidal JJ N
volume NN N
( ( N
VT NNP N
) ) N
, , N
respiratory JJ N
frequency NN N
( ( N
fR NN N
) ) N
, , N
inspiratory JJ N
and CC N
expiratory JJ N
time NN N
( ( N
TI NNP N
, , N
TE NNP N
) ) N
and CC N
mean JJ N
inspiratory NN N
flow NN N
( ( N
VT/TI NNP N
) ) N
using VBG N
a DT N
non-invasive JJ N
canopy-computer-spirometer NN N
system NN N
. . N

2 CD N
. . N

At IN N
rest NN N
, , N
males NNS N
had VBD N
greater JJR N
values NNS N
of IN N
VE NNP N
, , N
VT NNP N
, , N
TI NNP N
, , N
inspiratory JJ N
duty NN N
cycle NN N
( ( N
TI/TTOT NNP N
) ) N
, , N
VCO2 NNP N
and CC N
VO2 NNP N
, , N
and CC N
a DT N
lower JJR N
fR NN N
, , N
than IN N
females NNS N
. . N

3 CD N
. . N

At IN N
the DT N
lower JJR N
workload NN N
, , N
VO2 NNP N
, , N
VCO2 NNP N
, , N
VE NNP N
, , N
VT NNP N
and CC N
VT/TI NNP N
increased VBD N
linearly RB N
with IN N
increasing VBG N
pedalling VBG N
rate NN N
, , N
whereas WP N
at IN N
the DT N
higher JJR N
workload NN N
there EX N
was VBD N
a DT N
decrease NN N
in IN N
VO2 NNP N
and CC N
little JJ N
or CC N
no DT N
change NN N
in IN N
ventilatory NN N
parameters NNS N
from IN N
30 CD N
to TO N
50 CD N
cycles/min NN N
except IN N
for IN N
an DT N
increase NN N
in IN N
fR NN N
in IN N
females NNS N
. . N

4 CD N
. . N

While IN N
performing VBG N
supine JJ N
exercise NN N
, , N
there EX N
was VBD N
an DT N
effect NN N
of IN N
pedalling VBG N
rate NN N
on IN N
ventilatory NN N
and CC N
metabolic JJ N
parameters NNS N
at IN N
the DT N
low JJ N
workload NN N
( ( N
12 CD N
W NNP N
) ) N
which WDT N
diminished VBD N
at IN N
the DT N
higher JJR N
workload NN N
( ( N
37 CD N
W NNP N
) ) N
. . N

An DT N
increase NN N
in IN N
pedalling VBG N
rate NN N
appears VBZ N
to TO N
enhance VB N
efficiency NN N
at IN N
these DT N
low JJ N
workloads NNS N
. . N

5 CD N
. . N

Differences NNS N
between IN N
the DT N
sexes NNS N
during IN N
exercise NN N
generally RB N
include VBP N
: : N
( ( N
a DT N
) ) N
a DT N
higher JJR N
breathing NN N
frequency NN N
, , N
( ( N
b NN N
) ) N
a DT N
greater JJR N
mechanical JJ N
efficiency NN N
, , N
and CC N
( ( N
c NN N
) ) N
lower JJR N
ventilatory NN N
equivalents NNS N
of IN N
O2 NNP N
and CC N
CO2 NNP N
( ( N
VE/VO2 NNP N
and CC N
VE/VCO2 NNP N
) ) N
during IN N
the DT N
higher JJR N
workload NN N
in IN N
females NNS N
than IN N
males NNS N
. . N

-DOCSTART- -X- O O 23192919

B-type JJ N
natriuretic JJ N
peptide NN N
and CC N
risk NN N
of IN N
contrast-induced JJ 4_p
acute JJ 4_p
kidney NN 4_p
injury NN 4_p
in IN 4_p
acute JJ 4_p
ST-segment-elevation NNP 4_p
myocardial JJ 4_p
infarction NN 4_p
: : 4_p
a DT N
substudy NN N
from IN N
the DT N
HORIZONS-AMI NNP N
trial NN N
. . N

BACKGROUND NNP N
Contrast-induced NNP N
acute NN N
kidney NN N
injury NN N
( ( N
CI-AKI NNP N
) ) N
after IN N
percutaneous JJ N
coronary JJ N
intervention NN N
is VBZ N
associated VBN N
with IN N
adverse JJ N
short- NN N
and CC N
long-term JJ N
outcomes NNS N
. . N

However RB N
, , N
identification NN N
of IN N
patients NNS N
at IN N
risk NN N
for IN N
CI-AKI NNP N
is VBZ N
challenging VBG N
. . N

Using VBG N
a DT N
large JJ N
contemporary JJ N
randomized VBN N
trial NN N
database NN N
of IN N
patients NNS N
with IN N
ST-segment-elevation NNP N
myocardial JJ N
infarction NN N
, , N
we PRP N
therefore RB N
sought VBD N
to TO N
examine VB N
whether IN N
admission NN N
B-type NNP N
natriuretic JJ N
peptide NN N
( ( N
BNP NNP N
) ) N
levels NNS N
predict VBP N
the DT N
development NN N
of IN N
CI-AKI NNP N
. . N

METHODS NNP N
AND NNP N
RESULTS NNP N
A NNP N
total NN N
of IN N
979 CD N
ST-segment-elevation JJ N
myocardial JJ N
infarction NN N
patients NNS N
enrolled VBN N
in IN N
the DT N
Harmonizing NNP N
Outcomes NNP N
with IN N
Revascularization NNP N
and CC N
Stents NNP N
in IN N
Acute NNP N
Myocardial NNP N
Infarction NNP N
( ( N
HORIZONS-AMI NNP N
) ) N
trial NN N
had VBD N
BNP NNP N
levels NNS N
measured VBN N
in IN N
the DT N
emergency NN N
room NN N
prior RB N
to TO N
primary JJ N
percutaneous JJ N
coronary JJ N
intervention NN N
as IN N
part NN N
of IN N
the DT N
study NN N
protocol NN N
. . N

CI-AKI NNP N
was VBD N
defined VBN N
as IN N
a DT N
relative JJ N
increase NN N
in IN N
serum JJ N
creatinine NN N
of IN N
≥25 NNP N
% NN N
, , N
or CC N
an DT N
absolute JJ N
increase NN N
of IN N
≥0.5 NNP N
mg/dL NN N
, , N
occurring VBG N
within IN N
48 CD N
hours NNS N
after IN N
contrast NN N
administration NN N
. . N

Logistic JJ N
regression NN N
analysis NN N
was VBD N
used VBN N
to TO N
estimate VB N
the DT N
association NN N
of IN N
admission NN N
BNP NNP N
with IN N
development NN N
of IN N
CI-AKI NNP N
. . N

CI-AKI NNP N
occurred VBD N
in IN N
131 CD N
patients NNS N
( ( N
13.3 CD N
% NN N
) ) N
. . N

Baseline NNP N
BNP NNP N
was VBD N
a DT N
significant JJ N
univariable JJ N
correlate NN N
of IN N
CI-AKI NNP N
( ( N
odds NNS N
ratio VBP N
1.31 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
1.14-1.51 JJ N
; : N
P=0.0001 NNP N
) ) N
. . N

After IN N
multivariable JJ N
adjustment NN N
for IN N
clinical JJ N
, , N
laboratory NN N
, , N
and CC N
angiographic JJ N
variables NNS N
, , N
BNP NNP N
remained VBD N
a DT N
significant JJ N
independent JJ N
predictor NN N
of IN N
CI-AKI NNP N
( ( N
1.29 CD N
[ RB N
1.10 CD N
, , N
1.51 CD N
] NN N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Significant JJ N
net JJ N
reclassification NN N
improvement NN N
was VBD N
achieved VBN N
by IN N
addition NN N
of IN N
BNP NNP N
to TO N
the DT N
current JJ N
clinical JJ N
risk NN N
prediction NN N
model NN N
( ( N
net JJ N
reclassification NN N
improvement=0.177 NN N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
to TO N
the DT N
Mehran NNP N
Risk NNP N
Score NNP N
( ( N
net JJ N
reclassification NN N
improvement=0.100 NN N
; : N
P=0.015 NNP N
) ) N
. . N

CONCLUSIONS NNP N
Measurement NNP N
of IN N
serum NN N
BNP NNP N
at IN N
hospital JJ N
admission NN N
may MD N
help VB N
identify VB N
patients NNS N
who WP N
are VBP N
at IN N
risk NN N
for IN N
developing VBG N
CI-AKI NNP N
after IN N
primary JJ N
percutaneous JJ N
coronary JJ N
intervention NN N
in IN N
ST-segment-elevation NNP N
myocardial JJ N
infarction NN N
. . N

CLINICAL NNP N
TRIAL NNP N
REGISTRATION NNP N
URL NNP N
: : N
http NN N
: : N
//www.clinicaltrials.gov NN N
. . N

Unique NNP N
identifier NN N
: : N
NCT00433966 NNP N
. . N

-DOCSTART- -X- O O 24517028

Effects NNS N
of IN N
iron NN N
on IN N
the DT N
pharmacokinetics NNS N
of IN N
paracetamol NN N
in IN N
saliva NN N
. . N

Paracetamol NNP N
has VBZ N
been VBN N
reported VBN N
to TO N
chelate VB N
with IN N
iron NN N
. . N

It PRP N
was VBD N
found VBN N
that IN N
no DT N
in IN N
vitro JJ N
reaction NN N
between IN N
ferrous JJ N
ion NN N
and CC N
paracetamol NN N
. . N

Other JJ N
studies NNS N
found VBD N
that IN N
there EX N
is VBZ N
an DT N
aerobic JJ N
( ( N
in IN N
the DT N
gastrointestinal JJ N
tract NN N
) ) N
oxidation NN N
of IN N
ferrous JJ N
ion NN N
to TO N
ferric VB N
ion NN N
caused VBN N
in IN N
iron-paracetamol NN N
in IN N
vivo JJ N
reactions NNS N
. . N

The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
if IN N
iron NN N
interacts NNS N
with IN N
paracetamol NN N
and CC N
reduces NNS N
paracetamol JJ N
absorption NN N
. . N

A DT N
randomized JJ N
, , N
double-blind JJ N
, , N
cross-over JJ N
study NN N
design NN N
was VBD N
used VBN N
to TO N
assess VB N
the DT N
in IN N
vivo JJ N
interaction NN N
of IN N
paracetamol NN N
and CC N
ferrous JJ N
ion NN N
. . N

Paracetamol NNP N
( ( N
1.0 CD N
g NN N
) ) N
was VBD N
co-ignested JJ N
alone RB N
or CC N
with IN N
( ( N
300 CD N
mg NN N
) ) N
ferrous JJ N
sulphate NN N
by IN N
ten JJ N
healthy JJ 4_p
male NN N
volunteers NNS N
, , N
using VBG N
saliva JJ N
drug NN N
levels NNS N
as IN N
a DT N
parameter NN N
. . N

Concomitant NNP N
administration NN N
of IN N
ferrous JJ N
sulphate NN N
and CC N
paracetamol NN N
, , N
decreased VBN N
AUC8 NNP N
from IN N
42.88 CD N
+/- JJ N
3.8-34.25 JJ N
+/- JJ N
2.8 CD N
microg NN N
h NN N
mL NN N
( ( N
-1 NN N
) ) N
( ( N
p JJ N
= NNP N
0.04 CD N
) ) N
and CC N
Cmax NNP N
from IN N
18.75 CD N
+/- JJ N
1.9 CD N
to TO N
15.9 CD N
+/- JJ N
1.7 CD N
microg NN N
mL NN N
( ( N
-1 NN N
) ) N
( ( N
p JJ N
= NNP N
0.11 CD N
) ) N
, , N
while IN N
no DT N
change NN N
in IN N
tmax NN N
( ( N
p JJ N
= NNP N
0.5 CD N
) ) N
was VBD N
originated VBN N
. . N

A DT N
significant JJ N
difference NN N
was VBD N
found VBN N
in IN N
the DT N
paracetamol NN N
pharmacokinetic JJ N
parameter NN N
oral JJ N
clearance NN N
( ( N
C1/F NNP N
) ) N
( ( N
p JJ N
= NNP N
0.02 CD N
) ) N
and CC N
slightly RB N
increased VBN N
in IN N
volume NN N
of IN N
distribution NN N
( ( N
V NNP N
( ( N
d NN N
) ) N
/F NN N
) ) N
( ( N
p JJ N
= NNP N
0.10 CD N
) ) N
. . N

Co-administration NN N
of IN N
iron NN N
and CC N
paracetamol JJ N
results NNS N
in IN N
decreased JJ N
paracetamol NN N
absorption NN N
due JJ N
to TO N
an DT N
interaction NN N
between IN N
iron NN N
and CC N
paracetamol NN N
. . N

-DOCSTART- -X- O O 23379240

[ JJ N
Afala NNP N
in IN N
the DT N
treatment NN N
of IN N
patients NNS N
with IN N
BPH NNP 4_p
: : N
efficacy NN N
and CC N
safety NN N
] NN N
. . N

The DT N
double-blind JJ N
, , N
placebo-controlled JJ N
, , N
randomized JJ N
clinical JJ N
trial NN N
involving VBG N
94 CD N
patients NNS N
has VBZ N
evaluated VBN N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
domestic JJ N
preparation NN N
afala NN N
in IN N
patients NNS N
with IN N
symptoms NNS 4_p
of IN 4_p
I-II NNP 4_p
stages NNS 4_p
benign VBP 4_p
prostatic JJ 4_p
hyperplasia NN 4_p
( ( 4_p
BPH NNP 4_p
) ) 4_p
. . N

It PRP N
was VBD N
shown VBN N
that IN N
a DT N
6-month JJ N
course NN N
of IN N
treatment NN N
with IN N
afala NN N
at IN N
a DT N
dose NN N
of IN N
2 CD N
tablets NNS N
4 CD N
times NNS N
a DT N
day NN N
resulted VBD N
in IN N
a DT N
significant JJ N
reduction NN N
in IN N
the DT N
severity NN N
of IN N
urinary JJ N
disorders NNS N
, , N
estimated VBN N
by IN N
total JJ N
IPSS NNP N
score NN N
, , N
relative JJ N
to TO N
baseline VB N
values NNS N
and CC N
compared VBN N
to TO N
placebo VB N
therapy NN N
. . N

The DT N
most RBS N
pronounced JJ N
therapeutic JJ N
effects NNS N
of IN N
the DT N
drug NN N
were VBD N
registered VBN N
in IN N
respect NN N
of IN N
irritative JJ N
symptoms NNS N
of IN N
BPH NNP N
. . N

According VBG N
uroflowmetry NN N
, , N
peak JJ N
flow NN N
rate NN N
after IN N
6 CD N
months NNS N
of IN N
treatment NN N
was VBD N
increased VBN N
by IN N
more JJR N
than IN N
50 CD N
% NN N
. . N

Significant JJ N
clinical JJ N
benefit NN N
persisted VBD N
not RB N
only RB N
within IN N
the DT N
6-month JJ N
course NN N
of IN N
therapy NN N
, , N
but CC N
3 CD N
months NNS N
after IN N
. . N

Long-term JJ N
therapy NN N
had VBD N
no DT N
effect NN N
on IN N
the DT N
concentration NN N
of IN N
total JJ N
, , N
free JJ N
and CC N
complex JJ N
PSA NNP N
, , N
testosterone NN N
( ( N
total JJ N
and CC N
free JJ N
) ) N
, , N
dihydrotestosterone NN N
, , N
and CC N
prolactin NN N
in IN N
the DT N
blood NN N
. . N

Absence NN N
of IN N
adverse JJ N
effects NNS N
, , N
biochemical JJ N
abnormalities NNS N
, , N
changes NNS N
in IN N
clinical JJ N
blood NN N
and CC N
urine NN N
confirmed VBD N
the DT N
safety NN N
of IN N
6-month JJ N
therapy NN N
. . N

-DOCSTART- -X- O O 25888263

Effect NN N
of IN N
enzalutamide NN N
on IN N
health-related JJ N
quality NN N
of IN N
life NN N
, , N
pain NN N
, , N
and CC N
skeletal-related JJ N
events NNS N
in IN N
asymptomatic JJ 4_p
and CC 4_p
minimally RB 4_p
symptomatic JJ 4_p
, , 4_p
chemotherapy-naive JJ 4_p
patients NNS 4_p
with IN 4_p
metastatic JJ 4_p
castration-resistant JJ 4_p
prostate NN 4_p
cancer NN 4_p
( ( 4_p
PREVAIL NNP 4_p
) ) N
: : N
results NNS N
from IN N
a DT N
randomised VBN N
, , N
phase VB N
3 CD N
trial NN N
. . N

BACKGROUND NNP N
Enzalutamide NNP N
significantly RB N
increased VBD N
overall JJ N
survival NN N
and CC N
radiographic JJ N
progression-free JJ N
survival NN N
compared VBN N
with IN N
placebo NN N
in IN N
the DT N
PREVAIL NNP N
trial NN N
of IN N
asymptomatic JJ 4_p
and CC 4_p
minimally RB 4_p
symptomatic JJ 4_p
, , N
chemotherapy-naive JJ 4_p
patients NNS 4_p
with IN 4_p
metastatic JJ 4_p
castration-resistant JJ 4_p
prostate NN 4_p
cancer NN 4_p
. . N

We PRP N
report VBP N
the DT N
effect NN N
of IN N
enzalutamide NN N
on IN N
health-related JJ N
quality NN N
of IN N
life NN N
( ( N
HRQoL NNP N
) ) N
, , N
pain NN N
, , N
and CC N
skeletal-related JJ N
events NNS N
observed VBD N
during IN N
this DT N
trial NN N
. . N

METHODS NNP N
In IN N
this DT N
phase NN N
3 CD N
, , N
double-blind JJ N
trial NN N
, , N
patients NNS 4_p
were VBD 4_p
randomly RB 4_p
assigned VBN 4_p
( ( 4_p
1:1 CD 4_p
) ) 4_p
to TO 4_p
receive VB N
enzalutamide RB N
160 CD N
mg/day NN N
( ( N
n=872 JJ N
) ) N
or CC 4_p
placebo NN N
( ( N
n=845 JJ N
) ) N
orally RB N
. . N

HRQoL NNP N
was VBD N
assessed VBN N
at IN N
baseline NN N
and CC N
during IN N
treatment NN N
using VBG N
the DT N
Functional NNP N
Assessment NNP N
of IN N
Cancer NNP N
Therapy-Prostate NNP N
( ( N
FACT-P NNP N
) ) N
and CC N
EQ-5D JJ N
questionnaires NNS N
. . N

Pain NN N
status NN N
was VBD N
assessed VBN N
at IN N
screening NN N
, , N
baseline NN N
, , N
week NN N
13 CD N
, , N
and CC N
week NN N
25 CD N
with IN N
the DT N
Brief NNP N
Pain NNP N
Inventory NNP N
Short NNP N
Form NNP N
( ( N
BPI-SF NNP N
) ) N
. . N

The DT N
primary JJ N
analysis NN N
of IN N
HRQoL NNP N
data NNS N
used VBD N
a DT N
mixed-effects NNS N
model NN N
to TO N
test VB N
the DT N
difference NN N
between IN N
least JJS N
square JJ N
means NNS N
change VBP N
from IN N
baseline NN N
at IN N
week NN N
61 CD N
. . N

We PRP N
assessed VBD N
change NN N
from IN N
baseline NN N
, , N
percentage NN N
improvement NN N
, , N
and CC N
time NN N
to TO N
deterioration NN N
in IN N
HRQoL NNP N
and CC N
pain NN N
, , N
the DT N
proportion NN N
of IN N
patients NNS N
with IN N
a DT N
skeletal-related JJ N
event NN N
, , N
and CC N
time NN N
to TO N
first VB N
skeletal-related JJ N
event NN N
. . N

Analysis NN N
was VBD N
done VBN N
on IN N
the DT N
intention-to-treat JJ N
population NN N
. . N

This DT N
study NN N
is VBZ N
registered VBN N
with IN N
ClinicalTrials.gov NNP N
, , N
number NN N
NCT01212991 NNP N
. . N

FINDINGS NNP N
Median NNP N
treatment NN N
duration NN N
was VBD N
16·6 CD N
months NNS N
( ( N
IQR NNP N
10·1-21·1 CD N
) ) N
in IN N
the DT N
enzalutamide NN N
group NN N
and CC N
4·6 CD N
months NNS N
( ( N
2·8-9·7 JJ N
) ) N
in IN N
the DT N
placebo NN N
group NN N
. . N

The DT N
mixed-effects NNS N
model NN N
analyses VBZ N
showed VBD N
significant JJ N
treatment NN N
differences NNS N
in IN N
change NN N
from IN N
baseline NN N
to TO N
week NN N
61 CD N
with IN N
enzalutamide JJ N
compared VBN N
with IN N
placebo NN N
for IN N
most JJS N
FACT-P JJ N
endpoints NNS N
and CC N
EQ-5D NNP N
visual JJ N
analogue NN N
scale NN N
. . N

Median JJ N
time NN N
to TO N
deterioration VB N
in IN N
FACT-P NNP N
total JJ N
score NN N
was VBD N
11·3 CD N
months NNS N
( ( N
95 CD N
% NN N
CI NNP N
11·1-13·9 CD N
) ) N
in IN N
the DT N
enzalutamide NN N
group NN N
and CC N
5·6 CD N
months NNS N
( ( N
5·5-5·6 JJ N
) ) N
in IN N
the DT N
placebo NN N
groups NNS N
( ( N
hazard JJ N
ratio NN N
[ NNP N
HR NNP N
] VBD N
0·62 CD N
[ JJ N
95 CD N
% NN N
CI NNP N
0·54-0·72 CD N
] NNP N
; : N
p VBZ N
< $ N
0·0001 CD N
) ) N
. . N

A DT N
significantly RB N
greater JJR N
proportion NN N
of IN N
patients NNS N
in IN N
the DT N
enzalutamide NN N
group NN N
than IN N
in IN N
the DT N
placebo NN N
group NN N
reported VBD N
clinically RB N
meaningful JJ N
improvements NNS N
in IN N
FACT-P NNP N
total JJ N
score NN N
( ( N
327 CD N
[ RB N
40 CD N
% NN N
] NN N
of IN N
826 CD N
vs NNS N
181 CD N
[ JJ N
23 CD N
% NN N
] NN N
of IN N
790 CD N
) ) N
, , N
in IN N
EQ-5D NNP N
utility NN N
index NN N
( ( N
224 CD N
[ RB N
28 CD N
% NN N
] NN N
of IN N
812 CD N
vs NNS N
99 CD N
[ JJ N
16 CD N
% NN N
] NN N
of IN N
623 CD N
) ) N
, , N
and CC N
visual JJ N
analogue NN N
scale NN N
( ( N
218 CD N
[ RB N
27 CD N
% NN N
] NN N
of IN N
803 CD N
vs JJ N
106 CD N
of IN N
[ JJ N
18 CD N
% NN N
] JJ N
603 CD N
; : N
all DT N
p VBP N
< $ N
0·0001 CD N
) ) N
. . N

Median JJ N
time NN N
to TO N
progression NN N
in IN N
BPI-SF NNP N
pain NN N
at IN N
its PRP$ N
worst JJS N
was VBD N
5·7 CD N
months NNS N
( ( N
95 CD N
% NN N
CI NNP N
5·6-5·7 CD N
) ) N
in IN N
the DT N
enzalutamide NN N
group NN N
and CC N
5·6 CD N
months NNS N
( ( N
5·4-5·6 JJ N
) ) N
in IN N
the DT N
placebo NN N
group NN N
( ( N
HR NNP N
0·62 CD N
[ VBD N
95 CD N
% NN N
CI NNP N
0·53-0·74 CD N
] NNP N
; : N
p VBZ N
< $ N
0·0001 CD N
) ) N
. . N

Progression NN N
of IN N
pain NN N
at IN N
its PRP$ N
worst JJS N
was VBD N
less JJR N
common JJ N
in IN N
the DT N
enzalutamide NN N
group NN N
than IN N
in IN N
the DT N
placebo NN N
group NN N
at IN N
week NN N
13 CD N
( ( N
220 CD N
[ RB N
29 CD N
% NN N
] NN N
of IN N
769 CD N
vs NNS N
257 CD N
[ JJ N
42 CD N
% NN N
] NN N
of IN N
610 CD N
; : N
p NN N
< VBZ N
0·0001 CD N
) ) N
, , N
but CC N
not RB N
at IN N
week NN N
25 CD N
( ( N
225 CD N
[ RB N
32 CD N
% NN N
] NN N
of IN N
705 CD N
vs NNS N
135 CD N
[ JJ N
38 CD N
% NN N
] NN N
of IN N
360 CD N
; : N
p=0·068 NN N
) ) N
. . N

278 CD N
( ( N
32 CD N
% NN N
) ) N
of IN N
872 CD N
patients NNS N
in IN N
the DT N
enzalutamide NN N
group NN N
and CC N
309 CD N
( ( N
37 CD N
% NN N
) ) N
of IN N
845 CD N
patients NNS N
in IN N
the DT N
placebo NN N
group NN N
had VBD N
experienced VBN N
a DT N
skeletal-related JJ N
event NN N
by IN N
data NNS N
cutoff NN N
. . N

Median JJ N
time NN N
to TO N
first VB N
skeletal-related JJ N
events NNS N
in IN N
the DT N
enzalutamide NN N
group NN N
was VBD N
31·1 CD N
months NNS N
( ( N
95 CD N
% NN N
CI NNP N
29·5-not CD N
reached VBD N
) ) N
and CC N
31·3 CD N
months NNS N
( ( N
95 CD N
% NN N
CI NNP N
23·9-not CD N
reached VBD N
) ) N
in IN N
the DT N
placebo NN N
group NN N
( ( N
HR NNP N
0·72 CD N
[ VBD N
95 CD N
% NN N
CI NNP N
0·61-0·84 CD N
] NNP N
; : N
p VBZ N
< $ N
0·0001 CD N
) ) N
. . N

INTERPRETATION NNP N
In IN N
addition NN N
to TO N
improving VBG N
overall JJ N
survival JJ N
relative NN N
to TO N
placebo VB N
, , N
enzalutamide VB N
significantly RB N
improves VBZ N
patient-related JJ N
outcomes NNS N
and CC N
delays NNS N
occurrence NN 4_p
of IN 4_p
first JJ 4_p
skeletal-related JJ 4_p
event NN 4_p
in IN 4_p
chemotherapy-naive JJ 4_p
men NNS N
with IN 4_p
metastatic JJ 4_p
castration-resistant JJ N
prostate NN N
cancer NN N
. . N

FUNDING NNP N
Astellas NNP N
Pharma NNP N
and CC N
Medivation NNP N
. . N

-DOCSTART- -X- O O 22476876

Impact NN N
of IN N
the DT N
quantity NN N
and CC N
flavonoid JJ N
content NN N
of IN N
fruits NNS N
and CC N
vegetables NNS N
on IN N
markers NNS N
of IN N
intake NN N
in IN N
adults NNS N
with IN 4_p
an DT 4_p
increased VBN 4_p
risk NN 4_p
of IN 4_p
cardiovascular JJ 4_p
disease NN 4_p
: : N
the DT N
FLAVURS NNP N
trial NN N
. . N

PURPOSE NNP N
Limited NNP N
robust NN N
randomised VBD N
controlled VBN N
trials NNS N
investigating VBG N
fruit NN N
and CC N
vegetable JJ N
( ( N
F NNP N
& CC N
V NNP N
) ) N
intake VBP N
in IN N
people NNS 4_p
at IN 4_p
risk NN 4_p
of IN 4_p
cardiovascular JJ 4_p
disease NN 4_p
( ( 4_p
CVD NNP 4_p
) ) 4_p
exist VBP N
. . N

We PRP N
aimed VBD N
to TO N
design VB N
and CC N
validate VB N
a DT N
dietary JJ N
strategy NN N
of IN N
increasing VBG N
flavonoid-rich JJ N
versus NN N
flavonoid-poor JJ N
F NNP N
& CC N
V NNP N
consumption NN N
on IN N
nutrient JJ N
biomarker NN N
profile NN N
. . N

METHODS NNP N
A NNP N
parallel NN N
, , N
randomised VBN N
, , N
controlled VBN N
, , N
dose-response JJ N
dietary JJ N
intervention NN N
study NN N
. . N

Participants NNS 4_p
with IN 4_p
a DT 4_p
CVD NNP 4_p
relative JJ 4_p
risk NN 4_p
of IN 4_p
1.5 CD 4_p
assessed VBN 4_p
by IN 4_p
risk NN 4_p
scores NNS 4_p
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
the DT N
3 CD N
groups NNS N
: : N
habitual JJ N
( ( N
control NN N
, , N
CT NNP N
) ) N
, , N
high-flavonoid JJ N
( ( N
HF NNP N
) ) N
or CC N
low-flavonoid JJ N
( ( N
LF NNP N
) ) N
diets NNS N
. . N

While IN N
the DT N
CT NNP N
group NN N
( ( N
n JJ N
= NNP N
57 CD N
) ) N
consumed VBD N
their PRP$ N
habitual JJ N
diet NN N
throughout IN N
, , N
the DT N
HF NNP N
( ( N
n JJ N
= NNP N
58 CD N
) ) N
and CC N
LF NNP N
( ( N
n JJ N
= NNP N
59 CD N
) ) N
groups NNS N
sequentially RB N
increased VBD N
their PRP$ N
daily JJ N
F NNP N
& CC N
V NNP N
intake NN N
by IN N
an DT N
additional JJ N
2 CD N
, , N
4 CD N
and CC N
6 CD N
portions NNS N
for IN N
6-week JJ N
periods NNS N
during IN N
the DT N
18-week JJ N
study NN N
. . N

RESULTS NNP N
Compliance NNP N
to TO N
target VB N
numbers NNS N
and CC N
types NNS N
of IN N
F NNP N
& CC N
V NNP N
was VBD N
broadly RB N
met VBN N
and CC N
verified VBN N
by IN N
dietary JJ N
records NNS N
, , N
and CC N
plasma NN N
and CC N
urinary JJ N
biomarkers NNS N
. . N

Mean NNP N
( ( N
± NNP N
SEM NNP N
) ) N
number NN N
of IN N
F NNP N
& CC N
V NNP N
portions/day NN N
consumed VBN N
by IN N
the DT N
HF NNP N
and CC N
LF NNP N
groups NNS N
at IN N
baseline NN N
( ( N
3.8 CD N
± RB N
0.3 CD N
and CC N
3.4 CD N
± NNS N
0.3 CD N
) ) N
, , N
6 CD N
weeks NNS N
( ( N
6.3 CD N
± RB N
0.4 CD N
and CC N
5.8 CD N
± NNS N
0.3 CD N
) ) N
, , N
12 CD N
weeks NNS N
( ( N
7.0 CD N
± RB N
0.3 CD N
and CC N
6.8 CD N
± NNS N
0.3 CD N
) ) N
and CC N
18 CD N
weeks NNS N
( ( N
7.6 CD N
± RB N
0.4 CD N
and CC N
8.1 CD N
± NNS N
0.4 CD N
) ) N
, , N
respectively RB N
, , N
was VBD N
similar JJ N
at IN N
baseline NN N
yet RB N
higher JJR N
than IN N
the DT N
CT NNP N
group NN N
( ( N
3.9 CD N
± RB N
0.3 CD N
, , N
4.3 CD N
± NN N
0.3 CD N
, , N
4.6 CD N
± NN N
0.4 CD N
, , N
4.5 CD N
± $ N
0.3 CD N
) ) N
( ( N
P NNP N
= NNP N
0.015 CD N
) ) N
. . N

There EX N
was VBD N
a DT N
dose-dependent JJ N
increase NN N
in IN N
dietary JJ N
and CC N
urinary JJ N
flavonoids NNS N
in IN N
the DT N
HF NNP N
group NN N
, , N
with IN N
no DT N
change NN N
in IN N
other JJ N
groups NNS N
( ( N
P NNP N
= NNP N
0.0001 CD N
) ) N
. . N

Significantly RB N
higher JJR N
dietary JJ N
intakes NNS N
of IN N
folate NN N
( ( N
P NNP N
= NNP N
0.035 CD N
) ) N
, , N
non-starch JJ N
polysaccharides NNS N
( ( N
P NNP N
= NNP N
0.001 CD N
) ) N
, , N
vitamin FW N
C NNP N
( ( N
P NNP N
= NNP N
0.0001 CD N
) ) N
and CC N
carotenoids NNS N
( ( N
P NNP N
= NNP N
0.0001 CD N
) ) N
were VBD N
observed VBN N
in IN N
both DT N
intervention NN N
groups NNS N
compared VBN N
with IN N
CT NNP N
, , N
which WDT N
were VBD N
broadly RB N
supported VBN N
by IN N
nutrient JJ N
biomarker NN N
analysis NN N
. . N

CONCLUSIONS VB N
The DT N
success NN N
of IN N
improving VBG N
nutrient JJ N
profile NN N
by IN N
active JJ N
encouragement NN N
of IN N
F NNP N
& CC N
V NNP N
intake NN N
in IN N
an DT N
intervention NN N
study NN N
implies VBZ N
the DT N
need NN N
for IN N
a DT N
more RBR N
hands-on JJ N
public JJ N
health NN N
approach NN N
. . N

-DOCSTART- -X- O O 10811665

Outcome NN N
of IN N
CNS NNP N
disease NN N
at IN N
diagnosis NN N
in IN N
disseminated JJ 4_p
small JJ 4_p
noncleaved-cell JJ 4_p
lymphoma NN 4_p
and CC N
B-cell NNP 4_p
leukemia NN 4_p
: : N
a DT N
Children NNP N
's POS N
Cancer NNP 4_p
Group NNP N
study NN N
. . N

PURPOSE NNP N
To TO N
examine VB N
the DT N
impact NN N
of IN N
initial JJ N
CNS NNP N
involvement NN N
on IN N
outcome NN N
and CC N
patterns NNS N
of IN N
failure NN N
in IN N
patients NNS N
with IN N
disseminated JJ 4_p
small JJ 4_p
noncleaved-cell JJ 4_p
lymphoma NN 4_p
and CC N
B-cell NNP 4_p
leukemia NN 4_p
who WP N
were VBD N
treated VBN N
in IN N
four CD N
successive JJ N
Children NNP N
's POS N
Cancer NNP 4_p
Group NNP N
trials NNS N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
Of IN N
462 CD N
patients NNS N
with IN N
disseminated JJ 4_p
disease NN 4_p
, , N
49 CD N
( ( N
10.6 CD N
% NN N
) ) N
had VBD N
CNS NNP 4_p
disease NN N
at IN N
diagnosis NN N
( ( N
CNS+ NNP 4_p
) ) N
. . N

CNS NNP N
disease NN N
included VBD N
meningeal JJ N
disease NN N
or CC N
CNS NNP N
parenchymal JJ N
masses NNS N
with IN N
or CC N
without IN N
cranial JJ N
neuropathies NNS N
( ( N
CSF+/Mass NNP N
; : N
CNPs NNP N
) ) N
in IN N
36 CD N
patients NNS N
and CC N
isolated JJ N
CNPs NNP N
in IN N
13 CD N
. . N

Of IN N
the DT N
CNS+ NNP 4_p
patients NNS N
, , N
28 CD N
had VBD N
M2 NNP N
( ( N
5 CD N
% NN N
to TO N
25 CD N
% NN N
blasts NNS N
) ) N
or CC N
M3 NNP N
( ( N
> VB N
25 CD N
% NN N
blasts NNS N
) ) N
bone NN N
marrow JJ N
involvement NN N
. . N

All DT N
patients NNS N
received VBD N
protocol-based JJ N
systemic JJ N
and CC N
intrathecal JJ N
chemotherapy NN N
. . N

Thirty-six JJ N
patients NNS N
also RB N
received VBD N
CNS NNP N
irradiation NN N
. . N

RESULTS NNP N
Relapses NNPS N
occurred VBD N
in IN N
21 CD N
( ( N
43 CD N
% NN N
) ) N
of IN N
49 CD N
patients NNS N
, , N
predominantly RB N
in IN N
the DT N
CNS NNP N
( ( N
71 CD N
% NN N
) ) N
and CC N
bone NN N
marrow NN N
( ( N
52 CD N
% NN N
) ) N
. . N

The DT N
3-year JJ N
event-free JJ N
survival NN N
+/- JJ N
SE NNP N
for IN N
all DT N
patients NNS N
with IN N
CNS+ NNP N
disease NN N
was VBD N
45 CD N
% NN N
+/- JJ N
7 CD N
% NN N
. . N

Patients NNS N
with IN N
CSF+/Mass NNP N
had VBD N
a DT N
nominally RB N
higher JJR N
treatment NN N
failure NN N
rate NN N
compared VBN N
with IN N
patients NNS N
with IN N
CNS- NNP N
after IN N
adjusting VBG N
for IN N
marrow NN N
status NN N
and CC N
lactate VB N
dehydrogenase NN N
( ( N
LDH NNP N
) ) N
diagnosis NN N
, , N
with IN N
a DT N
relative JJ N
failure NN N
rate NN N
( ( N
RFR NNP N
) ) N
of IN N
1.52 CD N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
, , N
0.88 CD N
to TO N
2.6 CD N
; : N
P NNP N
=.15 NNP N
) ) N
. . N

In IN N
comparison NN N
, , N
the DT N
RFRs NNP N
for IN N
patients NNS N
with IN N
M2 NNP N
or CC N
M3 NNP N
marrow NN N
and CC N
for IN N
those DT N
with IN N
LDH NNP N
levels NNS N
greater JJR N
than IN N
500 CD N
IU/L NNP N
after IN N
adjusting VBG N
for IN N
CNS NNP N
disease NN N
were VBD N
1.4 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
0.96 CD N
to TO N
2.0 CD N
; : N
P NNP N
=.029 NNP N
) ) N
and CC N
2.2 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
1.5 CD N
to TO N
3.0 CD N
; : N
P NNP N
< NNP N
.001 NNP N
) ) N
, , N
respectively RB N
. . N

The DT N
RFR NNP N
for IN N
patients NNS N
with IN N
isolated JJ N
CNPs NNP N
was VBD N
0.87 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
0.36 CD N
to TO N
2.1 CD N
; : N
P NNP N
=.76 NNP N
) ) N
. . N

CONCLUSION NNP N
We PRP N
conclude VBP N
that IN N
, , N
with IN N
the DT N
treatments NNS N
used VBN N
during IN N
the DT N
period NN N
covered VBN N
by IN N
these DT N
studies NNS N
, , N
the DT N
presence NN N
of IN N
CSF+/Mass NNP N
CNS NNP N
disease NN N
at IN N
diagnosis NN N
was VBD N
associated VBN N
with IN N
a DT N
nominally RB N
worse JJR N
outcome JJ N
independent JJ N
of IN N
initial JJ N
bone NN N
marrow NN N
status NN N
and CC N
LDH NNP N
level NN N
, , N
but CC N
the DT N
effect NN N
was VBD N
not RB N
statistically RB N
significant JJ N
. . N

-DOCSTART- -X- O O 16712638

Joint JJ N
attention NN N
and CC N
symbolic JJ N
play NN N
in IN N
young JJ N
children NNS N
with IN N
autism NN 4_p
: : N
a DT N
randomized VBN N
controlled VBN N
intervention NN N
study NN N
. . N

BACKGROUND NNP N
Delays NNPS N
and CC N
deficits NNS N
in IN N
joint JJ N
attention NN N
and CC N
symbolic JJ N
play NN N
constitute NN N
two CD N
important JJ N
developmental NN N
problems NNS N
in IN N
young JJ N
children NNS N
with IN N
autism NN 4_p
. . N

These DT N
areas NNS N
of IN N
deficit NN N
have VBP N
been VBN N
well RB N
studied VBN N
in IN N
autism NN N
but CC N
have VBP N
rarely RB N
been VBN N
the DT N
focus NN N
of IN N
treatment NN N
efforts NNS N
( ( N
see VB N
Kasari NNP N
, , N
Freeman NNP N
, , N
& CC N
Paparella NNP N
, , N
2001 CD N
) ) N
. . N

In IN N
this DT N
study NN N
, , N
we PRP N
examine VBP N
the DT N
efficacy NN N
of IN N
targeted JJ N
interventions NNS N
of IN N
joint JJ N
attention NN N
and CC N
symbolic JJ N
play NN N
. . N

METHODS NNP N
Participants NNPS N
were VBD N
58 CD N
children NNS N
with IN N
autism NN 4_p
aged VBN N
3 CD N
and CC N
4 CD N
years NNS N
( ( N
46 CD N
boys NNS N
) ) N
. . N

Children NNP N
were VBD N
randomized VBN N
to TO N
a DT N
joint JJ N
attention NN N
intervention NN N
, , N
a DT N
symbolic JJ N
play NN N
intervention NN N
, , N
or CC N
control NN N
group NN N
. . N

Interventions NNS N
were VBD N
conducted VBN N
30 CD N
minutes NNS N
daily RB N
for IN N
5-6 JJ N
weeks NNS N
. . N

Both DT N
structured JJ N
assessments NNS N
of IN N
joint JJ N
attention NN N
and CC N
play NN N
skills NNS N
and CC N
mother-child JJ N
interactions NNS N
were VBD N
collected VBN N
pre NN N
and CC N
post NN N
intervention NN N
by IN N
independent JJ N
assessors NNS N
. . N

RESULTS NNP N
Results NNP N
indicate VBP N
that IN N
both DT N
intervention NN N
groups NNS N
improved VBN N
significantly RB N
over IN N
the DT N
control NN N
group NN N
on IN N
certain JJ N
behaviors NNS N
. . N

Children NNP N
in IN N
the DT N
joint JJ N
attention NN N
intervention NN N
initiated VBN N
significantly RB N
more RBR N
showing JJ N
and CC N
responsiveness NN N
to TO N
joint JJ N
attention NN N
on IN N
the DT N
structured VBN N
joint JJ N
attention NN N
assessment NN N
and CC N
more JJR N
child-initiated JJ N
joint NN N
attention NN N
in IN N
the DT N
mother-child JJ N
interaction NN N
. . N

The DT N
children NNS N
in IN N
the DT N
play NN N
group NN N
showed VBD N
more JJR N
diverse JJ N
types NNS N
of IN N
symbolic JJ N
play NN N
in IN N
interaction NN N
with IN N
their PRP$ N
mothers NNS N
and CC N
higher JJR N
play NN N
levels NNS N
on IN N
both DT N
the DT N
play NN N
assessment NN N
and CC N
in IN N
interaction NN N
with IN N
their PRP$ N
mothers NNS N
. . N

CONCLUSIONS VB N
This DT N
randomized VBN N
controlled JJ N
trial NN N
provides VBZ N
promising JJ N
data NNS N
on IN N
the DT N
specificity NN N
and CC N
generalizability NN N
of IN N
joint JJ N
attention NN N
and CC N
play NN N
interventions NNS N
for IN N
young JJ N
children NNS N
with IN N
autism NN N
. . N

Future JJ N
studies NNS N
need VBP N
to TO N
examine VB N
the DT N
long-term JJ N
effects NNS N
of IN N
these DT N
early JJ N
interventions NNS N
on IN N
children NNS N
's POS N
development NN N
. . N

-DOCSTART- -X- O O 7841058

The DT N
efficacy NN N
of IN N
audiotapes NNS N
in IN N
promoting VBG N
psychological JJ N
well-being NN N
in IN N
cancer NN 4_p
patients NNS N
: : N
a DT N
randomised JJ N
, , N
controlled JJ N
trial NN N
. . N

Open VB N
or CC N
uncontrolled JJ N
studies NNS N
have VBP N
suggested VBN N
that IN N
providing VBG N
cancer NN 4_p
patients NNS N
with IN N
audiotapes NNS N
of IN N
their PRP$ N
clinical JJ N
interviews NNS N
can MD N
improve VB N
information NN N
recall NN N
and CC N
reduce VB N
psychological JJ N
distress NN N
. . N

We PRP N
tested VBD N
these DT N
hypotheses NNS N
in IN N
a DT N
'clinician-blind JJ N
' '' N
, , N
prospective JJ N
, , N
randomised VBD N
controlled VBN N
trial NN N
. . N

A DT N
total NN N
of IN N
117 CD N
patients NNS N
newly RB N
referred VBN N
to TO N
a DT N
medical JJ N
oncology NN N
clinic NN N
who WP N
were VBD N
to TO N
be VB N
given VBN N
'bad CD N
news NN N
' POS N
had VBD N
their PRP$ N
consultations NNS N
audiotaped VBN N
. . N

Blind NNP N
to TO N
the DT N
clinician JJ N
, , N
patients NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
receive VB N
a DT N
copy NN N
of IN N
the DT N
tape NN N
to TO N
play VB N
at IN N
home NN N
or CC N
not RB N
( ( N
control VB N
group NN N
) ) N
. . N

At IN N
6 CD N
months NNS N
follow-up JJ N
, , N
tape NN N
group NN N
patients NNS N
reported VBD N
positive JJ N
attitudes NNS N
to TO N
the DT N
audiotape NN N
and CC N
were VBD N
shown VBN N
to TO N
recall VB N
significantly RB N
more JJR N
information NN N
about IN N
their PRP$ N
illness NN N
than IN N
did VBD N
controls NNS N
. . N

Overall JJ N
improvement NN N
in IN N
psychological JJ N
distress NN N
at IN N
1 CD N
and CC N
6 CD N
months NNS N
follow-up RB N
, , N
as IN N
measured VBN N
with IN N
the DT N
30-item JJ N
General NNP N
Health NNP N
Questionnaire NNP N
and CC N
the DT N
Hospital NNP N
Anxiety NNP N
and CC N
Depression NNP N
Scale NNP N
was VBD N
no DT N
different JJ N
in IN N
the DT N
two CD N
groups NNS N
. . N

However RB N
, , N
a DT N
second-order JJ N
interaction NN N
suggested VBD N
that IN N
poor-prognosis NN N
patients NNS N
were VBD N
disadvantaged VBN N
specifically RB N
by IN N
access NN N
to TO N
the DT N
audiotape NN N
, , N
with IN N
less JJR N
improvement NN N
in IN N
psychological JJ N
distress NN N
at IN N
6 CD N
months NNS N
follow-up JJ N
than IN N
non-tape JJ N
controls NNS N
. . N

Patient JJ N
access NN N
to TO N
audiotapes NNS N
of IN N
clinical JJ N
interviews NNS N
promotes VBZ N
factual JJ N
retention NN N
but CC N
does VBZ N
not RB N
reliably RB N
reduce VB N
psychological JJ N
distress NN N
and CC N
may MD N
be VB N
actively RB N
unhelpful JJ N
in IN N
some DT N
subgroups NNS N
of IN N
patients NNS N
. . N

-DOCSTART- -X- O O 16379507

Acute NNP N
and CC N
long-term JJ N
safety NN N
and CC N
tolerability NN N
of IN N
risperidone NN N
in IN N
children NNS N
with IN N
autism NN 4_p
. . N

Treatment-emergent JJ N
adverse JJ N
events NNS N
( ( N
AEs NNP N
) ) N
were VBD N
monitored VBN N
during IN N
an DT N
8-week JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
trial NN N
of IN N
risperidone NN N
( ( N
0.5-3.5 JJ N
mg/day NN N
) ) N
in IN N
101 CD N
children NNS N
and CC N
adolescents NNS N
with IN N
a DT N
lifetime JJ N
diagnosis NN N
of IN N
autistic JJ 4_p
disorder NN 4_p
. . N

In IN N
addition NN N
, , N
37 CD N
placebo NN N
nonresponders NNS N
received VBD N
open-label JJ N
risperidone NN N
for IN N
another DT N
8 CD N
weeks NNS N
. . N

Of IN N
all PDT N
the DT N
risperidone NN N
responders NNS N
( ( N
n=65 NN N
) ) N
, , N
63 CD N
entered VBD N
an DT N
open JJ N
extension NN N
of IN N
another DT N
16 CD N
weeks NNS N
( ( N
6 CD N
months NNS N
total JJ N
risperidone NN N
exposure NN N
) ) N
, , N
and CC N
32 CD N
of IN N
them PRP N
were VBD N
rerandomized VBN N
to TO N
either DT N
continued VBN N
risperidone NN N
therapy NN N
( ( N
n=16 JJ N
) ) N
or CC N
gradual JJ N
replacement NN N
with IN N
placebo NN N
( ( N
n=16 JJ N
) ) N
over IN N
8 CD N
weeks NNS N
. . N

We PRP N
collected VBD N
the DT N
following JJ N
measures NNS N
of IN N
safety NN N
and CC N
tolerability NN N
: : N
( ( N
1 CD N
) ) N
laboratory NN N
blood NN N
assessments NNS N
( ( N
CBC NNP N
with IN N
differential JJ N
, , N
electrolytes NNS N
, , N
and CC N
liver JJ N
function NN N
tests NNS N
) ) N
and CC N
urinalyses NNS N
, , N
( ( N
2 CD N
) ) N
vital NN N
signs NNS N
, , N
( ( N
3 CD N
) ) N
Side NNP N
Effects NNP N
Review NNP N
of IN N
AEs NNP N
thought VBD N
to TO N
be VB N
associated VBN N
with IN N
risperidone NN N
, , N
( ( N
4 CD N
) ) N
sleep NN N
records NNS N
, , N
( ( N
5 CD N
) ) N
Simpson NNP N
Angus NNP N
Neurological NNP N
Rating NNP N
Scale NNP N
( ( N
SARS NNP N
) ) N
, , N
( ( N
6 CD N
) ) N
Abnormal NNP N
Involuntary NNP N
Movement NNP N
Scale NNP N
( ( N
AIMS NNP N
) ) N
, , N
and CC N
( ( N
7 CD N
) ) N
height NN N
and CC N
weight NN N
. . N

No DT N
clinically RB N
significant JJ N
changes NNS N
were VBD N
found VBN N
on IN N
the DT N
lab NN N
tests NNS N
. . N

During IN N
the DT N
8-week JJ N
acute JJ N
trial NN N
, , N
the DT N
most RBS N
common JJ N
AEs NNP N
on IN N
the DT N
Side NNP N
Effects NNP N
Review NNP N
, , N
scored VBD N
as IN N
moderate JJ N
or CC N
higher JJR N
, , N
were VBD N
as IN N
follows VBZ N
( ( N
placebo NN N
and CC N
risperidone NN N
, , N
respectively RB N
) ) N
: : N
Somnolence NN N
( ( N
12 CD N
% NN N
and CC N
37 CD N
% NN N
) ) N
, , N
enuresis NN N
( ( N
29 CD N
% NN N
and CC N
33 CD N
% NN N
) ) N
, , N
excessive JJ N
appetite NN N
( ( N
10 CD N
% NN N
and CC N
33 CD N
% NN N
) ) N
, , N
rhinitis NN N
( ( N
8 CD N
% NN N
and CC N
16 CD N
% NN N
) ) N
, , N
difficulty NN N
waking NN N
( ( N
8 CD N
% NN N
and CC N
12 CD N
% NN N
) ) N
, , N
and CC N
constipation NN N
( ( N
12 CD N
% NN N
and CC N
10 CD N
% NN N
) ) N
. . N

" $ N
Difficulty NNP N
falling VBG N
asleep RB N
" NN N
and CC N
anxiety NN N
actually RB N
favored VBD N
the DT N
risperidone NN N
condition NN N
at IN N
statistically RB N
significant JJ N
levels NNS N
. . N

The DT N
same JJ N
AEs NNP N
tended VBD N
to TO N
recur VB N
through IN N
6 CD N
months NNS N
of IN N
treatment NN N
, , N
although IN N
often RB N
at IN N
reduced VBN N
levels NNS N
. . N

Using VBG N
Centers NNPS N
for IN N
Disease NNP N
Control NNP N
( ( N
CDC NNP N
) ) N
standardized VBD N
scores NNS N
, , N
both DT N
weight NN N
and CC N
body NN N
mass NN N
index NN N
( ( N
BMI NNP N
) ) N
increased VBD N
with IN N
risperidone NN N
during IN N
the DT N
acute JJ N
trial NN N
( ( N
0.5 CD N
and CC N
0.6 CD N
SDs NNP N
, , N
respectively RB N
, , N
for IN N
risperidone NN N
; : N
0.0 CD N
and CC N
0.1 CD N
SDs NNP N
, , N
respectively RB N
, , N
for IN N
placebo NN N
) ) N
and CC N
into IN N
open-label JJ N
extension NN N
( ( N
0.19 CD N
and CC N
0.16 CD N
SDs NNP N
, , N
respectively RB N
) ) N
, , N
although IN N
the DT N
amount NN N
of IN N
gain NN N
decelerated VBN N
with IN N
time NN N
. . N

Extrapyramidal NNP N
symptoms NNS N
, , N
as IN N
assessed VBN N
by IN N
the DT N
SARS NNP N
, , N
were VBD N
no DT N
more RBR N
common JJ N
for IN N
drug NN N
than IN N
placebo NN N
, , N
although IN N
drooling NN N
was VBD N
reported VBN N
more RBR N
often RB N
in IN N
the DT N
risperidone NN N
group NN N
. . N

There EX N
were VBD N
no DT N
differences NNS N
between IN N
groups NNS N
on IN N
the DT N
AIMS NNP N
. . N

Two CD N
subjects NNS N
had VBD N
seizures NNS N
( ( N
one CD N
taking VBG N
placebo NN N
) ) N
, , N
but CC N
these DT N
were VBD N
considered VBN N
unrelated JJ N
to TO N
active JJ N
drug NN N
. . N

Most JJS N
AEs NNPS N
were VBD N
mild JJ N
to TO N
moderate VB N
and CC N
failed VBD N
to TO N
interfere VB N
with IN N
therapeutic JJ N
changes NNS N
; : N
there EX N
were VBD N
no DT N
unanticipated JJ N
AEs NNP N
. . N

The DT N
side NN N
effects NNS N
of IN N
most JJS N
concern NN N
were VBD N
somnolence NN N
and CC N
weight JJ N
gain NN N
. . N

-DOCSTART- -X- O O 10971307

Influence NN N
of IN N
asimadoline NN N
, , N
a DT N
new JJ N
kappa-opioid JJ N
receptor NN N
agonist NN N
, , N
on IN N
tubular JJ N
water NN N
absorption NN N
and CC N
vasopressin NN 4_p
secretion NN 4_p
in IN 4_p
man NN N
. . 4_p

AIMS VBZ N
The DT N
purpose NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
effects NNS N
of IN N
asimadoline NN N
, , N
a DT N
new JJ N
kappa-opioid JJ N
agonist NN N
, , N
on IN N
renal JJ N
function NN N
and CC N
on IN N
hormones NNS N
related VBN N
to TO N
body NN N
fluid JJ N
balance NN N
as RB N
well RB N
as IN N
its PRP$ N
tolerability NN N
in IN N
healthy JJ 4_p
subjects NNS 4_p
. . N

METHODS NNP N
In IN N
a DT N
placebo-controlled JJ N
, , N
randomised JJ N
, , N
double-blind JJ N
crossover NN N
design NN N
we PRP N
studied VBD N
the DT N
effects NNS N
of IN N
single JJ N
oral JJ N
doses NNS N
of IN N
1 CD N
, , N
5 CD N
, , N
and CC N
10 CD N
mg NN N
of IN N
asimadoline NN N
, , N
in IN N
24 CD N
healthy JJ N
volunteers NNS N
. . N

Two CD N
hour NN N
control NN N
urine JJ N
collections NNS N
were VBD N
followed VBN N
by IN N
2 CD N
h NNS N
postdose JJ N
urine JJ N
collections NNS N
and CC N
subsequently RB N
2.5 CD N
% NN N
saline NN N
was VBD N
given VBN N
i.v NN N
. . N

at IN N
a DT N
rate NN N
of IN N
0.3 CD N
ml NNS N
min NN N
( ( N
-1 NNP N
) ) N
kg NN N
( ( N
-1 JJ N
) ) N
during IN N
another DT N
2 CD N
h NN N
urine JJ N
collection NN N
. . N

Blood NNP N
was VBD N
obtained VBN N
hourly RB N
. . N

Arginine-vasopressin NNP N
( ( N
AVP NNP N
) ) N
, , N
atrial JJ N
natriuretic JJ N
peptide NN N
( ( N
alpha-hANP JJ N
) ) N
, , N
endothelin FW N
( ( N
ET-1 NNP N
) ) N
and CC N
cAMP NN N
were VBD N
determined VBN N
by IN N
r.i.a NN N
. . N

or CC N
ELISA NNP N
. . N

RESULTS NNP N
GC-MS JJ N
measurements NNS N
revealed VBD N
Cmax NNP N
values NNS N
of IN N
asimadoline NN N
in IN N
plasma NN N
ranging VBG N
from IN N
18 CD N
ng JJ N
ml NN N
( ( N
-1 NN N
) ) N
at IN N
the DT N
1 CD N
mg NN N
dose NN N
, , N
91 CD N
ng NN N
ml NN N
( ( N
-1 NN N
) ) N
at IN N
the DT N
5 CD N
mg NN N
dose NN N
, , N
to TO N
214 CD N
ng NNS N
ml NN N
( ( N
-1 NN N
) ) N
at IN N
the DT N
10 CD N
mg NN N
dose NN N
after IN N
an DT N
average NN N
of IN N
1.1-1.4 JJ N
h. NN N
Without NNP N
effects NNS N
on IN N
blood NN N
pressure NN N
, , N
heart NN N
rate NN N
, , N
GFR NNP N
or CC N
urine JJ N
electrolyte JJ N
excretion NN N
, , N
urine JJ N
volume NN N
increased VBD N
after IN N
1-2 JJ N
h NN N
after IN N
administration NN N
of IN N
5 CD N
and CC N
10 CD N
mg NNS N
asimadoline VBP N
from IN N
3.3+/-1.3 JJ N
to TO N
5.6+/-1.4 JJ N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
and CC N
from IN N
3.2 CD N
+/-1.6 JJ N
to TO N
5.5+/-2.2 JJ N
ml NN N
min NN N
( ( N
-1 NN N
) ) N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
, , N
respectively RB N
. . N

CH2O NNP N
rose VBD N
from IN N
0.2+/-1.5 JJ N
to TO N
2.0+/-1.6 JJ N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
and CC N
from IN N
0.6+/-1.6 JJ N
to TO N
3.0+/-1.6 JJ N
ml NN N
min NN N
( ( N
-1 NN N
) ) N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

Urinary JJ N
excretion NN N
of IN N
AVP NNP N
was VBD N
suppressed VBN N
only RB N
with IN N
the DT N
10 CD N
mg NNS N
dose RB N
from IN N
46+/-23 JJ N
to TO N
25+/-15 JJ N
fmol NN N
min NN N
( ( N
-1 NN N
) ) N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
without IN N
and CC N
from IN N
410+/-206 JJ N
to TO N
181+/-125 JJ N
fmol NN N
min NN N
( ( N
-1 NN N
) ) N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
with IN N
stimulation NN N
by IN N
2.5 CD N
% NN N
saline NN N
. . N

Plasma NNP N
AVP NNP N
was VBD N
suppressed VBN N
only RB N
by IN N
the DT N
10 CD N
mg NN N
dose NN N
of IN N
asimadoline NN N
in IN N
six CD N
of IN N
eight CD N
subjects NNS N
during IN N
the DT N
2.5 CD N
% NN N
saline JJ N
infusion NN N
. . N

Changes NNS N
in IN N
the DT N
alpha-hANP JJ N
or CC N
ET-1 JJ N
systems NNS N
were VBD N
not RB N
affected VBN N
by IN N
asimadoline NN N
. . N

CONCLUSIONS NNP N
Asimadoline NNP N
is VBZ N
diuretic JJ N
in IN N
man NN N
after IN N
single JJ N
doses NNS N
of IN N
5 CD N
or CC N
10 CD N
mg NN N
probably RB N
through IN N
a DT N
direct JJ N
effect NN N
at IN N
the DT N
renal JJ N
tubular JJ N
level NN N
. . N

Suppression NN N
of IN N
AVP NNP N
secretion NN N
was VBD N
observed VBN N
only RB N
at IN N
the DT N
highest JJS N
dose JJ N
level NN N
of IN N
10 CD N
mg NN N
of IN N
asimadoline NN N
. . N

-DOCSTART- -X- O O 15922817

Results NNS N
of IN N
a DT N
multicenter NN N
, , N
8-week JJ N
, , N
parallel-group JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
double-dummy JJ N
, , N
Phase NNP N
III NNP N
clinical JJ N
trial NN N
to TO N
evaluate VB N
the DT N
efficacy NN N
and CC N
tolerability NN N
of IN N
amlodipine JJ N
maleate NN N
versus NN N
amlodipine NN N
besylate NN N
in IN N
Korean JJ N
patients NNS N
with IN N
mild JJ 4_p
to TO 4_p
moderate VB 4_p
hypertension NN 4_p
. . N

BACKGROUND NNP N
Recently RB N
, , N
amlodipine JJ N
maleate NN N
was VBD N
developed VBN N
and CC N
tested VBN N
in IN N
preclinical JJ N
and CC N
Phase NNP N
I PRP N
clinical JJ N
trials NNS N
in IN N
Korea NNP N
. . N

The DT N
studies NNS N
found VBD N
pharmacokinetics NNS N
and CC N
pharmacodynamics NNS N
similar JJ N
to TO N
those DT N
of IN N
amlodipine JJ N
besylate NN N
. . N

OBJECTIVE CC N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
efficacy NN N
and CC N
tolerability NN N
of IN N
amlodipine JJ N
maleate NN N
with IN N
those DT N
of IN N
amlodipine JJ N
besylate NN N
in IN N
Korean JJ 4_p
patients NNS 4_p
with IN N
mild JJ 4_p
to TO 4_p
moderate VB 4_p
hypertension NN 4_p
. . N

METHODS NNP N
This DT N
was VBD N
a DT N
multicenter NN N
, , N
8-week JJ N
, , N
parallel-group JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
double-dummy JJ N
, , N
Phase NNP N
III NNP N
clinical JJ N
trial NN N
. . N

Eligible JJ N
patients NNS N
were VBD N
Korean NNP N
, , N
aged VBD N
18 CD N
to TO N
75 CD N
years NNS N
, , N
had VBD N
hypertension NN 4_p
, , N
and CC N
were VBD 4_p
either RB 4_p
taking VBG 4_p
antihypertensive JJ 4_p
medications NNS 4_p
or CC 4_p
had VBD 4_p
a DT 4_p
documented VBN 4_p
sitting VBG 4_p
diastolic JJ 4_p
blood NN 4_p
pressure NN 4_p
of IN 4_p
90 CD 4_p
to TO 4_p
109 CD 4_p
mm NN 4_p
Hg NNP 4_p
. . N

After IN N
a DT N
washout JJ N
period NN N
of IN N
2 CD N
weeks NNS N
, , N
patients NNS N
were VBD N
randomized VBN N
to TO N
amlodipine VB N
maleate NN N
or CC N
amlodipine NN N
besylate NN N
for IN N
8 CD N
weeks NNS N
. . N

In IN N
both DT N
groups NNS N
, , N
the DT N
medications NNS N
were VBD N
initiated VBN N
at IN N
5 CD N
mg NN N
QD NNP N
. . N

At IN N
day NN N
29 CD N
, , N
the DT N
medication NN N
dose NN N
was VBD N
increased VBN N
to TO N
10 CD N
mg NNS N
QD NNP N
if IN N
sitting VBG N
diastolic JJ N
blood NN N
pressure NN N
( ( N
SiDBP NNP N
) ) N
was VBD N
> JJ N
or CC N
= JJ N
90 CD N
mm NN N
Hg NNP N
. . N

RESULTS NNP N
One CD N
hundred VBD N
eighteen JJ N
patients NNS N
were VBD N
enrolled VBN N
. . N

Fifty-seven JJ N
patients NNS N
received VBD N
amlodipine JJ N
maleate NN N
( ( N
29 CD N
men NNS N
, , N
28 CD N
women NNS N
; : N
mean VB N
[ NNP N
SD NNP N
] NNP N
age NN N
, , N
49.0 CD N
[ NN N
11.4 CD N
] CD N
years NNS N
) ) N
and CC N
61 CD N
received VBD N
amlodipine JJ N
besylate NN N
( ( N
35 CD N
men NNS N
, , N
26 CD N
women NNS N
; : N
mean VB N
[ NNP N
SD NNP N
] NNP N
age NN N
, , N
51.6 CD N
[ NN N
9.4 CD N
] CD N
years NNS N
) ) N
. . N

Baseline JJ N
mean NN N
( ( N
SD NNP N
) ) N
values NNS N
for IN N
sitting VBG N
systolic JJ N
blood NN N
pressure NN N
and CC N
SiDBP NNP N
were VBD N
152.0 CD N
( ( N
12.2 CD N
) ) N
mm NN N
Hg NNP N
and CC N
98.1 CD N
( ( N
5.6 CD N
) ) N
mm NN N
Hg NNP N
, , N
respectively RB N
, , N
for IN N
the DT N
amlodipine JJ N
maleate NN N
group NN N
and CC N
153.4 CD N
( ( N
14.0 CD N
) ) N
mm NN N
Hg NNP N
and CC N
98.1 CD N
( ( N
5.5 CD N
) ) N
mm NN N
Hg NNP N
, , N
respectively RB N
, , N
for IN N
the DT N
amlodipine JJ N
besylate NN N
group NN N
. . N

In IN N
this DT N
population NN N
, , N
amlodipine JJ N
maleate NN N
was VBD N
not RB N
inferior JJ N
to TO N
amlodipine VB N
besylate NN N
: : N
the DT N
lower JJR N
limit NN N
of IN N
the DT N
2-sided JJ N
95 CD N
% NN N
CI NNP N
for IN N
the DT N
treatment NN N
difference NN N
in IN N
SiDBP NNP N
was VBD N
greater JJR N
than IN N
-4 JJR N
mm NN N
Hg NNP N
. . N

The DT N
between-group JJ N
difference NN N
in IN N
SiDBP NNP N
response NN N
rate NN N
( ( N
the DT N
proportion NN N
of IN N
patients NNS N
who WP N
experienced VBD N
adequate JJ N
SiDBP NNP N
reductions NNS N
) ) N
did VBD N
not RB N
reach VB N
statistical JJ N
significance NN N
: : N
85.7 CD N
% NN N
( ( N
42/49 CD N
) ) N
for IN N
the DT N
amlodipine JJ N
maleate NN N
group NN N
and CC N
91.8 CD N
% NN N
( ( N
45/49 CD N
) ) N
for IN N
the DT N
amlodipine JJ N
besylate NN N
group NN N
. . N

Compliance NN N
rates NNS N
were VBD N
similar JJ N
between IN N
groups NNS N
, , N
with IN N
mean NN N
( ( N
SD NNP N
) ) N
compliance NN N
rates NNS N
of IN N
97.4 CD N
% NN N
( ( N
2.8 CD N
% NN N
) ) N
and CC N
97.1 CD N
% NN N
( ( N
3.6 CD N
% NN N
) ) N
in IN N
the DT N
amlodipine NN N
maleate NN N
and CC N
amlodipine JJ N
besylate NN N
groups NNS N
, , N
respectively RB N
. . N

Also RB N
, , N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
the DT N
incidences NNS N
of IN N
drug-related JJ N
clinical JJ N
and CC N
laboratory JJ N
adverse JJ N
events NNS N
; : N
the DT N
most RBS N
common JJ N
were VBD N
headache NN N
, , N
flushing NN N
, , N
facial JJ N
edema NN N
, , N
and CC N
paresthesia NN N
. . N

CONCLUSION NN N
In IN N
this DT N
population NN N
, , N
the DT N
efficacy NN N
and CC N
tolerability NN N
observed VBN N
with IN N
amlodipine JJ N
maleate NN N
were VBD N
similar JJ N
to TO N
those DT N
seen VBN N
with IN N
amlodipine JJ N
besylate NN N
. . N

-DOCSTART- -X- O O 2540788

Duration NN N
of IN N
chemotherapy NN N
in IN N
small JJ N
cell NN N
lung NN N
cancer NN N
: : N
a DT N
Cancer NNP N
Research NNP N
Campaign NNP N
trial NN N
. . N

A DT N
total NN N
of IN N
610 CD N
patients NNS N
with IN N
small JJ N
cell NN N
lung NN N
cancer NN N
were VBD N
entered VBN N
into IN N
a DT N
randomised JJ N
trial NN N
designed VBN N
to TO N
assess VB N
the DT N
effect NN N
of IN N
duration NN N
of IN N
initial JJ N
chemotherapy NN N
on IN N
survival NN N
. . N

Patients NNS N
were VBD N
randomised VBN N
to TO N
receive VB N
either DT N
four CD N
or CC N
eight CD N
courses NNS N
of IN N
cytotoxic NN N
chemotherapy NN N
with IN N
cyclophosphamide NN N
, , N
vincristine NN N
and CC N
etoposide NN N
and CC N
also RB N
randomised VBD N
to TO N
receive VB N
, , N
on IN N
disease NN N
progression NN N
, , N
either CC N
second JJ N
line NN N
chemotherapy NN N
( ( N
methotrexate NN N
and CC N
doxorubicin NN N
) ) N
or CC N
symptomatic JJ N
treatment NN N
only RB N
. . N

In IN N
the DT N
whole NN N
study NN N
196 CD N
( ( N
32.1 CD N
% NN N
) ) N
had VBD N
limited VBN N
disease NN N
and CC N
414 CD N
( ( N
67.9 CD N
% NN N
) ) N
extensive JJ N
disease NN N
. . N

During IN N
initial JJ N
chemotherapy VBD N
the DT N
response NN N
rate NN N
( ( N
complete JJ N
and CC N
partial JJ N
responses NNS N
) ) N
after IN N
four CD N
courses NNS N
of IN N
treatment NN N
was VBD N
61 CD N
% NN N
with IN N
no DT N
significant JJ N
increase NN N
in IN N
patients NNS N
receiving VBG N
eight CD N
courses NNS N
( ( N
63 CD N
% NN N
) ) N
. . N

In IN N
those DT N
randomised VBN N
to TO N
receive VB N
relapse NN N
chemotherapy VBZ N
the DT N
response NN N
rate NN N
was VBD N
improved VBN N
slightly RB N
for IN N
those DT N
who WP N
had VBD N
originally RB N
received VBN N
four CD N
courses NNS N
of IN N
chemotherapy NN N
( ( N
25.6 CD N
% NN N
) ) N
over IN N
those DT N
receiving VBG N
eight CD N
( ( N
18.7 CD N
% NN N
) ) N
. . N

The DT N
overall JJ N
results NNS N
show VBP N
that IN N
of IN N
the DT N
four CD N
possible JJ N
treatment NN N
randomizations NNS N
, , N
four CD N
courses NNS N
of IN N
chemotherapy NN N
alone NN N
is VBZ N
inferior JJ N
in IN N
terms NNS N
of IN N
overall JJ N
survival NN N
( ( N
30 CD N
weeks NNS N
median JJ N
survival NN N
) ) N
to TO N
the DT N
other JJ N
three CD N
treatment NN N
options NNS N
( ( N
39 CD N
weeks NNS N
median JJ N
survival NN N
, , N
P NNP N
less JJR N
than IN N
0.01 CD N
) ) N
. . N

In IN N
patients NNS N
responding VBG N
to TO N
initial JJ N
chemotherapy NN N
the DT N
disadvantage NN N
of IN N
four CD N
courses NNS N
of IN N
chemotherapy NN N
alone NN N
was VBD N
apparent JJ N
( ( N
median JJ N
survival NN N
of IN N
40 CD N
weeks NNS N
versus RB N
49 CD N
weeks NNS N
, , N
P NNP N
= NNP N
0.003 CD N
) ) N
but CC N
not RB N
if IN N
drug NN N
treatment NN N
was VBD N
given VBN N
on IN N
relapse NN N
. . N

The DT N
study NN N
shows VBZ N
that IN N
limiting VBG N
treatment NN N
to TO N
four CD N
courses NNS N
of IN N
chemotherapy NN N
alone NN N
is VBZ N
associated VBN N
with IN N
inferior JJ N
survival NN N
, , N
but CC N
this DT N
is VBZ N
not RB N
the DT N
case NN N
if IN N
chemotherapy NN N
is VBZ N
given VBN N
at IN N
relapse NN N
. . N

-DOCSTART- -X- O O 8628584

Relaxation NN N
and CC N
imagery NN N
and CC N
cognitive-behavioral JJ N
training NN N
reduce VB N
pain NN N
during IN N
cancer NN N
treatment NN N
: : N
a DT N
controlled JJ N
clinical JJ N
trial NN N
. . N

Few NNP N
controlled VBD N
clinical JJ N
trials NNS N
of IN N
psychological JJ N
interventions NNS N
for IN N
cancer NN N
pain NN N
relief NN N
exist NN N
in IN N
spite NN N
of IN N
frequent JJ N
support NN N
for IN N
their PRP$ N
importance NN N
as IN N
adjuncts NNS N
to TO N
medical JJ N
treatment NN N
. . N

This DT N
study NN N
compared VBN N
oral JJ N
mucositis NN N
pain NN N
levels NNS N
in IN N
4 CD N
groups NNS N
of IN N
cancer NN N
patients NNS N
receiving VBG N
bone NN N
marrow NN N
transplants NNS N
( ( N
BMT NNP N
) ) N
: : N
( ( N
1 CD N
) ) N
treatment NN N
as IN N
usual JJ N
control NN N
, , N
( ( N
2 CD N
) ) N
therapist NN N
support NN N
, , N
( ( N
3 CD N
) ) N
relaxation NN N
and CC N
imagery NN N
training NN N
, , N
and CC N
( ( N
4 CD N
) ) N
training NN N
in IN N
a DT N
package NN N
of IN N
cognitive-behavioral JJ N
coping NN N
skills NNS N
which WDT N
included VBD N
relaxation NN N
and CC N
imagery NN N
. . N

A DT N
total NN N
of IN N
94 CD N
patients NNS N
completed VBD N
the DT N
study NN N
which WDT N
involved VBD N
two CD N
training NN N
sessions NNS N
prior RB N
to TO N
treatment NN N
and CC N
twice RB N
a DT N
week NN N
'booster POS N
' POS N
sessions NNS N
during IN N
the DT N
first JJ N
5 CD N
weeks NNS N
of IN N
treatment NN N
. . N

Results NNS N
confirmed VBD N
our PRP$ N
hypothesis NN N
that IN N
patients NNS N
who WP N
received VBD N
either DT N
relaxation NN N
and CC N
imagery VB N
alone RB N
or CC N
patients NNS N
who WP N
received VBD N
the DT N
package NN N
of IN N
cognitive-behavioral JJ N
coping NN N
skills NNS N
would MD N
report VB N
less JJR N
pain NN N
than IN N
patients NNS N
in IN N
the DT N
other JJ N
2 CD N
groups NNS N
. . N

The DT N
hypothesis NN N
that IN N
the DT N
cognitive-behavioral JJ N
skills NNS N
package NN N
would MD N
have VB N
an DT N
additive JJ N
effect NN N
beyond IN N
relaxation NN N
and CC N
imagery NN N
alone RB N
was VBD N
not RB N
confirmed VBN N
. . N

Average JJ N
visual JJ N
analogue NN N
scale NN N
( ( N
VAS NNP N
) ) N
report NN N
of IN N
pain NN N
within IN N
the DT N
therapist JJ N
support NN N
group NN N
was VBD N
not RB N
significantly RB N
lower JJR N
than IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
= NNP N
0.103 CD N
) ) N
nor CC N
significantly RB N
higher JJR N
than IN N
the DT N
training NN N
groups NNS N
. . N

Patient JJ N
reports NNS N
of IN N
relative JJ N
helpfulness NN N
of IN N
the DT N
interventions NNS N
for IN N
managing VBG N
pain NN N
and CC N
nausea NN N
matched VBD N
the DT N
results NNS N
of IN N
VAS NNP N
reports NNS N
. . N

From IN N
these DT N
results NNS N
, , N
we PRP N
conclude VBP N
that DT N
relaxation NN N
and CC N
imagery NN N
training NN N
reduces NNS N
cancer NN N
treatment-related JJ N
pain NN N
; : N
adding VBG N
cognitive-behavioral JJ N
skills NNS N
to TO N
the DT N
relaxation NN N
with IN N
imagery NN N
does VBZ N
not RB N
, , N
on IN N
average NN N
, , N
further JJ N
improve VB N
pain NN N
relief NN N
. . N

-DOCSTART- -X- O O 3341795

Topical JJ N
fibronectin NN N
therapy NN N
for IN N
treatment NN N
of IN N
a DT N
patient NN N
with IN N
chronic JJ 4_p
stasis NN 4_p
ulcers NNS 4_p
. . N

-DOCSTART- -X- O O 9895371

Total JJ N
parenteral JJ N
nutrition NN N
with IN N
glutamine JJ N
dipeptide NN N
shortened VBD N
hospital JJ N
stays NNS N
and CC N
improved VBN N
immune JJ N
status NN N
and CC N
nitrogen NN N
economy NN N
after IN N
major JJ 4_p
abdominal JJ 4_p
surgery NN 4_p
. . N

-DOCSTART- -X- O O 23224592

Parents NNS N
' POS N
state NN N
and CC N
trait NN N
anxiety NN N
: : N
relationships NNS N
with IN N
anxiety NN N
severity NN N
and CC N
treatment NN N
response NN N
in IN N
adolescents NNS N
with IN N
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
. . N

Comorbid NNP N
anxiety NN N
is VBZ N
common JJ N
among IN N
children NNS N
with IN N
Autism NNP 4_p
Spectrum NNP 4_p
Disorder NNP 4_p
( ( 4_p
ASD NNP 4_p
) ) N
, , N
and CC N
parents NNS N
of IN N
children NNS N
with IN N
ASD NNP 4_p
are VBP N
more RBR N
likely JJ N
to TO N
have VB N
anxiety NN N
disorders NNS N
. . N

This DT N
study NN N
investigated VBD N
the DT N
relationship NN N
between IN N
parents NNS N
' POS N
state NN N
and CC N
trait NN N
anxiety NN 4_p
and CC N
parent-reported JJ N
internalizing NN N
and CC N
externalizing VBG N
symptoms NNS N
among IN N
adolescents NNS N
( ( N
n JJ N
= NNP N
30 CD N
) ) N
with IN N
ASD NNP 4_p
, , N
as RB N
well RB N
as IN N
the DT N
relationship NN N
of IN N
parents NNS N
' POS N
anxiety NN N
symptoms NNS N
and CC N
adolescent JJ N
treatment NN N
response NN N
in IN N
the DT N
context NN N
of IN N
a DT N
randomized VBN N
controlled VBN N
trial NN N
. . N

Parental JJ N
state NN N
anxiety NN N
correlated VBD N
with IN N
severity NN N
of IN N
adolescent JJ N
anxiety NN N
, , N
and CC N
trait NN N
anxiety NN N
in IN N
parents NNS N
correlated VBN N
with IN N
parent-reported JJ N
adolescent NN N
internalizing NN N
and CC N
externalizing NN N
symptoms NNS N
. . N

Also RB N
, , N
parents NNS N
of IN N
adolescent JJ N
treatment NN N
responders NNS N
experienced VBD N
a DT N
decrease NN N
in IN N
their PRP$ N
own JJ N
trait NN N
anxiety NN N
. . N

Findings NNS N
highlight VBD N
the DT N
importance NN N
of IN N
considering VBG N
parental JJ N
anxiety NN N
when WRB N
targeting VBG N
anxiety NN N
among IN N
youth NN N
with IN N
ASD NNP N
. . N

-DOCSTART- -X- O O 20010618

Effectiveness NN N
of IN N
initiating VBG N
treatment NN N
with IN N
valsartan/hydrochlorothiazide NN N
in IN N
patients NNS 4_p
with IN 4_p
stage-1 JJ 4_p
or CC 4_p
stage-2 JJ 4_p
hypertension NN 4_p
. . 4_p

This DT N
prospective JJ N
, , N
6-week JJ N
, , N
multicenter NN N
, , N
double-blind NN N
study NN N
examined VBD N
the DT N
benefits NNS N
of IN N
initiating VBG N
treatment NN N
with IN N
combination NN N
valsartan/hydrochlorothiazide NN N
( ( N
HCTZ NNP N
) ) N
compared VBN N
with IN N
initial JJ N
valsartan NNS N
monotherapy NN N
for IN N
648 CD N
patients NNS N
with IN N
stage-1 JJ N
or CC N
stage-2 JJ N
hypertension NN N
( ( N
age=52.6+/-10 JJ N
years NNS N
; : N
54 CD N
% NN N
male NN N
; : N
baseline VB N
blood NN N
pressure NN N
( ( N
BP NNP N
) ) N
=161/98 VBP N
mm JJ N
Hg NNP N
, , N
32 CD N
% NN N
stage NN N
1 CD N
) ) N
. . N

Patients NNS N
were VBD N
randomized VBN N
to TO N
valsartan VB N
80 CD N
mg NN N
( ( N
V-low NNP N
) ) N
, , N
valsartan $ N
160 CD N
mg NN N
( ( N
V-high NNP N
) ) N
or CC N
valsartan/HCTZ $ N
160/12.5 CD N
mg NN N
( ( N
V/HCTZ NNP N
) ) N
, , N
and CC N
electively RB N
titrated VBN N
after IN N
weeks NNS N
2 CD N
and CC N
4 CD N
to TO N
the DT N
next JJ N
dosage NN N
level NN N
( ( N
maximum JJ N
dose NN N
valsartan/HCTZ NN N
160/25 CD N
mg NN N
) ) N
if IN N
BP NNP N
remained VBD N
> JJ N
140/90 CD N
mm NN N
Hg NNP N
. . N

At IN N
end NN N
of IN N
the DT N
study NN N
, , N
patients NNS N
initiated VBN N
with IN N
V/HCTZ NNP N
required VBD N
less JJR N
titration JJ N
steps NNS N
compared VBN N
with IN N
the DT N
initial JJ N
valsartan NN N
monotherapy NN N
groups NNS N
( ( N
63 CD N
vs RB N
86 CD N
% NN N
required VBN N
titration NN N
by IN N
study JJ N
end NN N
, , N
respectively RB N
) ) N
and CC N
reached VBD N
the DT N
target NN N
BP NNP N
goal NN N
of IN N
< $ N
140/90 CD N
mm NN N
Hg NNP N
in IN N
a DT N
shorter JJ N
period NN N
of IN N
time NN N
( ( N
2.8 CD N
weeks NNS N
) ) N
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
vs NN N
V-low NNP N
( ( N
4.3 CD N
weeks NNS N
) ) N
and CC N
V-high NNP N
( ( N
3.9 CD N
weeks NNS N
) ) N
. . N

Initial JJ N
combination NN N
therapy NN N
was VBD N
also RB N
associated VBN N
with IN N
higher JJR N
BP NNP N
control NN N
rates NNS N
and CC N
greater JJR N
reductions NNS N
in IN N
both DT N
systolic JJ N
and CC N
diastolic JJ N
BP NNP N
from IN N
baseline NN N
( ( N
63 CD N
% NN N
, , N
-27.7+/-13/-15.1+/-8 NNP N
mm NNP N
Hg NNP N
) ) N
compared VBN N
with IN N
V-low NNP N
( ( N
46 CD N
% NN N
, , N
-21.2+/-13/-11.4+/-8 NNP N
mm NNP N
Hg NNP N
, , N
P NNP N
< NNP N
0.0001 CD N
) ) N
or CC N
V-high NNP N
( ( N
51 CD N
% NN N
, , N
-24.0+/-13/-12.0+/-10 NNP N
mm NNP N
Hg NNP N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

Overall JJ N
and CC N
drug-related JJ N
AEs NNP N
were VBD N
mild JJ N
to TO N
moderate VB N
and CC N
were VBD N
similar JJ N
between IN N
V/HCTZ NNP N
( ( N
53.1 CD N
and CC N
14.1 CD N
% NN N
, , N
respectively RB N
) ) N
and CC N
the DT N
two CD N
monotherapy NN N
groups NNS N
, , N
V-low NNP N
( ( N
50.5 CD N
and CC N
13.8 CD N
% NN N
) ) N
and CC N
V-high NNP N
( ( N
50.7 CD N
and CC N
11.8 CD N
% NN N
) ) N
. . N

In IN N
conclusion NN N
, , N
initiating VBG N
therapy NN N
with IN N
a DT N
combination NN N
of IN N
valsartan NN N
and CC N
low-dose JJ N
HCTZ NNP N
results NNS N
in IN N
early JJ N
, , N
improved JJ N
BP NNP N
efficacy NN N
with IN N
similar JJ N
tolerability NN N
as IN N
compared VBN N
with IN N
starting VBG N
treatment NN N
with IN N
a DT N
low JJ N
or CC N
higher JJR N
dose NN N
of IN N
valsartan NN N
for IN N
patients NNS N
with IN N
stage-1 JJ N
and CC N
stage-2 JJ N
hypertension NN N
. . N

-DOCSTART- -X- O O 22026323

Early JJ N
intervention NN N
for IN N
autism NN N
with IN N
a DT N
parent-delivered JJ N
Qigong JJ N
massage NN N
program NN N
: : N
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

A DT N
recent JJ N
randomized NN N
controlled VBD N
trial NN N
( ( N
RCT NNP N
) ) N
of IN N
a DT N
dual JJ N
parent NN N
and CC N
trainer-delivered JJ N
qigong JJ N
massage NN N
intervention NN N
for IN N
young JJ N
children NNS N
with IN N
autism NN 4_p
resulted VBN N
in IN N
improvement NN N
of IN N
measures NNS N
of IN N
autism NN N
as RB N
well RB N
as IN N
improvement NN N
of IN N
abnormal JJ N
sensory JJ N
responses NNS N
and CC N
self-regulation NN N
. . N

The DT N
RCT NNP N
evaluated VBD N
the DT N
effects NNS N
of IN N
the DT N
parent-delivered JJ N
component NN N
of IN N
the DT N
intervention NN N
. . N

Forty-seven JJ N
children NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
treatment NN N
and CC N
wait-list JJ N
control NN N
groups NNS N
. . N

Treatment NNP N
group NN N
children NNS N
received VBD N
the DT N
parent-delivered JJ N
program NN N
for IN N
4 CD N
mo NN N
. . N

Trained JJ N
therapists NNS N
provided VBD N
parent NN N
training NN N
and CC N
support NN N
. . N

Improvement NN N
was VBD N
evaluated VBN N
in IN N
two CD N
settings NNS N
-- : N
preschool NN N
and CC N
home NN N
-- : N
by IN N
teachers NNS N
( ( N
blind IN N
to TO N
group NN N
) ) N
and CC N
parents NNS N
. . N

Results NNS N
showed VBD N
that IN N
the DT N
parent-delivered JJ N
program NN N
was VBD N
effective JJ N
in IN N
improving VBG N
measures NNS N
of IN N
autism NN N
( ( N
medium JJ N
effect NN N
size NN N
) ) N
and CC N
sensory JJ N
and CC N
self-regulatory JJ N
responses NNS N
( ( N
large JJ N
effect NN N
size NN N
) ) N
. . N

Teacher NNP N
data NN N
on IN N
measures NNS N
of IN N
autism NN N
were VBD N
confirmed VBN N
by IN N
parent NN N
data NNS N
. . N

Results NNS N
indicate VBP N
that IN N
the DT N
parent-delivered JJ N
component NN N
of IN N
the DT N
program NN N
provided VBD N
effective JJ N
early JJ N
intervention NN N
for IN N
autism NN N
that WDT N
was VBD N
suitable JJ N
for IN N
delivery NN N
at IN N
home NN N
. . N

-DOCSTART- -X- O O 18629569

Effects NNS N
of IN N
a DT N
long-term JJ N
vitamin NN N
D NNP N
and CC N
calcium NN N
supplementation NN N
on IN N
falls NNS N
and CC N
parameters NNS N
of IN N
muscle NN N
function NN N
in IN N
community-dwelling JJ 4_p
older NN N
individuals NNS N
. . N

UNLABELLED NN N
In IN N
242 CD N
community-dwelling JJ N
seniors NNS N
, , N
supplementation NN N
with IN N
either DT N
1000 CD N
mg NN N
of IN N
calcium NN N
or CC N
1000 CD N
mg NN N
of IN N
calcium NN N
plus CC N
vitamin NN N
D NNP N
resulted VBD N
in IN N
a DT N
decrease NN N
in IN N
the DT N
number NN N
of IN N
subjects NNS N
with IN N
first JJ N
falls NNS N
of IN N
27 CD N
% NN N
at IN N
month NN N
12 CD N
and CC N
39 CD N
% NN N
at IN N
month NN N
20 CD N
. . N

Additionally RB N
, , N
parameters NNS N
of IN N
muscle NN N
function NN N
improved VBD N
significantly RB N
. . N

INTRODUCTION NNP N
The DT N
efficacy NN N
of IN N
vitamin NN N
D NNP N
and CC N
calcium NN N
supplementation NN N
on IN N
risk NN N
of IN N
falling VBG N
in IN N
the DT N
elderly JJ N
is VBZ N
discussed VBN N
controversially RB N
. . N

Randomized NNP N
controlled VBD N
trials NNS N
using VBG N
falls NNS N
as IN N
primary JJ N
outcome NN N
are VBP N
needed VBN N
. . N

We PRP N
investigated VBD N
long-term JJ N
effects NNS N
of IN N
calcium NN N
and CC N
vitamin NN N
D NNP N
on IN N
falls NNS N
and CC N
parameters NNS N
of IN N
muscle NN N
function NN N
in IN N
community-dwelling JJ N
elderly JJ N
women NNS N
and CC N
men NNS N
. . N

METHODS NNP N
Our PRP$ N
study NN N
population NN N
consisted VBD N
of IN N
242 CD N
individuals NNS N
recruited VBN N
by IN N
advertisements NNS N
and CC N
mailing VBG N
lists NNS N
( ( N
mean JJ N
[ NNP N
+/- NN N
SD NNP N
] NNP N
age NN N
, , N
77 CD N
+/- JJ N
4 CD N
years NNS N
) ) N
. . N

All DT N
serum JJ N
25-hydroxyvitamin JJ 4_p
D NNP N
( ( N
25 CD N
[ NNP N
OH NNP N
] NNP N
D NNP N
) ) N
levels NNS N
were VBD N
below IN N
78 CD N
nmol/l NN N
. . N

Individuals NNS N
received VBD N
in IN N
a DT N
double JJ N
blinded JJ N
fashion NN N
either DT N
1000 CD N
mg NN N
of IN N
calcium NN N
or CC N
1000 CD N
mg NN N
of IN N
calcium NN N
plus CC N
800 CD N
IU NNP N
of IN N
vitamin NNP N
D NNP N
per IN N
day NN N
over IN N
a DT N
treatment NN N
period NN N
of IN N
12 CD N
months NNS N
, , N
which WDT N
was VBD N
followed VBN N
by IN N
a DT N
treatment-free JJ N
but CC N
still RB N
blinded VBD N
observation JJ N
period NN N
of IN N
8 CD N
months NNS N
. . N

Falls NNP N
were VBD N
documented VBN N
using VBG N
diaries NNS N
. . N

The DT N
study NN N
took VBD N
place NN N
in IN N
Bad NNP N
Pyrmont NNP N
, , N
Germany NNP N
( ( N
latitude VBP N
52 CD N
degrees NNS N
) ) N
and CC N
Graz NNP N
, , N
Austria NNP N
( ( N
latitude VBP N
46 CD N
degrees NNS N
) ) N
. . N

RESULTS $ N
Compared VBD N
to TO N
calcium VB N
mono NN N
, , N
supplementation NN N
with IN N
calcium NN N
plus CC N
vitamin NN N
D NNP N
resulted VBD N
in IN N
a DT N
significant JJ N
decrease NN N
in IN N
the DT N
number NN N
of IN N
subjects NNS N
with IN N
first JJ N
falls NNS N
of IN N
27 CD N
% NN N
at IN N
month NN N
12 CD N
( ( N
RR NNP N
= NNP N
0.73 CD N
; : N
CI NNP N
= NNP N
0.54-0.96 NN N
) ) N
and CC N
39 CD N
% NN N
at IN N
month NN N
20 CD N
( ( N
RR NNP N
= NNP N
0.61 CD N
; : N
CI NNP N
= NNP N
0.34-0.76 NN N
) ) N
. . N

Concerning VBG N
secondary JJ N
endpoints NNS N
, , N
we PRP N
observed VBD N
significant JJ N
improvements NNS N
in IN N
quadriceps JJ N
strength NN N
of IN N
8 CD N
% NN N
, , N
a DT N
decrease NN N
in IN N
body NN N
sway NN N
of IN N
28 CD N
% NN N
, , N
and CC N
a DT N
decrease NN N
in IN N
time NN N
needed VBN N
to TO N
perform VB N
the DT N
TUG NNP N
test NN N
of IN N
11 CD N
% NN N
. . N

DISCUSSION NNP N
Combined NNP N
calcium NN N
and CC N
vitamin NN N
D NNP N
supplementation NN N
proved VBD N
superior JJ N
to TO N
calcium VB N
alone RB N
in IN N
reducing VBG N
the DT N
number NN N
of IN N
falls NNS N
and CC N
improving VBG N
muscle NN N
function NN N
in IN N
community-dwelling JJ N
older NN N
individuals NNS N
. . N

-DOCSTART- -X- O O 17404792

Successful JJ N
new JJ N
method NN N
of IN N
extracorporeal JJ N
percutaneous JJ N
endoscopic NN N
gastrostomy NN N
( ( N
E-PEG NNP N
) ) N
. . N

BACKGROUND NNP N
Although IN N
percutaneous JJ N
endoscopic NNS N
gastrostomy NN N
( ( N
PEG NNP N
) ) N
has VBZ N
become VBN N
popular JJ N
for IN N
patients NNS N
with IN N
swallowing VBG 4_p
disorders NNS 4_p
as IN 4_p
a DT 4_p
nutrition NN 4_p
support NN 4_p
or CC N
a DT N
decompressant NN N
of IN N
gastrointestine NN 4_p
, , N
perioperative JJ N
complications NNS N
associated VBN N
with IN N
PEG NNP N
have VBP N
not RB N
decreased VBN N
, , N
especially RB N
peristomal JJ N
infections NNS N
. . N

To TO N
reduce VB N
peristomal JJ N
infections NNS N
, , N
we PRP N
designed VBD N
a DT N
new JJ N
method NN N
of IN N
gastrostomy NN N
by IN N
extracorporeal JJ N
approach NN N
under IN N
endoscopic JJ N
observation NN N
, , N
named VBN N
as IN N
extra-corporeal JJ N
PEG NNP N
( ( N
E-PEG NNP N
) ) N
. . N

METHODS NNP N
Experimental NNP N
studies NNS N
for IN N
E-PEG NNP N
were VBD N
performed VBN N
repeatedly RB N
using VBG N
pigs NNS 4_p
under IN 4_p
general JJ 4_p
anesthesia NN 4_p
to TO N
confirm VB N
the DT N
safety NN N
of IN N
its PRP$ N
procedure NN N
for IN N
human JJ N
use NN N
. . N

After IN N
approval NN N
of IN N
institutional JJ N
ethics NNS N
review VBP N
board NN N
in IN N
our PRP$ N
university NN N
, , N
thirty JJ N
patients NNS N
with IN N
prior JJ N
consent NN N
participated VBN N
in IN N
this DT N
study NN N
. . N

The DT N
operation NN N
time NN N
, , N
the DT N
incidence NN N
rate NN N
of IN N
complications NNS N
and CC N
the DT N
hospital NN N
stay NN N
were VBD N
compared VBN N
between IN N
E-PEG NNP N
and CC N
ordinary JJ N
pull-method JJ N
PEG NNP N
groups NNS N
. . N

RESULTS NNP N
Two CD N
patients NNS N
( ( N
6.7 CD N
% NN N
) ) N
in IN N
E-PEG NNP N
group NN N
had VBD N
postoperative JJ N
complications NNS N
, , N
i.e. FW N
, , N
aspiration NN N
pneumonia NN N
and CC N
surgical JJ N
site NN N
infection NN N
. . N

The DT N
operation NN N
time NN N
of IN N
E-PEG NNP N
group NN N
was VBD N
5-16 JJ N
( ( N
mean JJ N
+/- JJ N
SD NN N
: : N
10.3 CD N
+/- JJ N
2.96 CD N
) ) N
min NN N
as IN N
compared VBN N
to TO N
14-37 JJ N
( ( N
mean JJ N
+/- JJ N
SD NN N
: : N
26.9 CD N
+/- JJ N
8.39 CD N
) ) N
min NN N
with IN N
pull-method JJ N
PEG NNP N
. . N

The DT N
postoperative JJ N
hospital NN N
day NN N
of IN N
E-PEG NNP N
was VBD N
within IN N
two CD N
days NNS N
except IN N
for IN N
the DT N
two CD N
complicated VBD N
cases NNS N
. . N

Significance NNP N
differences NNS N
of IN N
operation NN N
time NN N
, , N
complication NN N
rate NN N
and CC N
postoperative JJ N
hospital NN N
stay NN N
between IN N
those DT N
groups NNS N
observed VBD N
statistically RB N
. . N

CONCLUSIONS NNP N
These DT N
results NNS N
indicate VBP N
that IN N
E-PEG NNP N
was VBD N
safe JJ N
, , N
tolerable JJ N
and CC N
speedy NN N
when WRB N
compared VBN N
ordinary JJ N
pull-method JJ N
PEG NNP N
. . N

-DOCSTART- -X- O O 1984893

Unstable JJ 4_p
angina NN 4_p
. . N

Quality NN N
of IN N
life NN N
. . N

-DOCSTART- -X- O O 8640699

Fadrozole NNP N
HCL NNP N
( ( N
CGS-16949A NNP N
) ) N
versus NN N
megestrol NN N
acetate VBP N
treatment NN N
of IN N
postmenopausal NN 4_p
patients NNS N
with IN N
metastatic JJ 4_p
breast NN 4_p
carcinoma NN 4_p
: : N
results NNS N
of IN N
two CD N
randomized JJ N
double JJ N
blind NN N
controlled VBD N
multiinstitutional JJ N
trials NNS N
. . N

BACKGROUND NNP N
Breast NNP 4_p
cancer NN 4_p
patients NNS N
with IN 4_p
prior JJ 4_p
response NN 4_p
to TO 4_p
endocrine VB 4_p
therapy NN 4_p
achieve VB N
subsequent JJ N
benefit NN N
from IN N
additional JJ N
endocrine NN N
therapies NNS N
. . N

The DT N
efficacy NN N
and CC N
safety NN N
of IN N
an DT N
aromatase NN N
inhibitor NN N
, , N
fadrozole JJ N
HCL NNP N
, , N
were VBD N
compared VBN N
with IN N
megestrol NN N
acetate NN N
in IN N
post NN N
menopausal NN N
patients NNS N
who WP N
had VBD N
disease NN N
progression NN N
after IN N
receiving VBG N
antiestrogen NN N
therapy NN N
either DT N
for IN N
metastatic JJ N
disease NN N
or CC N
as IN N
adjuvant JJ N
therapy NN N
. . N

METHODS NNP N
In IN N
2 CD N
multiinstitutional JJ N
prospective JJ N
trials NNS N
, , N
683 CD N
postmenopausal NN N
patients NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
fadrozole JJ N
HCL NNP N
, , N
1 CD N
mg NN N
twice RB N
daily RB N
, , N
or CC N
megestrol NN N
acetate NN N
, , N
40 CD N
mg NN N
4 CD N
times NNS N
daily RB N
, , N
in IN N
a DT N
double JJ N
blind NN N
fashion NN N
after IN N
progression NN N
on IN N
first-line JJ N
hormonal JJ N
therapy NN N
. . N

Objective JJ N
response NN N
rates NNS N
, , N
time NN N
to TO N
progression NN N
, , N
survival NN N
and CC N
safety NN N
of IN N
the DT N
two CD N
regimens NNS N
were VBD N
compared VBN N
. . N

RESULTS NNP N
Results NNP N
of IN N
intent-to-treat JJ N
analyses NNS N
are VBP N
presented VBN N
in IN N
this DT N
study NN N
. . N

No DT N
significant JJ N
differences NNS N
were VBD N
detected VBN N
between IN N
the DT N
two CD N
treatment NN N
groups NNS N
in IN N
time NN N
to TO N
progression NN N
, , N
objective JJ N
response NN N
rates NNS N
, , N
duration NN N
of IN N
response NN N
, , N
and CC N
survival NN N
in IN N
either DT N
trial NN N
. . N

There EX N
were VBD N
no DT N
clinically RB N
meaningful JJ N
differences NNS N
between IN N
the DT N
treatment NN N
groups NNS N
in IN N
the DT N
incidence NN N
and CC N
severity NN N
of IN N
adverse JJ N
experiences NNS N
, , N
except IN N
that DT N
weight NN N
gain NN N
, , N
fluid JJ N
retention NN N
, , N
and CC N
dyspnea NN N
were VBD N
observed VBN N
in IN N
more JJR N
patients NNS N
in IN N
the DT N
megestrol NN N
acetate NN N
group NN N
compared VBN N
with IN N
those DT N
receiving VBG N
fadrozole JJ N
HCL NNP N
, , N
whereas JJ N
nausea NN N
and CC N
vomiting NN N
were VBD N
observed VBN N
in IN N
more JJR N
patients NNS N
in IN N
the DT N
fadrozole JJ N
HCL NNP N
group NN N
compared VBN N
with IN N
those DT N
receiving VBG N
megestrol NN N
acetate NN N
. . N

CONCLUSIONS NNP N
Fadrozole NNP N
HCL NNP N
was VBD N
as RB N
efficacious JJ N
as IN N
megestrol NN N
acetate NN N
in IN N
postmenopausal NN 4_p
patients NNS N
with IN N
metastatic JJ 4_p
breast NN 4_p
carcinoma NN 4_p
after IN N
one CD N
hormonal JJ N
therapy NN N
. . N

Adverse JJ N
experiences NNS N
were VBD N
mild JJ N
with IN N
both DT N
therapies NNS N
, , N
but CC N
megestrol NN N
acetate NN N
was VBD N
associated VBN N
wiht PDT N
a DT N
higher JJR N
frequency NN N
of IN N
weight NN N
gain NN N
, , N
fluid JJ N
retention NN N
and CC N
dyspnea NN N
, , N
whereas JJ N
fadrozole NN N
HCL NNP N
was VBD N
associated VBN N
with IN N
a DT N
higher JJR N
frequency NN N
of IN N
nausea NN N
and CC N
vomiting NN N
. . N

-DOCSTART- -X- O O 24602973

Prospective JJ N
randomized VBN N
trial NN N
of IN N
bispectral JJ N
index NN N
monitoring NN N
of IN N
sedation NN N
depth NN N
during IN N
flexible JJ N
bronchoscopy NN N
. . N

BACKGROUND IN N
The DT N
clinical JJ N
benefits NNS N
associated VBN N
with IN N
the DT N
use NN N
of IN N
the DT N
bispectral JJ N
index NN N
( ( N
BIS NNP N
) ) N
to TO N
monitor VB N
the DT N
depth NN N
of IN N
sedation NN N
during IN N
flexible JJ N
fiberoptic JJ N
bronchoscopy NN N
( ( N
FFB NNP N
) ) N
are VBP N
questionable JJ N
. . N

OBJECTIVES NNP N
To TO N
evaluate VB N
the DT N
added JJ N
value NN N
in IN N
terms NNS N
of IN N
procedural JJ N
safety NN N
and CC N
patients NNS N
' POS N
awareness NN N
of IN N
monitoring VBG N
sedation NN N
depth NN N
using VBG N
the DT N
BIS NNP N
compared VBN N
to TO N
conventional JJ N
clinical JJ N
judgment NN N
alone RB N
in IN N
patients NNS N
undergoing VBG N
FFB NNP N
under IN N
propofol JJ N
sedation NN N
. . N

METHODS NNP N
The DT N
cohort NN N
included VBD N
81 CD N
patients NNS N
undergoing JJ N
diagnostic JJ 4_p
or CC 4_p
therapeutic JJ 4_p
bronchoscopy NN 4_p
under IN 4_p
propofol NN 4_p
sedation NN 4_p
that WDT N
were VBD N
prospectively RB N
randomized VBN N
to TO N
guide VB N
the DT N
depth NN N
of IN N
sedation NN N
by IN N
BIS NNP N
monitoring NN N
( ( N
BIS NNP N
group NN N
; : N
n CC N
= VB N
40 CD N
) ) N
or CC N
conventional JJ N
monitoring NN N
( ( N
control JJ N
group NN N
; : N
n CC N
= VB N
41 CD N
) ) N
. . N

RESULTS VB N
The DT N
mean JJ N
durations NNS N
of IN N
the DT N
procedure NN N
were VBD N
18 CD N
and CC N
19 CD N
min NN N
in IN N
the DT N
BIS NNP N
and CC N
control NN N
groups NNS N
, , N
respectively RB N
. . N

No UH N
significant JJ N
difference NN N
was VBD N
noted VBN N
in IN N
the DT N
dosage NN N
of IN N
propofol NN N
used VBN N
between IN N
the DT N
BIS NNP N
and CC N
control NN N
groups NNS N
( ( N
168.7 CD N
vs. FW N
167.3 CD N
mg NN N
, , N
respectively RB N
) ) N
. . N

Average JJ N
sedation-related JJ N
oxygen NN N
saturation NN N
drop NN N
and CC N
transcutaneous JJ N
CO2 NNP N
rise NN N
were VBD N
not RB N
significantly RB N
different JJ N
between IN N
groups NNS N
. . N

There EX N
was VBD N
also RB N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
percentage NN N
of IN N
patients NNS N
that WDT N
required VBD N
either DT N
hemodynamic JJ N
support NN N
( ( N
5 CD N
vs. FW N
7.5 CD N
% NN N
, , N
respectively RB N
) ) N
, , N
oxygen JJ N
supplementation NN N
by IN N
100 CD N
% NN N
O2 NNP N
mask NN N
( ( N
67.5 CD N
vs. FW N
82.5 CD N
% NN N
, , N
respectively RB N
) ) N
or CC N
Ambu NNP N
face VBP N
mask JJ N
manual JJ N
ventilation NN N
( ( N
2.5 CD N
vs. FW N
5 CD N
% NN N
, , N
respectively RB N
) ) N
between IN N
the DT N
groups NNS N
. . N

No DT N
significant JJ N
difference NN N
was VBD N
noted VBN N
in IN N
terms NNS N
of IN N
patients NNS N
' POS N
awareness NN N
during IN N
the DT N
procedure NN N
, , N
which WDT N
was VBD N
assessed VBN N
following VBG N
recovery NN N
by IN N
a DT N
structured JJ N
Brice NNP N
interview NN N
. . N

CONCLUSION NNP N
Using VBG N
BIS NNP N
to TO N
guide VB N
the DT N
depth NN N
of IN N
sedation NN N
during IN N
propofol JJ N
sedation NN N
in IN N
patients NNS 4_p
undergoing VBG 4_p
FFB NNP 4_p
of IN 4_p
relatively RB 4_p
short JJ 4_p
duration NN 4_p
offers VBZ N
no DT N
clinically RB N
significant JJ N
advantages NNS N
over IN N
conventional JJ N
monitoring NN N
. . N

-DOCSTART- -X- O O 23747131

Concomitant NNP N
, , N
sequential JJ N
, , N
and CC N
hybrid JJ N
therapy NN N
for IN N
H. NNP N
pylori JJ N
eradication NN N
: : N
a DT N
pilot NN N
study NN N
. . N

BACKGROUND NNP N
AND NNP N
OBJECTIVE NNP N
Since IN N
the DT N
efficacy NN N
of IN N
the DT N
standard JJ N
triple NN N
therapies NNS N
for IN N
Helicobacter NNP N
pylori NN N
eradication NN N
has VBZ N
decreased VBN N
, , N
novel JJ N
antibiotic JJ N
regimens NNS N
have VBP N
been VBN N
introduced VBN N
, , N
including VBG N
concomitant NN N
, , N
sequential JJ N
, , N
and CC N
hybrid JJ N
therapies NNS N
. . N

We PRP N
aimed VBD N
to TO N
compare VB N
the DT N
cure NN N
rates NNS N
achieved VBN N
by IN N
these DT N
new JJ N
therapy NN N
regimens NNS N
. . N

METHODS NNP N
This DT N
was VBD N
a DT N
multicenter NN N
, , N
open-label JJ N
, , N
pilot NN N
study NN N
enrolling VBG N
consecutive JJ N
non-ulcer JJ 4_p
dyspepsia NN 4_p
patients NNS N
with IN N
H. NNP 4_p
pylori FW 4_p
infection NN 4_p
never RB N
previously RB N
treated VBN N
for IN N
the DT N
infection NN N
. . N

Patients NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
one CD N
of IN N
the DT N
following JJ N
treatments NNS N
: : N
( ( N
a DT N
) ) N
concomitant NN N
therapy NN N
: : N
omeprazole JJ N
20mg CD N
, , N
amoxicillin RB N
1g CD N
, , N
clarithromycin VBD N
500 CD N
mg NN N
, , N
and CC N
tinidazole JJ N
500 CD N
mg NN N
for IN N
5 CD N
days NNS N
; : N
( ( N
b NN N
) ) N
sequential JJ N
therapy NN N
: : N
omeprazole JJ N
20mg CD N
and CC N
amoxicillin $ N
1g CD N
for IN N
5 CD N
days NNS N
followed VBN N
by IN N
omeprazole JJ N
20mg CD N
, , N
clarithromycin VBD N
500 CD N
mg NN N
, , N
and CC N
tinidazole JJ N
500 CD N
mg NN N
for IN N
5 CD N
days NNS N
; : N
( ( N
c NN N
) ) N
hybrid JJ N
therapy NN N
: : N
omeprazole JJ N
20mg CD N
, , N
and CC N
amoxicillin VBZ N
1g CD N
for IN N
7 CD N
days NNS N
followed VBN N
by IN N
omeprazole JJ N
20mg CD N
, , N
amoxicillin RB N
1g CD N
, , N
clarithromycin VBD N
500 CD N
mg NN N
, , N
and CC N
tinidazole JJ N
500 CD N
mg NN N
, , N
for IN N
7 CD N
days NNS N
. . N

All DT N
drugs NNS N
were VBD N
administered VBN N
twice RB N
daily RB N
. . N

Bacterial JJ N
eradication NN N
was VBD N
checked VBN N
6 CD N
weeks NNS N
after IN N
treatment NN N
by IN N
using VBG N
a DT N
( ( N
13 CD N
) ) N
C-urea NNP N
breath NN N
test NN N
. . N

A DT N
10-day JJ N
, , N
second-line JJ N
therapy NN N
with IN N
omeprazole JJ N
20mg CD N
, , N
levofloxacin VBD N
250 CD N
mg NN N
, , N
and CC N
amoxicillin RB N
1g CD N
, , N
all DT N
given VBN N
twice RB N
daily RB N
, , N
was VBD N
offered VBN N
to TO N
the DT N
eradication NN N
failure NN N
patients NNS N
. . N

RESULTS NNP N
Overall NNP N
, , N
270 CD N
patients NNS N
were VBD N
enrolled VBN N
, , N
but CC N
13 CD N
patients NNS N
early RB N
interrupted VBN N
treatment NN N
due JJ N
to TO N
side VB N
effects NNS N
. . N

At IN N
intention-to-treat NN N
( ( N
ITT NNP N
) ) N
and CC N
per-protocol JJ N
analysis NN N
( ( N
PP NNP N
) ) N
, , N
the DT N
eradication NN N
rates NNS N
were VBD N
85.5 CD N
% NN N
and CC N
91.6 CD N
% NN N
with IN N
the DT N
concomitant JJ N
regimen NNS N
, , N
91.1 CD N
% NN N
and CC N
92.1 CD N
% NN N
with IN N
the DT N
sequential JJ N
therapy NN N
, , N
and CC N
80 CD N
% NN N
and CC N
85.7 CD N
% NN N
with IN N
the DT N
hybrid JJ N
regimen NNS N
. . N

Differences NNS N
were VBD N
not RB N
statistically RB N
significant JJ N
. . N

H. NNP N
pylori JJ N
infection NN N
was VBD N
cured VBN N
in IN N
10 CD N
( ( N
55.6 CD N
% NN N
) ) N
patients NNS N
with IN N
the DT N
second-line JJ N
regimen NNS N
. . N

CONCLUSION NN N
In IN N
our PRP$ N
study NN N
, , N
both DT N
concomitant NN N
and CC N
sequential JJ N
therapy NN N
, , N
but CC N
not RB N
hybrid JJ N
therapy NN N
, , N
reached VBN N
high JJ N
eradication NN N
rates NNS N
. . N

The DT N
success NN N
rate NN N
of IN N
second-line JJ N
levofloxacin-based JJ N
triple NN N
therapy NN N
is VBZ N
decreasing VBG N
. . N

-DOCSTART- -X- O O 16379508

Risperidone-induced JJ N
prolactin NN N
elevation NN N
in IN N
a DT N
prospective JJ N
study NN N
of IN N
children NNS N
, , N
adolescents NNS N
, , N
and CC N
adults NNS N
with IN N
mental JJ N
retardation NN N
and CC N
pervasive JJ N
developmental NN N
disorders NNS N
. . N

OBJECTIVE NNP N
Risperidone NNP N
is VBZ N
widely RB N
prescribed VBN N
for IN N
aggression NN N
and CC N
self-injury NN N
in IN N
children NNS N
, , N
adolescents NNS N
, , N
and CC N
adults NNS N
with IN N
mental JJ N
retardation NN N
( ( N
MR NNP N
) ) N
and CC N
pervasive JJ N
developmental NN N
disorders NNS N
( ( N
PDD NNP N
) ) N
. . N

Risperidone NNP N
elevates VBZ N
prolactin RB N
more JJR N
than IN N
other JJ N
atypical JJ N
antipsychotic JJ N
medications NNS N
. . N

Females NNS N
may MD N
show VB N
greater JJR N
prolactin NN N
elevation NN N
than IN N
males NNS N
. . N

METHOD NNP N
In IN N
this DT N
relatively RB N
long-term JJ N
study NN N
of IN N
risperidone NN N
efficacy NN N
and CC N
safety NN N
for IN N
aggression NN N
and CC N
self-injury NN N
in IN N
children NNS 4_p
, , 4_p
adolescents NNS 4_p
, , 4_p
and CC 4_p
adults NNS 4_p
with IN 4_p
MR NNP 4_p
and CC 4_p
PDDs NNP 4_p
, , N
serum NN N
prolactin NN N
was VBD N
measured VBN N
in IN N
a DT N
21-subject JJ 4_p
subset NN 4_p
during IN 4_p
the DT 4_p
course NN 4_p
of IN 4_p
a DT 4_p
double-blind JJ 4_p
, , 4_p
placebo-controlled JJ 4_p
trial NN 4_p
. . 4_p

Prolactin NNP N
was VBD N
measured VBN N
in IN N
ng/mL NN N
at IN N
baseline NN N
, , N
once RB N
during IN N
acute JJ N
treatment NN N
, , N
and CC N
once RB N
during IN N
maintenance NN N
. . N

RESULTS NNP N
In IN N
children NNS N
and CC N
adolescents NNS N
( ( N
n=10 NN N
) ) N
, , N
mean JJ N
age NN N
of IN N
12.5 CD N
years NNS N
, , N
prolactin NN N
increased VBD N
from IN N
mean JJ N
13.2+/-8.6 CD N
at IN N
baseline NN N
to TO N
31.0+/-11.6 JJ N
acutely RB N
and CC N
remained VBD N
elevated VBN N
at IN N
37.9+/-10.4 JJ N
in IN N
maintenance NN N
. . N

In IN N
adults NNS N
, , N
mean JJ N
age NN N
of IN N
35.3 CD N
years NNS N
, , N
prolactin NN N
increased VBD N
more JJR N
markedly RB N
from IN N
11.6+/-7.4 JJ N
baseline NN N
( ( N
n=11 JJ N
) ) N
to TO N
93.3+/-54.2 CD N
acutely RB N
but CC N
decreased VBD N
to TO N
67.8+/-62.9 JJ N
in IN N
maintenance NN N
( ( N
n=7 JJ N
) ) N
. . N

Prolactin NNP N
remained VBD N
significantly RB N
elevated VBN N
above IN N
normal JJ N
in IN N
all DT N
subjects NNS N
for IN N
at IN N
least JJS N
26 CD N
weeks NNS N
. . N

Mean NNP N
prolactin NN N
of IN N
adult NN N
females NNS N
, , N
while IN N
similar JJ N
to TO N
that DT N
of IN N
adult NN N
males NNS N
at IN N
baseline NN N
, , N
was VBD N
2.2 CD N
times NNS N
male JJ N
levels NNS N
acutely RB N
and CC N
3.7 CD N
times NNS N
greater JJR N
in IN N
maintenance NN N
. . N

CONCLUSION NN N
In IN N
this DT N
small JJ N
subset NN N
, , N
mean JJ N
prolactin NN N
elevation NN N
persisted VBD N
for IN N
at IN N
least JJS N
26 CD N
weeks NNS N
. . N

In IN N
adults NNS N
, , N
females NNS N
showed VBD N
significantly RB N
greater JJR N
elevations NNS N
than IN N
males NNS N
. . N

-DOCSTART- -X- O O 19106322

A DT N
randomized JJ N
breast-feeding JJ N
promotion NN N
intervention NN N
did VBD N
not RB N
reduce VB N
child NN N
obesity NN N
in IN N
Belarus NNP N
. . N

The DT N
evidence NN N
that IN N
breast-feeding JJ N
protects NNS N
against IN N
obesity NN N
is VBZ N
based VBN N
on IN N
observational JJ N
studies NNS N
, , N
with IN N
potential JJ N
for IN N
confounding VBG N
and CC N
selection NN N
bias NN N
. . N

This DT N
article NN N
summarizes VBZ N
a DT N
previously RB N
published VBN N
study NN N
in IN N
which WDT N
we PRP N
assessed VBD N
whether IN N
an DT N
intervention NN N
designed VBN N
to TO N
promote VB N
exclusive JJ N
and CC N
prolonged JJ N
breast-feeding NN N
affects VBZ N
children NNS N
's POS N
height NN N
, , N
weight NN N
, , N
adiposity NN N
, , N
and CC N
blood NN N
pressure NN N
( ( N
BP NNP N
) ) N
at IN N
age NN N
6.5 CD N
y NN N
. . N

The DT N
Promotion NN N
of IN N
Breastfeeding NNP N
Intervention NNP N
Trial NNP N
( ( N
PROBIT NNP N
) ) N
is VBZ N
a DT N
cluster-randomized JJ N
trial NN N
of IN N
a DT N
breast-feeding JJ N
promotion NN N
intervention NN N
based VBN N
on IN N
the DT N
WHO/UNICEF NNP N
Baby-Friendly NNP N
Hospital NNP N
Initiative NNP N
. . N

A NNP N
total NN N
of IN N
17,046 CD N
healthy JJ N
breast-fed JJ N
infants NNS N
were VBD N
enrolled VBN N
from IN N
31 CD N
Belarussian JJ N
maternity NN N
hospitals NNS N
and CC N
affiliated JJ N
clinics NNS N
, , N
of IN N
whom WP N
13,889 CD N
( ( N
81.5 CD N
% NN N
) ) N
were VBD N
followed VBN N
up RP N
at IN N
6.5 CD N
y NN N
with IN N
duplicate JJ N
measurements NNS N
of IN N
height NN N
, , N
weight NN N
, , N
waist JJ N
circumference NN N
, , N
triceps NNS N
and CC N
subscapular JJ N
skinfold NN N
thicknesses NNS N
, , N
systolic JJ N
and CC N
diastolic JJ N
BP NNP N
. . N

Analysis NN N
was VBD N
based VBN N
on IN N
intention NN N
to TO N
treat VB N
, , N
with IN N
statistical JJ N
adjustment NN N
for IN N
clustering VBG N
within IN N
hospitals/clinics NNS N
to TO N
permit VB N
inferences NNS N
at IN N
the DT N
individual JJ N
level NN N
. . N

The DT N
experimental JJ N
intervention NN N
led VBD N
to TO N
a DT N
large JJ N
increase NN N
in IN N
exclusive JJ N
breast-feeding NN N
at IN N
3 CD N
mo NN N
( ( N
43.3 CD N
% NN N
vs. FW N
6.4 CD N
% NN N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
a DT N
significantly RB N
higher JJR N
prevalence NN N
of IN N
any DT N
breast-feeding JJ N
throughout IN N
infancy NN N
. . N

No DT N
significant JJ N
intervention NN N
effects NNS N
were VBD N
observed VBN N
on IN N
height NN N
, , N
BMI NNP N
, , N
adiposity NN N
measures NNS N
, , N
or CC N
BP NNP N
. . N

The DT N
breast-feeding JJ N
promotion NN N
intervention NN N
resulted VBD N
in IN N
substantial JJ N
increases NNS N
in IN N
the DT N
duration NN N
and CC N
exclusivity NN N
of IN N
breast-feeding JJ N
yet RB N
did VBD N
not RB N
reduce VB N
measures NNS N
of IN N
adiposity NN N
at IN N
age NN N
6.5 CD N
y NN N
. . N

Previous JJ N
reports NNS N
of IN N
protective JJ N
effects NNS N
against IN N
obesity NN N
may MD N
reflect VB N
uncontrolled JJ N
bias NN N
caused VBN N
by IN N
confounding VBG N
and CC N
selection NN N
. . N

-DOCSTART- -X- O O 21266651

Factors NNS N
predictive VBP N
of IN N
severe JJ N
hypoglycemia NN N
in IN N
type NN N
1 CD N
diabetes NNS N
: : N
analysis NN N
from IN N
the DT N
Juvenile NNP N
Diabetes NNP N
Research NNP N
Foundation NNP N
continuous JJ N
glucose JJ N
monitoring VBG N
randomized VBN N
control NN N
trial NN N
dataset NN N
. . N

OBJECTIVE NNP N
Identify NNP N
factors NNS N
predictive VBP N
of IN N
severe JJ N
hypoglycemia NN N
( ( N
SH NNP N
) ) N
and CC N
assess VB N
the DT N
clinical JJ N
utility NN N
of IN N
continuous JJ N
glucose JJ N
monitoring NN N
( ( N
CGM NNP N
) ) N
to TO N
warn VB N
of IN N
impending VBG N
SH NNP N
. . N

RESEARCH NNP N
DESIGN NNP N
AND NNP N
METHODS NNP N
In IN N
a DT N
multicenter NN N
randomized VBN N
clinical JJ N
trial NN N
, , N
436 CD N
children NNS N
and CC N
adults NNS N
with IN N
type JJ N
1 CD N
diabetes NNS N
were VBD N
randomized VBN N
to TO N
a DT N
treatment NN N
group NN N
that WDT N
used VBD N
CGM NNP N
( ( N
N NNP N
= NNP N
224 CD N
) ) N
, , N
or CC N
a DT N
control NN N
group NN N
that WDT N
used VBD N
standard JJ N
home NN N
blood NN N
glucose JJ N
monitoring NN N
( ( N
N NNP N
= NNP N
212 CD N
) ) N
and CC N
completed VBD N
12 CD N
months NNS N
of IN N
follow-up NN N
. . N

After IN N
6 CD N
months NNS N
, , N
the DT N
original JJ N
control NN N
group NN N
initiated VBD N
CGM NNP N
while IN N
the DT N
treatment NN N
group NN N
continued VBD N
use NN N
of IN N
CGM NNP N
for IN N
6 CD N
months NNS N
. . N

Baseline NNP N
risk NN N
factors NNS N
for IN N
SH NNP N
were VBD N
evaluated VBN N
over IN N
12 CD N
months NNS N
of IN N
follow-up JJ N
using VBG N
proportional JJ N
hazards NNS N
regression NN N
. . N

CGM-derived JJ N
indices NNS N
of IN N
hypoglycemia NN N
were VBD N
used VBN N
to TO N
predict VB N
episodes NNS N
of IN N
SH NNP N
over IN N
a DT N
24-h JJ N
time NN N
horizon NN N
. . N

RESULTS VB N
The DT N
SH NNP N
rate NN N
was VBD N
17.9 CD N
per IN N
100 CD N
person-years NNS N
, , N
and CC N
a DT N
higher JJR N
rate NN N
was VBD N
associated VBN N
with IN N
the DT N
occurrence NN N
of IN N
SH NNP N
in IN N
the DT N
prior JJ N
6 CD N
months NNS N
and CC N
female JJ N
sex NN N
. . N

SH NNP N
frequency NN N
increased VBD N
eightfold RB N
when WRB N
30 CD N
% NN N
of IN N
CGM NNP N
values NNS N
were VBD N
≤ JJ N
70 CD N
mg/dL NN N
on IN N
the DT N
prior JJ N
day NN N
( ( N
4.5 CD N
vs. FW N
0.5 CD N
% NN N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
but CC N
the DT N
positive JJ N
predictive JJ N
value NN N
( ( N
PPV NNP N
) ) N
was VBD N
low JJ N
( ( N
< JJ N
5 CD N
% NN N
) ) N
. . N

Results NNS N
were VBD N
similar JJ N
for IN N
hypoglycemic JJ N
area NN N
under IN N
the DT N
curve NN N
and CC N
the DT N
low JJ N
blood NN N
glucose NN N
index NN N
calculated VBN N
by IN N
CGM NNP N
. . N

CONCLUSIONS NNP N
SH NNP N
in IN N
the DT N
6 CD N
months NNS N
prior RB N
to TO N
the DT N
study NN N
was VBD N
the DT N
strongest JJS N
predictor NN N
of IN N
SH NNP N
during IN N
the DT N
study NN N
. . N

CGM-measured JJ N
hypoglycemia NN N
over IN N
a DT N
24-h JJ N
span NN N
is VBZ N
highly RB N
associated VBN N
with IN N
SH NNP N
the DT N
following JJ N
day NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
but CC N
the DT N
PPV NNP N
is VBZ N
low JJ N
. . N

-DOCSTART- -X- O O 19309326

Cognitive JJ N
behavioral JJ N
therapy NN N
for IN N
anxiety NN 4_p
in IN 4_p
children NNS 4_p
with IN 4_p
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
: : 4_p
a DT N
randomized NN N
, , N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
Children NNP 4_p
with IN 4_p
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
often RB N
present JJ N
with IN N
comorbid NN N
anxiety NN N
disorders NNS N
that WDT N
cause VBP N
significant JJ N
functional JJ N
impairment NN N
. . N

This DT N
study NN N
tested VBD N
a DT N
modular JJ N
cognitive JJ N
behavioral JJ N
therapy NN N
( ( N
CBT NNP N
) ) N
program NN N
for IN N
children NNS N
with IN N
this DT N
profile NN N
. . N

A DT N
standard JJ N
CBT NNP N
program NN N
was VBD N
augmented VBN N
with IN N
multiple JJ N
treatment NN N
components NNS N
designed VBN N
to TO N
accommodate VB N
or CC N
remediate VB N
the DT N
social JJ N
and CC N
adaptive JJ N
skill NN N
deficits NNS N
of IN N
children NNS 4_p
with IN 4_p
ASD NNP 4_p
that WDT N
could MD N
pose VB N
barriers NNS N
to TO N
anxiety VB N
reduction NN N
. . N

METHOD NNP N
Forty NNP N
children NNS N
( ( N
7-11 CD N
years NNS N
old JJ N
) ) N
were VBD N
randomly RB N
assigned VBN N
to TO N
16 CD N
sessions NNS N
of IN N
CBT NNP N
or CC N
a DT N
3-month JJ N
waitlist NN N
( ( N
36 CD N
completed VBN N
treatment NN N
or CC N
waitlist NN N
) ) N
. . N

Therapists NNS N
worked VBD N
with IN N
individual JJ N
families NNS N
. . N

The DT N
CBT NNP N
model NN N
emphasized VBD N
behavioral JJ N
experimentation NN N
, , N
parent-training NN N
, , N
and CC N
school NN N
consultation NN N
. . N

Independent JJ N
evaluators NNS N
blind VBP N
to TO N
treatment NN N
condition NN N
conducted VBN N
structured JJ N
diagnostic JJ N
interviews NNS N
and CC N
parents NNS N
and CC N
children NNS N
completed VBN N
anxiety NN N
symptom NN N
checklists NNS N
at IN N
baseline NN N
and CC N
posttreatment/postwaitlist NN N
. . N

RESULTS NNP N
In IN N
intent-to-treat JJ N
analyses NNS N
, , N
78.5 CD N
% NN N
of IN N
the DT N
CBT NNP N
group NN N
met VBD N
Clinical JJ N
Global NNP N
Impressions-Improvement NNP N
scale NN N
criteria NNS N
for IN N
positive JJ N
treatment NN N
response NN N
at IN N
posttreatment NN N
, , N
as IN N
compared VBN N
to TO N
only RB N
8.7 CD N
% NN N
of IN N
the DT N
waitlist NN N
group NN N
. . N

CBT NNP N
also RB N
outperformed VBD N
the DT N
waitlist NN N
on IN N
diagnostic JJ N
outcomes NNS N
and CC N
parent NN N
reports NNS N
of IN N
child NN N
anxiety NN N
, , N
but CC N
not RB N
children NNS N
's POS N
self-reports NNS N
. . N

Treatment NN N
gains NNS N
were VBD N
maintained VBN N
at IN N
3-month JJ N
follow-up NN N
. . N

CONCLUSIONS VB N
The DT N
CBT NNP N
manual JJ N
employed VBN N
in IN N
this DT N
study NN N
is VBZ N
one CD N
of IN N
the DT N
first JJ N
adaptations NNS N
of IN N
an DT N
evidence-based JJ N
treatment NN N
for IN N
children NNS N
with IN N
autism NN N
spectrum NN N
disorders NNS N
. . N

Remission NN N
of IN N
anxiety NN N
disorders NNS N
appears VBZ N
to TO N
be VB N
an DT N
achievable JJ N
goal NN N
among IN N
high-functioning JJ N
children NNS N
with IN N
autism NN N
. . N

-DOCSTART- -X- O O 8892490

The DT N
evolving VBG N
clinical JJ N
status NN N
of IN N
patients NNS N
after IN N
a DT N
myocardial JJ N
infarction NN N
: : N
the DT N
importance NN N
of IN N
post-hospital JJ N
data NNS N
for IN N
mortality NN N
prediction NN N
. . N

Studies NNPS N
predicting VBG N
mortality NN N
after IN N
myocardial JJ 4_p
infarction NN 4_p
( ( 4_p
MI NNP 4_p
) ) N
usually RB N
rely VBP N
on IN N
in-hospital JJ N
data NNS N
, , N
and CC N
combine NN N
patients NNS 4_p
admitted VBN 4_p
for IN 4_p
the DT 4_p
first JJ 4_p
MI NNP 4_p
with IN 4_p
recurrent JJ 4_p
MI NNP 4_p
patients NNS 4_p
. . N

Since IN N
treatment NN N
decisions NNS N
are VBP N
often RB N
made VBN N
or CC N
modified VBN N
at IN N
the DT N
first JJ N
outpatient NN N
clinic JJ N
visit NN N
, , N
this DT N
study NN N
was VBD N
designed VBN N
to TO N
evaluate VB N
the DT N
importance NN N
of IN N
post-hospital JJ N
data NNS N
on IN N
mortality NN N
prediction NN N
after IN N
a DT N
first JJ N
myocardial JJ N
infarction NN N
( ( N
MI NNP N
) ) N
. . N

An DT N
inception NN N
cohort NN N
of IN N
patients NNS 4_p
enrolled VBN 4_p
in IN 4_p
the DT 4_p
Beta-Blocker NNP 4_p
in IN 4_p
Heart NNP 4_p
Attack NNP 4_p
Trial NNP 4_p
( ( N
n JJ N
= NN N
2830 CD N
) ) N
was VBD N
included VBN N
. . N

Forty-three JJ N
variables NNS N
( ( N
including VBG N
in-hospital JJ N
and CC N
post-hospital JJ N
data NNS N
) ) N
were VBD N
evaluated VBN N
using VBG N
stepwise NN N
logistic JJ N
regression NN N
. . N

Ten CD N
variables NNS N
were VBD N
independently RB N
associated VBN N
with IN N
1-year JJ N
mortality NN N
: : N
five CD N
used VBN N
in-hospital JJ N
data NNS N
( ( N
history NN N
of IN N
hypertension NN N
, , N
hypercholesterolemia NN N
, , N
congestive JJ N
heart NN N
failure NN N
[ NNP N
CHF NNP N
] NNP N
, , N
ventricular JJ N
tachycardia NN N
, , N
and CC N
age NN N
) ) N
; : N
and CC N
five CD N
variables NNS N
depended VBN N
on IN N
post-hospital JJ N
data NNS N
collected VBN N
at IN N
the DT N
first JJ N
outpatient JJ N
visit NN N
( ( N
CHF NNP N
after IN N
discharge NN N
, , N
New NNP N
York NNP N
Heart NNP N
Association NNP N
functional JJ N
class NN N
, , N
heart NN N
rate NN N
, , N
pulmonary JJ N
rates NNS N
, , N
and CC N
smoking NN N
) ) N
. . N

Two CD N
predictive JJ N
systems NNS N
were VBD N
developed VBN N
that IN N
partitioned JJ N
patients NNS N
into IN N
one CD N
of IN N
four CD N
classes NNS N
with IN N
distinct JJ N
mortality NN N
risks NNS N
: : N
a DT N
composite JJ N
system NN N
using VBG N
the DT N
10 CD N
in- JJ N
and CC N
post-hospital JJ N
variables NNS N
, , N
and CC N
a DT N
system NN N
using VBG N
only RB N
the DT N
5 CD N
in-hospital JJ N
variables NNS N
. . N

Mortality NNP N
risk NN N
for IN N
the DT N
composite JJ N
system NN N
classes NNS N
ranged VBD N
from IN N
0.6 CD N
to TO N
20.0 CD N
% NN N
( ( N
I PRP N
[ VBP N
n JJ N
= $ N
861 CD N
] NNP N
, , N
0.6 CD N
% NN N
; : N
II NNP N
[ NNP N
n RB N
= VBZ N
1151 CD N
] NN N
, , N
2.3 CD N
% NN N
; : N
III NNP N
[ NNP N
n MD N
=698 VB N
] NNP N
, , N
4.3 CD N
% NN N
; : N
IV NNP N
[ NNP N
n VBD N
= $ N
120 CD N
] NNP N
, , N
20.0 CD N
% NN N
) ) N
. . N

In IN N
contrast NN N
, , N
the DT N
range NN N
of IN N
mortality NN N
risk NN N
using VBG N
the DT N
in-hospital JJ N
data NNS N
only RB N
system NN N
was VBD N
less JJR N
( ( N
1 CD N
to TO N
8.3 CD N
% NN N
) ) N
. . N

Most JJS N
importantly RB N
, , N
a DT N
distinct JJ N
gradient NN N
within IN N
each DT N
class NN N
of IN N
the DT N
in-hospital JJ N
data NNS N
only RB N
system NN N
was VBD N
created VBN N
by IN N
the DT N
addition NN N
of IN N
the DT N
post-hospital JJ N
data NN N
. . N

This DT N
study NN N
demonstrates VBZ N
that IN N
risk NN N
stratification NN N
after IN N
an DT N
acute NN N
first RB N
MI NNP N
is VBZ N
improved VBN N
by IN N
the DT N
addition NN N
of IN N
post-hospital JJ N
data NNS N
. . N

-DOCSTART- -X- O O 14716650

Transcutaneous JJ N
electrical JJ N
nerve NN N
stimulation NN N
for IN N
postoperative JJ 4_p
pain NN 4_p
relief NN N
after IN N
total JJ 4_p
knee NN 4_p
arthroplasty NN 4_p
. . N

Transcutaneous JJ N
electrical JJ N
nerve NN N
stimulation NN N
( ( N
TENS NNP N
) ) N
has VBZ N
been VBN N
used VBN N
to TO N
treat VB N
chronic JJ N
pain NN N
syndromes NNS N
and CC N
has VBZ N
been VBN N
reported VBN N
to TO N
be VB N
of IN N
some DT N
utility NN N
in IN N
the DT N
treatment NN N
of IN N
postsurgical JJ N
pain NN N
. . N

A DT N
randomized JJ N
, , N
blinded VBD N
, , N
placebo-controlled JJ N
trial NN N
was VBD N
designed VBN N
to TO N
evaluate VB N
the DT N
utility NN N
of IN N
TENS NNP N
after IN N
total JJ 4_p
knee NN 4_p
arthroplasty NN 4_p
. . N

Patients NNS N
were VBD N
randomly RB N
enrolled VBN N
into IN N
patient-controlled JJ N
anesthesia NN N
( ( N
PCA NNP N
) ) N
alone RB N
, , N
PCA NNP N
plus CC N
TENS NNP N
, , N
or CC N
PCA NNP N
plus CC N
sham JJ N
TENS NNP N
. . N

The DT N
cumulative JJ N
dose NN N
of IN N
morphine NN N
by IN N
PCA NNP N
for IN N
each DT N
group NN N
was VBD N
used VBN N
as IN N
the DT N
end-point NN N
of IN N
the DT N
study NN N
. . N

There EX N
was VBD N
no DT N
significant JJ N
reduction NN N
in IN N
the DT N
requirement NN N
for IN N
patient-controlled JJ N
analgesia NN N
with IN N
or CC N
without IN N
TENS NNP N
. . N

We PRP N
conclude VBP N
that IN N
there EX N
is VBZ N
no DT N
utility NN N
for IN N
TENS NNP N
in IN N
the DT N
postoperative JJ N
management NN N
of IN N
pain NN N
after IN N
knee NN N
arthroplasty NN N
. . N

-DOCSTART- -X- O O 8245359

Femoral NNP N
vein NN N
delivery NN N
of IN N
contrast NN N
medium NN N
enhances VBZ N
transthoracic JJ N
echocardiographic JJ N
detection NN N
of IN N
patent NN N
foramen NNS N
ovale VBP N
. . N

OBJECTIVES IN N
We PRP N
postulated VBD N
that IN N
femoral JJ N
vein JJ N
delivery NN N
of IN N
contrast NN N
medium NN N
because IN N
of IN N
streaming NN N
, , N
might MD N
enhance VB N
precordial JJ N
echocardiographic JJ N
detection NN N
of IN N
patent NN N
foramen NNS N
ovale VBP N
. . N

BACKGROUND NNP N
Although IN N
precordial JJ N
contrast NN N
echocardiography NN N
is VBZ N
widely RB N
used VBN N
to TO N
diagnose VB N
patent JJ N
foramen NNS N
ovale RB N
, , N
this DT N
method NN N
is VBZ N
limited VBN N
by IN N
poor JJ N
sensitivity NN N
. . N

Previous JJ N
investigators NNS N
have VBP N
demonstrated VBN N
enhanced JJ N
detection NN N
of IN N
atrial JJ N
defects NNS N
by IN N
the DT N
dye-dilution NN N
technique NN N
after IN N
delivery NN N
of IN N
contrast NN N
medium NN N
into IN N
the DT N
inferior NN N
rather RB N
than IN N
the DT N
superior JJ N
vena NN N
cava NN N
. . N

METHODS NNP N
Transthoracic NNP N
contrast NN N
examinations NNS N
were VBD N
performed VBN N
in IN N
a DT N
randomly RB N
selected VBN N
group NN N
of IN N
70 CD N
patients NNS N
( ( N
without IN N
previous JJ N
history NN N
of IN N
cerebral JJ N
or CC N
systemic JJ N
embolus NN N
) ) N
undergoing VBG N
cardiac JJ N
catheterization NN N
. . N

Paired VBN N
contrast NN N
agent NN N
injections NNS N
( ( N
10 CD N
ml NN N
dextrose NN N
in IN N
water/0.25 NN N
ml NNP N
air NN N
) ) N
were VBD N
administered VBN N
from IN N
an DT N
upper JJ N
extremity NN N
vein NN N
and CC N
femoral JJ N
vein NN N
in IN N
each DT N
patient NN N
during IN N
spontaneous JJ N
respiration NN N
, , N
cough NN N
and CC N
Valsalva NNP N
maneuvers NNS N
. . N

Studies NNS N
were VBD N
interpreted VBN N
by IN N
an DT N
experienced JJ N
echocardiographer NN N
unaware NN N
of IN N
the DT N
sequence NN N
and CC N
site NN N
of IN N
injections NNS N
. . N

Positive JJ N
studies NNS N
were VBD N
semiquantitatively RB N
graded VBN N
from IN N
+1 NNP N
( ( N
minimal JJ N
left VBD N
ventricular JJ N
opacification NN N
) ) N
to TO N
+4 VB N
( ( N
intense JJ N
left VBD N
ventricular JJ N
opacification NN N
) ) N
. . N

Catheterization NN N
and CC N
echocardiographic JJ N
assessment NN N
of IN N
patent NN N
foramen NNS N
ovale VBP N
were VBD N
compared VBN N
in IN N
21 CD N
subjects NNS N
. . N

RESULTS NNP N
Patent NNP N
foramen NNS N
ovale NN N
was VBD N
detected VBN N
significantly RB N
more RBR N
often RB N
during IN N
femoral JJ N
vein NNS N
versus VBP N
upper JJ N
extremity NN N
contrast NN N
delivery NN N
( ( N
23 CD N
of IN N
70 CD N
patients NNS N
[ JJ N
prevalence RB N
33 CD N
% NN N
] NNP N
vs. IN N
9 CD N
of IN N
70 CD N
patients NNS N
[ JJ N
prevalence RB N
13 CD N
% NN N
] NN N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
. . N

The DT N
intensity NN N
of IN N
left JJ N
ventricular JJ N
opacification NN N
was VBD N
also RB N
greater JJR N
during IN N
femoral JJ N
vein NNS N
contrast NN N
injection NN N
. . N

Precordial JJ N
echocardiography NN N
combined VBN N
with IN N
femoral JJ N
contrast NN N
delivery NN N
was VBD N
significantly RB N
more RBR N
sensitive JJ N
than IN N
cardiac JJ N
catheterization NN N
for IN N
assessment NN N
of IN N
patent NN N
foramen NNS N
ovale VBP N
( ( N
8 CD N
of IN N
21 CD N
patients NNS N
vs. FW N
2 CD N
of IN N
21 CD N
patients NNS N
, , N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSIONS NNP N
Femoral NNP N
vein NNP N
contrast NN N
delivery NN N
significantly RB N
enhances VBZ N
the DT N
ability NN N
of IN N
precordial JJ N
contrast NN N
echocardiography NN N
to TO N
diagnose VB N
patent JJ N
foramen NNS N
ovale VBP N
. . N

Physiologic NNP N
patency NN N
of IN N
the DT N
foramen NNS N
ovale VBP N
is VBZ N
more RBR N
common JJ N
( ( N
prevalence JJ N
33 CD N
% NN N
) ) N
than IN N
previously RB N
documented VBN N
. . N

-DOCSTART- -X- O O 3304622

Dexamethasone NNP N
therapy NN N
and CC N
cortisol JJ N
excretion NN N
in IN N
severe JJ N
pediatric JJ N
head NN N
injury NN N
. . N

Glucocorticoids NNS N
are VBP N
used VBN N
in IN N
an DT N
attempt NN N
to TO N
reduce VB N
brain NN N
edema NN N
secondary JJ N
to TO N
head VB N
injury NN N
. . N

Nevertheless RB N
, , N
their PRP$ N
usefulness JJ N
remains NNS N
uncertain JJ N
and CC N
contradictory NN N
. . N

In IN N
a DT N
randomized JJ N
study NN N
of IN N
24 CD N
children NNS N
with IN N
severe JJ N
head NN N
injury NN N
, , N
urinary JJ N
free JJ N
cortisol NN N
was VBD N
measured VBN N
by IN N
radioimmunoassay NN N
. . N

Twelve CD N
patients NNS N
( ( N
group NN N
1 CD N
) ) N
received VBD N
dexamethasone NN N
and CC N
12 CD N
( ( N
group NN N
2 CD N
) ) N
did VBD N
not RB N
. . N

All DT N
patients NNS N
were VBD N
treated VBN N
with IN N
a DT N
standardized JJ N
regimen NN N
. . N

In IN N
group NN N
1 CD N
there EX N
was VBD N
complete JJ N
suppression NN N
of IN N
endogenous JJ N
cortisol NN N
production NN N
. . N

In IN N
group NN N
2 CD N
free JJ N
cortisol NN N
was VBD N
up RB N
to TO N
20-fold CD N
higher JJR N
than IN N
under IN N
basal JJ N
conditions NNS N
and CC N
reached VBN N
maximum JJ N
values NNS N
on IN N
days NNS N
1-3 RB N
. . N

Since IN N
the DT N
excretion NN N
of IN N
cortisol NN N
in IN N
urine JJ N
reflects VBZ N
the DT N
production NN N
rate NN N
closely RB N
and CC N
is VBZ N
not RB N
influenced VBN N
by IN N
liver NN N
function NN N
and CC N
barbiturates NNS N
, , N
the DT N
results NNS N
in IN N
group NN N
2 CD N
show NN N
that IN N
the DT N
endogenous JJ N
production NN N
of IN N
steroids NNS N
is VBZ N
an DT N
adequate JJ N
reaction NN N
to TO N
severe VB N
head JJ N
injury NN N
. . N

Exogenous JJ N
glucocorticoids NNS N
are VBP N
thus RB N
unlikely JJ N
to TO N
have VB N
any DT N
more JJR N
beneficial JJ N
effects NNS N
than IN N
endogenous JJ N
cortisol NN N
. . N

-DOCSTART- -X- O O 9430799

A DT N
carbohydrate NN N
meal NN N
attenuates VBZ N
the DT N
forearm NN N
vasoconstrictor NN N
response NN N
to TO N
lower VB N
body NN N
subatmospheric JJ N
pressure NN N
in IN N
healthy JJ N
young JJ N
adults NNS N
. . N

The DT N
cardiovascular NN N
( ( N
CV NNP N
) ) N
responses VBZ N
to TO N
meal VB N
ingestion NN N
and CC N
orthostasis NN N
are VBP N
well RB N
established VBN N
. . N

The DT N
effect NN N
of IN N
meal NN N
ingestion NN N
and CC N
meal JJ N
composition NN N
on IN N
the DT N
CV NNP N
responses NNS N
to TO N
orthostasis NNS N
are VBP N
unknown JJ N
. . N

The DT N
effect NN N
of IN N
high JJ N
carbohydrate NN N
( ( N
HC NNP N
) ) N
and CC N
high JJ N
fat NN N
( ( N
HF NNP N
) ) N
meal NN N
ingestion NN N
on IN N
the DT N
CV NNP N
responses NNS N
to TO N
simulated VBN N
orthostatic JJ N
stress NN N
( ( N
using VBG N
graded VBN N
lower JJR N
body NN N
subatmospheric JJ N
pressure NN N
( ( N
LBSP NNP N
) ) N
) ) N
was VBD N
assessed VBN N
in IN N
nine CD N
healthy JJ N
young JJ N
volunteers NNS N
. . N

Cardiac NNP N
output NN N
( ( N
CO NNP N
) ) N
, , N
forearm JJ N
blood NN N
flow NN N
( ( N
FABF NNP N
) ) N
heart NN N
rate NN N
( ( N
HR NNP N
) ) N
and CC N
blood NN N
pressure NN N
( ( N
BP NNP N
) ) N
were VBD N
measured VBN N
before IN N
and CC N
during IN N
LBSP NNP N
while IN N
fasted VBN N
and CC N
after IN N
eating VBG N
HC NNP N
and CC N
HF NNP N
meals NNS N
. . N

Ingestion NN N
of IN N
both DT N
meals NNS N
led VBD N
to TO N
an DT N
increase NN N
in IN N
CO NNP N
and CC N
HR NNP N
. . N

Both DT N
meals NNS N
resulted VBD N
in IN N
a DT N
fall NN N
in IN N
total JJ N
peripheral JJ N
resistance NN N
but CC N
only RB N
HC NNP N
led VBD N
to TO N
a DT N
significant JJ N
fall NN N
in IN N
BP NNP N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

HF NNP N
had VBD N
no DT N
effect NN N
on IN N
the DT N
CV NNP N
responses NNS N
to TO N
LBSP NNP N
, , N
whereas IN N
HC NNP N
resulted VBD N
in IN N
attenuated JJ N
FABF NNP N
and CC N
forearm JJ N
vascular NN N
resistance NN N
responses NNS N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

Thus RB N
, , N
ingestion NN N
of IN N
an DT N
HC NNP N
meal NN N
significantly RB N
attenuates VBZ N
the DT N
forearm NN N
vascular NN N
response NN N
to TO N
orthostatic JJ N
stress NN N
and CC N
the DT N
hypotensive JJ N
effect NN N
of IN N
orthostasis NN N
is VBZ N
additive JJ N
to TO N
that DT N
occurring VBG N
after IN N
an DT N
HC NNP N
meal NN N
. . N

-DOCSTART- -X- O O 10410152

[ JJ N
Efficacy NNP N
of IN N
combination NN N
with IN N
granisetron NN N
and CC N
methylprednisolone NN N
for IN N
nausea NN 4_p
, , 4_p
vomiting VBG 4_p
and CC 4_p
appetite JJ 4_p
loss NN 4_p
in IN 4_p
remission NN 4_p
induction NN 4_p
chemotherapy NN 4_p
of IN 4_p
acute JJ 4_p
myeloid NN 4_p
leukemia NN 4_p
-- : 4_p
a DT 4_p
randomized JJ N
comparative JJ N
trial NN N
between IN N
granisetron NN N
alone RB N
and CC N
granisetron JJ N
plus CC N
methylprednisolone JJ N
] NN N
. . N

The DT N
prevention NN N
of IN N
nausea NN N
, , N
vomiting VBG N
and CC N
appetite JJ N
loss NN N
induced VBN N
by IN N
remission NN N
induction NN N
chemotherapy NN N
for IN N
acute JJ 4_p
myeloid NN 4_p
leukemia NN 4_p
was VBD N
compared VBN N
by IN N
randomization NN N
between IN N
granisetron NN N
alone RB N
and CC N
combination NN N
with IN N
granisetron NN N
plus CC N
methylprednisolone NN N
. . N

Granisetron NNP N
was VBD N
administered VBN N
at IN N
40 CD N
micrograms/kg NN N
during IN N
chemotherapy NN N
, , N
and CC N
methylprednisolone NN N
was VBD N
administered VBN N
concomitantly RB N
at IN N
125 CD N
mg/body NN N
for IN N
3 CD N
days NNS N
or CC N
more JJR N
in IN N
the DT N
combination NN N
group NN N
. . N

The DT N
single JJ N
and CC N
combination NN N
groups NNS N
comprised VBD N
14 CD N
and CC N
13 CD N
patients NNS N
, , N
respectively RB N
, , N
and CC N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
background NN N
of IN N
both DT N
groups NNS N
. . N

To TO N
evaluate VB N
the DT N
effect NN N
they PRP N
were VBD N
scored VBN N
according VBG N
to TO N
4 CD N
grades NNS N
, , N
and CC N
evaluated VBD N
every DT N
24 CD N
hours NNS N
from IN N
the DT N
start NN N
of IN N
chemotherapy NN N
to TO N
5 CD N
days NNS N
after IN N
its PRP$ N
completion NN N
. . N

The DT N
complete JJ N
inhibition NN N
rate NN N
of IN N
vomiting VBG N
was VBD N
as RB N
high JJ N
as IN N
71.4 CD N
% NN N
and CC N
92.3 CD N
% NN N
in IN N
the DT N
single JJ N
and CC N
combination NN N
groups NNS N
, , N
respectively RB N
, , N
showing VBG N
no DT N
significant JJ N
difference NN N
. . N

The DT N
grade NN N
of IN N
vomiting VBG N
was VBD N
mild VBN N
in IN N
both DT N
groups NNS N
. . N

Nausea NN N
was VBD N
noted VBN N
in IN N
71.4 CD N
% NN N
and CC N
46.2 CD N
% NN N
, , N
respectively RB N
, , N
and CC N
the DT N
inhibitory JJ N
effect NN N
tended VBD N
to TO N
be VB N
higher JJR N
in IN N
the DT N
combination NN N
group NN N
. . N

Appetite NNP N
loss NN N
developed VBD N
in IN N
92.9 CD N
% NN N
and CC N
41.7 CD N
% NN N
, , N
respectively RB N
, , N
and CC N
the DT N
prevention NN N
effect NN N
was VBD N
clearly RB N
higher JJR N
in IN N
the DT N
combination NN N
group NN N
. . N

The DT N
prevention NN N
effects NNS N
on IN N
nausea NN N
7 CD N
, , N
8 CD N
and CC N
10 CD N
days NNS N
after IN N
the DT N
start NN N
of IN N
chemotherapy NN N
, , N
on IN N
appetite JJ N
loss NN N
2-10 JJ N
days NNS N
after IN N
it PRP N
, , N
and CC N
2-5 JJ N
days NNS N
after IN N
its PRP$ N
completion NN N
, , N
were VBD N
higher JJR N
in IN N
the DT N
combination NN N
group NN N
. . N

Granisetron NNP N
revealed VBD N
an DT N
excellent JJ N
inhibitory NN N
effect NN N
on IN N
vomiting VBG N
induced VBN N
by IN N
remission NN N
induction NN N
chemotherapy NN N
for IN N
acute JJ N
myeloid NN N
leukemia NN N
, , N
but CC N
combination NN N
with IN N
granisetron NN N
and CC N
methylprednisolone NN N
was VBD N
considered VBN N
useful JJ N
for IN N
nausea NN N
in IN N
the DT N
latter JJ N
half NN N
of IN N
the DT N
treatment NN N
period NN N
and CC N
for IN N
appetite JJ N
loss NN N
during IN N
the DT N
whole JJ N
period NN N
. . N

-DOCSTART- -X- O O 7810153

The DT N
effect NN N
of IN N
cisapride NN N
on IN N
delayed JJ N
colonic JJ N
transit NN N
time NN N
in IN N
patients NNS N
with IN N
idiopathic JJ 4_p
Parkinson NNP 4_p
's POS 4_p
disease NN 4_p
. . N

Disorders NNS 4_p
of IN 4_p
autonomic JJ 4_p
regulation NN 4_p
are VBP N
common JJ N
in IN N
patients NNS N
with IN N
Parkinson NNP 4_p
's POS 4_p
disease NN 4_p
( ( N
PD NNP 4_p
) ) N
. . N

Patients NNS N
most RBS N
frequently RB N
complain VBP N
of IN N
dysphagia NN N
and CC N
therapy NN N
resistant JJ N
constipation NN N
, , N
as RB N
far RB N
as IN N
the DT N
gastrointestinal JJ N
tract NN N
is VBZ N
concerned VBN N
. . N

These DT N
symptoms NNS N
have VBP N
to TO N
be VB N
attributed VBN N
to TO N
a DT N
neuronal JJ N
degeneration NN N
. . N

In IN N
a DT N
pilot NN N
study NN N
we PRP N
therefore RB N
investigated VBD N
the DT N
effect NN N
of IN N
stimulation NN N
of IN N
the DT N
myenteric JJ N
plexus NN N
by IN N
cisapride NN N
. . N

11 CD N
women NNS N
and CC N
13 CD N
men NNS N
were VBD N
examined VBN N
, , N
the DT N
average JJ N
age NN N
was VBD N
67.3 CD N
years NNS N
, , N
the DT N
Webster NNP N
rating NN N
17 CD N
points NNS N
. . N

In IN N
2 CD N
out IN N
of IN N
24 CD N
patients NNS N
, , N
colonic JJ N
transit NN N
was VBD N
prolonged VBN N
up RB N
to TO N
the DT N
limit NN N
, , N
both DT N
with IN N
and CC N
without IN N
therapy NN N
. . N

The DT N
other JJ N
22 CD N
patients NNS N
showed VBD N
an DT N
acceleration NN N
in IN N
transit NN N
on IN N
response NN N
to TO N
cisapride VB N
. . N

On IN N
average JJ N
the DT N
colonic JJ N
transit NN N
of IN N
130 CD N
hours NNS N
was VBD N
reduced VBN N
to TO N
79 CD N
hours NNS N
. . N

This DT N
objective JJ N
improvement NN N
was VBD N
associated VBN N
with IN N
a DT N
subjective JJ N
improvement NN N
. . N

Central JJ N
side NN N
effects NNS N
or CC N
a DT N
worsening NN N
of IN N
Parkinsonian JJ N
symptoms NNS N
were VBD N
not RB N
found VBN N
. . N

We PRP N
conclude VBP N
that DT N
cisapride NN N
is VBZ N
effective JJ N
in IN N
the DT N
treatment NN N
of IN N
constipation NN 4_p
in IN N
idiopathic JJ 4_p
PD NNP 4_p
. . N

-DOCSTART- -X- O O 25807670

Role NNP N
of IN N
warm JJ N
saline NN N
mouth NN N
rinse NN N
in IN N
prevention NN N
of IN N
alveolar JJ N
osteitis NN N
: : N
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

BACKGROUND VB N
The DT N
present JJ N
study NN N
was VBD N
aimed VBN N
at IN N
determining VBG N
the DT N
role NN N
warm JJ N
saline NN N
rinse NN N
in IN N
the DT N
prevention NN N
of IN N
alveolar JJ N
osteitis NN N
following VBG N
dental JJ N
extractions NNS N
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
Apparently NNP N
patients NNS N
aged VBD N
16 CD N
and CC N
above IN N
who WP N
were VBD N
referred VBN N
to TO N
the DT N
Oral NNP 4_p
Surgery NNP 4_p
Clinic NNP 4_p
of IN N
our PRP$ N
institution NN N
, , N
with IN N
an DT N
indication NN N
for IN N
non-surgical JJ 4_p
extraction NN 4_p
of IN 4_p
pathologic JJ 4_p
teeth NNS 4_p
were VBD N
prospectively RB N
and CC N
uniformly RB N
randomized VBN N
into IN N
warm JJ N
saline NN N
group NN N
and CC N
control NN N
. . N

The DT N
experimental JJ N
group NN N
( ( N
n JJ N
= NNP N
80 CD N
) ) N
were VBD N
instructed VBN N
to TO N
gargle VB N
6 CD N
times NNS N
daily RB N
with IN N
warm JJ N
saline NN N
and CC N
no DT N
such JJ N
instructions NNS N
were VBD N
given VBN N
to TO N
the DT N
second JJ N
group NN N
( ( N
n JJ N
= NNP N
80 CD N
) ) N
to TO N
serve VB N
as IN N
controls NNS N
. . N

Information NN N
on IN N
demographic NN N
, , N
indications NNS N
for IN N
extraction NN N
, , N
and CC N
development NN N
of IN N
alveolar JJ N
osteitis NN N
were VBD N
obtained VBN N
and CC N
analyzed VBN N
. . N

Comparative JJ N
statistics NNS N
were VBD N
done VBN N
using VBG N
Pearson NNP N
's POS N
chi NN N
square NN N
or CC N
Fisher NNP N
's POS N
exact JJ N
test NN N
as IN N
appropriate NN N
. . N

A DT N
p JJ N
value NN N
of IN N
less JJR N
than IN N
0.05 CD N
was VBD N
considered VBN N
significant JJ N
. . N

RESULTS VB N
The DT N
demographic JJ N
and CC N
other JJ N
baseline NN N
parameters NNS N
such JJ N
as IN N
indications NNS N
for IN N
extractions NNS N
were VBD N
comparable JJ N
among IN N
the DT N
study NN N
groups NNS N
( ( N
p JJ N
> NNP N
0.05 CD N
) ) N
. . N

The DT N
overall JJ N
prevalence NN N
of IN N
alveolar JJ N
osteitis NN N
was VBD N
13.7 CD N
% NN N
. . N

There EX N
was VBD N
a DT N
statistical JJ N
significant JJ N
difference NN N
between IN N
the DT N
study NN N
groups NNS N
with IN N
respect NN N
to TO N
development NN N
of IN N
alveolar JJ N
osteitis NN N
( ( N
X2 NNP N
= NNP N
15.00 CD N
, , N
df NN N
= VBD N
1 CD N
, , N
p NN N
= NNP N
0.001 CD N
) ) N
.The NN N
risk NN N
of IN N
development NN N
of IN N
alveolar JJ N
osteitis NN N
was VBD N
4 CD N
times NNS N
higher RBR N
in IN N
the DT N
control NN N
group NN N
( ( N
OR NNP N
= VBZ N
4.33 CD N
, , N
P NNP N
= NNP N
0.001 CD N
) ) N
. . N

CONCLUSION NNP N
Warm NNP N
saline NN N
mouth NN N
rinse JJ N
instruction NN N
is VBZ N
beneficial JJ N
in IN N
the DT N
prevention NN N
of IN N
development NN N
of IN N
alveolar JJ N
osteitis NN N
after IN N
dental JJ N
extractions NNS N
. . N

-DOCSTART- -X- O O 19396947

The DT N
effect NN N
of IN N
nebivolol JJ N
treatment NN N
on IN N
oxidative JJ N
stress NN N
and CC N
antioxidant JJ N
status NN N
in IN N
patients NNS N
with IN N
cardiac JJ 4_p
syndrome-X NN 4_p
. . N

BACKGROUND NNP N
Free JJ N
radical-mediated JJ N
oxidative JJ N
stress NN N
has VBZ N
been VBN N
implicated VBN N
in IN N
the DT N
etiopathogenesis NN N
of IN N
several JJ N
disorders NNS N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
elucidate VB N
the DT N
effect NN N
of IN N
treatment NN N
with IN N
nebivolol NN N
on IN N
the DT N
metabolic JJ N
state NN N
of IN N
oxidative JJ N
stress NN N
, , N
and CC N
antioxidant JJ N
status NN N
markers NNS N
in IN N
patients NNS N
with IN N
cardiac JJ 4_p
syndrome-X NN 4_p
( ( 4_p
CSX NNP 4_p
) ) 4_p
, , N
additionally RB N
, , N
to TO N
compare VB N
with IN N
the DT N
effect NN N
of IN N
metoprolol NN N
treatment NN N
. . N

METHODS NNP N
Thirty NNP N
patients NNS N
, , N
17 CD N
female NN N
and CC N
13 CD N
male NN N
, , N
with IN N
CSX NNP 4_p
were VBD N
enrolled VBN N
in IN N
the DT N
study NN N
. . N

Nebivolol NNP N
( ( N
5 CD N
mg/day NN N
) ) N
or CC N
metoprolol NN N
( ( N
50 CD N
mg/day NN N
) ) N
was VBD N
administrated VBN N
for IN N
12 CD N
weeks NNS N
. . N

Twelve VB N
hour NN N
fasting VBG N
blood NN N
samples NNS N
, , N
taken VBN N
at IN N
the DT N
initiation NN N
and CC N
on IN N
the DT N
third JJ N
month NN N
of IN N
therapy NN N
, , N
were VBD N
analyzed VBN N
for IN N
the DT N
levels NNS N
of IN N
malondialdehyde NN N
( ( N
MDA NNP N
) ) N
, , N
nitrite+nitrate JJ N
( ( N
NOx NNP N
) ) N
, , N
and CC N
the DT N
activity NN N
of IN N
myeloperoxidase NN N
( ( N
MPO NNP N
) ) N
, , N
superoxide JJ N
dismutase NN N
( ( N
SOD NNP N
) ) N
. . N

No DT N
patient NN N
presented VBD N
additional JJ N
risk NN N
factors NNS N
for IN N
increased JJ N
reactive JJ N
oxygen NN N
species NNS N
levels NNS N
. . N

RESULTS NNP N
Compared VBD N
with IN N
sixteen JJ N
control NN N
participants NNS N
, , N
patients NNS N
with IN N
CSX NNP N
had VBD N
significantly RB N
higher JJR N
activity NN N
of IN N
MPO NNP N
and CC N
levels NNS N
of IN N
MDA NNP N
, , N
but CC N
significantly RB N
lower JJR N
SOD NNP N
activity NN N
and CC N
levels NNS N
of IN N
NOx NNP N
before IN N
treatment NN N
. . N

After IN N
treatment NN N
, , N
MPO NNP N
activity NN N
and CC N
MDA NNP N
levels NNS N
were VBD N
significantly RB N
reduced VBN N
; : N
SOD NNP N
activity NN N
and CC N
NOx NNP N
levels NNS N
were VBD N
significantly RB N
increased VBN N
with IN N
nebivolol NN N
but CC N
remained VBD N
unchanged JJ N
with IN N
metoprolol NN N
. . N

CONCLUSION NN N
We PRP N
have VBP N
shown VBN N
that IN N
patients NNS N
with IN N
CSX NNP 4_p
who WP N
taken VBN N
nebivolol RB N
have VBP N
lower JJR N
serum NN N
MPO NNP N
activity NN N
, , N
levels NNS N
of IN N
MDA NNP N
and CC N
higher JJR N
serum NN N
SOD NNP N
activity NN N
, , N
NOx NNP N
levels NNS N
when WRB N
compared VBN N
with IN N
metoprolol JJ N
treatment NN N
. . N

Exercise NNP N
stress JJ N
test NN N
parameters NNS N
were VBD N
also RB N
ameliorated VBN N
in IN N
patients NNS N
who WP N
had VBD N
taken VBN N
nebivolol RB N
in IN N
contrast NN N
to TO N
metoprolol VB N
. . N

Nebivolol NNP N
treatment NN N
may MD N
be VB N
a DT N
novel JJ N
treatment NN N
strategy NN N
in IN N
cases NNS N
with IN N
CSX NNP N
in IN N
the DT N
future NN N
. . N

-DOCSTART- -X- O O 2691638

The DT N
Relaxation NNP N
Inventory NN N
: : N
self-report JJ N
scales NNS N
of IN N
relaxation NN N
training NN N
effects NNS N
. . N

The DT N
development NN N
of IN N
a DT N
self-report JJ N
measure NN N
to TO N
assess VB N
the DT N
effects NNS N
of IN N
relaxation NN N
training NN N
was VBD N
examined VBN N
. . N

A DT N
rigorous JJ N
statistical JJ N
method NN N
of IN N
scale JJ N
construction NN N
consisting NN N
of IN N
a DT N
modification NN N
of IN N
the DT N
scale JJ N
discrimination NN N
technique NN N
was VBD N
employed VBN N
, , N
resulting VBG N
in IN N
a DT N
45-item JJ N
questionnaire NN N
representing VBG N
three CD N
orthogonally RB N
derived VBN N
scales NNS N
. . N

The DT N
three CD N
scales NNS N
, , N
Physiological NNP N
Tension NNP N
, , N
Physical NNP N
Assessment NNP N
, , N
and CC N
Cognitive NNP N
Tension NNP N
, , N
demonstrated VBD N
adequate JJ N
internal JJ N
consistency NN N
with IN N
KR20 NNP N
reliability NN N
coefficients NNS N
of IN N
.89 NNP N
, , N
.95 NNP N
, , N
and CC N
.81 NNP N
, , N
respectively RB N
. . N

In IN N
a DT N
second JJ N
study NN N
of IN N
predictive JJ N
validity NN N
, , N
40 CD N
individuals NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
four CD N
conditions NNS N
: : N
relaxation NN N
training NN N
, , N
tension NN N
inducement NN N
, , N
pre-postcontrol NN N
, , N
or CC N
postcontrol NN N
. . N

Univariate NNP N
analysis NN N
of IN N
variance NN N
indicated VBN N
significant JJ N
findings NNS N
for IN N
each DT N
of IN N
the DT N
three CD N
dimensions NNS N
of IN N
the DT N
inventory NN N
. . N

The DT N
Physiological JJ N
Tension NNP N
Scale NNP N
detected VBD N
significant JJ N
increases NNS N
in IN N
tension NN N
following VBG N
tension NN N
inducement NN N
, , N
whereas IN N
the DT N
Physical NNP N
Assessment NNP N
Scale NNP N
and CC N
Cognitive NNP N
Tension NNP N
Scale NNP N
detected VBD N
increases NNS N
in IN N
relaxation NN N
following VBG N
relaxation NN N
training NN N
. . N

Recommendations NNS N
were VBD N
made VBN N
for IN N
future JJ N
research NN N
on IN N
the DT N
inventory NN N
. . N

-DOCSTART- -X- O O 20439105

Small NN N
but CC N
important JJ N
errors NNS N
in IN N
cardiovascular JJ N
risk NN N
calculation NN N
by IN N
practice NN N
nurses NNS N
: : N
a DT N
cross-sectional JJ N
study NN N
in IN N
randomised JJ N
trial NN N
setting NN N
. . N

BACKGROUND NNP N
Practice NNP N
nurses NNS N
play VBP N
an DT N
increasingly RB N
important JJ N
role NN N
in IN N
the DT N
prevention NN N
of IN N
cardiovascular JJ N
diseases NNS N
but CC N
we PRP N
do VBP N
not RB N
have VB N
evidence NN N
about IN N
the DT N
accuracy NN N
of IN N
their PRP$ N
cardiovascular JJ N
risk NN N
assessments NNS N
during IN N
real JJ N
practice NN N
consultations NNS N
. . N

OBJECTIVES NNP N
To TO N
examine VB N
how WRB N
nurses NNS N
perform VBP N
with IN N
regard NN N
to TO N
absolute VB N
10-year JJ N
cardiovascular JJ N
risk NN N
assessment NN N
in IN N
actual JJ N
practice NN N
. . N

DESIGN NNP N
Cross-sectional JJ N
study NN N
. . N

SETTING NN N
This DT N
study NN N
was VBD N
nested VBN N
in IN N
the DT N
IMPALA NNP N
study NN N
, , N
a DT N
clustered VBN N
randomised VBN N
controlled VBN N
trial NN N
involving VBG N
24 CD N
general JJ N
practices NNS N
in IN N
The DT N
Netherlands NNP N
. . N

PARTICIPANTS VB N
24 CD N
practice NN N
nurses NNS N
, , N
trained VBN N
in IN N
10-year JJ N
cardiovascular JJ N
risk NN N
assessment NN N
, , N
calculated VBD N
the DT N
risk NN N
of IN N
a DT N
total NN N
of IN N
421 CD N
patients NNS N
without IN N
established VBN N
cardiovascular JJ N
diseases NNS N
but CC N
eligible JJ N
for IN N
cardiovascular JJ N
risk NN N
assessment NN N
. . N

METHODS NNP N
The DT N
main JJ N
outcome NN N
measure NN N
was VBD N
the DT N
accuracy NN N
of IN N
risk NN N
assessments NNS N
, , N
defined VBN N
as IN N
( ( N
1 CD N
) ) N
the DT N
difference NN N
between IN N
the DT N
10-year JJ N
cardiovascular JJ N
risk NN N
percentage NN N
calculated VBN N
by IN N
nurses NNS N
and CC N
an DT N
independent JJ N
assessor NN N
, , N
and CC N
( ( N
2 CD N
) ) N
the DT N
agreement NN N
between IN N
the DT N
treatment NN N
categories NNS N
assigned VBN N
by IN N
the DT N
nurses NNS N
( ( N
low JJ N
, , N
moderate JJ N
or CC N
high JJ N
risk NN N
) ) N
and CC N
those DT N
assigned VBN N
by IN N
the DT N
independent JJ N
assessor NN N
. . N

RESULTS VB N
Thirty-one NNP N
( ( N
7.4 CD N
% NN N
) ) N
of IN N
the DT N
calculated JJ N
risk NN N
percentages NNS N
differed VBN N
by IN N
more JJR N
than IN N
our PRP$ N
preset NN N
limits NNS N
, , N
25 CD N
( ( N
81 CD N
% NN N
) ) N
being VBG N
underestimations NNS N
. . N

Elderly JJ N
patients NNS N
( ( N
OR NNP N
1.1 CD N
, , N
95 CD N
% NN N
CI NNP N
1.0-1.1 CD N
) ) N
, , N
male JJ N
patients NNS N
( ( N
vs. FW N
female NN N
OR NNP N
3.1 CD N
, , N
95 CD N
% NN N
CI NNP N
1.2-7.3 CD N
) ) N
, , N
and CC N
smoking NN N
patients NNS N
( ( N
vs. IN N
non-smoking NN N
OR NNP N
3.8 CD N
, , N
95 CD N
% NN N
CI NNP N
1.7-8.9 CD N
) ) N
were VBD N
more RBR N
likely JJ N
to TO N
have VB N
their PRP$ N
cardiovascular JJ N
risk NN N
miscalculated VBD N
. . N

Ten NNP N
( ( N
28 CD N
% NN N
) ) N
of IN N
the DT N
36 CD N
patients NNS N
who WP N
should MD N
be VB N
assigned VBN N
to TO N
the DT N
high-risk JJ N
treatment NN N
category NN N
according VBG N
to TO N
the DT N
independent JJ N
calculation NN N
, , N
were VBD N
missed VBN N
as IN N
high-risk JJ N
patients NNS N
by IN N
the DT N
practice NN N
nurses NNS N
. . N

CONCLUSIONS VB N
The DT N
overall JJ N
standard NN N
of IN N
accuracy NN N
of IN N
cardiovascular JJ N
risk NN N
assessment NN N
by IN N
trained JJ N
practice NN N
nurses NNS N
in IN N
actual JJ N
practice NN N
is VBZ N
high JJ N
. . N

However RB N
, , N
a DT N
significant JJ N
number NN N
of IN N
high-risk JJ N
patients NNS N
were VBD N
misclassified VBN N
, , N
with IN N
the DT N
probability NN N
that IN N
it PRP N
led VBD N
to TO N
missed VBN N
opportunities NNS N
for IN N
risk-reducing JJ N
interventions NNS N
. . N

As IN N
cardiovascular JJ N
risk NN N
assessments NNS N
are VBP N
frequently RB N
done VBN N
by IN N
nurses NNS N
in IN N
general JJ N
practice NN N
, , N
further JJ N
specific JJ N
training NN N
should MD N
be VB N
considered VBN N
to TO N
prevent VB N
undertreatment NN N
. . N

-DOCSTART- -X- O O 8978338

Colonoscopic NNP N
miss JJ N
rates NNS N
of IN N
adenomas NN 4_p
determined VBN N
by IN N
back-to-back JJ N
colonoscopies NNS N
. . N

BACKGROUND NNP N
& CC N
AIMS NNP N
The DT N
miss JJ N
rate NN N
of IN N
colonoscopy NN N
for IN N
neoplasms NN N
is VBZ N
poorly RB N
understood JJ N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
the DT N
miss JJ N
rate NN N
of IN N
colonoscopy NN N
by IN N
same JJ N
day NN N
back-to-back JJ N
colonoscopy NN N
. . N

METHODS NNP N
Two CD N
consecutive JJ N
same JJ N
day NN N
colonoscopies NNS N
were VBD N
performed VBN N
in IN N
183 CD N
patients NNS N
. . N

The DT N
patients NNS N
were VBD N
randomized VBN N
to TO N
undergo VB N
the DT N
second JJ N
colonoscopy NN N
by IN N
the DT N
same JJ N
or CC N
a DT N
different JJ N
endoscopist NN N
and CC N
in IN N
the DT N
same JJ N
or CC N
different JJ N
position NN N
. . N

RESULTS VB N
The DT N
overall JJ N
miss NN N
rate NN N
for IN N
adenomas NN N
was VBD N
24 CD N
% NN N
, , N
27 CD N
% NN N
for IN N
adenomas JJ N
< NN N
or CC N
= $ N
5 CD N
mm NN N
, , N
13 CD N
% NN N
for IN N
adenomas JJ N
6-9 JJ N
mm NN N
, , N
and CC N
6 CD N
% NN N
for IN N
adenomas JJ N
> NN N
or CC N
= $ N
1 CD N
cm NN N
. . N

Patients NNS N
with IN N
two CD N
or CC N
more JJR N
adenomas NNS N
at IN N
the DT N
first JJ N
examination NN N
were VBD N
more RBR N
likely JJ N
than IN N
patients NNS 4_p
with IN 4_p
no DT 4_p
or CC 4_p
one CD 4_p
adenoma NN 4_p
detected VBN N
at IN N
the DT N
first JJ N
examination NN N
to TO N
have VB N
one CD N
or CC N
more JJR N
adenomas NNS N
at IN N
the DT N
second JJ N
examination NN N
( ( N
odds NNS N
ratio NN N
, , N
3.3 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
1.69-6.46 JJ N
) ) N
. . N

Right JJ N
colon NN N
adenomas NNS N
were VBD N
missed VBN N
more RBR N
often RB N
( ( N
27 CD N
% NN N
) ) N
than IN N
left VBN N
colon NN N
adenomas NN N
( ( N
21 CD N
% NN N
) ) N
, , N
but CC N
the DT N
difference NN N
was VBD N
not RB N
significant JJ N
. . N

There EX N
was VBD N
evidence NN N
of IN N
variation NN N
in IN N
sensitivity NN N
between IN N
endoscopists NNS N
, , N
but CC N
significant JJ N
miss JJ N
rates NNS N
for IN N
small JJ N
adenomas NNS N
were VBD N
found VBN N
among IN N
essentially RB N
all DT N
endoscopists NNS N
. . N

CONCLUSIONS NNP N
Using NNP N
current JJ N
colonoscopic NN N
technology NN N
, , N
there EX N
are VBP N
significant JJ N
miss JJ N
rates NNS N
for IN N
adenomas JJ N
< $ N
1 CD N
cm NN N
even RB N
with IN N
meticulous JJ N
colonoscopy NN N
. . N

Miss JJ N
rates NNS N
are VBP N
low JJ N
for IN N
adenomas NN N
> NN N
or CC N
= $ N
1 CD N
cm NN N
. . N

The DT N
results NNS N
suggest VBP N
the DT N
need NN N
for IN N
improvements NNS N
in IN N
colonoscopic NN N
technology NN N
. . N

-DOCSTART- -X- O O 7608801

A DT N
randomized VBN N
, , N
controlled VBD N
trial NN N
of IN N
the DT N
efficacy NN N
of IN N
a DT N
heparin NN N
and CC N
vancomycin JJ N
solution NN N
in IN N
preventing VBG N
central JJ 4_p
venous JJ 4_p
catheter NN 4_p
infections NNS 4_p
in IN N
children NNS N
. . N

OBJECTIVE NN N
To TO N
determine VB N
whether IN N
adding VBG N
vancomycin NN N
to TO N
central JJ N
venous JJ N
catheter NN N
( ( N
CVC NNP N
) ) N
flush NN N
solution NN N
would MD N
significantly RB N
reduce VB N
the DT N
incidence NN N
of IN N
bacteremia NN N
attributable JJ N
to TO N
luminal JJ N
colonization NN N
with IN N
vancomycin-susceptible JJ N
organisms NNS N
. . N

STUDY NNP N
DESIGN NNP N
Fifty-five JJ N
children NNS N
with IN N
cancer NN 4_p
and CC N
eight CD N
children NNS N
given VBN N
total JJ 4_p
parenteral JJ 4_p
nutrition NN 4_p
by IN 4_p
the DT 4_p
surgery NN 4_p
or CC 4_p
nutrition NN 4_p
support NN 4_p
services NNS 4_p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
a DT N
heparin NN N
CVC NNP N
flush JJ N
solution NN N
( ( N
n JJ N
= NNP N
31 CD N
) ) N
or CC N
a DT N
heparin-vancomycin JJ N
CVC NNP N
flush NN N
solution NN N
( ( N
n JJ N
= NNP N
32 CD N
) ) N
. . N

RESULTS NNP N
During IN N
9158 CD N
catheter NN N
days NNS N
, , N
6.5 CD N
% NN N
of IN N
the DT N
patients NNS N
in IN N
the DT N
heparin NN N
group NN N
and CC N
15.6 CD N
% NN N
of IN N
the DT N
patients NNS N
in IN N
the DT N
heparin-vancomycin JJ N
group NN N
had VBD N
bacteremia VBN N
attributable JJ N
to TO N
luminal JJ N
colonization NN N
with IN N
vancomycin-susceptible JJ N
organisms NNS N
( ( N
p JJ N
= NNP N
0.43 CD N
) ) N
. . N

The DT N
mean JJ N
rates NNS N
of IN N
bacteremia NN N
attributable JJ N
to TO N
luminal JJ N
colonization NN N
with IN N
vancomycin-susceptible JJ N
organisms NNS N
were VBD N
0.6/1000 CD N
catheter NN N
days NNS N
in IN N
the DT N
heparin NN N
group NN N
and CC N
1.4/1000 CD N
catheter NN N
days NNS N
in IN N
the DT N
heparin-vancomycin JJ N
group NN N
( ( N
p JJ N
= NNP N
0.25 CD N
) ) N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
groups NNS N
when WRB N
the DT N
time NN N
to TO N
the DT N
first JJ N
episode NN N
of IN N
bacteremia NN N
attributable JJ N
to TO N
luminal JJ N
colonization NN N
with IN N
a DT N
vancomycin-susceptible JJ N
organism NN N
was VBD N
compared VBN N
by IN N
means NNS N
of IN N
Kaplan-Meier NNP N
survival NN N
estimates NNS N
. . N

Streptococcus NNP N
viridans NNPS N
infection NN N
was VBD N
not RB N
attributable JJ N
to TO N
luminal JJ N
colonization NN N
. . N

CONCLUSION VB N
The DT N
addition NN N
of IN N
vancomycin NN N
to TO N
heparin VB N
CVC NNP N
flush JJ N
solution NN N
did VBD N
not RB N
reduce VB N
bacteremia NN N
with IN N
vancomycin-susceptible JJ N
organisms NNS N
. . N

Bacteremia NNP N
with IN N
Streptococcus NNP N
viridans NNS N
was VBD N
not RB N
related VBN N
to TO N
the DT N
use NN N
of IN N
a DT N
CVC NNP N
. . N

-DOCSTART- -X- O O 23773944

[ JJ N
Closure NNP N
of IN N
persistent JJ 4_p
foramen NNS 4_p
ovale SYM 4_p
- : N
the DT N
last JJ N
closure NN N
? . N
] NN N
. . N

-DOCSTART- -X- O O 6365881

Netilmicin NNP N
versus NN N
tobramycin NN N
in IN N
multi-centre JJ N
studies NNS N
. . N

In IN N
two CD N
prospective JJ N
, , N
randomized JJ N
studies NNS N
conducted VBN N
in IN N
West NNP N
Germany NNP N
and CC N
involving VBG N
80 CD N
patients NNS N
, , N
netilmicin-ticarcillin NN N
was VBD N
compared VBN N
to TO N
tobramycin-ticarcillin NN N
in IN N
the DT N
treatment NN N
of IN N
serious JJ 4_p
systemic JJ 4_p
infections NNS 4_p
. . N

Both DT N
regimens NNS N
were VBD N
essentially RB N
identical JJ N
with IN N
respect NN N
to TO N
the DT N
clinical JJ N
and CC N
bacteriological JJ N
results NNS N
they PRP N
produced VBD N
. . N

The DT N
netilmicin JJ N
group NN N
developed VBD N
significantly RB N
less JJR N
nephrotoxicity NN N
than IN N
the DT N
tobramycin NN N
group NN N
( ( N
0 CD N
% NN N
versus IN N
15 CD N
% NN N
, , N
P NNP N
= NNP N
0.03 CD N
) ) N
. . N

Ototoxicity NNP N
also RB N
occurred VBD N
less RBR N
frequently RB N
in IN N
the DT N
netilmicin-treated JJ N
patients NNS N
( ( N
3 CD N
% NN N
versus IN N
10 CD N
% NN N
, , N
P NNP N
= NNP N
0.4 CD N
) ) N
. . N

In IN N
a DT N
large JJ N
collaborative NN N
study NN N
involving VBG N
15 CD N
centres NNS N
, , N
254 CD N
patients NNS N
were VBD N
enrolled VBN N
. . N

Clinical JJ N
and CC N
bacteriological JJ N
responses NNS N
were VBD N
excellent JJ N
, , N
with IN N
netilmicin JJ N
and CC N
tobramycin JJ N
equally RB N
effective JJ N
, , N
but CC N
the DT N
incidences NNS N
of IN N
nephrotoxicity NN N
and CC N
ototoxicity NN N
were VBD N
lower JJR N
in IN N
patients NNS N
treated VBN N
with IN N
netilmicin NN N
than IN N
those DT N
receiving VBG N
tobramycin NN N
. . N

-DOCSTART- -X- O O 8255984

A DT N
preliminary JJ N
trial NN N
of IN N
ascorbic JJ N
acid NN N
as IN N
supplemental JJ N
therapy NN N
for IN N
autism NN 4_p
. . 4_p

1 CD N
. . N

This DT N
study NN N
presents VBZ N
the DT N
results NNS N
of IN N
a DT N
30-week JJ N
double-blind NN N
, , N
placebo-controlled JJ N
trial NN N
exploring VBG N
the DT N
effectiveness NN N
of IN N
ascorbic JJ N
acid NN N
( ( N
8g/70kg/day CD N
) ) N
as IN N
a DT N
supplemental JJ N
pharmacological JJ N
treatment NN N
for IN N
autistic JJ N
children NNS N
in IN N
residential JJ N
treatment NN N
. . N

2 CD N
. . N

Residential JJ N
school NN N
children NNS N
( ( N
N NNP N
= NNP N
18 CD N
) ) N
were VBD N
randomly RB N
assigned VBN N
to TO N
either DT N
ascorbate-ascorbate-placebo JJ N
treatment NN N
order NN N
group NN N
or CC N
ascorbate-placebo-ascorbate JJ N
treatment NN N
order NN N
group NN N
. . N

Each DT N
treatment NN N
phase NN N
lasted VBD N
10 CD N
weeks NNS N
and CC N
behaviors NNS N
were VBD N
rated VBN N
weekly JJ N
using VBG N
the DT N
Ritvo-Freeman NNP N
scale NN N
. . N

3 CD N
. . N

Significant JJ N
group NN N
by IN N
phase NN N
interactions NNS N
were VBD N
found VBN N
for IN N
total JJ N
scores NNS N
and CC N
also RB N
sensory JJ N
motor NN N
scores NNS N
indicating VBG N
a DT N
reduction NN N
in IN N
symptom JJ N
severity NN N
associated VBN N
with IN N
the DT N
ascorbic JJ N
acid NN N
treatment NN N
. . N

4 CD N
. . N

These DT N
results NNS N
were VBD N
consistent JJ N
with IN N
a DT N
hypothesized VBN N
dopaminergic NN N
mechanism NN N
of IN N
action NN N
of IN N
ascorbic JJ N
acid NN N
. . N

-DOCSTART- -X- O O 17244100

Can MD N
patient VB N
coaching VBG N
reduce VB N
racial/ethnic JJ N
disparities NNS N
in IN N
cancer NN N
pain NN N
control NN N
? . N
Secondary JJ N
analysis NN N
of IN N
a DT N
randomized VBN N
controlled VBN N
trial NN N
. . N

PURPOSE NNP N
Minority NNP 4_p
patients NNS 4_p
with IN 4_p
cancer NN 4_p
experience NN N
worse JJR N
control NN N
of IN N
their PRP$ N
pain NN N
than IN N
do VBP N
their PRP$ N
white JJ N
counterparts NNS N
. . N

This DT N
disparity NN N
may MD N
, , N
in IN N
part NN N
, , N
reflect VBP N
more JJR N
miscommunication NN N
between IN N
minority NN 4_p
patients NNS 4_p
and CC N
their PRP$ N
physicians NNS N
. . N

Therefore RB N
, , N
we PRP N
examined VBD N
whether IN N
patient NN N
coaching NN N
could MD N
reduce VB N
disparities NNS N
in IN N
pain NN N
control NN N
in IN N
a DT N
secondary JJ N
analysis NN N
of IN N
a DT N
randomized VBN N
controlled VBN N
trial NN N
. . N

METHODS NNP N
Sixty-seven JJ N
English-speaking NNP N
adult NN N
cancer NN 4_p
outpatients NNS 4_p
, , N
including VBG N
15 CD N
minorities NNS N
, , N
with IN N
moderate JJ N
pain NN N
over IN N
the DT N
prior JJ N
2 CD N
weeks NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
the DT N
experimental NN N
( ( N
N NNP N
= NNP N
34 CD N
) ) N
or CC N
control VB N
group NN N
( ( N
N NNP N
= NNP N
33 CD N
) ) N
. . N

Experimental JJ N
patients NNS N
received VBD N
a DT N
20-minute JJ N
individualized JJ N
education NN N
and CC N
coaching VBG N
session NN N
to TO N
increase VB N
knowledge NN N
of IN N
pain NN N
self-management JJ N
, , N
to TO N
redress VB N
personal JJ N
misconceptions NNS N
about IN N
pain NN N
treatment NN N
, , N
and CC N
to TO N
rehearse VB N
an DT N
individually RB N
scripted VBN N
patient-physician JJ N
dialog NN N
about IN N
pain NN N
control NN N
. . N

The DT N
control NN N
group NN N
received VBD N
standardized JJ N
information NN N
on IN N
controlling VBG N
pain NN N
. . N

Data NNP N
on IN N
average NN N
pain NN N
( ( N
0-10 JJ N
scale NN N
) ) N
were VBD N
collected VBN N
at IN N
enrollment NN N
and CC N
2-week JJ N
follow-up NN N
. . N

RESULTS NNP N
At IN N
enrollment NN N
, , N
minority NN 4_p
patients NNS 4_p
had VBD N
significantly RB N
more RBR N
pain NN N
than IN N
their PRP$ N
white JJ N
counterparts NNS N
( ( N
6.0 CD N
vs NN N
5.0 CD N
, , N
P NNP N
= NNP N
0.05 CD N
) ) N
. . N

At IN N
follow-up JJ N
, , N
minorities NNS N
in IN N
the DT N
control NN N
group NN N
continued VBD N
to TO N
have VB N
more JJR N
pain NN N
( ( N
6.4 CD N
vs NN N
4.7 CD N
, , N
P NNP N
= NNP N
0.01 CD N
) ) N
, , N
whereas RB N
in IN N
the DT N
experimental JJ N
group NN N
, , N
disparities NNS N
were VBD N
eliminated VBN N
( ( N
4.0 CD N
vs NN N
4.3 CD N
, , N
P NNP N
= NNP N
0.71 CD N
) ) N
. . N

The DT N
effect NN N
of IN N
the DT N
intervention NN N
on IN N
reducing VBG N
disparities NNS N
was VBD N
significant JJ N
( ( N
P NNP N
= NNP N
0.04 CD N
) ) N
. . N

CONCLUSIONS NNP N
Patient NNP N
coaching VBG N
offers NNS N
promise RB N
as IN N
a DT N
means NN N
of IN N
reducing VBG N
racial/ethnic JJ N
disparities NNS N
in IN N
pain NN N
control NN N
. . N

Larger NNP N
studies NNS N
are VBP N
needed VBN N
to TO N
validate VB N
these DT N
findings NNS N
and CC N
to TO N
explore VB N
possible JJ N
mechanisms NNS N
. . N

-DOCSTART- -X- O O 16044227

Investigation NN N
of IN N
maxillary JJ N
tooth NN N
sizes NNS N
in IN N
patients NNS N
with IN N
palatal JJ N
canine NN N
displacement NN N
. . N

AIM IN N
The DT N
aim NN N
of IN N
this DT N
retrospective JJ N
trial NN N
was VBD N
to TO N
investigate VB N
differences NNS N
in IN N
mesiodistal JJ N
and CC N
vestibulo-oral JJ N
crown NN N
sizes NNS N
of IN N
naturally RB N
, , N
fully-erupted JJ N
permanent JJ N
maxillary JJ N
teeth NNS N
between IN N
patients NNS N
with IN N
and CC N
without IN N
palatal JJ N
canine NN N
displacement NN N
. . N

PATIENTS NNP N
AND CC N
METHOD NNP N
115 CD N
patients NNS N
( ( N
mean JJ N
age NN N
: : N
14 CD N
years NNS N
10 CD N
months NNS N
; : N
females NNS N
: : N
77 CD N
males NNS N
: : N
38 CD N
) ) N
treated VBN N
in IN N
the DT N
Department NNP N
of IN N
Orthodontics NNP N
, , N
University NNP N
of IN N
Munich NNP N
were VBD N
included VBN N
in IN N
the DT N
study NN N
. . N

65 CD 4_p
of IN 4_p
the DT 4_p
patients NNS 4_p
showed VBD 4_p
at IN 4_p
least JJS 4_p
one CD 4_p
palatally-displaced JJ 4_p
canine NN 4_p
. . 4_p

Diagnosis NN 4_p
and CC 4_p
the DT 4_p
location NN 4_p
of IN 4_p
the DT 4_p
displacement NN 4_p
were VBD 4_p
determined VBN 4_p
on IN 4_p
the DT 4_p
basis NN 4_p
of IN 4_p
standardized JJ 4_p
radiographs NN 4_p
and CC 4_p
confirmed VBN 4_p
by IN 4_p
surgical JJ 4_p
documentation NN 4_p
. . 4_p

Each DT N
maxillary JJ N
tooth NN N
's POS N
mesiodistal JJ N
and CC N
vestibulo-oral JJ N
width NN N
was VBD N
measured VBN N
using VBG N
a DT N
dial JJ N
caliper NN N
on IN N
each DT N
dental JJ N
cast NN N
. . N

Excluded VBN N
were VBD N
partially-erupted JJ N
teeth NNS N
and CC N
surfaces NNS N
with IN N
caries NNS N
or CC N
restorations NNS N
that WDT N
had VBD N
to TO N
be VB N
measured VBN N
. . N

An DT N
analysis NN N
of IN N
available JJ N
space NN N
was VBD N
made VBN N
by IN N
evaluating VBG N
the DT N
pre-treatment JJ N
dental JJ N
casts NNS N
of IN N
all DT N
patients NNS N
included VBN N
in IN N
the DT N
study NN N
. . N

RESULTS NNP N
Comparing VBG N
the DT N
tooth JJ N
widths NNS N
of IN N
patients NNS N
with IN N
unilateral JJ N
canine NN N
displacement NN N
with IN N
the DT N
corresponding JJ N
contralateral JJ N
quadrants NNS N
, , N
we PRP N
noted VBD N
a DT N
statistically RB N
significant JJ N
difference NN N
, , N
namely RB N
that IN N
the DT N
central JJ N
and CC N
lateral JJ N
incisors NNS N
and CC N
the DT N
canines NNS N
of IN N
the DT N
affected JJ N
side NN N
were VBD N
narrower JJR N
than IN N
those DT N
of IN N
the DT N
non-affected JJ N
side NN N
in IN N
the DT N
same JJ N
patient NN N
. . N

Moreover RB N
, , N
the DT N
displaced JJ N
upper JJ N
canines NNS N
showed VBD N
an DT N
increase NN N
in IN N
vestibulo-oral JJ N
dimension NN N
. . N

Overall JJ N
tooth JJ N
width NN N
( ( N
including VBG N
all DT N
tooth DT N
groups NNS N
) ) N
in IN N
patients NNS N
with IN N
palatally-displaced JJ N
canines NNS N
was VBD N
significantly RB N
less JJR N
than IN N
that DT N
in IN N
the DT N
control NN N
group NN N
. . N

However RB N
, , N
when WRB N
comparing VBG N
the DT N
crown JJ N
diameters NNS N
of IN N
unilaterally- JJ N
and CC N
bilaterally-affected JJ N
patients NNS N
, , N
no DT N
differences NNS N
in IN N
tooth-size NN N
were VBD N
observed VBN N
. . N

The DT N
space-analysis NN N
showed VBD N
excessive JJ N
dental-arch JJ N
space NN N
in IN N
patients NNS N
with IN N
a DT N
palatally-displaced JJ N
canine NN N
. . N

CONCLUSION NNP N
Patients NNPS N
affected VBN N
by IN N
palatal JJ N
canine NN N
displacement NN N
showed VBD N
significantly RB N
smaller JJR N
maxillary JJ N
tooth DT N
size NN N
. . N

-DOCSTART- -X- O O 25524655

Most JJS N
functional JJ N
outcomes NNS N
are VBP N
similar JJ N
for IN N
men NNS N
and CC N
women NNS N
after IN N
hip JJ N
fracture NN N
: : N
a DT N
secondary JJ N
analysis NN N
of IN N
the DT N
enhancing VBG N
mobility NN N
after IN N
hip NN N
fracture NN N
trial NN N
. . N

BACKGROUND VB N
The DT N
impact NN N
of IN N
gender NN N
on IN N
functional JJ N
outcomes NNS N
after IN N
hip NN N
fracture NN N
is VBZ N
not RB N
known VBN N
. . N

We PRP N
aimed VBD N
to TO N
determine VB N
the DT N
extent NN N
to TO N
which WDT N
gender NN N
influenced VBD N
functional JJ N
outcome NN N
and CC N
response NN N
to TO N
exercise VB N
in IN N
older JJR N
people NNS N
after IN N
hip JJ 4_p
fracture NN 4_p
, , N
and CC N
to TO N
determine VB N
if IN N
any DT N
differences NNS N
persisted VBN N
after IN N
adjusting VBG N
for IN N
cognition NN N
, , N
weight NN N
and CC N
age NN N
. . N

METHOD NNP N
Secondary JJ N
analysis NN N
of IN N
data NNS N
from IN N
the DT N
Enhancing NNP N
Mobility NNP N
After IN N
Hip NNP 4_p
Fracture NNP 4_p
trial NN N
in IN N
which WDT N
older JJR N
people NNS N
after IN N
hip JJ N
fracture NN N
received VBD N
either CC N
a DT N
lower JJR N
or CC N
higher JJR N
intensity NN N
exercise NN N
program NN N
. . N

Functional NNP N
outcomes NNS N
included VBD N
physical JJ N
performance NN N
and CC N
self-reported JJ N
measures NNS N
. . N

Regression NNP N
models NNS N
were VBD N
used VBN N
to TO N
compare VB N
genders NNS N
at IN N
baseline NN N
, , N
week NN N
4 CD N
and CC N
week NN N
16 CD N
, , N
with IN N
adjustment NN N
for IN N
baseline NN N
values NNS N
, , N
cognition NN N
, , N
weight NN N
and CC N
age NN N
. . N

Interaction NN N
terms NNS N
were VBD N
used VBN N
to TO N
assess VB N
a DT N
differential JJ N
impact NN N
of IN N
the DT N
intervention NN N
by IN N
gender NN N
. . N

RESULTS NNP N
Outcome NNP N
data NNS N
were VBD N
available JJ N
for IN N
160 CD N
participants NNS N
, , N
30 CD N
men NNS N
( ( N
19 CD N
% NN N
) ) N
and CC N
130 CD N
women NNS N
( ( N
81 CD N
% NN N
) ) N
at IN N
baseline NN N
, , N
with IN N
the DT N
withdrawal NN N
of IN N
4 CD N
men NNS N
( ( N
13 CD N
% NN N
) ) N
and CC N
6 CD N
women NNS N
( ( N
5 CD N
% NN N
) ) N
at IN N
week NN N
16 CD N
. . N

There EX N
were VBD N
no DT N
gender NN N
differences NNS N
for IN N
any DT N
baseline JJ N
measures NNS N
or CC N
for IN N
most JJS N
of IN N
the DT N
19 CD N
functional JJ N
outcome NN N
measures NNS N
at IN N
weeks NNS N
4 CD N
and CC N
16 CD N
. . N

At IN N
week NN N
4 CD N
men NNS N
performed VBD N
better RBR N
in IN N
knee NN N
extensor NN N
strength NN N
( ( N
2.1 CD N
kg NN N
, , N
95 CD N
% NN N
CI NNP N
0.6 CD N
to TO N
3.7 CD N
, , N
p NN N
< NNP N
0.01 CD N
) ) N
. . N

This DT N
difference NN N
did VBD N
not RB N
persist VB N
after IN N
adjustment NN N
for IN N
body NN N
weight NN N
, , N
however RB N
persisted VBN N
after IN N
adjusting VBG N
for IN N
baseline NN N
, , N
cognition NN N
, , N
and CC N
age NN N
( ( N
p JJ N
= NNP N
0.038 CD N
) ) N
. . N

At IN N
week NN N
4 CD N
, , N
men NNS N
performed VBD N
better RBR N
in IN N
coordinated JJ N
stability NN N
( ( N
-10.0 JJ N
error NN N
score NN N
, , N
95 CD N
% NN N
CI NNP N
-17.6 NNP N
to TO N
-2.4 VB N
, , N
p=0.010 NN N
) ) N
and CC N
this DT N
persisted VBN N
after IN N
adjusting VBG N
for IN N
baseline NN N
values NNS N
only RB N
but CC N
not RB N
for IN N
cognition NN N
and CC N
age NN N
( ( N
p JJ N
= NNP N
0.073 CD N
) ) N
. . N

At IN N
week NN N
16 CD N
, , N
men NNS N
performed VBD N
better RBR N
in IN N
coordinated JJ N
stability NN N
( ( N
-10.2 JJ N
error NN N
score NN N
, , N
95 CD N
% NN N
CI NNP N
-18.4 NNP N
to TO N
-1.9 VB N
, , N
p=0.016 NN N
) ) N
and CC N
this DT N
persisted VBN N
after IN N
adjusting VBG N
only RB N
for IN N
cognitive JJ N
impairment NN N
( ( N
p JJ N
= NNP N
0.029 CD N
) ) N
but CC N
not RB N
for IN N
age NN N
and CC N
baseline NN N
( ( N
p JJ N
= NNP N
0.135 CD N
) ) N
. . N

There EX N
was VBD N
no DT N
indication NN N
of IN N
a DT N
differential JJ N
impact NN N
of IN N
intervention NN N
type NN N
on IN N
the DT N
basis NN N
of IN N
gender NN N
. . N

CONCLUSIONS VB N
A DT N
few JJ N
between IN N
gender NN N
differences NNS N
were VBD N
observed VBN N
in IN N
strength NN N
and CC N
balance NN N
, , N
however RB N
these DT N
appeared VBD N
to TO N
be VB N
confounded VBN N
by IN N
body NN N
weight NN N
, , N
age NN N
and/or JJ N
cognition NN N
. . N

-DOCSTART- -X- O O 18982929

Can MD N
HMG NNP N
Co-A NNP N
reductase NN N
inhibitors NNS N
( ( N
" JJ N
statins NNS N
" VBP N
) ) N
slow VB N
the DT N
progression NN N
of IN N
age-related JJ 4_p
macular JJ 4_p
degeneration NN 4_p
? . N
The DT N
age-related JJ N
maculopathy NN N
statin NN N
study NN N
( ( N
ARMSS NNP N
) ) N
. . N

Age-related JJ 4_p
macular JJ 4_p
degeneration NN 4_p
( ( 4_p
AMD NNP 4_p
) ) 4_p
is VBZ N
responsible JJ N
for IN N
the DT N
majority NN N
of IN N
visual JJ N
impairment NN N
in IN N
the DT N
Western JJ N
world NN N
. . N

The DT N
role NN N
of IN N
cholesterol-lowering JJ N
medications NNS N
, , N
HMG NNP N
Co-A NNP N
reductase NN N
inhibitors NNS N
or CC N
statins NNS N
, , N
in IN N
reducing VBG N
the DT N
risk NN N
of IN N
AMD NNP N
or CC N
of IN N
delaying VBG N
its PRP$ N
progression NN N
has VBZ N
not RB N
been VBN N
fully RB N
investigated VBN N
. . N

A DT N
3-year JJ N
prospective JJ N
randomized VBN N
controlled JJ N
trial NN N
of IN N
40 CD N
mg NN N
simvastatin NN N
per IN N
day NN N
compared VBN N
to TO N
placebo VB N
in IN N
subjects NNS N
at IN N
high JJ N
risk NN N
of IN N
AMD NNP 4_p
progression NN N
is VBZ N
described VBN N
. . N

This DT N
paper NN N
outlines VBZ N
the DT N
primary JJ N
aims NNS N
of IN N
the DT N
Age-Related NNP N
Maculopathy NNP N
Statin NNP N
Study NNP N
( ( N
ARMSS NNP N
) ) N
, , N
and CC N
the DT N
methodology NN N
involved VBN N
. . N

Standardized NNP N
clinical JJ N
grading NN N
of IN N
macular JJ N
photographs NN N
and CC N
comparison NN N
of IN N
serial JJ N
macular JJ N
digital NN N
photographs NN N
, , N
using VBG N
the DT N
International NNP N
grading NN N
scheme NN N
, , N
form VB N
the DT N
basis NN N
for IN N
assessment NN N
of IN N
primary JJ N
study NN N
outcomes NNS N
. . N

In IN N
addition NN N
, , N
macular JJ N
function NN N
is VBZ N
assessed VBN N
at IN N
each DT N
visit NN N
with IN N
detailed JJ N
psychophysical JJ N
measurements NNS N
of IN N
rod NN N
and CC N
cone NN N
function NN N
. . N

Information NN N
collected VBN N
in IN N
this DT N
study NN N
will MD N
assist VB N
in IN N
the DT N
assessment NN N
of IN N
the DT N
potential JJ N
value NN N
of IN N
HMG NNP N
Co-A NNP N
reductase NN N
inhibitors NNS N
( ( N
statins NNS N
) ) N
in IN N
reducing VBG N
the DT N
risk NN N
of IN N
AMD NNP N
progression NN N
. . N

-DOCSTART- -X- O O 16208798

Single-use NNP N
plaque NN N
removal NN N
efficacy NN N
of IN N
three CD N
power NN N
toothbrushes NNS N
. . N

OBJECTIVES NNP N
To TO N
compare VB N
the DT N
safety NN N
and CC N
plaque NN N
removal NN N
efficacy NN N
of IN N
two CD N
oscillating/rotating/pulsating VBG N
toothbrushes NNS N
( ( N
Oral-B NNP N
ProfessionalCare NNP N
7000 CD N
[ NNP N
PC NN N
7000 CD N
] NN N
and CC N
Oral-B JJ N
3D CD N
Excel NNP N
[ VBD N
3DE CD N
] NN N
) ) N
and CC N
a DT N
high-frequency NN N
toothbrush NN N
( ( N
Sonicare NNP N
Advance NNP N
, , N
Philips NNP N
Oral NNP N
Healthcare NNP N
; : N
SA NNP N
) ) N
in IN N
a DT N
single-use NN N
, , N
examiner-blind NN N
, , N
three CD N
period NN N
crossover NN N
study NN N
. . N

METHODS NNP N
After IN N
refraining VBG N
from IN N
all DT N
oral JJ N
hygiene NN N
procedures NNS N
for IN N
23-25 JJ N
hours NNS N
, , N
subjects NNS N
received VBD N
an DT N
oral JJ N
tissue NN N
examination NN N
and CC N
those DT N
with IN N
pre-brushing JJ N
whole JJ N
mouth NN N
mean JJ N
plaque NN N
scores NNS N
> VBP N
or CC N
= VBP N
0.6 CD N
based VBN N
on IN N
the DT N
Rustogi NNP N
et CC N
al NN N
. . N

Modified NNP N
Navy NNP N
Plaque NNP N
Index NNP N
were VBD N
randomly RB N
assigned VBN N
to TO N
treatment NN N
sequence NN N
. . N

After IN N
brushing VBG N
with IN N
the DT N
assigned JJ N
toothbrush NN N
and CC N
a DT N
commercially RB N
available JJ N
dentifrice NN N
for IN N
2 CD N
minutes NNS N
, , N
oral JJ N
tissues NNS N
were VBD N
then RB N
re-examined JJ N
and CC N
post-brushing JJ N
plaque NN N
scores NNS N
recorded VBN N
. . N

Following VBG N
a DT N
brief JJ N
washout JJ N
period NN N
between IN N
two CD N
additional JJ N
visits NNS N
, , N
the DT N
above NN N
procedures NNS N
were VBD N
repeated VBN N
with IN N
the DT N
two CD N
alternate NN N
toothbrushes NNS N
. . N

One CD N
examiner NN N
, , N
blinded VBD N
to TO N
the DT N
treatment NN N
sequence NN N
, , N
performed VBD N
all DT N
clinical JJ N
measurements NNS N
. . N

RESULTS VB N
A DT N
total NN N
of IN N
79 CD N
subjects NNS N
( ( N
28 CD N
males NNS N
and CC N
51 CD N
females NNS N
) ) N
were VBD N
enrolled VBN N
and CC N
completed VBN N
the DT N
study NN N
. . N

Each DT N
toothbrush NN N
was VBD N
found VBN N
to TO N
be VB N
safe JJ N
and CC N
significantly RB N
reduced VBN N
plaque NN N
levels NNS N
after IN N
a DT N
single JJ N
brushing NN N
. . N

The DT N
PC NN N
7000 CD N
and CC N
3DE CD N
were VBD N
equally RB N
more RBR N
effective JJ N
in IN N
plaque NN N
removal NN N
than IN N
the DT N
SA NNP N
, , N
at IN N
all DT N
tooth DT N
areas NNS N
, , N
reducing VBG N
plaque NN N
by IN N
59.0 CD N
% NN N
, , N
59.7 CD N
% NN N
and CC N
51.8 CD N
% NN N
, , N
respectively RB N
on IN N
whole JJ N
mouth NN N
surfaces NNS N
, , N
and CC N
by IN N
67.5 CD N
% NN N
, , N
67.8 CD N
% NN N
and CC N
59.4 CD N
% NN N
, , N
respectively RB N
on IN N
approximal JJ N
surfaces NNS N
. . N

CONCLUSIONS VB N
The DT N
action NN N
of IN N
the DT N
oscillating/rotating/pulsating NN N
toothbrushes NNS N
( ( N
Oral-B NNP N
ProfessionalCare NNP N
7000 CD N
and CC N
Oral-B NNP N
3D CD N
Excel NNP N
) ) N
was VBD N
more RBR N
effective JJ N
in IN N
plaque NN N
removal NN N
than IN N
the DT N
high-frequency NN N
toothbrush NN N
( ( N
Sonicare NNP N
Advance NNP N
) ) N
. . N

-DOCSTART- -X- O O 17179873

Depression NNP N
and CC N
anxiety NN N
in IN N
women NNS N
with IN N
breast NN 4_p
cancer NN 4_p
and CC N
their PRP$ N
partners NNS N
. . N

BACKGROUND NNP N
Psychosocial NNP N
interventions NNS N
can MD N
improve VB N
psychological JJ N
quality NN N
of IN N
life NN N
( ( N
symptoms NNS N
of IN N
depression NN N
and CC N
anxiety NN N
) ) N
of IN N
both DT N
women NNS N
with IN N
breast NN 4_p
cancer NN 4_p
and CC N
their PRP$ N
partners NNS N
, , N
but CC N
are VBP N
not RB N
offered VBN N
routinely RB N
to TO N
women NNS N
and CC N
their PRP$ N
partners NNS N
. . N

OBJECTIVE NNP N
To TO N
test VB N
the DT N
hypotheses NNS N
that IN N
telephone-delivered JJ N
psychosocial JJ N
interventions NNS N
decrease NN N
depression NN N
and CC N
anxiety NN N
in IN N
women NNS N
with IN N
breast NN 4_p
cancer NN 4_p
and CC N
their PRP$ N
partners NNS N
. . N

METHODS NNP N
The DT N
design NN N
of IN N
the DT N
study NN N
was VBD N
a DT N
three-wave JJ N
repeated JJ N
measures NNS N
with IN N
a DT N
between-subjects NNS N
factor NN N
( ( N
treatment NN N
group NN N
) ) N
. . N

Ninety-six JJ N
women NNS N
and CC N
their PRP$ N
96 CD N
partners NNS N
were VBD N
assigned VBN N
randomly RB N
to TO N
participate VB N
in IN N
one CD N
of IN N
three CD N
different JJ N
6-week JJ N
programs NNS N
: : N
( ( N
a DT N
) ) N
telephone NN N
interpersonal JJ N
counseling NN N
( ( N
TIP-C NNP N
) ) N
; : N
( ( N
b NN N
) ) N
self-managed JJ N
exercise NN N
; : N
or CC N
( ( N
c NN N
) ) N
attention NN N
control NN N
( ( N
AC NNP N
) ) N
. . N

RESULTS VB N
The DT N
mixed-model JJ N
analysis NN N
of IN N
variance NN N
for IN N
symptoms NNS N
of IN N
depression NN N
among IN N
women NNS N
with IN N
breast NN 4_p
cancer NN 4_p
revealed VBD N
women NNS N
's POS N
depressive JJ N
symptom NN N
scores NNS N
decreased VBN N
over IN N
time NN N
in IN N
all DT N
groups NNS N
. . N

For IN N
anxiety NN N
, , N
women NNS N
's POS N
symptoms NNS N
of IN N
anxiety NN N
decreased VBN N
in IN N
the DT N
TIP-C NNP N
and CC N
exercise NN N
groups NNS N
over IN N
time NN N
, , N
but CC N
not RB N
in IN N
the DT N
AC NNP N
group NN N
. . N

A DT N
parallel JJ N
set NN N
of IN N
analyses NNS N
was VBD N
conducted VBN N
on IN N
partners NNS N
' POS N
depression NN N
and CC N
anxiety NN N
data NNS N
. . N

Symptoms NNS N
of IN N
depression NN N
and CC N
anxiety NN N
among IN N
the DT N
partners NNS N
decreased VBD N
substantially RB N
over IN N
the DT N
course NN N
of IN N
the DT N
investigation NN N
. . N

Similar JJ N
to TO N
the DT N
women NNS N
, , N
partners NNS N
' POS N
symptoms NNS N
of IN N
anxiety NN N
decreased VBN N
significantly RB N
in IN N
the DT N
TIP-C NNP N
and CC N
exercise NN N
groups NNS N
, , N
but CC N
not RB N
in IN N
the DT N
AC NNP N
group NN N
. . N

DISCUSSION NNP N
Findings NNS N
from IN N
this DT N
study NN N
support NN N
that IN N
these DT N
telephone-delivered JJ N
psychosocial NN N
interventions NNS N
were VBD N
effective JJ N
for IN N
decreasing VBG N
symptoms NNS N
of IN N
depression NN N
and CC N
anxiety NN N
to TO N
improve VB N
psychological JJ N
quality NN N
of IN N
life NN N
when WRB N
compared VBN N
to TO N
an DT N
AC NNP N
group NN N
. . N

-DOCSTART- -X- O O 12704402

Effect NN N
of IN N
a DT N
high-protein JJ N
, , N
energy-restricted JJ N
diet NN N
on IN N
weight JJ N
loss NN N
and CC N
energy NN N
expenditure NN N
after IN N
weight JJ N
stabilization NN N
in IN N
hyperinsulinemic JJ 4_p
subjects NNS 4_p
. . 4_p

OBJECTIVE NN N
To TO N
determine VB N
the DT N
effect NN N
of IN N
replacing VBG N
some DT N
dietary JJ N
carbohydrate NN N
with IN N
protein NN N
, , N
during IN N
energy NN N
restriction NN N
, , N
on IN N
weight JJ N
loss NN N
, , N
total JJ N
energy NN N
expenditure NN N
( ( N
TEE NNP N
) ) N
, , N
resting VBG N
energy NN N
expenditure NN N
( ( N
REE NNP N
) ) N
, , N
respiratory JJ N
quotient NN N
( ( N
RQ NNP N
) ) N
, , N
and CC N
the DT N
thermic JJ N
effect NN N
of IN N
feeding NN N
( ( N
TEF NNP N
) ) N
in IN N
subjects NNS N
with IN N
hyperinsulinemia NN 4_p
. . N

DESIGN NNP N
Parallel NNP N
, , N
clinical JJ N
intervention NN N
study NN N
of IN N
12 CD N
weeks NNS N
energy NN N
restriction NN N
( ( N
6.5 CD N
MJ/day NNP N
) ) N
and CC N
4 CD N
weeks NNS N
energy NN N
balance NN N
( ( N
8.2 CD N
MJ/day NNP N
) ) N
in IN N
two CD N
groups NNS N
of IN N
subjects NNS N
randomly RB N
assigned VBN N
to TO N
either VB N
a DT N
high-protein NN N
( ( N
HP NNP N
) ) N
diet NN N
( ( N
27 CD N
% NN N
of IN N
energy NN N
( ( N
% NN N
E NNP N
) ) N
as IN N
protein NN N
, , N
45 CD N
% NN N
E NNP N
as IN N
carbohydrate NN N
) ) N
or CC N
a DT N
lower-protein JJ N
( ( N
LP NNP N
) ) N
diet NN N
( ( N
16 CD N
% NN N
E NNP N
as IN N
protein NN N
, , N
57 CD N
% NN N
E NNP N
as IN N
carbohydrate NN N
) ) N
. . N

SUBJECTS VB N
A DT N
total NN N
of IN N
36 CD N
obese JJ 4_p
nondiabetic JJ N
volunteers NNS N
with IN N
hyperinsulinemia NN 4_p
( ( N
10 CD N
males/26 NN N
females NNS N
, , N
aged VBD N
34-65 JJ N
y NN N
, , N
BMI NNP N
28-43 CD N
kg/m NN N
( ( N
2 CD N
) ) N
, , N
fasting VBG N
insulin JJ N
12-45 JJ N
mU/l NN N
) ) N
. . N

MEASUREMENTS NNP N
Body NNP N
weight VBD N
and CC N
composition NN N
, , N
TEE NNP N
, , N
REE NNP N
, , N
and CC N
RQ NNP N
were VBD N
measured VBN N
at IN N
baseline NN N
and CC N
at IN N
week NN N
16 CD N
. . N

In IN N
addition NN N
, , N
the DT N
TEF NNP N
to TO N
an DT N
HP NNP N
or CC N
LP NNP N
meal NN N
was VBD N
determined VBN N
for IN N
3 CD N
h NN N
, , N
at IN N
baseline NN N
and CC N
at IN N
week NN N
16 CD N
. . N

RESULTS NN N
After IN N
16 CD N
weeks NNS N
, , N
weight JJ N
loss NN N
was VBD N
similar JJ N
in IN N
response NN N
to TO N
each DT N
diet NN N
; : N
the DT N
overall JJ N
decrease NN N
was VBD N
7.9+/-0.6 JJ N
kg NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
of IN N
which WDT N
6.8+/-0.5 JJ N
kg NN N
was VBD N
fat JJ N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

REE NNP N
fell VBD N
similarly RB N
with IN N
each DT N
diet NN N
; : N
the DT N
overall JJ N
decrease NN N
was VBD N
719+/-106 JJ N
kJ/day NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

The DT N
TEF NNP N
was VBD N
2 CD N
% NN N
greater JJR N
after IN N
the DT N
HP NNP N
than IN N
after IN N
the DT N
LP NNP N
meal NN N
at IN N
baseline NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
and CC N
0.8 CD N
% NN N
greater JJR N
at IN N
week NN N
16 CD N
( ( N
P=0.35 NNP N
) ) N
. . N

After IN N
16 CD N
weeks NNS N
, , N
the DT N
TEF NNP N
was VBD N
not RB N
reduced VBN N
in IN N
either DT N
dietary JJ N
group NN N
. . N

There EX N
was VBD N
no DT N
change NN N
in IN N
TEE NNP N
after IN N
16 CD N
weeks NNS N
. . N

CONCLUSION NNP N
In IN N
subjects NNS N
with IN N
hyperinsulinemia PDT 4_p
an DT N
energy-restrictive JJ N
diet NN N
containing VBG N
an DT N
increased VBN N
protein-to-carbohydrate NN N
ratio NN N
does VBZ N
not RB N
enhance VB N
weight JJ N
loss NN N
or CC N
significantly RB N
affect JJ N
energy NN N
expenditure NN N
. . N

Caloric NNP N
restriction NN N
, , N
rather RB N
than IN N
the DT N
macronutrient JJ N
composition NN N
of IN N
the DT N
diet NN N
, , N
is VBZ N
the DT N
most RBS N
important JJ N
determinant NN N
of IN N
weight JJ N
loss NN N
. . N

-DOCSTART- -X- O O 20624257

Effects NNS N
of IN N
intravenous JJ N
iron NN N
combined VBN N
with IN N
low-dose JJ N
recombinant JJ N
human JJ N
erythropoietin NN N
on IN N
transfusion NN N
requirements NNS N
in IN N
iron-deficient JJ 4_p
patients NNS 4_p
undergoing VBG 4_p
bilateral JJ 4_p
total JJ 4_p
knee NN 4_p
replacement NN 4_p
arthroplasty NN 4_p
. . 4_p

BACKGROUND IN N
The DT N
authors NNS N
examined VBD N
the DT N
impact NN N
of IN N
parenteral JJ N
iron NN N
and CC N
recombinant JJ N
human JJ N
erythropoietin-β NN N
( ( N
rHuEPO-β JJ N
) ) N
administered VBN N
in IN N
the DT N
bilateral JJ N
total JJ N
knee NN N
replacement NN N
arthroplasty NN N
( ( N
TKRA NNP N
) ) N
, , N
on IN N
postoperative JJ N
anemia NN N
and CC N
transfusion NN N
requirements NNS N
in IN N
iron-deficient JJ N
patients NNS N
. . N

STUDY NNP N
DESIGN NNP N
AND NNP N
METHODS NNP N
A NNP N
total NN N
of IN N
108 CD N
iron-deficient JJ N
patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
two CD N
groups NNS N
: : N
Group NNP N
C NNP N
( ( N
control NN N
) ) N
or CC N
Group NNP N
IE NNP N
( ( N
200 CD N
mg NN N
of IN N
iron NN N
sucrose NN N
intravenously RB N
over IN N
1 CD N
hr NNS N
and CC N
3000 CD N
IU NNP N
of IN N
rHuEPO-β JJ N
subcutaneously NN N
during IN N
the DT N
operation NN N
and CC N
during IN N
the DT N
postoperative JJ N
period NN N
if IN N
the DT N
hemoglobin NN N
[ NNP N
Hb NNP N
] NNP N
level NN N
was VBD N
70-80 JJ N
g/L NN N
) ) N
. . N

One CD N
or CC N
2 CD N
units NNS N
of IN N
blood NN N
were VBD N
transfused VBN N
to TO N
patients NNS N
in IN N
both DT N
groups NNS N
according VBG N
to TO N
postoperative JJ N
Hb NNP N
level NN N
( ( N
between IN N
60 CD N
and CC N
70 CD N
g/L NN N
or CC N
betweeen JJ N
50 CD N
and CC N
60 CD N
g/L NN N
, , N
respectively RB N
) ) N
. . N

Perioperative JJ N
laboratory NN N
and CC N
clinical JJ N
outcomes NNS N
( ( N
Hb NNP N
, , N
iron NN N
variables NNS N
, , N
postoperative JJ N
bleeding NN N
amount NN N
, , N
and CC N
number NN N
of IN N
units NNS N
of IN N
RBCs NNP N
transfused VBD N
and CC N
incidences NNS N
) ) N
were VBD N
documented VBN N
. . N

RESULTS NNP N
Although IN N
preoperative JJ N
Hb NNP N
and CC N
the DT N
amount NN N
of IN N
postoperative JJ N
bleeding NN N
were VBD N
comparable JJ N
in IN N
the DT N
two CD N
groups NNS N
, , N
Hb NNP N
levels NNS N
at IN N
1 CD N
, , N
2 CD N
, , N
and CC N
3 CD N
days NNS N
and CC N
at IN N
2 CD N
and CC N
6 CD N
weeks NNS N
postoperation NN N
were VBD N
significantly RB N
higher JJR N
in IN N
Group NNP N
IE NNP N
. . N

Furthermore NNP N
, , N
the DT N
transfusion NN N
rate NN N
was VBD N
significantly RB N
lower JJR N
in IN N
Group NNP N
IE NNP N
( ( N
20.4 CD N
% NN N
vs. FW N
53.7 CD N
% NN N
, , N
p=0.011 NN N
) ) N
and CC N
the DT N
mean JJ N
number NN N
of IN N
red JJ N
blood NN N
cell NN N
units NNS N
transfused VBD N
was VBD N
markedly RB N
lower JJR N
in IN N
Group NNP N
IE NNP N
( ( N
0.2±0.5 CD N
vs. FW N
0.8±0.8 CD N
, , N
p=0.005 NN N
) ) N
. . N

Postoperative NNP N
iron NN N
, , N
ferritin NN N
, , N
and CC N
transferrin JJ N
saturation NN N
levels NNS N
were VBD N
significantly RB N
higher JJR N
in IN N
Group NNP N
IE NNP N
. . N

CONCLUSIONS NNP N
Treatment NNP N
with IN N
parenteral JJ N
iron NN N
and CC N
low-dose JJ N
rHuEPO-β NN N
in IN N
bilateral JJ N
TKRA NNP N
effectively RB N
attenuated VBD N
anemia NN N
and CC N
decreased VBN N
transfusion NN N
requirements NNS N
in IN N
iron-deficient JJ N
patients NNS N
. . N

-DOCSTART- -X- O O 19833610

Long-term JJ N
results NNS N
after IN N
intracoronary JJ N
injection NN N
of IN N
autologous JJ N
mononuclear JJ N
bone NN N
marrow NN N
cells NNS N
in IN N
acute JJ 4_p
myocardial JJ 4_p
infarction NN 4_p
: : 4_p
the DT N
ASTAMI NNP 4_p
randomised VBD N
, , N
controlled VBD N
study NN N
. . N

OBJECTIVE NNP N
To TO N
investigate VB N
long-term JJ N
safety NN N
and CC N
efficacy NN N
after IN N
intracoronary JJ N
injection NN N
of IN N
autologous JJ N
mononuclear JJ N
bone NN N
marrow NN N
cells NNS N
( ( N
mBMCs NN N
) ) N
in IN N
acute JJ 4_p
myocardial JJ 4_p
infarction NN 4_p
( ( 4_p
AMI NNP 4_p
) ) 4_p
. . N

DESIGN NNP N
Randomised VBD N
, , N
controlled VBD N
trial NN N
. . N

SETTING NN N
Two CD N
university NN N
hospitals NNS N
in IN N
Oslo NNP N
, , N
Norway NNP N
. . N

PATIENTS NNP N
Patients NNPS N
from IN N
the DT N
Autologous NNP N
Stem NNP N
cell NN N
Transplantation NNP N
in IN N
Acute NNP 4_p
Myocardial NNP 4_p
Infarction NNP 4_p
( ( 4_p
ASTAMI NNP 4_p
) ) 4_p
study NN N
were VBD N
re-assessed JJ N
3 CD N
years NNS N
after IN N
inclusion NN N
. . N

INTERVENTIONS NNP N
100 CD N
patients NNS N
with IN N
anterior JJ N
wall NN N
ST-elevation NNP 4_p
myocardial JJ 4_p
infarction NN 4_p
treated VBN N
with IN N
acute JJ N
percutaneous JJ 4_p
coronary JJ 4_p
intervention NN 4_p
( ( 4_p
PCI NNP 4_p
) ) 4_p
were VBD N
randomised VBN N
to TO N
receive VB N
intracoronary JJ N
injection NN N
of IN N
mBMCs NN N
( ( N
n JJ N
= NNP N
50 CD N
) ) N
or CC N
not RB N
( ( N
n JJ N
= NNP N
50 CD N
) ) N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Change NNP N
in IN N
left JJ N
ventricular NN N
( ( N
LV NNP N
) ) N
ejection NN N
fraction NN N
( ( N
primary JJ N
) ) N
. . N

Change NN N
in IN N
exercise NN N
capacity NN N
( ( N
peak JJ N
VO NNP N
( ( N
2 CD N
) ) N
) ) N
and CC N
quality NN N
of IN N
life NN N
( ( N
secondary JJ N
) ) N
. . N

Infarct NNP N
size NN N
( ( N
additional JJ N
aim NN N
) ) N
, , N
and CC N
safety NN N
. . N

RESULTS VB N
The DT N
rates NNS N
of IN N
adverse JJ N
clinical JJ N
events NNS N
in IN N
the DT N
groups NNS N
were VBD N
low JJ N
and CC N
equal JJ N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
groups NNS N
in IN N
change NN N
of IN N
global JJ N
LV NNP N
systolic JJ N
function NN N
by IN N
echocardiography NN N
or CC N
magnetic JJ N
resonance NN N
imaging NN N
( ( N
MRI NNP N
) ) N
during IN N
the DT N
follow-up JJ N
. . N

On IN N
exercise NN N
testing NN N
, , N
the DT N
mBMC-treated JJ N
patients NNS N
had VBD N
larger JJR N
improvement NN N
in IN N
exercise NN N
time NN N
from IN N
2-3 JJ N
weeks NNS N
to TO N
3 CD N
years NNS N
( ( N
1.5 CD N
minutes NNS N
vs VBP N
0.6 CD N
minutes NNS N
, , N
p VBP N
= RB N
0.05 CD N
) ) N
, , N
but CC N
the DT N
change NN N
in IN N
peak NN N
oxygen NN N
consumption NN N
did VBD N
not RB N
differ VB N
( ( N
3.0 CD N
ml/kg/min NN N
vs NN N
3.1 CD N
ml/kg/min NN N
, , N
p NN N
= NNP N
0.75 CD N
) ) N
. . N

CONCLUSION VB N
The DT N
results NNS N
indicate VBP N
that IN N
intracoronary JJ N
mBMC NN N
treatment NN N
in IN N
AMI NNP N
is VBZ N
safe JJ N
in IN N
the DT N
long JJ N
term NN N
. . N

A DT N
small JJ N
improvement NN N
in IN N
exercise NN N
time NN N
in IN N
the DT N
mBMC NN N
group NN N
was VBD N
found VBN N
, , N
but CC N
no DT N
other JJ N
effects NNS N
of IN N
treatment NN N
could MD N
be VB N
identified VBN N
3 CD N
years NNS N
after IN N
cell NN N
therapy NN N
. . N

-DOCSTART- -X- O O 16411994

Does VBZ N
a DT N
first JJ N
trimester NN N
dating VBG N
scan JJ N
using VBG N
crown JJ N
rump NN N
length NN N
measurement NN N
reduce VB N
the DT N
rate NN N
of IN N
induction NN N
of IN N
labour NN N
for IN N
prolonged JJ N
pregnancy NN N
? . N
An DT N
uncompleted JJ N
randomised VBD N
controlled JJ N
trial NN N
of IN N
463 CD N
women NNS N
. . N

OBJECTIVE NNP N
To TO N
evaluate VB N
the DT N
effect NN N
of IN N
a DT N
first JJ N
trimester NN N
ultrasound IN N
dating VBG N
scan JJ N
on IN N
the DT N
rate NN N
of IN N
induction NN N
of IN N
labour NN N
for IN N
prolonged JJ N
pregnancy NN N
. . N

DESIGN NNP N
Randomised VBD N
controlled VBN N
trial NN N
to TO N
include VB N
400 CD N
women NNS N
in IN N
each DT N
arm NN N
of IN N
the DT N
trial NN N
. . N

SETTING NN N
Participating VBG N
general JJ N
practices NNS N
and CC N
a DT N
district NN N
general JJ N
teaching NN N
hospital NN N
. . N

POPULATION NNP N
Women NNP N
attending VBG N
their PRP$ N
general JJ N
practitioner NN N
in IN N
the DT N
first JJ 4_p
trimester NN 4_p
to TO N
confirm VB N
pregnancy NN 4_p
, , N
in IN N
whom WP N
a DT N
first JJ N
trimester NN N
ultrasound JJ N
scan NN N
was VBD N
not RB N
indicated VBN N
. . N

METHODS NNP N
Women NNP N
randomised VBD N
to TO N
the DT N
study NN N
group NN N
( ( N
scan JJ N
group NN N
) ) N
underwent VBD N
an DT N
ultrasound JJ N
dating NN N
scan NN N
between IN N
8 CD N
and CC N
12 CD N
weeks NNS N
, , N
measuring VBG N
crown-rump JJ N
length NN N
. . N

The DT N
estimated JJ N
date NN N
of IN N
delivery NN N
( ( N
EDD NNP N
) ) N
was VBD N
changed VBN N
if IN N
there EX N
was VBD N
a DT N
discrepancy NN N
of IN N
more JJR N
than IN N
5 CD N
days NNS N
from IN N
the DT N
gestation NN N
, , N
calculated VBN N
from IN N
the DT N
last JJ N
menstrual JJ N
period NN N
( ( N
LMP NNP N
) ) N
. . N

For IN N
the DT N
remaining VBG N
women NNS N
( ( N
no-scan JJ N
group NN N
) ) N
, , N
gestation NN N
was VBD N
determined VBN N
using VBG N
the DT N
LMP NNP N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
The DT N
rate NN N
of IN N
induction NN N
of IN N
labour NN N
for IN N
prolonged JJ N
pregnancy NN N
. . N

RESULTS NNP N
Due NNP N
to TO N
circumstances NNS N
beyond IN N
the DT N
researchers NNS N
' POS N
control NN N
, , N
recruitment NN N
was VBD N
abandoned VBN N
when WRB N
463 CD N
women NNS N
had VBD N
been VBN N
enrolled VBN N
. . N

The DT N
EDD NNP N
was VBD N
adjusted VBN N
in IN N
13 CD N
( ( N
5.7 CD N
% NN N
) ) N
women NNS N
in IN N
the DT N
scan JJ N
group NN N
and CC N
in IN N
2 CD N
( ( N
0.9 CD N
% NN N
) ) N
in IN N
the DT N
no-scan JJ N
group NN N
. . N

There EX N
was VBD N
no DT N
difference NN N
in IN N
the DT N
rate NN N
of IN N
induction NN N
for IN N
prolonged JJ N
pregnancy NN N
between IN N
the DT N
scan JJ N
( ( N
19 CD N
[ RB N
8.2 CD N
% NN N
] NN N
) ) N
and CC N
the DT N
no-scan JJ N
( ( N
17 CD N
[ RB N
7.4 CD N
% NN N
] NN N
) ) N
groups NNS N
( ( N
relative JJ N
risk NN N
1.10 CD N
; : N
95 CD N
% NN N
CI NNP N
0.59-2.07 NN N
) ) N
. . N

CONCLUSIONS NNP N
Acknowledging VBG N
the DT N
reduced JJ N
numbers NNS N
recruited VBN N
for IN N
study NN N
, , N
it PRP N
is VBZ N
concluded VBN N
that IN N
there EX N
is VBZ N
no DT N
evidence NN N
that IN N
a DT N
first JJ N
trimester NN N
ultrasound IN N
dating VBG N
scan JJ N
reduces NNS N
the DT N
rate NN N
of IN N
induction NN N
of IN N
labour NN N
for IN N
prolonged JJ N
pregnancy NN N
and CC N
may MD N
result VB N
in IN N
a DT N
more RBR N
expensive JJ N
healthcare NN N
strategy NN N
. . N

-DOCSTART- -X- O O 15132762

Increased VBN N
repetitive JJ N
behaviours NNS N
and CC N
prolactin JJ N
responsivity NN N
to TO N
oral JJ N
m-chlorophenylpiperazine NN N
in IN N
adults NNS 4_p
with IN 4_p
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
. . 4_p

Autism NNP N
is VBZ N
a DT N
neurodevelopmental JJ N
disorder NN N
characterized VBN N
by IN N
dysfunction NN N
in IN N
three CD N
primary JJ N
behavioural JJ N
domains NNS N
: : N
repetitive JJ N
behaviours NNS N
, , N
social JJ N
deficits NNS N
, , N
and CC N
language NN N
abnormalities NNS N
. . N

There EX N
is VBZ N
evidence NN N
that IN N
abnormalities NNS N
exist VBP N
in IN N
the DT N
serotonin NN N
( ( N
5-HT JJ N
) ) N
system NN N
in IN N
autism NN N
spectrum NN N
patients NNS N
. . N

Furthermore RB N
, , N
5-HT JJ N
is VBZ N
known VBN N
to TO N
play VB N
a DT N
role NN N
in IN N
repetitive JJ N
and CC N
social JJ N
behaviours NN N
. . N

This DT N
study NN N
examined VBD N
the DT N
effect NN N
of IN N
m-chlorophenylpiperazine NN N
( ( N
m-CPP JJ N
) ) N
on IN N
repetitive JJ N
behaviours NNS N
and CC N
prolactin JJ N
response NN N
in IN N
11 CD N
adults NNS N
with IN N
autism NN N
or CC N
Aspergers NNS N
disorder VBP N
and CC N
8 CD N
age- JJ N
and CC N
gender-matched JJ N
healthy JJ N
controls NNS N
via IN N
randomized VBN N
double-blind NN N
, , N
m-CPP JJ N
and CC N
placebo JJ N
challenges NNS N
. . N

The DT N
primary JJ N
outcome NN N
measure NN N
was VBD N
an DT N
instrument NN N
rating NN N
six CD N
repetitive JJ N
behaviours NNS N
: : N
need NN N
to TO N
know VB N
, , N
repeating VBG N
, , N
ordering VBG N
, , N
need NN N
to TO N
tell/ask VB N
, , N
self-injury NN N
, , N
and CC N
touching VBG N
. . N

Patients NNS N
with IN N
autism NN N
spectrum NN N
disorders NNS N
showed VBD N
a DT N
significant JJ N
increase NN N
in IN N
repetitive JJ N
behaviours NNS N
at IN N
end-point NN N
following VBG N
oral JJ N
m-CPP NNS N
in IN N
comparison NN N
to TO N
placebo VB N
. . N

Additionally NNP N
subjects VBZ N
with IN N
autism NN N
spectrum NN N
disorders NNS N
showed VBD N
a DT N
significantly RB N
increased VBN N
prolactin NN N
response NN N
to TO N
m-CPP NN N
compared VBN N
to TO N
normal JJ N
controls NNS N
, , N
with IN N
neither DT N
group NN N
responding VBG N
to TO N
placebo VB N
. . N

This DT N
study NN N
provides VBZ N
further JJ N
evidence NN N
for IN N
altered JJ N
5-HT JJ N
sensitivity NN N
in IN N
individuals NNS N
with IN N
autism NN N
spectrum NN N
disorders NNS N
, , N
as RB N
well RB N
as IN N
a DT N
possible JJ N
relationship NN N
between IN N
repetitive JJ N
behaviours NNS N
in IN N
autism NN N
spectrum NN N
disorders NNS N
and CC N
abnormalities NNS N
in IN N
the DT N
5-HT JJ N
system NN N
. . N

-DOCSTART- -X- O O 12813449

Recombinant JJ N
human JJ N
thrombopoietin NN N
augments NNS N
mobilization NN N
of IN N
peripheral JJ N
blood NN N
progenitor NN N
cells NNS N
for IN N
autologous JJ 4_p
transplantation NN 4_p
. . 4_p

This DT N
study NN N
assessed VBD N
the DT N
ability NN N
of IN N
various JJ N
schedules NNS N
of IN N
recombinant JJ N
human JJ N
thrombopoietin NN N
( ( N
rhTPO NN N
) ) N
to TO N
enhance VB N
mobilization NN N
of IN N
peripheral JJ N
blood NN N
progenitor NN N
cells NNS N
( ( N
PBPCs NNP N
) ) N
in IN N
134 CD N
patients NNS N
with IN N
cancer NN 4_p
undergoing VBG N
high-dose JJ N
chemotherapy NN N
and CC N
autologous JJ N
PBPC NNP N
transplantation NN N
. . N

Patients NNS N
received VBD N
the DT N
study NN N
drug NN N
on IN N
days NNS N
1 CD N
, , N
3 CD N
, , N
and CC N
5 CD N
before IN N
initiation NN N
of IN N
granulocyte JJ N
colony-stimulating JJ N
factor NN N
( ( N
G-CSF NNP N
) ) N
10 CD N
microg/kg/day NN N
on IN N
day NN N
5 CD N
and CC N
pheresis NN N
starting VBG N
on IN N
day NN N
9 CD N
. . N

Randomly RB N
assigned JJ N
treatments NNS N
on IN N
days NNS N
1 CD N
, , N
3 CD N
, , N
and CC N
5 CD N
were VBD N
: : N
group NN N
1 CD N
( ( N
n=27 NN N
) ) N
placebo NN N
, , N
placebo NN N
, , N
rhTPO VBZ N
1.5 CD N
microg/kg NN N
; : N
group NN N
2 CD N
( ( N
n=27 NN N
) ) N
rhTPO VBZ N
1.5 CD N
microg/kg NN N
, , N
placebo NN N
, , N
placebo NN N
; : N
groups NNS N
3 CD N
( ( N
n=28 NN N
) ) N
and CC N
4 CD N
( ( N
n=22 NN N
) ) N
rhTPO VBZ N
0.5 CD N
microg/kg NN N
on IN N
all DT N
3 CD N
treatment NN N
days NNS N
; : N
and CC N
group NN N
5 CD N
( ( N
n=30 NN N
) ) N
placebo NN N
on IN N
all DT N
3 CD N
treatment NN N
days NNS N
. . N

After IN N
high-dose JJ N
chemotherapy NN N
and CC N
PBPC NNP N
transplantation NN N
, , N
groups NNS N
1 CD N
through IN N
4 CD N
received VBD N
rhTPO NN N
1.5 CD N
microg/kg NN N
days NNS N
0 CD N
, , N
+2 NNP N
, , N
+4 NNP N
, , N
and CC N
+6 VBZ N
with IN N
either DT N
G-CSF NNP N
5 CD N
microg/kg/day NN N
( ( N
groups NNS N
1-3 CD N
) ) N
or CC N
granulocyte-macrophage JJ N
colony-stimulating JJ N
factor NN N
250 CD N
microg/m NN N
( ( N
2 CD N
) ) N
/day NN N
( ( N
group NN N
4 CD N
) ) N
. . N

Group NNP N
5 CD N
received VBD N
placebo JJ N
plus CC N
G-CSF JJ N
5 CD N
microg/kg/day NN N
. . N

The DT N
addition NN N
of IN N
rhTPO NN N
to TO N
G-CSF NNP N
increased JJ N
median JJ N
CD34+ NNP N
cell NN N
yield/pheresis NN N
in IN N
cohorts NNS N
in IN N
which WDT N
rhTPO NN N
was VBD N
started VBN N
before IN N
day NN N
5 CD N
, , N
with IN N
higher JJR N
yields NNS N
in IN N
groups NNS N
2 CD N
( ( N
2.67 CD N
x RB N
10 CD N
( ( N
6 CD N
) ) N
/kg NN N
) ) N
and CC N
groups NNS N
3 CD N
and CC N
4 CD N
( ( N
3.10 CD N
x RB N
10 CD N
( ( N
6 CD N
) ) N
/kg NN N
) ) N
than IN N
in IN N
group NN N
1 CD N
( ( N
1.86 CD N
x RB N
10 CD N
( ( N
6 CD N
) ) N
/kg NN N
) ) N
or CC N
group NN N
5 CD N
( ( N
1.65 CD N
x RB N
10 CD N
( ( N
6 CD N
) ) N
/kg NN N
) ) N
( ( N
P=.006 NNP N
across IN N
groups NNS N
) ) N
. . N

Comparing VBG N
rhTPO NN N
to TO N
placebo VB N
, , N
higher JJR N
percentages NNS N
of IN N
patients NNS N
achieved VBN N
the DT N
minimum JJ N
yield NN N
of IN N
CD34+ NNP N
> NNP N
or CC N
=2 NNP N
x VBP N
10 CD N
( ( N
6 CD N
) ) N
/kg NN N
( ( N
92 CD N
% NN N
v JJ N
75 CD N
% NN N
; : N
P=.050 NNP N
) ) N
as RB N
well RB N
as IN N
the DT N
target NN N
yield NN N
of IN N
CD34+ NNP N
> NNP N
or CC N
=5 NNP N
x VBP N
10 CD N
( ( N
6 CD N
) ) N
/kg NN N
( ( N
73 CD N
% NN N
v JJ N
46 CD N
% NN N
; : N
P= NNP N
.041 NNP N
) ) N
. . N

rhTPO-treated JJ N
patients NNS N
required VBN N
fewer JJR N
phereses NNS N
to TO N
achieve VB N
minimum NN N
( ( N
P= NNP N
.011 NNP N
) ) N
and CC N
target NN N
( ( N
P= NNP N
.015 NNP N
) ) N
CD34+ NNP N
cell NN N
values NNS N
. . N

rhTPO VB N
given VBN N
after IN N
transplantation NN N
did VBD N
not RB N
speed VB N
platelet NN N
recovery NN N
. . N

No UH N
neutralizing JJ N
antibodies NNS N
were VBD N
observed VBN N
. . N

We PRP N
conclude VBP N
that IN N
rhTPO NN N
can MD N
safely RB N
enhance VB N
mobilization NN N
of IN N
PBPC NNP N
, , N
reduce VB N
the DT N
number NN N
of IN N
leukapheresis NN N
, , N
and CC N
allow VB N
more JJR N
patients NNS N
to TO N
meet VB N
minimal JJ N
cell NN N
yield NN N
requirements NNS N
to TO N
receive VB N
high-dose JJ N
chemotherapy NN N
with IN N
PBPC NNP N
transplantation NN N
. . N

-DOCSTART- -X- O O 17083268

The DT N
protective JJ N
effects NNS N
of IN N
angiotensin NN N
II NNP N
blockade NN N
with IN N
olmesartan JJ N
medoxomil NN N
on IN N
resistance NN N
vessel NN N
remodeling VBG N
( ( N
The DT N
VIOS NNP N
study NN N
) ) N
: : N
rationale NN N
and CC N
baseline NN N
characteristics NNS N
. . N

BACKGROUND IN N
The DT N
VIOS NNP N
( ( N
Vascular JJ N
Improvement NN N
with IN N
Olmesartan NNP N
medoxomil NNP N
Study NNP N
) ) N
study NN N
is VBZ N
a DT N
randomized JJ N
, , N
parallel JJ N
study NN N
to TO N
determine VB N
the DT N
relative JJ N
effects NNS N
of IN N
suppressing VBG N
the DT N
renin-angiotensin NN N
system NN N
( ( N
RAS NNP N
) ) N
with IN N
the DT N
angiotensin NN N
receptor NN N
antagonist NN N
olmesartan IN N
medoxomil NN N
versus NN N
suppressing VBG N
sympathetic JJ N
drive NN N
with IN N
the DT N
beta-adrenoceptor JJ N
antagonist NN N
atenolol NN N
on IN N
remodeling NN N
of IN N
the DT N
subcutaneous JJ N
small JJ N
resistance NN N
vessel NN N
. . N

Remodeling VBG N
of IN N
small JJ N
resistance NN N
vessels NNS N
may MD N
be VB N
the DT N
earliest JJS N
pathologic NN N
finding VBG N
associated VBN N
with IN N
hypertension NN N
. . N

It PRP N
may MD N
predate VB N
the DT N
onset NN N
of IN N
clinically RB N
apparent JJ N
hypertension NN N
. . N

METHODS NNP N
In IN N
this DT N
study NN N
, , N
100 CD N
patients NNS N
with IN N
stage NN 4_p
I PRP 4_p
hypertension VBP 4_p
are VBP N
characterized VBN N
at IN N
baseline NN N
before IN N
being VBG N
treated VBN N
for IN N
1 CD N
year NN N
to TO N
obtain VB N
a DT N
goal NN N
BP NNP N
of IN N
less JJR N
than IN N
140/90 CD N
mm JJ N
Hg NNP N
as IN N
defined VBN N
by IN N
Joint NNP N
National NNP N
Committee NNP N
( ( N
JNC NNP N
) ) N
-7 NN N
. . N

Resistance NNP N
vessel NN N
remodeling NN N
is VBZ N
determined VBN N
using VBG N
the DT N
gluteal NN N
fat JJ N
biopsy NN N
technique NN N
in IN N
the DT N
hypertensive JJ N
patients NNS N
and CC N
a DT N
group NN N
of IN N
normotensive JJ N
healthy JJ N
volunteers NNS N
. . N

Additionally RB N
, , N
efforts NNS N
will MD N
be VB N
made VBN N
to TO N
define VB N
whether IN N
noninvasive JJ N
hemodynamic JJ N
parameters NNS N
, , N
retinal JJ N
vessel FW N
measurement NN N
changes NNS N
, , N
or CC N
biologic JJ N
markers NNS N
may MD N
predict VB N
and CC N
track VB N
the DT N
underlying VBG N
vascular JJ N
morphologic NN N
and CC N
physiologic JJ N
changes NNS N
induced VBN N
by IN N
either DT N
regimen NNS N
during IN N
the DT N
12-month JJ N
treatment NN N
period NN N
. . N

RESULTS VB N
The DT N
primary JJ N
endpoint NN N
will MD N
be VB N
the DT N
degree NN N
of IN N
vascular JJ N
remodeling VBG N
as RB N
obtained VBN N
from IN N
percutaneous JJ N
biopsy NN N
of IN N
gluteal NN N
subcutaneous JJ N
resistance NN N
vessels NNS N
in IN N
each DT N
of IN N
two CD N
treatment NN N
arms NNS N
compared VBN N
with IN N
the DT N
normal JJ N
volunteers NNS N
. . N

The DT N
design NN N
of IN N
the DT N
study NN N
and CC N
the DT N
pertinent JJ N
baseline NN N
characteristics NNS N
of IN N
these DT N
patients NNS N
with IN N
uncomplicated JJ N
essential JJ N
hypertension NN N
are VBP N
presented VBN N
. . N

CONCLUSION VB N
The DT N
suppression NN N
of IN N
the DT N
RAS NNP N
by IN N
the DT N
blockade NN N
of IN N
angiotensin NN N
II NNP N
type NN N
1 CD N
( ( N
AT NNP N
( ( N
1 CD N
) ) N
) ) N
receptors NNS N
may MD N
demonstrate VB N
remodeling VBG N
effects NNS N
on IN N
the DT N
ubiquitous JJ N
small JJ N
resistance NN N
vessels NNS N
similar JJ N
to TO N
that DT N
seen VBN N
in IN N
the DT N
myocardium NN N
and CC N
renal JJ N
glomeruli NN N
, , N
thus RB N
affording VBG N
more JJR N
complete JJ N
end-organ JJ N
protection NN N
. . N

-DOCSTART- -X- O O 14650571

Can MD N
acupuncture VB N
ease VB N
the DT N
symptoms NNS N
of IN N
menopause NN 4_p
? . N
In IN N
a DT N
randomized JJ N
, , N
2-group JJ N
clinical JJ N
study NN N
, , N
acupuncture NN N
was VBD N
used VBN N
for IN N
the DT N
relief NN N
of IN N
menopausal NN 4_p
hot JJ 4_p
flushes NNS 4_p
, , N
sleep JJ 4_p
disturbances NNS 4_p
, , N
and CC N
mood NN 4_p
changes NNS 4_p
. . N

The DT N
experimental JJ N
acupuncture NN N
treatment NN N
consisted VBD N
of IN N
specific JJ N
acupuncture NN N
body NN N
points NNS N
related VBN N
to TO N
menopausal VB N
symptoms NNS N
. . N

The DT N
comparison JJ N
acupuncture NN N
treatment NN N
consisted VBN N
of IN N
a DT N
treatment NN N
designated VBN N
as IN N
a DT N
general JJ N
tonic NN N
specifically RB N
designed VBN N
to TO N
benefit VB N
the DT N
flow NN N
of IN N
Ch'i NNP N
( ( N
energy NN N
) ) N
. . N

Results NNS N
from IN N
the DT N
experimental JJ N
acupuncture NN N
treatment NN N
group NN N
showed VBD N
a DT N
decrease NN N
in IN N
mean JJ N
monthly JJ N
hot JJ N
flush NN N
severity NN N
for IN N
site-specific JJ N
acupuncture NN N
. . N

The DT N
comparison JJ N
acupuncture NN N
treatment NN N
group NN N
had VBD N
no DT N
significant JJ N
change NN N
in IN N
severity NN N
from IN N
baseline NN N
over IN N
the DT N
treatment NN N
phase NN N
. . N

Sleep JJ N
disturbances NNS N
in IN N
the DT N
experimental JJ N
acupuncture NN N
treatment NN N
group NN N
declined VBD N
over IN N
the DT N
study NN N
. . N

Mood NNP N
changes NNS N
in IN N
both DT N
the DT N
experimental JJ N
acupuncture NN N
treatment NN N
group NN N
and CC N
the DT N
comparison NN N
acupuncture NN N
treatment NN N
group NN N
showed VBD N
a DT N
significant JJ N
difference NN N
between IN N
the DT N
baseline NN N
and CC N
the DT N
third JJ N
month NN N
of IN N
the DT N
study NN N
. . N

Acupuncture NNP N
using VBG N
menopausal-specific JJ N
sites NNS N
holds VBZ N
promise NN N
for IN N
nonhormonal JJ N
relief NN N
of IN N
hot JJ N
flushes NNS N
and CC N
sleep JJ N
disturbances NNS N
. . N

-DOCSTART- -X- O O 22723176

The DT N
in IN N
vitro JJ N
effects NNS N
of IN N
verbascoside NN N
on IN N
human JJ 4_p
platelet NN 4_p
aggregation NN 4_p
. . 4_p

Preliminary NNP N
in IN N
vitro NN N
and CC N
animal NN N
studies NNS N
have VBP N
shown VBN N
that IN N
verbascoside NN N
, , N
a DT N
phenolic JJ N
compound NN N
, , N
may MD N
have VB N
several JJ N
favourable JJ N
biological JJ N
activities NNS N
, , N
including VBG N
an DT N
influence NN N
on IN N
endothelial JJ N
function NN N
and CC N
on IN N
platelet NN N
aggregation NN N
. . N

We PRP N
sought VBD N
to TO N
evaluate VB N
the DT N
effects NNS N
of IN N
verbascoside NN N
, , N
biotechnologically RB N
produced VBN N
from IN N
plant NN N
cell NN N
cultures NNS N
, , N
on IN N
human JJ N
platelet NN N
aggregation NN N
( ( N
PA NNP N
) ) N
. . N

The DT N
blood NN N
from IN N
40 CD N
aspirin-naïve JJ N
volunteers NNS N
with IN N
at IN N
least JJS N
one CD N
cardiovascular NN N
risk NN N
factor NN N
was VBD N
preincubated VBN N
in IN N
vitro NN N
with IN N
verbascoside NN N
( ( N
1 CD N
and CC N
2 CD N
mg/dL NN N
) ) N
and CC N
aspirin NN N
( ( N
100 CD N
μM NN N
) ) N
. . N

The DT N
blood NN N
from IN N
20 CD N
patients NNS N
with IN N
a DT N
prior JJ N
diagnosis NN N
of IN N
coronary JJ N
heart NN N
disease NN N
who WP N
were VBD N
chronically RB N
assuming VBG N
aspirin NN N
was VBD N
preincubated VBN N
in IN N
vitro NN N
with IN N
verbascoside NN N
( ( N
1 CD N
and CC N
2 CD N
mg/dL NN N
) ) N
. . N

PA NNP N
is VBZ N
measured VBN N
with IN N
a DT N
light JJ N
transmission NN N
aggregometry NN N
and CC N
multiplate NN N
analyzer NN N
. . N

As IN N
compared VBN N
to TO N
reference VB N
, , N
preincubation NN N
with IN N
verbascoside NN N
resulted VBD N
in IN N
a DT N
significant JJ N
inhibition NN N
of IN N
adenosine JJ N
diphosphate NN N
( ( N
ADP NNP N
) ) N
and CC N
arachidonic JJ N
acid NN N
( ( N
AA NNP N
) ) N
-induced VBD N
PA NNP N
( ( N
p VB N
< $ N
0.01 CD N
for IN N
both DT N
) ) N
. . N

Verbascoside $ N
2 CD N
mg/dL NN N
did VBD N
not RB N
show VB N
a DT N
stronger JJR N
effect NN N
as IN N
compared VBN N
to TO N
verbascoside VB N
1 CD N
mg/dL NN N
( ( N
p JJ N
= NNP N
0.4 CD N
) ) N
. . N

As IN N
expected VBN N
, , N
the DT N
in IN N
vitro JJ N
addition NN N
of IN N
aspirin NN N
reduced VBN N
AA NNP N
induced JJ N
PA NNP N
( ( N
p VB N
< RB N
0.01 CD N
) ) N
, , N
but CC N
not RB N
that IN N
induced VBN N
by IN N
ADP NNP N
( ( N
p JJ N
= NNP N
0.5 CD N
) ) N
. . N

The DT N
addition NN N
of IN N
verbascoside NN N
to TO N
the DT N
blood NN N
of IN N
aspirin-treated JJ N
patients NNS N
did VBD N
not RB N
improve VB N
the DT N
values NNS N
of IN N
PA NNP N
after IN N
AA NNP N
stimulus NN N
( ( N
p JJ N
= NNP N
0.8 CD N
) ) N
, , N
whereas IN N
it PRP N
ensured VBD N
a DT N
stronger JJR N
inhibition NN N
after IN N
ADP NNP N
stimulus NN N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
. . N

Verbascoside NNP N
in IN N
vitro JJ N
affects NNS N
PA VBN N
by IN N
mildly RB N
inhibiting VBG N
aggregation NN N
, , N
triggered VBD N
both DT N
by IN N
ADP NNP N
and CC N
AA NNP N
. . N

These DT N
preliminary JJ N
data NNS N
, , N
while IN N
intriguing NN N
, , N
require VBP N
confirmation NN N
in IN N
subjects NNS N
receiving VBG N
verbascoside NN N
orally RB N
in IN N
order NN N
to TO N
determine VB N
whether IN N
these DT N
findings NNS N
are VBP N
clinically RB N
relevant JJ N
. . N

-DOCSTART- -X- O O 25912520

Effects NNS N
of IN N
the DT N
Quest NNP N
to TO N
Lava NNP N
Mountain NNP N
Computer NNP N
Game NNP N
on IN N
Dietary NNP N
and CC N
Physical NNP N
Activity NNP N
Behaviors NNP N
of IN N
Elementary NNP N
School NNP N
Children NNP N
: : N
A DT N
Pilot NNP N
Group-Randomized NNP N
Controlled NNP N
Trial NNP N
. . N

BACKGROUND NNP N
Computer-based JJ N
educational JJ N
games NNS N
present VBP N
an DT N
opportunity NN N
for IN N
health NN N
education NN N
in IN N
school NN N
; : N
however RB N
, , N
their PRP$ N
feasibility NN N
in IN N
school NN N
settings NNS N
and CC N
effectiveness NN N
in IN N
changing VBG N
behavior NN N
are VBP N
poorly RB N
understood JJ N
. . N

OBJECTIVE NN N
To TO N
evaluate VB N
the DT N
feasibility NN N
, , N
acceptability NN N
, , N
and CC N
effects NNS N
of IN N
the DT N
Quest NNP N
to TO N
Lava NNP N
Mountain NNP N
( ( N
QTLM NNP N
) ) N
computer NN N
game NN N
on IN N
dietary JJ N
behaviors NNS N
, , N
physical JJ N
activity NN N
behaviors NNS N
, , N
and CC N
psychosocial JJ N
factors NNS N
among IN N
ethnically RB N
diverse JJ N
children NNS N
in IN N
Texas NNP N
. . N

DESIGN NNP N
Quasi-experimental JJ N
group-randomized JJ N
controlled VBN N
trial NN N
conducted VBN N
during IN N
the DT N
2012-2013 JJ N
school NN N
year NN N
. . N

PARTICIPANTS/SETTING CC N
A DT N
total NN N
of IN N
107 CD N
children NNS N
in IN N
fourth JJ N
and CC N
fifth JJ N
grade NN N
consented VBN N
. . N

There EX N
was VBD N
an DT N
attrition NN N
rate NN N
of IN N
8.8 CD N
% NN N
with IN N
a DT N
final JJ N
sample NN N
size NN N
of IN N
44 CD N
children NNS N
in IN N
three CD N
intervention NN N
schools NNS N
, , N
and CC N
a DT N
sample NN N
of IN N
50 CD N
children NNS N
in IN N
three CD N
comparison NN N
schools NNS N
. . N

Dietary NNP N
intake NN N
was VBD N
measured VBN N
using VBG N
two CD N
random JJ N
24-hour JJ N
recalls NNS N
, , N
whereas JJ N
child NN N
self-report JJ N
surveys NNS N
measured VBN N
diet JJ N
, , N
physical JJ N
activity NN N
, , N
and CC N
psychosocial JJ N
factors NNS N
before IN N
and CC N
after IN N
the DT N
intervention NN N
. . N

Process NNP N
data NN N
on IN N
QTLM NNP N
usability NN N
and CC N
back-end JJ N
server NN N
data NNS N
on IN N
QTLM NNP N
exposure NN N
and CC N
progress NN N
achieved VBN N
were VBD N
collected VBN N
. . N

INTERVENTION NNP N
QTLM NNP N
was VBD N
implemented VBN N
as IN N
part NN N
of IN N
the DT N
in-school NN N
or CC N
afterschool JJ N
program NN N
. . N

Recommended JJ N
game NN N
exposure NN N
duration NN N
was VBD N
90 CD N
min/wk NN N
for IN N
6 CD N
weeks NNS N
. . N

STATISTICAL JJ N
ANALYSIS NNP N
Analysis NNP N
of IN N
covariance NN N
or CC N
logistic JJ N
regression NN N
models NNS N
evaluated VBN N
effects NNS N
of IN N
QTLM NNP N
on IN N
diet JJ N
, , N
physical JJ N
activity NN N
, , N
and CC N
psychosocial JJ N
factors NNS N
. . N

Post NNP N
hoc JJ N
exploratory NN N
analysis NN N
examined VBD N
the DT N
changes NNS N
before IN N
and CC N
after IN N
the DT N
intervention NN N
in IN N
outcome JJ N
variables NNS N
among IN N
children NNS N
in IN N
the DT N
intervention NN N
group NN N
. . N

Significance NN N
was VBD N
set VBN N
at IN N
P NNP N
< NNP N
0.05 CD N
. . N

RESULTS NNP N
Children NNP N
played VBD N
an DT N
average NN N
of IN N
274±110 CD N
minutes NNS N
( ( N
approximately RB N
4.6 CD N
hours NNS N
) ) N
of IN N
QTLM NNP N
during IN N
the DT N
6 CD N
weeks NNS N
( ( N
51 CD N
% NN N
of IN N
recommended JJ N
dosage NN N
) ) N
. . N

Compared VBN N
with IN N
the DT N
comparison NN N
group NN N
, , N
children NNS N
in IN N
the DT N
intervention NN N
group NN N
reported VBD N
decreased JJ N
sugar NN N
consumption NN N
( ( N
P=0.021 NNP N
) ) N
and CC N
higher JJR N
nutrition/physical JJ N
activity NN N
attitudes NNS N
( ( N
P=0.041 NNP N
) ) N
pre- NN N
to TO N
postintervention NN N
. . N

There EX N
were VBD N
no DT N
significant JJ N
effects NNS N
of IN N
QTLM NNP N
on IN N
physical JJ N
activity NN N
. . N

However RB N
, , N
post NN N
hoc NN N
analysis NN N
showed VBD N
that IN N
higher JJR N
QTLM NNP N
exposure NN N
and CC N
gaming VBG N
progress NN N
was VBD N
associated VBN N
with IN N
increased JJ N
frequency NN N
of IN N
physical JJ N
activity NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSIONS NNP N
QTLM NNP N
has VBZ N
some DT N
promising JJ N
acceptability NN N
and CC N
initial JJ N
effects NNS N
on IN N
diet JJ N
and CC N
physical JJ N
activity NN N
behaviors NNS N
among IN N
children NNS N
in IN N
elementary JJ N
school NN N
. . N

-DOCSTART- -X- O O 25572620

Efficacy NN N
of IN N
a DT N
tobacco NN N
quitline NN N
among IN N
adult JJ N
cancer NN 4_p
survivors NNS 4_p
. . N

OBJECTIVE IN N
The DT N
purpose NN N
of IN N
the DT N
study NN N
( ( N
conducted VBN N
2010-2013 CD N
) ) N
was VBD N
to TO N
determine VB N
the DT N
efficacy NN N
of IN N
two CD N
common JJ N
types NNS N
of IN N
tobacco NN N
quitlines NNS N
in IN N
adult NN N
cancer NN 4_p
survivors NNS N
who WP N
regularly RB N
smoked VBD N
cigarettes NNS N
. . N

METHOD NNP N
Adult NNP N
onset VBD N
cancer NN 4_p
survivors NNS N
in IN N
Memphis NNP N
, , N
Tennessee NNP N
( ( N
n=427 UH N
, , N
67 CD N
% NN N
female NN N
, , N
60 CD N
% NN N
Caucasian JJ N
) ) N
were VBD N
randomized VBN N
either RB N
to TO N
a DT N
Proactive NNP N
( ( N
i.e. FW N
, , N
counselor-initiated JJ N
calls NNS N
) ) N
or CC N
Reactive NNP N
( ( N
i.e. FW N
, , N
participant-initiated JJ N
calls NNS N
) ) N
quitline NN N
. . N

Both DT N
conditions NNS N
also RB N
received VBD N
nicotine JJ N
replacement NN N
therapy NN N
. . N

The DT N
primary JJ N
outcome NN N
was VBD N
biochemically-verified JJ N
( ( N
i.e. FW N
, , N
salivary JJ N
cotinine NN N
) ) N
smoking NN N
cessation NN N
. . N

RESULTS NNP N
While IN N
12-month JJ N
self-reported JJ N
abstinence NN N
was VBD N
consistent JJ N
with IN N
other JJ N
published VBN N
studies NNS N
of IN N
smoking VBG N
cessation NN N
( ( N
22 CD N
% NN N
and CC N
26 CD N
% NN N
point NN N
prevalence NN N
abstinence NN N
for IN N
Proactive NNP N
and CC N
Reactive NNP N
conditions NNS N
, , N
respectively RB N
) ) N
, , N
48 CD N
% NN N
of IN N
participants NNS N
who WP N
were VBD N
tested VBN N
for IN N
cotinine NN N
failed VBD N
biochemical JJ N
verification NN N
, , N
indicating VBG N
a DT N
considerable JJ N
falsification NN N
of IN N
self-reported JJ N
cessation NN N
. . N

Adjusted VBN N
cessation NN N
rates NNS N
were VBD N
less JJR N
than IN N
5 CD N
% NN N
in IN N
both DT N
intervention NN N
conditions NNS N
. . N

CONCLUSION NNP N
Our PRP$ N
results NNS N
are VBP N
consistent JJ N
with IN N
other JJ N
studies NNS N
indicating VBG N
that IN N
traditional JJ N
smoking NN N
cessation NN N
interventions NNS N
are VBP N
ineffective JJ N
among IN N
cancer NN N
survivors NNS N
. . N

Moreover RB N
, , N
self-reports NNS N
of IN N
cessation NN N
were VBD N
unreliable JJ N
in IN N
cancer NN N
survivors NNS N
participating VBG N
in IN N
a DT N
quitline NN N
intervention NN N
, , N
indicating VBG N
that IN N
future JJ N
studies NNS N
should MD N
include VB N
biochemical JJ N
verification NN N
. . N

Given VBN N
the DT N
importance NN N
of IN N
smoking VBG N
cessation NN N
among IN N
cancer NN 4_p
survivors NNS N
and CC N
low JJ N
cessation NN N
rates NNS N
in IN N
the DT N
current JJ N
study NN N
, , N
it PRP N
may MD N
be VB N
necessary JJ N
to TO N
design VB N
alternative JJ N
interventions NNS N
for IN N
this DT N
population NN N
. . N

ClinicalTrials.gov NNP N
identifier NN N
: : N
NCT00827866 NNP N
. . N

-DOCSTART- -X- O O 11300174

Effectiveness NN N
of IN N
the DT N
school NN N
dental JJ N
screening VBG N
programme NN N
in IN N
stimulating VBG N
dental JJ N
attendance NN N
for IN N
children NNS N
in IN N
need NN N
of IN N
treatment NN N
in IN N
Northern NNP N
Ireland NNP N
. . N

UNLABELLED IN N
The DT N
school NN N
dental JJ N
screening NN N
programme NN N
has VBZ N
been VBN N
in IN N
existence NN N
from IN N
the DT N
beginning NN N
of IN N
the DT N
20th JJ N
century NN N
yet RB N
its PRP$ N
value NN N
in IN N
encouraging JJ N
attendance NN N
among IN N
children NNS N
with IN N
a DT N
dental JJ 4_p
health NN 4_p
need NN N
is VBZ N
not RB N
fully RB N
established VBN N
. . N

OBJECTIVE NNP N
To TO N
evaluate VB N
the DT N
effectiveness NN N
of IN N
school NN N
dental JJ N
screening NN N
in IN N
promoting VBG N
dental JJ N
attendance NN N
among IN N
children NNS N
with IN N
a DT N
treatment NN N
need NN N
and CC N
to TO N
examine VB N
the DT N
relative JJ N
importance NN N
of IN N
screening NN N
, , N
social JJ N
class NN N
and CC N
other JJ N
factors NNS N
in IN N
dental JJ N
attendance NN N
. . N

METHODS NNP N
Sixty-four JJ N
participating NN N
schools NNS N
were VBD N
assigned VBN N
to TO N
study VB N
and CC N
control VB N
groups NNS N
using VBG N
a DT N
stratified JJ N
, , N
blocked JJ N
randomisation NN N
technique NN N
. . N

The DT N
study NN N
group NN N
children NNS N
received VBD N
the DT N
standard JJ N
school NN N
dental JJ N
screening NN N
and CC N
the DT N
dental JJ N
attendance NN N
of IN N
those DT N
with IN N
a DT N
positive JJ N
screening NN N
result NN N
was VBD N
assessed VBN N
after IN N
2 CD N
months NNS N
by IN N
means NNS N
of IN N
a DT N
questionnaire NN N
issued VBN N
to TO N
the DT N
children NNS N
's POS N
parents NNS N
. . N

The DT N
control NN N
group NN N
children NNS N
were VBD N
not RB N
, , N
at IN N
this DT N
stage NN N
, , N
screened VBD N
, , N
yet CC N
their PRP$ N
parents NNS N
received VBD N
the DT N
same JJ N
questionnaire NN N
assessing VBG N
dental JJ N
attendance NN N
over IN N
the DT N
2-month JJ N
period NN N
. . N

However RB N
, , N
only RB N
questionnaires VBZ N
from IN N
control NN N
group NN N
children NNS N
who WP N
had VBD N
a DT N
positive JJ N
result NN N
at IN N
a DT N
subsequent JJ N
screening NN N
were VBD N
retained VBN N
for IN N
analysis NN N
. . N

RESULTS VB N
A DT N
total NN N
of IN N
2,321 CD N
children NNS N
were VBD N
screened VBN N
, , N
with IN N
980 CD N
having VBG N
a DT N
positive JJ N
result NN N
. . N

The DT N
mean JJ N
dmft NN N
of IN N
those DT N
screening VBG N
positive JJ N
was VBD N
4.85 CD N
. . N

In IN N
all DT N
, , N
664 CD N
completed VBN N
questionnaires NNS N
were VBD N
returned VBN N
, , N
giving VBG N
a DT N
response NN N
rate NN N
of IN N
67.8 CD N
% NN N
. . N

Dental JJ N
attendance NN N
was VBD N
reported VBN N
among IN N
45.5 CD N
% NN N
of IN N
the DT N
study NN N
group NN N
( ( N
n=352 NN N
) ) N
in IN N
the DT N
2 CD N
months NNS N
following VBG N
screening NN N
. . N

In IN N
the DT N
same JJ N
period NN N
, , N
27.6 CD N
% NN N
of IN N
the DT N
control NN N
group NN N
( ( N
n=312 RB N
) ) N
claimed VBD N
attendance NN N
. . N

The DT N
effect NN N
was VBD N
found VBN N
to TO N
be VB N
significant JJ N
among IN N
the DT N
high JJ N
employed VBN N
group NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
and CC N
the DT N
unemployed JJ N
group NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSION NNP N
School NNP N
dental JJ N
screening NN N
was VBD N
capable JJ N
of IN N
stimulating VBG N
dental JJ N
attendance NN N
. . N

The DT N
strong JJ N
effect NN N
among IN N
the DT N
lowest JJS N
socio-economic JJ N
group NN N
shows VBZ N
that IN N
school NN N
dental JJ N
screening NN N
may MD N
be VB N
used VBN N
to TO N
decrease VB N
dental JJ N
health NN N
inequalities NNS N
. . N

-DOCSTART- -X- O O 22690882

Effectiveness NN N
of IN N
web-based JJ N
tailored JJ N
smoking NN 4_p
cessation NN 4_p
advice NN N
reports NNS N
( ( N
iQuit NN N
) ) N
: : N
a DT N
randomized JJ N
trial NN N
. . N

AIMS NNP N
To TO N
determine VB N
whether IN N
web-based JJ N
tailored JJ N
cessation NN N
advice NN N
, , N
based VBN N
on IN N
social JJ N
cognitive JJ N
theory NN N
and CC N
the DT N
perspectives NNS N
on IN N
change NN N
model NN N
, , N
was VBD N
more RBR N
effective JJ N
in IN N
aiding VBG N
a DT N
quit NN N
attempt NN N
than IN N
broadly RB N
similar JJ N
web-based JJ N
advice NN N
that WDT N
was VBD N
not RB N
tailored VBN N
. . N

DESIGN JJ N
Participants NNS N
were VBD N
allocated VBN N
randomly RB N
to TO N
one CD N
of IN N
two CD N
groups NNS N
, , N
to TO N
receive VB N
either CC N
a DT N
cessation NN N
advice NN N
report NN N
and CC N
progress JJ N
report NN N
that WDT N
were VBD N
tailored VBN N
to TO N
individual-level JJ N
characteristics NNS N
or CC N
a DT N
cessation NN N
advice NN N
report NN N
that WDT N
presented VBD N
standardized JJ N
( ( N
non-tailored JJ N
) ) N
content NN N
. . N

Tailoring NNP N
was VBD N
based VBN N
on IN N
smoking-related JJ N
beliefs NN N
, , N
personal JJ N
characteristics NNS N
and CC N
smoking NN N
patterns NNS N
, , N
self-efficacy NN N
and CC N
outcome JJ N
expectations NNS N
. . N

SETTING NN N
Participant JJ N
enrolment NN N
and CC N
baseline NN N
assessments NNS N
were VBD N
conducted VBN N
remotely RB N
online JJ N
via IN N
the DT N
study NN N
website NN N
, , N
with IN N
the DT N
advice NN N
reports NNS N
presented VBN N
by IN N
the DT N
same JJ N
website NN N
. . N

PARTICIPANTS JJ N
Participants NNS N
( ( N
n IN N
= NNP N
1758 CD N
) ) N
were VBD N
visitors NNS N
to TO N
the DT N
QUIT NNP N
website NN N
who WP N
were VBD N
based VBN N
in IN N
the DT N
United NNP N
Kingdom NNP N
, , N
aged VBD N
18 CD N
years NNS N
or CC N
over RB N
and CC N
who WP N
smoked VBD N
cigarettes NNS N
or CC N
hand-rolled JJ N
tobacco NN N
. . N

MEASUREMENTS NNP N
Follow-up JJ N
assessments NNS N
were VBD N
made VBN N
at IN N
6 CD N
months NNS N
by IN N
telephone NN N
interview NN N
. . N

The DT N
primary JJ N
outcome NN N
measure NN N
was VBD N
self-reported JJ N
3 CD N
months NNS N
prolonged VBN N
abstinence NN N
, , N
and CC N
secondary JJ N
outcomes NNS N
were VBD N
1 CD N
month NN N
prolonged VBD N
abstinence NN N
, , N
7-day JJ N
and CC N
24-hour JJ N
point NN N
prevalence NN N
abstinence NN N
. . N

FINDINGS IN N
The DT N
intervention NN N
group NN N
did VBD N
not RB N
differ VB N
from IN N
the DT N
control NN N
group NN N
on IN N
the DT N
primary JJ N
outcome NN N
( ( N
9.1 CD N
% NN N
versus IN N
9.3 CD N
% NN N
; : N
odds NNS N
ratio VBP N
= $ N
1.02 CD N
95 CD N
% NN N
confidence NN N
interval JJ N
0.73-1.42 NN N
) ) N
or CC N
on IN N
any DT N
of IN N
the DT N
secondary JJ N
outcomes NNS N
. . N

Intervention NN N
participants NNS N
gave VBD N
more RBR N
positive JJ N
evaluations NNS N
of IN N
the DT N
materials NNS N
than IN N
control NN N
participants NNS N
. . N

CONCLUSIONS VB N
A DT N
web-based JJ N
intervention NN N
that WDT N
tailored VBD N
content JJ N
according VBG N
to TO N
smoking-related JJ N
beliefs NN N
, , N
personal JJ N
characteristics NNS N
and CC N
smoking NN N
patterns NNS N
, , N
self-efficacy NN N
and CC N
outcome NN N
expectations NNS N
, , N
was VBD N
not RB N
more RBR N
effective JJ N
than IN N
web-based JJ N
materials NNS N
presenting VBG N
broadly RB N
similar JJ N
non-tailored JJ N
information NN N
. . N

-DOCSTART- -X- O O 23438314

A DT N
randomized VBN N
controlled JJ N
trial NN N
of IN N
COMPASS NNP N
web-based JJ N
and CC N
face-to-face JJ N
teacher NN N
coaching NN N
in IN N
autism NN 4_p
. . N

OBJECTIVE CC N
Most JJS N
children NNS N
with IN N
autism NN 4_p
rely RB N
on IN N
schools NNS N
as IN N
their PRP$ N
primary JJ N
source NN N
of IN N
intervention NN N
, , N
yet RB N
research NN N
has VBZ N
suggested VBN N
that IN N
teachers NNS N
rarely RB N
use VBP N
evidence-based JJ N
practices NNS N
. . N

To TO N
address VB N
the DT N
need NN N
for IN N
improved JJ N
educational JJ N
outcomes NNS N
, , N
a DT N
previously RB N
tested VBN N
consultation NN N
intervention NN N
called VBD N
the DT N
Collaborative NNP N
Model NNP N
for IN N
Promoting VBG N
Competence NNP N
and CC N
Success NNP N
( ( N
COMPASS NNP N
; : N
Ruble NNP N
, , N
Dalrymple NNP N
, , N
& CC N
McGrew NNP N
, , N
2010 CD N
; : N
Ruble NNP N
, , N
Dalrymple NNP N
, , N
& CC N
McGrew NNP N
, , N
2012 CD N
) ) N
was VBD N
evaluated VBN N
in IN N
a DT N
2nd CD N
randomized VBN N
controlled VBN N
trial NN N
, , N
with IN N
the DT N
addition NN N
of IN N
a DT N
web-based JJ N
group NN N
. . N

METHOD NNP N
Forty-nine JJ N
teacher-child JJ N
dyads NNS N
were VBD N
randomized VBN N
into IN N
1 CD N
of IN N
3 CD N
groups NNS N
: : N
( ( N
1 CD N
) ) N
a DT N
placebo NN N
control NN N
( ( N
PBO NNP N
) ) N
group NN N
, , N
( ( N
2 CD N
) ) N
COMPASS NN N
followed VBN N
by IN N
face-to-face NN N
( ( N
FF NNP N
) ) N
coaching NN N
sessions NNS N
, , N
and CC N
( ( N
3 CD N
) ) N
COMPASS NN N
followed VBN N
by IN N
web-based JJ N
( ( N
WEB NNP N
) ) N
coaching NN N
sessions NNS N
. . N

Three CD N
individualized JJ N
goals NNS N
( ( N
social JJ N
, , N
communication NN N
, , N
and CC N
independence NN N
skills NNS N
) ) N
were VBD N
selected VBN N
for IN N
intervention NN N
for IN N
each DT N
child NN N
. . N

The DT N
primary JJ N
outcome NN N
of IN N
independent JJ N
ratings NNS N
of IN N
child NN N
goal NN N
attainment NN N
and CC N
several JJ N
process NN N
measures NNS N
( ( N
e.g. NN N
, , N
consultant NN N
and CC N
teacher NN N
fidelity NN N
) ) N
were VBD N
evaluated VBN N
. . N

RESULTS NNP N
Using VBG N
an DT N
intent-to-treat JJ N
approach NN N
, , N
findings NNS N
replicated VBD N
earlier RBR N
results NNS N
with IN N
a DT N
very RB N
large JJ N
effect NN N
size NN N
( ( N
d JJ N
= NNP N
1.41 CD N
) ) N
for IN N
the DT N
FF NNP N
group NN N
and CC N
a DT N
large JJ N
effect NN N
size NN N
( ( N
d JJ N
= NNP N
1.12 CD N
) ) N
for IN N
the DT N
WEB NNP N
group NN N
relative NN N
to TO N
the DT N
PBO NNP N
group NN N
. . N

There EX N
were VBD N
no DT N
differences NNS N
in IN N
overall JJ N
change NN N
across IN N
goal NN N
domains NNS N
between IN N
the DT N
FF NNP N
and CC N
WEB NNP N
groups NNS N
, , N
suggesting VBG N
the DT N
efficacy NN N
of IN N
videoconferencing VBG N
technology NN N
. . N

CONCLUSIONS NNP N
COMPASS NNP N
is VBZ N
effective JJ N
and CC N
results NNS N
in IN N
improved JJ N
educational JJ N
outcomes NNS N
for IN N
young JJ N
children NNS N
with IN N
autism NN 4_p
. . N

Videoconferencing NNP N
technology NN N
, , N
as IN N
a DT N
scalable JJ N
tool NN N
, , N
has VBZ N
promise NN N
for IN N
facilitating VBG N
access NN N
to TO N
autism NN N
specialists NNS N
and CC N
bridging VBG N
the DT N
research-to-practice JJ N
gap NN N
. . N

-DOCSTART- -X- O O 3123115

Serum NNP N
C-peptide NNP N
after IN N
6 CD N
months NNS N
on IN N
glibenclamide NN N
remains VBZ N
higher JJR N
than IN N
during IN N
insulin JJ N
treatment NN N
. . N

Serum NNP N
C-peptide NNP N
was VBD N
measured VBN N
fasting NN N
and CC N
6 CD N
minutes NNS N
after IN N
glucagon NN N
( ( N
1 CD N
mg NN N
given VBN N
intravenously RB N
) ) N
in IN N
49 CD N
patients NNS N
with IN N
non-insulin-dependent JJ 4_p
diabetes NNS 4_p
mellitus NNS 4_p
, , N
after IN N
4 CD N
and CC N
6 CD N
months NNS N
of IN N
successive JJ N
periods NNS N
of IN N
treatment NN N
with IN N
insulin NN N
and CC N
oral JJ N
hypoglycaemics NNS N
( ( N
glibenclamide NN N
and CC N
metformin NN N
) ) N
, , N
given VBN N
in IN N
random JJ N
order NN N
. . N

Glycaemic NNP N
control NN N
was VBD N
not RB N
significantly RB N
different JJ N
on IN N
the DT N
two CD N
treatments NNS N
, , N
but CC N
C-peptide NNP N
was VBD N
much RB N
higher JJR N
while IN N
the DT N
patients NNS N
were VBD N
on IN N
glibenclamide NN N
. . N

We PRP N
conclude VBP N
that IN N
glibenclamide NN N
stimulates VBZ N
pancreatic JJ N
insulin NN N
production NN N
even RB N
after IN N
6 CD N
months NNS N
treatment NN N
. . N

-DOCSTART- -X- O O 25919773

The DT N
impact NN N
of IN N
amalgam JJ N
dental JJ N
fillings NNS N
on IN N
the DT N
frequency NN N
of IN N
Helicobacter NNP N
pylori POS N
infection NN N
and CC N
H. NNP N
pylori JJ N
eradication NN N
rates NNS N
in IN N
patients NNS 4_p
treated VBN 4_p
with IN 4_p
concomitant NN 4_p
, , N
quadruple NN 4_p
, , 4_p
and CC 4_p
levofloxacin-based JJ 4_p
therapies NNS 4_p
. . N

BACKGROUND NNP N
AND NNP N
AIM NNP N
Mercury NNP N
exposure NN N
is VBZ N
encountered VBN N
most RBS N
commonly RB N
in IN N
individuals NNS 4_p
with IN 4_p
amalgam JJ 4_p
fillings NNS 4_p
. . 4_p

The DT N
toxic NN N
, , N
bactericidal NN N
, , N
and CC N
immunosuppressive JJ N
effects NNS N
of IN N
mercury NN N
are VBP N
well RB N
known VBN N
. . N

Furthermore NN N
, , N
multiple JJ N
antibiotic JJ N
resistance NN N
can MD N
be VB N
transferred VBN N
, , N
together RB N
with IN N
mercury NN N
resistance NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
frequency NN N
of IN N
Helicobacter NNP N
pylori FW N
infection NN N
in IN N
dyspeptic JJ 4_p
patients NNS 4_p
with IN 4_p
amalgam JJ 4_p
fillings NNS 4_p
and CC N
the DT 4_p
effect NN 4_p
of IN 4_p
the DT 4_p
amalgam JJ 4_p
fillings NNS 4_p
on IN 4_p
H. NNP 4_p
pylori JJ 4_p
eradication NN 4_p
rates NNS 4_p
in IN 4_p
these DT 4_p
patients NNS 4_p
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
Four NNP N
hundred VBD N
and CC N
seventy-five JJ N
patients NNS N
who WP N
presented VBD N
with IN N
dyspeptic JJ 4_p
complaints NNS 4_p
and CC N
underwent JJ 4_p
upper JJ 4_p
gastrointestinal JJ 4_p
endoscopy NN 4_p
and CC N
gastric JJ 4_p
biopsy NN 4_p
were VBD N
included VBN N
in IN N
this DT N
study NN N
. . N

One CD N
hundred CD N
and CC N
sixty-nine JJ N
( ( N
35.6 CD N
% NN N
) ) N
patients NNS N
were VBD N
negative JJ N
and CC N
306 CD N
( ( N
64.4 CD N
% NN N
) ) N
patients NNS N
were VBD N
positive JJ N
for IN N
H. NNP N
pylori NN N
. . N

All DT N
of IN N
the DT N
participants NNS N
underwent JJ N
dental JJ N
examinations NNS N
in IN N
a DT N
blinded JJ N
manner NN N
. . N

The DT N
participants NNS N
were VBD N
divided VBN N
into IN N
two CD N
groups NNS N
on IN N
the DT N
basis NN N
of IN N
the DT N
presence NN N
of IN N
amalgam JJ N
fillings NNS N
. . N

The DT N
H. NNP N
pylori-positive JJ N
patients NNS N
were VBD N
divided VBN N
randomly RB N
into IN N
three CD N
subgroups NNS N
: : N
patients NNS N
who WP N
received VBD N
concomitant JJ N
therapy NN N
( ( N
CT NNP N
) ) N
( ( N
rabeprazole-amoxicillin-clarithromycin-metronidazole JJ N
for IN N
14 CD N
days NNS N
; : N
n=122 CC N
) ) N
; : N
patients NNS N
who WP N
received VBD N
quadruple JJ N
therapy NN N
( ( N
QT NNP N
) ) N
( ( N
rabeprazole-tetracycline-metronidazole-colloidal JJ N
bismuth NN N
subcitrate NN N
for IN N
10 CD N
days NNS N
; : N
n=97 CC N
) ) N
; : N
and CC N
patients NNS N
who WP N
received VBD N
levofloxacin-based JJ N
therapy NN N
( ( N
LT NNP N
) ) N
( ( N
rabeprazole-amoxicillin-levofloxacin JJ N
for IN N
10 CD N
days NNS N
; : N
n=87 CC N
) ) N
. . N

Eradication NNP N
success NN N
was VBD N
detected VBN N
by IN N
a DT N
urea JJ N
breath NN N
test NN N
6 CD N
weeks NNS N
after IN N
the DT N
end NN N
of IN N
treatment NN N
. . N

RESULTS VB N
The DT N
frequency NN N
of IN N
H. NNP N
pylori FW N
infection NN N
was VBD N
significantly RB N
lower JJR N
in IN N
the DT N
filling NN N
group NN N
compared VBN N
with IN N
the DT N
nonfilling VBG N
group NN N
( ( N
53.7 CD N
and CC N
78.8 CD N
% NN N
, , N
respectively RB N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

The DT N
eradication NN N
rates NNS N
in IN N
the DT N
CT NNP N
, , N
QT NNP N
, , N
and CC N
LT NNP N
groups NNS N
were VBD N
65.5 CD N
, , N
67.0 CD N
, , N
and CC N
58.6 CD N
% NN N
, , N
respectively RB N
, , N
in IN N
the DT N
intention-to-treat NN N
( ( N
ITT NNP N
) ) N
analysis NN N
and CC N
69.6 CD N
, , N
70.7 CD N
, , N
and CC N
62.2 CD N
% NN N
, , N
respectively RB N
, , N
in IN N
the DT N
per-protocol NN N
( ( N
PP NNP N
) ) N
analysis NN N
. . N

In IN N
all DT N
of IN N
the DT N
H. NNP N
pylori-positive JJ 4_p
patients NNS 4_p
and CC N
separately RB N
in IN N
the DT N
CT NNP N
and CC N
LT NNP N
groups NNS N
, , N
the DT N
eradication NN N
rates NNS N
were VBD N
significantly RB N
lower JJR N
in IN N
the DT N
filling NN N
group NN N
compared VBN N
with IN N
the DT N
nonfilling VBG N
group NN N
. . N

However RB N
, , N
in IN N
the DT N
QT NNP N
group NN N
, , N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
patients NNS N
with IN N
and CC N
without IN N
fillings NNS N
( ( N
P=0.001 NNP N
, , N
0.003 CD N
, , N
0.012 CD N
, , N
0.14 CD N
, , N
respectively RB N
) ) N
. . N

Logistic JJ N
regression NN N
analysis NN N
showed VBD N
that IN N
the DT N
absence NN N
of IN N
amalgam NN N
filling VBG N
exerts NNS N
independent JJ N
effects NNS N
on IN N
the DT N
increased JJ N
frequency NN N
of IN N
H. NNP N
pylori FW N
infection NN N
and CC N
increased JJ N
rate NN N
of IN N
H. NNP N
pylori FW N
eradication NN N
. . N

CONCLUSION NNP N
This DT N
is VBZ N
the DT N
first JJ N
study NN N
to TO N
show VB N
a DT N
lower JJR N
frequency NN N
of IN N
H. NNP N
pylori FW N
colonization NN N
in IN N
patients NNS 4_p
with IN 4_p
amalgam JJ 4_p
fillings NNS 4_p
than IN N
without IN N
and CC N
that IN N
H. NNP N
pylori FW N
eradication NN N
rates NNS N
are VBP N
lower JJR N
in IN N
patients NNS 4_p
with IN 4_p
amalgam JJ 4_p
fillings NNS 4_p
compared VBN N
to TO N
those DT N
without IN N
. . N

-DOCSTART- -X- O O 9499947

[ JJ N
Value NNP N
of IN N
absorbable JJ N
clips NNS N
in IN N
laparoscopic JJ N
cholecystectomy NN N
. . N

A DT N
randomized JJ N
prospective JJ N
study NN N
] NNP N
. . N

Most JJS N
surgeons NNS N
use VBP N
metal JJ N
clips NNS N
in IN N
laparoscopic JJ N
cholecystectomy NN N
. . N

The DT N
aim NN N
of IN N
this DT N
prospective JJ N
randomized NN N
controlled VBD N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
absorbable JJ N
clips NNS N
in IN N
elective JJ N
laparoscopic NN N
cholecystectomy NN N
. . N

One CD N
hundred VBD N
consecutive JJ N
patients NNS N
with IN N
symptomatic JJ 4_p
gallstones NNS 4_p
without IN N
complications NNS N
were VBD N
randomized VBN N
into IN N
groups NNS N
; : N
group NN N
T NNP N
had VBD N
two CD N
metal JJ N
clips NNS N
( ( N
titan JJ N
clip NN N
ETHICONR NNP N
) ) N
, , N
group NN N
R NNP N
( ( N
laproclipR JJ N
Davis NNP N
and CC N
Geck NNP N
) ) N
had VBD N
one CD N
absorbable JJ N
clip NN N
applied VBN N
on IN N
the DT N
cystic JJ N
duct NN N
and CC N
cystic JJ N
artery NN N
. . N

The DT N
patients NNS N
were VBD N
followed VBN N
for IN N
one CD N
year NN N
. . N

There EX N
was VBD N
no DT N
difference NN N
between IN N
the DT N
two CD N
groups NNS N
concerning VBG N
operative JJ N
time NN N
, , N
hospital NN N
stay NN N
and CC N
postoperative JJ N
complications NNS N
. . N

The DT N
absorbable JJ N
clips NNS N
seem VBP N
to TO N
be VB N
as RB N
effective JJ N
as IN N
metal NN N
clips NNS N
in IN N
providing VBG N
hemostasis NN N
in IN N
cystic JJ N
artery NN N
and CC N
in IN N
cystic JJ N
duct NN N
ligation NN N
. . N

-DOCSTART- -X- O O 25284194

Selenium NNP N
Treatment NNP N
and CC N
Chagasic NNP N
Cardiopathy NNP N
( ( N
STCC NNP N
) ) N
: : N
study NN N
protocol NN N
for IN N
a DT N
double-blind JJ N
randomized NN N
controlled VBD N
trial NN N
. . N

BACKGROUND NNP N
Heart NNP N
disease NN N
progression NN N
occurs VBZ N
in IN N
30 CD N
% NN N
of IN N
patients NNS N
with IN N
chronic JJ N
Trypanosoma NNP N
cruzi NN N
infection NN N
. . N

Supplementation NN N
with IN N
selenium NN N
( ( N
Se NNP N
) ) N
in IN N
animal JJ N
model NN N
of IN N
T. NNP N
cruzi NN N
infection NN N
produced VBD N
promising JJ N
results NNS N
. . N

There EX N
is VBZ N
evidence NN N
that IN N
patients NNS 4_p
with IN 4_p
Chagas NNP 4_p
heart NN 4_p
disease NN 4_p
have VBP N
lower JJR N
Se NNP N
levels NNS N
than IN N
healthy JJ N
individuals NNS N
and CC N
patients NNS N
with IN N
T. NNP N
cruzi NN N
infection NN N
without IN N
of IN N
cardiac JJ N
disease NN N
. . N

The DT N
aim NN N
of IN N
this DT N
investigation NN N
is VBZ N
to TO N
estimate VB N
the DT N
effect NN N
of IN N
Se NNP N
treatment NN N
on IN N
prevention NN N
of IN N
heart NN N
disease NN N
progression NN N
in IN N
patients NNS 4_p
with IN 4_p
chagasic JJ 4_p
cardiopathy NN 4_p
. . N

METHODS NNP N
The DT N
Selenium NNP N
Treatment NNP N
and CC N
Chagasic NNP N
Cardiopathy NNP N
trial NN N
is VBZ N
a DT N
superiority NN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
, , N
randomized JJ N
clinical JJ N
trial NN N
. . N

The DT N
eligibility NN N
criteria NNS N
are VBP N
as IN N
follows VBZ N
: : N
( ( N
1 CD N
) ) N
a DT 4_p
Chagas NNP 4_p
disease NN 4_p
diagnosis NN 4_p
confirmed VBN 4_p
by IN 4_p
serology NN 4_p
; : N
( ( N
2 CD N
) ) N
segmental NN N
, , N
mild NN 4_p
or CC 4_p
moderate VB 4_p
global JJ 4_p
left NN 4_p
ventricular JJ 4_p
systolic JJ 4_p
dysfunction NN 4_p
; : 4_p
and CC N
( ( N
3 CD N
) ) N
age NN N
between IN N
18 CD N
and CC N
65 CD N
years NNS N
. . N

The DT N
exclusion NN N
criteria NNS N
are VBP N
as IN N
follows VBZ N
: : N
( ( N
1 CD N
) ) N
pregnancy NN N
, , N
( ( N
2 CD N
) ) N
diabetes VBZ 4_p
mellitus NN 4_p
, , 4_p
( ( N
3 CD N
) ) N
tobacco NN 4_p
use NN 4_p
, , 4_p
( ( N
4 CD N
) ) N
alcohol NN 4_p
abuse NN 4_p
, , N
( ( N
5 CD N
) ) N
evidence NN 4_p
of IN 4_p
nonchagasic JJ 4_p
heart NN 4_p
disease NN 4_p
, , N
( ( N
6 CD N
) ) N
depression NN 4_p
, , N
( ( N
7 CD N
) ) N
dysphagia NN 4_p
with IN N
evidence NN N
of IN N
food NN N
residues NNS N
in IN N
the DT N
esophagus NN N
, , N
( ( N
8 CD N
) ) N
dysphagia NN N
with IN N
weight JJ N
loss NN N
higher JJR N
than IN N
15 CD N
% NN N
of IN N
usual JJ N
weight NN N
in IN N
the DT N
last JJ N
four CD N
months NNS N
and/or RB N
( ( N
9 CD N
) ) N
conditions NNS N
that WDT N
may MD N
result VB N
in IN N
low JJ N
protocol NN N
adherence NN N
. . N

The DT N
intervention NN N
will MD N
be VB N
100 CD N
μg NNP N
of IN N
sodium NN N
selenite NN N
once RB N
daily JJ N
for IN N
365 CD N
consecutive JJ N
days NNS N
compared VBN N
to TO N
placebo VB N
. . N

The DT N
following VBG N
are VBP N
the DT N
primary JJ N
outcomes NNS N
to TO N
be VB N
measured VBN N
: : N
( ( N
1 CD N
) ) N
the DT N
trajectories NNS N
of IN N
the DT N
left NN N
ventricular JJ N
ejection NN N
fraction NN N
in IN N
the DT N
follow-up JJ N
period NN N
; : N
( ( N
2 CD N
) ) N
reduction NN N
of IN N
heart NN N
disease NN N
progression NN N
rates NNS N
, , N
with IN N
progression NN N
defined VBN N
as IN N
a DT N
10 CD N
% NN N
decrease NN N
in IN N
left JJ N
ventricular JJ N
ejection NN N
fraction NN N
; : N
and CC N
( ( N
3 CD N
) ) N
rate NN N
of IN N
hospital NN N
admissions NNS N
attributable JJ N
to TO N
dysrhythmia VB N
, , N
heart NN N
failure NN N
or CC N
stroke NN N
due JJ N
to TO N
Chagas NNP N
disease NN N
. . N

One CD N
hundred VBD N
thirty NN N
patients NNS N
will MD N
be VB N
randomly RB N
allocated VBN N
into IN N
either CC N
the DT N
intervention NN N
or CC N
placebo NN N
group NN N
at IN N
a DT N
ratio NN N
of IN N
1:1 CD N
. . N

The DT N
sequence NN N
allocation NN N
concealment NN N
and CC N
blinding NN N
were VBD N
planned VBN N
to TO N
be VB N
conducted VBN N
with IN N
the DT N
strategy NN N
of IN N
numbered JJ N
boxes NNS N
. . N

Both DT N
patients NNS N
and CC N
health-care JJ N
providers NNS N
will MD N
remain VB N
blinded JJ N
to TO N
the DT N
intervention NN N
groups NNS N
during IN N
the DT N
5 CD N
years NNS N
of IN N
follow-up NN N
. . N

DISCUSSION NNP N
If IN N
Se NNP N
treatment NN N
reduces VBZ N
the DT N
progression NN N
of IN N
Chagas NNP N
cardiopathy NN N
, , N
the DT N
inclusion NN N
of IN N
this DT N
micronutrient NN N
in IN N
the DT N
daily JJ N
diet NN N
can MD N
improve VB N
the DT N
therapeutic JJ N
regimen NNS N
for IN N
this DT N
neglected JJ N
tropical JJ N
disease NN N
at IN N
low JJ N
cost NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
Clinical NNP N
Trials.gov NNP N
ID NNP N
: : N
NCT00875173 NNP N
( ( N
registered VBD N
20 CD N
October NNP N
20 CD N
2008 CD N
) ) N
. . N

-DOCSTART- -X- O O 1516345

Double JJ N
blind IN N
comparison NN N
of IN N
Iomeprol NNP N
350 CD N
and CC N
Iopamidol NNP N
340 CD N
in IN N
intravenous JJ 4_p
digital JJ 4_p
subtraction NN 4_p
angiography NN 4_p
for IN N
peripheral JJ 4_p
vascular JJ 4_p
disease NN 4_p
. . N

A DT N
randomized JJ N
double JJ N
blind NN N
study NN N
was VBD N
undertaken VBN N
to TO N
compare VB N
the DT N
diagnostic JJ N
efficacy NN N
and CC N
side JJ N
effects NNS N
of IN N
a DT N
new JJ N
non-ionic JJ N
contrast NN N
medium NN N
Iomeprol NNP N
with IN N
a DT N
commonly RB N
used VBN N
one CD N
-- : N
Iopamidol NNP N
. . N

Visual NNP N
and CC N
densitometric JJ N
comparison NN N
was VBD N
made VBN N
of IN N
intravenous JJ N
digital JJ N
subtraction NN N
angiograms NNS N
performed VBD N
for IN N
peripheral JJ N
vascular JJ N
disease NN N
. . N

The DT N
results NNS N
show VBP N
the DT N
two CD N
media NNS N
to TO N
be VB N
similar JJ N
both DT N
in IN N
imaging VBG N
quality NN N
and CC N
in IN N
the DT N
incidence NN N
of IN N
associated JJ N
side NN N
effects NNS N
. . N

Ninety-eight JJ N
per IN N
cent NN N
of IN N
the DT N
intravenous JJ N
digital JJ N
subtraction NN N
angiograms NNS N
were VBD N
assessed VBN N
as IN N
adequate NN N
for IN N
clinical JJ N
management NN N
by IN N
the DT N
vascular JJ N
surgeon NN N
. . N

-DOCSTART- -X- O O 10889149

Atrophy NNP N
and CC N
intestinal JJ 4_p
metaplasia NN 4_p
one CD N
year NN N
after IN N
cure NN N
of IN N
H. NNP 4_p
pylori FW 4_p
infection NN 4_p
: : N
a DT N
prospective JJ N
, , N
randomized VBN N
study NN N
. . N

BACKGROUND NNP N
& CC N
AIMS NNP N
Helicobacter NNP N
pylori-infected JJ N
gastric JJ N
mucosa NN N
evolves VBZ N
through IN N
stages NNS N
of IN N
chronic JJ N
gastritis NN N
, , N
intestinal JJ N
metaplasia NN N
( ( N
IM NNP N
) ) N
, , N
glandular JJ N
atrophy NN N
( ( N
GA NNP N
) ) N
, , N
and CC N
dysplasia NN N
before IN N
carcinoma NN N
develops NNS N
. . N

We PRP N
studied VBD N
if IN N
H. NNP N
pylori FW N
eradication NN N
would MD N
alter VB N
the DT N
course NN N
of IN N
premalignant JJ N
histologic NN N
changes NNS N
in IN N
the DT N
stomach NN N
. . N

METHODS NNP N
Volunteers NNPS N
from IN N
the DT N
Yantai NNP N
County NNP N
in IN N
China NNP N
underwent JJ N
upper JJ N
endoscopy NN N
with IN N
biopsy NN N
specimens NNS N
obtained VBN N
from IN N
the DT N
antrum NN N
and CC N
corpus NN N
. . N

H. NNP N
pylori-infected JJ N
subjects NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
either RB N
a DT N
1-week JJ N
course NN N
of IN N
omeprazole JJ N
, , N
amoxicillin NN N
, , N
and CC N
clarithromycin NN N
( ( N
OAC NNP N
) ) N
or CC N
placebo NN N
. . N

At IN N
1 CD N
year NN N
, , N
endoscopies NNS N
with IN N
biopsies NNS N
were VBD N
repeated VBN N
. . N

RESULTS VB N
A DT N
total NN N
of IN N
587 CD N
H. NNP N
pylori-infected JJ N
subjects NNS N
were VBD N
randomized VBN N
to TO N
OAC NNP N
( ( N
n JJ N
= NNP N
295 CD N
) ) N
and CC N
placebo NN N
( ( N
n JJ N
= NNP N
292 CD N
) ) N
. . N

At IN N
1 CD N
year NN N
, , N
H. NNP N
pylori NN N
was VBD N
eradicated VBN N
in IN N
226 CD N
subjects NNS N
assigned VBN N
to TO N
OAC NNP N
. . N

In IN N
the DT N
placebo NN N
group NN N
, , N
245 CD N
patients NNS N
remained VBD N
H. NNP N
pylori NN N
infected VBD N
. . N

Analysis NN N
of IN N
paired JJ N
samples NNS N
obtained VBN N
from IN N
the DT N
same JJ N
patients NNS N
showed VBD N
that IN N
acute NN N
and CC N
chronic JJ N
gastritis NN N
decreased VBN N
in IN N
both DT N
the DT N
antrum NN N
and CC N
corpus NN N
after IN N
H. NNP N
pylori FW N
eradication NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
activity NN N
of IN N
IM NNP N
decreased VBD N
in IN N
antrum NN N
( ( N
P NNP N
= NNP N
0.014 CD N
) ) N
. . N

In IN N
the DT N
H. NNP N
pylori-infected JJ N
group NN N
, , N
antral JJ N
biopsy NN N
specimens NNS N
had VBD N
more RBR N
pronounced JJ N
acute NN N
gastritis NN N
( ( N
P NNP N
= NNP N
0.01 CD N
) ) N
, , N
whereas JJ N
corpus NN N
specimens NNS N
showed VBD N
increased VBN N
acute NN N
and CC N
chronic JJ N
gastritis NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
a DT N
marginal JJ N
increase NN N
in IN N
GA NNP N
( ( N
P NNP N
= NNP N
0.052 CD N
) ) N
. . N

When WRB N
histologic JJ N
changes NNS N
were VBD N
compared VBN N
between IN N
the DT N
2 CD N
groups NNS N
, , N
decrease NN N
in IN N
acute NN N
and CC N
chronic JJ N
gastritis NN N
was VBD N
more RBR N
frequent JJ N
after IN N
H. NNP N
pylori FW N
eradication NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
but CC N
changes NNS N
in IN N
IM NNP N
were VBD N
similar JJ N
. . N

In IN N
the DT N
H. NNP N
pylori-infected JJ N
group NN N
, , N
increase NN N
in IN N
GA NNP N
was VBD N
seen VBN N
in IN N
the DT N
corpus NN N
( ( N
P NNP N
= NNP N
0.01 CD N
) ) N
. . N

CONCLUSIONS NNP N
At IN N
1 CD N
year NN N
, , N
H. NNP N
pylori FW N
eradication NN N
is VBZ N
beneficial JJ N
in IN N
preventing VBG N
progression NN N
of IN N
pathologic JJ N
changes NNS N
of IN N
the DT N
gastric JJ N
mucosa NN N
. . N

-DOCSTART- -X- O O 11218508

The DT N
effect NN N
of IN N
splinting NN N
of IN N
teeth NNS N
in IN N
combination NN N
with IN N
reconstructive JJ 4_p
periodontal NN 4_p
surgery NN 4_p
in IN N
humans NNS 4_p
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
effect NN N
of IN N
splinting VBG N
teeth NNS N
on IN N
the DT N
results NNS N
of IN N
periodontal JJ N
reconstructive JJ N
surgery NN N
using VBG N
a DT N
specific JJ N
carbonate NN N
bone NN N
replacement NN N
graft NN N
( ( N
BRG NNP N
) ) N
material NN N
. . N

Forty-five JJ N
patients NNS N
were VBD N
randomly RB N
treated VBN N
with IN N
a DT N
periodontal JJ 4_p
surgery NN 4_p
approach NN N
. . N

Natural JJ N
coral JJ N
calcium NN N
BRG NNP N
was VBD N
utilised VBN N
in IN N
33 CD N
patients NNS N
. . N

This DT N
33-patient JJ N
group NN N
was VBD N
divided VBN N
into IN N
three CD N
equal JJ N
groups NNS N
. . N

In IN N
the DT N
presplint NN N
group NN N
, , N
teeth EX N
were VBD N
splinted VBN N
to TO N
at IN N
least JJS N
two CD N
rigid JJ N
teeth NNS N
before IN N
surgery NN N
, , N
in IN N
the DT N
postsplint NN N
group NN N
, , N
teeth EX N
were VBD N
splinted VBN N
at IN N
suture NN N
removal NN N
, , N
and CC N
in IN N
the DT N
nonsplint NN N
group NN N
, , N
the DT N
treated JJ N
teeth NNS N
were VBD N
not RB N
splinted VBN N
at IN N
all DT N
. . N

In IN N
12 CD N
patients NNS N
, , N
teeth NNS N
were VBD N
treated VBN N
with IN N
surgical JJ N
debridement NN N
( ( N
DEBR NNP N
) ) N
alone RB N
and CC N
not RB N
splinted VBN N
. . N

Periodontal JJ N
probing VBG N
depth NN N
( ( N
PPD NNP N
) ) N
, , N
clinical JJ N
probing VBG N
attachment JJ N
level NN N
( ( N
CPAL NNP N
) ) N
, , N
and CC N
tooth DT N
mobility NN N
were VBD N
measured VBN N
using VBG N
desmodontometry NN N
( ( N
DDM NNP N
) ) N
and CC N
periotest JJS N
( ( N
PTV NNP N
) ) N
with IN N
reproducible JJ N
methods NNS N
before IN N
surgery NN N
and CC N
at IN N
various JJ N
periods NNS N
up RB N
to TO N
1 CD N
year NN N
afterwards NNS N
. . N

A DT N
decrease NN N
in IN N
PPD NNP N
( ( N
5.4 CD N
mm NN N
, , N
SD NNP N
1.4 CD N
mm NN N
) ) N
and CC N
tooth DT N
mobility NN N
( ( N
DDM-horizontal JJ N
257 CD N
microns NNS N
, , N
SD NNP N
60 CD N
microns NNS N
) ) N
and CC N
a DT N
gain NN N
of IN N
CPAL NNP N
( ( N
5.1 CD N
mm NN N
, , N
SD NNP N
1.4 CD N
mm NN N
) ) N
were VBD N
seen VBN N
following VBG N
the DT N
use NN N
of IN N
BRG NNP N
in IN N
presplint NN N
teeth NNS N
. . N

In IN N
the DT N
same JJ N
group NN N
, , N
PPD NNP N
and CC N
tooth JJ N
mobility NN N
were VBD N
significantly RB N
reduced VBN N
compared VBN N
to TO N
nonsplint VB N
teeth NNS N
. . N

DEBR NNP N
alone RB N
showed VBD N
reductions NNS N
in IN N
tooth DT N
mobility NN N
and CC N
PPD NNP N
and CC N
a DT N
significantly RB N
smaller JJR N
gain NN N
in IN N
CPAL NNP N
than IN N
in IN N
presplint NN N
teeth NNS N
treated VBN N
with IN N
BRG NNP N
. . N

The DT N
less RBR N
favourable JJ N
improvement NN N
in IN N
periodontal JJ N
function NN N
of IN N
postsplint NN N
or CC N
nonsplint NN N
teeth NNS N
seemed VBD N
to TO N
be VB N
due JJ N
to TO N
the DT N
loss NN N
of IN N
BRG NNP N
material NN N
caused VBN N
by IN N
tooth DT N
mobility NN N
. . N

These DT N
results NNS N
indicate VBP N
that IN N
an DT N
undisturbed JJ N
wound NN N
healing VBG N
process NN N
using VBG N
BRG NNP N
together RB N
with IN N
tooth DT N
stability NN N
is VBZ N
beneficial JJ N
to TO N
overall JJ N
clinical JJ N
success NN N
. . N

-DOCSTART- -X- O O 22999292

Memantine NNP N
as IN N
adjunctive JJ N
treatment NN N
to TO N
risperidone VB N
in IN N
children NNS N
with IN N
autistic JJ 4_p
disorder NN 4_p
: : N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
trial NN N
. . N

Autism NNP N
is VBZ N
a DT N
neurodevelopmental JJ N
disorder NN N
that WDT N
causes VBZ N
significant JJ N
impairment NN N
in IN N
socialization NN N
and CC N
communication NN N
. . N

It PRP N
is VBZ N
also RB N
associated VBN N
with IN N
ritualistic JJ N
and CC N
stereotypical JJ N
behaviour NN N
. . N

Recent JJ N
studies NNS N
propose VBP N
both DT N
hyper-and JJ N
hypoglutamatergic NN N
ideologies NNS N
for IN N
autism NN N
. . N

The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
assess VB N
the DT N
effects NNS N
of IN N
memantine NN N
plus CC N
risperidone NN N
in IN N
the DT N
treatment NN N
of IN N
children NNS N
with IN N
autism NN 4_p
. . N

Children NNP N
with IN N
autism NN 4_p
were VBD N
randomly RB N
allocated VBN N
to TO N
risperidone VB N
plus JJ N
memantine NN N
or CC N
placebo NN N
plus CC N
risperidone NN N
for IN N
a DT N
10-wk JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
. . N

The DT N
dose NN N
of IN N
risperidone NN N
was VBD N
titrated VBN N
up RB N
to TO N
3 CD N
mg/d NNS N
and CC N
memantine NN N
was VBD N
titrated VBN N
to TO N
20 CD N
mg/d NN N
. . N

Children NNP N
were VBD N
assessed VBN N
at IN N
baseline NN N
and CC N
after IN N
2 CD N
, , N
4 CD N
, , N
6 CD N
, , N
8 CD N
and CC N
10 CD N
wk NN N
of IN N
starting VBG N
medication NN N
protocol NN N
. . N

The DT N
primary JJ N
outcome NN N
measure NN N
was VBD N
the DT N
irritability NN N
subscale NN N
of IN N
Aberrant NNP N
Behavior NNP N
Checklist-Community NNP N
( ( N
ABC-C NNP N
) ) N
. . N

Difference NN N
between IN N
the DT N
two CD N
treatment NN N
arms NNS N
was VBD N
significant JJ N
as IN N
the DT N
group NN N
that WDT N
received VBD N
memantine NN N
had VBD N
greater JJR N
reduction NN N
in IN N
ABC-C NNP N
subscale NN N
scores NNS N
for IN N
irritability NN N
, , N
stereotypic VB N
behaviour NN N
and CC N
hyperactivity NN N
. . N

Eight CD N
side-effects NNS N
were VBD N
observed VBN N
over IN N
the DT N
trial NN N
, , N
out IN N
of IN N
the DT N
25 CD N
side-effects NNS N
that IN N
the DT N
checklist NN N
included VBD N
. . N

The DT N
difference NN N
between IN N
the DT N
two CD N
groups NNS N
in IN N
the DT N
frequency NN N
of IN N
side-effects NNS N
was VBD N
not RB N
significant JJ N
. . N

The DT N
present JJ N
study NN N
suggests VBZ N
that IN N
memantine NN N
may MD N
be VB N
a DT N
potential JJ N
adjunctive JJ N
treatment NN N
strategy NN N
for IN N
autism NN N
and CC N
it PRP N
was VBD N
generally RB N
well RB N
tolerated VBN N
. . N

This DT N
trial NN N
is VBZ N
registered VBN N
with IN N
the DT N
Iranian JJ N
Clinical NNP N
Trials NNP N
Registry NNP N
( ( N
IRCT1138901151556N10 NNP N
; : N
www.irct.ir NN N
) ) N
. . N

-DOCSTART- -X- O O 21392837

Pharmacist NNP N
directed VBD N
home NN N
medication NN N
reviews NNS N
in IN N
patients NNS 4_p
with IN 4_p
chronic JJ 4_p
heart NN 4_p
failure NN 4_p
: : 4_p
a DT N
randomised JJ N
clinical JJ N
trial NN N
. . N

BACKGROUND NNP N
Chronic NNP 4_p
heart NN 4_p
failure NN 4_p
( ( 4_p
CHF NNP 4_p
) ) 4_p
accounts NNS N
for IN N
significant JJ N
morbidity NN N
, , N
mortality NN N
and CC N
health NN N
expenditure NN N
. . N

Furthermore NNP N
, , N
patients NNS 4_p
with IN 4_p
CHF NNP 4_p
are VBP N
often RB N
on IN N
numerous JJ N
pharmacological JJ N
agents NNS N
for IN N
their PRP$ N
comorbidities NNS N
. . N

The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
whether IN N
a DT N
pharmacist NN N
directed VBD N
home NN N
medication NN N
review NN N
intervention NN N
had VBD N
positive JJ N
effects NNS N
on IN N
CHF NNP 4_p
patient NN 4_p
outcomes NNS N
. . N

METHODS NNP N
A NNP N
total NN N
of IN N
120 CD N
patients NNS N
hospitalised VBN N
for IN N
CHF NNP 4_p
were VBD N
randomised VBN N
to TO N
receive VB N
a DT N
pharmacist NN N
directed VBD N
post-discharge JJ N
home NN N
medication NN N
review NN N
( ( N
n JJ N
= NN N
64 CD N
, , N
53.3 CD N
% NN N
) ) N
or CC N
standard JJ N
care NN N
( ( N
n JJ N
= NN N
56 CD N
, , N
46.7 CD N
% NN N
) ) N
. . N

Participants NNS N
were VBD N
followed VBN N
for IN N
6 CD N
months NNS N
. . N

Primary JJ N
outcomes NNS N
were VBD N
death NN N
, , N
CHF NNP N
hospitalisation NN N
and CC N
length NN N
of IN N
hospital NN N
stay NN N
. . N

RESULTS CC N
There EX N
were VBD N
no DT N
between IN N
group NN N
differences NNS N
in IN N
mortality NN N
( ( N
hazard JJ N
ratio NN N
= VBD N
1.41 CD N
, , N
0.50 CD N
to TO N
3.97 CD N
; : N
P NNP N
= NNP N
0.514 CD N
) ) N
or CC N
CHF NNP N
hospitalizations NNS N
( ( N
incidence NN N
rate NN N
ratio NN N
[ NNP N
IRR NNP N
] NNP N
= VBD N
1.74 CD N
95 CD N
% NN N
CI NNP N
: : N
0.85-3.60 JJ N
P NNP N
= NNP N
0.131 CD N
) ) N
over IN N
the DT N
6 CD N
month NN N
follow-up JJ N
period NN N
. . N

Days NNS N
of IN N
hospital NN N
stay NN N
for IN N
CHF NNP N
exacerbations NNS N
in IN N
the DT N
6 CD N
month NN N
follow-up NN N
were VBD N
significantly RB N
greater JJR N
in IN N
the DT N
intervention NN N
group NN N
( ( N
IRR NNP N
= NNP N
2.34 CD N
95 CD N
% NN N
CI NNP N
: : N
1.80-3.05 JJ N
P NNP N
= NNP N
0.000 CD N
) ) N
. . N

CONCLUSIONS NNP N
Post-discharge NNP N
pharmacy NN N
directed VBD N
home NN N
medication NN N
review NN N
appeared VBD N
to TO N
have VB N
no DT N
effect NN N
on IN N
mortality NN N
and CC N
health NN N
care NN N
utilisation NN N
above IN N
that DT N
achieved VBD N
with IN N
standard JJ N
care NN N
. . N

The DT N
post-acute JJ N
management NN N
of IN N
CHF NNP N
must MD N
be VB N
a DT N
collaborative JJ N
multi-disciplinary JJ N
effort NN N
by IN N
the DT N
health NN N
care NN N
team NN N
as IN N
it PRP N
is VBZ N
the DT N
additive JJ N
effect NN N
of IN N
interventions NNS N
that WDT N
are VBP N
most RBS N
effective JJ N
. . N

-DOCSTART- -X- O O 21990307

Phase NNP N
II NNP N
study NN N
of IN N
the DT N
effects NNS N
of IN N
ginger NN N
root NN N
extract NN N
on IN N
eicosanoids NNS N
in IN N
colon NN N
mucosa NN N
in IN N
people NNS N
at IN N
normal JJ 4_p
risk NN 4_p
for IN 4_p
colorectal JJ 4_p
cancer NN 4_p
. . N

Inhibitors NNS N
of IN N
COX NNP N
indicate VBP N
that IN N
upregulation NN N
of IN N
inflammatory JJ N
eicosanoids NNS N
produced VBN N
by IN N
COX NNP N
, , N
and CC N
in IN N
particular JJ N
prostaglandin NN N
E NNP N
( ( N
2 CD N
) ) N
( ( N
PGE NNP N
( ( N
2 CD N
) ) N
) ) N
, , N
are VBP N
early JJ N
events NNS N
in IN N
the DT N
development NN N
of IN N
colorectal JJ N
cancer NN N
( ( N
CRC NNP N
) ) N
. . N

Ginger NNP N
has VBZ N
shown VBN N
downregulation NN N
of IN N
COX NNP N
in IN N
vitro NN N
and CC N
decreased JJ N
incidence/multiplicity NN N
of IN N
adenomas NN N
in IN N
rats NNS N
. . N

This DT N
study NN N
was VBD N
conducted VBN N
to TO N
determine VB N
if IN N
2.0 CD N
g/d NN N
of IN N
ginger NN N
could MD N
decrease VB N
the DT N
levels NNS N
of IN N
PGE NNP N
( ( N
2 CD N
) ) N
, , N
13-hydroxy-octadecadienoic JJ N
acids NNS N
, , N
and CC N
5- JJ N
, , N
12- JJ N
, , N
and CC N
15-hydroxyeicosatetraenoic JJ N
acid NN N
( ( N
5- JJ N
, , N
12- JJ N
, , N
and CC N
15-HETE JJ N
) ) N
, , N
in IN N
the DT N
colon NN N
mucosa NN N
of IN N
healthy JJ 4_p
volunteers NNS N
. . N

To TO N
investigate VB N
this DT N
aim NN N
, , N
we PRP N
randomized VBD N
30 CD N
subjects NNS N
to TO N
2.0 CD N
g/d NN N
ginger NN N
or CC N
placebo NN N
for IN N
28 CD N
days NNS N
. . N

Flexible JJ N
sigmoidoscopy NN N
at IN N
baseline NN N
and CC N
day NN N
28 CD N
was VBD N
used VBN N
to TO N
obtain VB N
colon NN N
biopsies NNS N
. . N

A DT N
liquid JJ N
chromatography NN N
mass NN N
spectrometry NN N
method NN N
was VBD N
used VBN N
to TO N
determine VB N
eicosanoid JJ N
levels NNS N
in IN N
the DT N
biopsies NNS N
, , N
and CC N
levels NNS N
were VBD N
expressed VBN N
per IN N
protein NN N
or CC N
per IN N
free JJ N
arachidonic JJ N
acid NN N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
mean JJ N
percent NN N
change NN N
between IN N
baseline NN N
and CC N
day NN N
28 CD N
for IN N
any DT N
of IN N
the DT N
eicosanoids NNS N
, , N
when WRB N
normalized VBN N
to TO N
protein VB N
. . N

There EX N
was VBD N
a DT N
significant JJ N
decrease NN N
in IN N
mean JJ N
percent NN N
change NN N
in IN N
PGE NNP N
( ( N
2 CD N
) ) N
( ( N
P NNP N
= NNP N
0.05 CD N
) ) N
and CC N
5-HETE JJ N
( ( N
P NNP N
= NNP N
0.04 CD N
) ) N
, , N
and CC N
a DT N
trend NN N
toward IN N
significant JJ N
decreases NNS N
in IN N
12-HETE JJ N
( ( N
P NNP N
= NNP N
0.09 CD N
) ) N
and CC N
15-HETE JJ N
( ( N
P NNP N
= NNP N
0.06 CD N
) ) N
normalized VBN N
to TO N
free VB N
arachidonic JJ N
acid NN N
. . N

There EX N
was VBD N
no DT N
difference NN N
between IN N
the DT N
groups NNS N
in IN N
terms NNS N
of IN N
total JJ N
adverse JJ N
events NNS N
P NNP N
= NNP N
0.55 CD N
) ) N
. . N

On IN N
the DT N
basis NN N
of IN N
these DT N
results NNS N
, , N
it PRP N
seems VBZ N
that IN N
ginger NN N
has VBZ N
the DT N
potential JJ N
to TO N
decrease VB N
eicosanoid JJ N
levels NNS N
, , N
perhaps RB N
by IN N
inhibiting VBG N
their PRP$ N
synthesis NN N
from IN N
arachidonic JJ N
acid NN N
. . N

Ginger NNP N
also RB N
seemed VBD N
to TO N
be VB N
tolerable JJ N
and CC N
safe JJ N
. . N

Further JJ N
investigation NN N
in IN N
people NNS N
at IN N
high JJ N
risk NN N
for IN N
CRC NNP N
seems VBZ N
warranted VBN N
. . N

-DOCSTART- -X- O O 9207711

Effect NN N
of IN N
age NN N
and CC N
activity NN N
on IN N
knee NN N
joint JJ N
proprioception NN N
. . N

Falls NNP N
lead JJ N
to TO N
significant JJ N
morbidity NN N
and CC N
mortality NN N
in IN N
persons NNS 4_p
older JJR 4_p
than IN 4_p
65 CD 4_p
years NNS 4_p
of IN 4_p
age NN 4_p
. . 4_p

Impaired NNP N
proprioception NN N
may MD N
be VB N
a DT N
contributing JJ N
factor NN N
to TO N
falls NNS N
, , N
and CC N
this DT N
may MD N
be VB N
influenced VBN N
by IN N
the DT N
level NN N
of IN N
habitual JJ N
physical JJ N
activity NN N
. . N

The DT N
primary JJ N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
knee NNS 4_p
joint JJ 4_p
proprioception NN 4_p
among IN 4_p
young JJ 4_p
volunteers NNS 4_p
and CC 4_p
active JJ 4_p
and CC 4_p
sedentary JJ 4_p
elderly JJ 4_p
volunteers NNS 4_p
. . 4_p

Knee NNP N
joint JJ N
proprioception NN N
was VBD N
measured VBN N
through IN N
reproduction NN N
of IN N
static JJ N
knee NN N
angles NNS N
using VBG N
a DT N
Penny NNP N
and CC N
Giles NNP N
electrogoniometer RB N
. . N

The DT N
secondary JJ N
purpose NN N
of IN N
this DT N
investigation NN N
was VBD N
to TO N
test VB N
the DT N
reproducibility NN N
of IN N
the DT N
Penny NNP N
and CC N
Giles NNP N
electrogoniometer RB N
in IN N
measuring VBG N
static JJ N
knee NN N
angles NNS N
. . N

Sixteen NNP N
young JJ N
subjects NNS N
( ( N
age NN N
range NN N
, , N
19-27 JJ N
years NNS N
) ) N
and CC N
24 CD N
elderly JJ N
subjects NNS N
( ( N
age NN N
range NN N
, , N
60-86 JJ N
years NNS N
) ) N
participated VBD N
. . N

Subjects NNS N
were VBD N
given VBN N
a DT N
screening VBG N
history NN N
and CC N
physical JJ N
examination NN N
to TO N
exclude VB N
neuromuscular JJ N
or CC N
vestibular JJ N
disorders NNS N
or CC N
lower JJR N
limb NN N
injuries NNS N
. . N

Knee NNP N
joint JJ N
proprioception NN N
was VBD N
measured VBN N
two CD N
times NNS N
during IN N
one CD N
week NN N
. . N

The DT N
elderly JJ N
group NN N
was VBD N
separated VBN N
into IN N
active JJ N
and CC N
sedentary JJ N
subgroups NNS N
based VBN N
on IN N
their PRP$ N
level NN N
of IN N
activity NN N
during IN N
the DT N
past JJ N
year NN N
. . N

The DT N
electrogoniometer NN N
was VBD N
placed VBN N
laterally RB N
across IN N
the DT N
dominant JJ N
knee NN N
joint NN N
. . N

From IN N
the DT N
prone NN N
position NN N
each DT N
subject NN N
attained VBD N
one CD N
of IN N
ten NN N
randomly NNS N
predetermined VBD N
knee JJ N
joint JJ N
angles NNS N
from IN N
10 CD N
degrees NNS N
to TO N
60 CD N
degrees NNS N
. . N

The DT N
subject NN N
then RB N
returned VBD N
to TO N
the DT N
starting VBG N
position NN N
and CC N
reproduced VBD N
the DT N
test NN N
angle NN N
. . N

The DT N
absolute JJ N
angular JJ N
error NN N
( ( N
the DT N
absolute NN N
difference NN N
between IN N
the DT N
test NN N
angle NN N
and CC N
subject JJ N
perceived VBN N
angle NN N
of IN N
knee JJ N
flexion NN N
) ) N
was VBD N
determined VBN N
. . N

A DT N
positive JJ N
correlation NN N
was VBD N
found VBN N
between IN N
control NN N
visits NNS N
for IN N
all DT N
subjects NNS N
( ( N
r VB N
= RB N
0.88 CD N
) ) N
, , N
and CC N
significant JJ N
differences NNS N
were VBD N
observed VBN N
between IN N
young JJ N
( ( N
mean JJ N
, , N
2.01 CD N
+/- JJ N
0.46 CD N
degrees NNS N
) ) N
and CC N
active-fold JJ N
( ( N
mean JJ N
, , N
3.12 CD N
+/- JJ N
1.12 CD N
degrees NNS N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
young JJ N
and CC N
sedentary-old JJ N
( ( N
mean JJ N
, , N
4.58 CD N
+/- JJ N
1.93 CD N
degrees NNS N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
and CC N
active-old JJ N
and CC N
sedentary-old JJ N
( ( N
P NNP N
< NNP N
0.03 CD N
) ) N
. . N

These DT N
findings NNS N
demonstrate VBP N
that IN N
the DT N
Penny NNP N
and CC N
Giles NNP N
electrogoniometer NN N
is VBZ N
a DT N
reproducible JJ N
device NN N
for IN N
measuring VBG N
knee NN N
joint NN N
angles NNS N
in IN N
both DT N
young JJ N
and CC N
elderly JJ N
subjects NNS N
. . N

Furthermore RB N
, , N
we PRP N
found VBD N
that IN N
proprioception NN N
is VBZ N
diminished VBN N
with IN N
age NN N
and CC N
that IN N
regular JJ N
activity NN N
may MD N
attenuate VB N
this DT N
decline NN N
. . N

One CD N
strategy NN N
to TO N
reduce VB N
the DT N
incidence NN N
of IN N
poor JJ N
proprioception NN N
and CC N
fall NN N
with IN N
ageing NN N
may MD N
be VB N
regular JJ N
exercise NN N
. . N

-DOCSTART- -X- O O 22082673

Atrial JJ N
fibrillation NN N
catheter NN N
ablation NN N
versus NN N
surgical JJ N
ablation NN N
treatment NN N
( ( N
FAST NNP N
) ) N
: : N
a DT N
2-center JJ N
randomized JJ N
clinical JJ N
trial NN N
. . N

BACKGROUND NNP N
Catheter NNP N
ablation NN N
( ( N
CA NNP N
) ) N
and CC N
minimally RB N
invasive JJ N
surgical JJ N
ablation NN N
( ( N
SA NNP N
) ) N
have VBP N
become VBN N
accepted JJ N
therapy NN N
for IN N
antiarrhythmic JJ N
drug-refractory JJ N
atrial JJ N
fibrillation NN N
. . N

This DT N
study NN N
describes VBZ N
the DT N
first JJ N
randomized JJ N
clinical JJ N
trial NN N
comparing VBG N
their PRP$ N
efficacy NN N
and CC N
safety NN N
during IN N
a DT N
12-month JJ N
follow-up NN N
. . N

METHODS NNP N
AND CC N
RESULTS NNP N
One CD N
hundred VBD N
twenty-four JJ N
patients NNS N
with IN N
antiarrhythmic JJ 4_p
drug-refractory JJ 4_p
atrial JJ 4_p
fibrillation NN 4_p
with IN 4_p
left JJ 4_p
atrial JJ 4_p
dilatation NN 4_p
and CC 4_p
hypertension NN 4_p
( ( N
42 CD N
patients NNS N
, , N
33 CD N
% NN N
) ) N
or CC N
failed VBN 4_p
prior JJ 4_p
CA NNP 4_p
( ( N
82 CD N
patients NNS N
, , N
67 CD N
% NN N
) ) N
were VBD N
randomized VBN N
to TO N
CA NNP N
( ( N
63 CD N
patients NNS N
) ) N
or CC N
SA NNP N
( ( N
61 CD N
patients NNS N
) ) N
. . N

CA NNP N
consisted VBD N
of IN N
linear JJ N
antral JJ N
pulmonary JJ N
vein NN N
isolation NN N
and CC N
optional JJ N
additional JJ N
lines NNS N
. . N

SA NNP N
consisted VBD N
of IN N
bipolar JJ N
radiofrequency NN N
isolation NN N
of IN N
the DT N
bilateral JJ N
pulmonary JJ N
vein NN N
, , N
ganglionated VBD N
plexi JJ N
ablation NN N
, , N
and CC N
left VBD N
atrial JJ N
appendage NN N
excision NN N
with IN N
optional JJ N
additional JJ N
lines NNS N
. . N

Follow-up NN N
at IN N
6 CD N
and CC N
12 CD N
months NNS N
was VBD N
performed VBN N
by IN N
ECG NNP N
and CC N
7-day JJ N
Holter NNP N
recording NN N
. . N

The DT N
primary JJ N
end NN N
point NN N
, , N
freedom NN N
from IN N
left VBN N
atrial JJ N
arrhythmia NN N
> VBD N
30 CD N
seconds NNS N
without IN N
antiarrhythmic JJ N
drugs NNS N
after IN N
12 CD N
months NNS N
, , N
was VBD N
36.5 CD N
% NN N
for IN N
CA NNP N
and CC N
65.6 CD N
% NN N
for IN N
SA NNP N
( ( N
P=0.0022 NNP N
) ) N
. . N

There EX N
was VBD N
no DT N
difference NN N
in IN N
effect NN N
for IN N
subgroups NNS N
, , N
which WDT N
was VBD N
consistent NN N
at IN N
both DT N
sites NNS N
. . N

The DT N
primary JJ N
safety NN N
end NN N
point NN N
of IN N
significant JJ N
adverse JJ N
events NNS N
during IN N
the DT N
12-month JJ N
follow-up NN N
was VBD N
significantly RB N
higher JJR N
for IN N
SA NNP N
than IN N
for IN N
CA NNP N
( ( N
n=21 JJ N
[ RB N
34.4 CD N
% NN N
] JJ N
versus NN N
n=10 NN N
[ VBD N
15.9 CD N
% NN N
] NN N
; : N
P=0.027 NNP N
) ) N
, , N
driven VBN N
mainly RB N
by IN N
procedural JJ N
complications NNS N
such JJ N
as IN N
pneumothorax NN N
, , N
major JJ N
bleeding NN N
, , N
and CC N
the DT N
need NN N
for IN N
pacemaker NN N
. . N

In IN N
the DT N
CA NNP N
group NN N
, , N
1 CD N
patient NN N
died VBD N
at IN N
1 CD N
month NN N
of IN N
subarachnoid JJ N
hemorrhage NN N
. . N

CONCLUSION NNP N
In IN N
atrial JJ 4_p
fibrillation NN 4_p
patients NNS N
with IN N
dilated JJ 4_p
left JJ 4_p
atrium NN 4_p
and CC 4_p
hypertension NN 4_p
or CC N
failed VBD 4_p
prior RB 4_p
atrial JJ 4_p
fibrillation NN 4_p
CA NNP 4_p
, , N
SA NNP N
is VBZ N
superior JJ N
to TO N
CA NNP N
in IN N
achieving VBG N
freedom NN N
from IN N
left VBN N
atrial JJ N
arrhythmias NNS N
after IN N
12 CD N
months NNS N
of IN N
follow-up NN N
, , N
although IN N
the DT N
procedural JJ N
adverse JJ N
event NN N
rate NN N
is VBZ N
significantly RB N
higher JJR N
for IN N
SA NNP N
than IN N
for IN N
CA NNP N
. . N

CLINICAL NNP N
TRIAL NNP N
REGISTRATION NNP N
URL NNP N
: : N
http NN N
: : N
//clinicaltrials.gov NN N
. . N

Unique NNP N
identifier NN N
: : N
NCT00662701 NNP N
. . N

-DOCSTART- -X- O O 23992605

A DT N
comparison NN N
of IN N
Villalta-Prandoni NNP N
scale NN N
and CC N
venous JJ N
clinical JJ N
severity NN N
score NN N
in IN N
the DT N
assessment NN N
of IN N
post NN N
thrombotic JJ N
syndrome NN N
. . N

BACKGROUND NNP N
Post-thrombotic JJ N
syndrome NN N
( ( N
PTS NNP N
) ) N
is VBZ N
the DT N
most RBS N
important JJ N
late JJ N
complication NN N
of IN N
acute JJ N
deep JJ N
venous JJ N
thrombosis NN N
( ( N
DVT NNP N
) ) N
, , N
with IN N
as RB N
many JJ N
as IN N
two-thirds NNS N
of IN N
patients NNS N
developing VBG N
symptoms NNS N
of IN N
pain NN N
, , N
edema NN N
, , N
hyperpigmentation NN N
, , N
or CC N
ulceration NN N
. . N

Although IN N
several JJ N
instruments NNS N
are VBP N
available JJ N
for IN N
evaluation NN N
of IN N
the DT N
severity NN N
of IN N
PTS NNP N
, , N
including VBG N
the DT N
Villalta-Prandoni NNP N
scale NN N
( ( N
VPS NNP N
) ) N
and CC N
Venous JJ N
Clinical NNP N
Severity NNP N
Score NNP N
( ( N
VCSS NNP N
) ) N
, , N
no DT N
studies NNS N
have VBP N
yet RB N
compared VBN N
the DT N
2 CD N
instruments NNS N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
is VBZ N
to TO N
compare VB N
the DT N
2 CD N
instruments NNS N
as IN N
part NN N
of IN N
a DT N
larger JJR N
randomized VBN N
controlled VBD N
study NN N
that WDT N
assessed VBD N
the DT N
impact NN N
of IN N
graduated JJ N
compressive JJ N
stockings NNS N
in IN N
the DT N
prevention NN N
of IN N
PTS NNP N
. . N

METHODS NNP N
Sixty-nine JJ N
consecutive JJ N
patients NNS N
with IN N
acute JJ N
DVT NNP N
documented VBN N
by IN N
duplex JJ N
ultrasonography NN N
were VBD N
randomized VBN N
to TO N
treatment NN N
with IN N
30-40 JJ N
mm NN N
Hg NNP N
graduated VBD N
compressive JJ N
stockings NNS N
( ( N
GCS NNP N
) ) N
or CC N
no DT N
stockings NNS N
. . N

Patients NNS N
were VBD N
followed VBN N
clinically RB N
at IN N
months NNS N
1 CD N
, , N
3 CD N
, , N
6 CD N
, , N
12 CD N
, , N
18 CD N
, , N
and CC N
24 CD N
after IN N
the DT N
diagnosis NN N
of IN N
DVT NNP N
. . N

PTS NNP N
as IN N
defined VBN N
by IN N
the DT N
VPS NNP N
and CC N
VCSS NNP N
were VBD N
assessed VBN N
at IN N
these DT N
follow-up JJ N
visits NNS N
. . N

Based VBN N
upon IN N
the DT N
VPS NNP N
, , N
PTS NNP N
was VBD N
scored VBN N
as IN N
absent NN N
( ( N
score NN N
< VBZ N
3 CD N
or CC N
3 CD N
without IN N
objective JJ N
criteria NNS N
) ) N
, , N
mild FW N
to TO N
moderate VB N
( ( N
score NN N
≥3 NN N
with IN N
1 CD N
objective JJ N
criteria NNS N
) ) N
, , N
or CC N
severe RB N
( ( N
score VB N
≥4 NN N
) ) N
. . N

For IN N
the DT N
VCSS NNP N
, , N
PTS NNP N
was VBD N
considered VBN N
to TO N
be VB N
absent JJ N
( ( N
score VB N
≤3 NN N
) ) N
, , N
mild FW N
to TO N
moderate VB N
( ( N
score VB N
4-7 NN N
) ) N
, , N
or CC N
severe RB N
( ( N
score VB N
≥8 NN N
) ) N
. . N

The DT N
2 CD N
instruments NNS N
were VBD N
compared VBN N
for IN N
mild NN N
to TO N
moderate VB N
and CC N
severe JJ N
disease NN N
using VBG N
the DT N
Pearson NNP N
chi-squared JJ N
test NN N
and CC N
gamma NN N
statistic NN N
. . N

RESULTS NNP N
Good JJ N
correlation NN N
was VBD N
detected VBN N
in IN N
the DT N
ability NN N
of IN N
VPS NNP N
and CC N
VCSS NNP N
instruments NNS N
to TO N
detect VB N
mild NN N
to TO N
moderate VB N
disease NN N
( ( N
gamma JJ N
statistic JJ N
= NNP N
0.71-0.98 NN N
; : N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

For IN N
severe JJ N
disease NN N
, , N
a DT N
statistically RB N
significant JJ N
correlation NN N
was VBD N
not RB N
found VBN N
in IN N
the DT N
ability NN N
of IN N
the DT N
2 CD N
instruments NNS N
to TO N
detect VB N
disease NN N
( ( N
gamma JJ N
statistic JJ N
= NNP N
0.5-0.98 NN N
; : N
P NNP N
> NNP N
0.05 CD N
) ) N
, , N
especially RB N
at IN N
12 CD N
and CC N
24 CD N
months NNS N
. . N

CONCLUSION NNP N
Both NNP N
VPS NNP N
and CC N
the DT N
VCSS NNP N
scoring VBG N
systems NNS N
are VBP N
important JJ N
tools NNS N
in IN N
the DT N
identification NN N
and CC N
follow-up NN N
of IN N
PTS NNP N
. . N

There EX N
exists VBZ N
agreement NN N
between IN N
the DT N
2 CD N
instruments NNS N
for IN N
detecting VBG N
mild NN N
to TO N
moderate VB N
disease NN N
. . N

For IN N
severe JJ N
disease NN N
however RB N
, , N
VCSS NNP N
may MD N
possibly RB N
be VB N
a DT N
more RBR N
sensitive JJ N
instrument NN N
. . N

-DOCSTART- -X- O O 9553664

The DT N
role NN N
of IN N
pneumatic JJ N
compression NN N
in IN N
the DT N
treatment NN N
of IN N
postmastectomy NN 4_p
lymphedema NN 4_p
. . N

A DT N
randomized JJ N
phase NN N
III NNP N
study NN N
. . N

BACKGROUND NNP N
Pneumatic NNP N
compression NN N
is VBZ N
a DT N
frequently RB N
prescribed VBN N
physical JJ N
therapy NN N
for IN N
patients NNS N
affected VBN N
by IN N
postmastectomy JJ 4_p
lymphedema NN 4_p
but CC N
, , N
despite IN N
its PRP$ N
wide JJ N
use NN N
, , N
its PRP$ N
efficacy NN N
has VBZ N
not RB N
been VBN N
demonstrated VBN N
in IN N
phase NN N
III NNP N
studies NNS N
. . N

We PRP N
performed VBD N
a DT N
randomized VBN N
study NN N
comparing VBG N
pneumatic JJ N
compression NN N
versus IN N
no DT N
treatment NN N
in IN N
patients NNS N
with IN N
postmastectomy JJ 4_p
lymphedema NN 4_p
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
Patients NNPS N
with IN N
monolateral JJ 4_p
postmastectomy NN 4_p
lymphedema NN 4_p
were VBD N
randomized VBN N
to TO N
receive VB N
two CD N
cycles NNS N
of IN N
intermittent JJ N
pneumatic JJ N
compression NN N
( ( N
PC NNP N
group NN N
) ) N
, , N
i.e. FW N
, , N
five CD N
two-hour JJ N
sessions NNS N
per IN N
week NN N
for IN N
two CD N
weeks NNS N
, , N
to TO N
be VB N
repeated VBN N
after IN N
a DT N
five-week JJ N
interval NN N
, , N
or CC N
to TO N
no DT N
treatment NN N
( ( N
control VB N
group NN N
) ) N
. . N

The DT N
patients NNS N
in IN N
both DT N
groups NNS N
were VBD N
instructed VBN N
as IN N
to TO N
the DT N
prophylactic JJ N
hygienic NN N
care NN N
of IN N
the DT N
limb NN N
. . N

Lymphedema NNP N
was VBD N
assessed VBN N
by IN N
the DT N
sum NN N
of IN N
differences NNS N
in IN N
circumference NN N
measurements NNS N
between IN N
affected JJ N
and CC N
normal JJ N
limbs NNS N
( ( N
'delta NNP N
' POS N
) ) N
. . N

Response NNP N
was VBD N
defined VBN N
as IN N
a DT N
> NN N
or CC N
= VB N
25 CD N
% NN N
reduction NN N
in IN N
delta JJ N
value NN N
. . N

RESULTS NNP N
Eighty NNP N
patients NNS N
entered VBD N
the DT N
study NN N
. . N

No DT N
statistically RB N
significant JJ N
differences NNS N
in IN N
response NN N
rates NNS N
between IN N
the DT N
two CD N
groups NNS N
were VBD N
observed VBN N
: : N
20 CD N
% NN N
in IN N
the DT N
control NN N
group NN N
( ( N
95 CD N
% NN N
CI NNP N
: : N
9 CD N
% NN N
-36 NNP N
% NN N
) ) N
, , N
25 CD N
% NN N
in IN N
the DT N
PC NN N
group NN N
( ( N
95 CD N
% NN N
CI NNP N
: : N
13 CD N
% NN N
-41 CD N
% NN N
, , N
P NNP N
= NNP N
0.59 CD N
) ) N
. . N

The DT N
absolute JJ N
mean NN N
decrease NN N
in IN N
delta JJ N
value NN N
was VBD N
1.9 CD N
+/- JJ N
3.7 CD N
cm NN N
in IN N
the DT N
PC NN N
group NN N
and CC N
0.5 CD N
+/- JJ N
3.3 CD N
cm NN N
in IN N
the DT N
control NN N
group NN N
. . N

CONCLUSIONS NNP N
We PRP N
demonstrated VBD N
that IN N
intermittent JJ N
pneumatic JJ N
compression NN N
has VBZ N
a DT N
limited JJ N
clinical JJ N
role NN N
in IN N
the DT N
treatment NN N
of IN N
postmastectomy NN N
lymphedema NN N
. . N

Efforts NNS N
to TO N
prevent VB N
this DT N
complication NN N
should MD N
be VB N
undertaken VBN N
. . N

-DOCSTART- -X- O O 9084194

Doxymycine-cyanoacrylate NNP N
treatment NN N
of IN N
recurrent NN N
aphthous JJ N
ulcers NNS N
. . N

OBJECTIVE VB N
This DT N
study NN N
addressed VBD N
the DT N
efficacy NN N
of IN N
singularly RB N
applied VBN N
topical JJ N
doxymycine NN N
in IN N
the DT N
pain NN N
relief NN N
treatment NN N
of IN N
recurrent NN N
aphthous JJ N
stomatitis NN N
. . N

STUDY NNP N
DESIGN NNP N
Thirty-one CD N
patients NNS N
with IN N
recurrent JJ N
aphthous JJ 4_p
lesions NNS 4_p
were VBD N
examined VBN N
and CC N
divided VBN N
randomly RB N
in IN N
two CD N
groups NNS N
. . N

Experimental JJ N
group NN N
( ( N
n JJ N
= NNP N
15 CD N
) ) N
received VBD N
a DT N
topical JJ N
application NN N
of IN N
doxymycine NN N
and CC N
controls NNS N
( ( N
n JJ N
= NNP N
16 CD N
) ) N
received VBD N
calcii JJ N
gluconase NN N
in IN N
the DT N
same JJ N
manner NN N
. . N

Medications NNS N
were VBD N
covered VBN N
by IN N
isobutyl JJ N
cyanoacrylate NN N
( ( N
Iso-Dent JJ N
) ) N
. . N

Application NN N
was VBD N
made VBN N
only RB N
once RB N
during IN N
the DT N
recurrent NN N
aphthous JJ N
ulcer JJ N
episode NN N
. . N

RESULTS JJ N
Patients NNS N
recorded VBD N
their PRP$ N
pain NN N
level NN N
on IN N
a DT N
visual JJ N
analog NN N
scale NN N
for IN N
10 CD N
days NNS N
during IN N
healing VBG N
. . N

Pain VB N
decreased VBD N
more RBR N
rapidly RB N
in IN N
the DT N
experimental JJ N
group NN N
, , N
and CC N
a DT N
statistically RB N
significant JJ N
difference NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
in IN N
the DT N
pain NN N
intensity NN N
was VBD N
found VBN N
from IN N
the DT N
second JJ N
to TO N
the DT N
seventh JJ N
day NN N
after IN N
application NN N
of IN N
doxymycine NN N
. . N

CONCLUSIONS NNP N
In IN N
recurrent NN N
aphthous JJ N
ulcers NNS N
, , N
singular JJ N
treatment NN N
of IN N
topical JJ N
doxymycine-cyanoacrylate JJ N
relieves VBZ N
the DT N
pain NN N
intensity NN N
remarkably RB N
for IN N
6 CD N
days NNS N
after IN N
a DT N
1 CD N
day NN N
latency NN N
period NN N
. . N

Topical JJ N
doxymycine NN N
treatment NN N
further JJ N
exerts VBZ N
potential JJ N
to TO N
directly RB N
prevent VB N
tissue NN N
destruction NN N
and CC N
to TO N
indirectly RB N
suppress VB N
host NN N
inflammatory JJ N
reaction NN N
. . N

-DOCSTART- -X- O O 24214165

An DT N
intervention NN N
for IN N
sensory JJ N
difficulties NNS N
in IN N
children NNS N
with IN N
autism NN 4_p
: : N
a DT N
randomized JJ N
trial NN N
. . N

This DT N
study NN N
evaluated VBD N
a DT N
manualized VBN N
intervention NN N
for IN N
sensory JJ N
difficulties NNS N
for IN N
children NNS N
with IN N
autism NN N
, , N
ages VBZ N
4-8 CD N
years NNS N
, , N
using VBG N
a DT N
randomized JJ N
trial NN N
design NN N
. . N

Diagnosis NN N
of IN N
autism NN N
was VBD N
confirmed VBN N
using VBG N
gold JJ N
standard NN N
measures NNS N
. . N

Results NNP N
show VBP N
that IN N
the DT N
children NNS N
in IN N
the DT N
treatment NN N
group NN N
( ( N
n JJ N
= NNP N
17 CD N
) ) N
who WP N
received VBD N
30 CD N
sessions NNS N
of IN N
the DT N
occupational JJ N
therapy NN N
intervention NN N
scored VBD N
significantly RB N
higher JJR N
( ( N
p JJ N
= NN N
0.003 CD N
, , N
d NN N
= NNP N
1.2 CD N
) ) N
on IN N
Goal NNP N
Attainment NNP N
Scales NNP N
( ( N
primary JJ N
outcome NN N
) ) N
, , N
and CC N
also RB N
scored VBD N
significantly RB N
better RBR N
on IN N
measures NNS N
of IN N
caregiver NN N
assistance NN N
in IN N
self-care NN N
( ( N
p JJ N
= $ N
0.008 CD N
d NN N
= NNP N
0.9 CD N
) ) N
and CC N
socialization NN N
( ( N
p JJ N
= NN N
0.04 CD N
, , N
d NN N
= NNP N
0.7 CD N
) ) N
than IN N
the DT N
Usual NNP N
Care NNP N
control NN N
group NN N
( ( N
n JJ N
= NNP N
15 CD N
) ) N
. . N

The DT N
study NN N
shows VBZ N
high JJ N
rigor NN N
in IN N
its PRP$ N
measurement NN N
of IN N
treatment NN N
fidelity NN N
and CC N
use NN N
of IN N
a DT N
manualized VBN N
protocol NN N
, , N
and CC N
provides VBZ N
support NN N
for IN N
the DT N
use NN N
of IN N
this DT N
intervention NN N
for IN N
children NNS N
with IN N
autism NN 4_p
. . N

Findings NNS N
are VBP N
discussed VBN N
in IN N
terms NNS N
of IN N
their PRP$ N
implications NNS N
for IN N
practice NN N
and CC N
future JJ N
research NN N
. . N

-DOCSTART- -X- O O 2577555

[ JJ N
European JJ N
topic NN N
: : N
liver NN N
surgery NN N
II NNP N
-- : N
regional JJ N
chemotherapy NN N
] NN N
. . N

The DT N
most RBS N
important JJ N
methods NNS N
of IN N
regional JJ N
chemotherapy NN N
are VBP N
exemplified VBN N
by IN N
657 CD N
cases NNS N
of IN N
primary JJ N
and CC N
secondary JJ N
liver NN N
only RB N
malignancies VBZ N
. . N

I PRP N
. . N

Adjuvant JJ N
portal JJ N
therapy NN N
of IN N
the DT N
liver NN N
with IN N
resection NN N
of IN N
the DT N
colorectal JJ N
primary JJ N
malignancy NN N
seems VBZ N
to TO N
be VB N
advantageous JJ N
for IN N
advanced JJ N
tumors NNS N
. . N

II NNP N
. . N

It PRP N
is VBZ N
still RB N
unresolved JJ N
whether IN N
survival NN N
is VBZ N
prolonged VBN N
by IN N
adjuvant JJ N
treatment NN N
of IN N
the DT N
liver NN N
following VBG N
curative JJ N
resection NN N
of IN N
colorectal JJ N
liver NN N
metastases NNS N
. . N

III NNP N
. . N

The DT N
median JJ N
survival NN N
time NN N
( ( N
FUDR NNP N
, , N
pump NN N
) ) N
is VBZ N
17 CD N
months NNS N
for IN N
palliative JJ N
local JJ N
chemotherapy NN N
of IN N
unresectable JJ N
colorectal JJ N
liver NN N
metastases NNS N
. . N

IV NNP N
. . N

Primary NNP N
non-resectable JJ N
liver NN N
malignancies NNS N
show VBP N
the DT N
best JJS N
results NNS N
after IN N
chemoembolisation NN N
( ( N
Frankfurt NNP N
method NN N
) ) N
. . N

-DOCSTART- -X- O O 4101734

Fluorouracil NNP N
as IN N
an DT N
adjuvant NN N
to TO N
surgery VB N
in IN N
carcinoma NN 4_p
of IN 4_p
the DT 4_p
colon NN 4_p
. . N

-DOCSTART- -X- O O 23444169

Comparative NNP N
in IN N
vitro JJ N
dissolution NN N
and CC N
in IN N
vivo JJ N
bioavailability NN N
of IN N
diflunisal/naproxen JJ N
fixed-dose JJ N
combination NN N
tablets NNS N
and CC N
concomitant JJ N
administration NN N
of IN N
diflunisal NN N
and CC N
naproxen NN N
in IN N
healthy JJ N
adult NN N
subjects NNS N
. . N

A DT N
simple JJ N
validated JJ N
high-performance NN N
liquid NN N
chromatography NN N
( ( N
HPLC NNP N
) ) N
assay NN N
was VBD N
developed VBN N
for IN N
determination NN N
of IN N
diflunisal NN N
and CC N
naproxen NN N
in IN N
human JJ N
plasma NN N
samples NNS N
. . N

This DT N
is VBZ N
to TO N
compare VB N
the DT N
bioavailability NN N
of IN N
diflunisal-naproxen JJ N
fixed-dose JJ N
combination NN N
( ( N
FDC NNP N
) ) N
with IN N
their PRP$ N
separate JJ N
dosage NN N
forms NNS N
. . N

The DT N
in IN N
vitro JJ N
dissolution NN N
study NN N
was VBD N
adopted VBN N
to TO N
compare VB N
the DT N
dissolution NN N
behavior NN N
of IN N
FDC NNP N
with IN N
respect NN N
to TO N
separate VB N
marketed VBN N
tablets NNS N
. . N

In IN N
vivo NN N
study NN N
was VBD N
conducted VBN N
according VBG N
to TO N
a DT N
single-center NN N
, , N
randomized VBN N
, , N
single-dose JJ N
, , N
laboratory-blinded JJ N
, , N
2 CD N
Way NNP N
, , N
Cross-Over NNP N
Study NNP N
with IN N
a DT N
washout JJ N
period NN N
of IN N
10 CD N
days NNS N
. . N

Under IN N
fasting VBG N
conditions NNS N
, , N
24 CD N
healthy JJ N
Egyptian JJ N
male NN N
volunteers NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
receive VB N
a DT N
single JJ N
oral JJ N
dose NN N
of IN N
either DT N
one CD N
FDC NNP N
tablet NN N
or CC N
co-administration NN N
of IN N
two CD N
separate JJ N
diflunisal NN N
and CC N
naproxen RB N
marketed VBN N
tablets NNS N
. . N

Plasma NNP N
samples NNS N
were VBD N
obtained VBN N
over IN N
a DT N
72-h JJ N
interval NN N
and CC N
analyzed VBN N
for IN N
diflunisal NN N
and CC N
naproxen NN N
by IN N
reversed JJ N
phase NN N
liquid NN N
chromatography NN N
with IN N
UV NNP N
detection NN N
. . N

The DT N
pharmacokinetic JJ N
parameters NNS N
Cmax NNP N
, , N
AUC0-t NNP N
, , N
AUC0-∞ NNP N
, , N
tmax NN N
, , N
and CC N
t1/2 NNS N
were VBD N
determined VBN N
from IN N
plasma JJ N
concentration-time JJ N
profiles NNS N
. . N

The DT N
90 CD N
% NN N
confidence NN N
intervals NNS N
for IN N
the DT N
ratio NN N
of IN N
log NN N
transformed VBN N
values NNS N
of IN N
Cmax NNP N
, , N
AUC0-t NNP N
, , N
and CC N
AUCt-∞ NNP N
of IN N
the DT N
2 CD N
treatments NNS N
were VBD N
within IN N
the DT N
acceptable JJ N
range NN N
( ( N
0.8-1.25 JJ N
) ) N
for IN N
bioequivalence NN N
. . N

From IN N
pharmacokinetic JJ N
and CC N
in IN N
vitro JJ N
studies NNS N
perspectives NNS N
, , N
1 CD N
FDC NNP N
tablet NN N
demonstrated VBD N
similar JJ N
relative JJ N
bioavailability NN N
with IN N
the DT N
2 CD N
individual JJ N
-reference NN N
tablets NNS N
. . N

-DOCSTART- -X- O O 3189201

Educational JJ N
intervention NN N
for IN N
altering VBG N
water-sanitation NN N
behavior NN N
to TO N
reduce VB N
childhood NN N
diarrhea NN 4_p
in IN N
urban JJ N
Bangladesh NNP N
: : N
impact NN N
on IN N
nutritional JJ N
status NN N
. . N

We PRP N
evaluated VBD N
whether IN N
an DT N
educational JJ N
intervention NN N
that WDT N
was VBD N
effective JJ N
in IN N
reducing VBG N
childhood NN N
diarrhea NN N
also RB N
improved VBD N
childhood JJ N
nutritional JJ N
status NN N
. . N

Fifty-one CD N
communities NNS N
of IN N
38 CD N
families NNS N
each DT N
were VBD N
randomized VBN N
to TO N
receive VB N
the DT N
intervention NN N
or CC N
no DT N
intervention NN N
. . N

During IN N
1 CD N
y NNS N
of IN N
follow-up JJ N
the DT N
rate NN N
of IN N
diarrhea NN N
( ( N
per IN N
100 CD N
wk NN N
) ) N
in IN N
children NNS N
less JJR N
than IN N
6 CD N
y NN N
in IN N
the DT N
intervention NN N
group NN N
was VBD N
5.89 CD N
episodes NNS N
whereas VBP N
that IN N
in IN N
the DT N
nonintervention NN N
group NN N
was VBD N
7.55 CD N
episodes NNS N
( ( N
protective JJ N
efficacy NN N
22 CD N
% NN N
; : N
p CC N
less JJR N
than IN N
0.0001 CD N
) ) N
. . N

During IN N
the DT N
same JJ N
follow-up JJ N
period NN N
children NNS N
in IN N
both DT N
groups NNS N
exhibited VBD N
comparable JJ N
patterns NNS N
of IN N
weight JJ N
gain NN N
; : N
1 CD N
y NN N
after IN N
the DT N
intervention NN N
the DT N
mean JJ N
weight NN N
for IN N
age NN N
of IN N
children NNS N
in IN N
both DT N
groups NNS N
was VBD N
76 CD N
% NN N
of IN N
the DT N
NCHS NNP N
standard NN N
. . N

No DT N
significant JJ N
differences NNS N
were VBD N
observed VBN N
in IN N
the DT N
proportion NN N
of IN N
each DT N
group NN N
that WDT N
experienced VBD N
a DT N
major JJ N
deterioration NN N
or CC N
improvement NN N
of IN N
nutritional JJ N
status NN N
. . N

We PRP N
conclude VBP N
that IN N
an DT N
intervention NN N
that WDT N
reduces VBZ N
rates NNS N
of IN N
childhood NN N
diarrhea NN N
may MD N
not RB N
necessarily RB N
also RB N
improve VB N
nutritional JJ N
status NN N
. . N

-DOCSTART- -X- O O 12668582

Pharmacokinetics NNS N
and CC N
tolerance NN N
of IN N
single- JJ N
and CC N
multiple-dose JJ N
oral JJ N
or CC N
intravenous JJ N
linezolid NNS N
, , N
an DT N
oxazolidinone NN N
antibiotic JJ N
, , N
in IN N
healthy JJ N
volunteers NNS N
. . N

AIMS NNP N
To TO N
determine VB N
the DT N
pharmacokinetics NNS N
and CC N
tolerance NN N
of IN N
oral JJ N
and CC N
intravenous JJ N
linezolid NN N
, , N
an DT N
oxazolidinone NN N
antibiotic JJ N
, , N
in IN N
healthy JJ N
volunteers NNS N
following VBG N
single- JJ N
and CC N
multiple-dose JJ N
administration NN N
. . N

METHODS NNP N
In IN N
two CD N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
, , N
dose-escalating JJ N
trials NNS N
, , N
subjects NNS N
were VBD N
exposed VBN N
either RB N
to TO N
oral JJ N
( ( N
375 CD N
, , N
500 CD N
or CC N
625 CD N
mg NN N
) ) N
or CC N
intravenous JJ N
( ( N
500 CD N
or CC N
625 CD N
mg NN N
) ) N
linezolid VBD N
or CC N
placebo VB N
twice JJ N
daily RB N
. . N

Serial JJ N
blood NN N
and CC N
urine JJ N
samples NNS N
were VBD N
obtained VBN N
after IN N
the DT N
first- JJ N
and CC N
multiple-dose JJ N
administrations NNS N
for IN N
up IN N
to TO N
18 CD N
days NNS N
. . N

Non-compartmental JJ N
pharmacokinetic JJ N
analyses NNS N
were VBD N
used VBN N
to TO N
describe VB N
the DT N
disposition NN N
of IN N
linezolid JJ N
. . N

RESULTS NNP N
Plasma NNP N
linezolid JJ N
concentrations NNS N
and CC N
area NN N
under IN N
the DT N
concentration-time JJ N
curves NNS N
increased VBD N
proportionally RB N
with IN N
dose JJ N
irrespective NN N
of IN N
the DT N
route NN N
of IN N
administration NN N
. . N

Plasma NNP N
linezolid JJ N
concentrations NNS N
remained VBN N
above IN N
the DT N
MIC90 NNP N
for IN N
susceptible JJ N
target NN N
pathogens NNS N
( ( N
4.0 CD N
mg/L NN N
) ) N
for IN N
the DT N
majority NN N
of IN N
the DT N
12 CD N
h NN N
dosing VBG N
interval NN N
. . N

Mean JJ N
clearance NN N
, , N
half-life JJ N
and CC N
volume NN N
of IN N
distribution NN N
were VBD N
similar JJ N
irrespective NN N
of IN N
dose NN N
for IN N
both DT N
the DT N
oral JJ N
and CC N
intravenous JJ N
routes NNS N
. . N

Linezolid NNP N
was VBD N
well RB N
tolerated VBN N
and CC N
the DT N
frequency NN N
of IN N
drug-related JJ N
adverse JJ N
events NNS N
was VBD N
similar JJ N
between IN N
the DT N
linezolid JJ N
and CC N
placebo JJ N
groups NNS N
. . N

CONCLUSIONS NNP N
Oral NNP N
and CC N
intravenous JJ N
linezolid JJ N
exhibit NN N
linear JJ N
pharmacokinetics NNS N
, , N
with IN N
concentrations NNS N
remaining VBG N
above IN N
the DT N
target NN N
MIC90 NNP N
for IN N
most JJS N
of IN N
the DT N
dosing NN N
interval NN N
. . N

These DT N
results NNS N
support VBD N
a DT N
twice-daily JJ N
schedule NN N
for IN N
linezolid JJ N
and CC N
demonstrate VB N
the DT N
feasibility NN N
of IN N
converting VBG N
from IN N
intravenous JJ N
to TO N
oral JJ N
dosing NN N
without IN N
a DT N
dose JJ N
adjustment NN N
. . N

-DOCSTART- -X- O O 23839319

Total JJ N
intravenous JJ N
anesthesia NN N
using VBG N
remifentanil NN N
in IN N
extracorporeal NN 4_p
shock NN 4_p
wave VBP 4_p
lithotripsy NN 4_p
( ( 4_p
ESWL NNP 4_p
) ) 4_p
. . 4_p

Comparison NNP N
of IN N
two CD N
dosages NNS N
: : N
a DT N
randomized JJ N
clinical JJ N
trial NN N
. . N

BACKGROUND NNP N
Extracorporeal NNP N
Shock NNP N
Wave NNP N
Lithotripsy NNP N
is VBZ N
usually RB N
performed VBN N
in IN N
day NN N
surgery NN N
setting NN N
, , N
consequently RB N
people NNS N
who WP N
undergo VBP N
to TO N
this DT N
procedure NN N
need VB N
a DT N
safe JJ N
and CC N
fast JJ N
recovery NN N
. . N

Conscious JJ N
sedation NN N
with IN N
remifentanil NN N
can MD N
relieve VB N
from IN N
pain NN N
and CC N
keep VB N
patients NNS N
in IN N
touch JJ N
with IN N
anaesthesiologists NNS N
. . N

Few JJ N
publications NNS N
tell VBP N
about IN N
infusion NN N
rates NNS N
administered VBD N
to TO N
perform VB N
this DT N
procedure7 NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
is VBZ N
to TO N
assess VB N
which WDT N
is VBZ N
the DT N
most RBS N
appropriate JJ N
infusion NN N
rate NN N
. . N

METHODS CC N
Patients NNPS N
were VBD N
randomly RB N
assigned VBN N
to TO N
two CD N
groups NNS N
. . N

Two CD N
different JJ N
infusion NN N
rates NNS N
were VBD N
compared VBN N
: : N
0,05 CD N
mcg/kg/min NN N
, , N
GROUP NNP N
A NNP N
( ( N
N.=114 NNP N
) ) N
, , N
vs. FW N
0.1 CD N
µg/kg/min NNP N
, , N
GROUP NNP N
B NNP N
( ( N
N.=114 NNP N
) ) N
. . N

Patients NNS N
' POS N
vital JJ N
signs NNS N
, , N
additional JJ N
analgesic NN N
requests NNS N
, , N
PONV NNP N
( ( N
postoperative JJ N
nausea NN N
and CC N
vomiting NN N
) ) N
and CC N
other JJ N
side NN N
effects NNS N
were VBD N
registered VBN N
. . N

The DT N
deepness NN N
of IN N
sedation NN N
and CC N
patient NN N
's POS N
satisfaction NN N
were VBD N
evaluated VBN N
referring VBG N
to TO N
Obsever NNP N
's POS N
Assessment NNP N
of IN N
Alertness NNP N
and CC N
Sedation NNP N
scale NN N
( ( N
O/ASS NNP N
) ) N
and CC N
using VBG N
a DT N
Likert NNP N
's POS N
scale NN N
respectively RB N
. . N

Pain NNP N
intensity NN N
was VBD N
assessed VBN N
with IN N
a DT N
11-points NNS N
VAS NNP N
( ( N
visual JJ N
analogue NN N
scale NN N
) ) N
. . N

Differences NNS N
between IN N
groups NNS N
were VBD N
analyzed VBN N
using VBG N
Student NNP N
t JJ N
test NN N
for IN N
independent JJ N
variables NNS N
. . N

The DT N
χ2 JJ N
test NN N
was VBD N
used VBN N
to TO N
analyze VB N
categorical JJ N
variables NNS N
. . N

RESULTS VB N
The DT N
study NN N
enrolled VBD N
228 CD N
patients NNS N
and CC N
assigned VBD N
them PRP N
to TO N
two CD N
groups NNS N
( ( N
N.=114 NNP N
) ) N
. . N

No DT N
significant JJ N
differences NNS N
were VBD N
found VBN N
regarding VBG N
Likert NNP N
's POS N
scale NN N
values NNS N
( ( N
P=0.20 NNP N
) ) N
, , N
additional JJ N
analgesic JJ N
request NN N
( ( N
P=0.30 NNP N
) ) N
and CC N
mean JJ N
VAS NNP N
values NNS N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
between IN N
the DT N
two CD N
groups NNS N
. . N

The DT N
difference NN N
between IN N
the DT N
two CD N
groups NNS N
about IN N
PONV NNP N
, , N
hypotension NN N
, , N
oxygen NN N
desaturation NN N
and CC N
respiratory NN N
depression NN N
was VBD N
statistically RB N
significant JJ N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
, , N
as IN N
a DT N
matter NN N
of IN N
fact NN N
in IN N
group NN N
A NNP N
these DT N
side NN N
effects NNS N
occurred VBD N
less RBR N
frequently RB N
. . N

The DT N
fifth JJ N
degree NN N
of IN N
O/ASS NNP N
was VBD N
estimated VBN N
in IN N
about RB N
1.61±0.19 CD N
min NNS N
and CC N
2.987±0.20 CD N
min NN N
in IN N
group NN N
A NNP N
and CC N
in IN N
group NN N
B NNP N
respectively RB N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSION NNP N
According VBG N
with IN N
previous JJ N
results NNS N
remifentanil VBP N
at IN N
the DT N
infusion NN N
rate NN N
of IN N
0.05 CD N
µg/kg/min NNP N
provides VBZ N
an DT N
effective JJ N
analgesia NN N
, , N
causing VBG N
a DT N
lower JJR N
incidence NN N
of IN N
side NN N
effect NN N
than IN N
0.1 CD N
µg/kg/min NN N
, , N
granting VBG N
a DT N
fast JJ N
and CC N
safe JJ N
recovery NN N
. . N

-DOCSTART- -X- O O 9587285

Evaluation NN N
of IN N
lidocaine NN N
in IN N
human JJ 4_p
inferior JJ 4_p
alveolar JJ 4_p
nerve NN 4_p
block NN 4_p
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
measure VB N
the DT N
degree NN N
of IN N
anesthesia NN N
following VBG N
the DT N
administration NN N
of IN N
3.6 CD N
ml NN N
of IN N
2 CD N
% NN N
lidocaine JJ N
solutions NNS N
with IN N
either DT N
1:50,000 CD N
, , N
1:80,000 CD N
, , N
or CC N
1:100,000 CD N
for IN N
inferior JJ N
alveolar JJ N
nerve NN N
block NN N
and CC N
to TO N
compare VB N
the DT N
results NNS N
with IN N
those DT N
obtained VBN N
following VBG N
the DT N
administration NN N
of IN N
1.8 CD N
ml NN N
of IN N
the DT N
same JJ N
solutions NNS N
( ( N
1 CD N
) ) N
. . N

With IN N
the DT N
use NN N
of IN N
a DT N
repeated JJ N
measures NNS N
design NN N
, , N
30 CD N
subjects NNS N
randomly RB N
received VBD N
an DT N
inferior JJ N
alveolar JJ N
injection NN N
at IN N
three CD N
successive JJ N
appointments NNS N
. . N

The DT N
first JJ N
molar NN N
, , N
first RB N
premolar JJ N
, , N
lateral JJ N
incisor NN N
, , N
and CC N
contralateral JJ N
canine NN N
( ( N
control NN N
) ) N
were VBD N
blindly RB N
tested VBN N
with IN N
an DT N
Analytic NNP N
Technology NNP N
pulp NN N
tester NN N
at IN N
3-min JJ N
cycles NNS N
for IN N
50 CD N
min NN N
. . N

The DT N
degree NN N
of IN N
anesthesia NN N
was VBD N
comparable JJ N
for IN N
the DT N
three CD N
solutions NNS N
following VBG N
the DT N
administration NN N
of IN N
3.6 CD N
ml NNS N
of IN N
each DT N
solution NN N
. . N

Retrospective JJ N
evaluation NN N
showed VBD N
that IN N
the DT N
volume NN N
of IN N
the DT N
solution NN N
influenced VBD N
the DT N
degree NN N
of IN N
anesthesia NN N
. . N

-DOCSTART- -X- O O 15545310

A DT N
randomized VBN N
crossover NN N
study NN N
investigating VBG N
the DT N
influence NN N
of IN N
ranitidine NN N
or CC N
omeprazole NN N
on IN N
the DT N
pharmacokinetics NNS N
of IN N
cephalexin NN N
monohydrate NN N
. . N

Limited VBN N
data NNS N
characterize RBR N
pharmacokinetic JJ N
interactions NNS N
between IN N
cephalexin NN N
and CC N
ranitidine NN N
, , N
and CC N
no DT N
data NNS N
exist VBP N
for IN N
an DT N
interaction NN N
with IN N
proton NN N
pump NN N
inhibitors NNS N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
effects NNS N
of IN N
ranitidine NN N
or CC N
omeprazole JJ N
administration NN N
on IN N
the DT N
pharmacokinetics NNS N
and CC N
pharmacodynamics NNS N
of IN N
cephalexin NN N
. . N

A DT N
randomized JJ N
single- NN N
and CC N
multiple-dose JJ N
crossover NN N
study NN N
was VBD N
conducted VBN N
in IN N
healthy JJ 4_p
subjects NNS 4_p
ingesting VBG 4_p
cephalexin NN 4_p
before IN N
and CC N
after IN N
steady-state JJ N
administration NN N
of IN N
ranitidine NN N
or CC N
omeprazole NN N
. . N

Time-concentration NN N
profiles NNS N
were VBD N
determined VBN N
and CC N
pharmacokinetic JJ N
parameters NNS N
were VBD N
characterized VBN N
using VBG N
noncompartmental JJ N
methods NNS N
. . N

Pharmacokinetic JJ N
data NNS N
were VBD N
analyzed VBN N
in IN N
accordance NN N
with IN N
the DT N
two CD N
1-sided JJ N
test NN N
for IN N
bioequivalence NN N
. . N

The DT N
percentage NN N
of IN N
time NN N
that IN N
serum JJ N
concentrations NNS N
remain VBP N
above IN N
the DT N
MIC NNP N
( ( N
90 CD N
) ) N
during IN N
the DT N
dosing VBG N
interval NN N
( ( N
T NNP N
> NNP N
MIC NNP N
( ( N
90 CD N
) ) N
) ) N
for IN N
Streptococcus NNP N
pyogenes NNS N
and CC N
Staphylococcus NNP N
aureus RB N
associated VBD N
with IN N
the DT N
pharmacokinetic JJ N
profiles NNS N
was VBD N
calculated VBN N
. . N

The DT N
coadministration NN N
of IN N
cephalexin NN N
with IN N
ranitidine NN N
or CC N
omeprazole NN N
resulted VBD N
in IN N
relatively RB N
minor JJ N
changes NNS N
in IN N
C NNP N
( ( N
max NN N
) ) N
, , N
AUC NNP N
( ( N
infinity NN N
) ) N
, , N
t EX N
( ( N
1/2 CD N
) ) N
, , N
or CC N
CL/F NNP N
. . N

t NN N
( ( N
max NN N
) ) N
was VBD N
significantly RB N
prolonged VBN N
when WRB N
cephalexin NN N
was VBD N
administered VBN N
with IN N
ranitidine NN N
or CC N
omeprazole NN N
. . N

Suboptimal NNP N
T NNP N
> NNP N
MIC NNP N
( ( N
90 CD N
) ) N
was VBD N
observed VBN N
for IN N
cephalexin NN N
irrespective NN N
of IN N
acid JJ N
suppression NN N
. . N

Delay NNP N
in IN N
absorption NN N
of IN N
cephalexin NN N
resulted VBN N
in IN N
a DT N
decrease NN N
in IN N
the DT N
percentage NN N
of IN N
T NNP N
> NNP N
MIC NNP N
( ( N
90 CD N
) ) N
for IN N
certain JJ N
acid-suppressive JJ N
regimens NNS N
and CC N
pathogen NN N
combinations NNS N
. . N

With IN N
the DT N
exception NN N
of IN N
an DT N
increase NN N
in IN N
t NN N
( ( N
max NN N
) ) N
, , N
there EX N
were VBD N
no DT N
significant JJ N
pharmacokinetic JJ N
interactions NNS N
between IN N
cephalexin NN N
and CC N
ranitidine NN N
or CC N
omeprazole NN N
. . N

Delayed VBN N
t NN N
( ( N
max NN N
) ) N
associated VBN N
with IN N
acid JJ N
suppression NN N
may MD N
result VB N
in IN N
a DT N
diminished JJ N
T NNP N
> NNP N
MIC NNP N
( ( N
90 CD N
) ) N
. . N

-DOCSTART- -X- O O 23802768

Impact NN N
of IN N
MET NNP N
expression NN N
on IN N
outcome NN N
in IN N
BRAF NNP N
( ( N
V600E/K NNP N
) ) N
advanced VBD 4_p
melanoma NN 4_p
. . N

AIMS NNP N
Preclinical NNP N
data NN N
suggest NN N
that IN N
signalling VBG N
through IN N
the DT N
HGF-MET NNP N
pathway NN N
may MD N
confer VB N
resistance NN N
to TO N
BRAF NNP N
inhibition NN N
in IN N
BRAF NNP N
( ( N
V600E/K NNP N
) ) N
melanoma NN N
. . N

Therefore RB N
, , N
blockade NN N
of IN N
HGF-MET NNP N
signalling NN N
might MD N
be VB N
a DT N
valid JJ N
therapeutic JJ N
strategy NN N
, , N
in IN N
combination NN N
with IN N
BRAF NNP N
inhibition NN N
, , N
in IN N
BRAF NNP N
( ( N
V600E/K NNP N
) ) N
melanoma NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
clinical JJ N
relevance NN N
of IN N
these DT N
observations NNS N
by IN N
evaluating VBG N
the DT N
survival JJ N
impact NN N
of IN N
MET NNP N
expression NN N
in IN N
patients NNS N
with IN N
BRAF NNP 4_p
( ( 4_p
V600E/K NNP 4_p
) ) 4_p
advanced VBD 4_p
melanoma NN 4_p
treated VBN N
with IN N
vemurafenib NN N
. . N

METHODS NNP N
AND CC N
RESULTS NNP N
Formalin-fixed NNP N
tissue NN N
blocks NNS N
were VBD N
obtained VBN N
of IN N
tumours NNS N
from IN N
patients NNS N
enrolled VBN N
in IN N
the DT N
BRIM2 NNP 4_p
( ( N
n JJ N
= NNP N
59 CD N
) ) N
and CC N
BRIM3 NNP 4_p
( ( N
n JJ N
= NNP N
150 CD N
) ) N
trials NNS N
of IN N
vemurafenib NN N
in IN N
advanced JJ N
BRAF NNP N
( ( N
V600E/K NNP N
) ) N
melanoma NN N
. . N

Immunohistochemistry NNP N
for IN N
MET NNP N
( ( N
SP44 NNP N
rabbit VBP N
monoclonal JJ N
antibody NN N
) ) N
was VBD N
performed VBN N
with IN N
a DT N
highly RB N
validated VBN N
assay NN N
and CC N
clinically RB N
validated VBN N
scoring NN N
system NN N
. . N

Pretreatment NNP N
MET NNP N
expression NN N
was VBD N
frequent JJ N
at IN N
the DT N
≥1 NNP N
+ NNP N
cutoff NN N
( ( N
BRIM3 NNP N
, , N
31 CD N
% NN N
; : N
BRIM2 NNP N
, , N
49 CD N
% NN N
) ) N
, , N
but CC N
relatively RB N
infrequent JJ N
at IN N
the DT N
≥2 NNP N
+ NNP N
cutoff NN N
( ( N
BRIM3 NNP N
, , N
9 CD N
% NN N
; : N
BRIM2 NNP N
, , N
19 CD N
% NN N
) ) N
. . N

Retrospective JJ N
subset NN N
analyses NNS N
showed VBD N
that IN N
, , N
irrespective NN N
of IN N
the DT N
cutoff NN N
used VBD N
or CC N
the DT N
treatment NN N
arm NN N
, , N
MET NNP N
expression NN N
did VBD N
not RB N
show VB N
prognostic JJ N
significance NN N
, , N
in IN N
terms NNS N
of IN N
objective JJ N
response NN N
rate NN N
, , N
progression-free JJ N
survival NN N
, , N
or CC N
overall JJ N
survival NN N
. . N

CONCLUSIONS NNP N
MET NNP N
is VBZ N
expressed VBN N
in IN N
a DT N
proportion NN N
of IN N
BRAF NNP N
( ( N
V600E/K NNP N
) ) N
advanced VBD N
melanomas NN N
. . N

Further JJ N
analyses NNS N
on IN N
appropriately RB N
powered VBN N
subsets NNS N
are VBP N
needed VBN N
to TO N
determine VB N
the DT N
prognostic JJ N
and CC N
predictive JJ N
significance NN N
of IN N
MET NNP N
in IN N
vemurafenib-treated JJ N
melanoma NN N
. . N

-DOCSTART- -X- O O 8035029

Paromomycin NNP N
for IN N
cryptosporidiosis NN N
in IN N
AIDS NNP 4_p
: : 4_p
a DT N
prospective JJ N
, , N
double-blind JJ N
trial NN N
. . N

To TO N
test VB N
the DT N
effects NNS N
of IN N
paromomycin NN N
, , N
10 CD N
patients NNS N
with IN N
AIDS NNP N
and CC N
cryptosporidiosis NN N
were VBD N
randomized VBN N
to TO N
paromomycin VB N
or CC N
placebo VB N
in IN N
a DT N
double-blind JJ N
trial NN N
. . N

After IN N
14 CD N
days NNS N
, , N
patients NNS N
were VBD N
switched VBN N
to TO N
the DT N
other JJ N
treatment NN N
for IN N
14 CD N
additional JJ N
days NNS N
. . N

Measures NNS N
included VBD N
the DT N
number NN N
and CC N
character NN N
of IN N
each DT N
stool NN N
and CC N
weekly JJ N
24-h JJ N
stool NN N
specimens NNS N
for IN N
weight NN N
and CC N
oocyst NN N
excretion NN N
. . N

During IN N
the DT N
paromomycin NN N
treatment NN N
phase NN N
, , N
oocyst JJ N
excretion NN N
decreased VBD N
from IN N
314 CD N
x NNS N
10 CD N
( ( N
6 CD N
) ) N
to TO N
109 CD N
x NNS N
10 CD N
( ( N
6 CD N
) ) N
24 CD N
h NN N
( ( N
P NNP N
< NNP N
.02 NNP N
) ) N
. . N

Oocyst NNP N
excretion NN N
increased VBD N
for IN N
the DT N
4 CD N
patients NNS N
initially RB N
on IN N
placebo NNS N
compared VBN N
to TO N
a DT N
median JJ N
decrease NN N
of IN N
128 CD N
x NNS N
10 CD N
( ( N
6 CD N
) ) N
/24 NN N
h NN N
for IN N
the DT N
6 CD N
initially RB N
treated VBN N
with IN N
drug NN N
( ( N
P NNP N
< NNP N
.02 NNP N
) ) N
. . N

Stool NNP N
frequency NN N
also RB N
decreased VBD N
more RBR N
in IN N
those DT N
treated VBN N
with IN N
drug NN N
( ( N
3.6 CD N
fewer JJR N
vs. NN N
1.25 CD N
fewer/24 NN N
h NN N
, , N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

Trends NNS N
favored JJ N
drug NN N
over IN N
placebo NN N
for IN N
stool NN N
weight NN N
, , N
stool JJ N
character NN N
, , N
and CC N
Karnofsky NNP N
score NN N
. . N

Paromomycin NNP N
treatment NN N
resulted VBD N
in IN N
improvement NN N
in IN N
both DT N
clinical JJ N
and CC N
parasitologic JJ N
parameters NNS N
in IN N
cryptosporidiosis NN N
in IN N
AIDS NNP N
. . N

-DOCSTART- -X- O O 15274670

Effect NN N
of IN N
the DT N
motilin NN N
agonist NN N
KC NNP N
11458 CD N
on IN N
gastric JJ N
emptying VBG N
in IN N
diabetic JJ N
gastroparesis NN N
. . N

BACKGROUND NNP N
KC NNP N
11458 CD N
, , N
a DT N
motilin JJ N
agonist NN N
without IN N
antibiotic JJ N
properties NNS N
, , N
accelerates VBZ N
gastric JJ N
emptying VBG N
in IN N
animals NNS N
and CC N
healthy JJ 4_p
humans NNS 4_p
. . 4_p

AIM NNP N
To TO N
evaluate VB N
the DT N
acute JJ N
effects NNS N
of IN N
KC NNP N
11458 CD N
on IN N
gastric JJ N
emptying VBG N
in IN N
diabetic JJ N
gastroparesis NN N
. . N

METHODS NNP N
Twenty-nine JJ N
patients NNS N
( ( N
6 CD N
type NN N
1 CD N
and CC N
23 CD N
type NN N
2 CD N
) ) N
with IN N
gastroparesis NN 4_p
underwent JJ N
assessments NNS N
of IN N
: : N
( ( N
i NN N
) ) N
gastric NN N
emptying NN N
of IN N
a DT N
solid/liquid JJ N
meal NN N
using VBG N
scintigraphy NN N
, , N
( ( N
ii NN N
) ) N
glycaemic FW N
control NN N
( ( N
blood NN N
glucose NN N
at IN N
0 CD N
, , N
30 CD N
, , N
60 CD N
, , N
90 CD N
and CC N
120 CD N
min NN N
during IN N
the DT N
gastric JJ N
emptying VBG N
measurement NN N
) ) N
and CC N
( ( N
iii NN N
) ) N
upper IN N
gastrointestinal JJ N
and CC N
'meal-related JJ N
' '' N
symptoms NNS N
( ( N
questionnaire NN N
) ) N
, , N
at IN N
baseline NN N
and CC N
after IN N
treatment NN N
with IN N
KC NNP N
11458 CD N
in IN N
a DT N
dose NN N
of IN N
8 CD N
mg NNS N
t.d.s. NN N
, , N
or CC N
placebo NN N
for IN N
8 CD N
days NNS N
. . N

RESULTS NNP N
KC NNP N
11458 CD N
had VBD N
no DT N
statistically RB N
significant JJ N
or CC N
clinically RB N
relevant JJ N
effect NN N
on IN N
gastric JJ N
emptying NN N
of IN N
either CC N
the DT N
solid JJ N
intragastric JJ N
retention NN N
at IN N
100 CD N
min NN N
( ( N
T100 NNP N
) ) N
( ( N
P NNP N
= NNP N
0.87 CD N
) ) N
or CC N
liquid $ N
50 CD N
% NN N
emptying JJ N
time NN N
( ( N
T50 NNP N
) ) N
( ( N
P NNP N
= NNP N
0.17 CD N
) ) N
components NNS N
of IN N
the DT N
meal NN N
. . N

KC NNP N
11458 CD N
slightly RB N
worsened VBN N
( ( N
P NNP N
= NNP N
0.04 CD N
) ) N
upper JJ N
gastrointestinal NN N
symptoms NNS N
when WRB N
compared VBN N
with IN N
placebo NN N
. . N

The DT N
magnitude NN N
of IN N
the DT N
change NN N
in IN N
solid JJ N
gastric JJ N
emptying VBG N
correlated VBN N
with IN N
the DT N
change NN N
in IN N
the DT N
blood NN N
glucose JJ N
concentration NN N
( ( N
r JJ N
= VBZ N
0.49 CD N
; : N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSIONS NNP N
KC NNP N
11458 CD N
, , N
in IN N
a DT N
dose NN N
of IN N
8 CD N
mg NN N
t.d.s NN N
. . N

for IN N
8 CD N
days NNS N
, , N
does VBZ N
not RB N
accelerate VB N
gastric JJ N
emptying VBG N
in IN N
patients NNS N
with IN N
diabetic JJ N
gastroparesis NN N
. . N

The DT N
absence NN N
of IN N
efficacy NN N
may MD N
relate VB N
to TO N
an DT N
effect NN N
of IN N
hyperglycaemia NN N
. . N

-DOCSTART- -X- O O 11916791

The DT N
interaction NN N
between IN N
propofol NN N
and CC N
clonidine NN N
for IN N
loss NN N
of IN N
consciousness NN N
. . N

UNLABELLED NNP N
Clonidine NNP N
premedication NN N
reduces VBZ N
the DT N
intraoperative JJ N
requirement NN N
for IN N
opioids NNS N
and CC N
volatile JJ N
anesthetics NNS N
. . N

Clonidine NNP N
also RB N
reduces VBZ N
the DT N
induction NN N
dose NN N
of IN N
IV NNP N
anesthetics NNS N
. . N

There EX N
is VBZ N
no DT N
information NN N
, , N
however RB N
, , N
regarding VBG N
the DT N
effect NN N
of IN N
oral JJ N
clonidine NN N
premedication NN N
on IN N
the DT N
propofol NN N
blood NN N
concentrations NNS N
required VBD N
for IN N
loss NN N
of IN N
consciousness NN N
, , N
and CC N
the DT N
interaction NN N
between IN N
propofol NN N
and CC N
clonidine NN N
. . N

We PRP N
randomly RB N
administered VBD N
target NN N
effect-site JJ N
concentrations NNS N
of IN N
propofol NN N
ranging VBG N
from IN N
0.5 CD N
to TO N
5 CD N
. . N

0 CD N
microg/mL NN N
by IN N
using VBG N
computer-assisted JJ N
target-controlled JJ N
infusion NN N
to TO N
3 CD N
groups NNS N
of IN N
healthy JJ 4_p
male JJ N
patients NNS N
: : N
Control NNP N
( ( N
n JJ N
= NNP N
35 CD N
) ) N
, , N
2.5 CD N
microg/kg NN N
Clonidine NNP N
( ( N
n JJ N
= NNP N
36 CD N
) ) N
, , N
and CC N
5.0 CD N
microg/kg NNS N
Clonidine NNP N
( ( N
n JJ N
= NNP N
36 CD N
) ) N
groups NNS N
. . N

Nothing NN N
was VBD N
administered VBN N
to TO N
the DT N
Control NNP N
group NN N
. . N

Clonidine NNP N
( ( N
2.5 CD N
or CC N
5.0 CD N
microg/kg NN N
) ) N
was VBD N
administered VBN N
orally RB N
90 CD N
min NN N
before IN N
the DT N
induction NN N
of IN N
anesthesia NN N
in IN N
the DT N
Clonidine NNP N
groups NNS N
. . N

After IN N
equilibration NN N
between IN N
the DT N
blood NN N
and CC N
effect-site NN N
for IN N
15 CD N
min NN N
, , N
a DT N
verbal JJ N
command NN N
to TO N
open VB N
their PRP$ N
eyes NNS N
was VBD N
given VBN N
two CD N
times NNS N
to TO N
the DT N
patients NNS N
. . N

Arterial JJ N
blood NN N
samples NNS N
for IN N
analysis NN N
of IN N
the DT N
serum NN N
propofol NN N
and CC N
clonidine NN N
concentrations NNS N
were VBD N
taken VBN N
immediately RB N
before IN N
verbal JJ N
commands NNS N
were VBD N
given VBN N
. . N

Measured NNP N
serum VBD N
propofol JJ N
concentrations NNS N
in IN N
equilibrium NN N
with IN N
the DT N
effect-site NN N
at IN N
which WDT N
50 CD N
% NN N
of IN N
the DT N
patients NNS N
did VBD N
not RB N
respond VB N
to TO N
verbal VB N
commands NNS N
( ( N
EC50 NNP N
for IN N
loss NN N
of IN N
consciousness NN N
) ) N
were VBD N
determined VBN N
by IN N
logistic JJ N
regression NN N
. . N

The DT N
EC50 NNP N
+/- JJ N
SE NNP N
values NNS N
in IN N
the DT N
Control NNP N
, , N
2.5 CD N
microg/kg NN N
Clonidine NNP N
, , N
and CC N
5.0 CD N
microg/kg NNS N
Clonidine NNP N
groups NNS N
were VBD N
2.67 CD N
+/- JJ N
0.18 CD N
, , N
1.31 CD N
+/- JJ N
0.12 CD N
, , N
and CC N
0.91 CD N
+/- JJ N
0.13 CD N
microg/mL NN N
, , N
respectively RB N
. . N

The DT N
EC50 NNP N
in IN N
the DT N
2.5 CD N
and CC N
5.0 CD N
microg/kg NNS N
clonidine JJ N
groups NNS N
was VBD N
significantly RB N
smaller JJR N
than IN N
that DT N
in IN N
the DT N
Control NNP N
group NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

The DT N
use NN N
of IN N
a DT N
response NN N
surface NN N
modeling VBG N
analysis NN N
indicated VBD N
that IN N
there EX N
was VBD N
an DT N
additive JJ N
interaction NN N
between IN N
measured VBN N
arterial JJ N
propofol NN N
and CC N
clonidine NN N
concentrations NNS N
in IN N
relation NN N
to TO N
loss NN N
of IN N
consciousness NN N
. . N

These DT N
results NNS N
indicate VBP N
that IN N
propofol NN N
and CC N
clonidine NN N
act NN N
additively RB N
for IN N
loss NN N
of IN N
consciousness NN N
. . N

IMPLICATIONS NNP N
Oral NNP N
clonidine NN N
2.5 CD N
and CC N
5.0 CD N
microg/kg NN N
premedication NN N
decreases VBZ N
the DT N
propofol JJ N
concentration NN N
required VBN N
for IN N
loss NN N
of IN N
consciousness NN N
. . N

-DOCSTART- -X- O O 15223738

Evaluation NN N
of IN N
an DT N
aquatics NNS N
programme NN N
on IN N
fitness NN N
parameters NNS N
of IN N
individuals NNS N
with IN N
a DT N
brain NN 4_p
injury NN 4_p
. . N

The DT N
primary JJ N
objective NN N
was VBD N
to TO N
determine VB N
the DT N
effect NN N
of IN N
an DT N
aquatic JJ N
exercise NN N
programme NN N
on IN N
the DT N
physical JJ N
fitness NN N
of IN N
people NNS N
with IN N
a DT N
brain NN 4_p
injury NN 4_p
. . N

A DT N
pre-test-post-test JJ N
randomized-groups JJ N
design NN N
was VBD N
conducted VBN N
. . N

Sixteen JJ N
outpatients NNS N
with IN N
a DT N
brain NN 4_p
injury NN 4_p
were VBD N
included VBN N
in IN N
the DT N
study NN N
. . N

Eight CD N
participants NNS N
were VBD N
assigned VBN N
to TO N
an DT N
aquatic JJ N
exercise NN N
group NN N
and CC N
eight CD N
to TO N
a DT N
control NN N
group NN N
. . N

The DT N
components NNS N
of IN N
physical JJ N
fitness NN N
measured VBD N
included VBD N
cardiovascular JJ N
endurance NN N
, , N
body NN N
composition NN N
, , N
muscular JJ N
strength NN N
and CC N
endurance NN N
and CC N
flexibility NN N
. . N

Measurements NNS N
were VBD N
taken VBN N
pre- JJ N
and CC N
post-programme JJ N
. . N

Results NNP N
indicated VBD N
an DT N
increase NN N
in IN N
components NNS N
of IN N
physical JJ N
fitness NN N
for IN N
the DT N
experimental JJ N
group NN N
but CC N
not RB N
the DT N
control NN N
group NN N
. . N

Increases VBZ N
in IN N
fitness NN N
were VBD N
reported VBN N
as IN N
having VBG N
a DT N
positive JJ N
impact NN N
on IN N
the DT N
functional JJ N
capacity NN N
of IN N
individuals NNS N
in IN N
the DT N
exercise NN N
group NN N
as RB N
well RB N
as IN N
enhancing VBG N
the DT N
individual NN N
's POS N
ability NN N
to TO N
complete VB N
activities NNS N
of IN N
daily JJ N
living VBG N
successfully RB N
. . N

Results VB N
indicate JJ N
that IN N
aquatic JJ N
exercise NN N
may MD N
positively RB N
impact VB N
the DT N
primary JJ N
and CC N
secondary JJ N
physical JJ N
injuries NNS N
caused VBN N
by IN N
a DT N
brain NN N
injury NN N
. . N

-DOCSTART- -X- O O 7047002

Corticosteroid-induced JJ N
osteopenia NN N
and CC N
vitamin NN N
D NNP N
metabolism NN N
. . N

Effect NNP N
of IN N
vitamin NN N
D2 NNP N
, , N
calcium NN N
phosphate NN N
and CC N
sodium NN N
fluoride JJ N
administration NN N
. . N

Thirty-one CD N
patients NNS N
scheduled VBN N
for IN N
long-term JJ N
( ( N
24 CD N
weeks NNS N
) ) N
treatment NN N
with IN N
prednisone NN N
in IN N
comparatively RB N
high JJ N
doses NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
two CD N
further JJ N
treatment NN N
groups NNS N
. . N

Group NNP N
A NNP N
received VBD N
prednisone JJ N
plus CC N
'triple-treatment JJ N
' '' N
( ( N
vitamin FW N
D2 NNP N
45000 CD N
iu NN N
twice RB N
weekly RB N
, , N
sodium JJ N
fluoride RB N
50 CD N
mg NNS N
and CC N
calcium NN N
phosphate VBP N
4.5 CD N
g JJ N
daily RB N
) ) N
, , N
group NN N
B NNP N
received VBD N
only RB N
prednisone NN N
. . N

The DT N
study NN N
was VBD N
undertaken VBN N
in IN N
order NN N
to TO N
evaluate VB N
the DT N
effect NN N
of IN N
prednisone- NN N
and CC N
triple-treatment JJ N
upon IN N
bone JJ N
mineral NN N
content NN N
( ( N
BMC NNP N
) ) N
and CC N
vitamin $ N
D NNP N
metabolism NN N
. . N

The DT N
groups NNS N
were VBD N
comparable JJ N
with IN N
regard NN N
to TO N
age NN N
, , N
sex NN N
and CC N
prednisone NN N
dose NN N
. . N

BMC NNP N
fell VBD N
rapidly RB N
and CC N
similarly RB N
in IN N
both DT N
groups NNS N
, , N
demonstrating VBG N
that IN N
the DT N
triple-treatment NN N
has VBZ N
no DT N
preventive JJ N
effect NN N
on IN N
corticosteroid NN N
induced VBN N
osteopenia NN N
. . N

Serum NNP N
concentrations NNS N
of IN N
25OHD2 CD N
, , N
25OHD3 CD N
and CC N
1,25 CD N
( ( N
OH NNP N
) ) N
2D CD N
were VBD N
unchanged JJ N
in IN N
group NN N
B NNP N
( ( N
without IN N
triple-treatment NN N
) ) N
, , N
whereas RB N
in IN N
group NN N
A NNP N
25OHD2 CD N
increased VBD N
enormously RB N
, , N
25OHD3 CD N
was VBD N
suppressed VBN N
possibly RB N
by IN N
substrate NN N
competition NN N
for IN N
hydroxylation NN N
in IN N
the DT N
liver NN N
and CC N
1,25 CD N
( ( N
OH NNP N
) ) N
2D CD N
was VBD N
halved VBN N
. . N

The DT N
suppression NN N
of IN N
1,25 CD N
( ( N
OH NNP N
) ) N
2D CD N
may MD N
be VB N
an DT N
effect NN N
of IN N
raised VBD N
25OHD2 CD N
alone RB N
, , N
or CC N
in IN N
combination NN N
with IN N
corticosteroid JJ N
excess NN N
. . N

-DOCSTART- -X- O O 15055890

Perispinal JJ N
analgesia NN N
for IN N
labour NN N
followed VBN N
by IN N
patient-controlled JJ N
infusion NN N
with IN N
bupivacaine NN N
and CC N
sufentanil NN N
: : N
combined VBN N
spinal-epidural JJ N
vs. FW N
epidural JJ N
analgesia NN N
alone RB N
. . N

BACKGROUND NNP N
AND NNP N
OBJECTIVE NNP N
Combined NNP N
spinal-epidural JJ N
is VBZ N
an DT N
alternative JJ N
technique NN N
to TO N
epidural JJ N
analgesia NN N
for IN N
labour NN N
, , N
but CC N
its PRP$ N
benefits NNS N
are VBP N
not RB N
clearly RB N
identified VBN N
. . N

METHODS VB N
A DT N
prospective JJ N
, , N
blinded VBD N
, , N
randomized VBD N
study NN N
was VBD N
undertaken JJ N
involving VBG N
113 CD N
women NNS N
attending VBG N
a DT N
university NN N
hospital NN N
obstetric JJ N
department NN N
. . N

Analgesia NNP N
was VBD N
initiated VBN N
with IN N
intrathecal JJ N
bupivacaine NN N
0.25 CD N
% NN N
1 CD N
mL NN N
+ NNP N
sufentanil VBD N
5 CD N
microg NN N
in IN N
the DT N
combined JJ N
spinal-epidural JJ N
group NN N
( ( N
n JJ N
= NNP N
54 CD N
) ) N
, , N
and CC N
with IN N
bupivacaine JJ N
0.125 CD N
% NN N
+ JJ N
epinephrine NN N
2.5 CD N
microg NN N
mL NN N
( ( N
-1 NNP N
) ) N
+ VBD N
sufentanil $ N
7.5 CD N
microg NN N
in IN N
the DT N
epidural JJ N
group NN N
( ( N
n JJ N
= NNP N
59 CD N
) ) N
. . N

In IN N
both DT N
cases NNS N
this DT N
was VBD N
followed VBN N
by IN N
patient-controlled JJ N
epidural JJ N
analgesia NN N
with IN N
bupivacaine JJ N
0.125 CD N
% NN N
( ( N
+ JJ N
sufentanil NN N
0.25 CD N
microg NN N
mL NN N
( ( N
-1 NNP N
) ) N
) ) N
. . N

Duration NN N
of IN N
labour NN N
, , N
quality NN N
of IN N
analgesia NN N
and CC N
side-effects NNS N
were VBD N
compared VBN N
between IN N
groups NNS N
. . N

RESULTS NNP N
In IN N
the DT N
combined JJ N
spinal-epidural JJ N
group NN N
, , N
the DT N
onset NN N
of IN N
analgesia NN N
was VBD N
faster RBR N
( ( N
5 CD N
vs. FW N
15 CD N
min NN N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
the DT N
consumption NN N
of IN N
bupivacaine NN N
was VBD N
lower JJR N
( ( N
7.5 CD N
vs. FW N
11.3 CD N
mg NN N
h NN N
( ( N
-1 NNP N
) ) N
, , N
P NNP N
= NNP N
0.003 CD N
) ) N
and CC N
there EX N
was VBD N
less JJR N
unilateral JJ N
analgesia NN N
( ( N
14.8 CD N
% NN N
vs. FW N
40.7 CD N
% NN N
, , N
P NNP N
= NNP N
0.002 CD N
) ) N
than IN N
in IN N
the DT N
epidural JJ N
group NN N
. . N

The DT N
characteristics NNS N
of IN N
labour NN N
were VBD N
similar JJ N
in IN N
both DT N
groups NNS N
. . N

However RB N
, , N
in IN N
the DT N
combined JJ N
spinal-epidural JJ N
group NN N
, , N
there EX N
was VBD N
a DT N
higher JJR N
incidence NN N
of IN N
posterior JJ N
presentation NN N
( ( N
25.9 CD N
% NN N
vs. FW N
10 CD N
% NN N
, , N
P NNP N
= NNP N
0.03 CD N
) ) N
, , N
pruritus NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
hypotension NN N
( ( N
P NNP N
= NNP N
0.002 CD N
) ) N
, , N
somnolence NN N
( ( N
P NNP N
= NNP N
0.01 CD N
) ) N
, , N
nausea NN N
( ( N
P NNP N
= NNP N
0.02 CD N
) ) N
and CC N
one CD N
case NN N
of IN N
meningitis NN N
. . N

CONCLUSIONS VB N
The DT N
combined JJ N
spinal-epidural JJ N
technique NN N
provided VBD N
more RBR N
effective JJ N
analgesia NN N
during IN 4_p
labour JJR 4_p
than IN N
epidural JJ N
analgesia NN N
alone RB N
but CC N
offered VBN N
no DT N
other JJ N
advantage NN N
. . N

It PRP N
induced VBD N
more RBR N
adverse JJ N
effects NNS N
and CC N
this DT N
should MD N
be VB N
considered VBN N
before IN N
routinely RB N
using VBG N
the DT N
combined JJ N
spinal-epidural JJ N
technique NN N
. . N

-DOCSTART- -X- O O 12199005

Mandibular JJ N
advancement NN N
splint NN N
improves VBZ N
indices NNS N
of IN N
obstructive JJ 4_p
sleep NN 4_p
apnoea NN 4_p
and CC 4_p
snoring VBG 4_p
but CC N
side JJ N
effects NNS N
are VBP N
common JJ N
. . N

AIM NNP N
To TO N
assess VB N
the DT N
efficacy NN N
of IN N
a DT N
mandibular JJ N
advancement NN N
splint NN N
( ( N
MAS NNP N
) ) N
in IN N
the DT N
treatment NN N
of IN N
obstructive JJ N
sleep JJ N
apnoea NN N
syndrome NN N
( ( N
OSAS NNP N
) ) N
. . N

METHODS NNP N
Nineteen NNP N
patients NNS N
using VBG N
a DT N
MAS NNP N
for IN N
symptomatic JJ N
OSAS NNP N
underwent NN N
polysomnography NN N
, , N
with IN N
MAS NNP N
use NN N
randomised VBD N
to TO N
one CD N
half NN N
of IN N
the DT N
night NN N
. . N

Indices NNS N
of IN N
snoring VBG N
and CC N
OSAS NNP N
were VBD N
compared VBN N
. . N

Side NNP N
effects NNS N
, , N
compliance NN N
and CC N
treatment NN N
response NN N
were VBD N
evaluated VBN N
by IN N
questionnaire NN N
. . N

RESULTS NNP N
Use NNP N
of IN N
the DT N
MAS NNP N
improved VBD N
total JJ N
respiratory NN N
disturbance NN N
index NN N
( ( N
RDI NNP N
) ) N
from IN N
22.2 CD N
+/- JJ N
19.8 CD N
( ( N
SD NNP N
) ) N
events NNS N
per IN N
hour NN N
to TO N
16.5 CD N
+/- JJ N
21.4/hr CD N
( ( N
p NN N
= RB N
0.03 CD N
) ) N
, , N
supine JJ N
RDI NNP N
( ( N
30.8 CD N
+/- JJ N
23.8/hr CD N
to TO N
18.8 CD N
+/- JJ N
22.1/hr CD N
, , N
p NN N
= NNP N
0.01 CD N
) ) N
, , N
arousal JJ N
index NN N
( ( N
25.2 CD N
+/- JJ N
18.9/hr CD N
to TO N
19.3 CD N
+/- JJ N
14.2/hr CD N
, , N
p NN N
= NNP N
0.01 CD N
) ) N
and CC N
snoring VBG N
intensity NN N
( ( N
52.7 CD N
+/- JJ N
4.1 CD N
to TO N
50.7 CD N
+/- JJ N
2.7 CD N
dB NN N
, , N
p NN N
= NNP N
0.02 CD N
) ) N
but CC N
not RB N
total JJ N
snore NN N
frequency NN N
( ( N
p JJ N
> NNP N
0.05 CD N
) ) N
. . N

Using VBG N
polysomnographic JJ N
criteria NNS N
, , N
MAS NNP N
treatment NN N
was VBD N
completely RB N
successful JJ N
in IN N
four CD N
( ( N
21 CD N
% NN N
) ) N
patients NNS N
, , N
partially RB N
successful JJ N
in IN N
ten NN N
( ( N
52.6 CD N
% NN N
) ) N
and CC N
a DT N
failure NN N
in IN N
five CD N
( ( N
26.3 CD N
% NN N
) ) N
. . N

Treatment NN N
over IN N
a DT N
median NN N
of IN N
6.5 CD N
weeks NNS N
( ( N
range VB N
2-48 CD N
) ) N
was VBD N
perceived VBN N
as IN N
beneficial JJ N
by IN N
ten NN N
of IN N
eleven JJ N
partners NNS N
. . N

Fifteen JJ N
patients NNS N
( ( N
79 CD N
% NN N
) ) N
reported VBD N
side JJ N
effects NNS N
, , N
9 CD N
( ( N
46 CD N
% NN N
) ) N
did VBD N
not RB N
use VB N
the DT N
device NN N
every DT N
night NN N
and CC N
four CD N
( ( N
21 CD N
% NN N
) ) N
used VBD N
the DT N
device NN N
less JJR N
than IN N
three CD N
nights NNS N
per IN N
week NN N
. . N

CONCLUSION NNP N
The DT N
use NN N
of IN N
the DT N
MAS NNP N
resulted VBD N
in IN N
significant JJ N
reductions NNS N
in IN N
indices NNS N
of IN N
OSAS NNP N
and CC N
snoring VBG N
. . N

However RB N
, , N
a DT N
significant JJ N
number NN N
of IN N
patients NNS N
had VBD N
difficulty NN N
tolerating NN N
and CC N
regularly RB N
using VBG N
the DT N
device NN N
. . N

-DOCSTART- -X- O O 17280773

Desmopressin NNP N
in IN N
the DT N
treatment NN N
of IN N
nocturia NNS 4_p
: : 4_p
a DT N
double-blind NN N
, , N
placebo-controlled JJ N
study NN N
. . N

OBJECTIVES NNP N
To TO N
investigate VB N
efficacy NN N
, , N
safety NN N
, , N
and CC N
impact NN N
on IN N
quality NN N
of IN N
sleep NN N
of IN N
desmopressin NN N
in IN N
the DT N
treatment NN N
of IN N
nocturia NNS N
. . N

METHODS NNP N
Adults NNP N
aged VBD N
> NNP N
or CC N
=18 NNP N
yr NN N
with IN N
nocturia NNS N
( ( N
> CD N
or CC N
=2 VB N
voids/night NN N
) ) N
received VBD N
desmopressin JJ N
tablets NNS N
( ( N
0.1 CD N
, , N
0.2 CD N
, , N
or CC N
0.4 CD N
mg NN N
) ) N
during IN N
a DT N
3-wk JJ N
dose-titration NN N
period NN N
. . N

Patients NNS N
should MD N
show VB N
sufficient JJ N
response NN N
during IN N
the DT N
dose-titration JJ N
period NN N
( ( N
> CD N
or CC N
=20 CD N
% NN N
reduction NN N
in IN N
nocturnal JJ N
diuresis NN N
) ) N
and CC N
a DT N
return NN N
of IN N
nocturnal JJ N
diuresis NN N
to TO N
> VB N
or CC N
=80 VB N
% NN N
of IN N
baseline NN N
levels NNS N
during IN N
washout NN N
. . N

Eligible JJ N
patients NNS N
then RB N
entered VBD N
a DT N
3-wk JJ N
double-blind JJ N
treatment NN N
period NN N
and CC N
received VBD N
either CC N
desmopressin NN N
or CC N
placebo NN N
. . N

RESULTS CC N
127 CD N
patients NNS N
were VBD N
randomised VBN N
to TO N
either DT N
desmopressin NN N
( ( N
n=61 JJ N
) ) N
or CC N
placebo NN N
( ( N
n=66 JJ N
) ) N
. . N

Twenty NNP N
( ( N
33 CD N
% NN N
) ) N
desmopressin-treated JJ N
patients NNS N
compared VBN N
with IN N
seven CD N
( ( N
11 CD N
% NN N
) ) N
placebo-treated JJ N
patients NNS N
showed VBD N
a DT N
clinical JJ N
response NN N
, , N
defined VBD N
as IN N
a DT N
> NN N
or CC N
=50 CD N
% NN N
reduction NN N
in IN N
the DT N
number NN N
of IN N
nocturnal JJ N
voids NNS N
compared VBN N
with IN N
baseline NN N
( ( N
p=0.0014 NN N
) ) N
. . N

Compared VBN N
with IN N
placebo NN N
, , N
desmopressin NN N
resulted VBD N
in IN N
a DT N
significant JJ N
reduction NN N
in IN N
the DT N
mean JJ N
number NN N
of IN N
nocturnal JJ N
voids NNS N
( ( N
39 CD N
% NN N
reduction NN N
with IN N
desmopressin NN N
vs. FW N
15 CD N
% NN N
with IN N
placebo NN N
; : N
absolute JJ N
difference NN N
-0.84 NN N
, , N
p NN N
< NNP N
0.0001 CD N
) ) N
and CC N
duration NN N
of IN N
the DT N
first JJ N
sleep JJ N
period NN N
( ( N
prolonged VBN N
by IN N
108 CD N
min NNS N
with IN N
desmopressin NN N
vs. FW N
41 CD N
min NN N
with IN N
placebo NN N
; : N
p CC N
< VB N
0.0001 CD N
) ) N
. . N

Quality NN N
of IN N
sleep NN N
was VBD N
also RB N
improved VBN N
with IN N
desmopressin NN N
versus NN N
placebo NN N
( ( N
statistically RB N
significant JJ N
for IN N
one CD N
of IN N
the DT N
two CD N
parameters NNS N
evaluated VBD N
) ) N
. . N

Adverse JJ N
events NNS N
were VBD N
mainly RB N
mild JJ N
. . N

CONCLUSIONS NNP N
Oral NNP N
desmopressin NN N
tablets NNS N
provide VBP N
an DT N
effective JJ N
and CC N
well-tolerated JJ N
treatment NN N
for IN N
nocturia NN N
. . N

Compared VBN N
with IN N
placebo NN N
, , N
nocturnal JJ N
voiding NN N
frequency NN N
is VBZ N
reduced VBN N
, , N
duration NN N
of IN N
the DT N
first JJ N
sleep JJ N
period NN N
is VBZ N
increased VBN N
, , N
and CC N
sleep JJ N
quality NN N
may MD N
be VB N
improved VBN N
. . N

-DOCSTART- -X- O O 2286596

A DT N
comparative JJ N
study NN N
of IN N
ofloxacin NN N
and CC N
amoxycillin/clavulanate NN N
in IN N
hospitalized JJ N
patients NNS N
with IN N
lower JJR N
respiratory NN N
tract JJ N
infections NNS N
. . N

We PRP N
conducted VBD N
an DT N
open JJ N
randomized VBN N
trial NN N
to TO N
compare VB N
the DT N
efficacy NN N
of IN N
parenteral JJ N
and CC N
oral JJ N
ofloxacin NN N
with IN N
that DT N
of IN N
amoxycillin/clavulanate NN N
. . N

A DT N
total NN N
of IN N
121 CD N
patients NNS N
was VBD N
studied VBN N
; : N
92 CD N
were VBD N
clinically RB N
evaluable JJ N
. . N

Of IN N
these DT N
, , N
59 CD N
patients NNS N
were VBD N
treated VBN N
with IN N
ofloxacin NN N
and CC N
33 CD N
with IN N
the DT N
comparator NN N
drug NN N
. . N

Patients NNS N
were VBD N
given VBN N
the DT N
drugs NNS N
intravenously RB N
for IN N
a DT N
minimum NN N
of IN N
three CD N
days NNS N
followed VBN N
by IN N
oral JJ N
preparations NNS N
for IN N
the DT N
next JJ N
seven CD N
to TO N
ten VB N
days NNS N
. . N

Ofloxacin NNP N
was VBD N
usually RB N
administered VBN N
as IN N
a DT N
200 CD N
mg NN N
dose NN N
bd NN N
. . N

In IN N
the DT N
ofloxacin NN N
treated VBN N
group NN N
all DT N
patients NNS N
showed VBD N
clinical JJ N
improvement NN N
. . N

In IN N
the DT N
comparator NN N
group NN N
94 CD N
% NN N
improved VBN N
clinically RB N
( ( N
either CC N
a DT N
complete JJ N
or CC N
partial JJ N
response NN N
) ) N
, , N
while IN N
6 CD N
% NN N
were VBD N
clinical JJ N
failures NNS N
. . N

Of IN N
the DT N
bacteriologically RB N
evaluable JJ N
patients NNS N
19 CD N
of IN N
20 CD N
showed VBD N
a DT N
satisfactory JJ N
bacteriological JJ N
response NN N
in IN N
the DT N
ofloxacin NN N
treated VBD N
group NN N
, , N
while IN N
in IN N
the DT N
comparator NN N
group NN N
the DT N
bacteriological JJ N
response NN N
was VBD N
judged VBN N
satisfactory NN N
in IN N
14 CD N
of IN N
17 CD N
patients NNS N
. . N

A DT N
small JJ N
proportion NN N
of IN N
patients NNS N
( ( N
7 CD N
% NN N
) ) N
treated VBD N
with IN N
ofloxacin NN N
suffered VBD N
mild JJ N
adverse JJ N
effects NNS N
( ( N
nausea NN N
, , N
vomiting VBG N
, , N
headache NN N
, , N
hypotension NN N
and CC N
rash NN N
) ) N
. . N

On IN N
the DT N
whole NN N
, , N
ofloxacin NN N
was VBD N
well RB N
tolerated VBN N
by IN N
our PRP$ N
patients NNS N
. . N

The DT N
two CD N
deaths NNS N
that IN N
occurred VBD N
were VBD N
in IN N
the DT N
comparator NN N
group NN N
. . N

We PRP N
conclude VBP N
that DT N
ofloxacin NN N
in IN N
both DT N
oral JJ N
and CC N
parenteral JJ N
forms NNS N
is VBZ N
an DT N
effective JJ N
and CC N
safe JJ N
drug NN N
in IN N
the DT N
treatment NN N
of IN N
lower JJR N
respiratory NN N
tract JJ N
infections NNS N
. . N

-DOCSTART- -X- O O 12239448

Stepwise NNP N
hook NN N
extension NN N
technique NN N
for IN N
radiofrequency NN N
ablation NN N
therapy NN N
of IN N
hepatocellular JJ 4_p
carcinoma NN 4_p
. . N

OBJECTIVE CC N
Our PRP$ N
study NN N
was VBD N
designed VBN N
to TO N
examine VB N
the DT N
efficacy NN N
of IN N
stepwise NN N
hook NN N
extension NN N
technique NN N
for IN N
radiofrequency NN N
ablation NN N
( ( N
RFA NNP N
) ) N
therapy NN N
of IN N
hepatocellular JJ 4_p
carcinoma NN 4_p
in IN N
a DT N
randomized NN N
controlled VBN N
study NN N
. . N

METHOD NNP N
Twenty NNP N
patients NNS N
with IN N
hepatocellular JJ 4_p
carcinoma NN 4_p
measuring VBG 4_p
< $ 4_p
25 CD 4_p
mm NN 4_p
were VBD N
divided VBN N
randomly RB N
into IN N
two CD N
equal JJ N
groups NNS N
. . N

RFA NNP N
was VBD N
applied VBN N
using VBG N
our PRP$ N
new JJ N
stepwise NN N
hook NN N
extension NN N
technique NN N
in IN N
patients NNS N
of IN N
group NN N
1 CD N
, , N
and CC N
the DT N
full JJ N
extension NN N
method NN N
in IN N
group NN N
2 CD N
. . N

The DT N
10-hook JJ N
electrode NN N
of IN N
LeVeen NNP N
needle NN N
was VBD N
deployed VBN N
in IN N
four CD N
steps NNS N
to TO N
full JJ N
extension NN N
during IN N
ablation NN N
in IN N
group NN N
1 CD N
, , N
and CC N
full JJ N
extension NN N
at IN N
start NN N
of IN N
treatment NN N
in IN N
group NN N
2 CD N
. . N

RESULTS VB N
Roll-off NNP N
was VBD N
achieved VBN N
in IN N
all DT N
10 CD N
patients NNS N
of IN N
group NN N
1 CD N
, , N
indicative NN N
of IN N
sufficient JJ N
tumor NN N
coagulation NN N
, , N
but CC N
only RB N
in IN N
3 CD N
of IN N
10 CD N
patients NNS N
of IN N
group NN N
2 CD N
. . N

The DT N
median JJ N
time NN N
to TO N
completion NN N
of IN N
treatment NN N
was VBD N
6 CD N
min NN N
and CC N
55 CD N
s NN N
( ( N
range VB N
3 CD N
min NN N
to TO N
14 CD N
min NNS N
and CC N
3 CD N
s NN N
) ) N
and CC N
15 CD N
min NN N
( ( N
6-15 JJ N
min NN N
) ) N
, , N
respectively RB N
. . N

The DT N
total JJ N
power NN N
output NN N
used VBN N
for IN N
RF NNP N
was VBD N
lower JJR N
in IN N
group NN N
1 CD N
than IN N
in IN N
group NN N
2 CD N
( ( N
median JJ N
271 CD N
vs. FW N
1,045 CD N
W.m NNP N
) ) N
. . N

The DT N
diameters NNS N
of IN N
RFA-induced JJ N
lesions NNS N
were VBD N
not RB N
significantly RB N
different JJ N
between IN N
the DT N
groups NNS N
( ( N
group NN N
1 CD N
: : N
27 CD N
, , N
range NN N
23-37 JJ N
mm NN N
; : N
group NN N
2 CD N
: : N
23 CD N
, , N
0-42 JJ N
mm NN N
) ) N
. . N

CONCLUSIONS NNP N
Application NNP N
of IN N
RFA NNP N
using VBG N
stepwise NN N
hook NN N
extension NN N
technique NN N
is VBZ N
superior JJ N
to TO N
the DT N
full JJ N
extension NN N
method NN N
since IN N
it PRP N
produces VBZ N
the DT N
same JJ N
therapeutic JJ N
effects NNS N
within IN N
a DT N
short JJ N
period NN N
using VBG N
a DT N
lower JJR N
energy NN N
. . N

-DOCSTART- -X- O O 16119478

Clinical JJ N
efficacy NN N
of IN N
fluvoxamine NN N
and CC N
functional JJ N
polymorphism NN N
in IN N
a DT N
serotonin NN N
transporter NN N
gene NN N
on IN N
childhood NN N
autism NN 4_p
. . N

We PRP N
studied VBD N
the DT N
correlation NN N
between IN N
response NN N
to TO N
fluvoxamine VB N
and CC N
serotonin VB N
transporter NN N
gene NN N
promoter NN N
region NN N
polymorphism NN N
( ( N
5-HTTLPR JJ N
) ) N
. . N

Eighteen JJ N
children NNS N
with IN N
autistic JJ 4_p
disorder NN 4_p
completed VBD N
a DT N
12-week JJ N
double-blind NN N
, , N
placebo-controlled JJ N
, , N
randomized VBN N
crossover NN N
study NN N
of IN N
fluvoxamine NN N
. . N

Behavioral JJ N
assessments NNS N
were VBD N
obtained VBN N
before IN N
and CC N
at IN N
12 CD N
weeks NNS N
of IN N
treatment NN N
. . N

5-HTTLPR JJ N
( ( N
long JJ N
( ( N
l NN N
) ) N
or CC N
short JJ N
( ( N
s PRP N
) ) N
) ) N
, , N
was VBD N
analyzed VBN N
by IN N
the DT N
PCR NNP N
method NN N
. . N

Ten CD N
out IN N
of IN N
18 CD N
patients NNS N
responded VBD N
to TO N
fluvoxamine VB N
treatment NN N
; : N
allele CC N
type JJ N
analysis NN N
revealed VBD N
that IN N
clinical JJ N
global JJ N
effectiveness NN N
was VBD N
noted VBN N
significantly RB N
more RBR N
in IN N
the DT N
l NN N
allele NN N
than IN N
in IN N
the DT N
s NN N
allele NN N
. . N

However RB N
, , N
with IN N
respect NN N
to TO N
language NN N
use NN N
, , N
a DT N
significant JJ N
effectiveness NN N
was VBD N
noted VBN N
in IN N
the DT N
s NN N
allele NN N
. . N

5-HTTLPR JJ N
may MD N
influence VB N
the DT N
individual NN N
responses VBZ N
to TO N
fluvoxamine VB N
administration NN N
. . N

-DOCSTART- -X- O O 22045148

A DT N
simplified VBN N
score NN N
for IN N
transfer NN N
of IN N
patients NNS 4_p
requiring VBG 4_p
mechanical JJ 4_p
ventilation NN 4_p
to TO N
a DT N
long-term JJ N
care NN N
hospital NN N
. . N

BACKGROUND NNP N
Long-term NNP N
care NN N
hospitals NNS N
are VBP N
Medicare NNP N
providers NNS N
of IN N
postacute NN 4_p
care NN 4_p
that WDT N
have VBP N
a DT N
mean JJ N
length NN N
of IN N
stay NN N
of IN N
25 CD N
days NNS N
or CC N
more JJR N
. . N

Early JJ N
identification NN N
and CC N
timely JJ N
transfer NN N
of IN N
patients NNS N
requiring VBG N
mechanical JJ N
ventilation NN N
to TO N
such JJ N
hospitals NNS N
may MD N
improve VB N
the DT N
efficiency NN N
of IN N
inpatient NN N
care NN N
. . N

OBJECTIVES NNP N
To TO N
develop VB N
a DT N
predictive JJ N
model NN N
and CC N
a DT N
simplified VBN N
score NN N
for IN N
use NN N
on IN N
day NN N
7 CD N
of IN N
hospitalization NN N
to TO N
assess VB N
whether IN N
a DT N
patient NN N
receiving VBG N
mechanical JJ N
ventilation NN N
is VBZ N
likely JJ N
to TO N
require VB N
an DT N
additional JJ N
25 CD N
days NNS N
of IN N
hospitalization NN N
( ( N
ie JJ N
, , N
would MD N
qualify VB N
for IN N
transfer NN N
to TO N
a DT N
long-term JJ N
care NN N
hospital NN N
) ) N
. . N

METHODS CC N
A DT N
retrospective JJ N
, , N
cross-sectional JJ N
study NN N
using VBG N
hospital JJ N
discharge NN N
and CC N
billing NN N
data NNS N
from IN N
the DT N
2005 CD N
Nationwide NNP N
Inpatient NNP N
Sample NNP N
for IN N
54 CD N
686 CD N
Medicare NNP N
beneficiaries NNS N
admitted VBD N
to TO N
US NNP N
community NN N
hospitals NNS N
who WP N
met VBD N
the DT N
study NN N
's POS N
eligibility NN N
criteria NNS N
. . N

The DT N
outcome NN N
was VBD N
overall JJ N
length NN N
of IN N
stay NN N
( ( N
≥32 JJ N
vs NN N
< $ N
32 CD N
days NNS N
) ) N
. . N

Split-sample JJ N
validation NN N
was VBD N
used VBN N
. . N

Multivariable JJ N
survey-logistic JJ N
regression NN N
analyses NNS N
were VBD N
performed VBN N
to TO N
assess VB N
predictors NNS N
and CC N
probability NN N
of IN N
the DT N
outcome NN N
. . N

A DT N
simplified JJ N
score NN N
was VBD N
derived VBN N
from IN N
the DT N
final JJ N
predictive NN N
model NN N
. . N

RESULTS VB N
The DT N
discriminatory JJ N
power NN N
of IN N
the DT N
predictive JJ N
model NN N
was VBD N
0.75 CD N
and CC N
that IN N
of IN N
the DT N
simplified VBN N
score NN N
was VBD N
0.72 CD N
. . N

The DT N
model NN N
calibrated VBN N
well RB N
. . N

All DT N
predictors NNS N
were VBD N
significantly RB N
( ( N
P NNP N
< NNP N
.01 NNP N
) ) N
associated VBN N
with IN N
a DT N
hospitalization NN N
of IN N
32 CD N
days NNS N
or CC N
longer JJR N
; : N
having VBG N
a DT N
tracheostomy NN N
was VBD N
the DT N
strongest JJS N
predictor NN N
( ( N
odds NNS N
ratio NN N
, , N
4.74 CD N
) ) N
. . N

The DT N
simplified JJ N
scores NNS N
ranged VBD N
from IN N
-5 NN N
to TO N
110 CD N
points NNS N
and CC N
were VBD N
categorized VBN N
into IN N
3 CD N
classes NNS N
of IN N
risk NN N
. . N

CONCLUSIONS NNP N
Efforts NNPS N
to TO N
aid VB N
discharge NN N
decision NN N
making NN N
and CC N
optimize VB N
hospital JJ N
resource NN N
planning NN N
could MD N
take VB N
advantage NN N
of IN N
our PRP$ N
predictive JJ N
model NN N
and CC N
the DT N
simplified JJ N
scoring NN N
tool NN N
. . N

-DOCSTART- -X- O O 21705084

Adjusting VBG N
intraocular JJ N
pressure NN N
for IN N
central JJ N
corneal JJ N
thickness NN N
does VBZ N
not RB N
improve VB N
prediction NN N
models NNS N
for IN N
primary JJ N
open-angle JJ N
glaucoma NN N
. . N

PURPOSE NNP N
To TO N
determine VB N
if IN N
the DT N
accuracy NN N
of IN N
the DT N
baseline NN N
prediction NN N
model NN N
for IN N
the DT N
development NN N
of IN N
primary JJ N
open-angle JJ N
glaucoma NN N
( ( N
POAG NNP N
) ) N
in IN N
patients NNS N
with IN N
ocular JJ 4_p
hypertension NN 4_p
can MD N
be VB N
improved VBN N
by IN N
correcting VBG N
intraocular JJ N
pressure NN N
( ( N
IOP NNP N
) ) N
for IN N
central JJ N
corneal NN N
thickness NN N
( ( N
CCT NNP N
) ) N
. . N

DESIGN NNP N
Reanalysis NNP N
of IN N
the DT N
baseline NN N
prediction NN N
model NN N
for IN N
the DT N
development NN N
of IN N
POAG NNP N
from IN N
the DT N
Ocular NNP N
Hypertension NNP N
Treatment NNP N
Study NNP N
( ( N
OHTS NNP N
) ) N
substituting VBG N
IOP NNP N
adjusted VBD N
for IN N
CCT NNP N
using VBG N
5 CD N
different JJ N
correction NN N
formulae NN N
for IN N
unadjusted JJ N
IOP NNP N
. . N

PARTICIPANTS VB N
A DT N
total NN N
of IN N
1433 CD N
of IN N
1636 CD N
participants NNS N
randomized VBN N
to TO N
OHTS NNP 4_p
who WP N
had VBD N
complete JJ N
baseline NN N
data NNS N
for IN N
factors NNS N
in IN N
the DT N
prediction NN N
model NN N
: : N
age NN N
, , N
IOP NNP N
, , N
CCT NNP N
, , N
vertical JJ N
cup-to-disc NN N
ratio NN N
( ( N
VCDR NNP N
) ) N
, , N
and CC N
pattern JJ N
standard JJ N
deviation NN N
( ( N
PSD NNP N
) ) N
. . N

METHODS NNP N
Reanalysis NNP N
of IN N
the DT N
prediction NN N
model NN N
for IN N
the DT N
risk NN N
of IN N
developing VBG N
POAG NNP N
using VBG N
the DT N
same JJ N
baseline NN N
variables NNS N
( ( N
age NN N
, , N
IOP NNP N
, , N
CCT NNP N
, , N
VCDR NNP N
, , N
and CC N
PSD NNP N
) ) N
except IN N
that DT N
IOP NNP N
was VBD N
adjusted VBN N
for IN N
CCT NNP N
using VBG N
correction NN N
formulae NN N
. . N

A DT N
separate JJ N
Cox NNP N
proportional NN N
hazards NNS N
model NN N
was VBD N
run VBN N
using VBG N
IOP NNP N
adjusted VBD N
for IN N
CCT NNP N
by IN N
each DT N
of IN N
the DT N
5 CD N
formulae NN N
published VBN N
to TO N
date NN N
. . N

Models NNS N
were VBD N
run VBN N
including VBG N
and CC N
excluding VBG N
CCT NNP N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Predictive NNP N
accuracy NN N
of IN N
each DT N
Cox NNP N
proportional JJ N
hazards NNS N
model NN N
was VBD N
assessed VBN N
using VBG N
the DT N
c-statistic JJ N
and CC N
calibration JJ N
chi-square NN N
. . N

RESULTS NNP N
C-statistics NNPS N
for IN N
prediction NN N
models NNS N
that IN N
used VBD N
IOP NNP N
adjusted VBD N
for IN N
CCT NNP N
by IN N
various JJ N
formulas NNS N
ranged VBD N
from IN N
0.75 CD N
to TO N
0.77 CD N
, , N
no DT N
better JJR N
than IN N
the DT N
original JJ N
prediction NN N
model NN N
( ( N
0.77 CD N
) ) N
that WDT N
did VBD N
not RB N
adjust VB N
IOP NNP N
for IN N
CCT NNP N
. . N

Calibration NNP N
chi-square NN N
was VBD N
acceptable JJ N
for IN N
all DT N
models NNS N
. . N

Baseline NNP N
IOP NNP N
, , N
whether IN N
adjusted VBN N
for IN N
CCT NNP N
or CC N
not RB N
, , N
was VBD N
statistically RB N
significant JJ N
in IN N
all DT N
models NNS N
including VBG N
those DT N
with IN N
CCT NNP N
in IN N
the DT N
same JJ N
model NN N
. . N

The DT N
CCT NNP N
was VBD N
statistically RB N
significant JJ N
in IN N
all DT N
models NNS N
including VBG N
those DT N
with IN N
IOP NNP N
adjusted VBD N
for IN N
CCT NNP N
in IN N
the DT N
same JJ N
model NN N
. . N

CONCLUSIONS VB N
The DT N
calculation NN N
of IN N
individual JJ N
risk NN N
for IN N
developing VBG N
POAG NNP N
in IN N
ocular JJ 4_p
hypertensive JJ 4_p
individuals NNS N
is VBZ N
simpler JJR N
and CC N
equally RB N
accurate JJ N
using VBG N
IOP NNP N
and CC N
CCT NNP N
as IN N
measured VBN N
, , N
rather RB N
than IN N
applying VBG N
an DT N
adjustment NN N
formula NN N
to TO N
correct VB N
IOP NNP N
for IN N
CCT NNP N
. . N

-DOCSTART- -X- O O 20159310

A DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
, , N
phase NN N
I PRP N
study VBP N
of IN N
MEDI-545 NNP N
, , N
an DT N
anti-interferon-alfa JJ N
monoclonal NN N
antibody NN N
, , N
in IN N
subjects NNS N
with IN N
chronic JJ N
psoriasis NN N
. . N

BACKGROUND NNP N
Interferon-alfa NNP N
( ( N
IFN-alpha NNP N
) ) N
has VBZ N
been VBN N
implicated VBN N
in IN N
the DT N
pathogenesis NN N
of IN N
psoriasis NN N
. . N

OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
safety NN N
profile NN N
of IN N
MEDI-545 NNP N
, , N
a DT N
fully RB N
human JJ N
anti-IFN-alpha JJ N
monoclonal NN N
antibody NN N
and CC N
to TO N
explore VB N
its PRP$ N
effect NN N
on IN N
the DT N
involvement NN N
of IN N
type NN N
I PRP N
IFN-alpha VBP N
activity NN N
in IN N
the DT N
maintenance NN N
of IN N
established VBN N
plaque NN N
psoriasis NN N
. . N

METHODS NNP N
We PRP N
conducted VBD N
an DT N
18-week JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
, , N
dose-escalating JJ N
study NN N
in IN N
36 CD N
subjects NNS N
with IN N
chronic JJ N
plaque NN N
psoriasis NN N
. . N

Subjects VBZ N
received VBD N
one CD N
intravenous JJ N
dose NN N
of IN N
MEDI-545 NNP N
( ( N
0.3-30.0 JJ N
mg/kg NN N
) ) N
or CC N
placebo NN N
. . N

Study NNP N
outcomes NNS N
were VBD N
safety NN N
profile NN N
, , N
pharmacokinetics NNS N
, , N
immunogenicity NN N
, , N
and CC N
clinical JJ N
effects NNS N
. . N

RESULTS NNP N
There EX N
was VBD N
no DT N
difference NN N
in IN N
adverse JJ N
events NNS N
between IN N
MEDI-545 NNP N
and CC N
placebo NN N
. . N

Two CD N
serious JJ N
adverse JJ N
events NNS N
were VBD N
reported VBN N
; : N
one CD N
drug-related JJ N
hypotensive JJ N
infusion NN N
reaction NN N
occurred VBD N
in IN N
one CD N
subject NN N
in IN N
the DT N
30.0 CD N
mg/kg JJ N
MEDI-545 NNP N
dose NN N
group NN N
, , N
causing VBG N
discontinuation NN N
of IN N
study JJ N
drug NN N
in IN N
that DT N
subject NN N
and CC N
study NN N
dismissal NN N
of IN N
the DT N
other JJ N
subjects NNS N
in IN N
the DT N
same JJ N
cohort NN N
; : N
and CC N
a DT N
myocardial JJ N
infarction NN N
occurred VBD N
in IN N
one CD N
subject NN N
in IN N
the DT N
10 CD N
mg/kg JJ N
MEDI-545 NNP N
dose NN N
group NN N
, , N
which WDT N
was VBD N
considered VBN N
to TO N
be VB N
unrelated JJ N
to TO N
treatment NN N
. . N

MEDI-545 NNP N
was VBD N
nonimmunogenic JJ N
, , N
had VBD N
a DT N
half-life NN N
of IN N
21 CD N
days NNS N
, , N
showed VBD N
no DT N
significant JJ N
inhibition NN N
of IN N
the DT N
type NN N
I PRP N
IFN NNP N
gene NN N
signature NN N
, , N
and CC N
had VBD N
no DT N
clinical JJ N
activity NN N
. . N

LIMITATIONS VB N
The DT N
study NN N
addressed VBD N
only RB N
IFN-alpha NNP N
and CC N
chronic JJ N
psoriatic JJ N
lesions NNS N
. . N

CONCLUSION VB N
The DT N
safety NN N
profile NN N
of IN N
MEDI-545 NNP N
supports NNS N
further RBR N
clinical JJ N
development NN N
. . N

IFN-alpha NN N
does VBZ N
not RB N
appear VB N
to TO N
be VB N
significantly RB N
involved VBN N
in IN N
the DT N
maintenance NN N
of IN N
established VBN N
plaque NN N
psoriasis NN N
. . N

-DOCSTART- -X- O O 19330493

Fixed-dose JJ N
manidipine/delapril NN N
versus NN N
losartan/hydrochlorothiazide NN N
in IN N
hypertensive JJ 4_p
patients NNS N
with IN N
type JJ 4_p
2 CD 4_p
diabetes NNS 4_p
and CC N
microalbuminuria NNS 4_p
. . N

INTRODUCTION NNP N
Patients NNPS N
with IN N
diabetes NNS 4_p
complicated VBN N
by IN N
hypertension NN 4_p
and CC N
microalbuminuria NNS 4_p
have VBP N
elevated VBN N
cardiovascular JJ N
risk NN N
, , N
and CC N
controlling VBG N
blood NN N
pressure NN N
in IN N
these DT N
patients NNS N
is VBZ N
an DT N
urgent JJ N
clinical JJ N
priority NN N
. . N

The DT N
present JJ N
study NN N
aimed VBN N
to TO N
examine VB N
the DT N
effects NNS N
of IN N
a DT N
fixed-dose JJ N
combination NN N
of IN N
antihypertensives NNS N
on IN N
blood NN N
pressure NN N
and CC N
microalbuminuria NN N
. . N

METHODS NNP N
Patients NNPS N
with IN N
type JJ 4_p
2 CD 4_p
diabetes NNS 4_p
, , N
mild-to-moderate JJ N
hypertension NN 4_p
( ( N
diastolic JJ N
blood NN N
pressure NN N
85-105 JJ N
mmHg NN N
, , N
systolic JJ N
blood NN N
pressure NN N
< VBZ N
160 CD N
mmHg NN N
, , N
and CC N
24-hour JJ N
mean JJ N
systolic JJ N
blood NN N
pressure NN N
> VBZ N
130 CD N
mmHg NN N
) ) N
, , N
and CC N
microalbuminuria NNS 4_p
were VBD N
randomized VBN N
to TO N
1 CD N
year NN N
of IN N
doubleblind NN N
treatment NN N
with IN N
fixed-dose JJ N
manidipine/delapril NN N
( ( N
n=54 JJ N
) ) N
or CC N
losartan/hydrochlorothiazide JJ N
( ( N
HCTZ NNP N
) ) N
( ( N
n=56 JJ N
) ) N
. . N

RESULTS NNP N
Blood NNP N
pressure NN N
was VBD N
significantly RB N
reduced VBN N
at IN N
1 CD N
year NN N
in IN N
both DT N
groups NNS N
( ( N
-22.2/-14.6 JJ N
mmHg NN N
and CC N
-19.5/-14.3 NNP N
mmHg NN N
, , N
for IN N
systolic JJ N
and CC N
diastolic JJ N
blood NN N
pressure NN N
respectively RB N
, , N
P NNP N
< VBZ N
0.001 CD N
for IN N
each DT N
) ) N
, , N
with IN N
no DT N
significant JJ N
between-group JJ N
difference NN N
. . N

Reductions NNS N
in IN N
microalbuminuria NN N
occurred VBN N
in IN N
both DT N
groups NNS N
, , N
with IN N
mean JJ N
changes NNS N
at IN N
1 CD N
year NN N
of IN N
-3.9 NNP N
mg/mmol FW N
creatinine NN N
( ( N
95 CD N
% NN N
CI NNP N
-5.3 NNP N
, , N
-2.5 NNP N
) ) N
for IN N
manidipine/delapril NN N
( ( N
P NNP N
< VBZ N
0.001 CD N
vs. FW N
baseline NN N
) ) N
and CC N
-2.7 $ N
mg/mmol FW N
creatinine NN N
( ( N
95 CD N
% NN N
CI NNP N
-4.0 NNP N
, , N
-1.3 NNP N
) ) N
for IN N
losartan/HCTZ NN N
( ( N
P NNP N
< VBZ N
0.001 CD N
vs. NN N
baseline NN N
and CC N
P=0.199 NNP N
between IN N
groups NNS N
) ) N
. . N

Glycemia NNP N
over IN N
the DT N
1-year JJ N
study NN N
was VBD N
largely RB N
unaffected JJ N
; : N
the DT N
blood NN N
glucose JJ N
concentration NN N
was VBD N
reduced VBN N
from IN N
baseline NN N
with IN N
manidipine/delapril NN N
, , N
although IN N
not RB N
statistically RB N
significant JJ N
( ( N
mean JJ N
change NN N
-0.2 NNP N
mmol/L NN N
, , N
P=0.064 NNP N
) ) N
. . N

Both DT N
treatments NNS N
were VBD N
well RB N
tolerated VBN N
, , N
with IN N
discontinuation NN N
for IN N
adverse JJ N
events NNS N
for IN N
one CD N
( ( N
1.9 CD N
% NN N
) ) N
patient NN N
in IN N
the DT N
manidipine/delapril NN N
group NN N
and CC N
two CD N
( ( N
3.6 CD N
% NN N
) ) N
in IN N
the DT N
losartan/HCTZ NN N
group NN N
. . N

CONCLUSIONS VB N
A DT N
fixed-dose JJ N
manidipine/delapril NN N
combination NN N
represents VBZ N
a DT N
useful JJ N
addition NN N
to TO N
the DT N
treatment NN N
options NNS N
available JJ N
to TO N
control VB N
hypertension NN N
complicated VBN N
by IN N
diabetes NNS N
and CC N
microalbuminuria NNS N
. . N

-DOCSTART- -X- O O 11781402

A DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
MRI NNP N
study NN N
of IN N
anti-herpes NNS 4_p
virus JJ N
therapy NN N
in IN N
MS NNP 4_p
. . N

OBJECTIVE NNP N
To TO N
evaluate VB N
the DT N
effect NN N
of IN N
treatment NN N
with IN N
the DT N
antiherpes NNS N
drug NN N
valacyclovir NN N
on IN N
MRI-evident JJ N
lesions NNS N
in IN N
patients NNS N
with IN N
relapsing-remitting JJ N
MS NNP 4_p
in IN N
a DT N
phase NN N
2 CD N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
. . N

BACKGROUND NNP N
It PRP N
has VBZ N
been VBN N
postulated VBN N
from IN N
virologic JJ N
studies NNS N
that WDT N
herpesvirus VBP N
infection NN N
could MD N
play VB N
a DT N
role NN N
in IN N
the DT N
progression NN N
of IN N
MS. NNP N
METHODS NNP N
Patients NNPS N
were VBD N
eligible JJ N
for IN N
the DT N
study NN N
if IN N
they PRP N
had VBD N
had VBN N
two CD N
or CC N
more JJR N
MS JJ 4_p
relapses NNS N
in IN N
the DT N
2-year JJ N
period NN N
before IN N
enrollment NN N
. . N

Seventy JJ N
patients NNS N
with IN N
Expanded NNP N
Disability NNP N
Status NNP N
Scale NNP N
scores NNS N
of IN N
0 CD N
to TO N
5.5 CD N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
1 CD N
gram NN N
of IN N
valacyclovir NN N
( ( N
n JJ N
= NNP N
36 CD N
) ) N
or CC N
placebo NN N
( ( N
n JJ N
= NNP N
34 CD N
) ) N
three CD N
times NNS N
daily RB N
for IN N
24 CD N
weeks NNS N
. . N

Patients NNS N
underwent JJ N
MRI NNP N
every DT N
fourth JJ N
week NN N
for IN N
32 CD N
weeks NNS N
: : N
twice RB N
during IN N
pretreatment NN N
, , N
six CD N
times NNS N
during IN N
treatment NN N
, , N
and CC N
once RB N
after IN N
treatment NN N
. . N

Scoring VBG N
of IN N
neurologic JJ N
disability NN N
was VBD N
performed VBN N
at IN N
the DT N
start NN N
and CC N
end NN N
of IN N
the DT N
treatment NN N
period NN N
. . N

The DT N
primary JJ N
endpoint NN N
was VBD N
the DT N
number NN N
of IN N
new JJ N
active JJ N
MRI-evident JJ N
lesions NNS N
over IN N
24 CD N
weeks NNS N
of IN N
treatment NN N
. . N

Secondary JJ N
endpoints NNS N
included VBD N
other JJ N
MRI NNP N
measures NNS N
and CC N
clinical JJ N
endpoints NNS N
. . N

RESULTS VB N
The DT N
mean JJ N
number NN N
of IN N
new JJ N
active JJ N
lesions NNS N
+/- JJ N
SD NNP N
per IN N
patient NN N
during IN N
24 CD N
weeks NNS N
of IN N
treatment NN N
with IN N
valacyclovir NN N
was VBD N
11.9 CD N
+/- JJ N
17.6 CD N
and CC N
that IN N
during IN N
placebo NN N
treatment NN N
was VBD N
14.5 CD N
+/- JJ N
21.4 CD N
. . N

A DT N
protocol-planned JJ N
exploratory NN N
analysis NN N
stratified VBD N
patients NNS N
according VBG N
to TO N
baseline NN N
activity NN N
; : N
this DT N
analysis NN N
showed VBD N
that IN N
patients NNS N
with IN N
high JJ N
levels NNS N
of IN N
disease NN N
activity NN N
in IN N
the DT N
valacyclovir NN N
treatment NN N
group NN N
( ( N
n JJ N
= NNP N
17 CD N
) ) N
developed VBD N
fewer JJR N
new JJ N
active JJ N
lesions NNS N
per IN N
scan JJ N
than IN N
did VBD N
those DT N
in IN N
the DT N
placebo NN N
treatment NN N
group NN N
( ( N
n JJ N
= NNP N
11 CD N
) ) N
. . N

The DT N
median JJ N
number NN N
( ( N
Q NNP N
( ( N
1 CD N
) ) N
, , N
Q NNP N
( ( N
3 CD N
) ) N
range NN N
) ) N
of IN N
active JJ N
lesions NNS N
was VBD N
2.0 CD N
( ( N
1.38 CD N
, , N
3.96 CD N
) ) N
in IN N
the DT N
valacyclovir NN N
treatment NN N
group NN N
and CC N
6.5 CD N
( ( N
2.63 CD N
, , N
9.0 CD N
) ) N
in IN N
the DT N
placebo NN N
treatment NN N
group NN N
. . N

CONCLUSIONS NNP N
Valacyclovir NNP N
treatment NN N
did VBD N
not RB N
reduce VB N
the DT N
formation NN N
of IN N
active JJ N
lesions NNS N
in IN N
patients NNS N
with IN N
relapsing-remitting JJ N
MS NNP 4_p
who WP N
had VBD N
two CD N
or CC N
more JJR N
relapses NNS N
during IN N
the DT N
previous JJ N
2-year JJ N
period NN N
. . N

In IN N
a DT N
subgroup NN N
of IN N
patients NNS N
with IN N
high JJ N
levels NNS N
of IN N
disease NN N
activity NN N
who WP N
had VBD N
more JJR N
than IN N
one CD N
active JJ N
MRI-evident JJ N
lesion NN N
during IN N
4 CD N
weeks NNS N
, , N
valacyclovir FW N
treatment NN N
was VBD N
associated VBN N
with IN N
a DT N
reduced JJ N
number NN N
of IN N
new JJ N
active JJ N
MRI-evident JJ N
lesions NNS N
and CC N
with IN N
an DT N
increase NN N
in IN N
the DT N
number NN N
of IN N
scans NNS N
free JJ N
of IN N
new JJ N
active JJ N
lesions NNS N
. . N

The DT N
results NNS N
of IN N
the DT N
exploratory NN N
subgroup NN N
analysis NN N
provide VBP N
support NN N
for IN N
further JJ N
studies NNS N
of IN N
antiherpes NNS N
therapy NN N
for IN N
patients NNS N
with IN N
MS NNP 4_p
and CC N
high JJ N
levels NNS N
of IN N
MRI-evident JJ 4_p
disease NN 4_p
activity NN 4_p
. . N

-DOCSTART- -X- O O 25623276

The DT N
effects NNS N
of IN N
stimulation NN N
of IN N
the DT N
autonomic JJ N
nervous JJ N
system NN N
via IN N
perioperative JJ N
nutrition NN N
on IN N
postoperative JJ N
ileus NN N
and CC N
anastomotic JJ N
leakage NN N
following VBG N
colorectal JJ N
surgery NN N
( ( N
SANICS NNP N
II NNP N
trial NN N
) ) N
: : N
a DT N
study NN N
protocol NN N
for IN N
a DT N
double-blind JJ N
randomized NN N
controlled VBD N
trial NN N
. . N

BACKGROUND NNP N
Postoperative NNP N
ileus NN N
and CC N
anastomotic JJ N
leakage NN N
are VBP N
important JJ N
complications NNS N
following VBG N
colorectal JJ N
surgery NN N
associated VBN N
with IN N
short-term JJ N
morbidity NN N
and CC N
mortality NN N
. . N

Previous JJ N
experimental JJ N
and CC N
preclinical JJ N
studies NNS N
have VBP N
shown VBN N
that IN N
a DT N
short JJ N
intervention NN N
with IN N
enriched JJ N
enteral JJ N
nutrition NN N
dampens VBZ N
inflammation NN N
via IN N
stimulation NN N
of IN N
the DT N
autonomic JJ N
nervous JJ N
system NN N
and CC N
thereby RB N
reduces NNS N
postoperative JJ N
ileus NN N
. . N

Furthermore RB N
, , N
early JJ N
administration NN N
of IN N
enteral JJ N
nutrition NN N
reduced VBD N
anastomotic JJ N
leakage NN N
. . N

This DT N
study NN N
will MD N
investigate VB N
the DT N
effect NN N
of IN N
nutritional JJ N
stimulation NN N
of IN N
the DT N
autonomic JJ N
nervous JJ N
system NN N
just RB N
before RB N
, , N
during IN N
and CC N
early RB N
after IN N
colorectal JJ N
surgery NN N
on IN N
inflammation NN N
, , N
postoperative JJ N
ileus NN N
and CC N
anastomotic JJ N
leakage NN N
. . N

METHODS/DESIGN NNP N
This DT N
multicenter NN N
, , N
prospective JJ N
, , N
double-blind JJ N
, , N
randomized VBN N
controlled VBN N
trial NN N
will MD N
include VB N
280 CD N
patients NNS N
undergoing JJ N
colorectal JJ 4_p
surgery NN 4_p
. . N

All DT N
patients NNS N
will MD N
receive VB N
a DT N
selfmigrating JJ N
nasojejunal JJ N
tube NN N
that WDT N
will MD N
be VB N
connected VBN N
to TO N
a DT N
specially RB N
designed VBN N
blinded VBN N
tubing NN N
system NN N
. . N

Patients NNS N
will MD N
be VB N
allocated VBN N
either DT N
to TO N
the DT N
intervention NN N
group NN N
, , N
receiving VBG N
perioperative JJ N
nutrition NN N
, , N
or CC N
to TO N
the DT N
control NN N
group NN N
, , N
receiving VBG N
no DT N
nutrition NN N
. . N

The DT N
primary JJ N
endpoint NN N
is VBZ N
postoperative JJ N
ileus NN N
. . N

Secondary JJ N
endpoints NNS N
include VBP N
anastomotic JJ N
leakage NN N
, , N
local JJ N
and CC N
systemic JJ N
inflammation NN N
, , N
( ( N
aspiration NN N
) ) N
pneumonia NN N
, , N
surgical JJ N
complications NNS N
classified VBD N
according VBG N
to TO N
Clavien-Dindo NNP N
, , N
quality NN N
of IN N
life NN N
, , N
gut FW N
barrier JJR N
integrity NN N
and CC N
time NN N
until IN N
functional JJ N
recovery NN N
. . N

Furthermore NNP N
, , N
a DT N
cost-effectiveness JJ N
analysis NN N
will MD N
be VB N
performed VBN N
. . N

DISCUSSION NNP N
Activation NNP N
of IN N
the DT N
autonomic JJ N
nervous JJ N
system NN N
via IN N
perioperative JJ N
enteral JJ N
feeding NN N
is VBZ N
expected VBN N
to TO N
dampen VB N
the DT N
local JJ N
and CC N
systemic JJ N
inflammatory NN N
response NN N
. . N

Consequently RB N
, , N
postoperative JJ N
ileus NN N
will MD N
be VB N
reduced VBN N
as RB N
well RB N
as IN N
anastomotic JJ N
leakage NN N
. . N

The DT N
present JJ N
study NN N
is VBZ N
the DT N
first JJ N
to TO N
investigate VB N
the DT N
effects NNS N
of IN N
enriched JJ N
nutrition NN N
given VBN N
shortly RB N
before RB N
, , N
during IN N
and CC N
after IN N
surgery NN N
in IN N
a DT N
clinical JJ N
setting NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
ClinicalTrials.gov NNP N
: : N
NCT02175979 NNP N
- : N
date NN N
of IN N
registration NN N
: : N
25 CD N
June NNP N
2014 CD N
. . N

Dutch VB N
Trial JJ N
Registry NN N
: : N
NTR4670 NNP N
- : N
date NN N
of IN N
registration NN N
: : N
1 CD N
August NNP N
2014 CD N
. . N

-DOCSTART- -X- O O 24716680

Spironolactone NN N
for IN N
heart NN N
failure NN N
with IN N
preserved JJ N
ejection NN N
fraction NN N
. . N

BACKGROUND NNP N
Mineralocorticoid-receptor NNP N
antagonists NNS N
improve VBP N
the DT N
prognosis NN N
for IN N
patients NNS N
with IN N
heart NN 4_p
failure NN 4_p
and CC N
a DT N
reduced JJ N
left NN N
ventricular JJ N
ejection NN N
fraction NN N
. . N

We PRP N
evaluated VBD N
the DT N
effects NNS N
of IN N
spironolactone NN N
in IN N
patients NNS N
with IN N
heart NN 4_p
failure NN 4_p
and CC 4_p
a DT 4_p
preserved JJ 4_p
left NN 4_p
ventricular JJ 4_p
ejection NN 4_p
fraction NN 4_p
. . N

METHODS NNP N
In IN N
this DT N
randomized JJ N
, , N
double-blind JJ N
trial NN N
, , N
we PRP N
assigned VBD N
3445 CD N
patients NNS N
with IN N
symptomatic JJ 4_p
heart NN 4_p
failure NN 4_p
and CC 4_p
a DT 4_p
left JJ 4_p
ventricular JJ 4_p
ejection NN 4_p
fraction NN 4_p
of IN 4_p
45 CD 4_p
% NN 4_p
or CC 4_p
more JJR 4_p
to TO N
receive VB N
either DT N
spironolactone NN N
( ( N
15 CD N
to TO N
45 CD N
mg NNS N
daily RB N
) ) N
or CC N
placebo NN N
. . N

The DT N
primary JJ N
outcome NN N
was VBD N
a DT N
composite JJ N
of IN N
death NN N
from IN N
cardiovascular JJ N
causes NNS N
, , N
aborted VBD N
cardiac JJ N
arrest NN N
, , N
or CC N
hospitalization NN N
for IN N
the DT N
management NN N
of IN N
heart NN N
failure NN N
. . N

RESULTS NN N
With IN N
a DT N
mean JJ N
follow-up NN N
of IN N
3.3 CD N
years NNS N
, , N
the DT N
primary JJ N
outcome NN N
occurred VBD N
in IN N
320 CD N
of IN N
1722 CD N
patients NNS N
in IN N
the DT N
spironolactone NN N
group NN N
( ( N
18.6 CD N
% NN N
) ) N
and CC N
351 CD N
of IN N
1723 CD N
patients NNS N
in IN N
the DT N
placebo NN N
group NN N
( ( N
20.4 CD N
% NN N
) ) N
( ( N
hazard JJ N
ratio NN N
, , N
0.89 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
, , N
0.77 CD N
to TO N
1.04 CD N
; : N
P=0.14 NNP N
) ) N
. . N

Of IN N
the DT N
components NNS N
of IN N
the DT N
primary JJ N
outcome NN N
, , N
only RB N
hospitalization NN N
for IN N
heart NN N
failure NN N
had VBD N
a DT N
significantly RB N
lower JJR N
incidence NN N
in IN N
the DT N
spironolactone NN N
group NN N
than IN N
in IN N
the DT N
placebo NN N
group NN N
( ( N
206 CD N
patients NNS N
[ JJ N
12.0 CD N
% NN N
] NNP N
vs. IN N
245 CD N
patients NNS N
[ JJ N
14.2 CD N
% NN N
] NN N
; : N
hazard CC N
ratio NN N
, , N
0.83 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.69 CD N
to TO N
0.99 CD N
, , N
P=0.04 NNP N
) ) N
. . N

Neither CC N
total JJ N
deaths NNS N
nor CC N
hospitalizations NNS N
for IN N
any DT N
reason NN N
were VBD N
significantly RB N
reduced VBN N
by IN N
spironolactone NN N
. . N

Treatment NN N
with IN N
spironolactone NN N
was VBD N
associated VBN N
with IN N
increased JJ N
serum NN N
creatinine NN N
levels NNS N
and CC N
a DT N
doubling NN N
of IN N
the DT N
rate NN N
of IN N
hyperkalemia NN N
( ( N
18.7 CD N
% NN N
, , N
vs. FW N
9.1 CD N
% NN N
in IN N
the DT N
placebo NN N
group NN N
) ) N
but CC N
reduced JJ N
hypokalemia NN N
. . N

With IN N
frequent JJ N
monitoring NN N
, , N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
the DT N
incidence NN N
of IN N
serious JJ N
adverse JJ N
events NNS N
, , N
a DT N
serum JJ N
creatinine NN N
level NN N
of IN N
3.0 CD N
mg NNS N
per IN N
deciliter NN N
( ( N
265 CD N
μmol NN N
per IN N
liter NN N
) ) N
or CC N
higher JJR N
, , N
or CC N
dialysis NN N
. . N

CONCLUSIONS NNP N
In IN N
patients NNS N
with IN N
heart NN N
failure NN N
and CC N
a DT N
preserved JJ N
ejection NN N
fraction NN N
, , N
treatment NN N
with IN N
spironolactone NN N
did VBD N
not RB N
significantly RB N
reduce VB N
the DT N
incidence NN N
of IN N
the DT N
primary JJ N
composite JJ N
outcome NN N
of IN N
death NN N
from IN N
cardiovascular JJ N
causes NNS N
, , N
aborted VBD N
cardiac JJ N
arrest NN N
, , N
or CC N
hospitalization NN N
for IN N
the DT N
management NN N
of IN N
heart NN N
failure NN N
. . N

( ( N
Funded VBN N
by IN N
the DT N
National NNP N
Heart NNP N
, , N
Lung NNP N
, , N
and CC N
Blood NNP N
Institute NNP N
; : N
TOPCAT NNP N
ClinicalTrials.gov NNP N
number NN N
, , N
NCT00094302 NNP N
. . N

) ) N
. . N

-DOCSTART- -X- O O 24214189

QT/QTc NNP N
study NN N
conducted VBD N
in IN N
Japanese JJ 4_p
adult NN N
healthy JJ 4_p
subjects NNS 4_p
: : 4_p
a DT N
novel JJ N
xanthine NN N
oxidase NN N
inhibitor NN N
topiroxostat NN N
was VBD N
not RB N
associated VBN N
with IN N
QT NNP N
prolongation NN N
. . N

A DT N
QT/QTc NNP N
study NN N
was VBD N
conducted VBN N
in IN N
compliance NN N
with IN N
ICH NNP N
E14 NNP N
guideline NN N
to TO N
evaluate VB N
the DT N
effects NNS N
of IN N
a DT N
new JJ N
xanthine JJ N
oxidase NN N
inhibitor NN N
topiroxostat NN N
in IN N
Japanese JJ 4_p
healthy JJ 4_p
subjects NNS 4_p
. . N

Forty-eight JJ N
Japanese JJ N
healthy JJ N
subjects NNS N
( ( N
males NNS N
24 CD N
; : N
females NNS N
24 CD N
) ) N
received VBD N
a DT N
single JJ N
oral JJ N
dose NN N
of IN N
topiroxostat NN N
( ( N
60 CD N
or CC N
180 CD N
mg NN N
) ) N
, , N
moxifloxacin FW N
( ( N
400 CD N
mg NN N
) ) N
or CC N
placebo NN N
in IN N
a DT N
single-center JJ N
, , N
double-blind JJ N
, , N
four-period JJ N
crossover NN N
design NN N
. . N

Fridericia NNP N
's POS N
formula NN N
( ( N
QTcF NNP N
= NNP N
QT/RR NNP N
( ( N
0.33 CD N
) ) N
) ) N
was VBD N
used VBN N
as IN N
a DT N
primary JJ N
method NN N
for IN N
QT-interval JJ N
correction NN N
. . N

The DT N
mean JJ N
QTcF NNP N
was VBD N
prolonged VBN N
by IN N
moxifloxacin NN N
, , N
of IN N
which WDT N
largest JJS N
time-matched JJ N
difference NN N
from IN N
placebo JJ N
administration NN N
was VBD N
13.6 CD N
milliseconds NNS N
with IN N
90 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
of IN N
11.2 CD N
and CC N
15.9 CD N
milliseconds NNS N
at IN N
4 CD N
hours NNS N
post-dose JJ N
. . N

The DT N
mean JJ N
QTcF NNP N
was VBD N
hardly RB N
affected VBN N
by IN N
either DT N
dose NN N
of IN N
topiroxostat NN N
, , N
of IN N
which WDT N
largest JJS N
time-matched JJ N
difference NN N
from IN N
placebo JJ N
administration NN N
was VBD N
2.9 CD N
milliseconds NNS N
with IN N
90 CD N
% NN N
CI NNP N
of IN N
0.6 CD N
and CC N
5.3 CD N
milliseconds NNS N
at IN N
4 CD N
hours NNS N
post-dose JJ N
for IN N
60 CD N
mg NN N
, , N
and CC N
2.3 CD N
milliseconds NNS N
with IN N
90 CD N
% NN N
CI NNP N
of IN N
0 CD N
and CC N
4.7 CD N
milliseconds NNS N
at IN N
1 CD N
hour NN N
post-dose NN N
for IN N
180 CD N
mg NN N
. . N

The DT N
results NNS N
were VBD N
essentially RB N
the DT N
same JJ N
in IN N
the DT N
sex NN N
subgroup NN N
analysis NN N
. . N

Moxifloxacin NNP N
can MD N
be VB N
used VBN N
as IN N
a DT N
positive JJ N
control NN N
for IN N
QT/QTc NNP N
studies NNS N
in IN N
Japanese JJ N
subjects NNS N
; : N
and CC N
topiroxostat VB N
may MD N
not RB N
cause VB N
QT-interval JJ N
prolongation NN N
in IN N
males NNS N
as RB N
well RB N
as IN N
females NNS N
. . N

-DOCSTART- -X- O O 17152183

Cognitive-behavioural JJ N
stress NN N
management NN N
with IN N
HIV-positive JJ 4_p
homosexual JJ N
men NNS N
: : N
mechanisms NNS N
of IN N
sustained JJ N
reductions NNS N
in IN N
depressive JJ N
symptoms NNS N
. . N

BACKGROUND IN N
We PRP N
examined VBD N
the DT N
sustained JJ N
efficacy NN N
of IN N
a DT N
group-based JJ N
cognitive-behavioural JJ N
stress NN N
management NN N
( ( N
CBSM NNP N
) ) N
intervention NN N
in IN N
comparison NN N
to TO N
a DT N
modified VBN N
wait-list NN N
control NN N
condition NN N
on IN N
measures NNS N
of IN N
mood NN N
, , N
coping VBG N
and CC N
social JJ N
support NN N
in IN N
mildly RB N
symptomatic JJ N
HIV-positive JJ 4_p
homosexual JJ N
and CC N
bisexual JJ N
men NNS N
. . N

Participants NNS N
were VBD N
recruited VBN N
largely RB N
during IN N
the DT N
era NN N
prior RB N
to TO N
highly RB N
active JJ N
antiretroviral JJ N
therapy NN N
( ( N
HAART NNP N
; : N
1992-1997 JJ N
) ) N
. . N

METHODS NNP N
Men NNPS N
were VBD N
randomized VBN N
to TO N
either VB N
a DT N
10-week JJ N
, , N
group-based JJ N
CBSM NNP N
intervention NN N
( ( N
n JJ N
= NNP N
83 CD N
) ) N
or CC N
a DT N
psychoeducational JJ N
seminar NN N
group NN N
( ( N
n JJ N
= NNP N
46 CD N
) ) N
. . N

All DT N
participants NNS N
completed VBD N
a DT N
battery NN N
of IN N
psychosocial JJ N
questionnaires NNS N
administered VBN N
by IN N
a DT N
research NN N
assistant NN N
at IN N
baseline NN N
, , N
immediately RB N
following VBG N
the DT N
10-week JJ N
CBSM NNP N
intervention NN N
period NN N
, , N
and CC N
at IN N
a DT N
6-month JJ N
follow-up NN N
. . N

RESULTS NNP N
Men NNP N
in IN N
the DT N
CBSM NNP N
group NN N
maintained VBD N
previously RB N
observed VBN N
effects NNS N
on IN N
depressive NN N
symptoms NNS N
and CC N
perceived VBD N
social JJ N
support NN N
. . N

These DT N
sustained JJ N
effects NNS N
of IN N
CBSM NNP N
on IN N
depressive JJ N
symptoms NNS N
were VBD N
mediated VBN N
by IN N
10-week JJ N
increases NNS N
in IN N
cognitive JJ N
coping NN N
( ( N
i.e JJ N
. . N

positive JJ N
reframing NN N
) ) N
. . N

DISCUSSION NNP N
CBSM NNP N
appears VBZ N
to TO N
be VB N
a DT N
potentially RB N
efficacious JJ N
treatment NN N
that WDT N
reduces VBZ N
and CC N
maintains NNS N
lower JJR N
levels NNS N
of IN N
depressive NN N
symptoms NNS N
and CC N
enhances VBZ N
social JJ N
support NN N
in IN N
HIV-positive JJ N
homosexual JJ N
and CC N
bisexual JJ N
men NNS N
. . N

In IN N
particular JJ N
, , N
changes NNS N
in IN N
positive JJ N
reframing NN N
during IN N
the DT N
10-week JJ N
intervention NN N
period NN N
remain VBP N
a DT N
crucial JJ N
factor NN N
contributing VBG N
to TO N
sustained VBN N
reductions NNS N
in IN N
depressive JJ N
symptoms NNS N
. . N

-DOCSTART- -X- O O 24158898

Sequential JJ N
therapy NN N
versus IN N
standard JJ N
triple-drug JJ N
therapy NN N
for IN N
Helicobacter NNP N
pylori JJ N
eradication NN N
: : N
a DT N
randomized JJ N
study NN N
. . N

BACKGROUND NNP N
Antimicrobial NNP N
resistance NN N
has VBZ N
decreased VBN N
eradication NN N
rates NNS N
for IN N
Helicobacter NNP 4_p
pylori JJ 4_p
infection NN 4_p
worldwide NN N
. . N

A DT N
sequential JJ N
treatment NN N
schedule NN N
has VBZ N
been VBN N
reported VBN N
to TO N
be VB N
effective JJ N
, , N
but CC N
studies NNS N
published VBN N
to TO N
date NN N
were VBD N
performed VBN N
in IN N
Italy NNP N
. . N

We PRP N
undertook VBD N
this DT N
study NN N
to TO N
determine VB N
whether IN N
these DT N
results NNS N
could MD N
be VB N
replicated VBN N
in IN N
India NNP N
. . N

METHODS NNP N
A NNP N
randomized JJ N
, , N
open-labeled JJ N
, , N
prospective JJ N
controlled VBN N
trial NN N
comparing VBG N
sequential JJ N
vs. FW N
standard JJ N
triple-drug JJ N
therapy NN N
was VBD N
carried VBN N
out RP N
at IN N
Lokmanya NNP N
Tilak NNP N
Municipal NNP N
General NNP N
Hospital NNP N
, , N
Mumbai NNP N
. . N

Two CD N
hundred CD N
and CC N
thirty-one JJ N
patients NNS N
with IN N
dyspepsia NNS N
were VBD N
randomized VBN N
to TO N
a DT N
10-day JJ N
sequential JJ N
regimen NNS N
( ( N
40 CD N
mg NN N
of IN N
pantoprazole NN N
, , N
1 CD N
g NN N
of IN N
amoxicillin NN N
, , N
each DT N
administered VBN N
twice RB N
daily RB N
for IN N
the DT N
first JJ N
5 CD N
days NNS N
, , N
followed VBN N
by IN N
40 CD N
mg NNS N
of IN N
pantoprazole NN N
, , N
500 CD N
mg NN N
of IN N
clarithromycin NN N
, , N
and CC N
500 CD N
mg NN N
of IN N
tinidazole NN N
, , N
each DT N
administered VBN N
twice RB N
daily RB N
for IN N
the DT N
remaining VBG N
5 CD N
days NNS N
) ) N
or CC N
to TO N
standard VB N
14-day JJ N
therapy NN N
( ( N
40 CD N
mg NN N
of IN N
pantoprazole NN N
, , N
500 CD N
mg NN N
of IN N
clarithromycin NN N
, , N
and CC N
1 CD N
g NN N
of IN N
amoxicillin NN N
, , N
each DT N
administered VBN N
twice RB N
daily RB N
) ) N
. . N

RESULTS VB N
The DT N
eradication NN N
rate NN N
achieved VBN N
with IN N
the DT N
sequential JJ N
regimen NN N
was VBD N
significantly RB N
greater JJR N
than IN N
that DT N
obtained VBN N
with IN N
the DT N
triple JJ N
therapy NN N
. . N

Per-protocol JJ N
eradication NN N
rate NN N
of IN N
sequential JJ N
therapy NN N
was VBD N
92.4 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
85.8-96.1 CD N
% NN N
) ) N
vs. FW N
81.8 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
73.9-87.8 CD N
% NN N
) ) N
( ( N
p JJ N
= NNP N
0.027 CD N
) ) N
for IN N
standard JJ N
drug NN N
therapy NN N
. . N

Intention-to-treat JJ N
eradication NN N
rates NNS N
were VBD N
88.2 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
80.9-93.0 CD N
% NN N
) ) N
vs. FW N
79.1 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
71.1-85.4 CD N
% NN N
) ) N
, , N
p JJ N
= NN N
0.029 CD N
, , N
respectively RB N
. . N

The DT N
incidence NN N
of IN N
major JJ N
and CC N
minor JJ N
side NN N
effects NNS N
between IN N
therapy NN N
groups NNS N
was VBD N
not RB N
significantly RB N
different JJ N
( ( N
14.6 CD N
% NN N
in IN N
the DT N
triple JJ N
therapy NN N
group NN N
vs. FW N
23.5 CD N
% NN N
in IN N
sequential JJ N
group NN N
, , N
p VBP N
= RB N
0.12 CD N
) ) N
. . N

Follow NNP N
up RP N
was VBD N
incomplete JJ N
in IN N
3.3 CD N
% NN N
and CC N
4.7 CD N
% NN N
patients NNS N
in IN N
standard JJ N
and CC N
sequential JJ N
therapy NN N
groups NNS N
, , N
respectively RB N
. . N

Sequential JJ N
therapy NN N
includes VBZ N
one CD N
additional JJ N
antibiotic NN N
( ( N
tinidazole NN N
) ) N
that WDT N
is VBZ N
not RB N
contained VBN N
in IN N
standard JJ N
therapy NN N
. . N

CONCLUSIONS NNP N
Sequential NNP N
therapy NN N
was VBD N
significantly RB N
better JJR N
than IN N
standard JJ N
therapy NN N
for IN N
eradicating VBG N
H. NNP N
pylori JJ N
infection NN N
. . N

-DOCSTART- -X- O O 23017624

A DT N
home-based JJ N
exercise NN N
program NN N
to TO N
improve VB N
function NN N
, , N
fatigue NN N
, , N
and CC N
sleep JJ N
quality NN N
in IN N
patients NNS N
with IN N
Stage NNP N
IV NNP N
lung NN N
and CC N
colorectal JJ N
cancer NN N
: : N
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

CONTEXT NNP N
Exercise NNP N
benefits NNS N
patients NNS N
with IN N
cancer NN N
, , N
but CC N
studies NNS N
of IN N
home-based JJ N
approaches NNS N
, , N
particularly RB N
among IN N
those DT N
with IN N
Stage NNP N
IV NNP N
disease NN N
, , N
remain VBP N
small JJ N
and CC N
exploratory JJ N
. . N

OBJECTIVES NNP N
To TO N
conduct VB N
an DT N
adequately RB N
powered JJ N
trial NN N
of IN N
a DT N
home-based JJ N
exercise NN N
intervention NN N
that WDT N
can MD N
be VB N
facilely RB N
integrated VBN N
into IN N
established VBN N
delivery NN N
and CC N
reimbursement NN N
structures NNS N
. . N

METHODS NNP N
Sixty-six JJ 4_p
adults NNS 4_p
with IN 4_p
Stage NNP 4_p
IV NNP 4_p
lung NN 4_p
or CC 4_p
colorectal JJ 4_p
cancer NN 4_p
were VBD 4_p
randomized VBN 4_p
, , N
in IN N
an DT N
eight-week JJ N
trial NN N
, , N
to TO N
usual JJ N
care NN N
or CC N
incremental JJ N
walking NN N
and CC N
home-based JJ N
strength NN N
training NN N
. . N

The DT N
exercising VBG N
participants NNS N
were VBD N
instructed VBN N
during IN N
a DT N
single JJ N
physiotherapy NN N
visit NN N
and CC N
subsequently RB N
exercised VBN N
four CD N
days NNS N
or CC N
more JJR N
per IN N
week NN N
; : N
training NN N
and CC N
step-count NN N
goals NNS N
were VBD N
advanced VBN N
during IN N
bimonthly RB N
telephone NN N
calls VBZ N
. . N

The DT N
primary JJ N
outcome NN N
measure NN N
was VBD N
mobility NN N
assessed VBN N
with IN N
the DT N
Ambulatory NNP N
Post NNP N
Acute NNP N
Care NNP N
Basic NNP N
Mobility NNP N
Short NNP N
Form NNP N
. . N

Secondary JJ N
outcomes NNS N
included VBD N
ratings NNS N
of IN N
pain NN N
and CC N
sleep JJ N
quality NN N
as RB N
well RB N
as IN N
the DT N
ability NN N
to TO N
perform VB N
daily JJ N
activities NNS N
( ( N
Ambulatory NNP N
Post NNP N
Acute NNP N
Care NNP N
Daily NNP N
Activities NNP N
Short NNP N
Form NNP N
) ) N
, , N
quality NN N
of IN N
life NN N
( ( N
Functional NNP N
Assessment NNP N
of IN N
Cancer NNP N
Therapy-General NNP N
) ) N
, , N
and CC N
fatigue NN N
( ( N
Functional NNP N
Assessment NNP N
of IN N
Cancer NNP N
Therapy-Fatigue NNP N
) ) N
. . N

RESULTS NNP N
Three CD N
participants NNS N
dropped VBD N
out RP N
and CC N
seven CD N
died VBD N
( ( N
five CD N
in IN N
the DT N
intervention NN N
and CC N
two CD N
in IN N
the DT N
control NN N
group NN N
, , N
P=0.28 NNP N
) ) N
. . N

At IN N
Week JJ N
8 CD N
, , N
the DT N
intervention NN N
group NN N
reported VBD N
improved JJ N
mobility NN N
( ( N
P=0.01 NNP N
) ) N
, , N
fatigue NN N
( ( N
P=0.02 NNP N
) ) N
, , N
and CC N
sleep JJ N
quality NN N
( ( N
P=0.05 NNP N
) ) N
compared VBN N
with IN N
the DT N
usual JJ N
care NN N
group NN N
, , N
but CC N
did VBD N
not RB N
differ VB N
on IN N
the DT N
other JJ N
measures NNS N
. . N

CONCLUSION VB N
A DT N
home-based JJ N
exercise NN N
program NN N
seems VBZ N
capable JJ N
of IN N
improving VBG N
the DT N
mobility NN N
, , N
fatigue NN N
, , N
and CC N
sleep JJ N
quality NN N
of IN N
patients NNS N
with IN N
Stage NNP N
IV NNP N
lung NN N
and CC N
colorectal JJ N
cancer NN N
. . N

-DOCSTART- -X- O O 16595217

Conventional JJ N
in IN N
vitro JJ N
fertilization NN N
versus IN N
intracytoplasmic JJ N
sperm JJ N
injection NN N
in IN 4_p
patients NNS 4_p
with IN 4_p
borderline JJ 4_p
semen NNS 4_p
: : 4_p
a DT N
randomized JJ N
study NN N
using VBG N
sibling VBG N
oocytes NNS N
. . N

OBJECTIVE NN N
To TO N
determine VB N
whether IN N
patients NNS 4_p
with IN 4_p
borderline JJ 4_p
semen NNS 4_p
should MD N
be VB N
treated VBN N
with IN N
conventional JJ N
IVF NNP N
or CC N
intracytoplasmic JJ N
sperm JJ N
injection NN N
( ( N
ICSI NNP N
) ) N
. . N

DESIGN NNP N
Randomized NNP N
study NN N
. . N

SETTING VB N
A DT N
university NN N
medical JJ N
center NN N
in IN N
The DT N
Netherlands NNP N
. . N

PATIENT NNP N
( ( N
S NNP N
) ) N
One CD N
hundred VBN N
six CD N
couples NNS N
with IN N
borderline JJ 4_p
semen NNS 4_p
who WP N
were VBD N
undergoing VBG N
IVF NNP N
and CC N
ICSI NNP N
on IN N
sibling VBG N
oocytes NNS N
. . N

INTERVENTION NNP N
( ( N
S NNP N
) ) N
Performing VBG N
IVF NNP N
and CC N
ICSI NNP N
on IN N
sibling VBG N
oocytes NNS N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURE NNP N
( ( N
S NNP N
) ) N
Fertilization NNP N
and CC N
pregnancy NN N
rates NNS N
. . N

RESULT NNP N
( ( N
S NNP N
) ) N
One CD N
thousand CD N
five CD N
hundred VBN N
eighteen NN N
oocytes NNS N
were VBD N
collected VBN N
in IN N
106 CD N
oocyte JJ N
retrievals NNS N
: : N
849 CD N
oocytes NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
ICSI NNP N
, , N
of IN N
which WDT N
761 CD N
were VBD N
microinjected VBN N
, , N
and CC N
669 CD N
oocytes NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
IVF NNP N
. . N

In IN N
26 CD N
of IN N
the DT N
106 CD N
patients NNS N
, , N
there EX N
was VBD N
fertilization NN N
only RB N
after IN N
ICSI NNP N
and CC N
not RB N
after IN N
IVF NNP N
( ( N
IVF- NNP N
group NN N
) ) N
. . N

The DT N
fertilization NN N
rate NN N
was VBD N
51 CD N
% NN N
( ( N
92/182 CD N
oocytes NNS N
) ) N
. . N

In IN N
78 CD N
patients NNS N
, , N
there EX N
was VBD N
fertilization NN N
after IN N
both DT N
IVF NNP N
and CC N
ICSI NNP N
( ( N
IVF+ NNP N
group NN N
) ) N
; : N
the DT N
fertilization NN N
rate NN N
was VBD N
51 CD N
% NN N
for IN N
both DT N
the DT N
IVF- NNP N
and CC N
ICSI-treated NNP N
oocytes NNS N
( ( N
271/528 CD N
oocytes NNS N
and CC N
334/658 CD N
oocytes NNS N
, , N
respectively RB N
) ) N
. . N

In IN N
2 CD N
patients NNS N
, , N
there EX N
was VBD N
no DT N
fertilization NN N
after IN N
either DT N
IVF NNP N
( ( N
0/6 CD N
oocytes NNS N
) ) N
or CC N
ICSI NNP N
( ( N
0/9 CD N
oocytes NNS N
) ) N
. . N

Patients NNS N
of IN N
the DT N
IVF+ NNP N
group NN N
had VBD N
a DT N
higher JJR N
total JJ N
motile JJ N
sperm NN N
count NN N
after IN N
preparation NN N
than IN N
did VBD N
those DT N
of IN N
the DT N
IVF- NNP N
group NN N
. . N

More JJR N
high-quality JJ N
embryos NN N
were VBD N
obtained VBN N
after IN N
ICSI NNP N
in IN N
patients NNS N
of IN N
the DT N
IVF+ NNP N
group NN N
. . N

In IN N
101 CD N
patients NNS N
, , N
embryo FW N
transfer NN N
was VBD N
performed VBN N
: : N
26 CD N
in IN N
the DT N
IVF- NNP N
group NN N
and CC N
75 CD N
in IN N
the DT N
IVF+ NNP N
group NN N
. . N

No DT N
significant JJ N
differences NNS N
were VBD N
found VBN N
with IN N
regard NN N
to TO N
pregnancy VB N
rates NNS N
between IN N
those DT N
two CD N
groups NNS N
: : N
pregnancy NN N
rates NNS N
were VBD N
54 CD N
% NN N
in IN N
the DT N
IVF- NNP N
group NN N
and CC N
48 CD N
% NN N
in IN N
the DT N
IVF+ NNP N
group NN N
. . N

CONCLUSION NNP N
( ( N
S NNP N
) ) N
Performing VBG N
ICSI NNP N
on IN N
at IN N
least JJS N
some DT N
of IN N
the DT N
oocytes NNS N
will MD N
avoid VB N
unnecessary JJ N
fertilization NN N
failure NN N
in IN N
patients NNS 4_p
with IN 4_p
borderline JJ 4_p
semen NNS 4_p
: : N
in IN N
this DT N
study NN N
, , N
26 CD N
of IN N
104 CD N
cycles NNS N
( ( N
25 CD N
% NN N
) ) N
were VBD N
rescued VBN N
by IN N
ICSI NNP N
. . N

-DOCSTART- -X- O O 8589555

Synthetic JJ N
serum NN N
substitute NN N
( ( N
SSS NNP N
) ) N
: : N
a DT N
globulin-enriched JJ N
protein NN N
supplement NN N
for IN N
human JJ N
embryo JJ N
culture NN N
. . N

OBJECTIVE CC N
The DT N
purpose NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
evaluate VB N
whether IN N
an DT N
IVF NNP N
protein NN N
supplement NN N
prepared VBN N
from IN N
human JJ N
serum NN N
albumin NN N
( ( N
HSA NNP N
) ) N
and CC N
human JJ N
globulins NNS N
would MD N
retain VB N
performance NN N
characteristics NNS N
equivalent JJ N
to TO N
those DT N
reported VBN N
for IN N
the DT N
commercial JJ N
plasma NN N
expanders NNS N
, , N
Plasmatein NNP N
( ( N
Alpha NNP N
Therapeutics NNP N
, , N
Los NNP N
Angeles NNP N
, , N
California NNP N
) ) N
and CC N
Plasmanate NNP N
( ( N
Cutter NNP N
Biological NNP N
, , N
Miles NNP N
Inc. NNP N
, , N
Elkhart NNP N
, , N
Indiana NNP N
) ) N
. . N

METHODS NNP N
Pronuclear-stage JJ N
human JJ N
embryos NN N
were VBD N
randomly RB N
divided VBN N
and CC N
cultured VBN N
in IN N
human JJ N
tubal JJ N
fluid NN N
medium NN N
( ( N
HTF NNP N
) ) N
supplemented VBD N
with IN N
either DT N
HSA NNP N
( ( N
5 CD N
mg/mL NN N
) ) N
or CC N
Plasmatein NNP N
( ( N
10 CD N
% NN N
, , N
v/v NN N
; : N
5 CD N
mg/ml NN N
) ) N
as IN N
a DT N
means NN N
of IN N
indirectly RB N
assessing VBG N
the DT N
effect NN N
alpha- JJ N
and CC N
beta-globulins NNS N
have VBP N
on IN N
embryonic JJ N
development NN N
. . N

Those DT N
results NNS N
coupled VBD N
with IN N
the DT N
known VBN N
composition NN N
characteristics NNS N
of IN N
Plasmatein NNP N
were VBD N
used VBN N
as IN N
the DT N
starting VBG N
basis NN N
to TO N
formulate VB N
test JJ N
lots NNS N
of IN N
synthetic JJ N
serum NN N
substitute NN N
( ( N
SSS NNP N
) ) N
. . N

RESULTS NNP N
Significantly NNP N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
more JJR N
of IN N
the DT N
human JJ N
embryos NN N
cultured VBN N
in IN N
Plasmatein NNP N
supplemented VBD N
medium NN N
reached VBD N
the DT N
four-cell NN N
or CC N
greater JJR N
stage NN N
by IN N
40 CD N
hr NNS N
postinsemination NN N
than IN N
a DT N
comparable JJ N
group NN N
cultured VBD N
in IN N
HSA NNP N
alone RB N
. . N

Lot NNP N
1 CD N
of IN N
SSS NNP N
, , N
formulated VBD N
with IN N
HSA NNP N
( ( N
84 CD N
% NN N
of IN N
total JJ N
protein NN N
) ) N
and CC N
human JJ N
globulins NNS N
( ( N
16 CD N
% NN N
of IN N
total JJ N
protein NN N
) ) N
and CC N
an DT N
aqueous JJ N
lipoprotein NN N
fraction NN N
derived VBN N
from IN N
human JJ N
plasma NN N
( ( N
Excyte NNP N
IV NNP N
; : N
Miles NNP N
Diagnostics NNPS N
, , N
Kankakee NNP N
, , N
Illinois NNP N
) ) N
, , N
produced VBD N
accelerated VBN N
early JJ N
embryonic JJ N
growth NN N
relative JJ N
to TO N
control VB N
murine JJ N
embryos NNS N
grown VBN N
in IN N
the DT N
presence NN N
of IN N
Plasmatein NNP N
, , N
however RB N
, , N
the DT N
percentage NN N
of IN N
the DT N
embryos NN N
reaching VBG N
the DT N
hatched JJ N
blastocyst NN N
stage NN N
was VBD N
decreased VBN N
( ( N
45 CD N
vs RB N
100 CD N
% NN N
) ) N
. . N

Human JJ N
embryos NN N
from IN N
seven CD N
patients NNS N
, , N
randomized VBN N
to TO N
HTF NNP N
medium NN N
supplemented VBD N
with IN N
Plasmatein NNP N
or CC N
lot NN N
1 CD N
of IN N
SSS NNP N
, , N
showed VBD N
equivalent JJ N
growth NN N
at IN N
36-40 JJ N
hr NN N
postinsemination NN N
. . N

A DT N
microprecipitate NN N
developed VBN N
in IN N
media NNS N
supplemented VBN N
with IN N
lot NN N
1 CD N
after IN N
several JJ N
days NNS N
of IN N
culture NN N
. . N

The DT N
Excyte NNP N
IV NNP N
concentration NN N
was VBD N
reduced VBN N
and CC N
, , N
ultimately RB N
, , N
eliminated VBN N
from IN N
the DT N
subsequent JJ N
and CC N
final JJ N
prototype NN N
lots NNS N
of IN N
SSS NNP N
. . N

Murine NNP N
embryos JJ N
grown VBN N
in IN N
the DT N
presence NN N
of IN N
lipoprotein JJ N
free JJ N
SSS NNP N
showed VBD N
significantly RB N
accelerated VBN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
growth NN N
at IN N
17 CD N
hr NN N
postthaw NN N
compared VBN N
to TO N
Plasmatein NNP N
and CC N
all DT N
embryos NNS N
progressed VBN N
to TO N
hatching VBG N
by IN N
41 CD N
hr NN N
. . N

Human NNP N
embryos NN N
, , N
randomized VBN N
to TO N
either DT N
Plasmatein NNP N
or CC N
lot NN N
3 CD N
of IN N
SSS NNP N
, , N
showed VBD N
significantly RB N
accelerated VBN N
growth NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
when WRB N
scored VBN N
at IN N
38 CD N
hr NN N
following VBG N
insemination NN N
. . N

CONCLUSION NNP N
Synthetic NNP N
serum NN N
substitute NN N
provides VBZ N
a DT N
convient NN N
, , N
standardized JJ N
means NNS N
of IN N
adding VBG N
protein NN N
to TO N
media NNS N
used VBN N
in IN N
assisted JJ N
reproductive JJ N
technology NN N
( ( N
ART NNP N
) ) N
procedures NNS N
. . N

-DOCSTART- -X- O O 8792262

The DT N
influence NN N
of IN N
nonhandicapped JJ N
peers NNS N
on IN N
the DT N
social JJ N
interactions NNS N
of IN N
children NNS N
with IN N
a DT N
pervasive JJ 4_p
development NN 4_p
disorder NN 4_p
. . N

This DT N
study NN N
investigated VBD N
whether IN N
or CC N
not RB N
children NNS N
with IN N
autism NN 4_p
or CC N
a DT N
related JJ 4_p
pervasive JJ 4_p
developmental NN 4_p
disorder NN 4_p
( ( 4_p
PDD NNP 4_p
) ) 4_p
can MD N
benefit VB N
from IN N
regular JJ N
opportunities NNS N
to TO N
interact VB N
with IN N
a DT N
normally RB N
developing VBG N
peer NN N
, , N
matched VBD N
as IN N
to TO N
sex NN N
and CC N
age NN N
. . N

An DT N
experimental JJ N
design NN N
with IN N
random JJ N
assignment NN N
of IN N
subjects NNS N
to TO N
treatment NN N
and CC N
control NN N
groups NNS N
was VBD N
used VBN N
to TO N
demonstrate VB N
the DT N
impact NN N
of IN N
this DT N
peer-mediated JJ N
intervention NN N
. . N

In IN N
the DT N
treatment NN N
group NN N
, , N
we PRP N
found VBD N
significant JJ N
improvements NNS N
in IN N
the DT N
social JJ N
behavior NN N
of IN N
the DT N
children NNS N
with IN N
PDD NNP N
. . N

Several JJ N
gains NNS N
were VBD N
also RB N
generalized VBN N
to TO N
interactions NNS N
with IN N
an DT N
unfamiliar JJ N
nonhandicapped JJ N
peer NN N
, , N
to TO N
interactions NNS N
with IN N
another DT N
child NN N
with IN N
PDD NNP N
, , N
and CC N
to TO N
the DT N
large JJ N
school NN N
setting VBG N
. . N

In IN N
the DT N
untreated JJ N
control NN N
group NN N
, , N
no DT N
positive JJ N
changes NNS N
were VBD N
observed VBN N
. . N

Results VB N
suggest JJS N
that IN N
children NNS N
with IN N
PDD NNP 4_p
can MD N
develop VB N
peer JJ N
relations NNS N
if IN N
appropriate JJ N
social JJ N
contexts NN N
are VBP N
made VBN N
available JJ N
for IN N
them PRP N
. . N

-DOCSTART- -X- O O 20406576

The DT N
ScanBrit NNP N
randomised VBD N
, , N
controlled VBD N
, , N
single-blind JJ N
study NN N
of IN N
a DT N
gluten- JJ N
and CC N
casein-free JJ N
dietary JJ N
intervention NN N
for IN N
children NNS N
with IN N
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
. . N

There EX N
is VBZ N
increasing VBG N
interest NN N
in IN N
the DT N
use NN N
of IN N
gluten- JJ N
and CC N
casein-free JJ N
diets NNS N
for IN N
children NNS N
with IN N
autism NN N
spectrum NN N
disorders NNS N
( ( N
ASDs NNP N
) ) N
. . N

We PRP N
report VBP N
results NNS N
from IN N
a DT N
two-stage NN N
, , N
24-month JJ N
, , N
randomised VBN N
, , N
controlled VBN N
trial NN N
incorporating VBG N
an DT N
adaptive JJ N
'catch-up NN N
' POS N
design NN N
and CC N
interim JJ N
analysis NN N
. . N

Stage NN N
1 CD N
of IN N
the DT N
trial NN N
saw VBD N
72 CD N
Danish JJ N
children NNS N
( ( N
aged VBN N
4 CD N
years NNS N
to TO N
10 CD N
years NNS N
11 CD N
months NNS N
) ) N
assigned VBD N
to TO N
diet VB N
( ( N
A DT N
) ) N
or CC N
non-diet JJ N
( ( N
B NNP N
) ) N
groups NNS N
by IN N
stratified JJ N
randomisation NN N
. . N

Autism NNP N
Diagnostic NNP N
Observation NNP N
Schedule NNP N
( ( N
ADOS NNP N
) ) N
and CC N
the DT N
Gilliam NNP N
Autism NNP N
Rating NNP N
Scale NNP N
( ( N
GARS NNP N
) ) N
were VBD N
used VBN N
to TO N
assess VB N
core NN N
autism NN N
behaviours NNS N
, , N
Vineland NNP N
Adaptive NNP N
Behaviour NNP N
Scales NNP N
( ( N
VABS NNP N
) ) N
to TO N
ascertain VB N
developmental JJ N
level NN N
, , N
and CC N
Attention-Deficit NNP N
Hyperactivity NNP N
Disorder NNP N
- : N
IV NNP N
scale NN N
( ( N
ADHD-IV NNP N
) ) N
to TO N
determine VB N
inattention NN N
and CC N
hyperactivity NN N
. . N

Participants NNS N
were VBD N
tested VBN N
at IN N
baseline NN N
, , N
8 CD N
, , N
and CC N
12 CD N
months NNS N
. . N

Based VBN N
on IN N
per IN N
protocol NN N
repeated VBN N
measures NNS N
analysis NN N
, , N
data NNS N
for IN N
26 CD N
diet JJ N
children NNS N
and CC N
29 CD N
controls NNS N
were VBD N
available JJ N
at IN N
12 CD N
months NNS N
. . N

At IN N
this DT N
point NN N
, , N
there EX N
was VBD N
a DT N
significant JJ N
improvement NN N
to TO N
mean VB N
diet JJ N
group NN N
scores NNS N
( ( N
time*treatment JJ N
interaction NN N
) ) N
on IN N
sub-domains NNS N
of IN N
ADOS NNP N
, , N
GARS NNP N
and CC N
ADHD-IV NNP N
measures NNS N
. . N

Surpassing VBG N
of IN N
predefined JJ N
statistical JJ N
thresholds NNS N
as IN N
evidence NN N
of IN N
improvement NN N
in IN N
group NN N
A NNP N
at IN N
12 CD N
months NNS N
sanctioned VBD N
the DT N
re-assignment NN N
of IN N
group NN N
B NNP N
participants NNS N
to TO N
active JJ N
dietary JJ N
treatment NN N
. . N

Stage NN N
2 CD N
data NNS N
for IN N
18 CD N
group NN N
A NNP N
and CC N
17 CD N
group NN N
B NNP N
participants NNS N
were VBD N
available JJ N
at IN N
24 CD N
months NNS N
. . N

Multiple NNP N
scenario NN N
analysis NN N
based VBN N
on IN N
inter- JJ N
and CC N
intra-group JJ N
comparisons NNS N
showed VBD N
some DT N
evidence NN N
of IN N
sustained JJ N
clinical JJ N
group NN N
improvements NNS N
although IN N
possibly RB N
indicative JJ N
of IN N
a DT N
plateau NN N
effect NN N
for IN N
intervention NN N
. . N

Our PRP$ N
results NNS N
suggest VBP N
that IN N
dietary JJ N
intervention NN N
may MD N
positively RB N
affect VB N
developmental JJ N
outcome NN N
for IN N
some DT N
children NNS N
diagnosed VBN N
with IN N
ASD NNP N
. . N

In IN N
the DT N
absence NN N
of IN N
a DT N
placebo NN N
condition NN N
to TO N
the DT N
current JJ N
investigation NN N
, , N
we PRP N
are VBP N
, , N
however RB N
, , N
unable JJ N
to TO N
disqualify VB N
potential JJ N
effects NNS N
derived VBN N
from IN N
intervention NN N
outside IN N
of IN N
dietary JJ N
changes NNS N
. . N

Further JJ N
studies NNS N
are VBP N
required VBN N
to TO N
ascertain VB N
potential JJ N
best- NN N
and CC N
non-responders NNS N
to TO N
intervention NN N
. . N

The DT N
study NN N
was VBD N
registered VBN N
with IN N
ClincialTrials.gov NNP N
, , N
number NN N
NCT00614198 NNP N
. . N

-DOCSTART- -X- O O 26209587

Fixed-dose JJ N
combination NN N
of IN N
AR-13324 NNP N
and CC N
latanoprost NN N
: : N
a DT N
double-masked JJ N
, , N
28-day JJ N
, , N
randomised VBN N
, , N
controlled VBN N
study NN N
in IN N
patients NNS 4_p
with IN 4_p
open-angle JJ 4_p
glaucoma NN 4_p
or CC 4_p
ocular JJ 4_p
hypertension NN 4_p
. . 4_p

BACKGROUND/AIMS NNP N
To TO N
evaluate VB N
the DT N
ocular JJ N
hypotensive JJ N
efficacy NN N
of IN N
fixed-dose JJ N
combinations NNS N
of IN N
the DT N
Rho NNP N
kinase NN N
inhibitor NN N
and CC N
norepinephrine JJ N
transport NN N
inhibitor NN N
AR-13324 NNP N
( ( N
0.01 CD N
% NN N
and CC N
0.02 CD N
% NN N
) ) N
and CC N
latanoprost $ N
( ( N
PG324 NNP N
Ophthalmic NNP N
Solution NNP N
) ) N
relative VBP N
to TO N
the DT N
active JJ N
components NNS N
AR-13324 JJ N
0.02 CD N
% NN N
and CC N
latanoprost $ N
0.005 CD N
% NN N
, , N
used VBN N
bilaterally RB N
at IN N
night NN N
. . N

METHODS NNP N
This DT N
was VBD N
a DT N
double-masked JJ N
, , N
randomised VBN N
, , N
parallel JJ N
comparison NN N
study NN N
in IN N
patients NNS 4_p
with IN 4_p
open-angle JJ 4_p
glaucoma NN 4_p
or CC 4_p
ocular JJ 4_p
hypertension NN 4_p
. . 4_p

After IN N
washout NN N
, , N
patients NNS N
were VBD N
randomised VBN N
to TO N
one CD N
of IN N
four CD N
treatment NN N
arms NNS N
and CC N
treated VBD N
for IN N
28 CD N
days NNS N
. . N

The DT N
primary JJ N
efficacy NN N
variable NN N
was VBD N
mean JJ N
diurnal JJ N
intraocular JJ N
pressure NN N
( ( N
IOP NNP N
) ) N
at IN N
day NN N
29 CD N
. . N

RESULTS NN N
We PRP N
randomised VBD N
298 CD N
patients NNS N
, , N
of IN N
whom WP N
292 CD N
( ( N
98 CD N
% NN N
) ) N
completed VBD N
the DT N
study NN N
. . N

Mean NNP N
unmedicated VBD N
diurnal JJ N
IOPs NNP N
( ( N
study VB N
eye NN N
) ) N
was VBD N
25.1 CD N
, , N
25.1 CD N
, , N
26.0 CD N
and CC N
25.4 CD N
in IN N
the DT N
PG324 NNP N
0.01 CD N
% NN N
, , N
PG324 NNP N
0.02 CD N
% NN N
, , N
latanoprost NN N
and CC N
AR-13324 JJ N
0.02 CD N
% NN N
groups NNS N
, , N
respectively RB N
. . N

On IN N
day NN N
29 CD N
, , N
mean JJ N
diurnal JJ N
IOP NNP N
decreased VBD N
to TO N
17.3 CD N
, , N
16.5 CD N
, , N
18.4 CD N
and CC N
19.1 CD N
mm NN N
Hg NNP N
, , N
respectively RB N
. . N

For IN N
the DT N
primary JJ N
efficacy NN N
variable NN N
of IN N
mean JJ N
diurnal JJ N
IOP NNP N
at IN N
day NN N
29 CD N
, , N
PG324 NNP N
0.02 CD N
% NN N
met VBD N
the DT N
criterion NN N
for IN N
statistical JJ N
superiority NN N
relative NN N
to TO N
both DT N
latanoprost FW N
and CC N
AR-13324 NNP N
0.02 CD N
% NN N
( ( N
p JJ N
< NNP N
0.0001 CD N
) ) N
, , N
providing VBG N
additional JJ N
IOP NNP N
lowering NN N
of IN N
1.9 CD N
and CC N
2.6 CD N
mm NN N
Hg NNP N
, , N
respectively RB N
. . N

PG324 VB N
0.01 CD N
% NN N
also RB N
met VBD N
the DT N
criterion NN N
for IN N
superiority NN N
. . N

The DT N
most RBS N
frequently RB N
reported VBD N
adverse JJ N
event NN N
was VBD N
conjunctival JJ N
hyperaemia NN N
with IN N
an DT N
incidence NN N
of IN N
41 CD N
% NN N
( ( N
30/73 CD N
) ) N
, , N
40 CD N
% NN N
( ( N
29/73 CD N
) ) N
, , N
14 CD N
% NN N
( ( N
10/73 CD N
) ) N
and CC N
40 CD N
% NN N
( ( N
31/78 CD N
) ) N
in IN N
the DT N
PG324 NNP N
0.01 CD N
% NN N
, , N
PG324 NNP N
0.02 CD N
% NN N
, , N
latanoprost NN N
and CC N
AR-13324 JJ N
0.02 CD N
% NN N
groups NNS N
, , N
respectively RB N
. . N

CONCLUSIONS NNP N
In IN N
this DT N
short-term JJ N
study NN N
, , N
the DT N
fixed-dose JJ N
combination NN N
of IN N
AR-13324 NNP N
0.02 CD N
% NN N
and CC N
latanoprost $ N
0.005 CD N
% NN N
in IN N
PG324 NNP N
Ophthalmic NNP N
Solution NNP N
provides VBZ N
clinically RB N
and CC N
statistically RB N
superior JJ N
ocular JJ N
hypotensive JJ N
efficacy NN N
relative JJ N
to TO N
its PRP$ N
individual JJ N
active JJ N
components NNS N
at IN N
the DT N
same JJ N
concentrations NNS N
. . N

The DT N
only JJ N
safety NN N
finding NN N
of IN N
note NN N
was VBD N
transient JJ N
asymptomatic JJ N
conjunctival NN N
hyperaemia NN N
which WDT N
was VBD N
typically RB N
of IN N
mild JJ N
severity NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
NUMBER NNP N
NCT02207491 NNP N
. . N

-DOCSTART- -X- O O 8467027

[ JJ N
Prevention NNP N
of IN N
pneumonia NN 4_p
by IN N
endotracheal JJ N
micronebulization NN N
of IN N
tobramycin NN N
] NN N
. . N

In IN N
69 CD 4_p
artificially RB 4_p
ventilated JJ 4_p
patients NNS N
the DT N
clinical JJ N
, , N
bacteriological JJ N
and CC N
pharmacological JJ N
effects NNS N
of IN N
endotracheally RB N
administered VBN N
tobramycin NN N
were VBD N
studied VBN N
in IN N
comparison NN N
to TO N
a DT N
control NN N
group NN N
. . N

In IN N
the DT N
therapy NN N
group NN N
, , N
52 CD N
% NN N
of IN N
all DT N
specimens NNS N
were VBD N
sterile JJ N
, , N
in IN N
the DT N
control NN N
group NN N
only RB N
25 CD N
% NN N
. . N

During IN N
the DT N
first JJ N
4 CD N
days NNS N
these DT N
changes NNS N
were VBD N
significant JJ N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

In IN N
the DT N
therapy NN N
group NN N
the DT N
endotracheal JJ N
colonisation NN N
with IN N
ps NN N
. . N

aeruginosa NN N
was VBD N
significantly RB N
lower JJR N
between IN N
the DT N
4th CD N
and CC N
14th CD N
day NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
incidence NN N
of IN N
secondary JJ N
pneumonia NN N
was VBD N
reduced VBN N
from IN N
42 CD N
% NN N
to TO N
17.5 CD N
% NN N
( ( N
not RB N
significant JJ N
) ) N
. . N

Systemic JJ N
administration NN N
of IN N
antibiotics NNS N
, , N
e.g NN N
. . N

of IN N
aminoglycosides NNS N
, , N
was VBD N
significantly RB N
more RBR N
often RB N
necessary JJ N
in IN N
the DT N
control NN N
group NN N
. . N

No DT N
increasing VBG N
of IN N
growth NN N
of IN N
fungi NN N
in IN N
the DT N
upper JJ N
respiratory NN N
tract NN N
was VBD N
observed VBN N
, , N
but CC N
these DT N
was VBD N
a DT N
non-significantly RB N
higher JJR N
incidence NN N
mainly RB N
of IN N
staph NN N
. . N

epidermidis NN N
. . N

The DT N
application NN N
of IN N
80 CD N
mg NNS N
tobramycin RB N
four CD N
times NNS N
a DT N
day NN N
as IN N
an DT N
aerosol NN N
was VBD N
well RB N
tolerated VBN N
by IN N
the DT N
patients NNS N
. . N

Under IN N
there EX N
conditions NNS N
, , N
tobramycin NN N
could MD N
not RB N
be VB N
measured VBN N
in IN N
the DT N
serum NN N
. . N

No DT N
allergic JJ N
reactions NNS N
, , N
increased VBD N
respiratory NN N
pressures NNS N
or CC N
bronchoconstrictions NNS N
were VBD N
observed VBN N
. . N

-DOCSTART- -X- O O 14989068

[ RB N
Clinical NNP N
study NN N
on IN N
dan NN N
shao NN N
tang NN N
in IN N
treating VBG N
IgA NNP N
nephropathy NN N
of IN N
deficiency NN N
of IN N
yin NN N
with IN N
damp-heat JJ N
symptom NN N
] NNP N
. . N

OBJECTIVE NNP N
To TO N
explore VB N
the DT N
effect NN N
of IN N
Dan NNP N
Shao NNP N
Tang NNP N
( ( N
DST NNP N
) ) N
in IN N
treating VBG N
IgA NNP N
nephropathy NN N
( ( N
IgAN NNP N
) ) N
of IN N
deficiency NN N
of IN N
Yin NNP N
with IN N
damp-heat JJ N
symptom NN N
. . N

METHODS NNP N
90 CD N
patients NNS N
with IN N
IgAN NNP 4_p
of IN 4_p
deficiency NN 4_p
of IN 4_p
Yin NNP 4_p
with IN N
damp-heat JJ 4_p
symptom NN 4_p
were VBD N
randomly RB N
divided VBN N
into IN N
two CD N
groups NNS N
. . N

50 CD N
patients NNS N
in IN N
treatment NN N
group NN N
were VBD N
treated VBN N
with IN N
DST NNP N
and CC N
western JJ N
medicine NN N
and CC N
40 CD N
patients NNS N
in IN N
control NN N
group NN N
were VBD N
treated VBN N
only RB N
with IN N
western JJ N
medicine NN N
. . N

The DT N
effects NNS N
and CC N
changes NNS N
of IN N
the DT N
indexes NNS N
including VBG N
renal JJ N
function NN N
, , N
hematuria NN N
, , N
proteinuria NN N
, , N
blood NN N
IgA NNP N
before IN N
and CC N
after IN N
treatment NN N
were VBD N
observed VBN N
. . N

RESULTS NNP N
After IN N
six CD N
months NNS N
treatment NN N
, , N
the DT N
general JJ N
effective JJ N
rate NN N
in IN N
treatment NN N
group NN N
was VBD N
70.00 CD N
% NN N
, , N
which WDT N
was VBD N
markedly RB N
higher JJR N
than IN N
that DT N
in IN N
control NN N
group NN N
( ( N
37.50 CD N
% NN N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

Treatment NNP N
group NN N
is VBZ N
obviously RB N
better JJR N
than IN N
control NN N
group NN N
on IN N
decreasing VBG N
hematuria NN N
, , N
proteinuria NN N
, , N
blood NN N
IgA NNP N
and CC N
improving VBG N
renal JJ N
function NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSION NNP N
DST NNP N
is VBZ N
effective JJ N
on IN N
IgAN NNP N
of IN N
deficiency NN N
of IN N
Yin NNP N
with IN N
damp-heat JJ N
symptom NN N
. . N

-DOCSTART- -X- O O 21261975

Impact NN N
of IN N
early JJ N
parenteral JJ N
nutrition NN N
completing VBG N
enteral JJ N
nutrition NN N
in IN N
adult NN 4_p
critically RB 4_p
ill JJ 4_p
patients NNS 4_p
( ( N
EPaNIC NNP N
trial NN N
) ) N
: : N
a DT N
study NN N
protocol NN N
and CC N
statistical JJ N
analysis NN N
plan NN N
for IN N
a DT N
randomized VBN N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
For IN N
critically RB 4_p
ill JJ 4_p
patients NNS 4_p
treated VBN 4_p
in IN 4_p
intensive JJ 4_p
care NN 4_p
units NNS 4_p
( ( 4_p
ICU NNP 4_p
) ) N
, , N
two CD N
feeding NN N
strategies NNS N
are VBP N
currently RB N
being VBG N
advocated VBN N
, , N
one CD N
by IN N
American/Canadian JJ N
and CC N
the DT N
other JJ N
by IN N
European JJ N
expert NN N
guidelines NNS N
. . N

These DT N
guidelines NNS N
differ VBP N
particularly RB N
in IN N
the DT N
timing NN N
of IN N
initiating VBG N
parenteral JJ N
nutrition NN N
( ( N
PN NNP N
) ) N
in IN N
patients NNS 4_p
for IN 4_p
whom WP 4_p
enteral JJ 4_p
nutrition NN 4_p
( ( 4_p
EN NNP 4_p
) ) 4_p
does VBZ 4_p
not RB 4_p
reach VB 4_p
caloric JJ 4_p
targets NNS 4_p
. . N

METHODS/DESIGN NNP N
The DT N
EPaNIC NNP N
trial NN N
is VBZ N
an DT N
investigator-initiated JJ N
, , N
non-commercial JJ N
, , N
multi-center JJ N
, , N
randomized VBN N
, , N
controlled VBN N
, , N
clinical JJ N
trial NN N
with IN N
a DT N
parallel JJ N
group NN N
design NN N
. . N

This DT N
study NN N
compares VBZ N
early JJ N
( ( N
European JJ N
guideline NN N
) ) N
versus NN N
late JJ N
( ( N
American/Canadian JJ N
guideline NN N
) ) N
initiation NN N
of IN N
PN NNP N
when WRB N
EN NNP N
fails VBZ N
to TO N
reach VB N
a DT N
caloric JJ N
target NN N
. . N

In IN N
the DT N
early JJ N
PN NNP N
group NN N
, , N
PN NNP N
is VBZ N
initiated VBN N
within IN N
24-48 JJ N
hours NNS N
after IN N
ICU NNP N
admission NN N
to TO N
complete VB N
early JJ N
enteral JJ N
nutrition NN N
( ( N
EN NNP N
) ) N
up RB N
to TO N
a DT N
calculated JJ N
nutritional JJ N
target NN N
. . N

In IN N
the DT N
late JJ N
PN NNP N
group NN N
, , N
PN NNP N
completing VBG N
EN NNP N
is VBZ N
initiated VBN N
when WRB N
the DT N
target NN N
is VBZ N
not RB N
reached VBN N
on IN N
day NN N
8 CD N
. . N

In IN N
both DT N
groups NNS N
, , N
the DT N
same JJ N
early JJ N
EN NNP N
protocol NN N
is VBZ N
applied VBN N
. . N

The DT N
study NN N
is VBZ N
designed VBN N
to TO N
compare VB N
clinical JJ N
outcome NN N
( ( N
morbidity NN N
and CC N
mortality NN N
) ) N
in IN N
the DT N
2 CD N
study NN N
arms NNS N
as RB N
well RB N
as IN N
to TO N
address VB N
several JJ N
mechanistical JJ N
questions NNS N
. . N

We PRP N
here RB N
describe VBP N
the DT N
EPaNIC NNP N
study NN N
protocol NN N
and CC N
the DT N
statistical JJ N
analysis NN N
plan NN N
for IN N
the DT N
primary JJ N
report NN N
of IN N
the DT N
clinical JJ N
results NNS N
. . N

DISCUSSION NNP N
The DT N
study NN N
has VBZ N
been VBN N
initiated VBN N
as IN N
planned VBN N
on IN N
august NN N
01 CD N
2007 CD N
. . N

One CD N
interim JJ N
analysis NN N
advised VBD N
continuation NN N
of IN N
the DT N
trial NN N
. . N

The DT N
study NN N
will MD N
be VB N
completed VBN N
in IN N
February NNP N
2011 CD N
. . N

TRIAL NNP N
REGISTRATION NNP N
ClinicalTrials NNP N
( ( N
NCT NNP N
) ) N
: : N
NCT00512122 NN N
. . N

-DOCSTART- -X- O O 23749007

Ultracision NNP N
versus NN N
electrocautery NN N
in IN N
performing VBG N
modified JJ N
radical JJ N
mastectomy NN N
and CC N
axillary JJ N
lymph NN N
node NN N
dissection NN N
for IN N
breast NN 4_p
cancer NN 4_p
: : N
a DT N
prospective JJ N
randomized VBN N
control NN N
trial NN N
. . N

BACKGROUND NNP N
Treatment NNP N
for IN N
breast NN N
cancer NN N
has VBZ N
improved VBN N
dramatically RB N
over IN N
the DT N
decades NNS N
. . N

Nevertheless RB N
, , N
modified VBD N
radical JJ N
mastectomy NN N
with IN N
axillary JJ N
dissection NN N
remains VBZ N
the DT N
standard JJ N
treatment NN N
for IN N
most JJS N
patients NNS 4_p
, , 4_p
especially RB 4_p
those DT 4_p
with IN 4_p
big JJ 4_p
tumours NNS 4_p
. . N

The DT N
conventional JJ N
technology NN N
is VBZ N
to TO N
use VB N
diathermy NN N
to TO N
cut VB N
and CC N
coagulate VB N
blood NN N
vessels NNS N
. . N

The DT N
Ultracision NNP N
dissector NN N
has VBZ N
been VBN N
widely RB N
used VBN N
in IN N
laparoscopic NN N
surgery NN N
and CC N
is VBZ N
documented VBN N
to TO N
be VB N
safe JJ N
and CC N
fast JJ N
for IN N
cutting VBG N
and CC N
coagulating VBG N
tissue NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
is VBZ N
to TO N
compare VB N
ultracision NN N
to TO N
electrocautery VB N
, , N
looking VBG N
in IN N
terms NNS N
of IN N
amount NN N
of IN N
post NN N
operative JJ N
drainage NN N
, , N
duration NN N
of IN N
drain NN N
days NNS N
, , N
seroma JJ N
formation NN N
and CC N
other JJ N
complications NNS N
. . N

METHODOLOGY NNP N
This DT N
study NN N
was VBD N
a DT N
prospective JJ 4_p
randomized VBN 4_p
control NN 4_p
trial NN 4_p
of IN 4_p
modified JJ 4_p
radical JJ 4_p
mastectomy NN 4_p
performed VBD 4_p
for IN 4_p
breast NN 4_p
cancer NN 4_p
in IN 4_p
Pusat NNP 4_p
Perubatan NNP 4_p
Universiti NNP 4_p
Kebangsaan NNP 4_p
Malaysia NNP 4_p
( ( 4_p
PPUKM NNP 4_p
) ) 4_p
between IN 4_p
1st CD 4_p
June NNP 4_p
2007 CD 4_p
to TO 4_p
31st CD 4_p
December NNP 4_p
2008 CD 4_p
. . N

Patients NNS N
were VBD N
randomized VBN N
in IN N
two CD N
groups NNS N
: : N
group NN N
A NNP N
( ( N
n JJ N
= NNP N
20 CD N
) ) N
underwent NN 4_p
modified VBD 4_p
radical JJ 4_p
mastectomy NN 4_p
using VBG 4_p
ultracision NN 4_p
( ( 4_p
UC NNP 4_p
) ) 4_p
and CC N
group NN N
B NNP N
( ( N
n JJ N
= NNP N
20 CD N
) ) N
with IN N
the DT 4_p
conventional JJ 4_p
electrocautery NN 4_p
( ( 4_p
EC NNP 4_p
) ) 4_p
method NN 4_p
. . N

Main NNP N
outcome JJ N
measures NNS N
were VBD N
amount NN N
of IN N
drainage NN N
and CC N
duration NN N
of IN N
drain NN N
days NNS N
. . N

An DT N
unpaired JJ N
2-tailed JJ N
Student NN N
's POS N
t JJ N
test NN N
and CC N
the DT N
χ2 JJ N
test NN N
to TO N
compare VB N
the DT N
groups NNS N
. . N

RESULTS VB N
A DT N
total NN N
of IN N
40 CD N
patients NNS N
were VBD N
involved VBN N
in IN N
this DT N
study NN N
. . N

The DT N
majority NN N
of IN N
patients NNS N
were VBD N
Malay NNP N
( ( N
55 CD N
% NN N
) ) N
followed VBN N
by IN N
Chinese NNP N
( ( N
35 CD N
% NN N
) ) N
, , N
Indian JJ N
( ( N
5 CD N
% NN N
) ) N
and CC N
others NNS N
( ( N
5 CD N
% NN N
) ) N
. . N

The DT N
mean JJ N
volume NN N
of IN N
drainage NN N
from IN N
the DT N
axilla NN N
in IN N
the DT N
EC NNP N
group NN N
was VBD N
significantly RB N
higher JJR N
than IN N
UC NNP N
group NN N
[ VBD N
489.5 CD N
versus NN N
188.1 CD N
mls NN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
] NN N
. . N

The DT N
mean JJ N
volume NN N
of IN N
drainage NN N
from IN N
the DT N
breast NN N
and CC N
the DT N
total JJ N
drainage NN N
from IN N
both CC N
the DT N
breast NN N
and CC N
axilla NN N
was VBD N
also RB N
significantly RB N
higher RBR N
in IN N
the DT N
EC NNP N
group NN N
compared VBN N
to TO N
UC NNP N
[ NNP N
169.3 CD N
versus NN N
58.8 CD N
mls NN N
( ( N
p JJ N
= NNP N
0.004 CD N
) ) N
and CC N
663.7 CD N
versus NN N
247.0 CD N
mls NN N
( ( N
p JJ N
< NNP N
0.002 CD N
) ) N
respectively RB N
] JJ N
. . N

The DT N
drainage NN N
consequently RB N
showed VBD N
significant JJ N
reduction NN N
in IN N
terms NNS N
of IN N
drain NN N
days NNS N
in IN N
the DT N
axilla NN N
[ VBZ N
6 CD N
days NNS N
versus RB N
3 CD N
days NNS N
( ( N
p JJ N
< NNP N
0.002 CD N
) ) N
] NN N
and CC N
the DT N
breast NN N
[ JJ N
3 CD N
days NNS N
versus RB N
2 CD N
days NNS N
( ( N
p JJ N
< NNP N
0.002 CD N
) ) N
] NN N
in IN N
the DT N
UC NNP N
compared VBN N
to TO N
the DT N
EC NNP N
. . N

There EX N
was VBD N
no DT N
significant JJ N
complication NN N
in IN N
both DT N
arms NNS N
. . N

In IN N
conclusion NN N
, , N
the DT N
use NN N
of IN N
ultracision NN N
able JJ N
to TO N
reduce VB N
the DT N
amount NN N
of IN N
drainage NN N
and CC N
the DT N
number NN N
of IN N
drain NN N
days NNS N
after IN N
performing VBG N
modified VBD N
radical JJ N
mastectomy NN N
. . N

In IN N
doing VBG N
so RB N
, , N
the DT N
use NN N
of IN N
this DT N
technology NN N
enable JJ N
us PRP N
to TO N
discharge VB N
patients NNS N
earlier RBR N
without IN N
significant JJ N
morbidities NNS N
. . N

-DOCSTART- -X- O O 3673207

Pre-exposure JJ N
studies NNS N
with IN N
purified JJ N
chick JJ N
embryo NN N
cell NN N
culture NN N
rabies VBZ N
vaccine NN N
and CC N
human JJ N
diploid NN N
cell NN N
vaccine NN N
: : N
serological JJ N
and CC N
clinical JJ N
responses NNS N
in IN N
man NN N
. . N

Clinical JJ N
reactions NNS N
and CC N
neutralizing VBG N
antibody NN N
responses NNS N
to TO N
six CD N
pre-exposure NN N
regimens NNS N
of IN N
purified JJ N
chick JJ N
embryo NN N
cell NN N
culture NN N
rabies VBZ N
vaccine NN N
( ( N
PCECV NNP N
) ) N
and CC N
human JJ N
diploid NN N
cell NN N
strain NN N
rabies NNS N
vaccine VBP N
( ( N
HDCSV NNP N
) ) N
were VBD N
studied VBN N
in IN N
177 CD N
volunteers NNS N
. . N

Antibody NN N
kinetics NNS N
, , N
height NN N
of IN N
the DT N
response NN N
and CC N
persistence NN N
of IN N
antibody NN N
over IN N
two CD N
years NNS N
were VBD N
virtually RB N
identical JJ N
after IN N
PCECV NNP N
and CC N
HDCSV NNP N
. . N

An DT N
antibody NN N
response NN N
was VBD N
detected VBN N
in IN N
all DT N
subjects NNS N
on IN N
day NN N
14 CD N
when WRB N
the DT N
highest JJS N
titres NNS N
were VBD N
found VBN N
after IN N
two CD N
intramuscular JJ N
( ( N
i.m JJ N
. . N

) ) N
1.0 CD N
ml JJ N
doses NNS N
of IN N
a DT N
schedule NN N
of IN N
immunization NN N
on IN N
days NNS N
0 CD N
, , N
7 CD N
and CC N
21 CD N
. . N

In IN N
comparison NN N
, , N
a DT N
schedule NN N
of IN N
immunization NN N
on IN N
days NNS N
0 CD N
, , N
28 CD N
and CC N
56 CD N
ultimately RB N
evoked VBD N
the DT N
highest JJS N
titres NNS N
21 CD N
days NNS N
after IN N
the DT N
final JJ N
injection NN N
, , N
but CC N
antibody NN N
persisted VBD N
equally RB N
well RB N
over IN N
two CD N
years NNS N
with IN N
either DT N
schedule NN N
. . N

Neutralizing VBG N
antibody NN N
titres NNS N
were VBD N
lower JJR N
after IN N
intradermal JJ N
( ( N
i.d JJ N
. . N

) ) N
vaccination NN N
with IN N
0.1 CD N
ml NNS N
compared VBN N
to TO N
1.0 CD N
ml NN N
i.m NN N
. . N

on IN N
days NNS N
0 CD N
, , N
7 CD N
and CC N
21 CD N
, , N
but CC N
when WRB N
given VBN N
on IN N
days NNS N
0 CD N
, , N
28 CD N
and CC N
56 CD N
the DT N
responses NNS N
were VBD N
comparable JJ N
. . N

Three CD N
subjects NNS N
with IN N
a DT N
personal JJ N
or CC N
family NN N
history NN N
of IN N
atopy NN N
developed VBN N
urticarial JJ N
lesions NNS N
after IN N
PCECV NNP N
. . N

Both DT N
vaccines NNS N
were VBD N
otherwise RB N
well RB N
tolerated VBN N
. . N

-DOCSTART- -X- O O 20201949

Final JJ N
analysis NN N
of IN N
the DT N
UKLG NNP N
LY02 NNP N
trial NN N
comparing VBG N
6-8 JJ N
cycles NNS N
of IN N
CHOP NNP N
with IN N
3 CD N
cycles NNS N
of IN N
CHOP NNP N
followed VBN N
by IN N
a DT N
BEAM NNP N
autograft NN N
in IN N
patients NNS N
< JJ N
65 CD N
years NNS N
with IN N
poor JJ N
prognosis NN N
histologically RB N
aggressive JJ N
NHL NNP 4_p
. . N

This DT N
trial NN N
involved VBD N
457 CD N
patients NNS N
and CC N
sought VBD N
to TO N
assess VB N
the DT N
value NN N
of IN N
early JJ N
intensification NN N
with IN N
autologous JJ N
transplantation NN N
in IN N
patients NNS N
with IN N
poor JJ N
prognosis NN N
histologically RB N
aggressive JJ N
non-Hodgkin JJ 4_p
lymphoma NN 4_p
( ( N
NHL NNP N
) ) N
showing VBG N
a DT N
response NN N
to TO N
initial JJ N
CHOP NNP N
( ( N
cyclophosphamide NN N
, , N
doxorubicin NN N
, , N
vincristine NN N
, , N
prednisolone NN N
) ) N
chemotherapy NN N
. . N

Randomization NN N
was VBD N
made VBN N
at IN N
the DT N
time NN N
of IN N
diagnosis NN N
with IN N
223 CD N
assigned VBD N
to TO N
continuing VBG N
CHOP NNP N
and CC N
234 CD N
to TO N
3 CD N
cycles NNS N
of IN N
CHOP NNP N
followed VBN N
by IN N
a DT N
BEAM NNP N
( ( N
carmustine NN N
, , N
etoposide RB N
, , N
cytarabine NN N
, , N
melphalan NN N
) ) N
autograft NN N
. . N

Analysis NN N
was VBD N
on IN N
an DT N
intention NN N
to TO N
treat VB N
basis NN N
. . N

After IN N
the DT N
initial JJ N
three CD N
cycles NNS N
of IN N
CHOP NNP N
19 CD N
% NN N
of IN N
the DT N
whole JJ N
group NN N
were VBD N
in IN N
complete JJ N
response NN N
( ( N
CR NNP N
) ) N
and CC N
53 CD N
% NN N
in IN N
partial JJ N
remission NN N
( ( N
PR NNP N
) ) N
. . N

At IN N
the DT N
end NN N
of IN N
treatment NN N
86 CD N
% NN N
of IN N
patients NNS N
in IN N
the DT N
CHOP NNP N
arm NN N
had VBD N
responded VBN N
with IN N
58 CD N
% NN N
in IN N
CR NNP N
. . N

In IN N
the DT N
high-dose JJ N
therapy NN N
arm NN N
the DT N
overall JJ N
response NN N
rate NN N
was VBD N
83 CD N
% NN N
with IN N
64 CD N
% NN N
in IN N
CR NNP N
( ( N
difference NN N
between IN N
arms NNS N
not RB N
significant JJ N
) ) N
. . N

The DT N
progression-free JJ N
survival NN N
( ( N
PFS NNP N
) ) N
and CC N
overall JJ N
survival NN N
at IN N
5 CD N
years NNS N
for IN N
the DT N
continuing VBG N
CHOP NNP N
arm NN N
were VBD N
38 CD N
% NN N
and CC N
50 CD N
% NN N
respectively RB N
, , N
and CC N
for IN N
the DT N
autograft NN N
arm NN N
were VBD N
44 CD N
% NN N
and CC N
50 CD N
% NN N
( ( N
differences NNS N
not RB N
significant JJ N
) ) N
. . N

Of IN N
the DT N
patients NNS N
who WP N
attained VBD N
CR NNP N
and CC N
subsequently RB N
relapsed VBN N
, , N
there EX N
were VBD N
no DT N
long-term JJ N
survivors NNS N
in IN N
the DT N
autograft NN N
recipients NNS N
compared VBN N
to TO N
46 CD N
% NN N
of IN N
the DT N
continuing VBG N
CHOP NNP N
recipients NNS N
( ( N
P NNP N
= NNP N
0.0008 CD N
) ) N
. . N

In IN N
conclusion NN N
, , N
no DT N
survival JJ N
benefit NN N
was VBD N
demonstrated VBN N
for IN N
an DT N
early JJ N
autograft NN N
in IN N
first JJ N
response NN N
. . N

-DOCSTART- -X- O O 15523323

Impact NN N
of IN N
angiotensin-converting JJ N
enzyme JJ N
gene NN N
polymorphism NN N
on IN N
neurohormonal JJ N
responses NNS N
to TO N
high- JJ N
versus NN N
low-dose JJ N
enalapril NN N
in IN N
advanced JJ 4_p
heart NN 4_p
failure NN 4_p
. . 4_p

BACKGROUND CC N
The DT N
impact NN N
of IN N
angiotensin-converting JJ N
enzyme NN N
( ( N
ACE NNP N
) ) N
gene NN N
polymorphism NN N
on IN N
neurohormonal JJ N
dose JJ N
response NN N
to TO N
ACE NNP N
inhibitor NN N
therapy NN N
is VBZ N
unclear JJ N
. . N

METHODS NNP N
ACE NNP N
Insertion NNP N
( ( N
I PRP N
) ) N
or CC N
Deletion NNP N
( ( N
D NNP N
) ) N
genotype NN N
was VBD N
determined VBN N
in IN N
74 CD 4_p
patients NNS 4_p
with IN N
chronic JJ 4_p
heart NN 4_p
failure NN 4_p
who WP N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
either DT N
high-dose JJ N
or CC N
low-dose JJ N
enalapril NN N
over IN N
a DT N
period NN N
of IN N
6 CD N
months NNS N
. . N

Monthly JJ N
pre-enalapril JJ N
and CC N
post-enalapril JJ N
neurohormone NN N
levels NNS N
( ( N
serum JJ N
ACE NNP N
activity NN N
( ( N
sACE NN N
) ) N
, , N
plasma JJ N
angiotensin NN N
II NNP N
( ( N
A-II NNP N
) ) N
, , N
plasma JJ N
renin NN N
activity NN N
( ( N
PRA NNP N
) ) N
, , N
and CC N
serum VB N
aldosterone NN N
( ( N
ALDO NNP N
) ) N
were VBD N
compared VBN N
between IN N
genotype NN N
subgroups NNS N
and CC N
between IN N
patients NNS N
who WP N
received VBD N
high- JJ N
or CC N
low-dose JJ N
enalapril NN N
within IN N
each DT N
genotype NN N
subgroup NN N
. . N

RESULTS NNP N
At IN N
baseline NN N
, , N
predose/postdose JJ N
sACE NN N
and CC N
postdose JJ N
PRA NNP N
were VBD N
significantly RB N
higher JJR N
in IN N
the DT N
DD NNP N
genotype NN N
. . N

At IN N
6-month JJ N
follow-up NN N
, , N
postdose JJ N
sACE NN N
was VBD N
reduced VBN N
in IN N
a DT N
dose-dependent JJ N
fashion NN N
in IN N
all DT N
three CD N
genotypes NNS N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

However RB N
, , N
predose JJ N
and CC N
postdose JJ N
ALDO NNP N
and CC N
A-II NNP N
levels NNS N
did VBD N
not RB N
differ VB N
between IN N
each DT N
genotype NN N
subgroup NN N
at IN N
baseline NN N
or CC N
by IN N
enalapril JJ N
dose NN N
within IN N
each DT N
genotype NN N
subgroup NN N
. . N

ALDO NNP N
escape NN N
and CC N
A-II JJ N
reactivation NN N
were VBD N
not RB N
affected VBN N
by IN N
ACE NNP N
genotype NN N
or CC N
enalapril JJ N
dosage NN N
. . N

CONCLUSIONS NNP N
Predose NNP N
sACE NN N
were VBD N
consistently RB N
higher JJR N
in IN N
the DT N
DD NNP N
genotype NN N
when WRB N
compared VBN N
with IN N
ID NNP N
or CC N
II NNP N
subgroups NNS N
. . N

Despite IN N
a DT N
dose-dependent JJ N
suppression NN N
of IN N
sACE NN N
, , N
there EX N
were VBD N
no DT N
observed VBN N
statistically RB N
significant JJ N
differences NNS N
in IN N
ALDO NNP N
and CC N
A-II NNP N
suppression NN N
or CC N
escape NN N
with IN N
escalating VBG N
doses NNS N
of IN N
enalapril NN N
within IN N
each DT N
subgroup NN N
. . N

-DOCSTART- -X- O O 9564194

The DT N
problem NN N
of IN N
measurement NN N
error NN N
in IN N
multisite JJ N
clinical JJ N
trials NNS N
. . N

The DT N
implementation NN N
of IN N
a DT N
multisite NN N
, , N
randomized VBN N
, , N
clinical JJ N
psychopharmacologic JJ N
trial NN N
involves VBZ N
a DT N
substantial JJ N
investment NN N
of IN N
time NN N
and CC N
effort NN N
on IN N
the DT N
part NN N
of IN N
all DT N
participants NNS N
. . N

Because IN N
of IN N
their PRP$ N
complexity NN N
, , N
such JJ N
clinical JJ N
trials NNS N
present JJ N
unique JJ N
methodological JJ N
and CC N
design NN N
challenges NNS N
. . N

Indeed RB N
, , N
it PRP N
is VBZ N
not RB N
uncommon JJ N
for IN N
such JJ N
studies NNS N
to TO N
conclude VB N
with IN N
uninterpretable JJ N
results NNS N
, , N
due JJ N
in IN N
part NN N
to TO N
such JJ N
methodological JJ N
pitfalls NNS N
. . N

It PRP N
has VBZ N
been VBN N
suggested VBN N
that IN N
clarification NN N
of IN N
such JJ N
methodologic JJ N
dilemmas NN N
is VBZ N
one CD N
of IN N
the DT N
most RBS N
important JJ N
challenges NNS N
facing VBG N
the DT N
future NN N
of IN N
industry-sponsored JJ N
psychopharmacologic JJ N
drug NN N
development NN N
. . N

Among IN N
the DT N
many JJ N
factors NNS N
that WDT N
may MD N
contribute VB N
to TO N
problematic JJ N
clinical JJ N
trial NN N
results NNS N
, , N
error NN N
in IN N
measuring VBG N
the DT N
phenomena NN N
being VBG N
studied VBN N
is VBZ N
of IN N
particular JJ N
concern NN N
. . N

In IN N
this DT N
article NN N
, , N
we PRP N
describe VBP N
the DT N
outcome NN N
of IN N
an DT N
intensive JJ N
series NN N
of IN N
interrater JJ N
reliability NN N
training NN N
sessions NNS N
for IN N
the DT N
17-item JJ N
Hamilton NNP N
Depression NNP N
Rating NNP N
Scale NNP N
conducted VBD N
at IN N
the DT N
start NN N
of IN N
a DT N
Phase NNP N
II NNP N
multisite RB N
clinical JJ N
drug NN N
trial NN N
. . N

The DT N
data NN N
underscore IN N
the DT N
magnitude NN N
of IN N
error NN N
present NN N
in IN N
such JJ N
a DT N
test NN N
setting NN N
and CC N
provide VB N
preliminary JJ N
evidence NN N
for IN N
the DT N
potential JJ N
effect NN N
of IN N
this DT N
problem NN N
on IN N
the DT N
detection NN N
of IN N
clinical JJ N
change NN N
. . N

-DOCSTART- -X- O O 18752063

Positive JJ N
effects NNS N
of IN N
methylphenidate NN N
on IN N
social JJ N
communication NN N
and CC N
self-regulation NN N
in IN N
children NNS N
with IN N
pervasive JJ 4_p
developmental NN 4_p
disorders NNS 4_p
and CC 4_p
hyperactivity NN 4_p
. . N

This DT N
report NN N
examined VBD N
the DT N
effect NN N
of IN N
methylphenidate NN N
on IN N
social JJ N
communication NN N
and CC N
self-regulation NN N
in IN N
children NNS N
with IN N
pervasive JJ 4_p
developmental NN 4_p
disorders NNS 4_p
and CC 4_p
hyperactivity NN 4_p
in IN N
a DT N
secondary JJ N
analysis NN N
of IN N
RUPP NNP N
Autism NNP 4_p
Network NNP N
data NNS N
. . N

Participants NNS N
were VBD N
33 CD N
children NNS N
( ( N
29 CD N
boys NNS N
) ) N
between IN N
the DT N
ages NNS N
of IN N
5 CD N
and CC N
13 CD N
years NNS N
who WP N
participated VBD N
in IN N
a DT N
four-week JJ N
crossover NN N
trial NN N
of IN N
placebo NN N
and CC N
increasing VBG N
doses NNS N
of IN N
methylphenidate NN N
given VBN N
in IN N
random JJ N
order NN N
each DT N
for IN N
one CD N
week NN N
. . N

Observational JJ N
measures NNS N
of IN N
certain JJ N
aspects NNS N
of IN N
children NNS N
's POS N
social JJ N
communication NN N
, , N
self-regulation NN N
, , N
and CC N
affective JJ N
behavior NN N
were VBD N
obtained VBN N
each DT N
week NN N
. . N

A DT N
significant JJ N
positive JJ N
effect NN N
of IN N
methylphenidate NN N
was VBD N
seen VBN N
on IN N
children NNS N
's POS N
use NN N
of IN N
joint JJ N
attention NN N
initiations NNS N
, , N
response NN N
to TO N
bids NNS N
for IN N
joint JJ N
attention NN N
, , N
self-regulation NN N
, , N
and CC N
regulated VBD N
affective JJ N
state NN N
. . N

The DT N
results NNS N
go VBP N
beyond IN N
the DT N
recent JJ N
literature NN N
and CC N
suggest VBP N
that IN N
methylphenidate NN N
may MD N
have VB N
positive JJ N
effects NNS N
on IN N
social JJ N
behaviors NNS N
in IN N
children NNS N
with IN N
PDD NNP 4_p
and CC 4_p
hyperactivity NN 4_p
. . N

-DOCSTART- -X- O O 8735490

Accuracy NN N
of IN N
pelvic JJ 4_p
radiotherapy NN 4_p
: : N
prospective JJ N
analysis NN N
of IN N
90 CD N
patients NNS N
in IN N
a DT N
randomised JJ N
trial NN N
of IN N
blocked VBN N
versus FW N
standard JJ N
radiotherapy NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
assess VB N
the DT N
accuracy NN N
of IN N
pelvic JJ N
radiotherapy NN N
during IN N
a DT N
trial NN N
of IN N
blocked JJ N
radiotherapy NN N
at IN N
the DT N
Royal NNP N
Marsden NNP N
Hospital NNP N
, , N
UK NNP N
. . N

Prospective JJ N
evaluation NN N
was VBD N
performed VBN N
on IN N
90 CD N
patients NNS N
receiving VBG N
CT NNP N
planned VBD N
pelvic JJ 4_p
radiotherapy NN 4_p
using VBG N
weekly JJ N
anterior-posterior JJ N
and CC N
lateral JJ N
portal JJ N
films NNS N
. . N

Field NNP N
placement JJ N
errors NNS N
( ( N
FPEs NNP N
) ) N
were VBD N
calculated VBN N
by IN N
comparing VBG N
field NN N
centres NNS N
of IN N
each DT N
film NN N
with IN N
a DT N
designated JJ N
point NN N
of IN N
interest NN N
. . N

Data NNP N
was VBD N
evaluated VBN N
to TO N
calculate VB N
the DT N
overall JJ N
treatment NN N
simulator NN N
differences NNS N
, , N
the DT N
number NN N
of IN N
error JJ N
free JJ N
treatments NNS N
, , N
and CC N
mean VB N
treatment-simulator JJ N
position NN N
and CC N
to TO N
evaluate VB N
the DT N
role NN N
of IN N
systematic JJ N
versus NN N
random JJ N
errors NNS N
. . N

Age NNP N
, , N
weight NN N
, , N
disease NN N
site NN N
, , N
position NN N
of IN N
treatment NN N
, , N
fractionation NN N
, , N
blocked VBD N
versus JJ N
conventional JJ N
techniques NNS N
were VBD N
assessed VBN N
for IN N
their PRP$ N
effect NN N
on IN N
treatment NN N
accuracy NN N
. . N

The DT N
mean JJ N
absolute NN N
error NN N
between IN N
treatment NN N
and CC N
simulator NN N
films NNS N
was VBD N
anterior JJ N
right-left NN N
( ( N
ARL NNP N
) ) N
0.25 CD N
cm NN N
, , N
anterior JJ N
superior-inferior JJ N
( ( N
ASI NNP N
) ) N
0.32 CD N
cm NN N
, , N
lateral JJ N
anterior-posterior JJ N
( ( N
LAP NNP N
) ) N
0.42 CD N
cm NN N
, , N
and CC N
lateral JJ N
superior-inferior JJ N
( ( N
LSI NNP N
) ) N
0.28 CD N
cm NN N
. . N

On IN N
average JJ N
the DT N
field NN N
centre NN N
was VBD N
displaced VBN N
by IN N
0.66 CD N
cm NN N
( ( N
standard JJ N
deviation NN N
, , N
S.D NNP N
. . N

= VB N
0.34 CD N
) ) N
from IN N
that DT N
intended VBN N
. . N

On IN N
each DT N
treatment NN N
day NN N
29 CD N
% NN N
of IN N
anterior JJ N
films NNS N
and CC N
45 CD N
% NN N
of IN N
lateral JJ N
films NNS N
had VBD N
at IN N
least JJS N
one CD N
0.5 CD N
cm NN N
error NN N
. . N

Overall JJ N
59 CD N
% NN N
of IN N
treatments NNS N
had VBD N
at IN N
least JJS N
one CD N
0.5 CD N
cm NN N
error NN N
and CC N
9 CD N
% NN N
a DT N
1.0 CD N
cm NN N
error NN N
. . N

The DT N
field NN N
centre NN N
was VBD N
more JJR N
than IN N
0.5 CD N
cm NN N
from IN N
the DT N
position NN N
intended VBN N
in IN N
66 CD N
% NN N
of IN N
treatments NNS N
and CC N
over IN N
1 CD N
cm NNS N
for IN N
14 CD N
% NN N
of IN N
treatments NNS N
. . N

Analysis NN N
of IN N
variance NN N
showed VBD N
that IN N
both DT N
random NN N
and CC N
systematic JJ N
errors NNS N
occurred VBD N
in IN N
all DT N
directions NNS N
. . N

Though IN N
random JJ N
errors NNS N
were VBD N
of IN N
similar JJ N
magnitude NN N
in IN N
all DT N
direction NN N
( ( N
variance NN N
sigma NN N
2 CD N
= JJ N
0.06-0.09 JJ N
cm2 NN N
) ) N
; : N
systematic JJ N
errors NNS N
showed VBD N
a DT N
4-fold JJ N
variation NN N
being VBG N
greatest JJS N
in IN N
the DT N
LAP NNP N
direction NN N
( ( N
sigma JJ N
2 CD N
= JJ N
0.19 CD N
cm2 NN N
) ) N
and CC N
least JJS N
the DT N
ARL NNP N
direction NN N
( ( N
sigma JJ N
2 CD N
= JJ N
0.048 CD N
cm2 NN N
) ) N
. . N

No DT N
factor NN N
consistently RB N
predicted VBN N
for IN N
worse JJR N
outcome NN N
in IN N
all DT N
directions NNS N
. . N

Hypofractionated VBN N
treatments NNS N
were VBD N
less JJR N
accurate JJ N
in IN N
the DT N
LSI NNP N
direction NN N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

Systematic JJ N
errors NNS N
were VBD N
associated VBN N
in IN N
the DT N
ARL NNP N
direction NN N
with IN N
hypofractionation NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
and CC N
, , N
in IN N
the DT N
LSI NNP N
direction NN N
with IN N
weight NN N
( ( N
P NNP N
< NNP N
0.03 CD N
) ) N
and CC N
age NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

We PRP N
conclude VBP N
that DT N
significant JJ N
random NN N
and CC N
systematic JJ N
errors NNS N
can MD N
occur VB N
during IN N
pelvic JJ N
radiotherapy NN N
especially RB N
in IN N
the DT N
LAP NNP N
direction NN N
. . N

These DT N
results NNS N
suggest VBP N
that IN N
in IN N
the DT N
absence NN N
of IN N
a DT N
customised JJ N
immobilisation NN N
device NN N
, , N
to TO N
cover VB N
95 CD N
% NN N
of IN N
errors NNS N
, , N
margins NNS N
of IN N
0.6 CD N
cm NN N
for IN N
RL NNP N
and CC N
SI NNP N
directions NNS N
and CC N
0.9 CD N
cm NN N
for IN N
AP NNP N
direction NN N
should MD N
be VB N
allowed VBN N
between IN N
the DT N
planning NN N
and CC N
clinical JJ N
target NN N
volumes NNS N
. . N

However RB N
, , N
ideally RB N
, , N
each DT N
centre NN N
should MD N
determine VB N
their PRP$ N
own JJ N
margin NN N
requirements NNS N
according VBG N
to TO N
local JJ N
clinical JJ N
practice NN N
. . N

-DOCSTART- -X- O O 380614

Clofibrate NNP N
and CC N
diabetes VBZ N
control NN N
in IN N
patients NNS 4_p
treated VBN 4_p
with IN 4_p
oral JJ 4_p
hypoglycaemic JJ 4_p
agents NNS 4_p
. . N

1 CD N
. . N

Twenty-two JJ N
maturity-onset JJ N
type NN 4_p
diabetics NNS 4_p
treated VBD 4_p
with IN 4_p
oral JJ 4_p
hypoglycaemic JJ 4_p
agents NNS 4_p
entered VBD N
a DT N
single-blind JJ N
crossover NN N
study NN N
using VBG N
placebo NN N
( ( N
periods VB N
A DT N
and CC N
C NNP N
, , N
2 CD N
months NNS N
each DT N
) ) N
and CC N
clofibrate NN N
( ( N
2 CD N
g/day NN N
; : N
period NN N
B NNP N
; : N
2 CD N
months NNS N
) ) N
. . N

2 CD N
. . N

In IN N
thirteen JJ N
patients NNS N
, , N
under IN N
reasonably RB N
good JJ N
control NN N
, , N
clofibrate NN N
did VBD N
not RB N
reduce VB N
fasting VBG N
or CC N
post-prandial JJ N
blood NN N
glucose NN N
, , N
nor CC N
24 CD N
h NN N
glycosuria NN N
; : N
no DT N
improvement NN N
was VBD N
noted VBN N
in IN N
the DT N
M-value NNP N
, , N
an DT N
index NN N
of IN N
diabetes NNS N
control NN N
. . N

3 CD N
. . N

In IN N
contrast NN N
, , N
in IN N
nine CD N
patients NNS N
, , N
with IN N
poor JJ N
diabetes NNS N
control NN N
, , N
clofibrate NN N
reduced VBD N
24 CD N
h NN N
glycosuria NN N
and CC N
significantly RB N
improved VBD N
the DT N
M-value NNP N
. . N

4 CD N
. . N

In IN N
all DT N
patients NNS N
, , N
clofibrate JJ N
therapy NN N
was VBD N
associated VBN N
with IN N
a DT N
significant JJ N
19-23 JJ N
% NN N
reduction NN N
in IN N
plasma NN N
fibrinogen NN N
. . N

5 CD N
. . N

It PRP N
is VBZ N
suggested VBN N
that IN N
addition NN N
of IN N
clofibrate NN N
may MD N
be VB N
useful JJ N
in IN N
maturity-onset JJ N
diabetics NNS N
not RB N
adequately RB N
controlled VBN N
by IN N
diet NN N
combined VBN N
with IN N
oral JJ N
hypoglycaemic JJ N
agents NNS N
. . N

-DOCSTART- -X- O O 8473426

A DT N
controlled VBN N
study NN N
comparing VBG N
patients NNS N
with IN N
and CC N
without IN N
polycystic JJ 4_p
ovaries NNS 4_p
undergoing VBG N
in-vitro JJ N
fertilization NN N
. . N

The DT N
outcome NN N
of IN N
in-vitro JJ N
fertilization NN N
and CC N
embryo NN N
transfer NN N
( ( N
IVF-ET NNP N
) ) N
was VBD N
compared VBN N
in IN N
76 CD N
patients NNS N
with IN N
polycystic JJ 4_p
ovaries NNS 4_p
( ( N
PCO NNP N
) ) N
diagnosed VBD N
on IN N
pre-treatment JJ N
ultrasound JJ N
scan NN N
, , N
and CC N
76 CD N
control NN 4_p
patients NNS N
who WP N
had VBD N
normal JJ N
ovaries NNS N
and CC N
were VBD N
matched VBN N
for IN N
age NN N
, , N
cause NN N
of IN N
infertility NN N
and CC N
stimulation NN N
regimen NNS N
. . N

Despite IN N
receiving VBG N
significantly RB N
less JJR N
human JJ N
menopausal NN N
gonadotrophin NN N
( ( N
HMG NNP N
) ) N
, , N
patients NNS N
with IN N
PCO NNP 4_p
, , N
as IN N
compared VBN N
with IN N
controls NNS N
, , N
had VBD N
significantly RB N
higher JJR N
serum NN N
oestradiol NN N
levels NNS N
on IN N
the DT N
day NN N
of IN N
human JJ N
chorionic NN N
gonadotrophin NN N
administration NN N
( ( N
5940 CD N
+/- NN N
255 CD N
versus NN N
4370 CD N
+/- JJ N
240 CD N
pmol/l NN N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
developed VBD N
more JJR N
follicles NNS N
( ( N
14.9 CD N
+/- JJ N
0.7 CD N
versus NN N
9.8 CD N
+/- JJ N
0.6 CD N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
produced VBD N
more JJR N
oocytes NNS N
( ( N
9.3 CD N
+/- JJ N
0.6 CD N
versus NN N
6.8 CD N
+/- JJ N
0.5 CD N
, , N
P NNP N
= NNP N
0.003 CD N
) ) N
. . N

However RB N
, , N
fertilization NN N
rates NNS N
were VBD N
reduced VBN N
in IN N
the DT N
PCO NNP N
patients NNS N
( ( N
52.8 CD N
+/- JJ N
3.4 CD N
% NN N
versus NN N
66.1 CD N
+/- JJ N
3.4 CD N
% NN N
, , N
P NNP N
= NNP N
0.007 CD N
) ) N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
cleavage NN N
rates NNS N
. . N

The DT N
pregnancy NN N
rate/embryo NN N
transfer NN N
was VBD N
25.4 CD N
% NN N
in IN N
the DT N
PCO NNP 4_p
group NN N
and CC N
23.0 CD N
% NN N
in IN N
the DT N
group NN 4_p
with IN 4_p
normal JJ 4_p
ovaries NNS 4_p
. . N

There EX N
were VBD N
three CD N
high JJ N
order NN N
multiple JJ N
pregnancies NNS N
in IN N
the DT N
PCO NNP N
group NN N
compared VBN N
with IN N
none NN N
in IN N
the DT N
group NN N
with IN N
normal JJ N
ovaries NNS N
. . N

Of IN N
the DT N
PCO NNP N
patients NNS N
, , N
10.5 CD N
% NN N
developed VBD N
moderate/severe RB N
ovarian JJ N
hyperstimulation NN N
syndrome NN N
( ( N
OHSS NNP N
) ) N
compared VBN N
with IN N
none NN N
of IN N
the DT N
controls NNS N
( ( N
P NNP N
= NNP N
0.006 CD N
) ) N
. . N

Patients NNS N
with IN N
and CC N
without IN N
PCO NNP 4_p
undergoing VBG N
IVF NNP N
have VBP N
comparable JJ N
pregnancy NN N
and CC N
livebirth JJ N
rates NNS N
. . N

However RB N
, , N
it PRP N
is VBZ N
important JJ N
to TO N
diagnose VB N
PCO NNP N
before IN N
ovarian JJ N
stimulation NN N
is VBZ N
initiated VBN N
as IN N
these DT N
patients NNS N
are VBP N
more RBR N
likely JJ N
to TO N
develop VB N
moderate JJ N
or CC N
severe JJ N
OHSS NNP N
following VBG N
IVF-ET NNP N
. . N

-DOCSTART- -X- O O 11053333

Effect NN N
of IN N
systemic JJ N
nitric JJ N
oxide IN N
synthase JJ N
inhibition NN N
on IN N
postexercise NN 4_p
hypotension NN 4_p
in IN N
humans NNS N
. . N

An DT N
acute JJ N
bout NN N
of IN N
aerobic JJ N
exercise NN N
results NNS N
in IN N
a DT N
reduced JJ N
blood NN N
pressure NN N
that WDT N
lasts VBZ N
several JJ N
hours NNS N
. . N

Animal NNP N
studies NNS N
suggest VBP N
this DT N
response NN N
is VBZ N
mediated VBN N
by IN N
increased JJ N
production NN N
of IN N
nitric JJ N
oxide NN N
. . N

We PRP N
tested VBD N
the DT N
extent NN N
to TO N
which WDT N
systemic JJ N
nitric JJ N
oxide IN N
synthase JJ N
inhibition NN N
[ NNP N
N NNP N
( ( N
G NNP N
) ) N
-monomethyl-L-arginine NN N
( ( N
L-NMMA NNP N
) ) N
] NN N
can MD N
reverse VB N
the DT N
drop NN N
in IN N
blood NN N
pressure NN N
that WDT N
occurs VBZ N
after IN N
exercise NN N
in IN N
humans NNS N
. . N

Eight NNP N
healthy JJ N
subjects NNS N
underwent JJ N
parallel JJ N
experiments NNS N
on IN N
2 CD N
separate JJ N
days NNS N
. . N

The DT N
order NN N
of IN N
the DT N
experiments NNS N
was VBD N
randomized VBN N
between IN N
sham NN N
( ( N
60 CD N
min NN N
of IN N
seated JJ N
upright JJ N
rest NN N
) ) N
and CC N
exercise NN N
( ( N
60 CD N
min NN N
of IN N
upright JJ N
cycling NN N
at IN N
60 CD N
% NN N
peak NN N
aerobic JJ N
capacity NN N
) ) N
. . N

After IN N
both DT N
sham NN N
and CC N
exercise NN N
, , N
subjects VBZ N
received VBN N
, , N
in IN N
sequence NN N
, , N
systemic JJ N
alpha-adrenergic JJ N
blockade NN N
( ( N
phentolamine NN N
) ) N
and CC N
L-NMMA NNP N
. . N

Phentolamine NNP N
was VBD N
given VBN N
first RB N
to TO N
isolate VB N
the DT N
contribution NN N
of IN N
nitric JJ N
oxide NN N
to TO N
postexercise VB N
hypotension NN N
by IN N
preventing VBG N
reflex JJ N
changes NNS N
in IN N
sympathetic JJ N
tone NN N
that WDT N
result NN N
from IN N
systemic JJ N
nitric JJ N
oxide IN N
synthase JJ N
inhibition NN N
and CC N
to TO N
control VB N
for IN N
alterations NNS N
in IN N
resting VBG N
sympathetic JJ N
activity NN N
after IN N
exercise NN N
. . N

During IN N
each DT N
condition NN N
, , N
systemic JJ N
and CC N
regional JJ N
hemodynamics NNS N
were VBD N
measured VBN N
. . N

Throughout IN N
the DT N
study NN N
, , N
arterial JJ N
pressure NN N
and CC N
vascular JJ N
resistances NNS N
remained VBD N
lower JJR N
postexercise NN N
vs. FW N
postsham NN N
despite IN N
nitric JJ N
oxide JJ N
synthase NN N
inhibition NN N
( ( N
e.g. JJ N
, , N
mean JJ N
arterial JJ N
pressure NN N
after IN N
L-NMMA NNP N
was VBD N
108.0+/-2.4 JJ N
mmHg NN N
postsham NN N
vs. FW N
102.1+/-3.3 JJ N
mmHg NN N
postexercise NN N
; : N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Thus VB N
it PRP N
does VBZ N
not RB N
appear VB N
that IN N
postexercise NN N
hypotension NN N
is VBZ N
dependent JJ N
on IN N
increased JJ N
production NN N
of IN N
nitric JJ N
oxide NN N
in IN N
humans NNS N
. . N

-DOCSTART- -X- O O 11547366

Matched-pair JJ N
analysis NN N
of IN N
all-polyethylene JJ N
versus NN N
metal-backed JJ N
tibial JJ N
components NNS N
. . N

Forty-eight NNP N
matched VBD N
pairs NNS N
of IN N
osteoarthritic JJ 4_p
knees NNS N
from IN N
patients NNS N
who WP N
underwent VBP N
primary JJ N
total JJ N
knee NN N
arthroplasty NN N
with IN N
a DT N
round-on-round NN N
, , N
Apollo NNP N
Knee NNP N
System NNP N
were VBD N
studied VBN N
to TO N
evaluate VB N
the DT N
outcome NN N
between IN N
all-polyethylene JJ N
and CC N
metal-backed JJ N
tibial JJ N
components NNS N
. . N

Patients NNS N
were VBD N
matched VBN N
for IN N
patient JJ N
factors NNS N
, , N
preoperative JJ N
deformities NNS 4_p
, , N
cruciate JJ N
salvage NN N
or CC N
sacrifice NN N
, , N
and CC N
surgical JJ N
technique NN N
. . N

At IN N
the DT N
last JJ N
follow-up JJ N
( ( N
average JJ N
, , N
38.4 CD N
months NNS N
) ) N
, , N
there EX N
was VBD N
no DT N
statistically RB N
significant JJ N
difference NN N
in IN N
terms NNS N
of IN N
knee NN N
scores NNS N
, , N
patient JJ N
self-assessment NN N
, , N
and CC N
radiographic JJ N
outcomes NNS N
. . N

No DT N
component NN N
required VBN N
revision NN N
, , N
and CC N
no DT N
revisions NNS N
were VBD N
pending VBG N
. . N

Maintenance NN N
of IN N
these DT N
results NNS N
over IN N
time NN N
would MD N
project VB N
into IN N
better JJR N
long-term JJ N
success NN N
for IN N
all-polyethylene JJ N
tibial JJ N
components NNS N
because IN N
of IN N
the DT N
amount NN N
of IN N
wear NN N
and CC N
osteolysis NN N
with IN N
current JJ N
modular JJ N
metal-backed JJ N
tibial JJ N
components NNS N
. . N

We PRP N
advocate VBP N
the DT N
use NN N
of IN N
a DT N
more RBR N
cost-effective JJ N
all-polyethylene JJ N
tibial JJ N
component NN N
in IN N
elderly JJ N
patients NNS N
( ( N
> JJ N
70 CD N
years NNS N
old JJ N
) ) N
who WP N
are VBP N
not RB N
likely JJ N
to TO N
need VB N
the DT N
versatility NN N
of IN N
exchange NN N
of IN N
a DT N
modular JJ N
polyethylene NN N
insert NN N
because IN N
of IN N
wear NN N
. . N

-DOCSTART- -X- O O 15307010

Once-daily JJ N
versus NN N
twice-daily RB N
lamivudine NN N
, , N
in IN N
combination NN N
with IN N
zidovudine NN N
and CC N
efavirenz NN N
, , N
for IN N
the DT N
treatment NN N
of IN N
antiretroviral-naive JJ 4_p
adults NNS N
with IN N
HIV NNP 4_p
infection NN 4_p
: : N
a DT N
randomized JJ N
equivalence NN N
trial NN N
. . N

A DT N
randomized JJ N
, , N
double-blind JJ N
, , N
double-dummy JJ N
controlled VBN N
, , N
multicenter RBR N
trial NN N
was VBD N
conducted VBN N
that IN N
involved VBD N
554 CD N
antiretroviral-naive JJ N
human JJ 4_p
immunodeficiency NN 4_p
virus-infected JJ 4_p
adults NNS N
( ( N
plasma JJ N
HIV NNP N
type NN N
1 CD N
[ JJ N
HIV-1 NNP N
] NNP N
RNA NNP N
level NN N
, , N
> NNP N
or=400 VBZ N
copies/mL NN N
; : N
CD4 NNP N
( ( N
+ NNP N
) ) N
cell NN N
count NN N
, , N
> VBZ N
100 CD N
cells/mm NN N
( ( N
3 CD N
) ) N
) ) N
and CC N
compared VBN N
a DT N
300-mg JJ N
once-daily JJ N
( ( N
q.d JJ N
. . N

) ) N
regimen NNS N
of IN N
lamivudine NN N
( ( N
3TC CD N
) ) N
versus NN N
a DT N
150-mg JJ N
twice-daily JJ N
( ( N
b.i.d NN N
. . N

) ) N
regimen NNS N
of IN N
3TC CD N
, , N
combined VBN N
with IN N
zidovudine NN N
( ( N
300 CD N
mg NN N
b.i.d NN N
. . N

) ) N
and CC N
efavirenz $ N
( ( N
600 CD N
mg NN N
q.d NN N
. . N

) ) N
, , N
during IN N
a DT N
48-week JJ N
period NN N
. . N

Treatments NNS N
were VBD N
considered VBN N
equivalent JJ N
if IN N
the DT N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
for IN N
the DT N
difference NN N
in IN N
proportions NNS N
of IN N
patients NNS N
achieving VBG N
an DT N
HIV-1 JJ N
RNA NNP N
level NN N
of IN N
< $ N
400 CD N
copies/mL NN N
was VBD N
within IN N
the DT N
bound NN N
of IN N
-12 NN N
% NN N
to TO N
12 CD N
% NN N
. . N

At IN N
week NN N
48 CD N
of IN N
the DT N
study NN N
, , N
an DT N
intent-to-treat JJ N
analysis NN N
in IN N
which WDT N
patients NNS N
with IN N
missing VBG N
data NNS N
were VBD N
considered VBN N
to TO N
have VB N
experienced VBN N
treatment NN N
failure NN N
showed VBD N
that IN N
the DT N
3TC CD N
q.d NN N
. . N

and CC N
3TC CD N
b.i.d NN N
. . N

regimens NNS N
were VBD N
equivalent JJ N
( ( N
HIV-1 NNP N
RNA NNP N
level NN N
< VBD N
400 CD N
copies/mL NN N
, , N
178 CD N
[ JJ N
64 CD N
% NN N
] NN N
of IN N
278 CD N
vs. FW N
174 CD N
[ $ N
63 CD N
% NN N
] NN N
of IN N
276 CD N
; : N
treatment NN N
difference NN N
, , N
1 CD N
% NN N
[ JJ N
95 CD N
% NN N
CI NNP N
, , N
-7.1 NNP N
% NN N
to TO N
8.9 CD N
% NN N
] NN N
; : N
HIV-1 NNP N
RNA NNP N
level NN N
< VBD N
50 CD N
copies/mL NN N
, , N
165 CD N
[ JJ N
59 CD N
% NN N
] NN N
of IN N
278 CD N
vs. FW N
168 CD N
[ $ N
61 CD N
% NN N
] NN N
of IN N
276 CD N
; : N
treatment NN N
difference NN N
, , N
1.7 CD N
% NN N
[ JJ N
95 CD N
% NN N
CI NNP N
, , N
-9.7 NNP N
% NN N
to TO N
6.6 CD N
% NN N
] NN N
) ) N
. . N

Median JJ N
increase NN N
above IN N
baseline NN N
in IN N
CD4 NNP N
( ( N
+ NNP N
) ) N
cell NN N
count NN N
was VBD N
similar JJ N
( ( N
q.d JJ N
. . N

group NN N
, , N
+144 NNP N
cells/mm NN N
( ( N
3 CD N
) ) N
; : N
b.i.d NN N
. . N

group NN N
, , N
+146 NNP N
cells/mm NN N
( ( N
3 CD N
) ) N
) ) N
, , N
and CC N
the DT N
incidences NNS N
of IN N
adverse JJ N
events NNS N
, , N
disease NN N
progression NN N
, , N
and CC N
HIV-associated JJ N
conditions NNS N
were VBD N
comparable JJ N
. . N

-DOCSTART- -X- O O 11709366

Pharmacokinetic NNP N
study NN N
of IN N
human JJ 4_p
immunodeficiency NN 4_p
virus NN 4_p
protease NN N
inhibitors NNS N
used VBN N
in IN N
combination NN N
with IN N
amprenavir NN N
. . N

In IN N
an DT N
open-label JJ N
, , N
randomized VBN N
, , N
multicenter RBR N
, , N
multiple-dose JJ N
pharmacokinetic JJ N
study NN N
, , N
we PRP N
determined VBD N
the DT N
steady-state JJ N
pharmacokinetics NNS N
of IN N
amprenavir NN N
with IN N
and CC N
without IN N
coadministration NN N
of IN N
indinavir NN N
, , N
nelfinavir NN N
, , N
or CC N
saquinavir VB N
soft JJ N
gel NNS N
formulation NN N
in IN N
31 CD N
human JJ N
immunodeficiency NN N
virus NN N
type JJ N
1-infected JJ N
subjects NNS N
. . N

The DT N
results NNS N
indicated VBD N
that IN N
amprenavir NN N
plasma NN N
concentrations NNS N
were VBD N
decreased VBN N
by IN N
saquinavir JJ N
soft JJ N
gel NN N
capsule NN N
( ( N
by IN N
32 CD N
% NN N
for IN N
area NN N
under IN N
the DT N
concentration-time JJ N
curve NN N
at IN N
steady JJ N
state NN N
[ NNS N
AUC NNP N
( ( N
ss NN N
) ) N
] NN N
and CC N
37 CD N
% NN N
for IN N
peak NN N
plasma NN N
concentration NN N
at IN N
steady JJ N
state NN N
[ NNS N
C NNP N
( ( N
max NN N
, , N
ss NN N
) ) N
] NN N
) ) N
and CC N
increased VBN N
by IN N
indinavir NN N
( ( N
33 CD N
% NN N
for IN N
AUC NNP N
( ( N
ss NN N
) ) N
) ) N
. . N

Nelfinavir NNP N
significantly RB N
increased VBD N
amprenavir JJ N
minimum JJ N
drug NN N
concentration NN N
at IN N
steady JJ N
state NN N
( ( N
by IN N
189 CD N
% NN N
) ) N
but CC N
did VBD N
not RB N
affect VB N
amprenavir NN N
AUC NNP N
( ( N
ss NN N
) ) N
or CC N
C NNP N
( ( N
max NN N
, , N
ss NN N
) ) N
. . N

Nelfinavir NNP N
and CC N
saquinavir JJ N
steady-state JJ N
pharmacokinetics NNS N
were VBD N
unchanged JJ N
by IN N
coadministration NN N
with IN N
amprenavir NNS N
compared VBN N
with IN N
the DT N
historical JJ N
monotherapy NN N
data NNS N
. . N

Concentrations NNS N
of IN N
indinavir NN N
, , N
coadministered VBN N
with IN N
amprenavir NN N
, , N
in IN N
plasma NN N
decreased VBN N
in IN N
both DT N
single-dose JJ N
and CC N
steady-state JJ N
evaluations NNS N
. . N

The DT N
changes NNS N
in IN N
amprenavir JJ N
steady-state JJ N
pharmacokinetic JJ N
parameters NNS N
, , N
relative JJ N
to TO N
those DT N
for IN N
amprenavir JJ N
alone RB N
, , N
were VBD N
not RB N
consistent JJ N
among IN N
protease JJ N
inhibitors NNS N
, , N
nor CC N
were VBD N
the DT N
changes NNS N
consistent VBP N
with IN N
potential JJ N
interactions NNS N
in IN N
CYP3A4 NNP N
metabolism NN N
or CC N
P-glycoprotein JJ N
transport NN N
. . N

No UH N
dose JJ N
adjustment NN N
of IN N
either DT N
protease NN N
inhibitor NN N
in IN N
any DT N
of IN N
the DT N
combinations NNS N
studied VBN N
is VBZ N
needed VBN N
. . N

-DOCSTART- -X- O O 22265360

Effects NNS N
of IN N
risperidone NN N
and CC N
parent NN N
training NN N
on IN N
adaptive JJ N
functioning NN N
in IN N
children NNS 4_p
with IN 4_p
pervasive JJ 4_p
developmental NN 4_p
disorders NNS 4_p
and CC 4_p
serious JJ 4_p
behavioral JJ 4_p
problems NNS 4_p
. . 4_p

OBJECTIVE NNP N
Children NNP N
with IN N
Pervasive NNP N
Developmental NNP N
Disorders NNP N
( ( N
PDDs NNP N
) ) N
have VBP N
social JJ N
interaction NN N
deficits NNS N
, , N
delayed VBN N
communication NN N
, , N
and CC N
repetitive JJ N
behaviors NNS N
as RB N
well RB N
as IN N
impairments NNS N
in IN N
adaptive JJ N
functioning NN N
. . N

Many JJ N
children NNS N
actually RB N
show VBP N
a DT N
decline NN N
in IN N
adaptive JJ N
skills NNS N
compared VBN N
with IN N
age NN N
mates NNS N
over IN N
time NN N
. . N

METHOD VB N
This DT N
24-week JJ N
, , N
three-site JJ N
, , N
controlled VBD N
clinical JJ N
trial NN N
randomized VBD N
124 CD N
children NNS N
( ( N
4 CD N
through IN N
13 CD N
years NNS N
of IN N
age NN N
) ) N
with IN N
PDDs NNP N
and CC N
serious JJ N
behavioral JJ N
problems NNS N
to TO N
medication VB N
alone RB N
( ( N
MED NNP N
; : N
n CC N
= $ N
49 CD N
; : N
risperidone NN N
0.5 CD N
to TO N
3.5 CD N
mg/day NN N
; : N
if IN N
ineffective JJ N
, , N
switch VB N
to TO N
aripiprazole VB N
was VBD N
permitted VBN N
) ) N
or CC N
a DT N
combination NN N
of IN N
medication NN N
plus CC N
parent NN N
training NN N
( ( N
PT NNP N
) ) N
( ( N
COMB NNP N
; : N
n CC N
= VB N
75 CD N
) ) N
. . N

Parents NNS N
of IN N
children NNS N
in IN N
COMB NNP N
received VBD N
an DT N
average NN N
of IN N
11.4 CD N
PT NNP N
sessions NNS N
. . N

Standard NNP N
scores NNS N
and CC N
Age-Equivalent JJ N
scores NNS N
on IN N
Vineland NNP N
Adaptive NNP N
Behavior NNP N
Scales NNP N
were VBD N
the DT N
outcome NN N
measures NNS N
of IN N
primary JJ N
interest NN N
. . N

RESULTS NNP N
Seventeen JJ N
subjects NNS N
did VBD N
not RB N
have VB N
a DT N
post-randomization NN N
Vineland NNP N
assessment NN N
. . N

Thus RB N
, , N
we PRP N
used VBD N
a DT N
mixed JJ N
model NN N
with IN N
outcome NN N
conditioned VBN N
on IN N
the DT N
baseline NN N
Vineland NNP N
scores VBZ N
. . N

Both DT N
groups NNS N
showed VBD N
improvement NN N
over IN N
the DT N
24-week JJ N
trial NN N
on IN N
all DT N
Vineland NNP N
domains NNS N
. . N

Compared VBN N
with IN N
MED NNP N
, , N
Vineland NNP N
Socialization NNP N
and CC N
Adaptive NNP N
Composite NNP N
Standard NNP N
scores VBZ N
showed VBD N
greater JJR N
improvement NN N
in IN N
the DT N
COMB NNP N
group NN N
( ( N
p JJ N
= NNP N
.01 NNP N
and CC N
.05 NNP N
, , N
and CC N
effect NN N
sizes NNS N
= VBP N
0.35 CD N
and CC N
0.22 CD N
, , N
respectively RB N
) ) N
. . N

On IN N
Age NNP N
Equivalent NNP N
scores NNS N
, , N
Socialization NNP N
and CC N
Communication NNP N
domains NNS N
showed VBD N
greater JJR N
improvement NN N
in IN N
COMB NNP N
versus NN N
MED NNP N
( ( N
p JJ N
= NNP N
.03 NNP N
and CC N
0.05 CD N
, , N
and CC N
effect NN N
sizes NNS N
= VBP N
0.33 CD N
and CC N
0.14 CD N
, , N
respectively RB N
) ) N
. . N

Using VBG N
logistic JJ N
regression NN N
, , N
children NNS N
in IN N
the DT N
COMB NNP N
group NN N
were VBD N
twice RB N
as RB N
likely JJ N
to TO N
make VB N
at IN N
least JJS N
6 CD N
months NNS N
' POS N
gain NN N
( ( N
equal JJ N
to TO N
the DT N
passage NN N
of IN N
time NN N
) ) N
in IN N
the DT N
Vineland NNP N
Communication NNP N
Age NNP N
Equivalent NNP N
score NN N
compared VBN N
with IN N
MED NNP N
( ( N
p JJ N
= NNP N
.02 NNP N
) ) N
. . N

After IN N
controlling VBG N
for IN N
IQ NNP N
, , N
this DT N
difference NN N
was VBD N
no RB N
longer RBR N
significant JJ N
. . N

CONCLUSION NNP N
Reduction NNP N
of IN N
serious JJ N
maladaptive JJ N
behavior NN N
promotes NNS N
improvement NN N
in IN N
adaptive JJ N
behavior NN N
. . N

Medication NNP N
plus CC N
PT NNP N
shows VBZ N
modest JJ N
additional JJ N
benefit NN N
over IN N
medication NN N
alone RB N
. . N

Clinical JJ N
trial NN N
registration NN N
information-RUPP JJ N
PI NNP N
PDD NNP N
: : N
Drug NN N
and CC N
Behavioral NNP N
Therapy NNP N
for IN N
Children NNP N
With IN N
Pervasive NNP N
Developmental NNP N
Disorders NNP N
; : N
http NN N
: : N
//www.clinicaltrials.gov NN N
; : N
NCT00080145 NNP N
. . N

-DOCSTART- -X- O O 24930179

The DT N
effects NNS N
of IN N
prism NN N
adaptation NN N
on IN N
egocentric JJ N
metric JJ N
distance NN N
estimation NN N
. . N

OBJECTIVE CC N
The DT N
present JJ N
experiment NN N
evaluated VBD N
whether IN N
training VBG N
involving VBG N
throwing VBG N
transferred VBN N
to TO N
metric JJ N
distance NN N
estimation NN N
( ( N
i.e. FW N
, , N
describing VBG N
in IN N
feet NNS N
and CC N
inches VBZ N
the DT N
distance NN N
between IN N
oneself NN N
and CC N
targets NNS N
) ) N
. . N

BACKGROUND NNP N
In IN N
prior JJ N
work NN N
, , N
we PRP N
found VBD N
that IN N
metric JJ N
estimation NN N
training NN N
negatively RB N
transferred VBN N
to TO N
throwing VBG N
. . N

We PRP N
explained VBD N
our PRP$ N
results NNS N
in IN N
terms NNS N
of IN N
cognitive JJ N
intrusion NN N
. . N

The DT N
present JJ N
study NN N
tested VBD N
that IN N
possibility NN N
by IN N
swapping VBG N
our PRP$ N
training NN N
and CC N
transfer NN N
tasks NNS N
. . N

METHOD NNP N
During IN N
pretesting VBG N
, , N
participants NNS 4_p
verbally RB 4_p
estimated VBD 4_p
the DT 4_p
metric JJ 4_p
distances NNS 4_p
between IN 4_p
themselves PRP 4_p
and CC 4_p
targets NNS 4_p
, , 4_p
or CC 4_p
they PRP 4_p
threw VBD 4_p
a DT 4_p
beanbag NN 4_p
to TO 4_p
targets NNS 4_p
. . N

During IN N
training NN N
, , N
participants NNS N
donned VBD N
goggles NNS N
that WDT N
distorted VBD N
their PRP$ N
vision NN N
. . N

While IN N
wearing VBG N
the DT N
goggles NNS N
, , N
they PRP N
threw VBD N
a DT N
beanbag NN N
to TO N
targets NNS N
. . N

Half NNP N
received VBD N
feedback RB N
. . N

During IN N
posttesting VBG N
, , N
participants NNS N
removed VBD N
the DT N
distorting NN N
goggles NNS N
and CC N
completed VBD N
the DT N
same JJ N
task NN N
that IN N
they PRP N
performed VBD N
during IN N
pretesting VBG N
. . N

RESULTS VB N
The DT N
results NNS N
indicated VBD N
that IN N
the DT N
distorting NN N
goggles NNS N
degraded VBD N
throwing VBG N
at IN N
the DT N
beginning NN N
of IN N
training NN N
, , N
visual JJ N
feedback NN N
improved VBD N
throwing VBG N
during IN N
training NN N
, , N
the DT N
effects NNS N
of IN N
training VBG N
with IN N
feedback NN N
persisted VBN N
into IN N
the DT N
throwing VBG N
posttest NN N
, , N
and CC N
the DT N
effects NNS N
of IN N
training VBG N
with IN N
feedback NN N
did VBD N
not RB N
transfer VB N
to TO N
the DT N
verbal JJ N
metric JJ N
estimation NN N
posttest NN N
. . N

CONCLUSION NNP N
Training VBG N
involving VBG N
throwing NN N
was VBD N
effective JJ N
, , N
but CC N
did VBD N
not RB N
transfer VB N
to TO N
verbal VB N
metric JJ N
distance NN N
estimation NN N
. . N

This DT N
supports VBZ N
our PRP$ N
argument NN N
that IN N
the DT N
negative JJ N
transfer NN N
observed VBN N
in IN N
our PRP$ N
previous JJ N
study NN N
stemmed VBD N
from IN N
cognitive JJ N
intrusion NN N
. . N

APPLICATION VB N
The DT N
present JJ N
experiment NN N
suggests VBZ N
that IN N
the DT N
creation NN N
of IN N
distance NN N
estimation NN N
training NN N
should MD N
begin VB N
with IN N
a DT N
careful JJ N
analysis NN N
of IN N
the DT N
transfer NN N
task NN N
, , N
and CC N
that DT N
distance NN N
estimation NN N
training NN N
programs NNS N
should MD N
explicitly RB N
teach VB N
trainees NNS 4_p
that IN 4_p
their PRP$ 4_p
training NN 4_p
will MD N
not RB N
generalize VB N
to TO N
all DT N
distance NN N
estimation NN N
tasks NNS N
. . N

-DOCSTART- -X- O O 2936772

Comparative JJ N
efficacy NN N
of IN N
oral JJ N
erythromycin FW N
versus FW N
oral JJ N
tetracycline NN N
in IN N
the DT N
treatment NN N
of IN N
acne JJ N
vulgaris NN N
. . N

A DT N
double-blind JJ N
study NN N
. . N

The DT N
efficacy NN N
of IN N
erythromycin JJ N
base NN N
( ( N
E-Mycin JJ N
tablets NNS N
, , N
333 CD N
mg NN N
) ) N
and CC N
the DT N
efficacy NN N
of IN N
tetracycline JJ N
hydrochloride NN N
( ( N
Panmycin NNP N
tablets NNS N
) ) N
were VBD N
compared VBN N
in IN N
this DT N
double-blind NN N
, , N
randomized VBN N
study NN N
. . N

Two CD N
hundred VBD N
patients NNS N
with IN N
moderate JJ 4_p
to TO 4_p
moderately RB 4_p
severe JJ 4_p
acne NNS 4_p
vulgaris NNS 4_p
were VBD N
randomly RB N
assigned VBN N
to TO N
the DT N
study NN N
. . N

One CD N
hundred VBD N
patients NNS N
received VBD N
1 CD N
gm NN N
of IN N
erythromycin JJ N
base NN N
by IN N
mouth JJ N
per IN N
day NN N
for IN N
4 CD N
weeks NNS N
, , N
followed VBN N
by IN N
333 CD N
mg/day NN N
for IN N
8 CD N
weeks NNS N
, , N
plus CC N
placebo NN N
for IN N
tetracycline NN N
. . N

The DT N
second JJ N
group NN N
of IN N
patients NNS N
received VBD N
1 CD N
gm NN N
of IN N
tetracycline NN N
by IN N
mouth JJ N
per IN N
day NN N
for IN N
4 CD N
weeks NNS N
, , N
followed VBN N
by IN N
500 CD N
mg/day NN N
for IN N
8 CD N
weeks NNS N
, , N
plus CC N
placebo NN N
for IN N
erythromycin NN N
. . N

Both DT N
drugs NNS N
reduced VBD N
acne JJ N
severity NN N
to TO N
the DT N
same JJ N
extent NN N
. . N

Pustules NNP N
, , N
papules NNS N
, , N
and CC N
open JJ N
comedo NN N
counts NNS N
decreased VBN N
significantly RB N
over IN N
the DT N
12-week JJ N
period NN N
. . N

Seventy-seven JJ N
percent NN N
of IN N
the DT N
erythromycin-treated JJ N
patients NNS N
and CC N
89 CD N
% NN N
of IN N
the DT N
tetracycline-treated JJ N
patients NNS N
stated VBD N
that IN N
their PRP$ N
acne NN N
was VBD N
markedly RB N
improved VBN N
or CC N
improved VBN N
by IN N
week NN N
12 CD N
. . N

Most JJS N
of IN N
the DT N
side NN N
effects NNS N
in IN N
patients NNS N
treated VBN N
with IN N
erythromycin NNS N
were VBD N
gastrointestinal JJ N
symptoms NNS N
. . N

Among IN N
the DT N
side NN N
effects NNS N
in IN N
patients NNS N
treated VBN N
with IN N
tetracycline NN N
were VBD N
Candida NNP N
vaginitis NN N
in IN N
one CD N
patient NN N
and CC N
pseudotumor NN N
cerebri NN N
in IN N
one CD N
patient NN N
. . N

-DOCSTART- -X- O O 8676619

Fludarabine NN N
in IN N
chronic JJ 4_p
leukaemia NN 4_p
. . 4_p

-DOCSTART- -X- O O 3131904

[ JJ N
Supplementary NNP N
treatment NN N
with IN N
Esberitox NNP N
of IN N
female JJ 4_p
patients NNS 4_p
undergoing VBG 4_p
curative JJ 4_p
adjuvant JJ 4_p
irradiation NN 4_p
following VBG 4_p
breast NN 4_p
cancer NN 4_p
] NNP 4_p
. . N

1 CD N
. . N

The DT N
study NN N
was VBD N
supposed VBN N
to TO N
investigate VB N
a DT N
possible JJ N
prevention NN N
or CC N
reduction NN N
of IN N
the DT N
toxicity NN N
of IN N
radiotherapy NN N
by IN N
an DT N
additional JJ N
treatment NN N
with IN N
Esberitox NNP N
. . N

This DT N
question NN N
arose VBD N
when WRB N
performing VBG N
an DT N
investigation NN N
about IN N
the DT N
effect NN N
of IN N
Esberitox NNP N
in IN N
a DT N
combined JJ N
chemo-radiotherapy NN N
. . N

Whereas IN N
the DT N
latter JJ N
induces NNS N
above IN N
all PDT N
a DT N
systemic JJ N
damage NN N
to TO N
the DT N
hemopoietic JJ N
system NN N
, , N
radiotherapy NN N
is VBZ N
a DT N
regional JJ N
noxa NN N
. . N

2 CD N
. . N

The DT N
present JJ N
prospective JJ N
, , N
randomized VBD N
study NN N
was VBD N
conducted VBN N
with IN N
50 CD N
patients NNS N
submitted VBN N
to TO N
curative VB N
adjuvant JJ N
irradiation NN N
following VBG N
surgery NN N
for IN N
mammary JJ N
carcinoma NN N
. . N

The DT N
radiotherapy NN N
was VBD N
performed VBN N
in IN N
the DT N
same JJ N
way NN N
in IN N
all DT N
patients NNS N
with IN N
irradiations NNS N
of IN N
the DT N
thoracic NN N
wall NN N
and CC N
the DT N
regional JJ N
lymph NN N
nodes NNS N
. . N

Two CD N
groups NNS N
were VBD N
built VBN N
by IN N
randomization NN N
. . N

The DT N
study NN N
group NN N
received VBD N
an DT N
additional JJ N
treatment NN N
with IN N
Esberitox NNP N
, , N
the DT N
control NN N
group NN N
did VBD N
not RB N
receive VB N
an DT N
additional JJ N
treatment NN N
. . N

3 CD N
. . N

As IN N
a DT N
result NN N
, , N
no DT N
protective JJ N
influence NN N
of IN N
Esberitox NNP N
could MD N
be VB N
demonstrated VBN N
. . N

The DT N
parameters NNS N
investigated VBN N
were VBD N
the DT N
peripheral JJ N
blood NN N
count NN N
( ( N
leucocytes NNS N
, , N
granulocytes NNS N
, , N
lymphocytes NNS N
, , N
monocytes NNS N
, , N
thrombocytes NNS N
, , N
hemoglobin NN N
, , N
hematocrit NN N
) ) N
and CC N
the DT N
incidence NN N
of IN N
infections NNS N
. . N

4 CD N
. . N

This DT N
result NN N
diverging VBG N
from IN N
literature NN N
is VBZ N
discussed VBN N
. . N

It PRP N
is VBZ N
probably RB N
affected VBN N
by IN N
volume NN N
and CC N
extension NN N
of IN N
the DT N
injury NN N
induced VBN N
by IN N
a DT N
hematotoxic NN N
noxa NN N
and CC N
furthermore NN N
by IN N
the DT N
ability NN N
of IN N
regeneration NN N
. . N

If IN N
this DT N
ability NN N
is VBZ N
exhausted VBN N
, , N
the DT N
protective JJ N
effect NN N
of IN N
Esberitox NNP N
can MD N
act VB N
no DT N
longer JJR N
. . N

Therefore VB N
the DT N
essential JJ N
factor NN N
seems VBZ N
to TO N
be VB N
the DT N
duration NN N
of IN N
exposure NN N
to TO N
the DT N
noxa NN N
. . N

Esberitox NNP N
was VBD N
effective JJ N
in IN N
case NN N
of IN N
a DT N
short JJ N
toxicity NN N
, , N
it PRP N
was VBD N
ineffective JJ N
in IN N
case NN N
of IN N
prolonged JJ N
toxicity NN N
, , N
if IN N
the DT N
treatment NN N
continuity NN N
( ( N
noxa JJ N
) ) N
was VBD N
not RB N
broken VBN N
up RP N
by IN N
some DT N
regeneration NN N
intervals NNS N
. . N

The DT N
radiotherapy NN N
studied VBN N
in IN N
this DT N
trial NN N
had VBD N
a DT N
duration NN N
of IN N
50 CD N
days NNS N
, , N
and CC N
its PRP$ N
effect NN N
was VBD N
that IN N
of IN N
a DT N
longterm JJ N
injury NN N
. . N

-DOCSTART- -X- O O 9935021

Morphological JJ N
onset NN N
and CC N
early JJ N
diagnosis NN N
in IN N
apical JJ 4_p
hypertrophic JJ 4_p
cardiomyopathy NN 4_p
: : 4_p
a DT N
long JJ N
term NN N
analysis NN N
with IN N
nuclear JJ N
magnetic JJ N
resonance NN N
imaging NN N
. . N

OBJECTIVES VB N
A DT N
long-term JJ N
follow-up NN N
study NN N
with IN N
nuclear JJ N
magnetic JJ N
resonance NN N
( ( N
NMR NNP N
) ) N
imaging NN N
was VBD N
undertaken VBN N
to TO N
detect VB N
the DT N
morphological JJ N
onset NN N
and CC N
to TO N
establish VB N
the DT N
early JJ N
diagnosis NN N
in IN N
apical JJ N
hypertrophic JJ N
cardiomyopathy NN N
( ( N
HCM NNP N
) ) N
. . N

BACKGROUND VB N
A DT N
spadelike JJ N
configuration NN N
on IN N
left JJ N
ventriculogram NN N
( ( N
LVG NNP N
) ) N
is VBZ N
regarded VBN N
as IN N
a DT N
diagnostic JJ N
criterion NN N
for IN N
the DT N
classical JJ N
apical JJ N
HCM NNP N
. . N

There EX N
also RB N
exists VBZ N
a DT N
segmented JJ N
hypertrophy NN N
at IN N
the DT N
apical JJ N
level NN N
without IN N
indicating VBG N
the DT N
spadelike NN N
features NNS N
( ( N
a DT N
nonspade NN N
configuration NN N
) ) N
. . N

To TO N
detect VB N
the DT N
hypertrophied JJ N
myocardium NN N
of IN N
the DT N
nonspade JJ N
configuration NN N
, , N
circumferential JJ N
scrutiny NN N
of IN N
the DT N
apex NN N
is VBZ N
required VBN N
. . N

Although IN N
both DT N
configurations NNS N
can MD N
be VB N
underlying JJ N
causes NNS N
of IN N
giant JJ N
negative JJ N
T NNP N
waves NNS N
, , N
etiological JJ N
relationship NN N
between IN N
the DT N
two CD N
is VBZ N
not RB N
clarified VBN N
. . N

METHODS NNP N
The DT N
criteria NN N
for IN N
the DT N
spadelike NN N
configuration NN N
defined VBN N
on IN N
left JJ N
ventricular JJ N
short-axis JJ N
NMR NNP N
images NNS N
were VBD N
as IN N
follows VBZ N
: : N
( ( N
apical JJ N
maximal NN N
thickness NN N
> NN N
or CC N
= $ N
15 CD N
mm NN N
) ) N
, , N
( ( N
apical JJ N
anterior NN N
thickness NN N
over IN N
basal JJ N
anterior JJ N
thickness NN N
> NN N
or CC N
= VB N
1.3 CD N
) ) N
and CC N
( ( N
apical JJ N
posterior NN N
thickness NN N
over IN N
basal JJ N
posterior JJ N
thickness NN N
> NN N
or CC N
=1.3 NN N
) ) N
. . N

Thirteen JJ 4_p
patients NNS 4_p
who WP 4_p
had VBD 4_p
predominant JJ 4_p
hypertrophy NN 4_p
( ( 4_p
> CD 4_p
or CC 4_p
= VB 4_p
15 CD 4_p
mm NN 4_p
) ) 4_p
at IN 4_p
the DT 4_p
apical JJ 4_p
level NN 4_p
without IN 4_p
the DT 4_p
spadelike NN 4_p
configuration NN 4_p
underwent JJ 4_p
NMR NNP 4_p
imaging VBG 4_p
twice RB 4_p
before RB 4_p
and CC 4_p
after IN 4_p
54+/-10 JJ 4_p
months NNS 4_p
' POS 4_p
follow-up NN 4_p
. . 4_p

RESULTS NNP N
Apical NNP N
hypertrophy NN N
that WDT N
had VBD N
been VBN N
confined VBN N
to TO N
the DT N
lateral JJ N
wall NN N
in IN N
four CD N
, , N
the DT N
anterior-lateral JJ N
wall NN N
in IN N
two CD N
, , N
and CC N
the DT N
septal-anterior JJ N
wall NN N
in IN N
one CD N
developed NN N
to TO N
become VB N
circumferential JJ N
hypertrophy NN N
that WDT N
fulfilled VBD N
the DT N
criteria NNS N
for IN N
the DT N
spadelike NN N
configuration NN N
after IN N
the DT N
follow-up JJ N
period NN N
. . N

CONCLUSIONS VB N
The DT N
spadelike NN N
configuration NN N
can MD N
begin VB N
with IN N
the DT N
nonspade JJ N
configuration NN N
and CC N
therefore NN N
, , N
both DT N
can MD N
constitute VB N
a DT N
single JJ N
disease NN N
entity NN N
of IN N
apical JJ N
HCM NNP N
. . N

The DT N
early JJ N
diagnosis NN N
of IN N
apical JJ N
HCM NNP N
can MD N
be VB N
achieved VBN N
by IN N
identifying VBG N
the DT N
hypertrophy NN N
frequently RB N
confined VBN N
to TO N
the DT N
lateral JJ N
wall NN N
at IN N
the DT N
apical JJ N
level NN N
. . N

-DOCSTART- -X- O O 2184179

Topical JJ N
PUVA NNP N
, , N
etretinate NN N
, , N
and CC N
combined VBN N
PUVA NNP N
and CC N
etretinate VB N
for IN N
palmoplantar JJ N
pustulosis NN N
: : N
comparison NN N
of IN N
therapeutic JJ N
efficacy NN N
and CC N
the DT N
influences NNS N
of IN N
tonsillar JJ N
and CC N
dental JJ N
focal JJ N
infections NNS N
. . N

Twenty CD N
patients NNS N
with IN N
palmoplantar JJ 4_p
pustulosis NN 4_p
( ( 4_p
PPP NNP 4_p
) ) 4_p
were VBD N
treated VBN N
with IN N
topical JJ N
PUVA NNP N
, , N
oral JJ N
etretinate NN N
( ( N
Re NNP N
) ) N
, , N
or CC N
combined VBN N
PUVA NNP N
and CC N
etretinate VB N
( ( N
Re-PUVA NNP N
) ) N
. . N

Re NNP N
and CC N
Re-PUVA NNP N
treated VBD N
sites NNS N
improved VBN N
and/or RB N
cleared VBN N
more RBR N
rapidly RB N
than IN N
PUVA NNP N
treated VBD N
sites NNS N
. . N

Complete JJ N
clearance NN N
was VBD N
observed VBN N
in IN N
six CD N
of IN N
ten NNS N
sites NNS N
treated VBD N
with IN N
Re-PUVA NNP N
, , N
two CD N
of IN N
ten NNS N
with IN N
Re NNP N
, , N
and CC N
one CD N
of IN N
ten NN N
sites NNS N
with IN N
PUVA NNP N
within IN N
12 CD N
weeks NNS N
. . N

UVA-control NNP N
sites VBZ N
failed VBD N
to TO N
be VB N
cleared VBN N
within IN N
12 CD N
weeks NNS N
. . N

Remission NNP N
periods NNS N
after IN N
stopping VBG N
the DT N
treatment NN N
were VBD N
1.5 CD N
+/- JJ N
0.5 CD N
weeks NNS N
( ( N
n JJ N
= NNP N
2 CD N
) ) N
with IN N
Re NNP N
, , N
10.5 CD N
+/- JJ N
11.4 CD N
weeks NNS N
( ( N
n JJ N
= NNP N
6 CD N
) ) N
with IN N
Re-PUVA NNP N
, , N
and CC N
one CD N
year NN N
( ( N
n JJ N
= NNP N
1 CD N
) ) N
with IN N
PUVA NNP N
. . N

These DT N
results NNS N
overall VBP N
suggested VBD N
that IN N
Re-PUVA NNP N
is VBZ N
the DT N
most RBS N
effective JJ N
treatment NN N
for IN N
PPP NNP N
. . N

Tonsillar NNP N
focal JJ N
infection NN N
( ( N
TFI NNP N
) ) N
and CC N
dental JJ N
focal JJ N
infection NN N
( ( N
DFI NNP N
) ) N
were VBD N
found VBN N
in IN N
6/20 CD N
and CC N
17/20 CD N
patients NNS N
, , N
respectively RB N
. . N

However RB N
, , N
the DT N
presence NN N
of IN N
focal JJ N
infection NN N
( ( N
FI NNP N
) ) N
, , N
TFI NNP N
and/or VBZ N
DFI NNP N
, , N
did VBD N
not RB N
appear VB N
to TO N
interfere VB N
with IN N
the DT N
therapeutic JJ N
activities NNS N
of IN N
Re NNP N
and/or NN N
PUVA NNP N
, , N
because IN N
the DT N
complete JJ N
clearance NN N
rates NNS N
and CC N
remission NN N
periods NNS N
in IN N
FI NNP N
( ( N
+ NNP N
) ) N
patients NNS N
were VBD N
comparable JJ N
with IN N
those DT N
in IN N
FI NNP N
( ( N
- : N
) ) N
patients NNS N
. . N

-DOCSTART- -X- O O 15963401

Inhibition NN N
of IN N
awake JJ N
sympathetic JJ N
nerve NN N
activity NN N
of IN N
heart NN 4_p
failure NN 4_p
patients NNS N
with IN N
obstructive JJ 4_p
sleep NN 4_p
apnea NN 4_p
by IN N
nocturnal JJ N
continuous JJ N
positive JJ N
airway NN N
pressure NN N
. . N

OBJECTIVES CC N
This DT N
study NN N
was VBD N
designed VBN N
to TO N
determine VB N
whether IN N
reductions NNS N
in IN N
morning NN N
systolic JJ N
blood NN N
pressure NN N
( ( N
BP NNP N
) ) N
elicited VBN N
by IN N
treatment NN N
of IN N
moderate JJ N
to TO N
severe VB N
obstructive JJ N
sleep JJ N
apnea NN N
( ( N
OSA NNP N
) ) N
in IN N
heart NN 4_p
failure NN 4_p
( ( 4_p
HF NNP 4_p
) ) 4_p
patients NNS N
are VBP N
associated VBN N
with IN N
a DT N
reduction NN N
in IN N
sympathetic JJ N
vasoconstrictor NN N
tone NN N
. . N

BACKGROUND NNP N
Daytime NNP N
muscle NN N
sympathetic JJ N
nerve NN N
activity NN N
( ( N
MSNA NNP N
) ) N
is VBZ N
elevated VBN N
in IN N
HF NNP 4_p
patients NNS N
with IN N
coexisting VBG 4_p
OSA NNP 4_p
. . N

In IN N
our PRP$ N
recent JJ N
randomized VBN N
trial NN N
in IN N
HF NNP N
, , N
abolition NN N
of IN N
OSA NNP N
by IN N
continuous JJ N
positive JJ N
airway NN N
pressure NN N
( ( N
CPAP NNP N
) ) N
increased VBD N
left JJ N
ventricular JJ N
ejection NN N
fraction NN N
( ( N
LVEF NNP N
) ) N
and CC N
lowered VBD N
morning NN N
systolic JJ N
BP NNP N
. . N

METHODS NNP N
Muscle NNP N
sympathetic JJ N
nerve NN N
activity NN N
, , N
BP NNP N
, , N
and CC N
heart NN N
rate NN N
( ( N
HR NNP N
) ) N
of IN N
medically RB N
treated VBN N
HF NNP 4_p
patients NNS N
( ( N
EF NNP N
< RB N
45 CD N
% NN N
) ) N
and CC N
OSA NNP 4_p
( ( N
apnea-hypopnea JJ N
index NN N
> VBD N
or CC N
=20/h CD N
of IN N
sleep NN N
) ) N
were VBD N
recorded VBN N
on IN N
the DT N
morning NN N
after IN N
overnight JJ N
polysomnography NN N
, , N
and CC N
again RB N
one CD N
month NN N
after IN N
patients NNS N
were VBD N
randomly RB N
allocated VBN N
nocturnal JJ N
CPAP NNP N
treatment NN N
or CC N
no DT N
CPAP NNP N
( ( N
control NN N
) ) N
. . N

RESULTS NNP N
In IN N
nine CD N
control NN N
patients NNS N
, , N
there EX N
were VBD N
no DT N
significant JJ N
changes NNS N
in IN N
the DT N
severity NN N
of IN N
OSA NNP N
, , N
MSNA NNP N
, , N
systolic JJ N
BP NNP N
, , N
or CC N
HR NNP N
. . N

In IN N
contrast NN N
, , N
in IN N
the DT N
8 CD N
CPAP-treated JJ N
patients NNS N
, , N
OSA NNP N
was VBD N
attenuated VBN N
, , N
and CC N
there EX N
were VBD N
significant JJ N
reductions NNS N
in IN N
daytime JJ N
MSNA NNP N
( ( N
from IN N
58 CD N
+/- JJ N
4 CD N
bursts/min NN N
to TO N
48 CD N
+/- JJ N
5 CD N
bursts/min NN N
; : N
84 CD N
+/- JJ N
4 CD N
bursts/100 JJ N
heart NN N
beats VBZ N
to TO N
72 CD N
+/- JJ N
5 CD N
bursts/100 JJ N
heart NN N
beats VBZ N
; : N
p NN N
< VBZ N
0.001 CD N
and CC N
p VB N
= JJ N
0.003 CD N
, , N
respectively RB N
) ) N
, , N
systolic JJ N
BP NNP N
( ( N
from IN N
135 CD N
+/- JJ N
5 CD N
mm NN N
Hg NNP N
to TO N
120 CD N
+/- JJ N
6 CD N
mm NN N
Hg NNP N
, , N
p NN N
= NNP N
0.03 CD N
) ) N
, , N
and CC N
HR NNP N
( ( N
from IN N
69 CD N
+/- JJ N
2 CD N
min NN N
( ( N
-1 NN N
) ) N
to TO N
66 CD N
+/- JJ N
2 CD N
min NN N
( ( N
-1 NNP N
) ) N
; : N
p CC N
= VB N
0.013 CD N
) ) N
. . N

CONCLUSIONS NNP N
Treatment NNP N
of IN N
coexisting VBG 4_p
OSA NNP 4_p
by IN N
CPAP NNP N
in IN N
HF NNP 4_p
patients NNS N
lowers NNS N
daytime JJ N
MSNA NNP N
, , N
systolic JJ N
BP NNP N
, , N
and CC N
HR NNP N
. . N

Inhibition NNP N
of IN N
increased JJ N
central JJ N
sympathetic JJ N
vasoconstrictor NN N
outflow NN N
is VBZ N
one CD N
mechanism NN N
by IN N
which WDT N
nocturnal JJ N
CPAP NNP N
reduces NNS N
awake VBP N
BP NNP N
in IN N
HF NNP 4_p
patients NNS N
with IN N
moderate JJ N
to TO N
severe VB N
OSA NNP 4_p
. . N

-DOCSTART- -X- O O 17603862

Effects NNS N
of IN N
low-level JJ N
laser NN N
and CC N
plyometric JJ N
exercises NNS N
in IN N
the DT N
treatment NN N
of IN N
lateral JJ 4_p
epicondylitis NN 4_p
. . 4_p

OBJECTIVE CC N
This DT N
study NN N
was VBD N
undertaken VBN N
to TO N
compare VB N
the DT N
effectiveness NN N
of IN N
a DT N
protocol NN N
of IN N
combination NN N
of IN N
laser NN N
with IN N
plyometric JJ N
exercises NNS N
and CC N
a DT N
protocol NN N
of IN N
placebo NN N
laser NN N
with IN N
the DT N
same JJ N
program NN N
, , N
in IN N
the DT N
treatment NN N
of IN N
tennis NN 4_p
elbow NN 4_p
. . 4_p

BACKGROUND NNP N
DATA NNP N
The DT N
use NN N
of IN N
low-level JJ N
laser NN N
has VBZ N
been VBN N
recommended VBN N
for IN N
the DT N
management NN N
of IN N
tennis NN 4_p
elbow NN 4_p
with IN N
contradictory JJ N
results NNS N
. . N

Also RB N
, , N
plyometric JJ N
exercises NNS N
was VBD N
recommended VBN N
for IN N
the DT N
treatment NN N
of IN N
the DT N
tendinopathy NN N
. . N

METHODS NNP N
Fifty NNP N
patients NNS N
who WP N
had VBD N
tennis NN N
elbow NN N
participated VBD N
in IN N
the DT N
study NN N
and CC N
were VBD N
randomised VBN N
into IN N
two CD N
groups NNS N
. . N

Group NNP N
A NNP N
( ( N
n JJ N
= NNP N
25 CD N
) ) N
was VBD N
treated VBN N
with IN N
a DT N
904 CD N
Ga-As NNP N
laser NN N
CW NNP N
, , N
frequency NN N
50 CD N
Hz NNP N
, , N
intensity NN N
40 CD N
mW NN N
and CC N
energy NN N
density NN N
2.4 CD N
J/cm NNP N
( ( N
2 CD N
) ) N
, , N
plus CC N
plyometric JJ N
exercises NNS N
and CC N
group NN N
B NNP N
( ( N
n JJ N
= NNP N
25 CD N
) ) N
that WDT N
received VBD N
placebo NNS N
laser RBR N
plus CC N
the DT N
same JJ N
plyometric JJ N
exercises NNS N
. . N

During IN N
eight CD N
weeks NNS N
of IN N
treatment NN N
, , N
the DT N
patients NNS N
of IN N
the DT N
two CD N
groups NNS N
received VBD N
12 CD N
sessions NNS N
of IN N
laser NN N
or CC N
placebo NN N
, , N
two CD N
sessions NNS N
per IN N
week NN N
( ( N
weeks NNS N
1-4 RB N
) ) N
and CC N
one CD N
session NN N
per IN N
week NN N
( ( N
weeks NNS N
5-8 RB N
) ) N
. . N

Pain NN N
at IN N
rest NN N
, , N
at IN N
palpation NN N
on IN N
the DT N
lateral JJ N
epicondyle NN N
, , N
during IN N
resisted VBN N
wrist JJ N
extension NN N
, , N
middle JJ N
finger NN N
test NN N
, , N
and CC N
strength NN N
testing NN N
was VBD N
evaluated VBN N
using VBG N
Visual NNP N
Analogue NNP N
Scales NNP N
. . N

Also RB N
it PRP N
was VBD N
evaluated VBN N
the DT N
grip NN N
strength NN N
, , N
the DT N
range NN N
of IN N
motion NN N
and CC N
weight JJ N
test NN N
. . N

Parameters NNS N
were VBD N
determined VBN N
before IN N
the DT N
treatment NN N
, , N
at IN N
the DT N
end NN N
of IN N
the DT N
eighth JJ N
week NN N
course NN N
of IN N
treatment NN N
( ( N
week NN N
8 CD N
) ) N
, , N
and CC N
eighth RB N
( ( N
week NN N
8 CD N
) ) N
after IN N
the DT N
end NN N
of IN N
treatment NN N
. . N

RESULTS NNP N
Relative NNP N
to TO N
the DT N
group NN N
B NNP N
, , N
the DT N
group NN N
A NNP N
had VBD N
( ( N
1 CD N
) ) N
a DT N
significant JJ N
decrease NN N
of IN N
pain NN N
at IN N
rest NN N
at IN N
the DT N
end NN N
of IN N
8 CD N
weeks NNS N
of IN N
the DT N
treatment NN N
( ( N
p JJ N
< NNP N
0.005 CD N
) ) N
and CC N
at IN N
the DT N
end NN N
of IN N
following VBG N
up RP N
period NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
, , N
( ( N
2 CD N
) ) N
a DT N
significant JJ N
decrease NN N
in IN N
pain NN N
at IN N
palpation NN N
and CC N
pain NN N
on IN N
isometric JJ N
testing VBG N
at IN N
8 CD N
weeks NNS N
of IN N
treatment NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
, , N
and CC N
at IN N
8 CD N
weeks NNS N
follow-up JJ N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
, , N
( ( N
3 CD N
) ) N
a DT N
significant JJ N
decrease NN N
in IN N
pain NN N
during IN N
middle JJ N
finger NN N
test NN N
at IN N
the DT N
end NN N
of IN N
8 CD N
weeks NNS N
of IN N
treatment NN N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
, , N
and CC N
at IN N
the DT N
end NN N
of IN N
the DT N
follow-up JJ N
period NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
, , N
( ( N
4 CD N
) ) N
a DT N
significant JJ N
decrease NN N
of IN N
pain NN N
during IN N
grip NN N
strength NN N
testing VBG N
at IN N
8 CD N
weeks NNS N
of IN N
treatment NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
, , N
and CC N
at IN N
8 CD N
weeks NNS N
follow-up JJ N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
, , N
( ( N
5 CD N
) ) N
a DT N
significant JJ N
increase NN N
in IN N
the DT N
wrist NN N
range NN N
of IN N
motion NN N
at IN N
8 CD N
weeks NNS N
follow-up JJ N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
, , N
( ( N
6 CD N
) ) N
an DT N
increase NN N
in IN N
grip JJ N
strength NN N
at IN N
8 CD N
weeks NNS N
of IN N
treatment NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
and CC N
at IN N
8 CD N
weeks NNS N
follow-up JJ N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
, , N
and CC N
( ( N
7 CD N
) ) N
a DT N
significant JJ N
increase NN N
in IN N
weight-test JJ N
at IN N
8 CD N
weeks NNS N
of IN N
treatment NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
and CC N
at IN N
8 CD N
weeks NNS N
follow-up JJ N
( ( N
p JJ N
< NNP N
0.005 CD N
) ) N
. . N

CONCLUSION VB N
The DT N
results NNS N
suggested VBD N
that IN N
the DT N
combination NN N
of IN N
laser NN N
with IN N
plyometric JJ N
exercises NNS N
was VBD N
more RBR N
effective JJ N
treatment NN N
than IN N
placebo FW N
laser NN N
with IN N
the DT N
same JJ N
plyometric JJ N
exercises NNS N
at IN N
the DT N
end NN N
of IN N
the DT N
treatment NN N
as RB N
well RB N
as IN N
at IN N
the DT N
follow-up NN N
. . N

Future JJ N
studies NNS N
are VBP N
needed VBN N
to TO N
establish VB N
the DT N
relative JJ N
and CC N
absolute JJ N
effectiveness NN N
of IN N
the DT N
above JJ N
protocol NN N
. . N

-DOCSTART- -X- O O 11931782

Safety NN N
of IN N
intravitreous JJ N
fomivirsen NN N
for IN N
treatment NN N
of IN N
cytomegalovirus NN 4_p
retinitis NN 4_p
in IN 4_p
patients NNS 4_p
with IN 4_p
AIDS NNP 4_p
. . 4_p

PURPOSE NNP N
To TO N
report VB N
data NNS N
regarding VBG N
the DT N
safety NN N
of IN N
intravitreous JJ N
fomivirsen NN N
for IN N
treatment NN N
of IN N
cytomegalovirus NN N
( ( N
CMV NNP N
) ) N
retinitis NN N
in IN N
patients NNS N
with IN N
acquired JJ N
immunodeficiency NN N
syndrome NN N
( ( N
AIDS NNP N
) ) N
. . N

DESIGN NNP N
Critical NNP N
review NN N
of IN N
safety NN N
data NNS N
from IN N
three CD N
randomized NNS N
controlled VBD N
clinical JJ N
trials NNS N
with IN N
supplemental JJ N
information NN N
from IN N
an DT N
expanded VBN N
drug NN N
access NN N
program NN N
. . N

METHODS NNP N
Adverse NNP N
ocular JJ N
events NNS N
reported VBN N
by IN N
clinician JJ N
investigators NNS N
were VBD N
listed VBN N
using VBG N
terms NNS N
modified VBN N
from IN N
the DT N
COSTART NNP N
dictionary NN N
. . N

Data NNP N
for IN N
two CD N
doses NNS N
( ( N
165-microg/injection JJ N
[ NN N
35 CD N
eyes NNS N
, , N
30 CD N
patients NNS N
] JJ N
and CC N
330-microg/injection JJ N
[ NN N
153 CD N
eyes NNS N
, , N
120 CD N
patients NNS N
] JJ N
) ) N
and CC N
two CD N
330-microg/injection JJ N
dose JJ N
schedules NNS N
of IN N
different JJ N
intensity NN N
were VBD N
pooled VBN N
to TO N
calculate VB N
incidence NN N
rates NNS N
for IN N
each DT N
event NN N
. . N

Rates NNS N
were VBD N
calculated VBN N
as IN N
" JJ N
events/patient-year JJ N
" NN N
( ( N
based VBN N
on IN N
total JJ N
cumulative JJ N
reported VBD N
events NNS N
and CC N
duration NN N
of IN N
treatment NN N
) ) N
for IN N
events NNS N
that WDT N
could MD N
recur VB N
during IN N
treatment NN N
. . N

Rates NNS N
were VBD N
calculated VBN N
as IN N
" JJ N
patients NNS N
with IN N
events/person-year JJ N
" NN N
for IN N
the DT N
following JJ N
events NNS N
: : N
retinal JJ N
detachment NN N
, , N
cataract NN N
, , N
visual JJ N
field NN N
disturbance NN N
, , N
and CC N
retinal JJ N
pigment NN N
epitheliopathy NN N
. . N

To TO N
assess VB N
the DT N
ability NN N
to TO N
manage VB N
events NNS N
, , N
we PRP N
reviewed VBD N
treatments NNS N
given VBN N
for IN N
two CD N
events NNS N
( ( N
anterior JJ N
chamber NN N
inflammation NN N
, , N
increased VBD N
intraocular JJ N
pressure NN N
) ) N
in IN N
one CD N
trial NN N
. . N

We PRP N
also RB N
report VBP N
an DT N
analysis NN N
comparing VBG N
the DT N
proportion NN N
of IN N
eyes NNS N
that WDT N
developed VBD N
one CD N
or CC N
more JJR N
key JJ N
events NNS N
to TO N
the DT N
cumulative JJ N
number NN N
of IN N
injections NNS N
. . N

RESULTS JJ N
Incidence NN N
rates NNS N
were VBD N
dose JJ N
and CC N
schedule JJ N
dependent NN N
( ( N
165 CD N
microg/injection NN N
, , N
4.06 CD N
events/patient-year JJ N
; : N
330 CD N
microg/injection NN N
, , N
6.58 CD N
events/patient-year JJ N
[ NNP N
less JJR N
intense JJ N
regimen NNS N
] VBP N
and CC N
8.35 CD N
events/patient-year JJ N
[ NNP N
more JJR N
intense JJ N
regimen NNS N
] VBP N
) ) N
. . N

The DT N
most RBS N
frequently RB N
reported VBN N
events NNS N
were VBD N
anterior JJ N
chamber NN N
inflammation NN N
and CC N
increased VBD N
intraocular JJ N
pressure NN N
. . N

We PRP N
found VBD N
no DT N
evidence NN N
that IN N
the DT N
proportion NN N
of IN N
patients NNS N
with IN N
events NNS N
increased VBN N
as IN N
the DT N
number NN N
of IN N
injections NNS N
increased VBN N
. . N

CONCLUSIONS NNP N
Intravitreous NNP N
fomivirsen NN N
is VBZ N
well RB N
tolerated VBN N
with IN N
an DT N
acceptable JJ N
safety NN N
profile NN N
. . N

Adverse JJ N
ocular JJ N
events NNS N
associated VBN N
with IN N
doses NNS N
and CC N
schedules NNS N
used VBN N
clinically RB N
can MD N
be VB N
managed VBN N
successfully RB N
with IN N
medical JJ N
therapy NN N
. . N

-DOCSTART- -X- O O 10089089

Piperacillin/tazobactam NNP N
plus CC N
tobramycin JJ N
versus NN N
ceftazidime NN N
plus CC N
tobramycin NN N
as IN N
empiric JJ N
therapy NN N
for IN N
fever NN N
in IN N
severely RB N
neutropenic JJ N
patients NNS N
. . N

The DT N
objective NN N
of IN N
this DT N
trial NN N
was VBD N
to TO N
evaluate VB N
the DT N
potential JJ N
advantages NNS N
of IN N
the DT N
combination NN N
of IN N
piperacillin NN N
and CC N
tazobactam NN N
in IN N
the DT N
control NN N
of IN N
fever NN 4_p
in IN 4_p
neutropenic JJ 4_p
patients NNS 4_p
. . 4_p

In IN N
this DT N
single-center NN N
study NN N
, , N
patients NNS N
who WP N
experienced VBD N
a DT N
total NN N
of IN N
247 CD N
febrile JJ N
episodes NNS N
were VBD N
prospectively RB N
randomized VBN N
to TO N
receive VB N
either RB N
our PRP$ N
standard JJ N
regimen NNS N
, , N
ceftazidime RB N
3 CD N
g/day NN N
( ( N
1 CD N
g NN N
t.i.d NN N
. . N

) ) N
plus CC N
tobramycin $ N
3 CD N
mg/kg JJ N
per IN N
day NN N
( ( N
1.5 CD N
mg/kg NN N
b.i.d NN N
. . N

) ) N
, , N
or CC N
piperacillin VB N
12 CD N
g/day JJ N
plus CC N
tazobactam JJ N
1.5 CD N
g/day NN N
( ( N
4 CD N
g+0.5 NN N
g NN N
t.i.d NN N
. . N

) ) N
plus CC N
tobramycin $ N
3 CD N
mg/kg JJ N
per IN N
day NN N
( ( N
1.5 CD N
mg/kg RB N
b.i.d. NN N
) ) N
. . N

Vancomycin NNP N
was VBD N
added VBN N
in IN N
all DT N
cases NNS N
of IN N
persistent JJ N
fever NN N
in IN N
the DT N
ceftazidime NN N
arm NN N
, , N
but CC N
only RB N
when WRB N
there EX N
was VBD N
microbiologically RB N
documented VBN N
resistance NN N
in IN N
the DT N
piperacillin/tazobactam NN N
arm NN N
. . N

All DT N
247 CD N
episodes NNS N
were VBD N
evaluable JJ N
by IN N
" JJ N
intent-to-treat JJ N
" NN N
analysis NN N
. . N

The DT N
two CD N
populations NNS N
were VBD N
well RB N
matched VBN N
in IN N
terms NNS N
of IN N
age NN N
, , N
gender NN N
, , N
underlying VBG N
disease NN N
, , N
chemotherapy NN N
received VBD N
, , N
oral JJ N
decontamination NN N
, , N
clinical JJ N
and CC N
bacterial JJ N
documentation NN N
, , N
and CC N
severity NN N
and CC N
duration NN N
of IN N
neutropenia NN N
. . N

Initial JJ N
antibacterial JJ N
therapy NN N
was VBD N
successful JJ N
( ( N
apyrexia NN N
at IN N
72 CD N
h NN N
, , N
without IN N
antibiotic JJ N
change NN N
) ) N
more RBR N
frequently RB N
( ( N
P NNP N
= NNP N
0.008 CD N
) ) N
with IN N
the DT N
regimen NNS N
containing VBG N
piperacillin/tazobactam NN N
( ( N
54.4 CD N
% NN N
) ) N
than IN N
with IN N
the DT N
one CD N
including VBG N
ceftazidime NN N
( ( N
37.6 CD N
% NN N
) ) N
. . N

Fewer JJR N
( ( N
P NNP N
= NNP N
0.02 CD N
) ) N
major JJ N
infectious JJ N
events NNS N
( ( N
infectious JJ N
death NN N
or CC N
delay NN N
in IN N
treatment NN N
of IN N
underlying JJ N
disease NN N
due JJ N
to TO N
infection NN N
) ) N
were VBD N
observed VBN N
during IN N
piperacillin/ JJ N
tazobactam JJ N
treatment NN N
( ( N
2.6 CD N
% NN N
) ) N
than IN N
with IN N
the DT N
ceftazidime NN N
regimen NNS N
( ( N
11.3 CD N
% NN N
) ) N
, , N
despite IN N
a DT N
lower JJR N
frequency NN N
of IN N
glycopeptide JJ N
addition NN N
when WRB N
piperacillin/tazobactam NN N
was VBD N
used VBN N
( ( N
54.4 CD N
% NN N
versus IN N
77.4 CD N
% NN N
) ) N
according VBG N
to TO N
the DT N
rules NNS N
adopted VBN N
. . N

This DT N
trial NN N
confirmed VBD N
the DT N
efficacy NN N
of IN N
the DT N
piperacillin/tazobactam NN N
combination NN N
for IN N
empirical JJ N
treatment NN N
of IN N
febrile JJ N
neutropenic JJ N
patients NNS N
. . N

This DT N
antibiotic JJ N
combination NN N
permitted VBD N
a DT N
dramatic JJ N
decrease NN N
in IN N
empiric JJ N
glycopeptide NN N
antibiotic JJ N
administration NN N
in IN N
such JJ N
patients NNS N
. . N

-DOCSTART- -X- O O 16571852

Web-based JJ N
weight NN N
management NN N
programs NNS N
in IN N
an DT N
integrated JJ N
health NN N
care NN N
setting NN N
: : N
a DT N
randomized NN N
, , N
controlled VBN N
trial NN N
. . N

OBJECTIVE UH N
To TO N
assess VB N
the DT N
efficacy NN N
of IN N
a DT N
Web-based JJ N
tailored JJ N
behavioral JJ N
weight JJ N
management NN N
program NN N
compared VBN N
with IN N
Web-based JJ N
information-only JJ N
weight NN N
management NN N
materials NNS N
. . N

RESEARCH NNP N
METHODS NNP N
AND NNP N
PROCEDURES NNP N
Participants NNP N
, , N
2862 CD N
eligible JJ N
overweight NN 4_p
and CC 4_p
obese JJ 4_p
( ( 4_p
BMI NNP 4_p
= VBZ 4_p
27 CD 4_p
to TO 4_p
40 CD 4_p
kg/m2 NNS 4_p
) ) 4_p
members NNS N
from IN N
four CD N
regions NNS N
of IN N
Kaiser NNP N
Permanente NNP N
's POS N
integrated JJ N
health NN N
care NN N
delivery NN N
system NN N
, , N
were VBD N
randomized VBN N
to TO N
receive VB N
either CC N
a DT N
tailored VBN N
expert NN N
system NN N
or CC N
information-only JJ N
Web-based JJ N
weight NN N
management NN N
materials NNS N
. . N

Weight NNP N
change NN N
and CC N
program NN N
satisfaction NN N
were VBD N
assessed VBN N
by IN N
self-report NN N
through IN N
an DT N
Internet-based JJ N
survey NN N
at IN N
3- JJ N
and CC N
6-month JJ N
follow-up JJ N
periods NNS N
. . N

RESULTS NNP N
Significantly NNP N
greater JJR N
weight JJ N
loss NN N
at IN N
follow-up NN N
was VBD N
found VBN N
among IN N
participants NNS N
assigned VBN N
to TO N
the DT N
tailored VBN N
expert NN N
system NN N
than IN N
among IN N
those DT N
assigned VBN N
to TO N
the DT N
information-only JJ N
condition NN N
. . N

Subjects NNS N
in IN N
the DT N
tailored VBN N
expert NN N
system NN N
lost VBD N
a DT N
mean NN N
of IN N
3 CD N
+/- JJ N
0.3 CD N
% NN N
of IN N
their PRP$ N
baseline NN N
weight NN N
, , N
whereas JJ N
subjects NNS N
in IN N
the DT N
information-only JJ N
condition NN N
lost VBD N
a DT N
mean NN N
of IN N
1.2 CD N
+/- JJ N
0.4 CD N
% NN N
( ( N
p JJ N
< NNP N
0.0004 CD N
) ) N
. . N

Participants NNS N
were VBD N
also RB N
more RBR N
likely JJ N
to TO N
report VB N
that IN N
the DT N
tailored VBN N
expert NN N
system NN N
was VBD N
personally RB N
relevant JJ N
, , N
helpful JJ N
, , N
and CC N
easy JJ N
to TO N
understand VB N
. . N

Notably RB N
, , N
36 CD N
% NN N
of IN N
enrollees NNS N
were VBD N
African-American JJ N
, , N
with IN N
enrollment NN N
rates NNS N
higher RBR N
than IN N
the DT N
general JJ N
proportion NN N
of IN N
African JJ N
Americans NNPS N
in IN N
any DT N
of IN N
the DT N
study NN N
regions NNS N
. . N

DISCUSSION NNP N
The DT N
results NNS N
of IN N
this DT N
large JJ N
, , N
randomized VBD N
control NN N
trial NN N
show VBP N
the DT N
potential JJ N
benefit NN N
of IN N
the DT N
Web-based JJ N
tailored VBN N
expert NN N
system NN N
for IN N
weight JJ N
management NN N
compared VBN N
with IN N
a DT N
Web-based JJ N
information-only JJ N
weight JJ N
management NN N
program NN N
. . N

-DOCSTART- -X- O O 22131601

MSLT NNP N
in IN N
primary JJ N
insomnia NN N
: : N
stability NN N
and CC N
relation NN N
to TO N
nocturnal JJ N
sleep NN N
. . N

STUDY NNP N
OBJECTIVES NNP N
To TO N
assess VB N
the DT N
stability NN N
of IN N
the DT N
multiple JJ N
sleep JJ N
latency NN N
test NN N
( ( N
MSLT NNP N
) ) N
in IN N
primary JJ N
insomnia NN N
and CC N
its PRP$ N
relation NN N
to TO N
total JJ N
sleep JJ N
time NN N
. . N

DESIGN NNP N
Randomized NNP N
, , N
double-blind NN N
, , N
placebo NN N
controlled VBD N
, , N
clinical JJ N
trial NN N
. . N

SETTING NN N
Outpatient NN N
with IN N
sleep JJ N
laboratory NN N
assessments NNS N
in IN N
months NNS N
1 CD N
and CC N
8 CD N
of IN N
treatment NN N
. . N

PARTICIPANTS VB N
Ninety-five JJ N
primary JJ N
insomniacs NN 4_p
, , N
32-64 CD N
years NNS N
old JJ N
and CC N
55 CD N
age- JJ N
and CC N
sex-matched JJ N
general JJ N
population-based JJ N
, , N
representative JJ N
controls NNS N
. . N

INTERVENTIONS NNP N
After IN N
a DT N
screening JJ N
nocturnal JJ N
polysomnograms NNS N
( ( N
NPSG NNP N
) ) N
and CC N
MSLT NNP N
the DT N
following JJ N
day NN N
, , N
participants NNS N
with IN N
primary JJ 4_p
insomnia NNS 4_p
were VBD N
randomized VBN N
to TO N
take VB N
zolpidem NN N
10 CD N
mg NN N
( ( N
n JJ N
= NNP N
50 CD N
) ) N
or CC N
placebo NN N
( ( N
n JJ N
= NNP N
45 CD N
) ) N
nightly RB N
for IN N
12 CD N
months NNS N
. . N

During IN N
months NNS N
1 CD N
and CC N
8 CD N
, , N
while IN N
taking VBG N
their PRP$ N
prescribed JJ N
treatments NNS N
, , N
NPSGs NNP N
and CC N
MSLTs NNP N
the DT N
following JJ N
day NN N
were VBD N
conducted VBN N
. . N

A DT N
population-based JJ N
sample NN N
served VBD N
as IN N
controls NNS N
and CC N
received VBD N
a DT N
single JJ N
NPSG NNP N
followed VBN N
by IN N
MSLT NNP N
. . N

RESULTS NNP N
Mean NNP N
daily JJ N
sleep NN N
latency NN N
on IN N
the DT N
screening VBG N
MSLT NNP N
of IN N
insomniacs NN N
was VBD N
normally RB N
distributed VBN N
across IN N
the DT N
full JJ N
range NN N
of IN N
MSLT NNP N
scores NNS N
and CC N
significantly RB N
higher JJR N
than IN N
those DT N
of IN N
a DT N
population-based JJ N
representative NN N
control NN N
sample NN N
( ( N
P NNP N
< NNP N
0.006 CD N
) ) N
. . N

The DT N
insomniacs NN N
with IN N
the DT N
highest JJS N
screening NN N
MSLTs NNP N
had VBD N
the DT N
shortest JJS N
screening NN N
total JJ N
sleep JJ N
times NNS N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
MSLTs NNP N
of IN N
insomniacs NN N
during IN N
treatment NN N
in IN N
study JJ N
month NN N
1 CD N
were VBD N
correlated VBN N
( ( N
r VB N
= RB N
0.44 CD N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
with IN N
their PRP$ N
month NN N
8 CD N
MSLT NNP N
. . N

The DT N
mean JJ N
MSLT NNP N
score NN N
of IN N
the DT N
zolpidem NNP N
group NN N
did VBD N
not RB N
differ VB N
from IN N
that DT N
of IN N
the DT N
placebo NN N
group NN N
, , N
and CC N
the DT N
stability NN N
within IN N
treatment NN N
groups NNS N
also RB N
did VBD N
not RB N
differ VB N
. . N

CONCLUSIONS NNP N
These DT N
data NNS N
support NN N
the DT N
hypothesis NN N
that IN N
some DT N
insomniacs NN N
show VBP N
a DT N
reliable JJ N
disorder NN N
of IN N
hyperarousal NN N
with IN N
increased JJ N
wake NN N
drive NN N
both DT N
at IN N
night NN N
and CC N
during IN N
the DT N
day NN N
. . N

-DOCSTART- -X- O O 7975860

Correlation NN N
between IN N
in IN N
vivo JJ N
humoral JJ N
and CC N
in IN N
vitro JJ N
cellular JJ N
immune NN N
responses NNS N
following VBG N
immunization NN N
with IN N
hepatitis NN N
B NNP N
surface NN N
antigen NN N
( ( N
HBsAg NNP N
) ) N
vaccines NNS N
. . N

To TO N
study VB N
the DT N
regulation NN N
of IN N
the DT N
human JJ 4_p
immune NN 4_p
response NN 4_p
to TO 4_p
hepatitis VB 4_p
B NNP 4_p
surface NN 4_p
antigen NN 4_p
( ( N
HBsAg NNP N
) ) N
we PRP N
have VBP N
carefully RB N
monitored VBN N
the DT N
in IN N
vivo JJ N
humoral JJ N
and CC N
in IN N
vitro JJ N
cellular JJ N
immune NN N
responses NNS N
to TO N
HBsAg NNP N
in IN N
50 CD N
subjects NNS N
receiving VBG 4_p
four CD 4_p
doses NNS 4_p
of IN 4_p
hepatitis NN 4_p
B NNP 4_p
vaccine NN 4_p
according VBG N
to TO N
a DT N
0 CD N
, , N
1 CD N
, , N
2 CD N
, , N
12 CD N
month NN N
vaccination NN N
scheme NN N
. . N

Twenty-three JJ N
subjects NNS N
were VBD N
given VBN N
a DT N
plasma-derived JJ N
vaccine NN N
( ( N
Hevac NNP N
B NNP N
) ) N
and CC N
27 CD N
received VBD N
a DT N
recombinant JJ N
HBsAg NNP N
vaccine NN N
( ( N
yeast-derived JJ N
; : N
Engerix-B NNP N
) ) N
. . N

The DT N
humoral JJ N
and CC N
cellular JJ N
immune NN N
responses NNS N
were VBD N
measured VBN N
before IN N
vaccination NN N
( ( N
day NN N
0 CD N
) ) N
; : N
6 CD N
days NNS N
after IN N
the DT N
second JJ N
dose NN N
( ( N
day NN N
36 CD N
) ) N
; : N
6 CD N
days NNS N
( ( N
day NN N
66 CD N
) ) N
, , N
2 CD N
months NNS N
( ( N
day NN N
120 CD N
) ) N
and CC N
10 CD N
months NNS N
( ( N
day NN N
365 CD N
) ) N
after IN N
the DT N
third JJ N
dose NN N
and CC N
1 CD N
month NN N
after IN N
the DT N
fourth JJ N
dose NN N
( ( N
day NN N
395 CD N
) ) N
. . N

Based VBN N
on IN N
the DT N
kinetics NNS N
of IN N
the DT N
humoral JJ N
immune NN N
responses NNS N
, , N
the DT N
vaccinees NNS N
could MD N
be VB N
classified VBN N
into IN N
fast NN N
, , N
intermediate JJ N
and CC N
slow/non-responders NNS N
. . N

Based VBN N
on IN N
the DT N
magnitude NN N
of IN N
the DT N
immune JJ N
response NN N
( ( N
anti-HBs JJ N
titre NN N
) ) N
on IN N
day NN N
395 CD N
, , N
the DT N
vaccinees NNS N
could MD N
be VB N
divided VBN N
into IN N
high JJ N
( ( N
> FW N
or CC N
= VB N
2000 CD N
U NNP N
l-1 NN N
) ) N
and CC N
low JJ N
( ( N
< CD N
or CC N
= VB N
2000 CD N
U NNP N
l-1 NN N
) ) N
responders NNS N
. . N

A DT N
close JJ N
correlation NN N
between IN N
the DT N
kinetics NNS N
and CC N
the DT N
magnitude NN N
of IN N
the DT N
humoral JJ N
immune NN N
response NN N
was VBD N
observed VBN N
. . N

The DT N
in IN N
vivo JJ N
anti-HBs JJ N
response NN N
was VBD N
measured VBN N
using VBG N
commercially RB N
available JJ N
immunoradiometric JJ N
assays NNS N
. . N

The DT N
in IN N
vitro NN N
cellular JJ N
immune JJ N
response NN N
was VBD N
measured VBN N
using VBG N
an DT N
HBsAg-specific JJ N
lymphoproliferation NN N
assay NN N
. . N

Because IN N
of IN N
interassay JJ N
variability NN N
the DT N
results NNS N
were VBD N
considered VBN N
as IN N
dichotomous JJ N
variables NNS N
( ( N
proliferation NN N
versus IN N
non-proliferation NN N
) ) N
for IN N
further JJ N
data NNS N
analysis NN N
. . N

A DT N
statistically RB N
significant JJ N
correlation NN N
was VBD N
observed VBN N
between IN N
the DT N
kinetics NNS N
and CC N
magnitude NN N
of IN N
the DT N
humoral JJ N
immune JJ N
response NN N
on IN N
the DT N
one CD N
hand NN N
and CC N
the DT N
in IN N
vitro JJ N
anti-HBs JJ N
response NN N
on IN N
the DT N
other JJ N
hand NN N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -X- O O 4407133

Letter NN N
: : N
Cephaloridine NN N
and CC N
gentamicin NN N
in IN N
prophylaxis NN 4_p
of IN N
surgical JJ 4_p
wound NN 4_p
infection NN 4_p
. . N

-DOCSTART- -X- O O 24549163

A DT N
randomised JJ N
double-blind NN N
control NN N
study NN N
of IN N
early JJ N
intracoronary JJ N
autologous JJ N
bone NN N
marrow NN N
cell NN N
infusion NN N
in IN N
acute JJ 4_p
myocardial JJ 4_p
infarction NN 4_p
( ( N
REGENERATE-AMI NNP N
) ) N
. . N

INTRODUCTION NNP N
Acute NNP N
myocardial JJ N
infarction NN N
( ( N
AMI NNP N
) ) N
remains VBZ N
a DT N
major JJ N
cause NN N
of IN N
mortality NN N
and CC N
morbidity NN N
worldwide VBP N
despite IN N
the DT N
latest JJS N
therapeutic JJ N
advances NNS N
designed VBN N
to TO N
decrease VB N
myocardial JJ N
injury NN N
. . N

Preclinical NNP N
and CC N
emerging VBG N
clinical JJ N
evidence NN N
show NN N
that IN N
the DT N
intracoronary JJ N
injection NN N
of IN N
autologous JJ N
bone NN N
marrow NN N
mononuclear JJ N
cells NNS N
( ( N
BMCs NNP N
) ) N
following VBG N
AMI NNP N
leads VBZ N
to TO N
improvement NN N
in IN N
left JJ N
ventricular JJ N
ejection NN N
function NN N
( ( N
LVEF NNP N
) ) N
. . N

In IN N
this DT N
clinical JJ N
trial NN N
we PRP N
will MD N
for IN N
the DT N
first JJ N
time NN N
assess VB N
the DT N
effect NN N
of IN N
early JJ N
( ( N
< JJ N
24 CD N
h NN N
) ) N
infusion NN N
of IN N
autologous JJ N
BMCs NNP N
following VBG N
AMI NNP N
on IN N
cardiac JJ N
function NN N
. . N

METHODS NNP N
AND CC N
ANALYSIS NNP N
REGENERATE-AMI NNP N
is VBZ N
a DT N
double-blind JJ N
, , N
randomised VBN N
, , N
multicentre FW N
, , N
placebo-controlled JJ N
trial NN N
to TO N
determine VB N
whether IN N
early JJ N
( ( N
< JJ N
24 CD N
h NN N
) ) N
intracoronary JJ N
infusion NN N
of IN N
BMCs NNP N
improves NNS N
LVEF NNP N
after IN N
AMI NNP N
. . N

The DT N
study NN N
will MD N
enrol VB N
100 CD N
patients NNS N
presenting VBG N
with IN N
an DT N
anterior JJ N
AMI NNP 4_p
demonstrating VBG N
anterior JJ N
regional JJ N
wall NN N
motion NN N
abnormality NN N
. . N

Patients NNS N
will MD N
be VB N
randomised VBN N
to TO N
receive VB N
intracoronary JJ N
infusion NN N
of IN N
BMCs NNP N
or CC N
placebo NN N
( ( N
0.9 CD N
% NN N
saline NN N
) ) N
. . N

Primary JJ N
endpoint NN N
will MD N
be VB N
change NN N
in IN N
LVEF NNP N
at IN N
1 CD N
year NN N
compared VBN N
to TO N
baseline VB N
, , N
measured VBN N
by IN N
cardiac JJ N
MRI NNP N
. . N

Secondary JJ N
endpoints NNS N
at IN N
6 CD N
months NNS N
include VBP N
the DT N
change NN N
in IN N
global JJ N
LVEF NNP N
relative NN N
to TO N
baseline VB N
measured VBN N
by IN N
quantitative JJ N
left NN N
ventriculography NN N
and CC N
echocardiography NN N
, , N
as RB N
well RB N
as IN N
major JJ N
adverse JJ N
cardiac NN N
events NNS N
which WDT N
is VBZ N
also RB N
measured VBN N
at IN N
1 CD N
year NN N
. . N

ETHICS NNP N
AND CC N
DISSEMINATION NNP N
The DT N
study NN N
will MD N
be VB N
performed VBN N
in IN N
agreement NN N
with IN N
the DT N
Declaration NNP N
of IN N
Helsinki NNP N
and CC N
is VBZ N
approved VBN N
by IN N
local JJ N
ethics NNS N
committee NN N
( ( N
NRES NNP N
Committee NNP N
London NNP N
West NNP N
London NNP N
: : N
07/Q0603/76 CD N
) ) N
. . N

TRIAL NNP N
REGISTRATION NNP N
http NN N
: : N
//clincialtrials.gov NN N
( ( N
NCT00765453 NNP N
) ) N
. . N

The DT N
results NNS N
of IN N
the DT N
trial NN N
will MD N
be VB N
published VBN N
according VBG N
to TO N
the DT N
CONSORT NNP N
statement NN N
and CC N
will MD N
be VB N
presented VBN N
at IN N
conferences NNS N
and CC N
reported VBD N
in IN N
peer-reviewed JJ N
journals NNS N
. . N

-DOCSTART- -X- O O 16281190

Single-session JJ N
behavioral JJ N
treatment NN N
of IN N
earthquake-related JJ 4_p
posttraumatic JJ 4_p
stress NN 4_p
disorder NN 4_p
: : N
a DT N
randomized JJ N
waiting NN N
list NN N
controlled VBD N
trial NN N
. . N

In IN N
an DT N
attempt NN N
to TO N
develop VB N
a DT N
brief JJ N
treatment NN N
for IN N
disaster NN 4_p
survivors NNS 4_p
, , N
the DT N
present JJ N
study NN N
examined VBD N
the DT N
effectiveness NN N
of IN N
a DT N
single JJ N
session NN N
of IN N
modified JJ N
behavioral JJ N
treatment NN N
in IN N
earthquake-related JJ N
posttraumatic JJ N
stress NN N
disorder NN N
. . N

Fifty-nine JJ N
earthquake NN 4_p
survivors NNS 4_p
in IN N
Turkey NNP N
were VBD N
randomized VBN N
into IN N
either DT N
single-session NN N
modified VBD N
behavioral JJ N
treatment NN N
( ( N
SSBT NNP N
) ) N
designed VBN N
to TO N
enhance VB N
sense NN N
of IN N
control NN N
over IN N
earthquake-related JJ N
fears NNS N
or CC N
waiting VBG N
list NN N
control NN N
condition NN N
( ( N
WL NNP N
) ) N
. . N

The DT N
WL NNP N
group NN N
received VBD N
SSBT NNP N
after IN N
a DT N
second JJ N
baseline NN N
assessment NN N
. . N

Follow-ups NNS N
were VBD N
at IN N
weeks NNS N
6 CD N
, , N
12 CD N
, , N
24 CD N
, , N
and CC N
at IN N
1-2 JJ N
years NNS N
posttreatment NN N
. . N

Significant JJ N
treatment NN N
effects NNS N
were VBD N
found VBN N
on IN N
all DT N
measures NNS N
at IN N
posttreatment NN N
. . N

The DT N
improvement NN N
rate NN N
was VBD N
49 CD N
% NN N
at IN N
week NN N
6 CD N
; : N
it PRP N
rose VBD N
to TO N
80 CD N
% NN N
by IN N
week NN N
12 CD N
, , N
85 CD N
% NN N
by IN N
week NN N
24 CD N
, , N
and CC N
83 CD N
% NN N
by IN N
the DT N
1-2-year JJ N
follow-up NN N
. . N

Brief JJ N
behavioral JJ N
treatment NN N
has VBZ N
promise VBN N
as IN N
a DT N
cost-effective JJ N
intervention NN N
for IN N
disaster NN 4_p
survivors NNS 4_p
. . N

-DOCSTART- -X- O O 8282676

Naltrexone NN N
in IN N
autistic JJ 4_p
children NNS N
: : N
behavioral NN N
symptoms NNS N
and CC N
attentional JJ N
learning NN N
. . N

OBJECTIVE UH N
To TO N
assess VB N
critically RB N
the DT N
short-term JJ N
efficacy NN N
and CC N
safety NN N
of IN N
naltrexone NN N
in IN N
autistic JJ 4_p
children NNS N
and CC N
its PRP$ N
effects NNS N
on IN N
discrimination NN N
learning NN N
in IN N
the DT N
laboratory NN N
. . N

METHOD NNP N
A NNP N
parallel JJ N
group NN N
design NN N
was VBD N
employed VBN N
. . N

After IN N
a DT N
2-week JJ N
placebo NN N
baseline NN N
period NN N
, , N
children NNS N
were VBD N
randomly RB N
assigned VBN N
either RB N
to TO N
naltrexone CD N
or CC N
to TO N
placebo VB N
for IN N
a DT N
period NN N
of IN N
3 CD N
weeks NNS N
followed VBN N
by IN N
a DT N
one-week JJ N
posttreatment NN N
placebo NN N
period NN N
. . N

Multiple JJ N
raters NNS N
and CC N
rating NN N
scales NNS N
were VBD N
employed VBN N
in IN N
a DT N
variety NN N
of IN N
conditions NNS N
. . N

Forty-one CD N
children NNS N
, , N
all DT N
inpatients NNS 4_p
, , N
ages VBZ N
2.9 CD N
to TO N
7.8 CD N
years NNS N
, , N
completed VBD N
the DT N
study NN N
. . N

Naltrexone NNP N
reduced VBD N
hyperactivity NN N
and CC N
had VBD N
no DT N
effect NN N
on IN N
discrimination NN N
learning NN N
in IN N
the DT N
laboratory NN N
. . N

There EX N
was VBD N
a DT N
suggestion NN N
that IN N
it PRP N
had VBD N
a DT N
beneficial JJ N
effect NN N
on IN N
decreasing VBG N
self-injurious JJ N
behavior NN N
. . N

Untoward JJ N
effects NNS N
were VBD N
mild JJ N
and CC N
transient NN N
. . N

CONCLUSION NNP N
In IN N
the DT N
present JJ N
study NN N
, , N
naltrexone RB N
significantly RB N
reduced VBN N
only RB N
hyperactivity NN 4_p
, , N
and CC N
no DT N
serious JJ N
untoward JJ N
effects NNS N
were VBD N
observed VBN N
. . N

The DT N
effectiveness NN N
of IN N
naltrexone NN N
in IN N
the DT N
treatment NN N
of IN N
autism NN N
and CC N
self-injurious JJ N
behavior NN N
requires VBZ N
additional JJ N
assessment NN N
in IN N
a DT N
sample NN N
of IN N
children NNS N
with IN N
moderate JJ 4_p
to TO 4_p
severe VB 4_p
self-injurious JJ 4_p
behavior NN 4_p
. . N

-DOCSTART- -X- O O 20952020

Cardiovascular JJ N
safety NN N
of IN N
degarelix NN N
: : N
results NNS N
from IN N
a DT N
12-month JJ N
, , N
comparative JJ N
, , N
randomized VBN N
, , N
open JJ N
label NN N
, , N
parallel JJ N
group NN N
phase NN N
III NNP N
trial NN N
in IN N
patients NNS 4_p
with IN 4_p
prostate JJ 4_p
cancer NN 4_p
. . 4_p

PURPOSE NNP N
We PRP N
assessed VBD N
the DT N
cardiovascular JJ N
safety NN N
profile NN N
of IN N
degarelix NN N
, , N
a DT N
new JJ N
gonadotropin-releasing JJ N
hormone NN N
antagonist NN N
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
This DT N
is VBZ N
the DT N
first JJ N
report NN N
to TO N
our PRP$ N
knowledge NN N
on IN N
cardiovascular JJ N
safety NN N
data NNS N
from IN N
a DT N
completed VBN N
1-year JJ N
randomized NNS N
controlled VBD N
trial NN N
of IN N
leuprolide JJ N
acetate NN N
vs NN N
degarelix NN N
. . N

Outcomes CC N
considered VBN N
in IN N
these DT N
analyses NNS N
included VBD N
the DT N
QT NNP N
interval NN N
by IN N
central JJ N
reading NN N
and CC N
analysis NN N
, , N
and CC N
cardiovascular JJ N
adverse JJ N
events NNS N
. . N

On IN N
multivariate NN N
analyses NNS N
relationships VBP N
between IN N
selected VBN N
baseline NN N
factors NNS N
and CC N
cardiovascular JJ N
events NNS N
were VBD N
evaluated VBN N
. . N

RESULTS VB N
There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
treatment NN N
groups NNS N
for IN N
mean JJ N
change NN N
in IN N
Fridericia NNP N
's POS N
correction NN N
of IN N
QT NNP N
during IN N
the DT N
trial NN N
. . N

Markedly RB N
abnormal JJ N
Fridericia NNP N
's POS N
correction NN N
of IN N
QT NNP N
values NNS N
( ( N
500 CD N
milliseconds NNS N
or CC N
greater JJR N
) ) N
were VBD N
observed VBN N
in IN N
only RB N
a DT N
small JJ N
number NN N
of IN N
subjects NNS N
by IN N
treatment NN N
group NN N
, , N
that WDT N
is VBZ N
2 CD N
( ( N
less JJR N
than IN N
1 CD N
% NN N
) ) N
in IN N
the DT N
pooled JJ N
degarelix NN N
group NN N
and CC N
2 CD N
( ( N
1 CD N
% NN N
) ) N
in IN N
the DT N
leuprolide NN N
group NN N
. . N

Supraventricular JJ N
arrhythmias NN N
were VBD N
the DT N
most RBS N
common JJ N
type NN N
of IN N
arrhythmias NN N
, , N
affecting VBG N
2 CD N
% NN N
of IN N
subjects NNS N
in IN N
the DT N
pooled JJ N
degarelix NN N
group NN N
and CC N
4 CD N
% NN N
in IN N
the DT N
leuprolide NN N
group NN N
. . N

Other JJ N
arrhythmias JJ N
occurred VBN N
in IN N
1 CD N
% NN N
or CC N
less JJR N
of IN N
subjects NNS N
by IN N
treatment NN N
group NN N
. . N

The DT N
most RBS N
frequently RB N
reported VBD N
cardiac JJ N
disorder NN N
was VBD N
ischemic JJ N
heart NN N
disease NN N
, , N
which WDT N
occurred VBD N
in IN N
4 CD N
% NN N
of IN N
subjects NNS N
treated VBN N
with IN N
degarelix NN N
and CC N
10 CD N
% NN N
of IN N
those DT N
on IN N
leuprolide NN N
. . N

Cox NNP N
proportional JJ N
hazard NN N
ratio NN N
estimates NNS N
for IN N
selected VBN N
baseline NN N
covariates NNS N
showed VBD N
a DT N
significantly RB N
increased VBN N
risk NN N
of IN N
cardiovascular JJ N
events NNS N
by IN N
age NN N
( ( N
p=0.0459 NN N
) ) N
and CC N
systolic JJ N
blood NN N
pressure NN N
( ( N
p=0.0061 NN N
) ) N
. . N

CONCLUSIONS NNP N
In IN N
men NNS N
with IN N
prostate NN 4_p
cancer NN 4_p
degarelix NN N
and CC N
leuprolide NN N
have VBP N
similar JJ N
cardiovascular JJ N
safety NN N
profiles NNS N
. . N

These DT N
observations NNS N
suggest VBP N
that IN N
the DT N
cardiovascular JJ N
events NNS N
associated VBN N
with IN N
both DT N
agents NNS N
result VBP N
from IN N
hypogonadism NN N
rather RB N
than IN N
a DT N
direct JJ N
drug NN N
effect NN N
. . N

-DOCSTART- -X- O O 26173631

Eltrombopag NNP N
dose JJ N
predictors NNS N
in IN N
thrombocytopenic JJ 4_p
subjects NNS 4_p
with IN 4_p
hepatitis NN 4_p
C NNP 4_p
virus NN 4_p
infection NN 4_p
. . N

This DT N
study NN N
aims VBZ N
to TO N
identify VB N
patient JJ N
characteristics NNS N
that WDT N
predict VBP N
effective JJ N
eltrombopag NN N
dosage NN N
for IN N
the DT N
treatment NN N
of IN N
Hepatitis NNP N
C NNP N
virus NN N
( ( N
HCV NNP N
) ) N
-related VBD N
thrombocytopenia NN N
. . N

Demographic NNP N
, , N
clinical JJ N
and CC N
genetic JJ N
data NNS N
collected VBN N
from IN N
thrombocytopenic JJ 4_p
patients NNS N
( ( N
n JJ N
= NN N
1463 CD N
, , N
age NN N
≥ VBD N
18 CD N
years NNS N
) ) N
with IN N
chronic JJ N
HCV NNP 4_p
infection NN 4_p
who WP N
were VBD N
able JJ N
to TO N
achieve VB N
a DT N
target NN N
platelet NN N
count NN N
of IN N
> $ N
90 CD N
× $ N
10 CD N
( ( N
9 CD N
) ) N
/L NN N
following VBG N
eltrombopag JJ N
treatment NN N
. . N

Patients NNS N
were VBD N
categorized VBN N
into IN N
four CD N
groups NNS N
( ( N
25 CD N
, , N
50 CD N
, , N
75 CD N
, , N
and CC N
100 CD N
mg NN N
) ) N
based VBN N
on IN N
the DT N
eltrombopag NN N
dose NN N
needed VBN N
to TO N
achieve VB N
the DT N
target NN N
platelet NN N
count NN N
. . N

Eltrombopag NNP N
dose JJ N
predictors NNS N
were VBD N
identified VBN N
using VBG N
a DT N
two CD N
stage NN N
approach NN N
. . N

First NNP N
, , N
bivariate NN N
analysis NN N
, , N
using VBG N
anova NN N
for IN N
continuous JJ N
variables NNS N
and CC N
Chi-square NNP N
test NN N
for IN N
categorical JJ N
variables NNS N
, , N
was VBD N
performed VBN N
to TO N
identify VB N
possible JJ N
predictors NNS N
of IN N
eltrombopag NN N
dose NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Second JJ N
, , N
ordinal JJ N
logistic JJ N
regression NN N
with IN N
stepwise NN N
addition NN N
followed VBN N
by IN N
backward NN N
deletion NN N
was VBD N
then RB N
performed VBN N
using VBG N
predictors NNS N
identified VBN N
in IN N
bivariate NN N
analysis NN N
step NN N
to TO N
produce VB N
final JJ N
model NN N
containing VBG N
independent JJ N
predictors NNS N
at IN N
P NNP N
< NNP N
0.05 CD N
. . N

Ordinal NNP N
logistic JJ N
model NN N
identified VBD N
several JJ N
predictors NNS N
of IN N
eltrombopag NN N
dose NN N
. . N

Predictors NNS N
of IN N
higher JJR N
eltrombopag NN N
dose JJ N
include NN N
: : N
having VBG N
a DT N
HCV NNP N
genotype NN N
2 CD N
or CC N
3 CD N
, , N
being VBG N
Central/South NNP N
Asian NNP N
, , N
being VBG N
White NNP N
( ( N
Caucasian JJ N
or CC N
European JJ N
heritage NN N
) ) N
, , N
increased VBD N
weight NN N
, , N
and CC N
increased VBD N
spleen JJ N
length NN N
. . N

Predictors NNS N
of IN N
lower JJR N
eltrombopag NN N
dose JJ N
include NN N
: : N
female JJ N
gender NN N
, , N
increased VBN N
age NN N
, , N
having VBG N
a DT N
higher JJR N
ALP NNP N
plasma JJ N
concentration NN N
, , N
increased VBD N
creatinine JJ N
clearance NN N
, , N
increased VBD N
baseline NN N
lymphocytes NNS N
count NN N
, , N
and CC N
increased VBD N
baseline NN N
platelet NN N
count NN N
. . N

In IN N
conclusion NN N
, , N
this DT N
study NN N
identified VBD N
patient JJ N
characteristics NNS N
that WDT N
predict VBP N
effective JJ N
eltrombopag NN N
dose NN N
for IN N
the DT N
treatment NN N
of IN N
HCV-related NNP N
thrombocytopenia NN N
. . N

Early JJ N
selection NN N
of IN N
the DT N
optimal JJ N
eltrombopag NN N
dose NN N
expedites VBZ N
the DT N
initiation NN N
of IN N
antiviral JJ N
therapy NN N
. . N

This DT N
is VBZ N
expected VBN N
to TO N
improve VB N
the DT N
antiviral JJ N
therapy NN N
outcome NN N
before IN N
the DT N
patient NN N
progress NN N
into IN N
liver JJ N
decompensation NN N
. . N

-DOCSTART- -X- O O 9732932

Relationship NN N
between IN N
biliary NN N
and CC N
serum NN N
bile NN N
acids NNS N
and CC N
response NN N
to TO N
ursodeoxycholic JJ N
acid NN N
in IN N
patients NNS 4_p
with IN 4_p
primary JJ 4_p
biliary JJ 4_p
cirrhosis NN 4_p
. . 4_p

OBJECTIVE NNP N
Ursodeoxycholic NNP N
acid NN N
( ( N
UDCA NNP N
) ) N
improves VBZ N
liver JJ N
biochemistries NNS N
and CC N
enriches VBZ N
the DT N
bile NN N
with IN N
UDCA NNP N
in IN N
patients NNS N
with IN N
primary JJ N
biliary JJ N
cirrhosis NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
whether IN N
the DT N
degree NN N
of IN N
enrichment NN N
of IN N
bile NN N
correlated VBN N
with IN N
that DT N
of IN N
serum NN N
and CC N
whether IN N
either DT N
of IN N
these DT N
measures NNS N
correlated VBD N
with IN N
improvement NN N
in IN N
measures NNS N
of IN N
liver NN N
disease NN N
. . N

METHODS NNP N
In IN N
a DT N
randomized JJ N
study NN N
, , N
biliary JJ N
and CC N
serum JJ N
bile NN N
acid NN N
analyses NNS N
were VBD N
performed VBN N
at IN N
entry NN N
and CC N
after IN N
2 CD N
yr NN N
of IN N
UDCA NNP N
or CC N
placebo NN N
. . N

RESULTS VB N
The DT N
percentage NN N
of IN N
ursodeoxycholic JJ N
acid NN N
in IN N
bile NN N
increased VBN N
by IN N
42 CD N
% NN N
in IN N
the DT N
UDCA NNP N
group NN N
( ( N
n JJ N
= NNP N
61 CD N
) ) N
compared VBN N
with IN N
8 CD N
% NN N
in IN N
the DT N
placebo NN N
group NN N
( ( N
n JJ N
= NNP N
57 CD N
) ) N
( ( N
p JJ N
< NNP N
0.0001 CD N
) ) N
. . N

Measurement NN N
of IN N
serum NN N
bile NN N
acids NNS N
in IN N
32 CD N
patients NNS N
( ( N
18 CD N
ursodeoxycholic JJ N
acid NN N
, , N
14 CD N
placebo NN N
) ) N
indicated VBD N
that IN N
at IN N
2 CD N
yr NN N
, , N
ursodeoxycholic JJ N
acid NN N
comprised VBD N
65 CD N
% NN N
of IN N
serum NN N
bile NN N
acids NNS N
in IN N
the DT N
treated JJ N
group NN N
and CC N
7 CD N
% NN N
in IN N
the DT N
placebo NN N
group NN N
. . N

Agreement NNP N
between IN N
bile NN N
and CC N
serum NN N
was VBD N
fair JJ N
( ( N
r JJ N
= NN N
0.75 CD N
, , N
p NN N
< NN N
or CC N
= VB N
0.00002 CD N
) ) N
because IN N
in IN N
some DT N
patients NNS N
, , N
plasma NNS N
but CC N
not RB N
biliary JJ N
bile NN N
acids NNS N
were VBD N
enriched VBN N
with IN N
UDCA NNP N
. . N

Changes NNS N
in IN N
biliary JJ N
ursodeoxycholic JJ N
acid NN N
correlated VBN N
significantly RB N
but CC N
weakly RB N
with IN N
the DT N
changes NNS N
in IN N
serum NN N
alkaline NN N
phosphatase NN N
, , N
AST NNP N
, , N
bilirubin NN N
, , N
and CC N
in IN N
Mayo NNP N
risk NN N
score NN N
. . N

Correlations NNS N
between IN N
changes NNS N
in IN N
serum NN N
bile NN N
acid JJ N
composition NN N
and CC N
biochemical JJ N
measures NNS N
of IN N
disease NN N
activity NN N
were VBD N
even RB N
weaker JJR N
. . N

CONCLUSION VB N
The DT N
measurement NN N
of IN N
biliary JJ N
bile NN N
acids NNS N
is VBZ N
superior JJ N
to TO N
that DT N
of IN N
serum NN N
bile NN N
acids NNS N
for IN N
assessing VBG N
the DT N
compliance NN N
and CC N
changes NNS N
in IN N
the DT N
circulating NN N
bile JJ N
acids NNS N
in IN N
patients NNS N
receiving VBG N
ursodeoxycholic JJ N
acid NN N
for IN N
the DT N
treatment NN N
of IN N
primary JJ N
biliary JJ N
cirrhosis NN N
. . N

Furthermore NNP N
, , N
measures VBZ N
to TO N
further JJ N
increase VB N
the DT N
proportion NN N
of IN N
ursodeoxycholic JJ N
acid NN N
in IN N
circulating VBG N
bile JJ N
acids NNS N
should MD N
be VB N
explored VBN N
. . N

-DOCSTART- -X- O O 24418366

The DT N
effect NN N
of IN N
recent JJ N
bereavement NN N
on IN N
outcomes NNS N
in IN N
a DT N
primary JJ N
care NN N
depression NN N
intervention NN N
study NN N
. . N

OBJECTIVES NNP N
Although IN N
bereavement NN N
and CC N
depression NN N
are VBP N
both DT N
common JJ N
in IN N
older JJR N
primary JJ N
care NN N
patients NNS N
, , N
the DT N
effect NN N
of IN N
bereavement NN N
on IN N
depression NN N
intervention NN N
outcomes NNS N
is VBZ N
unknown JJ N
. . N

We PRP N
examined VBD N
whether IN N
standard JJ N
interventions NNS N
for IN N
depression NN N
in IN N
primary JJ N
care NN N
were VBD N
as IN N
effective JJ N
for IN N
bereaved VBN N
as IN N
for IN N
non-bereaved JJ N
depressed JJ N
patients NNS N
. . N

DESIGN NNP N
Randomized NNP N
controlled VBD N
trial NN N
. . N

SETTING NN N
Twenty CD N
community-based JJ N
primary JJ N
care NN N
practices NNS N
in IN N
New NNP N
York NNP N
City NNP N
, , N
greater JJR N
Philadelphia NNP N
, , N
and CC N
Pittsburgh NNP N
. . N

Randomization NNP N
to TO N
either DT N
intervention NN N
or CC N
usual JJ N
care NN N
occurred VBN N
by IN N
practice NN N
. . N

PARTICIPANTS CC N
Patients NNPS N
aged VBD N
60 CD N
years NNS N
or CC N
older JJR N
who WP N
met VBD N
criteria NNS N
for IN N
major JJ 4_p
depression NN 4_p
or CC N
clinically RB 4_p
significant JJ 4_p
minor JJ 4_p
depression NN 4_p
( ( N
N NNP N
= NNP N
599 CD N
) ) N
. . N

Patients NNS N
who WP N
did VBD N
not RB N
complete VB N
the DT N
bereavement JJ N
measure NN N
or CC N
who WP N
were VBD N
missing VBG N
4-month JJ N
data NNS N
were VBD N
excluded VBN N
( ( N
final JJ N
N NNP N
= NNP N
417 CD N
) ) N
. . N

INTERVENTION NNP N
Study-trained JJ N
depression NN N
care NN N
managers NNS N
offered VBD N
guideline-concordant JJ N
recommendations NNS N
to TO N
primary VB N
care NN N
physicians NNS N
at IN N
intervention NN N
sites NNS N
and CC N
assisted VBD N
patients NNS N
with IN N
treatment NN N
adherence NN N
. . N

Patients NNS 4_p
who WP 4_p
did VBD 4_p
not RB 4_p
wish VB 4_p
to TO 4_p
take VB 4_p
antidepressants NNS 4_p
could MD 4_p
receive VB 4_p
interpersonal JJ 4_p
psychotherapy NN 4_p
. . N

MEASUREMENTS NNP N
Bereavement NNP N
was VBD N
captured VBN N
using VBG N
the DT N
Louisville NNP N
Older NNP N
Persons NNP N
Events NNP N
Schedule NNP N
. . N

Depression NNP N
severity NN N
was VBD N
assessed VBN N
using VBG N
the DT N
24-item JJ N
Hamilton NNP N
Depression NNP N
Rating NNP N
Scale NNP N
( ( N
HDRS NNP N
) ) N
. . N

Outcomes CC N
at IN N
4 CD N
months NNS N
were VBD N
remission NN N
( ( N
HDRS NNP N
≤7 NNP N
) ) N
and CC N
response NN N
( ( N
HDRS NNP N
reduction NN N
≥50 CD N
% NN N
from IN N
baseline NN N
) ) N
. . N

RESULTS NNP N
Logistic JJ N
regressions NNS N
indicated VBD N
that IN N
, , N
for IN N
non-bereaved JJ N
participants NNS N
, , N
response NN N
and CC N
remission NN N
were VBD N
higher JJR N
in IN N
intervention NN N
than IN N
usual JJ N
care NN N
. . N

However RB N
, , N
recently RB N
bereaved VBD N
older JJR N
adults NNS N
were VBD N
less RBR N
likely JJ N
to TO N
achieve VB N
response NN N
or CC N
remission NN N
at IN N
4 CD N
months NNS N
if IN N
treated VBN N
in IN N
the DT N
intervention NN N
condition NN N
. . N

CONCLUSIONS NNP N
Standard NNP N
depression NN N
care NN N
management NN N
appears VBZ N
to TO N
be VB N
ineffective JJ N
among IN N
recently RB N
bereaved VBN N
older JJR N
primary JJ N
care NN N
patients NNS N
. . N

Greater NNP N
attention NN N
should MD N
be VB N
paid VBN N
in IN N
primary JJ N
care NN N
to TO N
emotional JJ N
distress NN N
in IN N
the DT N
context NN N
of IN N
bereavement NN N
. . N

-DOCSTART- -X- O O 1997878

Sinemet NNP 4_p
CR NNP 4_p
in IN 4_p
Parkinson NNP 4_p
's POS 4_p
disease NN 4_p
. . 4_p

Sinemet NNP N
CR NNP N
, , N
a DT N
controlled JJ N
release NN N
carbidopa/levodopa NN N
preparation NN N
, , N
was VBD N
compared VBN N
to TO N
conventional JJ N
carbidopa/levodopa NN N
in IN N
a DT N
double JJ N
blind NN N
, , N
placebo-controlled JJ N
trial NN N
. . N

Comparable JJ N
clinical JJ N
benefits NNS N
and CC N
adverse JJ N
effects NNS N
were VBD N
noted VBN N
with IN N
the DT N
two CD N
medications NNS N
. . N

However RB N
significantly RB N
less RBR N
frequent JJ N
dosing NN N
was VBD N
necessary JJ N
with IN N
Sinemet NNP N
CR NNP N
. . N

-DOCSTART- -X- O O 23118720

Clinical JJ N
trial NN N
: : N
marine NN N
lipid JJ N
suppositories NNS N
as IN N
laxatives NNS N
. . N

UNLABELLED JJ N
Cod-liver JJ N
oil NN N
and CC N
other JJ N
marine NN N
products NNS N
containing VBG N
polyunsaturated JJ N
fatty JJ N
acids NNS N
have VBP N
anti-inflammatory JJ N
, , N
anti-bacterial JJ N
and CC N
anti-viral JJ N
effects NNS N
and CC N
may MD N
be VB N
useful JJ N
in IN N
the DT N
treatment NN N
of IN N
various JJ N
inflammatory NN N
and CC N
infectious JJ N
diseases NNS N
. . N

We PRP N
developed VBD N
suppositories NNS N
and CC N
ointment NN N
with IN N
30 CD N
% NN N
free JJ N
fatty JJ N
acid NN N
( ( N
FFA NNP N
) ) N
extract NN N
from IN N
omega-3 JJ N
fish JJ N
oil NN N
. . N

Our PRP$ N
purpose NN N
was VBD N
to TO N
evaluate VB N
the DT N
safety NN N
of IN N
marine JJ N
lipid JJ N
suppositories NNS N
and CC N
ointment NN N
in IN N
healthy JJ 4_p
volunteers NNS 4_p
and CC N
to TO N
explore VB N
the DT N
laxative JJ N
effect NN N
of IN N
the DT N
suppositories NNS N
. . N

Thirty NNP N
healthy JJ N
volunteers NNS N
were VBD N
randomized VBN N
either RB N
to TO N
a DT N
study NN N
group NN N
administrating VBG N
30 CD N
% NN N
FFA NNP N
suppositories NNS N
and CC N
applying VBG N
30 CD N
% NN N
FFA NNP N
ointment NN N
to TO N
the DT N
perianal JJ N
region NN N
twice RB N
per IN N
day NN N
for IN N
two CD N
weeks NNS N
, , N
or CC N
to TO N
a DT N
control NN N
group NN N
using VBG N
placebo NN N
suppositories NNS N
and CC N
ointment NN N
in IN N
a DT N
double JJ N
blinded JJ N
manner NN N
. . N

RESULTS NNP N
No NNP N
serious JJ N
toxic NN N
effects NNS N
or CC N
irritation NN N
were VBD N
observed VBN N
. . N

In IN N
the DT N
study NN N
group NN N
93 CD N
% NN N
felt VBD N
the DT N
urge NN N
to TO N
defecate VB N
after IN N
administration NN N
of IN N
the DT N
suppositories NNS N
as IN N
compared VBN N
to TO N
37 CD N
% NN N
in IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
= NNP N
0.001 CD N
) ) N
. . N

Subsequently RB N
90 CD N
% NN N
in IN N
the DT N
study NN N
group NN N
defecated VBD N
, , N
compared VBN N
to TO N
33 CD N
% NN N
in IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
= NNP N
0.001 CD N
) ) N
. . N

CONCLUSION VB N
The DT N
marine JJ N
lipid JJ N
suppositories NNS N
and CC N
ointment NN N
were VBD N
well RB N
tolerated VBN N
with IN N
no DT N
significant JJ N
toxic JJ N
side NN N
effects NNS N
observed VBD N
during IN N
the DT N
study NN N
period NN N
. . N

The DT N
suppositories NNS N
have VBP N
a DT N
distinct JJ N
laxative JJ N
effect NN N
and CC N
we PRP N
aim VBP N
to TO N
explore VB N
this DT N
effect NN N
in IN N
further JJ N
clinical JJ N
trials NNS N
. . N

-DOCSTART- -X- O O 21635675

Short-term JJ N
metabolic JJ N
effects NNS N
of IN N
prednisone NN N
administration NN N
in IN N
healthy JJ 4_p
subjects NNS N
. . N

AIMS NNP N
Supraphysiologic NNP N
glucocorticoid NN N
activity NN N
is VBZ N
well RB N
established VBN N
to TO N
cause VB N
impaired JJ N
glucose JJ N
tolerance NN N
and CC N
insulin NN N
resistance NN N
, , N
yet RB N
no DT N
study NN N
has VBZ N
evaluated VBN N
dose-dependent JJ N
effects NNS N
of IN N
low-dose JJ N
prednisone NN N
during IN N
short-term JJ N
oral JJ N
administration NN N
. . N

METHODS NNP N
The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
quantify VB N
the DT N
effects NNS N
of IN N
daily JJ N
10 CD N
or CC N
25 CD N
mg NNS N
prednisone JJ N
administration NN N
for IN N
one CD N
week NN N
on IN N
insulin NN N
sensitivity NN N
by IN N
employing VBG N
a DT N
two-step JJ N
hyperinsulinemic JJ N
euglycemic JJ N
glucose NN N
clamp NN N
( ( N
Step JJ N
1 CD N
: : N
insulin NN N
infusion NN N
= VBD N
20 CD N
mU/m²/min NN N
; : N
Step CC N
2 CD N
: : N
insulin NN N
infusion NN N
= VBD N
80 CD N
mU/m²/min NN N
) ) N
in IN N
healthy JJ N
, , N
lean JJ N
males NNS N
. . N

The DT N
amount NN N
of IN N
glucose NN N
infused VBN N
at IN N
steady-state JJ N
to TO N
maintain VB N
stable JJ N
blood NN N
glucose JJ N
[ $ N
90 CD N
mg/dl NN N
( ( N
4.95 CD N
mmol/l NN N
) ) N
] NN N
was VBD N
used VBN N
to TO N
calculate VB N
several JJ N
indices NNS N
of IN N
insulin NN N
sensitivity NN N
. . N

RESULTS NNP N
During IN N
Step NNP N
1 CD N
of IN N
the DT N
clamp NN N
, , N
whole JJ N
body NN N
glucose JJ N
disposal NN N
( ( N
M NNP N
) ) N
was VBD N
reduced VBN N
by IN N
35 CD N
% NN N
( ( N
p JJ N
= NNP N
0.003 CD N
) ) N
and CC N
M/I NNP N
was VBD N
reduced VBN N
by IN N
29 CD N
% NN N
( ( N
p JJ N
= NNP N
0.025 CD N
) ) N
for IN N
25 CD N
mg NN N
prednisone NN N
compared VBN N
to TO N
placebo VB N
. . N

No DT N
appreciable JJ N
effect NN N
of IN N
10 CD N
mg NN N
prednisone NN N
was VBD N
observed VBN N
. . N

During IN N
Step NNP N
2 CD N
, , N
M NNP N
was VBD N
reduced VBN N
by IN N
33 CD N
% NN N
( ( N
p JJ N
= NNP N
0.001 CD N
) ) N
and CC N
15 CD N
% NN N
( ( N
p JJ N
= NNP N
0.006 CD N
) ) N
for IN N
25 CD N
and CC N
10 CD N
mg NN N
prednisone NN N
compared VBN N
to TO N
placebo VB N
; : N
and CC N
M/I NNP N
ratio NN N
was VBD N
reduced VBN N
by IN N
31 CD N
% NN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
and CC N
13 CD N
% NN N
( ( N
p JJ N
= NNP N
0.026 CD N
) ) N
, , N
respectively RB N
. . N

The DT N
insulin NN N
sensitivity NN N
index NN N
, , N
Si NNP N
, , N
calculated VBD N
as IN N
the DT N
quotient NN N
of IN N
augmentation NN N
of IN N
M/I NNP N
between IN N
Step NNP N
1 CD N
and CC N
2 CD N
, , N
was VBD N
reduced VBN N
by IN N
35.3 CD N
% NN N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
and CC N
23.5 CD N
% NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
for IN N
25 CD N
and CC N
10 CD N
mg NN N
prednisone NN N
, , N
respectively RB N
. . N

CONCLUSION NNP N
Administration NNP N
of IN N
relatively RB N
low JJ N
pharmacological JJ N
doses NNS N
of IN N
prednisone NN N
for IN N
one CD N
week NN N
impaired JJ N
insulin NN N
sensitivity NN N
in IN N
a DT N
dose-dependent JJ N
manner NN N
in IN N
healthy JJ N
males NNS N
. . N

These DT N
observed JJ N
changes NNS N
in IN N
insulin NN N
sensitivity NN N
are VBP N
likely JJ N
to TO N
be VB N
clinically RB N
relevant JJ N
, , N
especially RB N
in IN N
individuals NNS N
predisposed VBN N
to TO N
develop VB N
glucose JJ N
intolerance NN N
. . N

-DOCSTART- -X- O O 20338811

CD4+FOXP3+ NNP N
regulatory JJ N
T NNP N
cell NN N
depletion NN N
by IN N
low-dose JJ N
cyclophosphamide NN N
prevents NNS N
recurrence NN N
in IN N
patients NNS N
with IN N
large JJ N
condylomata NNS N
acuminata NNS N
after IN N
laser NN N
therapy NN N
. . N

Condylomata NNP N
acuminata NN N
( ( N
CA NNP N
) ) N
caused VBN N
by IN N
human JJ N
papillomavirus NN N
( ( N
HPV NNP N
) ) N
is VBZ N
a DT N
common JJ N
sexually RB N
transmitted JJ N
disease NN N
with IN N
half PDT N
a DT N
million CD N
new JJ N
cases NNS N
diagnosed VBN N
in IN N
the DT N
United NNP N
States NNPS N
per IN N
year NN N
and CC N
the DT N
annual JJ N
increase NN N
in IN N
incidence NN N
in IN N
China NNP N
. . N

Recurrence NNP N
is VBZ N
a DT N
major JJ N
challenge NN N
for IN N
CA NNP N
treatment NN N
. . N

Recently RB N
, , N
we PRP N
demonstrated VBD N
that IN N
FOXP3 NNP N
( ( N
+ NNP N
) ) N
regulatory JJ N
T NNP N
( ( N
Treg NNP N
) ) N
cells NNS N
mediate VBP N
the DT N
immunosuppression NN N
in IN N
large JJ N
genital JJ N
warts NNS N
. . N

Here RB N
, , N
we PRP N
further VBP N
report VB N
that IN N
low-dose JJ N
cyclophosphamide NN N
( ( N
CY NNP N
) ) N
, , N
a DT N
conventional JJ N
chemotherapy JJ N
drug NN N
, , N
can MD N
effectively RB N
prevent VB N
the DT N
recurrence NN N
of IN N
large JJ N
CA NNP N
in IN N
clinical JJ N
patients NNS N
after IN N
laser NN N
therapy NN N
. . N

Surprisingly RB N
, , N
although IN N
9 CD N
out IN N
of IN N
52 CD N
patients NNS N
recur JJ N
six CD N
weeks NNS N
after IN N
the DT N
combination NN N
treatment NN N
, , N
the DT N
re-administration NN N
of IN N
low-dose JJ N
CY NNP N
alone RB N
completely RB N
eliminates VBZ N
most JJS N
recurred JJ N
lesions NNS N
. . N

We PRP N
provide VBP N
evidence NN N
that IN N
low-dose JJ N
CY NNP N
not RB N
only RB N
depletes VBZ N
patients NNS N
' POS N
Treg NNP N
cells NNS N
and CC N
enhances NNS N
function NN N
of IN N
HPV-specific NNP N
T NNP N
cells NNS N
and CC N
NK NNP N
cells NNS N
in IN N
the DT N
periphery NN N
, , N
but CC N
also RB N
ameliorates VBZ N
the DT N
immune JJ N
milieu NN N
of IN N
the DT N
lesion NN N
site NN N
, , N
leading VBG N
to TO N
the DT N
elimination NN N
of IN N
remnant JJ N
viruses NNS N
. . N

These DT N
findings NNS N
have VBP N
important JJ N
clinical JJ N
significance NN N
, , N
and CC N
potentially RB N
lead JJ N
to TO N
a DT N
therapeutic JJ N
breakthrough NN N
for IN N
the DT N
treatment NN N
of IN N
CA NNP N
. . N

-DOCSTART- -X- O O 9393422

The DT N
influence NN N
of IN N
preoperative JJ N
antibiotics NNS N
on IN N
success NN N
of IN N
endosseous JJ N
implants NNS N
up IN N
to TO N
and CC N
including VBG N
stage NN N
II NNP N
surgery NN N
: : N
a DT N
study NN N
of IN N
2,641 CD N
implants NNS N
. . N

According VBG N
to TO N
the DT N
American NNP N
College NNP N
of IN N
Surgeons NNP N
, , N
complex JJ N
oral JJ N
surgical JJ N
procedures NNS N
, , N
including VBG N
the DT N
transoral JJ N
placement NN N
of IN N
endosseous JJ N
implants NNS N
, , N
are VBP N
of IN N
the DT N
type NN N
that WDT N
may MD N
require VB N
prophylactic JJ N
antibiotics NNS N
. . N

However RB N
, , N
the DT N
routine JJ N
use NN N
of IN N
prophylactic JJ N
antibiotics NNS N
in IN N
the DT N
field NN N
of IN N
dental JJ N
implantology NN N
continues VBZ N
to TO N
be VB N
controversial JJ N
, , N
and CC N
their PRP$ N
utilization NN N
varies NNS N
widely RB N
. . N

No UH N
data NN N
from IN N
a DT N
randomized JJ N
prospective JJ N
clinical JJ N
study NN N
of IN N
the DT N
prophylactic JJ N
use NN N
of IN N
antibiotics NNS N
in IN N
implant JJ N
surgery NN N
have VBP N
been VBN N
previously RB N
published VBN N
. . N

As IN N
part NN N
of IN N
the DT N
comprehensive JJ N
Dental NNP N
Implant NNP N
Clinical NNP N
Research NNP N
Group NNP N
clinical JJ N
implant NN N
study NN N
, , N
the DT N
preoperative NN N
or CC N
postoperative JJ N
use NN N
of IN N
antibiotics NNS N
, , N
the DT N
type NN N
used VBN N
, , N
and CC N
the DT N
duration NN N
of IN N
coverage NN N
was VBD N
left VBN N
to TO N
the DT N
discretion NN N
of IN N
the DT N
surgeon NN N
. . N

These DT N
data NNS N
were VBD N
recorded VBN N
and CC N
correlated VBN N
with IN N
failure NN N
of IN N
osseointegration NN N
during IN N
healing VBG N
( ( N
stage NN N
I PRP N
) ) N
and CC N
at IN N
stage NN N
II NNP N
surgery NN N
( ( N
uncovering VBG N
) ) N
. . N

The DT N
results NNS N
showed VBD N
that IN N
significantly RB N
fewer JJR N
failures NNS N
occurred VBD N
when WRB N
preoperative JJ N
antibiotics NNS N
were VBD N
used VBN N
. . N

-DOCSTART- -X- O O 25617202

Effect NN N
of IN N
self-collection NN N
of IN N
HPV NNP N
DNA NNP N
offered VBN N
by IN N
community NN N
health NN N
workers NNS N
at IN N
home NN N
visits NNS N
on IN N
uptake NN N
of IN N
screening VBG N
for IN N
cervical JJ N
cancer NN N
( ( N
the DT N
EMA NNP N
study NN N
) ) N
: : N
a DT N
population-based JJ N
cluster-randomised JJ N
trial NN N
. . N

BACKGROUND NNP N
Control NNP N
of IN N
cervical JJ N
cancer NN N
in IN N
developing VBG N
countries NNS N
has VBZ N
been VBN N
hampered VBN N
by IN N
a DT N
failure NN N
to TO N
achieve VB N
high JJ N
screening VBG N
uptake NN N
. . N

HPV NNP N
DNA NNP N
self-collection NN N
could MD N
increase VB N
screening VBG N
coverage NN N
, , N
but CC N
implementation NN N
of IN N
this DT N
technology NN N
is VBZ N
difficult JJ N
in IN N
countries NNS 4_p
of IN 4_p
middle JJ 4_p
and CC 4_p
low JJ 4_p
income NN 4_p
. . N

We PRP N
investigated VBD N
whether IN N
offering VBG N
HPV NNP N
DNA NNP N
self-collection NN N
during IN N
routine JJ N
home NN N
visits NNS N
by IN N
community NN N
health NN N
workers NNS N
could MD N
increase VB N
cervical JJ N
screening NN N
. . N

METHODS NNP N
We PRP N
did VBD N
a DT N
population-based JJ N
cluster-randomised JJ N
trial NN N
in IN N
the DT N
province NN 4_p
of IN 4_p
Jujuy NNP 4_p
, , 4_p
Argentina NNP 4_p
, , N
between IN N
July NNP N
1 CD N
, , N
2012 CD N
, , N
and CC N
Dec NNP N
31 CD N
, , N
2012 CD N
. . N

Community NNP N
health NN N
workers NNS N
were VBD N
eligible JJ N
for IN N
the DT N
study NN N
if IN N
they PRP N
scored VBD N
highly RB N
on IN N
a DT N
performance NN N
score NN N
, , N
and CC N
women NNS N
aged VBN N
30 CD N
years NNS N
or CC N
older JJR N
were VBD N
eligible JJ N
for IN N
enrolment NN N
by IN N
the DT N
community NN N
health NN N
worker NN N
. . N

200 CD N
community NN N
health NN N
workers NNS N
were VBD N
randomly RB N
allocated VBN N
in IN N
a DT N
1:1 CD N
ratio NN N
to TO N
either CC N
the DT N
intervention NN N
group NN N
( ( N
offered VBN N
women NNS N
the DT N
chance NN N
to TO N
self-collect VB N
a DT N
sample NN N
for IN N
cervical JJ N
screening NN N
during IN N
a DT N
home NN N
visit NN N
) ) N
or CC N
the DT N
control NN N
group NN N
( ( N
advised JJ N
women NNS N
to TO N
attend VB N
a DT N
health NN N
clinic NN N
for IN N
cervical JJ N
screening NN N
) ) N
. . N

The DT N
primary JJ N
outcome NN N
was VBD N
screening VBG N
uptake NN N
, , N
measured VBN N
as IN N
the DT N
proportion NN N
of IN N
women NNS N
having VBG N
any DT N
HPV NNP N
screening NN N
test NN N
within IN N
6 CD N
months NNS N
of IN N
the DT N
community NN N
health NN N
worker NN N
visit NN N
. . N

Analysis NN N
was VBD N
by IN N
intention NN N
to TO N
treat VB N
. . N

This DT N
trial NN N
is VBZ N
registered VBN N
with IN N
ClinicalTrials.gov NNP N
, , N
number NN N
NCT02095561 NNP N
. . N

FINDINGS NNP N
100 CD N
community NN N
health NN N
workers NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
the DT N
intervention NN N
group NN N
and CC N
100 CD N
were VBD N
assigned VBN N
to TO N
the DT N
control NN N
group NN N
; : N
nine CD N
did VBD N
not RB N
take VB N
part NN N
. . N

191 CD N
participating VBG N
community NN N
health NN N
workers NNS N
( ( N
94 CD N
in IN N
the DT N
intervention NN N
group NN N
and CC N
97 CD N
in IN N
the DT N
control NN N
group NN N
) ) N
initially RB N
contacted JJ N
7650 CD N
women NNS N
; : N
of IN N
3632 CD N
women NNS N
contacted VBN N
by IN N
community NN N
health NN N
workers NNS N
in IN N
the DT N
intervention NN N
group NN N
, , N
3049 CD N
agreed VBD N
to TO N
participate VB N
; : N
of IN N
4018 CD N
women NNS N
contacted VBN N
by IN N
community NN N
health NN N
workers NNS N
in IN N
the DT N
control NN N
group NN N
, , N
2964 CD N
agreed VBD N
to TO N
participate VB N
. . N

2618 CD N
( ( N
86 CD N
% NN N
) ) N
of IN N
3049 CD N
women NNS N
in IN N
the DT N
intervention NN N
group NN N
had VBD N
any DT N
HPV NNP N
test NN N
within IN N
6 CD N
months NNS N
of IN N
the DT N
community NN N
health NN N
worker NN N
visit NN N
, , N
compared VBN N
with IN N
599 CD N
( ( N
20 CD N
% NN N
) ) N
of IN N
2964 CD N
in IN N
the DT N
control NN N
group NN N
( ( N
risk NN N
ratio NN N
4·02 CD N
, , N
95 CD N
% NN N
CI NNP N
3·44-4·71 CD N
) ) N
. . N

INTERPRETATION JJ N
Offering VBG N
self-collection NN N
of IN N
samples NNS N
for IN N
HPV NNP N
testing VBG N
by IN N
community NN N
health NN N
workers NNS N
during IN N
home NN N
visits NNS N
resulted VBD N
in IN N
a DT N
four-fold JJ N
increase NN N
in IN N
screening VBG N
uptake NN N
, , N
showing VBG N
that IN N
this DT N
strategy NN N
is VBZ N
effective JJ N
to TO N
improve VB N
cervical JJ N
screening NN N
coverage NN N
. . N

This DT N
intervention NN N
reduces VBZ N
women NNS N
's POS N
barriers NNS N
to TO N
screening VBG N
and CC N
results NNS N
in IN N
a DT N
substantial JJ N
and CC N
rapid JJ N
increase NN N
in IN N
coverage NN N
. . N

Our PRP$ N
findings NNS N
suggest VBP N
that IN N
HPV NNP N
testing VBG N
could MD N
be VB N
extended VBN N
throughout IN N
Argentina NNP N
and CC N
in IN N
other JJ N
countries NNS N
to TO N
increase VB N
cervical JJ N
screening NN N
coverage NN N
. . N

FUNDING NN N
Instituto NNP N
Nacional NNP N
del FW N
Cáncer NNP N
( ( N
Argentina NNP N
) ) N
. . N

-DOCSTART- -X- O O 9076205

Vitrectomy NN N
with IN N
silicone JJ N
oil NN N
or CC N
long-acting NN N
gas NN N
in IN N
eyes NNS 4_p
with IN 4_p
severe JJ 4_p
proliferative JJ 4_p
vitreoretinopathy NN 4_p
: : 4_p
results NNS N
of IN N
additional JJ N
and CC N
long-term JJ N
follow-up NN N
. . N

Silicone NNP N
Study NNP N
report VBD N
11 CD N
. . N

BACKGROUND VB N
The DT N
Silicone NNP N
Study NNP N
evaluated VBD N
the DT N
outcomes NNS N
of IN N
vitreoretinal JJ N
surgery NN N
for IN N
retinal JJ 4_p
detachment NN 4_p
with IN 4_p
proliferative JJ 4_p
vitreoretinopathy NN 4_p
( ( 4_p
PVR NNP 4_p
) ) 4_p
. . 4_p

OBJECTIVE UH N
To TO N
evaluate VB N
short-term JJ N
( ( N
up IN N
to TO N
36 CD N
months NNS N
) ) N
outcomes VBZ N
in IN N
eyes NNS N
randomized VBN N
to TO N
silicone VB N
oil NN N
or CC N
perfluoropropane NN N
gas NN N
and CC N
long-term JJ N
( ( N
up IN N
to TO N
72 CD N
months NNS N
) ) N
outcomes VBZ N
in IN N
eyes NNS N
with IN N
attached JJ N
maculas NNS N
at IN N
36 CD N
months NNS N
. . N

DESIGN NNP N
Prospective NNP N
, , N
randomized VBD N
, , N
multicentered VBD N
surgical JJ N
trial NN N
. . N

SETTING CC N
Community- JJ N
and CC N
university-based JJ N
vitreoretinal JJ N
practices NNS N
. . N

PATIENTS VB N
Two-hundred JJ N
sixty-five JJ N
eyes NNS N
with IN N
PVR NNP N
randomized VBD N
to TO N
perfluoropropane VB N
gas NN N
and CC N
silicone NN N
oil NN N
with IN N
follow-up NN N
through IN N
3 CD N
years NNS N
( ( N
cohort VB N
1 CD N
) ) N
and CC N
249 CD N
eyes NNS N
with IN N
attached JJ N
maculas NNS N
at IN N
36 CD N
months NNS N
( ( N
121 CD N
eyes NNS N
randomized VBN N
to TO N
long-acting JJ N
gas NN N
[ NN N
either CC N
sulfur JJ N
hexafluoride NN N
or CC N
perfluoropropane NN N
] NNS N
and CC N
128 CD N
eyes NNS N
randomized VBN N
to TO N
silicone VB N
oil NN N
) ) N
with IN N
follow-up NN N
up RB N
to TO N
6 CD N
years NNS N
( ( N
cohort VB N
2 CD N
) ) N
. . N

Both DT N
cohorts NNS N
consisted VBD N
of IN N
eyes NNS N
that WDT N
had VBD N
and CC N
had VBD N
not RB N
undergone JJ N
vitrectomy NN N
for IN N
PVR NNP N
( ( N
groups NNS N
1 CD N
and CC N
2 CD N
, , N
respectively RB N
) ) N
before IN N
randomization NN N
. . N

Of IN N
the DT N
265 CD N
eyes NNS N
in IN N
cohort NN N
1 CD N
, , N
24-month JJ N
follow-up JJ N
data NNS N
were VBD N
available JJ N
for IN N
218 CD N
eyes NNS N
( ( N
82 CD N
% NN N
) ) N
and CC N
36-month JJ N
follow-up JJ N
data NNS N
were VBD N
available JJ N
for IN N
196 CD N
eyes NNS N
( ( N
74 CD N
% NN N
) ) N
. . N

Of IN N
208 CD N
eyes NNS N
in IN N
cohort NN N
2 CD N
, , N
48-month JJ N
follow-up JJ N
data NNS N
were VBD N
available JJ N
for IN N
146 CD N
eyes NNS N
( ( N
70 CD N
% NN N
) ) N
, , N
60-month JJ N
follow-up JJ N
data NNS N
for IN N
119 CD N
eyes NNS N
( ( N
57 CD N
% NN N
) ) N
, , N
and CC N
72-month JJ N
follow-up JJ N
data NNS N
for IN N
73 CD N
eyes NNS N
( ( N
35 CD N
% NN N
) ) N
. . N

INTERVENTIONS NNP N
Vitrectomy NNP N
surgery NN N
for IN N
PVR NNP N
with IN N
a DT N
long-acting JJ N
gas NN N
or CC N
silicone NN N
oil NN N
as IN N
the DT N
intraocular JJ N
tamponade NN N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Changes NNP N
in IN N
visual JJ N
acuity NN N
, , N
recurrent JJ N
retinal JJ N
detachment NN N
, , N
and CC N
incidence NN N
of IN N
complications NNS N
. . N

RESULTS NNP N
In IN N
group NN N
1 CD N
of IN N
cohort NN N
1 CD N
, , N
compared VBN N
with IN N
oil-treated JJ N
eyes NNS N
, , N
gas-treated JJ N
eyes NNS N
had VBD N
a DT N
higher JJR N
rate NN N
of IN N
complete JJ N
retinal JJ N
reattachment NN N
from IN N
18 CD N
to TO N
36 CD N
months NNS N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

No UH N
other JJ N
differences NNS N
were VBD N
found VBN N
. . N

In IN N
group NN N
2 CD N
of IN N
cohort NN N
1 CD N
, , N
no DT N
notable JJ N
differences NNS N
were VBD N
found VBN N
between IN N
treatment NN N
arms NNS N
. . N

In IN N
cohort NN N
2 CD N
, , N
during IN N
6 CD N
years NNS N
of IN N
follow-up NN N
, , N
attachment NN N
of IN N
the DT N
macula NN N
was VBD N
maintained VBN N
for IN N
all DT N
eyes NNS N
. . N

No DT N
notable JJ N
differences NNS N
in IN N
the DT N
rates NNS N
of IN N
complete JJ N
retinal JJ N
attachment NN N
, , N
visual JJ N
acuity NN N
of IN N
5/200 CD N
or CC N
better JJR N
, , N
or CC N
glaucoma NN N
were VBD N
found VBN N
between IN N
treatment NN N
groups NNS N
. . N

In IN N
contrast NN N
, , N
gas-treated JJ N
eyes NNS N
had VBD N
more RBR N
hypotony JJ N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

Silicone CD N
oil-treated JJ N
eyes NNS N
that WDT N
underwent JJ N
subsequent JJ N
surgery NN N
were VBD N
more RBR N
likely JJ N
to TO N
have VB N
the DT N
oil NN N
retained VBN N
( ( N
P NNP N
= NNP N
.02 NNP N
) ) N
. . N

Compared VBN N
with IN N
oil-retained JJ N
eyes NNS N
, , N
oil-removed JJ N
eyes NNS N
had VBD N
higher JJR N
rates NNS N
of IN N
complete JJ N
posterior JJ N
attachment NN N
( ( N
P NNP N
= NNP N
.01 NNP N
) ) N
and CC N
of IN N
a DT N
visual JJ N
acuity NN N
of IN N
5/200 CD N
or CC N
better JJR N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
and CC N
less RBR N
keratopathy JJ N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

Compared VBN N
with IN N
oil-removed JJ N
eyes NNS N
, , N
gas-treated JJ N
eyes NNS N
had VBD N
a DT N
worse JJ N
visual JJ N
acuity NN N
outcome NN N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
and CC N
more JJR N
hypotony NN N
( ( N
P NNP N
< NNP N
.01 NNP N
) ) N
. . N

CONCLUSION VB N
The DT N
Silicone NNP N
Study NNP N
showed VBD N
that IN N
silicone NN N
oil NN N
and CC N
perfluoropropane NN N
gas NN N
were VBD N
equal JJ N
in IN N
most JJS N
respects NNS N
for IN N
the DT N
management NN N
of IN N
retinal JJ N
detachments NNS N
with IN N
PVR NNP N
. . N

Success NNP N
in IN N
the DT N
first JJ N
surgery NN N
for IN N
PVR NNP N
is VBZ N
paramount NN N
for IN N
obtaining VBG N
better JJR N
visual JJ N
results NNS N
. . N

Overall JJ N
, , N
surgery NN N
for IN N
PVR NNP N
had VBD N
a DT N
high JJ N
likelihood NN N
of IN N
retinal JJ N
reattachment NN N
, , N
and CC N
if IN N
anatomically RB N
and CC N
visually RB N
successful JJ N
at IN N
3 CD N
years NNS N
, , N
there EX N
is VBZ N
an DT N
excellent JJ N
chance NN N
that IN N
the DT N
results NNS N
will MD N
be VB N
maintained VBN N
over IN N
the DT N
long-term JJ N
. . N

-DOCSTART- -X- O O 12036809

Do VB N
colonic JJ N
short-chain NN N
fatty JJ N
acids NNS N
contribute NN N
to TO N
the DT N
long-term JJ N
adaptation NN N
of IN N
blood NN N
lipids NNS N
in IN N
subjects NNS N
with IN N
type JJ 4_p
2 CD 4_p
diabetes NNS 4_p
consuming VBG N
a DT N
high-fiber JJ N
diet NN N
? . N
BACKGROUND NNP N
We PRP N
recently RB N
obtained VBD N
evidence NN N
of IN N
long-term JJ N
adaptation NN N
of IN N
blood NN N
lipids NNS N
to TO N
changes NNS N
in IN N
intakes NNS N
of IN N
carbohydrate NN N
and CC N
fiber NN N
in IN N
subjects NNS N
with IN N
type JJ 4_p
2 CD 4_p
diabetes NNS 4_p
. . N

OBJECTIVE IN N
We PRP N
determined VBD N
the DT N
effect NN N
of IN N
increased JJ N
carbohydrate NN N
and CC N
fiber NN N
intakes NNS N
on IN N
serum JJ N
short-chain JJ N
fatty JJ N
acids NNS N
( ( N
SCFAs NNP N
) ) N
and CC N
the DT N
relation NN N
between IN N
changes NNS N
in IN N
serum NN N
acetate NN N
and CC N
changes NNS N
in IN N
blood NN N
lipids NNS N
. . N

DESIGN NNP N
Subjects VBZ N
with IN N
type NN 4_p
2 CD 4_p
diabetes NNS 4_p
( ( N
n JJ N
= NNP N
62 CD N
) ) N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
approximately RB N
10 CD N
% NN N
of IN N
energy NN N
from IN N
low-fiber JJ N
breakfast NN N
cereal NN N
( ( N
LF NNP N
diet NN N
) ) N
, , N
high-fiber JJ N
breakfast NN N
cereal NN N
( ( N
HF NNP N
diet NN N
) ) N
, , N
or CC N
monounsaturated VBN N
fatty JJ N
acids NNS N
( ( N
MUFA NNP N
diet NN N
) ) N
for IN N
6 CD N
mo NNS N
. . N

RESULTS NNP N
Carbohydrate NNP N
intakes NNS N
were VBD N
higher JJR N
in IN N
the DT N
LF NNP N
and CC N
HF NNP N
groups NNS N
than IN N
in IN N
the DT N
MUFA NNP N
group NN N
( ( N
54 CD N
% NN N
compared VBN N
with IN N
43 CD N
% NN N
) ) N
, , N
and CC N
more JJR N
fiber NN N
was VBD N
consumed VBN N
by IN N
the DT N
HF NNP N
group NN N
( ( N
approximately RB N
50 CD N
g/d NNS N
) ) N
than IN N
by IN N
the DT N
LF NNP N
or CC N
MUFA NNP N
group NN N
( ( N
approximately RB N
23 CD N
g/d NN N
) ) N
. . N

Fasting VBG N
serum JJ N
SCFAs NNP N
did VBD N
not RB N
change VB N
significantly RB N
over IN N
the DT N
first JJ N
3 CD N
mo NN N
. . N

Between CC N
3 CD N
and CC N
6 CD N
mo NN N
, , N
serum JJ N
acetate NN N
tended VBD N
( ( N
NS NNP N
) ) N
to TO N
decrease VB N
in IN N
the DT N
LF NNP N
group NN N
( ( N
from IN N
69 CD N
+/- JJ N
4 CD N
to TO N
59 CD N
+/- JJ N
5 CD N
micromol/L NN N
) ) N
and CC N
increase VB N
in IN N
the DT N
HF NNP N
group NN N
( ( N
from IN N
100 CD N
+/- JJ N
18 CD N
to TO N
107 CD N
+/- JJ N
17 CD N
micromol/L NN N
) ) N
, , N
with IN N
no DT N
significant JJ N
change NN N
in IN N
the DT N
MUFA NNP N
group NN N
. . N

Serum NNP N
butyrate NN N
did VBD N
not RB N
change VB N
significantly RB N
in IN N
the DT N
LF NNP N
or CC N
MUFA NNP N
group NN N
but CC N
increased VBD N
in IN N
the DT N
HF NNP N
group NN N
( ( N
from IN N
2.5 CD N
+/- JJ N
0.5 CD N
to TO N
3.1 CD N
+/- JJ N
0.6 CD N
micromol/L NN N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Changes NNS N
in IN N
serum NN N
acetate NN N
from IN N
0 CD N
to TO N
3 CD N
mo NNS N
were VBD N
not RB N
related VBN N
to TO N
changes NNS N
in IN N
lipids NNS N
. . N

However RB N
, , N
changes NNS N
in IN N
serum NN N
acetate NN N
from IN N
3 CD N
to TO N
6 CD N
mo NNS N
were VBD N
positively RB N
related VBN N
to TO N
changes NNS N
in IN N
the DT N
ratio NN N
of IN N
total JJ N
to TO N
HDL NNP N
cholesterol NN N
( ( N
P NNP N
= NNP N
0.041 CD N
) ) N
and CC N
in IN N
fasting NN N
( ( N
P NNP N
= NNP N
0.013 CD N
) ) N
and CC N
postprandial JJ N
( ( N
P NNP N
= NNP N
0.016 CD N
) ) N
triacylglycerols NNS N
. . N

CONCLUSIONS NNP N
In IN N
subjects NNS N
with IN N
type JJ 4_p
2 CD 4_p
diabetes NNS 4_p
, , N
changes NNS N
in IN N
serum NN N
SCFAs NNP N
in IN N
response NN N
to TO N
changes NNS N
in IN N
carbohydrate NN N
and CC N
fiber NN N
intakes NNS N
took VBD N
many JJ N
months NNS N
to TO N
occur VB N
, , N
and CC N
the DT N
changes NNS N
in IN N
serum NN N
acetate NN N
were VBD N
significantly RB N
related VBN N
to TO N
the DT N
long-term JJ N
adaptive JJ N
changes NNS N
in IN N
blood NN N
lipids NNS N
. . N

-DOCSTART- -X- O O 8619354

Iobitridol NNP N
300 CD N
compared VBN N
to TO N
iopromide VB N
300 CD N
-- : N
a DT N
double-blind JJ N
randomized JJ N
phase-III NN N
study NN N
of IN N
clinical JJ N
tolerance NN N
in IN N
total JJ 4_p
body NN 4_p
CT. NNP 4_p
UNLABELLED NNP N
PURPOSE NNP N
, , N
MATERIAL NNP N
AND NNP N
METHODS NNP N
: : N
The DT N
clinical JJ N
safety NN N
of IN N
iobitriodol JJ N
300 CD N
mg NN N
I/ml NNP N
and CC N
iopromide RB N
300 CD N
mg NNS N
I/ml NNP N
were VBD N
compared VBN N
in IN N
a DT N
randomized JJ N
double JJ N
blind IN N
phase-III JJ N
study NN N
conducted VBD N
on IN N
60 CD N
patients NNS N
undergoing JJ N
abdominal JJ N
CT NNP N
for IN N
a DT N
variety NN N
of IN N
indications NNS N
. . N

Each DT N
examination NN N
was VBD N
rated VBN N
as IN N
diagnostic JJ N
or CC N
nondiagnostic JJ N
and CC N
the DT N
image NN N
quality NN N
was VBD N
noted VBN N
. . N

Nature NN N
, , N
onset NN N
, , N
intensity NN N
as RB N
well RB N
as IN N
outcome NN N
of IN N
each DT N
adverse JJ N
reaction NN N
were VBD N
recorded VBN N
. . N

RESULTS NNP N
There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
imaging VBG N
quality NN N
and CC N
side NN N
effects NNS N
between IN N
the DT N
contrast NN N
media NNS N
. . N

In IN N
this DT N
study NN N
, , N
both DT N
iobitridol NNS N
and CC N
iopromide NN N
provided VBD N
excellent JJ N
image NN N
quality NN N
and CC N
a DT N
low JJ N
rate NN N
of IN N
side NN N
effects NNS N
. . N

CONCLUSION NNP N
Iobitridol NNP N
is VBZ N
a DT N
safe JJ N
and CC N
effective JJ N
nonionic JJ N
contrast NN N
agent NN N
for IN N
contrast-enhanced JJ N
body NN N
CT NNP N
. . N

-DOCSTART- -X- O O 24689172

Safety NNP N
evaluation NN N
of IN N
lasalocid NN N
use NN N
in IN N
Chinese JJ N
ring-necked JJ N
pheasants NNS N
( ( N
Phasianus NNP N
colchicus NN N
) ) N
. . N

Coccidiosis NN N
remains VBZ N
a DT N
significant JJ N
threat NN N
to TO N
the DT N
welfare NN N
of IN N
game NN 4_p
farm-reared JJ 4_p
pheasants NNS 4_p
in IN 4_p
the DT 4_p
United NNP 4_p
States NNPS 4_p
. . 4_p

Although IN N
lasalocid NN N
has VBZ N
been VBN N
demonstrated VBN N
to TO N
be VB N
effective JJ N
against IN N
pheasant JJ N
specific JJ N
coccidia NN N
, , N
information NN N
regarding VBG N
its PRP$ N
safety NN N
in IN N
this DT N
species NNS N
is VBZ N
lacking VBG N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
gather VB N
data NNS N
on IN N
the DT N
safety NN N
of IN N
lasalocid NN N
when WRB N
fed NN N
to TO N
Chinese JJ N
ring-necked JJ N
pheasants NNS N
at IN N
one CD N
, , N
two CD N
, , N
and CC N
three CD N
times NNS N
the DT N
recommended JJ N
high JJ N
dose NN N
of IN N
lasalocid NN N
used VBN N
for IN N
prevention NN N
of IN N
coccidiosis NN N
in IN N
other JJ N
poultry NN N
at IN N
three CD N
times NNS N
the DT N
normal JJ N
treatment NN N
period NN N
. . N

Pheasant JJ N
chicks NNS N
( ( N
approximately RB N
1 CD N
day-old JJ N
; : N
n CC N
= VB N
160 CD N
) ) N
were VBD N
randomly RB N
blocked VBN N
by IN N
sex NN N
into IN N
four CD N
treatment NN N
groups NNS N
and CC N
given VBN N
their PRP$ N
respective JJ N
diets NNS N
continuously RB N
for IN N
6 CD N
wk NN N
. . N

No DT N
significant JJ N
differences NNS N
were VBD N
observed VBN N
in IN N
overall JJ N
feed NN N
consumption NN N
, , N
weight NN N
gain NN N
, , N
feed VBN N
conversion NN N
rates NNS N
, , N
clinical JJ N
pathology NN N
measurements NNS N
, , N
or CC N
tissue NN N
gross JJ N
and CC N
histopathologic JJ N
evaluations NNS N
between IN N
controls NNS N
and CC N
treatment NN N
groups NNS N
associated VBN N
with IN N
lasalocid JJ N
administration NN N
. . N

Based VBN N
on IN N
the DT N
results NNS N
of IN N
this DT N
study NN N
it PRP N
appears VBZ N
that IN N
lasalocid NN N
fed VBN N
at IN N
the DT N
recommended JJ N
rate NN N
of IN N
125 CD N
ppm NN N
is VBZ N
safe JJ N
in IN N
Chinese JJ N
ring-necked JJ N
pheasants NNS N
. . N

-DOCSTART- -X- O O 21047593

Lead-time NN N
in IN N
the DT N
European NNP N
Randomised VBD N
Study NNP N
of IN N
Screening NNP N
for IN N
Prostate NNP 4_p
Cancer NNP 4_p
. . 4_p

BACKGROUND NNP N
Lead-time NNP N
is VBZ N
defined VBN N
as IN N
the DT N
time NN N
by IN N
which WDT N
screening VBG N
advances VBZ N
the DT N
diagnosis NN N
compared VBN N
with IN N
absence NN N
of IN N
screening VBG N
. . N

A DT N
sufficiently RB N
long JJ N
lead-time JJ N
needs NNS N
to TO N
be VB N
achieved VBN N
so RB N
that IN N
cancer NN N
can MD N
be VB N
detected VBN N
while IN N
still RB N
curable JJ N
. . N

A DT N
very RB N
short JJ N
lead-time NN N
may MD N
indicate VB N
poor JJ N
sensitivity NN N
of IN N
the DT N
screening JJ N
test NN N
, , N
while IN N
a DT N
very RB N
long JJ N
lead-time JJ N
suggests NNS N
overdiagnosis NN N
. . N

MATERIAL NNP N
AND NNP N
METHODS NNP N
In IN N
the DT N
first JJ N
screening NN N
round NN N
, , N
a DT N
total NN N
of IN N
56,294 CD N
men NNS N
aged VBN N
55-74 CD N
years NNS N
were VBD N
screened VBN N
with IN N
serum NN N
prostate NN N
specific JJ N
antigen NN N
( ( N
PSA NNP N
) ) N
in IN N
five CD N
countries NNS N
of IN N
the DT N
European NNP N
Randomised VBD N
Study NNP N
of IN N
Screening NNP N
for IN N
Prostate NNP 4_p
Cancer NNP 4_p
( ( N
ERSPC NNP N
) ) N
with IN N
an DT N
overall JJ N
detection NN N
rate NN N
( ( N
prevalence NN N
) ) N
of IN N
2.8 CD N
% NN N
( ( N
1972 CD N
prostate NN N
cancers NNS N
) ) N
. . N

Prostate NNP 4_p
cancer NN 4_p
incidence NN N
among IN N
92,142 CD N
men NNS N
randomly RB N
allocated VBN N
to TO N
the DT N
control NN N
arm NN N
of IN N
the DT N
trial NN N
was VBD N
also RB N
assessed VBN N
. . N

Lead-time NNP N
was VBD N
estimated VBN N
as IN N
the DT N
time NN N
required VBN N
to TO N
accumulate VB N
a DT N
similar JJ N
cumulative JJ N
risk NN N
of IN N
prostate NN N
cancer NN N
in IN N
the DT N
control NN N
arm NN N
to TO N
the DT N
detection NN N
rate NN N
in IN N
the DT N
intervention NN N
arm NN N
, , N
i.e NN N
. . N

from IN N
the DT N
ratio NN N
of IN N
detection NN N
rate NN N
( ( N
prevalence NN N
of IN N
screen-detected JJ N
cases NNS N
) ) N
and CC N
expected VBN N
incidence NN N
( ( N
cumulative JJ N
risk NN N
) ) N
. . N

RESULTS NNP N
Using VBG N
a DT N
serum JJ N
PSA NNP N
cut-off NN N
of IN N
4 CD N
ng/ml NNS N
, , N
the DT N
mean JJ N
lead-time NN N
in IN N
the DT N
whole NN N
study NN N
population NN N
was VBD N
estimated VBN N
as IN N
6.8 CD N
years NNS N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
95 CD N
% NN N
CI NNP N
) ) N
7.9-8.4 NN N
) ) N
. . N

It PRP N
was VBD N
8 CD N
years NNS N
in IN N
The DT N
Netherlands NNP N
, , N
6 CD N
in IN N
Sweden NNP N
and CC N
Finland NNP N
, , N
5 CD N
in IN N
Italy NNP N
and CC N
4 CD N
in IN N
Belgium NNP N
. . N

The DT N
mean JJ N
lead-time NN N
was VBD N
similar JJ N
, , N
6-7 JJ N
years NNS N
, , N
at IN N
ages NNS N
50-64 CD N
years NNS N
, , N
but CC N
close RB N
to TO N
8 CD N
years NNS N
among IN N
men NNS N
aged VBN N
65-74 CD N
years NNS N
. . N

A DT N
lower JJR N
PSA NNP N
cut-off JJ N
level NN N
of IN N
3 CD N
ng/ml NNS N
used VBN N
in IN N
Sweden NNP N
and CC N
The DT N
Netherlands NNP N
prolonged VBD N
the DT N
mean JJ N
lead-time JJ N
by IN N
approximately RB N
1 CD N
year NN N
. . N

Lead-time NNP N
based VBN N
on IN N
advanced JJ N
prostate NN N
cancer NN N
only RB N
was VBD N
slightly RB N
shorter JJR N
, , N
mean JJ N
5.3 CD N
years NNS N
( ( N
95 CD N
% NN N
CI NNP N
4.6-6.0 CD N
) ) N
. . N

The DT N
lead-time NN N
for IN N
the DT N
second JJ N
screening NN N
round NN N
was VBD N
slightly RB N
shorter JJR N
than IN N
that DT N
for IN N
the DT N
first JJ N
( ( N
5.9 CD N
, , N
95 CD N
% NN N
CI NNP N
5.4-6.4 CD N
) ) N
, , N
reflecting VBG N
a DT N
similar JJ N
relation NN N
between IN N
detection NN N
rate NN N
and CC N
control NN N
group NN N
incidence NN N
. . N

CONCLUSION VB N
The DT N
lead-time NN N
for IN N
prostate NN N
cancer NN N
found VBD N
in IN N
ERSPC NNP N
substantially RB N
exceeded VBD N
that IN N
found NN N
for IN N
breast NN N
, , N
cervical JJ N
and CC N
colorectal JJ N
cancer NN N
screening NN N
. . N

One CD N
round NN N
of IN N
prostate NN N
cancer NN N
screening VBG N
can MD N
advance VB N
clinical JJ N
diagnosis NN N
by IN N
4-8 JJ N
years NNS N
. . N

Overdiagnosis NN N
or CC N
detection NN N
of IN N
non-progressive JJ N
tumours NNS N
may MD N
contribute VB N
substantially RB N
to TO N
the DT N
lead-time NN N
. . N

-DOCSTART- -X- O O 24635110

Prophylactic JJ N
training NN N
for IN N
the DT N
prevention NN N
of IN N
radiotherapy-induced JJ N
trismus NN N
- : N
a DT N
randomised JJ N
study NN N
. . N

BACKGROUND NNP N
Radiotherapy-induced JJ N
trismus NN N
( ( N
RTIT NNP N
) ) N
is VBZ N
a DT N
debilitating VBG N
condition NN N
without IN N
any DT N
proven JJ N
effective JJ N
treatment NN N
. . N

This DT N
study NN N
investigates VBZ N
the DT N
effectiveness NN N
of IN N
prophylactic JJ N
training NN N
to TO N
prevent VB N
RTIT NNP N
during IN N
and CC N
up RB N
to TO N
12 CD N
months NNS N
after IN N
completed VBN 4_p
RT NNP 4_p
in IN 4_p
patients NNS 4_p
with IN 4_p
head NN 4_p
and CC 4_p
neck NN 4_p
cancer NN 4_p
( ( 4_p
HNC NNP 4_p
) ) 4_p
, , N
also RB N
investigating VBG N
the DT N
incidence NN N
of IN N
RTIT NNP N
. . N

METHODS NNP N
Sixty-six JJ N
consecutive JJ N
patients NNS N
from IN N
two CD N
RT NNP N
clinics NNS N
in IN N
Sweden NNP N
were VBD N
randomised VBN N
into IN N
one CD N
of IN N
two CD N
groups NNS N
: : N
training NN N
with IN N
TheraBite NNP N
( ( N
® NNP N
) ) N
Jaw NNP N
Motion NNP N
Rehabilitation NNP N
System NNP N
( ( N
™ NNP N
) ) N
or CC N
a DT N
control NN N
group NN N
. . N

Maximum NNP N
interincisal JJ N
openings NNS N
( ( N
MIO NNP N
) ) N
were VBD N
recorded VBN N
at IN N
baseline NN N
and CC N
once RB N
a DT N
week NN N
during IN N
treatment NN N
, , N
three CD N
, , N
six CD N
and CC N
12 CD N
months NNS N
after IN N
completed VBN N
RT NNP N
. . N

Training NNP N
frequency NN N
was VBD N
recorded VBN N
by IN N
patients NNS N
in IN N
a DT N
log NN N
book NN N
. . N

RESULTS CC N
There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
MIO NNP N
between IN N
the DT N
intervention NN N
and CC N
control NN N
groups NNS N
at IN N
any DT N
of IN N
the DT N
measurement NN N
points NNS N
. . N

Patients NNS N
in IN N
both DT N
groups NNS N
maintained VBD N
their PRP$ N
normal JJ N
variation NN N
in IN N
MIO NNP N
at IN N
12 CD N
months NNS N
after IN N
completed VBN N
RT NNP N
. . N

A NNP N
small JJ N
group NN N
of IN N
patients NNS N
in IN N
the DT N
control NN N
group NN N
had VBD N
a DT N
17 CD N
% NN N
mean JJ N
decrease NN N
in IN N
MIO NNP N
by IN N
week NN N
6 CD N
compared VBN N
to TO N
baseline VB N
and CC N
improved VB N
their PRP$ N
MIO NNP N
by IN N
using VBG N
the DT N
training NN N
programme NN N
. . N

There EX N
was VBD N
a DT N
significant JJ N
mean JJ N
difference NN N
in IN N
MIO NNP N
from IN N
baseline NN N
to TO N
week NN N
6 CD N
( ( N
3 CD N
mm NN N
, , N
p NN N
= NNP N
0.018 CD N
) ) N
, , N
and CC N
month NN N
6 CD N
( ( N
2.7 CD N
mm NN N
, , N
p NN N
= NNP N
0.040 CD N
) ) N
, , N
for IN N
patients NNS N
receiving VBG N
3D CD N
conformal JJ N
radiotherapy NN N
. . N

There EX N
was VBD N
a DT N
significant JJ N
difference NN N
in IN N
MIO NNP N
between IN N
patients NNS N
treated VBN N
with IN N
RT NNP N
and CC N
concurrent JJ N
chemotherapy NN N
compared VBN N
to TO N
patients NNS N
with IN N
RT NNP N
only RB N
at IN N
12 CD N
months NNS N
( ( N
p JJ N
= NNP N
0.033 CD N
) ) N
. . N

CONCLUSIONS JJ N
Patients NNS 4_p
with IN 4_p
HNC NNP 4_p
undergoing VBG 4_p
high JJ 4_p
dose NN 4_p
RT NNP N
do VBP N
not RB N
need VB N
to TO N
be VB N
burdened VBN N
with IN N
an DT N
intense JJ N
prophylactic JJ N
training NN N
programme NN N
during IN N
RT NNP N
and CC N
up RB N
to TO N
12 CD N
months NNS N
after IN N
completed VBN N
RT NNP N
. . N

MIO NNP N
measurements NNS N
during IN N
RT NNP N
and CC N
up RB N
to TO N
12 CD N
months NNS N
after IN N
completed VBN N
RT NNP N
are VBP N
recommended VBN N
to TO N
identify VB N
a DT N
small JJ N
risk NN N
group NN N
who WP N
are VBP N
an DT N
exception NN N
and CC N
may MD N
need VB N
a DT N
training NN N
programme NN N
. . N

-DOCSTART- -X- O O 10036953

[ JJ N
Triple NNP N
therapy NN N
regimens VBZ N
involving VBG N
H2 NNP N
blockaders NNS N
for IN N
therapy NN N
of IN N
Helicobacter NNP N
pylori FW N
infections NNS N
] VBP N
. . N

Comparison NNP N
of IN N
ranitidine NN N
and CC N
lansoprazole NN N
in IN N
short-term JJ N
low-dose JJ N
triple NN N
therapy NN N
for IN N
Helicobacter NNP N
pylori JJ N
infection NN N
. . N

To TO N
evaluate VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
two CD N
1-week JJ N
low-dose JJ N
triple-therapy JJ N
drug NN N
regimens NNS N
involving VBG N
antisecretory NN N
drugs NNS N
for IN N
Helicobacter NNP N
pylori JJ N
infection NN N
, , N
99 CD N
patients NNS N
with IN N
H. NNP 4_p
pylori FW 4_p
infection NN 4_p
were VBD N
treated VBN N
with IN N
either DT N
lansoprazole NN N
( ( N
LPZ NNP N
) ) N
or CC N
ranitidine NN N
( ( N
RNT NNP N
) ) N
used VBD N
together RB N
with IN N
clarithromycin NN N
( ( N
CAM NNP N
) ) N
and CC N
metrinidazole $ N
( ( N
MTZ NNP N
) ) N
. . N

The DT N
drug NN N
combination NN N
and CC N
administration NN N
periods NNS N
in IN N
the DT N
PPI NNP N
group NN N
were VBD N
LPZ NNP N
30 CD N
mg NN N
, , N
CAM NNP N
400 CD N
mg NN N
, , N
MTZ NNP N
500 CD N
mg NN N
( ( N
LCM NNP N
group NN N
) ) N
. . N

The DT N
ranitidine NN N
group NN N
received VBD N
RNT NNP N
300 CD N
mg NN N
, , N
CAM NNP N
400 CD N
mg NN N
, , N
MTZ NNP N
500 CD N
mg NN N
( ( N
RCM NNP N
group NN N
) ) N
. . N

The DT N
cure NN N
rate NN N
of IN N
H. NNP N
pylori FW N
infection NN N
was VBD N
88 CD N
% NN N
in IN N
the DT N
LCM NNP N
group NN N
; : N
95 CD N
% NN N
CI NNP N
79-97 CD N
and CC N
92 CD N
% NN N
in IN N
the DT N
RCM NNP N
group NN N
; : N
95 CD N
% NN N
CI NNP N
84-99 CD N
. . N

-DOCSTART- -X- O O 25957107

Effect NN N
of IN N
Chinese NNP N
herbal JJ N
medicine NN N
on IN N
vascular JJ N
functions NNS N
during IN N
60-day JJ N
head-down JJ N
bed NN N
rest NN N
. . N

PURPOSE NNP N
Chinese JJ N
herbal JJ N
medicine NN N
is VBZ N
a DT N
promising JJ N
countermeasure NN N
against IN N
cardiovascular JJ 4_p
dysfunction NN 4_p
associated VBN N
with IN N
a DT N
sedentary JJ N
lifestyle NN N
. . N

We PRP N
examined VBD N
the DT N
impact NN N
of IN N
the DT N
Chinese JJ N
herb NN N
, , N
Taikong NNP N
Yangxin NNP N
, , N
on IN N
the DT N
micro- JJ N
and CC N
macrovascular JJ N
dysfunction NN N
associated VBN N
with IN N
a DT N
60-day JJ N
bed NN N
rest NN N
. . N

METHODS NNP N
Fourteen NNP N
healthy JJ N
men NNS N
were VBD N
randomly RB N
divided VBN N
into IN N
two CD N
groups NNS N
: : N
those DT N
given VBN N
herbal JJ N
supplement NN N
, , N
and CC N
the DT N
control NN N
group NN N
; : N
the DT N
two CD N
groups NNS N
underwent VBD N
a DT N
60-day JJ N
bed NN N
rest NN N
. . N

The DT N
macrovasculature NN N
was VBD N
assessed VBN N
by IN N
sonography NN N
. . N

Skin NNP N
microvascular JJ N
functions NNS N
were VBD N
assessed VBN N
with IN N
laser NN N
Doppler NNP N
. . N

The DT N
plasma JJ N
level NN N
of IN N
endothelial JJ N
microparticles NNS N
( ( N
EMPs NNP N
) ) N
, , N
markers NNS N
of IN N
endothelial JJ N
injury NN N
, , N
was VBD N
determined VBN N
. . N

RESULTS NNP N
Bed NNP N
rest NN N
induced VBD N
a DT N
33 CD N
% NN N
decrease NN N
in IN N
the DT N
femoral JJ N
artery NN N
diameter NN N
and CC N
compliance NN N
whereas NNS N
carotid VBP N
wall NN N
thickness NN N
, , N
diameter NN N
, , N
and CC N
compliance NN N
remained VBD N
unchanged JJ N
. . N

The DT N
early JJ N
phase NN N
of IN N
endothelium-dependent JJ N
vasodilation NN N
to TO N
ACh NNP N
was VBD N
unmodified VBN N
by IN N
bed NN N
rest NN N
, , N
while IN N
the DT N
late JJ N
phase NN N
was VBD N
reduced VBN N
by IN N
30 CD N
% NN N
along IN N
with IN N
a DT N
twofold JJ N
increase NN N
in IN N
EMPs NNP N
. . N

In IN N
those DT N
given VBN N
Taikong NNP N
Yangxin NNP N
, , N
the DT N
early JJ N
phase NN N
was VBD N
amplified VBN N
by IN N
2.5-fold JJ N
, , N
and CC N
the DT N
effects NNS N
of IN N
bed NN N
rest NN N
on IN N
the DT N
late JJ N
phase NN N
were VBD N
prevented VBN N
. . N

CONCLUSION NNP N
These DT N
findings NNS N
indicate VBP N
that IN N
Taikong NNP N
Yangxin NNP N
ameliorates VBZ N
endothelium-dependent JJ N
vasodilation NN N
, , N
likely RB N
by IN N
improving VBG N
the DT N
NO NNP N
pathway NN N
. . N

The DT N
study NN N
suggests VBZ N
Taikong NNP N
Yangxin NNP N
as IN N
a DT N
new JJ N
countermeasure NN N
to TO N
prevent VB N
the DT N
changes NNS N
in IN N
microvascular JJ N
function NN N
induced VBN N
by IN N
physical JJ N
inactivity NN N
. . N

-DOCSTART- -X- O O 17276748

Developmental JJ N
disabilities NNS N
modification NN N
of IN N
the DT N
Children NNP N
's POS N
Global NNP N
Assessment NNP N
Scale NNP N
. . N

BACKGROUND NNP N
Interventions NNP N
for IN N
pervasive JJ N
developmental NN N
disorders NNS N
( ( N
PDD NNP N
) ) N
aim NN N
to TO N
alleviate VB N
symptoms NNS N
and CC N
improve VB N
functioning NN N
. . N

To TO N
measure VB N
global JJ N
functioning NN N
in IN N
treatment NN N
studies NNS N
, , N
the DT N
Children NNP N
's POS N
Global NNP N
Assessment NNP N
Scale NNP N
was VBD N
modified VBN N
and CC N
psychometric JJ N
properties NNS N
of IN N
the DT N
revised VBN N
version NN N
( ( N
DD-CGAS NNP N
) ) N
were VBD N
assessed VBN N
in IN N
children NNS N
with IN N
PDD NNP N
. . N

METHODS NNP N
Developmental NNP N
disabilities-relevant JJ N
descriptors NNS N
were VBD N
developed VBN N
for IN N
the DT N
DD-CGAS NNP N
, , N
and CC N
administration NN N
procedures NNS N
were VBD N
established VBN N
to TO N
enhance VB N
rater NN N
consistency NN N
. . N

Ratings NNS N
of IN N
clinical JJ N
case NN N
vignettes NNS N
were VBD N
used VBN N
to TO N
assess VB N
inter-rater JJ N
reliability NN N
and CC N
temporal JJ N
stability NN N
. . N

Validity NNP N
was VBD N
assessed VBN N
by IN N
correlating VBG N
the DT N
DD-CGAS NNP N
with IN N
measures NNS N
of IN N
functioning NN N
and CC N
symptoms NNS N
in IN N
83 CD N
youngsters NNS N
with IN N
PDD NNP N
. . N

Sensitivity NNP N
to TO N
change VB N
was VBD N
assessed VBN N
by IN N
comparing VBG N
change NN N
from IN N
baseline NN N
to TO N
post-treatment JJ N
with IN N
change NN N
on IN N
the DT N
Aberrant NNP N
Behavior NNP N
Checklist-Irritability NNP N
and CC N
Clinical NNP N
Global NNP N
Impressions-Improvement NNP N
subscale JJ N
scores NNS N
in IN N
a DT N
subset NN N
of IN N
14 CD N
children NNS N
. . N

RESULTS NNP N
Inter-rater JJ N
reliability NN N
( ( N
intraclass JJ N
correlation NN N
coefficient NN N
[ NNP N
ICC NNP N
] NNP N
= NNP N
.79 NNP N
) ) N
and CC N
temporal JJ N
stability NN N
( ( N
average JJ N
ICC NNP N
= NNP N
.86 NNP N
) ) N
were VBD N
excellent JJ N
. . N

The DT N
DD-CGAS JJ N
scores NNS N
correlated VBN N
with IN N
measures NNS N
of IN N
functioning NN N
and CC N
symptoms NNS N
with IN N
moderate JJ N
to TO N
large JJ N
effect NN N
sizes VBZ N
. . N

Changes NNS N
on IN N
the DT N
DD-CGAS NNP N
correlated VBD N
with IN N
changes NNS N
on IN N
the DT N
Aberrant NNP N
Behavior NNP N
Checklist-I NNP N
( ( N
r NN N
= NNP N
-.71 NNP N
) ) N
and CC N
Global JJ N
Impressions NNP N
Scale-I NNP N
( ( N
r NN N
= NNP N
-.52 NNP N
) ) N
. . N

The DT N
pre-post JJ N
DD-CGAS NNP N
change NN N
had VBD N
an DT N
effect NN N
size NN N
of IN N
.72 NNP N
. . N

CONCLUSIONS VB N
The DT N
DD-CGAS NNP N
is VBZ N
a DT N
reliable JJ N
instrument NN N
with IN N
apparent JJ N
convergent NN N
validity NN N
for IN N
measuring VBG N
global JJ N
functioning NN N
of IN N
children NNS N
with IN N
PDD NNP N
in IN N
treatment NN N
studies NNS N
. . N

-DOCSTART- -X- O O 8911127

The DT N
impact NN N
of IN N
a DT N
psychological JJ N
intervention NN N
on IN N
quality NN N
of IN N
life NN N
in IN N
non-metastatic JJ 4_p
breast NN 4_p
cancer NN 4_p
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
whether IN N
psychological JJ N
intervention NN N
had VBD N
a DT N
beneficial JJ N
effect NN N
on IN N
the DT N
quality NN N
of IN N
life NN N
and CC N
behaviour NN N
of IN N
women NNS N
diagnosed VBN N
with IN N
breast NN 4_p
cancer NN 4_p
. . N

36 CD N
consecutive JJ N
patients NNS N
with IN N
non-metastatic JJ 4_p
breast NN 4_p
cancer NN 4_p
assigned VBD N
to TO N
surgery VB N
and CC N
systemic VB N
chemotherapy NN N
were VBD N
randomised VBN N
to TO N
receive VB N
either DT N
psychological JJ N
intervention NN N
( ( N
weekly JJ N
cognitive VBP N
individual JJ N
psychotherapy NN N
and CC N
bimonthly JJ N
family NN N
counselling VBG N
) ) N
or CC N
standard JJ N
follow-up NN N
. . N

Personality NNP N
( ( N
16-PF JJ N
and CC N
IIQ NNP N
) ) N
, , N
quality NN N
of IN N
life NN N
( ( N
FLIC NNP N
) ) N
, , N
and CC N
depression NN N
( ( N
BDI NNP N
) ) N
scores NNS N
were VBD N
the DT N
endpoints NNS N
for IN N
this DT N
study NN N
, , N
and CC N
the DT N
questionnaires NNS N
were VBD N
completed VBN N
by IN N
the DT N
patients NNS N
at IN N
diagnosis NN N
, , N
and CC N
up RB N
to TO N
9 CD N
months NNS N
after IN N
diagnosis NN N
. . N

Cognitive JJ N
psychotherapy NN N
and CC N
family NN N
counselling NN N
improved VBD N
both DT N
depression NN N
and CC N
quality NN N
of IN N
life NN N
indexes NNS N
compared VBN N
with IN N
the DT N
control NN N
group NN N
. . N

Better NNP N
emotional JJ N
coping NN N
behaviours NNS N
were VBD N
also RB N
revealed VBN N
by IN N
some DT N
changes NNS N
in IN N
personality NN N
traits NNS N
in IN N
the DT N
intervention NN N
group NN N
. . N

-DOCSTART- -X- O O 25080906

[ JJ N
Effect NNP N
of IN N
zero-balanced JJ N
ultrafiltration NN N
and CC N
modified VBN N
ultrafiltration NN N
on IN N
pulmonary JJ N
function NN N
after IN 4_p
cardiac JJ 4_p
surgery NN 4_p
in IN N
infants NNS N
] NNP N
. . N

OBJECTIVE NNP N
To TO N
determine VB N
the DT N
protective JJ N
effect NN N
of IN N
zero-balanced JJ N
ultrafiltration NN N
and CC N
modified VBN N
ultrafiltration NN N
on IN N
infants NNS N
' POS N
pulmonary JJ N
function NN N
after IN N
cardiac JJ 4_p
surgery NN 4_p
. . N

METHODS NNP N
Sixty NNP N
infants NNS N
with IN N
congenital JJ 4_p
heart NN 4_p
diseases NNS 4_p
were VBD N
randomly RB N
divided VBN N
into IN N
3 CD N
groups NNS N
: : N
a DT N
zero-balanced JJ N
ultrafiltration NN N
group NN N
( ( N
Z NNP N
group NN N
) ) N
, , N
a DT N
modified JJ N
ultrafiltration NN N
group NN N
( ( N
M NNP N
group NN N
) ) N
and CC N
a DT N
zero-balanced JJ N
ultrafiltration NN N
with IN N
modified JJ N
ultrafiltration NN N
group NN N
( ( N
Z+M NNP N
group NN N
) ) N
. . N

Oxygenation NNP N
index NN N
( ( N
OI NNP N
) ) N
, , N
difference NN N
of IN N
alveoli-arterial JJ N
oxygen NN N
pressure NN N
( ( N
P NNP N
( ( N
A-α NNP N
) ) N
O2 NNP N
) ) N
, , N
static JJ N
lung NN N
compliance NN N
( ( N
Cstat NNP N
) ) N
, , N
and CC N
airway RB N
resistance NN N
( ( N
Raw NNP N
) ) N
were VBD N
measured VBN N
before IN N
caridopulmonary JJ N
bypass NN N
( ( N
CPB NNP N
, , N
T1 NNP N
) ) N
, , N
20 CD N
minutes NNS N
after IN N
the DT N
CPB NNP N
( ( N
T2 NNP N
) ) N
, , N
2 CD N
h NN N
after IN N
the DT N
operation NN N
( ( N
T3 NNP N
) ) N
, , N
6 CD N
h NN N
after IN N
the DT N
operation NN N
( ( N
T4 NNP N
) ) N
and CC N
12 CD N
h NN N
after IN N
the DT N
operation NN N
( ( N
T5 NNP N
) ) N
. . N

The DT N
time NN N
of IN N
mechanical JJ N
ventilation NN N
was VBD N
also RB N
monitored VBN N
. . N

RESULTS NNP N
After IN N
the DT N
CPB NNP N
, , N
OI NNP N
and CC N
Cstat NNP N
in IN N
all DT N
groups NNS N
decreased VBD N
significantly RB N
, , N
while IN N
Raw NNP N
and CC N
P NNP N
( ( N
A-α NNP N
) ) N
O2 NNP N
increased VBD N
significantly RB N
. . N

At IN N
T3 NNP N
, , N
T4 NNP N
and CC N
T5 NNP N
, , N
OI NNP N
and CC N
Cstat NNP N
in IN N
the DT N
Z+M NNP N
group NN N
were VBD N
significantly RB N
higher JJR N
than IN N
those DT N
in IN N
the DT N
Z NNP N
group NN N
and CC N
the DT N
M NNP N
group NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
, , N
Raw NNP N
and CC N
P NNP N
( ( N
A-α NNP N
) ) N
O2 NNP N
in IN N
the DT N
Z+M NNP N
group NN N
were VBD N
significantly RB N
lower JJR N
than IN N
those DT N
in IN N
the DT N
Z NNP N
group NN N
and CC N
the DT N
M NNP N
group NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
ventilation NN N
time NN N
in IN N
the DT N
Z+M NNP N
group NN N
was VBD N
significantly RB N
shorter JJR N
than IN N
that DT N
in IN N
the DT N
Z NNP N
group NN N
and CC N
the DT N
M NNP N
group NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSION NNP N
Zero-balanced JJ N
ultrafiltration NN N
and CC N
modified JJ N
ultrafiltration NN N
can MD N
effectively RB N
promote VB N
the DT N
pulmonary JJ N
function NN N
after IN N
cardiac JJ N
surgery NN N
in IN N
infants NNS N
. . N

-DOCSTART- -X- O O 15857741

Acustimulation NNP N
wrist NN N
bands NNS N
are VBP N
not RB N
effective JJ N
for IN N
the DT N
control NN N
of IN N
chemotherapy-induced JJ N
nausea NN N
in IN N
women NNS N
with IN N
breast NN 4_p
cancer NN 4_p
. . N

This DT N
experiment NN N
examined VBD N
the DT N
efficacy NN N
of IN N
an DT N
acustimulation NN N
wrist NN N
band NN N
for IN N
the DT N
relief NN N
of IN N
chemotherapy-induced JJ N
nausea NN N
using VBG N
a DT N
randomized JJ N
three-arm JJ N
clinical JJ N
trial NN N
( ( N
active JJ N
acustimulation NN N
, , N
sham JJ N
acustimulation NN N
, , N
and CC N
no DT N
acustimulation NN N
) ) N
in IN N
96 CD N
women NNS N
with IN N
breast NN 4_p
cancer NN 4_p
who WP N
experienced VBD N
nausea NN 4_p
at IN 4_p
their PRP$ 4_p
first JJ 4_p
chemotherapy NN 4_p
treatment NN 4_p
. . N

Five CD N
outcomes NNS N
related VBN N
to TO N
wrist VB N
band NN N
efficacy NN N
( ( N
acute JJ N
nausea NN N
, , N
delayed VBN N
nausea NN N
, , N
vomiting VBG N
, , N
QOL NNP N
, , N
and CC N
total JJ N
amount NN N
of IN N
antiemetic JJ N
medication NN N
used VBN N
) ) N
were VBD N
examined VBN N
. . N

The DT N
five CD N
outcomes NNS N
were VBD N
examined VBN N
separately RB N
using VBG N
analysis NN N
of IN N
covariance NN N
controlling VBG N
for IN N
age NN N
and CC N
severity NN N
of IN N
past JJ N
nausea NN N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
any DT N
of IN N
these DT N
study NN N
measures NNS N
among IN N
the DT N
three CD N
treatment NN N
conditions NNS N
( ( N
P NNP N
> VBZ N
0.1 CD N
for IN N
all DT N
) ) N
. . N

Study NNP N
results NNS N
do VBP N
not RB N
support VB N
the DT N
hypothesis NN N
that WDT N
acustimulation NN N
bands NNS N
are VBP N
efficacious JJ N
as IN N
an DT N
adjunct NN N
to TO N
pharmacological JJ N
antiemetics NNS N
for IN N
control NN N
of IN N
chemotherapy-related JJ N
nausea NN N
in IN N
female JJ N
breast NN 4_p
cancer NN 4_p
patients NNS N
. . N

-DOCSTART- -X- O O 17356153

Compliance NN N
with IN N
continuous JJ N
passive JJ N
movement NN N
is VBZ N
low JJ N
after IN N
surgical JJ N
treatment NN N
of IN N
idiopathic JJ 4_p
club JJ 4_p
foot NN 4_p
in IN N
infants NNS N
: : N
a DT N
prospective JJ N
, , N
double-blinded JJ N
clinical JJ N
study NN N
. . N

Treatment NN N
by IN N
continuous JJ N
passive JJ N
movement NN N
at IN N
home NN N
is VBZ N
an DT N
alternative JJ N
to TO N
immobilisation NN N
in IN N
a DT N
cast NN N
after IN N
surgery NN N
for IN N
club JJ N
foot NN N
. . N

Compliance NN N
with IN N
the DT N
recommended JJ N
treatment NN N
, , N
of IN N
at IN N
least JJS N
four CD N
hours NNS N
daily RB N
, , N
is VBZ N
unknown JJ N
. . N

The DT N
duration NN N
of IN N
treatment NN N
was VBD N
measured VBN N
in IN N
24 CD N
of IN N
27 CD N
consecutive JJ N
children NNS N
with IN N
a DT N
mean JJ N
age NN N
of IN N
24 CD N
months NNS N
( ( N
5 CD N
to TO N
75 CD N
) ) N
following VBG 4_p
posteromedial JJ 4_p
release NN 4_p
for IN N
idiopathic JJ N
club JJ N
foot NN N
. . N

Only RB N
21 CD N
% NN N
( ( N
5 CD N
) ) N
of IN N
the DT N
children NNS N
used VBD N
the DT N
continuous JJ N
passive JJ N
movement NN N
machine NN N
as IN N
recommended JJ N
. . N

The DT N
mean JJ N
duration NN N
of IN N
treatment NN N
at IN N
home NN N
each DT N
day NN N
was VBD N
126 CD N
minutes NNS N
( ( N
11 CD N
to TO N
496 CD N
) ) N
. . N

The DT N
mean JJ N
range NN N
of IN N
movement NN N
for IN N
plantar NN N
flexion NN N
improved VBD N
from IN N
15.2 CD N
degrees NNS N
( ( N
10.0 CD N
degrees NNS N
to TO N
20.6 CD N
degrees NNS N
) ) N
to TO N
18.7 CD N
degrees NNS N
( ( N
10.0 CD N
degrees NNS N
to TO N
33.0 CD N
degrees NNS N
) ) N
and CC N
for IN N
dorsiflexion NN N
from IN N
12.3 CD N
degrees NNS N
( ( N
7.4 CD N
degrees NNS N
to TO N
19.4 CD N
degrees NNS N
) ) N
to TO N
18.9 CD N
degrees NNS N
( ( N
10.0 CD N
degrees NNS N
to TO N
24.1 CD N
degrees NNS N
) ) N
( ( N
both DT N
, , N
p NN N
= NNP N
0.0001 CD N
) ) N
when WRB N
the DT N
first JJ N
third NN N
of IN N
therapy NN N
was VBD N
compared VBN N
with IN N
the DT N
last JJ N
third JJ N
. . N

A DT N
low JJ N
level NN N
of IN N
patient JJ N
compliance NN N
must MD N
be VB N
considered VBN N
when WRB N
the DT N
outcome NN N
after IN N
treatment NN N
at IN N
home NN N
is VBZ N
interpreted VBN N
. . N

-DOCSTART- -X- O O 23592849

The DT N
role NN N
of IN N
treatment NN N
fidelity NN N
on IN N
outcomes NNS N
during IN N
a DT N
randomized JJ N
field NN N
trial NN N
of IN N
an DT N
autism NN 4_p
intervention NN N
. . N

This DT N
randomized JJ N
field NN N
trial NN N
comparing VBG N
Strategies NNS N
for IN N
Teaching VBG N
based VBN N
on IN N
Autism NNP N
Research NNP N
and CC N
Structured NNP N
Teaching NNP N
enrolled VBD N
educators NNS N
in IN N
33 CD N
kindergarten-through-second-grade JJ N
autism NN 4_p
support NN N
classrooms NNS N
and CC N
119 CD N
students NNS N
, , N
aged VBN N
5-8 CD N
years NNS N
in IN N
the DT N
School NNP N
District NNP N
of IN N
Philadelphia NNP N
. . N

Students NNS N
were VBD N
assessed VBN N
at IN N
the DT N
beginning NN N
and CC N
end NN N
of IN N
the DT N
academic JJ N
year NN N
using VBG N
the DT N
Differential NNP N
Ability NNP N
Scales NNP N
. . N

Program NNP N
fidelity NN N
was VBD N
measured VBN N
through IN N
video NN N
coding NN N
and CC N
use NN N
of IN N
a DT N
checklist NN N
. . N

Outcomes CC N
were VBD N
assessed VBN N
using VBG N
linear JJ N
regression NN N
with IN N
random JJ N
effects NNS N
for IN N
classroom NN N
and CC N
student NN N
. . N

Average JJ N
fidelity NN N
was VBD N
57 CD N
% NN N
in IN N
Strategies NNP N
for IN N
Teaching NNP N
based VBN N
on IN N
Autism NNP N
Research NNP N
classrooms NNS N
and CC N
48 CD N
% NN N
in IN N
Structured NNP N
Teaching NNP N
classrooms NNS N
. . N

There EX N
was VBD N
a DT N
9.2-point JJ N
( ( N
standard JJ N
deviation NN N
= NNP N
9.6 CD N
) ) N
increase NN N
in IN N
Differential NNP N
Ability NNP N
Scales NNP N
score RB N
over IN N
the DT N
8-month JJ N
study NN N
period NN N
, , N
but CC N
no DT N
main JJ N
effect NN N
of IN N
program NN N
. . N

There EX N
was VBD N
a DT N
significant JJ N
interaction NN N
between IN N
fidelity NN N
and CC N
group NN N
. . N

In IN N
classrooms NNS N
with IN N
either DT N
low JJ N
or CC N
high JJ N
program NN N
fidelity NN N
, , N
students NNS N
in IN N
Strategies NNP N
for IN N
Teaching NNP N
based VBN N
on IN N
Autism NNP 4_p
Research NNP N
experienced VBD N
a DT N
greater JJR N
gain NN N
in IN N
Differential NNP N
Ability NNP N
Scales NNP N
score RB N
than IN N
students NNS N
in IN N
Structured NNP N
Teaching NNP N
( ( N
11.2 CD N
vs. RB N
5.5 CD N
points NNS N
and CC N
11.3 CD N
vs. FW N
8.9 CD N
points NNS N
, , N
respectively RB N
) ) N
. . N

In IN N
classrooms NNS N
with IN N
moderate JJ N
fidelity NN N
, , N
students NNS N
in IN N
Structured NNP N
Teaching NNP N
experienced VBD N
a DT N
greater JJR N
gain NN N
than IN N
students NNS N
in IN N
Strategies NNP N
for IN N
Teaching NNP N
based VBN N
on IN N
Autism NNP 4_p
Research NNP N
( ( N
10.1 CD N
vs. RB N
4.4 CD N
points NNS N
) ) N
. . N

The DT N
results NNS N
suggest VBP N
significant JJ N
variability NN N
in IN N
implementation NN N
of IN N
evidence-based JJ N
practices NNS N
, , N
even RB N
with IN N
supports NNS N
, , N
and CC N
also RB N
suggest VBP N
the DT N
need NN N
to TO N
address VB N
challenging VBG N
issues NNS N
related VBN N
to TO N
implementation VB N
measurement NN N
in IN N
community NN N
settings NNS N
. . N

-DOCSTART- -X- O O 10499652

Gabexate NNP N
mesilate NN N
and CC N
antithrombin NN N
III NNP N
for IN N
intraoperative JJ N
anticoagulation NN N
in IN N
heparin NN 4_p
pretreated VBN 4_p
patients NNS N
. . N

Thirty NNP N
patients NNS N
scheduled VBN N
for IN N
elective JJ 4_p
myocardial JJ 4_p
revascularization NN 4_p
and CC N
having VBG N
undergone JJ N
preoperative JJ 4_p
heparin NN 4_p
treatment NN 4_p
have VBP N
been VBN N
admitted VBN N
to TO N
this DT N
prospective JJ N
, , N
randomized VBN N
study NN N
. . N

The DT N
aim NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
test VB N
two CD N
different JJ N
strategies NNS N
for IN N
preserving VBG N
circulating VBG N
antithrombin JJ N
III NNP N
( ( N
AT-III NNP N
) ) N
during IN N
cardiopulmonary JJ N
bypass NN N
. . N

Patients NNS N
in IN N
the DT N
control NN N
group NN N
( ( N
group NN N
C NNP N
, , N
n JJ N
= NNP N
10 CD N
) ) N
were VBD N
treated VBN N
with IN N
a DT N
standard JJ N
heparinization NN N
( ( N
300 CD N
IU/kg NNP N
) ) N
. . N

Patients NNS N
in IN N
group NN N
A NNP N
( ( N
n JJ N
= NNP N
10 CD N
) ) N
received VBD N
the DT N
same JJ N
management NN N
plus CC N
two CD N
doses NNS N
of IN N
purified JJ N
antithrombin NN N
III NNP N
( ( N
1000 CD N
IU NNP N
each DT N
) ) N
. . N

Patients NNS N
in IN N
group NN N
GA NNP N
received VBD N
200 CD N
IU/kg NNP N
heparin NN N
and CC N
a DT N
continuous JJ N
infusion NN N
of IN N
heparin NN N
( ( N
100 CD N
IU/kg/h NNP N
) ) N
and CC N
gabexate JJ N
mesilate NN N
( ( N
2 CD N
mg/kg/h NN N
) ) N
plus CC N
the DT N
same JJ N
dose NN N
of IN N
antithrombin JJ N
III NNP N
as IN N
group NN N
A NNP N
. . N

Both NNP N
group NN N
A NNP N
and CC N
group NN N
GA NNP N
demonstrated VBD N
a DT N
preservation NN N
of IN N
circulating VBG N
AT-III NNP N
when WRB N
compared VBN N
to TO N
group NN N
C NNP N
; : N
this DT N
effect NN N
was VBD N
more RBR N
pronounced JJ N
in IN N
group NN N
GA NNP N
. . N

The DT N
total JJ N
heparin NN N
dosage NN N
was VBD N
less RBR N
in IN N
group NN N
GA NNP N
than IN N
in IN N
groups NNS N
A NNP N
and CC N
C. NNP N
Purified NNP N
AT-III NNP N
administration NN N
is VBZ N
recommended VBN N
in IN N
heparin NN 4_p
pretreated JJ 4_p
patients NNS N
; : N
the DT N
addition NN N
of IN N
gabexate NN N
mesilate NN N
to TO N
this DT N
protocol NN N
decreases VBZ N
the DT N
heparin NN N
requirement NN N
and CC N
increases VBZ N
the DT N
AT-III JJ N
preservation NN N
. . N

-DOCSTART- -X- O O 25659440

Reducing VBG N
blood NN N
loss NN N
in IN N
simultaneous JJ 4_p
bilateral JJ 4_p
total NN 4_p
knee NN 4_p
arthroplasty NN 4_p
: : N
combined VBN N
intravenous-intra-articular JJ N
tranexamic JJ N
acid NN N
administration NN N
. . N

A DT N
prospective JJ N
randomized NN N
controlled VBD N
trial NN N
. . N

BACKGROUND NNP N
We PRP N
asked VBD N
whether IN N
tranexamic JJ N
acid NN N
( ( N
TXA NNP N
) ) N
administration NN N
could MD N
reduce VB N
blood NN N
loss NN N
and CC N
blood NN N
transfusion NN N
requirements NNS N
after IN N
simultaneous JJ 4_p
bilateral JJ 4_p
total NN 4_p
knee NN 4_p
arthroplasty NN 4_p
( ( 4_p
TKA NNP 4_p
) ) 4_p
. . N

This DT N
study NN N
examined VBD N
the DT N
role NN N
of IN N
a DT N
novel JJ N
method NN N
of IN N
TXA NNP N
administration NN N
in IN N
TKA NNP N
. . N

METHODS NNP N
TXA NNP N
was VBD N
administered VBN N
as IN N
a DT N
bolus NN N
dose NN N
of IN N
15 CD N
mg/kg NNS N
10 CD N
min NN N
before IN N
the DT N
inflation NN N
of IN N
the DT N
tourniquet NN N
on IN N
the DT N
first JJ N
side NN N
. . N

This DT N
was VBD N
followed VBN N
by IN N
intra-articular JJ N
administration NN N
of IN N
3 CD N
grams NNS N
at IN N
10 CD N
min NN N
before IN N
the DT N
deflation NN N
of IN N
the DT N
tourniquet NN N
. . N

IV NNP N
infusion NN N
of IN N
10 CD N
mg/kg/h NN N
was VBD N
continued VBN N
for IN N
3h CD N
following VBG N
completion NN N
on IN N
the DT N
second JJ N
side NN N
. . N

We PRP N
measured VBD N
volume NN N
of IN N
drained JJ N
blood NN N
48 CD N
h NN N
postoperatively RB N
, , N
decrease NN N
in IN N
hemoglobin NN N
levels NNS N
12h CD N
postoperatively RB N
, , N
amount NN N
of IN N
blood NN N
transfused VBN N
( ( N
BT NNP N
) ) N
, , N
and CC N
number NN N
of IN N
patients NNS N
requiring VBG N
allogenic JJ N
BT NNP N
. . N

RESULTS NNP N
Median JJ N
postoperative JJ N
volume NN N
of IN N
drained JJ N
blood NN N
was VBD N
lower JJR N
in IN N
the DT N
group NN N
receiving VBG N
TXA NNP N
( ( N
500.00 CD N
mL NN N
) ) N
than IN N
in IN N
control NN N
subjects NNS N
( ( N
900.00 CD N
mL NN N
) ) N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
[ VBD N
95 CD N
% NN N
CI NNP N
( ( N
-525.00 NNP N
) ) N
to TO N
( ( N
-300.00 NNP N
) ) N
] NN N
. . N

The DT N
median JJ N
hemoglobin NN N
decrease NN N
12 CD N
h NN N
postoperatively RB N
was VBD N
lower JJR N
in IN N
patients NNS N
receiving VBG N
TXA NNP N
( ( N
2.10 CD N
g/dL NN N
) ) N
than IN N
in IN N
control NN N
subjects NNS N
( ( N
3.10 CD N
g/dL NN N
) ) N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
[ VBD N
95 CD N
% NN N
CI NNP N
( ( N
-1.60 NNP N
) ) N
to TO N
( ( N
-0.60 NNP N
) ) N
] NN N
. . N

The DT N
amount NN N
of IN N
BT NNP N
and CC N
number NN N
of IN N
patients NNS N
requiring VBG N
BT NNP N
were VBD N
lower JJR N
in IN N
patients NNS N
receiving VBG N
TXA NNP N
than IN N
in IN N
control NN N
subjects NNS N
. . N

Nevertheless RB N
, , N
the DT N
number NN N
of IN N
allogeneic JJ N
units NNS N
of IN N
packed JJ N
red JJ N
blood NN N
cells NNS N
transfused VBN N
in IN N
the DT N
postoperative JJ N
period NN N
was VBD N
not RB N
significantly RB N
higher RBR N
in IN N
the DT N
control NN N
group NN N
than IN N
in IN N
the DT N
TXA NNP N
group NN N
( ( N
p=0.109 NN N
) ) N
[ VBZ N
95 CD N
% NN N
CI NNP N
( ( N
0.101 CD N
) ) N
to TO N
( ( N
0.117 CD N
) ) N
] NN N
. . N

CONCLUSIONS VB N
This DT N
prospective JJ N
randomized NN N
study NN N
showed VBD N
that IN N
during IN N
simultaneous JJ N
bilateral JJ N
TKA NNP N
, , N
TXA NNP N
reduced VBD N
blood NN N
loss NN N
with IN N
negligible JJ N
side NN N
effects NNS N
. . N

-DOCSTART- -X- O O 6344196

The DT N
role NN N
of IN N
the DT N
MA-sensitive JJ N
leukocyte NN N
chemotaxis NN N
in IN N
rheumatoid JJ 4_p
arthritis NN 4_p
. . N

A DT N
randomized JJ N
double-blind JJ N
clinical JJ N
trial NN N
of IN N
griseofulvin NN N
treatment NN N
. . N

Polymorphonuclear JJ N
leukocyte NN N
( ( N
PMN NNP N
) ) N
chemotaxis NN N
is VBZ N
thought VBN N
to TO N
play VB N
an DT N
essential JJ N
role NN N
in IN N
the DT N
pathogenesis NN N
of IN N
rheumatoid JJ N
arthritis NN N
. . N

PMN NNP N
chemotaxis NN N
is VBZ N
in IN N
part NN N
sensitive NN N
to TO N
microtubule VB N
antagonists NNS N
( ( N
MAs NNP N
) ) N
, , N
e.g RB N
. . N

colchicine NN N
. . N

The DT N
antimycotic JJ N
antibiotic JJ N
griseofulvin NN N
inhibits VBZ N
the DT N
MA-sensitive JJ N
PMN NNP N
chemotaxis NN N
in IN N
vitro NN N
in IN N
concentrations NNS N
far RB N
below IN N
those DT N
obtained VBN N
in IN N
serum NN N
during IN N
antimycotic JJ N
therapy NN N
. . N

The DT N
role NN N
of IN N
the DT N
MA-sensitive JJ N
chemotaxis NN N
in IN N
rheumatoid JJ N
arthritis NN N
could MD N
thus RB N
be VB N
elucidated VBN N
by IN N
a DT N
clinical JJ N
trial NN N
of IN N
griseofulvin NN N
treatment NN N
. . N

Griseofulvin NNP N
( ( N
n JJ N
= NNP N
20 CD N
) ) N
was VBD N
tested VBN N
in IN N
a DT N
randomized JJ N
double-blind NN N
study NN N
versus IN N
placebo NN N
( ( N
m JJ N
= NNP N
19 CD N
) ) N
during IN N
one CD N
year NN N
in IN N
patients NNS N
with IN N
rheumatoid JJ 4_p
arthritis NN 4_p
of IN N
mild-moderate JJ 4_p
activity NN 4_p
. . N

No DT N
beneficial JJ N
effect NN N
of IN N
griseofulvin NN N
treatment NN N
was VBD N
noted VBN N
on IN N
clinical JJ N
symptoms NNS N
or CC N
laboratory JJ N
parameters NNS N
of IN N
rheumatoid JJ N
arthritis NN N
. . N

Moreover RB N
, , N
the DT N
placebo-treated JJ N
patients NNS N
showed VBD N
more RBR N
improvement NN N
than IN N
the DT N
griseofulvin-treated JJ N
patients NNS N
. . N

It PRP N
is VBZ N
therefore RB N
suggested VBN N
that IN N
the DT N
MA-sensitive JJ N
chemotaxis NN N
plays VBZ N
a DT N
reparative JJ N
role NN N
in IN N
the DT N
inflammatory JJ N
lesions NNS N
of IN N
rheumatoid JJ N
arthritis NN N
. . N

-DOCSTART- -X- O O 23975885

Increase NN N
in IN N
2-long JJ N
terminal JJ N
repeat NN N
circles NNS N
and CC N
decrease NN N
in IN N
D-dimer NNP N
after IN N
raltegravir JJ N
intensification NN N
in IN N
patients NNS N
with IN N
treated JJ N
HIV NNP 4_p
infection NN 4_p
: : N
a DT N
randomized JJ N
, , N
placebo-controlled JJ N
trial NN N
. . N

BACKGROUND VB N
The DT N
degree NN N
to TO N
which WDT N
human JJ N
immunodeficiency NN N
virus NN N
( ( N
HIV NNP N
) ) N
continues VBZ N
to TO N
replicate VB N
during IN N
antiretroviral JJ N
therapy NN N
( ( N
ART NNP N
) ) N
is VBZ N
controversial JJ N
. . N

We PRP N
conducted VBD N
a DT N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
to TO N
assess VB N
whether IN N
raltegravir JJ N
intensification NN N
reduces NNS N
low-level JJ N
viral JJ N
replication NN N
, , N
as IN N
defined VBN N
by IN N
an DT N
increase NN N
in IN N
the DT N
level NN N
of IN N
2-long JJ N
terminal JJ N
repeat NN N
( ( N
2-LTR JJ N
) ) N
circles NNS N
. . N

METHODS NNP N
Thirty-one JJ N
subjects NNS N
with IN N
an DT N
ART-suppressed JJ N
plasma NN N
HIV NNP N
RNA NNP N
level NN N
of IN N
< $ N
40 CD N
copies/mL NN N
and CC N
a DT N
CD4 NNP N
( ( N
+ NNP N
) ) N
T-cell NNP N
count NN N
of IN N
≥350 NNP N
cells/mm NN N
( ( N
3 CD N
) ) N
for IN N
≥1 JJ N
year NN N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
raltegravir NN N
400 CD N
mg NN N
twice RB N
daily RB N
or CC N
placebo VB N
for IN N
24 CD N
weeks NNS N
. . N

2-LTR JJ N
circles NNS N
were VBD N
analyzed VBN N
by IN N
droplet NN N
digital JJ N
polymerase NN N
chain NN N
reaction NN N
at IN N
weeks NNS N
0 CD N
, , N
1 CD N
, , N
2 CD N
, , N
and CC N
8 CD N
. . N

RESULTS VB N
The DT N
median JJ N
duration NN N
of IN N
ART NNP N
suppression NN N
was VBD N
3.8 CD N
years NNS N
. . N

The DT N
raltegravir NN N
group NN N
had VBD N
a DT N
significant JJ N
increase NN N
in IN N
the DT N
level NN N
of IN N
2-LTR JJ N
circles NNS N
, , N
compared VBN N
to TO N
the DT N
placebo NN N
group NN N
. . N

The DT N
week NN N
1 CD N
to TO N
0 CD N
ratio NN N
was VBD N
8.8-fold JJ N
higher JJR N
( ( N
P NNP N
= NNP N
.0025 NNP N
) ) N
and CC N
the DT N
week NN N
2 CD N
to TO N
0 CD N
ratio NN N
was VBD N
5.7-fold JJ N
higher JJR N
( ( N
P NNP N
= NNP N
.023 NNP N
) ) N
in IN N
the DT N
raltegravir NN N
vs. FW N
placebo NN N
group NN N
. . N

Intensification NNP N
also RB N
led VBD N
to TO N
a DT N
statistically RB N
significant JJ N
decrease NN N
in IN N
the DT N
D-dimer NNP N
level NN N
, , N
compared VBN N
to TO N
placebo VB N
( ( N
P NNP N
= NNP N
.045 NNP N
) ) N
. . N

CONCLUSIONS NNP N
Raltegravir NNP N
intensification NN N
resulted VBD N
in IN N
a DT N
rapid JJ N
increase NN N
in IN N
the DT N
level NN N
of IN N
2-LTR JJ N
circles NNS N
in IN N
a DT N
proportion NN N
of IN N
subjects NNS N
, , N
indicating VBG N
that IN N
low-level JJ N
viral JJ N
replication NN N
persists NNS N
in IN N
some DT N
individuals NNS N
even RB N
after IN N
long-term JJ N
ART NNP N
. . N

Intensification NNP N
also RB N
reduced VBD N
the DT N
D-dimer NNP N
level NN N
, , N
a DT N
coagulation NN N
biomarker NN N
that WDT N
is VBZ N
predictive JJ N
of IN N
morbidity NN N
and CC N
mortality NN N
among IN N
patients NNS N
receiving VBG N
treatment NN N
for IN N
HIV NNP N
infection NN N
. . N

-DOCSTART- -X- O O 17972479

Hitting VBG N
the DT N
target NN N
: : N
relatively RB N
easy JJ N
, , N
yet RB N
absolutely RB N
difficult JJ N
. . N

It PRP N
is VBZ N
generally RB N
agreed VBN N
that IN N
absolute-direction NN 4_p
judgments NNS 4_p
require VBP N
information NN N
about IN N
eye NN N
position NN N
, , N
whereas JJ N
relative-direction NN N
judgments NNS N
do VBP N
not RB N
. . N

The DT N
source NN N
of IN N
this DT N
eye-position JJ N
information NN N
, , N
particularly RB N
during IN N
monocular JJ N
viewing NN N
, , N
is VBZ N
a DT N
matter NN N
of IN N
debate NN N
. . N

It PRP N
may MD N
be VB N
either CC N
binocular VB N
eye NN N
position NN N
, , N
or CC N
the DT N
position NN N
of IN N
the DT N
viewing-eye JJ N
only RB N
, , N
that DT N
is VBZ N
crucial JJ N
. . N

Using VBG N
more RBR N
ecologically RB N
valid JJ N
stimulus NN N
situations NNS N
than IN N
the DT N
traditional JJ N
LED NNP N
in IN N
the DT N
dark NN N
, , N
we PRP N
performed VBD N
two CD N
experiments NNS N
. . N

In IN N
experiment JJ N
1 CD N
, , N
observers NNS 4_p
threw VBD 4_p
darts NNS 4_p
at IN 4_p
targets NNS 4_p
that WDT 4_p
were VBD 4_p
fixated VBN 4_p
either RB 4_p
monocularly RB 4_p
or CC 4_p
binocularly RB 4_p
. . 4_p

In IN N
experiment JJ N
2 CD N
, , N
observers NNS N
aimed VBD N
a DT N
laser NN N
gun NN N
at IN N
targets NNS N
while IN N
fixating VBG N
either CC N
the DT N
rear NN N
or CC N
the DT N
front JJ N
gunsight NN N
monocularly RB N
, , N
or CC N
the DT N
target NN N
either CC N
monocularly JJ 4_p
or CC 4_p
binocularly RB 4_p
. . N

We PRP N
measured VBD N
the DT N
accuracy NN N
and CC N
precision NN N
of IN N
the DT N
observers NNS N
' POS N
absolute- JJ N
and CC N
relative-direction JJ N
judgments NNS N
. . N

We PRP N
found VBD N
that IN N
( ( N
a DT N
) ) N
relative-direction NN N
judgments NNS N
were VBD N
precise JJ N
and CC N
independent JJ N
of IN N
phoria NN N
, , N
and CC N
( ( N
b NN N
) ) N
monocular JJ N
absolute-direction NN N
judgments NNS N
were VBD N
inaccurate JJ N
, , N
and CC N
the DT N
magnitude NN N
of IN N
the DT N
inaccuracy NN N
was VBD N
predictable JJ N
from IN N
the DT N
magnitude NN N
of IN N
phoria NN N
. . N

These DT N
results NNS N
confirm VBP N
that IN N
relative-direction NN N
judgments NNS N
do VBP N
not RB N
require VB N
information NN N
about IN N
eye NN N
position NN N
. . N

Moreover RB N
, , N
they PRP N
show VBP N
that IN N
binocular JJ N
eye-position NN N
information NN N
is VBZ N
crucial JJ N
when WRB N
judging VBG N
the DT N
absolute JJ N
direction NN N
of IN N
both DT N
monocular JJ N
and CC N
binocular JJ N
targets NNS N
. . N

-DOCSTART- -X- O O 21204103

Interleukin-6 NNP N
receptor NN N
inhibition NN N
with IN N
tocilizumab NN N
and CC N
attainment NN N
of IN N
disease NN N
remission NN N
in IN N
rheumatoid JJ N
arthritis NN N
: : N
the DT N
role NN N
of IN N
acute-phase JJ N
reactants NNS N
. . N

OBJECTIVE NN N
To TO N
determine VB N
the DT N
effects NNS N
of IN N
tocilizumab NN N
on IN N
rheumatoid NN N
arthritis NN N
( ( N
RA NNP N
) ) N
disease NN N
activity NN N
and CC N
remission NN N
assessment NN N
, , N
using VBG N
measures NNS N
that WDT N
do VBP N
or CC N
do VB N
not RB N
comprise VB N
acute-phase JJ N
reactants NNS N
. . N

METHODS NNP N
Simplified NNP N
Disease NNP N
Activity NNP N
Index NNP N
( ( N
SDAI NNP N
) ) N
scores VBZ N
, , N
Clinical JJ N
Disease NNP N
Activity NNP N
Index NNP N
( ( N
CDAI NNP N
) ) N
scores VBZ N
, , N
and CC N
the DT N
Disease NNP N
Activity NNP N
Score NNP N
in IN N
28 CD N
joints NNS N
( ( N
DAS28 NNP N
) ) N
were VBD N
calculated VBN N
using VBG N
data NNS N
from IN N
tocilizumab JJ N
trials NNS N
in IN N
patients NNS 4_p
with IN 4_p
RA NNP 4_p
in IN 4_p
whom WP 4_p
disease NN 4_p
had VBD 4_p
remained VBN 4_p
active JJ 4_p
despite IN 4_p
treatment NN 4_p
with IN 4_p
disease-modifying JJ 4_p
antirheumatic JJ 4_p
drugs NNS 4_p
. . 4_p

The DT N
CDAI NNP N
does VBZ N
not RB N
contain VB N
an DT N
acute-phase JJ N
reactant NN N
component NN N
. . N

Disease NNP N
activity NN N
states NNS N
, , N
including VBG N
remission NN N
, , N
were VBD N
defined VBN N
using VBG N
established VBN N
cut NN N
points NNS N
; : N
for IN N
the DT N
DAS28 NNP N
, , N
an DT N
alternative JJ N
cut NN N
point NN N
of IN N
< $ N
2.4 CD N
was VBD N
also RB N
used VBN N
. . N

RESULTS JJ N
Changes NNS N
in IN N
the DT N
DAS28 NNP N
, , N
the DT N
SDAI NNP N
score NN N
, , N
and CC N
the DT N
CDAI NNP N
score NN N
among IN N
patients NNS N
receiving VBG N
tocilizumab NN N
were VBD N
significantly RB N
higher JJR N
than IN N
those DT N
among IN N
patients NNS N
receiving VBG N
placebo NN N
, , N
and CC N
the DT N
magnitude NN N
of IN N
these DT N
changes NNS N
was VBD N
similar JJ N
for IN N
the DT N
SDAI NNP N
and CC N
the DT N
CDAI NNP N
. . N

Among IN N
patients NNS N
who WP N
achieved VBD N
50 CD N
% NN N
improvement NN N
in IN N
disease NN N
activity NN N
according VBG N
to TO N
the DT N
American NNP N
College NNP N
of IN N
Rheumatology NNP N
criteria NNS N
, , N
only RB N
∼20 VBZ N
% NN N
required VBN N
a DT N
reduction NN N
in IN N
acute-phase JJ N
reactant NN N
values NNS N
in IN N
order NN N
to TO N
fulfill VB N
the DT N
criteria NNS N
. . N

However RB N
, , N
DAS28 NNP N
remission NN N
rates NNS N
were VBD N
higher JJR N
( ( N
even RB N
when WRB N
using VBG N
the DT N
lower JJR N
cut NN N
point NN N
) ) N
than IN N
the DT N
SDAI NNP N
and CC N
CDAI NNP N
remission NN N
rates NNS N
. . N

Only RB N
a DT N
minority NN N
of IN N
tocilizumab-treated JJ N
patients NNS N
with IN N
DAS28 NNP N
remission NN N
also RB N
had VBD N
disease NN N
remission NN N
according VBG N
to TO N
the DT N
SDAI NNP N
( ( N
26 CD N
% NN N
) ) N
or CC N
CDAI NNP N
( ( N
∼21 NNP N
% NN N
) ) N
. . N

With IN N
infliximab JJ N
treatment NN N
, , N
SDAI NNP N
and CC N
CDAI NNP N
remission NN N
rates NNS N
were VBD N
of IN N
the DT N
same JJ N
magnitude NN N
as IN N
those DT N
observed VBN N
with IN N
tocilizumab JJ N
treatment NN N
, , N
and CC N
DAS28 NNP N
remission NN N
rates NNS N
were VBD N
lower JJR N
. . N

Tocilizumab-treated JJ N
patients NNS N
with IN N
DAS28 NNP N
remission NN N
but CC N
without IN N
CDAI NNP N
remission NN N
had VBD N
significantly RB N
higher JJR N
swollen JJ N
joint JJ N
counts NNS N
but CC N
lower JJR N
erythrocyte NN N
sedimentation NN N
rates NNS N
( ( N
ESRs NNP N
) ) N
compared VBN N
with IN N
patients NNS N
with IN N
SDAI NNP N
or CC N
CDAI NNP N
remission NN N
. . N

CONCLUSION NNP N
Disease NNP N
activity NN N
in IN N
RA NNP N
is VBZ N
reduced VBN N
by IN N
tocilizumab NN N
treatment NN N
, , N
irrespective NN N
of IN N
the DT N
type NN N
of IN N
composite JJ N
measure NN N
used VBN N
to TO N
evaluate VB N
disease NN N
activity NN N
. . N

Remission NN N
rates NNS N
were VBD N
much RB N
higher JJR N
using VBG N
the DT N
DAS28 NNP N
compared VBN N
with IN N
the DT N
SDAI NNP N
and CC N
CDAI NNP N
, , N
due JJ N
to TO N
the DT N
high JJ N
weight NN N
of IN N
the DT N
ESR NNP N
in IN N
the DT N
DAS28 NNP N
and CC N
the DT N
effect NN N
of IN N
tocilizumab NN N
on IN N
the DT N
ESR NNP N
. . N

Using VBG N
the DT N
stringent NN N
SDAI NNP N
and CC N
CDAI NNP N
criteria NNS N
, , N
however RB N
, , N
remission NN N
rates NNS N
in IN N
patients NNS N
treated VBN N
with IN N
tocilizumab NNS N
were VBD N
in IN N
the DT N
same JJ N
range NN N
as IN N
those DT N
seen VBN N
in IN N
patients NNS N
treated VBN N
with IN N
tumor NN N
necrosis NN N
factor NN N
inhibitors NNS N
. . N

-DOCSTART- -X- O O 9438269

Electrical JJ N
sources NNS N
of IN N
P300 NNP N
event-related JJ N
brain NN N
potentials NNS N
revealed VBN N
by IN N
low JJ N
resolution NN N
electromagnetic JJ N
tomography NN N
. . N

2 CD N
. . N

Effects NNS N
of IN N
nootropic JJ N
therapy NN N
in IN N
age-associated JJ 4_p
memory NN 4_p
impairment NN 4_p
. . N

In IN N
a DT N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
the DT N
effects NNS N
of IN N
Actovegin NNP N
on IN N
frontal JJ N
and CC N
parietal JJ N
electrical JJ N
P300 NNP N
sources NNS N
revealed VBN N
by IN N
low JJ N
resolution NN N
electromagnetic JJ N
tomography NN N
( ( N
LORETA NNP N
) ) N
were VBD N
studied VBN N
in IN N
age-associated JJ N
memory NN N
impairment NN N
( ( N
AAMI NNP N
) ) N
patients NNS N
. . N

Actovegin NNP N
is VBZ N
a DT N
protein-free JJ N
metabolically RB N
active JJ N
hemoderivative JJ N
improving NN N
oxygen NN N
and CC N
glucose JJ N
utilization NN N
. . N

Each DT N
patient NN N
had VBD N
, , N
in IN N
randomized JJ N
order NN N
, , N
a DT N
treatment NN N
of IN N
2 CD N
weeks NNS N
with IN N
250 CD N
ml NNS N
20 CD N
% NN N
Actovegin NNP N
and CC N
250 CD N
ml NNS N
placebo JJ N
daily RB N
. . N

Auditory NNP N
ERPs NNP N
were VBD N
recorded VBN N
before RB N
and CC N
5 CD N
h NN N
after IN N
drug NN N
administration NN N
on IN N
day NN N
1 CD N
( ( N
acute JJ N
effect NN N
) ) N
and CC N
on IN N
day NN N
15 CD N
( ( N
subacute NN N
and CC N
superimposed JJ N
effect NN N
) ) N
. . N

Compared VBN N
to TO N
age- JJ N
and CC N
sex-matched JJ N
normal JJ N
controls NNS N
, , N
AAMI NNP N
patients NNS N
showed VBD N
a DT N
trend NN N
towards VBZ N
P300 NNP N
latency NN N
prolongation NN N
and CC N
a DT N
significantly RB N
reduced VBN N
P300 NNP N
global JJ N
field NN N
power NN N
( ( N
GFP NNP N
) ) N
. . N

Maximal NNP N
LORETA NNP N
source NN N
strength NN N
did VBD N
not RB N
differ VB N
from IN N
controls NNS N
. . N

After IN N
Actovegin NNP N
parietal JJ N
P300 NNP N
scalp NN N
amplitudes NNS N
increased VBD N
, , N
while IN N
frontal JJ N
and CC N
temporal JJ N
amplitudes NNS N
decreased VBD N
as IN N
compared VBN N
to TO N
placebo VB N
. . N

This DT N
increase NN N
in IN N
hilliness NN N
, , N
measured VBN N
by IN N
the DT N
GFP NNP N
, , N
was VBD N
significant JJ N
. . N

Moreover RB N
, , N
the DT N
parietal JJ N
P300 NNP N
source NN N
strength NN N
increased VBD N
after IN N
acute NN N
, , N
subacute NN N
and CC N
superimposed JJ N
infusion NN N
of IN N
Actovegin NNP N
as IN N
compared VBN N
to TO N
placebo VB N
. . N

This DT N
may MD N
reflect VB N
improved JJ N
availability NN N
of IN N
cognitive JJ N
processing NN N
resources NNS N
in IN N
the DT N
parietal JJ N
cortex NN N
, , N
an DT N
area NN N
that WDT N
on IN N
the DT N
one CD N
hand NN N
plays VBZ N
an DT N
important JJ N
role NN N
in IN N
fundamental JJ N
aspects NNS N
of IN N
attention NN N
and CC N
on IN N
the DT N
other JJ N
hand NN N
has VBZ N
been VBN N
found VBN N
to TO N
be VB N
functionally RB N
impaired VBN N
in IN N
dementia NN N
. . N

-DOCSTART- -X- O O 22434360

Pemetrexed NNP N
in IN N
combination NN N
with IN N
cisplatin JJ N
versus NN N
cisplatin NN N
monotherapy NN N
in IN N
patients NNS N
with IN N
recurrent NN N
or CC N
metastatic JJ N
head NN 4_p
and CC 4_p
neck NN 4_p
cancer NN 4_p
: : N
final JJ N
results NNS N
of IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
, , N
phase VB N
3 CD N
study NN N
. . N

BACKGROUND NNP N
Recurrent NNP N
or CC N
metastatic JJ N
squamous JJ 4_p
cell NN 4_p
carcinoma NN 4_p
of IN N
the DT N
head NN N
and CC N
neck NN N
( ( N
SCCHN NNP N
) ) N
is VBZ N
associated VBN N
with IN N
poor JJ N
survival NN N
. . N

Platinum-based JJ N
chemotherapy NN N
is VBZ N
often RB N
a DT N
first-line JJ N
treatment NN N
. . N

Pemetrexed NNP N
has VBZ N
shown VBN N
single-agent JJ N
activity NN N
in IN N
SCCHN NNP N
and CC N
in IN N
combination NN N
with IN N
cisplatin NN N
for IN N
other JJ N
tumors NNS N
. . N

This DT N
trial NN N
examined VBD N
the DT N
efficacy NN N
of IN N
pemetrexed-cisplatin NN N
for IN N
SCCHN NNP N
. . N

METHODS NNP N
In IN N
a DT N
double-blind JJ N
phase NN N
3 CD N
trial NN N
, , N
patients NNS N
with IN N
recurrent NN N
or CC N
metastatic JJ N
SCCHN NNP 4_p
and CC N
no DT N
prior JJ N
systemic JJ N
therapy NN N
for IN N
metastatic JJ N
disease NN N
were VBD N
randomized VBN N
to TO N
pemetrexed VB N
( ( N
500 CD N
mg/m NN N
( ( N
2 CD N
) ) N
) ) N
plus CC N
cisplatin NN N
( ( N
75 CD N
mg/m NN N
( ( N
2 CD N
) ) N
; : N
n CC N
= VB N
398 CD N
) ) N
or CC N
placebo JJ N
plus CC N
cisplatin NN N
( ( N
75 CD N
mg/m NN N
( ( N
2 CD N
) ) N
; : N
n CC N
= VB N
397 CD N
) ) N
to TO N
assess VB N
overall JJ N
survival NN N
( ( N
OS NNP N
) ) N
and CC N
secondary JJ N
endpoints NNS N
. . N

RESULTS NNP N
Median JJ N
OS NNP N
was VBD N
7.3 CD N
months NNS N
in IN N
the DT N
pemetrexed-cisplatin JJ N
arm NN N
and CC N
6.3 CD N
months NNS N
in IN N
the DT N
placebo-cisplatin JJ N
arm NN N
( ( N
hazard JJ N
ratio NN N
[ NNP N
HR NNP N
] NNP N
, , N
0.87 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
, , N
0.75-1.02 NNP N
; : N
P NNP N
= NNP N
.082 NNP N
) ) N
. . N

Median JJ N
progression-free JJ N
survival NN N
( ( N
PFS NNP N
, , N
months NNS N
) ) N
was VBD N
similar JJ N
in IN N
both DT N
treatment NN N
arms NNS N
( ( N
pemetrexed-cisplatin NN N
, , N
3.6 CD N
; : N
placebo-cisplatin NN N
, , N
2.8 CD N
; : N
HR NNP N
, , N
0.88 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.76-1.03 NNP N
; : N
P NNP N
= NNP N
.166 NNP N
) ) N
. . N

Among IN N
patients NNS N
with IN N
performance NN N
status NN N
0 CD N
or CC N
1 CD N
, , N
pemetrexed-cisplatin NN N
( ( N
n JJ N
= NNP N
347 CD N
) ) N
led VBD N
to TO N
longer JJR N
OS NNP N
and CC N
PFS NNP N
than IN N
placebo-cisplatin NN N
( ( N
n JJ N
= VBZ N
343 CD N
; : N
8.4 CD N
vs IN N
6.7 CD N
months NNS N
; : N
HR NNP N
, , N
0.83 CD N
; : N
P NNP N
= NNP N
.026 NNP N
; : N
4.0 CD N
vs IN N
3.0 CD N
months NNS N
; : N
HR NNP N
, , N
0.84 CD N
; : N
P NNP N
= NNP N
.044 NNP N
, , N
respectively RB N
) ) N
. . N

Among IN N
patients NNS N
with IN N
oropharyngeal JJ 4_p
cancers NNS 4_p
, , N
pemetrexed-cisplatin NN N
( ( N
n JJ N
= NNP N
86 CD N
) ) N
resulted VBD N
in IN N
longer JJR N
OS NNP N
and CC N
PFS NNP N
than IN N
placebo-cisplatin NN N
( ( N
n JJ N
= VBZ N
106 CD N
; : N
9.9 CD N
vs IN N
6.1 CD N
months NNS N
; : N
HR NNP N
, , N
0.59 CD N
; : N
P NNP N
= NNP N
.002 NNP N
; : N
4.0 CD N
vs IN N
3.4 CD N
months NNS N
; : N
HR NNP N
, , N
0.73 CD N
; : N
P NNP N
= NNP N
.047 NNP N
, , N
respectively RB N
) ) N
. . N

Pemetrexed-cisplatin JJ N
toxicity NN N
was VBD N
consistent JJ N
with IN N
studies NNS N
in IN N
other JJ N
tumors NNS N
. . N

CONCLUSIONS NNP N
Pemetrexed-cisplatin NNP N
compared VBN N
with IN N
placebo-cisplatin NN N
did VBD N
not RB N
significantly RB N
improve VB N
survival NN N
for IN N
the DT N
intent-to-treat JJ N
population NN N
. . N

However RB N
, , N
in IN N
a DT N
prespecified JJ N
subgroup NN N
analysis NN N
, , N
pemetrexed-cisplatin NN N
showed VBD N
OS NNP N
and CC N
PFS NNP N
advantage NN N
for IN N
patients NNS N
with IN N
performance NN N
status NN N
0 CD N
or CC N
1 CD N
or CC N
oropharyngeal JJ N
cancers NNS N
. . N

-DOCSTART- -X- O O 22709747

Rationale NNP N
and CC N
study VB N
design NN N
of IN N
the DT N
increase NN N
of IN N
vagal JJ N
tone NN N
in IN N
heart NN N
failure NN N
study NN N
: : N
INOVATE-HF NNP N
. . N

BACKGROUND NNP N
Imbalance NNP N
between IN N
the DT N
parasympathetic JJ N
and CC N
sympathetic JJ N
nervous JJ N
systems NNS N
is VBZ N
a DT N
recognized VBN N
contributor NN N
to TO N
progression NN N
of IN N
chronic JJ N
heart NN N
failure NN N
. . N

Current JJ N
therapy NN N
with IN N
beta NN N
adrenergic JJ N
antagonists NNS N
is VBZ N
designed VBN N
to TO N
moderate VB N
the DT N
up-regulation NN N
of IN N
norepinephrine NN N
and CC N
sympathetic JJ N
effects NNS N
; : N
however RB N
, , N
to TO N
date NN N
, , N
there EX N
are VBP N
no DT N
therapies NNS N
that WDT N
specifically RB N
address VBP N
the DT N
withdrawal NN N
of IN N
parasympathetic JJ N
influences NNS N
on IN N
cardiac JJ N
function NN N
and CC N
structure NN N
. . N

METHODS/RESULTS NNP N
In IN N
order NN N
to TO N
evaluate VB N
the DT N
impact NN N
of IN N
vagus NN N
nerve NN N
stimulation NN N
, , N
an DT N
international JJ N
multi-center NN N
randomized VBD N
clinical JJ N
trial NN N
( ( N
INOVATE-HF NNP N
) ) N
has VBZ N
been VBN N
designed VBN N
to TO N
assess VB N
safety NN N
and CC N
efficacy NN N
of IN N
vagus NN N
nerve NN N
stimulation NN N
in IN N
symptomatic JJ N
patients NNS N
with IN N
heart NN N
failure NN N
on IN N
optimal JJ N
medical JJ N
therapy NN N
using VBG N
the DT N
CardioFit NNP N
System NNP N
( ( N
BioControl NNP N
Medical NNP N
, , N
Yehud NNP N
, , N
Israel NNP N
) ) N
. . N

Up UH N
to TO N
650 CD N
patients NNS N
from IN N
80 CD N
sites NNS N
will MD N
be VB N
recruited VBN N
and CC N
randomized VBN N
in IN N
a DT N
3:2 CD N
ratio NN N
to TO N
receive VB N
active JJ N
treatment NN N
or CC N
standard NN N
optimal JJ N
medical JJ N
therapy NN N
. . N

Inclusion NNP N
criteria NNS N
include VBP N
left JJ N
ventricular JJ N
systolic JJ N
dysfunction NN N
, , N
the DT N
presence NN N
of IN N
New NNP N
York NNP N
Heart NNP N
Association NNP N
Class NNP N
III NNP N
symptoms NNS N
, , N
sinus NN N
rhythm NN N
, , N
and CC N
QRS NNP N
width VBD N
less JJR N
than IN N
120 CD N
milliseconds NNS N
. . N

The DT N
study NN N
is VBZ N
powered VBN N
to TO N
detect VB N
differences NNS N
in IN N
the DT N
primary JJ N
efficacy JJ N
end NN N
point NN N
of IN N
all-cause JJ N
mortality NN N
and CC N
heart NN N
failure NN N
hospitalization NN N
and CC N
2 CD N
safety NN N
end NN N
points NNS N
. . N

CONCLUSION NNP N
Vagal NNP N
nerve NN N
stimulation NN N
with IN N
CardioFit NNP N
as IN N
a DT N
treatment NN N
for IN N
symptomatic JJ N
heart NN N
failure NN N
is VBZ N
under IN N
active JJ N
investigation NN N
as IN N
a DT N
novel JJ N
approach NN N
to TO N
restore VB N
balance NN N
between IN N
the DT N
sympathetic JJ N
and CC N
parasympathetic JJ N
nervous JJ N
systems NNS N
. . N

If IN N
shown VBN N
to TO N
be VB N
safe JJ N
and CC N
effective JJ N
in IN N
decreasing VBG N
heart NN N
failure NN N
events NNS N
and CC N
mortality NN N
, , N
this DT N
novel JJ N
approach NN N
will MD N
impact VB N
the DT N
treatment NN N
paradigm NN N
for IN N
heart NN N
failure NN N
. . N

-DOCSTART- -X- O O 6756508

Randomized NNP N
clinical JJ N
trial NN N
of IN N
tamoxifen JJ N
plus CC N
sequential JJ N
CMF NNP N
chemotherapy NN N
versus NN N
tamoxifen NN N
alone RB N
in IN N
postmenopausal JJ 4_p
women NNS N
with IN N
advanced JJ 4_p
breast NN 4_p
cancer NN 4_p
. . N

Eighty-eight JJ N
postmenopausal JJ N
women NNS N
with IN N
metastatic JJ N
breast NN N
cancer NN N
, , N
in IN N
whom WP N
estrogen NN 4_p
receptors NNS 4_p
( ( 4_p
ER NNP 4_p
) ) 4_p
were VBD 4_p
positive JJ 4_p
or CC 4_p
unknown JJ 4_p
, , N
were VBD N
treated VBN N
on IN N
a DT N
controlled VBN N
trial NN N
to TO N
determine VB N
the DT N
effectiveness NN N
of IN N
tamoxifen NN N
and CC N
to TO N
assess VB N
the DT N
therapeutic JJ N
advantage NN N
of IN N
sequentially RB N
adding VBG N
low-dose JJ N
cyclophosphamide-methotrexate-5-fluorouracil NN N
( ( N
CMF NNP N
) ) N
chemotherapy NN N
in IN N
tamoxifen JJ N
responders NNS N
. . N

Patients NNS N
with IN N
known JJ N
ER NNP N
negative JJ N
status NN N
were VBD N
not RB N
studied VBN N
. . N

After IN N
the DT N
initial JJ N
12-week JJ N
treatment NN N
with IN N
tamoxifen NN N
alone RB N
, , N
60 CD N
% NN N
of IN N
ER NNP N
positive JJ N
patients NNS N
achieved VBD N
complete JJ N
or CC N
partial JJ N
response NN N
as IN N
did VBD N
35 CD N
% NN N
in IN N
whom WP N
ER NNP N
were VBD N
unknown JJ N
. . N

Response VB N
status NN N
further RB N
improved VBN N
in IN N
18 CD N
% NN N
randomized VBN N
to TO N
continue VB N
tamoxifen VB N
alone RB N
vs JJ N
31 CD N
% NN N
in IN N
whom WP N
CMF NNP N
was VBD N
added VBN N
to TO N
tamoxifen VB N
. . N

There EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
in IN N
time NN N
to TO N
the DT N
development NN N
of IN N
progressive JJ N
disease NN N
or CC N
survival NN N
between IN N
the DT N
ER NNP N
positive JJ N
and CC N
ER NNP N
unknown JJ N
patients NNS N
or CC N
between IN N
the DT N
tamoxifen NN N
and CC N
tamoxifen JJ N
plus CC N
CMF JJ N
groups NNS N
. . N

We PRP N
conclude VBP N
that DT N
inability NN N
to TO N
determine VB N
ER NNP N
status NN N
should MD N
not RB N
prejudice VB N
against IN N
the DT N
use NN N
of IN N
tamoxifen NN N
in IN N
postmenopausal NN N
patients NNS N
with IN N
advanced JJ N
breast NN N
cancer NN N
. . N

No DT N
benefit NN N
has VBZ N
been VBN N
demonstrated VBN N
from IN N
the DT N
addition NN N
of IN N
CMF NNP N
chemotherapy NN N
in IN N
tamoxifen JJ N
responders NNS N
. . N

-DOCSTART- -X- O O 4353587

A DT N
study NN N
of IN N
postoperative JJ 4_p
cytostatic JJ 4_p
medication NN 4_p
in IN N
patients NNS N
with IN 4_p
operable JJ 4_p
carcinoma NN 4_p
of IN 4_p
the DT 4_p
lung NN 4_p
. . N

-DOCSTART- -X- O O 25542821

Efficacy NN N
and CC N
safety NN N
of IN N
repeated VBN N
use NN N
of IN N
ulipristal JJ N
acetate NN N
in IN N
uterine JJ 4_p
fibroids NNS 4_p
. . 4_p

OBJECTIVE NNP N
To TO N
investigate VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
repeated VBN N
12-week JJ N
courses NNS N
of IN N
5 CD N
or CC N
10 CD N
mg JJ N
daily NN N
of IN N
ulipristal JJ N
acetate NN N
for IN N
intermittent JJ N
treatment NN N
of IN N
symptomatic JJ 4_p
uterine JJ 4_p
fibroids NNS 4_p
. . 4_p

DESIGN NNP N
Double-blind NNP N
, , N
randomized JJ N
administration NN N
of IN N
two CD N
12-week JJ N
courses NNS N
of IN N
ulipristal JJ N
acetate NN N
. . N

SETTING NNP N
Gynecology NNP 4_p
centers NNS 4_p
. . 4_p

PATIENT NNP N
( ( N
S NNP N
) ) N
A NNP N
total NN N
of IN N
451 CD N
patients NNS N
with IN N
symptomatic JJ 4_p
uterine JJ 4_p
fibroid NN 4_p
( ( 4_p
s NN 4_p
) ) 4_p
and CC 4_p
heavy JJ 4_p
bleeding NN 4_p
. . N

INTERVENTION NNP N
( ( N
S NNP N
) ) N
Two CD N
repeated VBD N
12-week JJ N
treatment NN N
courses NNS N
of IN N
daily JJ N
5 CD N
or CC N
10 CD N
mg NN N
of IN N
ulipristal JJ N
acetate NN N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURE NNP N
( ( N
S NNP N
) ) N
Amenorrhea NNP N
, , N
controlled VBD N
bleeding NN N
, , N
fibroid JJ N
volume NN N
, , N
quality NN N
of IN N
life NN N
( ( N
QoL NNP N
) ) N
, , N
pain NN N
. . N

RESULT NNP N
( ( N
S NNP N
) ) N
In IN N
the DT N
5- JJ N
and CC N
10-mg JJ N
treatment NN N
groups NNS N
( ( N
62 CD N
% NN N
and CC N
73 CD N
% NN N
of IN N
patients NNS N
, , N
respectively RB N
) ) N
achieved VBD N
amenorrhea NN N
during IN N
both DT N
treatment NN N
courses NNS N
. . N

Proportions NNS N
of IN N
patients NNS N
achieving VBG N
controlled VBD N
bleeding VBG N
during IN N
two CD N
treatment NN N
courses NNS N
were VBD N
> JJ N
80 CD N
% NN N
. . N

Menstruation NN N
resumed VBD N
after IN N
each DT N
treatment NN N
course NN N
and CC N
was VBD N
diminished VBN N
compared VBN N
with IN N
baseline NN N
. . N

After IN N
the DT N
second JJ N
treatment NN N
course NN N
, , N
median JJ N
reductions NNS N
from IN N
baseline NN N
in IN N
fibroid JJ N
volume NN N
were VBD N
54 CD N
% NN N
and CC N
58 CD N
% NN N
for IN N
the DT N
patients NNS N
receiving VBG N
5 CD N
and CC N
10 CD N
mg NN N
of IN N
ulipristal JJ N
acetate NN N
, , N
respectively RB N
. . N

Pain NN N
and CC N
QoL NNP N
improved VBN N
in IN N
both DT N
groups NNS N
. . N

Ulipristal JJ N
acetate NN N
was VBD N
well RB N
tolerated VBN N
with IN N
less JJR N
than IN N
5 CD N
% NN N
of IN N
patients NNS N
discontinuing VBG N
treatment NN N
due JJ N
to TO N
adverse JJ N
events NNS N
. . N

CONCLUSION NNP N
( ( N
S NNP N
) ) N
Repeated VBD N
12-week JJ N
courses NNS N
of IN N
daily JJ N
oral JJ N
ulipristal JJ N
acetate NN N
( ( N
5 CD N
and CC N
10 CD N
mg NN N
) ) N
effectively RB N
control VBP N
bleeding VBG N
and CC N
pain NN N
, , N
reduce VB N
fibroid JJ N
volume NN N
, , N
and CC N
restore VB N
QoL NNP N
in IN N
patients NNS N
with IN N
symptomatic JJ N
fibroids NNS N
. . N

CLINICAL NNP N
TRIAL NNP N
REGISTRATION NNP N
NUMBER NNP N
NCT01629563 NNP N
( ( N
PEARL NNP N
IV NNP N
) ) N
. . N

-DOCSTART- -X- O O 9777717

Evaluation NN N
of IN N
the DT N
safety NN N
, , N
immunogenicity NN N
, , N
and CC N
pharmacokinetic JJ N
profile NN N
of IN N
a DT N
new JJ N
, , N
highly RB N
purified VBN N
, , N
heat-treated JJ N
equine NN N
rabies NNS N
immunoglobulin VBP N
, , N
administered VBD N
either CC N
alone RB N
or CC N
in IN N
association NN N
with IN N
a DT N
purified JJ N
, , N
Vero-cell NNP N
rabies VBZ N
vaccine NN N
. . N

A DT N
clinical JJ N
evaluation NN N
of IN N
a DT N
new JJ N
, , N
purified JJ N
, , N
heat-treated JJ N
equine NN N
rabies NNS N
immunoglobulin VBP N
( ( N
PHT-Erig NNP N
) ) N
, , N
F NNP N
( ( N
ab IN N
' POS N
) ) N
2 CD N
preparation NN N
, , N
was VBD N
carried VBN N
out RP N
in IN N
Thailand NNP N
and CC N
in IN N
the DT N
Philippines-two JJ N
countries NNS N
where WRB N
rabies NNS N
is VBZ N
endemic JJ N
. . N

An DT N
initial JJ N
prospective NN N
, , N
randomised VBN N
, , N
controlled VBN N
trial NN N
( ( N
Study NNP N
1 CD N
) ) N
, , N
compared VBN N
the DT N
safety NN N
and CC N
pharmacokinetics NNS N
( ( N
serum JJ N
concentrations NNS N
of IN N
rabies NNS N
antibodies NNS N
) ) N
after IN N
administration NN N
either DT N
of IN N
PHT-Erig NNP N
or CC N
of IN N
a DT N
commercially-available JJ N
, , N
equine JJ N
rabies NNS N
immune VBP N
globulin NN N
( ( N
Erig NNP N
PMC NNP N
) ) N
. . N

A DT N
second JJ N
trial NN N
( ( N
Study NNP N
2 CD N
) ) N
simulated VBD N
post-exposure JJ N
rabies NNS N
prophylaxis VBN N
by IN N
using VBG N
a DT N
reference NN N
cell NN N
culture NN N
vaccine NN N
, , N
the DT N
purified JJ N
Vero-cell NNP N
rabies NNS N
vaccine NN N
( ( N
PVRV NNP N
) ) N
, , N
administered VBN N
in IN N
association NN N
with IN N
either DT N
Erig NNP N
PMC NNP N
or CC N
PHT-Erig NNP N
. . N

In IN N
Study NNP N
1 CD N
, , N
27 CD N
healthy JJ N
, , N
Thai NNP N
adults NNS N
received VBD N
a DT N
40 CD N
IU NNP N
kg NN N
( ( N
-1 NNP N
) ) N
dose NN N
of IN N
either DT N
Erig NNP N
PMC NNP N
( ( N
n JJ N
= NNP N
12 CD N
) ) N
or CC N
PHT-Erig NNP N
( ( N
n JJ N
= NNP N
15 CD N
) ) N
via IN N
the DT N
intramuscular NN N
( ( N
i.m JJ N
. . N

) ) N
route NN N
; : N
half NN N
of IN N
the DT N
dose NN N
was VBD N
injected VBN N
into IN N
the DT N
deltoid JJ N
area NN N
and CC N
the DT N
other JJ N
half NN N
into IN N
the DT N
buttocks NNS N
. . N

Serum NNP N
for IN N
rabies NNS N
antibody JJ N
determination NN N
and CC N
F NNP N
( ( N
ab IN N
' POS N
) ) N
2 CD N
concentration NN N
was VBD N
collected VBN N
at IN N
hours NNS N
( ( N
H NNP N
) ) N
0 CD N
, , N
6 CD N
and CC N
12 CD N
, , N
and CC N
on IN N
day NN N
( ( N
D NNP N
) ) N
2 CD N
, , N
3 CD N
, , N
4 CD N
, , N
6 CD N
, , N
8 CD N
, , N
10 CD N
, , N
12 CD N
and CC N
15 CD N
. . N

Both DT N
products NNS N
were VBD N
safe JJ N
, , N
with IN N
no DT N
serious JJ N
adverse JJ N
events NNS N
, , N
and CC N
in IN N
particular JJ N
, , N
no DT N
anaphylactic JJ N
reactions NNS N
or CC N
serum NN N
sickness NN N
was VBD N
reported VBN N
. . N

A DT N
statistical JJ N
comparison NN N
of IN N
the DT N
pharmacokinetic JJ N
parameters NNS N
did VBD N
not RB N
demonstrate VB N
bioequivalence NN N
of IN N
the DT N
two CD N
products NNS N
. . N

Nonetheless RB N
, , N
the DT N
relative JJ N
bioavailability NN N
of IN N
93 CD N
% NN N
and CC N
the DT N
similar JJ N
absorption NN N
rates NNS N
suggest VBP N
the DT N
pharmacokinetic JJ N
profiles NNS N
of IN N
Erig NNP N
and CC N
PHT-Erig NNP N
are VBP N
similar JJ N
. . N

The DT N
antibody NN N
level NN N
in IN N
either DT N
group NN N
were VBD N
low JJ N
throughout IN N
the DT N
15-day JJ N
study NN N
period NN N
. . N

The DT N
geometric JJ N
mean NN N
titer NN N
( ( N
GMT NNP N
) ) N
values NNS N
ranged VBD N
from IN N
group NN N
0.027-0.117 CD N
IU NNP N
ml NN N
( ( N
-1 NN N
) ) N
in IN N
the DT N
Erig NNP N
group NN N
and CC N
from IN N
0.029 CD N
to TO N
0.072 CD N
IU NNP N
ml NN N
( ( N
-1 NN N
) ) N
in IN N
the DT N
PHT-Erig NNP N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
evolution NN N
of IN N
GMT NNP N
values NNS N
for IN N
the DT N
two CD N
groups NNS N
. . N

In IN N
Study NNP N
2 CD N
, , N
71 CD N
healthy JJ N
volunteers NNS N
received VBD N
40 CD N
IU NNP N
kg NN N
( ( N
-1 JJ N
) ) N
via IN N
the DT N
intramuscular JJ N
route NN N
of IN N
either DT N
Erig NNP N
PMC NNP N
( ( N
n JJ N
= NNP N
36 CD N
) ) N
or CC N
PHT-Erig NNP N
( ( N
n JJ N
= NNP N
35 CD N
) ) N
on IN N
D0 NNP N
, , N
in IN N
association NN N
with IN N
five CD N
doses NNS N
of IN N
PVRV NNP N
on IN N
D0 NNP N
, , N
D3 NNP N
, , N
D7 NNP N
, , N
D14 NNP N
and CC N
D28 NNP N
. . N

The DT N
safety NN N
evaluation NN N
was VBD N
performed VBN N
during IN N
the DT N
28-day JJ N
follow-up NN N
and CC N
serum NN N
samples NNS N
for IN N
anti-rabies NNS N
antibody JJ N
titration NN N
were VBD N
collected VBN N
on IN N
D0 NNP N
( ( N
before IN N
injection NN N
) ) N
D3 NNP N
, , N
D7 NNP N
, , N
D14 NNP N
and CC N
D28 NNP N
. . N

No NNP N
serious JJ N
reactions NNS N
were VBD N
reported VBN N
in IN N
either DT N
group NN N
. . N

In IN N
particular JJ N
, , N
no DT N
immediate JJ N
( ( N
anaphylactic JJ N
type NN N
) ) N
or CC N
delayed VBN N
( ( N
serum JJ N
sickness NN N
) ) N
allergic NN N
reactions NNS N
were VBD N
observed VBN N
. . N

Over IN N
the DT N
28-day JJ N
follow-up JJ N
period NN N
, , N
GMT NNP N
profiles NNS N
of IN N
the DT N
two CD N
groups NNS N
were VBD N
statistically RB N
equivalent JJ N
. . N

On IN N
D14 NNP N
, , N
100 CD N
% NN N
of IN N
the DT N
subjects NNS N
had VBD N
protective JJ N
antibody NN N
titers NNS N
( ( N
anti-rabies JJ N
antibodies NNS N
> VBP N
or CC N
= VBP N
0.5 CD N
IU NNP N
ml NN N
( ( N
-1 NNP N
) ) N
, , N
which WDT N
is VBZ N
the DT N
WHO-recommended JJ N
level NN N
of IN N
seroconversion NN N
) ) N
, , N
and CC N
Erig NNP N
PMC NNP N
and CC N
PHT-Erig NNP N
were VBD N
indistinguishable JJ N
according VBG N
to TO N
the DT N
clinical JJ N
definition NN N
chosen VBN N
. . N

On IN N
D28 NNP N
, , N
the DT N
GMT NNP N
values NNS N
were VBD N
33.2 CD N
IU NNP N
ml NN N
( ( N
-1 NN N
) ) N
( ( N
95 CD N
% NN N
CI NNP N
, , N
23.8-46.1 JJ N
IU NNP N
ml NN N
( ( N
-1 NNP N
) ) N
) ) N
in IN N
the DT N
Erig NNP N
PMC/PVRV NNP N
group NN N
and CC N
31.4 CD N
IU NNP N
ml NN N
( ( N
-1 NN N
) ) N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
CI NNP N
, , N
23.4-42.2 JJ N
IU NNP N
ml NN N
( ( N
-1 NNP N
) ) N
) ) N
in IN N
the DT N
PHT-Erig/PVRV NNP N
group NN N
, , N
showing VBG N
evidence NN N
of IN N
adequate JJ N
vaccine-induced JJ N
antibody NN N
responses NNS N
in IN N
both DT N
groups NNS N
. . N

The DT N
increased JJ N
purity NN N
, , N
the DT N
heat-treatment JJ N
step NN N
introduced VBN N
in IN N
the DT N
manufacturing NN N
process NN N
of IN N
PHT-Erig NNP N
, , N
and CC N
the DT N
good JJ N
clinical JJ N
results NNS N
substantiate VBP N
the DT N
use NN N
of IN N
this DT N
new JJ N
generation NN N
, , N
purified JJ N
equine NN N
F NNP N
( ( N
ab IN N
' POS N
) ) N
2 CD N
preparation NN N
in IN N
the DT N
post-exposure JJ N
prophylaxis NN N
of IN N
rabies NNS N
. . N

-DOCSTART- -X- O O 24737062

Classification NN N
of IN N
motor NN N
imagery NN N
performance NN N
in IN N
acute JJ 4_p
stroke NN 4_p
. . N

OBJECTIVE NNP N
Effective NNP N
motor NN N
imagery NN N
performance NN N
, , N
seen VBN N
as IN N
strong JJ N
suppression NN N
of IN N
the DT N
sensorimotor NN N
rhythm NN N
, , N
is VBZ N
the DT N
key JJ N
element NN N
in IN N
motor NN N
imagery NN N
therapy NN N
. . N

Therefore RB N
, , N
optimization NN N
of IN N
methods NNS N
to TO N
classify VB N
whether IN N
the DT N
subject NN N
is VBZ N
performing VBG N
the DT N
imagery NN N
task NN N
is VBZ N
a DT N
prerequisite NN N
. . N

An DT N
optimal JJ N
classification NN N
method NN N
should MD N
have VB N
high JJ N
performance NN N
accuracy NN N
and CC N
use VB N
a DT N
small JJ N
number NN N
of IN N
channels NNS N
. . N

We PRP N
investigated VBD N
the DT N
additional JJ N
benefit NN N
of IN N
the DT N
common JJ N
spatial JJ N
pattern NN N
filtering NN N
( ( N
CSP NNP N
) ) N
to TO N
a DT N
linear JJ N
discriminant JJ N
analysis NN N
( ( N
LDA NNP N
) ) N
classifier NN N
, , N
for IN N
different JJ N
channel NN N
configurations NNS N
. . N

METHODS NNP N
Ten NNP N
hemispheric JJ N
acute NN N
stroke NN N
patients NNS N
and CC N
11 CD N
healthy JJ N
subjects NNS N
were VBD N
included VBN N
. . N

EEGs NNP N
were VBD N
recorded VBN N
using VBG N
60 CD N
channels NNS N
. . N

The DT N
classifier NN N
was VBD N
trained VBN N
with IN N
a DT N
motor NN N
execution NN N
task NN N
. . N

For IN N
both DT N
healthy JJ N
controls NNS N
and CC N
patients NNS N
, , N
analysis NN N
of IN N
recordings NNS N
was VBD N
initially RB N
limited VBN N
to TO N
3 CD N
and CC N
11 CD N
electrodes NNS N
recording VBG N
from IN N
the DT N
motor NN N
cortex JJ N
area NN N
, , N
and CC N
later RB N
repeated VBD N
using VBG N
45 CD N
electrodes NNS N
. . N

RESULTS NNP N
No NNP N
significant JJ N
improvement NN N
on IN N
the DT N
addition NN N
of IN N
CSP NNP N
to TO N
LDA NNP N
was VBD N
found VBN N
( ( N
in IN N
both DT N
cases NNS N
, , N
the DT N
area NN N
under IN N
the DT N
receiving NN N
operating VBG N
characteristic JJ N
( ( N
AU-ROC NNP N
) ) N
≈ VBZ N
0.70 CD N
( ( N
acceptable JJ N
) ) N
) ) N
. . N

We PRP N
then RB N
repeated VBD N
the DT N
LDA+CSP NNP N
method NN N
on IN N
recordings NNS N
of IN N
45 CD N
electrodes NNS N
, , N
since IN N
the DT N
use NN N
of IN N
imagery JJ N
neuronal JJ N
circuits NNS N
may MD N
well RB N
extend VB N
beyond IN N
the DT N
motor NN N
area NN N
. . N

AU-ROC NNP N
rose VBD N
to TO N
0.90 CD N
, , N
but CC N
no DT N
virtual JJ N
'most POS N
responsible JJ N
' '' N
electrode NN N
was VBD N
observed VBN N
. . N

Finally RB N
, , N
in IN 4_p
mild-to-moderate JJ 4_p
stroke NN 4_p
patients NNS 4_p
we PRP N
could MD N
successfully RB N
use VB N
the DT N
EEG NNP N
data NNS N
recorded VBD N
from IN N
the DT N
healthy JJ N
hemisphere NN N
to TO N
train VB N
the DT N
classifier NN N
( ( N
AU-ROC NNP N
≈ NNP N
0.70 CD N
) ) N
. . N

SIGNIFICANCE NNP N
Including VBG N
only RB N
the DT N
channels NNS N
on IN N
the DT N
unaffected JJ N
motor NN N
cortex NN N
is VBZ N
sufficient JJ N
to TO N
train VB N
a DT N
classifier NN N
. . N

-DOCSTART- -X- O O 15816106

The DT N
influence NN N
of IN N
epidermal JJ N
growth NN N
factor NN N
receptor NN N
and CC N
tumor NN N
differentiation NN N
on IN N
the DT N
response NN N
to TO N
accelerated VBN N
radiotherapy NN N
of IN N
squamous JJ 4_p
cell NN 4_p
carcinomas NN 4_p
of IN 4_p
the DT 4_p
head NN 4_p
and CC 4_p
neck NN 4_p
in IN N
the DT N
randomized JJ N
DAHANCA NNP N
6 CD N
and CC N
7 CD N
study NN N
. . N

BACKGROUND NNP N
AND NNP N
PURPOSE NNP N
Reduction NNP N
of IN N
the DT N
overall JJ N
treatment NN N
time NN N
of IN N
radiotherapy NN N
has VBZ N
increased VBN N
locoregional JJ N
control NN N
and CC N
disease NN N
specific JJ N
survival NN N
in IN N
squamous JJ 4_p
cell NN 4_p
carcinomas NN 4_p
of IN 4_p
the DT 4_p
head NN 4_p
and CC 4_p
neck NN 4_p
( ( 4_p
HNSCC NNP 4_p
) ) N
, , N
but CC N
the DT N
response NN N
is VBZ N
heterogeneous JJ N
. . N

EGFr NNP N
is VBZ N
often RB N
overexpressed VBN N
in IN N
HNSCC NNP N
and CC N
has VBZ N
been VBN N
related VBN N
to TO N
the DT N
repopulation NN N
taking VBG N
place NN N
during IN N
radiotherapy NN N
. . N

The DT N
aim NN N
of IN N
the DT N
current JJ N
study NN N
was VBD N
to TO N
address VB N
the DT N
influence NN N
of IN N
EGFr NNP N
and CC N
histopathological JJ N
differentiation NN N
when WRB N
the DT N
overall JJ N
treatment NN N
time NN N
of IN N
radiotherapy NN N
was VBD N
moderately RB N
reduced VBN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
Eight NNP N
hundred VBD N
and CC N
three CD N
patients NNS N
with IN N
representative JJ N
pretreatment NN N
tissue NN N
samples NNS N
from IN N
the DT N
randomized VBN N
DAHANCA NNP N
6 CD N
and CC N
7 CD N
study NN N
of IN N
5 CD N
vs. FW N
6 CD N
fx/wk NN N
of IN N
radiotherapy NN N
. . N

EGFr NNP N
was VBD N
visualized VBN N
using VBG N
immunohistochemistry NN N
and CC N
separated VBN N
into IN N
high JJ N
and CC N
low JJ N
expression NN N
before IN N
correlation NN N
with IN N
clinical JJ N
data NNS N
. . N

RESULTS NNP N
Tumors NNPS N
with IN N
high JJ N
EGFr NNP N
( ( N
84 CD N
% NN N
) ) N
responded VBD N
better RBR N
to TO N
moderately RB N
accelerated JJ N
radiotherapy NN N
, , N
than IN N
carcinomas NNS N
with IN N
low JJ N
EGFr NNP N
, , N
using VBG N
locoregional JJ N
control NN N
as IN N
endpoint NN N
and CC N
a DT N
similar JJ N
pattern NN N
was VBD N
seen VBN N
, , N
stratifying VBG N
by IN N
well/moderate NN N
vs. FW N
poor JJ N
tumor NN N
differentiation NN N
. . N

Therefore RB N
, , N
a DT N
combined JJ N
parameter NN N
was VBD N
constructed VBN N
showing VBG N
a DT N
more RBR N
prominent JJ N
separation NN N
of IN N
response NN N
: : N
tumors NNS N
with IN N
high JJ N
EGFr NNP N
and CC N
well/moderate JJ N
differentiation NN N
did VBD N
benefit VB N
from IN N
moderate JJ N
acceleration NN N
of IN N
treatment NN N
regarding VBG N
locoregional JJ N
control NN N
, , N
HR NNP N
0.54 CD N
( ( N
0.37-0.78 NN N
) ) N
, , N
whereas NNS N
such JJ N
an DT N
effect NN N
was VBD N
not RB N
seen VBN N
in IN N
tumors NNS N
with IN N
low JJ N
EGFr NNP N
and/or NN N
poor JJ N
differentiation NN N
, , N
HR NNP N
0.8 CD N
( ( N
0.51-1.25 NN N
) ) N
. . N

These DT N
results NNS N
reflected VBD N
the DT N
disease NN N
specific JJ N
survival NN N
as IN N
well RB N
and CC N
were VBD N
confirmed VBN N
in IN N
multivariable JJ N
analyses NNS N
. . N

CONCLUSIONS NNP N
Moderately RB N
accelerated JJ N
fractionation NN N
is VBZ N
superior JJ N
to TO N
conventional JJ N
treatment NN N
in IN N
HNSCC NNP N
but CC N
the DT N
response NN N
is VBZ N
heterogeneous JJ N
and CC N
may MD N
be VB N
predicted VBN N
by IN N
high JJ N
expression NN N
of IN N
EGFr NNP N
and CC N
well/moderate JJ N
tumor NN N
differentiation NN N
. . N

-DOCSTART- -X- O O 24281134

Predictors NNS N
of IN N
postdischarge NN N
outcomes NNS N
from IN N
information NN N
acquired VBN N
shortly RB N
after IN N
admission NN N
for IN N
acute JJ 4_p
heart NN 4_p
failure NN 4_p
: : N
a DT N
report NN N
from IN N
the DT N
Placebo-Controlled NNP N
Randomized NNP N
Study NNP N
of IN N
the DT N
Selective NNP N
A1 NNP N
Adenosine NNP N
Receptor NNP N
Antagonist NNP N
Rolofylline NNP N
for IN N
Patients NNP N
Hospitalized NNP 4_p
With IN 4_p
Acute NNP 4_p
Decompensated NNP 4_p
Heart NNP 4_p
Failure NNP 4_p
and CC 4_p
Volume NN 4_p
Overload NNP 4_p
to TO N
Assess NNP N
Treatment NNP N
Effect NNP N
on IN N
Congestion NNP N
and CC N
Renal NNP N
Function NNP N
( ( N
PROTECT NNP N
) ) N
Study NNP N
. . N

BACKGROUND NNP N
Acute NNP 4_p
heart NN 4_p
failure NN 4_p
is VBZ N
a DT N
common JJ N
reason NN N
for IN N
admission NN N
, , N
and CC N
outcome NN N
is VBZ N
often RB N
poor JJ N
. . N

Improved VBN N
prognostic JJ N
risk NN N
stratification NN N
may MD N
assist VB N
in IN N
the DT N
design NN N
of IN N
future JJ N
trials NNS N
and CC N
in IN N
patient JJ N
management NN N
. . N

Using VBG N
data NNS N
from IN N
a DT N
large JJ N
randomized JJ N
trial NN N
, , N
we PRP N
explored VBD N
the DT N
prognostic JJ N
value NN N
of IN N
clinical JJ N
variables NNS N
, , N
measured VBN N
at IN N
hospital JJ N
admission NN N
for IN N
acute JJ N
heart NN N
failure NN N
, , N
to TO N
determine VB N
whether IN N
a DT N
few JJ N
selected VBN N
variables NNS N
were VBD N
inferior JJ N
to TO N
an DT N
extended VBN N
data NN N
set NN N
. . N

METHODS NNP N
AND CC N
RESULTS NNP N
The DT N
prognostic JJ N
model NN N
included VBD N
37 CD N
clinical JJ N
characteristics NNS N
collected VBN N
at IN N
baseline NN N
in IN N
PROTECT NNP N
, , N
a DT N
study NN N
comparing VBG N
rolofylline NN N
and CC N
placebo NN N
in IN N
2033 CD N
patients NNS N
admitted VBN 4_p
with IN 4_p
acute JJ 4_p
heart NN 4_p
failure NN 4_p
. . N

Prespecified VBN N
outcomes NNS N
at IN N
30 CD N
days NNS N
were VBD N
death NN N
or CC N
rehospitalization NN N
for IN N
any DT N
reason NN N
; : N
death NN N
or CC N
rehospitalization NN N
for IN N
cardiovascular NN N
or CC N
renal JJ N
reasons NNS N
; : N
and CC N
, , N
at IN N
both DT N
30 CD N
and CC N
180 CD N
days NNS N
, , N
all-cause JJ N
mortality NN N
. . N

No DT N
variable JJ N
had VBD N
a DT N
c-index NN N
> NN N
0.70 CD N
, , N
and CC N
few JJ N
had VBD N
values NNS N
> $ N
0.60 CD N
; : N
c-indices NNS N
were VBD N
lower JJR N
for IN N
composite JJ N
outcomes NNS N
than IN N
for IN N
mortality NN N
. . N

Blood NNP N
urea NN N
was VBD N
generally RB N
the DT N
strongest JJS N
single JJ N
predictor NN N
. . N

Eighteen NNP N
variables NNS N
contributed VBD N
independent JJ N
prognostic JJ N
information NN N
, , N
but CC N
a DT N
reduced JJ N
model NN N
using VBG N
only RB N
8 CD N
items NNS N
( ( N
age NN N
, , N
previous JJ N
heart NN N
failure NN N
hospitalization NN N
, , N
peripheral JJ N
edema NN N
, , N
systolic JJ N
blood NN N
pressure NN N
, , N
serum NN N
sodium NN N
, , N
urea JJ N
, , N
creatinine NN N
, , N
and CC N
albumin NN N
) ) N
performed VBD N
similarly RB N
. . N

For IN N
prediction NN N
of IN N
all-cause JJ N
mortality NN N
at IN N
180 CD N
days NNS N
, , N
the DT N
model NN N
c-index NN N
using VBG N
all DT N
variables NNS N
was VBD N
0.72 CD N
and CC N
for IN N
the DT N
simplified JJ N
model NN N
, , N
also RB N
0.72 CD N
. . N

CONCLUSIONS VB N
A NNP N
few JJ N
simple JJ N
clinical JJ N
variables NNS N
measured VBN N
on IN N
admission NN N
in IN N
patients NNS N
with IN N
acute JJ 4_p
heart NN 4_p
failure NN 4_p
predict VBP N
a DT N
variety NN N
of IN N
adverse JJ N
outcomes NNS N
with IN N
accuracy NN N
similar JJ N
to TO N
more RBR N
complex JJ N
models NNS N
. . N

However RB N
, , N
predictive JJ N
models NNS N
were VBD N
of IN N
only RB N
moderate JJ N
accuracy NN N
, , N
especially RB N
for IN N
outcomes NNS N
that WDT N
included VBD N
nonfatal JJ N
events NNS N
. . N

Better NNP N
methods NNS N
of IN N
risk NN N
stratification NN N
are VBP N
required VBN N
. . N

CLINICAL JJ N
TRIAL NNP N
REGISTRATION NNP N
URL NNP N
: : N
http NN N
: : N
//www.clinicaltrials.gov NN N
. . N

Unique JJ N
identifiers NNS N
: : N
NCT00328692 NNP N
and CC N
NCT00354458 NNP N
. . N

-DOCSTART- -X- O O 15688961

Effects NNS N
of IN N
an DT N
antimicrobial JJ N
additive NN N
to TO N
toothbrushes NNS N
on IN N
residual JJ N
periodontal NN N
pathogens NNS N
. . N

OBJECTIVE NNP N
Previous JJ N
studies NNS N
have VBP N
reported VBN N
the DT N
link NN N
between IN N
residual JJ N
microbial JJ N
contamination NN N
of IN N
toothbrushes NNS N
and CC N
periodontal JJ 4_p
diseases NNS 4_p
. . N

The DT N
goal NN N
of IN N
this DT N
pilot NN N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
effects NNS N
of IN N
an DT N
antimicrobial JJ N
additive NN N
( ( N
Microban NNP N
) ) N
to TO N
toothbrushes NNS N
on IN N
residual JJ N
retention NN N
of IN N
periodontal JJ N
pathogens NNS N
. . N

METHODOLOGY NNP N
Twenty NNP N
patients NNS N
had VBD N
one CD N
side NN N
of IN N
their PRP$ N
mouths NNS N
brushed VBN N
with IN N
a DT N
toothbrush NN N
containing VBG N
the DT N
antimicrobial JJ N
agent NN N
( ( N
experimental JJ N
side NN N
) ) N
, , N
and CC N
the DT N
other JJ N
side NN N
with IN N
a DT N
toothbrush NN N
containing VBG N
no DT N
agent NN N
( ( N
control NN N
) ) N
. . N

Toothbrushes NNS N
were VBD N
air-dried JJ N
( ( N
25 CD N
degrees NNS N
C NNP N
) ) N
for IN N
four CD N
or CC N
24 CD N
hours NNS N
. . N

Toothbrush NNP N
heads NNS N
were VBD N
vortexed JJ N
and CC N
cultured VBD N
for IN N
Prevotella NNP N
species NNS N
( ( N
Ps NNP N
) ) N
, , N
Porphyromonas NNP N
gingivalis NN N
( ( N
Pg NNP N
) ) N
, , N
Actinobacillus NNP N
actinomycetemcomitans NNS N
( ( N
Aa NNP N
) ) N
, , N
and CC N
non-specific JJ N
colony-forming JJ N
units NNS N
( ( N
NS NNP N
) ) N
. . N

The DT N
plates NNS N
were VBD N
incubated VBN N
and CC N
counted VBN N
. . N

Means NNPS N
and CC N
standard JJ N
deviations NNS N
were VBD N
calculated VBN N
, , N
and CC N
data NNS N
were VBD N
analyzed VBN N
using VBG N
a DT N
series NN N
of IN N
t-tests NNS N
( ( N
paired VBN N
and CC N
unpaired VBN N
) ) N
and CC N
Wilcoxon NNP N
matched-pairs JJ N
signed-rank JJ N
test NN N
. . N

RESULTS NNP N
No NNP N
significant JJ N
inter- JJ N
or CC N
intra-group JJ N
differences NNS N
in IN N
mean JJ N
counts NNS N
were VBD N
found VBN N
; : N
however RB N
, , N
when WRB N
four-hour JJ N
and CC N
24-hour JJ N
data NNS N
for IN N
Aa NNP N
, , N
Pg NNP N
, , N
or CC N
NS NNP N
were VBD N
combined VBN N
, , N
experimental JJ N
counts NNS N
were VBD N
lower JJR N
than IN N
controls NNS N
in IN N
39/50 CD N
( ( N
78 CD N
% NN N
) ) N
of IN N
the DT N
matched VBN N
pairs NNS N
( ( N
Wilcoxon NNP N
signed-rank JJ N
test NN N
p NN N
= NNP N
0.01 CD N
) ) N
. . N

CONCLUSION NNP N
Toothbrushes NNP N
containing VBG N
the DT N
antimicrobial JJ N
additive NN N
showed VBD N
lower JJR N
microbial NN N
counts NNS N
than IN N
those DT N
without IN N
, , N
but CC N
between-group JJ N
means NNS N
were VBD N
not RB N
statistically RB N
significant JJ N
. . N

-DOCSTART- -X- O O 15305197

A DT N
randomised JJ N
comparison NN N
of IN N
UK NNP 4_p
genetic JJ 4_p
risk NN 4_p
counselling NN 4_p
services NNS 4_p
for IN 4_p
familial JJ 4_p
cancer NN 4_p
: : 4_p
psychosocial JJ N
outcomes NNS N
. . N

The DT N
aim NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
compare VB N
psychosocial JJ N
outcomes NNS N
for IN N
50 CD N
new JJ N
clinic JJ N
attendees NNS N
, , N
referred VBD N
for IN N
cancer NN N
genetic JJ N
counselling NN N
to TO N
five CD N
UK NNP N
centres NNS N
. . N

The DT N
centres NNS N
represented VBD N
England NNP N
, , N
Scotland NNP N
and CC N
Wales NNP N
, , N
and CC N
were VBD N
randomly RB N
selected VBN N
from IN N
groups NNS N
ranked VBN N
by IN N
different JJ N
levels NNS N
of IN N
clinical JJ N
activity NN N
in IN N
cancer NN N
genetics NNS N
practice NN N
. . N

Questionnaires NNS N
assessed VBD N
demographic JJ N
data NNS N
, , N
risk NN N
perception NN N
, , N
mental JJ N
health NN N
and CC N
use NN N
of IN N
health NN N
services NNS N
pre-consultation NN N
and CC N
at IN N
1 CD N
and CC N
12 CD N
months NNS N
follow-up RB N
. . N

Satisfaction NN N
was VBD N
measured VBN N
for IN N
attendees NNS N
and CC N
referring VBG N
doctors NNS N
at IN N
follow-up NN N
. . N

A DT N
total NN N
of IN N
256 CD N
unaffected JJ N
adults NNS N
fulfilled VBD N
the DT N
study NN N
criteria NNS N
. . N

The DT N
five CD N
centres NNS N
varied VBD N
widely RB N
with IN N
respect NN N
to TO N
service NN N
organisation NN N
and CC N
activity NN N
, , N
but CC N
all DT N
had VBD N
a DT N
greater JJR N
proportion NN N
of IN N
unaffected JJ N
attendees NNS N
with IN N
a DT N
breast NN N
cancer NN N
risk NN N
( ( N
61-91 CD N
% NN N
) ) N
than IN N
either CC N
a DT N
bowel NN N
cancer NN N
risk NN N
( ( N
0-33 CD N
% NN N
) ) N
or CC N
ovarian JJ N
cancer NN N
risk NN N
( ( N
3-25 CD N
% NN N
) ) N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
the DT N
psychosocial JJ N
data NN N
between IN N
centres NNS N
pre-counselling VBG N
. . N

No DT N
significant JJ N
change NN N
over IN N
time NN N
occurred VBN N
for IN N
any DT N
of IN N
the DT N
centres NNS N
for IN N
risk NN N
perception NN N
or CC N
general JJ N
psychological JJ N
distress NN N
. . N

There EX N
were VBD N
significant JJ N
differences NNS N
between IN N
centres NNS N
in IN N
reduction NN N
of IN N
cancer NN N
worry NN N
from IN N
baseline NN N
to TO N
12 CD N
months NNS N
and CC N
with IN N
the DT N
number NN N
of IN N
women NNS N
who WP N
were VBD N
recommended VBN N
to TO N
have VB N
mammographic JJ N
surveillance NN N
who WP N
had VBD N
not RB N
received VBN N
this DT N
. . N

Overall JJ N
, , N
one-third JJ N
of IN N
women NNS N
for IN N
whom WP N
mammography NN N
had VBD N
been VBN N
recommended VBN N
had VBD N
not RB N
been VBN N
screened VBN N
within IN N
1 CD N
year NN N
of IN N
follow-up NN N
. . N

Subsequent JJ N
attendance NN N
at IN N
the DT N
GP NNP N
, , N
but CC N
not RB N
at IN N
a DT N
hospital NN N
, , N
was VBD N
associated VBN N
with IN N
risk NN N
level NN N
, , N
but CC N
differences NNS N
between IN N
centres NNS N
could MD N
not RB N
be VB N
analysed VBN N
. . N

Satisfaction NN N
differed VBD N
significantly RB N
between IN N
centres NNS N
for IN N
4 CD N
: : N
14 CD N
aspects NNS N
of IN N
service NN N
provision NN N
and CC N
with IN N
3 CD N
: : N
17 CD N
items NNS N
concerning VBG N
communication NN N
; : N
satisfaction NN N
was VBD N
high JJ N
overall JJ N
. . N

Over IN N
90 CD N
% NN N
of IN N
referring VBG N
doctors NNS N
were VBD N
moderately/very RB N
satisfied VBN N
with IN N
the DT N
service NN N
, , N
but CC N
23 CD N
% NN N
were VBD N
dissatisfied VBN N
with IN N
waiting VBG N
times NNS N
and CC N
19 CD N
% NN N
with IN N
access NN N
to TO N
preventive VB N
treatment NN N
. . N

Results NNS N
differed VBD N
significantly RB N
between IN N
centres NNS N
for IN N
doctor NN N
's POS N
satisfaction NN N
with IN N
the DT N
provision NN N
of IN N
referral JJ N
criteria NNS N
and CC N
prescribing VBG N
information NN N
. . N

In IN N
conclusion NN N
, , N
there EX N
were VBD N
relatively RB N
few JJ N
significant JJ N
differences NNS N
in IN N
psychosocial JJ N
outcomes NNS N
between IN N
centres NNS N
, , N
considering VBG N
the DT N
wide JJ N
variation NN N
in IN N
service NN N
organisation NN N
and CC N
activity NN N
. . N

These DT N
significant JJ N
differences NNS N
were VBD N
not RB N
consistent JJ N
across IN N
the DT N
centres NNS N
, , N
therefore RB N
, , N
differences NNS N
could MD N
not RB N
be VB N
linked VBN N
to TO N
specific JJ N
aspects NNS N
of IN N
service NN N
provision NN N
. . N

-DOCSTART- -X- O O 8259746

Comparison NNP N
of IN N
outcome NN N
of IN N
labetalol NN 4_p
or CC 4_p
hydralazine JJ 4_p
therapy NN 4_p
during IN 4_p
hypertension NN 4_p
in IN 4_p
pregnancy NN 4_p
in IN 4_p
very RB 4_p
low JJ 4_p
birth NN 4_p
weight NN 4_p
infants NNS 4_p
. . 4_p

Ninety-seven JJ 4_p
women NNS 4_p
with IN 4_p
moderate JJ 4_p
to TO 4_p
severe VB 4_p
preeclampsia NN 4_p
( ( 4_p
PE NNP 4_p
) ) 4_p
were VBD N
allocated VBN N
at IN N
random NN N
to TO N
labetalol VB N
or CC N
hydralazine VB N
treatment NN N
. . N

Of IN N
these DT N
, , N
22 CD N
women NNS N
with IN N
severe JJ N
PE NNP N
gave VBD N
birth NN N
to TO N
neonates NNS N
with IN N
VLBW NNP N
( ( N
very RB N
low JJ N
birth NN N
weight NN N
< NN N
or CC N
= JJ N
1500 CD N
g NN N
) ) N
. . N

Seven VBN N
were VBD N
allocated VBN N
to TO N
labetalol VB N
treatment NN N
( ( N
Group NNP N
A NNP N
) ) N
, , N
eight CD N
to TO N
hydralazine VB N
treatment NN N
( ( N
Group NNP N
B NNP N
) ) N
and CC N
seven CD N
women NNS N
received VBD N
both DT N
drugs NNS N
due JJ N
to TO N
poor JJ N
blood NN N
pressure NN N
control NN N
with IN N
a DT N
single JJ N
drug NN N
therapy NN N
( ( N
Group NNP N
C NNP N
) ) N
. . N

No DT N
difference NN N
in IN N
cesarean JJ N
section NN N
rate NN N
or CC N
in IN N
the DT N
indication NN N
for IN N
operative JJ N
delivery NN N
could MD N
be VB N
seen VBN N
. . N

Gestational JJ N
age NN N
was VBD N
29.9 CD N
weeks NNS N
( ( N
25.4-32.5 JJ N
) ) N
in IN N
Group NNP N
A NNP N
, , N
28.6 CD N
weeks NNS N
( ( N
26.6-33.4 JJ N
) ) N
in IN N
Group NNP N
B NNP N
and CC N
27.3 CD N
weeks NNS N
( ( N
26.7-31.1 JJ N
) ) N
in IN N
Group NNP N
C NNP N
( ( N
median JJ N
and CC N
range NN N
) ) N
. . N

Birth NNP N
weight VBD N
did VBD N
not RB N
differ VB N
between IN N
groups NNS N
and CC N
13 CD N
of IN N
the DT N
22 CD N
infants NNS N
weighed VBN N
below IN N
1000 CD N
g. NN N
There EX N
was VBD N
a DT N
tendency NN N
to TO N
lower VB N
Apgar NNP N
scores NNS N
at IN N
five CD N
minutes NNS N
in IN N
the DT N
hydralazine NN N
group NN N
. . N

Time NNP N
spent NN N
in IN N
the DT N
neonatal JJ N
intensive JJ N
care NN N
unit NN N
did VBD N
not RB N
differ VB N
between IN N
groups NNS N
. . N

Five CD N
of IN N
the DT N
11 CD N
neonates NNS N
with IN N
gestational JJ N
age NN N
( ( N
GA NNP N
) ) N
< VBD N
or CC N
= $ N
28 CD N
weeks NNS N
and CC N
three CD N
of IN N
the DT N
seven CD N
neonates NNS N
in IN N
GA NNP N
29-30 JJ N
weeks NNS N
died VBD N
. . N

Neither CC N
the DT N
number NN N
of IN N
infants NNS 4_p
requiring VBG N
intermittent JJ N
positive JJ N
pressure NN N
ventilation NN N
or CC N
duration NN N
of IN N
O2- NNP N
treatment NN N
, , N
nor CC N
number NN N
of IN N
infants NNS N
with IN N
respiratory JJ N
distress JJ N
syndrome NN N
differed VBD N
between IN N
groups NNS N
. . N

We PRP N
did VBD N
not RB N
find VB N
any DT N
difference NN N
in IN N
the DT N
outcome NN N
of IN N
the DT N
VLBW NNP N
infants NNS N
when WRB N
the DT N
hypertensive NN N
mother NN N
had VBD N
been VBN N
treated VBN N
with IN N
either DT N
hydralazine NN N
or CC N
labetalol NN N
. . N

-DOCSTART- -X- O O 10448447

Befriending NNP N
as IN N
an DT N
intervention NN N
for IN N
chronic JJ N
depression NN N
among IN N
women NNS N
in IN N
an DT N
inner JJ N
city NN N
. . N

2 CD N
: : N
Role NN N
of IN N
fresh-start JJ N
experiences NNS N
and CC N
baseline JJ N
psychosocial JJ N
factors NNS N
in IN N
remission NN N
from IN N
depression NN N
. . N

BACKGROUND NNP N
Volunteer NNP N
befriending NN N
promoted VBD N
remission NN N
of IN N
chronic JJ N
depression NN N
when WRB N
clinical JJ N
and CC N
other JJ N
treatment NN N
variables NNS N
were VBD N
controlled VBN N
. . N

AIMS NNP N
To TO N
examine VB N
the DT N
role NN N
of IN N
other JJ N
psychosocial JJ N
factors NNS N
relevant VBP N
for IN N
outcome NN N
. . N

METHOD NNP N
Factors NNPS N
measured VBD N
at IN N
baseline NN N
interview NN N
were VBD N
examined VBN N
in IN N
multivariate NN N
analyses NNS N
along IN N
with IN N
psychosocial JJ N
factors NNS N
occurring VBG N
during IN N
follow-up JJ N
, , N
such JJ N
as IN N
'fresh-start JJ N
' POS N
experiences NNS N
and CC N
new JJ N
severe JJ N
events NNS N
and CC N
difficulties NNS N
. . N

RESULTS NNP N
Fresh-start JJ N
experiences NNS N
and CC N
a DT N
standard JJ N
attachment NN N
style NN N
were VBD N
found VBN N
to TO N
enhance VB N
chances NNS N
of IN N
remission NN N
, , N
with IN N
new JJ N
severe JJ N
stressors NNS N
and CC N
markedly RB N
poor JJ N
coping VBG N
strategies NNS N
liable JJ N
to TO N
prevent VB N
it PRP N
, , N
with IN N
volunteer NN N
befriending VBG N
continuing VBG N
to TO N
play VB N
a DT N
role NN N
. . N

CONCLUSIONS VB N
The DT N
positive JJ N
result NN N
reported VBN N
in IN N
the DT N
preceding JJ N
paper NN N
is VBZ N
unlikely JJ N
to TO N
be VB N
an DT N
artefact NN N
. . N

However RB N
, , N
fresh-start JJ N
experiences NNS N
, , N
absence NN N
of IN N
new JJ N
severe JJ N
stressors NNS N
and CC N
standard JJ N
attachment NN N
style NN N
were VBD N
more RBR N
important JJ N
predictors NNS N
of IN N
remission NN N
. . N

This DT N
knowledge NN N
might MD N
profitably RB N
be VB N
incorporated VBN N
into IN N
the DT N
evaluation NN N
of IN N
existing VBG N
treatments NNS N
. . N

-DOCSTART- -X- O O 3885865

[ JJ N
Randomized NNP N
control NN N
study NN N
of IN N
high-dose JJ N
metoclopramide NN N
in IN N
the DT N
prevention NN N
of IN N
CDDP-induced NNP N
emesis NN N
] NN N
. . N

The DT N
effect NN N
of IN N
high-dose JJ N
metoclopramide NN N
( ( N
2 CD N
mg/kg NN N
, , N
4 CD N
times NNS N
every DT N
2 CD N
hours NNS N
) ) N
on IN N
the DT N
emesis NN N
of IN N
patients NNS N
treated VBN N
with IN N
CDDP NNP N
( ( N
80 CD N
mg/m2 NN N
) ) N
was VBD N
examined VBN N
by IN N
randomized VBN N
control NN N
trial NN N
. . N

The DT N
above JJ N
metoclopramide NN N
regimen NNS N
significantly RB N
suppressed VBD N
the DT N
frequency NN N
of IN N
vomiting VBG N
on IN N
the DT N
day NN N
of IN N
CDDP NNP N
administration NN N
. . N

The DT N
duration NN N
of IN N
nausea NN N
and CC N
anorexia NN N
after IN N
CDDP NNP N
treatment NN N
was VBD N
also RB N
shortened VBN N
by IN N
high-dose JJ N
metoclopramide JJ N
administration NN N
. . N

-DOCSTART- -X- O O 14662278

Determination NN N
of IN N
vital JJ N
status NN N
at IN N
the DT N
end NN N
of IN N
the DT N
DIG NNP N
trial NN N
. . N

The DT N
Digitalis NNP N
Investigation NNP N
Group NNP N
( ( N
DIG NNP N
) ) N
trial NN N
was VBD N
a DT N
randomized JJ N
, , N
double-blind JJ N
placebo-controlled JJ N
trial NN N
whose WP$ N
primary JJ N
objective NN N
was VBD N
to TO N
determine VB N
whether IN N
digoxin NN N
had VBD N
beneficial JJ N
, , N
harmful JJ N
, , N
or CC N
no DT N
effect NN N
on IN N
total JJ N
mortality NN N
in IN N
patients NNS 4_p
with IN 4_p
heart NN 4_p
failure NN 4_p
who WP 4_p
were VBD 4_p
in IN 4_p
sinus NN 4_p
rhythm NN 4_p
and CC 4_p
whose WP$ 4_p
ejection NN 4_p
fraction NN 4_p
was VBD 4_p
< JJ 4_p
/=0.45 NNP 4_p
. . 4_p

The DT N
study NN N
was VBD N
designed VBN N
as IN N
a DT N
large JJ N
simple JJ N
trial NN N
with IN N
a DT 4_p
large JJ 4_p
number NN 4_p
of IN 4_p
centers NNS 4_p
( ( 4_p
302 CD 4_p
) ) 4_p
in IN 4_p
the DT 4_p
United NNP 4_p
States NNPS 4_p
and CC 4_p
Canada NNP 4_p
, , 4_p
many JJ 4_p
of IN 4_p
which WDT 4_p
were VBD 4_p
inexperienced VBN 4_p
in IN 4_p
research NN 4_p
. . 4_p

To TO N
ensure VB N
that IN N
the DT N
results NNS N
of IN N
the DT N
trial NN N
would MD N
be VB N
reported VBN N
accurately RB N
without IN N
possible JJ N
bias NN N
due JJ N
to TO N
missing VBG N
data NNS N
, , N
the DT N
study NN N
leadership NN N
decided VBD N
that IN N
no DT N
outcome NN N
results NNS N
would MD N
be VB N
reported VBN N
until IN N
the DT N
vital JJ N
status NN N
at IN N
the DT N
end NN N
of IN N
the DT N
study NN N
was VBD N
known VBN N
for IN N
at IN N
least JJS N
97 CD N
% NN N
of IN N
the DT N
study NN N
participants NNS N
. . N

Planning VBG N
for IN N
closeout NN N
of IN N
the DT N
study NN N
began VBD N
a DT N
year NN N
prior RB N
to TO N
the DT N
common JJ N
end NN N
date NN N
of IN N
December NNP N
31 CD N
, , N
1995 CD N
and CC N
included VBD N
plans NNS N
for IN N
obtaining VBG N
vital JJ N
status NN N
on IN N
December NNP N
31 CD N
, , N
1995 CD N
. . N

Participants NNS N
were VBD N
given VBN N
postcards NNS N
at IN N
their PRP$ N
final JJ N
study NN N
visit NN N
to TO N
be VB N
completed VBN N
and CC N
mailed VBN N
on IN N
or CC N
after IN N
January NNP N
1 CD N
, , N
1996 CD N
. . N

Of IN N
5602 CD N
postcards NNS N
distributed VBN N
, , N
5070 CD N
( ( N
90.5 CD N
% NN N
) ) N
were VBD N
completed VBN N
and CC N
returned VBN N
. . N

A DT N
contract NN N
search NN N
agency NN N
was VBD N
hired VBN N
to TO N
locate VB N
the DT N
remaining VBG N
participants NNS N
. . N

Of IN N
the DT N
total JJ N
7788 CD N
participants NNS N
entered VBD N
into IN N
the DT N
DIG NNP N
trial NN N
, , N
only RB N
97 CD N
participants NNS N
( ( N
1.2 CD N
% NN N
) ) N
could MD N
not RB N
have VB N
their PRP$ N
vital JJ N
status NN N
as IN N
of IN N
December NNP N
31 CD N
, , N
1995 CD N
determined VBD N
. . N

It PRP N
is VBZ N
recommended VBN N
that IN N
investigators NNS N
having VBG N
an DT N
outcome NN N
measure NN N
with IN N
a DT N
common JJ N
end NN N
date NN N
include VBP N
plans NNS N
in IN N
their PRP$ N
protocols NNS N
for IN N
obtaining VBG N
their PRP$ N
measures NNS N
and CC N
activate VBP N
those DT N
plans NNS N
as RB N
early RB N
as IN N
possible JJ N
during IN N
the DT N
course NN N
of IN N
the DT N
study NN N
. . N

-DOCSTART- -X- O O 17525360

Effect NN N
of IN N
facial JJ N
sensory JJ N
re-training NN N
on IN N
sensory JJ N
thresholds NNS N
. . N

Nearly RB N
100 CD N
% NN N
of IN N
patients NNS 4_p
experience JJ 4_p
trauma NN 4_p
to TO 4_p
the DT 4_p
trigeminal JJ 4_p
nerve NN 4_p
during IN 4_p
orthognathic JJ 4_p
surgery NN 4_p
, , 4_p
impairing VBG 4_p
sensation NN 4_p
and CC 4_p
sensory JJ 4_p
function NN 4_p
on IN 4_p
the DT 4_p
face NN 4_p
. . 4_p

In IN N
a DT N
recent JJ N
randomized JJ N
clinical JJ N
trial NN N
, , N
people NNS N
who WP N
performed VBD N
sensory JJ N
re-training JJ N
exercises NNS N
reported VBD N
less RBR N
difficulty NN N
related VBN N
to TO N
residual JJ N
numbness NN N
and CC N
decreased VBD N
lip JJR N
sensitivity NN N
than IN N
those DT N
who WP N
performed VBD N
standard JJ N
opening NN N
exercises VBZ N
only RB N
. . N

We PRP N
hypothesized VBD N
that IN N
re-training JJ N
reduces NNS N
the DT N
impaired JJ N
performance NN N
on IN N
neurosensory JJ N
tests NNS N
of IN N
tactile JJ N
function NN N
that WDT N
is VBZ N
commonly RB N
observed JJ N
post-surgically RB N
. . N

We PRP N
analyzed VBD N
thresholds NNS N
for IN N
contact NN N
detection NN N
, , N
two-point JJ N
discrimination NN N
, , N
and CC N
two-point JJ N
perception NN N
, , N
obtained VBN N
during IN N
the DT N
clinical JJ N
trial NN N
before IN N
and CC N
at IN N
1 CD N
, , N
3 CD N
, , N
and CC N
6 CD N
months NNS N
after IN N
surgery NN N
, , N
to TO N
assess VB N
tactile JJ N
detection NN N
and CC N
discriminative JJ N
sensitivities NNS N
, , N
and CC N
subjective JJ N
interpretation NN N
of IN N
tactile JJ N
stimulation NN N
, , N
respectively RB N
. . N

Post-surgery NN N
, , N
the DT N
retrained JJ N
persons NNS N
exhibited VBD N
less RBR N
impairment JJ N
, , N
on IN N
average NN N
, , N
than IN N
non-retrained JJ N
persons NNS N
only RB N
in IN N
two-point JJ N
perception NN N
( ( N
P NNP N
< NNP N
0.025 CD N
) ) N
, , N
suggesting VBG N
that IN N
retrained VBD N
persons NNS N
experienced VBD N
or CC N
interpreted VBD N
the DT N
tactile NN N
stimuli VBZ N
differently RB N
than IN N
did VBD N
non-retrained JJ N
persons NNS N
. . N

-DOCSTART- -X- O O 9099447

Partial-area JJ 4_p
method NN 4_p
in IN 4_p
bioequivalence NN 4_p
assessment NN N
: : N
naproxen NN N
. . N

Regulatory NNP N
authorities NNS N
require VBP N
demonstration NN N
of IN N
bioequivalence NN 4_p
through IN N
comparisons NNS N
of IN N
different JJ N
pharmacokinetic JJ N
parameters NNS N
, , N
the DT N
area NN N
under IN N
the DT N
plasma JJ N
concentration-time JJ N
curve NN N
( ( N
AUC NNP N
) ) N
, , N
the DT N
maximum JJ N
plasma JJ N
concentration NN N
( ( N
Cmax NNP N
) ) N
, , N
and CC N
the DT N
time NN N
to TO N
reach VB N
peak JJ N
concentration NN N
( ( N
Tmax NNP N
) ) N
. . N

The DT N
applicability NN N
and CC N
validity NN N
of IN N
regulatory JJ N
requirements NNS N
have VBP N
been VBN N
widely RB N
criticized VBN N
on IN N
statistical JJ N
and CC N
clinical JJ N
relevance NN N
grounds NNS N
. . N

For IN N
most JJS N
noncomplicated JJ N
absorption NN N
models NNS N
, , N
the DT N
AUC NNP N
correlates VBZ N
well RB N
with IN N
the DT N
extent NN N
of IN N
absorption NN N
. . N

However RB N
, , N
in IN N
nonlinear JJ N
models NNS N
of IN N
absorption NN N
, , N
in IN N
mechanisms NN N
involving VBG N
recycling NN N
of IN N
drugs NNS N
, , N
and CC N
for IN N
drugs NNS N
with IN N
long JJ N
half-life NN N
, , N
the DT N
use NN N
of IN N
total JJ N
AUC NNP N
( ( N
from IN N
zero CD N
to TO N
infinity NN N
) ) N
can MD N
give VB N
erroneous JJ N
and CC N
clinically RB N
irrelevant JJ N
results NNS N
since IN N
the DT N
area NN N
is VBZ N
mostly RB N
determined VBN N
by IN N
elimination NN N
phase NN N
or CC N
by IN N
recycling VBG N
. . N

The DT N
calculation NN N
of IN N
total JJ N
AUC NNP N
also RB N
involves VBZ N
prolonged JJ N
sampling NN N
, , N
adding VBG N
to TO N
the DT N
cost NN N
and CC N
risks NNS N
associated VBN N
with IN N
bioequivalence NN N
studies NNS N
. . N

The DT N
use NN N
of IN N
Cmax NNP N
or CC N
Tmax NNP N
as IN N
a DT N
measure NN N
of IN N
rate NN N
of IN N
absorption NN N
, , N
to TO N
correlate VB N
with IN N
clinical JJ N
relevance NN N
, , N
is VBZ N
widely RB N
criticized VBN N
on IN N
logical JJ N
, , N
technical JJ N
, , N
and CC N
statistical JJ N
grounds NNS N
. . N

For IN N
drugs NNS N
used VBN N
on IN N
a DT N
multiple-dose JJ N
basis NN N
, , N
Cmax NNP N
and CC N
Tmax NNP N
evaluations NNS N
become VBP N
redundant JJ N
since IN N
the DT N
average JJ N
plateau NN N
concentration NN N
is VBZ N
not RB N
affected VBN N
by IN N
these DT N
parameters NNS N
. . N

To TO N
resolve VB N
the DT N
drawbacks NNS N
in IN N
the DT N
traditional JJ N
methodology NN N
of IN N
bioequivalence NN N
evaluation NN N
, , N
the DT N
use NN N
of IN N
partial JJ N
areas NNS N
in IN N
lieu NN N
of IN N
total JJ N
AUC NNP N
, , N
Tmax NNP N
, , N
and CC N
Cmax NNP N
is VBZ N
suggested VBN N
. . N

This DT N
study NN N
investigates VBZ N
the DT N
logic NN N
and CC N
robustness NN N
of IN N
the DT N
partial-area JJ N
method NN N
in IN N
establishing VBG N
bioequivalence NN N
. . N

We PRP N
conclude VBP N
that IN N
the DT N
5h CD N
AUC NNP N
is VBZ N
a DT N
more RBR N
relevant JJ N
parameter NN N
to TO N
establish VB N
naproxen NNS N
bioequivalence NN N
than IN N
AUCinf NNP N
. . N

We PRP N
recommend VBP N
against IN N
using VBG N
symmetrical JJ N
confidence NN N
intervals NNS N
and CC N
report NN N
excellent JJ N
agreement NN N
among IN N
several JJ N
methods NNS N
of IN N
calculating VBG N
confidence NN N
intervals NNS N
, , N
probability NN N
values NNS N
, , N
and CC N
nonparametric JJ N
tests NNS N
. . N

We PRP N
suggest VBP N
that IN N
a DT N
single-point JJ N
short-term JJ N
AUC NNP N
is VBZ N
a DT N
better JJR N
indicator NN N
of IN N
the DT N
bioequivalence NN N
of IN N
generic JJ N
products NNS N
than IN N
the DT N
total JJ N
AUC NNP N
, , N
Cmax NNP N
, , N
and CC N
Tmax NNP N
as IN N
required VBN N
currently RB N
by IN N
the DT N
regulatory JJ N
authorities NNS N
. . N

-DOCSTART- -X- O O 8098276

Short-term JJ N
effects NNS N
of IN N
denopamine NN N
on IN N
anaerobic JJ N
threshold NN N
and CC N
related JJ N
parameters NNS N
in IN N
patients NNS N
with IN N
chronic JJ 4_p
heart NN 4_p
failure NN 4_p
: : N
a DT N
double-blind JJ N
crossover NN N
study NN N
. . N

BACKGROUND IN N
The DT N
short-term JJ N
effects NNS N
of IN N
denopamine NN N
, , N
an DT N
orally RB N
available JJ N
beta-stimulant JJ N
, , N
on IN N
exercise NN N
capacity NN N
were VBD N
studied VBN N
in IN N
patients NNS N
with IN N
chronic JJ N
heart NN N
failure NN N
. . N

METHODS NNP N
AND CC N
RESULTS NNP N
Nineteen NNP N
patients NNS N
entered VBD N
the DT N
study NN N
. . N

Three CD N
patients NNS N
had VBD N
ischemic JJ 4_p
heart NN 4_p
disease NN 4_p
, , N
13 CD N
had VBD N
dilated VBN 4_p
cardiomyopathy NN 4_p
, , N
and CC N
three CD N
had VBD N
valvular JJ 4_p
disease NN 4_p
; : 4_p
16 CD N
patients NNS N
were VBD N
in IN N
New NNP N
York NNP N
Heart NNP N
Association NNP N
class NN N
II NNP N
, , N
and CC N
three CD N
patients NNS N
were VBD N
in IN N
New NNP N
York NNP N
Heart NNP N
Association NNP N
class NN N
III NNP N
. . N

Symptom-limited JJ N
exercise NN N
testing NN N
( ( N
ramp VB N
protocol NN N
) ) N
on IN N
a DT N
bicycle NN N
ergometer NN N
with IN N
gas NN N
exchange NN N
analysis NN N
was VBD N
conducted VBN N
1 CD N
hour NN N
after IN N
oral JJ N
administration NN N
of IN N
either CC N
20 CD N
mg NN N
denopamine NN N
or CC N
placebo NN N
. . N

Drug NNP N
administration NN N
sequence NN N
was VBD N
randomly RB N
assigned VBN N
in IN N
a DT N
double-blind JJ N
crossover NN N
method NN N
, , N
with IN N
1 CD N
week NN N
between IN N
drugs NNS N
. . N

Peak NNP N
VO2 NNP N
was VBD N
20.4 CD N
+/- JJ N
3.2 CD N
and CC N
21.2 CD N
+/- JJ N
3.1 CD N
ml/min/kg NN N
, , N
respectively RB N
, , N
for IN N
those DT N
administered VBN N
the DT N
placebo NN N
and CC N
the DT N
drug NN N
, , N
and CC N
anaerobic JJ N
threshold NN N
was VBD N
13.1 CD N
+/- JJ N
2.1 CD N
and CC N
14.0 CD N
+/- JJ N
2.0 CD N
ml/min/kg NN N
. . N

There EX N
was VBD N
a DT N
significant JJ N
increase NN N
in IN N
peak JJ N
VO2 NNP N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
and CC N
anaerobic JJ N
threshold NN N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
with IN N
denopamine NN N
, , N
whereas IN N
no DT N
significant JJ N
change NN N
was VBD N
observed VBN N
in IN N
peak JJ N
work NN N
rate NN N
or CC N
exercise NN N
time NN N
. . N

Denopamine NNP N
increased VBD N
heart NN N
rate NN N
in IN N
patients NNS N
with IN N
atrial JJ 4_p
fibrillation NN 4_p
but CC N
had VBD N
little JJ N
effect NN N
on IN N
heart NN N
rate NN N
in IN N
patients NNS N
with IN N
sinus JJ 4_p
rhythm NN 4_p
. . N

CONCLUSION NNP N
Data NNP N
obtained VBD N
from IN N
gas NN N
exchange NN N
analysis NN N
are VBP N
more RBR N
sensitive JJ N
and CC N
potentially RB N
more RBR N
useful JJ N
in IN N
the DT N
detection NN N
of IN N
short-term JJ N
changes NNS N
in IN N
exercise NN N
capacity NN N
than IN N
data NNS N
obtained VBN N
from IN N
either CC N
exercise JJ N
time NN N
or CC N
peak JJ N
work NN N
rate NN N
, , N
indexes NNS N
that WDT N
are VBP N
commonly RB N
used VBN N
to TO N
assess VB N
drug NN N
therapy NN N
. . N

Patients NNS N
with IN N
mild-to-moderate JJ 4_p
heart NN 4_p
failure NN 4_p
with IN N
sinus NN 4_p
rhythm NN 4_p
, , N
but CC N
not RB N
those DT N
with IN N
atrial JJ 4_p
fibrillation NN 4_p
because IN N
of IN N
its PRP$ N
frequent JJ N
induction NN N
of IN N
tachycardia NN 4_p
, , N
may MD N
be VB N
good JJ N
candidates NNS N
for IN N
denopamine NN N
therapy NN N
. . N

-DOCSTART- -X- O O 17156222

Midazolam NNP N
vs NN N
ondansetron NN N
for IN N
preventing VBG N
postoperative JJ N
nausea NN N
and CC N
vomiting NN N
: : N
a DT N
randomised JJ N
controlled VBN N
trial NN N
. . N

We PRP N
compared VBN N
the DT N
prophylactic JJ N
anti-emetic JJ N
efficacy NN N
of IN N
midazolam NN N
and CC N
ondansetron NN N
in IN N
90 CD N
patients NNS N
scheduled VBN N
for IN N
minor JJ 4_p
gynaecological JJ 4_p
( ( 4_p
hysteroscopy NN 4_p
) ) 4_p
or CC 4_p
urological JJ 4_p
( ( 4_p
ureteroscopy JJ 4_p
) ) 4_p
procedures NNS 4_p
planned VBN N
to TO N
last JJ N
1-2 JJ N
h NN N
under IN N
sevoflurane NN 4_p
anaesthesia NN 4_p
with IN N
spontaneous JJ N
ventilation NN N
of IN N
the DT N
lungs NNS N
via IN N
a DT N
laryngeal JJ N
mask NN N
airway NN N
. . N

Midazolam NNP N
2 CD N
mg NN N
or CC N
ondansetron $ N
4 CD N
mg NN N
were VBD N
administered VBN N
intravenously RB N
30 CD N
min NN N
before IN N
the DT N
end NN N
of IN N
surgery NN N
. . N

The DT N
proportions NNS N
of IN N
patients NNS N
who WP N
experienced VBD N
postoperative JJ 4_p
nausea NN 4_p
and CC 4_p
vomiting NN 4_p
in IN N
the DT N
first JJ N
24 CD N
h NN N
( ( N
30 CD N
% NN N
and CC N
27 CD N
% NN N
for IN N
the DT N
midazolam NN N
and CC N
ondansetron NN N
groups NNS N
, , N
respectively RB N
) ) N
were VBD N
similar JJ N
in IN N
the DT N
two CD N
groups NNS N
. . N

The DT N
incidence NN N
of IN N
postoperative JJ N
nausea NN N
and CC N
vomiting NN N
was VBD N
significantly RB N
smaller JJR N
in IN N
both DT N
groups NNS N
than IN N
predicted VBN N
according VBG N
to TO N
the DT N
patients NNS N
' POS N
underlying JJ N
risks NNS N
( ( N
midazolam JJ N
group NN N
: : N
p NN N
= VBZ N
0.018 CD N
; : N
ondansetron VBN N
group NN N
: : N
p NN N
= VBZ N
0.017 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
average JJ N
sedation NN N
scores NNS N
or CC N
pain NN N
scores NNS N
. . N

Treatment NNP N
using VBG N
ondansetron NN N
for IN N
anti-emetic JJ N
prophylaxis NN N
did VBD N
not RB N
provide VB N
a DT N
superior JJ N
benefit NN N
compared VBN N
to TO N
midazolam VB N
in IN N
the DT N
present JJ N
study NN N
. . N

-DOCSTART- -X- O O 20491838

Influence NN N
of IN N
bony NN 4_p
defects NNS 4_p
on IN N
implant JJ N
stability NN N
. . N

INTRODUCTION NNP N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
analyze VB N
the DT N
evolution NN N
of IN N
implant JJ N
mechanical JJ N
stability NN N
in IN N
different JJ N
types/sizes NNS N
of IN N
bony NN 4_p
defects NNS 4_p
using VBG N
both DT N
Periotest NNP N
and CC N
Osstell NNP N
devices NNS N
as IN N
" JJ N
objective JJ N
tools NNS N
. . N

" JJ N
MATERIALS NNP N
AND NNP N
METHODS NNP N
Thirty-two NNP N
implants NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
one CD N
of IN N
the DT N
four CD N
types NNS N
of IN N
bone NN 4_p
defects NNS 4_p
: : N
marginal JJ 4_p
bone NN 4_p
loss NN 4_p
, , N
peri-apical JJ 4_p
bone NN 4_p
defect NN 4_p
, , N
constant JJ 4_p
width NN 4_p
dehiscence NN 4_p
and CC N
constant JJ 4_p
length NN 4_p
dehiscences NNS 4_p
. . N

Periotest/Osstell NNP N
measurements NNS N
were VBD N
completed VBN N
before IN N
and CC N
during IN N
staged VBN N
bone NN N
removal NN N
( ( N
to TO N
enlarge VB N
defect JJ N
size NN N
) ) N
. . N

RESULTS NNP N
Significant JJ N
differences NNS N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
with IN N
initial JJ N
values NNS N
were VBD N
found VBN N
after IN N
a DT N
2 CD N
mm NN N
marginal JJ N
bone NN N
removal NN N
( ( N
Osstell/Periotest NNP N
) ) N
; : N
for IN N
a DT N
peri-apical JJ N
bone NN N
lesion NN N
, , N
after IN N
removal NN N
of IN N
5 CD N
mm NN N
( ( N
Osstell NNP N
) ) N
or CC N
8 CD N
mm NN N
( ( N
Periotest NNP N
) ) N
; : N
for IN N
a DT N
6-mm-long JJ N
dehiscence NN N
, , N
after IN N
removal NN N
up RB N
to TO N
180 CD N
degrees NNS N
of IN N
the DT N
implant JJ N
perimeter NN N
( ( N
Osstell/Periotest NNP N
) ) N
; : N
for IN N
a DT N
3-mm-wide JJ N
dehiscence NN N
, , N
after IN N
removal NN N
of IN N
10 CD N
mm NN N
( ( N
Osstell NNP N
) ) N
or CC N
6 CD N
mm NN N
( ( N
Periotest NNP N
) ) N
. . N

CONCLUSION NNP N
Periotest NNP N
and CC N
Osstell NNP N
are VBP N
in IN N
general JJ N
not RB N
very RB N
sensitive JJ N
in IN N
the DT N
identification NN N
of IN N
peri-implant JJ N
bone NN N
destruction NN N
, , N
except IN N
for IN N
marginal JJ N
bone NN N
loss NN N
. . N

-DOCSTART- -X- O O 15695500

Long-term JJ N
follow-up NN N
of IN N
a DT N
randomized JJ N
trial NN N
of IN N
fludarabine-mitoxantrone NN N
, , N
compared VBN N
with IN N
cyclophosphamide NN N
, , N
doxorubicin NN N
, , N
vindesine NN N
, , N
prednisone NN N
( ( N
CHVP NNP N
) ) N
, , N
as IN N
first-line JJ N
treatment NN N
of IN N
elderly JJ 4_p
patients NNS 4_p
with IN 4_p
advanced JJ 4_p
, , 4_p
low-grade JJ 4_p
non-Hodgkin NN 4_p
's POS 4_p
lymphoma NN 4_p
before IN 4_p
the DT 4_p
era NN 4_p
of IN 4_p
monoclonal JJ 4_p
antibodies NNS 4_p
. . 4_p

BACKGROUND NNP N
This DT N
randomized VBN N
study NN N
compared VBN N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
fludarabine-mitoxantrone NN N
( ( N
FM NNP N
) ) N
with IN N
mini-CHVP NN N
( ( N
cyclophosphamide NN N
, , N
doxorubicin NN N
, , N
vindesine NN N
, , N
prednisone NN N
) ) N
in IN N
elderly JJ 4_p
patients NNS 4_p
with IN 4_p
advanced JJ 4_p
, , 4_p
low-grade JJ 4_p
non-Hodgkin NN 4_p
's POS 4_p
lymphoma NN 4_p
. . 4_p

PATIENTS NNP N
AND CC N
METHODS NNP N
End NNP N
points NNS N
were VBD N
remission JJ N
rates NNS N
[ VBP N
overall JJ N
response NN N
( ( N
OR NNP N
) ) N
and CC N
complete JJ N
response NN N
( ( N
CR NNP N
) ) N
] NN N
, , N
failure-free JJ N
survival NN N
( ( N
FFS NNP N
) ) N
, , N
survival JJ N
and CC N
toxicity NN N
. . N

One CD N
hundred CD N
and CC N
fifty-five JJ N
patients NNS N
were VBD N
randomized VBN N
, , N
144 CD N
were VBD N
evaluable JJ N
for IN N
safety NN N
and CC N
142 CD N
for IN N
response NN N
. . N

Each DT N
treatment NN N
arm NN N
was VBD N
given VBN N
as IN N
six CD N
monthly JJ N
cycles NNS N
, , N
followed VBN N
by IN N
three CD N
bimonthly JJ N
cycles NNS N
. . N

FM NNP N
comprised VBD N
fludarabine NN N
( ( N
20 CD N
mg/m NN N
( ( N
2 CD N
) ) N
i.v NN N
. . N

) ) N
, , N
days NNS N
1-5 CD N
, , N
plus CC N
mitoxantrone NN N
( ( N
10 CD N
mg/m NN N
( ( N
2 CD N
) ) N
i.v NN N
. . N

) ) N
, , N
day NN N
1 CD N
. . N

CHVP NNP N
cycles NNS N
comprised VBD N
cyclophosphamide NN N
( ( N
750 CD N
mg/m NN N
( ( N
2 CD N
) ) N
i.v NN N
. . N

infusion NN N
) ) N
, , N
doxorubicin NN N
( ( N
25 CD N
mg/m NN N
( ( N
2 CD N
) ) N
i.v NN N
. . N

) ) N
and CC N
vindesine NN N
( ( N
3 CD N
mg/m NN N
( ( N
2 CD N
) ) N
i.v NN N
. . N

) ) N
on IN N
day NN N
1 CD N
, , N
and CC N
prednisone NN N
( ( N
50 CD N
mg/m NN N
( ( N
2 CD N
) ) N
) ) N
on IN N
days NNS N
1-5 JJ N
. . N

RESULTS NNP N
FM NNP N
therapy NN N
resulted VBD N
in IN N
superior JJ N
remission NN N
rates NNS N
( ( N
OR CC N
81 CD N
% NN N
versus IN N
64 CD N
% NN N
, , N
CR NNP N
49 CD N
% NN N
versus IN N
17 CD N
% NN N
; : N
P NNP N
= NNP N
0.0004 CD N
) ) N
. . N

Median JJ N
FFS NNP N
for IN N
FM NNP N
patients NNS N
was VBD N
36 CD N
months NNS N
, , N
compared VBN N
with IN N
19 CD N
months NNS N
for IN N
CHVP NNP N
patients NNS N
, , N
and CC N
has VBZ N
not RB N
yet RB N
been VBN N
reached VBN N
for IN N
early JJ N
CR NNP N
patients NNS N
at IN N
53 CD N
months NNS N
. . N

Treatment NNP N
arm NN N
was VBD N
the DT N
major JJ N
risk NN N
factor NN N
influencing VBG N
survival NN N
. . N

Both DT N
treatments NNS N
were VBD N
well RB N
tolerated VBN N
, , N
with IN N
only RB N
few JJ N
infectious JJ N
complications NNS N
. . N

CONCLUSION NNP N
FM NNP N
was VBD N
more RBR N
effective JJ N
than IN N
CHVP NNP N
in IN N
achieving VBG N
OR NNP N
and CC N
CR NNP N
, , N
and CC N
favorably RB N
affected VBD N
the DT N
outcome NN N
. . N

-DOCSTART- -X- O O 18157013

Minimally RB N
invasive JJ N
treatment NN N
combined VBN N
with IN N
cytokine-induced JJ N
killer NN N
cells NNS N
therapy VBP N
lower JJR N
the DT N
short-term JJ N
recurrence NN N
rates NNS N
of IN N
hepatocellular JJ 4_p
carcinomas NN 4_p
. . N

The DT N
recurrence NN N
of IN N
hepatocellular JJ N
carcinoma NN N
( ( N
HCC NNP N
) ) N
after IN N
minimally RB N
invasive JJ N
therapy NN N
is VBZ N
frequent JJ N
. . N

Adoptive JJ N
immunotherapy NN N
is VBZ N
thought VBN N
to TO N
be VB N
an DT N
effective JJ N
method NN N
to TO N
lower JJR N
recurrence NN N
and CC N
metastasis NN N
rates NNS N
of IN N
malignant JJ N
tumors NNS N
. . N

Therefore RB N
, , N
85 CD N
HCC NNP N
patients NNS N
after IN N
transcatheter JJ N
arterial JJ N
chemoembolization NN N
and CC N
radiofrequency NN N
ablation NN N
therapy NN N
were VBD N
randomized VBN N
to TO N
immunotherapy VB N
group NN N
and CC N
no DT N
adjuvant JJ N
therapy NN N
group NN N
. . N

Autologous JJ N
cytokine-induced JJ N
killer NN N
( ( N
CIK NNP N
) ) N
cells NNS N
were VBD N
transfused VBN N
via IN N
hepatic JJ N
artery NN N
to TO N
the DT N
patients NNS N
. . N

The DT N
alteration NN N
of IN N
levels NNS N
of IN N
lymphocyte JJ N
subsets NNS N
in IN N
peripheral JJ N
blood NN N
of IN N
patients NNS N
was VBD N
examined VBN N
by IN N
flow JJ N
cytometry NN N
. . N

All DT N
patients NNS N
were VBD N
screened VBN N
by IN N
computed JJ N
tomography NN N
every DT N
2 CD N
months NNS N
to TO N
observe VB N
the DT N
tumor NN 4_p
recurrent NN 4_p
conditions NNS 4_p
. . N

After IN N
CIK NNP N
cell NN N
infusions NNS N
, , N
the DT N
percentages NNS N
of IN N
CD3+ NNP N
, , N
CD4+ NNP N
, , N
CD56+ NNP N
, , N
CD3+CD56+ NNP N
cells NNS N
, , N
and CC N
CD4+/CD8+ NNP N
ratio VBP N
increased VBN N
from IN N
68.6+/-11.0 CD N
% NN N
, , N
31.1+/-9.0 CD N
% NN N
, , N
15.6+/-7.9 CD N
% NN N
, , N
5.2+/-3.1 CD N
% NN N
, , N
and CC N
1.1+/-0.5 JJ N
to TO N
70.7+/-10.1 CD N
% NN N
, , N
33.5+/-8.0 CD N
% NN N
, , N
18.4+/-9.4 CD N
% NN N
, , N
5.9+/-2.8 CD N
% NN N
, , N
and CC N
1.3+/-0.7 JJ N
, , N
respectively RB N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
; : N
whereas IN N
the DT N
percentage NN N
of IN N
CD8 NNP N
cells NNS N
decreased VBN N
from IN N
31.1+/-7.8 CD N
% NN N
to TO N
28.6+/-8.3 CD N
% NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
1-year JJ N
and CC N
18-month JJ N
recurrence NN N
rates NNS N
of IN N
the DT N
study NN N
group NN N
were VBD N
8.9 CD N
% NN N
and CC N
15.6 CD N
% NN N
, , N
compared VBN N
with IN N
30.0 CD N
% NN N
and CC N
40.0 CD N
% NN N
of IN N
the DT N
control NN N
group NN N
( ( N
both DT N
P NNP N
value NN N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
data NN N
suggest NN N
that IN N
CIK NNP N
cell NN N
transfusion NN N
is VBZ N
an DT N
effective JJ N
treatment NN N
. . N

It PRP N
can MD N
boost VB N
the DT N
immunologic JJ N
function NN N
in IN N
HCC NNP 4_p
patients NNS N
and CC N
plays VBZ N
an DT N
important JJ N
role NN N
in IN N
reducing VBG N
the DT N
recurrence NN N
rate NN N
of IN N
HCC NNP N
. . N

-DOCSTART- -X- O O 2990708

Intensive JJ N
induction NN N
chemotherapy NN N
for IN N
small JJ N
cell NN N
anaplastic JJ N
carcinoma NN N
of IN N
the DT N
lung NN N
. . N

The DT N
role NN N
of IN N
intensive JJ N
induction NN N
chemotherapy NN N
in IN N
small JJ N
cell NN N
cancer NN N
of IN N
the DT N
lung NN N
remains VBZ N
unclear JJ N
. . N

Twenty-eight JJ N
newly RB N
diagnosed VBN N
patients NNS N
with IN N
small JJ 4_p
cell NN 4_p
lung NN 4_p
cancer NN 4_p
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
high-dose JJ N
or CC N
standard-dose JJ N
cyclophosphamide NN N
, , N
vincristine NN N
, , N
and CC N
semustine NN N
in IN N
a DT N
trial NN N
where WRB N
the DT N
dose NN N
of IN N
induction NN N
chemotherapy NN N
was VBD N
the DT N
sole JJ N
treatment NN N
variable JJ N
. . N

Complete JJ N
responses NNS N
( ( N
CR NNP N
) ) N
were VBD N
achieved VBN N
in IN N
57 CD N
% NN N
of IN N
patients NNS N
receiving VBG N
high-dose JJ N
therapy NN N
as IN N
compared VBN N
to TO N
21 CD N
% NN N
of IN N
patients NNS N
receiving VBG N
standard-dose JJ N
therapy NN N
( ( N
P NNP N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

There EX N
was VBD N
a DT N
higher JJR N
rate NN N
of IN N
severe JJ N
toxicity NN N
in IN N
the DT N
high-dose JJ N
group NN N
( ( N
P NNP N
less JJR N
than IN N
0.01 CD N
) ) N
. . N

The DT N
overall JJ N
median JJ N
survival NN N
was VBD N
not RB N
improved VBN N
( ( N
36 CD N
weeks NNS N
for IN N
the DT N
high-dose JJ N
group NN N
vs VBD N
43 CD N
weeks NNS N
for IN N
the DT N
standard-dose JJ N
group NN N
) ) N
; : N
however RB N
, , N
the DT N
median JJ N
survival NN N
in IN N
patients NNS N
achieving VBG N
CR NNP N
was VBD N
prolonged VBN N
( ( N
92 CD N
weeks NNS N
for IN N
the DT N
high-dose JJ N
group NN N
vs VBD N
50 CD N
weeks NNS N
for IN N
the DT N
standard-dose JJ N
group NN N
) ) N
. . N

These DT N
effects NNS N
were VBD N
most RBS N
pronounced VBN N
in IN N
patients NNS N
with IN N
extensive JJ N
disease NN N
; : N
a DT N
CR NNP N
after IN N
induction NN N
was VBD N
achieved VBN N
in IN N
five CD N
of IN N
nine CD N
patients NNS N
treated VBN N
with IN N
high JJ N
doses NNS N
but CC N
not RB N
in IN N
any DT N
of IN N
those DT N
treated VBN N
with IN N
standard JJ N
doses NNS N
( ( N
P NNP N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

A NNP N
small JJ N
group NN N
of IN N
patients NNS N
appear VBP N
to TO N
benefit VB N
by IN N
achieving VBG N
a DT N
long-term JJ N
remission NN N
with IN N
intensive JJ N
induction NN N
chemotherapy NN N
, , N
but CC N
this DT N
effect NN N
may MD N
be VB N
offset VBN N
by IN N
increased JJ N
morbidity NN N
. . N

-DOCSTART- -X- O O 15985559

Long JJ N
term NN N
follow VBP N
up IN N
of IN N
patients NNS N
treated VBN N
for IN N
Helicobacter NNP 4_p
pylori JJ 4_p
infection NN 4_p
. . N

BACKGROUND NNP N
Helicobacter NNP N
pylori POS N
infection NN N
induces NNS N
progressive JJ N
inflammatory JJ N
changes NNS N
in IN N
the DT N
gastric JJ N
mucosa NN N
that WDT N
may MD N
lead VB N
to TO N
gastric JJ N
cancer NN N
. . N

Understanding VBG N
long JJ N
term NN N
effects NNS N
resulting VBG N
from IN N
the DT N
cure NN N
of IN N
this DT N
infection NN N
is VBZ N
needed VBN N
to TO N
design VB N
cancer NN N
prevention NN N
strategies NNS N
. . N

METHODS NNP N
A NNP N
cohort NN N
of IN N
795 CD N
adults NNS N
with IN N
preneoplastic JJ 4_p
gastric JJ 4_p
lesions NNS 4_p
was VBD N
randomised VBN N
to TO N
receive VB N
anti-H JJ N
pylori NN N
treatment NN N
and/or JJ N
antioxidants NNS N
. . N

At IN N
the DT N
end NN N
of IN N
six CD N
years NNS N
of IN N
intervention NN N
, , N
those DT N
who WP N
did VBD N
not RB N
receive VB N
anti-H JJ N
pylori NN N
treatment NN N
were VBD N
offered VBN N
it PRP N
. . N

Gastric JJ N
biopsies NNS N
were VBD N
obtained VBN N
at IN N
baseline NN N
, , N
and CC N
at IN N
3 CD N
, , N
6 CD N
, , N
and CC N
12 CD N
years NNS N
. . N

A DT N
histopathology NN N
score NN N
was VBD N
utilised VBN N
to TO N
document VB N
changes NNS N
in IN N
gastric JJ N
lesions NNS N
. . N

Non-linear JJ N
mixed JJ N
models NNS N
were VBD N
used VBN N
to TO N
estimate VB N
the DT N
cumulative JJ N
effect NN N
of IN N
H NNP N
pylori JJ N
clearance NN N
on IN N
histopathology NN N
scores NNS N
adjusted VBN N
for IN N
follow VB N
up RP N
time NN N
, , N
interventions NNS N
, , N
and CC N
confounders NNS N
. . N

RESULTS NNP N
Ninety NNP N
seven CD N
per IN N
cent NN N
of IN N
subjects NNS N
were VBD N
H NNP N
pylori JJ N
positive JJ N
at IN N
baseline NN N
, , N
and CC N
53 CD N
% NN N
were VBD N
positive JJ N
at IN N
12 CD N
years NNS N
. . N

Subjects NNS N
accumulated JJ N
1703 CD N
person NN N
years NNS N
free JJ N
of IN N
infection NN N
. . N

A DT N
multivariate NN N
model NN N
showed VBD N
a DT N
significant JJ N
regression NN N
in IN N
histopathology NN N
score NN N
as IN N
a DT N
function NN N
of IN N
the DT N
square NN N
of IN N
H NNP N
pylori FW N
negative JJ N
time NN N
. . N

Subjects NNS N
who WP N
were VBD N
H NNP N
pylori JJ N
negative JJ N
had VBD N
14.8 CD N
% NN N
more JJR N
regression NN N
and CC N
13.7 CD N
% NN N
less JJR N
progression NN N
than IN N
patients NNS N
who WP N
were VBD N
positive JJ N
at IN N
12 CD N
years NNS N
( ( N
p JJ N
= NNP N
0.001 CD N
) ) N
. . N

The DT N
rate NN N
of IN N
healing NN N
of IN N
gastric JJ N
lesions NNS N
occurred VBD N
more RBR N
rapidly RB N
as IN N
years NNS N
free JJ N
of IN N
infection NN N
accumulated VBN N
, , N
and CC N
was VBD N
more RBR N
pronounced JJ N
in IN N
less RBR N
advanced JJ N
lesions NNS N
. . N

CONCLUSIONS NNP N
Preneoplastic NNP N
gastric JJ N
lesions NNS N
regress NN N
at IN N
a DT N
rate NN N
equal JJ N
to TO N
the DT N
square NN N
of IN N
time NN N
in IN N
patients NNS N
rendered JJ N
free JJ N
of IN N
H NNP N
pylori JJ N
infection NN N
. . N

Our PRP$ N
findings NNS N
suggest VBP N
that IN N
patients NNS N
with IN N
preneoplastic JJ 4_p
gastric JJ 4_p
lesions NNS 4_p
should MD N
be VB N
treated VBN N
and CC N
cured VBN N
of IN N
their PRP$ N
H NNP N
pylori NN N
infection NN N
. . N

-DOCSTART- -X- O O 23114568

Linguistic JJ N
alignment NN N
in IN N
adults NNS N
with IN N
and CC N
without IN N
Asperger NNP N
's POS N
syndrome NN N
. . N

Individuals NNS N
with IN N
Asperger NNP 4_p
's POS 4_p
syndrome NN 4_p
( ( 4_p
AS IN 4_p
) ) 4_p
often RB N
have VBP N
difficulties NNS N
with IN N
social JJ N
interactions NNS N
and CC N
conversations NNS N
. . N

We PRP N
investigated VBD N
if IN N
these DT N
difficulties NNS N
could MD N
be VB N
attributable JJ N
to TO N
a DT N
deficit NN N
in IN N
the DT N
ability NN N
to TO N
linguistically RB N
converge VB N
with IN N
an DT N
interlocutor NN N
, , N
which WDT N
is VBZ N
posited VBN N
to TO N
be VB N
important JJ N
for IN N
successful JJ N
communication NN N
. . N

To TO N
that DT N
end NN N
, , N
participants NNS N
completed VBD N
two CD N
cooperative JJ N
tasks NNS N
with IN N
a DT N
confederate NN N
, , N
which WDT N
allowed VBD N
us PRP N
to TO N
measure VB N
linguistic JJ N
alignment NN N
with IN N
the DT N
confederate NN N
in IN N
terms NNS N
of IN N
lexical JJ N
choice NN N
, , N
syntactic JJ N
structure NN N
and CC N
spatial JJ N
frame NN N
of IN N
reference NN N
. . N

There EX N
was VBD N
no DT N
difference NN N
in IN N
the DT N
performance NN N
of IN N
individuals NNS N
with IN N
AS NNP 4_p
and CC N
matched VBD N
controls NNS N
and CC N
both DT N
groups NNS N
showed VBD N
significant JJ N
alignment NN N
with IN N
the DT N
confederate NN N
at IN N
all DT N
three CD N
levels NNS N
. . N

We PRP N
conclude VBP N
that IN N
linguistic JJ N
alignment NN N
is VBZ N
intact JJ N
in IN N
adults NNS N
with IN N
AS NNP 4_p
engaged VBN N
in IN N
structured JJ N
, , N
goal-directed JJ N
social JJ N
interactions NNS N
. . N

-DOCSTART- -X- O O 23482762

Satisfactory JJ N
sampling NN N
in IN N
cytological JJ 4_p
cervical JJ 4_p
diagnosis NN 4_p
: : N
comparison NN N
between IN N
a DT N
conventional JJ N
and CC N
a DT N
new JJ N
sampling NN N
device NN N
. . N

AIM NNP N
Inadequate NNP N
cervical JJ N
sampling NN N
is VBZ N
the DT N
most RBS N
frequent JJ N
cause NN N
of IN N
misdiagnosis NN N
in IN N
cervical JJ 4_p
cancer NN 4_p
screening NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
test VB N
the DT N
ability NN N
of IN N
PapCone® NNP N
versus IN N
the DT N
conventional JJ N
sampling NN N
method NN N
( ( N
Ayre NNP N
's POS N
spatula NN N
plus CC N
cytobrush NN N
) ) N
to TO N
collect VB N
ectocervical JJ N
and CC N
glandular JJ N
cells NNS N
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
In IN N
18 CD N
healthy JJ 4_p
women NNS N
, , N
two CD N
ecto-endocervical JJ N
samples NNS N
, , N
obtained VBN N
by IN N
two CD N
different JJ N
methods NNS N
, , N
were VBD N
obtained VBN N
at IN N
a DT N
three-month JJ N
interval NN N
. . N

Qualitative JJ N
and CC N
quantitative JJ N
parameters NNS N
were VBD N
evaluated VBN N
. . N

Ultrastructure NN N
features NNS N
of IN N
sampling VBG N
devices NNS N
were VBD N
analyzed VBN N
by IN N
scanning VBG N
electron NN N
microscopy NN N
( ( N
SEM NNP N
) ) N
before IN N
and CC N
after IN N
sampling VBG N
. . N

RESULTS VB N
The DT N
χ NNP N
( ( N
2 CD N
) ) N
test NN N
revealed VBD N
a DT N
statistically RB N
significant JJ N
difference NN N
between IN N
the DT N
two CD N
methods NNS N
: : N
PapCone® NNP N
caused VBD N
less JJR N
cell NN N
overlap NN N
and CC N
sampled VBD N
less JJR N
white JJ N
blood NN N
cells NNS N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
and CC N
more RBR N
metaplastic JJ N
cells NNS N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
. . N

SEM NNP N
evaluation NN N
highlighted VBD N
the DT N
porous JJ N
and CC N
spongy JJ N
structure NN N
of IN N
PapCone® NNP N
that WDT N
was VBD N
responsible JJ N
for IN N
the DT N
large JJ N
number NN N
of IN N
glandular JJ N
cells NNS N
on IN N
its PRP$ N
surface NN N
. . N

CONCLUSION NNP N
Cervical NNP N
smears NNS N
performed VBN N
by IN N
PapCone® NNP N
were VBD N
adequate JJ N
and CC N
generally RB N
easier JJR N
to TO N
screen VB N
than IN N
conventionally RB N
performed VBN N
ones NNS N
. . N

-DOCSTART- -X- O O 21324150

Efficacy NN N
of IN N
a DT N
family NN N
practice-based JJ N
lifestyle JJ N
intervention NN N
program NN N
to TO N
increase VB N
physical JJ N
activity NN N
and CC N
reduce VB N
clinical JJ N
and CC N
physiological JJ N
markers NNS N
of IN N
vascular JJ N
health NN N
in IN N
patients NNS N
with IN N
high JJ 4_p
normal JJ 4_p
blood NN 4_p
pressure NN 4_p
and/or RB N
high JJ 4_p
normal JJ 4_p
blood NN 4_p
glucose NN 4_p
( ( 4_p
SNAC NNP 4_p
) ) 4_p
: : N
study NN N
protocol NN N
for IN N
a DT N
randomized VBN N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
Previous JJ N
interventions NNS N
to TO N
increase VB N
physical JJ N
activity NN N
and CC N
reduce VB N
cardiovascular JJ N
risk NN N
factors NNS N
have VBP N
been VBN N
targeted VBN N
at IN N
individuals NNS N
with IN N
established VBN N
disease NN N
; : N
less CC N
attention NN N
has VBZ N
been VBN N
given VBN N
to TO N
intervention VB N
among IN N
individuals NNS N
with IN N
high JJ 4_p
risk NN 4_p
for IN 4_p
disease NN 4_p
nor CC N
has VBZ N
there RB N
been VBN N
determination NN N
of IN N
the DT N
influence NN N
of IN N
setting VBG N
in IN N
which WDT N
the DT N
intervention NN N
is VBZ N
provided VBN N
. . N

In IN N
particular JJ N
, , N
family NN N
practice NN N
represents VBZ N
an DT N
ideal JJ N
setting NN N
for IN N
the DT N
provision NN N
and CC N
long-term JJ N
maintenance NN N
of IN N
lifestyle JJ N
interventions NNS N
for IN N
patients NNS N
at IN N
risk NN N
( ( N
ie JJ N
high-normal JJ 4_p
blood NN 4_p
pressure NN 4_p
or CC 4_p
impaired JJ 4_p
glucose JJ 4_p
tolerance NN 4_p
) ) N
. . N

METHODS/DESIGN PDT N
The DT N
Staged NNP N
Nutrition NNP N
and CC N
Activity NNP N
Counseling NNP N
( ( N
SNAC NNP N
) ) N
study NN N
is VBZ N
a DT N
randomized JJ N
clustered JJ N
design NN N
clinical JJ N
trial NN N
that WDT N
will MD N
investigate VB N
the DT N
effectiveness NN N
and CC N
efficacy NN N
of IN N
a DT N
multi-component JJ N
lifestyle JJ N
intervention NN N
on IN N
cardiovascular JJ N
disease NN N
risk NN N
factors NNS N
and CC N
vascular JJ N
function NN N
in IN N
patients NNS N
at IN N
risk NN N
in IN N
primary JJ N
care NN N
. . N

Patients NNS N
will MD N
be VB N
randomized VBN N
by IN N
practice NN N
to TO N
either VB N
a DT N
standard NN N
of IN N
care NN N
lifestyle JJ N
intervention NN N
or CC N
a DT N
behaviourally-based JJ N
, , N
matched VBD N
prescriptive JJ N
physical JJ N
activity NN N
and CC N
diet JJ N
change NN N
program NN N
. . N

The DT N
primary JJ N
goal NN N
is VBZ N
to TO N
increase VB N
physical JJ N
activity NN N
and CC N
improve VB N
dietary JJ N
intake NN N
according VBG N
to TO N
Canada NNP N
's POS N
Guides NNP N
to TO N
Physical NNP N
Activity NNP N
Healthy NNP N
Eating NNP N
over IN N
24 CD N
months NNS N
. . N

The DT N
primary JJ N
intention NN N
to TO N
treat VB N
analysis NN N
will MD N
compare VB N
behavioral JJ N
, , N
physiological JJ N
and CC N
metabolic JJ N
outcomes NNS N
at IN N
6 CD N
, , N
12 CD N
and CC N
24 CD N
months NNS N
post-randomization JJ N
including VBG N
estimation NN N
of IN N
incident JJ N
hypertension NN N
and/or NN N
diabetes VBZ N
. . N

DISCUSSION VB N
The DT N
design NN N
features NNS N
of IN N
our PRP$ N
trial NN N
, , N
and CC N
the DT N
practical JJ N
problems NNS N
( ( N
and CC N
solutions NNS N
) ) N
associated VBN N
with IN N
implementing VBG N
these DT N
design NN N
features NNS N
, , N
particularly RB N
those DT N
that IN N
result NN N
in IN N
potential JJ N
delay NN N
between IN N
recruitment NN N
, , N
baseline NN N
data NNS N
collection NN N
, , N
randomization NN N
, , N
intervention NN N
, , N
and CC N
assessment NN N
will MD N
be VB N
discussed VBN N
. . N

Results NNS N
of IN N
the DT N
SNAC NNP N
trial NN N
will MD N
provide VB N
scientific JJ N
rationale NN N
for IN N
the DT N
implementation NN N
of IN N
this DT N
lifestyle JJ N
intervention NN N
in IN N
primary JJ N
care NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
ISRCTN NNP N
: : N
ISRCTN:42921300 NNP N
. . N

-DOCSTART- -X- O O 17432640

[ JJ N
Clinical NNP N
observation NN N
on IN N
different JJ N
acupuncture NN N
and CC N
moxibustion NN N
therapies NNS N
for IN N
treatment NN N
of IN N
postsurgical JJ 4_p
gastroparesis NN 4_p
syndrome NN 4_p
] NNP 4_p
. . N

OBJECTIVE NNP N
To TO N
optimize VB N
therapy NN N
of IN N
acupuncture NN N
and CC N
moxibustion NN N
for IN N
postsurgical JJ 4_p
gastroparesis NN 4_p
syndrome NN 4_p
( ( 4_p
PGS NNP 4_p
) ) 4_p
. . N

METHODS NNP N
Forty-one JJ N
cases NNS N
of IN N
PGS NNP 4_p
were VBD N
randomly RB N
divided VBN N
into IN N
3 CD N
groups NNS N
in IN N
order NN N
of IN N
visiting VBG N
. . N

Group NNP N
A NNP N
( ( N
n JJ N
= NNP N
17 CD N
) ) N
were VBD N
treated VBN N
by IN N
warming VBG N
needle JJ N
moxibustion NN N
, , N
group NN N
B NNP N
( ( N
n JJ N
= NNP N
12 CD N
) ) N
by IN N
acupuncture NN N
plus CC N
auricular JJ N
point NN N
sticking NN N
, , N
and CC N
group NN N
C NNP N
( ( N
n JJ N
= NNP N
12 CD N
) ) N
by IN N
routine JJ N
acupuncture NN N
. . N

Changes NNS N
of IN N
gastric JJ N
drainage NN N
volume NN N
, , N
therapeutic JJ N
times NNS N
and CC N
cured JJ N
rate NN N
were VBD N
investigated VBN N
in IN N
the DT N
3 CD N
groups NNS N
. . N

RESULTS NNP N
All PDT N
the DT N
3 CD N
therapeutic JJ N
methods NNS N
could MD N
significantly RB N
decrease VB N
gastric JJ N
drainage NN N
volume NN N
. . N

The DT N
cured JJ N
rate NN N
was VBD N
100.0 CD N
% NN N
and CC N
the DT N
therapeutic JJ N
times NNS N
was VBD N
( ( N
7.24 CD N
+/- JJ N
3.87 CD N
) ) N
in IN N
the DT N
group NN N
A NNP N
, , N
66.7 CD N
% NN N
, , N
( ( N
9.83 CD N
+/- JJ N
4.60 CD N
) ) N
times NNS N
in IN N
the DT N
group NN N
B NNP N
and CC N
75.0 CD N
% NN N
, , N
( ( N
15.25 CD N
+/- JJ N
3.81 CD N
) ) N
times NNS N
in IN N
the DT N
group NN N
C NNP N
, , N
with IN N
significant JJ N
differences NNS N
in IN N
the DT N
cured JJ N
rate NN N
and CC N
the DT N
therapeutic JJ N
times NNS N
among IN N
the DT N
3 CD N
groups NNS N
( ( N
P NNP N
< NNP N
0.05 CD N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

CONCLUSION NNP N
The DT N
warming VBG N
needle JJ N
moxibustion NN N
is VBZ N
the DT N
best JJS N
method NN N
for IN N
PGS NNP 4_p
, , N
with IN N
less RBR N
therapeutic JJ N
times NNS N
, , N
high JJ N
cured VBN N
rate NN N
and CC N
rapid JJ N
effect NN N
. . N

-DOCSTART- -X- O O 25681235

Assessment NN N
of IN N
paravalvular JJ N
aortic JJ N
regurgitation NN N
after IN N
transcatheter NN 4_p
aortic JJ 4_p
valve NN 4_p
replacement NN 4_p
: : 4_p
intra-core JJ N
laboratory NN N
variability NN N
. . N

BACKGROUND NNP N
There EX N
is VBZ N
significant JJ N
disparity NN N
in IN N
the DT N
reported JJ N
incidence NN N
of IN N
moderate JJ 4_p
and CC 4_p
severe JJ 4_p
paravalvular JJ 4_p
aortic JJ 4_p
regurgitation NN 4_p
( ( N
PAR NNP N
) ) N
between IN N
the DT N
Placement NNP 4_p
of IN 4_p
Aortic NNP 4_p
Transcatheter NNP 4_p
Valves NNP 4_p
( ( 4_p
PARTNER NNP 4_p
) ) 4_p
I PRP 4_p
and CC 4_p
PARTNER NNP 4_p
II NNP 4_p
trials NNS 4_p
, , N
which WDT N
may MD N
be VB N
related VBN N
to TO N
the DT N
echocardiographic JJ N
methodologies NNS N
used VBN N
by IN N
separate JJ N
core NN N
laboratories NNS N
. . N

To TO N
further RBR N
explore VB N
the DT N
variability NN N
in IN N
echocardiographic JJ N
interpretation NN N
of IN N
PAR NNP N
, , N
agreement NN N
between IN N
the DT N
grading NN N
of IN N
PAR NNP N
by IN N
the DT N
core NN N
laboratory NN N
of IN N
PARTNER NNP N
IIB NNP N
was VBD N
compared VBN N
with IN N
that DT N
by IN N
a DT N
consortium NN N
of IN N
echocardiography NN N
core NN N
laboratory NN N
directors NNS N
. . N

METHODS NNP N
The DT N
PARTNER NNP N
IIB NNP N
core NN N
laboratory NN N
reevaluated VBD N
patients NNS N
using VBG N
primarily RB N
the DT N
circumferential JJ N
extent NN N
of IN N
the DT N
regurgitant NN N
jet NN N
for IN N
PAR NNP N
. . N

A NNP N
consortium NN N
of IN N
echocardiography NN N
core NN N
laboratory NN N
directors NNS N
was VBD N
formed VBN N
to TO N
evaluate VB N
the DT N
echocardiographic JJ N
images NNS N
and CC N
to TO N
grade VB N
PAR NNP N
and CC N
central JJ N
and CC N
total JJ N
aortic JJ N
regurgitation NN N
in IN N
a DT N
randomly JJ N
chosen NN N
subset NN N
of IN N
the DT N
randomized JJ N
patients NNS N
in IN N
the DT N
PARTNER NNP N
IIB NNP N
trial NN N
using VBG N
a DT N
multiwindow NN N
, , N
multiparametric JJ N
approach NN N
. . N

Both CC N
a DT N
four-class JJ N
scale NN N
( ( N
none NN N
or CC N
trace NN N
, , N
mild NN N
, , N
moderate JJ N
, , N
and CC N
severe RB N
) ) N
and CC N
a DT N
seven-class NN N
( ( N
none NN N
, , N
trace NN N
, , N
mild NN N
, , N
mild NN N
to TO N
moderate VB N
, , N
moderate VB N
, , N
moderate VB N
to TO N
severe VB N
, , N
and CC N
severe RB N
) ) N
scale NN N
were VBD N
used VBN N
. . N

Levels NNP N
of IN N
grading VBG N
agreement NN N
between IN N
the DT N
consortium NN N
and CC N
original JJ N
core NN N
laboratory NN N
in IN N
both DT N
scales NNS N
were VBD N
determined VBN N
using VBG N
weighted JJ N
κ JJ N
statistics NNS N
. . N

RESULTS NNP N
Only RB N
87 CD N
patients NNS N
assessed VBN N
for IN N
PAR NNP 4_p
by IN N
the DT N
consortium NN N
could MD N
be VB N
paired VBN N
with IN N
readings NNS N
by IN N
the DT N
PARTNER NNP N
IIB NNP N
core NN N
laboratory NN N
. . N

Using VBG N
the DT N
four-class NN N
grading VBG N
scheme NN N
the DT N
weighted JJ N
κ NNP N
statistic NN N
for IN N
PAR NNP N
was VBD N
0.481 CD N
( ( N
95 CD N
% NN N
confidence NN N
limits NNS N
, , N
0.367 CD N
, , N
0.595 CD N
) ) N
. . N

Using VBG N
the DT N
seven-class JJ N
scale NN N
, , N
the DT N
weighted JJ N
κ NNP N
statistic NN N
for IN N
PAR NNP N
was VBD N
0.517 CD N
( ( N
95 CD N
% NN N
confidence NN N
limits NNS N
, , N
0.431 CD N
, , N
0.607 CD N
) ) N
. . N

For IN N
either DT N
grading VBG N
scheme NN N
, , N
15.9 CD N
% NN N
of IN N
patients NNS N
graded VBN N
by IN N
the DT N
PARTNER NNP N
IIB NNP N
core NN N
laboratory NN N
as IN N
having VBG N
moderate JJ N
PAR NNP N
would MD N
have VB N
been VBN N
graded VBN N
as IN N
having VBG N
mild JJ N
PAR NNP N
using VBG N
the DT N
multiparametric JJ N
approach NN N
. . N

Similar JJ N
results NNS N
were VBD N
seen VBN N
for IN N
central JJ N
and CC N
total JJ N
aortic JJ N
regurgitation NN N
assessments NNS N
. . N

CONCLUSIONS NNP N
Using NNP N
primarily RB N
the DT N
circumferential JJ N
extent NN N
criteria NNS N
, , N
the DT N
PARTNER NNP N
IIB NNP N
core NN N
laboratory NN N
overestimated VBD N
the DT N
severity NN N
of IN N
PAR NNP N
compared VBN N
to TO N
the DT N
consortium NN N
using VBG N
a DT N
multi-parametric JJ N
approach NN N
. . N

Although IN N
a DT N
more RBR N
granular JJ N
classification NN N
scheme NN N
for IN N
PAR NNP N
may MD N
slightly RB N
improve VB N
concordance NN N
between IN N
core NN N
laboratories NNS N
, , N
differences NNS N
in IN N
the DT N
incidence NN N
of IN N
moderate JJ N
or CC N
severe JJ N
PAR NN N
are VBP N
likely JJ N
related VBN N
to TO N
differences NNS N
in IN N
grading VBG N
methodology NN N
. . N

A DT N
multiparametric JJ N
approach NN N
is VBZ N
advocated VBN N
, , N
and CC N
other JJ N
echocardiographic JJ N
methods NNS N
for IN N
assessing VBG N
PAR NNP N
deserve VB N
further RB N
study NN N
. . N

-DOCSTART- -X- O O 15534261

Impact NN N
of IN N
antioxidants NNS N
, , N
zinc NN N
, , N
and CC N
copper NN N
on IN N
cognition NN N
in IN N
the DT N
elderly JJ N
: : N
a DT N
randomized NN N
, , N
controlled VBN N
trial NN N
. . N

Participants NNS N
in IN N
the DT N
Age-Related JJ N
Eye NNP N
Disease NNP N
Study NNP N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
daily JJ N
antioxidants NNS N
( ( N
vitamin JJ N
C NNP N
, , N
500 CD N
mg NN N
; : N
vitamin CC N
E NNP N
, , N
400 CD N
IU NNP N
; : N
beta NN N
carotene NN N
, , N
15 CD N
mg NN N
) ) N
, , N
zinc NN N
and CC N
copper NN N
( ( N
zinc NN N
, , N
80 CD N
mg NN N
; : N
cupric JJ N
oxide NN N
, , N
2 CD N
mg NN N
) ) N
, , N
antioxidants NNS N
plus CC N
zinc NN N
and CC N
copper NN N
, , N
or CC N
placebo NN N
. . N

A DT N
cognitive JJ N
battery NN N
was VBD N
administered VBN N
to TO N
2,166 CD N
elderly JJ N
persons NNS N
after IN N
a DT N
median NN N
of IN N
6.9 CD N
years NNS N
of IN N
treatment NN N
. . N

Treatment NNP N
groups NNS N
did VBD N
not RB N
differ VB N
on IN N
any DT N
of IN N
the DT N
six CD N
cognitive JJ N
tests NNS N
( ( N
p JJ N
> VBP N
0.05 CD N
for IN N
all DT N
) ) N
. . N

These DT N
results NNS N
do VBP N
not RB N
support VB N
a DT N
beneficial JJ N
or CC N
harmful JJ N
effect NN N
of IN N
antioxidants NNS N
or CC N
zinc NN N
and CC N
copper NN N
on IN N
cognition NN N
in IN N
older JJR N
adults NNS N
. . N

-DOCSTART- -X- O O 1759534

Long-term JJ N
growth NN N
hormone NN N
treatment NN N
in IN N
growth NN 4_p
hormone NN 4_p
deficient NN 4_p
adults NNS N
. . N

Growth NNP N
hormone NN N
treatment NN N
in IN N
GH-deficient NNP 4_p
adults NNS 4_p
has VBZ N
proved VBN N
beneficial JJ N
in IN N
recent JJ N
short-term JJ N
trials NNS N
, , N
but CC N
long-term JJ N
results NNS N
have VBP N
not RB N
yet RB N
been VBN N
reported VBN N
. . N

Thirteen JJ N
GH-deficient JJ 4_p
adults NNS 4_p
( ( N
4 CD N
females NNS N
, , N
9 CD N
males NNS N
; : N
mean FW N
( ( N
SEM NNP N
) ) N
age NN N
26.4 CD N
( ( N
1.7 CD N
) ) N
years NNS N
) ) N
, , N
who WP N
had VBD N
completed VBN N
4 CD N
months NNS N
of IN N
GH NNP N
therapy NN N
in IN N
a DT N
double-blind JJ N
placebo-controlled JJ N
cross-over NN N
study NN N
were VBD N
followed VBN N
, , N
for IN N
further JJ N
16.1 CD N
( ( N
0.8 CD N
) ) N
months NNS N
of IN N
uninterrupted JJ N
GH NNP N
therapy NN N
in IN N
an DT N
open JJ N
design NN N
. . N

A DT N
significant JJ N
mean JJ N
increase NN N
of IN N
1.3 CD N
cm NN N
in IN N
linear JJ N
height NN N
was VBD N
recorded VBN N
, , N
whereas IN N
body NN N
mass NN N
index NN N
remained VBD N
unchanged JJ N
. . N

Mean JJ N
muscle NN N
volume NN N
of IN N
the DT N
thigh NN N
, , N
estimated VBN N
by IN N
computerised JJ N
tomography NN N
, , N
increased VBD N
significantly RB N
compared VBN N
with IN N
that DT N
of IN N
the DT N
initial JJ N
placebo NN N
period NN N
( ( N
p JJ N
= NNP N
0.01 CD N
) ) N
, , N
and CC N
a DT N
slight JJ N
decrease NN N
was VBD N
recorded VBN N
in IN N
adipose JJ N
tissue NN N
volume NN N
of IN N
the DT N
thigh NN N
( ( N
p JJ N
= NNP N
0.10 CD N
) ) N
and CC N
subscapular JJ N
skinfold NN N
thickness NN N
( ( N
p JJ N
= NNP N
0.10 CD N
) ) N
. . N

Still RB N
, , N
the DT N
muscle NN N
to TO N
fat VB N
ratio NN N
of IN N
the DT N
thigh NN N
was VBD N
significantly RB N
lower JJR N
compared VBN N
with IN N
that DT N
of IN N
normal JJ 4_p
subjects NNS N
( ( N
72.6/27.4 CD N
vs RB N
77.9/22.1 CD N
) ) N
( ( N
p NN N
less JJR N
than IN N
0.01 CD N
) ) N
. . N

The DT N
mean JJ N
isometric JJ N
strength NN N
of IN N
the DT N
quadriceps JJ N
muscles NNS N
increased VBD N
significantly RB N
during IN N
long-term JJ N
GH NNP N
therapy NN N
( ( N
p NN N
less JJR N
than IN N
0.01 CD N
) ) N
, , N
but CC N
remained VBD N
lower JJR N
compared VBN N
with IN N
that DT N
of IN N
normal JJ N
subjects NNS N
( ( N
1.66 CD N
( ( N
0.10 CD N
) ) N
vs NN N
2.13 CD N
( ( N
0.11 CD N
) ) N
Nm/kg NNP N
body NN N
weight NN N
) ) N
. . N

Exercise NN N
capacity NN N
performed VBN N
on IN N
a DT N
bicycle NN N
ergometer NN N
increased VBD N
significantly RB N
after IN N
long-term JJ N
therapy NN N
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
, , N
but CC N
still RB N
did VBD N
not RB N
reach VB N
the DT N
values NNS N
seen VBN N
in IN N
normal JJ N
subjects NNS N
( ( N
22.5 CD N
( ( N
3.4 CD N
) ) N
vs NN N
37.4 CD N
( ( N
4.2 CD N
) ) N
watt.min.kg-1 NN N
. . N

No DT N
adverse JJ N
reactions NNS N
were VBD N
recorded VBN N
during IN N
long-term JJ N
therapy NN N
and CC N
hemoglobin NN N
A1c NNP N
remained VBD N
unchanged JJ N
. . N

These DT N
data NNS N
suggest VBP N
that IN N
long-term JJ N
GH NNP N
replacement NN N
therapy NN N
in IN N
GH-deficient NNP N
adults NNS N
has VBZ N
beneficial JJ N
effects NNS N
on IN N
several JJ N
physiological JJ N
features NNS N
which WDT N
are VBP N
subnormal JJ N
in IN N
these DT N
patients NNS N
. . N

-DOCSTART- -X- O O 23870503

Can MD N
a DT N
questionnaire NN N
predict NN N
vitamin NN N
D NNP N
status NN N
in IN N
postmenopausal NN 4_p
women NNS 4_p
? . N
OBJECTIVE NNP N
Our PRP$ N
objective NN N
was VBD N
to TO N
determine VB N
whether IN N
a DT N
questionnaire NN N
can MD N
identify VB N
individuals NNS N
with IN N
vitamin NN 4_p
D NNP 4_p
insufficiency NN 4_p
( ( 4_p
VDI NNP 4_p
) ) 4_p
. . 4_p

DESIGN NNP N
Women NNP N
completed VBD N
the DT N
Vitamin NNP N
D NNP N
& CC N
Sun NNP N
( ( N
VIDSUN NNP N
) ) N
questionnaire NN N
and CC N
we PRP N
measured VBD N
their PRP$ N
serum JJ N
25-hydrocyvitamin JJ N
D NNP N
( ( N
25 CD N
( ( N
OH NNP N
) ) N
D NNP N
) ) N
levels NNS N
. . N

We PRP N
assessed VBD N
the DT N
sensitivity NN N
and CC N
specificity NN N
of IN N
the DT N
questionnaire NN N
to TO N
identify VB N
VDI NNP N
( ( N
25 CD N
( ( N
OH NNP N
) ) N
D NNP N
level NN N
< VBD N
50 CD N
nmol/l NN N
) ) N
. . N

SETTING NNP N
Clinical JJ N
Research NNP N
Unit NNP N
, , N
University NNP N
of IN N
Wisconsin-Madison NNP N
. . N

SUBJECTS NNP N
Postmenopausal NNP N
women NNS N
. . N

RESULTS NNP N
We PRP N
recruited VBD N
609 CD N
postmenopausal JJ N
women NNS N
with IN N
a DT N
mean JJ N
age NN N
of IN N
61 CD N
( ( N
sd JJ N
6 CD N
years NNS N
) ) N
, , N
of IN N
whom WP N
113 CD N
( ( N
19 CD N
% NN N
) ) N
had VBD N
VDI NNP N
. . N

Women NNP N
with IN N
VDI NNP N
were VBD N
more RBR N
likely JJ N
to TO N
be VB N
black JJ N
( ( N
17 CD N
% NN N
v. JJ N
2 CD N
% NN N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
heavier JJR N
( ( N
BMI NNP N
33.0 CD N
( ( N
sd VB N
7 CD N
) ) N
kg/m2 NN N
v. $ N
29.0 CD N
( ( N
sd VB N
7 CD N
) ) N
kg/m2 NN N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
less RBR N
likely JJ N
to TO N
tan VB N
in IN N
the DT N
past JJ N
year NN N
( ( N
49 CD N
% NN N
v. JJ N
72 CD N
% NN N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
use VBP N
sunscreen JJ N
( ( N
57 CD N
% NN N
v. JJ N
72 CD N
% NN N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
or CC N
report VB N
sun NN N
exposure NN N
in IN N
the DT N
last JJ N
3 CD N
months NNS N
. . N

They PRP N
consumed VBD N
less JJR N
vitamin JJ N
D NNP N
from IN N
supplements NNS N
( ( N
2.15 CD N
( ( N
sd VB N
5.24 CD N
) ) N
μg/d NN N
( ( N
86 CD N
( ( N
sd VB N
210 CD N
) ) N
IU/d NNP N
) ) N
v. VBZ N
4.55 CD N
( ( N
sd VB N
8.48 CD N
) ) N
μg/d NN N
( ( N
188 CD N
( ( N
sd VB N
344 CD N
) ) N
IU/d NNP N
) ) N
, , N
P NNP N
= NNP N
0.003 CD N
) ) N
. . N

In IN N
logistic JJ N
regression NN N
models NNS N
, , N
black JJ N
race NN N
, , N
BMI NNP N
, , N
suntan NN N
within IN N
the DT N
past JJ N
year NN N
, , N
sun NN N
exposure NN N
in IN N
the DT N
past JJ N
3 CD N
months NNS N
, , N
sunscreen JJ N
use NN N
and CC N
supplemental JJ N
vitamin NN N
D NNP N
intake NN N
were VBD N
the DT N
most RBS N
useful JJ N
questions NNS N
to TO N
identify VB N
VDI NNP N
. . N

From IN N
these DT N
six CD N
items NNS N
, , N
a DT N
composite JJ N
score NN N
of IN N
≤ $ N
2.25 CD N
demonstrated VBN N
≥89 CD N
% NN N
sensitivity NN N
but CC N
≤35 CD N
% NN N
specificity NN N
for IN N
VDI NNP N
. . N

CONCLUSIONS NNP N
The DT N
VIDSUN NNP N
questionnaire NN N
provides VBZ N
an DT N
initial JJ N
tool NN N
to TO N
identify VB N
postmenopausal JJ N
women NNS N
at IN N
high JJ N
or CC N
low JJ N
risk NN N
of IN N
VDI NNP N
. . N

Existing VBG N
studies NNS N
suggest VBP N
that IN N
inclusion NN N
of IN N
physical JJ N
activity NN N
and CC N
TAG NNP N
levels NNS N
might MD N
improve VB N
the DT N
performance NN N
of IN N
the DT N
VIDSUN NNP N
questionnaire NN N
. . N

-DOCSTART- -X- O O 1996926

Repeatability NN N
and CC N
protocol JJ N
comparability NN N
of IN N
presyncopal JJ 4_p
symptom NN 4_p
limited VBD 4_p
lower JJR 4_p
body NN 4_p
negative JJ 4_p
pressure NN 4_p
exposures NNS 4_p
. . 4_p

Data NNS N
on IN N
repeatability NN N
and CC N
comparability NN N
of IN N
different JJ N
presyncopal JJ N
symptom-limited JJ N
lower JJR N
body NN N
negative JJ N
pressure NN N
( ( N
PSL-LBNP NNP N
) ) N
exposure NN N
protocols NNS N
, , N
while IN N
scarce NN N
, , N
are VBP N
critical JJ N
to TO N
the DT N
interpretation NN N
of IN N
studies NNS N
using VBG N
PSL-LBNP NNP N
methods NNS N
. . N

To TO N
investigate VB N
if IN N
PSL-LBNP JJ N
tolerance NN N
, , N
heart NN N
rate NN N
, , N
and CC N
blood NN N
pressure NN N
were VBD N
repeatable JJ N
, , N
11 CD N
subjects NNS 4_p
were VBD 4_p
exposed VBN 4_p
to TO 4_p
4 CD 4_p
PSL-LBNP JJ 4_p
tests NNS 4_p
; : 4_p
each DT N
test NN N
occurring VBG N
at IN N
the DT N
same JJ N
time NN N
of IN N
day NN N
, , N
separated VBN N
by IN N
at IN N
least JJS N
72 CD N
h NN N
, , N
and CC N
using VBG N
the DT N
same JJ N
protocol NN N
. . N

No DT N
significant JJ N
differences NNS N
were VBD N
found VBN N
in IN N
either CC N
the DT N
heart NN N
rate NN N
or CC N
blood NN N
pressure NN N
responses VBZ N
to TO N
the DT N
PSL-LBNP NNP N
or CC N
the DT N
tolerance NN N
indices NNS N
( ( N
cumulative JJ N
stress NN N
index NN N
; : N
maximum JJ N
negative JJ N
pressure NN N
tolerated VBN N
; : N
and CC N
duration NN N
of IN N
negative JJ N
pressure NN N
exposure NN N
) ) N
. . N

To TO N
study VB N
the DT N
comparability NN N
of IN N
different JJ N
PSL-LBNP NNP N
protocols NNS N
, , N
nine CD N
subjects NNS N
were VBD N
exposed VBN N
randomly RB N
to TO N
five CD N
PSL-LBNP JJ N
tests NNS N
using VBG N
protocols NNS N
that WDT N
varied VBD N
in IN N
stage NN N
duration NN N
but CC N
not RB N
pressure NN N
profile NN N
. . N

The DT N
protocols NNS N
had VBD N
1- CD N
, , N
3- CD N
, , N
5- JJ N
, , N
7- JJ N
, , N
or CC N
9-min JJ N
stage NN N
durations NNS N
. . N

These DT N
PSL-LBNP JJ N
exposures NNS N
were VBD N
conducted VBN N
at IN N
the DT N
same JJ N
time NN N
of IN N
day NN N
and CC N
separated VBN N
by IN N
at IN N
least JJS N
72 CD N
h. NN N
While IN N
no DT N
differences NNS N
were VBD N
noted VBN N
in IN N
either CC N
the DT N
response NN N
pattern NN N
or CC N
magnitude NN N
of IN N
heart NN N
rate NN N
or CC N
blood NN N
pressure NN N
to TO N
the DT N
differing NN N
protocols NNS N
, , N
the DT N
cumulative JJ N
stress NN N
index NN N
and CC N
the DT N
duration NN N
of IN N
negative JJ N
pressure NN N
exposure NN N
varied VBD N
proportionally RB N
with IN N
the DT N
length NN N
of IN N
the DT N
stage NN N
durations NNS N
. . N

With IN N
the DT N
exception NN N
of IN N
the DT N
1-min JJ N
protocol NN N
, , N
the DT N
maximum JJ N
negative JJ N
pressure NN N
tolerated VBD N
did VBD N
not RB N
vary JJ N
regardless NN N
of IN N
the DT N
protocol NN N
used VBN N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -X- O O 18672629

Less NNP N
tachycardia NN N
in IN N
adults NNS N
when WRB N
using VBG N
atropine VBP N
0.9 CD N
mg NNS N
compared VBN N
with IN N
1.2 CD N
mg NNS N
plus CC N
neostigmine JJ N
2.5 CD N
mg NN N
. . N

OBJECTIVE CC N
Compare NNP N
the DT N
increase NN N
in IN N
heart NN N
rate NN N
in IN N
adults NNS N
after IN N
0.9 CD N
vs. FW N
1.2 CD N
mg NN N
of IN N
atropine JJ N
plus CC N
neostigmine JJ N
2.5 CD N
mg NN N
as IN N
the DT N
non-depolarizing JJ N
muscle NN N
relaxant NN N
reversal NN N
agent NN N
. . N

MATERIAL NNP N
AND NNP N
METHOD NNP N
A NNP N
randomized NN N
, , N
double JJ N
blind NN N
, , N
controlled VBN N
trial NN N
on IN N
46 CD N
adults NNS N
ASA NNP N
I-II NNP N
, , N
undergoing VBG N
elective JJ N
gynecological NN N
or CC N
general JJ N
surgery NN N
with IN N
balanced JJ N
general JJ N
anesthesia NN N
was VBD N
performed VBN N
. . N

The DT N
subjects NNS N
were VBD N
randomized VBN N
into IN N
two CD N
groups NNS N
, , N
After IN N
surgery NN N
, , N
the DT N
study NN N
group NN N
received VBD N
0.9 CD N
mg NN N
of IN N
atropine NN N
, , N
while IN N
the DT N
control NN N
group NN N
received VBD N
1.2 CD N
mg NN N
of IN N
atropine NN N
. . N

Both DT N
groups NNS N
received VBD N
2.5 CD N
mg NN N
of IN N
neostigmine JJ N
simultaneously RB N
. . N

RESULTS VB N
The DT N
heart NN N
rate NN N
and CC N
blood NN N
pressure NN N
were VBD N
taken VBN N
at IN N
0 CD N
, , N
1 CD N
, , N
2 CD N
, , N
3 CD N
, , N
4 CD N
, , N
5 CD N
, , N
6 CD N
, , N
7 CD N
, , N
8 CD N
, , N
9 CD N
, , N
10 CD N
, , N
15 CD N
, , N
20 CD N
, , N
25 CD N
, , N
and CC N
30 CD N
min NN N
after IN N
the DT N
injection NN N
. . N

The DT N
increase NN N
in IN N
heart NN N
rate NN N
and CC N
blood NN N
pressure NN N
between IN N
the DT N
two CD N
groups NNS N
were VBD N
compared VBN N
. . N

The DT N
heart NN N
rate NN N
( ( N
at IN N
3 CD N
, , N
4 CD N
, , N
5 CD N
, , N
and CC N
6 CD N
min NN N
) ) N
of IN N
patients NNS N
in IN N
the DT N
study NN N
group NN N
increased VBD N
significantly RB N
less JJR N
than IN N
that DT N
of IN N
patients NNS N
in IN N
the DT N
control NN N
group NN N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
blood NN N
pressure NN N
between IN N
groups NNS N
and CC N
no DT N
side NN N
effects NNS N
occurred VBD N
. . N

CONCLUSION VB N
The DT N
authors NNS N
conclude VBP N
that IN N
0.9 CD N
mg NN N
of IN N
atropine NN N
with IN N
2.5 CD N
mg NNS N
neostigmine JJ N
can MD N
be VB N
safely RB N
used VBN N
as IN N
the DT N
reversal NN N
agent NN N
for IN N
a DT N
non-depolarizing JJ N
muscle NN N
relaxant NN N
, , N
particularly RB N
in IN N
patients NNS N
for IN N
whom WP N
any DT N
increase NN N
in IN N
heart NN N
rate NN N
would MD N
be VB N
harmful JJ N
. . N

-DOCSTART- -X- O O 3315991

Intravenous NNP N
lignocaine NN N
& CC N
haemodynamic JJ N
responses NNS N
to TO N
cystoscopy VB 4_p
. . N

-DOCSTART- -X- O O 23773886

An DT N
Exploratory NNP N
, , N
Open-Label NNP N
, , N
Randomized NNP N
Trial NNP N
Comparing NNP N
Risperidone NNP N
Long-Acting NNP N
Injectable NNP N
with IN N
Oral NNP N
Antipsychotic NNP N
Medication NNP N
in IN N
the DT N
Treatment NNP N
of IN N
Early NNP 4_p
Psychosis NNP 4_p
. . 4_p

Few JJ N
studies NNS N
have VBP N
examined VBN N
effectiveness NN N
and CC N
tolerability NN N
of IN N
risperidone NN N
long-acting JJ N
injections NNS N
( ( N
RLAI NNP N
) ) N
in IN N
the DT N
early JJ N
phase NN N
of IN N
a DT N
schizophrenia NN 4_p
spectrum NN 4_p
( ( 4_p
SS NNP 4_p
) ) 4_p
disorder NN 4_p
using VBG N
a DT N
randomized VBN N
controlled VBN N
trial NN N
( ( N
RCT NNP N
) ) N
design NN N
. . N

Eighty-five JJ N
patients NNS N
in IN N
early JJ N
phase NN N
of IN N
an DT N
SS NNP 4_p
disorder NN 4_p
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
oral JJ N
second-generation NN N
antipsychotics NNS N
( ( N
SGAs NNP N
; : N
n=41 CC N
) ) N
or CC N
RLAI NNP N
( ( N
n=44 NN N
) ) N
over IN N
two CD N
years NNS N
. . N

Analyses NNS N
were VBD N
conducted VBN N
on IN N
eligible JJ N
participants NNS N
( ( N
n=77 NN N
) ) N
for IN N
the DT N
stabilization NN N
( ( N
maximum JJ N
18 CD N
weeks NNS N
) ) N
and CC N
maintenance NN N
phases NNS N
( ( N
up RB N
to TO N
Week NNP N
104 CD N
) ) N
on IN N
primary JJ N
outcome JJ N
measures NNS N
of IN N
time NN N
to TO N
stabilization NN N
and CC N
relapse NN N
, , N
change NN N
in IN N
symptoms NNS N
and CC N
safety NN N
, , N
and CC N
comparisons NNS N
made VBN N
across IN N
the DT N
two CD N
groups NNS N
. . N

Both DT N
groups NNS N
showed VBD N
improvement NN N
on IN N
Positive NNP N
and CC N
Negative NNP N
Syndrome NNP N
Scale NNP N
( ( N
PANSS NNP N
) ) N
scores NNS N
and CC N
Clinical NNP N
Global NNP N
Impression-Severity NNP N
( ( N
CGI-S NNP N
) ) N
scores VBZ N
. . N

There EX N
were VBD N
no DT N
time NN N
X NNP N
group NN N
interactions NNS N
on IN N
any DT N
of IN N
the DT N
primary JJ N
outcome NN N
measures NNS N
. . N

Post NNP N
hoc JJ N
examination NN N
revealed VBD N
that IN N
the DT N
RLAI NNP N
group NN N
showed VBD N
greater JJR N
change NN N
on IN N
CGI-S NNP N
and CC N
PANSS NNP N
negative JJ N
symptom NN N
scores NNS N
during IN N
the DT N
stabilization NN N
phase NN N
, , N
while IN N
the DT N
oral JJ N
group NN N
reached VBD N
the DT N
same JJ N
level NN N
of IN N
improvement NN N
during IN N
the DT N
maintenance NN N
phase NN N
. . N

The DT N
current JJ N
exploratory NN N
study NN N
suggests VBZ N
that-within VBP N
an DT N
RCT NNP N
design-RLAI NN N
and CC N
oral JJ N
SGAs NNP N
are VBP N
equally RB N
effective JJ N
and CC N
have VBP N
similar JJ N
safety NN N
profiles NNS N
in IN N
patients NNS N
in IN N
the DT N
early JJ N
phase NN N
of IN N
SS NNP N
disorders NNS N
. . N

Thus RB N
, , N
RLAI NNP N
offers VBZ N
no DT N
advantage NN N
to TO N
patients NNS N
in IN N
early JJ N
phase NN N
of IN N
SS NNP N
disorders NNS N
, , N
but CC N
is VBZ N
likely JJ N
to TO N
be VB N
effective JJ N
and CC N
safe JJ N
for IN N
those DT N
who WP N
may MD N
have VB N
problems NNS N
with IN N
adherence NN N
and CC N
may MD N
either RB N
choose VB N
to TO N
take VB N
it PRP N
or CC N
be VB N
prescribed VBN N
under IN N
conditions NNS N
of IN N
external JJ N
control NN N
such JJ N
as IN N
community NN N
treatment NN N
orders NNS N
. . N

-DOCSTART- -X- O O 25675062

A DT N
randomized JJ N
, , N
double-blind JJ N
controlled VBD N
trial NN N
of IN N
lumbar NN N
interlaminar JJ N
epidural JJ N
injections NNS N
in IN N
central JJ N
spinal JJ N
stenosis NN N
: : N
2-year JJ N
follow-up NN N
. . N

BACKGROUND NNP N
While IN N
low JJ N
back RB N
pain NN N
is VBZ N
the DT N
number NN N
one CD N
cause NN N
of IN N
disability NN N
in IN N
the DT N
United NNP N
States NNPS N
, , N
lumbar VBP 4_p
spinal JJ 4_p
stenosis NN 4_p
along IN N
with IN N
intervertebral JJ N
disc NN N
herniation NN N
and CC N
degenerative JJ N
spondylolisthesis NN N
is VBZ N
one CD N
of IN N
the DT N
3 CD N
most JJS N
common JJ N
diagnosis NN N
of IN N
low JJ N
back RB N
and CC N
leg NN N
pain NN N
for IN N
which WDT N
surgery NN N
is VBZ N
performed VBN N
. . N

Numerous JJ N
modalities NNS N
of IN N
treatments NNS N
including VBG N
drug NN N
therapy NN N
and CC N
complex JJ N
surgical JJ N
fusions NNS N
have VBP N
been VBN N
recommended VBN N
for IN N
treatment NN N
of IN N
central JJ N
spinal JJ N
stenosis NN N
. . N

Epidural JJ N
injections NNS N
are VBP N
one CD N
of IN N
the DT N
commonly NN N
performed VBD N
nonsurgical JJ N
interventions NNS N
in IN N
managing VBG N
central JJ N
spinal JJ N
stenosis NN N
; : N
however RB N
, , N
there EX N
has VBZ N
been VBN N
paucity NN N
of IN N
literature NN N
in IN N
reference NN N
to TO N
efficacy NN N
of IN N
epidural JJ N
injections NNS N
in IN N
managing VBG N
central JJ N
spinal JJ N
stenosis NN N
with IN N
lumbar NN N
interlaminar JJ N
epidural JJ N
injections NNS N
. . N

STUDY NNP N
DESIGN NNP N
A NNP N
randomized JJ N
, , N
double-blind JJ N
, , N
active JJ N
controlled VBN N
trial NN N
. . N

SETTING NN N
Private JJ N
interventional JJ N
pain NN N
management NN N
practice NN N
and CC N
specialty NN N
referral JJ N
center NN N
in IN N
the DT N
United NNP N
States NNPS N
. . N

OBJECTIVE NNP N
To TO N
assess VB N
the DT N
effectiveness NN N
of IN N
lumbar NN N
interlaminar JJ N
epidural JJ N
injections NNS N
with IN N
or CC N
without IN N
steroids NNS N
in IN N
providing VBG N
effective JJ N
and CC N
long-lasting JJ N
pain NN N
relief NN N
with IN N
improvement NN N
in IN N
functional JJ N
status NN N
for IN N
the DT N
management NN N
of IN N
chronic NN N
low JJ N
back RB N
and CC N
lower JJR N
extremity NN N
pain NN N
related VBN N
to TO N
lumbar VB N
central JJ N
spinal JJ N
stenosis NN N
. . N

METHODS NNP N
A NNP N
randomized JJ N
, , N
double-blind JJ N
, , N
active-control JJ N
trial NN N
was VBD N
designed VBN N
with IN N
the DT N
inclusion NN N
of IN N
120 CD N
patients NNS N
assigned VBN N
to TO N
2 CD N
groups NNS N
. . N

Group NNP N
I PRP N
patients NNS N
received VBD N
lumbar JJ N
interlaminar JJ N
epidural JJ N
injections NNS N
of IN N
local JJ N
anesthetic JJ N
( ( N
lidocaine JJ N
0.5 CD N
% NN N
) ) N
6 CD N
mL NN N
, , N
whereas WP N
Group NNP N
II NNP N
received VBD N
lumbar JJ N
interlaminar JJ N
epidural JJ N
injections NNS N
with IN N
local JJ N
anesthetic NN N
( ( N
lidocaine JJ N
0.5 CD N
% NN N
) ) N
5 CD N
mL NN N
mixed JJ N
with IN N
1 CD N
mL NNS N
of IN N
steroids NNS N
and CC N
6 CD N
mg NN N
of IN N
betamethasone NN N
. . N

OUTCOMES NNP N
ASSESSMENT NNP N
Outcomes NNP N
were VBD N
assessed VBN N
utilizing VBG N
the DT N
numeric JJ N
pain NN N
rating NN N
scale NN N
( ( N
NRS NNP N
) ) N
and CC N
Oswestry NNP N
Disability NNP N
Index NNP N
( ( N
ODI NNP N
) ) N
at IN N
3 CD N
, , N
6 CD N
, , N
12 CD N
, , N
18 CD N
, , N
and CC N
24 CD N
months NNS N
post VBN N
treatment NN N
. . N

The DT N
primary JJ N
outcome NN N
measure NN N
was VBD N
significant JJ N
improvement NN N
, , N
defined VBD N
as IN N
50 CD N
% NN N
improvement NN N
in IN N
pain NN N
and CC N
disability NN N
scores NNS N
. . N

RESULTS NNP N
Significant JJ N
relief NN N
and CC N
functional JJ N
status NN N
improvement NN N
was VBD N
seen VBN N
in IN N
72 CD N
% NN N
and CC N
73 CD N
% NN N
of IN N
patients NNS N
in IN N
Groups NNP N
I PRP N
and CC N
II NNP N
at IN N
the DT N
end NN N
of IN N
2 CD N
years NNS N
considering VBG N
all DT N
participants NNS N
; : N
however RB N
, , N
this DT N
was VBD N
84 CD N
% NN N
and CC N
85 CD N
% NN N
in IN N
the DT N
successful JJ N
group NN N
. . N

Overall JJ N
significant JJ N
improvement NN N
was VBD N
achieved VBN N
for IN N
65.7 CD N
± JJ N
37.3 CD N
weeks NNS N
in IN N
Group NNP N
1 CD N
and CC N
68.9 CD N
± RB N
37.7 CD N
weeks NNS N
in IN N
Group NNP N
II NNP N
at IN N
the DT N
end NN N
of IN N
2 CD N
years NNS N
when WRB N
all DT N
participants NNS N
were VBD N
considered VBN N
; : N
whereas NNS N
, , N
this DT N
was VBD N
77 CD N
± JJ N
27.8 CD N
weeks NNS N
and CC N
77.9 CD N
± RB N
30.2 CD N
weeks NNS N
when WRB N
they PRP N
were VBD N
separated VBN N
into IN N
successful JJ N
categories NNS N
. . N

The DT N
average JJ N
number NN N
of IN N
procedures NNS N
per IN N
patient NN N
was VBD N
5 CD N
to TO N
6 CD N
in IN N
both DT N
groups NNS N
. . N

LIMITATIONS NNP N
Limitations NNPS N
of IN N
this DT N
trial NN N
include VBP N
lack NN N
of IN N
placebo NN N
control NN N
group NN N
and CC N
treatment NN N
of IN N
patients NNS N
with IN N
multiple JJ N
procedures NNS N
over IN N
a DT N
period NN N
of IN N
2 CD N
years NNS N
. . N

CONCLUSION NNP N
Lumbar NNP N
interlaminar JJ N
epidural JJ N
injections NNS N
of IN N
local JJ N
anesthetic JJ N
with IN N
or CC N
without IN N
steroids NNS N
provide VBP N
relief NN N
in IN N
a DT N
significant JJ N
proportion NN N
of IN N
patients NNS N
with IN N
lumbar JJ 4_p
central JJ 4_p
spinal JJ 4_p
stenosis NN 4_p
. . N

CLINICAL NNP N
TRIAL NNP N
NCT00681447 NNP N
. . N

-DOCSTART- -X- O O 10719133

Blood NNP N
pressure NN N
biofeedback NN N
treatment NN N
of IN N
white-coat JJ N
hypertension NN N
. . N

OBJECTIVE CC N
The DT N
objective NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
compare VB N
blood NN N
pressure NN N
( ( N
BP NNP N
) ) N
biofeedback NN N
treatment NN N
( ( N
BF NNP N
) ) N
effects NNS N
between IN N
white-coat JJ N
hypertension NN N
and CC N
essential JJ N
hypertension NN N
. . N

METHODS NNP N
Fifteen NNP N
white-coat JJ 4_p
hypertensive JJ 4_p
out-patients NNS N
and CC N
23 CD N
essential JJ 4_p
hypertensive JJ 4_p
out-patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
groups NNS N
A NNP N
or CC N
B NNP N
. . N

Subjects NNS N
in IN N
group NN N
A NNP N
underwent NN N
BF NNP N
once RB N
a DT N
week NN N
for IN N
a DT N
total NN N
of IN N
four CD N
sessions NNS N
. . N

Those DT N
in IN N
group NN N
B NNP N
visited VBD N
the DT N
clinic NN N
only RB N
to TO N
measure VB N
BP NNP N
and CC N
later RB N
underwent VBD N
the DT N
same JJ N
BF NNP N
. . N

RESULTS NNP N
In IN N
group NN N
A NNP N
, , N
BPs NNP N
of IN N
white-coat JJ N
hypertensives NNS N
and CC N
essential JJ N
hypertensives NNS N
were VBD N
significantly RB N
reduced VBN N
by IN N
22/11 CD N
and CC N
14/8 CD N
mmHg NN N
, , N
respectively RB N
. . N

In IN N
group NN N
B NNP N
, , N
they PRP N
were VBD N
unchanged JJ N
during IN N
the DT N
same JJ N
period NN N
but CC N
later RB N
suppressed VBN N
by IN N
BF NNP N
. . N

Under IN N
BF NNP N
, , N
pulse NN N
and CC N
respiratory NN N
rates NNS N
were VBD N
significantly RB N
higher JJR N
, , N
and CC N
elevation NN N
of IN N
diastolic JJ N
BP NNP N
due JJ N
to TO N
mental JJ N
stress NN N
testing NN N
was VBD N
better RBR N
suppressed VBN N
in IN N
white-coat NN N
hypertensives NNS N
than IN N
in IN N
essential JJ N
hypertensives NNS N
. . N

CONCLUSION VB N
This DT N
treatment NN N
was VBD N
effective JJ N
in IN N
both DT N
types NNS N
of IN N
hypertension NN N
, , N
and CC N
pressor NN N
response NN N
to TO N
stress VB N
seems VBZ N
to TO N
be VB N
important JJ N
in IN N
the DT N
differentiated JJ N
BF NNP N
effect NN N
. . N

-DOCSTART- -X- O O 1642441

[ JJ N
Comparison NNP N
of IN N
the DT N
efficacy/tolerability NN N
ratio NN N
of IN N
cibenzoline NN N
and CC N
propafenone NN N
in IN N
the DT N
treatment NN N
of IN N
ventricular JJ N
arrhythmia NN N
] NNP N
. . N

Cibenzoline NNP N
( ( N
C NNP N
) ) N
was VBD N
compared VBN N
with IN N
propafenone NN N
( ( N
P NNP N
) ) N
in IN N
18 CD N
adult NN N
patients NNS N
( ( N
7 CD N
women NNS N
and CC N
11 CD N
men NNS N
) ) N
aged VBD N
50 CD N
+/- JJ N
7 CD N
in IN N
double-blind NN N
, , N
placebo-controlled JJ N
crossover NN N
trial NN N
. . N

After IN N
a DT N
therapeutic JJ N
wash-out NN N
period NN N
corresponding VBG N
to TO N
5 CD N
times NNS N
the DT N
half-life NN N
of IN N
previous JJ N
anti-arrhythmic JJ N
drugs NNS N
, , N
patients NNS N
with IN N
more JJR N
than IN N
100 CD N
premature JJ N
ventricular JJ N
contractions NNS N
( ( N
PVC NNP N
) ) N
per IN N
hour NN N
in IN N
two CD N
24 CD N
hour NN N
Holter NNP N
records NNS N
obtained VBN N
at IN N
an DT N
interval NN N
of IN N
7 CD N
days NNS N
were VBD N
treated VBN N
in IN N
succession NN N
and CC N
after IN N
randomised VBN N
by IN N
C NNP N
( ( N
390 CD N
mg/day NN N
in IN N
3 CD N
divided JJ N
doses NNS N
) ) N
and CC N
P NNP N
( ( N
900 CD N
mg/day NN N
in IN N
3 CD N
divided JJ N
doses NNS N
) ) N
for IN N
a DT N
period NN N
of IN N
two CD N
weeks NNS N
, , N
each DT N
active JJ N
sequence NN N
being VBG N
followed VBN N
by IN N
a DT N
two CD N
week NN N
wash-out JJ N
period NN N
. . N

Efficacy NNP N
( ( N
based VBN N
upon IN N
the DT N
decrease NN N
in IN N
PVC/hour NNP N
in IN N
a DT N
24 CD N
hour NN N
Holter NNP N
) ) N
and CC N
tolerability NN N
were VBD N
evaluated VBN N
at IN N
the DT N
end NN N
of IN N
each DT N
sequence NN N
, , N
with IN N
samples NNS N
drawn VBN N
at IN N
the DT N
same JJ N
times NNS N
for IN N
assay NN N
of IN N
the DT N
study NN N
drugs NNS N
. . N

Three CD N
patients NNS N
dropped VBD N
out IN N
of IN N
the DT N
trial NN N
, , N
1 CD N
with IN N
each DT N
active JJ N
drug NN N
( ( N
for IN N
epigastric RB N
pain NN N
) ) N
and CC N
1 CD N
with IN N
dummy NN N
. . N

No DT N
significant JJ N
difference NN N
was VBD N
seen VBN N
between IN N
the DT N
two CD N
drugs NNS N
regarding VBG N
the DT N
decrease NN N
in IN N
the DT N
total JJ N
number NN N
of IN N
PVC/hour NNP N
in IN N
the DT N
15 CD N
patients NNS N
completing VBG N
the DT N
cross-over JJ N
protocol NN N
. . N

A DT N
reduction NN N
in IN N
PVC/hour NNP N
of IN N
more JJR N
than IN N
70 CD N
per IN N
cent NN N
was VBD N
seen VBN N
in IN N
7 CD N
patients NNS N
with IN N
C NNP N
and CC N
in IN N
9 CD N
patients NNS N
with IN N
P. NNP N
C NNP N
was VBD N
better RBR N
tolerated VBN N
than IN N
P NNP N
on IN N
the DT N
basis NN N
of IN N
both DT N
clinical JJ N
and CC N
electrocardiographic JJ N
parameters NNS N
. . N

One CD N
patient NN N
developed VBD N
troublesome JJ N
adverse JJ N
reactions NNS N
with IN N
C NNP N
as IN N
compared VBN N
with IN N
4 CD N
patients NNS N
in IN N
the DT N
case NN N
of IN N
P. NNP N
A NNP N
more JJR N
than IN N
20 CD N
per IN N
cent NN N
increase NN N
in IN N
QRS NNP N
was VBD N
seen VBN N
in IN N
7 CD N
patients NNS N
with IN N
C NNP N
and CC N
in IN N
10 CD N
patients NNS N
with IN N
P NNP N
, , N
the DT N
figures NNS N
for IN N
PR NNP N
being VBG N
2 CD N
and CC N
6 CD N
patients NNS N
respectively RB N
. . N

One CD N
patient NN N
showed VBD N
a DT N
proarrhythmic JJ N
effect NN N
with IN N
P. NNP N
Plasma NNP N
levels NNS N
of IN N
C NNP N
were VBD N
significantly RB N
higher JJR N
in IN N
responders NNS N
( ( N
328 CD N
+/- JJ N
149 CD N
ng/ml NN N
) ) N
than IN N
in IN N
non-responders NNS N
( ( N
137 CD N
+/- JJ N
41 CD N
ng/ml NN N
, , N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

No DT N
significant JJ N
difference NN N
was VBD N
found VBN N
concerning VBG N
plasma NN N
levels NNS N
of IN N
P NNP N
( ( N
578 CD N
+/- JJ N
477 CD N
ng/ml NNS N
compared VBN N
with IN N
646 CD N
+/- JJ N
457 CD N
ng/ml NN N
, , N
p NN N
greater JJR N
than IN N
0.05 CD N
) ) N
. . N

In IN N
conclusion NN N
, , N
the DT N
efficacy/tolerability NN N
ratio NN N
in IN N
this DT N
population NN N
with IN N
a DT N
low JJ N
risk NN N
of IN N
serious JJ N
rhythm JJ N
events NNS N
appeared VBD N
to TO N
be VB N
better JJR N
with IN N
C NNP N
than IN N
with IN N
P NNP N
. . N

-DOCSTART- -X- O O 8644688

Effect NN N
of IN N
n-3 JJ N
polyunsaturated JJ N
fatty JJ N
acid NNS N
intake VBP N
on IN N
phospholipid JJ N
fatty JJ N
acid JJ N
composition NN N
in IN N
plasma NN N
and CC N
erythrocytes NNS N
. . N

To TO N
characterize VB N
the DT N
time NN N
course NN N
of IN N
plasma NN N
and CC N
red JJ N
blood NN N
cell NN N
( ( N
RBC NNP N
) ) N
changes NNS N
after IN N
n-3 JJ N
polyunsaturated JJ N
fatty JJ N
acid NN N
( ( N
PUFA NNP N
) ) N
supplementation NN N
, , N
20 CD N
healthy JJ N
male NN N
volunteers NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
either DT N
four CD N
1-g JJ N
capsules NNS N
of IN N
n-3 JJ N
PUFA NNP N
ethyl NN N
esters NNS N
or CC N
four CD N
1-g JJ N
capsules NNS N
of IN N
olive JJ N
oil NN N
( ( N
as IN N
placebo NN N
) ) N
for IN N
a DT N
period NN N
of IN N
4 CD N
mo NN N
, , N
followed VBN N
by IN N
a DT N
3-mo JJ N
washout NN N
period NN N
. . N

Fatty NNP N
acids NNS N
of IN N
plasma NN N
and CC N
RBC NNP N
phospholipid JJ N
fractions NNS N
were VBD N
analyzed VBN N
at IN N
0 CD N
, , N
2 CD N
, , N
and CC N
4 CD N
mo NN N
of IN N
treatment NN N
and CC N
at IN N
1 CD N
, , N
2 CD N
, , N
and CC N
3 CD N
mo NN N
of IN N
washout NN N
. . N

During IN N
n-3 JJ N
PUFA NNP N
supplementation NN N
, , N
accumulations NNS N
of IN N
eicosapentaenoic NN N
( ( N
EPA NNP N
) ) N
, , N
docosapentaenoic FW N
( ( N
DPA NNP N
) ) N
, , N
and CC N
docosahexaenoic NN N
( ( N
DHA NNP N
) ) N
acids NNS N
were VBD N
marked VBN N
after IN N
2 CD N
mo NN N
with IN N
differences NNS N
among IN N
different JJ N
fractions NNS N
of IN N
plasma NN N
and CC N
RBCs NNP N
in IN N
further JJ N
accumulation NN N
up RB N
to TO N
4 CD N
mo NN N
. . N

During IN N
the DT N
first JJ N
and CC N
second JJ N
months NNS N
of IN N
the DT N
washout NN N
, , N
slight JJ N
differences NNS N
were VBD N
observed VBN N
in IN N
changes NNS N
of IN N
various JJ N
fatty JJ N
acids NNS N
among IN N
different JJ N
phospholipid JJ N
fractions NNS N
, , N
but CC N
after IN N
3 CD N
mo NN N
of IN N
washout NN N
, , N
only RB N
minor JJ N
alterations NNS N
were VBD N
still RB N
detectable JJ N
with IN N
respect NN N
to TO N
pretreatment VB N
values NNS N
. . N

These DT N
data NNS N
confirm VBP N
the DT N
complex JJ N
relations NNS N
among IN N
different JJ N
fatty JJ N
acid NN N
pools NNS N
after IN N
n-3 JJ N
PUFA NNP N
supplementation NN N
. . N

-DOCSTART- -X- O O 8521712

Differential JJ N
effects NNS N
on IN N
bone NN N
density NN N
of IN N
progestogen-only JJ N
methods NNS N
for IN N
contraception NN N
in IN N
premenopausal JJ 4_p
women NNS 4_p
. . 4_p

The DT N
question NN N
of IN N
differential JJ N
effects NNS N
on IN N
bone NN N
density NN N
by IN N
two CD N
different JJ N
types NNS N
of IN N
progestogen-only JJ N
methods NNS N
for IN N
contraception NN N
in IN N
premenopausal JJ N
women NNS N
was VBD N
addressed VBN N
. . N

Data NNS N
from IN N
a DT N
prospective JJ N
randomized VBN N
clinical JJ N
trial NN N
among IN N
22 CD N
premenopausal JJ N
women NNS N
, , N
age NN N
32.6 CD N
( ( N
range JJ N
20-45 CD N
years NNS N
) ) N
, , N
who WP N
were VBD N
randomly RB N
assigned VBN N
to TO N
either DT N
of IN N
two CD N
treatments NNS N
with IN N
continuous JJ N
progestogens NNS N
for IN N
contraception NN N
were VBD N
analyzed VBN N
; : N
depot-medroxyprogesterone JJ N
acetate NN N
( ( N
DMPA NNP N
) ) N
or CC N
continuous JJ N
levonorgestrel NN N
treatment NN N
with IN N
subdermal JJ N
implants NNS N
( ( N
Norplant NNP N
) ) N
, , N
respectively RB N
. . N

Forearm NNP N
bone NN N
density NN N
( ( N
BMDprox NNP N
) ) N
increased VBD N
with IN N
2.94 CD N
% NN N
( ( N
p JJ N
= NNP N
0.006 CD N
) ) N
in IN N
women NNS N
who WP N
were VBD N
prescribed VBN N
levonorgestrel NN N
, , N
which WDT N
was VBD N
in IN N
contrast NN N
to TO N
stable JJ N
values NNS N
in IN N
those DT N
prescribed JJ N
depot-medroxy-progesterone JJ N
acetate NN N
; : N
group NN N
difference NN N
at IN N
6 CD N
months NNS N
for IN N
BMDprox NNP N
3.4 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
1.3 CD N
, , N
5.5 CD N
; : N
p NN N
= VBZ N
0.025 CD N
) ) N
and CC N
BMDdist $ N
4.1 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
- : N
1.3 CD N
, , N
9.6 CD N
; : N
p NN N
= VBZ N
0.077 CD N
) ) N
. . N

The DT N
changes NNS N
in IN N
bone NN N
density NN N
were VBD N
consistent JJ N
with IN N
the DT N
changes NNS N
in IN N
biochemical JJ N
indices NNS N
for IN N
bone NN N
metabolism NN N
; : N
DMPA NNP N
users NNS N
showed VBD N
signs NNS N
of IN N
increased VBN N
bone NN N
turnover NN N
and CC N
users NNS N
of IN N
levonorgestrel NN N
showed VBD N
increased JJ N
bone NN N
formation NN N
with IN N
increased JJ N
levels NNS N
of IN N
both DT N
alkaline JJ N
phosphatase NN N
( ( N
p JJ N
= NNP N
0.004 CD N
) ) N
and CC N
osteocalcin $ N
( ( N
p JJ N
= NNP N
0.007 CD N
) ) N
. . N

The DT N
findings NNS N
suggest VBP N
an DT N
increase NN N
in IN N
bone JJ N
density NN N
during IN N
treatment NN N
with IN N
levonorgestrel NN N
and CC N
stable JJ N
values NNS N
during IN N
short-term JJ N
administration NN N
of IN N
DMPA NNP N
, , N
in IN N
standard JJ N
clinical JJ N
doses NNS N
for IN N
contraception NN N
. . N

-DOCSTART- -X- O O 4037540

Differential JJ N
inhibition NN N
of IN N
bronchoconstriction NN N
by IN N
the DT N
calcium NN N
channel NN N
blockers NNS N
, , N
verapamil NN N
and CC N
nifedipine NN N
. . N

Recent JJ N
studies NNS N
have VBP N
demonstrated VBN N
that IN N
the DT N
calcium NN N
channel NN N
blocking VBG N
agents NNS N
can MD N
inhibit VB N
experimentally RB N
induced JJ N
bronchoconstriction NN N
in IN N
asthmatics NNS 4_p
, , N
but CC N
their PRP$ N
protective JJ N
action NN N
has VBZ N
been VBN N
variable JJ N
. . N

To TO N
clarify VB N
the DT N
influence NN N
of IN N
stimulus NN N
intensity NN N
and CC N
choice NN N
of IN N
calcium NN N
blocker NN N
on IN N
these DT N
reported VBN N
differences NNS N
in IN N
outcome NN N
, , N
we PRP N
performed VBD N
noncumulative JJ N
thermal JJ N
stimulus-response JJ N
curves NNS N
using VBG N
isocapnic JJ N
hyperventilation NN N
of IN N
cold JJ N
air NN N
in IN N
8 CD N
asthmatics NNS 4_p
. . N

Subjects NNS N
received VBD N
pretreatment JJ N
with IN N
orally RB N
administered VBN N
nifedipine NN N
( ( N
20 CD N
mg NN N
) ) N
, , N
intravenously RB N
administered VBN N
verapamil NN N
( ( N
10 CD N
mg NN N
bolus NN N
followed VBN N
by IN N
a DT N
continuous JJ N
infusion NN N
) ) N
, , N
or CC N
appropriate JJ N
placebos NNS N
in IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
fashion NN N
. . N

Verapamil NNP N
afforded VBD N
no DT N
consistent JJ N
protection NN N
against IN N
the DT N
thermal JJ N
challenges NNS N
, , N
whereas NNS N
nifedipine VBP N
significantly RB N
blunted VBN N
the DT N
bronchoconstrictor NN N
response NN N
to TO N
stimuli NNS N
of IN N
low JJ N
( ( N
p NN N
less JJR N
than IN N
0.02 CD N
) ) N
and CC N
middle JJ N
( ( N
p NN N
less JJR N
than IN N
0.03 CD N
) ) N
intensity NN N
. . N

At IN N
the DT N
highest JJS N
thermal JJ N
burden NN N
, , N
the DT N
effect NN N
of IN N
nifedipine NN N
was VBD N
inconsistent JJ N
and CC N
not RB N
significantly RB N
different JJ N
from IN N
that DT N
of IN N
placebo NN N
. . N

These DT N
results NNS N
indicate VBP N
that IN N
the DT N
protection NN N
from IN N
bronchoconstriction NN N
afforded VBN N
by IN N
the DT N
calcium NN N
channel NN N
blockers NNS N
depends VBZ N
on IN N
the DT N
choice NN N
of IN N
agent NN N
and CC N
the DT N
intensity NN N
of IN N
the DT N
bronchoconstricting NN N
stimulus NN N
, , N
and CC N
they PRP N
raise VBP N
the DT N
possibility NN N
that IN N
the DT N
contribution NN N
of IN N
transmembrane NN N
calcium NN N
ion NN N
influx NN N
to TO N
the DT N
pathogenesis NN N
of IN N
bronchoconstriction NN N
may MD N
vary VB N
according VBG N
to TO N
stimulus JJ N
intensity NN N
. . N

-DOCSTART- -X- O O 11154142

Unopposed VBN N
estrogen NN N
increases NNS N
total JJ N
plasma JJ N
factor NN N
VII NNP N
, , N
but CC N
not RB N
active JJ N
factor NN N
VII NNP N
-- : N
a DT N
short-term JJ N
placebo-controlled JJ N
study NN N
in IN N
healthy JJ 4_p
postmenopausal NN 4_p
women NNS N
. . N

Estrogen NNP N
therapy NN N
may MD N
increase VB N
the DT N
risk NN N
of IN N
arterial JJ N
thromboembolism NN N
, , N
at IN N
least JJS N
in IN N
the DT N
short JJ N
term NN N
. . N

In IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
and CC N
placebo-controlled JJ N
study NN N
in IN N
25 CD N
healthy JJ 4_p
postmenopausal NN 4_p
women NNS N
( ( N
52.5 CD N
+/- JJ N
2.8 CD N
years NNS N
) ) N
, , N
we PRP N
therefore VBP N
examined VBD N
the DT N
short-term JJ N
effect NN N
of IN N
unopposed JJ N
estrogen NN N
on IN N
the DT N
fasting NN N
and CC N
fat-load-stimulated JJ N
plasma NN N
levels NNS N
of IN N
total JJ N
factor NN N
VII NNP N
versus NN N
active JJ N
factor NN N
VII NNP N
. . N

Plasma NNP N
total JJ N
factor NN N
VII NNP N
was VBD N
measured VBN N
by IN N
use NN N
of IN N
a DT N
chromogenic JJ N
assay NN N
; : N
plasma CC N
active JJ N
FVII NNP N
by IN N
a DT N
recently RB N
developed VBN N
method NN N
using VBG N
truncated JJ N
tissue NN N
factor NN N
. . N

As IN N
compared VBN N
to TO N
placebo VB N
, , N
8 CD N
weeks NNS N
of IN N
oral JJ N
17beta-estradiol JJ N
( ( N
2 CD N
mg NNS N
daily RB N
) ) N
increased VBD N
the DT N
mean NN N
fasting NN N
and CC N
postprandial JJ N
plasma NN N
levels NNS N
of IN N
total JJ N
factor NN N
VII NNP N
by IN N
17 CD N
and CC N
21 CD N
% NN N
points NNS N
, , N
respectively RB N
( ( N
both DT N
P NNP N
< NNP N
0.01 CD N
) ) N
, , N
but CC N
did VBD N
not RB N
affect VB N
the DT N
fasting NN N
and/or JJ N
postprandial JJ N
plasma NN N
levels NNS N
of IN N
active JJ N
factor NN N
VII NNP N
( ( N
mean JJ N
change NN N
both DT N
0.05 CD N
ng/mL NN N
; : N
P NNP N
> NNP N
0.35 CD N
) ) N
. . N

Furthermore UH N
, , N
the DT N
change NN N
in IN N
the DT N
fasting JJ N
level NN N
of IN N
total JJ N
factor NN N
VII NNP N
after IN N
therapy NN N
was VBD N
not RB N
associated VBN N
with IN N
the DT N
change NN N
in IN N
the DT N
fasting JJ N
level NN N
of IN N
active JJ N
factor NN N
VII NNP N
( ( N
r VB N
= RB N
0.27 CD N
; : N
P NNP N
= NNP N
0.21 CD N
) ) N
. . N

These DT N
findings NNS N
argue VBP N
against IN N
the DT N
idea NN N
that WDT N
elevated VBD N
levels NNS N
of IN N
total JJ N
factor NN N
VII NNP N
underlie VBZ N
an DT N
increased VBN N
risk NN N
of IN N
arterial JJ N
thromboembolism NN N
in IN N
postmenopausal JJ 4_p
women NNS N
using VBG N
unopposed JJ N
estrogen NN N
replacement NN N
. . N

-DOCSTART- -X- O O 7552649

Active JJ N
treatment NN N
programs NNS N
for IN N
patients NNS 4_p
with IN 4_p
chronic JJ 4_p
low JJ 4_p
back RB 4_p
pain NN 4_p
: : 4_p
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
observer-blinded JJ N
study NN N
. . N

Several JJ N
new JJ N
studies NNS N
have VBP N
indicated VBN N
that IN N
an DT N
active JJ N
approach NN N
to TO N
patients NNS 4_p
with IN 4_p
chronic JJ 4_p
disabling VBG 4_p
low JJ 4_p
back RB 4_p
pain NN 4_p
( ( 4_p
LBP NNP 4_p
) ) 4_p
seems VBZ N
effective JJ N
. . N

Some DT N
of IN N
these DT N
studies NNS N
emphasize VBP N
the DT N
importance NN N
of IN N
dealing VBG N
with IN N
the DT N
patient NN N
's POS N
total JJ N
situation NN N
in IN N
comprehensive JJ N
multidisciplinary JJ N
programs NNS N
-- : N
the DT N
bio-psycho-social JJ N
model NN N
. . N

However RB N
, , N
these DT N
programs NNS N
are VBP N
expensive JJ N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
rehabilitation NN N
outcome NN N
from IN N
three CD N
different JJ N
active JJ N
programs NNS N
in IN N
terms NNS N
of IN N
: : N
( ( N
1 CD N
) ) N
return-to-work NN N
rate NN N
, , N
( ( N
2 CD N
) ) N
days NNS N
of IN N
sick JJ N
leave NN N
, , N
( ( N
3 CD N
) ) N
health-care NN N
contacts NNS N
, , N
( ( N
4 CD N
) ) N
pain NN N
and CC N
disability NN N
scores NNS N
, , N
and CC N
( ( N
5 CD N
) ) N
staying VBG N
physically RB N
active JJ N
. . N

The DT N
subjects NNS N
included VBD N
132 CD N
patients NNS N
randomized VBN N
to TO N
the DT N
study NN N
, , N
of IN N
whom WP N
123 CD N
started VBD N
one CD N
of IN N
the DT N
treatment NN N
programs NNS N
. . N

They PRP N
had VBD N
all DT N
had VBN N
at IN N
least JJS N
6 CD N
months NNS N
of IN N
chronic JJ N
LBP NNP N
. . N

The DT N
patients NNS N
were VBD N
randomized VBN N
into IN N
one CD N
of IN N
three CD N
programs NNS N
: : N
group NN N
1 CD N
-- : N
a DT N
full-time JJ N
, , N
intensive JJ N
3-week JJ N
multidisciplinary JJ N
program NN N
, , N
including VBG N
active JJ N
physical JJ N
and CC N
ergonomic JJ N
training NN N
and CC N
psychological JJ N
pain NN N
management NN N
, , N
followed VBN N
by IN N
1 CD N
day NN N
weekly VB N
for IN N
the DT N
subsequent JJ N
3 CD N
weeks NNS N
; : N
group NN N
2 CD N
-- : N
active JJ N
physical JJ N
training NN N
, , N
twice RB N
a DT N
week NN N
for IN N
6 CD N
weeks NNS N
, , N
for IN N
a DT N
total NN N
of IN N
24h CD N
; : N
group NN N
3 CD N
-- : N
psychological JJ N
pain NN N
management NN N
combined VBN N
with IN N
active JJ N
physical JJ N
training NN N
, , N
twice RB N
a DT N
week NN N
for IN N
6 CD N
weeks NNS N
, , N
also RB N
for IN N
a DT N
total NN N
of IN N
24h CD N
. . N

The DT N
results NNS N
presented VBN N
here RB N
are VBP N
based VBN N
on IN N
data NNS N
collected VBN N
4 CD N
months NNS N
following VBG N
treatment NN N
, , N
which WDT N
shows VBZ N
an DT N
86 CD N
% NN N
response NN N
rate NN N
. . N

The DT N
initial JJ N
examination NN N
and CC N
the DT N
follow-up JJ N
evaluation NN N
were VBD N
performed VBN N
by IN N
a DT N
blinded VBN N
observer NN N
. . N

The DT N
results NNS N
show VBP N
that IN N
4 CD N
months NNS N
after IN N
treatment NN N
, , N
the DT N
intensive JJ N
multidisciplinary JJ N
program NN N
is VBZ N
superior JJ N
to TO N
the DT N
less RBR N
intensive JJ N
programs NNS N
in IN N
terms NNS N
of IN N
return-to-work NN N
rate NN N
, , N
health-care JJ N
contacts NNS N
, , N
pain NN N
and CC N
disability NN N
scores NNS N
, , N
and CC N
staying VBG N
physically RB N
active JJ N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -X- O O 21262119

Dark-phase NNP N
light JJ N
contamination NN N
disrupts NNS N
circadian JJ N
rhythms NN N
in IN N
plasma JJ N
measures NNS N
of IN N
endocrine NN 4_p
physiology NN 4_p
and CC 4_p
metabolism NN 4_p
in IN N
rats NNS N
. . N

Dark-phase NNP N
light JJ N
contamination NN N
can MD N
significantly RB N
disrupt VB N
chronobiologic JJ N
rhythms NN N
, , N
thereby RB N
potentially RB N
altering VBG N
the DT N
endocrine NN N
physiology NN N
and CC N
metabolism NN N
of IN N
experimental JJ N
animals NNS N
and CC N
influencing VBG N
the DT N
outcome NN N
of IN N
scientific JJ N
investigations NNS N
. . N

We PRP N
sought VBD N
to TO N
determine VB N
whether IN N
exposure NN N
to TO N
low-level JJ N
light JJ N
contamination NN N
during IN N
the DT N
dark JJ N
phase NN N
influenced VBD N
the DT N
normally RB N
entrained JJ N
circadian JJ N
rhythms NN N
of IN N
various JJ N
substances NNS N
in IN N
plasma NN N
. . N

Male JJ N
Sprague-Dawley JJ N
rats NNS N
( ( N
n JJ N
= $ N
6 CD N
per IN N
group NN N
) ) N
were VBD N
housed VBN N
in IN N
photobiologic JJ N
light-exposure JJ N
chambers NNS N
configured VBD N
to TO N
create VB N
1 CD N
) ) N
a DT N
12:12-h JJ N
light NN N
: : N
dark JJ N
cycle NN N
without IN N
dark-phase JJ N
light JJ N
contamination NN N
( ( N
control JJ N
condition NN N
; : N
123 CD N
μW/cm NN N
( ( N
2 CD N
) ) N
, , N
lights NNS N
on IN N
at IN N
0600 CD N
) ) N
, , N
2 CD N
) ) N
experimental NN N
exposure NN N
to TO N
a DT N
low JJ N
level NN N
of IN N
light NN N
during IN N
the DT N
12-h JJ N
dark NN N
phase NN N
( ( N
with IN N
0.02 CD N
, , N
0.05 CD N
, , N
0.06 CD N
, , N
or CC N
0.08 CD N
μW/cm NNS N
( ( N
2 CD N
) ) N
light NN N
at IN N
night NN N
) ) N
, , N
or CC N
3 CD N
) ) N
constant JJ N
bright JJ N
light NN N
( ( N
123 CD N
μW/cm NNP N
( ( N
2 CD N
) ) N
) ) N
. . N

Dietary NNP N
and CC N
water NN N
intakes NNS N
were VBD N
recorded VBN N
daily RB N
. . N

After IN N
2 CD N
wk NN N
, , N
rats VB N
underwent JJ N
6 CD N
low-volume JJ N
blood NN N
draws NNS N
at IN N
4-h JJ N
intervals NNS N
( ( N
beginning VBG N
at IN N
0400 CD N
) ) N
during IN N
both DT N
the DT N
light NN N
and CC N
dark JJ N
phases NNS N
. . N

Circadian JJ N
rhythms NN N
in IN N
dietary JJ N
and CC N
water NN N
intake NN N
and CC N
levels NNS N
of IN N
plasma NN N
total JJ N
fatty JJ N
acids NNS N
and CC N
lipid JJ N
fractions NNS N
remained VBD N
entrained JJ N
during IN N
exposure NN N
to TO N
either DT N
control NN N
conditions NNS N
or CC N
low-intensity NN N
light NN N
during IN N
the DT N
dark JJ N
phase NN N
. . N

However RB N
, , N
these DT N
patterns NNS N
were VBD N
disrupted VBN N
in IN N
rats NNS N
exposed VBN N
to TO N
constant VB N
bright JJ N
light NN N
. . N

Circadian JJ N
patterns NNS N
of IN N
plasma NN N
melatonin NN N
, , N
glucose NN N
, , N
lactic JJ N
acid NN N
, , N
and CC N
corticosterone NN N
were VBD N
maintained VBN N
in IN N
all DT N
rats NNS N
except IN N
those DT N
exposed VBN N
to TO N
constant VB N
bright JJ N
light NN N
or CC N
the DT N
highest JJS N
level NN N
of IN N
light NN N
during IN N
the DT N
dark JJ N
phase NN N
. . N

Therefore RB N
even RB N
minimal JJ N
light JJ N
contamination NN N
during IN N
the DT N
dark JJ N
phase NN N
can MD N
disrupt VB N
normal JJ N
circadian JJ N
rhythms NN N
of IN N
endocrine JJ N
metabolism NN N
and CC N
physiology NN N
and CC N
may MD N
alter VB N
the DT N
outcome NN N
of IN N
scientific JJ N
investigations NNS N
. . N

-DOCSTART- -X- O O 8752254

Continuous JJ N
and CC N
cyclical JJ N
clodronate NN N
therapies NNS N
and CC N
bone NN N
density NN N
in IN N
postmenopausal JJ 4_p
bone NN 4_p
loss NN 4_p
. . N

OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
effectiveness NN N
of IN N
different JJ N
clodronate NN N
regimens NNS N
in IN N
postmenopausal JJ 4_p
osteoporosis NN 4_p
. . N

METHODS NNP N
In IN N
groups NNS N
of IN N
20 CD N
, , N
60 CD N
women NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
three CD N
treatments NNS N
: : N
oral JJ N
calcium NN N
, , N
1000 CD N
mg/day NN N
; : N
oral JJ N
calcium NN N
plus CC N
oral JJ N
clodronate NN N
, , N
400 CD N
mg/day NN N
; : N
oral JJ N
calcium NN N
plus CC N
oral JJ N
clodronate NN N
, , N
400 CD N
mg/day NN N
for IN N
30 CD N
days NNS N
, , N
followed VBN N
by IN N
a DT N
60-day JJ N
period NN N
of IN N
calcium JJ N
supplement NN N
alone RB N
. . N

This DT N
last JJ N
regimen NN N
was VBD N
repeated VBN N
four CD N
times NNS N
in IN N
the DT N
12-month JJ N
study NN N
period NN N
. . N

RESULTS JJ N
Patients NNPS N
who WP N
received VBD 4_p
calcium NN 4_p
alone RB N
showed VBD N
a DT N
decline NN N
in IN N
spinal JJ N
bone NN N
mass NN N
, , N
both DT N
after IN N
6 CD N
and CC N
12 CD N
months NNS N
( ( N
P NNP N
< NNP N
.03 NNP N
and CC N
P NNP N
< NNP N
.005 NNP N
, , N
respectively RB N
) ) N
; : N
femoral JJ N
density NN N
in IN N
this DT N
group NN N
also RB N
decreased VBD N
after IN N
6 CD N
and CC N
12 CD N
months NNS N
( ( N
P NNP N
< NNP N
.002 NNP N
and CC N
P NNP N
< NNP N
.05 NNP N
, , N
respectively RB N
) ) N
. . N

On IN N
the DT N
other JJ N
hand NN N
, , N
both DT N
clodronate-treated JJ N
groups NNS N
had VBD N
increased VBN N
levels NNS N
of IN N
lumbar NN N
bone NN N
mass NN N
compared VBN N
with IN N
controls NNS N
, , N
both DT N
after IN N
6 CD N
and CC N
12 CD N
months NNS N
of IN N
therapy NN N
. . N

However RB N
, , N
at IN N
the DT N
end NN N
of IN N
the DT N
study NN N
, , N
patients NNS N
treated VBD N
with IN N
cyclical JJ N
clodronate NN N
had VBD N
higher JJR N
spinal JJ N
bone NN N
mass NN N
compared VBN N
with IN N
those DT N
treated VBN N
continuously RB N
( ( N
3.32 CD N
+/- JJ N
0.71 CD N
versus NN N
0.43 CD N
+/- JJ N
0.89 CD N
% NN N
, , N
P NNP N
< NNP N
.02 NNP N
) ) N
. . N

After IN N
6 CD N
months NNS N
, , N
femoral JJ N
bone NN N
density NN N
was VBD N
significantly RB N
higher JJR N
both DT N
in IN N
subjects NNS N
treated VBN N
with IN N
clodronate NN N
, , N
both DT N
cyclically RB N
and CC N
continuously RB N
( ( N
P NNP N
< NNP N
.01 NNP N
) ) N
, , N
compared VBN N
with IN N
controls NNS N
. . N

Continuous JJ N
clodronate NN N
treatment NN N
resulted VBD N
in IN N
a DT N
clear JJ N
fall NN N
in IN N
biochemical JJ N
indices NNS N
of IN N
bone NN N
resorption NN N
, , N
together RB N
with IN N
a DT N
consequent JJ N
decrease NN N
in IN N
osteocalcin NN N
at IN N
6 CD N
( ( N
P NNP N
< NNP N
.02 NNP N
) ) N
and CC N
12 CD N
months NNS N
( ( N
P NNP N
< NNP N
.003 NNP N
) ) N
and CC N
a DT N
significant JJ N
increase NN N
in IN N
parathyroid JJ N
hormone NN N
after IN N
12 CD N
months NNS N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
of IN N
therapy NN N
. . N

CONCLUSION NNP N
One-year JJ N
treatment NN N
with IN N
clodronate NN N
induces NNS N
a DT N
gain NN N
in IN N
bone NN N
mass NN N
, , N
especially RB N
in IN N
the DT N
spine NN N
. . N

The DT N
continuous JJ N
regimen NN N
does VBZ N
not RB N
result VB N
in IN N
any DT N
further JJ N
benefit NN N
in IN N
lumbar NN N
bone NN N
density NN N
over IN N
the DT N
cyclical JJ N
one CD N
, , N
probably RB N
because IN N
of IN N
a DT N
greater JJR N
suppression NN N
of IN N
bone NN N
turnover NN N
. . N

-DOCSTART- -X- O O 21946197

[ JJ N
Impact NNP N
of IN N
heparin NN N
on IN N
coagulation NN N
index NN N
during IN N
the DT N
therapy NN N
of IN N
molecular JJ N
adsorbent NN N
recirculating VBG N
system NN N
in IN N
patients NNS N
with IN N
liver JJ 4_p
failure NN 4_p
] NNP 4_p
. . N

OBJECTIVE NNP N
To TO N
investigate VB N
the DT N
impact NN N
of IN N
coagulative JJ N
parameters NNS N
on IN N
different JJ N
anticoagulation NN N
systems NNS N
in IN N
molecular JJ N
adsorbent NN N
recirculating VBG N
system NN N
( ( N
MARS NNP N
) ) N
in IN N
subjects NNS N
with IN N
liver JJ 4_p
failure NN 4_p
, , N
and CC N
to TO N
evaluate VB N
the DT N
safety NN N
of IN N
different JJ N
anticoagulation NN N
methods NNS N
. . N

METHODS NNP N
A NNP N
prospective JJ N
experimental JJ N
observation NN N
was VBD N
designed VBN N
. . N

According VBG N
to TO N
anticoagulation NN N
Methods NNP N
, , N
174 CD N
MARS NNP N
treatment NN N
sessions NNS N
for IN N
146 CD N
patients NNS N
with IN N
liver JJ N
failure NN N
and CC N
prothrombin JJ N
time NN N
activity NN N
percentage NN N
( ( N
PTA NNP N
) ) N
≤ VBD N
40 CD N
% NN N
were VBD N
randomly RB N
divided VBN N
into IN N
2 CD N
groups NNS N
: : N
92 CD N
MARS NNP N
treatment NN N
sessions NNS N
in IN N
the DT N
heparin-free JJ N
group NN N
and CC N
82 CD N
in IN N
the DT N
low-dose JJ N
heparin NN N
group NN N
. . N

Time NNP N
points NNS N
of IN N
0 CD N
, , N
0.5 CD N
, , N
1 CD N
, , N
2 CD N
, , N
3 CD N
, , N
4 CD N
, , N
5 CD N
and CC N
6 CD N
h NNS N
were VBD N
selected VBN N
to TO N
observe VB N
the DT N
coagulation NN N
changes NNS N
of IN N
prothrombin NN N
time NN N
( ( N
PT NNP N
) ) N
, , N
PTA NNP N
, , N
thrombin JJ N
time NN N
( ( N
TT NNP N
) ) N
, , N
activated VBN N
partial JJ N
thromboplastin NN N
time NN N
( ( N
APTT NNP N
) ) N
and CC N
international JJ N
normalized VBN N
ratio NN N
( ( N
INR NNP N
) ) N
dynamically RB N
. . N

Adverse JJ N
events NNS N
such JJ N
as IN N
line NN N
/ VBP N
filter NN N
coagulation NN N
, , N
rupture NN N
and CC N
bleeding NN N
were VBD N
also RB N
investigated VBN N
and CC N
compared VBN N
due JJ N
to TO N
frequency NN N
and CC N
severity NN N
between IN N
the DT N
2 CD N
groups NNS N
. . N

RESULTS NNP N
There EX N
was VBD N
no DT N
difference NN N
in IN N
PT NNP N
, , N
PTA NNP N
, , N
INR NNP N
between IN N
the DT N
2 CD N
groups NNS N
, , N
but CC N
significant JJ N
differences NNS N
were VBD N
observed VBN N
in IN N
APTT NNP N
and CC N
TT NNP N
and CC N
fibrinogen NN N
( ( N
Fbg NNP N
) ) N
. . N

APTT NNP N
and CC N
TT NNP N
levels NNS N
in IN N
the DT N
low-dose JJ N
heparin NN N
group NN N
was VBD N
increased VBN N
rapidly RB N
after IN N
the DT N
first JJ N
given VBN N
dose NN N
of IN N
anticoagulant JJ N
heparin NN N
and CC N
reached VBD N
the DT N
peak NN N
within IN N
30 CD N
min.The NN N
levels NNS N
at IN N
each DT N
time NN N
point NN N
was VBD N
statistically RB N
different JJ N
between IN N
the DT N
2 CD N
groups NNS N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

A DT N
significant JJ N
difference NN N
in IN N
the DT N
Fbg NNP N
level NN N
was VBD N
obtained VBN N
between IN N
the DT N
2 CD N
groups NNS N
. . N

In IN N
the DT N
low-dose JJ N
heparin NN N
group NN N
it PRP N
was VBD N
stabilized VBN N
and CC N
increased VBN N
slightly RB N
at IN N
the DT N
end NN N
of IN N
the DT N
treatment NN N
. . N

While IN N
in IN N
the DT N
heparin-free JJ N
group NN N
it PRP N
was VBD N
decreased VBN N
gradually RB N
and CC N
reached VBD N
a DT N
ravine NN N
at IN N
the DT N
end NN N
of IN N
the DT N
treatment NN N
. . N

A DT N
curve NN N
was VBD N
observed VBN N
after IN N
2.5 CD N
h NN N
treatment NN N
between IN N
the DT N
2 CD N
groups NNS N
( ( N
P=0.001 NNP N
) ) N
. . N

There EX N
were VBD N
2 CD N
cases NNS N
of IN N
severe JJ N
bleeding NN N
after IN N
MARS NNP N
was VBD N
finished VBN N
in IN N
the DT N
heparin NN N
group NN N
, , N
and CC N
1 CD N
was VBD N
terminated VBN N
because IN N
of IN N
degree JJ N
III NNP N
clotting NN N
in IN N
the DT N
heparin-free JJ N
group NN N
. . N

CONCLUSION NNP N
Fibrinogen NNP N
should MD N
be VB N
adsorbed VBN N
while IN N
the DT N
blood NN N
touches VBZ N
the DT N
MARS NNP N
circuit NN N
path NN N
and CC N
anticoagulants NNS N
can MD N
prevent VB N
it PRP N
. . N

Comprehensive JJ N
analysis NN N
of IN N
blood NN N
platelet NN N
count NN N
( ( N
BPC NNP N
) ) N
, , N
fibrin JJ N
degradation NN N
products NNS N
( ( N
FDP NNP N
) ) N
, , N
D-dimer NNP N
and CC N
clinical JJ N
symptoms NNS N
is VBZ N
critical JJ N
and CC N
required VBN N
to TO N
determine VB N
the DT N
coagulation NN N
status NN N
to TO N
select VB N
an DT N
anticoagulation NN N
system NN N
before IN N
MARS NNP N
. . N

The DT N
use NN N
of IN N
low JJ N
dose JJ N
heparin NN N
in IN N
MARS NNP N
improves VBZ N
the DT N
disorder NN N
of IN N
hypercoagulable JJ N
state NN N
during IN N
the DT N
high JJ N
coaguation NN N
period NN N
, , N
while IN N
heparin-free JJ N
during IN N
low JJ N
coagulation NN N
period NN N
can MD N
effectively RB N
prevent VB N
the DT N
occurrence NN N
of IN N
bleeding NN N
and CC N
improve VB N
the DT N
mechanism NN N
of IN N
blood NN N
coagulation NN N
by IN N
reducing VBG N
heparin-like JJ N
substance NN N
in IN N
the DT N
blood NN N
. . N

-DOCSTART- -X- O O 16177585

Effects NNS N
of IN N
an DT N
Internet-based JJ N
intervention NN N
on IN N
plasma NNS N
glucose JJ N
levels NNS N
in IN N
patients NNS N
with IN N
type JJ 4_p
2 CD 4_p
diabetes NNS 4_p
. . N

This DT N
study NN N
applied VBD N
a DT N
12-week JJ N
educational JJ N
intervention NN N
that WDT N
used VBD N
both DT N
the DT N
cellular JJ N
phone NN N
and CC N
the DT N
Internet NNP N
to TO N
send VB N
short JJ N
message NN N
service NN N
. . N

Forty-two NNP N
diabetic JJ 4_p
patients NNS N
were VBD N
asked VBN N
to TO N
access NN N
a DT N
Web NNP N
site NN N
by IN N
using VBG N
a DT N
cellular JJ N
phone NN N
or CC N
wire NN N
Internet NNP N
and CC N
input VB N
their PRP$ N
blood NN N
glucose NN N
levels NNS N
every DT N
day NN N
. . N

Patients NNS N
were VBD N
sent VBN N
the DT N
optimal JJ N
recommendations NNS N
by IN N
both DT N
the DT N
cellular JJ N
phone NN N
and CC N
the DT N
Internet NNP N
. . N

After IN N
12 CD N
weeks NNS N
, , N
the DT N
patients NNS N
had VBD N
a DT N
mean JJ N
decrease NN N
of IN N
28.6 CD N
mg/dL NNS N
in IN N
fasting VBG N
plasma NN N
glucose NN N
and CC N
78.4 CD N
mg/dL NN N
in IN N
2-hour JJ N
postprandial JJ N
blood NN N
sugar NN N
levels NNS N
and CC N
a DT N
mean JJ N
increase NN N
in IN N
the DT N
care NN N
satisfaction NN N
score NN N
. . N

-DOCSTART- -X- O O 18299305

Safety NN N
and CC N
tolerability NN N
of IN N
cold-adapted JJ N
influenza NN N
vaccine NN N
, , N
trivalent NN N
, , N
in IN N
infants NNS N
younger JJR N
than IN N
6 CD N
months NNS N
of IN N
age NN N
. . N

OBJECTIVE NNP N
Young NNP N
children NNS N
are VBP N
at IN N
high JJ N
risk NN N
for IN N
influenza-related JJ N
complications NNS N
. . N

Vaccination NN N
of IN N
close JJ N
household NN N
contacts NNS N
is VBZ N
recommended VBN N
to TO N
provide VB N
indirect JJ N
protection NN N
to TO N
children NNS N
< $ N
6 CD N
months NNS N
of IN N
age NN N
. . N

Studies NNS N
have VBP N
shown VBN N
that IN N
live JJ N
, , N
cold-adapted JJ N
influenza NN N
vaccine NN N
, , N
trivalent NN N
, , N
is VBZ N
efficacious JJ N
in IN N
children NNS N
. . N

To TO N
assess VB N
the DT N
risks NNS N
associated VBN N
with IN N
inadvertent JJ N
exposure NN N
of IN N
infants NNS N
to TO N
vaccine VB N
viruses NNS N
from IN N
vaccinated JJ N
contacts NNS N
, , N
this DT N
study NN N
was VBD N
designed VBN N
to TO N
evaluate VB N
the DT N
safety NN N
and CC N
tolerability NN N
of IN N
cold-adapted JJ N
influenza NN N
vaccine NN N
, , N
trivalent NN N
, , N
administered VBN N
intranasally RB N
to TO N
healthy JJ 4_p
children NNS N
6 CD N
to TO N
< VB N
24 CD N
weeks NNS N
of IN N
age NN N
. . N

METHODS NNP N
Healthy NNP 4_p
infants NNS N
aged VBD N
6 CD N
to TO N
< VB N
16 CD N
weeks NNS N
and CC N
16 CD N
to TO N
< VB N
24 CD N
weeks NNS N
, , N
respectively RB N
, , N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
2 CD N
doses NNS N
of IN N
influenza JJ N
vaccine NN N
, , N
or CC N
placebo VB N
intranasally RB N
35 CD N
+/- JJ N
7 CD N
days NNS N
apart RB N
. . N

Reactogenicity NN N
events NNS N
were VBD N
monitored VBN N
for IN N
11 CD N
days NNS N
after IN N
each DT N
dose NN N
. . N

Other JJ N
adverse JJ N
events NNS N
were VBD N
monitored VBN N
through IN N
28 CD N
to TO N
35 CD N
days NNS N
after IN N
dose JJ N
2 CD N
. . N

RESULTS NN N
Of IN N
the DT N
infants NNS N
aged VBD N
6 CD N
to TO N
< VB N
16 CD N
weeks NNS N
, , N
31 CD N
received VBD N
influenza JJ N
vaccine NN N
and CC N
28 CD N
received VBD N
placebo NN N
, , N
and CC N
of IN N
those DT N
aged VBN N
16 CD N
to TO N
< VB N
24 CD N
weeks NNS N
, , N
30 CD N
received VBD N
influenza JJ N
vaccine NN N
and CC N
31 CD N
received VBD N
placebo NN N
. . N

In IN N
the DT N
6- JJ N
to TO N
< VB N
16-week JJ N
cohort NN N
, , N
more JJR N
influenza JJ N
vaccine NN N
, , N
recipients NNS N
experienced VBD N
irritability NN N
( ( N
66.7 CD N
% NN N
vs JJ N
35.7 CD N
% NN N
) ) N
and CC N
runny JJ N
nose NN N
or CC N
nasal JJ N
congestion NN N
( ( N
63.3 CD N
% NN N
vs JJ N
33.3 CD N
% NN N
) ) N
after IN N
dose JJ N
1 CD N
but CC N
not RB N
dose JJ N
2 CD N
. . N

There EX N
were VBD N
no DT N
significant JJ N
increases NNS N
in IN N
any DT N
other JJ N
reactogenicity NN N
events NNS N
or CC N
adverse JJ N
events NNS N
in IN N
the DT N
vaccine NN N
recipients NNS N
compared VBN N
with IN N
the DT N
placebo NN N
group NN N
. . N

CONCLUSIONS NNP N
Although IN N
there EX N
was VBD N
an DT N
increase NN N
in IN N
mild JJ N
reactogenicity NN N
events NNS N
in IN N
children NNS N
6 CD N
to TO N
< VB N
16 CD N
weeks NNS N
of IN N
age NN N
, , N
cold-adapted JJ N
influenza NN N
vaccine NN N
, , N
trivalent NN N
, , N
was VBD N
generally RB N
well RB N
tolerated VBN N
in IN N
infants NNS N
6 CD N
to TO N
< VB N
24 CD N
weeks NNS N
of IN N
age NN N
. . N

These DT N
findings NNS N
support NN N
further JJ N
evaluation NN N
of IN N
cold-adapted JJ N
influenza NN N
vaccine NN N
, , N
trivalent NN N
, , N
in IN N
infants NNS N
< VBP N
6 CD N
months NNS N
of IN N
age NN N
. . N

-DOCSTART- -X- O O 15319704

Ropinirole NNP N
as IN N
a DT N
treatment NN N
of IN N
restless JJ 4_p
legs JJ 4_p
syndrome NN 4_p
in IN 4_p
patients NNS 4_p
on IN 4_p
chronic JJ 4_p
hemodialysis NN 4_p
: : 4_p
an DT N
open JJ N
randomized VBN N
crossover NN N
trial NN N
versus NN N
levodopa NN N
sustained VBD N
release NN N
. . N

OBJECTIVE NNP N
Restless NNP N
legs VBZ N
syndrome NN N
( ( N
RLS NNP N
) ) N
is VBZ N
a DT N
common JJ N
neurologic JJ N
condition NN N
characterized VBN N
by IN N
uncomfortable JJ N
and CC N
unpleasant JJ N
sensations NNS N
in IN N
the DT N
legs NN N
, , N
occurring VBG N
primarily RB N
at IN N
rest NN N
, , N
which WDT N
are VBP N
usually RB N
worse JJR N
in IN N
the DT N
evening NN N
and CC N
are VBP N
alleviated VBN N
by IN N
movement NN N
. . N

RLS NNP N
is VBZ N
present JJ N
in IN N
20-40 JJ N
% NN N
of IN N
patients NNS N
with IN N
renal JJ 4_p
failure NN 4_p
. . N

This DT N
study NN N
was VBD N
a DT N
14-week JJ N
open JJ N
, , N
randomized VBN N
, , N
crossover JJ N
trial NN N
of IN N
ropinirole NN N
vs. FW N
levodopa NN N
sustained VBN N
release NN N
( ( N
SR NNP N
) ) N
in IN N
11 CD N
patients NNS N
with IN N
RLS NNP N
on IN N
chronic JJ N
hemodialysis NN N
. . N

METHODS NNP N
Eleven NNP N
patients NNS N
( ( N
7 CD N
men NNS N
, , N
4 CD N
women NNS N
) ) N
were VBD N
enrolled VBN N
in IN N
the DT N
study NN N
. . N

They PRP N
received VBD N
either CC N
levodopa JJ N
SR NNP N
or CC N
ropinirole VB N
for IN N
6 CD N
weeks NNS N
, , N
followed VBN N
by IN N
a DT N
washout NN N
week NN N
, , N
then RB N
the DT N
alternate NN N
treatment NN N
for IN N
6 CD N
weeks NNS N
. . N

Patients NNS N
rated VBD N
the DT N
severity NN N
of IN N
RLS NNP N
by IN N
means NNS N
of IN N
a DT N
6-item JJ N
questionnaire NN N
developed VBN N
by IN N
the DT N
International NNP N
Restless NNP N
Legs NNP N
Study NNP N
Group NNP N
( ( N
6-item JJ N
IRLS NNP N
) ) N
, , N
by IN N
the DT N
Clinical NNP N
Global NNP N
Impression NNP N
( ( N
CGI NNP N
) ) N
scale NN N
, , N
and CC N
by IN N
sleep JJ N
diaries NNS N
. . N

RESULTS NNP N
Under IN N
treatment NN N
with IN N
levodopa JJ N
SR NNP N
, , N
1 CD N
patient NN N
presented VBN N
severe JJ N
vomiting NN N
, , N
leading VBG N
to TO N
study VB N
discontinuation NN N
. . N

The DT N
10 CD N
patients NNS N
who WP 4_p
completed VBD 4_p
the DT 4_p
study NN 4_p
reported VBD N
a DT N
33.5 CD N
% NN N
improvement NN N
( ( N
from IN N
16.7 CD N
+/- JJ N
3.2 CD N
to TO N
11.1 CD N
+/- JJ N
4 CD N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
of IN N
the DT N
6-item JJ N
IRLS NNP N
scores NNS N
during IN N
levodopa JJ N
SR NNP N
treatment NN N
and CC N
a DT N
73.5 CD N
% NN N
improvement NN N
( ( N
from IN N
16.6 CD N
+/- JJ N
2.8 CD N
to TO N
4.4 CD N
+/- JJ N
3.8 CD N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
during IN N
ropinirole JJ N
treatment NN N
. . N

By IN N
the DT N
end NN N
of IN N
the DT N
study NN N
the DT N
mean JJ N
levodopa NN N
SR NNP N
dosage NN N
was VBD N
190 CD N
mg/d NN N
and CC N
the DT N
mean JJ N
ropinirole NN N
dosage NN N
was VBD N
1.45 CD N
mg/d NN N
. . N

Ropinirole NNP N
was VBD N
superior JJ N
to TO N
levodopa VB N
SR NNP N
in IN N
reducing VBG N
6-item JJ N
IRLS NNP N
scores NNS N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
in IN N
increasing VBG N
sleep JJ N
time NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

The DT N
patient NN N
CGI NNP N
scale NN N
showed VBD N
a DT N
significant JJ N
difference NN N
favoring VBG N
ropinirole NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

There EX N
was VBD N
no DT N
significant JJ N
carryover NN N
or CC N
period NN N
effect NN N
for IN N
any DT N
outcome JJ N
measure NN N
. . N

Four CD N
patients NNS N
reported VBD N
a DT N
complete JJ N
reversion NN N
of IN N
RLS NNP N
symptoms NNS N
during IN N
ropinirole JJ N
treatment NN N
at IN N
doses NNS N
ranging VBG N
from IN N
0.25-2 JJ N
mg/d NN N
. . N

CONCLUSIONS NNP N
These DT N
results NNS N
suggest VBP N
that IN N
ropinirole NN N
is VBZ N
more RBR N
effective JJ N
than IN N
levodopa JJS N
SR NNP N
in IN N
the DT N
treatment NN N
of IN N
RLS NNP N
in IN N
patients NNS N
on IN N
chronic JJ N
hemodialysis NN N
. . N

-DOCSTART- -X- O O 15088136

Bisphosphonate JJ N
infusions NNS N
: : N
patient NN N
preference NN N
, , N
safety NN N
and CC N
clinic JJ N
use NN N
. . N

GOALS NNP N
OF NNP N
WORK NNP N
We PRP N
set VBD N
out RP N
to TO N
assess VB N
the DT N
preference NN N
of IN N
patients NNS N
with IN N
common JJ N
cancers NNS 4_p
involving VBG N
bone NN N
receiving VBG N
intravenous JJ N
bisphosphonate NN N
therapy NN N
for IN N
either DT N
pamidronate NN N
( ( N
P NNP N
) ) N
or CC N
zoledronic JJ N
acid NN N
( ( N
Z NNP N
) ) N
and CC N
their PRP$ N
preference NN N
for IN N
the DT N
location NN N
of IN N
the DT N
infusion NN N
( ( N
clinic JJ N
or CC N
home NN N
) ) N
. . N

We PRP N
also RB N
aimed VBD N
to TO N
monitor VB N
these DT N
patients NNS N
' POS N
renal JJ N
safety NN N
, , N
and CC N
to TO N
compare VB N
their PRP$ N
time NN N
in IN N
clinic NN N
to TO N
receive VB N
P NNP N
and CC N
Z NNP N
infusions NNS N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
Enrolled NNP N
in IN N
the DT N
study NN N
were VBD N
184 CD N
patients NNS N
, , N
and CC N
all DT N
received VBD N
initial JJ N
infusions NNS N
of IN N
Z NNP N
( ( N
so RB N
any DT N
first JJ N
infusion NN N
reactions NNS N
did VBD N
not RB N
confound VB N
preferences NNS N
for IN N
P NNP N
) ) N
. . N

For IN N
their PRP$ N
second JJ N
and CC N
third JJ N
infusions NNS N
, , N
patients NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
Z NNP N
then RB N
P NNP N
or CC N
P NNP N
then RB N
Z NNP N
, , N
and CC N
questioned VBD N
on IN N
their PRP$ N
preferences NNS N
. . N

For IN N
up IN N
to TO N
1 CD N
year NN N
they PRP N
continued VBD N
on IN N
Z NNP N
infusions NNS N
every DT N
3-4 JJ N
weeks NNS N
, , N
while IN N
their PRP$ N
renal JJ N
safety NN N
was VBD N
monitored VBN N
. . N

Where NNP N
practical JJ N
, , N
later JJ N
infusions NNS N
were VBD N
given VBN N
at IN N
home NN N
( ( N
rather RB N
than IN N
in IN N
the DT N
clinic NN N
) ) N
and CC N
patients NNS N
questioned VBN N
on IN N
their PRP$ N
preferred JJ N
infusion NN N
location NN N
. . N

In IN N
a DT N
convenience NN N
subset NN N
of IN N
43 CD N
patients NNS N
, , N
clinic JJ N
use NN N
for IN N
Z NNP N
and CC N
P NNP N
infusions NNS N
was VBD N
also RB N
measured VBN N
by IN N
timing VBG N
infusions NNS N
and CC N
other JJ N
procedures NNS N
. . N

MAIN NNP N
RESULTS NNP N
Of IN N
144 CD N
patients NNS N
who WP N
received VBD N
a DT N
third JJ N
infusion NN N
, , N
138 CD N
responded VBD N
to TO N
questions NNS N
on IN N
bisphosphonate NN N
preference NN N
, , N
and CC N
of IN N
these DT N
138 CD N
, , N
92 CD N
% NN N
( ( N
127 CD N
) ) N
preferred VBD N
Z NNP N
to TO N
P VB N
, , N
because IN N
shorter JJR N
infusions NNS N
caused VBD N
less JJR N
disruption NN N
to TO N
their PRP$ N
day NN N
. . N

Only RB N
12 CD N
% NN N
of IN N
eligible JJ N
patients NNS N
( ( N
16/138 CD N
) ) N
received VBD N
home NN N
infusions NNS N
, , N
but CC N
13/14 CD N
questioned VBD N
preferred VBN N
this DT N
location NN N
. . N

Among IN N
184 CD N
patients NNS N
, , N
19 CD N
episodes NNS N
of IN N
renal JJ N
impairment NN N
were VBD N
noted VBN N
, , N
mostly RB N
owing VBG N
to TO N
disease VB N
progression NN N
( ( N
e.g JJ N
. . N

obstructive JJ N
uropathy JJ N
) ) N
, , N
with IN N
none NN N
linked VBN N
to TO N
Z NNP N
therapy NN N
. . N

The DT N
mean JJ N
clinic JJ N
time NN N
taken VBN N
to TO N
receive VB N
Z NNP N
and CC N
any DT N
concomitant JJ N
therapy NN N
was VBD N
about IN N
half PDT N
that DT N
for IN N
P NNP N
( ( N
78 CD N
vs RB N
161 CD N
min NN N
) ) N
. . N

CONCLUSIONS NNP N
Cancer NNP 4_p
patients NNS N
prefer VBP N
shorter JJR N
bisphosphonate JJ N
infusions-and NN N
at IN N
home NN N
, , N
where WRB N
practical JJ N
. . N

Regular JJ N
Z NNP N
4 CD N
mg NN N
infusions NNS N
appear VBP N
to TO N
be VB N
safe JJ N
in IN N
these DT N
patients NNS N
, , N
with IN N
routine JJ N
monitoring NN N
of IN N
serum JJ N
creatinine NN N
. . N

Using VBG N
Z NNP N
rather RB N
than IN N
P NNP N
could MD N
save VB N
busy JJ N
cancer NN N
centres NNS N
time NN N
and CC N
improve VB N
patient JJ N
satisfaction NN N
. . N

-DOCSTART- -X- O O 8882257

Injection NN N
pain NN N
with IN N
propofol NN N
. . N

Reduction NN N
with IN N
aspiration NN N
of IN N
blood NN N
. . N

A DT N
randomised JJ N
, , N
controlled VBN N
, , N
single-blind NN N
study NN N
was VBD N
performed VBN N
on IN N
100 CD N
patients NNS N
to TO N
investigate VB N
a DT N
new JJ N
method NN N
of IN N
reducing VBG N
pain NN N
on IN N
propofol NN N
injection NN N
. . N

Aspiration NNP N
of IN N
2 CD N
ml NN N
of IN N
the DT N
patient NN N
's POS N
blood NN N
into IN N
a DT N
syringe NN N
of IN N
propofol NN N
immediately RB N
before IN N
injection NN N
was VBD N
compared VBN N
with IN N
the DT N
addition NN N
of IN N
lignocaine NN N
20 CD N
mg NN N
or CC N
normal JJ N
saline JJ N
2 CD N
ml NN N
to TO N
the DT N
propofol NN N
before IN N
injection NN N
. . N

The DT N
addition NN N
of IN N
blood NN N
was VBD N
significantly RB N
more RBR N
effective JJ N
in IN N
reducing VBG N
pain NN N
on IN N
injection NN N
than IN N
the DT N
addition NN N
of IN N
saline NN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
, , N
but CC N
was VBD N
not RB N
significantly RB N
more RBR N
effective JJ N
than IN N
the DT N
addition NN N
of IN N
lignocaine NN N
. . N

-DOCSTART- -X- O O 12120773

A DT N
scanning NN N
electron NN N
microscopic NN N
study NN N
of IN N
different JJ N
caries NNS 4_p
removal VBP 4_p
techniques NNS 4_p
on IN 4_p
human JJ 4_p
dentin NN 4_p
. . 4_p

Scanning VBG N
electron NN N
microscopy NN N
( ( N
SEM NNP N
) ) N
evaluated VBD N
the DT N
effect NN N
of IN N
different JJ N
caries NNS N
removal VBP N
techniques NNS N
on IN N
human JJ N
dentin NN N
topography NN N
. . N

Thirty-six NNP N
extracted VBD N
human JJ N
carious JJ N
mandibular NN N
molars NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
six CD N
groups NNS N
according VBG N
to TO N
caries NNS N
removal NN N
technique NN N
. . N

Carious JJ N
tissue NN N
was VBD N
removed VBN N
by IN N
hand NN N
excavation NN N
, , N
bur JJ N
excavation NN N
, , N
air-abrasion NN N
, , N
laser JJR N
ablation NN N
, , N
chemomechanical JJ N
methods NNS N
and CC N
sono-abrasion NN N
. . N

The DT N
remaining VBG N
dentin NN N
surfaces NNS N
were VBD N
replicated VBN N
and CC N
gold-coated JJ N
. . N

The DT N
surfaces NNS N
were VBD N
examined VBN N
using VBG N
SEM NNP N
and CC N
distinct JJ N
differences NNS N
in IN N
appearance NN N
were VBD N
observed VBN N
among IN N
specimens NNS N
treated VBN N
with IN N
different JJ N
caries NNS N
removal NN N
techniques NNS N
. . N

While IN N
hand-excavated JJ N
, , N
bur-excavated JJ N
and CC N
air-abraded JJ N
carious JJ N
dentin NN N
surfaces NNS N
were VBD N
covered VBN N
with IN N
a DT N
residual JJ N
smear NN N
layer NN N
, , N
sono-abrasion NN N
with IN N
patent JJ N
dentinal JJ N
tubules NNS N
completely RB N
removed VBD N
the DT N
smear JJ N
layer NN N
. . N

A DT N
few JJ N
patent NN N
orifices NNS N
of IN N
dentinal JJ N
tubules NNS N
were VBD N
observed VBN N
in IN N
dentin NN N
subjected VBN N
to TO N
laser VB N
ablation NN N
and CC N
chemo-mechanical JJ N
caries NNS N
removal NN N
. . N

-DOCSTART- -X- O O 23532629

Erythropoietin NNP N
treatment NN N
in IN N
chemotherapy-induced JJ N
anemia NN N
in IN N
previously RB N
untreated VBN N
advanced JJ 4_p
esophagogastric JJ 4_p
cancer NN 4_p
patients NNS 4_p
. . N

BACKGROUND NNP N
The DT N
impact NN N
of IN N
erythropoiesis-stimulating JJ N
agents NNS N
in IN N
chemotherapy-induced JJ N
anemia NN N
has VBZ N
been VBN N
a DT N
constant JJ N
topic NN N
of IN N
debate NN N
over IN N
recent JJ N
years NNS N
. . N

We PRP N
prospectively RB N
assessed VBD N
the DT N
efficacy NN N
of IN N
epoetin NN N
beta NN N
( ( N
Epo-b NNP N
) ) N
in IN N
improving VBG N
hemoglobin NN N
( ( N
Hb NNP N
) ) N
levels NNS N
and CC N
outcome NN N
in IN N
patients NNS N
within IN N
an DT N
open JJ N
label NN N
, , N
randomized VBD N
clinical JJ N
phase NN N
II NNP N
trial NN N
with IN N
advanced JJ 4_p
or CC 4_p
metastatic JJ 4_p
gastric/esophagogastric JJ 4_p
cancer NN 4_p
. . N

METHODS NNP N
Previously RB 4_p
untreated VBD 4_p
patients NNS 4_p
were VBD 4_p
randomized VBN 4_p
to TO N
receive VB N
3-weekly JJ N
cycles NNS N
of IN N
capecitabine NN N
( ( N
1000 CD N
mg/m NN N
( ( N
2 CD N
) ) N
bid NN N
) ) N
for IN N
14 CD N
days NNS N
plus CC N
on IN N
day NN N
1 CD N
either CC N
irinotecan JJ N
250 CD N
mg/m NN N
( ( N
2 CD N
) ) N
or CC N
cisplatin $ N
80 CD N
mg/m NN N
( ( N
2 CD N
) ) N
. . N

Epo-b NNP N
( ( N
30000 CD N
IU NNP N
once RB N
weekly RB N
) ) N
was VBD N
initiated VBN N
in IN N
patients NNS N
with IN N
Hb NNP N
< NNP N
11 CD N
g/dl NN N
and CC N
continued VBD N
until IN N
Hb NNP N
≥12 NNP N
g/dl NN N
was VBD N
reached VBN N
. . N

If IN N
after IN N
4 CD N
weeks NNS N
the DT N
Hb NNP N
increase NN N
was VBD N
< JJ N
0.5 CD N
g/dl NN N
, , N
Epo-b NNP N
was VBD N
increased VBN N
to TO N
30000 CD N
IU NNP N
, , N
twice RB N
weekly RB N
. . N

RESULTS NNP N
Of IN N
118 CD N
patients NNS N
enrolled VBD N
, , N
32 CD N
received VBD N
Epo-b NNP N
treatment NN N
; : N
of IN N
these DT N
, , N
65 CD N
% NN N
achieved VBD N
an DT N
increase NN N
in IN N
Hb NNP N
levels NNS N
of IN N
at IN N
least JJS N
2 CD N
g/dl NN N
, , N
with IN N
74 CD N
% NN N
achieving VBG N
the DT N
target NN N
Hb NNP N
of IN N
≥12 NNP N
g/dl NN N
. . N

Within IN N
the DT N
study NN N
population NN N
, , N
patients NNS N
receiving VBG N
Epo-b NNP N
showed VBD N
better JJR N
overall JJ N
survival NN N
( ( N
median JJ N
14.5 CD N
vs. FW N
8.0 CD N
months NNS N
, , N
P NNP N
= NNP N
0.056 CD N
) ) N
as RB N
well RB N
as IN N
a DT N
significantly RB N
improved VBN N
disease NN N
control NN N
rate NN N
( ( N
78 CD N
vs. FW N
55 CD N
% NN N
, , N
P NNP N
= NNP N
0.025 CD N
) ) N
. . N

Patients NNS N
in IN N
the DT N
irinotecan JJ N
group NN N
profited VBD N
significantly RB N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
in IN N
terms NNS N
of IN N
progression-free JJ N
survival NN N
and CC N
overall JJ N
survival NN N
under IN N
Epo-b NNP N
treatment NN N
( ( N
median JJ N
6.5 CD N
vs JJ N
4.1 CD N
months NNS N
and CC N
median JJ N
15.4 CD N
vs JJ N
8.4 CD N
months NNS N
, , N
respectively RB N
) ) N
. . N

CONCLUSIONS NNP N
Epo-b NNP N
was VBD N
effective JJ N
in IN N
raising VBG N
Hb NNP N
levels NNS N
in IN N
patients NNS N
with IN N
advanced JJ N
esophagogastric JJ N
cancer NN N
. . N

Patients NNS N
receiving VBG N
Epo-b NNP N
had VBD N
a DT N
significantly RB N
increased VBN N
response NN N
to TO N
chemotherapy VB N
and CC N
a DT N
clear JJ N
trend NN N
to TO N
improved VBN N
survival NN N
. . N

-DOCSTART- -X- O O 22964266

Mindfulness-based JJ N
therapy NN N
in IN N
adults NNS N
with IN 4_p
an DT 4_p
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
: : 4_p
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

Research NN N
shows VBZ N
that IN N
depression NN N
and CC N
anxiety NN N
disorders NNS N
are VBP N
the DT N
most RBS N
common JJ N
psychiatric JJ N
concern NN N
in IN N
autism NN N
spectrum NN N
disorders NNS N
( ( N
ASD NNP N
) ) N
. . N

Mindfulness-based JJ N
therapy NN N
( ( N
MBT NNP N
) ) N
has VBZ N
been VBN N
found VBN N
effective JJ N
in IN N
reducing VBG N
anxiety NN N
and CC N
depression NN N
symptoms NNS N
, , N
however RB N
research NN N
in IN N
autism NN N
is VBZ N
limited VBN N
. . N

Therefore RB N
, , N
we PRP N
examined VBD N
the DT N
effects NNS N
of IN N
a DT N
modified JJ N
MBT NNP N
protocol NN N
( ( N
MBT-AS NNP N
) ) N
in IN N
high-functioning NN 4_p
adults NNS N
with IN N
ASD NNP 4_p
. . N

42 CD N
participants NNS N
were VBD N
randomized VBN N
into IN N
a DT N
9-week JJ N
MBT-AS JJ N
training NN N
or CC N
a DT N
wait-list JJ N
control NN N
group NN N
. . N

Results NNP N
showed VBD N
a DT N
significant JJ N
reduction NN N
in IN N
depression NN N
, , N
anxiety NN N
and CC N
rumination NN N
in IN N
the DT N
intervention NN N
group NN N
, , N
as IN N
opposed VBN N
to TO N
the DT N
control NN N
group NN N
. . N

Furthermore RB N
, , N
positive JJ N
affect NN N
increased VBN N
in IN N
the DT N
intervention NN N
group NN N
, , N
but CC N
not RB N
in IN N
the DT N
control NN N
group NN N
. . N

Concluding NNP N
, , N
the DT N
present JJ N
study NN N
is VBZ N
the DT N
first JJ N
controlled VBN N
trial NN N
to TO N
demonstrate VB N
that IN N
adults NNS N
with IN N
ASD NNP N
can MD N
benefit VB N
from IN N
MBT-AS NNP N
. . N

-DOCSTART- -X- O O 5410150

The DT N
need NN N
for IN N
chemotherapy NN N
after IN N
prolonged JJ N
complete JJ N
remission NN N
in IN N
acute JJ 4_p
leukemia NN 4_p
of IN N
childhood NN N
. . N

-DOCSTART- -X- O O 484261

A DT N
controlled VBN N
study NN N
of IN N
early JJ N
discharge NN N
after IN N
uncomplicated JJ N
myocardial JJ 4_p
infarction NN 4_p
. . N

Out IN N
of IN N
383 CD N
myocardial JJ 4_p
infarction NN 4_p
( ( 4_p
MI NNP 4_p
) ) 4_p
patients NNS N
aged VBN N
below IN N
70 CD N
years NNS N
, , N
252 CD N
( ( N
66 CD N
% NN N
) ) N
were VBD N
judged VBN N
after IN N
the DT N
third JJ N
day NN N
in IN N
hospital NN N
to TO N
have VB N
had VBN N
uncomplicated VBN 4_p
infarctions NNS 4_p
. . 4_p

These DT N
patients NNS N
were VBD N
allocated VBN N
at IN N
random NN N
to TO N
two CD N
groups NNS N
, , N
one CD N
of IN N
which WDT N
was VBD N
given VBN N
treatment NN N
for IN N
8 CD N
days NNS N
and CC N
the DT N
other JJ N
for IN N
15 CD N
days NNS N
. . N

No DT N
significant JJ N
differences NNS N
in IN N
mortality NN N
, , N
morbidity NN N
or CC N
incapacity NN N
for IN N
work NN N
could MD N
be VB N
detected VBN N
during IN N
the DT N
three-month JJ N
period NN N
of IN N
follow-up NN N
. . N

The DT N
findings NNS N
thus RB N
support VBP N
previous JJ N
conclusions NNS N
that WDT N
early RB N
discharge VBP N
from IN N
hospital NN N
after IN N
uncomplicated JJ N
MI NNP N
is VBZ N
not RB N
associated VBN N
with IN N
greater JJR N
risk NN N
for IN N
the DT N
patient NN N
than IN N
later RB N
discharge NN N
. . N

-DOCSTART- -X- O O 15181401

[ JJ N
Cardiac NNP N
protection NN N
is VBZ N
a DT N
clinical JJ N
evidence NN N
] NN N
. . N

AIM NNP N
Anaesthetics NNPS N
may MD N
have VB N
protective JJ N
effect NN N
against IN N
myocardial JJ N
ischemia NN N
. . N

We PRP N
aimed VBD N
to TO N
investigate VB N
if IN N
sevoflurane JJ N
administration NN N
could MD N
exert VB N
myocardial JJ N
protection NN N
during IN N
following VBG N
coronary JJ N
occlusion NN N
in IN N
patients NNS N
with IN N
coronary JJ 4_p
artery NN 4_p
disease NN 4_p
. . N

METHODS NNP N
a DT N
) ) N
. . N

EXPERIMENTAL NNP N
DESIGN NNP N
prospective JJ N
, , N
randomized VBN N
study NN N
. . N

b NN N
) ) N
. . N

SETTING NN N
University NNP N
Hospital NNP N
, , N
cardiac JJ N
surgical JJ N
operative NN N
theatre NN N
. . N

c NN N
) ) N
. . N

PATIENTS $ N
42 CD N
patients NNS N
with IN N
coronary JJ N
artery NN N
disease NN N
, , N
scheduled VBN N
to TO N
undergo VB N
coronary JJ N
surgery NN N
. . N

INCLUSION NNP N
CRITERIA NNP N
severe JJ 4_p
coronary JJ 4_p
stenosis NN 4_p
of IN 4_p
anterior JJ 4_p
descending VBG 4_p
coronary JJ 4_p
artery NN 4_p
; : N
no DT 4_p
collateral NN 4_p
flow NN 4_p
on IN 4_p
angiography NN 4_p
; : N
at IN 4_p
least JJS 4_p
two CD 4_p
normokinetic JJ 4_p
segments NNS 4_p
in IN 4_p
the DT 4_p
myocardial JJ 4_p
region NN 4_p
supplied VBN 4_p
by IN 4_p
the DT 4_p
vessel NN 4_p
being VBG 4_p
bypassed VBN 4_p
. . N

PATIENTS NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
( ( N
group NN N
S NNP N
) ) N
or CC N
not RB N
( ( N
group NN N
C NNP N
) ) N
sevoflurane NN N
administration NN N
for IN N
15 CD N
min NN N
just RB N
before RB N
coronary JJ N
occlusion NN N
. . N

d NN N
) ) N
. . N

INTERVENTIONS NNP N
Transoesophageal NNP N
Tissue NNP N
Doppler NNP N
echocardiographic JJ N
examination NN N
of IN N
myocardial JJ N
systolic NN N
and CC N
early JJ N
diastolic NN N
velocities NNS N
in IN N
both DT N
groups NNS N
basally RB N
and CC N
60 CD N
s NN N
after IN N
coronary JJ N
occlusion NN N
by IN N
the DT N
surgeon NN N
. . N

e NN N
) ) N
. . N

MEASURES NNP N
systolic JJ N
and CC N
early JJ N
diastolic JJ N
velocities NNS N
were VBD N
registered VBN N
by IN N
Tissue NNP N
Doppler NNP N
from IN N
a DT N
long-axis JJ N
view NN N
of IN N
the DT N
interventricular JJ N
septum NN N
or CC N
the DT N
anterior JJ N
wall NN N
of IN N
the DT N
left JJ N
ventricle NN N
. . N

RESULTS NNP N
In IN N
group NN N
C NNP N
a DT N
significant JJ N
reduction NN N
of IN N
systolic JJ N
and CC N
diastolic JJ N
intramyocardial JJ N
velocities NNS N
was VBD N
found VBN N
during IN N
myocardial JJ N
ischemia NN N
due JJ N
to TO N
coronary JJ N
occlusion NN N
. . N

CONCLUSION NNP N
Treatment NNP N
with IN N
sevoflurane NN N
before IN N
coronary JJ N
occlusion NN N
seem VBP N
effective JJ N
in IN N
reducing VBG N
functional JJ N
myocardial JJ N
impairment NN N
due JJ N
to TO N
ischemia VB N
. . N

-DOCSTART- -X- O O 16124442

Efficacy NN N
and CC N
safety NN N
of IN N
zidovudine NN N
and CC N
zalcitabine NN N
combined VBN N
with IN N
a DT N
combination NN N
of IN N
herbs NN N
in IN N
the DT N
treatment NN N
of IN N
HIV-infected NNP 4_p
Thai NNP 4_p
patients NNS 4_p
. . N

A DT N
randomized JJ N
double JJ N
blind NN N
placebo NN N
controlled VBD N
trial NN N
to TO N
determine VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
combined-herbs JJ N
( ( N
SH NNP N
) ) N
given VBN N
with IN N
zidovudine NN N
( ( N
ZDV NNP N
) ) N
and CC N
zalcitabine NN N
( ( N
ddC NN N
) ) N
for IN N
the DT N
treatment NN N
of IN N
HIV NNP 4_p
infection NN N
in IN N
Thai NNP N
adults NNS N
was VBD N
conducted VBN N
in IN N
3 CD N
hospitals NNS N
in IN N
northern JJ N
Thailand NNP N
during IN N
2002 CD N
to TO N
2003 CD N
. . N

The DT N
eligible JJ N
subjects NNS N
were VBD N
HIV-infected JJ 4_p
Thai NNP N
adults NNS N
who WP N
had VBD N
never RB N
received VBN N
anti-retrovirals NNS N
, , N
had VBD N
a DT N
Karnofski NNP N
Performance NNP N
Score NNP N
( ( N
KPS NNP N
) ) N
of IN N
> NN N
or CC N
= $ N
70 CD N
, , N
and CC N
had VBD N
no DT N
opportunistic JJ N
infections NNS 4_p
. . N

The DT N
subjects NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
either CC N
a DT N
combination NN N
of IN N
ZDV NNP N
200 CD N
mg NN N
three CD N
times NNS N
per IN N
day NN N
, , N
ddC VB N
0.75 CD N
mg NN N
three CD N
times NNS N
per IN N
day NN N
, , N
and CC N
SH NNP N
2.5 CD N
g NN N
three CD N
times NNS N
per IN N
day NN N
or CC N
a DT N
combination NN N
of IN N
ZDV NNP N
200 CD N
mg NN N
three CD N
times NNS N
per IN N
day NN N
, , N
ddC VB N
0.75 CD N
mg NN N
three CD N
times NNS N
per IN N
day NN N
, , N
and CC N
placebo VBZ N
2.5 CD N
g NN N
three CD N
times NNS N
per IN N
day NN N
for IN N
24 CD N
weeks NNS N
. . N

The DT N
main JJ N
outcome NN N
measures NNS N
were VBD N
HIV-RNA NNP N
, , N
CD4 NNP N
cells NNS N
, , N
and CC N
blood NN N
chemistry NN N
profiles VBZ N
prior RB N
to TO N
the DT N
treatment NN N
and CC N
then RB N
every DT N
4 CD N
weeks NNS N
for IN N
24 CD N
weeks NNS N
. . N

The DT N
baseline NN N
characteristics NNS N
of IN N
60 CD N
evaluable JJ N
subjects NNS N
, , N
40 CD N
in IN N
the DT N
SH NNP N
group NN N
and CC N
20 CD N
in IN N
the DT N
placebo NN N
group NN N
, , N
were VBD N
not RB N
significantly RB N
different JJ N
. . N

HIV NNP N
RNA NNP N
at IN N
week NN N
4 CD N
and CC N
thereafter RB N
was VBD N
significantly RB N
decreased VBN N
from IN N
the DT N
baseline NN N
value NN N
in IN N
both DT N
groups NNS N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

However RB N
, , N
the DT N
decline NN N
in IN N
HIV NNP N
RNA NNP N
in IN N
the DT N
SH NNP N
group NN N
was VBD N
significantly RB N
more JJR N
than IN N
that DT N
in IN N
the DT N
placebo NN N
group NN N
. . N

The DT N
CD4 NNP N
cells NNS N
in IN N
the DT N
SH NNP N
group NN N
at IN N
week NN N
12 CD N
and CC N
thereafter RB N
were VBD N
significantly RB N
increased VBN N
from IN N
the DT N
baseline NN N
value NN N
. . N

Serious JJ N
adverse JJ N
events NNS N
in IN N
the DT N
two CD N
groups NNS N
were VBD N
not RB N
observed VBN N
. . N

It PRP N
is VBZ N
concluded VBN N
that IN N
an DT N
addition NN N
of IN N
SH NNP N
herbs NNS N
to TO N
two CD N
nucleoside JJ N
reverse NN N
transcriptase NN N
inhibitors NNS N
has VBZ N
greater JJR N
antiviral JJ N
activity NN N
than IN N
antiretrovirals NNS N
only RB N
. . N

The DT N
SH NNP N
herbs NN N
may MD N
be VB N
an DT N
alternative NN N
for IN N
the DT N
third JJ N
anti-retroviral JJ N
agent NN N
in IN N
the DT N
triple JJ N
drug NN N
regimen NNS N
for IN N
the DT N
treatment NN N
of IN N
HIV NNP N
infected VBD N
patients NNS N
in IN N
countries NNS N
with IN N
limited JJ N
resources NNS N
. . N

-DOCSTART- -X- O O 20472253

Effects NNS N
of IN N
fish JJ N
oil NN N
supplementation NN N
on IN N
markers NNS N
of IN N
the DT N
metabolic JJ N
syndrome NN N
. . N

OBJECTIVE UH N
To TO N
investigate VB N
whether IN N
fish JJ N
oil NN N
affects NNS N
cardiovascular JJ N
risk NN N
factors NNS N
during IN N
the DT N
adolescent JJ N
growth NN N
spurt NN N
. . N

STUDY NNP N
DESIGN NNP N
A NNP N
total NN N
of IN N
78 CD N
boys NNS N
age NN N
13-15 CD N
years NNS N
with IN N
a DT N
mean JJ 4_p
body NN 4_p
fat JJ 4_p
percentage NN 4_p
of IN 4_p
30 CD 4_p
% NN 4_p
+/-9 JJ 4_p
% NN 4_p
were VBD N
randomly RB N
assigned VBN N
to TO N
consume VB N
fish JJ N
oil NN N
( ( N
providing VBG N
1.5 CD N
g NN N
of IN N
n-3 JJ N
long-chain NN N
polyunsaturated VBD N
fatty JJ N
acid/day NN N
) ) N
or CC N
vegetable JJ N
oil NN N
( ( N
control NN N
) ) N
for IN N
16 CD N
weeks NNS N
. . N

The DT N
oils NNS N
were VBD N
included VBN N
in IN N
bread NN N
. . N

RESULTS NNP N
After IN N
the DT N
intervention NN N
, , N
the DT N
red JJ N
blood NN N
cell NN N
( ( N
RBC NNP N
) ) N
content NN N
of IN N
eicosapentaenoic JJ N
acid NN N
( ( N
EPA NNP N
) ) N
and CC N
docosahexaenoic JJ N
acid NN N
( ( N
DHA NNP N
) ) N
were VBD N
1.2 CD N
% NN N
+/-0.5 JJ N
% NN N
and CC N
6.7 CD N
% NN N
+/-1.6 JJ N
% NN N
, , N
respectively RB N
, , N
in IN N
the DT N
those DT N
receiving VBG N
fish JJ N
oil NN N
( ( N
FO NNP N
group NN N
) ) N
, , N
compared VBN N
with IN N
0.6 CD N
% NN N
+/-0.3 JJ N
% NN N
and CC N
4.1 CD N
% NN N
+/-0.9 JJ N
% NN N
in IN N
the DT N
control NN N
group NN N
. . N

Systolic NNP N
blood NN N
pressure NN N
( ( N
SBP NNP N
) ) N
was VBD N
3.8+/-1.4 JJ N
mm NN N
Hg NNP N
lower JJR N
( ( N
P NNP N
< NNP N
.006 NNP N
) ) N
and CC N
diastolic JJ N
blood NN N
pressure NN N
( ( N
DBP NNP N
) ) N
was VBD N
2.6+/-1.1 JJ N
mm NN N
Hg NNP N
lower JJR N
( ( N
P NNP N
< NNP N
.01 NNP N
) ) N
in IN N
the DT N
FO NNP N
group NN N
compared VBN N
with IN N
the DT N
control NN N
group NN N
. . N

Plasma NNP N
triacylglycerol NN N
( ( N
TAG NNP N
) ) N
concentration NN N
and CC N
insulin JJ N
sensitivity NN N
were VBD N
unaffected VBN N
by IN N
either DT N
of IN N
the DT N
treatments NNS N
. . N

Plasma NNP N
high-density NN N
lipoprotein NN N
( ( N
HDL NNP N
) ) N
and CC N
non-HDL JJ N
cholesterol NN N
were VBD N
increased VBN N
by IN N
5 CD N
% NN N
and CC N
7 CD N
% NN N
, , N
respectively RB N
, , N
in IN N
the DT N
FO NNP N
group NN N
, , N
and CC N
by IN N
2 CD N
% NN N
and CC N
0 CD N
% NN N
in IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
< NNP N
.01-.02 NN N
) ) N
. . N

The DT N
changes NNS N
in IN N
RBC NNP N
EPA NNP N
content NN N
were VBD N
inversely RB N
correlated VBN N
with IN N
the DT N
changes NNS N
in IN N
SBP NNP N
and CC N
DBP NNP N
and CC N
directly RB N
correlated VBN N
with IN N
the DT N
increases NNS N
in IN N
HDL NNP N
cholesterol NN N
and CC N
non-HDL JJ N
cholesterol NN N
concentrations NNS N
. . N

No DT N
association NN N
was VBD N
seen VBN N
between IN N
RBC NNP N
EPA NNP N
and CC N
plasma VB N
TAG NNP N
concentration NN N
or CC N
insulin JJ N
sensitivity NN N
. . N

CONCLUSION NNP N
Fish NNP N
oil NN N
improves VBZ N
BP NNP N
in IN N
normotensive JJ 4_p
and CC 4_p
normolipidemic JJ 4_p
slightly RB N
overweight JJ N
adolescent NN N
boys NNS N
. . N

-DOCSTART- -X- O O 16378639

Wavefront-guided JJ N
versus NN N
standard NN N
LASIK NNP N
enhancement NN N
for IN N
residual JJ N
refractive JJ N
errors NNS N
. . N

OBJECTIVE NNP N
To TO N
assess VB N
efficacy NN N
, , N
safety NN N
, , N
predictability NN N
, , N
stability NN N
, , N
and CC N
changes NNS N
in IN N
higher-order NN N
aberrations NNS N
( ( N
HOAs NNP N
) ) N
and CC N
contrast JJ N
sensitivity NN N
( ( N
CS NNP N
) ) N
after IN N
wavefront-guided JJ N
and CC N
standard JJ N
LASIK NNP N
enhancement NN N
for IN N
the DT N
correction NN N
of IN N
residual JJ N
refractive JJ N
errors NNS N
. . N

DESIGN NNP N
Prospective NNP N
, , N
randomized VBD N
, , N
comparative JJ N
clinical JJ N
study NN N
. . N

PARTICIPANTS NNP N
Twenty NNP N
eyes NNS N
of IN N
20 CD N
consecutive JJ N
patients NNS N
( ( N
spherical JJ N
equivalent NN N
[ NNP N
SE NNP N
] NNP N
, , N
-2.01+/-1.36 NNP N
diopters NNS N
[ NNP N
D NNP N
] NNP N
) ) N
treated VBD N
with IN N
wavefront-guided JJ N
Zyoptix NNP N
Ablation NNP N
Refinement NNP N
software NN N
( ( N
ZAR NNP N
) ) N
LASIK NNP N
and CC N
20 CD N
eyes NNS N
of IN N
20 CD N
consecutive JJ N
patients NNS N
( ( N
SE NNP N
, , N
-1.81+/-1.21 NNP N
D NNP N
) ) N
treated VBD N
with IN N
standard JJ N
Planoscan NNP N
LASIK NNP N
, , N
both DT N
for IN N
residual JJ 4_p
refractive JJ 4_p
error NN 4_p
enhancement NN 4_p
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Efficacy NNP N
, , N
safety NN N
, , N
predictability NN N
, , N
stability NN N
, , N
HOAs NNP N
, , N
and CC N
CS NNP N
were VBD N
evaluated VBN N
before IN N
and CC N
after IN N
enhancement NN N
at IN N
6 CD N
months NNS N
' POS N
follow-up NN N
. . N

METHODS NNP N
Uncorrected VBD N
visual JJ N
acuity NN N
( ( N
UCVA NNP N
) ) N
, , N
best-corrected JJ N
visual JJ N
acuity NN N
( ( N
BCVA NNP N
) ) N
, , N
manifest JJS N
refraction NN N
, , N
CS NNP N
by IN N
means NNS N
of IN N
the DT N
Functional NNP N
Acuity NNP N
Contrast NNP N
Test NNP N
, , N
and CC N
HOAs NNP N
by IN N
means NNS N
of IN N
Zywave NNP N
aberrometry NN N
were VBD N
evaluated VBN N
preoperatively RB N
and CC N
6 CD N
months NNS N
after IN N
retreatment NN N
. . N

RESULTS NNP N
At IN N
6 CD N
months NNS N
postoperatively RB N
, , N
UCVA NNP N
was VBD N
20/25 CD N
or CC N
better JJR N
in IN N
100 CD N
% NN N
of IN N
the DT N
eyes NNS N
. . N

Efficacy NN N
indexes NNS N
were VBD N
1.09 CD N
for IN N
ZAR NNP N
patients NNS N
and CC N
0.95 CD N
for IN N
Planoscan JJ N
patients NNS N
. . N

No DT N
eyes NNS N
lost VBN N
> CD N
or CC N
=1 JJ N
line NN N
of IN N
BCVA NNP N
; : N
in IN N
the DT N
ZAR NNP N
group NN N
, , N
2 CD N
eyes NNS N
gained VBD N
1 CD N
line NN N
and CC N
6 CD N
eyes NNS N
gained VBN N
> CD N
or CC N
=2 JJ N
lines NNS N
; : N
in IN N
the DT N
Planoscan NNP N
group NN N
, , N
3 CD N
eyes NNS N
gained VBD N
1 CD N
line NN N
. . N

The DT N
ZAR NNP N
group NN N
showed VBD N
a DT N
percentage NN N
of IN N
eyes NNS N
( ( N
94.4 CD N
% NN N
) ) N
within IN N
the DT N
0.5-D JJ N
range NN N
in IN N
SE NNP N
higher JJR N
than IN N
that DT N
shown VBN N
by IN N
the DT N
Planoscan NNP N
group NN N
( ( N
88.8 CD N
% NN N
) ) N
. . N

After IN N
6 CD N
months NNS N
, , N
the DT N
HOA NNP N
root NN N
mean NN N
square NN N
( ( N
RMS NNP N
) ) N
increased VBD N
on IN N
average NN N
by IN N
a DT N
factor NN N
of IN N
1.44 CD N
for IN N
the DT N
Planoscan NNP N
group NN N
( ( N
P NNP N
= NNP N
0.003 CD N
) ) N
. . N

No UH N
change NN N
or CC N
reduction NN N
in IN N
HOA NNP N
RMS NNP N
was VBD N
found VBN N
in IN N
the DT N
ZAR NNP N
group NN N
( ( N
factor NN N
of IN N
0.96 CD N
; : N
P NNP N
> NNP N
0.01 CD N
) ) N
. . N

Contrast NNP N
sensitivity NN N
was VBD N
reduced VBN N
in IN N
the DT N
Planoscan NNP N
group NN N
only RB N
at IN N
the DT N
highest JJS N
spatial JJ N
frequency NN N
( ( N
18 CD N
cycles NNS N
per IN N
degree NN N
; : N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

There EX N
was VBD N
a DT N
significant JJ N
reduction NN N
of IN N
CS NNP N
as IN N
a DT N
function NN N
of IN N
HOA NNP N
increase NN N
for IN N
the DT N
Planoscan NNP N
group NN N
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

No UH N
changes NNS N
were VBD N
observed VBN N
for IN N
the DT N
ZAR NNP N
group NN N
at IN N
any DT N
spatial JJ N
frequency NN N
( ( N
1.5-18 JJ N
cycles NNS N
per IN N
degree NN N
; : N
P NNP N
> NNP N
0.01 CD N
) ) N
. . N

CONCLUSIONS NNP N
Wavefront-guided JJ N
LASIK NNP N
using VBG N
the DT N
ZAR NNP N
algorithm NN N
is VBZ N
an DT N
effective JJ N
and CC N
safe JJ N
procedure NN N
for IN N
treatment NN N
of IN N
residual JJ N
refractive JJ N
errors NNS N
. . N

Wavefront-guided JJ N
LASIK NNP N
does VBZ N
not RB N
increase VB N
HOAs NNP N
and CC N
does VBZ N
not RB N
modify VB N
CS NNP N
compared VBN N
with IN N
preoperative JJ N
values NNS N
. . N

Wavefront-guided JJ N
LASIK NNP N
seems VBZ N
to TO N
be VB N
better JJR N
than IN N
standard JJ N
LASIK NNP N
for IN N
retreatments NNS N
. . N

-DOCSTART- -X- O O 24104511

Correlation NN N
of IN N
cognitive JJ N
and CC N
social JJ N
outcomes NNS N
among IN N
children NNS 4_p
with IN 4_p
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
in IN N
a DT N
randomized JJ N
trial NN N
of IN N
behavioral JJ N
intervention NN N
. . N

Although IN N
social JJ N
impairments NNS N
are VBP N
considered VBN N
the DT N
hallmark NN N
deficit NN N
of IN N
autism NN N
, , N
many JJ N
behavioral JJ N
intervention NN N
studies NNS N
rely VBP N
on IN N
cognitive JJ N
functioning NN N
as IN N
a DT N
primary JJ N
outcome NN N
. . N

Fewer JJR N
studies NNS N
have VBP N
examined VBN N
whether IN N
changes NNS N
in IN N
cognition NN N
are VBP N
associated VBN N
with IN N
changes NNS N
in IN N
social JJ N
functioning NN N
. . N

This DT N
study NN N
examined VBD N
whether IN N
cognitive JJ N
gains NNS N
among IN N
192 CD N
students NNS N
from IN N
47 CD N
kindergarten-through-second-grade JJ N
autism NN N
support NN N
classrooms NNS N
participating VBG N
in IN N
a DT N
year-long JJ N
behavioral JJ N
intervention NN N
study NN N
were VBD N
associated VBN N
with IN N
gains NNS N
in IN N
social JJ N
functioning NN N
. . N

Children NNP N
's POS N
gains NNS N
in IN N
cognitive JJ N
ability NN N
were VBD N
modestly RB N
associated VBN N
with IN N
independent JJ N
assessors NNS N
' POS N
and CC N
teachers NNS N
' POS N
evaluations NNS N
of IN N
social JJ N
functioning NN N
but CC N
were VBD N
not RB N
associated VBN N
with IN N
changes NNS N
in IN N
parent NN N
ratings NNS N
. . N

Observed VBN N
social JJ N
gains NNS N
were VBD N
not RB N
commensurate JJ N
with IN N
gains NNS N
in IN N
cognition NN N
, , N
suggesting VBG N
the DT N
need NN N
both DT N
for IN N
interventions NNS N
that WDT N
directly RB N
target VBP N
social JJ N
functioning NN N
and CC N
relevant JJ N
field NN N
measures NNS N
of IN N
social JJ N
functioning NN N
. . N

-DOCSTART- -X- O O 18555063

Anxiety NN 4_p
sensitivity NN 4_p
as IN N
an DT N
incremental JJ N
predictor NN N
of IN N
later JJ 4_p
anxiety NN 4_p
symptoms NNS 4_p
and CC 4_p
syndromes NNS 4_p
. . N

Although IN N
anxiety NN 4_p
sensitivity NN 4_p
( ( N
AS NNP N
) ) N
has VBZ N
been VBN N
shown VBN N
to TO N
predict VB N
anxiety NN 4_p
symptoms NNS 4_p
and CC 4_p
panic NN 4_p
, , N
this DT N
literature NN N
is VBZ N
limited VBN N
in IN N
regard NN N
to TO N
evaluating VBG N
AS NNP N
as IN N
an DT N
incremental JJ N
predictor NN N
of IN N
anxiety NN 4_p
psychopathology NN 4_p
relative VBP N
to TO N
other JJ N
established VBN N
risk NN N
factors NNS N
including VBG N
sex NN N
and CC N
negative JJ N
affect NN N
. . N

The DT N
present JJ N
report NN N
prospectively RB N
evaluated VBD N
whether IN N
AS NNP N
was VBD N
predictive NN N
of IN N
later JJ N
changes NNS N
in IN N
anxiety NN N
symptoms NNS N
after IN N
controlling VBG N
for IN N
potential JJ N
confounding NN N
factors NNS N
. . N

Consistent JJ N
with IN N
hypothesis NN N
, , N
AS NNP N
was VBD N
found VBN N
to TO N
be VB N
a DT N
significant JJ N
, , N
incremental JJ N
predictor NN N
of IN N
anxiety NN N
symptoms NNS N
over IN N
time NN N
, , N
even RB N
after IN N
controlling VBG N
for IN N
sex NN N
and CC N
negative JJ N
affectivity NN N
. . N

These DT N
data NNS N
provide VBP N
novel JJ N
evidence NN N
for IN N
the DT N
unique JJ N
association NN N
between IN N
AS NNP N
of IN N
the DT N
development NN N
of IN N
anxiety NN 4_p
symptoms NNS 4_p
. . 4_p

-DOCSTART- -X- O O 11849797

Prophylactic JJ N
use NN N
of IN N
amifostine NN N
to TO N
prevent VB N
radiochemotherapy-induced JJ N
mucositis NN N
and CC N
xerostomia NN N
in IN N
head-and-neck JJ N
cancer NN N
. . N

PURPOSE NNP N
To TO N
determine VB N
the DT N
prophylactic JJ N
properties NNS N
of IN N
amifostine NN N
against IN N
acute JJ N
and CC N
late JJ N
toxicities NNS N
from IN N
radiochemotherapy NN N
in IN N
patients NNS N
with IN N
head-and-neck JJ N
cancer NN N
. . N

METHODS NNP N
AND CC N
MATERIALS NNP N
Fifty NNP N
patients NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
conventional JJ N
radiotherapy NN N
( ( N
RT NNP N
) ) N
( ( N
2-Gy JJ N
fractions NNS N
, , N
5 CD N
days NNS N
weekly RB N
, , N
to TO N
a DT N
total NN N
of IN N
60-74 JJ N
Gy NNP N
, , N
depending VBG N
on IN N
the DT N
tumor NN N
localization NN N
and CC N
TNM NNP N
classification NN N
) ) N
and CC N
carboplatin NN N
( ( N
90 CD N
mg/m NN N
( ( N
2 CD N
) ) N
infusion NN N
once RB N
per IN N
week NN N
before IN N
RT NNP N
) ) N
. . N

Amifostine NNP N
( ( N
300 CD N
mg/m NN N
( ( N
2 CD N
) ) N
) ) N
was VBD N
administered VBN N
in IN N
the DT N
study NN N
group NN N
only RB N
15-30 JJ N
min NN N
before IN N
RT NNP N
for IN N
6-7.5 JJ N
weeks NNS N
. . N

The DT N
primary JJ N
study NN N
end NN N
point NN N
was VBD N
the DT N
grading NN N
of IN N
acute NN N
and CC N
late JJ N
nonhematologic NN N
toxicities NNS N
( ( N
mucositis NN N
, , N
dysphagia NN N
, , N
xerostomia NN N
) ) N
induced VBN N
by IN N
radiochemotherapy NN N
. . N

Secondary JJ N
end NN N
points NNS N
included VBD N
treatment NN N
duration NN N
, , N
hematologic JJ N
toxicity NN N
, , N
and CC N
clinical JJ N
outcome NN N
. . N

RESULTS VB N
The DT N
treatment NN N
duration NN N
was VBD N
significantly RB N
shorter JJR N
in IN N
the DT N
amifostine-treated JJ N
group NN N
( ( N
p JJ N
= NNP N
0.013 CD N
) ) N
, , N
because IN N
treatment NN N
interruptions NNS N
were VBD N
more RBR N
frequent JJ N
in IN N
the DT N
control NN N
group NN N
. . N

Acute NNP N
toxicities NNS N
( ( N
mucositis NN N
and CC N
dysphagia NN N
) ) N
were VBD N
less JJR N
severe JJ N
in IN N
the DT N
amifostine-treated JJ N
group NN N
. . N

By IN N
Week JJ N
3 CD N
, , N
all DT N
in IN N
the DT N
control NN N
group NN N
experienced VBD N
Grade NNP N
2 CD N
mucositis NN N
compared VBN N
with IN N
only RB N
9 CD N
% NN N
in IN N
the DT N
amifostine-treated JJ N
group NN N
( ( N
p JJ N
< NNP N
0.0001 CD N
) ) N
. . N

By IN N
Week JJ N
5 CD N
, , N
52.2 CD N
% NN N
of IN N
the DT N
patients NNS N
in IN N
the DT N
control NN N
group NN N
experienced VBD N
Grade NNP N
4 CD N
mucositis NN N
compared VBN N
with IN N
4.5 CD N
% NN N
in IN N
the DT N
amifostine-treated JJ N
group NN N
( ( N
p JJ N
= NNP N
0.0006 CD N
) ) N
. . N

Similar JJ N
results NNS N
were VBD N
obtained VBN N
for IN N
dysphagia NN N
. . N

At IN N
3 CD N
months NNS N
of IN N
follow-up NN N
, , N
only RB N
27 CD N
% NN N
of IN N
patients NNS N
in IN N
the DT N
study NN N
group NN N
experienced VBD N
Grade NNP N
2 CD N
xerostomia NN N
compared VBN N
with IN N
73.9 CD N
% NN N
in IN N
the DT N
control NN N
group NN N
( ( N
p JJ N
= NNP N
0.0001 CD N
) ) N
. . N

Eighteen JJ N
months NNS N
after IN N
cessation NN N
of IN N
therapy NN N
, , N
the DT N
proportion NN N
of IN N
patients NNS N
with IN N
Grade NNP N
2 CD N
xerostomia NN N
was VBD N
4.5 CD N
% NN N
vs. FW N
30.4 CD N
% NN N
for IN N
each DT N
respective JJ N
treatment NN N
group NN N
( ( N
p JJ N
= NNP N
0.047 CD N
) ) N
. . N

Cytoprotection NN N
with IN N
amifostine NN N
did VBD N
not RB N
affect VB N
treatment NN N
outcome NN N
, , N
with IN N
90.9 CD N
% NN N
complete JJ N
responses NNS N
in IN N
the DT N
amifostine-treated JJ N
group NN N
compared VBN N
with IN N
78.3 CD N
% NN N
in IN N
the DT N
control NN N
group NN N
( ( N
p JJ N
= NNP N
0.414 CD N
) ) N
. . N

CONCLUSION NNP N
Amifostine NNP N
was VBD N
effective JJ N
in IN N
reducing VBG N
mucositis NN N
and CC N
dysphagia NN N
resulting VBG N
from IN N
radiochemotherapy NN N
in IN N
patients NNS N
with IN N
head-and-neck JJ N
cancer NN N
. . N

Furthermore NNP N
, , N
amifostine NN N
reduced VBD N
the DT N
severity NN N
of IN N
late JJ N
xerostomia NN N
, , N
a DT N
side NN N
effect NN N
of IN N
RT NNP N
with IN N
long-lasting JJ N
consequences NNS N
. . N

Amifostine NNP N
treatment NN N
did VBD N
not RB N
affect VB N
the DT N
clinical JJ N
outcome NN N
. . N

-DOCSTART- -X- O O 2586565

Peritoneovenous JJ N
shunting VBG N
as IN N
compared VBN N
with IN N
medical JJ N
treatment NN N
in IN N
patients NNS 4_p
with IN 4_p
alcoholic JJ 4_p
cirrhosis NN 4_p
and CC 4_p
massive JJ 4_p
ascites NNS 4_p
. . 4_p

Veterans NNPS N
Administration NNP N
Cooperative NNP N
Study NNP N
on IN N
Treatment NNP N
of IN N
Alcoholic NNP N
Cirrhosis NNP N
with IN N
Ascites NNP N
. . N

The DT N
optimal JJ N
management NN N
of IN N
severe JJ N
ascites NNS N
in IN N
patients NNS 4_p
with IN 4_p
alcoholic JJ 4_p
cirrhosis NN 4_p
has VBZ N
not RB N
been VBN N
defined VBN N
. . N

in IN N
a DT N
5 CD N
1/2-year JJ N
study NN N
, , N
we PRP N
randomly VBP N
assigned VBN N
299 CD N
men NNS N
with IN N
alcoholic JJ N
cirrhosis NN N
, , N
who WP N
had VBD N
persistent NN N
or CC N
recurrent NN N
severe JJ N
ascites VBZ N
despite IN N
a DT N
standard JJ N
medical JJ N
regimen NNS N
, , N
to TO N
receive VB N
either RB N
intensive JJ N
medical JJ N
treatment NN N
or CC N
peritoneovenous JJ N
( ( N
LeVeen NNP N
) ) N
shunting VBG N
. . N

We PRP N
identified VBD N
three CD N
risk NN N
groups NNS N
: : N
Group NNP N
1 CD N
had VBD N
normal JJ N
or CC N
mildly RB N
abnormal JJ N
results NNS N
on IN N
liver-function NN N
tests NNS N
, , N
Group NNP N
2 CD N
had VBD N
more RBR N
severe JJ N
liver NN N
dysfunction NN N
or CC N
previous JJ N
complications NNS N
, , N
and CC N
Group NNP N
3 CD N
had VBD N
severe JJ N
prerenal JJ N
azotemia NN N
without IN N
kidney NN N
disease NN N
. . N

For IN N
the DT N
patients NNS N
who WP N
received VBD N
the DT N
medical JJ N
treatment NN N
and CC N
those DT N
who WP N
received VBD N
the DT N
surgical JJ N
treatment NN N
combined VBN N
, , N
the DT N
median JJ N
survival NN N
times NNS N
were VBD N
1093 CD N
days NNS N
in IN N
Group NNP N
1 CD N
, , N
222 CD N
days NNS N
in IN N
Group NNP N
2 CD N
, , N
and CC N
37 CD N
days NNS N
in IN N
Group NNP N
3 CD N
( ( N
P NNP N
less JJR N
than IN N
or CC N
equal JJ N
to TO N
0.01 CD N
) ) N
for IN N
all DT N
comparisons NNS N
) ) N
. . N

For IN N
all PDT N
the DT N
groups NNS N
combined VBN N
, , N
the DT N
median JJ N
time NN N
to TO N
the DT N
resolution NN N
of IN N
ascites NNS N
was VBD N
5.4 CD N
weeks NNS N
for IN N
medical JJ N
patients NNS N
and CC N
3.0 CD N
weeks NNS N
for IN N
surgical JJ N
patients NNS N
( ( N
P NNP N
less JJR N
than IN N
0.01 CD N
) ) N
. . N

Within IN N
each DT N
risk NN N
group NN N
, , N
mortality NN N
during IN N
the DT N
initial JJ N
hospitalization NN N
and CC N
median JJ N
long-term JJ N
survival NN N
were VBD N
similar JJ N
among IN N
patients NNS N
receiving VBG N
either DT N
treatment NN N
. . N

However RB N
, , N
the DT N
median JJ N
time NN N
to TO N
the DT N
recurrence NN N
of IN N
ascites NNS N
in IN N
Group NNP N
1 CD N
was VBD N
4 CD N
months NNS N
in IN N
medical JJ N
patients NNS N
, , N
as IN N
compared VBN N
with IN N
18 CD N
months NNS N
in IN N
surgical JJ N
patients NNS N
( ( N
P NNP N
= NNP N
0.01 CD N
) ) N
; : N
in IN N
Group NNP N
2 CD N
it PRP N
was VBD N
3 CD N
months NNS N
in IN N
medical JJ N
patients NNS N
as IN N
compared VBN N
with IN N
12 CD N
months NNS N
in IN N
surgical JJ N
patients NNS N
( ( N
P NNP N
= NNP N
0.04 CD N
) ) N
. . N

The DT N
median JJ N
duration NN N
of IN N
hospitalization NN N
was VBD N
longer RBR N
in IN N
medical JJ N
patients NNS N
than IN N
in IN N
surgical JJ N
patients NNS N
( ( N
6.1 CD N
vs. RB N
2.4 CD N
weeks NNS N
in IN N
Group NNP N
1 CD N
[ NNP N
P NNP N
less JJR N
than IN N
0.001 CD N
] NNS N
and CC N
5.0 CD N
vs. FW N
3.1 CD N
weeks NNS N
in IN N
Group NNP N
2 CD N
[ NNP N
P NNP N
less JJR N
than IN N
0.01 CD N
] NN N
) ) N
. . N

Group NNP N
3 CD N
was VBD N
too RB N
small JJ N
to TO N
permit VB N
a DT N
meaningful JJ N
comparison NN N
. . N

During IN N
the DT N
initial JJ N
hospitalization NN N
, , N
the DT N
incidence NN N
of IN N
infections NNS N
, , N
gastrointestinal JJ N
bleeding NN N
, , N
and CC N
encephalopathy NN N
was VBD N
similar JJ N
among IN N
the DT N
medical JJ N
and CC N
surgical JJ N
patients NNS N
. . N

We PRP N
conclude VBP N
that DT N
peritoneovenous JJ N
shunting NN N
alleviated VBD N
disabling VBG N
ascites NNS N
more RBR N
rapidly RB N
than IN N
medical JJ N
management NN N
. . N

However RB N
, , N
survival NN N
was VBD N
closely RB N
related VBN N
to TO N
the DT N
severity NN N
of IN N
the DT N
illness NN N
at IN N
the DT N
time NN N
of IN N
randomization NN N
and CC N
was VBD N
not RB N
altered VBN N
by IN N
shunting VBG N
. . N

-DOCSTART- -X- O O 19565731

[ JJ N
Clinical NNP N
observation NN N
on IN N
acupuncture NN N
combined VBN N
with IN N
Yizhi NNP N
Jiannao NNP N
granules NNS N
for IN N
treatment NN N
of IN N
Alzheimer NNP N
's POS N
disease NN N
] NNP N
. . N

OBJECTIVE NNP N
To TO N
observe VB N
clinical JJ N
therapeutic JJ N
effect NN N
of IN N
acupuncture NN N
combined VBN N
with IN N
Yizhi NNP N
Jiannao NNP N
Granules NNP N
for IN N
treatment NN N
of IN N
Alzheimer NNP N
's POS N
disease NN N
and CC N
its PRP$ N
effects NNS N
on IN N
intelligence NN N
, , N
daily JJ N
life NN N
and CC N
social JJ N
activity NN N
ability NN N
. . N

METHODS NNP N
Eighty-four JJ N
cases NNS N
were VBD N
randomly RB N
divided VBN N
into IN N
3 CD N
groups NNS N
, , N
28 CD N
cases NNS N
in IN N
each DT N
group NN N
. . N

The DT N
combined JJ N
acupuncture NN N
and CC N
medication NN N
group NN N
was VBD N
treated VBN N
with IN N
acupuncture NN N
at IN N
Baihui NNP N
( ( N
GV NNP N
20 CD N
) ) N
, , N
Sishencong NNP N
( ( N
EX-HN NNP N
1 CD N
) ) N
, , N
Dazhui NNP N
( ( N
GV NNP N
14 CD N
) ) N
, , N
Guanyuan NNP N
( ( N
CV NNP N
4 CD N
) ) N
, , N
etc FW N
. . N

and CC N
oral JJ N
administration NN N
of IN N
Yizhi NNP N
Jiannao NNP N
Granules NNP N
; : N
the DT N
Chinese NNP N
herb NN N
group NN N
was VBD N
treated VBN N
with IN N
Yizhi NNP N
Jiannao NNP N
Granules NNP N
, , N
and CC N
the DT N
western JJ N
medicine NN N
group NN N
with IN N
oral JJ N
administration NN N
of IN N
Aricept NNP N
. . N

The DT N
scores NNS N
for IN N
the DT N
Mini-Mental JJ N
State NNP N
Examination NNP N
( ( N
MMSE NNP N
) ) N
, , N
Ability NNP N
of IN N
Daily NNP N
Life NNP N
( ( N
ADL NNP N
) ) N
and CC N
the DT N
therapeutic JJ N
effects NNS N
were VBD N
assessed VBN N
and CC N
compared VBN N
before IN N
treatment NN N
and CC N
after IN N
treatment NN N
for IN N
12 CD N
weeks NNS N
among IN N
the DT N
groups NNS N
. . N

RESULTS NNP N
After IN N
treatment NN N
, , N
the DT N
scores NNS N
for IN N
MMSE NNP N
and CC N
ADL NNP N
were VBD N
improved VBN N
in IN N
the DT N
combined JJ N
acupuncture NN N
and CC N
medication NN N
group NN N
, , N
the DT N
Chinese JJ N
herb NN N
group NN N
and CC N
the DT N
western JJ N
medicine NN N
group NN N
, , N
which WDT N
were VBD N
better RBR N
in IN N
the DT N
combined JJ N
acupuncture NN N
and CC N
medication NN N
group NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
total JJ N
effective JJ N
rate NN N
of IN N
85.7 CD N
% NN N
in IN N
the DT N
combined JJ N
acupuncture NN N
and CC N
medication NN N
group NN N
was VBD N
better JJR N
than IN N
71.4 CD N
% NN N
in IN N
the DT N
Chinese JJ N
herb NN N
group NN N
and CC N
67.9 CD N
% NN N
in IN N
the DT N
western JJ N
medicine NN N
group NN N
. . N

CONCLUSION NNP N
Acupuncture NNP N
combined VBN N
with IN N
Yizhi NNP N
Jiannao NNP N
Granules NNP N
has VBZ N
a DT N
significant JJ N
therapeutic JJ N
effect NN N
on IN N
Alzheimer NNP N
's POS N
disease NN N
, , N
which WDT N
is VBZ N
better JJR N
than IN N
that DT N
of IN N
Yizhi NNP N
Jiannao NNP N
Granules NNP N
or CC N
Aricept NNP N
. . N

-DOCSTART- -X- O O 17943674

Effects NNS N
of IN N
vacuum-compression NN N
therapy NN N
on IN N
healing NN N
of IN N
diabetic JJ 4_p
foot NN 4_p
ulcers NNS 4_p
: : N
randomized VBN N
controlled JJ N
trial NN N
. . N

A DT N
single-blind JJ N
, , N
randomized VBN N
controlled VBD N
trial NN N
was VBD N
conducted VBN N
to TO N
evaluate VB N
vacuum-compression NN N
therapy NN N
( ( N
VCT NNP N
) ) N
for IN N
the DT N
healing NN N
of IN N
diabetic JJ 4_p
foot NN 4_p
ulcers NNS 4_p
. . N

Eighteen NNP N
diabetic JJ 4_p
patients NNS N
with IN N
foot JJ 4_p
ulcers NNS 4_p
were VBD N
recruited VBN N
through IN N
simple JJ N
nonprobability NN N
sampling VBG N
. . N

Subjects NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
either DT N
an DT N
experimental JJ N
or CC N
a DT N
control NN N
group NN N
. . N

Before IN N
and CC N
after IN N
intervention NN N
, , N
the DT N
foot NN N
ulcer JJ N
surface NN N
area NN N
was VBD N
estimated VBN N
stereologically RB N
, , N
based VBN N
on IN N
Cavalieri NNP N
's POS N
principle NN N
. . N

The DT N
experimental JJ N
group NN N
was VBD N
treated VBN N
with IN N
VCT NNP N
in IN N
addition NN N
to TO N
conventional JJ N
therapy NN N
for IN N
10 CD N
sessions NNS N
. . N

The DT N
control NN N
group NN N
received VBD N
only RB N
conventional JJ N
therapy NN N
, , N
including VBG N
debridement NN N
, , N
blood NN N
glucose NNS N
control NN N
agents NNS N
, , N
systemic JJ N
antibiotics NNS N
, , N
wound IN N
cleaning VBG N
with IN N
normal JJ N
saline NN N
, , N
offloading VBG N
( ( N
pressure NN N
relief NN N
) ) N
, , N
and CC N
daily RB N
wound JJ N
dressings NNS N
. . N

The DT N
mean JJ N
foot NN N
ulcer JJ N
surface NN N
area NN N
decreased VBD N
from IN N
46.88 CD N
+/- JJ N
9.28 CD N
mm NN N
( ( N
2 CD N
) ) N
to TO N
35.09 CD N
+/- JJ N
4.09 CD N
mm NN N
( ( N
2 CD N
) ) N
in IN N
the DT N
experimental JJ N
group NN N
( ( N
p JJ N
= NNP N
0.006 CD N
) ) N
and CC N
from IN N
46.62 CD N
+/- JJ N
10.03 CD N
mm NN N
( ( N
2 CD N
) ) N
to TO N
42.89 CD N
+/- JJ N
8.1 CD N
mm NN N
( ( N
2 CD N
) ) N
in IN N
the DT N
control NN N
group NN N
( ( N
p JJ N
= NNP N
0.01 CD N
) ) N
. . N

After IN N
treatment NN N
, , N
the DT N
experimental JJ N
group NN N
significantly RB N
improved VBN N
in IN N
measures NNS N
of IN N
foot NN N
ulcer JJ N
surface NN N
area NN N
compared VBN N
with IN N
the DT N
control NN N
group NN N
( ( N
p JJ N
= NNP N
0.024 CD N
) ) N
. . N

VCT NNP N
enhances VBZ N
diabetic JJ N
foot NN N
ulcer NN N
healing VBG N
when WRB N
combined VBN N
with IN N
appropriate JJ N
wound NN N
care NN N
. . N

-DOCSTART- -X- O O 12031821

Improved VBN N
fibrinolysis NN N
after IN N
1-year JJ N
treatment NN N
with IN N
HMG NNP N
CoA NNP N
reductase NN N
inhibitors NNS N
in IN N
patients NNS 4_p
with IN 4_p
coronary JJ 4_p
heart NN 4_p
disease NN 4_p
. . N

The DT N
study NN N
was VBD N
aimed VBN N
to TO N
investigate VB N
the DT N
effect NN N
of IN N
two CD N
different JJ N
statins NNS N
on IN N
the DT N
levels NNS N
of IN N
haemostatic JJ N
variables NNS N
reflecting VBG N
procoagulant NN N
and CC N
fibrinolytic JJ N
activity NN N
in IN N
patients NNS 4_p
with IN 4_p
coronary JJ 4_p
heart NN 4_p
disease NN 4_p
( ( 4_p
CHD NNP 4_p
) ) 4_p
, , N
with IN N
the DT N
hypothesis NN N
that WDT N
statins VBZ N
might MD N
beneficially RB N
modify VB N
these DT N
levels NNS N
. . N

Fifty-eight JJ N
patients NNS N
were VBD N
randomized VBN N
to TO N
treatment NN N
with IN N
atorvastatin NN N
( ( N
n=28 JJ N
) ) N
or CC N
simvastatin NN N
( ( N
n=30 JJ N
) ) N
for IN N
1 CD N
year NN N
. . N

The DT N
starting VBG N
dose NN N
in IN N
both DT N
groups NNS N
was VBD N
20 CD N
mg/day NN N
. . N

Fasting VBG N
blood NN N
samples NNS N
were VBD N
collected VBN N
before IN N
and CC N
after IN N
12-month JJ N
treatment NN N
for IN N
determinations NNS N
of IN N
fibrinogen NN N
, , N
prothrombin JJ N
fragment NN N
1+2 CD N
( ( N
F1+2 NNP N
) ) N
, , N
plasma JJ N
D-dimer NNP N
, , N
soluble JJ N
tissue NN N
factor NN N
, , N
tissue NN N
plasminogen NN N
activator NN N
( ( N
tPA NN N
) ) N
antigen NN N
, , N
tPA NN N
activity NN N
, , N
plasminogen NN N
activator NN N
inhibitor JJ N
type-1 JJ N
activity NN N
( ( N
PAI-1 NNP N
activity NN N
) ) N
and CC N
serum JJ N
D-dimer NNP N
as IN N
a DT N
global JJ N
test NN N
of IN N
fibrinolytic JJ N
activity NN N
. . N

In IN N
the DT N
total JJ N
population NN N
, , N
improved VBN N
fibrinolytic JJ N
activity NN N
was VBD N
observed VBN N
after IN N
1 CD N
year NN N
with IN N
increased JJ N
levels NNS N
of IN N
serum NN N
D-dimer NNP N
( ( N
P=.001 NNP N
) ) N
and CC N
tPA JJ N
activity NN N
( ( N
P=.024 NNP N
) ) N
and CC N
a DT N
reduction NN N
in IN N
tPA NN N
antigen NN N
( ( N
P=.048 NNP N
) ) N
. . N

No DT N
statistically RB N
significant JJ N
changes NNS N
were VBD N
observed VBN N
in IN N
any DT N
of IN N
the DT N
measured JJ N
coagulation NN N
variables NNS N
. . N

Separately RB N
examined VBD N
, , N
an DT N
improved JJ N
fibrinolytic JJ N
profile NN N
was VBD N
seen VBN N
in IN N
the DT N
atorvastatin NN N
group NN N
with IN N
a DT N
significant JJ N
increase NN N
in IN N
serum JJ N
D-dimer NNP N
( ( N
P=.005 NNP N
) ) N
, , N
a DT N
borderline JJ N
increase NN N
in IN N
tPA JJ N
activity NN N
( ( N
P=.083 NNP N
) ) N
and CC N
a DT N
borderline NN N
reduction NN N
in IN N
tPA NN N
antigen NN N
( ( N
P=.069 NNP N
) ) N
. . N

Within IN N
the DT N
simvastatin NN N
group NN N
, , N
a DT N
reduction NN N
in IN N
prothrombin NN N
F1+2 NNP N
was VBD N
observed VBN N
( ( N
P=.038 NNP N
) ) N
. . N

The DT N
differences NNS N
in IN N
changes NNS N
between IN N
the DT N
groups NNS N
were VBD N
statistically RB N
significant JJ N
only RB N
for IN N
global JJ N
fibrinolysis NN N
( ( N
serum JJ N
D-dimer NNP N
, , N
P=.046 NNP N
) ) N
. . N

In IN N
conclusion NN N
, , N
an DT N
improved JJ N
fibrinolytic JJ N
profile NN N
was VBD N
observed VBN N
after IN N
statin NN N
treatment NN N
, , N
most RBS N
pronounced JJ N
with IN N
atorvastatin NN N
. . N

The DT N
results NNS N
indicate VBP N
that IN N
the DT N
drugs NNS N
promote VBP N
a DT N
profibrinolytic JJ N
profile NN N
, , N
and CC N
may MD N
in IN N
part NN N
explain VBP N
the DT N
benefit NN N
of IN N
statin NN N
treatment NN N
rendered VBN N
in IN N
the DT N
prevention NN N
of IN N
CHD NNP N
. . N

-DOCSTART- -X- O O 16600723

Clinical JJ N
usefulness NN N
of IN N
serum NN N
prostate NN N
specific JJ N
antigen NN N
for IN N
the DT N
detection NN N
of IN N
prostate NN 4_p
cancer NN 4_p
is VBZ N
preserved VBN N
in IN N
men NNS N
receiving VBG N
the DT N
dual JJ N
5alpha-reductase JJ N
inhibitor NN N
dutasteride NN N
. . N

PURPOSE NNP N
We PRP N
determined VBD N
whether IN N
the DT N
decrease NN N
in IN N
serum NN N
PSA NNP N
seen VBN N
with IN N
5alpha-reductase JJ N
inhibitors NNS N
affects VBZ N
the DT N
clinical JJ N
usefulness NN N
of IN N
PSA NNP N
for IN N
prostate NN N
cancer NN N
screening VBG N
using VBG N
data NNS N
from IN N
2 CD N
dutasteride JJ N
benign JJ N
prostatic JJ N
hyperplasia NN N
studies NNS N
. . N

MATERIALS NNP N
AND NNP N
METHODS NNP N
A NNP N
total NN N
of IN N
2,802 CD N
men NNS N
50 CD N
years NNS N
or CC N
older JJR N
with IN N
a DT N
clinical JJ N
diagnosis NN N
of IN N
benign JJ 4_p
prostatic JJ 4_p
hyperplasia NN 4_p
, , N
no DT 4_p
history NN 4_p
of IN 4_p
prostate NN 4_p
cancer NN 4_p
, , 4_p
PSA NNP 4_p
1.5 CD 4_p
to TO 4_p
10 CD 4_p
ng/ml NNS 4_p
, , 4_p
prostate NN 4_p
volume NN 4_p
30 CD 4_p
cc NN 4_p
or CC 4_p
greater JJR 4_p
, , 4_p
an DT 4_p
American NNP 4_p
Urological NNP 4_p
Association NNP 4_p
symptom VBD 4_p
score NN 4_p
of IN 4_p
12 CD 4_p
or CC 4_p
greater JJR 4_p
and CC 4_p
peak JJ 4_p
urinary JJ 4_p
flow NN 4_p
rate NN 4_p
15 CD 4_p
ml NN 4_p
per IN 4_p
second NN 4_p
or CC 4_p
less JJR 4_p
were VBD N
randomized VBN N
to TO N
0.5 CD N
mg NNS N
dutasteride JJ N
daily RB N
or CC N
matching VBG N
placebo NN N
for IN N
24 CD N
months NNS N
. . N

Increases NNS N
in IN N
PSA NNP N
from IN N
baseline NN N
and CC N
the DT N
maximum JJ N
increase NN N
from IN N
nadir JJ N
to TO N
month NN N
24 CD N
were VBD N
compared VBN N
between IN N
the DT N
groups NNS N
and CC N
analyzed VBN N
by IN N
prostate NN N
cancer NN N
status NN N
, , N
as IN N
determined VBN N
by IN N
PSA NNP N
driven JJ N
biopsy NN N
and CC N
an DT N
advised JJ N
cutoff NN N
of IN N
more JJR N
than IN N
4 CD N
ng/ml NNS N
after IN N
doubling VBG N
to TO N
correct VB N
for IN N
dutasteride JJ N
treatment NN N
with IN N
sensitivity NN N
and CC N
specificity NN N
calculated VBN N
for IN N
each DT N
. . N

RESULTS NNP N
In IN N
placebo NN N
treated VBN N
men NNS N
without IN N
prostate NN N
cancer NN N
there EX N
was VBD N
an DT N
8.3 CD N
% NN N
median JJ N
increase NN N
in IN N
PSA NNP N
at IN N
month NN N
24 CD N
compared VBN N
with IN N
-59.5 CD N
% NN N
in IN N
those DT N
who WP N
received VBD N
dutasteride RB N
, , N
using VBG N
doubled VBD N
values NNS N
to TO N
correct VB N
for IN N
dutasteride JJ N
treatment NN N
. . N

In IN N
those DT N
with IN N
prostate JJ N
cancer NN N
these DT N
changes NNS N
were VBD N
23.8 CD N
% NN N
and CC N
-37.2 CD N
% NN N
, , N
respectively RB N
. . N

Using VBG N
the DT N
upper JJ N
PSA NNP N
limit NN N
of IN N
4 CD N
ng/ml JJ N
sensitivity NN N
for IN N
prostate NN N
cancer NN N
in IN N
men NNS N
receiving VBG N
dutasteride NN N
vs NN N
placebo NN N
was VBD N
0.737 CD N
vs NN N
0.804 CD N
, , N
while IN N
specificity NN N
was VBD N
0.671 CD N
vs JJ N
0.578 CD N
. . N

Using VBG N
a DT N
PSA NNP N
increase NN N
from IN N
nadir NN N
of IN N
0.8 CD N
ng/ml IN N
the DT N
sensitivity NN N
of IN N
dutasteride NN N
was VBD N
0.548 CD N
and CC N
its PRP$ N
specificity NN N
was VBD N
0.795 CD N
. . N

CONCLUSIONS VB N
A DT N
doubling JJ N
factor NN N
is VBZ N
effective JJ N
for IN N
maintaining VBG N
the DT N
sensitivity NN N
and CC N
specificity NN N
of IN N
PSA NNP N
for IN N
prostate NN N
cancer NN N
detection NN N
in IN N
men NNS N
on IN N
dutasteride NN N
. . N

Increases VBZ N
in IN N
serum NN N
PSA NNP N
in IN N
men NNS N
receiving VBG N
dutasteride NN N
should MD N
be VB N
considered VBN N
suspicious JJ N
and CC N
serial JJ N
PSA NNP N
measurements NNS N
should MD N
be VB N
used VBN N
to TO N
evaluate VB N
changes NNS N
from IN N
nadir NN N
. . N

-DOCSTART- -X- O O 14628158

Removal NN N
of IN N
hypertrophied JJ N
anal JJ N
papillae NN N
and CC N
fibrous JJ N
anal JJ N
polyps NN N
increases NNS N
patient JJ N
satisfaction NN N
after IN 4_p
anal JJ 4_p
fissure NN 4_p
surgery NN 4_p
. . 4_p

BACKGROUND NNP N
Hypertrophied NNP N
anal JJ N
papillae NN N
and CC N
fibrous JJ N
anal JJ N
polyps NNS N
are VBP N
frequently RB N
found VBN N
in IN N
association NN N
with IN N
chronic JJ N
fissure NN N
in IN N
ano NN N
. . N

Usually RB N
, , N
no DT N
specific JJ N
attention NN N
is VBZ N
given VBN N
to TO N
them PRP N
and CC N
they PRP N
are VBP N
considered VBN N
normal JJ N
findings NNS N
. . N

The DT N
present JJ N
prospective JJ N
study NN N
was VBD N
aimed VBN N
at IN N
determining VBG N
whether IN N
removal NN N
of IN N
hypertrophied JJ N
anal JJ N
papillae NN N
and CC N
fibrous JJ N
anal JJ N
polyps NNS N
while IN N
dealing VBG N
with IN N
chronic JJ N
fissure NN N
in IN N
ano JJ N
confers NNS N
long-term JJ N
benefit NN N
to TO N
patients NNS N
. . N

METHODS NNP N
Between NNP N
July NNP N
1999 CD N
and CC N
December NNP N
2000 CD N
, , N
140 CD N
patients NNS N
undergoing JJ N
anal JJ N
sphincterotomy NN N
were VBD N
randomized VBN N
into IN N
two CD N
groups NNS N
to TO N
have VB N
their PRP$ N
fibrous JJ N
polyps NNS N
and CC N
hypertrophied VBD N
anal JJ N
papillae NN N
either DT N
removed VBN N
by IN N
radiofrequency NN N
surgery NN N
or CC N
left VBN N
intact JJ N
. . N

After IN N
two CD N
years NNS N
, , N
they PRP N
underwent VBP N
a DT N
detailed JJ N
interview NN N
by IN N
an DT N
independent JJ N
, , N
masked JJ N
investigator NN N
. . N

RESULTS NNP N
Overall JJ N
84 CD N
% NN N
of IN N
patients NNS N
who WP N
had VBD N
polyp NN N
and CC N
papilla NN N
removal NN N
rated VBD N
the DT N
outcome NN N
of IN N
their PRP$ N
surgery NN N
as IN N
excellent NN N
or CC N
good JJ N
in IN N
comparison NN N
to TO N
58 CD N
% NN N
of IN N
controls NNS N
. . N

The DT N
mean JJ N
satisfaction NN N
grading NN N
was VBD N
9.2 CD N
on IN N
a DT N
visual JJ N
analogue NN N
scale NN N
in IN N
the DT N
treatment NN N
group NN N
compared VBN N
to TO N
8.1 CD N
in IN N
controls NNS N
( ( N
p=0.004 NN N
) ) N
. . N

CONCLUSION NNP N
Removal NNP N
of IN N
hypertrophied JJ N
anal JJ N
papillae NN N
and CC N
fibrous JJ N
anal JJ N
polyps NNS N
should MD N
be VB N
an DT N
essential JJ N
part NN N
of IN N
treatment NN N
of IN N
chronic JJ N
fissure NN N
in IN N
ano NN N
. . N

Persistence NN N
of IN N
these DT N
structures NNS N
leaves VBZ N
behind IN N
a DT N
sense NN N
of IN N
incomplete JJ N
treatment NN N
, , N
reducing VBG N
the DT N
overall JJ N
satisfaction NN N
on IN N
the DT N
part NN N
of IN N
the DT N
patient NN N
. . N

Radiofrequency NNP N
procedure NN N
is VBZ N
useful JJ N
in IN N
eradication NN N
of IN N
these DT N
concomitant JJ N
pathologies NNS N
. . N

-DOCSTART- -X- O O 19661796

Preliminary JJ N
evaluation NN N
of IN N
psychoeducational JJ N
support NN N
interventions NNS N
on IN N
quality NN N
of IN N
life NN N
in IN N
rural JJ N
breast NN 4_p
cancer NN 4_p
survivors NNS N
after IN N
primary JJ N
treatment NN N
. . N

Although IN N
most JJS N
cancer NN N
survivors NNS N
are VBP N
at IN N
risk NN N
for IN N
being VBG N
lost VBN N
in IN N
the DT N
transition NN N
from IN N
treatment NN N
to TO N
survivorship VB N
, , N
rural JJ N
breast NN N
cancer NN N
survivors NNS N
face VBP N
special JJ N
challenges NNS N
that WDT N
might MD N
place VB N
them PRP N
at IN N
particular JJ N
risk NN N
. . N

This DT N
small-scale JJ N
preliminary JJ N
study NN N
had VBD N
2 CD N
specific JJ N
aims NNS N
: : N
( ( N
aim IN N
1 CD N
) ) N
establish VB N
the DT N
feasibility NN N
of IN N
rural JJ N
breast NN N
cancer NN N
survivors NNS N
participation VBP N
in IN N
a DT N
longitudinal JJ N
quality NN N
of IN N
life NN N
( ( N
QOL NNP N
) ) N
intervention NN N
trial NN N
and CC N
( ( N
aim VB N
2 CD N
) ) N
determine VB N
the DT N
effects NNS N
of IN N
the DT N
Breast NNP N
Cancer NNP N
Education NNP N
Intervention NNP N
( ( N
BCEI NNP N
) ) N
on IN N
overall JJ N
QOL NNP N
. . N

Fifty-three JJ N
rural JJ N
breast NN N
cancer NN N
survivors NNS N
were VBD N
randomized VBN N
to TO N
either DT N
an DT N
experimental JJ N
( ( N
n JJ N
= NNP N
27 CD N
) ) N
or CC N
a DT N
wait-control JJ N
arm NN N
( ( N
n JJ N
= NNP N
26 CD N
) ) N
. . N

Participants NNS N
in IN N
the DT N
experimental JJ N
arm NN N
received VBD N
the DT N
BCEI NNP N
consisting NN N
of IN N
3 CD N
face-to-face JJ N
education NN N
and CC N
support NN N
sessions NNS N
and CC N
2 CD N
face-to-face NN N
and CC N
3 CD N
telephone NN N
follow-up JJ N
sessions NNS N
, , N
along IN N
with IN N
supplemental JJ N
written VBN N
and CC N
audiotape JJ N
materials NNS N
over IN N
a DT N
6-month JJ N
period NN N
. . N

Breast NNP N
Cancer NNP N
Education NNP N
Intervention NNP N
modules NNS N
and CC N
interventions NNS N
are VBP N
organized VBN N
within IN N
a DT N
QOL NNP N
framework NN N
. . N

To TO N
address VB N
the DT N
possible JJ N
effects NNS N
of IN N
attention NN N
, , N
wait-control JJ N
participants NNS N
received VBD N
3 CD N
face-to-face JJ N
sessions NNS N
and CC N
3 CD N
telephone NN N
sessions NNS N
during IN N
the DT N
first JJ N
6 CD N
months NNS N
of IN N
participation NN N
in IN N
the DT N
study NN N
, , N
but CC N
not RB N
the DT N
BCEI NNP N
intervention NN N
. . N

Research NNP N
questions NNS N
addressing VBG N
aim NN N
1 CD N
were VBD N
as IN N
follows VBZ N
: : N
( ( N
a DT N
) ) N
can MD N
rural VB N
breast NN N
cancer NN N
survivors NNS N
be VB N
recruited VBN N
into IN N
a DT N
longitudinal JJ N
intervention NN N
trial NN N
, , N
and CC N
( ( N
b NN N
) ) N
can MD N
their PRP$ N
participation NN N
be VB N
retained VBN N
. . N

Research NNP N
questions NNS N
for IN N
aim NN N
2 CD N
were VBD N
as IN N
follows VBZ N
: : N
( ( N
a DT N
) ) N
do VBP N
participants NNS N
who WP N
received VBD N
the DT N
BCEI NNP N
show NN N
improvement NN N
in IN N
overall JJ N
QOL NNP N
, , N
and CC N
( ( N
b NN N
) ) N
is VBZ N
the DT N
QOL NNP N
improvement NN N
sustained VBD N
over IN N
time NN N
. . N

Data NNS N
were VBD N
analyzed VBN N
using VBG N
repeated-measures JJ N
general JJ N
linear NN N
mixed JJ N
models NNS N
. . N

Results NNS N
demonstrated VBD N
the DT N
ability NN N
to TO N
recruit VB N
and CC N
retain VB N
53 CD N
rural JJ N
breast NN N
cancer NN N
survivors NNS N
, , N
that IN N
the DT N
experimental JJ N
arm NN N
showed VBD N
improvement NN N
in IN N
overall JJ N
QOL NNP N
( ( N
P NNP N
= NNP N
.013 NNP N
) ) N
, , N
and CC N
that IN N
there EX N
were VBD N
significant JJ N
differences NNS N
in IN N
overall JJ N
QOL NNP N
between IN N
the DT N
experimental JJ N
and CC N
wait-control JJ N
groups NNS N
at IN N
both DT N
months NNS N
3 CD N
and CC N
6 CD N
. . N

Thus RB N
, , N
it PRP N
appears VBZ N
that IN N
at IN N
least JJS N
some DT N
rural JJ N
breast NN N
cancer NN N
survivors NNS N
can MD N
and CC N
will MD N
participate VB N
in IN N
a DT N
larger JJR N
trial NN N
and CC N
will MD N
maintain VB N
their PRP$ N
participation NN N
and CC N
that IN N
those DT N
that WDT N
do VBP N
participate VB N
experience NN N
significant JJ N
QOL NNP N
benefit NN N
. . N

-DOCSTART- -X- O O 1376306

Induction NNP N
chemotherapy NN N
in IN N
head NN 4_p
and CC 4_p
neck NN 4_p
cancer NN 4_p
: : N
results NNS N
of IN N
a DT N
phase NN N
III NNP N
trial NN N
. . N

Between IN N
December NNP N
1982 CD N
and CC N
October NNP N
1986 CD N
, , N
131 CD N
patients NNS N
with IN N
stage JJ 4_p
II-III-IV NNP 4_p
squamous JJ 4_p
cell NN 4_p
carcinoma NN 4_p
of IN 4_p
the DT 4_p
oropharynx NN 4_p
or CC 4_p
oral JJ 4_p
cavity NN 4_p
were VBD N
randomized VBN N
to TO N
induction VB N
chemotherapy NN N
, , N
consisting VBG N
of IN N
bleomycin NN N
( ( N
10 CD N
mg/m2/day NN N
in IN N
continuous JJ N
infusion NN N
from IN N
day NN N
1 CD N
to TO N
day NN N
5 CD N
) ) N
, , N
methotrexate NN N
( ( N
120 CD N
mg/m2 NN N
on IN N
day NN N
2 CD N
) ) N
followed VBN N
by IN N
folinic JJ N
acid NN N
, , N
5-fluorouracil JJ N
( ( N
5 CD N
FU NNP N
) ) N
( ( N
600 CD N
mg/m2 NN N
on IN N
day NN N
2 CD N
) ) N
, , N
and CC N
cisplatin NN N
( ( N
120 CD N
mg/m2 NN N
on IN N
day NN N
4 CD N
) ) N
every DT N
4 CD N
weeks NNS N
for IN N
a DT N
total NN N
of IN N
three CD N
cycles NNS N
followed VBN N
by IN N
definitive JJ N
locoregional JJ N
treatment NN N
versus IN N
locoregional JJ N
treatment NN N
alone RB N
. . N

The DT N
modalities NNS N
of IN N
definitive JJ N
treatment NN N
( ( N
radiotherapy JJ N
+/- JJ N
surgery NN N
) ) N
were VBD N
chosen VBN N
prior RB N
to TO N
randomization NN N
. . N

A DT N
total NN N
of IN N
116 CD N
patients NNS N
were VBD N
evaluable JJ N
. . N

Of IN N
55 CD N
patients NNS N
in IN N
the DT N
chemotherapy NN N
arm NN N
, , N
four CD N
( ( N
7 CD N
% NN N
) ) N
had VBD N
a DT N
complete JJ N
response NN N
( ( N
CR NNP N
) ) N
and CC N
23 CD N
( ( N
42 CD N
% NN N
) ) N
a DT N
partial JJ N
response NN N
( ( N
PR NNP N
) ) N
following VBG N
the DT N
induction NN N
regimen NNS N
. . N

At IN N
the DT N
completion NN N
of IN N
locoregional JJ N
treatment NN N
, , N
76 CD N
% NN N
( ( N
42 CD N
of IN N
55 CD N
) ) N
of IN N
patients NNS N
in IN N
the DT N
experimental JJ N
group NN N
were VBD N
in IN N
CR NNP N
compared VBN N
to TO N
89 CD N
% NN N
( ( N
54 CD N
of IN N
61 CD N
) ) N
in IN N
the DT N
control NN N
group NN N
. . N

There EX N
was VBD N
no DT N
difference NN N
in IN N
survival NN N
, , N
cause-specific JJ N
survival NN N
, , N
and CC N
pattern NN N
of IN N
relapse NN N
between IN N
both DT N
groups NNS N
. . N

The DT N
median JJ N
survival NN N
was VBD N
22 CD N
months NNS N
in IN N
the DT N
chemotherapy NN N
group NN N
and CC N
29 CD N
months NNS N
in IN N
the DT N
control NN N
group NN N
. . N

Responders NNS N
to TO N
chemotherapy VB N
did VBD N
not RB N
fare VB N
better JJR N
than IN N
nonresponders NNS N
. . N

Chemotherapy-related JJ N
toxicities NNS N
were VBD N
few JJ N
and CC N
most JJS N
of IN N
them PRP N
related VBN N
to TO N
cisplatin VB N
which WDT N
was VBD N
reduced VBN N
to TO N
100 CD N
mg/m2 NN N
for IN N
35 CD N
patients NNS N
. . N

There EX N
were VBD N
no DT N
treatment-related JJ N
deaths NNS N
and CC N
, , N
in IN N
the DT N
experimental JJ N
arm NN N
of IN N
the DT N
trial NN N
, , N
no DT N
increased VBN N
morbidity NN N
from IN N
locoregional JJ N
treatment NN N
. . N

This DT N
induction NN N
regimen NN N
does VBZ N
not RB N
offer VB N
any DT N
advantages NNS N
over IN N
standard JJ N
treatment NN N
. . N

-DOCSTART- -X- O O 14616133

Mometasone NNP N
furoate NN N
nasal NN N
spray NN N
improves VBZ N
olfactory JJ N
performance NN N
in IN N
seasonal JJ 4_p
allergic JJ 4_p
rhinitis NN 4_p
. . N

-DOCSTART- -X- O O 10594393

Ursodeoxycholic JJ N
acid NN N
has VBZ N
no DT N
influence NN N
on IN N
function NN N
after IN N
restorative JJ N
proctocolectomy NN N
in IN N
ulcerative JJ 4_p
colitis NN 4_p
. . N

BACKGROUND NNP N
Poor NNP N
pouch JJ N
function NN N
is VBZ N
associated VBN N
with IN N
impaired JJ N
bile NN N
acid NN N
absorption NN N
and CC N
increased VBD N
faecal JJ N
loss NN N
of IN N
bile JJ N
acids NNS N
. . N

Bile NNP N
acid JJ N
replacement NN N
therapy NN N
might MD N
therefore RB N
be VB N
of IN N
clinical JJ N
benefit NN N
, , N
provided VBD N
that IN N
diarrhoea NN N
is VBZ N
not RB N
aggravated VBN N
by IN N
therapy NN N
. . N

AIM NNP N
To TO N
investigate VB N
the DT N
role NN N
of IN N
exogenous JJ N
bile NN N
acid NN N
therapy NN N
in IN N
patients NNS 4_p
with IN 4_p
poor JJ 4_p
pouch JJ 4_p
function NN 4_p
after IN N
restorative JJ N
proctocolectomy NN N
for IN N
ulcerative JJ N
colitis NN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
Twenty NNP N
ulcerative JJ 4_p
colitis NN 4_p
patients NNS N
with IN N
poor JJ 4_p
pouch JJ 4_p
function NN 4_p
( ( N
score NN N
> VBZ N
4 CD N
on IN N
a DT N
12-point JJ N
score NN N
) ) N
were VBD N
recruited VBN N
for IN N
inclusion NN N
to TO N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
crossover NN N
, , N
placebo-controlled JJ N
trial NN N
of IN N
ursodeoxycholic JJ N
acid NN N
( ( N
10 CD N
mg/kg NNS N
per IN N
day NN N
in IN N
two CD N
divided JJ N
doses NNS N
for IN N
1 CD N
month NN N
) ) N
. . N

RESULTS VB N
A DT N
total NN N
of IN N
16 CD N
patients NNS N
completed VBD N
the DT N
study NN N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
functional JJ N
score NN N
or CC N
bowel NN N
frequency NN N
following VBG N
treatment NN N
irrespective NN N
of IN N
whether IN N
the DT N
active JJ N
treatment NN N
was VBD N
given VBN N
before IN N
or CC N
after IN N
placebo NN N
. . N

CONCLUSIONS NNP N
We PRP N
conclude VBP N
that IN N
ursodeoxycholic JJ N
acid NN N
given VBN N
over IN N
4 CD N
weeks NNS N
had VBD N
no DT N
influence NN N
on IN N
functional JJ N
score NN N
or CC N
bowel NN N
frequency NN N
after IN N
restorative JJ N
proctocolectomy NN N
for IN N
U.C NNP N
. . N

-DOCSTART- -X- O O 17597498

Improvement NN N
in IN N
sensory JJ N
impairment NN N
and CC N
social JJ N
interaction NN N
in IN N
young JJ N
children NNS N
with IN N
autism NN N
following VBG N
treatment NN N
with IN N
an DT N
original JJ N
Qigong NNP N
massage NN N
methodology NN N
. . N

In IN N
clinical JJ N
research NN N
, , N
sensory JJ N
impairment NN N
is VBZ N
considered VBN N
one CD N
of IN N
the DT N
core NN N
deficits NNS N
in IN N
autism NN N
and CC N
is VBZ N
associated VBN N
with IN N
impaired JJ N
socialization NN N
, , N
behavioral JJ N
disturbances NNS N
and CC N
bowel NN N
and CC N
sleep JJ N
problems NNS N
. . N

The DT N
effectiveness NN N
of IN N
the DT N
Cignolini NNP N
methodology NN N
, , N
an DT N
original JJ N
Qigong NNP N
massage NN N
methodology NN N
, , N
in IN N
treating VBG N
sensory JJ 4_p
impairment NN 4_p
in IN 4_p
young JJ 4_p
children NNS 4_p
with IN N
autism NN N
was VBD N
evaluated VBN N
in IN N
a DT N
small JJ N
, , N
controlled VBN N
study NN N
. . N

Thirteen NNP N
children NNS N
with IN 4_p
autism NN 4_p
between IN N
the DT N
ages NNS N
of IN N
three CD N
and CC N
six CD N
received VBD N
daily JJ N
treatment NN N
according VBG N
to TO N
the DT N
methodology NN N
for IN N
5 CD N
months NNS N
. . N

Compared VBN N
with IN N
untreated JJ N
children NNS N
, , N
treated VBD N
children NNS N
experienced VBD N
significant JJ N
improvement NN N
of IN N
their PRP$ N
sensory JJ N
impairment NN N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
, , N
and CC N
demonstrated VBD N
increased VBN N
social JJ N
skills NNS N
( ( N
p JJ N
< NNP N
0.04 CD N
) ) N
and CC N
basic JJ N
living NN N
skills NNS N
( ( N
p JJ N
< NNP N
0.02 CD N
) ) N
on IN N
standardized JJ N
measures NNS N
. . N

In IN N
addition NN N
, , N
all DT N
of IN N
the DT N
children NNS N
with IN N
bowel NN N
and CC N
sleep JJ N
abnormalities NNS N
demonstrated VBD N
improvement NN N
after IN N
treatment NN N
. . N

-DOCSTART- -X- O O 8478759

Comparison NNP N
of IN N
rectal JJ N
midazolam NN N
and CC N
diazepam NN N
for IN N
premedication NN N
in IN N
pediatric JJ N
dental JJ 4_p
patients NNS 4_p
. . N

Rectally RB N
administered VBN N
midazolam NN N
( ( N
0.35 CD N
mg/kg NN N
) ) N
and CC N
diazepam NN N
( ( N
0.70 CD N
mg/kg NN N
) ) N
were VBD N
compared VBN N
with IN N
each DT N
other JJ N
and CC N
with IN N
placebo NN N
for IN N
preanesthetic JJ N
medication NN N
in IN N
children NNS N
undergoing VBG 4_p
dental JJ 4_p
extractions NNS 4_p
. . N

All DT N
rectal JJ N
medications NNS N
were VBD N
very RB N
well RB N
accepted VBN N
, , N
but CC N
mask JJ N
acceptance NN N
, , N
improvement NN N
in IN N
anxiety NN N
, , N
and CC N
sedation NN N
were VBD N
best RBS N
in IN N
the DT N
midazolam NN N
group NN N
. . N

Improvement NNP N
in IN N
anxiety NN N
and CC N
sedation NN N
were VBD N
significantly RB N
better RBR N
in IN N
the DT N
two CD N
drug NN N
groups NNS N
than IN N
in IN N
those DT N
patients NNS N
who WP N
had VBD N
received VBN N
placebo NN N
. . N

Thirty NNP N
minutes NNS N
after IN N
rectal JJ N
administration NN N
of IN N
midazolam NNS N
, , N
patients NNS N
showed VBD N
a DT N
decrease NN N
in IN N
both DT N
systolic JJ N
and CC N
diastolic JJ N
blood NN N
pressure NN N
and CC N
heart NN N
rate NN N
. . N

Although IN N
these DT N
decreases NNS N
differed VBD N
significantly RB N
from IN N
the DT N
premedication NN N
values NNS N
, , N
they PRP N
were VBD N
probably RB N
of IN N
little JJ N
clinical JJ N
importance NN N
. . N

Only RB N
minor JJ N
adverse JJ N
effects NNS N
were VBD N
observed VBN N
in IN N
this DT N
study NN N
. . N

Overall NNP N
rectally RB N
administered VBD N
midazolam NNS N
appeared VBD N
to TO N
be VB N
somewhat RB N
more RBR N
efficacious JJ N
than IN N
diazepam NN N
. . N

-DOCSTART- -X- O O 12551867

Acute NNP N
intravenous JJ N
L-arginine JJ N
infusion NN N
decreases VBZ N
endothelin-1 JJ N
levels NNS N
and CC N
improves VBZ N
endothelial JJ N
function NN N
in IN N
patients NNS N
with IN N
angina JJ 4_p
pectoris NN 4_p
and CC N
normal JJ N
coronary JJ N
arteriograms NNS 4_p
: : N
correlation NN N
with IN N
asymmetric JJ N
dimethylarginine NN N
levels NNS N
. . N

BACKGROUND NNP N
We PRP N
tested VBD N
the DT N
hypothesis NN N
that WDT N
asymmetric JJ N
dimethylarginine NN N
( ( N
ADMA NNP N
) ) N
levels NNS N
could MD N
be VB N
elevated VBN N
and CC N
influence VB N
endothelin-1 JJ N
and CC N
nitric JJ N
oxide NN N
release NN N
and CC N
action NN N
in IN N
patients NNS N
with IN N
cardiac JJ 4_p
syndrome NN 4_p
X NNP 4_p
( ( N
CSX NNP N
) ) N
. . N

In IN N
addition NN N
, , N
we PRP N
evaluated VBD N
whether IN N
an DT N
intravenous JJ N
infusion NN N
of IN N
L-arginine NNP N
would MD N
improve VB N
endothelial JJ N
function NN N
in IN N
these DT N
subjects NNS N
. . N

METHODS NNP N
AND CC N
RESULTS NNP N
Nine NNP N
patients NNS N
with IN N
CSX NNP N
and CC N
14 CD N
control NN N
subjects NNS N
underwent VBD N
a DT N
continuous JJ N
infusion NN N
of IN N
L-arginine NNP N
( ( N
0.125 CD N
g/min NN N
) ) N
or CC N
saline NN N
for IN N
120 CD N
minutes NNS N
. . N

Sixty NNP N
minutes NNS N
after IN N
L-arginine NNP N
or CC N
saline JJ N
infusions NNS N
, , N
an DT N
intravenous JJ N
insulin NN N
bolus NN N
( ( N
0.1 CD N
U/kg NNP N
) ) N
combined VBD N
with IN N
a DT N
euglycemic JJ N
clamp NN N
was VBD N
performed VBN N
. . N

Basal NNP N
ADMA NNP N
and CC N
endothelin-1 JJ N
levels NNS N
were VBD N
higher JJR N
in IN N
patients NNS N
with IN N
CSX NNP N
than IN N
in IN N
controls NNS N
. . N

At IN N
the DT N
end NN N
of IN N
the DT N
first JJ N
hour NN N
of IN N
infusion NN N
, , N
compared VBN N
with IN N
saline NN N
, , N
L-arginine JJ N
infusion NN N
increased VBD N
basal JJ N
forearm NN N
blood NN N
flow NN N
, , N
nitrite JJ N
and CC N
nitrate JJ N
( ( N
NOx NNP N
) ) N
, , N
and CC N
forearm NN N
cGMP NN N
release NN N
and CC N
decreased VBD N
endothelin-1 NN N
. . N

After IN N
insulin NN N
bolus NN N
, , N
during IN N
saline NN N
, , N
insulin-induced JJ N
NOx NNP N
, , N
endothelin-1 JJ N
, , N
and CC N
forearm NN N
cGMP NN N
release NN N
was VBD N
almost RB N
abolished VBN N
. . N

Conversely RB N
, , N
L-arginine NNP N
restored VBD N
a DT N
physiological JJ N
profile NN N
of IN N
all DT N
endothelial JJ N
variables NNS N
compared VBN N
with IN N
control NN N
subjects NNS N
. . N

In IN N
control NN N
subjects NNS N
, , N
compared VBN N
with IN N
saline JJ N
infusion NN N
, , N
L-arginine JJ N
infusion NN N
did VBD N
not RB N
modify VB N
any DT N
parameter NN N
. . N

ADMA NNP N
levels NNS N
were VBD N
positively RB N
correlated VBN N
with IN N
basal JJ N
endothelin-1 JJ N
levels NNS N
and CC N
negatively RB N
correlated VBN N
with IN N
insulin-induced JJ N
incremental JJ N
levels NNS N
of IN N
NOx NNP N
and CC N
forearm NN N
cGMP NN N
release NN N
. . N

CONCLUSIONS NNP N
Plasma NNP N
ADMA NNP N
levels NNS N
are VBP N
increased VBN N
in IN N
patients NNS N
with IN N
CSX NNP N
, , N
and CC N
they PRP N
are VBP N
correlated VBN N
with IN N
increases NNS N
in IN N
endothelin-1 JJ N
and CC N
reductions NNS N
in IN N
insulin-induced JJ N
increments NNS N
in IN N
plasma NN N
NOx NNP N
and CC N
cGMP NN N
, , N
effects NNS N
that WDT N
are VBP N
reversed VBN N
by IN N
intravenous JJ N
L-arginine NNP N
. . N

These DT N
data NNS N
suggest VBP N
that IN N
increased VBD N
ADMA NNP N
levels NNS N
play VBP N
a DT N
role NN N
in IN N
the DT N
abnormal JJ N
vascular JJ N
reactivity NN N
that WDT N
is VBZ N
observed VBN N
in IN N
patients NNS N
with IN N
CSX NNP N
. . N

-DOCSTART- -X- O O 8374255

Torasemide NNP N
versus NN N
furosemide NN N
in IN N
cirrhosis NN N
: : N
a DT N
long-term JJ N
, , N
double-blind JJ N
, , N
randomized JJ N
clinical JJ N
study NN N
. . N

The DT N
effects NNS N
of IN N
long-term JJ N
therapy NN N
( ( N
70 CD N
days NNS N
) ) N
with IN N
torasemide NN N
( ( N
20 CD N
mg/day NN N
) ) N
, , N
a DT N
new JJ N
loop NN N
diuretic JJ N
, , N
were VBD N
compared VBN N
with IN N
those DT N
of IN N
furosemide NN N
( ( N
50 CD N
mg/day NN N
) ) N
in IN N
a DT N
randomized JJ N
double-blind JJ N
trial NN N
. . N

Both DT N
drugs NNS N
were VBD N
administered VBN N
in IN N
association NN N
with IN N
spironolactone NN N
( ( N
200 CD N
mg/day NN N
) ) N
in IN N
28 CD N
nonazotemic JJ N
cirrhotic JJ N
patients NNS N
with IN N
controlled JJ N
ascites NNS N
. . N

The DT N
treatments NNS N
did VBD N
not RB N
modify VB N
creatinine JJ N
clearance NN N
and CC N
exhibited VBD N
a DT N
similar JJ N
effect NN N
on IN N
body NN N
weight NN N
, , N
urinary JJ N
volume NN N
, , N
and CC N
fractional JJ N
excretion NN N
of IN N
uric JJ N
acid NN N
, , N
sodium NN N
, , N
and CC N
chloride NN N
. . N

The DT N
effect NN N
of IN N
torasemide NN N
on IN N
fractional JJ N
potassium NN N
excretion NN N
was VBD N
lower JJR N
than IN N
that DT N
of IN N
furosemide NN N
. . N

Torasemide VB N
showed VBD N
higher JJR N
sparing VBG N
effect NN N
than IN N
furosemide NN N
on IN N
calcium NN N
, , N
inorganic JJ N
phosphate NN N
, , N
and CC N
magnesium NN N
excretion NN N
and CC N
stronger JJR N
action NN N
on IN N
free JJ N
water NN N
clearance NN N
. . N

No DT N
changes NNS N
in IN N
serum NN N
parameters NNS N
were VBD N
induced VBN N
by IN N
either DT N
treatment NN N
. . N

Two CD N
episodes NNS N
of IN N
hepatic JJ N
encephalopathy NN N
occurred VBD N
in IN N
the DT N
torasemide NN N
group NN N
. . N

In IN N
view NN N
of IN N
its PRP$ N
effects NNS N
on IN N
sodium NN N
and CC N
water NN N
excretion NN N
and CC N
on IN N
other JJ N
urinary JJ N
parameters NNS N
, , N
torasemide NN N
can MD N
represent VB N
an DT N
alternative JJ N
tool NN N
for IN N
the DT N
long-term JJ N
treatment NN N
of IN N
ascites NNS N
. . N

-DOCSTART- -X- O O 23808817

Patient JJ N
satisfaction NN N
with IN N
nutrition NN N
services NNS N
amongst JJ N
cancer NN 4_p
patients NNS 4_p
treated VBN 4_p
with IN 4_p
autologous JJ 4_p
stem NN 4_p
cell NN 4_p
transplantation NN 4_p
: : N
a DT N
comparison NN N
of IN N
usual JJ N
and CC N
extended JJ N
care NN N
. . N

BACKGROUND NNP N
This DT N
study NN N
aimed VBD N
to TO N
determine VB N
patient JJ N
satisfaction NN N
with IN N
clinical JJ N
nutrition NN N
services NNS N
delivered VBN N
by IN N
an DT N
accredited JJ N
practicing NN N
dietitian JJ N
amongst NN N
cancer NN 4_p
patients NNS 4_p
treated VBN 4_p
with IN 4_p
autologous JJ 4_p
stem NN 4_p
cell NN 4_p
transplantation NN 4_p
that WDT N
was VBD N
provided VBN N
with IN N
usual JJ N
and CC N
extended VBD N
care NN N
at IN N
100 CD N
days NNS N
post-transplantation NN N
. . N

METHODS JJ N
Patients NNPS N
were VBD N
randomised VBN N
to TO N
receive VB N
usual JJ N
nutrition NN N
care NN N
or CC N
extended VBN N
nutrition NN N
care NN N
during IN N
the DT N
course NN N
of IN N
their PRP$ N
stem NN N
cell NN N
transplantation NN N
. . N

After IN N
hospital JJ N
discharge NN N
, , N
usual JJ N
care NN N
patients NNS N
received VBD N
no DT N
further JJ N
nutrition NN N
support NN N
, , N
whereas RB N
extended VBN N
care NN N
patients NNS N
received VBD N
telephone NN N
dietary JJ N
counselling NN N
from IN N
the DT N
same JJ N
dietitian NN N
for IN N
up IN N
to TO N
100 CD N
days NNS N
post-transplantation NN N
. . N

The DT N
patient JJ N
satisfaction NN N
with IN N
clinical JJ N
nutrition NN N
service NN N
questionnaire NN N
was VBD N
completed VBN N
anonymously RB N
at IN N
100 CD N
days NNS N
post-transplantation NN N
. . N

Group NNP N
comparisons NNS N
were VBD N
made VBN N
using VBG N
independent JJ N
t-tests NNS N
. . N

RESULTS NNP N
Thirty-seven JJ N
patients NNS N
consented VBN N
to TO N
participate VB N
in IN N
the DT N
study NN N
( ( N
54 CD N
% NN N
male NN N
; : N
mean JJ N
age NN N
58.7 CD N
± JJ N
9.5 CD N
years NNS N
; : N
median JJ 4_p
body NN 4_p
mass NN 4_p
index NN 4_p
26.8 CD 4_p
kg NN 4_p
m NN 4_p
( ( 4_p
-2 NNP 4_p
) ) N
, , N
range VBP 4_p
16.4-47.6 JJ 4_p
kg NN 4_p
m NN 4_p
( ( 4_p
-2 NNP 4_p
) ) 4_p
) ) 4_p
; : N
33 CD N
patients NNS N
completed VBD N
the DT N
study NN N
and CC N
28 CD N
patients NNS N
returned VBD N
the DT N
questionnaire NN N
( ( N
response NN N
rate NN N
= VBD N
85 CD N
% NN N
) ) N
. . N

All DT N
components NNS N
of IN N
the DT N
questionnaire NN N
were VBD N
rated VBN N
highly RB N
by IN N
both DT N
groups NNS N
; : N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
groups NNS N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

Although IN N
not RB N
statistically RB N
significant JJ N
, , N
extended VBD N
care NN N
patients NNS N
who WP N
received VBD N
at IN N
least JJS N
three CD N
telephone NN N
calls VBZ N
rated VBN N
a DT N
higher JJR N
overall JJ N
satisfaction NN N
compared VBN N
to TO N
those DT N
who WP N
received VBD N
less JJR N
calls NNS N
; : N
this DT N
difference NN N
was VBD N
clinically RB N
important JJ N
( ( N
score JJ N
difference NN 4_p
= NNP 4_p
0.56 CD 4_p
) ) N
. . N

CONCLUSIONS NNP N
Cancer NNP 4_p
patients NNS 4_p
treated VBD 4_p
with IN 4_p
autologous JJ 4_p
stem NN 4_p
cell NN 4_p
transplantation NN N
were VBD N
satisfied VBN N
with IN N
usual JJ N
and CC N
extended JJ 4_p
nutrition NN 4_p
care NN 4_p
. . N

Extended NNP N
care NN N
patients NNS N
who WP N
received VBD N
at IN N
least JJS N
three CD N
telephone NN N
calls VBZ N
after IN N
hospital NN N
discharge NN N
were VBD N
more JJR N
satisfied JJ N
than IN N
those DT N
with IN N
less JJR N
frequent JJ N
intervention NN N
. . N

Further JJ N
exploration NN N
regarding VBG N
the DT N
frequency NN N
and CC N
intensity NN N
of IN N
nutrition NN N
service NN N
is VBZ N
required VBN N
. . N

-DOCSTART- -X- O O 1853794

A DT N
comparison NN N
of IN N
single-dose JJ N
versus NN N
conventional-dose JJ N
antibiotic JJ N
treatment NN N
of IN N
bacteriuria NN N
in IN N
elderly JJ N
women NNS N
. . N

The DT N
efficacy NN N
of IN N
single-dose JJ N
antibiotic JJ N
therapy NN N
for IN N
the DT N
treatment NN N
of IN N
bacteriuria NN N
in IN N
a DT N
group NN N
of IN N
non-catheterized JJ N
elderly JJ N
women NNS N
was VBD N
compared VBN N
with IN N
that DT N
of IN N
conventional JJ N
7-10 JJ N
day NN N
courses NNS N
of IN N
antibiotic JJ N
therapy NN N
. . N

Thirty-one JJ N
women NNS N
received VBD N
single-dose JJ N
treatment NN N
and CC N
22 CD N
conventional-dose JJ N
treatment NN N
. . N

The DT N
cure NN N
rates NNS N
at IN N
1 CD N
and CC N
6 CD N
weeks NNS N
for IN N
the DT N
single-dose JJ N
treatments NNS N
were VBD N
52 CD N
% NN N
and CC N
38 CD N
% NN N
, , N
respectively RB N
, , N
and CC N
the DT N
cure NN N
rates NNS N
for IN N
the DT N
conventional-dose JJ N
treatments NNS N
at IN N
1 CD N
and CC N
6 CD N
weeks NNS N
were VBD N
59 CD N
% NN N
and CC N
52 CD N
% NN N
, , N
respectively RB N
. . N

It PRP N
is VBZ N
concluded VBN N
that IN N
there EX N
may MD N
be VB N
a DT N
place NN N
for IN N
the DT N
use NN N
of IN N
single-dose JJ N
antibiotic JJ N
therapy NN N
for IN N
the DT N
treatment NN N
of IN N
selected VBN N
elderly JJ N
women NNS N
with IN N
bacteriuria NN N
, , N
but CC N
larger JJR N
studies NNS N
are VBP N
needed VBN N
. . N

-DOCSTART- -X- O O 26678641

Efficacy NN N
of IN N
colchicine NN N
versus NN N
placebo NN N
for IN N
the DT N
treatment NN N
of IN N
pericardial JJ 4_p
effusion NN 4_p
after IN N
open-heart JJ 4_p
surgery NN 4_p
: : N
A DT N
randomized JJ N
, , N
placebo-controlled JJ N
trial NN N
. . N

BACKGROUND NNP N
Pericardial NNP 4_p
effusion NN 4_p
( ( 4_p
PE NNP 4_p
) ) 4_p
, , N
a DT N
common JJ N
complication NN N
after IN N
open-heart JJ N
surgery NN N
, , N
accounts NNS N
for IN N
50 CD N
% NN N
to TO N
85 CD N
% NN N
of IN N
patients NNS N
. . N

Although IN N
reversible JJ N
in IN N
most JJS N
of IN N
the DT N
cases NNS N
, , N
it PRP N
could MD N
be VB N
life NN N
threatening VBG N
in IN N
the DT N
occurrence NN N
of IN N
tamponade NN N
in IN N
large JJ N
effusions NNS N
. . N

We PRP N
aimed VBD N
to TO N
determine VB N
the DT N
therapeutic JJ N
efficacy NN N
of IN N
colchicine NN N
on IN N
PE NNP 4_p
after IN N
open-heart JJ 4_p
surgery NN 4_p
. . N

METHODS NNP N
The DT N
study NN N
is VBZ N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
triple-blind JJ N
, , N
placebo-controlled JJ N
single-center JJ N
trial NN N
at IN N
Tehran NNP N
Heart NNP N
Center NNP N
. . N

A NNP N
total NN N
of IN N
149 CD N
patients NNS N
with IN N
mild JJ 4_p
or CC 4_p
moderate JJ 4_p
PE NNP 4_p
in IN N
transthoracic NN N
echocardiography NN N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
1 CD N
mg/d NNS N
colchicine NN N
( ( N
n JJ N
= NNP N
74 CD N
) ) N
or CC N
1 CD N
tablet NN N
of IN N
placebo NN N
( ( N
n JJ N
= NNP N
75 CD N
) ) N
for IN N
2 CD N
weeks NNS N
and CC N
then RB N
underwent JJ N
follow-up JJ N
echocardiography NN N
. . N

RESULTS NNP N
Baseline NNP N
and CC N
clinical JJ N
characteristics NNS N
were VBD N
not RB N
significantly RB N
different JJ N
between IN N
the DT N
2 CD N
study NN N
groups NNS N
except IN N
for IN N
age NN N
( ( N
P NNP N
= NNP N
.02 NNP N
) ) N
and CC N
graft JJ N
numbers NNS N
( ( N
P NNP N
= NNP N
.005 NNP N
) ) N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
pretreatment NN N
and CC N
posttreatment NN N
PE NNP N
sizes VBZ N
between IN N
the DT N
2 CD N
study NN N
groups NNS N
( ( N
P NNP N
= NNP N
.440 NNP N
and CC N
.844 NNP N
, , N
respectively RB N
) ) N
. . N

Median JJ N
( ( N
25th-75th JJ N
percentiles NNS N
) ) N
of IN N
effusion NN N
changes NNS N
was VBD N
5 CD N
mm NN N
( ( N
1-7.6 JJ N
mm NN N
) ) N
in IN N
the DT N
colchicine NN N
group NN N
and CC N
5 CD N
mm NN N
( ( N
1-6.6 JJ N
mm NN N
) ) N
in IN N
the DT N
placebo NN N
group NN N
( ( N
P NNP N
= NNP N
.932 NNP N
) ) N
. . N

Intervention NNP N
had VBD N
no DT N
significant JJ N
impact NN N
on IN N
pretreatment NN N
and CC N
posttreatment JJ N
effusion NN N
values NNS N
and CC N
changes NNS N
in IN N
isolated JJ N
coronary JJ N
artery NN N
bypass NN N
graft NN N
surgery NN N
patients NNS N
( ( N
P NNP N
= NNP N
.607 NNP N
, , N
.539 NNP N
, , N
and CC N
.628 NNP N
, , N
respectively RB N
) ) N
. . N

After IN N
adjustment NN N
for IN N
possible JJ N
confounders NNS N
, , N
there EX N
was VBD N
still RB N
no DT N
significant JJ N
difference NN N
in IN N
postoperative JJ N
PE NNP N
between IN N
the DT N
2 CD N
study NN N
groups NNS N
( ( N
t JJ N
= NNP N
-0.285 NNP N
, , N
P NNP N
= NNP N
.776 NNP N
) ) N
. . N

CONCLUSION NNP N
We PRP N
concluded VBD N
that IN N
prescription NN N
of IN N
colchicine NN N
does VBZ N
not RB N
seem VB N
to TO N
be VB N
effective JJ N
in IN N
treatment NN N
of IN N
asymptomatic JJ N
postoperative JJ N
PE NNP 4_p
. . N

This DT N
could MD N
be VB N
justified VBN N
in IN N
case NN N
that IN N
the DT N
etiology NN N
of IN N
most JJS N
of IN N
the DT N
PEs NNP 4_p
might MD N
be VB N
contribution NN N
of IN N
noninflammatory JJ N
factors NNS N
which WDT N
are VBP N
better JJR N
to TO N
be VB N
dealt VBN N
with IN N
observational JJ N
approaches NNS N
. . N

-DOCSTART- -X- O O 15541087

Pimecrolimus NNP N
cream VBZ N
1 CD N
% NN N
vs. FW N
betamethasone CD N
17-valerate JJ N
0.1 CD N
% NN N
cream NN N
in IN N
the DT N
treatment NN N
of IN N
seborrhoeic JJ N
dermatitis NN N
. . N

A DT N
randomized JJ N
open-label JJ N
clinical JJ N
trial NN N
. . N

BACKGROUND NNP N
Seborrhoeic NNP N
dermatitis NN N
is VBZ N
a DT N
chronic JJ N
inflammatory NN N
disease NN N
with IN N
remissions NNS N
and CC N
exacerbations NNS N
, , N
characterized VBN N
by IN N
erythema NN N
, , N
scaling VBG N
and CC N
pruritus JJ N
primarily RB N
on IN N
the DT N
face NN N
, , N
scalp NN N
and CC N
chest NN N
. . N

Corticosteroids NNP N
and CC N
antifungals NNS N
are VBP N
the DT N
mainstay NN N
of IN N
therapy NN N
. . N

However RB N
, , N
chronic JJ N
use NN N
of IN N
corticosteroids NNS N
is VBZ N
associated VBN N
with IN N
side-effects NNS N
such JJ N
as IN N
skin JJ N
atrophy NN N
and CC N
telangiectasia NN N
. . N

Pimecrolimus NNP N
, , N
an DT N
inhibitor NN N
of IN N
calcineurin NN N
, , N
has VBZ N
been VBN N
used VBN N
successfully RB N
in IN N
one CD N
patient NN N
with IN N
seborrhoeic JJ N
dermatitis NN N
. . N

OBJECTIVES CC N
The DT N
objective NN N
of IN N
this DT N
randomized VBN N
open-label JJ N
clinical JJ N
trial NN N
was VBD N
to TO N
compare VB N
the DT N
efficacy NN N
and CC N
tolerability NN N
of IN N
pimecrolimus NN N
in IN N
comparison NN N
with IN N
a DT N
potent NN N
corticosteroid NN N
( ( N
betamethasone CD N
17-valerate NN N
) ) N
in IN N
the DT N
treatment NN N
of IN N
seborrhoeic JJ N
dermatitis NN N
. . N

METHODS NNP N
Twenty NNP N
patients NNS N
with IN N
seborrhoeic JJ N
dermatitis NN N
were VBD N
included VBN N
in IN N
this DT N
study NN N
, , N
11 CD N
patients NNS N
in IN N
the DT N
pimecrolimus JJ N
1 CD N
% NN N
cream NN N
group NN N
and CC N
nine CD N
patients NNS N
in IN N
the DT N
betamethasone NN N
17-valerate JJ N
0.1 CD N
% NN N
cream NN N
group NN N
. . N

Patients NNS N
were VBD N
instructed VBN N
to TO N
use VB N
a DT N
thin JJ N
layer NN N
of IN N
the DT N
study NN N
products NNS N
twice RB N
daily RB N
at IN N
the DT N
lesional JJ N
area NN N
and CC N
to TO N
discontinue VB N
treatment NN N
as RB N
soon RB N
as IN N
symptoms NNS N
were VBD N
absent JJ N
. . N

Clinical JJ N
measures NNS N
assessed VBN N
were VBD N
erythema RB N
, , N
scaling VBG N
and CC N
pruritus NN N
which WDT N
were VBD N
evaluated VBN N
using VBG N
a DT N
four-point JJ N
scale NN N
( ( N
0-3 JJ N
) ) N
. . N

RESULTS NNP N
Both NNP N
pimecrolimus FW N
and CC N
betamethasone NN N
were VBD N
highly RB N
effective JJ N
in IN N
the DT N
treatment NN N
of IN N
seborrhoeic JJ N
dermatitis NN N
. . N

Betamethasone NNP N
reduced VBD N
all DT N
three CD N
parameters NNS N
, , N
erythema NN N
, , N
scaling VBG N
and CC N
pruritus NN N
, , N
faster JJR N
than IN N
pimecrolimus NN N
, , N
but CC N
the DT N
differences NNS N
in IN N
reduction NN N
were VBD N
not RB N
statistically RB N
significant JJ N
. . N

Relapses NNS N
were VBD N
observed VBN N
more RBR N
frequently RB N
and CC N
were VBD N
more JJR N
severe JJ N
with IN N
betamethasone NN N
than IN N
with IN N
pimecrolimus NN N
. . N

Moreover RB N
, , N
pruritus NN N
was VBD N
not RB N
observed VBN N
after IN N
discontinuation NN N
of IN N
treatment NN N
from IN N
day NN N
15 CD N
and CC N
beyond IN N
in IN N
the DT N
pimecrolimus NN N
group NN N
, , N
whereas IN N
it PRP N
was VBD N
reported VBN N
in IN N
most JJS N
patients NNS N
of IN N
the DT N
betamethasone NN N
group NN N
. . N

This DT N
difference NN N
was VBD N
statistically RB N
significant JJ N
. . N

CONCLUSIONS VB N
It PRP N
appears VBZ N
that IN N
pimecrolimus NN N
, , N
a DT N
nonsteroidal JJ N
topical JJ N
treatment NN N
, , N
may MD N
be VB N
an DT N
excellent JJ N
alternative JJ N
therapeutic JJ N
modality NN N
for IN N
treating VBG N
seborrhoeic JJ N
dermatitis NN N
. . N

-DOCSTART- -X- O O 17149529

Further JJ N
validation NN N
of IN N
the DT N
alcohol NN N
dependence NN N
scale NN N
as IN N
an DT N
index NN N
of IN N
severity NN N
. . N

OBJECTIVE CC N
The DT N
Alcohol NNP N
Dependence NNP N
Scale NNP N
( ( N
ADS NNP N
) ) N
yields VBZ N
continuous JJ N
scores NNS N
purported VBN N
to TO N
reflect VB N
the DT N
severity NN N
of IN N
the DT N
dependence NN N
syndrome NN N
. . N

We PRP N
evaluated VBD N
the DT N
concurrent JJ N
validity NN N
of IN N
the DT N
ADS NNP N
as IN N
a DT N
general JJ N
measure NN N
of IN N
severity NN N
and CC N
the DT N
screening VBG N
accuracy NN N
of IN N
the DT N
total JJ N
score NN N
and CC N
subscales NNS N
to TO N
detect VB N
Diagnostic NNP N
and CC N
Statistical NNP N
Manual NNP N
of IN N
Mental NNP N
Disorders NNP N
, , N
Fourth NNP N
Edition NNP N
( ( N
DSM-IV NNP N
) ) N
, , N
physiological JJ N
dependence NN N
. . N

METHOD NNP N
Treatment-seeking JJ N
, , N
alcohol-dependent JJ 4_p
individuals NNS N
entering VBG N
the DT N
Combining NNP N
Pharmacotherapies NNPS N
and CC N
Behavioral NNP N
Interventions NNP N
for IN N
Alcohol NNP 4_p
Dependence NNP 4_p
( ( N
COMBINE NNP N
) ) N
Study NNP N
( ( N
N NNP N
= NNP N
1,372 CD N
; : N
69 CD N
% NN N
men NNS N
) ) N
completed VBD N
the DT N
ADS NNP N
, , N
diagnostic JJ N
interviews NNS N
, , N
and CC N
other JJ N
measures NNS N
before IN N
randomization NN N
. . N

Analyses NNS N
of IN N
variance NN N
tested VBN N
differences NNS N
between IN N
ADS NNP N
quartiles NNS N
on IN N
alcohol- JJ N
related JJ N
measures NNS N
. . N

Areas NNP N
under IN N
the DT N
receiver NN N
operating VBG N
characteristic JJ N
( ( N
AUROC NNP N
) ) N
curve NN N
assessed VBD N
screening VBG N
accuracy NN N
for IN N
DSM-IV NNP N
physiological JJ N
dependence NN N
( ( N
tolerance NN N
or CC N
withdrawal NN N
) ) N
or CC N
withdrawal VB N
alone RB N
. . N

RESULTS NNP N
ADS NNP N
quartiles VBZ N
differed VBN N
on IN N
age NN N
, , N
other JJ N
demographics NNS N
, , N
and CC N
prior RB N
treatment NN N
episodes NNS N
. . N

Linear JJ N
correlation NN N
showed VBD N
moderate JJ N
to TO N
large JJ N
magnitude NN N
associations NNS N
with IN N
alcohol-related JJ N
self-report JJ N
measures NNS N
and CC N
most JJS N
indices NNS N
of IN N
consumption NN N
. . N

ADS NNP N
quartiles NNS N
differed VBD N
significantly RB N
on IN N
proportion NN N
with IN N
DSM-IV NNP N
physiological JJ N
dependence NN N
, , N
but CC N
AUROC NNP N
curves NNS N
indicated VBD N
that IN N
the DT N
ADS NNP N
had VBD N
limited VBN N
accuracy NN N
as IN N
a DT N
continuous JJ N
measure NN N
to TO N
detect VB N
DSMIV NNP N
physiological JJ N
dependence NN N
( ( N
AUROC NNP N
= NNP N
.75 NNP N
[ VBD N
95 CD N
% NN N
confidence NN N
interval NN N
{ ( N
CI NNP N
} ) N
: : N
.70-.79 JJ N
] NN N
and CC N
.67 NNP N
[ VBP N
95 CD N
% NN N
CI NNP N
: : N
.60-.74 JJ N
] NN N
for IN N
men NNS N
and CC N
women NNS N
, , N
respectively RB N
; : N
p CC N
= NNP N
.08 NNP N
) ) N
or CC N
withdrawal VB N
alone RB N
( ( N
AUROC NNP N
= NNP N
.77 NNP N
[ VBD N
95 CD N
% NN N
CI NNP N
: : N
.74-.80 JJ N
] NN N
and CC N
.74 NNP N
[ VBP N
95 CD N
% NN N
CI NNP N
: : N
.69-.79 JJ N
] NN N
for IN N
men NNS N
and CC N
women NNS N
, , N
respectively RB N
; : N
p CC N
= NNP N
.30 NNP N
) ) N
. . N

Screening VBG N
accuracy NN N
was VBD N
comparably RB N
limited VBN N
based VBN N
on IN N
ADS NNP N
subscales NNS N
reflecting VBG N
psychoperceptual JJ N
or CC N
psychophysical JJ N
withdrawal NN N
. . N

CONCLUSIONS VB N
The DT N
ADS NNP N
reflected VBD N
variation NN N
in IN N
symptom JJ N
severity NN N
but CC N
did VBD N
not RB N
adequately RB N
identify VB N
physiological JJ N
dependence NN N
or CC N
withdrawal NN N
in IN N
treatment-seeking JJ N
individuals NNS N
with IN N
DSM-IV NNP 4_p
alcohol NN 4_p
dependence NN 4_p
. . N

-DOCSTART- -X- O O 25719544

Mask NNP N
ventilation NN N
with IN N
two CD N
different JJ N
face NN N
masks NNS N
in IN N
the DT N
delivery NN N
room NN N
for IN N
preterm JJ N
infants NNS N
: : N
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
If IN N
an DT N
infant NN N
fails VBZ N
to TO N
initiate VB N
spontaneous JJ N
breathing NN N
after IN N
birth NN N
, , N
international JJ N
guidelines NNS N
recommend VBP N
a DT N
positive JJ N
pressure NN N
ventilation NN N
( ( N
PPV NNP N
) ) N
. . N

However RB N
, , N
PPV NNP N
by IN N
face NN N
mask NN N
is VBZ N
frequently RB N
inadequate JJ N
because IN N
of IN N
leak NN N
between IN N
the DT N
face NN N
and CC N
mask NN N
. . N

Despite IN N
a DT N
variety NN N
of IN N
available JJ N
face NN N
masks NNS N
, , N
none NN N
have VBP N
been VBN N
prospectively RB N
compared VBN N
in IN N
a DT N
randomized JJ N
fashion NN N
. . N

We PRP N
aimed VBD N
to TO N
evaluate VB N
and CC N
compare VB N
leak NN N
between IN N
two CD N
commercially RB N
available JJ N
round NN N
face NN N
masks NNS N
( ( N
Fisher NNP N
& CC N
Paykel NNP N
( ( N
F NNP N
& CC N
P NNP N
) ) N
and CC N
Laerdal NNP N
) ) N
in IN N
preterm NN N
infants NNS N
< VBP N
33 CD N
weeks NNS N
gestational JJ N
age NN N
in IN N
the DT N
delivery NN N
room NN N
. . N

METHODS NNP N
Infants NNPS N
born VBN N
at IN N
the DT N
Royal NNP N
Alexandra NNP N
Hospital NNP N
from IN N
April NNP N
to TO N
September NNP N
2013 CD N
at IN N
< $ N
33 CD N
weeks NNS N
gestational JJ N
age NN N
who WP N
received VBD N
mask NN N
PPV NNP N
in IN N
the DT N
delivery NN N
room NN N
routinely RB N
had VBD N
a DT N
flow NN N
sensor NN N
placed VBD N
between IN N
the DT N
mask NN N
and CC N
T-piece NNP N
resuscitator NN N
. . N

Infants NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
PPV NNP N
with IN N
either CC N
a DT N
F NNP N
& CC N
P NNP N
or CC N
Laerdal NNP N
face NN N
mask NN N
. . N

All DT N
resuscitators NNS N
were VBD N
trained VBN N
in IN N
the DT N
use NN N
of IN N
both DT N
face NN N
masks NNS N
. . N

We PRP N
compared VBN N
mask NN N
leak NN N
, , N
airway NN N
pressures NNS N
, , N
tidal JJ N
volume NN N
and CC N
ventilation NN N
rate NN N
between IN N
the DT N
two CD N
groups NNS N
. . N

RESULTS NNP N
Fifty-six JJ N
preterm JJ N
infants NNS N
( ( N
n=28 NN N
in IN N
each DT N
group NN N
) ) N
were VBD N
enrolled VBN N
; : N
mean±s.d NN N
. . N

gestational JJ N
age NN N
28±3 CD N
weeks NNS N
; : N
birth NN N
weight VBD N
1210±448 CD N
g NN N
; : N
and CC N
30 CD N
( ( N
52 CD N
% NN N
) ) N
were VBD N
male JJ N
. . N

Apgar JJ N
scores NNS N
at IN N
1 CD N
and CC N
5 CD N
min NNS N
were VBD N
5±3 CD N
and CC N
7±2 CD N
, , N
respectively RB N
. . N

Infants NNS N
randomized VBD N
to TO N
the DT N
F NNP N
& CC N
P NNP N
face NN N
mask NN N
and CC N
Laerdal NNP N
face NN N
mask NN N
had VBD N
similar JJ N
mask NN N
leak NN N
( ( N
30 CD N
( ( N
25-38 JJ N
) ) N
versus NN N
35 CD N
( ( N
24-46 JJ N
) ) N
% NN N
, , N
median JJ N
( ( N
interquartile JJ N
range NN N
) ) N
, , N
respectively RB N
, , N
P=0.40 NNP N
) ) N
and CC N
tidal JJ N
volume NN N
( ( N
7.1 CD N
( ( N
4.9-8.9 JJ N
) ) N
versus NN N
6.6 CD N
( ( N
5.2-8.9 JJ N
) ) N
ml NN N
kg NN N
( ( N
-1 NNP N
) ) N
, , N
P=0.69 NNP N
) ) N
during IN N
PPV NNP N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
ventilation NN N
rate NN N
, , N
inflation NN N
time NN N
or CC N
airway NN N
pressures NNS N
between IN N
groups NNS N
. . N

CONCLUSION NNP N
The DT N
use NN N
of IN N
either DT N
face NN N
mask NN N
during IN N
PPV NNP N
in IN N
the DT N
delivery NN N
room NN N
yields NNS N
similar JJ N
mask NN N
leak NN N
in IN N
preterm JJ N
infants NNS N
< VBP N
33 CD N
weeks NNS N
gestational JJ N
age NN N
. . N

-DOCSTART- -X- O O 16940738

A DT N
double-blind JJ N
randomized NN N
controlled VBD N
trial NN N
of IN N
oral JJ N
misoprostol NN N
and CC N
intramuscular JJ N
syntometrine NN N
in IN N
the DT N
management NN N
of IN N
the DT N
third JJ 4_p
stage NN 4_p
of IN 4_p
labor NN 4_p
. . N

BACKGROUND IN N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
oral JJ N
misoprostol NN N
400 CD N
mug NN N
with IN N
intramuscular JJ N
syntometrine NN N
in IN N
the DT N
management NN N
of IN N
the DT N
third JJ N
stage NN N
of IN N
labor NN N
. . N

MATERIAL NNP N
AND CC N
METHODS NNP N
This DT N
was VBD N
a DT N
double-blind JJ N
randomized NN N
controlled VBD N
trial NN N
conducted VBN N
in IN N
a DT N
tertiary JJ N
care NN N
hospital NN N
. . N

Three CD N
hundred VBD N
and CC N
fifty-five JJ N
women NNS N
randomized VBN N
to TO N
receive VB N
either DT N
oral JJ N
misoprostol NN N
400 CD N
mug NN N
or CC N
intramuscular JJ N
syntometrine NN N
in IN N
the DT N
third JJ 4_p
stage NN 4_p
of IN 4_p
labor NN 4_p
were VBD N
studied VBN N
. . N

The DT N
change NN N
in IN N
hemoglobin JJ N
level NN N
from IN N
before IN N
to TO N
48 CD N
h NN N
after IN N
delivery NN N
, , N
use NN N
of IN N
additional JJ N
oxytocics NNS N
and CC N
treatment NN N
related JJ N
side NN N
effects NNS N
were VBD N
the DT N
main JJ N
outcome NN N
measures NNS N
. . N

RESULTS NNP N
There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
two CD N
groups NNS N
in IN N
terms NNS N
of IN N
the DT N
change NN N
in IN N
hemoglobin JJ N
level NN N
and CC N
mean JJ N
blood NN N
loss NN N
. . N

The DT N
incidence NN N
of IN N
shivering NN N
was VBD N
significantly RB N
higher JJR N
in IN N
the DT N
misoprostol NN N
group NN N
whilst VBD N
that IN N
of IN N
vomiting NN N
was VBD N
significantly RB N
higher JJR N
in IN N
the DT N
syntometrine NN N
group NN N
. . N

There EX N
were VBD N
no DT N
differences NNS N
in IN N
the DT N
incidence NN N
of IN N
nausea NN N
, , N
headache NN N
, , N
diarrhea NN N
and CC N
pyrexia NN N
between IN N
the DT N
two CD N
groups NNS N
. . N

CONCLUSION NNP N
Orally RB N
administered VBD N
misoprostol NN N
at IN N
a DT N
dose NN N
of IN N
400 CD N
mug NN N
is VBZ N
an DT N
acceptable JJ N
alternative NN N
in IN N
preventing VBG N
post-partum JJ N
blood NN N
loss NN N
, , N
as IN N
measured VBN N
by IN N
the DT N
peri-partum JJ N
change NN N
in IN N
hemoglobin JJ N
level NN N
and CC N
was VBD N
not RB N
associated VBN N
with IN N
an DT N
increased JJ N
incidence NN N
of IN N
side NN N
effects NNS N
. . N

-DOCSTART- -X- O O 12096292

Pain NN N
and CC N
fatigue JJ N
management NN N
: : N
results NNS N
of IN N
a DT N
nursing NN N
randomized VBN N
clinical JJ N
trial NN N
. . N

PURPOSE/OBJECTIVES NNP N
Through IN N
a DT N
randomized JJ N
clinical JJ N
trial NN N
, , N
to TO N
compare VB N
patients NNS N
undergoing VBG N
an DT N
initial JJ N
course NN N
of IN N
chemotherapy NN N
who WP N
report VBP N
pain NN N
and CC N
fatigue NN N
at IN N
baseline NN N
and CC N
who WP N
are VBP N
receiving VBG N
conventional JJ N
care NN N
alone RB N
with IN N
those DT N
receiving VBG N
conventional JJ N
care NN N
plus CC N
a DT N
nursing NN N
intervention NN N
on IN N
outcomes NNS N
reported VBN N
at IN N
20 CD N
weeks NNS N
. . N

SETTING NN N
Chemotherapy NNP N
clinics NNS N
of IN N
two CD N
comprehensive JJ N
and CC N
two CD N
community NN N
cancer NN 4_p
centers NNS N
. . N

METHODS NNP N
Interviews NNP N
were VBD N
conducted VBN N
at IN N
baseline NN N
and CC N
10 CD N
and CC N
20 CD N
weeks NNS N
. . N

An DT N
18-week JJ N
, , N
10-contact JJ N
nursing NN N
intervention NN N
utilizing VBG N
problem-solving JJ N
approaches NNS N
to TO N
symptom VB N
management NN N
and CC N
improving VBG N
physical JJ N
functioning NN N
and CC N
emotional JJ N
health NN N
was VBD N
implemented VBN N
. . N

SAMPLE VB N
The DT N
sample NN N
consisted VBD N
of IN N
53 CD N
patients NNS N
in IN N
the DT N
experimental JJ N
arm NN N
and CC N
60 CD N
in IN N
the DT N
control NN N
arm NN N
who WP N
reported VBD N
pain NN N
and CC N
fatigue NN N
at IN N
baseline NN N
. . N

VARIABLES NNP N
Pain NNP N
and CC N
fatigue NN N
, , N
numbers NNS N
of IN N
other JJ N
symptoms NNS N
, , N
and CC N
physical JJ N
role NN N
impact NN N
and CC N
social-functioning JJ N
subscales NNS N
from IN N
the DT N
Medical NNP N
Outcomes NNP N
Study NNP N
36 CD N
Short NNP N
Form NNP N
. . N

FINDINGS NNP N
Patients NNPS N
who WP N
received VBD N
the DT N
intervention NN N
reported VBD N
a DT N
significant JJ N
reduction NN N
in IN N
the DT N
number NN N
of IN N
symptoms NNS N
experienced VBN N
and CC N
improved VBN N
physical JJ N
and CC N
social JJ N
functioning NN N
. . N

Fewer JJR N
patients NNS N
in IN N
the DT N
experimental JJ N
arm NN N
reported VBD N
both DT N
pain NN N
and CC N
fatigue NN N
at IN N
20 CD N
weeks NNS N
. . N

CONCLUSIONS NNP N
Behavioral NNP N
interventions NNS N
targeted VBD N
to TO N
patients NNS N
with IN N
pain NN N
and CC N
fatigue NN N
can MD N
reduce VB N
symptom JJ N
burden NN N
, , N
improve VB N
the DT N
quality NN N
of IN N
the DT N
daily JJ N
life NN N
of IN N
patients NNS N
, , N
and CC N
demonstrate VB N
the DT N
" JJ N
value-added JJ N
" JJ N
role NN N
of IN N
nursing VBG N
care NN N
for IN N
patients NNS N
undergoing JJ N
chemotherapy NN N
. . N

IMPLICATIONS NNP N
FOR IN N
NURSING NNP N
These DT N
data NNS N
support NN N
the DT N
" JJ N
value-added JJ N
" JJ N
role NN N
of IN N
nursing NN N
interventions NNS N
for IN N
symptom JJ N
management NN N
and CC N
improved JJ N
quality NN N
of IN N
life NN N
during IN N
the DT N
course NN N
of IN N
cancer NN N
treatment NN N
. . N

-DOCSTART- -X- O O 1835223

Intravenous JJ N
or CC N
intramuscular JJ N
teicoplanin NN N
once RB N
daily JJ N
for IN N
skin NN 4_p
and CC 4_p
soft-tissue JJ 4_p
infections NNS 4_p
. . N

Teicoplanin NNP N
is VBZ N
a DT N
new JJ N
glycopeptide NN N
antibiotic JJ N
with IN N
potent JJ N
activity NN N
against IN N
gram-positive JJ N
bacteria NNS N
and CC N
pharmacokinetics NNS N
that WDT N
allow VBP N
once RB N
daily JJ N
administration NN N
. . N

To TO N
study VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
teicoplanin NN N
for IN N
skin NN N
and CC N
soft-tissue NN N
infections NNS N
, , N
75 CD N
patients NNS N
received VBD N
teicoplanin JJ N
intravenously RB N
( ( N
38 CD N
) ) N
or CC N
intramuscularly RB N
( ( N
37 CD N
, , N
of IN N
which WDT N
16 CD N
were VBD N
outpatients NNS N
) ) N
. . N

Of IN N
62 CD N
clinically RB N
evaluable JJ N
patients NNS N
, , N
97 CD N
percent NN N
of IN N
teicoplanin NN N
iv NN N
and CC N
93 CD N
percent NN N
of IN N
teicoplanin NN N
im NN N
patients NNS N
were VBD N
cured VBN N
or CC N
improved VBN N
. . N

All DT N
teicoplanin JJ N
iv NN N
patients NNS N
and CC N
64 CD N
percent NN N
of IN N
teicoplanin NN N
im NN N
patients NNS N
were VBD N
cured VBN N
microbiologically RB N
at IN N
24-48 JJ N
hours NNS N
posttherapy NN N
. . N

Persistence NN N
of IN N
organisms NNS N
frequently RB N
was VBD N
associated VBN N
with IN N
skin JJ N
ulcers NNS N
or CC N
abscess JJ N
cavities NNS N
and CC N
usually RB N
had VBD N
no DT N
bearing NN N
on IN N
clinical JJ N
outcome NN N
. . N

Possible JJ N
adverse JJ N
clinical JJ N
and CC N
laboratory JJ N
reactions NNS N
caused VBN N
by IN N
teicoplanin NN N
occurred VBD N
in IN N
4 CD N
of IN N
38 CD N
teicoplanin JJ N
iv NN N
patients NNS N
( ( N
11 CD N
percent NN N
) ) N
and CC N
in IN N
8 CD N
of IN N
37 CD N
teicoplanin JJ N
im NN N
patients NNS N
( ( N
22 CD N
percent NN N
) ) N
. . N

Reactions NNPS N
were VBD N
mild JJ N
and CC N
resolved VBN N
with IN N
discontinuation NN N
of IN N
teicoplanin NN N
in IN N
most JJS N
cases NNS N
. . N

In IN N
this DT N
study NN N
, , N
teicoplanin NN N
appeared VBD N
to TO N
be VB N
safe JJ N
, , N
efficacious JJ N
, , N
and CC N
convenient NN N
for IN N
both DT N
hospital JJ N
staff NN N
and CC N
patients NNS N
, , N
and CC N
potentially RB N
cost-effective JJ N
for IN N
the DT N
treatment NN N
of IN N
skin NN N
and CC N
soft-tissue JJ N
infections NNS N
. . N

In IN N
particular JJ N
, , N
teicoplanin JJ N
appears VBZ N
to TO N
be VB N
appropriate JJ N
for IN N
outpatient JJ N
parenteral JJ N
therapy NN N
. . N

-DOCSTART- -X- O O 9116082

Confounding VBG N
by IN N
indication NN N
? . N
-DOCSTART- -X- O O 23481373

Development NNP N
of IN N
the DT N
Therapist NNP N
Empathy NNP N
Scale NNP N
. . N

BACKGROUND NNP N
Few JJ N
measures NNS N
exist VBP N
to TO N
examine VB N
therapist NN N
empathy NN N
as IN N
it PRP N
occurs VBZ N
in IN N
session NN N
. . N

AIMS VB N
A DT N
9-item JJ N
observer NN N
rating NN N
scale NN N
, , N
called VBD N
the DT N
Therapist NNP N
Empathy NNP N
Scale NNP N
( ( N
TES NNP N
) ) N
, , N
was VBD N
developed VBN N
based VBN N
on IN N
Watson NNP N
's POS N
( ( N
1999 CD N
) ) N
work NN N
to TO N
assess VB N
affective JJ N
, , N
cognitive JJ N
, , N
attitudinal JJ N
, , N
and CC N
attunement JJ N
aspects NNS N
of IN N
therapist NN N
empathy NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
inter-rater JJ N
reliability NN N
, , N
internal JJ N
consistency NN N
, , N
and CC N
construct NN N
and CC N
criterion NN N
validity NN N
of IN N
the DT N
TES NNP N
. . N

METHOD NNP N
Raters NNPS N
evaluated VBD N
therapist JJ 4_p
empathy NN N
in IN N
315 CD N
client NN N
sessions NNS N
conducted VBN N
by IN N
91 CD N
therapists NNS 4_p
, , N
using VBG N
data NNS N
from IN N
a DT N
multi-site JJ N
therapist NN N
training NN N
trial NN N
( ( N
Martino NNP N
et RB N
al. RB N
, , N
2010 CD N
) ) N
in IN N
Motivational NNP 4_p
Interviewing NNP 4_p
( ( N
MI NNP N
) ) N
. . N

RESULTS JJ N
Inter-rater JJ N
reliability NN N
( ( N
ICC NNP N
= NNP N
.87 NNP N
to TO N
.91 VB N
) ) N
and CC N
internal JJ N
consistency NN N
( ( N
Cronbach NNP N
's POS N
alpha NN N
= NNP N
.94 NNP N
) ) N
were VBD N
high JJ N
. . N

Confirmatory NNP N
factor NN N
analyses NNS N
indicated VBD N
some DT N
support NN N
for IN N
single-factor JJ N
fit NN N
. . N

Convergent NNP N
validity NN N
was VBD N
supported VBN N
by IN N
correlations NNS N
between IN N
TES NNP N
scores NNS N
and CC N
MI NNP N
fundamental JJ N
adherence NN N
( ( N
r JJ N
range NN N
.50 NN N
to TO N
.67 VB N
) ) N
and CC N
competence NN N
scores NNS N
( ( N
r NN N
range NN N
.56 NN N
to TO N
.69 VB N
) ) N
. . N

Discriminant JJ N
validity NN N
was VBD N
indicated VBN N
by IN N
negative JJ N
or CC N
nonsignificant JJ N
correlations NNS N
between IN N
TES NNP N
and CC N
MI-inconsistent NNP N
behavior NN N
( ( N
r JJ N
range NN N
.05 NN N
to TO N
-.33 VB N
) ) N
. . N

CONCLUSIONS VB N
The DT N
TES NNP N
demonstrates VBZ N
excellent JJ N
inter-rater JJ N
reliability NN N
and CC N
internal JJ N
consistency NN N
. . N

RESULTS NNP N
indicate VBP N
some DT N
support NN N
for IN N
a DT N
single-factor JJ N
solution NN N
and CC N
convergent NN N
and CC N
discriminant JJ N
validity NN N
. . N

Future JJ N
studies NNS N
should MD N
examine VB N
the DT N
use NN N
of IN N
the DT N
TES NNP N
to TO N
evaluate VB N
therapist NN 4_p
empathy NN N
in IN N
different JJ N
psychotherapy NN N
approaches NNS N
and CC N
to TO N
determine VB N
the DT N
impact NN N
of IN N
therapist NN N
empathy NN N
on IN N
client NN N
outcome NN N
. . N

-DOCSTART- -X- O O 2074057

[ JJ N
Therapy NNP N
with IN N
alpha-interferon NN N
in IN N
non-Hodgkin NN 4_p
's POS 4_p
lymphoma NN 4_p
with IN 4_p
a DT 4_p
low JJ 4_p
grade NN 4_p
of IN 4_p
malignancy NN 4_p
( ( N
correct JJ N
title NN N
supplied VBD N
from IN N
Table NNP N
of IN N
Contents NNP N
) ) N
] NN N
. . N

-DOCSTART- -X- O O 384574

Results NNS N
of IN N
a DT N
prospective JJ N
randomized VBN N
study NN N
of IN N
hepatic JJ N
artery NN N
infusion NN N
with IN N
5-fluorouracil JJ N
versus NN N
intravenous JJ N
5-fluorouracil JJ N
in IN N
patients NNS N
with IN N
hepatic JJ 4_p
metastases NNS 4_p
from IN N
colorectal JJ 4_p
cancer NN 4_p
: : N
A DT N
Central NNP N
Oncology NNP N
Group NNP N
study NN N
. . N

In IN N
a DT N
controlled VBN N
, , N
prospectively RB N
randomized VBN N
trial NN N
, , N
74 CD N
patients NNS N
with IN N
hepatic JJ 4_p
metastases NNS 4_p
from IN N
colorectal JJ 4_p
cancer NN 4_p
were VBD N
randomized VBN N
to TO N
either DT N
intra-arterial JJ N
hepatic JJ N
artery NN N
infusion NN N
with IN N
5-fluorouracil JJ N
( ( N
5-FU JJ N
) ) N
or CC N
systemic JJ N
chemotherapy NN N
with IN N
5-FU JJ N
. . N

In IN N
61 CD N
acceptable JJ N
patients NNS N
, , N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
terms NNS N
of IN N
response NN N
rate NN N
, , N
time NN N
to TO N
progression NN N
, , N
duration NN N
of IN N
the DT N
response NN N
, , N
and CC N
survival JJ N
rate NN N
. . N

Though IN N
the DT N
response NN N
rate NN N
for IN N
the DT N
intra-arterial JJ N
infusion NN N
arm NN N
was VBD N
slightly RB N
higher JJR N
than IN N
for IN N
the DT N
systemic JJ N
arm NN N
, , N
the DT N
difference NN N
was VBD N
not RB N
significant JJ N
, , N
and CC N
the DT N
intra-arterial JJ N
infusion NN N
arm NN N
was VBD N
associated VBN N
with IN N
a DT N
greater JJR N
incidence NN N
of IN N
nausea NN N
, , N
vomiting VBG N
, , N
diarrhea NN N
, , N
in IN N
addition NN N
to TO N
complications NNS N
of IN N
femoral-arterial JJ N
thrombosis NN N
, , N
bleeding NN N
, , N
and CC N
infection NN N
at IN N
the DT N
catheter NN N
site NN N
not RB N
seen VBN N
in IN N
patients NNS N
treated VBN N
by IN N
systemic JJ N
chemotherapy NN N
. . N

Patients NNS N
with IN N
an DT N
objective JJ N
response NN N
to TO N
chemotherapy VB N
on IN N
either DT N
treatment NN N
arm NN N
survived VBD N
twice RB N
as RB N
long RB N
as IN N
the DT N
nonresponders NNS N
. . N

Long-term JJ N
survival NN N
in IN N
one CD N
patient NN N
, , N
77 CD N
months NNS N
, , N
can MD N
occasionally RB N
be VB N
achieved VBN N
in IN N
patients NNS N
with IN N
hepatic JJ N
metastases NNS N
. . N

-DOCSTART- -X- O O 6455048

Relief NN N
of IN N
osteoporotic JJ 4_p
backache NN 4_p
with IN N
fluoride NN N
, , N
calcium NN N
, , N
and CC N
calciferol NN N
. . N

In IN N
a DT N
prospective JJ N
randomized VBN N
clinical JJ N
trial NN N
comprising VBG N
22 CD 4_p
postmenopausal JJ N
women NNS N
with IN N
backache NN 4_p
and CC 4_p
a DT 4_p
halisteretic JJ 4_p
spine NN 4_p
with IN 4_p
crush JJ 4_p
fracture NN 4_p
( ( 4_p
s NN 4_p
) ) 4_p
, , N
12 CD 4_p
women NNS N
completed VBD N
a DT N
12-week JJ N
therapy NN N
with IN N
sodium NN N
fluoride NN N
, , N
calcium NN N
and CC N
calciferol NN N
and CC N
10 CD N
with IN N
placebo NN N
. . N

A DT N
statistically RB N
significant JJ N
improvement NN N
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
, , N
evaluated VBN N
by IN N
a DT N
four-stage JJ N
scale NN N
on IN N
pains NNS N
, , N
infirmity NN N
, , N
and CC N
consumption NN N
of IN N
analgesics NNS N
, , N
was VBD N
observed VBN N
in IN N
the DT N
actively RB N
treated JJ N
patients NNS N
. . N

-DOCSTART- -X- O O 24022375

The DT N
effect NN N
of IN N
person-centred JJ N
dementia NN N
care NN N
to TO N
prevent VB N
agitation NN N
and CC N
other JJ N
neuropsychiatric JJ N
symptoms NNS N
and CC N
enhance JJ N
quality NN N
of IN N
life NN N
in IN N
nursing NN 4_p
home NN 4_p
patients NNS 4_p
: : N
a DT N
10-month JJ N
randomized NN N
controlled VBD N
trial NN N
. . N

AIMS IN N
We PRP N
examined VBD N
whether IN N
Dementia NNP N
Care NNP N
Mapping NNP N
( ( N
DCM NNP N
) ) N
or CC N
the DT N
VIPS NNP N
practice NN N
model NN N
( ( N
VPM NNP N
) ) N
is VBZ N
more RBR N
effective JJ N
than IN N
education NN N
of IN N
the DT N
nursing NN N
home NN N
staff NN N
about IN N
dementia NN N
( ( N
control VB N
group NN N
) ) N
in IN N
reducing VBG N
agitation NN N
and CC N
other JJ N
neuropsychiatric JJ N
symptoms NNS N
as RB N
well RB N
as IN N
in IN N
enhancing VBG N
the DT N
quality NN N
of IN N
life NN N
among IN N
nursing JJ N
home NN N
patients NNS N
. . N

METHODS VB N
A DT N
10-month JJ N
three-armed JJ N
cluster-randomized JJ N
controlled VBN N
trial NN N
compared VBN N
DCM NNP N
and CC N
VPM NNP N
with IN N
control NN N
. . N

Of IN N
624 CD N
nursing NN N
home NN N
patients NNS N
with IN N
dementia NN 4_p
, , N
446 CD N
completed VBD N
follow-up JJ N
assessments NNS N
. . N

The DT N
primary JJ N
outcome NN N
was VBD N
the DT N
change NN N
on IN N
the DT N
Brief JJ N
Agitation NNP N
Rating NNP N
Scale NNP N
( ( N
BARS NNP N
) ) N
. . N

Secondary JJ N
outcomes NNS N
were VBD N
changes NNS N
on IN N
the DT N
10-item JJ N
version NN N
of IN N
the DT N
Neuropsychiatric NNP N
Inventory NNP N
Questionnaire NNP N
( ( N
NPI-Q NNP N
) ) N
, , N
the DT N
Cornell NNP N
Scale NNP N
for IN N
Depression NNP N
in IN N
Dementia NNP N
( ( N
CSDD NNP N
) ) N
and CC N
the DT N
Quality NN N
of IN N
Life NNP N
in IN N
Late-Stage NNP N
Dementia NNP N
( ( N
QUALID NNP N
) ) N
scale NN N
. . N

RESULTS NNP N
Changes NNP N
in IN N
the DT N
BARS NNP N
score NN N
did VBD N
not RB N
differ VB N
significantly RB N
between IN N
the DT N
DCM NNP N
and CC N
the DT N
control NN N
group NN N
or CC N
between IN N
the DT N
VPM NNP N
and CC N
the DT N
control NN N
group NN N
after IN N
10 CD N
months NNS N
. . N

Positive JJ N
differences NNS N
were VBD N
found VBN N
for IN N
changes NNS N
in IN N
the DT N
secondary JJ N
outcomes NNS N
: : N
the DT N
NPI-Q NNP N
sum NN N
score NN N
as RB N
well RB N
as IN N
the DT N
subscales NNS N
NPI-Q NNP N
agitation NN N
and CC N
NPI-Q JJ N
psychosis NN N
were VBD N
in IN N
favour NN N
of IN N
both DT N
interventions NNS N
versus VBP N
control NN N
, , N
the DT N
QUALID NNP N
score NN N
was VBD N
in IN N
favour NN N
of IN N
DCM NNP N
versus NN N
control NN N
and CC N
the DT N
CSDD NNP N
score NN N
was VBD N
in IN N
favour NN N
of IN N
VPM NNP N
versus NN N
control NN N
. . N

CONCLUSIONS NNP N
This DT N
study NN N
failed VBD N
to TO N
find VB N
a DT N
significant JJ N
effect NN N
of IN N
both DT N
interventions NNS N
on IN N
the DT N
primary JJ N
outcome NN N
. . N

Positive JJ N
effects NNS N
on IN N
the DT N
secondary JJ N
outcomes NNS N
indicate VBP N
that IN N
the DT N
methods NNS N
merit VBP N
further JJ N
investigation NN N
. . N

-DOCSTART- -X- O O 9230829

Mortality NN N
in IN N
patients NNS N
with IN N
small JJ N
choroidal NNS N
melanoma NN N
. . N

COMS NNP N
report NN N
no DT N
. . N

4 CD N
. . N

The DT N
Collaborative JJ N
Ocular NNP N
Melanoma NNP N
Study NNP N
Group NNP N
. . N

OBJECTIVE NNP N
To TO N
describe VB N
the DT N
clinical JJ N
characteristics NNS N
and CC N
survival JJ N
experience NN N
of IN N
a DT N
prospectively RB N
followed VBN N
up RP N
group NN N
of IN N
patients NNS N
with IN N
small JJ N
choroidal NNS N
melanoma NN N
. . N

METHODS NNP N
The DT N
Collaborative NNP N
Ocular NNP N
Melanoma NNP N
Study NNP N
( ( N
COMS NNP N
) ) N
is VBZ N
a DT N
set NN N
of IN N
clinical JJ N
trials NNS N
designed VBN N
to TO N
compare VB N
the DT N
role NN N
of IN N
radiotherapy NN N
and CC N
enucleation NN N
in IN N
the DT N
treatment NN N
of IN N
medium NN N
and CC N
large-size JJ N
choroidal NN N
melanoma NN N
. . N

From IN N
December NNP N
1986 CD N
to TO N
August NNP N
1989 CD N
, , N
patients NNS N
with IN N
small JJ N
choroidal NN N
melanoma NN N
, , N
not RB N
large JJ N
enough RB N
to TO N
be VB N
eligible JJ N
for IN N
the DT N
COMS NNP N
clinical JJ N
trials NNS N
, , N
were VBD N
offered VBN N
participation NN N
in IN N
a DT N
nonrandomized JJ N
prospective JJ N
follow-up NN N
study NN N
. . N

Small NNP N
choroidal JJ N
melanomas NN N
were VBD N
defined VBN N
as IN N
1.0 CD N
to TO N
3.0 CD N
mm NNS N
in IN N
apical JJ N
height NN N
and CC N
at IN N
least JJS N
5.0 CD N
mm NN N
in IN N
basal NN N
diameter NN N
. . N

A DT N
total NN N
of IN N
204 CD N
patients NNS N
were VBD N
enrolled VBN N
in IN N
the DT N
study NN N
. . N

Patients NNS N
were VBD N
followed VBN N
up RP N
annually RB N
through IN N
August NNP N
1989 CD N
. . N

Two CD N
additional JJ N
assessments NNS N
of IN N
treatment NN N
status NN N
and CC N
mortality NN N
were VBD N
conducted VBN N
in IN N
1993-1994 JJ N
and CC N
1995-1996 JJ N
. . N

The DT N
median JJ N
length NN N
of IN N
follow-up NN N
was VBD N
92 CD N
months NNS N
. . N

Eight NNP N
percent NN N
of IN N
patients NNS N
were VBD N
treated VBN N
at IN N
the DT N
time NN N
of IN N
study NN N
enrollment NN N
and CC N
an DT N
additional JJ N
33 CD N
% NN N
were VBD N
treated VBN N
during IN N
follow-up JJ N
. . N

RESULTS JJ N
Twenty-seven JJ N
patients NNS N
have VBP N
died VBN N
; : N
6 CD N
deaths NNS N
were VBD N
reported VBN N
by IN N
the DT N
clinical JJ N
center NN N
as IN N
due JJ N
to TO N
metastatic JJ N
melanoma NN N
. . N

The DT N
Kaplan-Meier NNP N
estimate NN N
of IN N
5-year JJ N
all-cause JJ N
mortality NN N
was VBD N
6.0 CD N
% NN N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
2.7 CD N
% NN N
-9.3 NNP N
% NN N
) ) N
and CC N
8-year JJ N
all-cause NN N
mortality NN N
was VBD N
14.9 CD N
% NN N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
9.6 CD N
% NN N
-20.2 NNP N
% NN N
) ) N
. . N

CONCLUSIONS NNP N
Otherwise NNP N
healthy JJ N
patients NNS N
, , N
average JJ N
age NN N
of IN N
60 CD N
years NNS N
, , N
without IN N
a DT N
previous JJ N
diagnosis NN N
of IN N
malignant JJ N
disease NN N
who WP N
have VBP N
small JJ N
choroidal JJ N
lesions NNS N
judged VBD N
to TO N
be VB N
melanoma VBN N
have VBP N
a DT N
low JJ N
risk NN N
of IN N
dying VBG N
within IN N
5 CD N
years NNS N
. . N

-DOCSTART- -X- O O 25342205

Dexmedetomidine NNP N
pretreatment NN N
alleviates VBZ N
propofol JJ 4_p
injection NN 4_p
pain NN 4_p
. . 4_p

OBJECTIVE CC N
The DT N
incidence NN N
of IN N
propofol JJ N
injection NN N
pain NN N
during IN N
induction NN N
of IN N
general JJ N
anesthesia NN N
varies NNS N
from IN N
28 CD N
% NN N
to TO N
90 CD N
% NN N
. . N

This DT N
prospective JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
evaluated VBD N
the DT N
effect NN N
of IN N
dexmedetomidine NN N
( ( N
DEX NNP N
) ) N
for IN N
reducing VBG N
the DT N
incidence NN N
and CC N
severity NN N
of IN N
propofol JJ N
injection NN N
pain NN N
. . N

METHODS NNP N
Patients NNPS N
undergoing VBG N
elective JJ N
surgical JJ N
procedures NNS N
were VBD N
randomly RB N
allocated VBN N
into IN N
seven CD N
groups NNS N
of IN N
30 CD N
patients NNS N
each DT N
. . N

Experimental JJ N
treatments NNS N
were VBD N
intravenously RB N
administered VBN N
over IN N
10 CD N
min NNS N
( ( N
total JJ N
volume NN N
10 CD N
mL NN N
) ) N
prior RB N
to TO N
intravenous JJ N
propofol NN N
injection NN N
, , N
as IN N
follows VBZ N
: : N
group NN N
I PRP N
, , N
the DT N
control NN N
group NN N
, , N
was VBD N
given VBN N
isotonic JJ N
saline NN N
. . N

Patients NNS N
in IN N
groups NNS N
II NNP N
, , N
III NNP N
, , N
and CC N
IV NNP N
received VBD N
DEX NNP N
0.25 CD N
µg/kg NNP N
, , N
0.5 CD N
µg/kg NN N
, , N
or CC N
1.0 CD N
µg/kg NNS N
, , N
respectively RB N
, , N
mixed JJ N
with IN N
isotonic JJ N
saline NN N
immediately RB N
before IN N
propofol JJ N
injection NN N
. . N

Patients NNS N
in IN N
groups NNS N
V NNP N
, , N
VI NNP N
, , N
and CC N
VII NNP N
received VBD N
DEX NNP N
as IN N
above NN N
, , N
but CC N
5 CD N
minutes NNS N
before IN N
propofol JJ N
injection NN N
. . N

Propofol NNP N
consisted VBD N
of IN N
1 CD N
% NN N
long-chain JJ N
triglyceride NN N
propofol NN N
( ( N
2.5 CD N
mg/kg NN N
) ) N
injected VBD N
at IN N
1 CD N
mL/s NNS N
. . N

RESULTS NNP N
Median JJ N
propofol NN N
injection NN N
pain NN N
score NN N
was VBD N
0.00 CD N
( ( N
IQR NNP N
0.00-3.00 NN N
) ) N
in IN N
patients NNS N
who WP N
received VBD N
1.0 CD N
µg/kg NNP N
DEX NNP N
5 CD N
min NN N
before IN N
the DT N
propofol NN N
injection NN N
( ( N
group NN N
VII NNP N
) ) N
, , N
and CC N
only RB N
1 CD N
patient NN N
( ( N
of IN N
30 CD N
) ) N
in IN N
this DT N
group NN N
received VBD N
a DT N
pain NN N
score NN N
> VBD N
2 CD N
. . N

The DT N
median JJ N
pain NN N
score NN N
and CC N
number NN N
of IN N
patients NNS N
with IN N
pain NN N
scores NNS N
> VBP N
2 CD N
in IN N
group NN N
VII NNP N
were VBD N
both DT N
significantly RB N
less JJR N
than IN N
in IN N
the DT N
control NN N
( ( N
group NN N
I PRP N
; : N
p CC N
= $ N
0.000 CD N
, , N
both DT N
) ) N
. . N

There EX N
were VBD N
no DT N
differences NNS N
in IN N
either DT N
mean JJ N
arterial JJ N
pressure NN N
or CC N
heart NN N
rate NN N
at IN N
any DT N
time NN N
point NN N
after IN N
DEX NNP N
injection NN N
among IN N
the DT N
groups NNS N
. . N

CONCLUSIONS NNP N
Pretreatment NNP N
with IN N
intravenous JJ N
DEX NNP N
1 CD N
µg/kg VBD N
5 CD N
min NN N
prior RB N
to TO N
injection NN N
of IN N
long-chain JJ N
triglyceride NN N
propofol NN N
is VBZ N
effective JJ N
and CC N
safe JJ N
in IN N
reducing VBG N
the DT N
incidence NN N
and CC N
severity NN N
of IN N
pain NN N
due JJ N
to TO N
propofol VB N
injection NN N
. . N

-DOCSTART- -X- O O 22219012

Pre-bent JJ N
instruments NNS N
used VBN N
in IN N
single-port JJ N
laparoscopic NN N
surgery NN N
versus IN N
conventional JJ N
laparoscopic NN N
surgery NN N
: : N
comparative JJ N
study NN N
of IN N
performance NN N
in IN N
a DT N
dry JJ N
lab NN N
. . N

BACKGROUND NNP N
Different NNP N
types NNS N
of IN N
single-incision NN N
laparoscopic NN N
surgery NN N
( ( N
SILS NNP N
) ) N
have VBP N
become VBN N
increasingly RB N
popular JJ N
. . N

Although IN N
SILS NNP N
is VBZ N
technically RB N
even RB N
more RBR N
challenging JJ N
than IN N
conventional JJ N
laparoscopy NN N
, , N
published VBN N
data NNS N
of IN N
first JJ N
clinical JJ N
series NN N
seem VBP N
to TO N
demonstrate VB N
the DT N
feasibility NN N
of IN N
these DT N
approaches NNS N
. . N

Various JJ N
attempts NNS N
have VBP N
been VBN N
made VBN N
to TO N
overcome VB N
restrictions NNS N
due JJ N
to TO N
loss NN N
of IN N
triangulation NN N
in IN N
SILS NNP N
by IN N
specially RB N
designed VBN N
SILS-specific JJ N
instruments NNS N
. . N

This DT N
study NN N
involving VBG N
novices NNS N
in IN N
a DT N
dry JJ N
lab NN N
compared VBN N
task NN N
performances NNS N
between IN N
conventional JJ N
laparoscopic NN N
surgery NN N
( ( N
CLS NNP N
) ) N
and CC N
single-port JJ N
laparoscopic NN N
surgery NN N
( ( N
SPLS NNP N
) ) N
using VBG N
newly RB N
designed VBN N
pre-bent JJ N
instruments NNS N
. . N

METHODS NNP N
In IN N
this DT N
study NN N
, , N
90 CD N
medical JJ N
students NNS N
without IN N
previous JJ N
experience NN N
in IN N
laparoscopic NN N
techniques NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
undergo VB N
one CD N
of IN N
three CD N
procedures NNS N
: : N
CLS NNP N
, , N
SPLS NNP N
using VBG N
two CD N
pre-bent JJ N
instruments NNS N
( ( N
SPLS-pp NNP N
) ) N
, , N
or CC N
SPLS NNP N
using VBG N
one CD N
pre-bent NN N
and CC N
one CD N
straight NN N
laparoscopic NN N
instrument NN N
( ( N
SPLS-ps NNP N
) ) N
. . N

In IN N
the DT N
dry JJ N
lab NN N
, , N
the DT N
participants NNS N
performed VBD N
four CD N
typical JJ N
laparoscopic NN N
tasks NNS N
of IN N
increasing VBG N
difficulty NN N
. . N

Evaluation NNP N
included VBD N
performance NN N
times NNS N
or CC N
number NN N
of IN N
completed VBN N
tasks NNS N
within IN N
a DT N
given VBN N
time NN N
frame NN N
. . N

All DT N
performances NNS N
were VBD N
videotaped VBN N
and CC N
evaluated VBN N
for IN N
unsuccessful JJ N
attempts NNS N
and CC N
unwanted JJ N
interactions NNS N
of IN N
instruments NNS N
. . N

Using VBG N
subjective JJ N
questionnaires NNS N
, , N
the DT N
participants NNS N
rated VBN N
difficulties NNS N
with IN N
two-dimensional JJ N
vision NN N
and CC N
coordination NN N
of IN N
instruments NNS N
. . N

RESULTS NNP N
Task NNP N
performances NNS N
were VBD N
significantly RB N
better RBR N
in IN N
the DT N
CLS NNP N
group NN N
than IN N
in IN N
either DT N
SPLS NNP N
group NN N
. . N

The DT N
SPLS-ps NNP N
group NN N
showed VBD N
a DT N
tendency NN N
toward IN N
better JJR N
performances NNS N
than IN N
the DT N
SPLS-pp NNP N
group NN N
, , N
but CC N
the DT N
difference NN N
was VBD N
not RB N
significant JJ N
. . N

Video NNP N
sequences NNS N
and CC N
participants` NN N
questionnaires NNS N
showed VBD N
instrument JJ N
interaction NN N
as IN N
the DT N
major JJ N
problem NN N
in IN N
the DT N
single-incision NN N
surgery NN N
groups NNS N
. . N

CONCLUSIONS NNP N
Although IN N
SILS NNP N
is VBZ N
feasible JJ N
, , N
as IN N
shown VBN N
in IN N
clinical JJ N
series NN N
published VBN N
by IN N
laparoscopically RB N
experienced JJ N
experts NNS N
, , N
SILS NNP N
techniques NNS N
are VBP N
demanding VBG N
due JJ N
to TO N
restrictions NNS N
that IN N
come VBP N
with IN N
the DT N
loss NN N
of IN N
triangulation NN N
. . N

These DT N
can MD N
be VB N
compensated VBN N
only RB N
partially RB N
by IN N
currently RB N
available JJ N
SILS-designed JJ N
instruments NNS N
. . N

The DT N
future NN N
of IN N
SILS NNP N
depends VBZ N
on IN N
further JJ N
improvements NNS N
in IN N
the DT N
available JJ N
equipment NN N
or CC N
the DT N
development NN N
of IN N
new JJ N
approaches NNS N
such JJ N
as IN N
needlescopically RB N
assisted VBN N
or CC N
robotically RB N
assisted JJ N
procedures NNS N
. . N

-DOCSTART- -X- O O 18635304

Placebo-controlled JJ N
trial NN N
evaluating VBG N
safety NN N
with IN N
12-months JJ N
continuous JJ N
use NN N
of IN N
6 CD N
% NN N
hydrogen NN N
peroxide IN N
whitening VBG N
strips NNS N
. . N

OBJECTIVE NNP N
To TO N
assess VB N
the DT N
safety NN N
and CC N
tolerability NN N
of IN N
6 CD N
% NN N
hydrogen NN N
peroxide IN N
whitening VBG N
strips NNS N
over IN N
12 CD N
months NNS N
. . N

METHODS NNP N
80 CD N
adults NNS N
were VBD N
randomly RB N
assigned VBN N
equally RB N
to TO N
one CD N
of IN N
two CD N
treatments NNS N
: : N
6 CD N
% NN N
hydrogen NN N
peroxide JJ N
strips NNS N
or CC N
placebo VB N
strips NNS N
. . N

Strips NNS N
were VBD N
worn JJ N
5 CD N
min JJ N
daily RB N
for IN N
12 CD N
months NNS N
. . N

Safety NNP N
and CC N
tolerability NN N
were VBD N
assessed VBN N
via IN N
oral JJ N
status NN N
interviews NNS N
and CC N
oral JJ N
examinations NNS N
at IN N
baseline NN N
and CC N
after IN N
1 CD N
, , N
2 CD N
, , N
3 CD N
, , N
6 CD N
, , N
9 CD N
, , N
and CC N
12 CD N
months NNS N
of IN N
use NN N
. . N

RESULTS NNP N
Tooth NNP N
sensitivity NN N
and CC N
oral JJ N
irritation NN N
were VBD N
the DT N
two CD N
most JJS N
common JJ N
adverse JJ N
events NNS N
. . N

After IN N
12 CD N
months NNS N
use RB N
, , N
tooth DT N
sensitivity NN N
was VBD N
reported VBN N
by IN N
10 CD N
% NN N
of IN N
subjects NNS N
in IN N
the DT N
6 CD N
% NN N
strip NN N
group NN N
with IN N
a DT N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
of IN N
( ( N
2.8 CD N
% NN N
, , N
23.7 CD N
% NN N
) ) N
and CC N
5 CD N
% NN N
of IN N
subjects NNS N
in IN N
the DT N
placebo NN N
group NN N
with IN N
a DT N
95 CD N
% NN N
CI NNP N
of IN N
( ( N
0.6 CD N
% NN N
, , N
16.9 CD N
% NN N
) ) N
. . N

The DT N
occurrence NN N
of IN N
reported VBN N
oral JJ N
irritation NN N
was VBD N
0 CD N
% NN N
in IN N
the DT N
6 CD N
% NN N
strip NN N
group NN N
with IN N
a DT N
95 CD N
% NN N
CI NNP N
of IN N
( ( N
0 CD N
% NN N
, , N
8.8 CD N
% NN N
) ) N
and CC N
2.5 CD N
% NN N
in IN N
the DT N
placebo NN N
strip NN N
group NN N
with IN N
a DT N
95 CD N
% NN N
CI NNP N
of IN N
( ( N
0.1 CD N
% NN N
, , N
13.2 CD N
% NN N
) ) N
. . N

The DT N
occurrence NN N
of IN N
observed JJ N
oral JJ N
irritation NN N
was VBD N
also RB N
similar JJ N
between IN N
groups NNS N
. . N

The DT N
groups NNS N
did VBD N
not RB N
differ VB N
significantly RB N
( ( N
p JJ N
> NNP N
0.67 CD N
) ) N
for IN N
the DT N
percent NN N
of IN N
subjects NNS N
with IN N
each DT N
type NN N
of IN N
adverse JJ N
event NN N
. . N

In IN N
the DT N
6 CD N
% NN N
strip NN N
group NN N
, , N
two CD N
subjects NNS N
discontinued VBN N
product NN N
use NN N
due JJ N
to TO N
an DT N
adverse JJ N
event NN N
( ( N
tooth JJ N
sensitivity NN N
) ) N
compared VBN N
to TO N
no DT N
subjects NNS N
in IN N
the DT N
placebo NN N
group NN N
. . N

Groups NNP N
did VBD N
not RB N
differ VB N
significantly RB N
( ( N
p JJ N
> NNP N
0.49 CD N
) ) N
with IN N
respect NN N
to TO N
this DT N
outcome NN N
. . N

CONCLUSION NNP N
Use NNP N
of IN N
6 CD N
% NN N
hydrogen NN N
peroxide IN N
whitening VBG N
strips NNS N
over IN N
12 CD N
months NNS N
resulted VBN N
in IN N
a DT N
safety NN N
profile NN N
similar JJ N
to TO N
that DT N
seen VBN N
with IN N
placebo JJ N
strips NNS N
. . N

-DOCSTART- -X- O O 15492353

Risperidone NN N
in IN N
the DT N
treatment NN N
of IN N
disruptive JJ N
behavioral NN N
symptoms NNS N
in IN N
children NNS 4_p
with IN 4_p
autistic JJ 4_p
and CC 4_p
other JJ 4_p
pervasive JJ 4_p
developmental NN 4_p
disorders NNS 4_p
. . 4_p

OBJECTIVE NNP N
To TO N
investigate VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
risperidone NN N
for IN N
the DT N
treatment NN N
of IN N
disruptive JJ N
behavioral NN N
symptoms NNS N
in IN N
children NNS N
with IN N
autism NN 4_p
and CC 4_p
other JJ 4_p
pervasive JJ 4_p
developmental NN 4_p
disorders NNS 4_p
( ( 4_p
PDD NNP 4_p
) ) N
. . N

METHODS NNP N
In IN N
this DT N
8-week JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
trial NN N
, , N
risperidone/placebo JJ N
solution NN N
( ( N
0.01-0.06 JJ N
mg/kg/day NN N
) ) N
was VBD N
administered VBN N
to TO N
79 CD N
children NNS N
who WP N
were VBD N
aged VBN N
5 CD N
to TO N
12 CD N
years NNS N
and CC N
had VBD N
PDD NNP 4_p
. . N

Behavioral NNP N
symptoms NNS N
were VBD N
assessed VBN N
using VBG N
the DT N
Aberrant NNP N
Behavior NNP N
Checklist NNP N
( ( N
ABC NNP N
) ) N
, , N
Nisonger NNP N
Child NNP N
Behavior NNP N
Rating NNP N
Form NNP N
, , N
and CC N
Clinical JJ N
Global NNP N
Impression-Change NNP N
. . N

Safety NNP N
assessments NNS N
included VBD N
vital JJ N
signs NNS N
, , N
electrocardiogram NN N
, , N
extrapyramidal NN N
symptoms NNS N
, , N
adverse JJ N
events NNS N
, , N
and CC N
laboratory NN N
tests NNS N
. . N

RESULTS NNP N
Subjects NNPS N
who WP N
were VBD N
taking VBG N
risperidone NN N
( ( N
mean JJ N
dosage NN N
: : N
0.04 CD N
mg/kg/day NN N
; : N
1.17 CD N
mg/day NN N
) ) N
experienced VBD N
a DT N
significantly RB N
greater JJR N
mean JJ N
decrease NN N
on IN N
the DT N
irritability NN N
subscale NN N
of IN N
the DT N
ABC NNP N
( ( N
primary JJ N
endpoint NN N
) ) N
compared VBN N
with IN N
those DT N
who WP N
were VBD N
taking VBG N
placebo NN N
. . N

By IN N
study NN N
endpoint NN N
, , N
risperidone-treated JJ N
subjects NNS N
exhibited VBD N
a DT N
64 CD N
% NN N
improvement NN N
over IN N
baseline NN N
in IN N
the DT N
irritability NN N
score NN N
almost RB N
double JJ N
that IN N
of IN N
placebo-treated JJ N
subjects NNS N
( ( N
31 CD N
% NN N
) ) N
. . N

Risperidone-treated JJ N
subjects NNS N
also RB N
exhibited VBD N
significantly RB N
greater JJR N
decreases NNS N
on IN N
the DT N
other JJ N
4 CD N
subscales NNS N
of IN N
the DT N
ABC NNP N
; : N
on IN N
the DT N
conduct NN N
problem NN N
, , N
insecure/anxious JJ N
, , N
hyperactive JJ N
, , N
and CC N
overly RB N
sensitive JJ N
subscales NNS N
of IN N
the DT N
Nisonger NNP N
Child NNP N
Behavior NNP N
Rating NNP N
Form NNP N
( ( N
parent JJ N
version NN N
) ) N
; : N
and CC N
on IN N
the DT N
Visual NNP N
Analog NNP N
Scale NNP N
of IN N
the DT N
most RBS N
troublesome JJ N
symptom NN N
. . N

More JJR N
risperidone-treated JJ N
subjects NNS N
( ( N
87 CD N
% NN N
) ) N
showed VBD N
global JJ N
improvement NN N
in IN N
their PRP$ N
condition NN N
compared VBN N
with IN N
the DT N
placebo NN N
group NN N
( ( N
40 CD N
% NN N
) ) N
. . N

Somnolence NN N
, , N
the DT N
most RBS N
frequently RB N
reported VBD N
adverse JJ N
event NN N
, , N
was VBD N
noted VBN N
in IN N
72.5 CD N
% NN N
versus IN N
7.7 CD N
% NN N
of IN N
subjects NNS N
( ( N
risperidone NN N
vs NN N
placebo NN N
) ) N
and CC N
seemed VBD N
manageable JJ N
with IN N
dose/dose-schedule JJ N
modification NN N
. . N

Risperidone-treated JJ N
subjects NNS N
experienced VBD N
statistically RB N
significantly RB N
greater JJR N
increases NNS N
in IN N
weight NN N
( ( N
2.7 CD N
vs RB N
1.0 CD N
kg NN N
) ) N
, , N
pulse JJ N
rate NN N
, , N
and CC N
systolic JJ N
blood NN N
pressure NN N
. . N

Extrapyramidal NNP N
symptoms JJ N
scores NNS N
were VBD N
comparable JJ N
between IN N
groups NNS N
. . N

CONCLUSIONS NNP N
Risperidone NNP N
was VBD N
well RB N
tolerated VBN N
and CC N
efficacious JJ N
in IN N
treating VBG N
behavioral JJ N
symptoms NNS N
associated VBN N
with IN N
PDD NNP N
in IN N
children NNS N
. . N

-DOCSTART- -X- O O 21321333

Intermittent JJ N
theta-burst JJ N
transcranial JJ N
magnetic JJ N
stimulation NN N
for IN N
treatment NN N
of IN N
Parkinson NNP 4_p
disease NN 4_p
. . 4_p

OBJECTIVE UH N
To TO N
investigate VB N
the DT N
safety NN N
and CC N
efficacy NN N
of IN N
intermittent JJ N
theta-burst JJ N
stimulation NN N
( ( N
iTBS NN N
) ) N
in IN N
the DT N
treatment NN N
of IN N
motor NN N
symptoms NNS N
in IN N
Parkinson NNP N
disease NN N
( ( N
PD NNP N
) ) N
. . N

BACKGROUND NNP N
Progression NNP N
of IN N
PD NNP N
is VBZ N
characterized VBN N
by IN N
the DT N
emergence NN N
of IN N
motor NN N
deficits NNS N
, , N
which WDT N
eventually RB N
respond VBZ N
less JJR N
to TO N
dopaminergic VB N
therapy NN N
and CC N
pose VB N
a DT N
therapeutic JJ N
challenge NN N
. . N

Repetitive JJ N
transcranial JJ N
magnetic JJ N
stimulation NN N
( ( N
rTMS NN N
) ) N
has VBZ N
shown VBN N
promising JJ N
results NNS N
in IN N
improving VBG N
gait NN N
, , N
a DT N
major JJ N
cause NN N
of IN N
disability NN N
, , N
and CC N
may MD N
provide VB N
a DT N
therapeutic JJ N
alternative NN N
. . N

iTBS NN N
is VBZ N
a DT N
novel JJ N
type NN N
of IN N
rTMS NN N
that WDT N
may MD N
be VB N
more RBR N
efficacious JJ N
than IN N
conventional JJ N
rTMS NN N
. . N

METHODS NNP N
In IN N
this DT N
randomized JJ N
, , N
double-blind JJ N
, , N
sham-controlled JJ N
study NN N
, , N
we PRP N
investigated VBD N
safety NN N
and CC N
efficacy NN N
of IN N
iTBS NN N
of IN N
the DT N
motor NN N
and CC N
dorsolateral JJ N
prefrontal NN N
cortices NNS N
in IN N
8 CD N
sessions NNS N
over IN N
2 CD N
weeks NNS N
( ( N
evidence NN N
Class NNP N
I PRP N
) ) N
. . N

Assessment NN N
of IN N
safety NN N
and CC N
clinical JJ N
efficacy NN N
over IN N
a DT N
1-month JJ N
period NN N
included VBD N
timed JJ N
tests NNS N
of IN N
gait NN N
and CC N
bradykinesia NN N
, , N
Unified NNP N
Parkinson NNP N
's POS N
Disease NNP N
Rating NNP N
Scale NNP N
( ( N
UPDRS NNP N
) ) N
, , N
and CC N
additional JJ N
clinical NN N
, , N
neuropsychological JJ N
, , N
and CC N
neurophysiologic JJ N
measures NNS N
. . N

RESULTS NNP N
We PRP N
investigated VBD N
26 CD N
patients NNS N
with IN N
mild JJ N
to TO N
moderate VB N
PD NNP 4_p
: : N
13 CD N
received VBD N
iTBS NN N
and CC N
13 CD N
sham JJ N
stimulation NN N
. . N

We PRP N
found VBD N
beneficial JJ N
effects NNS N
of IN N
iTBS NN N
on IN N
mood NN N
, , N
but CC N
no DT N
improvement NN N
of IN N
gait NN N
, , N
bradykinesia NN N
, , N
UPDRS NNP N
, , N
and CC N
other JJ N
measures NNS N
. . N

EEG/EMG NNP N
monitoring NN N
recorded VBD N
no DT N
pathologic JJ N
increase NN N
of IN N
cortical JJ N
excitability NN N
or CC N
epileptic JJ N
activity NN N
. . N

Few JJ N
reported VBD N
discomfort NN N
or CC N
pain NN N
and CC N
one CD N
experienced JJ N
tinnitus NN N
during IN N
real JJ N
stimulation NN N
. . N

CONCLUSION NNP N
iTBS NN N
of IN N
the DT N
motor NN N
and CC N
prefrontal JJ N
cortices NNS N
appears VBZ N
safe JJ N
and CC N
improves VBZ N
mood NN N
, , N
but CC N
failed VBD N
to TO N
improve VB N
motor NN N
performance NN N
and CC N
functional JJ N
status NN N
in IN N
PD NNP N
. . N

CLASSIFICATION NNP N
OF IN N
EVIDENCE NNP N
This DT N
study NN N
provides VBZ N
Class NNP N
I PRP N
evidence NN N
that IN N
iTBS NN N
was VBD N
not RB N
effective JJ N
for IN N
gait NN N
, , N
upper JJ N
extremity NN N
bradykinesia NN N
, , N
or CC N
other JJ N
motor NN N
symptoms NNS N
in IN N
PD NNP N
. . N

-DOCSTART- -X- O O 17331650

The DT N
study NN N
of IN N
inhibiting VBG N
systematic JJ N
inflammatory JJ N
response NN N
syndrome NN N
by IN N
applying VBG N
xenogenic JJ N
( ( N
porcine NN N
) ) N
acellular NN N
dermal JJ N
matrix NN N
on IN N
second-degree JJ 4_p
burns NNS 4_p
. . N

OBJECTIVE NNP N
To TO N
investigate VB N
the DT N
influence NN N
of IN N
xenogenic NNP N
( ( N
porcine NN N
) ) N
acellular NN N
dermal JJ N
matrix NN N
on IN N
the DT N
systematic JJ N
inflammatory JJ N
reaction NN N
syndrome NN N
( ( N
SIRS NNP N
) ) N
, , N
and CC N
the DT N
reaction NN N
of IN N
burn NN 4_p
patients NNS 4_p
to TO N
tissue VB N
damage NN N
upon IN N
application NN N
to TO N
second-degree JJ 4_p
burn NN 4_p
wounds NNS 4_p
. . N

METHOD NNP N
Seventy-two JJ N
cases NNS N
of IN N
patients NNS N
with IN N
acute JJ 4_p
second-degree JJ 4_p
burns NNS 4_p
were VBD N
enrolled VBN N
in IN N
the DT N
study NN N
. . N

According VBG N
to TO N
the DT N
total JJ N
burn NN N
surface NN N
area NN N
( ( N
TBSA NNP N
) ) N
and CC N
the DT N
treatment NN N
methods NNS N
, , N
we PRP N
randomly RB N
divided VBD N
the DT N
patients NNS N
into IN N
four CD N
groups NNS N
. . N

Group NNP N
A NNP N
( ( N
treatment NN N
group NN N
) ) N
: : N
patients NNS N
with IN N
less JJR N
than IN N
30 CD N
% NN N
TBSA NNP N
covered VBD N
with IN N
xenogenic JJ N
acellular JJ N
dermal NN N
matrix NN N
. . N

Group NNP N
B NNP N
( ( N
control VB N
group NN N
) ) N
: : N
patients NNS N
with IN N
less JJR N
than IN N
30 CD N
% NN N
TBSA NNP N
covered VBD N
with IN N
betadine JJ N
ointment NN N
gauzes NNS N
. . N

Group NNP N
C NNP N
( ( N
treatment NN N
group NN N
) ) N
: : N
patients NNS N
with IN N
more JJR N
than IN N
30 CD N
% NN N
TBSA NNP N
covered VBD N
with IN N
porcine JJ N
acellular JJ N
dermal NN N
matrix NN N
. . N

Group NNP N
D NNP N
( ( N
control VB N
group NN N
) ) N
: : N
patients NNS N
with IN N
more JJR N
than IN N
30 CD N
% NN N
TBSA NNP N
covered VBD N
with IN N
betadine JJ N
ointment NN N
gauzes NNS N
. . N

Serum NNP N
level NN N
of IN N
C-reactive JJ N
protein NN N
( ( N
CRP NNP N
) ) N
was VBD N
measured VBN N
by IN N
single JJ N
radial JJ N
immunodiffusion NN N
method NN N
on IN N
1 CD N
, , N
4 CD N
, , N
7 CD N
and CC N
14 CD N
days NNS N
postburn VBP N
. . N

RESULTS VB N
The DT N
serum JJ N
level NN N
of IN N
CRP NNP N
in IN N
group NN N
A NNP N
was VBD N
significantly RB N
less JJR N
than IN N
that DT N
of IN N
in IN N
group NN N
B NNP N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
on IN N
days NNS N
4 CD N
, , N
7 CD N
and CC N
14 CD N
. . N

The DT N
serum JJ N
level NN N
of IN N
CRP NNP N
in IN N
group NN N
C NNP N
increased VBD N
slowly RB N
, , N
descended VBD N
quickly RB N
and CC N
was VBD N
significantly RB N
less JJR N
than IN N
that DT N
of IN N
in IN N
group NN N
D NNP N
on IN N
days NNS N
4 CD N
, , N
7 CD N
and CC N
14 CD N
. . N

CONCLUSION VB N
The DT N
application NN N
of IN N
xenogenic NNP N
( ( N
porcine NN N
) ) N
acellular NN N
dermal JJ N
matrix NN N
on IN N
second-degree JJ 4_p
burn NN 4_p
wound NN 4_p
can MD N
decrease VB N
serum JJ N
level NN N
of IN N
CRP NNP N
of IN N
the DT N
patients NNS N
, , N
which WDT N
may MD N
play VB N
an DT N
important JJ N
role NN N
in IN N
reducing VBG N
SIRS NNP N
and CC N
sepsis NN N
incidence NN N
. . N

-DOCSTART- -X- O O 21844080

Comparative JJ N
effectiveness NN N
of IN N
exercise NN N
electrocardiography NN N
with IN N
or CC N
without IN N
myocardial JJ N
perfusion NN N
single JJ N
photon NN N
emission NN N
computed VBD N
tomography NN N
in IN N
women NNS 4_p
with IN 4_p
suspected JJ 4_p
coronary JJ 4_p
artery NN 4_p
disease NN 4_p
: : 4_p
results NNS N
from IN N
the DT N
What WP N
Is VBZ N
the DT N
Optimal NNP N
Method NNP N
for IN N
Ischemia NNP N
Evaluation NNP N
in IN N
Women NNP N
( ( N
WOMEN NNP N
) ) N
trial NN N
. . N

BACKGROUND NNP N
There EX N
is VBZ N
a DT N
paucity NN N
of IN N
randomized JJ N
trials NNS N
regarding VBG N
diagnostic JJ N
testing NN N
in IN N
women NNS 4_p
with IN 4_p
suspected JJ 4_p
coronary JJ 4_p
artery NN 4_p
disease NN 4_p
( ( 4_p
CAD NNP 4_p
) ) 4_p
. . 4_p

It PRP N
remains VBZ N
unclear JJ N
whether IN N
the DT N
addition NN N
of IN N
myocardial JJ N
perfusion NN N
imaging NN N
( ( N
MPI NNP N
) ) N
to TO N
the DT N
standard JJ N
ECG NNP N
exercise NN N
treadmill NN N
test NN N
( ( N
ETT NNP N
) ) N
provides VBZ N
incremental JJ N
information NN N
to TO N
improve VB N
clinical JJ N
decision NN N
making NN N
in IN N
women NNS N
with IN N
suspected JJ N
CAD NNP N
. . N

METHODS NNP N
AND CC N
RESULTS NNP N
We PRP N
randomized VBD N
symptomatic JJ N
women NNS N
with IN N
suspected JJ N
CAD NNP N
, , N
an DT N
interpretable JJ N
ECG NNP N
, , N
and CC N
≥5 NNP N
metabolic JJ N
equivalents NNS N
on IN N
the DT N
Duke NNP N
Activity NNP N
Status NNP N
Index NNP N
to TO N
1 CD N
of IN N
2 CD N
diagnostic JJ N
strategies NNS N
: : N
ETT NNP N
or CC N
exercise NN N
MPI NNP N
. . N

The DT N
primary JJ N
end NN N
point NN N
was VBD N
2-year JJ N
incidence NN N
of IN N
major JJ N
adverse JJ N
cardiac NN N
events NNS N
, , N
defined VBN N
as IN N
CAD NNP N
death NN N
or CC N
hospitalization NN N
for IN N
an DT N
acute JJ N
coronary JJ N
syndrome NN N
or CC N
heart NN N
failure NN N
. . N

A DT N
total NN N
of IN N
824 CD N
women NNS N
were VBD N
randomized VBN N
to TO N
ETT NNP N
or CC N
exercise NN N
MPI NNP N
. . N

For IN N
women NNS N
randomized VBN N
to TO N
ETT NNP N
, , N
ECG NNP N
results NNS N
were VBD N
normal JJ N
in IN N
64 CD N
% NN N
, , N
indeterminate NN N
in IN N
16 CD N
% NN N
, , N
and CC N
abnormal JJ N
in IN N
20 CD N
% NN N
. . N

By IN N
comparison NN N
, , N
the DT N
exercise NN N
MPI NNP N
results NNS N
were VBD N
normal JJ N
in IN N
91 CD N
% NN N
, , N
mildly RB N
abnormal JJ N
in IN N
3 CD N
% NN N
, , N
and CC N
moderate VB N
to TO N
severely RB N
abnormal JJ N
in IN N
6 CD N
% NN N
. . N

At IN N
2 CD N
years NNS N
, , N
there EX N
was VBD N
no DT N
difference NN N
in IN N
major JJ N
adverse JJ N
cardiac NN N
events NNS N
( ( N
98.0 CD N
% NN N
for IN N
ETT NNP N
and CC N
97.7 CD N
% NN N
for IN N
MPI NNP N
; : N
P=0.59 NNP N
) ) N
. . N

Compared VBN N
with IN N
ETT NNP N
, , N
index NN N
testing VBG N
costs NNS N
were VBD N
higher JJR N
for IN N
exercise NN N
MPI NNP N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
whereas JJ N
downstream NN N
procedural NN N
costs NNS N
were VBD N
slightly RB N
lower JJR N
( ( N
P=0.0008 NNP N
) ) N
. . N

Overall UH N
, , N
the DT N
cumulative JJ N
diagnostic JJ N
cost NN N
savings NNS N
was VBD N
48 CD N
% NN N
for IN N
ETT NNP N
compared VBN N
with IN N
exercise NN N
MPI NNP N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

CONCLUSIONS NNP N
In IN N
low-risk JJ N
, , N
exercising VBG N
women NNS N
, , N
a DT N
diagnostic JJ N
strategy NN N
that WDT N
uses VBZ N
ETT NNP N
versus NN N
exercise NN N
MPI NNP N
yields NNS N
similar JJ N
2-year JJ N
posttest NN N
outcomes NNS N
while IN N
providing VBG N
significant JJ N
diagnostic JJ N
cost NN N
savings NNS N
. . N

The DT N
ETT NNP N
with IN N
selective JJ N
follow-up JJ N
testing NN N
should MD N
be VB N
considered VBN N
as IN N
the DT N
initial JJ N
diagnostic JJ N
strategy NN N
in IN N
symptomatic JJ N
women NNS N
with IN N
suspected JJ N
CAD NNP N
. . N

CLINICAL NNP N
TRIAL NNP N
REGISTRATION NNP N
http NN N
: : N
//www.clinicaltrials.gov NN N
. . N

Unique NNP N
identifier NN N
: : N
NCT00282711 NNP N
. . N

-DOCSTART- -X- O O 25044819

Reducing VBG N
the DT N
psychological JJ N
distress NN N
of IN N
family NN N
caregivers NNS N
of IN N
home NN N
based VBN N
palliative JJ 4_p
care NN 4_p
patients NNS 4_p
: : N
longer JJR N
term NN N
effects NNS N
from IN N
a DT N
randomised VBN N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
Palliative NNP N
care NN N
incorporates VBZ N
comprehensive JJ N
support NN N
of IN N
family NN N
caregivers NNS N
because IN N
many JJ N
of IN N
them PRP N
experience VB N
burden NN N
and CC N
distress NN N
. . N

However RB N
, , N
evidence-based JJ N
support NN N
initiatives NNS N
are VBP N
few JJ N
. . N

PURPOSE NNP N
We PRP N
evaluated VBD N
a DT N
one-to-one JJ N
psychoeducational JJ N
intervention NN N
aimed VBN N
at IN N
mitigating VBG N
the DT N
distress NN N
of IN N
caregivers NNS N
of IN N
patients NNS N
with IN N
advanced JJ N
cancer NN 4_p
receiving VBG 4_p
home-based JJ 4_p
palliative JJ 4_p
care NN 4_p
. . N

We PRP N
hypothesised VBD N
that IN N
caregivers NNS N
would MD N
report VB N
decreased JJ N
distress NN N
as IN N
assessed VBN N
by IN N
the DT N
General NNP N
Health NNP N
Questionnaire NNP N
( ( N
GHQ NNP N
) ) N
. . N

METHOD CC N
A DT N
randomised VBN N
controlled VBN N
trial NN N
comparing VBG N
two CD N
versions NNS N
of IN N
the DT N
delivery NN N
of IN N
the DT N
intervention NN N
( ( N
one CD N
face-to-face NN N
home NN N
visit NN N
plus CC N
telephone NN N
calls VBZ N
versus IN N
two CD N
visits NNS N
) ) N
plus CC N
standard JJ N
care NN N
to TO N
a DT N
control NN N
group NN N
( ( N
standard JJ N
care NN N
only RB N
) ) N
across IN N
four CD N
sites NNS N
in IN N
Australia NNP N
. . N

RESULTS NNP N
Recruitment NNP N
to TO N
the DT N
one CD N
visit NN N
condition NN N
was VBD N
57 CD N
, , N
the DT N
two CD N
visit NN N
condition NN N
93 CD N
, , N
and CC N
the DT N
control NN 4_p
148 CD N
. . N

We PRP N
previously RB N
reported VBD N
non-significant JJ N
changes NNS N
in IN N
distress NN N
between IN N
times NNS N
1 CD N
( ( N
baseline NN N
) ) N
and CC N
2 CD N
( ( N
1-week JJ N
post-intervention NN N
) ) N
but CC N
significant JJ N
gains NNS N
in IN N
competence NN N
and CC N
preparedness NN N
. . N

We PRP N
report VBP N
here RB N
changes NNS N
in IN N
distress NN N
between IN N
times NNS N
1 CD N
and CC N
3 CD N
( ( N
8-week JJ N
post-death NN N
) ) N
. . N

There EX N
was VBD N
significantly RB N
less JJR N
worsening VBG N
in IN N
distress NN N
between IN N
times NNS N
1 CD N
and CC N
3 CD N
in IN N
the DT N
one CD N
visit NN N
intervention NN N
group NN N
than IN N
in IN N
the DT N
control NN N
group NN N
; : N
however RB N
, , N
no DT N
significant JJ N
difference NN N
was VBD N
found VBN N
between IN N
the DT N
two CD N
visit NN N
intervention NN N
and CC N
the DT N
control NN N
group NN N
. . N

CONCLUSIONS NNP N
These DT N
results NNS N
are VBP N
consistent JJ N
with IN N
the DT N
aim NN N
of IN N
the DT N
intervention NN N
, , N
and CC N
they PRP N
support VBP N
existing VBG N
evidence NN N
demonstrating VBG N
that IN N
relatively RB N
short JJ N
psychoeducational JJ N
interventions NNS N
can MD N
help VB N
family NN N
caregivers NNS N
who WP N
are VBP N
supporting VBG N
a DT N
dying VBG N
relative NN N
. . N

The DT N
sustained JJ N
benefit NN N
during IN N
the DT N
bereavement JJ N
period NN N
may MD N
also RB N
have VB N
positive JJ N
resource NN N
implications NNS N
, , N
which WDT N
should MD N
be VB N
the DT N
subject NN N
of IN N
future JJ N
inquiry NN N
. . N

-DOCSTART- -X- O O 8779018

Deep JJ 4_p
vein NN 4_p
thrombosis NN 4_p
after IN N
major JJ 4_p
reconstructive JJ 4_p
spinal NN 4_p
surgery NN 4_p
. . N

STUDY NNP N
DESIGN NNP N
A NNP N
prospective JJ N
study NN N
was VBD N
performed VBN N
. . N

OBJECTIVES IN N
The DT N
goals NNS N
of IN N
the DT N
study NN N
were VBD N
to TO N
determine VB N
the DT N
incidence NN N
of IN N
deep JJ 4_p
vein NN 4_p
thrombosis NN 4_p
after IN N
major JJ 4_p
adult NN 4_p
spinal JJ 4_p
surgery NN 4_p
and CC N
the DT N
optimal JJ N
mode NN N
of IN N
prophylaxis NN N
in IN N
this DT N
surgical JJ N
population NN N
. . N

SUMMARY NNP N
OF IN N
BACKGROUND NNP N
DATA NNP N
Few NNP N
studies NNS N
have VBP N
evaluated VBN N
deep JJ N
vein NN N
thrombosis NN N
incidence NN N
and CC N
prophylaxis NN N
after IN N
major JJ 4_p
adult NN 4_p
spinal JJ 4_p
surgery NN 4_p
. . N

Incidence NN N
rates NNS N
have VBP N
ranged VBN N
from IN N
0.9-14 CD N
% NN N
. . N

METHODS NNP N
Three CD N
hundred VBD N
twenty-nine JJ N
patients NNS N
were VBD N
evaluated VBN N
. . N

One CD N
hundred VBD N
ten JJ N
patients NNS N
were VBD N
randomized VBN N
to TO N
3 CD N
different JJ N
deep JJ N
vein NN N
thrombosis NN N
prophylaxis NN N
groups NNS N
. . N

These DT N
patients NNS N
had VBD N
duplex JJ N
doppler NN N
scans NNS N
between IN N
the DT N
fifth NN N
and CC N
seventh JJ N
postoperative JJ N
days NNS N
. . N

The DT N
remaining VBG N
219 CD N
patients NNS N
formed VBD N
a DT N
nonrandomized JJ N
group NN N
and CC N
received VBD N
either CC N
thrombosis JJ N
embolic JJ N
deterrent NN N
stockings NNS N
alone RB N
or CC N
thrombosis VB N
embolic JJ N
deterrent NN N
stockings NNS N
and CC N
pneumatic JJ N
compression NN N
boots NNS N
for IN N
deep JJ N
vein NN N
thrombosis NN N
prophylaxis NN N
. . N

The DT N
type NN N
of IN N
deep JJ N
vein NN N
thrombosis NN N
prophylaxis NN N
in IN N
this DT N
group NN N
was VBD N
based VBN N
on IN N
surgeon NN N
preference NN N
. . N

All DT N
329 CD N
patients NNS N
were VBD N
followed VBN N
for IN N
clinical JJ N
signs NNS N
and CC N
symptoms NNS N
of IN N
thromboembolic JJ N
disease NN N
. . N

Patients NNS N
were VBD N
followed VBN N
clinically RB N
for IN N
a DT N
minimum NN N
of IN N
1 CD N
year NN N
. . N

RESULTS NNP N
All DT N
110 CD N
prophylaxis NNS N
study NN N
group NN N
patients NNS N
were VBD N
clinically RB N
asymptomatic JJ N
and CC N
109 CD N
duplex JJ N
scans NNS N
were VBD N
normal JJ N
. . N

One CD N
scan NN N
was VBD N
indeterminate JJ N
and CC N
a DT N
follow-up JJ N
venogram NN N
was VBD N
negative JJ N
. . N

Two CD N
patients NNS N
in IN N
the DT N
coumadin NN N
group NN N
( ( N
5.7 CD N
% NN N
) ) N
experienced VBD N
excessive JJ N
blood NN N
loss NN N
. . N

One CD N
of IN N
the DT N
219 CD N
patients NNS N
from IN N
the DT N
nonrandomized VBN N
group NN N
developed VBD N
a DT N
clinically RB N
detectable JJ N
proximal JJ N
deep JJ N
vein NN N
thrombosis NN N
which WDT N
was VBD N
confirmed VBN N
by IN N
duplex JJ N
ultra-sonography NN N
. . N

The DT N
overall JJ N
clinical JJ N
incidence NN N
of IN N
deep JJ N
vein NN N
thrombosis NN N
was VBD N
0.3 CD N
% NN N
( ( N
1 CD N
in IN N
329 CD N
patients NNS N
) ) N
. . N

CONCLUSIONS VB N
This DT N
low JJ N
0.3 CD N
% NN N
rate NN N
is VBZ N
in IN N
agreement NN N
with IN N
recent JJ N
studies NNS N
that WDT N
focus VBP N
on IN N
thromboembolic JJ N
disease NN N
. . N

Given VBN N
the DT N
low JJ N
incidence NN N
, , N
routine JJ N
screening NN N
for IN N
asymptomatic JJ N
thrombi NN N
appears VBZ N
unwarranted JJ N
. . N

In IN N
addition NN N
, , N
mechanical JJ N
prophylaxis NN N
with IN N
graduated JJ N
compression NN N
stockings NNS N
and CC N
pneumatic JJ N
compression NN N
boots NNS N
is VBZ N
preferable JJ N
to TO N
anticoagulation VB N
therapy NN N
. . N

-DOCSTART- -X- O O 1659236

A DT N
randomized JJ N
trial NN N
of IN N
an DT N
interim JJ N
methadone NN N
maintenance NN N
clinic NN N
. . N

BACKGROUND NNP N
Interim NNP N
methadone NN N
maintenance NN N
has VBZ N
been VBN N
proposed VBN N
as IN N
a DT N
method NN N
of IN N
providing VBG N
clinically RB N
effective JJ N
services NNS N
to TO N
heroin VB 4_p
addicts NNS 4_p
waiting VBG N
for IN N
treatment NN N
in IN N
standard JJ N
comprehensive JJ N
methadone NN N
maintenance NN N
programs NNS N
. . N

METHODS NNP N
A NNP N
clinic NN N
that WDT N
provided VBD N
initial JJ N
medical JJ N
evaluation NN N
, , N
methadone NN N
medication NN N
, , N
and CC N
AIDS NNP N
education NN N
, , N
but CC N
did VBD N
not RB N
include VB N
formal JJ N
drug NN N
abuse NN N
counseling NN N
or CC N
other JJ N
social JJ N
support NN N
services NNS N
was VBD N
established VBN N
in IN N
New NNP N
York NNP N
City NNP N
. . N

A NNP N
sample NN N
of IN N
301 CD N
volunteer NN N
subjects NNS N
recruited VBN N
from IN N
the DT N
waiting VBG N
list NN N
for IN N
treatment NN N
in IN N
the DT N
Beth NNP N
Israel NNP N
methadone NN N
program NN N
were VBD N
randomly RB N
assigned VBN N
to TO N
immediate VB N
entry NN N
into IN N
the DT N
interim JJ N
clinic NN N
or CC N
a DT N
control NN N
group NN N
. . N

RESULTS CC N
There EX N
were VBD N
no DT N
differences NNS N
in IN N
initial JJ N
levels NNS N
of IN N
illicit JJ N
drug NN N
use NN N
across IN N
the DT N
experimental JJ N
and CC N
control NN N
groups NNS N
. . N

One-month JJ N
urinalysis JJ N
follow-up NN N
data NNS N
showed VBD N
a DT N
significant JJ N
reduction NN N
in IN N
heroin NN N
use NN N
in IN N
the DT N
experimental JJ N
group NN N
( ( N
from IN N
63 CD N
% NN N
positive JJ N
at IN N
intake NN N
to TO N
29 CD N
% NN N
positive JJ N
) ) N
with IN N
no DT N
change NN N
in IN N
the DT N
control NN N
group NN N
( ( N
62 CD N
% NN N
to TO N
60 CD N
% NN N
positive JJ N
) ) N
. . N

No DT N
significant JJ N
change NN N
was VBD N
observed VBN N
in IN N
cocaine NN N
urinalyses NNS N
( ( N
approximately RB N
70 CD N
% NN N
positive JJ N
for IN N
both DT N
groups NNS N
at IN N
intake NN N
and CC N
follow-up NN N
) ) N
. . N

A DT N
higher JJR N
percentage NN N
of IN N
the DT N
experimental JJ N
group NN N
were VBD N
in IN N
treatment NN N
at IN N
16-month JJ N
follow-up NN N
( ( N
72 CD N
% NN N
vs JJ N
56 CD N
% NN N
) ) N
. . N

CONCLUSIONS NNP N
Limited NNP N
services NNS N
interim VBP N
methadone JJ N
maintenance NN N
can MD N
reduce VB N
heroin NNS N
use VBP N
among IN N
persons NNS N
awaiting VBG N
entry NN N
into IN N
comprehensive JJ N
treatment NN N
and CC N
increase VB N
the DT N
percentage NN N
entering VBG N
treatment NN N
. . N

-DOCSTART- -X- O O 15814479

Development NNP N
of IN N
the DT N
WAIS-III NNP N
general JJ N
ability NN N
index NN N
estimate NN N
( ( N
GAI-E NNP N
) ) N
. . N

The DT N
WAIS-III JJ N
General NNP N
Ability NNP N
Index NNP N
( ( N
GAI NNP N
; : N
Tulsky NNP N
, , N
Saklofske NNP N
, , N
Wilkins NNP N
, , N
& CC N
Weiss NNP N
, , N
2001 CD N
) ) N
is VBZ N
a DT N
recently RB N
developed VBN N
, , N
6-subtest JJ N
measure NN N
of IN N
global JJ N
intellectual JJ N
functioning NN N
. . N

However RB N
, , N
clinical JJ N
use NN N
of IN N
the DT N
GAI NNP N
is VBZ N
currently RB N
limited VBN N
by IN N
the DT N
absence NN N
of IN N
a DT N
method NN N
to TO N
estimate VB N
premorbid NN N
functioning VBG N
as IN N
measured VBN N
by IN N
this DT N
index NN N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
develop VB N
regression NN N
equations NNS N
to TO N
estimate VB N
GAI NNP N
scores NNS N
from IN N
demographic JJ N
variables NNS N
and CC N
WAIS-III JJ N
subtest NN N
performance NN N
. . N

Participants NNS N
consisted VBD N
of IN N
those DT N
subjects NNS N
in IN N
the DT N
WAIS-III JJ N
standardization NN N
sample NN N
that WDT N
has VBZ N
complete JJ N
demographic JJ N
data NNS N
( ( N
N=2,401 NNP N
) ) N
and CC N
were VBD N
randomly RB N
divided VBN N
into IN N
two CD N
groups NNS N
. . N

The DT N
first JJ N
group NN N
( ( N
n=1,200 RB N
) ) N
was VBD N
used VBN N
to TO N
develop VB N
the DT N
formulas NN N
( ( N
i.e. FW N
, , N
Development NNP N
group NN N
) ) N
and CC N
the DT N
second JJ N
( ( N
n=1,201 JJ N
) ) N
group NN N
was VBD N
used VBN N
to TO N
validate VB N
the DT N
prediction NN N
algorithms NN N
( ( N
i.e. FW N
, , N
Validation NNP N
group NN N
) ) N
. . N

Demographic JJ N
variables NNS N
included VBD N
age NN N
, , N
education NN N
, , N
ethnicity NN N
, , N
gender NN N
and CC N
region NN N
of IN N
country NN N
. . N

Subtest NNP N
variables NNS N
included VBD N
vocabulary JJ N
, , N
information NN N
, , N
picture NN N
completion NN N
, , N
and CC N
matrix NN N
reasoning VBG N
raw JJ N
scores NNS N
. . N

Ten CD N
regression NN N
algorithms NNS N
were VBD N
generated VBN N
designed VBN N
to TO N
estimate VB N
GAI NNP N
. . N

The DT N
GAI-Estimate NNP N
( ( N
GAI-E NNP N
) ) N
algorithms NN N
accounted VBD N
for IN N
58 CD N
% NN N
to TO N
82 CD N
% NN N
of IN N
the DT N
variance NN N
. . N

The DT N
standard JJ N
error NN N
of IN N
estimate NN N
ranged VBN N
from IN N
6.44 CD N
to TO N
9.57 CD N
. . N

The DT N
correlations NNS N
between IN N
actual JJ N
and CC N
estimated JJ N
GAI NNP N
ranged VBD N
from IN N
r=.76 NN N
to TO N
r=.90 VB N
. . N

These DT N
algorithms NNS N
provided VBD N
accurate JJ N
estimates NNS N
of IN N
GAI NNP N
in IN N
the DT N
WAIS-III JJ N
standardization NN N
sample NN N
. . N

Implications NNS N
for IN N
estimating VBG N
GAI NNP N
in IN N
patients NNS N
with IN N
known VBN N
or CC N
suspected VBN N
neurological JJ N
dysfunction NN N
is VBZ N
discussed VBN N
and CC N
future JJ N
research NN N
is VBZ N
proposed VBN N
. . N

-DOCSTART- -X- O O 12093332

Bovine NNP N
pericardium NN N
vs NN N
dacron NN N
for IN N
patch NN N
angioplasty NN N
after IN 4_p
carotid JJ 4_p
endarterectomy NN 4_p
: : N
a DT N
prospective JJ N
randomized NN N
study NN N
. . N

HYPOTHESIS NNP N
Bovine NNP N
pericardium NN N
( ( N
BP NNP N
) ) N
demonstrates VBZ N
improved JJ N
intraoperative JJ N
hemostasis NN N
and CC N
equivalent JJ N
perioperative JJ N
morbidity NN N
compared VBN N
with IN N
Dacron NNP N
when WRB N
used VBN N
as IN N
patch JJ N
material NN N
for IN N
angioplasty NN N
following VBG N
carotid JJ N
endarterectomy NN N
. . N

OBJECTIVE UH N
To TO N
prospectively RB N
compare VB N
BP NNP N
and CC N
Dacron NNP N
patch NN N
angioplasty NN N
after IN N
carotid JJ N
endarterectomy NN N
in IN N
a DT N
randomized JJ N
fashion NN N
. . N

METHODS NNP N
Ninety-five JJ N
consecutive JJ N
primary JJ N
carotid NN 4_p
endarterectomies NNS 4_p
were VBD N
performed VBN N
in IN N
a DT N
prospective JJ N
randomized VBN N
fashion NN N
in IN N
92 CD N
patients NNS N
. . N

Fifty-one CD N
procedures NNS N
were VBD N
performed VBN N
using VBG N
BP NNP N
and CC N
44 CD N
using VBG N
Dacron NNP N
. . N

Intraoperative JJ N
suture NN N
line NN N
bleeding NN N
was VBD N
subjectively RB N
evaluated VBN N
by IN N
observing VBG N
bleeding VBG N
at IN N
3 CD N
and CC N
4 CD N
minutes NNS N
following VBG N
carotid JJ N
cross-clamp JJ N
removal NN N
and CC N
then RB N
objectively RB N
weighing VBG N
the DT N
sponge NN N
used VBN N
to TO N
tamponade VB N
bleeding VBG N
during IN N
these DT N
time NN N
intervals NNS N
. . N

Perioperative JJ N
morbidity NN N
, , N
including VBG N
cervical JJ N
wound NN N
hematoma NN N
, , N
transient JJ N
ischemic JJ N
attack NN N
, , N
and CC N
stroke NN N
, , N
and CC N
perioperative JJ N
mortality NN N
were VBD N
recorded VBN N
. . N

Statistical JJ N
analysis NN N
was VBD N
performed VBN N
using VBG N
paired JJ N
t NN N
tests NNS N
, , N
chi NN N
( ( N
2 CD N
) ) N
analysis NN N
, , N
Fisher NNP N
exact JJ N
test NN N
, , N
or CC N
multiple JJ N
linear JJ N
regression NN N
as IN N
appropriate JJ N
. . N

RESULTS JJ N
Suture NNP N
line NN N
bleeding VBG N
at IN N
3 CD N
minutes NNS N
was VBD N
present JJ N
in IN N
7 CD N
( ( N
14 CD N
% NN N
) ) N
of IN N
51 CD N
patients NNS N
in IN N
the DT N
BP NNP N
group NN N
and CC N
24 CD N
( ( N
55 CD N
% NN N
) ) N
of IN N
44 CD N
patients NNS N
in IN N
the DT N
Dacron NNP N
group NN N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

Suture JJ N
line NN N
bleeding NN N
evaluated VBD N
at IN N
4 CD N
minutes NNS N
was VBD N
present JJ N
in IN N
2 CD N
( ( N
4 CD N
% NN N
) ) N
of IN N
51 CD N
patients NNS N
in IN N
the DT N
BP NNP N
group NN N
and CC N
13 CD N
( ( N
30 CD N
% NN N
) ) N
of IN N
44 CD N
patients NNS N
in IN N
the DT N
Dacron NNP N
group NN N
( ( N
P NNP N
=.001 NNP N
) ) N
. . N

Net JJ N
+/- JJ N
SEM NNP N
sponge NN N
weight NN N
( ( N
total JJ N
intraoperative JJ N
suture NN N
line NN N
bleeding VBG N
) ) N
was VBD N
6.25 CD N
+/- JJ N
0.55 CD N
g NN N
in IN N
the DT N
BP NNP N
group NN N
and CC N
16.34 CD N
+/- JJ N
1.85 CD N
g NN N
in IN N
the DT N
Dacron NNP N
group NN N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

Total JJ N
suture NN N
line NN N
bleeding NN N
was VBD N
significantly RB N
affected VBN N
by IN N
activated JJ N
clotting NN N
time NN N
; : N
however RB N
, , N
multivariate JJ N
analysis NN N
demonstrated VBD N
that IN N
bleeding NN N
was VBD N
significantly RB N
less JJR N
with IN N
BP NNP N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
even RB N
after IN N
adjusting VBG N
for IN N
differences NNS N
in IN N
activated JJ N
clotting NN N
time NN N
. . N

CONCLUSIONS NNP N
Bovine NNP N
pericardium NN N
demonstrated VBD N
a DT N
statistically RB N
significant JJ N
decrease NN N
in IN N
intraoperative JJ N
suture NN N
line NN N
bleeding VBG N
compared VBN N
with IN N
Dacron NNP N
. . N

Handling VBG N
characteristics NNS N
were VBD N
judged VBN N
by IN N
the DT N
surgeons NNS N
to TO N
be VB N
superior JJ N
for IN N
BP NNP N
. . N

Therefore RB N
, , N
we PRP N
believe VBP N
BP NNP N
may MD N
be VB N
an DT N
alternative JJ N
to TO N
Dacron NNP N
when WRB N
performing VBG N
patch NN N
angioplasty NN N
of IN N
the DT N
carotid NN N
artery NN N
after IN N
endarterectomy NN N
. . N

-DOCSTART- -X- O O 15141043

A DT N
comparison NN N
of IN N
laparoscopically RB N
assisted VBN N
and CC N
open JJ N
colectomy NN N
for IN N
colon NN 4_p
cancer NN 4_p
. . N

BACKGROUND NNP N
Minimally NNP N
invasive JJ N
, , N
laparoscopically RB N
assisted VBN N
surgery NN N
was VBD N
first RB N
considered VBN N
in IN N
1990 CD N
for IN N
patients NNS 4_p
undergoing VBG 4_p
colectomy NN 4_p
for IN 4_p
cancer NN 4_p
. . N

Concern VB N
that IN N
this DT N
approach NN N
would MD N
compromise VB N
survival NN N
by IN N
failing VBG N
to TO N
achieve VB N
a DT N
proper JJ N
oncologic JJ N
resection NN N
or CC N
adequate JJ N
staging NN N
or CC N
by IN N
altering VBG N
patterns NNS N
of IN N
recurrence NN N
( ( N
based VBN N
on IN N
frequent JJ N
reports NNS N
of IN N
tumor NN N
recurrences NNS N
within IN N
surgical JJ N
wounds NNS N
) ) N
prompted VBD N
a DT N
controlled VBN N
trial NN N
evaluation NN N
. . N

METHODS NNP N
We PRP N
conducted VBD N
a DT N
noninferiority NN N
trial NN N
at IN N
48 CD N
institutions NNS N
and CC N
randomly RB N
assigned VBD N
872 CD N
patients NNS N
with IN N
adenocarcinoma NN 4_p
of IN 4_p
the DT 4_p
colon NN 4_p
to TO N
undergo VB N
open JJ N
or CC N
laparoscopically RB N
assisted VBN N
colectomy NN N
performed VBN N
by IN N
credentialed JJ N
surgeons NNS N
. . N

The DT N
median JJ N
follow-up NN N
was VBD N
4.4 CD N
years NNS N
. . N

The DT N
primary JJ N
end NN N
point NN N
was VBD N
the DT N
time NN N
to TO N
tumor VB N
recurrence NN N
. . N

RESULTS NN N
At IN N
three CD N
years NNS N
, , N
the DT N
rates NNS N
of IN N
recurrence NN N
were VBD N
similar JJ N
in IN N
the DT N
two CD N
groups NNS N
-- : N
16 CD N
percent NN N
among IN N
patients NNS N
in IN N
the DT N
group NN N
that WDT N
underwent JJ N
laparoscopically RB N
assisted VBN N
surgery NN N
and CC N
18 CD N
percent NN N
among IN N
patients NNS N
in IN N
the DT N
open-colectomy JJ N
group NN N
( ( N
two-sided JJ N
P=0.32 NNP N
; : N
hazard PRP$ N
ratio NN N
for IN N
recurrence NN N
, , N
0.86 CD N
; : N
95 CD N
percent NN N
confidence NN N
interval NN N
, , N
0.63 CD N
to TO N
1.17 CD N
) ) N
. . N

Recurrence NN N
rates NNS N
in IN N
surgical JJ N
wounds NNS N
were VBD N
less JJR N
than IN N
1 CD N
percent NN N
in IN N
both DT N
groups NNS N
( ( N
P=0.50 NNP N
) ) N
. . N

The DT N
overall JJ N
survival NN N
rate NN N
at IN N
three CD N
years NNS N
was VBD N
also RB N
very RB N
similar JJ N
in IN N
the DT N
two CD N
groups NNS N
( ( N
86 CD N
percent NN N
in IN N
the DT N
laparoscopic-surgery JJ N
group NN N
and CC N
85 CD N
percent NN N
in IN N
the DT N
open-colectomy JJ N
group NN N
; : N
P=0.51 NNP N
; : N
hazard PRP$ N
ratio NN N
for IN N
death NN N
in IN N
the DT N
laparoscopic-surgery JJ N
group NN N
, , N
0.91 CD N
; : N
95 CD N
percent NN N
confidence NN N
interval NN N
, , N
0.68 CD N
to TO N
1.21 CD N
) ) N
, , N
with IN N
no DT N
significant JJ N
difference NN N
between IN N
groups NNS N
in IN N
the DT N
time NN N
to TO N
recurrence VB N
or CC N
overall JJ N
survival NN N
for IN N
patients NNS N
with IN N
any DT N
stage NN N
of IN N
cancer NN N
. . N

Perioperative JJ N
recovery NN N
was VBD N
faster RBR N
in IN N
the DT N
laparoscopic-surgery NN N
group NN N
than IN N
in IN N
the DT N
open-colectomy JJ N
group NN N
, , N
as IN N
reflected VBN N
by IN N
a DT N
shorter NN N
median JJ N
hospital NN N
stay NN N
( ( N
five CD N
days NNS N
vs. FW N
six CD N
days NNS N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
briefer VBP N
use NN N
of IN N
parenteral JJ N
narcotics NNS N
( ( N
three CD N
days NNS N
vs. FW N
four CD N
days NNS N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
oral JJ N
analgesics NNS N
( ( N
one CD N
day NN N
vs. FW N
two CD N
days NNS N
, , N
P=0.02 NNP N
) ) N
. . N

The DT N
rates NNS N
of IN N
intraoperative JJ N
complications NNS N
, , N
30-day JJ N
postoperative JJ N
mortality NN N
, , N
complications NNS N
at IN N
discharge NN N
and CC N
60 CD N
days NNS N
, , N
hospital JJ N
readmission NN N
, , N
and CC N
reoperation NN N
were VBD N
very RB N
similar JJ N
between IN N
groups NNS N
. . N

CONCLUSIONS NNP N
In IN N
this DT N
multi-institutional JJ N
study NN N
, , N
the DT N
rates NNS N
of IN N
recurrent JJ N
cancer NN N
were VBD N
similar JJ N
after IN N
laparoscopically RB N
assisted VBN N
colectomy NN N
and CC N
open JJ N
colectomy NN N
, , N
suggesting VBG N
that IN N
the DT N
laparoscopic NN N
approach NN N
is VBZ N
an DT N
acceptable JJ N
alternative NN N
to TO N
open VB N
surgery NN N
for IN N
colon NN N
cancer NN N
. . N

-DOCSTART- -X- O O 9351400

Dose-response NNP N
comparison NN N
of IN N
RRR-alpha-tocopherol NNP N
and CC N
all-racemic JJ N
alpha-tocopherol NN N
on IN N
LDL NNP N
oxidation NN N
. . N

Much JJ N
data NNS N
have VBP N
accrued VBN N
in IN N
support NN N
of IN N
the DT N
concept NN N
that IN N
oxidation NN N
of IN N
LDL NNP N
is VBZ N
a DT N
key JJ N
early JJ N
step NN N
in IN N
atherogenesis NN N
. . N

The DT N
most RBS N
consistent JJ N
data NNS N
with IN N
respect NN N
to TO N
micronutrient VB N
antioxidants NNS N
and CC N
atherosclerosis NN N
appear VBP N
to TO N
relate VB N
to TO N
alpha-tocopherol NN N
( ( N
AT NNP N
) ) N
, , N
the DT N
predominant JJ N
lipid-soluble JJ N
antioxidant NN N
in IN N
LDL NNP N
. . N

There EX N
are VBP N
scant JJ N
data NNS N
on IN N
the DT N
direct JJ N
comparison NN N
of IN N
RRR-AT NNP N
and CC N
all-racemic JJ N
( ( N
rac NN N
) ) N
-AT NN N
on IN N
LDL NNP N
oxidizability NN N
. . N

Hence NNP N
, , N
the DT N
aim NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
examine VB N
the DT N
relative JJ N
effects NNS N
of IN N
RRR-AT NNP N
and CC N
all-rac-AT NN N
on IN N
plasma NN N
antioxidant NN N
levels NNS N
and CC N
LDL NNP N
oxidation NN N
in IN N
healthy JJ N
persons NNS N
in IN N
a DT N
dose-response JJ N
study NN N
. . N

The DT N
effect NN N
of IN N
RRR-AT NNP N
and CC N
all-rac-AT NN N
at IN N
doses NNS N
of IN N
100 CD N
, , N
200 CD N
, , N
400 CD N
, , N
and CC N
800 CD N
IU/d NNP N
on IN N
plasma NN N
and CC N
LDL NNP N
AT NNP N
levels NNS N
and CC N
LDL NNP N
oxidation NN N
was VBD N
tested VBN N
in IN N
a DT N
randomized JJ N
, , N
placebo-controlled JJ N
study NN N
of IN N
79 CD N
healthy JJ N
subjects NNS N
. . N

Copper-catalyzed JJ N
oxidation NN N
of IN N
LDL NNP N
was VBD N
monitored VBN N
by IN N
measuring VBG N
the DT N
formation NN N
of IN N
conjugated JJ N
dienes NNS N
and CC N
lipid JJ N
peroxides NNS N
over IN N
an DT N
8-hour JJ N
time NN N
course NN N
at IN N
baseline NN N
and CC N
again RB N
after IN N
8 CD N
weeks NNS N
. . N

Plasma NNP N
AT NNP N
, , N
lipid-standardized JJ N
AT NNP N
, , N
and CC N
LDL NNP N
AT NNP N
levels NNS N
rose VBD N
in IN N
a DT N
dose-dependent JJ N
fashion NN N
in IN N
both DT N
the DT N
RRR-AT NNP N
and CC N
all-rac-AT JJ N
groups NNS N
compared VBN N
with IN N
baseline NN N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
plasma NN N
, , N
lipid-standardized JJ N
, , N
and CC N
LDL NNP N
AT NNP N
levels NNS N
between IN N
RRR-AT NNP N
and CC N
all-rac-AT JJ N
supplementation NN N
at IN N
any DT N
dose JJ N
comparison NN N
. . N

The DT N
lag NN N
phases NNS N
of IN N
oxidation NN N
were VBD N
significantly RB N
prolonged VBN N
with IN N
doses NNS N
> VBP N
or CC N
= VBP N
400 CD N
IU/d NNP N
of IN N
RRR-AT NNP N
and CC N
all-rac-AT JJ N
, , N
as IN N
measured VBN N
by IN N
conjugated-dienes NNS N
assay NNS N
and CC N
at IN N
400 CD N
IU/d NNP N
of IN N
RRR-AT NNP N
and CC N
800 CD N
IU/d NNP N
of IN N
both DT N
forms NNS N
of IN N
AT NNP N
by IN N
lipid JJ N
peroxide NN N
assay NN N
. . N

Again NNP N
, , N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
the DT N
lag NN N
phase NN N
of IN N
oxidation NN N
at IN N
each DT N
dose NN N
for IN N
RRR-AT NNP N
when WRB N
compared VBN N
with IN N
all-rac-AT NN N
. . N

Also RB N
, , N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
LDL NNP N
oxidation NN N
after IN N
in IN N
vitro JJ N
enrichment NN N
of IN N
LDL NNP N
with IN N
RRR-AT NNP N
and CC N
all-rac-AT JJ N
. . N

Thus RB N
, , N
supplementation NN N
with IN N
either DT N
RRR-AT JJ N
or CC N
all-rac-AT JJ N
resulted VBN N
in IN N
similar JJ N
increases NNS N
in IN N
plasma NN N
and CC N
LDL NNP N
AT NNP N
levels NNS N
at IN N
equivalent JJ N
IU NNP N
doses NNS N
, , N
and CC N
the DT N
degree NN N
of IN N
protection NN N
against IN N
copper-catalyzed JJ N
LDL NNP N
oxidation NN N
was VBD N
only RB N
evident JJ N
at IN N
doses NNS N
> VBP N
or CC N
= VBP N
400 CD N
IU/d NNP N
for IN N
both DT N
forms NNS N
. . N

-DOCSTART- -X- O O 7924475

Treatment NN N
of IN N
acute JJ N
asthma NN N
. . N

Lack NNP N
of IN N
therapeutic JJ N
benefit NN N
and CC N
increase NN N
of IN N
the DT N
toxicity NN N
from IN N
aminophylline JJ N
given VBN N
in IN N
addition NN N
to TO N
high JJ N
doses NNS N
of IN N
salbutamol NN N
delivered VBN N
by IN N
metered-dose JJ N
inhaler NN N
with IN N
a DT N
spacer NN N
. . N

We PRP N
conducted VBD N
a DT N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
to TO N
determine VB N
if IN N
intravenous JJ N
aminophylline NN N
adds VBZ N
any DT N
benefit NN N
to TO N
high JJ N
doses NNS N
of IN N
inhaled JJ N
salbutamol NN N
in IN N
patients NNS N
who WP N
presented VBD N
for IN N
treatment NN N
of IN N
acute JJ 4_p
asthma NN 4_p
. . N

We PRP N
studied VBD N
94 CD N
patients NNS N
( ( N
mean JJ N
age NN N
, , N
35.6 CD N
+/- JJ N
11.2 CD N
years NNS N
) ) N
with IN N
moderate JJ 4_p
to TO 4_p
severe VB 4_p
acute JJ 4_p
asthma NN 4_p
. . N

All DT N
patients NNS N
received VBD N
therapy NN N
with IN N
salbutamol NN N
delivered VBN N
with IN N
metered-dose JJ N
inhaler NN N
( ( N
MDI NNP N
) ) N
into IN N
a DT N
spacer NN N
device NN N
( ( N
Volumatic NNP N
) ) N
in IN N
four CD N
puffs NNS N
( ( N
400 CD N
micrograms NNS N
) ) N
at IN N
10-min JJ N
interval NN N
, , N
and CC N
intravenous JJ N
hydrocortisone NN N
( ( N
500 CD N
mg NN N
) ) N
. . N

Patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
either CC N
a DT N
loading NN N
dose NN N
of IN N
intravenous JJ N
aminophylline NN N
followed VBN N
by IN N
a DT N
routine JJ N
infusion NN N
( ( N
n JJ N
= NNP N
45 CD N
) ) N
or CC N
an DT N
equal JJ N
volume NN N
of IN N
placebo NN N
as IN N
a DT N
loading NN N
dose NN N
and CC N
infusion NN N
( ( N
n JJ N
= NNP N
49 CD N
) ) N
. . N

The DT N
two CD N
groups NNS N
showed VBD N
no DT N
differences NNS N
in IN N
measurements NNS N
of IN N
peak JJ N
expiratory NN N
flow NN N
, , N
FEV1 NNP N
, , N
and CC N
FVC NNP N
at IN N
baseline NN N
and CC N
at IN N
the DT N
end NN N
of IN N
treatment NN N
. . N

However RB N
, , N
the DT N
patients NNS N
treated VBN N
with IN N
aminophylline NN N
had VBD N
significantly RB N
more RBR N
adverse JJ N
effects NNS N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
differences NNS N
in IN N
the DT N
final JJ N
mean NN N
dose NN N
of IN N
salbutamol NN N
( ( N
6.3 CD N
+/- JJ N
44.5 CD N
mg NN N
for IN N
the DT N
placebo NN N
group NN N
and CC N
5.8 CD N
+/- JJ N
4.2 CD N
mg NN N
for IN N
the DT N
aminophylline NN N
group NN N
) ) N
, , N
hospital JJ N
admission NN N
rate NN N
( ( N
10.2 CD N
percent NN N
for IN N
the DT N
placebo NN N
group NN N
and CC N
9.0 CD N
percent NN N
for IN N
the DT N
aminophylline NN N
group NN N
) ) N
, , N
and CC N
mean JJ N
duration NN N
of IN N
Emergency NNP N
Department NNP N
treatment NN N
( ( N
2.5 CD N
+/- JJ N
1.83 CD N
h NN N
for IN N
the DT N
placebo NN N
group NN N
and CC N
2.37 CD N
+/- JJ N
1.75 CD N
h NN N
for IN N
the DT N
aminophylline NN N
group NN N
) ) N
. . N

The DT N
results NNS N
were VBD N
similar JJ N
when WRB N
the DT N
patients NNS N
were VBD N
divided VBN N
in IN N
accord NN N
with IN N
the DT N
degree NN N
of IN N
respiratory NN N
obstruction NN N
( ( N
baseline JJ N
FEV1 NNP N
< NNP N
30 CD N
percent NN N
of IN N
predicted VBN N
) ) N
and CC N
theophylline JJ N
level NN N
at IN N
30 CD N
min NN N
of IN N
treatment NN N
( ( N
placebo JJ N
group NN N
patients NNS N
with IN N
theophylline JJ N
level NN N
< VBD N
10 CD N
mg/L NN N
vs NN N
aminophylline NN N
group NN N
patients NNS N
with IN N
theophylline JJ N
level NN N
> NN N
or CC N
= $ N
10 CD N
mg/L NN N
) ) N
. . N

We PRP N
conclude VBP N
that DT N
intravenous JJ N
aminophylline NN N
adds VBZ N
to TO N
the DT N
toxicity NN N
but CC N
not RB N
the DT N
efficacy NN N
of IN N
inhaled JJ N
salbutamol NN N
in IN N
the DT N
treatment NN N
of IN N
acute JJ N
exacerbations NNS N
of IN N
asthma NN N
. . N

-DOCSTART- -X- O O 9006598

Improving VBG N
care NN 4_p
givers NNS 4_p
' POS 4_p
satisfaction NN 4_p
with IN 4_p
information NN 4_p
received VBN 4_p
during IN 4_p
hospitalization NN 4_p
. . 4_p

As IN N
competition NN N
for IN N
patient NN N
volume NN N
escalates VBZ N
among IN N
hospital JJ N
providers NNS N
, , N
administrators NNS N
must MD N
identify VB N
ways NNS N
to TO N
attract VB N
new JJ 4_p
patients NNS 4_p
and CC 4_p
maintain NN 4_p
or CC 4_p
increase VB 4_p
patient JJ 4_p
volume NN 4_p
. . 4_p

Family NNP N
care NN N
givers NNS N
are VBP N
known VBN N
to TO N
greatly RB N
influence JJ N
individuals NNS N
' POS N
choices NNS N
in IN N
these DT N
matters NNS N
of IN N
selection NN N
of IN N
healthcare NN N
services NNS N
and CC N
providers NNS N
. . N

The DT N
results NNS N
of IN N
a DT N
successful JJ N
nurse-initiated JJ N
daily JJ N
phone NN N
calls VBZ N
program NN N
, , N
designed VBN N
to TO N
improve VB N
family NN N
care NN N
giver NN N
satisfaction NN N
by IN N
enhancing VBG N
the DT N
provision NN N
of IN N
patient-specific JJ N
information NN N
, , N
are VBP N
presented VBN N
. . N

The DT N
components NNS N
of IN N
the DT N
program NN N
, , N
associated VBN N
costs NNS N
, , N
and CC N
implications NNS N
on IN N
delivery NN N
of IN N
care NN N
are VBP N
discussed VBN N
. . N

-DOCSTART- -X- O O 22244705

The DT N
relationship NN N
of IN N
alexithymia NN N
to TO N
emotional JJ N
dysregulation NN N
within IN N
an DT N
alcohol NN N
dependent JJ N
treatment NN N
sample NN N
. . N

Difficulties NNS N
regulating VBG N
emotions NNS N
have VBP N
implications NNS N
for IN N
the DT N
development NN N
, , N
maintenance NN N
, , N
and CC N
recovery NN N
from IN N
alcohol NN N
problems NNS N
. . N

One CD N
construct NN N
thought NN N
to TO N
impede VB N
the DT N
regulation NN N
of IN N
emotion NN N
is VBZ N
alexithymia JJ N
. . N

Alexithymia NNP N
is VBZ N
characterized VBN N
by IN N
difficulties NNS N
identifying VBG N
, , N
differentiating VBG N
and CC N
expressing VBG N
feelings NNS N
, , N
a DT N
limited JJ N
imagination NN N
and CC N
fantasy JJ N
life NN N
, , N
and CC N
an DT N
externally-oriented JJ N
thinking NN N
style NN N
( ( N
e.g. UH N
, , N
prefer VBP N
talking VBG N
about IN N
daily JJ N
activities NNS N
rather RB N
than IN N
feelings NNS N
) ) N
. . N

Given VBN N
that IN N
poor JJ N
emotion NN N
regulation NN N
skills NNS N
have VBP N
been VBN N
found VBN N
to TO N
predict VB N
posttreatment NN N
levels NNS N
of IN N
alcohol NN N
use NN N
, , N
and CC N
that IN N
several JJ N
defining VBG N
characteristics NNS N
of IN N
alexithymia JJ N
bear JJ N
similarity NN N
to TO N
deficits NNS N
in IN N
emotion NN N
regulation NN N
skills NNS N
, , N
it PRP N
is VBZ N
possible JJ N
that IN N
alexithymia NN N
may MD N
predict VB N
poorer JJR N
alcohol NN N
treatment NN N
outcomes NNS N
. . N

Thus RB N
, , N
the DT N
present JJ N
study NN N
first RB N
examined VBD N
the DT N
relationship NN N
of IN N
alexithymia NN N
to TO N
several JJ N
other JJ N
emotion NN N
regulation NN N
measures NNS N
and CC N
then RB N
investigated VBD N
the DT N
impact NN N
of IN N
alexithymia NN N
on IN N
attrition NN N
and CC N
alcohol NN N
treatment NN N
outcomes NNS N
in IN N
men NNS N
and CC N
women NNS N
( ( N
N=77 NNP N
) ) N
enrolled VBD N
in IN N
a DT N
12-week JJ N
cognitive-behavioral JJ N
intervention NN N
for IN N
alcohol NN N
dependence NN N
. . N

At IN N
baseline NN N
, , N
higher JJR N
scores NNS N
on IN N
alexithymia NN N
were VBD N
associated VBN N
poorer JJR N
emotion NN N
regulation NN N
skills NNS N
, , N
fewer JJR N
percent NN N
days NNS N
abstinent NN N
, , N
greater JJR N
alcohol NN N
dependence NN N
severity NN N
, , N
and CC N
several JJ N
high-risk JJ N
drinking NN N
situations NNS N
. . N

Alexithymia NNP N
was VBD N
unrelated JJ N
to TO N
attrition NN N
and CC N
to TO N
level NN N
of IN N
alcohol NN N
consumption NN N
at IN N
posttreatment NN N
. . N

Overall UH N
, , N
the DT N
construct NN N
of IN N
alexithymia NN N
is VBZ N
shown VBN N
to TO N
be VB N
related VBN N
to TO N
several JJ N
theoretically-related JJ N
constructs NNS N
( ( N
e.g. NN N
, , N
emotion NN N
regulation NN N
, , N
mindfulness NN N
) ) N
but CC N
demonstrated VBD N
a DT N
limited JJ N
relationship NN N
to TO N
drinking VBG N
outcomes NNS N
in IN N
those DT 4_p
seeking VBG 4_p
treatment NN 4_p
for IN 4_p
alcohol NN 4_p
dependence NN 4_p
. . 4_p

-DOCSTART- -X- O O 23857884

CT NNP N
and CC N
MRI NNP N
measurements NNS N
of IN N
tibial JJ N
tubercle-trochlear JJ N
groove NN N
distances NNS N
are VBP N
not RB N
equivalent JJ N
in IN N
patients NNS N
with IN N
patellar JJ 4_p
instability NN 4_p
. . N

BACKGROUND NNP N
Tibial NNP N
tubercle-trochlear JJ N
groove NN N
distance NN N
( ( N
TT-TG NNP N
) ) N
is VBZ N
a DT N
commonly RB N
used VBN N
measurement NN N
for IN N
surgical JJ N
decision NN N
making NN N
in IN N
patients NNS N
with IN N
patellofemoral JJ 4_p
malalignment NN 4_p
and CC 4_p
instability NN 4_p
. . N

This DT N
measurement NN N
has VBZ N
historically RB N
been VBN N
performed VBN N
utilizing JJ N
axial JJ N
computed VBN N
tomography NN N
( ( N
CT NNP N
) ) N
. . N

More RBR N
recently RB N
, , N
magnetic JJ N
resonance NN N
imaging NN N
( ( N
MRI NNP N
) ) N
has VBZ N
been VBN N
proposed VBN N
as IN N
an DT N
equivalent JJ N
method NN N
, , N
but CC N
this DT N
has VBZ N
not RB N
yet RB N
been VBN N
fully RB N
validated VBN N
. . N

PURPOSE NNP N
To TO N
determine VB N
the DT N
reliability NN N
of IN N
TT-TG NNP N
distance NN N
measurements NNS N
on IN N
both DT N
MRI NNP N
and CC N
CT NNP N
and CC N
to TO N
determine VB N
whether IN N
the DT N
measurements NNS N
are VBP N
interchangeable JJ N
with IN N
one CD N
another DT N
. . N

STUDY NNP N
DESIGN NNP N
Cohort NNP N
study NN N
( ( N
diagnosis NN N
) ) N
; : N
Level NNP N
of IN N
evidence NN N
, , N
2 CD N
. . N

METHODS NNP N
All DT N
patients NNS N
with IN N
patellar JJ 4_p
instability NN 4_p
who WP N
underwent VBD N
both DT N
CT NNP N
and CC N
MRI NNP N
of IN N
the DT N
knee NN N
from IN N
2003 CD N
to TO N
2011 CD N
were VBD N
included VBN N
( ( N
n JJ N
= $ N
59 CD N
knees NNS N
in IN N
54 CD N
patients NNS N
) ) N
. . N

Two CD N
fellowship-trained JJ N
musculoskeletal JJ N
radiologists NNS N
measured VBD N
the DT N
TT-TG NNP N
distances NNS N
for IN N
each DT N
patient NN N
by IN N
CT NNP N
and CC N
MRI NNP N
in IN N
a DT N
randomized JJ N
, , N
blinded JJ N
fashion NN N
. . N

Interobserver NNP N
reliability NN N
was VBD N
calculated VBN N
between IN N
radiologists NNS N
for IN N
both DT N
imaging VBG N
modalities NNS N
, , N
and CC N
intermethod JJ N
reliability NN N
was VBD N
calculated VBN N
between IN N
the DT N
2 CD N
imaging NN N
modalities NNS N
. . N

The DT N
results NNS N
are VBP N
reported VBN N
using VBG N
intraclass NN N
correlation NN N
coefficients NNS N
( ( N
ICCs NNP N
) ) N
and CC N
Bland-Altman JJ N
analysis NN N
. . N

RESULTS VB N
The DT N
59 CD N
knees NNS N
had VBD N
a DT N
mean JJ N
TT-TG JJ N
distance NN N
of IN N
16.9 CD N
mm NN N
( ( N
range NN N
, , N
8.3-25.8 JJ N
mm NN N
) ) N
by IN N
CT NNP N
and CC N
14.7 CD N
mm NN N
( ( N
range NN N
, , N
1.5-25.1 JJ N
mm NN N
) ) N
by IN N
MRI NNP N
. . N

Interobserver NNP N
reliability NN N
between IN N
the DT N
radiologists NNS N
was VBD N
considered VBN N
excellent NN N
for IN N
both DT N
CT NNP N
and CC N
MRI NNP N
( ( N
ICC NNP N
= NNP N
0.777 CD N
and CC N
0.843 CD N
, , N
respectively RB N
) ) N
. . N

When WRB N
comparing VBG N
CT NNP N
to TO N
MRI NNP N
, , N
the DT N
ICC NNP N
was VBD N
considered VBN N
only RB N
fair JJ N
for IN N
each DT N
of IN N
the DT N
raters NNS N
( ( N
0.532 CD N
and CC N
0.539 CD N
) ) N
. . N

Eleven JJ N
patients NNS N
( ( N
19 CD N
% NN N
) ) N
had VBD N
a DT N
TT-TG JJ N
distance NN N
of IN N
≥20 NNP N
mm NN N
on IN N
CT NNP N
preoperatively RB N
and CC N
underwent JJ N
distal JJ N
realignment NN N
by IN N
tibial JJ N
tubercle NN N
osteotomy NN N
. . N

In IN N
this DT N
surgical JJ N
subgroup NN N
, , N
the DT N
mean JJ N
TT-TG NNP N
distance NN N
was VBD N
22.5 CD N
mm NN N
( ( N
range NN N
, , N
19.8-25.8 JJ N
mm NN N
) ) N
by IN N
CT NNP N
and CC N
only RB N
18.7 CD N
mm NN N
( ( N
range NN N
, , N
14.4-22.8 JJ N
mm NN N
) ) N
by IN N
MRI NNP N
for IN N
a DT N
mean JJ N
difference NN N
of IN N
3.80 CD N
mm NN N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

CONCLUSION VB N
The DT N
TT-TG JJ N
distance NN N
can MD N
be VB N
measured VBN N
with IN N
excellent JJ N
interrater NN N
reliability NN N
on IN N
both DT N
MRI NNP N
and CC N
CT NNP N
; : N
however RB N
, , N
the DT N
values NNS N
derived VBN N
from IN N
these DT N
2 CD N
tests NNS N
may MD N
not RB N
be VB N
interchangeable JJ N
. . N

This DT N
observation NN N
should MD N
be VB N
taken VBN N
into IN N
consideration NN N
when WRB N
MRI NNP N
is VBZ N
used VBN N
for IN N
surgical JJ N
planning NN N
because IN N
MRI NNP N
may MD N
underestimate VB N
the DT N
TT-TG NNP N
distance NN N
when WRB N
compared VBN N
with IN N
CT NNP N
. . N

-DOCSTART- -X- O O 23610236

A DT N
play NN N
and CC N
joint JJ N
attention NN N
intervention NN N
for IN N
teachers NNS 4_p
of IN 4_p
young JJ 4_p
children NNS 4_p
with IN 4_p
autism NN 4_p
: : 4_p
a DT N
randomized VBN N
controlled VBN N
pilot NN N
study NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
pilot VB N
test VB N
a DT N
classroom-based JJ N
intervention NN N
focused VBD N
on IN N
facilitating VBG N
play NN N
and CC N
joint JJ N
attention NN N
for IN N
young JJ N
children NNS N
with IN N
autism NN N
in IN N
self-contained JJ N
special JJ N
education NN N
classrooms NNS N
. . N

Thirty-three JJ N
children NNS N
with IN N
autism NN N
between IN N
the DT N
ages NNS N
of IN N
3 CD N
and CC N
6 CD N
years NNS N
participated VBN N
in IN N
the DT N
study NN N
with IN N
their PRP$ N
classroom NN N
teachers NNS N
( ( N
n JJ N
= NNP N
14 CD N
) ) N
. . N

The DT N
14 CD N
preschool NN N
special JJ N
education NN N
teachers NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
three CD N
groups NNS N
: : N
( ( N
1 CD N
) ) N
symbolic NN N
play NN N
then RB N
joint JJ N
attention NN N
intervention NN N
, , N
( ( N
2 CD N
) ) N
joint NN N
attention NN N
then RB N
symbolic JJ N
intervention NN N
, , N
and CC N
( ( N
3 CD N
) ) N
wait-list NN N
control NN N
period NN N
then RB N
further RB N
randomized VBN N
to TO N
either DT N
group NN N
1 CD N
or CC N
group NN N
2 CD N
. . N

In IN N
the DT N
intervention NN N
, , N
teachers NNS N
participated VBD N
in IN N
eight CD N
weekly JJ N
individualized VBN N
1-h JJ N
sessions NNS N
with IN N
a DT N
researcher NN N
that WDT N
emphasized VBD N
embedding VBG N
strategies NNS N
targeting VBG N
symbolic JJ N
play NN N
and CC N
joint JJ N
attention NN N
into IN N
their PRP$ N
everyday JJ N
classroom NN N
routines NNS N
and CC N
activities NNS N
. . N

The DT N
main JJ N
child NN N
outcome NN N
variables NNS N
of IN N
interest NN N
were VBD N
collected VBN N
through IN N
direct JJ N
classroom NN N
observations NNS N
. . N

Findings NNS N
indicate VBP N
that IN N
teachers NNS N
can MD N
implement VB N
an DT N
intervention NN N
to TO N
significantly RB N
improve VB N
joint JJ N
engagement NN N
of IN N
young JJ N
children NNS N
with IN N
autism NN N
in IN N
their PRP$ N
classrooms NNS N
. . N

Furthermore RB N
, , N
multilevel NN N
analyses NNS N
showed VBD N
significant JJ N
increases NNS N
in IN N
joint JJ N
attention NN N
and CC N
symbolic JJ N
play NN N
skills NNS N
. . N

Thus RB N
, , N
these DT N
pilot NN N
data NNS N
emphasize VBP N
the DT N
need NN N
for IN N
further JJ N
research NN N
and CC N
implementation NN N
of IN N
classroom-based JJ N
interventions NNS N
targeting VBG N
play NN N
and CC N
joint JJ N
attention NN N
skills NNS N
for IN N
young JJ N
children NNS N
with IN N
autism NN N
. . N

-DOCSTART- -X- O O 25319807

Benefit NN N
of IN N
adjuvant JJ N
interferon NN N
alfa-2b NN N
( ( N
IFN-α NNP N
) ) N
therapy NN N
in IN 4_p
melanoma NN 4_p
patients NNS 4_p
with IN 4_p
high JJ 4_p
serum NN 4_p
MMP-8 NNP 4_p
levels NNS 4_p
. . N

Matrix NNP N
metalloproteinases NNS N
( ( N
MMPs NNP N
) ) N
are VBP N
important JJ N
enzymes NNS N
in IN N
tissue NN N
turnover NN N
and CC N
various JJ N
inflammatory JJ N
processes NNS N
. . N

In IN N
this DT N
study NN N
, , N
it PRP N
was VBD N
evaluated VBN N
whether IN N
serum JJ N
MMP-8 NNP N
can MD N
predict VB N
the DT N
response NN N
to TO N
adjuvant VB N
interferon JJ N
alfa-2b JJ N
( ( N
IFN-α NNP N
) ) N
therapy NN N
in IN N
patients NNS N
with IN N
operated JJ N
high-risk JJ N
cutaneous JJ N
melanoma NN 4_p
. . N

Pre-treatment JJ N
sera NN N
from IN N
460 CD N
patients NNS N
with IN N
stage JJ 4_p
IIB-IIIC JJ 4_p
melanoma NN 4_p
were VBD 4_p
analyzed VBN 4_p
for IN 4_p
MMP-8 NNP 4_p
. . N

The DT N
patients NNS N
were VBD N
randomized VBN N
after IN N
surgery NN N
to TO N
adjuvant VB N
IFN-α NNP N
for IN N
12 CD N
or CC N
24 CD N
months NNS N
( ( N
n JJ N
= NNP N
313 CD N
) ) N
or CC N
observation NN N
only RB N
( ( N
n JJ N
= NNP N
147 CD N
) ) N
. . N

The DT N
median JJ N
serum NN N
MMP-8 NNP N
level NN N
was VBD N
used VBN N
to TO N
classify VB N
the DT N
patients NNS N
into IN N
a DT N
low JJ N
MMP-8 NNP N
( ( N
n JJ N
= NNP N
232 CD N
) ) N
and CC N
a DT N
high JJ N
MMP-8 NNP N
( ( N
n JJ N
= NNP N
228 CD N
) ) N
group NN N
. . N

In IN N
the DT N
high JJ N
MMP-8 NNP N
subgroup NN N
, , N
IFN-α NNP N
therapy NN N
significantly RB N
improved VBN N
relapse-free JJ N
survival NN N
( ( N
RFS NNP N
) ) N
. . N

RFS NNP N
was VBD N
36.8 CD N
months NNS 4_p
in IN 4_p
patients NNS 4_p
with IN 4_p
high JJ 4_p
MMP-8 JJ 4_p
levels NNS 4_p
receiving VBG N
IFN-α NNP N
therapy NN N
, , N
whereas WP N
RFS NNP N
for IN N
those DT N
with IN N
high JJ N
MMP-8 JJ N
levels NNS N
with IN N
observation NN N
only RB N
was VBD N
10.6 CD N
months NNS N
( ( N
P NNP N
= NNP N
0.027 CD N
) ) N
. . N

Median JJ N
overall JJ N
survival NN 4_p
for IN 4_p
patients NNS 4_p
with IN 4_p
high JJ 4_p
MMP-8 NNP 4_p
and CC N
observation NN N
only RB N
was VBD N
36.7 CD N
versus NN N
71.7 CD N
months NNS N
in IN N
those DT N
receiving VBG N
IFN-α NNP N
( ( N
P NNP N
= NNP N
0.13 CD N
) ) N
. . N

In IN N
a DT N
multivariate NN N
model NN N
, , N
IFN-α NNP N
therapy NN N
was VBD N
a DT N
significant JJ N
predictor NN N
of IN N
favorable JJ N
RFS NNP N
( ( N
HR NNP N
0.74 CD N
; : N
95 CD N
% NN N
CI NNP N
0.55-0.99 CD N
; : N
P NNP N
= NNP N
0.048 CD N
) ) N
, , N
after IN N
adjustment NN N
for IN N
pre-treatment JJ N
MMP-8 NNP N
( ( N
HR NNP N
1.17 CD N
; : N
95 CD N
% NN N
CI NNP N
0.88-1.55 CD N
; : N
P NNP N
= NNP N
0.28 CD N
) ) N
, , N
gender FW N
( ( N
HR NNP N
1.16 CD N
; : N
95 CD N
% NN N
CI NNP N
0.86-1.56 CD N
; : N
P NNP N
= NNP N
0.32 CD N
) ) N
, , N
age NN N
( ( N
HR NNP N
1.00 CD N
; : N
95 CD N
% NN N
CI NNP N
1.00-1.02 CD N
; : N
P NNP N
= NNP N
0.12 CD N
) ) N
, , N
ulceration NN N
( ( N
HR NNP N
1.09 CD N
; : N
95 CD N
% NN N
CI NNP N
0.81-1.46 CD N
; : N
P NNP N
= NNP N
0.58 CD N
) ) N
, , N
and CC N
the DT N
presence NN N
of IN N
node JJ N
metastases NNS N
( ( N
HR NNP N
1.36 CD N
; : N
95 CD N
% NN N
CI NNP N
1.17-1.58 CD N
; : N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

In IN N
conclusion NN N
, , N
patients NNS N
with IN N
high JJ N
serum NN N
MMP-8 NNP N
levels NNS N
may MD N
benefit VB N
from IN N
adjuvant JJ N
IFN-α NNP N
therapy NN N
, , N
but CC N
this DT N
observation NN N
should MD N
be VB N
further RB N
investigated VBN N
. . N

-DOCSTART- -X- O O 991148

Study NNP N
of IN N
cytosine NN N
arabinoside NN N
( ( N
NSC-63878 NNP N
) ) N
synchronization NN N
plus CC N
vincristine NN N
( ( N
NSC-67574 NNP N
) ) N
, , N
prednisone NN N
( ( N
NSC-10023 NNP N
) ) N
, , N
and CC N
L-asparaginase NNP N
( ( N
NSC-109229 NNP N
) ) N
for IN N
remission NN N
induction NN N
in IN N
advanced JJ 4_p
acute NN 4_p
leukemia NN 4_p
in IN N
children NNS N
. . N

Cytosine NNP N
arabinoside NN N
( ( N
CA NNP N
) ) N
was VBD N
utilized VBN N
in IN N
efforts NNS N
to TO N
synchronize VB N
leukemic JJ N
cells NNS N
in IN N
DNA NNP N
synthesis NN N
for IN N
treatment NN N
with IN N
vincristine NN N
, , N
prednisone NN N
, , N
and CC N
L-asparaginase NNP N
in IN N
children NNS N
with IN N
acute JJ 4_p
leukemia NN 4_p
in IN 4_p
relapse NN 4_p
. . N

The DT N
results NNS N
did VBD N
not RB N
indicate VB N
any DT N
therapeutic JJ N
advantage NN N
for IN N
patients NNS N
treated VBN N
with IN N
this DT N
combination NN N
compared VBN N
to TO N
those DT N
treated VBN N
without IN N
any DT N
attempt NN N
at IN N
CA NNP N
synchronization NN N
. . N

-DOCSTART- -X- O O 22330261

Bilateral NNP N
transversus NN N
abdominis NN N
plane NN N
block NN N
does VBZ N
not RB N
decrease VB N
postoperative JJ N
pain NN N
after IN N
laparoscopic NN N
cholecystectomy NN N
when WRB N
compared VBN N
with IN N
local JJ N
anesthetic JJ N
infiltration NN N
of IN N
trocar NN N
insertion NN N
sites NNS N
. . N

BACKGROUND NNP N
AND NNP N
OBJECTIVES NNP N
Transversus NNP N
abdominis NN N
plane NN N
( ( N
TAP NNP N
) ) N
block NN N
has VBZ N
been VBN N
shown VBN N
to TO N
reduce VB N
pain NN N
and CC N
analgesic JJ N
requirements NNS N
after IN N
abdominal JJ N
surgery NN N
. . N

Our PRP$ N
hypothesis NN N
was VBD N
that IN N
bilateral JJ N
TAP NNP N
blocks NNS N
decrease NN N
pain NN N
after IN N
laparoscopic NN N
cholecystectomy NN N
when WRB N
compared VBN N
with IN N
local JJ N
anesthetic JJ N
infiltration NN N
of IN N
trocar NN N
insertion NN N
sites NNS N
. . N

METHODS NNP N
Eighty NNP N
patients NNS N
undergoing VBG N
laparoscopic JJ 4_p
cholecystectomy NN 4_p
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
bilateral JJ N
TAP NNP N
blocks NNS N
or CC N
local JJ N
anesthetic JJ N
infiltration NN N
of IN N
trocar NN N
insertion NN N
sites VBZ N
with IN N
ropivacaine JJ N
0.5 CD N
% NN N
. . N

Postoperative JJ N
pain NN N
scores NNS N
and CC N
analgesic JJ N
use NN N
for IN N
the DT N
first JJ N
24 CD N
hrs NN N
were VBD N
recorded VBN N
. . N

RESULTS NNP N
Eighty NNP N
patients NNS N
were VBD N
enrolled VBN N
in IN N
the DT N
study NN N
. . N

After IN N
exclusions NNS N
, , N
data NNS N
were VBD N
analyzed VBN N
on IN N
39 CD N
patients NNS N
in IN N
group NN N
T NNP N
( ( N
bilateral JJ N
TAP NNP N
block NN N
) ) N
and CC N
35 CD N
patients NNS N
in IN N
group NN N
I PRP N
( ( N
infiltration NN N
) ) N
. . N

There EX N
was VBD N
no DT N
statistically RB N
significant JJ N
difference NN N
in IN N
pain NN N
scores NNS N
on IN N
the DT N
numeric JJ N
analog NN N
scale NN N
( ( N
0-10 JJ N
) ) N
between IN N
the DT N
groups NNS N
at IN N
4 CD N
hrs NN N
after IN N
surgery NN N
( ( N
P NNP N
= NNP N
0.18 CD N
) ) N
or CC N
during IN N
the DT N
24 CD N
hrs NN N
after IN N
surgery NN N
( ( N
P NNP N
= NNP N
0.23 CD N
) ) N
. . N

The DT N
time NN N
interval NN N
from IN N
anesthesia JJ N
start NN N
to TO N
surgery VB N
start NN N
was VBD N
greater JJR N
in IN N
group NN N
T NNP N
than IN N
group NN N
I PRP N
( ( N
48 CD N
vs RB N
35 CD N
mins NNS N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
found VBD N
in IN N
analgesic JJ N
use NN N
during IN N
the DT N
first JJ N
24 CD N
hrs NN N
after IN N
surgery NN N
. . N

CONCLUSIONS NNP N
Bilateral NNP N
ultrasound-guided JJ N
TAP NNP N
block NN N
is VBZ N
equivalent JJ N
to TO N
local JJ N
anesthetic JJ N
infiltration NN N
of IN N
trocar NN N
insertion NN N
sites VBZ N
for IN N
overall JJ N
postoperative JJ N
pain NN N
in IN N
a DT N
heterogeneous JJ N
group NN N
of IN N
patients NNS N
undergoing VBG N
laparoscopic JJ N
cholecystectomy NN N
. . N

-DOCSTART- -X- O O 16562630

The DT N
effect NN N
of IN N
random JJ N
modulation NN N
of IN N
functional JJ N
electrical JJ N
stimulation NN N
parameters NNS N
on IN N
muscle NN 4_p
fatigue NN 4_p
. . N

Muscle NNP N
contractions NNS N
induced VBN N
by IN N
functional JJ N
electrical JJ N
stimulation NN N
( ( N
FES NNP N
) ) N
tend VBP N
to TO N
result VB N
in IN N
rapid JJ N
muscle NN N
fatigue NN N
, , N
which WDT N
greatly RB N
limits VBZ N
activities NNS N
such JJ N
as IN N
FES-assisted JJ N
standing NN N
and CC N
walking NN N
. . N

It PRP N
was VBD N
hypothesized VBN N
that IN N
muscle NN N
fatigue NN N
caused VBN N
by IN N
FES NNP N
could MD N
be VB N
reduced VBN N
by IN N
randomly RB N
modulating VBG N
parameters NNS N
of IN N
the DT N
electrical JJ N
stimulus NN N
. . N

Seven NNP N
paraplegic JJ N
subjects NNS N
participated VBN N
in IN N
this DT N
study NN N
. . N

While IN N
subjects NNS N
were VBD N
seated VBN N
, , N
FES NNP N
was VBD N
applied VBN N
to TO N
quadriceps NNS N
and CC N
tibialis JJ N
anterior JJ N
muscles NNS N
bilaterally RB N
using VBG N
surface NN N
electrodes NNS N
. . N

The DT N
isometric JJ N
force NN N
was VBD N
measured VBN N
, , N
and CC N
the DT N
time NN N
for IN N
the DT N
force NN N
to TO N
drop VB N
by IN N
3 CD N
dB NN N
( ( N
fatigue JJ N
time NN N
) ) N
and CC N
the DT N
normalized JJ N
force-time JJ N
integral JJ N
( ( N
FTI NNP N
) ) N
were VBD N
determined VBN N
. . N

Four CD N
different JJ N
modes NNS N
of IN N
FES NNP N
were VBD N
applied VBN N
in IN N
random JJ N
order NN N
: : N
constant JJ N
stimulation NN N
, , N
randomized VBN N
frequency NN N
( ( N
mean JJ N
40 CD N
Hz NNP N
) ) N
, , N
randomized VBN N
current JJ N
amplitude NN N
, , N
and CC N
randomized VBD N
pulsewidth NN N
( ( N
mean JJ N
250 CD N
micros NN N
) ) N
. . N

In IN N
randomized JJ N
trials NNS N
, , N
stimulation NN N
parameters NNS N
were VBD N
stochastically RB N
modulated VBN N
every DT N
100 CD N
ms NN N
in IN N
a DT N
range NN N
of IN N
+/-15 NNP N
% NN N
using VBG N
a DT N
uniform JJ N
probability NN N
distribution NN N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
fatigue NN N
time NN N
measurements NNS N
for IN N
the DT N
four CD N
modes NNS N
of IN N
stimulation NN N
. . N

There EX N
was VBD N
also RB N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
FTI NNP N
measurements NNS N
. . N

Therefore RB N
, , N
our PRP$ N
particular JJ N
method NN N
of IN N
stochastic JJ N
modulation NN N
of IN N
the DT N
stimulation NN N
parameters NNS N
, , N
which WDT N
involved VBD N
moderate JJ N
( ( N
15 CD N
% NN N
) ) N
variations NNS N
updated VBN N
every DT N
100 CD N
ms NN N
and CC N
centered VBD N
around IN N
40 CD N
Hz NNP N
, , N
appeared VBD N
to TO N
have VB N
no DT N
effect NN N
on IN N
muscle NN N
fatigue NN N
. . N

There EX N
was VBD N
a DT N
strong JJ N
correlation NN N
between IN N
maximum JJ N
force NN N
measurements NNS N
and CC N
stimulation NN N
order NN N
, , N
which WDT N
was VBD N
not RB N
apparent JJ N
in IN N
the DT N
fatigue JJ N
time NN N
or CC N
FTI NNP N
measurements NNS N
. . N

It PRP N
was VBD N
concluded VBN N
that IN N
a DT N
10-min JJ N
rest NN N
period NN N
between IN N
stimulation NN N
trials NNS N
was VBD N
insufficient JJ N
to TO N
allow VB N
full JJ N
recovery NN N
of IN N
muscle NN N
strength NN N
. . N

-DOCSTART- -X- O O 16503545

[ JJ N
Effect NNP N
of IN N
Selaginella NNP N
combined VBD N
with IN N
radiotherapy NN N
on IN N
nasopharyngeal JJ 4_p
carcinoma NN 4_p
] NNP N
. . N

OBJECTIVE NNP N
To TO N
observe VB N
the DT N
Chinese JJ N
herbal JJ N
medicine NN N
Selaginella-induced NNP N
radiosensitization NN N
of IN N
terminal JJ 4_p
nasopharyngeal JJ 4_p
carcinoma NN 4_p
( ( 4_p
NPC NNP 4_p
) ) 4_p
. . N

METHODS NNP N
Totally RB N
180 CD N
patients NNS N
with IN N
NPC NNP 4_p
were VBD N
divided VBN N
equally RB N
into IN N
3 CD N
groups NNS N
with IN N
the DT N
same JJ N
radiotherapeutic JJ N
protocols NNS N
. . N

The DT N
patients NNS N
in IN N
group NN N
A NNP N
received VBD N
radiotherapy NN N
alone RB N
, , N
those DT N
in IN N
group NN N
B NNP N
were VBD N
given VBN N
daily JJ N
Selaginella NNP N
( ( N
30 CD N
g NN N
) ) N
prepared VBD N
into IN N
50 CD N
ml JJ N
decoction NN N
during IN N
the DT N
entire JJ N
course NN N
of IN N
radiotherapy NN N
, , N
and CC N
those DT N
in IN N
group NN N
C NNP N
had VBD N
Selaginella NNP N
30 CD N
g JJ N
daily RB N
in IN N
the DT N
late JJ N
course NN N
of IN N
radiotherapy NN N
. . N

RESULTS VB N
The DT N
complete JJ N
remission NN N
rate NN N
of IN N
nasopharyngeal JJ N
primary JJ N
lesions NNS N
in IN N
groups NNS N
B NNP N
and CC N
C NNP N
was VBD N
significantly RB N
higher JJR N
than IN N
that DT N
in IN N
group NN N
A NNP N
, , N
with IN N
also RB N
significantly RB N
higher JJR N
complete JJ N
remission NN N
rates NNS N
of IN N
the DT N
cervical JJ N
lymph NN N
nodes NNS N
. . N

The DT N
acute JJ N
toxicity NN N
of IN N
the DT N
skin NN N
and CC N
mucous JJ N
membrane NN N
was VBD N
milder RBR N
in IN N
the DT N
latter JJ N
two CD N
groups NNS N
, , N
but CC N
the DT N
differences NNS N
were VBD N
not RB N
significant JJ N
. . N

CONCLUSION NNP N
Selaginella NNP N
may MD N
induce VB N
radiosensitization NN N
for IN N
terminal JJ 4_p
NPC NNP 4_p
and CC N
does VBZ N
not RB N
increase VB N
the DT N
acute JJ N
toxicity NN N
of IN N
radiotherapy NN N
. . N

-DOCSTART- -X- O O 15453848

Position NN N
of IN N
anterior JJ N
capsulorhexis NN N
and CC N
posterior JJ N
capsule NN N
opacification NN N
. . N

PURPOSE NNP N
To TO N
evaluate VB N
whether IN N
the DT N
position NN N
of IN N
the DT N
anterior JJ N
continuous JJ N
curvilinear NN N
capsulorhexis NN N
influences VBZ N
the DT N
rate NN N
of IN N
posterior JJ N
capsule NN N
opacification NN N
( ( N
PCO NNP N
) ) N
. . N

METHODS CC N
A DT N
total NN N
of IN N
119 CD N
patients NNS N
, , N
aged VBN N
61-86 CD N
years NNS N
, , N
underwent JJ N
cataract NN 4_p
surgery NN 4_p
with IN 4_p
phacoemulsification NN 4_p
performed VBN N
by IN N
a DT N
single JJ N
surgeon NN N
. . N

The DT N
patients NNS N
were VBD N
randomized VBN N
to TO N
implantation NN N
with IN N
either CC N
a DT N
silicone NN N
intraocular NN N
lens NNS N
( ( N
IOL NNP N
) ) N
( ( N
SI40NB NNP N
, , N
Allergan NNP N
) ) N
or CC N
an DT N
AcrySof NNP N
IOL NNP N
( ( N
MA60BM NNP N
, , N
Alcon NNP N
) ) N
. . N

Three CD N
years NNS N
after IN N
surgery NN N
, , N
the DT N
rate NN N
of IN N
PCO NNP N
was VBD N
analysed VBN N
using VBG N
the DT N
evaluation NN N
of IN N
posterior JJ N
capsule NN N
opacification NN N
computer NN N
software NN N
( ( N
EPCO NNP N
) ) N
. . N

The DT N
results NNS N
were VBD N
related VBN N
to TO N
the DT N
capsulorhexis NN N
position NN N
, , N
which WDT N
was VBD N
assessed VBN N
with IN N
a DT N
retroillumination NN N
photograph NN N
. . N

RESULTS VB N
If IN N
the DT N
capsulorhexis NN N
was VBD N
located VBN N
partially RB N
or CC N
completely RB N
off IN N
the DT N
optics NNS N
of IN N
the DT N
IOL NNP N
, , N
compared VBN N
to TO N
totally RB N
on IN N
the DT N
IOL NNP N
, , N
significantly RB N
more JJR N
PCO NNP N
was VBD N
found VBN N
( ( N
p JJ N
= NNP N
0.0014 CD N
) ) N
. . N

When WRB N
comparing VBG N
within IN N
each DT N
IOL NNP N
type NN N
, , N
patients NNS N
with IN N
AcrySof NNP N
IOLs NNP N
were VBD N
found VBN N
to TO N
have VB N
significantly RB N
less JJR N
PCO NNP N
when WRB N
the DT N
capsulorhexis NN N
was VBD N
totally RB N
on IN N
the DT N
optic JJ N
( ( N
p JJ N
= NNP N
0.0048 CD N
) ) N
. . N

This DT N
difference NN N
was VBD N
also RB N
significant JJ N
in IN N
the DT N
silicone NN N
group NN N
( ( N
p JJ N
= NNP N
0.041 CD N
) ) N
. . N

CONCLUSION VB N
A NNP N
relatively RB N
small JJ N
and CC N
central JJ N
capsulorhexis NN N
allowing VBG N
for IN N
the DT N
complete JJ N
covering NN N
of IN N
the DT N
IOL NNP N
optics NNS N
by IN N
the DT N
rhexis NN N
edges VBZ N
seems VBZ N
to TO N
protect VB N
against IN N
PCO NNP N
in IN N
cataract NN N
surgery NN N
, , N
with IN N
both DT N
round-edged JJ N
silicone NN N
IOLs NNP N
and CC N
sharp-edged JJ N
hydrophobic JJ N
acrylic JJ N
IOLs NNP N
. . N

-DOCSTART- -X- O O 16413605

Project NN N
Towards NNP N
No NNP 4_p
Drug NNP 4_p
Abuse NNP 4_p
: : N
long-term JJ N
substance NN N
use NN N
outcomes VBZ N
evaluation NN N
. . N

OBJECTIVES CC N
This DT N
paper NN N
presents VBZ N
up IN N
to TO N
5 CD N
years NNS N
post-program JJ N
outcomes NNS N
of IN N
Project NNP N
Towards NNP N
No NNP 4_p
Drug NNP 4_p
Abuse NNP 4_p
( ( N
Project NNP N
TND NNP N
) ) N
, , N
a DT N
drug NN N
abuse NN N
prevention NN N
program NN N
conducted VBN N
in IN N
South NNP N
California NNP N
alternative JJ N
high JJ N
school NN N
system NN N
during IN N
years NNS N
1994-1999 JJ N
. . N

METHODS PDT N
The DT N
effects NNS N
of IN N
a DT N
9-session JJ N
health NN N
motivation NN N
-- : N
social JJ N
skills NNS N
-- : N
decision-making JJ N
curriculum NN N
were VBD N
evaluated VBN N
. . N

Twenty-one CD N
schools NNS N
recruited VBN N
were VBD N
randomly RB N
assigned VBN N
to TO N
standard VB N
care NN N
( ( N
control NN N
) ) N
, , N
classroom NN N
only RB N
, , N
or CC N
a DT N
classroom NN N
plus CC N
semester-long JJ N
school-as-community JJ N
component NN N
. . N

Last JJ N
30-day JJ N
use NN N
of IN N
cigarettes NNS N
, , N
alcohol NN N
, , N
marijuana NN N
, , N
and CC N
hard JJ N
drugs NNS N
were VBD N
assessed VBN N
at IN N
three CD N
time NN N
intervals NNS N
: : N
short-term JJ N
( ( N
year NN N
1 CD N
) ) N
, , N
middle-term JJ N
( ( N
years NNS N
2 CD N
or CC N
3 CD N
) ) N
, , N
and CC N
long-term JJ N
( ( N
years NNS N
4 CD N
or CC N
5 CD N
) ) N
. . N

Multilevel NNP N
random JJ N
coefficients NNS N
modeling VBG N
were VBD N
employed VBN N
to TO N
estimate VB N
the DT N
adjusted JJ N
levels NNS N
of IN N
substance NN N
use NN N
. . N

RESULTS NNP N
Among IN N
1578 CD N
baseline NN N
subjects NNS N
, , N
follow-up JJ N
data NNS N
were VBD N
available JJ N
for IN N
68 CD N
% NN N
( ( N
year NN N
1 CD N
) ) N
, , N
66 CD N
% NN N
( ( N
years NNS N
2 CD N
or CC N
3 CD N
) ) N
, , N
and CC N
46 CD N
% NN N
( ( N
years NNS N
4 CD N
or CC N
5 CD N
) ) N
of IN N
subjects NNS N
, , N
respectively RB N
. . N

Results NNS N
revealed VBD N
significant JJ N
positive JJ N
long-term JJ N
program NN N
effects NNS N
for IN N
hard JJ N
drug NN N
use NN N
at IN N
year NN N
4 CD N
or CC N
5 CD N
for IN N
the DT N
two CD N
program NN N
interventions NNS N
( ( N
P NNP N
= NNP N
0.02 CD N
) ) N
. . N

CONCLUSIONS NNP N
Project NNP N
TND NNP N
reduced VBD N
hard JJ N
drug NN N
use NN N
in IN N
the DT N
46 CD N
% NN N
who WP N
were VBD N
successfully RB N
followed VBN N
. . N

It PRP N
is VBZ N
the DT N
first JJ N
program NN N
to TO N
demonstrate VB N
long-term JJ N
self-reported JJ N
behavioral JJ N
effects NNS N
on IN N
hard JJ N
drug NN N
use NN N
among IN N
high-risk JJ N
youth NN N
by IN N
using VBG N
a DT N
school-based JJ N
, , N
limited-session JJ N
model NN N
. . N

-DOCSTART- -X- O O 3001523

Treatment NN N
of IN N
varicella-zoster JJ N
virus NN N
infection NN N
in IN N
severely RB N
immunocompromised JJ N
patients NNS N
. . N

A DT N
randomized JJ N
comparison NN N
of IN N
acyclovir NN N
and CC N
vidarabine NN N
. . N

In IN N
a DT N
prospective JJ N
, , N
randomized JJ N
trial NN N
, , N
we PRP N
compared VBN N
intravenous JJ N
acyclovir NNS N
and CC N
vidarabine NN N
in IN N
the DT N
treatment NN N
of IN N
varicella-zoster JJ N
virus NN N
infection NN N
in IN N
severely RB N
immunocompromised JJ N
patients NNS N
who WP N
presented VBD N
within IN N
72 CD N
hours NNS N
of IN N
onset NN N
of IN N
the DT N
infection NN N
. . N

Eleven JJ N
patients NNS N
were VBD N
treated VBN N
in IN N
each DT N
group NN N
. . N

Cutaneous JJ N
dissemination NN N
of IN N
infection NN N
occurred VBD N
in IN N
none NN N
of IN N
the DT N
10 CD N
acyclovir NN N
recipients NNS N
and CC N
in IN N
5 CD N
of IN N
the DT N
10 CD N
vidarabine NN N
recipients NNS N
who WP N
had VBD N
presented VBN N
with IN N
localized JJ N
dermatomal JJ N
disease NN N
( ( N
P NNP N
= NNP N
0.016 CD N
) ) N
. . N

As IN N
compared VBN N
with IN N
vidarabine NN N
, , N
acyclovir JJ N
treatment NN N
shortened VBD N
the DT N
median JJ N
periods NNS N
during IN N
which WDT N
cultures NNS N
were VBD N
positive JJ N
for IN N
the DT N
virus NN N
( ( N
four CD N
vs. FW N
seven CD N
days NNS N
, , N
P NNP N
= NNP N
0.004 CD N
) ) N
and CC N
new JJ N
lesions NNS N
formed VBN N
( ( N
three CD N
vs. IN N
six CD N
days NNS N
, , N
P NNP N
= NNP N
0.03 CD N
) ) N
. . N

Acyclovir NNP N
also RB N
shortened VBD N
the DT N
median JJ N
interval NN N
until IN N
the DT N
first JJ N
decrease NN N
in IN N
pain NN N
( ( N
4 CD N
vs. FW N
7 CD N
days NNS N
, , N
P NNP N
= NNP N
0.005 CD N
) ) N
, , N
the DT N
pustulation NN N
of IN N
all DT N
lesions NNS N
( ( N
4 CD N
vs. FW N
7 CD N
days NNS N
, , N
P NNP N
= NNP N
0.0004 CD N
) ) N
, , N
the DT N
crusting NN N
of IN N
all DT N
lesions NNS N
( ( N
7 CD N
vs. FW N
17 CD N
days NNS N
, , N
P NNP N
= NNP N
0.0003 CD N
) ) N
, , N
and CC N
the DT N
complete JJ N
healing NN N
of IN N
lesions NNS N
( ( N
17 CD N
vs. FW N
28 CD N
days NNS N
, , N
P NNP N
= NNP N
0.003 CD N
) ) N
. . N

In IN N
addition NN N
, , N
acyclovir NN N
reduced VBD N
the DT N
incidence NN N
of IN N
fever NN N
( ( N
two CD N
vs. FW N
eight CD N
patients NNS N
, , N
P NNP N
= NNP N
0.015 CD N
) ) N
. . N

We PRP N
conclude VBP N
that DT N
acyclovir NN N
is VBZ N
better JJR N
than IN N
vidarabine NN N
for IN N
the DT N
treatment NN N
of IN N
varicella-zoster JJ N
infection NN N
in IN N
immunocompromised JJ N
patients NNS N
. . N

-DOCSTART- -X- O O 2405107

Randomized VBN N
study NN N
of IN N
continuous JJ N
infusion NN N
fluorouracil NN N
versus NN N
fluorouracil NN N
plus CC N
cisplatin NN N
in IN N
patients NNS N
with IN N
metastatic JJ 4_p
colorectal JJ 4_p
cancer NN 4_p
. . N

One CD N
hundred VBD N
twenty-two JJ N
chemotherapy-naive JJ N
patients NNS N
with IN N
histologically RB N
confirmed VBN N
colorectal JJ 4_p
adenocarcinoma NN 4_p
were VBD N
entered VBN N
into IN N
a DT N
randomized JJ N
trial NN N
comparing VBG N
infusional JJ N
fluorouracil NN N
( ( N
FU NNP N
) ) N
versus NN N
cisplatin NN N
( ( N
CDDP NNP N
) ) N
and CC N
FU NNP N
. . N

In IN N
both DT N
groups NNS N
, , N
patients NNS N
received VBD N
continuous JJ N
infusion NN N
FU NNP N
1,000 CD N
mg/m2/d NN N
for IN N
5 CD N
consecutive JJ N
days NNS N
every DT N
4 CD N
weeks NNS N
. . N

Patients NNS N
randomized VBD N
to TO N
CDDP/FU NNP N
also RB N
received VBD N
CDDP NNP N
20 CD N
mg/m2 NN N
intravenous JJ N
( ( N
IV NNP N
) ) N
bolus NN N
on IN N
days NNS N
1 CD N
to TO N
5 CD N
of IN N
each DT N
cycle NN N
. . N

Patients NNS N
were VBD N
comparable JJ N
in IN N
terms NNS N
of IN N
age NN N
, , N
performance NN N
status NN N
, , N
baseline VB N
laboratory NN N
values NNS N
, , N
dominant JJ N
sites NNS N
of IN N
measurable JJ N
disease NN N
, , N
and CC N
percent NN N
of IN N
liver JJ N
involvement NN N
. . N

The DT N
partial JJ N
response NN N
rate NN N
was VBD N
significantly RB N
greater JJR N
in IN N
patients NNS N
who WP N
received VBD N
CDDP/FU NNP N
versus NN N
FU NNP N
alone RB N
( ( N
25 CD N
% NN N
v JJ N
3 CD N
% NN N
, , N
P NNP N
= NNP N
.001 NNP N
) ) N
. . N

Patients NNPS N
who WP N
received VBD N
CDDP/FU NNP N
experienced VBD N
significantly RB N
greater JJR N
toxicity NN N
compared VBN N
with IN N
FU NNP N
alone RB N
: : N
grades NNS N
3 CD N
and CC N
4 CD N
hematologic JJ N
toxicity NN N
occurred VBD N
in IN N
22 CD N
% NN N
and CC N
0 CD N
% NN N
of IN N
patients NNS N
, , N
respectively RB N
( ( N
P NNP N
= NNP N
.0001 NNP N
) ) N
; : N
grades VBZ N
2 CD N
to TO N
4 CD N
nausea NN N
and CC N
vomiting NN N
occurred VBD N
in IN N
80 CD N
% NN N
and CC N
15 CD N
% NN N
of IN N
patients NNS N
, , N
respectively RB N
( ( N
P NNP N
= NNP N
.0001 NNP N
) ) N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
either CC N
the DT N
duration NN N
of IN N
response NN N
( ( N
median JJ N
, , N
6 CD N
and CC N
4.7 CD N
months NNS N
for IN N
CDDP/FU NNP N
and CC N
FU NNP N
groups NNS N
, , N
respectively RB N
) ) N
or CC N
survival NN N
( ( N
median JJ N
10 CD N
, , N
and CC N
12 CD N
months NNS N
, , N
respectively RB N
) ) N
. . N

Compared VBN N
with IN N
infusional JJ N
FU NNP N
alone RB N
, , N
CDDP/FU NNP N
provided VBD N
a DT N
significantly RB N
greater JJR N
partial JJ N
response NN N
rate NN N
with IN N
increased JJ N
toxicity NN N
, , N
but CC N
it PRP N
did VBD N
not RB N
improve VB N
overall JJ N
survival NN N
in IN N
patients NNS N
with IN N
advanced JJ 4_p
colorectal JJ 4_p
carcinoma NN 4_p
. . N

Therefore RB N
, , N
the DT N
use NN N
of IN N
CDDP/FU NNP N
as IN N
routine JJ N
therapy NN N
for IN N
the DT N
treatment NN N
of IN N
colorectal JJ N
carcinoma NN N
can MD N
not RB N
be VB N
recommended VBN N
. . N

-DOCSTART- -X- O O 11395821

Laparoscopic NNP N
vs NN N
open JJ N
appendectomy NN N
in IN N
overweight JJ 4_p
patients NNS N
. . N

BACKGROUND NNP N
Laparoscopic NNP N
appendectomy NN N
( ( N
LA NNP N
) ) N
has VBZ N
been VBN N
associated VBN N
with IN N
a DT N
faster JJ N
recovery NN N
and CC N
less RBR N
postoperative JJ N
pain NN N
than IN N
the DT N
open JJ N
technique NN N
. . N

However RB N
, , N
few JJ N
data NNS N
are VBP N
available JJ N
on IN N
the DT N
clinical JJ N
outcome NN N
of IN N
LA NNP N
in IN N
overweight JJ N
patients NNS N
. . N

METHODS NNP N
A NNP N
group NN N
of IN N
106 CD N
patients NNS N
with IN N
a DT N
body NN N
mass NN N
index NN N
( ( N
BMI NNP N
) ) N
> VBD N
26.4 CD N
, , N
representing VBG N
the DT N
upper JJ N
quintile NN N
of IN N
500 CD N
prospectively RB N
randomized JJ N
patients NNS N
, , N
were VBD N
included VBN N
in IN N
the DT N
study NN N
. . N

They PRP N
were VBD N
randomized VBN N
to TO N
undergo VB N
either DT N
laparoscopic NN N
or CC N
open JJ N
appendectomy NN N
( ( N
OA NNP N
) ) N
. . N

Operating NN N
and CC N
anesthesia NN N
times NNS N
, , N
postoperative JJ N
pain NN N
, , N
complications NNS N
, , N
hospital NN N
stay NN N
, , N
functional JJ N
index NN N
( ( N
1 CD N
week NN N
postoperatively RB N
) ) N
, , N
sick JJ N
leave VBP N
, , N
and CC N
time NN N
to TO N
full JJ N
recovery NN N
were VBD N
documented VBN N
. . N

RESULTS NNP N
In IN N
OA NNP N
, , N
the DT N
operating NN N
time NN N
for IN N
overweight JJ N
patients NNS N
was VBD N
significantly RB N
longer JJR N
than IN N
that DT N
for IN N
patients NNS N
in IN N
the DT N
normal JJ N
weight NN N
range NN N
( ( N
40 CD N
vs RB N
35 CD N
min NN N
, , N
p NN N
< NNP N
0.05 CD N
) ) N
. . N

In IN N
LA NNP N
, , N
there EX N
was VBD N
no DT N
difference NN N
in IN N
operating NN N
time NN N
between IN N
the DT N
normal JJ N
and CC N
overweight JJ N
patients NNS N
. . N

Overweight JJ N
patients NNS N
who WP N
underwent JJ N
LA NNP N
had VBD N
longer RBR N
operating NN N
and CC N
anesthesia NN N
times NNS N
than IN N
their PRP$ N
OA NNP N
counterparts NNS N
( ( N
55 CD N
vs RB N
40 CD N
min NN N
, , N
p NN N
< VBD N
0.001 CD N
; : N
and CC N
125 CD N
vs NN N
100 CD N
min NN N
, , N
p NN N
< VBD N
0.001 CD N
, , N
respectively RB N
) ) N
. . N

Postoperative JJ N
pain NN N
was VBD N
significantly RB N
greater JJR N
in IN N
overweight JJ N
patients NNS N
who WP N
underwent VBP N
OA NNP N
than IN N
in IN N
those DT N
treated VBN N
with IN N
the DT N
laparoscopic NN N
technique NN N
. . N

Postoperative JJ N
pain NN N
was VBD N
also RB N
significantly RB N
greater JJR N
in IN N
overweight JJ N
patients NNS N
subjected VBN N
to TO N
OA NNP N
than IN N
in IN N
patients NNS N
of IN N
normal JJ N
weight NN N
after IN N
4 CD N
weeks NNS N
; : N
the DT N
clinical JJ N
significance NN N
may MD N
, , N
however RB N
, , N
be VB N
of IN N
less JJR N
importance NN N
since IN N
the DT N
values NNS N
are VBP N
low JJ N
( ( N
0.26 CD N
vs NN N
0.09 CD N
, , N
p NN N
< NNP N
0.05 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
two CD N
operating VBG N
techniques NNS N
in IN N
terms NNS N
of IN N
complications NNS N
. . N

Hospital NNP N
stay NN N
was VBD N
longer JJR N
for IN N
overweight NN N
patients NNS N
than IN N
for IN N
normal-weight JJ N
patients NNS N
undergoing VBG N
OA NNP N
( ( N
3.0 CD N
vs NN N
2.0 CD N
, , N
p NN N
< NNP N
0.01 CD N
) ) N
. . N

The DT N
functional JJ N
index NN N
did VBD N
not RB N
differ VB N
between IN N
any DT N
group NN N
of IN N
patients NNS N
. . N

Sick NNP N
leave NN N
was VBD N
longer JJR N
for IN N
overweight JJ N
patients NNS N
who WP N
underwent VBP N
OA NNP N
than IN N
for IN N
normal-weight JJ N
patients NNS N
treated VBN N
with IN N
the DT N
same JJ N
technique NN N
( ( N
17 CD N
vs RB N
13 CD N
days NNS N
, , N
p VBP N
< RB N
0.01 CD N
) ) N
. . N

In IN N
the DT N
laparoscopic NN N
group NN N
, , N
however RB N
, , N
there EX N
were VBD N
no DT N
differences NNS N
between IN N
the DT N
overweight NN N
and CC N
normal-weight JJ N
patients NNS N
. . N

Time NN N
to TO N
full JJ N
recovery NN N
was VBD N
greater JJR N
in IN N
overweight JJ N
patients NNS N
subjected VBN N
to TO N
OA NNP N
than IN N
in IN N
the DT N
overweight JJ N
patients NNS N
in IN N
the DT N
LA NNP N
group NN N
( ( N
22 CD N
vs RB N
15 CD N
days NNS N
, , N
p VBP N
< RB N
0.001 CD N
) ) N
. . N

CONCLUSION NN N
In IN N
this DT N
study NN N
, , N
overweight JJ N
patients NNS N
who WP N
were VBD N
submitted VBN N
to TO N
LA NNP N
had VBD N
less RBR N
postoperative JJ N
pain NN N
and CC N
a DT N
faster RBR N
postoperative JJ N
recovery NN N
than IN N
overweight JJ N
patients NNS N
who WP N
had VBD N
OA NNP N
. . N

LA NNP N
also RB N
abolished VBD N
some DT N
of IN N
the DT N
negative JJ N
effects NNS N
that WDT N
overweight VBD N
had VBD N
on IN N
operating NN N
time NN N
, , N
hospital NN N
stay NN N
, , N
and CC N
sick JJ N
leave NN N
with IN N
the DT N
open JJ N
technique NN N
. . N

However RB N
, , N
anesthesia NN N
and CC N
operating NN N
times NNS N
were VBD N
significantly RB N
longer RBR N
in IN N
LA NNP N
for IN N
both DT N
overweight JJ N
patients NNS N
and CC N
those DT N
with IN N
a DT N
normal JJ N
BMI NNP N
. . N

-DOCSTART- -X- O O 20726255

[ NN N
Study NNP N
on IN N
safety NN N
and CC N
immunogenicity NN N
of IN N
oral JJ N
poliomyelitis NN N
attenuated VBD N
live JJ N
vaccine NN N
( ( N
human JJ N
diploid NN N
cell NN N
) ) N
] NN N
. . N

OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
safety NN N
and CC N
Immunogenicity NNP N
of IN N
the DT N
Poliomyelitis NNP N
vaccine NN N
( ( N
Human NNP N
Diploid NNP N
Cell NNP N
) ) N
in IN N
> NN N
or CC N
=2 VB N
month-old JJ N
children NNS N
. . N

METHODS NNP N
A NNP N
random NN N
, , N
blind NN N
and CC N
control NN N
trial NN N
, , N
1200 CD N
healthy JJ N
children NNS N
of IN N
2-5 JJ N
months NNS N
old JJ N
in IN N
Jiangsu NNP N
province NN N
were VBD N
administered VBN N
OPV NNP 4_p
( ( 4_p
HDC NNP 4_p
) ) 4_p
vaccine NN 4_p
and CC N
control NN N
vaccines NNS N
. . N

The DT N
antibody NN N
was VBD N
tested VBN N
by IN N
neutralization NN N
test NN N
. . N

RESULTS NNP N
After IN N
3 CD N
doses NNS N
of IN N
the DT N
OPV NNP N
( ( N
HDC NNP N
) ) N
vaccine NN N
, , N
the DT N
systemic JJ N
reactions NNS N
were VBD N
mild JJ N
. . N

After IN N
1 CD N
month NN N
of IN N
vaccination NN N
with IN N
3 CD N
doses NNS N
of IN N
the DT N
OPV NNP N
( ( N
HDC NNP N
) ) N
vaccine NN N
, , N
the DT N
immune JJ N
success NN N
rates NNS N
of IN N
I PRP N
, , N
II NNP N
, , N
III NNP N
type NN N
were VBD N
98.28 CD N
% NN N
, , N
99.45 CD N
% NN N
, , N
and CC N
95.71 CD N
% NN N
respectively RB N
, , N
the DT N
GMTs NNP N
of IN N
I PRP N
, , N
II NNP N
, , N
III NNP N
type NN N
in IN N
susceptible JJ N
children NNS N
were VBD N
1:1243.72 CD N
, , N
1:234.38 CD N
and CC N
1:273.10 CD N
respectively RB N
. . N

CONCLUSIONS VB N
The DT N
OPV NNP N
( ( N
HDC NNP N
) ) N
vaccine NN N
was VBD N
safe JJ N
and CC N
immunogenicity NN N
for IN N
the DT N
children NNS N
> VBP N
or CC N
=2 JJ N
months NNS N
old JJ N
. . N

-DOCSTART- -X- O O 8155449

Risk NN N
of IN N
aspiration NN N
with IN N
the DT N
laryngeal NN N
mask NN N
. . N

In IN N
order NN N
to TO N
assess VB N
if IN N
the DT N
use NN N
of IN N
the DT N
laryngeal JJ N
mask NN N
airway NN N
is VBZ N
associated VBN N
with IN N
an DT N
increased VBN N
risk NN N
of IN N
gastric JJ N
regurgitation NN N
during IN N
mechanical JJ N
ventilation NN N
, , N
we PRP N
studied VBD N
50 CD N
patients NNS N
allocated VBD N
randomly RB N
to TO N
undergo VB N
anaesthesia NN N
with IN N
either DT N
artificial JJ N
ventilation NN N
with IN N
isoflurane NN N
and CC N
nitrous JJ N
oxide NN N
in IN N
oxygen NN N
and CC N
atracurium NN N
( ( N
group NN N
A NNP N
) ) N
or CC N
spontaneous JJ N
ventilation NN N
with IN N
isoflurane NN N
and CC N
nitrous JJ N
oxide NN N
in IN N
oxygen NN N
( ( N
group NN N
B NNP N
) ) N
. . N

In IN N
both DT N
groups NNS N
a DT N
laryngeal JJ N
mask NN N
airway NN N
was VBD N
used VBN N
. . N

Regurgitation NNP N
was VBD N
assessed VBN N
by IN N
the DT N
patient NN N
ingesting VBG N
a DT N
methylene NN N
blue JJ N
capsule NN N
10 CD N
min NN N
before IN N
induction NN N
of IN N
anaesthesia NN N
and CC N
examining VBG N
the DT N
oropharynx NN N
by IN N
direct JJ N
laryngoscopy NN N
at IN N
the DT N
end NN N
of IN N
surgery NN N
. . N

In IN N
one CD N
patient NN N
in IN N
each DT N
group NN N
, , N
there EX N
was VBD N
staining VBG N
of IN N
the DT N
oropharynx NN N
with IN N
blue JJ N
dye NN N
at IN N
the DT N
end NN N
of IN N
surgery NN N
. . N

In IN N
the DT N
patient NN N
in IN N
group NN N
A NNP N
, , N
dye NN N
was VBD N
present JJ N
in IN N
the DT N
trachea NN N
and CC N
bronchi NN N
. . N

-DOCSTART- -X- O O 1829841

[ RB 4_p
4 CD 4_p
years NNS 4_p
' POS 4_p
experience NN 4_p
with IN 4_p
a DT 4_p
balloon-expandable JJ 4_p
endoprosthesis NN 4_p
. . 4_p

Experimental JJ 4_p
and CC 4_p
clinical JJ 4_p
application NN 4_p
] NNP 4_p
. . N

During IN N
a DT N
4-year JJ N
period NN N
of IN N
clinical JJ N
application NN N
of IN N
the DT N
balloon-expandable JJ N
Palmaz NNP N
stent NN N
, , N
a DT N
randomized JJ N
trial NN N
comparing VBG N
stent JJ N
implantation NN N
and CC N
traditional JJ N
balloon NN N
angioplasty NN N
of IN N
iliac JJ 4_p
arteries NNS 4_p
in IN 4_p
arterial JJ 4_p
occlusive JJ 4_p
disease NN 4_p
was VBD N
started VBN N
. . N

The DT N
first JJ N
long-term JJ N
results NNS N
, , N
recorded VBD N
after IN N
2 CD N
years NNS N
, , N
indicate VBP N
statistically RB N
significant JJ N
differences NNS N
in IN N
the DT N
complication NN N
rate NN N
( ( N
after IN N
stenting VBG 4_p
2/62 CD 4_p
and CC N
after IN N
angioplasty JJ 4_p
5/69 CD 4_p
) ) 4_p
and CC N
patency NN N
( ( N
greater JJR N
than IN N
or CC N
equal JJ N
to TO N
70 CD N
% NN N
of IN N
original JJ N
lumen NNS N
size NN N
upon IN N
stent JJ N
implantation NN N
or CC N
balloon NN N
inflation NN N
: : N
95 CD N
% NN N
after IN N
stenting VBG N
and CC N
72 CD N
% NN N
after IN N
angioplasty NN N
) ) N
. . N

Clinical JJ N
improvement NN N
after IN N
2 CD N
years NNS N
was VBD N
89 CD N
% NN N
after IN N
stenting VBG N
and CC N
70 CD N
% NN N
after IN N
angioplasty NN N
. . N

Parallel NNP N
to TO N
the DT N
clinical JJ 4_p
trials NNS 4_p
, , N
experimental JJ N
canine NN N
artery NN N
stenting NN N
was VBD N
performed VBN N
to TO N
evaluate VB N
differences NNS N
in IN N
the DT N
long-term JJ N
patency NN N
of IN N
stents NNS N
exposed VBN N
to TO N
restricted VBN N
flow NN N
. . N

Significant JJ N
differences NNS N
in IN N
neointimal JJ N
healing NN N
were VBD N
found VBN N
between IN N
normally RB N
perfused VBN N
stents NNS N
and CC N
stents NNS N
with IN N
artificially RB N
reduced VBN N
flow NN N
: : N
during IN N
the DT N
total JJ N
observation NN N
period NN N
of IN N
6 CD N
months NNS N
the DT N
neointimal JJ N
height NN N
was VBD N
up RB N
to TO N
200 CD N
% NN N
higher JJR N
in IN N
flow-restricted JJ N
stents NNS N
, , N
while IN N
the DT N
histological JJ N
composition NN N
of IN N
the DT N
neointima NN N
was VBD N
the DT N
same JJ N
as IN N
with IN N
normally RB N
perfused VBN N
stents NNS N
. . N

-DOCSTART- -X- O O 15039684

A DT N
randomized JJ N
, , N
double-blinded JJ N
, , N
placebo-controlled JJ N
trial NN N
of IN N
phenytoin NN N
for IN N
the DT N
prevention NN N
of IN N
early JJ N
posttraumatic JJ N
seizures NNS N
in IN N
children NNS N
with IN N
moderate JJ N
to TO N
severe VB N
blunt NN N
head JJ N
injury NN N
. . N

STUDY NNP N
OBJECTIVE NNP N
We PRP N
determine VBP N
the DT N
efficacy NN N
of IN N
prophylactic JJ N
phenytoin NN N
in IN N
preventing VBG N
early JJ N
posttraumatic JJ N
seizures NNS N
in IN N
children NNS N
with IN N
moderate JJ N
to TO N
severe VB N
blunt NN N
head JJ N
injury NN N
. . N

METHODS NNP N
Children NNP 4_p
younger JJR 4_p
than IN 4_p
16 CD 4_p
years NNS 4_p
and CC 4_p
experiencing VBG 4_p
moderate JJ 4_p
to TO 4_p
severe VB 4_p
blunt NN 4_p
head JJ 4_p
injury NN 4_p
were VBD N
randomized VBN N
to TO N
receive VB N
phenytoin NN N
or CC N
placebo NN N
within IN N
60 CD N
minutes NNS N
of IN N
presentation NN N
at IN N
3 CD N
pediatric JJ N
trauma NN N
centers NNS N
. . N

The DT N
primary JJ N
endpoint NN N
was VBD N
posttraumatic JJ N
seizures NNS N
within IN N
48 CD N
hours NNS N
; : N
secondary JJ N
endpoints NNS N
were VBD N
survival JJ N
and CC N
neurologic JJ N
outcome NN N
30 CD N
days NNS N
after IN N
injury NN N
. . N

A DT N
Bayesian JJ N
decision-theoretic JJ N
clinical JJ N
trial NN N
design NN N
was VBD N
used VBN N
to TO N
determine VB N
the DT N
probability NN N
of IN N
remaining VBG N
posttraumatic JJ N
seizure NN N
free JJ N
for IN N
each DT N
treatment NN N
group NN 4_p
. . 4_p

RESULTS NNP N
One CD N
hundred VBD N
two CD N
patients NNS N
were VBD N
enrolled VBN N
, , N
with IN N
a DT N
median JJ N
age NN N
of IN N
6.1 CD N
years NNS N
. . N

Sixty-eight JJ N
percent NN N
were VBD N
boys NNS N
. . N

The DT N
2 CD N
treatment NN N
groups NNS N
were VBD N
well RB N
matched VBN N
. . N

During IN N
the DT N
48-hour JJ N
observation NN N
period NN N
, , N
3 CD N
( ( N
7 CD N
% NN N
) ) N
of IN N
46 CD N
patients NNS N
given VBN N
phenytoin NNS N
and CC N
3 CD N
( ( N
5 CD N
% NN N
) ) N
of IN N
56 CD N
patients NNS N
given VBN N
placebo NNS N
experienced VBD N
a DT N
posttraumatic JJ N
seizure NN N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
treatment NN N
groups NNS N
in IN N
survival NN N
or CC N
neurologic JJ N
outcome NN N
after IN N
30 CD N
days NNS N
. . N

According VBG N
to TO N
these DT N
results NNS N
, , N
the DT N
probability NN N
that WDT N
phenytoin NN N
has VBZ N
the DT N
originally RB N
hypothesized VBN N
effect NN N
of IN N
reducing VBG N
the DT N
rate NN N
of IN N
early JJ N
posttraumatic JJ N
seizures NNS N
by IN N
12.5 CD N
% NN N
is VBZ N
0.0053 CD N
. . N

The DT N
probability NN N
that WDT N
phenytoin NN N
has VBZ N
any DT N
prophylactic JJ N
efficacy NN N
is VBZ N
0.383 CD N
. . N

The DT N
median JJ N
effect NN N
size NN N
in IN N
this DT N
trial NN N
was VBD N
-0.015 NNP N
( ( N
seizure JJ N
rate NN N
increased VBN N
by IN N
1.5 CD N
% NN N
in IN N
the DT N
phenytoin NN N
group NN N
) ) N
, , N
95 CD N
% NN N
probability NN N
interval NN N
-0.127 NN N
to TO N
0.091 CD N
( ( N
12.7 CD N
% NN N
higher JJR N
rate NN N
of IN N
posttraumatic JJ N
seizures NNS N
to TO N
a DT N
9.1 CD N
% NN N
lower JJR N
rate NN N
of IN N
posttraumatic JJ N
seizures NNS N
with IN N
phenytoin NN N
) ) N
. . N

CONCLUSION VB N
The DT N
rate NN N
of IN N
early JJ N
posttraumatic JJ N
seizures NNS N
in IN N
children NNS N
may MD N
be VB N
much RB N
lower JJR N
than IN N
previously RB N
reported VBN N
. . N

Phenytoin VB N
did VBD N
not RB N
substantially RB N
reduce VB N
that DT N
rate NN N
. . N

-DOCSTART- -X- O O 21309696

Safety NN N
and CC N
efficacy NN N
of IN N
donepezil NN N
in IN N
children NNS 4_p
and CC 4_p
adolescents NNS 4_p
with IN 4_p
autism NN 4_p
: : 4_p
neuropsychological JJ N
measures NNS N
. . N

OBJECTIVE NNP N
There EX N
has VBZ N
been VBN N
recent JJ N
interest NN N
in IN N
the DT N
use NN N
of IN N
cognitive JJ N
enhancing VBG N
drugs NNS N
, , N
such JJ N
as IN N
cholinesterase NN N
inhibitors NNS N
, , N
as IN N
a DT N
possible JJ N
treatment NN N
for IN N
executive NN N
functioning NN N
( ( N
EF NNP N
) ) N
deficits NNS N
in IN N
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
( ( 4_p
ASD NNP 4_p
) ) 4_p
. . 4_p

The DT N
goal NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
assess VB N
the DT N
tolerability NN N
, , N
safety NN N
, , N
and CC N
efficacy NN N
of IN N
donepezil NN N
on IN N
EF NNP N
in IN N
a DT N
sample NN 4_p
of IN 4_p
children NNS 4_p
and CC 4_p
adolescents NNS 4_p
with IN 4_p
ASD NNP 4_p
. . 4_p

METHOD NNP N
Thirty-four JJ 4_p
children NNS 4_p
and CC 4_p
adolescents NNS 4_p
with IN 4_p
ASD NNP 4_p
( ( 4_p
age NN 4_p
range NN 4_p
8-17 CD 4_p
years NNS 4_p
; : 4_p
IQ NNP 4_p
> NNP 4_p
75 CD 4_p
) ) 4_p
were VBD 4_p
enrolled VBN 4_p
in IN N
a DT N
10-week JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
trial NN N
of IN N
donepezil NN N
( ( N
doses NNS N
of IN N
5 CD N
and CC N
10 CD N
mg NN N
) ) N
, , N
followed VBN N
by IN N
a DT N
10-week JJ N
open JJ N
label NN N
trial NN N
for IN N
placebo NN N
nonresponders NNS N
. . N

RESULTS VB N
The DT N
effect NN N
of IN N
donepezil NN N
treatment NN N
on IN N
EF NNP N
was VBD N
examined VBN N
. . N

Despite IN N
improvement NN N
on IN N
a DT N
number NN N
of IN N
EF NNP N
measures NNS N
, , N
no DT N
statistically RB N
significant JJ N
between-group JJ N
differences NNS N
were VBD N
found VBN N
( ( N
with IN N
gains NNS N
observed VBN N
for IN N
both DT N
the DT N
placebo NN N
and CC N
donepezil NN N
groups NNS N
) ) N
. . N

CONCLUSIONS VB N
The DT N
results NNS N
suggest VBP N
that IN N
short-term JJ N
treatment NN N
with IN N
donepezil NN N
may MD N
have VB N
limited VBN N
impact NN N
on IN N
cognitive JJ N
functioning NN N
in IN N
ASD NNP N
. . N

Future NNP N
controlled VBD N
trials NNS N
may MD N
need VB N
to TO N
consider VB N
a DT N
longer RBR N
treatment NN N
period NN N
to TO N
detect VB N
significant JJ N
gains NNS N
on IN N
EF NNP N
measures NNS N
. . N

-DOCSTART- -X- O O 12718385

A DT N
randomized JJ N
trial NN N
comparing VBG N
intravesical JJ N
instillations NNS N
of IN N
mitoxantrone NN N
and CC N
doxorubicin NN N
in IN N
patients NNS N
with IN N
superficial JJ N
bladder NN N
cancer NN N
. . N

BACKGROUND NNP N
This DT N
randomized JJ N
trial NN N
was VBD N
conducted VBN N
to TO N
compare VB N
the DT N
efficacy NN N
and CC N
side JJ N
effects NNS N
of IN N
intravesical JJ N
mitoxantrone NN N
instillation NN N
with IN N
those DT N
of IN N
doxorubicin NN N
in IN N
superficial JJ N
bladder NN N
cancer NN N
following VBG N
transurethral JJ N
resection NN N
. . N

METHODS NNP N
Sixty-three JJ N
patients NNS N
were VBD N
randomized VBN N
into IN N
mitoxantrone NN N
and CC N
doxorubicin NN N
groups NNS N
. . N

Most JJS N
of IN N
the DT N
patients NNS N
enrolled VBN N
were VBD N
elderly JJ N
people NNS N
( ( N
mean JJ N
age NN N
, , N
71 CD N
years NNS N
) ) N
. . N

The DT N
instilled JJ N
doses NNS N
of IN N
doxorubicin NN N
and CC N
mitoxantrone NN N
were VBD N
30 CD N
and CC N
14 CD N
mg NN N
, , N
respectively RB N
. . N

Disease NNP N
recurrence NN N
and CC N
side NN N
effects NNS N
were VBD N
compared VBN N
using VBG N
Fisher NNP N
's POS N
exact JJ N
test NN N
. . N

The DT N
interval NN N
to TO N
recurrence NN N
was VBD N
shown VBN N
by IN N
Kaplan-Meier NNP N
survivorship NN N
curves NNS N
, , N
and CC N
the DT N
log-rank JJ N
test NN N
was VBD N
used VBN N
to TO N
compare VB N
the DT N
time NN N
to TO N
recurrence VB N
. . N

RESULTS VB N
The DT N
median JJ N
follow-up JJ N
period NN N
was VBD N
36 CD N
months NNS N
. . N

Thirty-three JJ N
patients NNS N
received VBD N
mitoxantrone NN N
, , N
whereas JJ N
30 CD N
patients NNS N
used VBN N
doxorubicin NN N
. . N

The DT N
recurrence NN N
rate NN N
in IN N
the DT N
doxorubicin NN N
group NN N
was VBD N
30 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
: : N
19.8 CD N
% NN N
-38.8 NNP N
% NN N
) ) N
, , N
while IN N
it PRP N
was VBD N
27.3 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
: : N
17.5 CD N
% NN N
-36.8 NNP N
% NN N
) ) N
in IN N
the DT N
mitoxantrone NN N
group NN N
. . N

The DT N
median JJ N
recurrence-free JJ N
survival NN N
in IN N
the DT N
mitoxantrone NN N
group NN N
and CC N
in IN N
the DT N
doxorubicin NN N
group NN N
was VBD N
22 CD N
and CC N
20 CD N
months NNS N
, , N
respectively RB N
( ( N
p=0.580 NN N
) ) N
. . N

Higher JJR N
recurrence NN N
rates NNS N
were VBD N
found VBN N
for IN N
Grade NNP N
III NNP N
and CC N
multiple JJ N
primary JJ N
tumors NNS N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
response NN N
rates NNS N
( ( N
p=0.784 NN N
) ) N
. . N

The DT N
incidence NN N
of IN N
side NN N
effects NNS N
was VBD N
20 CD N
% NN N
in IN N
the DT N
doxorubicin NN N
group NN N
and CC N
21.2 CD N
% NN N
in IN N
the DT N
mitoxantrone NN N
group NN N
. . N

However RB N
, , N
the DT N
difference NN N
was VBD N
not RB N
significant JJ N
( ( N
p JJ N
> NNP N
0.99 CD N
) ) N
. . N

CONCLUSIONS VB N
The DT N
results NNS N
revealed VBD N
that IN N
the DT N
efficacy NN N
and CC N
side JJ N
effects NNS N
of IN N
mitoxantrone NN N
were VBD N
similar JJ N
to TO N
those DT N
of IN N
doxorubicin NN N
. . N

Especially RB N
for IN N
patients NNS N
with IN N
pulmonary JJ N
tuberculosis NN N
or CC N
aged VBN N
patients NNS N
with IN N
primary JJ N
bladder NN N
tumors NNS N
, , N
mitoxantrone NN N
and CC N
doxorubicin NN N
may MD N
be VB N
the DT N
tolerable JJ N
and CC N
effective JJ N
intravesical JJ N
agents NNS N
. . N

-DOCSTART- -X- O O 15528779

Low-intensity NNP N
exercise NN N
and CC N
reduction NN N
of IN N
the DT N
risk NN N
for IN N
falls NNS N
among IN N
at-risk JJ N
elders NNS N
. . N

BACKGROUND NNP N
Among IN N
elderly JJ N
persons NNS N
, , N
falls VBZ N
account NN N
for IN N
87 CD N
% NN N
of IN N
all DT N
fractures NNS N
and CC N
are VBP N
contributing VBG N
factors NNS N
in IN N
many JJ N
nursing NN N
home NN N
admissions NNS N
. . N

This DT N
study NN N
evaluated VBD N
the DT N
effect NN N
of IN N
an DT N
easily RB N
implemented VBN N
, , N
low-intensity JJ N
exercise NN N
program NN N
on IN N
the DT N
incidence NN 4_p
of IN 4_p
falls NNS 4_p
and CC 4_p
the DT 4_p
time NN 4_p
to TO 4_p
first VB 4_p
fall NN 4_p
among IN 4_p
a DT 4_p
clinically RB 4_p
defined JJ 4_p
population NN 4_p
of IN 4_p
elderly JJ 4_p
men NNS 4_p
and CC 4_p
women NNS 4_p
. . 4_p

METHODS VB N
This DT N
community-based JJ N
, , N
randomized JJ N
trial NN N
compared VBN N
the DT N
exercise NN N
intervention NN N
with IN N
a DT N
no-intervention JJ N
control NN N
. . N

The DT N
participants NNS N
were VBD N
294 CD N
men NNS N
and CC N
women NNS N
, , N
aged VBD N
60 CD N
years NNS N
or CC N
older JJR N
, , N
who WP N
had VBD N
either CC N
a DT N
hospital JJ N
admission NN N
or CC N
bed NN N
rest NN N
for IN N
2 CD N
days NNS N
or CC N
more JJR N
within IN N
the DT N
previous JJ N
month NN N
. . N

Exercise NN N
participants NNS N
were VBD N
scheduled VBN N
to TO N
attend VB N
exercise NN N
sessions NNS N
lasting VBG N
45 CD N
minutes NNS N
, , N
including VBG N
warm-up JJ N
and CC N
cool-down JJ N
, , N
3 CD N
times NNS N
a DT N
week NN N
for IN N
8 CD N
weeks NNS N
( ( N
24 CD N
sessions NNS N
) ) N
. . N

Assessments NNS N
included VBD N
gait NN N
and CC N
balance NN N
measures NNS N
, , N
self-reported JJ N
physical JJ N
function NN N
, , N
the DT N
number NN N
of IN N
medications NNS N
being VBG N
taking VBG N
at IN N
baseline NN N
, , N
participant JJ N
age NN N
, , N
sex NN N
, , N
and CC N
history NN N
of IN N
falling VBG N
. . N

Falls NNS N
were VBD N
tracked VBN N
for IN N
1 CD N
year NN N
after IN N
each DT N
participant NN N
's POS N
baseline JJ N
assessment NN N
. . N

RESULTS VB N
29 CD N
% NN N
of IN N
the DT N
study NN N
participants NNS N
reported VBD N
a DT N
fall NN N
during IN N
the DT N
study NN N
period NN N
. . N

The DT N
effect NN N
of IN N
exercise NN N
in IN N
preventing VBG N
falls NNS N
varied VBN N
significantly RB N
by IN N
baseline JJ N
physical JJ N
function NN N
level NN N
( ( N
p JJ N
< NN N
or CC N
=.002 NN N
) ) N
. . N

The DT N
risk NN N
for IN N
falls NNS N
decreased VBN N
for IN N
exercise NN N
participants NNS N
with IN N
low JJ N
baseline NN N
physical JJ N
functioning NN N
( ( N
hazard JJ N
ratio NN N
, , N
.51 NN N
) ) N
but CC N
increased VBD N
for IN N
exercise NN N
participants NNS N
with IN N
high JJ N
baseline NN N
physical JJ N
functioning NN N
( ( N
hazard JJ N
ratio NN N
, , N
3.51 CD N
) ) N
. . N

CONCLUSIONS VB N
This DT N
easily RB N
implemented VBN N
, , N
low-intensity JJ N
exercise NN N
program NN N
appears VBZ N
to TO N
reduce VB N
the DT N
risk NN N
for IN N
falls NNS N
among IN N
elderly JJ N
men NNS N
and CC N
women NNS N
recovering VBG N
from IN N
recent JJ N
hospitalizations NNS N
, , N
bed VBD N
rest NN N
, , N
or CC N
both DT N
who WP N
have VBP N
low JJ N
levels NNS N
of IN N
physical JJ N
functioning NN N
. . N

-DOCSTART- -X- O O 17961229

How WRB N
well RB N
do VB N
blood NN N
folate VB N
concentrations NNS N
predict VBP N
dietary JJ N
folate NN N
intakes NNS N
in IN N
a DT N
sample NN N
of IN N
Canadian JJ N
lactating VBG N
women NNS N
exposed VBN N
to TO N
high JJ N
levels NNS N
of IN N
folate NN 4_p
? . N
An DT N
observational JJ N
study NN N
. . N

BACKGROUND NNP N
In IN N
1998 CD N
, , N
mandatory JJ N
folic JJ N
acid JJ N
fortification NN N
of IN N
white JJ N
flour NN N
and CC N
select JJ N
cereal NN N
grain NN N
products NNS N
was VBD N
implemented VBN N
in IN N
Canada NNP N
with IN N
the DT N
intention NN N
to TO N
increase VB N
dietary JJ N
folate JJ N
intakes NNS N
of IN N
reproducing VBG 4_p
women NNS N
. . N

Folic NNP N
acid JJ N
fortification NN N
has VBZ N
produced VBN N
a DT N
dramatic JJ N
increase NN N
in IN N
blood NN N
folate JJ N
concentrations NNS N
among IN N
reproductive JJ N
age NN N
women NNS N
, , N
and CC N
a DT N
reduction NN N
in IN N
neural JJ N
tube NN N
defect NN N
( ( N
NTD NNP N
) ) N
-affected VBD N
pregnancies NNS N
. . N

In IN N
response NN N
to TO N
improved VBN N
blood NN N
folate NN N
concentrations NNS N
, , N
many JJ N
health NN N
care NN N
professionals NNS N
are VBP N
asking VBG N
whether IN N
a DT N
folic JJ N
acid NN N
supplement NN N
is VBZ N
necessary JJ N
for IN N
NTD NNP N
prevention NN N
among IN N
women NNS N
with IN N
high JJ 4_p
blood NN 4_p
folate NN 4_p
values NNS 4_p
, , N
and CC N
how WRB N
reliably RB N
high JJ N
RBC NNP N
folate NN N
concentrations NNS N
predict VBP N
folate JJ N
intakes NNS N
shown VBN N
in IN N
randomized VBN N
controlled JJ N
trials NNS N
to TO N
be VB N
protective JJ N
against IN N
NTDs NNP N
. . N

The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
how WRB N
predictive JJ N
blood NN N
folate NN N
concentrations NNS N
and CC N
folate NN N
intakes NNS N
are VBP N
of IN N
each DT N
other JJ N
in IN N
a DT N
sample NN N
of IN N
well-educated JJ N
lactating VBG N
Canadian JJ N
women NNS N
exposed VBN N
to TO N
high JJ N
levels NNS N
of IN N
synthetic JJ 4_p
folate NN 4_p
. . N

METHODS NNP N
The DT N
relationship NN N
between IN N
blood NN N
folate NN N
concentrations NNS N
and CC N
dietary JJ N
folate NN N
intakes NNS N
, , N
determined VBN N
by IN N
weighed VBN N
food NN N
records NNS N
, , N
were VBD N
assessed VBN N
in IN N
a DT N
sample NN N
of IN N
predominantly RB N
university-educated JJ N
lactating VBG N
women NNS N
( ( N
32 CD N
+/- JJ N
4 CD N
yr NN N
) ) N
at IN N
4- JJ N
( ( N
n JJ N
= NNP N
53 CD N
) ) N
and CC N
16-wk JJ N
postpartum NN N
( ( N
n JJ N
= NNP N
55 CD N
) ) N
. . N

RESULTS NNP N
Median JJ N
blood NN N
folate NN N
concentrations NNS N
of IN N
all DT N
participants NNS N
were VBD N
well RB N
above IN N
plasma NN N
and CC N
RBC NNP N
folate VBP N
cut-off NN N
levels NNS N
indicative CD N
of IN N
deficiency NN N
( ( N
6.7 CD N
and CC N
317 CD N
nmol/L NN N
, , N
respectively RB N
) ) N
and CC N
all DT N
, , N
except IN N
for IN N
2 CD N
subjects NNS N
, , N
were VBD N
above IN N
the DT N
cut-off NN N
for IN N
NTD-risk NNP N
reduction NN N
( ( N
> $ N
906 CD N
nmol/L NN N
) ) N
. . N

Only RB N
modest JJ N
associations NNS N
existed VBD N
between IN N
total JJ N
folate NN N
intakes NNS N
and CC N
plasma NN N
( ( N
r JJ N
= NN N
0.46 CD N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
RBC NNP N
( ( N
r VB N
= RB N
0.36 CD N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
folate NN N
concentrations NNS N
at IN N
16-wk JJ N
postpartum NN N
. . N

Plasma NNP N
and CC N
RBC NNP N
folate VBP N
values NNS N
at IN N
16-wk JJ N
postpartum NN N
correctly RB N
identified VBD N
the DT N
quartile NN N
of IN N
folate JJ N
intake NN N
of IN N
only RB N
26 CD N
of IN N
55 CD N
( ( N
47 CD N
% NN N
) ) N
and CC N
18 CD N
of IN N
55 CD N
( ( N
33 CD N
% NN N
) ) N
of IN N
subjects NNS N
, , N
respectively RB N
. . N

The DT N
mean JJ N
RBC NNP N
folate NN N
concentration NN N
of IN N
women NNS N
consuming VBG N
151-410 JJ N
microg/d NN N
of IN N
synthetic JJ N
folate NN N
( ( N
2nd CD N
quartile NN N
of IN N
intake NN N
) ) N
did VBD N
not RB N
differ VB N
from IN N
that DT N
of IN N
women NNS N
consuming VBG N
> JJ N
410 CD N
microg/d NN N
( ( N
3rd CD N
and CC N
4th CD N
quartile NN N
) ) N
. . N

CONCLUSION NNP N
Folate NNP N
intakes NNS N
, , N
estimated VBN N
by IN N
food NN N
composition NN N
tables NNS N
, , N
and CC N
blood NN N
folate NN N
concentrations NNS N
are VBP N
not RB N
predictive JJ N
of IN N
each DT N
other JJ N
in IN N
Canadian JJ N
lactating VBG N
women NNS N
exposed VBN N
to TO N
high JJ N
levels NNS N
of IN N
folate NN N
. . N

Synthetic JJ N
intakes NNS N
> VBP N
151-410 JJ N
microg/d NN N
in IN N
these DT N
women NNS N
produced VBD N
little JJ N
additional JJ N
benefit NN N
in IN N
terms NNS N
of IN N
maximizing VBG N
RBC NNP N
content NN N
. . N

More JJR N
studies NNS N
are VBP N
needed VBN N
to TO N
examine VB N
the DT N
relationship NN N
between IN N
blood NN N
folate NN N
concentration NN N
and CC N
NTD NNP N
risk NN N
. . N

Until IN N
data NNS N
from IN N
such JJ N
studies NNS N
are VBP N
available JJ N
, , N
women NNS N
planning VBG N
a DT N
pregnancy NN N
should MD N
continue VB N
to TO N
consume VB N
a DT N
daily JJ N
folic JJ N
acid JJ N
supplement NN N
of IN N
400 CD N
microg NN N
. . N

-DOCSTART- -X- O O 20647483

Letter NN N
by IN N
Begg NNP N
et CC N
al NN N
regarding VBG N
article NN N
, , N
" VBZ N
The DT N
effects NNS N
of IN N
vitamin NN N
d NN N
supplementation NN N
on IN N
physical JJ N
function NN N
and CC N
quality NN N
of IN N
life NN N
in IN N
older JJR N
heart NN 4_p
failure NN 4_p
patients NNS 4_p
: : N
a DT N
randomized NN N
controlled VBN N
trial NN N
" NN N
. . N

-DOCSTART- -X- O O 22968615

[ JJ N
Clinical NNP N
efficiency NN N
of IN N
cytokines NNS N
in IN N
prophylactics NNS N
and CC N
treatment NN N
of IN N
infectious JJ 4_p
and CC 4_p
inflammatory JJ 4_p
complications NNS 4_p
after IN N
oral JJ 4_p
surgery NN 4_p
procedures NNS N
] VBP N
. . N

The DT N
study NN N
presents VBZ N
the DT N
results NNS N
of IN N
prevention NN N
and CC N
treatment NN N
of IN N
infectious JJ N
and CC N
inflammatory JJ N
complications NNS N
after IN N
oral JJ N
surgery NN N
procedures NNS N
. . N

Combined VBN N
therapy NN N
with IN N
antibiotics NNS N
and CC N
superlimf NN N
promotes VBZ N
a DT N
more RBR N
rapid JJ N
reduction NN N
in IN N
the DT N
duration NN N
of IN N
clinical JJ N
symptoms NNS N
and CC N
duration NN N
of IN N
treatment NN N
than IN N
monotherapy NN N
with IN N
antibiotics NNS N
. . N

Results NNS N
of IN N
the DT N
study NN N
substantiate VBP N
the DT N
feasibility NN N
of IN N
using VBG N
superlimf NN N
in IN N
outpatient JJ N
oral JJ N
surgical JJ N
procedures NNS N
for IN N
infectious JJ N
and CC N
inflammatory JJ N
complications NNS N
treatment NN N
. . N

-DOCSTART- -X- O O 12882611

Phonophoresis NNP N
versus NN N
topical JJ N
application NN N
of IN N
ketoprofen NN N
: : N
comparison NN N
between IN N
tissue NN N
and CC N
plasma NN N
levels NNS N
. . N

BACKGROUND NNP N
AND CC N
PURPOSE NNP N
Over IN N
the DT N
last JJ N
few JJ N
decades NNS N
, , N
application NN N
of IN N
ultrasound NN N
has VBZ N
been VBN N
attempted VBN N
to TO N
enhance VB N
transdermal JJ N
transport NN N
of IN N
several JJ N
drugs NNS N
, , N
a DT N
method NN N
referred VBD N
to TO N
as IN N
" JJ N
phonophoresis NN N
. . N

" VB N
The DT N
purposes NNS N
of IN N
this DT N
study NN N
were VBD N
to TO N
examine VB N
the DT N
influence NN N
of IN N
ultrasound NN N
on IN N
the DT N
transdermal JJ N
delivery NN N
of IN N
ketoprofen NN N
in IN N
humans NNS N
and CC N
to TO N
compare VB N
the DT N
concentrations NNS N
found VBD N
after IN N
continuous JJ N
and CC N
pulsed JJ N
application NN N
. . N

SUBJECTS NNP N
AND NNP N
METHODS NNP N
Twenty-six NNP N
patients NNS N
with IN N
knee NN 4_p
disorders NNS 4_p
requiring VBG 4_p
arthroscopy NN 4_p
were VBD N
randomly RB N
assigned VBN N
to TO N
1 CD N
of IN N
3 CD N
groups NNS N
. . N

Just NNP N
before IN N
surgery NN N
, , N
phonophoresis NN N
of IN N
a DT N
ketoprofen NN N
gel NN N
( ( N
Fastum NNP N
gel NN N
) ) N
was VBD N
given VBN N
to TO N
group NN N
A NNP N
using VBG N
continuous JJ N
ultrasound NN N
( ( N
1 CD N
MHz NNP N
, , N
1.5 CD N
W/cm2 NNP N
, , N
for IN N
5 CD N
minutes NNS N
) ) N
. . N

Group NNP N
B NNP N
received VBD N
the DT N
same JJ N
treatment NN N
but CC N
with IN N
pulsed JJ N
ultrasound NN N
( ( N
100 CD N
Hz NNP N
, , N
20 CD N
% NN N
duty NN N
cycle NN N
) ) N
. . N

Group NNP N
C NNP N
received VBD N
5 CD N
minutes NNS N
of IN N
sham NN N
ultrasound NN N
with IN N
the DT N
ketoprofen NN N
gel NN N
. . N

The DT N
ultrasound JJ N
head NN N
was VBD N
moved VBN N
over IN N
a DT N
10-cm2 JJ N
area NN N
using VBG N
small JJ N
, , N
continuous JJ N
, , N
circular JJ N
movements NNS N
. . N

Biopsies NNS N
of IN N
adipose JJ N
tissue NN N
and CC N
synovial JJ N
tissue NN N
were VBD N
taken VBN N
during IN N
surgery NN N
to TO N
evaluate VB N
the DT N
local JJ N
penetration NN N
of IN N
the DT N
drug NN N
. . N

Blood NN N
samples NNS N
also RB N
were VBD N
collected VBN N
to TO N
determine VB N
whether IN N
ketoprofen NN N
entered VBD N
the DT N
systemic JJ N
circulation NN N
. . N

RESULTS VB N
The DT N
concentration NN N
of IN N
ketoprofen NN N
in IN N
plasma NN N
was VBD N
negligible JJ N
in IN N
all DT N
3 CD N
groups NNS N
. . N

The DT N
concentration NN N
of IN N
ketoprofen NN N
in IN N
synovial JJ N
tissue NN N
differed VBD N
from IN N
that IN N
in IN N
fat JJ N
tissue NN N
. . N

A DT N
difference NN N
in IN N
concentration NN N
of IN N
ketoprofen NN N
in IN N
synovial JJ N
tissue NN N
was VBD N
found VBN N
between IN N
group NN N
C NNP N
and CC N
groups NNS N
A NNP N
and CC N
B NNP N
. . N

The DT N
concentration NN N
of IN N
ketoprofen NN N
in IN N
fat JJ N
tissue NN N
and CC N
synovial JJ N
tissue NN N
was VBD N
consistently RB N
higher JJR N
in IN N
group NN N
B NNP N
than IN N
in IN N
group NN N
A NNP N
. . N

DISCUSSION NNP N
AND CC N
CONCLUSION NNP N
This DT N
study NN N
confirms VBZ N
that IN N
phonophoresis NN N
of IN N
ketoprofen NN N
allows VBZ N
the DT N
attainment NN N
of IN N
higher JJR N
local JJ N
concentrations NNS N
, , N
whereas JJ N
systemic JJ N
exposure NN N
is VBZ N
lower JJR N
. . N

The DT N
results NNS N
indicate VBP N
that IN N
, , N
in IN N
contrast NN N
to TO N
sham VB N
phonopheresis NN N
, , N
ultrasound NN N
can MD N
increase VB N
the DT N
transdermal JJ N
delivery NN N
of IN N
ketoprofen NN N
. . N

-DOCSTART- -X- O O 23929781

Anemia NNP N
and CC N
associated VBN N
clinical JJ N
outcomes NNS N
in IN N
patients NNS 4_p
with IN 4_p
heart NN 4_p
failure NN 4_p
due JJ 4_p
to TO 4_p
reduced VB 4_p
left JJ 4_p
ventricular JJ 4_p
systolic JJ 4_p
function NN 4_p
. . 4_p

BACKGROUND NNP N
Anemia NNP N
is VBZ N
associated VBN N
with IN N
decreased JJ N
functional JJ N
capacity NN N
, , N
reduced VBD N
quality NN N
of IN N
life NN N
, , N
and CC N
worsened VBD N
outcomes NNS N
among IN N
patients NNS 4_p
with IN 4_p
heart NN 4_p
failure NN 4_p
( ( 4_p
HF NNP 4_p
) ) 4_p
due JJ 4_p
to TO 4_p
reduced VB 4_p
left JJ 4_p
ventricular JJ 4_p
ejection NN 4_p
fraction NN 4_p
( ( 4_p
HFREF NNP 4_p
) ) N
. . N

We PRP N
sought VBD N
to TO N
evaluate VB N
the DT N
independent JJ N
effect NN N
of IN N
anemia NN N
on IN N
clinical JJ N
outcomes NNS N
among IN N
those DT N
with IN N
HFREF NNP 4_p
. . N

HYPOTHESIS NNP N
Anemia NNP N
is VBZ N
associated VBN N
with IN N
cardiovascular JJ N
events NNS N
in IN N
patients NNS 4_p
with IN 4_p
heart NN 4_p
failure NN 4_p
. . N

METHODS PDT N
The DT N
HF-ACTION NNP N
trial NN N
was VBD N
a DT N
prospective JJ N
, , N
randomized JJ N
trial NN N
of IN N
exercise NN N
therapy NN N
vs NN N
usual JJ N
care NN N
in IN N
2331 CD N
patients NNS N
with IN N
HFREF NNP 4_p
. . N

Patients NNS 4_p
with IN 4_p
New NNP 4_p
York NNP 4_p
Heart NNP 4_p
Association NNP 4_p
class NN 4_p
II NNP 4_p
to TO 4_p
IV NNP 4_p
HF NNP 4_p
and CC N
left VBD 4_p
ventricular JJ 4_p
ejection NN 4_p
fractions NNS 4_p
of IN 4_p
≤ JJ 4_p
35 CD 4_p
% NN 4_p
were VBD N
recruited VBN N
. . N

Hemoglobin NNP N
( ( N
Hb NNP N
) ) N
was VBD N
measured VBN N
up RB N
to TO N
1 CD N
year NN N
prior RB N
to TO N
entry NN N
and CC N
was VBD N
stratified VBN N
by IN N
quintile NN N
. . N

Anemia NNP N
was VBD N
defined VBN N
as IN N
baseline NN N
Hb NNP N
< VBZ N
13 CD N
g/dL NN N
and CC N
< $ N
12 CD N
g/dL NN N
in IN N
men NNS N
and CC N
women NNS N
, , N
respectively RB N
. . N

Hemoglobin NNP N
was VBD N
assessed VBN N
in IN N
2 CD N
models NNS N
: : N
a DT N
global JJ N
prediction NN N
model NN N
that WDT N
had VBD N
been VBN N
previously RB N
developed VBN N
, , N
and CC N
a DT N
modified JJ N
model NN N
including VBG N
variables NNS N
associated VBN N
with IN N
anemia NN N
and CC N
the DT N
studied JJ N
outcomes NNS N
. . N

RESULTS NNP N
Hemoglobin NNP N
was VBD N
available JJ N
at IN N
baseline NN N
in IN N
1763 CD N
subjects NNS N
( ( N
76 CD N
% NN N
of IN N
total JJ N
study NN N
population NN N
) ) N
; : N
their PRP$ N
median JJ N
age NN N
was VBD N
59.0 CD N
years NNS N
, , N
73 CD N
% NN N
were VBD N
male JJ N
, , N
and CC N
62 CD N
% NN N
were VBD N
Caucasian JJ N
. . N

The DT N
prevalence NN N
of IN N
anemia NN N
was VBD N
515/1763 CD N
( ( N
29 CD N
% NN N
) ) N
. . N

Older JJR N
age NN N
, , N
female JJ N
sex NN N
, , N
African JJ N
American NNP N
race NN N
, , N
diabetes VBZ N
, , N
hypertension NN N
, , N
and CC N
lower JJR N
estimated VBN N
glomerular JJ N
filtration NN N
rates NNS N
were VBD N
all DT N
more RBR N
frequent JJ N
in IN N
lower JJR N
Hb NNP N
quintiles NNS N
. . N

Over IN N
a DT N
median JJ N
follow-up NN N
of IN N
30 CD N
months NNS N
, , N
the DT N
primary JJ N
outcome NN N
of IN N
all-cause JJ N
mortality NN N
or CC N
all-cause JJ N
hospitalization NN N
occurred VBD N
in IN N
78 CD N
% NN N
of IN N
those DT N
with IN N
anemia NN N
and CC N
64 CD N
% NN N
in IN N
those DT N
without IN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

The DT N
secondary JJ N
outcomes NNS N
of IN N
all-cause JJ N
mortality NN N
alone RB N
, , N
cardiovascular JJ N
( ( N
CV NNP N
) ) N
mortality NN N
or CC N
CV NNP N
hospitalization NN N
, , N
and CC N
CV NNP N
mortality NN N
or CC N
HF NNP N
hospitalization NN N
occurred VBD N
in IN N
23 CD N
% NN N
vs JJ N
15 CD N
% NN N
, , N
67 CD N
% NN N
vs JJ N
54 CD N
% NN N
, , N
and CC N
44 CD N
vs NNS N
29 CD N
% NN N
, , N
respectively RB N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Heart NNP N
failure NN N
hospitalizations NNS N
occurred VBD N
in IN N
36 CD N
% NN N
vs JJ N
22 CD N
% NN N
, , N
and CC N
urgent JJ N
outpatient NN N
visits NNS N
for IN N
HF NNP N
exacerbations NNS N
occurred VBD N
in IN N
67 CD N
% NN N
and CC N
55 CD N
% NN N
, , N
respectively RB N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

For IN N
the DT N
global JJ N
model NN N
, , N
there EX N
was VBD N
an DT N
association NN N
observed VBD N
for IN N
anemia NN N
and CC N
all-cause JJ N
mortality NN N
or CC N
hospitalization NN N
( ( N
adjusted VBN N
hazard RB N
ratio JJ N
[ NNP N
HR NNP N
] NN N
: : N
1.15 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NN N
: : N
1.01-1.32 JJ N
, , N
P NNP N
= NNP N
0.04 CD N
) ) N
, , N
but CC N
other JJ N
outcomes NNS N
were VBD N
not RB N
significant JJ N
at IN N
P NNP N
< NNP N
0.05 CD N
. . N

In IN N
the DT N
modified JJ N
model NN N
, , N
the DT N
adjusted JJ N
HR NNP N
for IN N
anemia NN N
and CC N
the DT N
primary JJ N
outcome NN N
of IN N
all-cause JJ N
mortality NN N
or CC N
all-cause JJ N
hospitalization NN N
was VBD N
1.25 CD N
( ( N
95 CD N
% NN N
CI NNP N
: : N
1.10-1.42 JJ N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

There EX N
were VBD N
independent JJ N
associations NNS N
between IN N
anemia NN N
and CC N
all-cause JJ N
death NN N
( ( N
HR NNP N
: : N
1.11 CD N
, , N
95 CD N
% NN N
CI NNP N
: : N
0.87-1.42 JJ N
, , N
P NNP N
= NNP N
0.38 CD N
) ) N
, , N
CV NNP N
death NN N
or CC N
CV NNP N
hospitalization NN N
( ( N
HR NNP N
: : N
1.16 CD N
, , N
95 CD N
% NN N
CI NNP N
: : N
1.01-1.33 JJ N
, , N
P NNP N
= NNP N
0.035 CD N
) ) N
, , N
and CC N
CV NNP N
death NN N
and CC N
HF NNP N
hospitalization NN N
( ( N
HR NNP N
: : N
1.27 CD N
, , N
95 CD N
% NN N
CI NNP N
: : N
1.06-1.51 JJ N
, , N
P NNP N
= NNP N
0.008 CD N
) ) N
. . N

CONCLUSIONS NNP N
Anemia NNP N
modestly RB N
is VBZ N
associated VBN N
with IN N
increased JJ N
rates NNS N
of IN N
death NN N
, , N
hospitalization NN N
, , N
and CC N
HF NNP N
exacerbation NN N
in IN 4_p
patients NNS 4_p
with IN 4_p
chronic JJ 4_p
HFREF NNP 4_p
. . N

After IN N
adjusting VBG N
for IN N
other JJ N
important JJ N
covariates NNS N
, , N
anemia NN N
is VBZ N
independently RB N
associated VBN N
with IN N
an DT N
excess JJ N
hazard NN N
for IN N
all-cause JJ N
mortality NN N
and CC N
all-cause JJ N
hospitalization NN N
. . N

Anemia NNP N
is VBZ N
also RB N
associated VBN N
with IN N
combinations NNS N
of IN N
CV NNP N
death NN N
and CC N
CV/HF NNP N
hospitalizations NNS N
as IN N
composite JJ N
endpoints NNS N
. . N

-DOCSTART- -X- O O 2882234

Comparison NNP N
of IN N
endotracheal NN N
and CC N
peripheral JJ N
intravenous JJ N
adrenaline NN N
in IN N
cardiac JJ 4_p
arrest NN 4_p
. . 4_p

Is VBZ N
the DT N
endotracheal JJ N
route NN N
reliable NN N
? . N
Twelve CD N
patients NNS N
presenting VBG N
to TO N
an DT N
accident NN N
and CC N
emergency NN N
department NN N
in IN N
asystolic JJ N
cardiac JJ N
arrest NN N
were VBD N
randomly RB N
allocated VBN N
to TO N
treatment NN N
with IN N
endotracheal JJ N
adrenaline NN N
( ( N
five CD N
patients NNS N
) ) N
or CC N
peripheral JJ N
intravenous JJ N
adrenaline NN N
( ( N
seven CD N
patients NNS N
) ) N
. . N

Femoral-artery JJ N
blood NN N
samples NNS N
were VBD N
taken VBN N
for IN N
assay NN N
of IN N
adrenaline NN N
and CC N
noradrenaline NN N
. . N

After IN N
intravenous JJ N
adrenaline NN N
there EX N
was VBD N
a DT N
good JJ N
clinical JJ N
and CC N
biochemical JJ N
response NN N
, , N
but CC N
after IN N
endotracheal JJ N
adrenaline NN N
there EX N
was VBD N
no DT N
change NN N
in IN N
serum JJ N
adrenaline NN N
and CC N
no DT N
measurable JJ N
clinical JJ N
response NN N
. . N

The DT N
endotracheal JJ N
route NN N
of IN N
adrenaline JJ N
administration NN N
is VBZ N
not RB N
reliable JJ N
in IN N
out-of-hospital JJ N
cardiac JJ N
arrest NN N
. . N

-DOCSTART- -X- O O 11536065

[ JJ N
Comparison NNP N
between IN N
anterior JJ N
rhinomanometry NN N
and CC N
impulse-oscillometric JJ N
rhinometry NN N
found VBD N
within IN N
nasal JJ 4_p
allergen JJ 4_p
provocation NN N
] NNP N
. . N

UNLABELLED NNP N
Besides IN N
the DT N
standard JJ N
method NN N
of IN N
anterior JJ N
rhinomanometry NN N
( ( N
aR NN N
) ) N
, , N
the DT N
impulse-oscillometric JJ N
rhinometry NN N
( ( N
IOS NNP N
) ) N
is VBZ N
available JJ N
for IN N
measurements NNS N
of IN N
the DT N
nasal JJ N
resistance NN N
. . N

The DT N
aR NN N
is VBZ N
a DT N
procedure NN N
dependent NN N
on IN N
the DT N
cooperation NN N
of IN N
the DT N
patient NN N
, , N
whereas JJ N
IOS NNP N
is VBZ N
measured VBN N
regardless RB N
from IN N
the DT N
breathing NN N
activities NNS N
of IN N
the DT N
patient NN N
. . N

We PRP N
examined VBD N
weather RP N
the DT N
resistance-measurement NN N
by IN N
means NNS N
of IN N
IOS NNP N
in IN N
comparison NN N
to TO N
the DT N
aR NN N
is VBZ N
a DT N
more RBR N
suitable JJ N
method NN N
for IN N
nasal JJ N
allergic JJ N
provocation NN N
. . N

METHOD NNP N
17 CD N
patients NNS N
with IN N
anamnestic JJ N
known VBN N
rhinokonjunktivitis NN 4_p
( ( N
6 CD N
f NN N
, , N
11 CD N
m NN N
) ) N
had VBD N
a DT N
pricktest NN N
and CC N
then RB N
a DT N
nasal JJ N
provocation NN N
testing VBG N
with IN N
an DT N
allergen NN N
which WDT N
provoked VBD N
a DT N
reaction NN N
on IN N
the DT N
skin NN N
. . N

The DT N
complete JJ N
resistance NN N
of IN N
the DT N
nose NN N
was VBD N
measured VBN N
in IN N
a DT N
randomized JJ N
order NN N
by IN N
means NNS N
of IN N
aR NN N
and CC N
IOS NNP N
. . N

RESULTS VB N
The DT N
complete JJ N
resistance NN N
showed VBD N
neither CC N
in IN N
the DT N
basic JJ N
measurement NN N
( ( N
aR JJ N
0,38 CD N
+/- JJ N
0,14 CD N
kPa/l/s NN N
; : N
IOS NNP N
0,38 CD N
+/- JJ N
0,11 CD N
kPa/l/s NN N
) ) N
nor CC N
in IN N
the DT N
control NN N
solution NN N
( ( N
aR JJ N
0,38 CD N
+/- JJ N
0,14 CD N
; : N
IOS NNP N
0,39 CD N
+/- JJ N
0,14 CD N
) ) N
nor CC N
after IN N
application NN N
of IN N
the DT N
allergenic JJ N
solution NN N
( ( N
15 CD N
min NN N
: : N
aR JJ N
0,69 CD N
+/- JJ N
0,27 CD N
; : N
IOS NNP N
0,77 CD N
+/- JJ N
0,42 CD N
; : N
30 CD N
min NN N
: : N
aR JJ N
0,65 CD N
+/- JJ N
0,29 CD N
; : N
IOS NNP N
0,6 CD N
+/- JJ N
0,38 CD N
) ) N
a DT N
significant JJ N
difference NN N
between IN N
the DT N
two CD N
methods NNS N
. . N

The DT N
results NNS N
of IN N
the DT N
measurement NN N
of IN N
aR NN N
and CC N
IOS NNP N
after IN N
the DT N
allergenic JJ N
solution NN N
showed VBD N
a DT N
positive JJ N
correlation NN N
( ( N
15 CD N
min NN N
: : N
r NN N
= VBZ N
0,63 CD N
, , N
p NN N
< VBD N
0,01 CD N
; : N
30 CD N
min NN N
: : N
r NN N
= VBZ N
0,67 CD N
, , N
p NN N
< NNP N
0,01 CD N
) ) N
. . N

We PRP N
found VBD N
by IN N
means NNS N
of IN N
clinic NN N
and CC N
measurement NN N
methods NNS N
in IN N
the DT N
aR NN N
of IN N
7 CD N
patients NNS N
a DT N
positive JJ N
reaction NN N
, , N
within IN N
7 CD N
patient NN N
a DT N
negative JJ N
reaction NN N
, , N
3 CD N
patients NNS N
had VBD N
a DT N
unspecific JJ N
nasal NN N
hyperreactivity NN N
. . N

There EX N
was VBD N
a DT N
correspondence NN N
in IN N
6 CD N
of IN N
the DT N
7 CD N
patients NNS N
with IN N
positive JJ N
reaction NN N
in IN N
aR NN N
between IN N
both DT N
methods NNS N
. . N

4 CD N
of IN N
the DT N
7 CD N
results NNS N
with IN N
negative JJ N
reaction NN N
in IN N
the DT N
aR NN N
would MD N
have VB N
been VBN N
positive JJ N
then RB N
underlying VBG N
the DT N
same JJ N
criteria NNS N
in IN N
the DT N
IOS NNP N
without IN N
announcing VBG N
the DT N
symptomscore NN N
a DT N
relevant JJ N
clinical JJ N
symptomatic NN N
while IN N
testing VBG N
. . N

CONCLUSION NNP N
IOS NNP N
is VBZ N
a DT N
suitable JJ N
procedure NN N
for IN N
nasal JJ N
provocation NN N
testing VBG N
and CC N
provides VBZ N
results NNS N
similar JJ N
to TO N
the DT N
aR NN N
. . N

In IN N
comparison NN N
to TO N
aR VB N
IOS NNP N
is VBZ N
not RB N
dependent JJ N
on IN N
the DT N
patients NNS N
cooperation NN N
. . N

Due NNP N
to TO N
its PRP$ N
higher JJR N
sensitivity NN N
the DT N
valid JJ N
limits NNS N
of IN N
the DT N
aR NN N
at IN N
provocation NN N
testings NNS N
can MD N
not RB N
be VB N
transferred VBN N
to TO N
IOS NNP N
to TO N
avoid VB N
a DT N
false JJ N
positive JJ N
reaction NN N
. . N

-DOCSTART- -X- O O 10100592

A DT N
comparative JJ N
study NN N
of IN N
administration NN N
methods NNS N
of IN N
granisetron NN N
injection NN N
used VBN N
to TO N
treat VB N
nausea/vomiting VBG N
induced VBN N
by IN N
cancer NN N
chemotherapy NN N
without IN N
cisplatin NN N
in IN N
tumors NNS 4_p
of IN 4_p
hematopoietic JJ 4_p
organs NNS 4_p
. . 4_p

Keihanshin NNP N
Study NNP N
Group NNP N
of IN N
Hematological NNP N
Malignancies NNP N
. . N

PURPOSE VB N
The DT N
antiemetic JJ N
effect NN N
of IN N
granisetron NN N
injection NN N
at IN N
a DT N
dose NN N
of IN N
40 CD N
microg/kg NNS N
used VBN N
in IN N
the DT N
treatment NN N
of IN N
nausea/vomiting VBG N
induced VBN N
by IN N
multidrug NN N
combined VBN N
cancer NN N
chemotherapy NN N
excluding VBG N
cisplatin NN N
in IN N
patients NNS 4_p
with IN 4_p
tumors NNS 4_p
of IN 4_p
hematopoietic JJ 4_p
organs NNS 4_p
was VBD N
evaluated VBN N
by IN N
comparing VBG N
a DT N
30-min JJ N
infusion NN N
and CC N
a DT N
slow JJ N
intravenous JJ N
injection NN N
given VBN N
over IN N
30 CD N
s. JJ N
METHODS NNP N
A DT N
two-group JJ N
random-allocation NN N
comparative NN N
study NN N
was VBD N
performed VBN N
with IN N
the DT N
cooperation NN N
of IN N
multiple JJ 4_p
institutions NNS 4_p
using VBG 4_p
a DT 4_p
central JJ 4_p
registration NN 4_p
system NN 4_p
. . N

RESULTS NNP N
In IN N
the DT N
treatment NN N
of IN N
acute JJ N
clinical JJ N
symptoms NNS N
, , N
appetite NN N
was VBD N
described VBN N
as IN N
" JJ N
similar JJ N
to TO N
that IN N
during IN N
good JJ N
health NN N
" NN N
by IN N
61.1 CD N
% NN N
of IN N
patients NNS N
( ( N
55/93 CD N
) ) N
in IN N
the DT N
instillation NN N
group NN N
and CC N
by IN N
47.3 CD N
% NN N
( ( N
44/93 CD N
) ) N
in IN N
the DT N
slow JJ N
injection NN N
group NN N
, , N
a DT N
significant JJ N
advantage NN N
in IN N
the DT N
infusion NN N
group NN N
. . N

However RB N
, , N
no DT N
significant JJ N
differences NNS N
in IN N
the DT N
number NN N
of IN N
episodes NNS N
of IN N
vomiting NN N
, , N
the DT N
severity NN N
of IN N
nausea NN N
or CC N
clinical JJ N
efficacy NN N
were VBD N
found VBN N
. . N

In IN N
the DT N
final JJ N
clinical JJ N
evaluation NN N
and CC N
assessment NN N
of IN N
usefulness NN N
based VBN N
on IN N
the DT N
subjective JJ N
judgement NN N
of IN N
physicians NNS N
throughout IN N
the DT N
entire JJ N
therapeutic JJ N
period NN N
, , N
no DT N
differences NNS N
were VBD N
discernible JJ N
. . N

No DT N
side NN N
effects NNS N
were VBD N
reported VBN N
for IN N
either DT N
method NN N
and CC N
there EX N
was VBD N
no DT N
indication NN N
of IN N
a DT N
sex NN N
difference NN N
concerning VBG N
efficacy NN N
. . N

However RB N
, , N
the DT N
efficacy NN N
in IN N
patients NNS N
with IN N
an DT N
anemic JJ N
tendency NN N
was VBD N
slightly RB N
inferior JJ N
. . N

CONCLUSIONS VB N
The DT N
maintenance NN N
of IN N
appetite NN N
during IN N
the DT N
administration NN N
of IN N
anticancer NN N
drugs NNS N
is VBZ N
very RB N
important JJ N
to TO N
maintain VB N
patients NNS N
' POS N
daily JJ N
activities NNS N
and CC N
quality NN N
of IN N
life NN N
. . N

The DT N
present JJ N
results NNS N
support VB N
the DT N
usefulness NN N
of IN N
infusion NN N
of IN N
granisetron NN N
as IN N
an DT N
administration NN N
method NN N
during IN N
chemotherapy NN N
for IN N
malignant JJ N
hemopathy NN N
. . N

-DOCSTART- -X- O O 7676782

Comparison NNP N
of IN N
eltanolone NN N
and CC N
thiopental NN N
in IN N
anaesthesia NN N
for IN N
termination NN 4_p
of IN N
pregnancy NN 4_p
. . 4_p

Eltanolone NNP N
, , N
a DT N
new JJ N
steroid JJ N
hypnotic NN N
, , N
was VBD N
compared VBN N
to TO N
thiopental VB N
in IN N
short JJ N
anaesthesia NN N
. . N

Sixty NNP N
unpremedicated VBD N
, , N
Asa NNP N
1-2 JJ N
women NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
eltanolone NN N
0.6 CD N
( ( N
group NN N
E1 NNP N
) ) N
or CC N
0.8 CD N
mg.kg-1 JJ N
( ( N
group NN N
E2 NNP N
) ) N
or CC N
thiopental JJ N
4 CD N
mg.kg-1 NN N
( ( N
group NN N
T NNP N
) ) N
for IN N
induction NN N
of IN N
anaesthesia NN N
. . N

One CD N
minute NN N
before IN N
induction NN N
glycopyrrolate NN N
0.2 CD N
mg NN N
and CC N
alfentanil JJ N
15 CD N
micrograms.kg-1 JJ N
i.v NN N
. . N

were VBD N
administered VBN N
. . N

If IN N
induction NN N
failed VBD N
, , N
additional JJ N
boluses NNS N
of IN N
the DT N
test NN N
drug NN N
were VBD N
given VBN N
. . N

Anaesthesia NNP N
was VBD N
maintained VBN N
with IN N
67 CD N
% NN N
nitrous JJ N
oxide NN N
in IN N
oxygen NN N
, , N
and CC N
additional JJ N
bolus NN N
doses NNS N
of IN N
the DT N
test NN N
drug NN N
were VBD N
given VBN N
in IN N
a DT N
standardized JJ N
fashion NN N
, , N
if IN N
needed VBN N
. . N

Recovery NN N
was VBD N
assessed VBN N
by IN N
a DT N
research NN N
nurse NN N
blinded VBD N
to TO N
the DT N
agent NN N
used VBN N
. . N

Mean JJ N
+/- JJ N
s.d NN N
. . N

induction NN N
doss NN N
were VBD N
0.7 CD N
+/- JJ N
0.1 CD N
mg.kg-1 NN N
( ( N
group NN N
E1 NNP N
) ) N
, , N
0.8 CD N
+/- JJ N
0.1 CD N
mg.kg-1 NN N
( ( N
group NN N
E2 NNP N
) ) N
and CC N
4.0 CD N
+/- JJ N
0.0 CD N
mg.kg-1 NN N
( ( N
group NN N
T NNP N
) ) N
. . N

Induction NN N
time NN N
was VBD N
prolonged VBN N
in IN N
the DT N
group NN N
E1 NNP N
compared VBN N
to TO N
the DT N
other JJ N
two CD N
groups NNS N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Side JJ N
effects NNS N
were VBD N
few JJ N
in IN N
all DT N
groups NNS N
, , N
but CC N
involuntary JJ N
muscle NN N
movements NNS N
or CC N
hypertonus NN N
occurred VBD N
in IN N
23 CD N
% NN N
of IN N
the DT N
patients NNS N
in IN N
the DT N
eltanolone NN N
and CC N
in IN N
3 CD N
% NN N
in IN N
the DT N
thiopental JJ N
groups NNS N
( ( N
n.s NN N
) ) N
. . N

Early JJ N
recovery NN N
( ( N
eye NN N
opening NN N
, , N
orientation NN N
and CC N
sitting VBG N
) ) N
was VBD N
slower VBN N
in IN N
both DT N
eltanolone NN N
groups NNS N
compared VBN N
to TO N
the DT N
thiopental JJ N
group NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

No UH N
differences NNS N
between IN N
the DT N
groups NNS N
were VBD N
found VBN N
in IN N
toleration NN N
of IN N
oral JJ N
fluids NNS N
, , N
walking VBG N
, , N
voiding VBG N
, , N
postoperative JJ N
analgesic JJ N
requirements NNS N
or CC N
postoperative JJ N
nausea NN N
and CC N
vomiting NN N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -X- O O 19159477

An DT N
emergency NN N
clinical JJ N
pathway NN N
for IN N
stroke NN N
patients NNS N
-- : N
results NNS N
of IN N
a DT N
cluster NN N
randomised VBN N
trial NN N
( ( N
isrctn41456865 NN N
) ) N
. . N

BACKGROUND NNP N
Emergency NNP N
Clinical NNP N
Pathways NNP N
( ( N
ECP NNP N
) ) N
for IN N
stroke NN N
have VBP N
never RB N
been VBN N
tested VBN N
in IN N
randomized VBN N
controlled JJ N
trials NNS N
( ( N
RCTs NNP N
) ) N
. . N

OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
effectiveness NN N
of IN N
an DT N
ECP NNP N
for IN N
stroke NN N
patients NNS N
in IN N
Latium NNP N
( ( N
Italy NNP N
) ) N
emergency NN N
system NN N
. . N

METHODS NNP N
cluster-RCT NN N
designed VBN N
to TO N
compare VB N
stroke JJ N
patient JJ N
referrals NNS N
by IN N
Emergency NNP N
Medical NNP N
Service NNP N
( ( N
EMS NNP N
) ) N
and CC N
Emergency NNP N
Room NNP N
( ( N
ER NNP N
) ) N
health NN N
professionals NNS N
trained VBN N
in IN N
the DT N
ECP NNP N
, , N
with IN N
those DT N
of IN N
non-trained JJ N
EMS NNP N
and CC N
ER NNP N
controls NNS N
. . N

Primary NNP N
outcome JJ N
measure NN N
was VBD N
the DT N
proportion NN N
of IN N
eligible JJ 4_p
( ( 4_p
aged VBN 4_p
< NNP 4_p
/= $ 4_p
80 CD 4_p
and CC 4_p
symptom JJ 4_p
onset NN 4_p
< NNP 4_p
/= VBZ 4_p
6 CD 4_p
hours NNS 4_p
) ) 4_p
stroke VBD 4_p
patients NNS 4_p
referred VBN 4_p
to TO 4_p
a DT 4_p
stroke NN 4_p
unit NN 4_p
( ( 4_p
SU NNP 4_p
) ) 4_p
. . 4_p

Intention NN N
to TO N
treat VB N
( ( N
ITT NNP N
) ) N
and CC N
per-protocol JJ N
( ( N
PP NNP N
) ) N
analyses NNS N
were VBD N
performed VBN N
, , N
and CC N
risk NN N
ratios NNS N
( ( N
RR NNP N
) ) N
adjusted VBN N
by IN N
age NN N
, , N
gender NN N
and CC N
area NN N
, , N
were VBD N
calculated VBN N
. . N

RESULTS JJ N
2656 CD N
patients NNS N
in IN N
the DT N
intervention NN N
arm NN N
and CC N
2239 CD N
in IN N
the DT N
control NN N
arm NN N
required VBN N
assistance NN N
; : N
78.3 CD N
% NN N
of IN N
the DT N
former JJ N
and CC N
80.6 CD N
% NN N
of IN N
the DT N
latter NN N
were VBD N
admitted VBN N
to TO N
hospitals NNS N
, , N
and CC N
respectively RB N
74.8 CD N
% NN N
and CC N
78.3 CD N
% NN N
were VBD N
confirmed VBN N
strokes NNS N
. . N

Of IN N
the DT N
eligible JJ N
confirmed JJ N
strokes NNS N
, , N
106/434 CD N
( ( N
24.4 CD N
% NN N
) ) N
in IN N
the DT N
intervention NN N
arm NN N
and CC N
43/328 CD N
( ( N
13.1 CD N
% NN N
) ) N
in IN N
the DT N
control NN N
arm NN N
were VBD N
referred VBN N
to TO N
the DT N
SU NNP N
in IN N
the DT N
ITT NNP N
analysis NN N
( ( N
RR NNP N
= NNP N
2.01 CD N
; : N
95 CD N
% NN N
CI NNP N
: : N
0.79-4.00 NN N
) ) N
, , N
and CC N
respectively RB N
105/243 CD N
( ( N
43.2 CD N
% NN N
) ) N
and CC N
43/311 CD N
( ( N
13.8 CD N
% NN N
) ) N
in IN N
the DT N
PP NNP N
analysis NN N
( ( N
RR NNP N
= NNP N
3.21 CD N
; : N
95 CD N
% NN N
CI NNP N
: : N
1.62-4.98 JJ N
) ) N
. . N

Of IN N
patients NNS N
suitable JJ N
for IN N
i.v NN N
. . N

thrombolysis NN N
, , N
15/175 CD N
( ( N
8.6 CD N
% NN N
) ) N
in IN N
the DT N
intervention NN N
arm NN N
and CC N
2/115 CD N
( ( N
1.7 CD N
% NN N
) ) N
in IN N
the DT N
control NN N
arm NN N
received VBN N
thrombolysis NN N
( ( N
p JJ N
= NNP N
0.02 CD N
) ) N
in IN N
the DT N
ITT NNP N
analysis NN N
, , N
and CC N
respectively RB N
15/99 CD N
( ( N
15.1 CD N
% NN N
) ) N
and CC N
2/107 CD N
( ( N
1.9 CD N
% NN N
) ) N
( ( N
p JJ N
= NNP N
0.001 CD N
) ) N
in IN N
the DT N
PP NNP N
analysis NN N
. . N

CONCLUSION NNP N
Our PRP$ N
data NNS N
suggest VBP N
potenti JJ N
efficiency NN N
and CC N
feasibility NN N
of IN N
an DT N
ECP NNP N
. . N

The DT N
integration NN N
of IN N
EMS NNP N
and CC N
ERs NNP N
with IN N
SU NNP N
networks NNS N
for IN N
organised JJ N
acute NN N
stroke NN N
care NN N
is VBZ N
feasible JJ N
and CC N
may MD N
ameliorate VB N
the DT N
quality NN N
of IN N
care NN N
for IN N
stroke NN N
patients NNS N
. . N

TRIAL NNP N
REGISTRATION NNP N
Current NNP N
Controlled NNP N
Trials NNP N
( ( N
ISRCTN41456865 NNP N
) ) N
. . N

-DOCSTART- -X- O O 7969211

Naltrexone NN N
, , N
an DT N
opiate JJ N
antagonist NN N
, , N
fails VBZ N
to TO N
modify VB N
motor NN N
symptoms NNS N
in IN N
patients NNS 4_p
with IN 4_p
Parkinson NNP 4_p
's POS 4_p
disease NN 4_p
. . 4_p

One CD N
month NN N
of IN N
adjunct JJ N
treatment NN N
with IN N
naltrexone NN N
( ( N
100 CD N
mg/day NN N
) ) N
was VBD N
compared VBN N
with IN N
placebo NN N
in IN N
a DT N
double-blind NN N
, , N
randomized VBN N
, , N
cross-over JJ N
design NN N
in IN N
two CD 4_p
groups NNS 4_p
of IN 4_p
patients NNS 4_p
with IN 4_p
Parkinson NNP 4_p
's POS 4_p
disease NN 4_p
. . 4_p

The DT N
first JJ N
group NN N
was VBD N
composed VBN N
of IN N
10 CD N
patients NNS 4_p
with IN 4_p
a DT 4_p
moderate JJ 4_p
motor NN 4_p
impairment NN 4_p
insufficiently RB 4_p
controlled VBN 4_p
by IN 4_p
monotherapy NN 4_p
with IN 4_p
bromocriptine NN 4_p
. . N

The DT N
second JJ N
group NN N
was VBD N
composed VBN N
of IN N
eight CD N
patients NNS N
with IN N
L-dopa-induced JJ N
peak-dose JJ N
dyskinesia NN N
. . N

Naltrexone CC N
as IN N
compared VBN N
with IN N
placebo NN N
did VBD N
not RB N
demonstrate VB N
any DT N
significant JJ N
change NN N
in IN N
motor NN N
function NN N
in IN N
either DT N
group NN N
. . N

These DT N
negative JJ N
clinical JJ N
results NNS N
do VBP N
not RB N
support VB N
a DT N
significant JJ N
role NN N
of IN N
endogenous JJ N
opioid JJ N
systems NNS N
in IN N
the DT N
pathophysiology NN N
of IN N
motor NN N
impairment NN N
in IN N
Parkinson NNP N
's POS N
disease NN N
. . N

-DOCSTART- -X- O O 21661164

[ JJ 4_p
Diabetic NNP 4_p
retinopathy NN 4_p
candesartan NN N
trial NN N
] NN N
. . N

-DOCSTART- -X- O O 20839989

Effect NN N
of IN N
a DT N
synthetic JJ N
appeasing VBG N
pheromone NN N
on IN N
behavioral JJ N
, , N
neuroendocrine JJ N
, , N
immune JJ N
, , N
and CC N
acute-phase JJ N
perioperative JJ N
stress NN N
responses NNS N
in IN N
dogs NNS N
. . N

OBJECTIVE NNP N
To TO N
study VB N
the DT N
effects NNS N
of IN N
a DT N
synthetic JJ N
, , N
dog-appeasing JJ N
pheromone NN N
( ( N
sDAP NN N
) ) N
on IN N
the DT N
behavioral JJ N
, , N
neuroendocrine JJ N
, , N
immune JJ N
, , N
and CC N
acute-phase JJ N
perioperative JJ N
stress NN N
responses NNS N
in IN N
dogs NNS N
undergoing VBG N
elective JJ N
orchiectomy NN N
or CC N
ovariohysterectomy NN N
. . N

DESIGN NNP N
Randomized NNP N
, , N
controlled VBD N
clinical JJ N
trial NN N
. . N

ANIMALS $ N
46 CD N
dogs NNS N
housed VBN N
in IN N
animal NN N
shelters NNS N
and CC N
undergoing VBG N
elective JJ N
orchiectomy NN N
or CC N
ovariohysterectomy NN N
. . N

PROCEDURES NNP N
Intensive NNP N
care NN N
unit NN N
cages NNS N
were VBD N
sprayed VBN N
with IN N
sDAP JJ N
solution NN N
or CC N
sham NN N
treated VBN N
with IN N
the DT N
carrier NN N
used VBN N
in IN N
the DT N
solution NN N
20 CD N
minutes NNS N
prior RB N
to TO N
use VB N
. . N

Dogs NNS N
( ( N
n JJ N
= NN N
24 CD N
and CC N
22 CD N
in IN N
the DT N
sDAP NN N
and CC N
sham JJ N
treatment NN N
exposure NN N
groups NNS N
, , N
respectively RB N
) ) N
were VBD N
placed VBN N
in IN N
treated JJ N
cages NNS N
for IN N
30 CD N
minutes NNS N
before IN N
and CC N
after IN N
surgery NN N
. . N

Indicators NNS N
of IN N
stress NN N
( ( N
ie NN N
, , N
alterations NNS N
in IN N
behavioral JJ N
, , N
neuroendocrine JJ N
, , N
immune JJ N
, , N
and CC N
acute-phase JJ N
responses NNS N
) ) N
were VBD N
evaluated VBN N
perioperatively RB N
. . N

Behavioral JJ N
response NN N
variables NNS N
, , N
salivary JJ N
cortisol NN N
concentration NN N
, , N
WBC NNP N
count NN N
, , N
and CC N
serum JJ N
concentrations NNS N
of IN N
glucose NN N
, , N
prolactin NN N
, , N
haptoglobin NN N
, , N
and CC N
C-reactive JJ N
protein NN N
were VBD N
analyzed VBN N
. . N

RESULTS NNP N
Behavioral NNP N
response NN N
variables NNS N
and CC N
serum NN N
prolactin NN N
concentration NN N
were VBD N
influenced VBN N
by IN N
sDAP NN N
exposure NN N
. . N

Dogs NNS N
exposed VBD N
to TO N
sDAP VB N
were VBD N
more RBR N
likely JJ N
to TO N
have VB N
alertness NN N
and CC N
visual JJ N
exploration NN N
behaviors NNS N
after IN N
surgery NN N
than IN N
were VBD N
dogs NNS N
exposed VBN N
to TO N
sham VB N
treatment NN N
. . N

Decreases VBZ N
in IN N
serum NN N
prolactin NN N
concentrations NNS N
in IN N
response NN N
to TO N
perioperative JJ N
stress NN N
were VBD N
significantly RB N
smaller JJR N
in IN N
dogs NNS N
exposed VBN N
to TO N
sDAP VB N
, , N
compared VBN N
with IN N
findings NNS N
in IN N
dogs NNS N
exposed VBN N
to TO N
the DT N
sham NN N
treatment NN N
. . N

Variables NNS N
examined VBD N
to TO N
evaluate VB N
the DT N
hypothalamic-pituitary-adrenal JJ N
axis NN N
, , N
immune JJ N
system NN N
, , N
and CC N
acute-phase JJ N
responses NNS N
were VBD N
unaffected VBN N
by IN N
treatment NN N
. . N

CONCLUSIONS NNP N
AND NNP N
CLINICAL NNP N
RELEVANCE NNP N
sDAP NN N
appeared VBD N
to TO N
affect VB N
behavioral JJ N
and CC N
neuroendocrine JJ N
perioperative JJ N
stress NN N
responses NNS N
by IN N
modification NN N
of IN N
lactotropic JJ N
axis NN N
activity NN N
. . N

Use NN N
of IN N
sDAP NN N
in IN N
a DT N
clinical JJ N
setting NN N
may MD N
improve VB N
the DT N
recovery NN N
and CC N
welfare NN N
of IN N
dogs NNS N
undergoing VBG N
surgery NN N
. . N

-DOCSTART- -X- O O 23587455

Effects NNS N
of IN N
parecoxib NN N
on IN N
morphine NN N
analgesia NN N
after IN N
gynecology JJ N
tumor NN N
operation NN N
: : N
a DT N
randomized JJ N
trial NN N
of IN N
parecoxib NN N
used VBN N
in IN N
postsurgical JJ N
pain NN N
management NN N
. . N

BACKGROUND VB N
The DT N
analgesic JJ N
efficacy NN N
of IN N
parecoxib NN N
in IN N
postsurgical JJ N
pain NN N
management NN N
has VBZ N
been VBN N
confirmed VBN N
in IN N
minimally RB N
invasive JJ N
surgery NN N
. . N

However RB N
, , N
little JJ N
is VBZ N
known VBN N
about IN N
its PRP$ N
effects NNS N
used VBN N
in IN N
combination NN N
with IN N
opioids NNS N
and CC N
about IN N
its PRP$ N
potential JJ N
for IN N
opioid-sparing JJ N
effects NNS N
in IN N
complex JJ N
operations NNS N
. . N

This DT N
study NN N
was VBD N
performed VBN N
to TO N
investigate VB N
the DT N
influence NN N
of IN N
parecoxib NN N
on IN N
morphine NN N
analgesia NN N
after IN N
gynecological JJ N
tumor NN N
surgery NN N
. . N

METHODS NNP N
Eighty NNP N
patients NNS N
undergoing VBG N
gynecological JJ N
tumor NN N
resection NN N
were VBD N
randomized VBN N
to TO N
receive VB N
either RB N
intravenous JJ N
parecoxib NN N
at IN N
a DT N
dose NN N
of IN N
40 CD N
mg NNS N
( ( N
Group NNP N
P NNP N
, , N
n JJ N
= NNP N
40 CD N
) ) N
followed VBN N
by IN N
40 CD N
mg NNS N
every DT N
12 CD N
h NN N
for IN N
48 CD N
h NN N
or CC N
saline NN N
as IN N
a DT N
control NN N
( ( N
Group NNP N
C NNP N
, , N
n JJ N
= NNP N
40 CD N
) ) N
30 CD N
min NN N
before IN N
induction NN N
of IN N
anesthesia NN N
, , N
followed VBN N
by IN N
saline NN N
at IN N
the DT N
same JJ N
time NN N
points NNS N
after IN N
the DT N
operation NN N
. . N

All DT N
patients NNS N
had VBD N
access NN N
to TO N
patient-controlled JJ N
analgesia NN N
with IN N
intravenous JJ N
morphine NN N
. . N

Patients NNS N
were VBD N
assessed VBN N
with IN N
respect NN N
to TO N
pain VB N
score NN N
( ( N
visual JJ N
analog NN N
scale NN N
from IN N
0-10 JJ N
) ) N
, , N
cumulative JJ N
morphine NN N
requirement NN N
, , N
satisfaction NN N
score NN N
, , N
and CC N
side JJ N
effects NNS N
at IN N
2 CD N
, , N
6 CD N
, , N
12 CD N
, , N
24 CD N
, , N
and CC N
48 CD N
h NN N
after IN N
surgery NN N
. . N

RESULTS VB N
A DT N
total NN N
of IN N
79 CD N
patients NNS N
were VBD N
evaluated VBN N
. . N

The DT N
cumulative JJ N
dose NN N
of IN N
morphine NN N
administered VBN N
at IN N
each DT N
time NN N
point NN N
was VBD N
lower JJR N
in IN N
Group NNP N
P NNP N
than IN N
in IN N
Group NNP N
C NNP N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
, , N
at IN N
2 CD N
h NN N
( ( N
3.81 CD N
± RB N
0.35 CD N
versus NN N
4.13 CD N
± JJ N
0.45 CD N
; : N
P NNP N
= NNP N
0.01 CD N
) ) N
, , N
6 CD N
h NN N
( ( N
16.20 CD N
± RB N
1.49 CD N
versus NN N
19.60 CD N
± JJ N
0.35 CD N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
12 CD N
h NN N
( ( N
26.29 CD N
± RB N
2.75 CD N
versus NN N
32.49 CD N
± JJ N
2.42 CD N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
24 CD N
h NN N
( ( N
41.72 CD N
± RB N
2.70 CD N
versus NN N
49.97 CD N
± JJ N
4.53 CD N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
and CC N
48 CD N
h NN N
( ( N
60.06 CD N
± RB N
4.00 CD N
versus NN N
65.68 CD N
± JJ N
3.23 CD N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Compared VBN N
with IN N
Group NNP N
C NNP N
, , N
Group NNP N
P NNP N
had VBD N
significantly RB N
lower JJR N
visual JJ N
analog NN N
scale NN N
scores NNS N
at IN N
rest NN N
and CC N
with IN N
movement NN N
, , N
respectively RB N
, , N
at IN N
2 CD N
h NN N
( ( N
4.2 CD N
, , N
P NNP N
< NNP N
0.001 CD N
and CC N
5.0 CD N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
6 CD N
h NN N
( ( N
3.6 CD N
, , N
P NNP N
< NNP N
0.001 CD N
and CC N
4.5 CD N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
12 CD N
h NN N
( ( N
3.0 CD N
, , N
P NNP N
= NNP N
0.017 CD N
and CC N
4.0 CD N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
24 CD N
h NN N
( ( N
2.1 CD N
, , N
P NNP N
< NNP N
0.001 CD N
and CC N
3.4 CD N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
and CC N
48 CD N
h NN N
( ( N
1.8 CD N
, , N
P NNP N
< NNP N
0.001 CD N
and CC N
2.6 CD N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

The DT N
satisfaction NN N
score NN N
was VBD N
higher RBR N
in IN N
Group NNP N
P NNP N
than IN N
in IN N
Group NNP N
C NNP N
( ( N
8.6 CD N
± RB N
0.3 CD N
versus NN N
6.8 CD N
± NN N
0.7 CD N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
side NN N
effects NNS N
between IN N
the DT N
two CD N
groups NNS N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

CONCLUSIONS VB N
The DT N
use NN N
of IN N
parecoxib NN N
with IN N
patient-controlled JJ N
analgesic JJ N
morphine NN N
in IN N
postoperative JJ N
analgesia NN N
resulted VBD N
in IN N
comprehensive JJ N
enhancement NN N
of IN N
the DT N
analgesic JJ N
efficacy NN N
, , N
reducing VBG N
the DT N
opioid JJ N
requirement NN N
and CC N
increasing VBG N
patient JJ N
satisfaction NN N
after IN N
gynecological JJ N
tumor NN N
surgery NN N
. . N

-DOCSTART- -X- O O 18681363

[ JJ N
Intra-uterine JJ N
insemination NN N
with IN N
controlled JJ N
ovarian JJ N
hyperstimulation NN N
compared VBN N
to TO N
an DT N
expectant JJ N
management NN N
in IN N
couples NNS N
with IN N
unexplained JJ 4_p
subfertility NN 4_p
and CC 4_p
an DT 4_p
intermediate JJ 4_p
prognosis NN 4_p
: : N
a DT N
randomised JJ N
study NN N
] NNP N
. . N

OBJECTIVE NNP N
Intrauterine NNP N
insemination NN N
( ( N
IUI NNP N
) ) N
with IN N
controlled JJ N
ovarian JJ N
hyperstimulation NN N
( ( N
COH NNP N
) ) N
is VBZ N
commonly RB N
used VBN N
as IN N
treatment NN N
of IN N
first JJ N
choice NN N
in IN N
couples NNS N
with IN N
unexplained JJ 4_p
subfertility NN 4_p
. . N

This DT N
treatment NN N
should MD N
only RB N
be VB N
applied VBN N
when WRB N
there EX N
is VBZ N
a DT N
realistic JJ N
increase NN N
in IN N
chance NN N
of IN N
pregnancy NN N
, , N
particularly RB N
because IN N
it PRP N
carries VBZ N
the DT N
increased VBN N
risk NN N
of IN N
multiple JJ N
pregnancies NNS N
. . N

We PRP N
evaluated VBD N
the DT N
effectiveness NN N
of IN N
IUI NNP N
with IN N
COH NNP N
relative VBP N
to TO N
expectant VB N
management NN N
in IN N
couples NNS N
with IN N
unexplained JJ 4_p
subfertility NN 4_p
and CC N
an DT N
intermediate JJ N
prognosis NN N
of IN N
a DT N
spontaneous JJ N
ongoing JJ N
pregnancy NN N
. . N

DESIGN NNP N
Multicentre NNP N
randomised VBD N
clinical JJ N
study NN N
. . N

METHOD NNP N
253 CD N
couples NNS N
with IN N
unexplained JJ 4_p
subfertility NN 4_p
and CC 4_p
a DT 4_p
probability NN 4_p
of IN 4_p
a DT 4_p
spontaneous JJ 4_p
ongoing JJ 4_p
pregnancy NN 4_p
of IN 4_p
30 CD 4_p
% NN 4_p
to TO 4_p
40 CD 4_p
% NN 4_p
within IN N
12 CD N
months NNS N
, , N
were VBD N
randomly RB N
assigned VBN N
to TO N
IUI NNP N
with IN N
COH NNP N
for IN N
6 CD N
months NNS N
or CC N
expectant JJ N
management NN N
for IN N
6 CD N
months NNS N
. . N

The DT N
primary JJ N
endpoint NN N
of IN N
our PRP$ N
study NN N
was VBD N
ongoing JJ N
pregnancy NN N
within IN N
6 CD N
months NNS N
. . N

Analysis NN N
was VBD N
carried VBN N
out RP N
according VBG N
to TO N
the DT N
intention NN N
to TO N
treat VB N
principle NN N
. . N

This DT N
study NN N
was VBD N
registered VBN N
with IN N
the DT N
Dutch JJ N
Trial NNP N
Register NNP N
and CC N
has VBZ N
the DT N
International NNP N
Standard NNP N
Randomised VBD N
Clinical JJ N
Trial NNP N
number NN N
ISRCTN72675518 NNP N
. . N

RESULTS NNP N
Of IN N
the DT N
253 CD N
couples NNS N
included VBD N
, , N
127 CD N
couples NNS N
were VBD N
allocated VBN N
to TO N
IUI NNP N
with IN N
COH NNP N
and CC N
126 CD N
to TO N
expectant VB N
management NN N
. . N

In IN N
the DT N
intervention NN N
group NN N
, , N
42 CD N
women NNS N
( ( N
33 CD N
% NN N
) ) N
conceived VBD N
, , N
of IN N
which WDT N
29 CD N
pregnancies NNS N
were VBD N
ongoing VBG N
( ( N
23 CD N
% NN N
) ) N
. . N

In IN N
the DT N
expectant JJ N
management NN N
group NN N
, , N
40 CD N
women NNS N
( ( N
32 CD N
% NN N
) ) N
conceived VBD N
, , N
of IN N
which WDT N
34 CD N
pregnancies NNS N
were VBD N
ongoing VBG N
( ( N
27 CD N
% NN N
) ) N
( ( N
relative JJ N
risk NN N
: : N
0.85 CD N
; : N
95 CD N
% NN N
CI NNP N
: : N
0.63-1.1 NN N
) ) N
. . N

In IN N
the DT N
expectant JJ N
management NN N
group NN N
one CD N
twin NN N
pregnancy NN N
occurred VBD N
and CC N
in IN N
the DT N
intervention NN N
group NN N
one CD N
woman NN N
conceived VBD N
twins NNS N
and CC N
one CD N
a DT N
triplet NN N
. . N

CONCLUSION VB N
A DT N
substantial JJ N
beneficial JJ N
effect NN N
of IN N
IUI NNP N
with IN N
COH NNP N
in IN N
couples NNS N
with IN N
unexplained JJ N
subfertility NN N
and CC N
an DT N
intermediate JJ N
prognosis NN N
can MD N
be VB N
excluded VBN N
. . N

Expectant JJ N
management NN N
for IN N
a DT N
period NN N
of IN N
6 CD N
months NNS N
therefore RB N
appears VBZ N
justified JJ N
in IN N
these DT N
couples NNS N
. . N

-DOCSTART- -X- O O 3385217

Actions NNS N
of IN N
platelet NN N
activating VBG N
factor NN N
( ( N
PAF NNP N
) ) N
homologues NNS N
and CC N
their PRP$ N
combinations NNS N
on IN N
neutrophil JJ 4_p
chemokinesis NN 4_p
and CC N
cutaneous JJ 4_p
inflammatory NN 4_p
responses NNS 4_p
in IN N
man NN N
. . N

The DT N
inflammatory JJ N
actions NNS N
of IN N
synthetic JJ N
C16:0 NNP N
and CC N
C18:0 NNP N
platelet NN N
activating VBG N
factor NN N
( ( N
PAF NNP N
) ) N
homologues NNS N
, , N
both DT N
alone RB N
and CC N
in IN N
combination NN N
, , N
have VBP N
been VBN N
compared VBN N
in IN N
an DT N
in IN N
vitro JJ N
human JJ N
neutrophil JJ 4_p
chemokinesis NN 4_p
assay NN N
and CC N
by IN N
intradermal JJ N
injection NN N
in IN N
human JJ N
skin NN N
. . N

In IN N
the DT N
chemokinesis NN N
assay NN N
, , N
the DT N
maximum JJ N
distance NN N
moved VBN N
by IN N
neutrophils NNS N
in IN N
the DT N
presence NN N
of IN N
C18:0 NNP N
PAF NNP N
was VBD N
significantly RB N
greater JJR N
than IN N
that DT N
seen VBN N
with IN N
the DT N
C16:0 NNP N
compound NN N
. . N

A DT N
mixture NN N
of IN N
C16:0 NNP N
and CC N
C18:0 NNP N
PAFs NNP N
in IN N
a DT N
ratio NN N
of IN N
1:9 CD N
appeared VBD N
to TO N
be VB N
more RBR N
active JJ N
than IN N
in IN N
a DT N
ratio NN N
of IN N
3:1 CD N
. . N

Intradermal JJ N
injection NN N
of IN N
the DT N
C16:0 NNP N
and CC N
C18:0 NNP N
PAF NNP N
homologues NNS N
induced VBD N
dose-dependent JJ N
increases NNS N
in IN N
weal JJ N
volume NN N
and CC N
flare JJ N
area NN N
responses NNS N
which WDT N
were VBD N
not RB N
significantly RB N
different JJ N
. . N

Combination NN N
of IN N
these DT N
phospholipids NNS N
in IN N
a DT N
ratio NN N
of IN N
3:1 CD N
or CC N
1:9 CD N
of IN N
C16:0 NN N
: : N
C18:0 NN N
did VBD N
not RB N
significantly RB N
alter VB N
the DT N
dose JJ N
response NN N
curves NNS N
. . N

Thus RB N
, , N
changes NNS N
in IN N
the DT N
chain NN N
length NN N
of IN N
the DT N
alkyl JJ N
substituent NN N
of IN N
synthetic JJ N
PAF NNP N
homologues NNS N
and CC N
combination NN N
of IN N
these DT N
homologues NNS N
, , N
in IN N
ratios NNS N
found VBN N
in IN N
vivo NN N
or CC N
formed VBN N
by IN N
leukocytes NNS N
in IN N
vitro NN N
, , N
did VBD N
not RB N
alter VB N
the DT N
cutaneous JJ 4_p
inflammatory NN 4_p
responses NNS 4_p
to TO N
PAF NNP N
in IN N
man NN N
. . N

The DT N
C18:0 NNP N
homologue NN N
was VBD N
, , N
however RB N
, , N
more RBR N
active JJ N
as IN N
a DT N
human JJ N
neutrophil NN N
chemoattractant NN N
in IN N
vitro NN N
. . N

-DOCSTART- -X- O O 17617281

Codeine/acetaminophen NNP N
and CC N
hydrocodone/acetaminophen JJ N
combination NN N
tablets NNS N
for IN N
the DT N
management NN N
of IN N
chronic JJ 4_p
cancer NN 4_p
pain NN 4_p
in IN N
adults NNS N
: : N
a DT N
23-day JJ N
, , N
prospective JJ N
, , N
double-blind JJ N
, , N
randomized VBN N
, , N
parallel-group JJ N
study NN N
. . N

BACKGROUND NNP N
Analgesics NNPS N
are VBP N
an DT N
essential JJ N
component NN N
of IN N
the DT N
treatment NN N
of IN N
cancer-associated JJ N
pain NN N
. . N

Pharmacologic NNP N
treatment NN N
is VBZ N
usually RB N
begun VBN N
with IN N
nonopioid JJ N
analgesics NNS N
, , N
most JJS N
frequently RB N
acetaminophen VBP N
. . N

If IN N
pain JJ N
relief NN N
is VBZ N
not RB N
achieved VBN N
, , N
the DT N
so-called JJ N
" NNP N
weak JJ N
" NNP N
opioids NNS N
, , N
such JJ N
as IN N
codeine NN N
and CC N
hydrocodone NN N
, , N
may MD N
be VB N
used VBN N
in IN N
combination NN N
with IN N
acetaminophen NN N
. . N

Adverse JJ N
effects NNS N
( ( N
AEs NNP N
) ) N
of IN N
the DT N
opioids NNS N
include VBP N
constipation NN N
, , N
somnolence NN N
, , N
nausea NN N
, , N
and CC N
vomiting VBG N
. . N

Based VBN N
on IN N
the DT N
results NNS N
of IN N
a DT N
literature NN N
search NN N
, , N
data NNS N
comparing VBG N
the DT N
effects NNS N
of IN N
the DT N
opioids NNS N
are VBP N
lacking VBG N
. . N

OBJECTIVE CC N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
analgesic JJ N
efficacy NN N
and CC N
tolerability NN N
of IN N
codeine NN N
phosphate NN N
versus IN N
hydrocodone NN N
bitartrate NN N
in IN N
combination NN N
with IN N
acetaminophen NN N
in IN N
the DT N
relief NN N
of IN N
cancer-related JJ N
pain NN N
. . N

METHODS NNP N
This DT N
23-day JJ N
, , N
prospective JJ N
, , N
double-blind JJ N
, , N
randomized VBN N
, , N
parallel-group JJ N
study NN N
was VBD N
conducted VBN N
at IN N
3 CD N
Colombian JJ N
centers NNS N
: : N
University NNP N
Libre NNP N
, , N
Social NNP N
Security NNP N
Institute NNP N
, , N
and CC N
General NNP N
Hospital NNP N
of IN N
Medellín NNP N
, , N
Cali NNP N
, , N
Colombia NNP N
. . N

Outpatients NNS N
with IN N
cancer NN N
were VBD N
eligible JJ N
for IN N
the DT N
study NN N
if IN N
they PRP N
were VBD N
aged VBN N
> JJ N
-18 CD N
years NNS N
and CC N
had VBD N
chronic VBN N
( ( N
duration NN N
, , N
> NNP N
/= VBZ N
3 CD N
months NNS N
) ) N
moderate VBP N
to TO N
severe VB N
cancer-related JJ N
pain NN N
( ( N
score NN N
on IN N
10-cm JJ N
visual JJ N
analog NN N
scale NN N
[ NNP N
VAS NNP N
] NNP N
, , N
> VBD N
3 CD N
cm NN N
[ NN N
moderate JJ N
] NN N
; : N
score NN N
on IN N
a DT N
4-point JJ N
verbal JJ N
pain-intensity NN N
scale NN N
, , N
> VBZ N
1 CD N
[ NN N
moderate JJ N
] NN N
) ) N
. . N

Eligible JJ N
patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
1 CD N
tablet NN N
of IN N
codeine/acetaminophen NN N
( ( N
C/A NNP N
) ) N
30/500 CD N
mg NN N
or CC N
hydrocodone/acetaminophen NN N
( ( N
H/A NNP N
) ) N
5/500 CD N
mg NN N
PO NNP N
q4h NN N
( ( N
total JJ N
daily JJ N
doses NNS N
, , N
150/2500 CD N
and CC N
25/2500 CD N
mg NN N
, , N
respectively RB N
) ) N
for IN N
23 CD N
days NNS N
. . N

In IN N
both DT N
groups NNS N
, , N
if IN N
pain JJ N
intensity NN N
was VBD N
rated VBN N
as IN N
> JJ N
3 CD N
on IN N
the DT N
VAS NNP N
at IN N
week NN N
1 CD N
or CC N
2 CD N
, , N
the DT N
dosage NN N
was VBD N
doubled VBN N
. . N

The DT N
primary JJ N
end NN N
point NN N
was VBD N
the DT N
proportion NN N
of IN N
patients NNS N
who WP N
achieved VBD N
pain NN N
relief NN N
( ( N
defined VBN N
as IN N
a DT N
score NN N
of IN N
> $ N
1 CD N
on IN N
a DT N
5-point JJ N
verbal NN N
rating NN N
scale NN N
[ NNP N
VRS NNP N
] NNP N
( ( N
0 CD N
= NNP N
none NN N
; : N
1 CD N
= IN N
a DT N
little JJ N
; : N
2 CD N
= IN N
some DT N
; : N
3 CD N
= IN N
a DT N
lot NN N
; : N
and CC N
4 CD N
= NNP N
complete JJ N
) ) N
on IN N
study NN N
days NNS N
1 CD N
and CC N
2 CD N
and CC N
weeks NNS N
1 CD N
, , N
2 CD N
, , N
and CC N
3 CD N
. . N

The DT N
secondary JJ N
end NN N
point NN N
was VBD N
the DT N
proportion NN N
of IN N
patients NNS N
in IN N
whom WP N
pain NN N
was VBD N
decreased VBN N
( ( N
VAS NNP N
score RB N
, , N
< NNP N
- : N
3 CD N
cm NN N
) ) N
. . N

AEs $ N
were VBD N
self-reported VBN N
on IN N
a DT N
4-point JJ N
VRS NNP N
( ( N
0 CD N
= NNP N
absent NN N
; : N
1 CD N
= NNP N
mild NN N
; : N
2 CD N
= NN N
moderate NN N
; : N
and CC N
3 CD N
= NNP N
severe RB N
) ) N
. . N

RESULTS NNP N
Of IN N
the DT N
121 CD N
patients NNS N
who WP N
participated VBD N
, , N
59 CD N
received VBD N
C/A NNP N
and CC N
62 CD N
received VBD N
H/A NNP N
. . N

Of IN N
the DT N
total JJ N
number NN N
of IN N
cases NNS N
, , N
59 CD N
% NN N
were VBD N
aged VBN N
60 CD N
to TO N
89 CD N
years NNS N
, , N
and CC N
55 CD N
% NN N
were VBD N
men NNS N
. . N

At IN N
baseline NN N
, , N
88 CD N
% NN N
of IN N
the DT N
patients NNS N
described VBD N
their PRP$ N
pain NN N
intensity NN N
as IN N
moderate JJ N
; : N
12 CD N
% NN N
, , N
severe JJ N
. . N

Of IN N
the DT N
patients NNS N
who WP N
received VBD N
C/A NNP N
, , N
58 CD N
% NN N
responded VBD N
to TO N
the DT N
initial JJ N
dosage NN N
of IN N
150/2500 CD N
mg/d NN N
, , N
and CC N
8 CD N
% NN N
of IN N
the DT N
patients NNS N
responded VBD N
to TO N
the DT N
double JJ N
dosage NN N
; : N
34 CD N
% NN N
did VBD N
not RB N
experience VB N
pain NN N
relief NN N
. . N

In IN N
patients NNS N
with IN N
H/A NNP N
, , N
pain NN N
was VBD N
reported VBN N
as IN N
absent NN N
or CC N
mild NN N
in IN N
56 CD N
% NN N
of IN N
patients NNS N
at IN N
the DT N
starting VBG N
dosage NN N
of IN N
25/2500 CD N
mg/d NN N
; : N
an DT N
additional JJ N
15 CD N
% NN N
of IN N
the DT N
patients NNS N
responded VBD N
to TO N
the DT N
double JJ N
dosage NN N
; : N
the DT N
remaining VBG N
29 CD N
% NN N
of IN N
patients NNS N
did VBD N
not RB N
experience VB N
any DT N
pain NN N
relief NN N
. . N

None NN N
of IN N
the DT N
between-group JJ N
differences NNS N
in IN N
response NN N
rates NNS N
were VBD N
significant JJ N
. . N

The DT N
most RBS N
common JJ N
AEs NNP N
in IN N
the DT N
C/A NNP N
and CC N
H/A NNP N
groups NNS N
were VBD N
constipation NN N
( ( N
36 CD N
% NN N
and CC N
29 CD N
% NN N
, , N
respectively RB N
) ) N
, , N
dizziness NN N
( ( N
24 CD N
% NN N
and CC N
19 CD N
% NN N
) ) N
, , N
vomiting VBG N
( ( N
24 CD N
% NN N
and CC N
16 CD N
% NN N
) ) N
, , N
and CC N
dry JJ N
mouth NN N
( ( N
15 CD N
% NN N
and CC N
18 CD N
% NN N
) ) N
, , N
with IN N
no DT N
significant JJ N
differences NNS N
between IN N
groups NNS N
. . N

CONCLUSION NNP N
In IN N
this DT N
study NN N
, , N
efficacy NN N
and CC N
tolerability NN N
were VBD N
comparable JJ N
between IN N
C/A NNP N
and CC N
H/A NNP N
over IN N
23 CD N
days NNS N
of IN N
treatment NN N
in IN N
these DT N
patients NNS N
with IN N
moderate JJ N
or CC N
severe JJ N
, , N
chronic JJ N
, , N
cancer-related JJ N
pain NN N
. . N

-DOCSTART- -X- O O 7584286

Why WRB N
are VBP N
there RB N
sometimes RB N
concreteness JJ N
effects NNS N
in IN N
memory NN 4_p
for IN N
prose NN N
? . N
Four CD N
experiments NNS N
explored VBD N
on-line JJ N
encoding NN N
strategies NNS N
and CC N
memory NN 4_p
for IN N
high JJ 4_p
imagery NN 4_p
and CC N
low JJ 4_p
imagery NN 4_p
texts NN N
. . N

Results NNP N
consistently RB N
indicated VBD N
that IN N
concreteness NN N
effects NNS N
in IN N
memory NN N
for IN N
text JJ N
depend NN N
on IN N
how WRB N
materials NNS N
are VBP N
presented VBN N
in IN N
several JJ N
different JJ N
respects NNS N
. . N

Most JJS N
importantly RB N
, , N
the DT N
experiments NNS N
clarified VBD N
apparently RB N
contradictory JJ N
results NNS N
of IN N
previous JJ N
studies NNS N
by IN N
indicating VBG N
that IN N
concreteness NN N
effects NNS N
generally RB N
do VBP N
not RB N
occur VB N
in IN N
memory NN N
for IN N
prose NN N
when WRB N
imageability NN N
is VBZ N
manipulated VBN N
between-subjects NNS N
, , N
and CC N
that IN N
their PRP$ N
occurrence NN N
when WRB N
imageability NN N
is VBZ N
manipulated VBN N
within-subjects NNS N
depends NNS N
on IN N
the DT N
order NN N
occurrence NN N
when WRB N
imageability NN N
is VBZ N
manipulated VBN N
within-subjects NNS N
depends NNS N
on IN N
the DT N
order NN N
of IN N
presentation NN N
. . N

In IN N
addition NN N
, , N
moving VBG N
window JJ N
analyses NNS N
of IN N
text JJ N
processing NN N
strategies NNS N
indicated VBD N
that IN N
differential JJ N
strategies NNS N
observed VBN N
in IN N
previous JJ N
studies NNS N
when WRB N
subjects NNS N
listened VBD N
to TO N
high JJ N
vs NN N
low JJ N
imagery NN N
text NN N
do VBP N
not RB N
generalize VB N
to TO N
reading NN N
of IN N
the DT N
same JJ N
materials NNS N
. . N

Potential JJ N
explanations NNS N
for IN N
the DT N
pattern NN N
of IN N
results NNS N
are VBP N
evaluated VBN N
, , N
and CC N
implications NNS N
for IN N
theories NNS N
of IN N
mental JJ N
imagery NN N
and CC N
memory NN N
are VBP N
considered VBN N
. . N

-DOCSTART- -X- O O 9196141

Dose-response JJ N
relationship NN N
of IN N
complementary JJ N
radiotherapy NN N
following VBG N
four CD N
cycles NNS N
of IN N
combination NN N
chemotherapy NN N
in IN N
intermediate-stage JJ N
Hodgkin NNP 4_p
's POS 4_p
disease NN 4_p
. . N

PURPOSE NNP N
To TO N
determine VB N
the DT N
appropriate JJ N
irradiation NN N
dose NN N
after IN N
four CD N
cycles NNS N
of IN N
modern JJ N
combination NN N
chemotherapy NN 4_p
in IN N
nonbulky JJ N
involved JJ N
field NN N
( ( N
IF/BF NNP N
) ) N
and CC N
noninvolved VBN N
extended-field NN N
( ( N
EF/IF NNP N
) ) N
sites VBZ N
in IN N
patients NNS N
with IN N
intermediate-stage JJ N
Hodgkin NNP 4_p
's POS 4_p
disease NN 4_p
( ( N
HD NNP 4_p
) ) N
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
HD NNP 4_p
patients NNS N
in IN N
stage NN 4_p
I PRP 4_p
to TO 4_p
IIIA NNP 4_p
with IN N
a DT N
large JJ 4_p
mediastinal JJ 4_p
mass NN 4_p
, , N
E NNP 4_p
stage NN 4_p
, , N
or CC N
massive JJ 4_p
spleen JJ 4_p
involvement NN 4_p
were VBD N
treated VBN N
with IN N
two CD N
double JJ N
cycles NNS N
of IN N
alternating VBG N
cyclophosphamide NN N
, , N
vincristine NN N
, , N
procarbazine NN N
, , N
and CC N
prednisone NN N
( ( N
COPP NNP N
) ) N
plus CC N
doxorubicin JJ N
, , N
bleomycin NN N
, , N
vinblastine NN N
, , N
and CC N
dacarbazine NN N
( ( N
ABVD NNP N
) ) N
followed VBN N
by IN N
EF NNP N
irradiation NN N
in IN N
two CD N
successive JJ N
trials NNS N
( ( N
HD1 NNP N
and CC N
HD5 NNP N
) ) N
. . N

In IN N
the DT N
HD1 NNP N
trial NN N
( ( N
1983 CD N
to TO N
1988 CD N
) ) N
, , N
146 CD N
patients NNS N
who WP N
responded VBD N
to TO N
chemotherapy VB 4_p
were VBD N
randomized VBN N
to TO N
receive VB N
20 CD N
Gy NNP N
( ( N
70 CD N
patients NNS N
) ) N
or CC N
40 CD N
Gy NNP N
( ( N
76 CD N
patients NNS N
) ) N
of IN N
EF NNP N
irradiation NN N
in IN N
all DT N
fields NNS N
outside IN N
bulky JJ N
disease NN N
sites NNS N
. . N

A DT N
cohort NN N
of IN N
111 CD N
patients NNS N
who WP N
fulfilled VBD N
the DT N
same JJ N
inclusion NN N
criteria NNS N
in IN N
the DT N
subsequent JJ N
trial NN N
HD5 NNP N
( ( N
1988 CD N
to TO N
1993 CD N
) ) N
were VBD N
treated VBN N
with IN N
30 CD N
Gy NNP N
. . N

Bulky NNP N
disease NN N
always RB N
received VBD N
40 CD N
Gy NNP N
. . N

RESULTS NNP N
Freedom-from-treatment-failure NNP N
( ( N
FFTF NNP N
) ) N
and CC N
survival NN N
( ( N
SV NNP N
) ) N
curves VBZ N
showed VBD N
no DT N
differences NNS N
between IN N
the DT N
20- JJ N
, , N
30- JJ N
, , N
and CC N
40-Gy JJ N
groups NNS N
. . N

However RB N
, , N
acute JJ N
toxicities NNS N
were VBD N
more RBR N
frequent JJ N
in IN N
the DT N
40-Gy JJ N
arm NN N
. . N

Analysis NN N
of IN N
relapse NN N
patterns NNS N
showed VBD N
that IN N
18 CD N
of IN N
26 CD N
relapsing VBG N
patients NNS N
either CC N
failed VBD N
to TO N
respond VB N
in IN N
initial JJ N
bulky NN N
sites NNS N
( ( N
n JJ N
= NNP N
5 CD N
) ) N
or CC N
had VBD N
an DT N
extranodal JJ N
relapse NN N
( ( N
n JJ N
= NNP N
9 CD N
) ) N
or CC N
both DT N
( ( N
n JJ N
= NNP N
4 CD N
) ) N
. . N

After IN N
5 CD N
years NNS N
, , N
the DT N
cumulative JJ N
risk NN N
for IN N
relapse NN N
in IN N
bulky NN N
sites NNS N
is VBZ N
10 CD N
% NN N
, , N
despite IN N
40 CD N
Gy NNP N
of IN N
radiation NN N
. . N

CONCLUSION NNP N
Our PRP$ N
results NNS N
strongly RB N
suggest VBP N
that IN N
there EX N
is VBZ N
no DT N
relevant JJ N
radiotherapy NN N
dose JJ N
effect NN N
in IN N
the DT N
range NN N
between IN N
20 CD N
Gy NNP N
and CC N
40 CD N
Gy NNP N
in IN N
IF/BF NNP N
and CC N
EF/IF NNP N
after IN N
4 CD N
months NNS N
of IN N
modern JJ N
polychemotherapy NN 4_p
in IN N
patients NNS N
with IN N
intermediate-stage JJ 4_p
HD NNP 4_p
. . N

Relapse NNP N
patterns VBZ N
indicate VB N
that IN N
patients NNS N
destined VBD N
to TO N
relapse VB N
need VB N
more JJR N
systemic JJ N
, , N
rather RB N
than IN N
local JJ N
, , N
treatment NN N
. . N

Based VBN N
on IN N
our PRP$ N
data NNS N
, , N
we PRP N
conclude VBP N
that IN N
20 CD N
Gy NNP N
is VBZ N
sufficient JJ N
in IN N
EF/IF NNP N
of IN N
intermediate-stage JJ N
HD NNP N
following VBG N
four CD N
cycles NNS N
of IN N
modern JJ N
polychemotherapy NN N
. . N

-DOCSTART- -X- O O 3286673

Pulsatile NNP N
insulin NN N
delivery NN N
is VBZ N
more RBR N
efficient JJ N
than IN N
continuous JJ N
infusion NN N
in IN N
modulating VBG N
islet NN N
cell NN N
function NN N
in IN N
normal JJ 4_p
subjects NNS 4_p
and CC 4_p
patients NNS 4_p
with IN 4_p
type JJ 4_p
1 CD 4_p
diabetes NNS 4_p
. . 4_p

The DT N
respective JJ N
modulating NN N
effects NNS N
of IN N
continuous JJ N
and CC N
intermittent JJ N
insulin NN N
delivery NN N
on IN N
pancreatic JJ N
islet NN N
cell NN N
function NN N
were VBD N
studied VBN N
in IN N
seven CD N
normal JJ N
men NNS N
and CC N
nine CD N
insulin-dependent NN N
( ( N
type JJ N
1 CD N
) ) N
diabetic JJ N
patients NNS N
. . N

In IN N
the DT N
normal JJ N
men NNS N
, , N
saline NN N
or CC N
continuous JJ N
( ( N
0.8 CD N
mU RB N
kg-1 JJ N
min-1 NN N
) ) N
or CC N
pulsatile NN N
( ( N
5.2 CD N
mU RB N
kg-1 JJ N
min-1 NNS N
, , N
with IN N
a DT N
switching VBG N
on/off RP N
length NN N
of IN N
2/11 CD N
min NN N
) ) N
human JJ N
insulin NN N
were VBD N
delivered VBN N
on IN N
different JJ N
days NNS N
and CC N
in IN N
random JJ N
order NN N
. . N

Despite IN N
hyperinsulinemia NN N
, , N
blood NN N
glucose NN N
was VBD N
kept VBN N
close RB N
to TO N
its PRP$ N
basal NN N
value NN N
by IN N
the DT N
glucose JJ N
clamp NN N
technique NN N
. . N

The DT N
diabetic JJ N
patients NNS N
also RB N
were VBD N
infused VBN N
in IN N
random JJ N
order NN N
and CC N
on IN N
different JJ N
days NNS N
with IN N
either DT N
saline NN N
or CC N
a DT N
smaller JJR N
amount NN N
of IN N
insulin NN N
delivered VBN N
continuously RB N
( ( N
0.15 CD N
mU RB N
kg-1 JJ N
min-1 NN N
) ) N
or CC N
in IN N
a DT N
pulsatile JJ N
manner NN N
( ( N
0.97 CD N
mU RB N
kg-1 JJ N
min-1 NN N
for IN N
2 CD N
min NN N
, , N
followed VBN N
by IN N
11 CD N
min NNS N
during IN N
which WDT N
no DT N
insulin NN N
was VBD N
infused VBN N
) ) N
. . N

In IN N
all DT N
experiments NNS N
, , N
5 CD N
g NN N
arginine NN N
were VBD N
given VBN N
iv NNS N
as IN N
a DT N
bolus NN N
dose JJ N
30 CD N
min NN N
before IN N
the DT N
end NN N
of IN N
the DT N
study NN N
, , N
and CC N
plasma VB N
C-peptide NNP N
and CC N
glucagon NN N
levels NNS N
were VBD N
determined VBN N
to TO N
assess VB N
islet NN N
cell NN N
function NN N
. . N

In IN N
the DT N
normal JJ N
men NNS N
, , N
insulin NN N
administration NN N
resulted VBD N
in IN N
a DT N
significant JJ N
decline NN N
of IN N
basal NN N
plasma NN N
glucagon NN N
and CC N
C-peptide JJ N
levels NNS N
and CC N
in IN N
a DT N
clear-cut JJ N
decrease NN N
in IN N
the DT N
arginine-induced JJ N
glucagon NN N
response NN N
. . N

These DT N
effects NNS N
of IN N
insulin NN N
were VBD N
significantly RB N
more RBR N
marked JJ N
when WRB N
insulin NN N
was VBD N
delivered VBN N
in IN N
a DT N
pulsatile NN N
rather RB N
than IN N
a DT N
continuous JJ N
manner NN N
. . N

In IN N
the DT N
insulin-dependent JJ N
diabetic JJ N
patients NNS N
, , N
the DT N
lower JJR N
dose NN N
of IN N
insulin NN N
infused VBN N
continuously RB N
did VBD N
not RB N
alter VB N
the DT N
basal NN N
or CC N
arginine-stimulated JJ N
glucagon NN N
response NN N
. . N

In IN N
contrast NN N
, , N
when WRB N
the DT N
same JJ N
amount NN N
of IN N
insulin NN N
was VBD N
delivered VBN N
intermittently RB N
, , N
arginine-induced JJ N
glucagon NN N
release NN N
was VBD N
greatly RB N
reduced VBN N
. . N

Thus RB N
, , N
these DT N
data NNS N
support NN N
the DT N
concept NN N
that WDT N
insulin VBZ N
per IN N
se NN N
is VBZ N
a DT N
potent JJ N
physiological JJ N
modulator NN N
of IN N
islet NN N
A- NNP N
and CC N
B-cell NNP N
function NN N
. . N

Furthermore RB N
, , N
they PRP N
suggest VBP N
that IN N
these DT N
effects NNS N
of IN N
insulin NN N
are VBP N
reinforced VBN N
when WRB N
the DT N
hormone NN N
is VBZ N
administered VBN N
in IN N
an DT N
intermittent JJ N
manner NN N
in IN N
an DT N
attempt NN N
to TO N
reproduce VB N
the DT N
pulsatile NN N
physiological JJ N
release NN N
of IN N
insulin NN N
. . N

-DOCSTART- -X- O O 8018108

Endurance NNP N
physical JJ N
activity NN N
, , N
diet JJ N
and CC N
fibrinolysis NN N
. . N

The DT N
impact NN N
of IN N
long-term JJ N
, , N
heavy JJ N
exercise NN N
on IN N
recently RB N
established VBN N
cardiovascular/thromboembolic JJ N
risk NN N
factors NNS N
of IN N
the DT N
fibrinolytic JJ N
system NN N
, , N
tissue NN N
plasminogen NN N
activator NN N
( ( N
tPA NN N
) ) N
and CC N
plasminogen NN N
activator NN N
inhibitor NN N
( ( N
PAI-1 NNP N
) ) N
in IN N
relation NN N
to TO N
food NN N
composition NN N
was VBD N
studied VBN N
. . N

Twenty NNP N
healthy JJ N
men NNS N
, , N
aged VBN N
18-55 CD N
years NNS N
participated VBN N
in IN N
a DT N
14-day JJ N
skiing NN N
tour NN N
through IN N
the DT N
Swedish JJ N
mountains NNS N
, , N
carrying VBG N
a DT N
pack NN N
load NN N
of IN N
30 CD N
kg NNS N
, , N
and CC N
spending VBG N
each DT N
night NN N
in IN N
self-dug JJ N
igloos NN N
( ( N
ambient JJ N
temp NN N
-10 NN N
degrees NNS N
to TO N
-25 VB N
degrees NNS N
C NNP N
) ) N
, , N
and CC N
were VBD N
randomized VBN N
to TO N
2 CD N
food NN N
regimens NNS N
having VBG N
30 CD N
or CC N
40 CD N
energy NN N
percent NN N
of IN N
fat NN N
. . N

Individual JJ N
records NNS N
were VBD N
kept VBN N
of IN N
all DT N
consumed VBN N
food NN N
. . N

Citrated VBD N
plasma NN N
was VBD N
obtained VBN N
before IN N
and CC N
after IN N
1 CD N
and CC N
2 CD N
weeks NNS N
of IN N
exercise NN N
: : N
tPA NN N
release NN N
was VBD N
assessed VBN N
by IN N
a DT N
10 CD N
min NN N
venous JJ N
occlusion NN N
( ( N
VO NNP N
) ) N
test NN N
. . N

At IN N
baseline NN N
, , N
daily JJ N
dietary JJ N
fiber NN N
intake NN N
correlated VBD N
negatively RB N
with IN N
PAI-1 NNP N
activity NN N
. . N

Already RB N
after IN N
the DT N
first JJ N
week NN N
of IN N
the DT N
skiing VBG N
tour NN N
there EX N
were VBD N
significant JJ N
drops NNS N
in IN N
PAI-1 NNP N
activities NNS N
, , N
cholesterol NN N
and CC N
triglycerides NNS N
. . N

The DT N
tPA JJ N
mass NN N
concentrations NNS N
also RB N
dropped VBD N
, , N
both DT N
before IN N
and CC N
after IN N
VO NNP N
, , N
but CC N
tPA JJ N
activities NNS N
were VBD N
unchanged JJ N
, , N
as IN N
were VBD N
von JJ N
Willebrand NNP N
factor NN N
( ( N
vWF NN N
) ) N
levels NNS N
. . N

These DT N
changes NNS N
were VBD N
related VBN N
mainly RB N
to TO N
the DT N
expenditure NN N
of IN N
energy NN N
, , N
calculated VBN N
from IN N
the DT N
food NN N
consumption NN N
, , N
and CC N
appeared VBD N
to TO N
be VB N
mediated VBN N
through IN N
changed VBN N
insulin NN N
sensitivity NN N
and CC N
decreased VBD N
body NN N
fat JJ N
mass NN N
. . N

The DT N
energy NN N
percent NN N
of IN N
fat NN N
in IN N
the DT N
food NN N
had VBD N
no DT N
differential JJ N
impact NN N
. . N

The DT N
effects NNS N
receded VBD N
a DT N
few JJ N
weeks NNS N
after IN N
cessation NN N
of IN N
the DT N
endurance NN N
exercise NN N
. . N

Thus RB N
, , N
endurance JJ N
physical JJ N
activity NN N
improves VBZ N
the DT N
fibrinolytic JJ N
risk NN N
factor NN N
profile NN N
by IN N
reducing VBG N
PAI-1 NNP N
while IN N
leaving VBG N
tPA JJ N
activity NN N
unaffected VBD N
, , N
independently RB N
of IN N
food NN N
composition NN N
. . N

A DT N
low JJ N
dietary JJ N
fiber NN N
intake NN N
appears VBZ N
to TO N
be VB N
associated VBN N
with IN N
higher JJR N
PAI-1 NN N
activities NNS N
at IN N
baseline NN N
. . N

-DOCSTART- -X- O O 23512255

Lengthening VBG N
the DT N
moment NN N
arm NN N
of IN N
the DT N
patella NN N
confers NNS N
enhanced VBD N
extensor NN N
mechanism NN N
power NN N
following VBG N
total JJ 4_p
knee JJ 4_p
arthroplasty NN 4_p
. . N

We PRP N
investigated VBD N
whether IN N
a DT N
postulated JJ N
biomechanical JJ N
advantage NN N
conferred VBD N
to TO N
the DT N
extensor NN N
mechanism NN N
by IN N
a DT N
change NN N
in IN N
knee NN N
implant JJ N
design NN N
was VBD N
detectable JJ N
in IN N
patients NNS N
by IN N
direct JJ N
physical JJ N
testing NN N
. . N

212 CD N
TKA JJ 4_p
patients NNS N
were VBD N
enrolled VBN N
in IN N
a DT N
double JJ N
blind NN N
randomized VBD N
controlled VBN N
trial NN N
to TO N
receive VB N
either CC N
a DT N
traditional JJ N
implant NN N
or CC N
one CD N
which WDT N
incorporated VBD N
new JJ N
design NN N
features NNS N
. . N

Extensor NNP N
mechanism NN N
power NN N
output NN N
and CC N
physical JJ N
performance NN N
on IN N
a DT N
battery NN N
of IN N
timed JJ N
functional JJ N
activities NNS N
was VBD N
assessed VBN N
pre-operatively RB N
and CC N
then RB N
at IN N
6 CD N
, , N
26 CD N
, , N
and CC N
52 CD N
weeks NNS N
post-operatively RB N
. . N

Significantly RB N
enhanced JJ N
power NN N
output NN N
was VBD N
observed VBN N
in IN N
both DT N
groups NNS N
post-arthroplasty VBP N
; : N
however RB N
, , N
the DT N
new JJ N
design NN N
implant JJ N
group NN N
demonstrated VBD N
a DT N
greater JJR N
change NN N
in IN N
power NN N
output NN N
than IN N
the DT N
traditional JJ N
implant NN N
group NN N
. . N

Posthoc NNP N
testing VBG N
of IN N
between IN N
group NN N
differences NNS N
highlighted VBD N
greater JJR N
improvement NN N
at IN N
all DT N
post-operative JJ N
assessments NNS N
. . N

At IN N
52 CD N
weeks NNS N
, , N
patients NNS N
receiving VBG N
the DT N
implant NN N
with IN N
the DT N
postulated JJ N
biomechanical JJ N
advantage NN N
achieved VBD N
116 CD N
% NN N
of IN N
the DT N
power NN N
output NN N
of IN N
their PRP$ N
contralateral JJ N
limb NN N
, , N
whereas JJ N
patients NNS N
with IN N
the DT N
traditional JJ N
design NN N
achieved VBD N
90 CD N
% NN N
. . N

No DT N
between IN N
group NN N
difference NN N
was VBD N
detected VBN N
in IN N
the DT N
patient NN N
's POS N
time NN N
to TO N
complete VB N
functional JJ N
tasks NNS N
. . N

Thus RB N
, , N
patients NNS N
receiving VBG N
a DT N
knee NN N
implant NN N
of IN N
a DT N
modern JJ N
design NN N
( ( N
theoretically RB N
able JJ N
to TO N
confer VB N
a DT N
mechanical JJ N
advantage NN N
to TO N
the DT N
extensor NN N
mechanism NN N
) ) N
were VBD N
found VBN N
to TO N
generate VB N
significantly RB N
greater JJR N
extensor NN N
power NN N
than IN N
those DT N
receiving VBG N
a DT N
traditional JJ N
implant NN N
without IN N
the DT N
postulated JJ N
mechanical JJ N
advantage NN N
. . N

-DOCSTART- -X- O O 12816740

Antiinflammatory JJ N
effects NNS N
of IN N
the DT N
phosphodiesterase-4 JJ N
inhibitor NN N
cilomilast NN N
( ( N
Ariflo NNP N
) ) N
in IN N
chronic JJ 4_p
obstructive JJ 4_p
pulmonary JJ 4_p
disease NN 4_p
. . N

Cilomilast NNP N
( ( N
Ariflo NNP N
) ) N
, , N
a DT N
new JJ N
oral JJ N
phosphodiesterase-4 JJ N
selective JJ N
inhibitor NN N
, , N
improves VBZ N
lung JJ N
function NN N
in IN N
chronic JJ N
obstructive JJ N
pulmonary JJ N
disease NN N
( ( N
COPD NNP N
) ) N
. . N

We PRP N
have VBP N
evaluated VBN N
its PRP$ N
antiinflammatory JJ N
effects NNS N
in IN N
59 CD N
patients NNS N
with IN N
COPD NNP 4_p
randomized VBD N
to TO N
receive VB N
cilomilast NN N
, , N
15 CD N
mg NN N
two CD N
times NNS N
a DT N
day NN N
, , N
or CC N
placebo NN N
for IN N
12 CD N
weeks NNS N
. . N

Induced NNP N
sputum JJ N
differential NN N
cell NN N
counts NNS N
were VBD N
obtained VBN N
at IN N
baseline NN N
and CC N
at IN N
five CD N
further JJ N
visits NNS N
. . N

Interleukin-8 NNP N
and CC N
neutrophil JJ N
elastase NN N
were VBD N
measured VBN N
in IN N
sputum NN N
supernatant NN N
. . N

Bronchial JJ N
biopsies NNS N
obtained VBN N
at IN N
baseline NN N
and CC N
at IN N
Week NNP N
10 CD N
were VBD N
immunostained VBN N
and CC N
counted VBN N
for IN N
neutrophils NNS N
, , N
CD8+ NNP N
and CC N
CD4+ NNP N
T-lymphocyte NNP N
subsets NNS N
, , N
and CC N
CD68+ NNP N
macrophages NNS N
. . N

Cells NNP N
expressing VBG N
the DT N
genes NNS N
for IN N
interleukin-8 NN N
and CC N
tumor NN N
necrosis NN N
factor-alpha NN N
were VBD N
identified VBN N
by IN N
in IN N
situ JJ N
hybridization NN N
and CC N
quantified VBD N
. . N

Compared VBN N
with IN N
placebo NN N
, , N
analysis NN N
of IN N
variance NN N
( ( N
ANOVA NNP N
) ) N
of IN N
the DT N
change NN N
from IN N
baseline NN N
showed VBD N
that IN N
cilomilast NN N
did VBD N
not RB N
alter VB N
any DT N
sputum JJ N
endpoint NN N
or CC N
FEV1 NNP N
. . N

However RB N
, , N
bronchial JJ N
biopsies NNS N
demonstrated VBD N
that IN N
cilomilast NN N
treatment NN N
was VBD N
associated VBN N
with IN N
reductions NNS N
in IN N
CD8+ NNP N
( ( N
p JJ N
= VBZ N
0.001 CD N
; : N
ANOVA NNP N
) ) N
and CC N
CD68+ NNP N
cells NNS N
( ( N
p JJ N
< VBZ N
0.05 CD N
; : N
ANOVA NNP N
) ) N
. . N

In IN N
addition NN N
, , N
by IN N
Poisson NNP N
analysis NN N
, , N
comparison NN N
of IN N
cell NN N
counts NNS N
analyzed VBN N
as IN N
a DT N
ratio NN N
of IN N
active JJ N
to TO N
placebo VB N
demonstrated JJ N
reductions NNS N
of IN N
CD8+ NNP N
( ( N
48 CD N
% NN N
p NN N
< NNP N
0.01 CD N
) ) N
and CC N
CD68+ NNP N
( ( N
47 CD N
% NN N
p NN N
= NNP N
0.001 CD N
) ) N
cells NNS N
. . N

This DT N
is VBZ N
the DT N
first JJ N
demonstration NN N
of IN N
reduction NN N
by IN N
any DT N
agent NN N
of IN N
airway JJ N
tissue NN N
inflammatory NN N
cells NNS N
characteristic JJ N
of IN N
COPD NNP N
. . N

Phosphodiesterase-4 JJ N
inhibitors NNS N
represent VBP N
a DT N
promising JJ N
new JJ N
class NN N
of IN N
substances NNS N
for IN N
use NN N
in IN N
antiinflammatory JJ N
treatment NN N
of IN N
this DT N
disease NN N
. . N

-DOCSTART- -X- O O 9399611

Evaluation NN N
of IN N
hypertensive JJ 4_p
patients NNS N
after IN N
care NN N
provided VBN N
by IN N
community NN N
pharmacists NNS N
in IN N
a DT N
rural JJ 4_p
setting NN 4_p
. . N

We PRP N
evaluated VBD N
blood NN N
pressure NN N
control NN N
, , N
quality NN N
of IN N
life NN N
, , N
quality NN N
of IN N
care NN N
, , N
and CC N
satisfaction NN N
of IN N
patients NNS N
who WP N
were VBD N
monitored VBN N
by IN N
specially RB N
trained VBN N
community NN N
pharmacists NNS N
in IN N
a DT N
group NN N
medical JJ N
practice NN N
. . N

After IN N
participating VBG N
in IN N
an DT N
intensive JJ N
skill NN N
development NN N
program NN N
, , N
pharmacists NNS N
performed VBD N
in IN N
an DT N
interdisciplinary JJ N
team NN N
in IN N
a DT N
rural JJ N
clinic NN N
. . N

The DT N
primary JJ N
objective NN N
was VBD N
assessed VBN N
by IN N
evaluating VBG N
outcome JJ N
variables NNS N
at IN N
6 CD N
months NNS N
compared VBN N
with IN N
baseline NN N
in IN N
25 CD N
patients NNS N
randomly RB N
assigned VBN N
to TO N
a DT N
study NN N
group NN N
. . N

A DT N
control NN N
group NN N
of IN N
26 CD N
patients NNS N
was VBD N
also RB N
evaluated VBN N
to TO N
determine VB N
if IN N
outcome JJ N
variables NNS N
remained VBD N
constant JJ N
from IN N
baseline NN N
to TO N
6 CD N
months NNS N
. . N

Systolic NNP N
blood NN N
pressure NN N
was VBD N
reduced VBN N
in IN N
the DT N
study NN N
group NN N
( ( N
151 CD N
mm NN N
Hg NNP N
baseline NN N
, , N
140 CD N
mm NN N
Hg NNP N
at IN N
6 CD N
mo NN N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
and CC N
diastolic JJ N
blood NN N
pressure NN N
was VBD N
significantly RB N
lower JJR N
at IN N
2 CD N
, , N
4 CD N
, , N
and CC N
5 CD N
months NNS N
compared VBN N
with IN N
baseline NN N
. . N

Ratings NNS N
from IN N
a DT N
blinded VBN N
peer NN N
review NN N
panel NN N
indicated VBD N
significant JJ N
improvement NN N
in IN N
the DT N
appropriateness NN N
of IN N
the DT N
blood NN N
pressure NN N
regimen NNS N
, , N
going VBG N
from IN N
8.7 CD N
+/- JJ N
4.7 CD N
to TO N
10.9 CD N
+/- JJ N
4.5 CD N
in IN N
the DT N
study NN N
group NN N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
, , N
but CC N
they PRP N
did VBD N
not RB N
change VB N
in IN N
the DT N
control NN N
group NN N
. . N

Several JJ N
quality NN N
of IN N
life NN N
scores NNS N
improved VBN N
significantly RB N
in IN N
the DT N
study NN N
group NN N
after IN N
6 CD N
months NNS N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

These DT N
included VBD N
physical JJ N
functioning NN N
( ( N
61.6 CD N
vs RB N
70.7 CD N
) ) N
, , N
physical JJ N
role NN N
limitations NNS N
( ( N
56.8 CD N
vs RB N
72.8 CD N
) ) N
, , N
and CC N
bodily RB N
pain NN N
( ( N
60.0 CD N
vs RB N
71.7 CD N
) ) N
at IN N
baseline NN N
and CC N
6 CD N
months NNS N
, , N
respectively RB N
. . N

There EX N
were VBD N
no DT N
significant JJ N
changes NNS N
in IN N
the DT N
control NN N
group NN N
. . N

Patient JJ N
satisfaction NN N
scores NNS N
were VBD N
consistently RB N
higher JJR N
in IN N
the DT N
study NN N
group NN N
at IN N
the DT N
end NN N
of IN N
the DT N
study NN N
. . N

Our PRP$ N
results NNS N
indicate VBP N
that IN N
when WRB N
community NN N
pharmacists VBZ N
in IN N
a DT N
clinic JJ N
setting NN N
are VBP N
trained VBN N
and CC N
included VBN N
as IN N
members NNS N
of IN N
the DT N
primary JJ N
care NN N
team NN N
, , N
significant JJ N
improvements NNS N
in IN N
blood NN N
pressure NN N
control NN N
, , N
quality NN N
of IN N
life NN N
, , N
and CC N
patient JJ N
satisfaction NN N
can MD N
be VB N
achieved VBN N
. . N

-DOCSTART- -X- O O 7942578

Effects NNS N
of IN N
a DT N
fish-oil JJ N
and CC N
vegetable-oil JJ N
formula NN N
on IN N
aggregation NN N
and CC N
ethanolamine-containing JJ N
lysophospholipid JJ N
generation NN N
in IN N
activated JJ N
human JJ N
platelets NNS N
and CC N
on IN N
leukotriene JJ N
production NN N
in IN N
stimulated JJ N
neutrophils NNS N
. . N

The DT N
effects NNS N
of IN N
consuming VBG N
a DT N
liquid JJ N
formula NN N
containing VBG N
either CC N
fish JJ N
oil NN N
enriched VBN N
in IN N
omega-3 JJ N
fatty JJ N
acids NNS N
or CC N
vegetable JJ N
oil NN N
enriched VBN N
in IN N
oleic JJ N
acid NN N
was VBD N
evaluated VBN N
in IN N
20 CD N
male JJ N
subjects NNS N
randomly RB N
allocated VBN N
into IN N
two CD N
groups NNS N
over IN N
a DT N
42-d JJ N
period NN N
. . N

A DT N
decrease NN N
in IN N
collagen-induced JJ N
aggregation NN N
by IN N
using VBG N
washed JJ N
platelet NN N
suspensions NNS N
was VBD N
found VBN N
in IN N
both DT N
groups NNS N
after IN N
nutritional JJ N
supplementation NN N
. . N

A DT N
considerable JJ N
rise NN N
in IN N
omega-3 JJ N
and CC N
a DT N
decrease NN N
in IN N
omega-6 JJ N
fatty JJ N
acids NNS N
occurred VBD N
in IN N
the DT N
platelet NN N
phospholipid JJ N
with IN N
fish-oil JJ N
consumption NN N
. . N

The DT N
degree NN N
of IN N
eicosapentaenoic NN N
acid NN N
( ( N
EPA NNP N
, , N
20:5n-3 JJ N
) ) N
enrichment NN N
( ( N
fish-oil JJ N
group NN N
) ) N
was VBD N
dramatically RB N
greater JJR N
in IN N
the DT N
ether-containing JJ N
plasmenylethanolamine NN N
( ( N
13.5 CD N
mol CD N
% NN N
of IN N
fatty JJ N
acids NNS N
; : N
mol CD N
% NN N
of IN N
fatty JJ N
acids NNS N
= VBP N
moles NNS N
per IN N
100 CD N
moles NNS N
of IN N
total JJ N
fatty JJ N
acids NNS N
) ) N
than IN N
in IN N
phosphatidylethanolamine NN N
( ( N
2.8 CD N
mol CD N
% NN N
) ) N
or CC N
phosphatidylcholine NN N
( ( N
2.9 CD N
mol CD N
% NN N
) ) N
. . N

Neither CC N
treatment NN N
significantly RB N
influenced VBD N
the DT N
agonist-induced JJ N
accumulation NN N
of IN N
lysoplasmenylethanolamine NN N
as IN N
derived JJ N
via IN N
phospholipase NN N
A2 NNP N
hydrolysis NN N
of IN N
plasmenylethanolamine NN N
. . N

HPLC NNP N
measurements NNS N
of IN N
eicosanoid JJ N
production NN N
in IN N
A23187-stimulated NNP N
neutrophils NNS N
revealed VBD N
a DT N
considerable JJ N
decrease NN N
in IN N
the DT N
formation NN N
of IN N
arachidonic JJ N
acid-derived JJ N
leukotriene NN N
B4 NNP N
( ( N
LTB4 NNP N
) ) N
, , N
by IN N
41 CD N
% NN N
, , N
and CC N
5-HETE JJ N
( ( N
5-hydroxyeicosatetraenoic JJ N
acid NN N
) ) N
, , N
by IN N
30 CD N
% NN N
, , N
in IN N
the DT N
fish-oil JJ N
group NN N
along IN N
with IN N
the DT N
appearance NN N
of IN N
the DT N
corresponding JJ N
EPA-derived JJ N
products NNS N
[ JJ N
LTB5 NNP N
and CC N
5-HEPE JJ N
( ( N
5-hydroxyeicosapentaenoic JJ N
acid NN N
) ) N
] NN N
. . N

No DT N
such JJ N
alterations NNS N
in IN N
the DT N
formation NN N
of IN N
lipoxygenase NN N
products NNS N
were VBD N
found VBN N
with IN N
the DT N
vegetable JJ N
oil NN N
treatment NN N
. . N

-DOCSTART- -X- O O 1593244

Clinical JJ N
evaluation NN N
of IN N
the DT N
contact NN N
sensitization NN N
potential NN N
of IN N
a DT N
transdermal JJ N
nicotine NN N
system NN N
( ( N
Nicoderm NNP N
) ) N
BACKGROUND NNP N
Transdermal NNP N
nicotine NN N
therapy NN N
has VBZ N
shown VBN N
promise NN N
as IN N
a DT N
smoking NN N
cessation NN N
aid NN N
, , N
but CC N
questions NNS N
about IN N
its PRP$ N
contact NN N
sensitization NN N
potential NN N
and CC N
long-term JJ N
topical JJ N
safety NN N
have VBP N
been VBN N
raised VBN N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
the DT N
contact NN N
sensitization NN N
potential NN N
of IN N
one CD 4_p
nicotine NN 4_p
transdermal NN 4_p
system NN 4_p
( ( 4_p
Nicoderm NNP 4_p
, , 4_p
Marion NNP 4_p
Merrell NNP 4_p
Dow NNP 4_p
Inc NNP 4_p
, , 4_p
Kansas NNP 4_p
City NNP 4_p
, , 4_p
Mo NNP 4_p
, , 4_p
and CC 4_p
ALZA NNP 4_p
Corporation NNP 4_p
, , 4_p
Palo NNP 4_p
Alto NNP 4_p
, , 4_p
Calif NNP 4_p
) ) 4_p
in IN 4_p
a DT 4_p
population NN 4_p
who WP 4_p
were VBD 4_p
allowed VBN 4_p
to TO 4_p
continue VB 4_p
smoking VBG 4_p
. . 4_p

METHODS NNP N
This DT N
study NN N
comprised VBD N
two CD N
phases NNS N
separated VBN N
by IN N
a DT N
2-week JJ N
rest NN N
interval NN N
. . N

During IN N
phase NN N
1 CD N
, , N
a DT N
42-day JJ N
open-label JJ N
induction NN N
period NN N
, , N
subjects VBZ N
wore IN N
only RB N
active JJ N
transdermal JJ N
nicotine JJ N
systems NNS N
. . N

During IN N
phase NN N
2 CD N
, , N
a DT N
4-day JJ N
double-blind JJ N
challenge NN N
period NN N
, , N
subjects NNS N
wore VBD N
active JJ N
and CC N
placebo JJ N
systems NNS N
concurrently RB N
. . N

Upon IN N
removal NN N
of IN N
each DT N
patch NN N
, , N
skin NN N
sites NNS N
were VBD N
evaluated VBN N
for IN N
signs NNS N
of IN N
irritation NN N
, , N
and CC N
subjective JJ N
complaints NNS N
such JJ N
as IN N
itching NN N
or CC N
burning NN N
were VBD N
recorded VBN N
. . N

RESULTS NNP N
Of IN N
the DT N
186 CD N
subjects NNS N
completing VBG N
the DT N
study NN N
, , N
3 CD N
( ( N
1.6 CD N
% NN N
) ) N
exhibited VBD N
evidence NN N
of IN N
delayed JJ N
contact NN N
sensitization NN N
manifested VBD N
as IN N
erythema NN N
with IN N
or CC N
without IN N
infiltration NN N
and CC N
confined VBD N
solely RB N
to TO N
sites NNS N
of IN N
active JJ N
transdermal JJ N
nicotine NN N
system NN N
application NN N
. . N

Nonallergic NNP N
skin JJ N
irritation NN N
was VBD N
observed VBN N
in IN N
less JJR N
than IN N
3 CD N
% NN N
of IN N
all DT N
applications NNS N
. . N

All DT N
reactions NNS N
resolved VBN N
without IN N
incident NN N
. . N

No DT N
subjects NNS N
developed VBD N
systemic JJ N
reactions NNS N
. . N

CONCLUSIONS VB N
The DT N
transdermal JJ N
nicotine NN N
system NN N
used VBN N
in IN N
this DT N
trial NN N
had VBD N
a DT N
low JJ N
contact NN N
sensitization NN N
incidence NN N
and CC N
was VBD N
well RB N
tolerated VBN N
topically RB N
with IN N
minimal JJ N
irritation NN N
. . N

-DOCSTART- -X- O O 15877748

Treatment NN N
of IN N
peri-implantitis NN N
by IN N
the DT N
Vector NNP N
system NN N
. . N

AIM NNP N
To TO N
compare VB N
the DT N
effectiveness NN N
of IN N
treatment NN N
of IN N
peri-implantitis NN N
with IN N
a DT N
novel JJ N
ultrasonic JJ N
device NN N
, , N
the DT N
Vector NNP N
system NN N
, , N
with IN N
that DT N
of IN N
subgingival JJ N
debridement NN N
with IN N
carbon NN N
fiber NN N
curettes NNS N
. . N

MATERIAL NNP N
AND CC N
METHODS NNP N
The DT N
study NN N
, , N
comprising VBG N
11 CD N
patients NNS N
with IN N
at IN N
least JJS N
two CD N
screw JJ N
type NN N
implants NNS 4_p
with IN 4_p
bleeding VBG 4_p
on IN 4_p
probing VBG 4_p
( ( 4_p
BOP NNP 4_p
) ) 4_p
, , 4_p
probing VBG N
pocket NN N
depth NN N
( ( N
PPD NNP N
) ) N
> VBD N
or CC N
=5 JJ N
mm NN N
, , N
and CC N
at IN N
least JJS N
1.5 CD 4_p
mm JJ 4_p
radiographic JJ 4_p
bone NN 4_p
loss NN 4_p
and CC 4_p
exposed VBN 4_p
implant JJ 4_p
threads NNS 4_p
, , N
was VBD N
carried VBN N
out RP N
as IN N
a DT N
single JJ N
blind NN N
randomized VBD N
clinical JJ N
trial NN N
. . N

At IN N
baseline JJ N
one CD N
randomly NN N
chosen VBN N
implant JJ N
in IN N
each DT N
patient NN N
was VBD N
treated VBN N
by IN N
the DT N
Vector NNP N
system NN N
( ( N
test NN N
) ) N
while IN N
the DT N
other JJ N
implant NN N
( ( N
control NN N
) ) N
was VBD N
treated VBN N
by IN N
submucosal JJ N
debridement NN N
with IN N
a DT N
carbon NN N
fiber NN N
curette NN N
. . N

After IN N
3 CD N
months NNS N
, , N
the DT N
same JJ N
treatments NNS N
were VBD N
repeated VBN N
. . N

Plaque NNP N
, , N
BOP NNP N
, , N
and CC N
PPD NNP N
were VBD N
recorded VBN N
on IN N
all DT N
implant JJ N
surfaces NNS N
at IN N
baseline NN N
, , N
and CC N
after IN N
3 CD N
and CC N
6 CD N
months NNS N
. . N

Bone NN N
levels NNS N
were VBD N
recorded VBN N
on IN N
radiographs NN N
taken VBN N
prior RB N
to TO N
the DT N
start NN N
of IN N
the DT N
study NN N
, , N
and CC N
after IN N
6 CD N
months NNS N
. . N

RESULTS NNP N
Oral NNP N
hygiene NN N
around IN N
both DT N
test NN N
and CC N
control NN N
implants NNS N
was VBD N
improved VBN N
at IN N
3 CD N
and CC N
6 CD N
months NNS N
compared VBN N
with IN N
baseline NN N
. . N

At IN N
6 CD N
months NNS N
, , N
four CD N
of IN N
the DT N
Vector-treated NNP N
sites NNS N
, , N
and CC N
only RB N
one CD N
site NN N
treated VBN N
with IN N
curettes NNS N
, , N
had VBD N
stopped VBN N
to TO N
bleed VB N
. . N

In IN N
neither CC N
the DT N
test NN N
nor CC N
the DT N
control NN N
group NN N
, , N
were VBD N
there EX N
any DT N
differences NNS N
between IN N
baseline NN N
and CC N
6 CD N
months NNS N
regarding VBG N
PPD NNP N
and CC N
bone NN N
levels NNS N
. . N

CONCLUSION NNP N
Although IN N
there EX N
was VBD N
a DT N
greater JJR N
reduction NN N
in IN N
the DT N
number NN N
of IN N
sites NNS N
with IN N
BOP NNP N
following VBG N
treatment NN N
with IN N
the DT N
Vector NNP N
system NN N
than IN N
following VBG N
instrumentation NN N
with IN N
carbon NN N
fiber NN N
curettes NNS N
, , N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
two CD N
methods NNS N
. . N

-DOCSTART- -X- O O 9134405

A DT N
randomised JJ N
trial NN N
evaluating VBG N
pain NN N
and CC N
bleeding NN N
after IN N
a DT N
first JJ 4_p
trimester NN 4_p
miscarriage NN 4_p
treated VBD N
surgically RB N
or CC N
medically RB N
. . N

Miscarriage NN N
treated VBD N
surgically RB N
and CC N
medically RB N
were VBD N
compared VBN N
in IN N
a DT N
randomised JJ N
controlled VBN N
trial NN N
evaluating VBG N
pain NN N
and CC N
bleeding NN N
. . N

Surgery NN N
is VBZ N
associated VBN N
with IN N
less JJR N
pain NN N
( ( N
P NNP N
< NNP N
0.03 CD N
) ) N
and CC N
vaginal JJ N
bleeding NN N
( ( N
duration NN N
and CC N
severity NN N
, , N
P NNP N
= NNP N
0.001 CD N
) ) N
than IN N
medical JJ N
treatment NN N
, , N
fewer JJR N
daily JJ N
hospital NN N
attendances NNS N
( ( N
2.5 CD N
compared VBN N
with IN N
three CD N
, , N
P NNP N
= NNP N
0.04 CD N
) ) N
but CC N
a DT N
greater JJR N
drop NN N
in IN N
haemoglobin JJ N
concentration NN N
( ( N
difference NN N
, , N
1 CD N
g/dl NN N
; : N
CI95 NNP N
% NN N
= NNP N
0.3-1.6 NN N
) ) N
. . N

-DOCSTART- -X- O O 7259216

Topical JJ N
treatment NN N
of IN N
alopecia NN N
areata NN N
. . N

It PRP N
has VBZ N
been VBN N
shown VBN N
previously RB N
that IN N
alopecia JJ N
areata NNS N
can MD N
be VB N
treated VBN N
with IN N
dinitrochlorobenzene NN N
( ( N
DNCB NNP N
) ) N
and CC N
other JJ N
contact NN N
allergens NNS N
. . N

Whether IN N
these DT N
agents NNS N
work NN N
by IN N
inducing VBG N
immunologic JJ N
stimulation NN N
or CC N
simply RB N
a DT N
nonspecific JJ N
inflammatory NN N
reaction NN N
has VBZ N
not RB N
been VBN N
definitively RB N
demonstrated VBN N
. . N

To TO N
test VB N
the DT N
relative JJ N
importance NN N
of IN N
these DT N
two CD N
mechanisms NNS N
, , N
we PRP N
have VBP N
randomly RB N
studied VBN N
22 CD 4_p
patients NNS 4_p
with IN 4_p
alopecia JJ 4_p
areata NNS 4_p
to TO 4_p
whom WP 4_p
either DT 4_p
DNCB NNP 4_p
or CC 4_p
croton VB 4_p
oil NN 4_p
was VBD 4_p
applied VBN 4_p
topically RB 4_p
. . 4_p

Sixty-three JJ N
percent NN N
of IN N
patients NNS N
without IN N
spontaneous JJ N
regrowth NN N
of IN N
hair NN N
regrew NNS N
hair NN N
after IN N
DNCB NNP N
application NN N
. . N

None NN N
of IN N
those DT N
treated VBN N
with IN N
croton NN N
oil NN N
regrew VBD N
hair NN N
when WRB N
treated VBN N
later RB N
with IN N
DNCB NNP N
. . N

Therefore NNP N
, , N
a DT N
proved JJ N
contact NN N
allergen NN N
was VBD N
shown VBN N
to TO N
be VB N
required VBN N
for IN N
therapeutic JJ N
success NN N
. . N

Patient JJ N
acceptance NN N
of IN N
the DT N
induced JJ N
contact NN N
dermatitis NN N
was VBD N
excellent JJ N
. . N

In IN N
light NN N
of IN N
recent JJ N
data NNS N
on IN N
the DT N
mutagenicity NN N
of IN N
DNCB NNP N
to TO N
bacteria NNS N
, , N
other JJ N
contact NN N
allergens NNS N
for IN N
topical JJ N
immunotherapy NN N
are VBP N
being VBG N
sought VBN N
. . N

-DOCSTART- -X- O O 18781287

Efficacy NN N
of IN N
topical JJ N
azithromycin NN N
ophthalmic JJ N
solution NN N
1 CD N
% NN N
in IN N
the DT N
treatment NN N
of IN N
posterior JJ 4_p
blepharitis NN 4_p
. . N

INTRODUCTION NNP N
Azithromycin NNP N
, , N
a DT N
broad-spectrum JJ N
antibiotic JJ N
with IN N
potent JJ N
anti-inflammatory JJ N
activities NNS N
, , N
has VBZ N
the DT N
potential JJ N
to TO N
effectively RB N
treat VB N
blepharitis NN 4_p
, , N
an DT N
inflammatory JJ 4_p
disease NN 4_p
of IN N
the DT N
eyelid JJ N
with IN N
abnormal JJ N
eyelid JJ N
flora NN N
as IN N
an DT N
etiologic JJ N
determinant NN N
. . N

The DT N
present JJ N
study NN N
compared VBN N
the DT N
efficacy NN N
of IN N
topical JJ N
azithromycin NN N
ophthalmic JJ N
solution NN N
1 CD N
% NN N
( ( N
AzaSite NNP N
; : N
Inspire NNP N
Pharmaceuticals NNP N
, , N
Inc NNP N
, , N
NC NNP N
, , N
USA NNP N
) ) N
combined VBD N
with IN N
warm JJ N
compresses NNS N
( ( N
azithromycin JJ N
group NN N
) ) N
to TO N
warm JJ N
compresses NNS N
alone RB N
( ( N
compress JJ N
group NN N
) ) N
in IN N
patients NNS N
with IN N
posterior JJ N
blepharitis NN N
. . N

METHODS NNP N
Twenty-one CD N
patients NNS N
diagnosed VBN N
with IN N
posterior JJ 4_p
blepharitis NN 4_p
were VBD N
randomized VBN N
in IN N
an DT N
open-label JJ N
study NN N
to TO N
receive VB N
either DT N
azithromycin NN N
plus CC N
warm JJ N
compresses NNS N
( ( N
10 CD N
patients NNS N
) ) N
, , N
or CC N
compresses VBZ N
alone RB N
( ( N
11 CD N
patients NNS N
) ) N
. . N

All DT N
patients NNS N
were VBD N
instructed VBN N
to TO N
apply VB N
compresses NNS N
to TO N
each DT N
eye NN N
for IN N
5-10 JJ N
minutes NNS N
twice RB N
daily RB N
for IN N
14 CD N
days NNS N
. . N

Each DT N
eye NN N
in IN N
the DT N
azithromycin NN N
group NN N
also RB N
received VBD N
azithromycin JJ N
solution NN N
( ( N
1 CD N
drop NN N
) ) N
twice RB N
daily RB N
for IN N
the DT N
first JJ N
2 CD N
days NNS N
followed VBN N
by IN N
once RB N
daily JJ N
for IN N
the DT N
next JJ N
12 CD N
days NNS N
. . N

Patients NNS N
were VBD N
evaluated VBN N
at IN N
study NN N
initiation NN N
( ( N
visit IN N
1 CD N
) ) N
and CC N
at IN N
end NN N
of IN N
treatment NN N
( ( N
visit IN N
2 CD N
) ) N
for IN N
the DT N
severity NN N
of IN N
five CD N
clinical JJ N
signs NNS N
: : N
eyelid JJ N
debris NN N
, , N
eyelid JJ N
redness NN N
, , N
eyelid JJ N
swelling NN N
, , N
meibomian JJ N
gland NN N
( ( N
MG NNP N
) ) N
plugging NN N
, , N
and CC N
the DT N
quality NN N
of IN N
MG NNP N
secretion NN N
. . N

At IN N
visit NN N
2 CD N
, , N
patients NNS N
also RB N
rated VBD N
their PRP$ N
degree NN N
of IN N
overall JJ N
symptomatic JJ N
relief NN N
. . N

RESULTS NNP N
Twenty NNP N
patients NNS N
completed VBD N
the DT N
study NN N
. . N

At IN N
visit NN N
2 CD N
, , N
patients NNS N
in IN N
the DT N
azithromycin NN N
group NN N
demonstrated VBD N
significant JJ N
improvements NNS N
in IN N
MG NNP N
plugging NN N
, , N
MG NNP N
secretions NNS N
, , N
and CC N
eyelid JJ N
redness NN N
as IN N
compared VBN N
with IN N
the DT N
compress NN N
group NN N
. . N

In IN N
the DT N
azithromycin NN N
group NN N
, , N
MG NNP N
plugging VBG N
resolved VBN N
completely RB N
in IN N
three CD N
patients NNS N
and CC N
MG NNP N
secretion NN N
returned VBD N
to TO N
normal JJ N
in IN N
two CD N
patients NNS N
; : N
no DT N
such JJ N
results NNS N
were VBD N
seen VBN N
in IN N
the DT N
compress NN N
group NN N
. . N

Furthermore RB N
, , N
a DT N
higher JJR N
percentage NN N
of IN N
patients NNS N
in IN N
the DT N
azithromycin NN N
group NN N
rated VBD N
overall JJ N
symptomatic JJ N
relief NN N
as IN N
excellent NN N
or CC N
good JJ N
. . N

Visual JJ N
acuity NN N
measurements NNS N
and CC N
biomicroscopic JJ N
evaluation NN N
revealed VBD N
no DT N
ocular JJ N
safety NN N
issues NNS N
. . N

CONCLUSION NNP N
Azithromycin NNP N
ophthalmic JJ N
solution NN N
in IN N
combination NN N
with IN N
warm JJ N
compresses NNS N
provided VBD N
a DT N
significantly RB N
greater JJR N
clinical JJ N
benefit NN N
than IN N
warm JJ N
compresses NNS N
alone RB N
in IN N
treating VBG N
the DT N
signs NNS N
and CC N
symptoms NNS N
of IN N
posterior JJ N
blepharitis NN N
. . N

-DOCSTART- -X- O O 12614193

ACE NNP N
inhibitors NNS N
or CC N
AT-1 JJ N
antagonists NNS N
- : N
which WDT N
is VBZ N
OPTIMAAL NNP N
after IN N
acute JJ N
myocardial JJ N
infarction NN N
? . N
OPTIMAAL NNP N
( ( N
Optimal NNP N
Trial NNP N
in IN N
Myocardial NNP N
Infarction NNP N
with IN N
the DT N
Angiotensin NNP N
II NNP N
Antagonist NNP N
Losartan NNP N
) ) N
is VBZ N
the DT N
first JJ N
major JJ N
study NN N
to TO N
compare VB N
an DT N
angiotensin NN N
II NNP N
Type NNP N
1 CD N
antagonist NN N
losartan NN N
( ( N
Cozaar NNP N
trade NN N
mark NN N
, , N
Merck NNP N
) ) N
with IN N
an DT N
ACE NNP N
inhibitor NN N
captonpril NN N
( ( N
Capoten NNP N
trade NN N
mark NN N
, , N
Elan NNP N
) ) N
after IN N
myocardial JJ 4_p
infarction NN 4_p
in IN N
patients NNS N
with IN N
left JJ 4_p
ventricular JJ 4_p
dysfunction NN 4_p
. . N

Patients NNS N
were VBD N
assigned VBN N
to TO N
a DT N
target NN N
dose NN N
of IN N
losartan JJ N
50 CD N
mg/day NN N
and CC N
captopril NN N
50 CD N
mg NN N
t.i.d. NN N
, , N
as IN N
tolerated VBN N
. . N

The DT N
primary JJ N
end NN N
point NN N
was VBD N
all-cause JJ N
mortality NN N
and CC N
there EX N
were VBD N
499 CD N
( ( N
18 CD N
% NN N
) ) N
and CC N
447 CD N
( ( N
16 CD N
% NN N
) ) N
deaths NNS N
in IN N
the DT N
losartan NN N
and CC N
captopril NN N
group NN N
, , N
respectively RB N
( ( N
p JJ N
= NNP N
0.07 CD N
) ) N
. . N

However RB N
, , N
there EX N
were VBD N
significantly RB N
more JJR N
cardiovascular JJ N
deaths NNS N
with IN N
losartan NN N
( ( N
420 CD N
, , N
15 CD N
% NN N
) ) N
than IN N
with IN N
captopril NN N
( ( N
363 CD N
, , N
13 CD N
% NN N
; : N
p CC N
= VB N
0.03 CD N
) ) N
. . N

Losartan NNP N
was VBD N
better RBR N
tolerated VBN N
than IN N
captopril NN N
with IN N
fewer JJR N
patients NNS N
discontinuing VBG N
medication NN N
( ( N
17 CD N
versus RB N
23 CD N
% NN N
for IN N
losartan NN N
and CC N
captopril NN N
, , N
respectively RB N
) ) N
. . N

In IN N
conclusion NN N
, , N
if IN N
tolerated VBN N
, , N
captopril NN N
should MD N
remain VB N
the DT N
preferred JJ N
treatment NN N
for IN N
patients NNS N
after IN N
complicated VBN N
acute JJ N
myocardial JJ N
infarction NN N
. . N

-DOCSTART- -X- O O 9088586

Effects NNS N
of IN N
frusemide NN N
and CC N
hypoxia NN N
on IN N
the DT N
pulmonary JJ 4_p
vascular NN 4_p
bed NN 4_p
in IN N
man NN N
. . N

AIMS NNP N
Diuretic NNP N
therapy NN N
is VBZ N
conventionally RB N
used VBN N
to TO N
treat VB N
oedema NNS 4_p
in IN N
patients NNS N
with IN N
hypoxic JJ 4_p
cor NN 4_p
pulmonale NN 4_p
. . N

This DT N
condition NN N
is VBZ N
associated VBN N
with IN N
activation NN N
of IN N
the DT N
renin NN N
angiotensin NN N
system NN N
( ( N
RAS NNP N
) ) N
with IN N
elevated JJ N
levels NNS N
of IN N
angiotensin NN N
II NNP N
( ( N
ANG NNP N
II NNP N
) ) N
, , N
a DT N
potent JJ N
pulmonary JJ N
pressor NN N
agent NN N
. . N

We PRP N
explored VBD N
the DT N
hypothesis NN N
that WDT N
RAS NNP N
activation NN N
by IN N
diuretic JJ N
therapy NN N
might MD N
therefore VB N
worsen JJ N
hypoxic NN N
pulmonary JJ N
vasoconstriction NN N
via IN N
the DT N
effects NNS N
of IN N
ANG NNP N
II NNP N
on IN N
the DT N
pulmonary JJ N
vascular NN N
bed NN N
. . N

METHODS NNP N
Eight NNP N
normal JJ N
volunteers NNS N
were VBD N
studied VBN N
on IN N
2 CD N
separate JJ N
days NNS N
. . N

They PRP N
either DT N
received VBD N
40 CD N
mg NNS N
frusemide JJ N
daily RB N
or CC N
placebo VB N
for IN N
4 CD N
days NNS N
and CC N
were VBD N
then RB N
rendered VBN N
hypoxaemic NN N
, , N
by IN N
breathing VBG N
an DT N
N2/O2 NNP N
mixture NN N
for IN N
20 CD N
min NN N
to TO N
achieve VB N
an DT N
SaO2 NNP N
of IN N
85-90 CD N
% NN N
adjusted VBN N
for IN N
a DT N
further JJ N
20 CD N
min NN N
to TO N
achieve VB N
an DT N
SaO2 NNP N
of IN N
75-80 CD N
% NN N
. . N

Pulsed VBN N
wave VBP N
doppler NN N
echocardiography NN N
was VBD N
used VBN N
to TO N
measure VB N
mean JJ N
pulmonary JJ N
artery NN N
pressure NN N
, , N
cardiac JJ N
output NN N
and CC N
hence RB N
pulmonary JJ N
vascular JJ N
resistance NN N
( ( N
PVR NNP N
) ) N
. . N

RESULTS NNP N
Plasma NNP N
renin NN N
activity NN N
( ( N
PRA NNP N
) ) N
was VBD N
significantly RB N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
increased VBN N
after IN N
prior JJ N
treatment NN N
with IN N
frusemide JJ N
compared VBN N
with IN N
placebo NN N
at IN N
all DT N
time NN N
points NNS N
. . N

Prior NNP N
treatment NN N
with IN N
frusemide NN N
significantly RB N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
increased VBD N
PVR NNP N
compared VBN N
with IN N
placebo NN N
at IN N
baseline NN N
: : N
185 CD N
+/- JJ N
17 CD N
vs JJ N
132 CD N
+/- JJ N
10 CD N
dyn JJ N
s JJ N
cm-5 NN N
at IN N
an DT N
SaO2 NNP N
of IN N
85-90 JJ N
% NN N
: : N
291 CD N
+/- JJ N
18 CD N
vs JJ N
229 CD N
+/- JJ N
16 CD N
dyn JJ N
s JJ N
cm-5 NN N
and CC N
at IN N
SaO2 NNP N
of IN N
75-80 CD N
% NN N
: : N
356 CD N
+/- JJ N
12 CD N
vs JJ N
296 CD N
+/- JJ N
17 CD N
dyn JJ N
s JJ N
cm-5 NN N
respectively RB N
. . N

However RB N
, , N
the DT N
delta-PVR JJ N
response NN N
to TO N
hypoxaemia NN N
was VBD N
not RB N
significantly RB N
altered VBN N
by IN N
frusemide NN N
compared VBN N
with IN N
placebo NN N
. . N

In IN N
contrast NN N
to TO N
its PRP$ N
effect NN N
on IN N
the DT N
pulmonary JJ N
vasculature NN N
prior JJ N
treatment NN N
with IN N
frusemide NN N
did VBD N
not RB N
significantly RB N
alter VB N
systemic JJ N
haemodynamic JJ N
parameters NNS N
either CC N
at IN N
baseline NN N
or CC N
during IN N
hypoxia NN N
. . N

CONCLUSIONS NNP N
Thus NNP N
, , N
prior JJ N
treatment NN N
with IN N
frusemide NN N
increased VBD N
baseline JJ N
pulmonary JJ N
vascular NN N
resistance NN N
and CC N
significantly RB N
augmented VBD N
the DT N
hypoxaemic JJ N
pulmonary JJ N
vascular NN N
response NN N
in IN N
additive JJ N
fashion NN N
. . N

It PRP N
is VBZ N
hypothesised VBN N
that IN N
this DT N
effect NN N
of IN N
frusemide NN N
may MD N
be VB N
due JJ N
to TO N
RAS NNP N
activation NN N
with IN N
ANG NNP N
II NNP N
mediated VBD N
pulmonary JJ N
vasoconstriction NN N
. . N

-DOCSTART- -X- O O 19544653

[ NN N
Clinilal NNP N
study NN N
of IN N
medical JJ N
ozone NN N
therapy NN N
in IN N
chronic JJ 4_p
hepatitis NN 4_p
B NNP 4_p
of IN N
20 CD N
patients NNS N
] JJ N
. . N

OBJECTIVE NN N
To TO N
study VB N
the DT N
effect NN N
of IN N
medical JJ N
ozone NN N
in IN N
the DT N
treatment NN N
of IN N
chronic JJ 4_p
hepatitis NN 4_p
B NNP 4_p
. . N

METHODS NNP N
42 CD N
patients NNS N
with IN N
chronic JJ 4_p
hepatitis NN 4_p
B NNP 4_p
were VBD N
divided VBN N
randomly RB N
into IN N
two CD N
groups NNS N
. . N

22 CD N
patients NNS N
treated VBN N
with IN N
basic JJ N
therapy NN N
were VBD N
as IN N
a DT N
control NN N
group NN N
. . N

20 CD N
patients NNS N
treated VBN N
with IN N
basic JJ N
therapy NN N
plus CC N
ozone NN N
therapy NN N
were VBD N
taken VBN N
as IN N
a DT N
treatment NN N
group NN N
. . N

Index NN N
of IN N
biochemistry NN N
and CC N
virology NN N
were VBD N
studied VBN N
at IN N
initial JJ N
and CC N
post-treatment JJ N
8 CD N
weeks NNS N
. . N

RESULTS NNP N
After IN N
the DT N
treatment NN N
, , N
liver JJ N
function NN N
of IN N
the DT N
treatment NN N
group NN N
and CC N
the DT N
control NN N
group NN N
had VBD N
more RBR N
significant JJ N
improvement NN N
. . N

The DT N
treatment NN N
group NN N
complete JJ N
effective JJ N
and CC N
partial JJ N
effective JJ N
were VBD N
10 CD N
% NN N
and CC N
35 CD N
% NN N
difference NN N
. . N

The DT N
control NN N
group NN N
complete JJ N
effective JJ N
and CC N
partial JJ N
effective JJ N
were VBD N
4.6 CD N
% NN N
and CC N
13.6 CD N
% NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSION NNP N
Treatment NNP N
of IN N
medical JJ N
ozone NN N
on IN N
patients NNS N
with IN N
chronic JJ 4_p
hepatitis NN 4_p
B NNP 4_p
is VBZ N
effective JJ N
. . N

-DOCSTART- -X- O O 3277760

Randomized VBN N
study NN N
of IN N
six CD 4_p
umbilical JJ 4_p
cord NN 4_p
care NN 4_p
regimens VBZ 4_p
. . 4_p

Comparing VBG N
length NN N
of IN N
attachment NN N
, , N
microbial JJ N
control NN N
, , N
and CC N
satisfaction NN N
. . N

Two CD 4_p
hundred VBD 4_p
and CC 4_p
seventy VB 4_p
one CD 4_p
infants NNS 4_p
were VBD 4_p
enrolled VBN 4_p
in IN 4_p
a DT 4_p
study NN 4_p
to TO 4_p
compare VB 4_p
six CD 4_p
different JJ 4_p
methods NNS 4_p
of IN 4_p
treating VBG 4_p
the DT 4_p
umbilical JJ 4_p
cord NN 4_p
. . 4_p

Antimicrobial NNP N
control NN N
was VBD N
equal JJ N
for IN N
all DT N
methods NNS N
. . N

Repeated VBN N
triple JJ N
dye NN N
application NN N
was VBD N
considered VBN N
least JJS N
acceptable JJ N
by IN N
staff NN N
and CC N
parents NNS N
and CC N
had VBD N
the DT N
longest JJS N
attachment JJ N
time NN N
. . N

Povidone-iodine NN N
was VBD N
associated VBN N
with IN N
the DT N
shortest JJS N
attachment JJ N
time NN N
and CC N
was VBD N
most RBS N
liked JJ N
. . N

If IN N
there EX N
is VBZ N
no DT N
special JJ N
need NN N
to TO N
treat VB N
a DT N
specific JJ N
nosocomial JJ N
outbreak NN N
, , N
duration NN N
of IN N
cord NN N
attachment NN N
and CC N
satisfaction NN N
of IN N
staff NN N
and CC N
parents NNS N
can MD N
help VB N
clinicians NNS N
decide VB N
on IN N
a DT N
cord NN N
care NN N
regimen NNS N
. . N

-DOCSTART- -X- O O 11064610

Comparison NNP N
of IN N
alfentanil NN N
, , N
fentanyl NN N
and CC N
sufentanil NN N
for IN N
total JJ N
intravenous JJ N
anaesthesia NN N
with IN N
propofol NN N
in IN N
patients NNS 4_p
undergoing VBG 4_p
coronary JJ 4_p
artery NN 4_p
bypass NN 4_p
surgery NN 4_p
. . 4_p

We PRP N
have VBP N
studied VBN N
the DT N
pharmacokinetics NNS N
and CC N
pharmacodynamics NNS N
of IN N
alfentanil NN N
, , N
fentanyl NN N
and CC N
sufentanil VB N
together RB N
with IN N
propofol NN N
in IN N
patients NNS 4_p
undergoing VBG 4_p
coronary JJ 4_p
artery NN 4_p
bypass NN 4_p
graft NN 4_p
surgery NN 4_p
( ( 4_p
CABG NNP 4_p
) ) 4_p
. . 4_p

Sixty JJ N
patients NNS N
( ( N
age NN N
40-73 CD N
yr NN N
, , N
56 CD N
male NN N
) ) N
were VBD N
assigned VBN N
randomly RB N
to TO N
receive VB N
alfentanil NN N
, , N
fentanyl NN N
or CC N
sufentanil NN N
and CC N
propofol NN N
. . N

Plasma NNP N
concentrations NNS N
of IN N
these DT N
drugs NNS N
and CC N
times NNS N
for IN N
the DT N
plasma NN N
concentration NN N
to TO N
decrease VB N
by IN N
50 CD N
% NN N
( ( N
t50 NN N
) ) N
and CC N
80 CD N
% NN N
( ( N
t80 NN N
) ) N
after IN N
cessation NN N
of IN N
the DT N
infusion NN N
were VBD N
determined VBN N
. . N

Times NNS N
were VBD N
recorded VBN N
to TO N
awakening VBG N
and CC N
tracheal JJ N
extubation NN N
. . N

Total JJ N
dose NN N
and CC N
plasma JJ N
concentrations NNS N
of IN N
propofol NN N
were VBD N
similar JJ N
in IN N
all DT N
groups NNS N
. . N

Mean NNP N
total JJ N
doses NNS N
of IN N
alfentanil NN N
, , N
fentanyl NN N
and CC N
sufentanil NN N
were VBD N
443 CD N
, , N
45 CD N
and CC N
4.4 CD N
micrograms NNS N
kg-1 JJ N
, , N
respectively RB N
. . N

Time NN N
to TO N
awakening VBG N
did VBD N
not RB N
differ VB N
significantly RB N
. . N

In IN N
patients NNS N
receiving VBG N
fentanyl NN N
, , N
the DT N
trachea NN N
was VBD N
extubated VBN N
on IN N
average JJ N
2 CD N
h NN N
later RB N
than IN N
in IN N
those DT N
receiving VBG N
sufentanil NN N
and CC N
3 CD N
h NN N
later RB N
than IN N
in IN N
those DT N
receiving VBG N
alfentanil NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
t80 NN N
of IN N
fentanyl NN N
was VBD N
longer JJR N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
than IN N
that DT N
of IN N
alfentanil NN N
or CC N
sufentanil NN N
, , N
and CC N
there RB N
was VBD N
a DT N
linear JJ N
correlation NN N
between IN N
the DT N
t80 NN N
of IN N
the DT N
opioid NN N
and CC N
the DT N
time NN N
to TO N
tracheal VB N
extubation NN N
( ( N
r JJ N
= VBZ N
0.51 CD N
; : N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

However RB N
, , N
the DT N
t50 NN N
values NNS N
for IN N
these DT N
opioids NNS N
were VBD N
similar JJ N
and CC N
did VBD N
not RB N
correlate VB N
with IN N
recovery NN N
time NN N
. . N

In IN N
conclusion NN N
, , N
patients NNS N
undergoing VBG N
CABG NNP N
and CC N
who WP N
were VBD N
anaesthetized VBN N
with IN N
fentanyl NN N
and CC N
propofol NN N
needed VBN N
mechanical JJ N
ventilatory NN N
support NN N
for IN N
a DT N
significantly RB N
longer JJR N
time NN N
than IN N
those DT N
receiving VBG N
alfentanil NN N
or CC N
sufentanil NN N
and CC N
propofol NN N
. . N

On IN N
the DT N
basis NN N
of IN N
the DT N
interindividual JJ N
variation NN N
observed VBD N
, , N
the DT N
time NN N
to TO N
tracheal VB N
extubation NN N
was VBD N
most RBS N
predictable JJ N
in IN N
patients NNS N
receiving VBG N
alfentanil NN N
and CC N
most RBS N
variable JJ N
in IN N
patients NNS N
receiving VBG N
fentanyl NN N
, , N
a DT N
finding NN N
which WDT N
may MD N
be VB N
important JJ N
if IN N
the DT N
patients NNS N
are VBP N
transferred VBN N
to TO N
a DT N
step-down JJ N
unit NN N
on IN N
the DT N
evening NN N
of IN N
the DT N
operation NN N
. . N

-DOCSTART- -X- O O 23392460

A DT N
randomized JJ N
double-blind JJ N
comparison NN N
of IN N
coformulated JJ N
elvitegravir/cobicistat/emtricitabine/tenofovir NN N
disoproxil NN N
fumarate NN N
versus NN N
efavirenz/emtricitabine/tenofovir NN N
disoproxil NN N
fumarate NN N
for IN N
initial JJ N
treatment NN N
of IN N
HIV-1 NNP 4_p
infection NN 4_p
: : 4_p
analysis NN N
of IN N
week NN N
96 CD N
results NNS N
. . N

We PRP N
report VBP N
week NN N
96 CD N
results NNS N
from IN N
a DT N
phase NN N
3 CD N
trial NN N
of IN N
elvitegravir/cobicistat/emtricitabine/tenofovir NN N
disoproxil NN N
fumarate NN N
( ( N
EVG/COBI/FTC/TDF NNP N
, , N
n JJ N
= NNP N
348 CD N
) ) N
vs NN N
efavirenz/emtricitabine/tenofovir JJ N
disoproxil NN N
fumarate NN N
( ( N
EFV/FTC/TDF NNP N
, , N
n JJ N
= NNP N
352 CD N
) ) N
. . N

At IN N
week NN N
48 CD N
, , N
EVG/COBI/FTC/TDF NNP N
was VBD N
noninferior JJ N
to TO N
EFV/FTC/TDF NNP N
( ( N
88 CD N
% NN N
vs JJ N
84 CD N
% NN N
, , N
difference NN N
+3.6 CD N
% NN N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
: : N
-1.6 CD N
% NN N
to TO N
8.8 CD N
% NN N
) ) N
. . N

Virologic NNP N
success NN N
( ( N
HIV-1 NNP N
RNA NNP N
< NNP N
50 CD N
copies/mL NN N
) ) N
was VBD N
maintained VBN N
at IN N
week NN N
96 CD N
( ( N
84 CD N
% NN N
vs JJ N
82 CD N
% NN N
, , N
difference NN N
+2.7 CD N
% NN N
, , N
95 CD N
% NN N
CI NNP N
: : N
-2.9 CD N
% NN N
to TO N
8.3 CD N
% NN N
) ) N
. . N

Discontinuation NN N
due JJ N
to TO N
adverse JJ N
events NNS N
was VBD N
low JJ N
( ( N
5 CD N
% NN N
vs JJ N
7 CD N
% NN N
) ) N
. . N

Median JJ N
changes NNS N
in IN N
serum NN N
creatinine NN N
( ( N
mg/dL NN N
) ) N
at IN N
week NN N
96 CD N
were VBD N
similar JJ N
to TO N
week NN N
48 CD N
. . N

These DT N
results NNS N
support VBP N
the DT N
durable JJ N
efficacy NN N
and CC N
long-term JJ N
safety NN N
of IN N
EVG/COBI/FTC/TDF NNP N
. . N

-DOCSTART- -X- O O 12006271

N-butyl JJ N
cyanoacrylate NN N
embolization NN N
of IN N
cerebral JJ N
arteriovenous JJ N
malformations NNS N
: : N
results NNS N
of IN N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
multi-center JJ N
trial NN N
. . N

BACKGROUND NNP N
AND CC N
PURPOSE NNP N
Liquid NNP N
N-butyl NNP N
cyanoacrylate NN N
( ( N
n-BCA JJ N
) ) N
use NN N
for IN N
the DT N
treatment NN N
of IN N
arteriovenous JJ N
malformations NNS N
( ( N
AVM NNP N
) ) N
in IN N
the DT N
brain NN N
has VBZ N
become VBN N
part NN N
of IN N
medical JJ N
practice NN N
. . N

However RB N
, , N
no DT N
study NN N
has VBZ N
led VBN N
to TO N
the DT N
Food NNP N
and CC N
Drug NNP N
Administration NNP N
's POS N
approval NN N
of IN N
n-BCA JJ N
for IN N
intravascular JJ N
use NN N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
verify VB N
the DT N
effectiveness NN N
and CC N
safety NN N
of IN N
an DT N
n-BCA/Tantalum JJ N
Powder/Ethiodized NNP N
Oil NNP N
mixture NN N
, , N
compared VBN N
with IN N
conventional JJ N
treatment NN N
( ( N
Trufill NNP N
polyvinyl VBZ N
alcohol NN N
[ NNP N
PVA NNP N
] NNP N
) ) N
for IN N
preoperative JJ N
embolization NN N
of IN N
cerebral JJ N
AVM NNP N
. . N

METHODS NNP N
Between NNP N
October NNP N
15 CD N
, , N
1996 CD N
, , N
and CC N
March NNP N
24 CD N
, , N
1999 CD N
, , N
104 CD N
patients NNS N
at IN N
13 CD N
centers NNS N
were VBD N
prospectively RB N
randomized VBN N
to TO N
undergo VB N
embolization NN N
using VBG N
an DT N
n-BCA/Tantalum JJ N
Powder/Ethiodol NNP N
mixture NN N
or CC N
Trufill NNP N
PVA NNP N
. . N

The DT N
pre-embolization NN N
therapy NN N
goals NNS N
were VBD N
determined VBN N
in IN N
terms NNS N
of IN N
the DT N
number NN N
of IN N
pedicles NNS N
to TO N
be VB N
embolized VBN N
and CC N
the DT N
percent NN N
of IN N
nidus JJ N
reduction NN N
expected VBN N
. . N

Embolization NN N
results NNS N
were VBD N
evaluated VBN N
by IN N
a DT N
central JJ N
laboratory NN N
. . N

Subsequent JJ N
surgical JJ N
resection NN N
data NNS N
were VBD N
recorded VBN N
. . N

Safety NNP N
evaluation NN N
data NNS N
included VBD N
recording VBG N
device NN N
complications NNS N
, , N
procedure NN N
complications NNS N
, , N
and CC N
intracranial JJ N
events/overall NN N
neurologic JJ N
outcomes NNS N
, , N
which WDT N
could MD N
be VB N
either CC N
device-related JJ N
, , N
procedure-related JJ N
, , N
or CC N
both DT N
. . N

RESULTS VB N
The DT N
reduction NN N
of IN N
AVM NNP N
dimensions NNS N
( ( N
79.4 CD N
% NN N
in IN N
the DT N
n-BCA JJ N
group NN N
and CC N
86.9 CD N
% NN N
in IN N
the DT N
PVA NNP N
group NN N
) ) N
and CC N
the DT N
mean JJ N
number NN N
of IN N
vessels NNS N
embolized VBN N
( ( N
2.2 CD N
in IN N
the DT N
n-BCA JJ N
group NN N
and CC N
2.1 CD N
in IN N
the DT N
PVA NNP N
group NN N
) ) N
was VBD N
similar JJ N
in IN N
the DT N
two CD N
groups NNS N
. . N

Coils NNS N
were VBD N
used VBN N
more RBR N
commonly RB N
with IN N
PVA NNP N
embolization NN N
( ( N
P NNP N
< NNP N
.0001 NNP N
) ) N
. . N

No UH N
differences NNS N
were VBD N
detected VBN N
in IN N
surgical JJ N
resection NN N
time NN N
, , N
number NN N
of IN N
patients NNS N
who WP N
required VBD N
transfusion NN N
, , N
volume NN N
and CC N
number NN N
of IN N
transfusion NN N
units NNS N
, , N
or CC N
type NN N
and CC N
volume NN N
of IN N
fluid JJ N
replacement NN N
. . N

Glasgow NNP N
Outcome NNP N
Scale NNP N
scores NNS N
were VBD N
not RB N
significantly RB N
different JJ N
between IN N
the DT N
two CD N
groups NNS N
before IN N
treatment NN N
, , N
after IN N
embolization NN N
, , N
or CC N
after IN N
resection NN N
. . N

Two CD N
of IN N
42 CD N
patients NNS N
who WP N
underwent JJ N
resection NN N
and CC N
had VBD N
been VBN N
treated VBN N
with IN N
n-BCA JJ N
experienced JJ N
post-resection NN N
hematoma NN N
, , N
compared VBN N
with IN N
eight CD N
of IN N
45 CD N
patients NNS N
who WP N
underwent JJ N
resection NN N
and CC N
had VBD N
been VBN N
treated VBN N
with IN N
PVA NNP N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

CONCLUSION VB N
This DT N
prospective JJ N
, , N
randomized JJ N
trial NN N
showed VBD N
that IN N
n-BCA JJ N
is VBZ N
equivalent JJ N
to TO N
PVA NNP N
as IN N
a DT N
preoperative JJ N
embolic JJ N
agent NN N
for IN N
treatment NN N
of IN N
cerebral JJ 4_p
AVM NNP 4_p
as IN N
determined VBN N
by IN N
percent NN N
of IN N
nidus JJ N
reduction NN N
and CC N
number NN N
of IN N
feeding VBG N
pedicles NNS N
embolized VBN N
. . N

-DOCSTART- -X- O O 11060324

Commentary NNP N
on IN N
" NNP 4_p
cytoreduction NN 4_p
nephrectomy NN 4_p
in IN 4_p
metastatic JJ 4_p
renal JJ 4_p
cancer NN 4_p
: : 4_p
the DT N
results NNS N
of IN N
Southwest NNP 4_p
Oncology NNP 4_p
Group NNP 4_p
Trial NNP 4_p
8949 CD N
" NN N
. . N

-DOCSTART- -X- O O 7036084

[ JJ 4_p
Credé NNP 4_p
's POS 4_p
prevention NN 4_p
method NN 4_p
has VBZ N
lost VBN N
its PRP$ N
justification NN N
today NN N
] NNP N
. . N

-DOCSTART- -X- O O 16253098

Oral NNP N
health NN N
impacts NNS N
on IN N
daily JJ N
living NN N
related VBN N
to TO N
four CD N
different JJ N
treatment NN N
protocols NNS N
for IN N
chronic JJ 4_p
periodontitis NN 4_p
. . N

BACKGROUND IN N
The DT N
aims NNS N
of IN N
this DT N
study NN N
were VBD N
to TO N
evaluate VB N
the DT N
oral JJ N
health NN N
impacts NNS N
perceived VBN N
by IN N
patients NNS N
submitted VBN N
to TO N
different JJ N
treatments NNS N
of IN N
chronic JJ 4_p
periodontitis NN 4_p
and CC N
their PRP$ N
association NN N
with IN N
clinical JJ N
parameters NNS N
. . N

METHODS NNP N
Sixty NNP N
patients NNS N
were VBD N
assigned VBN N
to TO N
one CD N
of IN N
the DT N
following JJ N
therapeutic JJ N
groups NNS N
: : N
control NN N
, , N
treated VBN N
with IN N
full-mouth JJ N
scaling NN N
and CC N
root NN N
planing NN N
( ( N
SRP NNP N
) ) N
; : N
test $ N
1 CD N
, , N
treated VBN N
with IN N
SRP NNP N
and CC N
400 CD N
mg NNS N
systemically RB N
administered VBN N
metronidazole NN N
( ( N
MET NNP N
) ) N
three CD N
times NNS N
per IN N
day NN N
for IN N
10 CD N
days NNS N
; : N
test JJS N
2 CD N
, , N
treated VBN N
with IN N
SRP NNP N
and CC N
professional JJ N
supragingival NN N
plaque NN N
removal NN N
( ( N
PP NNP N
) ) N
every DT N
week NN N
for IN N
3 CD N
months NNS N
; : N
and CC N
test VB N
3 CD N
, , N
treated VBN N
with IN N
SRP NNP N
and CC N
MET NNP N
plus CC N
PP NNP N
. . N

Clinical NNP N
periodontal JJ N
measurements NNS N
and CC N
data NNS N
regarding VBG N
patients NNS N
' POS N
oral JJ N
health NN N
impacts NNS N
( ( N
perceived VBN N
impacts NNS N
on IN N
bleeding VBG N
gums NNS N
, , N
gingival JJ N
recession NN N
, , N
sensitivity NN N
to TO N
cold VB N
, , N
packing VBG N
foods NNS N
, , N
aesthetics NNS N
, , N
bad JJ N
breath NN N
, , N
and CC N
tooth DT N
mobility NN N
) ) N
were VBD N
collected VBN N
at IN N
baseline NN N
and CC N
3 CD N
months NNS N
after IN N
therapy NN N
. . N

RESULTS NNP N
All NNP N
groups NNS N
presented VBD N
significant JJ N
improvement NN N
in IN N
oral JJ N
health NN N
perceived VBD N
impacts NNS N
. . N

There EX N
was VBD N
no DT N
statistically RB N
significant JJ N
difference NN N
in IN N
the DT N
improvement NN N
of IN N
oral JJ N
health NN N
impacts NNS N
among IN N
groups NNS N
subjected VBN N
to TO N
different JJ N
treatments NNS N
. . N

The DT N
clinical JJ N
data NNS N
of IN N
percentage NN N
of IN N
deep JJ N
probing VBG N
depth NN N
, , N
deep JJ N
clinical JJ N
attachment NN N
level NN N
, , N
and CC N
bleeding VBG N
on IN N
probing VBG N
were VBD N
found VBN N
to TO N
be VB N
correlated VBN N
significantly RB N
with IN N
oral JJ N
health NN N
impacts NNS N
. . N

CONCLUSIONS NNP N
Periodontal NNP N
treatment NN N
leads VBZ N
to TO N
a DT N
significant JJ N
reduction NN N
of IN N
self-perceived JJ N
impacts NNS N
regardless RB N
of IN N
the DT N
non-surgical JJ N
treatment NN N
protocol NN N
employed VBN N
. . N

Most JJS N
of IN N
the DT N
clinical JJ N
data NNS N
were VBD N
associated VBN N
with IN N
oral JJ N
health NN N
impacts NNS N
. . N

-DOCSTART- -X- O O 15272537

Human JJ N
achaete-scute JJ N
homologue NN N
( ( N
hASH1 NN N
) ) N
mRNA NN N
level NN N
as IN N
a DT N
diagnostic JJ N
marker NN N
to TO N
distinguish VB N
esthesioneuroblastoma NN 4_p
from IN N
poorly RB N
differentiated VBN N
tumors NNS 4_p
arising VBG N
in IN N
the DT N
sinonasal NN N
tract NN N
. . N

Distinction NN N
of IN N
high-grade JJ N
esthesioneuroblastomas NN 4_p
from IN N
other JJ 4_p
poorly RB 4_p
differentiated VBN 4_p
tumors NNS 4_p
arising VBG 4_p
in IN 4_p
the DT 4_p
nasal JJ 4_p
cavity NN 4_p
is VBZ N
an DT N
important JJ N
diagnostic JJ N
challenge NN N
because IN N
it PRP N
determines VBZ N
patient JJ N
management NN N
and CC N
prognosis NN N
. . N

The DT N
human JJ N
achaete-scute JJ N
homologue NN N
( ( N
hASH1 NN N
) ) N
gene NN N
is VBZ N
critical JJ N
in IN N
olfactory JJ N
neuronal JJ N
differentiation NN N
and CC N
is VBZ N
expressed VBN N
in IN N
immature NN N
olfactory NN N
cells NNS N
; : N
therefore RB N
, , N
it PRP N
could MD N
have VB N
potential JJ N
use NN N
as IN N
a DT N
diagnostic JJ N
marker NN N
The DT N
aim NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
determine VB N
the DT N
value NN N
of IN N
hASH1 JJ N
messenger NN N
RNA NNP N
( ( N
mRNA NN N
) ) N
levels NNS N
in IN N
differentiating VBG N
esthesioneuroblastoma NN N
from IN N
other JJ N
poorly RB N
differentiated VBN N
tumors NNS N
. . N

A DT N
real-time JJ N
polymerase NN N
chain NN N
reaction NN N
assay NN N
was VBD N
developed VBN N
, , N
permitting VBG N
the DT N
comparative JJ N
determination NN N
of IN N
hASH1 NN N
mRNA NN N
levels NNS N
in IN N
triplicate NN N
in IN N
a DT N
double-blind JJ N
pilot NN N
study NN N
including VBG N
24 CD N
frozen JJ N
cases NNS N
of IN N
esthesioneuroblastoma NN N
and CC N
poorly RB N
differentiated VBN N
tumors NNS N
. . N

All DT N
4 CD N
positive JJ N
cases NNS N
were VBD N
esthesioneuroblastomas JJ N
, , N
and CC N
all DT N
19 CD N
poorly RB N
differentiated VBN N
tumors NNS N
were VBD N
negative JJ N
. . N

In IN N
addition NN N
, , N
there EX N
was VBD N
an DT N
inverse JJ N
association NN N
between IN N
the DT N
grade NN N
of IN N
esthesioneuroblastomas NN N
and CC N
hASH1 NN N
mRNA NN N
levels NNS N
. . N

The DT N
hASH1 NN N
mRNA FW N
level NN N
might MD N
represent VB N
a DT N
useful JJ N
tool NN N
for IN N
distinguishing VBG N
esthesioneuroblastoma NN N
from IN N
poorly RB N
differentiated VBN N
tumors NNS N
of IN N
the DT N
sinonasal JJ N
region NN N
. . N

-DOCSTART- -X- O O 16794570

Modulation NN N
of IN N
human JJ N
motor NN N
cortex NN N
excitability NN N
by IN N
single JJ N
doses NNS N
of IN N
amantadine NN N
. . N

Amantadine-sulfate NNP N
has VBZ N
been VBN N
used VBN N
for IN N
several JJ N
decades NNS N
to TO N
treat VB N
acute JJ N
influenza NN N
A NNP N
, , N
Parkinson NNP N
's POS N
disease NN N
( ( N
PD NNP N
) ) N
, , N
and CC N
acute NN N
or CC N
chronic JJ N
drug-induced JJ N
dyskinesia NN N
. . N

Several JJ N
mechanisms NNS N
of IN N
actions NNS N
detected VBN N
in IN N
vivo/in JJ N
vitro JJ N
including VBG N
N-methyl-D-aspartate NNP N
( ( N
NMDA NNP N
) ) N
-receptor NN N
antagonism NN N
, , N
blockage NN N
of IN N
potassium NN N
channels NNS N
, , N
dopamine JJ N
receptor NN N
agonism NN N
, , N
enhancement NN N
of IN N
noradrenergic JJ N
release NN N
, , N
and CC N
anticholinergic JJ N
effects NNS N
have VBP N
been VBN N
described VBN N
. . N

We PRP N
used VBD N
transcranial JJ N
magnetic JJ N
stimulation NN N
( ( N
TMS NNP N
) ) N
to TO N
evaluate VB N
the DT N
effect NN N
of IN N
single JJ N
doses NNS N
of IN N
amantadine NN N
on IN N
human JJ N
motor NN N
cortex NN N
excitability NN N
in IN N
normal JJ 4_p
subjects NNS N
. . N

Using VBG N
a DT N
double-blind JJ N
, , N
placebo-controlled JJ N
, , N
crossover NN N
study NN N
design NN N
, , N
motor NN N
thresholds NNS N
, , N
recruitment NN N
curves NNS N
, , N
cortical JJ N
stimulation-induced JJ N
silent JJ N
period NN N
( ( N
CSP NNP N
) ) N
, , N
short JJ N
intracortical JJ N
inhibition NN N
( ( N
ICI NNP N
) ) N
, , N
intracortical JJ N
facilitation NN N
( ( N
ICF NNP N
) ) N
, , N
and CC N
late JJ N
inhibition NN N
( ( N
L-ICI NNP N
) ) N
in IN N
14 CD N
healthy JJ 4_p
subjects NNS N
were VBD N
investigated VBN N
after IN N
oral JJ N
doses NNS N
of IN N
50 CD N
and CC N
100 CD N
mg NNS N
amantadine VBP N
with IN N
single JJ N
and CC N
paired JJ N
pulse NN N
TMS NNP N
paradigms NN N
. . N

Spinal NNP N
cord NN N
excitability NN N
was VBD N
investigated VBN N
by IN N
distal JJ N
latencies NNS N
and CC N
M-amplitudes NNS N
of IN N
the DT N
abductor NN N
digiti NN N
minimi NN N
muscle NN N
. . N

After IN N
intake NN N
of IN N
amantadine NN N
, , N
a DT N
significant JJ N
dose-dependent JJ N
decrease NN N
of IN N
ICF NNP N
was VBD N
noticed VBN N
as RB N
well RB N
as IN N
a DT N
significant JJ N
increase NN N
of IN N
L-ICI NNP N
as IN N
compared VBN N
to TO N
placebo VB N
. . N

The DT N
effect NN N
on IN N
ICF NNP N
and CC N
L-ICI NNP N
significantly RB N
correlated VBD N
with IN N
amantadine JJ N
serum NN N
levels NNS N
. . N

ICI NNP N
was VBD N
slightly RB N
increased VBN N
after IN N
amantadine JJ N
intake NN N
, , N
but CC N
the DT N
effect NN N
failed VBD N
to TO N
be VB N
significant JJ N
. . N

Furthermore RB N
, , N
amantadine NN N
had VBD N
no DT N
significant JJ N
effects NNS N
on IN N
motor NN N
thresholds NNS N
, , N
MEP NNP N
recruitment NN N
curves NNS N
, , N
CSP NNP N
, , N
or CC N
peripheral JJ N
excitability NN N
. . N

In IN N
conclusion NN N
, , N
a DT N
low JJ N
dose NN N
of IN N
amantadine NN N
is VBZ N
sufficient JJ N
in IN N
modulating VBG N
human JJ N
motor NN N
cortex NN N
excitability NN N
. . N

The DT N
decrease NN N
of IN N
ICF NNP N
and CC N
increase NN N
of IN N
L-ICI NNP N
may MD N
reflect VB N
glutamatergic JJ N
modulation NN N
or CC N
a DT N
polysynaptic JJ N
interaction NN N
of IN N
glutamatergic NN N
and CC N
GABA-ergic JJ N
circuits NNS N
. . N

Although IN N
amantadine NN N
has VBZ N
several JJ N
mechanisms NNS N
of IN N
action NN N
, , N
the DT N
NMDA-receptor NNP N
antagonism NN N
seems VBZ N
to TO N
be VB N
the DT N
most RBS N
relevant JJ N
effect NN N
on IN N
cortical JJ N
excitability NN N
. . N

As IN N
L-ICI JJ N
can MD N
be VB N
influenced VBN N
by IN N
this DT N
type NN N
of IN N
drug NN N
, , N
it PRP N
may MD N
be VB N
an DT N
interesting JJ N
parameter NN N
for IN N
studies NNS N
of IN N
motor NN N
learning NN N
and CC N
use-dependent JJ N
plasticity NN N
. . N

-DOCSTART- -X- O O 19169289

Pegfilgrastim NN N
for IN N
peripheral JJ N
CD34+ NNP N
mobilization NN N
in IN N
patients NNS 4_p
with IN 4_p
solid JJ 4_p
tumours NNS 4_p
. . N

The DT N
efficacy NN N
of IN N
pegfilgrastim+/-chemotherapy NN N
for IN N
mobilizing VBG N
stem NN N
cells NNS N
in IN N
patients NNS N
with IN N
solid JJ 4_p
tumours NN 4_p
was VBD N
assessed VBN N
. . N

In IN N
cycle NN N
0 CD N
, , N
a DT N
14-day JJ N
prechemotherapy NN N
cycle NN N
, , N
patients NNS N
( ( N
N=61 NNP N
) ) N
were VBD N
randomized VBN N
open-label NN N
to TO N
single JJ N
doses NNS N
of IN N
pegfilgrastim NN N
( ( N
6 CD N
, , N
12 CD N
or CC N
18 CD N
mg NN N
) ) N
on IN N
day NN N
1 CD N
, , N
or CC N
daily RB N
filgrastim NNS N
( ( N
10 CD N
microg/kg NN N
) ) N
for IN N
< NN N
or CC N
=7 JJ N
days NNS N
. . N

Mean JJ N
peak JJ N
peripheral JJ N
CD34+ NNP N
cell NN N
counts NNS N
increased VBD N
with IN N
pegfilgrastim NN N
dose NN N
, , N
but CC N
were VBD N
significantly RB N
higher JJR N
than IN N
filgrastim JJR N
only RB N
at IN N
the DT N
18 CD N
mg NN N
dose NN N
( ( N
10.17 CD N
vs RB N
4.96 CD N
x JJ N
10 CD N
( ( N
4 CD N
) ) N
/ml NN N
; : N
P=0.014 NNP N
) ) N
. . N

In IN N
the DT N
clinically NN N
relevant JJ N
period NN N
of IN N
days NNS N
3-7 CD N
, , N
both DT N
12 CD N
and CC N
18 CD N
mg NN N
pegfilgrastim NN N
doses NNS N
produced VBD N
significantly RB N
higher JJR N
peak NN N
CD34+ NNP N
counts VBZ N
( ( N
8.18 CD N
and CC N
9.96 CD N
vs NN N
4.51 CD N
x NN N
10 CD N
( ( N
4 CD N
) ) N
/ml NN N
for IN N
filgrastim NN N
; : N
P=0.034 NNP N
and CC N
0.006 CD N
) ) N
. . N

In IN N
cycle NN N
1 CD N
, , N
patients NNS N
received VBD N
carboplatin/paclitaxel NNS N
on IN N
day NN N
1 CD N
, , N
followed VBD N
from IN N
day NN N
2 CD N
by IN N
pegfilgrastim JJ N
6-18 JJ N
mg NN N
or CC N
daily JJ N
filgrastim NN N
( ( N
5 CD N
microg/kg/day NN N
for IN N
< NN N
or CC N
=14 NNP N
days NNS N
) ) N
as IN N
per IN N
randomization NN N
in IN N
cycle NN N
0 CD N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
mean JJ N
peak NN N
CD34+ NNP N
count NN N
between IN N
pegfilgrastim NN N
and CC N
filgrastim NN N
, , N
but CC N
there EX N
was VBD N
an DT N
advantage NN N
for IN N
pegfilgrastim NN N
18 CD N
mg NN N
in IN N
the DT N
relevant JJ N
period NN N
of IN N
days NNS N
7-12 NNP N
( ( N
3.14 CD N
vs RB N
1.19 CD N
x JJ N
10 CD N
( ( N
4 CD N
) ) N
/ml NN N
; : N
P=0.043 NNP N
) ) N
. . N

A DT N
single JJ N
pegfilgrastim NN N
dose NN N
( ( N
> CD N
or CC N
=6 VB N
mg NN N
) ) N
could MD N
be VB N
substituted VBN N
for IN N
daily JJ N
filgrastim NN N
in IN N
cytokine-only JJ N
peripheral JJ N
CD34+ NNP N
cell NN N
mobilization NN N
. . N

-DOCSTART- -X- O O 16257339

Gefitinib NNP N
plus CC N
best JJS N
supportive JJ N
care NN N
in IN N
previously RB N
treated VBN N
patients NNS N
with IN N
refractory JJ 4_p
advanced JJ 4_p
non-small-cell JJ 4_p
lung NN 4_p
cancer NN 4_p
: : 4_p
results NNS N
from IN N
a DT N
randomised VBN N
, , N
placebo-controlled JJ N
, , N
multicentre JJ N
study NN N
( ( N
Iressa NNP N
Survival NNP N
Evaluation NNP N
in IN N
Lung NNP N
Cancer NNP N
) ) N
. . N

BACKGROUND VB N
This DT N
placebo-controlled JJ N
phase NN N
III NNP N
study NN N
investigated VBD N
the DT N
effect NN N
on IN N
survival NN N
of IN N
gefitinib NN N
as IN N
second-line JJ N
or CC N
third-line JJ N
treatment NN N
for IN N
patients NNS N
with IN N
locally RB 4_p
advanced JJ 4_p
or CC 4_p
metastatic JJ 4_p
non-small-cell JJ 4_p
lung NN 4_p
cancer NN 4_p
. . N

METHODS NNP N
1692 CD N
patients NNS N
who WP N
were VBD N
refractory JJ 4_p
to TO 4_p
or CC 4_p
intolerant VB 4_p
of IN 4_p
their PRP$ 4_p
latest JJS 4_p
chemotherapy NN 4_p
regimen NNS 4_p
were VBD N
randomly RB N
assigned VBN N
in IN N
a DT N
ratio NN N
of IN N
two CD N
to TO N
one CD N
either DT N
gefitinib NN N
( ( N
250 CD N
mg/day NN N
) ) N
or CC N
placebo NN N
, , N
plus CC N
best JJS N
supportive JJ N
care NN N
. . N

The DT N
primary JJ N
endpoint NN N
was VBD N
survival VBN N
in IN N
the DT N
overall JJ N
population NN N
of IN N
patients NNS N
and CC N
those DT N
with IN N
adenocarcinoma NN N
. . N

The DT N
primary JJ N
analysis NN N
of IN N
the DT N
population NN N
for IN N
survival NN N
was VBD N
by IN N
intention NN N
to TO N
treat VB N
. . N

This DT N
study NN N
has VBZ N
been VBN N
submitted VBN N
for IN N
registration NN N
with IN N
ClinicalTrials.gov NNP N
, , N
number NN N
1839IL/709 CD N
. . N

FINDINGS JJ N
1129 CD N
patients NNS N
were VBD N
assigned VBN N
gefitinib NNS N
and CC N
563 CD N
placebo NN N
. . N

At IN N
median JJ N
follow-up NN N
of IN N
7.2 CD N
months NNS N
, , N
median JJ N
survival NN N
did VBD N
not RB N
differ VB N
significantly RB N
between IN N
the DT N
groups NNS N
in IN N
the DT N
overall JJ N
population NN N
( ( N
5.6 CD N
months NNS N
for IN N
gefitinib NN N
and CC N
5.1 CD N
months NNS N
for IN N
placebo NN N
; : N
hazard CC N
ratio VB N
0.89 CD N
[ JJ N
95 CD N
% NN N
CI NNP N
0.77-1.02 CD N
] NNP N
, , N
p=0.087 NN N
) ) N
or CC N
among IN N
the DT N
812 CD N
patients NNS N
with IN N
adenocarcinoma NN N
( ( N
6.3 CD N
months NNS N
vs RB N
5.4 CD N
months NNS N
; : N
0.84 CD N
[ IN N
0.68-1.03 JJ N
] NN N
, , N
p=0.089 NN N
) ) N
. . N

Preplanned VBN N
subgroup NN N
analyses VBZ N
showed VBN N
significantly RB N
longer RBR N
survival NN N
in IN N
the DT N
gefitinib NN N
group NN N
than IN N
the DT N
placebo NN N
group NN N
for IN N
never-smokers NNS N
( ( N
n=375 NN N
; : N
0.67 CD N
[ IN N
0.49-0.92 JJ N
] NN N
, , N
p=0.012 NN N
; : N
median JJ N
survival NN N
8.9 CD N
vs NN N
6.1 CD N
months NNS N
) ) N
and CC N
patients NNS N
of IN N
Asian JJ N
origin NN N
( ( N
n=342 JJ N
; : N
0.66 CD N
[ IN N
0.48-0.91 JJ N
] NN N
, , N
p=0.01 NN N
; : N
median JJ N
survival NN N
9.5 CD N
vs NN N
5.5 CD N
months NNS N
) ) N
. . N

Gefitinib NNP N
was VBD N
well RB N
tolerated VBN N
, , N
as IN N
in IN N
previous JJ N
studies NNS N
. . N

INTERPRETATION NNP N
Treatment NNP N
with IN N
gefitinib NN N
was VBD N
not RB N
associated VBN N
with IN N
significant JJ N
improvement NN N
in IN N
survival NN N
in IN N
either DT N
coprimary JJ N
population NN N
. . N

There EX N
was VBD N
pronounced JJ N
heterogeneity NN N
in IN N
survival JJ N
outcomes NNS N
between IN N
groups NNS N
of IN N
patients NNS N
, , N
with IN N
some DT N
evidence NN N
of IN N
benefit NN N
among IN N
never-smokers NNS N
and CC N
patients NNS N
of IN N
Asian JJ N
origin NN N
. . N

-DOCSTART- -X- O O 23065684

Potential JJ N
effect NN N
of IN N
the DT N
risk NN N
of IN N
ovarian JJ N
cancer NN N
algorithm NN N
( ( N
ROCA NNP N
) ) N
on IN N
the DT N
mortality NN N
outcome NN N
of IN N
the DT N
Prostate NNP N
, , N
Lung NNP N
, , N
Colorectal NNP N
and CC N
Ovarian NNP N
( ( N
PLCO NNP N
) ) N
trial NN N
. . N

Recently RB N
, , N
the DT N
Prostate NNP N
, , N
Lung NNP N
, , N
Colorectal NNP N
and CC N
Ovarian NNP N
( ( N
PLCO NNP N
) ) N
Trial NNP N
reported VBD N
no DT N
mortality NN N
benefit NN N
for IN N
annual JJ N
screening NN N
with IN N
CA-125 NNP N
and CC N
transvaginal JJ N
ultrasound NN N
( ( N
TVU NNP N
) ) N
. . N

Currently NNP N
ongoing VBG N
is VBZ N
the DT N
UK NNP N
Collaborative NNP N
Trial NNP N
of IN N
Ovarian JJ N
Cancer NNP N
Screening NNP N
( ( N
UKCTOCS NNP N
) ) N
, , N
which WDT N
utilizes VBZ N
the DT N
risk NN N
of IN N
ovarian JJ N
cancer NN N
algorithm NN N
( ( N
ROCA NNP N
) ) N
, , N
a DT N
statistical JJ N
tool NN N
that IN N
considers NNS N
current JJ N
and CC N
past JJ N
CA125 NNP N
values NNS N
to TO N
determine VB N
ovarian JJ N
cancer NN N
risk NN N
. . N

In IN N
contrast NN N
, , N
PLCO NNP N
used VBD N
a DT N
single JJ N
cutoff NN N
for IN N
CA125 NNP N
, , N
based VBN N
on IN N
current JJ N
levels NNS N
alone RB N
. . N

We PRP N
investigated VBD N
whether IN N
having VBG N
had VBD N
used VBN N
ROCA NNP N
in IN N
PLCO NNP N
could MD N
have VB N
, , N
under IN N
optimal JJ N
assumptions NNS N
, , N
resulted VBD N
in IN N
a DT N
significant JJ N
mortality NN N
benefit NN N
by IN N
applying VBG N
ROCA NNP N
to TO N
PLCO NNP N
CA125 NNP N
screening VBG N
values NNS N
. . N

A DT N
best-case JJ N
scenario NN N
assumed VBD N
that IN N
all DT 4_p
cancers NNS 4_p
showing VBG 4_p
a DT 4_p
positive JJ 4_p
screen NN 4_p
result NN 4_p
earlier RBR 4_p
with IN 4_p
ROCA NNP 4_p
than IN 4_p
under IN 4_p
the DT 4_p
PLCO NNP 4_p
protocol NN N
would MD N
have VB N
avoided VBN N
mortality NN N
; : N
under IN N
a DT N
stage-shift JJ N
scenario NN N
, , N
such JJ N
women NNS N
were VBD N
assigned VBN N
survival JJ N
equivalent NN N
to TO N
Stage VB N
I/II NNP N
screen-detected JJ N
cases NNS N
. . N

Updated VBN N
PLCO NNP N
data NNS N
show VBP N
132 CD N
intervention NN N
arm NN N
ovarian JJ N
cancer NN N
deaths NNS N
versus VBP N
119 CD N
in IN N
usual JJ N
care NN N
( ( N
relative JJ N
risk NN N
, , N
RR NNP N
= NNP N
1.11 CD N
) ) N
. . N

Forty-three JJ N
ovarian JJ N
cancer NN N
cases NNS N
, , N
25 CD N
fatal NN N
, , N
would MD N
have VB N
been VBN N
detected VBN N
earlier RBR N
with IN N
ROCA NNP N
, , N
with IN N
a DT N
median JJ N
( ( N
minimum JJ N
) ) N
advance NN N
time NN N
for IN N
fatal JJ N
cases NNS N
of IN N
344 CD N
( ( N
147 CD N
) ) N
days NNS N
. . N

Best-case JJ N
and CC N
stage-shift JJ N
scenarios NNS N
gave VBD N
25 CD N
and CC N
19 CD N
deaths NNS N
prevented VBN N
with IN N
ROCA NNP N
, , N
for IN N
RRs NNP N
of IN N
0.90 CD N
( ( N
95 CD N
% NN N
CI NNP N
: : N
0.69-1.17 NN N
) ) N
and CC N
0.95 CD N
( ( N
95 CD N
% NN N
CI NNP N
: : N
0.74-1.23 NN N
) ) N
, , N
respectively RB N
. . N

Having VBG N
utilized JJ N
ROCA NNP N
in IN N
PLCO NNP N
would MD N
not RB N
have VB N
led VBN N
to TO N
a DT N
significant JJ N
mortality NN N
benefit NN N
of IN N
screening VBG N
. . N

However RB N
, , N
ROCA NNP N
could MD N
still RB N
show VB N
a DT N
significant JJ N
effect NN N
in IN N
other JJ N
screening NN N
trials NNS N
, , N
including VBG N
UKCTOCS NNP N
. . N

-DOCSTART- -X- O O 9931911

[ JJ N
Intra-arterial JJ N
( ( N
5-FU/FA JJ N
and CC N
FUDR NNP N
) ) N
versus VBP N
systemic JJ N
chemotherapy NN N
( ( N
5-FU/FA JJ N
) ) N
of IN N
non-resectable JJ 4_p
colorectal JJ 4_p
liver NN 4_p
metastases NNS 4_p
] VBP N
. . N

The DT N
relative JJ N
efficacy NN N
of IN N
HAI NNP N
FUDR NNP N
, , N
HAI NNP N
5-FU/FA CD N
, , N
and CC N
i.v NN N
. . N

5-FU/FA JJ N
chemotherapy NN N
for IN N
the DT N
treatment NN N
of IN N
unresectable JJ N
colorectal JJ N
liver NN N
metastases NNS N
was VBD N
compared VBN N
in IN N
a DT N
prospective JJ N
randomized VBN N
clinical JJ N
trial NN N
. . N

The DT N
response NN N
rate NN N
after IN N
HAI NNP N
treatment NN N
was VBD N
significantly RB N
higher JJR N
as IN N
compared VBN N
to TO N
i.v VB N
. . N

treatment NN N
with IN N
no DT N
statistical JJ N
benefit NN N
regarding VBG N
survival NN N
and CC N
time NN N
to TO N
progression NN N
. . N

HAI NNP N
FUDR NNP N
treatment NN N
was VBD N
inferior JJ N
as IN N
compared VBN N
to TO N
HAI NNP N
or CC N
i.v NN N
. . N

5-FU/FA JJ N
. . N

i.v NN N
. . N

5-FU/FA-therapy NN N
is VBZ N
therefore IN N
the DT N
method NN N
of IN N
choice NN N
outside IN N
clinical JJ N
trials NNS N
. . N

-DOCSTART- -X- O O 16200817

Addition NN N
of IN N
fexofenadine NN N
to TO N
inhaled VB N
corticosteroid JJ N
therapy NN N
to TO N
reduce VB N
inflammatory JJ 4_p
biomarkers NNS 4_p
in IN 4_p
atopic NN 4_p
asthma NN 4_p
. . 4_p

BACKGROUND IN N
We PRP N
previously RB N
showed VBD N
that IN N
H1-antihistamines NNP N
may MD N
shift VB N
the DT N
PC20 NNP N
( ( N
provocation NN N
concentration NN N
that WDT N
caused VBD N
a DT N
decrease NN N
in IN N
forced JJ N
expiratory NN N
volume NN N
in IN N
1 CD N
second NN N
of IN N
20 CD N
% NN N
) ) N
threshold NN N
to TO N
adenosine VB N
monophosphate NN N
( ( N
AMP NNP N
) ) N
challenge NN N
but CC N
may MD N
paradoxically RB N
prolong VB N
recovery NN N
. . N

OBJECTIVES UH N
To TO N
measure VB N
AMP NNP N
recovery NN N
using VBG N
a DT N
constant JJ N
predetermined VBN N
AMP NNP N
PC20 NNP N
and CC N
to TO N
evaluate VB N
whether IN N
fexofenadine NN N
use NN N
confers NNS N
add-on JJ N
effects NNS N
to TO N
treatment NN N
with IN N
either DT N
fluticasone NN N
propionate NN N
alone RB N
or CC N
combined VBN N
fluticasone CD N
propionate-salmeterol NN N
. . N

METHODS NNP N
Fourteen NNP N
atopic NN N
patients NNS N
with IN N
mild-to-moderate JJ N
asthma NN N
( ( N
forced JJ N
expiratory NN N
volume NN N
in IN N
1 CD N
second NN N
of IN N
76 CD N
% NN N
) ) N
completed VBD N
a DT N
double-blind NN N
, , N
randomized VBN N
, , N
crossover NN N
study NN N
consisting VBG N
of IN N
3-week JJ N
treatment NN N
blocks NNS N
of IN N
either DT N
fluticasone JJ N
propionate-salmeterol NN N
, , N
250 CD N
microg NN N
twice RB N
daily RB N
, , N
or CC N
fluticasone JJ N
propionate NN N
alone RB N
, , N
250 CD N
microg NN N
twice RB N
daily RB N
, , N
in IN N
conjunction NN N
with IN N
either DT N
fexofenadine NN N
, , N
180 CD N
mg NN N
once RB N
daily JJ N
, , N
or CC N
matched VBD N
placebo NN N
. . N

Recovery NN N
after IN N
a DT N
predetermined JJ N
AMP NNP N
PC20 NNP N
challenge NN N
was VBD N
measured VBN N
( ( N
primary JJ N
outcome NN N
) ) N
, , N
along IN N
with IN N
exhaled JJ N
nitric JJ N
oxide NN N
levels NNS N
, , N
plasma NN N
eosinophil NN N
cationic JJ N
protein NN N
levels NNS N
, , N
peripheral JJ N
eosinophil NN N
counts NNS N
, , N
pulmonary JJ N
function NN N
, , N
diary JJ N
card NN N
outcomes NNS N
, , N
and CC N
quality NN N
of IN N
life NN N
( ( N
all DT N
secondary JJ N
outcomes NNS N
) ) N
. . N

RESULTS CC N
There EX N
were VBD N
no DT N
differences NNS N
in IN N
any DT N
of IN N
the DT N
primary JJ N
or CC N
secondary JJ N
outcomes NNS N
when WRB N
fexofenadine NN N
was VBD N
added VBN N
to TO N
treatment NN N
with IN N
either DT N
fluticasone JJ N
propionate-salmeterol NN N
or CC N
fluticasone NN N
propionate NN N
alone RB N
. . N

The DT N
mean NN N
AMP NNP N
recovery NN N
time NN N
was VBD N
25.0 CD N
vs NN N
23.4 CD N
minutes NNS N
for IN N
fexofenadine NN N
and CC N
placebo NN N
, , N
respectively RB N
, , N
as IN N
add-on JJ N
to TO N
fluticasone-salmeterol NN N
and CC N
22.5 CD N
vs NN N
23.9 CD N
minutes NNS N
, , N
respectively RB N
, , N
as IN N
add-on JJ N
to TO N
fluticasone VB N
alone RB N
. . N

CONCLUSION NNP N
Fexofenadine NNP N
did VBD N
not RB N
affect VB N
recovery NN N
to TO N
a DT N
fixed VBN N
dose NN N
of IN N
AMP NNP N
challenge NN N
or CC N
any DT N
other JJ N
surrogate JJ N
inflammatory NN N
markers NNS N
when WRB N
given VBN N
as IN N
add-on JJ N
therapy NN N
to TO N
corticosteroid-treatedatopic JJ 4_p
asthmatic JJ 4_p
patients NNS 4_p
. . 4_p

-DOCSTART- -X- O O 24309381

An DT N
intervention NN N
to TO N
decrease VB N
stigma NN N
in IN N
young JJ N
adults NNS N
with IN N
sickle NN 4_p
cell NN 4_p
disease NN 4_p
. . N

Young NNP N
adults NNS N
with IN N
sickle NN 4_p
cell NN 4_p
disease NN 4_p
( ( 4_p
SCD NNP 4_p
) ) 4_p
are VBP N
often RB N
stigmatized VBN N
when WRB N
they PRP N
seek VBP N
care NN N
for IN N
pain NN N
. . N

The DT N
purpose NN N
of IN N
this DT N
pilot NN N
study NN N
was VBD N
to TO N
test VB N
an DT N
intervention NN N
to TO N
decrease VB N
health-related JJ N
stigma NN N
during IN N
care-seeking NN N
. . N

Young NNP N
adults NNS N
with IN N
SCD NNP 4_p
ages VBZ N
18 CD N
to TO N
35 CD N
years NNS N
( ( N
n JJ N
= NNP N
90 CD N
) ) N
were VBD N
randomized VBN N
to TO N
either VB N
the DT N
care-seeking JJ N
intervention NN N
( ( N
CSI NNP N
) ) N
or CC N
an DT N
attention NN N
control NN N
group NN N
that WDT N
participated VBD N
in IN N
life NN N
review NN N
interviews NNS N
. . N

The DT N
two CD N
groups NNS N
were VBD N
compared VBN N
by IN N
t NN N
tests NNS N
and CC N
longitudinal JJ N
data NNS N
analyses NNS N
on IN N
the DT N
change NN N
from IN N
baseline NN N
to TO N
the DT N
last JJ N
time NN N
point NN N
in IN N
total JJ N
health-related JJ N
stigma NN N
and CC N
health-related JJ N
stigma NN N
by IN N
doctors NNS N
. . N

Findings NNS N
suggest VBP N
that IN N
the DT N
CSI NNP N
was VBD N
associated VBN N
with IN N
significant JJ N
increased JJ N
awareness NN N
of IN N
perceived JJ N
total JJ N
stigma NN N
and CC N
stigma NN N
by IN N
doctors NNS N
compared VBN N
with IN N
the DT N
attention NN N
control NN N
group NN N
. . N

These DT N
findings NNS N
are VBP N
promising VBG N
in IN N
terms NNS N
of IN N
lessons NNS N
learned VBN N
from IN N
a DT N
pilot NN N
intervention NN N
that WDT N
focused VBD N
on IN N
the DT N
role NN N
communication NN N
skills NNS N
play VBP N
in IN N
decreasing VBG N
health-related JJ N
stigma NN N
in IN N
young JJ N
adults NNS N
with IN N
SCD NNP 4_p
. . N

-DOCSTART- -X- O O 3370523

Moisture-vapour-permeable JJ N
film NN N
as IN N
an DT N
outpatient JJ N
burn NN 4_p
dressing VBG N
. . N

This DT N
study NN N
compares VBZ N
a DT N
moisture-vapour-permeable JJ N
film NN N
( ( N
MVPF NNP N
) ) N
with IN N
silver NN N
sulphadiazine NN N
in IN N
a DT N
randomized JJ N
prospective JJ N
manner NN N
for IN N
the DT N
treatment NN N
of IN N
outpatient NN N
burns NNS 4_p
. . N

The DT N
two CD N
treatment NN N
groups NNS N
were VBD N
closely RB N
matched VBN N
in IN N
age NN N
, , N
sex NN N
, , N
per IN N
cent NN N
of IN N
BSA NNP N
burned VBD 4_p
, , N
and CC N
in IN N
burn JJ 4_p
severity NN N
and CC N
locations NNS N
. . N

The DT N
MVPF NNP N
group NN N
demonstrated VBD N
a DT N
39.0 CD N
per IN N
cent NN N
greater JJR N
reduction NN N
in IN N
pain NN N
after IN N
application NN N
of IN N
the DT N
dressing NN N
over IN N
the DT N
silver JJ N
sulphadiazine NN N
group NN N
. . N

Patients NNS N
in IN N
the DT N
MVPF NNP N
film NN N
group NN N
also RB N
reported VBD N
significantly RB N
less JJR N
difficulty NN N
in IN N
wound NN N
care NN N
and CC N
in IN N
dressing VBG N
interference NN N
with IN N
their PRP$ N
daily JJ N
functions NNS N
. . N

The DT N
clinical JJ N
infection NN N
rate NN N
and CC N
time NN N
to TO N
healing VBG N
were VBD N
similar JJ N
in IN N
both DT N
groups NNS N
. . N

In IN N
the DT N
management NN N
of IN N
outpatient NN N
burns NNS 4_p
, , N
MVPF NNP N
was VBD N
found VBN N
to TO N
be VB N
superior JJ N
to TO N
silver VB N
sulphadiazine NN N
. . N

-DOCSTART- -X- O O 24352377

Mitigation NN N
of IN N
sociocommunicational JJ N
deficits NNS N
of IN N
autism NN 4_p
through IN N
oxytocin-induced JJ N
recovery NN N
of IN N
medial JJ N
prefrontal JJ N
activity NN N
: : N
a DT N
randomized JJ N
trial NN N
. . N

IMPORTANCE NNP N
Sociocommunicational NNP N
deficits NNS N
make VBP N
it PRP N
difficult JJ N
for IN N
individuals NNS 4_p
with IN 4_p
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
( ( 4_p
ASD NNP 4_p
) ) N
to TO N
understand VB N
communication NN N
content NN N
with IN N
conflicting VBG N
verbal JJ N
and CC N
nonverbal JJ N
information NN N
. . N

Despite IN N
growing VBG N
prospects NNS N
for IN N
oxytocin NN N
as IN N
a DT N
therapeutic JJ N
agent NN N
for IN N
ASD NNP N
, , N
no DT N
direct JJ N
neurobiological JJ N
evidence NN N
exists NNS N
for IN N
oxytocin NN N
's POS N
beneficial JJ N
effects NNS N
on IN N
this DT N
core NN N
symptom NN N
of IN N
ASD NNP N
. . N

This DT N
is VBZ N
slowing VBG N
clinical JJ N
application NN N
of IN N
the DT N
neuropeptide NN N
. . N

OBJECTIVE UH N
To TO N
directly RB N
examine VB N
whether IN N
oxytocin NN N
has VBZ N
beneficial JJ N
effects NNS N
on IN N
the DT N
sociocommunicational JJ N
deficits NNS N
of IN N
ASD NNP N
using VBG N
both DT N
behavioral JJ N
and CC N
neural JJ N
measures NNS N
. . N

DESIGN NNP N
, , N
SETTING NNP N
, , N
AND NNP N
PARTICIPANTS NNP N
At IN N
the DT N
University NNP N
of IN N
Tokyo NNP N
Hospital NNP N
, , N
we PRP N
conducted VBD N
a DT N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
, , N
within-subject-crossover JJ N
, , N
single-site JJ N
experimental JJ N
trial NN N
in IN N
which WDT N
intranasal NN N
oxytocin NN N
and CC N
placebo NN N
were VBD N
administered VBN N
. . N

A DT N
total NN N
of IN N
40 CD N
highly RB N
functioning VBG N
men NNS N
with IN N
ASD NNP N
participated VBD N
and CC N
were VBD N
randomized VBN N
in IN N
the DT N
trial NN N
. . N

INTERVENTIONS NNP N
Single-dose JJ N
intranasal JJ N
administration NN N
of IN N
oxytocin NN N
( ( N
24 CD N
IU NNP N
) ) N
and CC N
placebo NN N
. . N

MAIN NNP N
OUTCOMES NNP N
AND NNP N
MEASURES NNP N
Using NNP N
functional JJ N
magnetic JJ N
resonance NN N
imaging NN N
, , N
we PRP N
examined VBD N
effects NNS N
of IN N
oxytocin NN N
on IN N
behavioral JJ N
neural JJ N
responses NNS N
of IN N
the DT N
participants NNS N
to TO N
a DT N
social JJ N
psychological JJ N
task NN N
. . N

In IN N
our PRP$ N
previous JJ N
case-control NN N
study NN N
using VBG N
the DT N
same JJ N
psychological JJ N
task NN N
, , N
when WRB N
making VBG N
decisions NNS N
about IN N
social JJ N
information NN N
with IN N
conflicting VBG N
verbal JJ N
and CC N
nonverbal JJ N
contents NNS N
, , N
participants NNS N
with IN N
ASD NNP N
made VBD N
judgments NNS N
based VBN N
on IN N
nonverbal JJ N
contents NNS N
less RBR N
frequently RB N
with IN N
longer JJR N
time NN N
and CC N
could MD N
not RB N
induce VB N
enough JJ N
activation NN N
in IN N
the DT N
medial JJ N
prefrontal JJ N
cortex NN N
. . N

Therefore RB N
, , N
our PRP$ N
main JJ N
outcomes NNS N
and CC N
measures NNS N
were VBD N
the DT N
frequency NN N
of IN N
the DT N
nonverbal JJ N
information-based JJ N
judgments NNS N
( ( N
NVJs NNP N
) ) N
, , N
the DT N
response NN N
time NN N
for IN N
NVJs NNP N
, , N
and CC N
brain NN N
activity NN N
of IN N
the DT N
medial JJ N
prefrontal JJ N
cortex NN N
during IN N
NVJs NNP N
. . N

RESULTS NNP N
Intranasal NNP N
oxytocin VBZ N
enabled VBD N
the DT N
participants NNS N
to TO N
make VB N
NVJs NNP N
more RBR N
frequently RB N
( ( N
P NNP N
= NNP N
.03 NNP N
) ) N
with IN N
shorter JJR N
response NN N
time NN N
( ( N
P NNP N
= NNP N
.02 NNP N
) ) N
. . N

During IN N
the DT N
mitigated JJ N
behavior NN N
, , N
oxytocin NN N
increased VBD N
the DT N
originally RB N
diminished VBN N
brain NN N
activity NN N
in IN N
the DT N
medial JJ N
prefrontal NN N
cortex NN N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

Moreover RB N
, , N
oxytocin PRP N
enhanced VBD N
functional JJ N
coordination NN N
in IN N
the DT N
area NN N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
, , N
and CC N
the DT N
magnitude NN N
of IN N
these DT N
neural JJ N
effects NNS N
was VBD N
predictive JJ N
of IN N
the DT N
behavioral JJ N
effects NNS N
( ( N
P NNP N
≤ NNP N
.01 NNP N
) ) N
. . N

CONCLUSIONS NNP N
AND CC N
RELEVANCE NNP N
These DT N
findings NNS N
provide VBP N
the DT N
first JJ N
neurobiological JJ N
evidence NN N
for IN N
oxytocin NN N
's POS N
beneficial JJ N
effects NNS N
on IN N
sociocommunicational JJ N
deficits NNS N
of IN N
ASD NNP N
and CC N
give VB N
us PRP N
the DT N
initial JJ N
account NN N
for IN N
neurobiological JJ N
mechanisms NNS N
underlying VBG N
any DT N
beneficial JJ N
effects NNS N
of IN N
the DT N
neuropeptide NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
umin.ac.jp/ctr JJ N
Identifier NNP N
: : N
UMIN000002241 NN N
and CC N
UMIN000004393 NNP N
. . N

-DOCSTART- -X- O O 23130813

Emotional JJ N
reactivity NN N
to TO N
social JJ N
rejection NN N
and CC N
negative JJ N
evaluation NN N
among IN N
persons NNS N
with IN N
borderline JJ 4_p
personality NN 4_p
features NNS N
. . N

The DT N
present JJ N
study NN N
examined VBD N
the DT N
emotional JJ N
reactivity NN N
of IN N
persons NNS N
with IN N
heightened JJ 4_p
borderline NN 4_p
personality NN 4_p
( ( 4_p
BP NNP 4_p
) ) 4_p
features VBZ N
to TO N
social JJ N
rejection NN N
and CC N
negative JJ N
evaluation NN N
in IN N
the DT N
laboratory NN N
. . N

Individuals NNS N
with IN N
high JJ 4_p
levels NNS 4_p
of IN N
BP NNP 4_p
features NNS N
( ( N
n JJ N
= NNP N
30 CD N
) ) N
and CC N
controls NNS N
with IN N
low JJ 4_p
levels NNS 4_p
of IN N
BP NNP 4_p
features NNS N
( ( N
n JJ N
= NNP N
44 CD N
) ) N
were VBD N
randomly RB N
assigned VBN N
to TO N
a DT N
condition NN N
involving VBG N
negative JJ N
evaluation NN N
based VBN N
on IN N
writing NN N
( ( N
negative JJ N
evaluation/academic NN N
) ) N
, , N
or CC N
a DT N
condition NN N
involving VBG N
negative JJ N
evaluation NN N
based VBN N
on IN N
personal JJ N
characteristics NNS N
as RB N
well RB N
as IN N
social JJ N
rejection NN N
( ( N
negative JJ N
evaluation/social JJ N
rejection NN N
) ) N
. . N

Hypothesis $ N
1 CD N
was VBD N
that IN N
high-BP JJ 4_p
individuals NNS N
, , N
but CC N
not RB N
low-BP JJ 4_p
controls NNS N
, , N
would MD N
show VB N
greater JJR N
emotional JJ N
reactivity NN N
to TO N
the DT N
negative JJ N
evaluation/social JJ N
rejection NN N
stressor NN N
, , N
compared VBN N
with IN N
the DT N
negative JJ N
evaluation/academic JJ N
( ( N
writing VBG N
) ) N
stressor NN N
. . N

Hypothesis $ N
2 CD N
was VBD N
that IN N
high-BP JJ 4_p
individuals NNS N
would MD N
specifically RB N
show VB N
greater JJR N
reactivity NN N
of IN N
shame- JJ N
and CC N
anger-related JJ N
emotions NNS N
to TO N
the DT N
negative JJ N
evaluation/social JJ N
rejection NN N
stressor NN N
compared VBN N
with IN N
the DT N
negative JJ N
evaluation/academic JJ N
stressor NN N
. . N

Findings NNS N
indicated VBD N
that IN N
high-BP JJ 4_p
individuals NNS N
showed VBD N
heightened VBN N
emotional JJ N
reactivity NN N
to TO N
the DT N
social JJ N
rejection NN N
stressor NN N
but CC N
not RB N
to TO N
the DT N
negative JJ N
evaluation NN N
stressor NN N
, , N
but CC N
the DT N
opposite JJ N
pattern NN N
occurred VBD N
for IN N
controls NNS N
. . N

In IN N
addition NN N
, , N
there EX N
was VBD N
evidence NN N
for IN N
heightened JJ N
reactivity NN N
of IN N
irritability NN N
, , N
distress NN N
, , N
and CC N
shame NN N
for IN N
the DT N
high-BP JJ N
group NN N
, , N
specifically RB N
in IN N
the DT N
social JJ N
rejection NN N
condition NN N
. . N

-DOCSTART- -X- O O 16254100

Pathology NN N
parameters NNS N
and CC N
adjuvant JJ N
tamoxifen NN N
response NN N
in IN N
a DT N
randomised JJ N
premenopausal NN 4_p
breast NN 4_p
cancer NN 4_p
trial NN N
. . N

BACKGROUND NNP N
Subgroups NNP N
of IN N
breast NN N
cancer NN N
that WDT N
have VBP N
an DT N
impaired JJ N
response NN N
to TO N
endocrine VB N
treatment NN N
, , N
despite IN N
hormone NN N
receptor NN N
positivity NN N
, , N
are VBP N
still RB N
poorly RB N
defined VBN N
. . N

Breast NNP N
cancer NN N
can MD N
be VB N
subdivided VBN N
according VBG N
to TO N
standard JJ N
pathological JJ N
parameters NNS N
including VBG N
histological JJ N
type NN N
, , N
grade NN N
, , N
and CC N
assessment NN N
of IN N
proliferation NN N
. . N

These DT N
parameters NNS N
are VBP N
the DT N
net JJ N
result NN N
of IN N
combinations NNS N
of IN N
genetic JJ N
alterations NNS N
effecting VBG N
tumour JJ N
behaviour NN N
and CC N
could MD N
potentially RB N
reflect VB N
subtypes NNS N
that IN N
respond NN N
differently RB N
to TO N
endocrine VB N
treatment NN N
. . N

AIMS NNP N
To TO N
investigate VB N
the DT N
usefulness NN N
of IN N
these DT N
parameters NNS N
as IN N
predictors NNS N
of IN N
the DT N
response NN N
to TO N
tamoxifen VB N
in IN N
premenopausal JJ 4_p
women NNS N
with IN N
breast NN 4_p
cancer NN 4_p
. . N

MATERIALS/METHODS NNP N
Clinically NNP N
established VBD N
pathological JJ N
parameters NNS N
were VBD N
assessed VBN N
and CC N
related VBN N
to TO N
the DT N
tamoxifen NN N
response NN N
in IN N
500 CD N
available JJ N
tumour NN N
specimens NNS N
from IN N
564 CD N
premenopausal NN N
patients NNS N
with IN N
breast JJ N
cancer NN N
randomised VBD N
to TO N
either DT N
two CD N
years NNS N
of IN N
tamoxifen NN N
or CC N
no DT N
treatment NN N
with IN N
14 CD N
years NNS N
of IN N
follow NN N
up RB N
. . N

Proliferation NN N
was VBD N
further RB N
evaluated VBN N
by IN N
immunohistochemical JJ N
Ki-67 NNP N
expression NN N
. . N

RESULTS NNP N
Oestrogen NNP N
receptor NN N
positive JJ N
ductal JJ N
carcinomas NN N
responded VBD N
as IN N
expected VBN N
to TO N
tamoxifen VB N
, , N
whereas IN N
the DT N
difference NN N
in IN N
recurrence NN N
free JJ N
survival NN N
between IN N
control NN N
and CC N
tamoxifen NN N
treated VBD N
patients NNS N
was VBD N
less RBR N
apparent JJ N
in IN N
the DT N
relatively RB N
few JJ N
lobular JJ N
carcinomas NN N
. . N

For IN N
histological JJ N
grade NN N
, , N
there EX N
was VBD N
no DT N
obvious JJ N
difference NN N
in IN N
treatment NN N
response NN N
between IN N
the DT N
groups NNS N
. . N

The DT N
relation NN N
between IN N
proliferation NN N
and CC N
tamoxifen NN N
response NN N
seemed VBD N
to TO N
be VB N
more RBR N
complex JJ N
, , N
with IN N
a DT N
clear JJ N
response NN N
in IN N
tumours NN N
with IN N
high JJ N
and CC N
low JJ N
proliferation NN N
, , N
whereas JJ N
tumours NN N
with IN N
intermediate JJ N
proliferation NN N
defined VBN N
by IN N
Ki-67 NNP N
responded VBD N
more RBR N
poorly RB N
. . N

CONCLUSIONS NNP N
Clinically NNP N
established VBD N
pathology NN N
parameters NNS N
seem VBP N
to TO N
mirror VB N
the DT N
endocrine NN N
treatment NN N
response NN N
and CC N
could MD N
potentially RB N
be VB N
valuable JJ N
in IN N
future JJ N
treatment NN N
decisions NNS N
for IN N
patients NNS 4_p
with IN 4_p
breast JJ 4_p
cancer NN 4_p
. . N

-DOCSTART- -X- O O 7528271

Multicyclic NNP N
, , N
dose-intensive JJ N
chemotherapy NN N
supported VBN N
by IN N
sequential JJ N
reinfusion NN N
of IN N
hematopoietic JJ N
progenitors NNS N
in IN N
whole JJ N
blood NN N
. . N

PURPOSE NN N
To TO N
support VB N
multicyclic JJ N
, , N
dose-intensive JJ N
chemotherapy NN N
, , N
we PRP N
assessed VBD N
the DT N
effects NNS N
of IN N
reinfusing VBG N
hematopoietic JJ N
progenitors NNS N
collected VBN N
at IN N
each DT N
cycle NN N
in IN N
leukapheresis JJ N
product NN N
or CC N
whole JJ N
blood NN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
Twenty-five JJ N
patients NNS N
with IN 4_p
small-cell JJ 4_p
lung NN 4_p
cancer NN 4_p
( ( 4_p
SCLC NNP 4_p
) ) 4_p
were VBD N
treated VBN N
with IN N
six CD N
cycles NNS N
of IN N
ifosfamide NN N
, , N
carboplatin NN N
, , N
and CC N
etoposide RB N
( ( N
ICE NNP N
) ) N
with IN N
granulocyte JJ N
colony-stimulating JJ N
factor NN N
( ( N
G-CSF NNP N
) ) N
300 CD N
micrograms/d NN N
subcutaneously RB N
( ( N
SC NNP N
) ) N
on IN N
days NNS N
4 CD N
to TO N
15 CD N
. . N

Hematopoietic JJ N
progenitors NNS N
collected VBD N
during IN N
each DT N
cycle NN N
were VBD N
reinfused VBN N
on IN N
day NN N
3 CD N
of IN N
the DT N
next JJ N
cycle NN N
. . N

Cohort NNP N
1 CD N
( ( N
n JJ N
= NNP N
6 CD N
) ) N
was VBD N
treated VBN N
every DT N
3 CD N
weeks NNS N
, , N
with IN N
leukapheresis NN N
after IN N
2 CD N
weeks NNS N
and CC N
cryopreservation NN N
of IN N
the DT N
leukapheresis NN N
product NN N
. . N

Chemotherapy NNP N
was VBD N
given VBN N
if IN N
the DT N
WBC NNP N
count NN N
was VBD N
> JJ N
or CC N
= JJ N
3 CD N
x JJ N
10 CD N
( ( N
9 CD N
) ) N
/L NN N
and CC N
platelet NN N
count NN N
> NNP N
or CC N
= $ N
100 CD N
x $ N
10 CD N
( ( N
9 CD N
) ) N
/L NN N
. . N

Cohort NNP N
2 CD N
( ( N
n JJ N
= NNP N
7 CD N
) ) N
was VBD N
treated VBN N
every DT N
2 CD N
weeks NNS N
, , N
with IN N
leukapheresis NN N
on IN N
day NN N
1 CD N
of IN N
the DT N
next JJ N
cycle NN N
and CC N
storage NN N
of IN N
the DT N
leukapheresis NN N
product NN N
at IN N
4 CD N
degrees NNS N
C. NNP N
Cohort NNP N
3 CD N
( ( N
n JJ N
= NNP N
12 CD N
) ) N
was VBD N
treated VBN N
every DT N
2 CD N
weeks NNS N
, , N
with IN N
500 CD N
to TO N
750 CD N
mL NNS N
of IN N
blood NN N
drawn VBN N
by IN N
venesection NN N
on IN N
day NN N
1 CD N
of IN N
the DT N
next JJ N
cycle NN N
and CC N
stored VBD N
at IN N
4 CD N
degrees NNS N
C. NNP N
In IN N
cohorts NNS N
2 CD N
and CC N
3 CD N
, , N
chemotherapy NN N
was VBD N
given VBN N
if IN N
the DT N
WBC NNP N
count NN N
was VBD N
> JJ N
or CC N
= JJ N
3 CD N
x JJ N
10 CD N
( ( N
9 CD N
) ) N
/L NN N
and CC N
platelet NN N
count NN N
> NNP N
or CC N
= $ N
30 CD N
x $ N
10 CD N
( ( N
9 CD N
) ) N
/L NN N
. . N

Blood NNP N
and CC N
leukapheresis NN N
products NNS N
were VBD N
assayed VBN N
for IN N
hematopoietic JJ N
progenitors NNS N
. . N

RESULTS NNP N
ICE NNP N
chemotherapy NN N
with IN N
G-CSF NNP N
was VBD N
effective JJ N
in IN N
mobilizing VBG N
blood NN N
progenitors NNS N
( ( N
median JJ N
, , N
120-fold JJ N
) ) N
. . N

Long-term JJ N
cultures NNS N
showed VBD N
no DT N
evidence NN N
of IN N
stem-cell JJ N
depletion NN N
. . N

The DT N
cytotoxic JJ N
dose-intensity NN N
of IN N
standard JJ N
every-4-weeks JJ N
ICE NNP N
is VBZ N
100 CD N
% NN N
. . N

In IN N
the DT N
first JJ N
three CD N
cycles NNS N
, , N
it PRP N
was VBD N
134 CD N
% NN N
( ( N
median JJ N
) ) N
in IN N
cohort NN N
1 CD N
and CC N
200 CD N
% NN N
in IN N
cohorts NNS N
2 CD N
and CC N
3 CD N
( ( N
P NNP N
< NNP N
.0001 NNP N
) ) N
. . N

Toxicity NN N
and CC N
supportive JJ N
care NN N
requirements NNS N
were VBD N
not RB N
increased VBN N
. . N

CONCLUSION VB N
The DT N
dose-intensity NN N
of IN N
ICE NNP N
chemotherapy NN N
can MD N
be VB N
doubled VBN N
by IN N
reinfusing VBG N
hematopoietic JJ N
progenitors NNS N
collected VBN N
by IN N
leukapheresis NN N
or CC N
venesection NN N
and CC N
stored VBD N
at IN N
4 CD N
degrees NNS N
C NNP N
. . N

-DOCSTART- -X- O O 17940245

Intravenous JJ N
sodium NN N
valproate NN N
versus NN N
diazepam NN N
infusion NN N
for IN N
the DT N
control NN N
of IN N
refractory NN 4_p
status NN 4_p
epilepticus NN 4_p
in IN N
children NNS N
: : N
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

An DT N
open-label JJ N
, , N
randomized VBN N
controlled VBD N
study NN N
was VBD N
conducted VBN N
at IN N
a DT N
tertiary JJ N
care NN N
teaching VBG N
hospital NN N
to TO N
compare VB N
efficacy NN N
and CC N
safety NN N
of IN N
intravenous JJ N
sodium NN N
valproate NN N
versus NN N
diazepam NN N
infusion NN N
for IN N
control NN N
of IN N
refractory NN N
status NN N
epilepticus NN N
. . N

Forty NNP N
children NNS N
with IN N
refractory NN 4_p
status NN 4_p
epilepticus NN 4_p
were VBD N
randomized VBN N
to TO N
receive VB N
either RB N
intravenous JJ N
sodium NN N
valproate NN N
or CC N
diazepam JJ N
infusion NN N
. . N

Refractory JJ N
status NN N
epilepticus NN N
was VBD N
controlled VBN N
in IN N
80 CD N
% NN N
of IN N
the DT N
valproate NN N
and CC N
85 CD N
% NN N
of IN N
the DT N
diazepam NN N
patients NNS N
. . N

The DT N
median JJ N
time NN N
to TO N
control VB N
refractory JJ N
status NN N
epilepticus NN N
was VBD N
less RBR N
in IN N
the DT N
valproate NN N
group NN N
( ( N
5 CD N
minutes NNS N
) ) N
than IN N
the DT N
diazepam NN N
group NN N
( ( N
17 CD N
minutes NNS N
; : N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

None NN N
of IN N
the DT N
patients NNS N
in IN N
the DT N
valproate NN N
group NN N
required VBN N
ventilation NN N
or CC N
developed JJ N
hypotension NN N
, , N
whereas NNS N
in IN N
the DT N
diazepam NN N
group NN N
60 CD N
% NN N
required VBN N
ventilation NN N
and CC N
50 CD N
% NN N
developed JJ N
hypotension NN N
after IN N
starting VBG N
diazepam JJ N
infusion NN N
. . N

No DT N
adverse JJ N
effects NNS N
on IN N
liver NN N
functions NNS N
were VBD N
seen VBN N
with IN N
valproate NN N
. . N

It PRP N
is VBZ N
concluded VBN N
that IN N
intravenous JJ N
sodium NN N
valproate NN N
is VBZ N
an DT N
effective JJ N
alternative NN N
to TO N
diazepam VB N
infusion NN N
in IN N
controlling VBG N
refractory NN N
status NN N
epilepticus NN N
in IN N
children NNS N
and CC N
is VBZ N
free JJ N
of IN N
respiratory JJ N
depression NN N
and CC N
hypotension NN N
. . N

-DOCSTART- -X- O O 17664467

Clinical JJ N
benefit NN N
with IN N
docetaxel JJ N
plus CC N
fluorouracil JJ N
and CC N
cisplatin NNS N
compared VBN N
with IN N
cisplatin NN N
and CC N
fluorouracil NN N
in IN N
a DT N
phase NN N
III NNP N
trial NN N
of IN N
advanced JJ 4_p
gastric NN 4_p
or CC 4_p
gastroesophageal NN 4_p
cancer NN 4_p
adenocarcinoma NN 4_p
: : N
the DT N
V-325 NNP N
Study NNP N
Group NNP N
. . N

PURPOSE NNP N
For IN N
patients NNS N
with IN N
advanced JJ 4_p
gastric NN 4_p
or CC 4_p
gastroesophageal NN 4_p
cancer NN 4_p
( ( 4_p
AGGEC NNP 4_p
) ) 4_p
providing VBG N
clinical JJ N
benefit NN N
with IN N
improved JJ N
palliation NN N
is VBZ N
highly RB N
desirable JJ N
. . N

However RB N
, , N
a DT N
prospective JJ N
evaluation NN N
of IN N
clinical JJ N
benefit NN N
in IN N
AGGEC NNP N
patients NNS N
has VBZ N
never RB N
before RB N
been VBN N
reported VBN N
in IN N
a DT N
phase NN N
III NNP N
setting NN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
In IN N
a DT N
multinational JJ N
trial NN N
( ( N
V325 NNP N
) ) N
, , N
445 CD N
patients NNS N
were VBD N
randomly RB N
assigned VBN N
and CC N
treated VBN N
with IN N
either DT N
docetaxel JJ N
plus CC N
cisplatin JJ N
and CC N
fluorouracil NN N
( ( N
DCF NNP N
) ) N
or CC N
cisplatin NN N
and CC N
fluorouracil NN N
( ( N
CF NNP N
) ) N
. . N

Clinical JJ N
benefit NN N
was VBD N
prospectively RB N
evaluated VBN N
in IN N
this DT N
trial NN N
as IN N
a DT N
secondary JJ N
end NN N
point NN N
. . N

The DT N
primary JJ N
measure NN N
for IN N
clinical JJ N
benefit NN N
analysis NN N
was VBD N
time NN N
to TO N
definitive VB N
worsening NN N
by IN N
one CD N
or CC N
more JJR N
categories NNS N
of IN N
Karnofsky NNP N
performance NN N
status NN N
( ( N
KPS NNP N
) ) N
. . N

Secondary JJ N
clinical JJ N
benefit NN N
end NN N
points NNS N
included VBD N
time NN N
to TO N
5 CD N
% NN N
definitive JJ N
weight NN N
loss NN N
, , N
time NN N
to TO N
definitive JJ N
worsening NN N
of IN N
appetite NN N
by IN N
one CD N
grade NN N
, , N
pain-free JJ N
survival NN N
( ( N
defined VBN N
as IN N
time NN N
to TO N
first JJ N
appearance NN N
of IN N
pain NN N
) ) N
, , N
and CC N
time NN N
to TO N
first JJ N
cancer NN N
pain-related JJ N
opioid JJ N
intake NN N
. . N

Clinical JJ N
benefit NN N
assessments NNS N
were VBD N
recorded VBN N
at IN N
each DT N
clinic JJ N
visit NN N
. . N

RESULTS NNP N
Clinical JJ N
benefit NN N
assessments NNS N
were VBD N
performed VBN N
in IN N
more JJR N
than IN N
75 CD N
% NN N
of IN N
patients NNS N
throughout IN N
V325 NNP N
. . N

DCF NNP N
significantly RB N
prolonged VBD N
time NN N
to TO N
definitive JJ N
worsening NN N
of IN N
KPS NNP N
compared VBN N
with IN N
CF NNP N
( ( N
median JJ N
, , N
6.1 CD N
v NN N
4.8 CD N
months NNS N
; : N
hazard RB N
ratio NN N
, , N
1.38 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
1.08 CD N
to TO N
1.76 CD N
; : N
log-rank JJ N
P NNP N
= NNP N
.009 NNP N
) ) N
. . N

Although IN N
time NN N
to TO N
definitive JJ N
weight NN N
loss NN N
and CC N
time NN N
to TO N
definitive JJ N
worsening NN N
of IN N
appetite NN N
favored VBN N
DCF NNP N
, , N
the DT N
results NNS N
were VBD N
not RB N
statistically RB N
significant JJ N
. . N

Pain-free JJ N
survival NN N
and CC N
time NN N
to TO N
first JJ N
cancer NN N
pain-related JJ N
opioid JJ N
intake NN N
were VBD N
comparable JJ N
. . N

CONCLUSION NN N
To TO N
our PRP$ N
knowledge NN N
, , N
V325 NNP N
is VBZ N
the DT N
first JJ N
phase NN N
III NNP N
trial NN N
to TO N
report VB N
clinical JJ N
benefit NN N
in IN N
AGGEC NNP N
patients NNS N
. . N

Clinical JJ N
benefit NN N
was VBD N
assessed VBN N
beyond IN N
protocol-specific JJ N
chemotherapy NN N
. . N

The DT N
addition NN N
of IN N
D NNP N
to TO N
CF NNP N
not RB N
only RB N
significantly RB N
improved VBN N
clinical JJ N
benefit NN N
but CC N
also RB N
improved JJ N
quality NN N
of IN N
life NN N
, , N
time NN N
to TO N
progression NN N
, , N
and CC N
overall JJ N
survival NN N
compared VBN N
with IN N
CF NNP N
. . N

-DOCSTART- -X- O O 26449739

Rituximab NNP N
maintenance NN N
improves VBZ N
survival NN N
in IN N
male JJ N
patients NNS N
with IN N
diffuse JJ 4_p
large JJ 4_p
B-cell NNP 4_p
lymphoma NN 4_p
. . N

Results NNS N
of IN N
the DT N
HD2002 NNP N
prospective JJ N
multicentre NN N
randomized VBD N
phase NN N
III NNP N
trial NN N
. . N

In IN N
the DT N
multicentre NN N
prospective JJ N
randomized VBN N
HD2002 NNP N
trial NN N
, , N
rituximab JJ N
maintenance NN N
therapy NN N
( ( N
375 CD N
mg/m NN N
( ( N
2 CD N
) ) N
every DT N
3 CD N
months NNS N
for IN N
2 CD N
years NNS N
) ) N
versus VBP N
observation NN N
was VBD N
evaluated VBN N
for IN N
CD20 NNP N
( ( N
+ NNP N
) ) N
B-cell NNP N
lymphoma NN N
. . N

Out IN N
of IN N
321 CD N
patients NNS N
[ JJ N
161 CD N
randomized VBN N
to TO N
the DT N
treatment NN N
group NN N
( ( N
TG NNP N
) ) N
, , N
160 CD N
to TO N
the DT N
observation NN N
group NN N
( ( N
OG NNP N
) ) N
] NN N
, , N
295 CD N
data NNS N
sets NNS N
were VBD N
evaluable JJ N
for IN N
statistical JJ N
analysis NN N
. . N

Estimated VBN N
5-year JJ N
relapse-free JJ N
survival NN N
( ( N
RFS NNP N
) ) N
was VBD N
81 CD N
% NN N
in IN N
the DT N
TG NNP N
and CC N
70 CD N
% NN N
in IN N
the DT N
OG NNP N
( ( N
logrank JJ N
test NN N
, , N
P NNP N
= NNP N
0·047 CD N
) ) N
. . N

In IN N
the DT N
diffuse NN N
large JJ N
B-cell NNP N
lymphoma NN N
( ( N
DLBCL NNP N
) ) N
subgroup NN N
( ( N
n JJ N
= NNP N
152 CD N
) ) N
, , N
5-year JJ N
RFS NNP N
was VBD N
excellent JJ N
, , N
at IN N
87 CD N
% NN N
in IN N
the DT N
TG NNP N
and CC N
84 CD N
% NN N
in IN N
the DT N
OG NNP N
( ( N
logrank JJ N
test NN N
, , N
P NNP N
= NNP N
0·35 CD N
) ) N
. . N

Of IN N
note NN N
, , N
only RB N
in IN N
male JJ N
patients NNS N
of IN N
the DT N
DLBCL NNP N
subgroup NN N
was VBD N
RFS NNP N
significantly RB N
superior VBZ N
in IN N
the DT N
TG NNP N
in IN N
comparison NN N
to TO N
the DT N
OG NNP N
( ( N
5-year JJ N
RFS NNP N
: : N
88 CD N
% NN N
vs. FW N
74 CD N
% NN N
; : N
logrank JJ N
test NN N
, , N
P NNP N
= NNP N
0·05 CD N
) ) N
. . N

Cox NNP N
regression NN N
analysis NN N
showed VBD N
a DT N
significant JJ N
interaction NN N
between IN N
treatment NN N
and CC N
gender NN N
regarding VBG N
overall JJ N
survival NN N
( ( N
OS NNP N
) ) N
( ( N
P NNP N
= NNP N
0·006 CD N
) ) N
and CC N
RFS NNP N
( ( N
P NNP N
= NNP N
0·02 CD N
) ) N
, , N
with IN N
a DT N
lower JJR N
hazard NN N
in IN N
females NNS N
than IN N
males NNS N
in IN N
the DT N
OG NNP N
[ NNP N
OS NNP N
: : N
hazard NN N
ratio NN N
( ( N
HR NNP N
) ) N
( ( N
female JJ N
: : N
male NN N
) ) N
= VBZ N
0·11 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
= VBZ N
0·00-1·03 JJ N
; : N
RFS NNP N
: : N
HR NNP N
( ( N
female JJ N
: : N
male NN N
) ) N
= VBZ N
0·27 CD N
; : N
95 CD N
% NN N
CI NNP N
= NNP N
0·05-0·97 JJ N
] NNP N
, , N
and CC N
no DT N
significant JJ N
differences NNS N
between IN N
males NNS N
and CC N
females NNS N
in IN N
the DT N
TG NNP N
. . N

We PRP N
conclude VBP N
that IN N
Rituximab NNP N
maintenance NN N
therapy NN N
improves VBZ N
survival NN N
in IN N
male JJ N
patients NNS N
with IN N
DLBCL NNP N
. . N

-DOCSTART- -X- O O 25465111

The DT N
durability NN N
of IN N
endovascular JJ N
coiling VBG N
versus NN N
neurosurgical JJ N
clipping NN N
of IN N
ruptured JJ 4_p
cerebral JJ 4_p
aneurysms NNS 4_p
: : 4_p
18 CD N
year NN N
follow-up NN N
of IN N
the DT N
UK NNP 4_p
cohort NN 4_p
of IN 4_p
the DT 4_p
International NNP 4_p
Subarachnoid NNP 4_p
Aneurysm NNP 4_p
Trial NNP 4_p
( ( 4_p
ISAT NNP 4_p
) ) 4_p
. . N

BACKGROUND NNP N
Previous NNP N
analyses NNS N
of IN N
the DT N
International NNP 4_p
Subarachnoid NNP 4_p
Aneurysm NNP 4_p
Trial NNP 4_p
( ( 4_p
ISAT NNP 4_p
) ) 4_p
cohort NN 4_p
have VBP N
reported VBN N
on IN N
the DT N
risks NNS N
of IN N
recurrent NN N
subarachnoid JJ N
haemorrhage NN N
and CC N
death NN N
or CC N
dependency NN N
for IN N
a DT N
minimum NN N
of IN N
5 CD N
years NNS N
and CC N
up RB N
to TO N
a DT N
maximum NN N
of IN N
14 CD N
years NNS N
after IN N
treatment NN N
of IN N
a DT N
ruptured JJ N
intracranial JJ N
aneurysm NN N
with IN N
either DT N
neurosurgical JJ N
clipping NN N
or CC N
endovascular JJ N
coiling NN N
. . N

At IN N
1 CD N
year NN N
there RB N
was VBD N
a DT N
7 CD N
% NN N
absolute NN N
and CC N
a DT N
24 CD N
% NN N
relative JJ N
risk NN N
reduction NN N
of IN N
death NN N
and CC N
dependency NN N
in IN N
the DT N
coiling VBG N
group NN N
compared VBN N
with IN N
the DT N
clipping VBG N
group NN N
, , N
but CC N
the DT N
medium-term JJ N
results NNS N
showed VBD N
the DT N
increased VBN N
need NN N
for IN N
re-treatment NN N
of IN N
the DT N
target NN N
aneurysm NN N
in IN N
the DT N
patients NNS N
given VBN N
coiling VBG N
. . N

We PRP N
report VBP N
the DT N
long-term JJ N
follow-up NN N
of IN N
patients NNS N
in IN N
this DT N
UK NNP N
cohort NN N
. . N

METHODS NNP N
In IN N
ISAT NNP N
, , N
patients NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
either DT N
neurosurgical JJ N
clipping NN N
or CC N
endovascular JJ N
coiling NN N
after IN N
a DT N
subarachnoid JJ N
haemorrhage NN N
, , N
assuming VBG N
treatment NN N
equipoise NN N
, , N
between IN N
Sept NNP N
12 CD N
, , N
1994 CD N
, , N
and CC N
May NNP N
1 CD N
, , N
2002 CD N
. . N

We PRP N
followed VBD N
up RP N
1644 CD N
patients NNS N
in IN N
22 CD N
UK NNP N
neurosurgical JJ N
centres NNS N
for IN N
death NN N
and CC N
clinical JJ N
outcomes NNS N
for IN N
10·0-18·5 JJ N
years NNS N
. . N

We PRP N
assessed VBD N
dependency NN N
as IN N
self-reported JJ N
modified JJ N
Rankin NNP N
scale NN N
score NN N
obtained VBN N
through IN N
yearly RB N
questionnaires NNS N
. . N

Data NNP N
for IN N
recurrent NN N
aneurysms NNS N
and CC N
rebleeding VBG N
events NNS N
were VBD N
collected VBN N
from IN N
questionnaires NNS N
and CC N
from IN N
hospital NN N
and CC N
general JJ N
practitioner NN N
records NNS N
. . N

The DT N
Office NNP N
for IN N
National NNP N
Statistics NNPS N
supplied VBD N
data NNS N
on IN N
deaths NNS N
. . N

This DT N
study NN N
is VBZ N
registered VBN N
, , N
number NN N
ISRCTN49866681 NNP N
. . N

FINDINGS NNP N
At IN N
10 CD N
years NNS N
, , N
674 CD N
( ( N
83 CD N
% NN N
) ) N
of IN N
809 CD N
patients NNS N
allocated VBD N
endovascular JJ N
coiling NN N
and CC N
657 CD N
( ( N
79 CD N
% NN N
) ) N
of IN N
835 CD N
patients NNS N
allocated JJ N
neurosurgical JJ N
clipping NN N
were VBD N
alive JJ N
( ( N
odds NNS N
ratio VBP N
[ CD N
OR NNP N
] $ N
1·35 CD N
, , N
95 CD N
% NN N
CI NNP N
1·06-1·73 CD N
) ) N
. . N

Of IN N
1003 CD N
individuals NNS N
who WP N
returned VBD N
a DT N
questionnaire NN N
at IN N
10 CD N
years NNS N
, , N
435 CD N
( ( N
82 CD N
% NN N
) ) N
patients NNS N
treated VBN N
with IN N
endovascular JJ N
coiling NN N
and CC N
370 CD N
( ( N
78 CD N
% NN N
) ) N
patients NNS N
treated VBN N
with IN N
neurosurgical JJ N
clipping VBG N
were VBD N
independent JJ N
( ( N
modified JJ N
Rankin NNP N
scale NN N
score NN N
0-2 JJ N
; : N
OR CC N
1·25 CD N
; : N
95 CD N
% NN N
CI NNP N
0·92-1·71 NN N
) ) N
. . N

Patients NNS N
in IN N
the DT N
endovascular JJ N
treatment NN N
group NN N
were VBD N
more RBR N
likely JJ N
to TO N
be VB N
alive JJ N
and CC N
independent JJ N
at IN N
10 CD N
years NNS N
than IN N
were VBD N
patients NNS N
in IN N
the DT N
neurosurgery NN N
group NN N
( ( N
OR NNP N
1·34 CD N
, , N
95 CD N
% NN N
CI NNP N
1·07-1·67 CD N
) ) N
. . N

33 CD N
patients NNS N
had VBD N
a DT N
recurrent JJ N
subarachnoid JJ N
haemorrhage NN N
more JJR N
than IN N
1 CD N
year NN N
after IN N
their PRP$ N
initial JJ N
haemorrhage NN N
( ( N
17 CD N
from IN N
the DT N
target NN N
aneurysm NN N
) ) N
. . N

INTERPRETATION NNP N
Although IN N
rates NNS N
of IN N
increased JJ N
dependency NN N
alone RB N
did VBD N
not RB N
differ VB N
between IN N
groups NNS N
, , N
the DT N
probability NN N
of IN N
death NN N
or CC N
dependency NN N
was VBD N
significantly RB N
greater JJR N
in IN N
the DT N
neurosurgical JJ N
group NN N
than IN N
in IN N
the DT N
endovascular JJ N
group NN N
. . N

Rebleeding VBG N
was VBD N
more RBR N
likely JJ N
after IN N
endovascular JJ N
coiling NN N
than IN N
after IN N
neurosurgical JJ N
clipping NN N
, , N
but CC N
the DT N
risk NN N
was VBD N
small JJ N
and CC N
the DT N
probability NN N
of IN N
disability-free JJ N
survival NN N
was VBD N
significantly RB N
greater JJR N
in IN N
the DT N
endovascular NN N
group NN N
than IN N
in IN N
the DT N
neurosurgical JJ N
group NN N
at IN N
10 CD N
years NNS N
. . N

FUNDING NN N
UK NNP N
Medical NNP N
Research NNP N
Council NNP N
. . N

-DOCSTART- -X- O O 25810108

A DT N
randomised JJ N
controlled VBN N
comparison NN N
between IN N
stimulating VBG N
and CC N
standard JJ N
catheters NNS N
for IN N
lumbar NN N
plexus NN N
block NN N
. . N

The DT N
aim NN N
of IN N
this DT N
randomised VBN N
, , N
prospective JJ N
, , N
blinded VBD N
study NN N
was VBD N
to TO N
evaluate VB N
if IN N
stimulating JJ N
catheters NNS N
can MD N
decrease VB N
the DT N
minimum JJ N
effective JJ N
anaesthetic JJ N
volume NN N
in IN N
50 CD N
% NN N
of IN N
patients NNS 4_p
during IN 4_p
lumbar JJ 4_p
plexus NN 4_p
block NN 4_p
using VBG N
mepivacaine JJ N
1.5 CD N
% NN N
compared VBN N
with IN N
standard JJ N
catheters NNS N
. . N

Fifty-eight JJ N
patients NNS N
of IN N
ASA NNP N
physical JJ N
status NN N
1-3 CD N
were VBD N
randomly RB N
allocated VBN N
to TO N
receive VB N
a DT N
lumbar NN 4_p
plexus NN 4_p
block NN 4_p
via IN N
a DT N
stimulating NN N
or CC N
standard JJ 4_p
catheter NN 4_p
, , N
with IN N
29 CD N
in IN N
each DT N
group NN N
. . N

The DT N
first JJ N
dose NN N
was VBD N
30 CD N
ml NN N
and CC N
subsequent JJ N
doses NNS N
were VBD N
determined VBN N
using VBG N
the DT N
up-and-down JJ N
staircase NN N
method NN N
. . N

The DT N
minimum JJ N
effective JJ N
anaesthetic JJ N
volume50 NN N
was VBD N
12.2 CD N
ml NN N
( ( N
95 CD N
% NN N
CI NNP N
7.3-17.1 NNP N
ml NN N
) ) N
using VBG N
the DT N
stimulating NN N
catheter NN N
and CC N
24.8 CD N
ml NN N
( ( N
95 CD N
% NN N
CI NNP N
23.2-27.5 CD N
ml NN N
) ) N
with IN N
the DT N
standard JJ N
catheter NN N
( ( N
p JJ N
< NNP N
0.0001 CD N
) ) N
. . N

Complete JJ N
lumbar NN N
plexus NN N
block NN N
was VBD N
achieved VBN N
with IN N
the DT N
initial JJ N
dose NN N
of IN N
mepivacaine NN N
in IN N
29 CD N
( ( N
100 CD N
% NN N
) ) N
patients NNS N
in IN N
the DT N
stimulating JJ N
catheter NN N
group NN N
and CC N
20 CD N
( ( N
69 CD N
% NN N
) ) N
patients NNS N
in IN N
the DT N
standard JJ N
catheter NN N
group NN N
( ( N
p JJ N
= NNP N
0.002 CD N
) ) N
. . N

This DT N
study NN N
showed VBD N
that IN N
use NN N
of IN N
a DT N
stimulating JJ N
catheter NN N
halves VBZ N
the DT N
minimum JJ N
effective JJ N
anaesthetic JJ N
volume50 NN N
of IN N
mepivacaine JJ N
1.5 CD N
% NN N
while IN N
increasing VBG N
the DT N
success NN N
rate NN N
in IN N
patients NNS N
receiving VBG N
continuous JJ N
lumbar NN N
plexus NN N
block NN N
. . N

-DOCSTART- -X- O O 21610189

Do VB N
sheltered VBD N
workshops NNS N
enhance VB N
employment NN N
outcomes NNS N
for IN N
adults NNS 4_p
with IN 4_p
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
? . N
This DT N
study NN N
investigated VBD N
whether IN N
sheltered VBN N
workshops NNS N
help VBP N
prepare VB N
individuals NNS N
with IN N
autism NN N
spectrum NN N
disorder NN N
( ( N
ASD NNP N
) ) N
for IN N
competitive JJ N
employment NN N
within IN N
the DT N
community NN N
. . N

Two CD N
groups NNS N
of IN N
individuals NNS N
were VBD N
compared VBN N
: : N
( ( 4_p
a DT 4_p
) ) 4_p
215 CD 4_p
supported VBN 4_p
employees NNS 4_p
who WP 4_p
were VBD 4_p
in IN 4_p
sheltered JJ 4_p
workshops NNS 4_p
prior RB 4_p
to TO 4_p
entering VBG 4_p
supported JJ 4_p
employment NN 4_p
and CC 4_p
( ( 4_p
b NN 4_p
) ) 4_p
215 CD 4_p
supported VBN 4_p
employees NNS 4_p
who WP 4_p
were VBD 4_p
not RB 4_p
in IN 4_p
sheltered JJ 4_p
workshops NNS 4_p
. . 4_p

Individuals NNS N
from IN N
both DT N
groups NNS N
were VBD N
matched VBN N
based VBN N
on IN N
their PRP$ N
primary JJ N
diagnosis NN N
, , N
secondary JJ N
diagnosis NN N
( ( N
if IN N
present NN N
) ) N
, , N
and CC N
gender NN N
. . N

Results NNS N
showed VBD N
that IN N
there EX N
were VBD N
no DT N
differences NNS N
in IN N
rates NNS N
of IN N
employment NN N
between IN N
these DT N
two CD N
groups NNS N
. . N

However RB N
, , N
individuals NNS N
who WP N
participated VBD N
in IN N
sheltered JJ N
workshops NNS N
earned VBD N
significantly RB N
less JJR N
( ( N
US NNP N
$ $ N
129.36 CD N
versus NN N
US NNP N
$ $ N
191.42 CD N
per IN N
week NN N
) ) N
, , N
and CC N
cost NN N
significantly RB N
more RBR N
to TO N
serve VB N
( ( N
US NNP N
$ $ N
6,065.08 CD N
versus NN N
US NNP N
$ $ N
2,440.60 CD N
) ) N
, , N
than IN N
their PRP$ N
non-sheltered JJ N
workshop NN N
peers NNS N
. . N

Results NNS N
presented VBD N
here RB N
suggest VBP N
that IN N
individuals NNS N
with IN N
ASD NNP N
achieve VBP N
better RBR N
vocational JJ N
outcomes NNS N
if IN N
they PRP N
do VBP N
not RB N
participate VB N
in IN N
sheltered JJ N
workshops NNS N
prior RB N
to TO N
enrolling VBG N
in IN N
supported JJ N
employment NN N
. . N

-DOCSTART- -X- O O 14596755

Including VBG N
a DT N
'no CD N
active JJ N
intervention NN N
' POS N
arm NN N
in IN N
surgical JJ N
trials NNS N
is VBZ N
possible JJ N
: : N
evidence NN N
from IN N
the DT N
CLasP NNP N
randomised VBD N
trial NN N
. . N

OBJECTIVES UH N
To TO N
examine VB N
the DT N
impact NN N
of IN N
including VBG N
a DT N
'no CD N
active JJ N
intervention NN N
' POS N
arm NN N
( ( N
called VBN N
'conservative CD N
management NN N
' '' N
) ) N
in IN N
a DT N
randomised JJ N
controlled VBN N
trial NN N
comparing VBG N
treatments NNS N
( ( N
including VBG N
surgery NN N
) ) N
for IN N
men NNS N
with IN N
lower JJR N
urinary JJ N
tract NN N
symptoms NNS N
related VBN N
to TO N
benign VB 4_p
prostatic JJ 4_p
enlargement NN 4_p
. . 4_p

METHODS NNP N
Outcomes VBZ N
7.5 CD N
months NNS N
after IN N
randomisation NN N
were VBD N
acceptability NN N
of IN N
randomisation NN N
, , N
overall JJ N
acceptability NN N
of IN N
and CC N
satisfaction NN N
with IN N
conservative JJ N
management NN N
, , N
impact NN N
on IN N
quality NN N
of IN N
life NN N
, , N
perceived VBD N
need NN N
for IN N
further JJ N
treatment NN N
and CC N
treatment NN N
failure NN N
( ( N
defined VBD N
a DT N
priori NN N
) ) N
. . N

RESULTS NNP N
In IN N
total JJ N
, , N
177 CD N
( ( N
out IN N
of IN N
755 CD N
) ) N
patients NNS N
refused VBD N
randomisation NN N
, , N
including VBG N
31 CD N
% NN N
who WP N
did VBD N
not RB N
want VB N
surgery NN N
and CC N
22 CD N
% NN N
who WP N
wanted VBD N
surgery NN N
. . N

Most JJS N
men NNS N
randomised VBD N
to TO N
conservative JJ N
management NN N
were VBD N
willing JJ N
to TO N
undertake VB N
it PRP N
as IN N
part NN N
of IN N
a DT N
trial NN N
but CC N
at IN N
the DT N
end NN N
of IN N
the DT N
trial NN N
they PRP N
were VBD N
divided VBN N
between IN N
those DT N
who WP N
wanted VBD N
to TO N
continue VB N
with IN N
it PRP N
and CC N
those DT N
who WP N
expected VBD N
surgery NN N
. . N

At IN N
follow-up JJ N
, , N
39 CD N
% NN N
of IN N
conservative JJ N
management NN N
patients NNS N
requested VBD N
surgery NN N
, , N
and CC N
interference NN N
of IN N
symptoms NNS N
with IN N
life NN N
and CC N
an DT N
unsuccessful JJ N
outcome NN N
were VBD N
more JJR N
commonly RB N
reported VBN N
in IN N
this DT N
arm NN N
. . N

There EX N
were VBD N
no DT N
appreciable JJ N
differences NNS N
between IN N
treatment NN N
groups NNS N
in IN N
terms NNS N
of IN N
treatment NN N
failures NNS N
. . N

CONCLUSIONS NNP N
Including VBG N
a DT N
'no CD N
active JJ N
intervention NN N
' POS N
arm NN N
did VBD N
not RB N
appear VB N
to TO N
have VB N
a DT N
detrimental JJ N
effect NN N
on IN N
patient JJ N
recruitment NN N
or CC N
the DT N
completion NN N
of IN N
this DT N
trial NN N
in IN N
the DT N
short-term JJ N
; : N
overall JJ N
, , N
conservative JJ N
management NN N
was VBD N
successfully RB N
completed VBN N
by IN N
the DT N
majority NN N
of IN N
patients NNS N
during IN N
the DT N
trial NN N
period NN N
, , N
suggesting VBG N
that IN N
researchers NNS N
need VBP N
not RB N
avoid VB N
including VBG N
a DT N
no-intervention JJ N
arm NN N
in IN N
surgical JJ N
trials NNS N
as RB N
long RB N
as IN N
they PRP N
take VBP N
care NN N
with IN N
its PRP$ N
presentation NN N
. . N

-DOCSTART- -X- O O 219802

Estrogen NNP N
therapy NN N
for IN N
severe JJ N
persistent JJ 4_p
depressions NNS 4_p
in IN N
women NNS N
. . N

Positive JJ N
results NNS N
are VBP N
reported VBN N
from IN N
a DT N
double-blind JJ N
study NN N
of IN N
estrogen NN N
therapy NN N
administered VBD N
to TO N
severely RB 4_p
depressed JJ 4_p
, , N
inpatient JJ N
women NNS N
who WP N
had VBD N
failed VBN N
to TO N
respond VB N
to TO N
various JJ N
conventional JJ N
treatments NNS N
of IN N
depression NN 4_p
. . N

Large JJ N
doses NNS N
of IN N
oral JJ N
conjugated VBN N
estrogen NN N
were VBD N
administered VBN N
for IN N
a DT N
three-month JJ N
period NN N
to TO N
23 CD N
premenopausal NN N
and CC N
postmenopausal JJ N
inpatient JJ N
women NNS N
. . N

Placebos NNS N
were VBD N
administered VBN N
for IN N
a DT N
comparable JJ N
period NN N
to TO N
17 CD N
similar JJ N
patients NNS N
. . N

The DT N
posttreatment JJ N
Hamilton NNP N
ratings NNS N
of IN N
depression NN N
were VBD N
significantly RB N
reduced VBN N
in IN N
the DT N
estrogen-treated JJ N
group NN N
, , N
but CC N
not RB N
in IN N
the DT N
placebo NN N
group NN N
. . N

Possible JJ N
physiological JJ N
mechanisms NNS N
are VBP N
discussed VBN N
. . N

The DT N
risk-benefit JJ N
ratio NN N
for IN N
estrogen NN N
therapy NN N
of IN N
depression NN N
in IN N
these DT N
patients NNS N
was VBD N
judged VBN N
to TO N
be VB N
favorable JJ N
. . N

However RB N
, , N
periodic JJ N
endometrial JJ N
biopsies NNS N
are VBP N
required VBN N
to TO N
monitor VB N
the DT N
endometrial JJ N
response NN N
of IN N
women NNS N
receiving VBG N
high JJ N
doses NNS N
of IN N
estrogens NNS N
. . N

-DOCSTART- -X- O O 17045894

Enhanced NNP N
baroreceptor NN N
control NN N
of IN N
the DT N
cardiovascular JJ N
system NN N
by IN N
polyunsaturated JJ N
Fatty NNP N
acids NNS N
in IN N
heart NN 4_p
failure NN 4_p
patients NNS 4_p
. . 4_p

OBJECTIVES IN N
The DT N
intention NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
test VB N
the DT N
hypothesis NN N
that WDT N
, , N
in IN N
heart NN 4_p
failure NN 4_p
patients NNS 4_p
, , N
dietary JJ N
supplementation NN N
of IN N
polyunsaturated JJ N
fatty JJ N
acids NNS N
( ( N
PUFA NNP N
) ) N
enhances VBZ N
arterial JJ N
baroreceptor NN N
control NN N
of IN N
the DT N
cardiovascular JJ N
system NN N
. . N

BACKGROUND NNP N
Administration NNP N
of IN N
PUFA NNP N
reduces VBZ N
the DT N
risk NN N
of IN N
life-threatening JJ N
arrhythmias NNS N
in IN N
patients NNS N
surviving VBG N
myocardial JJ N
infarction NN N
. . N

This DT N
might MD N
result VB N
from IN N
potentiation NN N
of IN N
arterial JJ N
baroreflexes NNS N
, , N
but CC N
whether IN N
or CC N
not RB N
PUFA NNP N
enhance NN N
baroreflex NN N
function NN N
has VBZ N
never RB N
been VBN N
studied VBN N
in IN N
humans NNS N
. . N

METHODS NNP N
Patients NNPS N
with IN N
post-myocardial JJ N
infarction NN N
left VBD N
ventricular JJ N
dysfunction NN N
underwent JJ N
beat-to-beat JJ N
blood NN N
pressure NN N
( ( N
BP NNP N
) ) N
( ( N
Finapres NNP N
, , N
Ohmeda NNP N
Inc. NNP N
, , N
Englewood NNP N
, , N
Colorado NNP N
) ) N
and CC N
R-R JJ N
interval NN N
( ( N
electrocardiogram NN N
) ) N
recording NN N
; : N
baroreceptor NN N
reflexes NNS N
were VBD N
assessed VBN N
from IN N
the DT N
bradycardic NN N
and CC N
depressor NN N
responses NNS N
to TO N
graded VB N
neck NN N
suction NN N
( ( N
NS NNP N
) ) N
as RB N
well RB N
as IN N
by IN N
computation NN N
of IN N
the DT N
alpha NN N
" NNP N
spontaneous JJ N
" NNP N
baroreflex NN N
sensitivity NN N
index NN N
. . N

Assessments NNS N
were VBD N
repeated VBN N
after IN N
prolonged JJ N
treatment NN N
with IN N
PUFA NNP N
( ( N
2 CD N
g/die NN N
, , N
n JJ N
= NNP N
15 CD N
) ) N
or CC N
placebo NN N
( ( N
n JJ N
= NNP N
10 CD N
) ) N
. . N

RESULTS NNP N
Baseline NNP N
BP NNP N
and CC N
R-R NNP N
interval NN N
were VBD N
unaffected VBN N
by IN N
PUFA NNP N
. . N

Both DT N
reflex JJ N
depressor NN N
and CC N
bradycardic JJ N
responses NNS N
to TO N
NS NNP N
increased VBN N
after IN N
PUFA NNP N
( ( N
respectively RB N
from IN N
-0.09 JJ N
+/- JJ N
0.01 CD N
to TO N
-0.16 VB N
+/- JJ N
0.01 CD N
mm NN N
Hg NNP N
x NNP N
mm NN N
Hg NNP N
( ( N
-1 NNP N
) ) N
, , N
p JJ N
< NN N
0.01 CD N
, , N
and CC N
from IN N
1.25 CD N
+/- JJ N
0.9 CD N
to TO N
1.76 CD N
+/- JJ N
1.1 CD N
ms NN N
x NNP N
mm NN N
Hg NNP N
( ( N
-1 NNP N
) ) N
, , N
p JJ N
< NNP N
0.04 CD N
) ) N
but CC N
not RB N
after IN N
placebo NN N
. . N

The DT N
spontaneous JJ N
baroreflex JJ N
sensitivity NN N
increased VBN N
in IN N
the DT N
PUFA NNP N
( ( N
from IN N
8.99 CD N
+/- JJ N
1.4 CD N
to TO N
12.2 CD N
+/- JJ N
1.2 CD N
ms NN N
x NNP N
mm NN N
Hg NNP N
( ( N
-1 NNP N
) ) N
, , N
p JJ N
< NNP N
0.02 CD N
) ) N
but CC N
not RB N
in IN N
the DT N
placebo NN N
group NN N
. . N

Polyunsaturated VBN N
fatty JJ N
acids NNS N
( ( N
but CC N
not RB N
placebo VB N
) ) N
treatment NN N
also RB N
significantly RB N
increased VBD N
R-R NNP N
interval JJ N
total JJ N
variance NN N
and CC N
low-frequency NN N
and CC N
high-frequency NN N
spectral JJ N
powers NNS N
. . N

CONCLUSIONS NNP N
Dietary NNP N
PUFA NNP N
supplementation NN N
markedly RB N
potentiates VBZ N
baroreflex JJ N
function NN N
and CC N
enhances NNS N
heart NN N
rate NN N
variability NN N
in IN N
patients NNS N
with IN N
stable JJ N
congestive JJ N
heart NN N
failure NN N
. . N

-DOCSTART- -X- O O 11246578

Work-related JJ 4_p
stress NN 4_p
and CC 4_p
early JJ 4_p
atherosclerosis NN 4_p
. . 4_p

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
examine VB N
the DT N
link NN N
between IN N
work-related JJ N
stress NN N
and CC N
early JJ 4_p
atherosclerosis NN 4_p
as IN N
measured VBN N
by IN N
common JJ N
carotid JJ N
artery JJ N
intima-media JJ N
thickness NN N
and CC N
focal JJ N
lesions NNS N
in IN N
the DT N
common JJ N
carotid NN N
artery NN N
and CC N
bifurcation NN N
. . N

Four CD N
hundred VBD N
sixty-seven JJ N
members NNS N
of IN N
an DT N
occupational JJ N
cohort NN N
( ( N
total JJ N
N NNP N
= NNP N
573 CD N
) ) N
were VBD N
examined VBN N
via IN N
questionnaires NNS N
and CC N
B-mode NNP N
ultrasound NN N
. . N

We PRP N
used VBD N
multiple JJ N
linear JJ N
and CC N
logistic JJ N
models NNS N
to TO N
regress VB N
lesion NN N
risk NN N
and CC N
intima-media JJ N
thickness NN N
on IN N
work-related JJ N
stress NN N
scores NNS N
from IN N
a DT N
questionnaire NN N
administered VBN N
at IN N
an DT N
18-month JJ N
follow-up JJ N
examination NN N
. . N

In IN N
an DT N
age-adjusted JJ N
model NN N
, , N
the DT N
prevalence NN N
of IN N
carotid JJ N
lesions NNS N
among IN N
men NNS N
scoring VBG N
in IN N
the DT N
highest JJS N
stress NN N
quintile NN N
was VBD N
36 CD N
% NN N
compared VBN N
with IN N
21 CD N
% NN N
among IN N
men NNS N
in IN N
the DT N
lowest JJS N
quintile NN N
. . N

We PRP N
also RB N
observed VBD N
an DT N
increase NN N
in IN N
intima-media JJ N
thickness NN N
in IN N
the DT N
highest JJS N
quintile JJ N
relative NN N
to TO N
the DT N
lowest JJS N
( ( N
difference NN N
= RB N
0.048 CD N
+/- JJ N
0.025 CD N
mm NN N
) ) N
among IN N
men NNS N
. . N

Among IN N
women NNS N
, , N
stress NN N
was VBD N
not RB N
related VBN N
to TO N
the DT N
prevalence NN N
of IN N
lesions NNS N
or CC N
intima-media JJ N
thickness NN N
. . N

These DT N
findings NNS N
suggest VBP N
that IN N
men NNS N
with IN N
greater JJR N
work-related JJ 4_p
stress NN 4_p
are VBP N
at IN N
increased VBN N
risk NN N
for IN N
atherosclerotic JJ N
disease NN N
. . N

Women NNP N
in IN N
this DT N
age NN N
group NN N
may MD N
be VB N
protected VBN N
from IN N
such JJ N
effects NNS N
, , N
or CC N
current JJ N
work-place JJ N
questionnaires NNS N
may MD N
not RB N
accurately RB N
assess JJ N
stress NN N
in IN N
women NNS N
. . N

-DOCSTART- -X- O O 21484517

The DT N
effects NNS N
of IN N
face NN N
expertise NN N
training NN N
on IN N
the DT N
behavioral JJ N
performance NN N
and CC N
brain NN N
activity NN N
of IN N
adults NNS N
with IN N
high JJ N
functioning VBG N
autism NN N
spectrum NN N
disorders NNS N
. . N

The DT N
effect NN N
of IN N
expertise NN N
training NN N
with IN N
faces VBZ N
was VBD N
studied VBN N
in IN N
adults NNS N
with IN N
ASD NNP N
who WP N
showed VBD N
initial JJ N
impairment NN N
in IN N
face NN N
recognition NN N
. . N

Participants NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
a DT N
computerized JJ N
training NN N
program NN N
involving VBG N
either CC N
faces VBZ N
or CC N
houses NNS N
. . N

Pre- JJ N
and CC N
post-testing NN N
included VBD N
standardized JJ N
and CC N
experimental JJ N
measures NNS N
of IN N
behavior NN N
and CC N
event-related JJ N
brain NN N
potentials NNS N
( ( N
ERPs NNP N
) ) N
, , N
as RB N
well RB N
as IN N
interviews NNS N
after IN N
training NN N
. . N

After IN N
training NN N
, , N
all DT N
participants NNS N
met VBD N
behavioral JJ N
criteria NNS N
for IN N
expertise NN N
with IN N
the DT N
specific JJ N
stimuli NN N
on IN N
which WDT N
they PRP N
received VBD N
training NN N
. . N

Scores NNS N
on IN N
standardized JJ N
measures NNS N
improved VBN N
after IN N
training VBG N
for IN N
both DT N
groups NNS N
, , N
but CC N
only RB N
the DT N
face NN N
training NN N
group NN N
showed VBD N
an DT N
increased JJ N
face NN N
inversion NN N
effect NN N
behaviorally RB N
and CC N
electrophysiological JJ N
changes NNS N
to TO N
faces VBZ N
in IN N
the DT N
P100 NNP N
component NN N
. . N

These DT N
findings NNS N
suggest VBP N
that IN N
individuals NNS N
with IN N
ASD NNP N
can MD N
gain VB N
expertise NN N
in IN N
face NN N
processing NN N
through IN N
training NN N
. . N

-DOCSTART- -X- O O 15482502

A DT N
new JJ N
social JJ N
communication NN N
intervention NN N
for IN N
children NNS 4_p
with IN 4_p
autism NN 4_p
: : 4_p
pilot NN N
randomised VBD N
controlled VBN N
treatment NN N
study NN N
suggesting VBG N
effectiveness NN N
. . N

BACKGROUND NNP N
Psychosocial NNP N
treatments NNS N
are VBP N
the DT N
mainstay NN N
of IN N
management NN N
of IN N
autism NN N
in IN N
the DT N
UK NNP N
but CC N
there EX N
is VBZ N
a DT N
notable JJ N
lack NN N
of IN N
a DT N
systematic JJ N
evidence NN N
base NN N
for IN N
their PRP$ N
effectiveness NN N
. . N

Randomised VBN N
controlled JJ N
trial NN N
( ( N
RCT NNP N
) ) N
studies NNS N
in IN N
this DT N
area NN N
have VBP N
been VBN N
rare JJ N
but CC N
are VBP N
essential JJ N
because IN N
of IN N
the DT N
developmental JJ N
heterogeneity NN N
of IN N
the DT N
disorder NN N
. . N

We PRP N
aimed VBD N
to TO N
test VB N
a DT N
new JJ N
theoretically RB N
based VBN N
social JJ N
communication NN N
intervention NN N
targeting VBG N
parental JJ N
communication NN N
in IN N
a DT N
randomised JJ N
design NN N
against IN N
routine JJ N
care NN N
alone RB N
. . N

METHODS NNP N
The DT N
intervention NN N
was VBD N
given VBN N
in IN N
addition NN N
to TO N
existing VBG N
care NN N
and CC N
involved VBN N
regular JJ N
monthly JJ N
therapist NN N
contact NN N
for IN N
6 CD N
months NNS N
with IN N
a DT N
further JJ N
6 CD N
months NNS N
of IN N
2-monthly JJ N
consolidation NN N
sessions NNS N
. . N

It PRP N
aimed VBD N
to TO N
educate VB N
parents NNS N
and CC N
train VB N
them PRP N
in IN N
adapted VBN N
communication NN N
tailored VBN N
to TO N
their PRP$ N
child NN N
's POS N
individual JJ N
competencies NNS N
. . N

Twenty-eight JJ N
children NNS N
with IN N
autism NN N
were VBD N
randomised VBN N
between IN N
this DT N
treatment NN N
and CC N
routine JJ N
care NN N
alone RB N
, , N
stratified VBD N
for IN N
age NN N
and CC N
baseline NN N
severity NN N
. . N

Outcome NNP N
was VBD N
measured VBN N
at IN N
12 CD N
months NNS N
from IN N
commencement NN N
of IN N
intervention NN N
, , N
using VBG N
standardised JJ N
instruments NNS N
. . N

RESULTS NNP N
All NNP N
cases NNS N
studied VBD N
met VBN N
full JJ N
Autism NNP N
Diagnostic NNP N
Interview NNP N
( ( N
ADI NNP N
) ) N
criteria NN N
for IN N
classical JJ N
autism NN N
. . N

Treatment NN N
and CC N
controls NNS N
had VBD N
similar JJ N
routine JJ N
care NN N
during IN N
the DT N
study NN N
period NN N
and CC N
there EX N
were VBD N
no DT N
study NN N
dropouts VBZ N
after IN N
treatment NN N
had VBD N
started VBN N
. . N

The DT N
active JJ N
treatment NN N
group NN N
showed VBD N
significant JJ N
improvement NN N
compared VBN N
with IN N
controls NNS N
on IN N
the DT N
primary JJ N
outcome JJ N
measure NN N
-- : N
Autism NNP N
Diagnostic NNP N
Observation NNP N
Schedule NNP N
( ( N
ADOS NNP N
) ) N
total NN N
score NN N
, , N
particularly RB N
in IN N
reciprocal JJ N
social JJ N
interaction NN N
-- : N
and CC N
on IN N
secondary JJ N
measures NNS N
of IN N
expressive JJ N
language NN N
, , N
communicative JJ N
initiation NN N
and CC N
parent-child JJ N
interaction NN N
. . N

Suggestive JJ N
but CC N
non-significant JJ N
results NNS N
were VBD N
found VBN N
in IN N
Vineland NNP N
Adaptive NNP N
Behaviour NNP N
Scales NNP N
( ( N
Communication NNP N
Sub-domain NNP N
) ) N
and CC N
ADOS NNP N
stereotyped VBD N
and CC N
restricted VBD N
behaviour NN N
domain NN N
. . N

CONCLUSIONS VB N
A DT N
Randomised JJ N
Treatment NNP N
Trial NNP N
design NN N
of IN N
this DT N
kind NN N
in IN N
classical JJ N
autism NN N
is VBZ N
feasible JJ N
and CC N
acceptable JJ N
to TO N
patients NNS N
. . N

This DT N
pilot NN N
study NN N
suggests VBZ N
significant JJ N
additional JJ N
treatment NN N
benefits NNS N
following VBG N
a DT N
targeted JJ N
( ( N
but CC N
relatively RB N
non-intensive JJ N
) ) N
dyadic VBZ N
social JJ N
communication NN N
treatment NN N
, , N
when WRB N
compared VBN N
with IN N
routine JJ N
care NN N
. . N

The DT N
study NN N
needs VBZ N
replication NN N
on IN N
larger JJR N
and CC N
independent JJ N
samples NNS N
. . N

It PRP N
should MD N
encourage VB N
further JJ N
RCT NNP N
designs NNS N
in IN N
this DT N
area NN N
. . N

-DOCSTART- -X- O O 8828933

Regular JJ N
replacement NN N
of IN N
extended VBN 4_p
wear NN 4_p
rigid JJ 4_p
gas NN 4_p
permeable JJ 4_p
contact NN 4_p
lenses NNS 4_p
. . N

PURPOSE NNP N
While IN N
the DT N
benefits NNS N
of IN N
planned JJ N
replacement NN N
of IN N
soft JJ N
contact NN N
lenses NNS N
have VBP N
been VBN N
investigated VBN N
, , N
the DT N
question NN N
of IN N
whether IN N
there EX N
are VBP N
any DT N
clinical JJ N
benefits NNS N
to TO N
planned VBN N
replacement NN N
of IN N
rigid JJ N
gas NN N
permeable NN N
( ( N
RGP NNP N
) ) N
lenses VBZ N
does VBZ N
not RB N
appear VB N
to TO N
have VB N
been VBN N
addressed VBN N
experimentally RB N
. . N

We PRP N
aimed VBD N
to TO N
determine VB N
the DT N
benefits NNS N
of IN N
regular JJ N
replacement NN N
of IN N
extended VBN N
wear NN N
RGP NNP N
contact NN N
lenses VBZ N
. . N

METHODS NNP N
We PRP N
conducted VBD N
a DT N
prospective JJ N
, , N
single-center JJ 4_p
, , 4_p
controlled VBN 4_p
, , 4_p
double-masked JJ 4_p
study NN 4_p
of IN N
39 CD N
RGP NNP 4_p
lens VBZ 4_p
wearers NNS 4_p
. . N

The DT N
subjects NNS N
were VBD N
divided VBN N
into IN N
two CD N
groups NNS N
and CC N
wore NN N
extended VBD N
wear JJ N
Quantum NNP N
2 CD N
lenses NNS N
( ( N
Dk NNP N
= NNP N
120 CD N
) ) N
for IN N
12 CD N
months NNS N
. . N

Subjects NNS N
in IN N
Group NNP N
I PRP N
replaced VBD N
lenses NNS N
every DT N
3 CD N
months NNS N
, , N
whereas VBP N
those DT N
in IN N
Group NNP N
II NNP N
were VBD N
not RB N
scheduled VBN N
to TO N
replace VB N
their PRP$ N
lenses NNS N
. . N

The DT N
integrity NN N
of IN N
the DT N
lenses NNS N
and CC N
the DT N
ocular JJ N
responses NNS N
to TO N
lens NNS N
wear WDT N
were VBD N
monitored VBN N
in IN N
both DT N
groups NNS N
every DT N
three CD N
months NNS N
. . N

RESULTS NNP N
Compared VBD N
to TO N
lenses NNS N
worn VBN N
by IN N
subjects NNS N
in IN N
Group NNP N
I PRP N
, , N
lenses VBZ N
worn VBN N
by IN N
Group NNP N
II NNP N
subjects VBZ N
showed VBD N
significantly RB N
more RBR N
mucous JJ N
coating NN N
, , N
lens VBZ N
binding NN N
, , N
and CC N
corneal NN N
staining NN N
over IN N
time NN N
( ( N
P NNP N
< NNP N
0.05 CD N
; : N
ANCOVA NNP N
) ) N
. . N

There EX N
was VBD N
no DT N
difference NN N
in IN N
microcystic JJ N
or CC N
tarsal JJ N
conjunctiva JJ N
response NN N
, , N
lens VBZ N
comfort NN N
, , N
refractive JJ N
change NN N
, , N
or CC N
visual JJ N
acuity NN N
between IN N
the DT N
two CD N
groups NNS N
. . N

CONCLUSIONS NNP N
We PRP N
advocate VBP N
that DT N
to TO N
maintain VB N
optimal JJ N
lens NNS N
integrity NN N
and CC N
ocular JJ N
health NN N
, , N
RGP NNP N
lenses VBZ N
used VBN N
for IN N
extended JJ N
wear NN N
should MD N
be VB N
replaced VBN N
every DT N
3 CD N
to TO N
6 CD N
months NNS N
. . N

-DOCSTART- -X- O O 23827399

Percutaneous JJ N
coronary JJ N
intervention NN N
in IN N
patients NNS N
with IN N
previous JJ N
coronary JJ N
artery NN N
bypass NN N
grafting NN N
( ( N
from IN N
the DT N
j-Cypher JJ N
Registry NNP N
) ) N
. . N

A DT N
paucity NN N
of IN N
data NNS N
is VBZ N
available JJ N
from IN N
large-scale JJ N
studies NNS N
evaluating VBG N
the DT N
long-term JJ N
outcomes NNS N
of IN N
percutaneous JJ N
coronary JJ N
intervention NN N
in IN N
patients NNS N
who WP N
had VBD N
previously RB N
undergone JJ N
coronary JJ N
artery NN N
bypass NN N
grafting NN N
( ( N
CABG NNP N
) ) N
in IN N
the DT N
drug-eluting JJ N
stent NN N
era NN N
. . N

Of IN N
12,812 CD N
patients NNS N
who WP N
had VBD N
undergone JJ N
sirolimus-eluting JJ N
stent NN N
implantation NN N
in IN N
the DT N
j-Cypher JJ N
registry NN N
, , N
919 CD N
( ( N
7.2 CD N
% NN N
) ) N
had VBD N
a DT N
history NN N
of IN N
CABG NNP N
and CC N
had VBD N
significantly RB N
higher JJR N
crude JJ N
5-year JJ N
mortality NN N
( ( N
19.9 CD N
% NN N
vs JJ N
14.0 CD N
% NN N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
. . N

After IN N
adjusting VBG N
for IN N
confounders NNS N
, , N
the DT N
excess JJ N
risk NN N
of IN N
death NN N
was VBD N
no RB N
longer RBR N
significant JJ N
( ( N
hazard JJ N
ratio NN N
0.99 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
0.83 CD N
to TO N
1.18 CD N
, , N
p NN N
= NNP N
0.90 CD N
) ) N
, , N
and CC N
the DT N
adjusted VBN N
risk NN N
of IN N
target NN N
lesion NN N
revascularization NN N
was VBD N
significantly RB N
higher JJR N
in IN N
patients NNS N
with IN N
previous JJ N
CABG NNP N
than IN N
in IN N
those DT N
without IN N
( ( N
hazard NN N
ratio NN N
1.25 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
1.06 CD N
to TO N
1.47 CD N
, , N
p NN N
= NNP N
0.01 CD N
) ) N
. . N

Of IN N
the DT N
patients NNS N
with IN N
previous JJ N
CABG NNP N
, , N
those DT N
who WP N
had VBD N
undergone JJ N
≥1 NNP N
saphenous JJ N
vein NN N
graft NN N
intervention NN N
had VBD N
significantly RB N
higher JJR N
adjusted JJ N
risks NNS N
of IN N
cardiac JJ N
death NN N
( ( N
hazard JJ N
ratio NN N
2.21 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
1.26 CD N
to TO N
3.76 CD N
, , N
p NN N
= NNP N
0.01 CD N
) ) N
, , N
myocardial JJ N
infarction NN N
( ( N
hazard JJ N
ratio NN N
2.56 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
1.10 CD N
to TO N
5.60 CD N
, , N
p NN N
= NNP N
0.03 CD N
) ) N
, , N
target NN N
lesion NN N
revascularization NN N
( ( N
hazard JJ N
ratio NN N
2.65 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
1.82 CD N
to TO N
3.81 CD N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
, , N
and CC N
definite JJ N
stent NN N
thrombosis NN N
( ( N
hazard JJ N
ratio NN N
7.70 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
1.99 CD N
to TO N
29.1 CD N
, , N
p NN N
= NNP N
0.004 CD N
) ) N
compared VBN N
with IN N
those DT N
who WP N
underwent VBP N
percutaneous JJ N
coronary JJ N
intervention NN N
only RB N
for IN N
the DT N
native JJ N
coronary JJ N
artery NN N
. . N

In IN N
conclusion NN N
, , N
the DT N
adjusted JJ N
mortality NN N
was VBD N
similar JJ N
between IN N
patients NNS N
with IN N
and CC N
without IN N
previous JJ N
CABG NNP N
, , N
despite IN N
a DT N
significantly RB N
different JJ N
risk NN N
of IN N
target NN N
lesion NN N
revascularization NN N
. . N

Among IN N
the DT N
patients NNS N
with IN N
previous JJ N
CABG NNP N
, , N
those DT N
with IN N
saphenous JJ N
vein NN N
graft NN N
intervention NN N
using VBG N
a DT N
first-generation JJ N
drug-eluting JJ N
stent NN N
had VBD N
worse JJR N
clinical JJ N
outcomes NNS N
than IN N
those DT N
with IN N
a DT N
native JJ N
coronary JJ N
artery NN N
target NN N
only RB N
. . N

-DOCSTART- -X- O O 22695168

The DT N
effects NNS N
of IN N
orthotic JJ N
heel NN N
lifts NNS N
on IN N
Achilles NNP N
tendon NNP N
force NN N
and CC N
strain NN N
during IN N
running VBG N
. . N

This DT N
study NN N
assessed VBD N
the DT N
effects NNS N
of IN N
orthotic JJ N
heel NN N
lifts NNS N
on IN N
Achilles NNP N
tendon NN N
( ( N
AT NNP N
) ) N
force NN N
and CC N
strain NN N
during IN N
running VBG N
. . N

Ten CD N
females NNS N
ran VBD N
barefoot NN N
over IN N
a DT N
force NN N
plate NN N
in IN N
three CD N
conditions NNS N
: : N
no DT N
heel NN N
lifts NNS N
( ( N
NHL NNP N
) ) N
, , N
with IN N
12 CD N
mm NNS N
heel JJ N
lifts NNS N
( ( N
12HL CD N
) ) N
and CC N
with IN N
18 CD N
mm NNS N
heel JJ N
lifts NNS N
( ( N
18HL CD N
) ) N
. . N

Kinematics NNS N
for IN N
the DT N
right JJ N
lower JJR N
limb NN N
were VBD N
collected VBN N
( ( N
200 CD N
Hz NNP N
) ) N
. . N

AT NNP N
force NN N
was VBD N
calculated VBN N
from IN N
inverse JJ N
dynamics NNS N
. . N

AT NNP N
strain NN N
was VBD N
determined VBN N
from IN N
kinematics NNS N
and CC N
ultrasound JJ N
images NNS N
of IN N
medial JJ N
gastrocnemius NN N
( ( N
50 CD N
Hz NNP N
) ) N
. . N

Peak NNP N
AT NNP N
strain NN N
was VBD N
less JJR N
for IN N
18HL CD N
( ( N
5.5 CD N
± RB N
4.4 CD N
% NN N
) ) N
than IN N
for IN N
NHL NNP N
( ( N
7.4 CD N
± RB N
4.2 CD N
% NN N
) ) N
( ( N
p JJ N
= NNP N
.029 NNP N
, , N
effect NN N
size NN N
[ NNP N
ES NNP N
] NNP N
= NNP N
0.44 CD N
) ) N
but CC N
not RB N
for IN N
12HL CD N
( ( N
5.8 CD N
± RB N
4.8 CD N
% NN N
) ) N
versus NN N
NHL NNP N
( ( N
ES NNP N
= NNP N
0.35 CD N
) ) N
. . N

Peak NNP N
AT NNP N
force NN N
was VBD N
significantly RB N
( ( N
p JJ N
= NNP N
.024 NNP N
, , N
ES NNP N
= NNP N
0.42 CD N
) ) N
less JJR N
for IN N
18HL CD N
( ( N
2382 CD N
± $ N
717 CD N
N NNP N
) ) N
than IN N
for IN N
NHL NNP N
( ( N
2710 CD N
± $ N
830 CD N
N NNP N
) ) N
but CC N
not RB N
for IN N
12HL CD N
( ( N
2538 CD N
± $ N
823 CD N
N NNP N
, , N
ES NNP N
= NNP N
0.21 CD N
) ) N
. . N

The DT N
18HL CD N
reduced VBD N
ankle JJ N
dorsiflexion NN N
but CC N
not RB N
flexion-extension JJ N
ankle NN N
moments NNS N
and CC N
increased VBD N
the DT N
AT NNP N
moment NN N
arm NN N
compared VBN N
with IN N
NHL NNP N
. . N

Thus NNP N
, , N
18HL CD N
reduced VBN N
force NN N
and CC N
strain NN N
on IN N
the DT N
AT NNP N
during IN N
running VBG N
via IN N
a DT N
reduction NN N
in IN N
dorsiflexion NN N
, , N
which WDT N
lengthened VBD N
the DT N
AT NNP N
moment NN N
arm NN N
. . N

Therefore RB N
, , N
heel NN N
lifts NNS N
could MD N
be VB N
used VBN N
to TO N
reduce VB N
AT NNP N
loading NN N
and CC N
strain NN N
during IN N
the DT N
rehabilitation NN N
of IN N
AT NNP N
injuries NNS N
. . N

-DOCSTART- -X- O O 6391269

Fentanyl NNP N
supplementation NN N
to TO N
inhalation NN 4_p
anaesthesia NN 4_p
. . N

In IN N
eight CD N
out IN N
of IN N
15 CD N
healthy JJ 4_p
patients NNS N
undergoing VBG N
body NN 4_p
surface NN 4_p
surgery NN 4_p
, , N
the DT N
effect NN N
of IN N
a DT N
fentanyl JJ N
infusion NN N
on IN N
a DT N
conventional JJ N
thiopentone NN N
, , N
nitrous JJ N
oxide NN N
, , N
oxygen NN N
and CC N
halothane NN N
anaesthetic NN N
was VBD N
studied VBN N
. . N

The DT N
fentanyl JJ N
infusion NN N
( ( N
2 CD N
micrograms/kg/hour NN N
) ) N
reduced VBD N
the DT N
induction NN N
dose NN N
of IN N
thiopentone NN N
and CC N
caused VBD N
marked JJ N
respiratory JJ N
depression NN N
with IN N
a DT N
reduction NN N
in IN N
the DT N
patients NNS N
' POS N
response NN N
to TO N
surgery NN N
. . N

The DT N
mean JJ N
arterial JJ N
pressures NNS N
and CC N
pulse JJ N
rates NNS N
were VBD N
not RB N
significantly RB N
different JJ N
in IN N
each DT N
group NN N
throughout IN N
the DT N
course NN N
of IN N
the DT N
operation NN N
. . N

The DT N
fentanyl NN N
made VBD N
no DT N
difference NN N
to TO N
the DT N
patients NNS N
' POS N
postoperative JJ N
analgesic JJ N
requirements NNS N
or CC N
to TO N
their PRP$ N
recovery NN N
in IN N
the DT N
first JJ N
24 CD N
hours NNS N
. . N

-DOCSTART- -X- O O 21316048

Anastrozole NNP N
single-dose JJ N
protocol NN N
in IN N
women NNS N
with IN N
oligo- JJ N
or CC N
anovulatory JJ 4_p
infertility NN 4_p
: : N
results NNS N
of IN N
a DT N
randomized JJ N
phase NN N
II NNP N
dose-response NN N
study NN N
. . N

OBJECTIVE NNP N
To TO N
compare VB N
the DT N
effects NNS N
of IN N
anastrozole NN N
and CC N
clomiphene NN N
citrate NN N
( ( N
CC NNP N
) ) N
on IN N
follicular NN N
development NN N
and CC N
ovulation NN N
in IN N
infertile JJ N
women NNS N
with IN N
ovulatory JJ 4_p
dysfunction NN 4_p
. . N

DESIGN NNP N
Phase NNP N
II NNP N
, , N
prospective JJ N
, , N
randomized VBN N
, , N
assessor-blind JJ N
, , N
multicenter NN N
, , N
dose-finding NN N
, , N
noninferiority NN N
study NN N
. . N

SETTING NNP N
Outpatient NNP N
. . N

PATIENT NNP N
( ( N
S NNP N
) ) N
Infertile NNP N
women NNS N
with IN N
ovulatory JJ N
dysfunction NN N
, , N
aged VBN N
18-35 CD N
years NNS N
, , N
and CC N
body NN N
mass NN N
index NN N
< VBD N
35 CD N
kg/m NN N
( ( N
2 CD N
) ) N
. . N

INTERVENTION NNP N
( ( N
S NNP N
) ) N
Single-dose JJ N
anastrozole NN N
at IN N
5 CD N
mg NN N
( ( N
n JJ N
= NNP N
39 CD N
) ) N
, , N
10 CD N
mg NN N
( ( N
n JJ N
= NNP N
39 CD N
) ) N
, , N
20 CD N
mg NN N
( ( N
n JJ N
= NNP N
39 CD N
) ) N
, , N
or CC N
30 CD N
mg NN N
( ( N
n JJ N
= NNP N
38 CD N
) ) N
or CC N
a DT N
5-day JJ N
course NN N
of IN N
CC NNP N
at IN N
50 CD N
mg/d NN N
( ( N
n JJ N
= NNP N
39 CD N
) ) N
as IN N
starting VBG N
doses NNS N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURE NNP N
( ( N
S NNP N
) ) N
The DT N
primary JJ N
endpoint NN N
was VBD N
the DT N
ovulation NN N
rate NN N
in IN N
the DT N
first JJ N
treatment NN N
cycle NN N
( ( N
cycle NN N
1 CD N
) ) N
. . N

Ovulation NN N
was VBD N
defined VBN N
as IN N
a DT N
midluteal JJ N
phase NN N
serum NN N
P NNP N
level NN N
≥ VBD N
10 CD N
ng/mL NN N
or CC N
clinical JJ N
pregnancy NN N
. . N

RESULT NNP N
( ( N
S NNP N
) ) N
In IN N
cycle NN N
1 CD N
the DT N
ovulation NN N
rates NNS N
for IN N
a DT N
single JJ N
dose NN N
of IN N
anastrozole NN N
at IN N
5 CD N
, , N
10 CD N
, , N
20 CD N
, , N
and CC N
30 CD N
mg NNS N
were VBD N
46.2 CD N
% NN N
, , N
41.0 CD N
% NN N
, , N
23.1 CD N
% NN N
, , N
and CC N
28.9 CD N
% NN N
, , N
respectively RB N
, , N
whereas NNS N
that IN N
for IN N
CC NNP N
at IN N
50 CD N
mg/d NN N
was VBD N
61.5 CD N
% NN N
. . N

Among IN N
women NNS N
with IN N
fewer JJR N
than IN N
six CD N
menses NNS N
per IN N
year NN N
, , N
the DT N
cumulative JJ N
ovulation NN N
rates NNS N
over IN N
three CD N
cycles NNS N
were VBD N
comparable JJ N
in IN N
the DT N
anastrozole JJ N
5 CD N
mg NN N
( ( N
52.4 CD N
% NN N
) ) N
and CC N
CC $ N
50 CD N
mg/d NN N
( ( N
42.3 CD N
% NN N
) ) N
groups NNS N
. . N

CONCLUSION NNP N
( ( N
S NNP N
) ) N
In IN N
terms NNS N
of IN N
ovulation NN N
rates NNS N
in IN N
cycle NN N
1 CD N
, , N
single-dose JJ N
anastrozole NN N
at IN N
5 CD N
, , N
10 CD N
, , N
20 CD N
, , N
and CC N
30 CD N
mg NN N
was VBD N
not RB N
as RB N
effective JJ N
as IN N
CC NNP N
at IN N
50 CD N
mg/d NN N
for IN N
5 CD N
days NNS N
( ( N
noninferiority NN N
was VBD N
not RB N
shown VBN N
) ) N
. . N

-DOCSTART- -X- O O 3081148

Combined VBN N
use NN N
of IN N
vasopressin NN N
and CC N
synthetic JJ N
hypothalamic JJ N
releasing NN N
factors NNS N
as IN N
a DT N
new JJ N
test NN N
of IN N
anterior JJ N
pituitary JJ N
function NN N
. . N

Nine NNP 4_p
normal JJ 4_p
volunteers NNS 4_p
and CC 4_p
15 CD 4_p
patients NNS 4_p
with IN 4_p
pituitary JJ 4_p
disorders NNS 4_p
were VBD N
given VBN N
a DT N
combined JJ N
test NN N
of IN N
anterior JJ N
pituitary JJ N
function NN N
using VBG N
four CD N
hypothalamic JJ N
releasing VBG N
factors NNS N
and CC N
arginine JJ N
vasopressin NN N
. . N

Rapid JJ N
sequential JJ N
intravenous JJ N
infusions NNS N
of IN N
human JJ N
corticotrophin NN N
releasing VBG N
factor NN N
100 CD N
micrograms NNS N
, , N
growth NN N
hormone NN N
releasing VBG N
factor NN N
100 CD N
micrograms NNS N
, , N
luteinising VBG N
hormone NN N
releasing VBG N
hormone NN N
100 CD N
micrograms NNS N
, , N
and CC N
thyrotrophin IN N
releasing VBG N
hormone NN N
200 CD N
micrograms NNS N
were VBD N
administered VBN N
. . N

Arginine NNP N
vasopressin NN N
( ( N
10 CD N
pressor NN N
units NNS N
) ) N
was VBD N
given VBN N
intramuscularly RB N
at IN N
the DT N
same JJ N
time NN N
. . N

Plasma NNP N
or CC N
serum NN N
samples NNS N
were VBD N
assayed VBN N
for IN N
concentrations NNS N
of IN N
cortisol NN N
, , N
growth NN N
hormone NN N
, , N
luteinising VBG N
hormone NN N
, , N
follicle NN N
stimulating VBG N
hormone NN N
, , N
prolactin NN N
, , N
and CC N
thyroid JJ N
stimulating VBG N
hormone NN N
at IN N
multiple JJ N
times NNS N
for IN N
120 CD N
minutes NNS N
. . N

No DT N
troublesome JJ N
side NN N
effects NNS N
occurred VBD N
. . N

The DT N
results NNS N
of IN N
the DT N
releasing VBG N
factor NN N
combined VBD N
test NN N
with IN N
arginine JJ N
vasopressin NN N
were VBD N
compared VBN N
in IN N
the DT N
same JJ N
subjects NNS N
with IN N
a DT N
conventional JJ N
combined JJ N
test NN N
using VBG N
insulin NN N
together RB N
with IN N
thyrotrophin JJ N
releasing VBG N
hormone NN N
and CC N
luteinising VBG N
hormone NN N
releasing VBG N
hormone NN N
. . N

No DT N
difference NN N
was VBD N
observed VBN N
in IN N
the DT N
basal NN N
and CC N
peak JJ N
concentrations NNS N
of IN N
luteinising VBG N
hormone NN N
, , N
follicle NN N
stimulating VBG N
hormone NN N
, , N
thyroid JJ N
stimulating VBG N
hormone NN N
, , N
and CC N
prolactin NN N
. . N

Both DT N
cortisol NN N
and CC N
growth NN N
hormone NN N
responses VBZ N
to TO N
the DT N
releasing VBG N
factors NNS N
with IN N
arginine JJ N
vasopressin NN N
were VBD N
much RB N
greater JJR N
than IN N
those DT N
seen VBN N
with IN N
insulin NN N
induced VBN N
hypoglycaemia NN N
or CC N
the DT N
combined JJ N
releasing NN N
factors NNS N
without IN N
arginine JJ N
vasopressin NN N
. . N

Patients NNS N
with IN N
pituitary JJ N
hypo-function NN N
were VBD N
similarly RB N
recognised VBN N
in IN N
both DT N
studies NNS N
. . N

There EX N
was VBD N
a DT N
rapid JJ N
increase NN N
in IN N
all DT N
hormone NN N
values NNS N
with IN N
a DT N
peak NN N
usually RB N
by IN N
60 CD N
minutes NNS N
. . N

In IN N
most JJS N
people NNS N
adequate VBP N
assessment NN N
of IN N
individual JJ N
hormone NN N
reserves NNS N
may MD N
be VB N
achieved VBN N
using VBG N
basal NN N
, , N
30 CD N
minute NN N
, , N
and CC N
60 CD N
minute NN N
samples NNS N
. . N

This DT N
new JJ N
combined JJ N
releasing NN N
factor NN N
test NN N
appears VBZ N
to TO N
be VB N
a DT N
safe JJ N
, , N
rapid JJ N
, , N
and CC N
useful JJ N
test NN N
of IN N
anterior JJ N
pituitary JJ N
function NN N
. . N

-DOCSTART- -X- O O 24898665

Patients NNS N
with IN 4_p
relapsed JJ 4_p
follicular JJ 4_p
lymphoma NN 4_p
treated VBN N
with IN N
rituximab JJ N
versus NN N
tositumomab NN N
and CC N
iodine JJ N
I-131 NNP N
tositumomab NN N
. . N

-DOCSTART- -X- O O 18957505

Treatment NN N
with IN N
the DT N
dipeptidyl JJ N
peptidase-4 JJ N
inhibitor NN N
vildagliptin NN N
improves VBZ N
fasting VBG N
islet-cell JJ N
function NN N
in IN N
subjects NNS N
with IN N
type JJ N
2 CD N
diabetes NNS N
. . N

CONTEXT NNP N
Dipeptidyl NNP N
peptidase NN N
4 CD N
( ( N
DPP-4 NNP N
) ) N
inhibitors NNS N
are VBP N
proposed VBN N
to TO N
lower VB N
blood NN N
glucose NN N
in IN N
type NN N
2 CD N
diabetes NNS N
mellitus FW N
( ( N
T2DM NNP N
) ) N
by IN N
prolonging VBG N
the DT N
activity NN N
of IN N
the DT N
circulating NN N
incretins NNS N
, , N
glucose-dependent JJ N
insulinotropic NN N
polypeptide NN N
( ( N
GIP NNP N
) ) N
and CC N
glucagon-like JJ N
peptide NN N
1 CD N
( ( N
GLP-1 NNP N
) ) N
. . N

Consistent JJ N
with IN N
this DT N
mechanism NN N
of IN N
action NN N
, , N
DPP-4 NNP N
inhibitors NNS N
improve VBP N
glucose JJ N
tolerance NN N
after IN N
meals NNS N
by IN N
increasing VBG N
insulin NN N
and CC N
reducing VBG N
glucagon NN N
levels NNS N
in IN N
the DT N
plasma NN N
. . N

However RB N
, , N
DPP-4 NNP N
inhibitors NNS N
also RB N
reduce VB N
fasting VBG N
blood NN N
glucose NN N
, , N
an DT N
unexpected JJ N
effect NN N
because IN N
circulating VBG N
levels NNS N
of IN N
active JJ N
GIP NNP N
and CC N
GLP-1 NNP N
are VBP N
low JJ N
in IN N
the DT N
postabsorptive JJ N
state NN N
. . N

OBJECTIVE CC N
The DT N
objective NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
examine VB N
the DT N
effects NNS N
of IN N
DPP-4 NNP N
inhibition NN N
on IN N
fasting VBG N
islet NN N
function NN N
. . N

DESIGN NNP N
We PRP N
conducted VBD N
a DT N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
trial NN N
. . N

SETTING VB N
The DT N
study NN N
was VBD N
performed VBN N
in IN N
General NNP N
Clinical NNP N
Research NNP N
Centers NNPS N
at IN N
two CD N
University NNP N
Hospitals NNP N
. . N

SUBJECTS NNP N
Forty-one JJ N
subjects NNS N
with IN N
T2DM NNP N
were VBD N
treated VBN N
with IN N
metformin NN N
or CC N
diet NN N
, , N
having VBG N
good JJ N
glycemic NNS N
control NN N
with IN N
glycosylated JJ N
hemoglobin NN N
values NNS N
of IN N
6.2-7.5 JJ N
% NN N
. . N

INTERVENTION JJ N
Subjects NNPS N
were VBD N
treated VBN N
with IN N
vildagliptin NN N
( ( N
50 CD N
mg NN N
twice RB N
daily RB N
) ) N
or CC N
placebo NN N
for IN N
3 CD N
months NNS N
, , N
followed VBN N
by IN N
a DT N
2-wk JJ N
washout NN N
. . N

Major JJ N
Outcome JJ N
Measure NN N
: : N
We PRP N
measured VBD N
insulin JJ N
secretion NN N
in IN N
response NN N
to TO N
iv VB N
glucose JJ N
and CC N
arginine JJ N
before NN N
and CC N
after IN N
treatment NN N
and CC N
after IN N
drug NN N
washout NN N
. . N

RESULTS CC N
There EX N
were VBD N
small JJ N
and CC N
comparable JJ N
reductions NNS N
in IN N
glycosylated JJ N
hemoglobin NN N
in IN N
both DT N
groups NNS N
over IN N
3 CD N
months NNS N
. . N

Vildagliptin NNP N
increased VBD N
fasting VBG N
GLP-1 NNP N
levels NNS N
in IN N
subjects NNS N
taking VBG N
metformin NN N
, , N
but CC N
not RB N
those DT N
managed VBN N
with IN N
diet JJ N
, , N
and CC N
raised VBD N
active JJ N
GIP NNP N
levels NNS N
slightly RB N
. . N

DPP-4 JJ N
inhibitor NN N
treatment NN N
improved VBD N
the DT N
acute JJ N
insulin NN N
and CC N
C-peptide JJ N
responses NNS N
to TO N
glucose VB N
( ( N
50 CD N
and CC N
100 CD N
% NN N
respectively RB N
; : N
P NNP N
< NNP N
0.05 CD N
) ) N
and CC N
increased VBD N
the DT N
slope NN N
of IN N
the DT N
C-peptide NNP N
response NN N
to TO N
glucose VB N
( ( N
33 CD N
% NN N
; : N
P NNP N
= NNP N
0.023 CD N
) ) N
. . N

CONCLUSION NNP N
Vildagliptin NNP N
improves VBZ N
islet JJ N
function NN N
in IN N
T2DM NNP N
under IN N
fasting VBG N
conditions NNS N
. . N

This DT N
suggests VBZ N
that IN N
DPP-4 NNP N
inhibition NN N
has VBZ N
metabolic JJ N
benefits NNS N
in IN N
addition NN N
to TO N
enhancing VBG N
meal-induced JJ N
GLP-1 NNP N
and CC N
GIP NNP N
activity NN N
. . N

-DOCSTART- -X- O O 10442506

Effects NNS N
of IN N
amlodipine NN N
and CC N
enalapril NN N
on IN N
platelet NN N
function NN N
in IN N
patients NNS N
with IN N
mild JJ N
to TO N
moderate VB N
hypertension NN 4_p
. . N

OBJECTIVE CC N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
effect NN N
of IN N
amlodipine NN N
and CC N
enalapril NN N
on IN N
platelet NN N
aggregation NN N
, , N
and CC N
platelet NN N
production NN N
of IN N
malondialdehyde NN N
in IN N
patients NNS N
with IN N
mild JJ N
to TO N
moderate VB N
arterial JJ 4_p
hypertension NN 4_p
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
A NNP N
parallel NN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
was VBD N
carried VBN N
out RP N
in IN N
24 CD N
patients NNS N
( ( N
2 CD N
groups NNS N
of IN N
12 CD N
patients NNS N
each DT N
) ) N
. . N

Initially RB N
all DT N
patients NNS N
received VBD N
placebo NNS N
for IN N
four CD N
weeks NNS N
; : N
then RB N
amlodipine VB N
, , N
5 CD N
mg JJ N
daily JJ N
or CC N
enalapril JJ N
20 CD N
mg JJ N
daily RB N
taken VBN N
once RB N
a DT N
day NN N
at IN N
7 CD N
am VBP N
. . N

Dosage NN N
was VBD N
doubled VBN N
after IN N
4 CD N
weeks NNS N
when WRB N
diastolic JJ N
blood NN N
pressure NN N
was VBD N
> JJ N
90 CD N
mmHg NN N
in IN N
sitting VBG N
position NN N
, , N
the DT N
treatment NN N
was VBD N
continued VBN N
for IN N
12 CD N
weeks NNS N
. . N

At IN N
the DT N
end NN N
of IN N
placebo NN N
and CC N
active JJ N
phases NNS N
a DT N
platelet NN N
aggregation NN N
test NN N
, , N
using VBG N
adenosine JJ N
diphosphate NN N
, , N
collagen NN N
and CC N
adrenaline NN N
, , N
and CC N
a DT N
platelet NN N
malondialdehyde NN N
production NN N
test NN N
, , N
either RB N
in IN N
basal NN N
conditions NNS N
( ( N
MDA-basal NNP N
) ) N
and CC N
after IN N
the DT N
stimulation NN N
of IN N
arachidonic JJ N
acid NNS N
pathway RB N
by IN N
adding VBG N
ethylmaleimide NN N
( ( N
MDA-activated JJ N
) ) N
were VBD N
carried VBN N
out RP N
. . N

RESULTS VB N
Blood NNP N
pressure NN N
was VBD N
reduced VBN N
by IN N
both DT N
agents NNS N
, , N
enalapril NN N
and CC N
amlodipine NN N
. . N

Enalapril NNP N
controlled VBD N
58.3 CD N
% NN N
of IN N
hypertensive JJ 4_p
patients NNS N
with IN N
an DT N
average JJ N
dosage NN N
of IN N
31.7 CD N
mg/daily RB N
. . N

Amlodipine NNP N
controlled VBD N
75 CD N
% NN N
of IN N
patients NNS N
with IN N
a DT N
dosage NN N
of IN N
7.1 CD N
mg/daily RB N
. . N

Platelet NNP N
aggregation NN N
was VBD N
reduced VBN N
by IN N
amlodipine NN N
in IN N
15.9 CD N
% NN N
for IN N
ADP NNP N
( ( N
10 CD N
microM NN N
) ) N
; : N
17.4 CD N
% NN N
for IN N
collagen NN N
( ( N
2 CD N
microg/ml NN N
) ) N
and CC N
19.9 CD N
% NN N
for IN N
adrenaline NN N
( ( N
2 CD N
microM NN N
) ) N
( ( N
p JJ N
< NNP N
0.025 CD N
) ) N
. . N

Meanwhile RB N
enalapril JJ N
slightly RB N
increased VBN N
platelet NN N
aggregation NN N
by IN N
6.7 CD N
% NN N
, , N
1.3 CD N
% NN N
and CC N
5.6 CD N
% NN N
for IN N
the DT N
three CD N
agents NNS N
, , N
respectively RB N
( ( N
p JJ N
> NN N
0.05 CD N
, , N
ns NN N
) ) N
. . N

Malondialdehyde NNP N
was VBD N
reduced VBN N
by IN N
amlodipine NN N
in IN N
45.33 CD N
% NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
for IN N
MDA-basal NNP N
; : N
3.76 CD N
% NN N
( ( N
p JJ N
> NNP N
0.05 CD N
) ) N
for IN N
MDA-activated NNP N
; : N
and CC N
the DT N
ratio JJ N
MDA-basal JJ N
: : N
MDA-activated JJ N
in IN N
36.79 CD N
% NN N
( ( N
p JJ N
< NNP N
0.005 CD N
) ) N
. . N

Meanwhile RB N
enalapril JJ N
increased VBD N
MDA-basal NNP N
in IN N
2.89 CD N
% NN N
; : N
MDA-activated NNP N
in IN N
3.58 CD N
% NN N
and CC N
reduced VBD N
the DT N
ratio NN N
MDA-basal JJ N
: : N
MDA-activated JJ N
, , N
in IN N
10.34 CD N
% NN N
( ( N
p JJ N
> NNP N
0.05 CD N
) ) N
. . N

CONCLUSION NNP N
Both DT N
agents NNS N
, , N
enalapril NN N
and CC N
amlodipine NN N
, , N
reduced VBD N
blood NN N
pressure NN N
, , N
but CC N
only RB N
amlodipine VB N
reduced VBN N
platelet JJ N
aggregation NN N
and CC N
platelet NN N
production NN N
of IN N
malondialdehyde NN N
, , N
indicating VBG N
its PRP$ N
action NN N
on IN N
the DT N
arachidonic JJ N
acid NN N
metabolic JJ N
pathway NN N
. . N

-DOCSTART- -X- O O 17156651

[ JJ N
Efficacy NNP N
and CC N
safety NN N
of IN N
extended-release JJ N
niacin JJ N
alone NN N
or CC N
with IN N
atorvastatin NN N
for IN N
lipid JJ N
profile JJ N
modification NN N
] NNP N
. . N

OBJECTIVE NNP N
To TO N
evaluate VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
extended-release JJ N
niacin NN N
( ( N
niacin JJ N
ER NNP N
) ) N
either CC N
alone RB N
or CC N
in IN N
combination NN N
with IN N
atorvastatin NN N
for IN N
the DT N
lipid JJ N
profile NN N
modification NN N
in IN N
the DT N
patients NNS N
with IN N
coronary JJ N
heart NN N
disease NN N
( ( N
CHD NNP N
) ) N
and CC N
its PRP$ N
equivalents NNS N
. . N

METHODS NNP N
One CD N
hundred CD N
and CC N
ten JJ N
patients NNS N
with IN N
CHD NNP N
and CC N
its PRP$ N
equivalents NNS N
with IN N
serum JJ N
total JJ N
cholesterol NN N
( ( N
TC NNP N
) ) N
> VBD N
or CC N
= $ N
3.5 CD N
mmol/L NN N
were VBD N
randomly RB N
assigned VBN N
into IN N
three CD N
treatment NN N
groups NNS N
: : N
( ( N
1 CD N
) ) N
atorvastatin NN N
group NN N
( ( N
n JJ N
= NNP N
38 CD N
) ) N
, , N
receiving VBG N
atorvastatin NN N
10 CD N
mg/d NN N
for IN N
8 CD N
weeks NNS N
; : N
( ( N
2 CD N
) ) N
niacin NN N
ER NNP N
group NN N
( ( N
n JJ N
= NNP N
38 CD N
) ) N
, , N
given VBN N
niacin NNS N
ER NNP N
500 CD N
mg/d NN N
for IN N
4 CD N
weeks NNS N
and CC N
then RB N
1000 CD N
mg/d NN N
for IN N
4 CD N
weeks NNS N
; : N
( ( N
3 CD N
) ) N
combination NN N
treatment NN N
group NN N
( ( N
n JJ N
= NNP N
34 CD N
) ) N
, , N
treated VBN N
with IN N
atorvastatin NN N
( ( N
10 CD N
mg/d NN N
) ) N
plus CC N
niacin JJ N
ER NNP N
, , N
with IN N
the DT N
dose JJ N
initiating NN N
from IN N
500 CD N
mg/d NN N
, , N
and CC N
increasing VBG N
to TO N
1000 CD N
mg/d NN N
after IN N
4 CD N
weeks NNS N
, , N
for IN N
8 CD N
weeks NNS N
. . N

The DT N
serums NNS N
lipid JJ N
profiles NNS N
and CC N
adverse JJ N
effects NNS N
were VBD N
assessed VBN N
in IN N
all PDT N
the DT N
patients NNS N
before IN N
treatment NN N
, , N
and CC N
4 CD N
and CC N
8 CD N
weeks NNS N
after IN N
treatment NN N
. . N

RESULTS NNP N
( ( N
1 CD N
) ) N
After IN N
8 CD N
weeks NNS N
of IN N
treatment NN N
, , N
the DT N
serum JJ N
level NN N
of IN N
triglyceride NN N
( ( N
TG NNP N
) ) N
and CC N
high-density JJ N
lipoprotein NN N
cholesterol NN N
( ( N
HDL-C NNP N
) ) N
were VBD N
reduced VBN N
by IN N
30 CD N
% NN N
and CC N
16 CD N
% NN N
respectively RB N
in IN N
the DT N
niacin JJ N
ER NNP N
group NN N
compared VBN N
with IN N
the DT N
baseline NN N
values NNS N
( ( N
both DT N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

After IN N
8 CD N
weeks NNS N
, , N
the DT N
TC NNP N
, , N
low-density NN N
lipoprotein NN N
cholesterol NN N
( ( N
LDL-C NNP N
) ) N
, , N
and CC N
TG NNP N
in IN N
the DT N
atorvastatin NN N
group NN N
decreased VBN N
by IN N
19 CD N
% NN N
, , N
26 CD N
% NN N
, , N
and CC N
17 CD N
% NN N
respectively RB N
compared VBN N
with IN N
the DT N
baseline NN N
values NNS N
( ( N
all DT N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Combination NNP N
treatment NN N
decreased VBD N
the DT N
TC NNP N
, , N
LDL-C NNP N
, , N
and CC N
TG NNP N
levels NNS N
by IN N
28 CD N
% NN N
, , N
38 CD N
% NN N
, , N
and CC N
39 CD N
% NN N
respectively RB N
, , N
and CC N
increased VBD N
the DT N
HDL-C NNP N
level NN N
by IN N
23 CD N
% NN N
( ( N
all DT N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
improvement NN N
in IN N
TC NNP N
and CC N
LDL-C NNP N
achieved VBN N
by IN N
combination NN N
treatment NN N
was VBD N
superior JJ N
to TO N
treatment NN N
of IN N
atorvastatin NN N
alone RB N
and CC N
treatment NN N
of IN N
niacin JJ N
ER NNP N
alone RB N
( ( N
all DT N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

( ( N
2 CD N
) ) N
The DT N
rate NN N
of IN N
achieving VBG N
the DT N
LDL-C JJ N
goal NN N
of IN N
The DT N
National NNP N
Cholesterol NNP N
Education NNP N
Program NNP N
( ( N
NCEP NNP N
) ) N
in IN N
Adult NNP N
Treatment NNP N
Panel NNP N
III NNP N
( ( N
ATP NNP N
III NNP N
) ) N
in IN N
the DT N
combination NN N
therapy NN N
group NN N
was VBD N
73.5 CD N
% NN N
, , N
significantly RB N
higher JJR N
than IN N
those DT N
of IN N
the DT N
atorvastatin NN N
and CC N
niacin JJ N
groups NNS N
( ( N
47.7 CD N
% NN N
and CC N
42.1 CD N
% NN N
respectively RB N
, , N
both DT N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

( ( N
3 CD N
) ) N
Adverse NNP N
effect NN N
, , N
such JJ N
as IN N
flushing NN N
( ( N
15.8 CD N
% NN N
) ) N
and CC N
gastrointestinal JJ N
symptoms NNS N
( ( N
23.7 CD N
% NN N
) ) N
were VBD N
found VBN N
in IN N
the DT N
niacin JJ N
ER NNP N
group NN N
, , N
however RB N
, , N
no DT N
more JJR N
adverse JJ N
effects NNS N
were VBD N
found VBN N
in IN N
the DT N
combination NN N
therapy NN N
group NN N
. . N

There EX N
were VBD N
no DT N
serious JJ N
adverse JJ N
events NNS N
in IN N
all DT N
groups NNS N
. . N

CONCLUSION NNP N
Niacin NNP N
ER NNP N
has VBZ N
a DT N
favorable JJ N
effect NN N
in IN N
modulating VBG N
the DT N
blood NN N
lipid JJ N
profile NN N
, , N
especially RB N
in IN N
reducing VBG N
TG NNP N
and CC N
elevating VBG N
HDL-C NNP N
. . N

Combined VBN N
statin NN N
with IN N
niacin NN N
may MD N
produce VB N
a DT N
more JJR N
global JJ N
and CC N
effective JJ N
improvement NN N
in IN N
lipid JJ N
blood NN N
levels NNS N
than IN N
monotherapy NN N
and CC N
is VBZ N
generally RB N
safe JJ N
and CC N
well RB N
tolerable JJ N
. . N

-DOCSTART- -X- O O 23642776

Extra NNP N
virgin NN N
olive JJ N
oil NN N
( ( N
EVOO NNP N
) ) N
consumption NN N
and CC N
antioxidant JJ N
status NN N
in IN N
healthy JJ 4_p
institutionalized VBN N
elderly JJ N
humans NNS N
. . N

Recent JJ N
studies NNS N
show VBP N
that IN N
the DT N
elderly JJ N
have VBP N
increased VBN N
oxidative JJ N
stress NN N
and CC N
impaired JJ N
antioxidant NN N
defense NN N
systems NNS N
. . N

Our PRP$ N
study NN N
aims VBZ N
to TO N
evaluate VB N
the DT N
effects NNS N
of IN N
daily JJ N
consumption NN N
of IN N
EVOO NNP N
in IN N
the DT N
healthy JJ N
institutionalized JJ N
elderly RB N
. . N

We PRP N
studied VBD N
anthropometric JJ N
, , N
biochemical JJ N
and CC N
antioxidant JJ N
parameters NNS N
in IN N
62 CD N
subjects NNS N
aged VBN N
65-96 CD N
years NNS N
after IN N
a DT N
6-week JJ N
daily JJ N
intake NN N
of IN N
polyphenol-rich JJ N
EVOO NNP N
with IN N
high JJ N
oleuropein NNS N
derivative JJ N
contents NNS N
. . N

Subjects NNS N
were VBD N
divided VBN N
into IN N
a DT N
control NN N
group NN N
( ( N
CG NNP N
) ) N
who WP N
maintained VBD N
their PRP$ N
dietary JJ N
habits NNS N
( ( N
n=39 NN N
) ) N
and CC N
an DT N
olive JJ N
group NN N
( ( N
OG NNP N
) ) N
who WP N
consumed VBD N
EVOO NNP N
as IN N
the DT N
only RB N
added JJ N
fat NN N
, , N
plus CC N
a DT N
daily JJ N
dose NN N
of IN N
50ml CD N
( ( N
n=23 NN N
) ) N
. . N

We PRP N
found VBD N
a DT N
significant JJ N
reduction NN N
of IN N
total JJ N
cholesterol NN N
( ( N
TC NNP N
) ) N
, , N
HDL NNP N
, , N
LDL NNP N
and CC N
TGs NNP N
in IN N
OG NNP N
subjects NNS N
and CC N
a DT N
significant JJ N
increase NN N
of IN N
HDL NNP N
levels NNS N
. . N

There EX N
was VBD N
no DT N
significant JJ N
variation NN N
in IN N
the DT N
CG NNP N
parameters NNS N
. . N

In IN N
OG NNP N
the DT N
total JJ N
antioxidant JJ N
capacity NN N
( ( N
TAC NNP N
) ) N
in IN N
plasma NN N
increased VBN N
with IN N
significant JJ N
differences NNS N
over IN N
CG NNP N
. . N

Plasma NNP N
hydroxytyrosol NN N
( ( N
OH-Tyr NNP N
) ) N
concentration NN N
showed VBD N
a DT N
significant JJ N
increase NN N
after IN N
EVOO NNP N
intervention NN N
. . N

Daily JJ N
consumption NN N
of IN N
EVOO NNP N
was VBD N
found VBN N
to TO N
have VB N
positive JJ N
effects NNS N
on IN N
lipid JJ N
profiles NNS N
, , N
OH-Tyr NNP N
levels NNS N
and CC N
TAC NNP N
. . N

The DT N
results NNS N
also RB N
show VBP N
a DT N
significant JJ N
increase NN N
of IN N
catalase NN N
( ( N
CAT NNP N
) ) N
in IN N
erythrocytes NNS N
and CC N
a DT N
decrease NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
in IN N
superoxide JJ N
dismutase NN N
( ( N
SOD NNP N
) ) N
and CC N
glutathione JJ N
peroxidase NN N
( ( N
GH-PX NNP N
) ) N
activity NN N
after IN N
EVOO NNP N
intake NN N
. . N

To TO N
our PRP$ N
knowledge NN N
, , N
no DT N
other JJ N
study NN N
has VBZ N
examined VBN N
the DT N
effects NNS N
of IN N
EVOO NNP N
consumption NN N
on IN N
biochemical JJ N
parameters NNS N
, , N
antioxidant JJ N
capacity NN N
and CC N
antioxidant JJ N
enzyme NN N
activity NN N
in IN N
healthy JJ 4_p
elderly JJ N
subjects NNS N
. . N

In IN N
conclusion NN N
, , N
our PRP$ N
results NNS N
show VBP N
that IN N
nutritional JJ N
intervention NN N
with IN N
EVOO NNP N
improves VBZ N
antioxidant JJ N
status NN N
in IN N
healthy JJ 4_p
elderly JJ N
people NNS N
. . N

-DOCSTART- -X- O O 12585821

The DT N
development NN N
and CC N
evaluation NN N
of IN N
a DT N
computer-based JJ N
program NN N
to TO N
test VB N
and CC N
to TO N
teach VB N
the DT N
recognition NN N
of IN N
facial JJ N
affect NN N
. . N

Autism NNP N
is VBZ N
a DT N
chronic JJ N
pervasive JJ N
neurodevelopmental JJ N
disorder NN N
characterized VBN N
by IN N
the DT N
early JJ N
onset NN N
of IN N
social JJ N
and CC N
communicative JJ N
impairments NNS N
as RB N
well RB N
as IN N
restricted VBN N
, , N
ritualized VBN N
, , N
stereotypic JJ N
behavior NN N
. . N

The DT N
endophenotype NN N
of IN N
autism NN N
includes VBZ N
neuropsychological JJ N
deficits NNS N
, , N
for IN N
instance NN N
a DT N
lack NN N
of IN N
" NNP N
Theory NNP N
of IN N
Mind NNP N
" NNP N
and CC N
problems NNS N
recognizing VBG N
facial JJ N
affect NN N
. . N

In IN N
this DT N
study NN N
, , N
we PRP N
report VBP N
the DT N
development NN N
and CC N
evaluation NN N
of IN N
a DT N
computer-based JJ N
program NN N
to TO N
teach VB N
and CC N
test VB N
the DT N
ability NN N
to TO N
identify VB N
basic JJ N
facially RB N
expressed VBN N
emotions NNS N
. . N

10 CD N
adolescent NN N
or CC N
adult NN N
subjects NNS N
with IN N
high-functioning JJ 4_p
autism NN 4_p
or CC 4_p
Asperger-syndrome NNP 4_p
were VBD N
included VBN N
in IN N
the DT N
investigation NN N
. . N

A DT N
priori FW N
the DT N
facial JJ N
affect NN N
recognition NN N
test NN N
had VBD N
shown VBN N
good JJ N
psychometric NN N
properties NNS N
in IN N
a DT N
normative JJ N
sample NN N
( ( N
internal JJ N
consistency NN N
: : N
rtt=.91-.95 NN N
; : N
retest JJS N
reliability NN N
: : N
rtt=.89-.92 NN N
) ) N
. . N

In IN N
a DT N
prepost NN N
design NN N
, , N
one CD N
half NN N
of IN N
the DT N
sample NN N
was VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
computer NN N
treatment NN N
while IN N
the DT N
other JJ N
half NN N
of IN N
the DT N
sample NN N
served VBD N
as IN N
control NN N
group NN N
. . N

The DT N
training NN N
was VBD N
conducted VBN N
for IN N
five CD N
weeks NNS N
, , N
consisting VBG N
of IN N
two CD N
hours NNS N
training VBG N
a DT N
week NN N
. . N

The DT N
trained JJ N
individuals NNS N
improved VBN N
significantly RB N
on IN N
the DT N
affect JJ N
recognition NN N
task NN N
, , N
but CC N
not RB N
on IN N
any DT N
other JJ N
measure NN N
. . N

Results VB N
support NN N
the DT N
usefulness NN N
of IN N
the DT N
program NN N
to TO N
teach VB N
the DT N
detection NN N
of IN N
facial JJ N
affect NN N
. . N

However RB N
, , N
the DT N
improvement NN N
found VBD N
is VBZ N
limited VBN N
to TO N
a DT N
circumscribed JJ N
area NN N
of IN N
social-communicative JJ N
function NN N
and CC N
generalization NN N
is VBZ N
not RB N
ensured VBN N
. . N

-DOCSTART- -X- O O 19801029

Comparison NNP N
of IN N
the DT N
effect NN N
of IN N
intra-arterial JJ N
versus NN N
intravenous JJ N
heparin NN N
on IN N
radial JJ 4_p
artery NN 4_p
occlusion NN 4_p
after IN 4_p
transradial JJ 4_p
catheterization NN 4_p
. . 4_p

Radial JJ N
artery NN N
occlusion NN N
( ( N
RAO NNP N
) ) N
is VBZ N
an DT N
infrequent NN N
, , N
asymptomatic JJ N
, , N
complication NN N
of IN N
transradial JJ N
catheterization NN N
and CC N
probably RB N
1 CD N
of IN N
the DT N
few JJ N
. . N

Intravenous JJ N
heparin NN N
and CC N
patent NN N
hemostasis NN N
lower RBR N
its PRP$ N
incidence NN N
. . N

A DT N
possible JJ N
local JJ N
effect NN N
of IN N
intra-arterially RB N
administered VBN N
heparin NN N
during IN N
transradial JJ N
procedures NNS N
has VBZ N
not RB N
been VBN N
evaluated VBN N
. . N

We PRP N
studied VBD N
500 CD N
consecutive JJ N
patients NNS N
randomized VBN N
to TO N
an DT N
intravenous JJ N
group NN N
( ( N
n JJ N
= NNP N
250 CD N
) ) N
, , N
receiving VBG N
50 CD N
U/kg NNP N
of IN N
unfractionated JJ N
heparin NN N
( ( N
maximal JJ N
dose VBP N
5,000 CD N
U NNP N
) ) N
intravenously RB N
, , N
and CC N
an DT N
intra-arterial JJ N
group NN N
( ( N
n JJ N
= NNP N
250 CD N
) ) N
receiving VBG N
the DT N
same JJ N
dose JJ N
intra-arterially RB N
. . N

All DT N
patients NNS N
received VBD N
a DT N
vasodilator NN N
" NN N
cocktail NN N
" NNP N
intra-arterially RB N
and CC N
underwent JJ N
cardiac JJ N
catheterization NN N
using VBG N
a DT N
5F CD N
introducer NN N
sheath NN N
and CC N
catheters NNS N
. . N

The DT N
activated JJ N
clotting NN N
time NN N
was VBD N
measured VBN N
at IN N
the DT N
end NN N
of IN N
the DT N
procedure NN N
. . N

All DT N
patients NNS N
received VBD N
hemostasis NN N
with IN N
a DT N
radial JJ N
compression NN N
device NN N
( ( N
TR NNP N
Band NNP N
) ) N
, , N
applied VBN N
after IN N
sheath NN N
removal NN N
, , N
for IN N
2 CD N
hours NNS N
. . N

A DT N
plethysmographic JJ N
evaluation NN N
for IN N
RAO NNP N
was VBD N
performed VBN N
at IN N
24 CD N
hours NNS N
and CC N
30 CD N
days NNS N
after IN N
the DT N
procedure NN N
. . N

Early JJ N
RAO NNP N
occurred VBD N
in IN N
5.6 CD N
% NN N
( ( N
n JJ N
= NNP N
14 CD N
) ) N
of IN N
the DT N
intravenous JJ N
group NN N
and CC N
6 CD N
% NN N
( ( N
n JJ N
= NNP N
15 CD N
) ) N
of IN N
the DT N
intra-arterial JJ N
group NN N
. . N

The DT N
difference NN N
was VBD N
not RB N
statistically RB N
significant JJ N
( ( N
chi-square JJ N
= NN N
0.037 CD N
, , N
p NN N
> NNP N
0.8 CD N
) ) N
. . N

Chronic NNP N
RAO NNP N
occurred VBD N
in IN N
3.2 CD N
% NN N
, , N
( ( N
n JJ N
= NNP N
8 CD N
) ) N
of IN N
the DT N
intravenous JJ N
group NN N
compared VBN N
to TO N
4 CD N
% NN N
( ( N
n JJ N
= NNP N
10 CD N
) ) N
of IN N
the DT N
intra-arterial JJ N
group NN N
. . N

The DT N
difference NN N
was VBD N
not RB N
statistically RB N
significant JJ N
( ( N
chi-square JJ N
= NN N
0.231 CD N
, , N
p NN N
> NNP N
0.6 CD N
) ) N
. . N

The DT N
activated JJ N
clotting NN N
time NN N
was VBD N
211 CD N
+/- JJ N
16 CD N
seconds NNS N
in IN N
the DT N
intravenous JJ N
group NN N
and CC N
213 CD N
+/- JJ N
17 CD N
seconds NNS N
in IN N
the DT N
intra-arterial JJ N
group NN N
, , N
a DT N
statistically RB N
insignificant JJ N
difference NN N
( ( N
t JJ N
= NNP N
-1.095 NNP N
, , N
p NN N
> NNP N
0.2 CD N
) ) N
. . N

In IN N
conclusion NN N
, , N
intra-arterial JJ N
and CC N
intravenous JJ N
heparin NNS N
administration NN N
provide VBP N
comparable JJ N
efficacy NN N
in IN N
preventing VBG N
RAO NNP N
, , N
favoring VBG N
a DT N
probable JJ N
systemically RB N
mediated VBD N
mechanism NN N
of IN N
action NN N
, , N
rather RB N
than IN N
a DT N
local JJ N
effect NN N
. . N

-DOCSTART- -X- O O 16199793

Family RB N
education NN N
for IN N
people NNS 4_p
with IN 4_p
schizophrenia NN 4_p
in IN N
Beijing NNP N
, , N
China NNP N
: : N
randomised VBD N
controlled JJ N
trial NN N
. . N

BACKGROUND NNP N
Much NNP N
of IN N
China NNP N
lacks VBZ N
well-developed JJ N
services NNS N
for IN N
people NNS N
with IN N
schizophrenia NN 4_p
and CC N
their PRP$ N
families NNS N
, , N
and CC N
most JJS N
of IN N
the DT N
existing VBG N
services NNS N
focus NN N
on IN N
hospitals NNS N
. . N

There EX N
is VBZ N
a DT N
need NN N
for IN N
culturally RB N
sensitive JJ N
family NN N
treatments NNS N
offered VBN N
by IN N
nurses NNS N
. . N

AIMS NNP N
To TO N
conduct VB N
a DT N
longitudinal JJ N
experimental NN N
study NN N
examining VBG N
the DT N
effect NN N
of IN N
patient NN N
and CC N
family NN N
education NN N
in IN N
a DT N
sample NN N
of IN N
Chinese JJ N
people NNS N
with IN N
schizophrenia NN 4_p
. . N

METHOD NNP N
A NNP N
randomised VBD N
controlled VBN N
trial NN N
was VBD N
conducted VBN N
in IN N
a DT N
large JJ N
hospital NN N
with IN N
a DT N
was VBD N
conducted VBN N
in IN N
a DT N
large JJ N
hospital NN N
with IN N
a DT N
sample NN N
of IN N
101 CD N
patients NNS N
with IN N
schizophrenia NN 4_p
and CC N
their PRP$ N
families NNS N
. . N

Data NNS N
were VBD N
collected VBN N
at IN N
admission NN N
and CC N
at IN N
discharge NN N
, , N
and CC N
then RB N
at IN N
3 CD N
and CC N
9 CD N
months NNS N
after IN N
discharge NN N
. . N

The DT N
intervention NN N
group NN N
received VBD N
family NN N
education NN N
, , N
and CC N
data NNS N
on IN N
their PRP$ N
knowledge NN N
about IN N
schizophrenia NN N
, , N
symptoms NNS N
, , N
functioning VBG N
, , N
psychosocial JJ N
behaviour NN N
, , N
relapse NN N
and CC N
medication NN N
adherence NN N
were VBD N
collected VBN N
and CC N
compared VBN N
with IN N
the DT N
control NN N
group NN N
. . N

RESULTS NNP N
There EX N
was VBD N
a DT N
significant JJ N
improvement NN N
in IN N
knowledge NN N
about IN N
schizophrenia NN N
in IN N
the DT N
experimental JJ N
group NN N
and CC N
a DT N
significant JJ N
difference NN N
in IN N
symptom JJ N
scores NNS N
and CC N
functioning VBG N
at IN N
9 CD N
months NNS N
after IN N
discharge NN N
. . N

Patients NNS N
who WP N
were VBD N
nonadherent JJ N
to TO N
medication NN N
regimens NNS N
were VBD N
more RBR N
likely JJ N
to TO N
relapse VB N
. . N

CONCLUSIONS NNP N
Family NNP N
education NN N
on IN N
schizophrenia NN N
by IN N
nurses NNS N
in IN N
China NNP N
was VBD N
effective JJ N
in IN N
improving VBG N
knowledge NN N
and CC N
promoting VBG N
improvement NN N
in IN N
patients NNS N
' POS N
symptoms NNS N
. . N

-DOCSTART- -X- O O 6516935

Rational-emotive JJ N
therapy NN N
and CC N
the DT N
reduction NN N
of IN N
interpersonal JJ N
anxiety NN N
in IN N
junior JJ N
high JJ N
school NN N
students NNS N
. . N

This DT N
study NN N
evaluated VBD N
the DT N
effectiveness NN N
of IN N
rational-emotive JJ N
therapy NN N
and CC N
rational-emotive JJ N
imagery NN N
. . N

Fifty-nine JJ N
junior JJ N
high JJ N
school NN N
students NNS N
who WP N
volunteered VBD N
to TO N
participate VB N
in IN N
treatment NN N
for IN N
interpersonal JJ N
anxiety NN 4_p
were VBD N
randomly RB N
assigned VBN N
to TO N
rational-emotive JJ N
therapy NN N
without IN N
imagery NN N
( ( N
RET NNP N
) ) N
, , N
rational-emotive JJ N
therapy NN N
with IN N
imagery NN N
( ( N
REI NNP N
) ) N
, , N
relationship-oriented JJ N
counseling NN N
( ( N
ROC NNP N
) ) N
, , N
and CC N
waiting-list JJ N
control NN N
( ( N
WLC NNP N
) ) N
groups NNS N
. . N

Groups NNP N
met VBD N
for IN N
seven CD N
50-minute JJ N
treatment NN N
sessions NNS N
during IN N
a DT N
three-week JJ N
period NN N
. . N

Assessments NNS N
were VBD N
conducted VBN N
at IN N
pretreatment NN N
, , N
posttreatment NN N
, , N
and CC N
three-week JJ N
follow-up NN N
. . N

Both DT N
self-report JJ N
and CC N
sociometric JJ N
measures NNS N
were VBD N
used VBN N
to TO N
evaluate VB N
treatment NN N
outcome NN N
. . N

At IN N
postassessment NN N
, , N
both CC N
the DT N
RET NNP N
and CC N
REI NNP N
groups NNS N
were VBD N
rated VBN N
on IN N
sociometric JJ N
measures NNS N
as IN N
significantly RB N
less RBR N
interpersonally RB N
anxious JJ N
than IN N
the DT N
WLC NNP N
group NN N
. . N

Mean NNP N
scores VBZ N
favored VBD N
the DT N
RET NNP N
and CC N
REI NNP N
groups NNS N
, , N
but CC N
no DT N
significant JJ N
differences NNS N
between IN N
these DT N
groups NNS N
and CC N
the DT N
ROC NNP N
group NN N
were VBD N
obtained VBN N
. . N

The DT N
self-report JJ N
measure NN N
did VBD N
not RB N
significantly RB N
differentiate VBP N
between IN N
groups NNS N
, , N
but CC N
the DT N
REI NNP N
group NN N
demonstrated VBD N
significant JJ N
pre- JJ N
to TO N
follow-up JJ N
changes NNS N
. . N

Both CC N
the DT N
RET NNP N
and CC N
REI NNP N
groups NNS N
yielded VBD N
greater JJR N
reductions NNS N
in IN N
irrational JJ N
thinking NN N
than IN N
did VBD N
the DT N
ROC NNP N
and CC N
WLC NNP N
groups NNS N
. . N

In IN N
addition NN N
, , N
the DT N
pattern NN N
of IN N
the DT N
results NNS N
supported VBD N
the DT N
use NN N
of IN N
rational-emotive JJ N
imagery NN N
as IN N
a DT N
component NN N
of IN N
rational-emotive JJ N
therapy NN N
. . N

The DT N
practical JJ N
implications NNS N
of IN N
these DT N
findings NNS N
are VBP N
discussed VBN N
. . N

-DOCSTART- -X- O O 7862876

Neuroendocrine NNP N
effects NNS N
of IN N
sumatriptan NN N
. . N

The DT N
neuroendocrine JJ N
effects NNS N
of IN N
the DT N
5-HT JJ N
receptor NN N
agonist NN N
, , N
sumatriptan NN N
( ( N
6 CD N
mg RB N
subcutaneously RB N
) ) N
, , N
were VBD N
studied VBN N
in IN N
11 CD 4_p
healthy JJ 4_p
male NN 4_p
subjects NNS 4_p
using VBG N
a DT N
placebo-controlled JJ N
, , N
cross-over JJ N
design NN N
. . N

Compared VBN N
to TO N
placebo VB N
, , N
sumatriptan VB N
significantly RB N
lowered VBN N
levels NNS N
of IN N
plasma NN N
prolactin NN N
but CC N
increased VBD N
those DT N
of IN N
plasma JJ N
growth NN N
hormone NN N
. . N

There EX N
was VBD N
no DT N
effect NN N
on IN N
plasma NN N
cortisol NN N
concentrations NNS N
. . N

The DT N
neuroendocrine JJ N
effects NNS N
of IN N
sumatriptan JJ N
differ NN N
from IN N
those DT N
of IN N
previously RB N
described VBN N
5-HT-receptor JJ N
agonists NNS N
, , N
and CC N
may MD N
be VB N
a DT N
consequence NN N
of IN N
selective JJ N
activation NN N
of IN N
5-HT1D JJ N
or CC N
5-HT1B JJ N
receptors NNS N
. . N

However RB N
, , N
the DT N
present JJ N
data NNS N
can MD N
not RB N
exclude VB N
the DT N
possibility NN N
that IN N
the DT N
neuroendocrine JJ N
changes NNS N
reflect VBP N
nonspecific JJ N
stress NN N
responses NNS N
or CC N
changes NNS N
in IN N
pituitary JJ N
blood NN N
flow NN N
. . N

-DOCSTART- -X- O O 16354710

Using VBG N
dietetic JJ N
assistants NNS N
to TO N
improve VB N
the DT N
outcome NN N
of IN N
hip JJ 4_p
fracture NN 4_p
: : N
a DT N
randomised JJ N
controlled JJ N
trial NN N
of IN N
nutritional JJ N
support NN N
in IN N
an DT N
acute NN 4_p
trauma NN 4_p
ward NN 4_p
. . N

OBJECTIVE UH N
To TO N
examine VB N
how WRB N
improved JJ N
attention NN N
to TO N
nutritional JJ N
status NN N
and CC N
dietary JJ N
intake NN N
, , N
achieved VBN N
through IN N
the DT N
employment NN N
of IN N
dietetic JJ N
assistants NNS N
( ( N
DAs NNP N
) ) N
, , N
will MD N
affect VB N
postoperative JJ N
clinical JJ N
outcome NN N
among IN N
elderly JJ N
women NNS N
with IN N
hip JJ 4_p
fracture NN 4_p
. . N

DESIGN NNP N
Open NNP N
prospective NN N
randomised VBD N
controlled VBN N
trial NN N
, , N
comparing VBG N
conventional JJ N
nursing NN N
care NN N
with IN N
the DT N
additional JJ N
nutritional JJ N
support NN N
provided VBN N
by IN N
DA NNP N
. . N

SETTING NNP N
Thirty-eight NNP N
bedded VBD N
acute JJ N
trauma NN N
ward NN N
in IN N
a DT N
teaching JJ N
hospital NN N
. . N

PARTICIPANTS VB N
All DT N
but CC N
11 CD N
of IN N
344 CD N
consecutive JJ N
admissions NNS N
with IN N
acute JJ N
nonpathological JJ N
hip NN N
fracture NN N
were VBD N
approached VBN N
. . N

Three CD N
hundred VBD N
and CC N
eighteen JJ N
( ( N
93 CD N
% NN N
) ) N
agreed VBD N
to TO N
inclusion NN N
. . N

Sixteen NNP N
were VBD 4_p
ineligible JJ 4_p
as IN N
they PRP N
were VBD N
immediately RB N
transferred VBN N
to TO N
another DT N
acute NN N
ward NN N
, , N
were VBD N
managed VBN N
conservatively RB N
or CC N
died VBD N
preoperatively RB N
. . N

PRIMARY NNP N
OUTCOME NNP N
MEASURE NNP N
Postoperative NNP N
mortality NN N
in IN N
the DT N
acute JJ N
trauma NN N
unit NN N
. . N

SECONDARY NNP N
OUTCOME NNP N
MEASURES NNP N
Postoperative NNP N
mortality NN N
at IN N
4 CD N
months NNS N
after IN N
fracture NN N
, , N
length NN N
of IN N
stay NN N
, , N
energy NN N
intake NN N
and CC N
nutritional JJ N
status NN N
. . N

RESULTS NNP N
DA-supported JJ N
participants NNS N
were VBD N
less RBR N
likely JJ N
to TO N
die VB N
in IN N
the DT N
acute JJ N
ward NN N
( ( N
4.1 CD N
versus RB N
10.1 CD N
% NN N
, , N
P NNP N
= NNP N
0.048 CD N
) ) N
. . N

This DT N
effect NN N
was VBD N
still RB N
apparent JJ N
at IN N
4 CD N
month NN N
follow-up NN N
( ( N
13.1 CD N
versus RB N
22.9 CD N
% NN N
, , N
P NNP N
= NNP N
0.036 CD N
) ) N
. . N

DA-supported JJ N
subjects NNS N
had VBD N
significantly RB N
better RBR N
mean JJ N
daily JJ N
energy NN N
intake NN N
( ( N
1,105 CD N
kcal JJ N
versus NN N
756 CD N
kcal/24 NN N
h NN N
, , N
95 CD N
% NN N
CI NNP N
259-440 JJ N
kcal/24 NN N
h NN N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
significantly RB N
smaller JJR N
reduction NN N
in IN N
mid-arm JJ N
circumference NN N
during IN N
their PRP$ N
inpatient JJ N
stay NN N
( ( N
0.39 CD N
cm NN N
, , N
P NNP N
= NNP N
0.002 CD N
) ) N
and CC N
nonsignificantly RB N
favourable JJ N
results NNS N
for IN N
other JJ N
anthropometric JJ N
and CC N
laboratory JJ N
measurements NNS N
. . N

CONCLUSION NNP N
Dietetic NNP N
or CC N
nutrition NN N
assistants NNS N
are VBP N
being VBG N
introduced VBN N
in IN N
units NNS N
across IN N
the DT N
UK NNP N
. . N

This DT N
, , N
the DT N
largest JJS N
ever RB N
study NN N
of IN N
nutritional JJ N
support NN N
after IN N
hip NN N
fracture NN N
, , N
shows VBZ N
that IN N
their PRP$ N
employment NN N
significantly RB N
reduced VBD N
patients NNS N
' POS N
risk NN N
of IN N
dying VBG N
in IN N
the DT N
acute JJ N
trauma NN N
unit NN N
; : N
an DT N
effect NN N
that WDT N
persisted VBD N
at IN N
4 CD N
month NN N
follow-up NN N
. . N

-DOCSTART- -X- O O 7706098

The DT N
effect NN N
of IN N
patient JJ N
position NN N
on IN N
the DT N
reproducibility NN N
of IN N
cardiac JJ N
output NN N
measurements NNS N
. . N

OBJECTIVE NN N
To TO N
determine VB N
the DT N
effect NN N
of IN N
patient JJ N
position NN N
on IN N
the DT N
reproducibility NN N
of IN N
cardiac JJ N
output NN N
measurements NNS N
. . N

DESIGN NNP N
Prospective NNP N
, , N
two-group JJ N
quasi-experimental JJ N
design NN N
. . N

Convenience NN N
sample NN N
. . N

SETTING CC N
The DT N
study NN N
involved VBD N
two CD N
intensive JJ N
care NN N
units NNS N
in IN N
two CD N
adult NN N
acute NN N
care NN N
hospitals NNS N
. . N

PATIENTS NNP N
Thirty NNP N
patients NNS N
admitted VBD N
to TO N
the DT N
intensive JJ N
care NN N
unit NN N
who WP N
had VBD N
a DT N
thermodilution NN 4_p
pulmonary JJ 4_p
artery NN 4_p
catheter NN 4_p
in IN N
place NN N
. . N

Ages NNS N
ranged VBD N
from IN N
39 CD N
to TO N
80 CD N
years NNS N
( ( N
mean NN N
of IN N
66.4 CD N
+/- JJ N
11.3 CD N
years NNS N
) ) N
. . N

OUTCOME NNP N
MEASURES NNP N
Thermodilution NNP N
cardiac NN N
output NN N
measurements NNS N
. . N

INTERVENTION NNP N
The DT N
subjects NNS N
were VBD N
placed VBN N
in IN N
one CD N
of IN N
two CD N
groups NNS N
, , N
initially RB N
by IN N
flipping VBG N
a DT N
coin NN N
then RB N
into IN N
alternate NN N
groups NNS N
. . N

Group NNP N
A NNP N
subjects NNS N
were VBD N
placed VBN N
supine NN N
, , N
and CC N
after IN N
5 CD N
minutes NNS N
had VBD N
cardiac JJ N
output NN N
measurements NNS N
performed VBN N
. . N

They PRP N
were VBD N
then RB N
placed VBN N
in IN N
the DT N
45-degree JJ N
upright JJ N
position NN N
, , N
and CC N
after IN N
an DT N
additional JJ N
5 CD N
minutes NNS N
had VBD N
cardiac JJ N
output NN N
measurements NNS N
performed VBN N
. . N

Group NNP N
B NNP N
subjects NNS N
were VBD N
first RB N
placed VBN N
in IN N
the DT N
45-degree JJ N
upright JJ N
position NN N
, , N
and CC N
after IN N
5 CD N
minutes NNS N
had VBD N
cardiac JJ N
output NN N
measurements NNS N
performed VBN N
. . N

They PRP N
were VBD N
then RB N
placed VBN N
in IN N
the DT N
supine NN N
flat JJ N
position NN N
, , N
and CC N
after IN N
an DT N
additional JJ N
5 CD N
minutes NNS N
had VBD N
cardiac JJ N
output NN N
measurements NNS N
performed VBN N
. . N

RESULTS NNP N
Seventy NNP N
percent NN N
( ( N
n JJ N
= NNP N
30 CD N
) ) N
of IN N
the DT N
sample JJ N
population NN N
displayed VBD N
a DT N
lower JJR N
cardiac NN N
output NN N
in IN N
the DT N
45-degree JJ N
upright JJ N
position NN N
than IN N
that DT N
obtained VBN N
in IN N
the DT N
supine JJ N
position NN N
, , N
with IN N
the DT N
decrease NN N
ranging VBG N
from IN N
1 CD N
% NN N
to TO N
32 CD N
% NN N
( ( N
mean JJ N
decrease NN N
11 CD N
% NN N
) ) N
. . N

Forty CD N
percent NN N
( ( N
n JJ N
= NNP N
30 CD N
) ) N
of IN N
cardiac JJ N
output NN N
measurements NNS N
obtained VBN N
in IN N
the DT N
45-degree JJ N
upright NN N
were VBD N
greater JJR N
than IN N
or CC N
equal JJ N
to TO N
10 CD N
% NN N
less JJR N
than IN N
those DT N
obtained VBN N
in IN N
the DT N
supine NN N
flat JJ N
position NN N
. . N

The DT N
differences NNS N
in IN N
cardiac JJ N
output NN N
were VBD N
analyzed VBN N
with IN N
the DT N
paired JJ N
t JJ N
test NN N
. . N

which WDT N
produced VBD N
a DT N
95 CD N
% NN N
confidence NN N
interval NN N
from IN N
-0.539 NN N
to TO N
-0.083 VB N
. . N

The DT N
two-group JJ N
Wilcoxon NNP N
test NN N
was VBD N
used VBN N
to TO N
analyze VB N
the DT N
mean JJ N
cardiac JJ N
output NN N
with IN N
the DT N
patient NN N
in IN N
the DT N
supine NN N
, , N
flat JJ N
position NN N
and CC N
in IN N
the DT N
45-degree JJ N
upright JJ N
position NN N
. . N

The DT N
mean JJ N
cardiac JJ N
output NN N
at IN N
0 CD N
degrees NNS N
was VBD N
found VBN N
to TO N
be VB N
statistically RB N
significant JJ N
higher JJR N
( ( N
p JJ N
= NNP N
0.0083 CD N
) ) N
than IN N
the DT N
mean JJ N
cardiac JJ N
output NN N
at IN N
45 CD N
degrees NNS N
. . N

The DT N
effect NN N
of IN N
coexisting VBG N
variables NNS N
was VBD N
analyzed VBN N
with IN N
the DT N
Kruskal-Wallis NNP N
. . N

The DT N
use NN N
of IN N
vasoconstrictors NNS N
was VBD N
the DT N
only JJ N
variable NN N
that WDT N
had VBD N
a DT N
statistically RB N
significant JJ N
change NN N
in IN N
cardiac JJ N
output NN N
associated VBN N
with IN N
a DT N
change NN N
in IN N
position NN N
. . N

CONCLUSIONS NNP N
These DT N
results NNS N
indicate VBP N
that IN N
cardiac JJ N
output NN N
measurements NNS N
are VBP N
affected VBN N
by IN N
alterations NNS N
in IN N
patient JJ N
position NN N
. . N

To TO N
ensure VB N
accurate JJ N
comparisons NNS N
between IN N
consecutive JJ N
cardiac JJ N
output NN N
measurements NNS N
, , N
the DT N
researchers NNS N
recommend VBP N
that IN N
the DT N
position NN N
in IN N
which WDT N
the DT N
cardiac NN N
output NN N
measurements NNS N
are VBP N
performed VBN N
be VB N
documented VBN N
and CC N
the DT N
cardiac JJ N
output NN N
measurements NNS N
be VB N
conducted VBN N
in IN N
a DT N
uniform JJ N
position NN N
. . N

-DOCSTART- -X- O O 17717526

Effects NNS N
of IN N
alfuzosin NN N
10 CD N
mg NN N
once RB N
daily RB N
on IN N
sexual JJ N
function NN N
in IN N
men NNS N
treated VBN N
for IN N
symptomatic JJ 4_p
benign NN 4_p
prostatic JJ 4_p
hyperplasia NN 4_p
. . N

We PRP N
evaluated VBD N
the DT N
effects NNS N
of IN N
extended-release JJ N
alfuzosin NN N
HCl NNP N
10 CD N
mg NN N
once RB N
daily JJ N
( ( N
q.d JJ N
. . N

) ) N
on IN N
sexual JJ N
function NN N
in IN N
men NNS N
with IN N
lower JJR 4_p
urinary JJ 4_p
tract NN 4_p
symptoms NNS 4_p
associated VBN N
with IN N
benign JJ 4_p
prostatic JJ 4_p
hyperplasia NN 4_p
( ( 4_p
BPH NNP 4_p
) ) 4_p
. . N

In IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
of IN N
men NNS N
aged VBN N
> NN N
or CC N
= $ N
50 CD N
years NNS N
, , N
after IN N
a DT N
28-day JJ N
placebo NN N
run-in JJ N
period NN N
, , N
patients NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
alfuzosin NN N
10 CD N
mg NN N
q.d NN N
. . N

or CC N
matching VBG N
placebo NN N
for IN N
28 CD N
days NNS N
. . N

The DT N
mean JJ N
change NN N
from IN N
baseline NN N
( ( N
day NN N
1 CD N
) ) N
in IN N
sexual JJ N
function NN N
on IN N
day NN N
29 CD N
was VBD N
assessed VBN N
using VBG N
the DT N
Danish JJ N
Prostate NNP N
Symptom NNP N
Score NNP N
Sex NNP N
( ( N
DAN-PSSsex NNP N
) ) N
questionnaire NN N
. . N

A DT N
total NN N
of IN N
372 CD N
patients NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
alfuzosin NN N
( ( N
n=186 JJ N
) ) N
or CC N
placebo NN N
( ( N
n=186 JJ N
) ) N
, , N
with IN N
355 CD N
completing VBG N
the DT N
study NN N
. . N

At IN N
baseline NN N
, , N
64 CD N
% NN N
of IN N
the DT N
patients NNS N
reported VBD N
erectile JJ 4_p
dysfunction NN 4_p
( ( 4_p
ED NNP 4_p
) ) 4_p
and CC N
63 CD N
% NN N
reported VBD N
ejaculatory JJ 4_p
dysfunction NN 4_p
( ( 4_p
EjD NNP 4_p
) ) 4_p
. . N

For IN N
the DT N
320 CD N
patients NNS N
who WP N
completed VBD N
the DT N
DAN-PSSsex NNP N
, , N
alfuzosin NN N
treatment NN N
was VBD N
associated VBN N
with IN N
a DT N
significant JJ N
improvement NN N
in IN N
the DT N
mean JJ N
change NN N
from IN N
baseline NN N
in IN N
erectile JJ N
function NN N
on IN N
day NN N
29 CD N
compared VBN N
with IN N
placebo NN N
( ( N
P=0.02 NNP N
) ) N
. . N

No DT N
significant JJ N
difference NN N
was VBD N
observed VBN N
between IN N
the DT N
two CD N
treatment NN N
groups NNS N
in IN N
the DT N
mean JJ N
change NN N
from IN N
baseline NN N
in IN N
ejaculatory JJ N
function NN N
on IN N
day NN N
29 CD N
. . N

For IN N
patients NNS N
with IN N
ED NNP N
at IN N
baseline NN N
, , N
a DT N
marginal JJ N
improvement NN N
in IN N
erectile JJ N
function NN N
was VBD N
demonstrated VBN N
with IN N
alfuzosin NN N
treatment NN N
( ( N
P=0.09 NNP N
vs NNP N
placebo NN N
) ) N
. . N

For IN N
patients NNS N
with IN N
EjD NNP N
at IN N
baseline NN N
, , N
the DT N
mean JJ N
change NN N
from IN N
baseline NN N
in IN N
ejaculatory JJ N
function NN N
with IN N
alfuzosin NN N
was VBD N
comparable JJ N
to TO N
that DT N
with IN N
placebo NN N
. . N

Dizziness NNP N
was VBD N
the DT N
most RBS N
common JJ N
adverse JJ N
event NN N
with IN N
alfuzosin NN N
treatment NN N
( ( N
5 CD N
vs RB N
0 CD N
% NN N
with IN N
placebo NN N
) ) N
, , N
with IN N
other JJ N
adverse JJ N
events NNS N
reported VBN N
with IN N
comparable JJ N
frequency NN N
in IN N
both DT N
treatment NN N
groups NNS N
. . N

After IN N
1 CD N
month NN N
of IN N
treatment NN N
, , N
alfuzosin RB N
10 CD N
mg NN N
q.d NN N
. . N

significantly RB N
improved VBN N
erectile JJ N
function NN N
in IN N
men NNS N
with IN N
lower JJR N
urinary JJ N
tract NN N
symptoms/ NN N
benign JJ N
prostatic JJ N
hypertrophy NN N
and CC N
had VBD N
no DT N
adverse JJ N
effect NN N
on IN N
ejaculatory NN N
function NN N
. . N

-DOCSTART- -X- O O 24350695

A DT N
randomized VBN N
controlled JJ N
trial NN N
of IN N
nonlinear JJ N
frequency NN N
compression NN N
versus IN N
conventional JJ N
processing NN N
in IN N
hearing VBG N
aids NNS N
: : N
speech NN N
and CC N
language NN N
of IN N
children NNS 4_p
at IN 4_p
three CD 4_p
years NNS 4_p
of IN 4_p
age NN 4_p
. . 4_p

OBJECTIVE UH N
To TO N
determine VB N
the DT N
effect NN N
of IN N
nonlinear JJ N
frequency NN N
compression NN N
( ( N
NLFC NNP N
) ) N
on IN N
children NNS N
's POS N
development NN N
of IN N
speech NN N
and CC N
language NN N
at IN N
three CD N
years NNS N
of IN N
age NN N
. . N

DESIGN VB N
A DT N
randomized NN N
controlled VBD N
trial NN N
was VBD N
conducted VBN N
as IN N
part NN N
of IN N
the DT N
population-based JJ N
longitudinal JJ N
study NN N
on IN N
outcomes NNS N
of IN N
children NNS N
with IN N
hearing VBG N
impairment NN N
( ( N
LOCHI NNP N
) ) N
. . N

Participants NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
fitting VBG N
with IN N
NLFC NNP N
( ( N
Phonak NNP N
Naida NNP N
V NNP N
SP NNP N
or CC N
UP NNP N
) ) N
or CC N
with IN N
conventional JJ N
processing NN N
in IN N
hearing VBG N
aids NNS N
, , N
prescribed VBN N
by IN N
using VBG N
either CC N
the DT N
NAL NNP N
or CC N
the DT N
DSL NNP N
formula NN N
. . N

Standardized JJ N
tests NNS N
of IN N
speech NN N
production NN N
, , N
receptive JJ N
and CC N
expressive JJ N
language NN N
were VBD N
administered VBN N
, , N
and CC N
parent NN N
ratings NNS N
were VBD N
collected VBN N
. . N

All DT N
assessments NNS N
were VBD N
double-blinded JJ N
. . N

STUDY NNP N
SAMPLE NNP N
Participants NNP N
were VBD N
44 CD N
of IN N
the DT N
450 CD N
children NNS N
in IN N
the DT N
LOCHI NNP N
cohort NN N
. . N

RESULTS NNP N
Compared VBD N
to TO N
children NNS N
using VBG N
conventional JJ N
processing NN N
, , N
receptive JJ N
and CC N
expressive JJ N
language NN N
was VBD N
higher JJR N
but CC N
receptive JJ N
vocabulary NN N
and CC N
consonant JJ N
articulation NN N
scores NNS N
were VBD N
lower JJR N
for IN N
children NNS N
who WP N
use VBP N
NLFC NNP N
. . N

There EX N
was VBD N
increased VBN N
substitution NN N
of IN N
affricates NNS N
by IN N
fricatives NNS N
for IN N
children NNS N
using VBG N
NLFC NNP N
, , N
compared VBN N
to TO N
children NNS N
using VBG N
conventional JJ N
amplification NN N
. . N

After IN N
allowing VBG N
for IN N
the DT N
effect NN N
of IN N
multiple JJ N
demographic JJ N
variables NNS N
, , N
the DT N
difference NN N
in IN N
global JJ N
language NN N
scores NNS N
between IN N
groups NNS N
was VBD N
not RB N
significant JJ N
( ( N
effect NN N
: : N
0.8 CD N
[ $ N
95 CD N
% NN N
confidence NN N
interval NN N
: : N
- : N
6.7 CD N
, , N
8.3 CD N
] NN N
) ) N
. . N

CONCLUSIONS NNP N
There EX N
is VBZ N
insufficient JJ N
evidence NN N
to TO N
indicate VB N
a DT N
difference NN N
in IN N
language NN N
ability NN N
between IN N
children NNS N
using VBG N
NLFC NNP N
and CC N
those DT N
using VBG N
conventional JJ N
amplification NN N
. . N

-DOCSTART- -X- O O 16435344

Randomized VBN N
, , N
placebo-controlled JJ N
, , N
double-blind JJ N
clinical JJ N
trial NN N
evaluating VBG N
the DT N
treatment NN N
of IN N
plantar NN 4_p
fasciitis NN 4_p
with IN N
an DT N
extracoporeal NN N
shockwave NN N
therapy NN N
( ( N
ESWT NNP N
) ) N
device NN N
: : N
a DT N
North JJ N
American JJ N
confirmatory NN N
study NN N
. . N

Despite IN N
numerous JJ N
publications NNS N
and CC N
clinical JJ N
trials NNS N
, , N
the DT N
results NNS N
of IN N
treatment NN N
of IN N
recalcitrant JJ 4_p
chronic JJ 4_p
plantar NN 4_p
fasciitis NN 4_p
with IN N
extracorporeal JJ N
shockwave JJ N
therapy NN N
( ( N
ESWT NNP N
) ) N
still RB N
remain VBP N
equivocal JJ N
as IN N
to TO N
whether IN N
or CC N
not RB N
this DT N
treatment NN N
provides VBZ N
relief NN N
from IN N
the DT N
pain NN N
associated VBN N
with IN N
this DT N
condition NN N
. . N

The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
whether IN N
extracorporeal NN N
shock NN N
wave VBP N
therapy NN N
can MD N
safely RB N
and CC N
effectively RB N
relieve VB N
the DT N
pain NN N
associated VBN N
with IN N
chronic JJ N
plantar NN N
fasciitis NN N
compared VBN N
to TO N
placebo VB N
treatment NN N
, , N
as IN N
demonstrated VBN N
by IN N
pain NN N
with IN N
walking NN N
in IN N
the DT N
morning NN N
. . N

This DT N
was VBD N
set VBN N
in IN N
a DT N
multicenter NN N
, , N
randomized VBN N
, , N
placebo-controlled JJ N
, , N
double-blind JJ N
, , N
confirmatory JJ N
clinical JJ N
study NN N
undertaken VBN N
in IN N
four CD N
outpatient NN N
orthopedic NN N
clinics NNS N
. . N

The DT N
patients NNS N
, , N
114 CD N
adult NN N
subjects NNS N
with IN N
chronic JJ 4_p
plantar NN 4_p
fasciitis NN 4_p
, , 4_p
recalcitrant JJ 4_p
to TO 4_p
conservative JJ 4_p
therapies NNS 4_p
for IN N
at IN N
least JJS N
6 CD N
months NNS N
, , N
were VBD N
randomized VBN N
to TO N
two CD N
groups NNS N
. . N

Treatment NNP N
consisted VBD N
of IN N
approximately RB N
3,800 CD N
total JJ N
shock NN N
waves NNS N
( ( N
+/-10 JJ N
) ) N
reaching VBG N
an DT N
approximated JJ N
total NN N
energy NN N
delivery NN N
of IN N
1,300 CD N
mJ/mm NN N
( ( N
2 CD N
) ) N
( ( N
ED+ NNP N
) ) N
in IN N
a DT N
single JJ N
session NN N
versus IN N
placebo NN N
treatment NN N
. . N

This DT N
study NN N
demonstrated VBD N
a DT N
statistically RB N
significant JJ N
difference NN N
between IN N
treatment NN N
groups NNS N
in IN N
the DT N
change NN N
from IN N
baseline NN N
to TO N
3 CD N
months NNS N
in IN N
the DT N
primary JJ N
efficacy NN N
outcome NN N
of IN N
pain NN N
during IN N
the DT N
first JJ N
few JJ N
minutes NNS N
of IN N
walking VBG N
measured VBN N
by IN N
a DT N
visual JJ N
analog NN N
scale NN N
. . N

There EX N
was VBD N
also RB N
a DT N
statistically RB N
significant JJ N
difference NN N
between IN N
treatments NNS N
in IN N
the DT N
number NN N
of IN N
participants NNS N
whose WP$ N
changes NNS N
in IN N
Visual NNP N
Analog NNP N
Scale NNP N
scores VBZ N
met VBD N
the DT N
study NN N
definition NN N
of IN N
success NN N
at IN N
both DT N
6 CD N
weeks NNS N
and CC N
3 CD N
months NNS N
posttreatment NN N
; : N
and CC N
between IN N
treatment NN N
groups NNS N
in IN N
the DT N
change NN N
from IN N
baseline NN N
to TO N
3 CD N
months NNS N
posttreatment NN N
in IN N
the DT N
Roles NNP N
and CC N
Maudsley NNP N
Score NNP N
. . N

The DT N
results NNS N
of IN N
this DT N
study NN N
confirm VBP N
that IN N
ESWT NNP N
administered VBD N
with IN N
the DT N
Dornier NNP N
Epos NNP N
Ultra NNP N
is VBZ N
a DT N
safe JJ N
and CC N
effective JJ N
treatment NN N
for IN N
recalcitrant JJ N
plantar NN N
fasciitis NN N
. . N

-DOCSTART- -X- O O 9400786

MSL-109 NNP N
adjuvant JJ N
therapy NN N
for IN N
cytomegalovirus NN 4_p
retinitis NN 4_p
in IN N
patients NNS N
with IN N
acquired JJ N
immunodeficiency NN N
syndrome NN N
: : N
the DT N
Monoclonal NNP N
Antibody NNP N
Cytomegalovirus NNP N
Retinitis NNP N
Trial NNP N
. . N

The DT N
Studies NNPS N
of IN N
Ocular JJ 4_p
Complications NNS 4_p
of IN N
AIDS NNP N
Research NNP N
Group NNP N
. . N

AIDS NNP N
Clinical JJ N
Trials NNP N
Group NNP N
. . N

OBJECTIVE NNP N
To TO N
evaluate VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
an DT N
intravenous JJ N
human JJ N
monoclonal NN N
antibody NN N
to TO N
cytomegalovirus VB N
( ( N
CMV NNP N
) ) N
, , N
MSL-109 NNP N
, , N
as IN N
adjuvant JJ N
treatment NN N
for IN N
CMV NNP N
retinitis NN N
. . N

METHODS NNP N
Two CD N
hundred VBD N
nine CD N
patients NNS N
with IN N
acquired JJ 4_p
immunodeficiency NN 4_p
syndrome NN 4_p
and CC N
active JJ N
CMV NNP 4_p
retinitis NN 4_p
were VBD N
enrolled VBN N
in IN N
a DT N
multicenter NN N
, , N
phase NN N
2/3 CD N
, , N
randomized VBN N
, , N
placebo-controlled JJ N
clinical JJ N
trial NN N
. . N

Patients NNS N
received VBD N
adjuvant JJ N
treatment NN N
with IN N
MSL-109 NNP N
, , N
60 CD N
mg NN N
intravenously RB N
every DT N
2 CD N
weeks NNS N
, , N
or CC N
placebo NN N
. . N

Randomization NN N
was VBD N
stratified VBN N
on IN N
the DT N
basis NN N
of IN N
whether IN N
patients NNS N
had VBD N
untreated VBN N
or CC N
relapsed VBN N
retinitis NN N
. . N

Primary JJ N
drug NN N
therapy NN N
for IN N
CMV NNP N
retinitis NN N
was VBD N
determined VBN N
by IN N
the DT N
treating NN N
physician NN N
. . N

RESULTS VB N
The DT N
rates NNS N
of IN N
retinitis NN N
progression NN N
, , N
as IN N
evaluated VBN N
in IN N
a DT N
masked JJ N
fashion NN N
, , N
were VBD N
3.04/person-year JJ N
in IN N
the DT N
MSL-109-treated NNP N
group NN N
and CC N
3.05/person-year JJ N
in IN N
the DT N
placebo-treated JJ N
group NN N
( ( N
P=.98 NNP N
; : N
Wald NNP N
test NN N
) ) N
; : N
the DT N
median JJ N
times NNS N
to TO N
progression NN N
were VBD N
67 CD N
days NNS N
in IN N
the DT N
MSL-109-treated NNP N
group NN N
and CC N
65 CD N
days NNS N
in IN N
the DT N
placebo-treated JJ N
group NN N
. . N

No DT N
differences NNS N
between IN N
the DT N
2 CD N
groups NNS N
were VBD N
noted VBN N
in IN N
the DT N
rates NNS N
of IN N
increase NN N
in IN N
retinal JJ N
area NN N
involved VBN N
by IN N
CMV NNP N
, , N
visual JJ N
field NN N
loss NN N
, , N
or CC N
visual JJ N
acuity NN N
outcomes NNS N
. . N

The DT N
mortality NN N
rate NN N
in IN N
the DT N
MSL-109-treated NNP N
group NN N
was VBD N
0.68/person-year JJ N
, , N
and CC N
in IN N
the DT N
placebo-treated JJ N
group NN N
, , N
0.31/person-year JJ N
( ( N
P=.01 NNP N
) ) N
. . N

The DT N
mortality NN N
difference NN N
was VBD N
not RB N
explained VBN N
by IN N
differences NNS N
in IN N
baseline NN N
variables NNS N
or CC N
in IN N
concurrent JJ N
antiretroviral JJ N
therapy NN N
. . N

Among IN N
patients NNS N
with IN N
newly RB N
diagnosed VBN N
retinitis NN N
, , N
mortality NN N
rates NNS N
were VBD N
similar JJ N
( ( N
MSL-109 NNP N
, , N
0.41/person-year JJ N
; : N
placebo NN N
, , N
0.42/person-year JJ N
; : N
P=.95 NNP N
) ) N
, , N
whereas JJ N
among IN N
patients NNS N
with IN N
relapsed JJ N
retinitis NN N
the DT N
MSL-109-treated NNP N
group NN N
had VBD N
a DT N
greater JJR N
mortality NN N
rate NN N
( ( N
MSL-109 NNP N
, , N
0.83/person-year JJ N
; : N
placebo NN N
, , N
0.24/person-year JJ N
; : N
P=.003 NNP N
) ) N
. . N

However RB N
, , N
the DT N
mortality NN N
rate NN N
in IN N
the DT N
placebo-treated JJ N
patients NNS N
with IN N
relapsed JJ N
CMV NNP N
retinitis NN N
was VBD N
lower JJR N
than IN N
that DT N
in IN N
the DT N
placebo-treated JJ N
patients NNS N
with IN N
newly RB N
diagnosed VBN N
CMV NNP N
retinitis NN N
and CC N
lower JJR N
than IN N
that DT N
in IN N
other JJ N
trials NNS N
of IN N
patients NNS N
with IN N
relapsed JJ N
CMV NNP N
retinitis NN N
. . N

CONCLUSIONS NNP N
Intravenous NNP N
MSL-109 NNP N
, , N
60 CD N
mg NN N
every DT N
2 CD N
weeks NNS N
, , N
appeared VBD N
to TO N
be VB N
ineffective JJ N
adjuvant JJ N
therapy NN N
for IN N
CMV NNP N
retinitis NN N
. . N

The DT N
mortality NN N
rate NN N
was VBD N
higher RBR N
in IN N
the DT N
MSL-109-treated NNP N
group NN N
, , N
but CC N
the DT N
reasons NNS N
for IN N
this DT N
difference NN N
remain NN N
uncertain JJ N
. . N

-DOCSTART- -X- O O 22527308

Successful JJ N
treatment NN N
of IN N
blepharitis NN 4_p
with IN N
bibrocathol NN N
( ( N
Posiformin® NNP N
2 CD N
% NN N
) ) N
. . N

BACKGROUND NNP N
Bibrocathol NNP N
is VBZ N
a DT N
well-established JJ N
antiseptic JJ N
drug NN N
for IN N
the DT N
treatment NN N
of IN N
acute NN N
eyelid JJ N
diseases NNS N
like IN N
blepharitis NN N
. . N

Despite IN N
its PRP$ N
frequent JJ N
use NN N
in IN N
clinical JJ N
practice NN N
, , N
no DT N
controlled JJ N
clinical JJ N
trial NN N
on IN N
the DT N
efficacy NN N
of IN N
bibrocathol $ N
2 CD N
% NN N
eye NN N
ointment NN N
has VBZ N
been VBN N
performed VBN N
until IN N
now RB N
. . N

The DT N
aim NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
investigate VB N
efficacy NN N
, , N
safety NN N
and CC N
tolerability NN N
of IN N
bibrocathol NN N
( ( N
Posiformin® NNP N
2 CD N
% NN N
) ) N
eye NN N
ointment NN N
in IN N
patients NNS N
diagnosed VBN N
with IN N
blepharitis NN N
. . N

METHODS NNP N
In IN N
this DT N
multi-center NN N
, , N
randomized VBN N
, , N
double-masked JJ N
, , N
placebo-controlled JJ N
parallel-group NN N
comparison NN N
, , N
the DT N
change NN N
of IN N
signs NNS N
and CC N
symptoms NNS N
( ( N
sum VB N
score NN N
) ) N
of IN N
blepharitis NN N
in IN N
197 CD N
patients NNS N
( ( N
ITT NNP N
( ( N
intention-to-treat-group JJ N
) ) N
; : N
mean JJ N
age NN N
56 CD N
± JJ N
18 CD N
years NNS N
, , N
56 CD N
% NN N
female NN N
, , N
active JJ N
drug NN N
: : N
vehicle NN N
= IN N
97:100 CD N
) ) N
over IN N
2 CD N
weeks NNS N
treatment NN N
with IN N
bibrocathol JJ N
2 CD N
% NN N
eye NN N
ointment NN N
was VBD N
evaluated VBN N
. . N

RESULTS JJ N
Patients NNPS N
receiving VBG N
bibrocathol RB N
2 CD N
% NN N
showed VBD N
greater JJR N
improvement NN N
in IN N
the DT N
sum NN N
score NN N
than IN N
the DT N
placebo NN N
patients NNS N
( ( N
p JJ N
< NN N
0.0001 CD N
, , N
Cohen NNP N
's POS N
effect NN N
size NN N
d NN N
= NNP N
0.73 CD N
) ) N
. . N

Also RB N
, , N
the DT N
results NNS N
from IN N
further JJ N
efficacy NN N
assessments NNS N
improvement NN N
of IN N
single JJ N
symptoms NNS N
and CC N
ocular JJ N
discomfort NN N
measured VBN N
by IN N
a DT N
VAS NNP N
( ( N
visual JJ N
analogue NN N
scale NN N
) ) N
supported VBD N
treatment NN N
with IN N
bibrocathol NN N
. . N

Patients NNS N
and CC N
investigators NNS N
provided VBD N
favorable JJ N
tolerability NN N
ratings NNS N
preferring VBG N
bibrocathol NN N
over IN N
placebo NN N
. . N

No DT N
safety NN N
issues NNS N
were VBD N
observed VBN N
with IN N
regard NN N
to TO N
intraocular JJ N
pressure NN N
, , N
visual JJ N
acuity NN N
, , N
or CC N
occurrence NN N
of IN N
adverse JJ N
events NNS N
. . N

CONCLUSIONS NNP N
Blepharitis NNP N
therapy NN N
with IN N
the DT N
antiseptic JJ N
bibrocathol NN N
2 CD N
% NN N
in IN N
this DT N
trial NN N
was VBD N
highly RB N
efficacious JJ N
and CC N
safe JJ N
. . N

-DOCSTART- -X- O O 14970775

Injection NN N
pain NN N
and CC N
postinjection NN N
pain NN N
of IN N
the DT N
palatal-anterior JJ N
superior JJ N
alveolar JJ N
injection NN N
, , N
administered VBN N
with IN N
the DT N
Wand NNP N
Plus NNP N
system NN N
, , N
comparing VBG N
2 CD N
% NN N
lidocaine NN N
with IN N
1:100,000 CD N
epinephrine NN N
to TO N
3 CD N
% NN N
mepivacaine NN N
. . N

PURPOSE VB N
The DT N
purpose NN N
of IN N
this DT N
prospective JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
study NN N
was VBD N
to TO N
compare VB N
injection NN N
pain NN N
and CC N
postinjection NN N
pain NN N
of IN N
2 CD N
% NN N
lidocaine NN N
with IN N
1:100,000 CD N
epinephrine NN N
and CC N
3 CD N
% NN N
mepivacaine NN N
using VBG N
the DT N
computer-assisted JJ N
Wand NNP N
Plus NNP N
injection NN N
system NN N
to TO N
administer VB N
the DT N
palatal-anterior JJ N
superior JJ N
alveolar NN N
( ( N
P-ASA NNP N
) ) N
injection NN N
. . N

Additionally RB N
study NN N
was VBD N
done VBN N
to TO N
determine VB N
if IN N
the DT N
use NN N
of IN N
topical JJ N
anesthetic NN N
decreased VBD N
the DT N
pain NN N
of IN N
needle JJ N
insertion NN N
with IN N
the DT N
P-ASA NNP N
injection NN N
. . N

STUDY NNP N
DESIGN NNP N
Using VBG N
a DT N
crossover NN N
design NN N
, , N
40 CD N
subjects NNS N
randomly RB N
received VBD N
, , N
in IN N
a DT N
double-blind JJ N
manner NN N
, , N
P-ASA NNP N
injections NNS N
of IN N
1.4 CD N
mL NN N
of IN N
2 CD N
% NN N
lidocaine NN N
with IN N
1:100,000 CD N
epinephrine NN N
and CC N
1.4 CD N
mL NN N
of IN N
3 CD N
% NN N
mepivacaine NN N
, , N
at IN N
2 CD N
separate JJ N
appointments NNS N
. . N

The DT N
P-ASA JJ N
injection NN N
was VBD N
administered VBN N
, , N
utilizing VBG N
the DT N
Wand NNP N
Plus NNP N
system NN N
, , N
6 CD N
to TO N
10 CD N
mm NN N
into IN N
the DT N
incisive JJ N
canal NN N
located VBN N
lingual JJ N
to TO N
the DT N
central JJ N
incisors NNS N
. . N

The DT N
pain NN N
of IN N
needle JJ N
insertion NN N
, , N
needle JJ N
placement NN N
, , N
solution NN N
deposition NN N
and CC N
postinjection NN N
pain NN N
were VBD N
recorded VBN N
on IN N
a DT N
Heft-Parker NNP N
visual JJ N
analog NN N
scale NN N
for IN N
the DT N
2 CD N
P-ASA JJ N
injections NNS N
. . N

Eighty JJ N
injections NNS N
were VBD N
randomly RB N
administered VBN N
in IN N
the DT N
study NN N
, , N
40 CD N
using VBG N
topical JJ N
anesthetic JJ N
gel NN N
and CC N
40 CD N
using VBG N
a DT N
placebo NN N
gel NN N
. . N

RESULTS NNP N
For IN N
needle JJ N
insertion NN N
, , N
30 CD N
% NN N
of IN N
the DT N
subjects NNS N
reported VBN N
moderate/severe RB N
pain NN N
with IN N
the DT N
lidocaine JJ N
solution NN N
and CC N
43 CD N
% NN N
reported VBN N
moderate/severe RB N
pain NN N
with IN N
the DT N
mepivacaine JJ N
solution NN N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
( ( N
P NNP N
> NNP N
.05 NNP N
) ) N
between IN N
the DT N
topical JJ N
and CC N
placebo JJ N
groups NNS N
. . N

For IN N
needle JJ N
placement NN N
into IN N
the DT N
incisive JJ N
canal NN N
, , N
54 CD N
% NN N
of IN N
the DT N
subjects NNS N
reported VBN N
moderate/severe RB N
pain NN N
with IN N
the DT N
lidocaine JJ N
solution NN N
and CC N
58 CD N
% NN N
reported VBN N
moderate/severe RB N
pain NN N
with IN N
the DT N
mepivacaine JJ N
solution NN N
. . N

For IN N
anesthetic JJ N
solution NN N
deposition NN N
, , N
8 CD N
% NN N
of IN N
the DT N
subjects NNS N
reported VBN N
moderate JJ N
pain NN N
with IN N
the DT N
lidocaine JJ N
solution NN N
and CC N
12 CD N
% NN N
reported VBN N
moderate JJ N
pain NN N
with IN N
the DT N
mepivacaine JJ N
solution NN N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
( ( N
P NNP N
> NNP N
.05 NNP N
) ) N
between IN N
the DT N
lidocaine NN N
and CC N
mepivacaine JJ N
solutions NNS N
. . N

Regarding VBG N
postinjection NN N
pain NN N
, , N
when WRB N
anesthesia NN N
wore VBD N
off RP N
on IN N
the DT N
day NN N
of IN N
the DT N
injection NN N
, , N
20 CD N
% NN N
of IN N
the DT N
subjects NNS N
reported VBN N
moderate/severe RB N
pain NN N
with IN N
the DT N
lidocaine JJ N
solution NN N
and CC N
14 CD N
% NN N
reported VBN N
moderate/severe RB N
pain NN N
with IN N
the DT N
mepivacaine JJ N
solution NN N
. . N

Pain NNP N
ratings NNS N
decreased VBD N
over IN N
the DT N
next JJ N
3 CD N
days NNS N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
( ( N
P NNP N
> NNP N
.05 NNP N
) ) N
between IN N
the DT N
lidocaine NN N
and CC N
mepivacaine JJ N
solutions NNS N
. . N

Postinjection NNP N
, , N
12 CD N
% NN N
and CC N
18 CD N
% NN N
of IN N
the DT N
subjects NNS N
experienced VBD N
temporary JJ N
numbness/paresthesia NN N
of IN N
the DT N
incisive JJ N
papilla NN N
with IN N
the DT N
lidocaine NN N
and CC N
mepivacaine JJ N
solutions NNS N
, , N
respectively RB N
. . N

Twenty CD N
percent NN N
and CC N
28 CD N
% NN N
of IN N
the DT N
subjects NNS N
had VBD N
incisive JJ N
papilla NN N
swelling VBG N
or CC N
soreness NN N
with IN N
the DT N
lidocaine NN N
and CC N
mepivacaine JJ N
solutions NNS N
, , N
respectively RB N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
( ( N
P NNP N
> NNP N
.05 NNP N
) ) N
between IN N
the DT N
lidocaine NN N
and CC N
mepivacaine JJ N
solutions NNS N
. . N

CONCLUSIONS VB N
The DT N
P-ASA NNP N
injection NN N
of IN N
1.4 CD N
mL NN N
of IN N
2 CD N
% NN N
lidocaine NN N
with IN N
1:100,000 CD N
epinephrine NN N
or CC N
3 CD N
% NN N
mepivacaine NN N
, , N
administered VBN N
with IN N
the DT N
Wand NNP N
Plus NNP N
, , N
has VBZ N
the DT N
potential JJ N
to TO N
be VB N
a DT N
painful JJ N
injection NN N
. . N

The DT N
use NN N
of IN N
topical JJ N
anesthetic NN N
did VBD N
not RB N
significantly RB N
reduce VB N
pain NN N
of IN N
needle JJ N
insertion NN N
when WRB N
compared VBN N
to TO N
a DT N
placebo NN N
. . N

The DT N
incidence NN N
of IN N
postinjection NN N
pain NN N
, , N
temporary JJ N
numbness/paresthesia NN N
, , N
and CC N
incisive JJ N
papilla NN N
swelling VBG N
or CC N
soreness NN N
would MD N
indicate VB N
that IN N
some DT N
pain NN N
and CC N
problems NNS N
occur VBP N
with IN N
the DT N
P-ASA NNP N
technique NN N
, , N
regardless RB N
of IN N
whether IN N
2 CD N
% NN N
lidocaine NN N
with IN N
1:100,000 CD N
epinephrine NN N
or CC N
3 CD N
% NN N
mepivacaine NN N
is VBZ N
used VBN N
. . N

-DOCSTART- -X- O O 23466353

Topical JJ N
treatment NN N
of IN N
tinea NN N
pedis NNS N
using VBG N
6 CD N
% NN N
coriander NN N
oil NN N
in IN N
unguentum NN N
leniens NNS N
: : N
a DT N
randomized NN N
, , N
controlled VBN N
, , N
comparative JJ N
pilot NN N
study NN N
. . N

BACKGROUND NNP N
The DT N
antifungal JJ N
activity NN N
of IN N
coriander NN N
oil NN N
has VBZ N
already RB N
been VBN N
demonstrated VBN N
in IN N
vitro NN N
. . N

OBJECTIVE NNP N
Evaluation NN N
of IN N
the DT N
efficacy NN N
and CC N
tolerability NN N
of IN N
6 CD N
% NN N
coriander NN N
oil NN N
in IN N
unguentum NN N
leniens NNS N
in IN N
the DT N
treatment NN N
of IN N
interdigital JJ N
tinea NN N
pedis NN N
. . N

METHODS NNP N
Half-side NNP N
comparative NN N
pilot NN N
study NN N
on IN N
subjects NNS N
with IN N
symmetric JJ N
, , N
bilateral JJ N
interdigital JJ N
tinea NN N
pedis NN N
. . N

Active JJ N
drug NN N
and CC N
placebo NN N
control NN N
were VBD N
applied VBN N
twice RB N
daily RB N
on IN N
the DT N
affected JJ N
areas NNS N
, , N
and CC N
follow-up JJ N
visits NNS N
were VBD N
performed VBN N
on IN N
days NNS N
14 CD N
and CC N
28 CD N
. . N

RESULTS VB N
40 CD N
participants NNS N
( ( N
mean JJ N
age NN N
52.5 CD N
years NNS N
, , N
60 CD N
% NN N
male NN N
) ) N
were VBD N
included VBN N
in IN N
the DT N
study NN N
. . N

For IN N
6 CD N
% NN N
coriander NN N
oil NN N
in IN N
unguentum NN N
leniens NNS N
, , N
a DT N
highly RB N
significant JJ N
improvement NN N
of IN N
the DT N
clinical JJ N
signs NNS N
( ( N
p VB N
< RB N
0.0001 CD N
) ) N
was VBD N
observed VBN N
during IN N
the DT N
entire JJ N
observation NN N
period NN N
; : N
the DT N
number NN N
of IN N
positive JJ N
fungal NN N
cultures NNS N
also RB N
tended VBD N
to TO N
decrease VB N
( ( N
p JJ N
= NNP N
0.0654 CD N
) ) N
. . N

The DT N
tolerability NN N
of IN N
the DT N
tested JJ N
substances NNS N
was VBD N
good JJ N
. . N

CONCLUSION NNP N
Coriander NNP N
oil NN N
is VBZ N
effective JJ N
and CC N
well RB N
tolerated VBN N
in IN N
the DT N
treatment NN N
of IN N
interdigital JJ N
tinea NN N
pedis NN N
. . N

-DOCSTART- -X- O O 8561526

A DT N
community-based JJ N
randomized JJ N
trial NN N
of IN N
praziquantel NN N
to TO N
control VB N
schistosomiasis NN N
morbidity NN N
in IN N
schoolchildren NN N
in IN N
Zambia NNP N
. . N

A DT N
community-based JJ N
, , N
double-blind JJ N
, , N
randomized JJ N
trial NN N
of IN N
praziquantel NN N
was VBD N
carried VBN N
out RP N
in IN N
an DT N
area NN N
of IN N
Zambia NNP N
endemic FW N
for IN N
schistosomiasis NN 4_p
. . N

The DT N
aim NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
assess VB N
the DT N
impact NN N
of IN N
the DT N
treatment NN N
on IN N
Schistosoma NNP N
mansoni NNP N
morbidity NN N
. . N

A DT N
total NN N
of IN N
377 CD N
infected JJ N
children NNS N
, , N
aged VBD N
seven CD N
to TO N
19 CD N
years NNS N
, , N
was VBD N
randomized VBN N
into IN N
two CD N
groups NNS N
: : N
one CD N
of IN N
190 CD N
( ( N
group NN N
A NNP N
) ) N
and CC N
one CD N
of IN N
187 CD N
( ( N
group NN N
B NNP N
) ) N
. . N

All DT N
children NNS N
were VBD N
treated VBN N
with IN N
40 CD N
mg NNS N
praziquantel/kg NN N
at IN N
the DT N
start NN N
of IN N
the DT N
study NN N
. . N

Six CD N
months NNS N
later RB N
, , N
the DT N
children NNS N
in IN N
group NN N
A NNP N
were VBD N
re-treated JJ N
with IN N
the DT N
same JJ N
dose NN N
of IN N
praziquantel NN N
, , N
while IN N
the DT N
children NNS N
in IN N
group NN N
B NNP N
were VBD N
given VBN N
placebos NNS N
. . N

All DT N
children NNS N
were VBD N
followed VBN N
up RP N
three CD N
, , N
six CD N
and CC N
12 CD N
months NNS N
after IN N
the DT N
initial JJ N
treatment NN N
, , N
morbidity NN N
being VBG N
clinically RB N
evaluated VBN N
at IN N
the DT N
six- JJ N
and CC N
12-month JJ N
follow-ups NNS N
. . N

The DT N
results NNS N
show VBP N
that IN N
, , N
in IN N
both DT N
groups NNS N
of IN N
children NNS N
, , N
there EX N
were VBD N
significant JJ N
reductions NNS N
in IN N
splenomegaly NN N
, , N
hepatomegaly NN N
, , N
and CC N
subjective JJ N
symptoms NNS N
of IN N
morbidity NN N
six CD N
and CC N
12 CD N
months NNS N
after IN N
initial JJ N
treatment NN N
. . N

However RB N
, , N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
, , N
between IN N
the DT N
two CD N
groups NNS N
, , N
in IN N
the DT N
prevalences NNS N
of IN N
these DT N
symptoms NNS N
of IN N
morbidity NN N
. . N

It PRP N
therefore RB N
appears VBZ N
that IN N
once-yearly JJ N
treatment NN N
of IN N
children NNS N
, , N
in IN N
this DT N
and CC N
similar JJ N
endemic JJ N
areas NNS N
, , N
is VBZ N
sufficient JJ N
to TO N
reduce VB N
schistosomiasis NN N
morbidity NN N
to TO N
, , N
and CC N
maintain VB N
it PRP N
at IN N
, , N
a DT N
tolerable JJ N
level NN N
. . N

-DOCSTART- -X- O O 11545629

Penetration NN N
of IN N
ofloxacin NN N
and CC N
ciprofloxacin NN N
into IN N
the DT N
aqueous JJ N
humor NN N
of IN N
eyes NNS N
with IN N
functioning VBG N
filtering VBG N
blebs NN N
: : N
a DT N
randomized JJ N
trial NN N
. . N

OBJECTIVE NN N
To TO N
determine VB N
concentrations NNS N
of IN N
ofloxacin NN N
and CC N
ciprofloxacin NN N
hydrochloride NN N
in IN N
aqueous JJ N
humor NN N
after IN N
topical JJ N
or CC N
combined VBN N
topical JJ N
and CC N
oral JJ N
administration NN N
in IN N
eyes NNS N
with IN N
filtering VBG N
blebs NN N
. . N

DESIGN VB N
A DT N
prospective JJ N
, , N
investigator-masked JJ N
, , N
randomized VBN N
, , N
controlled VBD N
comparative JJ N
study NN N
involving VBG N
36 CD N
eyes NNS N
of IN N
34 CD N
patients NNS N
with IN N
functioning VBG N
filtering VBG N
blebs NNS N
who WP N
were VBD N
to TO N
undergo VB N
cataract NN N
surgery NN N
. . N

Treatment NN N
groups NNS N
received VBD N
either RB N
topical JJ N
ofloxacin NN N
or CC N
topical JJ N
ciprofloxacin NN N
( ( N
instillation NN N
of IN N
0.3 CD N
% NN N
ophthalmic JJ N
solution NN N
every DT N
30 CD N
minutes NNS N
for IN N
4 CD N
hours NNS N
before IN N
surgery NN N
) ) N
, , N
or CC N
a DT N
combined JJ N
topical JJ N
plus CC N
oral JJ N
regimen NNS N
( ( N
ciprofloxacin JJ N
hydrochloride NN N
, , N
four CD N
100-mg JJ N
tablets NNS N
, , N
or CC N
ofloxacin RB N
, , N
one CD N
400-mg JJ N
tablet NN N
, , N
administered VBN N
24-26 JJ N
, , N
12-14 JJ N
, , N
and CC N
2 CD N
hours NNS N
preceding VBG N
surgery NN N
) ) N
. . N

The DT N
main JJ N
outcome NN N
measure NN N
was VBD N
antibiotic JJ N
concentration NN N
measured VBN N
by IN N
chromatographic JJ N
separation NN N
and CC N
mass NN N
spectrometry NN N
of IN N
aqueous JJ N
samples NNS N
obtained VBN N
during IN N
surgery NN N
. . N

RESULTS NNP N
Topical NNP N
antibiotic JJ N
treatment NN N
yielded VBN N
mean JJ N
concentrations NNS N
of IN N
ofloxacin NN N
, , N
0.75 CD N
microg/mL NN N
, , N
and CC N
ciprofloxacin NN N
, , N
0.21 CD N
microg/mL NN N
, , N
in IN N
aqueous JJ N
. . N

With IN N
combined JJ N
topical JJ N
and CC N
oral JJ N
therapy NN N
, , N
significantly RB N
more JJR N
ofloxacin NN N
was VBD N
measured VBN N
than IN N
ciprofloxacin NN N
( ( N
3.84 CD N
microg/mL NN N
vs NN N
0.35 CD N
microg/mL NN N
[ NNP N
P NNP N
< NNP N
.001 NNP N
] NNP N
) ) N
. . N

The DT N
combination NN N
regimen NNS N
produced VBD N
significantly RB N
greater JJR N
ofloxacin NN N
levels NNS N
than IN N
did VBD N
topical JJ N
therapy NN N
alone RB N
( ( N
P NNP N
=.007 NNP N
) ) N
. . N

CONCLUSIONS NNP N
Ofloxacin NNP N
penetrates VBZ N
better JJR N
than IN N
ciprofloxacin NN N
into IN N
the DT N
aqueous JJ N
of IN N
eyes NNS N
with IN N
filtering VBG N
blebs NNS N
, , N
particularly RB N
after IN N
combined VBN N
topical JJ N
and CC N
oral JJ N
administration NN N
, , N
by IN N
which WDT N
ofloxacin NN N
reaches VBZ N
more JJR N
than IN N
a DT N
10-fold JJ N
greater JJR N
concentration NN N
than IN N
does VBZ N
ciprofloxacin VB N
. . N

Combined VBN N
topical JJ N
and CC N
oral JJ N
therapy NN N
with IN N
ofloxacin NN N
may MD N
be VB N
beneficial JJ N
in IN N
the DT N
treatment NN N
of IN N
bleb-associated JJ N
infections NNS N
. . N

-DOCSTART- -X- O O 10901647

Transesophageal NNP N
echocardiography NN N
in IN N
quantification NN N
of IN N
emboli NN N
during IN N
femoral JJ N
nailing NN N
: : N
reamed VBN N
versus NN N
unreamed JJ N
techniques NNS N
. . N

We PRP N
quantified VBD N
the DT N
embolic JJ N
load NN N
to TO N
the DT N
lungs NNS N
created VBN N
with IN N
two CD N
different JJ N
techniques NNS N
of IN N
femoral JJ N
nailing NN N
. . N

Eleven JJ N
patients NNS N
with IN N
12 CD N
traumatic JJ N
femur NN N
fractures NNS N
were VBD N
randomized VBN N
to TO N
reamed VB N
( ( N
7 CD N
fractures NNS N
) ) N
and CC N
unreamed JJ N
( ( N
5 CD N
fractures NNS N
) ) N
groups NNS N
. . N

Intramedullary JJ N
nailing NN N
was VBD N
with IN N
the DT N
AO/ASIF* NNP N
universal NN N
reamed VBD N
or CC N
unreamed JJ N
nail NN N
. . N

Transesophageal NNP N
echocardiography NN N
( ( N
TEE NNP N
) ) N
was VBD N
used VBN N
to TO N
evaluate VB N
the DT N
quantity NN N
and CC N
quality NN N
of IN N
emboli NN N
generated VBN N
by IN N
nailing VBG N
. . N

Data NNS N
were VBD N
analyzed VBN N
using VBG N
software NN N
that WDT N
digitized VBD N
the DT N
TEE NNP N
images NNS N
and CC N
quantified VBD N
the DT N
area NN N
of IN N
embolic JJ N
particles NNS N
in IN N
each DT N
frame NN N
. . N

The DT N
duration NN N
of IN N
each DT N
level NN N
of IN N
embolic JJ N
phenomena NNS N
( ( N
zero CD N
, , N
moderate JJ N
, , N
severe JJ N
) ) N
was VBD N
used VBN N
to TO N
determine VB N
total JJ N
embolic JJ N
load NN N
with IN N
various JJ N
steps NNS N
( ( N
fracture NN N
manipulation NN N
, , N
proximal JJ N
portal JJ N
opening NN N
, , N
reaming NN N
, , N
and CC N
nail JJ N
passage NN N
) ) N
. . N

Manual JJ N
grading NN N
of IN N
emboli NN N
correlated VBN N
highly RB N
with IN N
software NN N
quantification NN N
. . N

Our PRP$ N
data NNS N
confirm VBP N
the DT N
presence NN N
and CC N
similarity NN N
of IN N
emboli JJ N
generation NN N
with IN N
both DT N
methods NNS N
of IN N
intramedullary JJ N
nailing NN N
. . N

Unreamed NNP N
nails NNS N
do VBP N
not RB N
protect VB N
the DT N
patient NN N
from IN N
pulmonary JJ N
embolization NN N
of IN N
marrow NN N
contents NNS N
. . N

-DOCSTART- -X- O O 14685645

Prediction NN N
of IN N
the DT N
response NN N
to TO N
citalopram VB N
and CC N
reboxetine VB N
in IN N
post-stroke NN 4_p
depressed JJ 4_p
patients NNS 4_p
. . N

RATIONALE NNP N
AND NNP N
OBJECTIVE NNP N
Depression NNP N
is VBZ N
a DT N
significant JJ N
complication NN N
of IN N
stroke NN N
. . N

The DT N
effectiveness NN N
of IN N
antidepressant JJ N
drugs NNS N
in IN N
the DT N
management NN N
of IN N
post-stroke JJ N
depression NN N
( ( N
PSD NNP N
) ) N
has VBZ N
been VBN N
widely RB N
investigated VBN N
. . N

However RB N
, , N
the DT N
choice NN N
of IN N
antidepressant JJ N
drug NN N
is VBZ N
critically RB N
influenced VBN N
by IN N
its PRP$ N
safety NN N
and CC N
tolerability NN N
and CC N
by IN N
its PRP$ N
effect NN N
on IN N
concurrent NN N
pathologies NNS N
. . N

Here RB N
we PRP N
investigate VBP N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
a DT N
selective JJ N
serotonin NN N
reuptake NN N
inhibitor NN N
( ( N
SSRI NNP N
) ) N
, , N
citalopram NN N
, , N
and CC N
a DT N
noradrenaline JJ N
reuptake NN N
inhibitor NN N
( ( N
NARI NNP N
) ) N
, , N
reboxetine NN N
, , N
in IN N
post-stroke JJ N
patients NNS N
affected VBN N
by IN N
anxious JJ 4_p
depression NN 4_p
or CC N
retarded VBN 4_p
depression NN 4_p
. . N

METHODS NNP N
This DT N
was VBD N
a DT N
randomized JJ N
double-blind NN N
study NN N
. . N

Seventy-four JJ N
post-stroke NN 4_p
depressed JJ 4_p
patients NNS N
were VBD N
diagnosed VBN N
as IN N
affected VBN N
by IN N
anxious JJ N
or CC N
retarded VBN N
depression NN N
by IN N
using VBG N
a DT N
synoptic JJ N
table NN N
. . N

Randomisation NN N
was VBD N
planned VBN N
so RB N
that IN N
50 CD N
% NN N
of IN N
the DT N
patients NNS N
in IN N
each DT N
subgroup NN N
were VBD N
assigned VBN N
for IN N
16 CD N
weeks NNS N
to TO N
treatment NN N
with IN N
citalopram NN N
and CC N
the DT N
remaining VBG N
50 CD N
% NN N
were VBD N
assigned VBN N
to TO N
treatment NN N
with IN N
reboxetine NN N
. . N

The DT N
Beck NNP N
Depression NNP N
Inventory NNP N
( ( N
BDI NNP N
) ) N
, , N
the DT N
Hamilton NNP N
Depression NNP N
Rating NNP N
Scale NNP N
( ( N
HDRS NNP N
) ) N
and CC N
a DT N
synoptic JJ N
table NN N
were VBD N
used VBN N
to TO N
score VB N
depressive JJ N
symptoms NNS N
. . N

RESULTS NNP N
Both NNP N
citalopram NN N
and CC N
reboxetine NN N
showed VBD N
good JJ N
safety NN N
and CC N
tolerability NN N
. . N

Citalopram NNP N
exhibited VBD N
greater JJR N
efficacy NN N
in IN N
anxious JJ N
depressed JJ N
patients NNS N
, , N
while IN N
reboxetine NN N
was VBD N
more RBR N
effective JJ N
in IN N
retarded JJ N
depressed JJ N
patients NNS N
. . N

CONCLUSIONS NNP N
Citalopram NNP N
or CC N
other JJ N
SSRIs NNP N
and CC N
reboxetine NN N
may MD N
be VB N
of IN N
first JJ N
choice NN N
treatment NN N
in IN N
PSD NNP N
because IN N
of IN N
their PRP$ N
good JJ N
efficacy NN N
and CC N
lack NN N
of IN N
severe JJ N
side NN N
effects NNS N
. . N

In IN N
addition NN N
, , N
PSD NNP 4_p
patients NNS N
should MD N
be VB N
classified VBN N
according VBG N
to TO N
their PRP$ N
clinical JJ N
profile NN N
( ( N
similarly RB N
to TO N
patients NNS N
affected VBN N
by IN N
primary JJ N
depression NN N
) ) N
for IN N
the DT N
selection NN N
of IN N
SSRIs NNP N
or CC N
reboxetine VB N
as IN N
drugs NNS N
of IN N
choice NN N
in IN N
particular JJ N
subgroups NNS N
of IN N
patients NNS N
. . N

-DOCSTART- -X- O O 22847319

Assessing VBG N
the DT N
bioequivalence NN N
of IN N
topical JJ N
retinoid NN N
products NNS N
by IN N
pharmacodynamic JJ N
assay NN N
. . N

PURPOSE NNP N
To TO N
develop VB N
a DT N
simple JJ N
pharmacodynamic NN 4_p
( ( 4_p
PD NNP 4_p
) ) 4_p
assay VBP 4_p
for IN N
the DT N
evaluation NN N
of IN N
the DT N
bioequivalence NN N
of IN N
topically RB N
applied VBN N
retinoid NN N
products NNS N
. . N

METHODS NNP N
Daily NNP N
applications NNS N
of IN N
products NNS N
containing VBG N
tretinoin NN N
or CC N
adapalene NN N
were VBD N
made VBN N
to TO N
the DT N
forearms NNS 4_p
of IN 4_p
human JJ 4_p
subjects NNS 4_p
for IN N
up IN N
to TO N
21 CD N
days NNS N
. . N

Percutaneous JJ N
absorption NN N
was VBD N
enhanced VBN N
through IN N
the DT N
use NN N
of IN N
polyethylene NN N
film NN N
occlusion NN N
( ( N
5 CD N
h NN N
) ) N
. . N

Pharmacologic NNP N
activity NN N
was VBD N
assessed VBN N
through IN N
the DT N
daily JJ N
measurement NN N
of IN N
three CD N
cutaneous JJ N
responses NNS N
intimately RB N
linked VBN N
to TO N
retinoid-induced JJ N
changes NNS N
in IN N
epidermal JJ N
differentiation NN N
: : N
( ( N
1 CD N
) ) N
erythema NN N
; : N
( ( N
2 CD N
) ) N
exfoliation NN N
( ( N
scaling/peeling VBG N
) ) N
, , N
and CC N
( ( N
3 CD N
) ) N
increased VBD N
transepidermal JJ N
water NN N
loss NN N
. . N

RESULTS VB N
The DT N
PD NNP N
model NN N
exhibited VBD N
the DT N
sensitivity NN N
and CC N
specificity NN N
required VBN N
to TO N
function VB N
as IN N
a DT N
bioequivalence NN N
surrogate NN N
. . N

It PRP N
was VBD N
possible JJ N
to TO N
differentiate VB N
between IN N
: : N
( ( N
1 CD N
) ) N
three CD N
concentrations NNS N
of IN N
tretinoin NN N
in IN N
a DT N
commercial JJ N
cream NN N
product NN N
line NN N
; : N
( ( N
2 CD N
) ) N
two CD N
concentrations NNS N
of IN N
tretinoin NN N
in IN N
a DT N
commercial JJ N
gel NN N
product NN N
line NN N
; : N
( ( N
3 CD N
) ) N
different JJ N
vehicles NNS N
( ( N
gel NN N
vs. FW N
cream NN N
) ) N
containing VBG N
the DT N
same JJ N
concentration NN N
of IN N
tretinoin NN N
, , N
and CC N
( ( N
4 CD N
) ) N
tretinoin NN N
and CC N
adapalene NN N
at IN N
the DT N
same JJ N
concentration NN N
. . N

The DT N
applicability NN N
of IN N
this DT N
model NN N
for IN N
bioequivalence NN N
testing NN N
was VBD N
established VBN N
by IN N
showing VBG N
that IN N
it PRP N
had VBD N
sufficient JJ N
power NN N
to TO N
determine VB N
that DT N
three CD N
test NN N
tretinoin NN N
cream NN N
products NNS N
and CC N
two CD N
approved VBD N
generic JJ N
tretinoin NN N
gel NN N
products NNS N
were VBD N
equivalent JJ N
to TO N
their PRP$ N
corresponding JJ N
reference NN N
products NNS N
. . N

CONCLUSIONS VB N
A DT N
surrogate NN N
PD NNP N
model NN N
to TO N
assess VB N
retinoid JJ N
bioequivalence NN N
has VBZ N
been VBN N
developed VBN N
. . N

-DOCSTART- -X- O O 12787235

Changing VBG N
Childbirth NN N
: : N
a DT N
pilot NN N
project NN N
. . N

OBJECTIVE UH N
To TO N
compare VB N
the DT N
outcomes NNS N
of IN N
an DT N
adapted JJ N
pilot NN N
Changing NNP N
Childbirth NNP N
initiative JJ N
providing VBG N
continuity NN N
of IN N
care NN N
by IN N
a DT N
group NN N
of IN N
known VBN N
midwives NNS N
with IN N
traditional JJ N
maternity NN N
care NN N
. . N

DESIGN NNP N
Between-groups NNP N
trial NN N
to TO N
compare VB N
levels NNS N
of IN N
satisfaction NN N
and CC N
clinical JJ N
outcomes NNS N
for IN N
two CD N
groups NNS N
of IN N
women NNS N
, , N
cared VBD N
for IN N
either DT N
under IN N
this DT N
Changing NNP N
Childbirth NNP N
scheme NN N
or CC N
the DT N
traditional JJ N
model NN N
of IN N
care NN N
. . N

METHOD NNP N
Of IN N
the DT N
200 CD N
women NNS N
who WP N
agreed VBD N
to TO N
participate VB N
in IN N
the DT N
project NN N
, , N
100 CD N
were VBD N
randomly RB N
allocated VBN N
to TO N
the DT N
pilot NN N
scheme NN N
and CC N
100 CD N
to TO N
the DT N
traditional JJ N
care NN N
package NN N
. . N

During IN N
the DT N
postpartum JJ N
period NN N
, , N
information NN N
was VBD N
collected VBN N
via IN N
a DT N
questionnaire NN N
about IN N
participants NNS N
' POS N
levels NNS N
of IN N
satisfaction NN N
with IN N
a DT N
variety NN N
of IN N
aspects NNS N
of IN N
care NN N
provided VBN N
during IN N
the DT N
antenatal JJ N
, , N
delivery NN N
and CC N
postpartum NN N
periods NNS N
. . N

Data NNS N
about IN N
clinical JJ N
outcomes NNS N
for IN N
the DT N
two CD N
groups NNS N
were VBD N
also RB N
obtained VBN N
. . N

RESULTS JJ N
Women NNP N
in IN N
the DT N
pilot NN N
group NN N
had VBD N
significantly RB N
more RBR N
continuity NN N
of IN N
care NN N
throughout IN N
each DT N
of IN N
the DT N
three CD N
periods NNS N
, , N
were VBD N
generally RB N
more RBR N
satisfied JJ N
with IN N
their PRP$ N
care NN N
, , N
felt VBD N
that IN N
they PRP N
had VBD N
more JJR N
choice NN N
over IN N
a DT N
variety NN N
of IN N
aspects NNS N
of IN N
care NN N
and CC N
experienced VBD N
no DT N
compromise NN N
in IN N
clinical JJ N
outcomes NNS N
( ( N
P NNP N
= VBZ N
0.05 CD N
or CC N
less JJR N
in IN N
each DT N
case NN N
) ) N
. . N

IMPLICATIONS NNP N
FOR NNP N
PRACTICE NNP N
Many NNP N
previous JJ N
attempts NNS N
to TO N
introduce VB N
the DT N
Changing NNP N
Childbirth NNP N
initiative NN N
have VBP N
revealed VBN N
significant JJ N
problems NNS N
, , N
particularly RB N
with IN N
regard NN N
to TO N
the DT N
continuity NN N
of IN N
carer NN N
requirement NN N
. . N

Taking VBG N
account NN N
of IN N
local JJ N
health NN N
care NN N
needs NNS N
and CC N
existing VBG N
provision NN N
, , N
the DT N
present JJ N
study NN N
adapted VBD N
this DT N
concept NN N
to TO N
continuity NN N
of IN N
care NN N
. . N

This DT N
did VBD N
not RB N
apparently RB N
affect VBP N
any DT N
of IN N
the DT N
guiding VBG N
principles NNS N
contained VBN N
in IN N
the DT N
original JJ N
document NN N
, , N
and CC N
yet RB N
enhanced VBN N
satisfaction NN N
. . N

It PRP N
would MD N
appear VB N
that IN N
the DT N
Changing NNP N
Childbirth NNP N
agenda NN N
can MD N
be VB N
adapted VBN N
and CC N
integrated VBN N
with IN N
local JJ N
health NN N
care NN N
situations NNS N
without IN N
sacrificing VBG N
any DT N
of IN N
the DT N
overarching JJ N
principles NNS N
. . N

-DOCSTART- -X- O O 17082978

A DT N
randomized VBN N
controlled JJ N
trial NN N
of IN N
a DT N
cognitive JJ N
behavioural JJ N
intervention NN N
for IN N
anger JJ N
management NN N
in IN N
children NNS N
diagnosed VBN N
with IN N
Asperger NNP N
syndrome NN N
. . N

The DT N
purpose NN N
of IN N
the DT N
study NN N
described VBD N
was VBD N
to TO N
evaluate VB N
the DT N
effectiveness NN N
of IN N
a DT N
cognitive JJ N
behavioural JJ N
intervention NN N
for IN N
anger JJ N
management NN N
with IN N
children NNS N
diagnosed VBN N
with IN N
Asperger NNP N
syndrome NN N
. . N

Forty-five JJ N
children NNS N
and CC N
their PRP$ N
parents NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
either DT N
intervention NN N
or CC N
wait-list JJ N
control NN N
conditions NNS N
. . N

Children NNP N
in IN N
the DT N
intervention NN N
participated VBD N
in IN N
six CD N
2-h JJ N
weekly JJ N
sessions NNS N
while IN N
parents NNS N
participated VBN N
in IN N
a DT N
larger JJR N
parent NN N
group NN N
. . N

Parent NN N
reports NNS N
indicated VBD N
a DT N
significant JJ N
decrease NN N
in IN N
episodes NNS N
of IN N
anger NN N
following VBG N
intervention NN N
and CC N
a DT N
significant JJ N
increase NN N
in IN N
their PRP$ N
own JJ N
confidence NN N
in IN N
managing VBG N
anger NN N
in IN N
their PRP$ N
child NN N
. . N

Qualitative JJ N
information NN N
gathered VBN N
from IN N
parents NNS N
and CC N
teachers NNS N
indicated VBD N
some DT N
generalization NN N
of IN N
strategies NNS N
learned VBN N
in IN N
the DT N
clinic JJ N
setting NN N
to TO N
both DT N
home NN N
and CC N
school NN N
settings NNS N
. . N

Limitations NNS N
of IN N
the DT N
study NN N
and CC N
suggestions NNS N
for IN N
future JJ N
research NN N
are VBP N
also RB N
discussed VBN N
. . N

-DOCSTART- -X- O O 24666361

Predictors NNS N
of IN N
local JJ N
adverse JJ N
effects NNS N
caused VBN N
by IN N
topical JJ N
tretinoin NN N
cream NN N
0·1 CD N
% NN N
in IN N
the DT 4_p
Veterans NNP 4_p
Affairs NNP 4_p
Topical NNP 4_p
Tretinoin NNP 4_p
Chemoprevention NNP 4_p
trial NN 4_p
. . N

BACKGROUND NNP N
Topical NNP N
tretinoin NN N
is VBZ N
commonly RB N
prescribed VBN N
, , N
but CC N
its PRP$ N
frequent JJ N
adverse JJ N
effects NNS N
are VBP N
barriers NNS N
to TO N
use VB N
. . N

Predictors NNS N
of IN N
resistance NN N
or CC N
susceptibility NN N
to TO N
retinoid VB N
irritation NN N
are VBP N
not RB N
known VBN N
. . N

OBJECTIVE UH N
To TO N
identify VB N
baseline JJ N
patient NN N
characteristics NNS N
associated VBN N
with IN N
adverse JJ N
effects NNS N
of IN N
topical JJ N
tretinoin NN N
. . N

METHODS NNP N
This DT N
cohort NN N
study NN N
used VBN N
data NNS N
collected VBD N
from IN N
324 CD N
participants NNS N
in IN N
the DT N
Veterans NNP N
Affairs NNP N
Topical NNP N
Tretinoin NNP N
Chemoprevention NNP N
trial NN N
who WP N
were VBD N
randomized VBN N
to TO N
apply VB N
tretinoin JJ N
cream NN N
on IN N
the DT N
face NN N
and CC N
ears NNS N
. . N

Univariate NNP N
and CC N
multivariate VB N
logistic JJ N
regression NN N
models NNS N
were VBD N
used VBN N
to TO N
examine VB N
the DT N
associations NNS N
between IN N
baseline NN N
characteristics NNS N
and CC N
local JJ N
adverse JJ N
effects NNS N
. . N

RESULTS NNP N
One CD N
hundred CD N
and CC N
ninety-seven JJ N
patients NNS N
( ( N
61 CD N
% NN N
of IN N
those DT N
randomized VBN N
to TO N
tretinoin VB N
) ) N
reported VBD N
local JJ N
adverse JJ N
effects NNS N
within IN N
6 CD N
months NNS N
. . N

Clinical JJ N
signs NNS N
of IN N
severe JJ N
photodamage NN N
at IN N
baseline NN N
[ NNP N
odds NNS N
ratio NN N
( ( N
OR NNP N
) ) N
0·15 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
0·04-0·54 NN N
] NN N
and CC N
history NN N
of IN N
acne NN N
( ( N
OR CC N
0·46 CD N
, , N
95 CD N
% NN N
CI NNP N
0·27-0·77 NN N
) ) N
were VBD N
associated VBN N
with IN N
a DT N
decreased JJ N
risk NN N
of IN N
adverse JJ N
effects NNS N
to TO N
tretinoin VB N
. . N

The DT N
use NN N
of IN N
other JJ N
topical JJ N
medications NNS N
at IN N
enrolment NN N
( ( N
OR CC N
1·88 CD N
, , N
95 CD N
% NN N
CI NNP N
1·15-3·08 CD N
) ) N
predicted VBD N
an DT N
increase NN N
in IN N
adverse JJ N
effects NNS N
. . N

CONCLUSIONS NNP N
In IN N
this DT N
study NN N
population NN N
, , N
the DT N
common JJ N
indications NNS N
of IN N
topical JJ N
tretinoin NN N
treatment NN N
were VBD N
associated VBN N
with IN N
lower JJR N
risks NNS N
of IN N
adverse JJ N
effects NNS N
. . N

The DT N
concurrent NN N
use NN N
of IN N
other JJ N
topical JJ N
medications NNS N
may MD N
worsen VB N
irritation NN N
caused VBN N
by IN N
tretinoin NN N
. . N

-DOCSTART- -X- O O 12131309

Is VBZ N
periprostatic JJ N
local JJ N
anesthesia NN N
for IN N
transrectal JJ 4_p
ultrasound NN 4_p
guided VBD 4_p
prostate NN 4_p
biopsy NN 4_p
associated VBN N
with IN N
increased JJ N
infectious JJ N
or CC N
hemorrhagic JJ N
complications NNS N
? . N
A DT N
prospective JJ N
randomized VBN N
trial NN N
. . N

PURPOSE NNP N
Periprostatic NNP N
local JJ N
anesthesia NN N
for IN N
prostate NN N
biopsy NN N
requires VBZ N
2 CD N
or CC N
more JJR N
extra JJ N
needle JJ N
punctures NNS N
and CC N
injection NN N
of IN N
the DT N
local JJ N
anesthetic NN N
through IN N
the DT N
highly RB N
colonized JJ N
rectum NN N
. . N

To TO N
our PRP$ N
knowledge NN N
we PRP N
report VBP N
the DT N
first JJ N
prospective JJ N
randomized VBN N
trial NN N
to TO N
assess VB N
the DT N
infectious JJ N
or CC N
hemorrhagic JJ N
complications NNS N
associated VBN N
with IN N
this DT N
method NN N
. . N

MATERIALS NNP N
AND NNP N
METHODS NNP N
A NNP N
total NN N
of IN N
100 CD 4_p
consecutive JJ N
patients NNS N
with IN N
sterile JJ 4_p
urine JJ 4_p
cultures NNS 4_p
underwent JJ N
transrectal JJ 4_p
ultrasound NN 4_p
guided VBD 4_p
prostate NN 4_p
biopsy NN 4_p
. . N

They PRP N
were VBD N
randomized VBN N
to TO N
receive VB N
a DT N
periprostatic JJ N
nerve NN N
block NN N
or CC N
no DT N
anesthesia NN N
. . N

Patients NNS N
were VBD N
evaluated VBN N
for IN N
the DT N
amount NN N
of IN N
rectal NN N
and CC N
urethral JJ N
bleeding NN N
, , N
and CC N
symptoms NNS N
and CC N
signs NNS N
of IN N
infection NN N
after IN N
biopsy NN N
. . N

RESULTS VB N
The DT N
amount NN N
of IN N
urethral JJ N
bleeding NN N
was VBD N
slight JJ N
and CC N
similar JJ N
in IN N
the DT N
2 CD N
groups NNS N
. . N

Rectal JJ N
bleeding NN N
was VBD N
significantly RB N
less RBR N
in IN N
the DT N
patients NNS N
who WP N
received VBD N
anesthesia NN N
. . N

High JJ N
fever NN N
( ( N
greater JJR N
than IN N
37.8C CD N
) ) N
was VBD N
more RBR N
frequent JJ N
in IN N
the DT N
nerve NN N
block NN N
group NN N
and CC N
2 CD N
patients NNS N
in IN N
this DT N
group NN N
required VBD N
rehospitalization NN N
. . N

Bacteriuria NNP N
in IN N
post-biopsy JJ N
urine JJ N
cultures NNS N
was VBD N
significantly RB N
more JJR N
common JJ N
in IN N
the DT N
anesthesia NN N
group NN N
. . N

CONCLUSIONS NNP N
Our PRP$ N
results NNS N
suggest VBP N
that IN N
periprostatic JJ N
local JJ N
anesthesia NN N
for IN N
prostate JJ N
biopsy NN N
does VBZ N
not RB N
increase VB N
the DT N
risk NN N
of IN N
urethral JJ N
bleeding NN N
. . N

It PRP N
is VBZ N
associated VBN N
with IN N
a DT N
decreased JJ N
incidence NN N
of IN N
rectal JJ N
bleeding NN N
, , N
presumably RB N
due JJ N
to TO N
decreased JJ N
patient NN N
discomfort NN N
. . N

The DT N
incidence NN N
of IN N
bacteriuria NN N
was VBD N
significantly RB N
higher JJR N
in IN N
the DT N
anesthesia NN N
group NN N
. . N

High NNP N
fever NN N
and CC N
hospitalization NN N
due JJ N
to TO N
infectious JJ N
complications NNS N
were VBD N
also RB N
more RBR N
common JJ N
in IN N
the DT N
local JJ N
anesthesia NN N
group NN N
, , N
although IN N
not RB N
statistically RB N
significant JJ N
. . N

Prospective JJ N
randomized JJ N
trials NNS N
seem VBP N
warranted VBN N
to TO N
determine VB N
the DT N
optimum JJ N
antibiotic JJ N
prophylaxis NN N
regimen NNS N
in IN N
patients NNS N
undergoing VBG N
biopsy NN N
with IN N
a DT N
periprostatic JJ N
nerve NN N
block NN N
. . N

-DOCSTART- -X- O O 3998250

Psychophysiological JJ N
outcome NN N
of IN N
behavioral JJ N
and CC N
pharmacological JJ N
treatments NNS N
of IN N
agoraphobia NN 4_p
. . 4_p

-DOCSTART- -X- O O 9023640

Effects NNS N
of IN N
omeprazole NN N
and CC N
amoxycillin NN N
on IN N
the DT N
human JJ N
oral JJ N
and CC N
gastrointestinal JJ N
microflora NNS N
in IN N
patients NNS 4_p
with IN 4_p
Helicobacter NNP 4_p
pylori JJ 4_p
infection NN 4_p
. . 4_p

Fourteen JJ N
patients NNS N
with IN N
Helicobacter NNP N
pylori FW N
infection NN N
were VBD N
treated VBN N
with IN N
omeprazole JJ N
capsules NNS N
20 CD N
mg NNS N
and CC N
amoxycillin NN N
capsules NNS N
1000 CD N
mg JJ N
twice RB N
daily RB N
for IN N
14 CD N
days NNS N
and CC N
14 CD N
patients NNS N
with IN N
omeprazole JJ N
capsules NNS N
20 CD N
mg NNS N
and CC N
placebo VB N
twice RB N
daily RB N
for IN N
14 CD N
days NNS N
. . N

Samples NNS N
from IN N
saliva NN N
, , N
dental JJ N
plaque NN N
and CC N
faeces NNS N
and CC N
biopsies NNS N
from IN N
antrum NN N
and CC N
corpus NN N
were VBD N
analysed VBN N
in IN N
order NN N
to TO N
determine VB N
the DT N
ecological JJ N
changes NNS N
in IN N
the DT N
normal JJ N
microflora NN N
. . N

Several JJ N
microorganisms NNS N
were VBD N
affected VBN N
by IN N
both DT N
treatment NN N
regimens NNS N
. . N

Two CD N
patients NNS N
were VBD N
colonised VBN N
with IN N
enterobacteria NNS N
in IN N
the DT N
oral JJ N
cavity NN N
and CC N
stomach NN N
during IN N
the DT N
omeprazole JJ N
plus CC N
amoxycillin JJ N
treatment NN N
. . N

A DT N
general JJ N
increase NN N
in IN N
the DT N
number NN N
of IN N
microorganisms NNS N
from IN N
gastric JJ N
mucosa NN N
was VBD N
observed VBN N
in IN N
both DT N
treatment NN N
groups NNS N
. . N

A DT N
selection NN N
of IN N
resistant JJ N
enterobacteria NN N
and CC N
an DT N
increase NN N
in IN N
beta-lactamase JJ N
production NN N
was VBD N
observed VBN N
in IN N
the DT N
faecal JJ N
samples NNS N
during IN N
the DT N
omeprazole JJ N
plus CC N
amoxycillin JJ N
treatment NN N
. . N

Eradication NN N
of IN N
H. NNP N
pylori NN N
in IN N
the DT N
omeprazole-amoxycillin JJ N
group NN N
was VBD N
50 CD N
% NN N
and CC N
in IN N
the DT N
omeprazole JJ N
placebo NN N
group NN N
0 CD N
% NN N
four CD N
weeks NNS N
after IN N
treatment NN N
. . N

No DT N
viable JJ N
H. NNP N
pylori NN N
were VBD N
cultivated VBN N
in IN N
the DT N
saliva NN N
, , N
dental JJ N
plaque NN N
or CC N
faecal JJ N
samples NNS N
. . N

Treatment NN N
with IN N
omeprazole JJ N
20 CD N
mg NN N
and CC N
amoxycillin NN N
1000 CD N
mg NN N
twice RB N
daily RB N
for IN N
14 CD N
days NNS N
altered VBD N
the DT N
normal JJ N
microflora NN N
in IN N
the DT N
oral JJ N
, , N
gastric JJ N
and CC N
intestinal JJ N
tract NN N
and CC N
antibiotic JJ N
resistant JJ N
microorganisms NNS N
increased VBD N
in IN N
numbers NNS N
in IN N
the DT N
intestinal JJ N
microflora NN N
. . N

-DOCSTART- -X- O O 7826791

Co-administration NN N
of IN N
pethidine NN N
and CC N
clonidine NN N
: : N
a DT N
spinal JJ N
anaesthetic JJ N
technique NN N
for IN N
total JJ N
hip NN N
replacement NN N
. . N

Co-administration NN N
of IN N
pethidine NN N
0.75 CD N
mg NN N
kg-1 NN N
and CC N
clonidine NN N
75 CD N
micrograms NNS N
intrathecally RB N
provided VBD N
good JJ N
intraoperative JJ N
anaesthesia NN N
for IN N
total JJ N
hip NN N
replacement NN N
, , N
similar JJ N
to TO N
that DT N
obtained VBN N
using VBG N
0.5 CD N
% NN N
isobaric JJ N
bupivacaine NN N
. . N

Sensory NNP N
and CC N
motor NN N
block NN N
were VBD N
of IN N
shorter JJR N
duration NN N
than IN N
that DT N
after IN N
0.5 CD N
% NN N
isobaric JJ N
bupivacaine NN N
and CC N
0.5 CD N
% NN N
isobaric JJ N
bupivacaine NN N
with IN N
morphine JJ N
0.5 CD N
mg NN N
( ( N
P NNP N
< VBZ N
0.001 CD N
sensory JJ N
block NN N
, , N
P NNP N
< VBZ N
0.001 CD N
motor NN N
block NN N
) ) N
. . N

Postoperative JJ N
morphine NN N
consumption NN N
, , N
measured VBN N
using VBG N
a DT N
patient-controlled JJ N
system NN N
, , N
was VBD N
similar JJ N
to TO N
that DT N
in IN N
patients NNS N
in IN N
the DT N
bupivacaine NN N
only RB N
group NN N
( ( N
pethidine-clonidine JJ N
: : N
median JJ N
39 CD N
mg/24 NN N
h NN N
; : N
bupivacaine NN N
: : N
median JJ N
34 CD N
mg/24 NN N
h NN N
) ) N
but CC N
greater JJR N
than IN N
that DT N
in IN N
the DT N
bupivacaine-morphine JJ N
group NN N
( ( N
median JJ N
8 CD N
mg/24 NN N
h NN N
) ) N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Visual JJ N
analogue NN N
pain NN N
scores NNS N
after IN N
operation NN N
were VBD N
similar JJ N
to TO N
those DT N
with IN N
bupivacaine JJ N
alone NN N
at IN N
all DT N
but CC N
one CD N
of IN N
the DT N
recording NN N
times NNS N
but CC N
were VBD N
greater JJR N
than IN N
those DT N
in IN N
patients NNS N
who WP N
received VBD N
bupivacaine NN N
and CC N
morphine NN N
at IN N
4 CD N
, , N
6 CD N
and CC N
10 CD N
h NN N
after IN N
operation NN N
( ( N
P NNP N
< NNP N
0.001 CD N
, , N
P NNP N
< NNP N
0.04 CD N
, , N
P NNP N
< NNP N
0.02 CD N
) ) N
. . N

The DT N
combination NN N
did VBD N
not RB N
offer VB N
any DT N
major JJ N
advantage NN N
over IN N
conventional JJ N
agents NNS N
. . N

-DOCSTART- -X- O O 3886510

[ JJ N
Clinical JJ N
trials NNS N
with IN N
pirprofen NN N
and CC N
naproxen NN N
in IN N
patients NNS 4_p
with IN 4_p
gonarthrosis NN 4_p
and CC 4_p
coxarthrosis NN 4_p
] NN N
. . N

-DOCSTART- -X- O O 22583635

Long-term JJ N
decrease NN N
in IN N
bladder NN N
cancer NN N
recurrence NN N
with IN N
hexaminolevulinate NN N
enabled VBN N
fluorescence NN N
cystoscopy NN N
. . N

PURPOSE NNP N
We PRP N
assessed VBD N
the DT N
impact NN N
of IN N
hexaminolevulinate NN N
fluorescence NN N
cystoscopic NN N
detection NN N
of IN N
papillary JJ N
, , N
nonmuscle JJ N
invasive JJ N
bladder NN N
cancer NN N
on IN N
the DT N
long-term JJ N
recurrence NN N
rate NN N
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
Long-term NNP N
followup NN N
was VBD N
assessed VBN N
in IN N
551 CD N
participants NNS N
enrolled VBN N
in IN N
a DT N
prospective JJ N
, , N
randomized JJ N
study NN N
of IN N
fluorescence NN N
cystoscopy NN N
for IN N
Ta NNP N
or CC N
T1 NNP N
urothelial JJ N
bladder NN N
cancer NN N
. . N

In IN N
the DT N
original JJ N
study NN N
280 CD N
patients NNS N
in IN N
the DT N
white JJ N
light JJ N
cystoscopy NN N
group NN N
and CC N
271 CD N
in IN N
the DT N
fluorescence NN N
cystoscopy NN N
group NN N
were VBD N
followed VBN N
with IN N
cystoscopy NN N
for IN N
3 CD N
, , N
6 CD N
and CC N
9 CD N
months NNS N
after IN N
initial JJ N
resection NN N
or CC N
until IN N
recurrence NN N
. . N

A DT N
study NN N
extension NN N
protocol NN N
was VBD N
done VBN N
for IN N
long-term JJ N
followup NN N
of IN N
these DT N
patients NNS N
. . N

RESULTS NNP N
Followup NNP N
information NN N
was VBD N
obtained VBN N
for IN N
261 CD N
of IN N
the DT N
280 CD N
patients NNS N
( ( N
93 CD N
% NN N
) ) N
in IN N
the DT N
white JJ N
light NN N
group NN N
and CC N
255 CD N
of IN N
the DT N
271 CD N
( ( N
94 CD N
% NN N
) ) N
in IN N
the DT N
fluorescence NN N
group NN N
. . N

Median JJ N
followup NN N
in IN N
the DT N
white JJ N
light NN N
and CC N
fluorescence NN N
groups NNS N
was VBD N
53.0 CD N
and CC N
55.1 CD N
months NNS N
, , N
and CC N
83 CD N
( ( N
31.8 CD N
% NN N
) ) N
and CC N
97 CD N
patients NNS N
( ( N
38 CD N
% NN N
) ) N
remained VBD N
tumor JJ N
free JJ N
, , N
respectively RB N
. . N

Median JJ N
time NN N
to TO N
recurrence VB N
was VBD N
9.4 CD N
months NNS N
in IN N
the DT N
white JJ N
light NN N
group NN N
and CC N
16.4 CD N
months NNS N
in IN N
the DT N
fluorescence NN N
group NN N
( ( N
p JJ N
= NNP N
0.04 CD N
) ) N
. . N

The DT N
intravesical JJ N
therapy NN N
rate NN N
was VBD N
similar JJ N
in IN N
the DT N
2 CD N
groups NNS N
( ( N
46 CD N
% NN N
and CC N
45 CD N
% NN N
, , N
respectively RB N
) ) N
. . N

Cystectomy NNP N
was VBD N
done VBN N
in IN N
22 CD N
of IN N
280 CD N
cases NNS N
( ( N
7.9 CD N
% NN N
) ) N
in IN N
the DT N
white JJ N
light NN N
group NN N
and CC N
in IN N
13 CD N
of IN N
the DT N
271 CD N
( ( N
4.8 CD N
% NN N
) ) N
in IN N
the DT N
fluorescence NN N
group NN N
( ( N
p JJ N
= NNP N
0.16 CD N
) ) N
. . N

CONCLUSIONS NNP N
Hexaminolevulinate NNP N
fluorescence NN N
cystoscopy NN N
significantly RB N
improves VBZ N
long-term JJ N
bladder NN N
cancer NN N
time NN N
to TO N
recurrence VB N
with IN N
a DT N
trend NN N
toward IN N
improved JJ N
bladder NN N
preservation NN N
. . N

-DOCSTART- -X- O O 9777899

Preventing VBG N
disability NN N
and CC N
managing VBG N
chronic JJ N
illness NN N
in IN N
frail JJ 4_p
older NN N
adults NNS N
: : N
a DT N
randomized JJ N
trial NN N
of IN N
a DT N
community-based JJ N
partnership NN N
with IN N
primary JJ N
care NN N
. . N

BACKGROUND NNP N
Effective NNP N
new JJ N
strategies NNS N
that WDT N
complement VBP N
primary JJ N
care NN N
are VBP N
needed VBN N
to TO N
reduce VB N
disability NN N
risks NNS N
and CC N
improve VB N
self-management NN N
of IN N
chronic JJ N
illness NN N
in IN N
frail JJ 4_p
older JJR N
people NNS N
living VBG N
in IN N
the DT N
community NN N
. . N

OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
impact NN N
of IN N
a DT N
1-year JJ N
, , N
senior JJ N
center-based JJ N
chronic JJ N
illness NN N
self-management NN N
and CC N
disability NN N
prevention NN N
program NN N
on IN N
health NN N
, , N
functioning NN N
, , N
and CC N
healthcare JJ N
utilization NN N
in IN N
frail JJ N
older JJR N
adults NNS N
. . N

DESIGN VB N
A DT N
randomized NN N
controlled VBN N
trial NN N
. . N

SETTING NN N
A DT N
large JJ N
senior JJ N
center NN N
located VBN N
in IN N
a DT N
northeast NN N
Seattle NNP N
suburb NN N
. . N

The DT N
trial NN N
was VBD N
conducted VBN N
in IN N
collaboration NN N
with IN N
primary JJ N
care NN N
providers NNS N
of IN N
two CD N
large JJ N
managed VBD N
care NN N
organizations NNS N
. . N

PARTICIPANTS VB N
A DT N
total NN N
of IN N
201 CD N
chronically RB N
ill JJ N
older JJR N
adults NNS N
seniors NNS N
aged VBD N
70 CD N
and CC N
older JJR N
recruited VBN N
through IN N
medical JJ N
practices NNS N
. . N

INTERVENTION VB N
A NNP N
targeted JJ N
, , N
multi-component JJ N
disability NN N
prevention NN N
and CC N
disease JJ N
self-management JJ N
program NN N
led VBN N
by IN N
a DT N
geriatric JJ N
nurse NN N
practitioner NN N
( ( N
GNP NNP N
) ) N
. . N

MEASUREMENTS NNP N
Self-reported JJ N
Physical NNP N
function NN N
, , N
physical JJ N
performance NN N
tests NNS N
, , N
health NN N
care NN N
utilization NN N
, , N
and CC N
health NN N
behaviors NNS N
. . N

RESULTS NNP N
Each DT N
of IN N
101 CD N
intervention NN N
participants NNS N
met VBD N
with IN N
the DT N
GNP NNP N
from IN N
1 CD N
to TO N
8 CD N
times NNS N
( ( N
median JJ N
= NNP N
3 CD N
) ) N
during IN N
the DT N
study NN N
year NN N
. . N

The DT N
intervention NN N
group NN N
showed VBD N
less JJR N
decline NN N
in IN N
function NN N
, , N
as IN N
measured VBN N
by IN N
disability NN N
days NNS N
and CC N
lower JJR N
scores NNS N
on IN N
the DT N
Health NNP N
Assessment NNP N
Questionnaire NNP N
. . N

Other JJ N
measures NNS N
of IN N
function NN N
, , N
including VBG N
the DT N
SF-36 NNP N
and CC N
a DT N
battery NN N
of IN N
physical JJ N
performance NN N
tests NNS N
, , N
did VBD N
not RB N
change VB N
with IN N
the DT N
intervention NN N
. . N

The DT N
number NN N
of IN N
hospitalized JJ N
participants NNS N
increased VBN N
by IN N
69 CD N
% NN N
among IN N
the DT N
controls NNS N
and CC N
decreased VBN N
by IN N
38 CD N
% NN N
in IN N
the DT N
intervention NN N
group NN N
( ( N
P NNP N
= NNP N
.083 NNP N
) ) N
. . N

The DT N
total JJ N
number NN N
of IN N
inpatient JJ N
hospital NN N
days NNS N
during IN N
the DT N
study NN N
year NN N
was VBD N
significantly RB N
less RBR N
in IN N
the DT N
intervention NN N
group NN N
compared VBN N
with IN N
controls NNS N
( ( N
total JJ N
days NNS N
= VBP N
33 CD N
vs NN N
116 CD N
, , N
P NNP N
= NNP N
.049 NNP N
) ) N
. . N

The DT N
intervention NN N
led VBD N
to TO N
significantly RB N
higher JJR N
levels NNS N
of IN N
physical JJ N
activity NN N
and CC N
senior JJ N
center NN N
participation NN N
and CC N
significant JJ N
reductions NNS N
in IN N
the DT N
use NN N
of IN N
psychoactive JJ N
medications NNS N
. . N

CONCLUSIONS VB N
This DT N
project NN N
provides VBZ N
evidence NN N
that IN N
a DT N
community-based JJ N
collaboration NN N
with IN N
primary JJ N
care NN N
providers NNS N
can MD N
improve VB N
function NN N
and CC N
reduce VB N
inpatient JJ N
utilization NN N
in IN N
chronically RB 4_p
ill JJ 4_p
older JJR N
adults NNS N
. . N

Linking VBG N
organized VBN N
medical JJ N
care NN N
with IN N
complementary JJ N
community-based JJ N
interventions NNS N
may MD N
be VB N
a DT N
promising JJ N
direction NN N
for IN N
research NN N
and CC N
practice NN N
. . N

-DOCSTART- -X- O O 11191952

[ JJ N
Diphtheria NNP N
antitoxin NN N
level NN N
2 CD N
years NNS N
after IN N
booster NN N
vaccination NN N
] NNP N
. . N

In IN N
a DT N
prospective JJ N
, , N
controlled VBN N
, , N
randomized VBN N
, , N
multicenter RBR N
study VBP N
the DT N
immunogenicity NN N
of IN N
a DT N
single JJ N
( ( N
day NN N
0 CD N
) ) N
and CC N
two CD N
( ( N
day NN N
0 CD N
, , N
28 CD N
) ) N
booster NN N
vaccination NN N
against IN N
diphtheria NN N
were VBD N
compared VBN N
in IN N
subjects NNS 4_p
who WP 4_p
had VBD 4_p
received VBN 4_p
their PRP$ 4_p
last JJ 4_p
diphtheria NN 4_p
vaccination NN 4_p
more JJR 4_p
than IN 4_p
10 CD 4_p
years NNS 4_p
ago RB 4_p
. . 4_p

Both DT N
short-term JJ N
and CC N
long-term JJ N
immunogenicity NN N
was VBD N
assessed VBN N
by IN N
determining VBG N
diphtheria NN N
antitoxin NN N
levels NNS N
four CD N
weeks NNS N
after IN N
vaccination NN N
and CC N
after IN N
one CD N
and CC N
two CD N
years NNS N
. . N

102 CD N
subjects NNS N
received VBD N
the DT N
first JJ N
booster NN N
vaccination NN N
, , N
and CC N
83 CD N
were VBD N
vaccinated VBN N
twice RB N
. . N

Prior NNP N
to TO N
the DT N
first JJ N
vaccination NN N
27 CD N
% NN N
of IN N
the DT N
subjects NNS N
had VBD N
a DT N
diphtheria NN N
antitoxin NN N
level NN N
below IN N
0.01 CD N
I.U./ml NNP N
; : N
after IN N
the DT N
first JJ N
booster NN N
only RB N
5 CD N
% NN N
were VBD N
unprotected VBN N
. . N

The DT N
second JJ N
booster NN N
did VBD N
not RB N
show VB N
a DT N
significant JJ N
effect NN N
, , N
however RB N
, , N
in IN N
1 CD N
of IN N
the DT N
5 CD N
subjects NNS N
who WP N
were VBD N
still RB N
unprotected VBN N
after IN N
the DT N
first JJ N
booster NN N
the DT N
second JJ N
elicited VBD N
an DT N
antitoxin JJ N
level NN N
of IN N
more JJR N
than IN N
0.01 CD N
I.U./ml NNP N
. . N

After IN N
one CD N
and CC N
two CD N
years NNS N
7 CD N
% NN N
and CC N
8 CD N
% NN N
of IN N
the DT N
subjects NNS N
had VBD N
diphtheria VBN N
antitoxin JJ N
level NN N
below IN N
0.01 CD N
I.U./ml NNP N
. . N

A NNP N
serological JJ N
effect NN N
of IN N
a DT N
second JJ N
booster NN N
vaccination NN N
four CD N
weeks NNS N
after IN N
the DT N
first JJ N
one NN N
could MD N
not RB N
be VB N
demonstrated VBN N
neither RB N
after IN N
one CD N
nor CC N
after IN N
two CD N
years NNS N
. . N

-DOCSTART- -X- O O 20113305

Hunter NNP N
DBT NNP N
project NN N
: : N
randomized VBN N
controlled VBD N
trial NN N
of IN N
dialectical JJ N
behaviour NN N
therapy NN N
in IN N
women NNS 4_p
with IN 4_p
borderline JJ 4_p
personality NN 4_p
disorder NN 4_p
. . 4_p

OBJECTIVE JJ N
Deliberate NNP N
self-harm NN N
( ( N
DSH NNP N
) ) N
, , N
general JJ N
hospital NN N
admission NN N
and CC N
psychiatric JJ N
hospital NN N
admission NN N
are VBP N
common JJ N
in IN N
women NNS 4_p
meeting VBG 4_p
criteria NNS 4_p
for IN 4_p
borderline NN 4_p
personality NN 4_p
disorder NN 4_p
( ( 4_p
BPD NNP 4_p
) ) 4_p
. . 4_p

Dialectical JJ N
behaviour NN N
therapy NN N
( ( N
DBT NNP N
) ) N
has VBZ N
been VBN N
reported VBN N
to TO N
be VB N
effective JJ N
in IN N
reducing VBG N
DSH NNP N
and CC N
hospitalization NN N
. . N

METHOD NNP N
A NNP N
randomized VBD N
controlled JJ N
trial NN N
of IN N
73 CD N
female JJ N
subjects NNS N
meeting VBG N
criteria NNS N
for IN N
BPD NNP N
was VBD N
carried VBN N
out RP N
with IN N
intention-to-treat JJ N
analyses NNS N
and CC N
per-protocol JJ N
analyses NNS N
. . N

The DT N
intervention NN N
was VBD N
DBT NNP N
and CC N
the DT N
control NN N
condition NN N
was VBD N
treatment NN N
as IN N
usual JJ N
plus CC N
waiting JJ N
list NN N
for IN N
DBT NNP N
( ( N
TAU+WL NNP N
) ) N
, , N
with IN N
outcomes NNS N
measured VBN N
after IN N
6 CD N
months NNS N
. . N

Primary JJ N
outcomes NNS N
were VBD N
differences NNS N
in IN N
proportions NNS N
and CC N
event NN N
rates NNS N
of IN N
: : N
any DT N
DSH NNP N
; : N
general JJ N
hospital NN N
admission NN N
for IN N
DSH NNP N
and CC N
any DT N
psychiatric JJ N
admission NN N
; : N
and CC N
mean VB N
difference NN N
in IN N
length NN N
of IN N
stay NN N
for IN N
any DT N
hospitalization NN N
. . N

Secondary JJ N
outcomes NNS N
were VBD N
disability NN N
and CC N
quality NN N
of IN N
life NN N
measures NNS N
. . N

RESULTS NNP N
Both NNP N
groups NNS N
showed VBD N
a DT N
reduction NN N
in IN N
DSH NNP N
and CC N
hospitalizations NNS N
, , N
but CC N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
DSH NNP N
, , N
hospital JJ N
admissions NNS N
or CC N
length NN N
of IN N
stay NN N
in IN N
hospital NN N
between IN N
groups NNS N
. . N

Disability NNP N
( ( N
days NNS N
spent VBN N
in IN N
bed NN N
) ) N
and CC N
quality NN N
of IN N
life NN N
( ( N
Physical NNP N
, , N
Psychological NNP N
and CC N
Environmental NNP N
domains NNS N
) ) N
were VBD N
significantly RB N
improved VBN N
for IN N
the DT N
DBT NNP N
group NN N
. . N

CONCLUSION NNP N
DBT NNP N
produced VBD N
non-significant JJ N
reductions NNS N
in IN N
DSH NNP N
and CC N
hospitalization NN N
when WRB N
compared VBN N
to TO N
the DT N
TAU+WL NNP N
control NN N
, , N
due JJ N
in IN N
part NN N
to TO N
the DT N
lower JJR N
than IN N
expected VBN N
rates NNS N
of IN N
hospitalization NN N
in IN N
the DT N
control NN N
condition NN N
. . N

Nevertheless NNP N
, , N
DBT NNP N
showed VBD N
significant JJ N
benefits NNS N
for IN N
the DT N
secondary JJ N
outcomes NNS N
of IN N
improved JJ N
disability NN N
and CC N
quality NN N
of IN N
life NN N
scores NNS N
, , N
a DT N
clinically RB N
useful JJ N
result NN N
that WDT N
is VBZ N
also RB N
in IN N
keeping VBG N
with IN N
the DT N
theoretical JJ N
constructs NNS N
of IN N
the DT N
benefits NNS N
of IN N
DBT NNP N
. . N

-DOCSTART- -X- O O 1282182

Prevention NN N
of IN N
coronary JJ 4_p
spasm NN 4_p
by IN N
nicorandil NNS N
: : N
comparison NN N
with IN N
nifedipine NN N
. . N

The DT N
efficacy NN N
of IN N
nicorandil NN N
was VBD N
compared VBN N
with IN N
that DT N
of IN N
nifedipine NN N
in IN N
13 CD N
patients NNS N
with IN N
vasospastic JJ 4_p
angina NNS 4_p
enrolled VBN N
in IN N
a DT N
randomized JJ N
, , N
placebo-controlled JJ N
, , N
crossover NN N
study NN N
. . N

All DT N
patients NNS N
had VBD N
a DT N
coronary JJ 4_p
spasm NN 4_p
during IN N
coronary JJ 4_p
arteriography NN 4_p
, , N
either CC N
spontaneously RB N
or CC N
ergometrine-induced JJ N
. . N

During IN N
two CD N
consecutive JJ N
periods NNS N
of IN N
2 CD N
days NNS N
, , N
patients NNS N
received VBD N
active JJ N
drugs NNS N
or CC N
placebo NN N
in IN N
a DT N
randomized JJ N
order NN N
. . N

Each DT N
patient NN N
received VBD N
single JJ N
oral JJ N
doses NNS N
of IN N
30 CD N
mg NN N
nicorandil NN N
, , N
10 CD N
mg NN N
nifedipine NN N
, , N
and CC N
, , N
on IN N
2 CD N
days NNS N
, , N
a DT N
placebo NN N
. . N

One CD N
hour NN N
after IN N
drug NN N
intake NN N
, , N
patients NNS N
underwent VBD N
an DT N
ergometrine JJ N
test NN N
with IN N
increasing VBG N
doses NNS N
of IN N
Methergin NNP N
( ( N
ergometrine NN N
) ) N
( ( N
0.05 CD N
, , N
0.10 CD N
, , N
0.20 CD N
, , N
and CC N
0.40 CD N
mg NN N
every DT N
5 CD N
min NN N
) ) N
. . N

After IN N
placebo NN N
, , N
the DT N
tests NNS N
always RB N
were VBD N
positive JJ N
, , N
and CC N
the DT N
ECG NNP N
changes NNS N
occurred VBD N
at IN N
the DT N
same JJ N
+/- JJ N
1 CD N
dose NN N
of IN N
ergometrine NN N
in IN N
10 CD N
cases NNS N
, , N
showing VBG N
good JJ N
reproducibility NN N
. . N

After IN N
nicorandil NN N
, , N
the DT N
tests NNS N
were VBD N
negative JJ N
in IN N
nine CD N
patients NNS N
and CC N
positive JJ N
for IN N
a DT N
higher JJR N
or CC N
lower JJR N
dose NN N
of IN N
ergometrine NN N
in IN N
three CD N
and CC N
one CD N
patient NN N
, , N
respectively RB N
( ( N
p JJ N
= $ N
0.0034 CD N
vs. FW N
placebo NN N
) ) N
. . N

After IN N
nifedipine NN N
, , N
the DT N
tests NNS N
were VBD N
negative JJ N
in IN N
five CD N
patients NNS N
and CC N
positive JJ N
for IN N
a DT N
higher JJR N
or CC N
the DT N
same JJ N
dose NN N
of IN N
ergometrine NN N
in IN N
four CD N
and CC N
four CD N
patients NNS N
, , N
respectively RB N
( ( N
p JJ N
= $ N
0.0039 CD N
vs. FW N
placebo NN N
) ) N
. . N

Nifedipine NNP N
( ( N
10 CD N
mg NN N
) ) N
and CC N
nicorandil $ N
( ( N
30 CD N
mg NN N
) ) N
were VBD N
equally RB N
effective JJ N
in IN N
eight CD N
patients NNS N
; : N
in IN N
the DT N
remaining VBG N
five CD N
patients NNS N
, , N
nicorandil NNS N
had VBD N
better JJR N
results NNS N
( ( N
p JJ N
= NNP N
0.06 CD N
) ) N
. . N

Nicorandil NNP N
( ( N
30 CD N
mg NN N
) ) N
prevents VBZ N
ergometrine-induced JJ N
coronary JJ N
spasm NN N
. . N

This DT N
compound NN N
may MD N
be VB N
beneficial JJ N
in IN N
patients NNS N
with IN N
vasospastic JJ 4_p
angina NN 4_p
. . N

-DOCSTART- -X- O O 18067498

Enhancing VBG N
attitudes NNS N
and CC N
intentions NNS N
in IN N
prospective JJ 4_p
blood NN 4_p
donors NNS 4_p
: : N
evaluation NN N
of IN N
a DT N
new JJ N
donor NN N
recruitment NN N
brochure NN N
. . N

BACKGROUND NNP N
Although IN N
little JJ N
empiric JJ N
evidence NN N
has VBZ N
been VBN N
published VBN N
concerning VBG N
the DT N
efficacy NN N
of IN N
blood NN N
donor NN N
recruitment NN N
materials NNS N
, , N
research NN N
suggests VBZ N
that IN N
simple JJ N
attempts NNS N
to TO N
enhance VB N
knowledge NN N
may MD N
not RB N
be VB N
sufficient JJ N
to TO N
motivate VB N
donation NN N
. . N

In IN N
contrast NN N
, , N
recent JJ N
donor NN N
motivation NN N
studies NNS N
highlight VBD N
the DT N
importance NN N
of IN N
anxiety NN N
, , N
attitudes NNS N
, , N
and CC N
perceived VBD N
ability NN N
to TO N
cope VB N
with IN N
donation NN N
( ( N
i.e. JJ N
, , N
self-efficacy NN N
) ) N
as IN N
crucial JJ N
determinants NNS N
of IN N
donation NN N
intention NN N
. . N

Therefore RB N
, , N
recruitment JJ N
materials NNS N
that WDT N
specifically RB N
address VBP N
these DT N
constructs NNS N
have VBP N
the DT N
potential JJ N
to TO N
outperform VB N
traditional JJ N
educational JJ N
brochures NNS N
. . N

STUDY NNP N
DESIGN NNP N
AND NNP N
METHODS NNP N
Participants NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
read VB N
one CD N
of IN N
three CD N
brochures NNS N
: : N
1 CD N
) ) N
a DT N
new JJ N
brochure NN N
addressing VBG N
common JJ N
donor NN N
concerns NNS N
and CC N
suggesting VBG N
specific JJ N
coping VBG N
strategies NNS N
, , N
2 CD N
) ) N
a DT N
standard JJ N
blood NN N
center NN N
brochure NN N
, , N
or CC N
3 CD N
) ) N
a DT N
control JJ N
brochure NN N
on IN N
healthy JJ N
eating NN N
and CC N
exercise NN N
. . N

Standardized JJ N
questionnaires NNS N
were VBD N
completed VBN N
before IN N
and CC N
after IN N
the DT N
brochures NNS N
to TO N
assess VB N
change NN N
in IN N
blood NN N
donation NN N
anxiety NN N
, , N
attitude NN N
, , N
self-efficacy NN N
, , N
and CC N
intention NN N
. . N

RESULTS NNP N
Although IN N
no DT N
significant JJ N
changes NNS N
were VBD N
noted VBN N
for IN N
the DT N
control NN N
brochure NN N
, , N
after IN N
reading VBG N
the DT N
new JJ N
brochure NN N
participants NNS N
reported VBD N
significant JJ N
improvements NNS N
in IN N
attitude NN N
, , N
anxiety NN N
, , N
self-efficacy NN N
, , N
and CC N
donation NN N
intention NN N
. . N

The DT N
standard JJ N
donation NN N
brochure NN N
had VBD N
an DT N
intermediate JJ N
effect NN N
. . N

CONCLUSION NNP N
Efforts NNPS N
to TO N
address VB N
common JJ N
donor NN N
fears NNS N
and CC N
to TO N
provide VB N
useful JJ N
coping VBG N
suggestions NNS N
may MD N
improve VB N
the DT N
effectiveness NN N
of IN N
blood NN N
donation NN N
recruitment NN N
materials NNS N
. . N

-DOCSTART- -X- O O 11748974

Fibrin NNP N
application NN N
for IN N
preventing VBG N
lymphocysts NNS N
after IN N
retroperitoneal JJ N
lymphadenectomy NN N
in IN N
patients NNS N
with IN N
gynecologic JJ 4_p
malignancies NNS 4_p
. . N

OBJECTIVE IN N
We PRP N
performed VBD N
a DT N
randomized VBN N
, , N
prospective JJ N
trial NN N
to TO N
assess VB N
the DT N
impact NN N
of IN N
fibrin JJ N
glue NN N
on IN N
the DT N
incidence NN N
of IN N
lymphocysts NNS N
after IN N
systematic JJ N
pelvic NN N
or CC N
pelvic NN N
and CC N
paraaortic JJ N
lymphadenectomy NN N
in IN N
patients NNS N
with IN N
gynecologic JJ 4_p
malignancies NNS 4_p
. . N

METHODS NNP N
Ninety-three JJ N
consecutive JJ N
patients NNS N
with IN N
gynecologic JJ 4_p
pelvic JJ 4_p
malignancies NNS 4_p
who WP N
underwent VBP N
surgery NN N
including VBG N
pelvic NN N
or CC N
pelvic NN N
and CC N
paraaortic JJ N
lymphadenectomy NN N
were VBD N
randomized VBN N
during IN N
surgery NN N
to TO N
be VB N
treated VBN N
with IN N
fibrin JJ N
glue NN N
or CC N
not RB N
. . N

Serial JJ N
computed JJ N
tomography NN N
( ( N
CT NNP N
) ) N
scans NNS N
were VBD N
performed VBN N
during IN N
follow-up JJ N
. . N

CT NNP N
findings NNS N
of IN N
a DT N
smooth JJ N
and CC N
thin-walled JJ N
cavity NN N
filled VBN N
with IN N
a DT N
water-equivalent JJ N
fluid NN N
, , N
sharply RB N
demarcated VBN N
from IN N
its PRP$ N
surroundings NNS N
and CC N
without IN N
signs NNS N
of IN N
infiltration NN N
were VBD N
interpreted VBN N
as IN N
lymphocysts NNS N
. . N

RESULTS NNP N
Forty-seven JJ N
patients NNS N
( ( N
51 CD N
% NN N
) ) N
were VBD N
treated VBN N
with IN N
fibrin JJ N
glue NN N
and CC N
46 CD N
( ( N
49 CD N
% NN N
) ) N
were VBD N
not RB N
. . N

All DT N
93 CD N
patients NNS N
underwent JJ N
pelvic JJ N
lymphadenectomy NN N
; : N
15 CD N
patients NNS N
( ( N
32 CD N
% NN N
) ) N
of IN N
the DT N
fibrin NN N
group NN N
and CC N
12 CD N
( ( N
26 CD N
% NN N
) ) N
of IN N
the DT N
controls NNS N
also RB N
underwent JJ N
paraaortic JJ N
lymphadenectomy NN N
. . N

We PRP N
found VBD N
no DT N
significant JJ N
differences NNS N
between IN N
patients NNS N
who WP N
received VBD N
fibrin JJ N
glue NN N
and CC N
those DT N
who WP N
did VBD N
not RB N
. . N

CONCLUSION NNP N
Intraoperative NNP N
application NN N
of IN N
fibrin JJ N
glue NN N
did VBD N
not RB N
reduce VB N
the DT N
rate NN N
of IN N
postoperative JJ N
lymphocysts NNS N
after IN N
lymphadenectomy NN N
and CC N
had VBD N
no DT N
impact NN N
on IN N
any DT N
follow-up JJ N
parameter NN N
. . N

Its PRP$ N
use NN N
seems VBZ N
not RB N
to TO N
be VB N
indicated VBN N
in IN N
systematic JJ N
gynecologic NN N
pelvic NN N
or CC N
pelvic NN N
and CC N
paraaortic JJ N
lymphadenectomy NN N
. . N

-DOCSTART- -X- O O 18485420

Atypical JJ N
recruitment NN N
of IN N
medial JJ N
prefrontal JJ N
cortex NN N
in IN N
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
: : 4_p
an DT N
fMRI NN N
study NN N
of IN N
two CD N
executive NN N
function NN N
tasks NNS N
. . N

Recent JJ N
studies NNS N
have VBP N
suggested VBN N
an DT N
uneven JJ N
profile NN N
of IN N
executive JJ N
dysfunction NN N
in IN N
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
( ( 4_p
ASD NNP 4_p
) ) 4_p
. . 4_p

For IN N
example NN N
, , N
some DT N
authors NNS N
have VBP N
reported VBN N
deficits NNS N
on IN N
newly RB N
developed VBN N
tests NNS N
of IN N
executive NN N
function NN N
sensitive JJ N
to TO N
rostral JJ N
prefrontal JJ N
function NN N
, , N
despite IN N
spared VBN N
, , N
or CC N
even RB N
superior JJ N
, , N
performance NN N
on IN N
other JJ N
tests NNS N
. . N

We PRP N
investigated VBD N
the DT N
performance NN N
of IN N
a DT N
group NN N
of IN N
high-functioning JJ N
participants NNS N
with IN N
ASD NNP N
( ( N
N=15 NNP N
) ) N
and CC N
an DT N
age- JJ N
and CC N
IQ-matched JJ N
control NN N
group NN N
( ( N
N=18 NNP N
) ) N
on IN N
two CD N
executive NN N
function NN N
tests NNS N
, , N
whilst VBP N
undergoing JJ N
functional JJ N
magnetic JJ N
resonance NN N
imaging NN N
( ( N
fMRI NN N
) ) N
. . N

Behaviourally NNP N
, , N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
two CD N
groups NNS N
. . N

In IN N
a DT N
classical JJ N
test NN N
of IN N
executive NN N
function NN N
( ( N
random JJ N
response NN N
generation NN N
) ) N
, , N
BOLD NNP N
signal NN N
differed VBD N
between IN N
the DT N
groups NNS N
in IN N
the DT N
cerebellum NN N
but CC N
not RB N
in IN N
the DT N
frontal JJ N
lobes NN N
. . N

However RB N
, , N
on IN N
a DT N
new JJ N
test NN N
of IN N
executive NN N
function NN N
( ( N
selection NN N
between IN N
stimulus-oriented JJ N
and CC N
stimulus-independent JJ N
thought NN N
) ) N
, , N
the DT N
ASD NNP N
group NN N
exhibited VBD N
significantly RB N
greater JJR N
signal-change NN N
in IN N
medial JJ N
rostral JJ N
prefrontal NN N
cortex NN N
( ( N
especially RB N
Brodmann NNP N
Area NNP N
10 CD N
) ) N
in IN N
the DT N
comparison NN N
of IN N
stimulus-oriented JJ N
versus NN N
stimulus-independent JJ N
attention NN N
. . N

In IN N
addition NN N
, , N
the DT N
new JJ N
test NN N
( ( N
but CC N
not RB N
the DT N
classical JJ N
test NN N
) ) N
provided VBD N
evidence NN N
for IN N
abnormal JJ N
functional JJ N
organisation NN N
of IN N
medial JJ N
prefrontal JJ N
cortex NN N
in IN N
ASD NNP 4_p
. . 4_p

These DT N
results NNS N
underline VBP N
the DT N
heterogeneity NN N
of IN N
different JJ N
tests NNS N
of IN N
executive NN N
function NN N
, , N
and CC N
suggest VBP N
that IN N
executive NN N
functioning NN N
in IN N
ASD NNP 4_p
is VBZ N
associated VBN N
with IN N
task-specific JJ N
functional JJ N
change NN N
. . N

-DOCSTART- -X- O O 11549300

Dipyridamole NNP N
in IN N
chronic JJ 4_p
stable JJ 4_p
angina NN 4_p
pectoris NN 4_p
; : N
a DT N
randomized VBN N
, , N
double JJ N
blind NN N
, , N
placebo-controlled JJ N
, , N
parallel JJ N
group NN N
study NN N
. . N

BACKGROUND NNP N
Oral NNP N
dipyridamole NN N
induces NNS N
accumulation NN N
of IN N
endogenous JJ N
adenosine NN N
, , N
which WDT N
in IN N
a DT N
hypoxic NN N
milieu NN N
exerts VBZ N
experimentally RB N
an DT N
angiogenic JJ N
effect NN N
on IN N
coronary JJ N
collateral NN N
circulation NN N
. . N

A DT N
meta-analysis NN N
of IN N
13 CD N
randomized JJ N
placebo-controlled JJ N
trials NNS N
published VBN N
between IN N
1960 CD N
and CC N
1992 CD N
showed VBD N
evidence NN N
of IN N
benefit NN N
for IN N
dipyridamole NN N
in IN N
the DT N
treatment NN N
of IN N
angina JJ N
pectoris NN N
, , N
especially RB N
with IN N
longer JJR N
duration NN N
of IN N
treatment NN N
. . N

Aim NNP N
To TO N
assess VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
dipyridamole NN N
in IN N
the DT N
treatment NN N
of IN N
patients NNS 4_p
with IN 4_p
chronic JJ 4_p
stable JJ 4_p
angina NN 4_p
in IN 4_p
a DT 4_p
large JJ 4_p
scale NN 4_p
, , 4_p
international JJ 4_p
, , N
randomized VBN N
, , N
placebo-controlled JJ N
, , N
parallel JJ N
group NN N
study NN N
. . N

METHODS NNP N
Four CD N
hundred VBD N
patients NNS N
with IN N
chronic JJ N
stable JJ N
angina NN N
pectoris NN N
and CC N
a DT N
positive JJ N
treadmill NN N
exercise NN N
test NN N
were VBD N
randomized VBN N
to TO N
receive VB N
either RB N
modified JJ N
release NN N
dipyridamole NN N
( ( N
200 CD N
mg NN N
b.i.d NN N
. . N

p.o. NN N
, , N
n=198 NN N
) ) N
or CC N
corresponding VBG N
placebo NN N
( ( N
n=202 JJ N
) ) N
, , N
for IN N
24 CD N
weeks NNS N
as IN N
an DT N
add-on JJ N
to TO N
conventional JJ N
antianginal JJ N
therapy NN N
and CC N
for IN N
4 CD N
additional JJ N
weeks NNS N
as IN N
monotherapy NN N
-- : N
the DT N
latter NN N
after IN N
withdrawal NN N
of IN N
standard JJ N
treatment NN N
with IN N
calcium NN N
antagonists NNS N
and/or VBP N
beta-blockers NNS N
and/or JJ N
long-acting JJ N
( ( N
prophylactic JJ N
) ) N
nitrates NNS N
. . N

RESULTS NNP N
Of IN N
the DT N
198 CD N
patients NNS N
randomized VBN N
to TO N
dipyridamole VB N
, , N
134 CD N
completed VBD N
the DT N
add-on NN N
and CC N
only RB N
12 CD N
the DT N
monotherapy NN N
phase NN N
. . N

Of IN N
the DT N
202 CD N
patients NNS N
randomized VBN N
to TO N
placebo VB N
, , N
162 CD N
reached VBD N
the DT N
add-on JJ N
and CC N
only RB N
12 CD N
the DT N
monotherapy NN N
phase NN N
. . N

Serious JJ N
adverse JJ N
events NNS N
occurred VBD N
in IN N
15 CD N
patients NNS N
with IN N
dipyridamole JJ N
and CC N
in IN N
12 CD N
with IN N
placebo NN N
( ( N
7.6 CD N
% NN N
vs NN N
6.0 CD N
, , N
P=0.52 NNP N
) ) N
. . N

Increase NN N
over IN N
the DT N
baseline NN N
treadmill NN N
exercise NN N
test NN N
was VBD N
similar JJ N
in IN N
the DT N
treatment NN N
groups NNS N
at IN N
each DT N
stage NN N
of IN N
the DT N
trial NN N
for IN N
all PDT N
the DT N
main JJ N
efficacy NN N
parameters NNS N
: : N
total JJ N
treadmill NN N
exercise NN N
test NN N
duration NN N
; : N
time NN N
to TO N
first JJ N
anginal JJ N
pain NN N
( ( N
except IN N
for IN N
a DT N
-13 NN N
s NN N
difference NN N
in IN N
favour NN N
of IN N
placebo NN N
at IN N
week NN N
24 CD N
; : N
P=0.040 NNP N
) ) N
; : N
time NN N
to TO N
ST NNP N
segment NN N
depression NN N
> VBD N
0.1 CD N
mVolt NN N
( ( N
except IN N
for IN N
a DT N
+21 JJ N
s NN N
difference NN N
in IN N
favour NN N
of IN N
dipyridamole NN N
at IN N
week NN N
8 CD N
; : N
P=0.024 NNP N
; : N
this DT N
latter JJ N
difference NN N
was VBD N
totally RB N
attributable JJ N
to TO N
patients NNS N
with IN N
lower JJR N
exercise NN N
tolerance NN N
-- : N
Bruce NNP N
stage NN N
II NNP N
at IN N
study NNP N
entry NN N
) ) N
. . N

CONCLUSION NNP N
In IN N
patients NNS 4_p
with IN 4_p
chronic JJ 4_p
stable JJ 4_p
angina NN 4_p
treated VBN 4_p
with IN 4_p
regular JJ 4_p
antianginal JJ 4_p
background NN 4_p
medication NN 4_p
, , N
the DT N
use NN N
of IN N
oral JJ N
dipyridamole NN N
is VBZ N
safe JJ N
and CC N
well RB N
tolerated VBN N
. . N

Antianginal NNP N
and CC N
antiischaemic JJ N
efficacy NN N
, , N
as IN N
assessed VBN N
by IN N
exercise NN N
testing NN N
, , N
is VBZ N
comparable JJ N
to TO N
placebo VB N
, , N
except IN N
for IN N
a DT N
beneficial JJ N
effect NN N
on IN N
time NN N
to TO N
ischaemia VB N
after IN N
2 CD N
months NNS N
, , N
totally RB N
attributable JJ N
to TO N
patients NNS N
with IN N
lower JJR N
exercise NN N
tolerance NN N
at IN N
study NN N
entry NN N
. . N

-DOCSTART- -X- O O 1488874

Oscillatory NN 4_p
potentials NNS N
, , N
retinopathy NN 4_p
, , N
and CC N
long-term JJ N
glucose NN N
control NN N
in IN N
insulin-dependent JJ 4_p
diabetes NNS 4_p
. . N

The DT N
main JJ N
objective NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
assess JJ N
effects NNS N
of IN N
long-term JJ N
lowering NN N
of IN N
glucosylated JJ N
hemoglobin NN N
( ( N
HbA1 NNP N
% NN N
) ) N
on IN N
neurosensory JJ N
function NN N
in IN N
insulin-dependent JJ 4_p
diabetes NNS 4_p
. . N

Individual NNP N
( ( N
OP-1 NNP N
, , N
OP-2 NNP N
, , N
OP-3 NNP N
) ) N
and CC N
summed VBN N
( ( N
OP-sum NNP N
) ) N
amplitudes NNS N
of IN N
oscillatory JJ N
potentials NNS N
( ( N
OPs NNP N
) ) N
of IN N
electroretinography NN N
were VBD N
recorded VBN N
at IN N
study JJ N
start NN N
and CC N
7-years NNS N
later RB N
in IN N
45 CD N
patients NNS N
( ( N
the DT N
Oslo NNP N
study NN N
) ) N
. . N

As IN N
an DT N
overall JJ N
7-year JJ N
change NN N
, , N
amplitudes NNS N
of IN N
OP-2 NNP N
, , N
OP-3 NNP N
and CC N
OP-sum NNP N
were VBD N
reduced VBN N
( ( N
p JJ N
< NNP N
0.0001-0.01 NN N
) ) N
, , N
retinopathy JJ N
worsened VBD N
( ( N
p JJ N
= NNP N
0.005 CD N
) ) N
, , N
intraocular JJ N
pressure NN N
decreased VBN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
, , N
systolic JJ N
blood NN N
pressure NN N
increased VBD N
( ( N
p JJ N
< NNP N
0.0002 CD N
) ) N
, , N
and CC N
glycemic JJ N
control NN N
improved VBN N
from IN N
HbA1 NNP N
of IN N
11.2 CD N
+/- JJ N
2.2 CD N
% NN N
at IN N
study JJ N
start NN N
to TO N
a DT N
7-year JJ N
cumulative JJ N
mean NN N
of IN N
9.5 CD N
+/- JJ N
1.5 CD N
% NN N
( ( N
p JJ N
< NNP N
0.0001 CD N
) ) N
. . N

Multiple JJ N
regression NN N
analysis NN N
did VBD N
not RB N
identify VB N
any DT N
independent JJ N
relations NNS N
between IN N
change NN N
in IN N
OP-1 NNP N
, , N
OP-2 NNP N
, , N
OP-3 NNP N
, , N
OP-sum NNP N
and CC N
change NN N
in IN N
glycemic JJ N
control NN N
or CC N
background NN N
variables NNS N
, , N
including VBG N
change NN N
in IN N
age NN N
and CC N
duration NN N
of IN N
diabetes NNS N
. . N

However RB N
, , N
cross-sectional JJ N
observations NNS N
at IN N
7 CD N
years NNS N
showed VBD N
negative JJ N
correlations NNS N
between IN N
all DT N
OPs NNP N
and CC N
age NN N
( ( N
p JJ N
< NNP N
0.0001-0.003 NN N
) ) N
, , N
and CC N
between IN N
OP-3 NNP N
and CC N
duration NN N
( ( N
p JJ N
= NNP N
0.003 CD N
) ) N
and CC N
counts NNS N
of IN N
microaneurysms NNS N
( ( N
p JJ N
= NNP N
0.02 CD N
) ) N
. . N

The DT N
data NN N
suggest NN N
that IN N
various JJ N
clinical JJ N
background NN N
variables NNS N
may MD N
influence VB N
individual JJ N
and CC N
summed VBD N
amplitudes NNS N
of IN N
OPs NNP N
differently RB N
. . N

Reduced NNP N
neurosensory JJ N
retinal JJ N
function NN N
( ( N
OPs NNP N
) ) N
seemed VBD N
to TO N
appear VB N
after IN N
7-years NNS N
, , N
independently RB N
of IN N
vascular JJ N
defects NNS N
of IN N
retinopathy JJ N
and CC N
long-term JJ N
improvement NN N
in IN N
glucose JJ N
control NN N
. . N

-DOCSTART- -X- O O 22565413

Internet-based JJ N
program NN N
for IN N
coping VBG N
with IN N
cancer NN N
: : N
a DT N
randomized NN N
controlled VBN N
trial NN N
with IN N
hematologic JJ 4_p
cancer NN 4_p
patients NNS N
. . N

OBJECTIVE NNP N
Psychosocial NNP N
patient NN N
care NN N
in IN N
oncology NN N
is VBZ N
no DT N
longer RB N
limited VBN N
to TO N
the DT N
inpatient NN N
setting NN N
. . N

Outpatient NNP N
services NNS N
are VBP N
in IN N
demand NN N
. . N

Internet-based JJ N
interventions NNS N
could MD N
aid VB N
in IN N
optimizing VBG N
service NN N
delivery NN N
across IN N
disciplines NNS N
. . N

The DT N
effectiveness NN N
of IN N
an DT N
Internet-based JJ N
program NN N
for IN N
hematologic JJ 4_p
cancer NN 4_p
patients NNS N
was VBD N
tested VBN N
in IN N
a DT N
randomized NN N
controlled VBN N
trial NN N
under IN N
field NN N
experimental JJ N
conditions NNS N
. . N

METHODS VB N
A DT N
4-week JJ N
cognitive-behavioral JJ N
program NN N
for IN N
coping VBG N
with IN N
cancer NN N
was VBD N
offered VBN N
to TO N
hematologic VB 4_p
cancer NN 4_p
patients NNS N
online VBP N
. . N

One CD N
hundred VBD N
eighty-six JJ N
registrants NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
an DT N
intervention NN N
group NN N
( ( N
n JJ N
= NNP N
105 CD N
) ) N
or CC N
a DT N
waiting JJ N
list NN N
( ( N
n JJ N
= NNP N
81 CD N
) ) N
. . N

The DT N
outcome NN N
measures NNS N
, , N
'mental JJ N
adjustment NN N
' POS N
( ( N
MAC NNP N
) ) N
and CC N
'psychological JJ N
distress NN N
' POS N
( ( N
BSI NNP N
) ) N
, , N
were VBD N
assessed VBN N
at IN N
registration NN N
and CC N
after IN N
4 CD N
weeks NNS N
. . N

Patient JJ N
satisfaction NN N
was VBD N
assessed VBN N
( ( N
ZUF-8 NNP N
) ) N
, , N
and CC N
complete-cases NNS N
and CC N
intention-to-treat JJ N
analyses NNS N
were VBD N
performed VBN N
. . N

RESULTS NNP N
At IN N
registration NN N
, , N
the DT N
majority NN N
of IN N
participants NNS N
displayed VBN N
clinically RB N
significant JJ N
distress NN N
( ( N
BSI NNP N
) ) N
and CC N
lacked JJ N
alternative JJ N
access NN N
concerning VBG N
psychosocial JJ N
care NN N
. . N

One CD N
hundred VBD N
eleven JJ N
patients NNS N
filled VBN N
out RP N
the DT N
post NN N
questionnaire NN N
at IN N
4 CD N
weeks NNS N
. . N

In IN N
contrast NN N
to TO N
the DT N
waiting VBG N
list NN N
, , N
the DT N
intervention NN N
group NN N
displayed VBD N
a DT N
significant JJ N
increase NN N
in IN N
fighting VBG N
spirit NN N
( ( N
d JJ N
= VBZ N
0.42 CD N
; : N
CI NNP N
95 CD N
% NN N
, , N
0.04 CD N
to TO N
0.80 CD N
) ) N
. . N

The DT N
effect NN N
was VBD N
confirmed VBN N
by IN N
intention-to-treat NN N
analysis NN N
( ( N
d JJ N
= VBZ N
0.33 CD N
; : N
CI NNP N
95 CD N
% NN N
, , N
0.04 CD N
to TO N
0.62 CD N
) ) N
. . N

Otherwise NNP N
, , N
no DT N
effects NNS N
were VBD N
observed VBN N
. . N

Patient JJ N
satisfaction NN N
with IN N
the DT N
program NN N
was VBD N
high JJ N
. . N

CONCLUSION VB N
The DT N
results NNS N
demonstrate VBP N
the DT N
potential JJ N
efficacy NN N
of IN N
Internet-based JJ N
programs NNS N
while IN N
highlighting VBG N
their PRP$ N
limitations NNS N
. . N

Future NNP N
research NN N
is VBZ N
needed VBN N
to TO N
clarify VB N
and CC N
optimize VB N
efficacy NN N
, , N
taking VBG N
different JJ N
program NN N
components NNS N
and CC N
patient JJ N
characteristics NNS N
into IN N
particular JJ N
consideration NN N
. . N

-DOCSTART- -X- O O 19682342

Large-dose JJ N
intravenous JJ N
ferric NNS N
carboxymaltose VBP N
injection NN N
for IN N
iron NN N
deficiency NN N
anemia NN 4_p
in IN N
heavy JJ N
uterine JJ 4_p
bleeding NN 4_p
: : N
a DT N
randomized NN N
, , N
controlled VBN N
trial NN N
. . N

BACKGROUND VB N
The DT N
objective NN N
was VBD N
to TO N
evaluate VB N
efficacy NN N
and CC N
safety NN N
of IN N
rapid JJ N
, , N
large-dose JJ N
intravenous JJ N
( ( N
IV NNP N
) ) N
administration NN N
of IN N
ferric JJ N
carboxymaltose NN N
compared VBN N
to TO N
oral JJ N
iron NN N
in IN N
correcting VBG N
iron NN N
deficiency NN N
anemia NN N
due JJ N
to TO N
heavy JJ N
uterine JJ N
bleeding NN N
. . N

STUDY NNP N
DESIGN NNP N
AND NNP N
METHODS NNP N
In IN N
a DT N
randomized NN N
, , N
controlled VBN N
trial NN N
, , N
477 CD N
women NNS N
with IN N
anemia NN 4_p
, , 4_p
iron NN 4_p
deficiency NN 4_p
, , 4_p
and CC 4_p
heavy JJ 4_p
uterine JJ 4_p
bleeding NN 4_p
were VBD N
assigned VBN N
to TO N
receive VB N
either DT N
IV NNP N
ferric NN N
carboxymaltose NN N
( ( N
< JJ N
or=1000 NN N
mg NN N
over IN N
15 CD N
min NNS N
, , N
repeated VBD N
weekly JJ N
to TO N
achieve VB N
a DT N
total JJ N
calculated JJ N
replacement NN N
dose NN N
) ) N
or CC N
325 CD N
mg NN N
of IN N
ferrous JJ N
sulfate NN N
( ( N
65 CD N
mg NN N
elemental JJ N
iron NN N
) ) N
prescribed VBD N
orally RB N
thrice JJ N
daily RB N
for IN N
6 CD N
weeks NNS N
. . N

RESULTS NNP N
Compared VBD N
to TO N
those DT N
assigned VBN N
to TO N
ferrous JJ N
sulfate NN N
, , N
more JJR N
patients NNS N
assigned VBD N
to TO N
ferric VB N
carboxymaltose NN N
responded VBN N
with IN N
a DT N
hemoglobin NN N
( ( N
Hb NNP N
) ) N
increase NN N
of IN N
2.0 CD N
g/dL NN N
or CC N
more JJR N
( ( N
82 CD N
% NN N
vs. FW N
62 CD N
% NN N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
for IN N
treatment NN N
difference NN N
12.2-28.3 CD N
, , N
p VBZ N
< NNP N
0.001 CD N
) ) N
, , N
more JJR N
achieved VBD N
a DT N
3.0 CD N
g/dL NN N
or CC N
more JJR N
increase NN N
( ( N
53 CD N
% NN N
vs. FW N
36 CD N
% NN N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
, , N
and CC N
more JJR N
achieved JJ N
correction NN N
( ( N
Hb NNP N
> NNP N
or= VBD N
12 CD N
g/dL NN N
) ) N
of IN N
anemia NN N
( ( N
73 CD N
% NN N
vs. FW N
50 CD N
% NN N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
. . N

Patients NNS N
treated VBD N
with IN N
ferric JJ N
carboxymaltose NN N
compared VBN N
to TO N
those DT N
prescribed VBN N
ferrous JJ N
sulfate NN N
reported VBD N
greater JJR N
gains NNS N
in IN N
vitality NN N
and CC N
physical JJ N
function NN N
and CC N
experienced JJ N
greater JJR N
improvement NN N
in IN N
symptoms NNS N
of IN N
fatigue NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
serious JJ N
adverse JJ N
drug NN N
events NNS N
. . N

CONCLUSIONS NNP N
In IN N
patients NNS N
with IN N
iron NN N
deficiency NN N
anemia NN N
due JJ N
to TO N
heavy JJ N
uterine JJ N
bleeding NN N
, , N
rapid JJ N
IV NNP N
administration NN N
of IN N
large JJ N
doses NNS N
of IN N
a DT N
new JJ N
iron NN N
agent NN N
, , N
ferric JJ N
carboxymaltose NN N
, , N
is VBZ N
more RBR N
effective JJ N
than IN N
oral JJ N
iron NN N
therapy NN N
in IN N
correcting VBG N
anemia NN N
, , N
replenishing VBG N
iron NN N
stores NNS N
, , N
and CC N
improving VBG N
quality NN N
of IN N
life NN N
. . N

-DOCSTART- -X- O O 19207781

Esophageal JJ N
damage NN N
during IN N
radiofrequency NN N
ablation NN N
of IN N
atrial JJ N
fibrillation NN N
: : N
impact NN N
of IN N
energy NN N
settings NNS N
, , N
lesion NN N
sets NNS N
, , N
and CC N
esophageal JJ N
visualization NN N
. . N

INTRODUCTION NNP N
Atrioesophageal NNP N
fistula NN N
is VBZ N
an DT N
uncommon JJ N
but CC N
often RB N
lethal JJ N
complication NN N
of IN N
atrial JJ 4_p
fibrillation NN 4_p
( ( 4_p
AF NNP 4_p
) ) 4_p
ablation NN 4_p
. . N

The DT N
purpose NN N
of IN N
our PRP$ N
study NN N
was VBD N
to TO N
prospectively RB N
investigate VB N
the DT N
incidence NN N
of IN N
esophageal JJ N
ulcerations NNS N
( ( N
ESUL NNP N
) ) N
as RB N
well RB N
as IN N
the DT N
impact NN N
of IN N
energy NN N
settings NNS N
, , N
radiofrequency NN N
lesion NN N
sets NNS N
, , N
and CC N
direct JJ N
visualization NN N
of IN N
the DT N
esophagus NN N
on IN N
esophageal NN N
wall JJ N
injury NN N
. . N

METHODS NNP N
AND CC N
RESULTS NNP N
One CD N
hundred VBD N
seventy-five JJ N
patients NNS N
, , N
57.1 CD N
% NN N
paroxysmal JJ N
AF NNP N
, , N
78.5 CD N
% NN N
male NN N
, , N
underwent JJ N
AF NNP 4_p
ablation NN 4_p
and CC 4_p
esophagoscopy $ 4_p
24 CD N
hours NNS N
thereafter RB N
. . N

We PRP N
performed VBD N
a DT N
2:1:1-randomization JJ N
as IN N
follows VBZ N
: : N
CONTROL NNP N
GROUP NNP N
Ablation NNP N
without IN N
visualization NN N
of IN N
the DT N
esophagus NN N
using VBG N
25 CD N
Watt NNP N
( ( N
W NNP N
) ) N
power NN N
limit NN N
on IN N
the DT N
posterior NN N
wall NN N
, , N
n JJ N
= NN N
70 CD N
. . N

Visualization NN N
and CC N
15 CD N
W NNP N
maximum NN N
: : N
Ablation NN N
guided VBN N
by IN N
barium NN N
visualization NN N
of IN N
the DT N
esophageal JJ N
course NN N
using VBG N
a DT N
limit NN N
of IN N
15 CD N
W NNP N
, , N
n JJ N
= NN N
35 CD N
. . N

Visualization NN N
and CC N
25 CD N
W NNP N
" NNP N
short JJ N
burns NNS N
" NNS N
: : N
Ablation NN N
guided VBN N
by IN N
barium NN N
visualization NN N
using VBG N
25 CD N
W NNP N
and CC N
" NNP N
short JJ N
burns NNS N
" NNP N
( ( N
max NN N
. . N

5 CD N
sec NN N
) ) N
, , N
n JJ N
= NN N
35 CD N
. . N

Patients NNS N
performed VBN N
under IN N
general JJ N
anesthesia NN N
( ( N
n JJ N
= NNP N
35 CD N
) ) N
were VBD N
separated VBN N
as IN N
a DT N
nasogastric JJ N
tube NN N
for IN N
visualization NN N
of IN N
the DT N
esophagus NN N
was VBD N
used VBN N
. . N

In IN N
total JJ N
, , N
we PRP N
found VBD N
2.9 CD N
% NN N
of IN N
patients NNS N
( ( N
5/175 CD N
) ) N
presenting NN N
ESUL NNP N
. . N

Parameters NNS N
discriminating VBG N
the DT N
development NN N
of IN N
ESUL NNP N
in IN N
a DT N
specific JJ N
patient NN N
were VBD N
type NN N
of IN N
AF NNP N
, , N
maximum JJ N
energy NN N
delivered VBN N
, , N
usage NN N
of IN N
a DT N
nasogastric JJ N
tube NN N
, , N
and CC N
additional JJ N
left NN N
atrial JJ N
lines NNS N
. . N

Visualization NN N
of IN N
the DT N
esophageal JJ N
course NN N
by IN N
barium NN N
contrast NN N
was VBD N
not RB N
able JJ N
to TO N
prevent VB N
ESUL NNP N
. . N

CONCLUSION NNP N
ESUL NNP N
is VBZ N
a DT N
rare JJ N
finding NN N
when WRB N
using VBG N
a DT N
reasonable JJ N
energy NN N
maximum NN N
of IN N
25 CD N
W NNP N
with IN N
open-irrigated JJ N
tip NN N
catheters NNS N
at IN N
the DT N
posterior JJ N
wall NN N
. . N

Lower NNP N
energy NN N
settings NNS N
may MD N
increase VB N
safety NN N
without IN N
losing VBG N
efficacy NN N
. . N

Additional JJ N
linear JJ N
radiofrequency NN N
lesions NNS N
increase VBP N
the DT N
risk NN N
of IN N
ESUL NNP N
development NN N
. . N

-DOCSTART- -X- O O 24184410

There EX N
is VBZ N
no DT N
sweet JJ N
escape NN N
from IN N
social JJ N
pain NN N
: : N
glucose NN N
does VBZ N
not RB N
attenuate VB N
the DT N
effects NNS 4_p
of IN 4_p
ostracism NN 4_p
. . N

Ostracism NN N
causes VBZ N
social JJ N
pain NN N
and CC N
is VBZ N
known VBN N
to TO N
activate VB N
regions NNS N
of IN N
the DT N
brain NN N
that WDT N
are VBP N
involved VBN N
in IN N
the DT N
representation NN N
of IN N
physical JJ N
pain NN N
. . N

Previous JJ N
research NN N
has VBZ N
observed VBN N
that IN N
acetominophen NN N
( ( N
a DT N
common JJ N
pain NN N
reliever NN N
) ) N
can MD N
reduce VB N
the DT N
pain NN N
of IN N
exclusion NN N
. . N

The DT N
taste NN N
and CC N
consumption NN N
of IN N
glucose NN N
can MD N
also RB N
relieve VB N
physical JJ N
pain NN N
, , N
and CC N
the DT N
purpose NN N
of IN N
the DT N
current JJ N
study NN N
was VBD N
to TO N
examine VB N
whether IN N
it PRP N
might MD N
also RB N
reduce VB N
the DT N
negative JJ N
emotional JJ 4_p
effects NNS 4_p
of IN 4_p
ostracism NN 4_p
. . N

In IN N
an DT N
appropriately RB N
powered JJ N
experiment NN N
, , N
participants NNS 4_p
were VBD 4_p
given VBN 4_p
25g CD 4_p
of IN 4_p
glucose NN 4_p
or CC N
a DT 4_p
sucralose JJ 4_p
placebo NN 4_p
before IN 4_p
being VBG 4_p
ostracized VBN 4_p
while IN 4_p
playing VBG 4_p
Cyberball NNP 4_p
. . N

Strong NNP N
effects NNS N
of IN N
ostracism NN N
were VBD N
observed VBN N
, , N
however RB N
, , N
there EX N
was VBD N
no DT N
effect NN N
of IN N
glucose NN N
on IN N
immediate JJ N
or CC N
delayed VBN N
self-reported JJ N
needs NNS N
or CC N
mood NN N
. . N

These DT N
results NNS N
are VBP N
discussed VBN N
in IN N
reference NN N
to TO N
the DT N
possibility NN N
that IN N
social JJ N
pain NN N
is VBZ N
unlike IN N
physical JJ N
pain NN N
since IN N
the DT N
latter NN N
is VBZ N
affected VBN N
by IN N
glucose NN N
, , N
which WDT N
is VBZ N
believed VBN N
to TO N
lessen VB N
pain NN N
by IN N
increasing VBG N
endogenous JJ N
opioid NN N
activity NN N
. . N

-DOCSTART- -X- O O 22732966

Nutritional JJ N
orientation NN N
, , N
knowledge NN N
and CC N
quality NN N
of IN N
diet NN N
in IN N
heart NN 4_p
failure NN 4_p
: : N
randomized JJ N
clinical JJ N
trial NN N
. . N

BACKGROUND NNP N
Non-pharmacological JJ N
measures NNS N
are VBP N
recommended VBN N
for IN N
heart NN 4_p
failure NN 4_p
patients NNS 4_p
. . N

However RB N
, , N
most JJS N
studies NNS N
evaluate VBP N
low JJ N
sodium NN N
diet NN N
, , N
while IN N
little JJ N
is VBZ N
known VBN N
about IN N
the DT N
effects NNS N
of IN N
interventions NNS N
to TO N
improve VB N
adherence NN N
and CC N
knowledge NN N
of IN N
patients NNS N
about IN N
diet JJ N
content NN N
. . N

OBJECTIVE UH N
To TO N
evaluate VB N
if IN N
a DT N
global JJ N
nutritional JJ N
orientation NN N
could MD N
affect VB N
nutritional JJ N
knowledge NN N
, , N
adherence NN N
to TO N
food NN N
guidelines NNS N
, , N
anthropometrics NNS N
and CC N
quality NN N
of IN N
life NN N
in IN N
heart NN 4_p
failure NN 4_p
patients NNS 4_p
. . 4_p

METHODS NNP N
Forty NNP N
six CD N
patients NNS N
were VBD N
randomized VBN N
to TO N
intervention VB N
or CC N
control VB N
group NN N
. . N

Both DT N
groups NNS N
received VBD N
usual JJ N
care NN N
with IN N
medical JJ N
and CC N
nursing JJ N
staff NN N
; : N
the DT N
intervention NN N
group NN N
received VBD N
additional JJ N
nutritional JJ N
guidance NN N
about IN N
diet JJ N
and CC N
its PRP$ N
relationship NN N
with IN N
disease NN N
, , N
sources NNS N
of IN N
nutrients NNS N
, , N
and CC N
reduction NN N
of IN N
dietary JJ N
sodium NN N
and CC N
fats NNS N
. . N

Enforcement NN N
of IN N
the DT N
nutritional JJ N
guidance NN N
was VBD N
performed VBN N
after IN N
4 CD N
weeks NNS N
. . N

Both DT N
groups NNS N
were VBD N
evaluated VBN N
at IN N
baseline NN N
, , N
and CC N
after IN N
6 CD N
weeks NNS N
and CC N
6 CD N
months NNS N
. . N

Evaluations NNS N
included VBD N
anthropometric JJ N
parameters NNS N
, , N
sodium NN N
excretion NN N
in IN N
24-hour JJ N
urine NN N
, , N
dietary JJ N
recall NN N
, , N
nutrition NN N
knowledge NN N
and CC N
quality NN N
of IN N
life NN N
questionnaires NNS N
. . N

RESULTS NNP N
Mean NNP N
age NN N
of IN N
included JJ N
patients NNS N
was VBD N
58 CD N
± JJ N
10 CD N
years NNS N
and CC N
70 CD N
% NN N
were VBD N
male JJ N
. . N

After IN N
6 CD N
months NNS N
of IN N
follow-up NN N
, , N
the DT N
nutritional JJ N
knowledge NN N
of IN N
intervention NN N
group NN N
increased VBD N
compared VBN N
to TO N
control VB N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

Caloric NNP N
, , N
fat NN N
and CC N
sodium NN N
intake NN N
decreased VBN N
in IN N
the DT N
intervention NN N
group NN N
compared VBN N
to TO N
control VB N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

No DT N
significant JJ N
differences NNS N
were VBD N
seen VBN N
in IN N
quality NN N
of IN N
life NN N
or CC N
anthropometric JJ N
parameters NNS N
. . N

CONCLUSIONS NNP N
Nutritional NNP N
orientation NN N
was VBD N
effective JJ N
to TO N
modify VB N
1 CD N
) ) N
knowledge NN N
about IN N
food NN N
and CC N
nutrition NN N
, , N
and CC N
2 CD N
) ) N
quality NN N
of IN N
diet NN N
in IN N
outpatients NNS 4_p
with IN 4_p
heart NN 4_p
failure NN 4_p
. . N

Further JJ N
studies NNS N
are VBP N
necessary JJ N
to TO N
evaluate VB N
the DT N
benefits NNS N
on IN N
quality NN N
of IN N
life NN N
and CC N
prognosis NN N
. . N

-DOCSTART- -X- O O 15477492

Recurrent JJ 4_p
tuberculosis NN 4_p
in IN N
the DT N
United NNP N
States NNPS N
and CC N
Canada NNP N
: : N
relapse NN N
or CC N
reinfection NN N
? . N
Recurrence NN N
of IN N
active JJ 4_p
tuberculosis NN 4_p
after IN 4_p
treatment NN 4_p
can MD N
be VB N
due JJ N
to TO N
relapse VB N
of IN N
infection NN N
with IN N
the DT N
same JJ N
strain NN N
or CC N
reinfection NN N
with IN N
a DT N
new JJ N
strain NN N
of IN N
Mycobacterium NNP N
tuberculosis NN N
. . N

The DT N
proportion NN N
of IN N
recurrent JJ N
tuberculosis NN N
cases NNS N
caused VBN N
by IN N
reinfection NN N
has VBZ N
varied VBN N
widely RB N
in IN N
previous JJ N
studies NNS N
. . N

We PRP N
evaluated VBD N
cases NNS N
of IN N
recurrent JJ N
tuberculosis NN N
in IN N
two CD N
prospective JJ N
clinical JJ N
trials NNS N
: : N
a DT N
randomized JJ N
study NN N
of IN N
two CD N
regimens NNS N
for IN N
the DT N
last JJ N
4 CD N
months NNS N
of IN N
treatment NN N
( ( N
n JJ N
= NNP N
1,075 CD N
) ) N
and CC N
a DT N
study NN N
of IN N
a DT N
twice-weekly JJ N
rifabutin-containing JJ N
regimen NNS N
for IN N
human JJ 4_p
immunodeficiency NN 4_p
virus-infected JJ 4_p
tuberculosis NN 4_p
( ( N
n JJ N
= NNP N
169 CD N
) ) N
. . N

Isolates VBZ N
at IN N
diagnosis NN N
and CC N
from IN N
positive JJ N
cultures NNS N
after IN N
treatment NN N
completion NN N
underwent NN N
genotyping VBG N
using VBG N
IS6110 NNP N
( ( N
with IN N
secondary JJ N
genotyping NN N
for IN N
isolates NNS N
with IN N
less JJR N
than IN N
six CD N
copies NNS N
of IN N
IS6110 NNP N
) ) N
. . N

Of IN N
85 CD N
patients NNS N
having VBG 4_p
a DT 4_p
positive JJ 4_p
culture NN 4_p
after IN 4_p
completing VBG 4_p
treatment NN 4_p
, , N
6 CD N
( ( N
7.1 CD N
% NN N
) ) N
were VBD N
classified VBN N
as IN N
false-positive JJ N
cultures NNS N
by IN N
a DT N
review NN N
committee NN N
blinded VBD N
to TO N
treatment NN N
assignment NN N
. . N

Of IN N
the DT N
remaining VBG N
75 CD N
cases NNS N
with IN N
recurrent JJ N
tuberculosis NN N
and CC N
genotyping VBG N
data NNS N
available JJ N
, , N
72 CD N
( ( N
96 CD N
% NN N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
88.8-99.2 CD N
% NN N
) ) N
paired VBD N
isolates NNS N
had VBD N
the DT N
same JJ N
genotype NN N
; : N
only RB N
3 CD N
( ( N
4 CD N
% NN N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
0.8-11.2 CD N
% NN N
) ) N
had VBD N
a DT N
different JJ N
genotype NN N
and CC N
were VBD N
categorized VBN N
as IN N
reinfection NN N
. . N

We PRP N
conclude VBP N
that DT N
recurrent NN 4_p
tuberculosis NN 4_p
in IN N
the DT N
United NNP N
States NNPS N
and CC N
Canada NNP N
, , N
countries NNS N
with IN N
low JJ N
rates NNS N
of IN N
tuberculosis NN N
, , N
is VBZ N
rarely RB N
due JJ N
to TO N
reinfection VB N
with IN N
a DT N
new JJ N
strain NN N
of IN N
M. NNP N
tuberculosis NN N
. . N

-DOCSTART- -X- O O 16095446

Nitrous JJ N
oxide JJ N
diffusion NN N
into IN N
tracheal JJ N
tube JJ N
cuffs NNS N
-- : N
efficacy NN N
of IN N
a DT N
new JJ N
prototype NN N
cuff NN N
pressure NN N
release NN N
valve NN N
. . N

BACKGROUND IN N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
performance NN N
of IN N
a DT N
new JJ N
cuff NN N
pressure NN N
release NN N
valve NN N
( ( N
CPRV NNP N
) ) N
, , N
in IN N
which WDT N
the DT N
release NN N
pressure NN N
can MD N
be VB N
adjusted VBN N
from IN N
10 CD N
to TO N
25 CD N
cmH2O NNS N
, , N
particularly RB N
intended VBN N
to TO N
control VB N
pressure NN N
in IN N
paediatric JJ 4_p
cuffed NN 4_p
tracheal NN 4_p
tubes NNS 4_p
and CC N
to TO N
avoid VB N
cuff NN N
hyperinflation NN N
caused VBN N
by IN N
N2O NNP N
diffusion NN N
. . N

METHODS NNP N
In IN N
vitro NN N
: : N
the DT N
PRV NNP N
was VBD N
set VBN N
to TO N
10 CD N
, , N
15 CD N
, , N
20 CD N
or CC N
25 CD N
cmH2O JJ N
release NN N
pressure NN N
and CC N
connected VBN N
to TO N
a DT N
cuffed NN N
tube NN N
placed VBD N
into IN N
a DT N
box NN N
flushed VBN N
with IN N
66 CD N
% NN N
N2O NNP N
in IN N
O2 NNP N
. . N

The DT N
cuff NN N
pressure NN N
was VBD N
monitored VBN N
with IN N
and CC N
without IN N
CPRV NNP N
for IN N
60 CD N
min NN N
. . N

Experiments NNS N
were VBD N
performed VBN N
four CD N
times NNS N
using VBG N
two CD N
different JJ N
CPRVs NNP N
. . N

In IN N
vivo NN N
: : N
with IN N
Institutional NNP N
Review NNP N
Board NNP N
approval NN N
, , N
CPRV NNP N
was VBD N
studied VBN N
in IN N
50 CD N
children NNS N
undergoing VBG N
general JJ 4_p
anaesthesia NN 4_p
with IN 4_p
tracheal JJ 4_p
intubation NN 4_p
and CC 4_p
standardized JJ 4_p
anaesthesia NN 4_p
technique NN 4_p
( ( N
including VBG N
66 CD N
% NN N
N2O NNP N
in IN N
O2 NNP N
) ) N
and CC N
ventilator JJ N
settings NNS N
. . N

Patients NNS N
were VBD N
randomized VBN N
into IN N
two CD N
groups NNS N
( ( N
with IN N
and CC N
without IN N
CPRV NNP N
) ) N
. . N

The DT N
cuff JJ N
pressure NN N
baseline NN N
was VBD N
20 CD N
cmH2O NN N
and CC N
CPRV NNP N
was VBD N
set VBN N
to TO N
25 CD N
cmH2O NN N
. . N

If IN N
the DT N
cuff NN N
pressure NN N
exceeded VBD N
25 CD N
cmH2O NN N
, , N
it PRP N
was VBD N
manually RB N
released VBN N
to TO N
20 CD N
cmH2O NN N
. . N

The DT N
numbers NNS N
of IN N
deflations NNS N
in IN N
both DT N
groups NNS N
were VBD N
noted VBN N
and CC N
compared VBN N
by IN N
Mann-Whitney NNP N
U-test NNP N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

RESULTS NNP N
In IN N
vitro NN N
: : N
the DT N
cuff NN N
pressure NN N
exceeded VBD N
50 CD N
cmH2O NN N
after IN N
60 CD N
min NN N
without IN N
CPRV NNP N
, , N
but CC N
did VBD N
not RB N
exceed VB N
the DT N
settings NNS N
with IN N
CPRV NNP N
. . N

In IN N
vivo NN N
: : N
there EX N
was VBD N
no DT N
need NN N
to TO N
manually RB N
deflate VB N
the DT N
cuff NN N
in IN N
the DT N
CPRV NNP N
group NN N
but CC N
, , N
in IN N
every DT N
patient NN N
in IN N
the DT N
control NN N
group NN N
, , N
three CD N
( ( N
two CD N
to TO N
seven CD N
) ) N
deflating VBG N
manoeuvres NNS N
were VBD N
required VBN N
within IN N
the DT N
first JJ N
hour NN N
of IN N
anaesthesia NN N
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

CONCLUSION VB N
The DT N
CPRV NNP N
allows VBZ N
reliable JJ N
cuff NN N
pressure NN N
release NN N
at IN N
various JJ N
pressure NN N
levels NNS N
and CC N
reliably RB N
prevents NNS N
cuff JJ N
pressure NN N
increases NNS N
caused VBN N
by IN N
N2O NNP N
. . N

-DOCSTART- -X- O O 8966003

[ JJ N
Drug NNP N
therapy NN N
of IN N
condylomata NN N
acuminata NNS N
] RB N
. . N

This DT N
study NN N
seeks VBZ N
to TO N
evaluate VB N
two CD N
candidate NN N
regimens NNS N
( ( N
5-fluorouracil JJ N
and CC N
interferon NN N
) ) N
as IN N
adjuvants NNS N
to TO N
optimally RB N
performed VBN N
laser NN N
surgery NN N
in IN N
the DT N
treatment NN N
of IN N
condylomata NN 4_p
acuminata NNS 4_p
. . N

Skillful NNP N
laser NN N
ablation NN N
can MD N
remove VB N
any DT N
volume NN N
of IN N
human JJ N
papillomavirus-associated JJ N
vulvar NN N
disease NN N
but CC N
can MD N
not RB N
prevent VB N
reactivation NN N
of IN N
the DT N
surrounding VBG N
latent JJ N
viral JJ N
reservoir NN N
during IN N
postoperative JJ N
healing NN N
. . N

Conversely RB N
, , N
interferon NN N
and CC N
5-fluorouracil JJ N
are VBP N
relatively RB N
ineffective JJ N
as IN N
primary JJ N
therapies NNS N
. . N

This DT N
study NN N
involves VBZ N
118 CD N
evaluable JJ N
patients NNS N
: : N
32 CD N
in IN N
the DT N
laser-CO2 JJ N
group NN N
, , N
34 CD N
in IN N
the DT N
5-fluorouracil JJ N
group NN N
and CC N
52 CD N
in IN N
the DT N
interferon NN N
group NN N
. . N

At IN N
assessment NN N
of IN N
final JJ N
outcome NN N
, , N
it PRP N
was VBD N
found VBN N
that IN N
43 CD N
of IN N
52 CD N
( ( N
82 CD N
% NN N
) ) N
assessable JJ N
patients NNS N
in IN N
the DT N
adjuvant JJ N
interferon NN N
arm NN N
were VBD N
controlled VBN N
by IN N
a DT N
single JJ N
laser NN N
ablation NN N
as IN N
compared VBN N
with IN N
only RB N
17 CD N
of IN N
34 CD N
( ( N
50 CD N
% NN N
) ) N
in IN N
the DT N
5-fluorouracil JJ N
group NN N
and CC N
13 CD N
of IN N
32 CD N
( ( N
40 CD N
% NN N
) ) N
in IN N
the DT N
laser NN N
alone RB N
group NN N
. . N

There EX N
was VBD N
no DT N
statistical JJ N
difference NN N
in IN N
outcome NN N
within IN N
the DT N
5-fluorouracil JJ N
and CC N
laser VBZ N
only RB N
arms NNS N
. . N

Conversely RB N
, , N
a DT N
relatively RB N
low JJ N
dose NN N
of IN N
recombinant JJ N
interferon NN N
, , N
used VBN N
in IN N
combination NN N
with IN N
effective JJ N
surgical JJ N
deleulking NN N
, , N
can MD N
markedly RB N
reduce VB N
the DT N
risk NN N
of IN N
postoperative JJ N
recurrence NN N
. . N

-DOCSTART- -X- O O 7492158

The DT N
effect NN N
of IN N
iron NN N
in IN N
formula NN N
milk NN N
after IN N
6 CD N
months NNS N
of IN N
age NN N
. . N

Ninety NNP N
two CD N
normal JJ 4_p
birthweight JJ 4_p
infants NNS N
aged VBD N
6 CD N
months NNS N
entered VBD N
a DT N
double JJ N
blind NN N
controlled VBD N
trial NN N
which WDT N
compared VBN N
a DT N
follow NN N
on IN N
formula NN N
milk NN N
with IN N
no DT N
added JJ N
iron NN N
against IN N
the DT N
same JJ N
formula NN N
milk NN N
containing VBG N
1.2 CD N
mg NN N
of IN N
iron NN N
per IN N
100 CD N
ml NN N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
social JJ N
class NN N
or CC N
demographic JJ N
characteristics NNS N
of IN N
the DT N
two CD N
treatment NN N
groups NNS N
or CC N
in IN N
the DT N
proportion NN N
of IN N
each DT N
group NN N
completing VBG N
the DT N
trial NN N
. . N

There EX N
was VBD N
no DT N
difference NN N
between IN N
the DT N
two CD N
groups NNS N
in IN N
the DT N
quantity NN N
of IN N
milk NN N
taken VBN N
but CC N
the DT N
amounts NNS N
taken VBN N
lessened VBD N
between IN N
6 CD N
and CC N
18 CD N
months NNS N
of IN N
age NN N
. . N

There EX N
was VBD N
no DT N
difference NN N
between IN N
the DT N
two CD N
groups NNS N
with IN N
respect NN N
to TO N
mean VB N
haemoglobin NN N
and CC N
median JJ N
serum NN N
ferritin NN N
at IN N
6 CD N
, , N
9 CD N
, , N
12 CD N
, , N
15 CD N
, , N
and CC N
18 CD N
months NNS N
of IN N
age NN N
. . N

Very RB N
few JJ N
infants NNS N
developed VBD N
iron NN N
deficiency NN N
anaemia NN N
in IN N
either CC N
group NN N
but CC N
there EX N
was VBD N
a DT N
tendency NN N
for IN N
serum NN N
ferritin NN N
levels NNS N
to TO N
fall VB N
between IN N
6 CD N
and CC N
18 CD N
months NNS N
of IN N
age NN N
in IN N
both DT N
groups NNS N
. . N

The DT N
results NNS N
suggest VBP N
that IN N
iron NN N
added VBD N
to TO N
follow VB N
on IN N
milk NN N
was VBD N
not RB N
an DT N
important JJ N
source NN N
of IN N
dietary JJ N
iron NN N
in IN N
the DT N
infants NNS N
studied VBN N
. . N

-DOCSTART- -X- O O 9180065

Randomised VBN N
controlled JJ N
trial NN N
of IN N
graded JJ N
exercise NN N
in IN N
patients NNS N
with IN N
the DT N
chronic JJ 4_p
fatigue NN 4_p
syndrome NN 4_p
. . N

OBJECTIVE UH N
To TO N
test VB N
the DT N
efficacy NN N
of IN N
a DT N
graded JJ N
aerobic JJ N
exercise NN N
programme NN N
in IN N
the DT N
chronic JJ 4_p
fatigue NN 4_p
syndrome NN 4_p
. . N

DESIGN NNP N
Randomised VBD N
controlled VBN N
trial NN N
with IN N
control NN N
treatment NN N
crossover NN N
after IN N
the DT N
first JJ N
follow VB N
up RP N
examination NN N
. . N

SETTING NN N
Chronic NNP N
fatigue NN N
clinic NN N
in IN N
a DT N
general JJ N
hospital NN N
department NN N
of IN N
psychiatry NN N
. . N

SUBJECTS NNP N
66 CD N
patients NNS N
with IN N
the DT N
chronic JJ 4_p
fatigue NN 4_p
syndrome NN 4_p
who WP N
had VBD N
neither CC N
a DT N
psychiatric JJ 4_p
disorder NN 4_p
nor CC N
appreciable JJ 4_p
sleep JJ 4_p
disturbance NN 4_p
. . N

INTERVENTIONS NNP N
Random NNP N
allocation NN N
to TO N
12 CD N
weeks NNS N
of IN N
either DT N
graded VBN N
aerobic NN N
exercise NN N
or CC N
flexibility NN N
exercises NNS N
and CC N
relaxation NN N
therapy NN N
. . N

Patients NNS N
who WP N
completed VBD N
the DT N
flexibility NN N
programme NN N
were VBD N
invited VBN N
to TO N
cross VB N
over IN N
to TO N
the DT N
exercise NN N
programme NN N
afterwards NNS N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURE NNP N
The DT N
self NN N
rated VBN N
clinical JJ N
global JJ N
impression NN N
change NN N
score NN N
, , N
" VB N
very RB N
much RB N
better RBR N
" NN N
or CC N
" VB N
much JJ N
better JJR N
" NN N
being VBG N
considered VBN N
as IN N
clinically RB N
important JJ N
. . N

RESULTS VB N
Four CD N
patients NNS N
receiving VBG N
exercise NN N
and CC N
three CD N
receiving VBG N
flexibility NN N
treatment NN N
dropped VBD N
out RP N
before IN N
completion NN N
. . N

15 CD N
of IN N
29 CD N
patients NNS N
rated VBN N
themselves PRP N
as IN N
better JJR N
after IN N
completing VBG N
exercise NN N
treatment NN N
compared VBN N
with IN N
eight CD N
of IN N
30 CD N
patients NNS N
who WP N
completed VBD N
flexibility NN N
treatment NN N
. . N

Analysis NN N
by IN N
intention NN N
to TO N
treat VB N
gave VBD N
similar JJ N
results NNS N
( ( N
17/33 CD N
v RB N
9/33 CD N
patients NNS N
better RBR N
) ) N
. . N

Fatigue NNP N
, , N
functional JJ N
capacity NN N
, , N
and CC N
fitness NN N
were VBD N
significantly RB N
better RBR N
after IN N
exercise NN N
than IN N
after IN N
flexibility NN N
treatment NN N
. . N

12 CD N
of IN N
22 CD N
patients NNS N
who WP N
crossed VBD N
over IN N
to TO N
exercise VB N
after IN N
flexibility NN N
treatment NN N
rated VBN N
themselves PRP N
as IN N
better JJR N
after IN N
completing VBG N
exercise NN N
treatment NN N
32 CD N
of IN N
47 CD N
patients NNS N
rated VBN N
themselves PRP N
as IN N
better JJR N
three CD N
months NNS N
after IN N
completing VBG N
supervised JJ N
exercise NN N
treatment NN N
35 CD N
of IN N
47 CD N
patients NNS N
rated VBN N
themselves PRP N
as IN N
better JJR N
one CD N
year NN N
after IN N
completing VBG N
supervised JJ N
exercise NN N
treatment NN N
. . N

CONCLUSION NNP N
These DT N
findings NNS N
support VBP N
the DT N
use NN N
of IN N
appropriately RB N
prescribed VBN N
graded VBN N
aerobic JJ N
exercise NN N
in IN N
the DT N
management NN N
of IN N
patients NNS N
with IN N
the DT N
chronic JJ 4_p
fatigue NN 4_p
syndrome NN 4_p
. . N

-DOCSTART- -X- O O 17482439

Fine NNP N
needle JJ N
aspiration NN N
coupled VBN N
with IN N
real-time JJ N
PCR NNP N
: : N
a DT N
painless JJ N
methodology NN N
to TO N
study VB N
adaptive JJ N
functional JJ N
changes NNS N
in IN N
skeletal JJ N
muscle NN N
. . N

BACKGROUND NNP N
AND NNP N
AIM NNP N
In IN N
this DT N
study NN N
we PRP N
developed VBD N
a DT N
new JJ N
methodology NN N
for IN N
obtaining VBG N
human JJ N
skeletal JJ N
muscle NN N
samples NNS N
to TO N
evaluate VB N
gene NN N
expression NN N
. . N

This DT N
approach NN N
is VBZ N
based VBN N
on IN N
a DT N
fine JJ N
needle JJ N
aspiration NN N
technique NN N
, , N
which WDT N
allows VBZ N
us PRP N
to TO N
extract VB N
a DT N
small JJ N
tissue NN N
sample NN N
in IN N
a DT N
significantly RB N
less RBR N
invasive JJ N
manner NN N
than IN N
with IN N
classic JJ N
biopsy NN N
. . N

METHODS NNP N
AND CC N
RESULTS NNP N
Multiplex NNP N
tandem VBD N
RT-PCR NNP N
was VBD N
used VBN N
to TO N
determine VB N
the DT N
mRNA NN N
levels NNS N
of IN N
genes NNS N
involved VBN N
in IN N
ATP NNP N
production NN N
and CC N
mitochondrial JJ N
biogenesis NN N
in IN N
muscle NN N
tissue NN N
. . N

Samples NNS N
of IN N
vastus NN N
lateralis NNS N
muscle NN N
were VBD N
obtained VBN N
from IN N
21 CD N
healthy JJ 4_p
subjects NNS N
with IN N
different JJ 4_p
fitness NN 4_p
levels NNS 4_p
. . N

The DT N
principal JJ N
findings NNS N
in IN N
our PRP$ N
study NN N
show VB N
a DT N
strong JJ N
correlation NN N
between IN N
PGC-1alpha NNP N
and CC N
COX5B NNP N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
and CC N
between IN N
PGC-1alpha NNP N
and CC N
MT-CO2 NNP N
( ( N
p=0.017 NN N
) ) N
expression NN N
. . N

Furthermore NNP N
, , N
a DT N
significant JJ N
positive JJ N
correlation NN N
between IN N
mtDNA NN N
content NN N
and CC N
the DT N
percentage NN N
of IN N
MHCI NNP N
present NN N
in IN N
the DT N
aspired JJ N
samples NNS N
were VBD N
found VBN N
( ( N
p=0.028 NN N
) ) N
. . N

These DT N
data NNS N
are VBP N
in IN N
agreement NN N
with IN N
current JJ N
knowledge NN N
on IN N
skeletal JJ N
muscle NN N
physiology NN N
and CC N
show VB N
the DT N
reliability NN N
of IN N
the DT N
proposed VBN N
method NN N
. . N

CONCLUSION VB N
This DT N
painless JJ N
methodology NN N
can MD N
be VB N
used VBN N
to TO N
investigate VB N
, , N
in IN N
vivo NN N
, , N
human JJ N
muscle NN N
RNA NNP N
and CC N
DNA NNP N
adaptations NNS N
in IN N
response NN N
to TO N
either DT N
physiological JJ N
and/or NN N
pharmacological JJ N
stimuli NN N
. . N

This DT N
method NN N
has VBZ N
major JJ N
clinical JJ N
relevance NN N
, , N
such JJ N
as IN N
its PRP$ N
application NN N
in IN N
clarifying VBG N
the DT N
mechanisms NN N
underling VBG N
metabolic JJ N
and CC N
systemic JJ N
disorders NNS N
. . N

-DOCSTART- -X- O O 9172668

[ JJ N
Initial NNP N
nuclear JJ N
magnetic JJ N
resonance NN N
tomography NN N
results NNS N
of IN N
the DT N
treatment NN N
course NN N
of IN N
avascular JJ 4_p
femur NNS 4_p
head VBP 4_p
necrosis NN 4_p
after IN N
femoral JJ 4_p
core NN 4_p
decompression NN 4_p
] NNP N
. . N

The DT N
vascular JJ 4_p
femoral JJ 4_p
head NN 4_p
necrosis NN 4_p
is VBZ N
a DT N
serious JJ N
illness NN N
, , N
especially RB N
when WRB N
appearing VBG N
in IN N
patients NNS N
aged VBD N
30 CD N
to TO N
50 CD N
years NNS N
. . N

Many JJ N
etiologic JJ N
factors NNS N
cause VBP N
a DT N
femoral JJ N
head NN N
necrosis NN N
such JJ N
as IN N
, , N
for IN N
example NN N
, , N
high-dose JJ N
steroids NNS N
, , N
abuse NN N
of IN N
alcohol NN N
, , N
defect NN 4_p
of IN 4_p
bone NN 4_p
marrow NN 4_p
and CC N
trauma NN 4_p
of IN 4_p
the DT 4_p
hip NN 4_p
. . N

Often VB N
the DT N
X-ray JJ N
photograph NN N
leads VBZ N
to TO N
the DT N
diagnosis NN N
in IN N
the DT N
second JJ N
stage NN N
( ( N
ARCO NNP N
1992 CD N
) ) N
or CC N
in IN N
the DT N
third JJ N
stage NN N
, , N
when WRB N
the DT N
femoral JJ N
head NN N
has VBZ N
begun VBN N
to TO N
collapse VB N
. . N

The DT N
stage NN N
IIc NNP N
and CC N
III NNP N
shows VBZ N
an DT N
evident JJ N
enhancement NN N
in IN N
contrast NN N
media NNS N
in IN N
MRI NNP N
. . N

Contrast NNP N
enhancement NN N
is VBZ N
demonstrated VBN N
by IN N
STIR NNP N
, , N
FATSAT NNP N
, , N
T1-weighted NNP N
and CC N
dynamic JJ N
screening NN N
sequence NN N
. . N

The DT N
characteristics NNS N
of IN N
the DT N
contrast NN N
media NNS N
enhancement VBP N
argue NN N
for IN N
an DT N
active JJ N
concomitant NN N
process NN N
of IN N
destruction NN N
and CC N
regeneration NN N
. . N

This DT N
stage NN N
has VBZ N
the DT N
best JJS N
chances NNS N
for IN N
a DT N
drug NN N
or CC N
a DT N
surgical JJ N
therapy NN N
. . N

The DT N
evaluation NN N
of IN N
the DT N
signal JJ N
intensity NN N
by IN N
the DT N
dynamic JJ N
screening NN N
sequence NN N
is VBZ N
considered VBN N
as IN N
an DT N
objective JJ N
contribution NN N
for IN N
the DT N
staging NN N
of IN N
the DT N
femoral JJ N
head NN N
necrosis NN N
. . N

This DT N
enables VBZ N
one CD N
to TO N
differentiate VB N
between IN N
the DT N
curable JJ N
stage NN N
IIc NNP N
and CC N
the DT N
stage NN N
III NNP N
, , N
showing VBG N
the DT N
beginning NN N
of IN N
breakdown NN 4_p
of IN 4_p
the DT 4_p
femoral JJ 4_p
head NN 4_p
. . N

-DOCSTART- -X- O O 17241298

Comparison NNP N
of IN N
7-day JJ N
and CC N
14-day JJ N
proton NN N
pump IN N
inhibitor-containing JJ N
triple JJ N
therapy NN N
for IN N
Helicobacter NNP 4_p
pylori JJ 4_p
eradication NN 4_p
: : N
neither CC N
treatment NN N
duration NN N
provides VBZ N
acceptable JJ N
eradication NN N
rate NN N
in IN N
Korea NNP N
. . N

BACKGROUND NNP N
AND CC N
AIMS NNP N
Although IN N
triple JJ N
combination NN N
therapy NN N
containing VBG N
a DT N
proton NN N
pump NN N
inhibitor NN N
( ( N
PPI NNP N
) ) N
and CC N
two CD N
antibiotics NNS N
is VBZ N
considered VBN N
as IN N
a DT N
standard JJ N
regimen NN N
for IN N
the DT N
first-line JJ N
anti-Helicobacter JJ N
pylori NN N
treatment NN N
, , N
there EX N
are VBP N
still RB N
debates NNS N
on IN N
the DT N
ideal JJ N
duration NN N
of IN N
treatment NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
efficacies NNS N
of IN N
7-day JJ N
and CC N
14-day JJ N
PPI-containing JJ N
triple NN N
therapy NN N
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
This DT N
study NN N
was VBD N
performed VBN N
in IN N
a DT N
randomized JJ N
, , N
multicenter NN N
, , N
prospective JJ N
manner NN N
. . N

After IN N
upper JJ 4_p
gastrointestinal JJ 4_p
endoscopy NN 4_p
, , N
H. NNP 4_p
pylori-infected JJ 4_p
patients NNS N
with IN N
a DT N
gastric JJ 4_p
ulcer NN 4_p
and/or VBZ 4_p
a DT 4_p
duodenal JJ 4_p
ulcer NN 4_p
were VBD N
randomly RB N
assigned VBN N
to TO N
a DT N
PAC7 NNP N
group NN N
( ( N
omeprazole JJ N
20 CD N
mg NN N
or CC N
equivalent JJ N
dose NN N
of IN N
other JJ N
PPIs NNP N
, , N
amoxicillin NN N
1000 CD N
mg NN N
, , N
and CC N
clarithromycin VBZ N
500 CD N
mg NN N
twice RB N
daily RB N
for IN N
7 CD N
days NNS N
) ) N
or CC N
to TO N
a DT N
PAC14 NNP N
group NN N
( ( N
the DT N
same JJ N
regimen NN N
as IN N
the DT N
PAC7 NNP N
group NN N
but CC N
for IN N
14 CD N
days NNS N
) ) N
. . N

H. NNP N
pylori NN N
status NN N
was VBD N
evaluated VBN N
by IN N
( ( N
13 CD N
) ) N
C NNP N
urea JJ N
breath NN N
test NN N
5 CD N
weeks NNS N
after IN N
anti-ulcer JJ N
treatment NN N
completion NN N
. . N

RESULTS VB N
A DT N
total NN N
of IN N
598 CD N
patients NNS N
were VBD N
enrolled VBN N
; : N
337 CD N
were VBD N
randomized VBN N
to TO N
the DT N
PAC7 NNP N
group NN N
and CC N
261 CD N
to TO N
the DT N
PAC14 NNP N
group NN N
. . N

The DT N
two CD N
groups NNS N
were VBD N
comparable JJ N
in IN N
terms NNS N
of IN N
baseline NN N
characteristics NNS N
. . N

The DT N
eradication NN N
rates NNS N
of IN N
the DT N
PAC7 NNP N
group NN N
were VBD N
not RB N
inferior JJ N
to TO N
those DT N
of IN N
the DT N
PAC14 NNP N
group NN N
in IN N
both DT N
intention-to-treat JJ N
analysis NN N
( ( N
71.2 CD N
% NN N
vs. FW N
75.5 CD N
% NN N
) ) N
and CC N
per-protocol JJ N
analysis NN N
( ( N
83.6 CD N
% NN N
vs. FW N
86.6 CD N
% NN N
) ) N
. . N

Incidences NNS N
of IN N
adverse JJ N
events NNS N
were VBD N
comparable JJ N
. . N

CONCLUSIONS NNP N
Although IN N
the DT N
7-day JJ N
PPI-containing JJ N
triple JJ N
anti-H. JJ N
pylori NN N
therapy NN N
is VBZ N
not RB N
inferior JJ N
to TO N
the DT N
14-day JJ N
therapy NN N
, , N
neither CC N
treatment NN N
duration NN N
provides VBZ N
acceptable JJ N
eradication NN N
rate NN N
reaching VBG N
90 CD N
% NN N
in IN N
per-protocol JJ N
analysis NN N
. . N

New NNP N
combination NN N
regimen NNS N
with IN N
higher JJR N
efficacy NN N
should MD N
be VB N
developed VBN N
as IN N
a DT N
first-line JJ N
eradication NN N
therapy NN N
for IN N
H. NNP 4_p
pylori NN 4_p
in IN N
Korea NNP N
. . N

-DOCSTART- -X- O O 20157845

Can MD N
incentives VB N
undermine JJ N
intrinsic JJ N
motivation NN N
to TO N
participate VB N
in IN N
epidemiologic JJ N
surveys NNS N
? . N
Response JJ N
rates NNS N
to TO N
surveys NNS N
are VBP N
decreasing VBG N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
use NN N
of IN N
lottery JJ N
tickets NNS N
as IN N
incentives NNS N
in IN N
an DT N
epidemiologic JJ 4_p
control NN 4_p
group NN 4_p
. . 4_p

A DT N
self-administered JJ 4_p
questionnaire NN 4_p
was VBD 4_p
sent VBN 4_p
to TO 4_p
parents NNS 4_p
in IN 4_p
the DT 4_p
municipality NN 4_p
of IN 4_p
Stockholm NNP 4_p
, , 4_p
Sweden NNP 4_p
, , 4_p
who WP 4_p
were VBD 4_p
to TO 4_p
be VB 4_p
used VBN 4_p
as IN 4_p
a DT 4_p
control NN 4_p
group NN 4_p
in IN 4_p
a DT 4_p
study NN 4_p
addressing VBG 4_p
stress NN 4_p
in IN 4_p
parents NNS 4_p
of IN 4_p
children NNS N
with IN 4_p
cancer NN 4_p
. . 4_p

A DT N
stratified JJ N
random JJ N
sample NN N
of IN N
450 CD N
parents NNS N
were VBD N
randomized VBN N
into IN N
three CD N
incentive JJ N
groups NNS N
: : N
( ( N
a DT N
) ) N
no DT N
incentive NN N
; : N
( ( N
b NN N
) ) N
a DT N
promised JJ N
incentive NN N
of IN N
one CD N
lottery NN N
ticket NN N
to TO N
be VB N
received VBN N
upon IN N
reply NN N
; : N
( ( N
c NN N
) ) N
a DT N
promised JJ N
incentive NN N
of IN N
one CD N
lottery NN N
ticket NN N
to TO N
be VB N
received VBN N
upon IN N
reply NN N
and CC N
an DT N
additional JJ N
lottery NN N
ticket NN N
upon IN N
reply NN N
within IN N
1 CD N
week NN N
. . N

The DT N
overall JJ N
response NN N
rate NN N
across IN N
the DT N
three CD N
groups NNS N
was VBD N
65.3 CD N
% NN N
. . N

The DT N
response NN N
rate NN N
was VBD N
highest JJS N
in IN N
the DT N
no DT N
incentive NN N
group NN N
( ( N
69.3 CD N
% NN N
) ) N
and CC N
lowest JJS N
in IN N
the DT N
one CD N
plus CC N
one CD N
lottery NN N
ticket NN N
group NN N
( ( N
62.0 CD N
% NN N
) ) N
. . N

In IN N
a DT N
survival JJ N
analysis NN N
, , N
the DT N
difference NN N
between IN N
the DT N
two CD N
response NN N
curves NNS N
was VBD N
significant JJ N
by IN N
the DT N
log-rank JJ N
test NN N
( ( N
P NNP N
= NNP N
0.04 CD N
) ) N
, , N
with IN N
the DT N
no DT N
incentive NN N
group NN N
having VBG N
a DT N
shorter JJR N
time NN N
to TO N
response NN N
than IN N
the DT N
incentive NN N
group NN N
. . N

Our PRP$ N
findings NNS N
suggest VBP N
that IN N
the DT N
use NN N
of IN N
lottery JJ N
tickets NNS N
as IN N
incentives NNS N
to TO N
increase VB N
participation NN N
in IN N
a DT N
mail NN N
questionnaire NN N
among IN N
parents NNS N
may MD N
be VB N
less RBR N
valuable JJ N
or CC N
even RB N
harmful JJ N
. . N

Incentives NNS N
may MD N
undermine VB N
motivation NN N
in IN N
studies NNS N
in IN N
which WDT N
the DT N
intrinsic JJ N
motivation NN N
of IN N
the DT N
respondents NNS N
is VBZ N
already RB N
high JJ N
. . N

-DOCSTART- -X- O O 24799074

Development NNP N
and CC N
in IN N
vitro/in JJ N
vivo JJ N
evaluation NN N
of IN N
immediate JJ N
release NN N
perindopril NN N
tablets NNS N
. . N

Perindopril NNP N
erbumine NN N
( ( N
PE NNP N
) ) N
is VBZ N
a DT N
BCS NNP N
( ( N
Biopharmaceutics NNPS N
Classification NNP N
System NNP N
) ) N
class NN N
3 CD N
drug NN N
with IN N
high JJ N
solubility NN N
and CC N
low JJ N
permeability NN N
. . N

It PRP N
is VBZ N
an DT N
inhibitor NN N
of IN N
the DT N
enzyme NN N
that WDT N
converts VBZ N
angiotensin NN N
I PRP N
( ( N
Angiotensin NNP N
Converting NNP N
Enzyme NNP N
, , N
ACE NNP N
) ) N
into IN N
angiotensin NN N
II NNP N
as RB N
well RB N
as IN N
causing VBG N
the DT N
degradation NN N
of IN N
the DT N
vasodilator NN N
bradykinin NN N
into IN N
an DT N
inactive JJ N
heptapeptide NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
develop VB N
an DT N
alternative JJ N
drug NN N
product NN N
by IN N
using VBG N
a DT N
different JJ N
salt NN N
of IN N
perindopril NN N
and CC N
to TO N
evaluate VB N
the DT N
bioequivalence NN N
between IN N
PE NNP N
, , N
not RB N
still RB N
licensed VBN N
, , N
and CC N
perindopril JJ N
arginine NN N
( ( N
PA NNP N
) ) N
, , N
licensed VBD N
in IN N
many JJ N
countries NNS N
, , N
and CC N
to TO N
prepare VB N
PE NNP N
tablets NNS N
by IN N
using VBG N
direct JJ N
compression NN N
method NN N
. . N

Many JJ N
different JJ N
formulations NNS N
were VBD N
prepared VBN N
, , N
among IN N
which WDT N
F3-coded NNP N
formulation NN N
was VBD N
only RB N
selected VBN N
due JJ N
to TO N
releasing VBG N
of IN N
98.03 CD N
% NN N
active JJ N
substance NN N
at IN N
45th CD N
minute NN N
. . N

Bioequivalence NNP N
study NN N
was VBD N
planned VBN N
as IN N
a DT N
cross-designed JJ N
, , N
randomized VBN N
, , N
open-labeled JJ N
, , N
single-dose JJ N
, , N
single-center JJ N
study NN N
and CC N
conducted VBN N
in IN N
24 CD N
male NN N
healthy JJ 4_p
volunteers NNS 4_p
via IN 4_p
peroral JJ 4_p
route NN 4_p
. . N

The DT N
results NNS N
of IN N
bioequivalence NN N
study NN N
were VBD N
evaluated VBN N
for IN N
Perindopril NNP N
and CC N
Perindoprilat NNP N
according VBG N
to TO N
Cmax NNP N
, , N
tmax NN N
and CC N
AUC NNP N
criteria NNS N
. . N

The DT N
geometric JJ N
mean JJ N
ratios NNS N
( ( N
90 CD N
% NN N
CI NNP N
) ) N
of IN N
perindopril NN N
and CC N
perindoprilat NN N
followed VBD N
test NN N
and CC N
reference NN N
drug NN N
were VBD N
calculated VBN N
for IN N
AUC0-t NNP N
and CC N
Cmax NNP N
, , N
105.946 CD N
% NN N
( ( N
100.218-112.002 CD N
% NN N
) ) N
and CC N
110.437 CD N
% NN N
( ( N
102.534-118.948 CD N
% NN N
) ) N
; : N
109.542 CD N
% NN N
( ( N
98.364-121.992 CD N
% NN N
) ) N
and CC N
115.729 CD N
% NN N
( ( N
101.031-132.565 CD N
% NN N
) ) N
, , N
respectively RB N
. . N

The DT N
90 CD N
% NN N
confidence NN N
intervals NNS N
of IN N
them PRP N
were VBD N
found VBN N
within IN N
the DT N
standard JJ N
bioequivalence NN N
range NN N
( ( N
80-125 CD N
% NN N
) ) N
. . N

-DOCSTART- -X- O O 18523583

Heart NNP N
rate NN N
variability NN N
characteristics NNS N
in IN N
sedentary JJ N
postmenopausal JJ N
women NNS N
following VBG N
six CD N
months NNS N
of IN N
exercise NN N
training NN N
: : N
the DT N
DREW NNP N
study NN N
. . N

BACKGROUND NNP N
Decreased VBD N
heart NN N
rate NN N
variability NN N
( ( N
HRV NNP N
) ) N
is VBZ N
associated VBN N
with IN N
a DT N
higher JJR N
risk NN N
of IN N
mortality NN N
. . N

Overall JJ N
, , N
postmenopausal JJ 4_p
women NNS 4_p
have VBP N
lower JJR N
levels NNS N
of IN N
HRV NNP N
than IN N
premenopausal JJ N
women NNS N
, , N
which WDT N
may MD N
be VB N
additionally RB N
complicated VBN N
by IN N
lifestyle JJ N
related JJ N
behaviors NNS N
such JJ N
as IN N
physical JJ N
inactivity NN N
and CC N
obesity NN N
. . N

Though IN N
cardiorespiratory JJ N
exercise NN N
training NN N
increases NNS N
HRV NNP N
, , N
little JJ N
is VBZ N
known VBN N
regarding VBG N
the DT N
exercise NN N
dose NN N
necessary JJ N
to TO N
promote VB N
this DT N
improvement NN N
. . N

METHODOLOGY/PRINCIPAL NNP N
FINDINGS NNP N
Our PRP$ N
primary JJ N
aim NN N
was VBD N
to TO N
measure VB N
HRV NNP N
in IN N
post-menopausal JJ N
women NNS N
following VBG N
6-months JJ N
of IN N
exercise NN N
training NN N
. . N

We PRP N
examined VBD N
supine JJ 4_p
resting VBG 4_p
HRV NNP 4_p
in IN 4_p
373 CD 4_p
post-menopausal JJ 4_p
women NNS 4_p
( ( 4_p
45-75 JJ 4_p
y NN 4_p
) ) 4_p
after IN 4_p
6-months CD 4_p
of IN 4_p
randomly NN 4_p
assigned VBN 4_p
and CC N
double-blinded JJ N
administered JJ N
exercise NN N
training NN N
exercise NN N
training NN N
at IN N
50 CD N
% NN N
, , N
100 CD N
% NN N
and CC N
150 CD N
% NN N
of IN N
the DT N
NIH NNP N
Consensus NNP N
Development NNP N
Panel NNP N
's POS N
recommended JJ N
minimal JJ N
physical JJ N
activity NN N
level NN N
. . N

This DT N
corresponded VBD N
to TO N
4 CD N
, , N
8 CD N
, , N
or CC N
12 CD N
kcal/kg NNS N
per IN N
week NN N
( ( N
KKW NNP N
) ) N
of IN N
energy NN N
expenditure NN N
. . N

At IN N
baseline NN N
, , N
we PRP N
observed VBD N
no DT N
significant JJ N
differences NNS N
in IN N
HRV NNP N
or CC N
hormone NN N
replacement NN N
use NN N
between IN N
treatment NN N
groups NNS N
. . N

However RB N
, , N
we PRP N
did VBD N
observe VB N
that DT N
Caucasian JJ N
women NNS N
and CC N
those DT N
taking VBG N
antidepressant JJ N
medications NNS N
had VBD N
lower JJR N
levels NNS N
of IN N
baseline NN N
HRV NNP N
. . N

After IN N
6-months JJ N
of IN N
exercise NN N
intervention NN N
, , N
we PRP N
observed VBD N
a DT N
dose JJ N
dependent JJ N
increase NN N
in IN N
all DT N
parasympathetically RB N
derived VBN N
time NN N
and CC N
frequency NN N
domain NN N
measurements NNS N
across IN N
exercise NN N
groups NNS N
after IN N
adjustment NN N
for IN N
age NN N
, , N
ethnicity NN N
, , N
antidepressants NNS N
, , N
and CC N
baseline NN N
rMSSD NN N
( ( N
all DT N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

For IN N
example NN N
, , N
the DT N
parasympathetic JJ N
index NN N
rMSSD NN N
was VBD N
greater JJR N
than IN N
control NN N
( ( N
23.19+/-1.0 JJ N
) ) N
for IN N
the DT N
4-KKW JJ N
( ( N
25.98+/-0.8 JJ N
; : N
P NNP N
= NNP N
0.14 CD N
) ) N
, , N
8-KKW JJ N
( ( N
27.66+/-1.0 JJ N
; : N
P NNP N
< NNP N
0.05 CD N
) ) N
, , N
and CC N
12-KKW JJ N
( ( N
27.40+/-0.0 JJ N
; : N
P NNP N
< NNP N
0.05 CD N
) ) N
groups NNS N
at IN N
follow-up JJ N
. . N

CONCLUSIONS/SIGNIFICANCE NNP N
Moderate NNP N
intensity NN N
exercise NN N
training NN N
exercise NN N
is VBZ N
sufficient JJ N
to TO N
improve VB N
HRV NNP N
in IN N
previously RB N
sedentary JJ N
postmenopausal NN N
women NNS N
in IN N
a DT N
dose-dependent JJ N
manner NN N
, , N
as IN N
4-KKW JJ N
is VBZ N
insufficient JJ N
to TO N
improve VB N
parasympathetic JJ N
indices NNS N
of IN N
HRV NNP N
, , N
while IN N
12-KKW JJ N
conferred VBD N
no DT N
greater JJR N
improvement NN N
than IN N
8-KKW JJ N
. . N

TRIAL NNP N
REGISTRATION NNP N
Clinicaltrials.gov NNP N
NCT NNP N
00011193 CD N
. . N

-DOCSTART- -X- O O 22079088

Safety NN N
and CC N
efficacy NN N
of IN N
sitaxsentan JJ N
50 CD N
and CC N
100 CD N
mg NNS N
in IN N
patients NNS N
with IN 4_p
pulmonary JJ 4_p
arterial JJ 4_p
hypertension NN 4_p
. . N

OBJECTIVE UH N
To TO N
assess VB N
safety NN N
and CC N
efficacy NN N
of IN N
sitaxsentan JJ N
50 CD N
and CC N
100 CD N
mg NNS N
in IN N
patients NNS N
with IN 4_p
pulmonary JJ 4_p
arterial JJ 4_p
hypertension NN 4_p
( ( 4_p
PAH NNP 4_p
) ) 4_p
. . N

BACKGROUND NNP N
Sitaxsentan NNP N
is VBZ N
a DT N
highly RB N
selective JJ N
endothelin-A JJ N
receptor NN N
antagonist NN N
that WDT N
was VBD N
recently RB N
withdrawn VBN N
by IN N
the DT N
manufacturer NN N
because IN N
of IN N
a DT N
pattern NN N
of IN N
idiosyncratic JJ N
liver JJ N
injury NN N
. . N

METHODS NNP N
Before IN N
sitaxsentan NN N
withdrawal NN N
, , N
this DT N
18-week JJ N
double-blind NN N
, , N
placebo-controlled JJ N
study NN N
randomized VBD N
patients NNS N
with IN N
PAH NNP N
to TO N
receive VB N
placebo NN N
or CC N
sitaxsentan VB N
50 CD N
or CC N
100 CD N
mg NNS N
once RB N
daily RB N
. . N

The DT N
primary JJ N
efficacy NN N
endpoint NN N
was VBD N
change NN N
from IN N
baseline NN N
in IN N
6-min JJ N
walk NN N
distance NN N
( ( N
6MWD CD N
) ) N
at IN N
week NN N
18 CD N
. . N

Changes NNS N
in IN N
World NNP N
Health NNP N
Organization NNP N
( ( N
WHO NNP N
) ) N
functional JJ N
class NN N
and CC N
time NN N
to TO N
clinical JJ N
worsening NN N
( ( N
TTCW NNP N
) ) N
were VBD N
secondary JJ N
endpoints NNS N
. . N

The DT N
primary JJ N
efficacy NN N
analysis NN N
was VBD N
powered VBN N
for IN N
sitaxsentan JJ N
100 CD N
mg NN N
versus NN N
placebo NN N
. . N

RESULTS NNP N
Of IN N
98 CD N
randomized JJ N
patients NNS N
, , N
61 CD N
% NN N
were VBD N
WHO NNP N
functional JJ N
class NN N
II NNP N
at IN N
baseline NN 4_p
. . N

Improvement NN N
from IN N
baseline NN N
to TO N
week NN N
18 CD N
in IN N
6MWD CD N
occurred VBD N
with IN N
sitaxsentan JJ N
100 CD N
but CC N
not RB N
50 CD N
mg NNS N
; : N
a DT N
strong JJ N
placebo NN N
effect NN N
was VBD N
observed VBN N
. . N

At IN N
week NN N
18 CD N
, , N
WHO NNP N
functional VBP N
class NN N
was VBD N
improved VBN N
or CC N
maintained VBN N
in IN N
more RBR N
patients NNS N
receiving VBG N
sitaxsentan JJ N
100 CD N
mg NN N
than IN N
placebo NN N
( ( N
P NNP N
= NNP N
0.038 CD N
) ) N
; : N
0 CD N
% NN N
versus IN N
12 CD N
% NN N
of IN N
patients NNS N
deteriorated VBN N
, , N
respectively RB N
. . N

TTCW NNP N
was VBD N
not RB N
significantly RB N
different JJ N
for IN N
100-mg JJ N
sitaxsentan NN N
patients NNS N
than IN N
placebo NN N
( ( N
P NNP N
= NNP N
0.090 CD N
) ) N
. . N

Adverse JJ N
events NNS N
( ( N
AEs NNP N
) ) N
occurring VBG N
more RBR N
frequently RB N
with IN N
sitaxsentan NN N
( ( N
50 CD N
or CC N
100 CD N
mg NN N
) ) N
included VBD N
headache NN N
, , N
peripheral JJ N
edema NN N
, , N
dizziness NN N
, , N
nausea NN N
, , N
extremity NN N
pain NN N
, , N
and CC N
fatigue NN N
; : N
most JJS N
AEs NNP N
were VBD N
of IN N
mild NN N
or CC N
moderate JJ N
severity NN N
. . N

CONCLUSION NNP N
Sitaxsentan NNP N
100 CD N
mg NN N
improved VBD N
functional JJ N
class NN N
but CC N
not RB 4_p
6MWD CD 4_p
in IN 4_p
PAH NNP 4_p
patients NNS 4_p
who WP 4_p
were VBD 4_p
mostly RB 4_p
WHO NNP 4_p
functional JJ 4_p
class NN 4_p
II NNP 4_p
at IN 4_p
baseline NN N
. . N

No DT N
patient NN N
receiving VBG N
sitaxsentan JJ N
100 CD N
mg NN N
experienced VBD N
clinical JJ N
worsening NN N
; : N
sitaxsentan NN N
was VBD N
well RB N
tolerated VBN N
. . N

-DOCSTART- -X- O O 15051597

LDL NNP N
cholesterol-raising JJ N
effect NN N
of IN N
low-dose JJ N
docosahexaenoic NN N
acid NN N
in IN N
middle-aged JJ N
men NNS N
and CC N
women NNS N
. . N

BACKGROUND NNP N
Long-chain JJ N
n-3 JJ N
polyunsaturated VBN N
fatty JJ N
acids NNS N
have VBP N
variable JJ N
effects NNS N
on IN N
LDL NNP N
cholesterol NN N
, , N
and CC N
the DT N
effects NNS N
of IN N
docosahexaenoic NN N
acid NN N
( ( N
DHA NNP N
) ) N
are VBP N
uncertain JJ N
. . N

OBJECTIVE IN N
The DT N
objective NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
determine VB N
the DT N
effect NN N
on IN N
blood NN N
lipids NNS N
of IN N
a DT N
daily JJ N
intake NN N
of IN N
0.7 CD N
g JJ N
DHA NNP N
as IN N
triacylglycerol NN N
in IN N
middle-aged JJ N
men NNS N
and CC N
women NNS N
. . N

DESIGN NNP N
Men NNP N
and CC N
women NNS N
aged VBN N
40-65 JJ N
y NN N
( ( N
n JJ N
= NNP N
38 CD N
) ) N
underwent NN N
a DT N
double-blind NN N
, , N
randomized VBN N
, , N
placebo-controlled JJ N
, , N
crossover JJ N
trial NN N
of IN N
treatment NN N
with IN N
0.7 CD N
g NNS N
DHA/d NNP N
for IN N
3 CD N
mo NNS N
. . N

RESULTS NNP N
DHA NNP N
supplementation NN N
increased VBD N
the DT N
DHA NNP N
concentration NN N
in IN N
plasma NN N
by IN N
76 CD N
% NN N
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
and CC N
the DT N
proportion NN N
in IN N
erythrocyte JJ N
lipids NNS N
by IN N
58 CD N
% NN N
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

Values NNS N
for IN N
serum NN N
total JJ N
cholesterol NN N
, , N
LDL NNP N
cholesterol NN N
, , N
and CC N
plasma NN N
apolipoprotein NN N
B NNP N
concentrations NNS N
were VBD N
4.2 CD N
% NN N
( ( N
0.22 CD N
mmol/L NN N
; : N
P NNP N
= NNP N
0.04 CD N
) ) N
, , N
7.1 CD N
% NN N
( ( N
0.23 CD N
mmol/L NN N
; : N
P NNP N
= NNP N
0.004 CD N
) ) N
, , N
and CC N
3.4 CD N
% NN N
( ( N
P NNP N
= NNP N
0.03 CD N
) ) N
higher JJR N
, , N
respectively RB N
, , N
with IN N
DHA NNP N
treatment NN N
than IN N
with IN N
placebo NN N
. . N

In IN N
addition NN N
, , N
the DT N
LDL NNP N
cholesterol NN N
: : N
apolipoprotein NN N
B NNP N
ratio NN N
was VBD N
3.1 CD N
% NN N
higher JJR N
with IN N
DHA NNP N
treatment NN N
than IN N
with IN N
placebo NN N
( ( N
P NNP N
= NNP N
0.04 CD N
) ) N
, , N
which WDT N
suggested VBD N
an DT N
increase NN N
in IN N
LDL NNP N
size NN N
. . N

Plasma NNP N
lathosterol NN N
and CC N
plant NN N
sterol NN N
concentrations NNS N
were VBD N
unaffected VBN N
by IN N
treatment NN N
. . N

CONCLUSION VB N
A DT N
daily JJ N
intake NN N
of IN N
approximately RB N
0.7 CD N
g JJ N
DHA NNP N
increases VBZ N
LDL NNP N
cholesterol NN N
by IN N
7 CD N
% NN N
in IN N
middle-aged JJ N
men NNS N
and CC N
women NNS N
. . N

It PRP N
is VBZ N
suggested VBN N
that IN N
DHA NNP N
down-regulates VBZ N
the DT N
expression NN N
of IN N
the DT N
LDL NNP N
receptor NN N
. . N

-DOCSTART- -X- O O 8333941

Fusidic NNP N
acid VBZ N
prophylaxis NN N
before IN N
cataract JJ N
surgery NN N
: : N
patient JJ N
self-administration NN N
. . N

In IN N
a DT N
placebo-controlled JJ N
, , N
randomised JJ N
, , N
double-blind JJ N
clinical JJ N
trial NN N
, , N
the DT N
authors NNS N
evaluated VBD N
the DT N
efficacy NN N
of IN N
patient-administered JJ N
1 CD N
% NN N
fusidic JJ N
acid RB N
viscous JJ N
eye NN N
drops NNS N
in IN N
clearing VBG N
the DT N
commonest JJS N
organisms JJ N
causing VBG N
pseudophakic NN N
endophthalmitis NN N
( ( N
Staphylococcus NNP N
epidermidis RB N
and CC N
aureus RB N
) ) N
from IN N
the DT N
lids NNS N
and CC N
conjunctivae NN N
of IN N
79 CD N
patients NNS N
before IN N
cataract JJ N
surgery NN N
. . N

The DT N
treatment NN N
group NN N
self-administered JJ N
fusidic JJ N
acid NN N
viscous JJ N
eye NN N
drops VBZ N
four CD N
times NNS N
daily RB N
for IN N
seven CD N
days NNS N
before IN N
surgery NN N
; : N
the DT N
placebo NN N
group NN N
received VBD N
inert JJ N
ophthalmic JJ N
drops NNS N
. . N

Fellow NNP N
eyes NNS N
of IN N
both DT N
groups NNS N
remained VBD N
untreated JJ N
as IN N
a DT N
natural JJ N
control NN N
. . N

Lower JJR N
fornix NN N
and CC N
lid JJ N
margin NN N
cultures NNS N
were VBD N
taken VBN N
from IN N
both DT N
eyes NNS N
before IN N
and CC N
after IN N
treatment NN N
. . N

Before IN N
treatment NN N
, , N
there EX N
was VBD N
no DT N
statistical JJ N
difference NN N
in IN N
organism NN N
counts NNS N
between IN N
the DT N
groups NNS N
. . N

After IN N
treatment NN N
, , N
eyes NNS N
receiving VBG N
fusidic JJ N
acid NNS N
were VBD N
more RBR N
likely JJ N
to TO N
be VB N
free JJ N
of IN N
clinically RB N
relevant JJ N
Staphylococcus NNP N
spp NN N
. . N

than IN N
all DT N
pre-treatment JJ N
eyes NNS N
( ( N
for IN N
lids NNS N
, , N
P NNP N
< NNP N
0.001 CD N
; : N
conjunctivae NN N
, , N
P NNP N
= NNP N
0.02 CD N
) ) N
. . N

A DT N
highly RB N
significant JJ N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
number NN N
of IN N
lid JJ N
margins NNS N
were VBD N
rendered VBN N
'clinically RB N
clean JJ N
' '' N
( ( N
i.e. FW N
, , N
0-49 JJ N
organisms/swab NN N
) ) N
by IN N
fusidic JJ N
acid NN N
when WRB N
compared VBN N
with IN N
untreated JJ N
eyes NNS N
. . N

Treatment NNP N
also RB N
effectively RB N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
reduced VBD N
the DT N
numbers NNS N
of IN N
bacteria NNS N
isolated VBN N
from IN N
conjunctivae NN N
. . N

This DT N
study NN N
indicates VBZ N
that IN N
there EX N
is VBZ N
a DT N
highly RB N
significant JJ N
reduction NN N
of IN N
Staphylococcus NNP N
spp NN N
. . N

( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
non-Staphylococcus JJ N
spp NN N
. . N

( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
attainment NN N
of IN N
sterile JJ N
eyes NNS N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
at IN N
operation NN N
gained VBN N
by IN N
patient JJ N
self-administration NN N
of IN N
1 CD N
% NN N
fusidic JJ N
acid RB N
four CD N
times NNS N
daily RB N
for IN N
seven CD N
days NNS N
before IN N
surgery NN N
. . N

-DOCSTART- -X- O O 8131429

Videofluoroscopic NNP N
evidence NN N
of IN N
aspiration NN N
predicts NNS N
pneumonia NN N
and CC N
death NN N
but CC N
not RB N
dehydration NN N
following VBG N
stroke NN N
. . N

In IN N
order NN N
to TO N
assess VB N
the DT N
risk NN N
of IN N
pneumonia NN N
, , N
dehydration NN N
, , N
and CC N
death NN N
associated VBN N
with IN N
videofluoroscopic JJ N
evidence NN N
of IN N
aspiration NN N
following VBG N
stroke NN 4_p
, , N
the DT N
clinical JJ N
records NNS N
of IN N
26 CD N
patients NNS N
with IN N
aspiration NN N
and CC N
33 CD N
randomly RB N
selected VBN N
, , N
case-matched JJ N
, , N
dysphagic JJ 4_p
controls NNS 4_p
without IN 4_p
videofluoroscopic JJ 4_p
evidence NN 4_p
of IN 4_p
aspiration NN 4_p
were VBD N
reviewed VBN N
. . N

The DT N
videofluoroscopic NN N
modified VBD N
barium NN N
swallow NN N
technique NN N
included VBD N
5 CD N
ml-thin JJ N
and CC N
thick JJ N
liquid NN N
barium NN N
, , N
5 CD N
ml NN N
barium NN N
pudding NN N
, , N
and CC N
1/4 CD N
cookie NN N
coated VBN N
with IN N
barium NN N
, , N
plus CC N
additional JJ N
20 CD N
and CC N
30 CD N
ml NN N
of IN N
thin JJ N
liquid JJ N
barium NN N
. . N

Patients NNS N
were VBD N
assessed VBN N
a DT N
mean NN N
of IN N
2 CD N
+/- JJ N
1 CD N
SD NNP N
months NNS N
poststroke NN 4_p
and CC N
were VBD N
followed VBN N
for IN N
a DT N
mean NN N
of IN N
16 CD N
+/- JJ N
8 CD N
SD NNP N
months NNS N
poststroke RB 4_p
. . 4_p

The DT N
odds NNS N
ratio NN N
for IN N
developing VBG N
pneumonia NN N
was VBD N
7.6 CD N
times NNS N
greater JJR N
for IN N
those DT N
who WP N
aspirated VBD N
any DT N
amount NN N
of IN N
barium NN N
irrespective NN N
of IN N
its PRP$ N
consistency NN N
( ( N
p JJ N
= NNP N
0.05 CD N
) ) N
. . N

The DT N
odds NNS N
ratio NN N
for IN N
developing VBG N
pneumonia NN N
was VBD N
5.6 CD N
times NNS N
greater JJR N
for IN N
those DT N
who WP N
aspirated VBD N
thickened JJ N
liquids NNS N
or CC N
more JJR N
solid JJ N
consistencies NNS N
compared VBN N
with IN N
those DT N
who WP N
did VBD N
not RB N
aspirate VB N
, , N
or CC N
who WP N
aspirated VBD N
thin JJ N
liquids NNS N
only RB N
( ( N
p JJ N
= NNP N
0.06 CD N
) ) N
. . N

Dehydration NN N
was VBD N
unrelated JJ N
to TO N
the DT N
presence NN N
or CC N
absence NN N
of IN N
aspiration NN N
. . N

The DT N
odds NNS N
ratio NN N
for IN N
death NN N
was VBD N
9.2 CD N
times NNS N
greater JJR N
for IN N
those DT N
aspirating VBG N
thickened JJ N
liquids NNS N
or CC N
more JJR N
solid JJ N
consistencies NNS N
compared VBN N
with IN N
those DT N
who WP N
did VBD N
not RB N
aspirate VB N
or CC N
who WP N
aspirated VBD N
thin JJ N
liquids NNS N
only RB N
( ( N
p JJ N
= NNP N
0.01 CD N
) ) N
. . N

Aspiration NNP N
documented VBN N
by IN N
modified JJ N
videofluoroscopic NN N
barium NN N
swallow NN N
technique NN N
is VBZ N
associated VBN N
with IN N
a DT N
significant JJ N
increase NN N
in IN N
risk NN N
of IN N
pneumonia NN N
and CC N
death NN N
but CC N
not RB N
dehydration NN N
following VBG N
stroke NN N
. . N

-DOCSTART- -X- O O 25533997

Inverse NNP N
fluoxetine NN N
effects NNS N
on IN N
inhibitory NN N
brain NN N
activation NN N
in IN N
non-comorbid JJ N
boys NNS N
with IN N
ADHD NNP 4_p
and CC N
with IN N
ASD NNP 4_p
. . N

RATIONALE NNP N
Attention NNP N
deficit NN N
hyperactivity NN N
disorder NN N
( ( N
ADHD NNP N
) ) N
and CC N
autism NN N
spectrum NN N
disorder NN N
( ( N
ASD NNP N
) ) N
are VBP N
often RB N
comorbid JJ N
and CC N
have VBP N
both DT N
performance NN N
and CC N
brain NN N
dysfunctions NNS N
during IN N
motor NN N
response NN N
inhibition NN N
. . N

Serotonin NNP N
agonists VBZ N
modulate VBP N
motor NN N
response NN N
inhibition NN N
and CC N
have VBP N
shown VBN N
positive JJ N
behavioural JJ N
effects NNS N
in IN N
both DT N
disorders NNS N
. . N

AIMS IN N
We PRP N
therefore VBP N
used JJ N
functional JJ N
magnetic JJ N
resonance NN N
imaging NN N
( ( N
fMRI NN N
) ) N
to TO N
investigate VB N
the DT N
so RB N
far RB N
unknown JJ N
shared VBN N
and CC N
disorder-specific JJ N
inhibitory NN N
brain NN N
dysfunctions NNS N
in IN N
these DT N
two CD N
disorders NNS N
, , N
as RB N
well RB N
as IN N
the DT N
effects NNS N
of IN N
a DT N
single JJ N
dose NN N
of IN N
the DT N
selective JJ N
serotonin NN N
reuptake NN N
inhibitor NN N
fluoxetine NN N
. . N

METHODS NNP N
Age-matched JJ N
boys NNS N
with IN N
ADHD NNP 4_p
( ( N
18 CD N
) ) N
, , N
ASD NNP 4_p
( ( N
19 CD N
) ) N
and CC N
healthy JJ 4_p
controls NNS 4_p
( ( N
25 CD N
) ) N
were VBD N
compared VBN N
with IN N
fMRI NN N
during IN N
a DT N
stop JJ N
task NN N
measuring VBG N
motor NN N
inhibition NN N
. . N

Patients NNS N
were VBD N
scanned VBN N
twice RB N
, , N
under IN N
either DT N
an DT N
acute NN N
dose NN N
of IN N
fluoxetine NN N
or CC N
placebo NN N
in IN N
a DT N
double-blind JJ N
, , N
placebo-controlled JJ N
randomised JJ N
design NN N
. . N

Repeated VBN N
measures NNS N
analyses NNS N
within IN N
patients NNS N
assessed JJ N
drug NN N
effects NNS N
. . N

To TO N
test VB N
for IN N
potential JJ N
normalisation NN N
effects NNS N
of IN N
brain NN N
dysfunctions NNS N
, , N
patients NNS N
under IN N
each DT N
drug NN N
condition NN N
were VBD N
compared VBN N
to TO N
controls NNS N
. . N

RESULTS NNP N
Under IN N
placebo NN N
, , N
relative JJ N
to TO N
controls NNS N
, , N
ASD NNP 4_p
boys VBZ N
showed VBD N
overactivation NN N
in IN N
left NN N
and CC N
right JJ N
inferior JJ N
frontal JJ N
cortex NN N
( ( N
IFC NNP N
) ) N
, , N
while IN N
ADHD NNP 4_p
boys VBZ N
showed VBD N
disorder-specific JJ N
underactivation NN N
in IN N
orbitofrontal JJ N
cortex NN N
( ( N
OFC NNP N
) ) N
and CC N
basal $ N
ganglia NNS N
. . N

Under IN N
fluoxetine NN N
, , N
the DT N
prefrontal JJ N
dysfunctions NNS N
were VBD N
no RB N
longer JJR N
observed VBN N
, , N
due JJ N
to TO N
inverse JJ N
effects NNS N
of IN N
fluoxetine NN N
on IN N
these DT N
activations NNS N
: : N
fluoxetine NN N
downregulated VBD N
IFC NNP N
and CC N
OFC NNP N
activation NN N
in IN N
ASD NNP N
but CC N
upregulated VBD N
them PRP N
in IN N
ADHD NNP N
. . N

CONCLUSIONS NNP N
The DT N
findings NNS N
show VBP N
that IN N
fluoxetine NN N
normalises NNS N
frontal JJ N
lobe NN N
dysfunctions NNS N
in IN N
both DT N
disorders NNS N
via IN N
inverse JJ N
effects NNS N
, , N
downregulating VBG N
abnormally RB N
increased VBN N
frontal JJ N
activation NN N
in IN N
ASD NNP N
and CC N
upregulating VBG N
abnormally RB N
decreased VBN N
frontal JJ N
activation NN N
in IN N
ADHD NNP N
, , N
potentially RB N
reflecting VBG N
inverse JJ N
baseline NN N
serotonin NN N
levels NNS N
in IN N
both DT N
disorders NNS N
. . N

-DOCSTART- -X- O O 23361064

Temporal JJ N
expectation NN N
in IN N
focal JJ 4_p
hand NN 4_p
dystonia NN 4_p
. . N

Patients NNS N
with IN N
writer NN 4_p
's POS 4_p
cramp NN 4_p
present JJ N
sensory NN N
and CC N
representational JJ N
abnormalities NNS N
relevant VBP N
to TO N
motor VB N
control NN N
, , N
such JJ N
as IN N
impairment NN N
in IN N
the DT N
temporal JJ N
discrimination NN N
between IN N
tactile JJ N
stimuli NNS N
and CC N
in IN N
pure JJ N
motor NN N
imagery NN N
tasks NNS N
, , N
like IN N
the DT N
mental JJ N
rotation NN N
of IN N
corporeal NN N
and CC N
inanimate JJ N
objects NNS N
. . N

However RB N
, , N
only RB N
limited JJ N
information NN N
is VBZ N
available JJ N
on IN N
the DT N
ability NN N
of IN N
patients NNS N
with IN N
dystonia NN 4_p
to TO N
process VB N
the DT N
time-dependent JJ N
features NNS N
( ( N
e.g NN N
. . N

speed NN N
) ) N
of IN N
movement NN N
in IN N
real JJ N
time NN N
. . N

The DT N
processing NN N
of IN N
time-dependent JJ N
features NNS N
of IN N
movement NN N
has VBZ N
a DT N
crucial JJ N
role NN N
in IN N
predicting VBG N
whether IN N
the DT N
outcome NN N
of IN N
a DT N
complex JJ N
motor NN N
sequence NN N
, , N
such JJ N
as IN N
handwriting NN N
or CC N
playing VBG N
a DT N
musical JJ N
passage NN N
, , N
will MD N
be VB N
consistent JJ N
with IN N
its PRP$ N
ultimate JJ N
goal NN N
, , N
or CC N
results NNS N
instead RB N
in IN N
an DT N
execution NN N
error NN N
. . N

In IN N
this DT N
study NN N
, , N
we PRP N
sought VBD N
to TO N
evaluate VB N
the DT N
implicit JJ N
ability NN N
to TO N
perceive VB N
the DT N
temporal JJ N
outcome NN N
of IN N
different JJ N
movements NNS N
in IN N
a DT N
group NN N
of IN N
patients NNS N
with IN N
writer NN 4_p
's POS 4_p
cramp NN 4_p
. . N

Fourteen JJ N
patients NNS N
affected VBN N
by IN N
writer NN N
's POS N
cramp NN N
in IN N
the DT N
right JJ N
hand NN N
and CC N
17 CD N
age- JJ N
and CC N
gender-matched JJ N
healthy JJ N
subjects NNS N
were VBD N
recruited VBN N
for IN N
the DT N
study NN N
. . N

Subjects NNS N
were VBD N
asked VBN N
to TO N
perform VB N
a DT N
temporal JJ N
expectation NN N
task NN N
by IN N
predicting VBG N
the DT N
end NN N
of IN N
visually RB N
perceived VBN N
human JJ N
body NN N
motion NN N
( ( N
handwriting VBG N
, , N
i.e NN N
. . N

the DT N
action NN N
performed VBN N
by IN N
the DT N
human JJ N
body NN N
segment NN N
specifically RB N
affected VBN N
by IN N
writer NN N
's POS N
cramp NN N
) ) N
or CC N
inanimate JJ N
object JJ N
motion NN N
( ( N
a DT N
moving VBG N
circle NN N
reaching VBG N
a DT N
spatial JJ N
target NN N
) ) N
. . N

Videos NNP N
representing VBG N
movements NNS N
were VBD N
shown VBN N
in IN N
full JJ N
before IN N
experimental JJ N
trials NNS N
; : N
the DT N
actual JJ N
tasks NNS N
consisted VBN N
of IN N
watching VBG N
the DT N
same JJ N
videos NN N
, , N
but CC N
interrupted VBD N
after IN N
a DT N
variable JJ N
interval NN N
( ( N
'pre-dark NNP N
' POS N
) ) N
from IN N
its PRP$ N
onset VBN N
by IN N
a DT N
dark JJ N
interval NN N
of IN N
variable JJ N
duration NN N
. . N

During IN N
the DT N
'dark NNP N
' POS N
interval NN N
, , N
subjects NNS N
were VBD N
asked VBN N
to TO N
indicate VB N
when WRB N
the DT N
movement NN N
represented VBN N
in IN N
the DT N
video NN N
reached VBD N
its PRP$ N
end NN N
by IN N
clicking VBG N
on IN N
the DT N
space NN N
bar NN N
of IN N
the DT N
keyboard NN N
. . N

We PRP N
also RB N
included VBD N
a DT N
visual JJ N
working JJ N
memory NN N
task NN N
. . N

Performance NN N
on IN N
the DT N
timing NN N
task NN N
was VBD N
analysed VBN N
measuring VBG N
the DT N
absolute JJ N
value NN N
of IN N
timing VBG N
error NN N
, , N
the DT N
coefficient NN N
of IN N
variability NN N
and CC N
the DT N
percentage NN N
of IN N
anticipation NN N
responses NNS N
. . N

Patients NNS N
with IN N
writer NN 4_p
's POS 4_p
cramp NN 4_p
exhibited VBD N
greater JJR N
absolute JJ N
timing NN N
error NN N
compared VBN N
with IN N
control NN N
subjects NNS N
in IN N
the DT N
human JJ N
body NN N
motion NN N
task NN N
( ( N
whereas IN N
no DT N
difference NN N
was VBD N
observed VBN N
in IN N
the DT N
inanimate NN N
object JJ N
motion NN N
task NN N
) ) N
. . N

No DT N
effect NN N
of IN N
group NN N
was VBD N
documented VBN N
on IN N
the DT N
visual JJ N
working JJ N
memory NN N
tasks NNS N
. . N

Absolute NNP N
timing VBG N
error NN N
on IN N
the DT N
human JJ N
body NN N
motion NN N
task NN N
did VBD N
not RB N
significantly RB N
correlate VB N
with IN N
symptom JJ N
severity NN N
, , N
disease VB N
duration NN N
or CC N
writing VBG N
speed NN N
. . N

Our PRP$ N
findings NNS N
suggest VBP N
an DT N
alteration NN N
of IN N
the DT N
writing VBG N
movement NN N
representation NN N
at IN N
a DT N
central JJ N
level NN N
and CC N
are VBP N
consistent JJ N
with IN N
the DT N
view NN N
that IN N
dystonia NN N
is VBZ N
not RB N
a DT N
purely RB N
motor NN N
disorder NN N
, , N
but CC N
it PRP N
also RB N
involves VBZ N
non-motor NN N
( ( N
sensory JJ N
, , N
cognitive JJ N
) ) N
aspects NNS N
related VBN N
to TO N
movement NN N
processing NN N
and CC N
planning NN N
. . N

-DOCSTART- -X- O O 3287907

Analgesic JJ N
efficacy NN N
of IN N
piroxicam NN N
in IN N
the DT N
treatment NN N
of IN N
postoperative JJ N
pain NN N
. . N

Two CD N
randomized JJ N
, , N
double-blind JJ N
, , N
single-dose JJ N
studies NNS N
were VBD N
conducted VBN N
to TO N
assess VB N
the DT N
analgesic JJ N
efficacy NN N
and CC N
safety NN N
of IN N
piroxicam NN N
for IN N
the DT N
treatment NN N
of IN N
moderate JJ N
or CC N
severe JJ N
postoperative JJ N
pain NN N
. . N

Study NNP N
1 CD N
evaluated VBD N
the DT N
analgesic JJ N
efficacy NN N
of IN N
piroxicam NN N
20 CD N
mg NN N
compared VBN N
with IN N
that DT N
of IN N
codeine NN N
sulfate NN N
60 CD N
mg NN N
and CC N
placebo NN N
. . N

A DT N
final JJ N
patient NN N
population NN N
of IN N
149 CD N
subjects NNS N
rated VBN N
pain JJ N
intensity NN N
and CC N
pain NN N
relief NN N
at IN N
one CD N
half NN N
hour NN N
and CC N
one CD N
hour NN N
following VBG N
treatment NN N
and CC N
then RB N
hourly RB N
for IN N
six CD N
hours NNS N
, , N
with IN N
a DT N
global JJ N
assessment NN N
made VBN N
at IN N
the DT N
completion NN N
of IN N
24 CD N
hours NNS N
. . N

Piroxicam NNP N
20 CD N
mg NN N
was VBD N
significantly RB N
more RBR N
efficacious JJ N
than IN N
placebo NN N
for IN N
all DT N
analgesic JJ N
variables NNS N
, , N
including VBG N
the DT N
sum NN N
of IN N
the DT N
pain NN N
intensity NN N
differences NNS N
( ( N
SPID NNP N
) ) N
, , N
total JJ N
pain NN N
relief NN N
( ( N
TOTAL NNP N
) ) N
, , N
percent JJ N
SPID NNP N
, , N
duration NN N
of IN N
effect NN N
, , N
and CC N
time NN N
to TO N
remedication NN N
. . N

Codeine VB N
60 CD N
mg NN N
was VBD N
significantly RB N
superior JJ N
to TO N
placebo VB N
for IN N
percent NN N
SPID NNP N
and CC N
some DT N
hourly JJ N
measures NNS N
. . N

Piroxicam NNP N
20 CD N
mg NN N
was VBD N
significantly RB N
more RBR N
effective JJ N
than IN N
codeine VBP N
60 CD N
mg NN N
for IN N
percent NN N
SPID NNP N
and CC N
a DT N
few JJ N
hourly JJ N
measures NNS N
including VBG N
time NN N
to TO N
remedication NN N
. . N

Study NNP N
2 CD N
assessed VBD N
the DT N
efficacy NN N
of IN N
piroxicam NN N
20 CD N
mg NN N
or CC N
40 CD N
mg NNS N
compared VBN N
with IN N
aspirin JJ N
648 CD N
mg NN N
and CC N
placebo NN N
. . N

Sixty CD N
patients NNS N
rated VBN N
their PRP$ N
pain NN N
intensity NN N
and CC N
relief NN N
hourly RB N
for IN N
12 CD N
hours NNS N
and CC N
at IN N
24 CD N
hours NNS N
after IN N
administration NN N
of IN N
study JJ N
medication NN N
. . N

Both DT N
doses NNS N
of IN N
piroxicam NN N
were VBD N
significantly RB N
more RBR N
effective JJ N
than IN N
placebo NN N
from IN N
Hours $ N
2 CD N
to TO N
12 CD N
for IN N
pain NN N
intensity NN N
difference NN N
( ( N
PID NNP N
) ) N
and CC N
relief NN N
scores NNS N
, , N
as RB N
well RB N
as IN N
for IN N
SPID NNP N
and CC N
TOTAL NNP N
. . N

Aspirin NNP N
was VBD N
significantly RB N
more RBR N
effective JJ N
than IN N
placebo NN N
from IN N
Hours $ N
2 CD N
to TO N
8 CD N
for IN N
relief NN N
and CC N
Hours $ N
2 CD N
to TO N
10 CD N
for IN N
PID NNP N
as RB N
well RB N
as IN N
SPID NNP N
and CC N
TOTAL NNP N
. . N

Piroxicam NNP N
40 CD N
mg NN N
was VBD N
significantly RB N
more RBR N
effective JJ N
than IN N
aspirin RB N
648 CD N
mg NN N
for IN N
SPID NNP N
, , N
TOTAL NNP N
, , N
and CC N
hourly RB N
measures NNS N
beginning VBG N
with IN N
Hour NNP N
6 CD N
through IN N
Hour NNP N
12 CD N
. . N

Piroxicam VB N
20 CD N
mg NN N
was VBD N
significantly RB N
better JJR N
than IN N
aspirin NN N
for IN N
a DT N
few JJ N
hourly JJ N
measures NNS N
: : N
Hours $ N
7 CD N
to TO N
9 CD N
for IN N
relief NN N
and CC N
Hour $ N
7 CD N
for IN N
PID NNP N
. . N

In IN N
addition NN N
, , N
effects NNS N
of IN N
piroxicam NN N
20 CD N
mg NN N
had VBD N
a DT N
significantly RB N
longer JJR N
duration NN N
than IN N
aspirin NN N
. . N

Similarly RB N
, , N
piroxicam VBD N
20 CD N
mg NN N
had VBD N
a DT N
significantly RB N
longer JJR N
time NN N
to TO N
remedication VB N
compared VBN N
with IN N
aspirin NN N
and CC N
placebo NN N
. . N

The DT N
results NNS N
of IN N
these DT N
studies NNS N
provide VBP N
evidence NN N
in IN N
support NN N
of IN N
the DT N
longer JJR N
duration NN N
of IN N
analgesic JJ N
efficacy NN N
of IN N
piroxicam NNS N
compared VBN N
with IN N
codeine NN N
or CC N
aspirin NN N
in IN N
patients NNS N
with IN N
postoperative JJ N
pain NN N
. . N

-DOCSTART- -X- O O 1640362

Performance NN N
of IN N
a DT N
modified VBN N
starch NN N
hydrophilic NN N
matrix NN N
for IN N
the DT N
sustained JJ N
release NN N
of IN N
theophylline NN N
in IN N
healthy JJ 4_p
volunteers NNS 4_p
. . 4_p

Two CD N
experimental JJ N
formulations NNS N
of IN N
theophylline NN N
with IN N
a DT N
hydrophilic JJ N
starch NN N
matrix NN N
were VBD N
evaluated VBN N
for IN N
their PRP$ N
sustained-release JJ N
characteristics NNS N
after IN N
single JJ N
administration NN N
in IN N
healthy JJ N
human JJ N
volunteers NNS N
. . N

Theo-dur NN N
was VBD N
chosen VBN N
as IN N
a DT N
reference NN N
sustained-release JJ N
formulation NN N
. . N

In IN N
a DT N
first JJ N
study NN N
, , N
the DT N
extent NN N
of IN N
absorption NN N
was VBD N
similar JJ N
for IN N
a DT N
syrup NN N
, , N
for IN N
Theo-dur NNP N
, , N
and CC N
for IN N
the DT N
experimental JJ N
formulation NN N
of IN N
theophylline NN N
with IN N
70 CD N
% NN N
drum-dried JJ N
corn NN N
starch NN N
as IN N
the DT N
sustained-release JJ N
agent NN N
( ( N
DDCS-70 NNP N
) ) N
. . N

The DT N
maximal JJ N
plasma NN N
concentration NN N
( ( N
Cmax NNP N
) ) N
was VBD N
significantly RB N
lower JJR N
, , N
and CC N
the DT N
time NN N
to TO N
reach VB N
Cmax NNP N
as RB N
well RB N
as IN N
the DT N
time NN N
span NN N
during IN N
which WDT N
the DT N
plasma NN N
concentration NN N
was VBD N
at IN N
least JJS N
75 CD N
% NN N
of IN N
the DT N
Cmax NNP N
were VBD N
significantly RB N
higher JJR N
for IN N
Theo-dur NNP N
than IN N
for IN N
the DT N
DDCS-70 NNP N
formulation NN N
. . N

A DT N
sustained-release JJ N
profile NN N
, , N
as IN N
for IN N
Theo-dur NNP N
, , N
was VBD N
not RB N
reached VBN N
for IN N
DDCS-70 NNP N
. . N

In IN N
a DT N
second JJ N
study NN N
the DT N
influence NN N
of IN N
the DT N
starch NN N
: : N
drug NN N
ratio NN N
on IN N
the DT N
bioavailability NN N
was VBD N
investigated VBN N
. . N

The DT N
decrease NN N
in IN N
starch NN N
content NN N
from IN N
70 CD N
to TO N
50 CD N
% NN N
of IN N
the DT N
formulation NN N
did VBD N
not RB N
improve VB N
the DT N
plasma NN N
concentration-time JJ N
profile NN N
towards NNS N
a DT N
sustained-release JJ N
profile NN N
. . N

-DOCSTART- -X- O O 15172423

Comparative JJ N
effects NNS N
of IN N
valsartan JJ N
versus NN N
amlodipine NN N
on IN N
left JJ N
ventricular JJ N
mass NN N
and CC N
reactive JJ N
oxygen NN N
species NNS N
formation NN N
by IN N
monocytes NNS N
in IN N
hypertensive JJ 4_p
patients NNS 4_p
with IN 4_p
left JJ 4_p
ventricular JJ 4_p
hypertrophy NN 4_p
. . 4_p

OBJECTIVES NNP N
To TO N
compare VB N
the DT N
effects NNS N
of IN N
the DT N
angiotensin NN N
receptor NN N
blocker NN N
( ( N
ARB NNP N
) ) N
valsartan VBP N
versus IN N
the DT N
calcium NN N
channel NN N
blocker NN N
amlodipine NN N
, , N
reactive JJ N
oxygen NN N
species NNS N
( ( N
ROS NNP N
) ) N
formation NN N
by IN N
monocytes NNS N
, , N
C-reactive JJ N
protein NN N
( ( N
CRP NNP N
) ) N
, , N
and CC N
left VBD N
ventricular NN N
( ( N
LV NNP N
) ) N
mass NN N
were VBD N
studied VBN N
in IN N
104 CD N
hypertensive JJ N
patients NNS N
with IN N
left JJ N
ventricular JJ N
hypertrophy NN N
( ( N
LVH NNP N
) ) N
. . N

BACKGROUND NNP N
There EX N
is VBZ N
evidence NN N
that IN N
ARBs NNP N
have VBP N
blood VBN N
pressure NN N
( ( N
BP NNP N
) ) N
-independent NN N
effects NNS N
on IN N
LV NNP N
mass NN N
. . N

Whether NNP N
regression NN N
of IN N
LV NNP N
mass NN N
by IN N
ARBs NNP N
is VBZ N
correlated VBN N
to TO N
ROS NNP N
formation NN N
by IN N
monocytes NNS N
and CC N
CRP NNP N
is VBZ N
not RB N
fully RB N
understood JJ N
yet RB N
. . N

METHODS VB N
A DT N
cross-sectional JJ N
and CC N
prospective JJ N
study NN N
was VBD N
performed VBN N
. . N

Participants NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
either VB N
the DT N
80-mg JJ N
valsartan NN N
( ( N
n JJ N
= NNP N
52 CD N
) ) N
or CC N
5-mg JJ N
amlodipine NN N
( ( N
n JJ N
= NNP N
52 CD N
) ) N
group NN N
and CC N
were VBD N
treated VBN N
for IN N
eight CD N
months NNS N
. . N

The DT N
left JJ N
ventricular JJ N
mass NN N
index NN N
( ( N
LVMI NNP N
) ) N
was VBD N
calculated VBN N
from IN N
two-dimensional JJ N
M-mode NNP N
echocardiography NN N
. . N

Formation NN N
of IN N
ROS NNP N
by IN N
monocytes NNS N
was VBD N
measured VBN N
by IN N
gated VBN N
flow JJ N
cytometry NN N
. . N

In IN N
addition NN N
, , N
CRP NNP N
, , N
plasma JJ N
renin NN N
activity NN N
, , N
plasma NN N
aldosterone NN N
, , N
and CC N
traditional JJ N
risk NN N
factors NNS N
were VBD N
assessed VBN N
. . N

RESULTS NNP N
Multiple NNP N
regression NN N
analysis NN N
showed VBD N
a DT N
significant JJ N
correlation NN N
between IN N
LVMI NNP N
and CC N
ROS NNP N
formation NN N
by IN N
monocytes NNS N
and CC N
between IN N
LVMI NNP N
and CC N
CRP NNP N
. . N

Treatment NNP N
reduced VBD N
BP NNP N
to TO N
a DT N
similar JJ N
extent NN N
in IN N
both DT N
groups NNS N
. . N

Valsartan NNP N
significantly RB N
reduced VBD N
LVMI NNP N
after IN N
eight CD N
months NNS N
, , N
but CC N
amlodipine NN N
had VBD N
less RBR N
effect NN N
( ( N
16 CD N
% NN N
vs. FW N
1.2 CD N
% NN N
, , N
n JJ N
= NN N
50 CD N
, , N
p NN N
< NNP N
0.01 CD N
) ) N
. . N

Formation NN N
of IN N
ROS NNP N
by IN N
monocytes NNS N
was VBD N
reduced VBN N
to TO N
a DT N
greater JJR N
extent NN N
with IN N
valsartan NN N
than IN N
with IN N
amlodipine NN N
( ( N
28 CD N
% NN N
vs. FW N
2 CD N
% NN N
, , N
n JJ N
= NN N
50 CD N
, , N
p NN N
< NNP N
0.01 CD N
) ) N
. . N

Valsartan NNP N
but CC N
not RB N
amlodipine VB N
reduced VBN N
CRP NNP N
levels NNS N
. . N

A DT N
significant JJ N
correlation NN N
between IN N
changes NNS N
in IN N
ROS NNP N
formation NN N
by IN N
monocytes NNS N
and CC N
LVMI NNP N
or CC N
between IN N
CRP NNP N
and CC N
LVMI NNP N
was VBD N
observed VBN N
. . N

CONCLUSIONS VB N
The DT N
ARB NNP N
valsartan NN N
has VBZ N
BP-independent JJ N
effects NNS N
on IN N
LVH NNP N
, , N
ROS NNP N
formation NN N
by IN N
monocytes NNS N
, , N
and CC N
CRP NNP N
in IN N
hypertensive JJ N
patients NNS N
with IN N
LVH NNP N
. . N

-DOCSTART- -X- O O 18957157

Impact NN N
of IN N
isotonic JJ N
and CC N
hypertonic JJ N
saline NN N
solutions NNS N
on IN N
mucociliary JJ N
activity NN N
in IN N
various JJ N
nasal JJ 4_p
pathologies NNS 4_p
: : N
clinical JJ N
study NN N
. . N

OBJECTIVE NNP N
To TO N
investigate VB N
the DT N
impact NN N
of IN N
nasal JJ N
irrigation NN N
with IN N
isotonic JJ N
or CC N
hypertonic JJ N
sodium NN N
chloride JJ N
solution NN N
on IN N
mucociliary JJ N
clearance NN N
time NN N
in IN N
patients NNS N
with IN N
allergic JJ 4_p
rhinitis NN 4_p
, , N
acute JJ 4_p
sinusitis NN 4_p
and CC N
chronic JJ 4_p
sinusitis NN 4_p
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
Mucociliary NNP N
clearance NN N
time NN N
was VBD N
measured VBN N
using VBG N
the DT N
saccharine JJ N
clearance NN N
test NN N
on IN N
132 CD N
adults NNS N
before IN N
and CC N
after IN N
10 CD N
days NNS N
' POS N
application NN N
of IN N
intranasal NN N
isotonic NN N
or CC N
hypertonic JJ N
saline NN N
. . N

Patient JJ N
numbers NNS N
were VBD N
as IN N
follows VBZ N
: : N
controls NNS N
, , N
45 CD N
; : N
allergic JJ N
rhinitis NN N
, , N
21 CD N
; : N
acute JJ N
sinusitis NN N
, , N
24 CD N
; : N
and CC N
chronic JJ N
sinusitis NN N
, , N
42 CD N
. . N

The DT N
results NNS N
before IN N
and CC N
after IN N
irrigation NN N
were VBD N
compared VBN N
using VBG N
the DT N
Wilcoxon NNP N
t-test NN N
. . N

RESULTS NNP N
Before IN N
application NN N
of IN N
saline JJ N
solutions NNS N
, , N
mucociliary JJ N
clearance NN N
times NNS N
in IN N
the DT N
three CD N
patient NN N
treatment NN N
groups NNS N
were VBD N
found VBN N
to TO N
be VB N
significantly RB N
delayed VBN N
, , N
compared VBN N
with IN N
the DT N
control NN N
group NN N
. . N

Irrigation NN N
with IN N
hypertonic JJ N
saline NN N
restored VBN N
impaired JJ N
mucociliary JJ N
clearance NN N
in IN N
chronic JJ N
sinusitis NN N
patients NNS N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
, , N
while IN N
isotonic JJ N
saline NN N
improved VBD N
mucociliary JJ N
clearance NN N
times NNS N
significantly RB N
in IN N
allergic JJ N
rhinitis NN N
and CC N
acute JJ N
sinusitis NN N
patients NNS N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSION NNP N
Nasal NNP N
irrigation NN N
with IN N
isotonic JJ N
or CC N
hypertonic JJ N
saline NN N
can MD N
improve VB N
mucociliary JJ N
clearance NN N
time NN N
in IN N
various JJ N
nasal JJ N
pathologies NNS N
. . N

However RB N
, , N
these DT N
solutions NNS N
should MD N
be VB N
selectively RB N
prescribed IN N
rather RB N
than IN N
used VBN N
based VBN N
on IN N
anecdotal JJ N
evidence NN N
. . N

Further JJ N
studies NNS N
should MD N
be VB N
conducted VBN N
to TO N
develop VB N
a DT N
protocol NN N
for IN N
standardised VBN N
use NN N
of IN N
saline JJ N
solution NN N
irrigation NN N
in IN N
various JJ N
nasal JJ N
pathologies NNS N
. . N

-DOCSTART- -X- O O 7997386

Effect NN N
of IN N
intravenous JJ N
fructose-1,6-diphosphate NN N
on IN N
myocardial JJ N
contractility NN N
in IN N
patients NNS N
with IN N
left JJ 4_p
ventricular JJ 4_p
dysfunction NN 4_p
. . N

STUDY NNP N
OBJECTIVE NNP N
To TO N
examine VB N
the DT N
effects NNS N
of IN N
fructose-1,6-diphosphate NN N
on IN N
myocardial JJ N
performance NN N
using VBG N
nuclear JJ N
scintigraphy NN N
. . N

DESIGN NNP N
Prospective NNP N
, , N
randomized VBD N
, , N
single-blind JJ N
, , N
parallel JJ N
study NN N
. . N

SETTING NNP N
Urban NNP N
teaching VBG N
hospital JJ N
clinical JJ N
research NN N
center NN N
. . N

PATIENTS JJ N
Individuals NNS N
with IN N
New NNP 4_p
York NNP 4_p
Heart NNP 4_p
Association NNP 4_p
functional JJ 4_p
class NN 4_p
II-III NNP 4_p
heart NN 4_p
failure NN 4_p
( ( 4_p
mild JJ 4_p
to TO 4_p
moderate VB 4_p
) ) N
. . N

INTERVENTIONS JJ N
Subjects NNPS N
received VBD N
either DT N
intravenous JJ N
fructose-1,6-diphosphate JJ N
125 CD N
mg/kg NN N
or CC N
normal JJ N
saline JJ N
1.3 CD N
ml/kg NN N
every DT N
12 CD N
hours NNS N
over IN N
10 CD N
minutes NNS N
for IN N
four CD N
consecutive JJ N
doses NNS N
. . N

Left NNP N
ventricular JJ N
performance NN N
was VBD N
assessed VBN N
by IN N
radionuclide NN N
ventriculography NN N
at IN N
baseline NN N
and CC N
within IN N
60 CD N
minutes NNS N
after IN N
the DT N
fourth JJ N
infusion NN N
. . N

Vital JJ N
signs NNS N
were VBD N
monitored VBN N
throughout IN N
the DT N
study NN N
period NN N
. . N

MEASUREMENTS NNP N
AND CC N
MAIN NNP N
RESULTS NNP N
Fructose-1,6-diphosphate NNP N
resulted VBD N
in IN N
a DT N
modest JJ N
7 CD N
% NN N
increase NN N
in IN N
left JJ N
ventricular JJ N
ejection NN N
fraction NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

Peak JJ N
ejection NN N
rate NN N
and CC N
peak VB N
diastolic JJ N
filling VBG N
rate NN N
did VBD N
not RB N
change VB N
significantly RB N
. . N

There EX N
were VBD N
no DT N
changes NNS N
in IN N
blood NN N
pressure NN N
or CC N
heart NN N
rate NN N
with IN N
either DT N
fructose-1,6-diphosphate JJ N
or CC N
placebo NN N
. . N

CONCLUSIONS NNP N
Fructose-1,6-diphosphate NNP N
produces VBZ N
a DT N
modest JJ N
but CC N
significant JJ N
increase NN N
in IN N
left JJ N
ventricular JJ N
ejection NN N
fraction NN N
in IN N
patients NNS N
with IN N
mild JJ N
to TO N
moderate VB N
heart NN 4_p
failure NN 4_p
. . N

-DOCSTART- -X- O O 2956874

Placebo-controlled JJ N
study NN N
of IN N
oral JJ N
enoximone NN N
in IN N
congestive JJ N
heart NN N
failure NN N
with IN N
initial JJ N
and CC N
final JJ N
intravenous JJ N
hemodynamic JJ N
evaluation NN N
. . N

Seventeen JJ N
patients NNS N
with IN N
stable JJ 4_p
congestive JJ 4_p
heart NN 4_p
failure NN 4_p
( ( 4_p
class NN 4_p
II NNP 4_p
and CC 4_p
III NNP 4_p
New NNP 4_p
York NNP 4_p
Heart NNP 4_p
Association NNP 4_p
) ) 4_p
received VBD N
intravenous JJ N
and CC N
oral JJ N
enoximone NN N
in IN N
a DT N
2-part JJ N
study NN N
. . N

Hemodynamic NNP N
data NNS N
were VBD N
first RB N
obtained VBN N
after IN N
intravenous JJ N
administration NN N
of IN N
0.75 CD N
mg/kg NN N
of IN N
enoximone NN N
; : N
data NNS N
were VBD N
again RB N
obtained VBN N
after IN N
12 CD N
weeks NNS N
of IN N
therapy NN N
with IN N
either DT N
oral JJ N
enoximone NN N
( ( N
150 CD N
mg RB N
3 CD N
times NNS N
daily RB N
) ) N
or CC N
placebo NN N
. . N

The DT N
efficacy NN N
and CC N
safety NN N
of IN N
oral JJ N
enoximone NN N
were VBD N
also RB N
studied VBN N
in IN N
a DT N
12-week JJ N
, , N
double-blind JJ N
randomized JJ N
format NN N
. . N

In IN N
the DT N
intravenous JJ N
study NN N
, , N
enoximone NN N
was VBD N
delivered VBN N
over IN N
5 CD N
minutes NNS N
and CC N
hemodynamic JJ N
data NNS N
were VBD N
measured VBN N
for IN N
up RB N
to TO N
12 CD N
hours NNS N
after IN N
. . N

Cardiac NNP N
index NN N
increased VBD N
2.76 CD N
+/- JJ N
0.63 CD N
to TO N
3.42 CD N
+/- JJ N
0.72 CD N
liters/min/m2 NN N
) ) N
, , N
pulmonary JJ N
wedge NN N
pressure NN N
decreased VBN N
( ( N
19.5 CD N
+/- JJ N
8.8 CD N
to TO N
14.6 CD N
+/- JJ N
8.0 CD N
mm NN N
Hg NNP N
) ) N
as IN N
did VBD N
mean VB N
arterial JJ N
blood NN N
pressure NN N
( ( N
101 CD N
+/- JJ N
14.8 CD N
to TO N
85 CD N
+/- JJ N
13.7 CD N
mm NN N
Hg NNP N
) ) N
and CC N
systemic JJ N
vascular NN N
resistance NN N
( ( N
1,880 CD N
+/- JJ N
573 CD N
to TO N
1,254 CD N
+/- JJ N
383 CD N
dynes NNS N
s RB N
cm-5 NN N
) ) N
. . N

Heart NNP N
rate NN N
increased VBD N
slightly RB N
( ( N
82 CD N
+/- JJ N
17 CD N
to TO N
86 CD N
+/- JJ N
14 CD N
beats/min NN N
) ) N
. . N

All PDT N
these DT N
changes NNS N
were VBD N
maximal JJ N
1 CD N
to TO N
2 CD N
hours NNS N
after IN N
infusion NN N
and CC N
lasted VBD N
8 CD N
hours NNS N
at IN N
least JJS N
. . N

Patients NNS N
were VBD N
then RB N
randomized VBN N
double-blind NN N
to TO N
oral JJ N
treatment NN N
. . N

Baseline NNP N
values VBZ N
showed VBD N
that IN N
the DT N
7 CD N
patients NNS N
who WP N
received VBD N
placebo NN N
had VBD N
more RBR N
severe JJ N
CHF NNP N
. . N

Therefore NNP N
, , N
comparison NN N
might MD N
be VB N
biased VBN N
. . N

Patient NNP N
overall JJ N
assessment NN N
showed VBD N
a DT N
continuous JJ N
benefit NN N
in IN N
both DT N
groups NNS N
. . N

Ejection NNP N
fraction NN N
improved VBD N
from IN N
30.1 CD N
+/- JJ N
6.8 CD N
% NN N
to TO N
33.9 CD N
+/- JJ N
9.9 CD N
% NN N
in IN N
the DT N
enoximone NN N
group NN N
while IN N
it PRP N
remained VBD N
unchanged JJ N
with IN N
placebo NN N
( ( N
23.4 CD N
+/- JJ N
6.5 CD N
% NN N
to TO N
23.4 CD N
+/- JJ N
1.5 CD N
% NN N
) ) N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -X- O O 18957616

Hyperinsulinemia NNP N
fails VBZ N
to TO N
augment VB N
ET-1 JJ N
action NN N
in IN N
the DT N
skeletal JJ N
muscle NN N
vascular JJ N
bed NN N
in IN N
vivo NN N
in IN N
humans NNS N
. . N

Endogenous JJ N
endothelin JJ N
action NN N
is VBZ N
augmented VBN N
in IN N
human JJ N
obesity NN N
and CC N
type NN N
2 CD N
diabetes NNS N
and CC N
contributes NNS N
to TO N
endothelial JJ N
dysfunction NN N
and CC N
impairs VB N
insulin-mediated JJ N
vasodilation NN N
in IN N
humans NNS N
. . N

We PRP N
hypothesized VBD N
that IN N
insulin JJ N
resistance-associated JJ N
hyperinsulinemia NN N
could MD N
preferentially RB N
drive VB N
endothelin-mediated JJ N
vasoconstriction NN N
. . N

We PRP N
applied VBD N
hyperinsulinemic-euglycemic JJ N
clamps NNS N
with IN N
higher JJR N
insulin NN N
dosing VBG N
in IN N
obese JJ 4_p
subjects NNS 4_p
than IN N
lean JJ 4_p
subjects NNS 4_p
( ( N
30 CD N
vs. FW N
10 CD N
mU.m NN N
( ( N
-2 NNP N
) ) N
.min NNP N
( ( N
-1 NNP N
) ) N
, , N
respectively RB N
) ) N
, , N
with IN N
the DT N
goal NN N
of IN N
matching VBG N
insulin NN N
's POS N
nitric JJ N
oxide NN N
( ( N
NO NNP N
) ) N
-mediated VBD N
vascular JJ N
effects NNS N
. . N

We PRP N
predicted VBD N
that IN N
, , N
under IN N
these DT N
circumstances NNS N
, , N
insulin-stimulated JJ N
endothelin-1 JJ N
( ( N
ET-1 NNP N
) ) N
action NN N
( ( N
assessed VBN N
with IN N
the DT N
type NN N
A NNP N
endothelin NN N
receptor NN N
antagonist IN N
BQ-123 NNP N
) ) N
would MD N
be VB N
augmented VBN N
in IN N
proportion NN N
to TO N
hyperinsulinemia VB N
. . N

NO DT N
bioactivity NN N
was VBD N
assessed VBN N
using VBG N
the DT N
nitric JJ N
oxide JJ N
synthase NN N
inhibitor NN N
N NNP N
( ( N
G NNP N
) ) N
-monomethyl-l-arginine NN N
. . N

Insulin-mediated JJ N
vasodilation NN N
and CC N
insulin-stimulated JJ N
NO NNP N
bioavailability NN N
were VBD N
well RB N
matched VBN N
across IN N
groups NNS N
by IN N
this DT N
approach NN N
. . N

As IN N
expected VBN N
, , N
steady-state JJ N
insulin NN N
levels NNS N
were VBD N
approximately RB N
threefold JJ N
higher JJR N
in IN N
obese JJ N
than IN N
lean JJ N
subjects NNS N
( ( N
109.2 CD N
+/- JJ N
10.2 CD N
pmol/l NN N
vs. FW N
518.4 CD N
+/- JJ N
84.0 CD N
, , N
P NNP N
= NNP N
0.03 CD N
) ) N
. . N

Despite IN N
this DT N
, , N
the DT N
augmentation NN N
of IN N
insulin-mediated JJ N
vasodilation NN N
by IN N
BQ-123 NNP N
was VBD N
not RB N
different JJ N
between IN N
groups NNS N
. . N

ET-1 JJ N
flux NN N
across IN N
the DT N
leg NN N
was VBD N
not RB N
augmented VBN N
by IN N
insulin NN N
alone RB N
but CC N
was VBD N
increased VBN N
with IN N
the DT N
addition NN N
of IN N
BQ-123 NNP N
to TO N
insulin VB N
( ( N
P NNP N
= VBZ N
0.01 CD N
BQ-123 JJ N
effect NN N
, , N
P NNP N
= NNP N
not RB N
significant JJ N
comparing VBG N
groups NNS N
) ) N
. . N

Endothelin NNP N
antagonism NN N
augmented VBD N
insulin-stimulated JJ N
NO NNP N
bioavailability NN N
and CC N
NOx NNP N
flux NN N
, , N
but CC N
not RB N
differently RB N
between IN N
groups NNS N
and CC N
not RB N
proportional JJ N
to TO N
hyperinsulinemia VB N
. . N

These DT N
findings NNS N
do VBP N
not RB N
support VB N
the DT N
hypothesis NN N
that WDT N
insulin VBZ N
resistance-associated JJ N
hyperinsulinemia NN N
preferentially RB N
drives VBZ N
endothelin-mediated JJ N
vasoconstriction NN N
. . N

-DOCSTART- -X- O O 11134799

A DT N
randomized JJ N
trial NN N
in IN N
simultaneous JJ 4_p
pancreas-kidney JJ 4_p
transplantation NN 4_p
: : N
portal JJ N
versus NN N
systemic JJ N
venous JJ N
drainage NN N
of IN N
the DT N
pancreas NN N
allograft NN N
. . N

-DOCSTART- -X- O O 2711711

[ JJ N
Dose-reduced NNP N
antihypertensive JJ N
agents NNS N
-- : N
use NN N
in IN N
complex JJ N
nonmedicamentous JJ N
therapy NN N
of IN N
hypertension NN N
] NNP N
. . N

In IN N
order NN N
to TO N
estimate VB N
the DT N
influence NN N
of IN N
a DT N
non-medicamentous JJ N
therapy NN N
( ( N
CNT NNP N
) ) N
on IN N
the DT N
consumption NN N
of IN N
medicaments NNS N
and CC N
coronary JJ N
risk NN N
in IN N
high JJ N
blood NN N
pressure NN N
73 CD N
hypertensives NNS 4_p
of IN N
a DT N
medicamentously RB N
stabilized VBN N
CNT-group NNP N
were VBD N
examined VBN N
in IN N
comparison NN N
to TO N
a DT N
group NN N
of IN N
the DT N
same JJ N
size NN N
of IN N
patients NNS N
with IN N
hypertension NN 4_p
who WP N
were VBD N
managed VBN N
exclusively RB N
medicamentously RB N
for IN N
behaviour NN N
of IN N
blood NN N
pressure NN N
, , N
need NN N
of IN N
antihypertensive JJ N
drugs NNS N
and CC N
changes NNS N
of IN N
hypertension-associated JJ N
risk NN N
factors NNS N
. . N

After IN N
an DT N
exactly RB N
controlled VBN N
6-month JJ N
treatment NN N
hypertensives NNS 4_p
with IN N
additionally RB N
recommended VBN N
far-reaching NN N
CNT NNP N
showed VBD N
an DT N
economization NN N
of IN N
medicaments NNS N
by IN N
scarcely RB N
the DT N
half NN N
in IN N
comparison NN N
to TO N
the DT N
reference NN N
group NN N
. . N

By IN N
means NNS N
of IN N
suitable JJ N
control NN N
methods VBZ N
a DT N
causal JJ N
non-medicamentously RB N
conditioned JJ N
decrease NN N
of IN N
blood NN N
pressure NN N
could MD N
be VB N
excluded VBN N
. . N

A DT N
different JJ N
need NN N
of IN N
antihypertensive JJ N
drugs NNS N
was VBD N
simulated VBN N
by IN N
the DT N
exacter JJ N
intake NN N
of IN N
medicaments NNS N
in IN N
the DT N
index-patients NNS N
. . N

Notwithstanding VBG N
the DT N
metabolic JJ N
effects NNS N
of IN N
the DT N
additional JJ N
therapy NN N
have VBP N
induced VBN N
a DT N
positive JJ N
change NN N
of IN N
atherogenic JJ N
lipids NNS N
. . N

The DT N
examinations NNS N
indicate VBP N
in IN N
general JJ N
the DT N
difficulty NN N
of IN N
the DT N
judgement NN N
of IN N
efficacy NN N
of IN N
non-medicamentous JJ N
therapeutic JJ N
measures NNS N
in IN N
connection NN N
with IN N
a DT N
rational JJ N
dose-reduced JJ N
long-term JJ N
therapy NN N
with IN N
antihypertensive JJ N
drugs NNS N
. . N

-DOCSTART- -X- O O 10557909

Effect NN N
of IN N
guided JJ N
imagery NN N
on IN N
length NN N
of IN N
stay NN N
, , N
pain NN N
and CC N
anxiety NN N
in IN N
cardiac JJ 4_p
surgery NN 4_p
patients NNS 4_p
. . N

-DOCSTART- -X- O O 23229426

Does NNP N
single JJ N
use NN N
of IN N
an DT N
autologous JJ N
transfusion NN N
system NN N
in IN N
TKA NNP 4_p
reduce VB N
the DT N
need NN N
for IN N
allogenic JJ N
blood NN N
? . N
: : N
a DT N
prospective JJ N
randomized VBN N
trial NN N
. . N

BACKGROUND NNP N
Mechanical NNP N
autotransfusion NN N
systems NNS N
for IN N
washed JJ N
shed VBN N
blood NN N
( ( N
WSB NNP N
) ) N
were VBD N
introduced VBN N
to TO N
reduce VB N
the DT N
need NN N
for IN N
postoperative JJ N
allogenic JJ N
blood NN N
transfusions NNS N
( ( N
ABTs NNP N
) ) N
. . N

Although IN N
some DT N
authors NNS N
have VBP N
postulated VBN N
decreased JJ N
requirements NNS N
for IN N
ABT NNP N
by IN N
using VBG N
autologous JJ N
retransfusion NN N
devices NNS N
, , N
other JJ N
trials NNS N
, , N
mostly RB N
evaluating VBG N
retransfusion NN N
devices NNS N
for IN N
unwashed JJ N
shed VBN N
blood NN N
( ( N
USB NNP N
) ) N
, , N
verified VBD N
a DT N
small JJ N
or CC N
no DT N
benefit NN N
in IN N
reducing VBG N
the DT N
need NN N
for IN N
postoperative JJ N
ABT NNP N
. . N

Because IN N
of IN N
these DT N
contradictory JJ N
findings NNS N
it PRP N
is VBZ N
still RB N
unclear JJ N
whether IN N
autologous JJ N
retransfusion NN N
systems NNS N
for IN N
WSB NNP N
can MD N
reduce VB N
transfusion NN N
requirements NNS N
. . N

QUESTIONS/PURPOSES NNP N
We PRP N
therefore VBP N
asked VBD N
whether IN N
one CD N
such JJ N
autologous JJ N
transfusion NN N
system NN N
for IN N
WSB NNP N
can MD N
reduce VB N
the DT N
requirements NNS N
for IN N
postoperative JJ N
ABT NNP N
. . N

METHODS NNP N
In IN N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
controlled VBN N
study NN N
, , N
we PRP N
enrolled VBD N
151 CD N
patients NNS N
undergoing JJ N
TKA NNP 4_p
. . N

In IN N
Group NNP N
A NNP N
( ( N
n=76 JJ N
patients NNS N
) ) N
, , N
the DT N
autotransfusion NN N
system NN N
was VBD N
used VBN N
for IN N
a DT N
total NN N
of IN N
6 CD N
hours NNS N
( ( N
intraoperatively RB N
and CC N
postoperatively RB N
) ) N
and CC N
the DT N
WSB NNP N
was VBD N
retransfused VBN N
after IN N
processing VBG N
. . N

In IN N
Control NNP N
Group NNP N
B NNP N
( ( N
n=75 JJ N
patients NNS N
) ) N
, , N
a DT N
regular JJ N
drain NN N
without IN N
suction NN N
was VBD N
used VBN N
. . N

We PRP N
used VBD N
signs NNS N
of IN N
anemia NN N
and/or VBP N
a DT N
hemoglobin NN N
value NN N
less JJR N
than IN N
8 CD N
g/dL NN N
as IN N
indications NNS N
for IN N
transfusion NN N
. . N

If IN N
necessary JJ N
, , N
we PRP N
administered VBD N
one CD N
or CC N
two CD N
units NNS N
of IN N
allogenic JJ N
blood NN N
. . N

RESULTS NNP N
Twenty-three JJ N
patients NNS N
( ( N
33 CD N
% NN N
) ) N
in IN N
Group NNP N
A NNP N
, , N
who WP N
received VBD N
an DT N
average NN N
of IN N
283 CD N
mL NN N
( ( N
range NN N
, , N
160-406 JJ N
mL NN N
) ) N
of IN N
salvaged VBN N
blood NN N
, , N
needed VBD N
a DT N
mean NN N
of IN N
2.1 CD N
units NNS N
of IN N
allogenic JJ N
blood NN N
, , N
compared VBN N
with IN N
23 CD N
patients NNS N
( ( N
33 CD N
% NN N
) ) N
in IN N
Control NNP N
Group NNP N
B NNP N
who WP N
needed VBD N
a DT N
mean NN N
of IN N
2.1 CD N
units NNS N
of IN N
allogenic JJ N
blood NN N
. . N

CONCLUSIONS NNP N
We PRP N
found VBD N
the DT N
use NN N
of IN N
an DT N
autotransfusion NN N
system NN N
did VBD N
not RB N
reduce VB N
the DT N
rate NN N
of IN N
postoperative JJ N
ABTs NNP N
. . N

LEVEL NNP N
OF IN N
EVIDENCE NNP N
Level NNP N
II NNP N
, , N
therapeutic JJ N
study NN N
. . N

See VB N
the DT N
Guidelines NNP N
for IN N
Authors NNP N
for IN N
a DT N
complete JJ N
description NN N
of IN N
levels NNS N
of IN N
evidence NN N
. . N

-DOCSTART- -X- O O 16671415

Decompressive JJ N
craniectomy NN N
in IN N
traumatic JJ N
brain NN N
injury NN N
: : N
the DT N
randomized JJ N
multicenter NN N
RESCUEicp NNP N
study NN N
( ( N
www.RESCUEicp.com NN N
) ) N
. . N

The DT N
RESCUEicp NNP N
( ( N
Randomized NNP N
Evaluation NNP N
of IN N
Surgery NNP N
with IN N
Craniectomy NNP N
for IN N
Uncontrollable JJ N
Elevation NN N
of IN N
intracranial JJ N
pressure NN N
) ) N
study NN N
has VBZ N
been VBN N
established VBN N
to TO N
determine VB N
whether IN N
decompressive JJ N
craniectomy NN N
has VBZ N
a DT N
role NN N
in IN N
the DT N
management NN N
of IN N
patients NNS N
with IN N
traumatic JJ N
brain NN N
injury NN N
and CC N
raised VBD N
intracranial JJ N
pressure NN N
that WDT N
does VBZ N
not RB N
respond VB N
to TO N
initial JJ N
treatment NN N
measures NNS N
. . N

We PRP N
describe VBP N
the DT N
concept NN N
of IN N
decompressive JJ N
craniectomy NN N
in IN N
traumatic JJ N
brain NN N
injury NN N
and CC N
the DT N
rationale NN N
and CC N
protocol NN N
of IN N
the DT N
RESCUEicp NNP N
study NN N
. . N

-DOCSTART- -X- O O 7708953

The DT N
influence NN N
of IN N
breast NN N
size NN N
on IN N
late JJ N
radiation NN N
effects NNS N
and CC N
association NN N
with IN N
radiotherapy NN N
dose JJ N
inhomogeneity NN N
. . N

A DT N
prospective JJ N
assessment NN N
of IN N
late JJ N
changes NNS N
in IN N
breast NN N
appearance NN N
in IN N
559 CD N
patients NNS N
after IN 4_p
tumour JJ 4_p
excision NN 4_p
and CC 4_p
radiotherapy NN 4_p
for IN N
early JJ 4_p
breast NN 4_p
cancer NN 4_p
noted VBD N
a DT N
strong JJ N
association NN N
with IN N
breast NN N
size NN N
. . N

Only RB N
3/48 CD N
( ( N
6 CD N
% NN N
) ) N
patients NNS N
with IN N
small JJ N
breasts NNS N
developed VBD N
moderate JJ N
or CC N
severe JJ N
late JJ N
changes NNS N
compared VBN N
with IN N
94/423 CD N
( ( N
22 CD N
% NN N
) ) N
with IN N
medium NN N
sized VBN N
breasts NNS N
and CC N
34/88 CD N
( ( N
39 CD N
% NN N
) ) N
patients NNS N
with IN N
large JJ N
breasts NNS N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

One CD N
possibility NN N
is VBZ N
that IN N
greater JJR N
radiation NN N
changes NNS N
are VBP N
related VBN N
to TO N
greater JJR N
dose JJ N
inhomogeneity NN N
in IN N
women NNS N
with IN N
large JJ N
breasts NNS N
. . N

To TO N
explore VB N
this DT N
hypothesis NN N
, , N
radiation NN N
dose JJ N
distributions NNS N
were VBD N
assessed VBN N
in IN N
a DT N
separate JJ N
group NN N
of IN N
37 CD N
women NNS N
in IN N
whom WP N
three-level JJ N
transverse NN N
computer NN N
tomographic JJ N
images NNS N
of IN N
the DT N
breast NN N
in IN N
the DT N
treatment NN N
position NN N
were VBD N
available JJ N
. . N

A DT N
significant JJ N
correlation NN N
was VBD N
found VBN N
between IN N
breast NN N
size NN N
and CC N
dose NN N
inhomogeneity NN N
which WDT N
may MD N
account VB N
for IN N
the DT N
marked JJ N
changes NNS N
in IN N
breast NN N
appearance NN N
reported VBD N
in IN N
women NNS N
with IN N
large JJ N
breasts NNS N
. . N

-DOCSTART- -X- O O 6364880

Suppression NN N
of IN N
immediate JJ N
and CC N
late JJ N
anti-IgE-induced JJ N
skin NN N
reactions NNS N
by IN N
topically RB N
applied VBN N
alcohol/onion NN N
extract NN N
. . N

In IN N
a DT N
double JJ N
blind NN N
study NN N
, , N
alcohol/onion NN N
extract NN N
( ( N
5 CD N
% NN N
ethanol NN N
) ) N
was VBD N
injected VBN N
simultaneously RB N
with IN N
20 CD N
IU NNP N
and CC N
200 CD N
IU NNP N
rabbit NN N
anti-human-IgE JJ N
intradermally RB N
in IN N
12 CD N
adult NN 4_p
volunteers NNS 4_p
( ( 4_p
6 CD N
atopics NNS 4_p
, , 4_p
6 CD N
non-atopics NNS 4_p
) ) 4_p
. . 4_p

Diameters NNS N
of IN N
wheals NNS N
and CC N
flares NNS N
were VBD N
measured VBN N
10 CD N
min NN N
after IN N
and CC N
compared VBN N
with IN N
control NN N
sites NNS N
challenged VBD N
with IN N
20 CD N
IU NNP N
and CC N
200 CD N
IU NNP N
anti-IgE NN N
in IN N
a DT N
5 CD N
% NN N
ethanol JJ N
solution NN N
. . N

The DT N
skin NN N
sites NNS N
were VBD N
then RB N
treated VBN N
epidermally RB N
with IN N
45 CD N
% NN N
alcohol/onion NN N
extract NN N
and CC N
45 CD N
% NN N
ethanol NN N
under IN N
occlusion NN N
. . N

Diameters NNS N
of IN N
late JJ N
cutaneous JJ N
reactions NNS N
were VBD N
measured VBN N
hourly RB N
. . N

Oedema NNP N
formation NN N
was VBD N
clinically RB N
estimated VBN N
according VBG N
to TO N
an DT N
arbitrary JJ N
scale NN N
and CC N
skin NN N
thickness NN N
measured VBN N
with IN N
a DT N
calliper NN N
. . N

In IN N
the DT N
onion-treated JJ N
skin NN N
sites VBZ N
the DT N
wheal JJ N
areas NNS N
were VBD N
significantly RB N
reduced VBN N
( ( N
20 CD N
IU NNP N
: : N
control NN N
: : N
108 CD N
+/- JJ N
53 CD N
mm2 NN N
; : N
onion NN N
69 CD N
+/- JJ N
42 CD N
mm2 NN N
, , N
P NNP N
less JJR N
than IN N
0.05 CD N
; : N
200 CD N
IU NNP N
anti-IgE JJ N
: : N
control NN N
: : N
152 CD N
+/- JJ N
25 CD N
mm2 NN N
, , N
onion NN N
: : N
138 CD N
+/- JJ N
26 CD N
mm2 NN N
, , N
P NNP N
less JJR N
than IN N
0.02 CD N
) ) N
. . N

The DT N
oedema JJ N
formation NN N
during IN N
the DT N
late JJ N
phase NN N
skin JJ N
reaction NN N
was VBD N
markedly RB N
depressed JJ N
( ( N
P NNP N
less JJR N
than IN N
0.005 CD N
at IN N
2 CD N
h NN N
, , N
P NNP N
less JJR N
than IN N
0.01 CD N
at IN N
4 CD N
and CC N
6 CD N
h NN N
, , N
P NNP N
less JJR N
than IN N
0.02 CD N
at IN N
8 CD N
h NN N
) ) N
. . N

The DT N
extent NN N
of IN N
late JJ N
skin NN N
reactions NNS N
was VBD N
slightly RB N
, , N
but CC N
not RB N
significantly RB N
reduced VBN N
. . N

Obviously RB N
, , N
onions NNS N
contain VBP N
pharmacologically RB N
active JJ N
substances NNS N
with IN N
anti-inflammatory JJ N
and/or NN N
allergic NN N
properties NNS N
. . N

-DOCSTART- -X- O O 26138912

Predicting VBG N
Overall JJ N
Survival NNP N
After IN N
Stereotactic NNP N
Ablative NNP N
Radiation NNP N
Therapy NNP N
in IN N
Early-Stage NNP N
Lung NNP N
Cancer NNP N
: : N
Development NNP N
and CC N
External NNP N
Validation NNP N
of IN N
the DT N
Amsterdam NNP N
Prognostic NNP N
Model NNP N
. . N

PURPOSE VB N
A NNP N
prognostic JJ N
model NN N
for IN N
5-year JJ N
overall JJ N
survival NN N
( ( N
OS NNP N
) ) N
, , N
consisting VBG N
of IN N
recursive JJ N
partitioning NN N
analysis NN N
( ( N
RPA NNP N
) ) N
and CC N
a DT N
nomogram NN N
, , N
was VBD N
developed VBN N
for IN N
patients NNS N
with IN N
early-stage JJ 4_p
non-small JJ 4_p
cell NN 4_p
lung NN 4_p
cancer NN 4_p
( ( 4_p
ES-NSCLC NNP 4_p
) ) 4_p
treated VBD 4_p
with IN 4_p
stereotactic JJ 4_p
ablative JJ 4_p
radiation NN 4_p
therapy NN 4_p
( ( 4_p
SABR NNP 4_p
) ) 4_p
. . N

METHODS NNP N
AND NNP N
MATERIALS NNP N
A NNP N
primary JJ N
dataset NN N
of IN N
703 CD N
ES-NSCLC JJ 4_p
SABR NNP 4_p
patients NNS N
was VBD N
randomly RB N
divided VBN N
into IN N
a DT N
training NN N
( ( N
67 CD N
% NN N
) ) N
and CC N
an DT N
internal JJ N
validation NN N
( ( N
33 CD N
% NN N
) ) N
dataset NN N
. . N

In IN N
the DT N
former JJ N
group NN N
, , N
21 CD N
unique JJ N
parameters NNS N
consisting VBG N
of IN N
patient NN N
, , N
treatment NN N
, , N
and CC N
tumor NN N
factors NNS N
were VBD N
entered VBN N
into IN N
an DT N
RPA NNP N
model NN N
to TO N
predict VB N
OS NNP N
. . N

Univariate NNP N
and CC N
multivariate NN N
models NNS N
were VBD N
constructed VBN N
for IN N
RPA-selected JJ N
factors NNS N
to TO N
evaluate VB N
their PRP$ N
relationship NN N
with IN N
OS NNP N
. . N

A DT N
nomogram NN N
for IN N
OS NNP N
was VBD N
constructed VBN N
based VBN N
on IN N
factors NNS N
significant JJ N
in IN N
multivariate NN N
modeling NN N
and CC N
validated VBN N
with IN N
calibration NN N
plots NNS N
. . N

Both CC N
the DT N
RPA NNP N
and CC N
the DT N
nomogram NN N
were VBD N
externally RB N
validated VBN N
in IN N
independent JJ N
surgical JJ N
( ( N
n JJ N
= NNP N
193 CD N
) ) N
and CC N
SABR NNP N
( ( N
n JJ N
= NNP N
543 CD N
) ) N
datasets NNS N
. . N

RESULTS NNP N
RPA NNP N
identified VBD N
2 CD N
distinct JJ N
risk NN N
classes NNS N
based VBN N
on IN N
tumor NN N
diameter NN N
, , N
age NN N
, , N
World NNP N
Health NNP N
Organization NNP N
performance NN N
status NN N
( ( N
PS NNP N
) ) N
and CC N
Charlson NNP N
comorbidity NN N
index NN N
. . N

This DT N
RPA NNP N
had VBD N
moderate JJ N
discrimination NN N
in IN N
SABR NNP N
datasets NNS N
( ( N
c-index NN N
range NN N
: : N
0.52-0.60 JJ N
) ) N
but CC N
was VBD N
of IN N
limited JJ N
value NN N
in IN N
the DT N
surgical JJ N
validation NN N
cohort NN N
. . N

The DT N
nomogram JJ N
predicting NN N
OS NNP N
included VBD N
smoking VBG N
history NN N
in IN N
addition NN N
to TO N
RPA-identified JJ N
factors NNS N
. . N

In IN N
contrast NN N
to TO N
RPA NNP N
, , N
validation NN N
of IN N
the DT N
nomogram NN N
performed VBN N
well RB N
in IN N
internal JJ N
validation NN N
( ( N
r NN N
( ( N
2 CD N
) ) N
= FW N
0.97 CD N
) ) N
and CC N
external JJ N
SABR NNP N
( ( N
r NN N
( ( N
2 CD N
) ) N
= FW N
0.79 CD N
) ) N
and CC N
surgical JJ N
cohorts NNS N
( ( N
r NN N
( ( N
2 CD N
) ) N
= FW N
0.91 CD N
) ) N
. . N

CONCLUSIONS VB N
The DT N
Amsterdam NNP N
prognostic JJ N
model NN N
is VBZ N
the DT N
first JJ N
externally RB N
validated VBN N
prognostication NN N
tool NN N
for IN N
OS NNP N
in IN N
ES-NSCLC NNP N
treated VBD N
with IN N
SABR NNP N
available JJ N
to TO N
individualize VB N
patient JJ N
decision NN N
making NN N
. . N

The DT N
nomogram NN N
retained VBD N
strong JJ N
performance NN N
across IN N
surgical JJ N
and CC N
SABR NNP N
external JJ N
validation NN N
datasets NNS N
. . N

RPA NNP N
performance NN N
was VBD N
poor JJ N
in IN N
surgical JJ N
patients NNS N
, , N
suggesting VBG N
that IN N
2 CD N
different JJ N
distinct JJ N
patient NN N
populations NNS N
are VBP N
being VBG N
treated VBN N
with IN N
these DT N
2 CD N
effective JJ N
modalities NNS N
. . N

-DOCSTART- -X- O O 22884754

Effect NN N
of IN N
antipsychotic JJ N
drugs NNS N
on IN N
cortical JJ N
thickness NN N
. . N

A DT N
randomized JJ N
controlled VBN N
one-year JJ N
follow-up NN N
study NN N
of IN N
haloperidol NN N
, , N
risperidone NN N
and CC N
olanzapine NN N
. . N

BACKGROUND NNP N
Imaging NNP N
evidence NN N
indicates VBZ N
that IN N
brain NN N
alterations NNS N
are VBP N
primary JJ N
to TO N
the DT N
full-blown JJ N
onset NN N
of IN N
schizophrenia NN N
and CC N
seem VBP N
to TO N
progress VB N
across IN N
time NN N
. . N

The DT N
potential JJ N
effects NNS N
of IN N
antipsychotic JJ N
medication NN N
on IN N
brain NN N
structure NN N
represent VBP N
a DT N
key JJ N
factor NN N
in IN N
understanding VBG N
brain NN N
changes NNS N
in IN N
psychosis NN N
. . N

We PRP N
aimed VBD N
to TO N
investigate VB N
the DT N
effects NNS N
of IN N
low JJ N
doses NNS N
of IN N
haloperidol NN N
, , N
risperidone NN N
and CC N
olanzapine NN N
on IN N
cortical JJ N
thickness NN N
. . N

METHOD NNP N
We PRP N
investigated VBD N
the DT N
effects NNS N
of IN N
risperidone NN 4_p
( ( N
N=16 NNP N
) ) N
, , N
olanzapine JJ 4_p
( ( N
N=18 NNP N
) ) N
and CC N
low JJ N
doses NNS N
of IN N
haloperidol NN 4_p
( ( N
N=18 NNP N
) ) N
in IN N
cortical JJ N
thickness NN N
changes NNS N
during IN N
1-year JJ N
follow-up JJ N
period NN N
in IN N
a DT N
large JJ N
and CC N
heterogeneous JJ N
sample NN N
of IN N
schizophrenia NN 4_p
spectrum NN 4_p
patients NNS N
. . N

The DT N
relationship NN N
between IN N
cortical JJ N
thickness NN N
changes NNS N
and CC N
clinical JJ N
and CC N
cognitive JJ N
outcome NN N
was VBD N
also RB N
assessed VBN N
. . N

A DT N
group NN N
of IN N
45 CD N
healthy JJ 4_p
volunteers NNS N
was VBD N
also RB N
longitudinally RB N
evaluated VBN N
. . N

Magnetic JJ N
resonance NN N
imaging VBG N
brain NN N
scans NNS N
( ( N
1.5T CD N
) ) N
were VBD N
obtained VBN N
and CC N
images NNS N
were VBD N
analyzed VBN N
by IN N
using VBG N
BRAINS2 NNP N
. . N

RESULTS NNP N
There EX N
were VBD N
no DT N
significant JJ N
effects NNS N
of IN N
time NN N
( ( N
F NNP N
( ( N
1,47 CD N
) ) N
< NN N
1.66 CD N
; : N
P NNP N
> NNP N
0.204 CD N
) ) N
, , N
treatment NN N
group NN N
( ( N
F NNP N
( ( N
2,47 CD N
) ) N
< NN N
1.47 CD N
; : N
P NNP N
> NNP N
0.242 CD N
) ) N
or CC N
group-by-time JJ N
interaction NN N
( ( N
F NNP N
( ( N
2,47 CD N
) ) N
< NN N
1.82 CD N
; : N
P NNP N
> NNP N
0.174 CD N
) ) N
for IN N
any DT N
of IN N
the DT N
cortical JJ N
thickness NN N
variables NNS N
. . N

When WRB N
the DT N
group NN N
of IN N
healthy JJ N
controls NNS N
was VBD N
included VBN N
in IN N
the DT N
analyses NNS N
, , N
it PRP N
is VBZ N
of IN N
note NN N
that IN N
group-by-time JJ N
interaction NN N
showed VBD N
a DT N
significant JJ N
result NN N
for IN N
the DT N
frontal JJ N
lobe NN N
at IN N
trend NN N
level NN N
( ( N
F NNP N
( ( N
3,81 CD N
) ) N
=2.686 NN N
; : N
P=0.052 NNP N
) ) N
. . N

After IN N
the DT N
Bonferroni NNP N
adjustment NN N
for IN N
multiple JJ N
comparisons NNS N
, , N
there EX N
were VBD N
no DT N
significant JJ N
associations NNS N
between IN N
changes NNS N
in IN N
cortical JJ N
thickness NN N
and CC N
clinical JJ N
and CC N
cognitive JJ N
outcome NN N
. . N

CONCLUSIONS NNP N
Low NNP N
doses NNS N
of IN N
haloperidol NN N
, , N
risperidone NN N
, , N
and CC N
olanzapine NN N
seem VBP N
to TO N
equally RB N
affect VB N
gray JJ N
matter NN N
cortical JJ N
thickness NN N
, , N
overall JJ N
and CC N
lobes JJ N
, , N
at IN N
the DT N
medium-term NN N
( ( N
1 CD N
year NN N
) ) N
. . N

The DT N
clinical JJ N
effectiveness NN N
of IN N
treatments NNS N
was VBD N
not RB N
significantly RB N
related VBN N
to TO N
changes NNS N
in IN N
cortical JJ N
thickness NN N
. . N

-DOCSTART- -X- O O 11699803

Multisite NNP N
, , N
double-blind NN N
, , N
placebo-controlled JJ N
trial NN N
of IN N
porcine NN N
secretin NN N
in IN N
autism NN 4_p
. . N

OBJECTIVE UH N
To TO N
examine VB N
the DT N
efficacy NN N
of IN N
intravenous JJ N
porcine NN N
secretin NN N
for IN N
the DT N
treatment NN N
of IN N
autistic JJ 4_p
disorder NN 4_p
. . 4_p

METHOD NNP N
Randomized NNP N
, , N
double-blind NN N
, , N
placebo-controlled JJ N
, , N
crossover JJ N
design NN N
. . N

Fifty-six JJ N
subjects NNS N
with IN N
autistic JJ 4_p
disorder NN 4_p
received VBD N
either CC N
a DT N
secretin NN N
or CC N
placebo NN N
infusion NN N
at IN N
baseline NN N
and CC N
the DT N
other JJ N
substance NN N
at IN N
week NN N
4 CD N
. . N

Subjects NNS N
were VBD N
given VBN N
the DT N
Autism NNP N
Diagnostic NNP N
Observation NNP N
Schedule NNP N
( ( N
ADOS NNP N
) ) N
and CC N
other JJ N
pertinent JJ N
developmental JJ N
measures NNS N
at IN N
baseline NN N
and CC N
at IN N
weeks NNS N
4 CD N
and CC N
8 CD N
to TO N
assess VB N
drug NN N
effects NNS N
. . N

RESULTS NNP N
For IN N
the DT N
primary JJ N
efficacy NN N
analysis NN N
, , N
change NN N
of IN N
ADOS NNP N
social-communication NN N
total JJ N
score NN N
from IN N
week NN N
0 CD N
to TO N
week NN N
4 CD N
, , N
no DT N
statistically RB N
significant JJ N
difference NN N
was VBD N
obtained VBN N
between IN N
placebo NN N
( ( N
-0.8 JJ N
+/- JJ N
2.9 CD N
) ) N
and CC N
secretin JJ N
groups NNS N
( ( N
-0.6 JJ N
+/- JJ N
1.4 CD N
; : N
t54 NN N
= VBZ N
0.346 CD N
, , N
p NN N
< NNP N
.73 NNP N
) ) N
. . N

The DT N
other JJ N
measures NNS N
showed VBD N
no DT N
treatment NN N
effect NN N
for IN N
secretin NN N
compared VBN N
with IN N
placebo NN N
. . N

CONCLUSION NNP N
There EX N
was VBD N
no DT N
evidence NN N
for IN N
efficacy NN N
of IN N
secretin NN N
in IN N
this DT N
randomized JJ N
, , N
placebo-controlled JJ N
, , N
double-blind JJ N
trial NN N
. . N

-DOCSTART- -X- O O 22039290

Armodafinil NNP N
and CC N
modafinil NN N
in IN N
patients NNS N
with IN N
excessive JJ 4_p
sleepiness NN 4_p
associated VBN N
with IN N
shift NN N
work NN N
disorder NN N
: : N
a DT N
pharmacokinetic/pharmacodynamic JJ N
model NN N
for IN N
predicting VBG N
and CC N
comparing VBG N
their PRP$ N
concentration-effect JJ N
relationships NNS N
. . N

Armodafinil NNP N
, , N
the DT N
longer JJR N
lasting JJ N
R-isomer NNP N
of IN N
racemic JJ N
modafinil NN N
, , N
improves VBZ N
wakefulness NN N
in IN N
patients NNS N
with IN N
excessive JJ 4_p
sleepiness NN 4_p
associated VBN N
with IN N
shift NN 4_p
work NN 4_p
disorder NN 4_p
( ( N
SWD NNP N
) ) N
. . N

Pharmacokinetic JJ N
studies NNS N
suggest VBP N
that IN N
armodafinil NN N
achieves VBZ N
higher JJR N
plasma NN N
concentrations NNS N
than IN N
modafinil NN N
late JJ N
in IN N
a DT N
dose JJ N
interval NN N
following VBG N
equal JJ N
oral JJ N
doses NNS N
. . N

Pooled VBN N
Multiple JJ N
Sleep NNP N
Latency NNP N
Test NNP N
( ( N
MSLT NNP N
) ) N
data NN N
from IN N
2 CD N
randomized NNS N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
trials NNS N
in IN N
463 CD N
patients NNS N
with IN N
SWD NNP 4_p
, , N
1 CD N
with IN N
armodafinil JJ N
150 CD N
mg/d NN N
and CC N
1 CD N
with IN N
modafinil NN N
200 CD N
mg/d NN N
( ( N
both DT N
administered VBN N
around IN N
2200 CD N
h NN N
before IN N
night NN N
shifts NNS N
) ) N
, , N
were VBD N
used VBN N
to TO N
build VB N
a DT N
pharmacokinetic/pharmacodynamic JJ N
model NN N
. . N

Predicted VBN N
plasma JJ N
drug NN N
concentrations NNS N
were VBD N
obtained VBN N
by IN N
developing VBG N
and CC N
applying VBG N
a DT N
population NN N
pharmacokinetic JJ N
model NN N
using VBG N
nonlinear JJ N
mixed-effects NNS N
modeling VBG N
. . N

Armodafinil $ N
200 CD N
mg NN N
produced VBD N
a DT N
plasma JJ N
concentration NN N
above IN N
the DT N
EC NNP N
( ( N
50 CD N
) ) N
( ( N
4.6 CD N
µg/mL NN N
) ) N
for IN N
9 CD N
hours NNS N
, , N
whereas NNS N
modafinil VBP N
200 CD N
mg NN N
did VBD N
not RB N
exceed VB N
the DT N
EC NNP N
( ( N
50 CD N
) ) N
. . N

Consequently RB N
, , N
armodafinil NN N
produced VBD N
greater JJR N
increases NNS N
in IN N
predicted JJ N
placebo-subtracted JJ N
MSLT NNP N
times NNS N
of IN N
0.5-1 JJ N
minute NN N
( ( N
up IN N
to TO N
10 CD N
hours NNS N
after IN N
dosing VBG N
) ) N
compared VBN N
with IN N
modafinil NN N
. . N

On IN N
a DT N
milligram-to-milligram JJ N
basis NN N
, , N
armodafinil RB N
200 CD N
mg NNS N
consistently RB N
increased VBD N
wakefulness RB N
more RBR N
than IN N
modafinil RB N
200 CD N
mg NNS N
, , N
including VBG N
times NNS N
late RB N
in IN N
the DT N
8-hour JJ N
shift NN N
. . N

-DOCSTART- -X- O O 1741218

Acute NNP N
prolactin NN N
and CC N
oxytocin JJ N
responses NNS N
and CC N
milk NN N
yield NN N
to TO N
infant VB N
suckling NN N
and CC N
artificial JJ N
methods NNS N
of IN N
expression NN N
in IN N
lactating VBG N
women NNS N
. . N

Breast-feeding NN N
is VBZ N
today NN N
the DT N
major JJ N
form NN N
of IN N
infant JJ N
nutrition NN N
in IN N
the DT N
immediate JJ N
postpartum NN N
period NN N
. . N

Despite IN N
this DT N
, , N
recent JJ N
trends NNS N
in IN N
modern JJ N
life-styles NNS N
have VBP N
raised VBN N
obstacles NNS N
to TO N
successful JJ N
lactation NN N
. . N

These DT N
include VBP N
infant NN N
illness NN N
and CC N
maternal JJ N
responsibilities NNS N
outside IN N
the DT N
home NN N
, , N
both DT N
requiring VBG N
separation NN N
from IN N
the DT N
mother NN N
. . N

While IN N
the DT N
hormonal JJ N
dynamics NNS N
of IN N
infant JJ N
suckling NN N
are VBP N
understood JJ N
, , N
little JJ N
is VBZ N
known VBN N
about IN N
the DT N
effects NNS N
of IN N
artificial JJ N
methods NNS N
of IN N
milk NN N
expression NN N
. . N

A DT N
variety NN N
of IN N
breast NN N
pumps NNS N
exist VBP N
in IN N
the DT N
current JJ N
US NNP N
market NN N
which WDT N
vary VBP N
considerably RB N
in IN N
price NN N
and CC N
effectiveness NN N
. . N

To TO N
understand VB N
better JJR N
the DT N
ability NN N
of IN N
these DT N
pumps NNS N
to TO N
assist VB N
women NNS N
in IN N
the DT N
maintenance NN N
of IN N
lactation NN N
, , N
the DT N
current JJ N
study NN N
was VBD N
undertaken VBN N
to TO N
evaluate VB N
their PRP$ N
effects NNS N
on IN N
milk NN N
yield NN N
and CC N
prolactin NN N
and CC N
oxytocin NN N
release NN N
when WRB N
compared VBN N
to TO N
natural JJ N
infant NN N
suckling NN N
. . N

Twenty-three JJ N
women NNS 4_p
who WP N
were VBD N
exclusively RB N
breast-feeding VBG N
their PRP$ N
infants NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
serially RB N
use VB N
several JJ N
pumping VBG N
methods NNS N
, , N
as RB N
well RB N
as IN N
infant NN N
suckling NN N
, , N
with IN N
blood NN N
being VBG N
taken VBN N
at IN N
10-minute JJ N
intervals NNS N
to TO N
determine VB N
the DT N
hormonal JJ N
responses NNS N
. . N

The DT N
results NNS N
reveal VBP N
variability NN N
in IN N
the DT N
prolactin NN N
responses VBZ N
to TO N
the DT N
artificial JJ N
pumping NN N
methods NNS N
, , N
with IN N
the DT N
greatest JJS N
responses NNS N
found VBN N
with IN N
an DT N
electric JJ N
pulsatile NN N
pump NN N
; : N
these DT N
responses NNS N
compare VBP N
favorably RB N
with IN N
those DT N
of IN N
natural JJ N
infant NN N
suckling NN N
. . N

Other JJ N
methods NNS N
were VBD N
less RBR N
successful JJ N
in IN N
causing VBG N
prolactin JJ N
elevations NNS N
. . N

No DT N
differences NNS N
were VBD N
seen VBN N
among IN N
the DT N
methods NNS N
in IN N
the DT N
oxytocin JJ N
response NN N
. . N

The DT N
results NNS N
of IN N
this DT N
study NN N
demonstrate VB N
striking JJ N
differences NNS N
in IN N
the DT N
ability NN N
of IN N
breast-pumping JJ N
methods NNS N
to TO N
produce VB N
an DT N
acute NN N
and CC N
sustained VBD N
prolactin NNS N
rise NN N
in IN N
breast-feeding JJ N
mothers NNS N
. . N

The DT N
large JJ N
discrepancies NNS N
found VBD N
suggest VBP N
the DT N
need NN N
for IN N
further JJ N
studies NNS N
in IN N
to TO N
enable JJ N
women NNS N
and CC N
health NN N
care NN N
providers NNS N
to TO N
choose VB N
the DT N
most RBS N
appropriate JJ N
method NN N
for IN N
milk NN N
expression NN N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -X- O O 9704200

Postoperative JJ N
injection NN N
of IN N
phenylbutazone NN N
does VBZ N
not RB N
influence VB N
fibrinolytic JJ N
shutdown NN N
. . N

Twenty-nine JJ N
patients NNS N
undergoing VBG N
cholecystectomy NN N
because IN N
of IN N
chronic JJ 4_p
calculous JJ 4_p
cholecystitis NN 4_p
were VBD N
randomised VBN N
to TO N
receive VB N
phenylbutazone NN N
10 CD N
mg/kg NN N
intramuscularly RB N
or CC N
a DT N
control NN N
injection NN N
( ( N
vehicle-containing JJ N
local JJ N
anaesthetic NN N
) ) N
immediately RB N
after IN N
completion NN N
of IN N
surgery NN N
. . N

Fibrinogen NNP N
and CC N
plasminogen NN N
concentrations NNS N
in IN N
plasma NN N
, , N
plasminogen NN N
activator NN N
inhibitor NN N
activity NN N
in IN N
plasma NN N
and CC N
fibrinolytic JJ N
activity NN N
in IN N
concentrated JJ N
euglobulins NNS N
were VBD N
determined VBN N
before IN N
surgery NN N
and CC N
on IN N
the DT N
first JJ N
, , N
third JJ N
and CC N
seventh JJ N
postoperative JJ N
days NNS N
. . N

Phenylbutazone NNP N
delayed VBD N
the DT N
postoperative JJ N
rise NN N
of IN N
fibrinogen NN N
concentration NN N
and CC N
reduced VBD N
the DT N
plasminogen NN N
level NN N
on IN N
the DT N
first JJ N
day NN N
after IN N
surgery NN N
. . N

Fibrinolytic JJ N
activity NN N
in IN N
euglobulins NNS N
was VBD N
decreased VBN N
after IN N
the DT N
operation NN N
in IN N
both DT N
groups NNS N
. . N

The DT N
great JJ N
dispersion NN N
of IN N
the DT N
results NNS N
of IN N
plasminogen NN N
activator NN N
inhibitor NN N
activity NN N
was VBD N
the DT N
plausible JJ N
cause NN N
of IN N
the DT N
lack NN N
of IN N
any DT N
significant JJ N
difference NN N
in IN N
this DT N
variable JJ N
. . N

The DT N
postoperative JJ N
fibrinolytic JJ N
shutdown NN N
, , N
reflected VBN N
by IN N
the DT N
decrease NN N
of IN N
fibrinolytic JJ N
activity NN N
, , N
was VBD N
unaffected VBN N
by IN N
phenylbutazone NN N
. . N

It PRP N
can MD N
be VB N
speculated VBN N
, , N
however RB N
, , N
that IN N
the DT N
decline NN N
of IN N
plasminogen NN N
concentration NN N
after IN N
surgery NN N
in IN N
patients NNS N
receiving VBG N
this DT N
drug NN N
was VBD N
the DT N
result NN N
of IN N
its PRP$ N
stimulatory JJ N
influence NN N
on IN N
the DT N
conversion NN N
of IN N
plasminogen NN N
into IN N
plasmin NN N
. . N

-DOCSTART- -X- O O 25350539

Matching VBG N
doses NNS N
of IN N
distraction NN N
with IN N
child NN N
risk NN 4_p
for IN 4_p
distress NN 4_p
during IN N
a DT N
medical JJ N
procedure NN N
: : N
a DT N
randomized JJ N
clinical JJ N
trial NN N
. . N

BACKGROUND NNP N
Parents NNPS N
often RB N
want VBP N
to TO N
provide VB N
support NN N
to TO N
their PRP$ N
children NNS N
during IN N
medical JJ N
procedures NNS N
, , N
but CC N
not RB N
all DT N
parents NNS N
are VBP N
effective JJ N
in IN N
providing VBG N
distraction NN N
after IN N
brief JJ N
training NN N
. . N

OBJECTIVE CC N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
effects NNS N
of IN N
three CD N
doses NNS N
of IN N
distraction NN N
intervention NN N
for IN N
children NNS N
at IN N
high JJ 4_p
and CC 4_p
medium NN 4_p
risk NN 4_p
for IN 4_p
procedure-related JJ 4_p
distress NN 4_p
. . N

METHODS NNP N
Children NNP N
undergoing VBG N
scheduled VBN 4_p
intravenous JJ 4_p
insertions NNS 4_p
for IN 4_p
diagnostic JJ 4_p
or CC 4_p
treatment NN 4_p
purposes NNS 4_p
and CC N
their PRP$ N
parents NNS N
participated VBN N
. . N

A DT N
computerized JJ N
application NN N
, , N
Children NNP N
, , N
Parents NNP N
and CC N
Distraction NNP N
, , N
was VBD N
used VBN N
to TO N
predict VB N
distress NN N
risk NN N
. . N

Doses NNS N
of IN N
intervention NN N
were VBD N
basic JJ N
( ( N
parents NNS N
trained VBN N
on IN N
providing VBG N
distraction NN N
) ) N
, , N
enhanced VBN N
( ( N
basic JJ N
training NN N
plus CC N
tailored JJ N
instructions NNS N
, , N
environmental JJ N
modifications NNS N
, , N
and CC N
support NN N
and CC N
guidance NN N
from IN N
the DT N
research NN N
assistant NN N
) ) N
, , N
and CC N
professional JJ N
( ( N
a DT N
trained VBN N
research NN N
assistant NN N
provided VBD N
distraction NN N
) ) N
. . N

Outcome JJ N
measures NNS N
were VBD N
Observational NNP N
Scale NNP N
of IN N
Behavioral NNP N
Distress-Revised JJ N
for IN N
behavioral JJ N
distress NN N
, , N
Oucher NNP N
for IN N
self-reported JJ N
pain NN N
, , N
parent JJ N
report NN N
of IN N
child JJ N
distress NN N
, , N
and CC N
salivary JJ N
cortisol NN N
for IN N
physiological JJ N
distress NN N
. . N

RESULTS VB N
A DT N
total NN N
of IN N
574 CD N
children NNS N
, , N
ages VBZ N
4-10 JJ N
, , N
and CC N
their PRP$ N
parents NNS N
participated VBN N
. . N

The DT N
Children NNP N
, , N
Parents NNP N
and CC N
Distraction NNP N
predicted VBD N
that IN N
the DT N
risk NN N
for IN N
distress NN N
was VBD N
high JJ N
for IN N
156 CD N
children NNS N
, , N
medium NN N
for IN N
372 CD N
, , N
and CC N
low JJ N
for IN N
46 CD N
. . N

Children NNP N
predicted VBD N
to TO N
have VB N
higher JJR N
risk NN N
for IN N
distress NN N
displayed VBD N
more RBR N
behavioral JJ N
distress NN N
( ( N
p JJ N
< NNP N
.01 NNP N
) ) N
. . N

Children NNP N
in IN N
the DT N
medium-risk JJ N
group NN N
who WP N
had VBD N
the DT N
professional JJ N
intervention NN N
displayed VBD N
significantly RB N
less RBR N
behavioral JJ N
distress NN N
( ( N
p JJ N
< NNP N
.001 NNP N
) ) N
. . N

Children NNP N
in IN N
the DT N
high-risk JJ N
group NN N
tended VBD N
to TO N
have VB N
less JJR N
behavioral JJ N
distress NN N
when WRB N
receiving VBG N
the DT N
professional JJ N
intervention NN N
( ( N
p JJ N
= NNP N
.07 NNP N
) ) N
. . N

There EX N
were VBD N
no DT N
significant JJ N
group NN N
differences NNS N
for IN N
self-report NN N
of IN N
pain NN N
, , N
parent JJ N
report NN N
of IN N
distress NN N
, , N
or CC N
cortisol NN N
levels NNS N
. . N

DISCUSSION NNP N
Some DT N
parents NNS N
may MD N
need VB N
additional JJ N
training NN N
in IN N
providing VBG N
distraction NN N
to TO N
their PRP$ N
children NNS N
during IN N
procedures NNS N
, , N
and CC N
some DT N
children NNS 4_p
at IN 4_p
medium NN 4_p
and CC 4_p
high JJ 4_p
risk NN 4_p
for IN 4_p
distress NN 4_p
may MD N
need VB N
professional JJ N
support NN N
. . N

Parents NNS N
should MD N
be VB N
asked VBN N
about IN N
their PRP$ N
preferences NNS N
in IN N
acting VBG N
as IN N
the DT N
distraction NN N
coach NN N
and CC N
, , N
if IN N
willing JJ N
, , N
be VB N
provided VBN N
as IN N
much JJ N
training NN N
and CC N
support NN N
as IN N
possible JJ N
in IN N
the DT N
clinical JJ N
situation NN N
. . N

-DOCSTART- -X- O O 8169405

Multidose NNP N
, , N
live VBP N
attenuated VBN N
, , N
cold-recombinant JJ N
, , N
trivalent JJ N
influenza NN N
vaccine NN N
in IN N
infants NNS N
and CC N
young JJ N
children NNS N
. . N

Twenty-two NNP N
healthy JJ 4_p
infants NNS N
and CC N
children NNS N
received VBD N
either DT N
cold-recombinant JJ N
, , N
trivalent JJ N
influenza NN N
vaccine NN N
or CC N
placebo NN N
in IN N
a DT N
three-dose JJ N
vaccine NN N
trial NN N
. . N

Most JJS N
( ( N
82 CD N
% NN N
) ) N
who WP N
received VBD N
vaccine NN N
were VBD N
seronegative JJ N
to TO N
all DT N
three CD N
vaccine NN N
strains NNS N
( ( N
10 CD N
( ( N
6 CD N
) ) N
TCID50/dose NNP N
each DT N
) ) N
: : N
A/Kawasaki/9/86 NNP N
( ( N
H1N1 NNP N
) ) N
, , N
A/Los NNP N
Angeles/2/87 NNP N
( ( N
H3N2 NNP N
) ) N
, , N
and CC N
B/Yamagata/16/88 NNP N
. . N

Vaccine NNP N
was VBD N
administered VBN N
intranasally RB N
at IN N
time NN N
0 CD N
and CC N
2 CD N
and CC N
4 CD N
months NNS N
later RB N
. . N

The DT N
vaccine NN N
was VBD N
well RB N
tolerated VBN N
and CC N
immunogenic JJ N
when WRB N
administered VBN N
in IN N
a DT N
multidose JJ N
regimen NNS N
. . N

The DT N
first JJ N
dose NN N
stimulated VBN N
antibody NN N
to TO N
H1 NNP N
, , N
H3 NNP N
, , N
and CC N
B NNP N
in IN N
59 CD N
% NN N
, , N
94 CD N
% NN N
, , N
and CC N
35 CD N
% NN N
of IN N
vaccinees NNS N
, , N
respectively RB N
, , N
by IN N
hemagglutination NN N
inhibition NN N
( ( N
HAI NNP N
) ) N
or CC N
ELISA NNP N
. . N

After IN N
two CD N
doses NNS N
of IN N
vaccine NN N
, , N
93 CD N
% NN N
, , N
93 CD N
% NN N
, , N
and CC N
80 CD N
% NN N
had VBD N
antibody VBN N
by IN N
HAI NNP N
or CC N
ELISA NNP N
to TO N
H1 NNP N
, , N
H3 NNP N
, , N
and CC N
B NNP N
, , N
respectively RB N
. . N

Most JJS N
vaccinees NNS N
( ( N
67 CD N
% NN N
) ) N
responded VBD N
to TO N
all DT N
three CD N
viruses NNS N
after IN N
two CD N
doses NNS N
of IN N
vaccine NN N
. . N

The DT N
third JJ N
dose NN N
contributed VBD N
little JJ N
to TO N
the DT N
vaccine NN N
's POS N
immunogenicity NN N
. . N

Multidose NNP N
trivalent JJ N
influenza NN N
vaccine NN N
is VBZ N
safe JJ N
and CC N
induces VBZ N
an DT N
immune JJ N
response NN N
in IN N
most JJS N
vaccinees NNS N
after IN N
two CD N
doses NNS N
. . N

-DOCSTART- -X- O O 3430295

Comparison NNP N
of IN N
ketoconazole NN N
and CC N
griseofulvin NN N
in IN N
the DT N
treatment NN N
of IN N
tinea NN 4_p
pedis NN 4_p
. . N

Twenty-nine JJ N
patients NNS N
with IN N
mycologically RB N
proven VBN N
tinea NN 4_p
pedis NNS 4_p
were VBD N
randomly RB N
allocated VBN N
to TO N
oral JJ N
treatment NN N
with IN N
either DT N
ketoconazole JJ N
200 CD N
mg JJ N
daily JJ N
or CC N
griseofulvin JJ N
1 CD N
g JJ N
daily RB N
for IN N
a DT N
period NN N
of IN N
up IN N
to TO N
8 CD N
weeks NNS N
. . N

Mycological JJ N
cure NN N
rate NN N
at IN N
4 CD N
weeks NNS N
was VBD N
33 CD N
% NN N
for IN N
ketoconazole NN N
and CC N
29 CD N
% NN N
for IN N
griseofulvin NN N
, , N
and CC N
at IN N
8 CD N
weeks NNS N
was VBD N
53 CD N
% NN N
and CC N
57 CD N
% NN N
respectively RB N
. . N

The DT N
efficacy NN N
of IN N
both DT N
drugs NNS N
in IN N
the DT N
treatment NN N
of IN N
interdigital JJ N
tinea NN N
pedis NN N
is VBZ N
similar JJ N
, , N
and CC N
is VBZ N
considerably RB N
lower JJR N
than IN N
that DT N
found VBD N
with IN N
topical JJ N
imidazole NN N
preparations NNS N
where WRB N
cure NN N
rates NNS N
of IN N
over IN N
70 CD N
% NN N
are VBP N
generally RB N
expected VBN N
. . N

-DOCSTART- -X- O O 1884668

Levels NNS N
of IN N
opioid JJ 4_p
physical JJ 4_p
dependence NN 4_p
in IN N
heroin NN 4_p
addicts NNS 4_p
. . N

The DT N
levels NNS N
of IN N
opioid JJ N
physical JJ N
dependence NN N
in IN N
a DT N
group NN N
of IN N
long-term JJ N
heroin NN 4_p
addicts NNS 4_p
were VBD N
ascertained VBN N
by IN N
measuring VBG N
the DT N
severity NN N
of IN N
the DT N
opioid JJ N
withdrawal NN N
syndrome NN N
before IN N
and CC N
after IN N
pharmacological JJ N
challenge NN N
with IN N
either DT N
0.4 CD N
mg NN N
naloxone NN N
or CC N
placebo NN N
. . N

Prior NNP N
to TO N
challenge VB N
, , N
patients NNS N
manifested VBD N
some DT N
subjective JJ N
symptoms NNS N
but CC N
few JJ N
objective JJ N
signs NNS N
of IN N
opioid JJ N
withdrawal NN N
. . N

Patients NNS N
who WP N
received VBD N
placebo NN N
( ( N
n JJ N
= NNP N
18 CD N
) ) N
showed VBD N
a DT N
significant JJ N
increase NN N
in IN N
the DT N
mean NN N
score NN N
on IN N
one CD N
of IN N
three CD N
rating NN N
scales NNS N
used VBN N
to TO N
assess VB N
opioid JJ N
withdrawal NN N
. . N

Patients NNS N
who WP N
received VBD N
naloxone NN N
( ( N
n JJ N
= NNP N
58 CD N
) ) N
showed VBD N
significant JJ N
increases NNS N
in IN N
mean JJ N
scores NNS N
on IN N
all DT N
three CD N
rating NN N
scales NNS N
, , N
but CC N
this DT N
was VBD N
due JJ N
primarily RB N
to TO N
increases NNS N
observed VBN N
in IN N
a DT N
minority NN N
of IN N
patients NNS N
. . N

Sixty-one CD N
percent NN N
of IN N
patients NNS N
failed VBD N
to TO N
manifest VB N
clinically RB N
significant JJ N
changes NNS N
in IN N
subjective NN N
symptoms NNS N
, , N
and CC N
74 CD N
% NN N
of IN N
patients NNS N
failed VBD N
to TO N
manifest VB N
clinically RB N
significant JJ N
changes NNS N
in IN N
objective JJ N
signs NNS N
of IN N
opioid JJ N
withdrawal NN N
following VBG N
naloxone JJ N
administration NN N
. . N

The DT N
results NNS N
suggest VBP N
that IN N
a DT N
substantial JJ N
subgroup NN N
of IN N
heroin NN N
addicts NNS N
are VBP N
able JJ N
to TO N
use VB N
opioids NNS N
regularly RB N
while IN N
maintaining VBG N
relatively RB N
low JJ N
levels NNS N
of IN N
physical JJ N
dependence NN N
. . N

-DOCSTART- -X- O O 16585311

Evaluation NN N
of IN N
nonpharmacologic JJ N
methods NNS N
of IN N
pain NN N
and CC N
anxiety NN N
management NN N
for IN N
laceration NN N
repair NN N
in IN N
the DT N
pediatric JJ N
emergency NN N
department NN N
. . N

BACKGROUND NNP N
Nonpharmacologic NNP N
interventions NNS N
, , N
such JJ N
as IN N
distraction NN N
, , N
have VBP N
been VBN N
shown VBN N
to TO N
be VB N
powerful JJ N
adjuncts NNS N
in IN N
reducing VBG N
pain NN N
and CC N
anxiety NN N
in IN N
children NNS N
with IN N
both DT N
acute NN 4_p
and CC 4_p
chronic JJ 4_p
painful JJ 4_p
conditions NNS 4_p
. . N

There EX N
are VBP N
no DT N
controlled JJ N
studies NNS N
evaluating VBG N
these DT N
interventions NNS N
as IN N
adjuncts NNS N
to TO N
facilitate VB N
completion NN N
of IN N
painful JJ N
procedures NNS N
in IN N
the DT N
pediatric JJ N
emergency NN N
department NN N
( ( N
ED NNP N
) ) N
. . N

OBJECTIVE IN N
We PRP N
assessed VBD N
the DT N
effectiveness NN N
of IN N
distraction NN N
techniques NNS N
in IN N
reducing VBG N
the DT N
sensory NN N
and CC N
affective JJ N
components NNS N
of IN N
pain NN N
among IN N
pediatric JJ 4_p
patients NNS 4_p
undergoing JJ 4_p
laceration NN 4_p
repair NN 4_p
in IN 4_p
the DT 4_p
ED NNP 4_p
. . N

METHODS NNP N
Eligible JJ N
children NNS N
between IN N
6 CD N
and CC N
18 CD N
years NNS N
of IN N
age NN N
( ( N
N NNP N
= NNP N
240 CD N
) ) N
presenting NN 4_p
to TO 4_p
the DT 4_p
ED NNP 4_p
for IN 4_p
laceration NN 4_p
repair NN 4_p
were VBD N
randomly RB N
assigned VBN N
to TO N
an DT N
intervention NN N
or CC N
control NN N
arm NN N
. . N

Those DT N
assigned VBN N
to TO N
the DT N
intervention NN N
arm NN N
were VBD N
given VBN N
a DT N
choice NN N
of IN N
age-appropriate JJ N
distracters NNS N
during IN N
laceration NN N
repair NN N
. . N

Quantitative JJ N
measures NNS N
of IN N
pain NN N
intensity NN N
, , N
situational JJ N
anxiety NN N
, , N
and CC N
pain NN N
distress NN N
( ( N
as IN N
perceived VBN N
by IN N
the DT N
parent NN N
) ) N
were VBD N
assessed VBN N
by IN N
using VBG N
the DT N
7-point JJ N
Facial NNP N
Pain NNP N
Scale NNP N
, , N
State NNP N
Trait NNP N
Anxiety NNP N
Inventory NNP N
for IN N
Children NNP N
, , N
and CC N
a DT N
visual JJ N
analog NN N
scale NN N
, , N
respectively RB N
, , N
before IN N
and CC N
after IN N
laceration NN N
repair NN N
. . N

The DT N
State NNP N
Trait NNP N
Anxiety NNP N
Inventory NNP N
for IN N
Children NNP N
was VBD N
performed VBN N
in IN N
children NNS N
> VBP N
or CC N
= VBP N
10 CD N
years NNS N
of IN N
age NN N
. . N

RESULTS NNP N
There EX N
was VBD N
no DT N
difference NN N
in IN N
mean JJ N
change NN N
in IN N
Facial NNP N
Pain NNP N
Scale NNP N
scores VBZ N
between IN N
the DT N
control NN N
and CC N
the DT N
intervention NN N
groups NNS N
in IN N
children NNS N
< VBP N
10 CD N
years NNS N
of IN N
age NN N
. . N

Multivariate NNP N
analysis NN N
in IN N
this DT N
same JJ N
age NN N
group NN N
showed VBD N
that IN N
the DT N
intervention NN N
was VBD N
independently RB N
associated VBN N
with IN N
a DT N
reduction NN N
in IN N
pain NN N
distress NN N
as IN N
perceived VBN N
by IN N
parents NNS N
based VBN N
on IN N
the DT N
mean JJ N
change NN N
in IN N
visual JJ N
analog NN N
scale NN N
scores NNS N
. . N

In IN N
older JJR N
children NNS N
, , N
the DT N
intervention NN N
was VBD N
independently RB N
associated VBN N
with IN N
reduction NN N
in IN N
situational JJ N
anxiety NN N
but CC N
not RB N
in IN N
pain NN N
intensity NN N
or CC N
in IN N
parental JJ N
perception NN N
of IN N
pain NN N
distress NN N
. . N

CONCLUSIONS VB N
The DT N
use NN N
of IN N
distraction NN N
techniques NNS N
is VBZ N
effective JJ N
in IN N
reducing VBG N
situational JJ N
anxiety NN N
in IN N
older JJR N
children NNS N
and CC N
lowering VBG N
parental JJ N
perception NN N
of IN N
pain NN N
distress NN N
in IN N
younger JJR N
children NNS N
. . N

This DT N
technique NN N
may MD N
have VB N
a DT N
role NN N
in IN N
improving VBG N
the DT N
quality NN N
of IN N
management NN N
of IN N
procedural JJ N
pain NN N
in IN N
a DT N
pediatric JJ N
ED NNP N
setting NN N
. . N

-DOCSTART- -X- O O 12238830

Combination NN N
of IN N
sotalol NN N
and CC N
magnesium NN N
prevents NNS N
atrial JJ N
fibrillation NN N
after IN N
coronary JJ N
artery NN N
bypass NN N
grafting NN N
. . N

BACKGROUND NNP N
Atrial NNP N
fibrillation NN N
( ( N
AF NNP N
) ) N
is VBZ N
a DT N
common JJ N
complication NN N
reported VBD N
in IN N
20 CD N
% NN N
to TO N
40 CD N
% NN N
of IN N
patients NNS N
after IN 4_p
coronary JJ 4_p
operations NNS 4_p
. . N

Sotalol NNP N
alone RB N
and CC N
magnesium VB N
alone RB N
have VBP N
been VBN N
shown VBN N
to TO N
partially RB N
decrease VB N
the DT N
incidence NN N
of IN N
AF NNP N
. . N

The DT N
goal NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
these DT N
two CD N
pharmacological JJ N
agents NNS N
, , N
used VBD N
alone RB N
or CC N
in IN N
combination NN N
, , N
to TO N
reduce VB N
postoperative JJ N
AF NNP N
. . N

METHODS NNP N
Two CD N
hundred VBD N
seven CD N
consecutive JJ N
coronary JJ N
artery NN N
bypass NN N
patients NNS N
( ( N
mean JJ N
age NN N
62 CD N
+/- JJ N
11 CD N
years NNS N
) ) N
were VBD N
randomized VBN N
to TO N
receive VB N
sotalol NN N
alone RB N
( ( N
80 CD N
mg NN N
twice RB N
daily RB N
for IN N
5 CD N
days NNS N
starting VBG N
from IN N
the DT N
morning NN N
of IN N
the DT N
first JJ N
postoperative JJ N
day NN N
) ) N
( ( N
group NN N
S NNP N
) ) N
, , N
magnesium NN N
alone RB N
( ( N
1.5 CD N
g NNS N
daily RB N
for IN N
6 CD N
days NNS N
starting VBG N
in IN N
the DT N
operating NN N
room NN N
just RB N
before IN N
cardiopulmonary JJ N
bypass NN N
) ) N
( ( N
group NN N
M NNP N
) ) N
, , N
both DT N
pharmacologic JJ N
agents NNS N
at IN N
the DT N
same JJ N
dosages NNS N
( ( N
group NN N
S+M NNP N
) ) N
, , N
or CC N
no DT N
antiarrhythmic JJ N
agents NNS N
( ( N
group NN N
CTR NNP N
) ) N
. . N

All DT N
patients NNS N
with IN N
an DT N
ejection NN N
fraction NN N
less JJR N
than IN N
0.40 CD N
were VBD N
excluded VBN N
. . N

RESULTS VB N
The DT N
incidence NN N
of IN N
postoperative JJ N
AF NNP N
was VBD N
11.8 CD N
% NN N
( ( N
6/51 CD N
) ) N
in IN N
the DT N
S NNP N
group NN N
, , N
14.8 CD N
% NN N
( ( N
8/54 CD N
) ) N
in IN N
the DT N
M NNP N
group NN N
, , N
1.9 CD N
% NN N
( ( N
1/52 CD N
) ) N
in IN N
the DT N
S+M NNP N
group NN N
, , N
and CC N
38 CD N
% NN N
( ( N
19/50 CD N
) ) N
in IN N
the DT N
CTR NNP N
group NN N
. . N

The DT N
following JJ N
differences NNS N
were VBD N
significant JJ N
: : N
group NN N
CTR NNP N
versus NN N
groups NNS N
S NNP N
, , N
M NNP N
, , N
and CC N
S+M NNP N
with IN N
values NNS N
of IN N
p NN N
= NN N
0.002 CD N
, , N
p NN N
= VBD N
0.007 CD N
and CC N
p VB N
< JJ N
0.0001 CD N
, , N
respectively RB N
; : N
and CC N
group NN N
S+M NNP N
versus NN N
groups NNS N
S NNP N
and CC N
M NNP N
with IN N
p JJ N
= $ N
0.04 CD N
and CC N
p VB N
= JJ N
0.01 CD N
, , N
respectively RB N
. . N

CONCLUSIONS NNP N
Incidence NNP N
of IN N
AF NNP N
after IN N
coronary JJ N
operation NN N
was VBD N
significantly RB N
reduced VBN N
by IN N
the DT N
administration NN N
of IN N
sotalol JJ N
alone NN N
and CC N
magnesium NN N
alone RB N
; : N
more RBR N
importantly RB N
, , N
the DT N
incidence NN N
was VBD N
further RBR N
reduced VBN N
by IN N
combining VBG N
these DT N
agents NNS N
. . N

-DOCSTART- -X- O O 1911013

Effects NNS N
of IN N
flumazenil NN N
on IN N
cerebral JJ N
blood NN N
flow NN N
and CC N
oxygen NN N
consumption NN N
after IN N
midazolam NN N
anaesthesia NN N
for IN N
craniotomy NN N
. . N

Cerebral JJ N
blood NN N
flow NN N
( ( N
CBF NNP N
) ) N
and CC N
cerebral JJ N
metabolic NN N
rate NN N
for IN N
oxygen NN N
( ( N
CMRO2 NNP N
) ) N
were VBD N
measured VBN N
by IN N
a DT N
modification NN N
of IN N
the DT N
Kety-Schmidt NNP N
technique NN N
using VBG N
i.v JJ N
. . N

xenon-133 NN N
in IN N
20 CD N
patients NNS N
undergoing JJ N
craniotomy NN N
for IN N
supratentorial JJ N
cerebral JJ N
tumours NNS N
. . N

Anaesthesia NNP N
was VBD N
induced VBN N
and CC N
maintained VBN N
with IN N
midazolam NN N
, , N
fentanyl NN N
and CC N
nitrous JJ N
oxide NN N
. . N

Pancuronium NN N
was VBD N
given VBN N
for IN N
neuromuscular JJ N
block NN N
. . N

The DT N
lungs NNS N
were VBD N
ventilated VBN N
to TO N
normocapnia VB N
. . N

The DT N
first JJ N
flow NN N
measurements NNS N
were VBD N
performed VBN N
approximately RB N
1 CD N
h NNS N
after IN N
induction NN N
of IN N
anaesthesia NN N
. . N

At IN N
the DT N
end NN N
of IN N
operation NN N
the DT N
patients NNS N
were VBD N
allocated VBN N
to TO N
two CD N
groups NNS N
. . N

Ten CD N
patients NNS N
were VBD N
given VBN N
flumazenil JJ N
0.01 CD N
mg JJ N
kg-1 NN N
and CC N
5 CD N
min NN N
later RB N
the DT N
second JJ N
flow NN N
measurement NN N
was VBD N
performed VBN N
. . N

In IN N
the DT N
other JJ N
10 CD N
patients NNS N
the DT N
second JJ N
flow NN N
measurement NN N
was VBD N
performed VBN N
before IN N
the DT N
administration NN N
of IN N
flumazenil NN N
. . N

Plasma NNP N
concentrations NNS N
of IN N
midazolam NN N
were VBD N
measured VBN N
at IN N
the DT N
time NN N
of IN N
each DT N
measurement NN N
of IN N
CBF NNP N
. . N

There EX N
was VBD N
no DT N
difference NN N
between IN N
the DT N
groups NNS N
in IN N
plasma JJ N
concentration NN N
of IN N
midazolam NN N
, , N
CBF NNP N
or CC N
CMRO2 NNP N
. . N

Flumazenil NNP N
had VBD N
no DT N
effect NN N
on IN N
CBF NNP N
and CC N
CMRO2 NNP N
. . N

-DOCSTART- -X- O O 25086152

Assessing VBG N
the DT N
benefit NN N
of IN N
a DT N
personalized JJ N
EHR-generated JJ N
informed JJ N
consent NN N
in IN N
a DT N
dental JJ N
school NN N
setting VBG N
. . N

Informed VBN N
consents NNS N
are VBP N
routinely RB N
used VBN N
as IN N
an DT N
important JJ N
source NN N
of IN N
information NN N
to TO N
help VB N
patients NNS N
make VB N
appropriate JJ N
clinical JJ N
decisions NNS N
. . N

However RB N
, , N
current JJ N
standard JJ N
consent NN N
forms NNS N
may MD N
not RB N
accomplish VB N
their PRP$ N
intended VBN N
purpose NN N
due JJ N
to TO N
the DT N
variety NN N
of IN N
patient JJ N
literacy NN N
and CC N
experiences NNS N
and CC N
, , N
in IN N
the DT N
dental JJ N
school NN N
setting NN N
, , N
the DT N
developing VBG N
competence NN N
of IN N
students NNS N
. . N

The DT N
purpose NN N
of IN N
this DT N
pilot NN N
study NN N
was VBD N
to TO N
test VB N
the DT N
efficacy NN N
of IN N
a DT N
personalized VBN N
informed JJ N
consent NN N
generated VBD N
through IN N
an DT N
electronic JJ N
health NN N
record NN N
( ( N
EHR NNP N
) ) N
at IN N
one CD N
dental JJ N
school NN N
and CC N
its PRP$ N
role NN N
in IN N
patient JJ N
decision NN N
making NN N
. . N

In IN N
the DT N
study NN N
, , N
a DT N
set NN N
of IN N
informed JJ N
consents NNS N
, , N
or CC N
SmartConsents NNS N
, , N
were VBD N
developed VBN N
for IN N
specific JJ N
diagnoses NNS N
and CC N
procedures NNS N
, , N
enhanced VBN N
with IN N
graphics NNS N
, , N
and CC N
delivered VBD N
through IN N
the DT N
school NN N
's POS N
EHR NNP N
. . N

Fifty NNP N
patients NNS N
were VBD N
recruited VBN N
in IN N
the DT N
school NN N
's POS N
Urgent NNP N
Care NNP N
Clinic NNP N
and CC N
divided VBN N
evenly RB N
into IN N
two CD N
groups NNS N
: : N
one CD N
( ( N
control NN N
) ) N
receiving VBG N
the DT N
standard JJ N
consent NN N
, , N
with IN N
the DT N
second JJ N
receiving VBG N
a DT N
SmartConsent NNP N
. . N

Following VBG N
treatment NN N
, , N
patients NNS N
were VBD N
assessed VBN N
based VBN N
on IN N
demographics NNS N
, , N
decisional JJ N
conflict NN N
, , N
satisfaction NN N
, , N
health NN N
literacy NN N
, , N
and CC N
knowledge NN N
. . N

Overall JJ N
, , N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
main JJ N
effects NNS N
between IN N
SmartConsent NNP N
and CC N
standard NN N
informed VBD N
consents NNS N
for IN N
decisional JJ N
conflict NN N
and CC N
satisfaction NN N
, , N
although IN N
significant JJ N
differences NNS N
were VBD N
identified VBN N
during IN N
secondary JJ N
analysis NN N
of IN N
satisfaction NN N
, , N
gender NN N
, , N
and CC N
ethnicity NN N
. . N

The DT N
study NN N
also RB N
demonstrated VBD N
the DT N
potential NN N
for IN N
consents NNS N
to TO N
aid VB N
the DT N
student NN N
provider NN N
in IN N
better JJR N
communicating NN N
with IN N
patients NNS N
. . N

-DOCSTART- -X- O O 24920862

Variations NNS N
in IN N
EEG NNP N
discharges NNS N
predict VBP N
ADHD NNP N
severity NN N
within IN N
individual JJ N
Smith-Lemli-Opitz JJ N
patients NNS N
. . N

OBJECTIVE IN N
We PRP N
sought VBD N
to TO N
examine VB N
the DT N
prevalence NN N
of IN N
EEG NNP N
abnormalities NNS N
in IN N
Smith-Lemli-Opitz NNP 4_p
syndrome NN 4_p
( ( 4_p
SLOS NNP 4_p
) ) 4_p
as RB N
well RB N
as IN N
the DT N
relationship NN N
between IN N
interictal JJ N
epileptiform NN N
discharges NNS N
( ( N
IEDs NNP N
) ) N
and CC N
within-subject JJ N
variations NNS N
in IN N
attentional JJ N
symptom NN N
severity NN N
. . N

METHODS NNP N
In IN N
the DT N
context NN N
of IN N
a DT N
clinical JJ N
trial NN N
for IN N
SLOS NNP N
, , N
we PRP N
performed VBD N
cross-sectional JJ N
and CC N
repeated-measure JJ N
observational JJ N
studies NNS N
of IN N
the DT N
relationship NN N
between IN N
EEG NNP N
findings NNS N
and CC N
cognitive/behavioral JJ N
factors NNS N
on IN N
23 CD N
children NNS N
( ( N
aged VBN N
4-17 CD N
years NNS N
) ) N
. . N

EEGs NNP N
were VBD N
reviewed VBN N
for IN N
clinical JJ N
abnormalities NNS N
, , N
including VBG N
IEDs NNP N
, , N
by IN N
readers NNS N
blinded VBD N
to TO N
participants NNS N
' POS N
behavioral NN N
symptoms NNS N
. . N

Between-group JJ N
differences NNS N
in IN N
baseline JJ N
characteristics NNS N
of IN N
participants NNS N
with IN N
and CC N
without IN N
IEDs NNP N
were VBD N
analyzed VBN N
. . N

Within-subject JJ N
analyses NNS N
examined VBD N
the DT N
association NN N
between IN N
the DT N
presence NN N
of IN N
IEDs NNP N
and CC N
changes NNS N
in IN N
attention-deficit/hyperactivity NN N
disorder NN N
( ( N
ADHD NNP N
) ) N
symptoms NNS N
. . N

RESULTS NNP N
Of IN N
85 CD N
EEGs NNP N
, , N
43 CD N
( ( N
51 CD N
% NN N
) ) N
were VBD N
abnormal JJ N
, , N
predominantly RB N
because IN N
of IN N
IEDs NNP N
. . N

Only RB N
one CD N
subject NN N
had VBD N
documented VBN N
clinical JJ N
seizures NNS N
. . N

IEDs NNP N
clustered VBD N
in IN N
13 CD N
subjects NNS N
( ( N
57 CD N
% NN N
) ) N
, , N
whereas $ N
9 CD N
subjects NNS N
( ( N
39 CD N
% NN N
) ) N
had VBD N
EEGs NNP N
consistently RB N
free JJ N
of IN N
IEDs NNP N
. . N

While IN N
there EX N
were VBD N
no DT N
significant JJ N
group NN N
differences NNS N
in IN N
sex NN N
, , N
age NN N
, , N
intellectual JJ N
disability NN N
, , N
language NN N
level NN N
, , N
or CC N
baseline VB N
ADHD NNP N
symptoms NNS N
, , N
autistic JJ N
symptoms NNS N
tended VBD N
to TO N
be VB N
more RBR N
prevalent JJ N
in IN N
the DT N
" NNP N
IED NNP N
" NNP N
group NN N
( ( N
according VBG N
to TO N
Autism NNP N
Diagnostic NNP N
Observation NNP N
Schedule-2 NNP N
criteria NNS N
) ) N
. . N

Within JJ N
individuals NNS N
, , N
the DT N
presence NN N
of IN N
IEDs NNP N
on IN N
a DT N
particular JJ N
EEG NNP N
predicted VBD N
, , N
on IN N
average NN N
, , N
a DT N
27 CD N
% NN N
increase NN N
in IN N
ADHD NNP N
symptom NN N
severity NN N
. . N

CONCLUSIONS NNP N
Epileptiform NNP N
discharges NNS N
are VBP N
common JJ N
in IN N
SLOS NNP N
, , N
despite IN N
a DT N
relatively RB N
low JJ N
prevalence NN N
of IN N
epilepsy NN N
. . N

Fluctuations NNS N
in IN N
the DT N
presence NN N
of IN N
epileptiform NN N
discharges NNS N
within IN N
individual JJ N
children NNS N
with IN N
a DT N
developmental JJ N
disability NN N
syndrome NN N
may MD N
be VB N
associated VBN N
with IN N
fluctuations NNS N
in IN N
ADHD NNP N
symptomatology NN N
, , N
even RB N
in IN N
the DT N
absence NN N
of IN N
clinical JJ N
seizures NNS N
. . N

-DOCSTART- -X- O O 20124059

Minimally RB N
invasive JJ N
compared VBN N
with IN N
traditional JJ N
transgluteal NN N
approach NN N
for IN N
total JJ 4_p
hip NN 4_p
arthroplasty NN 4_p
: : N
a DT N
comparative JJ N
gait NN N
analysis NN N
. . N

BACKGROUND NNP N
Minimally NNP N
invasive JJ N
total NN N
hip NN N
arthroplasty NN N
is VBZ N
purported VBN N
to TO N
allow VB N
an DT N
improved JJ N
and CC N
faster JJ N
rehabilitation NN N
in IN N
the DT N
immediate JJ N
postoperative JJ N
period NN N
because IN N
of IN N
reduced JJ N
soft-tissue JJ N
damage NN N
compared VBN N
with IN N
total JJ N
hip NN N
arthroplasty NN N
performed VBD N
with IN N
use NN N
of IN N
a DT N
standard JJ N
approach NN N
. . N

In IN N
the DT N
present JJ N
study NN N
, , N
a DT N
minimally RB N
invasive JJ N
approach NN N
was VBD N
compared VBN N
with IN N
a DT N
traditional JJ N
standard NN N
approach NN N
in IN N
terms NNS N
of IN N
the DT N
effect NN N
on IN N
gait NN N
kinematics NNS N
as IN N
demonstrated VBN N
with IN N
gait NN N
analysis NN N
and CC N
electromyography NN N
. . N

METHODS NNP N
Twenty NNP N
randomized VBD N
patients NNS N
who WP N
underwent VBP N
a DT N
primary JJ 4_p
total JJ 4_p
hip NN 4_p
replacement NN 4_p
with IN N
use NN N
of IN N
a DT N
minimally RB N
invasive JJ N
modified VBN N
Watson-Jones JJ N
approach NN N
( ( N
minimally RB N
invasive JJ N
group NN N
) ) N
were VBD N
compared VBN N
with IN N
a DT N
group NN N
of IN N
twenty NN N
patients NNS N
who WP N
underwent VBD N
a DT N
total JJ N
hip NN N
arthroplasty NN N
with IN N
use NN N
of IN N
a DT N
standard JJ N
transgluteal NN N
Hardinge NNP N
approach NN N
( ( N
standard JJ N
group NN N
) ) N
. . N

All DT N
patients NNS N
received VBD N
the DT N
same JJ N
cementless NN N
implant NN N
, , N
inserted VBN N
with IN N
use NN N
of IN N
standard JJ N
instruments NNS N
, , N
and CC N
all DT N
operations NNS N
were VBD N
performed VBN N
by IN N
a DT N
single JJ N
, , N
experienced JJ N
surgeon NN N
. . N

The DT N
patients NNS N
were VBD N
evaluated VBN N
with IN N
use NN N
of IN N
three-dimensional JJ N
gait NN N
analysis NN N
and CC N
dynamic JJ N
electromyograms NNS N
at IN N
three CD N
time NN N
points NNS N
: : N
preoperatively RB N
, , N
ten JJ N
days NNS N
postoperatively RB N
, , N
and CC N
twelve VB N
weeks NNS N
postoperatively RB N
. . N

Temporospatial JJ N
and CC N
joint-kinematic JJ N
parameters NNS N
were VBD N
evaluated VBN N
. . N

RESULTS VB N
There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
two CD N
groups NNS N
with IN N
regard NN N
to TO N
the DT N
temporospatial JJ N
variables NNS N
of IN N
velocity NN N
, , N
cadence NN N
, , N
step NN N
length NN N
, , N
and CC N
stride JJ N
length NN N
at IN N
any DT N
tested JJ N
time NN N
point NN N
. . N

With IN N
regard NN N
to TO N
the DT N
range NN N
of IN N
motion NN N
of IN N
the DT N
operatively RB N
treated JJ N
hip NN N
, , N
the DT N
minimally RB N
invasive JJ N
group NN N
had VBD N
a DT N
smaller JJR N
decrease NN N
at IN N
the DT N
ten-day JJ N
time NN N
point NN N
in IN N
comparison NN N
with IN N
the DT N
standard JJ N
group NN N
. . N

However RB N
, , N
this DT N
finding NN N
was VBD N
not RB N
significant JJ N
. . N

The DT N
reduction NN N
in IN N
the DT N
range NN N
of IN N
motion NN N
was VBD N
mainly RB N
caused VBN N
by IN N
reduced JJ N
hip NN N
extension NN N
. . N

A DT N
compensatory JJ N
increase NN N
in IN N
the DT N
pelvic JJ N
tilt NN N
was VBD N
observed VBN N
in IN N
both DT N
groups NNS N
. . N

One CD N
patient NN N
in IN N
the DT N
standard NN N
group NN N
showed VBD N
a DT N
positive JJ N
Trendelenburg NNP N
gait NN N
ten NN N
days NNS N
postoperatively RB N
; : N
it PRP N
had VBD N
disappeared VBN N
completely RB N
at IN N
the DT N
twelve-week JJ N
time NN N
point NN N
. . N

CONCLUSIONS NNP N
With IN N
regard NN N
to TO N
gait VB N
kinematics NNS N
in IN N
the DT N
early JJ N
postoperative JJ N
period NN N
( ( N
three CD N
months NNS N
) ) N
, , N
the DT N
present JJ N
study NN N
showed VBD N
no DT N
significant JJ N
benefit NN N
for IN N
patients NNS N
who WP N
underwent VBD N
a DT N
total JJ 4_p
hip NN 4_p
arthroplasty NN 4_p
through IN N
a DT N
minimally RB N
invasive JJ N
Watson-Jones NNS N
approach NN N
in IN N
comparison NN N
with IN N
those DT N
who WP N
were VBD N
managed VBN N
with IN N
a DT N
standard JJ 4_p
transgluteal NN 4_p
approach NN 4_p
. . N

-DOCSTART- -X- O O 3296982

Need NN N
for IN N
insulin NN N
therapy NN N
in IN N
type NN 4_p
II NNP 4_p
diabetes VBZ 4_p
mellitus NN 4_p
. . N

A DT N
randomized JJ N
trial NN N
. . N

To TO N
identify VB N
patients NNS N
with IN N
type JJ 4_p
II NNP 4_p
diabetes VBZ 4_p
mellitus NN 4_p
for IN N
whom WP N
insulin NN N
therapy NN N
is VBZ N
most RBS N
beneficial JJ N
, , N
we PRP N
conducted VBD N
a DT N
randomized VBN N
controlled VBN N
trial NN N
in IN N
the DT N
general JJ N
medicine NN N
clinic NN N
of IN N
a DT N
university NN N
hospital NN N
. . N

Asymptomatic NNP N
, , N
obese JJ 4_p
, , N
insulin-treated JJ N
patients NNS N
were VBD N
given VBN N
diet JJ N
and CC N
diabetes VBZ N
education NN N
and CC N
, , N
in IN N
half NN N
of IN N
these DT N
patients NNS N
, , N
insulin JJ N
therapy NN N
was VBD N
withdrawn VBN N
. . N

Over IN N
six CD N
months NNS N
, , N
patients NNS N
developing VBG N
hyperglycemic JJ N
symptoms NNS N
or CC N
acetonemia NN N
were VBD N
counted VBN N
as IN N
study NN N
failures NNS N
. . N

Failure NN N
criteria NNS N
developed VBD N
in IN N
13 CD N
of IN N
25 CD N
insulin-withdrawal JJ N
patients NNS N
, , N
at IN N
a DT N
median NN N
of IN N
four CD N
weeks NNS N
after IN N
withdrawal NN N
, , N
compared VBN N
with IN N
two CD N
of IN N
24 CD N
control NN N
subjects NNS N
. . N

Elevated VBN N
stimulated VBD N
glucose JJ N
levels NNS N
predicted VBD N
the DT N
need NN N
for IN N
insulin JJ N
therapy NN N
. . N

Hyperglycemia NNP N
worsened VBD N
in IN N
insulin-withdrawal JJ N
patients NNS N
who WP N
did VBD N
not RB N
meet VB N
study JJ N
failure NN N
criteria NNS N
, , N
but CC N
it PRP N
improved VBD N
in IN N
control NN N
patients NNS N
. . N

Study NNP N
patients NNS N
were VBD N
insulin JJ N
deficient NN N
as IN N
shown VBN N
by IN N
low JJ N
baseline NN N
C NNP N
peptide NN N
values NNS N
( ( N
0.43 CD N
+/- JJ N
0.05 CD N
nmol/L NN N
) ) N
. . N

The DT N
prompt JJ N
metabolic JJ N
decompensation NN N
precipitated VBN N
by IN N
insulin NN N
withdrawal NN N
suggests VBZ N
that IN N
insulin-deficient JJ N
patients NNS N
may MD N
benefit VB N
from IN N
insulin NN N
therapy NN N
and CC N
may MD N
need VB N
it PRP N
to TO N
prevent VB N
symptomatic JJ N
hyperglycemia NN N
. . N

-DOCSTART- -X- O O 10190267

Rett NNP 4_p
syndrome NN 4_p
: : 4_p
randomized VBN N
controlled VBD N
trial NN N
of IN N
L-carnitine NNP N
. . N

Rett NNP N
syndrome NN N
is VBZ N
a DT N
severe JJ N
neurodevelopmental JJ N
disorder NN N
of IN N
unknown JJ N
etiology NN N
, , N
occurring VBG N
almost RB N
exclusively RB N
in IN N
female JJ 4_p
patients NNS 4_p
. . 4_p

The DT N
etiology NN N
and CC N
functional JJ N
significance NN N
of IN N
plasma JJ N
carnitine NN N
deficiency NN N
seen VBN N
in IN N
some DT N
patients NNS N
with IN N
Rett NNP N
syndrome NN N
is VBZ N
unknown JJ N
. . N

To TO N
investigate VB N
whether IN N
L-carnitine JJ N
might MD N
be VB N
of IN N
benefit NN N
in IN N
Rett NNP N
syndrome NN N
, , N
a DT N
randomized VBN N
, , N
placebo-controlled JJ N
, , N
double-blind JJ N
crossover NN N
trial NN N
of IN N
L-carnitine NNP N
has VBZ N
been VBN N
completed VBN N
in IN N
35 CD N
subjects NNS N
. . N

Eight-week JJ N
treatment NN N
phases NNS N
were VBD N
completed VBN N
for IN N
both DT N
a DT N
placebo NN N
and CC N
L-carnitine NNP N
. . N

Outcome NNP N
was VBD N
measured VBN N
by IN N
parents/caregivers NNS N
and CC N
at IN N
medical JJ N
follow-up NN N
using VBG N
three CD N
established VBN N
tools NNS N
: : N
the DT N
Rett NNP N
Syndrome NNP N
Motor NNP N
Behavioral NNP N
Assessment NNP N
, , N
the DT N
Hand NNP N
Apraxia NNP N
Scale NNP N
, , N
and CC N
the DT N
Patient NNP N
Well-Being NNP N
Index NNP N
. . N

Analysis NNP N
comparing VBG N
change NN N
between IN N
baseline NN N
and CC N
week NN N
8 CD N
of IN N
treatment NN N
for IN N
L-carnitine NNP N
and CC N
the DT N
placebo NN N
showed VBD N
that IN N
both DT N
parents/caregivers NNS N
and CC N
medical JJ N
follow-up NN N
detected JJ N
improvements NNS N
in IN N
the DT N
subjects NNS N
' POS N
well-being NN N
. . N

In IN N
addition NN N
, , N
medical JJ N
review NN N
showed VBD N
an DT N
improvement NN N
on IN N
the DT N
Hand NNP N
Apraxia NNP N
Scale NNP N
for IN N
a DT N
higher JJR N
proportion NN N
of IN N
girls NNS N
on IN N
L-carnitine NNP N
. . N

Identification NN N
of IN N
predictors NNS N
of IN N
clinical JJ N
improvement NN N
has VBZ N
been VBN N
limited VBN N
by IN N
the DT N
power NN N
of IN N
the DT N
study NN N
. . N

These DT N
findings NNS N
suggest VBP N
that IN N
L-carnitine NNP N
is VBZ N
of IN N
benefit NN N
in IN N
some DT N
patients NNS N
with IN N
Rett NNP N
syndrome NN N
. . N

While IN N
L-carnitine NNP N
did VBD N
not RB N
lead VB N
to TO N
major JJ N
functional JJ N
changes NNS N
in IN N
ability NN N
, , N
the DT N
type NN N
of IN N
changes NNS N
reported VBN N
could MD N
still RB N
have VB N
a DT N
substantial JJ N
impact NN N
on IN N
the DT N
girls NNS N
and CC N
their PRP$ N
families NNS N
. . N

Information NN N
is VBZ N
still RB N
needed VBN N
, , N
however RB N
, , N
to TO N
determine VB N
if IN N
only RB N
subgroups NNS N
of IN N
girls NNS N
with IN N
the DT N
disorder NN N
are VBP N
responsive JJ N
to TO N
L-carnitine NNP N
and CC N
the DT N
appropriate JJ N
duration NN N
of IN N
therapy NN N
. . N

-DOCSTART- -X- O O 6143667

Effect NN N
of IN N
beta-blocking NN N
drugs NNS N
on IN N
beta-cell NN N
function NN N
and CC N
insulin NN N
sensitivity NN N
in IN N
hypertensive JJ 4_p
non-diabetic JJ 4_p
patients NNS 4_p
. . 4_p

The DT N
effects NNS N
of IN N
two CD N
beta-blocking JJ N
drugs NNS N
on IN N
endogenous JJ N
insulin NN N
secretion NN N
and CC N
insulin NN N
sensitivity NN N
were VBD N
investigated VBN N
in IN N
a DT N
double-blind JJ N
cross-over NN N
study NN N
in IN N
13 CD 4_p
hypertensive JJ 4_p
patients NNS 4_p
. . 4_p

The DT N
patients NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
each DT N
of IN N
three CD N
2-week JJ N
treatment NN N
periods NNS N
with IN N
propranolol JJ N
80 CD N
mg NN N
b.i.d. NN N
, , N
atenolol RB N
50 CD N
mg NN N
b.i.d NN N
. . N

and CC N
placebo JJ N
b.i.d NN N
. . N

Endogenous JJ N
insulin NN N
secretion NN N
was VBD N
assessed VBN N
by IN N
measuring VBG N
serum JJ N
insulin NN N
and CC N
C-peptide NNP N
before IN N
and CC N
6 CD N
min NN N
after IN N
iv JJ N
administration NN N
of IN N
glucagon NN N
; : N
insulin JJ N
sensitivity NN N
was VBD N
determined VBN N
by IN N
measuring VBG N
insulin NN N
binding VBG N
to TO N
erythrocytes NNS N
, , N
and CC N
as IN N
the DT N
glucose JJ N
disappearance NN N
rate NN N
( ( N
KITT NNP N
) ) N
after IN N
i.v NN N
. . N

insulin NN N
. . N

Fasting VBG N
concentrations NNS N
of IN N
serum JJ N
free JJ N
fatty NN N
acids NNS N
( ( N
S-FFA NNP N
) ) N
and CC N
plasma JJ N
gastric JJ N
inhibitory NN N
polypeptide NN N
( ( N
P-GIP NNP N
) ) N
were VBD N
also RB N
recorded VBN N
during IN N
the DT N
three CD N
study NN N
periods NNS N
. . N

Both DT N
propranolol NN N
and CC N
atenolol NN N
reduced VBD N
blood NN N
pressure NN N
, , N
heart NN N
rate NN N
and CC N
S-FFA NNP N
concentrations NNS N
compared VBN N
to TO N
placebo VB N
, , N
and CC N
all DT N
patients NNS N
showed VBD N
measurable JJ N
plasma JJ N
concentrations NNS N
of IN N
propranolol NN N
and CC N
atenolol NN N
. . N

The DT N
results NNS N
can MD N
be VB N
considered VBN N
representative JJ N
, , N
therefore RB N
, , N
of IN N
clinical JJ N
beta-blockade NN N
. . N

The DT N
two CD N
drugs NNS N
did VBD N
not RB N
significantly RB N
influence VB N
the DT N
fasting NN N
blood NN N
glucose JJ N
level NN N
. . N

There EX N
was VBD N
an DT N
increase NN N
in IN N
fasting VBG N
and CC N
glucagon-stimulated JJ N
serum NN N
C-peptide NNP N
concentration NN N
during IN N
propranolol JJ N
therapy NN N
compared VBN N
with IN N
placebo NN N
( ( N
p JJ N
= NN N
0.037 CD N
and CC N
p VB N
= JJ N
0.030 CD N
, , N
respectively RB N
) ) N
, , N
although IN N
this DT N
was VBD N
not RB N
reflected VBN N
by IN N
a DT N
significant JJ N
change NN N
in IN N
serum JJ N
insulin NN N
. . N

Propranolol NNP N
and CC N
atenolol RB N
did VBD N
not RB N
significantly RB N
influence JJ N
insulin NN N
binding NN N
to TO N
erythrocytes NNS N
, , N
but CC N
they PRP N
clearly RB N
reduced VBD N
the DT N
glucose JJ N
disappearance NN N
rate NN N
KITT NNP N
was VBD N
compared VBN N
to TO N
placebo VB N
( ( N
p JJ N
= NN N
0.0036 CD N
and CC N
p VB N
= NNP N
0.0003 CD N
) ) N
, , N
respectively RB N
) ) N
. . N

The DT N
findings NNS N
support VBP N
the DT N
view NN N
that IN N
beta-blocking JJ N
drugs NNS N
can MD N
influence VB N
glucose JJ N
metabolism NN N
by IN N
mechanisms NNS N
other JJ N
than IN N
inhibition NN N
of IN N
endogenous JJ N
insulin NN N
secretion NN N
. . N

-DOCSTART- -X- O O 24992750

Comparison NNP N
of IN N
clinical JJ N
effectiveness NN N
of IN N
acupuncture NN N
and CC N
a DT N
Western JJ N
drug NN N
on IN N
allergic JJ 4_p
rhinitis NN 4_p
: : 4_p
study NN N
protocol NN N
for IN N
a DT N
randomized VBN N
controlled VBN N
trial NN N
. . N

OBJECTIVE UH N
To TO N
compare VB N
the DT N
efficacy NN N
of IN N
an DT N
acupuncture NN N
regimen NN N
for IN N
persistent JJ 4_p
allergic JJ 4_p
rhinitis NN 4_p
( ( 4_p
PER NNP 4_p
) ) 4_p
, , N
aimed VBN N
at IN N
improving VBG N
a DT N
patient NN N
's POS N
mind NN N
or CC N
Shen NNP N
in IN N
Traditional NNP N
Chinese NNP N
Medicine NNP N
, , N
to TO N
that DT N
of IN N
a DT N
second-generation JJ N
Hi-receptor NNP N
antagonist NN N
, , N
cetirizine JJ N
hydrochloride NN N
. . N

METHODS NNP N
This DT N
multicenter NN N
, , N
randomized VBN N
, , N
controlled VBD N
clinical JJ N
trial NN N
on IN N
PER NNP N
will MD N
be VB N
conducted VBN N
at IN N
three CD N
institutions NNS N
in IN N
China NNP N
. . N

The DT N
total JJ N
study NN N
period NN N
will MD N
be VB N
9 CD N
weeks NNS N
. . N

After IN N
a DT N
1-week JJ N
preparatory NN N
screening VBG N
period NN N
, , N
240 CD N
eligible JJ N
participants NNS N
with IN N
PER NNP N
will MD N
be VB N
randomized VBN N
to TO N
receive VB N
acupuncture NN N
or CC N
pharmacotherapy NN N
( ( N
1:1 CD N
) ) N
for IN N
4 CD N
weeks NNS N
with IN N
a DT N
4-week JJ N
follow-up NN N
. . N

The DT N
primary JJ N
outcome NN N
will MD N
be VB N
changes NNS N
in IN N
7-day JJ N
average JJ N
total JJ N
nasal JJ N
symptom NN N
score NN N
. . N

Secondary JJ N
outcome NN N
measures NNS N
include VBP N
rhinoconjunctivitis JJ N
quality NN N
of IN N
life NN N
questionnaire NN N
score NN N
and CC N
total JJ N
non-nasal JJ N
symptom NN N
score NN N
. . N

RESULTS VB N
The DT N
presence NN N
and CC N
seriousness NN N
of IN N
psychological JJ N
and CC N
emotional JJ N
impairments NNS N
should MD N
be VB N
considered VBN N
in IN N
therapeutic JJ N
programs NNS N
for IN N
allergic JJ N
rhinitis NN N
. . N

No DT N
clinical JJ N
trial NN N
for IN N
treating VBG N
allergic JJ N
rhinitis NN N
via IN N
acupuncture NN N
regulation NN N
of IN N
psychological JJ N
and CC N
emotional JJ N
activities NNS N
has VBZ N
been VBN N
reported VBN N
. . N

CONCLUSION VB N
The DT N
findings NNS N
of IN N
the DT N
trial NN N
will MD N
allow VB N
us PRP N
to TO N
determine VB N
the DT N
effects NNS N
of IN N
the DT N
mind NN N
( ( N
Shen NNP N
) ) N
-regulation NN N
treatment NN N
approach NN N
. . N

We PRP N
will MD N
also RB N
be VB N
able JJ N
to TO N
confirm VB N
if IN N
the DT N
effects NNS N
of IN N
acupuncture NN N
are VBP N
equivalent JJ N
to TO N
those DT N
of IN N
the DT N
conventional JJ N
drug NN N
cetirizine NN N
hydrochloride NN N
. . N

-DOCSTART- -X- O O 14617595

Remifentanil NNP N
with IN N
morphine JJ N
transitional JJ N
analgesia NN N
shortens VBZ N
neurological JJ N
recovery NN N
compared VBN N
to TO N
fentanyl VB N
for IN N
supratentorial JJ N
craniotomy NN N
. . N

PURPOSE NNP N
To TO N
compare VB N
the DT N
recovery NN N
profiles NNS N
, , N
efficacy NN N
and CC N
safety NN N
of IN N
remifentanil NN N
and CC N
morphine NN N
for IN N
transitional JJ N
analgesia NN N
with IN N
fentanyl NN N
in IN N
patients NNS N
undergoing VBG N
elective JJ 4_p
craniotomy NN 4_p
for IN N
supratentorial JJ 4_p
mass NN 4_p
lesions NNS 4_p
. . N

METHODS NNP N
Ninety-one JJ N
patients NNS N
were VBD N
enrolled VBN N
in IN N
this DT N
prospective JJ N
, , N
randomized VBN N
, , N
multicentre FW N
study NN N
. . N

Anesthesia NNP N
was VBD N
induced VBN N
with IN N
thiopental JJ N
and CC N
remifentanil NN N
( ( N
1.0 CD N
micro NN N
g NN N
x NNP N
kg NN N
( ( N
-1 NNP N
) ) N
bolus NN N
and CC N
a DT N
1 CD N
micro NN N
g NN N
x NNP N
kg NN N
( ( N
-1 NNP N
) ) N
x VBP N
min NN N
( ( N
-1 NNP N
) ) N
infusion NN N
) ) N
or CC N
fentanyl NN N
( ( N
1 CD N
micro NN N
g NN N
x NNP N
kg NN N
( ( N
-1 NNP N
) ) N
bolus NN N
and CC N
a DT N
1.0 CD N
micro NN N
g NN N
x NNP N
kg NN N
( ( N
-1 NNP N
) ) N
x VBP N
min NN N
( ( N
-1 NNP N
) ) N
infusion NN N
) ) N
. . N

The DT N
opioid JJ N
infusion NN N
continued VBD N
until IN N
the DT N
level NN N
of IN N
anesthesia NN N
was VBD N
deemed VBN N
appropriate JJ N
for IN N
intubation NN N
. . N

Anesthesia NNP N
was VBD N
maintained VBN N
with IN N
N NNP N
( ( N
2 CD N
) ) N
O/O NNP N
( ( N
2 CD N
) ) N
, , N
isoflurane $ N
0.5 CD N
MAC NNP N
and CC N
remifentanil VB N
0.2 CD N
micro NN N
g NN N
x NNP N
kg NN N
( ( N
-1 NNP N
) ) N
x VBP N
min NN N
( ( N
-1 JJ N
) ) N
or CC N
fentanyl $ N
0.04 CD N
micro NN N
g NN N
x NNP N
kg NN N
( ( N
-1 NNP N
) ) N
x VBP N
min NN N
( ( N
-1 NNP N
) ) N
. . N

At IN N
bone NN N
flap NN N
replacement NN N
, , N
either DT N
morphine NN N
0.08 CD N
mg NN N
x NN N
kg NN N
( ( N
-1 NN N
) ) N
( ( N
remifentanil JJ N
group NN N
) ) N
or CC N
saline NN N
( ( N
fentanyl JJ N
group NN N
) ) N
was VBD N
given VBN N
. . N

RESULTS NNP N
Systolic NNP N
blood NN N
pressure NN N
was VBD N
greater JJR N
in IN N
those DT N
receiving VBG N
fentanyl NN N
during IN N
induction NN N
( ( N
145.6 CD N
+/-17.5 JJ N
mmHg NN N
vs NN N
128.8 CD N
+/-18.3 JJ N
mmHg NN N
; : N
P NNP N
= NNP N
0.006 CD N
) ) N
and CC N
intubation NN N
( ( N
126.9 CD N
+/-17.1 JJ N
vs NN N
110.9 CD N
+/-16.5 JJ N
mmHg NN N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Median JJ N
time NN N
to TO N
tracheal VB N
extubation NN N
was VBD N
similar JJ N
but CC N
less RBR N
variable JJ N
in IN N
the DT N
remifentanil NN N
group NN N
( ( N
remifentanil JJ N
= $ N
8 CD N
min NN N
: : N
range NN N
= VBZ N
2-44 JJ N
min NN N
; : N
fentanyl CC N
= $ N
8 CD N
min NN N
: : N
range NN N
= VBZ N
1-732 JJ N
min NN N
) ) N
. . N

The DT N
fentanyl JJ N
patients NNS N
required VBD N
a DT N
longer JJR N
time NN N
to TO N
achieve VB N
the DT N
first JJ N
normal JJ N
neurological JJ N
score NN N
( ( N
fentanyl JJ N
= $ N
38.0 CD N
min NN N
; : N
remifentanil CC N
= $ N
26.0 CD N
min NN N
; : N
P NNP N
= NNP N
0.035 CD N
) ) N
. . N

Both CC N
the DT N
anesthesiologists NNS N
and CC N
the DT N
recovery NN N
room NN N
nurses NNS N
rated VBD N
remifentanil JJ N
better RBR N
with IN N
respect NN N
to TO N
level NN N
of IN N
consciousness NN N
. . N

Analgesics NNS N
were VBD N
required VBN N
earlier RBR N
in IN N
patients NNS N
receiving VBG N
remifentanil NN N
; : N
median JJ N
time NN N
0.5 CD N
vs NN N
1.08 CD N
hr NN N
, , N
P NNP N
< VBZ N
0.001 CD N
. . N

CONCLUSIONS NNP N
Remifentanil NNP N
is VBZ N
a DT N
suitable JJ N
alternative NN N
to TO N
fentanyl VB N
in IN N
supratentorial JJ N
craniotomy NN N
. . N

Time NN N
to TO N
preoperative VB N
neurological JJ N
recovery NN N
is VBZ N
faster RBR N
and CC N
morphine VB N
provides VBZ N
some DT N
transitional JJ N
analgesia NN N
without IN N
compromising VBG N
the DT N
quality NN N
of IN N
recovery NN N
. . N

-DOCSTART- -X- O O 23715475

Yoga JJ N
effects NNS N
on IN N
mood NN N
and CC N
quality NN N
of IN N
life NN N
in IN N
Chinese JJ N
women NNS N
undergoing VBG N
heroin JJ 4_p
detoxification NN 4_p
: : N
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
Yoga NNP N
, , N
as IN N
a DT N
mind-body NN N
therapy NN N
, , N
is VBZ N
effective JJ N
in IN N
improving VBG N
quality NN N
of IN N
life NN N
for IN N
patients NNS N
with IN N
chronic JJ N
diseases NNS N
, , N
yet RB N
little JJ N
is VBZ N
known VBN N
about IN N
its PRP$ N
effectiveness NN N
in IN N
female JJ N
heroin NN N
addicts NNS N
. . N

OBJECTIVES IN N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
effects NNS N
of IN N
yoga NN N
on IN N
mood NN N
status NN N
and CC N
quality NN N
of IN N
life NN N
among IN N
women NNS N
undergoing VBG N
detoxification NN N
for IN N
heroin NN N
dependence NN N
in IN N
China NNP N
. . N

METHOD NNP N
This DT N
study NN N
was VBD N
a DT N
randomized VBN N
controlled VBN N
trial NN N
. . N

Seventy-five JJ N
women NNS N
aged VBN N
20-37 CD N
years NNS N
undergoing JJ N
detoxification NN N
for IN N
heroin NN N
dependence NN N
at IN N
AnKang NNP N
Hospital NNP N
were VBD N
allocated VBN N
randomly RB N
into IN N
an DT N
intervention NN N
or CC N
a DT N
control NN N
group NN N
. . N

Women NNS N
in IN N
the DT N
intervention NN N
group NN N
received VBD N
a DT N
6-month JJ N
yoga NN N
intervention NN N
in IN N
addition NN N
to TO N
hospital VB N
routine JJ N
care NN N
, , N
and CC N
women NNS N
in IN N
the DT N
control NN N
group NN N
received VBD N
hospital JJ N
routine NN N
care NN N
only RB N
. . N

Mood NNP N
status NN N
and CC N
quality NN N
of IN N
life NN N
were VBD N
assessed VBN N
using VBG N
the DT N
Profile NNP N
of IN N
Mood NNP N
States NNPS N
and CC N
Medical NNP N
Outcomes NNP N
Study NNP N
36-item JJ N
Short-Form NNP N
Health NNP N
Survey NNP N
at IN N
baseline NN N
and CC N
following VBG N
3 CD N
and CC N
6 CD N
months NNS N
of IN N
treatment NN N
. . N

Repeated-measures JJ N
analysis NN N
of IN N
variance NN N
was VBD N
used VBN N
to TO N
evaluate VB N
treatment NN N
and CC N
time NN N
effects NNS N
on IN N
mood NN N
and CC N
quality NN N
of IN N
life NN N
. . N

RESULTS NNP N
Most JJS N
female JJ N
heroin NN 4_p
addicts NNS 4_p
were VBD N
young JJ N
and CC N
single JJ N
, , N
with IN N
a DT N
low JJ N
education NN N
level NN N
. . N

Most JJS N
had VBD N
used VBN N
heroin NN N
by IN N
injection NN N
. . N

Mood NNP N
state NN N
and CC N
quality NN N
of IN N
life NN N
of IN N
female JJ N
heroin NN N
addicts NNS N
were VBD N
poor JJ N
. . N

The DT N
intervention NN N
group NN N
showed VBD N
a DT N
significant JJ N
improvement NN N
in IN N
mood NN N
status NN N
and CC N
quality NN N
of IN N
life NN N
over IN N
time NN N
compared VBN N
with IN N
their PRP$ N
counterparts NNS N
in IN N
the DT N
control NN N
group NN N
. . N

CONCLUSION NNP N
Yoga NNP N
may MD N
improve VB N
mood NN N
status NN N
and CC N
quality NN N
of IN N
life NN N
for IN N
women NNS N
undergoing VBG N
detoxification NN N
for IN N
heroin NN N
dependence NN N
. . N

Yoga CC N
can MD N
be VB N
used VBN N
as IN N
an DT N
auxiliary JJ N
treatment NN N
with IN N
traditional JJ N
hospital NN N
routine NN N
care NN N
for IN N
these DT N
women NNS N
. . N

-DOCSTART- -X- O O 12358251

Tegaserod NNP N
, , N
a DT N
5-hydroxytryptamine JJ N
type NN N
4 CD N
receptor NN N
partial JJ N
agonist NN N
, , N
is VBZ N
devoid JJ N
of IN N
electrocardiographic JJ N
effects NNS N
. . N

OBJECTIVES NNP N
Certain NNP N
GI NNP N
prokinetic JJ N
agents NNS N
have VBP N
been VBN N
shown VBN N
to TO N
affect VB N
cardiac JJ N
repolarization NN N
, , N
which WDT N
may MD N
be VB N
associated VBN N
with IN N
life-threatening JJ N
arrhythmias NNS N
. . N

The DT N
selective JJ N
5-hydroxytryptamine JJ N
type NN N
4 CD N
receptor NN N
partial JJ N
agonist NN N
tegaserod NN N
is VBZ N
a DT N
novel JJ N
promotile NN N
agent NN N
developed VBD N
for IN N
the DT N
treatment NN N
of IN N
functional JJ N
motility NN N
disorders NNS N
such JJ N
as IN N
irritable JJ N
bowel NN N
syndrome NN N
( ( N
IBS NNP N
) ) N
. . N

The DT N
aim NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
cardiac JJ N
safety NN N
profile NN N
of IN N
tegaserod NN N
through IN N
analysis NN N
of IN N
electrocardiographic JJ N
data NNS N
from IN N
clinical JJ N
studies NNS N
conducted VBN N
in IN N
patients NNS N
with IN N
IBS NNP 4_p
and CC N
a DT N
study NN N
conducted VBN N
in IN N
healthy JJ 4_p
male JJ N
subjects NNS N
. . N

METHODS NNP N
In IN N
three CD N
randomized NNS N
, , N
double JJ N
blind NN N
, , N
placebo-controlled JJ N
, , N
parallel JJ N
group NN N
clinical JJ N
studies NNS N
, , N
2516 CD N
IBS NNP 4_p
patients NNS N
with IN N
symptoms NNS N
of IN N
abdominal JJ 4_p
pain NN 4_p
and CC N
constipation NN 4_p
received VBD N
tegaserod JJ N
2 CD N
or CC N
6 CD N
mg JJ N
b.i.d NN N
. . N

( ( N
n JJ N
= NN N
1679 CD N
) ) N
or CC N
placebo NN N
( ( N
n JJ N
= NNP N
837 CD N
) ) N
for IN N
12 CD N
wk NN N
. . N

In IN N
an DT N
additional JJ N
study NN N
, , N
36 CD N
healthy JJ 4_p
male NN N
subjects NNS N
received VBD N
iv NN N
. . N

single JJ N
doses NNS N
of IN N
tegaserod NN N
( ( N
0.8 CD N
mg NN N
to TO N
20 CD N
mg NN N
) ) N
or CC N
placebo NN N
. . N

Standard NNP N
12-lead JJ N
electrocardiograms NNS N
were VBD N
recorded VBN N
at IN N
baseline NN N
and CC N
during IN N
treatment NN N
. . N

Baseline NNP N
values NNS N
were VBD N
compared VBN N
with IN N
data NNS N
collected VBN N
during IN N
the DT N
treatment NN N
period NN N
. . N

RESULTS VB N
The DT N
proportion NN N
of IN N
patients NNS N
with IN N
prolongation NN N
of IN N
the DT N
QTc NNP N
interval NN N
was VBD N
the DT N
same JJ N
for IN N
placebo NN N
and CC N
tegaserod NN N
, , N
as IN N
was VBD N
the DT N
frequency NN N
of IN N
overall JJ N
electrocardiographic JJ N
abnormalities NNS N
. . N

No DT N
ventricular NN N
or CC N
supraventricular JJ N
tachycardia NN N
was VBD N
observed VBN N
. . N

Comparable JJ N
electrocardiographic JJ N
results NNS N
were VBD N
obtained VBN N
during IN N
placebo NN N
and CC N
tegaserod NN N
treatment NN N
. . N

In IN N
healthy JJ 4_p
volunteers NNS 4_p
, , N
tegaserod NN N
at IN N
i.v NN N
. . N

doses NNS N
resulting VBG N
in IN N
plasma NN N
concentrations NNS N
up IN N
to TO N
100 CD N
times NNS N
those DT N
measured VBN N
after IN N
therapeutic JJ N
doses NNS N
( ( N
6 CD N
mg NN N
b.i.d NN N
. . N

) ) N
did VBD N
not RB N
influence VB N
electrocardiographic JJ N
parameters NNS N
. . N

CONCLUSIONS NNP N
Tegaserod NNP N
is VBZ N
devoid JJ N
of IN N
electrocardiographic JJ N
effects NNS N
and CC N
is VBZ N
not RB N
expected VBN N
to TO N
adversely RB N
influence VB N
cardiac JJ N
function NN N
. . N

These DT N
data NNS N
confirm VBP N
preclinical JJ N
findings NNS N
. . N

-DOCSTART- -X- O O 12505565

Treatment JJ N
effects NNS N
of IN N
eptifibatide NN N
in IN N
planned JJ N
coronary JJ N
stent NN N
implantation NN N
in IN N
patients NNS N
with IN N
chronic JJ N
kidney NN N
disease NN N
( ( N
ESPRIT NNP N
Trial NNP N
) ) N
. . N

The DT N
role NN N
of IN N
platelet NN N
glycoprotein NN N
IIb/IIIa NNP N
inhibitor NN N
therapy NN N
in IN N
patients NNS N
with IN N
mild JJ N
renal JJ N
impairment NN N
is VBZ N
not RB N
well RB N
characterized VBN N
. . N

Our PRP$ N
objective NN N
was VBD N
to TO N
explore VB N
the DT N
associations NNS N
of IN N
creatinine JJ N
clearance NN N
( ( N
CrCl NNP N
) ) N
with IN N
outcomes NNS N
in IN N
a DT N
trial NN N
of IN N
eptifibatide JJ N
therapy NN N
in IN N
patients NNS N
who WP N
underwent VBP N
percutaneous JJ N
coronary JJ N
intervention NN N
( ( N
PCI NNP N
) ) N
. . N

We PRP N
analyzed VBD N
48-hour CD N
and CC N
30-day JJ N
outcomes NNS N
of IN N
patients NNS N
enrolled VBN N
in IN N
the DT N
Enhanced NNP N
Suppression NNP N
of IN N
the DT N
Platelet NNP N
IIb/IIIa NNP N
Receptor NNP N
with IN N
Integrilin NNP N
Therapy NNP N
( ( N
ESPRIT NNP N
) ) N
trial NN N
. . N

Patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
placebo VB N
or CC N
eptifibatide VB N
as IN N
an DT N
adjunct NN N
to TO N
stent VB N
implantation NN N
( ( N
1,755 CD N
with IN N
CrCl NNP N
> NNP N
or CC N
=60 NNP N
ml/min NN N
and CC N
289 CD N
with IN N
CrCl NNP N
< NNP N
60 CD N
ml/min NN N
) ) N
. . N

CrCl NNP N
was VBD N
calculated VBN N
using VBG N
the DT N
Cockcroft NNP N
and CC N
Gault NNP N
formula NN N
, , N
and CC N
the DT N
associations NNS N
of IN N
CrCl NNP N
with IN N
outcomes NNS N
were VBD N
evaluated VBN N
using VBG N
logistic JJ N
regression NN N
models NNS N
. . N

Patients NNS N
with IN N
CrCl NNP N
< NNP N
60 CD N
ml/min NN N
were VBD N
more RBR N
likely JJ N
to TO N
be VB N
older JJR N
, , N
women NNS N
, , N
hypertensive JJ N
, , N
and CC N
have VBP N
a DT N
history NN N
of IN N
coronary JJ N
artery NN N
bypass NN N
surgery NN N
, , N
stroke NN N
, , N
or CC N
peripheral JJ N
vascular JJ N
disease NN N
. . N

The DT N
interaction NN N
of IN N
eptifibatide NN N
with IN N
CrCl NNP N
had VBD N
borderline JJ N
significance NN N
for IN N
the DT N
30-day JJ N
outcome NN N
( ( N
p JJ N
= NNP N
0.109 CD N
) ) N
. . N

Treatment JJ N
effect NN N
trended VBD N
toward IN N
a DT N
greater JJR N
magnitude NN N
in IN N
patients NNS N
with IN N
lower JJR N
CrCl NNP N
( ( N
60 CD N
ml/min NN N
) ) N
( ( N
odds NNS N
ratio VBP N
0.53 CD N
, , N
confidence NN N
interval NN N
0.34 CD N
to TO N
0.83 CD N
) ) N
compared VBN N
with IN N
those DT N
with IN N
higher JJR N
CrCl NNP N
( ( N
90 CD N
ml/min NN N
) ) N
( ( N
odds NNS N
ratio VBP N
0.68 CD N
, , N
confidence NN N
interval NN N
0.49 CD N
to TO N
0.94 CD N
) ) N
. . N

An DT N
accompanying VBG N
increase NN N
in IN N
bleeding VBG N
risk NN N
also RB N
was VBD N
not RB N
apparent JJ N
with IN N
lower JJR N
CrCl NNP N
. . N

The DT N
treatment NN N
effect NN N
of IN N
eptifibatide NN N
is VBZ N
realized VBN N
regardless RB N
of IN N
renal JJ N
function NN N
and CC N
trends VBZ N
toward IN N
being VBG N
greater JJR N
in IN N
patients NNS N
with IN N
mild JJ N
renal JJ N
impairment NN N
. . N

-DOCSTART- -X- O O 15383046

Atrial NNP N
remodeling NN N
after IN N
mitral JJ N
valve NN N
surgery NN N
in IN N
patients NNS N
with IN N
permanent JJ 4_p
atrial JJ 4_p
fibrillation NN 4_p
. . N

BACKGROUND NNP N
Mitral NNP N
valve NNP N
pathology NN N
is VBZ N
frequently RB N
associated VBN N
with IN N
auricular JJ N
dilatation NN N
and CC N
atrial JJ N
fibrillation NN N
. . N

Mitral JJ N
surgery NN N
allows VBZ N
an DT N
immediate JJ N
surgical JJ N
auricular NN N
remodeling NN N
and CC N
besides NNS N
in IN N
those DT N
cases NNS N
in IN N
which WDT N
sinus NN N
rhythm NN N
is VBZ N
reached VBN N
, , N
it PRP N
is VBZ N
followed VBN N
by IN N
a DT N
late JJ N
remodeling NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
is VBZ N
to TO N
investigate VB N
the DT N
process NN N
of IN N
postoperative JJ N
auricular JJ N
remodeling VBG N
in IN N
patients NNS N
with IN N
permanent JJ 4_p
atrial JJ 4_p
fibrillation NN 4_p
undergoing VBG N
mitral JJ N
surgery NN N
. . N

METHODS NNP N
In IN N
a DT N
prospective JJ N
randomized VBN N
trial NN N
, , N
50 CD N
patients NNS N
with IN N
permanent JJ 4_p
atrial JJ 4_p
fibrillation NN 4_p
and CC N
dilated VBD 4_p
left JJ 4_p
atrium NN 4_p
, , N
submitted VBN N
to TO N
surgical JJ N
mitral JJ N
repair NN N
, , N
were VBD N
divided VBN N
into IN N
two CD N
groups NNS N
: : N
Group NNP N
I PRP N
contained VBD N
25 CD N
patients NNS N
with IN N
left JJ 4_p
auricular JJ 4_p
reduction NN 4_p
and CC 4_p
mitral JJ 4_p
surgery NN 4_p
, , N
and CC N
Group NNP N
II NNP N
contained VBD N
25 CD N
patients NNS N
with IN N
isolated JJ 4_p
valve NN 4_p
surgery NN 4_p
. . N

Both DT N
groups NNS N
were VBD N
considered VBN N
homogeneous JJ N
in IN N
the DT N
preoperative JJ N
assessment NN N
. . N

RESULTS NNP N
After IN N
a DT N
mean JJ N
follow-up NN N
of IN N
31 CD N
months NNS N
, , N
46 CD N
% NN N
of IN N
patients NNS N
included VBN N
in IN N
Group NNP N
I PRP N
versus VBP N
18 CD N
% NN N
of IN N
patients NNS N
included VBN N
in IN N
Group NNP N
II NNP N
restarted VBD N
sinus JJ N
rhythm NN N
( ( N
p JJ N
= NNP N
0.06 CD N
) ) N
. . N

An DT N
auricular JJ N
remodeling NN N
with IN N
size NN N
regression NN N
occurred VBD N
in IN N
those DT N
patients NNS N
who WP N
recovered VBD N
from IN N
sinus NN N
rhythm NN N
, , N
worthy NN N
of IN N
remark NN N
in IN N
Group NNP N
II NNP N
( ( N
-10.8 CD N
% NN N
of IN N
left JJ N
auricular JJ N
volume NN N
reduction NN N
in IN N
Group NNP N
I PRP N
compared VBN N
to TO N
-21.5 VB N
% NN N
in IN N
Group NNP N
II NNP N
; : N
p CC N
< VB N
0.05 CD N
) ) N
. . N

A DT N
new JJ N
atrial JJ N
enlargement NN N
took VBD N
place NN N
in IN N
those DT N
patients NNS N
who WP N
remained VBD N
with IN N
atrial JJ N
fibrillation NN N
( ( N
+16.8 CD N
% NN N
left VBD N
auricular JJ N
volume NN N
in IN N
Group NNP N
I PRP N
vs. VBP N
+8.4 CD N
% NN N
in IN N
Group NNP N
II NNP N
; : N
p CC N
< VB N
0.05 CD N
) ) N
. . N

CONCLUSIONS NNP N
Mitral NNP N
surgery NN N
produces VBZ N
an DT N
atrial JJ N
postoperative NN N
volume NN N
that IN N
decrease NN N
especially RB N
when WRB N
reduction NN N
techniques NNS N
are VBP N
employed VBN N
. . N

Late JJ N
left VBD N
atrial JJ N
remodeling VBG N
depended VBN N
on IN N
the DT N
type NN N
of IN N
atrial JJ N
rhythm NN N
and CC N
postoperative JJ N
surgical JJ N
volume NN N
. . N

-DOCSTART- -X- O O 12954577

Randomized VBN N
, , N
double-blind JJ N
, , N
multicenter JJ N
trial NN N
comparing VBG N
two CD N
doses NNS N
of IN N
arzoxifene NN N
( ( N
LY353381 NNP N
) ) N
in IN N
hormone-sensitive JJ 4_p
advanced JJ 4_p
or CC 4_p
metastatic JJ 4_p
breast NN 4_p
cancer NN 4_p
patients NNS 4_p
. . N

BACKGROUND NNP N
This DT N
randomized VBN N
, , N
double-blind JJ N
, , N
phase NN N
II NNP N
study NN N
assessed VBD N
two CD N
doses NNS N
of IN N
the DT N
selective JJ N
estrogen NN N
receptor NN N
modulator NN N
arzoxifene NN N
in IN N
women NNS N
with IN 4_p
advanced JJ 4_p
breast NN 4_p
cancer NN 4_p
. . N

The DT N
primary JJ N
end NN N
point NN N
was VBD N
to TO N
choose VB N
the DT N
best JJS N
of IN N
two CD N
doses NNS N
of IN N
arzoxifene NN N
based VBN N
on IN N
the DT N
response NN N
rate NN N
or CC N
the DT N
clinical JJ N
benefit NN N
rate NN N
( ( N
CBR NNP N
) ) N
. . N

Pharmacokinetics NNPS N
and CC N
toxicities NNS N
were VBD N
also RB N
assessed VBN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
Ninety-two NNP N
patients NNS N
with IN N
advanced JJ N
breast NN N
cancer NN N
received VBD N
arzoxifene JJ N
20 CD N
or CC N
50 CD N
mg/day NN N
. . N

Tumor NNP N
response NN N
was VBD N
assessed VBN N
using VBG N
World NNP N
Health NNP N
Organization NNP N
criteria NNS N
. . N

Toxicities NNS N
were VBD N
graded VBN N
according VBG N
to TO N
the DT N
National NNP N
Cancer NNP N
Institute NNP N
Common NNP N
Toxicity NNP N
Criteria NNP N
( ( N
NCI-CTC NNP N
) ) N
system NN N
. . N

Pharmacokinetic JJ N
data NNS N
were VBD N
analyzed VBN N
using VBG N
the DT N
NONMEM NNP N
software NN N
program NN N
( ( N
GloboMax NNP N
, , N
Hanover NNP N
, , N
MD NNP N
, , N
USA NNP N
) ) N
. . N

RESULTS JJ N
Response JJ N
rates NNS N
in IN N
the DT N
20 CD N
mg NN N
arm NN N
were VBD N
numerically RB N
higher JJR N
than IN N
the DT N
50-mg JJ N
arm NN N
according VBG N
to TO N
the DT N
investigator NN N
( ( N
40.5 CD N
% NN N
versus IN N
36.4 CD N
% NN N
) ) N
and CC N
the DT N
independent JJ N
review NN N
panel NN N
( ( N
42.9 CD N
% NN N
versus IN N
27.3 CD N
% NN N
) ) N
. . N

CBR NNP N
was VBD N
higher RBR N
in IN N
the DT N
20 CD N
mg NN N
arm NN N
according VBG N
to TO N
the DT N
investigator NN N
( ( N
64.3 CD N
% NN N
versus IN N
61.4 CD N
% NN N
) ) N
and CC N
the DT N
independent JJ N
review NN N
panel NN N
( ( N
59.5 CD N
% NN N
versus IN N
47.7 CD N
% NN N
) ) N
. . N

Arzoxifene NNP N
was VBD N
well RB N
tolerated VBN N
. . N

There EX N
were VBD N
no DT N
study NN N
drug-related JJ N
deaths NNS N
. . N

Mean NNP N
observed VBD N
steady-state JJ N
plasma JJ N
concentrations NNS N
of IN N
arzoxifene NN N
were VBD N
3.62 CD N
and CC N
7.48 CD N
ng/ml NN N
for IN N
the DT N
20 CD N
and CC N
50 CD N
mg NN N
doses NNS N
, , N
respectively RB N
. . N

CONCLUSIONS VB N
There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
efficacy NN N
or CC N
safety NN N
between IN N
20 CD N
and CC N
50 CD N
mg NN N
of IN N
arzoxifene NN N
. . N

Accordingly RB N
, , N
arzoxifene VBZ N
20 CD N
mg/day NN N
was VBD N
selected VBN N
for IN N
further JJ N
study NN N
in IN N
patients NNS N
with IN N
breast JJ N
cancer NN N
. . N

-DOCSTART- -X- O O 7032533

Double-blind NNP N
study NN N
on IN N
the DT N
activity NN N
of IN N
plafibride NN N
in IN N
the DT N
treatment NN N
of IN N
type NN N
IV NNP N
hyperlipoproteinemia NN N
. . N

The DT N
effects NNS N
of IN N
a DT N
new JJ N
drug NN N
, , N
N-2- NNP N
( ( N
p-chlorophenoxy JJ N
) ) N
-isobutyryl-N'-morpholinomethylurea NN N
( ( N
plafibride NN N
, , N
ITA NNP N
104 CD N
) ) N
, , N
were VBD N
studied VBN N
in IN N
a DT N
double JJ N
blind NN N
study NN N
lasting VBG N
four CD N
months NNS N
on IN N
a DT N
group NN N
of IN N
30 CD N
patients NNS N
with IN N
a DT N
type NN N
IV NNP N
hyperlipoproteinemia NN N
. . N

In IN N
the DT N
patients NNS N
treated VBN N
with IN N
the DT N
active JJ N
drug NN N
significant JJ N
reductions NNS N
in IN N
blood NN N
triglycerides NNS N
were VBD N
obtained VBN N
, , N
with IN N
a DT N
trend NN N
to TO N
normal JJ N
. . N

Reduction NN N
in IN N
blood NN N
cholesterol NN N
was VBD N
inconsistent JJ N
and CC N
not RB N
significant JJ N
. . N

As IN N
for IN N
the DT N
lipoproteinogram NN N
, , N
a DT N
tendency NN N
towards IN N
a DT N
decrease NN N
in IN N
the DT N
pre-beta-lipoprotein JJ N
fraction NN N
was VBD N
observed VBN N
and CC N
so RB N
was VBD N
a DT N
non-significant JJ N
tendency NN N
towards IN N
an DT N
increase NN N
in IN N
the DT N
alpha- JJ N
and CC N
beta-lipoprotein JJ N
fractions NNS N
. . N

Studies NNS N
on IN N
the DT N
platelet NN N
functioning NN N
showed VBD N
an DT N
obvious JJ N
decrease NN N
in IN N
platelet NN N
aggregation NN N
in IN N
those DT N
patients NNS N
treated VBN N
with IN N
the DT N
active JJ N
drug NN N
. . N

This DT N
was VBD N
very RB N
evident JJ N
for IN N
the DT N
ADP NNP N
and CC N
adrenaline JJ N
inductors NNS N
and CC N
rather RB N
less RBR N
significant JJ N
for IN N
collagen NN N
. . N

Neither CC N
platelet NN N
adhesiveness NN N
nor CC N
aggregation NN N
rate NN N
changed VBN N
. . N

Tolerance NN N
of IN N
the DT N
drug NN N
was VBD N
generally RB N
excellent JJ N
. . N

In IN N
one CD N
patient NN N
a DT N
decrease NN N
in IN N
some DT N
palpebral JJ N
xanthelasmas NN N
was VBD N
observed VBN N
after IN N
two CD N
months NNS N
of IN N
treatment NN N
with IN N
the DT N
active JJ N
drug NN N
. . N

In IN N
only RB N
one CD N
case NN N
there EX N
was VBD N
heartburn NN N
and CC N
this DT N
was VBD N
corrected VBN N
with IN N
alkalines NNS N
. . N

In IN N
one CD N
other JJ N
case NN N
an DT N
urticarial JJ N
rash NN N
appeared VBD N
, , N
but CC N
disappeared VBD N
spontaneously RB N
when WRB N
the DT N
drug NN N
was VBD N
temporarily RB N
stopped VBN N
and CC N
did VBD N
not RB N
reappear VB N
when WRB N
it PRP N
was VBD N
administered VBN N
again RB N
. . N

During IN N
the DT N
trial NN N
no DT N
evidence NN N
of IN N
renal JJ N
, , N
hepatic JJ N
or CC N
hematological JJ N
malfunctions NNS N
were VBD N
observed VBN N
. . N

However RB N
, , N
a DT N
slight JJ N
tendency NN N
towards IN N
an DT N
increase NN N
in IN N
the DT N
GOT NNP N
, , N
GPT NNP N
and CC N
LDH NNP N
was VBD N
observed VBN N
, , N
which WDT N
was VBD N
not RB N
statistically RB N
significant JJ N
. . N

The DT N
drug NN N
tested VBD N
may MD N
be VB N
very RB N
useful JJ N
in IN N
the DT N
treatment NN N
of IN N
type NN N
IV NNP N
hyperlipoproteinemia NN N
, , N
especially RB N
in IN N
those DT N
forms NNS N
in IN N
which WDT N
an DT N
increase NN N
in IN N
thromboembolic JJ N
risk NN N
is VBZ N
suspected VBN N
, , N
either RB N
associated VBN N
with IN N
, , N
or CC N
secondary JJ N
to TO N
, , N
the DT N
actual JJ N
atherosclerotic JJ N
disease NN N
. . N

-DOCSTART- -X- O O 17393618

Effects NNS N
of IN N
electro-acupuncture NN N
on IN N
T NNP N
cell NN N
subpopulations NNS N
, , N
NK NNP N
activity NN N
, , N
humoral JJ N
immunity NN N
and CC N
leukocyte NN N
count NN N
in IN N
patients NNS N
undergoing JJ N
chemotherapy NN 4_p
. . N

OBJECTIVE UH N
To TO N
observe VB N
the DT N
effects NNS N
of IN N
electro-acupuncture NN N
on IN N
T NNP N
cell NN N
subpopulations NNS N
, , N
natural JJ N
killer NN N
cell NN N
( ( N
NK NNP N
) ) N
activity NN N
, , N
humoral JJ N
immunity NN N
and CC N
leukocyte NN N
count NN N
in IN N
patients NNS N
undergoing JJ N
chemotherapy NN 4_p
. . N

METHODS NNP N
Electro-acupuncture NN N
was VBD N
added VBN N
for IN N
patients NNS N
undergoing JJ N
chemotherapy NN 4_p
. . N

Tests NNS N
were VBD N
done VBN N
on IN N
T NNP N
cell NN N
subpopulations NNS N
, , N
NK NNP N
activity NN N
, , N
humoral JJ N
immunity NN N
and CC N
leukocyte JJ N
count NN N
before IN N
treatment NN N
and CC N
after IN N
4 CD N
courses NNS N
of IN N
treatment NN N
. . N

RESULTS NNP N
After IN N
4 CD N
courses NNS N
of IN N
treatment NN N
with IN N
chemotherapy NN N
and CC N
electro-acupuncture NN N
, , N
no DT N
obvious JJ N
changes NNS N
were VBD N
found VBN N
in IN N
T NNP N
cell NN N
subpopulations NNS N
, , N
NK NNP N
activity NN N
, , N
humoral JJ N
immunity NN N
and CC N
leukocyte NN N
count NN N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
as IN N
compared VBN N
with IN N
those DT N
before IN N
treatment NN N
. . N

Patients NNS N
undergoing VBG N
chemotherapy NN N
combined VBN N
with IN N
electro-acupuncture NN N
showed VBD N
obviously RB N
higher JJR N
leukocyte NN N
count NN N
than IN N
that DT N
of IN N
the DT N
control NN N
group NN N
given VBN N
no DT N
leukogenic JJ N
drugs NNS N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

CONCLUSION NNP N
Electro-acupuncture NN N
may MD N
reduce VB N
immunologic JJ N
damage NN N
caused VBN N
by IN N
chemotherapy NN N
, , N
thus RB N
it PRP N
can MD N
be VB N
used VBN N
as IN N
the DT N
auxiliary JJ N
therapy NN N
for IN N
patients NNS N
undergoing JJ N
chemotherapy NN 4_p
. . N

-DOCSTART- -X- O O 11360574

[ JJ N
Clinical NNP N
and CC N
experimental JJ N
research NN N
of IN N
Epimedium NNP N
brevicornum NN N
in IN N
relieving VBG N
neuroendocrino-immunological JJ 4_p
effect NN 4_p
inhibited VBN N
by IN N
exogenous JJ N
glucocorticoid NN N
] NN N
. . N

OBJECTIVE UH N
To TO N
study VB N
protective JJ N
effect NN N
of IN N
Epimedium NNP N
brevicornum NN N
( ( N
EB NNP N
) ) N
on IN N
hypothalamus-pituitary-adrenal-thymus NN N
( ( N
HPAT NNP N
) ) N
axis NN N
inhibited VBN N
by IN N
exogenous JJ N
glucocorticoid NN N
. . N

METHODS NNP N
In IN N
clinical JJ N
research NN N
, , N
variation NN N
of IN N
cortisol NN N
, , N
adrenocorticotrophin NN N
( ( N
ACTH NNP N
) ) N
, , N
lymphocyte JJ N
proliferative JJ N
reaction NN N
were VBD N
observed VBN N
before IN N
and CC N
after IN N
medication NN N
in IN N
65 CD N
patients NNS N
took VBD N
prednisone NN N
, , N
and CC N
were VBD N
randomly RB N
divided VBN N
into IN N
Fufang NNP N
prednisone NN N
group NN N
( ( N
mixture NN N
of IN N
prednisone NN N
and CC N
EB NNP N
) ) N
and CC N
prednisone NN N
group NN N
. . N

An DT N
experimental JJ N
model NN N
of IN N
HPAT NNP N
axis NN N
inhibited VBN N
by IN N
corticosterone NN N
( ( N
CORT NNP N
) ) N
was VBD N
established VBN N
to TO N
observe VB N
the DT N
effect NN N
of IN N
EB NNP N
on IN N
relevant JJ N
indices NNS N
of IN N
HPAT NNP N
axis NN N
. . N

RESULTS VB N
The DT N
level NN N
of IN N
ACTH NNP N
and CC N
CORT NNP N
in IN N
plasma NN N
decreased VBN N
and CC N
lymphocyte JJ N
proliferative JJ N
reaction NN N
reduced VBN N
in IN N
patients NNS N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

In IN N
experimental JJ N
study NN N
, , N
monoaminic JJ N
transmitters NNS N
activated VBN N
in IN N
hypothalamus NN N
; : N
weight NN N
of IN N
pituitary JJ N
, , N
adrenal JJ N
and CC N
thymus NN N
decreased VBN N
; : N
number NN N
of IN N
CRH NNP N
positive JJ N
neurons NNS N
in IN N
hypothalamic JJ N
paraventricular JJ N
nucleus NN N
, , N
CRH NNP N
positive JJ N
neurofibrilin NN N
median JJ N
eminence NN N
and CC N
anterior JJ N
pituitary JJ N
ACTH NNP N
positive JJ N
secretory NN N
cells NNS N
decreased VBD N
; : N
adrenal JJ N
fasciculate NN N
zone NN N
and CC N
thymus NN N
cortex NN N
atrophies NNS N
; : N
NK NNP N
cell VBP N
cytotoxicity NN N
and CC N
the DT N
level NN N
of IN N
IL-2 NNP N
and CC N
gamma-IFN NN N
which WDT N
were VBD N
produced VBN N
by IN N
lymphocytes NNS N
reduced VBN N
in IN N
CORT-rats NNP N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

There EX N
were VBD N
significant JJ N
difference NN N
between IN N
Fufang NNP N
prednisone NN N
group NN N
( ( N
clinical JJ N
research NN N
) ) N
or CC N
EB NNP N
group NN N
( ( N
experimental JJ N
research NN N
) ) N
and CC N
CORT NNP N
control NN N
groups NNS N
, , N
P NNP N
< VBZ N
0.05 CD N
. . N

CONCLUSION NNP N
EB NNP N
could MD N
relieve VB N
neuroendocrino-immunological JJ N
effect NN N
inhibited VBN N
by IN N
exogenous JJ N
glucocorticoid NN N
. . N

-DOCSTART- -X- O O 24065423

The DT N
effect NN N
of IN N
leukocyte NN N
reduction NN N
filters NNS N
on IN N
inflammatory NN N
mediator NN N
release NN N
during IN N
coronary JJ N
artery NN N
bypass NN N
grafting NN N
. . N

BACKGROUND NNP N
Extracorporeal NNP N
circulation NN N
used VBN N
during IN N
coronary JJ N
artery NN N
bypass NN N
grafting VBG N
triggers NNS N
systemic JJ N
inflammatory JJ N
response NN N
with IN N
neutrophil JJ N
activation NN N
which WDT N
adversely RB N
affects VBZ N
ischaemic/reperfused JJ N
myocardium NN N
. . N

One CD N
method NN N
of IN N
myocardial JJ N
protection NN N
during IN N
cardiac JJ N
surgery NN N
is VBZ N
the DT N
use NN N
of IN N
blood NN N
cardioplegia NN N
. . N

Its PRP$ N
protective JJ N
effect NN N
is VBZ N
related VBN N
to TO N
cardiac VB N
cooling NN N
and CC N
metabolism NN N
reduction NN N
, , N
oxygen VBP N
supply NN N
from IN N
erythrocytes NNS N
, , N
and CC N
reactive JJ N
oxygen NN N
species NNS N
scavenging VBG N
. . N

However RB N
, , N
blood NN N
cardioplegia NN N
is VBZ N
also RB N
associated VBN N
with IN N
myocardial JJ N
damage NN N
induced VBN N
by IN N
undesirable JJ N
morphotic JJ N
blood NN N
elements NNS N
. . N

AIM NNP N
To TO N
evaluate VB N
the DT N
effect NN N
of IN N
the DT N
use NN N
of IN N
leukocyte JJ N
reduction NN N
filters NNS N
on IN N
the DT N
activity NN N
of IN N
polymorphonuclear NN N
neutrophils NNS N
( ( N
PMN NNP N
) ) N
in IN N
patients NNS N
undergoing VBG N
surgical JJ 4_p
myocardial JJ 4_p
revascularisation NN 4_p
. . N

PMN NNP N
activity NN N
was VBD N
evaluated VBN N
based VBN N
on IN N
measurements NNS N
of IN N
plasma JJ N
activity NN N
of IN N
granulocyte NN N
enzymes NNS N
, , N
lysozyme NN N
and CC N
beta-glucuronidase NN N
. . N

METHODS NNP N
We PRP N
studied VBD N
40 CD N
patients NNS N
who WP N
underwent VBP N
myocardial JJ N
revascularisation NN N
using VBG N
extracorporeal JJ N
circulation NN N
. . N

Patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
two CD N
equal JJ N
groups NNS N
: : N
in IN N
Group NNP N
I PRP N
, , N
blood VBD N
cardioplegia NN N
was VBD N
administered VBN N
using VBG N
leukocyte JJ N
reduction NN N
filters NNS N
, , N
and CC N
in IN N
Group NNP N
II NNP N
, , N
leukocyte JJ N
reduction NN N
filters NNS N
were VBD N
not RB N
used VBN N
for IN N
blood NN N
cardioplegia NN N
. . N

Measurements NNS N
were VBD N
performed VBN N
in IN N
plasma NN N
of IN N
arterial JJ N
and CC N
coronary JJ N
sinus NN N
blood NN N
samples NNS N
collected VBD N
before IN N
aortic JJ N
clamping NN N
, , N
immediately RB N
after IN N
unclamping VBG N
, , N
and CC N
after IN N
25 CD N
min NN N
of IN N
reperfusion NN N
. . N

In IN N
addition NN N
, , N
blood NN N
cardioplegic JJ N
solution NN N
samples NNS N
were VBD N
collected VBN N
in IN N
Group NNP N
I PRP N
from IN N
the DT N
lines NNS N
proximal NN N
and CC N
distal NN N
to TO N
the DT N
filter NN N
during IN N
first JJ N
and CC N
last JJ N
administration NN N
. . N

Plasma NNP N
levels NNS N
of IN N
lysozyme NN N
and CC N
beta-glucuronidase NN N
were VBD N
determined VBN N
using VBG N
previously RB N
described VBN N
methods NNS N
. . N

RESULTS NNP N
We PRP N
found VBD N
a DT N
significant JJ N
decrease NN N
in IN N
PMN NNP N
count NN N
in IN N
filtered JJ N
blood NN N
cardioplegic JJ N
solution NN N
during IN N
its PRP$ N
first JJ N
administration NN N
( ( N
0.27 CD N
± RB N
0.07 CD N
G/L NNP N
) ) N
compared VBN N
to TO N
samples NNS N
collected VBN N
before IN N
filter JJ N
passage NN N
( ( N
1.73 CD N
± RB N
0.049 CD N
G/L NNP N
) ) N
. . N

Also RB N
during IN N
last JJ N
administration NN N
, , N
PMN NNP N
count NN N
in IN N
filtered JJ N
blood NN N
cardioplegic JJ N
solution NN N
was VBD N
decreased VBN N
compared VBN N
to TO N
samples NNS N
collected VBN N
before IN N
filter JJ N
passage NN N
( ( N
0.66 CD N
± RB N
0.35 CD N
G/L NNP N
vs. FW N
3.64 CD N
± $ N
1.14 CD N
G/L NNP N
, , N
respectively RB N
) ) N
. . N

Significantly RB N
lower JJR N
( ( N
p JJ N
< NNP N
0.02 CD N
) ) N
plasma VB N
beta-glucuronidase JJ N
levels NNS N
were VBD N
found VBN N
in IN N
arterial JJ N
blood NN N
samples NNS N
in IN N
Group NNP N
I PRP N
compared VBN N
to TO N
Group NNP N
II NNP N
( ( N
5.59 CD N
± RB N
1.63 CD N
μg/mL NNS N
immediately RB N
after IN N
aortic JJ N
unclamping NN N
and CC N
6.59 CD N
± NNS N
1.98 CD N
μg/mL NNS N
after IN N
25 CD N
min NN N
of IN N
reperfusion NN N
in IN N
Group NNP N
I PRP N
vs. VBP N
10.19 CD N
± JJ N
2.66 CD N
and CC N
12.83 CD N
± NNS N
1.88 CD N
μg/mL NNS N
, , N
respectively RB N
, , N
in IN N
Group NNP N
II NNP N
) ) N
. . N

Beta-glucuronidase JJ N
levels NNS N
in IN N
coronary JJ N
sinus NN N
blood NN N
samples NNS N
collected VBN N
after IN N
aortic JJ N
unclamping NN N
and CC N
at IN N
the DT N
end NN N
of IN N
reperfusion NN N
were VBD N
significantly RB N
higher JJR N
in IN N
Group NNP N
II NNP N
compared VBN N
to TO N
Group NNP N
I PRP N
( ( N
p JJ N
< NNP N
0.04 CD N
) ) N
. . N

In IN N
Group NNP N
I PRP N
, , N
plasma FW N
lysozyme NN N
levels NNS N
in IN N
arterial JJ N
and CC N
venous JJ N
blood NN N
samples NNS N
did VBD N
not RB N
show VB N
significant JJ N
changes NNS N
during IN N
the DT N
surgery NN N
. . N

In IN N
contrast NN N
, , N
plasma VBP N
lysozyme JJ N
level NN N
in IN N
coronary JJ N
sinus NN N
blood NN N
samples NNS N
at IN N
the DT N
end NN N
of IN N
reperfusion NN N
in IN N
Group NNP N
II NNP N
was VBD N
significantly RB N
higher JJR N
compared VBN N
to TO N
that DT N
in IN N
pre-clamping JJ N
samples NNS N
( ( N
p JJ N
< NNP N
0.014 CD N
) ) N
. . N

CONCLUSIONS NN N
With IN N
the DT N
use NN N
of IN N
leukocyte JJ N
reduction NN N
filters NNS N
, , N
we PRP N
found VBD N
significantly RB N
lower JJR N
beta-glucuronidase NN N
levels NNS N
in IN N
arterial JJ N
and CC N
coronary JJ N
sinus NN N
blood NN N
samples NNS N
. . N

These DT N
findings NNS N
seem VBP N
to TO N
confirm VB N
reduced VBN N
PMN NNP N
activation NN N
and/or NN N
reduced VBD N
myocardial JJ N
infiltration NN N
by IN N
activated JJ N
PMN NNP N
. . N

Plasma NNP N
levels NNS N
of IN N
lysozyme NN N
, , N
a DT N
characteristic JJ N
product NN N
of IN N
PMN NNP N
degranulation NN N
, , N
did VBD N
not RB N
show VB N
significant JJ N
differences NNS N
between IN N
the DT N
study NN N
groups NNS N
. . N

-DOCSTART- -X- O O 17334477

Comparison NNP N
of IN N
the DT N
effect NN N
of IN N
gonadotropin-releasing NN N
hormone NN N
analog NN N
( ( N
Diphereline NNP N
) ) N
and CC N
Cabergoline NNP N
( ( N
Dostinex NNP N
) ) N
treatment NN N
on IN N
uterine JJ 4_p
myoma NN 4_p
regression NN 4_p
. . N

OBJECTIVE UH N
To TO N
investigate VB N
the DT N
effect NN N
of IN N
cabergoline NN N
( ( N
Dostinex NNP N
, , N
a DT N
dopamine JJ N
agonist NN N
) ) N
on IN N
the DT N
myoma NN N
growth NN N
compared VBN N
to TO N
Diphereline NNP N
( ( N
a DT N
gonadotropin-releasing NN N
hormone NN N
agonist NN N
) ) N
. . N

METHODS NNP N
This DT N
study NN N
took VBD N
place NN N
in IN N
the DT N
Department NNP N
of IN N
Obstetrics NNP N
and CC N
Gynecology NNP N
of IN N
Tabriz NNP N
University NNP N
of IN N
Medical NNP N
Sciences NNPS N
, , N
Tabriz NNP N
, , N
Iran NNP N
from IN N
July NNP N
2004 CD N
to TO N
December NNP N
2005 CD N
. . N

Fifty NNP N
women NNS N
with IN N
uterine JJ 4_p
myoma NN 4_p
, , N
who WP N
met VBD N
the DT N
criteria NNS N
of IN N
the DT N
study NN N
thoroughly RB N
, , N
were VBD N
randomly RB N
allocated VBN N
into IN N
2 CD N
equal JJ N
groups NNS N
to TO N
take VB N
either DT N
Diphereline NNP N
or CC N
Cabergoline NNP N
. . N

The DT N
first JJ N
Group NNP N
took VBD N
3.75 CD N
mg NN N
of IN N
Diphereline NNP N
4 CD N
times NNS N
every DT N
28 CD N
days NNS N
and CC N
the DT N
second JJ N
group NN N
took VBD N
0.5 CD N
mg NN N
of IN N
Cabergoline NNP N
once RB N
a DT N
week NN N
for IN N
6 CD N
weeks NNS N
. . N

RESULTS VB N
The DT N
Cabergoline NNP N
was VBD N
well RB N
tolerated VBN N
and CC N
fewer JJR N
adverse JJ N
effects NNS N
were VBD N
noted VBN N
. . N

The DT N
tumor NN N
regressed VBD N
significantly RB N
and CC N
volume NN N
reduction NN N
rate NN N
of IN N
individual JJ N
tumor NN N
nodule NN N
varied VBD N
from IN N
46-53 CD N
% NN N
. . N

The DT N
gonadotropin NN N
releasing VBG N
hormone JJ N
agonist NN N
group NN N
all DT N
responded VBD N
to TO N
the DT N
treatment NN N
, , N
and CC N
volume NN N
reduction NN N
rate NN N
of IN N
the DT N
individual JJ N
tumor NN N
nodule NN N
varied VBD N
from IN N
21-97 CD N
% NN N
. . N

The DT N
extent NN N
of IN N
tumor NN N
shrinkage NN N
was VBD N
positively RB N
correlated VBN N
to TO N
the DT N
number NN N
of IN N
nodules NNS N
( ( N
p=0.881 NN N
, , N
p NN N
< VBD N
0.005 CD N
and CC N
0.701 CD N
, , N
p NN N
< NNP N
0.005 CD N
) ) N
. . N

CONCLUSION NNP N
In IN N
light NN N
of IN N
therapeutic JJ N
efficacy NN N
and CC N
few JJ N
adverse JJ N
effects NNS N
, , N
the DT N
dopamine NN N
agonists NNS N
may MD N
hold VB N
promise NN N
as IN N
novel JJ N
treatment NN N
modalities NNS N
for IN N
leiomyoma NN N
. . N

Further JJ N
studies NNS N
are VBP N
warranted VBN N
to TO N
determine VB N
the DT N
optimal JJ N
strategy NN N
for IN N
the DT N
treatment NN N
of IN N
leiomyoma NN N
through IN N
these DT N
agents NNS N
. . N

-DOCSTART- -X- O O 17078451

Treatment NN N
of IN N
psoriasis NN 4_p
vulgaris NN 4_p
by IN N
oral JJ N
administration NN N
of IN N
yin JJ N
xie NNP N
ping NN N
granules NNS N
-- : N
a DT N
clinical JJ N
report NN N
of IN N
60 CD N
cases NNS N
. . N

-DOCSTART- -X- O O 12486433

Comparison NNP N
of IN N
percutaneous JJ N
transmitral JJ N
commissurotomy NN N
with IN N
Inoue NNP N
balloon NN N
technique NN N
and CC N
metallic JJ N
commissurotomy NN N
: : N
immediate JJ N
and CC N
short-term JJ N
follow-up JJ N
results NNS N
of IN N
a DT N
randomized JJ N
study NN N
. . N

BACKGROUND NNP N
The DT N
Inoue NNP N
balloon NN N
technique NN N
for IN N
mitral JJ N
commissurotomy NN N
is VBZ N
well RB N
established VBN N
and CC N
carried VBN N
out RP N
worldwide NN N
. . N

Metallic NNP N
commissurotomy NN N
is VBZ N
reported VBN N
to TO N
be VB N
a DT N
cheaper JJR N
and CC N
effective JJ N
alternative NN N
to TO N
balloon VB N
mitral JJ N
commissurotomy NN N
. . N

METHODS NNP N
One CD N
hundred VBD N
patients NNS N
were VBD N
randomized VBN N
into IN N
2 CD N
groups NNS N
to TO N
undergo VB N
percutaneous JJ N
transmitral JJ N
commissurotomy NN N
( ( N
PTMC NNP N
) ) N
by IN N
means NNS N
of IN N
the DT N
Inoue NNP N
balloon NN N
technique NN N
( ( N
IBMC NNP N
, , N
n JJ N
= NNP N
49 CD N
) ) N
or CC N
metallic JJ N
commissurotomy NN N
( ( N
PMMC NNP N
, , N
n JJ N
= NNP N
51 CD N
) ) N
. . N

Patients NNS N
were VBD N
crossed VBN N
over IN N
to TO N
the DT N
other JJ N
technique NN N
when WRB N
the DT N
initial JJ N
technique NN N
was VBD N
a DT N
failure NN N
. . N

Success NN N
of IN N
valvotomy NN N
, , N
procedure-related JJ N
complications NNS N
, , N
and CC N
follow-up JJ N
events NNS N
of IN N
the DT N
2 CD N
techniques NNS N
were VBD N
compared VBN N
. . N

RESULTS NNP N
Basal NNP N
echocardiographic JJ N
and CC N
hemodynamic JJ N
data NNS N
were VBD N
similar JJ N
in IN N
both DT N
groups NNS N
. . N

Procedural NNP N
success NN N
was VBD N
similar JJ N
in IN N
both DT N
groups NNS N
: : N
45 CD N
of IN N
49 CD N
procedures NNS N
( ( N
91.8 CD N
% NN N
) ) N
in IN N
the DT N
IBMC NNP N
group NN N
, , N
compared VBN N
with IN N
46 CD N
of IN N
51 CD N
procedures NNS N
( ( N
90.18 CD N
% NN N
) ) N
in IN N
the DT N
PMMC NNP N
group NN N
( ( N
P NNP N
= NNP N
1.0 CD N
) ) N
. . N

Crossover NNP N
was VBD N
also RB N
comparable JJ N
, , N
with IN N
1 CD N
occurring VBG N
in IN N
the DT N
IBMC NNP N
group NN N
, , N
compared VBN N
with IN N
3 CD N
in IN N
the DT N
PMMC NNP N
group NN N
. . N

Complications NNS N
such JJ N
as IN N
cardiac JJ N
tamponade NN N
and CC N
mitral JJ N
regurgitation NN N
( ( N
requiring VBG N
or CC N
not RB N
requiring VBG N
mitral JJ N
valve FW N
replacement NN N
) ) N
were VBD N
similar JJ N
in IN N
both DT N
groups NNS N
, , N
with IN N
3 CD N
complications NNS N
in IN N
the DT N
IBMC NNP N
group NN N
, , N
compared VBN N
with IN N
4 CD N
complications NNS N
in IN N
the DT N
PMMC NNP N
group NN N
( ( N
P NNP N
=.29 NNP N
) ) N
. . N

After IN N
a DT N
follow-up JJ N
period NN N
of IN N
approximately RB N
4 CD N
months NNS N
, , N
both DT N
groups NNS N
had VBD N
similar JJ N
event NN N
rates NNS N
and CC N
comparable JJ N
hemodynamic JJ N
parameters NNS N
( ( N
P NNP N
= NNP N
not RB N
significant JJ N
) ) N
. . N

CONCLUSIONS NNP N
Both NNP N
IBMC NNP N
and CC N
PMMC NNP N
are VBP N
successful JJ N
means NNS N
of IN N
providing VBG N
relief NN N
from IN N
severe JJ 4_p
mitral JJ 4_p
stenosis NN 4_p
with IN N
a DT N
gain NN N
in IN N
valve JJ N
area NN N
and CC N
reduction NN N
in IN N
transmitral JJ N
gradient NN N
. . N

Both DT N
techniques NNS N
have VBP N
similar JJ N
procedural JJ N
success NN N
, , N
complication NN N
rates NNS N
, , N
and CC N
follow-up JJ N
events NNS N
. . N

-DOCSTART- -X- O O 16304214

Comparison NNP N
of IN N
antihypertensives NNS N
after IN N
coronary JJ 4_p
artery NN 4_p
surgery NN 4_p
. . N

Hypertension NN N
following VBG N
coronary JJ 4_p
artery JJ 4_p
bypass NN 4_p
grafting NN 4_p
is VBZ N
a DT N
common JJ N
problem NN N
that WDT N
may MD N
result VB N
in IN N
postoperative JJ N
myocardial JJ N
infraction NN N
or CC N
bleeding NN N
, , N
Hemodynamic NNP N
effects NNS N
were VBD N
compared VBN N
in IN N
45 CD N
hypertensive JJ 4_p
coronary JJ 4_p
bypass NN 4_p
patients NNS N
randomized VBN N
to TO N
receive VB N
either DT N
diltiazem NN N
, , N
nitroglycerin NN N
, , N
or CC N
sodium NN N
nitroprusside RB N
. . N

Diltiazem NNP N
was VBD N
administered VBN N
as IN N
an DT N
intravenous JJ N
bolus NN N
of IN N
0.3 CD N
mg.kg-1 NN N
within IN N
5 CD N
min NN N
, , N
followed VBN N
by IN N
infusion NN N
of IN N
0.1-0.8 JJ N
mg.kg-1.h-1 NN N
in IN N
group NN N
1 CD N
. . N

Nitroglycerin NNP N
was VBD N
infused VBN N
at IN N
a DT N
rate NN N
of IN N
1-3 JJ N
microg.kg.h-1 NN N
in IN N
group NN N
2 CD N
, , N
and CC N
sodium NN N
nitroprusside NN N
was VBD N
given VBN N
at IN N
a DT N
rate NN N
of IN N
1-3 JJ N
microg.kg-1.min-1 NN N
in IN N
group NN N
3 CD N
. . N

Hemodynamic JJ N
measurements NNS N
were VBD N
carried VBN N
out RP N
before IN N
infusion NN N
( ( N
T1 NNP N
) ) N
and CC N
at IN N
30 CD N
min NN N
( ( N
T2 NNP N
) ) N
, , N
2 CD N
h NN N
( ( N
T3 NNP N
) ) N
, , N
and CC N
12 CD N
h NN N
( ( N
T4 NNP N
) ) N
after IN N
initiation NN N
of IN N
treatment NN N
in IN N
the DT N
intensive JJ N
care NN N
unit NN N
. . N

Mean NNP N
arterial JJ N
pressure NN N
decreased VBN N
significantly RB N
in IN N
all DT N
groups NNS N
. . N

There EX N
were VBD N
no DT N
differences NNS N
among IN N
groups NNS N
at IN N
T1 NNP N
and CC N
T2 NNP N
. . N

At IN N
T3 NNP N
, , N
heart NN N
rate NN N
in IN N
group NN N
2 CD N
was VBD N
significantly RB N
higher JJR N
than IN N
group NN N
1 CD N
. . N

At IN N
T3 NNP N
and CC N
T4 NNP N
, , N
the DT N
double JJ N
product NN N
was VBD N
highest JJS N
in IN N
group NN N
3 CD N
( ( N
group NN N
1 CD N
vs. NN N
3 CD N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
. . N

These DT N
results NNS N
suggest VBP N
that IN N
the DT N
hemodynamic JJ N
effects NNS N
of IN N
the DT N
3 CD N
drugs NNS N
are VBP N
similar JJ N
within IN N
the DT N
first JJ N
30 CD N
min NN N
. . N

However RB N
, , N
after IN N
30 CD N
min NN N
, , N
diltiazem NN N
affords NNS N
better RBR N
myocardial JJ N
performance NN N
and CC N
more RBR N
effective JJ N
control NN N
of IN N
hypertension NN N
. . N

-DOCSTART- -X- O O 22419350

Most RBS N
effective JJ N
regimen NNS N
of IN N
tranexamic JJ N
acid NN N
in IN N
knee NN 4_p
arthroplasty NN 4_p
: : N
a DT N
prospective JJ N
randomized NN N
controlled VBD N
study NN N
in IN N
240 CD N
patients NNS N
. . N

BACKGROUND NNP N
The DT N
antifibrinolytic JJ N
tranexamic JJ N
acid NN N
reduces NNS N
surgical JJ N
blood NN N
loss NN N
, , N
but CC N
studies NNS N
have VBP N
not RB N
identified VBN N
an DT N
optimal JJ N
regimen NNS N
. . N

QUESTIONS/PURPOSES NNP N
We PRP N
studied VBD N
different JJ N
dosages NNS N
, , N
timings NNS N
, , N
and CC N
modes NNS N
of IN N
administration NN N
to TO N
identify VB N
the DT N
most RBS N
effective JJ N
regimen NNS N
of IN N
tranexamic JJ N
acid NN N
in IN N
achieving VBG N
maximum JJ N
reduction NN N
of IN N
blood NN N
loss NN N
in IN N
TKA NNP N
. . N

METHODS NNP N
We PRP N
prospectively RB N
studied VBD N
five CD N
regimens NNS N
( ( N
four CD N
intravenous NN N
, , N
one CD N
local JJ N
; : N
40 CD N
patients NNS N
each DT N
) ) N
with IN N
a DT N
control NN N
group NN N
( ( N
no DT N
tranexamic JJ N
acid NN N
) ) N
. . N

The DT N
four CD N
intravenous JJ N
( ( N
10-mg/kg JJ N
dose NN N
) ) N
regimens VBZ N
included VBN N
( ( N
1 CD N
) ) N
intraoperative NN N
dose NN N
( ( N
IO NNP N
) ) N
given VBN N
before IN N
tourniquet JJ N
deflation NN N
, , N
( ( N
2 CD N
) ) N
additional JJ N
preoperative NN N
dose NN N
( ( N
POIO NNP N
) ) N
, , N
( ( N
3 CD N
) ) N
additional JJ N
postoperative NN N
dose NN N
( ( N
IOPO NNP N
) ) N
, , N
and CC N
( ( N
4 CD N
) ) N
all DT N
three CD N
doses NNS N
( ( N
POIOPO NNP N
) ) N
. . N

The DT N
fifth JJ N
regimen NN N
was VBD N
a DT N
single JJ N
local JJ N
application NN N
( ( N
LA NNP N
) ) N
. . N

Two CD N
independent JJ N
parameters NNS N
of IN N
drain NN N
loss NN N
and CC N
total JJ N
blood NN N
loss NN N
, , N
calculated VBN N
by IN N
the DT N
hemoglobin NN N
balance NN N
method NN N
, , N
were VBD N
evaluated VBN N
statistically RB N
. . N

RESULTS NNP N
Both NNP N
parameters NNS N
were VBD N
reduced VBN N
in IN N
all DT N
five CD N
regimens NNS N
as IN N
against IN N
the DT N
control NN N
. . N

A DT N
significant JJ N
reduction NN N
in IN N
drain NN N
loss NN N
was VBD N
seen VBN N
in IN N
the DT N
POIO NNP N
, , N
IOPO NNP N
, , N
and CC N
POIOPO NNP N
groups NNS N
whereas VBP N
total JJ N
blood NN N
loss NN N
was VBD N
significantly RB N
reduced VBN N
in IN N
the DT N
POIO NNP N
, , N
POIOPO NNP N
, , N
and CC N
LA NNP N
groups NNS N
. . N

The DT N
POIOPO NNP N
group NN N
had VBD N
the DT N
least JJS N
drain JJ N
loss NN N
( ( N
303 CD N
mL NN N
) ) N
and CC N
least JJS N
total JJ N
blood NN N
loss NN N
( ( N
688 CD N
mL NN N
) ) N
. . N

The DT N
IO NNP N
group NN N
had VBD N
the DT N
greatest JJS N
drain NN N
loss NN N
and CC N
the DT N
IOPO NNP N
group NN N
the DT N
greatest JJS N
total JJ N
blood NN N
loss NN N
. . N

CONCLUSIONS NNP N
Single-dose JJ N
tranexamic JJ N
acid NN N
did VBD N
not RB N
give VB N
effective JJ N
results NNS N
. . N

The DT N
two-dose JJ N
regimen NNS N
of IN N
POIO NNP N
was VBD N
the DT N
least JJS N
amount NN N
necessary JJ N
for IN N
effective JJ N
results NNS N
. . N

When WRB N
compared VBN N
against IN N
the DT N
control NN N
, , N
this DT N
regimen NNS N
produced VBD N
reduction NN N
of IN N
drain NN N
loss NN N
and CC N
total JJ N
blood NN N
loss NN N
, , N
whereas IN N
the DT N
IOPO NNP N
regimen NNS N
did VBD N
not RB N
. . N

The DT N
three-dose JJ N
regimen NNS N
of IN N
POIOPO NNP N
produced VBD N
maximum JJ N
effective JJ N
reduction NN N
of IN N
drain NN N
loss NN N
and CC N
total JJ N
blood NN N
loss NN N
. . N

-DOCSTART- -X- O O 26712084

Pembrolizumab NNP N
versus NN N
docetaxel NN N
for IN N
previously RB 4_p
treated VBN 4_p
, , 4_p
PD-L1-positive JJ 4_p
, , 4_p
advanced JJ 4_p
non-small-cell JJ 4_p
lung NN 4_p
cancer NN 4_p
( ( N
KEYNOTE-010 NNP N
) ) N
: : N
a DT N
randomised JJ N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
Despite IN N
recent JJ N
advances NNS N
in IN N
the DT N
treatment NN N
of IN N
advanced JJ 4_p
non-small-cell JJ 4_p
lung NN 4_p
cancer NN 4_p
, , N
there EX N
remains VBZ N
a DT N
need NN N
for IN N
effective JJ N
treatments NNS N
for IN N
progressive JJ N
disease NN N
. . N

We PRP N
assessed VBD N
the DT N
efficacy NN N
of IN N
pembrolizumab NN N
for IN N
patients NNS N
with IN N
previously RB 4_p
treated VBN 4_p
, , 4_p
PD-L1-positive JJ 4_p
, , 4_p
advanced JJ 4_p
non-small-cell JJ 4_p
lung NN 4_p
cancer NN 4_p
. . N

METHODS NNP N
We PRP N
did VBD N
this DT N
randomised VBN N
, , N
open-label JJ N
, , N
phase VB N
2/3 CD N
study NN N
at IN N
202 CD N
academic JJ N
medical JJ N
centres NNS N
in IN N
24 CD N
countries NNS N
. . N

Patients NNS 4_p
with IN 4_p
previously RB 4_p
treated VBN 4_p
non-small-cell JJ 4_p
lung NN 4_p
cancer NN 4_p
with IN 4_p
PD-L1 NNP 4_p
expression NN 4_p
on IN 4_p
at IN 4_p
least JJS 4_p
1 CD 4_p
% NN 4_p
of IN 4_p
tumour JJ 4_p
cells NNS 4_p
were VBD N
randomly RB N
assigned VBN N
( ( N
1:1:1 CD N
) ) N
in IN N
blocks NNS N
of IN N
six CD N
per IN N
stratum NN N
with IN N
an DT N
interactive JJ N
voice-response NN N
system NN N
to TO N
receive VB N
pembrolizumab NN N
2 CD N
mg/kg NN N
, , N
pembrolizumab VBP N
10 CD N
mg/kg NN N
, , N
or CC N
docetaxel VB N
75 CD N
mg/m NN N
( ( N
2 CD N
) ) N
every DT N
3 CD N
weeks NNS N
. . N

The DT N
primary JJ N
endpoints NNS N
were VBD N
overall JJ N
survival NN N
and CC N
progression-free JJ N
survival NN N
both DT N
in IN N
the DT N
total JJ N
population NN N
and CC N
in IN N
patients NNS N
with IN N
PD-L1 NNP N
expression NN N
on IN N
at IN N
least JJS N
50 CD N
% NN N
of IN N
tumour JJ N
cells NNS N
. . N

We PRP N
used VBD N
a DT N
threshold NN N
for IN N
significance NN N
of IN N
p NN N
< NN N
0.00825 CD N
( ( N
one-sided JJ N
) ) N
for IN N
the DT N
analysis NN N
of IN N
overall JJ N
survival NN N
and CC N
a DT N
threshold NN N
of IN N
p NN N
< $ N
0.001 CD N
for IN N
progression-free JJ N
survival NN N
. . N

This DT N
trial NN N
is VBZ N
registered VBN N
at IN N
ClinicalTrials.gov NNP N
, , N
number NN N
NCT01905657 NNP N
. . N

FINDINGS NNP N
Between NNP N
Aug NNP N
28 CD N
, , N
2013 CD N
, , N
and CC N
Feb NNP N
27 CD N
, , N
2015 CD N
, , N
we PRP N
enrolled VBD N
1034 CD N
patients NNS N
: : N
345 CD N
allocated VBD N
to TO N
pembrolizumab VB N
2 CD N
mg/kg NN N
, , N
346 CD N
allocated VBD N
to TO N
pembrolizumab VB N
10 CD N
mg/kg NN N
, , N
and CC N
343 CD N
allocated VBN N
to TO N
docetaxel VB N
. . N

By IN N
Sept NNP N
30 CD N
, , N
2015 CD N
, , N
521 CD N
patients NNS N
had VBD N
died VBN N
. . N

In IN N
the DT N
total JJ N
population NN N
, , N
median JJ N
overall JJ N
survival NN N
was VBD N
10.4 CD N
months NNS N
with IN N
pembrolizumab JJ N
2 CD N
mg/kg NN N
, , N
12.7 CD N
months NNS N
with IN N
pembrolizumab JJ N
10 CD N
mg/kg NN N
, , N
and CC N
8.5 CD N
months NNS N
with IN N
docetaxel NN N
. . N

Overall JJ N
survival NN N
was VBD N
significantly RB N
longer JJR N
for IN N
pembrolizumab NN N
2 CD N
mg/kg NN N
versus NN N
docetaxel NN N
( ( N
hazard JJ N
ratio NN N
[ NNP N
HR NNP N
] NNP N
0.71 CD N
, , N
95 CD N
% NN N
CI NNP N
0.58-0.88 CD N
; : N
p=0.0008 NN N
) ) N
and CC N
for IN N
pembrolizumab JJ N
10 CD N
mg/kg NN N
versus NN N
docetaxel NN N
( ( N
0.61 CD N
, , N
0.49-0.75 CD N
; : N
p CC N
< VB N
0.0001 CD N
) ) N
. . N

Median JJ N
progression-free JJ N
survival NN N
was VBD N
3.9 CD N
months NNS N
with IN N
pembrolizumab JJ N
2 CD N
mg/kg NN N
, , N
4.0 CD N
months NNS N
with IN N
pembrolizumab JJ N
10 CD N
mg/kg NN N
, , N
and CC N
4.0 CD N
months NNS N
with IN N
docetaxel NN N
, , N
with IN N
no DT N
significant JJ N
difference NN N
for IN N
pembrolizumab NN N
2 CD N
mg/kg NN N
versus NN N
docetaxel NN N
( ( N
0.88 CD N
, , N
0.74-1.05 CD N
; : N
p=0.07 NN N
) ) N
or CC N
for IN N
pembrolizumab JJ N
10 CD N
mg/kg NN N
versus NN N
docetaxel NN N
( ( N
HR NNP N
0.79 CD N
, , N
95 CD N
% NN N
CI NNP N
0.66-0.94 CD N
; : N
p=0.004 NN N
) ) N
. . N

Among IN N
patients NNS N
with IN N
at IN N
least JJS N
50 CD N
% NN N
of IN N
tumour JJ N
cells NNS N
expressing VBG N
PD-L1 NNP N
, , N
overall JJ N
survival NN N
was VBD N
significantly RB N
longer RBR N
with IN N
pembrolizumab JJ N
2 CD N
mg/kg NN N
than IN N
with IN N
docetaxel NN N
( ( N
median JJ N
14.9 CD N
months NNS N
vs RB N
8.2 CD N
months NNS N
; : N
HR NNP N
0.54 CD N
, , N
95 CD N
% NN N
CI NNP N
0.38-0.77 CD N
; : N
p=0.0002 NN N
) ) N
and CC N
with IN N
pembrolizumab JJ N
10 CD N
mg/kg NN N
than IN N
with IN N
docetaxel NN N
( ( N
17.3 CD N
months NNS N
vs RB N
8.2 CD N
months NNS N
; : N
0.50 CD N
, , N
0.36-0.70 CD N
; : N
p CC N
< VB N
0.0001 CD N
) ) N
. . N

Likewise NNP N
, , N
for IN N
this DT N
patient JJ N
population NN N
, , N
progression-free JJ N
survival NN N
was VBD N
significantly RB N
longer RBR N
with IN N
pembrolizumab JJ N
2 CD N
mg/kg NN N
than IN N
with IN N
docetaxel NN N
( ( N
median JJ N
5.0 CD N
months NNS N
vs RB N
4.1 CD N
months NNS N
; : N
HR NNP N
0.59 CD N
, , N
95 CD N
% NN N
CI NNP N
0.44-0.78 CD N
; : N
p=0.0001 NN N
) ) N
and CC N
with IN N
pembrolizumab JJ N
10 CD N
mg/kg NN N
than IN N
with IN N
docetaxel NN N
( ( N
5.2 CD N
months NNS N
vs RB N
4.1 CD N
months NNS N
; : N
0.59 CD N
, , N
0.45-0.78 CD N
; : N
p CC N
< VB N
0.0001 CD N
) ) N
. . N

Grade VBN N
3-5 JJ N
treatment-related JJ N
adverse JJ N
events NNS N
were VBD N
less JJR N
common JJ N
with IN N
pembrolizumab NN N
than IN N
with IN N
docetaxel NN N
( ( N
43 CD N
[ RB N
13 CD N
% NN N
] NN N
of IN N
339 CD N
patients NNS N
given VBN N
2 CD N
mg/kg NNS N
, , N
55 CD N
[ JJ N
16 CD N
% NN N
] NN N
of IN N
343 CD N
given VBN N
10 CD N
mg/kg NN N
, , N
and CC N
109 CD N
[ JJ N
35 CD N
% NN N
] NN N
of IN N
309 CD N
given VBN N
docetaxel NN N
) ) N
. . N

INTERPRETATION NNP N
Pembrolizumab NNP N
prolongs NNS N
overall JJ N
survival NN N
and CC N
has VBZ N
a DT N
favourable JJ N
benefit-to-risk JJ N
profile NN N
in IN N
patients NNS N
with IN N
previously RB N
treated VBN N
, , N
PD-L1-positive JJ N
, , N
advanced JJ N
non-small-cell JJ N
lung NN N
cancer NN N
. . N

These DT N
data NNS N
establish VB N
pembrolizumab NN N
as IN N
a DT N
new JJ N
treatment NN N
option NN N
for IN N
this DT N
population NN N
and CC N
validate VB N
the DT N
use NN N
of IN N
PD-L1 NNP N
selection NN N
. . N

FUNDING NNP N
Merck NNP N
& CC N
Co NNP N
. . N

-DOCSTART- -X- O O 16108781

Economic JJ N
evaluation NN N
of IN N
a DT N
nursing-led JJ N
inpatient JJ N
unit NN N
: : N
the DT N
impact NN N
of IN N
findings NNS N
on IN N
management NN N
decisions NNS N
of IN N
service NN N
utility NN N
and CC N
sustainability NN N
. . N

AIMS IN N
The DT N
nursing-led JJ N
inpatient NN N
unit NN N
is VBZ N
designed VBN N
to TO N
substitute VB N
for IN N
a DT N
period NN N
of IN N
care NN N
in IN N
acute JJ N
hospital NN N
wards NNS N
and CC N
to TO N
improve VB N
patient NN N
outcome NN N
prior RB N
to TO N
discharge VB N
to TO N
the DT N
community NN N
. . N

This DT N
paper NN N
aims VBZ N
to TO N
evaluate VB N
the DT N
cost NN N
, , N
from IN N
the DT N
UK NNP N
National NNP N
Health NNP N
Service NNP N
perspective NN N
, , N
of IN N
transfer NN N
to TO N
a DT N
nursing-led JJ N
inpatient NN N
unit NN N
for IN N
intermediate JJ N
care NN N
and CC N
to TO N
discuss VB N
the DT N
impact NN N
of IN N
these DT N
findings NNS N
to TO N
the DT N
future NN N
development NN N
and CC N
sustainability NN N
of IN N
the DT N
nursing-led JJ N
inpatient NN N
unit NN N
. . N

BACKGROUND NNP N
Recent NNP N
economic JJ N
analyses NNS N
have VBP N
showed VBN N
that IN N
nursing-led JJ N
inpatient JJ N
units NNS N
are VBP N
associated VBN N
with IN N
increased JJ N
costs NNS N
of IN N
care NN N
with IN N
length NN N
of IN N
stay NN N
as IN N
the DT N
main JJ N
driver NN N
of IN N
inpatient NN N
costs NNS N
. . N

METHOD VB N
The DT N
cost-effectiveness JJ N
analysis NN N
was VBD N
part NN N
of IN N
a DT N
randomized-controlled JJ N
trial NN N
with IN N
a DT N
sample JJ 4_p
size NN 4_p
of IN 4_p
175 CD 4_p
, , 4_p
of IN 4_p
which WDT 4_p
89 CD 4_p
were VBD 4_p
in IN 4_p
the DT 4_p
nursing-led JJ 4_p
inpatient NN 4_p
unit NN 4_p
arm NN 4_p
and CC 4_p
86 CD 4_p
in IN 4_p
the DT 4_p
control NN 4_p
arm NN 4_p
. . 4_p

Resource NNP N
use NN N
data NNS N
included VBD N
length NN N
of IN N
stay NN N
, , N
investigations NNS N
performed VBD N
, , N
multiprofessional JJ N
input NN N
and CC N
nursing NN N
input NN N
. . N

Clinical JJ N
outcome NN N
was VBD N
measured VBN N
using VBG N
Barthel NNP N
Index NNP N
, , N
a DT N
functional JJ N
status NN N
measure NN N
. . N

RESULTS NNP N
Cost NNP N
per IN N
day NN N
was VBD N
lower JJR N
on IN N
the DT N
nursing-led JJ N
inpatient NN N
unit NN N
although IN N
cost NN N
per IN N
hospital NN N
stay NN N
was VBD N
higher JJR N
due JJ N
to TO N
significantly RB N
increased JJ N
length NN N
of IN N
stay NN N
. . N

Postdischarge NNP N
community NN N
care NN N
costs NNS N
were VBD N
lower JJR N
. . N

The DT N
incremental JJ N
cost-effectiveness JJ N
ratio NN N
of IN N
the DT N
treatment NN N
was VBD N
1044 CD N
pounds NNS N
sterling JJ N
per IN N
point NN N
improvement NN N
of IN N
the DT N
Barthel NNP N
Index NNP N
. . N

CONCLUSIONS VB N
The DT N
nursing-led JJ N
inpatient NN N
unit NN N
was VBD N
associated VBN N
with IN N
higher JJR N
costs NNS N
however RB N
, , N
the DT N
question NN N
of IN N
whether IN N
the DT N
nursing-led JJ N
inpatient NN N
unit NN N
is VBZ N
cost-effective JJ N
has VBZ N
not RB N
been VBN N
clearly RB N
answered VBN N
because IN N
of IN N
the DT N
limited JJ N
follow-up JJ N
period NN N
of IN N
the DT N
study NN N
. . N

The DT N
increased JJ N
cost NN N
of IN N
care NN N
on IN N
the DT N
nursing-led JJ N
inpatient NN N
unit NN N
was VBD N
not RB N
a DT N
major JJ N
factor NN N
in IN N
local JJ N
management NN N
decisions NNS N
about IN N
the DT N
future NN N
of IN N
the DT N
unit NN N
. . N

The DT N
changes NNS N
in IN N
the DT N
context NN N
of IN N
service NN N
provision NN N
within IN N
which WDT N
the DT N
nursing-led JJ N
inpatient NN N
unit NN N
operated VBD N
as IN N
a DT N
result NN N
of IN N
substantial JJ N
investment NN N
in IN N
intermediate JJ N
care NN N
did VBD N
have VB N
a DT N
major JJ N
impact NN N
. . N

-DOCSTART- -X- O O 8428787

Effect NN N
of IN N
reduced JJ N
alcohol NN N
consumption NN N
on IN N
blood NN N
pressure NN N
in IN N
untreated JJ N
hypertensive JJ 4_p
men NNS N
. . N

Fifty-four CD N
untreated JJ N
, , N
mildly RB N
hypertensive JJ N
men NNS N
whose WP$ N
daily JJ N
alcohol NN N
consumption NN N
was VBD N
> JJ N
or CC N
= JJ N
28 CD N
ml NN N
ethanol NN N
and CC N
who WP N
drank VBP N
at IN N
least JJS N
4 CD N
times NNS N
per IN N
week NN N
took VBD N
part NN N
in IN N
a DT N
randomized NN N
, , N
controlled VBD N
crossover RB N
trial NN N
. . N

The DT N
purpose NN N
of IN N
the DT N
trial NN N
was VBD N
to TO N
test VB N
the DT N
effects NNS N
of IN N
alcohol NN N
reduction NN N
on IN N
blood NN N
pressure NN N
. . N

After IN N
a DT N
2-week JJ N
familiarization NN N
period NN N
, , N
the DT N
participants NNS N
were VBD N
assigned VBN N
to TO N
either CC N
a DT N
reduced JJ N
alcohol NN N
drinking NN N
group NN N
or CC N
a DT N
usual JJ N
drinking NN N
group NN N
for IN N
3 CD N
weeks NNS N
( ( N
experimental JJ N
period NN N
1 CD N
) ) N
. . N

The DT N
situation NN N
was VBD N
then RB N
reversed VBN N
for IN N
the DT N
next JJ N
3 CD N
weeks NNS N
( ( N
experimental JJ N
period NN N
2 CD N
) ) N
. . N

The DT N
participants NNS N
were VBD N
requested VBN N
to TO N
limit VB N
their PRP$ N
daily JJ N
alcohol NN N
consumption NN N
to TO N
zero CD N
or CC N
reduce VB N
it PRP N
as RB N
much RB N
as IN N
possible JJ N
for IN N
the DT N
reduced JJ N
alcohol NN N
consumption NN N
period NN N
. . N

The DT N
self-reported JJ N
alcohol NN N
consumption NN N
was VBD N
56.1 CD N
+/- JJ N
3.6 CD N
( ( N
SEM NNP N
) ) N
ml/day NN N
during IN N
the DT N
usual JJ N
alcohol NN N
drinking NN N
period NN N
and CC N
26.1 CD N
+/- JJ N
3.0 CD N
ml/day NN N
during IN N
the DT N
period NN N
of IN N
reduced JJ N
alcohol NN N
consumption NN N
. . N

Systolic NNP N
and CC N
diastolic JJ N
blood NN N
pressures NNS N
in IN N
the DT N
intervention NN N
group NN N
were VBD N
found VBN N
by IN N
analysis NN N
of IN N
variance NN N
to TO N
be VB N
significantly RB N
lower JJR N
( ( N
2.6-4.8 JJ N
and CC N
2.2-3.0 JJ N
mm NN N
Hg NNP N
, , N
respectively RB N
) ) N
than IN N
those DT N
in IN N
the DT N
control NN N
group NN N
during IN N
experimental JJ N
period NN N
2 CD N
for IN N
systolic JJ N
blood NN N
pressure NN N
and CC N
experimental JJ N
period NN N
1 CD N
for IN N
diastolic JJ N
blood NN N
pressure NN N
. . N

Significant NNP N
( ( N
3.6 CD N
mm RB N
Hg NNP N
) ) N
and CC N
nonsignificant JJ N
( ( N
1.9 CD N
mm RB N
Hg NNP N
) ) N
decreases VBZ N
in IN N
systolic JJ N
and CC N
diastolic JJ N
blood NN N
pressure NN N
, , N
respectively RB N
, , N
were VBD N
observed VBN N
. . N

The DT N
method NN N
of IN N
Hills NNP N
and CC N
Armitage NNP N
was VBD N
used VBN N
, , N
reducing VBG N
ethanol NNS N
in IN N
daily JJ N
alcohol NN N
consumption NN N
by IN N
28 CD N
ml NN N
. . N

The DT N
lowering VBG N
effect NN N
of IN N
reduced JJ N
alcohol NN N
consumption NN N
on IN N
blood NN N
pressure NN N
was VBD N
independent JJ N
of IN N
changes NNS N
in IN N
salt NN N
consumption NN N
, , N
which WDT N
were VBD N
estimated VBN N
by IN N
24-hour JJ N
urine JJ N
collection NN N
and CC N
body NN N
weight NN N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -X- O O 14711190

Effects NNS N
of IN N
low JJ N
and CC N
high JJ N
doses NNS N
of IN N
atorvastatin NN N
on IN N
arterial JJ N
compliance NN N
. . N

At IN N
the DT N
beginning NN N
of IN N
atherosclerosis NN N
before IN N
evidence NN N
of IN N
morphological JJ N
lesions NNS N
or CC N
plaques NNS N
, , N
vascular JJ N
distensibility NN N
or CC N
arterial JJ N
compliance NN N
decreased VBN N
gradually RB N
. . N

This DT N
endothelial JJ N
dysfunction NN N
is VBZ N
regarded VBN N
as IN N
an DT N
early JJ N
feature NN N
of IN N
atherosclerosis NN N
. . N

In IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
study NN N
design NN N
, , N
group NN N
1 CD N
( ( N
12 CD 4_p
patients NNS N
; : N
7 CD 4_p
males NNS 4_p
, , N
5 CD 4_p
females NNS 4_p
) ) N
with IN N
serum JJ 4_p
LDL-C JJ 4_p
levels NNS 4_p
higher JJR N
than IN N
170 CD N
mg/dL NN N
and CC N
without IN N
any DT N
other JJ N
risk NN N
factor NN N
for IN N
atherosclerosis NN 4_p
received VBD N
three CD N
months NNS N
of IN N
20 CD N
mg/day JJ N
atorvastatin FW N
treatment NN N
while IN N
group NN N
11 CD N
( ( N
8 CD 4_p
males NNS 4_p
, , N
4 CD 4_p
females NNS 4_p
) ) N
with IN N
the DT N
same JJ N
characteristics NNS N
received VBD N
80 CD N
mg/day NN N
. . N

Baseline NNP N
and CC N
posttreatment JJ N
serum NN N
lipid JJ N
fractions NNS N
and CC N
arterial JJ N
compliance NN N
were VBD N
measured VBN N
. . N

Arterial JJ N
compliance NN N
was VBD N
measured VBN N
noninvasively RB N
in IN N
the DT N
left JJ N
common JJ N
carotid NN N
artery NN N
with IN N
color NN N
Doppler NNP N
ultrasound NN N
. . N

Atorvastatin NNP N
reduced VBD N
total JJ N
cholesterol NN N
( ( N
TC NNP N
) ) N
, , N
LDL-C NNP N
, , N
and CC N
triglyceride NN N
levels NNS N
by IN N
32 CD N
% NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
40.8 CD N
% NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
and CC N
19 CD N
% NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
respectively RB N
, , N
and CC N
increased VBD N
HDL-C NNP N
by IN N
6.9 CD N
% NN N
, , N
( ( N
P NNP N
= NNP N
0.002 CD N
) ) N
in IN N
the DT N
first JJ N
group NN N
. . N

In IN N
the DT N
second JJ N
group NN N
these DT N
reductions NNS N
were VBD N
38.5 CD N
% NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
46.2 CD N
% NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
and CC N
26.78 CD N
% NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
respectively RB N
, , N
and CC N
the DT N
increase NN N
in IN N
HDL NNP N
was VBD N
7.8 CD N
% NN N
( ( N
P NNP N
= NNP N
0.03 CD N
) ) N
. . N

It PRP N
was VBD N
observed VBN N
that IN N
the DT N
decrease NN N
in IN N
serum NN N
TC NNP N
, , N
LDL-C NNP N
and CC N
triglyceride NN N
levels NNS N
were VBD N
significantly RB N
higher JJR N
in IN N
the DT N
second JJ N
group NN N
than IN N
the DT N
first JJ N
group NN N
. . N

With IN N
atorvastatin NN N
, , N
the DT N
distensibility NN N
coefficient NN N
( ( N
DC NNP N
) ) N
and CC N
compliance NN N
coefficient NN N
( ( N
CC NNP N
) ) N
increased VBD N
from IN N
18.7 CD N
+/- JJ N
3.4 CD N
to TO N
21.3 CD N
+/- JJ N
2.9 CD N
10 CD N
( ( N
-3 NN N
) ) N
x NN N
kPa NN N
( ( N
-1 NN N
) ) N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
from IN N
0.69 CD N
+/- JJ N
0.05 CD N
to TO N
0.77 CD N
+/- JJ N
0.03 CD N
mm2 NN N
x NN N
kPa NN N
( ( N
-1 NN N
) ) N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
in IN N
the DT N
first JJ N
group NN N
while IN N
they PRP N
changed VBD N
from IN N
18.3 CD N
+/- JJ N
3.6 CD N
to TO N
21.9 CD N
+/- JJ N
3.0 CD N
10 CD N
( ( N
-3 NN N
) ) N
x NN N
kPa NN N
( ( N
-1 NN N
) ) N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
from IN N
0.70 CD N
+/- JJ N
0.04 CD N
to TO N
0.81 CD N
+/- JJ N
0.01 CD N
mm2 NN N
x NN N
kPa NN N
( ( N
-1 NN N
) ) N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
respectively RB N
, , N
in IN N
the DT N
second JJ N
group NN N
. . N

DC NNP N
and CC N
CC NNP N
increased VBD N
in IN N
both DT N
groups NNS N
, , N
but CC N
the DT N
differences NNS N
between IN N
the DT N
groups NNS N
were VBD N
not RB N
significant JJ N
. . N

High JJ N
doses NNS N
of IN N
atorvastatin NN N
reduce VB N
blood NN N
lipid NN N
levels NNS N
more RBR N
than IN N
conventional JJ N
doses NNS N
, , N
however RB N
, , N
the DT N
change NN N
in IN N
compliance NN N
is VBZ N
not RB N
dose-dependent JJ N
. . N

As IN N
endothelial JJ N
dysfunction NN N
is VBZ N
regarded VBN N
as IN N
an DT N
early JJ N
feature NN N
of IN N
atherosclerosis NN N
, , N
there EX N
would MD N
be VB N
no RB N
need NN N
to TO N
administer VB N
aggressive JJ N
doses NNS N
in IN N
a DT N
patient NN N
without IN N
any DT N
risk NN N
factors NNS N
other JJ N
than IN N
hyperlipidemia NN N
. . N

-DOCSTART- -X- O O 14736356

Single-needle JJ N
acupuncture NN N
alleviates VBZ N
gag JJ N
reflex NN N
during IN 4_p
transesophageal JJ 4_p
echocardiography NN 4_p
: : 4_p
a DT N
blinded VBN N
, , N
randomized VBN N
, , N
controlled VBD N
pilot NN N
trial NN N
. . N

OBJECTIVES UH N
To TO N
study VB N
the DT N
effect NN N
of IN N
single-needle JJ N
acupuncture NN N
in IN N
suppressing VBG N
gag-reflex JJ N
in IN N
transesophageal JJ N
echocardiography NN N
( ( N
TEE NNP N
) ) N
. . N

DESIGN NNP N
Prospective NNP N
, , N
blinded VBD N
trial NN N
. . N

Settings/locations NNS N
: : N
Patients NNS 4_p
with IN 4_p
ischemic JJ 4_p
stroke NN 4_p
or CC 4_p
transient JJ 4_p
ischemic JJ 4_p
attack NN 4_p
undergoing JJ 4_p
TEE NNP 4_p
because IN 4_p
of IN 4_p
presumed JJ 4_p
cardioembolic JJ 4_p
origin NN 4_p
in IN 4_p
a DT 4_p
specialized JJ 4_p
stroke NN 4_p
unit NN 4_p
of IN 4_p
the DT 4_p
Johann NNP 4_p
Wolfgang NNP 4_p
Goethe-University NNP 4_p
, , 4_p
Frankfurt/Main NNP 4_p
, , 4_p
Germany NNP 4_p
. . 4_p

Subjects/Study NNP N
interventions NNS N
: : N
Forty-one CD N
( ( N
41 CD N
) ) N
patients NNS N
were VBD N
studied VBN N
. . N

Patients NNS N
received VBD N
single-needle JJ N
acupuncture NN N
with IN N
a DT N
0.2 CD N
x NN N
13 CD N
mm NN N
disposable JJ N
acupuncture NN N
needle NN N
( ( N
Suzhou NNP N
Medical NNP N
Appliances NNP N
, , N
China NNP N
) ) N
, , N
10-mm JJ N
deep NN N
either NN N
at IN N
Chengjiang NNP N
( ( N
midline NN N
between IN N
lower JJR N
lip NN N
and CC N
chin NN N
) ) N
or CC N
superficially RB N
at IN N
a DT N
sham NN N
point NN N
( ( N
tip NN N
of IN N
the DT N
chin NN N
) ) N
during IN N
TEE NNP N
or CC N
no DT N
acupuncture NN N
for IN N
alleviating VBG N
gag NN N
reflex NN N
. . N

OUTCOME NNP N
MEASURES NNP N
Severity NNP N
of IN N
gagging NN N
was VBD N
rated VBN N
on IN N
a DT N
visual-analogue JJ N
scale NN N
. . N

RESULTS VB N
The DT N
acupuncture NN N
group NN N
experienced VBD N
significantly RB N
less RBR N
gagging VBG N
than IN N
the DT N
sham NN N
group NN N
( ( N
p JJ N
= NNP N
0.037 CD N
) ) N
or CC N
the DT N
nonacupuncture NN N
group NN N
( ( N
p JJ N
= NNP N
0.013 CD N
) ) N
. . N

CONCLUSIONS NNP N
Acupuncture NNP N
of IN N
CV24 NNP N
is VBZ N
an DT N
easy JJ N
to TO N
apply VB N
and CC N
effective JJ N
method NN N
to TO N
reduce VB N
gag NN N
reflex NN N
during IN N
TEE NNP N
. . N

-DOCSTART- -X- O O 15446660

Faulty NNP N
Japanese JJ N
sentences NNS N
are VBP N
judged VBN N
more RBR N
grammatical JJ N
when WRB N
punctuation NN N
is VBZ N
used VBN N
: : N
negative JJ N
implications NNS N
for IN N
Chomsky NNP N
's POS N
principle NN N
of IN N
Full NNP N
Interpretation NNP N
. . N

88 CD N
adult JJ N
Japanese JJ 4_p
speakers NNS N
judged VBD N
the DT N
grammaticality NN N
of IN N
isolated JJ N
simple JJ N
bitransitive JJ N
sentences NNS N
involving VBG N
an DT N
uninterpretable JJ N
extra JJ N
argument NN N
in IN N
addition NN N
to TO N
three CD N
legitimate JJ N
arguments NNS N
. . N

The DT N
sentences NNS N
thus RB N
violated VBD N
Chomsky NNP N
's POS N
principle NN N
of IN N
Full NNP N
Interpretation NNP N
which WDT N
prohibits VBZ N
the DT N
structure NN N
building NN N
of IN N
a DT N
sentence NN N
including VBG N
uninterpretable JJ N
elements NNS N
. . N

The DT N
primary JJ N
variable NN N
of IN N
interest NN N
was VBD N
the DT N
presence NN N
or CC N
absence NN N
of IN N
punctuation NN N
, , N
i.e. FW N
, , N
commas NN N
, , N
which WDT N
enclosed VBD N
the DT N
extra JJ N
argument NN N
. . N

Findings NNS N
showed VBD N
that IN N
sentences NNS N
with IN N
punctuation NN N
were VBD N
judged VBN N
more RBR N
grammatical JJ N
than IN N
the DT N
ones NNS N
without IN N
punctuation NN N
, , N
with IN N
an DT N
average JJ N
score NN N
of IN N
judged JJ N
grammaticality NN N
exceeding VBG N
3 CD N
on IN N
a DT N
7-point JJ N
scale NN N
( ( N
1 CD N
=least RB N
grammatical JJ N
; : N
7=most CD N
grammatical NN N
) ) N
. . N

This DT N
score NN N
would MD N
not RB N
be VB N
expected VBN N
if IN N
the DT N
speakers NNS N
possess NN N
and CC N
judge NN N
the DT N
sentences NNS N
in IN N
conformity NN N
with IN N
the DT N
principle NN N
of IN N
Full NNP N
Interpretation NNP N
. . N

-DOCSTART- -X- O O 25432505

Effectiveness NN N
of IN N
a DT N
fundamental JJ N
motor NN N
skill NN N
intervention NN N
for IN N
4-year-old JJ N
children NNS N
with IN N
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
: : N
A DT N
pilot NN N
study NN N
. . N

A DT N
wait-list JJ N
control NN N
experimental JJ N
design NN N
was VBD N
employed VBN N
to TO N
investigate VB N
the DT N
effectiveness NN N
of IN N
a DT N
fundamental JJ N
motor NN N
skill NN N
intervention NN N
at IN N
improving VBG N
the DT N
motor NN N
skills NNS N
, , N
adaptive JJ N
behavior NN N
, , N
and CC N
social JJ N
skills NNS N
of IN N
4-year-old JJ N
children NNS N
with IN N
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
( ( N
experimental JJ N
n NN N
= VBD N
5 CD N
, , N
control NN N
n JJ N
= NNP N
4 CD N
) ) N
; : N
the DT N
impact NN N
of IN N
intervention NN N
intensity NN N
was VBD N
also RB N
explored VBN N
. . N

The DT N
experimental JJ N
group NN N
significantly RB N
improved VBN N
their PRP$ N
object JJ N
manipulation NN N
and CC N
overall JJ N
motor NN N
scores NNS N
from IN N
pre- JJ N
to TO N
post-intervention NN N
. . N

The DT N
wait-list JJ N
control NN N
design NN N
revealed VBD N
no DT N
group-by-time JJ N
interactions NNS N
; : N
however RB N
, , N
with IN N
the DT N
groups NNS N
combined VBD N
time NN N
was VBD N
a DT N
significant JJ N
factor NN N
for IN N
all DT N
motor NN N
variables NNS N
. . N

There EX N
were VBD N
no DT N
significant JJ N
changes NNS N
in IN N
adaptive JJ N
behavior NN N
and CC N
social JJ N
skills NNS N
. . N

These DT N
preliminary JJ N
findings NNS N
suggest VBP N
that IN N
a DT N
fundamental JJ N
motor NN N
skill NN N
intervention NN N
may MD N
benefit VB N
young JJ N
children NNS N
with IN N
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
. . N

Future JJ N
research NN N
with IN N
larger JJR N
samples NNS N
is VBZ N
warranted VBN N
. . N

-DOCSTART- -X- O O 17443855

Long-term JJ N
results NNS N
of IN N
a DT N
randomized JJ N
clinical JJ N
trial NN N
of IN N
Shouldice NNP 4_p
, , 4_p
Lichtenstein NNP 4_p
and CC 4_p
transabdominal JJ 4_p
preperitoneal NN 4_p
hernia NN 4_p
repairs NNS N
. . N

INTRODUCTION NNP N
There EX N
is VBZ N
an DT N
ongoing JJ N
debate NN N
about IN N
the DT N
preferred JJ N
technique NN N
for IN N
inguinal JJ N
hernia NN N
repair NN N
. . N

In IN N
this DT N
randomized VBN N
study NN N
the DT N
long-term JJ N
results NNS N
of IN N
Shouldice NNP N
, , N
Lichtenstein NNP N
and CC N
transabdominal JJ N
preperitoneal NN N
( ( N
TAPP NNP N
) ) N
hernia NN N
repair NN N
were VBD N
compared VBN N
. . N

METHODS NNP N
Some DT N
280 CD N
men NNS N
with IN N
a DT N
primary JJ 4_p
hernia NN 4_p
were VBD N
randomized VBN N
prospectively RB N
to TO N
undergo VB N
Shouldice NNP N
, , N
tension-free JJ N
Lichtenstein NNP N
or CC N
laparoscopic JJ N
TAPP NNP N
repair NN N
. . N

Patients NNS N
were VBD N
examined VBN N
after IN N
52 CD N
months NNS N
to TO N
assess VB N
hernia NN N
recurrence NN N
, , N
nerve NN N
damage NN N
, , N
testicular JJ N
atrophy NN N
and CC N
patient JJ N
satisfaction NN N
. . N

RESULTS NNP N
Hernia NNP N
recurrence NN N
occurred VBD N
in IN N
six CD N
patients NNS N
after IN N
Shouldice NNP N
repair NN N
, , N
and CC N
in IN N
one CD N
patient NN N
each DT N
after IN N
Lichtenstein NNP N
and CC N
TAPP NNP N
repairs NNS N
. . N

All DT N
recurrences NNS N
after IN N
tension-free JJ N
repairs NNS N
were VBD N
diagnosed VBN N
within IN N
the DT N
first JJ N
year NN N
after IN N
surgery NN N
. . N

Nerve CC N
injuries NNS N
were VBD N
significantly RB N
more RBR N
frequent JJ N
after IN N
open JJ N
Shouldice NNP N
and CC N
Lichtenstein NNP N
repairs NNS N
. . N

Patient JJ N
satisfaction NN N
was VBD N
greatest JJS N
after IN N
laparoscopic JJ N
TAPP NNP N
repair NN N
. . N

CONCLUSION NNP N
Tension-free NNP N
repair NN N
was VBD N
superior JJ N
to TO N
the DT N
non-mesh JJ N
Shouldice NNP N
technique NN N
. . N

The DT N
open JJ N
anterior JJ N
approach NN N
to TO N
the DT N
groin NN N
was VBD N
associated VBN N
with IN N
demonstrable JJ N
nerve NN N
injury NN N
, , N
and CC N
laparoscopic JJ N
TAPP NNP N
repair NN N
was VBD N
the DT N
most RBS N
effective JJ N
approach NN N
in IN N
the DT N
hands NNS N
of IN N
an DT N
experienced JJ N
surgeon NN N
. . N

-DOCSTART- -X- O O 22007005

Use NNP N
of IN N
an DT N
Internet NNP N
portal NN N
to TO N
improve VB N
community-based JJ N
pediatric JJ N
ADHD NNP 4_p
care NN N
: : N
a DT N
cluster NN N
randomized VBN N
trial NN N
. . N

OBJECTIVE NN N
To TO N
determine VB N
the DT N
effectiveness NN N
of IN N
a DT N
quality NN N
improvement NN N
program NN N
to TO N
improve VB N
pediatricians NNS N
' POS N
adherence NN N
to TO N
existing VBG N
, , N
evidence-based JJ N
, , N
attention-deficit/hyperactivity JJ N
disorder NN N
( ( N
ADHD NNP N
) ) N
practice NN N
guidelines NNS N
. . N

METHODS NNP N
Forty-nine JJ N
community-based JJ N
pediatricians NNS N
at IN N
8 CD N
practices NNS N
participated VBN N
in IN N
a DT N
cluster-randomized JJ N
trial NN N
. . N

Practices NNS N
were VBD N
matched VBN N
according VBG N
to TO N
the DT N
numbers NNS N
of IN N
pediatricians NNS N
and CC N
the DT N
proportions NNS N
of IN N
patients NNS N
receiving VBG N
Medicaid NNP N
. . N

The DT N
medical JJ N
charts NNS N
for IN N
a DT N
random JJ N
sample NN N
of IN N
patients NNS N
with IN N
ADHD NNP N
for IN N
each DT N
of IN N
the DT N
participating VBG N
pediatricians NNS N
were VBD N
examined VBN N
at IN N
baseline NN N
and CC N
6 CD N
months NNS N
. . N

All DT N
practices NNS N
participated VBN N
in IN N
4 CD N
sessions NNS N
of IN N
training NN N
, , N
including VBG N
didactic JJ N
lectures NNS N
and CC N
office NN N
flow NN N
modification NN N
workshops NNS N
. . N

Practices NNS N
were VBD N
then RB N
given VBN N
access NN N
to TO N
an DT N
ADHD NNP N
Internet NNP N
portal NN N
that WDT N
allowed VBD N
parents NNS N
, , N
teachers NNS N
, , N
and CC N
pediatricians NNS N
to TO N
input VB N
information NN N
( ( N
eg NN N
, , N
rating NN N
scales NNS N
) ) N
about IN N
patients NNS N
, , N
after IN N
which WDT N
information NN N
was VBD N
scored VBN N
, , N
interpreted VBN N
, , N
and CC N
formatted VBN N
in IN N
a DT N
report NN N
style NN N
that WDT N
was VBD N
helpful JJ N
for IN N
assessment NN N
and CC N
treatment NN N
of IN N
patients NNS N
with IN N
ADHD NNP N
. . N

Physicians NNPS N
evaluated VBD N
their PRP$ N
practice NN N
behaviors NNS N
quarterly RB N
and CC N
addressed VBD N
underperforming JJ N
areas NNS N
. . N

RESULTS NNP N
Pediatricians NNPS N
in IN N
the DT N
intervention NN N
group NN N
, , N
compared VBN N
with IN N
those DT N
in IN N
the DT N
control NN N
group NN N
, , N
demonstrated VBD N
significantly RB N
higher JJR N
rates NNS N
of IN N
many JJ N
American JJ N
Academy NNP N
of IN N
Pediatrics-recommended NNP N
ADHD NNP N
care NN N
practices NNS N
, , N
including VBG N
collection NN N
of IN N
parent NN N
( ( N
Cohen NNP N
's POS N
d NN N
= VBZ N
0.69 CD N
) ) N
and CC N
teacher $ N
( ( N
d JJ N
= NNP N
0.68 CD N
) ) N
rating NN N
scales NNS N
for IN N
assessment NN N
of IN N
children NNS N
with IN N
ADHD NNP N
, , N
use NN N
of IN N
Diagnostic NNP N
and CC N
Statistical NNP N
Manual NNP N
of IN N
Mental NNP N
Disorders NNP N
, , N
Fourth NNP N
Edition NNP N
, , N
criteria NNS N
( ( N
d VB N
= RB N
0.85 CD N
) ) N
, , N
and CC N
use NN N
of IN N
teacher NN N
rating NN N
scales NNS N
to TO N
monitor VB N
treatment NN N
responses NNS N
( ( N
d VB N
= RB N
1.01 CD N
) ) N
. . N

CONCLUSION VB N
A DT N
quality NN N
improvement NN N
intervention NN N
that WDT N
can MD N
be VB N
widely RB N
disseminated VBN N
by IN N
using VBG N
Internet-based JJ N
information NN N
technology NN N
significantly RB N
improved VBD N
the DT N
quality NN N
of IN N
ADHD NNP N
care NN N
in IN N
community-based JJ N
pediatric JJ N
settings NNS N
. . N

-DOCSTART- -X- O O 12636954

The DT N
effects NNS N
of IN N
peer NN N
counseling VBG N
on IN N
smoking VBG N
cessation NN N
and CC N
reduction NN N
. . N

OBJECTIVE UH N
To TO N
evaluate VB N
a DT N
peer NN N
counseling VBG N
intervention NN N
for IN N
pregnant JJ 4_p
smokers NNS 4_p
. . N

METHODS NNP N
One CD N
hundred VBD N
forty-two NN N
pregnant NN 4_p
, , N
predominantly RB N
Hispanic JJ N
women NNS N
were VBD N
assigned VBN N
to TO N
a DT N
peer-led JJ N
smoking NN N
cessation NN N
program NN N
or CC N
to TO N
usual JJ N
care NN N
. . N

RESULTS NNP N
Compared VBD N
with IN N
usual JJ N
care NN N
, , N
peer NN N
counseling NN N
reduced VBN N
smoking NN N
( ( N
-9.1 JJ N
versus NN N
-4.5 NNP N
cigarettes VBZ N
daily RB N
, , N
P NNP N
=.03 NNP N
) ) N
, , N
but CC N
did VBD N
not RB N
affect VB N
absolute JJ N
quit NN N
rates NNS N
( ( N
24 CD N
% NN N
versus IN N
21 CD N
% NN N
) ) N
at IN N
36 CD N
weeks NNS N
' POS N
gestation NN N
. . N

Infant NNP N
birth NN N
weight VBD N
negatively RB N
correlated VBN N
with IN N
cigarettes NNS N
smoked VBN N
per IN N
day NN N
( ( N
r VB N
= NNP N
-0.29 NNP N
, , N
P NNP N
< NNP N
.01 NNP N
) ) N
and CC N
expired JJ N
carbon NN N
monoxide NN N
( ( N
r JJ N
= NNP N
-0.39 NN N
, , N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
at IN N
delivery NN N
. . N

Birth NNP N
weight VBD N
for IN N
infants NNS N
born VBN N
to TO N
women NNS N
who WP N
quit VBP N
smoking VBG N
averaged VBD N
7.2 CD N
lb JJ N
versus NN N
6.8 CD N
and CC N
6.3 CD N
lb NN N
for IN N
mothers NNS N
smoking VBG N
one CD N
to TO N
six CD N
and CC N
more JJR N
than IN N
six CD N
cigarettes NNS N
per IN N
day NN N
at IN N
delivery NN N
( ( N
P NNP N
< NNP N
.01 NNP N
) ) N
. . N

CONCLUSION NNP N
Peer NNP N
counseling NN N
reduced VBD N
the DT N
number NN N
of IN N
cigarettes NNS N
smoked VBN N
daily RB N
but CC N
did VBD N
not RB N
increase VB N
cigarette NN N
abstinence NN N
rates NNS N
. . N

Infant NNP N
birth NN N
weight NN N
increases NNS N
with IN N
both DT N
smoking VBG N
cessation NN N
and CC N
smoking NN N
reduction NN N
, , N
suggesting VBG N
that IN N
peer NN N
counseling VBG N
intervention NN N
programs NNS N
may MD N
improve VB N
newborn JJR N
health NN N
despite IN N
their PRP$ N
failure NN N
to TO N
affect VB N
smoking VBG N
cessation NN N
. . N

-DOCSTART- -X- O O 7820060

Interferon NNP N
treatment NN N
for IN N
hairy NN 4_p
cell NN 4_p
leukemia NN 4_p
. . N

An DT N
update NN N
on IN N
a DT N
cohort NN N
of IN N
69 CD N
patients NNS N
treated VBN N
from IN N
1983 CD N
to TO N
1986 CD N
. . N

We PRP N
report VBP N
follow-up JJ N
information NN N
on IN N
69 CD N
hairy NN 4_p
cell NN 4_p
leukemia NN 4_p
( ( 4_p
HCL NNP 4_p
) ) 4_p
patients NNS N
treated VBN N
with IN N
interferon JJ N
alfa-2b NN N
( ( N
IFN NNP N
) ) N
as IN N
primary JJ N
treatment NN N
from IN N
1983 CD N
to TO N
1986 CD N
. . N

Follow-up NNP N
through IN N
April NNP N
, , N
1993 CD N
shows VBZ N
that IN N
only RB N
14 CD N
patients NNS N
have VBP N
expired VBN N
. . N

Forty-seven CD N
of IN N
the DT N
61 CD N
patients NNS N
completing VBG N
the DT N
intended JJ N
12 CD N
or CC N
more JJR N
months NNS N
of IN N
initial JJ N
IFN NNP N
treatment NN N
were VBD N
eventually RB N
considered VBN N
IFN NNP N
failures NNS N
. . N

Forty-three CD N
required JJ N
re-treatment NN N
( ( N
41 CD N
received VBD N
a DT N
second JJ N
course NN N
of IN N
IFN NNP N
and CC N
2 CD N
received VBD N
pentostatin NN N
) ) N
. . N

Four CD N
patients NNS N
died VBD N
without IN N
further JJ N
therapy NN N
for IN N
HCL NNP N
. . N

The DT N
median JJ N
time NN N
to TO N
interferon VB N
failure NN N
was VBD N
31.3 CD N
months NNS N
. . N

Fourteen JJ N
patients NNS N
are VBP N
alive JJ N
and CC N
have VBP N
not RB N
required VBN N
further RBR N
treatment NN N
after IN N
completing VBG N
their PRP$ N
initial JJ N
12 CD N
or CC N
more JJR N
months NNS N
of IN N
interferon NN N
. . N

Fifteen JJ N
patients NNS N
underwent VBD N
a DT N
third JJ N
course NN N
of IN N
interferon NN N
therapy NN N
at IN N
a DT N
median JJ N
time NN N
after IN N
completion NN N
of IN N
a DT N
second JJ N
course NN N
of IN N
IFN NNP N
of IN N
1.0 CD N
year NN N
. . N

Eighteen JJ N
patients NNS N
were VBD N
eventually RB N
treated VBN N
with IN N
pentostatin NN N
and CC N
ten VB N
with IN N
2-chlorodeoxyadenosine JJ N
( ( N
2-CdA JJ N
) ) N
. . N

Thirteen JJ N
patients NNS N
developed VBD N
a DT N
second JJ N
malignancy NN N
; : N
six CD N
of IN N
these DT N
patients NNS N
developed VBD N
a DT N
hematologic JJ N
malignancy NN N
between IN N
44.6 CD N
months NNS N
and CC N
99.1 CD N
months NNS N
after IN N
initiation NN N
of IN N
interferon NN N
therapy NN N
. . N

We PRP N
conclude VBP N
that IN N
although IN N
interferon NN N
provides VBZ N
excellent JJ N
palliation NN N
, , N
that IN N
most JJS N
patients NNS N
will MD N
eventually RB N
require VB N
further JJ N
treatment NN N
with IN N
interferon NN N
or CC N
chemotherapy NN N
. . N

Future JJ N
trials NNS N
in IN N
HCL NNP N
must MD N
be VB N
aware JJ N
of IN N
the DT N
risk NN N
of IN N
second JJ N
malignancies NNS N
. . N

-DOCSTART- -X- O O 17715164

Anti-inflammatory JJ N
effects NNS N
of IN N
inhaled JJ N
carbon NN N
monoxide NN N
in IN N
patients NNS N
with IN N
COPD NNP 4_p
: : N
a DT N
pilot NN N
study NN N
. . N

In IN N
vitro NN N
and CC N
in IN N
vivo JJ N
studies NNS N
have VBP N
shown VBN N
that IN N
carbon NN N
monoxide NN N
( ( N
CO NNP N
) ) N
has VBZ N
both DT N
anti-inflammatory JJ N
and CC N
anti-oxidant JJ N
capacities NNS N
. . N

Since IN N
chronic JJ N
obstructive JJ N
pulmonary JJ N
disease NN N
( ( N
COPD NNP N
) ) N
is VBZ N
characterised VBN N
by IN N
inflammation NN N
and CC N
oxidative JJ N
stress NN N
, , N
low-dose JJ N
CO NNP N
could MD N
be VB N
of IN N
therapeutic JJ N
use NN N
. . N

The DT N
aim NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
feasibility NN N
and CC N
anti-inflammatory JJ N
effects NNS N
of IN N
100-125 JJ N
ppm NN N
CO NNP N
inhalation NN N
in IN N
patients NNS N
with IN N
stable JJ 4_p
COPD NNP 4_p
. . N

In IN N
total JJ N
, , N
20 CD N
ex-smoking JJ N
COPD NNP 4_p
patients NNS N
with IN N
post-bronchodilator NN N
forced JJ N
expiratory NN N
volume NN N
in IN N
one CD N
second NN N
( ( N
FEV NNP N
( ( N
1 CD N
) ) N
) ) N
> $ N
1.20 CD N
L NNP N
and CC N
FEV NNP N
( ( N
1 CD N
) ) N
/forced VBD N
vital JJ N
capacity NN N
< VBP N
70 CD N
% NN N
were VBD N
enrolled VBN N
in IN N
a DT N
randomised JJ N
, , N
placebo-controlled JJ N
, , N
crossover NN N
study NN N
. . N

Effects NNS N
on IN N
inflammation NN N
were VBD N
measured VBN N
in IN N
induced JJ N
sputum NN N
and CC N
blood NN N
. . N

CO NNP N
inhalation NN N
was VBD N
feasible JJ N
and CC N
patients NNS N
' POS N
vital JJ N
signs NNS N
were VBD N
unaffected VBN N
; : N
2 CD N
h.day NN N
( ( N
-1 NNP N
) ) N
inhalation NN N
of IN N
low-dose JJ N
CO NNP N
on IN N
4 CD N
consecutive JJ N
days NNS N
led VBD N
to TO N
a DT N
maximal JJ N
individual JJ N
carboxyhaemoglobin NN N
level NN N
of IN N
4.5 CD N
% NN N
. . N

Two CD N
exacerbations NNS N
occurred VBD N
in IN N
the DT N
CO NNP N
period NN N
. . N

CO NNP N
inhalation NN N
led VBD N
to TO N
trends NNS N
in IN N
reduced JJ N
sputum NN N
eosinophils NNS N
( ( N
median JJ N
reduction NN N
0.25 CD N
% NN N
point NN N
) ) N
and CC N
improved JJ N
responsiveness NN N
to TO N
methacholine VB N
( ( N
median JJ N
provocative NN N
concentration NN N
causing VBG N
a DT N
20 CD N
% NN N
fall NN N
in IN N
FEV NNP N
( ( N
1 CD N
) ) N
0.85 CD N
versus $ N
0.63 CD N
mg.mL NN N
( ( N
-1 NNP N
) ) N
) ) N
. . N

Inhalation NN N
of IN N
100-125 JJ N
ppm NN N
carbon NN N
monoxide NN N
by IN N
patients NNS N
with IN N
chronic JJ 4_p
obstructive JJ 4_p
pulmonary JJ 4_p
disease NN 4_p
in IN 4_p
a DT 4_p
stable JJ 4_p
phase NN 4_p
was VBD N
feasible JJ N
and CC N
led VBD N
to TO N
trends NNS N
in IN N
reduction NN N
of IN N
sputum NN N
eosinophils NNS N
and CC N
improvement NN N
of IN N
responsiveness NN N
to TO N
methacholine VB N
. . N

Further NNP N
studies NNS N
need VBP N
to TO N
confirm VB N
the DT N
safety NN N
and CC N
efficacy NN N
in IN N
inflammatory JJ 4_p
lung NN 4_p
diseases NNS 4_p
. . N

-DOCSTART- -X- O O 20594308

Non-pharmacological JJ N
care NN N
for IN N
patients NNS 4_p
with IN 4_p
generalized JJ 4_p
osteoarthritis NN 4_p
: : 4_p
design NN N
of IN N
a DT N
randomized JJ N
clinical JJ N
trial NN N
. . N

BACKGROUND NNP N
Non-pharmacological JJ N
treatment NN N
( ( N
NPT NNP N
) ) N
is VBZ N
a DT N
useful JJ N
treatment NN N
option NN N
in IN N
the DT N
management NN N
of IN N
hip NN N
or CC N
knee NN N
osteoarthritis NN N
. . N

To TO N
our PRP$ N
knowledge NN N
however RB N
, , N
no DT N
studies NNS N
have VBP N
investigated VBN N
the DT N
effect NN N
of IN N
NPT NNP N
in IN N
patients NNS N
with IN N
generalized JJ N
osteoarthritis NN N
( ( N
GOA NNP N
) ) N
. . N

The DT N
primary JJ N
aim NN N
of IN N
this DT N
study NN N
is VBZ N
to TO N
compare VB N
the DT N
effectiveness NN N
of IN N
two CD N
currently RB N
existing VBG N
health NN N
care NN N
programs NNS N
with IN N
different JJ N
intensity NN N
and CC N
mode NN N
of IN N
delivery NN N
on IN N
daily JJ N
functioning NN N
in IN N
patients NNS N
with IN N
GOA NNP N
. . N

The DT N
secondary JJ N
objective NN N
is VBZ N
to TO N
compare VB N
the DT N
cost-effectiveness NN N
of IN N
both DT N
interventions NNS N
. . N

METHODS/DESIGN NNP N
In IN N
this DT N
randomized VBN N
, , N
single JJ N
blind NN N
, , N
clinical JJ N
trial NN N
with IN N
active JJ N
controls NNS N
, , N
we PRP N
aim VBP N
to TO N
include VB N
170 CD N
patients NNS N
with IN N
GOA NNP N
. . N

The DT N
experimental JJ N
intervention NN N
consist NN N
of IN N
six CD N
self-management JJ N
group NN N
sessions NNS N
provided VBN N
by IN N
a DT N
multi-disciplinary JJ N
team NN N
( ( N
occupational JJ N
therapist NN N
, , N
physiotherapist NN N
, , N
dietician JJ N
and CC N
specialized JJ N
nurse NN N
) ) N
. . N

The DT N
active JJ N
control NN N
group NN N
consists VBZ N
of IN N
two CD N
group NN N
sessions NNS N
and CC N
four CD N
sessions NNS N
by IN N
telephone NN N
, , N
provided VBN N
by IN N
a DT N
specialized JJ N
nurse NN N
and CC N
physiotherapist NN N
. . N

Both DT N
therapies NNS N
last JJ N
six CD N
weeks NNS N
. . N

Main NNP N
study NN N
outcome NN N
is VBZ N
daily JJ N
functioning VBG N
during IN N
the DT N
first JJ N
year NN N
after IN N
the DT N
treatment NN N
, , N
assessed VBN N
on IN N
the DT N
Health NNP N
Assessment NNP N
Questionnaire NNP N
. . N

Secondary JJ N
outcomes NNS N
are VBP N
health NN N
related JJ N
quality NN N
of IN N
life NN N
, , N
specific JJ N
complaints NNS N
, , N
fatigue NN N
, , N
and CC N
costs NNS N
. . N

Illness NNP N
cognitions NNS N
, , N
global JJ N
perceived VBN N
effect NN N
and CC N
self-efficacy NN N
, , N
will MD N
also RB N
be VB N
assessed VBN N
for IN N
a DT N
responder NN N
analysis NN N
. . N

Outcome CC N
assessments NNS N
are VBP N
performed VBN N
directly RB N
after IN N
the DT N
intervention NN N
, , N
after IN N
26 CD N
weeks NNS N
and CC N
after IN N
52 CD N
weeks NNS N
. . N

DISCUSSION NN N
This DT N
article NN N
describes VBZ N
the DT N
design NN N
of IN N
a DT N
randomized VBN N
, , N
single JJ N
blind NN N
, , N
clinical JJ N
trial NN N
with IN N
a DT N
one CD N
year NN N
follow VB N
up IN N
to TO N
compare VB N
the DT N
costs NNS N
and CC N
effectiveness NN N
of IN N
two CD N
non-pharmacological JJ N
interventions NNS N
with IN N
different JJ N
modes NNS N
of IN N
delivery NN N
for IN N
patients NNS N
with IN N
GOA NNP N
. . N

TRIAL NNP N
REGISTRATION NNP N
Dutch NNP N
Trial NNP N
Register NNP N
NTR2137 NNP N
. . N

-DOCSTART- -X- O O 15131557

Primary JJ N
stenting NN N
of IN N
occluded JJ N
native JJ N
coronary JJ N
arteries NNS N
: : N
final JJ N
results NNS N
of IN N
the DT N
Primary NNP N
Stenting NNP N
of IN N
Occluded NNP N
Native NNP N
Coronary NNP N
Arteries NNP N
( ( N
PRISON NNP N
) ) N
study NN N
. . N

BACKGROUND NNP N
Primary NNP N
intracoronary JJ N
stent NN N
placement NN N
after IN N
successfully RB N
crossing VBG N
chronic JJ N
total JJ N
coronary JJ N
occlusions NNS N
may MD N
decrease VB N
the DT N
high JJ N
restenosis NN N
rate NN N
at IN N
long-term JJ N
follow-up JJ N
compared VBN N
with IN N
conventional JJ N
balloon NN N
angioplasty NN N
. . N

METHODS NNP N
In IN N
a DT N
prospective JJ N
, , N
randomized JJ N
trial NN N
, , N
balloon NN N
angioplasty NN N
was VBD N
compared VBN N
with IN N
stent JJ N
implantation NN N
for IN N
the DT N
treatment NN N
of IN N
chronic JJ 4_p
total JJ 4_p
occlusions NNS 4_p
. . N

Patients NNS N
were VBD N
followed VBN N
for IN N
12 CD N
months NNS N
with IN N
angiographic JJ N
follow-up NN N
at IN N
6 CD N
months NNS N
. . N

Quantitative JJ N
coronary JJ N
analysis NN N
was VBD N
performed VBN N
by IN N
an DT N
independent JJ N
core NN N
lab NN N
. . N

RESULTS VB N
A DT N
total NN N
of IN N
200 CD N
patients NNS N
were VBD N
enrolled VBN N
. . N

Baseline JJ N
characteristics NNS N
were VBD N
evenly RB N
distributed VBN N
. . N

After IN N
the DT N
procedure NN N
the DT N
mean NN N
minimal JJ N
luminal JJ N
diameter NN N
in IN N
the DT N
conventional JJ N
group NN N
was VBD N
2.34 CD N
+/- JJ N
0.46 CD N
mm NN N
versus NN N
2.90 CD N
+/- JJ N
0.41 CD N
mm NN N
in IN N
the DT N
stented VBN N
group NN N
( ( N
P NNP N
< NNP N
.0001 NNP N
) ) N
. . N

The DT N
6-month JJ N
angiographic JJ N
follow-up NN N
showed VBD N
a DT N
mean JJ N
minimal JJ N
luminal JJ N
diameter NN N
of IN N
1.57 CD N
+/- JJ N
0.74 CD N
mm NN N
in IN N
the DT N
conventional JJ N
group NN N
versus VBD N
1.93 CD N
+/- JJ N
0.85 CD N
mm NN N
in IN N
the DT N
stented VBN N
group NN N
( ( N
P NNP N
=.009 NNP N
) ) N
and CC N
a DT N
mean JJ N
diameter NN N
stenosis NN N
of IN N
44.7 CD N
% NN N
+/- JJ N
25.0 CD N
% NN N
versus IN N
35.5 CD N
% NN N
+/- JJ N
26.5 CD N
% NN N
( ( N
P NNP N
=.036 NNP N
) ) N
. . N

Binary JJ N
angiographic JJ N
restenosis NN N
( ( N
> JJ N
50 CD N
% NN N
diameter JJ N
stenosis NN N
) ) N
was VBD N
seen VBN N
in IN N
33 CD N
% NN N
in IN N
the DT N
conventional JJ N
group NN N
versus VBD N
22 CD N
% NN N
in IN N
the DT N
stented VBN N
group NN N
( ( N
P NNP N
=.137 NNP N
) ) N
. . N

The DT N
reocclusion NN N
rates NNS N
were VBD N
7.3 CD N
% NN N
and CC N
8.2 CD N
% NN N
, , N
respectively RB N
( ( N
P NNP N
= NNP N
1.00 CD N
) ) N
. . N

At IN N
12 CD N
month NN N
follow-up NN N
, , N
the DT N
rate NN N
of IN N
target NN N
lesion NN N
revascularization NN N
was VBD N
significantly RB N
higher JJR N
in IN N
the DT N
conventional JJ N
group NN N
( ( N
29 CD N
% NN N
versus IN N
13 CD N
% NN N
, , N
P NNP N
< NNP N
.0001 NNP N
) ) N
. . N

CONCLUSION NNP N
These DT N
data NNS N
demonstrate NN N
that IN N
stenting VBG N
of IN N
chronic JJ N
total JJ N
occlusions NNS N
is VBZ N
superior JJ N
to TO N
balloon VB N
angioplasty JJ N
alone RB N
with IN N
a DT N
statistically RB N
significant JJ N
reduction NN N
in IN N
the DT N
need NN N
for IN N
target NN N
lesion NN N
revascularization NN N
and CC N
a DT N
lower JJR N
, , N
but CC N
not RB N
significant JJ N
, , N
restenosis NN N
rate NN N
. . N

-DOCSTART- -X- O O 10200837

Behavioral NNP N
and CC N
physiological JJ N
effects NNS N
of IN N
deep JJ N
pressure NN N
on IN N
children NNS 4_p
with IN 4_p
autism NN 4_p
: : 4_p
a DT N
pilot NN N
study NN N
evaluating VBG N
the DT N
efficacy NN N
of IN N
Grandin NNP N
's POS N
Hug NNP N
Machine NNP N
. . N

OBJECTIVE NNP N
One CD N
symptom NN N
common JJ N
to TO N
many JJ N
persons NNS N
with IN N
autism NN N
is VBZ N
a DT N
high JJ N
arousal NN N
or CC N
anxiety NN N
level NN N
. . N

This DT N
study NN N
investigated VBD N
the DT N
effects NNS N
of IN N
deep JJ N
pressure NN N
on IN N
arousal NN N
and CC N
anxiety NN N
reduction NN N
in IN N
autism NN N
with IN N
Grandin NNP N
's POS N
Hug NNP N
Machine NNP N
, , N
a DT N
device NN N
that WDT N
allows VBZ N
self-administration NN N
of IN N
lateral JJ N
body NN N
pressure NN N
. . N

METHOD NNP N
Twelve NNP N
children NNS N
with IN N
autism NN N
were VBD N
randomly RB N
assigned VBN N
to TO N
either DT N
an DT N
experimental JJ N
group NN N
( ( N
receiving VBG N
deep JJ N
pressure NN N
) ) N
or CC N
a DT N
placebo NN N
group NN N
( ( N
not RB N
receiving VBG N
deep JJ N
pressure NN N
but CC N
in IN N
the DT N
disengaged JJ N
Hug NNP N
Machine NNP N
) ) N
. . N

All DT N
children NNS N
received VBD N
two CD N
20-min JJ N
sessions NNS N
a DT N
week NN N
over IN N
a DT N
6-week JJ N
period NN N
. . N

Arousal NNP N
was VBD N
measured VBN N
behaviorally RB N
with IN N
the DT N
Conners NNPS N
Parent NNP N
Rating NNP N
Scale NNP N
and CC N
physiologically RB N
with IN N
galvanic JJ N
skin NN N
response NN N
( ( N
GSR NNP N
) ) N
readings NNS N
. . N

RESULTS NNP N
Behavioral NNP N
results NNS N
indicated VBD N
a DT N
significant JJ N
reduction NN N
in IN N
tension NN N
and CC N
a DT N
marginally RB N
significant JJ N
reduction NN N
in IN N
anxiety NN N
for IN N
children NNS N
who WP N
received VBD N
the DT N
deep JJ N
pressure NN N
compared VBN N
with IN N
the DT N
children NNS N
who WP N
did VBD N
not RB N
. . N

Additionally RB N
, , N
children NNS N
in IN N
the DT N
experimental JJ N
group NN N
, , N
whose WP$ N
GSR NNP N
measures NNS N
decreased VBD N
, , N
on IN N
average NN N
, , N
after IN N
deep JJ N
pressure NN N
, , N
were VBD N
somewhat RB N
more RBR N
likely JJ N
to TO N
have VB N
higher JJR N
GSR NNP N
arousal VBZ N
a DT N
priori NN N
. . N

CONCLUSION NNP N
These DT N
preliminary JJ N
findings NNS N
support VBP N
the DT N
hypothesis NN N
that WDT N
deep JJ N
pressure NN N
may MD N
have VB N
a DT N
calming JJ N
effect NN N
for IN N
persons NNS N
with IN N
autism NN N
, , N
especially RB N
those DT N
with IN N
high JJ N
levels NNS N
of IN N
arousal NN N
or CC N
anxiety NN N
. . N

-DOCSTART- -X- O O 2015394

Allogeneic NNP N
marrow NN N
transplantation NN N
in IN N
patients NNS N
with IN N
chronic JJ 4_p
myeloid NN 4_p
leukemia NN 4_p
in IN 4_p
the DT 4_p
chronic JJ 4_p
phase NN 4_p
: : N
a DT N
randomized JJ N
trial NN N
of IN N
two CD N
irradiation NN N
regimens NNS N
. . N

A DT N
randomized JJ N
trial NN N
was VBD N
performed VBN N
to TO N
compare VB N
two CD N
regimens NNS N
of IN N
total JJ N
body NN N
irradiation NN N
in IN N
patients NNS N
with IN N
chronic JJ 4_p
myeloid NN 4_p
leukemia NN 4_p
treated VBN 4_p
by IN 4_p
allogeneic JJ 4_p
marrow NN 4_p
transplantation NN 4_p
while IN 4_p
in IN 4_p
the DT 4_p
chronic JJ 4_p
phase NN 4_p
. . N

All DT N
patients NNS N
received VBD N
cyclophosphamide JJ N
120 CD N
mg/kg NN N
followed VBN N
by IN N
total JJ N
body NN N
irradiation NN N
and CC N
marrow NN N
from IN N
HLA-identical JJ N
siblings NNS N
. . N

Cyclosporine NNP N
and CC N
methotrexate NN N
were VBD N
used VBN N
for IN N
prophylaxis NN N
against IN N
acute JJ N
graft-versus-host JJ N
disease NN N
. . N

Fifty-seven JJ N
patients NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
2.0 CD N
Gy NNP N
fractions NNS N
of IN N
irradiation NN N
daily NN N
for IN N
6 CD N
days NNS N
and CC N
59 CD N
were VBD N
randomized VBN N
to TO N
receive VB N
2.25 CD N
Gy NNP N
fractions NNS N
daily RB N
for IN N
7 CD N
days NNS N
. . N

The DT N
probabilities NNS N
of IN N
relapse NN N
at IN N
4 CD N
years NNS N
were VBD N
0.25 CD N
for IN N
the DT N
12.0 CD N
Gy NNP N
group NN N
and CC N
0.00 CD N
for IN N
the DT N
15.75 CD N
Gy NNP N
group NN N
( ( N
P NNP N
= NNP N
.008 NNP N
) ) N
. . N

The DT N
actuarial JJ N
probabilities NNS N
of IN N
survival NN N
and CC N
relapse-free JJ N
survival NN N
at IN N
4 CD N
years NNS N
were VBD N
0.60 CD N
and CC N
0.58 CD N
among IN N
the DT N
patients NNS N
who WP N
received VBD N
12.0 CD N
Gy NNP N
compared VBN N
with IN N
0.66 CD N
and CC N
0.66 CD N
for IN N
those DT N
who WP N
received VBD N
15.75 CD N
Gy NNP N
. . N

The DT N
4-year JJ N
probabilities NNS N
of IN N
transplant-related JJ N
mortality NN N
were VBD N
0.24 CD N
and CC N
0.34 CD N
respectively RB N
( ( N
P NNP N
= NNP N
.13 NNP N
) ) N
while IN N
the DT N
probability NN N
of IN N
moderate JJ N
to TO N
severe VB N
acute JJ N
graft-versus-host JJ N
disease NN N
was VBD N
0.33 CD N
for IN N
the DT N
12.0 CD N
Gy NNP N
group NN N
and CC N
0.44 CD N
for IN N
the DT N
15.75 CD N
Gy NNP N
group NN N
( ( N
P NNP N
= NNP N
.15 NNP N
) ) N
. . N

The DT N
lower JJR N
relapse NN N
probability NN N
in IN N
the DT N
patients NNS N
receiving VBG N
the DT N
higher JJR N
dose NN N
of IN N
total JJ N
body NN N
irradiation NN N
did VBD N
not RB N
result VB N
in IN N
improved JJ N
survival NN N
because IN N
mortality NN N
from IN N
causes VBZ N
other JJ N
than IN N
relapse NN N
was VBD N
increased VBN N
. . N

-DOCSTART- -X- O O 21576129

Impact NN N
of IN N
dronedarone NN N
on IN N
hospitalization NN N
burden NN N
in IN N
patients NNS 4_p
with IN 4_p
atrial JJ 4_p
fibrillation NN 4_p
: : 4_p
results NNS N
from IN N
the DT N
ATHENA NNP N
study NN N
. . N

AIMS NNP N
Cardiovascular NNP N
( ( N
CV NNP N
) ) N
hospitalization NN N
is VBZ N
a DT N
predictor NN N
of IN N
CV NNP N
mortality NN N
and CC N
has VBZ N
a DT N
negative JJ N
impact NN N
on IN N
patients NNS N
' POS N
quality NN N
of IN N
life NN N
. . N

The DT N
primary JJ N
endpoint NN N
of IN N
A NNP N
placebo-controlled JJ N
, , N
double-blind JJ N
, , N
parallel-arm JJ N
Trial NNP N
to TO N
assess VB N
the DT N
efficacy NN N
of IN N
dronedarone NN N
400 CD N
mg NN N
bid NN N
for IN N
the DT N
prevention NN N
of IN N
cardiovascular JJ N
Hospitalization NNP N
or CC N
death NN N
from IN N
any DT N
cause NN N
in IN N
patiENTs NN 4_p
with IN 4_p
Atrial NNP 4_p
fibrillation/atrial JJ 4_p
flutter NN 4_p
( ( 4_p
ATHENA NNP 4_p
) ) 4_p
, , N
a DT N
composite NN N
of IN N
first JJ N
CV NNP N
hospitalization NN N
or CC N
death NN N
from IN N
any DT N
cause NN N
, , N
was VBD N
significantly RB N
reduced VBN N
by IN N
dronedarone NN N
. . N

This DT N
post NN N
hoc NN N
analysis NN N
evaluated VBD N
the DT N
secondary JJ N
endpoint NN N
of IN N
CV NNP N
hospitalization NN N
and CC N
the DT N
clinical JJ N
benefit NN N
of IN N
dronedarone NN N
on IN N
the DT N
number NN N
and CC N
duration NN N
of IN N
CV NNP N
hospitalizations NNS N
in IN N
patients NNS N
with IN N
atrial JJ N
fibrillation NN N
( ( N
AF NNP N
) ) N
. . N

METHODS NNP N
AND CC N
RESULTS NNP N
ATHENA NNP N
was VBD N
a DT N
double-blind NN N
, , N
parallel JJ N
group NN N
study NN N
in IN N
4628 CD 4_p
patients NNS 4_p
with IN 4_p
a DT 4_p
history NN 4_p
of IN 4_p
paroxysmal/persistent NN 4_p
AF NNP 4_p
and CC 4_p
additional JJ 4_p
risk NN 4_p
factors NNS 4_p
, , N
treated VBN N
with IN N
placebo NN N
or CC N
dronedarone NN N
. . N

Dronedarone NNP N
treatment NN N
significantly RB N
reduced VBD N
the DT N
risk NN N
of IN N
first JJ N
CV NNP N
hospitalization NN N
( ( N
P NNP N
< VBZ N
0.0001 CD N
vs. FW N
placebo NN N
) ) N
, , N
while IN N
the DT N
risk NN N
of IN N
first JJ N
non-CV JJ N
hospitalization NN N
was VBD N
similar JJ N
in IN N
both DT N
groups NNS N
( ( N
P NNP N
= NNP N
0.77 CD N
) ) N
. . N

About IN N
half NN N
of IN N
the DT N
CV NNP N
hospitalizations NNS N
were VBD N
AF-related JJ N
, , N
with IN N
a DT N
median JJ N
duration NN N
of IN N
hospital JJ N
stay NN N
of IN N
four CD N
nights NNS N
. . N

The DT N
risk NN N
of IN N
any DT N
hospitalization NN N
for IN N
AF NNP N
[ NNP N
hazard NN N
ratio NN N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
) ) N
0.626 CD N
( ( N
0.546-0.719 NN N
) ) N
] NN N
and CC N
duration NN N
of IN N
hospital NN N
stay NN N
were VBD N
significantly RB N
reduced VBN N
by IN N
dronedarone NN N
( ( N
P NNP N
< VBZ N
0.0001 CD N
vs. FW N
placebo NN N
) ) N
. . N

Dronedarone NNP N
treatment NN N
reduced VBD N
total JJ N
hospitalizations NNS N
for IN N
acute JJ N
coronary JJ N
syndrome NN N
( ( N
P NNP N
= NNP N
0.0105 CD N
) ) N
and CC N
the DT N
time NN N
between IN N
the DT N
first JJ N
AF/atrial NNP N
flutter NN N
recurrence NN N
and CC N
CV NNP N
hospitalization/death NN N
( ( N
P NNP N
= NNP N
0.0048 CD N
) ) N
. . N

Hospitalization NNP N
burden NN N
was VBD N
significantly RB N
reduced VBN N
across IN N
all DT N
levels NNS N
of IN N
care NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Cumulative JJ N
incidence NN N
data NNS N
indicated VBD N
that IN N
the DT N
effects NNS N
of IN N
dronedarone NN N
persisted VBN N
for IN N
at IN N
least JJS N
24 CD N
months NNS N
. . N

CONCLUSION NNP N
Dronedarone NNP N
reduced VBD N
the DT N
risk NN N
for IN N
CV NNP N
hospitalization NN N
and CC N
the DT N
total JJ N
hospitalization NN N
burden NN N
in IN N
this DT N
patient NN N
group NN N
. . N

The DT N
trial NN N
is VBZ N
registered VBN N
under IN N
ClinicalTrials.gov NNP N
# # N
NCT NNP N
00174785 CD N
. . N

-DOCSTART- -X- O O 8018457

Interactive JJ N
effects NNS N
of IN N
indomethacin NN N
, , N
angiotensin NN N
II NNP N
and CC N
frusemide VB N
on IN N
renal JJ N
haemodynamics NNS N
and CC N
natriuresis NN N
in IN N
man NN N
. . N

The DT N
responses NNS N
of IN N
renal JJ N
haemodynamic NN N
and CC N
natriuretic JJ N
indices NNS N
to TO N
the DT N
oral JJ N
prostaglandin NN N
synthetase NN N
inhibitor NN N
indomethacin NN N
( ( N
200 CD N
mg NN N
) ) N
, , N
to TO N
infused VBN N
angiotensin NN N
II NNP N
( ( N
1 CD N
ng RB N
min-1 JJ N
kg-1 NN N
) ) N
and CC N
to TO N
the DT N
combination NN N
of IN N
the DT N
two CD N
were VBD N
studies NNS N
in IN N
placebo-controlled JJ N
fashion NN N
in IN N
eight CD 4_p
normal JJ N
male JJ 4_p
subjects NNS N
both DT N
prior JJ N
to TO N
and CC N
following VBG N
administration NN N
of IN N
intravenous JJ N
frusemide NN N
( ( N
20 CD N
mg NN N
) ) N
. . N

As IN N
compared VBN N
with IN N
placebo NN N
, , N
angiotensin NN N
II NNP N
infusion NN N
alone RB N
caused VBD N
significant JJ N
reductions NNS N
in IN N
absolute JJ N
rate NN N
of IN N
sodium NN N
excretion NN N
, , N
fractional JJ N
sodium NN N
excretion NN N
, , N
urine JJ N
flow NN N
rate NN N
and CC N
effective JJ N
renal JJ N
plasma NN N
flow NN N
( ( N
all DT N
P NNP N
< NNP N
0.001 CD N
vs NN N
placebo NN N
) ) N
but CC N
had VBD N
no DT N
effect NN N
on IN N
glomerular JJ N
filtration NN N
rate NN N
. . N

The DT N
only JJ N
change NN N
observed VBD N
in IN N
these DT N
parameters NNS N
with IN N
indomethacin JJ N
alone NN N
was VBD N
a DT N
small JJ N
but CC N
significant JJ N
reduction NN N
in IN N
urine JJ N
flow NN N
rate NN N
( ( N
P NNP N
< VBZ N
0.005 CD N
vs NN N
placebo NN N
) ) N
. . N

As IN N
compared VBN N
with IN N
the DT N
effects NNS N
of IN N
angiotensin JJ N
II NNP N
alone RB N
, , N
indomethacin JJ N
pre-treatment NN N
followed VBN N
by IN N
angiotensin NN N
II NNP N
infusion NN N
led VBD N
to TO N
much RB N
greater JJR N
falls NNS N
in IN N
absolute JJ N
rate NN N
of IN N
sodium NN N
excretion NN N
, , N
fractional JJ N
sodium NN N
excretion NN N
, , N
urine JJ N
flow NN N
rate NN N
and CC N
effective JJ N
renal JJ N
plasma NN N
flow NN N
( ( N
all DT N
P NNP N
< NNP N
0.0001 CD N
vs NN N
placebo NN N
) ) N
associated VBN N
with IN N
a DT N
significant JJ N
reduction NN N
in IN N
glomerular JJ N
filtration NN N
rate NN N
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
not RB N
observed VBN N
with IN N
angiotensin JJ N
II NNP N
alone RB N
. . N

Frusemide NNP N
administration NN N
at IN N
the DT N
midpoint NN N
of IN N
each DT N
study NN N
limb NN N
resulted VBD N
in IN N
each DT N
case NN N
in IN N
a DT N
prompt JJ N
15 CD N
to TO N
20 CD N
fold JJ N
increase NN N
in IN N
natriuresis NN N
. . N

The DT N
renal JJ N
haemodynamic NN N
and CC N
natriuretic JJ N
effects NNS N
of IN N
angiotensin NN N
II NNP N
, , N
indomethacin NN N
and CC N
their PRP$ N
combination NN N
were VBD N
not RB N
qualitatively RB N
different JJ N
from IN N
those DT N
observed VBN N
in IN N
the DT N
pre-frusemide JJ N
phase NN N
. . N

Our PRP$ N
findings NNS N
provide VBP N
a DT N
clear JJ N
demonstration NN N
in IN N
man NN N
of IN N
the DT N
important JJ N
homeostatic JJ N
role NN N
of IN N
renal JJ N
prostaglandins NNS N
in IN N
preserving VBG N
renal JJ N
function NN N
, , N
particularly RB N
glomerular JJ N
filtration NN N
, , N
under IN N
conditions NNS N
of IN N
elevated JJ N
circulating VBG N
angiotensin NN N
II NNP N
. . N

-DOCSTART- -X- O O 1479049

Clonidine NNP N
treatment NN N
of IN N
hyperactive JJ 4_p
and CC 4_p
impulsive JJ 4_p
children NNS 4_p
with IN 4_p
autistic JJ 4_p
disorder NN 4_p
. . 4_p

Many JJ N
autistic JJ N
children NNS N
have VBP N
associated VBN N
problems NNS N
of IN N
inattention NN N
, , N
impulsivity NN N
, , N
and CC N
hyperactivity NN N
that WDT N
limit VBZ N
the DT N
effectiveness NN N
of IN N
educational JJ N
and CC N
behavioral JJ N
interventions NNS N
. . N

Few NNP N
controlled VBD N
psychopharmacologic JJ N
trials NNS N
have VBP N
been VBN N
conducted VBN N
in IN N
autistic JJ N
children NNS N
to TO N
determine VB N
which WDT N
agents NNS N
may MD N
be VB N
effective JJ N
for IN N
these DT N
associated VBN N
features NNS N
. . N

Eight NNP N
male NN N
children NNS N
( ( N
8.1 CD N
+/- JJ N
2.8 CD N
years NNS N
) ) N
with IN N
autistic JJ N
disorder NN N
, , N
diagnosed VBN N
by IN N
DSM-III-R NNP N
criteria NNS N
, , N
completed VBD N
a DT N
placebo-controlled JJ N
, , N
double-blind JJ N
crossover NN N
trial NN N
of IN N
clonidine NN N
. . N

Subjects NNS N
were VBD N
included VBN N
in IN N
the DT N
study NN N
if IN N
they PRP N
had VBD N
inattention NN N
, , N
impulsivity NN N
, , N
and CC N
hyperactivity NN N
that WDT N
was VBD N
excessive JJ N
for IN N
their PRP$ N
developmental JJ N
level NN N
. . N

Subjects NNS N
had VBD N
not RB N
tolerated VBN N
or CC N
responded VBN N
to TO N
other JJ N
psychopharmacologic JJ N
treatments NNS N
( ( N
neuroleptics NNS N
, , N
methylphenidate NN N
, , N
or CC N
desipramine NN N
) ) N
. . N

Teacher PRP$ N
ratings NNS N
on IN N
the DT N
Aberrant NNP N
Behavior NNP N
Checklist NNP N
irritability NN N
, , N
stereotypy NN N
, , N
hyperactivity NN N
, , N
and CC N
inappropriate JJ N
speech NN N
factors NNS N
were VBD N
lower JJR N
during IN N
treatment NN N
with IN N
clonidine NN N
than IN N
during IN N
treatment NN N
with IN N
placebo NN N
. . N

Attention NNP N
deficit NN N
disorder NN N
with IN N
hyperactivity NN N
: : N
Comprehensive NNP N
Teacher NNP N
's POS N
Rating NNP N
Scale NNP N
ratings NNS N
were VBD N
not RB N
significantly RB N
improved VBN N
during IN N
the DT N
study NN N
, , N
except IN N
for IN N
oppositional JJ N
behavior NN N
. . N

Parent NN N
Conners NNPS N
Abbreviated NNP N
Parent-Teacher NNP N
Questionnaire NNP N
ratings NNS N
significantly RB N
improved VBN N
during IN N
clonidine JJ N
treatment NN N
. . N

Clonidine NNP N
led VBD N
to TO N
increased VBN N
ratings NNS N
of IN N
the DT N
side NN N
effects NNS N
of IN N
drowsiness NN N
and CC N
decreased JJ N
activity NN N
. . N

Clinician JJ N
ratings NNS N
( ( N
Children NNP N
's POS N
Psychiatric NNP N
Rating NNP N
Scale NNP N
Autism NNP N
, , N
Hyperactivity NNP N
, , N
Anger NNP N
and CC N
Speech NNP N
Deviance NNP N
factors NNS N
; : N
Children NNP N
's POS N
Global NNP N
Assessment NNP N
Scale NNP N
; : N
Clinical NNP N
Global NNP N
Impressions NNP N
efficacy NN N
) ) N
of IN N
videotaped JJ N
sessions NNS N
were VBD N
not RB N
significantly RB N
different JJ N
between IN N
clonidine NN N
and CC N
placebo NN N
. . N

Clonidine NNP N
was VBD N
modestly RB N
effective JJ N
in IN N
the DT N
short-term JJ N
treatment NN N
of IN N
irritability NN N
and CC N
hyperactivity NN N
in IN N
some DT N
children NNS 4_p
with IN 4_p
autistic JJ 4_p
disorder NN 4_p
. . 4_p

-DOCSTART- -X- O O 16360994

Prehydration NNP N
alone RB N
is VBZ N
sufficient JJ N
to TO N
prevent VB N
contrast-induced JJ N
nephropathy JJ N
after IN N
day-only JJ N
angiography NN 4_p
procedures NNS 4_p
-- : N
a DT N
randomised JJ N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
Contrast NNP N
agents NNS N
used VBN N
in IN N
angiography NN N
procedures NNS N
for IN N
patients NNS N
with IN N
cardiovascular JJ 4_p
disease NN 4_p
are VBP N
known VBN N
to TO N
cause VB N
contrast-induced JJ N
nephropathy NN N
( ( N
CIN NNP N
) ) N
, , N
which WDT N
may MD N
be VB N
partially RB N
due JJ N
to TO N
the DT N
production NN N
of IN N
nephrotoxic JJ N
oxygen-free JJ N
radicals NNS N
. . N

It PRP N
is VBZ N
uncertain JJ N
whether IN N
administration NN N
of IN N
intravenous JJ N
( ( N
IV NNP N
) ) N
anti-oxidant NN N
, , N
N-acetylcysteine NNP N
( ( N
NAC NNP N
) ) N
, , N
can MD N
prevent VB N
reduction NN N
in IN N
renal JJ N
function NN N
and CC N
whether IN N
this DT N
is VBZ N
a DT N
cost-effective JJ N
approach NN N
. . N

METHODS NNP N
Sixty-five JJ N
day-only JJ N
patients NNS N
with IN N
renal JJ 4_p
impairment NN 4_p
( ( 4_p
mean JJ 4_p
serum NN 4_p
creatinine NN 4_p
concentration NN 4_p
0.16+/-0.03 NNP 4_p
mmol/l NN 4_p
) ) 4_p
due JJ N
to TO N
undergo JJ 4_p
coronary JJ 4_p
or CC 4_p
peripheral JJ 4_p
angiography NN 4_p
and/or NN 4_p
stenting VBG 4_p
were VBD N
randomly RB N
assigned VBN N
to TO N
IV NNP N
NAC NNP N
300 CD N
or CC N
600 CD N
mg NNS N
immediately RB N
before IN N
and CC N
after IN N
the DT N
procedure NN N
or CC N
IV NNP N
fluid VBP N
alone RB N
. . N

RESULTS NNP N
Of IN N
the DT N
60 CD N
patients NNS N
with IN N
complete JJ N
data NNS N
, , N
none NN N
had VBD N
acute VBN N
CIN NNP N
( ( N
increase NN N
in IN N
serum JJ N
creatinine NN N
concentration NN N
> NN N
or CC N
= $ N
0.044 CD N
mmol/l NN N
, , N
48 CD N
h NN N
after IN N
administration NN N
of IN N
contrast NN N
agent NN N
) ) N
. . N

Eight CD N
patients NNS N
( ( N
13 CD N
% NN N
) ) N
have VBP N
demonstrated VBN N
an DT N
increase NN N
in IN N
their PRP$ N
serum NN N
creatinine NN N
concentration NN N
> NN N
or CC N
= $ N
0.044 CD N
mmol/l JJ N
30 CD N
days NNS N
after IN N
administration NN N
of IN N
contrast NN N
agent NN N
: : N
2/19 CD N
( ( N
11 CD N
% NN N
) ) N
in IN N
the DT N
control NN N
group NN N
, , N
2/21 CD N
( ( N
10 CD N
% NN N
) ) N
in IN N
the DT N
600 CD N
mg NN N
NAC NNP N
group NN N
and CC N
4/20 CD N
( ( N
20 CD N
% NN N
) ) N
the DT N
300 CD N
mg NN N
NAC NNP N
group NN N
( ( N
p JJ N
= NNP N
0.66 CD N
) ) N
. . N

The DT N
mean JJ N
volumes NNS N
of IN N
contrast NN N
agent NN N
used VBN N
and CC N
prehydration NN N
given VBN N
for IN N
each DT N
of IN N
the DT N
three CD N
groups NNS N
did VBD N
not RB N
differ VB N
significantly RB N
( ( N
p JJ N
> NNP N
0.83 CD N
) ) N
. . N

There EX N
was VBD N
significant JJ N
improvement NN N
in IN N
creatinine JJ N
clearance NN N
within IN N
each DT N
group NN N
from IN N
baseline NN N
to TO N
30 CD N
days NNS N
( ( N
p JJ N
< NN N
or CC N
= VB N
0.03 CD N
) ) N
, , N
but CC N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
groups NNS N
at IN N
48 CD N
h NN N
and CC N
30 CD N
days NNS N
( ( N
p JJ N
> NN N
or CC N
= VB N
0.43 CD N
) ) N
. . N

Considering VBG N
the DT N
cost NN N
of IN N
NAC NNP N
and CC N
its PRP$ N
administration NN N
, , N
we PRP N
estimate VBP N
that IN N
this DT N
would MD N
translate VB N
to TO N
a DT N
saving NN N
of IN N
dollar NN N
26,637 CD N
per IN N
annum NN N
. . N

CONCLUSION NNP N
For IN N
day-stay JJ N
patients NNS N
with IN N
mild-to-moderate JJ 4_p
chronic JJ 4_p
renal JJ 4_p
impairment NN 4_p
undergoing VBG 4_p
angiography NN 4_p
and/or NN 4_p
intervention NN 4_p
, , N
prehydration NN N
alone RB N
is VBZ N
less RBR N
complicated JJ N
and CC N
more RBR N
cost-effective JJ N
than IN N
a DT N
combination NN N
of IN N
IV NNP N
NAC NNP N
( ( N
at IN N
doses NNS N
used VBN N
) ) N
and CC N
hydration NN N
. . N

-DOCSTART- -X- O O 9405728

Biochemical JJ N
markers NNS N
as IN N
predictors NNS N
of IN N
bone JJ N
mineral JJ N
density NN N
changes NNS N
after IN 4_p
GnRH NNP 4_p
agonist NN 4_p
treatment NN 4_p
. . 4_p

To TO N
evaluate VB N
bone NN N
biochemical JJ N
markers NNS N
as IN N
predictors NNS N
of IN N
the DT N
efficacy NN N
of IN N
a DT N
hormone NN 4_p
replacement NN 4_p
therapy NN 4_p
( ( N
HRT NNP N
) ) N
, , N
we PRP N
studied VBD N
the DT N
bone NN N
changes NNS N
induced VBN N
by IN N
the DT N
cessation NN N
and CC N
return NN N
of IN N
ovarian JJ N
function NN N
in IN N
28 CD N
patients NNS N
treated VBD N
for IN N
6 CD N
months NNS N
with IN N
a DT N
GnRH NNP N
agonist NN N
. . N

This DT N
model NN N
reproduced VBD N
the DT N
effects NNS N
observed VBN N
in IN N
postmenopausal JJ N
women NNS N
with IN N
high JJ N
bone NN N
turnover NN N
treated VBN N
with IN N
HRT NNP N
. . N

At IN N
the DT N
end NN N
of IN N
the DT N
treatment NN N
, , N
Z NNP N
scores NNS N
were VBD N
1.8 CD N
+/- JJ N
0.3 CD N
for IN N
Crosslaps NNP N
( ( N
CTx NNP N
) ) N
and CC N
deoxypyridinoline NN N
( ( N
D-Pyr NNP N
) ) N
, , N
and CC N
1.1 CD N
+/- JJ N
0.2 CD N
for IN N
bone NN N
alkaline NN N
phosphatase NN N
( ( N
B-ALP NNP N
) ) N
and CC N
osteocalcin $ N
( ( N
OC NNP N
) ) N
. . N

This DT N
indicated VBD N
an DT N
imbalance NN N
in IN N
bone NN N
remodeling VBG N
with IN N
a DT N
high JJ N
bone NN N
resorption NN N
. . N

Bone NNP N
mineral JJ N
density NN N
( ( N
BMD NNP N
) ) N
fell VBD N
by IN N
4.2 CD N
+/- JJ N
2.5 CD N
% NN N
. . N

The DT N
changes NNS N
in IN N
BMD NNP N
between IN N
the DT N
6th CD N
and CC N
12th CD N
months NNS N
were VBD N
0 CD N
. . N

34 CD N
+/- JJ N
2.24 CD N
and CC N
-1.73 VB N
+/- JJ N
3.25 CD N
% NN N
at IN N
the DT N
lumbar NN N
spine NN N
and CC N
the DT N
femoral JJ N
neck NN N
, , N
respectively RB N
. . N

Biochemical JJ N
markers NNS N
except IN N
urinary JJ N
calcium NN N
and CC N
hydroxyproline NN N
measured VBN N
at IN N
6 CD N
months NNS N
were VBD N
positively RB N
correlated VBN N
with IN N
the DT N
BMD NNP N
changes NNS N
at IN N
the DT N
lumbar NN N
spine NN N
. . N

After IN N
the DT N
resumption NN N
of IN N
menstruation NN N
, , N
13 CD N
of IN N
28 CD N
women NNS N
displayed VBD N
positive JJ N
spine NN N
BMD NNP N
changes NNS N
between IN N
the DT N
6th CD N
and CC N
12th CD N
months NNS N
; : N
in IN N
this DT N
group NN N
, , N
bone RB N
biochemical JJ N
markers NNS N
measured VBD N
at IN N
6 CD N
months NNS N
were VBD N
significantly RB N
higher JJR N
( ( N
P NNP N
= NNP N
0.02 CD N
) ) N
. . N

Stepwise NNP N
regression NN N
analysis NN N
showed VBD N
that IN N
the DT N
association NN N
of IN N
B-ALP NNP N
and CC N
D-Pyr NNP N
measured VBD N
at IN N
6 CD N
months NNS N
explained VBD N
40 CD N
% NN N
of IN N
BMD NNP N
variance NN N
and CC N
the DT N
association NN N
of IN N
B-ALP NNP N
, , N
PTH NNP N
, , N
and CC N
estradiol RB N
56 CD N
% NN N
. . N

We PRP N
conclude VBP N
that IN N
measuring VBG N
individual JJ N
biochemical JJ N
bone NN N
markers NNS N
can MD N
help VB N
to TO N
predict VB N
the DT N
bone NN N
effect NN N
of IN N
an DT N
increase NN N
in IN N
the DT N
circulating NN N
estradiol NN N
in IN N
women NNS N
with IN N
ovarian JJ N
deficiency NN N
. . N

-DOCSTART- -X- O O 15119720

Bitewing NNP N
film NN N
quality NN N
: : N
a DT N
clinical JJ N
comparison NN N
of IN N
the DT N
loop NN N
vs. FW N
holder NN N
techniques NNS N
. . N

OBJECTIVE NNP N
To TO N
compare VB N
in IN N
vivo JJ N
bitewing NN N
film NN N
quality NN N
using VBG N
the DT N
holder NN N
versus IN N
the DT N
paper NN N
loop NN N
technique NN N
. . N

METHOD NNP N
AND CC N
MATERIALS NNP N
Four NNP N
bitewing VBG N
films NNS N
were VBD N
taken VBN N
from IN N
the DT N
right NN N
and CC N
left VBD N
premolar JJ N
and CC N
molar JJ N
regions NNS N
of IN N
45 CD N
dental JJ N
students NNS N
using VBG N
both DT N
the DT N
bitewing NN N
holder NN N
and CC N
paper NN N
loop NN N
techniques NNS N
. . N

A DT N
total NN N
of IN N
360 CD N
films NNS N
were VBD N
taken VBN N
and CC N
assessed VBN N
by IN N
an DT N
experienced JJ N
practitioner NN N
not RB N
apprised VBN N
of IN N
the DT N
bitewing NN N
technique NN N
used VBN N
. . N

Of IN N
interest NN N
were VBD N
: : N
( ( N
1 CD N
) ) N
the DT N
number NN N
of IN N
overlaps NNS N
and CC N
the DT N
percentage NN N
of IN N
teeth NNS N
showing VBG N
the DT N
alveolar JJ N
crest NN N
; : N
( ( N
2 CD N
) ) N
proper NN N
film NN N
positioning NN N
; : N
and CC N
( ( N
3 CD N
) ) N
the DT N
percentage NN N
of IN N
cone NN N
cutting NN N
. . N

A DT N
Poisson NNP N
regression NN N
using VBG N
generalized VBN N
estimating VBG N
equations NNS N
( ( N
GEEs NNP N
) ) N
was VBD N
used VBN N
to TO N
estimate VB N
the DT N
difference NN N
in IN N
overlap NN N
between IN N
the DT N
two CD N
techniques NNS N
. . N

For IN N
proper JJ N
positioning NN N
and CC N
cone NN N
cutting NN N
, , N
logistic JJ N
regressions NNS N
using VBG N
GEEs NNP N
were VBD N
used VBN N
. . N

RESULTS VB N
The DT N
average JJ N
number NN N
of IN N
horizontal JJ N
overlaps NNS N
for IN N
the DT N
loop NN N
and CC N
holder NN N
techniques NNS N
at IN N
the DT N
right JJ N
premolar NN N
, , N
right JJ N
molar NN N
, , N
left VBD N
premolar JJ N
, , N
and CC N
left VBD N
molar NN N
were VBD N
1.64 CD N
, , N
2.11 CD N
, , N
2.16 CD N
, , N
2.78 CD N
, , N
and CC N
1.64 CD N
, , N
2.00 CD N
, , N
2.00 CD N
, , N
2.18 CD N
, , N
respectively RB N
. . N

The DT N
loop NN N
technique NN N
was VBD N
1.11 CD N
times NNS N
more RBR N
likely JJ N
to TO N
cause VB N
overlapping VBG N
than IN N
the DT N
holder NN N
technique NN N
. . N

The DT N
highest JJS N
percentage NN N
of IN N
teeth NNS N
showing VBG N
the DT N
alveolar JJ N
crest NN N
by IN N
the DT N
loop NN N
technique NN N
was VBD N
97.8 CD N
% NN N
in IN N
the DT N
mandibular JJ N
second JJ N
premolar NN N
and CC N
first JJ N
molar NN N
. . N

With IN N
respect NN N
to TO N
film NN N
positioning NN N
, , N
the DT N
loop NN N
technique NN N
was VBD N
1.12 CD N
times NNS N
more RBR N
likely JJ N
to TO N
cause VB N
improper JJ N
positioning NN N
than IN N
the DT N
holder NN N
technique NN N
. . N

Both DT N
techniques NNS N
demonstrated VBN N
minimal JJ N
cone NN N
cutting NN N
( ( N
1 CD N
in IN N
the DT N
loop NN N
versus NN N
0 CD N
in IN N
the DT N
holder NN N
) ) N
. . N

CONCLUSION VB N
The DT N
quality NN N
of IN N
bitewing VBG N
films NNS N
taken VBN N
by IN N
the DT N
loop NN N
and CC N
holder NN N
techniques NNS N
was VBD N
not RB N
significantly RB N
different JJ N
. . N

-DOCSTART- -X- O O 22965298

Preschool NNP N
based VBN N
JASPER NNP N
intervention NN N
in IN N
minimally RB N
verbal JJ N
children NNS N
with IN N
autism NN N
: : N
pilot NN N
RCT NNP N
. . N

In IN N
this DT N
pilot NN N
study NN N
, , N
we PRP N
tested VBD N
the DT N
effects NNS N
of IN N
a DT N
novel JJ N
intervention NN N
( ( N
JASPER NNP N
, , N
Joint NNP N
Attention NNP N
Symbolic NNP N
Play NNP N
Engagement NNP N
and CC N
Regulation NNP N
) ) N
on IN N
3 CD N
to TO N
5 CD N
year NN N
old JJ N
, , N
minimally RB N
verbal JJ N
children NNS N
with IN N
autism NN N
who WP N
were VBD N
attending VBG N
a DT N
non-public JJ N
preschool NN N
. . N

Participants NNS N
were VBD N
randomized VBN N
to TO N
a DT N
control NN N
group NN N
( ( N
treatment NN N
as IN N
usual JJ N
, , N
30 CD N
h NN N
of IN N
ABA-based JJ N
therapy NN N
per IN N
week NN N
) ) N
or CC N
a DT N
treatment NN N
group NN N
( ( N
substitution NN N
of IN N
30 CD N
min NN N
of IN N
JASPER NNP N
treatment NN N
, , N
twice RB N
weekly RB N
during IN N
their PRP$ N
regular JJ N
program NN N
) ) N
. . N

A DT N
baseline NN N
of IN N
12 CD N
weeks NNS N
in IN N
which WDT N
no DT N
changes NNS N
were VBD N
noted VBN N
in IN N
core NN N
deficits NNS N
was VBD N
followed VBN N
by IN N
12 CD N
weeks NNS N
of IN N
intervention NN N
for IN N
children NNS N
randomized VBN N
to TO N
the DT N
JASPER NNP N
treatment NN N
. . N

Participants NNS N
in IN N
the DT N
treatment NN N
group NN N
demonstrated VBD N
greater JJR N
play NN N
diversity NN N
on IN N
a DT N
standardized JJ N
assessment NN N
. . N

Effects NNS N
also RB N
generalized VBD N
to TO N
the DT N
classroom NN N
, , N
where WRB N
participants NNS N
in IN N
the DT N
treatment NN N
group NN N
initiated VBD N
more JJR N
gestures NNS N
and CC N
spent VB N
less JJR N
time NN N
unengaged JJ N
. . N

These DT N
results NNS N
provide VBP N
further JJ N
support NN N
that WDT N
even RB N
brief VBP N
, , N
targeted JJ N
interventions NNS N
on IN N
joint JJ N
attention NN N
and CC N
play NN N
can MD N
improve VB N
core NN N
deficits NNS N
in IN N
minimally RB N
verbal JJ N
children NNS N
with IN N
ASD NNP N
. . N

-DOCSTART- -X- O O 24852722

Causes NNS N
of IN N
variation NN N
in IN N
BCG NNP N
vaccine NN N
efficacy NN N
: : N
examining VBG N
evidence NN N
from IN N
the DT N
BCG NNP N
REVAC NNP N
cluster NN N
randomized VBD N
trial NN N
to TO N
explore VB N
the DT N
masking NN N
and CC N
the DT N
blocking NN N
hypotheses NNS N
. . N

BCG NNP N
protection NN N
varies NNS N
and CC N
in IN N
some DT N
places NNS N
( ( N
nearest JJS N
the DT N
equator NN N
) ) N
is VBZ N
low JJ N
or CC N
absent NN N
. . N

Understanding VBG N
this DT N
variation NN N
can MD N
inform VB N
the DT N
efforts NNS N
to TO N
develop VB N
new JJ N
vaccines NNS N
against IN N
tuberculosis NN N
. . N

Two CD N
main JJ N
hypotheses NNS N
are VBP N
used VBN N
to TO N
explain VB N
this DT N
variation NN N
: : N
under IN N
masking VBG N
, , N
new JJ N
vaccines NNS N
are VBP N
unlikely JJ N
to TO N
increase VB N
protection NN N
; : N
under IN N
blocking VBG N
new JJ N
vaccines NNS N
have VBP N
a DT N
greater JJR N
potential JJ N
to TO N
be VB N
effective JJ N
when WRB N
BCG NNP N
is VBZ N
not RB N
. . N

We PRP N
conducted VBD N
a DT N
cluster NN N
randomized VBN N
trial NN N
to TO N
explored VB N
the DT N
masking NN N
and CC N
blocking VBG N
hypotheses NNS N
by IN N
studying VBG N
BCG NNP N
vaccine NN N
efficacy NN N
of IN N
neonatal JJ N
vaccination NN N
and CC N
when WRB N
administered VBN N
for IN N
the DT N
first JJ N
or CC N
a DT N
second JJ N
( ( N
revaccination NN N
) ) N
time NN N
at IN N
school NN N
age NN N
in IN N
two CD N
sites NNS N
( ( N
Manaus NNP N
close RB N
and CC N
Salvador NNP N
further RB N
south RB N
from IN N
the DT N
equator NN N
) ) N
. . N

Seven VBN N
hundred CD N
and CC N
sixty VBD N
three CD N
state NN N
schools NNS N
were VBD N
matched VBN N
on IN N
socio JJ N
economic JJ N
characteristics NNS N
of IN N
the DT N
neighborhood NN N
and CC N
239,934 CD N
children NNS N
were VBD N
randomized VBN N
to TO N
vaccine VB N
( ( N
BCG NNP N
vaccination NN N
at IN N
school NN N
age NN N
) ) N
or CC N
control VB N
group NN N
. . N

Protection NN N
by IN N
first JJ N
BCG NNP N
vaccination NN N
at IN N
school NN N
age NN N
was VBD N
high JJ N
in IN N
Salvador NNP N
( ( N
34 CD N
% NN N
, , N
95 CD N
% NN N
CI NNP N
7-53 CD N
% NN N
, , N
p=0.017 NN N
) ) N
but CC N
low JJ N
in IN N
Manaus NNP N
( ( N
8 CD N
% NN N
, , N
95 CD N
% NN N
CI NNP N
t0 VBZ N
39-40 CD N
% NN N
, , N
p=0.686 NN N
) ) N
. . N

For IN N
revaccination NN N
at IN N
school NN N
age NN N
, , N
protection NN N
was VBD N
modest JJ N
in IN N
Salvador NNP N
( ( N
19 CD N
% NN N
, , N
95 CD N
% NN N
CI NNP N
3-33 CD N
% NN N
, , N
p=0.022 NN N
) ) N
and CC N
absent NN N
in IN N
Manaus NNP N
( ( N
1 CD N
% NN N
, , N
95 CD N
% NN N
CI NNP N
to TO N
27-23 CD N
% NN N
, , N
p=0.932 NN N
) ) N
. . N

Vaccine NNP N
efficacy NN N
for IN N
neonatal JJ N
vaccination NN N
was VBD N
similar JJ N
in IN N
Salvador NNP N
( ( N
40 CD N
% NN N
, , N
95 CD N
% NN N
CI NNP N
22-54 CD N
% NN N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
and CC N
Manaus NNP N
( ( N
36 CD N
% NN N
, , N
95 CD N
% NN N
CI NNP N
11-53 CD N
% NN N
, , N
p=0.008 NN N
) ) N
. . N

Variation NN N
in IN N
BCG NNP N
efficacy NN N
was VBD N
marked VBN N
when WRB N
vaccine NN N
was VBD N
given VBN N
at IN N
school NN N
age NN N
but CC N
absent NN N
at IN N
birth NN N
, , N
which WDT N
points VBZ N
towards NNS N
blocking VBG N
as IN N
the DT N
dominant JJ N
mechanism NN N
. . N

New NNP N
tuberculosis NN N
vaccines NNS N
that WDT N
overcome VBP N
or CC N
by IN N
pass NN N
this DT N
blocking VBG N
effect NN N
could MD N
confer VB N
protection NN N
in IN N
situations NNS N
where WRB N
BCG NNP N
is VBZ N
not RB N
protective JJ N
. . N

-DOCSTART- -X- O O 26510728

Chronic NNP N
fatigue NN N
syndrome NN N
( ( N
CFS NNP N
) ) N
or CC N
myalgic JJ N
encephalomyelitis NN N
( ( N
ME NNP N
) ) N
is VBZ N
different JJ N
in IN N
children NNS N
compared VBN N
to TO N
in IN N
adults NNS N
: : N
a DT N
study NN N
of IN N
UK NNP N
and CC N
Dutch NNP N
clinical JJ N
cohorts NNS N
. . N

OBJECTIVE NNP N
To TO N
investigate VB N
differences NNS N
between IN N
young JJ N
children NNS N
, , N
adolescents NNS N
and CC N
adults NNS N
with IN N
chronic JJ 4_p
fatigue NN 4_p
syndrome/myalgic NN 4_p
encephalomyelitis NN 4_p
( ( 4_p
CFS/ME NNP 4_p
) ) 4_p
. . N

STUDY NNP N
DESIGN NNP N
Comparison NNP N
of IN N
clinical JJ N
cohorts NNS N
from IN N
8 CD N
paediatric NN N
and CC N
27 CD N
adult NN N
CFS/ME NNP N
services NNS N
in IN N
the DT N
UK NNP N
and CC N
a DT N
paediatric NN N
randomised VBD N
controlled VBN N
trial NN N
from IN N
the DT N
Netherlands NNP N
. . N

Outcome NNP N
measures VBZ N
include VBP N
: : N
fatigue NN N
( ( N
the DT N
UK-Chalder NNP N
Fatigue NNP N
Scale NNP N
) ) N
; : N
Disability NNP N
( ( N
the DT N
UK-SF-36 NNP N
physical JJ N
function NN N
subscale NN N
; : N
the DT N
Netherlands-CHQ-CF87 NNP N
) ) N
; : N
school NN N
attendance NN N
, , N
pain NN N
, , N
anxiety NN N
and CC N
depression NN N
( ( N
the DT N
UK-Hospital NNP N
Anxiety NNP N
& CC N
Depression NNP N
Scale NNP N
, , N
Spence NNP N
Children NNP N
's POS N
Anxiety NNP N
Scale NNP N
; : N
the DT N
Netherlands-Spielberger NNP N
State-Trait NNP N
Anxiety NNP N
Inventory NNP N
for IN N
Children NNP N
, , N
Children NNP N
's POS N
Depression NNP N
Inventory NNP N
) ) N
; : N
symptoms NNS N
; : N
time-to-assessment JJ N
; : N
and CC N
body NN N
mass NN N
index NN N
. . N

We PRP N
used VBD N
multinomial JJ N
regression NN N
to TO N
compare VB N
younger JJR N
( ( N
aged VBN N
< RB N
12 CD N
years NNS N
) ) N
and CC N
older JJR N
( ( N
aged VBN N
12-18 CD N
years NNS N
) ) N
children NNS N
with IN N
adults NNS N
, , N
and CC N
logistic JJ N
regression NN N
to TO N
compare VB N
UK NNP N
and CC N
Dutch NNP N
adolescents NNS N
. . N

RESULTS NNP N
Younger NNP N
children NNS N
had VBD N
a DT N
more RBR N
equal JJ N
gender NN N
balance NN N
compared VBN N
to TO N
adolescents NNS N
and CC N
adults NNS N
. . N

Adults NNS N
had VBD N
more JJR N
disability NN N
and CC N
fatigue NN N
, , N
and CC N
had VBD N
been VBN N
ill RB N
for IN N
longer JJR N
. . N

Younger JJR N
children NNS N
were VBD N
less RBR N
likely JJ N
to TO N
have VB N
cognitive JJ N
symptoms NNS N
( ( N
OR CC N
0.18 CD N
( ( N
95 CD N
% NN N
CI NNP N
0.13 CD N
to TO N
0.25 CD N
) ) N
) ) N
and CC N
more RBR N
likely JJ N
to TO N
present VB N
with IN N
a DT N
sore NN N
throat NN N
( ( N
OR CC N
1.42 CD N
( ( N
1.07 CD N
to TO N
1.90 CD N
) ) N
. . N

Adolescents NNS N
were VBD N
more RBR N
likely JJ N
to TO N
have VB N
headaches NNS N
( ( N
81.1 CD N
% NN N
, , N
OR CC N
1.56 CD N
( ( N
1.36 CD N
% NN N
to TO N
1.80 CD N
% NN N
) ) N
) ) N
and CC N
less RBR N
likely JJ N
to TO N
have VB N
tender NN N
lymph NN N
nodes NNS N
, , N
palpitations NNS N
, , N
dizziness NN N
, , N
general JJ N
malaise NN N
and CC N
pain NN N
, , N
compared VBN N
to TO N
adults NNS N
. . N

Adolescents NNS N
were VBD N
more RBR N
likely JJ N
to TO N
have VB N
comorbid VBN N
depression NN N
( ( N
OR CC N
1.51 CD N
( ( N
1.33 CD N
to TO N
1.72 CD N
) ) N
) ) N
and CC N
less RBR N
likely JJ N
to TO N
have VB N
anxiety NN N
( ( N
OR CC N
0.46 CD N
( ( N
0.41 CD N
to TO N
0.53 CD N
) ) N
) ) N
compared VBN N
to TO N
adults NNS N
. . N

CONCLUSIONS NNP N
Paediatricians NNPS N
need VBP N
to TO N
recognise VB N
that DT N
children NNS N
with IN N
CFS/ME NNP N
present JJ N
differently RB N
from IN N
adults NNS N
. . N

Whether IN N
these DT N
differences NNS N
reflect VBP N
an DT N
underlying JJ N
aetiopathology NN N
requires VBZ N
further JJ N
investigation NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
NUMBERS NNP N
FITNET NNP N
trial NN N
registration NN N
numbers NNS N
are VBP N
ISRCTN59878666 NNP N
and CC N
NCT00893438 NNP N
. . N

This DT N
paper NN N
includes VBZ N
secondary JJ N
( ( N
post-results NNS N
) ) N
analysis NN N
of IN N
data NNS N
from IN N
this DT N
trial NN N
, , N
but CC N
are VBP N
unrelated JJ N
to TO N
trial NN N
outcomes NNS N
. . N

-DOCSTART- -X- O O 20875504

Action NNP N
observation NN N
treatment NN N
improves VBZ N
recovery NN N
of IN N
postsurgical JJ 4_p
orthopedic JJ 4_p
patients NNS 4_p
: : N
evidence NN N
for IN N
a DT N
top-down JJ N
effect NN N
? . N
OBJECTIVE UH N
To TO N
assess VB N
whether IN N
action NN N
observation NN N
treatment NN N
( ( N
AOT NNP N
) ) N
may MD N
also RB N
improve VB N
motor NN N
recovery NN N
in IN N
postsurgical JJ 4_p
orthopedic JJ 4_p
patients NNS N
, , N
in IN N
addition NN N
to TO N
conventional JJ N
physiotherapy NN N
. . N

DESIGN NNP N
Randomized NNP N
controlled VBD N
trial NN N
. . N

SETTING NNP N
Department NNP N
of IN N
rehabilitation NN N
. . N

PARTICIPANTS JJ N
Patients NNPS N
( ( N
N=60 NNP N
) ) N
admitted VBD N
to TO N
our PRP$ N
department NN N
postorthopedic NN N
surgery NN N
were VBD N
randomly RB N
assigned VBN N
to TO N
either VB N
a DT N
case NN N
( ( N
n=30 NN N
) ) N
or CC N
control NN N
( ( N
n=30 JJ N
) ) N
group NN N
. . N

Exclusion NN N
criteria NNS N
were VBD N
age NN N
18 CD N
years NNS N
or CC N
younger JJR N
and CC N
90 CD N
years NNS N
or CC N
older JJR N
, , N
Mini-Mental JJ N
State NNP N
Examination NNP N
score NN N
of IN N
21 CD N
of IN N
30 CD N
or CC N
lower JJR N
, , N
no DT N
ambulating VBG N
order NN N
, , N
advanced JJ N
vision NN N
impairment NN N
, , N
malignancy NN N
, , N
pneumonia NN N
, , N
or CC N
heart NN N
failure NN N
. . N

INTERVENTIONS NNP N
All NNP N
participants NNS N
underwent JJ N
conventional JJ N
physiotherapy NN N
. . N

In IN N
addition NN N
, , N
patients NNS N
in IN N
the DT N
case NN N
group NN N
were VBD N
asked VBN N
to TO N
observe VB N
video JJ N
clips NNS N
showing VBG N
daily JJ N
actions NNS N
and CC N
to TO N
imitate VB N
them PRP N
afterward RB N
. . N

Patients NNS N
in IN N
the DT N
control NN N
group NN N
were VBD N
asked VBN N
to TO N
observe VB N
video JJ N
clips NNS N
with IN N
no DT N
motor NN N
content NN N
and CC N
to TO N
execute VB N
the DT N
same JJ N
actions NNS N
as IN N
patients NNS N
in IN N
the DT N
case NN N
group NN N
afterward RB N
. . N

Participants NNS N
were VBD N
scored VBN N
on IN N
functional JJ N
scales NNS N
at IN N
baseline NN N
and CC N
after IN N
treatment NN N
by IN N
a DT N
physician NN N
blinded VBD N
to TO N
group NN N
assignment NN N
. . N

MAIN NNP N
OUTCOMES NNP N
MEASURES NNP N
Changes NNP N
in IN N
FIM NNP N
and CC N
Tinetti NNP N
scale NN N
scores NNS N
, , N
and CC N
dependence NN N
on IN N
walking VBG N
aids NNS N
. . N

RESULTS NNP N
At IN N
baseline NN N
, , N
groups NNS N
did VBD N
not RB N
differ VB N
in IN N
clinical JJ N
and CC N
functional JJ N
scale NN N
scores NNS N
. . N

After IN N
treatment NN N
, , N
patients NNS N
in IN N
the DT N
case NN N
group NN N
scored VBD N
better JJR N
than IN N
patients NNS N
in IN N
the DT N
control NN N
group NN N
( ( N
FIM NNP N
total NN N
score NN N
, , N
P=.02 NNP N
; : N
FIM NNP N
motor NN N
subscore NN N
, , N
P=.001 NNP N
; : N
Tinetti NNP N
scale NN N
score NN N
, , N
P=.04 NNP N
) ) N
; : N
patients NNS N
in IN N
the DT N
case NN N
group NN N
were VBD N
assigned VBN N
more RBR N
frequently RB N
to TO N
1 CD N
crutch NN N
( ( N
P=.01 NNP N
) ) N
. . N

CONCLUSIONS NNP N
In IN N
addition NN N
to TO N
conventional JJ N
physiotherapy NN N
, , N
AOT NNP N
is VBZ N
effective JJ N
in IN N
the DT N
rehabilitation NN N
of IN N
postsurgical JJ N
orthopedic JJ N
patients NNS N
. . N

The DT N
present JJ N
results NNS N
strongly RB N
support VB N
top-down JJ N
effects NNS N
of IN N
this DT N
treatment NN N
in IN N
motor NN N
recovery NN N
, , N
even RB N
in IN N
nonneurologic JJ N
patients NNS N
. . N

-DOCSTART- -X- O O 6360773

Effect NN N
of IN N
cicloxilic JJ N
acid NN N
on IN N
bile NN N
lipid JJ N
composition NN N
in IN N
patients NNS N
with IN N
gallstones NNS 4_p
: : N
a DT N
multicenter NN N
trial NN N
. . N

24 CD N
gallstone NN 4_p
patients NNS 4_p
were VBD N
treated VBN N
with IN N
cicloxilic JJ N
acid NN N
, , N
an DT N
agent NN N
endowed VBN N
with IN N
choleretic JJ N
activity NN N
, , N
at IN N
the DT N
dose NN N
of IN N
240 CD N
mg/day NN N
for IN N
1 CD N
month NN N
. . N

24 CD N
comparable JJ 4_p
patients NNS 4_p
on IN 4_p
placebo NN 4_p
treatment NN 4_p
acted VBD N
as IN N
controls NNS N
. . N

Bile NNP N
lipid JJ N
composition NN N
was VBD N
determined VBN N
and CC N
the DT N
saturation NN N
index NN N
calculated VBD N
before IN N
and CC N
after IN N
treatment NN N
, , N
on IN N
samples NNS N
collected VBN N
by IN N
duodenal JJ N
siphonage NN N
after IN N
caerulein JJ N
stimulation NN N
, , N
in IN N
both DT N
groups NNS N
. . N

In IN N
the DT N
cicloxilic JJ N
group NN N
there EX N
was VBD N
little JJ N
or CC N
no DT N
change NN N
in IN N
bile NN N
salts NNS N
and CC N
phospholipids NNS N
, , N
whereas NNS N
biliary VBP N
cholesterol NN N
concentration NN N
was VBD N
significantly RB N
reduced VBN N
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
and CC N
consequently RB N
the DT N
lithogenic JJ N
index NN N
lowered VBD N
( ( N
from IN N
1.5 CD N
to TO N
1.2 CD N
, , N
p NN N
less JJR N
than IN N
0.01 CD N
) ) N
. . N

Cicloxilic JJ N
acid NN N
can MD N
have VB N
a DT N
place NN N
in IN N
gallstone NN N
disease NN N
therapy NN N
in IN N
association NN N
with IN N
the DT N
litholytic JJ N
bile NN N
acids NNS N
or CC N
in IN N
the DT N
prevention NN N
of IN N
gallstone NN N
formation NN N
in IN N
high-risk JJ N
populations NNS N
. . N

-DOCSTART- -X- O O 21938889

The DT N
effects NNS N
of IN N
therapeutic JJ N
instrumental JJ N
music NN N
performance NN N
on IN N
endurance NN N
level NN N
, , N
self-perceived JJ N
fatigue NN N
level NN N
, , N
and CC N
self-perceived JJ N
exertion NN N
of IN N
inpatients NNS 4_p
in IN 4_p
physical JJ 4_p
rehabilitation NN 4_p
. . 4_p

The DT N
present JJ N
study NN N
investigated VBD N
the DT N
effects NNS N
of IN N
a DT N
Neurologic NNP N
Music NNP N
Therapy NNP N
( ( N
NMT NNP N
) ) N
sensory-motor NN N
rehabilitation NN N
technique NN N
, , N
Therapeutic NNP N
Instrumental NNP N
Music NNP N
Performance NNP N
( ( N
TIMP NNP N
) ) N
as IN N
compared VBN N
to TO N
Traditional NNP N
Occupational NNP N
Therapy NNP N
( ( N
TOT NNP N
) ) N
, , N
on IN N
endurance NN N
, , N
self-perceived JJ N
fatigue NN N
, , N
and CC N
self-perceived JJ N
exertion NN N
of IN N
35 CD N
hospitalized JJ N
patients NNS N
in IN N
physical JJ 4_p
rehabilitation NN 4_p
. . N

The DT N
present JJ N
study NN N
attempted VBD N
to TO N
examine VB N
whether IN N
an DT N
active JJ N
musical JJ N
experience NN N
such JJ N
as IN N
TIMP NNP N
with IN N
musical JJ N
cueing NN N
( ( N
i.e. FW N
, , N
rhythmic JJ N
auditory NN N
cueing VBG N
) ) N
during IN N
physical JJ N
exercises NNS N
influences VBZ N
one CD N
's POS N
perception NN N
of IN N
pain NN N
, , N
fatigue NN N
, , N
and CC N
exertion NN N
. . N

All DT N
participants NNS N
were VBD N
diagnosed VBN N
with IN N
a DT N
neurologic JJ 4_p
disorder NN 4_p
or CC N
had VBD N
recently RB N
undergone JJ N
orthopedic JJ 4_p
surgery NN 4_p
. . N

Investigators NNS N
measured VBD N
the DT N
effects NNS N
of IN N
TOT NNP N
and CC N
TIMP NNP N
during IN N
upper JJ N
extremity NN N
exercise NN N
of IN N
the DT N
less RBR N
affected JJ N
or CC N
stronger JJR N
upper JJ N
extremity NN N
. . N

Results NNP N
showed VBD N
no DT N
significant JJ N
difference NN N
on IN N
endurance NN N
measures NNS N
between IN N
the DT N
2 CD N
treatment NN N
conditions NNS N
( ( N
TIMP NNP N
and CC N
TOT NNP N
) ) N
. . N

Statistically NNP N
significant JJ N
differences NNS N
were VBD N
found VBN N
between IN N
TIMP NNP N
and CC N
TOT NNP N
when WRB N
measuring VBG N
their PRP$ N
effects NNS N
on IN N
perceived JJ N
exertion NN N
and CC N
perceived VBD N
fatigue NN N
. . N

TIMP NNP N
resulted VBD N
in IN N
significantly RB N
less JJR N
perception NN N
of IN N
fatigue NN N
and CC N
exertion NN N
levels NNS N
than IN N
TOT NNP N
. . N

TIMP NNP N
can MD N
be VB N
used VBN N
foran JJ N
effective JJ N
sensory-motor NN N
rehabilitation NN N
technique NN N
to TO N
decrease VB N
perceived JJ N
exertion NN N
and CC N
fatigue JJ N
level NN N
of IN N
inpatients NNS N
in IN N
physical JJ 4_p
rehabilitation NN 4_p
. . N

-DOCSTART- -X- O O 20973712

Line-item JJ N
analysis NN N
of IN N
the DT N
Aberrant NNP N
Behavior NNP N
Checklist NNP N
: : N
results NNS N
from IN N
two CD N
studies NNS N
of IN N
aripiprazole NN N
in IN N
the DT N
treatment NN N
of IN N
irritability NN 4_p
associated VBN N
with IN N
autistic JJ 4_p
disorder NN 4_p
. . N

OBJECTIVES CC N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
aripiprazole NN N
in IN N
the DT N
treatment NN N
of IN N
discrete JJ N
symptoms NNS N
of IN N
irritability NN N
associated VBN N
with IN N
autistic JJ N
disorder NN N
, , N
as RB N
well RB N
as IN N
other JJ N
symptoms NNS N
captured VBN N
on IN N
the DT N
Aberrant NNP N
Behavior NNP N
Checklist NNP N
( ( N
ABC NNP N
) ) N
. . N

METHODS NNP N
This DT N
was VBD N
a DT N
post NN N
hoc NN N
analysis NN N
of IN N
data NNS N
from IN N
two CD N
8-week JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
multicenter JJ N
trials NNS N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
aripiprazole NN N
dosed VBN N
flexibly RB N
( ( N
2-15 JJ N
mg/day NN N
, , N
n=47 NN N
) ) N
or CC N
fixed VBN N
( ( N
5 CD N
, , N
10 CD N
, , N
or CC N
15 CD N
mg/day NN N
, , N
n JJ N
= NNP N
166 CD N
) ) N
versus NN N
placebo NN N
( ( N
flexibly RB N
dosed VBN N
, , N
n JJ N
= VBP N
51 CD N
; : N
fixed VBN N
dose NN N
, , N
n JJ N
= NNP N
52 CD N
) ) N
. . N

The DT N
effects NNS N
of IN N
treatment NN N
on IN N
the DT N
58 CD N
ABC NNP N
items NNS N
were VBD N
evaluated VBN N
. . N

RESULTS NNP N
Statistically NNP N
significantly RB N
greater JJR N
improvement NN N
was VBD N
seen VBN N
with IN N
aripiprazole JJ N
versus NN N
placebo NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
for IN N
all DT N
arms NNS N
in IN N
both DT N
trials NNS N
on IN N
the DT N
ABC-Irritability NNP N
total JJ N
subscale NN N
score NN N
and CC N
on IN N
the DT N
following JJ N
individual JJ N
ABC-Irritability NNP N
items NNS N
: : N
Mood NNP N
changes NNS N
quickly RB N
, , N
cries/screams NNS N
inappropriately RB N
, , N
and CC N
stamps JJ N
feet/bangs NNS N
objects NNS N
. . N

Several JJ N
additional JJ N
items NNS N
measuring VBG N
tantrum-like JJ N
behaviors NNS N
improved VBN N
in IN N
the DT N
flexibly RB N
dosed VBN N
trial NN N
and CC N
at IN N
least JJS N
one CD N
arm NN N
of IN N
the DT N
fixed-dose JJ N
trial NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

Measures NNS N
of IN N
self-injurious JJ N
behavior NN N
, , N
which WDT N
had VBD N
low JJ N
baseline NN N
values NNS N
, , N
demonstrated VBD N
numerical JJ N
, , N
but CC N
not RB N
statistically RB N
significant JJ N
, , N
improvement NN N
in IN N
both DT N
trials NNS N
. . N

Statistically RB N
significantly RB N
greater JJR N
improvement NN N
in IN N
ABC NNP N
Stereotypic NNP N
Behavior NNP N
and CC N
Hyperactivity NNP N
total JJ N
subscale NN N
scores NNS N
was VBD N
also RB N
consistent JJ N
across IN N
all DT N
arms NNS N
in IN N
both DT N
trials NNS N
. . N

In IN N
particular JJ N
, , N
there EX N
was VBD N
a DT N
cluster NN N
of IN N
items NNS N
related VBN N
to TO N
hyperkinesis VB N
that WDT N
were VBD N
consistently RB N
sensitive JJ N
to TO N
treatment NN N
. . N

CONCLUSIONS NNP N
Aripiprazole NNP N
is VBZ N
efficacious JJ N
in IN N
the DT N
treatment NN N
of IN N
irritability NN N
in IN N
children NNS N
and CC N
adolescents NNS N
with IN N
autistic JJ 4_p
disorder NN 4_p
, , N
particularly RB N
with IN N
respect NN N
to TO N
symptoms NNS N
associated VBN N
with IN N
tantrum JJ N
behavior NN N
. . N

-DOCSTART- -X- O O 17491486

Treatment NN N
of IN N
periodontal JJ 4_p
disease NN 4_p
and CC N
the DT N
risk NN N
of IN N
preterm JJ N
birth NN N
. . N

-DOCSTART- -X- O O 1793881

Midazolam NNP N
as IN N
a DT N
main JJ N
anesthesia NN N
induction NN N
agent NN N
-- : N
a DT N
comparison NN N
with IN N
thiopental JJ N
and CC N
diazepam NN N
. . N

A DT N
clinical JJ N
randomized JJ N
investigation NN N
was VBD N
undertaken VBN N
to TO N
determine VB N
the DT N
value NN N
of IN N
midazolam NN N
as IN N
a DT N
narcotic JJ N
adjuvant NN N
for IN N
anesthetic JJ N
induction NN N
. . N

Thirty NNP N
ASA NNP 4_p
I-II NNP 4_p
adult NN N
patients NNS N
undergoing VBG N
selective JJ N
surgery NN N
were VBD N
allocated VBN N
randomly RB N
into IN N
two CD N
groups NNS N
to TO N
receive VB N
one CD N
of IN N
the DT N
following JJ N
agents NNS N
: : N
midazolam NN N
0.3 CD N
mg/kg NN N
, , N
thiopental JJ N
5 CD N
mg/kg NN N
, , N
or CC N
diazepam VB N
0.4 CD N
mg/kg NN N
. . N

The DT N
induction NN N
time NN N
as IN N
measured VBN N
from IN N
the DT N
onset NN N
of IN N
injection NN N
to TO N
loss NN N
of IN N
the DT N
eyelash NN N
reflex NN N
was VBD N
shortest VBN N
in IN N
the DT N
case NN N
of IN N
thiopental NN N
; : N
while IN N
a DT N
lower JJR N
frequency NN N
of IN N
apnea NN N
, , N
lesser JJR N
suppression NN N
of IN N
circulation NN N
, , N
and CC N
lack NN N
of IN N
venous JJ N
irritation NN N
were VBD N
points NNS N
favoring VBG N
midazolam NN N
. . N

However RB N
, , N
further JJ N
study NN N
is VBZ N
needed VBN N
to TO N
clarify VB N
the DT N
moderate JJ N
cardiovascular JJ N
response NN N
seen VBN N
during IN N
intubation NN N
in IN N
some DT N
cases NNS N
as RB N
well RB N
as IN N
to TO N
elucidate VB N
any DT N
patient JJ N
population NN N
differences NNS N
. . N

-DOCSTART- -X- O O 25865864

Fall NN N
rates NNS N
in IN N
hospital JJ 4_p
rehabilitation NN 4_p
units NNS 4_p
after IN N
individualised JJ N
patient NN N
and CC N
staff NN N
education NN N
programmes NNS N
: : N
a DT N
pragmatic JJ N
, , N
stepped-wedge JJ N
, , N
cluster-randomised JJ N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
Falls NNP N
are VBP N
the DT N
most RBS N
frequent JJ N
adverse JJ N
events NNS N
that WDT N
are VBP N
reported VBN N
in IN N
hospitals NNS N
. . N

We PRP N
examined VBD N
the DT N
effectiveness NN N
of IN N
individualised JJ N
falls-prevention NN N
education NN N
for IN N
patients NNS N
, , N
supported VBN N
by IN N
training NN N
and CC N
feedback NN N
for IN N
staff NN N
, , N
delivered VBN N
as IN N
a DT N
ward-level JJ N
programme NN N
. . N

METHODS NNP N
Eight NNP N
rehabilitation NN N
units NNS N
in IN N
general JJ N
hospitals NNS N
in IN N
Australia NNP N
participated VBD N
in IN N
this DT N
stepped-wedge NN N
, , N
cluster-randomised JJ N
study NN N
, , N
undertaken JJ N
during IN N
a DT N
50 CD N
week NN N
period NN N
. . N

Units NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
intervention VB N
or CC N
control VB N
groups NNS N
by IN N
use NN N
of IN N
computer-generated JJ N
, , N
random JJ N
allocation NN N
sequences NNS N
. . N

We PRP N
included VBD N
patients NNS N
admitted VBN N
to TO N
the DT N
unit NN N
during IN N
the DT N
study NN N
with IN N
a DT N
Mini-Mental JJ 4_p
State NNP 4_p
Examination NNP 4_p
( ( 4_p
MMSE NNP 4_p
) ) N
score NN N
of IN N
more JJR N
than IN N
23/30 CD N
to TO N
receive VB N
individualised JJ N
education NN N
that WDT N
was VBD N
based VBN N
on IN N
principles NNS N
of IN N
changes NNS N
in IN N
health NN N
behaviour NN N
from IN N
a DT N
trained JJ N
health NN N
professional NN N
, , N
in IN N
addition NN N
to TO N
usual JJ N
care NN N
. . N

We PRP N
provided VBD N
information NN N
about IN N
patients NNS N
' POS N
goals NNS N
, , N
feedback NN N
about IN N
the DT N
ward NN N
environment NN N
, , N
and CC N
perceived VBD N
barriers NNS N
to TO N
engagement VB N
in IN N
falls-prevention NN N
strategies NNS N
to TO N
staff NN N
who WP N
were VBD N
trained VBN N
to TO N
support VB N
the DT N
uptake NN N
of IN N
strategies NNS N
by IN N
patients NNS N
. . N

The DT N
coprimary JJ N
outcome NN N
measures NNS N
were VBD N
patient JJ N
rate NN N
of IN N
falls NNS N
per IN N
1000 CD N
patient-days NNS N
and CC N
the DT N
proportion NN N
of IN N
patients NNS N
who WP N
were VBD N
fallers NNS N
. . N

All DT N
analyses NNS N
were VBD N
by IN N
intention NN N
to TO N
treat VB N
. . N

This DT N
trial NN N
is VBZ N
registered VBN N
with IN N
the DT N
Australian JJ N
New NNP N
Zealand NNP N
Clinical NNP N
Trials NNP N
registry NN N
, , N
number NN N
ACTRN12612000877886 NNP N
) ) N
. . N

FINDINGS NNP N
Between NNP N
Jan NNP N
13 CD N
, , N
and CC N
Dec NNP N
27 CD N
, , N
2013 CD N
, , N
3606 CD N
patients NNS N
were VBD N
admitted VBN N
to TO N
the DT N
eight CD N
units NNS N
( ( N
n=1983 JJ N
control NN N
period NN N
; : N
n=1623 CC N
intervention NN N
period NN N
) ) N
. . N

There EX N
were VBD N
fewer JJR N
falls NNS N
( ( N
n=196 NN N
, , N
7·80/1000 CD N
patient-days JJ N
vs NN N
n=380 NN N
, , N
13·78/1000 CD N
patient-days NNS N
, , N
adjusted VBN N
rate NN N
ratio NN N
0·60 CD N
[ NN N
robust JJ N
95 CD N
% NN N
CI NNP N
0·42-0·94 CD N
] NNP N
, , N
p=0·003 NN N
) ) N
, , N
injurious JJ N
falls NNS N
( ( N
n=66 NN N
, , N
2·63/1000 CD N
patient-days JJ N
vs NN N
131 CD N
, , N
4·75/1000 CD N
patient-days NNS N
, , N
0·65 CD N
[ NN N
robust JJ N
95 CD N
% NN N
CI NNP N
0·42-0·88 CD N
] NNP N
, , N
p=0·006 NN N
) ) N
, , N
and CC N
fallers NNS N
( ( N
n=136 JJ N
[ RB N
8·38 CD N
% NN N
] JJ N
vs NN N
n=248 NN N
[ VBD N
12·51 CD N
% NN N
] NN N
adjusted VBN N
odds NNS N
ratio VBP N
0·55 CD N
[ NNP N
robust JJ N
95 CD N
% NN N
CI NNP N
0·38 CD N
to TO N
0·81 CD N
] NNS N
, , N
p=0·003 NN N
) ) N
in IN N
the DT N
intervention NN N
compared VBN N
with IN N
the DT N
control NN N
group NN N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
length NN N
of IN N
stay NN N
( ( N
intervention NN N
median RB N
11 CD N
days NNS N
[ JJ N
IQR NNP N
7-19 JJ N
] NNP N
, , N
control NN N
10 CD N
days NNS N
[ RB N
6-18 JJ N
] NN N
) ) N
. . N

INTERPRETATION NNP N
Individualised VBD N
patient JJ N
education NN N
programmes NNS N
combined VBN N
with IN N
training NN N
and CC N
feedback NN N
to TO N
staff NN N
added VBN N
to TO N
usual JJ N
care NN N
reduces VBZ N
the DT N
rates NNS N
of IN N
falls NNS N
and CC N
injurious JJ 4_p
falls NNS 4_p
in IN 4_p
older JJR 4_p
patients NNS 4_p
in IN 4_p
rehabilitation NN 4_p
hospital-units NNS N
. . N

FUNDING NN N
State NNP N
Health NNP N
Research NNP N
Advisory NNP N
Council NNP N
, , N
Department NNP N
of IN N
Health NNP N
, , N
Government NNP N
of IN N
Western NNP N
Australia NNP N
. . N

-DOCSTART- -X- O O 21048041

Pharmacogenetic JJ N
interaction NN N
analysis NN N
for IN N
the DT N
efficacy NN N
of IN N
systemic JJ N
treatment NN N
in IN N
metastatic JJ 4_p
colorectal JJ 4_p
cancer NN 4_p
. . 4_p

BACKGROUND NNP N
Pharmacogenetic NNP N
markers NNS N
related VBN N
to TO N
drug NN N
metabolism NN N
and CC N
mechanisms NNS N
of IN N
action NN N
could MD N
help VB N
to TO N
better VB N
select JJ N
patients NNS N
with IN N
metastatic JJ 4_p
colorectal NN 4_p
cancer NN 4_p
( ( 4_p
mCRC NN 4_p
) ) 4_p
for IN N
treatment NN N
. . N

Genetic JJ N
interaction NN N
analysis NN N
is VBZ N
used VBN N
as IN N
a DT N
rational JJ N
tool NN N
to TO N
study VB N
the DT N
contribution NN N
of IN N
polygenic JJ N
variation NN N
in IN N
relation NN N
to TO N
drug NN N
response NN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
A NNP N
selection NN N
of IN N
17 CD N
polymorphisms NNS N
in IN N
genes NNS N
encoding VBG N
drug NN N
targets NNS N
, , N
pathway NN N
molecules NNS N
and CC N
detoxification NN N
enzymes NNS N
was VBD N
analyzed VBN N
in IN N
279 CD N
previously RB 4_p
untreated JJ 4_p
mCRC NN 4_p
patients NNS N
treated VBN N
with IN N
capecitabine NN N
, , N
oxaliplatin NN N
and CC N
bevacizumab NN N
( ( N
CAPOX-B NNP N
) ) N
. . N

Multifactor NNP N
dimensionality NN N
reduction NN N
analysis NN N
was VBD N
used VBN N
to TO N
identify VB N
a DT N
genetic JJ N
interaction NN N
profile NN N
for IN N
progression-free JJ N
survival NN N
( ( N
PFS NNP N
) ) N
. . N

RESULTS NNP N
Median JJ N
PFS NNP N
was VBD N
10.9 CD N
[ JJ N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
9.4-12.4 CD N
] JJ N
months NNS N
. . N

A NNP N
genetic JJ N
interaction NN N
profile NN N
consisting VBG N
of IN N
the DT N
TYMS NNP N
enhancer NN N
region NN N
and CC N
VEGF NNP N
+405G NNP N
> NNP N
C NNP N
polymorphisms NN N
was VBD N
significantly RB N
associated VBN N
with IN N
PFS NNP N
. . N

Median JJ N
PFS NNP N
was VBD N
13.3 CD N
( ( N
95 CD N
% NN N
CI NNP N
11.4-15.3 CD N
) ) N
and CC N
9.7 CD N
( ( N
95 CD N
% NN N
CI NNP N
7.6-11.8 CD N
) ) N
months NNS N
for IN N
the DT N
beneficial JJ N
and CC N
unfavorable JJ N
genetic JJ N
profiles NNS N
, , N
respectively RB N
, , N
corresponding VBG N
to TO N
a DT N
hazards NNS N
ratio NN N
for IN N
PFS NNP N
of IN N
1.58 CD N
( ( N
95 CD N
% NN N
CI NNP N
1.14-2.19 CD N
) ) N
. . N

None NN N
of IN N
the DT N
studied JJ N
polymorphisms NNS N
were VBD N
individually RB N
associated VBN N
with IN N
PFS NNP N
. . N

CONCLUSIONS NNP N
Our PRP$ N
results NNS N
support VB N
a DT N
genetic JJ N
interaction NN N
between IN N
the DT N
TYMS NNP N
enhancer NN N
region NN N
and CC N
VEGF NNP N
+405G NNP N
> NNP N
C NNP N
polymorphisms NN N
as IN N
a DT N
predictor NN N
of IN N
the DT N
efficacy NN N
of IN N
CAPOX-B NNP N
in IN N
mCRC NN 4_p
patients NNS N
. . N

-DOCSTART- -X- O O 26214440

Radiofrequency NNP N
thermocoagulation NN N
combined VBN N
with IN N
pulsed JJ N
radiofrequency NN N
helps VBZ N
relieve VB N
postoperative JJ N
complications NNS N
of IN N
trigeminal JJ N
neuralgia NN N
. . N

Trigeminal NNP N
neuralgia NN N
is VBZ N
a DT N
sudden JJ N
, , N
severe JJ N
condition NN N
characterized VBN N
by IN N
stabbing VBG N
and CC N
recurrent JJ N
pain NN N
. . N

Radiofrequency NNP N
thermocoagulation NN N
( ( N
RFT NNP N
) ) N
and CC N
pulsed JJ N
radiofrequency NN N
( ( N
PRF NNP N
) ) N
are VBP N
common JJ N
surgical JJ N
interventions NNS N
used VBN N
to TO N
treat VB N
trigeminal JJ N
neuralgia NN N
. . N

This DT N
study NN N
aimed VBD N
to TO N
investigate VB N
the DT N
therapeutic JJ N
effects NNS N
and CC N
associated JJ N
complications NNS N
of IN N
a DT N
combination NN N
of IN N
RFT NNP N
and CC N
PRF NNP N
in IN N
the DT N
treatment NN N
of IN N
trigeminal JJ N
neuralgia NN N
. . N

Computed VBN N
tomography-guided JJ N
percutaneous JJ N
RFT NNP N
of IN N
the DT N
Gasserian JJ N
ganglion NN N
was VBD N
performed VBN N
on IN N
80 CD N
patients NNS N
with IN N
trigeminal JJ 4_p
neuralgia NNS 4_p
. . N

Patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
either DT N
group NN N
A NNP N
( ( N
RFT NNP N
at IN N
70°C CD N
) ) N
or CC N
group NN N
B NNP N
( ( N
RFT NNP N
at IN N
75°C CD N
) ) N
. . N

Patients NNS N
in IN N
each DT N
group NN N
were VBD N
divided VBN N
into IN N
2 CD N
subgroups NNS N
, , N
receiving VBG N
percutaneous JJ N
RFT NNP N
( ( N
240 CD N
s NN N
) ) N
with IN N
or CC N
without IN N
PRF NNP N
( ( N
42°C CD N
, , N
2 CD N
Hz NNP N
, , N
240 CD N
s NN N
) ) N
. . N

Six CD N
months NNS N
later RB N
, , N
pain NN N
relief NN N
and CC N
complication NN N
status NN N
were VBD N
evaluated VBN N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
visual JJ N
analogue NN N
scores NNS N
among IN N
groups NNS N
with IN N
RFT NNP N
at IN N
70° CD N
or CC N
75°C CD N
, , N
with IN N
or CC N
without IN N
PRF NNP N
. . N

Data NNP N
showed VBD N
that IN N
facial JJ N
numbness NN N
and CC N
postoperative JJ N
masticatory NN N
muscle NN N
weakness NN N
recovered VBD N
more RBR N
rapidly RB N
in IN N
patients NNS N
receiving VBG N
combined VBN N
RFT NNP N
and CC N
PRF NNP N
treatment NN N
. . N

Decreased VBN N
corneal NN N
reflex NN N
was VBD N
relieved VBN N
to TO N
a DT N
significantly RB N
greater JJR N
extent NN N
in IN N
groups NNS N
receiving VBG N
PRF NNP N
than IN N
those DT N
without IN N
. . N

Thus NNP N
, , N
compared VBN N
to TO N
the DT N
use NN N
of IN N
RFT NNP N
at IN N
75°C CD N
alone RB N
, , N
the DT N
combination NN N
of IN N
PRF NNP N
and CC N
RFT NNP N
helped VBD N
eliminate VB N
postoperative JJ N
complications NNS N
, , N
such JJ N
as IN N
facial JJ N
numbness NN N
, , N
masticatory JJ N
muscle NN N
weakness NN N
, , N
and CC N
decreased VBD N
corneal NN N
reflex NN N
, , N
indicating VBG N
that IN N
it PRP N
could MD N
be VB N
useful JJ N
for IN N
surgically RB N
treating VBG N
trigeminal JJ N
neuralgia NN N
. . N

-DOCSTART- -X- O O 21430242

Fecal JJ N
butyrate NN N
levels NNS N
vary VBP N
widely RB N
among IN N
individuals NNS N
but CC N
are VBP N
usually RB N
increased VBN N
by IN N
a DT N
diet JJ N
high JJ N
in IN N
resistant JJ N
starch NN N
. . N

Butyrate NNP N
and CC N
other JJ N
SCFA NNP N
produced VBN N
by IN N
bacterial JJ N
fermentation NN N
of IN N
resistant JJ N
starch NN N
( ( N
RS NNP N
) ) N
or CC N
nonstarch JJ N
polysaccharides NNS N
( ( N
NSP NNP N
) ) N
promote VBP N
human JJ N
colonic JJ N
health NN N
. . N

To TO N
examine VB N
variation NN N
in IN N
fecal JJ N
variables NNS N
, , N
especially RB N
butyrate JJ N
, , N
among IN N
individuals NNS N
and CC N
the DT N
response NN N
to TO N
these DT N
fibers NNS N
, , N
a DT N
randomized VBN N
cross-over NN N
study NN N
was VBD N
conducted VBN N
that IN N
compared VBN N
the DT N
effects NNS N
of IN N
foods NNS N
supplying VBG N
25 CD N
g NN N
of IN N
NSP NNP N
or CC N
25 CD N
g NN N
of IN N
NSP NNP N
plus CC N
22 CD N
g NN N
of IN N
RS/d NNP N
over IN N
4 CD N
wk NNS N
in IN N
46 CD 4_p
healthy JJ 4_p
adults NNS 4_p
( ( 4_p
16 CD 4_p
males NNS 4_p
, , 4_p
30 CD 4_p
females NNS 4_p
; : 4_p
age NN 4_p
31-66 JJ 4_p
y NN 4_p
) ) 4_p
. . 4_p

Fecal JJ N
SCFA NNP N
levels NNS N
varied VBD N
widely RB N
among IN N
participants NNS N
at IN N
entry NN N
( ( N
butyrate JJ N
concentrations NNS N
: : N
3.5-32.6 JJ N
mmol/kg NN N
; : N
butyrate JJ N
excretions NNS N
: : N
0.3-18.2 JJ N
mmol/48 NN N
h NN N
) ) N
. . N

BMI NNP N
explained VBD N
27 CD N
% NN N
of IN N
inter-individual JJ N
butyrate NN N
variation NN N
, , N
whereas JJ N
protein NN N
, , N
starch NN N
, , N
carbohydrate NN N
, , N
fiber NN N
, , N
and CC N
fat JJ N
intake NN N
explained VBD N
up RB N
to TO N
16 CD N
, , N
6 CD N
, , N
2 CD N
, , N
4 CD N
, , N
and CC N
2 CD N
% NN N
of IN N
butyrate NN N
variation NN N
, , N
respectively RB N
. . N

Overall JJ N
, , N
acetate NN N
, , N
butyrate NN N
, , N
and CC N
total JJ N
SCFA NNP N
concentrations NNS N
were VBD N
higher JJR N
when WRB N
participants NNS N
consumed VBD N
RS NNP N
compared VBN N
with IN N
entry NN N
and CC N
NSP NNP N
diets NNS N
, , N
but CC N
individual JJ N
responses NNS N
varied VBD N
. . N

Individual NNP N
and CC N
total JJ N
fecal JJ N
SCFA NNP N
excretion NN N
, , N
weight NN N
, , N
and CC N
moisture NN N
were VBD N
higher JJR N
than IN N
those DT N
for IN N
habitual JJ N
diets NNS N
when WRB N
either DT N
fiber NN N
diet NN N
was VBD N
consumed VBN N
. . N

SCFA NNP N
concentrations NNS N
( ( N
except IN N
butyrate NN N
) ) N
and CC N
excretions NNS N
were VBD N
higher JJR N
for IN N
males NNS N
than IN N
for IN N
females NNS N
. . N

Butyrate NNP N
levels NNS N
increased VBD N
in IN N
response NN N
to TO N
RS NNP N
in IN N
most JJS N
individuals NNS N
but CC N
often RB N
decreased VBD N
when WRB N
entry NN N
levels NNS N
were VBD N
high JJ N
. . N

Fecal JJ N
butyrate NN N
and CC N
ammonia JJ N
excretions NNS N
were VBD N
positively RB N
associated VBN N
( ( N
( ( N
2 CD N
) ) N
= NN N
0.76 CD N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

In IN N
conclusion NN N
, , N
fecal JJ N
butyrate NN N
levels NNS N
vary VBP N
widely RB N
among IN N
individuals NNS N
but CC N
consuming VBG N
a DT N
diet JJ N
high JJ N
in IN N
RS NNP N
usually RB N
increases VBZ N
levels NNS N
and CC N
may MD N
help VB N
maintain VB N
colorectal JJ N
health NN N
. . N

-DOCSTART- -X- O O 7976148

Oesophageal JJ 4_p
intubation NN 4_p
can MD N
be VB N
undetected VBN N
by IN N
auscultation NN N
of IN N
the DT N
chest NN N
. . N

Prompt NNP N
detection NN N
of IN N
oesophageal JJ N
intubation NN N
is VBZ N
a DT N
primary JJ N
concern NN N
in IN N
anaesthetic JJ N
practice NN N
. . N

This DT N
blind NN N
, , N
randomised VBD N
study NN N
evaluates NNS N
three CD N
widely RB N
used JJ N
tests NNS N
of IN N
intubation NN N
. . N

Forty NNP 4_p
patients NNS 4_p
had VBD N
both DT N
their PRP$ N
trachea NN N
and CC N
oesophagus NN N
intubated VBN N
, , N
each DT N
patient NN N
was VBD N
studied VBN N
twice RB N
. . N

Auscultation NN N
of IN N
the DT N
epigastrium NN N
, , N
right NN N
and CC N
left VBD N
axilla NN N
is VBZ N
more RBR N
reliable JJ N
than IN N
auscultation NN N
of IN N
the DT N
chest NN N
, , N
and CC N
the DT N
anaesthetist NN 4_p
's POS 4_p
feeling NN N
when WRB N
he PRP N
squeezes VBZ N
the DT N
bag NN N
. . N

P NNP N
= VBD N
0.001 CD N
and CC N
P NNP N
= NNP N
0.048 CD N
, , N
respectively RB N
. . N

The DT N
tests NNS N
were VBD N
carried VBN N
out RP N
after IN N
gastric JJ N
distension NN N
with IN N
gas NN N
had VBD N
occurred VBN N
. . N

We PRP N
conclude VBP N
that DT N
auscultation NN N
of IN N
epigastrium NN N
, , N
right NN N
and CC N
left VBD N
axilla NN N
, , N
are VBP N
recommended VBN N
. . N

-DOCSTART- -X- O O 26151440

A DT N
controlled JJ N
trial NN N
of IN N
the DT N
SibworkS NNP N
group NN N
program NN N
for IN N
siblings NNS N
of IN N
children NNS N
with IN N
special JJ 4_p
needs NNS 4_p
. . N

Siblings NNS N
of IN N
children NNS N
with IN N
a DT N
disability NN 4_p
are VBP N
an DT N
at IN N
risk NN N
group NN N
for IN N
emotional JJ N
and CC N
behavioral JJ N
problems NNS N
. . N

This DT N
study NN N
evaluated VBD N
an DT N
intervention NN N
to TO N
promote VB N
the DT N
emotional JJ N
and CC N
behavioral JJ N
functioning NN N
of IN N
siblings NNS N
of IN N
children NNS N
with IN N
disabilities NNS 4_p
and CC 4_p
chronic JJ 4_p
health NN 4_p
conditions NNS 4_p
. . N

SibworkS NNP N
is VBZ N
a DT N
six-week JJ N
manual-based JJ N
, , N
cognitive-behavioral JJ N
group NN N
support NN N
program NN N
focussed VBN N
on IN N
strengthening VBG N
siblings NNS N
' POS N
perceived VBN N
social JJ N
support NN N
, , N
self-esteem JJ N
, , N
problem-solving JJ N
skills NNS N
, , N
adaptive JJ N
coping NN N
behaviors NNS N
and CC N
positive JJ N
sibling NN N
relationships NNS N
. . N

Fifty-six JJ N
children NNS N
aged VBN N
7-12 CD N
were VBD N
allocated VBN N
to TO N
either CC N
the DT N
SibworkS NNP N
program NN N
( ( N
n=30 JJ N
) ) N
or CC N
waitlist JJ N
control NN N
( ( N
n=26 JJ N
) ) N
in IN N
alternating VBG N
sequence NN N
. . N

The DT N
primary JJ N
outcome NN N
was VBD N
siblings NNS N
' POS N
emotional JJ N
and CC N
behavioral JJ N
functioning NN N
. . N

Additional JJ N
outcomes NNS N
were VBD N
self-esteem JJ N
, , N
perceived VBD N
social JJ N
support NN N
, , N
the DT N
sibling NN N
relationship NN N
and CC N
coping NN N
behaviors NNS N
. . N

Siblings NNS N
were VBD N
followed-up JJ N
immediately RB N
after IN N
the DT N
intervention NN N
and CC N
at IN N
3-months JJ N
. . N

Siblings NNS N
participating VBG N
in IN N
the DT N
SibworkS NNP N
intervention NN N
were VBD N
reported VBN N
to TO N
have VB N
fewer JJR N
emotional JJ N
and CC N
behavioral JJ N
difficulties NNS N
than IN N
siblings NNS N
in IN N
the DT N
control NN N
group NN N
immediately RB N
following VBG N
the DT N
intervention NN N
and CC N
at IN N
the DT N
3-month JJ N
follow-up NN N
. . N

Participation NN N
in IN N
SibworkS NNP N
was VBD N
associated VBN N
with IN N
fewer JJR N
emotional JJ N
and CC N
behavioral JJ N
difficulties NNS N
for IN N
siblings NNS N
. . N

Implications NNS N
for IN N
practice NN N
and CC N
future JJ N
research NN N
include VBP N
recommendations NNS N
for IN N
improving VBG N
program NN N
participation NN N
. . N

-DOCSTART- -X- O O 15233698

Six-month JJ N
trial NN N
of IN N
on-demand JJ N
rabeprazole NN N
10 CD N
mg NN N
maintains NNS N
symptom JJ N
relief NN N
in IN N
patients NNS N
with IN N
non-erosive JJ 4_p
reflux NN 4_p
disease NN 4_p
. . N

BACKGROUND NNP N
Compliance NNP N
studies NNS N
have VBP N
shown VBN N
that IN N
patients NNS 4_p
with IN 4_p
reflux NN 4_p
symptoms NNS 4_p
generally RB N
take VBP N
their PRP$ N
medication NN N
only RB N
when WRB N
experiencing VBG N
these DT N
symptoms NNS N
. . N

AIM NNP N
To TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
on-demand JJ N
rabeprazole JJ N
maintenance NN N
therapy NN N
in IN N
patients NNS N
with IN N
non-erosive JJ 4_p
reflux NN 4_p
disease NN 4_p
. . N

METHODS NNP N
This DT N
multicentre NN N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
, , N
withdrawal NN N
study NN N
compared VBN N
6 CD N
months NNS N
of IN N
on-demand JJ N
treatment NN N
with IN N
rabeprazole JJ N
10 CD N
mg NN N
vs. FW N
placebo NN N
. . N

Adults NNS N
with IN N
a DT N
history NN N
of IN N
reflux NN 4_p
symptoms NNS N
, , N
a DT N
negative JJ N
endoscopy NN N
, , N
and CC N
> NNP N
or CC N
= VB N
3 CD N
days NNS N
of IN N
moderate JJ N
to TO N
very RB N
severe JJ N
heartburn NN 4_p
in IN N
the DT N
7 CD N
days NNS N
before IN N
enrollment NN N
( ( N
N NNP N
= NNP N
535 CD N
) ) N
entered VBD N
4 CD N
weeks NNS N
of IN N
open-label NN N
, , N
acute JJ N
treatment NN N
with IN N
rabeprazole JJ N
10 CD N
mg NN N
once RB N
daily JJ N
. . N

Patients NNS N
with IN N
complete JJ N
symptom NN N
relief NN N
then RB N
entered VBD N
the DT N
on-demand JJ N
phase NN N
. . N

The DT N
primary JJ N
end-point NN N
was VBD N
discontinuation NN N
due JJ N
to TO N
lack VB N
of IN N
heartburn NN N
control NN N
during IN N
the DT N
on-demand JJ N
phase NN N
. . N

RESULTS NNP N
Eighty-three JJ N
percent NN N
( ( N
432 CD N
of IN N
523 CD N
) ) N
of IN N
patients NNS N
reported VBD N
complete JJ N
symptom NN N
relief NN N
at IN N
the DT N
end NN N
of IN N
the DT N
acute JJ N
phase NN N
. . N

During IN N
on-demand JJ N
treatment NN N
, , N
rates NNS N
of IN N
discontinuation NN N
because IN N
of IN N
inadequate JJ N
heartburn NN N
control NN N
were VBD N
20 CD N
% NN N
( ( N
28 CD N
of IN N
139 CD N
) ) N
for IN N
placebo NN N
vs. FW N
6 CD N
% NN N
( ( N
16 CD N
of IN N
279 CD N
) ) N
for IN N
rabeprazole NN N
( ( N
P NNP N
< NNP N
0.00001 CD N
) ) N
. . N

Antacid NNP N
use NN N
was VBD N
twofold JJ N
higher JJR N
in IN N
the DT N
placebo NN N
group NN N
vs. FW N
the DT N
rabeprazole NN N
group NN N
( ( N
P NNP N
= NNP N
0.0009 CD N
) ) N
. . N

CONCLUSIONS NNP N
Rabeprazole NNP N
10 CD N
mg NN N
once RB N
daily JJ N
is VBZ N
highly RB N
effective JJ N
in IN N
acute JJ N
symptom NN N
relief NN N
and CC N
as IN N
on-demand JJ N
long-term JJ N
maintenance NN N
therapy NN N
in IN N
non-erosive JJ 4_p
reflux NN 4_p
disease NN 4_p
patients NNS N
. . N

-DOCSTART- -X- O O 18806616

Monitoring NN N
of IN N
the DT N
central JJ N
pulse JJ N
pressure NN N
is VBZ N
useful JJ N
for IN N
detecting VBG N
cardiac JJ N
overload NN N
during IN N
antiadrenergic JJ N
treatment NN N
: : N
the DT N
Japan NNP N
Morning NNP N
Surge NNP N
1 CD N
study NN N
. . N

OBJECTIVE NNP N
Lowering NNP N
of IN N
the DT N
central JJ N
pulse JJ N
pressure NN N
( ( N
PP NNP N
) ) N
has VBZ N
been VBN N
shown VBN N
to TO N
contribute VB N
to TO N
an DT N
improvement NN N
of IN N
the DT N
cardiac JJ N
damage NN N
beyond IN N
that DT N
of IN N
lowering VBG N
the DT N
brachial JJ N
PP NNP N
. . N

We PRP N
assessed VBD N
the DT N
hypothesis NN N
that IN N
the DT N
change NN N
in IN N
the DT N
central JJ N
PP NNP N
is VBZ N
more RBR N
useful JJ N
than IN N
that DT N
in IN N
the DT N
brachial JJ N
PP NNP N
in IN N
the DT N
assessment NN N
of IN N
the DT N
change NN N
in IN N
cardiac JJ N
load NN N
. . N

METHODS NNP N
We PRP N
studied VBD N
434 CD N
treated JJ N
hypertensive JJ 4_p
patients NNS 4_p
whose WP$ N
home NN N
systolic NN 4_p
blood NN 4_p
pressure NN 4_p
was VBD 4_p
135 CD 4_p
mmHg NN 4_p
or CC 4_p
higher JJR 4_p
. . N

They PRP N
were VBD N
followed VBN N
for IN N
6 CD N
months NNS N
after IN N
allocation NN N
to TO N
either VB N
a DT N
control NN N
group NN N
or CC N
an DT N
added JJ N
treatment NN N
group NN N
( ( N
doxazosin JJ N
1-4 JJ N
mg NN N
and CC N
atenolol NN N
when WRB N
needed VBN N
) ) N
. . N

We PRP N
measured VBD N
the DT N
brachial NN N
and CC N
central JJ N
( ( N
carotid NN N
) ) N
blood NN N
pressure NN N
simultaneously RB N
using VBG N
a DT N
validated JJ N
device NN N
, , N
and CC N
the DT N
B-type NNP N
natriuretic JJ N
peptide NN N
at IN N
baseline NN N
and CC N
at IN N
the DT N
sixth JJ N
month NN N
of IN N
treatment NN N
. . N

RESULTS NNP N
In IN N
the DT N
added JJ N
treatment NN N
group NN N
, , N
the DT N
brachial JJ N
systolic JJ N
blood NN N
pressure NN N
was VBD N
successfully RB N
reduced VBN N
, , N
but CC N
the DT N
central JJ N
PP NNP N
increased VBD N
significantly RB N
, , N
whereas IN N
the DT N
other JJ N
blood NN N
pressure NN N
parameters NNS N
did VBD N
not RB N
change NN N
from IN N
the DT N
baseline NN N
. . N

In IN N
the DT N
added JJ N
treatment NN N
group NN N
, , N
the DT N
change NN N
in IN N
the DT N
B-type NNP N
natriuretic JJ N
peptide NN N
was VBD N
significantly RB N
correlated VBN N
with IN N
the DT N
change NN N
in IN N
the DT N
brachial JJ N
PP NNP N
( ( N
r VB N
= RB N
0.18 CD N
) ) N
, , N
central JJ N
systolic JJ N
blood NN N
pressure NN N
( ( N
r JJ N
= NNP N
0.18 CD N
) ) N
, , N
central JJ N
PP NNP N
( ( N
r VB N
= RB N
0.26 CD N
) ) N
, , N
and CC N
PP NNP N
amplification NN N
( ( N
r JJ N
= NNP N
-0.22 NNP N
) ) N
even RB N
after IN N
adjusting VBG N
for IN N
the DT N
confounding NN N
factors NNS N
. . N

The DT N
correlation NN N
with IN N
the DT N
central JJ N
PP NNP N
was VBD N
stronger JJR N
than IN N
with IN N
the DT N
brachial JJ N
PP NNP N
( ( N
P NNP N
= NNP N
0.018 CD N
) ) N
or CC N
central JJ N
systolic JJ N
blood NN N
pressure NN N
( ( N
P NNP N
= NNP N
0.002 CD N
) ) N
, , N
and CC N
these DT N
relationships NNS N
were VBD N
essentially RB N
the DT N
same JJ N
even RB N
after IN N
adjustment NN N
for IN N
the DT N
use NN N
of IN N
atenolol NN N
or CC N
the DT N
change NN N
in IN N
heart NN N
rate NN N
. . N

CONCLUSION NNP N
This DT N
study NN N
showed VBD N
that IN N
the DT N
central JJ N
PP NNP N
measurement NN N
may MD N
be VB N
more RBR N
important JJ N
to TO N
assess VB N
cardiac JJ N
load NN N
than IN N
the DT N
brachial JJ N
PP NNP N
during IN N
antiadrenergic JJ N
treatment NN N
. . N

-DOCSTART- -X- O O 21574725

On IN N
the DT N
benign JJ N
qualities NNS N
of IN N
behavioral JJ 4_p
disinhibition NN 4_p
: : N
because IN N
of IN N
the DT N
prosocial JJ 4_p
nature NN 4_p
of IN 4_p
people NNS 4_p
, , N
behavioral JJ N
disinhibition NN N
can MD N
weaken VB N
pleasure NN N
with IN N
getting VBG N
more JJR N
than IN N
you PRP N
deserve VBP N
. . N

This DT N
article NN N
focuses VBZ N
on IN N
social JJ N
situations NNS N
in IN N
which WDT N
people NNS N
are VBP N
surprised VBN N
about IN N
what WP N
is VBZ N
happening VBG N
and CC N
inhibited VBN N
about IN N
how WRB N
to TO N
respond VB N
to TO N
the DT N
situation NN N
at IN N
hand NN N
. . N

We PRP N
study VBP N
these DT N
situations NNS N
by IN N
examining VBG N
a DT N
classic JJ N
topic NN N
in IN N
social JJ N
psychology NN N
: : N
how WRB N
people NNS 4_p
respond VBP 4_p
to TO 4_p
receiving VBG 4_p
better JJR 4_p
outcomes NNS 4_p
than IN 4_p
are VBP 4_p
deserved VBN 4_p
. . N

In IN N
these DT N
situations NNS N
, , N
the DT N
actions NNS N
of IN N
an DT N
authority NN N
or CC N
a DT N
coworker NN N
push NN N
in IN N
the DT N
direction NN N
of IN N
accepting VBG N
and CC N
enjoying VBG N
the DT N
unfair JJ N
outcome NN N
, , N
whereas JJ N
personal JJ N
values NNS N
for IN N
most JJS N
people NNS N
push VBP N
in IN N
the DT N
direction NN N
of IN N
rejecting VBG N
or CC N
being VBG N
displeased VBN N
with IN N
the DT N
outcome NN N
. . N

This DT N
conflict NN N
may MD N
inhibit VB N
people NNS N
's POS N
response NN N
to TO N
the DT N
advantageous JJ N
but CC N
unfair JJ N
outcomes NNS N
. . N

If IN N
people NNS N
are VBP N
indeed RB N
inhibited VBN N
about IN N
how WRB N
to TO N
respond VB N
to TO N
these DT N
kinds NNS N
of IN N
outcomes NNS N
, , N
then RB N
lowering VBG N
behavioral JJ N
inhibition NN N
by IN N
reminding VBG N
people NNS N
of IN N
having VBG N
acted VBN N
in IN N
the DT N
past NN N
without IN N
inhibitions NNS N
( ( N
in IN N
a DT N
manner NN N
that WDT N
is VBZ N
unrelated JJ N
to TO N
the DT N
outcomes NNS N
participants NNS N
subsequently RB N
receive VBP N
) ) N
should MD N
affect VB N
reactions NNS N
to TO N
the DT N
outcomes NNS N
. . N

Specifically RB N
, , N
we PRP N
hypothesize VBP N
that IN N
because IN N
many JJ N
people NNS N
are VBP N
prosocial JJ N
and CC N
want VBP N
to TO N
adhere VB N
to TO N
principles NNS N
of IN N
fairness NN N
, , N
reminders NNS N
of IN N
behavioral JJ N
disinhibition NN N
will MD N
lead VB N
to TO N
less JJR N
pleasure NN N
with IN N
the DT N
unfairly RB N
obtained VBN N
outcomes RB N
. . N

The DT N
results NNS N
of IN N
8 CD N
experiments NNS N
( ( N
conducted VBN N
both DT N
inside IN N
and CC N
outside IN N
the DT N
psychology NN N
laboratory NN N
) ) N
revealed VBD N
evidence NN N
for IN N
this DT N
benign JJ N
disinhibition NN N
effect NN N
on IN N
various JJ N
reactions NNS N
to TO N
outcomes NNS N
that WDT N
are VBP N
better JJR N
than IN N
deserved VBN N
. . N

In IN N
further JJ N
accordance NN N
with IN N
our PRP$ N
line NN N
of IN N
reasoning NN N
, , N
the DT N
effect NN N
is VBZ N
particularly RB N
pronounced VBN N
among IN N
those DT N
who WP N
adhere VBP N
to TO N
a DT N
prosocial JJ N
orientation NN N
or CC N
who WP N
have VBP N
adopted VBN N
a DT N
prosocial JJ N
mindset NN N
and CC N
is VBZ N
not RB N
observed VBN N
among IN N
those DT N
with IN N
proself JJ N
orientations NNS N
or CC N
mindsets NNS N
. . N

-DOCSTART- -X- O O 15538933

Blockade NN N
of IN N
endogenous JJ N
growth NN N
hormone-releasing VBG N
hormone NN N
receptors NNS N
dissociates VBZ N
nocturnal JJ N
growth NN N
hormone NN N
secretion NN N
and CC N
slow-wave JJ N
sleep NN N
. . N

OBJECTIVES CC N
A NNP N
temporal JJ N
association NN N
between IN N
non-rapid JJ N
eye NN N
movement NN N
( ( N
NREM NNP N
) ) N
sleep VBP N
stages NNS N
3 CD N
and CC N
4 CD N
and CC N
nocturnal JJ N
augmentation NN N
of IN N
GH NNP N
release NN N
was VBD N
found VBN N
long RB N
ago RB N
, , N
yet RB N
the DT N
precise NN N
mechanism NN N
for IN N
this DT N
association NN N
has VBZ N
not RB N
been VBN N
identified VBN N
. . N

It PRP N
has VBZ N
been VBN N
shown VBN N
, , N
however RB N
that IN N
pulsatile JJ N
GHRH NNP N
administration NN N
increases VBZ N
both DT N
slow-wave JJ N
sleep NN N
( ( N
SWS NNP N
) ) N
and CC N
GH NNP N
. . N

Based VBN N
on IN N
these DT N
data NNS N
, , N
a DT N
role NN N
for IN N
GHRH NNP N
as IN N
an DT N
inducer NN N
of IN N
SWS NNP N
was VBD N
proposed VBN N
. . N

To TO N
test VB N
this DT N
hypothesis NN N
, , N
we PRP N
have VBP N
performed VBN N
the DT N
corollary JJ N
experiment NN N
whereby WRB N
the DT N
action NN N
of IN N
endogenous JJ N
GHRH NNP N
has VBZ N
been VBN N
antagonized VBN N
. . N

DESIGN NNP N
Healthy NNP 4_p
men NNS 4_p
( ( 4_p
20-33 CD 4_p
years NNS 4_p
old JJ 4_p
) ) 4_p
had VBD N
an DT N
infusion NN N
of IN N
GHRH NNP N
antagonist NN N
( ( N
( ( N
N-Ac-Tyr NNP N
( ( N
1 CD N
) ) N
, , N
D-Arg NNP N
( ( N
2 CD N
) ) N
) ) N
GHRH-29 NNP N
( ( N
NH NNP N
( ( N
2 CD N
) ) N
) ) N
) ) N
or CC N
saline NN N
for IN N
a DT N
12-h JJ N
period NN N
, , N
between IN N
2100 CD N
and CC N
0900 CD N
h. NN N
An DT N
i.v NN N
. . N

bolus NN N
of IN N
GHRH NNP N
was VBD N
given VBN N
at IN N
0700 CD N
h NN N
and CC N
GH NNP N
samples NNS N
were VBD N
drawn VBN N
from IN N
0700 CD N
to TO N
0900 CD N
h NN N
to TO N
document VB N
the DT N
efficacy NN N
of IN N
GH NNP N
suppression NN N
by IN N
the DT N
GHRH NNP N
antagonist NN N
. . N

METHODS NNP N
A NNP N
limited JJ N
montage NN N
sleep NN N
study NN N
was VBD N
recorded VBN N
from IN N
2300 CD N
to TO N
0700 CD N
h NN N
during IN N
each DT N
admission NN N
. . N

Plasma NNP N
GH NNP N
concentrations NNS N
were VBD N
analyzed VBN N
by IN N
the DT N
use NN N
of IN N
a DT N
sensitive JJ N
chemiluminometric JJ N
assay NN N
. . N

RESULTS NNP N
Effectiveness NNP N
of IN N
the DT N
GHRH NNP N
antagonist NN N
was VBD N
validated VBN N
in IN N
all DT N
subjects NNS N
by IN N
demonstrating VBG N
93+/-1.8 CD N
% NN N
( ( N
P=0.012 NNP N
) ) N
suppression NN N
of IN N
GH NNP N
response NN N
to TO N
a DT N
GHRH NNP N
bolus NN N
. . N

Polysomnography NNP N
demonstrated VBD N
that IN N
the DT N
percentage NN N
of IN N
SWS NNP N
was VBD N
not RB N
different JJ N
when WRB N
saline NN N
and CC N
GHRH NNP N
antagonist VBP N
nights NNS N
were VBD N
compared VBN N
( ( N
P=0.607 NNP N
) ) N
; : N
other JJ N
quantifiable JJ N
sleep JJ N
parameters NNS N
were VBD N
also RB N
unchanged JJ N
. . N

CONCLUSIONS NNP N
We PRP N
conclude VBP N
that DT N
endogenous JJ N
GHRH NNP N
is VBZ N
indispensable JJ N
for IN N
the DT N
nocturnal JJ N
augmentation NN N
of IN N
GH NNP N
secretion NN N
, , N
but CC N
that IN N
it PRP N
is VBZ N
unlikely JJ N
to TO N
participate VB N
in IN N
the DT N
genesis NN N
of IN N
SWS NNP N
. . N

-DOCSTART- -X- O O 25224595

Caphosol NNP N
( ( N
® NNP N
) ) N
mouthwash VBP N
gives VBZ N
no DT N
additional JJ N
protection NN N
against IN N
oral JJ N
mucositis NN N
compared VBN N
to TO N
cryotherapy VB N
alone RB N
in IN 4_p
stem NN 4_p
cell NN 4_p
transplantation NN 4_p
. . N

A DT N
pilot NN N
study NN N
. . N

PURPOSE NNP N
To TO N
investigate VB N
if IN N
adding VBG N
Caphosol NNP N
( ( N
® NNP N
) ) N
, , N
a DT N
mouthwash JJ N
solution NN N
, , N
to TO N
oral JJ N
cryotherapy NN N
( ( N
OC NNP N
) ) N
further RBR N
protects NNS N
against IN N
oral JJ N
mucositis NN N
( ( N
OM NNP N
) ) N
, , N
a DT N
toxic JJ N
painful JJ N
complication NN N
to TO N
high VB N
dose JJ N
chemotherapy NN N
. . N

METHOD NNP N
The DT N
study NN N
was VBD N
a DT N
randomised JJ N
, , N
controlled VBN N
, , N
study NN N
design NN 4_p
. . N

Patients NNS N
≥16 JJ N
years NNS N
scheduled VBN N
for IN N
allogeneic JJ 4_p
stem NN 4_p
cell NN 4_p
transplantation NN 4_p
were VBD N
included VBN N
consecutively RB N
and CC N
randomised VBD N
to TO N
experimental VB N
group NN N
receiving VBG N
OC NNP N
combined VBN N
with IN N
Caphosol NNP N
( ( N
® NNP N
) ) N
( ( N
n JJ N
= NNP N
20 CD N
) ) N
or CC N
control VB N
group NN N
receiving VBG N
OC NNP N
only RB N
( ( N
n JJ N
= NNP N
20 CD N
) ) N
. . N

OC NNP N
was VBD N
given VBN N
from IN N
start NN N
to TO N
end VB N
of IN N
HDCT NNP N
. . N

Caphosol NNP N
( ( N
® NNP N
) ) N
, , N
from IN N
day NN N
0 CD N
to TO N
day NN N
21 CD N
. . N

RESULT VB N
There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
regarding VBG N
age NN N
or CC N
gender NN N
between IN N
the DT N
groups NNS N
. . N

Mucositis NNP N
was VBD N
assessed VBN N
with IN N
the DT N
World NNP N
Health NNP N
Organisation NNP N
( ( N
WHO NNP N
) ) N
grading VBG N
scale NN N
. . N

Pain NN N
was VBD N
assessed VBN N
with IN N
a DT N
10 CD N
cm NN N
visual JJ N
analogue NN N
scale NN N
( ( N
VAS NNP N
) ) N
from IN N
0 CD N
= JJ N
no DT N
pain NN N
to TO N
10 CD N
= NNS N
worst RBR N
imaginable JJ N
pain NN N
. . N

Start NNP N
and CC N
duration NN N
of IN N
therapy NN N
with IN N
pain NN N
relieving VBG N
drugs NNS N
, , N
serum VBD N
C-reactive JJ N
protein NN N
values NNS N
, , N
and CC N
number NN N
of IN N
days NNS N
of IN N
hospitalisation NN N
were VBD N
collected VBN N
from IN N
the DT N
medical JJ N
records NNS N
. . N

Data NNS N
on IN N
OM NNP N
, , N
oral JJ N
pain NN N
, , N
use NN N
of IN N
i.v NN N
. . N

opioids NNS N
and CC N
total JJ N
parenteral JJ N
nutrition NN N
were VBD N
collected VBN N
during IN N
22 CD N
days NNS N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
groups NNS N
on IN N
OM NNP N
, , N
oral JJ N
pain NN N
, , N
use NN N
of IN N
i.v NN N
. . N

opioids NNS N
or CC N
TPN NNP N
between IN N
the DT N
groups NNS N
. . N

CONCLUSION NNP N
The DT N
study NN N
showed VBD N
no DT N
additional JJ N
effect NN N
of IN N
combining VBG N
Caphosol NNP N
( ( N
® NNP N
) ) N
with IN N
OC NNP N
. . N

-DOCSTART- -X- O O 19174717

Bevacizumab NNP N
compared VBN N
with IN N
macular JJ N
laser NN N
grid JJ N
photocoagulation NN N
for IN N
cystoid JJ N
macular JJ N
edema NN N
in IN N
branch JJ N
retinal JJ N
vein NN N
occlusion NN N
. . N

INTRODUCTION NNP N
To TO N
evaluate VB N
the DT N
outcome NN N
of IN N
cystoid JJ N
macular JJ N
edema NN N
treated VBN N
with IN N
intravitreal JJ N
injections NNS N
of IN N
bevacizumab NN N
and CC N
macular JJ N
grid NN N
laser NN N
photocoagulation NN N
( ( N
GLP NNP N
) ) N
, , N
in IN N
patients NNS N
with IN N
perfused JJ N
branch NN N
retinal JJ N
vein NN N
occlusion NN N
. . N

METHODS NNP N
Thirty NNP N
eyes NNS N
of IN N
30 CD N
consecutive JJ N
patients NNS N
with IN N
cystoid JJ N
macular JJ N
edema NN N
secondary JJ N
to TO N
nonischemic JJ N
branch NN N
retinal JJ N
vein NN N
occlusion NN N
were VBD N
assigned VBN N
to TO N
either DT N
GLP NNP N
group NN N
or CC N
to TO N
intravitreal VB N
bevacizumab NN N
( ( N
IB NNP N
) ) N
group NN N
. . N

Complete NNP N
ophthalmologic JJ N
examinations NNS N
were VBD N
performed VBN N
just RB N
before IN N
GLP NNP N
and CC N
IB NNP N
injection NN N
at IN N
1 CD N
, , N
3 CD N
, , N
6 CD N
, , N
and CC N
12 CD N
months NNS N
after IN N
treatment NN N
. . N

Changes NNS N
in IN N
logarithm NN N
of IN N
minimum JJ N
angle NN N
of IN N
resolution NN N
( ( N
logMAR JJ N
) ) N
best-corrected JJ N
visual JJ N
acuity NN N
( ( N
BCVA NNP N
) ) N
, , N
central JJ N
macular JJ N
thickness NN N
( ( N
CMT NNP N
) ) N
shown VBN N
by IN N
optical JJ N
coherence NN N
tomography-3 NN N
were VBD N
evaluated VBN N
. . N

RESULTS NNP N
Baseline NNP N
BCVA NNP N
( ( N
logMAR NN N
) ) N
and CC N
CMT NNP N
were VBD N
, , N
respectively RB N
, , N
0.89 CD N
+/- JJ N
0.13 CD N
and CC N
650 CD N
+/- JJ N
140 CD N
microm NN N
for IN N
the DT N
GLP NNP N
group NN N
, , N
0.87 CD N
+/- JJ N
0.16 CD N
and CC N
690 CD N
+/- JJ N
120 CD N
microm NN N
for IN N
the DT N
IB NNP N
group NN N
. . N

After IN N
the DT N
treatment NN N
, , N
at IN N
1 CD N
, , N
3 CD N
, , N
6 CD N
, , N
and CC N
12 CD N
months NNS N
in IN N
the DT N
GLP NNP N
group NN N
, , N
BCVA NNP N
had VBD N
improved VBN N
by IN N
0.19 CD N
, , N
0.22 CD N
, , N
0.21 CD N
, , N
and CC N
0.20 CD N
logMAR NN N
, , N
CMT NNP N
had VBD N
decreased VBN N
by IN N
40 CD N
% NN N
, , N
41.3 CD N
% NN N
, , N
40.5 CD N
% NN N
, , N
and CC N
42 CD N
% NN N
. . N

In IN N
the DT N
IB NNP N
group NN N
, , N
BCVA NNP N
had VBD N
improved VBN N
by IN N
0.31 CD N
, , N
0.32 CD N
, , N
0.30 CD N
, , N
and CC N
0.31 CD N
logMAR NN N
and CC N
CMT NNP N
had VBD N
decreased VBN N
by IN N
59.5 CD N
% NN N
, , N
59 CD N
% NN N
, , N
60 CD N
% NN N
, , N
and CC N
60.3 CD N
% NN N
. . N

The DT N
group NN N
receiving VBG N
bevacizumab NN N
had VBD N
better JJR N
BCVA NNP N
and CC N
lower JJR N
CMT NNP N
values NNS N
at IN N
all DT N
time NN N
points NNS N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSION NNP N
Intravitreal NNP N
bevacizumab NN N
injection NN N
improves VBZ N
BCVA NNP N
and CC N
reduces NNS N
CMT NNP N
more JJR N
than IN N
GLP NNP N
. . N

Intravitreal NNP N
bevacizumab JJ N
injection NN N
was VBD N
well RB N
tolerated VBN N
and CC N
could MD N
be VB N
used VBN N
as IN N
primary JJ N
treatment NN N
in IN N
patients NNS N
with IN N
cystoid JJ N
macular JJ N
edema NN N
secondary JJ N
to TO N
perfused VBN N
branch NN N
retinal JJ N
vein NN N
occlusion NN N
. . N

-DOCSTART- -X- O O 20356395

Comparison NNP N
of IN N
yoga NNP N
versus NN N
stretching VBG N
for IN N
chronic JJ 4_p
low JJ 4_p
back RB 4_p
pain NN 4_p
: : N
protocol NN N
for IN N
the DT N
Yoga NNP N
Exercise NNP N
Self-care NNP N
( ( N
YES NNP N
) ) N
trial NN N
. . N

BACKGROUND NNP N
Back NNP N
pain NN N
, , N
one CD N
of IN N
the DT N
most RBS N
prevalent JJ N
conditions NNS N
afflicting VBG N
American JJ N
adults NNS N
, , N
is VBZ N
the DT N
leading VBG N
reason NN N
for IN N
using VBG N
complementary JJ N
and CC N
alternative JJ N
medicine NN N
( ( N
CAM NNP N
) ) N
therapies NNS N
. . N

Yoga NNP N
is VBZ N
an DT N
increasingly RB N
popular JJ N
" NNP N
mind-body NN N
" NNP N
CAM NNP N
therapy NN N
often RB N
used VBN N
for IN N
relieving VBG N
back RB N
pain NN N
and CC N
several JJ N
small JJ N
studies NNS N
have VBP N
found VBN N
yoga RB N
effective JJ N
for IN N
this DT N
condition NN N
. . N

This DT N
study NN N
will MD N
assess VB N
whether IN N
yoga NN N
is VBZ N
effective JJ N
for IN N
treating VBG N
chronic JJ N
low JJ N
back RB N
pain NN N
compared VBN N
with IN N
self PRP N
care NN N
and CC N
exercise NN N
and CC N
will MD N
explore VB N
the DT N
mechanisms NNS N
responsible JJ N
for IN N
any DT N
observed JJ N
benefits NNS N
. . N

METHODS/DESIGN NNP N
A NNP N
total NN N
of IN N
210 CD 4_p
participants NNS N
with IN N
low JJ 4_p
back RB 4_p
pain NN 4_p
lasting NN N
at IN N
least JJS N
3 CD N
months NNS N
will MD N
be VB N
recruited VBN N
from IN N
primary JJ N
care NN N
clinics NNS N
of IN N
a DT N
large JJ N
healthcare NN N
system NN N
based VBN N
in IN N
Seattle NNP N
. . N

They PRP N
will MD N
be VB N
randomized VBN N
in IN N
a DT N
2:2:1 CD N
ratio NN N
to TO N
receive VB N
12 CD N
weekly JJ N
yoga NN N
classes NNS N
, , N
12 CD N
weekly JJ N
conventional JJ N
therapeutic JJ N
exercise NN N
classes NNS N
of IN N
comparable JJ N
physical JJ N
exertion NN N
, , N
or CC N
a DT N
self-care JJ N
book NN N
. . N

Interviewers NNS N
masked VBD N
to TO N
participants NNS N
' POS N
treatment NN N
group NN N
will MD N
assess VB N
outcomes NNS N
at IN N
baseline NN N
and CC N
6 CD N
, , N
12 CD N
and CC N
26 CD N
weeks NNS N
after IN N
randomization NN N
. . N

Primary JJ N
outcomes NNS N
will MD N
be VB N
back-related JJ N
dysfunction NN N
and CC N
symptom NN N
bothersomeness NN N
. . N

In IN N
addition NN N
, , N
data NNS N
will MD N
be VB N
collected VBN N
on IN N
physical JJ N
measurements NNS N
( ( N
e.g. NN N
, , N
flexion NN N
) ) N
at IN N
baseline NN N
and CC N
12 CD N
weeks NNS N
and CC N
saliva NN N
samples NNS N
will MD N
be VB N
obtained VBN N
at IN N
baseline NN N
, , N
6 CD N
and CC N
12 CD N
weeks NNS N
. . N

Information NN N
will MD N
be VB N
collected VBN N
on IN N
specific JJ N
physical JJ N
, , N
psychological JJ N
, , N
and CC N
physiological JJ N
factors NNS N
to TO N
allow VB N
exploration NN N
of IN N
possible JJ N
mechanisms NNS N
of IN N
action NN N
through IN N
which WDT N
yoga NN N
could MD N
relieve VB N
back RB N
pain NN N
and CC N
dysfunction NN N
. . N

The DT N
effectiveness NN N
of IN N
yoga NN N
will MD N
be VB N
assessed VBN N
using VBG N
analysis NN N
of IN N
covariance NN N
( ( N
using VBG N
general JJ N
estimating VBG N
equations NNS N
- : N
GEE NNP N
) ) N
within IN N
an DT N
intention-to-treat JJ N
context NN N
. . N

If IN N
yoga NN N
is VBZ N
found VBN N
effective JJ N
, , N
further JJ N
analyses NNS N
will MD N
explore VB N
whether IN N
yoga NN N
's POS N
benefits NNS N
are VBP N
attributable JJ N
to TO N
physical JJ N
, , N
psychological JJ N
and/or NN N
physiological JJ N
factors NNS N
. . N

CONCLUSIONS VB N
This DT N
study NN N
will MD N
provide VB N
the DT N
clearest JJS N
evidence NN N
to TO N
date NN N
about IN N
the DT N
value NN N
of IN N
yoga NN N
as IN N
a DT N
therapeutic JJ N
option NN N
for IN N
treating VBG N
chronic JJ 4_p
back RB 4_p
pain NN 4_p
, , N
and CC N
if IN N
the DT N
results NNS N
are VBP N
positive JJ N
, , N
will MD N
help VB N
focus VB N
future JJ N
, , N
more RBR N
in-depth JJ N
, , N
research NN N
on IN N
the DT N
most RBS N
promising JJ N
potential JJ N
mechanisms NN N
of IN N
action NN N
identified VBN N
by IN N
this DT N
study NN N
. . N

-DOCSTART- -X- O O 9105060

Leukotriene NNP N
antagonist NN N
prevents NNS N
exacerbation NN N
of IN N
asthma NN 4_p
during IN N
reduction NN N
of IN N
high-dose JJ N
inhaled JJ N
corticosteroid NN N
. . N

The DT N
Tokyo NNP N
Joshi-Idai NNP N
Asthma NNP N
Research NNP N
Group NNP N
. . N

To TO N
test VB N
whether IN N
the DT N
leukotriene JJ N
antagonist JJ N
ONO-1078 NNP N
( ( N
pranlukast NN N
) ) N
prevents VBZ N
asthma JJ 4_p
exacerbations NNS N
during IN N
reduction NN N
of IN N
high-dose JJ N
inhaled JJ N
corticosteroid NN N
, , N
we PRP N
conducted VBD N
a DT N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
in IN N
79 CD N
asthma NN 4_p
patients NNS 4_p
requiring VBG N
high JJ N
doses NNS N
( ( N
1,500 CD N
microg/d NN N
or CC N
more JJR N
) ) N
of IN N
inhaled JJ 4_p
beclomethasone NN 4_p
dipropionate NN 4_p
( ( N
BDI NNP N
) ) N
for IN N
clinical JJ N
control NN N
( ( N
duration NN N
of IN N
asthma NN N
, , N
11.0 CD N
+/- JJ N
3.1 CD N
yr NN N
; : N
duration NN N
of IN N
BDI NNP N
treatment NN N
, , N
0.5 CD N
+/- JJ N
0.3 CD N
yr NN N
; : N
FEV1 NNP N
percentage NN N
of IN N
predicted VBN N
, , N
80.7 CD N
+/- JJ N
2.0 CD N
% NN N
) ) N
. . N

After IN N
a DT N
2-wk JJ N
run-in JJ N
period NN N
, , N
the DT N
doses NNS N
of IN N
BDI NNP N
were VBD N
halved VBN N
, , N
while IN N
the DT N
patients NNS N
were VBD N
assigned VBN N
to TO N
receive VB N
orally RB N
ONO-1078 NNP N
, , N
450 CD N
mg NN N
twice RB N
daily RB N
, , N
or CC N
placebo NN N
. . N

In IN N
the DT N
placebo NN N
group NN N
FEV1 NNP N
decreased VBN N
by IN N
0.33 CD N
+/- JJ N
0.20 CD N
L NNP N
after IN N
6 CD N
wk NN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

Likewise NNP N
, , N
morning NN N
and CC N
evening NN N
PEF NNP N
decreased VBN N
by IN N
46 CD N
+/- JJ N
7 CD N
L/min NNP N
and CC N
18 CD N
+/- JJ N
6 CD N
L/min NNP N
, , N
respectively RB N
. . N

By IN N
contrast NN N
these DT N
variables NNS N
were VBD N
sustained VBN N
above IN N
baseline NN N
in IN N
the DT N
ONO-1078 NNP N
group NN N
. . N

The DT N
number NN N
of IN N
daytime NN N
and CC N
nighttime JJ N
asthma NN N
symptoms NNS N
and CC N
the DT N
use NN N
of IN N
beta2-agonist NN N
increased VBN N
in IN N
the DT N
placebo NN N
group NN N
, , N
whereas IN N
they PRP N
remained VBD N
unchanged JJ N
in IN N
the DT N
ONO-1078 NNP N
group NN N
. . N

In IN N
the DT N
placebo NN N
group NN N
concentrations NNS N
of IN N
serum NN N
eosinophil NN N
cationic JJ N
protein NN N
and CC N
exhaled VBD N
nitric JJ N
oxide NN N
increased VBD N
( ( N
p JJ N
= NN N
0.007 CD N
and CC N
p VB N
= JJ N
0.025 CD N
, , N
respectively RB N
) ) N
, , N
compared VBN N
with IN N
no DT N
change NN N
in IN N
the DT N
ONO-1078 NNP N
group NN N
. . N

Therefore RB N
, , N
the DT N
leukotriene JJ N
antagonist JJ N
ONO-1078 JJ N
prevents NNS N
the DT N
asthma JJ 4_p
deterioration NN N
provoked VBN N
by IN N
a DT N
6-wk JJ N
reduction NN N
of IN N
the DT N
dose NN N
of IN N
inhaled JJ N
BDI NNP N
into IN N
half NN N
. . N

-DOCSTART- -X- O O 9855086

Optimization NN N
of IN N
acid JJ N
suppression NN N
for IN N
patients NNS N
with IN N
peptic JJ 4_p
ulcer NN 4_p
bleeding NN 4_p
: : N
an DT N
intragastric JJ N
pH-metry NN N
study NN N
with IN N
omeprazole NN N
. . N

OBJECTIVE UH N
To TO N
study VB N
whether IN N
an DT N
intravenous JJ N
infusion NN N
dose NN N
of IN N
omeprazole NN N
( ( N
80 CD N
mg NN N
+ VBD N
8 CD N
mg/h NN N
) ) N
during IN N
24 CD N
h NNS N
can MD N
be VB N
subsequently RB N
reduced VBN N
with IN N
maintained JJ N
effect NN N
. . N

Second NNP N
, , N
to TO N
study VB N
the DT N
effect NN N
of IN N
oral JJ N
omeprazole JJ N
20 CD N
mg NN N
given VBN N
once RB N
or CC N
twice RB N
daily RB N
up IN N
to TO N
day NN N
10 CD N
, , N
after IN N
cessation NN N
of IN N
a DT N
3-day JJ N
intravenous JJ N
infusion NN N
( ( N
80 CD N
mg NN N
+ VBD N
8 CD N
mg/h NN N
) ) N
. . N

DESIGN NNP N
Prospective NNP N
, , N
randomized VBD N
, , N
partly RB N
blinded VBD N
study NN N
. . N

METHODS NNP N
Twelve NNP N
Helicobacter NNP 4_p
pylori NN 4_p
( ( 4_p
+ NNP 4_p
) ) 4_p
patients NNS 4_p
and CC N
12 CD N
H. NNP 4_p
pylori NN 4_p
( ( 4_p
- : 4_p
) ) 4_p
subjects NNS 4_p
were VBD N
included VBN N
. . N

In IN N
part NN N
I PRP N
the DT N
patients NNS N
received VBD N
omeprazole JJ N
, , N
80 CD N
mg NN N
+ VBD N
8 CD N
mg/h NN N
, , N
during IN N
24 CD N
h NN N
followed VBN N
by IN N
8 CD N
, , N
4 CD N
or CC N
2 CD N
mg/h NN N
. . N

In IN N
part NN N
II NNP N
the DT N
subjects NNS N
received VBD N
80 CD N
mg NNS N
+ VBD N
8 CD N
mg/h NN N
during IN N
3 CD N
days NNS N
followed VBN N
by IN N
20 CD N
mg NNS N
omeprazole JJ N
orally RB N
, , N
once RB N
or CC N
twice JJ N
daily JJ N
until IN N
day NN N
10 CD N
. . N

Intragastric NNP N
pH NN N
was VBD N
measured VBN N
. . N

RESULTS NNP N
All NNP N
H. NNP N
pylori FW N
( ( N
+ NN N
) ) N
patients NNS N
showed VBD N
a DT N
rapid JJ N
increase NN N
of IN N
intragastric JJ N
pH NN N
with IN N
a DT N
mean JJ N
intragastric JJ N
pH NN N
of IN N
6.7 CD N
during IN N
the DT N
second JJ N
half NN N
of IN N
the DT N
first JJ N
day NN N
. . N

After IN N
the DT N
subsequent JJ N
dose NN N
reduction NN N
, , N
the DT N
mean JJ N
pH NN N
decreased VBD N
to TO N
6.1-6.2 JJ N
. . N

Patients NNPS N
continuing VBG N
on IN N
8 CD N
mg/h NN N
showed VBD N
the DT N
best JJS N
results NNS N
. . N

Likewise NNP N
, , N
all DT N
H. NNP N
pylori NN N
( ( N
- : N
) ) N
subjects VBZ N
showed VBD N
a DT N
rapid JJ N
and CC N
sustained JJ N
reduction NN N
of IN N
intragastric JJ N
acidity NN N
during IN N
the DT N
infusion NN N
. . N

Subsequent NNP N
dose JJ N
reduction NN N
to TO N
20 CD N
mg NNS N
once RB N
daily RB N
led VBN N
to TO N
a DT N
stable JJ N
fraction NN N
of IN N
time NN N
with IN N
pH JJ N
> JJ N
3 CD N
of IN N
72 CD N
% NN N
. . N

CONCLUSIONS NNP N
Omeprazole NNP N
given VBN N
as IN N
a DT N
continuous JJ N
infusion NN N
of IN N
80 CD N
mg NNS N
+ VBD N
8 CD N
mg/h NN N
for IN N
72 CD N
h NN N
followed VBN N
by IN N
omeprazole JJ N
20 CD N
mg NN N
once RB N
daily RB N
raised VBD N
the DT N
intragastric JJ N
pH NN N
to TO N
and CC N
above JJ N
levels NNS N
alleged VBN N
to TO N
allow VB N
haemostasis NN N
in IN N
patients NNS N
with IN N
peptic JJ 4_p
ulcer NN 4_p
bleeding NN 4_p
and CC N
subsequent JJ N
healing NN N
of IN N
the DT N
ulcer NN N
. . N

-DOCSTART- -X- O O 8904679

Impact NN N
of IN N
triiodothyronine NN N
on IN N
the DT N
survival NN N
of IN N
high-risk JJ 4_p
patients NNS 4_p
undergoing VBG 4_p
open JJ 4_p
heart NN 4_p
surgery NN 4_p
. . N

Experimental NNP N
and CC N
clinical JJ N
studies NNS N
have VBP N
shown VBN N
the DT N
beneficial JJ N
effects NNS N
of IN N
triiodothyronine NN N
( ( N
T3 NNP N
) ) N
following VBG N
myocardial JJ N
revascularization NN N
on IN N
cardiopulmonary JJ N
bypass NN N
( ( N
CPB NNP N
) ) N
. . N

In IN N
this DT N
study NN N
, , N
open-label JJ N
T3 NNP N
was VBD N
administered VBN N
to TO N
68 CD N
high-risk JJ N
patients NNS N
undergoing VBG 4_p
open JJ 4_p
heart NN 4_p
surgery NN 4_p
. . N

The DT N
New NNP N
Jersey NNP N
Risk NNP N
Assessment NNP N
was VBD N
used VBN N
to TO N
calculate VB N
the DT N
preoperative NN N
estimated VBD N
surgical JJ N
mortality NN N
. . N

A DT N
loading VBG N
dose NN N
of IN N
T3 NNP N
was VBD N
administered VBN N
: : N
( ( N
a DT N
) ) N
at IN N
release NN N
of IN N
the DT N
aortic JJ N
cross-clamp NN N
, , N
( ( N
b NN N
) ) N
whenever WRB N
the DT N
patient NN N
became VBD N
CPB NNP N
dependent NN N
, , N
( ( N
c NN N
) ) N
if IN N
the DT N
patient NN N
exhibited VBD N
low JJ N
cardiac NN N
output NN N
after IN N
discontinuing VBG N
CPB NNP N
and CC N
( ( N
d NN N
) ) N
as IN N
pretreatment NN N
before IN N
initiating VBG N
CPB NNP N
. . N

All NNP N
therapeutic JJ N
modalities NNS N
were VBD N
followed VBN N
by IN N
a DT N
continuous JJ N
T3 NNP N
infusion NN N
. . N

Following VBG N
T3 NNP N
therapy NN N
, , N
CPB NNP N
was VBD N
discontinued VBN N
in IN N
all DT N
patients NNS N
. . N

Based VBN N
upon IN N
discriminant JJ N
analysis NN N
, , N
a DT N
total NN N
of IN N
26 CD N
deaths NNS N
were VBD N
expected VBN N
from IN N
the DT N
entire JJ N
group NN N
, , N
but CC N
only RB N
7 CD N
patients NNS N
died VBD N
, , N
therefore RB N
, , N
the DT N
observed JJ N
mortality NN N
was VBD N
reduced VBN N
by IN N
72 CD N
% NN N
( ( N
p JJ N
< NNP N
0.007 CD N
) ) N
. . N

The DT N
use NN N
of IN N
T3 NNP N
had VBD N
a DT N
major JJ N
impact NN N
on IN N
reducing VBG N
surgical JJ N
mortality NN N
, , N
and CC N
may MD N
be VB N
advocated VBN N
as IN N
a DT N
new JJ N
therapeutic JJ N
modality NN N
in IN N
patients NNS N
with IN N
high JJ N
estimated VBN N
mortality NN N
undergoing VBG N
open JJ 4_p
heart NN 4_p
surgery NN 4_p
. . N

-DOCSTART- -X- O O 17926617

[ JJ N
Effects NNS N
of IN N
electroacupuncture NN N
combined VBN N
with IN N
behavior JJ N
therapy NN N
on IN N
intelligence NN N
and CC N
behavior NN N
of IN N
children NNS N
of IN N
autism NN 4_p
] NNP N
. . N

OBJECTIVE NNP N
To TO N
find VB N
out RP N
an DT N
effective JJ N
therapy NN N
for IN N
autism NN N
. . N

METHODS NNP N
Sixty NNP N
children NNS N
of IN N
autism NN 4_p
were VBD N
randomly RB N
divided VBN N
into IN N
an DT N
electroacupuncture NN N
( ( N
EA NNP N
) ) N
plus CC N
behavior JJ N
therapy NN N
group NN N
and CC N
a DT N
behavior JJ N
therapy NN N
group NN N
, , N
30 CD N
cases NNS N
in IN N
each DT N
group NN N
. . N

The DT N
patients NNS N
in IN N
the DT N
two CD N
groups NNS N
were VBD N
treated VBN N
with IN N
routine JJ N
behavior NN N
, , N
with IN N
EA NNP N
at IN N
Baihui NNP N
( ( N
GV NNP N
20 CD N
) ) N
, , N
Sishencong NNP N
( ( N
EX-HN NNP N
1 CD N
) ) N
, , N
Shenting NNP N
( ( N
GV NNP N
24 CD N
) ) N
, , N
Benshen NNP N
( ( N
GB NNP N
13 CD N
) ) N
, , N
Yintang NNP N
( ( N
EX-HN NNP N
3 CD N
) ) N
, , N
Naohu NNP N
( ( N
GV NNP N
17 CD N
) ) N
, , N
Naokong NNP N
( ( N
GB NNP N
19 CD N
) ) N
, , N
Neiguan NNP N
( ( N
PC NNP N
6 CD N
) ) N
and CC N
scalp JJ N
acupuncture NN N
at IN N
Speech NNP N
Areas NNP N
I PRP N
, , N
II NNP N
, , N
III NNP N
added VBD N
for IN N
the DT N
EA NNP N
plus CC N
behavior JJ N
therapy NN N
group NN N
. . N

Their PRP$ N
therapeutic JJ N
effects NNS N
were VBD N
observed VBN N
, , N
and CC N
the DT N
picture NN N
and CC N
vocabulary JJ N
scale NN N
( ( N
PPVT NNP N
) ) N
and CC N
behavior JJ N
ability NN N
were VBD N
detected VBN N
. . N

RESULTS VB N
The DT N
total JJ N
effective JJ N
rate NN N
was VBD N
86.7 CD N
% NN N
in IN N
the DT N
EA NNP N
plus CC N
behavior JJ N
therapy NN N
group NN N
which WDT N
was VBD N
better JJR N
than IN N
56.7 CD N
% NN N
of IN N
the DT N
behavior JJ N
therapy NN N
group NN N
, , N
and CC N
had VBD N
significant JJ N
enhancement NN N
in IN N
sensation NN N
, , N
association NN N
, , N
body NN N
, , N
and CC N
ability NN N
of IN N
self-care NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
and CC N
was VBD N
better JJR N
than IN N
the DT N
behavior JJ N
therapy NN N
group NN N
in IN N
sensation NN N
, , N
body NN N
and CC N
self-care JJ N
factors NNS N
, , N
with IN N
no DT N
significantly RB N
improvement NN N
in IN N
the DT N
scores NNS N
of IN N
PPVT NNP N
in IN N
the DT N
two CD N
groups NNS N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

CONCLUSION NNP N
EA NNP N
combined VBD N
with IN N
behavior JJ N
therapy NN N
can MD N
significantly RB N
improve VB N
clinical JJ N
symptoms NNS N
of IN N
autism NN N
, , N
but CC N
does VBZ N
not RB N
improve VB N
intelligence NN N
. . N

-DOCSTART- -X- O O 12005275

Rizatriptan NNP N
5 CD N
mg NN N
for IN N
the DT N
acute JJ N
treatment NN N
of IN N
migraine NN 4_p
in IN N
adolescents NNS N
: : N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
. . N

OBJECTIVE NNP N
To TO N
investigate VB N
the DT N
tolerability NN N
and CC N
efficacy NN N
of IN N
rizatriptan JJ N
5 CD N
mg NN N
in IN N
adolescent JJ N
migraineurs NNS N
. . N

METHODS NNP N
Randomized NNP N
, , N
double-blind NN N
, , N
placebo-controlled JJ N
study NN N
. . N

Patients NNS N
aged VBD N
12 CD N
to TO N
17 CD N
years NNS N
received VBD N
rizatriptan JJ N
5 CD N
mg NN N
( ( N
n JJ N
= NNP N
149 CD N
) ) N
or CC N
placebo NN N
( ( N
n JJ N
= NNP N
147 CD N
) ) N
for IN N
a DT N
moderate JJ N
or CC N
severe JJ N
headache NN N
and CC N
for IN N
up RB N
to TO N
two CD N
recurrences NNS N
. . N

Headache NNP N
severity NN N
, , N
presence NN N
or CC N
absence NN N
of IN N
associated VBN N
symptoms NNS N
, , N
and CC N
functional JJ N
disability NN N
were VBD N
assessed VBN N
over IN N
a DT N
4-hour JJ N
postdose JJ N
period NN N
, , N
and CC N
any DT N
adverse JJ N
events NNS N
were VBD N
recorded VBN N
. . N

The DT N
primary JJ N
efficacy NN N
measure NN N
was VBD N
pain-free JJ N
status NN N
at IN N
2 CD N
hours NNS N
postdose RB N
. . N

RESULTS NNP N
Rizatriptan NNP N
5 CD N
mg NN N
was VBD N
well RB N
tolerated VBN N
. . N

The DT N
most RBS N
commonly RB N
reported VBD N
adverse JJ N
events NNS N
( ( N
all DT N
with IN N
incidence NN N
of IN N
5 CD N
% NN N
or CC N
less JJR N
) ) N
among IN N
patients NNS N
receiving VBG N
rizatriptan NNS N
were VBD N
dry JJ N
mouth NN N
, , N
dizziness NN N
, , N
asthenia/fatigue NN N
, , N
nausea NN N
, , N
and CC N
somnolence NN N
. . N

The DT N
percentage NN N
of IN N
patients NNS N
pain-free JJ N
at IN N
2 CD N
hours NNS N
was VBD N
32 CD N
% NN N
for IN N
rizatriptan JJ N
5 CD N
mg NN N
versus NN N
28 CD N
% NN N
for IN N
placebo NN N
( ( N
P=.474 NNP N
) ) N
. . N

The DT N
percentage NN N
of IN N
patients NNS N
with IN N
pain NN N
relief NN N
( ( N
reduction NN N
of IN N
predose JJ N
pain NN N
intensity NN N
to TO N
mild VB N
or CC N
none NN N
) ) N
at IN N
2 CD N
hours NNS N
was VBD N
66 CD N
% NN N
for IN N
rizatriptan JJ N
versus NN N
56 CD N
% NN N
for IN N
placebo NN N
( ( N
P=.079 NNP N
) ) N
. . N

Placebo NNP N
response NN N
rates NNS N
were VBD N
higher JJR N
than IN N
those DT N
typically RB N
observed VBN N
in IN N
previous JJ N
studies NNS N
of IN N
rizatriptan NN N
in IN N
adults NNS N
. . N

Compared VBN N
with IN N
placebo NN N
, , N
rizatriptan VBP N
significantly RB N
improved VBN N
functional JJ N
disability NN N
at IN N
1.5 CD N
and CC N
2 CD N
hours NNS N
, , N
and CC N
nausea NN N
at IN N
1 CD N
and CC N
1.5 CD N
hours NNS N
. . N

Post NNP N
hoc NN N
analysis NN N
showed VBD N
a DT N
significant JJ N
benefit NN N
of IN N
rizatriptan JJ N
versus NN N
placebo NN N
in IN N
the DT N
percentage NN N
of IN N
patients NNS N
who WP N
had VBD N
pain NN N
relief NN N
when WRB N
their PRP$ N
migraine NN N
attacks NNS N
were VBD N
treated VBN N
on IN N
weekends NNS N
( ( N
65 CD N
% NN N
versus IN N
36 CD N
% NN N
, , N
P=.046 NNP N
) ) N
compared VBN N
with IN N
weekdays NNS N
( ( N
66 CD N
% NN N
versus IN N
61 CD N
% NN N
, , N
P=.365 NNP N
) ) N
, , N
and CC N
the DT N
weekend NN N
placebo NN N
response NN N
rate NN N
was VBD N
similar JJ N
to TO N
that DT N
seen VBN N
in IN N
adults NNS N
. . N

CONCLUSIONS NNP N
Rizatriptan NNP N
5 CD N
mg NN N
was VBD N
well RB N
tolerated VBN N
and CC N
effective JJ N
on IN N
some DT N
measures NNS N
when WRB N
used VBN N
in IN N
adolescents NNS N
for IN N
the DT N
treatment NN N
of IN N
a DT N
migraine JJ N
attack NN 4_p
. . N

-DOCSTART- -X- O O 10685169

Effect NN N
of IN N
topical JJ N
rh-TGF-beta JJ N
1 CD N
on IN N
second JJ 4_p
intention NN 4_p
wound IN 4_p
healing VBG 4_p
in IN N
horses NNS N
. . N

OBJECTIVE NNP N
To TO N
investigate VB N
the DT N
effects NNS N
on IN N
wound IN N
healing NN N
of IN N
transforming VBG N
growth NN N
factor-beta JJ N
1 CD N
as IN N
a DT N
topical JJ N
treatment NN N
to TO N
full-thickness NN N
, , N
excisional JJ N
wounds NNS N
of IN N
the DT N
distal JJ N
limb NN N
of IN N
horses NNS N
. . N

DESIGN VB N
A DT N
randomised JJ N
block NN N
study NN N
using VBG N
four CD N
horses NNS N
, , N
each DT N
with IN N
wounds NNS N
assigned VBN N
to TO N
four CD N
treatment NN N
groups NNS N
. . N

ANIMALS NNP N
Four CD N
adult NN N
Standardbred NNP N
geldings NNS N
. . N

PROCEDURE NNP N
Four NNP N
, , N
4 CD N
cm2 NN N
, , N
full-thickness JJ N
wounds NNS N
were VBD N
created VBN N
on IN N
the DT N
dorsomedial JJ N
and CC N
dorsolateral JJ N
aspect NN N
of IN N
the DT N
metacarpus NN N
or CC N
metatarsus NN N
of IN N
each DT N
limb NN N
of IN N
four CD N
horses NNS N
, , N
giving VBG N
a DT N
total NN N
of IN N
64 CD N
wounds NNS N
. . N

For IN N
each DT N
limb NN N
, , N
wounds NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
four CD N
treatment NN N
groups NNS N
: : N
no DT N
treatment NN N
( ( N
control NN N
) ) N
, , N
carrier NN N
( ( N
Methyl NNP N
Cellulose NNP N
gel NN N
) ) N
, , N
50 CD N
ng/wound IN N
rhTGF-beta JJ N
1 CD N
in IN N
carrier NN N
, , N
and CC N
500 CD N
ng/wound JJ N
rhTGF-beta JJ N
1 CD N
in IN N
carrier NN N
. . N

Wounds NNS N
were VBD N
treated VBN N
on IN N
day NN N
0 CD N
and CC N
day NN N
8 CD N
. . N

Effects NNS N
of IN N
treatment NN N
were VBD N
evaluated VBN N
on IN N
the DT N
basis NN N
of IN N
the DT N
presence NN N
of IN N
exuberant JJ N
granulation NN N
tissue NN N
requiring VBG N
excision NN N
, , N
number NN N
of IN N
times NNS N
excision NN N
was VBD N
required VBN N
, , N
total JJ N
wound JJ N
area NN N
, , N
area NN N
of IN N
epithelialisation NN N
, , N
area NN N
of IN N
granulation NN N
, , N
and CC N
histological JJ N
evaluation NN N
of IN N
biopsy NN N
samples NNS N
of IN N
wounds NNS N
on IN N
day NN N
8 CD N
and CC N
excised VBD N
wounds NNS N
on IN N
day NN N
21 CD N
. . N

RESULTS NNP N
Topical JJ N
application NN N
of IN N
TGF-beta NNP N
1 CD N
at IN N
the DT N
two CD N
concentrations NNS N
studied VBN N
had VBD N
no DT N
significant JJ N
effect NN N
on IN N
the DT N
total JJ N
area NN N
of IN N
wounds NNS N
( ( N
P NNP N
= NNP N
0.7 CD N
) ) N
, , N
the DT N
area NN N
of IN N
granulation NN N
tissue NN N
( ( N
P NNP N
= NNP N
0.78 CD N
) ) N
, , N
the DT N
area NN N
of IN N
epithelialisation NN N
( ( N
P NNP N
= NNP N
0.92 CD N
) ) N
, , N
histological JJ N
assessment NN N
or CC N
subjective JJ N
clinical JJ N
assessment NN N
of IN N
wounds NNS N
. . N

CONCLUSION NNP N
TGF-beta NNP N
1 CD N
had VBD N
no DT N
beneficial JJ N
effects NNS N
on IN N
wound NN N
healing NN N
. . N

Additional JJ N
trials NNS N
are VBP N
needed VBN N
to TO N
test VB N
if IN N
it PRP N
has VBZ N
value NN N
for IN N
wound NN N
treatment NN N
in IN N
horses NNS N
. . N

-DOCSTART- -X- O O 10550137

Granulocyte-macrophage JJ N
colony-stimulating JJ N
factor NN N
treatment NN N
before IN N
doxorubicin NN N
and CC N
cyclophosphamide NN N
chemotherapy NN N
priming VBG N
in IN N
women NNS 4_p
with IN 4_p
early-stage JJ 4_p
breast NN 4_p
cancer NN 4_p
. . 4_p

PURPOSE NNP N
To TO N
determine VB N
if IN N
inhibition NN N
of IN N
stem-cell JJ N
activity NN N
induced VBN N
by IN N
granulocyte-macrophage JJ N
colony-stimulating JJ N
factor NN N
( ( N
[ JJ N
GM-CSF NNP N
] NNP N
; : N
Sargramostim NNP N
; : N
Immunex NNP N
Corporation NNP N
, , N
Seattle NNP N
, , N
WA NNP N
) ) N
withdrawal NN N
or CC N
priming VBG N
protects NNS N
hematopoietic JJ N
stem NN N
cells NNS N
from IN N
the DT N
cytotoxic JJ N
effects NNS N
of IN N
adjuvant JJ N
chemotherapy NN N
for IN N
early-stage JJ 4_p
breast NN 4_p
cancer NN 4_p
. . 4_p

PATIENTS NNP N
AND CC N
METHODS NNP N
Serial NNP N
blood NN N
counts NNS N
were VBD N
performed VBN N
in IN N
20 CD N
women NNS N
with IN N
early-stage JJ N
breast NN N
cancer NN N
receiving VBG N
four CD N
courses NNS N
of IN N
cyclophosphamide NN N
and CC N
doxorubicin NN N
chemotherapy NN N
. . N

By IN N
a DT N
double-blind JJ N
, , N
placebo-controlled JJ N
, , N
balanced JJ N
randomization NN N
, , N
subjects VBZ N
received VBN N
GM-CSF NNP N
priming VBG N
on IN N
days NNS N
5 CD N
to TO N
1 CD N
for IN N
courses NNS N
1 CD N
and CC N
3 CD N
or CC N
courses NNS N
2 CD N
and CC N
4 CD N
. . N

RESULTS VB N
Compared NNP N
with IN N
before RB N
priming VBG N
, , N
after IN N
priming VBG N
the DT N
times NNS N
to TO N
neutrophil VB N
nadir NN N
( ( N
12.8 CD N
+/- JJ N
2.5 CD N
days NNS N
v RB N
14.8 CD N
+/- JJ N
1.5 CD N
days NNS N
, , N
respectively RB N
; : N
P NNP N
=.0001 NNP N
) ) N
and CC N
platelet NN N
nadir NN N
( ( N
mean JJ N
+/- JJ N
SD NNP N
, , N
10.1 CD N
+/- JJ N
1.9 CD N
days NNS N
v RB N
11.1 CD N
+/- JJ N
2.2 CD N
days NNS N
, , N
P NNP N
< NNP N
.05 NNP N
) ) N
were VBD N
shorter JJR N
, , N
indicating VBG N
a DT N
shift NN N
of IN N
cytotoxicity NN N
to TO N
later RB N
progenitors NNS N
. . N

The DT N
neutrophil JJ N
nadir NN N
was VBD N
similar JJ N
with IN N
and CC N
without IN N
priming VBG N
( ( N
mean JJ N
+/- JJ N
SD NNP N
, , N
490 CD N
+/- JJ N
310/microL CD N
v JJ N
550 CD N
+/- JJ N
350/microL CD N
, , N
respectively RB N
; : N
P NNP N
=.2 NNP N
) ) N
; : N
however RB N
, , N
on IN N
day NN N
16 CD N
the DT N
mean NN N
neutrophil NN N
count NN N
was VBD N
higher JJR N
( ( N
mean JJ N
+/- JJ N
SD NNP N
, , N
1030 CD N
+/- JJ N
580/microL CD N
v JJ N
690 CD N
+/- JJ N
370/microL CD N
, , N
P NNP N
=.004 NNP N
) ) N
, , N
and CC N
the DT N
proportion NN N
of IN N
patients NNS N
with IN N
a DT N
neutrophil JJ N
count NN N
less JJR N
than IN N
500/microL CD N
was VBD N
lower JJR N
after IN N
priming VBG N
than IN N
before IN N
( ( N
six CD N
of IN N
35 CD N
or CC N
17 CD N
. . N

1 CD N
% NN N
v JJ N
12 CD N
of IN N
34 CD N
or CC N
35.3 CD N
% NN N
, , N
respectively RB N
; : N
P NNP N
=.04 NNP N
) ) N
. . N

The DT N
platelet NN N
nadir NN N
was VBD N
higher JJR N
( ( N
mean JJ N
+/- JJ N
SD NNP N
, , N
166,000 CD N
+/- JJ N
51,000/microL CD N
after IN N
priming VBG N
v JJ N
151,000 CD N
+/- JJ N
45,000/microL CD N
before IN N
priming NN N
, , N
P NNP N
=.007 NNP N
) ) N
, , N
and CC N
the DT N
duration NN N
of IN N
thrombocytopenia NN N
, , N
ie NN N
, , N
a DT N
platelet NN N
count NN N
less JJR N
than IN N
150,000/microL CD N
, , N
was VBD N
shorter JJR N
( ( N
1.5 CD N
+/- JJ N
2.1 CD N
days NNS N
v RB N
2.8 CD N
+/- JJ N
2.9 CD N
days NNS N
, , N
P NNP N
=.0025 NNP N
) ) N
after IN N
priming VBG N
. . N

Episodes NNS N
of IN N
fever NN N
and CC N
neutropenia NN N
were VBD N
not RB N
observed VBN N
. . N

CONCLUSIONS NNP N
GM-CSF NNP N
priming VBG N
from IN N
days NNS N
5 CD N
to TO N
1 CD N
before IN N
doxorubicin NN N
and CC N
cyclophosphamide NN N
chemotherapy NN N
was VBD N
associated VBN N
with IN N
an DT N
earlier JJR N
neutrophil NN N
and CC N
platelet NN N
nadir NN N
. . N

On IN N
day NN N
16 CD N
, , N
a DT N
higher JJR N
mean JJ N
neutrophil NN N
count NN N
and CC N
a DT N
lower JJR N
proportion NN N
of IN N
patients NNS N
with IN N
severe JJ N
( ( N
< JJ N
500/microL CD N
) ) N
neutropenia NN N
were VBD N
observed VBN N
. . N

Beneficial JJ N
effects NNS N
on IN N
the DT N
severity NN N
and CC N
duration NN N
of IN N
thrombocytopenia NN N
were VBD N
also RB N
noted VBN N
. . N

These DT N
observations NNS N
support VBP N
the DT N
hypothesis NN N
that IN N
GM-CSF NNP N
priming VBG N
protects NNS N
hematopoietic JJ N
progenitors NNS N
from IN N
the DT N
cytotoxic JJ N
effects NNS N
of IN N
chemotherapy NN N
. . N

-DOCSTART- -X- O O 18618513

Randomized VBN N
trial NN N
of IN N
a DT N
decision NN N
aid NN N
for IN N
individuals NNS N
considering VBG N
genetic JJ N
testing NN N
for IN N
hereditary JJ N
nonpolyposis NN N
colorectal NN N
cancer NN N
risk NN N
. . N

BACKGROUND NNP N
Despite IN N
the DT N
potential JJ N
benefits NNS N
of IN N
genetic JJ N
testing VBG N
for IN N
hereditary JJ N
nonpolyposis NN N
colorectal NN N
cancer NN N
( ( N
HNPCC NNP N
) ) N
risk NN N
, , N
individuals NNS N
can MD N
find VB N
the DT N
genetic JJ N
testing VBG N
decision-making JJ N
process NN N
complicated VBN N
and CC N
challenging VBG N
. . N

The DT N
goal NN N
of IN N
the DT N
current JJ N
study NN N
was VBD N
to TO N
measure VB N
the DT N
effectiveness NN N
of IN N
a DT N
tailored JJ N
decision NN N
aid NN N
designed VBN N
specifically RB N
to TO N
assist VB N
individuals NNS N
to TO N
make VB N
informed JJ N
decisions NNS N
regarding VBG N
genetic JJ N
testing NN N
for IN N
HNPCC NNP N
risk NN N
. . N

METHODS NNP N
In IN N
all DT N
, , N
153 CD N
individuals NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
the DT N
decision NN N
aid NN N
or CC N
a DT N
control JJ N
pamphlet NN N
at IN N
the DT N
end NN N
of IN N
their PRP$ N
first JJ N
genetic JJ N
counseling NN N
consultation NN N
. . N

Of IN N
these DT N
, , N
109 CD N
( ( N
71.2 CD N
% NN N
) ) N
completed VBD N
the DT N
first JJ N
questionnaire NN N
1 CD N
week NN N
after IN N
consultation NN N
, , N
whereas IN N
95 CD N
( ( N
62.1 CD N
% NN N
) ) N
completed VBD N
the DT N
6-month JJ N
follow-up JJ N
questionnaire NN N
. . N

RESULTS CC N
Although IN N
the DT N
decision NN N
aid NN N
had VBD N
no DT N
significant JJ N
effect NN N
on IN N
postdecisional JJ N
regret NN N
or CC N
actual JJ N
genetic JJ N
testing VBG N
decision NN N
, , N
the DT N
trial NN N
results NNS N
demonstrated VBD N
that IN N
participants NNS N
who WP N
received VBD N
the DT N
decision NN N
aid NN N
had VBD N
significantly RB N
lower JJR N
levels NNS N
of IN N
decisional JJ N
conflict NN N
( ( N
ie JJ N
, , N
uncertainty NN N
) ) N
regarding VBG N
genetic JJ N
testing NN N
( ( N
chi-square JJ N
( ( N
1 CD N
) ) N
= NN N
8.97 CD N
; : N
P NNP N
= NNP N
.003 NNP N
) ) N
and CC N
were VBD N
more RBR N
likely JJ N
to TO N
be VB N
classified VBN N
as IN N
having VBG N
made VBN N
an DT N
informed JJ N
choice NN N
concerning VBG N
genetic JJ N
testing NN N
( ( N
chi-square JJ N
( ( N
1 CD N
) ) N
= NN N
4.37 CD N
; : N
P NNP N
= NNP N
.037 NNP N
) ) N
than IN N
participants NNS N
who WP N
received VBD N
a DT N
control NN N
pamphlet NN N
. . N

Also RB N
, , N
men NNS N
who WP N
received VBD N
the DT N
decision NN N
aid NN N
had VBD N
significantly RB N
higher JJR N
knowledge NN N
levels NNS N
regarding VBG N
genetic JJ N
testing NN N
compared VBN N
with IN N
men NNS N
who WP N
received VBD N
the DT N
control NN N
pamphlet NN N
, , N
whereas JJ N
no DT N
such JJ N
differences NNS N
were VBD N
found VBN N
for IN N
women NNS N
( ( N
chi-square NN N
( ( N
2 CD N
) ) N
= NN N
6.76 CD N
; : N
P NNP N
= NNP N
.034 NNP N
) ) N
. . N

CONCLUSIONS VB N
A DT N
decision NN N
aid NN N
for IN N
individuals NNS N
considering VBG N
genetic JJ N
testing NN N
for IN N
HNPCC NNP N
is VBZ N
an DT N
effective JJ N
intervention NN N
to TO N
reduce VB N
uncertainty NN N
and CC N
assist JJ N
individuals NNS N
to TO N
make VB N
an DT N
informed JJ N
choice NN N
regarding VBG N
genetic JJ N
testing NN N
for IN N
HNPCC NNP N
after IN N
genetic JJ N
counseling NN N
. . N

-DOCSTART- -X- O O 1548248

A DT N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
of IN N
the DT N
efficacy NN N
of IN N
transdermal JJ N
clonidine NN N
in IN N
autism NN 4_p
. . N

BACKGROUND NNP N
Autistic JJ 4_p
individuals NNS N
often RB N
exhibit VBP N
hyperarousal JJ 4_p
behaviors NNS 4_p
( ( N
e.g. NN N
, , N
stereotyped VBD N
body NN N
movements NNS N
, , N
self-stimulation NN N
, , N
hypervigilance NN N
, , N
and CC N
hyperactivity NN N
) ) N
. . N

Clonidine NNP N
, , N
an DT N
alpha JJ N
2-adrenergic JJ N
receptor NN N
agonist NN N
, , N
has VBZ N
been VBN N
shown VBN N
to TO N
be VB N
effective JJ N
in IN N
reducing VBG N
impulsivity NN N
, , N
inattention NN N
, , N
and CC N
hyperactivity NN N
associated VBN N
with IN N
attention NN N
deficit NN N
disorder NN N
with IN N
hyperactivity NN N
. . N

This DT N
study NN N
investigated VBD N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
transdermal JJ N
clonidine NN N
in IN N
reducing VBG N
hyperarousal JJ 4_p
behaviors NNS N
associated VBN N
with IN N
autism NN 4_p
. . N

METHOD VB N
A DT N
double-blind JJ N
, , N
placebo-crossover JJ N
study NN N
with IN N
transdermal JJ N
clonidine NN N
was VBD N
performed VBN N
in IN N
nine CD N
autistic JJ 4_p
males NNS N
( ( N
aged VBN N
5 CD N
to TO N
33 CD N
years NNS N
) ) N
. . N

Subjects VBZ N
received VBN N
either DT N
clonidine NN N
( ( N
approximately RB N
0.005 CD N
mg/kg/day NN N
) ) N
or CC N
placebo VBN N
by IN N
a DT N
weekly JJ N
transdermal NN N
patch NN N
. . N

Each DT N
trial NN N
lasted VBD N
4 CD N
weeks NNS N
with IN N
a DT N
2-week JJ N
washout NN N
period NN N
between IN N
treatment NN N
phases NNS N
. . N

Subjects NNS N
were VBD N
evaluated VBN N
every DT N
2 CD N
weeks NNS N
by IN N
clinician JJ N
raters NNS N
and CC N
weekly JJ N
by IN N
parents NNS N
. . N

RESULTS VB N
The DT N
clonidine NN N
treatment NN N
showed VBD N
a DT N
significant JJ N
difference NN N
from IN N
placebo NN N
treatment NN N
on IN N
three CD N
subscales NNS N
of IN N
the DT N
Ritvo-Freeman NNP N
Real NNP N
Life NNP N
Rating NNP N
Scale NNP N
( ( N
i.e. FW N
, , N
social JJ N
relationship NN N
to TO N
people NNS N
, , N
affectual JJ N
responses NNS N
, , N
and CC N
sensory JJ N
responses NNS N
) ) N
. . N

The DT N
Clinical JJ N
Global NNP N
Impressions NNP N
scale NN N
indicated VBD N
that IN N
clonidine NN N
produced VBD N
a DT N
significant JJ N
improvement NN N
on IN N
severity NN N
of IN N
illness NN N
, , N
global JJ N
improvement NN N
, , N
and CC N
efficacy NN N
index NN N
for IN N
therapeutic JJ N
effect NN N
of IN N
the DT N
drug NN N
. . N

A DT N
patient JJ N
global JJ N
rating NN N
scale NN N
showed VBD N
clonidine JJ N
treatment NN N
resulted VBD N
in IN N
significant JJ N
improvement NN N
in IN N
comparison NN N
with IN N
placebo NN N
. . N

Adverse JJ N
effects NNS N
included VBN N
sedation NN N
and CC N
fatigue NN N
during IN N
the DT N
first JJ N
2 CD N
weeks NNS N
of IN N
clonidine NN N
treatment NN N
. . N

CONCLUSION NNP N
Results NNP N
from IN N
this DT N
preliminary JJ N
study NN N
show NN N
that IN N
clonidine NN N
was VBD N
effective JJ N
in IN N
reducing VBG N
several JJ N
hyperarousal NN N
behaviors NNS N
and CC N
improved VBN N
social JJ N
relationships NNS N
in IN N
some DT N
autistic JJ 4_p
subjects NNS N
. . N

Further JJ N
studies NNS N
are VBP N
needed VBN N
in IN N
a DT N
larger JJR N
autistic JJ 4_p
population NN N
to TO N
determine VB N
the DT N
dose-response JJ N
relationship NN N
of IN N
clonidine NN N
. . N

-DOCSTART- -X- O O 22136317

Outcomes NNS N
of IN N
Japanese JJ N
breast NN 4_p
cancer NN 4_p
patients NNS 4_p
treated VBN N
with IN N
pre-operative JJ N
and CC N
post-operative JJ N
anastrozole NN N
or CC N
tamoxifen NN N
. . N

The DT N
present JJ N
study NN N
examined VBD N
long-term JJ N
efficacy NN N
outcomes NNS N
in IN N
a DT N
subgroup NN N
of IN N
postmenopausal NN N
, , N
estrogen VBP N
receptor-positive JJ N
Japanese JJ N
breast NN 4_p
cancer NN 4_p
patients NNS 4_p
from IN N
the DT N
Pre-Operative JJ N
" NNP N
Arimidex NNP N
" NNP N
Compared NNP N
with IN N
Tamoxifen NNP N
trial NN N
, , N
following VBG N
pre-operative JJ N
( ( N
3 CD N
months NNS N
) ) N
and CC N
post-operative JJ N
( ( N
5 CD N
years NNS N
) ) N
adjuvant VBP N
treatment NN N
with IN N
either DT N
anastrozole NN N
or CC N
tamoxifen NN N
. . N

Patients NNS N
with IN N
large JJ N
, , N
potentially RB N
operable JJ N
, , N
locally-advanced JJ N
breast NN N
cancer NN N
were VBD N
randomized VBN N
to TO N
receive VB N
anastrozole NN N
( ( N
1 CD N
mg/day NN N
) ) N
plus CC N
tamoxifen JJ N
placebo NN N
or CC N
tamoxifen NN N
( ( N
20 CD N
mg/day NN N
) ) N
plus CC N
anastrozole JJ N
placebo NN N
pre-operatively RB N
. . N

After IN N
surgery NN N
at IN N
3 CD N
months NNS N
, , N
patients NNS N
continued VBD N
on IN N
the DT N
same JJ N
study NN N
medication NN N
as IN N
adjuvant JJ N
therapy NN N
for IN N
up IN N
to TO N
5 CD N
years NNS N
or CC N
until IN N
recurrence NN N
, , N
intolerable JJ N
toxicity NN N
or CC N
withdrawal NN N
of IN N
patient JJ N
consent NN N
. . N

Recurrence-free JJ N
survival NN N
and CC N
overall JJ N
survival NN N
were VBD N
measured VBN N
from IN N
the DT N
date NN N
of IN N
randomization NN N
to TO N
the DT N
date NN N
of IN N
recurrence NN N
or CC N
death NN N
, , N
whichever WDT N
occurred VBD N
first RB N
. . N

Patients NNS N
were VBD N
monitored VBN N
for IN N
adverse JJ N
events NNS N
throughout IN N
the DT N
study NN N
period NN N
and CC N
up RB N
to TO N
30 CD N
days NNS N
following VBG N
administration NN N
of IN N
the DT N
last JJ N
study NN N
medication NN N
. . N

During IN N
post-operative JJ N
adjuvant JJ N
therapy NN N
, , N
4/48 CD N
( ( N
8 CD N
% NN N
) ) N
anastrozole NN N
and CC N
25/49 CD N
( ( N
51 CD N
% NN N
) ) N
tamoxifen NN N
patients NNS N
experienced VBD N
recurrence NN N
. . N

There EX N
was VBD N
a DT N
significant JJ N
difference NN N
in IN N
recurrence-free JJ N
survival NN N
between IN N
the DT N
two CD N
groups NNS N
( ( N
hazard JJ N
ratio NN N
0.14 CD N
; : N
95 CD N
% NN N
confidence NN N
interval JJ N
0.05-0.41 NN N
; : N
P NNP N
= NNP N
0.0003 CD N
) ) N
. . N

There EX N
was VBD N
a DT N
significant JJ N
increase NN N
in IN N
overall JJ N
survival NN N
with IN N
anastrozole NN N
( ( N
0.21 CD N
; : N
0.05-0.96 CD N
; : N
P NNP N
= NNP N
0.0436 CD N
) ) N
and CC N
there EX N
were VBD N
2/48 CD N
( ( N
4 CD N
% NN N
) ) N
and CC N
10/49 CD N
( ( N
20 CD N
% NN N
) ) N
deaths NNS N
with IN N
anastrozole JJ N
and CC N
tamoxifen NN N
, , N
respectively RB N
. . N

Most JJS N
patients NNS N
responding VBG N
to TO N
pre-operative JJ N
therapy NN N
remained VBD N
recurrence-free JJ N
. . N

Sequential JJ N
pre-operative/post-operative JJ N
treatment NN N
with IN N
anastrozole JJ N
resulted VBN N
in IN N
lower JJR N
recurrence NN N
and CC N
death NN N
rates NNS N
, , N
compared VBN N
with IN N
tamoxifen NN N
. . N

-DOCSTART- -X- O O 12201937

Effect NN N
of IN N
diuresis NN N
on IN N
extracorporeal NN N
shockwave VBP N
lithotripsy VBN N
treatment NN N
of IN N
ureteric JJ 4_p
calculi NN 4_p
. . 4_p

OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
effect NN N
of IN N
diuresis NN N
during IN N
extracorporeal JJ N
shockwave JJ N
lithotripsy NN N
( ( N
ESWL NNP N
) ) N
treatment NN N
of IN N
ureteric JJ N
calculi NN N
. . N

The DT N
purpose NN N
is VBZ N
to TO N
improve VB N
stone NN N
fragmentation NN N
and CC N
clearance NN N
rates NNS N
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
One NNP 4_p
hundred VBD 4_p
and CC 4_p
six CD 4_p
consecutive JJ 4_p
patients NNS 4_p
with IN 4_p
ureteric JJ 4_p
calculi NNS 4_p
at IN 4_p
different JJ 4_p
levels NNS 4_p
were VBD N
treated VBN N
by IN N
ESWL NNP N
using VBG N
Siemens NNP N
Lithostar NNP N
2 CD N
machine NN N
. . N

Patients NNS N
have VBP N
been VBN N
randomized VBN N
into IN N
two CD N
treatment NN N
groups NNS N
. . N

The DT N
first JJ N
group NN N
was VBD N
treated VBN N
by IN N
standard JJ N
ESWL NNP N
and CC N
included VBD N
54 CD N
patients NNS N
. . N

The DT N
second JJ N
group NN N
was VBD N
treated VBN N
by IN N
ESWL NNP N
with IN N
diuresis NN N
during IN N
the DT N
ESWL NNP N
session NN N
. . N

Shock NNP N
waves NNS N
were VBD N
given VBN N
at IN N
a DT N
rate NN N
of IN N
90 CD N
shocks/minute NN N
with IN N
energy NN N
starting VBG N
from IN N
10 CD N
up RB N
to TO N
18 CD N
KV NNP N
. . N

During IN N
the DT N
ESWL NNP N
session NN N
the DT N
patient NN N
belonging NN N
to TO N
the DT N
second JJ N
group NN N
received VBD N
i.v RB N
. . N

infusion NN N
of IN N
500 CD N
ml NNS N
normal JJ N
saline JJ N
containing VBG N
40 CD N
mg JJ N
furosemide RB N
as IN N
a DT N
diuretic JJ N
. . N

The DT N
stone NN N
fragmentation NN N
and CC N
clearance NN N
rates NNS N
were VBD N
the DT N
two CD N
end NN N
points NNS N
for IN N
evaluation NN N
. . N

RESULTS VB N
The DT N
average JJ N
number NN N
of IN N
sessions NNS N
per IN N
stone NN N
was VBD N
1.92 CD N
and CC N
1.5 CD N
and CC N
the DT N
average JJ N
number NN N
of IN N
shocks NNS N
per IN N
stone NN N
was VBD N
6295 CD N
and CC N
5300 CD N
for IN N
the DT N
first JJ N
and CC N
second JJ N
treatment NN N
groups NNS N
respectively RB N
. . N

Stone CD N
fragmentation NN N
rate NN N
was VBD N
47/54 CD N
( ( N
87 CD N
% NN N
) ) N
and CC N
50/52 CD N
( ( N
96.2 CD N
% NN N
) ) N
and CC N
the DT N
stone NN N
clearance NN N
( ( N
success NN N
) ) N
rate NN N
was VBD N
47/54 CD N
( ( N
87 CD N
% NN N
) ) N
and CC N
48/52 CD N
( ( N
92.3 CD N
% NN N
) ) N
for IN N
the DT N
first JJ N
and CC N
the DT N
second JJ N
groups NNS N
respectively RB N
. . N

Analysis NN N
of IN N
the DT N
results NNS N
in IN N
relation NN N
to TO N
stone VB N
location NN N
showed VBD N
that IN N
the DT N
two CD N
treatment NN N
groups NNS N
were VBD N
comparable JJ N
for IN N
upper JJ N
and CC N
middle JJ N
ureteric JJ N
calculi NN N
. . N

However RB N
for IN N
distal JJ N
ureteric JJ N
stones NNS N
, , N
the DT N
addition NN N
of IN N
diuresis NN N
during IN N
ESWL NNP N
was VBD N
associated VBN N
with IN N
a DT N
lower JJR N
mean JJ N
number NN N
of IN N
ESWL NNP N
sessions NNS N
and CC N
shocks NNS N
per IN N
stone NN N
compared VBN N
with IN N
standard JJ N
ESWL NNP N
: : N
1.38 CD N
and CC N
4950 CD N
for IN N
ESWL NNP N
with IN N
diuresis NN N
compared VBN N
with IN N
2.9 CD N
and CC N
8544 CD N
for IN N
standard JJ N
ESWL NNP N
respectively RB N
. . N

The DT N
stone NN N
fragmentation NN N
and CC N
3-month JJ N
clearance NN N
( ( N
success NN N
) ) N
rates NNS N
were VBD N
clearly RB N
higher JJR N
: : N
93.8 CD N
% NN N
and CC N
87.5 CD N
% NN N
respectively RB N
for IN N
ESWL NNP N
with IN N
diuresis NN N
compared VBN N
with IN N
70.6 CD N
% NN N
( ( N
for IN N
both DT N
fragmentation NN N
and CC N
clearance NN N
) ) N
with IN N
standard JJ N
ESWL NNP N
. . N

CONCLUSIONS NNP N
Diuresis NNP N
is VBZ N
a DT N
useful JJ N
, , N
inexpensive JJ N
and CC N
safe JJ N
adjunct NN N
to TO N
ESWL NNP N
of IN N
ureteric JJ N
stones NNS N
. . N

It PRP N
markedly RB N
improves VBZ N
the DT N
results NNS N
of IN N
ESWL NNP N
treatment NN N
of IN N
distal JJ N
ureteric JJ N
stones NNS N
compared VBN N
with IN N
standard JJ N
ESWL NNP N
. . N

-DOCSTART- -X- O O 8015776

Laser-aided JJ N
external JJ N
drainage NN N
of IN N
subretinal JJ 4_p
fluid NN 4_p
: : N
prospective JJ N
randomized VBN N
comparison NN N
with IN N
needle JJ N
drainage NN N
. . N

In IN N
a DT N
prospective JJ N
randomized VBN N
study NN N
of IN N
50 CD N
consecutive JJ N
eyes NNS N
, , N
we PRP N
compared VBN N
the DT N
safety NN N
and CC N
efficacy NN N
of IN N
draining VBG N
subretinal JJ N
fluid NN N
transchoroidally RB N
in IN N
primary JJ N
scleral JJ N
buckling NN N
for IN N
rhegmatogenous JJ N
retinal JJ N
detachment NN N
using VBG N
a DT N
needle JJ N
, , N
with IN N
the DT N
safety NN N
and CC N
efficacy NN N
of IN N
the DT N
same JJ N
procedure NN N
using VBG N
an DT N
angulated VBN N
endolaser NN N
probe NN N
set VBN N
at IN N
1 CD N
W NNP N
for IN N
0.2 CD N
seconds NNS N
, , N
using VBG N
an DT N
average NN N
of IN N
2.4 CD N
laser NN N
burns NNS N
. . N

There EX N
were VBD N
no DT N
significant JJ N
complications NNS N
associated VBN N
with IN N
the DT N
laser-aided JJ N
drainage NN N
procedures NNS N
( ( N
25 CD N
eyes NNS N
) ) N
. . N

In IN N
the DT N
transchoroidal NN N
needle JJ N
drainage NN N
procedures NNS N
( ( N
25 CD N
eyes NNS N
) ) N
, , N
subretinal JJ N
hemorrhage NN N
occurred VBD N
in IN N
three CD N
eyes NNS N
and CC N
retinal JJ N
incarceration NN N
in IN N
one CD N
. . N

Thus VB N
, , N
though IN N
our PRP$ N
numbers NNS N
are VBP N
small JJ N
, , N
there EX N
appears VBZ N
to TO N
be VB N
some DT N
advantage NN N
of IN N
laser-assisted JJ N
drainage NN N
in IN N
terms NNS N
of IN N
a DT N
lower JJR N
incidence NN N
of IN N
complications NNS N
. . N

-DOCSTART- -X- O O 16038713

Superior JJ N
efficacy NN N
of IN N
clopidogrel NN N
plus CC N
acetylsalicylic JJ N
acid NNS N
compared VBN N
with IN N
extended-release JJ N
dipyridamole JJ N
plus CC N
acetylsalicylic JJ N
acid NN N
in IN N
preventing VBG N
arterial JJ N
thrombogenesis NN N
in IN N
healthy JJ 4_p
volunteers NNS N
. . N

INTRODUCTION NNP N
Recent NNP N
ex NN N
vivo NN N
platelet NN N
aggregometry NN N
data NNS N
indicate VBP N
that IN N
clopidogrel NN N
75 CD N
mg/day JJ N
plus CC N
acetylsalicylic JJ N
acid NN N
( ( N
ASA NNP N
) ) N
75 CD N
mg/day NN N
is VBZ N
a DT N
more RBR N
potent JJ N
antiplatelet NN N
regimen NNS N
than IN N
the DT N
marketed JJ N
combination NN N
of IN N
dipyridamole+ASA NN N
. . N

The DT N
present JJ N
study NN N
was VBD N
designed VBN N
to TO N
assess VB N
the DT N
antithrombotic JJ N
effect NN N
of IN N
both DT N
dual JJ N
antiplatelet NN N
regimens NNS N
using VBG N
a DT N
human JJ N
ex NN N
vivo NN N
model NN N
of IN N
arterial JJ N
thrombosis NN N
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
This DT N
was VBD N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
, , N
crossover NN N
study NN N
. . N

During IN N
two CD N
10-day JJ N
treatment NN N
periods NNS N
separated VBN N
by IN N
a DT N
14-day JJ N
washout NN N
period NN N
, , N
23 CD N
healthy JJ 4_p
male NN N
volunteers NNS N
received VBD N
once-daily RB N
clopidogrel JJ N
75 CD N
mg NN N
plus CC N
acetylsalicylic JJ N
acid NN N
75 CD N
mg NN N
, , N
or CC N
twice-daily RB N
extended-release JJ N
dipyridamole NN N
200 CD N
mg NN N
plus CC N
acetylsalicylic JJ N
acid NN N
25 CD N
mg NN N
. . N

Assessments NNS N
were VBD N
made VBN N
at IN N
baseline NN N
and CC N
on IN N
Day NNP N
10 CD N
of IN N
each DT N
period NN N
. . N

Arterial JJ N
thrombus NN N
formation NN N
was VBD N
induced VBN N
ex JJ N
vivo NN N
by IN N
exposing VBG N
a DT N
collagen-coated JJ N
surface NN N
in IN N
a DT N
parallel-plate JJ N
perfusion NN N
chamber NN N
to TO N
native JJ N
blood NN N
for IN N
3 CD N
min NN N
( ( N
arterial JJ N
wall NN N
shear NN N
rate NN N
2600 CD N
s NN N
( ( N
-1 NNP N
) ) N
) ) N
. . N

Total JJ N
platelet NN N
and CC N
fibrin JJ N
deposition NN N
was VBD N
determined VBN N
by IN N
immunoenzymatic JJ N
methods NNS N
. . N

RESULTS NNP N
Compared VBD N
with IN N
baseline NN N
values NNS N
, , N
the DT N
mean JJ N
inhibition NN N
of IN N
total JJ N
platelet NN N
deposition NN N
was VBD N
63.9+/-5.9 JJ N
% NN N
with IN N
clopidogrel JJ N
plus CC N
acetylsalicylic JJ N
acid NN N
, , N
compared VBN N
with IN N
18.4+/-5.6 CD N
% NN N
for IN N
extended-release JJ N
dipyridamole JJ N
plus CC N
acetylsalicylic JJ N
acid NN N
( ( N
67 CD N
% NN N
reduction NN N
; : N
95 CD N
% NN N
CI NNP N
, , N
49-79 JJ N
% NN N
; : N
p CC N
< VB N
0.0001 CD N
) ) N
. . N

Corresponding VBG N
figures NNS N
for IN N
fibrin JJ N
deposition NN N
were VBD N
64.9+/-4.8 CD N
% NN N
and CC N
18.3+/-9.7 CD N
% NN N
, , N
respectively RB N
( ( N
58 CD N
% NN N
reduction NN N
; : N
95 CD N
% NN N
CI NNP N
, , N
45-67 JJ N
% NN N
; : N
p CC N
< VB N
0.0001 CD N
) ) N
. . N

Both DT N
treatments NNS N
were VBD N
well RB N
tolerated VBN N
. . N

CONCLUSIONS NNP N
Clopidogrel NNP N
plus CC N
acetylsalicylic JJ N
acid NN N
showed VBD N
significantly RB N
superior JJ N
antithrombotic JJ N
efficacy NN N
compared VBN N
with IN N
extended-release JJ N
dipyridamole JJ N
plus CC N
acetylsalicylic JJ N
acid NN N
in IN N
preventing VBG N
arterial JJ N
thrombogenesis NN N
in IN N
humans NNS N
. . N

-DOCSTART- -X- O O 12538218

A DT N
comparison NN N
of IN N
the DT N
upper JJ N
lip NN N
bite JJ N
test NN N
( ( N
a DT N
simple JJ N
new JJ N
technique NN N
) ) N
with IN N
modified VBN N
Mallampati NNP N
classification NN N
in IN N
predicting VBG N
difficulty NN N
in IN N
endotracheal JJ 4_p
intubation NN 4_p
: : N
a DT N
prospective JJ N
blinded VBN N
study NN N
. . N

We PRP N
explored VBD N
the DT N
possibility NN N
that IN N
a DT N
simple JJ N
and CC N
single JJ N
test NN N
could MD N
replace VB N
the DT N
modified JJ N
Mallampati NNP N
score NN N
for IN N
either CC N
a DT N
difficult JJ N
or CC N
an DT N
unaccomplished JJ N
tracheal NN N
intubation NN N
in IN N
an DT N
impending JJ N
hypoxic NN 4_p
patient NN N
. . N

Three CD N
hundred VBD N
adult NN N
patients NNS N
were VBD N
enrolled VBN N
in IN N
this DT N
study NN N
. . N

They PRP N
were VBD N
subjected VBN N
to TO N
the DT N
following JJ N
assessments NNS N
: : N
1 CD N
) ) N
oropharyngeal NN N
class NN N
according VBG N
to TO N
the DT N
modified VBN N
Mallampati NNP N
criteria NNS N
; : N
2 CD N
) ) N
the DT N
new JJ N
, , N
upper JJ N
lip NN N
bite IN N
criteria-class NN N
I PRP N
= VBP N
lower JJR N
incisors NNS N
can MD N
bite VB N
the DT N
upper JJ N
lip NN N
above IN N
the DT N
vermilion NN N
line NN N
, , N
class NN N
II NNP N
= NNP N
lower JJR N
incisors NNS N
can MD N
bite VB N
the DT N
upper JJ N
lip NN N
below IN N
the DT N
vermilion NN N
line NN N
, , N
and CC N
class NN N
III NNP N
= NNP N
lower JJR N
incisors NNS N
can MD N
not RB N
bite VB N
the DT N
upper JJ N
lip NN N
; : N
and CC N
3 CD N
) ) N
laryngeal NN N
view NN N
grading VBG N
according VBG N
to TO N
Cormack NNP N
's POS N
criteria NNS N
. . N

The DT N
incidence NN N
of IN N
difficult JJ N
intubation NN N
was VBD N
5.7 CD N
% NN N
. . N

The DT N
upper JJ N
lip NN N
bite NN N
test NN N
showed VBD N
significantly RB N
higher JJR N
specificity NN N
and CC N
accuracy NN N
than IN N
the DT N
modified JJ N
Mallampati NNP N
test NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Comparisons NNS N
of IN N
sensitivity NN N
, , N
positive JJ N
and CC N
negative JJ N
predictive NN N
values NNS N
, , N
between IN N
the DT N
two CD N
tests NNS N
, , N
however RB N
, , N
did VBD N
not RB N
reveal VB N
any DT N
significant JJ N
differences NNS N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

In IN N
conclusion NN N
, , N
the DT N
upper JJ N
lip NN N
bite JJ N
test NN N
is VBZ N
an DT N
acceptable JJ N
option NN N
for IN N
predicting VBG N
difficult JJ 4_p
intubation NN 4_p
as IN N
a DT N
simple NN N
, , N
single JJ N
test NN N
. . N

-DOCSTART- -X- O O 17505452

[ JJ N
Laparoscopic NNP N
lymphadenectomy NN N
as IN N
treatment NN N
of IN N
endometrial JJ 4_p
cancer NN 4_p
] NNP 4_p
. . N

AIM NNP N
This DT N
study NN N
compares VBZ N
the DT N
effects NNS N
of IN N
laparoscopic JJ N
lymphadenectomy JJ N
versus IN N
those DT N
of IN N
abdominal JJ N
lymphadenectomy NN N
in IN N
patients NNS 4_p
with IN 4_p
endometrial JJ 4_p
cancer NN 4_p
. . 4_p

METHODS NNP N
A NNP N
prospective JJ N
randomized NN N
study NN N
was VBD N
performed VBN N
among IN N
80 CD N
patients NNS N
randomly RB N
assigned VBN N
to TO N
laparoscopic VB 4_p
lymphadenectomy NN 4_p
and CC 4_p
to TO 4_p
abdominal JJ 4_p
lymphadenectomy NN 4_p
in IN 4_p
the DT 4_p
treatment NN 4_p
of IN 4_p
endometrial JJ 4_p
cancer NN 4_p
. . N

Clinical JJ N
outcomes NNS N
and CC N
complications NNS N
were VBD N
compared VBN N
for IN N
1 CD N
year NN N
of IN N
follow-up NN N
. . N

RESULTS NNP N
Forty NNP N
patients NNS N
were VBD N
assigned VBN N
to TO N
laparoscopic VB N
lymphadenectomy NN N
and CC N
40 CD N
patients NNS N
to TO N
abdominal JJ N
lymphadenectomy NN N
. . N

The DT N
laparoscopic NN N
approach NN N
was VBD N
associated VBN N
with IN N
a DT N
longer RBR N
operative JJ N
time NN N
( ( N
234.1 CD N
min NN N
vs NN N
137.3 CD N
min NN N
) ) N
but CC N
was VBD N
less JJR N
painful JJ N
( ( N
VAS NNP N
5.3 CD N
vs NN N
7.9 CD N
; : N
P NNP N
< NNP N
0.000 CD N
) ) N
and CC N
resulted VBN N
in IN N
a DT N
shorter JJR N
hospital NN N
stay NN N
( ( N
4.4+/-1 JJ N
vs NN N
7.9+/-1.2 JJ N
days NNS N
; : N
P NNP N
< NNP N
0.000 CD N
) ) N
. . N

At IN N
6 CD N
weeks NNS N
the DT N
quality NN N
of IN N
life NN N
was VBD N
better RBR N
in IN N
patients NNS N
who WP N
had VBD N
laparoscopic VBN N
lymphadenectomy JJ N
( ( N
SF-12 NNP N
) ) N
. . N

CONCLUSION NNP N
Laparoscopic NNP N
lymphadenectomy NN N
was VBD N
associated VBN N
with IN N
a DT N
significantly RB N
lower JJR N
rate NN N
of IN N
major JJ N
and CC N
minor JJ N
postoperative JJ N
complications NNS N
and CC N
a DT N
better JJR N
short JJ N
term NN N
quality NN N
of IN N
life NN N
. . N

-DOCSTART- -X- O O 4772206

The DT N
gastric JJ N
emptying NN N
and CC N
small JJ N
intestinal JJ N
transit NN N
after IN N
highly RB N
selective JJ N
vagotomy NN 4_p
without IN N
drainage NN N
and CC N
selective JJ 4_p
vagotomy NN 4_p
with IN 4_p
pyloroplasty NN 4_p
. . N

-DOCSTART- -X- O O 2527542

The DT N
influence NN N
of IN N
prostaglandin NN N
inhibition NN N
by IN N
indomethacin NN N
on IN N
blood NN N
pressure NN N
and CC N
renal JJ N
function NN N
in IN N
hypertensive JJ 4_p
patients NNS N
treated VBN N
with IN N
cilazapril NN N
. . N

1 CD N
. . N

In IN N
a DT N
placebo-controlled JJ N
double-blind JJ N
cross-over NN N
study NN N
lasting VBG N
6 CD N
weeks NNS N
, , N
twenty JJ N
patients NNS N
with IN N
essential JJ 4_p
hypertension NN 4_p
were VBD N
treated VBN N
with IN N
placebo NN N
for IN N
2 CD N
weeks NNS N
followed VBN N
by IN N
oral JJ N
cilazapril NN N
2.5 CD N
mg NN N
once RB N
a DT N
day NN N
or CC N
oral JJ N
indomethacin NN N
50 CD N
mg NN N
twice RB N
daily RB N
for IN N
2 CD N
weeks NNS N
. . N

Afterwards NNS N
they PRP N
received VBD N
the DT N
combination NN N
of IN N
both DT N
drugs NNS N
for IN N
a DT N
further JJ N
2 CD N
weeks NNS N
. . N

2 CD N
. . N

Cilazapril NNP N
significantly RB N
lowered VBD N
systolic JJ N
and CC N
diastolic JJ N
blood NN N
pressure NN N
for IN N
a DT N
period NN N
of IN N
24 CD N
h NNS N
post JJ N
administration NN N
. . N

3 CD N
. . N

Indomethacin NNP N
significantly RB N
attenuated VBD N
the DT N
antihypertensive JJ N
activity NN N
of IN N
cilazapril NN N
. . N

This DT N
was VBD N
more RBR N
pronounced JJ N
in IN N
those DT N
patients NNS N
who WP N
were VBD N
treated VBN N
for IN N
the DT N
initial JJ N
2 CD N
weeks NNS N
with IN N
indomethacin JJ N
plus CC N
placebo NN N
( ( N
and CC N
subsequently RB N
with IN N
cilazapril NN N
in IN N
addition NN N
) ) N
than IN N
in IN N
the DT N
subjects NNS N
who WP N
first RB N
received VBD N
cilazapril JJ N
plus CC N
placebo NN N
and CC N
then RB N
the DT N
combination NN N
. . N

4 CD N
. . N

Correspondingly VB N
the DT N
decrease NN N
of IN N
plasma JJ N
renin NN N
activity NN N
( ( N
PRA NNP N
) ) N
and CC N
urinary JJ N
prostaglandin NN N
excretion NN N
( ( N
PGE2 NNP N
) ) N
was VBD N
more RBR N
pronounced JJ N
in IN N
those DT N
patients NNS N
treated VBD N
initially RB N
with IN N
indomethacin NN N
. . N

5 CD N
. . N

The DT N
effect NN N
of IN N
indomethacin NN N
on IN N
the DT N
antihypertensive JJ N
effect NN N
of IN N
cilazapril NN N
appears VBZ N
to TO N
depend VB N
upon IN N
the DT N
sequence NN N
of IN N
drug NN N
administration NN N
. . N

-DOCSTART- -X- O O 24488157

A DT N
parent-mediated JJ N
intervention NN N
that WDT N
targets VBZ N
responsive JJ N
parental JJ N
behaviors NNS N
increases VBZ N
attachment JJ N
behaviors NNS N
in IN N
children NNS N
with IN N
ASD NNP 4_p
: : N
results NNS N
from IN N
a DT N
randomized JJ N
clinical JJ N
trial NN N
. . N

The DT N
current JJ N
study NN N
is VBZ N
a DT N
randomized JJ N
clinical JJ N
trial NN N
evaluating VBG N
the DT N
efficacy NN N
of IN N
Focused JJ N
Playtime NNP N
Intervention NNP N
( ( N
FPI NNP N
) ) N
in IN N
a DT N
sample NN N
of IN N
70 CD N
children NNS N
with IN N
Autism NNP 4_p
Spectrum NNP 4_p
Disorder NNP 4_p
. . N

This DT N
parent-mediated JJ N
intervention NN N
has VBZ N
previously RB N
been VBN N
shown VBN N
to TO N
significantly RB N
increase VB N
responsive JJ N
parental JJ N
communication NN N
( ( N
Siller NNP N
et RB N
al RB N
. . N

in IN N
J NNP N
Autism NNP N
Dev NNP N
Disord NNP N
43:540-555 CD N
, , N
2013a CD N
) ) N
. . N

The DT N
current JJ N
analyses NNS N
focus VBP N
on IN N
children NNS N
's POS N
attachment NN N
related VBN N
outcomes NNS N
. . N

Results NNS N
revealed VBD N
that IN N
children NNS N
who WP N
were VBD N
randomly RB N
assigned VBN N
to TO N
FPI NNP N
showed VBD N
bigger JJR N
increases NNS N
in IN N
attachment-related JJ N
behaviors NNS N
, , N
compared VBN N
to TO N
children NNS N
assigned VBN N
to TO N
the DT N
control NN N
condition NN N
. . N

Significant JJ N
treatment NN N
effects NNS N
of IN N
FPI NNP N
were VBD N
found VBN N
for IN N
both DT N
an DT N
observational JJ N
measure NN N
of IN N
attachment-related JJ N
behaviors NNS N
elicited VBD N
during IN N
a DT N
brief JJ N
separation-reunion JJ N
episode NN N
and CC N
a DT N
questionnaire JJ N
measure NN N
evaluating VBG N
parental JJ N
perceptions NNS N
of IN N
child JJ N
attachment NN N
. . N

The DT N
theoretical JJ N
and CC N
clinical JJ N
implications NNS N
of IN N
these DT N
findings NNS N
are VBP N
discussed VBN N
. . N

-DOCSTART- -X- O O 6729651

High-dose JJ N
weekly JJ N
fractionation NN N
radiotherapy NN N
in IN N
advanced JJ 4_p
cancer NN 4_p
of IN 4_p
the DT 4_p
uterine JJ 4_p
cervix NN 4_p
. . N

A DT N
trial NN N
comparing VBG N
two CD N
different JJ N
radiotherapy NN N
techniques NNS N
and CC N
schedules NNS N
in IN N
the DT N
treatment NN N
of IN N
83 CD N
patients NNS N
with IN N
advanced JJ N
cancer NN N
of IN N
the DT N
uterine JJ N
cervix NN N
( ( N
stage JJ N
IIIB NNP N
) ) N
employing VBG N
external JJ N
irradiation NN N
alone RB N
is VBZ N
described VBN N
. . N

The DT N
one CD N
technique NN N
, , N
used VBD N
routinely RB N
in IN N
this DT N
department NN N
, , N
employed VBD N
a DT N
conventional JJ N
daily JJ N
fractionation NN N
schedule NN N
while IN N
the DT N
other JJ N
used VBD N
a DT N
high-dose JJ N
weekly JJ N
fractionation NN N
regimen NNS N
. . N

The DT N
techniques NNS N
are VBP N
described VBN N
. . N

The DT N
aim NN N
of IN N
the DT N
trial NN N
was VBD N
to TO N
compare VB N
the DT N
efficacy NN N
and CC N
morbidity NN N
of IN N
these DT N
two CD N
methods NNS N
of IN N
treatment NN N
. . N

Dose NNP N
distribution NN N
curves NNS N
in IN N
cross-section NN N
and CC N
midsagittal JJ N
planes NNS N
are VBP N
shown VBN N
and CC N
calculations NNS N
or CC N
equivalent JJ N
doses NNS N
at IN N
various JJ N
selected VBN N
points NNS N
using VBG N
Ellis NNP N
's POS N
nominal JJ N
single-dose JJ N
formula NN N
are VBP N
tabulated VBN N
. . N

The DT N
2-year JJ N
survival NN N
figures NNS N
were VBD N
33 CD N
% NN N
for IN N
the DT N
daily JJ N
fractionation NN N
technique NN N
and CC N
22 CD N
% NN N
for IN N
the DT N
weekly JJ N
regimen NN N
. . N

Serious JJ N
late JJ N
complication NN N
rates NNS N
were VBD N
6 CD N
% NN N
for IN N
the DT N
daily JJ N
regimen NNS N
and CC N
22 CD N
% NN N
for IN N
the DT N
weekly JJ N
schedule NN N
. . N

These DT N
differences NNS N
are VBP N
not RB N
statistically RB N
significant JJ N
. . N

Late JJ N
complication NN N
rates NNS N
in IN N
the DT N
weekly JJ N
fractionation NN N
regimen NNS N
appeared VBD N
to TO N
be VB N
lower JJR N
than IN N
figures NNS N
quoted VBN N
by IN N
other JJ N
authors NNS N
. . N

Local JJ N
control NN N
within IN N
the DT N
irradiated JJ N
volume NN N
was VBD N
better RBR N
in IN N
the DT N
group NN N
treated VBN N
by IN N
the DT N
daily JJ N
fractionation NN N
method NN N
. . N

-DOCSTART- -X- O O 3859359

Comparison NNP N
of IN N
maintenance NN N
treatment NN N
regimens NNS N
for IN N
first JJ N
central JJ 4_p
nervous JJ 4_p
system NN 4_p
relapse NN 4_p
in IN N
children NNS N
with IN N
acute JJ 4_p
lymphocytic JJ 4_p
leukemia NN 4_p
. . N

A DT N
Pediatric NNP N
Oncology NNP N
Group NNP N
study NN N
. . N

Eighty-seven JJ N
children NNS N
with IN N
central JJ 4_p
nervous JJ 4_p
system NN 4_p
( ( 4_p
CNS NNP 4_p
) ) 4_p
leukemia NN 4_p
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
induction NN N
intrathecal JJ N
chemotherapy NN N
( ( N
ITC NNP N
) ) N
and CC N
cranial JJ N
irradiation NN N
( ( N
CRT NNP N
) ) N
plus CC N
maintenance NN N
ITC NNP N
, , N
or CC N
induction NN N
ITC NNP N
and CC N
craniospinal JJ N
irradiation NN N
( ( N
CSpRT NNP N
) ) N
with IN N
no DT N
maintenance NN N
ITC NNP N
. . N

ITC NNP N
consisted VBD N
of IN N
six CD N
weekly JJ N
injections NNS N
of IN N
methotrexate NN N
, , N
hydrocortisone NN N
, , N
and CC N
arabinosylcytosine NN N
. . N

Also RB N
, , N
intensification NN N
of IN N
systemic JJ N
induction NN N
and CC N
maintenance NN N
chemotherapy NN N
was VBD N
given VBN N
. . N

CRT NNP N
+ NNP N
ITC NNP N
was VBD N
given VBN N
as IN N
CRT NNP N
, , N
2400 CD N
rad NN N
in IN N
12 CD N
fractions NNS N
followed VBN N
by IN N
ITC NNP N
maintenance NN N
bimonthly NN N
for IN N
2 CD N
years NNS N
. . N

Craniospinal JJ N
irradiation NN N
consisted VBD N
of IN N
CRT NNP N
+ NNP N
1400 CD N
rad NN N
in IN N
ten JJ N
fractions NNS N
to TO N
the DT N
spine NN N
. . N

Randomization NN N
was VBD N
stratified VBN N
according VBG N
to TO N
whether IN N
CNS NNP N
leukemia NN N
occurred VBD N
at IN N
initial JJ N
diagnosis NN N
of IN N
acute JJ N
lymphocytic JJ N
leukemia NN N
( ( N
ALL DT N
) ) N
( ( N
Stratum NNP N
I PRP N
, , N
15 CD N
patients NNS N
) ) N
, , N
during IN N
first JJ N
bone NN N
marrow NN N
( ( N
BM NNP N
) ) N
remission NN N
( ( N
Stratum NNP N
II NNP N
, , N
49 CD N
patients NNS N
) ) N
, , N
simultaneous JJ N
with IN N
first JJ N
BM NNP N
relapse NN N
( ( N
Stratum NNP N
III NNP N
, , N
12 CD N
patients NNS N
) ) N
, , N
or CC N
during IN N
second JJ N
BM NNP N
remission NN N
( ( N
Stratum NNP N
IV NNP N
, , N
11 CD N
patients NNS N
) ) N
. . N

The DT N
median JJ N
follow-up NN N
for IN N
patients NNS N
who WP N
remain VBP N
at IN N
risk NN N
is VBZ N
15 CD N
+ JJ N
months NNS N
. . N

Eight NNP N
children NNS N
( ( N
seven CD N
on IN N
CRT NNP N
+ NNP N
ITC NNP N
, , N
one CD N
on IN N
CSpRT NNP N
) ) N
developed VBD N
presumed VBN N
therapy RB N
related VBN N
encephalopathy NN N
. . N

In IN N
Stratum NNP N
II NNP N
, , N
16 CD N
of IN N
29 CD N
( ( N
55 CD N
% NN N
) ) N
patients NNS N
receiving VBG N
CRT NNP N
+ NNP N
ITC NNP N
experienced VBD N
adverse JJ N
events NNS N
: : N
3 CD N
deaths NNS N
during IN N
continuous JJ N
complete JJ N
remission NN N
( ( N
CCR NNP N
) ) N
and CC N
13 CD N
relapses NNS N
( ( N
2 CD N
CNS NNP N
, , N
1 CD N
CNS NNP N
+ NNP N
BM NNP N
, , N
1 CD N
BM NNP N
+ NNP N
testes VBZ N
, , N
and CC N
2 CD N
testes NNS N
) ) N
as IN N
compared VBN N
with IN N
only RB N
5 CD N
relapses NNS N
in IN N
20 CD N
( ( N
25 CD N
% NN N
) ) N
patients NNS N
on IN N
CSpRT NNP N
( ( N
1 CD N
CNS NNP N
, , N
1 CD N
CNS NNP N
+ NNP N
BM NNP N
, , N
1 CD N
BM NNP N
, , N
and CC N
2 CD N
testes NNS N
) ) N
. . N

The DT N
children NNS N
on IN N
both DT N
regimens NNS N
were VBD N
comparable JJ N
for IN N
sex NN N
, , N
race NN N
, , N
age NN N
at IN N
initial JJ N
ALL NNP N
diagnosis NN N
, , N
time NN N
from IN N
ALL NNP N
diagnosis NN N
to TO N
first JJ N
episode NN N
of IN N
CNS NNP N
leukemia NN N
, , N
systemic JJ N
therapy NN N
both DT N
before IN N
and CC N
after IN N
CNS NNP N
relapse NN N
, , N
and CC N
number NN N
of IN N
blasts NNS N
in IN N
the DT N
spinal JJ N
fluid NN N
at IN N
diagnosis NN N
of IN N
CNS NNP N
leukemia NN N
. . N

The DT N
conclusion NN N
is VBZ N
that IN N
children NNS N
with IN N
isolated JJ N
CNS NNP N
leukemia NN N
can MD N
achieve VB N
prolonged JJ N
survival NN N
with IN N
aggressive JJ N
therapy NN N
, , N
and CC N
that IN N
CSpRT NNP N
is VBZ N
possibly RB N
less RBR N
toxic JJ N
and CC N
more RBR N
likely JJ N
than IN N
is VBZ N
CRT NNP N
+ NNP N
ITC NNP N
to TO N
prevent VB N
subsequent JJ N
BM NNP N
and CC N
testicular JJ N
relapse NN N
( ( N
P NNP N
less JJR N
than IN N
0.02 CD N
) ) N
, , N
but CC N
not RB N
subsequent JJ N
CNS NNP N
relapse NN N
( ( N
P NNP N
= NNP N
0.7 CD N
) ) N
. . N

A DT N
possible JJ N
systemic JJ N
therapy NN N
effect NN N
of IN N
spinal JJ N
irradiation NN N
is VBZ N
postulated VBN N
to TO N
explain VB N
the DT N
superiority NN N
of IN N
CSpRT NNP N
. . N

-DOCSTART- -X- O O 6448998

The DT N
treatment NN N
of IN N
acne JJ 4_p
vulgaris NN 4_p
in IN N
general JJ N
practice NN N
. . N

A DT N
double-blind JJ N
assessment NN N
of IN N
co-trimoxazole JJ N
and CC N
tetracycline NN N
. . N

-DOCSTART- -X- O O 11535502

Relationships NNS N
between IN N
age NN N
at IN N
diagnosis NN N
, , N
clinical JJ N
features NNS N
, , N
and CC N
outcome NN N
of IN N
therapy NN N
in IN N
children NNS N
treated VBN 4_p
in IN 4_p
the DT 4_p
Medical NNP 4_p
Research NNP 4_p
Council NNP 4_p
AML NNP 4_p
10 CD 4_p
and CC 4_p
12 CD 4_p
trials NNS 4_p
for IN 4_p
acute JJ 4_p
myeloid NN 4_p
leukemia NN 4_p
. . 4_p

Between NNP N
May NNP N
1988 CD N
and CC N
June NNP N
2000 CD N
, , N
698 CD N
children NNS N
were VBD N
treated VBN N
in IN N
the DT N
Medical NNP N
Research NNP N
Council NNP N
acute VBZ 4_p
myeloid JJ 4_p
leukemia NN 4_p
10 CD N
and CC N
12 CD N
trials NNS N
. . N

The DT N
presenting NN N
features NNS N
and CC N
outcomes NNS N
of IN N
therapy NN N
in IN N
these DT N
children NNS N
were VBD N
compared VBN N
by IN N
age NN N
. . N

Although IN N
there EX N
was VBD N
no DT N
single JJ N
cutoff NN N
in IN N
age NN N
, , N
younger JJR N
children NNS N
were VBD N
more RBR N
likely JJ N
to TO N
have VB N
intermediate JJ N
risk NN N
and CC N
less RBR N
likely JJ N
to TO N
have VB N
favorable JJ N
cytogenetics NNS N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
, , N
and CC N
they PRP N
had VBD N
a DT N
higher JJR N
incidence NN N
of IN N
translocations NNS N
involving VBG N
chromosome NN N
11q23 CD N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

The DT N
distribution NN N
of IN N
French-American-British NNP N
( ( N
FAB NNP N
) ) N
types NNS N
also RB N
varied VBD N
with IN N
age NN N
; : N
FAB NNP N
types VBZ N
M5 NNP N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
and CC N
M7 NNP N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
were VBD N
more JJR N
common JJ N
in IN N
early JJ N
childhood NN N
, , N
whereas IN N
older JJR N
children NNS N
were VBD N
more RBR N
likely JJ N
to TO N
have VB N
FAB NNP N
types NNS N
M0 NNP N
( ( N
P NNP N
=.03 NNP N
) ) N
, , N
M1 NNP N
( ( N
P NNP N
=.04 NNP N
) ) N
, , N
M2 NNP N
( ( N
P NNP N
=.005 NNP N
) ) N
, , N
and CC N
M3 NNP N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

Involvement NN N
of IN N
the DT N
central JJ N
nervous JJ N
system NN N
at IN N
diagnosis NN N
was VBD N
also RB N
more JJR N
common JJ N
in IN N
the DT N
youngest JJS N
children NNS N
( ( N
P NNP N
=.01 NNP N
) ) N
. . N

Younger JJR N
children NNS N
had VBD N
more RBR N
severe JJ N
diarrhea NN N
( ( N
P NNP N
=.002 NNP N
) ) N
, , N
whereas JJ N
older JJR N
children NNS N
had VBD N
worse JJR N
nausea NN N
and CC N
vomiting NN N
( ( N
P NNP N
=.01 NNP N
) ) N
after IN N
chemotherapy NN N
. . N

When WRB N
adjusted VBN N
for IN N
other JJ N
important JJ N
factors NNS N
, , N
complete JJ N
remission NN N
rates NNS N
were VBD N
similar JJ N
( ( N
P NNP N
=.5 NNP N
) ) N
and CC N
although IN N
there EX N
was VBD N
less RBR N
resistant JJ N
disease NN N
in IN N
younger JJR N
children NNS N
( ( N
P NNP N
=.003 NNP N
) ) N
, , N
this DT N
was VBD N
partially RB N
balanced VBN N
by IN N
a DT N
slight JJ N
increase NN N
in IN N
deaths NNS N
during IN N
induction NN N
therapy NN N
in IN N
younger JJR N
patients NNS N
( ( N
P NNP N
=.06 NNP N
) ) N
. . N

On IN N
multivariate NN N
analysis NN N
overall JJ N
survival NN N
( ( N
P NNP N
=.02 NNP N
) ) N
, , N
event-free JJ N
survival NN N
( ( N
P NNP N
=.02 NNP N
) ) N
, , N
and CC N
disease-free JJ N
survival NN N
were VBD N
better JJR N
( ( N
P NNP N
=.06 NNP N
) ) N
in IN N
younger JJR N
children NNS N
due JJ N
to TO N
a DT N
lower JJR N
relapse NN N
rate NN N
( ( N
P NNP N
=.02 NNP N
) ) N
especially RB N
in IN N
the DT N
bone NN N
marrow NN N
( ( N
P NNP N
=.02 NNP N
) ) N
. . N

-DOCSTART- -X- O O 25087908

The DT N
effects NNS N
of IN N
a DT N
course NN N
of IN N
intranasal JJ N
oxytocin NN N
on IN N
social JJ N
behaviors NNS N
in IN N
youth NN N
diagnosed VBN N
with IN N
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
: : N
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
There EX N
is VBZ N
increasing VBG N
interest NN N
in IN N
oxytocin NN N
as IN N
a DT N
therapeutic JJ N
to TO N
treat VB N
social JJ N
deficits NNS N
in IN N
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
( ( 4_p
ASD NNP 4_p
) ) 4_p
. . 4_p

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
efficacy NN N
of IN N
a DT N
course NN N
of IN N
oxytocin JJ N
nasal NN N
spray NN N
to TO N
improve VB N
social JJ N
behavior NN N
in IN N
youth NN N
with IN N
ASD NNP 4_p
. . N

METHODS NNP N
In IN N
a DT N
double-blind JJ N
, , N
placebo-controlled JJ N
trial NN N
across IN N
two CD 4_p
Australian JJ 4_p
university NN 4_p
sites NNS 4_p
between IN 4_p
February NNP 4_p
2009 CD 4_p
and CC 4_p
January NNP 4_p
2012 CD 4_p
, , 4_p
50 CD N
male NN N
participants NNS N
aged VBN N
between IN N
12 CD N
and CC N
18 CD N
years NNS N
, , N
with IN N
Autistic NNP 4_p
or CC 4_p
Asperger NNP 4_p
's POS 4_p
Disorder NNP 4_p
, , N
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
oxytocin NN N
( ( N
n JJ N
= NNP N
26 CD N
) ) N
or CC N
placebo NN N
( ( N
n JJ N
= NNP N
24 CD N
) ) N
nasal NN N
sprays NNS N
( ( N
either CC N
18 CD N
or CC N
24 CD N
International NNP N
Units NNP N
) ) N
, , N
administered VBN N
twice-daily RB N
for IN N
8 CD N
weeks NNS N
. . N

Participants NNS N
were VBD N
assessed VBN N
at IN N
baseline NN N
, , N
after IN N
4- JJ N
and CC N
8-weeks CD N
of IN N
treatment NN N
, , N
and CC N
at IN N
3-month JJ N
follow-up NN N
. . N

Primary JJ N
outcomes NNS N
were VBD N
change NN N
in IN N
total JJ N
scores NNS N
on IN N
the DT N
caregiver-completed JJ N
Social NNP N
Responsiveness NNP N
Scale NNP N
and CC N
clinician-ratings NNS N
on IN N
the DT N
Clinical JJ N
Global NNP N
Impressions-Improvement NNP N
scale NN N
. . N

Secondary JJ N
assessments NNS N
included VBD N
caregiver NN N
reports NNS N
of IN N
repetitive JJ N
and CC N
other JJ N
developmental JJ N
behaviors NNS N
and CC N
social JJ N
cognition NN N
. . N

CLINICAL NNP N
TRIAL NNP N
REGISTRATION NNP N
Australian NNP N
New NNP N
Zealand NNP N
Clinical NNP N
Trials NNP N
Registry NNP N
www.anzctr.org.au VBD N
ACTRN12609000513213 NNP N
. . N

RESULTS NNP N
Participants NNPS N
who WP N
received VBD N
oxytocin RB N
showed VBN N
no DT N
benefit NN N
following VBG N
treatment NN N
on IN N
primary JJ N
or CC N
secondary JJ N
outcomes NNS N
. . N

However RB N
, , N
caregivers NNS N
who WP N
believed VBD N
their PRP$ N
children NNS N
received VBN N
oxytocin RB N
reported VBN N
greater JJR N
improvements NNS N
compared VBN N
to TO N
caregivers NNS N
who WP N
believed VBD N
their PRP$ N
child NN N
received VBD N
placebo NN N
. . N

Nasal NNP N
sprays NNS N
were VBD N
well RB N
tolerated VBN N
and CC N
there EX N
was VBD N
no DT N
evidence NN N
of IN N
increased JJ N
side NN N
effects NNS N
resulting VBG N
from IN N
oxytocin JJ N
administration NN N
. . N

CONCLUSIONS VB N
This DT N
is VBZ N
the DT N
first JJ N
evaluation NN N
of IN N
the DT N
efficacy NN N
for IN N
a DT N
course NN N
of IN N
oxytocin JJ N
treatment NN N
for IN N
youth NN N
with IN N
ASD NNP N
. . N

Although IN N
results NNS N
did VBD N
not RB N
suggest VB N
clinical JJ N
efficacy NN N
, , N
further JJ N
research NN N
is VBZ N
needed VBN N
to TO N
explore VB N
alternative JJ N
delivery NN N
methods NNS N
, , N
earlier JJR N
age NN N
of IN N
intervention NN N
, , N
and CC N
the DT N
influence NN N
of IN N
caregiver NN N
expectation NN N
on IN N
treatment NN N
response NN N
. . N

-DOCSTART- -X- O O 24928832

A DT N
randomized VBN N
, , N
phase VB N
II NNP N
study NN N
of IN N
afatinib JJ N
versus NN N
cetuximab NN N
in IN N
metastatic JJ 4_p
or CC 4_p
recurrent JJ 4_p
squamous JJ 4_p
cell NN 4_p
carcinoma NN 4_p
of IN 4_p
the DT 4_p
head NN 4_p
and CC 4_p
neck NN 4_p
. . N

BACKGROUND NNP N
Afatinib NNP N
is VBZ N
an DT N
oral JJ N
, , N
irreversible JJ N
ErbB NNP N
family NN N
blocker NN N
that WDT N
has VBZ N
shown VBN N
activity NN N
in IN N
epidermal JJ N
growth NN N
factor NN N
receptor NN N
( ( N
EGFR NNP N
) ) N
-mutated VBD N
lung NN N
cancer NN N
. . N

We PRP N
hypothesized VBD N
that IN N
the DT N
agent NN N
would MD N
have VB N
greater JJR N
antitumor NN N
activity NN N
compared VBN N
with IN N
cetuximab NN N
in IN N
recurrent NN 4_p
or CC 4_p
metastatic JJ 4_p
( ( 4_p
R/M NNP 4_p
) ) 4_p
head NN 4_p
and CC 4_p
neck NN 4_p
squamous JJ 4_p
cell NN 4_p
carcinoma NN 4_p
( ( 4_p
HNSCC NNP 4_p
) ) 4_p
patients NNS 4_p
, , N
whose WP$ N
disease NN 4_p
has VBZ 4_p
progressed VBN 4_p
after IN 4_p
platinum-containing JJ 4_p
therapy NN 4_p
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
An DT N
open-label JJ N
, , N
randomized VBN N
, , N
phase VB N
II NNP N
trial NN N
was VBD N
conducted VBN N
in IN N
43 CD N
centers NNS N
; : N
124 CD N
patients NNS N
were VBD N
randomized VBN N
( ( N
1 CD N
: : N
1 CD N
) ) N
to TO N
either DT N
afatinib NN N
( ( N
50 CD N
mg/day NN N
) ) N
or CC N
cetuximab NN N
( ( N
250 CD N
mg/m NN N
( ( N
2 CD N
) ) N
/week NN N
) ) N
until IN N
disease JJ N
progression NN N
or CC N
intolerable JJ N
adverse JJ N
events NNS N
( ( N
AEs NNP N
) ) N
( ( N
stage NN N
I PRP N
) ) N
, , N
with IN N
optional JJ N
crossover NN N
( ( N
stage JJ N
II NNP N
) ) N
. . N

The DT N
primary JJ N
end NN N
point NN N
was VBD N
tumor JJ N
shrinkage NN N
before IN N
crossover NN N
assessed VBN N
by IN N
investigator NN N
( ( N
IR NNP N
) ) N
and CC N
independent JJ N
central JJ N
review NN N
( ( N
ICR NNP N
) ) N
. . N

RESULTS VB N
A DT N
total NN N
of IN N
121 CD N
patients NNS N
were VBD N
treated VBN N
( ( N
61 CD N
afatinib NN N
, , N
60 CD N
cetuximab NN N
) ) N
and CC N
68 CD N
crossed VBN N
over IN N
to TO N
stage VB N
II NNP N
( ( N
32 CD N
and CC N
36 CD N
respectively RB N
) ) N
. . N

In IN N
stage NN N
I PRP N
, , N
mean JJ N
tumor NN N
shrinkage NN N
by IN N
IR/ICR NNP N
was VBD N
10.4 CD N
% NN N
/16.6 CD N
% NN N
with IN N
afatinib NN N
and CC N
5.4 CD N
% NN N
/10.1 CD N
% NN N
with IN N
cetuximab NN N
( ( N
P NNP N
= NNP N
0.46/0.30 CD N
) ) N
. . N

Objective JJ N
response NN N
rate NN N
was VBD N
16.1 CD N
% NN N
/8.1 CD N
% NN N
with IN N
afatinib NN N
and CC N
6.5 CD N
% NN N
/9.7 CD N
% NN N
with IN N
cetuximab NN N
( ( N
IR/ICR NNP N
) ) N
. . N

Comparable JJ N
disease NN N
control NN N
rates NNS N
were VBD N
observed VBN N
with IN N
afatinib NN N
( ( N
50 CD N
% NN N
) ) N
and CC N
cetuximab NN N
( ( N
56.5 CD N
% NN N
) ) N
by IN N
IR NNP N
; : N
similar JJ N
results NNS N
were VBD N
seen VBN N
by IN N
ICR NNP N
. . N

Most JJS N
common JJ N
grade NN N
≥3 JJ N
drug-related JJ N
AEs NNP N
( ( N
DRAEs NNP N
) ) N
were VBD N
rash/acne VBN N
( ( N
18 CD N
% NN N
versus IN N
8.3 CD N
% NN N
) ) N
, , N
diarrhea NN N
( ( N
14.8 CD N
% NN N
versus IN N
0 CD N
% NN N
) ) N
, , N
and CC N
stomatitis/mucositis NN N
( ( N
11.5 CD N
% NN N
versus IN N
0 CD N
% NN N
) ) N
with IN N
afatinib NN N
and CC N
cetuximab NN N
, , N
respectively RB N
. . N

Patients NNS N
with IN N
DRAEs NNP N
leading VBG N
to TO N
treatment NN N
discontinuation NN N
were VBD N
23 CD N
% NN N
with IN N
afatinib NN N
and CC N
5 CD N
% NN N
with IN N
cetuximab NN N
. . N

In IN N
stage NN N
II NNP N
, , N
disease VB N
control NN N
rate NN N
( ( N
IR/ICR NNP N
) ) N
was VBD N
38.9 CD N
% NN N
/33.3 CD N
% NN N
with IN N
afatinib NN N
and CC N
18.8 CD N
% NN N
/18.8 CD N
% NN N
with IN N
cetuximab NN N
. . N

CONCLUSION NNP N
Afatinib NNP N
showed VBD N
antitumor JJ N
activity NN N
comparable JJ N
to TO N
cetuximab VB N
in IN N
R/M NNP N
HNSCC NNP N
in IN N
this DT N
exploratory JJ N
phase NN N
II NNP N
trial NN N
, , N
although IN N
more JJR N
patients NNS N
on IN N
afatinib JJ N
discontinued VBN N
treatment NN N
due JJ N
to TO N
AEs NNP N
. . N

Sequential NNP N
EGFR/ErbB NNP N
treatment NN N
with IN N
afatinib NN N
and CC N
cetuximab NN N
provided VBD N
sustained JJ N
clinical JJ N
benefit NN N
in IN N
patients NNS N
after IN N
crossover NN N
, , N
suggesting VBG N
a DT N
lack NN N
of IN N
cross-resistance NN N
. . N

-DOCSTART- -X- O O 175669

Comparison NNP N
of IN N
split-course JJ N
radiation NN N
therapy NN N
and CC N
continuous JJ N
radiation NN N
therapy NN N
for IN N
unresectable JJ 4_p
bronchogenic JJ 4_p
carcinoma NN 4_p
: : N
5 CD N
year NN N
results NNS N
. . N

One CD N
hundred CD N
and CC N
eighty-eight JJ N
patients NNS N
with IN N
inoperable JJ 4_p
or CC N
unresectable JJ 4_p
bronchogenic JJ 4_p
carcinoma NN 4_p
were VBD N
stratified VBN N
by IN N
cell NN N
type NN N
, , N
TNM NNP N
staging NN N
, , N
and CC N
prior RB N
surgery NN N
and CC N
then RB N
randomized VBN N
into IN N
two CD N
treatment NN N
groups NNS N
: : N
continuous JJ N
radiation NN N
therapy NN N
and CC N
split-course JJ N
radiation NN N
therapy NN N
. . N

There EX N
was VBD N
no DT N
difference NN N
in IN N
clinical JJ N
or CC N
objective JJ N
improvement NN N
in IN N
the DT N
two CD N
groups NNS N
. . N

Survival JJ N
rates NNS N
for IN N
cases NNS N
of IN N
squamous JJ N
cell NN N
carcinoma NN N
, , N
small JJ N
cell NN N
carcinoma NN N
, , N
and CC N
adrenocarcinoma NN N
were VBD N
the DT N
same JJ N
after IN N
both DT N
regimens NNS N
of IN N
therapy NN N
. . N

Split-course JJ N
therapy NN N
resulted VBD N
in IN N
a DT N
significantly RB N
better JJR N
survival NN N
rate NN N
in IN N
cases NNS N
of IN N
large JJ N
cell NN N
carcinoma NN N
but CC N
the DT N
number NN N
of IN N
cases NNS N
was VBD N
small JJ N
. . N

We PRP N
doubt VBP N
that IN N
the DT N
difference NN N
is VBZ N
clinically RB N
significant JJ N
. . N

Objective JJ N
roentgenographic JJ N
response NN N
was VBD N
accompanied VBN N
by IN N
improved JJ N
survival NN N
in IN N
squamous JJ N
cell NN N
carcinoma NN N
, , N
but CC N
not RB N
in IN N
the DT N
other JJ N
three CD N
cell NN N
types NNS N
. . N

Split-course JJ N
radiation NN N
therapy NN N
is VBZ N
superior JJ N
to TO N
continuous JJ N
radiation NN N
therapy NN N
because IN N
it PRP N
is VBZ N
better RBR N
tolerated VBN N
by IN N
the DT N
patient NN N
and CC N
because IN N
re-examination NN N
of IN N
the DT N
patient NN N
prior RB N
to TO N
the DT N
second JJ N
half NN N
of IN N
split-course JJ N
therapy NN N
permits VBZ N
the DT N
detection NN N
of IN N
new JJ N
metastatic JJ N
disease NN N
that WDT N
has VBZ N
become VBN N
manifest JJS N
during IN N
the DT N
rest NN N
period NN N
and CC N
spares VBZ N
the DT N
patient NN N
the DT N
futile JJ N
second JJ N
half NN N
of IN N
radiation NN N
therapy NN N
. . N

-DOCSTART- -X- O O 8292465

The DT N
incidence NN N
of IN N
first-dose JJ N
hypotension NN N
with IN N
quinapril NN N
in IN N
patients NNS N
with IN N
mild JJ 4_p
to TO 4_p
moderate VB 4_p
hypertension NN 4_p
. . N

A DT N
total NN N
of IN N
2242 CD N
patients NNS N
with IN N
mild JJ 4_p
to TO 4_p
moderate VB 4_p
hypertension NN 4_p
( ( N
diastolic JJ N
pressure NN N
95-120 CD N
mmHg NN N
) ) N
were VBD N
randomised VBN N
on IN N
a DT N
double-blind JJ N
basis NN N
to TO N
receive VB N
a DT N
single JJ N
dose NN N
of IN N
placebo NN N
, , N
5 CD N
mg NN N
quinapril NN N
or CC N
10 CD N
mg JJ N
quinapril NN N
. . N

Patients NNS N
were VBD N
identified VBN N
who WP N
: : N
( ( N
a DT N
) ) N
met VBD N
the DT N
blood NN N
pressure NN N
( ( N
BP NNP N
) ) N
criteria NNS N
for IN N
first-dose JJ N
hypotension NN N
( ( N
sitting VBG 4_p
or CC 4_p
standing VBG 4_p
systolic JJ 4_p
BP NNP 4_p
< NNP 4_p
100 CD 4_p
mmHg NN 4_p
, , N
or CC N
a DT 4_p
fall NN 4_p
in IN 4_p
systolic JJ 4_p
BP NNP 4_p
> NN 4_p
or CC 4_p
= $ 4_p
20 CD 4_p
mmHg NN 4_p
on IN 4_p
standing VBG 4_p
) ) N
; : N
( ( N
b NN N
) ) N
had VBD N
symptoms NNS 4_p
suggestive JJ 4_p
of IN 4_p
hypotension NN 4_p
; : N
and CC N
( ( N
c NN N
) ) N
met VBD N
the DT N
BP NNP N
criteria NNS N
and CC N
had VBD N
symptoms NNS N
. . N

In IN N
all DT N
three CD N
classifications NNS N
there EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
between IN N
the DT N
incidences NNS N
in IN N
placebo NN N
and CC N
combined VBD N
active JJ N
treatment NN N
groups NNS N
, , N
or CC N
between IN N
those DT N
in IN N
the DT N
two CD N
quinapril NN N
groups NNS N
. . N

No RB N
associated JJ N
serious JJ N
adverse JJ N
events NNS N
were VBD N
reported VBN N
. . N

In IN N
the DT N
low-risk JJ 4_p
population NN 4_p
studied VBD N
, , N
it PRP N
would MD N
appear VB N
that IN N
the DT N
incidence NN N
of IN N
first-dose JJ N
hypotension NN N
with IN N
quinapril NN N
is VBZ N
similar JJ N
to TO N
placebo VB N
and CC N
is VBZ N
not RB N
dose-related JJ N
. . N

-DOCSTART- -X- O O 8908288

Final JJ N
report NN N
of IN N
a DT N
randomized VBN N
controlled VBN N
study NN N
with IN N
streptococcal JJ N
preparation NN N
OK-432 NNP N
as IN N
a DT N
supplementary JJ N
immunopotentiator NN N
for IN N
laryngeal JJ N
cancer NN N
. . N

We PRP N
conducted VBD N
a DT N
randomized VBN N
controlled VBN N
study NN N
of IN N
streptococcal JJ N
preparation NN N
OK-432 NNP N
on IN N
120 CD N
newly RB N
identified VBN N
cases NNS N
of IN N
laryngeal JJ N
squamous JJ N
cell NN N
carcinoma NN N
who WP N
were VBD N
registered VBN N
at IN N
10 CD N
participating VBG N
institutions NNS N
between IN N
November NNP N
1984 CD N
and CC N
October NNP N
1989 CD N
. . N

The DT N
patients NNS N
were VBD N
divided VBN N
into IN N
two CD N
groups NNS N
: : N
those DT N
in IN N
early JJ N
stages NNS N
( ( N
stage NN N
I PRP N
or CC N
II NNP N
) ) N
and CC N
those DT N
in IN N
advanced JJ N
stages NNS N
( ( N
stage NN N
III NNP N
or CC N
IV NNP N
) ) N
; : N
these DT N
groups NNS N
were VBD N
further RB N
subdivided VBN N
into IN N
an DT N
immunotherapy NN N
group NN N
( ( N
receiving VBG N
OK-432 NNP N
) ) N
and CC N
a DT N
control NN N
group NN N
( ( N
who WP N
did VBD N
not RB N
receive VB N
OK-432 NNP N
) ) N
. . N

The DT N
usefulness NN N
of IN N
OK-432 NNP N
was VBD N
studied VBN N
using VBG N
the DT N
sealed VBN N
envelope NN N
method NN N
. . N

The DT N
basic JJ N
therapy NN N
for IN N
all DT N
cases NNS N
was VBD N
radiotherapy NN N
and CC N
, , N
when WRB N
required VBN N
, , N
surgery NN N
. . N

As IN N
adjuvant JJ N
therapy NN N
, , N
5Fu CD N
or CC N
derivatives NNS N
were VBD N
administered VBN N
to TO N
all DT N
cases NNS N
from IN N
the DT N
beginning NN N
of IN N
the DT N
treatment NN N
period NN N
to TO N
one CD N
year NN N
after IN N
the DT N
basic JJ N
therapy NN N
, , N
with IN N
the DT N
exception NN N
of IN N
cases NNS N
in IN N
whom WP N
side NN N
effects NNS N
were VBD N
serious JJ N
enough RB N
to TO N
contraindicate VB N
use NN N
of IN N
the DT N
drug NN N
. . N

The DT N
target NN N
administration NN N
period NN N
was VBD N
5 CD N
years NNS N
. . N

Of IN N
the DT N
initial JJ N
120 CD N
cases NNS N
, , N
11 CD N
cases NNS N
were VBD N
disqualified VBN N
( ( N
3 CD N
cases NNS N
of IN N
double JJ N
cancer NN N
and CC N
8 CD N
of IN N
incomplete JJ N
primary JJ N
therapy NN N
) ) N
and CC N
the DT N
remaining VBG N
109 CD N
were VBD N
used VBN N
for IN N
evaluation NN N
. . N

The DT N
5-year JJ N
survival NN N
rate NN N
and CC N
the DT N
5-year JJ N
recurrence-free JJ N
rate NN N
were VBD N
76 CD N
% NN N
and CC N
84 CD N
% NN N
, , N
respectively RB N
, , N
in IN N
the DT N
immunized JJ N
groups NNS N
( ( N
both DT N
the DT N
early JJ N
and CC N
advanced JJ N
groups NNS N
) ) N
, , N
whereas VBP N
the DT N
same JJ N
rates NNS N
for IN N
the DT N
control NN N
groups NNS N
were VBD N
78 CD N
% NN N
and CC N
75 CD N
% NN N
. . N

There EX N
was VBD N
a DT N
tendency NN N
for IN N
the DT N
immunized JJ N
groups NNS N
to TO N
enjoy VB N
a DT N
slightly RB N
longer RBR N
recurrence-free JJ N
period NN N
. . N

Over IN N
a DT N
24-month JJ N
observation NN N
period NN N
the DT N
immunized JJ N
group NN N
always RB N
had VBD N
higher JJR N
levels NNS N
of IN N
peripheral JJ N
leukocytes NNS N
and CC N
peripheral JJ N
lymphocytes NNS N
; : N
this DT N
difference NN N
was VBD N
significant JJ N
for IN N
the DT N
first JJ N
21 CD N
months NNS N
. . N

Inhibition NN N
of IN N
bone NN N
marrow NN N
function NN N
is VBZ N
sometimes RB N
observed VBN N
with IN N
radiotherapy NN N
. . N

It PRP N
is VBZ N
hoped VBN N
that IN N
, , N
if IN N
this DT N
inhibition NN N
can MD N
be VB N
mitigated VBN N
, , N
it PRP N
will MD N
be VB N
possible JJ N
to TO N
assist VB N
the DT N
compromised VBN N
immune NN N
system NN N
and CC N
maintain VB N
a DT N
certain JJ N
level NN N
of IN N
immune JJ N
performance NN N
which WDT N
will MD N
prevent VB N
recurrence NN N
and CC N
improve VB N
survival NN N
rate NN N
. . N

In IN N
the DT N
present JJ N
study NN N
we PRP N
observed VBD N
a DT N
tendency NN N
of IN N
the DT N
lower JJR N
recurrence NN N
rate NN N
in IN N
the DT N
immunized JJ N
group NN N
, , N
and CC N
we PRP N
hypothesize VBP N
that IN N
OK-432 NNP N
is VBZ N
effective JJ N
in IN N
extending VBG N
the DT N
recurrence-free JJ N
period NN N
. . N

-DOCSTART- -X- O O 24105031

Supplementation NN N
effect NN N
with IN N
slow-release JJ N
urea NN N
in IN N
feed NN N
blocks NNS N
for IN N
Thai NNP N
beef NN N
cattle NNS N
-- : N
nitrogen DT N
utilization NN N
, , N
blood NN 4_p
biochemistry NN 4_p
, , N
and CC N
hematology NN N
. . N

Four CD N
Thai NNP N
male NN N
native JJ N
beef NN N
cattle NNS N
, , N
initial JJ 4_p
body NN 4_p
weight NN 4_p
( ( 4_p
BW NNP 4_p
) ) 4_p
of IN 4_p
100 CD 4_p
± JJ 4_p
3.0 CD 4_p
kg NNS 4_p
were VBD N
randomly RB N
assigned VBN N
in IN N
a DT N
4 CD N
× NN N
4 CD N
Latin NNP N
square JJ N
design NN N
to TO N
receive VB N
four CD N
dietary JJ N
treatments NNS N
with IN N
inclusion NN N
of IN N
urea JJ N
calcium NN N
sulphate NN N
mixture NN N
( ( N
U-cas NNP N
) ) N
in IN N
feed NN N
block NN N
( ( N
FB NNP N
) ) N
at IN N
0 CD N
, , N
120 CD N
, , N
150 CD N
, , N
and CC N
180 CD N
g/kg NN N
dry JJ N
matter NN N
( ( N
DM NNP N
) ) N
. . N

Total JJ N
intakes NNS N
were VBD N
increased VBN N
with IN N
the DT N
increasing VBG N
level NN N
of IN N
U-cas JJ N
supplementation NN N
in IN N
FB NNP N
and CC N
the DT N
result NN N
obtained VBD N
the DT N
highest JJS N
when WRB N
supplementation NN N
of IN N
U-cas NNP N
in IN N
FB NNP N
at IN N
180 CD N
, , N
followed VBN N
by IN N
150 CD N
, , N
120 CD N
, , N
and CC N
0 CD N
g/kg NN N
DM NNP N
, , N
respectively RB N
. . N

Moreover RB N
, , N
supplementation NN N
of IN N
U-cas NNP N
in IN N
FB NNP N
at IN N
180 CD N
g/kg NNS N
DM NNP N
could MD N
reduce VB N
total JJ N
N NNP N
excretion NN N
( ( N
4.1 CD N
g/day NN N
) ) N
, , N
as IN N
compared VBN N
to TO N
others NNS N
treatments NNS N
, , N
while IN N
N NNP N
retention NN N
and CC N
proportion NN N
of IN N
N NNP N
retention NN N
to TO N
N NNP N
intake VB N
were VBD N
increased VBN N
up RB N
to TO N
6.9 CD N
g/day NN N
and CC N
14.9 CD N
% NN N
, , N
respectively RB N
. . N

On IN N
the DT N
other JJ N
hand NN N
, , N
the DT N
blood NN N
biochemistry NN N
and CC N
hematological JJ N
parameters NNS N
were VBD N
not RB N
different JJ N
among IN N
treatments NNS N
except IN N
concentration NN N
of IN N
plasma JJ N
urea JJ N
N NNP N
, , N
plasma NN N
glucose NN N
, , N
and CC N
total JJ N
blood NN N
protein NN N
were VBD N
improved VBN N
especially RB N
with IN N
U-cas JJ N
supplementation NN N
at IN N
180 CD N
g/kg NN N
DM NNP N
in IN N
FB NNP N
. . N

In IN N
conclusion NN N
, , N
supplementation NN N
of IN N
U-cas NNP N
at IN N
180 CD N
g/kg NN N
in IN N
FB NNP N
improved VBD N
feed JJ N
intake NN N
, , N
N NNP N
utilization NN N
, , N
and CC N
blood NN N
biochemistry NN N
in IN N
Thai NNP N
native JJ N
beef NN N
cattle NNS N
fed VBP N
on IN N
rice NN N
straw NN N
. . N

-DOCSTART- -X- O O 21207788

Controlled VBN N
, , N
prospective JJ N
, , N
randomized VBN N
, , N
clinical JJ N
evaluation NN N
of IN N
partial JJ N
ceramic JJ N
crowns NNS N
inserted VBN N
with IN N
RelyX NNP N
Unicem NNP N
with IN N
or CC N
without IN N
selective JJ N
enamel NN N
etching VBG N
. . N

1-year JJ N
results NNS N
. . N

PURPOSE NNP N
To TO N
compare VB N
the DT N
performance NN N
of IN N
partial JJ N
ceramic JJ N
crowns NNS N
( ( N
PCCs NNP N
) ) N
inserted VBD N
with IN N
RelyX NNP N
Unicem NNP N
( ( N
RXU NNP N
) ) N
either CC N
with IN N
( ( N
RXU+E NNP N
) ) N
or CC N
without IN N
( ( N
RXU NNP N
) ) N
selective VBP N
enamel JJ N
etching NN N
. . N

METHODS NNP N
34 CD N
patients NNS N
( ( N
15 CD N
male NN N
, , N
19 CD N
female NN N
) ) N
participated VBD N
in IN N
the DT N
investigation NN N
, , N
with IN N
a DT N
total NN N
of IN N
68 CD N
PCC NNP N
restorations NNS N
. . N

In IN N
each DT N
patient NN N
, , N
one CD N
PCC NNP N
was VBD N
randomly RB N
assigned VBN N
to TO N
insertion NN N
with IN N
RXU NNP N
, , N
the DT N
second JJ N
PCC NNP N
was VBD N
assigned VBN N
to TO N
insertion NN N
with IN N
RXU+E NNP N
. . N

The DT N
PCCs NNPS N
were VBD N
CAD/CAM NNP N
fabricated VBD N
using VBG N
the DT N
Cerec NNP N
3 CD N
system NN N
. . N

RXU NN N
: : N
25 CD N
PCCs NNP N
were VBD N
placed VBN N
in IN N
molars NNS N
, , N
nine CD N
in IN N
premolars NNS N
. . N

RXU+E NN N
: : N
26 CD N
PCCs NNP N
were VBD N
placed VBN N
in IN N
molars NNS N
, , N
eight CD N
in IN N
premolars NNS N
. . N

The DT N
restorations NNS N
were VBD N
clinically RB N
rated VBN N
using VBG N
modified VBN N
United NNP N
States NNPS N
Public NNP N
Health NNP N
Service NNP N
( ( N
USPHS NNP N
) ) N
criteria NNS N
at IN N
baseline NN N
, , N
6 CD N
and CC N
12 CD N
months NNS N
after IN N
placement NN N
. . N

The DT N
median JJ N
patient NN N
age NN N
was VBD N
41 CD N
years NNS N
( ( N
24-59 CD N
years NNS N
) ) N
. . N

The DT N
median JJ N
( ( N
25-75 CD N
% NN N
) ) N
PBI NNP N
was VBD N
6 CD N
% NN N
( ( N
3-9 CD N
% NN N
) ) N
. . N

RESULTS NNP N
All DT N
patients NNS N
were VBD N
available JJ N
for IN N
the DT N
three CD N
recall NN N
appointments NNS N
. . N

One CD N
PCC NNP N
( ( N
RXU NNP N
) ) N
debonded VBD N
after IN N
11 CD N
months NNS N
in IN N
situ NN N
, , N
one CD N
PCC NNP N
( ( N
RXU+E NNP N
) ) N
fractured VBD N
after IN N
12 CD N
months NNS N
in IN N
situ NN N
. . N

Both DT N
restorations NNS N
had VBD N
to TO N
be VB N
replaced VBN N
. . N

At IN N
the DT N
12 CD N
months NNS N
recall RB N
, , N
66 CD N
of IN N
68 CD N
controlled JJ N
restorations NNS N
were VBD N
functional JJ N
without IN N
need NN N
of IN N
replacement NN N
. . N

The DT N
evaluation NN N
using VBG N
USHPS NNP N
criteria NNS N
revealed VBD N
a DT N
significant JJ N
decrease NN N
of IN N
alfa JJ N
ratings NNS N
over IN N
time NN N
with IN N
respect NN N
to TO N
criteria VB N
marginal JJ N
adaptation NN N
and CC N
marginal JJ N
discoloration NN N
. . N

No DT N
statistically RB N
significant JJ N
differences NNS N
between IN N
the DT N
two CD N
luting VBG N
techniques NNS N
, , N
RXU NNP N
and CC N
RXU+E NNP N
, , N
we PRP N
reobserved VBD N
during IN N
the DT N
observation NN N
period NN N
of IN N
1 CD N
year NN N
. . N

Within IN N
the DT N
limitations NNS N
of IN N
the DT N
present JJ N
study NN N
, , N
adhesive JJ N
luting NN N
with IN N
RXU NNP N
with IN N
or CC N
without IN N
selective JJ N
enamel NN N
etching NN N
can MD N
be VB N
recommended VBN N
. . N

-DOCSTART- -X- O O 16739368

[ JJ N
Rapidity NNP N
of IN N
pain NN N
relief NN N
, , N
medication NN N
requirement NN N
and CC N
patient JJ N
satisfaction NN N
with IN N
reflux JJ N
treatment NN N
in IN N
the DT N
physician NN N
's POS N
office NN N
] NN N
. . N

Treatment NN N
of IN N
gastroesophageal NN 4_p
reflux NN 4_p
disease NN 4_p
( ( N
GERD NNP 4_p
) ) N
with IN N
proton NN N
pump NN N
inhibitors NNS N
was VBD N
investigated VBN N
in IN N
three CD N
controlled VBD N
prospective JJ N
, , N
randomized JJ N
open JJ N
studies NNS N
. . N

Lansoprazole NNP N
, , N
omeprazole JJ N
MUPS NNP N
and CC N
esomeprazole NN N
were VBD N
compared VBN N
under IN N
doctor NN N
's POS N
office NN N
conditions NNS N
. . N

The DT N
outcomes NNS N
of IN N
interest NN N
were VBD N
the DT N
rapidity NN N
of IN N
pain NN N
relief NN N
achieved VBN N
with IN N
a DT N
single JJ N
dose NN N
, , N
effectiveness NN N
and CC N
patient JJ N
satisfaction NN N
with IN N
on IN N
demand NN N
therapy NN N
. . N

In IN N
the DT N
first JJ N
study NN N
, , N
180 CD N
patients NNS N
with IN N
chronic JJ 4_p
and CC 4_p
prolonged JJ 4_p
episodes NNS 4_p
of IN 4_p
reflux NN 4_p
were VBD N
investigated VBN N
. . N

Time NN N
to TO N
pain VB N
relief NN N
following VBG N
a DT N
single JJ N
dose NN N
was VBD N
1.1 CD N
+/- JJ N
0.8 CD N
hours NNS N
with IN N
30 CD N
mg NNS N
lansoprazole JJ N
, , N
3.0 CD N
+/- JJ N
2.5 CD N
hours NNS N
with IN N
20 CD N
mgomeprazole JJ N
MUPS NNP N
and CC N
2.1 CD N
+/- JJ N
1.2 CD N
hours NNS N
with IN N
40 CD N
mg NNS N
esomeprazole JJ N
. . N

Studies NNS N
2 CD N
and CC N
3 CD N
were VBD N
designed VBN N
as IN N
cross-over NN N
studies NNS N
intended VBN N
to TO N
investigate VB N
drug NN N
consumption NN N
. . N

In IN N
study NN N
2 CD N
, , N
the DT N
amount NN N
of IN N
lansoprazole NN N
consumed VBN N
was VBD N
approximately RB N
50 CD N
% NN N
less JJR N
than IN N
that DT N
of IN N
omeprazole NN N
, , N
and CC N
this DT N
translated VBN N
to TO N
81 CD N
% NN N
patient JJ N
satisfaction NN N
with IN N
lansoprazole JJ N
compared VBN N
with IN N
only RB N
9.5 CD N
% NN N
for IN N
omeprazole NN N
. . N

In IN N
study NN N
3 CD N
comparing VBG N
lansoprazole NN N
and CC N
esomeprazole NN N
, , N
consumption NN N
of IN N
the DT N
former JJ N
was VBD N
85 CD N
% NN N
that WDT N
of IN N
the DT N
latter NN N
. . N

58 CD N
% NN N
of IN N
the DT N
patients NNS N
opted VBD N
to TO N
continuetreatment VB N
with IN N
lansoprazole NN N
, , N
compared VBN N
with IN N
only RB N
25 CD N
% NN N
in IN N
the DT N
case NN N
of IN N
esomeprazole NN N
. . N

The DT N
appreciably RB N
greater JJR N
patient JJ N
satisfaction NN N
with IN N
lansoprazole NN N
was VBD N
due JJ N
tothe NN N
faster RBR N
pain NN N
relief NN N
achieved VBN N
with IN N
this DT N
drug NN N
. . N

-DOCSTART- -X- O O 19047882

Acceptability NNP N
of IN N
an DT N
Electronic JJ N
Self-Report JJ N
Assessment NNP N
Program NNP N
for IN N
patients NNS N
with IN N
cancer NN N
. . N

Eliciting VBG N
symptom NN N
and CC N
quality NN N
of IN N
life NN N
information NN N
from IN N
patients NNS N
is VBZ N
an DT N
important JJ N
component NN N
of IN N
medical JJ N
and CC N
nursing NN N
care NN N
processes VBZ N
. . N

Traditionally RB N
, , N
this DT N
information NN N
has VBZ N
been VBN N
collected VBN N
with IN N
paper NN N
and CC N
pencil NN N
. . N

However RB N
, , N
this DT N
approach NN N
presents VBZ N
several JJ N
barriers NNS N
, , N
including VBG N
delays NNS N
in IN N
receiving VBG N
information NN N
, , N
difficulty NN N
in IN N
integrating VBG N
responses NNS N
with IN N
electronic JJ N
records NNS N
, , N
and CC N
the DT N
time NN N
required VBN N
to TO N
manually RB N
score VB N
questionnaires NNS N
for IN N
measurement NN N
purposes NNS N
. . N

One CD N
solution NN N
that WDT N
addresses VBZ N
many JJ N
of IN N
these DT N
barriers NNS N
is VBZ N
the DT N
adoption NN N
of IN N
computerized JJ N
screening NN N
for IN N
symptom NN N
and CC N
quality-of-life JJ N
information NN N
. . N

This DT N
research NN N
explored VBD N
the DT N
acceptability NN N
of IN N
asking VBG N
symptom NN N
and CC N
quality-of-life JJ N
questions NNS N
using VBG N
the DT N
Electronic NNP N
Self NNP N
Report NNP N
Assessment-Cancer NNP N
program NN N
on IN N
wireless NN N
laptops NNS N
equipped VBN N
with IN N
touch-screen JJ N
format NN N
. . N

Acceptability NNP N
data NNS N
were VBD N
explored VBN N
with IN N
respect NN N
to TO N
whether IN N
any DT N
differences NNS N
may MD N
be VB N
attributed VBN N
to TO N
demographics NNS N
and CC N
symptom NN N
and CC N
quality-of-life NN N
levels NNS N
, , N
such JJ N
as IN N
depression NN N
and CC N
cognitive JJ N
and CC N
emotional JJ N
functioning NN N
. . N

This DT N
evaluation NN N
used VBN N
descriptive JJ N
and CC N
univariate JJ N
statistics NNS N
to TO N
examine VB N
data NNS N
from IN N
342 CD 4_p
participants NNS 4_p
from IN 4_p
the DT 4_p
ongoing JJ 4_p
ESRA-C NNP 4_p
randomized VBD 4_p
clinical JJ 4_p
trial NN 4_p
. . 4_p

Research NN N
participants NNS N
for IN N
the DT N
ESRA-C NNP N
study NN N
were VBD N
recruited VBN N
from IN N
the DT N
Seattle NNP N
Cancer NNP N
Care NNP N
Alliance NNP N
, , N
a DT N
consortium NN N
among IN N
the DT N
University NNP N
of IN N
Washington NNP N
Medical NNP N
Center NNP N
, , N
Fred NNP N
Hutchinson NNP N
Cancer NNP N
Research NNP N
Center NNP N
, , N
and CC N
Children NNP N
's POS N
Hospital NNP N
and CC N
Regional NNP N
Medical NNP N
Center NNP N
in IN N
Seattle NNP N
, , N
WA NNP N
. . N

The DT N
sample NN N
consisted VBD N
of IN N
342 CD N
adult NN N
participants NNS N
who WP N
completed VBD N
both DT N
baseline NN N
and CC N
follow-up JJ N
survey NN N
sessions NNS N
. . N

Medical NNP N
oncology NN N
represented VBD N
the DT N
largest JJS N
recruitment NN 4_p
group NN 4_p
( ( N
45.3 CD N
% NN N
) ) N
, , N
followed VBN N
by IN N
stem NN N
cell NN N
transplant NN N
( ( N
34.5 CD N
% NN N
) ) N
and CC N
radiation NN N
oncology NN N
( ( N
20.2 CD N
% NN N
) ) N
. . N

The DT N
primary JJ N
finding NN N
was VBD N
that IN N
patients NNS N
were VBD N
generally RB N
able JJ N
to TO N
use VB N
ESRA-C JJ N
quickly RB N
and CC N
without IN N
difficulty NN N
in IN N
a DT N
real-world JJ N
clinical JJ N
setting NN N
and CC N
that IN N
they PRP N
were VBD N
overall JJ N
quite RB N
satisfied VBN N
with IN N
the DT N
ESRA-C JJ N
program NN N
. . N

Significant JJ N
differences NNS N
were VBD N
found VBN N
in IN N
several JJ N
acceptability NN N
areas NNS N
with IN N
respect NN N
to TO N
demographics NNS N
and CC N
quality NN N
of IN N
life NN N
measures NNS N
such JJ N
as IN N
age NN N
, , N
sex NN N
, , N
and CC N
severe JJ N
distress NN N
. . N

This DT N
analysis NN N
confirms VBZ N
that IN N
the DT N
ESRA-C NNP N
application NN N
for IN N
collecting VBG N
symptom NN N
and CC N
quality NN N
of IN N
life NN N
information NN N
is VBZ N
easy JJ N
for IN N
patients NNS N
to TO N
use VB N
and CC N
acceptable JJ N
across IN N
a DT N
range NN N
of IN N
user JJ N
characteristics NNS N
. . N

We PRP N
intend VBP N
to TO N
build VB N
on IN N
our PRP$ N
work NN N
by IN N
using VBG N
the DT N
survey NN N
platform NN N
in IN N
other JJ N
modalities NNS N
while IN N
ensuring VBG N
that IN N
the DT N
patient NN N
's POS N
preferences NNS N
are VBP N
considered VBN N
at IN N
all DT N
times NNS N
. . N

-DOCSTART- -X- O O 20940688

Patients NNS N
appreciation NN N
for IN N
information NN N
on IN N
anesthesia NN N
and CC N
anxiolysis NN N
in IN N
dentistry NN N
. . N

AIM NNP N
The DT N
research NN N
regards VBZ N
information NN N
on IN N
anesthesia NN N
to TO N
patients NNS N
undergoing VBG N
oral JJ N
surgery NN N
. . N

Every DT N
patient NN N
evaluated VBD N
the DT N
information NN N
received VBD N
at IN N
the DT N
end NN N
of IN N
the DT N
preoperative JJ N
visit NN N
and CC N
in IN N
the DT N
postoperative JJ N
period NN N
. . N

METHODS NNP N
One CD N
hundred-fifty JJ N
dental JJ N
patients NNS N
were VBD N
asked VBN N
about IN N
the DT N
most RBS N
appreciated JJ N
information NN N
received VBN N
in IN N
the DT N
preoperative JJ N
visit NN N
on IN N
the DT N
anxiolytic JJ N
technique NN N
, , N
local JJ N
anesthesia NN N
and CC N
treatment NN N
of IN N
the DT N
perioperative JJ N
pain NN N
. . N

Afterwards IN N
the DT N
patients NNS N
had VBD N
to TO N
report VB N
on IN N
their PRP$ N
reaction NN N
to TO N
the DT N
content NN N
of IN N
the DT N
preoperative JJ N
visit NN N
and CC N
information NN N
quality NN N
. . N

On IN N
a DT N
phone NN N
interview NN N
they PRP N
had VBD N
to TO N
evaluate VB N
their PRP$ N
appreciation NN N
of IN N
the DT N
anxiolytic JJ N
technique NN N
, , N
their PRP$ N
perception NN N
during IN N
loco-regional JJ N
anesthesia NN N
and CC N
incidence NN N
of IN N
pain NN N
and CC N
edema NN N
. . N

RESULTS VB N
The DT N
most RBS N
appreciated JJ N
details NNS N
were VBD N
those DT N
on IN N
the DT N
intervention NN N
, , N
pharmacologic JJ N
treatment NN N
, , N
postoperative JJ N
complicances NNS N
, , N
postoperative JJ N
pain NN N
and CC N
operative JJ N
competence NN N
; : N
less CC N
appreciated JJ N
were VBD N
those DT N
on IN N
loco-regional JJ N
anesthesia NN N
, , N
duration NN N
of IN N
the DT N
intervention NN N
, , N
anxiolytic JJ N
techniques NNS N
, , N
hospital JJ N
reception NN N
and CC N
permanence NN N
in IN N
the DT N
hospital NN N
. . N

Ninety-eight JJ N
percent NN N
of IN N
the DT N
patients NNS N
considered VBN N
to TO N
have VB N
been VBN N
adequately RB N
informed VBN N
on IN N
a DT N
context NN N
judged VBN N
to TO N
be VB N
extraordinary JJ N
( ( N
99.3 CD N
% NN N
) ) N
, , N
96.6 CD N
% NN N
indicated VBD N
the DT N
information NN N
as IN N
necessary JJ N
, , N
98.6 CD N
% NN N
appreciated VBD N
the DT N
treatment NN N
of IN N
the DT N
intraoperative JJ N
and CC N
postoperative JJ N
( ( N
99.3 CD N
% NN N
) ) N
pain NN N
and CC N
99.3 CD N
% NN N
the DT N
anxiolytic JJ N
treatment NN N
. . N

On IN N
the DT N
telephone NN N
interview NN N
, , N
100 CD N
% NN N
of IN N
patients NNS N
expressed VBN N
satisfaction NN N
for IN N
the DT N
experienced JJ N
intraoperative JJ N
tranquillity NN N
, , N
91.3 CD N
% NN N
complained VBD N
for IN N
not RB N
having VBG N
received VBN N
in IN N
the DT N
past NN N
a DT N
similar JJ N
preoperative JJ N
visit NN N
, , N
99.3 CD N
% NN N
wished VBD N
a DT N
diffused JJ N
application NN N
of IN N
the DT N
information NN N
. . N

The DT N
loco-regional JJ N
anesthesia NN N
was VBD N
associated VBN N
to TO N
psychological JJ N
detachment NN N
in IN N
84 CD N
% NN N
of IN N
the DT N
cases NNS N
and CC N
the DT N
incidence NN N
of IN N
postoperative JJ N
pain NN N
was VBD N
of IN N
36 CD N
% NN N
. . N

CONCLUSION NNP N
The DT N
information NN N
on IN N
the DT N
anxiolytic JJ N
techniques NNS N
, , N
loco-regional JJ N
anesthesia NN N
, , N
treatment NN N
of IN N
perioperative JJ N
pain NN N
and CC N
postoperative JJ N
distress NN N
was VBD N
enthusiastically RB N
accepted VBN N
and CC N
albeit VBN N
initially RB N
induced JJ N
feelings NNS N
of IN N
astonishment NN N
resulted VBD N
to TO N
be VB N
appreciated VBN N
and CC N
preferred VBN N
in IN N
the DT N
whole NN N
of IN N
the DT N
patients NNS N
. . N

-DOCSTART- -X- O O 7134226

Inhibition NN N
of IN N
spontaneous JJ N
platelet NN N
aggregation NN N
and CC N
adhesion NN N
by IN N
indobufen NN N
( ( N
K NNP N
3920 CD N
) ) N
. . N

A DT N
randomized JJ N
, , N
double-blind JJ N
crossover NN N
study NN N
on IN N
platelet NN N
, , N
coagulation NN N
and CC N
fibrinolysis NN N
function NN N
tests NNS N
. . N

In IN N
a DT N
randomized JJ N
double-blind NN N
crossover NN N
study NN N
in IN N
12 CD N
patients NNS N
with IN N
atherosclerotic JJ 4_p
disease NN 4_p
, , N
the DT N
effect NN N
of IN N
2 CD N
dosages NNS N
( ( N
100 CD N
and CC N
200 CD N
mg NN N
twice RB N
daily RB N
) ) N
of IN N
indobufen NN N
, , N
a DT N
new JJ N
synthetic JJ N
inhibition NN N
of IN N
platelet NN N
aggregation NN N
, , N
on IN N
some DT N
platelet NN N
functions NNS N
, , N
coagulation NN N
and CC N
fibrinolysis NN N
tests NNS N
was VBD N
investigated VBN N
. . N

Regardless NNP N
of IN N
the DT N
dosage NN N
used VBN N
, , N
indobufen NN N
was VBD N
shown VBN N
to TO N
induce VB N
a DT N
prompt JJ N
normalization NN N
of IN N
the DT N
enhanced JJ N
platelet NN N
aggregation NN N
of IN N
these DT N
patients NNS N
. . N

The DT N
effect NN N
lasted VBD N
for IN N
the DT N
entire JJ N
period NN N
of IN N
drug NN N
administration NN N
and CC N
in IN N
50 CD N
% NN N
of IN N
patients NNS N
a DT N
normal JJ N
platelet NN N
aggregation NN N
was VBD N
maintained VBN N
until IN N
the DT N
fourth JJ N
day NN N
after IN N
discontinuation NN N
of IN N
the DT N
drug NN N
. . N

Indobufen NNP N
was VBD N
also RB N
able JJ N
to TO N
reduce VB N
platelet NN N
adhesiveness NN N
and CC N
to TO N
lengthen VB N
bleeding NN N
time NN N
, , N
especially RB N
when WRB N
the DT N
higher JJR N
dosage NN N
was VBD N
used VBN N
. . N

-DOCSTART- -X- O O 7699494

A DT N
comparison NN N
of IN N
1- JJ N
and CC N
3-minute JJ N
lockout NN N
periods NNS N
during IN N
patient-controlled JJ 4_p
sedation NN 4_p
with IN 4_p
midazolam NN 4_p
. . 4_p

PURPOSE VB N
The DT N
maximum JJ N
effect NN N
of IN N
midazolam NN N
injected VBN N
intravenously RB N
occurs VBZ N
in IN N
about IN N
3 CD N
minutes NNS N
. . N

Patient-controlled JJ N
sedation NN N
carried VBD N
out RP N
with IN N
1-mg JJ N
increments NNS N
of IN N
midazolam NN N
at IN N
3-minute JJ N
intervals NNS N
provides VBZ N
comparable JJ N
conditions NNS N
to TO N
that DT N
of IN N
doctor-controlled JJ N
sedation NN N
carried VBD N
out RP N
with IN N
1-mg JJ N
increments NNS N
at IN N
1-minute JJ N
intervals NNS N
, , N
except IN N
for IN N
the DT N
longer JJR N
duration NN N
taken VBN N
for IN N
the DT N
patients NNS N
to TO N
achieve VB N
satisfactory JJ N
sedation NN N
prior RB N
to TO N
surgery NN N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
find VB N
out RP N
how WRB N
safe JJ N
it PRP N
would MD N
be VB N
to TO N
shorten VB N
the DT N
interval NN N
of IN N
increments NNS N
of IN N
midazolam NN N
to TO N
1 CD N
minute NN N
in IN N
patient-controlled JJ N
sedation NN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
In IN N
a DT N
randomized VBN N
crossover NN N
study NN N
, , N
26 CD N
patients NNS N
undergoing JJ N
bilateral JJ 4_p
lower JJR 4_p
third JJ 4_p
molar JJ 4_p
surgery NN 4_p
at IN N
two CD N
visits NNS N
had VBD N
patient-controlled JJ N
sedation NN N
with IN N
1 CD N
mg NNS N
midazolam JJ N
increments NNS N
at IN N
1-minute JJ N
or CC N
3-minute JJ N
intervals NNS N
at IN N
one CD N
visit NN N
and CC N
the DT N
alternative NN N
at IN N
the DT N
other JJ N
visit NN N
. . N

RESULTS VB N
The DT N
time NN N
taken VBN N
for IN N
patients NNS N
to TO N
achieve VB N
a DT N
degree NN N
of IN N
sedation NN N
that IN N
they PRP N
thought VBD N
was VBD N
sufficient JJ N
to TO N
tolerate VB N
the DT N
surgery NN N
was VBD N
significantly RB N
longer RBR N
when WRB N
the DT N
increment NN N
interval NN N
was VBD N
3 CD N
minutes NNS N
( ( N
t JJ N
= NNP N
-4.8 NNP N
; : N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

Both DT N
techniques NNS N
provided VBD N
good JJ N
operating NN N
conditions NNS N
, , N
stable JJ N
vital JJ N
signs NNS N
, , N
mild NN N
to TO N
moderate VB N
sedation NN N
, , N
without IN N
loss NN N
of IN N
verbal JJ N
contact NN N
. . N

CONCLUSION VB N
A DT N
significant JJ N
majority NN N
preferred VBD N
the DT N
sedation NN N
technique NN N
with IN N
1-minute JJ N
increment NN N
intervals NNS N
( ( N
chi VB N
2 CD N
= JJ N
4.6 CD N
; : N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

-DOCSTART- -X- O O 19368912

What WP N
is VBZ N
the DT N
optimum JJ N
maximal JJ N
gonadotropin NN N
dosage NN N
used VBN N
in IN N
microdose JJ 4_p
flare-up JJ 4_p
cycles NNS 4_p
in IN 4_p
poor JJ 4_p
responders NNS 4_p
? . N
OBJECTIVE NNP N
To TO N
find VB N
out RP N
the DT N
optimum JJ N
maximal JJ N
dosage NN N
of IN N
recombinant JJ N
follicle NN N
stimulating VBG N
hormone NN N
( ( N
rFSH NN N
) ) N
in IN N
microdose JJ N
gonadotropin-releasing JJ N
hormone NN N
analog NN N
( ( N
GnRH-a NNP N
) ) N
flare NN N
cycles NNS N
in IN N
poor JJ N
responders NNS N
. . N

DESIGN NNP N
Prospective NNP N
randomized VBD N
study NN N
. . N

SETTING NNP N
Private NNP N
infertility NN N
clinic NN N
. . N

PATIENT NNP N
( ( N
S NNP N
) ) N
A NNP N
total NN N
of IN N
119 CD N
women NNS N
were VBD N
taken VBN N
into IN N
the DT N
study NN N
. . N

INTERVENTION NNP N
( ( N
S NNP N
) ) N
The DT N
study NN N
group NN N
underwent VBD N
a DT N
microdose JJ N
protocol NN N
with IN N
a DT N
GnRH-agonist JJ N
followed VBN N
by IN N
rFSH JJ N
administration NN N
. . N

On IN N
the DT N
third JJ N
day NN N
of IN N
GnRH-a NNP N
administration NN N
, , N
119 CD N
patients NNS N
were VBD N
randomized VBN N
in IN N
three CD N
groups NNS N
to TO N
receive VB N
daily JJ N
fixed VBN N
doses NNS N
of IN N
300 CD N
IU NNP N
of IN N
rFSH NN N
( ( N
group NN N
A NNP N
, , N
n JJ N
= NNP N
38 CD N
) ) N
, , N
or CC N
450 CD N
IU NNP N
of IN N
rFSH NN N
( ( N
group NN N
B NNP N
, , N
n JJ N
= NNP N
39 CD N
) ) N
, , N
or CC N
600 CD N
IU NNP N
of IN N
rFSH NN N
( ( N
group NN N
C NNP N
, , N
n JJ N
= NNP N
42 CD N
) ) N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURE NNP N
( ( N
S NNP N
) ) N
Peak NNP N
E NNP N
( ( N
2 CD N
) ) N
levels NNS N
, , N
days NNS N
of IN N
stimulation NN N
with IN N
rFSH NN N
, , N
total JJ N
rFSH NN N
dosage NN N
, , N
total JJ N
number NN N
of IN N
oocytes NNS N
retrieved VBN N
, , N
M2 NNP N
oocytes VBZ N
retrieved VBN N
, , N
total JJ N
number NN N
of IN N
embryos NN N
, , N
number NN N
of IN N
embryos NN N
transferred VBN N
, , N
number NN N
of IN N
Grade-1 NNP N
embryos NN N
transferred VBD N
, , N
clinical JJ N
pregnancy NN N
rate NN N
( ( N
positive JJ N
fetal JJ N
cardiac JJ N
activity NN N
) ) N
, , N
and CC N
cancellation NN N
rates NNS N
of IN N
stimulation NN N
and CC N
embryo NN N
transfer NN N
. . N

RESULT NNP N
( ( N
S NNP N
) ) N
Clinical NNP N
pregnancy NN N
rates NNS N
were VBD N
13.1 CD N
% NN N
, , N
15.3 CD N
% NN N
, , N
and CC N
16.1 CD N
% NN N
for IN N
group NN N
A NNP N
, , N
group NN N
B NNP N
, , N
and CC N
group NN N
C NNP N
, , N
respectively RB N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
the DT N
age NN N
, , N
peak JJ N
serum NN N
E NNP N
( ( N
2 CD N
) ) N
concentration NN N
, , N
days NNS N
of IN N
stimulation NN N
with IN N
rFSH NN N
, , N
total JJ N
number NN N
of IN N
M2 NNP N
oocytes VBZ N
retrieved VBN N
, , N
number NN N
of IN N
embryos NN N
transferred VBN N
, , N
clinical JJ N
pregnancy NN N
rates NNS N
, , N
and CC N
cancellation NN N
rates NNS N
of IN N
stimulation NN N
and CC N
embryo NN N
transfer NN N
between IN N
the DT N
three CD N
groups NNS N
except IN N
for IN N
total JJ N
rFSH JJ N
dosage NN N
. . N

CONCLUSION NNP N
( ( N
S NNP N
) ) N
There EX N
is VBZ N
no DT N
need NN N
to TO N
use VB N
doses NNS N
above IN N
300 CD N
IU NNP N
of IN N
rFSH NN N
to TO N
increase VB N
the DT N
pregnancy NN N
rate NN N
in IN N
microdose JJ N
cycles NNS N
. . N

In IN N
addition NN N
, , N
because IN N
the DT N
duration NN N
of IN N
stimulation NN N
does VBZ N
not RB N
differ VB N
between IN N
the DT N
groups NNS N
, , N
the DT N
usage NN N
of IN N
300 CD N
IU NNP N
rFSH NN N
in IN N
microdose JJ N
cycles NNS N
results NNS N
in IN N
less JJR N
total JJ N
amount NN N
of IN N
rFSH NN N
consumed VBN N
in IN N
a DT N
cycle NN N
compared VBN N
with IN N
higher JJR N
dosages NNS N
, , N
and CC N
this DT N
would MD N
obviously RB N
cost VB N
less JJR N
money NN N
to TO N
the DT N
patients NNS N
. . N

-DOCSTART- -X- O O 5573167

Response JJ N
latencies NNS N
to TO N
auditory VB N
stimuli NNS N
in IN N
autistic JJ N
children NNS N
engaged VBN N
in IN N
self-stimulatory JJ 4_p
behavior NN 4_p
. . N

-DOCSTART- -X- O O 3556337

Effects NNS N
of IN N
nifedipine NN N
on IN N
gastric JJ 4_p
acid JJ 4_p
secretion NN 4_p
and CC N
gastrin NN 4_p
release NN 4_p
in IN N
man NN N
. . N

As IN N
calcium NN N
is VBZ N
important JJ N
in IN N
the DT N
regulation NN N
of IN N
gastric JJ N
acid JJ N
secretion NN N
and CC N
gastrin NN N
release NN N
, , N
we PRP N
have VBP N
examined VBN N
the DT N
effect NN N
of IN N
the DT N
calcium NN N
antagonist NN N
nifedipine NN N
on IN N
these DT N
processes NNS N
in IN N
man NN N
. . N

Nifedipine CC N
30 CD N
mg NNS N
orally RB N
inhibited VBN N
basal NN N
acid NN N
output NN N
by IN N
37 CD N
% NN N
( ( N
p NN N
less JJR N
than IN N
0.025 CD N
) ) N
and CC N
that IN N
stimulated VBN N
by IN N
low JJ N
infusion NN N
rates NNS N
of IN N
pentagastrin NN N
-- : N
that WDT N
is VBZ N
, , N
0.031 CD N
and CC N
0.062 CD N
microgram/kg/h NN N
by IN N
44 CD N
% NN N
( ( N
p JJ N
= NNP N
0.05 CD N
) ) N
and CC N
39 CD N
% NN N
( ( N
p NN N
less JJR N
than IN N
0.02 CD N
) ) N
respectively RB N
. . N

On IN N
increasing VBG N
the DT N
pentagastrin JJ N
infusion NN N
rate NN N
the DT N
inhibition NN N
was VBD N
surmounted VBN N
suggesting VBG N
it PRP N
was VBD N
competitive JJ N
in IN N
type NN N
. . N

Nifedipine NNP N
did VBD N
not RB N
affect VB N
basal NN N
or CC N
Oxo NNP N
meal NN N
stimulated VBD N
gastrin JJ N
concentrations NNS N
in IN N
normal JJ N
volunteers NNS N
nor CC N
did VBD N
it PRP N
affect VB N
resting VBG N
serum JJ N
gastrin NN N
or CC N
calcium NN N
stimulated JJ N
increase NN N
in IN N
gastrin NN N
in IN N
a DT N
single JJ N
patient NN N
with IN N
Zollinger-Ellison NNP 4_p
syndrome NN 4_p
. . N

These DT N
findings NNS N
are VBP N
consistent JJ N
with IN N
the DT N
transmembrane NN N
flux NN N
of IN N
calcium NN N
ions NNS N
being VBG N
involved VBN N
in IN N
basal NN N
and CC N
pentagastrin NN 4_p
stimulated VBD 4_p
acid JJ 4_p
secretion NN 4_p
in IN N
man NN N
. . N

-DOCSTART- -X- O O 24266796

Stimulus JJ N
over-selectivity NN N
in IN N
temporal JJ N
brain NN N
injury NN N
: : N
mindfulness NN N
as IN N
a DT N
potential JJ N
intervention NN N
. . N

OBJECTIVE IN N
The DT N
current JJ N
study NN N
aimed VBD N
to TO N
investigate VB N
the DT N
impact NN N
of IN N
brief JJ N
mindfulness JJ N
training NN N
on IN N
the DT N
performance NN N
of IN N
a DT N
sample NN N
of IN N
patients NNS N
with IN N
TBI NNP N
in IN N
an DT N
over-selectivity JJ N
task NN N
. . N

PARTICIPANTS VB N
Twenty-four JJ N
patients NNS N
who WP N
had VBD N
suffered VBN N
TBI NNP N
and CC N
reported VBD N
problems NNS N
with IN N
focused JJ N
or CC N
sustained JJ N
attention NN N
. . N

METHOD NNP N
The DT N
study NN N
was VBD N
a DT N
between-subjects JJ N
design NN N
( ( N
mindfulness JJ N
intervention NN N
vs NNS N
control NN N
) ) N
with IN N
difference NN N
between IN N
number NN N
of IN N
most JJS N
and CC N
least JJS N
chosen JJ N
stimulus JJ N
selections NNS N
on IN N
an DT N
over-selectivity JJ N
task NN N
as IN N
the DT N
dependent JJ N
measure NN N
. . N

RESULTS VB N
The DT N
results NNS N
of IN N
this DT N
study NN N
indicated VBD N
that IN N
stimulus JJ N
over-selectivity NN N
was VBD N
present JJ N
in IN N
a DT N
group NN N
of IN N
patients NNS N
with IN N
TBI NNP N
. . N

However RB N
, , N
the DT N
level NN N
of IN N
emergent JJ N
over-selectivity NN N
was VBD N
significantly RB N
reduced VBN N
by IN N
a DT N
mindfulness NN N
induction NN N
when WRB N
compared VBN N
to TO N
a DT N
no- JJ N
intervention NN N
control NN N
group NN N
. . N

CONCLUSIONS VB N
The DT N
findings NNS N
are VBP N
discussed VBN N
in IN N
terms NNS N
of IN N
the DT N
efficacy NN N
of IN N
mindfulness NN N
training NN N
in IN N
reducing VBG N
TBI-related JJ N
cognitive JJ N
deficits NNS N
. . N

-DOCSTART- -X- O O 15810908

B-domain NNP N
deleted VBD N
recombinant JJ N
factor NN N
VIII NNP N
preparations NNS N
are VBP N
bioequivalent JJ N
to TO N
a DT N
monoclonal JJ N
antibody NN N
purified VBD N
plasma-derived JJ N
factor NN N
VIII NNP N
concentrate NN N
: : N
a DT N
randomized JJ N
, , N
three-way JJ N
crossover NN N
study NN N
. . N

BACKGROUND NNP N
Deletion NNP N
of IN N
the DT N
B-domain NNP N
of IN N
recombinant JJ N
blood NN N
coagulation NN N
factor NN N
VIII NNP N
( ( N
BDDrFVIII NNP N
) ) N
increases VBZ N
the DT N
manufacturing VBG N
yield NN N
of IN N
the DT N
product NN N
but CC N
does VBZ N
not RB N
impair VB N
in IN N
vitro NN N
or CC N
in IN N
vivo JJ N
functionality NN N
. . N

BDDrFVIII NNP N
( ( N
ReFacto NNP N
) ) N
has VBZ N
been VBN N
developed VBN N
with IN N
the DT N
additional JJ N
benefit NN N
of IN N
being VBG N
formulated VBN N
without IN N
human JJ N
albumin NN N
. . N

OBJECTIVE CC N
The DT N
primary JJ N
objective NN N
of IN N
this DT N
three-way JJ N
crossover-design NN N
study NN N
was VBD N
to TO N
compare VB N
the DT N
pharmacokinetic JJ N
( ( N
PK NNP N
) ) N
parameters NNS N
of IN N
two CD N
BDDrFVIII NNP N
formulations NNS N
( ( N
one CD N
reconstituted VBN N
with IN N
5 CD N
mL NNS N
of IN N
sterile JJ N
water NN N
, , N
the DT N
other JJ N
reconstituted VBD N
with IN N
4 CD N
mL NNS N
sodium JJ N
chloride RB N
0.9 CD N
% NN N
USP NNP N
) ) N
with IN N
those DT N
of IN N
a DT N
plasma-derived JJ N
, , N
full-length JJ N
FVIII NNP N
preparation NN N
( ( N
Hemofil NNP N
M NNP N
) ) N
in IN N
patients NNS N
with IN N
haemophilia PDT 4_p
A DT 4_p
to TO N
determine VB N
bioequivalence NN N
. . N

METHODS VB N
A NNP N
series NN N
of IN N
blood NN N
samples NNS N
were VBD N
collected VBN N
over IN N
a DT N
period NN N
of IN N
48 CD N
h NN N
after IN N
i.v NN N
. . N

administration NN N
of IN N
each DT N
of IN N
the DT N
FVIII NNP N
preparations NNS N
. . N

Plasma NNP N
FVIII NNP N
activity NN N
was VBD N
determined VBN N
using VBG N
a DT N
validated JJ N
chromogenic JJ N
substrate NN N
assay NN N
. . N

Plasma NNP N
FVIII NNP N
activity NN N
vs. FW N
time NN N
curves NNS N
was VBD N
characterized VBN N
for IN N
a DT N
standard JJ N
set NN N
of IN N
PK NNP N
parameter NN N
estimates NNS N
. . N

Two CD N
parameter NN N
estimates NNS N
, , N
the DT N
maximum JJ N
plasma JJ N
concentration NN N
( ( N
Cmax NNP N
) ) N
and CC N
the DT N
area NN N
under IN N
plasma JJ N
concentration NN N
vs. FW N
time NN N
curves NNS N
( ( N
AUCs NNP N
) ) N
, , N
were VBD N
used VBN N
to TO N
evaluate VB N
bioequivalence NN N
. . N

The DT N
two CD N
preparations NNS N
were VBD N
considered VBN N
bioequivalent NN N
if IN N
the DT N
90 CD N
% NN N
confidence NN N
intervals NNS N
for IN N
the DT N
ratio NN N
of IN N
geometric JJ N
means NNS N
for IN N
Cmax NNP N
and CC N
AUCs NNP N
fell VBD N
within IN N
the DT N
bioequivalence NN N
window NN N
of IN N
80 CD N
% NN N
to TO N
125 CD N
% NN N
. . N

RESULTS/CONCLUSION NNP N
Results NNP N
show VBP N
that IN N
each DT N
BDDrFVIII NNP N
formulation NN N
is VBZ N
bioequivalent JJ N
to TO N
Hemofil NNP N
M NNP N
and CC N
the DT N
two CD N
formulations NNS N
of IN N
BDDrFVIII NNP N
are VBP N
bioequivalent JJ N
to TO N
each DT N
other JJ N
. . N

-DOCSTART- -X- O O 18307223

Closure NN N
of IN N
the DT N
femoral JJ N
artery NN N
after IN N
cardiac JJ N
catheterization NN N
: : N
a DT N
comparison NN N
of IN N
Angio-Seal NNP N
, , N
StarClose NNP N
, , N
and CC N
manual JJ N
compression NN N
. . N

OBJECTIVES NNP N
To TO N
compare VB N
Angio-Seal NNP N
( ( N
AS NNP N
) ) N
and CC N
StarClose NNP N
( ( N
SC NNP N
) ) N
and CC N
manual JJ N
compression NN N
( ( N
MC NNP N
) ) N
on IN N
efficacy NN N
of IN N
hemostasis NN N
, , N
complication NN N
rate NN N
, , N
safety NN N
of IN N
early JJ N
mobilization NN N
, , N
and CC N
patient JJ N
comfort NN N
. . N

BACKGROUND NNP N
Closure NNP N
of IN N
the DT N
femoral JJ N
artery NN N
after IN N
cardiac JJ N
catheterization NN N
can MD N
be VB N
obtained VBN N
through IN N
different JJ N
methods NNS N
. . N

Today NN N
, , N
physicians NNS N
can MD N
choose VB N
from IN N
a DT N
number NN N
of IN N
different JJ N
devices NNS N
to TO N
achieve VB N
arterial JJ N
closure NN N
. . N

METHODS NNP N
In IN N
a DT N
prospective JJ N
trial NN N
450 CD N
patients NNS N
were VBD N
randomized VBN N
to TO N
AS NNP N
, , N
SC NNP N
, , N
or CC N
MC NNP N
. . N

Patients NNS N
were VBD N
mobilized VBN N
1 CD N
to TO N
2 CD N
hr NN N
after IN N
device NN N
placement NN N
, , N
and CC N
6 CD N
hr NN N
after IN N
MC NNP N
. . N

Data NNP N
were VBD N
collected VBN N
during IN N
hospital JJ N
admission NN N
and CC N
by IN N
telephone NN N
at IN N
one CD N
month NN N
after IN N
hospital JJ N
discharge NN N
. . N

RESULTS JJ N
Devices NNPS N
were VBD N
used VBN N
in IN N
138/150 CD N
allocated JJ N
to TO N
AS NNP N
and CC N
124/150 CD N
allocated VBN N
to TO N
SC NNP N
patients NNS N
( ( N
92 CD N
% NN N
vs. FW N
83 CD N
% NN N
, , N
P NNP N
= NNP N
0.015 CD N
) ) N
Patients NNS N
with IN N
MC NNP N
experienced VBD N
more JJR N
pain NN N
during IN N
sheath NN N
removal NN N
than IN N
patients NNS N
receiving VBG N
a DT N
device NN N
, , N
and CC N
rated VBD N
their PRP$ N
period NN N
of IN N
bed NN N
rest NN N
as IN N
less RBR N
comfortable JJ N
. . N

Oozing VBG N
and CC N
need VB N
for IN N
pressure NN N
bandage NN N
at IN N
the DT N
puncture NN N
site NN N
were VBD N
observed VBN N
in IN N
37 CD N
AS IN N
patients NNS N
and CC N
57 CD N
SC NNP N
patients NNS N
( ( N
25 CD N
% NN N
vs. FW N
38 CD N
% NN N
, , N
P NNP N
= NNP N
0.002 CD N
) ) N
. . N

Hematoma NNP N
occurred VBD N
in IN N
15 CD N
AS IN N
patients NNS N
, , N
in IN N
17 CD N
SC NNP N
patients NNS N
, , N
and CC N
in IN N
14 CD N
MC NNP N
patients NNS N
( ( N
11 CD N
vs. FW N
14 CD N
vs. FW N
9 CD N
% NN N
, , N
ns NN N
) ) N
. . N

CONCLUSION NNP N
There EX N
is VBZ N
no DT N
difference NN N
in IN N
safety NN N
between IN N
the DT N
three CD N
methods NNS N
of IN N
arterial JJ N
closure NN N
. . N

SC NNP N
was VBD N
more RBR N
often RB N
not RB N
used VBN N
or CC N
successfully RB N
deployed VBN N
. . N

SC JJ N
patients NNS N
more RBR N
often RB N
had VBD N
continuing VBG N
oozing VBG N
. . N

On IN N
patient JJ N
comfort NN N
, , N
closure NN N
devices NNS N
performed VBD N
better JJR N
than IN N
MC NNP N
. . N

Early JJ N
ambulation NN N
in IN N
patients NNS N
with IN N
a DT N
closure NN N
device NN N
is VBZ N
safe JJ N
. . N

AS NNP N
is VBZ N
the DT N
preferred JJ N
method NN N
of IN N
arterial JJ N
closure NN N
after IN N
cardiac JJ N
catheterization NN N
. . N

-DOCSTART- -X- O O 11331721

Repeated VBN N
doses NNS N
of IN N
porcine NN N
secretin NN N
in IN N
the DT N
treatment NN N
of IN N
autism NN 4_p
: : N
a DT N
randomized JJ N
, , N
placebo-controlled JJ N
trial NN N
. . N

BACKGROUND NNP N
AND CC N
OBJECTIVES NNP N
Anecdotal NNP N
reports NNS N
on IN N
the DT N
efficacy NN N
of IN N
secretin NN N
in IN N
autism NN N
raised VBN N
great JJ N
hopes NNS N
for IN N
the DT N
treatment NN N
of IN N
children NNS N
with IN N
this DT N
disorder NN N
. . N

Initial JJ N
single-dose JJ N
, , N
randomized VBN N
, , N
controlled VBN N
trials NNS N
failed VBD N
to TO N
demonstrate VB N
any DT N
therapeutic JJ N
effects NNS N
of IN N
secretin NN N
. . N

The DT N
present JJ N
study NN N
is VBZ N
the DT N
first JJ N
to TO N
test VB N
the DT N
outcome NN N
of IN N
repeated VBN N
doses NNS N
and CC N
to TO N
examine VB N
whether IN N
there EX N
is VBZ N
a DT N
subgroup NN N
of IN N
children NNS N
who WP N
are VBP N
more RBR N
likely JJ N
to TO N
achieve VB N
positive JJ N
effects NNS N
. . N

METHOD NNP N
Sixty-four JJ N
children NNS N
with IN N
autism NN N
( ( N
ages VBZ N
2-7 CD N
years NNS N
; : N
55 CD N
boys NNS N
and CC N
9 CD N
girls NNS N
) ) N
with IN N
a DT N
range NN N
of IN N
intelligence NN N
quotient NN N
and CC N
verbal JJ N
ability NN N
were VBD N
randomly RB N
assigned VBN N
, , N
in IN N
a DT N
double-blind JJ N
manner NN N
, , N
to TO N
secretin VB N
or CC N
placebo VB N
groups NNS N
. . N

Children NNP N
received VBD N
2 CD N
doses NNS N
of IN N
placebo NN N
or CC N
porcine NN N
secretin NN N
, , N
6 CD N
weeks NNS N
apart RB N
. . N

Assessments NNS N
were VBD N
performed VBN N
at IN N
baseline NN N
and CC N
3 CD N
weeks NNS N
after IN N
each DT N
injection NN N
using VBG N
several JJ N
outcome JJ N
measures NNS N
. . N

RESULTS NNP N
There EX N
were VBD N
no DT N
group NN N
differences VBZ N
on IN N
formal JJ N
measures NNS N
of IN N
language NN N
, , N
cognition NN N
, , N
or CC N
autistic JJ N
symptomatology NN N
. . N

Subgroupings NNS N
based VBN N
on IN N
cognitive JJ N
level NN N
, , N
the DT N
presence NN N
or CC N
absence NN N
of IN N
diarrhea NN N
, , N
or CC N
a DT N
history NN N
of IN N
regression NN N
failed VBD N
to TO N
show VB N
any DT N
significant JJ N
therapeutic JJ N
effects NNS N
of IN N
secretin NN N
. . N

CONCLUSION NNP N
No DT N
evidence NN N
is VBZ N
provided VBN N
for IN N
the DT N
efficacy NN N
of IN N
repeated JJ N
doses NNS N
of IN N
porcine NN N
secretin NN N
in IN N
the DT N
treatment NN N
of IN N
children NNS N
with IN N
autism NN N
. . N

The DT N
possible JJ N
relationship NN N
between IN N
relief NN N
of IN N
biological JJ N
symptoms NNS N
and CC N
enhanced VBD N
skill JJ N
performance NN N
is VBZ N
discussed VBN N
. . N

-DOCSTART- -X- O O 15821644

Combined JJ N
administration NN N
of IN N
nitric JJ N
oxide NN N
gas NN N
and CC N
iloprost NN N
during IN N
cardiopulmonary JJ 4_p
bypass NN 4_p
reduces NNS N
platelet VBP N
dysfunction NN N
: : N
a DT N
pilot NN N
clinical JJ N
study NN N
. . N

BACKGROUND NNP N
Thrombocytopenia NNP N
and CC N
platelet VB N
dysfunction NN N
are VBP N
major JJ N
mechanisms NNS N
of IN N
cardiopulmonary JJ N
bypass-induced JJ N
postoperative JJ N
hemorrhage NN N
. . N

This DT N
study NN N
evaluated VBD N
the DT N
effects NNS N
of IN N
low JJ N
amounts NNS N
of IN N
nitric JJ N
oxide NN N
, , N
iloprost NN N
( ( N
prostacyclin JJ N
analog NN N
) ) N
, , N
and CC N
their PRP$ N
combination NN N
administered VBN N
directly RB N
into IN N
the DT N
oxygenator NN N
on IN N
platelet NN N
function NN N
, , N
platelet-leukocyte JJ N
interactions NNS N
, , N
and CC N
postoperative JJ N
blood NN N
loss NN N
in IN N
patients NNS N
undergoing VBG N
coronary JJ 4_p
artery NN 4_p
bypass NN 4_p
grafting NN N
. . N

METHODS NNP N
Blood NNP N
samples NNS N
from IN N
41 CD N
patients NNS N
randomized VBN N
to TO N
the DT N
control NN N
, , N
nitric JJ N
oxide NN N
( ( N
20 CD N
ppm NN N
) ) N
, , N
iloprost FW N
( ( N
2 CD N
ng RB N
x JJ N
kg NN N
-1 NNP N
x NNP N
min NNP N
-1 NNP N
) ) N
, , N
or CC N
nitric JJ N
oxide JJ N
plus CC N
iloprost JJ N
groups NNS N
were VBD N
collected VBN N
during IN N
cardiopulmonary JJ 4_p
bypass NN 4_p
. . N

Platelets NNS N
and CC N
leukocytes NNS N
were VBD N
enumerated VBN N
. . N

Platelet NNP N
membrane NN N
glycoprotein NN N
Ib NNP N
and CC N
glycoprotein NN N
IIb/IIIa NNP N
, , N
P-selectin NNP N
, , N
platelet-derived JJ N
microparticles NNS N
, , N
leukocyte JJ N
CD11b/CD18 NNP N
( ( N
Mac-1 NNP N
) ) N
, , N
and CC N
platelet-leukocyte JJ N
aggregate NN N
were VBD N
quantified VBN N
by IN N
means NNS N
of IN N
flow JJ N
cytometry NN N
. . N

Collagen NNP N
and CC N
thrombin JJ N
receptor-activating JJ N
peptide-induced JJ N
platelet NN N
aggregation NN N
in IN N
whole JJ N
blood NN N
was VBD N
analyzed VBN N
by IN N
means NNS N
of IN N
aggregometry NN N
. . N

RESULTS NNP N
Both NNP N
nitric JJ N
oxide NN N
or CC N
iloprost NN N
attenuated JJ N
cardiopulmonary JJ N
bypass-induced JJ N
thrombocytopenia NN N
, , N
reduction NN N
of IN N
glycoprotein NN N
Ib NNP N
and CC N
glycoprotein VB N
IIb NNP N
levels NNS N
, , N
translocation NN N
of IN N
P-selectin NNP N
, , N
microparticle NN N
formation NN N
, , N
Mac-1 NNP N
upregulation NN N
, , N
and CC N
suppression NN N
of IN N
collagen-induced JJ N
aggregation NN N
. . N

Nitric NNP N
oxide IN N
plus CC N
iloprost NN N
was VBD N
significantly RB N
more RBR N
effective JJ N
in IN N
preventing VBG N
thrombocytopenia NN N
, , N
microparticle NN N
formation NN N
, , N
and CC N
P-selectin NNP N
translocation NN N
. . N

Moreover RB N
, , N
this DT N
treatment NN N
preserved VBD N
thrombin JJ N
receptor-activating JJ N
peptide-induced JJ N
aggregation NN N
, , N
which WDT N
was VBD N
not RB N
rescued VBN N
by IN N
single JJ N
treatments NNS N
. . N

Both DT N
nitric JJ N
oxide NN N
and CC N
nitric JJ N
oxide NN N
plus CC N
iloprost NN N
attenuated JJ N
postoperative JJ N
blood NN N
loss NN N
. . N

CONCLUSIONS NNP N
Nitric NNP N
oxide IN N
plus CC N
iloprost VB N
reduced VBN N
the DT N
deleterious JJ N
effects NNS N
of IN N
cardiopulmonary JJ N
bypass NN N
, , N
such JJ N
as IN N
thrombocytopenia NN N
, , N
platelet NN N
activation NN N
, , N
platelet-leukocyte JJ N
aggregate NN N
formation NN N
, , N
and CC N
suppression NN N
of IN N
platelet NN N
aggregative JJ N
responses NNS N
. . N

The DT N
reduced JJ N
postoperative JJ N
bleeding NN N
observed VBN N
with IN N
this DT N
treatment NN N
suggests VBZ N
that IN N
this DT N
is VBZ N
a DT N
new JJ N
and CC N
clinically RB N
feasible JJ N
therapeutic JJ N
option NN N
for IN N
patients NNS N
subjected VBN N
to TO N
cardiopulmonary JJ 4_p
bypass NN 4_p
. . N

-DOCSTART- -X- O O 17149715

A DT N
double-blind JJ N
placebo-controlled JJ N
trial NN N
of IN N
zonisamide NN N
( ( N
zonegran NN N
) ) N
in IN N
the DT N
treatment NN N
of IN N
essential JJ N
tremor NN N
. . N

Medical JJ N
therapy NN N
for IN N
essential JJ 4_p
tremor NN 4_p
( ( 4_p
ET NNP 4_p
) ) 4_p
, , N
a DT N
common JJ N
movement NN N
disorder NN N
, , N
is VBZ N
often RB N
inadequate JJ N
. . N

We PRP N
performed VBD N
a DT N
double-blind JJ N
placebo-controlled JJ N
randomized VBN N
trial NN N
to TO N
evaluate VB N
the DT N
efficacy NN N
and CC N
tolerability NN N
of IN N
zonisamide NN N
( ( N
ZNS NNP N
) ) N
, , N
an DT N
antiepileptic JJ N
agent NN N
, , N
in IN N
treating VBG N
ET NNP N
. . N

Twenty CD N
patients NNS N
( ( N
mean JJ N
age NN N
, , N
60 CD N
+/- JJ N
15 CD N
years NNS N
) ) N
with IN N
ET NNP 4_p
were VBD N
randomized VBN N
to TO N
receive VB N
ZNS NNP N
or CC N
placebo NN N
. . N

ZNS NNP N
was VBD N
initiated VBN N
at IN N
a DT N
dosage NN N
of IN N
100 CD N
mg/day NN N
and CC N
escalated VBD N
to TO N
200 CD N
mg/day NNS N
at IN N
day NN N
14 CD N
. . N

Patients NNS N
were VBD N
evaluated VBN N
by IN N
accelerometry NN N
and CC N
the DT N
Fahn-Tolosa-Marin NNP N
( ( N
FTM NNP N
) ) N
rating NN N
scale NN N
at IN N
baseline NN N
and CC N
days NNS N
14 CD N
and CC N
28 CD N
, , N
as RB N
well RB N
as IN N
the DT N
Clinical NNP N
Global NNP N
Impression NNP N
( ( N
CGI-C NNP N
) ) N
scale NN N
at IN N
day NN N
28 CD N
. . N

At IN N
endpoint NN N
, , N
subjects NNS N
assigned VBD N
to TO N
ZNS NNP N
were VBD N
taking VBG N
a DT N
mean JJ N
dosage NN N
of IN N
160 CD N
+/- JJ N
50 CD N
mg/day NN N
. . N

There EX N
were VBD N
no DT N
significant JJ N
improvements NNS N
in IN N
the DT N
FTM NNP N
total JJ N
score NN N
or CC N
its PRP$ N
subsections NNS N
. . N

Tremor NNP N
amplitude NN N
as IN N
assessed VBN N
by IN N
accelerometry NN N
significantly RB N
improved VBN N
in IN N
the DT N
ZNS NNP N
group NN N
compared VBN N
to TO N
the DT N
placebo NN N
group NN N
at IN N
endpoint NN N
relative NN N
to TO N
baseline VB N
( ( N
-0.50 JJ N
+/- JJ N
0.72 CD N
vs. FW N
0.30 CD N
+/- JJ N
0.79 CD N
m/s NN N
( ( N
2 CD N
) ) N
; : N
P NNP N
= NNP N
0.03 CD N
) ) N
. . N

On IN N
the DT N
CGI-C NNP N
, , N
60 CD N
% NN N
( ( N
n JJ N
= NNP N
6 CD N
) ) N
of IN N
patients NNS N
in IN N
the DT N
ZNS NNP N
group NN N
felt VBD N
that IN N
their PRP$ N
tremor NN N
was VBD N
unchanged JJ N
, , N
while IN N
the DT N
remaining VBG N
patients NNS N
felt VBD N
that IN N
their PRP$ N
tremor NN N
was VBD N
" NNP N
minimally RB N
improved VBD N
. . N

" NNP N
Thirty NNP N
percent NN N
( ( N
n JJ N
= NNP N
3 CD N
) ) N
of IN N
patients NNS N
taking VBG N
ZNS NNP N
discontinued VBD N
the DT N
study NN N
due JJ N
to TO N
side VB N
effects NNS N
( ( N
fatigue NN N
, , N
headache NN N
, , N
paresthesias NN N
) ) N
while IN N
taking VBG N
100 CD N
mg JJ N
per IN N
day NN N
. . N

ZNS NNP N
did VBD N
not RB N
provide VB N
significant JJ N
improvements NNS N
in IN N
clinical JJ N
rating NN N
scales NNS N
at IN N
study NN N
endpoint NN N
compared VBN N
to TO N
placebo VB N
and CC N
was VBD N
only RB N
modestly RB N
well RB N
tolerated VBN N
. . N

ZNS NNP N
was VBD N
effective JJ N
in IN N
reducing VBG N
tremor JJ N
amplitude NN N
as IN N
measured VBN N
by IN N
accelerometry NN N
. . N

-DOCSTART- -X- O O 17853393

Severe NNP N
enteropathy NN N
among IN N
patients NNS 4_p
with IN 4_p
stage NN 4_p
II/III NNP 4_p
colon NN 4_p
cancer NN 4_p
treated VBN N
on IN N
a DT N
randomized JJ N
trial NN N
of IN N
bolus JJ N
5-fluorouracil/leucovorin JJ N
plus CC N
or CC N
minus CC N
oxaliplatin NN N
: : N
a DT N
prospective JJ N
analysis NN N
. . N

BACKGROUND NNP N
Cases NNP N
of IN N
severe JJ N
gastrointestinal JJ N
toxicity NN N
were VBD N
monitored VBN N
prospectively RB N
during IN N
NSABP NNP N
C-07 NNP N
, , N
a DT N
randomized JJ N
clinical JJ N
trial NN N
of IN N
adjuvant JJ N
therapy NN N
for IN N
patients NNS 4_p
with IN 4_p
stage NN 4_p
II/III NNP 4_p
colon NN 4_p
cancer NN 4_p
. . 4_p

METHODS NNP N
Patients NNPS N
were VBD N
treated VBN N
with IN N
weekly JJ N
bolus NN N
5-fluorouracil JJ N
( ( N
5-FU JJ N
) ) N
and CC N
leucovorin $ N
( ( N
FL NNP N
; : N
" NNP N
Roswell NNP N
Park NNP N
Regimen NNP N
" NNP N
) ) N
or CC N
the DT N
same JJ N
regimen NNS N
plus CC N
oxaliplatin NN N
( ( N
FLOX NNP N
) ) N
. . N

RESULTS NNP N
Of IN N
1857 CD N
patients NNS N
, , N
79 CD N
( ( N
4.3 CD N
% NN N
) ) N
developed VBD N
a DT N
syndrome NN N
of IN N
bowel NN N
wall NN N
injury NN N
( ( N
BWI NNP N
, , N
small JJ N
or CC N
large JJ N
) ) N
characterized VBN N
by IN N
hospitalization NN N
for IN N
the DT N
management NN N
of IN N
severe JJ N
diarrhea NN N
or CC N
dehydration NN N
and CC N
radiographic JJ N
or CC N
endoscopic JJ N
evidence NN N
of IN N
bowel NN N
wall NN N
thickening NN N
or CC N
ulceration NN N
. . N

Fifty-one CD N
( ( N
64.6 CD N
% NN N
) ) N
of IN N
these DT N
adverse JJ N
events NNS N
occurred VBD N
in IN N
patients NNS N
treated VBN N
with IN N
FLOX NNP N
and CC N
28 CD N
( ( N
35.4 CD N
% NN N
) ) N
in IN N
those DT N
treated VBN N
with IN N
FL NNP N
( ( N
P NNP N
< NNP N
.01 NNP N
) ) N
. . N

Enteric JJ N
sepsis NN N
( ( N
ES NNP N
) ) N
, , N
characterized VBN N
by IN N
grade NN N
3 CD N
or CC N
greater JJR N
diarrhea NN N
and CC N
grade VBD N
4 CD N
neutropenia NN N
with IN N
or CC N
without IN N
proven JJ N
bacteremia NN N
occurred VBD N
in IN N
22 CD N
patients NNS N
treated VBN N
with IN N
FLOX NNP N
, , N
versus NN N
8 CD N
in IN N
those DT N
treated VBN N
with IN N
FL NNP N
( ( N
P NNP N
= NNP N
.01 NNP N
) ) N
. . N

Patients NNPS N
> JJ N
60 CD N
years NNS N
were VBD N
at IN N
higher JJR N
risk NN N
for IN N
BWI NNP N
after IN N
treatment NN N
with IN N
FLOX NNP N
( ( N
6.7 CD N
% NN N
) ) N
versus NN N
treatment NN N
with IN N
FL NNP N
( ( N
2.9 CD N
% NN N
, , N
P NNP N
< NNP N
.01 NNP N
) ) N
. . N

Female JJ N
patients NNS N
had VBD N
a DT N
higher JJR N
incidence NN N
of IN N
BWI NNP N
with IN N
FLOX NNP N
( ( N
9.1 CD N
% NN N
) ) N
than IN N
with IN N
FL NNP N
( ( N
3.9 CD N
% NN N
, , N
P NNP N
< NNP N
.01 NNP N
) ) N
. . N

Severe JJ N
gastrointestinal JJ N
toxicity NN N
usually RB N
occurred VBD N
during IN N
the DT N
third JJ N
or CC N
fourth JJ N
week NN N
on IN N
the DT N
first JJ N
cycle NN N
of IN N
therapy NN N
, , N
required VBN N
hospitalization NN N
, , N
and CC N
was VBD N
managed VBN N
with IN N
fluids NNS N
, , N
antidiarrheals NNS N
, , N
and CC N
antibiotics NNS N
. . N

There EX N
were VBD N
5 CD N
deaths NNS N
( ( N
0.3 CD N
% NN N
) ) N
due JJ N
to TO N
enteropathy VB N
, , N
2 CD N
related VBN N
to TO N
ES NNP N
and CC N
3 CD N
related VBN N
to TO N
both DT N
BWI NNP N
and CC N
ES NNP N
. . N

Seventy-one CD N
percent NN N
of IN N
patients NNS N
resumed VBN N
treatment NN N
with IN N
FL NNP N
after IN N
recovery NN N
. . N

CONCLUSIONS NNP N
Patients NNPS N
treated VBD N
with IN N
adjuvant JJ N
FL NNP N
should MD N
be VB N
closely RB N
monitored VBN N
for IN N
diarrhea NN N
and CC N
aggressively RB N
managed VBN N
, , N
especially RB N
if IN N
oxaliplatin VBN N
has VBZ N
been VBN N
added VBN N
to TO N
the DT N
regimen NNS N
. . N

Society NN N
. . N

-DOCSTART- -X- O O 16596861

Nurse-led JJ N
cardiac NN N
clinics NNS N
for IN N
adults NNS N
with IN N
coronary JJ 4_p
heart NN 4_p
disease NN 4_p
. . N

This DT N
information NN N
on IN N
best NN N
practice NN N
is VBZ N
based VBN N
on IN N
a DT N
systematic JJ N
review NN N
of IN N
research NN N
, , N
published VBN N
by IN N
Blackwell NNP N
Publishing NNP N
Asia NNP N
and CC N
conducted VBN N
by IN N
the DT N
Centre NNP N
for IN N
Evidence-based JJ N
Nursing NNP N
South NNP N
Australia NNP N
, , N
a DT N
collaborating VBG N
centre NN N
of IN N
the DT N
Joanna NNP N
Briggs NNP N
Institute NNP N
( ( N
JBI NNP N
) ) N
. . N

The DT N
primary JJ N
references NNS N
on IN N
which WDT N
this DT N
information NN N
is VBZ N
based VBN N
are VBP N
provided VBN N
in IN N
the DT N
systematic JJ N
review NN N
report NN N
available JJ N
online JJ N
via IN N
Blackwell NNP N
Synergy NNP N
www.blackwell-synergy.com NN N
and CC N
to TO N
members NNS N
of IN N
the DT N
institute NN N
via IN N
the DT N
web JJ N
site NN N
: : N
www.joannabriggs.edu.au NN N
. . N

This DT N
information NN N
sheet NN N
covers VBZ N
the DT N
following JJ N
: : N
Nurse-led JJ N
education NN N
and CC N
self-help NN N
. . N

Education NN N
and CC N
motivational JJ N
interview NN N
. . N

Audit NNP N
and CC N
recall NN N
. . N

Secondary JJ N
prevention NN N
. . N

-DOCSTART- -X- O O 24915929

Quantifying VBG N
narrative JJ N
ability NN N
in IN N
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
: : 4_p
a DT N
computational JJ N
linguistic JJ N
analysis NN N
of IN N
narrative JJ N
coherence NN N
. . N

Autism NNP 4_p
is VBZ N
a DT N
neurodevelopmental JJ N
disorder NN N
characterized VBN N
by IN N
serious JJ N
difficulties NNS N
with IN N
the DT N
social JJ N
use NN N
of IN N
language NN N
, , N
along IN N
with IN N
impaired JJ N
social JJ N
functioning NN N
and CC N
ritualistic/repetitive JJ N
behaviors NNS N
( ( N
American NNP N
Psychiatric NNP N
Association NNP N
in IN N
Diagnostic NNP N
and CC N
statistical JJ N
manual NN N
of IN N
mental JJ N
disorders NNS N
: : N
DSM-5 NNP N
, , N
5th CD N
edn NN N
. . N

American NNP N
Psychiatric NNP N
Association NNP N
, , N
Arlington NNP N
, , N
2013 CD N
) ) N
. . N

While IN N
substantial JJ N
heterogeneity NN N
exists VBZ N
in IN N
symptom JJ N
expression NN N
, , N
impairments NNS N
in IN N
language NN N
discourse NN N
skills NNS N
, , N
including VBG N
narrative JJ N
( ( N
or CC N
storytelling VBG N
) ) N
, , N
are VBP N
universally RB N
observed VBN N
in IN N
autism NN N
( ( N
Tager-Flusberg NNP N
et RB N
al RB N
. . N

in IN N
Handbook NNP N
on IN N
autism NN N
and CC N
pervasive JJ N
developmental NN N
disorders NNS N
, , N
3rd CD N
edn NN N
. . N

Wiley NNP N
, , N
New NNP N
York NNP N
, , N
pp JJ N
335-364 CD N
, , N
2005 CD N
) ) N
. . N

This DT N
study NN N
applied VBD N
a DT N
computational JJ N
linguistic JJ N
tool NN N
, , N
Latent NNP N
Semantic NNP N
Analysis NNP N
( ( N
LSA NNP N
) ) N
, , N
to TO N
objectively RB N
characterize VB N
narrative JJ N
performance NN N
in IN N
high-functioning JJ 4_p
individuals NNS N
with IN N
autism NN 4_p
and CC N
typically-developing NN N
controls NNS N
, , N
across IN N
two CD N
different JJ N
narrative JJ N
contexts NN N
that WDT N
differ VBP N
in IN N
the DT N
interpersonal JJ N
and CC N
cognitive JJ N
demands NNS N
placed VBN N
on IN N
the DT N
narrator NN N
. . N

Results NNS N
indicated VBD N
that IN N
high-functioning JJ 4_p
individuals NNS N
with IN N
autism NN 4_p
produced VBN N
narratives NNS N
comparable JJ N
in IN N
semantic JJ N
content NN N
to TO N
those DT N
produced VBN N
by IN N
controls NNS N
when WRB N
narrating VBG N
from IN N
a DT N
picture NN N
book NN N
, , N
but CC N
produced VBD N
narratives NNS N
diminished VBN N
in IN N
semantic JJ N
quality NN N
in IN N
a DT N
more RBR N
demanding JJ N
narrative JJ N
recall NN N
task NN N
. . N

This DT N
pattern NN N
is VBZ N
similar JJ N
to TO N
that DT N
detected VBN N
from IN N
analyses NNS N
of IN N
hand-coded JJ N
picture NN N
book NN N
narratives NNS N
in IN N
prior JJ N
research NN N
, , N
and CC N
extends VBZ N
findings NNS N
to TO N
an DT N
additional JJ N
narrative JJ N
context NN N
that WDT N
proves VBZ N
particularly RB N
challenging VBG N
for IN N
individuals NNS N
with IN N
autism NN 4_p
. . N

Results NNS N
are VBP N
discussed VBN N
in IN N
terms NNS N
of IN N
the DT N
utility NN N
of IN N
LSA NNP N
as IN N
a DT N
quantitative JJ N
, , N
objective JJ N
, , N
and CC N
efficient JJ N
measure NN N
of IN N
narrative JJ N
ability NN N
. . N

-DOCSTART- -X- O O 24694924

An DT N
oxytocin-induced JJ N
facilitation NN N
of IN N
neural JJ N
and CC N
emotional JJ N
responses NNS N
to TO N
social JJ N
touch NN N
correlates NNS N
inversely RB N
with IN N
autism NN 4_p
traits NNS 4_p
. . 4_p

Social JJ N
communication NN N
through IN N
touch NN N
and CC N
mutual JJ N
grooming NN N
can MD N
convey VB N
highly RB N
salient JJ N
socio-emotional JJ N
signals NNS N
and CC N
has VBZ N
been VBN N
shown VBN N
to TO N
involve VB N
the DT N
neuropeptide JJ N
oxytocin NN N
( ( N
OXT NNP N
) ) N
in IN N
several JJ N
species NNS N
. . N

Less NNP N
is VBZ N
known VBN N
about IN N
the DT N
modulatory JJ N
influence NN N
of IN N
OXT NNP N
on IN N
the DT N
neural JJ N
and CC N
emotional JJ N
responses NNS N
to TO N
human JJ N
interpersonal JJ N
touch NN N
. . N

The DT N
present JJ N
randomized VBN N
placebo NN N
( ( N
PLC NNP N
) ) N
-controlled VBD N
within-subject JJ N
pharmaco-functional JJ N
magnetic JJ N
resonance NN N
imaging NN N
( ( N
fMRI NN N
) ) N
study NN N
was VBD N
designed VBN N
to TO N
test VB N
the DT N
hypothesis NN N
that IN N
a DT N
single JJ N
intranasal NN N
dose NN N
of IN N
synthetic JJ N
OXT NNP N
( ( N
24 CD N
IU NNP N
) ) N
would MD N
facilitate VB N
both DT N
neural JJ N
and CC N
emotional JJ N
responses NNS N
to TO N
interpersonal VB N
touch NN N
in IN N
a DT N
context- NN N
( ( N
female JJ N
vs NN N
male NN N
touch NN N
) ) N
and CC N
trait- JJ N
( ( N
autistic JJ N
trait NN N
load NN N
) ) N
specific JJ N
manner NN N
. . N

Specifically RB N
, , N
the DT N
experimental JJ N
rationale NN N
was VBD N
to TO N
manipulate VB N
the DT N
reward NN N
value NN N
of IN N
interpersonal JJ N
touch JJ N
independent JJ N
of IN N
the DT N
intensity NN N
and CC N
type NN N
of IN N
actual JJ N
cutaneous JJ N
stimulation NN N
administered VBN N
. . N

Thus NNP N
, , N
40 CD N
heterosexual JJ 4_p
males NNS N
believed VBN N
that IN N
they PRP N
were VBD N
touched VBN N
by IN N
either CC N
a DT N
man NN N
or CC N
a DT N
woman NN N
, , N
although IN N
in IN N
fact NN N
an DT N
identical JJ N
pattern NN N
of IN N
touch NN N
was VBD N
always RB N
given VBN N
by IN N
the DT N
same JJ N
female JJ N
experimenter NN N
blind NN N
to TO N
condition NN N
type NN N
. . N

Our PRP$ N
results NNS N
show VBP N
that IN N
OXT NNP N
increased VBD N
the DT N
perceived JJ N
pleasantness NN N
of IN N
female JJ N
, , N
but CC N
not RB N
male JJ N
touch NN N
, , N
and CC N
associated VBD N
neural JJ N
responses NNS N
in IN N
insula NN N
, , N
precuneus NN N
, , N
orbitofrontal JJ N
, , N
and CC N
pregenual JJ N
anterior JJ N
cingulate NN N
cortex NN N
. . N

Moreover RB N
, , N
the DT N
behavioral JJ N
and CC N
neural JJ N
effects NNS N
of IN N
OXT NNP N
were VBD N
negatively RB N
correlated VBN N
with IN N
autistic-like JJ N
traits NNS N
. . N

Taken VB N
together RB N
, , N
this DT N
is VBZ N
the DT N
first JJ N
study NN N
to TO N
show VB N
that IN N
the DT N
perceived VBN N
hedonic JJ N
value NN N
of IN N
human JJ N
heterosexual JJ N
interpersonal JJ N
touch NN N
is VBZ N
facilitated VBN N
by IN N
OXT NNP N
in IN N
men NNS N
, , N
but CC N
that IN N
its PRP$ N
behavioral JJ N
and CC N
neural JJ N
effects NNS N
in IN N
this DT N
context NN N
are VBP N
blunted VBN N
in IN 4_p
individuals NNS 4_p
with IN 4_p
autistic JJ 4_p
traits NNS 4_p
. . N

-DOCSTART- -X- O O 25070364

The DT N
effects NNS N
of IN N
low- JJ N
, , N
medium- JJ N
, , N
and CC N
high-oil NN N
distillers NNS N
dried VBD N
grains NNS N
with IN N
solubles NNS N
on IN N
growth NN N
performance NN N
, , N
nutrient JJ N
digestibility NN N
, , N
and CC N
fat JJ N
quality NN N
in IN N
finishing VBG N
pigs NNS N
. . N

A DT N
total NN N
of IN N
1,480 CD N
pigs NNS N
were VBD N
used VBN N
in IN N
3 CD N
experiments NNS N
to TO N
determine VB N
the DT N
effects NNS N
of IN N
corn NN N
distillers NNS N
dried VBD N
grains NNS N
with IN N
solubles NNS N
( ( N
DDGS NNP N
) ) N
varying VBG N
in IN N
oil NN N
content NN N
on IN N
growth NN N
performance NN N
, , N
carcass NN N
traits NNS N
, , N
and CC N
nutrient JJ N
digestibility NN N
in IN N
finishing VBG N
pigs NNS N
. . N

In IN N
Exp NNP N
. . N

1 CD N
, , N
1,198 CD N
pigs NNS N
( ( N
PIC NNP N
Line NNP N
337 CD N
× NN N
1050 CD N
; : N
initially RB N
46.1 CD N
kg NNS N
) ) N
were VBD N
allotted VBN N
to TO N
a DT N
corn-soybean JJ N
meal-based JJ N
diet NN N
or CC N
diets NNS N
with IN N
20 CD N
or CC N
40 CD N
% NN N
of IN N
a DT N
5.4 CD N
% NN N
oil NN N
DDGS NNP N
( ( N
29.5 CD N
% NN N
CP NNP N
, , N
8.9 CD N
% NN N
ADF NNP N
, , N
and CC N
21.8 CD N
% NN N
NDF NNP N
; : N
as-fed JJ N
basis NN N
) ) N
or CC N
a DT N
9.6 CD N
% NN N
oil NN N
DDGS NNP N
( ( N
29.6 CD N
% NN N
CP NNP N
, , N
15.3 CD N
% NN N
ADF NNP N
, , N
and CC N
28.6 CD N
% NN N
NDF NNP N
; : N
as-fed JJ N
basis NN N
) ) N
. . N

From IN N
d JJ N
0 CD N
to TO N
82 CD N
, , N
ADG NNP N
was VBD N
unaffected VBN N
by IN N
DDGS NNP N
source NN N
or CC N
level NN N
. . N

However RB N
, , N
increasing VBG N
5.4 CD N
% NN N
oil NN N
DDGS NNP N
decreased VBD N
( ( N
linear JJ N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
G NN N
: : N
F NNP N
, , N
whereas JJ N
G NNP N
: : N
F NN N
did VBD N
not RB N
change VB N
among IN N
pigs NNS N
fed VBP N
9.6 CD N
% NN N
oil NN N
DDGS NNP N
( ( N
DDGS NNP N
source NN N
× NNP N
level NN N
interaction NN N
; : N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

Regardless NNP N
of IN N
DDGS NNP N
source NN N
, , N
carcass NN N
yield NN N
and CC N
HCW NNP N
decreased VBD N
( ( N
linear JJ N
, , N
P NNP N
< NNP N
0.04 CD N
) ) N
with IN N
increasing VBG N
DDGS NNP N
. . N

Increasing VBG N
DDGS NNP N
increased VBD N
jowl NN N
iodine NN N
value NN N
( ( N
IV NNP N
) ) N
, , N
but CC N
the DT N
magnitude NN N
was VBD N
greater JJR N
in IN N
pigs NNS N
fed VBP N
the DT N
9.6 CD N
% NN N
oil NN N
DDGS NNP N
compared VBN N
with IN N
those DT N
fed JJ N
5.4 CD N
% NN N
oil NN N
DDGS NNP N
( ( N
DDGS NNP N
source NN N
× NNP N
level NN N
interaction NN N
; : N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

In IN N
Exp NNP N
. . N

2 CD N
, , N
270 CD N
pigs NNS N
( ( N
PIC NNP N
Line NNP N
327 CD N
× NN N
1050 CD N
; : N
initially RB N
46.5 CD N
kg NNS N
) ) N
were VBD N
allotted VBN N
a DT N
corn-soybean JJ N
meal-based JJ N
diet NN N
or CC N
diets NNS N
with IN N
20 CD N
or CC N
40 CD N
% NN N
of IN N
a DT N
9.4 CD N
% NN N
oil NN N
DDGS NNP N
( ( N
29.4 CD N
% NN N
CP NNP N
, , N
19.6 CD N
% NN N
ADF NNP N
, , N
and CC N
34.5 CD N
% NN N
NDF NNP N
; : N
as-fed JJ N
basis NN N
) ) N
or CC N
a DT N
12.1 CD N
% NN N
oil NN N
DDGS NNP N
( ( N
28.5 CD N
% NN N
CP NNP N
, , N
17.6 CD N
% NN N
ADF NNP N
, , N
and CC N
31.4 CD N
% NN N
NDF NNP N
; : N
as-fed JJ N
basis NN N
) ) N
. . N

From IN N
d JJ N
0 CD N
to TO N
75 CD N
, , N
ADG NNP N
increased VBD N
and CC N
then RB N
decreased VBD N
for IN N
pigs NNS N
fed VBN N
9.4 CD N
% NN N
oil NN N
DDGS NNP N
but CC N
was VBD N
unchanged JJ N
for IN N
pigs NNS N
fed VBN N
12.1 CD N
% NN N
oil NN N
DDGS NNP N
( ( N
quadratic JJ N
interaction NN N
, , N
P NNP N
< NNP N
0.02 CD N
) ) N
. . N

Increasing VBG N
DDGS NNP N
increased VBD N
( ( N
linear JJ N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
jowl NN N
IV NNP N
and CC N
tended VBD N
( ( N
linear JJ N
, , N
P NNP N
< NNP N
0.07 CD N
) ) N
to TO N
increase VB N
G NNP N
: : N
F. NNP N
Regardless NNP N
of IN N
source NN N
, , N
HCW NNP N
and CC N
carcass JJ N
yield NN N
decreased VBD N
( ( N
linear JJ N
, , N
P NNP N
< NNP N
0.05 CD N
) ) N
as IN N
DDGS NNP N
increased VBD N
. . N

In IN N
Exp NNP N
. . N

3 CD N
, , N
nutrient JJ N
digestibility NN N
of IN N
the DT N
4 CD N
DDGS NNP N
sources NNS N
was VBD N
determined VBN N
using VBG N
pigs NNS N
fed VBN N
either RB N
a DT N
corn-based JJ N
basal NN N
diet NN N
( ( N
96.6 CD N
% NN N
corn NN N
and CC N
3.4 CD N
% NN N
vitamins NNS N
and CC N
minerals NNS N
) ) N
or CC N
a DT N
DDGS NNP N
diet NN N
with IN N
50 CD N
% NN N
basal NN N
diet JJ N
and CC N
50 CD N
% NN N
DDGS NNP N
. . N

On IN N
an DT N
as-fed JJ N
basis NN N
, , N
corn NN N
contained VBD N
3,871 CD N
and CC N
3,515 CD N
kcal/kg NN N
GE NNP N
and CC N
DE NNP N
, , N
respectively RB N
. . N

The DT N
5.4 CD N
, , N
9.6 CD N
, , N
9.4 CD N
, , N
and CC N
12.1 CD N
% NN N
oil NN N
DDGS NNP N
contained VBD N
4,347 CD N
, , N
4,648 CD N
, , N
4,723 CD N
, , N
and CC N
4,904 CD N
kcal/kg NN N
( ( N
as-fed JJ N
basis NN N
) ) N
GE NNP N
and CC N
3,417 CD N
, , N
3,690 CD N
, , N
3,838 CD N
, , N
and CC N
3,734 CD N
kcal/kg NN N
DE NNP N
, , N
respectively RB N
( ( N
as-fed JJ N
basis NN N
) ) N
. . N

Stepwise NNP N
regression NN N
indicated VBD N
that IN N
the DT N
oil NN N
( ( N
ether CC N
extract NN N
) ) N
content NN N
was VBD N
the DT N
only JJ N
significant JJ N
variable NN N
to TO N
explain VB N
differences NNS N
in IN N
energy NN N
content NN N
. . N

The DT N
equations NNS N
generated VBD N
to TO N
predict VB N
DE NNP N
and CC N
NE NNP N
as IN N
a DT N
function NN N
of IN N
oil NN N
content NN N
on IN N
an DT N
as-fed JJ N
basis NN N
were VBD N
DE NNP N
( ( N
kcal/kg NN N
) ) N
= VBZ N
62.347 CD N
× NN N
ether CC N
extract NN N
( ( N
% NN N
) ) N
+ VBZ N
3,058.13 CD N
( ( N
n JJ N
= NN N
5 CD N
, , N
adjusted VBN N
R NNP N
( ( N
2 CD N
) ) N
= FW N
0.41 CD N
) ) N
and CC N
NE NNP N
( ( N
kcal/kg NN N
) ) N
= VBZ N
115.011 CD N
× NN N
ether CC N
extract NN N
( ( N
% NN N
) ) N
+ VBZ N
1,501.01 CD N
( ( N
n JJ N
= NN N
5 CD N
, , N
adjusted VBN N
R NNP N
( ( N
2 CD N
) ) N
= FW N
0.86 CD N
) ) N
. . N

-DOCSTART- -X- O O 24824660

A DT N
trial NN N
of IN N
D-cycloserine NNP N
to TO N
treat VB N
stereotypies NNS N
in IN N
older JJR N
adolescents NNS N
and CC N
young JJ N
adults NNS N
with IN N
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
. . N

OBJECTIVES CC N
Autism NNP N
spectrum NN N
disorders NNS N
( ( N
ASDs NNP N
) ) N
have VBP N
core VBN N
impairments NNS N
in IN N
social JJ N
communication NN N
as RB N
well RB N
as IN N
the DT N
presence NN N
of IN N
repetitive JJ N
, , N
stereotypic JJ N
behaviors NNS N
and CC N
restricted JJ N
interests NNS N
. . N

Older JJR N
adolescents NNS N
and CC N
young JJ N
adults NNS N
are VBP N
particularly RB N
impacted VBN N
by IN N
these DT N
deficits NNS N
. . N

Preclinical NNP N
data NN N
implicate NN N
glutamatergic JJ N
dysfunction NN N
in IN N
the DT N
pathophysiology NN N
of IN N
ASDs NNP N
. . N

D-Cycloserine NNP N
( ( N
DCS NNP N
) ) N
, , N
a DT N
partial JJ N
glycineB NN N
agonist NN N
at IN N
the DT N
N-methyl-D-aspartic JJ N
acid NN N
receptor NN N
site NN N
, , N
has VBZ N
been VBN N
shown VBN N
to TO N
improve VB N
sociability NN N
in IN N
mouse NN N
models NNS N
and CC N
a DT N
small JJ N
human NN N
study NN N
. . N

The DT N
sensitivity NN N
of IN N
the DT N
obligatory JJ N
glycineB JJ N
co-agonist NN N
binding VBG N
site NN N
may MD N
change VB N
with IN N
daily JJ N
administration NN N
of IN N
DCS NNP N
as IN N
a DT N
result NN N
of IN N
agonist-induced JJ N
desensitization NN N
. . N

The DT N
efficacy NN N
of IN N
a DT N
" NN N
pulsed VBN N
" NNP N
once-weekly JJ N
administration NN N
versus IN N
" JJ N
daily JJ N
" NNP N
administration NN N
of IN N
DCS NNP N
was VBD N
compared VBN N
. . N

METHODS NNP N
Males NNP N
and CC N
females NNS N
, , N
ages VBZ N
14 CD N
to TO N
25 CD N
years NNS N
, , N
with IN N
a DT N
Diagnostic NNP 4_p
and CC 4_p
Statistical NNP 4_p
Manual NNP 4_p
of IN 4_p
Mental NNP 4_p
Disorders NNP 4_p
, , N
Fourth NNP 4_p
Edition NNP 4_p
Text NNP 4_p
Revision NNP 4_p
diagnosis NN 4_p
of IN 4_p
an DT 4_p
ASD NNP 4_p
were VBD N
enrolled VBN N
in IN N
a DT N
double-blind NN N
, , N
randomized VBN N
10-week JJ N
trial NN N
consisting NN N
of IN N
8 CD N
weeks NNS N
of IN N
active JJ N
drug NN N
with IN N
either DT N
weekly JJ N
or CC N
daily JJ N
administration NN N
of IN N
50 CD N
mg NN N
of IN N
DCS NNP N
followed VBN N
by IN N
a DT N
2-week JJ N
follow-up JJ N
visit NN N
. . N

RESULTS NNP N
For IN N
the DT N
purposes NNS N
of IN N
this DT N
study NN N
, , N
no DT N
statistical JJ N
or CC N
clinical JJ N
differences NNS N
existed VBD N
between IN N
the DT N
2 CD N
dosage NN N
groups NNS N
on IN N
the DT N
Aberrant NNP N
Behavior NNP N
Checklist NNP N
subscale NN N
3 CD N
, , N
which WDT N
measures VBZ N
stereotypies/repetitive JJ N
movements NNS N
. . N

When WRB N
combining VBG N
groups NNS N
, , N
a DT N
statistically RB N
significant JJ N
decrease NN N
of IN N
37 CD N
% NN N
was VBD N
found VBN N
from IN N
baseline NN N
to TO N
week NN N
8 CD N
when WRB N
study NN N
drug NN N
was VBD N
completed VBN N
using VBG N
a DT N
linear JJ N
mixed JJ N
effects NNS N
model FW N
( ( N
P NNP N
= NNP N
0.003 CD N
) ) N
. . N

CONCLUSIONS NNP N
D-Cycloserine NNP N
was VBD N
shown VBN N
to TO N
be VB N
effective JJ N
in IN N
improving VBG N
stereotypic NN N
symptoms NNS N
in IN N
older JJR N
adolescents NNS N
and CC N
young JJ N
adults NNS N
with IN N
ASDs NNP N
measured VBN N
by IN N
the DT N
Aberrant NNP N
Behavior NNP N
Checklist NNP N
subscale VBD N
3 CD N
. . N

In IN N
addition NN N
, , N
DCS NNP N
was VBD N
safe JJ N
and CC N
well RB N
tolerated VBN N
. . N

-DOCSTART- -X- O O 21639806

Exemestane NN N
for IN N
breast-cancer JJ N
prevention NN N
in IN N
postmenopausal JJ N
women NNS N
. . N

BACKGROUND NNP N
Tamoxifen NNP N
and CC N
raloxifene NN N
have VBP N
limited VBN N
patient JJ N
acceptance NN N
for IN N
primary JJ N
prevention NN N
of IN N
breast NN N
cancer NN N
. . N

Aromatase NNP N
inhibitors NNS N
prevent VBP N
more JJR N
contralateral JJ N
breast NN N
cancers NNS N
and CC N
cause NN N
fewer JJR N
side NN N
effects NNS N
than IN N
tamoxifen NN N
in IN N
patients NNS 4_p
with IN 4_p
early-stage JJ 4_p
breast NN 4_p
cancer NN 4_p
. . 4_p

METHODS NNP N
In IN N
a DT N
randomized JJ N
, , N
placebo-controlled JJ N
, , N
double-blind JJ N
trial NN N
of IN N
exemestane NN N
designed VBN N
to TO N
detect VB N
a DT N
65 CD N
% NN N
relative JJ N
reduction NN N
in IN N
invasive JJ N
breast NN N
cancer NN N
, , N
eligible JJ N
postmenopausal NN N
women NNS N
35 CD N
years NNS N
of IN N
age NN N
or CC N
older JJR N
had VBD N
at IN N
least JJS N
one CD N
of IN N
the DT N
following JJ N
risk NN N
factors NNS N
: : N
60 CD N
years NNS N
of IN N
age NN N
or CC N
older JJR N
; : N
Gail NNP N
5-year JJ N
risk NN N
score NN N
greater JJR N
than IN N
1.66 CD N
% NN N
( ( N
chances NNS N
in IN N
100 CD N
of IN N
invasive JJ N
breast NN N
cancer NN N
developing VBG N
within IN N
5 CD N
years NNS N
) ) N
; : N
prior JJ N
atypical JJ N
ductal NN N
or CC N
lobular JJ N
hyperplasia NN N
or CC N
lobular JJ N
carcinoma NN N
in IN N
situ NN N
; : N
or CC N
ductal JJ N
carcinoma NN N
in IN N
situ NN N
with IN N
mastectomy NN N
. . N

Toxic NNP N
effects NNS N
and CC N
health-related JJ N
and CC N
menopause-specific JJ N
qualities NNS N
of IN N
life NN N
were VBD N
measured VBN N
. . N

RESULTS VB N
A DT N
total NN N
of IN N
4560 CD N
women NNS N
for IN N
whom WP N
the DT N
median JJ N
age NN N
was VBD N
62.5 CD N
years NNS N
and CC N
the DT N
median JJ N
Gail NNP N
risk NN N
score NN N
was VBD N
2.3 CD N
% NN N
were VBD N
randomly RB N
assigned VBN N
to TO N
either DT N
exemestane NN N
or CC N
placebo NN N
. . N

At IN N
a DT N
median JJ N
follow-up NN N
of IN N
35 CD N
months NNS N
, , N
11 CD N
invasive JJ N
breast NN N
cancers NNS N
were VBD N
detected VBN N
in IN N
those DT N
given VBN N
exemestane NN N
and CC N
in IN N
32 CD N
of IN N
those DT N
given VBN N
placebo NNS N
, , N
with IN N
a DT N
65 CD N
% NN N
relative JJ N
reduction NN N
in IN N
the DT N
annual JJ N
incidence NN N
of IN N
invasive JJ N
breast NN N
cancer NN N
( ( N
0.19 CD N
% NN N
vs. FW N
0.55 CD N
% NN N
; : N
hazard CC N
ratio NN N
, , N
0.35 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
, , N
0.18 CD N
to TO N
0.70 CD N
; : N
P=0.002 NNP N
) ) N
. . N

The DT N
annual JJ N
incidence NN N
of IN N
invasive JJ N
plus CC N
noninvasive JJ N
( ( N
ductal JJ N
carcinoma NN N
in IN N
situ NN N
) ) N
breast NN N
cancers NNS N
was VBD N
0.35 CD N
% NN N
on IN N
exemestane NN N
and CC N
0.77 CD N
% NN N
on IN N
placebo NN N
( ( N
hazard JJ N
ratio NN N
, , N
0.47 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.27 CD N
to TO N
0.79 CD N
; : N
P=0.004 NNP N
) ) N
. . N

Adverse JJ N
events NNS N
occurred VBD N
in IN N
88 CD N
% NN N
of IN N
the DT N
exemestane NN N
group NN N
and CC N
85 CD N
% NN N
of IN N
the DT N
placebo NN N
group NN N
( ( N
P=0.003 NNP N
) ) N
, , N
with IN N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
two CD N
groups NNS N
in IN N
terms NNS N
of IN N
skeletal JJ N
fractures NNS N
, , N
cardiovascular JJ N
events NNS N
, , N
other JJ N
cancers NNS N
, , N
or CC N
treatment-related JJ N
deaths NNS N
. . N

Minimal JJ N
quality-of-life JJ N
differences NNS N
were VBD N
observed VBN N
. . N

CONCLUSIONS NNP N
Exemestane NNP N
significantly RB N
reduced VBD N
invasive JJ N
breast NN N
cancers NNS N
in IN N
postmenopausal JJ N
women NNS N
who WP N
were VBD N
at IN N
moderately RB N
increased VBN N
risk NN N
for IN N
breast NN N
cancer NN N
. . N

During IN N
a DT N
median JJ N
follow-up JJ N
period NN N
of IN N
3 CD N
years NNS N
, , N
exemestane NN N
was VBD N
associated VBN N
with IN N
no DT N
serious JJ N
toxic NN N
effects NNS N
and CC N
only RB N
minimal JJ N
changes NNS N
in IN N
health-related JJ N
quality NN N
of IN N
life NN N
. . N

( ( N
Funded VBN N
by IN N
Pfizer NNP N
and CC N
others NNS N
; : N
NCIC NNP N
CTG NNP N
MAP.3 NNP N
ClinicalTrials.gov NNP N
number NN N
, , N
NCT00083174 NNP N
. . N

) ) N
. . N

-DOCSTART- -X- O O 11013280

Phase NNP N
III NNP N
comparative JJ N
study NN N
of IN N
high-dose JJ N
cisplatin NN N
versus IN N
a DT N
combination NN N
of IN N
paclitaxel NN N
and CC N
cisplatin NN N
in IN N
patients NNS 4_p
with IN 4_p
advanced JJ 4_p
non-small-cell JJ 4_p
lung NN 4_p
cancer NN 4_p
. . 4_p

PURPOSE NNP N
New NNP N
effective JJ N
chemotherapy NN N
is VBZ N
needed VBN N
to TO N
improve VB N
the DT N
outcome NN N
of IN N
patients NNS 4_p
with IN 4_p
advanced JJ 4_p
non-small-cell JJ 4_p
lung NN 4_p
cancer NN 4_p
( ( 4_p
NSCLC NNP 4_p
) ) 4_p
. . 4_p

Paclitaxel NNP N
administered VBD N
as IN N
a DT N
single JJ N
agent NN N
or CC N
in IN N
combination NN N
with IN N
cisplatin NN N
has VBZ N
been VBN N
shown VBN N
to TO N
be VB N
a DT N
potentially RB N
new JJ N
useful JJ N
agent NN N
for IN N
the DT N
treatment NN N
of IN N
NSCLC NNP N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
Between NNP N
January NNP N
1995 CD N
and CC N
April NNP N
1996 CD N
, , N
414 CD N
patients NNS N
with IN N
stage NN N
IIIB NNP N
or CC N
IV NNP N
NSCLC NNP N
were VBD N
randomized VBN N
to TO N
received VB N
either RB N
a DT N
control NN N
arm NN N
of IN N
high-dose JJ N
cisplatin NN N
( ( N
100 CD N
mg/m NN N
( ( N
2 CD N
) ) N
) ) N
or CC N
a DT N
combination NN N
of IN N
paclitaxel NN N
( ( N
175 CD N
mg/m NN N
( ( N
2 CD N
) ) N
, , N
3-hour JJ N
infusion NN N
) ) N
and CC N
cisplatin NN N
( ( N
80 CD N
mg/m NN N
( ( N
2 CD N
) ) N
) ) N
every DT N
21 CD N
days NNS N
. . N

RESULTS NNP N
Compared VBD N
with IN N
the DT N
cisplatin-only JJ N
arm NN N
, , N
there EX N
was VBD N
a DT N
9 CD N
% NN N
improvement NN N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
0 CD N
% NN N
to TO N
19 CD N
% NN N
) ) N
in IN N
overall JJ N
response NN N
rate NN N
for IN N
the DT N
paclitaxel/cisplatin NN N
arm NN N
( ( N
17 CD N
% NN N
v JJ N
26 CD N
% NN N
, , N
respectively RB N
; : N
P=.028 NNP N
) ) N
. . N

Median JJ N
time NN N
to TO N
progression NN N
was VBD N
2.7 CD N
and CC N
4.1 CD N
months NNS N
in IN N
the DT N
control NN N
and CC N
paclitaxel/cisplatin NN N
arm NN N
, , N
respectively RB N
( ( N
P=.026 NNP N
) ) N
. . N

The DT N
study NN N
, , N
however RB N
, , N
failed VBD N
to TO N
show VB N
a DT N
significant JJ N
improvement NN N
in IN N
median JJ N
survival NN N
for IN N
the DT N
paclitaxel/cisplatin NN N
arm NN N
( ( N
8.6 CD N
months NNS N
in IN N
the DT N
control NN N
arm NN N
v NN N
8.1 CD N
months NNS N
in IN N
the DT N
paclitaxel/cisplatin NN N
arm NN N
, , N
P=.862 NNP N
) ) N
. . N

There EX N
was VBD N
more JJR N
hematotoxicity NN N
, , N
peripheral JJ N
neuropathy NN N
, , N
and CC N
arthralgia/myalgia NN N
on IN N
the DT N
paclitaxel/cisplatin NN N
arm NN N
, , N
whereas IN N
the DT N
high-dose JJ N
cisplatin NN N
arm NN N
produced VBD N
more JJR N
ototoxicity NN N
, , N
nausea NN N
, , N
vomiting NN N
, , N
and CC N
nephrotoxicity NN N
. . N

Quality NN N
of IN N
life NN N
( ( N
QOL NNP N
) ) N
was VBD N
similar JJ N
overall JJ N
between IN N
the DT N
two CD N
arms NNS N
. . N

CONCLUSION NN N
This DT N
large JJ N
randomized JJ N
phase NN N
III NNP N
trial NN N
failed VBD N
to TO N
show VB N
a DT N
significant JJ N
improvement NN N
in IN N
survival NN N
for IN N
the DT N
paclitaxel/cisplatin NN N
combination NN N
compared VBN N
with IN N
high-dose JJ N
cisplatin NN N
in IN N
patients NNS N
with IN N
advanced JJ N
NSCLC NNP N
. . N

However RB N
, , N
the DT N
paclitaxel/cisplatin NN N
combination NN N
did VBD N
produce VB N
a DT N
better JJR N
clinical JJ N
response NN N
, , N
resulting VBG N
in IN N
an DT N
increased JJ N
time NN N
to TO N
progression NN N
while IN N
providing VBG N
a DT N
similar JJ N
QOL NNP N
. . N

-DOCSTART- -X- O O 16889080

[ NN N
Pilot NNP N
results NNS N
of IN N
using VBG N
tamsulone-FS JJ N
in IN N
patients NNS N
with IN N
prostatic JJ 4_p
adenoma NN 4_p
according VBG N
to TO N
the DT N
results NNS N
of IN N
a DT N
randomized JJ N
multicenter NN N
comparative JJ N
trial NN N
] NN N
. . N

Tamsulone-FS NNP N
-- : N
a DT N
novel JJ N
Russian JJ N
alpha1A/D-adrenoblocker NN N
( ( N
Farm-Syntez NNP N
) ) N
-- : N
was VBD N
studied VBN N
in IN N
a DT N
randomized JJ N
multicenter NN N
comparative JJ N
trial NN N
in IN N
patients NNS N
with IN N
prostatic JJ 4_p
adenoma NN 4_p
. . N

Pilot NNP N
results NNS N
agreed VBD N
with IN N
other JJ N
trials NNS N
published VBN N
in IN N
the DT N
literature NN N
and CC N
demonstrated VBD N
tamsulone-FS JJ N
efficacy NN N
and CC N
safety NN N
for IN N
management NN N
of IN N
lower JJR N
urinary JJ N
tract NN N
symptoms NNS N
caused VBN N
by IN N
prostatic JJ N
adenoma NN N
. . N

The DT N
efficacy NN N
and CC N
safety NN N
of IN N
tamsulone-FS NN N
was VBD N
comparable JJ N
to TO N
those DT N
of IN N
omnik FW N
. . N

This DT N
drug NN N
can MD N
be VB N
recommended VBN N
for IN N
wide JJ N
clinical JJ N
practice NN N
in IN N
prostatic JJ N
adenoma NN N
. . N

It PRP N
is VBZ N
registered VBN N
by IN N
Roszdravnadzor NNP N
( ( N
certificate JJ N
N NNP N
LC-000859 NNP N
of IN N
03.11.2005 CD N
) ) N
and CC N
allowed VBN N
for IN N
production NN N
and CC N
sale NN N
. . N

-DOCSTART- -X- O O 17196275

Xuezhikang NN N
, , N
an DT N
extract NN N
of IN N
cholestin NN N
, , N
decreases VBZ N
plasma JJ N
inflammatory JJ N
markers NNS N
and CC N
endothelin-1 NN N
, , N
improve VB N
exercise-induced JJ N
ischemia NN N
and CC N
subjective JJ N
feelings NNS N
in IN N
patients NNS N
with IN N
cardiac JJ N
syndrome NN N
X NNP N
. . N

Previous JJ N
studies NNS N
have VBP N
demonstrated VBN N
that IN N
Xuezhikang NNP N
, , N
an DT N
extract NN N
of IN N
cholestin NN N
, , N
available JJ N
from IN N
Chinese JJ N
red JJ N
yeast NN N
rice NN N
, , N
could MD N
effectively RB N
modify VB N
lipid JJ N
profile NN N
. . N

The DT N
present JJ N
study NN N
was VBD N
undertaken VBN N
to TO N
investigate VB N
whether IN N
Xuezhikang NN N
could MD N
modify VB N
endothelin-1 JJ N
( ( N
ET-1 NNP N
) ) N
, , N
interleukin-6 JJ N
( ( N
IL-6 NNP N
) ) N
, , N
high-sensitivity JJ N
C-reactive JJ N
protein NN N
( ( N
CRP NNP N
) ) N
and CC N
exercise-induced JJ N
ischemia NN N
in IN N
patients NNS N
with IN N
cardiac JJ N
syndrome NN N
X NNP N
( ( N
CSX NNP N
) ) N
. . N

Thirty-six JJ N
patients NNS N
with IN N
CSX NNP N
were VBD N
randomly RB N
assigned VBN N
to TO N
1200 CD N
mg/d NN N
of IN N
Xuezhikang NNP N
or CC N
placebo VBN N
group NN N
( ( N
n=18 RB N
respectively RB N
) ) N
. . N

Blood NN N
samples NNS N
were VBD N
drawn VBN N
at IN N
day NN N
0 CD N
and CC N
day NN N
90 CD N
for IN N
measuring VBG N
above IN N
parameters NNS N
. . N

The DT N
treadmill NN N
exercise NN N
tests NNS N
and CC N
subjective JJ N
feelings NNS N
were VBD N
also RB N
assessed VBN N
at IN N
day NN N
0 CD N
and CC N
day NN N
90 CD N
. . N

The DT N
data NN N
showed VBD N
that IN N
Xuezhikang NNP N
therapy NN N
resulted VBD N
in IN N
significant JJ N
reductions NNS N
in IN N
total JJ N
cholesterol NN N
( ( N
TC NNP N
, , N
19 CD N
% NN N
) ) N
, , N
low-density JJ N
lipoprotein NN N
cholesterol NN N
( ( N
LDL-C NNP N
) ) N
( ( N
26 CD N
% NN N
) ) N
, , N
and CC N
triglycerides NNS N
( ( N
TG NNP N
) ) N
compared VBN N
with IN N
baseline NN N
( ( N
16 CD N
% NN N
, , N
p NN N
< VBD N
0.01 CD N
respectively RB N
) ) N
. . N

The DT N
data NN N
also RB N
showed VBD N
that IN N
Xuezhikang NNP N
led VBD N
significantly RB N
to TO N
reductions NNS N
in IN N
median JJ N
and CC N
log-CRP JJ N
levels NNS N
( ( N
38 CD N
% NN N
and CC N
44 CD N
% NN N
, , N
p NN N
< VBD N
0.01 CD N
respectively RB N
) ) N
, , N
IL-6 NNP N
( ( N
20 CD N
% NN N
, , N
p NN N
< NNP N
0.01 CD N
) ) N
, , N
and CC N
ET-1 NNP N
( ( N
47 CD N
% NN N
, , N
p NN N
< NNP N
0.01 CD N
) ) N
compared VBN N
with IN N
baseline NN N
. . N

The DT N
exercise NN N
duration NN N
, , N
and CC N
time NN N
to TO N
1 CD N
mm NNS N
ST-segment JJ N
depression NN N
was VBD N
significantly RB N
prolonged VBN N
after IN N
Xuezhikang NNP N
therapy NN N
( ( N
9 CD N
% NN N
and CC N
6 CD N
% NN N
, , N
p NN N
< VBD N
0.05 CD N
respectively RB N
) ) N
accompanied VBN N
by IN N
improvement NN N
of IN N
subjective JJ N
feelings NNS N
. . N

Data NNP N
suggested VBD N
that IN N
the DT N
benefit NN N
of IN N
Xuezhikang NNP N
resulted VBD N
in IN N
significant JJ N
modification NN N
vascular JJ N
function NN N
by IN N
reduction NN N
of IN N
ET-1 NNP N
, , N
inflammatory JJ N
markers NNS N
and CC N
LDL NNP N
cholesterol NN N
, , N
which WDT N
may MD N
be VB N
clinically RB N
important JJ N
for IN N
patients NNS N
with IN N
CSX NNP N
. . N

-DOCSTART- -X- O O 21664757

Positive JJ N
impact NN N
of IN N
crisis NN N
resource NN N
management NN N
training NN N
on IN N
no-flow JJ N
time NN N
and CC N
team NN N
member NN N
verbalisations NNS N
during IN N
simulated JJ N
cardiopulmonary JJ N
resuscitation NN N
: : N
a DT N
randomised JJ N
controlled VBN N
trial NN N
. . N

OBJECTIVES UH N
To TO N
evaluate VB N
the DT N
impact NN N
of IN N
video-based JJ N
interactive JJ N
crisis NN N
resource NN N
management NN N
( ( N
CRM NNP N
) ) N
training VBG N
on IN N
no-flow JJ N
time NN N
( ( N
NFT NNP N
) ) N
and CC N
on IN N
proportions NNS N
of IN N
team NN N
member NN N
verbalisations NNS N
( ( N
TMV NNP N
) ) N
during IN N
simulated VBN N
cardiopulmonary JJ N
resuscitation NN N
( ( N
CPR NNP N
) ) N
. . N

Further UH N
, , N
to TO N
investigate VB N
the DT N
link NN N
between IN N
team NN N
leader NN N
verbalisation NN N
accuracy NN N
and CC N
NFT NNP N
. . N

METHODS NNP N
The DT N
randomised VBN N
controlled VBD N
study NN N
was VBD N
embedded VBN N
in IN N
the DT N
obligatory NN N
advanced VBD N
life NN N
support NN N
( ( N
ALS NNP N
) ) N
course NN N
for IN N
final-year JJ N
medical JJ N
students NNS N
. . N

Students NNS N
( ( N
176 CD N
; : N
25.35±1.03 CD N
years NNS N
, , N
63 CD N
% NN N
female NN N
) ) N
were VBD N
alphabetically RB N
assigned VBN N
to TO N
44 CD N
four-person JJ N
teams NNS N
that WDT N
were VBD N
then RB N
randomly RB N
( ( N
computer-generated JJ N
) ) N
assigned VBN N
to TO N
either DT N
CRM NNP N
intervention NN N
( ( N
n=26 JJ N
) ) N
, , N
receiving VBG N
interactive JJ N
video-based JJ N
CRM-training NN N
, , N
or CC N
to TO N
control VB N
intervention NN N
( ( N
n=18 JJ N
) ) N
, , N
receiving VBG N
an DT N
additional JJ N
ALS-training NN N
. . N

Primary JJ N
outcomes NNS N
were VBD N
NFT NNP N
and CC N
proportions NNS N
of IN N
TMV NNP N
, , N
which WDT N
were VBD N
subdivided VBN N
into IN N
eight CD N
categories NNS N
: : N
four CD N
team NN N
leader NN N
verbalisations NNS N
( ( N
TLV NNP N
) ) N
with IN N
different JJ N
accuracy NN N
levels NNS N
and CC N
four CD N
follower JJR N
verbalisation NN N
categories NNS N
( ( N
FV NNP N
) ) N
. . N

Measurements NNS N
were VBD N
made VBN N
of IN N
all DT N
groups NNS N
administering VBG N
simulated JJ N
adult NN N
CPR NNP N
. . N

RESULTS NNP N
NFT NNP N
rates NNS N
were VBD N
significantly RB N
lower JJR N
in IN N
the DT N
CRM-training NNP N
group NN N
( ( N
31.4±6.1 CD N
% NN N
vs. FW N
36.3±6.6 CD N
% NN N
, , N
p=0.014 NN N
) ) N
. . N

Proportions NNS N
of IN N
all DT N
TLV NNP N
categories NNS N
were VBD N
higher JJR N
in IN N
the DT N
CRM-training NNP N
group NN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

Differences NNS N
in IN N
FV NNP N
were VBD N
only RB N
found VBN N
for IN N
one CD N
category NN N
( ( N
unsolicited JJ N
information NN N
) ) N
( ( N
p=0.012 NN N
) ) N
. . N

The DT N
highest JJS N
correlation NN N
with IN N
NFT NNP N
was VBD N
found VBN N
for IN N
high JJ N
accuracy NN N
TLV NNP N
( ( N
direct JJ N
orders NNS N
) ) N
( ( N
p=0.06 NN N
) ) N
. . N

CONCLUSIONS VB N
The DT N
inclusion NN N
of IN N
CRM NNP N
training NN N
in IN N
undergraduate JJ N
medical JJ N
education NN N
reduces NNS N
NFT NNP N
in IN N
simulated JJ N
CPR NNP N
and CC N
improves VBZ N
TLV NNP N
proportions NNS N
during IN N
simulated JJ N
CPR NNP N
. . N

Further NNP N
research NN N
will MD N
test VB N
how WRB N
these DT N
results NNS N
translate VBP N
into IN N
clinical JJ N
performance NN N
and CC N
patient JJ N
outcome NN N
. . N

-DOCSTART- -X- O O 23995030

Incremental JJ N
cost-effectiveness NN N
of IN N
pharmacotherapy NN N
and CC N
two CD N
brief JJ N
cognitive-behavioral JJ N
therapies NNS N
compared VBN N
with IN N
usual JJ N
care NN N
for IN N
panic JJ 4_p
disorder NN 4_p
and CC 4_p
noncardiac JJ 4_p
chest NN 4_p
pain NN 4_p
. . 4_p

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
assess VB N
the DT N
incremental JJ N
cost-effectiveness JJ N
ratios NNS N
( ( N
ICERs NNP N
) ) N
of IN N
two CD N
brief JJ N
cognitive-behavioral JJ N
therapy NN N
( ( N
CBT NNP N
) ) N
-based VBD N
interventions NNS N
and CC N
a DT N
pharmacological JJ N
treatment NN N
, , N
compared VBN N
with IN N
usual JJ N
care NN N
, , N
initiated VBN N
in IN N
the DT N
emergency NN N
department NN N
( ( N
ED NNP N
) ) N
for IN N
individuals NNS N
with IN N
panic JJ 4_p
disorder NN 4_p
( ( 4_p
PD NNP 4_p
) ) 4_p
with IN 4_p
a DT 4_p
chief JJ 4_p
complaint NN 4_p
of IN 4_p
noncardiac JJ 4_p
chest NN 4_p
pain NN 4_p
. . N

A DT N
total NN N
of IN N
69 CD N
patients NNS N
were VBD N
followed VBN N
up IN N
to TO N
6 CD N
months NNS N
. . N

The DT N
primary JJ N
outcome NN N
variables NNS N
were VBD N
direct JJ N
and CC N
indirect JJ N
costs NNS N
of IN N
treatment NN N
and CC N
PD NNP N
severity NN N
. . N

Panic JJ N
management NN N
( ( N
PM NNP N
) ) N
had VBD N
an DT N
ICER NNP N
of IN N
$ $ N
124.05 CD N
, , N
per IN N
the DT N
Anxiety NN N
Disorders NNP N
Interview NNP N
Schedule NNP N
for IN N
Diagnostic NNP N
and CC N
Statistical NNP N
Manual NNP N
of IN N
Mental NNP N
Disorders NNP N
, , N
Fourth NNP N
Edition NNP N
, , N
severity NN N
score NN N
change NN N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
, , N
$ $ N
54.63- JJ N
$ $ N
314.57 CD N
) ) N
, , N
compared VBN N
with IN N
pharmacotherapy NN N
( ( N
paroxetine NN N
) ) N
, , N
with IN N
an DT N
ICER NNP N
of IN N
$ $ N
213.90 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
$ $ N
133.51- JJ N
$ $ N
394.94 CD N
) ) N
, , N
and CC N
brief JJ N
CBT NNP N
, , N
with IN N
an DT N
ICER NNP N
of IN N
$ $ N
309.31 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
$ $ N
151.27- JJ N
$ $ N
548.28 CD N
) ) N
. . N

The DT N
pharmacological JJ N
and CC N
CBT JJ N
interventions NNS N
were VBD N
associated VBN N
with IN N
a DT N
greater JJR N
clinical JJ N
improvement NN N
compared VBN N
with IN N
usual JJ N
care NN N
at IN N
posttest NN N
. . N

PM NNP N
presented VBD N
a DT N
superior JJ N
ICER NNP N
, , N
suggesting VBG N
that IN N
it PRP N
may MD N
be VB N
a DT N
promising JJ N
treatment NN N
option NN N
to TO N
implement VB N
in IN N
EDs NNP N
. . N

-DOCSTART- -X- O O 9049582

Pharmacokinetic JJ N
properties NNS N
of IN N
YM17E NNP N
, , N
an DT N
inhibitor NN N
of IN N
acyl NN N
coenzyme NN N
A DT N
: : N
cholesterol NN N
acyl NN N
transferase NN N
, , N
and CC N
serum VB N
cholesterol NN N
levels NNS N
in IN N
healthy JJ 4_p
volunteers NNS N
. . N

We PRP N
conducted VBD N
a DT N
single JJ N
and CC N
repeat JJ N
oral JJ N
dose NN N
study NN N
of IN N
YM17E NNP N
, , N
a DT N
novel JJ N
inhibitor NN N
of IN N
acyl NN N
coenzyme NN N
A NNP N
( ( N
CoA NNP N
) ) N
: : N
cholesterol NN N
acyltransferase NN N
, , N
in IN N
healthy JJ 4_p
male NN N
volunteers NNS N
to TO N
evaluate VB N
the DT N
pharmacokinetic JJ N
profile NN N
, , N
tolerability NN N
and CC N
effect NN N
of IN N
the DT N
drug NN N
on IN N
serum NN N
cholesterol NN N
. . N

In IN N
the DT N
single JJ N
administration NN N
study NN N
, , N
YM17E NNP N
was VBD N
administered VBN N
after IN N
a DT N
meal NN N
to TO N
two CD N
groups NNS N
of IN N
subjects NNS N
( ( N
each DT N
containing VBG N
six CD N
subjects NNS N
taking VBG N
the DT N
drug NN N
and CC N
three CD N
taking VBG N
placebo NN N
) ) N
receiving VBG N
3 CD N
, , N
60 CD N
and CC N
300 CD N
mg NN N
or CC N
15 CD N
, , N
60 CD N
and CC N
450 CD N
mg NN N
YM17E NNP N
, , N
respectively RB N
. . N

Plasma NNP N
concentrations NNS N
of IN N
unchanged JJ N
drug NN N
following VBG N
single JJ N
oral JJ N
administration NN N
at IN N
3-300 JJ N
mg NN N
after IN N
a DT N
meal NN N
increased VBN N
with IN N
increasing VBG N
dose NN N
. . N

In IN N
contrast NN N
, , N
plasma NN N
concentrations NNS N
after IN N
administration NN N
of IN N
450 CD N
mg NNS N
were VBD N
almost RB N
the DT N
same JJ N
as IN N
after IN N
300 CD N
mg NN N
. . N

Unchanged VBD N
YM17E NNP N
was VBD N
not RB N
detected VBN N
in IN N
urine NN N
after IN N
single JJ N
administration NN N
, , N
suggesting VBG N
that IN N
it PRP N
was VBD N
excreted VBN N
via IN N
the DT N
bile NN N
or CC N
urine NN N
after IN N
metabolism NN N
. . N

Five CD N
active JJ N
metabolites NNS N
( ( N
M1 NNP N
, , N
M2-a NNP N
, , N
M2-b NNP N
, , N
M3 NNP N
and CC N
M4 NNP N
) ) N
were VBD N
observed VBN N
in IN N
plasma NN N
at IN N
concentrations NNS N
comparable JJ N
to TO N
those DT N
of IN N
unchanged JJ N
YM17E NNP N
. . N

Their PRP$ N
plasma JJ N
concentrations NNS N
increased VBD N
in IN N
a DT N
slightly RB N
greater JJR N
than IN N
dose-dependent JJ N
manner NN N
from IN N
3 CD N
to TO N
300 CD N
mg NN N
. . N

The DT N
effect NN N
of IN N
food NN N
was VBD N
studied VBN N
in IN N
an DT N
open JJ N
crossover NN N
design NN N
with IN N
a DT N
1-week JJ N
washout NN N
period NN N
. . N

Twelve NNP N
subjects VBZ N
received VBD N
150 CD N
mg NNS N
YM17E VBN N
in IN N
both DT N
the DT N
fasted VBN N
and CC N
post-prandial JJ N
states NNS N
. . N

The DT N
AUC NNP N
and CC N
Cmax NNP N
after IN N
fasting VBG N
were VBD N
closely RB N
similar JJ N
to TO N
those DT N
after IN N
a DT N
meal NN N
, , N
showing VBG N
that IN N
bioavailability NN N
was VBD N
not RB N
affected VBN N
by IN N
food NN N
intake NN N
. . N

In IN N
the DT N
repeated JJ N
oral JJ N
dose NN N
study NN N
, , N
the DT N
subjects NNS N
received VBD N
test JJ N
drug NN N
at IN N
150 CD N
mg NN N
or CC N
300 CD N
mg NN N
( ( N
n JJ N
= RB N
6 CD N
each DT N
) ) N
or CC N
placebo NN N
( ( N
n JJ N
= NNP N
3 CD N
) ) N
twice RB N
a DT N
day NN N
( ( N
after IN N
breakfast NN N
and CC N
after IN N
dinner NN N
) ) N
for IN N
7 CD N
days NNS N
. . N

On IN N
days NNS N
1 CD N
and CC N
7 CD N
, , N
the DT N
subjects NNS N
received VBD N
YM17E NNP N
once RB N
a DT N
day NN N
( ( N
after IN N
breakfast NN N
) ) N
for IN N
evaluation NN N
of IN N
pharmacokinetic JJ N
properties NNS N
. . N

After IN N
repeated VBN N
oral JJ N
administration NN N
of IN N
150 CD N
mg NN N
b.d. NN N
, , N
plasma JJ N
concentrations NNS N
reached VBD N
steady JJ N
state NN N
by IN N
day NN N
5 CD N
( ( N
mean JJ N
Cmin NNP N
48.6 CD N
ng.ml-1 NN N
) ) N
. . N

After IN N
repeated JJ N
administration NN N
of IN N
300 CD N
mg NN N
b.d. NN N
, , N
plasma JJ N
concentrations NNS N
prior RB N
to TO N
each DT N
daily JJ N
morning NN N
dose NN N
increased VBD N
up RB N
to TO N
the DT N
5th JJ N
day NN N
( ( N
mean JJ N
Cmin NNP N
166.6 CD N
ng.ml-1 NN N
) ) N
and CC N
then RB N
tended VBD N
to TO N
decrease VB N
until IN N
the DT N
7th JJ N
day NN N
. . N

No DT N
significant JJ N
signs NNS N
, , N
symptoms NNS N
or CC N
changes NNS N
in IN N
serum NN N
cholesterol NN N
levels NNS N
were VBD N
observed VBN N
during IN N
the DT N
single JJ N
and CC N
repeated JJ N
oral JJ N
dose NN N
studies NNS N
at IN N
150 CD N
mg NN N
b.d NN N
. . N

Although IN N
statistical JJ N
analysis NN N
was VBD N
not RB N
conducted VBN N
because IN N
of IN N
the DT N
small JJ N
number NN N
of IN N
subjects NNS N
, , N
all DT N
subjects NNS N
receiving VBG N
repeated VBD N
oral JJ N
administration NN N
of IN N
300 CD N
mg JJ N
twice RB N
daily RB N
showed VBD N
a DT N
25 CD N
% NN N
decrease NN N
in IN N
serum NN N
cholesterol NN N
level NN N
on IN N
day NN N
7 CD N
, , N
but CC N
also RB N
the DT N
simultaneous JJ N
occurrence NN N
of IN N
diarrhoea NN N
. . N

-DOCSTART- -X- O O 24768960

To TO N
excise VB N
or CC N
ablate VB N
endometriosis NN 4_p
? . N
A DT N
prospective JJ N
randomized VBN N
double-blinded JJ N
trial NN N
after IN N
5-year JJ N
follow-up NN N
. . N

STUDY NNP N
OBJECTIVE NNP N
To TO N
compare VB N
reduction NN N
of IN N
pain NN N
after IN N
laparoscopy NN N
for IN N
ablation NN N
or CC N
excision NN N
of IN N
endometriosis NN N
. . N

DESIGN NNP N
Prospective NNP N
, , N
randomized VBD N
, , N
double-blind JJ N
study NN N
( ( N
Canadian JJ N
Task NNP N
Force NNP N
classification NN N
I PRP N
) ) N
. . N

SETTING CC N
Endometriosis NNP 4_p
and CC N
pelvic JJ 4_p
pain NN 4_p
clinic NN N
at IN N
a DT N
university NN N
teaching VBG N
hospital NN N
. . N

PATIENTS NNP N
Women NNP N
of IN N
reproductive JJ N
age NN N
with IN N
pelvic JJ 4_p
pain NN 4_p
and CC N
visually RB N
proved JJ N
endometriosis NN 4_p
. . N

INTERVENTIONS NNP N
Subjects NNPS N
completed VBD N
a DT N
questionnaire NN N
rating NN N
various JJ N
kinds NNS N
of IN N
pain NN N
using VBG N
visual JJ N
analog NN N
scales NNS N
( ( N
VAS NNP N
) ) N
. . N

After IN N
visual JJ N
identification NN N
subjects NNS N
were VBD N
randomized VBN N
to TO N
treatment NN N
via IN N
ablation NN N
or CC N
excision NN N
by IN N
supervised JJ N
training NN N
gynecologists NNS N
as IN N
primary JJ N
surgeons NNS N
. . N

Follow-up JJ N
questionnaires NNS N
documented VBN N
pain NN N
levels NNS N
every DT N
3 CD N
months NNS N
for IN N
1 CD N
year NN N
and CC N
then RB N
every DT N
6 CD N
months NNS N
for IN N
5 CD N
years NNS N
. . N

MEASUREMENTS NNP N
AND CC N
MAIN NNP N
RESULTS NNP N
Change NNP N
in IN N
pain NN N
VAS NNP N
scores VBZ N
during IN N
5 CD N
years NNS N
after IN N
the DT N
operation NN N
and CC N
rates NNS N
of IN N
pregnancy NN N
, , N
repeat NN N
surgery NN N
, , N
and CC N
use NN N
of IN N
hormone NN N
therapy NN N
were VBD N
evaluated VBN N
. . N

There EX N
was VBD N
a DT N
reduction NN N
in IN N
all DT N
pain NN N
scores NNS N
over IN N
the DT N
5-year JJ N
follow-up NN N
in IN N
both DT N
treatment NN N
groups NNS N
. . N

A DT N
significantly RB N
greater JJR N
reduction NN N
in IN N
dyspareunia NN N
VAS NNP N
scores NNS N
was VBD N
observed VBN N
in IN N
the DT N
excision NN N
group NN N
at IN N
5 CD N
years NNS N
( ( N
p JJ N
= NN N
.03 NN N
at IN N
univariate JJ N
analysis NN N
, , N
and CC N
p NN N
= NN N
.007 NN N
at IN N
multivariate JJ N
analysis NN N
) ) N
. . N

More JJR N
women NNS N
in IN N
the DT N
ablation NN N
group NN N
continued VBD N
to TO N
receive VB N
medical JJ N
treatment NN N
of IN N
endometriosis NN N
at IN N
5 CD N
years NNS N
( ( N
p JJ N
= NNP N
.004 NNP N
) ) N
. . N

CONCLUSIONS NNP N
Surgical NNP N
treatment NN N
of IN N
endometriosis NN N
provides VBZ N
symptom JJ N
reduction NN N
for IN N
up IN N
to TO N
5 CD N
years NNS N
. . N

In IN N
some DT N
limited JJ N
areas NNS N
such JJ N
as IN N
deep JJ N
dyspareunia NN N
, , N
excision NN N
is VBZ N
more RBR N
effective JJ N
than IN N
ablation NN N
. . N

-DOCSTART- -X- O O 15193471

An DT N
open JJ N
and CC N
randomized JJ N
study NN N
comparing VBG N
the DT N
efficacy NN N
of IN N
standard JJ N
danazol NN N
and CC N
modified VBD N
triptorelin NN N
regimens NNS N
for IN N
postoperative JJ N
disease NN N
management NN N
of IN N
moderate JJ 4_p
to TO 4_p
severe JJ 4_p
endometriosis NN 4_p
. . N

OBJECTIVE UH N
To TO N
compare VB N
the DT N
efficacy NN N
of IN N
danazol NN N
and CC N
triptorelin NN N
( ( N
Decapeptyl NNP N
CR NNP N
, , N
Ferring NNP N
, , N
Kiel NNP N
, , N
Germany NNP N
) ) N
in IN N
the DT N
management NN N
of IN N
moderate JJ N
and CC N
severe JJ N
endometriosis NN N
in IN N
terms NNS N
of IN N
symptom NN N
control NN N
and CC N
revised VBN N
American JJ N
Fertility NNP N
Society NNP N
( ( N
AFS NNP N
) ) N
score NN N
reduction NN N
, , N
and CC N
to TO N
evaluate VB N
the DT N
hormonal JJ N
profile NN N
of IN N
patients NNS N
treated VBN N
with IN N
triptorelin NN N
every DT N
6 CD N
weeks NNS N
. . N

DESIGN NNP N
Open NNP N
and CC N
randomized VBN N
trial NN N
. . N

SETTING NN N
Kwong NNP N
Wah NNP N
Hospital NNP N
, , N
a DT N
large JJ N
public JJ N
hospital NN N
in IN N
an DT N
urban JJ N
location NN N
( ( N
Hong NNP N
Kong NNP N
) ) N
. . N

PATIENT NNP N
( ( N
S NNP N
) ) N
Forty NNP N
patients NNS N
after IN N
their PRP$ N
first JJ N
conservative JJ N
operation NN N
for IN N
endometriosis NN N
, , N
with IN N
surgical JJ N
confirmation NN N
of IN N
revised VBN N
AFS NNP 4_p
stage NN 4_p
III NNP 4_p
or CC 4_p
IV NNP 4_p
endometriosis NN 4_p
. . N

INTERVENTION NNP N
( ( N
S NNP N
) ) N
Postoperative VBP N
6 CD N
months NNS N
' POS N
therapy NN N
of IN N
danazol NN N
or CC N
triptorelin NN N
every DT N
6 CD N
weeks NNS N
, , N
postmedical JJ N
therapy NN N
second-look NN N
laparoscopy NN N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURE NNP N
( ( N
S NNP N
) ) N
Symptom NNP N
control NN N
and CC N
patients NNS N
' POS N
tolerance NN N
during IN N
medical JJ N
therapy NN N
, , N
posttherapy NN N
revised VBD N
AFS NNP N
score NN N
, , N
hormonal JJ N
profile NN N
during IN N
triptorelin JJ N
therapy NN N
. . N

RESULT NNP N
( ( N
S NNP N
) ) N
Pain NNP N
control NN N
was VBD N
similar JJ N
between IN N
danazol NN N
and CC N
triptorelin NN N
therapy NN N
. . N

There EX N
was VBD N
less JJR N
breakthrough IN N
bleeding NN N
with IN N
triptorelin NN N
. . N

More JJR N
patients NNS N
failed VBD N
to TO N
complete VB N
the DT N
whole JJ N
course NN N
of IN N
danazol NN N
because IN N
of IN N
its PRP$ N
side NN N
effects NNS N
. . N

The DT N
revised JJ N
AFS NNP N
score NN N
at IN N
second-look JJ N
laparoscopy NN N
did VBD N
not RB N
show VB N
a DT N
significant JJ N
difference NN N
between IN N
the DT N
two CD N
medications NNS N
. . N

Adequate NNP N
pituitary JJ N
suppression NN N
was VBD N
observed VBN N
with IN N
injection NN N
of IN N
triptorelin NN N
every DT N
6 CD N
weeks NNS N
. . N

CONCLUSION NNP N
( ( N
S NNP N
) ) N
Lengthening NNP N
of IN N
triptorelin JJ N
administration NN N
intervals NNS N
from IN N
4 CD N
weeks NNS N
to TO N
6 CD N
weeks NNS N
is VBZ N
effective JJ N
in IN N
maintaining VBG N
a DT N
hypoestrogenic JJ N
state NN N
. . N

Patients NNS N
were VBD N
more RBR N
compliant JJ N
with IN N
triptorelin NN N
than IN N
danazol NN N
. . N

Thus RB N
, , N
triptorelin JJ N
injection NN N
every DT N
6 CD N
weeks NNS N
is VBZ N
more JJR N
cost-effective JJ N
than IN N
conventional JJ N
regimens NNS N
. . N

-DOCSTART- -X- O O 1833682

Desogestrel NNP N
and CC N
gestodene NN N
in IN N
oral JJ N
contraceptives NNS N
: : N
12 CD N
months NNS N
' POS N
assessment NN N
of IN N
carbohydrate NN N
and CC N
lipoprotein JJ N
metabolism NN N
. . N

We PRP N
examined VBD N
the DT N
influence NN N
on IN N
carbohydrate NN N
and CC N
lipoprotein JJ N
metabolism NN N
of IN N
oral JJ N
contraceptives NNS N
( ( N
OCs NNP N
) ) N
containing VBG N
two CD N
new JJ N
third-generation NN N
progestogens NNS N
, , N
desogestrel NN N
and CC N
gestodene NN N
. . N

This DT N
was VBD N
a DT N
prospective JJ N
randomized NN N
study NN N
in IN N
which WDT N
monophasic JJ N
combinations NNS N
of IN N
20 CD N
micrograms NNS N
ethinyl VBP N
estradiol NN N
( ( N
E2 NNP N
) ) N
and CC N
150 CD N
micrograms NNS N
desogestrel VBD N
or CC N
30 CD N
micrograms NNS N
ethinyl VBP N
E2 NNP N
plus CC N
75 CD N
micrograms NNS N
gestodene VBP N
were VBD N
administered VBN N
to TO N
15 CD 4_p
and CC 4_p
19 CD 4_p
healthy JJ 4_p
women NNS 4_p
, , 4_p
respectively RB 4_p
. . 4_p

An DT N
oral JJ N
glucose NN N
tolerance NN N
test NN N
including VBG N
measurement NN N
of IN N
insulin NN N
response NN N
was VBD N
performed VBN N
before IN N
treatment NN N
and CC N
after IN N
3 CD N
, , N
6 CD N
, , N
and CC N
12 CD N
months NNS N
of IN N
treatment NN N
. . N

We PRP N
also RB N
determined VBD N
fasting VBG N
plasma JJ N
concentrations NNS N
of IN N
total JJ N
cholesterol NN N
; : N
high-density JJ N
lipoprotein NN N
cholesterol NN N
, , N
including VBG N
the DT N
subfractions NNS N
high-density NN N
lipoprotein2 NN N
cholesterol NN N
and CC N
high-density NN N
lipoprotein3 NN N
cholesterol NN N
; : N
low-density JJ N
lipoprotein NN N
cholesterol NN N
; : N
very RB N
low-density NN N
lipoprotein NN N
cholesterol NN N
; : N
and CC N
triglycerides NNS N
. . N

A DT N
transient JJ N
deterioration NN N
of IN N
glucose JJ N
tolerance NN N
was VBD N
observed VBN N
despite IN N
unchanged JJ N
levels NNS N
of IN N
insulin NN N
after IN N
treatment NN N
with IN N
both DT N
compounds NNS N
for IN N
3 CD N
months NNS N
. . N

In IN N
both DT N
groups NNS N
plasma VBP N
levels NNS N
of IN N
triglycerides NNS N
, , N
very RB N
low-density JJ N
lipoprotein NN N
cholesterol NN N
, , N
and CC N
high-density NN N
lipoprotein NN N
cholesterol NN N
increased VBD N
significantly RB N
after IN N
3 CD N
months NNS N
. . N

After IN N
12 CD N
months NNS N
, , N
a DT N
significant JJ N
increase NN N
in IN N
the DT N
high-density NN N
lipoprotein NN N
cholesterol/total JJ N
cholesterol NN N
ratio NN N
was VBD N
observed VBN N
in IN N
the DT N
ethinyl JJ N
E2-desogestrel NNP N
group NN N
, , N
and CC N
no DT N
persistent JJ N
changes NNS N
in IN N
low-density NN N
lipoprotein NN N
cholesterol NN N
could MD N
be VB N
demonstrated VBN N
in IN N
any DT N
of IN N
the DT N
groups NNS N
. . N

Our PRP$ N
results NNS N
indicate VBP N
that IN N
treatment NN N
with IN N
either DT N
compound NN N
for IN N
12 CD N
months NNS N
has VBZ N
no DT N
effect NN N
on IN N
carbohydrate NN N
or CC N
lipoprotein JJ N
metabolism NN N
known VBN N
to TO N
increase VB N
the DT N
risk NN N
of IN N
cardiovascular JJ N
disease NN N
. . N

-DOCSTART- -X- O O 26109247

A DT N
Randomized NNP N
Controlled NNP N
Trial NNP N
to TO N
Improve VB N
Social NNP N
Skills NNP N
in IN N
Young NNP N
Adults NNP N
with IN N
Autism NNP 4_p
Spectrum NNP 4_p
Disorder NNP 4_p
: : N
The DT N
UCLA NNP N
PEERS NNP N
( ( N
® NNP N
) ) N
Program NNP N
. . N

Research NNP N
suggests VBZ N
that IN N
impaired JJ N
social JJ N
skills NNS N
are VBP N
often RB N
the DT N
most RBS N
significant JJ N
challenge NN N
for IN N
those DT N
with IN N
autism NN N
spectrum NN N
disorder NN N
( ( N
ASD NNP N
) ) N
, , N
yet RB N
few JJ N
evidence-based JJ N
social JJ N
skills NNS N
interventions NNS N
exist VBP N
for IN N
adults NNS N
on IN 4_p
the DT 4_p
spectrum NN 4_p
. . N

This DT N
replication NN N
trial NN N
tested VBD N
the DT N
effectiveness NN N
of IN N
PEERS NNP N
, , N
a DT N
caregiver-assisted JJ N
social JJ N
skills NNS N
program NN N
for IN N
high-functioning JJ 4_p
young JJ N
adults NNS N
with IN N
ASD NNP N
. . N

Using VBG N
a DT N
randomized VBN N
controlled JJ N
design NN N
, , N
22 CD N
young JJ N
adults NNS N
18-24 JJ N
years NNS N
of IN N
age NN N
were VBD N
randomly RB N
assigned VBN N
to TO N
a DT N
treatment NN N
( ( N
n JJ N
= NNP N
12 CD N
) ) N
or CC N
delayed VBN N
treatment NN N
control NN N
( ( N
n JJ N
= NNP N
10 CD N
) ) N
group NN N
. . N

Results NNP N
revealed VBD N
that IN N
the DT N
treatment NN N
group NN N
improved VBD N
significantly RB N
in IN N
overall JJ N
social JJ N
skills NNS N
, , N
frequency NN N
of IN N
social JJ N
engagement NN N
, , N
and CC N
social JJ N
skills NNS N
knowledge NN N
, , N
and CC N
significantly RB N
reduced VBN N
ASD NNP N
symptoms NNS N
related VBN N
to TO N
social JJ N
responsiveness NN N
following VBG N
PEERS NNP N
. . N

Most JJS N
treatment NN N
gains NNS N
were VBD N
maintained VBN N
at IN N
a DT N
16-week JJ N
follow-up JJ N
assessment NN N
with IN N
new JJ N
improvements NNS N
observed VBN N
. . N

-DOCSTART- -X- O O 12044624

A DT N
single JJ N
infusion NN N
of IN N
intravenous JJ N
ketamine NN N
improves VBZ N
pain VBP N
relief NN N
in IN N
patients NNS 4_p
with IN 4_p
critical JJ 4_p
limb NN 4_p
ischaemia NN 4_p
: : 4_p
results NNS N
of IN N
a DT N
double JJ N
blind NN N
randomised VBD N
controlled VBN N
trial NN N
. . N

We PRP N
report VBP N
the DT N
first JJ N
double JJ N
blind NN N
randomised VBD N
controlled JJ N
trial NN N
of IN N
regular JJ N
opioids NNS N
and CC N
an DT N
infusion NN N
of IN N
low JJ N
dose NN N
( ( N
0.6 CD N
mg/kg NN N
) ) N
intravenous JJ N
ketamine NN N
compared VBN N
with IN N
opioids NNS N
and CC N
placebo NN N
in IN N
patients NNS N
with IN N
allodynia NN 4_p
, , N
hyperalgesia NN 4_p
and CC N
hyperpathia NN 4_p
secondary JJ 4_p
to TO 4_p
critical JJ 4_p
limb NN 4_p
ischaemia NN 4_p
. . N

Thirty-five JJ N
patients NNS N
completed VBD N
the DT N
study NN N
, , N
18 CD N
received VBD N
regular JJ N
opioids NNS N
plus CC N
ketamine NN N
, , N
while IN N
17 CD N
received VBD N
regular JJ N
opioids NNS N
plus CC N
placebo NN N
. . N

Using VBG N
the DT N
Brief NNP N
Pain NNP N
Inventory NNP N
, , N
the DT N
% NN N
pain NN N
relief NN N
that IN N
the DT N
patients NNS N
in IN N
the DT N
ketamine NN N
group NN N
attributed VBD N
to TO N
their PRP$ N
medication NN N
improved VBN N
significantly RB N
from IN N
50 CD N
% NN N
immediately RB N
pre-infusion NN N
to TO N
65 CD N
% NN N
24 CD N
h JJ N
post-infusion NN N
and CC N
69 CD N
% NN N
5 CD N
days NNS N
post VBN N
infusion NN N
. . N

Over IN N
the DT N
same JJ N
period NN N
, , N
the DT N
pain NN N
relief NN N
achieved VBN N
by IN N
the DT N
placebo NN N
group NN N
rose VBD N
from IN N
58 CD N
% NN N
pre-infusion NN N
to TO N
56 CD N
% NN N
24 CD N
h NN N
post NN N
infusion NN N
and CC N
then RB N
50 CD N
% NN N
relief NN N
5 CD N
days NNS N
later RB N
. . N

This DT N
was VBD N
statistically RB N
significant JJ N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
using VBG N
both DT N
the DT N
t-test NN N
and CC N
the DT N
Wilcoxon NNP N
Rank NNP N
Sum NNP N
test NN N
. . N

The DT N
ketamine NN N
group NN N
also RB N
showed VBD N
a DT N
statistically RB N
significant JJ N
difference NN N
24 CD N
h NN N
post NN N
infusion NN N
of IN N
the DT N
effect NN N
of IN N
pain NN N
on IN N
their PRP$ N
general JJ N
activity NN N
( ( N
P=0.03 NNP N
) ) N
and CC N
on IN N
their PRP$ N
enjoyment NN N
of IN N
life NN N
( ( N
P=0.004 NNP N
) ) N
. . N

This DT N
study NN N
shows VBZ N
that IN N
combining VBG N
a DT N
single JJ N
infusion NN N
of IN N
low JJ N
dose JJ N
ketamine NN N
with IN N
regular JJ N
opioid JJ N
analgesia NN N
can MD N
result VB N
in IN N
a DT N
significant JJ N
improvement NN N
in IN N
pain NN N
relief NN N
for IN N
this DT N
patient NN N
group NN N
. . N

-DOCSTART- -X- O O 17700649

Should MD N
snacks NNS N
be VB N
recommended VBN N
in IN N
obesity NN 4_p
treatment NN N
? . N
A DT N
1-year JJ N
randomized JJ N
clinical JJ N
trial NN N
. . N

OBJECTIVE UH N
To TO N
study VB N
the DT N
effect NN N
to TO N
recommend VB N
no DT N
snacks NNS N
vs VBP N
three CD N
snacks NNS N
per IN N
day NN N
on IN N
1-year JJ N
weight JJ N
loss NN N
. . N

The DT N
hypothesis NN N
was VBD N
that IN N
it PRP N
is VBZ N
easier JJR N
to TO N
control VB N
energy NN N
intake NN N
and CC N
lose VB N
weight NN N
if IN N
snacks NNS N
in IN N
between IN N
meals NNS N
are VBP N
omitted VBN N
. . N

SUBJECTS/METHOD NNP N
In IN N
total JJ N
140 CD N
patients NNS N
( ( N
36 CD N
men NNS 4_p
, , N
104 CD N
women NNS 4_p
) ) N
, , N
aged VBN N
18-60 CD N
years NNS N
and CC N
body NN N
mass NN N
index NN N
> VBD N
30 CD N
kg/m NN N
( ( N
2 CD N
) ) N
were VBD N
randomized VBN N
and CC N
93 CD N
patients NNS N
( ( N
27 CD N
men NNS 4_p
, , N
66 CD N
women NNS 4_p
) ) N
completed VBD N
the DT N
study NN N
. . N

A DT N
1-year JJ N
randomized JJ N
intervention NN N
trial NN N
was VBD N
conducted VBN N
with IN N
two CD N
treatment NN N
arms NNS N
with IN N
different JJ N
eating VBG N
frequencies NNS N
; : N
3 CD N
meals/day NN N
( ( N
3M CD N
) ) N
or CC N
3 CD N
meals NNS N
and CC N
3 CD N
snacks/day NN N
( ( N
3+3M CD N
) ) N
. . N

The DT N
patients NNS N
received VBD N
regular JJ N
and CC N
individualized JJ N
counseling NN N
by IN N
dieticians NNS N
. . N

Information NN N
on IN N
eating NN N
patterns NNS N
, , N
dietary JJ N
intake NN N
, , N
weight NN N
and CC N
metabolic JJ N
variables NNS N
was VBD N
collected VBN N
at IN N
baseline NN N
and CC N
after IN N
1 CD N
year NN N
. . N

RESULTS NNP N
Over IN N
1 CD N
year NN N
the DT N
3M CD N
group NN N
reported VBD N
a DT N
decrease NN N
in IN N
the DT N
number NN N
of IN N
snacks NNS N
whereas VBP N
the DT N
3+3M CD N
group NN N
reported VBD N
an DT N
increase NN N
( ( N
-1.1 JJ N
vs NN N
+0.4 NN N
snacks/day NN N
, , N
respectively RB N
, , N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

Both DT N
groups NNS N
decreased VBD N
energy NN N
intake NN N
and CC N
E NNP N
% NN N
( ( N
energy NN N
percent NN N
) ) N
fat NN N
and CC N
increased VBD N
E NNP N
% NN N
protein NN N
and CC N
fiber VB N
intake NN N
but CC N
there EX N
was VBD N
no DT N
differences NNS N
between IN N
the DT N
groups NNS N
. . N

Both DT N
groups NNS N
lost VBD N
weight NN N
, , N
but CC N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
weight JJ N
loss NN N
after IN N
1 CD N
year NN N
of IN N
treatment NN N
( ( N
3M CD N
vs RB N
3+3M=-4.1+/-6.1 JJ N
vs NN N
-5.9+/-9.4 NNP N
kg NN N
; : N
P=0.31 NNP N
) ) N
. . N

Changes NNS N
in IN N
metabolic JJ N
variables NNS N
did VBD N
not RB N
differ VB N
between IN N
the DT N
groups NNS N
, , N
except IN N
for IN N
high-density NN N
lipoprotein NN N
that WDT N
increased VBD N
in IN N
the DT N
3M CD N
group NN N
but CC N
not RB N
in IN N
3+3M CD N
group NN N
( ( N
P NNP N
< VBZ N
0.033 CD N
for IN N
group NN N
difference NN N
) ) N
. . N

CONCLUSION NNP N
Recommending VBG N
snacks NNS N
or CC N
not RB N
between IN N
meals NNS N
does VBZ N
not RB N
influence VB N
1-year JJ N
weight NN N
loss NN N
. . N

-DOCSTART- -X- O O 7831456

Naltrexone NNP N
plasma NN N
levels NNS N
, , N
clinical JJ N
response NN N
and CC N
effect NN N
on IN N
weight NN N
in IN N
autistic JJ 4_p
children NNS 4_p
. . 4_p

This DT N
research NN N
measured VBD N
naltrexone NN N
levels NNS N
in IN N
plasma NN N
, , N
to TO N
assess VB N
the DT N
relationship NN N
between IN N
behavioral JJ N
response NN N
to TO N
naltrexone CD N
and CC N
plasma NN N
levels NNS N
, , N
and CC N
the DT N
effects NNS N
of IN N
naltrexone NN N
on IN N
weight NN N
in IN N
hospitalized VBN 4_p
autistic JJ 4_p
children NNS 4_p
( ( 4_p
n JJ 4_p
= NNP 4_p
41 CD 4_p
) ) 4_p
. . 4_p

A DT N
double-blind JJ N
, , N
placebo-controlled JJ N
, , N
parallel JJ N
groups NNS N
design NN N
with IN N
fixed JJ N
dose NN N
was VBD N
used VBN N
, , N
with IN N
random JJ N
assignment NN N
to TO N
naltrexone CD N
or CC N
placebo VB N
. . N

Drug NNP N
plasma NN N
levels NNS N
were VBD N
analyzed VBN N
by IN N
gas NN N
chromatography/mass NN N
spectrometry NN N
, , N
and CC N
weights NNS N
were VBD N
obtained VBN N
weekly RB N
. . N

Naltrexone NN N
levels NNS N
measured VBN N
in IN N
17 CD N
children NNS N
ranged VBD N
from IN N
0.12 CD N
to TO N
5.60 CD N
ng/mL NNS N
( ( N
mean JJ N
= NN N
0.71 CD N
, , N
standard JJ N
error NN N
of IN N
the DT N
mean JJ N
= NNP N
0.32 CD N
) ) N
. . N

There EX N
was VBD N
no DT N
relationship NN N
between IN N
plasma NN N
levels NNS N
and CC N
age NN N
, , N
level NN N
of IN N
intellectual JJ N
functioning NN N
, , N
scores NNS N
on IN N
the DT N
14 CD N
selected VBD N
Children NNP N
's POS N
Psychiatric NNP N
Rating NNP N
Scale NNP N
( ( N
CPRS NNP N
) ) N
items NNS N
, , N
Clinical NNP N
Global NNP N
Impressions NNP N
, , N
Global NNP N
Clinical NNP N
Consensus NNP N
, , N
and CC N
the DT N
CPRS NNP N
hyperactivity NN N
factor NN N
. . N

There EX N
was VBD N
a DT N
trend NN N
( ( N
p JJ N
= NNP N
.06 NNP N
) ) N
for IN N
children NNS N
receiving VBG N
naltrexone NN N
in IN N
the DT N
highest JJS N
weight NN N
percentile NN N
( ( N
> CD N
or CC N
= VB N
90th CD N
) ) N
to TO N
lose VB N
weight NN N
( ( N
mean JJ N
= NNP N
-0.42 NNP N
kg NN N
) ) N
but CC N
this DT N
was VBD N
not RB N
the DT N
case NN N
for IN N
those DT N
in IN N
the DT N
lower JJR N
weight NN N
percentiles NNS N
( ( N
mean JJ N
= NNP N
+0.03 NNP N
kg NN N
) ) N
. . N

-DOCSTART- -X- O O 22565161

Once-daily RB N
MMX NNP N
( ( N
® NNP N
) ) N
mesalamine NN N
for IN N
endoscopic JJ N
maintenance NN N
of IN N
remission NN N
of IN N
ulcerative JJ 4_p
colitis NN 4_p
. . N

OBJECTIVES NNP N
Treatment NNP N
with IN N
mesalamine NN N
to TO N
maintain VB N
endoscopic JJ N
remission NN N
( ( N
mucosal JJ N
healing VBG N
) ) N
of IN N
ulcerative JJ N
colitis NN N
( ( N
UC NNP N
) ) N
has VBZ N
been VBN N
shown VBN N
to TO N
reduce VB N
the DT N
risk NN N
of IN N
relapse NN N
and CC N
is VBZ N
the DT N
recommended JJ N
first-line JJ N
maintenance NN N
therapy NN N
. . N

To TO N
improve VB N
treatment NN N
adherence NN N
, , N
a DT N
mesalamine NN N
formulation NN N
that WDT N
can MD N
be VB N
administered VBN N
once-daily RB N
, , N
MMX NNP N
( ( N
® NNP N
) ) N
mesalamine NN N
( ( N
Lialda NNP N
; : N
Shire NNP N
Pharmaceuticals NNP N
LLC NNP N
, , N
Wayne NNP N
, , N
PA NNP N
) ) N
, , N
was VBD N
developed VBN N
. . N

This DT N
study NN N
was VBD N
conducted VBN N
to TO N
determine VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
once-daily JJ N
MMX NNP N
mesalamine NN N
compared VBN N
with IN N
twice-daily JJ N
delayed-release JJ N
mesalamine NN N
( ( N
Asacol NNP N
; : N
Warner NNP N
Chilcott NNP N
, , N
Dublin NNP N
, , N
Ireland NNP N
) ) N
for IN N
maintaining VBG N
endoscopic JJ N
remission NN N
in IN N
patients NNS N
with IN N
UC NNP N
. . N

METHODS NNP N
A NNP N
multicenter NN N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
6-month JJ N
, , N
active-control JJ N
trial NN N
was VBD N
conducted VBN N
to TO N
assess VB N
the DT N
non-inferiority NN N
of IN N
once-daily JJ N
MMX NNP N
mesalamine NN N
2.4 CD N
g/day NN N
compared VBN N
with IN N
twice-daily JJ N
delayed-release JJ N
mesalamine NN N
at IN N
a DT N
total JJ N
daily JJ N
dose NN N
of IN N
1.6 CD N
g/day NN N
in IN N
patients NNS N
with IN N
UC NNP N
in IN N
endoscopic JJ N
remission NN N
. . N

The DT N
primary JJ N
end NN N
point NN N
was VBD N
maintenance NN N
of IN N
endoscopic JJ N
remission NN N
at IN N
month NN N
6 CD N
in IN N
the DT N
per-protocol NN N
( ( N
PP NNP N
) ) N
population NN N
. . N

RESULTS NNP N
Overall NNP N
, , N
826 CD N
patients NNS N
were VBD N
randomized VBN N
and CC N
dosed VBN N
. . N

The DT N
primary JJ N
objective JJ N
( ( N
non-inferiority NN N
) ) N
was VBD N
met VBN N
. . N

At IN N
month NN N
6 CD N
, , N
83.7 CD N
and CC N
77.8 CD N
% NN N
of IN N
patients NNS N
receiving VBG N
MMX NNP N
mesalamine NN N
in IN N
the DT N
PP NNP N
and CC N
intent-to-treat NN N
( ( N
ITT NNP N
) ) N
populations NNS N
, , N
respectively RB N
, , N
had VBD N
maintained VBN N
endoscopic JJ N
remission NN N
compared VBN N
with IN N
81.5 CD N
% NN N
( ( N
PP NNP N
) ) N
and CC N
76.9 CD N
% NN N
( ( N
ITT NNP N
) ) N
of IN N
patients NNS N
receiving VBG N
delayed-release JJ N
mesalamine NN N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
for IN N
difference NN N
: : N
-3.9 CD N
% NN N
, , N
8.1 CD N
% NN N
( ( N
PP NNP N
) ) N
; : N
-5.0 CD N
% NN N
, , N
6.9 CD N
% NN N
( ( N
ITT NNP N
) ) N
) ) N
. . N

Time NN N
to TO N
relapse VB N
was VBD N
not RB N
significantly RB N
different JJ N
between IN N
the DT N
two CD N
treatment NN N
groups NNS N
( ( N
log-rank JJ N
test NN N
, , N
P=0.5116 NNP N
( ( N
PP NNP N
) ) N
; : N
P=0.5455 NNP N
( ( N
ITT NNP N
) ) N
) ) N
. . N

The DT N
proportion NN N
of IN N
patients NNS N
with IN N
adverse JJ N
events NNS N
was VBD N
37.1 CD N
and CC N
36.0 CD N
% NN N
in IN N
patients NNS N
receiving VBG N
MMX NNP N
mesalamine NN N
and CC N
delayed-release JJ N
mesalamine NN N
, , N
respectively RB N
. . N

CONCLUSIONS NNP N
Once-daily JJ N
dosing NN N
of IN N
MMX NNP N
mesalamine NN N
2.4 CD N
g/day NN N
was VBD N
shown VBN N
to TO N
be VB N
well RB N
tolerated VBN N
and CC N
non-inferior JJ N
to TO N
twice-daily JJ N
dosing VBG N
with IN N
delayed-release JJ N
mesalamine NN N
1.6 CD N
g/day NN N
for IN N
maintenance NN N
of IN N
endoscopic JJ N
remission NN N
in IN N
patients NNS N
with IN N
UC NNP N
. . N

-DOCSTART- -X- O O 7928125

The DT N
effect NN N
of IN N
a DT N
culture-specific JJ N
education NN N
program NN N
to TO N
promote VB N
breastfeeding NN N
among IN N
Vietnamese JJ 4_p
women NNS N
in IN N
Sydney NNP N
. . N

The DT N
rate NN N
of IN N
breastfeeding VBG N
among IN N
immigrant JJ 4_p
Vietnamese JJ 4_p
women NNS N
in IN N
Western JJ N
countries NNS N
is VBZ N
low JJ N
compared VBN N
to TO N
those DT N
in IN N
Vietnam NNP N
. . N

To TO N
counteract VB N
this DT N
trend NN N
, , N
a DT N
language NN N
and CC N
culture NN N
specific JJ N
education NN N
program NN N
was VBD N
developed VBN N
. . N

An DT N
experimental JJ N
design NN N
was VBD N
used VBN N
to TO N
test VB N
the DT N
effectiveness NN N
of IN N
this DT N
program NN N
. . N

The DT N
sample NN N
consisted VBD N
of IN N
182 CD N
prenatal JJ 4_p
Vietnamese JJ 4_p
women NNS N
. . N

Data NNP N
collection NN N
included VBD N
questionnaires NNS N
and CC N
interviews NNS N
. . N

Results NNS N
suggested VBD N
that IN N
the DT N
education NN N
program NN N
had VBD N
significant JJ N
effects NNS N
on IN N
knowledge NN N
, , N
attitudes NNS N
, , N
planned VBD N
and CC N
actual JJ N
behaviour NN N
towards NNS N
breastfeeding VBG N
. . N

However RB N
, , N
the DT N
effect NN N
did VBD N
not RB N
sustain VB N
until IN N
6 CD N
months NNS N
postpartum NN N
. . N

Implications NNS N
for IN N
nursing NN N
practice NN N
and CC N
further JJ N
research NN N
are VBP N
discussed VBN N
. . N

-DOCSTART- -X- O O 22686292

Can MD N
simvastatin VB N
improve VB N
erectile JJ N
function NN N
and CC N
health-related JJ N
quality NN N
of IN N
life NN N
in IN N
men NNS N
aged VBN N
≥40 CD N
years NNS N
with IN N
erectile JJ N
dysfunction NN N
? . N
Results NNS N
of IN N
the DT N
Erectile NNP N
Dysfunction NNP N
and CC N
Statins NNP N
Trial NNP N
[ NNP N
ISRCTN66772971 NNP N
] NNP N
. . N

OBJECTIVE NNP N
To TO N
evaluate VB N
the DT N
effectiveness NN N
and CC N
cost-effectiveness NN N
of IN N
simvastatin NN N
on IN N
erectile JJ N
function NN N
and CC N
health-related JJ N
quality NN N
of IN N
life NN N
in IN N
men NNS N
aged VBN N
≥40 CD N
years NNS N
with IN N
erectile JJ N
dysfunction NN N
( ( N
ED NNP N
) ) N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
ED NNP N
is VBZ N
common JJ N
in IN N
men NNS N
aged VBN N
≥40 CD N
years NNS N
and CC N
impacts NNS N
upon VBP N
their PRP$ N
overall JJ N
health-related JJ N
quality NN N
of IN N
life NN N
and CC N
that IN N
of IN N
their PRP$ N
partners NNS N
. . N

Men NNP N
aged VBD N
≥40 CD N
years NNS N
who WP N
were VBD N
not RB N
receiving VBG N
lipid JJ N
lowering NN N
or CC N
anti-hypertensive JJ 4_p
medication NN N
and CC N
not RB N
at IN N
high JJ N
cardiovascular JJ N
risk NN N
were VBD N
recruited VBN N
from IN N
10 CD N
general JJ N
practices NNS N
in IN N
the DT N
East NNP N
of IN N
England NNP N
. . N

In IN N
total JJ N
, , N
173 CD N
eligible JJ N
men NNS N
with IN N
untreated JJ 4_p
ED NNP 4_p
were VBD N
randomized VBN N
to TO N
double-blind VB N
treatment NN N
with IN N
40 CD N
mg NNS N
of IN N
simvastatin NN N
or CC N
placebo NN N
once RB N
daily JJ N
for IN N
6 CD N
months NNS N
. . N

Data NNS N
were VBD N
collected VBN N
at IN N
three CD N
points NNS N
over IN N
30 CD N
weeks NNS N
. . N

The DT N
main JJ N
outcome NN N
was VBD N
erectile JJ N
function NN N
( ( N
International NNP N
Index NNP N
of IN N
Erectile NNP N
Function-5 NNP N
score NN N
) ) N
. . N

Secondary JJ N
outcomes NNS N
included VBD N
male JJ N
ED-specific JJ N
quality NN N
of IN N
life NN N
( ( N
MED-QoL NNP N
) ) N
, , N
quality-adjusted JJ N
life NN N
years NNS N
( ( N
QALYs NNP N
) ) N
using VBG N
the DT N
generic JJ N
Euroqol NNP N
measure NN N
( ( N
EQ-5D NNP N
) ) N
, , N
endothelial JJ N
function NN N
, , N
cardiovascular JJ N
risk NN N
, , N
cholesterol NN N
and CC N
health NN N
service NN N
costs NNS N
. . N

RESULTS NNP N
There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
erectile JJ N
function NN N
between IN N
the DT N
simvastatin NN N
and CC N
placebo NN N
groups NNS N
( ( N
mean JJ N
change NN N
, , N
1.28 CD N
vs NN N
0.07 CD N
, , N
z NN N
= VBD N
1.1 CD N
, , N
p NN N
= NNP N
0.27 CD N
) ) N
, , N
although IN N
a DT N
significant JJ N
improvement NN N
in IN N
MED-QoL NNP N
was VBD N
observed VBN N
( ( N
5 CD N
% NN N
vs JJ N
2 CD N
% NN N
, , N
z NN N
= VBD N
2.09 CD N
, , N
p NN N
= NNP N
0.04 CD N
) ) N
. . N

Both DT N
10-year JJ N
cardiovascular NN N
risk NN N
and CC N
low-density NN N
lipoprotein NN N
were VBD N
reduced VBN N
( ( N
cardiovascular JJ N
risk NN N
, , N
z NN N
= NNP N
-3.67 NNP N
, , N
p NN N
< VBD N
0.001 CD N
; : N
low-density JJ N
lipoprotein NN N
, , N
z NN N
= NNP N
-5.46 NNP N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
, , N
with IN N
no DT N
consistent JJ N
change NN N
in IN N
endothelial JJ N
function NN N
. . N

The DT N
frequency NN N
of IN N
sexual JJ N
encounters NNS N
is VBZ N
correlated VBN N
with IN N
improved JJ N
erectile JJ N
function NN N
. . N

The DT N
joint JJ N
distribution NN N
of IN N
costs NNS N
and CC N
QALY NNP N
benefits NNS N
indicates VBZ N
that IN N
the DT N
probability NN N
of IN N
simvastatin NN N
being VBG N
cost-effective JJ N
for IN N
willingness-to-pay JJ N
thresholds NNS N
of IN N
£20,000 NN N
and CC N
£30,000 NN N
is VBZ N
86 CD N
% NN N
and CC N
83 CD N
% NN N
, , N
respectively RB N
. . N

CONCLUSIONS NNP N
Identifying VBG N
men NNS N
with IN N
ED NNP N
provides VBZ N
an DT N
opportunity NN N
to TO N
modify VB N
future JJ N
cardiovascular JJ N
risk NN N
and CC N
to TO N
improve VB N
MED-QoL NNP N
by IN N
treating VBG N
them PRP N
with IN N
40 CD N
mg NNS N
of IN N
simvastatin NN N
. . N

The DT N
joint JJ N
analysis NN N
of IN N
costs NNS N
and CC N
QALY NNP N
benefits NNS N
suggests VBZ N
that IN N
there EX N
is VBZ N
high JJ N
probability NN N
that IN N
simvastatin NN N
is VBZ N
a DT N
cost-effective JJ N
strategy NN N
in IN N
men NNS N
with IN N
ED NNP N
. . N

The DT N
findings NNS N
could MD N
influence VB N
urological JJ N
and CC N
primary JJ N
care NN N
practice NN N
by IN N
including VBG N
questions NNS N
on IN N
ED NNP N
during IN N
routine JJ N
consultations NNS N
and CC N
relevant JJ N
clinical JJ N
protocols NNS N
. . N

This DT N
provides VBZ N
an DT N
opportunity NN N
to TO N
impart VB N
lifestyle JJ N
advice NN N
. . N

-DOCSTART- -X- O O 23782653

Home-based JJ N
reach-to-grasp JJ N
training NN N
for IN N
people NNS N
after IN 4_p
stroke NN 4_p
: : N
study NN N
protocol NN N
for IN N
a DT N
feasibility NN N
randomized VBN N
controlled VBN N
trial NN N
. . N

BACKGROUND VB N
This DT N
feasibility NN N
study NN N
is VBZ N
intended VBN N
to TO N
assess VB N
the DT N
acceptability NN N
of IN N
home-based JJ N
task-specific JJ N
reach-to-grasp NN N
( ( N
RTG NNP N
) ) N
training NN N
for IN N
people NNS N
with IN N
stroke NN 4_p
, , N
and CC N
to TO N
gather VB N
data NNS N
to TO N
inform VB N
recruitment NN N
, , N
retention NN N
, , N
and CC N
sample JJ N
size NN N
for IN N
a DT N
definitive JJ N
randomized NN N
controlled VBD N
trial NN N
. . N

METHODS/DESIGN NNP N
This DT N
is VBZ N
to TO N
be VB N
a DT N
randomized JJ N
controlled JJ N
feasibility NN N
trial NN N
recruiting VBG N
50 CD N
individuals NNS N
with IN N
upper-limb JJ 4_p
motor NN 4_p
impairment NN 4_p
after IN N
stroke NN 4_p
. . N

Participants NNS N
will MD N
be VB N
recruited VBN N
after IN 4_p
discharge NN 4_p
from IN 4_p
hospital NN 4_p
and CC 4_p
up RB 4_p
to TO 4_p
12 CD 4_p
months NNS 4_p
post-stroke RB 4_p
from IN N
hospital NN N
stroke NN 4_p
services NNS N
and CC N
community NN N
therapy-provider NN N
services NNS N
. . N

Participants NNS N
will MD N
be VB N
assessed VBN N
at IN N
baseline NN N
, , N
and CC N
then RB N
electronically RB N
randomized VBN N
and CC N
allocated VBN N
to TO N
group NN N
by IN N
minimization NN N
, , N
based VBN N
on IN N
the DT N
time NN N
post-stroke JJ N
and CC N
extent NN N
of IN N
upper-limb JJ N
impairment NN N
. . N

The DT N
intervention NN N
group NN N
will MD N
receive VB N
14 CD N
training NN N
sessions NNS N
, , N
each DT N
1 CD N
hour NN N
long RB N
, , N
with IN N
a DT N
physiotherapist NN N
over IN N
6 CD N
weeks NNS N
and CC N
will MD N
be VB N
encouraged VBN N
to TO N
practice NN N
independently RB N
for IN N
1 CD N
hour/day NN N
to TO N
give VB N
a DT N
total NN N
of IN N
56 CD N
hours NNS N
of IN N
training NN N
time NN N
per IN N
participant NN N
. . N

Participants NNS N
allocated VBD N
to TO N
the DT N
control NN N
group NN N
will MD N
receive VB N
arm NN N
therapy NN N
in IN N
accordance NN N
with IN N
usual JJ N
care NN N
. . N

Participants NNS N
will MD N
be VB N
measured VBN N
at IN N
7 CD N
weeks NNS N
post-randomization NN N
, , N
and CC N
followed-up NN N
at IN N
3 CD N
and CC N
6 CD N
months NNS N
post-randomization NN N
. . N

Primary JJ N
outcome NN N
measures NNS N
for IN N
assessment NN N
of IN N
arm NN N
function NN N
are VBP N
the DT N
Action NNP N
Research NNP N
Arm NNP N
Test NNP N
( ( N
ARAT NNP N
) ) N
and CC N
Wolf NNP N
Motor NNP N
Function NNP N
Test NNP N
( ( N
WMFT NNP N
) ) N
. . N

Secondary JJ N
measures NNS N
are VBP N
the DT N
Motor NNP N
Activity NNP N
Log NNP N
, , N
Stroke NNP N
Impact NNP N
Scale NNP N
, , N
Carer NNP N
Strain NNP N
Index NNP N
, , N
and CC N
health NN N
and CC N
social JJ N
care NN N
resource NN N
use NN N
. . N

All DT N
assessments NNS N
will MD N
be VB N
conducted VBN N
by IN N
a DT N
trained JJ N
assessor NN N
blinded VBD N
to TO N
treatment NN N
allocation NN N
. . N

Recruitment NNP N
, , N
adherence NN N
, , N
withdrawals NNS N
, , N
adverse JJ N
events NNS N
( ( N
AEs NNP N
) ) N
, , N
and CC N
completeness NN N
of IN N
data NNS N
will MD N
be VB N
recorded VBN N
and CC N
reported VBN N
. . N

DISCUSSION NNP N
This DT N
study NN N
will MD N
determine VB N
the DT N
acceptability NN N
of IN N
the DT N
intervention NN N
, , N
the DT N
characteristics NNS N
of IN N
the DT N
population NN N
recruited VBD N
, , N
recruitment NN N
and CC N
retention NN N
rates NNS N
, , N
descriptive JJ N
statistics NNS N
of IN N
outcomes NNS N
, , N
and CC N
incidence NN N
of IN N
AEs NNP N
. . N

It PRP N
will MD N
provide VB N
the DT N
information NN N
needed VBN N
for IN N
planning VBG N
a DT N
definitive JJ N
trial NN N
to TO N
test VB N
home-based JJ N
RTG NNP N
training NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
ISRCTN NNP N
ISRCTN56716589 NNP N
. . N

-DOCSTART- -X- O O 24713181

Effect NN N
of IN N
body NN N
mass NN N
index NN N
on IN N
hemiparetic JJ N
gait NN N
. . N

OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
relationship NN N
between IN N
body NN N
mass NN N
index NN N
( ( N
BMI NNP N
) ) N
and CC N
spatiotemporal JJ N
, , N
kinematic JJ N
, , N
and CC N
kinetic JJ N
gait NN N
parameters NNS N
in IN N
chronic JJ 4_p
hemiparetic JJ 4_p
stroke NN 4_p
survivors NNS N
. . N

DESIGN NNP N
Secondary JJ N
analysis NN N
of IN N
data NNS N
collected VBN N
in IN N
a DT N
randomized NN N
controlled VBN N
trial NN N
comparing VBG N
two CD N
12-week JJ N
ambulation NN N
training NN N
treatments NNS N
. . N

SETTING NN N
Academic NNP N
medical JJ N
center NN N
. . N

PARTICIPANTS NNP N
Chronic NNP 4_p
hemiparetic JJ 4_p
stroke NN 4_p
survivors NNS N
( ( N
N NNP N
= NNP N
108 CD N
, , N
> RB N
3 CD N
months NNS N
poststroke RB 4_p
) ) N
METHODS NNP N
Linear NNP N
regression NN N
analyses NNS N
were VBD N
performed VBN N
of IN N
BMI NNP N
, , N
and CC N
selected VBN N
pretreatment JJ N
gait NN N
parameters NNS N
were VBD N
recorded VBN N
using VBG N
quantitative JJ N
gait NN N
analysis NN N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Spatiotemporal NNP N
, , N
kinematic JJ N
, , N
and CC N
kinetic JJ N
gait NN N
parameters NNS N
. . N

RESULTS VB N
A NNP N
series NN N
of IN N
linear JJ N
regression NN N
models NNS N
that WDT N
controlled VBD N
for IN N
age NN N
, , N
gender NN N
, , N
stroke VBD N
type NN N
( ( N
ischemic JJ N
versus NN N
hemorrhagic NN N
) ) N
, , N
interval JJ N
poststroke NN N
, , N
level NN N
of IN N
motor NN N
impairment NN N
( ( N
Fugl-Meyer NNP N
score NN N
) ) N
, , N
and CC N
walking VBG N
speed NN N
found VBD N
BMI NNP N
to TO N
be VB N
positively RB N
associated VBN N
with IN N
step NN N
width NN N
( ( N
m NN N
) ) N
( ( N
β JJ N
= NN N
0.364 CD N
, , N
P NNP N
< NNP N
.001 NNP N
) ) N
, , N
positively RB N
associated VBN N
with IN N
peak JJ N
hip NN N
abduction NN N
angle NN N
of IN N
the DT N
nonparetic JJ N
limb NN N
during IN N
stance NN N
( ( N
deg NN N
) ) N
( ( N
β JJ N
= NN N
0.177 CD N
, , N
P NNP N
= NNP N
.040 NNP N
) ) N
, , N
negatively RB N
associated VBN N
with IN N
ankle JJ N
dorsiflexion NN N
angle NN N
at IN N
initial JJ N
contact NN N
of IN N
the DT N
paretic JJ N
limb NN N
( ( N
deg NN N
) ) N
( ( N
β JJ N
= NNP N
-0.222 NNP N
, , N
P NNP N
= NNP N
.023 NNP N
) ) N
, , N
and CC N
negatively RB N
associated VBN N
with IN N
peak NN N
ankle JJ N
power NN N
at IN N
push-off NN N
( ( N
W/kg NNP N
) ) N
of IN N
the DT N
paretic JJ N
limb NN N
( ( N
W/kg NNP N
) ) N
( ( N
β JJ N
= NNP N
-0.142 NNP N
, , N
P NNP N
= NNP N
.026 NNP N
) ) N
. . N

CONCLUSIONS NNP N
When WRB N
walking VBG N
at IN N
a DT N
similar JJ N
speed NN N
, , N
chronic JJ 4_p
hemiparetic JJ 4_p
stroke NN 4_p
subjects NNS N
with IN N
a DT N
higher JJR N
BMI NNP N
demonstrated VBD N
greater JJR N
step NN N
width NN N
, , N
greater JJR N
hip NN N
hiking NN N
of IN N
the DT N
paretic JJ N
lower JJR N
limb NN N
, , N
less RBR N
paretic JJ N
limb NN N
dorsiflexion NN N
at IN N
initial JJ N
contact NN N
, , N
and CC N
less RBR N
paretic JJ N
ankle NN N
power NN N
at IN N
push-off NN N
as IN N
compared VBN N
to TO N
stroke VB N
subjects NNS N
with IN N
a DT N
lower JJR N
BMI NNP N
and CC N
similar JJ N
level NN N
of IN N
motor NN N
impairment NN N
. . N

Further JJ N
studies NNS N
are VBP N
necessary JJ N
to TO N
determine VB N
the DT N
clinical JJ N
relevance NN N
of IN N
these DT N
findings NNS N
with IN N
respect NN N
to TO N
rehabilitation NN N
strategies NNS N
for IN N
gait JJ N
dysfunction NN N
in IN N
hemiparetic JJ N
patients NNS N
with IN N
higher JJR N
BMIs NNP 4_p
. . N

-DOCSTART- -X- O O 9071556

Effect NN N
of IN N
desonide NN N
ointment NN N
, , N
0.05 CD N
% NN N
, , N
on IN N
the DT N
hypothalamic-pituitary-adrenal JJ N
axis NN N
of IN N
children NNS N
with IN N
atopic NN 4_p
dermatitis NN 4_p
. . N

Desonide NNP N
ointment NN N
has VBZ N
demonstrated VBN N
a DT N
good JJ N
safety NN N
and CC N
efficacy NN N
profile NN N
during IN N
the DT N
many JJ N
years NNS N
it PRP N
has VBZ N
been VBN N
used VBN N
in IN N
treating VBG N
dermatoses NNS N
. . N

However RB N
, , N
there EX N
have VBP N
been VBN N
no DT N
controlled JJ N
clinical JJ N
trials NNS N
to TO N
evaluate VB N
its PRP$ N
systemic JJ N
safety NN N
when WRB N
used VBN N
in IN N
treating VBG N
children NNS N
. . N

Suppression NN N
of IN N
the DT N
hypothalamic-pituitary-adrenal JJ N
( ( N
HPA NNP N
) ) N
axis NN N
can MD N
occur VB N
after IN N
repeated JJ N
application NN N
of IN N
topical JJ N
corticosteroids NNS N
. . N

In IN N
general JJ N
, , N
the DT N
degree NN N
of IN N
suppression NN N
of IN N
the DT N
HPA NNP N
axis NN N
function NN N
is VBZ N
related VBN N
to TO N
the DT N
daily JJ N
dosage NN N
of IN N
steroid JJ N
given VBN N
, , N
the DT N
duration NN N
of IN N
its PRP$ N
administration NN N
, , N
the DT N
extent NN N
of IN N
body NN N
surface NN N
covered VBN N
, , N
and CC N
the DT N
potency NN N
of IN N
the DT N
corticosteroid NN N
. . N

This DT N
study NN N
sought VBD N
to TO N
determine VB N
the DT N
comparative JJ N
effects NNS N
of IN N
0.05 CD N
percent NN N
desonide NN N
and CC N
2.5 CD N
percent NN N
hydrocortisone NN N
ointments NNS N
on IN N
the DT N
HPA NNP N
axis NN N
of IN N
children NNS N
with IN N
atopic NN 4_p
dermatitis NN 4_p
. . N

There EX N
was VBD N
no DT N
suppression NN N
of IN N
early JJ N
morning NN N
cortisol NN N
in IN N
either DT N
treatment NN N
group NN N
. . N

The DT N
ACTH-stimulated JJ N
mean NN N
cortisol NN N
values NNS N
after IN N
four CD N
weeks NNS N
of IN N
treatment NN N
were VBD N
not RB N
significantly RB N
different JJ N
from IN N
the DT N
baseline NN N
values VBZ N
for IN N
either DT N
treatment NN N
group NN N
. . N

We PRP N
conclude VBP N
that IN N
neither CC N
0.05 CD N
percent NN N
desonide NN N
ointment NN N
nor CC N
2.5 CD N
percent NN N
hydrocortisone NN N
ointment NN N
compromised VBD N
the DT N
HPA NNP N
axis NN N
of IN N
children NNS N
with IN N
atopic NN 4_p
dermatitis NN 4_p
treated VBD N
topically RB N
for IN N
four CD N
weeks NNS N
. . N

-DOCSTART- -X- O O 23875574

Components NNS N
of IN N
working VBG N
memory NN N
and CC N
visual JJ N
selective JJ N
attention NN N
. . N

Load NNP N
theory NN N
( ( N
Lavie NNP N
, , N
N. NNP N
, , N
Hirst NNP N
, , N
A. NNP N
, , N
De NNP N
Fockert NNP N
, , N
J. NNP N
W. NNP N
, , N
& CC N
Viding NNP N
, , N
E. NNP N
[ NNP N
2004 CD N
] NNP N
. . N

Load NNP N
theory NN N
of IN N
selective JJ N
attention NN N
and CC N
cognitive JJ N
control NN N
. . N

Journal NNP N
of IN N
Experimental NNP N
Psychology NNP N
: : N
General NNP N
, , N
133 CD N
, , N
339-354 JJ N
. . N

) ) N
proposes VBZ N
that IN N
control NN N
of IN N
attention NN N
depends VBZ N
on IN N
the DT N
amount NN N
and CC N
type NN N
of IN N
load NN N
that WDT N
is VBZ N
imposed VBN N
by IN N
current JJ N
processing NN N
. . N

Specifically RB N
, , N
perceptual JJ N
load NN N
should MD N
lead VB N
to TO N
efficient JJ N
distractor NN N
rejection NN N
, , N
whereas IN N
working VBG N
memory NN N
load NN N
( ( N
dual-task JJ N
coordination NN N
) ) N
should MD N
hinder VB N
distractor NN N
rejection NN N
. . N

Studies NNPS N
support VBP N
load NN N
theory NN N
's POS N
prediction NN N
that IN N
working VBG N
memory NN N
load NN N
will MD N
lead VB N
to TO N
larger JJR N
distractor NN N
effects NNS N
; : N
however RB N
, , N
these DT N
studies NNS N
used VBD N
secondary JJ N
tasks NNS N
that WDT N
required VBD N
only RB N
verbal JJ N
working VBG N
memory NN N
and CC N
the DT N
central JJ N
executive NN N
. . N

The DT N
present JJ N
study NN N
examined VBD N
which WDT N
other JJ N
working VBG N
memory NN N
components NNS N
( ( N
visual JJ N
, , N
spatial JJ N
, , N
and CC N
phonological JJ N
) ) N
influence NN N
visual JJ 4_p
selective JJ 4_p
attention NN 4_p
. . N

Subjects NNS N
completed VBD N
an DT N
attentional JJ N
capture NN N
task NN N
alone RB N
( ( N
single-task JJ N
) ) N
or CC N
while IN N
engaged VBN N
in IN N
a DT N
working JJ N
memory NN N
task NN N
( ( N
dual-task JJ N
) ) N
. . N

Results CC N
showed VBD N
that IN N
along IN N
with IN N
the DT N
central JJ N
executive NN N
, , N
visual JJ N
and CC N
spatial JJ N
working VBG N
memory NN N
influenced VBD N
selective JJ N
attention NN N
, , N
but CC N
phonological JJ N
working VBG N
memory NN N
did VBD N
not RB N
. . N

Specifically RB N
, , N
attentional JJ N
capture NN N
was VBD N
larger JJR N
when WRB N
visual JJ N
or CC N
spatial JJ N
working VBG N
memory NN N
was VBD N
loaded VBN N
, , N
but CC N
phonological JJ N
working VBG N
memory NN N
load NN N
did VBD N
not RB N
affect VB N
attentional JJ N
capture NN N
. . N

The DT N
results NNS N
are VBP N
consistent JJ N
with IN N
load NN N
theory NN N
and CC N
suggest VBP N
specific JJ N
components NNS N
of IN N
working VBG N
memory NN N
influence NN N
visual JJ N
selective JJ N
attention NN N
. . N

-DOCSTART- -X- O O 2881132

Antibiotic JJ N
elimination NN N
of IN N
group-B JJ N
streptococci NN N
in IN N
urine NN N
in IN N
prevention NN N
of IN N
preterm JJ 4_p
labour NN 4_p
. . N

The DT N
presence NN N
of IN N
group-B JJ N
streptococci NN N
in IN N
the DT N
urine NN N
of IN N
pregnant JJ 4_p
women NNS N
seems VBZ N
to TO N
be VB N
associated VBN N
with IN N
preterm JJ N
labour NN N
. . N

Urine JJ N
samples NNS N
from IN N
4122 CD N
women NNS N
at IN N
27-31 JJ N
weeks NNS N
' POS N
gestation NN N
were VBD N
examined VBN N
for IN N
bacteria NNS N
. . N

Group-B JJ N
streptococci NN N
were VBD N
found VBN N
in IN N
the DT N
urine NN N
of IN N
69 CD N
women NNS N
. . N

In IN N
a DT N
double-blind NN N
, , N
controlled VBD N
study NN N
these DT N
patients NNS N
were VBD N
given VBN N
either CC N
penicillin NN N
( ( N
10 CD N
( ( N
6 CD N
) ) N
IU NNP N
three CD N
times NNS N
daily RB N
for IN N
6 CD N
days NNS N
; : N
37 CD N
patients NNS N
) ) N
or CC N
placebo NN N
( ( N
32 CD N
patients NNS N
) ) N
. . N

The DT N
rates NNS N
of IN N
primary JJ N
rupture NN N
of IN N
the DT N
membranes NNS N
( ( N
11 CD N
% NN N
v JJ N
53 CD N
% NN N
; : N
p CC N
less JJR N
than IN N
0.001 CD N
) ) N
and CC N
preterm VB N
labour NN N
( ( N
5.4 CD N
% NN N
v JJ N
38 CD N
% NN N
; : N
p CC N
less JJR N
than IN N
0.002 CD N
) ) N
were VBD N
significantly RB N
lower JJR N
in IN N
the DT N
penicillin NN N
group NN N
than IN N
in IN N
the DT N
placebo NN N
group NN N
. . N

These DT N
results NNS N
suggest VBP N
that IN N
treatment NN N
and CC N
follow-up NN N
to TO N
prevent VB N
recolonisation NN N
in IN N
pregnant JJ 4_p
women NNS N
with IN N
group-B JJ 4_p
streptococci NN 4_p
in IN N
the DT N
urine NN N
may MD N
reduce VB N
the DT N
frequency NN N
of IN N
preterm JJ N
labour NN N
in IN N
these DT N
patients NNS N
. . N

-DOCSTART- -X- O O 10742359

Impact NN N
of IN N
an DT N
encounter-based JJ N
prompting NN N
system NN N
on IN N
resident JJ 4_p
vaccine JJ 4_p
administration NN 4_p
performance NN 4_p
and CC 4_p
immunization NN 4_p
knowledge NN 4_p
. . 4_p

OBJECTIVES NNP N
To TO N
evaluate VB N
an DT N
encounter-based JJ N
immunization NN N
prompting VBG N
system NN N
on IN N
resident JJ N
performance NN N
in IN N
administering VBG N
vaccines NNS N
and CC N
knowledge NN N
of IN N
immunization NN N
guidelines NNS N
. . N

DESIGN/METHODS NNP N
Prospective NNP N
randomized VBD N
, , N
controlled VBD N
trial NN N
. . N

Subjects NNS N
were VBD N
first- JJ N
and CC N
second-year JJ N
pediatric JJ N
residents NNS N
in IN N
a DT N
hospital-based JJ N
continuity NN N
clinic NN N
. . N

The DT N
intervention NN N
group NN N
received VBD N
manual JJ N
prompts NNS N
of IN N
immunizations NNS N
due JJ N
. . N

Postclinic NNP N
chart NN N
review NN N
compared VBN N
immunizations NNS N
due JJ N
with IN N
those DT N
administered VBN N
. . N

Acceptable JJ N
and CC N
unacceptable JJ N
reasons NNS N
for IN N
not RB N
administering VBG N
vaccines NNS N
were VBD N
assigned VBN N
. . N

Resident NNP N
knowledge NN N
was VBD N
measured VBN N
by IN N
a DT N
70-item JJ N
examination NN N
. . N

RESULTS VB N
The DT N
intervention NN N
group NN N
had VBD N
significantly RB N
less RBR N
missed JJ N
opportunities/vaccine JJ N
administration NN N
errors NNS N
( ( N
11.4 CD N
% NN N
vs JJ N
21.6 CD N
% NN N
) ) N
. . N

The DT N
most RBS N
common JJ N
reason NN N
for IN N
unacceptable JJ N
errors NNS N
in IN N
the DT N
intervention NN N
group NN N
: : N
vaccine NN N
was VBD N
given VBN N
too RB N
early JJ N
; : N
in IN N
the DT N
control NN N
group NN N
: : N
vaccine NN N
was VBD N
postponed VBN N
to TO N
next JJ N
visit NN N
. . N

Pre- NNP N
and CC N
postintervention NN N
knowledge NN N
scores NNS N
were VBD N
similar JJ N
: : N
intervention NN N
group NN N
( ( N
75.5 CD N
% NN N
vs JJ N
80.7 CD N
% NN N
, , N
control NN N
group NN N
; : N
76.5 CD N
% NN N
vs JJ N
81.3 CD N
% NN N
) ) N
. . N

CONCLUSION NNP N
An DT N
immunization NN N
prompting VBG N
system NN N
in IN N
a DT N
hospital-based JJ N
pediatric JJ N
resident NN N
continuity NN N
clinic NN N
reduced VBD N
missed JJ N
opportunities/vaccine JJ N
administration NN N
errors NNS N
without IN N
significantly RB N
impacting VBG N
resident JJ N
knowledge NN N
of IN N
immunization NN N
guidelines.immunization NN N
schedule NN N
, , N
vaccination NN N
, , N
immunization NN N
, , N
prompting VBG N
systems NNS N
, , N
resident JJ N
education NN N
. . N

-DOCSTART- -X- O O 23905378

[ NN N
Treating VBG N
rheumatoid JJ N
arthritis NN N
patients NNS N
of IN N
Shen NNP N
deficiency NN N
and CC N
cold JJ N
invading NN N
syndrome NN N
by IN N
bushen NN N
quhan NN N
zhiwang CD N
decoction NN N
combined VBN N
methotrexate NN N
: : N
an DT N
evaluation NN N
of IN N
clinical JJ N
efficacy NN N
and CC N
safety NN N
] NN N
. . N

OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
clinical JJ N
efficacy NN N
and CC N
safety NN N
of IN N
bushen NN N
quhan NN N
zhiwang CD N
decoction NN N
( ( N
BQZD NNP N
) ) N
combined VBN N
methotrexate NN N
( ( N
MTX NNP N
) ) N
in IN N
treating VBG N
rheumatoid NN N
arthritis NN N
( ( N
RA NNP N
) ) N
. . N

METHODS CC N
A DT N
prospective JJ N
, , N
randomized VBN N
controlled VBD N
study NN N
was VBD N
carried VBN N
out RP N
. . N

RA NNP N
patients NNS N
of IN N
Shen NNP N
deficiency NN N
and CC N
cold JJ N
invading NN N
syndrome NN N
in IN N
the DT N
treatment NN N
group NN N
( ( N
120 CD N
cases NNS N
) ) N
were VBD N
treated VBN N
with IN N
BQZD NNP N
and CC N
MTX NNP N
( ( N
10 CD N
mg/week NN N
) ) N
, , N
while IN N
those DT N
in IN N
the DT N
control NN N
group NN N
( ( N
120 CD N
cases NNS N
) ) N
were VBD N
treated VBN N
with IN N
MTX NNP N
( ( N
10 CD N
mg/week NN N
) ) N
alone RB N
. . N

The DT N
therapeutic JJ N
course NN N
for IN N
all DT N
was VBD N
24 CD N
weeks NNS N
. . N

The DT N
efficacy NN N
and CC N
safety NN N
indices NNS N
were VBD N
evaluated VBN N
at IN N
the DT N
baseline NN N
and CC N
24 CD N
weeks NNS N
after IN N
treatment NN N
, , N
including VBG N
clinical JJ N
signs NNS N
and CC N
symptoms NNS N
, , N
condition NN N
assessment NN N
, , N
Health NNP N
Assessment NNP N
Questionnaire NNP N
( ( N
HAQ NNP N
) ) N
, , N
disease NN N
activity NN N
index NN N
28 CD N
( ( N
DAS28 NNP N
) ) N
, , N
laboratory JJ N
parameters NNS N
of IN N
erythrocyte JJ N
sedimentation NN N
rate NN N
( ( N
ESR NNP N
) ) N
and CC N
C-reactive JJ N
protein NN N
( ( N
CRP NNP N
) ) N
, , N
safety NN N
indicators NNS N
, , N
and CC N
Chinese NNP N
medical JJ N
syndrome NN N
integrals NNS N
. . N

RESULTS VB N
The DT N
total JJ N
effective JJ N
rate NN N
was VBD N
80 CD N
. . N

0 CD N
% NN N
in IN N
the DT N
treatment NN N
group NN N
, , N
better JJR N
than IN N
that DT N
of IN N
the DT N
control NN N
group NN N
( ( N
66.7 CD N
% NN N
) ) N
, , N
showing VBG N
statistical JJ N
difference NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

In IN N
the DT N
two CD N
groups NNS N
significant JJ N
improvement NN N
of IN N
clinical JJ N
signs NNS N
and CC N
symptoms NNS N
, , N
ESR NNP N
, , N
CRP NNP N
, , N
visual JJ N
analogue NN N
scale NN N
( ( N
VAS NNP N
) ) N
by IN N
both DT N
physicians NNS N
and CC N
patients NNS N
, , N
HAQ NNP N
, , N
DAS28 NNP N
, , N
and CC N
Chinese NNP N
medical JJ N
syndrome NN N
integrals NNS N
after IN N
treatment NN N
were VBD N
shown VBN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

Better JJR N
effects NNS N
were VBD N
obtained VBN N
in IN N
the DT N
treatment NN N
group NN N
in IN N
lessening VBG N
tender NN N
joint NN N
numbers NNS N
and CC N
swollen JJ N
joint NN N
numbers NNS N
, , N
VAS NNP N
by IN N
both DT N
physicians NNS N
and CC N
patients NNS N
, , N
DAS28 NNP N
, , N
and CC N
Chinese NNP N
medical JJ N
syndrome NN N
integrals NNS N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Besides NNP N
, , N
adverse JJ N
reactions NNS N
occurred VBD N
less RBR N
in IN N
the DT N
treatment NN N
group NN N
than IN N
in IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSIONS NNP N
BQZD NNP N
had VBD N
roles NNS N
in IN N
relieving VBG N
symptoms NNS N
, , N
improving VBG N
joint JJ N
functions NNS N
, , N
signs NNS N
, , N
ESR NNP N
, , N
and CC N
CRP NNP N
. . N

It PRP N
was VBD N
an DT N
effective JJ N
herb NN N
for IN N
RA NNP N
patients NNS N
of IN N
Shen NNP N
deficiency NN N
and CC N
cold JJ N
invading NN N
syndrome NN N
. . N

It PRP N
could MD N
enhance VB N
the DT N
efficacy NN N
and CC N
reduce VB N
adverse JJ N
reactions NNS N
of IN N
MTX NNP N
through IN N
synergistic JJ N
effects NNS N
with IN N
MTX NNP N
. . N

-DOCSTART- -X- O O 19122080

Detection NN N
of IN N
traumatic JJ N
arthrotomy NN N
of IN N
the DT N
knee NN N
using VBG N
the DT N
saline JJ N
solution NN N
load NN N
test NN N
. . N

BACKGROUND IN N
The DT N
saline JJ N
solution NN N
load NN N
test NN N
helps VBZ N
to TO N
determine VB N
if IN N
a DT N
wound NN N
extends VBZ N
into IN N
the DT N
knee NN N
joint NN N
. . N

Little JJ N
is VBZ N
known VBN N
about IN N
the DT N
volume NN N
of IN N
injected JJ N
intra-articular JJ N
saline NN N
solution NN N
that WDT N
is VBZ N
needed VBN N
to TO N
effectively RB N
rule VB N
in IN N
or CC N
rule VB N
out IN N
a DT N
traumatic JJ N
arthrotomy NN N
of IN N
the DT N
knee NN N
. . N

The DT N
purpose NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
determine VB N
the DT N
appropriate JJ N
volume NN N
and CC N
needle JJ N
location NN N
for IN N
the DT N
diagnosis NN N
of IN N
a DT N
traumatic JJ N
knee NN N
arthrotomy NN N
and CC N
to TO N
assess VB N
the DT N
effect NN N
of IN N
associated JJ N
variables NNS N
, , N
including VBG N
knee NN N
circumference NN N
, , N
body NN N
mass NN N
index NN N
, , N
and CC N
sex NN N
. . N

METHODS NNP N
Fifty-six NNP N
consecutive JJ N
patients NNS N
scheduled VBN 4_p
for IN 4_p
knee NN 4_p
arthroscopy NN 4_p
were VBD N
enrolled VBN N
. . N

A DT N
standard JJ N
inferolateral JJ N
arthroscopic NN N
portal NN N
was VBD N
made VBN N
with IN N
a DT N
single JJ N
stab NN N
incision NN N
with IN N
use NN N
of IN N
a DT N
number-11 JJ N
blade NN N
. . N

Injection NN N
sites NNS N
were VBD N
randomized VBN N
to TO N
either VB N
a DT N
superomedial NN N
or CC N
inferomedial JJ N
location NN N
. . N

The DT N
injection NN N
of IN N
normal JJ N
saline JJ N
solution NN N
at IN N
a DT N
rate NN N
of IN N
5 CD N
mL/sec NNS N
through IN N
an DT N
18-gauge JJ N
needle NN N
was VBD N
continued VBN N
while IN N
the DT N
knee NN N
was VBD N
moved VBN N
through IN N
a DT N
range NN N
of IN N
motion NN N
until IN N
fluid NNS N
extravasated VBN N
from IN N
the DT N
iatrogenic JJ N
laceration NN N
. . N

The DT N
volume NN N
of IN N
injected JJ N
fluid NN N
was VBD N
recorded VBN N
. . N

RESULTS VB N
The DT N
study NN N
group NN N
included VBD N
thirty-one JJ N
female NN N
patients NNS N
and CC N
twenty-five JJ N
male NN N
patients NNS N
with IN N
a DT N
combined JJ N
average JJ N
age NN N
of IN N
fifty JJ N
years NNS N
and CC N
an DT N
average JJ N
body NN N
mass NN N
index NN N
of IN N
30.9 CD N
. . N

In IN N
order NN N
to TO N
effectively RB N
diagnose VB N
50 CD N
% NN N
of IN N
the DT N
arthrotomies NNS N
, , N
75 CD N
mL NN N
of IN N
injected JJ N
fluid NN N
was VBD N
needed VBN N
; : N
the DT N
volumes NNS N
that WDT N
were VBD N
needed VBN N
in IN N
order NN N
to TO N
effectively RB N
diagnose VB N
75 CD N
% NN N
, , N
90 CD N
% NN N
, , N
95 CD N
% NN N
, , N
and CC N
99 CD N
% NN N
of IN N
the DT N
arthrotomies NNS N
were VBD N
110 CD N
, , N
145 CD N
, , N
155 CD N
, , N
and CC N
175 CD N
mL NN N
, , N
respectively RB N
. . N

The DT N
mean JJ N
volumes NNS N
of IN N
injected JJ N
fluid NN N
needed VBN N
for IN N
a DT N
positive JJ N
result NN N
at IN N
the DT N
inferomedial JJ N
and CC N
superomedial JJ N
needle JJ N
locations NNS N
were VBD N
64.0 CD N
and CC N
95.2 CD N
mL NN N
, , N
respectively RB N
; : N
this DT N
difference NN N
was VBD N
significant JJ N
( ( N
p JJ N
= NNP N
0.01 CD N
) ) N
. . N

There EX N
was VBD N
no DT N
correlation NN N
between IN N
necessary JJ N
injection NN N
volume NN N
and CC N
sex NN N
, , N
body NN N
mass NN N
index NN N
, , N
or CC N
knee VB N
circumference NN N
. . N

CONCLUSIONS NNP N
In IN N
order NN N
to TO N
detect VB N
95 CD N
% NN N
of IN N
1-cm JJ N
inferolateral JJ N
arthrotomies NNS N
of IN N
the DT N
knee NN N
with IN N
use NN N
of IN N
the DT N
saline JJ N
solution NN N
load NN N
test NN N
, , N
155 CD N
mL NN N
must MD N
be VB N
injected VBN N
. . N

An DT N
inferomedial JJ N
injection NN N
location NN N
requires VBZ N
significantly RB N
less JJR N
fluid NN N
than IN N
a DT N
superomedial JJ N
injection NN N
location NN N
does VBZ N
for IN N
the DT N
diagnosis NN N
of IN N
inferolateral JJ N
arthrotomies NNS N
of IN N
the DT N
knee NN N
. . N

-DOCSTART- -X- O O 24821891

Sociopsychological JJ N
tailoring VBG N
to TO N
address VB N
colorectal JJ N
cancer NN N
screening VBG N
disparities NNS N
: : N
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

PURPOSE NNP N
Interventions NNP N
tailored VBD N
to TO N
sociopsychological JJ N
factors NNS N
associated VBN N
with IN N
health NN N
behaviors NNS N
have VBP N
promise NN N
for IN N
reducing VBG N
colorectal JJ N
cancer NN N
screening VBG N
disparities NNS N
, , N
but CC N
limited VBD N
research NN N
has VBZ N
assessed VBN N
their PRP$ N
impact NN N
in IN N
multiethnic JJ N
populations NNS N
. . N

We PRP N
examined VBD N
whether IN N
an DT N
interactive JJ N
multimedia NN N
computer NN N
program NN N
( ( N
IMCP NNP N
) ) N
tailored VBD N
to TO N
expanded VB N
health NN N
belief NN N
model NN N
sociopsychological JJ N
factors NNS N
could MD N
promote VB N
colorectal JJ N
cancer NN N
screening NN N
in IN N
a DT N
multiethnic JJ 4_p
sample NN 4_p
. . N

METHODS NNP N
We PRP N
undertook VBD N
a DT N
randomized VBN N
controlled VBN N
trial NN N
, , N
comparing VBG N
an DT N
IMCP NNP N
tailored VBD N
to TO N
colorectal JJ N
cancer NN N
screening VBG N
self-efficacy NN N
, , N
knowledge NN N
, , N
barriers NNS N
, , N
readiness NN N
, , N
test NN N
preference NN N
, , N
and CC N
experiences NNS N
with IN N
a DT N
nontailored JJ N
informational JJ N
program NN N
, , N
both DT N
delivered VBN N
before IN N
office NN N
visits NNS N
. . N

The DT N
primary JJ N
outcome NN N
was VBD N
record-documented JJ N
colorectal JJ N
cancer NN N
screening VBG N
during IN N
a DT N
12-month JJ N
follow-up JJ N
period NN N
. . N

Secondary JJ N
outcomes NNS N
included VBD N
postvisit JJ N
sociopsychological JJ N
factor NN N
status NN N
and CC N
discussion NN N
, , N
as RB N
well RB N
as IN N
clinician JJ N
recommendation NN N
of IN N
screening VBG N
during IN N
office NN N
visits NNS N
. . N

We PRP N
enrolled VBD N
1,164 CD N
patients NNS N
stratified VBN N
by IN N
ethnicity NN N
and CC N
language NN N
( ( N
49.3 CD N
% NN N
non-Hispanic JJ N
, , N
27.2 CD N
% NN N
Hispanic/English NNP N
, , N
23.4 CD N
% NN N
Hispanic/Spanish NNP N
) ) N
from IN N
26 CD N
offices NNS N
around IN N
5 CD N
centers NNS N
( ( N
Sacramento NNP N
, , N
California NNP N
; : N
Rochester NNP N
and CC N
the DT N
Bronx NNP N
, , N
New NNP N
York NNP N
; : N
Denver NNP N
, , N
Colorado NNP N
; : N
and CC N
San NNP N
Antonio NNP N
, , N
Texas NNP N
) ) N
. . N

RESULTS NNP N
Adjusting NNP N
for IN N
ethnicity/language NN N
, , N
study NN N
center NN N
, , N
and CC N
the DT N
previsit NN N
value NN N
of IN N
the DT N
dependent NN N
variable NN N
, , N
compared VBN N
with IN N
control NN N
patients NNS N
, , N
the DT N
IMCP NNP N
led VBD N
to TO N
significantly RB N
greater JJR N
colorectal JJ N
cancer NN N
screening VBG N
knowledge NN N
, , N
self-efficacy NN N
, , N
readiness NN N
, , N
test NN N
preference NN N
specificity NN N
, , N
discussion NN N
, , N
and CC N
recommendation NN N
. . N

During IN N
the DT N
followup JJ N
period NN N
, , N
132 CD N
( ( N
23 CD N
% NN N
) ) N
IMCP NNP N
and CC N
123 CD N
( ( N
22 CD N
% NN N
) ) N
control NN N
patients NNS N
received VBD N
screening VBG N
( ( N
adjusted VBN N
difference NN N
= $ N
0.5 CD N
percentage NN N
points NNS N
, , N
95 CD N
% NN N
CI NNP N
-4.3 NNP N
to TO N
5.3 CD N
) ) N
. . N

IMCP NNP N
effects NNS N
did VBD N
not RB N
differ VB N
significantly RB N
by IN N
ethnicity/language NN N
. . N

CONCLUSIONS NNP N
Sociopsychological NNP N
factor NN N
tailoring NN N
was VBD N
no DT N
more RBR N
effective JJ N
than IN N
nontailored JJ N
information NN N
in IN N
encouraging VBG N
colorectal JJ N
cancer NN N
screening NN N
in IN N
a DT N
multiethnic JJ 4_p
sample NN 4_p
, , N
despite IN N
enhancing VBG N
sociopsychological JJ N
factors NNS N
and CC N
visit NN N
behaviors NNS N
associated VBN N
with IN N
screening NN N
. . N

The DT N
utility NN N
of IN N
sociopsychological JJ N
tailoring NN N
in IN N
addressing VBG N
screening VBG N
disparities NNS N
remains VBZ N
uncertain JJ N
. . N

-DOCSTART- -X- O O 5653418

One-trial JJ 4_p
learning VBG 4_p
with IN 4_p
control NN 4_p
of IN 4_p
item-difficulty NN 4_p
. . 4_p

-DOCSTART- -X- O O 24077211

Intrathecal JJ N
lentivirus-mediated JJ N
transfer NN N
of IN N
interleukin-10 JJ N
attenuates NNS N
chronic JJ N
constriction NN N
injury-induced JJ N
neuropathic JJ N
pain NN N
through IN N
modulation NN N
of IN N
spinal JJ N
high-mobility NN N
group NN N
box VBZ N
1 CD N
in IN N
rats NNS N
. . N

BACKGROUND NNP N
Neuropathic NNP N
pain NN N
is VBZ N
a DT N
complex JJ N
state NN N
of IN N
chronic JJ N
pain NN N
that WDT N
is VBZ N
usually RB N
accompanied VBN N
by IN N
peripheral JJ N
and CC N
central JJ N
nervous JJ N
system NN N
damage NN N
or CC N
dysfunction NN N
. . N

Previous JJ N
studies NNS N
have VBP N
indicated VBN N
that DT N
neuroinflammation NN N
in IN N
the DT N
spinal JJ N
cord NN N
is VBZ N
an DT N
important JJ N
contributor NN N
to TO N
neuropathological JJ N
and CC N
behavioral JJ N
abnormalities NNS N
. . N

A DT N
series NN N
of IN N
early JJ N
inflammatory NN N
markers NNS N
, , N
such JJ N
as IN N
IL-1 NNP N
, , N
TNF-α NNP N
, , N
and CC N
IFN-γ NNP N
, , N
and CC N
advanced VBD N
inflammatory JJ N
markers NNS N
, , N
such JJ N
as IN N
high-mobility NN N
group NN N
box VBZ N
1 CD N
( ( N
HMGB1 NNP N
) ) N
, , N
are VBP N
involved VBN N
in IN N
neuroinflammation NN N
. . N

STUDY NNP N
DESIGN NNP N
A NNP N
randomized NN N
, , N
double JJ N
blind NN N
, , N
controlled VBD N
animal JJ N
trial NN N
. . N

OBJECTIVE NN N
In IN N
this DT N
study NN N
, , N
a DT N
lentivirus NN N
delivering VBG N
human JJ N
IL-10 NNP N
( ( N
LV/hIL-10 NNP N
) ) N
was VBD N
administered VBN N
intrathecally RB N
to TO N
determine VB N
the DT N
effects NNS N
of IN N
IL-10 NNP N
on IN N
allodynia NN N
and CC N
hyperalgesia NN N
in IN N
a DT N
chronic JJ N
constriction NN N
injury-induced JJ N
( ( N
CCI NNP N
) ) N
rat VBP N
model NN N
of IN N
neuropathic JJ N
pain NN N
. . N

METHODS NNP N
Sprague-Dawley NNP N
rats NNS N
weighting VBG N
260 CD N
- : N
320 CD N
g NN N
were VBD N
randomly RB N
divided VBN N
into IN N
4 CD N
groups NNS N
. . N

Group NNP N
Sham NNP N
( ( N
Sham NNP N
) ) N
, , N
Group NNP N
CCI±Normal NNP N
Saline NNP N
( ( N
NS NNP N
) ) N
, , N
Group NNP N
CCI±LV/hIL-10 NNP N
( ( N
LV/hIL-10 NNP N
) ) N
, , N
and CC N
Group NNP N
CCI±LV/control NNP N
( ( N
vector NN N
) ) N
. . N

Rats NNPS N
in IN N
each DT N
group NN N
were VBD N
intrathecally RB N
delivered VBN N
with IN N
NS NNP N
, , N
LV/control NNP N
, , N
or CC N
recombinant JJ N
vector NN N
LV/hIL-10 NNP N
in IN N
a DT N
total JJ N
volume NN N
of IN N
10 CD N
μl NN N
. . N

Paw NNP N
withdrawal VBD N
mechanical JJ N
thresholds NNS N
( ( N
PWMT NNP N
) ) N
and CC N
paw $ N
withdrawal NN N
thermal JJ N
latency NN N
PWTL NNP N
were VBD N
measured VBN N
one CD N
day NN N
before IN N
CCI NNP N
( ( N
baseline NN N
) ) N
and CC N
0 CD N
, , N
3 CD N
, , N
7 CD N
, , N
14 CD N
, , N
and CC N
28 CD N
days NNS N
after IN N
intrathecal JJ N
administration NN N
. . N

Cerebrospinal JJ N
fluid NN N
( ( N
CSF NNP N
) ) N
samples NNS N
were VBD N
collected VBN N
during IN N
surgical JJ N
plane NN N
anesthesia NN N
and CC N
the DT N
collected JJ N
CSF NNP N
samples NNS N
were VBD N
used VBN N
to TO N
assay VB N
for IN N
human JJ N
IL-10 NNP N
, , N
rat VBZ N
IL-1β NNP N
, , N
rat VBZ N
IL-6 NNP N
, , N
and CC N
rat VB N
TNF-α JJ N
by IN N
enzyme-linked JJ N
immunosorbent NN N
assay NN N
( ( N
ELISA NNP N
) ) N
. . N

Animals NNS N
were VBD N
sacrificed VBN N
and CC N
the DT N
L4-5 NNP N
lumbar NN N
segment NN N
of IN N
the DT N
spinal JJ N
cord NN N
was VBD N
removed VBN N
for IN N
determination NN N
of IN N
green JJ N
fluorescent NN N
protein NN N
( ( N
GFP NNP N
) ) N
expression NN N
. . N

Immunohistochemical JJ N
analysis NN N
was VBD N
performed VBN N
using VBG N
anti JJ N
HMGB1 NNP N
antibodies NNS N
and CC N
the DT N
expression NN N
of IN N
HMGB1 NNP N
protein NN N
in IN N
the DT N
spinal JJ N
cord NN N
was VBD N
determined VBN N
by IN N
western JJ N
blot NN N
analysis NN N
after IN N
intrathecal JJ N
delivery NN N
( ( N
n JJ N
= RB N
8 CD N
each DT N
) ) N
. . N

RESULTS VB N
The DT N
results NNS N
show VBP N
that DT N
intrathecal JJ N
LV/hIL-10 NNP N
reverses NNS N
enhanced VBD N
pain NN N
states NNS N
. . N

Moreover RB N
, , N
the DT N
increased VBN N
level NN N
of IN N
HMGB1 NNP N
exhibited VBD N
in IN N
a DT N
late JJ N
stage NN N
of IN N
CCI NNP N
was VBD N
inhibited VBN N
by IN N
exogenous JJ N
overexpression NN N
of IN N
hIL-10 NN N
in IN N
the DT N
CCI NNP N
model NN N
. . N

Expression NN N
of IN N
HMGB1 NNP N
, , N
RAGE NNP N
, , N
and CC N
pAkt NNS N
were VBD N
lower JJR N
in IN N
CCI-induced NNP N
rats NNS N
treated VBD N
with IN N
LV/hIL-10 NNP N
than IN N
in IN N
those DT N
treated VBN N
with IN N
LV/control NNP N
( ( N
vector NN N
) ) N
or CC N
saline NN N
( ( N
NS NNP N
) ) N
. . N

Our PRP$ N
results NNS N
showed VBD N
that IN N
IL-10 NNP N
inhibits VBZ N
activation NN N
of IN N
the DT N
inflammatory JJ N
HMGB1-RAGE NNP N
pathway NN N
in IN N
the DT N
CCI NNP N
rat NN N
model NN N
. . N

LIMITATIONS NNP N
Further NNP N
experimental JJ N
investigations NNS N
are VBP N
needed VBN N
to TO N
clarify VB N
the DT N
specific JJ N
biological JJ N
roles NNS N
played VBN N
by IN N
HMGB1 NNP N
in IN N
IL-10-mediated NNP N
regulation NN N
of IN N
neuropathic JJ N
pain NN N
. . N

CONCLUSION NNP N
Our PRP$ N
results NNS N
indicate VBP N
that DT N
intrathecal JJ N
lentiviral-mediated JJ N
transfer NN N
of IN N
IL-10 NNP N
attenuates VBZ N
CCI-induced NNP N
neuropathic JJ N
pain NN N
in IN N
rats NNS N
. . N

The DT N
anti-thermal JJ N
hyperalgesia NN N
and CC N
anti-mechanical JJ N
allodynia NN N
may MD N
be VB N
partly RB N
attributable JJ N
to TO N
the DT N
decreased JJ N
expression NN N
of IN N
HMGB1 NNP N
and CC N
inhibition NN N
of IN N
HMGB1-RAGE NNP N
pathway NN N
. . N

-DOCSTART- -X- O O 10781855

Immunogenicity NN N
and CC N
reactogenicity NN N
of IN N
a DT N
group NN N
C NNP N
meningococcal JJ N
conjugate NN N
vaccine NN N
compared VBN N
with IN N
a DT N
group NN N
A+C NNP N
meningococcal JJ N
polysaccharide NN N
vaccine NN N
in IN N
adolescents NNS 4_p
in IN N
a DT N
randomised JJ N
observer-blind NN N
controlled VBN N
trial NN N
. . N

This DT N
study NN N
evaluated VBD N
the DT N
immunogenicity NN N
and CC N
reactogenicity NN N
of IN N
a DT N
group NN N
C NNP N
meningococcal JJ N
conjugate NN N
vaccine NN N
( ( N
MenC NNP N
) ) N
compared VBN N
with IN N
a DT N
group NN N
A+C NNP N
meningococcal JJ N
polysaccharide NN N
vaccine NN N
( ( N
MenPS NNP N
) ) N
in IN N
healthy JJ N
adolescents NNS N
. . N

Subjects NNS N
were VBD N
randomised VBN N
to TO N
receive VB N
one CD N
dose NN N
of IN N
either DT N
MenC NNP N
( ( N
n=92 NN N
) ) N
or CC N
MenPS NNP N
( ( N
n=90 NN N
) ) N
. . N

Group NNP N
C NNP N
meningococcal JJ N
IgG NNP N
antibody NN N
concentrations NNS N
and CC N
bactericidal JJ N
titres NNS N
were VBD N
higher JJR N
in IN N
the DT N
MenC NNP N
group NN N
than IN N
the DT N
MenPS NNP N
group NN N
at IN N
1 CD N
month NN N
( ( N
22.8 CD N
U/ml NNP N
vs NN N
4.0 CD N
U/ml NNP N
, , N
p NN N
< VBD N
0.001 CD N
, , N
and CC N
87 CD N
vs NN N
20 CD N
, , N
p NN N
< VBD N
0.001 CD N
, , N
respectively RB N
) ) N
and CC N
12 CD N
months NNS N
( ( N
6.1 CD N
U/ml NNP N
vs NN N
3.0 CD N
U/ml NNP N
, , N
p NN N
< VBD N
0.001 CD N
, , N
and CC N
81.3 CD N
vs NN N
20.2 CD N
, , N
p NN N
< VBD N
0.001 CD N
, , N
respectively RB N
) ) N
. . N

No DT N
differences NNS N
in IN N
post NN N
immunisation NN N
reaction NN N
rates NNS N
were VBD N
noted VBN N
between IN N
the DT N
two CD N
vaccinated VBD N
groups NNS N
. . N

This DT N
study NN N
demonstrated VBD N
the DT N
safety NN N
and CC N
enhanced JJ N
immunogenicity NN N
of IN N
the DT N
candidate NN N
meningococcal JJ N
conjugate NN N
vaccine NN N
as IN N
compared VBN N
with IN N
the DT N
licensed JJ N
polysaccharide NN N
vaccine NN N
in IN N
adolescents NNS N
. . N

-DOCSTART- -X- O O 7591314

The DT N
European JJ N
Myocardial NNP N
Infarction NNP N
Project NNP N
: : N
an DT N
assessment NN N
of IN N
pre-hospital JJ N
thrombolysis NN 4_p
. . N

The DT N
use NN N
of IN N
thrombolytic JJ N
agents NNS N
in IN N
patients NNS N
with IN N
suspected JJ N
myocardial JJ 4_p
infarction NN 4_p
has VBZ N
been VBN N
shown VBN N
to TO N
reduce VB N
early JJ N
and CC N
long-term JJ N
mortality NN N
by IN N
about IN N
20 CD N
% NN N
, , N
and CC N
it PRP N
has VBZ N
been VBN N
suggested VBN N
that IN N
since IN N
time NN N
is VBZ N
an DT N
important JJ N
factor NN N
, , N
pre-hospital JJ N
treatment NN N
would MD N
give VB N
better JJR N
results NNS N
. . N

However RB N
, , N
health NN N
deciders NNS N
need VBP N
reliable JJ N
data NNS N
on IN N
which WDT N
to TO N
base VB N
future JJ N
policies NNS N
concerning VBG N
this DT N
. . N

The DT N
European JJ N
Myocardial NNP N
Infarction NNP N
Project NNP N
was VBD N
a DT N
European JJ N
Economic NNP N
Community-supported NNP N
double-blind NN N
study NN N
designed VBN N
to TO N
evaluate VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
pre-hospital JJ N
early JJ N
thrombolytic JJ N
treatment NN N
in IN N
patients NNS N
with IN N
suspected JJ N
myocardial JJ 4_p
infarction NN 4_p
compared VBN N
with IN N
the DT N
same JJ N
treatment NN N
given VBN N
later RB N
in IN N
a DT N
hospital NN N
setting NN N
. . N

A DT N
total NN N
of IN N
5469 CD N
patients NNS N
in IN N
16 CD N
countries NNS N
were VBD N
randomised VBN N
by IN N
198 CD N
mobile JJ N
emergency NN N
units NNS N
to TO N
receive VB N
either DT N
pre-hospital JJ N
treatment NN N
with IN N
anistreplase NN N
, , N
the DT N
thrombolytic JJ N
agent NN N
used VBN N
, , N
followed VBN N
by IN N
placebo NN N
after IN N
hospital JJ N
admission NN N
( ( N
pre-hospital JJ N
group NN N
; : N
2750 CD N
patients NNS N
) ) N
, , N
or CC N
placebo NN N
followed VBN N
by IN N
anistreplase NN N
( ( N
hospital JJ N
group NN N
; : N
2719 CD N
patients NNS N
) ) N
. . N

The DT N
median JJ N
time NN N
delay NN N
between IN N
the DT N
injections NNS N
was VBD N
55 CD N
min NN N
. . N

A DT N
non-significant JJ N
decrease NN N
in IN N
30-day JJ N
mortality NN N
was VBD N
observed VBN N
in IN N
favour NN N
of IN N
the DT N
pre-hospital JJ N
group NN N
( ( N
13 CD N
% NN N
: : N
P NNP N
= NNP N
0.08 CD N
) ) N
, , N
whereas IN N
the DT N
decrease NN N
in IN N
cardiac JJ N
death NN N
observed VBD N
, , N
also RB N
in IN N
favour NN N
of IN N
the DT N
pre-hospital JJ N
group NN N
, , N
was VBD N
on IN N
the DT N
borderline NN N
of IN N
significance NN N
( ( N
16 CD N
% NN N
; : N
P NNP N
= NNP N
0.049 CD N
) ) N
. . N

Although IN N
some DT N
complications NNS N
occurred VBD N
more RBR N
frequently RB N
in IN N
the DT N
pre-hospital JJ N
group NN N
in IN N
the DT N
pre-hospital JJ N
period NN N
, , N
the DT N
overall JJ N
incidence NN N
for IN N
serious JJ N
complications NNS N
was VBD N
similar JJ N
for IN N
both DT N
groups NNS N
. . N

These DT N
results NNS N
show VBP N
that IN N
the DT N
pre-hospital JJ N
thrombolytic JJ N
strategy NN N
in IN N
patients NNS N
with IN N
suspected JJ N
myocardial JJ N
infarction NN N
is VBZ N
both DT N
effective JJ N
and CC N
safe JJ N
when WRB N
performed VBN N
by IN N
well-equipped JJ N
well-staffed JJ N
mobile JJ N
emergency NN N
units NNS N
. . N

-DOCSTART- -X- O O 11085402

Use NNP N
of IN N
World NNP N
Wide NNP N
Web-based JJ N
directories NNS N
for IN N
tracing VBG N
subjects NNS 4_p
in IN 4_p
epidemiologic JJ 4_p
studies NNS 4_p
. . N

The DT N
recent JJ N
availability NN N
of IN N
World NNP N
Wide NNP N
Web-based JJ N
directories NNS N
has VBZ N
opened VBN N
up RP N
a DT N
new JJ N
approach NN N
for IN N
tracing VBG N
subjects NNS N
in IN N
epidemiologic JJ N
studies NNS N
. . N

The DT N
completeness NN N
of IN N
two CD N
World NNP N
Wide NNP N
Web-based JJ N
directories NNS N
( ( N
Canada411 NNP N
and CC N
InfoSpace NNP N
Canada NNP N
) ) N
for IN N
subject JJ N
tracing NN N
was VBD N
evaluated VBN N
by IN N
using VBG N
a DT N
randomized VBN N
crossover NN N
design NN N
for IN N
346 CD N
adults NNS N
randomly RB N
selected VBN N
from IN N
respondents NNS N
in IN N
an DT N
ongoing JJ N
cohort NN N
study NN N
. . N

About IN N
half NN N
( ( N
56.4 CD N
% NN N
) ) N
of IN N
the DT N
subjects NNS N
were VBD N
successfully RB N
located VBN N
by IN N
using VBG N
either CC N
Canada411 NNP N
or CC N
InfoSpace NNP N
. . N

Of IN N
the DT N
43.6 CD N
% NN N
of IN N
the DT N
subjects NNS N
who WP N
could MD N
not RB N
be VB N
located VBN N
using VBG N
either CC N
directory NN N
, , N
the DT N
majority NN N
( ( N
73.5 CD N
% NN N
) ) N
were VBD N
female JJ N
. . N

Overall JJ N
, , N
there EX N
was VBD N
no DT N
clear JJ N
advantage NN N
of IN N
one CD N
directory NN N
over IN N
the DT N
other JJ N
. . N

Although IN N
Canada411 NNP N
could MD N
find VB N
significantly RB N
more RBR N
subjects NNS N
than IN N
InfoSpace NNP N
, , N
the DT N
number NN N
of IN N
potential JJ N
matches NNS N
returned VBN N
by IN N
Canada411 NNP N
was VBD N
also RB N
higher JJR N
, , N
which WDT N
meant VBD N
that IN N
a DT N
longer RBR N
list NN N
of IN N
potential JJ N
matches NNS N
had VBD N
to TO N
be VB N
examined VBN N
before IN N
a DT N
true JJ N
match NN N
could MD N
be VB N
found VBN N
. . N

One CD N
strategy NN N
to TO N
minimize VB N
the DT N
number NN N
of IN N
potential JJ N
matches NNS N
per IN N
true JJ N
match NN N
is VBZ N
to TO N
first JJ N
search NN N
by IN N
InfoSpace NNP N
with IN N
the DT N
last JJ N
name NN N
and CC N
first JJ N
name NN N
, , N
then RB N
by IN N
Canada411 NNP N
with IN N
the DT N
last JJ N
name NN N
and CC N
first JJ N
name NN N
, , N
and CC N
finally RB N
by IN N
InfoSpace NNP N
with IN N
the DT N
last JJ N
name NN N
and CC N
first JJ N
initial JJ N
. . N

Internet-based JJ N
searches NNS N
represent VBP N
a DT N
potentially RB N
useful JJ N
approach NN N
to TO N
tracing VBG N
subjects NNS N
in IN N
epidemiologic JJ N
studies NNS N
. . N

-DOCSTART- -X- O O 24767206

[ IN N
The DT N
effects NNS N
of IN N
tirofiban NN N
on IN N
acute JJ N
non-ST JJ N
segment NN N
elevation NN N
myocardial JJ 4_p
infarction NN 4_p
patients NNS N
not RB N
receiving VBG N
early JJ N
reperfusion NN N
intervention NN N
] NNP N
. . N

OBJECTIVE NNP N
To TO N
study VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
tirofiban NN N
in IN N
patients NNS N
with IN N
acute JJ 4_p
non-ST- JJ 4_p
segment NN 4_p
elevation NN 4_p
myocardial JJ 4_p
infarction NN 4_p
( ( 4_p
NSTEMI NNP 4_p
) ) 4_p
without IN N
early JJ N
reperfusion NN N
intervention NN N
. . N

METHODS NNP N
A NNP N
total NN N
of IN N
151 CD N
NSTEMI NNP 4_p
patients NNS N
without IN N
early JJ N
reperfusion NN N
intervention NN N
were VBD N
enrolled VBN N
in IN N
the DT N
study NN N
and CC N
randomized VBN N
to TO N
the DT N
tirofiban NN N
group NN N
( ( N
n JJ N
= NNP N
76 CD N
) ) N
and CC N
the DT N
control NN N
group NN N
( ( N
n JJ N
= NNP N
75 CD N
) ) N
. . N

Coronary JJ N
angiography NN N
was VBD N
performed VBN N
at IN N
day NN N
3 CD N
and CC N
day NN N
7 CD N
, , N
while IN N
percutaneous JJ N
coronary JJ N
intervention NN N
( ( N
PCI NNP N
) ) N
was VBD N
performed VBN N
when WRB N
necessary JJ N
. . N

Parameters NNS N
including VBG N
thrombolysis NN N
in IN N
myocardial JJ N
infarction NN N
( ( N
TIMI NNP N
) ) N
flow NN N
, , N
bleeding VBG N
complications NNS N
and CC N
clinic JJ N
events NNS N
within IN N
30 CD N
days NNS N
were VBD N
compared VBN N
between IN N
the DT N
two CD N
groups NNS N
. . N

RESULTS NNP N
Before IN N
PCI NNP N
, , N
no DT N
increase NN N
in IN N
the DT N
percentage NN N
of IN N
patient NN N
with IN N
TIMI NNP N
flow VBP N
better JJR N
than IN N
TIMI-2 NNP N
was VBD N
observed VBN N
by IN N
the DT N
treatment NN N
of IN N
tirofiban NN N
( ( N
69.3 CD N
% NN N
vs JJ N
78.9 CD N
% NN N
, , N
P NNP N
= NNP N
0.10 CD N
) ) N
. . N

While IN N
after IN N
PCI NNP N
, , N
significant JJ N
increase NN N
in IN N
the DT N
percentage NN N
of IN N
patient NN N
with IN N
TIMI NNP N
flow VBP N
better JJR N
than IN N
TIMI-2 NNP N
was VBD N
manifested VBN N
in IN N
the DT N
tirofiban NN N
group NN N
( ( N
96.0 CD N
% NN N
vs JJ N
100.0 CD N
% NN N
, , N
P NNP N
= NNP N
0.04 CD N
) ) N
. . N

Tirofiban NNP N
treatment NN N
also RB N
significantly RB N
decreased VBD N
the DT N
rate NN N
of IN N
poor JJ N
myocardial JJ N
perfusion NN N
after IN N
PCI NNP N
( ( N
19.7 CD N
% NN N
vs JJ N
34.7 CD N
% NN N
, , N
P NNP N
= NNP N
0.04 CD N
) ) N
. . N

There EX N
were VBD N
0 CD N
and CC N
4 CD N
major JJ N
adverse JJ N
cardiovascular NN N
events NNS N
( ( N
MACE NNP N
) ) N
within IN N
30 CD N
days NNS N
observed VBN N
in IN N
the DT N
tirofiban NN N
group NN N
and CC N
the DT N
control NN N
group NN N
( ( N
0.0 CD N
% NN N
vs JJ N
5.3 CD N
% NN N
, , N
P NNP N
= NNP N
0.05 CD N
) ) N
. . N

No DT N
difference NN N
between IN N
the DT N
two CD N
groups NNS N
was VBD N
found VBN N
in IN N
the DT N
bleeding NN N
complications NNS N
within IN N
30 CD N
days NNS N
including VBG N
the DT N
mild JJ N
hemorrhage NN N
( ( N
5 CD N
vs RB N
4 CD N
cases NNS N
, , N
P NNP N
= NNP N
0.75 CD N
) ) N
, , N
severe JJ N
hemorrhage NN N
( ( N
2 CD N
vs RB N
1 CD N
cases NNS N
, , N
P NNP N
= NNP N
0.56 CD N
) ) N
or CC N
severe JJ N
thrombocytopenia NN N
( ( N
2 CD N
vs RB N
0 CD N
cases NNS N
, , N
P NNP N
= NNP N
0.49 CD N
) ) N
. . N

CONCLUSIONS NNP N
Tirofiban NNP N
treatment NN N
does VBZ N
not RB N
increase VB N
the DT N
bleeding JJ N
complications NNS N
in IN N
NSTEMI NNP 4_p
patients NNS N
without IN N
early JJ N
PCI NNP N
. . N

Tirofiban NN N
can MD N
improve VB N
the DT N
TIMI NNP N
flow NN N
and CC N
the DT N
myocardial JJ N
perfusion NN N
after IN N
PCI NNP N
with IN N
less JJR N
MACE NNP N
within IN N
30 CD N
days NNS N
. . N

-DOCSTART- -X- O O 20865676

The DT N
effect NN N
of IN N
L-arginine NNP N
and CC N
citrulline NN N
on IN N
endothelial JJ N
function NN N
in IN N
patients NNS 4_p
in IN 4_p
heart NN 4_p
failure NN 4_p
with IN 4_p
preserved JJ 4_p
ejection NN 4_p
fraction NN 4_p
. . N

BACKGROUND NNP N
To TO N
evaluate VB N
the DT N
effect NN N
of IN N
the DT N
amino JJ N
acids NNS N
L-arginine JJ N
and CC N
citrulline NN N
on IN N
endothelial JJ N
function NN N
in IN N
patients NNS 4_p
in IN 4_p
stable JJ 4_p
diastolic NN 4_p
and CC 4_p
right JJ 4_p
heart NN 4_p
failure NN 4_p
using VBG N
photoplethysmography NN N
. . N

METHODS NNP N
Thirty NNP N
patients NNS N
from IN N
the DT N
Heart NNP 4_p
Failure NNP 4_p
Clinic NNP 4_p
of IN 4_p
the DT 4_p
Instituto NNP 4_p
Nacional NNP 4_p
de FW 4_p
Ciencias NNP 4_p
Médicas NNP 4_p
y NNP 4_p
Nutrición NNP 4_p
" NNP 4_p
Salvador NNP 4_p
Zubirán NNP 4_p
" NNP 4_p
underwent JJ 4_p
photoplethysmography NN 4_p
using VBG 4_p
the DT 4_p
hyperemia NN 4_p
technique NN 4_p
. . N

Index NNP N
finger VBD N
flow NN N
was VBD N
assessed VBN N
at IN N
baseline NN N
and CC N
after IN N
ischemia NN N
every DT N
30 CD N
s NN N
by IN N
maximum JJ N
amplitude JJ N
time NN N
( ( N
MAT NNP N
) ) N
, , N
total JJ N
time NN N
of IN N
the DT N
curve NN N
( ( N
TT NNP N
) ) N
and CC N
the DT N
index NN N
of IN N
the DT N
two CD N
( ( N
MAT/TT NNP N
< VBZ N
30 CD N
= NNP N
normal JJ N
) ) N
before IN N
and CC N
after IN N
the DT N
administration NN N
of IN N
L-arginine NNP N
( ( N
8 CD N
g/day NN N
in IN N
two CD N
doses NNS N
, , N
n JJ N
= NNP N
15 CD N
) ) N
or CC N
citrulline NN N
( ( N
3 CD N
g/day NN N
in IN N
one CD N
dose NN N
, , N
n JJ N
= NNP N
15 CD N
) ) N
for IN N
60 CD N
days NNS N
in IN N
addition NN N
to TO N
optimal VB N
pharmacological JJ N
treatment NN N
. . N

RESULTS CC N
There EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
between IN N
the DT N
two CD N
groups NNS N
at IN N
baseline NN N
. . N

After IN N
the DT N
intervention NN N
, , N
the DT N
MAT/TT NNP N
index NN N
of IN N
all DT N
patients NNS N
normalized VBN N
in IN N
each DT N
evaluation NN N
period NN N
with IN N
statistically RB N
significant JJ N
differences NNS N
. . N

Basal NNP N
L-arginine NNP N
group NN N
= VBD N
38.75 CD N
± NN N
11.52 CD N
, , N
final JJ N
23.32 CD N
± JJ N
6.08 CD N
, , N
p NN N
= VBD N
0.007 CD N
and CC N
basal JJ N
citrulline NN N
group NN N
= VBD N
41.4 CD N
± NN N
13.47 CD N
, , N
final JJ N
23.65 CD N
± JJ N
6.74 CD N
, , N
p NN N
= VBD N
0.007 CD N
at IN N
60-90 JJ N
s. JJ N
Post-ischemia NN N
: : N
basal NN N
L-arginine JJ N
36.60 CD N
± JJ N
11.51 CD N
, , N
final JJ N
18.81 CD N
± JJ N
15.13 CD N
, , N
p NN N
= VBD N
0.004 CD N
and CC N
basal JJ N
citrulline NN N
= $ N
49.51 CD N
± NNP N
15.17 CD N
, , N
final JJ N
27.13 CD N
± JJ N
7.87 CD N
, , N
p NN N
= VBD N
0.003 CD N
. . N

CONCLUSIONS VB N
The DT N
administration NN N
of IN N
L-arginine NNP N
and CC N
citrulline NN N
has VBZ N
a DT N
beneficial JJ N
effect NN N
on IN N
endothelial JJ N
function NN N
as IN N
shown VBN N
by IN N
the DT N
normalized JJ N
MAT/TT NNP N
index NN N
. . N

It PRP N
probably RB N
improves VBZ N
systemic JJ N
and CC N
pulmonary JJ N
hemodynamics NNS N
, , N
which WDT N
could MD N
help VB N
in IN N
the DT N
treatment NN 4_p
of IN 4_p
diastolic JJ 4_p
heart NN 4_p
failure NN N
. . N

-DOCSTART- -X- O O 2275907

Chloroprocaine NNP N
and CC N
lidocaine JJ N
decrease NN N
hospital NN N
stay NN N
and CC N
admission NN N
rate NN N
after IN N
outpatient JJ N
epidural JJ N
anesthesia NN N
. . N

Lumbar NNP N
epidural JJ N
anesthesia NN N
with IN N
20 CD N
ml NN N
of IN N
either DT N
3 CD N
% NN N
2-chloroprocaine JJ N
( ( N
C NNP N
) ) N
, , N
1.5 CD N
% NN N
lidocaine NN N
( ( N
L NNP N
) ) N
, , N
or CC N
1.5 CD N
% NN N
mepivacaine NN N
( ( N
M NNP N
) ) N
with IN N
epinephrine NN N
was VBD N
studied VBN N
in IN N
84 CD N
outpatients NNS N
undergoing JJ N
surgery NN N
( ( N
extracorporeal JJ N
shock NN N
wave NN N
lithotripsy NN N
( ( N
ESWL NNP N
] NNP N
. . N

The DT N
average JJ N
duration NN N
of IN N
the DT N
procedure NN N
was VBD N
31.9 CD N
minutes NNS N
. . N

The DT N
total JJ N
duration NN N
of IN N
sensory JJ N
anesthesia NN N
was VBD N
133 CD N
+/- JJ N
28 CD N
minutes NNS N
( ( N
C NNP N
) ) N
, , N
182 CD N
+/- JJ N
38 CD N
( ( N
L NNP N
) ) N
, , N
and CC N
247 CD N
+/- JJ N
42 CD N
( ( N
M NNP N
) ) N
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

Times NNS N
to TO N
discharge VB N
were VBD N
269 CD N
+/- JJ N
62 CD N
minutes NNS N
( ( N
C NNP N
) ) N
, , N
284 CD N
+/- JJ N
62 CD N
( ( N
L NNP N
) ) N
, , N
and CC N
357 CD N
+/- JJ N
71 CD N
( ( N
M NNP N
) ) N
. . N

The DT N
time NN N
to TO N
discharge VB N
with IN N
M NNP N
, , N
almost RB N
six CD N
hours NNS N
, , N
was VBD N
significantly RB N
longer JJR N
than IN N
with IN N
C NNP N
or CC N
L. NNP N
There EX N
was VBD N
a DT N
trend NN N
to TO N
an DT N
increasing VBG N
rate NN N
of IN N
unplanned JJ N
overnight JJ N
hospital NN N
admission NN N
with IN N
increasing VBG N
duration NN N
of IN N
the DT N
local JJ N
anesthetic JJ N
drug NN N
employed VBN N
. . N

Continuous JJ N
epidural JJ N
anesthesia NN N
with IN N
C NNP N
, , N
L NNP N
or CC N
M NNP N
appears VBZ N
safe JJ N
and CC N
effective JJ N
for IN N
outpatient JJ N
surgical JJ N
procedures NNS N
such JJ N
as IN N
ESWL NNP N
. . N

In IN N
contrast NN N
to TO N
previous JJ N
understanding NN N
, , N
mepivacaine NN N
produces VBZ N
significantly RB N
longer JJR N
anesthesia NN N
and CC N
recovery NN N
times NNS N
and CC N
may MD N
not RB N
be VB N
optimal JJ N
for IN N
outpatient JJ N
epidural JJ N
use NN N
. . N

-DOCSTART- -X- O O 24964689

Self-management JJ N
improvement NN N
program NN N
combined VBN N
with IN N
community NN N
involvement NN N
in IN N
Thai NNP 4_p
hypertensive JJ 4_p
population NN N
: : N
an DT N
action NN N
research NN N
. . N

OBJECTIVE UH N
To TO N
investigate VB N
the DT N
effectiveness NN N
of IN N
a DT N
program NN N
that WDT N
utilizes VBZ N
community NN N
involvement NN N
to TO N
improve VB N
the DT N
self-management JJ N
strategies NNS N
among IN N
people NNS N
living VBG N
with IN N
hypertension NN 4_p
. . N

MATERIAL NNP N
AND NNP N
METHOD NNP N
Forty-four NNP N
subjects NNS N
, , N
aged VBD N
35 CD N
to TO N
59-year-old JJ N
, , N
with IN N
hypertension NN 4_p
in IN N
Nakhon NNP 4_p
Pathom NNP 4_p
Province NNP 4_p
, , 4_p
Thailand NNP 4_p
, , N
were VBD N
randomly RB N
allocated VBN N
to TO N
either DT N
an DT N
experimental JJ N
group NN N
( ( N
n JJ N
= NNP N
22 CD N
) ) N
or CC N
a DT N
control NN N
group NN N
( ( N
n JJ N
= NNP N
20 CD N
) ) N
. . N

The DT N
experimental JJ N
group NN N
attended VBD N
a DT N
program NN N
to TO N
improve VB N
self-management JJ N
methods NNS N
based VBN N
on IN N
social JJ N
cognitive JJ N
theory NN N
( ( N
SCT NNP N
) ) N
. . N

The DT N
program NN N
lasted VBD N
12 CD N
weeks NNS N
, , N
consisted VBD N
of IN N
1 CD N
1/2 CD N
hours NNS N
meeting VBG N
once RB N
a DT N
week NN N
, , N
including VBG N
group NN N
meetings NNS N
and CC N
home NN N
visit NN N
monitoring NN N
. . N

Mann-Whitney NNP N
U NNP N
test NN N
and CC N
Friedman NNP N
test NN N
were VBD N
employed VBN N
to TO N
analyze VB N
the DT N
program NN N
's POS N
effectiveness NN N
. . N

RESULTS NNP N
After IN N
the DT N
program NN N
, , N
the DT N
mean JJ N
rank NN N
of IN N
the DT N
perceived JJ N
self-efficacy NN N
for IN N
the DT N
self-management JJ N
strategies NNS N
was VBD N
statistically RB N
different JJ N
between IN N
the DT N
two CD N
groups NNS N
( ( N
p JJ N
= NNP N
0.023 CD N
) ) N
. . N

In IN N
the DT N
experimental JJ N
group NN N
, , N
after IN N
the DT N
twelve NN N
week NN N
, , N
the DT N
mean JJ N
rank NN N
of IN N
perceived VBN N
self-efficacy NN N
and CC N
outcome JJ N
expectancy NN N
increased VBD N
and CC N
diastolic JJ N
blood NN N
pressure NN N
decreased VBN N
after IN N
the DT N
eight CD N
week NN N
. . N

CONCLUSION VB N
The DT N
program NN N
applied VBN N
social JJ N
cognitive JJ N
theory NN N
( ( N
SCT NNP N
) ) N
to TO N
promote VB N
self-management JJ N
techniques NNS N
, , N
increased VBD N
the DT N
health NN N
promoting VBG N
behavior NN N
among IN N
hypertensive JJ N
people NNS N
. . N

-DOCSTART- -X- O O 5090759

Psychiatric NNP N
treatment NN N
of IN N
eczema NN 4_p
: : N
a DT N
controlled JJ N
trial NN N
. . N

Seventy-two JJ N
patients NNS N
with IN N
eczema NNS 4_p
were VBD N
randomly RB N
allotted VBN N
to TO N
one CD N
of IN N
two CD N
treatment NN N
groups NNS N
: : N
A DT N
, , N
those DT N
receiving VBG N
dermatological JJ N
treatment NN N
only RB N
, , N
and CC N
B NNP N
, , N
those DT N
receiving VBG N
the DT N
same JJ N
dermatological JJ N
treatment NN N
plus CC N
psychiatric JJ N
treatment NN N
, , N
limited VBN N
where WRB N
possible JJ N
to TO N
four CD N
months NNS N
. . N

Cases NNS N
were VBD N
followed VBN N
up RP N
at IN N
six-monthly JJ N
dermatological JJ N
assessments NNS N
, , N
57 CD N
( ( N
79 CD N
% NN N
) ) N
for IN N
18 CD N
months NNS N
. . N

The DT N
findings NNS N
suggest VBP N
that IN N
in IN N
the DT N
presence NN N
of IN N
overt JJ N
emotional JJ N
disturbance NN N
, , N
of IN N
new JJ N
psychological JJ N
or CC N
psychophysiological JJ N
symptoms NNS N
preceding VBG N
the DT N
rash NN N
by IN N
up IN N
to TO N
a DT N
year NN N
, , N
and CC N
of IN N
high JJ N
motivation NN N
for IN N
it PRP N
, , N
brief JJ N
psychiatric JJ N
treatment NN N
improves VBZ N
the DT N
outcome NN N
in IN N
eczema NN N
( ( N
the DT N
proportion NN N
clear JJ N
at IN N
18 CD N
months NNS N
was VBD N
about IN N
doubled VBN N
) ) N
, , N
whereas NNS N
in IN N
their PRP$ N
absence NN N
such JJ N
treatment NN N
may MD N
worsen VB N
it PRP N
, , N
especially RB N
in IN N
the DT N
short JJ N
term NN N
. . N

-DOCSTART- -X- O O 18410301

Genital NNP N
responsiveness NN N
in IN N
healthy JJ 4_p
women NNS N
with IN 4_p
and CC 4_p
without IN 4_p
sexual JJ 4_p
arousal NN 4_p
disorder NN 4_p
. . N

INTRODUCTION NNP N
Most NNP N
pharmacological JJ N
treatments NNS N
that WDT N
are VBP N
currently RB N
being VBG N
developed VBN N
for IN N
women NNS N
with IN N
sexual JJ N
arousal NN N
disorder NN N
are VBP N
aimed VBN N
at IN N
remedying VBG N
a DT N
vasculogenic JJ N
deficit NN N
. . N

AIM VB N
This DT N
study NN N
investigated VBD N
whether IN N
pre- NN 4_p
and CC 4_p
postmenopausal JJ 4_p
women NNS N
with IN N
sexual JJ 4_p
arousal NN 4_p
disorder NN 4_p
are VBP N
less RBR N
genitally RB N
responsive JJ N
to TO N
visual JJ N
sexual JJ N
stimuli NN N
than IN N
pre- JJ N
and CC N
postmenopausal JJ N
women NNS N
without IN N
sexual JJ N
problems NNS N
. . N

METHOD NNP N
Twenty-nine NNP N
medically RB N
healthy JJ 4_p
women NNS 4_p
with IN N
sexual JJ 4_p
arousal NN 4_p
disorder NN 4_p
( ( N
15 CD 4_p
premenopausal NN 4_p
and CC N
14 CD 4_p
postmenopausal NN 4_p
) ) N
, , N
diagnosed VBD N
using VBG N
the DT N
Diagnostic NNP N
and CC N
Statistical NNP N
Manual NNP N
of IN N
Mental NNP N
Disorders NNP N
, , N
4th CD N
Edition NNP N
( ( N
DSM-IV NNP N
) ) N
criteria NN N
, , N
and CC N
30 CD N
age-matched JJ N
women NNS N
without IN 4_p
sexual JJ 4_p
problems NNS 4_p
( ( N
16 CD N
premenopausal NN N
and CC N
14 CD N
postmenopausal NN N
) ) N
were VBD N
shown VBN N
sexual JJ N
stimuli NNS N
depicting VBG N
cunnilingus NN N
and CC N
intercourse NN N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURE NNP N
Genital NNP N
arousal NN N
was VBD N
assessed VBN N
as IN N
vaginal JJ N
pulse NN N
amplitude NN N
( ( N
VPA NNP N
) ) N
using VBG N
vaginal JJ N
photoplethysmography NN N
. . N

RESULTS NNP N
Results NNP N
showed VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
two CD N
groups NNS N
in IN N
mean JJ N
and CC N
maximum JJ N
VPA NNP N
, , N
nor CC N
in IN N
latency NN N
of IN N
VPA NNP N
response NN N
. . N

CONCLUSION NNP N
Women NNP N
with IN N
sexual JJ N
arousal NN N
disorder NN N
diagnosed VBD N
according VBG N
to TO N
DSM-IV NNP N
criteria NNS N
were VBD N
not RB N
less RBR N
genitally RB N
responsive JJ N
to TO N
visual JJ N
sexual JJ N
stimuli NNS N
than IN N
women NNS N
without IN N
such JJ N
problems NNS N
. . N

These DT N
findings NNS N
are VBP N
in IN N
line NN N
with IN N
previous JJ N
studies NNS N
. . N

The DT N
sexual JJ N
problems NNS N
these DT N
women NNS N
report NN N
are VBP N
clearly RB N
not RB N
related VBN N
to TO N
their PRP$ N
potential JJ N
to TO N
become VB N
genitally RB N
aroused JJ N
. . N

We PRP N
argue VBP N
that IN N
the DT N
DSM-IV NNP N
criteria NNS N
for IN N
sexual JJ N
arousal NN N
disorder NN N
are VBP N
in IN N
need NN N
of IN N
revision NN N
. . N

In IN N
medically RB N
healthy JJ 4_p
women NNS N
, , N
impaired JJ N
genital JJ N
responsiveness NN N
is VBZ N
not RB N
a DT N
valid JJ N
diagnostic JJ N
criterion NN N
. . N

-DOCSTART- -X- O O 10671339

Granulocyte-macrophage JJ N
colony-stimulating JJ N
factor NN N
as IN N
immunomodulating VBG N
factor NN N
together RB N
with IN N
influenza JJ N
vaccination NN N
in IN N
stem NN 4_p
cell NN 4_p
transplant NN 4_p
patients NNS N
. . N

The DT N
effect NN N
of IN N
granulocyte-macrophage JJ N
colony-stimulating JJ N
factor NN N
( ( N
GM-CSF NNP N
) ) N
on IN N
the DT N
serological JJ N
response NN N
at IN N
influenza JJ N
vaccination NN N
was VBD N
studied VBN N
in IN N
117 CD N
patients NNS N
who WP N
had VBD N
undergone JJ 4_p
stem NN 4_p
cell NN 4_p
transplantation NN 4_p
( ( N
SCT NNP 4_p
) ) N
. . N

The DT N
vaccine NN N
response NN N
was VBD N
evaluated VBN N
as IN N
significant JJ N
increases NNS N
in IN N
levels NNS N
of IN N
influenza JJ N
hemagglutination-inhibition NN N
( ( N
HAI NNP N
) ) N
antibodies NNS N
and CC N
of IN N
IgG NNP N
antibodies NNS N
measured VBN N
by IN N
enzyme-linked JJ N
immunosorbent NN N
assay NN N
( ( N
ELISA NNP N
) ) N
. . N

There EX N
was VBD N
no DT N
difference NN N
in IN N
antibody NN N
response NN N
to TO N
either DT N
influenza VB N
A NNP N
or CC N
B NNP N
in IN N
64 CD N
patients NNS N
who WP N
received VBD N
GM-CSF NNP N
at IN N
vaccination NN N
, , N
compared VBN N
with IN N
the DT N
53 NNS N
who WP N
did VBD N
not RB N
. . N

In IN N
the DT N
subgroup NN N
of IN N
allogeneic JJ N
SCT NNP N
patients NNS N
, , N
HAI NNP N
showed VBD N
that IN N
the DT N
response NN N
rate NN N
to TO N
the DT N
influenza NN N
B NNP N
vaccine NN N
was VBD N
significantly RB N
higher JJR N
in IN N
the DT N
treatment NN N
group NN N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

ELISA NN N
showed VBD N
that IN N
autologous JJ N
SCT NNP N
patients NNS N
with IN N
breast JJ N
cancer NN N
who WP N
received VBD N
GM-CSF NNP N
had VBD N
a DT N
better JJR N
response NN N
to TO N
influenza VB N
A NNP N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
and CC N
B NNP N
( ( N
P NNP N
< NNP N
.01 NNP N
) ) N
. . N

At IN N
early JJ N
vaccination NN N
, , N
4-12 JJ N
months NNS N
after IN N
stem NN N
cell NN N
transplantation NN N
, , N
these DT N
responses NNS N
were VBD N
more RBR N
pronounced JJ N
. . N

GM-CSF JJ N
appears VBZ N
to TO N
improve VB N
the DT N
response NN N
to TO N
influenza VB N
vaccination NN N
in IN N
some DT N
groups NNS N
of IN N
SCT NNP 4_p
patients NNS 4_p
, , N
but CC N
only RB N
to TO N
a DT N
limited JJ N
extent NN N
. . N

-DOCSTART- -X- O O 11812696

Small-dose JJ N
selective JJ N
spinal NN N
anesthesia NN N
for IN N
short-duration JJ N
outpatient JJ N
laparoscopy NN N
: : N
recovery NN N
characteristics NNS N
compared VBN N
with IN N
desflurane NN N
anesthesia NN N
. . N

UNLABELLED IN N
We PRP N
conducted VBD N
a DT N
randomized VBN N
controlled VBN N
trial NN N
to TO N
compare VB N
the DT N
recovery NN N
characteristics NNS N
of IN N
selective JJ N
spinal JJ N
anesthesia NN N
( ( N
SSA NNP N
) ) N
and CC N
desflurane JJ N
anesthesia NN N
( ( N
DES NNP N
) ) N
in IN N
outpatient JJ N
gynecological JJ N
laparoscopy NN N
. . N

Twenty NNP N
ASA NNP 4_p
physical JJ 4_p
status NN 4_p
I PRP 4_p
patients NNS N
undergoing VBG N
gynecological JJ N
laparoscopy NN N
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
SSA NNP N
with IN N
lidocaine JJ N
10 CD N
mg NN N
+ NNP N
sufentanil VBD N
10 CD N
microg NN N
or CC N
general JJ N
anesthesia NN N
with IN N
DES NNP N
and CC N
N NNP N
( ( N
2 CD N
) ) N
O. NNP N
Intraoperative NNP N
conditions NNS N
, , N
recovery NN N
times NNS N
, , N
postanesthesia JJ N
recovery NN N
scores NNS N
, , N
and CC N
postoperative JJ N
outcomes NNS N
were VBD N
recorded VBN N
. . N

Intraoperative JJ N
conditions NNS N
were VBD N
comparable JJ N
in IN N
both DT N
groups NNS N
. . N

All DT N
patients NNS N
in IN N
the DT N
SSA NNP N
group NN N
were VBD N
awake RB N
and CC N
oriented VBN N
at IN N
the DT N
end NN N
of IN N
surgery NN N
, , N
whereas JJ N
patients NNS N
in IN N
the DT N
DES NNP N
group NN N
required VBD N
7 CD N
+/- JJ N
2 CD N
min NN N
for IN N
extubation NN N
and CC N
orientation NN N
. . N

SSA NNP N
patients NNS N
had VBD N
a DT N
significantly RB N
shorter JJR N
time NN N
to TO N
straight VB N
leg NN N
raising VBG N
( ( N
3 CD N
+/- JJ N
1 CD N
min NN N
versus NN N
9 CD N
+/- JJ N
4 CD N
min NN N
; : N
P NNP N
< NNP N
0.0001 CD N
) ) N
and CC N
to TO N
ambulation NN N
( ( N
3 CD N
+/- JJ N
0.9 CD N
min NN N
versus NN N
59 CD N
+/- JJ N
16 CD N
min NN N
; : N
P NNP N
< NNP N
0.0001 CD N
) ) N
compared VBN N
with IN N
the DT N
DES NNP N
group NN N
. . N

SSA NNP N
patients NNS N
had VBD N
significantly RB N
less RBR N
postoperative JJ N
pain NN N
than IN N
DES NNP N
patients NNS N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

We PRP N
concluded VBD N
that IN N
SSA NNP N
was VBD N
an DT N
effective JJ N
alternative NN N
to TO N
DES NNP N
for IN N
outpatient JJ N
gynecological JJ N
laparoscopy NN N
. . N

IMPLICATIONS NNP N
This DT N
study NN N
compared VBN N
the DT N
use NN N
of IN N
a DT N
desflurane NN N
general JJ N
anesthetic JJ N
to TO N
a DT N
small-dose JJ N
spinal JJ N
anesthetic NN N
in IN N
ambulatory JJ N
gynecological JJ N
laparoscopy NN N
. . N

Using VBG N
the DT N
spinal JJ N
technique NN N
, , N
patients NNS N
can MD N
walk VB N
from IN N
the DT N
operating NN N
room NN N
table NN N
to TO N
a DT N
stretcher NN N
on IN N
completion NN N
of IN N
surgery NN N
. . N

Their PRP$ N
recovery NN N
time NN N
was VBD N
similar JJ N
to TO N
that DT N
of IN N
the DT N
desflurane NN N
group NN N
. . N

-DOCSTART- -X- O O 24939380

Electrothermal JJ N
arthroscopic NN N
capsulorrhaphy NN N
: : N
old JJ N
technology NN N
, , N
new JJ N
evidence NN N
. . N

A DT N
multicenter NN N
randomized VBN N
clinical JJ N
trial NN N
. . N

BACKGROUND NNP N
Radiofrequency NNP N
technology NN N
for IN N
shoulder JJR 4_p
instability NN 4_p
was VBD N
rapidly RB N
adopted VBN N
despite IN N
limited JJ N
clinical JJ N
evidence NN N
and CC N
a DT N
poor JJ N
understanding NN N
of IN N
its PRP$ N
indications NNS N
. . N

Reports NNS N
of IN N
serious JJ N
adverse JJ N
events NNS N
followed VBD N
, , N
leading VBG N
to TO N
its PRP$ N
abandonment NN N
. . N

This DT N
paper NN N
presents VBZ N
findings NNS N
from IN N
a DT N
multicenter NN N
randomized VBN N
clinical JJ N
trial NN N
evaluating VBG N
the DT N
safety NN N
and CC N
efficacy NN N
of IN N
electrothermal JJ N
arthroscopic NN N
capsulorrhaphy NN N
( ( N
ETAC NNP N
) ) N
compared VBN N
with IN N
open JJ N
inferior JJ N
capsular JJ N
shift NN N
( ( N
ICS NNP N
) ) N
and CC N
reviews VBZ N
the DT N
role NN N
of IN N
randomized JJ N
trials NNS N
in IN N
adopting VBG N
new JJ N
technology NN N
. . N

METHODS NNP N
Patients NNPS N
( ( N
> JJ N
14 CD N
years NNS N
) ) N
diagnosed VBD N
with IN N
multidirectional JJ 4_p
instability NN 4_p
or CC N
multidirectional JJ 4_p
laxity NN 4_p
with IN 4_p
anteroinferior JJ 4_p
instability NN 4_p
and CC 4_p
failed VBD 4_p
nonoperative JJ 4_p
treatment NN 4_p
were VBD N
enrolled VBN N
. . N

Patients NNS N
with IN N
bone JJ N
lesions NNS N
or CC N
labral JJ N
, , N
biceps JJ N
anchor NN N
, , N
or CC N
full-thickness JJ N
rotator NN N
cuff NN N
tears NNS N
were VBD N
excluded VBN N
intraoperatively RB N
. . N

Outcomes NNP N
included VBD N
Western NNP N
Ontario NNP N
Shoulder NNP N
Instability NNP N
Index NNP N
, , N
function NN N
and CC N
recurrent JJ N
instability NN N
at IN N
2 CD N
years NNS N
postoperatively RB N
, , N
and CC N
surgical JJ N
times NNS N
. . N

RESULTS NNP N
Fifty-four JJ N
subjects NNS N
( ( N
mean JJ N
age NN N
, , N
23 CD N
years NNS N
; : N
37 CD N
women NNS N
) ) N
were VBD N
randomized VBN N
to TO N
ETAC NNP N
( ( N
n JJ N
= NNP N
28 CD N
) ) N
or CC N
open JJ N
ICS NNP N
( ( N
n JJ N
= NNP N
26 CD N
) ) N
. . N

The DT N
groups NNS N
were VBD N
comparable JJ N
at IN N
baseline NN N
, , N
except IN N
for IN N
external JJ N
rotation NN N
at IN N
the DT N
side NN N
. . N

At IN N
2 CD N
years NNS N
postoperatively RB N
, , N
there EX N
were VBD N
no DT N
statistically RB N
or CC N
clinically RB N
significant JJ N
differences NNS N
between IN N
groups NNS N
for IN N
the DT N
Western NNP N
Ontario NNP N
Shoulder NNP N
Instability NNP N
Index NNP N
( ( N
P NNP N
= NNP N
.71 NNP N
) ) N
, , N
American NNP N
Shoulder NNP N
and CC N
Elbow NNP N
Surgeons NNP N
score NN N
( ( N
P NNP N
= NNP N
.43 NNP N
) ) N
, , N
Constant JJ N
score NN N
( ( N
P NNP N
= NNP N
.43 NNP N
) ) N
, , N
and CC N
active JJ N
range NN N
of IN N
motion NN N
. . N

Recurrent NNP N
instability NN N
was VBD N
not RB N
statistically RB N
different JJ N
( ( N
ETAC NNP N
, , N
2 CD N
; : N
open JJ N
, , N
4 CD N
; : N
P NNP N
= NNP N
.41 NNP N
) ) N
. . N

ETAC NNP N
( ( N
23 CD N
minutes NNS N
) ) N
was VBD N
significantly RB N
shorter JJR N
than IN N
open JJ N
ICS NNP N
( ( N
59 CD N
minutes NNS N
) ) N
( ( N
P NNP N
< NNP N
.01 NNP N
) ) N
surgery NN N
. . N

Three CD N
subjects NNS N
( ( N
1 CD N
ETAC NNP N
, , N
2 CD N
open JJ N
) ) N
had VBD N
stiff JJ N
shoulders NNS N
. . N

CONCLUSIONS NNP N
At IN N
2 CD N
years NNS N
postoperatively RB N
, , N
quality NN N
of IN N
life NN N
and CC N
functional JJ N
outcomes NNS N
between IN N
groups NNS N
were VBD N
not RB N
clinically RB N
different JJ N
. . N

ETAC NNP N
had VBD N
fewer JJR N
complications NNS N
and CC N
episodes NNS N
of IN N
recurrence NN N
compared VBN N
with IN N
open JJ N
surgery NN N
. . N

This DT N
evidence NN N
reinforces VBZ N
the DT N
need NN N
to TO N
critically VB N
evaluate VB N
new JJ N
technology NN N
before IN N
widespread JJ N
clinical JJ N
use NN N
. . N

-DOCSTART- -X- O O 25053766

Effects NNS N
of IN N
a DT N
music NN N
therapy NN N
group NN N
intervention NN N
on IN N
enhancing VBG N
social JJ N
skills NNS N
in IN N
children NNS N
with IN N
autism NN 4_p
. . N

BACKGROUND NNP N
Research NNP N
indicates VBZ N
that IN N
music NN N
therapy NN N
can MD N
improve VB N
social JJ N
behaviors NNS N
and CC N
joint JJ N
attention NN N
in IN N
children NNS N
with IN N
Autism NNP 4_p
Spectrum NNP 4_p
Disorder NNP 4_p
( ( 4_p
ASD NNP 4_p
) ) 4_p
; : N
however RB N
, , N
more JJR N
research NN N
on IN N
the DT N
use NN N
of IN N
music NN N
therapy NN N
interventions NNS N
for IN N
social JJ N
skills NNS N
is VBZ N
needed VBN N
to TO N
determine VB N
the DT N
impact NN N
of IN N
group NN N
music NN N
therapy NN N
. . N

OBJECTIVE UH N
To TO N
examine VB N
the DT N
effects NNS N
of IN N
a DT N
music NN N
therapy NN N
group NN N
intervention NN N
on IN N
eye NN N
gaze NN N
, , N
joint JJ N
attention NN N
, , N
and CC N
communication NN N
in IN N
children NNS N
with IN N
ASD NNP 4_p
. . N

METHOD NNP N
Seventeen NNP N
children NNS N
, , N
ages VBZ N
6 CD N
to TO N
9 CD N
, , N
with IN N
a DT N
diagnosis NN N
of IN N
ASD NNP N
were VBD N
randomly RB N
assigned VBN N
to TO N
the DT N
music NN N
therapy NN N
group NN N
( ( N
MTG NNP N
) ) N
or CC N
the DT N
no-music JJ N
social JJ N
skills NNS N
group NN N
( ( N
SSG NNP N
) ) N
. . N

Children NNP N
participated VBD N
in IN N
ten JJ N
50-minute JJ N
group NN N
sessions NNS N
over IN N
a DT N
period NN N
of IN N
5 CD N
weeks NNS N
. . N

All DT N
group NN N
sessions NNS N
were VBD N
designed VBN N
to TO N
target VB N
social JJ N
skills NNS N
. . N

The DT N
Social NNP N
Responsiveness NNP N
Scale NNP N
( ( N
SRS NNP N
) ) N
, , N
the DT N
Autism NNP N
Treatment NNP N
Evaluation NNP N
Checklist NNP N
( ( N
ATEC NNP N
) ) N
, , N
and CC N
video JJ N
analysis NN N
of IN N
sessions NNS N
were VBD N
used VBN N
to TO N
evaluate VB N
changes NNS N
in IN N
social JJ N
behavior NN N
. . N

RESULTS CC N
There EX N
were VBD N
significant JJ N
between-group JJ N
differences NNS N
for IN N
joint JJ N
attention NN N
with IN N
peers NNS N
and CC N
eye NN N
gaze NN N
towards NNS N
persons NNS N
, , N
with IN N
participants NNS N
in IN N
the DT N
MTG NNP N
demonstrating NN N
greater JJR N
gains NNS N
. . N

There EX N
were VBD N
no DT N
significant JJ N
between-group NN N
differences NNS N
for IN N
initiation NN N
of IN N
communication NN N
, , N
response NN N
to TO N
communication NN N
, , N
or CC N
social JJ N
withdraw/behaviors NNS N
. . N

There EX N
was VBD N
a DT N
significant JJ N
interaction NN N
between IN N
time NN N
and CC N
group NN N
for IN N
SRS NNP N
scores NNS N
, , N
with IN N
improvements NNS N
for IN N
the DT N
MTG NNP N
but CC N
not RB N
the DT N
SSG NNP N
. . N

Scores NNS N
on IN N
the DT N
ATEC NNP N
did VBD N
not RB N
differ VB N
over IN N
time NN N
between IN N
the DT N
MTG NNP N
and CC N
SSG NNP N
. . N

CONCLUSIONS NNP N
The DT N
results NNS N
of IN N
this DT N
study NN N
support VB N
further JJ N
research NN N
on IN N
the DT N
use NN N
of IN N
music NN N
therapy NN N
group NN N
interventions NNS N
for IN N
social JJ N
skills NNS N
in IN N
children NNS N
with IN N
ASD NNP 4_p
. . N

Statistical JJ N
results NNS N
demonstrate VBP N
initial JJ N
support NN N
for IN N
the DT N
use NN N
of IN N
music NN N
therapy NN N
social JJ N
groups NNS N
to TO N
develop VB N
joint JJ N
attention NN N
. . N

-DOCSTART- -X- O O 12876178

Children NNP 4_p
with IN 4_p
autistic JJ 4_p
spectrum NN 4_p
disorders NNS 4_p
. . 4_p

II NN N
: : N
parents NNS 4_p
are VBP N
unable JJ N
to TO N
distinguish VB N
secretin NN N
from IN N
placebo NN N
under IN N
double-blind JJ N
conditions NNS N
. . N

BACKGROUND NNP N
Standardised VBD N
measures NNS N
of IN N
behaviour NNS N
have VBP N
failed VBN N
to TO N
detect VB N
short JJ N
term NN N
improvement NN N
in IN N
children NNS N
with IN N
autism NN N
following VBG N
treatment NN N
with IN N
secretin NN N
. . N

However RB N
, , N
it PRP N
is VBZ N
possible JJ N
that IN N
standardised JJ N
measures NNS N
are VBP N
insensitive JJ N
to TO N
dimensions NNS N
of IN N
child NN N
behaviour NN N
that WDT N
are VBP N
nonetheless RB N
detectable JJ N
by IN N
parents NNS N
. . N

AIM NNP N
To TO N
determine VB N
the DT N
ability NN N
of IN N
parents NNS N
of IN N
children NNS N
with IN N
autism NN N
to TO N
guess VB N
, , N
under IN N
double JJ N
blind NN N
conditions NNS N
, , N
whether IN N
their PRP$ N
child NN N
had VBD N
received VBN N
secretin NN N
or CC N
placebo NN N
. . N

METHODS NNP N
2x2 CD N
crossover NN N
randomised VBD N
blinded VBN N
study NN N
, , N
comparing VBG N
the DT N
effect NN N
of IN N
synthetic JJ N
human JJ N
secretin NN N
2 CD N
U/kg NNP N
to TO N
placebo VB N
( ( N
saline NN N
) ) N
. . N

Sixty CD N
two CD N
children NNS N
with IN N
autism NN N
( ( N
aged VBN N
43-103 CD N
months NNS N
) ) N
were VBD N
randomly RB N
allocated VBN N
to TO N
two CD N
groups NNS N
: : N
group NN N
1 CD N
received VBD N
placebo NN N
, , N
followed VBD N
six CD N
weeks NNS N
later RB N
by IN N
secretin NN N
, , N
and CC N
group NN N
2 CD N
received VBD N
secretin NN N
followed VBN N
by IN N
placebo NN N
. . N

At IN N
the DT N
conclusion NN N
of IN N
the DT N
study NN N
, , N
parents NNS N
were VBD N
asked VBN N
to TO N
guess VB N
their PRP$ N
child NN N
's POS N
group NN N
assignment NN N
. . N

RESULTS NNP N
Twenty NNP N
seven CD N
families NNS N
guessed VBD N
their PRP$ N
child NN N
's POS N
group NN N
assignment NN N
correctly RB N
and CC N
27 CD N
guessed VBN N
incorrectly RB N
. . N

In IN N
48 CD N
instances NNS N
, , N
parents NNS N
based VBN N
their PRP$ N
guess NN N
on IN N
perceived JJ N
improvement NN N
; : N
in IN N
six CD N
cases NNS N
, , N
parents NNS N
based VBN N
their PRP$ N
guess NN N
on IN N
perceived JJ N
deterioration NN N
. . N

Six NNP N
families NNS N
saw VBD N
no DT N
difference NN N
after IN N
either DT N
infusion NN N
, , N
and CC N
offered VBD N
no DT N
guess NN N
. . N

One CD N
family NN N
dropped VBD N
out RP N
after IN N
the DT N
first JJ N
infusion NN N
, , N
and CC N
one CD N
family NN N
was VBD N
lost VBN N
to TO N
follow VB N
up RP N
after IN N
the DT N
second JJ N
infusion NN N
. . N

CONCLUSION NNP N
In IN N
a DT N
controlled JJ N
setting NN N
, , N
parents NNS N
of IN N
young JJ N
children NNS N
with IN N
autism NN N
are VBP N
unable JJ N
to TO N
distinguish VB N
the DT N
short JJ N
term NN N
behavioural JJ N
effects NNS N
of IN N
secretin NN N
from IN N
placebo NN N
. . N

-DOCSTART- -X- O O 21978765

Phase NNP N
III NNP N
trial NN N
of IN N
induction NN N
gemcitabine NN N
or CC N
paclitaxel NN N
plus CC N
carboplatin NN N
followed VBN N
by IN N
paclitaxel JJ N
consolidation NN N
in IN N
ovarian JJ 4_p
cancer NN 4_p
. . N

OBJECTIVE CC N
The DT N
safety NN N
and CC N
efficacy NN N
of IN N
gemcitabine JJ N
plus CC N
carboplatin NN N
( ( N
GC NNP N
) ) N
or CC N
paclitaxel JJ N
plus CC N
carboplatin NN N
( ( N
TC NNP N
) ) N
induction NN N
regimens VBZ N
with IN N
or CC N
without IN N
paclitaxel JJ N
consolidation NN N
therapy NN N
were VBD N
assessed VBN N
in IN N
ovarian JJ 4_p
cancer NN 4_p
( ( 4_p
OC NNP 4_p
) ) 4_p
. . 4_p

METHODS JJ N
Patients NNPS 4_p
with IN 4_p
stage JJ 4_p
IC-IV JJ 4_p
OC NNP 4_p
were VBD N
randomized VBN N
to TO N
either DT N
GC NNP N
( ( N
gemcitabine JJ N
1,000 CD N
mg/m NN N
( ( N
2 CD N
) ) N
, , N
days NNS N
1 CD N
and CC N
8 CD N
, , N
plus CC N
carboplatin JJ N
area NN N
under IN N
the DT N
curve NN N
[ NNP N
AUC NNP N
] NNP N
5 CD N
, , N
day NN N
1 CD N
) ) N
or CC N
TC NNP N
( ( N
paclitaxel JJ N
175 CD N
mg/m NN N
( ( N
2 CD N
) ) N
plus CC N
carboplatin JJ N
AUC NNP N
6 CD N
, , N
day NN N
1 CD N
) ) N
every DT N
21 CD N
days NNS N
for IN N
up IN N
to TO N
six CD N
cycles NNS N
. . N

Patients NNS 4_p
with IN 4_p
complete JJ 4_p
response NN 4_p
( ( 4_p
CR NNP 4_p
) ) 4_p
were VBD N
allowed VBN N
optional JJ N
consolidation NN N
with IN N
paclitaxel JJ N
135 CD N
mg/m NN N
( ( N
2 CD N
) ) N
every DT N
28 CD N
days NNS N
for IN N
≤ JJ N
12 CD N
months NNS N
. . N

Patients NNS N
without IN N
CR NNP N
received VBD N
single-agent JJ N
crossover NN N
therapy NN N
at IN N
induction NN N
doses/schedules NNS N
until IN N
CR NNP N
, , N
disease NN N
progression NN N
( ( N
PD NNP N
) ) N
, , N
or CC N
unacceptable JJ N
toxicity NN 4_p
. . N

PD NNP N
or CC N
death NN N
in IN N
636 CD N
patients NNS N
was VBD N
required VBN N
to TO N
compare VB N
induction NN N
arms NNS N
with IN N
80 CD N
% NN N
statistical JJ N
power NN N
for IN N
progression-free JJ N
survival NN N
( ( N
PFS NNP N
) ) N
, , N
the DT N
primary JJ N
endpoint NN N
. . N

RESULTS NNP N
Randomized NNP N
induction NN N
therapy NN N
was VBD N
received VBN N
by IN N
820 CD N
of IN N
919 CD N
patients NNS N
enrolled VBD N
; : N
352 CD N
patients NNS N
with IN N
CR NNP N
received VBD N
paclitaxel JJ N
consolidation NN N
whereas NNS N
155 CD N
patients NNS N
without IN N
CR NNP N
received VBD N
single-agent JJ N
crossover NN N
therapy NN N
. . N

PFS NNP N
was VBD N
similar JJ N
for IN N
GC NNP N
and CC N
TC NNP N
( ( N
median JJ N
, , N
20.0 CD N
and CC N
22.2 CD N
months NNS N
, , N
respectively RB N
; : N
P=.199 NNP N
) ) N
. . N

Despite IN N
high JJ N
censoring NN N
rates NNS N
( ( N
> VB N
52 CD N
% NN N
) ) N
, , N
overall JJ N
survival NN N
was VBD N
longer JJR N
for IN N
TC NNP N
( ( N
median JJ N
, , N
57.3 CD N
versus NN N
43.8 CD N
months NNS N
for IN N
GC NNP N
; : N
P=.013 NNP N
) ) N
. . N

Controlling VBG N
for IN N
patient JJ N
characteristics NNS N
including VBG N
performance NN N
status NN N
, , N
residual JJ N
tumor NN N
size NN N
, , N
and CC N
tumor NN N
stage NN N
, , N
there EX N
was VBD N
no DT N
statistical JJ N
difference NN N
in IN N
a DT N
multivariate NN N
analysis NN N
( ( N
HR=1.22 NNP N
; : N
95 CD N
% NN N
CI=0.99-1.52 NNP N
; : N
P=.067 NNP N
) ) N
. . N

CONCLUSIONS NNP N
GC NNP N
does VBZ N
not RB N
improve VB N
PFS NNP N
over RB N
TC NNP N
as IN N
first-line JJ N
induction NN N
chemotherapy NN N
in IN N
OC NNP N
. . N

Although IN N
favoring VBG N
TC NNP N
, , N
overall JJ N
survival NN N
analyses NNS N
were VBD N
limited VBN N
by IN N
the DT N
study NN N
design NN N
and CC N
high JJ N
censoring NN N
rates NNS N
. . N

-DOCSTART- -X- O O 9101850

[ RB N
Restorative NNP N
proctectomy NN N
, , N
reconstruction NN N
of IN N
continuity NN N
with IN N
or CC N
without IN N
colon NN N
J NNP N
pouch JJ N
] NNP N
. . N

Of IN N
63 CD N
patients NNS N
undergoing JJ N
deep JJ 4_p
anterior JJ 4_p
resection NN 4_p
of IN 4_p
the DT 4_p
rectum NN 4_p
, , N
39 CD N
patients NNS N
received VBD N
a DT N
straight JJ N
colo-anal JJ N
anastomosis NN N
( ( N
CAA NNP N
) ) N
, , N
24 CD N
additionally RB N
had VBD N
a DT N
colon-j-pouch JJ N
( ( N
CPA NNP N
) ) N
constructed VBD N
. . N

Local NNP N
septic JJ N
complications NNS N
occurred VBD N
in IN N
12.5 CD N
% NN N
of IN N
patients NNS N
after IN N
pouch-anal JJ N
anastomosis NN N
compared VBN N
to TO N
20.5 CD N
% NN N
after IN N
colo-anal JJ N
anastomosis NN N
: : N
stool NN N
frequency NN N
, , N
after IN N
pouch-anal JJ N
anastomosis NN N
was VBD N
3.3 CD N
per IN N
24 CD N
h NN N
compared VBN N
to TO N
5.2 CD N
per IN N
24 CD N
h NN N
after IN N
straight JJ N
anastomosis NN N
within IN N
the DT N
first JJ N
year NN N
after IN N
ileostomy JJ N
closure NN N
( ( N
p JJ N
= NNP N
0.053 CD N
) ) N
; : N
continence NN N
was VBD N
slightly RB N
better RBR N
in IN N
the DT N
pouch JJ N
group NN N
( ( N
n.s RB N
. . N

) ) N
; : N
and CC N
anal JJ N
manometry NN N
showed VBD N
a DT N
significant JJ N
postoperative JJ N
decrease NN N
only RB N
in IN N
resting VBG N
pressure NN N
after IN N
straight JJ N
colo-anal JJ N
anastomosis NN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

Pouch JJ N
construction NN N
should MD N
be VB N
considered VBN N
after IN N
deep JJ N
rectal JJ N
resection NN N
, , N
as IN N
it PRP N
seems VBZ N
to TO N
improve VB N
functional JJ N
outcome NN N
and CC N
has VBZ N
fewer JJR N
local JJ N
septic NN N
complications NNS N
than IN N
straight JJ N
anastomosis NN N
. . N

-DOCSTART- -X- O O 25616941

Hepatic JJ N
cytoprotective JJ N
effect NN N
of IN N
ischemic JJ N
and CC N
anesthetic JJ N
preconditioning NN N
before IN N
liver JJ N
resection NN N
when WRB N
using VBG N
intermittent JJ N
vascular JJ N
inflow JJ N
occlusion NN N
: : N
a DT N
randomized JJ N
clinical JJ N
trial NN N
. . N

BACKGROUND NNP N
Ischemic NNP N
preconditioning NN N
( ( N
IPC NNP N
) ) N
and CC N
anesthetic JJ N
preconditioning NN N
( ( N
APC NNP N
) ) N
have VBP N
been VBN N
reported VBN N
to TO N
attenuate VB N
ischemia-reperfusion NN N
( ( N
IR NNP N
) ) N
injury NN N
after IN N
liver JJ N
resection NN N
under IN N
continuous JJ N
inflow JJ N
occlusion NN N
. . N

This DT N
study NN N
evaluates VBZ N
whether IN N
these DT N
strategies NNS N
enhance VBP N
hepatic JJ N
protection NN N
of IN N
remnant JJ N
liver NN N
against IN N
IR NNP N
after IN N
liver JJ 4_p
resection NN 4_p
with IN 4_p
intermittent JJ 4_p
clamping NN 4_p
( ( 4_p
INT NNP 4_p
) ) 4_p
. . N

METHODS CC N
A DT N
total NN N
of IN N
106 CD N
patients NNS N
without IN N
underlying VBG N
liver NN 4_p
disease NN 4_p
and CC N
submitted VBN N
to TO N
liver VB N
resection NN N
using VBG N
INT NNP N
were VBD N
randomized VBN N
into IN N
3 CD N
groups NNS N
: : N
IPC NNP N
( ( N
10 CD N
minutes NNS N
of IN N
inflow JJ N
occlusion NN N
followed VBN N
by IN N
10 CD N
minutes NNS N
of IN N
reperfusion NN N
before IN N
liver JJ N
transection NN N
) ) N
, , N
APC NNP N
( ( N
sevoflurane JJ N
administration NN N
for IN N
20 CD N
minutes NNS N
before IN N
liver JJ N
transection NN N
) ) N
, , N
and CC N
INT NNP N
( ( N
no DT N
preconditioning NN N
) ) N
. . N

Patients NNS N
were VBD N
also RB N
stratified VBN N
according VBG N
to TO N
the DT N
extent NN N
of IN N
the DT N
hepatectomy NN N
. . N

Cytoprotection NN N
was VBD N
evaluated VBN N
by IN N
comparing VBG N
hepatocyte NN N
and CC N
endothelial JJ N
dysfunction NN N
markers NNS N
, , N
apoptosis NN N
, , N
histologic JJ N
lesions NNS N
, , N
and CC N
postoperative JJ N
outcome NN N
. . N

RESULTS NNP N
No NNP N
differences NNS N
were VBD N
observed VBN N
in IN N
preoperative JJ N
chemotherapy NN N
and CC N
steatosis NN N
, , N
total JJ N
warm JJ N
ischemia NN N
time NN N
, , N
operative JJ N
time NN N
, , N
or CC N
blood NN N
loss NN N
. . N

Kinetics NNS N
of IN N
transaminases NNS N
( ( N
aspartate JJ N
aminotransferase NN N
, , N
P NNP N
= NNP N
.137 NNP N
; : N
alanine JJ N
aminotransferase NN N
, , N
P NNP N
= NNP N
.616 NNP N
) ) N
, , N
bilirubin FW N
( ( N
P NNP N
= NNP N
.980 NNP N
) ) N
, , N
and CC N
hyaluronic JJ N
acid NN N
increase NN N
( ( N
P NNP N
= NNP N
.514 NNP N
) ) N
revealed VBD N
no DT N
differences NNS N
. . N

Significant JJ N
apoptosis NN N
was VBD N
present JJ N
in IN N
40 CD N
% NN N
of IN N
patients NNS N
, , N
mild-to-moderate JJ N
leukocyte NN N
infiltration NN N
and CC N
steatosis NN N
in IN N
45 CD N
% NN N
and CC N
55 CD N
% NN N
, , N
respectively RB N
, , N
and CC N
mild VB N
sinusoidal JJ N
congestion NN N
in IN N
65 CD N
% NN N
, , N
with IN N
a DT N
similar JJ N
distribution NN N
in IN N
the DT N
3 CD N
groups NNS N
. . N

When WRB N
patients NNS N
were VBD N
stratified VBN N
by IN N
major JJ N
versus NN N
minor JJ N
resections NNS N
, , N
no DT N
differences NNS N
were VBD N
observed VBN N
in IN N
any DT N
of IN N
the DT N
variables NNS N
studied VBN N
. . N

Postoperative JJ N
clinical JJ N
outcomes NNS N
were VBD N
also RB N
similar JJ N
. . N

CONCLUSION NNP N
These DT N
results NNS N
suggest VBP N
that IN N
these DT N
protocols NNS N
of IN N
IPC NNP N
and CC N
APC NNP N
used VBD N
in IN N
this DT N
study NN N
do VBP N
not RB N
provide VB N
better JJR N
cytoprotection NN N
from IN N
IR NNP N
when WRB N
INT NNP N
is VBZ N
used VBN N
. . N

-DOCSTART- -X- O O 18371465

A DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
, , N
multicenter NN N
study NN N
to TO N
evaluate VB N
the DT N
cardioprotective JJ N
effects NNS N
of IN N
MC-1 NNP N
in IN N
patients NNS N
undergoing VBG N
high-risk JJ 4_p
coronary JJ 4_p
artery NN 4_p
bypass NN 4_p
graft NN 4_p
surgery NN 4_p
: : N
MC-1 NN N
to TO N
Eliminate VB N
Necrosis NNP N
and CC N
Damage NNP N
in IN N
Coronary NNP N
Artery NNP N
Bypass NNP N
Graft NNP N
Surgery NNP N
Trial NNP N
( ( N
MEND-CABG NNP N
) ) N
II NNP N
-- : N
study NN N
design NN N
and CC N
rationale NN N
. . N

BACKGROUND NNP N
Coronary NNP N
artery NN N
bypass NN N
graft NN N
( ( N
CABG NNP N
) ) N
surgery NN N
is VBZ N
effective JJ N
in IN N
relieving VBG N
angina NN N
and CC N
improving VBG N
survival NN N
and CC N
quality NN N
of IN N
life NN N
in IN N
patients NNS N
with IN N
obstructive JJ 4_p
coronary JJ 4_p
artery NN 4_p
disease NN 4_p
; : N
however RB N
, , N
recurrent JJ N
angina NN N
, , N
myocardial JJ N
infarction NN N
, , N
neurological JJ N
injury NN N
, , N
and CC N
death NN N
can MD N
occur VB N
in IN N
the DT N
perioperative NN N
and CC N
postoperative JJ N
period NN N
. . N

MC-1 NNP N
( ( N
pyridoxal IN N
5'-phosphate NN N
) ) N
is VBZ N
a DT N
novel JJ N
agent NN N
that WDT N
has VBZ N
shown VBN N
promise NN N
in IN N
reducing VBG N
myocardial JJ N
necrosis NN N
by IN N
reducing VBG N
cellular JJ N
calcium NN N
overload NN N
after IN N
percutaneous JJ N
coronary JJ N
intervention NN N
and CC N
CABG NNP N
surgery NN N
in IN N
high-risk JJ N
patients NNS N
undergoing VBG N
these DT N
procedures NNS N
. . N

METHODS NNP N
MEND-CABG NNP N
II NNP N
is VBZ N
a DT N
phase NN N
III NNP N
study NN N
evaluating VBG N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
MC-1 NNP N
in IN N
reducing VBG N
cardiovascular JJ N
morbidity NN N
and CC N
mortality NN N
after IN N
CABG NNP N
. . N

High-risk JJ 4_p
patients NNS 4_p
undergoing VBG 4_p
CABG NNP 4_p
surgery NN 4_p
will MD N
be VB N
randomly RB N
assigned VBN N
to TO N
receive VB N
either DT N
MC-1 NNP N
( ( N
250 CD N
mg/d NN N
) ) N
or CC N
matching VBG N
placebo NNS N
immediately RB N
before IN N
and CC N
continuing VBG N
for IN N
30 CD N
days NNS N
after IN N
the DT N
procedure NN N
. . N

The DT N
primary JJ N
end NN N
point NN N
is VBZ N
the DT N
occurrence NN N
of IN N
cardiovascular JJ N
death NN N
or CC N
nonfatal JJ N
myocardial JJ N
infarction NN N
through IN N
postoperative JJ N
day NN N
30 CD N
. . N

A DT N
total NN N
of IN N
3023 CD N
patients NNS N
were VBD N
enrolled VBN N
at IN N
130 CD N
sites NNS N
in IN N
Canada NNP N
, , N
the DT N
United NNP N
States NNPS N
, , N
and CC N
Germany NNP N
between IN N
October NNP N
2006 CD N
and CC N
September NNP N
2007 CD N
, , N
with IN N
results NNS N
anticipated VBN N
shortly RB N
after IN N
completion NN N
of IN N
90-day JJ N
follow-up NN N
in IN N
March NNP N
2008 CD N
. . N

CONCLUSIONS VB N
The DT N
data NN N
from IN N
the DT N
MEND-CABG NNP N
II NNP N
trial NN N
will MD N
establish VB N
whether IN N
peri- JJ N
and CC N
postoperative JJ N
treatment NN N
with IN N
MC-1 NNP N
can MD N
decrease VB N
the DT N
short- JJ N
and CC N
intermediate-term JJ N
morbidity NN N
and CC N
mortality NN N
of IN N
high-risk JJ N
patients NNS N
undergoing VBG N
CABG NNP N
surgery NN N
. . N

-DOCSTART- -X- O O 14627879

Parent-defined JJ N
target NN N
symptoms NNS N
respond NN N
to TO N
risperidone VB N
in IN N
RUPP NNP 4_p
autism NN 4_p
study NN N
: : N
customer NN N
approach NN N
to TO N
clinical JJ N
trials NNS N
. . N

OBJECTIVE VB N
A DT N
consumer-oriented JJ N
efficacy NN N
assessment NN N
in IN N
clinical JJ N
trials NNS N
should MD N
measure VB N
changes NNS N
in IN N
chief NN N
complaint NN N
and CC N
consumer NN N
request NN N
( ( N
symptoms NNS N
of IN N
most JJS N
concern NN N
to TO N
patient/caregiver NN N
) ) N
, , N
which WDT N
may MD N
be VB N
diluted VBN N
in IN N
change NN N
scores NNS N
of IN N
multisymptom NN N
scales NNS N
. . N

METHOD NNP N
In IN N
the DT N
Research NNP N
Units NNP N
on IN N
Pediatric NNP N
Psychopharmacology NNP N
( ( N
RUPP NNP N
) ) N
Autism NNP N
Network NNP N
8-week JJ N
double-blind JJ N
trial NN N
of IN N
risperidone NN N
versus NN N
placebo NN N
, , N
the DT N
chief JJ N
concerns NNS N
of IN N
parents NNS N
were VBD N
collected VBN N
at IN N
0 CD N
, , N
4 CD N
, , N
and CC N
8 CD N
weeks NNS N
( ( N
endpoint NN N
) ) N
, , N
in IN N
addition NN N
to TO N
standardized JJ N
primary JJ N
measures NNS N
. . N

Blinded NNP N
clinical JJ N
judges NNS N
rated VBN N
change NN N
from IN N
baseline NN N
to TO N
4 CD N
and CC N
8 CD N
weeks NNS N
on IN N
a DT N
9-point JJ N
scale NN N
( ( N
1 CD N
= NNP N
normalized VBD N
, , N
5 CD N
= NN N
unchanged JJ N
, , N
9 CD N
= NNP N
disastrous JJ N
) ) N
; : N
94 CD N
participants NNS N
had VBD N
usable JJ N
data NNS N
. . N

RESULTS VB N
The DT N
most RBS N
common JJ N
symptoms NNS N
identified VBN N
by IN N
parents NNS N
were VBD N
tantrums NNS N
, , N
aggression NN N
, , N
and CC N
hyperactivity NN N
. . N

Interrater NNP N
reliability NN N
was VBD N
excellent JJ N
. . N

Mean JJ N
ratings NNS N
at IN N
endpoint NN N
were VBD N
2.8 CD N
+/- JJ N
1.2 CD N
on IN N
risperidone NN N
and CC N
4.5 CD N
+/- JJ N
1.3 CD N
on IN N
placebo NN N
( ( N
p JJ N
< NNP N
.001 NNP N
) ) N
. . N

Ratings NNS N
were VBD N
collinear JJ N
with IN N
Clinical JJ N
Global NNP N
Impression-Improvement NN N
and CC N
Aberrant NNP N
Behavior NNP N
Checklist NNP N
Irritability NNP N
subscale NN N
( ( N
primary JJ N
dimensional JJ N
measure NN N
) ) N
. . N

Effect JJ N
size NN N
d NN N
was VBD N
1.4 CD N
, , N
compared VBN N
to TO N
1.2 CD N
on IN N
the DT N
Aberrant NNP N
Behavior NNP N
Checklist NNP N
Irritability NNP N
subscale NN N
. . N

Effect NNP N
sizes VBZ N
varied VBN N
twofold JJ N
by IN N
symptom JJ N
category NN N
, , N
largest JJS N
for IN N
self-injury NN N
( ( N
2.11 CD N
) ) N
and CC N
tantrums NNS N
( ( N
1.95 CD N
) ) N
. . N

CONCLUSIONS NNP N
Risperidone NNP N
was VBD N
superior JJ N
to TO N
placebo VB N
in IN N
reducing VBG N
symptoms NNS N
of IN N
most JJS N
concern NN N
to TO N
parents NNS N
of IN N
autistic JJ 4_p
children NNS N
with IN N
irritable JJ 4_p
behavior NN 4_p
. . N

Rating VBG N
individualized JJ N
participant-chosen JJ N
target NN N
symptoms NNS N
seems VBZ N
a DT N
reliable JJ N
, , N
sensitive JJ N
, , N
efficient JJ N
, , N
and CC N
consumer-friendly JJ N
way NN N
to TO N
assess VB N
treatment NN N
effect NN N
and CC N
might MD N
have VB N
clinical JJ N
application NN N
. . N

-DOCSTART- -X- O O 20608027

[ JJ N
Assessment NNP N
of IN N
natriuretic JJ N
peptide NN N
indices NNS N
and CC N
oxidative JJ N
stress NN N
in IN N
patients NNS N
with IN N
chronic JJ 4_p
heart NN 4_p
failure NN 4_p
] NNP N
. . N

The DT N
authors NNS N
have VBP N
studied VBN N
indices NNS N
of IN N
natriuretic JJ N
peptide NN N
and CC N
oxidative JJ N
stress NN N
in IN N
patients NNS N
with IN N
chronic JJ 4_p
heart NN 4_p
failure NN 4_p
( ( 4_p
CHF NNP 4_p
) ) 4_p
. . N

52 CD N
male JJ N
patients NNS N
with IN N
postinfarction NN N
cardiosclerosis NN N
( ( N
PICS NNP N
) ) N
who WP N
have VBP N
developed VBN N
CHF NNP 4_p
have VBP N
been VBN N
observed VBN N
. . N

The DT N
age NN N
of IN N
the DT N
patients NNS N
varied VBD N
from IN N
38 CD N
till NN N
60 CD N
. . N

It PRP N
was VBD N
established VBN N
that IN N
CHF NNP N
patients NNS N
with IN N
progression NN N
of IN N
the DT N
disease NN N
had VBD N
worsening NN N
of IN N
their PRP$ N
clinical JJ N
condition NN N
together RB N
with IN N
an DT N
increase NN N
of IN N
oxidative JJ N
stress NN N
which WDT N
was VBD N
characterized VBN N
through IN N
decrease NN N
of IN N
NO NNP N
metabolites NNS N
, , N
NADPH NNP N
-- : N
diaphorase NN N
( ( N
eNOS NN N
) ) N
, , N
increase NN N
of IN N
nitrite JJ N
reductase NN N
( ( N
iNOS NN N
) ) N
and CC N
peroxinitrite JJ N
( ( N
ONOO NNP N
) ) N
, , N
correlative JJ N
increase NN N
the DT N
level NN N
of IN N
brain NN N
natriuretic JJ N
peptide NN N
in IN N
blood NN N
plazma NN N
. . N

Reliable JJ N
connection NN N
between IN N
considerable JJ N
increase NN N
of IN N
oxidative JJ N
stress NN N
and CC N
the DT N
level NN N
of IN N
NT-pro NNP N
BNP NNP N
was VBD N
noted VBN N
in IN N
CHF NNP 4_p
patients NNS N
, , N
which WDT N
demands VBZ N
necessity NN N
of IN N
correction NN N
of IN N
observed JJ N
disorders NNS N
. . N

-DOCSTART- -X- O O 10720081

Growth NNP N
hormone NN N
( ( N
GH NNP N
) ) N
responses VBZ N
to TO N
GH-releasing NNP N
hormone NN N
alone RB N
or CC N
combined VBN N
with IN N
arginine NN N
in IN N
patients NNS N
with IN N
adrenal JJ 4_p
incidentaloma NN 4_p
: : N
evidence NN N
for IN N
enhanced JJ N
somatostatinergic JJ N
tone NN N
. . N

Spontaneous JJ N
and CC N
stimulated VBD N
GH NNP N
secretion NN N
is VBZ N
blunted VBN N
in IN N
hypercortisolemic JJ N
states NNS N
due JJ N
to TO N
increased VBN N
hypothalamic JJ N
somatostatinergic NN N
tone NN N
. . N

However RB N
, , N
no DT N
data NNS N
are VBP N
available JJ N
on IN N
the DT N
characteristics NNS N
of IN N
GH NNP N
secretion NN N
in IN N
patients NNS N
with IN N
incidentally RB N
discovered VBN N
adrenal JJ 4_p
adenomas NN 4_p
. . 4_p

They PRP N
represent VBP N
an DT N
interesting JJ N
model NN N
for IN N
studying VBG N
GH NNP N
secretion NN N
, , N
as IN N
a DT N
slight JJ N
degree NN N
of IN N
cortisol NN N
excess NN N
may MD N
frequently RB N
be VB N
observed VBN N
in IN N
such JJ N
patients NNS N
who WP N
do VBP N
not RB N
present VB N
with IN N
any DT N
clear JJ N
Cushingoid NNP N
sign NN N
. . N

In IN N
the DT N
present JJ N
study NN N
, , N
10 CD N
patients NNS N
( ( N
3 CD N
men NNS N
and CC N
7 CD N
women NNS N
, , N
aged VBD N
48-63 JJ N
yr NN N
) ) N
with IN N
an DT N
adrenal JJ N
mass NN N
discovered VBD N
serendipitously RB N
underwent JJ N
, , N
on IN N
separate JJ N
occasions NNS N
, , N
a DT N
GHRH NNP N
injection NN N
alone RB N
or CC N
combined VBN N
with IN N
an DT N
infusion NN N
of IN N
the DT N
functional JJ N
somatostatin NN N
antagonist NN N
, , N
arginine NN N
. . N

Thirteen JJ N
age-matched JJ N
healthy JJ 4_p
volunteers NNS 4_p
served VBD N
as IN N
controls NNS 4_p
. . N

Briefly NNP N
, , N
arginine NN N
( ( N
30 CD N
g NN N
) ) N
was VBD N
infused VBN N
from IN N
-30 NN N
to TO N
0 CD N
min NN N
, , N
and CC N
GHRH NNP N
( ( N
100 CD N
microg NN N
) ) N
was VBD N
injected VBN N
as IN N
a DT N
bolus NN N
at IN N
0 CD N
min NNS N
, , N
with IN N
measurement NN N
of IN N
serum NN N
GH NNP N
[ NNP N
immunoradiometric JJ N
assay NN N
( ( N
IRMA NNP N
) ) N
] VBP N
every DT N
15 CD N
min NN N
for IN N
150 CD N
min NN N
. . N

Plasma NNP N
IGF-I NNP N
( ( N
RIA NNP N
after IN N
acid-ethanol JJ N
extraction NN N
) ) N
was VBD N
measured VBN N
in IN N
a DT N
morning NN N
sample NN N
. . N

The DT N
diagnosis NN N
of IN N
cortical JJ N
adenoma NN N
was VBD N
based VBN N
on IN N
computed JJ N
tomography NN N
features NNS N
and CC N
pattern NN N
of IN N
uptake NN N
on IN N
adrenal JJ N
scintigraphy NN N
. . N

Patients NNS N
with IN N
obesity NN 4_p
and/or NN 4_p
diabetes NNS 4_p
were VBD 4_p
excluded VBN 4_p
. . N

The DT N
study NN N
design NN N
included VBD N
also RB N
an DT N
endocrine JJ N
work-up NN N
aimed VBN N
to TO N
study VB N
the DT N
hypothalamic-pituitary-adrenal JJ N
axis NN N
[ NNP N
urinary JJ N
free JJ N
cortisol NN N
( ( N
UFC NNP N
) ) N
excretion NN N
, , N
serum NN N
cortisol NN N
at IN N
0800 CD N
h NN N
, , N
plasma JJ N
ACTH NNP N
at IN N
0800 CD N
h NN N
, , N
morning NN N
cortisol NN N
after IN N
overnight JJ N
1 CD N
mg NN N
dexamethasone NN N
] NN N
. . N

Five CD N
of IN N
10 CD N
patients NNS N
showed VBD N
abnormalities NNS N
of IN N
the DT N
hypothalamic-pituitary-adrenal JJ N
axis NN N
, , N
including VBG N
borderline NN N
or CC N
increased VBN N
UFC JJ N
excretion NN N
in IN N
4 CD N
of IN N
them PRP N
accompanied VBN N
by IN N
blunted JJ N
ACTH NNP N
in IN N
2 CD N
cases NNS N
and CC N
failure NN N
of IN N
cortisol NN N
to TO N
suppress VB N
after IN N
dexamethasone NN N
in IN N
1 CD N
; : N
the DT N
fifth JJ N
patient NN N
displayed VBD N
low JJ N
ACTH NNP N
and CC N
resistance NN N
to TO N
dexamethasone VB N
suppression NN N
. . N

However RB N
, , N
all DT N
patients NNS N
had VBD N
a DT N
unilateral JJ N
uptake NN N
of IN N
the DT N
tracer NN N
on IN N
the DT N
side NN N
of IN N
the DT N
mass NN N
with IN N
suppression NN N
of IN N
the DT N
contralateral JJ N
normal JJ N
adrenal JJ N
gland NN N
. . N

As IN N
a DT N
group NN N
, , N
the DT N
patients NNS N
displayed VBD N
greater JJR N
UFC NNP N
excretion NN N
and CC N
lower JJR N
ACTH NNP N
concentrations NNS N
than IN N
the DT N
controls NNS N
. . N

GH NNP N
release NN N
after IN N
GHRH NNP N
treatment NN N
was VBD N
blunted VBN N
in IN N
patients NNS N
bearing VBG N
adrenal JJ 4_p
incidentaloma NNS 4_p
compared VBN N
with IN N
controls NNS N
( ( N
GH NNP N
peak NN N
, , N
5.7 CD N
+/- JJ N
5.2 CD N
vs. FW N
18.0 CD N
+/- JJ N
7.0 CD N
microg/L NN N
; : N
P NNP N
< NNP N
0.0001 CD N
) ) N
, , N
whereas JJ N
GHRH NNP N
plus CC N
arginine NN N
was VBD N
able JJ N
to TO N
elicit VB N
a DT N
comparable JJ N
response NN N
in IN N
the DT N
2 CD N
groups NNS N
( ( N
GH NNP N
peak NN N
, , N
33.5 CD N
+/- JJ N
20.3 CD N
vs. FW N
33.7 CD N
+/- JJ N
17.5 CD N
microg/L NN N
; : N
P NNP N
= NNP N
NS NNP N
) ) N
. . N

The DT N
ratio NN N
between IN N
GH NNP N
peaks NNS N
after IN N
GHRH NNP N
plus CC N
arginine NN N
and CC N
after IN N
GHRH NNP N
plus CC N
saline NN N
was VBD N
significantly RB N
greater JJR N
in IN N
patients NNS N
than IN N
in IN N
controls NNS N
( ( N
751 CD N
+/- JJ N
531 CD N
% NN N
vs. FW N
81 CD N
+/- JJ N
45 CD N
% NN N
; : N
P NNP N
= NNP N
0.0001 CD N
) ) N
. . N

Similar JJ N
data NNS N
were VBD N
obtained VBN N
when WRB N
comparing VBG N
GH NNP N
area NN N
under IN N
the DT N
curve NN N
after IN N
GHRH NNP N
plus CC N
saline NN N
or CC N
GHRH NNP N
plus CC N
arginine NN N
between IN N
the DT N
2 CD N
groups NNS N
. . N

In IN N
summary JJ N
, , N
the DT N
present JJ N
data NNS N
suggest VBP N
that IN N
in IN N
patients NNS N
with IN N
incidental JJ 4_p
adrenal JJ 4_p
adenomas IN 4_p
the DT N
GH NNP N
response NN N
to TO N
GHRH NNP N
is VBZ N
blunted VBN N
due JJ N
to TO N
increased VBN N
somatostatinergic NN N
tone NN N
, , N
as IN N
it PRP N
can MD N
be VB N
restored VBN N
to TO N
normal JJ N
by IN N
pretreatment NN N
with IN N
the DT N
functional JJ N
somatostatin NN N
antagonist JJ N
arginine NN N
. . N

The DT N
blunted JJ N
GH NNP N
release NN N
to TO N
GHRH NNP N
may MD N
be VB N
an DT N
early JJ N
and CC N
long JJ N
lasting JJ N
sign NN N
of IN N
autonomous JJ N
cortisol NNS N
secretion NN N
by IN N
the DT N
adrenal JJ N
adenoma NN N
. . N

-DOCSTART- -X- O O 21543343

A DT N
randomized JJ N
placebo-controlled JJ N
prevention NN N
trial NN N
of IN N
aspirin NN N
and/or NN N
resistant JJ N
starch NN N
in IN N
young JJ N
people NNS N
with IN N
familial JJ 4_p
adenomatous JJ 4_p
polyposis NN 4_p
. . N

Evidence NN N
supporting VBG N
aspirin NNS N
and CC N
resistant JJ N
starch NN N
( ( N
RS NNP N
) ) N
for IN N
colorectal JJ 4_p
cancer NN 4_p
prevention NN N
comes VBZ N
from IN N
epidemiologic JJ N
and CC N
laboratory JJ N
studies NNS N
( ( N
aspirin NN N
and CC N
RS NNP N
) ) N
and CC N
randomized VBN N
controlled JJ N
clinical JJ N
trials NNS N
( ( N
aspirin NN N
) ) N
. . N

Familial NNP N
adenomatous JJ N
polyposis NN N
( ( N
FAP NNP N
) ) N
strikes VBZ N
young JJ N
people NNS N
and CC N
, , N
untreated JJ N
, , N
confers NNS N
virtually RB N
a DT N
100 CD N
% NN N
risk NN N
of IN N
colorectal JJ N
cancer NN N
and CC N
early JJ N
death NN N
. . N

We PRP N
conducted VBD N
an DT N
international JJ N
, , N
multicenter NN N
, , N
randomized VBN N
, , N
placebo-controlled JJ N
trial NN N
of IN N
aspirin NN N
( ( N
600 CD N
mg/d NN N
) ) N
and/or NN N
RS NNP N
( ( N
30 CD N
g/d NN N
) ) N
for IN N
from IN N
1 CD N
to TO N
12 CD N
years NNS N
to TO N
prevent VB N
disease NN N
progression NN N
in IN N
FAP NNP N
patients NNS N
from IN N
10 CD N
to TO N
21 CD N
years NNS N
of IN N
age NN N
. . N

In IN N
a DT N
2 CD N
× NN N
2 CD N
factorial JJ N
design NN N
, , N
patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
the DT N
following VBG N
four CD N
study NN N
arms NNS N
: : N
aspirin NN N
plus CC N
RS NNP N
placebo NN N
; : N
RS NNP N
plus CC N
aspirin JJ N
placebo NN N
; : N
aspirin CC N
plus CC N
RS NNP N
; : N
RS NNP N
placebo NN N
plus CC N
aspirin JJ N
placebo NN N
; : N
they PRP N
were VBD N
followed VBN N
with IN N
standard JJ N
annual JJ N
clinical JJ N
examinations NNS N
including VBG N
endoscopy NN N
. . N

The DT N
primary JJ N
endpoint NN N
was VBD N
polyp JJ N
number NN N
in IN N
the DT N
rectum NN N
and CC N
sigmoid JJ N
colon NN N
( ( N
at IN N
the DT N
end NN N
of IN N
intervention NN N
) ) N
, , N
and CC N
the DT N
major JJ N
secondary JJ N
endpoint NN N
was VBD N
size NN N
of IN N
the DT N
largest JJS N
polyp NN N
. . N

A DT N
total NN N
of IN N
206 CD N
randomized JJ N
FAP NNP N
patients NNS N
commenced VBD N
intervention NN N
, , N
of IN N
whom WP N
133 CD N
had VBD N
at IN N
least JJS N
one CD N
follow-up JJ N
endoscopy NN N
and CC N
were VBD N
therefore RB N
included VBN N
in IN N
the DT N
primary JJ N
analysis NN N
. . N

Neither CC N
intervention NN N
significantly RB N
reduced VBN N
polyp NN N
count NN N
in IN N
the DT N
rectum NN N
and CC N
sigmoid JJ N
colon NN N
: : N
aspirin JJ N
relative JJ N
risk NN N
= VBP N
0.77 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
0.54-1.10 NNP N
; : N
versus NN N
nonaspirin IN N
arms NNS N
) ) N
; : N
RS NNP N
relative VBP N
risk NN N
= VBP N
1.05 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
0.73-1.49 NNP N
; : N
versus CD N
non-RS JJ N
arms NNS N
) ) N
. . N

There EX N
was VBD N
a DT N
trend NN N
toward IN N
a DT N
smaller JJR N
size NN N
of IN N
largest JJS N
polyp NN N
in IN N
patients NNS N
treated VBN N
with IN N
aspirin JJ N
versus NN N
nonaspirin NN N
-- : N
mean JJ N
3.8 CD N
mm NN N
versus NN N
5.5 CD N
mm NN N
for IN N
patients NNS N
treated JJ N
1 CD N
or CC N
more JJR N
years NNS N
( ( N
adjusted VBN N
P NNP N
= NNP N
0.09 CD N
) ) N
and CC N
mean $ N
3.0 CD N
mm NN N
versus NN N
6.0 CD N
mm NN N
for IN N
patients NNS N
treated VBD N
more JJR N
than IN N
1 CD N
year NN N
( ( N
P NNP N
= NNP N
0.02 CD N
) ) N
; : N
there EX N
were VBD N
similar JJ N
weaker JJR N
trends NNS N
with IN N
RS NNP N
versus IN N
non-RS JJ N
. . N

Exploratory NNP N
translational JJ N
endpoints NNS N
included VBD N
crypt JJ N
length NN N
( ( N
which WDT N
was VBD N
significantly RB N
shorter JJR N
in IN N
normal-appearing JJ N
mucosa NN N
in IN N
the DT N
RS NNP N
group NN N
over IN N
time NN N
) ) N
and CC N
laboratory JJ N
measures NNS N
of IN N
proliferation NN N
( ( N
including VBG N
Ki67 NNP N
) ) N
. . N

This DT N
clinical JJ N
trial NN N
is VBZ N
the DT N
largest JJS N
ever RB N
conducted VBN N
in IN N
the DT N
setting NN N
of IN N
FAP NNP N
and CC N
found VBD N
a DT N
trend NN N
of IN N
reduced JJ N
polyp NN N
load NN N
( ( N
number NN N
and CC N
size NN N
) ) N
with IN N
600 CD N
mg NNS N
of IN N
aspirin JJ N
daily JJ N
. . N

RS NNP N
had VBD N
no DT N
clinical JJ N
effect NN N
on IN N
adenomas NN N
. . N

-DOCSTART- -X- O O 2165088

Low-dose JJ N
clonidine NN N
administration NN N
in IN N
the DT N
treatment NN N
of IN N
mild NN 4_p
or CC 4_p
moderate JJ 4_p
essential JJ 4_p
hypertension NN 4_p
: : N
results NNS N
from IN N
a DT N
double-blind JJ N
placebo-controlled JJ N
study NN N
( ( N
Clobass NNP N
) ) N
. . N

The DT N
Clobass NNP N
Study NNP N
Group NNP N
. . N

Five CD N
hundred JJ N
and CC N
fifty-nine JJ N
hypertensive JJ N
outpatients NNS 4_p
with IN 4_p
diastolic JJ 4_p
blood NN 4_p
pressure NN 4_p
between IN 4_p
95 CD 4_p
and CC 4_p
110 CD 4_p
mmHg NN 4_p
participated VBN N
in IN N
this DT N
double-blind NN N
, , N
placebo-controlled JJ N
, , N
multicenter NN N
study NN N
. . N

Eligible JJ N
subjects NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
receive VB N
either DT N
clonidine NN N
( ( N
75 CD N
micrograms NNS N
twice RB N
daily RB N
) ) N
or CC N
a DT N
placebo NN N
. . N

After IN N
4 CD N
weeks NNS N
, , N
'responders NNS N
' POS N
to TO N
treatment NN N
( ( N
diastolic JJ N
blood NN N
pressure NN N
reduced VBD N
to TO N
less JJR N
than IN N
or CC N
equal JJ N
to TO N
90 CD N
mmHg NNS N
or CC N
by IN N
greater JJR N
than IN N
or CC N
equal JJ N
to TO N
10 CD N
mmHg NNS N
) ) N
were VBD N
kept VBN N
on IN N
monotherapy NN N
and CC N
checked VBN N
at IN N
4-weekly JJ N
intervals NNS N
for IN N
another DT N
3 CD N
months NNS N
. . N

Non-responders NNS N
were VBD N
given VBN N
15 CD N
mg JJ N
chlorthalidone NN N
and CC N
were VBD N
also RB N
checked VBN N
for IN N
a DT N
further JJ N
3 CD N
months NNS N
. . N

At IN N
the DT N
end NN N
of IN N
the DT N
first JJ N
month NN N
, , N
54.2 CD N
% NN N
of IN N
the DT N
subjects NNS N
were VBD N
responders NNS N
to TO N
clonidine VB N
and CC N
41.5 CD N
% NN N
were VBD N
responders NNS N
to TO N
the DT N
placebo NN N
( ( N
P NNP N
less JJR N
than IN N
0.05 CD N
for IN N
both DT N
groups NNS N
) ) N
. . N

Of IN N
the DT N
remaining VBG N
patients NNS N
, , N
69.0 CD N
% NN N
became VBD N
responders NNS N
to TO N
clonidine VB N
plus CC N
chlorthalidone VB N
, , N
whereas IN N
only RB N
34.7 CD N
% NN N
were VBD N
responders NNS N
to TO N
placebo VB N
plus CC N
chlorthalidone NN N
( ( N
P NNP N
less JJR N
than IN N
0.01 CD N
for IN N
both DT N
groups NNS N
) ) N
. . N

Withdrawals NNS N
from IN N
the DT N
study NN N
because IN N
of IN N
excessive JJ N
diastolic JJ N
blood NN N
pressure NN N
levels NNS N
were VBD N
about RB N
eight CD N
times NNS N
less RBR N
frequent JJ N
among IN N
the DT N
subjects NNS N
treated VBN N
with IN N
clonidine NN N
, , N
either CC N
alone RB N
or CC N
with IN N
chlorthalidone NN N
. . N

Dry NNP N
mouth NN N
was VBD N
twice RB N
as RB N
frequent JJ N
in IN N
the DT N
clonidine-treated JJ N
patients NNS N
, , N
but CC N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
incidence NN N
of IN N
all DT N
side NN N
effects NNS N
or CC N
the DT N
number NN N
of IN N
withdrawals NNS N
from IN N
the DT N
study NN N
because IN N
of IN N
side NN N
effects NNS N
between IN N
the DT N
two CD N
groups NNS N
. . N

We PRP N
conclude VBP N
that IN N
low-dose JJ N
clonidine NN N
is VBZ N
effective JJ N
in IN N
the DT N
treatment NN N
of IN N
mild NN N
or CC N
moderate JJ N
hypertension NN N
. . N

Clonidine-related JJ N
side NN N
effects NNS N
are VBP N
still RB N
evident JJ N
, , N
but CC N
the DT N
overall JJ N
tolerance NN N
profile NN N
for IN N
this DT N
reduced JJ N
dosage NN N
of IN N
the DT N
drug NN N
appears VBZ N
to TO N
be VB N
favorable JJ N
. . N

-DOCSTART- -X- O O 16804044

Psychological JJ N
well-being NN N
correlates NNS N
with IN N
free JJ N
thyroxine NN N
but CC N
not RB N
free JJ N
3,5,3'-triiodothyronine JJ N
levels NNS N
in IN N
patients NNS N
on IN N
thyroid JJ 4_p
hormone NN 4_p
replacement NN 4_p
. . N

CONTEXT NNP N
AND NNP N
OBJECTIVE NNP N
An DT N
association NN N
between IN N
mood NN N
disorders NNS N
and CC N
overt JJ N
thyroid JJ N
dysfunction NN N
is VBZ N
well RB N
established VBN N
, , N
but CC N
there EX N
are VBP N
few JJ N
data NNS N
on IN N
the DT N
potential NN N
for IN N
thyroid JJ N
hormone NN N
levels NNS N
closer RBR N
to TO N
the DT N
reference NN N
range NN N
to TO N
correlate VB N
with IN N
psychological JJ N
well-being NN N
. . N

DESIGN NNP N
, , N
SETTING NNP N
, , N
AND NNP N
PATIENTS NNP N
We PRP N
analyzed VBD N
the DT N
relationship NN N
between IN N
psychological JJ N
well-being NN N
and CC N
free JJ N
T NNP N
( ( N
4 CD N
) ) N
( ( N
fT4 NN N
) ) N
, , N
free JJ N
T NNP N
( ( N
3 CD N
) ) N
( ( N
fT3 NN N
) ) N
, , N
TSH NNP N
, , N
and CC N
total JJ N
rT NN N
( ( N
3 CD N
) ) N
in IN N
697 CD N
patients NNS N
on IN N
thyroid JJ 4_p
hormone NN 4_p
replacement NN 4_p
therapy NN 4_p
at IN N
entry NN N
to TO N
a DT N
randomized VBN N
, , N
controlled VBD N
trial NN N
of IN N
combined JJ N
T NNP N
( ( N
4 CD N
) ) N
and CC N
T NNP N
( ( N
3 CD N
) ) N
replacement NN N
therapy NN N
. . N

All DT N
patients NNS N
were VBD N
on IN N
100 CD N
mug NN N
or CC N
more JJR N
T NNP N
( ( N
4 CD N
) ) N
. . N

INTERVENTIONS NNP N
AND CC N
MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Psychological NNP N
well-being NN N
was VBD N
assessed VBN N
with IN N
General NNP N
Health NNP N
Questionnaire-12 NNP N
( ( N
GHQ-12 NNP N
) ) N
, , N
Thyroid NNP N
Symptom NNP N
Questionnaire NNP N
, , N
and CC N
Hospital NNP N
Anxiety NNP N
and CC N
Depression NNP N
Scale NNP N
. . N

RESULTS NNP N
fT NN N
( ( N
4 CD N
) ) N
and CC N
TSH NNP N
showed VBD N
a DT N
strong JJ N
correlation NN N
with IN N
GHQ-12 NNP N
scores NNS N
( ( N
fT4 SYM N
- : N
b NN N
: : N
-0.16 NN N
, , N
P NNP N
= NNP N
0.005 CD N
; : N
TSH NNP N
- : N
b NN N
: : N
0.663 CD N
, , N
P NNP N
= NNP N
0.04 CD N
) ) N
. . N

No UH N
correlations NNS N
were VBD N
seen VBN N
between IN N
the DT N
GHQ NNP N
scores NNS N
and CC N
fT3 NN N
( ( N
b NN N
: : N
0.318 CD N
, , N
P NNP N
= NNP N
0.275 CD N
) ) N
, , N
rT NN N
( ( N
3 CD N
) ) N
( ( N
b NN N
: : N
0.095 CD N
, , N
P NNP N
= NNP N
0.95 CD N
) ) N
, , N
rT NN N
( ( N
3 CD N
) ) N
to TO N
fT4 VB N
ratio NN N
( ( N
b NN N
: : N
71.83 CD N
, , N
P NNP N
= NNP N
0.09 CD N
) ) N
or CC N
fT3 VBN N
to TO N
rT VB N
( ( N
3 CD N
) ) N
ratio NN N
( ( N
b NN N
: : N
0.05 CD N
, , N
P NNP N
= NNP N
0.32 CD N
) ) N
. . N

The DT N
correlations NNS N
remained VBD N
when WRB N
the DT N
data NN N
set NN N
was VBD N
limited VBN N
to TO N
patients NNS N
with IN N
TSH NNP N
in IN N
the DT N
range NN N
0.3-4.0 JJ N
mIU/liter NN N
. . N

Similar JJ N
correlations NNS N
were VBD N
seen VBN N
with IN N
the DT N
Thyroid NNP N
Symptom NNP N
Questionnaire NNP N
, , N
although IN N
not RB N
with IN N
the DT N
Hospital NNP N
Anxiety NNP N
and CC N
Depression NNP N
Scale NNP N
scores NNS N
. . N

CONCLUSIONS NNP N
Differences NNPS N
in IN N
fT4 NN N
and CC N
TSH NNP N
concentration NN N
, , N
even RB N
within IN N
the DT N
reference NN N
range NN N
, , N
may MD N
be VB N
a DT N
determinant NN N
of IN N
psychological JJ N
well-being NN N
in IN N
treated JJ N
hypothyroid NN 4_p
patients NNS N
although IN N
not RB N
necessarily RB N
with IN N
symptoms NNS N
typical JJ N
of IN N
anxiety NN N
or CC N
depression NN N
. . N

-DOCSTART- -X- O O 22616853

Controlled-release NNP N
melatonin NN N
, , N
singly RB N
and CC N
combined VBN N
with IN N
cognitive JJ N
behavioural JJ N
therapy NN N
, , N
for IN N
persistent JJ N
insomnia NN 4_p
in IN N
children NNS N
with IN N
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
: : N
a DT N
randomized JJ N
placebo-controlled JJ N
trial NN N
. . N

Although IN N
melatonin NN N
and CC N
cognitive-behavioural JJ N
therapy NN N
have VBP N
shown VBN N
efficacy NN N
in IN N
treating VBG N
sleep JJ N
disorders NNS N
in IN N
children NNS N
with IN N
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
, , N
little JJ N
is VBZ N
known VBN N
about IN N
their PRP$ N
relative NN N
or CC N
combined VBN N
efficacy NN N
. . N

One CD N
hundred CD N
and CC N
sixty JJ N
children NNS N
with IN N
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
, , N
aged VBN N
4-10 CD N
years NNS N
, , N
suffering VBG N
from IN N
sleep JJ 4_p
onset NN 4_p
insomnia NN 4_p
and CC 4_p
impaired JJ 4_p
sleep JJ 4_p
maintenance NN 4_p
, , N
were VBD N
assigned VBN N
randomly RB N
to TO N
either DT N
( ( N
1 CD N
) ) N
combination NN N
of IN N
controlled-release JJ N
melatonin NN N
and CC N
cognitive-behavioural JJ N
therapy NN N
; : N
( ( N
2 CD N
) ) N
controlled-release NN N
melatonin NN N
; : N
( ( N
3 CD N
) ) N
four CD N
sessions NNS N
of IN N
cognitive-behavioural JJ N
therapy NN N
; : N
or CC N
( ( N
4 CD N
) ) N
placebo FW N
drug NN N
treatment NN N
condition NN N
for IN N
12 CD N
weeks NNS N
in IN N
a DT N
1 CD N
: : N
1 CD N
: : N
1 CD N
: : N
1 CD N
ratio NN N
. . N

Children NNP N
were VBD N
studied VBN N
at IN N
baseline NN N
and CC N
after IN N
12 CD N
weeks NNS N
of IN N
treatment NN N
. . N

Treatment NNP N
response NN N
was VBD N
assessed VBN N
with IN N
1-week JJ N
actigraphic JJ N
monitoring NN N
, , N
sleep JJ N
diary NN N
and CC N
sleep JJ N
questionnaire NN N
. . N

Main NNP N
outcome NN N
measures NNS N
, , N
derived VBN N
actigraphically RB N
, , N
were VBD N
sleep JJ N
latency NN N
, , N
total JJ N
sleep JJ N
time NN N
, , N
wake VBP N
after IN N
sleep JJ N
onset NN N
and CC N
number NN N
of IN N
awakenings NNS N
. . N

The DT N
active JJ N
treatment NN N
groups NNS N
all DT N
resulted VBD N
in IN N
improvements NNS N
across IN N
all DT N
outcome NN N
measures NNS N
, , N
with IN N
moderate-to-large JJ N
effect NN N
sizes VBZ N
from IN N
baseline NN N
to TO N
a DT N
12-week JJ N
assessment NN N
. . N

Melatonin NNP N
treatment NN N
was VBD N
mainly RB N
effective JJ N
in IN N
reducing VBG N
insomnia NN N
symptoms NNS N
, , N
while IN N
cognitive-behavioural JJ N
therapy NN N
had VBD N
a DT N
light JJ N
positive JJ N
impact NN N
mainly RB N
on IN N
sleep JJ N
latency NN N
, , N
suggesting VBG N
that IN N
some DT N
behavioural JJ N
aspects NNS N
might MD N
play VB N
a DT N
role NN N
in IN N
determining VBG N
initial JJ N
insomnia NN N
. . N

The DT N
combination NN N
treatment NN N
group NN N
showed VBD N
a DT N
trend NN N
to TO N
outperform VB N
other JJ N
active JJ N
treatment NN N
groups NNS N
, , N
with IN N
fewer JJR N
dropouts NNS N
and CC N
a DT N
greater JJR N
proportion NN N
of IN N
treatment NN N
responders NNS N
achieving VBG N
clinically RB N
significant JJ N
changes NNS N
( ( N
63.38 CD N
% NN N
normative JJ N
sleep JJ N
efficiency NN N
criterion NN N
of IN N
> $ N
85 CD N
% NN N
and CC N
84.62 CD N
% NN N
, , N
sleep JJ N
onset NN N
latency NN N
< VBD N
30 CD N
min NN N
) ) N
. . N

This DT N
study NN N
demonstrates VBZ N
that IN N
adding VBG N
behavioural JJ N
intervention NN N
to TO N
melatonin VB N
treatment NN N
seems VBZ N
to TO N
result VB N
in IN N
a DT N
better JJR N
treatment NN N
response NN N
, , N
at IN N
least JJS N
in IN N
the DT N
short JJ N
term NN N
. . N

-DOCSTART- -X- O O 3557014

Sucralfate NNP N
overcomes VBZ N
adverse JJ N
effect NN N
of IN N
cigarette NN N
smoking NN N
on IN N
duodenal JJ 4_p
ulcer NN 4_p
healing NN N
and CC N
prolongs NNS N
subsequent JJ N
remission NN N
. . N

A DT N
unicenter JJ N
, , N
single-blind JJ N
, , N
randomized VBD N
study NN N
was VBD N
conducted VBN N
on IN N
283 CD N
patients NNS N
with IN N
active JJ N
duodenal JJ 4_p
ulcer NN 4_p
to TO N
compare VB N
possible JJ N
factors NNS N
that WDT N
may MD N
affect VB N
healing NN N
and CC N
relapse NN N
in IN N
patients NNS N
treated VBN N
with IN N
a DT N
potent JJ N
antisecretory NN 4_p
agent NN 4_p
, , 4_p
cimetidine NN 4_p
, , 4_p
or CC N
a DT N
site-protective JJ 4_p
and CC 4_p
cytoprotective JJ 4_p
agent NN 4_p
, , N
sucralfate NN N
. . N

The DT N
endoscopic NN N
healing VBG N
rates NNS N
at IN N
4 CD N
wk NNS N
were VBD N
76 CD N
% NN N
and CC N
79 CD N
% NN N
, , N
respectively RB N
, , N
and CC N
cross-over JJ N
treatment NN N
of IN N
the DT N
failures NNS N
for IN N
a DT N
further JJ N
4 CD N
wk NN N
resulted VBD N
in IN N
68 CD N
% NN N
healing VBG N
with IN N
cimetidine NN N
and CC N
69 CD N
% NN N
healing VBG N
with IN N
sucralfate NN N
, , N
both DT N
differences NNS N
being VBG N
not RB N
statistically RB N
different JJ N
. . N

Unlike IN N
cimetidine NN N
, , N
healing VBG N
by IN N
sucralfate NN N
was VBD N
unaffected VBN N
by IN N
cigarette NN N
smoking NN N
, , N
reluctance NN N
to TO N
give VB N
up RP N
smoking NN N
, , N
habitual JJ N
use NN N
of IN N
alcohol NN N
, , N
high JJ N
maximal JJ N
acid NN N
output NN N
, , N
and CC N
large JJ N
ulcer JJ N
diameter NN N
. . N

In IN N
particular JJ N
, , N
the DT N
healing VBG N
rate NN N
of IN N
smokers NNS N
treated VBN N
with IN N
sucralfate NN N
( ( N
82 CD N
% NN N
) ) N
was VBD N
significantly RB N
greater JJR N
than IN N
that DT N
of IN N
smokers NNS N
treated VBN N
with IN N
cimetidine NN N
( ( N
63 CD N
% NN N
) ) N
. . N

Duodenal NNP N
bulb NN N
deformity NN N
significantly RB N
affected VBD N
healing NN N
in IN N
both DT N
groups NNS N
, , N
and CC N
was VBD N
the DT N
only JJ N
offsetting VBG N
factor NN N
identifiable JJ N
for IN N
sucralfate NN N
out IN N
of IN N
46 CD N
factors NNS N
examined VBD N
. . N

Of IN N
the DT N
patients NNS N
with IN N
healed JJ N
ulcers NNS 4_p
, , N
238 CD N
participated VBN N
in IN N
a DT N
24-mo JJ N
follow-up NN N
study NN N
consisting VBG N
of IN N
interviews NNS N
at IN N
2-mo JJ N
intervals NNS N
and CC N
endoscopy NN N
at IN N
4-mo JJ N
intervals NNS N
or CC N
whenever WRB N
symptoms NNS N
recurred VBD N
. . N

The DT N
cumulative JJ N
relapse NN N
rate NN N
was VBD N
significantly RB N
( ( N
p NN N
less JJR N
than IN N
0.007 CD N
) ) N
greater JJR N
in IN N
patients NNS N
healed VBN N
with IN N
cimetidine NN N
than IN N
with IN N
sucralfate NN N
, , N
50 CD N
% NN N
relapse NN N
occurring VBG N
at IN N
6 CD N
and CC N
12 CD N
mo NN N
, , N
respectively RB N
. . N

In IN N
both DT N
, , N
the DT N
cumulative JJ N
relapse NN N
rate NN N
was VBD N
significantly RB N
greater JJR N
in IN N
cigarette NN N
smokers NNS N
than IN N
in IN N
nonsmokers NNS N
, , N
but CC N
smokers NNS N
and CC N
nonsmokers NNS N
treated VBN N
with IN N
cimetidine NN N
relapsed VBN N
( ( N
50 CD N
% NN N
at IN N
4 CD N
and CC N
8 CD N
mo NN N
, , N
respectively RB N
) ) N
faster RBR N
than IN N
the DT N
corresponding JJ N
smokers NNS N
and CC N
nonsmokers NNS N
treated VBN N
with IN N
sucralfate NN N
( ( N
50 CD N
% NN N
at IN N
8 CD N
and CC N
18 CD N
mo NN N
, , N
respectively RB N
) ) N
. . N

Furthermore UH N
, , N
in IN N
cimetidine- NN N
but CC N
not RB N
sucralfate-healed JJ N
patients NNS N
, , N
early JJ N
ulcer NN N
relapse NN N
( ( N
within IN N
6 CD N
mo NN N
) ) N
was VBD N
associated VBN N
with IN N
short JJ N
duration NN N
of IN N
illness NN N
, , N
short JJ N
remission NN N
period NN N
, , N
long JJ N
symptomatic JJ N
spell NN N
, , N
and CC N
reluctance NN N
to TO N
give VB N
up RP N
smoking VBG N
. . N

We PRP N
conclude VBP N
that IN N
smoking VBG N
adversely RB N
affects VBZ N
duodenal JJ N
ulcer NN N
healing NN N
by IN N
cimetidine NN N
and CC N
hastens VBZ N
subsequent JJ N
relapse NN N
, , N
and CC N
that IN N
sucralfate NN N
overcomes VBZ N
the DT N
adverse JJ N
effect NN N
of IN N
smoking VBG N
on IN N
healing NN N
as IN N
encountered VBN N
with IN N
cimetidine NN N
, , N
and CC N
results NNS N
in IN N
a DT N
subsequent JJ N
remission NN N
period NN N
double JJ N
that IN N
of IN N
cimetidine NN N
. . N

-DOCSTART- -X- O O 6113821

Schizophrenia NNP N
. . N

A DT N
follow-up JJ N
study NN N
of IN N
the DT N
results NNS N
of IN N
five CD N
forms NNS N
of IN N
treatment NN N
. . N

Two CD 4_p
hundred VBD 4_p
twenty-eight JJ 4_p
first-admission NN 4_p
schizophrenic JJ 4_p
patients NNS 4_p
were VBD N
randomly RB N
assigned VBN N
to TO N
the DT N
following VBG N
five CD N
treatments NNS N
: : N
psychotherapy NN N
alone RB N
, , N
drug NN N
alone RB N
, , N
psychotherapy JJ N
plus CC N
drug NN N
, , N
electroconvulsive JJ N
therapy NN N
( ( N
ECT NNP N
, , N
and CC N
milieu NN N
. . N

A DT N
there- JJ N
to TO N
five-year JJ N
follow-up NN N
examined VBD N
their PRP$ N
course NN N
after IN N
release NN N
from IN N
the DT N
hospital NN N
. . N

The DT N
drug NN N
alone RB N
and CC N
ECT NNP N
groups NNS N
tended VBD N
to TO N
have VB N
the DT N
best JJS N
outcome NN N
and CC N
the DT N
psychotherapy NN N
alone RB N
group NN N
the DT N
worst JJS N
. . N

The DT N
positive JJ N
effect NN N
from IN N
prior JJ N
drug NN N
treatment NN N
began VBD N
to TO N
dissipate VB N
after IN N
three CD N
years NNS N
postadmission NN N
. . N

For IN N
the DT N
in-hospital JJ N
treatment NN N
successes NNS N
, , N
the DT N
advantage NN N
from IN N
drug NN N
treatment NN N
and CC N
the DT N
disadvantage NN N
from IN N
psychotherapy NN N
were VBD N
less JJR N
apparent JJ N
. . N

Overall JJ N
, , N
the DT N
follow-up JJ N
outcome NN N
is VBZ N
far RB N
from IN N
reassuring VBG N
, , N
whatever WP N
the DT N
type NN N
of IN N
treatment NN N
. . N

Even RB N
though IN N
a DT N
few JJ N
patients NNS N
may MD N
do VB N
well RB N
, , N
much JJ N
remains VBZ N
to TO N
be VB N
done VBN N
in IN N
and CC N
out IN N
of IN N
the DT N
hospital NN N
. . N

-DOCSTART- -X- O O 20828635

A DT N
randomized JJ N
trial NN N
of IN N
genetic JJ N
and CC N
environmental JJ N
risk NN N
assessment NN N
( ( N
GERA NNP N
) ) N
for IN N
colorectal JJ N
cancer NN N
risk NN N
in IN N
primary JJ N
care NN N
: : N
trial NN N
design NN N
and CC N
baseline NN N
findings NNS N
. . N

PURPOSE VB N
This DT N
paper NN N
describes VBZ N
an DT N
ongoing JJ N
randomized NN N
controlled VBD N
trial NN N
designed VBN N
to TO N
assess VB N
the DT N
impact NN N
of IN N
genetic JJ N
and CC N
environmental JJ N
risk NN N
assessment NN N
( ( N
GERA NNP N
) ) N
on IN N
colorectal JJ 4_p
cancer NN 4_p
( ( 4_p
CRC NNP 4_p
) ) 4_p
screening NN N
. . N

METHODS NNP N
The DT N
trial NN N
includes VBZ N
asymptomatic JJ 4_p
patients NNS 4_p
who WP N
are VBP N
50-79years NNS N
and CC N
are VBP 4_p
not RB 4_p
up-to-date JJ 4_p
with IN 4_p
CRC NNP 4_p
screening VBG 4_p
guidelines NNS 4_p
. . N

Patients NNS N
who WP N
responded VBD N
to TO N
a DT N
baseline NN N
telephone NN N
survey NN N
are VBP N
randomized VBN N
to TO N
a DT N
GERA NNP 4_p
or CC 4_p
Control NNP 4_p
group NN 4_p
. . N

GERA NNP N
group NN N
participants NNS N
meet VBP N
with IN N
a DT N
nurse NN N
, , N
decide VB N
whether IN N
to TO N
have VB N
a DT N
GERA NNP N
blood NN N
test NN N
( ( N
a DT N
combination NN N
of IN N
genetic JJ N
polymorphism NN N
and CC N
folate NN N
) ) N
, , N
and CC N
, , N
if IN N
tested VBN N
, , N
receive VBP N
GERA NNP N
feedback NN N
. . N

Follow-up NNP N
telephone NN N
surveys NNS N
are VBP N
conducted VBN N
at IN N
1 CD N
and CC N
6months CD N
. . N

A DT N
chart NN N
audit NN N
is VBZ N
performed VBN N
at IN N
6months CD N
. . N

RESULTS NNP N
Of IN N
2,223 CD N
eligible JJ N
patients NNS N
, , N
562 CD N
( ( N
25 CD N
% NN N
) ) N
have VBP N
enrolled VBN N
. . N

Patients NNS 4_p
who WP 4_p
enrolled VBD 4_p
in IN 4_p
the DT 4_p
study NN 4_p
were VBD 4_p
significantly RB 4_p
younger JJR 4_p
than IN 4_p
those DT 4_p
who WP 4_p
did VBD 4_p
not RB 4_p
( ( 4_p
p JJ 4_p
< NNP 4_p
0.001 CD 4_p
) ) 4_p
. . N

Participants NNS N
tended VBD N
to TO N
be VB N
50-59years JJ N
( ( N
64 CD N
% NN N
) ) N
, , N
female JJ N
( ( N
58 CD N
% NN N
) ) N
, , N
white JJ N
( ( N
52 CD N
% NN N
) ) N
, , N
married VBD N
( ( N
51 CD N
% NN N
) ) N
, , N
and CC N
have VBP N
more JJR N
than IN N
a DT N
high JJ N
school NN N
education NN N
( ( N
67 CD N
% NN N
) ) N
. . N

At IN N
baseline NN N
, , N
most JJS N
participants NNS N
had VBD N
some DT N
knowledge NN N
of IN N
CRC NNP N
screening NN N
and CC N
GERA NNP N
, , N
viewed VBD N
CRC NNP N
screening VBG N
favorably RB N
, , N
and CC N
reported VBD N
that IN N
they PRP N
had VBD N
decided VBN N
to TO N
do VB N
screening VBG N
. . N

Almost NNP N
half NN N
had VBD N
worries NNS N
and CC N
concerns NNS N
about IN N
CRC NNP N
. . N

CONCLUSIONS NNP N
One CD N
in IN N
four CD N
eligible JJ N
primary JJ N
care NN N
patients NNS N
enrolled VBN N
in IN N
the DT N
study NN N
. . N

Age NNP N
was VBD N
negatively RB N
associated VBN N
with IN N
enrollment NN N
. . N

Prospective JJ N
analyses NNS N
using VBG N
data NNS N
for IN N
all DT N
participants NNS N
will MD N
provide VB N
more RBR N
definitive JJ N
information NN N
on IN N
GERA NNP N
uptake NN N
and CC N
the DT N
impact NN N
of IN N
GERA NNP N
feedback NN N
. . N

-DOCSTART- -X- O O 8391792

Subcutaneous JJ N
low-molecular-weight JJ N
heparin NN N
compared VBN N
with IN N
continuous JJ N
intravenous JJ N
unfractionated JJ N
heparin NN N
in IN N
the DT N
treatment NN N
of IN N
proximal JJ 4_p
deep JJ 4_p
vein NN 4_p
thrombosis NN 4_p
. . N

BACKGROUND VB N
A DT N
low-molecular-weight JJ N
heparin NN N
, , N
enoxaparin JJ N
sodium NN N
, , N
has VBZ N
been VBN N
shown VBN N
to TO N
be VB N
effective JJ N
and CC N
safe JJ N
in IN N
preventing VBG N
deep JJ 4_p
vein NN 4_p
thrombosis NN 4_p
both DT N
in IN N
general JJ N
surgery NN N
and CC N
in IN N
high-risk JJ N
orthopedic JJ N
surgery NN N
. . N

We PRP N
conducted VBD N
a DT N
controlled VBN N
, , N
randomized VBN N
trial NN N
with IN N
enoxaparin NN N
in IN N
the DT N
treatment NN N
of IN N
established VBN N
deep JJ N
vein NN N
thrombosis NN N
. . N

METHODS NNP N
In IN N
a DT N
multicenter NN N
trial NN N
, , N
we PRP N
compared VBN N
fixed-dose RB N
subcutaneous JJ N
enoxaparin NN N
, , N
given VBN N
twice RB N
daily RB N
, , N
with IN N
adjusted-dose JJ N
intravenous JJ N
unfractionated JJ N
heparin NN N
( ( N
UFH NNP N
) ) N
given VBN N
by IN N
continuous JJ N
intravenous JJ N
infusion NN N
for IN N
the DT N
initial JJ N
10 CD N
days NNS N
of IN N
treatment NN N
of IN N
patients NNS N
with IN N
proximal JJ 4_p
vein NN 4_p
thrombosis NN 4_p
. . N

The DT N
primary JJ N
efficacy NN N
outcome NN N
was VBD N
the DT N
change NN N
of IN N
the DT N
size NN N
of IN N
the DT N
thrombus NN N
assessed VBN N
by IN N
repeated JJ N
venograms NNS N
between IN N
day NN N
0 CD N
and CC N
day NN N
10 CD N
. . N

The DT N
primary JJ N
analysis NN N
of IN N
safety NN N
was VBD N
based VBN N
on IN N
the DT N
incidence NN N
of IN N
major JJ N
bleeding VBG N
during IN N
10 CD N
days NNS N
of IN N
treatment NN N
. . N

RESULTS CC N
There EX N
were VBD N
67 CD N
patients NNS N
in IN N
each DT N
group NN N
. . N

Venographic NNP N
assessment NN N
of IN N
clot NN N
size NN N
evolution NN N
between IN N
day NN N
0 CD N
and CC N
day NN N
10 CD N
showed VBD N
a DT N
statistically RB N
significant JJ N
superiority NN N
( ( N
P NNP N
< NNP N
.002 NNP N
) ) N
of IN N
enoxaparin NN N
over IN N
the DT N
reference NN N
treatment NN N
with IN N
UFH NNP N
. . N

Moreover RB N
, , N
the DT N
incidence NN N
of IN N
overall JJ N
recurrent JJ N
thromboembolic JJ N
events NNS N
during IN N
10 CD N
days NNS N
of IN N
treatment NN N
was VBD N
significantly RB N
higher JJR N
( ( N
P NNP N
< NNP N
.002 NNP N
) ) N
in IN N
the DT N
UFH NNP N
group NN N
( ( N
seven CD N
of IN N
67 CD N
) ) N
than IN N
in IN N
the DT N
enoxaparin NN N
group NN N
( ( N
one CD N
of IN N
67 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
serious JJ N
bleeding VBG N
complications NNS N
in IN N
either DT N
group NN N
. . N

CONCLUSIONS NNP N
Enoxaparin NNP N
is VBZ N
at IN N
least JJS N
as IN N
effective JJ N
and CC N
safe JJ N
as IN N
UFH NNP N
under IN N
the DT N
conditions NNS N
of IN N
this DT N
study NN N
. . N

Moreover RB N
, , N
it PRP N
is VBZ N
more RBR N
comfortable JJ N
for IN N
patients NNS N
and CC N
less JJR N
time-consuming NN N
for IN N
nurses NNS N
and CC N
laboratories NNS N
. . N

Thus RB N
, , N
our PRP$ N
study NN N
confirmed VBD N
, , N
with IN N
the DT N
use NN N
of IN N
enoxaparin NN N
, , N
other JJ N
observations NNS N
that IN N
low-molecular-weight JJ N
heparin NN N
provides VBZ N
a DT N
real JJ N
therapeutic JJ N
advance NN N
in IN N
the DT N
treatment NN N
of IN N
deep JJ 4_p
vein NN 4_p
thrombosis NN 4_p
. . N

